https://www.biopharmawatch.com/news/PMN/promis-neurosciences-issues-letter-to-shareholders-pmn-20240108monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-publication-on-novel-target-for-als-pmn-20231220monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-closes-20-4-million-private-placement-financing-pmn-20230908monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-present-at-the-h-c-wainwright-25th-annual-global-investment-confer-pmn-20230906monthly0.5https://www.biopharmawatch.com/news/PMN/promis-showcases-preclinical-data-at-the-alzheimer-s-association-international-conference--pmn-20230717monthly0.5https://www.biopharmawatch.com/news/PMN/promis-announces-completion-of-continuance-pmn-20230714monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-holds-annual-meeting-of-shareholders-all-resolutions-approved-pmn-20230630monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-p-pmn-20230424monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-abstracts-accepted-for-presentation-at-the-american-academy-pmn-20230313monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-present-new-preclinical-data-for-pmn310-at-ad-pd-2023-pmn-20230313monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-present-at-the-oppenheimer-33rd-annual-healthcare-conference-pmn-20230308monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-second-quarter-2022-financial-and-operating-results-pmn-20220815monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-presents-at-2022-alzheimer-s-association-international-conference-pmn-20220802monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-present-at-2022-alzheimer-s-association-international-conference-pmn-20220727monthly0.5https://www.biopharmawatch.com/news/PMN/promis-announces-reverse-share-split-to-meet-nasdaq-listing-criteria-pmn-20220627monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-debt-amendment-and-conversion-pmn-20220622monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-filing-of-form-10-registration-statement-and-nasdaq-listing-pmn-20220622monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-authorization-of-series-1-preferred-shares-pmn-20220622monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-presents-at-the-2022-neuro4d-international-conference-pmn-20220517monthly0.5https://www.biopharmawatch.com/news/PMN/promis-holds-annual-and-special-meeting-of-shareholders-all-resolutions-approved-pmn-20220513monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-first-quarter-2022-results-pmn-20220513monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-reports-new-milestones-in-potential-therapeutic-approaches-for-amyotr-pmn-20220428monthly0.5https://www.biopharmawatch.com/news/PMN/promis-appoints-experienced-industry-veteran-larry-altstiel-as-chief-medical-officer-pmn-20220419monthly0.5https://www.biopharmawatch.com/news/PMN/promis-files-management-information-circular-in-connection-with-annual-general-and-special-pmn-20220407monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-presents-at-the-2022-american-academy-of-neurology-annual-meeting-pmn-20220407monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-present-at-the-10th-annual-neurodegenerative-drug-development-summ-pmn-20220324monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-presents-preclinical-results-of-its-experimental-alzheimer-s-vaccine--pmn-20220322monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-fiscal-year-2021-results-pmn-20220317monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-present-at-the-2022-international-conference-on-alzheimer-s-and-pa-pmn-20220310monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-pmn310-antibody-demonstrates-significant-cognitive-benefit-in-a-mouse-pmn-20220302monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-appoints-renowned-neuroscientists-dr-guy-rouleau-and-dr-alain-dagher--pmn-20220203monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-appoints-internationally-recognized-neuroscientist-dr-cheryl-wellingt-pmn-20220127monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-antibody-program-for-schizophrenia-therapy-and-recruitment--pmn-20220118monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-participate-in-the-biotech-showcase-2022-virtual-panel-discussion--pmn-20220107monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-participate-in-h-c-wainwright-bioconnect-2022-virtual-conference-pmn-20220106monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-issues-chairman-s-memorandum-pmn-20211216monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-shareholders-approve-special-resolution-pmn-20211202monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-third-quarter-2021-results-pmn-20211112monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-update-to-senior-management-team-pmn-20211022monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-appoints-accomplished-biotech-executive-dr-maggie-shafmaster-to-its-b-pmn-20211022monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-files-special-meeting-proxy-material-pmn-20211021monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-special-shareholder-meeting-pmn-20211007monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-present-at-the-second-annual-undruggable-leaders-forum-september-1-pmn-20210915monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-participate-in-h-c-wainwright-co-23rd-annual-investment-conference-pmn-20210913monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-appoints-accomplished-biotechnology-executive-josh-mandel-brehm-to-it-pmn-20210901monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-closes-upsized-us-20-125-000-public-offering-pmn-20210825monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-inc-announces-upsize-of-previously-announced-public-offering-of-units-pmn-20210818monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-inc-announces-pricing-of-us-15-million-public-offering-of-units-pmn-20210818monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-inc-announces-us-15-million-offering-of-units-pmn-20210817monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-second-quarter-2021-results-pmn-20210812monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-issues-chairman-s-memorandum-pmn-20210804monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-present-at-2021-alzheimer-s-association-international-conference-pmn-20210722monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-obtains-receipt-for-final-base-shelf-prospectus-pmn-20210708monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-results-of-annual-meeting-of-shareholders-pmn-20210702monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-congratulates-biogen-on-fda-accelerated-approval-of-aducanumab-for-al-pmn-20210608monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-files-preliminary-short-form-base-shelf-prospectus-pmn-20210603monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-appoints-renowned-scientist-dr-david-wishart-as-chief-physics-officer-pmn-20210527monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-initiates-commercialization-of-covid-19-serology-assay-pmn-20210525monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-re-initiates-path-to-ind-for-pmn310-with-producer-cell-line-developme-pmn-20210521monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-appoints-accomplished-biotechnology-executive-neil-warma-to-its-board-pmn-20210519monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-first-quarter-2021-results-pmn-20210514monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-appoints-renowned-neuroscientist-dr-rudolph-tanzi-as-chair-of-scienti-pmn-20210512monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-fiscal-year-2020-results-pmn-20210331monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-completes-us-7m-cdn-8-75m-financing-with-distinguished-group-of-bosto-pmn-20210322monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-offers-perspectives-on-recent-progress-in-the-alzheimer-s-amyloid-fie-pmn-20210202monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-strategic-priorities-for-2021-pmn-20210112monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-completes-offering-of-special-warrants-pmn-20201116monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-third-quarter-2020-results-pmn-20201111monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-offers-comments-on-recent-fda-advisory-committee-meeting-on-aducanuma-pmn-20201109monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-closes-first-tranche-of-private-placement-pmn-20201105monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-dr-neil-cashman-cso-to-speak-at-2020-als-one-research-symposium-pmn-20201030monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-adds-dr-david-wishart-to-its-scientific-advisory-board-pmn-20201029monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-up-to-3-million-private-placement-offering-of-special-warra-pmn-20201023monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-offers-its-perspective-on-the-likelihood-of-regulatory-approval-of-ad-pmn-20201021monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-neil-cashman-to-speak-at-protein-misfolding-drug-discovery-conference-pmn-20201013monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-develop-multivalent-vaccine-for-alzheimer-s-disease-pmn-20200922monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-participate-in-h-c-wainwright-co-22nd-annual-investment-conference-pmn-20200910monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-second-quarter-2020-results-pmn-20200813monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-results-of-annual-meeting-of-shareholders-pmn-20200729monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-and-bc-neuroimmunology-announce-revenue-sharing-joint-venture-agreeme-pmn-20200709monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-adjournment-and-change-of-location-of-annual-meeting-of-sha-pmn-20200624monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-and-collaborator-bc-neuroimmunology-announce-significant-progress-on--pmn-20200617monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-and-collaborative-team-receive-supercluster-award-supporting-avoidanc-pmn-20200528monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-chairman-s-update-details-new-programs-from-expanded-use-of-novel-tec-pmn-20200520monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-and-bc-neuroimmunology-expand-collaboration-to-develop-and-commercial-pmn-20200519monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-first-quarter-2020-results-pmn-20200513monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-identifies-multiple-novel-targets-on-sars-cov-2-for-development-of-a--pmn-20200512monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-develops-novel-antagonists-for-rack1-a-protein-involved-in-numerous-n-pmn-20200506monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-creates-novel-intrabodies-for-als-frontotemporal-dementia-and-other-n-pmn-20200430monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-commends-biogen-for-clarifying-aducanumab-regulatory-filing-pmn-20200422monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-collaboration-to-develop-serological-test-to-assess-covid-1-pmn-20200415monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-present-data-and-moderate-session-at-aaic-2020-pmn-20200407monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-approval-for-warrant-repricing-pmn-20200324monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-fiscal-year-2019-annual-results-pmn-20200318monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-initiates-natural-history-study-of-blood-based-biomarkers-in-alzheime-pmn-20200226monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-gross-proceeds-of-1-257-970-related-to-the-exercise-of-comm-pmn-20200225monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-participate-in-noble-capital-markets-16th-annual-investor-conferen-pmn-20200211monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-participate-in-the-bio-ceo-investor-conference-pmn-20200206monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-data-for-alzheimer-s-disease-program-targeting-tau-accepted-for-prese-pmn-20200129monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-present-at-sachs-3rd-annual-neuroscience-innovation-forum-pmn-20200109monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-issues-chairman-s-update-detailing-positive-outlook-for-alzheimer-s-d-pmn-20200108monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-completes-second-closing-of-private-placement-pmn-20191231monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-alzheimer-s-disease-program-takes-on-renewed-significance-following-p-pmn-20191210monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-completes-first-closing-of-private-placement-pmn-20191118monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-third-quarter-2019-results-pmn-20191114monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-undertaking-6-5m-private-placement-pmn-20191113monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-outlines-best-in-class-approach-to-amyloid-beta-targeting-drug-candid-pmn-20191107monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-advances-als-program-selectively-targeting-toxic-form-of-tdp-43-pmn-20191023monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-advances-alzheimer-s-disease-program-targeting-neurotoxic-forms-of-ta-pmn-20191017monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-identifies-novel-antibody-candidates-for-multiple-system-atrophy-pmn-20191008monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-executive-chairman-eugene-williams-to-speak-on-panel-at-fall-investor-pmn-20190916monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-present-at-h-c-wainwright-investor-conference-pmn-20190903monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-appoints-internationally-recognized-researcher-in-alzheimer-s-disease-pmn-20190827monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-second-quarter-2019-results-pmn-20190813monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-results-of-annual-meeting-of-shareholders-pmn-20190724monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-highlights-data-for-pmn310-at-aaic-2019-pmn-20190718monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-present-data-at-2019-alzheimer-s-association-international-confere-pmn-20190710monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-data-for-alzheimer-s-disease-clinical-candidate-pmn310-published-in-s-pmn-20190709monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-pmn310-shows-greater-therapeutic-potential-vs-other-amyloid-beta-dire-pmn-20190627monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-closing-private-placement-pmn-20190626monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-appoints-renowned-parkinson-s-disease-expert-dr-c-warren-olanow-to-sc-pmn-20190619monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-presents-lead-program-for-alzheimer-s-disease-at-prestigious-keystone-pmn-20190605monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-eugene-williams-to-present-at-jlabs-conference-on-innovations-in-neur-pmn-20190529monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-identifies-novel-antibodies-for-alzheimer-s-disease-with-selectivity--pmn-20190528monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-first-quarter-2019-results-pmn-20190514monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-participate-in-the-think-equity-investor-conference-pmn-20190423monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-participate-in-microcap-spring-investor-summit-2019-pmn-20190326monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-present-data-for-potential-best-in-class-antibody-candidates-for-p-pmn-20190319monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-fiscal-year-2018-annual-results-pmn-20190315monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-adds-pharmaceutical-leader-timothy-rothwell-to-board-of-advisors-pmn-20190221monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-completes-private-placement-of-units-pmn-20190123monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-participate-in-noblecon15-and-cantech-investment-conferences-pmn-20190117monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-present-at-sachs-associates-neuroscience-innovation-forum-and-chin-pmn-20181218monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-appoints-renowned-neuroscientist-dr-rudolph-tanzi-to-scientific-advis-pmn-20181217monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-issues-year-to-date-update-highlighting-2018-accomplishments-pmn-20181120monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-third-quarter-2018-results-pmn-20181113monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-discusses-critical-importance-of-selectively-targeting-the-root-cause-pmn-20181106monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-identifies-novel-targets-on-tau-protein-involved-in-the-development-o-pmn-20181031monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-identifies-novel-antibody-drug-candidates-for-parkinson-s-disease-pmn-20181011monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-appoints-james-kupiec-md-as-chief-medical-officer-pmn-20180913monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-present-at-upcoming-investor-conferences-pmn-20180125monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-issues-white-paper-entitled-not-all-amyloid-beta-therapeutics-are-cre-pmn-20180125monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-lead-product-candidate-for-alzheimer-s-disease-shows-potential-for-im-pmn-20180123monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-issues-response-to-recent-market-activity-pmn-20180122monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-lead-product-candidate-for-alzheimer-s-disease-pmn310-shows-potential-pmn-20180104monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-trading-on-otcqb-venture-market-pmn-20171204monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-third-quarter-2017-results-pmn-20171113monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-lead-product-candidate-pmn310-shows-desired-target-binding-profile-in-pmn-20171017monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-provides-third-quarter-update-for-2017-pmn-20171011monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-chief-scientific-officer-dr-neil-cashman-to-present-at-third-annual-r-pmn-20170928monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-independent-director-anthony-j-giovinazzo-recognized-with-inaugural-b-pmn-20170921monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-successful-humanization-of-lead-product-candidate-pmn310-fo-pmn-20170919monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-designates-pmn330-as-third-validated-lead-product-for-development-in--pmn-20170913monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-completes-second-closing-of-private-placement-pmn-20170828monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-second-quarter-2017-results-pmn-20170811monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-completes-first-closing-of-private-placement-pmn-20170809monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-grant-of-fast-track-designation-by-fda-to-pas-004-for-trea-ktta-20260401monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-1-million-award-by-als-association-to-study-the-efficacy-s-ktta-20251125monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-to-present-at-the-h-c-wainwright-27th-annual-global-investment-confe-ktta-20250828monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-completes-enrollment-and-initial-dosing-of-first-cohort-from-its-pha-ktta-20250731monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-initiation-of-phase-1-1b-study-of-pas-004-in-adult-nf1-pat-ktta-20250514monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-closing-of-5-million-public-offering-ktta-20250507monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-reports-positive-pharmacodynamic-results-demonstrating-robust-target-ktta-20250506monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-completion-of-enrollment-and-initial-dosing-of-patients-in-ktta-20250429monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-to-present-updated-data-from-ongoing-phase-1-trial-of-pas-004-in-adv-ktta-20250424monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-positive-safety-review-committee-src-recommendation-from-i-ktta-20250410monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-to-present-at-the-2025-cagla-neauxcancer-conference-ktta-20250324monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-positive-safety-review-committee-src-recommendation-from-i-ktta-20250205monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-opening-of-european-clinical-trial-sites-and-completes-ini-ktta-20250114monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-positive-safety-review-committee-src-recommendation-from-i-ktta-20241120monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-successful-completion-of-pas-004-chronic-toxicity-studies-ktta-20240909monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-appointment-of-dr-rebecca-brown-to-its-scientific-advisory-ktta-20240903monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-to-present-at-the-h-c-wainwright-26th-annual-global-investment-confe-ktta-20240828monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-completion-of-enrollment-and-initial-dosing-of-cohort-2-fo-ktta-20240613monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-to-present-new-preclinical-data-showing-pas-004-strongly-inhibits-nr-ktta-20240528monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-pas-004-abstract-accepted-for-poster-presentation-at-2024--ktta-20240429monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-the-first-cohort-has-completed-the-initial-dosing-in-its-p-ktta-20240424monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-opening-of-enrollment-in-the-u-s-for-its-phase-1-trial-of--ktta-20240213monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-invention-of-crystalline-form-of-pas-004-establishes-stren-ktta-20240108monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-fda-acceptance-of-ind-application-to-evaluate-pas-004-in-a-ktta-20240102monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-adjournment-of-reconvened-meeting-of-stockholders-to-decem-ktta-20231228monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-results-from-2023-annual-meeting-ktta-20231219monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-positive-in-vivo-preclinical-efficacy-data-for-pas-004-fro-ktta-20231211monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-adjournment-of-2023-annual-meeting-of-stockholders-ktta-20231129monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-outcome-of-pre-ind-meeting-with-fda-for-pas-004-clinical-d-ktta-20231129monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-to-participate-in-h-c-wainwright-25th-annual-global-investment-confe-ktta-20230907monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-special-committee-rejects-unsolicited-bid-from-lucy-scientific-disco-ktta-20230720monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-confirms-previous-creation-of-independent-special-committee-of-its-b-ktta-20230630monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-completion-of-gmp-manufacturing-for-pas-004-ktta-20230629monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-confirms-receipt-of-unsolicited-proposal-from-lucy-scientific-discov-ktta-20230606monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-abstract-accepted-for-poster-presentation-at-2023-neurofibromatosis--ktta-20230601monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-to-participate-in-ef-hutton-inaugural-global-conference-ktta-20230503monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-chairman-prof-lawrence-steinman-to-deliver-keynote-address-at-the-am-ktta-20230302monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-chairman-prof-lawrence-steinman-to-deliver-dr-kenneth-p-johnson-lect-ktta-20230223monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-chairman-prof-lawrence-steinman-to-receive-pioneer-in-medicine-award-ktta-20230216monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-signs-cmc-development-and-manufacturing-agreement-for-the-production-ktta-20230118monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-to-present-at-annual-meeting-of-the-antibody-society-conference-ktta-20221206monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-postpones-special-meeting-until-december-9-2022-at-9-00-am-eastern-t-ktta-20221129monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-to-present-tolerizing-vaccine-program-results-at-immunotherapy-2022--ktta-20221017monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-to-call-special-meeting-of-stockholders-ktta-20221003monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-appoints-life-sciences-and-health-care-executive-alfred-j-novak-to-i-ktta-20220920monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-further-strengthens-its-scientific-advisory-board-with-the-appointme-ktta-20220915monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-to-present-at-the-h-c-wainwright-24th-annual-global-investment-confe-ktta-20220909monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-to-present-results-of-tolerizing-vaccine-program-at-prestigious-inte-ktta-20220818monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-results-of-preclinical-study-demonstrating-tolerizing-vacc-ktta-20220811monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-urges-stockholders-to-reject-activist-camac-group-s-unjustified-camp-ktta-20220802monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-awarded-a-drug-development-research-grant-ktta-20220714monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-to-participate-in-the-h-c-wainwright-1st-annual-mental-health-confer-ktta-20220623monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-acquires-alpha-5-integrin-llc-ktta-20220622monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-to-present-at-the-noblecon18-investor-conference-2022-ktta-20220414monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-financial-and-business-results-for-the-fourth-quarter-and--ktta-20220330monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-collaboration-with-the-glimpse-group-ktta-20220308monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-plans-to-open-three-new-clinics-in-the-uk-by-mid-2022-ktta-20220224monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-strengthens-its-scientific-advisory-board-with-the-appointment-of-pr-ktta-20220209monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-initiates-new-chemical-entity-drug-development-program-in-multiple-s-ktta-20220203monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-opening-of-mental-health-clinic-in-los-angeles-and-broaden-ktta-20220126monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-opens-second-ketamine-therapy-clinic-in-the-united-kingdom-ktta-20211221monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-expands-its-mobile-clinics-into-florida-and-nevada-ktta-20211201monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-corp-announces-closing-of-30-4-million-private-placement-priced-at-a-ktta-20211129monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-adds-esketamine-nasal-spray-to-its-clinic-offerings-in-the-u-k-ktta-20211123monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-launches-in-home-intravenous-ketamine-therapy-in-major-u-s-cities-ex-ktta-20211117monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-collaborates-with-renowned-musician-and-producer-to-create-soundtrac-ktta-20211111monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-corp-establishes-scientific-advisory-board-and-names-dr-charles-b-ne-ktta-20211109monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-successful-treatment-of-first-patients-in-the-uk-with-keta-ktta-20211027monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-opens-its-first-ketamine-therapy-clinic-in-the-united-kingdom-ktta-20211014monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-corp-and-evotec-se-enter-into-drug-development-agreement-ktta-20211011monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-corp-to-present-at-the-benzinga-healthcare-small-cap-conference-ktta-20210929monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-corp-announces-closing-of-24-0-million-initial-public-offering-ktta-20210917monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-corp-announces-pricing-of-upsized-24-0-million-initial-public-offeri-ktta-20210915monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-presents-positive-clinical-data-at-asco-2026-bctx-20260601monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-bctx-20260526monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-positive-clinical-data-for-bria-imt-and-preclinical-data-for-next-gene-bctx-20260318monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-four-poster-presentations-at-the-2026-aacr-annual-meeting-bctx-20260310monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-announces-results-of-shareholder-meeting-bctx-20260305monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-presents-outstanding-phase-2-survival-promising-phase-3-clinical-data-at-sabcs-20-bctx-20251210monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-s-phase-3-patient-enrollment-on-track-for-1h2026-topline-data-readout-bctx-20251209monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025-bctx-20251125monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-selected-to-present-phase-2-3-clinical-data-at-sabcs-2025-bctx-20251118monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-positive-clinical-biomarker-data-of-phase-3-study-at-esmo-2025-bctx-20251013monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-selected-for-msk-s-2025-therapeutics-accelerator-program-for-bria-ots-for-cancer-bctx-20250813monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-proposed-effective-date-of-share-consolidation-bctx-20250806monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-adds-ucla-health-as-key-site-in-pivotal-phase-3-breast-cancer-study-bctx-20250731monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-awarded-new-zealand-patent-for-its-whole-cell-technology-bctx-20250730monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-s-subsidiary-briapro-files-patent-application-for-immuno-oncology-platform-with-n-bctx-20250729monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-two-clinical-data-poster-presentations-at-esmo-2025-bctx-20250725monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-closing-of-15-million-public-offering-bctx-20250716monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-adds-mayo-clinic-to-phase-3-study-in-metastatic-breast-cancer-bctx-20250715monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-s-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-met-bctx-20250711monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-reports-complete-and-sustained-resolution-of-brain-metastasis-and-sustained-regre-bctx-20250710monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-met-bctx-20250709monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-phase-2-survival-achievement-52-of-patients-surpass-one-year-milestone-in-metasta-bctx-20250708monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-bctx-20250702monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-positive-recommendation-from-data-safety-monitoring-board-for-pivotal-p-bctx-20250624monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-virtual-investor-presentations-on-thursday-june-12-and-thursday-june-26-bctx-20250604monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-reports-robust-overall-survival-and-clinical-benefit-data-at-asco-2025-bctx-20250602monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-bria-ots-phase-1-2-study-clears-safety-evaluation-doses-first-patient-in-combinat-bctx-20250527monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-abstracts-showcase-positive-survival-and-clinical-benefit-data-at-asco-2025-bctx-20250523monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-ceo-letter-to-shareholders-bctx-20250520monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-reports-late-breaker-phase-3-data-at-aacr-2025-positive-tolerability-profile-and--bctx-20250430monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-closing-of-13-8-million-public-offering-bctx-20250428monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-presents-benchmark-beating-survival-and-clinical-benefit-at-aacr-2025-advancement-bctx-20250428monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-confirms-100-resolution-of-lung-metastasis-with-bria-ots-bctx-20250424monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-four-clinical-data-presentations-at-asco-2025-bctx-20250423monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-bre-bctx-20250422monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer-bctx-20250416monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-s-subsidiary-briapro-develops-novel-antibodies-to-anti-cancer-target-b7-h3-bctx-20250410monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference-bctx-20250326monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-announces-results-of-shareholder-meeting-bctx-20250205monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-closing-of-public-offering-bctx-20250205monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-pricing-of-public-offering-bctx-20250204monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots-bctx-20250203monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-availability-of-annual-general-meeting-materials-and-alternative-voting-bctx-20241217monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-closing-of-5-5-million-public-offering-bctx-20241213monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-2024-sabcs-poster-highlights-ability-of-bria-imt-regimen-to-increase-cancer-fight-bctx-20241213monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-pricing-of-5-5-million-public-offering-bctx-20241212monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-presents-unprecedented-overall-survival-data-in-metastatic-breast-cancer-in-spotl-bctx-20241211monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-receives-green-light-from-data-safety-monitoring-board-for-its-phase-3-study-in-m-bctx-20241202monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-2024-sabcs-spotlight-poster-to-showcase-positive-overall-survival-data-across-all-bctx-20241126monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-provides-update-to-its-board-of-directors-bctx-20241125monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-first-patient-dosed-with-bria-ots-in-metastatic-breast-cancer-study-bctx-20241121monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-showcases-robust-anti-cancer-activity-of-personalized-off-the-shelf-immunotherapy-bctx-20241108monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-overall-survival-data-selected-for-spotlight-poster-at-2024-san-antonio-breast-ca-bctx-20241104monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-reports-outperforming-metastatic-breast-cancer-patients-and-standard-beating-surv-bctx-20241022monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-provides-phase-3-clinical-engagement-update-in-metastatic-breast-cancer-pivotal-s-bctx-20241015monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-closing-of-5-million-offering-bctx-20241002monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-fda-authorized-expanded-access-policy-for-metastatic-breast-cancer-pati-bctx-20240918monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-closing-of-8-5-million-offering-bctx-20240912monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-reports-positive-overall-survival-os-in-metastatic-breast-cancer-bctx-20240911monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-positive-pre-ind-meeting-with-fda-for-bria-pros-for-prostate-cancer-bctx-20240910monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-presents-clinical-efficacy-data-at-asco-2024-bctx-20240603monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-initiates-patient-enrollment-in-first-in-human-study-of-bria-ots-in-advanced-meta-bctx-20240530monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-clinical-supply-agreement-with-beigene-for-bria-ots-first-in-human-stud-bctx-20240528monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-doubles-progression-free-survival-pfs-and-reports-clinical-benefit-data-at-asco-2-bctx-20240524monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-closing-of-5-0-million-registered-direct-offering-bctx-20240517monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-oral-and-poster-presentations-at-asco-2024-bctx-20240424monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-2024-aacr-preclinical-poster-confirms-strong-anti-cancer-activity-of-bria-ots-and-bctx-20240410monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-showcases-data-demonstrating-unmatched-progression-free-survival-pfs-and-clinical-bctx-20240409monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-receives-and-executes-letter-of-intent-to-advance-clinical-development-of-breast--bctx-20240307monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-clinical-data-in-central-nervous-system-cns-metastasis-and-antibody-dr-bctx-20240306monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-provides-update-on-alleged-illegal-trading-of-public-securities-bctx-20240227monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-strong-clinical-data-in-breast-cancer-patients-reports-another-notable--bctx-20240207monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-announces-results-of-shareholder-meeting-bctx-20240131monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-images-confirm-robust-anti-tumor-activity-in-patient-with-eye-bulging-metastatic--bctx-20240104monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-reports-71-central-nervous-system-response-rate-in-advanced-breast-cancer-patient-bctx-20231228monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-highlights-outstanding-topline-survival-and-clinical-benefit-data-in-advanced-met-bctx-20231206monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-2023-sabcs-posters-confirm-activation-of-cancer-fighting-immune-cells-and-identif-bctx-20231206monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-forms-medical-advisory-board-of-distinguished-breast-cancer-specialists-to-advanc-bctx-20231025monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-presentations-at-the-2023-society-for-the-immunotherapy-of-cancer-sitc--bctx-20231018monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-host-virtual-key-opinion-leader-event-on-bria-imt-potential-in-advanced-metast-bctx-20231011monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-partners-with-new-york-cancer-blood-specialists-nycbs-for-pivotal-phase-3-study-o-bctx-20231004monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-initiates-pivotal-phase-3-study-of-bria-imt-in-advanced-metastatic-breast-cancer-bctx-20231003monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-accepts-letter-of-intent-from-weill-cornell-medicine-outlining-plans-to-initiate--bctx-20230831monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-announces-voting-results-from-special-meeting-bctx-20230818monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-awarded-national-cancer-institute-grant-to-advance-its-bria-ots-immunotherapy-for-bctx-20230816monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-clinical-and-survival-data-in-advanced-metastatic-breast-cancer-at-the-bctx-20230315monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-ceo-letter-to-shareholders-bctx-20230124monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-ceo-discusses-positive-clinical-results-of-its-breast-cancer-immunotherapy-treatm-bctx-20221115monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-new-clinical-trial-site-to-bring-novel-cancer-treatments-to-advanced-br-bctx-20221012monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-dece-bctx-20220928monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-presentation-at-the-2022-society-for-immunotherapy-of-cancer-sitc-annua-bctx-20220907monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-ceo-emphasizes-recent-key-developments-in-audio-interview-with-small-bctx-20210923monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-at-the-benzinga-healthcare-small-cap-conference-september-29-30-bctx-20210916monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-host-corporate-and-clinical-update-conference-call-wednesday-june-16-2021-at-4-bctx-20210609monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-ceo-gives-corporate-overview-plans-for-future-in-audio-interview-with-smallcapvoi-bctx-20210421monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-presents-clinical-data-at-the-american-association-for-cancer-resear-bctx-20210412monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-closing-of-us-25-million-public-offering-bctx-20210226monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-presents-clinical-data-at-2021-keystone-symposium-bctx-20210126monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-presentation-at-the-2021-keystone-symposia-conference-emerging-cell-the-bctx-20210112monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-presents-clinical-data-at-the-2020-san-antonio-breast-cancer-symposium-bctx-20201209monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-appoints-martin-schmieg-to-board-of-directors-bctx-20201201monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-closes-debt-financing-bctx-20201117monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-collaboration-with-the-national-cancer-institute-bctx-20201110monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-breast-cancer-survival-data-13-3-months-versus-7-2-9-8-months-bctx-20201021monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-clinical-findings-at-the-2020-san-antonio-breast-cancer-symposium-dece-bctx-20201006monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-at-the-3rd-annual-biologics-world-nordic-2020-bctx-20200915monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-awarded-research-grant-from-wiseman-cancer-research-foundation-bctx-20200904monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-announces-completion-of-shares-for-debt-issuance-bctx-20200818monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-presents-clinical-and-scientific-findings-at-the-annual-symposium-of-society-of-s-bctx-20200817monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-announces-shares-for-debt-issuance-bctx-20200811monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-files-provisional-patent-application-for-novel-treatment-and-diagnosis-of-coronav-bctx-20200624monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-presentation-of-clinical-and-scientific-findings-at-aacr-annual-meeting-bctx-20200622monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-ceo-to-present-at-3rd-annual-next-gen-immuno-oncology-congress-in-june-bctx-20200609monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-presents-clinical-findings-at-2020-american-society-of-clinical-oncology-asco-mee-bctx-20200529monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-files-patent-application-for-novel-immune-therapies-for-multiple-disease-indicati-bctx-20200520monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-presentation-and-abstract-publication-at-2020-american-society-of-clini-bctx-20200514monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-continues-business-and-clinical-operations-during-covid-19-pandemic-bctx-20200512monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-files-patent-application-for-novel-therapeutics-for-cancer-bctx-20200427monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-files-new-provisional-patent-application-for-antibody-based-treatment-of-infectio-bctx-20200421monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-files-coronavirus-immunotherapy-patent-bctx-20200414monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-clinical-data-at-2020-american-society-of-clinical-oncology-asco-annua-bctx-20200331monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-continues-clinical-operations-amidst-covid-19-pandemic-bctx-20200326monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-clinical-and-immune-activity-at-aacr-annual-meeting-bctx-20200226monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-proposed-public-offering-in-the-united-states-and-listing-on-nasdaq-bctx-20200221monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-grant-to-investigator-dr-saveri-bhattacharya-at-sidney-kimmel-cancer-ce-bctx-20200211monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-s-clinical-data-accepted-to-be-presented-at-the-annual-symposium-of-society-of-su-bctx-20200128monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-invited-to-present-at-mount-sinai-s-frontiers-in-academic-pathology-symposium-at--bctx-20200122monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-provides-update-on-remarkable-responder-bctx-20200113monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-outlines-new-high-responding-patient-group-biomarker-based-on-cancer-grade-bctx-20200109monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-completes-share-consolidation-bctx-20200102monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-announces-share-consolidation-bctx-20191224monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-at-biotech-showcase-2020-in-san-francisco-bctx-20191217monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-clinical-data-as-presented-at-the-2019-san-antonio-breast-cancer-sympos-bctx-20191213monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-clinical-findings-at-the-2019-san-antonio-breast-cancer-symposium-dece-bctx-20191112monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-voting-results-of-the-special-meeting-of-shareholders-bctx-20191024monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-closing-of-non-brokered-private-placement-of-568-444-bctx-20191015monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-to-file-amendment-to-management-information-circular-bctx-20191008monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-doses-first-patient-in-phase-i-iia-study-evaluating-bria-imt-in-combination-with--bctx-20191007monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-to-clarify-record-date-bctx-20191001monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-appoints-immunology-expert-dr-cara-l-haymaker-to-scientific-advisory-board-briace-bctx-20190925monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-private-placement-of-up-to-600-000-bctx-20190920monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-public-disclosure-remarkable-responder-in-combination-study-of-lead-can-bctx-20190919monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-september-19th-at-2nd-annual-next-gen-immuno-oncology-congress-in-phil-bctx-20190916monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-closing-of-upsized-non-brokered-private-placement-of-846-301-49-bctx-20190909monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-participation-at-the-21st-annual-global-investment-conference-in-new-yo-bctx-20190827monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-appoints-richard-j-berman-to-board-of-directors-bctx-20190812monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-350-000-equity-investment-by-board-of-directors-bctx-20190723monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-s-novel-technology-and-clinical-data-published-at-the-2019-american-society-of-cl-bctx-20190528monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-approves-new-board-of-directors-and-chairman-at-annual-and-special-meeting-of-sha-bctx-20190513monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-publication-at-american-society-of-clinical-oncology-asco-meeting-and-p-bctx-20190423monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-s-lead-candidate-combined-with-keytruda-strong-evidence-of-rapid-additive-or-syne-bctx-20190403monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-clinical-trial-collaboration-agreement-with-incyte-bctx-20190402monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-closing-of-upsized-oversubscribed-non-brokered-private-placement-of-2-9-bctx-20190401monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-announce-early-efficacy-data-of-lead-candidate-in-combination-with-keytruda-at-bctx-20190326monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-closes-first-tranche-of-previously-announced-non-brokered-private-placement-bctx-20190325monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-2-000-000-non-brokered-private-placement-offering-bctx-20190320monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-welcomes-biopharma-industry-experts-to-its-board-of-directors-bctx-20190318monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-highlights-recent-clinical-and-scientific-achievements-in-exclu-bctx-20190307monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-c-500-000-equity-investment-by-briacell-director-bctx-20190226monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-clinical-and-scientific-findings-with-new-insights-at-key-oncology-con-bctx-20190219monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-appoints-jamieson-bondarenko-to-its-board-of-directors-bctx-20190212monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-switch-to-novel-frozen-formulation-for-lead-cancer-drug-candidate-upcom-bctx-20190102monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-presents-positive-efficacy-data-with-lead-cancer-drug-candidate-in-phase-iia-mono-bctx-20181206monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-updated-clinical-data-including-early-safety-data-in-keytruda-combinat-bctx-20181119monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-s-ceo-talks-personalized-breast-cancer-treatment-technology-wit-bctx-20181106monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-initiates-dosing-in-phase-i-iia-combination-study-with-keytruda-or-yervoy-bctx-20181009monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-positive-phase-iia-proof-of-concept-data-in-advanced-breast-cancer-init-bctx-20180926monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-discusses-its-plan-to-revolutionize-cancer-immunotherapy-in-exc-bctx-20180925monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-adds-new-clinical-site-to-phase-iia-study-in-advanced-breast-cancer-and-expands-r-bctx-20180808monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-hold-conference-call-on-key-clinical-findings-activities-bctx-20180621monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-publishes-clinical-findings-in-2018-american-society-of-clinical-oncology-asco-me-bctx-20180529monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-s-lead-product-candidate-s-novel-mechanism-of-action-published-in-a-reputable-imm-bctx-20180521monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-activates-a-clinical-site-in-florida-for-phase-iia-study-of-its-lead-candidate-in-bctx-20180423monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-provides-highlights-of-scientific-and-clinical-findings-at-aacr-bctx-20180418monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-encouraging-clinical-data-at-aacr-2018-bctx-20180410monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-s-lead-product-candidate-mechanism-of-action-described-in-a-major-immunology-jour-bctx-20180403monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-completes-previously-announced-oversubscribed-non-brokered-private-placement-and--bctx-20180327monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-appoints-top-social-media-marketing-analyst-bctx-20180314monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-proposed-investment-by-leading-biotech-funds-and-concurrent-non-brokere-bctx-20180308monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-at-precision-breast-cancer-conference-bctx-20180301monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-attend-20th-annual-bio-ceo-investor-conference-bctx-20180207monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-opens-fourth-clinical-site-in-advanced-breast-cancer-bctx-20180206monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-presenting-at-upcoming-cancer-conference-bctx-20180205monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-update-early-evidence-of-efficacy-and-safety-of-bria-imt-bctx-20180131monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-provides-clinical-update-on-its-lead-immunotherapy-drug-in-advanced-breast-cancer-bctx-20180103monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-attend-biotech-showcase-2018-bctx-20180102monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-closing-of-warrant-incentive-program-bctx-20171221monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-advancement-of-its-small-molecule-program-and-patent-allowance-bctx-20171113monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-provides-clinical-update-on-its-lead-vaccine-candidate-briavax-bctx-20171106monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-warrant-incentive-program-bctx-20171013monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-repricing-of-warrants-bctx-20171003monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-adds-third-clinical-site-led-by-top-physician-scientist-dr-lukas-to-expand-phase--bctx-20170925monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-provides-research-update-bctx-20170914monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-provides-a-corporate-update-bctx-20170912monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-additional-capital-support-by-the-ceo-bctx-20170802monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-appoints-top-oncologist-and-opens-second-clinical-site-for-its-ongoing-clinical-t-bctx-20170731monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-expands-targeted-pipeline-via-acquisition-of-sapientia-pharmaceuticals-bctx-20170724monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-provides-clinical-update-on-its-ongoing-phase-i-iia-clinical-study-of-briavax-tm--bctx-20170719monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-completes-manufacturing-of-new-batch-of-briavax-tm-bctx-20170705monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-doses-second-patient-in-phase-i-iia-clinical-study-of-briavax-tm-in-advanced-brea-bctx-20170601monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-launches-its-scientific-advisory-board-bctx-20170531monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-first-patient-dosed-in-phase-i-iia-clinical-study-of-briavax-tm-in-adva-bctx-20170508monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-closes-ceo-equity-investment-bctx-20170324monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-receives-fda-clearance-to-initiate-phase-i-iia-clinical-trial-of-briavax-tm-in-pa-bctx-20170315monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-files-new-patent-application-for-its-whole-cell-breast-cancer-vaccine-and-compani-bctx-20170307monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-ceo-equity-investment-advances-company-s-lead-cancer-product-and-pipeline-expansi-bctx-20170227monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-moves-forward-to-initiate-phase-i-iia-clinical-study-for-briavax-tm-in-advanced-b-bctx-20170206monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-included-in-the-list-of-key-players-in-immuno-oncology-bctx-20170105monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-at-a-breast-cancer-symposium-and-enters-into-a-research-agreement-with-bctx-20161205monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-files-a-patent-application-for-its-companion-diagnostic-platform-to-complement-br-bctx-20161129monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-provides-clinical-development-update-on-briavax-tm-bctx-20161110monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-the-appointment-of-biotechnology-veteran-william-williams-as-new-ceo-an-bctx-20161026monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-appoints-new-york-based-rk-equity-advisors-and-truenorth-lifesciences-as-corporat-bctx-20160915monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-appoints-the-lead-principal-investigator-and-first-clinical-site-for-its-upcoming-bctx-20160817monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-appoints-contract-research-organization-cancer-insight-to-manage-its-upcoming-pha-bctx-20160518monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-adds-u-s-biotech-veteran-to-its-board-of-directors-bctx-20160510monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-completes-previously-announced-investment-with-leading-u-s-biotech-fund-and-non-b-bctx-20160503monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-files-a-patent-application-to-protect-additional-cancer-vaccines-with-genetic-fea-bctx-20160412monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-targeting-launch-of-its-phase-i-ii-clinical-trial-during-current-quarter-bctx-20160405monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-discovers-gene-signature-of-briavax-tm-cancer-vaccine-consistent-with-exceptional-bctx-20160329monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-receives-fda-authorization-to-initiate-phase-i-iia-trial-of-cell-based-immunother-bctx-20151104monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-to-present-at-14th-annual-bio-investor-forum-in-san-francisco-bctx-20151019monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-successfully-advances-towards-initiation-of-briavax-tm-phase-i-iia-c-bctx-20151008monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-launches-development-of-companion-diagnostic-product-briadx-tm-bctx-20150914monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-begins-trading-on-the-otcqb-anccf-and-presents-at-a-new-york-biotech-bctx-20150624monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-positive-response-from-fda-and-entry-into-a-definitive-agr-bctx-20150616monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-new-president-ceo-and-chairman-of-the-board-bctx-20150601monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-partner-with-top-u-s-medical-institution-washington-university-to-produce-its--bctx-20150527monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-successfully-completes-testing-requested-by-fda-bctx-20150519monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-submits-phase-i-ii-protocol-to-the-us-fda-bctx-20150310monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-to-present-at-the-2015-bio-ceo-and-investor-conference-bctx-20150204monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-top-us-oncologist-to-lead-its-clinical-trial-bctx-20150107monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-closing-of-go-public-onto-toronto-stock-exchange-venture-c-bctx-20141203monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-oversubscribed-financing-up-to-140-million-clrb-20260505monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-subset-of-clover-wam-clinical-trial-data-accepted-for-pres-clrb-20260421monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-enrolls-first-patient-in-clr-125-auger-emitting-radioconjugate-phase-1b-clinical-clrb-20260414monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-strategic-supply-agreement-with-ionetix-for-actinium-225-a-clrb-20251216monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-report-third-quarter-financial-results-and-host-a-conference-call-clrb-20251106monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-participate-in-multiple-upcoming-medical-meetings-and-industry-co-clrb-20250905monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-data-in-poster-presentation-at-the-american-association-f-clrb-20250903monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-data-in-oral-session-and-panel-discussions-at-the-america-clrb-20250827monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-report-second-quarter-financial-results-and-host-a-conference-cal-clrb-20250807monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-closing-of-6-9-million-underwritten-public-offering-includ-clrb-20250702monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-pricing-of-6-million-underwritten-public-offering-clrb-20250701monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-and-u-s-based-nusano-enter-into-multi-isotope-supply-agreement-clrb-20250626monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-submits-phase-1b-clinical-trial-protocol-to-us-food-and-drug-adminis-clrb-20250624monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-provides-update-on-clover-2-phase-1-clinical-trial-of-iopofosine-i-1-clrb-20250611monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-granted-u-s-fda-breakthrough-therapy-designation-for-iopofosine-i-131-in-waldens-clrb-20250604monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-report-first-quarter-financial-results-and-host-a-conference-call-clrb-20250507monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-37th-annual-roth-conference-clrb-20250311monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-report-full-year-financial-results-and-host-a-conference-call-on--clrb-20250305monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-c-clrb-20250205monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-provides-strategic-update-on-clinical-development-pipeline-programs--clrb-20241210monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-and-northstar-medical-radioisotopes-announce-partnership-for-supply--clrb-20241114monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-and-spectronrx-partner-to-manufacture-novel-phospholipid-radioconjug-clrb-20241112monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-report-third-quarter-financial-results-and-host-a-conference-call-clrb-20241111monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-selected-to-present-new-data-from-phase-2-clover-wam-study-in-oral-session-at-as-clrb-20241107monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-announce-first-quarter-financial-results-and-host-a-conference-ca-clrb-20240808monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-key-opinion-leader-event-to-review-the-full-results-from-its-clrb-20240627monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-and-city-of-hope-cancer-center-enter-collaboration-to-evaluate-iopof-clrb-20240529monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-guggenheim-healthcare-talks-radiopharmaceuticals-d-clrb-20240508monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-announce-first-quarter-financial-results-and-host-a-conference-ca-clrb-20240507monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-announce-2023-year-end-earnings-results-and-host-a-conference-cal-clrb-20240320monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-36th-annual-roth-conference-clrb-20240314monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-high-rate-of-complete-remission-in-investigator-initiated-ph-clrb-20240304monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences-c-clrb-20240207monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-enrollment-of-the-first-patient-in-pediatric-high-grade-gl-clrb-20240130monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-tranche-a-warrants-fully-exercised-providing-proceeds-of-4-clrb-20240125monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-complete-central-nervous-system-cns-clearance-in-relapsed-re-clrb-20240122monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-broadens-pipeline-with-targeted-alpha-therapy-tat-for-solid-tumors-a-clrb-20240116monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-with-texas-oncology-hematologist-m-yair-levy-clrb-20240112monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-partners-with-miba-a-data-subsidiary-of-american-oncology-network-to-clrb-20240111monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-announce-top-line-data-from-wm-pivotal-trial-on-january-8-2024-clrb-20240103monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-expands-iopofosine-i-131-collaboration-with-wisconsin-alumni-researc-clrb-20231219monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-strengthens-intellectual-property-protection-for-its-pdc-platform-clrb-20231212monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-targeted-radiopharmaceuticals-summit-europe-clrb-20231205monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-partners-with-florida-cancer-specialists-research-institute-to-suppo-clrb-20231025monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-announce-third-quarter-earnings-results-and-host-a-conference-cal-clrb-20231024monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-expands-commercialization-leadership-team-ahead-of-pivotal-data-for--clrb-20231017monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-expands-global-intellectual-property-portfolio-with-four-patent-gran-clrb-20231002monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-receives-european-medicines-agency-priority-medicines-prime-designat-clrb-20230918monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-closing-of-up-to-approximately-103-million-private-placeme-clrb-20230911monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-up-to-approximately-103-million-private-placement-financin-clrb-20230905monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-highlights-promising-interim-data-from-its-ongoing-study-of-iopofosi-clrb-20230628monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-to-participate-at-upcoming-banking-conferences-clrb-20230308monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-complete-response-in-a-relapsed-refractory-cns-lymphoma-pati-clrb-20230228monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-hires-dr-andrei-shustov-as-new-senior-vice-president-medical-clrb-20230215monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-shane-lea-as-chief-commercial-officer-clrb-20221130monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-presentation-of-data-on-clr-12120-series-of-targeted-alpha-clrb-20221121monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-resolution-of-breach-of-contract-and-intellectual-property-dispute-clrb-20221116monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-closing-of-concurrent-registered-direct-and-private-placem-clrb-20221025monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-concurrent-registered-direct-and-private-placement-offerin-clrb-20221021monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-stock-consolidation-clrb-20220721monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-key-commercial-team-appointments-clrb-20220412monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-to-participate-at-upcoming-banking-conferences-clrb-20220310monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-executive-leadership-changes-clrb-20220223monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-to-participate-in-fireside-chat-at-the-h-c-wainwright-bioconnect-conference-clrb-20220104monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-presented-data-from-its-ongoing-phase-2-clover-1-study-of-iopofosine-i-131-at-th-clrb-20211213monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-poster-presentation-at-the-63rd-american-society-for-hemat-clrb-20211208monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-to-present-at-bio-ceo-investor-digital-conference-clrb-20210210monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-closing-of-24-5-million-underwritten-public-offering-and-2-clrb-20201228monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-proposed-underwritten-public-offering-and-concurrent-priva-clrb-20201222monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-two-upcoming-investor-conferences-clrb-20200910monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-appoints-dr-igor-grachev-as-chief-medical-officer-clrb-20200107monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-data-from-20-patients-receiving-a-single-25mci-m2-bolus-dose-of-clr-13-clrb-20191216monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-oral-presentation-at-the-61st-annual-american-society-of-hematology-co-clrb-20191202monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-ladenburg-thalmann-2019-healthcare-conference-clrb-20190919monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-annual-bio-ceo-investor-conference-clrb-20190205monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-nobleconxv-noble-capital-markets-fifteenth-annual-inve-clrb-20190123monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-biotech-showcase-clrb-20190103monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-granted-japanese-patent-for-clr-131-clrb-20181211monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-ladenburg-thalmann-2018-healthcare-conference-clrb-20180927monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-20th-annual-rodman-renshaw-global-investment-confe-clrb-20180829monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-1-for-10-reverse-stock-split-clrb-20180713monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-granted-seminal-u-s-patent-for-phospholipid-ether-analogs-as-cancer-targeting-dr-clrb-20180327monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-2017-financial-results-and-business-update-conference-call-o-clrb-20180319monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-10th-annual-ld-micro-main-event-clrb-20171120monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-on-november-10-2017-to-report-third-quarter--clrb-20171102monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-successful-completion-of-7-76-million-registered-direct-of-clrb-20171012monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-cohort-four-data-and-partial-response-in-relapsed-or-refract-clrb-20170927monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-19th-annual-rodman-and-renshaw-global-investment-c-clrb-20170906monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-on-august-14-2017-to-report-second-quarter-2-clrb-20170803monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-on-may-11-2017-to-report-first-quarter-2017--clrb-20170502monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-s-radiotherapeutic-pdcs-demonstrate-an-increased-survival-benefit-using-multiple-clrb-20170427monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-strengthens-management-team-with-appointment-of-john-friend-m-d-as-c-clrb-20170412monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-29th-annual-roth-conference-clrb-20170306monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-noblecon13-clrb-20170126monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-9th-annual-biotech-showcase-clrb-20170105monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-presents-poster-at-the-58th-annual-meeting-of-the-american-society-o-clrb-20161206monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-pricing-of-8-000-000-public-offering-clrb-20161123monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-bio-investor-forum-clrb-20161013monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-seethru-equity-and-dawson-james-investor-conferences-clrb-20161011monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-oktoberinvestfest-clrb-20160921monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-ladenburg-thalmann-2016-healthcare-conference-clrb-20160919monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-18th-annual-rodman-renshaw-global-investment-confe-clrb-20160906monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-on-august-15-to-report-second-quarter-2016-f-clrb-20160808monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-uspto-issues-patent-for-new-phospholipid-drug-conjugate-pd-clrb-20160525monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-5th-annual-seethru-equity-microcap-investor-confer-clrb-20160524monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-on-may-12-2016-to-report-first-quarter-2016--clrb-20160504monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-pricing-of-7-000-000-public-offering-clrb-20160415monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-receives-positive-nasdaq-listing-determination-clrb-20160407monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-28th-annual-roth-capital-conference-clrb-20160308monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-on-march-10-to-report-year-end-2015-financia-clrb-20160307monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-provide-update-on-phase-1-multiple-myeloma-study-clrb-20151209monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-chief-scientific-officer-receives-international-recognition-for-pion-clrb-20151120monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-converts-patent-application-for-phospholipid-ether-analogs-as-cancer-clrb-20151110monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-on-november-12th-to-discuss-third-quarter-fi-clrb-20151105monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-provides-phospholipid-drug-conjugate-pdc-platform-development-update-clrb-20151102monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-2015-bio-investor-forum-clrb-20151016monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-closes-on-3-3-million-financing-clrb-20151002monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-awarded-2-3m-national-cancer-institute-fast-track-sbir-grant-to-adva-clrb-20151001monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-ladenburg-thalmann-2015-healthcare-conference-clrb-20150925monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-rodman-renshaw-17th-annual-global-investment-confe-clrb-20150903monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-introduces-phospholipid-ether-drug-conjugate-pdc-platform-for-target-clrb-20150821monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-2nd-quarter-financial-results-clrb-20150812monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-on-august-12th-to-discuss-second-quarter-fin-clrb-20150807monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-first-quarter-2015-financial-results-and-provides-update-on--clrb-20150521monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-on-may-21st-to-discuss-first-quarter-2015-re-clrb-20150520monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reschedules-release-of-first-quarter-financials-and-quarterly-confer-clrb-20150511monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-on-may-12th-to-discuss-first-quarter-2015-re-clrb-20150505monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-27th-annual-roth-conference-clrb-20150304monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-17th-annual-bio-ceo-investor-conference-2015-clrb-20150206monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-on-november-11th-to-discuss-third-quarter-20-clrb-20141106monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-participation-in-two-upcoming-investor-conferences-in-sept-clrb-20140905monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-second-quarter-2014-financial-results-and-recent-highlights-clrb-20140820monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-on-august-20th-to-discuss-second-quarter-201-clrb-20140818monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-1-for-20-reverse-stock-split-and-reduction-in-authorized-s-clrb-20140613monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-presentations-at-2014-american-society-of-clinical-oncolog-clrb-20140530monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-first-quarter-2014-financial-results-and-recent-highlights-clrb-20140514monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-on-may-14th-to-discuss-first-quarter-2014-re-clrb-20140512monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-on-march-25th-to-discuss-full-year-2013-fina-clrb-20140319monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-secures-additional-investment-from-chairman-alejandro-weinstein-at-30-premium-to-mar-plur-20260326monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expan-plur-20260218monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-successfully-completes-first-phase-of-resbiomed-program-for-placenta-derived-collage-plur-20260122monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade--plur-20251222monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-appoints-alejandro-weinstein-as-chairman-of-the-board-to-lead-strategic-shift-and-un-plur-20251209monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-and-subsidiaries-earn-multiple-industry-honors-named-as-overall-bioagriculture-compa-plur-20251113monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-partners-with-miss-universe-skincare-introducing-exosome-enhanced-regenerative-skinc-plur-20251111monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-ceo-issues-shareholder-letter-highlighting-strategic-growth-innovation-and-global-ma-plur-20250515monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-congratulates-mesoblast-on-fda-approval-of-first-mesenchymal-stromal-cell-therapy-fo-plur-20241219monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-shortlisted-for-cdmo-of-the-year-award-by-advanced-therapies-awards-2025-plur-20241209monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-evaluates-readiness-for-mass-production-of-plx-r18-for-acute-radiation-syndrome-amid-plur-20241125monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-collaborates-with-bar-ilan-university-to-advance-cancer-immunotherapy-for-solid-tumo-plur-20241028monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-s-cdmo-selected-to-manufacture-kadimastem-s-novel-cell-therapy-product-candidates-plur-20240718monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-announces-1-million-proof-of-concept-agreement-to-enhance-global-sustainable-vegetab-plur-20240708monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-subsidiary-ever-after-foods-secured-10-million-strategic-investment-to-solve-cultiva-plur-20240618monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-s-business-verticals-gain-traction-in-global-markets-leadership-to-participate-and-p-plur-20240328monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-inc-announces-1-for-8-reverse-share-split-plur-20240327monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-s-sustainable-cell-based-coffee-addresses-critical-challenges-revealed-in-internatio-plur-20240321monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-selected-as-cdmo-by-remedy-cell-for-cell-derived-cell-free-drug-manufacturing-plur-20240314monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-receives-first-ever-patent-approval-for-3d-bioreactor-technology-in-plant-cell-culti-plur-20240311monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-inc-announces-appointment-of-jim-roosevelt-jr-to-its-advisory-board-plur-20240306monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-s-innovation-across-various-industries-ceo-updates-on-recent-achievements-2024-goals-plur-20240228monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-launches-advanced-global-cell-therapy-contract-development-and-manufacturing-organiz-plur-20240108monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-and-bar-ilan-university-to-develop-plx-cells-for-the-treatment-of-cocaine-addiction-plur-20231221monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-s-plx-r18-increases-blood-cell-counts-and-reduces-need-for-transfusions-in-a-phase-i-plur-20230816monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-announces-appointment-of-entrepreneur-lorne-abony-to-board-of-directors-plur-20230713monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-prices-8-2-million-private-placement-offerings-priced-at-the-market-under-nasdaq-rul-plur-20221215monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-wins-biotech-breakthrough-cell-innovation-of-the-year-award-plur-20221110monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-to-present-and-participate-in-upcoming-conferences-plur-20221031monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-inc-changes-its-name-to-pluri-inc-reflecting-the-company-s-strategy-plur-20220725monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-reports-topline-results-from-its-phase-iii-study-of-muscle-regeneration-followin-plur-20220713monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-and-tnuva-to-ring-nasdaq-closing-bell-in-honor-of-new-partnership-plur-20220328monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-releases-plx-r18-hematology-phase-i-study-results-data-show-increase-in-all-bloo-plur-20220323monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-and-tnuva-appoint-food-tech-veteran-eyal-rosenthal-as-chief-executive-officer-of-plur-20220308monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-ceo-issues-shareholder-update-plur-20220302monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announce-the-closing-of-its-collaboration-with-tnuva-group-to-establish-cultured-plur-20220224monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-completes-enrollment-of-its-multinational-phase-iii-study-of-muscle-regeneration-plur-20211115monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-receives-approval-for-grant-from-the-israel-innovation-authority-to-develop-its--plur-20211110monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-ceo-issues-shareholder-update-plur-20210922monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-appoints-prof-varda-shalev-md-and-mr-doron-birger-to-join-its-board-of-directors-plur-20210719monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-brings-ards-associated-with-covid-19-phase-ii-studies-to-clinical-readout-plur-20210708monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-receive-20m-non-dilutive-funding-from-the-european-investment-bank-plur-20210525monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-reports-positive-topline-phase-i-results-in-innovative-hematology-program-which--plur-20210429monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-inc-announces-30-million-registered-direct-offering-plur-20210202monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-uplisting-to-the-nasdaq-global-market-plur-20210127monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-appointments-of-two-directors-to-board-plur-20210106monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-enters-collaboration-with-pharmaceutical-company-innovare-r-d-to-expand-pluriste-plur-20201229monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-dmc-recommendation-following-interim-analysis-of-its-phase-iii-cli-stu-plur-20201209monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-initial-results-from-its-phase-i-hct-study-with-plx-r18-demonstrating-plur-20201118monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-clearance-to-move-forward-with-enrollment-for-cohort-ii-in-an-investig-plur-20201013monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-expands-its-phase-ii-covid-19-european-clinical-trial-to-israel-plur-20201007monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-ceo-issues-shareholder-update-plur-20200915monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-launches-fda-cleared-covid-19-expanded-access-program-enabling-patient-treatment-plur-20200827monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-end-of-patient-enrollment-in-its-phase-i-hematology-study-plur-20200819monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-and-abu-dhabi-stem-cells-center-sign-mou-to-collaborate-in-the-development-of-ce-plur-20200817monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-expands-its-covid-19-program-to-europe-receives-pei-clearance-to-commence-phase--plur-20200810monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-activation-of-clinical-sites-and-commencement-of-patient-enrollment-in-plur-20200611monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-joins-forces-with-crispr-il-national-consortium-to-advance-development-of-cuttin-plur-20200603monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-provides-28-day-follow-up-for-ventilator-dependent-covid-19-patients-under-compa-plur-20200514monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-pricing-of-its-registered-direct-offering-for-aggregate-proceeds-of-15-plur-20200505monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-recaps-investor-analyst-call-reviewing-european-investment-bank-s-50-million-fin-plur-20200430monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-secures-50-million-non-dilutive-financing-from-the-european-investment-bank-to-s-plur-20200424monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-expands-its-compassionate-use-program-treated-first-covid-19-patient-in-u-s-unde-plur-20200413monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-treated-first-three-covid-19-patients-in-israel-under-compassionate-use-plur-20200330monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-receives-response-from-u-s-barda-for-acute-radiation-syndrome-research-proposal-plur-20200303monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-ceo-issues-shareholder-update-plur-20200210monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-completes-75-enrollment-in-its-pivotal-phase-iii-cli-clinical-study-plur-20191217monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-reaches-milestone-in-its-phase-iii-muscle-injury-study-completes-50-enrollment-plur-20191203monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-ceo-issues-shareholder-update-plur-20191112monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-recaps-key-opinion-leader-call-reviewing-hematological-programs-plur-20190916monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-to-host-key-opinion-leader-call-on-its-acute-radiation-syndrome-and-plur-20190909monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-to-host-key-opinion-leader-call-on-its-acute-radiation-syndrome-and-plur-20190821monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-and-u-s-department-of-defense-present-positive-data-from-studies-testing-plx-r18-plur-20190731monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-ceo-issues-shareholders-update-plur-20190724monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-one-for-ten-reverse-split-of-its-common-shares-plur-20190724monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-and-u-s-department-of-defense-to-announce-data-from-studies-testing-plx-r18-as-a-plur-20190717monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-completes-transition-period-of-co-ceo-structure-yaky-yanay-appointed-as-chief-ex-plur-20190624monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-strengthens-its-manufacturing-competitive-advantage-presents-its-first-proprieta-plur-20190617monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-files-patent-application-for-the-use-of-its-advanced-manufacturing-technology-in-plur-20190506monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-completes-interim-enrollment-in-pivotal-cli-study-targeting-potential-conditiona-plur-20190429monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-issues-shareholder-update-plur-20190423monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-inc-announces-pricing-of-its-public-offering-and-registered-direct--plur-20190404monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-inc-announces-proposed-public-offering-of-common-stock-and-warrants-plur-20190403monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-announces-completion-of-2nd-cohort-and-dsmb-approval-to-enroll-fina-plur-20190312monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-enters-into-collaboration-with-nasa-to-study-plx-therapeutic-benefits-in-space-m-plur-20190220monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-collaborate-with-israeli-ministry-of-defense-in-the-treatment-of-burn-injurie-plur-20190122monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-reports-successful-case-study-in-treatment-of-buerger-s-disease-pat-plur-20190109monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-concludes-positive-meeting-with-fda-on-development-plan-for-acute-radiation-synd-plur-20190103monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-recaps-key-opinion-leader-meeting-on-peripheral-artery-disease-pad-plur-20181217monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-enters-into-cell-thawing-device-license-agreement-with-chart-indust-plur-20181204monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-presents-data-from-first-cohort-in-ongoing-phase-i-hematological-study-at-the-am-plur-20181203monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-first-cohort-data-from-plx-r18-hematological-study-at-american-societ-plur-20181128monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-reports-fiscal-2019-first-quarter-results-and-provides-corporate-up-plur-20181108monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-selected-to-present-data-from-phase-ii-ic-study-at-the-american-hea-plur-20181018monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-announces-publication-in-jcsm-of-two-year-follow-up-data-from-phase-plur-20181010monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-reports-fiscal-2018-fourth-quarter-results-and-provides-corporate-update-plur-20180927monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-announces-fda-orphan-drug-designation-for-plx-cell-therapy-for-the--plur-20180925monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-initiates-two-pivotal-phase-iii-studies-in-israel-plur-20180808monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-granted-key-patent-in-japan-for-treatment-of-gi-following-acute-radiation-exposu-plur-20180726monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-signs-collaboration-agreement-with-thermo-fisher-scientific-plur-20180709monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-and-fukushima-university-report-positive-data-plx-r18-increases-survival-rates-a-plur-20180625monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-open-weekly-market-trading-at-tase-following-positive-study-results-plur-20180614monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-reports-positive-top-line-results-from-its-multinational-phase-ii-intermittent-c-plur-20180612monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-announce-top-line-results-of-its-multinational-phase-ii-intermittent-claudica-plur-20180604monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-reports-third-quarter-fiscal-2018-corporate-and-financial-highlights-plur-20180510monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-and-indiana-university-to-initiate-joint-project-evaluating-plx-r18-in-acute-rad-plur-20180423monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-plx-r18-improves-hematopoietic-transplantation-as-reported-in-scientific-journ-plur-20180227monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-issues-letter-to-shareholders-plur-20180207monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-plx-cells-significantly-inhibit-cancer-cell-growth-in-newly-published-study-plur-20180112monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-granted-manufacturer-authorization-and-good-manufacturing-practice-gmp-certifica-plur-20171212monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-data-on-plx-r18-in-treatment-of-acute-radiation-syndrome-at-american--plur-20171207monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-granted-key-u-s-patent-for-skeletal-muscle-regeneration-a-meaningful-asset-ahead-plur-20171122monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-reports-first-quarter-fiscal-2018-corporate-and-financial-highlights-plur-20171114monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-enters-into-agreement-with-tel-aviv-sourasky-medical-center-to-conduct-phase-i-i-plur-20171106monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-pricing-of-public-offering-of-common-stock-on-the-tel-aviv-stock-excha-plur-20171030monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-proposes-to-launch-a-public-offering-of-common-stock-on-the-tel-aviv-stock-excha-plur-20171029monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-expands-its-reach-in-the-treatment-of-impaired-hematopoietic-systems-with-a-euro-plur-20171023monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-receives-positive-feedback-from-fda-and-ema-as-company-prepares-for-phase-iii-tr-plur-20170926monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-strengthens-its-position-in-asia-awarded-two-new-patents-in-hong-kong-for-critic-plur-20170913monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-reports-fourth-quarter-and-fiscal-2017-corporate-and-financial-highlights-plur-20170911monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-advances-its-multinational-phase-iii-critical-limb-ischemia-study-targeting-init-plur-20170710monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-new-data-from-ars-study-at-radiology-conference-in-u-s-plur-20170629monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-provides-shareholder-update-on-corporate-and-clinical-developments-plur-20170522monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-promising-results-from-non-human-primate-pilot-study-of-plx-r18-in-acu-plur-20170503monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-reaches-milestone-of-100-granted-patents-including-coverage-of-leading-indicatio-plur-20170419monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-and-sosei-cvc-advancing-towards-finalizing-joint-venture-for-the-commercializati-plur-20170330monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-launches-co-ceo-structure-and-appoints-new-cfo-plur-20170329monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-reports-second-quarter-fiscal-2017-highlights-provides-calendar-2017-outlook-plur-20170213monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-closing-of-bought-offering-and-underwriter-s-exercise-in-full-of-over--plur-20170125monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-increases-previously-announced-bought-deal-offering-of-common-stock-and-warrants-plur-20170120monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-bought-deal-offering-plur-20170119monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-receives-clearance-from-germany-to-initiate-its-multinational-phase-iii-trial-in-plur-20170117monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-completes-patient-enrollment-in-a-large-multinational-phase-ii-trial-in-intermit-plur-20170112monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-phase-iii-study-of-plx-pad-cells-for-the-treatment-of-critical-limb-ischemia-c-plur-20170110monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-and-new-york-blood-center-to-collaborate-in-evaluating-plx-r18-as-an-adjuvant-th-plur-20161227monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-and-innovative-medical-management-co-ltd-mutually-agree-to-extend-the-time-to-ex-plur-20161223monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-and-sosei-cvc-to-establish-a-new-corporation-for-the-commercialization-of-plx-pa-plur-20161221monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-plx-r18-advances-into-second-cohort-of-dose-selection-study-for-treatment-of-a-plur-20161206monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-reports-first-quarter-fiscal-2017-corporate-and-financial-highlights-plur-20161115monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-30-million-equity-funding-approved-by-innovative-medical-management-co-s-share-plur-20161110monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-continues-to-strengthen-its-position-in-china-and-receives-key-cell-therapy-pate-plur-20161107monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-pivotal-phase-iii-critical-limb-ischemia-trial-approved-by-uk-regulatory-agenc-plur-20161101monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-signs-term-sheet-for-30-million-equity-investment-agreement-with-a-leading-insti-plur-20161025monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-ceo-zami-aberman-re-elected-to-alliance-for-regenerative-medicine-s-board-of-dir-plur-20161013monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-advances-towards-u-s-clinical-trial-in-plx-r18-and-announces-principal-investiga-plur-20160914monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-provides-fiscal-year-2016-corporate-and-financial-highlights-plur-20160912monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-conduct-symposium-on-plx-pad-potential-for-the-treatment-of-peripheral-artery-plur-20160908monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-phase-iii-critical-limb-ischemia-study-wins-8-million-grant-from-europe-s-hori-plur-20160809monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-receives-positive-feedback-from-fda-and-gears-up-for-phase-iii-trial-of-plx-pad--plur-20160802monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-advances-towards-multinational-phase-iii-trial-of-plx-pad-to-improve-recovery-fo-plur-20160727monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-participates-in-radiation-injury-treatment-network-conference-co-sponsored-by-na-plur-20160720monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-advances-its-u-s-fda-trial-in-hematologic-indication-plur-20160711monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-reports-data-showing-plx-pad-cells-effective-in-treating-duchenne-muscular-dystr-plur-20160622monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-completes-enrollment-of-150-patients-in-phase-ii-intermittent-claudication-trial-plur-20160516monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-reports-third-quarter-fiscal-2016-financial-highlights-and-clinical-development--plur-20160510monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-awarded-3-3-million-grant-by-israeli-government-plur-20160509monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-enters-into-licensing-agreement-with-tes-holdings-co-ltd-a-venture-company-deriv-plur-20160421monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-continues-to-strengthen-its-position-in-japan-granted-two-key-cell-therapy-paten-plur-20160413monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-reports-second-quarter-fiscal-2016-financial-highlights-and-clinical-development-plur-20160210monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-at-bio-ceo-investor-conference-in-new-york-city-on-february-8-2016-plur-20160126monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-receives-u-s-fda-clearance-to-initiate-clinical-trial-of-plx-r18-to-treat-insuff-plur-20160112monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-reaches-agreement-with-japan-s-pmda-on-protocol-for-final-trial-targeting-market-plur-20151221monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-at-phacilitate-cell-gene-therapy-world-conference-in-washington-dc-on-plur-20151217monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-and-united-therapeutics-end-licensing-agreement-report-positive-data-in-pulmonar-plur-20151208monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-signs-mou-for-collaboration-with-fukushima-medical-university-to-study-plx-r18-i-plur-20151203monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-at-global-scientific-investment-conferences-in-december-plur-20151124monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-new-data-on-plx-r18-at-american-society-of-hematology-s-annual-meetin-plur-20151117monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-provides-corporate-and-financial-highlights-for-first-quarter-of-its-fiscal-year-plur-20151109monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-participate-in-three-european-life-sciences-conferences-in-november-plur-20151027monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-charite-expand-cooperation-agreement-to-include-orthopedic-indications-plur-20151013monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-ceo-zami-aberman-elected-to-board-of-directors-of-the-alliance-for-regenerative--plur-20151007monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-and-niaid-met-with-u-s-fda-and-agreed-on-development-plan-for-initiation-of-pivo-plur-20150921monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-provides-corporate-and-financial-highlights-for-fiscal-year-2015-plur-20150910monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-completed-successful-meeting-with-the-u-s-fda-in-preparation-for-filing-an-ind-f-plur-20150909monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-president-yaky-yanay-elected-as-co-chairman-of-israel-advanced-technology-indust-plur-20150906monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-granted-u-s-patent-for-production-methods-and-use-of-placental-cell-therapy-in-a-plur-20150817monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-in-key-discussions-with-europe-s-adaptive-pathways-group-on-phase-ii-protocol-in-plur-20150810monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-announces-pricing-of-registered-direct-offering-of-common-stock-and-plur-20150625monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-granted-australian-patent-for-3d-cell-expansion-technology-use-of-plx-cells-in-b-plur-20150624monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-awarded-2-9-million-grant-by-israeli-government-plur-20150617monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-awarded-grant-from-israel-s-ministry-of-economy-for-marketing-its-plx-cell-thera-plur-20150603monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-granted-key-cell-patents-in-asia-russia-mexico-and-israel-plur-20150601monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-at-the-international-congress-of-radiation-research-and-chair-two-pan-plur-20150527monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-issues-letter-to-shareholders-plur-20150525monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-conduct-conference-at-tel-aviv-stock-exchange-to-review-regulatory-progress-a-plur-20150519monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-plx-cells-one-step-closer-to-entering-japan-s-accelerated-pathway-for-regenera-plur-20150513monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-hold-symposium-on-therapeutic-angiogenesis-for-peripheral-arterial-occlusive--plur-20150507monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-granted-european-patent-for-use-of-cells-to-help-treat-damaged-bone-marrow-plur-20150506monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-at-five-industry-and-finance-conferences-in-may-plur-20150504monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-clinical-advisory-board-prepares-phase-ii-clinical-trials-in-critical-limb-isc-plur-20150420monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-key-strategic-objectives-for-development-of-plx-r18-in-hematopoietic-i-plur-20150324monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-data-at-regenerative-medicine-conferences-in-japan-and-south-korea-plur-20150309monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-and-hadassah-medical-center-announce-significant-data-showing-plx-r18-cells-impr-plur-20150303monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-significant-new-finding-from-its-phase-i-ii-muscle-injury-trial-and-ex-plur-20150202monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-at-two-cell-therapy-conferences-in-january-2015-plur-20150113monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-issues-letter-to-shareholders-plur-20150112monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-granted-patent-for-foundational-cell-harvesting-technology-in-south-africa-plur-20150106monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-and-hadassah-medical-center-will-collaborate-to-study-potential-of-plx-rad-cells-plur-20141204monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-granted-patent-in-singapore-for-its-3d-cell-expansion-technology-plur-20141201monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-dr-ohad-karnieli-to-present-at-two-upcoming-scientific-conferences-plur-20141125monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-granted-patents-in-australia-and-new-zealand-for-use-of-placental-cells-in-the-t-plur-20141112monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-ceo-zami-aberman-to-present-at-two-regenerative-medicine-conferences-in-london-o-plur-20141110monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-advances-its-second-major-cell-therapy-product-line-from-development-to-large-sc-plur-20141021monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-wins-cell-therapy-patent-case-in-europe-european-patent-office-confirms-validity-plur-20141007monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-pursues-development-strategy-in-japan-where-new-law-accelerates-path-to-market-plur-20140916monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-deliver-scientific-presentations-at-3rd-international-placenta-stem-cell-soci-plur-20140910monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-at-financial-conferences-in-new-york-city-on-september-10th-and-17th--plur-20140904monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-host-investor-breakfast-and-webcast-on-july-23-in-new-york-city-plur-20140722monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-initiates-south-korean-arm-of-multinational-phase-ii-intermittent-claudication-t-plur-20140708monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-ohad-karnieli-to-deliver-a-plenary-presentation-on-cell-therapy-manufacturing--plur-20140630monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-selects-rotator-cuff-repair-as-new-orthopedic-indication-plur-20140625monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-granted-patent-in-russia-for-treatment-of-inflammatory-bowel-disease-using-place-plur-20140619monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-receives-patent-in-india-for-cell-therapy-production-methods-and-compositions-plur-20140616monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-exhibit-at-bio-international-convention-in-san-diego-on-june-23-26-2014-plur-20140610monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-issues-letter-to-shareholders-plur-20140605monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-move-forward-in-the-orthopedic-area-with-the-support-of-key-opinion-leaders-plur-20140529monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-participate-in-upcoming-financial-conferences-plur-20140527monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-receives-clearance-from-south-korea-to-use-plx-cells-manufactured-at-its-new-fac-plur-20140520monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-at-world-stem-cells-regenerative-medicine-congress-2014-in-london-plur-20140512monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-be-added-to-new-ta-tech-elite-stock-index-in-israel-plur-20140507monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-awarded-4-2-million-grant-by-israeli-government-plur-20140430monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-manufacturing-facility-approved-by-european-auditors-for-phase-iii-trials-plur-20140428monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-and-the-alliance-for-regenerative-medicine-advocate-for-industry-advancement-in--plur-20140422monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-deliver-key-commercialization-and-scientific-presentations-at-international-s-plur-20140416monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-scientists-to-present-a-poster-on-gvhd-participate-in-a-panel-discussion-at-the--plur-20140325monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-at-barclays-and-regenmed-financial-conferences-plur-20140311monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-ceo-zami-aberman-to-present-on-cell-gene-therapy-panel-discussion-at-bio-europe--plur-20140307monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-submits-fda-orphan-drug-application-for-preeclampsia-plur-20140220monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-receives-key-3d-cell-expansion-patent-in-australia-plur-20140218monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-ceo-zami-aberman-to-speak-on-panel-at-9th-annual-stem-cell-summit-on-february-18-plur-20140213monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-strengthens-executive-team-announces-senior-executive-appointments-plur-20140205monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-issues-letter-to-shareholders-plur-20140130monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-ceo-zami-aberman-to-present-at-phacilitate-cell-gene-therapy-forum-2014-plur-20140127monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-cell-manufacturing-facility-marks-major-milestone-with-german-regulatory-appro-plur-20140123monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-phase-i-ii-muscle-injury-trial-successfully-meets-primary-safety-efficacy-endp-plur-20140121monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-receives-key-placental-cell-therapy-patent-in-australia-plur-20140108monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-and-cha-move-forward-on-strategic-partnership-agreement-conclude-mutual-investme-plur-20131217monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-receives-regulatory-approval-to-extend-its-phase-ii-study-of-plx-pad-cells-in-th-plur-20131113monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-at-omics-group-s-2nd-international-conference-and-exhibition-on-cell--plur-20131023monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-scientific-poster-and-corporate-overview-at-stem-cell-meeting-on-the--plur-20131015monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-receives-israeli-ministry-of-health-approval-to-expand-its-phase-ii-clinical-tri-plur-20131002monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-plx-cells-demonstrate-efficacy-in-preclinical-study-for-graft-versus-host-dise-plur-20131001monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-granted-key-u-s-patent-for-the-treatment-of-peripheral-artery-disease-plur-20130911monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-awarded-a-3-3-million-grant-by-israeli-government-plur-20130806monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-completes-enrollment-for-phase-i-ii-muscle-injury-trial-plur-20130711monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-south-korean-partner-files-ind-with-korean-fda-for-plx-cells-plur-20130708monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-enters-into-strategic-partnership-and-licensing-agreement-with-cha-bio-diostech--plur-20130626monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-preclinical-results-for-its-plx-rad-cells-published-in-the-journal-plos-one-plur-20130620monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-provides-update-on-clinical-status-of-ic-trials-plur-20130619monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-deliver-two-presentations-during-israel-s-largest-biotech-conference-iati-bio-plur-20130610monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-receive-clinical-hold-notice-from-the-u-s-fda-plur-20130604monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-at-fda-symposium-plur-20130529monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-welcomes-parliamentary-state-secretary-of-the-german-federal-ministry-for-enviro-plur-20130522monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-develops-plx-rad-cells-for-use-in-hematology-plur-20130507monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-at-needham-healthcare-and-oppenheimer-israeli-investment-conferences--plur-20130430monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-expands-plx-product-portfolio-in-orthopedics-and-sports-medicine-plur-20130418monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-scientific-and-investment-conferences-for-april-2013-plur-20130410monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-reports-on-the-progress-of-its-phase-i-ii-clinical-trial-for-the-treatment-of-mu-plur-20130320monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-receives-fda-orphan-drug-status-designation-for-treatment-of-aplastic-anemia-plur-20130221monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-ceo-to-participate-in-key-roundtable-discussion-at-the-8th-annual-new-york-stem--plur-20130213monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-takes-possession-of-and-moving-into-new-state-of-the-art-manufacturing-facility-plur-20130130monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-updates-cell-manufacturing-industry-on-its-proprietary-3d-cell-expansion-technol-plur-20130122monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-receives-approval-to-expand-its-phase-ii-clinical-trial-in-intermittent-claudica-plur-20130115monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-ceo-letter-to-shareholders-plur-20130107monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-initiates-final-validation-of-new-manufacturing-facility-plur-20121227monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-at-oppenheimer-23rd-annual-healthcare-conference-plur-20121212monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-joins-both-the-ta-75-and-ta-100-indexes-on-the-tel-aviv-stock-exchange-plur-20121210monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-advances-its-intramuscular-hematology-program-assembles-clinical-advisory-board--plur-20121204monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-reports-status-of-orphan-drug-application-for-aplastic-anemia-plur-20121121monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-initiate-a-phase-i-ii-clinical-trial-in-muscle-injury-plur-20121114monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-comments-on-article-published-on-bloomberg-plur-20121109monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-completes-large-scale-cell-therapy-formulation-for-commercial-and-clinical-trial-plur-20121107monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-achieves-milestone-towards-completion-of-its-new-gmp-manufacturing-facility-for--plur-20121023monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-plx-cells-reduce-fibrotic-processes-plur-20121017monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-issues-letter-to-shareholders-highlighting-significant-achievements-on-several-f-plur-20121009monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-develops-point-of-care-thawing-device-for-plx-cells-plur-20121004monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-selects-fisher-bioservices-as-worldwide-dispatch-distributor-of-its-plx-cell-the-plur-20120927monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-closing-of-underwriters-option-to-purchase-additional-common-stock-plur-20120924monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-closing-of-public-offering-of-common-stock-and-warrants-to-purchase-co-plur-20120919monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-pricing-of-public-offering-of-common-stock-and-warrants-to-purchase-co-plur-20120913monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-proposed-public-offering-of-common-stock-and-warrants-to-purchase-comm-plur-20120912monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-files-for-orphan-drug-status-with-u-s-fda-for-use-of-plx-cells-in-treatment-of-a-plur-20120830monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-commences-u-s-fda-phase-ii-clinical-trial-for-intermittent-claudication-plur-20120823monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-and-world-renowned-charite-berlin-brandenburg-center-for-regenerative-therapies--plur-20120821monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-receives-approval-from-indian-ministry-of-health-for-use-of-plx-cells-in-phase-i-plur-20120816monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-moves-intermittent-claudication-indication-forward-in-europe-through-collaborati-plur-20120813monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-receives-approval-to-commence-a-phase-i-ii-study-for-muscle-regeneration-in-germ-plur-20120807monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-plx-cells-show-efficacy-in-treating-lung-disease-plur-20120731monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-set-to-enter-bone-marrow-disease-market-as-it-is-preparing-to-apply-plur-20120723monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-partners-with-cpc-clinical-research-for-peripheral-artery-disease-study-plur-20120718monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-cell-therapy-broadens-addressable-markets-demonstrates-systemic-eff-plur-20120619monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-at-jefferies-global-healthcare-conference-plur-20120605monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-ceo-letter-to-shareholders-plur-20120523monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-awarded-a-3-1-million-grant-by-israeli-government-plur-20120430monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-receives-u-s-fda-clearance-for-phase-ii-clinical-trial-in-intermittent-claudicat-plur-20120417monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-forms-peripheral-artery-disease-steering-committee-plur-20120403monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-to-present-at-three-conferences-in-april-plur-20120326monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-plx-cells-effective-in-treatment-of-acute-myocardial-infarction-ami-in-animal--plur-20120320monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-begins-up-scaling-its-plx-cell-bioreactors-plur-20120312monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-ceo-quarterly-update-plur-20120229monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-expand-research-development-of-radiation-exposure-treatment-plur-20120207monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-awarded-a-2-4-million-grant-from-israeli-government-plur-20120118monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-ceo-letter-to-shareholders-plur-20111122monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-positive-12-month-data-from-the-use-of-plx-pad-for-the-treatment-of-cr-plur-20111103monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-plx-cells-found-to-have-potential-to-treat-acute-radiation-syndrome-plur-20110907monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-to-present-at-leading-u-s-industry-conferences-plur-20110906monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-plx-cells-receive-orphan-drug-status-for-treatment-of-buerger-s-disease-plur-20110825monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-effectiveness-of-the-exclusive-license-agreement-to-develop-and-commer-plur-20110803monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-to-expand-manufacturing-with-new-gmp-facility-capable-of-an-annual--plur-20110726monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-and-united-therapeutics-enter-into-an-exclusive-license-agreement-to-develop-and-plur-20110620monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-to-present-at-upcoming-industry-conferences-plur-20110505monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-encouraging-six-month-follow-up-results-of-its-phase-i-critical-limb-i-plur-20110413monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-to-expand-testing-of-plx-cells-for-the-treatment-of-radiation-expos-plur-20110406monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-and-nyu-medical-center-partner-to-study-use-of-plx-cells-in-treatme-plur-20110315monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-to-present-at-leading-investor-conferences-plur-20110307monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-closing-of-public-offering-of-common-stock-and-warrants-to-purchase-co-plur-20110201monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-pricing-of-public-offering-of-common-stock-and-warrants-to-purchase-co-plur-20110127monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-proposed-public-offering-of-common-stock-and-warrants-to-purchase-comm-plur-20110126monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-on-track-to-proceed-to-a-phase-ii-iii-clinical-trial-in-critical-limb-ischemia-c-plur-20110118monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-approved-for-dual-listing-on-the-tel-aviv-stock-exchange-tase-plur-20101212monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-at-the-commercial-translation-of-regenerative-medicine-conference-plur-20101116monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-announces-interim-top-line-results-from-plx-pad-clinical-trials-plur-20100427monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-raises-2-7-million-in-private-placement-of-restricted-common-stock-plur-20100427monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-granted-european-union-patent-for-plurix-tm-three-dimensional-3d-bi-plur-20100323monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-to-present-at-the-roth-22nd-annual-oc-growth-conference-plur-20100309monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-receives-dsmb-approval-to-advance-to-final-dose-level-with-plx-pad-plur-20100302monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-completes-dosing-of-first-group-of-patients-in-europe-with-placenta-plur-20091201monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-provides-disclosure-pursuant-to-nasdaq-marketplace-rule-5250-b-2-plur-20091001monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-completes-enrollment-in-phase-2b-trial-evaluating-vyn201-for-the-treatme-vyne-20250106monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-participate-in-september-investor-conferences-vyne-20240903monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-granting-of-composition-of-matter-patent-for-vyn202-a-novel-bd-vyne-20240716monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-appointment-of-subhashis-banerjee-m-d-as-senior-vice-president-vyne-20240709monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-participate-in-leerink-partners-therapeutics-forum-vyne-20240626monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-dosing-of-first-participants-in-phase-1a-trial-of-novel-bd2-se-vyne-20240613monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-dosing-of-first-subject-in-phase-2b-vitiligo-trial-of-novel-be-vyne-20240605monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-fda-clearance-of-ind-application-for-vyn202-a-novel-bd2-select-vyne-20240506monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-oral-presentations-for-vyn201-at-the-2024-society-for-investig-vyne-20240501monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-participate-in-the-h-c-wainwright-2nd-annual-autoimmune-inflammatory--vyne-20240319monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-present-results-of-the-phase-1b-trial-for-vyn201-at-the-2024-global-v-vyne-20240227monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-participate-in-the-td-cowen-44th-annual-health-care-conference-vyne-20240221monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-positive-biomarker-data-from-successful-phase-1b-trial-of-vyn2-vyne-20240110monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-host-virtual-r-d-day-event-on-november-9-2023-vyne-20231107monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-closing-of-previously-announced-private-placement-of-88-2-mill-vyne-20231101monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-positive-results-from-preclinical-models-for-oral-bd2-selective--vyne-20231030monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-positive-data-from-phase-1b-trial-for-novel-bet-inhibitor-vyn2-vyne-20231030monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-confe-vyne-20230906monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-attend-bio-international-convention-vyne-20230518monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-positive-preclinical-data-for-inhaled-formulation-of-vyn201-in-vyne-20230419monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-positive-first-in-human-pharmacokinetic-and-hematology-data-fr-vyne-20230330monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammation-disease-vir-vyne-20230322monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-participate-in-the-43rd-annual-cowen-health-care-conference-vyne-20230222monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-positive-results-from-phase-1a-single-and-multiple-ascending-d-vyne-20230215monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-reverse-stock-split-vyne-20230210monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-first-vitiligo-patient-dosed-in-phase-1a-b-clinical-trial-of-n-vyne-20230109monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-participate-in-the-lifesci-partners-12th-annual-corporate-access-even-vyne-20221212monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-first-patent-granted-for-novel-bet-inhibitor-platform-vyne-20221207monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-participate-in-cantor-fitzgerald-s-medical-aesthetic-dermatology-opht-vyne-20221202monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-present-at-piper-sandler-34th-annual-healthcare-conference-vyne-20221118monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-first-subjects-dosed-in-phase-1a-b-clinical-trial-evaluating-p-vyne-20221117monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conferenc-vyne-20220906monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-present-at-the-b-t-cell-mediated-autoimmune-disease-drug-development--vyne-20220719monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-present-at-hc-wainwright-co-global-investment-conference-vyne-20220518monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-hosting-key-opinion-leader-event-on-novel-inhibet-bet-inhibitor-platform-vyne-20220510monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-present-at-lifesci-partners-immunology-inflammation-symposium-on-may--vyne-20220506monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-present-at-42nd-annual-cowen-healthcare-conference-vyne-20220303monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-participate-at-the-lifesci-partners-11th-annual-corporate-access-even-vyne-20220103monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-present-at-the-piper-sandler-33rd-annual-virtual-healthcare-conferenc-vyne-20211118monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-report-third-quarter-2021-financial-results-on-november-10-2021-vyne-20211028monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-formation-of-scientific-advisory-board-vyne-20211021monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-enrolls-first-patient-in-clinical-trial-of-fmx114-for-the-treatment-of-m-vyne-20211019monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-its-china-partner-s-enrollment-of-first-patient-in-phase-3-stu-vyne-20211005monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-present-at-the-cantor-fitzgerald-investment-conference-vyne-20210920monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference-vyne-20210908monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-licensing-of-bet-inhibitor-platform-for-immuno-inflammatory-co-vyne-20210812monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-approval-of-amzeeq-minocycline-and-zilxi-minocycline-in-chines-vyne-20210802monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021-vyne-20210727monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-initiation-of-investigator-initiated-trial-evaluating-amzeeq-m-vyne-20210719monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-participate-in-the-2nd-annual-jak-inhibitors-drug-development-digital-vyne-20210629monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-report-first-quarter-2021-financial-results-on-may-6-2021-vyne-20210428monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-present-at-upcoming-virtual-investor-conferences-vyne-20210304monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference-vyne-20210301monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-report-financial-results-for-the-year-ended-december-31-2020-on-march-vyne-20210223monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-reverse-stock-split-vyne-20210211monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-fda-approval-of-amzeeq-minocycline-label-update-vyne-20210201monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-closing-of-50-million-registered-direct-offering-of-common-sto-vyne-20210129monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-50-million-registered-direct-offering-of-common-stock-priced-a-vyne-20210126monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-contract-execution-for-amzeeq-minocycline-and-zilxi-minocyclin-vyne-20210121monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-present-at-the-lifesci-partners-10th-annual-healthcare-corporate-acce-vyne-20210105monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-successful-end-of-phase-2-meeting-with-the-fda-for-fcd105-in-acn-vyne-20201217monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-added-to-nasdaq-biotechnology-index-vyne-20201216monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-new-u-s-patent-expiring-in-2037-for-amzeeq-minocycline-topical-vyne-20201215monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-publication-of-long-term-safety-efficacy-data-for-zilxi-minocy-vyne-20201201monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference-vyne-20201125monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-report-third-quarter-2020-financial-results-on-november-5th-vyne-20201028monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-covered-status-for-zilxi-minocycline-with-express-scripts-vyne-20201007monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-to-host-physician-symposium-on-amzeeq-and-zilxi-vyne-20200923monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-formerly-menlo-therapeutics-to-present-at-the-cantor-fitzgerald-and-h-c--vyne-20200909monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-sets-annual-shareholder-meeting-aeon-20260424monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-reports-inducement-grants-under-nyse-american-llc-company-guide-section-711-aeon-20260403monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-receives-additional-notice-related-to-nyse-american-continued-listing-stand-aeon-20260403monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-reports-full-year-2025-financial-results-and-highlights-positive-comparativ-aeon-20260330monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-appoints-john-bencich-as-chief-financial-officer-aeon-20260309monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-abstract-accepted-for-presentation-at-2026-american-academy-of-neurology-aa-aeon-20260305monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-reports-inducement-grants-under-nyse-american-llc-company-guide-section-711-aeon-20251219monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-announces-execution-of-exchange-agreement-with-daewoong-aeon-20251215monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-announces-first-closing-of-pipe-investment-and-provides-update-on-fda-type--aeon-20251120monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-reports-third-quarter-2025-results-including-positive-abp-450-biosimilarity-aeon-20251114monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-reports-positive-and-robust-biosimilarity-results-identical-amino-acid-sequ-aeon-20251113monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-announces-fundraise-totaling-up-to-22-million-through-private-placement-and-aeon-20251113monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-announces-fda-bpd-type-2a-meeting-for-abp-450-on-november-19-aeon-20251001monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-reports-second-quarter-2025-financial-results-and-provides-corporate-update-aeon-20250812monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-reports-inducement-grants-under-nyse-american-llc-company-guide-section-711-aeon-20250421monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-co-aeon-20250324monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-inc-receives-notice-of-non-compliance-with-nyse-american-continued-listing--aeon-20250207monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-inc-announces-closing-of-20-0-million-underwritten-public-offering-aeon-20250107monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-inc-announces-launch-of-proposed-public-offering-aeon-20250104monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-reports-third-quarter-2024-financial-results-and-provides-corporate-update-aeon-20241113monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-announces-positive-outcome-from-fda-biosimilar-advisory-meeting-aeon-20240930monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-to-participate-in-the-h-c-wainwright-26th-annual-global-investment-conferen-aeon-20240819monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-reports-second-quarter-2024-financial-results-and-provides-corporate-update-aeon-20240812monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-announces-strategic-reprioritization-to-pursue-a-biosimilar-pathway-for-abp-aeon-20240709monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-announces-strategic-resource-reprioritization-and-cost-reduction-plan-aeon-20240529monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-reports-first-quarter-2024-financial-results-aeon-20240514monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-provides-update-on-development-pipeline-aeon-20240509monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-announces-redemption-of-public-warrants-aeon-20240329monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-reports-fourth-quarter-and-full-year-2023-financial-results-aeon-20240329monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-announces-clinical-update-and-productive-end-of-phase-2-meeting-with-fda-on-aeon-20240319monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-announces-15-million-financing-transaction-and-termination-of-forward-purch-aeon-20240319monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-presents-positive-clinical-and-pre-clinical-data-for-abp-450-prabotulinumto-aeon-20240118monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-completes-enrollment-in-phase-2-study-of-abp-450-prabotulinumtoxina-for-pre-aeon-20231212monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-reports-third-quarter-2023-financial-results-aeon-20231113monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-presents-positive-results-from-phase-2-clinical-trial-of-abp-450-prabotulin-aeon-20230829monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-receives-notice-of-allowance-from-uspto-for-a-patent-covering-use-of-botuli-aeon-20230824monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-announces-closing-of-business-combination-with-priveterra-acquisition-corp--aeon-20230724monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-to-host-key-opinion-leader-webinar-on-past-present-and-potential-future-tre-aeon-20230214monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-confirms-development-strategy-and-timelines-for-abp-450-unaffected-by-korea-aeon-20230211monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-completes-enrollment-in-phase-2-trial-of-abp-450-for-preventive-treatment-o-aeon-20221221monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-reports-positive-topline-results-from-phase-2-clinical-trial-of-abp-450-pra-aeon-20220923monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-raises-30-million-from-insiders-aeon-20220803monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-completes-enrollment-in-phase-2-clinical-study-of-abp-450-in-cervical-dysto-aeon-20220411monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-announces-the-appointment-of-alex-wilson-as-general-counsel-aeon-20210811monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-appoints-dr-chad-k-oh-as-chief-medical-officer-to-lead-clinical-development-aeon-20210609monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-doses-first-patient-in-phase-2-trial-of-abp-450-for-the-treatment-of-cervic-aeon-20210405monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-initiates-enrollment-in-phase-2-trial-of-abp-450-for-the-preventive-treatme-aeon-20210308monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-announces-fda-acceptance-of-ind-for-abp-450-as-a-treatment-for-cervical-dys-aeon-20200902monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-reports-first-quarter-2026-results-and-continued-stenoparib-developm-allr-20260515monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-ceo-to-present-at-precision-medicine-forum-europe-2026-in-stockholm-allr-20260508monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-provides-third-quarter-2025-financial-results-and-provides-business--allr-20251114monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-first-patient-enrolled-in-new-phase-2-clinical-trial-proto-allr-20250602monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-participation-in-pharma-partnering-summit-us-allr-20250512monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-provides-first-quarter-2025-update-highlighting-continued-stenoparib-allr-20250509monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-presents-novel-drug-response-predictor-drp-for-daratumumab-in-multip-allr-20250425monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-reports-full-year-2024-financial-results-and-provides-a-business-upd-allr-20250331monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-launches-comprehensive-effort-to-combat-potential-illegal-naked-shor-allr-20250324monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-presentation-of-phase-2-clinical-data-from-ongoing-trial-i-allr-20250317monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-final-settlement-with-the-u-s-securities-and-exchange-comm-allr-20250313monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-phase-2-trial-of-stenoparib-in-combination-with-temozolomi-allr-20250306monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-board-authorization-of-5-million-share-repurchase-program-allr-20250303monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-dismissal-of-securities-class-action-lawsuit-allr-20250226monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-to-begin-enrollment-for-new-phase-2-protocol-to-advance-stenoparib-t-allr-20250224monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-expansion-of-phase-2-clinical-trial-to-accelerate-developm-allr-20250206monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-filing-of-form-8-k-regarding-settlement-agreement-in-princ-allr-20250130monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-lo-allr-20241206monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-reports-key-progress-in-phase-2-stenoparib-trial-and-strategic-corpo-allr-20241118monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-reports-third-quarter-2024-financial-results-and-provides-recent-ope-allr-20241114monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-allr-20241106monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-lo-allr-20241029monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-to-be-granted-european-patent-for-drp-companion-diagnostic-for-steno-allr-20241022monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-remin-allr-20241018monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-remin-allr-20241010monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-allr-20241010monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-strengthens-leadership-with-key-appointments-to-accelerate-stenopari-allr-20241003monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-allr-20240918monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-lo-allr-20240917monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-new-cfo-and-inducement-grants-under-nasdaq-listing-rule-56-allr-20240913monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-takes-decisive-step-toward-regaining-nasdaq-compliance-with-nasdaq-l-allr-20240911monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-inc-announcement-if-you-have-suffered-losses-in-allarity-therapeutic-allr-20240820monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-inc-announcement-if-you-have-suffered-losses-in-allarity-therapeutic-allr-20240814monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-inc-announcement-if-you-have-suffered-losses-in-allarity-therapeutic-allr-20240808monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-inc-allr-investigation-bronstein-gewirtz-grossman-llc-encourages-inv-allr-20240807monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-inc-announcement-if-you-have-suffered-losses-in-allarity-therapeutic-allr-20240803monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-inc-allr-investigation-bronstein-gewirtz-grossman-llc-encourages-inv-allr-20240801monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-inc-allr-investigation-bronstein-gewirtz-grossman-llc-encourages-inv-allr-20240726monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-postponement-of-annual-stockholders-meeting-allr-20240726monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-encourages-shareholders-to-vote-for-the-reverse-stock-split-and-decrease-in-autho-allr-20240724monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-to-present-at-biomarkers-2024-allr-20240228monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-thomas-jensen-as-interim-ceo-and-appointment-of-jeremy-r-g-allr-20231212monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-s-early-phase-2-stenoparib-data-indicates-clinical-benefit-in-women-with-advanced-allr-20231205monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-to-present-at-biomarkers-europe-2023-allr-20231002monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-and-fivephusion-announce-collaboration-to-support-clinical-developme-allr-20230731monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-strengthens-board-of-directors-with-appointment-of-three-accomplishe-allr-20230724monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-reverse-stock-split-of-common-stock-allr-20230628monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-clarification-of-effective-date-for-reverse-stock-split-allr-20230627monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-adjournment-of-special-meeting-of-stockholders-allr-20230620monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-reverse-stock-split-of-common-stock-allr-20230324monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-adjournment-of-2023-annual-meeting-of-stockholders-allr-20230120monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-adjournment-of-2022-annual-meeting-of-stockholders-allr-20221107monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-to-present-at-ladenburg-thalmann-healthcare-conference-allr-20220916monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-appointment-of-new-auditor-allr-20220912monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-nasdaq-allr-diamond-in-the-rough-allr-20220811monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-refocuses-oncology-pipeline-strategy-towards-combination-therapies-allr-20220802monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-executive-leadership-transition-allr-20220629monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-strengthens-scientific-advisory-board-with-appointment-of-distinguis-allr-20220615monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-provides-update-on-dovitinib-program-allr-20220315monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-receives-refusal-to-file-letters-from-u-s-fda-allr-20220218monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-submits-new-drug-application-nda-to-the-u-s-fda-for-dovitinib-for-th-allr-20211222monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-delisting-and-last-day-of-trading-in-the-company-s-shares--allr-20211213monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-shareholder-acceptance-of-share-swap-offer-and-initiates-d-allr-20211211monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-a-s-publishes-offer-document-offering-to-acquire-company-shares-in-e-allr-20211124monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-publishes-interim-report-for-the-period-january-september-2021-allr-20211123monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-oral-parp-inhibitor-stenoparib-demonstrates-pre-clinical-antiviral-a-allr-20211111monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-and-lonza-collaborate-to-manufacture-dovitinib-a-renal-cell-carcinom-allr-20210923monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-presents-dovitinib-survival-data-from-drp-screened-rcc-patients-at-e-allr-20210916monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-receives-approximately-sek-16-5-million-us-1-9-million-from-subscrip-allr-20210914monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-extraordinary-exercise-period-for-warrants-of-series-allr--allr-20210826monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-files-form-s-4-registration-statement-with-u-s-securities-exchange-c-allr-20210823monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-publishes-interim-report-for-the-period-january-june-2021-allr-20210823monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-elaborates-on-the-contents-of-the-meeting-agenda-for-the-extraordina-allr-20210818monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-oral-parp-inhibitor-stenoparib-demonstrates-additional-pre-clinical--allr-20210805monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-and-lantern-pharma-enter-into-agreement-for-future-clinical-developm-allr-20210726monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-issues-share-units-as-payment-in-kind-for-services-rendered-during-r-allr-20210714monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-receives-acceptance-review-notification-from-u-s-fda-for-pre-market--allr-20210705monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-and-oncoheroes-biosciences-to-partner-on-pediatric-cancer-developmen-allr-20210614monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-completes-oversubscribed-rights-issue-allr-20210610monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-publishes-e-poster-detailing-the-molecular-pathways-covered-by-the-d-allr-20210609monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-publishes-interim-report-for-the-period-january-march-2021-allr-20210528monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-publishes-prospectus-supplement-allr-20210527monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-secures-investment-from-3i-fund-for-recapitalization-transition-to-l-allr-20210521monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-to-conduct-a-rights-issue-of-new-shares-and-publishes-prospectus-reg-allr-20210519monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-updates-preliminary-timetable-for-planned-rights-issue-allr-20210505monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-to-present-a-dovitinib-drp-e-poster-at-the-european-association-for--allr-20210429monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-submits-premarket-approval-application-to-u-s-fda-for-drp-companion--allr-20210402monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-publishes-its-annual-report-for-2020-allr-20210331monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-plans-fully-guaranteed-rights-issue-of-approximately-sek-100-million-allr-20210323monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-positive-data-from-preclinical-study-of-dovitinib-in-osteo-allr-20210309monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-initiates-phase-2-trial-of-ixempra-in-europe-for-the-treatment-of-me-allr-20210304monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-provides-update-on-pre-clinical-testing-of-stenoparib-s-antiviral-ac-allr-20210224monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-draws-down-the-fourth-tranche-under-its-convertible-note-agreement-w-allr-20210211monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-to-test-activity-of-its-parp-inhibitor-stenoparib-as-a-potential-the-allr-20210126monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-issues-new-shares-to-aalto-capital-in-connection-with-services-rende-allr-20210122monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-draws-down-the-third-tranche-under-its-convertible-note-agreement-wi-allr-20201222monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-expands-its-stenoparib-license-rights-to-include-anti-viral-uses-allr-20201214monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-publishes-interim-report-for-the-period-january-september-2020-allr-20201130monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-draws-down-the-second-tranche-under-its-convertible-note-agreement-w-allr-20201105monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-hires-new-chief-financial-officer-allr-20201104monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-gains-allowance-from-u-s-patent-and-trademark-office-for-new-drp-bio-allr-20201026monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-provides-update-on-dovitinib-program-allr-20201023monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-will-trade-under-new-short-name-allr-starting-on-12-october-2020-allr-20201009monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-announces-pipeline-and-business-updates-howl-20251218monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-participate-in-hanson-wade-s-6th-annual-cytokine-based-drug-devel-howl-20250513monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-presents-new-preclinical-data-further-characterizing-its-il-10-induk-howl-20250505monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-participate-in-upcoming-investor-conferences-howl-20250505monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer-howl-20250417monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-at-the-24th-annual-needham-virtual-healthcare-conference-howl-20250331monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-at-the-2025-leerink-partners-global-biopharma-conference-howl-20250304monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-appoints-anil-singhal-ph-d-to-its-board-of-directors-howl-20250224monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-provides-business-update-and-highlights-2025-strategic-outlook-howl-20250113monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-participate-in-the-7th-annual-evercore-isi-healthconx-healthcare--howl-20241120monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-presents-preclinical-and-clinical-data-at-the-society-for-immunother-howl-20241107monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-announces-promising-new-development-candidate-wtx-921-a-first-of-its-howl-20241031monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancer-s-sitc-howl-20241004monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-participate-in-the-h-c-wainwright-26th-annual-global-investment-c-howl-20240903monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-data-from-ongoing-phase-1-1b-clinical-trial-of-wtx-124-as-howl-20240601monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-participate-at-the-jefferies-global-healthcare-conference-howl-20240530monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-updated-data-from-phase-1-1b-clinical-trial-of-wtx-124-as-howl-20240523monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-announces-wtx-124-clinical-abstract-accepted-for-presentation-at-the-howl-20240424monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-presents-first-preclinical-data-highlighting-il-10-indukine-molecule-howl-20240423monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-presents-preclinical-results-demonstrating-anti-tumor-effects-of-pro-howl-20240405monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-first-of-its-kind-data-demonstrating-utility-for-predator-howl-20240404monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-at-the-2024-leerink-partners-global-biopharma-conference-howl-20240306monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2024-howl-20240305monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-appoints-michael-atkins-m-d-to-its-board-of-directors-howl-20240104monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-at-the-evercore-isi-healthconx-conference-howl-20231122monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-clinical-and-preclinical-data-at-the-society-for-immunoth-howl-20231031monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-howl-20230927monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-host-kol-event-highlighting-il-2-landscape-and-opportunity-for-wt-howl-20230911monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-participate-in-upcoming-investor-conferences-howl-20230905monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-at-the-jefferies-healthcare-conference-howl-20230601monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-participate-in-may-investor-conferences-howl-20230501monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-publishes-preclinical-data-on-mwtx-330-an-il-12-indukine-molecule-in-howl-20230419monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-announces-upcoming-presentation-at-aacr-annual-meeting-2023-howl-20230315monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-announces-initiation-of-patient-dosing-in-phase-1-study-of-wtx-330-howl-20230224monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference-howl-20230207monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-presents-preclinical-data-on-mwtx-330-a-surrogate-il-12-indukine-mol-howl-20221110monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-preclinical-data-at-society-for-immunotherapy-of-cancer-a-howl-20221107monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-at-the-h-c-wainwright-24th-annual-global-investment-confe-howl-20220907monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-announces-initiation-of-patient-dosing-in-phase-1-1b-clinical-trial--howl-20220901monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-participate-in-the-2022-wedbush-pacgrow-healthcare-virtual-confer-howl-20220803monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-participate-in-a-fireside-chat-at-the-jefferies-global-healthcare-howl-20220606monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-presents-promising-preclinical-data-on-its-two-lead-indukine-molecul-howl-20220408monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-announces-publication-of-data-demonstrating-the-preclinical-efficacy-howl-20220316monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-announces-upcoming-presentations-at-aacr-2022-annual-meeting-howl-20220315monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-at-the-svb-leerink-global-healthcare-conference-howl-20220208monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-conference-howl-20220105monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-added-to-the-nasdaq-biotechnology-index-howl-20211214monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-preclinical-data-on-indukine-molecules-at-the-63rd-americ-howl-20211201monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-at-upcoming-conferences-in-november-2021-howl-20211108monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-appoints-meeta-chatterjee-ph-d-to-its-board-of-directors-howl-20211028monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-data-on-its-indukine-product-candidates-at-the-society-fo-howl-20211027monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-at-upcoming-next-gen-cytokine-therapeutics-summit-howl-20210914monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference-howl-20210908monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-announces-clinical-trial-collaboration-with-merck-on-its-wtx-124-ind-howl-20210818monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-announces-its-addition-to-the-russell-2000-index-howl-20210624monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-appoints-chulani-karunatilake-ph-d-as-chief-technology-officer-howl-20210615monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021-howl-20210527monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-announces-pricing-of-upsized-initial-public-offering-howl-20210430monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-discovers-that-hcw11-040-prevents-bronchopulmonary-dysplasia-bpd-during-ind--hcwb-20260514monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-announces-positive-research-results-for-car-t-cell-therapy-manufactured-util-hcwb-20260316monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-to-showcase-important-updates-on-ind-enabling-studies-and-preclinical-succes-hcwb-20250627monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-announces-positive-results-of-studies-of-proprietary-compound-hcw9206-and-av-hcwb-20250513monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-founder-and-ceo-to-address-opportunities-and-challenges-in-biomanufacturing--hcwb-20250115monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-and-wy-biotech-announce-license-agreement-for-immunotherapeutic-product-cand-hcwb-20241118monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-second-quarter-2024-financial-results-and-business-highlights-correc-hcwb-20240823monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-participating-at-h-c-wainwright-25th-annual-global-investment-conference-in--hcwb-20230906monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-is-granted-third-fundamental-patent-u-s-patent-for-methods-of-treating-age-r-hcwb-20230614monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-secures-26-25-million-non-dilutive-financing-with-asset-backed-development-l-hcwb-20230427monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-poster-presentation-at-aacr-annual-meeting-2023-hcwb-20230413monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-enters-crada-with-national-cancer-institute-hcwb-20221208monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-is-granted-second-fundamental-patent-u-s-patent-for-multi-chain-chimeric-pol-hcwb-20221207monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-to-participate-in-h-c-wainwright-annual-global-life-sciences-conference-may--hcwb-20220523monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-to-showcase-two-novel-groups-of-fusion-molecules-created-with-proprietary-an-hcwb-20220505monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-ceo-hing-c-wong-ph-d-to-be-featured-speaker-at-the-third-annual-internationa-hcwb-20220419monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-to-present-at-2022-virtual-growth-conference-sponsored-by-the-maxim-group-an-hcwb-20220324monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-inc-announces-its-lead-product-candidate-shown-to-augment-anti-tumor-activit-hcwb-20220120monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-founder-and-ceo-dr-hing-c-wong-participating-in-cambridge-healthtech-institu-hcwb-20220119monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-to-participate-in-h-c-wainwright-bioconnect-conference-january-10-13-2022-hcwb-20220106monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-founder-and-ceo-dr-hing-c-wong-named-weaver-h-gaines-entrepreneur-of-the-yea-hcwb-20211213monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-announces-appointment-of-two-new-members-to-board-of-directors-hcwb-20211027monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-showcases-scientific-paper-in-molecular-therapy-highlighting-potential-of-hc-hcwb-20210824monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-article-published-in-cancer-immunology-research-validates-novel-tissue-facto-hcwb-20210817monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-inc-announces-closing-of-56-0-million-initial-public-offering-hcwb-20210722monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-first-quarter-2026-financial-results-hbio-20260512monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-university-expands-multifaceted-research-alliance-with-northpond-labs-to-advance-s-hbio-20260511monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-participate-in-upcoming-investor-conferences-hbio-20260507monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-reverse-stock-split-hbio-20260306monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-second-quarter-2025-financial-results-hbio-20250811monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-second-quarter-2025-earnings-conference-call-for-august-11-20-hbio-20250804monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-first-quarter-2025-financial-results-hbio-20250512monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-first-quarter-2025-earnings-conference-call-for-may-12-2025-a-hbio-20250505monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-cfo-transition-hbio-20250410monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-to-participate-in-two-investor-conferences-in-march-2025-hbio-20250312monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-fourth-quarter-and-full-year-2024-financial-results-hbio-20250312monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-showcase-latest-solutions-for-preclinical-and-organoid-applications--hbio-20250224monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-fourth-quarter-2024-earnings-conference-call-for-march-12-202-hbio-20250224monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-to-participate-in-the-sidoti-micro-cap-conference-hbio-20250113monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-third-quarter-2024-financial-results-hbio-20241107monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-third-quarter-2024-earnings-conference-call-for-november-7-20-hbio-20241029monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-showcase-innovative-technologies-at-society-for-neuroscience-sfn-ann-hbio-20241003monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-showcase-latest-solutions-for-preclinical-and-organoid-applications--hbio-20240918monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-to-participate-in-the-sidoti-small-cap-virtual-conference-hbio-20240905monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-second-quarter-2024-financial-results-hbio-20240808monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-second-quarter-2024-earnings-conference-call-for-august-8-202-hbio-20240802monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-to-present-and-host-one-on-one-meetings-at-the-14th-annual-east-coa-hbio-20240606monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-to-present-at-the-jefferies-global-healthcare-conference-on-june-5--hbio-20240523monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-to-participate-in-the-benchmark-healthcare-house-call-virtual-confe-hbio-20240516monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-first-quarter-2024-financial-results-hbio-20240507monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-first-quarter-2024-earnings-conference-call-for-may-7-2024-at-hbio-20240429monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-action-to-improve-operational-efficiency-and-support-ongoing--hbio-20240409monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-apparatus-regenerative-technology-reports-fourth-quarter-and-full-year-2023-financ-hbio-20240402monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-to-participate-in-march-2024-investor-conferences-sidoti-s-small-ca-hbio-20240311monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-fourth-quarter-2023-financial-results-hbio-20240307monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-showcase-latest-solutions-for-preclinical-and-organoid-applications--hbio-20240306monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-fourth-quarter-2023-earnings-conference-call-for-march-7-2024-hbio-20240227monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-present-at-benchmark-company-s-discovery-one-on-one-investor-confere-hbio-20231120monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-present-at-southwest-ideas-investor-conference-on-november-16-2023-hbio-20231109monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-third-quarter-2023-financial-results-hbio-20231107monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-showcase-latest-innovations-in-preclinical-and-organoid-research-at--hbio-20231106monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-third-quarter-2023-earnings-conference-call-for-november-7-20-hbio-20231030monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-and-etisense-announce-agreement-for-supply-and-distribution-of-decro-mi-hbio-20230918monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-second-quarter-2023-financial-results-hbio-20230808monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-present-at-sidoti-virtual-investor-conference-on-august-16-2023-hbio-20230803monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-second-quarter-2023-earnings-conference-call-for-august-8-202-hbio-20230727monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-set-to-join-russell-2000-and-3000-indexes-hbio-20230622monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-appoints-jennifer-cote-as-chief-financial-officer-hbio-20230620monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-present-at-sidoti-micro-cap-virtual-conference-may-10th-2023-hbio-20230502monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-first-quarter-2023-financial-results-hbio-20230425monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-initial-order-for-integrated-animal-behavior-monitoring-syste-hbio-20230418monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-first-quarter-2023-earnings-conference-call-for-april-25-2023-hbio-20230417monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-present-at-sidoti-investor-conference-march-22-23-2023-hbio-20230316monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-present-at-keybanc-capital-markets-life-sciences-medtech-investor-fo-hbio-20230316monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-fourth-quarter-2022-financial-results-hbio-20230309monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-fourth-quarter-2022-earnings-conference-call-for-march-9-2023-hbio-20230228monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-cfo-transition-hbio-20221212monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-third-quarter-2022-financial-results-hbio-20221108monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-third-quarter-2022-earnings-conference-call-for-november-8-20-hbio-20221102monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-second-quarter-2022-financial-results-hbio-20220804monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-second-quarter-2022-earnings-conference-call-for-august-4-202-hbio-20220726monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-first-quarter-2022-financial-results-hbio-20220504monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-introduces-smartstudy-first-of-kind-next-generation-inhalation-system-c-hbio-20220426monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-first-quarter-2022-earnings-conference-call-for-may-4-2022-at-hbio-20220421monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-fourth-quarter-2021-financial-results-hbio-20220308monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-wyss-institute-s-erapid-sensor-technology-licensed-to-antisoma-therapeutics-to-fac-hbio-20220307monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-fourth-quarter-2021-earnings-conference-call-for-march-8-2022-hbio-20220221monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-third-quarter-2021-financial-results-hbio-20211103monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-third-quarter-2021-earnings-conference-call-for-november-3-20-hbio-20211018monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-second-quarter-2021-financial-results-hbio-20210805monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-second-quarter-2021-earnings-conference-call-for-august-5-202-hbio-20210719monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-first-quarter-2021-financial-results-hbio-20210506monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-first-quarter-2021-earnings-conference-call-for-may-6-2021-at-hbio-20210419monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-fourth-quarter-2020-financial-results-hbio-20210310monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-fourth-quarter-2020-earnings-conference-call-for-march-10-202-hbio-20210218monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-new-credit-facility-hbio-20201222monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-attend-benchmark-s-9th-annual-discovery-one-on-one-conference-hbio-20201116monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-third-quarter-2020-financial-results-hbio-20201105monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-third-quarter-2020-earnings-conference-call-for-november-5-20-hbio-20201020monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-present-at-singular-research-compelling-values-webinar-hbio-20200916monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-second-quarter-2020-financial-results-hbio-20200805monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-second-quarter-2020-earnings-conference-call-for-august-5-202-hbio-20200720monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-issues-letter-to-shareholders-hbio-20200526monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-first-quarter-2020-financial-results-hbio-20200505monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-first-quarter-2020-earnings-conference-call-for-may-5-2020-at-hbio-20200423monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-appointment-of-susan-steele-to-board-of-directors-hbio-20200406monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-introduces-next-generation-inhalation-system-to-aid-in-the-fight-agains-hbio-20200323monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-fourth-quarter-2019-financial-results-hbio-20200226monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-fourth-quarter-2019-earnings-conference-call-for-february-26--hbio-20200211monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-attend-benchmark-s-8th-annual-discovery-one-on-one-conference-hbio-20191121monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-third-quarter-financial-results-hbio-20191105monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-hbio-20191101monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-executive-appointment-hbio-20191031monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-third-quarter-2019-earnings-conference-call-for-november-5-at-hbio-20191022monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-executive-appointment-hbio-20191021monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-strategic-action-plan-and-financial-targets-hbio-20190909monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-present-at-janney-healthcare-conference-hbio-20190904monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-elects-alan-edrick-to-board-of-directors-hbio-20190904monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-quarter-ended-june-30-2019-financial-results-hbio-20190725monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-hbio-20190719monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-second-quarter-2019-earnings-conference-call-for-july-25-at-4-hbio-20190719monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-names-michael-rossi-chief-financial-officer-hbio-20190718monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-subsidiary-data-sciences-international-launches-hardware-for-expanding--hbio-20190626monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-subsidiary-data-sciences-international-launches-digital-telemetry-impla-hbio-20190515monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-first-quarter-2019-financial-results-hbio-20190502monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-first-quarter-2019-conference-call-for-may-2-at-4-30-pm-et-hbio-20190423monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-subsidiary-data-sciences-international-wins-award-for-best-achievement--hbio-20190403monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-showcase-products-at-experimental-biology-2019-hbio-20190326monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-strong-fourth-quarter-and-year-end-2018-results-and-issues-2019-hbio-20190228monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-subsidiary-data-sciences-international-to-participate-at-sot-2019-with--hbio-20190226monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-fourth-quarter-2018-conference-call-for-february-28-at-4-30-p-hbio-20190219monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-presents-data-symposium-session-and-new-products-at-neuroscience-2018-hbio-20181102monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-third-quarter-2018-financial-results-hbio-20181025monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-names-kam-unninayar-as-chief-financial-officer-hbio-20181022monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-third-quarter-2018-conference-call-for-october-25-at-4-30-pm--hbio-20181018monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-management-change-hbio-20180822monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-second-quarter-2018-financial-results-hbio-20180726monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-second-quarter-2018-conference-call-for-july-26-at-4-30-pm-et-hbio-20180719monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-subsidiary-data-sciences-international-launches-two-telemetry-implants--hbio-20180620monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-subsidiary-data-sciences-international-launches-inhalation-exposure-sys-hbio-20180613monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-first-quarter-2018-financial-results-hbio-20180502monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-subsidiary-multi-channel-systems-launches-beta-cell-screening-system-fo-hbio-20180501monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-subsidiary-data-sciences-international-launches-two-telemetry-implants--hbio-20180501monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-first-quarter-2018-conference-call-for-may-2-at-4-30-pm-et-hbio-20180423monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-fourth-quarter-and-year-end-2017-results-hbio-20180301monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-fourth-quarter-2017-conference-call-for-march-1-at-4-30-pm-et-hbio-20180222monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-completes-acquisition-of-data-sciences-international-hbio-20180131monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-acquire-data-sciences-international-and-sells-denville-scientific-hbio-20180122monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-third-quarter-2017-financial-results-hbio-20171026monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-appoints-katherine-eade-and-thomas-loewald-to-the-board-of-directors-hbio-20171025monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-third-quarter-2017-conference-call-for-october-26-at-4-30-pm--hbio-20171018monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-second-quarter-2017-financial-results-hbio-20170727monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-second-quarter-2017-conference-call-for-july-27-at-4-30-pm-et-hbio-20170718monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-elects-james-green-as-chairman-of-board-of-directors-hbio-20170607monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-first-quarter-2017-financial-results-hbio-20170427monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-first-quarter-2017-conference-call-for-april-27-at-4-30-pm-et-hbio-20170419monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-fourth-quarter-and-year-end-2016-results-and-2017-financial-gui-hbio-20170309monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-fourth-quarter-2016-conference-call-for-march-9-at-4-30-pm-et-hbio-20170223monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-third-quarter-2016-financial-results-hbio-20161027monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-third-quarter-2016-conference-call-for-october-27-at-4-30-pm--hbio-20161013monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-second-quarter-2016-financial-results-hbio-20160728monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-second-quarter-2016-conference-call-for-july-28-at-8-30-am-et-hbio-20160718monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-attend-the-benchmark-company-llc-one-on-one-conference-in-milwaukee--hbio-20160531monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-first-quarter-2016-financial-results-hbio-20160512monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-regains-compliance-with-nasdaq-s-continued-listing-requirements-hbio-20160504monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-fourth-quarter-and-year-end-2015-results-preliminary-first-quar-hbio-20160429monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-delays-filing-of-annual-report-on-form-10-k-and-announces-preliminary-u-hbio-20160328monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-receives-nasdaq-delinquency-notice-hbio-20160317monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-delay-in-filing-form-10-k-hbio-20160314monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-third-quarter-2015-financial-results-and-updates-outlook-for-fu-hbio-20151029monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-showcase-array-of-new-products-at-society-for-neuroscience-2015-annu-hbio-20151016monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-third-quarter-2015-conference-call-for-october-29-at-8-30-am--hbio-20151015monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-q2-2015-revenues-increase-7-year-over-year-12-in-constant-currency-to-2-hbio-20150730monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-second-quarter-2015-conference-call-for-july-30-at-8-30-am-et-hbio-20150716monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-join-the-russell-3000-and-russell-global-indexes-hbio-20150623monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-appoints-james-green-to-the-board-of-directors-and-announces-retirement-hbio-20150430monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-first-quarter-2015-financial-results-hbio-20150430monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-first-quarter-2015-conference-call-for-april-30-at-11-00-am-e-hbio-20150421monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-fourth-quarter-2014-non-gaap-eps-increases-100-versus-fourth-quarter-20-hbio-20150226monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-appoints-ryan-atienza-to-vice-president-of-sales-at-its-denville-scient-hbio-20150218monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-fourth-quarter-and-year-end-2014-conference-call-for-february-hbio-20150213monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-acquires-all-operations-of-heka-electronik-hbio-20150108monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-present-at-inaugural-equities-com-small-cap-stars-conference-at-the--hbio-20141216monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-exhibit-at-society-for-neuroscience-2014-annual-meeting-in-washingto-hbio-20141113monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-appoints-bertrand-loy-to-board-of-directors-hbio-20141110monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-third-quarter-2014-results-hbio-20141030monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-nasdaq-hbio-to-ring-the-nasdaq-stock-market-closing-bell-hbio-20141017monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-third-quarter-2014-conference-call-for-october-30-2014-at-11--hbio-20141016monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-acquires-multi-channel-systems-mcs-gmbh-and-triangle-biosystems-inc-hbio-20141001monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-second-quarter-2014-results-hbio-20140731monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-second-quarter-2014-conference-call-for-july-31-2014-at-11-00-hbio-20140716monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-present-at-seethruequity-conference-in-new-york-city-on-may-28-hbio-20140514monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-first-quarter-2014-results-hbio-20140501monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-present-at-the-sidoti-micro-cap-conference-on-may-9-in-new-york-hbio-20140423monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-first-quarter-2014-conference-call-for-may-1-2014-at-11-00-am-hbio-20140417monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-names-ronald-aplin-to-vice-president-global-operations-and-quality-hbio-20140310monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-fourth-quarter-and-year-end-2013-results-hbio-20140227monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-schedules-fourth-quarter-and-year-end-2013-conference-call-for-february-hbio-20140214monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-realigns-global-operations-to-create-organizational-efficiencies-and-be-hbio-20131204monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-inducement-grants-to-recently-hired-executives-hbio-20131118monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-allocation-of-tax-basis-for-spin-off-of-harvard-apparatus-reg-hbio-20131113monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-becomes-pure-play-developer-manufacturer-and-marketer-of-tools-for-life-hbio-20131104monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reports-third-quarter-2013-results-hbio-20131031monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-appoints-yong-sun-as-vp-strategic-marketing-and-business-development-hbio-20131028monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-schedules-third-quarter-2013-conference-call-for-october-31-2013-at-hbio-20131022monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-appoints-yoav-sibony-as-vp-global-sales-hbio-20131021monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-names-robert-e-gagnon-as-chief-financial-officer-hbio-20131016monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-jeffrey-a-duchemin-as-new-ceo-hbio-20130827monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-schedules-second-quarter-2013-conference-call-for-august-1-2013-hbio-20130731monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-comments-on-regenerated-trachea-recipient-hannah-genevieve-warren-s-pas-hbio-20130708monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-announces-retirement-of-ceo-and-appointment-of-interim-ceo-hbio-20130515monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-to-participate-in-press-conference-today-to-discuss-landmark-surgery-hbio-20130430monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-schedules-first-quarter-2013-conference-call-for-may-2-2013-hbio-20130426monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-announces-receipt-of-private-letter-ruling-and-affirms-plan-to-spin-hbio-20130325monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-schedules-fourth-quarter-2012-conference-call-for-february-28-2013-hbio-20130225monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-announces-filing-of-ipo-registration-statement-for-harvard-apparatu-hbio-20121211monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-schedules-third-quarter-2012-conference-call-for-november-1-2012-hbio-20121026monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-schedules-second-quarter-2012-conference-call-for-august-2-2012-hbio-20120719monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-schedules-first-quarter-2012-conference-call-for-may-3-2012-hbio-20120501monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-comments-on-the-passing-of-christopher-lyles-hbio-20120306monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-schedules-fourth-quarter-2011-conference-call-for-march-1-2012-hbio-20120227monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-acquires-ahn-hbio-20120207monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-announces-participation-in-the-regenerative-medicine-insight-track--hbio-20120109monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-s-inbreath-bioreactor-used-in-world-s-second-successful-synthetic-trach-hbio-20111129monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-s-inbreath-bioreactor-highlighted-in-article-in-the-lancet-summarizing--hbio-20111128monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-schedules-third-quarter-2011-conference-call-for-november-3-2011-hbio-20111028monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-schedules-second-quarter-2011-conference-call-for-august-4-2011-hbio-20110728monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-acquires-cma-microdialysis-preclinical-business-hbio-20110701monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-ranked-massachusetts-1-biotech-company-in-boston-globe-100-hbio-20110519monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-schedules-first-quarter-2011-conference-call-for-april-28-2011-hbio-20110421monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-hbio-chief-executive-officer-to-ring-the-nasdaq-stock-market-closin-hbio-20110315monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-schedules-fourth-quarter-2010-conference-call-for-february-25-2011-hbio-20110224monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-schedules-fourth-quarter-2010-conference-call-for-february-25-2011-hbio-20110218monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-files-two-major-patents-in-field-of-regenerative-medicine-hbio-20101209monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-schedules-third-quarter-2010-conference-call-for-november-3-2010-hbio-20101015monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-acquires-coulbourn-instruments-a-leading-manufacturer-of-systems-us-hbio-20100823monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-schedules-second-quarter-2010-conference-call-for-august-5-2010-hbio-20100726monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-novel-bioreactor-helps-grow-first-functional-lung-for-successful-transp-hbio-20100720monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-schedules-first-quarter-2010-conference-call-for-april-29-2010-hbio-20100421monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-engages-the-investor-relations-group-hbio-20100304monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-president-david-green-to-present-at-cowen-and-company-30th-annual-healt-hbio-20100301monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-schedules-fourth-quarter-2009-conference-call-for-february-25-2010-hbio-20100218monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-schedules-third-quarter-2009-conference-call-for-november-4-2009-hbio-20091023monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-joins-russell-2000-index-hbio-20090721monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-schedules-second-quarter-2009-conference-call-for-august-6-2009-hbio-20090721monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-reports-first-quarter-2025-results-and-business-highlights-traw-20250515monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-announces-management-updates-traw-20250328monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-to-host-investor-event-on-bird-flu-and-covid-product-candidates-virtual-event-traw-20250326monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-announces-positive-topline-phase-1-data-for-flu-candidate-tivoxavir-marboxil-traw-20241008monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-announces-positive-topline-phase-1-results-for-covid-candidate-ratutrelvir-an-traw-20240930monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-inc-appoints-luba-greenwood-to-board-of-directors-traw-20240920monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-to-host-corporate-update-call-on-august-15-2024-at-8-00-am-et-traw-20240814monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-s-icar-poster-highlights-potency-of-covid-19-candidate-traw-20240523monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-completes-first-cohort-dosed-in-phase-1-trial-for-covid-therapy-traw-20240507monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-announces-new-employee-inducement-grants-traw-20240402monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-presents-positive-interim-data-from-phase-1b-clinical-study-of-gt-02287--ganx-20260526monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-to-present-at-oppenheimer-36th-annual-healthcare-life-sciences-conferenc-ganx-20260219monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-highlights-biomarker-evidence-supporting-disease-modifying-potential-of--ganx-20260106monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-to-host-virtual-kol-event-on-gt-02287-for-parkinson-s-disease-ganx-20251218monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-announces-positive-results-in-key-exploratory-endpoint-from-its-phase-1b-ganx-20251218monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-announces-pricing-of-7-0-million-public-offering-ganx-20250716monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-announces-completion-of-target-enrollment-in-phase-1b-clinical-study-eva-ganx-20250630monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-to-participate-in-upcoming-investor-conferences-ganx-20250610monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-announces-oral-presentation-at-2nd-gba1-meeting-ganx-20250529monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-advances-teverelix-program-towards-registrational-development-targeting-hig-mdcx-20260608monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-advances-skinject-into-registrational-development-for-gorlin-syndrome-mdcx-20260603monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-reports-first-quarter-2026-financial-results-and-provides-corporate-update-mdcx-20260514monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-to-present-new-teverelix-data-at-aace-2026-demonstrating-long-acting-hormon-mdcx-20260415monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-submits-optimized-phase-2-study-protocol-to-u-s-fda-for-teverelix-in-acute--mdcx-20260406monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-announces-skinject-phase-2-principal-investigator-and-key-opinion-leader-ko-mdcx-20260316monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-ltd-studies-demonstrate-long-acting-therapeutic-approach-with-stable-bone-t-mdcx-20260112monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-ltd-explore-novel-treatment-innovations-that-may-revolutionize-treatments-f-mdcx-20251124monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-ltd-announces-filing-of-fda-commissioner-s-national-priority-voucher-applic-mdcx-20251117monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-ltd-announces-collaboration-with-the-gorlin-syndrome-alliance-to-pursue-com-mdcx-20251029monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-ltd-appoints-faisal-mehmud-md-mrcp-as-chief-medical-officer-mdcx-20241118monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-announces-co-development-agreement-with-adbiotech-for-burixafor-gpc-100-xcur-20260422monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-be-xcur-20211225monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-be-xcur-20211220monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-be-xcur-20211215monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-deadline-alert-faruqi-faruqi-llp-securities-litigation-partner-james-josh-wilson-e-xcur-20211213monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-alert-bragar-eagel-squire-p-c-is-investigating-exicure-inc-on-behalf-of-exicure-st-xcur-20211213monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-alert-bragar-eagel-squire-p-c-is-investigating-exicure-inc-on-behalf-of-exicure-st-xcur-20211208monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-alert-bragar-eagel-squire-p-c-is-investigating-exicure-inc-on-behalf-of-exicure-st-xcur-20211203monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-alert-bragar-eagel-squire-p-c-is-investigating-exicure-inc-on-behalf-of-exicure-st-xcur-20211127monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-announces-positive-phase-1-data-for-topical-anti-tnf-compound-ast-005-in-patients--xcur-20161011monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-announces-dosing-of-first-patient-in-phase-1-trial-for-the-treatment-of-chronic-pl-xcur-20160426monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-co-founder-awarded-prestigious-dan-david-prize-xcur-20160212monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-co-founder-awarded-inaugural-sackler-prize-xcur-20151015monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-reports-first-quarter-2026-financial-results-lfwd-20260515monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-reports-fourth-quarter-and-full-year-2025-financial-results-lfwd-20260318monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-regains-compliance-with-nasdaq-minimum-bid-price-requirement-lfwd-20260311monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-18-2026-lfwd-20260310monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-to-report-second-quarter-financial-results-on-august-14-2025-lfwd-20250807monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-names-mark-grant-as-new-ceo-lfwd-20250519monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-to-present-at-sidoti-virtual-investor-conference-on-may-21-lfwd-20250519monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-ltd-reports-first-quarter-2025-financial-results-lfwd-20250515monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-completes-research-program-with-israeli-human-robot-interaction-consortium-to-int-lfwd-20250508monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-to-report-first-quarter-2025-financial-results-on-may-15-2025-lfwd-20250507monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-launches-sales-of-the-rewalk-7-personal-exoskeleton-in-u-s-market-lfwd-20250415monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-ltd-reports-fourth-quarter-and-full-year-2024-financial-results-lfwd-20250307monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-and-corlife-finalize-partnership-to-expand-workers-compensation-access-to-rewalk--lfwd-20250306monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-and-myolyn-expand-partnership-to-enhance-patient-access-to-myocycle-fes-cycling-t-lfwd-20250305monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-to-report-fourth-quarter-and-fiscal-year-end-2024-financial-results-on-march-7-20-lfwd-20250228monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-announces-ceo-transition-lfwd-20250219monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-finalizes-personal-exoskeleton-reimbursement-agreement-with-barmer-adding-8-5-mil-lfwd-20250205monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-to-host-virtual-investor-event-to-discuss-commercial-strategy-key-initiatives-and-lfwd-20250204monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-ceo-issues-year-end-2024-open-letter-to-shareholders-and-provides-2025-commercial-lfwd-20250113monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-cancels-its-extraordinary-general-meeting-of-shareholders-lfwd-20250113monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-announces-closing-of-5-million-registered-direct-offering-priced-at-the-market-un-lfwd-20250108monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-announces-5-million-registered-direct-offering-priced-at-the-market-under-nasdaq--lfwd-20250107monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-announces-postponement-of-its-extraordinary-general-meeting-of-shareholders-lfwd-20241227monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-ltd-reports-third-quarter-2024-financial-results-lfwd-20241112monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-announces-appointment-of-robert-j-marshall-to-its-board-of-directors-lfwd-20241107monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-to-report-third-quarter-financial-results-on-november-12-2024-lfwd-20241105monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-streamlines-u-s-operations-in-next-phase-of-growth-and-operational-efficiencies-lfwd-20241104monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-ltd-to-present-at-thinkequity-conference-on-oct-30-2024-lfwd-20241024monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-launches-direct-sales-of-alterg-product-line-in-germany-lfwd-20240924monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-announces-appointment-of-dr-keith-e-tansey-as-consulting-director-of-clinical-res-lfwd-20240910monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-s-first-annual-step-challenge-donates-5-000-to-german-association-for-people-livi-lfwd-20240905monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-lfwd-20240904monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-reports-second-quarter-2024-financial-results-lfwd-20240815monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-to-report-second-quarter-financial-results-on-august-15-2024-lfwd-20240808monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-announces-appointment-of-joseph-e-turk-as-incoming-chairman-of-its-board-of-direc-lfwd-20240702monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-unveils-newest-addition-to-its-alterg-anti-gravity-product-line-introducing-alter-lfwd-20240626monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-to-present-at-sidoti-virtual-investor-conference-on-june-12-lfwd-20240604monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-reports-first-quarter-2024-financial-results-lfwd-20240515monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-to-report-first-quarter-financial-results-on-may-15-2024-lfwd-20240507monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-announces-the-appointment-of-mike-swinford-to-its-board-of-directors-lfwd-20240419monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-ceo-issues-open-letter-to-shareholders-on-progress-to-finalize-exoskeleton-medica-lfwd-20240401monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-announces-reverse-share-split-lfwd-20240313monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-announces-the-centers-for-medicare-medicaid-services-cms-is-deferring-its-final-d-lfwd-20240301monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-reports-fourth-quarter-and-full-year-2023-financial-results-lfwd-20240227monthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-to-report-fourth-quarter-and-fiscal-year-end-2023-financial-results-on-february-2-lfwd-20240220monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-inc-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more-informati-lpcn-20260406monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-withdraws-preliminary-injunction-threat-against-marketing-of-clarus-therapeutics--lpcn-20190826monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-canaccord-genuity-37th-annual-growth-conference-lpcn-20170802monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-host-conference-call-and-webcast-to-discuss-top-line-results-from-the-dosing-v-lpcn-20170619monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-jefferies-2017-healthcare-conference-lpcn-20170602monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-completes-enrollment-in-the-lpcn-1021-fixed-dose-clinical-trials-lpcn-20170424monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-16th-annual-needham-healthcare-conference-lpcn-20170328monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-27th-annual-oppenheimer-conference-lpcn-20170314monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-full-year-of-2016-lpcn-20170306monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-29th-annual-roth-conference-lpcn-20170306monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-the-promotion-of-gregory-bass-to-chief-commercial-officer-lpcn-20170215monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-third-quarter-of-2016-lpcn-20161108monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-issuance-of-us-patent-9-480-690-lpcn-20161107monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-completes-post-action-meeting-with-fda-for-lpcn-1021-new-drug-application-lpcn-20161017monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-wins-dismissal-of-patent-infringement-lawsuit-related-to-lpcn-1021-lpcn-20161007monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-2016-ladenburg-thalmann-healthcare-conference-lpcn-20160920monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-second-quarter-of-2016-lpcn-20160809monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-36th-annual-canaccord-genuity-growth-conference-lpcn-20160804monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-added-to-russell-3000-and-russell-global-indexes-lpcn-20160627monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-first-quarter-of-2016-lpcn-20160509monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-15th-annual-needham-company-healthcare-conference-lpcn-20160406monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-full-year-of-2015-lpcn-20160310monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-28th-annual-roth-conference-lpcn-20160308monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-27th-annual-piper-jaffray-healthcare-conference-lpcn-20151124monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-adopts-stockholder-rights-plan-lpcn-20151113monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-third-quarter-of-2015-lpcn-20151112monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-pdufa-goal-date-for-lpcn-1021-nda-lpcn-20151112monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-presentation-of-lpcn-1021-clinical-data-at-21st-annual-smsna-meeting-lpcn-20151111monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-ladenburg-thalmann-2015-healthcare-conference-lpcn-20150922monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-second-quarter-of-2015-lpcn-20150811monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-35th-annual-canaccord-genuity-growth-conference-lpcn-20150805monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-s-oral-testosterone-well-tolerated-in-phase-3-study-lpcn-20150629monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-jmp-securities-life-sciences-conference-lpcn-20150616monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-development-plans-for-lpcn-1107-lpcn-20150608monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-appoints-dr-jyrki-mattila-as-chief-business-officer-lpcn-20150518monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-first-quarter-of-2015-lpcn-20150507monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-completion-of-lpcn-1021-oral-testosterone-phase-3-clinical-trial-lpcn-20150430monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-prices-30-2-million-public-offering-of-common-stock-lpcn-20150429monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-prices-30-2-million-public-offering-of-common-stock-lpcn-20150424monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-proposed-public-offering-of-common-stock-lpcn-20150423monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-full-year-2014-lpcn-20150311monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-27th-annual-roth-conference-lpcn-20150304monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-presentation-of-lpcn-1021-clinical-data-at-endo-2015-lpcn-20150227monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-cowen-and-company-35th-annual-health-care-conference-lpcn-20150224monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-inc-nasdaq-lpcn-to-ring-the-nasdaq-stock-market-closing-bell-lpcn-20150116monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-positive-phase-1b-top-line-results-with-lpcn-1107-in-pregnant-women-lpcn-20150112monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-piper-jaffray-26th-annual-healthcare-conference-lpcn-20141125monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-management-changes-lpcn-20141117monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-third-quarter-of-2014-lpcn-20141110monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-positive-top-line-results-in-phase-2a-study-of-lpcn-1111-lpcn-20141013monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-host-conference-call-and-webcast-to-discuss-top-line-results-from-the-phase-3--lpcn-20140923monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-second-quarter-of-2014-lpcn-20140813monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-issuance-of-u-s-patent-for-lpcn-1021-lpcn-20140715monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-added-to-russell-microcap-index-lpcn-20140630monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-jefferies-2014-global-healthcare-conference-lpcn-20140529monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-first-quarter-of-2014-lpcn-20140513monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-begin-trading-on-the-nasdaq-capital-market-lpcn-20140318monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-26th-annual-roth-conference-lpcn-20140305monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-2014-leerink-global-healthcare-conference-lpcn-20140204monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-new-appointments-to-its-board-of-directors-lpcn-20140107monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-chairman-receives-honorary-doctor-of-science-degree-from-the-university-of-michig-lpcn-20131213monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-inc-announces-exercise-and-closing-of-over-allotment-option-lpcn-20131206monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-inc-announces-pricing-of-public-offering-of-common-stock-lpcn-20131127monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-announces-year-end-and-fourth-quarter-2025-financial-results-and-pro-cmmb-20260319monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-announces-nebokitug-phase-2-spring-trial-results-in-primary-sclerosi-cmmb-20251202monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-to-participate-in-oppenheimer-s-movers-in-rare-disease-summit-cmmb-20251124monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-announces-first-quarter-2025-financial-results-and-provides-corporat-cmmb-20250515monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-announces-presentation-of-positive-nebokitug-phase-2-clinical-data-in-primary-scl-cmmb-20250505monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-reports-new-positive-clinical-data-at-easl-2025-supporting-nebokitug-s-impact-in--cmmb-20250428monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-announces-new-medical-and-clinical-appointments-cmmb-20250415monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-reports-positive-results-in-nebokitug-phase-2-psc-open-label-extension-trial-show-cmmb-20250327monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-announces-year-end-and-fourth-quarter-2024-financial-results-and-pro-cmmb-20250303monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-completes-successful-end-of-phase-2-meeting-and-aligns-with-fda-on-clear-and-effi-cmmb-20250219monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-to-participate-in-oppenheimer-35th-annual-healthcare-life-sciences-c-cmmb-20250203monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-to-participate-in-oppenheimer-s-movers-in-rare-disease-summit-cmmb-20241203monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-announces-third-quarter-2024-financial-results-and-provides-corporat-cmmb-20241114monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-to-report-third-quarter-2024-financial-results-and-provide-a-busines-cmmb-20241030monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-announces-late-breaking-oral-presentation-of-cm-101-phase-2-results--cmmb-20241015monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-to-present-at-october-2024-investor-conferences-cmmb-20241001monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-to-present-at-september-2024-investor-conferences-cmmb-20240828monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-announces-second-quarter-2024-financial-results-and-provides-corpora-cmmb-20240821monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-to-report-second-quarter-2024-financial-results-and-provide-a-busine-cmmb-20240812monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-announces-closing-of-10-million-private-placement-cmmb-20240730monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-cmmb-20240726monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-announces-10-million-private-placement-cmmb-20240725monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-announces-positive-phase-2-trial-results-cm-101-achieves-primary-and-cmmb-20240725monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-announces-new-publications-reinforcing-the-clinical-potential-of-its-cmmb-20240618monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-presents-data-supporting-the-clinical-potential-of-cm-101-as-a-novel-cmmb-20240606monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-to-participate-in-upcoming-scientific-conferences-cmmb-20240517monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-announces-first-quarter-2024-financial-results-and-provides-corporat-cmmb-20240509monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimu-cmmb-20240508monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-to-present-at-2024-aegis-virtual-conference-cmmb-20240502monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-to-report-first-quarter-2024-financial-results-and-provide-a-busines-cmmb-20240424monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-reports-new-peer-reviewed-publication-reinforcing-the-clinical-association-of-its-cmmb-20240418monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-to-host-virtual-key-opinion-leader-webinar-on-primary-sclerosing-cholangitis-on-a-cmmb-20240402monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-awarded-new-european-patent-for-cm-101-its-first-in-class-monoclonal-antibody-in--cmmb-20240325monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-and-agc-biologics-expand-partnership-to-manufacture-cm-101-for-phase-cmmb-20210623monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-new-thermal-dynamics-study-that-strengthens-clinical-foundation-and-marke-irix-20251208monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-present-at-the-sidoti-year-end-virtual-investor-conference-irix-20251205monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-third-quarter-2025-financial-results-on-november-11-2025-irix-20251028monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-first-quarter-2025-financial-results-on-may-13-2025-irix-20250430monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-comments-on-recent-stock-price-volatility-irix-20250314monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-27-2025-irix-20250313monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-milestone-five-year-study-confirms-the-long-term-effectiveness-and-safety-irix-20241218monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-comments-on-changing-glaucoma-reimbursement-landscape-irix-20241119monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-third-quarter-2024-financial-results-on-november-12-2024-irix-20241104monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-convertible-note-financing-irix-20240805monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-second-quarter-2024-financial-results-on-august-8-2024-irix-20240730monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-first-quarter-2024-financial-results-on-may-14-2024-irix-20240508monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-fourth-quarter-and-full-year-2023-financial-results-irix-20240326monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-schedules-fourth-quarter-and-full-year-2023-financial-results-and-update-on-strateg-irix-20240320monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-corporation-receives-european-patent-on-micropulse-technology-irix-20240206monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-first-patient-enrollment-in-micropulse-tlt-clinical-study-conducted-in-co-irix-20240124monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-launches-new-iridex-532-and-iridex-577-lasers-in-us-market-marking-35-years-of-lase-irix-20240111monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-confirms-medicare-administrative-contractors-retired-local-coverage-determinations--irix-20231228monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-host-third-quarter-financial-results-conference-call-on-november-14-2023-irix-20231113monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-third-quarter-financial-results-on-november-14-2023-irix-20231026monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-strategic-review-to-unlock-shareholder-value-irix-20230829monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-second-quarter-financial-results-on-august-10-2023-irix-20230727monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-first-quarter-financial-results-on-may-11-2023-irix-20230427monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-present-at-the-35th-annual-roth-conference-irix-20230307monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-introduces-new-research-and-showcases-five-events-at-the-ags-meeting-irix-20230302monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-9-2023-irix-20230223monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-participate-in-fireside-chat-with-stifel-equity-research-irix-20221206monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-third-quarter-2022-financial-results-on-november-10-2022-irix-20221027monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-showcases-its-non-incisional-treatments-for-glaucoma-introduces-sweep-management-so-irix-20220929monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-present-at-the-inaugural-gilmartin-group-emerging-growth-company-showcase-irix-20220818monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-second-quarter-2022-financial-results-on-august-15-2022-irix-20220801monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-obtains-regulatory-clearance-for-cyclo-g6-glaucoma-platform-in-china-irix-20220614monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-first-quarter-2022-financial-results-on-may-12-2022-irix-20220428monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-present-at-the-34th-annual-roth-conference-irix-20220308monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-fourth-quarter-and-full-year-2021-financial-results-on-march-10-2022-irix-20220224monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-present-at-the-2021-stifel-virtual-healthcare-conference-irix-20211112monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-third-quarter-2021-financial-results-on-november-11-2021-irix-20211028monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-present-at-the-lytham-partners-fall-2021-investor-conference-irix-20210930monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-present-at-the-2021-h-c-wainwright-ophthalmology-virtual-conference-irix-20210809monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-second-quarter-2021-financial-results-on-august-12-2021-irix-20210729monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-first-quarter-2021-financial-results-on-may-11-2021-irix-20210427monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-completes-transaction-with-topcon-corporation-irix-20210310monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-fourth-quarter-and-full-year-2020-financial-results-on-march-22-2021-irix-20210308monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-strategic-collaboration-with-topcon-corporation-irix-20210302monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-micropulse-transscleral-laser-therapy-now-accepted-in-the-european-glauco-irix-20201222monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-present-at-the-2020-stifel-virtual-healthcare-conference-irix-20201103monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-third-quarter-2020-financial-results-on-november-9-2020-irix-20201026monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-second-quarter-2020-financial-results-on-august-6-2020-irix-20200723monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-first-quarter-2020-financial-results-on-may-11-2020-irix-20200428monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-retirement-of-vp-finance-irix-20200330monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-fourth-quarter-and-full-year-2019-financial-results-on-march-12-2020-irix-20200228monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-launches-revised-micropulse-p3-device-for-glaucoma-irix-20200226monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-2019-third-quarter-financial-results-irix-20191107monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-present-at-the-2019-stifel-healthcare-conference-irix-20191105monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-third-quarter-2019-financial-results-on-november-7-2019-irix-20191024monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-second-quarter-2019-financial-results-on-august-6-2019-irix-20190723monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-s-micropulse-laser-technology-featured-in-several-glaucoma-and-retina-research-pres-irix-20190429monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-first-quarter-2019-financial-results-on-may-2-2019-irix-20190418monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-present-at-the-spring-investor-summit-irix-20190318monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-present-at-the-31st-annual-roth-conference-irix-20190306monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-2018-fourth-quarter-and-full-year-financial-results-irix-20190305monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-fourth-quarter-and-2018-financial-results-on-march-5-2019-irix-20190226monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-2018-third-quarter-financial-results-and-raises-full-year-2018-guidance-irix-20181101monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-participate-in-upcoming-investor-conferences-irix-20181025monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-third-quarter-2018-financial-results-on-november-1-2018-irix-20181018monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-pricing-of-public-offering-of-common-stock-irix-20180914monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-proposed-public-offering-of-common-stock-irix-20180913monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-fda-clearance-to-introduce-updated-trufocus-lio-premiere-laser-accessory--irix-20180906monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-cyclo-g6-laser-system-for-glaucoma-treatment-used-in-majority-of-top-u-s-ophthalmol-irix-20180830monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-2018-second-quarter-results-and-raises-full-year-2018-guidance-irix-20180802monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-second-quarter-2018-financial-results-on-august-2-2018-irix-20180719monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reaches-milestone-of-1000th-cyclo-g6-system-shipped-irix-20180710monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-approval-of-cyclo-g6-glaucoma-laser-system-in-korea-irix-20180619monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-2018-first-quarter-financial-results-irix-20180503monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-first-quarter-2018-financial-results-on-may-3-2018-irix-20180419monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-receives-ce-mark-for-transilluminated-probe-irix-20180320monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-2017-fourth-quarter-and-full-year-financial-results-irix-20180308monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-present-at-the-30th-annual-roth-conference-irix-20180227monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-fourth-quarter-and-2017-financial-results-on-march-8-2018-irix-20180220monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-preliminary-operational-and-financial-results-for-2017-fourth-quarter-and-irix-20180108monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-2017-third-quarter-financial-results-irix-20171102monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-present-at-upcoming-investor-conferences-irix-20171026monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-to-report-third-quarter-2017-financial-results-on-november-2-2017-irix-20171019monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-unveils-ai-nose-breakthrough-that-revolutionizes-smart-manufacturing-factory-automat-aimd-20240819monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-inc-to-present-at-small-cap-growth-virtual-investor-conference-february-7th-aimd-20240201monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-upcoming-presentation-of-additional-data-from-the-virage-phase-tovx-20260417monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-presentation-of-data-from-vcn-01-retinoblastoma-phase-1-clinic-tovx-20250527monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-reports-first-quarter-2025-operational-highlights-and-financial-results-tovx-20250514monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-closing-of-7-5-million-public-offering-tovx-20250508monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-presentation-of-data-from-the-phase-1b-2a-clinical-trial-of-sy-tovx-20250410monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-present-at-the-2025-neauxcancer-conference-tovx-20250319monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual-tovx-20250305monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-selected-as-finalist-in-international-competition-for-merck-kgaa-s-emea--tovx-20241031monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-achieves-target-patient-enrollment-in-the-virage-phase-2b-trial-of-vcn-0-tovx-20240923monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-reverse-stock-split-tovx-20240816monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-participate-in-the-a-g-p-virtual-healthcare-conference-tovx-20240514monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-discuss-the-trial-design-for-virage-a-phase-2b-clinical-study-of-syst-tovx-20240425monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-presentation-at-the-american-society-for-cell-and-gene-therapy-tovx-20240408monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-full-year-2023-operationa-tovx-20240319monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-participate-in-the-bio-europe-spring-conference-tovx-20240311monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-positive-recommendation-from-the-independent-data-monitoring-c-tovx-20240207monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-participate-in-the-b-riley-securities-annual-oncology-conference-tovx-20240116monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-third-quarter-2023-operat-tovx-20231106monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-participate-in-the-bio-europe-conference-tovx-20231102monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-presents-survival-outcomes-data-from-phase-1-study-evaluating-vcn-01-in--tovx-20231023monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-participate-in-the-emerging-growth-conference-tovx-20230928monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-second-quarter-2023-opera-tovx-20230801monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-appointment-of-ramon-alemany-ph-d-to-senior-vice-president-of--tovx-20230523monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operat-tovx-20230504monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-presentation-of-data-from-cohort-1-of-the-phase-1b-2a-clinical-tovx-20230413monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-reschedule-conference-call-and-webcast-to-discuss-fourth-quarter-and--tovx-20230324monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-fourth-quarter-and-full-y-tovx-20230320monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-participate-in-the-b-riley-securities-3rd-annual-oncology-conference-tovx-20230117monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-participate-in-upcoming-investor-conferences-tovx-20221201monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-reschedule-conference-call-and-webcast-to-discuss-third-quarter-2022--tovx-20221110monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-third-quarter-2022-operat-tovx-20221103monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-first-patient-dosed-in-second-cohort-of-phase-1b-2a-clinical-t-tovx-20221103monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-host-key-opinion-leader-webinar-on-lead-program-vcn-01-and-advancing--tovx-20221031monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-presentation-at-the-14th-international-oncolytic-virotherapy-i-tovx-20221024monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-publication-in-nature-communications-highlighting-advances-in-gamma-delta-inab-20260603monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-presents-updated-overall-survival-data-surpassing-19-5-months-for-deltex-dri-in-new-inab-20260601monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-presents-new-translational-data-demonstrating-deltex-dri-reshapes-the-immune-landsc-inab-20260514monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-showcase-next-generation-t-cell-engager-platform-and-new-clinical-data-at-upcomi-inab-20260506monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-inab-20260403monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-presents-updated-phase-i-ii-data-demonstrating-meaningful-and-durable-survival-impr-inab-20260112monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025-inab-20250318monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-the-td-cowen-45th-annual-health-care-conference-inab-20250226monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-conference-inab-20250224monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-inab-20250214monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-biotech-showcase-2025-in-san-francisco-inab-20250106monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-noble-capital-markets-twentieth-annual-emerging-growth-equity-confere-inab-20241202monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-plenary-oral-presentation-at-the-2024-society-for-neuro-oncology-sno-annu-inab-20241112monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-upcoming-presentation-at-the-2024-american-society-of-hematology-ash-annu-inab-20241105monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-pricing-of-12-4-million-private-placement-inab-20241001monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-clinical-pipeline-prioritization-to-focus-on-inb-100-for-acute-myeloid-le-inab-20240904monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-inab-20240829monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-second-quarter-2024-financial-results-and-recent-corporate-highlights-inab-20240808monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-the-h-c-wainwright-2nd-annual-immune-cell-engager-virtual-conference-inab-20240624monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-international-society-for-cell-gene-therapy-isct-2024-inab-20240524monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-inb-200-phase-1-study-data-in-newly-diagnosed-glioblastoma-to-be-presente-inab-20240523monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-upcoming-presentation-at-2024-european-hematology-association-congress-inab-20240514monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-demonstrates-robust-and-reproducible-gamma-delta-t-cell-therapy-manufacturing-in-or-inab-20240513monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-first-quarter-2024-financial-results-and-recent-corporate-highlights-inab-20240509monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-doses-first-patient-in-phase-2-clinical-trial-of-inb-400-in-newly-diagnosed-gliobla-inab-20240430monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-oral-presentation-at-the-upcoming-american-society-of-gene-cell-therapy-a-inab-20240424monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-noble-capital-markets-emerging-growth-virtual-healthcare-equity-confe-inab-20240416monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-new-preclinical-data-for-gamma-delta-nscar-t-cell-therapy-platform-at-aac-inab-20240409monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-new-preclinical-data-on-novel-gamma-delta-car-platform-candidate-at-aacr-inab-20240305monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-publication-on-novel-gamma-delta-t-cell-therapy-for-glioblastoma-in-front-inab-20240214monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-highlights-recent-company-accomplishments-and-outlines-2024-pipeline-goals-inab-20240104monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-positive-clinical-update-demonstrating-continued-durable-complete-remissi-inab-20231211monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-appoints-dr-corinne-epperly-to-board-of-directors-inab-20231207monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-host-investor-call-at-8-30-am-et-on-tuesday-december-12-to-discuss-updated-clini-inab-20231205monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-data-highlighting-potential-of-inb-200-and-inb-400-to-treat-patients-wit-inab-20231110monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-presents-biologic-correlative-data-from-the-inb-200-phase-1-trial-in-newly-diagnose-inab-20231106monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-presents-positive-data-update-from-induced-pluripotent-stem-cell-ipsc-platform-at-t-inab-20231103monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-new-positive-data-from-phase-1-trial-of-inb-100-at-2023-american-society-inab-20231102monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-participate-at-the-2023-truist-securities-biopharma-symposium-inab-20231101monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-presentations-at-the-society-for-immunology-of-cancer-sitc-38th-annual-me-inab-20230929monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-host-research-development-day-on-its-gamma-delta-t-cell-therapies-on-thursday-oc-inab-20230926monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-participate-at-the-2023-cantor-fitzgerald-global-healthcare-conference-inab-20230920monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-strengthens-intellectual-property-portfolio-with-newly-granted-global-patents-inab-20230919monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-participate-at-the-h-c-wainwright-25th-annual-global-investment-conference-inab-20230906monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-the-h-c-wainwright-immune-cell-engager-virtual-conference-inab-20230815monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-expands-capabilities-with-the-grand-opening-of-its-advanced-research-and-developmen-inab-20230808monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-new-preclinical-data-in-ovarian-cancer-to-be-presented-at-asgct-26th-annu-inab-20230502monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-appoints-jeremy-graff-ph-d-to-board-of-directors-inab-20230501monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-oral-presentation-of-new-inb-200-phase-1-data-in-glioblastoma-gbm-to-be-p-inab-20230426monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-receives-fda-orphan-drug-designation-for-inb-400-410-for-the-treatment-of-newly-dia-inab-20230425monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-new-positive-clinical-data-from-phase-1-trial-of-inb-100-at-ebmt-2023-an-inab-20230411monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-positive-preclinical-data-on-novel-gamma-delta-car-platform-at-aacr-annu-inab-20230316monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-the-cowen-43rd-annual-healthcare-conference-inab-20230301monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-the-h-c-wainwright-cell-therapy-virtual-conference-inab-20230221monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-the-b-riley-securities-3rd-annual-virtual-oncology-conference-inab-20230117monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-biotech-showcase-2023-in-san-francisco-inab-20230103monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-third-quarter-2022-financial-results-and-highlights-recent-company-progress-inab-20221110monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-positive-early-data-from-ongoing-phase-1-study-of-inb-100-at-the-64th-am-inab-20221103monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-november-investor-conferences-inab-20221101monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-cantor-oncology-hemonc-conference-inab-20220927monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-partners-with-the-dunbar-car-t-cell-program-at-the-university-of-louisville-as-the--inab-20220915monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-h-c-wainwright-24th-annual-global-investment-conference-inab-20220913monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-appoints-michael-r-bishop-m-d-to-its-scientific-advisory-board-inab-20220908monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-september-investor-and-scientific-conferences-inab-20220830monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-closing-of-10-25-million-underwritten-public-offering-of-common-stock-inab-20220816monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-appoints-kenneth-r-lamontagne-ph-d-to-lead-business-development-inab-20220712monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-july-investor-and-scientific-conferences-inab-20220630monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-presentation-at-jefferies-global-healthcare-conference-and-additional-jun-inab-20220608monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-positive-glioblastoma-multiforme-gbm-clinical-updates-from-the-inb-200-ph-inab-20220606monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-data-emerging-from-its-recently-unveiled-gamma-delta-t-cell-off-the-shelf-inab-20220517monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-unveils-induced-pluripotent-stem-cell-ipsc-platform-at-asgct-25th-annual-meeting-inab-20220505monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-may-investor-and-scientific-conferences-inab-20220504monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-continues-to-build-on-its-clinical-and-regulatory-team-with-two-key-appointments-inab-20220413monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-april-investor-and-scientific-conferences-inab-20220405monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-march-investor-and-scientific-conferences-inab-20220304monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-bio-ceo-investor-conference-and-next-generation-car-tcr-summit-inab-20220210monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-upcoming-january-investor-conferences-inab-20220110monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-clinical-updates-from-the-phase-1-clinical-trial-of-its-genetically-modif-inab-20220106monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-promotes-kate-rochlin-ph-d-to-chief-operating-officer-inab-20211209monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-appoints-trishna-goswami-m-d-as-chief-medical-officer-inab-20211116monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-preclinical-data-on-the-potential-for-gamma-delta-t-cell-therapy-combina-inab-20211111monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-scientific-conferences-in-november-pegs-europe-sitc-and-sno-inab-20211104monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-s-announces-peer-reviewed-publication-of-preclinical-results-using-proprietary-mgmt-inab-20211027monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-biofuture-2021-and-advanced-therapies-congress-expo-2021-inab-20211004monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-the-newyorkbio-virtual-breakfast-series-and-h-c-wainwright-23rd-annua-inab-20210830monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-completes-dosing-of-first-cohort-in-phase-1-clinical-trial-with-allogeneic-gamma-de-inab-20210811monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-appoints-emily-fairbairn-and-luba-greenwood-to-board-of-directors-inab-20210804monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-pricing-of-initial-public-offering-inab-20210730monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-launches-proposed-initial-public-offering-inab-20210722monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-completes-treatment-of-first-cohort-in-phase-1-clinical-trial-with-gamma-delta-t-ce-inab-20210607monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-presents-first-cohort-phase-1-clinical-data-on-inb-200-at-american-society-of-clini-inab-20210520monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-participate-in-upcoming-may-scientific-conferences-inab-20210505monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-demonstrates-in-vitro-activity-of-deltex-dri-car-t-cells-against-glioblastoma-multi-inab-20210409monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-presents-gamma-delta-t-cells-as-cancer-therapeutics-at-the-esmo-targeted-anticancer-inab-20210302monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-appoints-patrick-mccall-as-chief-financial-officer-inab-20210208monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-first-in-human-phase-1-trial-update-from-the-university-of-kansas-cancer--inab-20201203monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-to-present-at-upcoming-december-investor-conferences-inab-20201130monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-appoints-alan-s-roemer-as-chairman-inab-20201007monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-names-kate-rochlin-phd-assistant-vice-president-operations-and-innovation-inab-20200917monthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratne-erna-20260520monthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-unveils-breakthrough-preclinical-results-erna-101-achieves-100-surviva-erna-20260506monthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-highlights-key-catalysts-as-company-advances-toward-first-in-human-cli-erna-20260331monthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-announces-successful-pre-ind-fda-meeting-and-continues-progress-toward-erna-20260106monthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-presents-new-preclinical-data-at-american-society-of-hematology-ash-an-erna-20251208monthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-announces-oral-presentation-at-the-67th-american-society-of-hematology-erna-20251203monthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-secures-6-million-in-second-closing-under-securities-purchase-agreemen-erna-20250624monthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-announces-1-for-15-reverse-stock-split-erna-20250610monthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-announces-new-data-to-be-presented-at-asco-annual-meeting-2025-erna-20250528monthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna--erna-20250514monthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-presented-promising-data-on-innovative-cell-therapy-treatment-at-aacr--erna-20250429monthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-announces-new-data-to-be-presented-at-aacr-annual-meeting-2025-erna-20250422monthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-closes-new-funding-round-erna-20250403monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-the-noble-capital-markets-21st-emerging-growth-equity-confe-cocp-20251201monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-data-from-phase-1-study-of-first-in-class-norovirus-protease-i-cocp-20250710monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-participate-in-noble-capital-markets-2025-emerging-growth-virtual-equi-cocp-20250528monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-life-science-innovation-northwest-2025-conference-cocp-20250416monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-participate-in-a-fireside-chat-at-the-zacks-scr-life-sciences-virtual--cocp-20250306monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-advances-oral-pan-viral-protease-inhibitor-cdi-988-into-phase-1-multiple--cocp-20240926monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-highlights-its-novel-inhaled-and-oral-influenza-a-antiviral-cc-42344-at-t-cocp-20231129monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-the-noblecon-19-conference-on-december-4-2023-cocp-20231127monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-discuss-progress-with-novel-inhaled-and-oral-influenza-a-antiviral-cc--cocp-20231109monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-doses-first-subjects-in-clinical-study-of-cdi-988-for-pandemic-norovirus--cocp-20230928monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-participate-in-the-h-c-wainwright-global-investment-conference-cocp-20230905monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-second-quarter-2023-financial-results-and-provides-updates-on-its-cocp-20230814monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-selects-novel-oral-protease-inhibitor-cdi-988-as-norovirus-lead-cocp-20230808monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-receives-hrec-approval-to-initiate-phase-1-study-to-evaluate-oral-broad-s-cocp-20230531monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-presents-new-data-from-its-cc-42344-phase-1-influenza-a-study-at-the-7th--cocp-20230504monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-new-data-from-its-cc-42344-phase-1-influenza-a-study-at-the-7t-cocp-20230418monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-2022-financial-results-and-provides-updates-on-its-antiviral-drug-cocp-20230329monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-highlights-progress-with-its-antiviral-portfolio-at-the-virtual-invest-cocp-20230322monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-participation-in-virtual-investor-events-cocp-20230126monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-highly-favorable-safety-and-tolerability-results-from-a-phase-1-s-cocp-20221219monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-highlights-progress-with-cc-42344-as-a-potential-oral-treatment-for-pande-cocp-20221201monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-favorable-safety-data-from-the-phase-1-study-with-oral-antivira-cocp-20221117monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-third-quarter-2022-financial-results-and-provides-updates-on-its--cocp-20221114monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-participate-in-two-investor-conferences-in-november-cocp-20221102monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-granted-european-patent-covering-oral-antiviral-candidate-cc-42344-in-com-cocp-20221101monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-the-ld-micro-main-event-xv-cocp-20221019monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-cc-42344-phase-1-influenza-a-data-at-the-world-antiviral-congr-cocp-20221013monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-selects-cdi-988-for-clinical-development-as-an-oral-treatment-for-covid-1-cocp-20221011monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-the-dawson-james-securities-2022-small-cap-growth-conferenc-cocp-20221005monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-a-1-for-12-reverse-stock-split-cocp-20221003monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-participate-in-the-h-c-wainwright-global-investment-conference-cocp-20220906monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-engages-cro-to-conduct-phase-2a-human-challenge-influenza-a-clinical-tria-cocp-20220808monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-cc-42344-pharmacokinetic-data-in-influenza-a-once-daily-dosing-cocp-20220714monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-expands-collaboration-with-the-national-institute-of-allergy-and-infectio-cocp-20220601monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-the-h-c-wainwright-global-investment-conference-cocp-20220518monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-collaborates-with-the-national-institute-of-allergy-and-infectious-diseas-cocp-20220421monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-the-life-science-innovation-northwest-2022-conference-cocp-20220419monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-the-noble-capital-markets-noblecon18-conference-cocp-20220414monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-favorable-preliminary-data-from-phase-1-initial-cohorts-with-cc-4-cocp-20220412monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-participate-in-the-maxim-group-2022-virtual-growth-conference-cocp-20220322monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-initiates-enrollment-in-phase-1-influenza-a-study-with-novel-broad-spectr-cocp-20220310monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-participate-in-upcoming-investment-conferences-cocp-20220303monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-selects-two-lead-antiviral-drug-candidates-for-its-covid-19-oral-drug-pro-cocp-20220127monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-receives-fda-guidance-to-advance-clinical-development-of-its-covid-19-ant-cocp-20220106monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-the-h-c-wainwright-bioconnect-virtual-conference-cocp-20220104monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-discuss-progress-with-covid-19-antiviral-programs-and-clinical-strateg-cocp-20211202monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-presents-preclinical-data-from-covid-19-antiviral-programs-and-outlines-n-cocp-20211201monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-s-sars-cov-2-main-protease-inhibitors-demonstrate-pan-viral-activity-agai-cocp-20211108monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-submits-pre-investigational-new-drug-briefing-package-to-the-fda-for-clin-cocp-20211101monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-data-from-its-oral-and-intranasal-covid-19-therapeutics-progra-cocp-20211021monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-the-dawson-james-2021-small-cap-growth-conference-on-octobe-cocp-20211014monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-receives-australian-regulatory-clearance-to-initiate-phase-1-study-of-cc--cocp-20211006monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference-cocp-20210907monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-second-quarter-2021-financial-results-and-provides-antiviral-prog-cocp-20210816monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-s-sars-cov-2-3cl-protease-lead-cdi-45205-demonstrates-broad-spectrum-acti-cocp-20210729monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-joins-russell-microcap-index-cocp-20210628monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-completes-ind-enabling-studies-with-cc-42344-for-the-treatment-of-seasona-cocp-20210623monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-s-lead-covid-19-antiviral-cdi-45205-shown-to-be-active-against-sars-cov-2-and-tw-cocp-20210614monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-s-participation-in-the-noble-capital-markets-c-suite-interview-series-is--cocp-20210609monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-first-quarter-2021-financial-results-and-provides-business-update-cocp-20210517monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-closing-of-40-million-bought-deal-cocp-20210507monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-provides-update-on-its-covid-19-antiviral-discovery-and-development-progr-cocp-20210503monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-2020-financial-results-provides-business-update-including-antivir-cocp-20210317monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-extends-drug-discovery-collaboration-with-hitgen-and-interx-cocp-20210310monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-participate-in-the-virtual-33rd-annual-roth-conference-cocp-20210309monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference--cocp-20210302monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-presentation-at-the-reimagine-health-research-symposium-features-overview-cocp-20210121monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-further-development-of-influenza-a-b-antiviral-compounds-by-mer-cocp-20210119monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-to-present-at-the-3rd-annual-reimagine-health-research-symposium-cocp-20210114monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-virtual-noblecon17-conference-on-january-19-2021-cocp-20210112monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-h-c-wainwright-virtual-bioconnect-conference-cocp-20210105monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-selects-lead-compound-for-further-development-against-coronaviruses-cocp-20201222monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-third-quarter-2020-financial-results-and-provides-update-on-antiv-cocp-20201116monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-selected-to-present-at-the-world-antiviral-conference-cocp-20201110monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-the-h-c-wainwright-6th-annual-israel-conference-cocp-20201106monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-provides-update-on-influenza-a-program-cocp-20201019monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-notice-of-pendency-and-proposed-settlement-of-stockholder-deriv-cocp-20201002monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-the-h-c-wainwright-22nd-annual-global-investment-conference-cocp-20200908monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-closing-of-17-2-million-bought-deal-including-partial-exercise--cocp-20200831monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-second-quarter-2020-financial-results-and-provides-updates-on-ant-cocp-20200806monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-the-publication-by-collaborators-of-positive-data-demonstrating-cocp-20200804monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-first-quarter-2020-financial-results-and-provides-updates-on-anti-cocp-20200514monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-provides-covid-19-impact-update-on-development-programs-cocp-20200511monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-the-april-2020-virtual-investor-summit-cocp-20200415monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-6-8-million-registered-direct-offering-priced-at-the-market-cocp-20200309monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-11-0-million-registered-direct-offering-priced-at-the-market-cocp-20200227monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-inc-announces-license-agreement-with-kansas-state-university-research-fou-cocp-20200224monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-inc-s-structure-based-technology-has-demonstrated-broad-utility-in-develo-cocp-20200213monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-inc-to-present-at-noble-capital-markets-16th-annual-investor-conference-cocp-20200211monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-inc-announces-closing-of-2-2-million-registered-direct-offering-cocp-20200203monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-inc-prices-2-2-million-registered-direct-offering-cocp-20200129monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-the-12th-annual-ld-micro-main-event-cocp-20191204monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-third-quarter-2019-financial-results-and-provides-corporate-updat-cocp-20191112monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-presents-positive-data-from-u-s-phase-2a-study-of-cc-31244-demonstrating--cocp-20191111monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-inc-prices-3-000-000-underwritten-public-offering-cocp-20191031monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-inc-announces-proposed-underwritten-public-offering-of-common-stock-cocp-20191030monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-new-data-on-cc-31244-and-abstract-acceptance-for-poster-present-cocp-20191030monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-presents-data-at-the-26th-international-symposium-on-hepatitis-c-virus-an-cocp-20191008monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-abstract-accepted-for-poster-presentation-at-26th-international-cocp-20191001monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-the-2019-cantor-global-healthcare-conference-cocp-20190926monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-presents-positive-preclinical-data-for-cc-42344-at-the-options-x-for-the--cocp-20190903monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-abstract-accepted-for-oral-presentation-at-the-isirv-options-x--cocp-20190821monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-second-quarter-2019-financial-results-and-provides-corporate-upda-cocp-20190809monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-commences-patient-enrollment-for-hong-kong-phase-2a-study-of-cc-31244-for-cocp-20190520monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-first-quarter-2019-financial-results-and-provides-corporate-updat-cocp-20190510monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-2018-financial-results-and-provides-corporate-overview-and-busine-cocp-20190401monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-provides-update-on-clinical-development-program-evaluating-cc-31244-for-u-cocp-20190122monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-announces-board-changes-cocp-20190107monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-presentation-at-the-respidart-2018-frontiers-in-drug-developmen-cocp-20181130monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-presentation-of-preclinical-characterization-data-of-cc-42344-a-cocp-20181113monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-2018-third-quarter-financial-results-and-provides-corporate-updat-cocp-20181112monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-inc-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-invest-cocp-20181024monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-inc-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-invest-cocp-20181017monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-clinical-trial-agreement-for-investigator-initiated-phase-2a-st-cocp-20181008monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-inc-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that-cocp-20180927monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-completes-patient-enrollment-in-phase-2a-study-evaluating-cc-31244-for-ul-cocp-20180920monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-2018-second-quarter-financial-results-and-provides-corporate-upda-cocp-20180809monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-commences-enrollment-and-initiates-patient-dosing-in-phase-2a-study-evalu-cocp-20180628monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-inclusion-in-russell-microcap-index-cocp-20180625monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-nasdaq-closing-bell-ceremony-cocp-20180604monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-2018-first-quarter-financial-results-and-provides-corporate-updat-cocp-20180511monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-at-the-fred-hutch-and-merck-infectious-disease-summit-cocp-20180510monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-receives-fda-clearance-to-initiate-phase-2a-clinical-study-evaluating-cc--cocp-20180403monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-2017-financial-results-and-provides-corporate-overview-and-busine-cocp-20180322monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-uplist-to-the-nasdaq-capital-market-cocp-20180312monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-provides-update-on-reverse-stock-split-cocp-20180123monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-1-for-30-reverse-stock-split-cocp-20180123monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-filing-2017-third-quarter-financial-statements-and-provides-com-cocp-20171108monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-hitgen-and-interx-enter-into-drug-discovery-collaboration-cocp-20170905monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-filing-2017-second-quarter-financial-statements-and-provides-co-cocp-20170808monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-receives-investment-through-private-placement-cocp-20170424monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-financial-results-for-fourth-quarter-year-ended-december-31-2016--cocp-20170403monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-present-clinical-data-on-its-potent-pan-genotypic-ns5b-non-nucleoside--cocp-20170216monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-secures-australian-patent-approval-further-expanding-global-protection--aktx-20260427monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-asco-abstract-acceptance-highlights-potential-for-aktx-101-adc-to-treat-aktx-20260421monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-positive-preclinical-data-for-aktx-101-demonstrating-differenti-aktx-20260420monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-strategic-partnership-with-wuxi-xdc-to-advance-development-of-aktx-20260406monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-abstract-accepted-for-poster-presentation-at-the-american-ass-aktx-20260318monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-releases-virtual-investor-what-this-means-segment-aktx-20251218monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-highlights-preclinical-data-demonstrating-therapeutic-potential-of-lead-aktx-20251209monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-provides-corporate-update-and-highlights-its-adc-payload-innovation-exp-aktx-20251204monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment-aktx-20251125monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-appoints-biotech-finance-leader-kameel-d-farag-as-interim-chief-financi-aktx-20251118monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-filing-for-new-patent-for-novel-adc-platform-utilizing-splice-aktx-20250917monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-participate-in-the-virtual-investor-closing-bell-series-aktx-20250903monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-the-webull-financial-corporate-connect-webinar-series-bio-aktx-20250814monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-releases-virtual-investor-what-this-means-segment-aktx-20250729monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-continues-key-research-on-its-novel-antibody-drug-conjugate-payload-ph1-aktx-20250723monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-participates-in-the-virtual-investor-what-s-your-story-summer-spotlight-aktx-20250722monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-releases-virtual-investor-what-this-means-segment-highlighting-its-rece-aktx-20250625monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-bolsters-global-ip-estate-for-its-novel-antibody-drug-conjugate-adc-imm-aktx-20250618monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-releases-meet-the-team-video-featuring-recently-appointed-mark-f-kubik--aktx-20250529monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-live-with-webull-corporate-connect-virtual-biotech-invest-aktx-20250522monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-appoints-mark-f-kubik-as-head-of-business-development-oncology-aktx-20250501monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-releases-welcome-video-from-newly-appointed-chief-executive-officer-abi-aktx-20250422monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-appoints-biotechnology-industry-leader-abizer-gaslightwala-as-president-aktx-20250320monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-7-6-million-private-placement-offering-led-by-existing-shareh-aktx-20250303monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference-aktx-20250219monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-joins-webull-corporate-connect-service-platform-aktx-20250203monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-key-leadership-appointments-aktx-20241218monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-appoints-torsten-hombeck-ph-d-as-chief-financial-officer-aktx-20241216monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-regains-full-nasdaq-compliance-aktx-20241119monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-effectiveness-of-form-s-4-and-general-meeting-date-of-novembe-aktx-20241015monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-receives-positive-and-constructive-pre-ind-feedback-from-us-fda-for-pas-aktx-20240819monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-interim-ceo-employment-contract-demonstrating-alignment-with--aktx-20240605monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-secures-7-6-million-in-upsized-financing-round-aktx-20240604monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-pas-nomacopan-pre-clinical-electroretinography-erg-data-at-a-aktx-20240415monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-biotech-showcase-2024-aktx-20231214monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-a-poster-on-pre-clinical-development-of-long-acting-pas-noma-aktx-20231106monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-first-half-2023-financial-results-and-highlights-aktx-20230929monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-emerging-growth-conference-aktx-20230927monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-host-key-opinion-leader-webinar-on-hematopoietic-stem-cell-transplan-aktx-20230919monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-announces-ads-ratio-change-aktx-20230815monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-participate-in-a-g-p-s-virtual-healthcare-conference-aktx-20230516monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-host-key-opinion-leader-webinar-on-geographic-atrophy-and-the-potent-aktx-20230414monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-attend-arvo-2023-the-annual-meeting-of-the-association-for-research--aktx-20230411monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-a-case-study-from-the-phase-3-part-a-clinical-trial-of-nomaco-aktx-20230403monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-biotech-showcase-2023-aktx-20230104monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-participate-in-the-cantor-fitzgerald-medical-and-aesthetic-dermatolo-aktx-20221201monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-participate-in-the-ophthalmology-day-at-btig-aktx-20221122monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-participate-in-the-jefferies-london-healthcare-conference-aktx-20221109monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-participate-in-the-sidoti-november-2022-virtual-micro-cap-conference-aktx-20221031monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-second-quarter-2022-financial-results-and-highlights-recent-pip-aktx-20220927monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-participate-in-the-cantor-oncology-hemonc-conference-aktx-20220922monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-narrows-pipeline-focus-aktx-20220801monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-first-quarter-2022-financial-results-and-highlights-recent-pipe-aktx-20220720monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-results-from-compassionate-use-of-nomacopan-for-covid-19-cor-aktx-20220511monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-on-two-ongoing-programs-covering-age-related-macular-degener-aktx-20220321monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-new-data-supporting-use-of-drug-candidate-votucalis-targeting-aktx-20220309monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-bio-ceo-investor-conference-aktx-20220211monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-h-c-wainwright-bioconnect-virtual-conference-aktx-20220104monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-third-quarter-2021-financial-results-and-highlights-recent-clin-aktx-20211203monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-presentation-at-annual-complement-based-drug-development-summ-aktx-20211026monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference-aktx-20210922monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-second-quarter-2021-financial-results-and-highlights-recent-cli-aktx-20210922monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-its-phase-iii-plans-for-nomacopan-in-patients-with-bullous-p-aktx-20210910monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-the-h-c-wainwright-global-investment-conference-aktx-20210907monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-private-placement-aktx-20210707monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-q1-2021-financial-results-and-highlights-recent-clinical-progre-aktx-20210629monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-poster-presentation-of-phase-ii-bullous-pemphigoid-disease-an-aktx-20210422monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-participate-in-two-january-virtual-investor-conferences-aktx-20210106monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-third-quarter-2020-financial-results-and-highlights-recent-clin-aktx-20201211monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-phase-ii-data-from-bullous-pemphigoid-trial-at-european-acad-aktx-20201027monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-its-phase-iii-plans-at-the-international-pemphigus-pemphigoi-aktx-20200929monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-participate-in-two-september-virtual-investor-conferences-aktx-20200910monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-second-quarter-2020-financial-results-and-highlights-recent-cli-aktx-20200901monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-first-quarter-2020-financial-results-and-highlights-recent-clin-aktx-20200529monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-participate-in-strh-life-sciences-virtual-meeting-series-aktx-20200504monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-positive-topline-results-from-fully-recruited-phase-ii-study--aktx-20200501monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-third-quarter-2019-financial-results-and-highlights-recent-clin-aktx-20191104monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-participate-in-ladenburg-thalmann-healthcare-conference-aktx-20190918monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-participate-in-citi-and-h-c-wainwright-conferences-in-early-septembe-aktx-20190903monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-second-quarter-2019-financial-results-and-highlights-recent-cli-aktx-20190829monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-oral-presentation-of-nomacopan-phase-ii-data-in-patients-with-aktx-20190731monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-first-quarter-2019-financial-results-and-highlights-recent-clin-aktx-20190529monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-announces-third-quarter-2018-financial-results-and-business-highlights-aktx-20181115monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-aktx-20180925monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-poster-at-the-23rd-congress-of-the-european-hematology-assoc-aktx-20180615monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-report-fourth-quarter-and-full-year-2017-financial-and-operational-r-aktx-20180316monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-the-leerink-partners-global-healthcare-conference-aktx-20180207monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-phase-ii-cobalt-trial-of-coversin-in-patients-with-pnh-met-th-aktx-20171208monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-host-investor-and-analyst-event-during-the-59th-american-society-of--aktx-20171204monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-pricing-of-public-offering-of-american-depositary-shares-aktx-20171018monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-proposed-public-offering-of-american-depositary-shares-aktx-20171017monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-aktx-20170919monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-the-37th-annual-canaccord-genuity-growth-conference-aktx-20170810monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-24-hour-deadline-alert-approximately-24-hours-remain-claimsfiler-remind-aktx-20170711monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti--aktx-20170701monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-notice-rosen-law-firm-reminds-akari-therapeutics-plc-investors-of-important-deadline-aktx-20170623monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti--aktx-20170520monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti--aktx-20170515monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-lead-plaintiff-deadline-alert-faruqi-faruqi-llp-encourages-investors-who-suffered-lo-aktx-20170513monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-the-jefferies-complement-symposium-aktx-20170403monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-fda-fast-track-designation-for-coversin-aktx-20170330monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-r-d-day-on-april-24-2017-aktx-20170317monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-the-29th-annual-roth-conference-aktx-20170307monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-attend-upcoming-investor-conferences-in-february-aktx-20170131monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-expands-clinical-and-regulatory-teams-with-industry-veterans-aktx-20170104monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-fda-allowance-of-ind-for-clinical-development-of-coversin-in--aktx-20170103monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-corporate-update-with-new-positive-clinical-data-and-a-new-pi-aktx-20161205monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-attend-upcoming-investor-conferences-in-november-aktx-20161111monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-abstract-on-potential-once-weekly-pas-coversin-at-the-58th-a-aktx-20161103monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-appoints-new-members-to-its-board-of-directors-aktx-20161014monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-upcoming-investor-conferences-on-september-27-and-28-in-n-aktx-20160916monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-receipt-of-orphan-drug-designation-for-coversin-from-the-u-s--aktx-20160912monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-the-canaccord-genuity-36th-annual-growth-conference-aktx-20160804monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-receives-approval-from-the-uk-medicines-healthcare-products-regulatory--aktx-20160713monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-receives-positive-opinion-for-orphan-drug-designation-for-coversin-in-t-aktx-20160712monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-positive-interim-update-from-phase-ib-trial-demonstrating-sus-aktx-20160706monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-the-jmp-2016-life-sciences-conference-aktx-20160615monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-the-jefferies-2016-healthcare-conference-aktx-20160526monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-upcoming-data-presentation-at-the-21st-european-hematology-as-aktx-20160519monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-and-xl-protein-gmbh-sign-license-agreement-to-develop-a-long-acting-aktx-20160414monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-at-cowen-and-company-36th-annual-health-care-conference-aktx-20160301monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-participate-in-the-2016-suntrust-robinson-humphrey-orphan-drug-day-aktx-20160217monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-receives-approval-from-the-uk-medicines-healthcare-products-regulatory--aktx-20160129monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-participate-in-the-2016-canaccord-genuity-rare-disease-biopharma-one-aktx-20160127monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-additional-data-from-non-human-primate-safety-study-demonstra-aktx-20160105monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-update-from-non-human-primate-safety-study-at-international-p-aktx-20151207monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-nasdaq-aktx-to-ring-the-nasdaq-stock-market-opening-bell-aktx-20151204monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-upcoming-data-presentations-at-the-57th-american-society-of-h-aktx-20151105monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-closes-75-million-private-placement-aktx-20150921monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-reports-first-quarter-financial-results-and-provides-business-updates-icu-20260513monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-present-at-the-life-sciences-investor-forum-on-march-11th-icu-20260309monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-present-at-upcoming-biotech-showcase-2026-investor-conference-icu-20260106monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-1-for-10-reverse-split-icu-20251223monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-fda-approval-of-reduction-in-mandatory-enrollment-for-save-surve-icu-20251202monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-appointment-of-michael-messinger-as-cfo-icu-20251117monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-reports-third-quarter-2025-financial-results-and-provides-business-updates-icu-20251113monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-present-early-save-registry-data-of-quelimmune-in-pediatric-acute-kidne-icu-20250923monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-report-second-quarter-financial-results-on-august-13-2025-icu-20250807monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-reports-positive-results-for-quelimmune-therapy-in-pediatric-acute-kidney--icu-20250722monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-grows-customer-base-and-expands-quelimmune-surveillance-registry-icu-20250716monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-expands-quelimmune-adoption-for-critically-ill-pediatric-patients-with-acu-icu-20250708monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-reports-update-on-nasdaq-listing-status-icu-20250625monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-two-feature-stories-on-quelimmune-adoption-and-patient-testimoni-icu-20250624monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-cms-coverage-for-medicare-and-medicaid-eligible-patients-with-ca-icu-20250528monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-reaches-interim-enrollment-target-for-neutralize-aki-pivotal-trial-of-scd--icu-20250513monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-report-first-quarter-financial-results-on-may-14-2025-icu-20250507monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-ceo-interview-on-benzinga-all-access-to-occur-today-at-approxima-icu-20250430monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2-icu-20250324monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-closing-of-6-million-registered-direct-offering-priced-at-the-ma-icu-20250203monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-adds-fifth-hospital-customer-for-quelimmune-icu-20250127monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-activates-15th-site-for-its-adult-acute-kidney-injury-pivotal-trial-icu-20250122monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-begins-shipping-quelimmune-to-a-fourth-hospital-customer-icu-20250108monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-activates-14th-hospital-for-its-adult-aki-pivotal-trial-icu-20241223monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-alert-bragar-eagel-squire-p-c-is-investigating-seastar-medical-holding-corp-on-beh-icu-20241217monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-projects-multibillion-dollar-market-potential-for-its-selective-cytopheret-icu-20241211monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-hold-business-update-conference-call-on-december-11-2024-icu-20241204monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-activates-sentara-norfolk-general-hospital-and-provides-enrollment-update--icu-20241203monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-present-at-noble-capital-markets-noblecon20-on-december-4-2024-icu-20241126monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-reaches-milestone-of-100th-quelimmune-commercial-device-as-shipments-begin-icu-20241115monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-adds-second-hospital-customer-for-quelimmune-icu-20241031monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-that-stanford-medicine-is-cleared-to-actively-enroll-subjects-in-icu-20241023monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-distribute-quelimmune-directly-to-hospital-customers-icu-20241022monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-that-enrollment-in-its-adult-acute-kidney-injury-pivotal-trial-h-icu-20241018monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-showcase-new-mechanistic-data-highlighting-the-immunomodulatory-effect--icu-20241015monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-present-at-the-2024-maxim-healthcare-virtual-summit-icu-20241009monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-expands-neutralize-aki-pivotal-trial-adding-two-premier-military-medical-f-icu-20241008monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-reports-enrollment-momentum-in-its-pivotal-adult-aki-trial-icu-20240925monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-webcast-fireside-chat-at-the-h-c-wainwright-global-investment-conferenc-icu-20240905monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-strengthens-financial-position-with-elimination-of-all-long-term-debt-icu-20240904monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-holding-corporation-investors-please-contact-the-portnoy-law-firm-to-recov-icu-20240830monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-holding-corporation-sued-for-securities-law-violations-investors-should-co-icu-20240821monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-reports-second-quarter-2024-financial-results-and-provides-a-business-upda-icu-20240813monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-holding-corporation-sued-for-securities-law-violations-investors-should-co-icu-20240808monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-ships-first-quelimmune-product-order-to-u-s-distribution-partner-icu-20240712monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-closing-of-10-million-registered-direct-offering-priced-at-the-m-icu-20240711monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-icu-20240710monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-finalizes-fda-labeling-requirement-for-quelimmune-paving-the-way-for-first-icu-20240703monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-s-selective-cytopheretic-device-featured-in-two-presentations-at-the-42nd--icu-20240611monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-present-at-the-virtual-emerging-growth-conference-on-june-12-2024-icu-20240606monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-25-for-1-reverse-stock-split-icu-20240606monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-reports-first-quarter-2024-financial-results-and-provides-a-business-updat-icu-20240514monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-3-6-million-nih-grant-award-to-study-the-selective-cytopheretic--icu-20240430monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-present-at-the-noble-capital-markets-emerging-growth-virtual-healthcare-icu-20240411monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-provides-updates-on-enrollment-of-adult-pivotal-clinical-study-and-commerc-icu-20240312monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-sponsored-symposium-featuring-experts-discussing-pediatric-acute-kidney-in-icu-20240311monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-granted-canadian-patent-with-broad-claims-covering-the-selective-cytophere-icu-20240201monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-issued-u-s-patent-with-broad-claims-covering-use-of-the-selective-cytopher-icu-20240109monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-updates-subject-enrollment-in-its-pivotal-trial-with-the-selective-cytophe-icu-20231228monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-forms-scientific-advisory-board-of-world-renowned-pediatric-and-adult-clin-icu-20231213monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-present-at-the-dawson-james-small-cap-growth-conference-on-october-12-2-icu-20231005monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-hold-business-update-conference-call-today-at-4-00-p-m-eastern-time-icu-20230822monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-sponsor-the-critical-care-time-podcast-series-covering-vital-medical-is-icu-20230630monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-present-at-the-maxim-group-virtual-healthcare-conference-hosted-by-m-ve-icu-20230614monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-present-at-the-jmp-securities-life-sciences-conference-on-may-16-2023-icu-20230510monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-activation-of-first-clinical-site-in-pivotal-trial-with-selectiv-icu-20230419monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-present-at-the-emerging-growth-virtual-conference-on-march-22-2023-icu-20230315monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-s-selective-cytopheretic-device-to-be-featured-at-the-5th-chronic-kidney-d-icu-20230224monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-details-of-the-selective-cytopheretic-device-pivotal-study-in-cr-icu-20230215monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-hold-business-update-conference-call-on-february-15-2023-icu-20230214monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-receives-fda-approval-to-begin-study-with-selective-cytopheretic-device-to-icu-20230209monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2-icu-20230131monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-bolsters-operational-expertise-with-appointment-of-thomas-r-mullen-as-vice-icu-20221202monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-appoints-rick-barnett-as-chairman-of-the-board-of-directors-icu-20221129monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-s-lead-product-candidate-the-selective-cytopheretic-device-scd-included-in-icu-20221107monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-nasdaq-icu-announces-positive-interim-safety-findings-from-ongoing-study-e-icu-20221103monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-nasdaq-icu-commences-trading-on-nasdaq-capital-market-and-outlines-corpora-icu-20221031monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-appoints-dr-sai-prasad-iyer-ph-d-as-vp-medical-affairs-and-clinical-develo-icu-20220919monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-reports-first-successful-treatment-of-pediatric-patient-with-hemophagocyti-icu-20220801monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-submits-humanitarian-device-exemption-application-to-fda-for-use-of-select-icu-20220720monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-publication-of-clinical-trial-results-demonstrating-its-scd-sign-icu-20220607monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-appoints-kevin-chung-md-as-chief-medical-officer-icu-20220524monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-granted-fda-breakthrough-device-designation-for-a-novel-immunomodulatory-t-icu-20220503monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-participate-in-upcoming-investor-conferences-pasg-20260219monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-guggenheim-securities-healthcare-innovation-conference-pasg-20241106monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-chardan-s-8th-annual-genetic-medicines-conference-pasg-20240923monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-welcomes-tom-kassberg-to-board-of-directors-pasg-20240910monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-h-c-wainwright-26th-annual-global-investment-conference-pasg-20240830monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-participate-in-upcoming-investor-conferences-pasg-20240806monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-goldman-sachs-45th-annual-global-healthcare-conference-pasg-20240605monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-recipient-of-third-annual-tachi-yamada-scholarship-award-pasg-20240521monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-chardan-s-8th-annual-genetic-medicines-and-cell-therapy-manufact-pasg-20240422monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-seeks-pennsylvania-college-student-candidates-for-third-annual-tachi-yamada-sc-pasg-20240305monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-participate-in-upcoming-investor-conferences-pasg-20240227monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-guggenheim-healthcare-talks-6th-annual-biotechnology-conference-pasg-20240131monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-pasg-20231117monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-guggenheim-s-5th-annual-inflammation-neurology-immunology-confer-pasg-20231030monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pasg-20231020monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-chardan-s-7th-annual-genetic-medicines-conference-pasg-20230925monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-promising-interim-clinical-data-from-first-eight-patients-with-gm1-g-pasg-20230807monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-participate-in-upcoming-investor-conferences-pasg-20230801monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-welcomes-dolan-sondhi-ph-d-to-board-of-directors-pasg-20230731monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-goldman-sachs-44th-annual-global-healthcare-conference-pasg-20230605monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-recipient-of-second-annual-tachi-yamada-scholarship-award-pasg-20230504monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-pasg-20230421monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-chardan-s-7th-annual-genetic-medicines-and-cell-therapy-manufact-pasg-20230417monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-d-pasg-20230327monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-seeks-pennsylvania-college-student-candidates-for-second-annual-tachi-yamada-s-pasg-20230301monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-cowen-43rd-annual-health-care-conference-pasg-20230228monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-6-2023-pasg-20230227monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-updated-interim-data-from-imagine-1-study-for-gm1-gangliosidosis-at-pasg-20230215monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-pasg-20230120monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-guggenheim-4th-annual-immunology-neurology-day-pasg-20221108monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-report-third-quarter-2022-financial-results-on-november-10-2022-pasg-20221103monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pasg-20221014monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-appointment-of-william-chou-m-d-as-chief-executive-officer-pasg-20221010monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-chardan-s-6th-annual-genetic-medicines-conference-pasg-20220926monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pasg-20220819monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-doses-first-patient-in-global-clinical-trial-of-pbft02-gene-therapy-for-fronto-pasg-20220811monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-2022-wedbush-pacgrow-healthcare-virtual-conference-pasg-20220805monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-report-second-quarter-2022-financial-results-on-august-4-2022-pasg-20220728monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pasg-20220721monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-appoints-michael-kamarck-ph-d-to-board-of-directors-pasg-20220706monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-the-goldman-sachs-43rd-annual-global-healthcare-conference-pasg-20220609monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-receives-fda-clearance-of-ind-application-for-pbml04-for-treatment-of-metachro-pasg-20220608monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-leadership-transition-pasg-20220601monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-inducement-awards-under-nasdaq-listing-rule-5635-c-4-pasg-20220520monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-report-first-quarter-2022-financial-results-on-may-16-2022-pasg-20220509monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-updated-imagine-1-study-clinical-and-biomarker-data-at-the-american-pasg-20220502monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-inducement-awards-under-nasdaq-listing-rule-5635-c-4-pasg-20220422monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-publication-of-preclinical-data-that-support-ongoing-clinical-study--pasg-20220329monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-participate-in-upcoming-investor-conferences-pasg-20220328monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-provides-update-on-strategic-priorities-and-extends-cash-runway-pasg-20220315monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-doses-first-patient-in-global-clinical-trial-for-infantile-krabbe-disease-a-ra-pasg-20220310monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-participate-in-upcoming-march-investor-conferences-pasg-20220301monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-report-fourth-quarter-and-full-year-2021-financial-results-on-march-3-2022-pasg-20220224monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-showcase-gm1-gangliosidosis-and-krabbe-clinical-programs-at-2022-worldsympo-pasg-20220131monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-pasg-20220103monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-pipeline-expansion-and-clinical-program-update-pasg-20211208monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-inducement-award-under-nasdaq-listing-rule-5635-c-4-pasg-20211119monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-guggenheim-3rd-annual-neuro-immunology-conference-pasg-20211109monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-report-third-quarter-2021-financial-results-on-november-4-2021-pasg-20211028monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-participate-in-upcoming-october-conferences-pasg-20210927monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-inducement-awards-under-nasdaq-listing-rule-5635-c-4-pasg-20210917monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-maxine-gowen-ph-d-as-chairwoman-of-the-board-of-directors-pasg-20210907monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-citi-16th-annual-biopharma-virtual-conference-pasg-20210902monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-inducement-awards-under-nasdaq-listing-rule-5635-c-4-pasg-20210827monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-mourns-the-sudden-passing-of-chairman-of-the-board-tadataka-yamada-m-d-pasg-20210805monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-12th-annual-wedbush-pacgrow-healthcare-conference-pasg-20210804monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-report-second-quarter-2021-financial-results-on-august-5-2021-pasg-20210729monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-inducement-award-for-newly-appointed-chief-commercial-officer-under--pasg-20210721monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-key-executive-appointments-pasg-20210719monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-participate-in-upcoming-june-investor-conferences-pasg-20210526monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-pre-clinical-data-presentation-at-annual-asgct-meeting-pasg-20210511monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-host-virtual-r-d-event-on-may-17-pasg-20210510monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-partners-with-informeddna-to-offer-genetic-counseling-and-testing-for-patients-pasg-20210503monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-report-first-quarter-2021-financial-results-on-may-5-2021-pasg-20210429monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-receives-european-commission-orphan-designation-for-pbkr03-for-treatment-of-kr-pasg-20210405monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-first-patient-dosed-in-imagine-1-study-of-pbgm01-gene-therapy-for-in-pasg-20210401monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-participate-in-upcoming-april-investor-conferences-pasg-20210325monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-appoints-eliseo-o-salinas-m-d-msc-as-chief-research-development-officer-pasg-20210322monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-participate-in-upcoming-march-investor-conferences-pasg-20210302monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-report-fourth-quarter-and-full-year-2020-financial-results-on-march-3-2021-pasg-20210224monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-appoints-maxine-gowen-ph-d-to-board-of-directors-pasg-20210219monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-receives-fda-clearance-of-ind-application-for-pbft02-gene-therapy-candidate-fo-pasg-20210128monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-pricing-of-public-offering-pasg-20210122monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-launch-of-proposed-public-offering-pasg-20210119monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-host-first-of-a-series-of-2021-virtual-r-d-events-on-january-25-pasg-20210119monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-pasg-20210104monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-receives-fda-clearance-of-ind-application-for-lead-gene-therapy-candidate-pbgm-pasg-20210104monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-gene-therapy-manufacturing-research-and-development-site-pasg-20201216monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-receives-mhra-clinical-trial-authorization-for-pbgm01-for-treatment-of-gm1-gan-pasg-20201210monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-teams-with-catalent-to-start-cgmp-manufacturing-for-lead-gene-therapy-products-pasg-20201207monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-piper-sandler-32nd-annual-healthcare-conference-pasg-20201123monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-highlights-university-of-pennsylvania-s-gene-therapy-program-s-newly-published-pasg-20201111monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-participate-in-upcoming-november-investor-conferences-pasg-20201111monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-and-invitae-announce-collaboration-to-facilitate-genetic-testing-to-support-ea-pasg-20201109monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-report-third-quarter-2020-financial-results-on-november-10-2020-pasg-20201104monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-s-pbkr03-receives-orphan-drug-and-rare-pediatric-disease-designations-from-fda-pasg-20201028monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-s-pbgm01-receives-orphan-drug-designation-from-ema-for-treatment-of-gm1-gangli-pasg-20201026monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-publication-of-preclinical-data-that-show-single-injection-of-optimi-pasg-20201013monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-participate-in-2020-virtual-cell-gene-meeting-on-the-mesa-pasg-20201006monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-participate-in-upcoming-october-investor-conferences-pasg-20200925monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-publication-of-preclinical-gene-therapy-study-data-from-frontotempor-pasg-20200917monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-participate-in-citi-s-15th-annual-biopharma-virtual-conference-pasg-20200903monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-report-second-quarter-2020-financial-results-on-august-13-2020-pasg-20200807monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-added-to-russell-2000-index-pasg-20200626monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-goldman-sachs-41st-annual-global-healthcare-conference-pasg-20200604monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-receives-rare-pediatric-disease-designation-for-pbgm01-for-patients-with-gm1-g-pasg-20200521monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-presentation-of-data-from-animal-models-of-krabbe-disease-at-the-ame-pasg-20200512monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-expansion-of-gene-therapy-collaboration-with-university-of-pennsylva-pasg-20200507monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-report-first-quarter-2020-financial-results-on-may-11-2020-pasg-20200504monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-19th-annual-needham-healthcare-conference-pasg-20200408monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-participate-in-guggenheim-healthcare-talks-genomic-medicines-and-rare-disea-pasg-20200327monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-exercise-of-underwriters-option-to-purchase-additional-shares-pasg-20200309monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-appoints-athena-countouriotis-to-board-of-directors-pasg-20200305monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-pricing-of-initial-public-offering-pasg-20200228monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-appoints-bruce-goldsmith-ph-d-as-chief-executive-officer-pasg-20200128monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-appoints-sandip-kapadia-to-board-of-directors-pasg-20200110monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-piper-jaffray-31st-annual-healthcare-conference-pasg-20191127monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-barclays-gene-editing-gene-therapy-summit-pasg-20191106monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-appoints-richard-morris-as-chief-financial-officer-pasg-20191029monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-upcoming-investor-conferences-pasg-20190925monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-grows-management-team-with-chief-medical-officer-and-general-counsel-appointme-pasg-20190923monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-new-gene-therapy-development-program-for-patients-with-charcot-marie-pasg-20190909monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-closes-110-million-series-b-financing-pasg-20190904monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-morgan-stanley-17th-annual-global-healthcare-conference-pasg-20190903monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-launch-of-natural-history-study-to-evaluate-patients-with-gm1-gangli-pasg-20190813monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-2019-wedbush-pacgrow-healthcare-conference-pasg-20190806monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-expands-executive-management-team-pasg-20190725monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-new-dedicated-gene-therapy-manufacturing-suite-pasg-20190710monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-third-gene-therapy-development-program-in-krabbe-disease-and-support-pasg-20190530monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-jefferies-2019-healthcare-conference-pasg-20190529monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-appoints-saqib-islam-to-board-of-directors-pasg-20190328monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-at-the-cowen-and-company-39th-annual-health-care-conference-pasg-20190305monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-launches-with-115-5-million-series-a-to-develop-aav-delivered-therapeutics-to--pasg-20190214monthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-secures-11-0-million-in-non-dilutive-debt-financing-to-accelerate-growth-of-appr-scnx-20260507monthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-price--scnx-20260415monthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-broadens-commercial-access-for-rezenopy-highest-dose-fda-approved-naloxone-nasal-scnx-20260311monthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-holdings-inc-regains-compliance-with-nasdaq-listing-requirements-scnx-20250716monthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-holdings-announces-cancelation-of-eloc-scnx-20250617monthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-announces-executive-leadership-transition-scnx-20250522monthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-announces-fda-orange-book-patent-listing-for-arblitm-losartanpotassium-oral-susp-scnx-20250519monthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-announces-manufacturing-and-supply-chain-readiness-for-arblitm-losartan-potassiu-scnx-20250422monthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-holdings-inc-issues-annual-letter-to-shareholders-scnx-20250403monthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-announces-commercial-operations-leadership-and-strategic-agreement-with-syneos-h-scnx-20250325monthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-holdings-announces-draw-on-eloc-temporarily-suspends-further-draws-until-reachin-scnx-20250319monthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-holdings-inc-announces-dr-narasimhan-mani-s-participation-in-the-8th-annual-conf-scnx-20250121monthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-holdings-inc-announces-participation-in-the-microcap-conference-2025-scnx-20241217monthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-llc-a-wholly-owned-subsidiary-of-scienture-holdings-inc-nasdaq-scnx-announces-is-scnx-20241210monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-to-present-at-the-life-sciences-investor-forum-on-march-12-2026-11-am-phio-20260310monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-secures-new-investor-phio-20240517monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-presents-this-week-at-the-society-for-investigative-dermatology-sid-phio-20240516monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-completion-of-dosing-in-first-patient-cohort-in-ph-762-phas-phio-20240515monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-upcoming-presentation-at-the-annual-meeting-of-the-society--phio-20240430monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-upcoming-presentations-at-the-81st-annual-meeting-of-the-so-phio-20240416monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-upcoming-presentation-at-the-27th-annual-meeting-of-the-ame-phio-20240411monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-presenting-data-showing-intasyl-may-result-in-more-effective-cell-the-phio-20240321monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-addition-of-clinical-trial-sites-at-banner-md-anderson-canc-phio-20240313monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-patent-granted-by-uspto-strengthening-the-company-s-intelle-phio-20240306monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-data-showing-intasyl-may-result-in-more-effective-cell-ther-phio-20240131monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-first-us-patient-enrolled-in-phase-1b-clinical-trial-with-i-phio-20231109monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-presents-new-data-showing-intasyl-compound-targeting-ctla-4-enhances--phio-20231103monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-upcoming-presentation-at-the-38th-annual-meeting-of-the-soc-phio-20231012monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-presents-new-data-for-targeting-of-brd4-with-its-intasyl-compound-ph--phio-20231011monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-ceo-to-speak-at-wainwright-conference-in-new-york-in-september-phio-20230906monthly0.5https://www.biopharmawatch.com/news/CVM/cel-sci-corp-s-ceo-geert-kersten-interviewed-by-the-life-sciences-report-cvm-20150223monthly0.5https://www.biopharmawatch.com/news/CVM/cel-sci-has-been-cleared-to-begin-patient-enrollment-cvm-20140723monthly0.5https://www.biopharmawatch.com/news/CVM/cel-sci-ceo-geert-kersten-to-be-interviewed-live-today-on-clear-channel-business-talk-radi-cvm-20140325monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-approved-to-dual-list-on-upstream-kapa-20241119monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-to-present-at-the-ld-micro-main-event-xvii-kapa-20241022monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-to-participate-in-a-fireside-chat-at-the-2024-maxim-healthcare-virtual-summi-kapa-20241009monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-prices-6-2-million-initial-public-offering-kapa-20240916monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-doses-first-patient-in-phase-2-trial-of-lead-drug-candidate-env105-with-apal-kapa-20240130monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-doses-first-patients-in-phase-1-trial-of-lead-drug-candidate-env105-with-osi-kapa-20240116monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-ltd-please-contact-the-portnoy-law-firm-to-recover-your-losses-march-6-2023-dead-blrx-20230214monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-ltd-blrx-class-action-notice-contact-robbins-llp-for-information-regarding-the-c-blrx-20230202monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-ltd-blrx-class-action-alert-robbins-llp-urges-shareholders-with-significant-loss-blrx-20230126monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-ltd-please-contact-the-portnoy-law-firm-to-recover-your-losses-march-6-2023-dead-blrx-20230116monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-ltd-blrx-shareholder-alert-robbins-llp-reminds-investors-of-class-action-against-blrx-20230113monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-class-action-alert-submit-your-losses-to-johnson-fistel-blrx-20230105monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-acquires-exclusive-license-rights-from-algen-for-cancer-therapeutic-bl-7030-blrx-20110517monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-reacquires-rights-to-leading-schizophrenia-drug-candidate-bl-1020-blrx-20110511monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-receives-notice-of-allowance-from-uspto-for-patent-covering-bl-1020-drug-for-tre-blrx-20110404monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-announces-positive-topline-results-for-bl-1020-a-first-in-class-gaba-enhanced-an-blrx-20090914monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-reports-third-quarter-2021-financial-results-and-provides-business-u-kprx-20211115monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-in-mbrx-20260604monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-first-quarter-2026-financial-results-and-provides-clinical-update-on-piv-mbrx-20260515monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-s-annamycin-extends-survival-by-more-than-60-in-metastatic-pancreatic-cancer-pre-mbrx-20260423monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-releases-next-ceo-corner-segment-highlighting-annamycin-s-non-cardiotoxic-profil-mbrx-20260407monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-releases-next-ceo-corner-segment-highlighting-miracle-study-mbrx-20260311monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-exercise-of-warrants-for-8-3-million-gross-proceeds-mbrx-20260219monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-completion-of-treatment-for-the-45-patients-in-pivotal-miracle-phase-3-mbrx-20251209monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-new-investigator-initiated-study-of-annamycin-for-treating-pancreatic--mbrx-20251023monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-accelerates-recruitment-in-phase-3-acute-myeloid-leukemia-miracle-clinical-trial-mbrx-20250909monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-second-quarter-2025-financial-results-and-highlights-mbrx-20250813monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-unveils-promising-preclinical-data-of-annamycin-in-liver-cancer-trea-mbrx-20250806monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-receives-notice-of-intent-to-grant-new-european-patent-for-annamycin-mbrx-20250730monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-participates-in-the-virtual-investor-what-s-your-story-summer-spotlight-on-deman-mbrx-20250722monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-engages-industry-veteran-adriano-treve-to-explore-accelerated-strategic-partners-mbrx-20250717monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-expands-phase-3-miracle-clinical-trial-into-the-country-of-georgia-enrollment-up-mbrx-20250709monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-5-9-million-public-offering-mbrx-20250620monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-participates-in-virtual-investor-what-this-means-segment-mbrx-20250618monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-receives-positive-fda-feedback-on-pediatric-study-plan-for-annamycin-in-children-mbrx-20250618monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-participates-in-virtual-investor-what-this-means-segment-mbrx-20250611monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-releases-on-demand-kol-webcast-to-discuss-data-from-its-phase-1b-2-study-of-anna-mbrx-20250605monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-positive-topline-efficacy-results-from-u-s-phase-1b-2-clinical-trial-eva-mbrx-20250604monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-first-quarter-2025-financial-results-and-provides-corporate-update-mbrx-20250514monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-receives-european-medicines-agency-approval-to-expand-phase-3-miracle-clinical-t-mbrx-20250512monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conferenc-mbrx-20250507monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-world-health-organization-approval-of-naxtarubicin-as-international-no-mbrx-20250506monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-bolsters-annamycin-intellectual-property-portfolio-with-granting-of-two-new-u-s--mbrx-20250505monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-new-pre-clinical-data-for-annamycin-demonstrating-market-expansion-pot-mbrx-20250429monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-acceptance-of-abstract-to-be-presented-at-the-american-association-for-mbrx-20250417monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-doses-first-patient-in-pivotal-adaptive-phase-3-miracle-trial-mbrx-20250401monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-full-year-2024-financial-results-and-provides-corporate-update-mbrx-20250324monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-report-full-year-2024-financial-results-on-march-21-2025-and-host-conference--mbrx-20250319monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-the-life-sciences-investor-forum-mbrx-20200324monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-outlicensing-deal-to-accelerate-preclinical-and-clinical-development-mbrx-20190220monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-dr-james-l-abbruzzese-chief-of-medical-oncology-division-at-duke-unive-mbrx-20190117monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-patient-recruitment-begins-in-annamycin-clinical-trial-in-poland-mbrx-20190109monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-positive-data-for-its-pancreatic-cancer-drug-candidate-mbrx-20190103monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-conference-call-to-discuss-fda-filing-and-new-immune-checkpoint-data-o-mbrx-20181206monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-fda-filing-for-orphan-drug-designation-for-glioblastoma-drug-mbrx-20181206monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-breakthrough-discovery-for-its-wp1066-mbrx-20181204monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-new-data-further-supporting-its-lead-drug-for-treating-pancreatic-canc-mbrx-20181128monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-requests-fda-meeting-regarding-ind-for-new-cancer-drug-mbrx-20181115monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-new-independent-study-expands-potential-use-of-its-pancreatic-drug-can-mbrx-20181108monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-significant-milestone-achieved-in-glioblastoma-trial-mbrx-20181101monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-positive-data-on-wp1066-in-pre-clinical-trials-mbrx-20181025monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-new-data-discovery-confirming-significant-increase-in-potential-to-sta-mbrx-20181010monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-s-brain-cancer-drug-candidate-begins-patient-dosing-at-clinical-trial-being-cond-mbrx-20180913monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-seeks-approval-from-polish-regulatory-agency-for-skin-cancer-clinical-trial-mbrx-20180809monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-enrollment-opens-for-brain-tumor-trial-of-wp1066-mbrx-20180731monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-expects-to-meet-fda-ind-filing-requirements-for-its-pancreatic-cancer-drug-candi-mbrx-20180718monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-expands-operations-to-australia-taps-r-d-incentive-program-capped-at-20-000-000--mbrx-20180711monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-selected-for-the-russell-microcap-index-mbrx-20180626monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-2-3-million-registered-direct-offering-priced-at-the-market-mbrx-20180621monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-targets-accelerated-fda-approval-of-wp1732-pursues-development-for-ocular-tumors-mbrx-20180612monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-s-breakthrough-discovery-of-a-new-molecule-for-cancer-treatment-advances-to-deve-mbrx-20180606monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-invited-to-present-to-international-bioforum-2018-conference-mbrx-20180524monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-begin-clinical-trials-at-umc-southwest-cancer-center-mbrx-20180516monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-engagement-with-voisin-consulting-life-sciences-to-expand-annamycin-cl-mbrx-20180503monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-nasdaq-mbrx-to-ring-the-nasdaq-stock-market-closing-bell-in-celebrat-mbrx-20160602monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-host-a-c-bfri-20260309monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-inte-bfri-20251218monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-to-report-third-quarter-2025-financial-results-on-november-12-2025-and-hos-bfri-20251106monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-to-report-second-quarter-fy-2025-financial-results-on-august-13-2025-bfri-20250804monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-patent-for-propylene-glycol-free-formula-of-ameluz-aminolevulini-bfri-20250603monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-new-patent-protection-on-ameluz-until-2043-and-the-completion-of-bfri-20250515monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-and-almirall-launch-the-hats-on-challenge-to-raise-awareness-and-support-for-a-bfri-20250501monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-completion-of-patient-enrollment-in-phase-3-study-of-ameluz-amin-bfri-20250318monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-21--bfri-20250311monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-achievement-of-key-milestone-in-phase-3-study-of-ameluz-photodyn-bfri-20250108monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-100-rhodoled-xl-machines-now-placed-in-us-market-bfri-20241223monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-database-lock-of-phase-3-study-of-ameluz-photodynamic-therapy-pd-bfri-20241014monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-the-launch-of-a-new-fda-approved-red-light-source-the-rhodoled-xl-la-bfri-20240624monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-voting-results-from-2022-annual-meeting-of-stockholders-bfri-20221216monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-to-participate-in-benchmark-s-11th-annual-discovery-one-on-one-investor-co-bfri-20221130monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-to-participate-in-renmark-s-virtual-non-deal-roadshow-series-on-wednesday--bfri-20221128monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-to-launch-phase-3-clinical-study-evaluating-ameluz-pdt-for-the-treatment-of-ac-bfri-20221121monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-to-report-third-quarter-financial-results-on-november-14-2022-bfri-20221110monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-enters-into-agreements-to-purchase-options-of-biofrontera-ag-bfri-20221031monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-names-fred-leffler-as-chief-financial-officer-bfri-20221024monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-to-present-at-the-ld-micro-main-event-xv-investor-conference-bfri-20221020monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-to-sponsor-the-2022-fall-clinical-dermatology-conference-bfri-20221018monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-adopts-limited-duration-shareholder-rights-plan-bfri-20221014monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-to-participate-in-renmark-s-virtual-non-deal-roadshow-series-on-friday-oct-bfri-20221012monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-preliminary-product-revenues-for-the-third-quarter-of-2022-bfri-20221005monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-to-present-at-the-roth-inaugural-healthcare-opportunities-conference-bfri-20220929monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-s-marketing-campaign-and-website-for-ameluz-won-2022-pm360-trailblazer-awa-bfri-20220926monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-names-gerard-digirolamo-as-national-sales-director-bfri-20220913monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-notice-of-allowance-for-nanoemulsion-composition-of-matter-u-s-p-bfri-20220906monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-s-leslie-hopkins-named-pm360-trailblazer-2022-brand-champion-for-dermatolo-bfri-20220818monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-to-report-second-quarter-financial-results-on-august-12-2022-bfri-20220804monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-patent-in-australia-for-novel-illumination-protocols-granted-to--bfri-20220801monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-preliminary-product-revenues-for-the-second-quarter-of-2022-bfri-20220712monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-recognized-for-rapid-sales-growth-innovative-therapies-and-marketing-excel-bfri-20220609monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-to-participate-in-the-benchmark-healthcare-house-call-virtual-1x1-conferen-bfri-20220531monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-closing-of-9-4-million-private-placement-bfri-20220519monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-pricing-of-9-4-million-private-placement-bfri-20220516monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-to-report-first-quarter-financial-results-on-may-13-2022-bfri-20220506monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-to-showcase-actinic-keratosis-treatments-at-the-music-city-symposium-for-c-bfri-20220505monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-launches-new-patient-focused-websites-for-ameluz-and-xepi-bfri-20220421monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-fda-approval-of-biofrontera-pharma-gmbh-as-a-contract-laboratory-bfri-20220413monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-a-bfri-20220408monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-preliminary-product-revenues-for-the-first-quarter-of-2022-bfri-20220406monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-to-report-fourth-quarter-and-full-year-2021-financial-results-on-april-8-2-bfri-20220401monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-to-showcase-actinic-keratoses-and-impetigo-treatments-at-the-2022-american-aca-bfri-20220317monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-fda-orange-book-listing-of-u-s-patent-for-bf-rhodoled-xl-extends-bfri-20220314monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-to-present-at-the-34th-annual-roth-conference-bfri-20220309monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-appoints-kevin-d-weber-to-its-board-of-directors-bfri-20220307monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-decides-to-delist-ads-from-nasdaq-to-reduce-complexity-and-costs-bfri-20220214monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-provides-update-on-patient-recruitment-for-phase-iii-study-for-the-treatme-bfri-20220201monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-issues-letter-to-shareholders-highlighting-2021-successes-and-key-elements-bfri-20220118monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-participation-in-two-dermatology-conferences-in-january-bfri-20220110monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-reduction-of-biofrontera-ag-shareholding-to-less-than-50-through-bfri-20211230monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-enrollment-of-first-subject-in-phase-2b-clinical-trial-evaluatin-bfri-20211213monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-notice-of-allowance-for-u-s-method-of-use-patent-on-pdt-lamp-bfri-20211208monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-enrolls-first-subject-in-phase-1-safety-study-evaluating-photodynamic-ther-bfri-20211206monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-notice-of-allowance-for-u-s-patent-on-innovative-illumination-pr-bfri-20211202monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-closing-of-15-million-private-placement-bfri-20211202monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-reports-third-quarter-2021-financial-results-and-provides-business-update-bfri-20211130monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-to-report-third-quarter-financial-results-on-november-30-2021-bfri-20211123monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-announces-mediation-results-bfri-20211119monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-financial-results-for-the-third-quarter-and-nine-months-ended-septembe-bfri-20211117monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-kicks-off-us-clinical-study-program-for-ameluz-bfri-20211116monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-announces-initiation-of-clinical-studies-bfri-20211116monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-conference-call-to-discuss-third-quarter-2021-financial-results-to-be-held--bfri-20211109monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-closing-of-initial-public-offering-and-full-exercise-of-underwri-bfri-20211102monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-pricing-of-18-0-million-initial-public-offering-bfri-20211029monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-receives-fda-approval-of-the-bf-rhodoled-xl-lamp-bfri-20211022monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-preliminary-approximate-revenues-for-the-month-of-september-2021-bfri-20211001monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-preliminary-revenue-for-the-month-of-august-2021-bfri-20210908monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-financial-results-for-the-six-months-ended-june-30-2021-bfri-20210819monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-conference-call-to-discuss-half-year-2021-financial-results-to-be-held-on-a-bfri-20210812monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-preliminary-revenue-for-the-month-of-july-2021-bfri-20210809monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-enters-into-license-and-supply-agreement-with-medac-for-the-marketing-of-amelu-bfri-20210723monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-seeks-ipo-in-the-usa-bfri-20210706monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-preliminary-revenue-for-the-month-of-june-2021-bfri-20210706monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-provides-update-on-clinical-developments-bfri-20210622monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-preliminary-revenue-for-the-month-of-may-2021-bfri-20210607monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-q1-2021-financial-results-bfri-20210511monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-preliminary-revenue-for-the-month-of-april-2021-bfri-20210506monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-first-quarter-conference-call-to-be-held-on-may-12-2021-bfri-20210503monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-results-for-the-2020-financial-year-bfri-20210412monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-preliminary-revenue-for-q1-2021-bfri-20210408monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-conference-call-to-be-held-on-april-13-2021-to-discuss-fiscal-year-2-bfri-20210331monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-submits-application-for-fda-approval-of-new-bf-rhodoled-xl-lamp-bfri-20210331monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-announces-the-closing-of-the-capital-raise-with-gross-proceeds-of-eur-24-7--bfri-20210226monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-submits-study-report-of-pharmacokinetics-study-to-fda-bfri-20210224monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-announces-pricing-of-us-8-9-million-firm-commitment-public-offering-of-amer-bfri-20210224monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-ludwig-lutter-appointed-new-chief-financial-officer-effective-march-1-2021-bfri-20210202monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-preliminary-revenue-figures-for-the-full-year-2020-bfri-20210108monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-enters-into-a-license-and-supply-agreement-with-galenica-ab-for-the-marketing--bfri-20201207monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-resolves-mandatory-conversion-of-subordinated-mandatory-convertible-bonds-bfri-20201112monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-third-quarter-and-first-nine-months-2020-results-bfri-20201111monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-conference-call-to-be-held-on-november-12-2020-to-discuss-q3-2020-fi-bfri-20201102monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-receives-reasons-from-the-federal-court-of-justice-for-overturning-ruling-o-bfri-20201014monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-preliminary-unaudited-sales-revenue-for-the-third-quarter-of-2020-bfri-20201009monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-reports-completion-of-the-clinical-phase-of-the-pharmacokinetics-study-bfri-20201008monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-german-federal-supreme-court-overturns-ruling-of-the-cologne-higher-regiona-bfri-20200922monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-plans-mediation-to-resolve-legal-disputes-bfri-20200911monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-to-participate-in-two-upcoming-conferences-bfri-20200909monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-report-results-for-the-first-six-months-of-2020-bfri-20200826monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-conference-call-to-be-held-on-august-27-2020-to-discuss-half-year-20-bfri-20200819monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-announces-subscription-price-for-1-00-qualified-subordinated-mandatory-conv-bfri-20200810monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-resolves-to-issue-qualified-subordinated-mandatory-convertible-bonds-bfri-20200727monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-preliminary-unaudited-sales-revenue-for-the-first-six-months-of-2020-bfri-20200714monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-confirms-financing-need-bfri-20200630monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-q1-2020-financial-results-bfri-20200519monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-dismisses-case-against-dusa-pharmaceuticals-inc-in-california-state-court-bfri-20200513monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-conference-call-to-be-held-on-may-20-2020-to-discuss-first-quarter-2-bfri-20200512monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-full-year-2019-financial-results-bfri-20200420monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-enters-into-exclusive-license-agreement-with-maruho-co-ltd-bfri-20200420monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-preliminary-unaudited-sales-revenue-for-the-first-three-months-of-2020-bfri-20200417monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-to-propose-resolution-for-ordinary-capital-increase-to-the-annual-general-m-bfri-20200416monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-conference-call-to-be-held-on-april-21-2020-to-discuss-full-year-201-bfri-20200409monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-withdraws-subscription-offers-for-mandatory-convertible-bonds-bfri-20200323monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-implements-comprehensive-measures-to-reduce-costs-during-covid-19-pandemic-bfri-20200320monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-signs-non-binding-term-sheet-for-licensing-agreement-for-ameluz-in-poland-w-bfri-20200313monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-extends-subscription-period-for-mandatory-convertible-bonds-bfri-20200312monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-entered-into-binding-term-sheet-with-maruho-co-ltd-bfri-20200303monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-resolves-to-issue-qualified-subordinated-mandatory-convertible-bonds-bfri-20200226monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-provides-clinical-development-updates-bfri-20200219monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-1-year-follow-up-results-for-its-phase-iii-study-of-photodynamic-the-bfri-20200114monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-preliminary-sales-figures-for-the-full-year-2019-record-sales-in-the-bfri-20200110monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-strengthens-commercial-focus-with-reorganization-of-its-us-business-bfri-20200106monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-to-participate-in-upcoming-investor-conferences-bfri-20191122monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-third-quarter-2019-financial-results-and-revises-guidance-bfri-20191119monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-conference-call-on-november-19-2019-to-discuss-third-quarter-2019-fi-bfri-20191106monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-receives-award-at-fall-clinical-dermatology-conference-2019-bfri-20191023monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-preliminary-unaudited-sales-revenue-for-the-first-nine-months-of-2019-bfri-20191010monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-to-present-at-the-baader-investment-conference-bfri-20190917monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-files-label-extension-for-ameluz-in-eu-to-include-treatment-of-actinic-keratos-bfri-20190917monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-to-participate-at-the-lake-street-capital-markets-2019-best-ideas-growth-big-c-bfri-20190905monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-shows-robust-growth-during-first-six-months-of-2019-bfri-20190827monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-conference-call-on-august-27-2019-to-discuss-half-year-2019-financia-bfri-20190814monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-provides-update-on-cutanea-integration-bfri-20190805monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-preliminary-unaudited-sales-revenue-for-the-first-six-months-of-2019-bfri-20190709monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-to-present-at-two-upcoming-investor-conferences-bfri-20190612monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-nominates-new-candidate-for-the-supervisory-board-bfri-20190604monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-first-quarter-2019-financial-results-bfri-20190529monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-conference-call-on-may-29-2019-to-discuss-first-quarter-2019-financi-bfri-20190516monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-full-year-2018-financial-results-bfri-20190429monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-to-hold-extraordinary-shareholders-meeting-on-15-may-2019-bfri-20190426monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-further-positive-results-from-the-phase-iii-trial-with-ameluz-for-phot-bfri-20190416monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-conference-call-on-april-29-2019-to-discuss-2018-financial-results-bfri-20190416monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-preliminary-unaudited-sales-revenue-for-the-first-three-months-of-2019-bfri-20190415monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-provides-information-on-the-announced-voluntary-public-tender-offer-by-maruho--bfri-20190402monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-provides-corporate-update-conference-call-details-for-march-26-2019-bfri-20190325monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-usa-acquires-cutanea-life-sciences-inc-usa-bfri-20190325monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-positive-phase-iii-results-with-ameluz-for-photodynamic-therapy-of-act-bfri-20190320monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-and-maruho-co-ltd-conclude-cooperation-agreement-regarding-branded-generics-bfri-20190319monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-honored-with-prestigious-silver-stevie-r-award-for-outstanding-u-s-customer-se-bfri-20190225monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-implements-new-falsified-medicines-directive-bfri-20190211monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-preliminary-unaudited-sales-revenue-and-updates-consolidated-net-inc-bfri-20190122monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-receives-fda-approval-for-upscaling-of-batch-size-for-ameluz-production-bfri-20190108monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-to-participate-in-two-upcoming-investor-conferences-bfri-20181126monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-earnings-results-for-the-third-quarter-and-first-nine-months-of-2018-bfri-20181116monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-conference-call-to-discuss-q3-2018-financial-results-bfri-20181105monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-to-present-at-the-4th-annual-dawson-james-small-cap-growth-stock-conference-bfri-20181015monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-preliminary-unaudited-sales-revenue-for-the-first-nine-months-of-201-bfri-20181010monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-starts-patient-recruitment-for-u-s-phase-iii-trial-evaluating-ameluz-bf-rhodol-bfri-20180926monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-bfri-20180924monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-to-present-at-the-baader-investment-conference-bfri-20180919monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-uses-the-long-summer-months-to-introduce-daylight-photodynamic-therapy-pdt-wit-bfri-20180917monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-files-lawsuit-against-w-k-t-zours-deutsche-balaton-ag-and-further-defendants-bfri-20180612monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-first-quarter-2018-financial-results-bfri-20180530monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-reports-full-year-2017-financial-results-bfri-20180430monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-preliminary-unaudited-sales-revenues-for-the-1st-quarter-2018-bfri-20180412monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-announces-partial-waiver-of-lock-up-agreement-bfri-20180315monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-announces-closing-of-us12-9-million-firm-commitment-initial-public-offering-bfri-20180216monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-nasdaq-bfra-to-ring-the-nasdaq-stock-market-closing-bell-bfri-20180214monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-announces-pricing-of-us-12-million-firm-commitment-public-offering-of-ameri-bfri-20180214monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-biofrontera-reports-full-year-2015-financial-results-bfri-20160415monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-notice-of-annual-results-2016-bfri-20160407monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-nda-progress-update-for-bf-200-ala-bfri-20160404monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-biofrontera-ag-resolves-on-capital-increase-bfri-20160216monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-ag-pivotal-phase-iii-data-demonstrate-significant-efficacy-and-excellent-safet-bfri-20160211monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-major-breakthrough-in-apple-polyphenol-technology-set-t-bon-20231212monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-45-million-broccoli-product-order-with-beijing-huahai-k-bon-20231205monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-signing-mou-for-distributing-jiangwang-spirits-in-china-bon-20231006monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-record-first-half-year-revenue-and-net-income-bon-20230911monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-receives-nasdaq-notification-regarding-independent-board-requirem-bon-20230707monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-receives-nasdaq-notification-regarding-minimum-bid-deficiency-bon-20230621monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-launches-three-new-cruciferous-vegetable-based-powder-drinks-bon-20230602monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-voted-as-vice-chairman-unit-of-plant-extract-association-bon-20230526monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-appoints-wallace-lee-as-new-chief-financial-officer-bon-20230425monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-record-setting-full-fiscal-year-2022-results-bon-20230210monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-fy2022-earnings-release-date-and-webcast-bon-20230207monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-full-exercise-of-the-underwriter-s-over-allotment-optio-bon-20210702monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-closing-of-upsized-11-million-initial-public-offering-bon-20210628monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-publication-of-preclinical-data-in-journal-of-clinical-investigation-calc-20230606monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-expands-executive-team-with-new-appointments-calc-20230523monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-21-million-series-d-financing-calc-20210311monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-presents-new-clinical-data-demonstrating-improved-d-dimer-biomarker-levels-wit-calc-20210202monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-idmc-recommendation-to-continue-with-trial-evaluating-auxora-in-pati-calc-20201217monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-publication-of-preclinical-data-demonstrating-the-pathological-role--calc-20201113monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-appoints-daniel-geffken-as-interim-chief-financial-officer-calc-20201105monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-peer-reviewed-publication-of-positive-covid-19-data-and-initiation-o-calc-20200818monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-and-epipharma-enter-into-research-collaboration-to-discover-and-develop-crac-c-calc-20200721monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-data-showing-auxora-substantially-improved-outcomes-in-patients-with-calc-20200716monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-positive-topline-data-from-interim-analysis-of-trial-evaluating-auxo-calc-20200528monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-raises-15-million-in-series-c-financing-round-led-by-valence-life-sciences-calc-20200522monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-that-fda-has-strongly-recommended-moving-to-a-blinded-placebo-contro-calc-20200521monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-independent-safety-review-committee-recommendation-to-continue-phase-calc-20200507monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-expands-clinical-study-to-assess-cm4620-ie-in-patients-with-critical-covid-19--calc-20200430monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-data-from-phase-1-dose-escalation-clinical-study-of-bdc-30-bolt-20250325monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-inc-provides-update-on-global-cancer-immunotherapy-co-development-wit-bolt-20250211monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-presents-updated-preclinical-data-for-bdc-4182-and-key-learnings-from-bolt-20241107monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-announces-changes-to-its-board-of-directors-bolt-20240904monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-investors-have-the-opportunity-to-lead-bolt-biotherapeutics-inc-securities-fraud-laws-bolt-20240902monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-deadline-alert-rosen-a-global-and-leading-law-firm-encourages-bolt-biotherapeutics-in-bolt-20240901monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-bolt-biotherapeutics-inc-bolt-20240830monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-final-deadline-rosen-leading-trial-attorneys-encourages-bolt-biotherapeutics-inc-inve-bolt-20240828monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-participate-in-upcoming-september-conferences-bolt-20240828monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-bolt-biotherapeutics-inc-bolt-20240825monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-investors-have-the-opportunity-to-lead-bolt-biotherapeutics-inc-securities-fraud-laws-bolt-20240820monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-bolt-biotherapeutics-inc-bolt-20240819monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-bolt-biotherapeutics-inc-bolt-20240813monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-investors-have-the-opportunity-to-lead-bolt-biotherapeutics-inc-securities-fraud-laws-bolt-20240813monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-bolt-biotherapeutics-inc-bolt-20240807monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-investors-have-the-opportunity-to-lead-bolt-biotherapeutics-inc-securities-fraud-laws-bolt-20240806monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-bolt-biotherapeutics-inc-bolt-20240801monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-investors-have-the-opportunity-to-lead-bolt-biotherapeutics-inc-securities-fraud-laws-bolt-20240731monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-bolt-biotherapeutics-inc-bolt-20240726monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-investors-have-the-opportunity-to-lead-bolt-biotherapeutics-inc-securities-fraud-laws-bolt-20240724monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-stockholders-should-contact-shareholder-rights-law-firm-robbins-llp-for-information-a-bolt-20240722monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-bolt-biotherapeutics-inc-bolt-20240721monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-bolt-biotherapeutics-inc-bolt-20240715monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-class-action-alert-robbins-llp-reminds-stockholders-of-the-lead-plaintiff-deadline-in-bolt-20240710monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-alert-bragar-eagel-squire-p-c-is-investigating-bolt-biotherapeutics-inc-on-behalf-of--bolt-20240710monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-bolt-biotherapeutics-inc-bolt-20240709monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-bolt-biotherapeutics-inc-bolt-20240703monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-inc-investors-company-investigated-by-the-portnoy-law-firm-bolt-20240624monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-at-the-td-cowen-44th-annual-healthcare-conference-bolt-20240227monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-enrolls-first-patient-in-phase-2-clinical-study-evaluating-bdc-1001-i-bolt-20231205monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-at-stifel-2023-healthcare-conference-bolt-20231107monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-presents-updated-clinical-data-from-phase-1-dose-escalation-trial-of--bolt-20231023monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-data-at-the-society-for-immunotherapy-of-cancer-s-2023-ann-bolt-20231018monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-announces-first-patient-dosed-in-phase-1-2-study-of-bdc-3042-in-patie-bolt-20231017monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-new-clinical-data-from-completed-phase-1-2-dose-escalation-bolt-20231016monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-receives-orphan-drug-designation-for-bdc-1001-for-treatment-of-gastri-bolt-20230928monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-announces-issuance-of-u-s-patent-covering-dectin-2-targeting-agonist--bolt-20230912monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-participate-in-september-investor-conferences-bolt-20230905monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-initiates-phase-2-clinical-studies-of-bdc-1001-in-patients-with-her2--bolt-20230803monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-at-btig-virtual-biotechnology-conference-2023-bolt-20230731monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-highlights-comprehensive-clinical-data-from-phase-1-dose-escalation-t-bolt-20230525monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-clinical-data-from-phase-1-dose-escalation-trial-of-bdc-10-bolt-20230426monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-announces-positive-topline-data-from-bdc-1001-phase-1-dose-escalation-bolt-20230329monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-preclinical-data-for-bdc-3042-a-dectin-2-targeting-agonist-bolt-20230314monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-at-cowen-43rd-annual-healthcare-conference-bolt-20230228monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-at-february-investor-conferences-bolt-20230201monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-appoints-laura-berner-to-board-of-directors-bolt-20221214monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-preclinical-data-on-bdc-3042-dectin-2-targeting-agonistic--bolt-20221107monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-at-stifel-2022-healthcare-conference-bolt-20221101monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-at-morgan-stanley-20th-annual-global-healthcare-conference-bolt-20220831monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-ex-vivo-data-characterizing-the-myeloid-cell-landscape-in--bolt-20220527monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-at-21st-annual-needham-healthcare-conference-bolt-20220407monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-updates-for-three-preclinical-immuno-oncology-pipeline-pro-bolt-20220308monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-participate-in-upcoming-february-conferences-bolt-20220202monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-doses-first-patient-with-bdc-1001-in-combination-with-opdivo-nivoluma-bolt-20220106monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-appoints-nicole-onetto-m-d-to-board-of-directors-bolt-20211216monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-interim-clinical-data-on-bdc-1001-phase-1-2-clinical-trial-bolt-20211202monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-announces-changes-to-its-board-of-directors-bolt-20211119monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-presents-new-preclinical-data-on-three-pipeline-programs-at-society-f-bolt-20211112monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-at-stifel-2021-virtual-healthcare-conference-bolt-20211108monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-updates-on-three-pipeline-programs-at-the-2021-society-for-bolt-20211001monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-announces-clinical-collaboration-with-bristol-myers-squibb-to-study-b-bolt-20210908monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-participate-in-upcoming-september-investor-conferences-bolt-20210902monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-and-innovent-biologics-announce-collaboration-to-develop-three-new-on-bolt-20210826monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-presents-preliminary-results-from-phase-1-2-trial-of-lead-her2-target-bolt-20210604monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-announces-aacr-2021-presentation-of-boltbody-platform-mechanism-of-ac-bolt-20210410monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-to-present-at-20th-annual-needham-virtual-healthcare-conference-bolt-20210408monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-announces-closing-of-initial-public-offering-and-full-exercise-of-the-bolt-20210209monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-prices-upsized-initial-public-offering-bolt-20210205monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-multiple-publications-in-2026-describing-unique-utility-of-ogm-in-studie-bngo-20260611monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-a-56-increase-in-publications-describing-the-utility-of-ogm-in-rare-dise-bngo-20260505monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-two-fold-increase-in-ogm-studies-presented-at-the-2026-american-college--bngo-20260317monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-report-fourth-quarter-and-full-year-2025-financial-results-and-host-a-conferenc-bngo-20260309monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-reports-third-quarter-2025-results-and-highlights-recent-business-progress-bngo-20251113monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-publication-showing-utility-of-optical-genome-mapping-in-clinical-resear-bngo-20250807monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-present-at-the-canaccord-genuity-45th-annual-growth-conference-bngo-20250806monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-upgrades-to-its-software-and-compute-platforms-to-make-analysis-of-ogm-m-bngo-20250805monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-report-second-quarter-2025-financial-results-and-host-a-conference-call-webcast-bngo-20250731monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-recaps-momentum-behind-optical-genome-mapping-at-the-biennial-meeting-of-the-europ-bngo-20250730monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-recaps-global-momentum-behind-optical-genome-mapping-at-the-2025-annual-meeting-of-bngo-20250618monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-laboratories-announces-a-second-category-i-cpt-code-for-ogm-established-by-the-ama-bngo-20250519monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-reports-first-quarter-2025-results-and-highlights-recent-business-progress-bngo-20250514monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-laboratories-announces-publication-of-the-largest-study-to-date-evaluating-clinica-bngo-20250513monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-report-first-quarter-2025-financial-results-and-host-a-conference-call-webcast--bngo-20250507monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-publication-showing-ogm-can-provide-an-accurate-and-cost-effective-solut-bngo-20250423monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-french-publication-of-an-effective-method-for-analysis-of-multiple-myelo-bngo-20250408monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-reports-fourth-quarter-and-full-year-2024-results-and-provides-revenue-outlook-for-bngo-20250331monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-extensive-lineup-of-content-at-american-college-of-medical-genetics-and--bngo-20250318monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-report-fourth-quarter-and-full-year-2024-financial-results-and-host-a-conferenc-bngo-20250314monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-publication-reporting-first-use-of-ogm-to-detect-chromoanagenesis-a-key--bngo-20250313monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-effective-date-of-reverse-stock-split-bngo-20250122monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-use-of-ogm-in-preimplantation-genetic-testing-as-part-of-successful-live-bngo-20250114monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-reports-preliminary-fourth-quarter-and-full-year-2024-results-bngo-20250113monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-publication-showing-that-ogm-identifies-variant-that-indicates-use-of-pr-bngo-20250107monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-closing-of-10-million-registered-direct-offering-priced-at-the-market-un-bngo-20250106monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-amendment-to-senior-secured-convertible-debentures-in-debt-restructuring-bngo-20241231monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-publication-from-johns-hopkins-school-of-medicine-showing-that-ogm-outpe-bngo-20241223monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-the-publication-of-stockholder-letter-regarding-support-for-proxy-propos-bngo-20241219monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-presentations-at-the-american-society-of-hematology-ash-annual-meeting-t-bngo-20241210monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-reports-third-quarter-2024-results-and-highlights-recent-business-progress-bngo-20241113monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-report-third-quarter-2024-financial-results-and-host-a-conference-call-and-webc-bngo-20241107monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-closing-of-3-million-registered-direct-offering-priced-at-the-market-und-bngo-20241031monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-adjourns-special-meeting-of-stockholders-to-november-27-2024-bngo-20241031monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-publication-outlining-utility-of-ogm-for-resolution-of-myc-gene-rearrang-bngo-20241024monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-adjourns-special-meeting-of-stockholders-to-october-30-2024-bngo-20241003monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-reports-second-quarter-2024-results-and-highlights-recent-business-progress-bngo-20240807monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-presentation-of-optical-genome-mapping-utility-across-cancer-research-ap-bngo-20240801monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-present-at-the-canaccord-genuity-44th-annual-growth-conference-bngo-20240731monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-report-second-quarter-2024-financial-results-and-host-a-conference-call-and-web-bngo-20240731monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-publication-of-first-multi-site-study-to-analyze-the-utility-of-ogm-in-m-bngo-20240723monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-closing-of-up-to-30-million-registered-direct-offering-priced-at-the-mar-bngo-20240708monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-presentation-of-ogm-utility-across-stem-cell-therapy-applications-at-the-bngo-20240702monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-software-marketing-agreement-with-revvity-for-newborn-sequencing-researc-bngo-20240620monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-laboratories-announces-new-category-i-cpt-code-for-ogm-use-in-hematological-malign-bngo-20240617monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-robust-presence-at-upcoming-cytogenetics-conferences-eshg-and-acc-with-3-bngo-20240530monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-three-publications-demonstrating-ogm-s-utility-for-cell-and-gene-therapy-bngo-20240521monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-series-of-major-advancements-to-its-suite-of-computational-tools-for-com-bngo-20240509monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-reports-first-quarter-2024-results-and-highlights-recent-business-progress-bngo-20240508monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-report-first-quarter-2024-financial-results-and-host-a-conference-call-and-webc-bngo-20240501monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-present-at-the-rbc-capital-markets-2024-global-healthcare-conference-bngo-20240430monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-publication-showing-ogm-s-high-resolution-structural-variation-detection-bngo-20240424monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-and-diagens-sign-partnership-to-commercialize-the-first-ever-clinical-cytogenetic--bngo-20240417monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-publication-showing-that-ogm-detects-over-1250-structural-variants-inclu-bngo-20240411monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-publication-showing-that-ogm-identifies-genetic-aberrations-in-sarcoma-s-bngo-20240403monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-9-poster-presentations-and-introduces-new-high-throughput-stratys-system-bngo-20240402monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-publication-of-a-breast-cancer-study-showing-that-the-number-of-svs-dete-bngo-20240319monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-extensive-lineup-of-content-at-american-college-of-medical-genetics-and--bngo-20240307monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-reports-fourth-quarter-and-full-year-2023-results-and-provides-revenue-outlook-for-bngo-20240305monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-present-at-td-cowen-s-44th-annual-health-care-conference-bngo-20240229monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-report-fourth-quarter-and-year-end-2023-financial-results-and-host-a-conference-bngo-20240228monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-participate-in-the-btig-snowbird-medtech-digital-health-life-science-diagnostic-bngo-20240131monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-s-symposium-2024-featured-presentations-from-its-global-user-community-highlightin-bngo-20240130monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-publication-of-a-study-that-applied-ogm-to-discovery-of-structural-varia-bngo-20240125monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-publication-of-interim-readout-from-second-phase-of-clinical-trial-analy-bngo-20240124monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-full-commercial-release-of-the-stratys-system-for-high-throughput-optica-bngo-20240123monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-the-final-speaker-lineup-for-2024-symposium-with-33-ogm-presentations-an-bngo-20240119monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-peer-reviewed-publication-from-its-clinical-study-designed-to-support-og-bngo-20240111monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-2024-symposium-four-consecutive-days-of-ogm-presentations-and-live-panel-bngo-20240110monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-significant-upgrades-to-its-bionano-solve-pipeline-and-its-via-software--bngo-20231228monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-publication-of-largest-prospective-prenatal-study-comparing-ogm-to-chrom-bngo-20231226monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-laboratories-announces-publication-of-the-analytical-validation-of-its-ogm-based-l-bngo-20231212monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-presentations-featuring-ogm-utility-across-blood-cancer-research-at-the--bngo-20231206monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-publication-demonstrating-utility-of-ogm-to-assess-genome-integrity-of-c-bngo-20231129monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-presentation-of-ogm-utility-across-key-research-applications-at-the-asso-bngo-20231114monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-reports-third-quarter-2023-results-and-highlights-recent-business-progress-bngo-20231108monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-present-at-the-2023-stifel-healthcare-conference-bngo-20231101monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-report-third-quarter-2023-financial-results-and-host-a-conference-call-and-webc-bngo-20231101monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-presentation-of-ogm-utility-across-key-applications-at-the-american-soci-bngo-20231026monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-prices-80-0-million-financing-in-convertible-notes-and-warrants-announces-prelimin-bngo-20231011monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-pricing-of-80-0-million-registered-offering-and-concurrent-private-place-bngo-20231011monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-bngo-20230922monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-third-oem-partner-has-received-china-nmpa-approval-for-dna-isolation-pro-bngo-20230921monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-peer-reviewed-publication-on-the-utility-of-combining-ogm-and-wes-for-ev-bngo-20230906monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-publication-demonstrating-utility-of-ogm-as-an-alternative-to-kt-and-cma-bngo-20230830monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-second-oem-partner-has-received-china-nmpa-approval-for-dna-extraction-a-bngo-20230828monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement-bngo-20230821monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-laboratories-receives-college-of-american-pathologists-cap-accreditation-for-its-c-bngo-20230816monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-presentation-of-optical-genome-mapping-ogm-utility-across-cancer-researc-bngo-20230811monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-reports-second-quarter-2023-results-and-highlights-recent-business-progress-bngo-20230809monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-reverse-stock-split-bngo-20230804monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-report-second-quarter-2023-financial-results-and-host-a-conference-call-and-web-bngo-20230802monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-ogm-roadshow-tour-which-provides-education-on-the-company-s-workflow-and-bngo-20230731monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference-bngo-20230727monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-the-stratys-system-for-ogm-and-via-software-for-hematologic-malignancies-bngo-20230629monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-present-at-the-healthcare-virtual-conference-bngo-20230621monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-peer-reviewed-publication-on-the-utility-of-combining-ogm-and-a-523-gene-bngo-20230620monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-results-from-its-annual-meeting-of-stockholders-bngo-20230614monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-presentation-of-ogm-utility-across-stem-cell-therapy-applications-at-the-bngo-20230613monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-2023-winners-of-its-innovator-research-grant-program-bngo-20230612monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-extensive-lineup-of-content-at-european-conferences-featuring-ogm-utilit-bngo-20230608monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-commercial-release-of-new-kits-for-its-ionic-system-featuring-new-chemis-bngo-20230606monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-reports-first-quarter-2023-results-and-highlights-recent-business-progress-bngo-20230509monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-report-first-quarter-2023-financial-results-and-host-a-conference-call-and-webc-bngo-20230502monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-the-publication-of-stockholder-letter-regarding-support-for-proxy-propos-bngo-20230501monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-three-publications-demonstrating-ogm-s-utility-for-hematological-maligna-bngo-20230426monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-preliminary-q1-2023-results-and-business-updates-bngo-20230424monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-inc-investors-company-investigated-by-the-portnoy-law-firm-bngo-20230417monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-presentation-of-ogm-utility-across-cancer-genomics-research-applications-bngo-20230413monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-publication-that-demonstrates-ogm-s-utility-for-resolving-complex-geneti-bngo-20230406monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-first-study-using-ogm-to-discover-structural-variants-with-potential-rel-bngo-20230322monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-laboratories-expands-its-clinical-testing-menu-with-launch-of-ogm-based-laboratory-bngo-20230315monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-extensive-lineup-of-content-at-american-college-of-medical-genetics-and--bngo-20230313monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-fourth-quarter-and-full-year-2022-results-and-provides-revenue-ou-bngo-20230309monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-two-publications-from-its-clinical-study-designed-to-support-ogm-as-part-bngo-20230302monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-report-fourth-quarter-and-year-end-2022-financial-results-and-host-a-conference-bngo-20230301monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-present-at-the-43rd-annual-cowen-healthcare-conference-bngo-20230227monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-china-nmpa-approval-for-dna-extraction-and-labeling-products-for-ivd-use-bngo-20230222monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-shares-overview-of-agbt-pre-conference-workshop-program-along-with-details-of-comp-bngo-20230214monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-strategy-day-highlighted-the-company-s-strategic-initiatives-and-growth-plans-as-w-bngo-20230209monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-s-symposium-2023-featured-record-numbers-of-presentations-demonstrating-applicatio-bngo-20230202monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-laboratories-expands-its-clinical-testing-menu-with-launch-of-its-first-ogm-based--bngo-20230124monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-launch-of-next-generation-versions-of-its-reagent-kits-and-chip-consumab-bngo-20230123monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-the-final-speaker-lineup-for-symposium-2023-with-30-ogm-present-bngo-20230120monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-publication-of-interim-readout-from-clinical-trial-run-by-consortium-ana-bngo-20230118monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-accelerate-data-processing-solution-for-optical-genome-mapping-workflow-with-nv-bngo-20230112monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-publication-from-institut-curie-showing-utility-of-ogm-for-detection-of--bngo-20230111monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-2023-symposium-four-consecutive-days-of-ogm-presentations-and-l-bngo-20230110monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-host-strategy-day-on-february-2-2023-in-new-york-city-bngo-20230106monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-american-society-of-hematology-ash-annual-meeting-presentations-bngo-20221209monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-appoints-donna-polizio-as-its-first-ever-global-head-of-market-access-bngo-20221110monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-third-quarter-2022-financial-results-and-highlights-recent-busine-bngo-20221103monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-extensive-lineup-of-content-at-association-for-molecular-pathol-bngo-20221028monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-report-third-quarter-2022-financial-results-and-host-a-conference-call-bngo-20221027monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-global-user-event-at-bionano-laboratories-before-american-socie-bngo-20221024monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-presentation-of-ogm-utility-across-key-applications-at-american-bngo-20221020monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-six-user-presentations-of-ogm-results-in-cancer-genomics-resear-bngo-20221006monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-laboratories-to-provide-enhanced-genetic-counseling-and-patient-care-for-genetic-d-bngo-20220926monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-launch-of-clia-certified-bionano-laboratories-and-expands-its-c-bngo-20220923monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-publication-of-study-using-ogm-for-detection-of-balanced-chromo-bngo-20220921monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-publication-of-study-in-mds-and-aml-showing-utility-for-refined-bngo-20220914monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-publication-of-study-demonstrating-utility-of-ogm-as-part-of-a--bngo-20220908monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-participate-at-the-h-c-wainwright-24th-annual-global-investment-confer-bngo-20220907monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-the-first-publication-using-ogm-to-analyze-impact-of-chromothri-bngo-20220825monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-first-publication-using-ogm-for-detection-of-repeat-expansions--bngo-20220811monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-second-quarter-2022-financial-results-and-highlights-recent-busin-bngo-20220804monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-publication-of-landmark-research-study-in-myelodysplastic-syndr-bngo-20220801monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-report-second-quarter-2022-financial-results-and-host-a-conference-cal-bngo-20220728monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-its-participation-at-the-cancer-genomics-consortium-2022-annual-bngo-20220726monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-publication-of-a-new-study-using-ogm-to-investigate-chromosome--bngo-20220721monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-issuance-of-a-u-s-patent-for-analysis-of-small-nucleic-acid-fra-bngo-20220629monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-participation-at-the-european-association-for-cancer-research-e-bngo-20220616monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-participation-at-the-european-society-of-human-genetics-confere-bngo-20220610monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-publication-of-a-new-study-using-ogm-to-investigate-inversions--bngo-20220608monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-canadian-college-of-medical-geneticists-presentation-featuring--bngo-20220603monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-participation-at-the-advances-in-genome-biology-and-technology--bngo-20220602monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-glass-lewis-recommendation-and-encourages-stockholders-to-cast-their-vot-bngo-20220526monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-present-at-the-2022-h-c-wainwright-global-investment-conference-bngo-20220517monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-participation-at-the-2022-american-cytogenomics-conference-acc--bngo-20220513monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-a-publication-from-the-first-affiliated-hospital-of-zhengzhou-h-bngo-20220512monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-first-quarter-2022-financial-results-and-highlights-recent-busine-bngo-20220505monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-peer-reviewed-publication-of-neuroscore-model-to-predict-and-pr-bngo-20220429monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-report-first-quarter-2022-financial-results-and-host-a-conference-call-bngo-20220428monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-issuance-of-two-u-s-patents-for-novel-methods-that-expand-paten-bngo-20220414monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-release-of-version-6-2-of-its-nxclinical-software-with-signific-bngo-20220407monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-publication-of-a-new-study-using-ogm-combined-with-multiple-ana-bngo-20220406monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-participation-at-the-american-association-for-cancer-research-a-bngo-20220405monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-speaker-lineup-for-2022-china-symposium-bngo-20220325monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-present-at-the-2022-maxim-virtual-growth-conference-bngo-20220323monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-its-participation-at-the-american-college-of-medical-genetics-a-bngo-20220323monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-publication-of-comprehensive-validation-of-optical-genome-mappi-bngo-20220318monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-present-at-the-32nd-annual-oppenheimer-healthcare-conference-bngo-20220308monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-appoints-dr-aleks-rajkovic-to-its-board-of-directors-bngo-20220307monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-present-at-the-42nd-annual-cowen-healthcare-conference-bngo-20220303monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides--bngo-20220301monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-launch-of-its-rare-undiagnosed-genetic-disease-rugd-strategic-i-bngo-20220228monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-report-fourth-quarter-and-year-end-2021-financial-results-and-host-a-c-bngo-20220222monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-publication-of-prospective-study-demonstrating-performance-impr-bngo-20220222monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-appoints-helene-klein-as-its-first-ever-chief-people-officer-bngo-20220214monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-first-publication-demonstrating-ogm-as-an-alternative-to-karyot-bngo-20220211monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-present-at-the-2022-btig-medtech-digital-health-life-science-diagnosti-bngo-20220209monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-uk-footprint-expansion-with-adoption-of-its-saphyr-system-for-o-bngo-20220202monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-publication-of-the-first-study-to-combine-ogm-and-ngs-to-evalua-bngo-20220126monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-publication-by-international-covid-19-host-genome-structural-va-bngo-20220120monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-its-support-for-the-agmg-foundation-for-genetic-and-genomic-med-bngo-20220120monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-record-daily-attendance-for-2022-symposium-with-63-increase-rel-bngo-20220119monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-hosts-final-day-of-2022-symposium-with-presentations-demonstrating-the-co-bngo-20220113monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-hosts-day-3-of-2022-symposium-with-new-research-demonstrating-application-bngo-20220112monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-hosts-day-2-of-2022-symposium-with-new-research-demonstrating-how-ogm-det-bngo-20220111monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-hosts-day-1-of-2022-symposium-with-six-presentations-highlighting-the-sup-bngo-20220110monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-publication-of-interim-readout-from-the-consortium-conducting-a-bngo-20220110monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-the-final-speaker-lineup-for-2022-symposium-bngo-20220107monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-prototype-for-its-next-single-molecule-imaging-system-for-ogm-bngo-20211229monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-appoints-vince-wong-to-its-board-of-directors-bngo-20211223monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-the-launch-of-version-6-1-of-biodiscovery-s-nxclinical-software-bngo-20211216monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-2022-symposium-featuring-four-consecutive-days-of-ogm-presentat-bngo-20211209monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-publication-of-study-evaluating-optical-genome-mapping-for-high-bngo-20211208monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-appoints-dr-keith-gligorich-seasoned-leader-in-clia-certified-cap-accredi-bngo-20211129monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-peer-reviewed-publication-from-johns-hopkins-university-outlini-bngo-20211122monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-extensive-lineup-of-content-to-be-presented-at-the-annual-meeti-bngo-20211115monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-third-quarter-2021-financial-results-and-highlights-recent-busine-bngo-20211104monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-the-appointment-of-stephanie-hoyle-as-vp-corporate-marketing-an-bngo-20211104monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-major-updates-to-its-solve-and-access-data-solutions-adding-sig-bngo-20211103monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bngo-20211102monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-report-third-quarter-2021-financial-results-and-host-a-conference-call-bngo-20211028monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-american-society-of-human-genetics-presentations-featuring-opti-bngo-20211015monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-expands-commercial-leadership-team-to-accelerate-growth-of-saphyr-and-bol-bngo-20211006monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-eshg-lineup-featuring-11-customer-presentations-of-ogm-data-spa-bngo-20210826monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-second-quarter-2021-financial-results-and-highlights-recent-busin-bngo-20210804monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-report-second-quarter-2021-financial-results-and-host-a-conference-cal-bngo-20210728monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-a-record-number-of-optical-genome-mapping-presentations-schedul-bngo-20210727monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-s-optical-genome-mapping-for-acute-lymphoblastic-leukemia-subjects-at-the-universi-bngo-20210719monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-s-optical-genome-mapping-reveals-new-insights-and-prognostic-capabilities-compared-bngo-20210714monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-s-optical-genome-mapping-extensively-featured-at-the-2021-european-cytogenomics-co-bngo-20210713monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-back-to-back-publications-in-the-american-journal-of-human-gene-bngo-20210707monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-significant-progress-in-china-with-wehealth-shanghai-s-adoption-bngo-20210706monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-chief-medical-officer-dr-alka-chaubey-and-cancer-genomics-consortium-pres-bngo-20210702monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-present-at-the-2021-ladenburg-thalmann-healthcare-conference-bngo-20210701monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-added-to-membership-of-us-small-cap-russell-2000-index-bngo-20210628monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-appoints-richard-shippy-former-affymetrix-illumina-and-cradle-executive-a-bngo-20210614monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-appoints-jason-priar-former-genedx-sema4-and-perkinelmer-genomics-sales-l-bngo-20210607monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-present-at-the-2021-oppenheimer-medtech-tools-diagnostic-summit-bngo-20210519monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-first-quarter-2021-financial-results-and-highlights-recent-busine-bngo-20210513monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-report-first-quarter-2021-financial-results-and-host-a-conference-call-bngo-20210506monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-issuance-of-us-patent-for-targeted-labeling-strategy-to-complem-bngo-20210504monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-publication-of-new-approach-to-study-dna-replication-using-opti-bngo-20210422monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-sites-within-the-uk-s-national-health-system-have-adopted-its-s-bngo-20210421monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-pre-clinical-evaluation-of-optical-genome-mapping-by-the-founda-bngo-20210414monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-record-number-of-presentations-on-optical-genome-mapping-and-st-bngo-20210412monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-presentations-on-optical-genome-mapping-at-the-american-associa-bngo-20210407monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-continued-global-expansion-in-adoption-of-its-saphyr-system-wit-bngo-20210407monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-financial-results-for-the-three-and-twelve-months-ended-decembe-bngo-20210323monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-present-at-several-upcoming-investor-conferences-bngo-20210315monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-presented-at-h-c-wainwright-global-life-sciences-conference-bngo-20210310monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-report-fourth-quarter-and-year-end-2020-financial-results-and-host-a-c-bngo-20210309monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-customer-praxis-genomics-receives-dex-z-codes-from-palmetto-for-their-whole-genome-bngo-20210303monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-present-at-the-cowen-41st-annual-health-care-conference-bngo-20210302monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-be-featured-at-agbt-2021-with-presentations-of-scientific-discoveries-made-with-bngo-20210301monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-s-saphyr-data-prove-essential-in-creating-the-most-comprehensive-ethnically-divers-bngo-20210225monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-publishes-method-for-identifying-genes-likely-to-cause-neurological-diseases-based-bngo-20210222monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-present-at-the-btig-medtech-digital-health-life-science-diagnostic-too-bngo-20210211monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-chief-medical-officer-presents-vision-for-optical-genome-mapping-as-a-first-line-c-bngo-20210127monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-significantly-reduces-analysis-cost-and-time-to-actionable-results-with-update-to--bngo-20210126monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-closing-of-230-million-underwritten-public-offering-of-common-s-bngo-20210125monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-pricing-of-200-million-underwritten-public-offering-of-common-s-bngo-20210120monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement-bngo-20210113monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-closing-of-101-8-million-underwritten-public-offering-of-common-bngo-20210112monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-the-kick-off-of-its-next-generation-cytogenomics-symposium-the--bngo-20210111monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-pricing-of-88-5-million-underwritten-public-offering-of-common--bngo-20210108monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-publishes-study-on-autism-risk-genes-after-detailed-analysis-of-the-genom-bngo-20210104monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-bid-price-r-bngo-20201230monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-customer-praxis-genomics-accredited-by-college-of-american-pathologists-completing-bngo-20201228monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-achieves-key-milestone-with-software-update-for-its-saphyr-system-that-in-bngo-20201221monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-s-saphyr-system-used-to-characterize-virus-integration-into-human-genome-bngo-20201215monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-users-present-the-saphyr-system-as-a-novel-diagnostic-tool-for-hematologi-bngo-20201203monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-and-its-users-present-the-saphyr-system-for-optical-genome-mapping-and-va-bngo-20201119monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-third-quarter-2020-financial-results-and-provides-business-update-bngo-20201112monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-releases-major-update-to-its-suite-of-software-tools-that-simplifies-clin-bngo-20201021monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-saphyr-system-shown-to-be-indispensable-for-the-analysis-of-certain-genet-bngo-20201015monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-s-saphyr-plays-essential-role-in-identifying-three-previously-unknown-genetic-muta-bngo-20201008monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-positive-outcome-of-its-special-stockholder-meeting-bngo-20200930monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-continued-expansion-of-global-business-with-adoption-of-saphyr--bngo-20200929monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-present-at-the-september-2020-oppenheimer-fall-healthcare-life-sciences-medtech-bngo-20200921monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-data-provides-understanding-of-repeat-expansion-disorders-causing-muscular-dystrop-bngo-20200917monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-continues-to-see-expansion-in-the-adoption-of-saphyr-for-digital-cytogene-bngo-20200916monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-expands-its-diagnostic-testing-menu-with-launch-of-lineagen-s-epipaneldx--bngo-20200914monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-continued-expansion-of-european-business-with-adoption-of-saphy-bngo-20200910monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bngo-20200904monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-data-is-a-key-to-understanding-cancer-genome-structures-that-make-tumors--bngo-20200902monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-adjournment-of-special-meeting-of-stockholders-to-september-29--bngo-20200831monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-emphasizes-the-importance-of-supporting-the-proxy-proposal-to-increase-it-bngo-20200828monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-saphyr-services-offered-in-clia-certified-lab-expands-bionano-genomics-clinical-ap-bngo-20200820monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-appoints-industry-leading-cytogeneticist-dr-alka-chaubey-as-the-company-s-bngo-20200818monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-at-the-market-equity-program-bngo-20200817monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-second-quarter-2020-financial-results-and-provides-business-updat-bngo-20200813monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-featured-at-cancer-genomics-consortium-annual-meeting-with-multiple-data-readouts--bngo-20200810monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-report-second-quarter-2020-financial-results-and-host-a-conference-cal-bngo-20200807monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genome-imaging-provides-essential-scaffolding-results-in-high-profile-bat-genome-s-bngo-20200729monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genome-imaging-identifies-the-most-common-structural-variations-between-individual-bngo-20200723monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-data-is-essential-part-of-the-first-ever-complete-assembly-of-a-human-x-c-bngo-20200716monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-solidifies-its-entry-into-solid-tumor-analysis-with-launch-of-new-kit-and-bngo-20200709monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-first-quarter-2020-financial-results-and-provides-business-update-bngo-20200618monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-amendment-to-proxy-statement-for-annual-meeting-of-stockholders-bngo-20200618monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-report-first-quarter-2020-financial-results-and-host-a-conference-call-bngo-20200612monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-issuance-of-us-patent-for-combined-nanochannel-nanopore-device-bngo-20200608monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-to-participate-in-maxim-group-s-covid-19-virtual-conference-series-the-role-of-cel-bngo-20200527monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-adds-healthcare-and-genomics-industry-experts-with-experience-in-commerci-bngo-20200504monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-pricing-of-18-million-underwritten-public-offering-bngo-20200402monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-support-largest-study-to-date-on-covid-19-disease-susceptibility-bngo-20200331monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-will-be-used-in-research-identifying-gene-variants-that-contribute-to-cor-bngo-20200310monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-fourth-quarter-and-year-end-2019-financial-results-and-provides-b-bngo-20200305monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-report-fourth-quarter-and-year-end-2019-financial-results-and-host-a-c-bngo-20200228monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-releases-saphyr-updates-for-industry-leading-data-yields-that-enable-anal-bngo-20200224monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-data-drives-scientific-discoveries-in-solid-tumors-and-leukemias-to-be-pr-bngo-20200221monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genome-imaging-concordant-with-traditional-cytogenetics-in-landmark-leukemia-study-bngo-20200210monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-saphyr-system-is-adopted-by-genedx-for-the-clinical-detection-of-genetic--bngo-20200106monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-third-quarter-2019-financial-results-and-provides-business-update-bngo-20191107monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-report-third-quarter-2019-financial-results-and-host-a-conference-call-bngo-20191104monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-pricing-of-18-million-underwritten-public-offering-bngo-20191021monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-adoption-of-its-saphyr-system-by-clinical-cytogenetics-groups-i-bngo-20191016monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-present-at-the-h-c-wainwright-21st-annual-global-investment-conference-bngo-20190909monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-releases-users-video-presentations-of-preliminary-data-affirming-saphyr-s-bngo-20190830monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-second-quarter-2019-financial-results-and-provides-business-updat-bngo-20190808monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-report-second-quarter-2019-financial-results-and-host-a-conference-cal-bngo-20190802monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-appoints-kristiina-vuori-md-phd-to-its-board-of-directors-bngo-20190612monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-first-quarter-2019-financial-results-and-provides-business-update-bngo-20190509monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-report-first-quarter-2019-financial-results-and-host-a-conference-call-bngo-20190503monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-present-at-the-31st-annual-roth-conference-bngo-20190318monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-report-fourth-quarter-and-fiscal-year-2018-financial-results-and-host--bngo-20190312monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-present-at-the-cowen-and-company-39th-annual-health-care-conference-bngo-20190306monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-launches-new-capabilities-of-the-saphyr-system-to-significantly-increase--bngo-20190301monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-saphyr-system-used-for-highly-accurate-detection-of-the-genetic-disorder--bngo-20190206monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-report-third-quarter-2018-financial-results-and-host-conference-call-a-bngo-20181025monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-and-genoox-launch-integrated-platform-for-identification-of-structural-variants-in-bngo-20181017monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-structural-variation-results-presented-at-ashg-2018-provide-insights-in-c-bngo-20181016monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-the-separate-trading-of-its-common-stock-and-warrants-bngo-20180921monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-pricing-of-initial-public-offering-bngo-20180821monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-global-launch-of-its-new-direct-labeling-chemistry-for-genome-m-bngo-20180212monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-early-access-customers-to-present-groundbreaking-genome-assembly-data-usi-bngo-20180112monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genome-mapping-found-to-be-superior-to-existing-clinical-tests-for-the-identificat-bngo-20171101monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-structural-variation-data-featured-in-many-scientific-presentations-at-th-bngo-20171009monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-inversion-detection-algorithms-with-unmatched-sensitivity-bngo-20170905monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-immediate-availability-of-new-suite-of-genomic-analysis-tools-bngo-20170404monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-global-launch-of-saphyr-its-newest-and-most-advanced-system-for-bngo-20170213monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-multiple-presentations-demonstrating-how-its-next-generation-ma-bngo-20170207monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-industry-leading-detection-of-structural-variants-with-more-than--bngo-20170206monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-highlights-five-studies-at-pag-xxv-demonstrating-how-next-generation-mapp-bngo-20170116monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-36-posters-and-workshops-supporting-next-generation-mapping-to--bngo-20170111monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-s-next-generation-mapping-ngm-used-to-reveal-the-genome-structure-of-the-korean-ge-bngo-20161014monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-present-results-supporting-next-generation-mapping-in-human-genome-res-bngo-20161010monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-elects-david-barker-ph-d-former-chief-scientific-officer-of-illumina-as-chairman-o-bngo-20160908monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-and-berry-genomics-to-co-develop-next-generation-mapping-system-for-cfda--bngo-20160817monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-releases-updated-irys-data-solutions-for-improved-structural-variation-analysis-in-bngo-20160627monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-adoption-of-the-popular-vcf-format-bngo-20160607monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-next-generation-mapping-yields-superior-genomic-assemblies-with-greater-contiguity-bngo-20160510monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-launches-enhanced-genome-mapping-coverage-features-with-new-software-tool-bngo-20160504monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-32-posters-and-workshops-supporting-next-generation-mapping-to--bngo-20160107monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-highlights-study-using-next-generation-mapping-for-7-fold-improvement-in--bngo-20160105monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-highlights-results-from-next-generation-mapping-study-of-large-yellow-cro-bngo-20151015monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-research-collaboration-with-ucla-bngo-20151008monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-data-demonstrate-next-generation-mapping-as-new-standard-for-accurate-and-bngo-20151006monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-present-five-posters-supporting-next-generation-mapping-at-ashg-2015-a-bngo-20150928monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-sees-continued-adoption-of-their-irys-system-in-asia-pacific-bngo-20150722monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-positive-clinical-update-from-ongoing-pediatric-netherton--qnrx-20260616monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-provides-clinical-and-regulatory-update-for-qrx009-topical-rapamycin-qnrx-20260428monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-to-announce-corporate-update-and-fourth-quarter-and-full-year-2025-f-qnrx-20260319monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-to-provide-corporate-update-and-announce-third-quarter-2025-financia-qnrx-20251030monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-to-announce-second-quarter-2025-financial-results-on-thursday-august-qnrx-20250731monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-provides-product-portfolio-update-qnrx-20250729monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-releases-new-netherton-now-video-featuring-professor-jemima-mellerio-qnrx-20250626monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-fda-grants-rare-pediatric-disease-designation-for-qrx003-i-qnrx-20250624monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-initial-positive-clinical-data-for-qrx003-from-pediatric-p-qnrx-20250514monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-to-announce-first-quarter-2025-financial-results-on-tuesday-may-13-2-qnrx-20250506monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-rule-qnrx-20250430monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-releases-second-episode-of-its-living-with-netherton-series-as-part--qnrx-20250410monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-additional-positive-whole-body-clinical-data-from-ongoing--qnrx-20250402monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-files-u-s-patent-application-for-novel-topical-formulations-to-treat-qnrx-20250325monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2024-financial-results-on-t-qnrx-20250306monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-files-u-s-and-international-patent-applications-for-novel-topical-ra-qnrx-20250304monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-highly-positive-whole-body-clinical-data-from-ongoing-pedi-qnrx-20250227monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-launches-first-episode-of-netherton-now-video-series-to-raise-awaren-qnrx-20250225monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-launches-netherton-now-campaign-to-raise-awareness-of-netherton-synd-qnrx-20250204monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-further-clinical-evidence-of-qrx003-effectiveness-in-nethe-qnrx-20250123monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-further-positive-clinical-data-from-ongoing-pediatric-neth-qnrx-20250114monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-additional-positive-interim-data-from-ongoing-open-label-n-qnrx-20250106monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-fda-clearance-to-initiate-new-qrx003-netherton-syndrome-cl-qnrx-20241219monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-positive-interim-data-from-two-ongoing-netherton-syndrome--qnrx-20241218monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-initiates-clinical-testing-of-lead-product-in-pediatric-netherton-sy-qnrx-20241105monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-to-announce-third-quarter-2024-financial-results-on-thursday-novembe-qnrx-20241031monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-further-international-expansion-of-ongoing-clinical-trials-qnrx-20241022monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-insider-share-purchases-by-co-founders-ceo-and-coo-qnrx-20240909monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-to-initiate-clinical-study-for-peeling-skin-syndrome-qnrx-20240806monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-to-announce-second-quarter-2024-financial-results-on-thursday-august-qnrx-20240801monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-international-expansion-of-ongoing-clinical-trials-for-net-qnrx-20240627monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-to-sponsor-the-foundation-for-ichthyosis-related-skin-types-first-20-qnrx-20240625monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-signing-of-research-agreement-with-university-college-cork-qnrx-20240612monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-provides-corporate-update-and-announces-first-quarter-2024-financial-qnrx-20240509monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-to-announce-first-quarter-2024-financial-results-on-may-9-2024-qnrx-20240502monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-fourth-quarter-and-2023-financial-results-and-corporate-up-qnrx-20240307monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-pricing-of-6-5-million-public-offering-qnrx-20240305monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-files-u-s-and-international-patent-applications-for-novel-netherton--qnrx-20240208monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-fda-clearance-of-clinical-optimization-plan-for-qrx003-for-qnrx-20231213monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-third-quarter-2023-financial-results-and-corporate-update--qnrx-20231103monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-additional-positive-clinical-data-from-open-label-single-a-qnrx-20231024monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-second-quarter-2023-financial-results-and-corporate-update-qnrx-20230727monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-50-enrollment-in-open-label-netherton-syndrome-clinical-tr-qnrx-20230524monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-first-quarter-2023-financial-results-and-corporate-update--qnrx-20230502monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-doses-first-patient-in-open-label-netherton-syndrome-clinical-trial-qnrx-20230321monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-2022-corporate-update-conference-call-to-be-held-on-thursd-qnrx-20230302monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-dosing-of-first-patient-in-clinical-trial-in-netherton-syn-qnrx-20221213monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-provides-corporate-update-and-announces-third-quarter-2022-financial-qnrx-20221110monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-updated-timing-of-third-quarter-2022-corporate-update-conf-qnrx-20221103monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-to-report-third-quarter-2022-financial-results-and-provide-corporate-qnrx-20221101monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-plans-to-initiate-a-second-clinical-trial-in-netherton-syn-qnrx-20221018monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-establishes-patient-specific-website-for-ongoing-netherton-syndrome--qnrx-20220913monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-provides-corporate-update-and-announces-second-quarter-2022-financia-qnrx-20220818monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-to-report-second-quarter-2022-financial-results-and-provide-corporat-qnrx-20220811monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-closing-of-16-8-million-public-offering-qnrx-20220809monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-receipt-of-constructive-scientific-advice-from-ema-for-qrx-qnrx-20220728monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-and-endo-ventures-limited-enter-into-exclusive-distribution-and-supp-qnrx-20220715monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-opening-of-first-clinical-site-for-netherton-syndrome-clin-qnrx-20220706monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requir-qnrx-20220615monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-licensing-and-distribution-agreement-with-leading-rare-dis-qnrx-20220615monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-enters-exclusive-research-agreement-for-scleroderma-treatment-with-a-qnrx-20220523monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-fda-clearance-of-ind-for-its-lead-asset-qrx003-for-nethert-qnrx-20220425monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-submission-of-ind-for-its-lead-asset-qrx003-for-netherton--qnrx-20220315monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-submits-scientific-advice-briefing-document-to-ema-for-its-lead-asse-qnrx-20220310monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-extends-exclusive-distribution-agreement-with-er-kim-for-its-lead-as-qnrx-20220301monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-signs-exclusive-distribution-agreement-with-neopharm-for-its-lead-as-qnrx-20220217monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-signs-exclusive-distribution-agreement-with-er-kim-for-its-lead-asse-qnrx-20220210monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-signs-exclusive-distribution-agreement-with-orphandc-for-its-lead-as-qnrx-20220126monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-signs-exclusive-distribution-agreement-with-orpharm-llc-for-its-lead-qnrx-20211215monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-and-genpharm-services-sign-exclusive-license-and-distribution-agreem-qnrx-20211111monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-signs-exclusive-licensing-and-distribution-agreement-with-aft-pharma-qnrx-20211108monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-appoints-gordon-dunn-as-chief-financial-officer-qnrx-20211104monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-signing-of-exclusive-license-from-queensland-university-of-qnrx-20211102monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-gnpx-featured-in-audio-publication-discussing-new-research-on-breast-cancer-treatm-gnpx-20190926monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-gnpx-featured-in-publication-on-advances-in-potential-breast-cancer-treatments-gnpx-20190925monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-gnpx-featured-in-networknewsaudio-publication-discussing-promising-new-gene-therap-gnpx-20190509monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-gnpx-featured-in-networknewswire-publication-discussing-cancer-and-gene-therapy-tr-gnpx-20190411monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-gnpx-featured-in-networknewsaudio-publication-discussing-advanced-medical-cancer-t-gnpx-20190329monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-gnpx-featured-in-networknewswire-publication-discussing-innovative-cancer-treatmen-gnpx-20190328monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-inc-discusses-plans-to-expand-clinical-trials-in-fight-against-cancer-in-exclusive-gnpx-20190319monthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-appoints-kristopher-fishman-and-sanjiv-lal-to-nugevia-advisory-board-juns-20260407monthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-marks-transformational-first-year-as-a-public-company-entering-2026--juns-20251203monthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-launches-nugevia-a-premium-longevity-and-performance-supplement-line-juns-20250609monthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-highlights-upcoming-milestones-in-shareholder-letter-juns-20250408monthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-and-aquanova-ag-announce-strategic-collaboration-to-develop-longevit-juns-20250304monthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clini-juns-20250204monthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-announces-jotrol-manufacturing-agreement-with-catalent-to-support-ph-juns-20250203monthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-partners-with-zina-biopharmaceuticals-to-advance-phase-2a-parkinson--juns-20250130monthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-announces-strategic-focus-on-nlrp3-pathway-in-future-jotrol-trials-juns-20250113monthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-inc-announces-closing-of-11-million-initial-public-offering-juns-20241204monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europc-bcda-20260521monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-pre-submission-approval-package-for-helix-transendocardial-delivery-ca-bcda-20260317monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-cell-therapy-for-ischemic-heart-failure-to-progress-to-formal-clinical-consultat-bcda-20251216monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-election-of-new-board-director-marvin-slosman-and-completion-of-term-f-bcda-20251203monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-present-at-december-2025-csi-focus-devices-in-heart-failure-congress-bcda-20251201monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-strengthens-leadership-team-with-the-addition-of-farhan-shahab-as-vice-president-bcda-20251124monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-inc-bcda-2025-product-pipeline-and-strategy-analysis-report-bcda-20251021monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-second-quarter-2025-business-highlights-and-financial-results-bcda-20250811monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-host-q2-2025-corporate-update-and-financial-results-conference-call-on-august-bcda-20250806monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-provides-update-on-timing-of-regulatory-activities-seeking-fda-approval-and-japa-bcda-20250804monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-submits-request-for-clinical-data-review-meeting-with-japan-pmda-to-discuss-appr-bcda-20250724monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-new-united-states-patent-for-helix-biotherapeutic-delivery-system-bcda-20250625monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-participate-in-fireside-chat-at-a-g-p-virtual-healthcare-company-showcase-on--bcda-20250521monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-first-quarter-2025-business-highlights-and-financial-results-bcda-20250514monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-host-q1-2025-corporate-update-and-financial-results-conference-call-on-may-14-bcda-20250509monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-initiates-patient-enrollment-at-university-of-wisconsin-at-madison-for-ongoing-c-bcda-20250506monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-first-patient-in-phase-3-randomized-controlled-double-blind-cardiamp-h-bcda-20250501monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-positive-dsmb-review-of-cardiallo-allogeneic-cell-therapy-for-heart-fa-bcda-20250415monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-initiates-patient-enrollment-at-emory-university-school-of-medicine-for-ongoing--bcda-20250411monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-s-conference-call-today-monday-march-31-2025-to-be-held-at-4-30pm-edt-time-today-bcda-20250331monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-phase-3-cardiamp-hf-trial-of-novel-cardiac-cell-therapy-for-ischemic-heart-failu-bcda-20250331monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-2024-business-highlights-and-financial-results-bcda-20250326monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-host-2024-financial-results-and-corporate-update-conference-call-on-march-31--bcda-20250321monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-japanese-patent-for-helix-biotherapeutic-delivery-system-bcda-20250310monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-primary-outcome-measures-data-freeze-in-cardiamp-heart-failure-trial-f-bcda-20250227monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-completion-of-low-dose-cohort-enrollment-for-cardiallo-phase-i-ii-clinic-bcda-20250213monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-late-breaking-clinical-trial-presentation-on-cardiamp-heart-failure-tr-bcda-20250127monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-commercial-availability-of-morph-dna-steerable-introducer-product-fami-bcda-20241217monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-positive-consultation-with-japan-pmda-on-cardiamp-cell-therapy-for-isc-bcda-20241204monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-third-quarter-2024-business-highlights-and-financial-results-bcda-20241113monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-host-q3-2024-corporate-update-and-financial-results-conference-call-on-novemb-bcda-20241106monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-completes-phase-iii-randomized-double-blind-controlled-trial-of-autologous-cell--bcda-20241028monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-regains-full-compliance-with-nasdaq-listing-requirements-bcda-20240918monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-closing-of-upsized-7-2-million-public-offering-priced-at-the-market-un-bcda-20240909monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-pricing-of-upsized-7-2-million-public-offering-priced-at-the-market-un-bcda-20240830monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-fda-market-clearance-of-morph-dna-steerable-introducer-product-family-bcda-20240829monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-second-quarter-2024-business-highlights-and-financial-results-bcda-20240813monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-host-q2-2024-corporate-update-and-financial-results-conference-call-on-august-bcda-20240807monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-submits-for-fda-approval-of-morph-dna-steerable-introducer-product-family-bcda-20240730monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-united-states-patent-issuance-on-morph-dna-multi-directional-steerable-bcda-20240717monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-united-states-patent-issuance-on-intramyocardial-delivery-of-cell-aggr-bcda-20240607monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-reverse-stock-split-bcda-20240521monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-first-quarter-2024-business-highlights-and-financial-results-bcda-20240514monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-host-q1-2024-financial-results-and-corporate-update-conference-call-on-may-14-bcda-20240509monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-s-cardiamp-cell-therapy-chronic-myocardial-ischemia-trial-results-show-patient-b-bcda-20240501monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-completes-enrollment-of-cardiamp-cell-therapy-for-the-treatment-of-chronic-myoca-bcda-20240425monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-fourth-quarter-and-full-year-2023-business-highlights-and-financial-resu-bcda-20240327monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-host-2023-financial-results-and-corporate-update-conference-call-on-march-27--bcda-20240320monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-and-stemcardia-announce-biotherapeutic-delivery-partnership-bcda-20240313monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-cms-approval-of-coverage-for-cardiamp-cell-therapy-confirmatory-phase--bcda-20240312monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-positive-interim-results-from-phase-iii-cardiamp-cell-therapy-heart-fail-bcda-20240304monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-activation-of-cardiamp-heart-failure-ii-phase-3-pivotal-study-recently-bcda-20240208monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-two-scientific-abstracts-have-been-accepted-at-the-2024-technology-and-bcda-20240131monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-biotherapeutic-delivery-and-morph-access-innovations-business-development-update-bcda-20240103monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-doses-first-patient-in-cardiallo-phase-i-ii-clinical-trial-of-bcda-03-allogeneic-bcda-20231219monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-expected-cardiamp-heart-failure-japan-approval-timeline-based-on-pharm-bcda-20231218monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-shares-update-from-japan-pmda-consultation-on-cardiamp-autologous-cell-therapy-f-bcda-20231129monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-1-3-million-registered-direct-offering-of-common-stock-priced-at-the-m-bcda-20231116monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-fda-approval-of-cardiamp-heart-failure-ii-protocol-for-autologous-cell-bcda-20231114monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-third-quarter-2023-business-highlights-and-financial-results-bcda-20231108monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-host-q3-2023-corporate-update-and-financial-results-conference-call-on-novemb-bcda-20231101monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-completion-of-enrollment-in-phase-iii-cardiamp-hf-trial-and-plans-for--bcda-20231011monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-clarification-and-next-steps-on-its-autologous-cardiamp-cell-therapy-p-bcda-20230906monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-interim-efficacy-results-in-phase-iii-pivotal-cardiamp-cell-therapy-he-bcda-20230905monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-second-quarter-2023-business-highlights-and-financial-results-bcda-20230809monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-host-q2-2023-financial-results-and-corporate-update-conference-call-on-august-bcda-20230802monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-dsmb-recommendation-to-pause-new-enrollment-in-phase-iii-pivotal-cardi-bcda-20230724monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-completes-submission-of-cardiamp-cell-therapy-system-in-heart-failure-to-japan-s-bcda-20230705monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-fda-completes-review-of-proposed-adaptive-statistical-analysis-design--bcda-20230620monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-helix-biotherapeutic-delivery-patent-issuance-in-japan-bcda-20230608monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-timing-of-the-next-data-safety-monitoring-board-meeting-for-the-cardia-bcda-20230523monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-first-quarter-2023-business-highlights-and-financial-results-bcda-20230510monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-us-patent-on-bone-marrow-derived-neurokinin-1-receptor-positive-nk1r-m-bcda-20230509monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-host-q1-2023-financial-results-and-corporate-update-conference-call-on-may-10-bcda-20230504monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-presentations-at-next-generation-cardiovascular-drug-development-summit-now-avai-bcda-20230428monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-issuance-of-two-patents-related-to-technology-that-guides-intervention-bcda-20230404monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-fourth-quarter-and-full-year-2022-business-highlights-and-financial-resu-bcda-20230329monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-host-2022-financial-results-and-corporate-update-conference-call-on-march-29--bcda-20230316monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-and-cellprothera-enhance-collaboration-for-development-of-protheracytes-for-the--bcda-20230201monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-letter-to-shareholders-bcda-20221222monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-3-6-million-private-placement-of-common-stock-bcda-20221215monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-third-quarter-2022-business-highlights-and-financial-results-bcda-20221109monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-host-q3-2022-financial-results-and-corporate-update-conference-call-on-novemb-bcda-20221102monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-presents-positive-cardiamp-cell-therapy-heart-failure-trial-two-year-data-at-hfs-bcda-20221003monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-participation-at-h-c-wainwright-global-investment-conference-september-bcda-20220909monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-participate-in-cantor-fitzgerald-s-cell-and-genetic-medicines-conference-bcda-20220908monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-positive-dsmb-review-and-recommendation-to-continue-phase-iii-pivotal--bcda-20220831monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-enters-agreement-with-bluerock-therapeutics-to-provide-enabling-catheter-biother-bcda-20220824monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-second-quarter-2022-business-highlights-and-financial-results-bcda-20220810monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-host-q2-2022-financial-results-and-corporate-update-conference-call-on-august-bcda-20220804monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-first-canadian-clinical-site-for-cardiamp-cell-therapy-heart-failure-t-bcda-20220801monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-participate-in-upcoming-heart-and-pulmonary-therapy-development-symposia-bcda-20220712monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-us-patent-on-imaging-system-for-targeting-cardiac-therapies-bcda-20220615monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-first-quarter-2022-business-highlights-and-financial-results-bcda-20220511monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-host-q1-2022-financial-results-and-corporate-update-conference-call-on-may-11-bcda-20220504monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-fda-approval-of-its-ind-for-nk1r-mesenchymal-stem-cells-for-the-treatm-bcda-20220412monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-2021-financial-results-and-recent-business-highlights-bcda-20220329monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-host-2021-financial-results-and-corporate-update-conference-call-on-march-29--bcda-20220324monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-new-center-for-medicare-and-medicaid-services-reimbursement-code-appli-bcda-20220322monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-receives-no-objection-letter-from-health-canada-enabling-company-to-expand-cardi-bcda-20220301monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-positive-dsmb-review-and-recommendation-to-continue-phase-iii-pivotal--bcda-20220214monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-participation-at-the-upcoming-digital-medicine-medtech-showcase-and-th-bcda-20220110monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-establishes-new-manufacturing-facility-to-enable-its-cell-therapy-product-candid-bcda-20211215monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-third-quarter-2021-financial-results-and-business-highlights-bcda-20211110monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-release-third-quarter-2021-financial-results-november-10-2021-bcda-20211108monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-first-patient-treated-in-cardiamp-cell-therapy-trial-for-chronic-myoca-bcda-20211021monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-issued-new-u-s-patent-for-technology-that-enhances-control-for-interventional-ca-bcda-20211012monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-first-cross-over-patient-treated-in-cardiamp-cell-therapy-heart-failur-bcda-20211007monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-participation-at-the-a-g-p-biotech-specialty-pharma-conference-october-bcda-20211006monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-participation-at-the-h-c-wainwright-23rd-annual-global-investment-conf-bcda-20210909monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-participate-in-upcoming-investor-conferences-bcda-20210813monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-second-quarter-2021-financial-results-and-business-highlights-bcda-20210812monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-participate-in-a-fireside-chat-at-the-btig-virtual-biotechnology-conference-o-bcda-20210804monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-japanese-patent-on-imaging-system-for-targeting-cardiac-therapies-bcda-20210715monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-fourth-positive-dsmb-review-and-recommendation-to-continue-phase-iii-p-bcda-20210623monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-present-cardiamp-cell-therapy-clinical-trial-data-at-european-society-of-card-bcda-20210622monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-european-patent-office-decision-to-grant-patent-on-autologous-cell-the-bcda-20210621monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-be-added-to-the-russell-microcap-index-bcda-20210614monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-present-at-the-ld-micro-virtual-invitational-conference-on-june-8-2021-bcda-20210602monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-first-quarter-2021-financial-results-and-business-highlights-bcda-20210513monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-signs-agreement-with-leading-japanese-biotechnology-company-for-catheter-biother-bcda-20210426monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-2020-financial-results-and-recent-business-highlights-bcda-20210330monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-present-at-maxim-group-s-inaugural-emerging-growth-virtual-conference-bcda-20210315monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-signs-agreement-with-leading-japanese-pharmaceutical-company-for-catheter-biothe-bcda-20210223monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-clinical-leadership-changes-bcda-20210217monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-update-on-cell-therapy-product-development-and-2021-milestones-bcda-20210202monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-issued-new-u-s-patent-for-technology-that-enhances-control-for-cardiac-therapies-bcda-20201230monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-positive-dsmb-review-and-recommendation-to-continue-phase-iii-pivotal--bcda-20201217monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-inc-announces-10-5-million-registered-direct-offering-priced-at-the-market-under-bcda-20201216monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-inc-announces-8-5-million-registered-direct-offering-priced-at-the-market-under--bcda-20201215monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-anticipates-dsmb-feedback-on-interim-data-from-pivotal-phase-3-cardiamp-heart-fa-bcda-20201214monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-published-study-showing-helix-biotherapeutic-delivery-system-used-in-car-bcda-20201201monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-third-quarter-2020-financial-results-and-business-highlights-bcda-20201110monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-issued-new-patent-for-delivery-of-cardiac-cell-therapy-through-wrist-artery-bcda-20200929monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-present-at-the-ld-micro-500-virtual-conference-on-september-1-2020-bcda-20200826monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-second-quarter-2020-financial-results-and-business-highlights-bcda-20200813monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-conduct-mid-year-conference-call-and-corporate-update-august-13-2020-bcda-20200807monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-activation-of-pivotal-trial-studying-cardiamp-cell-therapy-trial-to-tr-bcda-20200701monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-cardiamp-heart-failure-pivotal-trial-continues-with-first-patient-rand-bcda-20200629monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-pricing-of-10-million-public-offering-bcda-20200617monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-first-quarter-2020-financial-results-and-business-highlights-bcda-20200515monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-positive-preclinical-results-supporting-investigational-new-drug-appli-bcda-20200505monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-fda-recommended-modifications-to-primary-endpoint-for-cardiamp-cell-th-bcda-20200430monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-awarded-new-u-s-patent-covering-helix-system-for-local-biotherapeutic-delivery-o-bcda-20200428monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-litigation-financing-in-the-case-captioned-boston-scientific-corp-et-a-bcda-20200414monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-2019-financial-results-and-recent-business-highlights-bcda-20200409monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-positive-dsmb-recommendation-to-continue-phase-iii-pivotal-cardiamp-he-bcda-20200331monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-timing-for-prespecified-data-safety-monitoring-board-report-on-pivotal-bcda-20200312monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-fda-clearance-for-morph-dna-deflectable-guide-catheter-bcda-20200114monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-new-u-s-patent-covering-cardiamp-cell-therapy-and-issuance-of-two-asia-bcda-20200108monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-2019-third-quarter-financial-results-and-business-highlights-bcda-20191119monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-present-at-dawson-james-securities-5th-annual-small-cap-growth-conference-bcda-20191028monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-receives-ce-mark-renewal-for-helix-biotherapeutic-delivery-catheter-and-morph-gu-bcda-20191008monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-the-appointment-of-two-new-board-members-bcda-20191002monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-initiates-commercial-release-of-avance-steerable-introducer-designed-to-enhance--bcda-20191001monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-positive-dsmb-recommendation-to-continue-phase-3-pivotal-cardiamp-hear-bcda-20190916monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-2019-second-quarter-financial-results-and-business-highlights-bcda-20190821monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-issuance-of-european-patent-for-breakthrough-diagnostic-assay-for-pati-bcda-20190808monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-closing-of-10-0-million-public-offering-bcda-20190806monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-pricing-of-10-0-million-public-offering-and-uplisting-to-nasdaq-bcda-20190802monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-signs-exclusive-development-agreement-with-astrazeneca-bcda-20190725monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-issuance-of-chinese-patent-for-image-guided-biotherapeutic-delivery-bcda-20190612monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-reverse-stock-split-and-plan-for-listing-on-a-major-stock-exchange-bcda-20190606monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-2019-first-quarter-financial-results-and-business-highlights-bcda-20190520monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-receives-fda-clearance-for-avance-steerable-introducer-for-transseptal-access-to-bcda-20190508monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-to-present-at-2015-stem-cell-meeting-on-the-mesa-bcda-20151006monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-inc-files-registration-statement-for-proposed-initial-public-offering-bcda-20150616monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-completes-enrollment-in-phase-2-sunrise-pd-trial-in-early-parkinson-s-disease-bivi-20260108monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-alert-bragar-eagel-squire-p-c-is-investigating-biovie-inc-on-behalf-of-long-term-st-bivi-20251009monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-host-virtual-kol-event-to-discuss-the-phase-2-study-of-bezisterim-for-the-treatm-bivi-20250514monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-present-rationale-and-design-of-phase-2-sunrise-pd-clinical-trial-at-the-30th-wo-bivi-20250507monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-unveils-corporate-advisory-board-featuring-neuralink-co-founder-former-executives-f-bivi-20250505monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-alert-bragar-eagel-squire-p-c-is-investigating-biovie-inc-on-behalf-of-long-term-st-bivi-20250501monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-initiates-sunrise-pd-clinical-trial-assessing-bezisterim-in-early-parkinson-s-disea-bivi-20250416monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-host-kol-investor-webcast-to-discuss-the-long-covid-treatment-landscape-and-its--bivi-20250327monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-alert-bragar-eagel-squire-p-c-is-investigating-biovie-inc-on-behalf-of-long-term-st-bivi-20250103monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-present-design-of-planned-phase-2-study-of-bezisterim-for-the-treatment-of-long--bivi-20241120monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-s-upcoming-parkinson-s-disease-clinical-trial-is-fully-funded-bivi-20241104monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-announces-closing-of-registered-direct-offering-and-concurrent-private-placemen-bivi-20241022monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-receives-notice-of-allowance-for-japan-patent-application-covering-novel-liquid-for-bivi-20241015monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-receives-notice-of-allowance-for-united-states-patent-application-covering-novel-li-bivi-20241001monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-announces-closing-of-public-offering-bivi-20240925monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-announces-pricing-of-public-offering-bivi-20240924monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-announces-proposed-public-offering-bivi-20240923monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-secures-all-scientific-approvals-needed-to-receive-additional-12-6-million-of-grant-bivi-20240916monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-fda-authorization-of-investigational-new-drug-application-for-phase-2-tri-bivi-20240903monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-clinical-data-showing-epigenetic-basis-for-how-bezisterim-may-modulate-in-bivi-20240827monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-present-overview-of-bezisterim-clinical-data-on-longevity-at-11th-aging-research-bivi-20240813monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-alignment-with-fda-on-clinical-trial-to-assess-bezisterim-in-parkinson-s--bivi-20240808monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-announces-reverse-stock-split-bivi-20240806monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-presents-protocol-design-of-upcoming-sunrise-pd-phase-2-trial-of-bezisterim-in-pati-bivi-20240625monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-present-protocol-design-for-upcoming-phase-2-trial-of-bezisterim-in-patients-wit-bivi-20240620monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-formation-of-advisory-board-for-bezisterim-in-long-covid-bivi-20240604monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-s-bezisterim-demonstrates-potential-improvements-in-sleep-fatigue-and-restless-leg--bivi-20240522monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-awarded-up-to-13-1-million-in-funding-from-u-s-department-of-defense-to-evaluate-be-bivi-20240429monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-presents-data-showing-potential-for-bezisterim-ne3107-to-reduce-inflammation-and-re-bivi-20240425monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-present-data-showing-how-ne3107-potentially-restores-homeostasis-via-specific-ge-bivi-20240418monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-deadline-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsui-bivi-20240317monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-bivi-faces-securities-fraud-class-action-after-uncovering-potential-scientific-misc-bivi-20240312monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-sued-by-block-leviton-llp-for-securities-law-violations-bivi-20240312monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-announces-closing-of-public-offering-bivi-20240306monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-march-19-2-bivi-20240304monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-announces-pricing-of-public-offering-bivi-20240304monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-shareholder-notice-faruqi-faruqi-securities-litigation-partner-james-josh-wilson-en-bivi-20240223monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-mar-bivi-20240222monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-class-action-the-gross-law-firm-reminds-biovie-investors-of-the-pending-class-a-bivi-20240221monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-bivi-faces-securities-fraud-class-action-after-uncovering-potential-scientific-misc-bivi-20240216monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-investor-deadline-approaching-faruqi-faruqi-llp-securities-litigation-partner-james-bivi-20240215monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-bivi-faces-securities-fraud-class-action-after-uncovering-potential-scientific-misc-bivi-20240212monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-investor-deadline-approaching-faruqi-faruqi-securities-litigation-partner-james-jos-bivi-20240208monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-sued-by-block-leviton-llp-for-securities-law-violations-bivi-20240207monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-participate-in-the-oppenheimer-34th-annual-healthcare-life-sciences-conference-bivi-20240206monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-bivi-faces-securities-fraud-class-action-after-uncovering-potential-scientific-misc-bivi-20240205monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-investor-deadline-approaching-faruqi-faruqi-securities-litigation-partner-james-jos-bivi-20240202monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-bivi-faces-securities-fraud-class-action-after-uncovering-potential-scientific-misc-bivi-20240201monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-bivi-stockholder-news-robbins-llp-reminds-investors-of-lead-plaintiff-deadline--bivi-20240130monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-shareholder-notice-faruqi-faruqi-securities-litigation-partner-james-josh-wilson-en-bivi-20240124monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-bivi-faces-securities-fraud-class-action-after-uncovering-potential-scientific-misc-bivi-20240123monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed--bivi-20240122monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-sued-by-block-leviton-llp-for-securities-law-violations-bivi-20240120monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-bivi-plunges-after-alzheimer-s-drug-fails-phase-3-due-to-protocol-deviations-at-tri-bivi-20240111monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-bivi-plunges-after-alzheimer-s-drug-fails-phase-3-due-to-protocol-deviations-at-tri-bivi-20240105monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-bivi-plunges-after-alzheimer-s-drug-fails-phase-3-due-to-protocol-deviations-at-tri-bivi-20231225monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-bivi-plunges-after-alzheimer-s-drug-fails-phase-3-due-to-protocol-deviations-at-tri-bivi-20231221monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-bivi-plunges-after-alzheimer-s-drug-fails-phase-3-due-to-protocol-deviations-at-tri-bivi-20231218monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-bivi-plunges-after-alzheimer-s-drug-fails-phase-3-due-to-protocol-deviations-at-tri-bivi-20231213monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-bivi-plunges-after-alzheimer-s-drug-fails-phase-3-due-to-protocol-deviations-at-tri-bivi-20231204monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-bivi-plunges-after-alzheimer-s-drug-fails-phase-3-due-to-protocol-deviations-at-tri-bivi-20231130monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-efficacy-data-from-phase-3-trial-of-ne3107-in-patients-with-mild-to-moder-bivi-20231129monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-presents-positive-clinical-safety-data-from-phase-2b-trial-of-biv201-in-refractory--bivi-20231113monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-participate-in-the-truist-securities-biopharma-symposium-bivi-20231102monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-host-conference-call-and-webcast-wednesday-november-1-2023-at-8-00-am-et-bivi-20231030monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-late-breaking-abstract-presenting-clinical-safety-data-from-the-company-s-bivi-20231026monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-present-blinded-data-on-ne3107-in-the-treatment-of-mild-to-moderate-alzheimer-s--bivi-20231019monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-completion-of-last-patient-treatment-visit-in-phase-3-trial-of-ne3107-in--bivi-20230926monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-participate-in-the-cantor-fitzgerald-global-healthcare-conference-bivi-20230919monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-presents-data-highlighting-baseline-characteristics-of-study-population-in-phase-3--bivi-20230911monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-hosting-virtual-kol-event-on-ne3107-in-alzheimer-s-disease-today-september-7-2023-bivi-20230907monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-host-virtual-kol-event-on-ne3107-in-alzheimer-s-disease-on-september-7-2023-bivi-20230831monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-presents-data-for-ne3107-at-2023-international-congress-of-parkinson-s-disease-and--bivi-20230828monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-issues-letter-to-shareholders-bivi-20230718monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-presents-data-showing-how-ne3107-may-potentially-regulate-dna-methylation-of-specif-bivi-20230717monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-present-data-showing-how-ne3107-potentially-regulates-dna-methylation-of-specifi-bivi-20230710monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-presents-data-highlighting-role-of-insulin-resistance-and-neuroinflammation-in-the--bivi-20230626monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes-bivi-20230623monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-present-of-ne3017-in-alzheimer-s-disease-data-at-83rd-scientific-sessions-of-the-bivi-20230621monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-presents-rationale-for-potentially-pivotal-trial-of-ne3107-in-the-treatment-of-park-bivi-20230516monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-present-data-from-ne3107-phase-2-open-label-trial-at-society-of-biological-psych-bivi-20230420monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-data-abstracts-from-ne3107-phase-2-trials-accepted-for-presentation-at-aa-bivi-20230417monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-data-from-phase-2-parkinson-s-disease-trial-accepted-for-presentation-at--bivi-20230321monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-registration-details-for-biovie-day-webinar-bivi-20230314monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-the-pausing-of-patient-enrollment-in-ascites-phase-2b-trial-encouraging-e-bivi-20230313monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference-bivi-20230309monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-additional-findings-from-phase-2-parkinson-s-disease-trial-more-patients--bivi-20230306monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-completion-of-patient-enrollment-in-phase-3-trial-assessing-ne3107-in-alz-bivi-20230302monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-biovie-day-to-be-held-march-23-2023-bivi-20230221monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-issues-letter-to-shareholders-bivi-20221207monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-additional-findings-from-phase-2-alzheimer-s-disease-trial-ne3107-appears-bivi-20221206monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-s-phase-3-trial-assessing-ne3107-in-alzheimer-s-disease-has-fully-enrolled-the-targ-bivi-20221129monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-present-data-from-investigator-sponsored-exploratory-biomarker-and-imaging-trial-bivi-20221115monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-present-data-on-characterizing-hospitalization-burden-of-ascites-at-aasld-liver--bivi-20221024monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-s-phase-2-trial-assessing-ne3107-s-pro-motoric-activity-in-parkinson-s-disease-is-f-bivi-20221019monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-issues-letter-to-shareholders-bivi-20221004monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-participate-in-cantor-fitzgerald-s-neurology-psychiatry-conference-bivi-20220929monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-patent-issuance-covering-ascites-treatment-with-biv201-bivi-20220623monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-participate-at-the-b-riley-securities-neuro-ophthalmology-conference-bivi-20220425monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-interview-to-air-on-bloomberg-u-s-on-the-redchip-money-report-bivi-20220310monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-participate-at-the-oppenheimer-virtual-annual-healthcare-conference-bivi-20220309monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-treatment-of-first-patient-in-phase-2-clinical-trial-of-ne3107-for-the-tr-bivi-20220120monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-participate-at-the-lifesci-partners-11th-annual-corporate-access-event-bivi-20211228monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-partnership-with-the-american-liver-foundation-bivi-20211209monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-hosting-key-opinion-leader-webinar-on-complications-of-advanced-liver-cirrhosis-and-bivi-20211104monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-the-appointment-of-a-new-chief-medical-officer-bivi-20211101monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-fda-authorization-to-initiate-phase-2-trials-assessing-ne3107-s-pro-motor-bivi-20211026monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-hosting-key-opinion-leader-webinar-on-neuroinflammation-and-insulin-resistance-and--bivi-20211013monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-present-at-cantor-virtual-global-healthcare-conference-bivi-20210922monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-present-at-oppenheimer-fall-healthcare-life-sciences-medtech-virtual-summit-bivi-20210915monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-announces-closing-of-public-offering-of-common-stock-bivi-20210811monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-announces-proposed-public-offering-of-common-stock-bivi-20210806monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-presents-data-supporting-use-of-ne3107-in-the-treatment-of-alzheimer-s-disease-at-2-bivi-20210727monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-present-rationale-for-use-of-ne3107-for-the-treatment-of-alzheimer-s-disease-at--bivi-20210722monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-added-to-russell-microcap-index-bivi-20210628monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-interview-to-air-on-bloomberg-television-u-s-on-the-redchip-money-report-bivi-20210625monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-first-patient-enrolled-in-biv201-phase-2b-clinical-trial-for-ascites-bivi-20210624monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-receives-fda-guidance-for-phase-3-clinical-trial-of-biv201-in-hrs-aki-bivi-20210623monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-interview-to-air-on-bloomberg-television-u-s-on-the-redchip-money-report-bivi-20210617monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-hosting-research-development-day-bivi-20210512monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-present-at-2021-b-riley-securities-neuroscience-conference-bivi-20210428monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-present-at-31st-annual-oppenheimer-healthcare-conference-bivi-20210311monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-commences-patient-screening-in-phase-2-clinical-trial-bivi-20210309monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-interview-to-air-on-bloomberg-tv-in-the-us-on-the-redchip-money-report-bivi-20210219monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-bivi-20201030monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-participate-in-b-riley-securities-liver-disease-therapeutics-day-on-october-29-2-bivi-20201029monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-advances-the-biv201-clinical-program-and-prefilled-syringe-bivi-20200611monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-manufactures-novel-terlipressin-prefilled-syringe-bivi-20191209monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-achieves-primary-objectives-in-phase-2a-clinical-trial-of-biv201-in-refractory-asci-bivi-20190430monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-present-at-thinkequity-conference-in-nyc-on-may-2nd-bivi-20190424monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-completes-patient-enrollment-for-its-phase-2a-clinical-trial-of-biv201-in-refractor-bivi-20190206monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-otcqb-bivi-attains-milestone-bivi-20180409monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-to-present-at-the-microcap-conference-in-new-york-on-april-9th-bivi-20180322monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-responds-to-japan-patent-office-and-comments-on-recent-stock-price-decline-bivi-20180307monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-apre-20260421monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-ceo-issues-letter-to-shareholders-highlighting-pipeline-progress-in-202-apre-20251218monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-agreement-with-md-anderson-cancer-center-to-explore-apr-1051--apre-20250311monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-twice-daily-bid-dosing-of-patients-in-aboya-119-clinical-tria-apre-20241211monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-present-at-maxim-2024-healthcare-virtual-summit-apre-20241014monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-presentations-at-eortc-nci-aacr-international-conference-on-m-apre-20241010monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-participate-in-the-lytham-partners-fall-2024-investor-conference-on--apre-20240925monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-present-at-the-life-sciences-investor-forum-on-september-19-apre-20240912monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-present-at-the-h-c-wainwright-annual-global-investment-conference-apre-20240909monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-present-at-the-h-c-wainwright-annual-global-investment-conference-apre-20240828monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-host-virtual-kol-event-on-apr-1051-a-highly-selective-and-potentiall-apre-20240621monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-that-safety-review-committee-src-endorses-dosing-of-patients--apre-20240528monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-attend-the-2024-rbc-capital-markets-global-healthcare-conference-apre-20240513monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-appointment-of-nadeem-q-mirza-m-d-m-p-h-as-chief-medical-offi-apre-20240502monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-fda-clearance-of-ind-for-apr-1051-its-next-generation-wee1-ki-apre-20240311monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-acceptance-of-abstracts-at-american-association-of-cancer-res-apre-20240305monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-submission-of-ind-application-for-apr-1051-a-next-generation--apre-20240206monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-present-at-ddr-inhibitors-summit-2024-apre-20240130monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-host-a-key-opinion-leader-kol-event-on-its-synthetic-lethality-sl-an-apre-20231024monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-two-posters-at-the-upcoming-2023-aacr-nci-eortc-international-apre-20230919monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-announces-preclinical-data-supporting-highly-differentiated-wee1-inhibitor-atrn-1051-apre-20230911monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conferen-apre-20230906monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-appoints-dr-jean-pierre-bizzari-to-its-board-of-directors-and-names-dr--apre-20230824monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-present-at-maxim-virtual-healthcare-conference-apre-20230614monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-present-at-bio-international-convention-apre-20230530monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-appoints-gabriela-gruia-m-d-to-board-of-directors-apre-20230508monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-presentation-of-preclinical-data-on-pipeline-programs-at-the--apre-20230316monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-present-at-oppenheimer-s-33rd-annual-healthcare-conference-apre-20230307monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-closing-of-5-5-million-underwritten-public-offering-of-common-apre-20230227monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-pricing-of-5-5-million-underwritten-public-offering-of-common-apre-20230223monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-phase-ii-sbir-award-from-the-national-cancer-institute-nci-apre-20230215monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-participate-in-6th-annual-dna-damage-and-response-ddr-inhibitors-sum-apre-20230119monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-dosing-of-first-patient-in-phase-1-2a-clinical-trial-of-oral--apre-20230111monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-poster-presentation-at-the-2022-rivkin-center-and-american-as-apre-20220922monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-participate-in-the-2022-h-c-wainwright-global-investment-conference-apre-20220908monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-participate-in-the-2022-wedbush-pacgrow-healthcare-conference-apre-20220802monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-on-thurs-apre-20220106monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-presents-primary-analysis-from-phase-2-trial-of-eprenetapopt-azacitidin-apre-20211213monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-present-data-from-clinical-trials-evaluating-eprenetapopt-at-63rd-am-apre-20211104monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-presents-data-from-phase-1-2-trial-of-eprenetapopt-apr-246-in-advanced--apre-20210920monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-present-data-from-phase-1-2-trial-of-eprenetapopt-in-advanced-solid--apre-20210914monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-clinical-hold-on-lymphoid-malignancy-program-apre-20210812monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-positive-results-from-phase-2-trial-of-eprenetapopt-azacitidi-apre-20210721monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-phase-1-2-trial-of-eprenetapopt-venetoclax-azacitidine-in-tp5-apre-20210616monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-participate-in-the-2021-oppenheimer-rare-orphan-disease-summit-apre-20210521monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-participate-in-the-2021-rbc-capital-markets-global-healthcare-confer-apre-20210518monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-host-virtual-r-d-day-on-april-22-2021-apre-20210416monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-receives-fda-orphan-drug-designation-for-eprenetapopt-for-the-treatment-apre-20210408monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-provide-apre-20210316monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-on-tuesd-apre-20210108monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-receives-fda-fast-track-designation-for-eprenetapopt-in-the-treatment-o-apre-20201130monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference-apre-20201119monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-highlight-changing-treatment-paradigm-in-mds-as-well-as-development--apre-20201030monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-launches-disease-awareness-website-for-healthcare-professionals-p53reac-apre-20201014monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-receives-ok-from-fda-to-initiate-phase-1-clinical-studies-for-next-gene-apre-20201007monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-present-at-upcoming-investor-conferences-apre-20200903monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-expansion-of-clinical-trial-evaluating-eprenetapopt-for-the-f-apre-20200716monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-presents-results-from-french-phase-ib-ii-clinical-trial-of-apr-246-epre-apre-20200612monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-completes-full-enrollment-of-phase-3-clinical-trial-in-tp53-mutant-myel-apre-20200603monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-present-at-2020-rbc-capital-markets-global-healthcare-conference-apre-20200518monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-launches-new-corporate-website-www-aprea-com-apre-20200406monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-appoints-gregory-s-wessels-as-vice-president-commercial-apre-20200213monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-receives-fda-breakthrough-therapy-designation-for-apr-246-in-combinatio-apre-20200130monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-on-tuesd-apre-20200109monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-presents-results-from-french-phase-ib-ii-clinical-trial-of-apr-246-and--apre-20191209monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-presents-results-from-u-s-phase-ib-ii-clinical-trial-of-apr-246-and-aza-apre-20191209monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-to-present-data-from-u-s-phase-1b-2-mds-aml-trial-and-french-phase-1b-2-apre-20191106monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-closing-of-initial-public-offering-and-full-exercise-of-under-apre-20191007monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-pricing-of-initial-public-offering-apre-20191003monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-presentation-at-the-35th-annual-j-p-morgan-healthcare-confere-apre-20170105monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-ab-names-christian-s-schade-president-chief-executive-officer-apre-20160616monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-announces-positive-data-from-a-clinical-phase-i-ii-study-with-apr-246-in-patients-wi-apre-20120918monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-reports-completion-of-the-phase-i-ii-safety-study-with-apr-246-in-cancer-patients-apre-20110223monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-appoints-jerry-lydon-to-lead-north-america-commercial-operations-trib-20260501monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-senior-executives-to-attend-attd-2026-to-advance-collaborations-following--trib-20260311monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-further-major-technical-breakthroughs-in-advancing-next-generati-trib-20260310monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-provides-business-and-trading-update-trib-20260310monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-receives-non-compliance-notice-regarding-nasdaq-global-select-requirement--trib-20260220monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-receives-non-compliance-notice-regarding-nasdaq-global-select-requirement--trib-20260213monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-awarded-a-major-order-for-9-million-trinscreen-hiv-tests-trib-20251223monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-launch-of-fda-cleared-preeclampsia-testing-service-trib-20250807monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-secures-key-regulatory-approval-for-offshored-and-outsourced-manufacturing-trib-20250624monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-publishes-fourth-quarter-and-fiscal-year-2024-financial-results-provides-a-trib-20250515monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-receives-non-compliance-notice-regarding-nasdaq-global-select-requirement--trib-20250314monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-further-strengthens-focus-on-continuous-glucose-monitoring-appoints-barcla-trib-20250313monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-additional-funding-to-support-transformation-plan-continued-deve-trib-20250228monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-reports-landmark-first-day-accuracy-gains-in-cgm-pre-pivotal-trial-trib-20250206monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-breakthrough-results-from-pre-pivotal-trial-of-disruptive-contin-trib-20250128monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-amended-credit-agreement-with-perceptive-to-enhance-liquidity-an-trib-20241224monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-receives-early-approval-from-the-world-health-organization-to-begin-offsho-trib-20241218monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-q3-2024-financial-results-trib-20241115monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-to-announce-q3-2024-financial-results-trib-20241114monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-regains-compliance-with-nasdaq-listing-requirements-trib-20241107monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-enters-oncology-space-with-acquisition-of-prostate-cancer-focused-epicaptu-trib-20241025monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-strategic-investment-in-novus-diagnostics-to-advance-rapid-sepsi-trib-20241025monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-positive-pre-pivotal-trial-results-for-its-next-generation-conti-trib-20241007monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-acquisition-of-metabolomics-diagnostics-to-grow-presence-in-mate-trib-20240924monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-to-initiate-cgm-market-study-in-india-in-furtherance-of-intended-collabora-trib-20240918monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-provides-an-update-on-the-continued-development-of-its-continuous-glucose--trib-20240909monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-appoints-global-life-sciences-leader-as-chief-commercial-officer-trib-20240903monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-increased-orders-for-trinscreen-hiv-and-raises-guidance-for-2024-trib-20240826monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-appoints-diabetes-care-veteran-as-biosensor-marketing-director-trib-20240820monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-q2-2024-financial-results-trib-20240814monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-to-announce-q2-2024-financial-results-trib-20240813monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-obtains-an-extension-to-demonstrate-compliance-with-nasdaq-listing-require-trib-20240806monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-provides-preliminary-second-quarter-2024-update-and-enters-into-uk-distrib-trib-20240802monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-appointment-of-a-new-cfo-trib-20240709monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-to-begin-european-pre-pivotal-trial-to-optimize-its-cgm-sensor-trib-20240624monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-attending-84th-scientific-sessions-of-the-american-diabetes-association-trib-20240610monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-launches-its-continuous-glucose-monitoring-microsite-to-showcase-its-innov-trib-20240603monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-q1-2024-financial-results-and-reiterates-guidance-trib-20240523monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-q1-2024-financial-results-trib-20240521monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-strategic-collaboration-with-medical-artificial-intelligence-com-trib-20240516monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-increased-orders-for-trinscreen-hiv-and-raises-guidance-for-2024-trib-20240513monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-welcomes-avinash-kale-as-continuous-glucose-monitor-programme-director-to--trib-20240508monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-fourth-quarter-and-fiscal-year-2023-financial-results-business-u-trib-20240404monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-q4-and-fiscal-year-2023-financial-results-trib-20240328monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-regains-compliance-with-nasdaq-minimum-closing-bid-price-rule-trib-20240308monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-finalizes-effective-date-of-ads-ratio-change-trib-20240215monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-announces-plan-to-implement-ads-ratio-change-trib-20240213monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-to-present-at-emerging-growth-conference-trib-20240208monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-application-for-early-sjogrens-syndrome-test-panel-pla-code-trib-20240207monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-q3-2023-financial-results-business-update-trib-20240131monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-entry-into-a-letter-of-intent-with-bayer-for-a-joint-partnership-trib-20240131monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-acquisition-of-the-cgm-assets-of-waveform-technologies-inc-trib-20240131monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-host-investor-call-trib-20240130monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-it-has-begun-shipments-of-its-new-hiv-screening-test-trinscreen--trib-20231227monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-management-changes-trib-20231218monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-receives-non-compliance-notice-regarding-nasdaq-global-select-requirement--trib-20231128monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-welcomes-the-decision-of-the-high-court-of-kenya-to-strike-out-the-applica-trib-20231010monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-q2-2023-financial-results-trib-20231003monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-second-quarter-fiscal-year-2023-financial-results-trib-20230927monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-receives-non-compliance-notice-regarding-nasdaq-minimum-bid-price-requirem-trib-20230911monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-that-it-has-received-510-k-clearance-from-the-u-s-food-and-drug--trib-20230807monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-q1-2023-financial-results-trib-20230706monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-first-quarter-fiscal-year-2023-financial-results-trib-20230703monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-regains-compliance-with-nasdaq-minimum-closing-bid-price-rule-trib-20230505monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-the-successful-closing-of-the-30-million-sale-of-its-life-scienc-trib-20230427monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-receives-non-compliance-notice-regarding-nasdaq-minimum-bid-price-requirem-trib-20230424monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-the-30-million-sale-of-its-life-sciences-supply-business-to-bios-trib-20230420monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-fourth-quarter-and-fiscal-year-2022-financial-results-trib-20230323monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-welcomes-trinscreen-hiv-s-inclusion-in-the-new-kenyan-hiv-testing-algorith-trib-20230322monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-fourth-quarter-and-fiscal-year-2022-financial-results-trib-20230316monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-entry-into-an-increased-loan-facility-to-fund-potential-acquisit-trib-20230222monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-strategic-partnership-with-imaware-to-deliver-integrated-diagnos-trib-20230109monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-q3-2022-financial-results-trib-20221215monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-third-quarter-fiscal-year-2022-financial-results-trib-20221209monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference-trib-20221130monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-2-2022-financial-results-and-preliminary-q3-2022-revenue-trib-20221103monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-second-quarter-fiscal-year-2022-financial-results-trib-20221101monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-the-appointment-of-tom-lindsay-to-its-board-of-directors-trib-20221026monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-the-appointment-of-aris-kekedjian-as-chairman-and-ceo-trib-20221003monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-of-agm-trib-20220930monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-1-2022-financial-results-trib-20220630monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-first-quarter-fiscal-year-2022-financial-results-trib-20220629monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-ce-mark-of-its-10-minute-covid-19-antigen-test-trib-20220520monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-the-successful-closing-of-its-strategic-investment-and-partnersh-trib-20220503monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-4-and-fiscal-year-2021-financial-results-trib-20220411monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-a-45-million-strategic-investment-and-partnership-with-the-mico--trib-20220411monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-the-world-health-organisation-approval-of-trinscreen-hiv-trib-20220214monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-the-successful-closing-of-its-debt-refinancing-trib-20220127monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-that-its-shareholders-have-approved-all-of-the-four-resolutions--trib-20220125monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-q3-2021-results-the-entry-into-a-81-250-000-loan-facility-to-ref-trib-20211215monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-for-q2-2021-trib-20210909monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-second-quarter-fiscal-year-2021-financial-results-trib-20210831monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-provides-a-business-development-update-for-q2-2021-trib-20210716monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-for-q1-2021-trib-20210525monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-first-quarter-fiscal-year-2021-financial-results-trib-20210519monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-the-submission-of-trinscreen-hiv-to-the-world-health-organisatio-trib-20210330monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-4-and-fiscal-year-2020-financial-results-trib-20210325monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-fourth-quarter-and-fiscal-year-2020-financial-results-trib-20210323monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-ce-mark-of-its-covid-19-igg-elisa-antibody-test-trib-20210105monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-for-q3-2020-trib-20201117monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-third-quarter-2020-financial-results-trib-20201029monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-for-q2-2020-trib-20200825monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-eua-submission-for-covid-19-elisa-antibody-test-trib-20200820monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-second-quarter-2020-financial-results-trib-20200818monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-subsidiary-primus-corporation-receives-fda-warning-letter-trib-20200817monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-for-q1-2020-trib-20200527monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-first-quarter-2020-financial-results-trib-20200514monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-4-and-fiscal-year-2019-financial-results-trib-20200331monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-fourth-quarter-and-fiscal-year-2019-financial-results-trib-20200324monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-for-q3-2019-trib-20191016monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-third-quarter-fiscal-year-2019-financial-results-trib-20191015monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-for-q2-2019-trib-20190820monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-second-quarter-fiscal-year-2019-financial-results-trib-20190815monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-for-q1-2019-trib-20190507monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-first-quarter-fiscal-year-2019-financial-results-trib-20190501monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-4-and-fiscal-year-2018-financial-results-trib-20190307monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-fourth-quarter-and-fiscal-year-2018-financial-results-trib-20190304monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-for-q3-2018-trib-20181023monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-third-quarter-fiscal-year-2018-financial-results-trib-20181016monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-for-q2-2018-trib-20180719monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-second-quarter-fiscal-year-2018-financial-results-trib-20180712monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-for-q1-2018-trib-20180501monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-first-quarter-fiscal-year-2018-financial-results-trib-20180420monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-4-and-fiscal-year-2017-financial-results-trib-20180307monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-fourth-quarter-and-fiscal-year-2017-financial-results-trib-20180305monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-for-q3-2017-trib-20171026monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-2017-third-quarter-financial-results-trib-20171013monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-for-q2-2017-trib-20170720monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-second-quarter-fiscal-year-2017-financial-results-trib-20170703monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-for-q1-2017-trib-20170427monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-first-quarter-fiscal-year-2017-financial-results-trib-20170418monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-4-and-fiscal-year-2016-financial-results-trib-20170314monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-fourth-quarter-and-fiscal-year-2016-financial-results-trib-20170224monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-3-financial-results-trib-20161025monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-third-quarter-fiscal-year-2016-financial-results-trib-20161012monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-withdrawal-of-troponin-fda-510-k-submission-trib-20161004monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-2-financial-results-trib-20160721monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-second-quarter-fiscal-year-2016-financial-results-trib-20160714monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-for-q1-2016-trib-20160419monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-first-quarter-fiscal-year-2016-financial-results-trib-20160415monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-for-q4-and-fiscal-year-2015-trib-20160303monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-fourth-quarter-and-fiscal-year-2015-financial-results-trib-20160226monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-fda-submission-of-high-sensitivity-troponin-i-product-trib-20151217monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-3-financial-results-trib-20151022monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-third-quarter-fiscal-year-2015-financial-results-trib-20151013monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-2-financial-results-enrolment-for-the-meritas-troponin-a-trib-20150728monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-second-quarter-fiscal-year-2015-financial-results-trib-20150717monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-1-results-eps-17-4-cents-dividend-of-22-cents-trib-20150430monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-first-quarter-fiscal-year-2015-financial-results-trib-20150423monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-closes-offering-of-115-million-of-4-00-exchangeable-senior-notes-due-2-trib-20150409monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-filing-of-2014-annual-report-trib-20150325monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-for-q4-and-fiscal-year-2014-trib-20150303monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-fourth-quarter-and-fiscal-year-2014-financial-results-trib-20150225monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-recommencement-of-us-clinical-trials-on-its-point-of-care-high-s-trib-20150223monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-clia-waiver-of-rapid-syphilis-test-trib-20141216monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-3-financial-results-and-temporary-suspension-of-meritas--trib-20141023monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-third-quarter-fiscal-2014-financial-results-trib-20141006monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-ce-marking-of-new-meritas-heart-failure-bnp-point-of-care-test-trib-20140925monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-2-financial-results-25-increase-in-operating-profits-trib-20140729monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-second-quarter-fiscal-year-2014-financial-results-trib-20140721monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-1-results-trib-20140429monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-first-quarter-fiscal-year-2014-financial-results-trib-20140416monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-for-q4-and-fiscal-year-2013-trib-20140304monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-fourth-quarter-and-fiscal-year-2013-financial-results-trib-20140219monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-european-approval-of-guideline-compliant-point-of-care-high-sens-trib-20140129monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-3-financial-results-acquisition-of-blood-bank-screening--trib-20131017monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-third-quarter-fiscal-year-2013-financial-results-trib-20130930monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-2-financial-results-and-acquisition-of-immco-diagnostics-trib-20130730monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-second-quarter-fiscal-year-2013-financial-results-trib-20130723monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-1-results-eps-of-20-cents-premier-regulatory-approval-in-trib-20130425monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-first-quarter-fiscal-year-2013-financial-results-trib-20130416monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-results-for-fiscal-year-2012-trib-20130305monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-fourth-quarter-and-fiscal-year-2012-financial-results-trib-20130220monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-3-financial-results-trib-20121018monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-third-quarter-fiscal-year-2012-financial-results-trib-20121004monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-2-financial-results-eps-of-20-cents-per-adr-an-increase--trib-20120712monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-second-quarter-fiscal-year-2012-financial-results-trib-20120705monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-added-to-membership-of-russell-global-index-trib-20120626monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-announces-details-of-its-dividend-and-share-buyback-program-trib-20120606monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-an-annual-dividend-of-15-cents-per-adr-an-increase-of-50-trib-20120425monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-1-financial-results-trib-20120419monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-first-quarter-fiscal-year-2012-financial-results-trib-20120410monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-4-financial-results-trib-20120305monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-announces-the-acquisition-of-fiomi-diagnostics-ab-trib-20120301monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-ce-marking-of-rapid-test-for-giardia-trib-20120228monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-fourth-quarter-and-fiscal-year-2011-financial-results-trib-20120216monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-fda-approval-of-premier-hb9210-trib-20111206monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-announces-quarter-3-financial-results-trib-20111020monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-to-announce-third-quarter-fiscal-year-2011-financial-results-trib-20111011monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biogenics-acquires-lab-and-intellectual-properties-trib-20060403monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-provides-hibergen-update-trib-20031114monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-secures-key-neurostimulation-legislative-provision-commends-u-s-house-p-nxl-20260521monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-advances-pivotal-clinical-trial-of-halo-clarity-toward-q2-2026-enrollme-nxl-20260422monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-advances-fda-alzheimer-s-strategy-following-landmark-leadership-meetings-in-the-u--nxl-20260415monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-receives-nasdaq-listing-status-notification-nxl-20260123monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-completes-fda-q-submission-meeting-for-gen-2-sync-neurostimulation-cons-nxl-20251203monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-s-15-milliamp-neurostimulation-device-demonstrates-promising-results-in-treating-g-nxl-20251118monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-appoints-carmi-masha-technologies-ltd-as-exclusive-distributor-in-israe-nxl-20251113monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-reconstitutes-scientific-advisory-board-with-leading-experts-to-advance-nxl-20250513monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-closing-of-previously-announced-5-0-million-underwritten-publ-nxl-20250506monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-initiates-fda-q-submission-process-for-gen-2-sync-following-encouraging-nxl-20250501monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-receives-irb-approval-in-brazil-and-begins-clinical-trial-for-anxiety-a-nxl-20250424monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-completion-of-phases-one-through-five-of-its-virtual-clinic-a-nxl-20250423monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-expresses-strong-support-for-health-tech-investment-act-to-advance-medi-nxl-20250421monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-secures-uspto-patent-for-deep-intracranial-frequency-stimulation-difs-t-nxl-20250414monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-enrolls-first-patients-and-advances-toward-treatment-in-ucsd-clinical-t-nxl-20250402monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-receives-notice-of-allowance-from-the-uspto-for-patent-covering-deep-in-nxl-20250303monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-initiation-of-patient-recruitment-for-ucsd-s-tbi-ptsd-clinica-nxl-20250228monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-welcomes-general-wesley-clark-to-military-government-advisory-board-nxl-20250226monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-ucsd-irb-approval-for-use-of-halo-clarity-in-clinical-trials--nxl-20250218monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-appointed-as-industry-co-chair-of-national-tbi-registry-coalition-nxl-20250210monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-s-breakthrough-difs-neurostimulation-device-demonstrates-reduction-in-blood-pressu-nxl-20250203monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-ceo-mark-white-issues-letter-to-shareholders-highlighting-recent-achiev-nxl-20250114monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-completes-phase-1of-its-innovative-virtual-clinic-nxl-20241223monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-ceo-provides-letter-to-shareholders-nxl-20241111monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-landmark-study-on-alzheimer-s-disease-and-deep-intracranial-f-nxl-20241028monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-planned-clinical-trial-utilizing-gen-3-halo-headset-in-partne-nxl-20241022monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-appoints-carolyn-shelton-as-senior-vice-president-of-clinical-quality-r-nxl-20241014monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-participates-in-congressional-roundtable-focused-on-emerging-virtual-th-nxl-20240905monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-selected-to-join-industry-coalition-breaking-barriers-to-substance-use--nxl-20240718monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-positive-clinical-study-data-in-major-depressive-disorder-and-nxl-20240626monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-awarded-key-patent-related-to-its-non-invasive-frequency-based-deep-bra-nxl-20240620monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-regulatory-approval-to-sell-nexalin-s-gen-2-15-ma-neurostimul-nxl-20240613monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-to-present-at-the-spring-microcap-rodeo-conference-on-june-6th-nxl-20240604monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-america-selected-to-join-the-national-traumatic-brain-injury-registry-coalition-to-nxl-20240522monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-regains-compliance-with-nasdaq-continued-listing-requirements-nxl-20240425monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-ceo-provides-letter-to-shareholders-nxl-20240410monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-accelerates-manufacturing-of-its-halo-clarity-following-successful-usab-nxl-20240409monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-awarded-key-patent-related-to-its-gen-3-halo-clarity-a-non-invasive-fre-nxl-20240404monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-the-appointment-of-government-affairs-veteran-william-a-hudso-nxl-20240402monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-positive-results-of-clinical-study-validating-its-gen-2-tacs--nxl-20240328monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-commences-sales-of-gen-2-neurostimulation-device-to-new-mental-health-c-nxl-20240314monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-poster-presentation-at-state-of-the-technology-meeting-neurot-nxl-20240313monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-positive-results-from-clinical-study-of-its-gen-2-tacs-device-nxl-20240306monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-regulatory-approval-in-oman-for-gen-2-neurostimulation-device-nxl-20240208monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-awarded-key-patent-related-to-its-non-invasive-frequency-based-deep-bra-nxl-20240123monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-unveils-next-generation-halo-clarity-nxl-20240111monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-reports-significant-positive-results-of-clinical-study-supporting-the-t-nxl-20231218monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-formation-of-new-military-government-advisory-board-to-be-led-nxl-20231025monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-publication-of-groundbreaking-deep-brain-stimulation-study-in-nxl-20231016monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-reports-results-of-clinical-study-supporting-the-therapeutic-benefits-o-nxl-20230807monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-s-ceo-mark-white-to-be-interviewed-live-on-the-big-biz-show-today-at-3pm-eastern-t-nxl-20230803monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-new-public-sector-division-to-capitalize-on-opportunities-to--nxl-20230726monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-abstract-accepted-for-presentation-at-2023-military-health-sy-nxl-20230710monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-inc-and-wider-come-limited-announce-joint-venture-agreement-to-advance--nxl-20230601monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-provides-2022-year-end-business-update-nxl-20230327monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-appoints-medical-device-veteran-michael-nketiah-as-senior-vice-presiden-nxl-20230124monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-ceo-provides-letter-to-shareholders-nxl-20230105monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-publication-of-a-white-paper-validating-its-tacs-device-for-t-nxl-20221114monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-inc-announces-closing-of-9-6-million-initial-public-offering-nxl-20220920monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-inc-announces-pricing-of-9-6-million-initial-public-offering-nxl-20220916monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-demonstrates-success-in-the-treatment-of-depression-nxl-20171109monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-may-be-the-future-of-opiate-addiction-treatment-nxl-20171107monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-up-to-10-million-cash-financing-imnn-20260604monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-present-phase-3-ovarian-cancer-study-of-imnn-001-at-esmo-congress-imnn-20251014monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-presents-imnn-001-phase-2-translational-data-in-advanced-ovarian-cancer-demonstrati-imnn-20250922monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-present-new-translational-data-of-imnn-001-supporting-phase-3-trial-of-immunothe-imnn-20250919monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference-imnn-20250902monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-recaps-highlights-from-2025-second-quarter-financial-results-conference-call-imnn-20250805monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-first-patient-dosed-in-phase-3-ovation-3-study-of-imnn-001-in-newly-diagn-imnn-20250730monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-hold-second-quarter-2025-financial-results-and-business-update-conference-call-o-imnn-20250729monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-reverse-stock-split-imnn-20250723monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-granted-continued-listing-extension-by-nasdaq-to-complete-compliance-plan-imnn-20250715monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-submits-plan-in-consultation-with-the-exchange-to-ensure-compliance-with-nasdaq-s-l-imnn-20250630monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-presents-positive-phase-2-translational-data-of-imnn-001-in-advanced-ovarian-cancer-imnn-20250618monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-placcine-dna-vaccine-technology-abstract-selected-for-oral-presentation-a-imnn-20250617monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-present-at-the-zacks-scr-life-sciences-virtual-investor-forum-on-june-12th-imnn-20250605monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-data-presented-at-asco-reinforces-unprecedented-overall-survival-in-ovari-imnn-20250603monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-ceo-recaps-a-year-of-clinical-achievement-and-solid-fundamentals-imnn-20250602monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-closes-up-to-9-75-million-private-placement-priced-at-the-market-under-nasdaq-rules-imnn-20250528monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-invited-to-present-translational-data-in-supporting-remarkable-phase-2-ovarian-canc-imnn-20250527monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-2025-asco-annual-meeting-oral-presentation-highlighting-unprecedented-sur-imnn-20250523monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-withdrawal-of-form-s-1-registration-statement-imnn-20250522monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-six-month-data-showing-durability-of-protection-for-next-generation-dna-v-imnn-20250515monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-first-site-initiated-for-pivotal-phase-3-ovation-3-study-of-imnn-001-in-n-imnn-20250508monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-data-from-phase-1-2-trial-evaluating-intraperitoneal-imnn-001-in-combinat-imnn-20250506monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-hold-first-quarter-2025-financial-results-and-business-update-conference-call-on-imnn-20250505monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-imnn-001-abstract-accepted-for-oral-presentation-at-2025-asco-annual-meet-imnn-20250421monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-new-immunogenicity-data-from-phase-1-clinical-trial-of-its-dna-vaccine-in-imnn-20250226monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-hold-2024-financial-results-and-business-update-conference-call-on-thursday-febr-imnn-20250220monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-translational-data-from-phase-1-2-ovation-2-study-of-imnn-001-in-advanced-imnn-20250219monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-positive-cmc-meeting-with-fda-for-imnn-001-in-treatment-of-advanced-ovari-imnn-20241219monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-continued-strong-improvement-in-overall-survival-data-from-randomized-pha-imnn-20241210monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-results-from-its-end-of-phase-2-meeting-with-the-fda-for-its-lead-imnn-00-imnn-20241125monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-presents-positive-data-from-phase-2-ovation-2-clinical-trial-of-imnn-001-in-advance-imnn-20241107monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-hold-third-quarter-2024-financial-results-and-business-update-conference-call-on-imnn-20241031monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-present-phase-2-data-of-imnn-001-in-treatment-of-newly-diagnosed-ovarian-cancer--imnn-20241030monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-host-r-d-day-on-september-18th-imnn-20240828monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-second-quarter-2024-financial-results-and-provides-a-business-update-imnn-20240814monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-hold-second-quarter-2024-financial-results-and-business-update-conference-call-o-imnn-20240807monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-report-topline-results-from-the-phase-2-ovation-2-study-with-imnn-001-in-advance-imnn-20240729monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-database-lock-for-phase-2-ovation-2-study-with-imnn-001-in-advanced-ovari-imnn-20240624monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-site-activation-for-imnn-101-phase-1-vaccine-study-imnn-20240513monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-hold-first-quarter-2024-financial-results-and-business-update-conference-call-on-imnn-20240506monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-s-ind-application-cleared-to-begin-human-testing-of-imnn-101-imnn-20240418monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-receives-1-3-million-from-sale-of-its-new-jersey-net-operating-losses-imnn-20240325monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-hold-2023-financial-results-and-business-update-conference-call-on-thursday-marc-imnn-20240321monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-files-ind-application-to-begin-human-testing-of-imnn-101-imnn-20240313monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-leadership-change-imnn-20240312monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-s-vp-of-r-d-to-present-at-the-vaccines-summit-2023-imnn-20231114monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-hold-third-quarter-2023-financial-results-and-business-update-conference-call-on-imnn-20231107monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-s-chief-science-officer-to-present-at-the-3rd-international-vaccines-congress-imnn-20231023monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-ceo-dr-corinne-le-goff-to-participate-in-a-panel-discussion-on-pandemic-preparednes-imnn-20231019monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-first-patient-enrolled-in-phase-1-2-clinical-trial-of-imnn-001-in-combina-imnn-20231018monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-appoints-dr-patrick-ott-to-its-scientific-advisory-board-imnn-20231006monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-interim-progression-free-survival-and-overall-survival-data-in-phase-1-2-ov-imnn-20230928monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-releases-enterprise-video-highlighting-the-company-s-mission-vision-values-breakthr-imnn-20230926monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reminds-investors-of-its-virtual-r-d-day-tomorrow-at-4-00-p-m-et-imnn-20230913monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-host-virtual-r-d-day-on-september-14th-beginning-at-4-00-p-m-et-imnn-20230907monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-participate-in-the-h-c-wainwright-global-investment-conference-imnn-20230905monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-enters-into-crada-for-preclinical-studies-of-placcine-modality-in-preventive-vaccin-imnn-20230824monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-expands-scientific-advisory-board-with-the-addition-of-dr-sachet-shukla-imnn-20230814monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-hold-second-quarter-2023-financial-results-and-business-update-conference-call-o-imnn-20230803monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-unveils-new-manufacturing-capabilities-at-huntsville-s-hudsonalpha-biotech-campus-imnn-20230627monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-inducement-grants-under-nasdq-listing-rule-5646-c-4-imnn-20230626monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-ceo-to-discuss-company-s-novel-non-viral-dna-therapy-option-at-the-mass-general-bri-imnn-20230612monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-s-ceo-presents-business-overview-to-investors-and-senior-biopharmaceutical-professi-imnn-20230608monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-presents-placcine-preclinical-data-at-the-2023-viruses-and-cells-gordon-research-co-imnn-20230530monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-hold-first-quarter-2023-financial-results-and-business-update-conference-call-on-imnn-20230504monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-presents-poster-at-the-american-association-for-cancer-research-annual-meeting-demo-imnn-20230419monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-hold-fourth-quarter-2022-financial-results-and-business-update-conference-call-o-imnn-20230323monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-presents-placcine-data-at-vaccine-technology-summit-2023-imnn-20230322monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-inducement-grants-under-nasdq-listing-rule-5646-c-4-imnn-20230321monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-abstract-accepted-for-presentation-at-the-american-association-for-cancer-imnn-20230315monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-ceo-issues-letter-to-shareholders-imnn-20230301monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-and-break-through-cancer-commence-enrollment-in-a-phase-1-2-clinical-study-of-imnn--imnn-20230227monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-receives-1-6-million-from-sale-of-its-new-jersey-net-operating-losses-imnn-20230112monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-enters-into-collaborative-research-agreement-with-the-wistar-institute-s-vaccine-im-imnn-20230105monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-inducement-grants-under-nasdq-listing-rule-5646-c-4-imnn-20221214monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-presentation-at-world-vaccine-immunotherapy-congress-highlights-placcine-preclinica-imnn-20221201monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-participate-in-the-a-g-p-alliance-global-partners-virtual-biotech-conference-on--imnn-20221122monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-strategic-investment-in-transomic-technologies-imnn-20221117monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-enters-into-technology-evaluation-agreement-with-acuitas-therapeutics-to-evaluate-i-imnn-20221110monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-hold-third-quarter-2022-financial-results-and-business-update-conference-call-on-imnn-20221107monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-partial-results-from-ongoing-non-human-primate-study-imnn-20221003monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-inducement-grants-under-nasdq-listing-rule-5646-c-4-imnn-20220929monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-to-present-at-chardan-s-6th-annual-genetic-medicines-conference-imnn-20220927monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-nasdaq-xbio-to-ring-the-nasdaq-stock-market-opening-bell-xbio-20170329monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-enters-into-asset-purchase-agreement-with-financing-component-for--xbio-20151116monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-s-major-strategic-shareholders-enter-into-long-term-lock-up-agreem-xbio-20151007monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-commences-third-cohort-of-phase-2-trials-on-drug-candidate-erepoxen-r--xbio-20150916monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-xbio-contracts-with-baxter-international-inc-have-been-assigned-to-bax-xbio-20150909monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-launches-digital-corporate-communication-channels-xbio-20150902monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-reports-phase-2-data-on-drug-candidate-erepoxen-r-for-anemia-xbio-20150714monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-completes-3-000-000-bridge-note-financing-xbio-20150708monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-announces-board-change-xbio-20150421monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-announces-ongoing-safety-data-from-phase-2-trial-of-erepoxen-r-xbio-20140630monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-announces-dosing-of-first-patient-on-dialysis-in-phase-2a-clinical-stu-xbio-20140611monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-strengthens-technology-patent-portfolio-xbio-20140609monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-to-present-at-the-third-annual-marcum-microcap-conference-xbio-20140529monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-announces-first-quarter-2014-financial-results-and-business-update-xbio-20140521monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-announces-positive-phase-1-clinical-results-for-psa-oxyntomodulin-for--xbio-20140512monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-appoints-industry-veteran-mark-leuchtenberger-as-chairman-of-the-board-xbio-20140505monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-announces-full-year-2013-financial-results-and-business-update-xbio-20140416monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-announces-positive-phase-1-clinical-data-for-pulmoxen-tm-for-treatment-xbio-20140407monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-appoints-darlene-deptula-hicks-to-board-of-directors-xbio-20140404monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-announces-opening-of-corporate-headquarters-and-r-d-facility-in-lexing-xbio-20140304monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-announces-ticker-symbol-change-to-xbio-xbio-20140214monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-appoints-timothy-cote-md-mph-former-head-of-fda-orphan-drug-division-t-xbio-20140210monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-announces-restructured-licensing-agreement-with-baxter-now-totaling-up-xbio-20140130monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-obtains-option-to-acquire-control-of-israeli-laser-radar-counter-drone-system-phge-20260331monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-issues-statement-regarding-recent-common-stock-trading-activity-phge-20260127monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-provides-update-on-bx004-phase-2b-trial-in-cystic-fibrosis-phge-20251125monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-inc-announces-1-for-19-reverse-stock-split-phge-20251114monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-report-third-quarter-2025-financial-results-and-program-updates-on-november-12-20-phge-20251105monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-report-second-quarter-2025-financial-results-and-program-updates-on-august-13-202-phge-20250806monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-successful-initiation-of-phase-2b-trial-with-first-patient-dosed-in-bx004--phge-20250714monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-ceo-jonathan-solomon-to-present-at-biomed-israel-2025-conference-phge-20250519monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-host-first-quarter-2025-financial-results-conference-call-and-webcast-on-may-15-2-phge-20250508monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-compliance-with-nyse-guidelines-on-audit-opinion-disclosure-phge-20250401monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-positive-topline-results-from-phase-2-trial-evaluating-bx211-for-the-treat-phge-20250331monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025-phge-20250319monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-inc-receives-notice-of-compliance-with-nyse-american-continued-listing-standards-phge-20241216monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-host-third-quarter-2024-financial-results-conference-call-and-webcast-on-november-phge-20241112monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-a-mandatory-unit-separation-phge-20241015monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-provide-latest-update-on-positive-phase-1b-2a-clinical-trial-data-for-bx004-at-th-phge-20240918monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-phge-20240904monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-present-positive-phase-1b-2a-clinical-trial-data-for-bx004-at-the-european-respir-phge-20240903monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-second-quarter-2024-financial-results-and-provides-business-and-program-upda-phge-20240815monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-inc-announces-1-for-10-reverse-stock-split-phge-20240815monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-host-second-quarter-2024-financial-results-conference-call-and-webcast-on-august--phge-20240808monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-inc-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance-phge-20240729monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-inc-announces-stockholder-approval-for-conversion-of-outstanding-series-x-convertibl-phge-20240710monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-inc-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-phge-20240530monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-present-phase-1b-2a-clinical-trial-data-for-bx004-at-the-47th-european-cystic-fib-phge-20240530monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-first-quarter-2024-financial-results-and-provides-business-and-program-updat-phge-20240521monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-host-first-quarter-2024-financial-results-conference-call-and-webcast-on-may-21-2-phge-20240515monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-present-at-the-2024-rbc-capital-markets-global-healthcare-conference-phge-20240506monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-present-data-from-phase-1b-2a-study-of-bx004-for-the-treatment-of-cystic-fibrosis-phge-20240423monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-the-appointment-of-susan-blum-to-its-board-of-directors-phge-20240418monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-compliance-with-nyse-guidelines-on-audit-opinion-disclosure-phge-20240404monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-host-fourth-quarter-and-full-year-2023-financial-results-conference-call-and-webc-phge-20240327monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-closing-of-the-acquisition-of-adaptive-phage-therapeutics-and-concurrent-5-phge-20240318monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-entry-into-merger-agreement-with-adaptive-phage-therapeutics-and-concurren-phge-20240306monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-receives-orphan-drug-designation-from-the-u-s-food-and-drug-administration-for-bx004-phge-20240104monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-host-virtual-key-opinion-leader-kol-event-to-review-the-positive-results-from-par-phge-20231130monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-positive-topline-results-from-part-2-of-the-phase-1b-2a-trial-evaluating-b-phge-20231129monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-present-data-from-ongoing-phase-1b-2a-study-evaluating-bx004-for-the-treatment-of-phge-20231027monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-the-appointment-of-edward-l-williams-to-its-board-of-directors-phge-20231018monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-completion-of-patient-dosing-in-part-2-of-the-phase-1b-2a-study-evaluating-phge-20231004monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-present-data-from-ongoing-phase-1b-2a-study-evaluating-bx004-for-the-treatment-of-phge-20230907monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-phge-20230906monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-host-second-quarter-2023-financial-results-conference-call-and-webcast-on-august--phge-20230802monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-present-part-1-data-from-phase-1b-2a-study-evaluating-bx004-for-the-treatment-of--phge-20230531monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-the-appointments-of-jason-m-marks-and-michael-e-dambach-to-board-of-direct-phge-20230512monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-host-first-quarter-2023-financial-results-conference-call-and-webcast-on-may-15th-phge-20230508monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-second-closing-of-7-5-million-private-placement-phge-20230505monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-host-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-webc-phge-20230327monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-7-5-million-private-placement-phge-20230222monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-positive-results-from-part-1-of-the-phase-1b-2a-study-evaluating-bx004-for-phge-20230222monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-present-at-h-c-wainwright-1st-annual-investor-conference-on-bacteriophage-phge-20221129monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-third-quarter-2022-financial-results-and-provides-business-update-phge-20221109monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-host-third-quarter-2022-financial-results-conference-call-and-webcast-on-november-phge-20221102monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-presenting-at-two-upcoming-conferences-in-november-phge-20211117monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-host-third-quarter-2021-financial-results-conference-call-and-webcast-on-november-phge-20211109monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-topline-results-of-phase-2-cosmetic-acne-study-phge-20211018monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-agreement-with-maruho-co-ltd-for-atopic-dermatitis-product-candidate-bx005-phge-20211013monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-present-at-upcoming-september-investor-conferences-phge-20210902monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-host-second-quarter-2021-financial-results-conference-call-and-webcast-on-august--phge-20210812monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-inc-announces-15-million-registered-direct-offering-phge-20210726monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-to-host-key-opinion-leader-event-on-bx003-for-the-treatment-of-inflammatory-bowel-di-phge-20210518monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-hosting-key-opinion-leader-symposium-on-novel-phage-product-for-acne-prone-skin-phge-20190909monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-positive-phase-2a-data-with-namodenoson-in-pancreatic-cancer-35-of-patien-canf-20260430monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-expands-namodenoson-anti-obesity-franchise-with-israeli-patent-allowance-canf-20260317monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-provides-update-on-clinical-and-financial-status-canf-20251216monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-9-year-survival-with-complete-cure-in-an-advanced-liver-cancer-patient-treated-wi-canf-20251118monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-2024-financial-results-and-clinical-update-canf-20250414monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-initiates-pivotal-phase-3-psoriasis-study-of-its-oral-drug-piclidenoson-with-fda--canf-20250324monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-partner-vetbiolix-accelerate-piclidenoson-development-with-advanced-clinical-tria-canf-20250320monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-to-initiate-phase-ii-study-in-the-rare-genetic-disease-lowe-syndrome-with-piclide-canf-20250319monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-fda-approved-compassionate-use-treatment-with-namodenoson-in-a-pancreatic-cancer--canf-20250318monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-innovative-publication-namodenoson-in-liver-cancer-treatment-alongside-with-cardi-canf-20250303monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-to-present-the-namodenoson-anti-obesity-effect-at-bio-ceo-investor-conf-canf-20250205monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-achieves-milestone-with-first-patient-dosing-in-pancreatic-cancer-phase-iia-clini-canf-20241111monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-anti-obesity-drug-namodenoson-received-patent-allowance-in-australia-canf-20241104monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-pancreatic-carcinoma-phase-iia-clinical-study-with-namodenoson-received-regulator-canf-20240916monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-first-half-2024-financial-results-progress-in-two-pivotal-phase-iii-clini-canf-20240829monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-exercise-of-warrants-for-approximately-5-0-million-in-gross-proceeds-canf-20240808monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-provides-namodenoson-patent-update-canf-20240729monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-applies-for-fda-orphan-drug-designation-for-namodenoson-in-the-treatment-of-pancr-canf-20240711monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-exercise-of-warrants-for-approximately-3-0-million-in-gross-proceeds-canf-20231121monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-exercise-of-warrants-for-cash-proceeds-of-10-million-canf-20211220monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-announces-pricing-of-5-million-public-offering-canf-20200210monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-announces-6-million-registered-direct-offering-canf-20190520monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-ltd-s-ceo-pnina-fishman-interviewed-by-the-life-sciences-report-canf-20150305monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-announces-clinical-and-corporate-developments-for-near-term-events-canf-20131022monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-closing-of-5-million-public-offering-priced-at-the-mark-pcsa-20250130monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-pricing-of-5-million-public-offering-priced-at-the-mark-pcsa-20250128monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-reports-third-quarter-business-highlights-and-financial-results-pcsa-20241030monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-first-patient-dosed-in-phase-2-clinical-trial-of-ngc-ca-pcsa-20241002monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-participate-in-investor-and-industry-conferences-during-septem-pcsa-20240903monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-provides-product-pipeline-and-financial-update-pcsa-20240828monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-positive-preclinical-data-for-ngc-iri-pcsa-20240819monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-fda-clearance-of-ind-application-for-a-phase-2-clinical-pcsa-20240730monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-names-russell-l-skibsted-as-chief-financial-officer-pcsa-20240717monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-positive-efficacy-results-from-preliminary-evaluation-o-pcsa-20240611monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-participate-in-the-ef-hutton-annual-global-conference-pcsa-20240506monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-names-dr-steven-cha-senior-vice-president-of-clinical-research-pcsa-20240430monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-presents-two-abstracts-at-the-aacr-annual-meeting-2024-including--pcsa-20240411monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-at-the-medinvest-biotech-and-pharma-investor-conferenc-pcsa-20240328monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-data-at-the-american-association-for-cancer-research-a-pcsa-20240325monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-at-the-2024-bio-ceo-investor-conference-pcsa-20240221monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-at-the-winter-wrap-up-microcap-rodeo-winter-2024-virtu-pcsa-20240214monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-rule-pcsa-20240206monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-closing-of-7-0-million-public-offering-pcsa-20240201monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-pricing-of-7-0-million-public-offering-pcsa-20240126monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-successful-completion-of-phase-1b-safety-evaluation-of--pcsa-20240125monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-expansion-of-ngc-cap-program-into-advanced-or-metastati-pcsa-20240119monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-effect-a-1-for-20-reverse-stock-split-pcsa-20240118monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-at-the-biotech-showcase-2024-pcsa-20240102monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-provides-interim-analysis-from-ongoing-phase-1b-trial-of-next-gen-pcsa-20231219monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-successful-phase-2-meeting-with-fda-for-next-generation-pcsa-20231213monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-at-the-medinvest-oncology-investor-conference-pcsa-20231130monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-issues-letter-to-shareholders-highlighting-corporate-strategy-dru-pcsa-20231129monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-inc-mourns-the-sudden-passing-of-board-member-virgil-thompson-pcsa-20231113monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-at-the-20th-orphan-drugs-and-rare-diseases-global-cong-pcsa-20231109monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-formation-of-oncology-advisory-board-with-renowned-key--pcsa-20231101monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-at-the-thinkequity-conference-pcsa-20231013monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-at-the-h-c-wainwright-25th-annual-global-investment-co-pcsa-20230906monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-provides-data-update-supporting-a-potential-personalized-treatmen-pcsa-20230817monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-at-the-sidoti-co-micro-cap-virtual-conference-pcsa-20230810monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-appoints-life-sciences-industry-veteran-george-ng-as-chief-execut-pcsa-20230808monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-participate-in-a-panel-on-interaction-with-the-fda-at-the-worl-pcsa-20230522monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-conduct-next-generation-chemotherapy-capecitabine-phase-2-tria-pcsa-20230518monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-pcs12852-gastroparesis-results-at-the-digestive-diseas-pcsa-20230428monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-provides-corporate-update-and-announces-year-end-2022-financial-r-pcsa-20230330monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-host-conference-call-to-discuss-2022-year-end-results-and-prov-pcsa-20230323monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-first-patient-dosed-in-the-300-mg-dose-group-with-next--pcsa-20230317monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-at-the-oppenheimer-33rd-annual-healthcare-conference-pcsa-20230307monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-prioritization-on-development-of-next-generation-chemot-pcsa-20230221monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-inc-announces-closing-of-6-25-million-registered-direct-offering--pcsa-20230215monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-inc-announces-6-25-million-registered-direct-offering-priced-at-t-pcsa-20230210monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-an-update-on-its-future-therapeutic-focus-and-strategy-pcsa-20230104monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-pcs12852-successfully-improves-the-clinical-symptoms-as-pcsa-20221214monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-third-quarter-financial-results-and-provides-corporate--pcsa-20221108monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-host-conference-call-to-discuss-third-quarter-2022-results-and-pcsa-20221102monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-successfully-identifies-next-generation-capecitabine-dosage-regimens-for-phase-2b-pcsa-20221101monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-provides-update-on-enrollment-across-all-clinical-programs-pcsa-20220915monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-at-h-c-wainwright-22nd-annual-global-investment-confer-pcsa-20220907monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-appoints-khoso-baluch-and-james-neal-to-its-board-of-directors-an-pcsa-20220816monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-second-quarter-2022-financial-results-and-provides-corp-pcsa-20220812monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-host-conference-call-to-discuss-its-second-quarter-2022-result-pcsa-20220805monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-launch-of-website-to-increase-awareness-of-ulcerative-n-pcsa-20220804monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-at-the-world-orphan-drug-congress-usa-july-11-13-2022-pcsa-20220712monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-first-quarter-2022-financial-results-and-provides-corpo-pcsa-20220512monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-host-conference-call-to-discuss-first-quarter-2022-results-and-pcsa-20220505monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-doses-first-patient-in-amended-phase-1b-protocol-for-pcs6422-comb-pcsa-20220420monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-first-patient-enrolled-in-the-pcs12852-phase-2a-trial-f-pcsa-20220405monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-year-end-2021-results-and-provides-corporate-update-pcsa-20220330monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-host-conference-call-to-discuss-fourth-quarter-2021-results-an-pcsa-20220323monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-ceo-dr-david-young-to-present-at-the-oppenheimer-32nd-annual-heal-pcsa-20220310monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-ceo-dr-david-young-issues-letter-to-shareholders-providing-outloo-pcsa-20220126monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-third-quarter-2021-results-and-provides-corporate-updat-pcsa-20211111monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-next-generation-capecitabine-combination-of-pcs6422-and-pcsa-20211104monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-schedules-conference-call-to-discuss-third-quarter-results-and-pr-pcsa-20211026monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-cleared-by-fda-to-proceed-with-phase-2a-trial-for-the-treatment-o-pcsa-20211012monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences-update-pcsa-20210916monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-at-the-world-orphan-drug-congress-usa-august-25-27-pcsa-20210823monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-second-quarter-2021-results-and-provides-corporate-upda-pcsa-20210812monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-schedules-conference-call-to-discuss-second-quarter-results-and-p-pcsa-20210806monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-announces-first-patient-dosed-in-pcs6422-study-in-gastrointestinal-cancer-pcsa-20210804monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-at-zooming-with-ld-micro-virtual-investor-event-on-jul-pcsa-20210727monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-at-access-to-giving-virtual-conference-on-july-14-2021-pcsa-20210706monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-enters-into-a-licensing-agreement-with-ocuphire-pharma-inc-for-th-pcsa-20210617monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-set-to-join-russell-microcap-index-pcsa-20210608monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-at-ld-micro-virtual-investor-conference-on-june-9-2021-pcsa-20210607monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences-pcsa-20210526monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-first-patient-dosed-in-its-randomized-double-blind-plac-pcsa-20210520monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences-pcsa-20210518monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-first-quarter-2021-results-and-provides-corporate-updat-pcsa-20210513monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-schedules-conference-call-to-discuss-first-quarter-results-and-pr-pcsa-20210507monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-year-end-2020-results-and-provides-corporate-update-pcsa-20210325monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-schedules-conference-call-to-discuss-fourth-quarter-results-and-p-pcsa-20210322monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-announces-sites-selected-for-phase-2b-clinical-trial-to-treat-patients-with-ulcer-pcsa-20210317monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-closing-of-a-10-2-million-private-placement-pcsa-20210302monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-10-2-million-strategic-financing-pcsa-20210217monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conferen-pcsa-20210111monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences-pcsa-20201116monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-third-quarter-2020-results-provides-corporate-update-pcsa-20201112monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-the-appointment-of-dr-khalid-islam-to-its-board-of-dire-pcsa-20201105monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-schedules-conference-call-to-discuss-third-quarter-results-and-pr-pcsa-20201103monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-appointment-of-michael-floyd-as-chief-operating-officer-pcsa-20201013monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-closes-19-2-million-public-offering-pcsa-20201006monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-pricing-of-19-2-million-public-offering-and-uplisting-t-pcsa-20201002monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-entered-into-a-contingent-precedent-in-licensing-agreement-with-e-pcsa-20200827monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-enters-into-a-licensing-agreement-with-yuhan-corporation-for-the--pcsa-20200820monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-that-it-has-entered-into-an-agreement-with-aposense-ltd-pcsa-20200601monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-to-move-forward-with-a-pcs499-phase-3-trial-after-a-successful-fd-pcsa-20200330monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-results-from-the-phase-2-study-in-necrobiosis-lipoidica-pcsa-20200317monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-formation-of-its-medical-and-scientific-advisory-board-pcsa-20200305monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-provides-shareholder-update-pcsa-20200225monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-appoints-geraldine-pannu-as-an-independent-director-to-the-board--pcsa-20200213monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-1-for-7-reverse-stock-split-of-its-common-stock-pcsa-20191220monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-provides-an-update-on-positive-results-from-pcs-499-phase-2-trial-pcsa-20191204monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-the-licensing-of-an-anti-fibrotic-anti-inflammatory-dru-pcsa-20190903monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-last-patient-enrolled-in-clinical-trial-to-evaluate-the-pcsa-20190826monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-provides-a-study-update-for-its-on-going-phase-2-safety-and-toler-pcsa-20190715monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-today-that-they-will-be-presenting-at-the-jeffries-2019-pcsa-20190520monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-today-that-they-will-be-presenting-at-the-cowen-confere-pcsa-20190311monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-first-patient-dosed-in-clinical-trial-to-evaluate-the-s-pcsa-20190129monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-presentation-of-pcs499-data-at-the-annual-meeting-of-am-pcsa-20190109monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-up-listing-to-otcqb-market-pcsa-20181206monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-that-it-has-been-assigned-the-license-for-the-clinical--pcsa-20180321monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-new-u-s-department-of-defense-award-clinical-trial-update-imrn-20251203monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-submits-imm-529-ind-to-fda-imrn-20251008monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-letter-to-shareholders-projects-update-imrn-20250530monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-travelan-continued-strong-sales-growth-imrn-20250117monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-new-research-collaboration-targeting-antimicrobial-resistance-imrn-20250115monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-travelan-clinical-trial-update-imrn-20250114monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-present-at-the-small-cap-growth-virtual-investor-conferenc-imrn-20241202monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-presentation-to-21st-virtual-investor-summit-microcap-event-imrn-20241121monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-participation-in-maxim-virtual-healthcare-conference-imrn-20241016monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-travelan-continued-strong-sales-growth-imrn-20241015monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-plans-phase-2-trial-for-imm-529-following-fda-review-imrn-20240905monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-new-u-s-department-of-defense-research-award-for-naval-medical-research--imrn-20240816monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-present-at-the-emerging-growth-conference-imrn-20240815monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-host-webinar-on-marketopen-direct-connect-imrn-20240807monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-record-travelan-sales-globally-australia-and-usa-imrn-20240715monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-requests-pre-ind-meeting-for-imm-529-with-fda-filing-imrn-20240702monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-present-at-the-emerging-growth-conference-imrn-20240605monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-board-changes-imrn-20240531monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-present-at-peak-sky-high-imrn-20240531monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-to-present-at-the-emerging-growth-conference-imrn-20240507monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-director-resignation-imrn-20240503monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-to-host-live-virtual-event-imrn-20240415monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-travelan-sales-continued-strong-growth-imrn-20240410monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-positive-results-support-travelan-progress-to-phase-3-clinical-trials-in-imrn-20240307monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-presentation-australian-biologics-festival-2024-imrn-20240221monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-achieves-record-travelan-sales-imrn-20240213monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-investor-webinar-presentation-imrn-20240208monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-achieves-record-half-yearly-travelan-sales-imrn-20240116monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-clinical-trials-update-imrn-20231222monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-first-patients-enrolled-in-campylobacter-challenge-clinical-study-imrn-20231204monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-investor-webinar-presentation-imrn-20231128monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-investor-webinar-presentation-imrn-20231113monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-presented-at-ausbioinvest-imrn-20231030monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-travelan-clinical-study-cohort-2-commences-imrn-20231018monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-achieves-record-quarterly-travelan-sales-imrn-20231011monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-achieves-record-monthly-travelan-sales-imrn-20230913monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-present-at-h-c-wainwright-imrn-20230911monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-to-present-at-the-military-health-system-research-symposium-imrn-20230814monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-first-patients-enrolled-in-travelan-clinical-study-imrn-20230725monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-present-at-bioshares-imrn-20230724monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-business-update-ateria-health-launches-juvia-in-australia-imrn-20230711monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-fy23-sales-increase-136-on-fy22-sales-imrn-20230705monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-chairman-transition-imrn-20230630monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-business-update-letter-to-shareholders-imrn-20230622monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-initiates-recruitment-of-travelan-clinical-study-imrn-20230530monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-fda-removed-clinical-hold-on-new-campylobacter-etec-therapeutic-paves-wa-imrn-20230508monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-present-at-coffee-microcaps-imrn-20230502monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-q3-fy23-business-update-presentation-imrn-20230419monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-q3-sales-reach-150-of-1h-sales-imrn-20230406monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-host-an-investor-webinar-imrn-20230215monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-us-dod-naval-medical-research-center-responds-to-fda-clinical-hold-for-new-campylo-imrn-20230125monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-receives-european-patent-on-drug-composition-to-treat-clostridioides-difficile-ass-imrn-20230117monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-receives-fda-approval-for-travelan-ind-application-imrn-20221223monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-submits-ind-application-to-fda-for-travelan-imrn-20221205monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-completes-strategic-investment-in-leading-gut-health-biotech-ateria-health-imrn-20221116monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-present-at-ausbioinvest-imrn-20221026monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-strategic-investment-in-leading-gut-health-biotech-ateria-health-imrn-20221013monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-executes-travelan-clinical-trial-agreement-with-us-based-pharmaron-imrn-20221004monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-host-an-investor-webinar-imrn-20220829monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-update-on-imm-124e-sars-cov-2-research-imrn-20220819monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-us-dod-naval-medical-research-center-receives-feedback-on-ind-application-for-new--imrn-20220726monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-north-american-travelan-sales-up-494-and-global-sales-up-431-imrn-20220711monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-receives-european-patent-notification-on-drug-composition-to-treat-clostridioides--imrn-20220707monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-us-dod-naval-medical-research-center-submits-ind-application-for-new-campylobacter-imrn-20220511monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-appoints-mr-steven-lydeamore-as-chief-executive-officer-imrn-20220506monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-travelan-global-sales-up-216-imrn-20220427monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-new-mtec-project-proposal-development-of-oral-immunotherapy-for-the-prevention-of--imrn-20220419monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-receives-aud-306-154-r-d-tax-concession-refund-imrn-20220117monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-receives-european-patent-on-drug-composition-to-treat-travelers-diarrhea-imrn-20220113monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-receives-a-6-2-million-award-from-u-s-dod-to-clinically-evaluate-a-military-streng-imrn-20220112monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-director-resignation-imrn-20210924monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-planned-acquisition-of-r-d-vaccine-company-imrn-20210923monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-to-participate-in-h-c-wainwright-co-bioconnect-2021-virtual-conference-imrn-20210111monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-sars-cov-2-research-agreement-with-monash-university-imrn-20201215monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-receives-aud-358-280-r-d-tax-concession-refund-imrn-20201124monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-travelers-diarrhea-market-update-imrn-20201012monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-announces-closing-of-20-0-million-registered-direct-offering-imrn-20200723monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-20-0-million-registered-direct-offering-imrn-20200721monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-reports-neutralizing-activity-against-sars-cov-2-key-points-imrn-20200721monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-partners-with-csiro-to-produce-a-new-oral-therapeutic-for-clinical-evaluation-by-t-imrn-20200619monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-board-relinquish-cash-payment-of-fees-imrn-20200428monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-north-american-travelan-sales-up-95-global-sales-up-60-imrn-20200420monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-provides-update-on-first-half-of-fy20-results-imrn-20200303monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-s-technology-platform-of-treatments-in-the-age-of-the-coronavirus-outbreak-imrn-20200203monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-dr-gary-s-jacob-to-present-at-biotech-showcase-conference-on-january-13-2020-imrn-20200108monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-plans-phase-3-trial-for-imm-124e-to-prevent-travelers-diarrhea-imrn-20191121monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-receives-aud-0-53m-r-d-tax-concession-refund-imrn-20191104monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-north-american-q1-sales-up-111-yoy-imrn-20191014monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-to-commence-non-deal-investor-roadshow-imrn-20190816monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-reports-results-in-severe-alcoholic-hepatitis-clinical-trial-imrn-20190808monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-to-host-investor-webinar-on-july-18-to-provide-update-on-recent-developments-imrn-20190717monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-prices-underwritten-public-offering-of-adss-imrn-20190717monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-proposed-public-offering-of-adss-imrn-20190716monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-north-american-revenue-surges-by-52-in-fy19-imrn-20190716monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-directors-increase-shareholdings-in-the-company-imrn-20190625monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-to-commence-us-non-deal-institutional-investor-roadshow-imrn-20190619monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-the-closing-of-public-offering-of-adss-imrn-20190530monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-prices-underwritten-public-offering-of-adss-imrn-20190524monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-proposed-public-offering-of-adss-imrn-20190523monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-dr-gary-s-jacob-to-present-at-the-thinkequity-conference-on-may-2-2019-imrn-20190430monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-appoints-ceo-dr-gary-s-jacob-to-board-of-directors-imrn-20190417monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-sales-surge-by-66-in-the-third-quarter-of-fy19-imrn-20190415monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-receives-u-s-patent-on-drug-composition-to-treat-clostridium-difficile-imrn-20190411monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-aims-to-secure-fda-approval-for-imm-124e-to-prevent-travelers-diarrhea-imrn-20190411monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-receives-1-19m-r-d-tax-concession-refund-imrn-20190108monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-appoints-gary-s-jacob-ph-d-experienced-us-based-biotechnology-executive-as-ceo-imrn-20181119monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-reports-record-revenue-exceeding-au-2-million-for-the-fy18-year-imrn-20180725monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-it-has-received-a-european-patent-grant-for-nash-treatment-imrn-20180724monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-board-appointment-imrn-20180626monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-reports-significant-alleviation-of-colitis-symptoms-in-preclinical-program-imrn-20180508monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-to-present-at-redchip-global-online-growth-conference-imrn-20180423monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-s-travelan-sales-continue-to-soar-in-third-quarter-of-fy2018-in-australian-us-mark-imrn-20180423monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-a-5-1m-private-placement-to-u-s-fund-imrn-20180313monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-progresses-discussions-with-institutional-funds-imrn-20180313monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-commences-us-non-deal-institutional-investor-roadshow-imrn-20180312monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-reports-positive-results-in-nash-clinical-trial-imrn-20180307monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-issues-correction-to-misleading-halt-announcement-headline-imrn-20180307monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-enrols-first-patients-in-clinical-study-of-imm-529-for-treatment-of-clostridium-di-imrn-20180131monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-to-receive-2-16m-r-d-tax-concession-refund-imrn-20180124monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-to-present-at-redchip-s-global-online-growth-conference-imrn-20171206monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-granted-us-patent-for-nash-treatment-imrn-20171115monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-successfully-completes-nash-phase-ii-clinical-study-milestone-imrn-20171109monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ltd-highlights-market-opportunity-following-recent-studies-on-antibiotic-correlati-imrn-20171017monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-highlights-recent-milestones-in-quest-to-effectively-treat-multiple-forms-of-fatty-imrn-20170919monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-commences-us-non-deal-institutional-investor-roadshow-imrn-20170815monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-approved-to-commence-clinical-study-in-c-difficile-infection-cdi-imrn-20170809monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ltd-announces-pricing-of-u-s-initial-public-offering-and-nasdaq-listing-raising-us-imrn-20170608monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-positive-results-of-imm-124e-in-acute-colitis-research-studies-imrn-20170418monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-completes-phase-ii-nash-clinical-trial-recruitment-imrn-20170220monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-initiates-nash-moa-studies-with-sanyalbio-and-with-duke-university-imrn-20170119monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-files-f-1-with-the-sec-imrn-20161222monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-receives-1-59m-r-d-tax-concession-refund-imrn-20161129monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-availability-of-redchip-conference-presentation-imrn-20160725monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-to-cooperate-with-leading-australian-universities-on-autism-research-imrn-20160720monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-rights-issue-raises-5-33m-imrn-20160707monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-significantly-expands-us-distribution-reach-with-mckesson-agreement-imrn-20160629monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-e-commerce-agreement-with-qbid-in-china-imrn-20160624monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-signs-shigella-vaccine-development-agreement-with-us-army-imrn-20160623monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-statistically-significant-results-of-triple-action-anti-infective-imm-52-imrn-20160112monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-executes-u-s-travelan-sales-agreement-with-medico-mart-inc-imrn-20151112monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-executes-us-travelan-sales-partnership-with-travelcare-worldwide-imrn-20151111monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-starts-nash-companion-diagnostic-collaboration-with-owl-s-l-imrn-20151109monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-s-infoods-ibs-data-accepted-for-presentation-at-digestive-disease-week-2026-bmra-20260429monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-launches-infoods-ibs-in-canada-through-partnerships-with-phoenix-airmid-biomedic-bmra-20260414monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-receives-first-commercial-order-for-its-h-pylori-test-hp-detect-from-one-of-the--bmra-20260318monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-s-infoods-ibs-product-featured-in-biotherapeutics-quarterly-a-henry-schein-publi-bmra-20251125monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-fiscal-2025-year-end-results-bmra-20250829monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-appoints-eric-b-chin-to-board-of-directors-and-audit-committee-chair-bmra-20250606monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-s-infoods-ibs-clinical-study-results-published-in-june-issue-of-gastroenterology-bmra-20250605monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-real-world-data-showing-49-reduction-in-ibs-symptoms-with-infoods-ibs-us-bmra-20250522monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-reverse-stock-split-bmra-20250416monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-third-quarter-fiscal-2025-financial-results-bmra-20250415monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-achieves-ivdr-certification-in-the-european-union-for-food-intolerance-tests-tar-bmra-20250226monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-s-infoods-ibs-clinical-trial-results-published-and-featured-in-gastroenterology--bmra-20250219monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-second-quarter-fiscal-2025-financial-results-bmra-20250115monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-secures-three-key-international-patents-for-infoods-technology-to-address-gerd-c-bmra-20241121monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-direct-to-consumer-availability-of-infoods-ibs-test-targeting-relief-f-bmra-20241030monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-first-quarter-fiscal-2025-financial-results-bmra-20241016monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-fiscal-2024-year-end-results-bmra-20240829monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-launches-at-home-sample-collection-for-infoods-ibs-significantly-expanding-acces-bmra-20240701monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-infoods-ibs-pilot-launch-with-prominent-1-100-member-physician-group-c-bmra-20240513monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-and-leading-uae-healthcare-company-forge-a-path-to-enhanced-colorectal-and-breas-bmra-20240429monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-provides-update-on-infoods-ibs-expansion-bmra-20240415monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-third-quarter-2024-financial-results-bmra-20240412monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-infoods-ibs-data-to-be-presented-at-the-upcoming-digestive-disease-week-ddw-2024-bmra-20240328monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-second-quarter-2024-financial-results-bmra-20240116monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-received-us-fda-510-k-clearance-for-their-hp-detect-elisa-test-product-designed--bmra-20231218monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-to-participate-in-14th-annual-craig-hallum-alpha-select-conference-on-november-1-bmra-20231110monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-expands-infoods-ibs-reach-with-addition-of-several-new-gi-groups-bmra-20231108monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-first-quarter-2024-financial-results-bmra-20231013monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-fiscal-2023-year-end-results-bmra-20230825monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-receives-notice-of-patent-allowance-in-china-for-a-potential-innovative-technolo-bmra-20230621monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-s-infoods-ibs-test-is-now-available-at-gastro-health-providing-a-revolutionary-n-bmra-20230417monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-q3-fiscal-2023-results-bmra-20230414monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-the-launch-of-infoods-ibs-as-a-laboratory-developed-test-ldt-first-pat-bmra-20230308monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-closing-of-8-million-underwritten-public-offering-of-common-stock-bmra-20230307monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-pricing-of-8-million-underwritten-public-offering-of-common-stock-bmra-20230303monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-financial-results-for-fiscal-2023-second-quarter-ended-november-30-2022-bmra-20230113monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-appoints-mayo-clinic-gastroenterologist-dr-brian-e-lacy-to-the-company-s-scienti-bmra-20230110monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-receives-kfda-and-ministry-of-health-approval-for-colorectal-screening-and-breas-bmra-20221208monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-infoods-ibs-data-presented-at-the-2022-american-college-of-gastroenterology-acg--bmra-20221102monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-30-increase-in-revenues-for-fiscal-q1-2023-vs-fiscal-q1-2022-bmra-20221013monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-s-aware-breast-self-exam-and-ez-detect-colon-disease-test-now-available-on-amazo-bmra-20220929monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-plans-launch-of-infoods-ibs-test-names-robert-carlson-as-chief-commercial-office-bmra-20220830monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-fiscal-2022-year-end-results-bmra-20220829monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-to-participate-at-btig-biotech-conference-bmra-20220623monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-ce-mark-for-its-h-pylori-diagnostic-test-hp-detect-bmra-20220512monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-fda-submission-for-a-test-to-detect-helicobacter-pylori-h-pylori-a-bac-bmra-20220426monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-111-increase-in-q3-fiscal-2022-revenues-to-7-6-million-vs-q3-fiscal-2021-bmra-20220414monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-record-financial-results-for-fiscal-second-quarter-ended-november-30-202-bmra-20220113monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-forms-scientific-advisory-board-for-colorectal-cancer-screening-bmra-20211119monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-receives-notice-of-allowance-from-canadian-patent-office-for-patent-covering-irr-bmra-20211104monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-launches-new-website-for-its-aware-breast-exam-device-bmra-20211029monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-results-for-fiscal-first-quarter-ended-august-31-2021-bmra-20211015monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-expects-completion-of-patient-enrollment-for-its-infoods-diagnostic-guided-thera-bmra-20210830monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-fiscal-2021-year-end-results-bmra-20210828monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-notice-of-allowance-for-patent-on-product-used-to-diagnose-and-treat-d-bmra-20210811monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-launches-new-website-for-its-ez-detect-colorectal-disease-screening-test-bmra-20210805monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-signs-exclusive-distribution-agreement-in-canada-for-its-new-and-proprietary-hel-bmra-20210624monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-receives-notice-of-allowance-from-mexican-patent-office-for-irritable-bowel-synd-bmra-20210615monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-to-participate-in-upcoming-investor-conferences-bmra-20210604monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-s-fast-15-minute-easy-to-use-covid-19-antigen-test-now-available-with-simple-nas-bmra-20210511monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-208-increase-in-q3-fiscal-2021-sales-over-q3-fiscal-2020-bmra-20210415monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-fiscal-2021-second-quarter-financial-results-and-provides-business-updat-bmra-20210115monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-s-infoods-irritable-bowel-syndrome-diagnostic-guided-therapy-clinical-trial-near-bmra-20201209monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-fiscal-2021-1st-quarter-financial-results-bmra-20201016monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-fiscal-year-end-may-31-2020-financial-results-bmra-20200901monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-notice-of-allowance-for-new-u-s-patent-application-covering-diagnostic-bmra-20200812monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-filing-of-new-three-year-shelf-registration-statement-bmra-20200722monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-third-quarter-financial-results-bmra-20200415monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-second-quarter-financial-results-sales-up-6-4-for-the-quarter-bmra-20200115monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-1st-quarter-fiscal-2020-financials-bmra-20191016monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-fiscal-year-end-2019-financial-results-bmra-20190830monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-signs-exclusive-distribution-agreement-in-china-for-its-colorectal-screening-tes-bmra-20190605monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-third-quarter-financial-results-bmra-20190416monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-notice-of-allowance-for-new-u-s-patent-application-covering-diagnostic-bmra-20190408monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-updates-for-h-pylori-clinical-studies-bmra-20190205monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-second-quarter-financial-results-bmra-20190115monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-s-diagnostic-product-guides-exclusionary-diet-treatment-to-successfully-alleviat-bmra-20181107monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-1st-quarter-fiscal-2019-financials-bmra-20181016monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-fiscal-year-end-2018-financial-results-bmra-20180830monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-receives-notice-of-allowance-for-irritable-bowel-syndrome-ibs-test-panel-and-met-bmra-20180802monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-first-patient-enrollment-in-clinical-study-for-new-irritable-bowel-syn-bmra-20180625monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-adds-harry-leider-md-mba-to-strategic-advisory-board-bmra-20180419monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-third-quarter-financial-results-bmra-20180417monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-second-quarter-financial-results-sales-up-12-7-for-the-quarter-bmra-20180116monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-signs-agreements-with-beth-israel-deaconess-university-of-michigan-to-initiate-c-bmra-20180108monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-extends-exclusive-license-agreement-with-celtis-pharm-telcon-pharmaceuticals-to--bmra-20171107monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-1st-quarter-fiscal-2018-financials-bmra-20171017monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-commences-clinical-studies-for-new-gastroenterology-h-pylori-test-bmra-20170912monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-fiscal-year-end-2017-financial-results-sales-up-12-7-for-the-year-bmra-20170830monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-point-of-care-product-distribution-agreement-with-a-multinational-phar-bmra-20170816monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-to-present-at-the-18th-annual-b-riley-co-investor-conference-on-may-24-2017-bmra-20170523monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-third-quarter-financial-results-sales-up-13-9-for-nine-months-bmra-20170417monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-to-present-at-the-29th-annual-roth-conference-on-march-13-2017-bmra-20170309monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-second-quarter-financial-results-sales-up-over-22-for-the-quarter-bmra-20170118monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-first-quarter-fiscal-2017-financial-results-sales-increase-over-prior--bmra-20161018monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-highlights-recent-scientific-reports-indicating-increased-prevalence-of-ibs-bmra-20161004monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-to-present-at-18th-annual-rodman-renshaw-global-investment-conference-bmra-20160906monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-year-end-results-bmra-20160830monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-approved-for-listing-on-the-nasdaq-capital-market-bmra-20160824monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-updates-shareholders-on-progress-of-commercialization-of-its-new-ibs-product-bmra-20160810monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-forms-strategic-advisory-board-and-expands-scientific-advisory-board-bmra-20160725monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-adds-dr-mark-sirgo-to-board-of-directors-bmra-20160718monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-signs-exclusive-license-agreement-for-korean-market-with-total-value-of-up-to-8--bmra-20160526monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-third-quarter-financial-results-sales-up-10-for-nine-months-bmra-20160415monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announced-that-its-international-patent-application-for-ibs-was-reviewed-by-the--bmra-20160314monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-to-present-at-the-roth-conference-on-march-16-2016-bmra-20160310monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-second-quarter-financial-results-bmra-20160115monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-executive-advisor-appointment-for-medical-affairs-and-research-bmra-20160108monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-first-quarter-results-sales-up-over-24-bmra-20151016monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-working-with-fda-on-submission-for-its-ibs-product-bmra-20150929monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-year-end-results-bmra-20150901monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-conference-call-regarding-its-product-and-recent-developments-in-the-i-bmra-20150706monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-its-first-brazilian-anvisa-approvals-and-a-new-distribution-channel-in-bmra-20150629monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-third-quarter-financial-results-and-establishes-scientific-advisory-bo-bmra-20150415monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-second-quarter-financial-results-bmra-20150115monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-has-filed-a-first-set-of-patent-applications-with-the-uspto-for-a-new-test-to-ai-bmra-20150114monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-first-quarter-results-bmra-20141016monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-year-end-results-bmra-20140902monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-to-supply-its-colorectal-screening-point-of-care-test-to-multinational-pharmaceu-bmra-20140811monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-two-new-china-cfda-approvals-and-a-new-distribution-channel-in-china-bmra-20140604monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-third-quarter-financial-results-bmra-20140415monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-completion-of-strategic-investment-bmra-20140122monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-second-quarter-financial-results-bmra-20140115monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-to-supply-two-of-its-point-of-care-products-to-multinational-pharmaceutical-comp-bmra-20140114monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-first-quarter-results-bmra-20131016monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-year-end-results-sales-up-over-6-bmra-20130830monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-receives-approval-to-market-its-h-pylori-and-pth-products-in-mexico-and-appoints-bmra-20130807monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-third-quarter-financial-results-bmra-20130416monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-second-quarter-financial-results-bmra-20130115monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-first-quarter-revenue-growth-of-20-9-net-income-up-over-147-bmra-20121015monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-year-end-results-sales-up-over-24-net-income-0-08-per-share-versus-0-0-bmra-20120830monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-third-quarter-financial-results-bmra-20120417monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-introduces-two-new-e-coli-tests-verotoxin-and-e-coli-0157-bmra-20120306monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-launches-new-patented-test-to-identify-individuals-at-risk-of-developing-severe--bmra-20120131monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-second-quarter-financial-results-bmra-20120118monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-first-quarter-revenue-growth-of-19-5-bmra-20111018monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-year-end-results-bmra-20110830monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-third-quarter-financial-results-bmra-20110415monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-second-quarter-financial-results-bmra-20110117monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-awarded-grants-under-the-qualifying-therapeutic-discovery-project-program-bmra-20101130monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-first-quarter-financial-results-bmra-20101018monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-year-end-results-bmra-20100831monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-receives-ce-european-approval-for-new-one-of-a-kind-simple-consumer-test-to-dete-bmra-20100823monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-purchases-patented-technology-and-manufacturing-rights-for-a-new-tpmt-test-to-in-bmra-20100608monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-third-quarter-financial-results-bmra-20100415monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-second-quarter-financial-results-bmra-20100120monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-purchases-the-technology-know-how-and-manufacturing-rights-for-7-new-gastrointes-bmra-20100112monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-plans-for-new-headquarters-in-irvine-california-bmra-20091028monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-first-quarter-financial-results-bmra-20091016monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-year-end-results-bmra-20090901monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-purchases-the-assets-technology-and-rights-for-new-celiac-disease-tests-bmra-20090428monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-receives-ce-mark-approval-for-5-minute-home-test-for-kidney-disease-screening-fo-bmra-20090421monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-third-quarter-financial-results-bmra-20090415monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-second-quarter-financial-results-bmra-20090115monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-first-quarter-financial-results-bmra-20081016monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-year-end-results-bmra-20080902monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-sale-of-minority-interest-in-lancer-orthodontics-inc-bmra-20080529monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-third-quarter-financial-results-bmra-20080415monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-second-quarter-financial-results-bmra-20080115monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-first-quarter-financial-results-bmra-20071016monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-record-year-end-results-bmra-20070830monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-receives-ce-mark-approval-for-15-minute-home-test-for-ulcer-screening-bmra-20070807monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-board-of-directors-adds-new-member-bmra-20070717monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-income-of-697-034-on-sale-of-securities-held-for-investment-bmra-20070620monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-board-of-directors-adds-new-member-bmra-20070502monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-third-quarter-financial-results-bmra-20070417monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-new-relationship-with-commercial-bank-of-california-and-a-new-line-of--bmra-20070410monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-second-quarter-financial-results-bmra-20070117monthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-biopharmaceuticals-to-acquire-psyga-bio-establishing-a-leading-psychedelic-biotechnolo-xtlb-20260429monthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-announces-receipt-of-staff-delist-determination-from-nasdaq-and-plans-to-request-heari-xtlb-20260227monthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-announces-receipt-of-nasdaq-notification-regarding-minimum-stockholders-equity-deficie-xtlb-20260123monthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-biopharmaceuticals-acquires-85-of-beyond-air-s-subsidiary-neuronos-entering-the-massiv-xtlb-20260113monthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-announces-receipt-of-nasdaq-notification-letter-regarding-minimum-bid-price-deficiency-xtlb-20251224monthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-provides-update-on-hepex-b-program-xtlb-20060719monthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-biopharmaceuticals-ltd-provides-update-to-2005-annual-report-on-form-20-f-xtlb-20060602monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-cap-accreditation-of-cnside-diagnostics-clinical-laboratory-pstv-20260604monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-cnside-diagnostic-platform-demonstrates-substantial-healthcare-cost-reduction-in-pati-pstv-20260526monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-receives-medicare-enrollment-approval-for-cnside-diagnostic-pstv-20260507monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-granting-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-pstv-20260422monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-appoints-randy-h-goodman-phd-mha-as-vice-president-of-value-strategy-heo-pstv-20260415monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-receives-ama-pla-code-for-cnside-csf-tumor-cell-enumeration-test-advanci-pstv-20260407monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-reverse-stock-split-pstv-20260331monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-present-new-analysis-at-ispor-showing-cnside-may-reduce-leptomeningea-pstv-20260319monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-read-out-of-type-b-meeting-with-the-fda-with-goal-of-accelerat-pstv-20260108monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-expansion-of-cnside-team-and-issuance-of-inducement-grants-pstv-20251209monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-highlights-three-reyobiq-clinical-data-presentations-at-2025-wfnos-sno-a-pstv-20251204monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-completion-of-u-s-fda-meeting-on-future-clinical-development-p-pstv-20251124monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-presents-positive-cnside-csf-assay-platform-results-at-the-2025-sno-asco-pstv-20250814monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-provides-us-launch-update-for-its-cnside-diagnostic-pstv-20250731monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-1-6-million-advance-payment-from-cprit-pstv-20250723monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-presents-respect-lm-clinical-trial-results-for-reyobiq-in-patients-with--pstv-20250715monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-two-cnside-presentations-at-the-upcoming-sno-asco-cns-metastas-pstv-20250710monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-initial-patients-successfully-treated-in-respect-lm-dose-optim-pstv-20250708monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-fda-agreement-to-initiate-respect-lm-dose-optimization-trial-f-pstv-20250630monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-provides-business-update-on-cnside-diagnostics-subsidiary-pstv-20250626monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-provide-business-update-and-host-conference-call-on-thursday-june-26--pstv-20250625monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-fda-clearance-of-its-investigational-new-drug-application-usin-pstv-20250625monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-comprehensive-restructuring-of-15-million-march-2025-equity-fi-pstv-20250624monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reyobiq-shows-clinical-benefit-and-safety-in-the-respect-lm-clinical-tri-pstv-20250514monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-participate-in-the-d-boral-capital-inaugural-global-conference-pstv-20250508monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-biotech-industry-veteran-kyle-guse-joins-its-board-of-director-pstv-20250423monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-presents-new-data-highlighting-clinical-benefit-and-safety-of-reyobiq-in-pstv-20250415monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate-pstv-20250320monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-pstv-20250319monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-regains-compliance-with-nasdaq-minimum-stockholders-equity-requirement-pstv-20250310monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-peer-reviewed-publication-in-nature-communications-highlightin-pstv-20250307monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-granted-u-s-fda-orphan-drug-designation-for-rhenium-186re-obisbemeda-for-pstv-20250306monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-new-employment-inducement-grants-pstv-20250305monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-secures-private-placement-of-approximately-15-million-in-gross-proceeds-pstv-20250304monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-advances-lead-drug-rhenium-186re-obisbemeda-for-patients-with-leptomenin-pstv-20250226monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-leadership-appointments-for-its-cnside-diagnostics-subsidiary-pstv-20250224monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-appoints-dr-michael-rosol-as-chief-development-officer-pstv-20250220monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-secures-5-7-million-financing-to-support-leptomeningeal-metastases-progr-pstv-20250218monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-presents-positive-respect-lm-phase-1-interim-data-for-breast-cancer-pati-pstv-20241217monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-showcase-respect-lm-phase-1-interim-data-for-leptomeningeal-metastase-pstv-20241204monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-expands-strategic-agreement-with-telix-isotherapeutics-group-for-rhenium-pstv-20241203monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-presents-positive-respect-lm-phase-1-interim-data-for-leptomeningeal-met-pstv-20241125monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-present-positive-foresee-clinical-trial-summary-demonstrating-utility-pstv-20241122monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-present-multi-institutional-experience-using-the-cnside-cerebrospinal-pstv-20241121monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-and-spectronrx-announce-radiotherapeutic-manufacturing-partnership-pstv-20241106monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-announce-third-quarter-financial-results-and-host-conference-call-on--pstv-20241105monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-showcases-leptomeningeal-metastases-programs-at-the-2024-sno-annual-meet-pstv-20241029monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-respect-gbm-clinical-trial-update-at-the-2024-congress-of-neurol-pstv-20241001monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-showcases-new-interim-respect-gbm-phase-2-trial-data-at-the-2024-congres-pstv-20240918monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conferenc-pstv-20240904monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-presents-positive-clinical-trial-results-at-the-2024-sno-asco-cns-metast-pstv-20240813monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-presents-positive-interim-respect-lm-phase-1-data-for-leptomeningeal-met-pstv-20240812monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-announce-second-quarter-financial-results-and-host-conference-call-on-pstv-20240808monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-showcases-leptomeningeal-metastases-programs-at-2024-sno-asco-conference-pstv-20240725monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-present-at-the-gordon-research-conference-radionuclide-theranostics-f-pstv-20240702monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-expands-management-team-and-reports-3-3m-advance-payment-from-cprit-pstv-20240607monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-new-employment-inducement-grants-pstv-20240517monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-announce-first-quarter-financial-results-and-host-conference-call-on--pstv-20240513monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-provides-highlights-regarding-leptomeningeal-metastases-acquisition-and--pstv-20240509monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-host-investor-call-to-discuss-leptomeningeal-cancer-related-acquisiti-pstv-20240508monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-private-placement-financing-of-up-to-18-million-pstv-20240506monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-receives-3-million-award-recommendation-from-the-united-states-departmen-pstv-20240422monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-present-at-the-national-comprehensive-cancer-network-annual-conferenc-pstv-20240327monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-validation-clinical-implementation-of-csf-01-leptomeningeal-ca-pstv-20240325monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-completes-dosing-in-cohort-5-of-respect-lm-phase-1-trial-of-rhenium-186r-pstv-20240311monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2023-financial-results-and-host-pstv-20240227monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-updates-financial-and-cash-guidance-for-2024-pstv-20231218monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-partners-with-k2bio-for-development-of-novel-tests-for-cerebrospinal-flu-pstv-20231212monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-present-at-the-5th-targeted-radiopharmaceuticals-summit-europe-pstv-20231129monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-host-virtual-kol-event-on-new-phase-2-respect-gbm-data-in-recurrent-g-pstv-20231115monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-granted-u-s-fda-orphan-drug-designation-to-rhenium-186re-obisbemeda-for--pstv-20231103monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-share-repurchase-program-pstv-20231031monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-present-at-the-society-for-neurooncology-annual-meeting-and-will-host-pstv-20231025monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-announce-third-quarter-2023-financial-results-and-host-conference-cal-pstv-20231023monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-completes-dosing-in-cohort-4-of-respect-lm-phase-1-clinical-trial-of-rhe-pstv-20231010monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-participate-in-the-jones-trading-healthcare-summit-and-thinkequity-co-pstv-20231009monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-receives-1-9-million-advance-payment-from-cprit-and-plans-to-present-at--pstv-20230911monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-enters-into-license-agreement-for-cerebrospinal-fluid-tumor-cell-enumera-pstv-20230908monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-initiates-part-b-of-respect-lm-phase-1-2a-trial-for-leptomeningeal-metas-pstv-20230905monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conferenc-pstv-20230830monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-respect-lm-phase-1-trial-data-at-the-2023-sno-asco-cns-cancer-co-pstv-20230811monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-announce-second-quarter-2023-financial-results-and-host-conference-ca-pstv-20230808monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-key-opinion-leader-roundtable-on-new-clinical-trial-data-being-pstv-20230808monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference-pstv-20230803monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-strengthens-clinical-program-with-the-appointment-of-pius-maliakal-as-vi-pstv-20230727monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-present-at-the-2023-sno-asco-cns-cancer-conference-pstv-20230727monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-present-at-the-2nd-annual-targeted-radiopharmaceuticals-summit-pstv-20230713monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-positive-interim-updates-from-two-respect-clinical-trials-at-snm-pstv-20230629monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-participate-in-the-2023-healthcare-virtual-conference-presented-by-ma-pstv-20230614monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-participation-at-upcoming-sno-pediatric-conference-and-snmmi-a-pstv-20230608monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-provides-company-update-today-pstv-20230601monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-topline-results-from-recurrent-glioblastoma-external-control-a-pstv-20230530monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-present-at-the-2023-virtual-june-investor-summit-pstv-20230525monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event-pstv-20230512monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-expands-collaboration-with-piramal-pharma-solutions-to-meet-increase-in--pstv-20230502monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-completes-enrollment-of-the-original-three-patients-required-for-cohort--pstv-20230419monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-participate-in-panel-at-the-canaccord-genuity-horizons-in-oncology-vi-pstv-20230418monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-completes-phase-1-part-a-of-the-respect-lm-clinical-trial-for-leptomenin-pstv-20230418monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-announce-first-quarter-2023-financial-results-and-host-conference-cal-pstv-20230412monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-successfully-treats-first-patient-in-cohort-8-of-respect-gbm-phase-1-2a--pstv-20230328monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-initiates-cohort-3-in-phase-1-part-a-of-the-respect-lm-trial-for-leptome-pstv-20230322monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2022-financial-results-and-host-pstv-20230214monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-completes-enrollment-in-second-respect-lm-phase-1-trial-cohort-of-rheniu-pstv-20230201monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-first-patient-dosed-in-respect-gbm-phase-2b-trial-of-rhenium-1-pstv-20230118monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-provides-updates-on-respect-clinical-trials-at-the-27th-annual-scientifi-pstv-20221119monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-provide-update-on-respect-clinical-trials-at-the-27th-annual-scientif-pstv-20221102monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-selection-of-rhenium-186re-obisbemeda-as-international-non-pro-pstv-20221026monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-presents-preliminary-safety-and-feasibility-data-from-respect-lm-clinica-pstv-20221019monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-present-at-the-thinkequity-conference-pstv-20221018monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-cal-pstv-20221006monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-patient-webinar-in-recognition-of-breast-cancer-awareness-mont-pstv-20221005monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-share-data-in-oral-presentations-from-ongoing-respect-clinical-trials-pstv-20221004monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-presents-positive-phase-1-data-from-respect-gbm-clinical-trial-at-the-eu-pstv-20220912monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-pstv-20220908monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-fda-meeting-summary-for-lead-drug-candidate-pstv-20220906monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-signs-first-saas-revenues-agreement-following-full-launch-of-myovista-insigh-hscs-20260505monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-provides-business-update-and-reports-fiscal-2025-financial-results-hscs-20250724monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-provides-business-update-and-reports-third-quarter-fiscal-2025-financial-res-hscs-20250313monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-inc-engages-integrous-communications-to-enhance-investor-communications-hscs-20250310monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-provides-business-update-and-reports-second-quarter-fiscal-2025-financial-re-hscs-20241216monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-ai-ecg-algorithms-assigned-cms-medicare-and-medicaid-reimbursement-hscs-20241113monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-to-participate-in-the-2024-maxim-healthcare-virtual-summit-hscs-20241014monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-provides-business-update-and-reports-first-quarter-fiscal-2025-financial-res-hscs-20240912monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-closes-non-dilutive-financing-to-increase-its-cash-runaway-ahead-of-upcoming-hscs-20240912monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-provides-business-update-and-reports-fiscal-2024-financial-results-hscs-20240729monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-selected-to-demonstrate-myovista-wavecg-at-the-united-nations-general-assemb-hscs-20240725monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-announces-allowance-of-u-s-patent-for-ai-ecg-assessment-of-left-ventricular--hscs-20240711monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-regains-compliance-with-nasdaq-listing-requirements-hscs-20240604monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-announces-further-internationalization-of-its-ai-ecg-patent-portfolio-hscs-20240520monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-announces-grant-of-fundamental-patent-by-the-european-patent-office-covering-hscs-20240424monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-to-present-at-the-ld-micro-invitational-xiv-conference-hscs-20240402monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-announces-podium-presentation-at-world-congress-of-anesthesiologists-on-the--hscs-20240326monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-reports-third-quarter-fiscal-2024-financial-results-hscs-20240314monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-announces-peer-reviewed-publication-evaluating-use-of-myovista-technology-to-hscs-20240312monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-announces-canada-patent-grant-covering-myovista-wavelet-technology-hscs-20240306monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-adds-key-advisor-to-its-scientific-advisory-board-hscs-20240226monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-expands-its-scientific-advisory-board-hscs-20240212monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-appoints-new-scientific-advisory-board-member-hscs-20240201monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-announces-results-and-adjournment-of-annual-shareholder-meeting-hscs-20240118monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-reminds-stockholders-to-vote-at-the-upcoming-annual-shareholder-meeting-hscs-20240103monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-reports-second-quarter-fiscal-2024-financial-results-hscs-20231214monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-receives-fda-confirmation-for-510-k-clearance-pathway-hscs-20231205monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-announces-closing-of-license-agreements-with-the-icahn-school-of-medicine-at-hscs-20231120monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-myovista-wavecgtm-selected-for-heart-screening-of-irish-garda-national-polic-hscs-20231113monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-issues-investor-update-highlighting-recent-key-achievements-and-positive-dev-hscs-20231019monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-receives-two-new-patent-allowances-expanding-its-international-patent-portfo-hscs-20230926monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-to-participate-in-the-maxim-group-virtual-tech-conference-series-emerging-gr-hscs-20230925monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-signs-definitive-agreements-with-the-icahn-school-of-medicine-at-mount-sinai-hscs-20230921monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-reports-first-quarter-fiscal-2024-financial-results-hscs-20230914monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-to-present-at-the-gilmartin-group-emerging-growth-showcase-hscs-20230912monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-named-electrocardiography-advancement-specialists-of-the-year-2023-usa-in-th-hscs-20230911monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-signs-distribution-agreement-with-medphy-technologies-mumbai-india-hscs-20230907monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-signs-distribution-agreement-with-fj-medical-denmark-hscs-20230831monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-myovista-wavecgtm-selected-to-be-used-in-irish-heart-screening-evaluation-hscs-20230824monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-announces-further-expansion-of-artificial-intelligence-ai-patent-portfolio-hscs-20230817monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-provides-business-update-and-reports-fiscal-2023-financial-results-hscs-20230719monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-named-as-a-top-10-healthcare-artificial-intelligence-solutions-provider-2023-hscs-20230517monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-announces-completion-of-patient-enrollment-for-fda-pivotal-study-of-myovista-hscs-20230509monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-to-participate-at-the-inaugural-ef-hutton-global-conference-hscs-20230508monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-to-participate-in-the-benchmark-company-s-virtual-individual-investor-health-hscs-20230502monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-to-present-at-the-planet-microcap-showcase-vegas-2023-hscs-20230417monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-provides-business-update-and-reports-third-quarter-fiscal-2023-financial-res-hscs-20230316monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-ceo-invited-as-featured-guest-on-the-big-biz-show-february-7-at-11-45-a-m-pa-hscs-20230207monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-granted-key-israeli-international-patent-for-its-myovista-wavelet-technology-hscs-20230206monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-announces-further-internationalization-of-its-patent-portfolio-hscs-20230203monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-ceo-to-participate-in-the-healthcare-it-virtual-conference-presented-by-maxi-hscs-20230120monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-appoints-david-r-wells-to-its-board-of-directors-an-experienced-capital-mark-hscs-20230104monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-provides-business-update-and-reports-second-quarter-fiscal-2023-financial-re-hscs-20221216monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-and-rutgers-university-announce-multi-year-collaboration-to-develop-ai-based-hscs-20221201monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-to-present-at-the-2022-rhk-disruptive-growth-conference-on-december-5-2022-hscs-20221128monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-to-participate-at-the-benchmark-discovery-one-on-one-investor-conference-on--hscs-20221121monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-myovista-technology-used-to-develop-ai-ecg-algorithm-to-identify-patients-at-hscs-20221110monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-granted-european-patent-for-proprietary-electrode-and-cable-connections-for--hscs-20221025monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-named-as-a-top-10-medtech-startup-2022-by-medtech-outlook-magazine-hscs-20221020monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-announces-major-milestone-with-the-issuance-of-cpt-codes-by-the-american-med-hscs-20221019monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-granted-u-s-patent-for-ecg-assessment-of-heart-diastolic-function-using-arti-hscs-20220920monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-provides-business-update-and-reports-first-quarter-fiscal-2023-financial-res-hscs-20220913monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-to-participate-and-showcase-the-myovista-at-the-inauguration-ceremony-of-the-hscs-20220912monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference-hscs-20220908monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-provides-corporate-update-and-reports-fiscal-2022-financial-results-hscs-20220801monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-ceo-to-participate-in-the-benzinga-all-access-event-on-july-15th-hscs-20220713monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-receives-orphan-drug-designation-for-apvo436-for-the-treatment-of-acut-apvo-20191206monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-and-alligator-bioscience-present-new-preclinical-data-for-alg-apv-527--apvo-20191108monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-third-quarter-2019-financial-results-apvo-20191107monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-provides-corporate-and-pipeline-update-apvo-20191003monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-introduces-new-adaptir-bispecific-antibody-candidate-intended-for-the--apvo-20190919monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-second-quarter-2019-financial-results-apvo-20190809monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-receives-4-3-million-milestone-payment-from-saol-international-limited-apvo-20190807monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-continued-progress-in-apvo210-and-apvo436-clinical-trials-apvo-20190725monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-launches-new-3000-iu-ixinity-assay-offering-enhanced-user-experience-a-apvo-20190625monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-first-quarter-2019-financial-results-apvo-20190509monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-ixinity-and-pipeline-progress-apvo-20190415monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-presents-new-preclinical-data-for-apvo436-and-alg-apv-527-at-the-ameri-apvo-20190402monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-to-present-new-preclinical-data-for-apvo436-and-alg-apv-527-at-the-ame-apvo-20190325monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-begins-phase-1-clinical-trial-of-apvo210-a-novel-bispecific-antibody-f-apvo-20190320monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-2018-financial-results-and-provides-business-update-apvo-20190318monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-announces-pricing-of-22-million-offering-of-common-stock-and-warrants-apvo-20190307monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-announces-proposed-public-offering-of-common-stock-and-warrants-apvo-20190306monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-highlights-key-2019-priorities-apvo-20190107monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-collects-3-3-million-in-escrow-funds-from-saol-therapeutics-apvo-20190103monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-announces-up-to-35-million-common-stock-purchase-agreement-with-lincol-apvo-20181221monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-doses-first-patient-in-phase-1-1b-clinical-trial-of-lead-next-generati-apvo-20181213monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-to-present-at-the-30th-annual-piper-jaffray-healthcare-conference-apvo-20181120monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-third-quarter-2018-financial-results-apvo-20181114monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-announces-expanded-growth-initiatives-for-ixinity-apvo-20181024monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-to-present-at-the-ladenburg-thalmann-2018-healthcare-conference-apvo-20180925monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-second-quarter-2018-financial-results-apvo-20180809monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-revises-term-loan-agreement-with-midcap-financial-reduces-cash-require-apvo-20180807monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-first-quarter-2018-financial-results-apvo-20180510monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-announces-ind-submission-for-apvo436-apvo-20180501monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-bispecific-antibody-apvo436-shows-robust-t-cell-activation-with-minima-apvo-20180416monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-2017-financial-results-and-provides-business-update-apvo-20180313monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-presents-new-patient-reported-data-with-ixinity-apvo-20180312monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-to-present-at-the-30th-annual-roth-conference-apvo-20180227monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-begins-patient-dosing-in-phase-2-clinical-trial-of-otlertuzumab-in-per-apvo-20180108monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-novel-bispecific-antibody-therapeutic-apvo436-shows-broad-activity-in--apvo-20171211monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-announces-plans-to-conduct-phase-2-study-of-otlertuzumab-in-peripheral-apvo-20171128monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-to-present-at-the-29th-annual-piper-jaffray-healthcare-conference-apvo-20171114monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-third-quarter-2017-financial-results-apvo-20171109monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-presents-new-preclinical-data-on-apvo436-a-next-generation-adaptir-bis-apvo-20171030monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-showcases-new-mechanism-of-action-for-its-adaptir-platform-at-the-infl-apvo-20171016monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-presents-new-data-on-enhanced-features-of-its-next-generation-adaptir--apvo-20171002monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-extends-cash-runway-20-million-retains-term-loan-agreement-with-midcap-apvo-20170928monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-completes-sale-of-hyperimmune-products-for-up-to-74-5-million-apvo-20170928monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-signs-agreement-for-up-to-74-5-million-to-sell-hyperimmune-commercial--apvo-20170831monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-and-morphosys-end-joint-development-and-commercialization-agreement-fo-apvo-20170831monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-and-alligator-bioscience-commence-ind-enabling-development-activities--apvo-20170817monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-second-quarter-2017-financial-results-apvo-20170810monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-and-alligator-bioscience-announce-plans-to-co-develop-novel-bispecific-apvo-20170720monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-highlights-key-features-of-its-adaptir-protein-therapeutic-platform-at-apvo-20170607monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-first-quarter-2017-financial-results-apvo-20170512monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-presents-detailed-overview-of-its-adaptir-protein-therapeutic-platform-apvo-20170505monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-presents-new-clinical-data-evaluating-the-safety-and-efficacy-of-ixini-apvo-20170410monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-next-generation-adaptir-bispecific-antibody-candidates-show-potent-imm-apvo-20170403monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-2016-financial-results-and-provides-business-update-apvo-20170331monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-announces-new-ixinity-supply-available-may-2017-apvo-20170315monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-expands-bispecific-antibody-portfolio-apvo-20170314monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-to-present-at-the-29th-annual-roth-conference-apvo-20170306monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-receives-20-million-payment-from-emergent-biosolutions-apvo-20170113monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-presents-data-on-its-adaptir-antibody-platform-at-the-16th-annual-pept-apvo-20170112monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-resumes-ixinity-manufacturing-anticipates-re-entering-the-market-in-th-apvo-20170104monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-announces-publication-of-phase-2-clinical-data-for-otlertuzumab-apvo-20161216monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-amends-collaboration-agreement-with-morphosys-ag-for-novel-immunothera-apvo-20161215monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-to-present-at-the-28th-annual-piper-jaffray-healthcare-conference-apvo-20161123monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-augments-leadership-team-apvo-20160915monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-files-provisional-patent-for-ibogaine-based-therapeutic-targeting-traumatic-br-silo-20260507monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-s-ptsd-program-advances-as-fda-fast-tracks-psychedelic-therapies-for-ptsd-silo-20260429monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-strategic-business-expansion-into-multi-billion-dollar-ai-agent-mark-silo-20260422monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy-silo-20260406monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-share-buyback-program-silo-20260223monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-2-5-million-registered-direct-offering-priced-at-the-market-under-na-silo-20250930monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-signs-strategic-agreement-with-fireblocks-to-advance-crypto-treasury-strategy--silo-20250923monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-secures-australian-patent-covering-licensed-ptsd-drug-candidate-expanding-glob-silo-20250903monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-s-alzheimer-s-candidate-spc-14-featured-in-leading-scientific-peer-reviewed-jo-silo-20250821monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-s-ptsd-candidate-spc-15-achieves-positive-safety-milestone-paving-way-for-acce-silo-20250819monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-appoints-crypto-infrastructure-pioneer-corwin-yu-to-launch-institutional-bitco-silo-20250805monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-completion-of-dosing-in-safety-study-of-ptsd-drug-spc-15-silo-20250716monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-advances-ptsd-drug-spc-15-toward-planned-2025-ind-submission-with-pre-clinical-silo-20250707monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-enters-into-letter-of-intent-to-form-joint-venture-with-hoth-therapeutics-to-d-silo-20250625monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-n-silo-20250611monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-board-of-directors-approves-purchase-of-bitcoin-as-treasury-reserve-asset-silo-20250605monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-partners-with-resyca-for-ind-supporting-intranasal-drug-device-study-of-ptsd-d-silo-20250521monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-closing-of-2-million-public-offering-silo-20250516monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-pricing-of-2-million-public-offering-silo-20250515monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-selects-veloxity-labs-for-bioanalytical-ind-enabling-study-for-our-novel-intra-silo-20250514monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-advances-ptsd-drug-spc-15-toward-first-in-human-trial-with-key-safety-study-in-silo-20250514monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-s-sp-26-ketamine-implant-meets-all-endpoints-in-fibromyalgia-study-silo-20250430monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusivel-silo-20250428monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15--silo-20250326monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-granted-u-s-patent-for-novel-intranasal-post-traumatic-stress-disorder-treatme-silo-20250226monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-inn-silo-20250218monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-positive-initial-pharmacokinetic-safety-and-tolerability-study-of-sp-silo-20250211monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-advances-intellectual-property-portfolio-with-provisional-patent-filing-for-pt-silo-20250122monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-awarded-us-patent-for-groundbreaking-ptsd-treatment-and-prepares-for-spc-15-cl-silo-20250108monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-issues-letter-to-shareholders-detailing-development-progress-and-potential-for-silo-20250102monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-initiates-pharmacokinetic-and-tolerability-study-for-sp-26-targeting-chronic-p-silo-20241218monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-enters-joint-development-agreement-for-sp-26-ketamine-implant-device-targeting-silo-20241129monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-positive-results-for-novel-spc-15-treatment-targeting-stress-related-silo-20241118monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-reports-positive-results-in-sterilization-and-dissolution-testing-of-sp-26-ket-silo-20241031monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-completion-of-fda-pre-ind-meeting-to-advance-development-of-spc-15-f-silo-20240910monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-expands-development-agreement-with-sever-pharma-for-novel-ketamine-implant-the-silo-20240814monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-partnership-with-global-cro-for-central-nervous-system-homing-peptid-silo-20240807monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-to-present-at-h-c-wainwright-annual-global-investment-conference-silo-20240726monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-closing-of-2-1-million-registered-direct-offering-priced-at-the-mark-silo-20240722monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-2-1-million-registered-direct-offering-priced-at-the-market-under-na-silo-20240719monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-and-resyca-bv-partner-on-device-and-cmc-development-for-intranasal-ptsd-drug-s-silo-20240718monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-secures-exclusive-global-license-for-alzheimer-s-therapeutic-silo-20240716monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-exclusive-global-license-for-lead-candidate-spc-15-targeting-ptsd-an-silo-20240708monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-partners-with-amplifybio-to-advance-spc-15-for-ptsd-and-anxiety-silo-20240626monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-successful-production-of-its-sp-26-ketamine-implant-for-fibromyalgia-silo-20240607monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-closing-of-2-million-registered-direct-offering-priced-at-the-market-silo-20240606monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-2-million-registered-direct-offering-priced-at-the-market-under-nasd-silo-20240605monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-submits-pre-investigational-new-drug-application-to-fda-for-spc-15-as-a-treatm-silo-20240604monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-positive-results-from-study-for-depression-treatment-remission-and-r-silo-20240521monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-to-participate-in-fda-meeting-exploring-emerging-therapeutic-interest-in-ketam-silo-20240514monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-positive-results-for-intranasal-ptsd-treatment-silo-20240423monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-set-to-acquire-exclusive-licensing-for-promising-alzheimer-s-disease-therapeut-silo-20240410monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-exercises-option-for-exclusive-license-agreement-for-first-in-class-ptsd-and-s-silo-20240320monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-files-patent-for-groundbreaking-ketamine-implant-therapeutic-to-target-fibromy-silo-20240318monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-completes-successful-dose-ranging-study-of-spc-15-intranasal-therapeutic-for-p-silo-20240228monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-s-sp-26-ketamine-implant-demonstrates-successful-drug-delivery-silo-20240214monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-pipeline-prioritization-for-2024-targeting-mental-health-chronic-pai-silo-20240201monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-positive-results-in-alzheimer-s-disease-study-silo-20240124monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-successfully-completes-first-phase-of-dose-ranging-study-of-spc-15-an-intranas-silo-20240104monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-and-partner-receive-regulatory-approval-to-begin-development-of-ketamine-impla-silo-20231228monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-enters-into-exclusive-license-agreement-with-medspray-pharma-bv-for-intranasal-silo-20231121monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-to-initiate-dose-ranging-study-of-novel-intranasal-therapeutic-spc-15-for-the--silo-20231108monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-s-spu-21-peptide-shows-positive-results-against-rheumatoid-arthritis-silo-20231016monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-initiates-human-factor-study-of-spc-15-for-the-treatment-of-ptsd-silo-20231011monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-positive-data-on-spc-15-for-ptsd-and-prepares-to-file-pre-investigat-silo-20230920monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-initiates-feasibility-study-of-spc-15-novel-intranasal-formulation-for-ptsd-silo-20230912monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-engages-clarivate-for-intellectual-property-and-patent-management-silo-20230810monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-reaches-positive-milestone-with-nasal-formulation-of-spc-15-for-anxiety-ptsd-a-silo-20230808monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-s-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent-silo-20230621monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-signs-agreement-to-develop-first-in-class-ketamine-implant-therapeutic-silo-20230613monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-participation-on-webull-corporate-communications-service-platform-silo-20230602monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-commences-study-of-novel-joint-homing-peptide-spu-21-silo-20230530monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-s-spc-15-awarded-u-s-patent-protecting-ongoing-r-d-of-therapeutic-for-stress-i-silo-20230509monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-to-present-at-psychedelic-drug-development-conference-silo-20230424monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-dis-silo-20230419monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-filing-of-patent-for-treatment-of-fibromyalgia-silo-20230327monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-positive-results-from-ind-enabling-study-of-sp-26-for-fibromyalgia-silo-20230315monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-filing-of-patent-for-treatment-of-alzheimer-s-silo-20230213monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-expansion-of-intellectual-property-portfolio-silo-20230202monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-stock-repurchase-program-silo-20230131monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-advances-clinical-study-analyzing-effects-of-psilocybin-on-inflammation-silo-20230110monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-positive-study-results-of-spu-21-for-arthritis-silo-20221230monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-issues-letter-to-shareholders-detailing-progress-on-pipeline-assets-combining--silo-20221201monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-initiates-study-of-novel-joint-homing-peptide-in-human-tissue-silo-20221121monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-achieves-new-milestone-for-sp-26-therapeutic-initiates-ind-enabling-study-of-t-silo-20221111monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-to-discuss-mainstream-pharma-and-psychedelics-at-wonderland-miami-conference-silo-20221026monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-data-supporting-therapeutic-potential-of-spc-14-for-alzheimer-s-dise-silo-20221020monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-extends-research-pact-for-alzheimer-s-and-stress-induced-anxiety-therapeutics-silo-20221018monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-initiates-toxicity-study-of-its-proprietary-ketamine-formulation-for-treatment-silo-20221010monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-to-present-at-the-dawson-james-small-cap-growth-conference-on-october-12-silo-20221006monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-initiates-fda-pre-investigational-new-drug-ind-package-for-time-released-ketam-silo-20221003monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-closing-of-5-75-million-public-offering-of-common-stock-nasdaq-listi-silo-20220930monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-uplisting-to-nasdaq-capital-market-and-pricing-of-5-million-public-o-silo-20220927monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-implementation-of-1-for-50-reverse-stock-split-in-preparation-for-pl-silo-20220915monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-positive-results-from-its-topically-administered-formulation-of-keta-silo-20220727monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-positive-results-in-subcutaneous-delivery-of-its-novel-liposomes-to--silo-20220712monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-expands-license-agreement-and-patent-portfolio-silo-20220623monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-successful-dosing-of-patients-suffering-from-parkinson-s-disease-in--silo-20220519monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-produces-spu-21-liposomes-for-rheumatoid-arthritis-study-silo-20220420monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-enters-into-agreement-with-contract-research-organization-for-pharmacokinetic--silo-20220331monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-extends-exclusive-option-agreement-for-homing-peptides-silo-20220203monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-inc-engages-donohoe-advisory-to-assist-with-its-efforts-to-obtain-a-listing-on-silo-20211214monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-grant-of-u-s-patent-for-its-novel-cns-homing-peptide-silo-20211202monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-and-strategic-partner-zylo-therapeutics-begin-development-process-for-novel-ke-silo-20211118monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-reports-third-quarter-results-and-operating-highlights-silo-20211111monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-enters-into-sponsored-research-agreement-with-columbia-university-to-develop-p-silo-20211027monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-achieves-milestone-partner-zylo-therapeutics-receive-dea-approval-to-advance-s-silo-20211007monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-advances-psychedelic-patent-portfolio-silo-20210825monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-that-jv-partner-zylo-therapeutics-successfully-completes-initial-ins-silo-20210811monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-awarded-notice-of-allowance-from-united-states-patent-and-trademark-office-for-silo-20210727monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-to-appear-on-national-media-broadcast-on-psychedelics-silo-20210721monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-enters-into-sponsored-research-agreement-with-the-university-of-maryland-balti-silo-20210712monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-extends-agreement-for-experimental-rheumatoid-arthritis-nanoparticle-homing-pe-silo-20210707monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-collaboration-with-university-california-san-francisco-to-study-psil-silo-20210608monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-submits-application-for-nasdaq-up-listing-silo-20210525monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-silo-20210513monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-silo-and-zylo-therapeutics-inc-zti-enter-into-joint-venture-agreement-to-focus-silo-20210428monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-silo-announces-plans-to-uplist-to-the-nasdaq-silo-20210422monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-finalizes-sublicense-deal-for-its-targeted-psilocybin-cancer-therapeutic-techn-silo-20210407monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-inc-enters-into-an-exclusive-option-agreement-with-the-university-of-maryland--silo-20210304monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-to-present-at-proactive-s-one2one-virtual-investor-forum-silo-20210223monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-licenses-novel-peptide-guided-drug-delivery-approach-for-the-treatment-of-ms-silo-20210218monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-private-placement-of-equity-definitive-agreement-for-4-275-million-i-silo-20210210monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-reaches-terms-with-university-of-maryland-baltimore-for-exclusive-license-of-c-silo-20210126monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-to-participate-in-virtual-conference-on-investing-in-psychedelics-silo-20210119monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-enters-into-sponsored-research-agreement-for-potential-multiple-sclerosis-trea-silo-20210113monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-provides-details-of-patent-license-agreement-for-psilocybin-and-cancer-applica-silo-20210111monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-silo-20210106monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-inc-enhances-scientific-advisory-board-with-appointment-of-dr-charles-b-nemero-silo-20201215monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-inc-expands-scientific-advisory-board-with-appointment-of-dr-peter-hendricks-o-silo-20201207monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-comments-on-recent-promotional-and-trading-activities-at-request-of-otc-market-silo-20201204monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-inc-expands-scientific-advisory-board-with-the-appointment-of-dr-joshua-woolle-silo-20201116monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-inc-announces-filing-of-three-u-s-provisional-patent-applications-silo-20201112monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-inc-launches-scientific-advisory-board-with-appointment-of-dr-matthew-johnson--silo-20201109monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-inc-silo-announces-successful-uplisting-to-the-otcqb-venture-market-silo-20201014monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-inc-enters-into-option-agreement-with-university-of-maryland-baltimore-for-cen-silo-20201013monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-phase-1-clinical-trial-initiation-rnaz-20240815monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-inc-announces-closing-of-public-offering-rnaz-20240724monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-inc-announces-pricing-of-public-offering-rnaz-20240723monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-inc-announces-proposed-public-offering-of-common-stock-rnaz-20240722monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reports-positive-data-from-first-in-human-clinical-study-using-nove-rnaz-20240529monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-open-letter-to-shareholders-rnaz-20240513monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-fda-clearance-to-initiate-phase-1-2-clinical-trial-with-t-rnaz-20240415monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reports-2023-results-provides-business-update-rnaz-20240403monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-appointment-of-daniel-vlock-m-d-as-chief-medical-officer-rnaz-20240328monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-and-akribion-genomics-report-progress-developing-crispr-derived-tec-rnaz-20240311monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-to-present-at-2024-rna-leaders-europe-congress-rnaz-20240306monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reports-publication-of-united-states-patent-application-covering-tr-rnaz-20240220monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-and-debiopharm-announce-collaboration-to-develop-targeted-nucleic-a-rnaz-20240129monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-closing-of-7-25-million-public-offering-rnaz-20240122monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-pricing-of-7-25-million-public-offering-rnaz-20240118monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reports-further-restructuring-to-reduce-expenses-and-increased-focu-rnaz-20240112monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-1-for-40-reverse-stock-split-rnaz-20240111monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-publishes-open-letter-outlining-company-s-progress-and-objectives-rnaz-20240104monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reports-positive-pre-clinical-results-in-metastatic-pancreatic-canc-rnaz-20231212monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-to-present-phase-0-data-at-2023-san-antonio-breast-cancer-symposium-rnaz-20231205monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-closing-of-1-2-million-registered-direct-offering-of-comm-rnaz-20231204monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-1-2-million-registered-direct-offering-of-common-stock-pr-rnaz-20231130monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reports-third-quarter-2023-results-provides-business-update-rnaz-20231114monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-withdraws-public-offering-rnaz-20231030monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-public-offering-of-common-stock-rnaz-20231026monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-prolonged-survival-in-murine-models-with-glioblastoma-tre-rnaz-20231026monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-preliminary-clinical-results-in-first-patient-in-phase-0--rnaz-20231024monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reports-successful-treatment-of-preclinical-melanoma-tumors-with-it-rnaz-20231016monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-closing-of-8-5-million-public-offering-rnaz-20230928monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-pricing-of-8-million-public-offering-rnaz-20230926monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-positive-pre-clinical-glioblastoma-results-with-lead-ther-rnaz-20230925monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-first-subject-dosed-with-radiolabeled-ttx-mc138-in-first--rnaz-20230823monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reports-second-quarter-2023-results-provides-business-update-rnaz-20230814monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-positive-results-in-non-human-primates-with-its-lead-ther-rnaz-20230731monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-ceo-letter-to-shareholders-rnaz-20230705monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-publication-of-new-data-supporting-the-use-of-ttx-mc138-f-rnaz-20230622monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-closing-of-7-million-public-offering-rnaz-20230609monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-pricing-of-7-million-public-offering-rnaz-20230606monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reports-positive-preclinical-results-with-its-lead-candidate-ttx-mc-rnaz-20230606monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-1-for-20-reverse-stock-split-rnaz-20230522monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-irb-approval-for-fda-cleared-first-in-human-clinical-tria-rnaz-20230427monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-strategic-expansion-of-its-product-portfolio-rnaz-20230426monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-equity-investment-from-white-lion-capital-to-help-fund-de-rnaz-20230414monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-to-present-at-aacr-annual-meeting-2023-rnaz-20230406monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-receives-notice-of-award-from-national-institutes-of-health-nih-for-rnaz-20230405monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-termination-of-previously-announced-sale-of-series-a-pref-rnaz-20230405monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-agreement-with-triton-funds-for-sale-of-series-a-converti-rnaz-20230403monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reports-2022-results-provides-business-update-rnaz-20230331monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-orphan-drug-designation-status-for-ttx-mc138-for-treatmen-rnaz-20230228monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-and-brain-biotech-join-forces-to-develop-a-crispr-derived-technolog-rnaz-20230222monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-closing-of-1-5-million-registered-direct-offering-of-comm-rnaz-20230217monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-1-5-million-registered-direct-offering-of-common-stock-pr-rnaz-20230216monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reports-positive-preclinical-results-with-its-immunotherapy-candida-rnaz-20230131monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-fda-authorization-to-proceed-with-first-in-human-clinical-rnaz-20221229monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-withdrawal-of-registration-statement-rnaz-20221206monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-eind-submission-to-us-fda-for-planned-first-in-human-clin-rnaz-20221130monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reports-third-quarter-2022-results-provides-business-update-rnaz-20221114monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reports-positive-preclinical-results-with-its-immunotherapy-candida-rnaz-20221109monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-to-present-at-sidoti-virtual-investor-conference-rnaz-20221107monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reports-positive-preclinical-results-with-its-lead-candidate-ttx-mc-rnaz-20221026monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-publication-of-feline-case-study-in-frontiers-in-oncology-rnaz-20221013monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-to-participate-at-the-chardan-6th-annual-genetic-medicines-conferen-rnaz-20220927monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-appoints-microrna-pioneer-dr-frank-slack-to-its-advisory-board-rnaz-20220908monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reports-second-quarter-2022-results-provides-business-update-rnaz-20220815monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-and-md-anderson-announce-strategic-alliance-to-advance-rna-therapie-rnaz-20220802monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-expansion-of-global-rna-oncology-patent-portfolio-rnaz-20220711monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-to-participate-at-bio-international-convention-rnaz-20220609monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-receives-national-institutes-of-health-nih-notice-of-award-rnaz-20220601monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-to-participate-at-h-c-wainwright-global-investment-conference-rnaz-20220520monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-acquires-option-for-radiotheranostic-technology-rnaz-20220519monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reports-first-quarter-2022-results-provides-business-update-rnaz-20220516monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-cto-dr-zdravka-medarova-to-moderate-7th-annual-rna-medicine-symposi-rnaz-20220413monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reports-2021-results-provides-business-update-rnaz-20220331monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-interview-to-air-on-bloomberg-u-s-on-the-redchip-money-report-rnaz-20220325monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-article-published-in-the-journal-cancers-detailing-the-po-rnaz-20220323monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-expansion-of-global-rna-oncology-patent-portfolio-rnaz-20220214monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-to-present-at-2020-bio-ceo-investor-conference-rnaz-20220210monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-to-participate-at-h-c-wainwright-bioconnect-conference-rnaz-20220106monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-to-participate-at-medinvest-oncology-investor-conference-rnaz-20211207monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-inc-nasdaq-sngx-to-ring-the-nasdaq-stock-market-closing-bell-sngx-20170830monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-develops-defenses-against-bioterrorism-sngx-20160616monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-inc-s-ceo-dr-christopher-schaber-interviewed-by-the-life-sciences-report-sngx-20160428monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-inc-s-ceo-christopher-schaber-interviewed-by-the-life-sciences-report-sngx-20150409monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-presents-phase-2-ozuriftamab-vedotin-oz-v-clinical-trial-data-demonstrating-compel-bcab-20250602monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-reports-first-quarter-2025-financial-results-and-highlights-recent-progress-bcab-20250506monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-participate-in-the-citizens-life-sciences-conference-bcab-20250430monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-announce-first-quarter-2025-financial-results-and-provide-business-highlights-o-bcab-20250429monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-poster-presentations-at-the-2025-american-association-for-cancer-researc-bcab-20250424monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-upcoming-poster-presentation-at-the-2025-american-society-of-clinical-on-bcab-20250423monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-reports-fourth-quarter-and-full-year-2024-financial-results-and-highlights-recent--bcab-20250327monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-two-poster-presentations-at-upcoming-medical-meetings-bcab-20250320monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-provide-busine-bcab-20250319monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-inc-announces-registered-direct-offering-to-advance-two-mid-stage-clinical-program-bcab-20241220monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-presented-data-characterizing-mutated-kras-genotype-and-clinical-outcomes-in-patie-bcab-20241216monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-upcoming-poster-presentation-at-the-iaslc-2024-hot-topic-in-basic-transl-bcab-20241210monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-reports-third-quarter-2024-financial-results-and-highlights-recent-progress-bcab-20241107monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-announce-third-quarter-2024-financial-results-and-provide-business-highlights-o-bcab-20241031monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-upcoming-poster-presentation-at-the-39th-society-for-immunotherapy-of-ca-bcab-20241004monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-upcoming-oral-presentation-at-the-society-for-melanoma-research-21st-int-bcab-20241001monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-and-context-therapeutics-announce-exclusive-worldwide-license-agreement-to-develop-bcab-20240923monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-presented-phase-2-ozuriftamab-vedotin-clinical-trial-data-demonstrating-meaningful-bcab-20240916monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-upcoming-poster-presentation-at-the-2024-european-society-for-medical-on-bcab-20240909monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-participate-in-the-h-c-wainwright-26th-annual-global-investment-conference-bcab-20240828monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-reports-second-quarter-2024-financial-results-and-highlights-recent-progress-bcab-20240808monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-announce-second-quarter-2024-financial-results-and-provide-business-highlights--bcab-20240801monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-highlighted-clinical-program-and-pipeline-updates-at-virtual-r-d-day-bcab-20240725monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-granted-fda-fast-track-designation-for-ozuriftamab-vedotin-cab-ror2-adc-for-treatm-bcab-20240723monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-host-virtual-r-d-day-on-clinical-program-and-pipeline-updates-on-july-25-2024-bcab-20240627monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-participate-in-the-jefferies-global-healthcare-conference-bcab-20240529monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-presenting-phase-1-evalstotug-clinical-trial-data-demonstrating-clinical-benefit-a-bcab-20240523monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-reports-first-quarter-2024-financial-results-and-highlights-recent-progress-bcab-20240514monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-participate-in-the-citizens-jmp-life-sciences-conference-bcab-20240508monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-announce-first-quarter-2024-financial-results-and-provide-business-highlights-o-bcab-20240507monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-fda-clearance-of-investigational-new-drug-application-for-ba3361-a-cab-n-bcab-20240506monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-upcoming-poster-presentation-at-the-2024-american-society-of-clinical-on-bcab-20240424monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-reports-fourth-quarter-and-full-year-2023-financial-results-and-highlights-recent--bcab-20240326monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-announce-fourth-quarter-and-full-year-2023-financial-results-and-provide-busine-bcab-20240319monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-poster-presentations-at-the-2024-american-association-for-cancer-researc-bcab-20240307monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-participate-in-the-42nd-annual-j-p-morgan-healthcare-conference-bcab-20231220monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-hosting-virtual-r-d-day-to-highlight-ba3071-cab-ctla-4-phase-1-data-in-multiple-so-bcab-20231213monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-host-virtual-r-d-day-to-review-ba3071-cab-ctla-4-phase-1-data-in-multiple-solid-bcab-20231206monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-presented-phase-2-clinical-trial-data-at-the-iaslc-2023-north-america-conference-o-bcab-20231205monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-participate-in-the-jmp-securities-hematology-and-oncology-summit-bcab-20231130monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-host-virtual-kol-event-to-review-iaslc-data-on-ba3011-in-nsclc-bcab-20231128monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-reports-third-quarter-2023-financial-results-and-highlights-recent-progress-bcab-20231107monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-participate-in-the-jefferies-london-healthcare-conference-bcab-20231106monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-s-jay-m-short-ph-d-selected-for-the-explorers-club-lowell-thomas-award-bcab-20231012monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-provides-guidance-on-near-term-milestones-and-plans-to-announce-third-quarter-2023-bcab-20231010monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference-bcab-20230906monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-participate-in-upcoming-investor-conferences-in-august-bcab-20230803monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-reports-second-quarter-2023-financial-results-and-highlights-recent-progress-bcab-20230801monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-announce-second-quarter-2023-financial-results-and-provide-business-highlights--bcab-20230725monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-added-to-membership-of-u-s-small-cap-russell-2000-index-bcab-20230626monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-participate-in-the-jefferies-healthcare-conference-bcab-20230531monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-reports-first-quarter-2023-financial-results-and-highlights-recent-progress-bcab-20230511monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-participate-in-the-jmp-securities-life-sciences-conference-bcab-20230508monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-o-bcab-20230504monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-reports-fourth-quarter-and-full-year-2022-financial-results-and-highlights-recent--bcab-20230323monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-announce-fourth-quarter-and-full-year-2022-financial-results-and-provide-busine-bcab-20230316monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-change-in-executive-leadership-bcab-20230227monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-fda-clearance-of-investigational-new-drug-application-for-ba3182-a-cab-e-bcab-20230223monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-provides-clinical-program-updates-and-upcoming-2023-milestones-bcab-20230110monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-participate-in-the-41st-annual-j-p-morgan-healthcare-conference-bcab-20221222monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-participate-in-the-jefferies-london-healthcare-conference-bcab-20221108monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-65-million-underwritten-offering-of-its-common-stock-bcab-20221104monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-reports-third-quarter-2022-financial-results-and-highlights-recent-progress-bcab-20221103monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-o-bcab-20221027monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-reports-second-quarter-2022-financial-results-and-highlights-recent-progress-bcab-20220809monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-participate-in-the-2022-btig-biotechnology-conference-bcab-20220803monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-announce-second-quarter-2022-financial-results-and-provide-business-highlights--bcab-20220802monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-participate-in-2022-jefferies-global-healthcare-conference-bcab-20220601monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-reports-first-quarter-2022-financial-results-and-highlights-recent-progress-bcab-20220504monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-to-announce-first-quarter-2022-financial-results-and-provide-business-highlights-o-bcab-20220408monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-and-beigene-form-worldwide-collaboration-to-develop-and-commercialize-novel-condit-bcab-20190409monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-ceo-issues-letter-to-shareholders-fblg-20260505monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-reports-q1-2026-financial-results-and-provides-corporate-update-fblg-20260430monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-presents-novel-thymus-organoid-platform-to-combat-age-related-immune-declin-fblg-20260410monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-to-present-at-9th-annual-bfc-global-healthcare-business-development-and-inv-fblg-20260106monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-announces-closing-of-1-7-million-registered-direct-offering-priced-at-the-m-fblg-20251216monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-announces-closing-of-1-5-million-registered-direct-offering-priced-at-the-m-fblg-20251125monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-announces-1-5-million-registered-direct-offering-priced-at-the-market-under-fblg-20251124monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-announces-closing-of-4-million-registered-direct-offering-priced-at-the-mar-fblg-20251120monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-announces-pricing-of-4-million-registered-direct-offering-priced-at-the-mar-fblg-20251119monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-reports-second-quarter-2025-financial-results-and-provides-corporate-update-fblg-20250731monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-to-present-at-the-advanced-wound-care-summit-usa-fblg-20250711monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-confirms-ability-to-manufacture-cybrocell-for-degenerative-disc-disease-and-fblg-20250709monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-to-present-at-exclusive-live-investor-webinar-and-q-a-session-on-july-10-fblg-20250707monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-closes-third-5-million-tranche-of-25-million-financing-fblg-20250616monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-to-present-at-the-bio-international-convention-2025-fblg-20250616monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-appoints-jason-d-davis-cpa-as-chief-financial-officer-fblg-20250609monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-presents-at-the-society-for-investigative-dermatology-annual-meeting-fblg-20250516monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-reports-first-quarter-2025-financial-results-and-provides-corporate-update-fblg-20250514monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-presents-at-the-thymus-2025-meeting-fblg-20250429monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-to-present-at-the-cell-gene-meeting-on-the-mediterranean-fblg-20250411monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-unveils-new-and-expanded-houston-laboratory-space-to-pursue-innovation-and--fblg-20250408monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-announces-scientific-advancement-in-confirmation-results-of-brain-tissue-re-fblg-20250402monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-reports-full-year-2024-financial-results-and-provides-corporate-update-fblg-20250331monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-announces-2025-annual-meeting-of-stockholders-fblg-20250327monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-to-present-at-the-german-nordic-joint-extracellular-matrix-meeting-fblg-20250321monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-files-patent-for-novel-approach-to-modulate-mitochondrial-activity-using-fi-fblg-20250304monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-and-charles-river-announce-completion-and-release-of-cywc628-master-cell-ba-fblg-20250227monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-to-host-in-person-analyst-day-to-provide-research-development-updates-fblg-20250205monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-closes-second-5-million-tranche-of-25-million-financing-fblg-20241230monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-announces-25-million-financing-fblg-20241223monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-files-patent-application-for-a-cell-based-therapeutic-for-the-treatment-of--fblg-20241119monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-files-patent-application-covering-reduction-of-blood-clots-associated-with--fblg-20241114monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-reports-third-quarter-2024-financial-results-and-provides-corporate-update-fblg-20241112monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-announces-updates-for-novel-artificial-thymus-organoid-technology-fblg-20241029monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-to-present-at-the-2024-thinkequity-conference-and-bio-europe-2024-fblg-20241028monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-and-charles-river-announce-collaboration-to-manufacture-fibroblast-cell-bas-fblg-20241018monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-issued-patent-for-fibroblast-delivery-of-tumor-inhibitory-agents-by-the-eur-fblg-20241016monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-to-participate-in-a-fireside-chat-at-2024-maxim-healthcare-virtual-summit-fblg-20241011monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-to-present-at-2024-cell-gene-meeting-on-the-mesa-fblg-20240930monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-engages-southern-star-research-as-cro-in-australia-fblg-20240919monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-announces-filing-of-patent-application-for-generation-of-functional-hematop-fblg-20240912monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-fblg-20240906monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-announces-filing-of-patent-application-for-wound-healing-using-an-adhesive--fblg-20240820monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-files-2024-second-quarter-report-fblg-20240807monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-to-present-at-jonestrading-healthcare-summit-2024-fblg-20240715monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-announces-preliminary-proof-of-concept-for-novel-artificial-thymus-organoid-fblg-20240625monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-set-to-join-russell-2000-index-fblg-20240613monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-to-present-at-extracellular-matrix-pharmacology-congress-2024-fblg-20240606monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-announces-2024-annual-meeting-of-stockholders-fblg-20240515monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-files-2024-first-quarter-report-fblg-20240514monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-to-present-at-the-bio-international-convention-2024-fblg-20240507monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-plans-to-collaborate-with-charles-river-to-manufacture-fibroblast-based-sph-fblg-20240425monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-granted-patent-for-regeneration-of-cartilage-type-cells-by-the-australian-p-fblg-20240411monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-presents-data-from-dermal-fibroblast-spheroid-based-treatment-of-chronic-wo-fblg-20240404monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-files-patent-application-covering-fibroblast-based-technology-for-the-poten-fblg-20240328monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-receives-regulatory-approval-for-biodefense-burn-pit--celz-20260106monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-announces-agreements-for-exercise-of-warrants-for-3-7-celz-20250306monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-announces-mid-term-follow-up-study-data-reporting-sig-celz-20250214monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-reports-positive-one-year-results-for-allostem-type-2-diabetes-celz-20250211monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-expands-collaboration-with-greenstone-biosciences-to--celz-20250205monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-announces-positive-initial-safety-tolerability-and-ef-celz-20250130monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-inc-advances-fda-cleared-adapt-clinical-trial-with-po-celz-20241113monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-initiates-development-of-ai-driven-diagnostic-and-tre-celz-20240724monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-provides-corporate-update-celz-20240710monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-announces-evolutionary-development-of-its-ipscelz-pro-celz-20240624monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-provides-business-update-and-reports-fourth-quarter-and-full-year-2021-ensc-20220331monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-participation-in-the-34th-annual-roth-conference-ensc-20220223monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-appoints-industry-veteran-lee-rauch-to-board-of-directors-ensc-20220208monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-engages-mz-group-to-lead-strategic-investor-relations-and-shareholder--ensc-20220131monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-results-of-special-meeting-of-stockholders-ensc-20220127monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-reminds-stockholders-to-vote-at-upcoming-special-meeting-ensc-20220119monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-first-cohort-dosing-in-bioequivalence-be-study-of-novel-taap-ensc-20220110monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-participation-in-the-h-c-wainwright-bioconnect-conference-ensc-20220105monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-achieves-successful-completion-of-part-a-of-multiple-ascending-dose-ma-ensc-20220104monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-first-patients-enrolled-in-phase-1-study-of-pf614-mpar-its-u-ensc-20211215monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-clinical-trial-progress-of-its-new-class-of-opioids-ensc-20211130monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-reports-third-quarter-2021-financial-results-and-recent-corporate-upda-ensc-20211115monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-completion-of-15-million-convertible-note-financing-ensc-20211108monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-grows-its-management-team-with-appointment-of-dr-linda-pestano-as-chie-ensc-20211026monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-15-million-convertible-note-financing-ensc-20210927monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-treatment-of-first-cohort-for-subjects-in-clinical-study-of--ensc-20210908monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-to-host-satellite-symposium-with-dr-jeffrey-gudin-at-painweek-2021-on--ensc-20210819monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-reports-second-quarter-2021-financial-results-and-recent-corporate-upd-ensc-20210816monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-notice-of-allowance-from-the-u-s-patent-and-trademark-office-ensc-20210805monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-bolsters-management-team-with-appointments-of-david-j-kovacs-as-vp-pub-ensc-20210726monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-to-host-virtual-investor-day-on-july-27-2021-ensc-20210721monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-receives-notice-of-award-for-year-three-of-multi-year-nida-grant-for-t-ensc-20210708monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-to-begin-trading-its-common-stock-on-the-nasdaq-capital-market-on-july-ensc-20210701monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-to-commence-trading-on-the-otc-on-july-1-2021-ensc-20210701monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-closing-of-merger-ensc-20210630monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-covistat-subsidiary-at-home-coronavirus-pill-commencing-to-phase-2-cli-ensc-20210507monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-receives-investigational-new-drug-allowance-for-its-unique-pf614-mpar--ensc-20210429monthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-establishes-center-of-excellence-in-china-to-accelerate-product-development-and-com-gels-20260604monthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-commences-veterinary-medicine-clinical-trial-to-support-an-fda-regulatory-pathway-gels-20260520monthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-announces-usd-3-5-million-strategic-debt-financing-to-accelerate-commercialization--gels-20260512monthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-furthers-asia-presence-through-partnership-with-hong-kong-flag-football-program-gels-20251216monthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-signs-three-year-sales-agreement-with-shenzhen-mana-health-management-co-strengthen-gels-20251209monthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-preclinical-study-demonstrates-enhanced-oral-delivery-of-oil-soluble-and-poorly-sol-gels-20251205monthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-to-present-at-investor-summit-virtual-on-december-9-2025-gels-20251202monthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-announces-positive-preclinical-results-demonstrating-enhanced-bioavailability-using-gels-20251124monthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-appoints-dr-paul-wynne-as-chief-scientific-officer-to-propel-innovative-ingestible--gels-20241219monthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-receives-fda-approval-of-its-suitability-petition-for-new-animal-drug-gels-20241217monthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-to-participate-in-the-benchmark-company-13th-annual-discovery-investor-conference-gels-20241209monthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-announces-largest-u-s-customer-increases-initial-order-by-50-to-meet-growing-market-gels-20241202monthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-announces-400-000-units-enter-into-production-in-november-2024-gels-20241126monthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-expands-operations-in-united-states-with-appointment-of-adam-bendell-as-president-o-gels-20241112monthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-limited-closes-us-5-2-million-initial-public-offering-gels-20241030monthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-limited-prices-us-5-2-million-initial-public-offering-gels-20241029monthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-strengthens-partnership-with-monash-innovation-labs-gels-20240806monthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-granted-first-u-s-patent-for-gel-based-blood-glucose-testing-product-and-methodolog-gels-20210913monthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-appoints-seasoned-pharma-and-tech-executive-james-pekarsky-as-chief-financial-offic-gels-20210722monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-convenes-annual-general-meeting-2026-adxn-20260605monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-spin-out-neurosterix-has-started-a-phase-1-clinical-study-with-m4-pam-ntx-253-for-sc-adxn-20260107monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-reports-2025-third-quarter-financial-results-and-provides-corporate-upd-adxn-20251204monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-report-2025-half-year-and-second-quarter-financial-results-on-septem-adxn-20250926monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-leads-chf-2-million-investment-in-stalicla-to-advance-precision-medicine-in-neuropsy-adxn-20250630monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-reports-q1-2025-financial-results-and-provides-corporate-update-adxn-20250619monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-convenes-annual-general-meeting-2025-adxn-20250603monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-partner-indivior-advances-gabab-positive-allosteric-modulator-program-successfully-t-adxn-20250512monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-enters-option-agreement-with-sinntaxis-for-an-exclusive-license-to-intellectual-prop-adxn-20250430monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-full-year-2024-financial-results-and-provides-corporate-update-adxn-20250425monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-release-full-year-2024-financial-results-and-host-conference-call-on-adxn-20250424monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-regains-rights-to-phase-2-mglu2-pam-asset-adx71149-adxn-20250417monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-2025-swiss-equities-baader-conference-adxn-20250108monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-third-quarter-2024-financial-results-and-provides-corporate-update-adxn-20241122monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-provisional-2024-third-quarter-results-showed-net-loss-compared-to-second-quarter-20-adxn-20241111monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-reports-2024-half-year-and-second-quarter-financial-results-and-provide-adxn-20240930monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-provisional-2024-half-year-and-second-quarter-result-increased-from-a-net-loss-to-a--adxn-20240919monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-participate-in-the-h-c-wainwright-26th-annual-global-investment-conference-adxn-20240904monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-and-indivior-select-clinical-candidates-from-gabab-positive-allosteric-modulator-res-adxn-20240827monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-s-partner-discontinues-adx71149-development-in-epilepsy-adxn-20240722monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-presents-positive-results-from-gabab-pam-cough-program-at-the-thirteenth-london-inte-adxn-20240715monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-thirteenth-london-international-cough-symposium-13th-lics-adxn-20240712monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-shareholders-approve-all-resolutions-at-annual-general-meeting-adxn-20240701monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-reports-q1-2024-financial-results-and-provides-corporate-update-adxn-20240606monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-convenes-annual-general-meeting-2024-adxn-20240605monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-release-q1-2024-financial-results-and-host-conference-call-on-june-6-adxn-20240531monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-bio-quity-europe-2024-adxn-20240508monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-provides-update-on-adx71149-phase-2-epilepsy-study-adxn-20240429monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-swiss-biotech-day-2024-adxn-20240419monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-reports-full-year-2023-financial-results-and-provides-corporate-update-adxn-20240418monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-release-full-year-2023-financial-results-and-host-conference-call-on-adxn-20240411monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-and-perceptive-launch-neurosterix-with-63-million-to-accelerate-development-of-allos-adxn-20240403monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-bio-europe-spring-2024-conference-adxn-20240314monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-enters-into-at-the-market-ads-offering-agreement-with-h-c-wainwright-co-llc-adxn-20240131monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-swiss-equities-baader-conference-adxn-20240109monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-biotech-showcase-2024-adxn-20240105monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-shareholders-approve-all-resolutions-at-extraordinary-general-meeting-adxn-20231220monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-creates-treasury-shares-adxn-20231214monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-q3-2023-financial-results-and-provides-corporate-update-adxn-20231129monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-convenes-extraordinary-general-meeting-adxn-20231128monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-release-third-quarter-2023-financial-results-and-host-conference-cal-adxn-20231123monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-adx71149-epilepsy-phase-2-study-completes-recruitment-of-patients-adxn-20231114monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-regains-nasdaq-listing-compliance-adxn-20231108monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-announces-participation-in-the-bio-europe-2023-conference-adxn-20231102monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-completes-ads-ratio-change-adxn-20231020monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-announces-plan-to-implement-ads-ratio-change-adxn-20231006monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-mglu2-nam-cognition-program-receives-4-million-grant-adxn-20230920monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-announces-participation-in-the-h-c-wainwright-25th-annual-global-investment-conferen-adxn-20230906monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-adx71149-phase-2-epilepsy-study-expected-to-readout-data-in-q2-2024-adxn-20230905monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-s-dipraglurant-development-in-post-stroke-recovery-supported-by-data-published-in-br-adxn-20230904monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-2023-half-year-and-second-quarter-financial-results-and-provides-corporate-u-adxn-20230810monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-release-half-year-2023-financial-results-and-host-conference-call-on-adxn-20230804monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-gabab-positive-allosteric-modulator-program-to-receive-additional-chf2-7-million-fro-adxn-20230803monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-mglu2pam-demonstrates-potential-in-substance-use-disorder-adxn-20230724monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-increases-issued-share-capital-to-create-treasury-shares-adxn-20230615monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-shareholders-approve-all-resolutions-at-annual-general-meeting-adxn-20230601monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency-adxn-20230518monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-q1-2023-financial-results-and-provides-corporate-update-adxn-20230511monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-announces-adx71149-phase-2-epilepsy-clinical-study-s-independent-interim-review-comm-adxn-20230510monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-convenes-annual-general-meeting-2023-adxn-20230505monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-release-q1-2023-financial-results-and-host-conference-call-on-may-11-adxn-20230504monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-completes-5-0-million-equity-financing-adxn-20230405monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-publishes-dipraglurant-data-showing-in-vivo-efficacy-on-motor-and-non-motor-symptoms-adxn-20230404monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-raises-5-0-million-in-equity-financing-adxn-20230403monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-full-year-2022-financial-results-and-provides-corporate-update-adxn-20230330monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-release-full-year-2022-financial-results-and-host-conference-call-on-adxn-20230328monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-announces-upcoming-conferences-it-will-participate-for-h1-2023-adxn-20230316monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-regains-nasdaq-listing-compliance-adxn-20230209monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-strategic-partner-completes-enrollment-in-adx71149-epilepsy-phase-2-study-part-1-adxn-20230206monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-provides-corporate-update-and-financial-guidance-adxn-20230119monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-and-indivior-extend-research-term-of-substance-use-disorder-gabab-positive-allosteri-adxn-20221208monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-q3-2022-financial-results-and-provides-corporate-update-adxn-20221111monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-report-third-quarter-2022-financial-results-and-host-conference-call-adxn-20221103monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency-adxn-20221103monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-increases-issued-share-capital-to-create-treasury-shares-adxn-20221101monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-sachs-associates-22nd-annual-biotech-in-europe-forum-baader-invest-adxn-20220920monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-2022-half-year-and-second-quarter-financial-results-and-provides-corporate-u-adxn-20220818monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-and-indivior-extend-gabab-positive-allosteric-modulator-research-collaboration-for-s-adxn-20220815monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-report-half-year-2022-financial-results-and-host-conference-call-on--adxn-20220812monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-completes-4-2-million-equity-financing-adxn-20220726monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-raises-4-2-million-in-equity-financing-adxn-20220722monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-provides-corporate-update-and-financial-guidance-adxn-20220721monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-completes-reduction-in-nominal-value-of-shares-adxn-20220721monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-terminates-dipraglurant-phase-2b-3-study-in-patients-with-dyskinesia-associated-with-adxn-20220617monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-provides-update-on-dipraglurant-blepharospasm-phase-2-feasibility-clinical-study-adxn-20220527monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-announces-participation-in-the-h-c-wainwright-global-investment-conference-adxn-20220519monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-announces-participation-in-the-22nd-bio-quity-europe-conference-adxn-20220513monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-shareholders-approve-all-resolutions-at-annual-general-meeting-adxn-20220510monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-q1-2022-financial-results-adxn-20220505monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-swiss-biotech-day-2022-adxn-20220428monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-b-riley-securities-neuro-ophthalmology-virtual-investor-conference-adxn-20220425monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-completes-patient-enrollment-for-dipraglurant-blepharospasm-phase-2-cli-adxn-20220413monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-expands-pipeline-with-selective-m4-positive-allosteric-modulator-program-for-the-tre-adxn-20220406monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-convenes-annual-general-meeting-2022-adxn-20220331monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-bio-europe-spring-2022-and-maxim-group-2022-virtual-growth-confere-adxn-20220324monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-full-year-2021-financial-results-and-provides-corporate-update-adxn-20220310monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-release-full-year-2021-financial-results-and-host-conference-call-on-adxn-20220307monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-virtual-sachs-associates-3rd-annual-european-healthtech-and-15th-a-adxn-20220224monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-increases-issued-share-capital-to-create-treasury-shares-adxn-20220203monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-swiss-equities-baader-virtual-conference-adxn-20220111monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-h-c-wainwright-bioconnect-virtual-conference-adxn-20220106monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-raises-10-0-million-in-equity-financing-adxn-20211217monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-provides-year-end-pipeline-development-update-adxn-20211215monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-virtual-german-equity-forum-adxn-20211118monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-h-c-wainwright-7th-annual-israel-virtual-conference-adxn-20211115monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-strategic-partner-successfully-completes-phase-1-in-japan-with-adx71149-adxn-20211115monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-q3-2021-financial-results-and-provides-corporate-update-adxn-20211104monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-release-q3-2021-financial-results-and-host-conference-call-on-novemb-adxn-20211101monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-investors-day-hosted-by-voxia-communication-adxn-20211006monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-10th-international-meeting-on-metabotropic-glutamate-receptors-adxn-20211004monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-cantor-global-healthcare-2021-conference-adxn-20210929monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-initiates-phase-2-clinical-study-with-dipraglurant-in-blepharospasm-adxn-20210929monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference-adxn-20210908monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-swiss-biotech-day-adxn-20210902monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-2021-half-year-and-second-quarter-financial-results-and-provides-corporate-u-adxn-20210805monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-release-half-year-2021-financial-results-and-host-conference-call-on-adxn-20210802monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-appoints-seasoned-pharma-drug-researcher-mikhail-kalinichev-as-head-of-translational-adxn-20210802monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-and-indivior-extend-research-collaboration-on-gabab-positive-allosteric-modulators-i-adxn-20210729monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-present-at-access-to-giving-virtual-conference-on-july-14-2021-adxn-20210707monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-stanford-university-and-university-of-copenhagen-publish-mglu2-structure-in-nature-u-adxn-20210701monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-establishes-at-the-market-ads-equity-sale-program-adxn-20210630monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-initiates-pivotal-phase-2b-3-study-with-dipraglurant-for-dyskinesia-ass-adxn-20210629monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-shareholders-approve-all-resolutions-at-annual-general-meeting-adxn-20210617monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-starts-phase-2-clinical-study-of-adx71149-for-epilepsy-adxn-20210607monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-participate-at-the-benchmark-company-healthcare-house-call-conference-adxn-20210524monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-s-dipraglurant-restores-synaptic-plasticity-in-models-of-dystonia-adxn-20210517monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-convenes-annual-general-meeting-2021-adxn-20210514monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-q1-2021-financial-results-and-provides-corporate-update-adxn-20210505monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-release-q1-2021-financial-results-and-host-conference-call-on-may-5--adxn-20210503monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-increases-issued-share-capital-to-create-treasury-shares-adxn-20210426monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-20th-annual-needham-virtual-healthcare-conference-adxn-20210413monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commiss-adxn-20210408monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-full-year-2020-financial-results-and-provides-corporate-update-adxn-20210311monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-release-full-year-2020-financial-results-and-host-conference-call-on-adxn-20210309monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-h-c-wainwright-global-life-sciences-conference-adxn-20210304monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-provides-trading-update-and-completes-2020-with-strong-cash-position-of-chf18-7-mill-adxn-20210217monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-gabab-positive-allosteric-modulator-demonstrates-promise-in-alcohol-use-disorder-adxn-20210216monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-adx71149-receives-ind-approval-to-start-a-phase-2a-clinical-study-in-epilepsy-adxn-20210121monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-baader-helvea-swiss-equities-conference-adxn-20210112monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-successfully-completes-11-5-million-capital-increase-including-full-exercise-of-unde-adxn-20210111monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-announces-pricing-of-10-0-million-global-offering-adxn-20210107monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-announces-filing-of-registration-statement-for-proposed-public-offering-of-securitie-adxn-20201214monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-q3-2020-financial-results-and-provides-corporate-update-adxn-20201103monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-release-q3-2020-financial-results-and-host-conference-call-on-novemb-adxn-20201102monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-receives-additional-2-8-million-from-indivior-and-extends-gabab-pam-research-collabo-adxn-20201102monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-investora-conference-adxn-20200923monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-participate-at-the-h-c-wainwright-22nd-annual-global-investment-conf-adxn-20200914monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-participate-at-the-biotechgate-digital-partnering-conference-adxn-20200831monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-and-the-sib-swiss-institute-of-bioinformatics-receive-innosuisse-grant-to-repurpose--adxn-20200827monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-2020-half-year-financial-results-and-provides-corporate-update-adxn-20200812monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-release-half-year-2020-financial-results-and-host-conference-call-on-adxn-20200810monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-participate-in-the-btig-virtual-biotechnology-conference-2020-adxn-20200806monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-mglu2-pam-program-to-advance-into-epilepsy-phase-2a-proof-of-concept-clinical-study-adxn-20200616monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-shareholders-approve-all-resolutions-at-annual-general-meeting-adxn-20200610monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-q1-2020-financial-results-and-provides-corporate-update-adxn-20200520monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-establishes-scientific-advisory-board-adxn-20200519monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-2019-full-year-audited-results-and-provides-corporate-update-adxn-20200408monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-report-2019-full-year-audited-results-on-april-8-2020-adxn-20200406monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-delays-start-of-dipraglurant-pivotal-study-and-reporting-2019-full-year-adxn-20200318monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-report-2019-full-year-audited-results-on-march-19-2020-adxn-20200313monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-appoints-prominent-neuroscience-drug-developer-darryle-d-schoepp-phd-as-adxn-20200303monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-present-at-the-cowen-and-company-40th-annual-health-care-conference-adxn-20200226monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-ring-the-nasdaq-stock-market-closing-bell-adxn-20200203monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-starts-trading-american-depositary-shares-on-nasdaq-under-ticker-adxn-adxn-20200129monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-provides-trading-update-and-completes-2019-with-cash-position-of-chf31-5-million-adxn-20200113monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-attend-38th-annual-j-p-morgan-healthcare-conference-adxn-20200108monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-receive-additional-800k-funding-from-indivior-for-gabab-pam-addiction-program-adxn-20191220monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-publicly-files-registration-statement-with-the-u-s-sec-to-facilitate-na-adxn-20191218monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-van-leeuwenhoeck-issues-update-equity-research-report-adxn-20191203monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-attend-jefferies-2019-london-healthcare-conference-adxn-20191113monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-attend-bio-europe-conference-in-hamburg-adxn-20191108monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-receive-additional-funding-from-indivior-for-gabab-pam-addiction-program-adxn-20191008monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-2019-half-year-financial-results-and-provides-corporate-update-adxn-20190930monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-release-half-year-2019-financial-results-and-host-conference-call-on-adxn-20190925monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-submits-registration-statement-with-the-u-s-sec-to-facilitate-nasdaq-li-adxn-20190924monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-led-consortium-receives-4-85-million-eurostars-grant-to-develop-novel-allosteric-mod-adxn-20190709monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-shareholders-approve-all-resolutions-at-annual-general-meeting-adxn-20190620monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-annual-general-meeting-scheduled-for-june-19-2019-adxn-20190528monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-increases-issued-share-capital-and-creates-treasury-shares-adxn-20190520monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-28th-medtech-investing-europe-conference-adxn-20190508monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-during-the-swiss-biotech-day-adxn-20190506monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-2018-full-year-audited-results-and-provides-corporate-update-adxn-20190430monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-announce-2018-full-year-audited-results-on-april-30-2019-adxn-20190429monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-participate-in-the-bioeurope-spring-conference-adxn-20190321monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-cowen-39th-annual-health-care-conference-on-march-13-2019-adxn-20190311monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-trading-update-in-accordance-with-art-53-of-the-six-listing-rules-ad-hoc-publicity-adxn-20190308monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-and-indivior-to-accelerate-additional-gabab-pam-compounds-for-addiction-as-indivior--adxn-20190214monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-trading-update-completes-2018-with-strong-cash-position-adxn-20190107monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-van-leeuwenhoeck-equity-research-report-highlights-deep-pipeline-well-funded-through-adxn-20181122monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-biotech-and-money-inv-tival-showcase-and-participate-in-the-jeffer-adxn-20181112monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-selective-mglu2-pam-adx71149-included-in-review-highlighting-promising-investigative-adxn-20181022monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-sachs-18th-annual-biotech-in-europe-forum-adxn-20181002monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-2018-half-year-financial-results-and-provides-corporate-update-adxn-20180928monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-recognised-in-final-shortlist-for-deal-of-the-year-at-lifestars-awards--adxn-20180925monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-investora-zurich-conference-on-27-september-adxn-20180925monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-adx10061-receives-1-2-million-funding-for-manufacture-and-investigator-led-clinical--adxn-20180920monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-s-selective-mglu2-pam-adx71149-shows-promise-in-treating-severe-panic-disorders-and--adxn-20180904monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-shareholders-approve-all-resolutions-at-annual-general-meeting-adxn-20180621monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-2017-full-year-results-and-provides-corporate-update-adxn-20180430monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-sucessfully-raises-chf40-million-in-capital-increase-adxn-20180329monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-shareholders-approved-all-board-proposals-at-extraordinary-general-meeting-adxn-20180319monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-secures-investor-commitment-for-chf40-million-capital-increase-following-successful--adxn-20180305monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-publishes-extraordinary-general-meeting-invitation-adxn-20180223monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-launches-chf40-million-capital-increase-with-commitment-from-specialist-us-healthcar-adxn-20180215monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-appoints-jean-philippe-rocher-as-co-head-of-discovery-and-member-of-the-executive-ma-adxn-20180207monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-provides-key-financial-indicators-and-trading-update-adxn-20180205monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-equity-research-report-update-issued-by-valuationlab-adxn-20180108monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-and-indivior-sign-strategic-partnership-to-accelerate-development-of-gabab-pams-as-a-adxn-20180103monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-adx71441-program-awarded-5-3-million-grant-from-us-national-institute-o-adxn-20171003monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-reports-first-half-2017-operating-highlights-and-financial-results-adxn-20170926monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-makes-changes-to-executive-management-team-adxn-20170918monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-shareholders-approved-all-board-proposals-at-2017-annual-general-meeting-adxn-20170623monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-annual-general-meeting-scheduled-for-22-june-2017-adxn-20170606monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-increases-issued-share-capital-and-creates-treasury-shares-adxn-20170531monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-adx71441-demonstrates-preclinical-analgesic-effects-adxn-20170509monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-adx71441-preclinical-results-for-treatment-of-alcohol-use-disorder-published-in-jour-adxn-20170504monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-provides-corporate-update-and-reports-2016-financial-results-adxn-20170405monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-raises-chf3-0-million-through-private-placement-of-treasury-shares-and-extends-cash--adxn-20170228monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-s-adx71149-anti-epileptic-effect-highlighted-in-scientific-journal-epilepsia-adxn-20170227monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-s-clinical-programs-and-discovery-platform-highlighted-in-review-of-allosteric-modul-adxn-20170206monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-awarded-835-000-grant-from-michael-j-fox-foundation-to-advance-trkb-pams-for-the-tre-adxn-20170131monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-adx71441-demonstrates-statistically-significant-efficacy-in-a-highly-translational-p-adxn-20170109monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-adx71441-pharmacological-profile-published-in-neuropharmacology-adxn-20161213monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-appoints-biopharmaceutical-industry-veteran-roger-g-mills-m-d-as-chief-medical-offic-adxn-20161128monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-to-conduct-phase-iia-proof-of-concept-study-of-dipraglurant-in-focal-ce-adxn-20161017monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-initiates-new-study-in-collaboration-with-us-national-institute-of-drug-abuse-with-a-adxn-20161011monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-reports-first-half-2016-operating-highlights-and-financial-results-adxn-20160930monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-collaborators-published-new-data-supporting-the-role-of-negative-allosteric-modulato-adxn-20160920monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-adx71441-demonstrates-positive-results-in-highly-translational-preclinical-model-of--adxn-20160727monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-shareholders-approved-all-board-proposals-at-2016-annual-general-meeting-adxn-20160624monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-mglur4-and-mglur7-programs-demonstrate-potential-in-preclinical-models-of-neurodegen-adxn-20160613monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-adx71441-demonstrates-positive-results-in-non-human-primate-model-of-cocaine-addicti-adxn-20160609monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-annual-general-meeting-scheduled-for-23-june-2016-adxn-20160602monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-dipraglurant-positive-phase-2-data-in-pd-lid-published-in-leading-peer-reviewed-jour-adxn-20160602monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-increases-issued-share-capital-and-creates-treasury-shares-adxn-20160530monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-reports-2015-financial-results-adxn-20160429monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-positive-results-of-an-mglu5-receptor-occupancy-study-with-dipraglurant-in-h-adxn-20160411monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-successful-completion-of-an-mglu5-receptor-occupancy-study-with-dipraglurant-adxn-20160315monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-dipraglurant-shows-highly-statistically-significant-anti-dyskinetic-effects-followin-adxn-20160111monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-dipraglurant-receives-orphan-drug-designation-from-the-fda-for-levodopa-induced-dysk-adxn-20160104monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-statistically-significant-positive-interim-data-for-dipraglurant-in-healthy--adxn-20151217monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-and-university-of-geneva-collaborators-awarded-swiss-grant-to-profile-addex-trkb-all-adxn-20151215monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-scientists-publish-new-data-supporting-the-potential-of-mglu4-receptor-positive-allo-adxn-20151209monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-moves-r-d-operations-to-geneva-s-campus-biotech-adxn-20151207monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-adx71441-included-in-the-ninds-anticonvulsant-screening-program-adxn-20151125monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-and-chuv-unil-collaborators-awarded-swiss-grant-to-advance-addex-mglur7-and-mglur4-a-adxn-20151123monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-adx71441-demonstrates-robust-efficacy-in-multiple-preclinical-models-of-alcohol-use--adxn-20151013monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-reports-first-half-2015-financial-results-adxn-20150930monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-adx71149-demonstrates-synergistic-efficacy-with-levetiracetam-in-preclinical-models--adxn-20150923monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-dipraglurant-demonstrates-anxiolytic-and-antidepressant-like-activity-in-multiple-pr-adxn-20150814monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-dipraglurant-dosed-in-first-subject-in-receptor-occupancy-study-in-collaboration-wit-adxn-20150722monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-shareholders-appoint-raymond-hill-and-tim-dyer-to-the-board-of-directors-and-approve-adxn-20150612monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-identifies-new-potential-use-of-mglu7-receptor-nams-to-treat-stress-induced-visceral-adxn-20150603monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-and-prof-pisani-present-dipraglurant-data-in-rare-inherited-forms-of-dystonia-adxn-20150529monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-annual-general-meeting-scheduled-for-11-june-2015-adxn-20150527monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-enters-collaboration-with-prof-pisani-to-explore-the-therapeutic-use-of-dipraglurant-adxn-20150507monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-reports-2014-financial-results-adxn-20150430monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-raises-chf2-8-million-in-a-private-placement-and-extends-cash-runway-through-2017-adxn-20150309monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-initiates-dipraglurant-receptor-occupancy-clinical-study-in-collaboration-with-johns-adxn-20150223monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-mglur2-nam-demonstrates-protection-in-preclinical-model-of-ischemic-neuronal-death-adxn-20150219monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-and-dystonia-medical-research-foundation-announce-partnership-to-explore-the-therape-adxn-20150119monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-completes-2014-with-strong-cash-position-and-provides-2015-strategic-update-adxn-20150109monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-and-niaaa-enter-collaboration-to-evaluate-adx71441-in-alcohol-use-disorder-adxn-20150107monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-amends-mglu2pam-collaboration-agreement-and-receives-usd757-000-adxn-20141217monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-and-the-charcot-marie-tooth-association-enter-collaboration-to-advance-adx71441-in-c-adxn-20141021monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-reports-first-half-2014-financial-results-adxn-20140930monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-adx71441-positive-results-in-preclinical-model-of-nicotine-addiction-adxn-20140710monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-shareholders-approve-all-board-proposals-at-annual-general-meeting-adxn-20140630monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-publishes-annual-general-meeting-agenda-adxn-20140612monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-publishes-annual-reports-2013-adxn-20140530monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-reports-2013-financial-results-adxn-20140430monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-top-line-data-from-adx71149-phase-2a-study-in-patients-with-major-depressive-adxn-20140207monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-and-nida-enter-collaboration-to-advance-adx71441-adx88178-in-drug-abuse-and-addictio-adxn-20131104monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-licensee-completes-enrolment-of-120-patients-in-a-phase-2-clinical-trial-of-adx71149-adxn-20131029monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-adx71441-dose-dependently-reduced-pmp22-expression-comparable-to-baclofen-in-a-pre-c-adxn-20131003monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-first-half-2013-financial-results-adxn-20130917monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-raises-chf3-2-million-in-a-private-placement-to-international-instituti-adxn-20130809monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-completes-restructuring-to-focus-on-capturing-potential-upside-from-its-partnered-as-adxn-20130531monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-announces-steps-to-capture-potential-upside-from-its-partnered-asset-and-preserve-va-adxn-20130528monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-validates-potential-efficacy-biomarker-for-phase-1-trial-of-its-gaba-b-positive-allo-adxn-20130521monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-that-dipragluant-demonstrated-dose-dependent-mglu5-receptor-occupancy-in-a-n-adxn-20130501monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-announces-cfo-tim-dyer-to-transition-to-external-consulting-role-adxn-20130430monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-adx71441-reduces-alcohol-intake-in-a-preclinical-model-of-chronic-alcohol-de-adxn-20130430monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-receives-approval-to-initiate-a-phase-1-first-in-man-clinical-study-for-adx71441-adxn-20130424monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-announces-issuance-of-a-broad-european-composition-of-matter-patent-for-dipraglurant-adxn-20130422monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-dipraglurant-normalizes-striatal-cholinergic-dysfunction-in-a-validated-preclinical--adxn-20130418monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-announces-presentation-of-dipraglurant-phase-2a-study-results-at-the-20-adxn-20130321monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-shareholders-approve-all-board-proposals-at-annual-general-meeting-adxn-20130320monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-awarded-1-mm-grant-from-the-michael-j-fox-foundation-for-parkinson-s-re-adxn-20130319monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-partners-with-viva-biotech-to-advance-allosteric-modulators-targeting-adenosine-2a-r-adxn-20130304monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-reports-2012-financial-results-adxn-20130228monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-focus-resources-on-clinical-pipeline-adxn-20130207monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-dipraglurant-reduces-motor-abnormalities-in-a-preclinical-model-relevant-for-several-adxn-20130129monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-announces-issuance-of-a-broad-us-composition-of-matter-patent-for-adx71441-adxn-20130122monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-announces-positive-data-with-adx71441-in-a-pre-clinical-transgenic-model-of-charcot--adxn-20130107monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-scientists-discover-and-characterize-the-first-potent-and-selective-small-molecule-n-adxn-20121220monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-dipraglurant-named-as-one-of-the-top-10-neuroscience-projects-to-watch-by-windhover--adxn-20121127monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-top-line-data-from-a-successful-phase-2a-clinical-study-with-adx71149-in-sch-adxn-20121105monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-adx71441-reduces-alcohol-intake-in-a-preclinical-model-of-alcohol-binge-drin-adxn-20121029monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-updates-financial-guidance-for-2012-adxn-20121024monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-raises-10-million-in-a-private-placement-to-international-institutional-adxn-20121012monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-scientists-present-new-data-on-oral-small-molecule-programs-targeting-gpcr-at-the-so-adxn-20121011monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-and-collaborators-awarded-swiss-cti-grant-to-develop-allosteric-modulators-for-neuro-adxn-20121002monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-mglur4-allosteric-modulator-effective-in-multiple-sclerosis-model-a-novel-oral-small-adxn-20120924monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-partner-doses-first-patient-in-phase-2-clinical-study-of-adx71149-for-the-treatment--adxn-20120917monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-first-half-2012-financial-results-adxn-20120822monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-first-half-2012-financial-results-next-wednesday-adxn-20120820monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-announces-the-publication-of-positive-data-on-the-efficacy-of-mglur4-positive-allost-adxn-20120716monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-appoints-dr-graham-dixon-as-chief-scientific-officer-and-head-of-research-adxn-20120703monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-phase-2a-dipraglurant-data-at-movement-disorder-society-s-international-c-adxn-20120618monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-partner-to-initiate-phase-2-clinical-trial-of-adx71149-for-the-treatment-of-major-de-adxn-20120605monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-shareholders-approve-all-board-proposals-at-annual-general-meeting-adxn-20120509monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-positive-preclinical-data-for-gaba-br-pam-oral-small-molecule-in-overactive--adxn-20120416monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-takes-steps-to-rightsize-operations-and-position-the-company-for-future-success-adxn-20120413monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-positive-top-line-phase-iia-data-for-dipraglurant-in-parkinson-s-disease-lev-adxn-20120321monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-changes-name-to-addex-therapeutics-launches-new-website-and-corporate-branding-adxn-20120321monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-pharmaceuticals-reports-2011-financial-results-adxn-20120223monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-pharmaceuticals-2011-financial-results-this-thursday-adxn-20120221monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-to-present-at-the-bio-ceo-investor-conference-adxn-20120210monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-better-tolerated-formulation-of-adx10059-reduces-acid-reflux-adxn-20080910monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-pharmaceuticals-reports-first-half-2008-financial-results-maiden-profit-adxn-20080728monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-appoints-laurent-galibert-head-of-inflammation-business-unit-adxn-20080728monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-first-half-2008-financial-results-monday-july-28-adxn-20080718monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-pharmaceuticals-starts-phase-i-adx10059-interaction-study-adxn-20080604monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-starts-adx10059-phase-i-formulation-selection-study-adxn-20080424monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-shareholders-elect-ray-hill-to-board-of-directors-at-the-2008-annual-general-meeting-adxn-20080418monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-appoints-laurent-massuyeau-as-head-of-business-development-adxn-20080418monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-pharmaceuticals-r-d-day-on-april-24-adxn-20080328monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-pharmaceuticals-2007-financial-results-adxn-20080226monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-achieves-first-milestone-in-parkinson-s-disease-collaboration-with-merck-co-inc-adxn-20080225monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-full-year-2007-financial-results-next-tuesday-adxn-20080221monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-and-merck-co-inc-enter-license-agreement-to-develop-a-drug-candidate-for-schizophren-adxn-20080103monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-announces-adx10059-phase-iia-acute-anxiety-data-adxn-20080103monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-and-merck-co-inc-collaborate-to-develop-drugs-for-parkinson-s-disease-adxn-20071203monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-webcast-and-conference-call-on-monday-adxn-20071130monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-pharmaceuticals-confirms-extension-of-major-shareholder-lock-up-adxn-20071129monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-presents-adx10059-gerd-data-at-conference-adxn-20071029monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-pharmaceuticals-appoints-head-of-adme-pk-adxn-20070817monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-pharmaceuticals-first-half-2007-financial-results-adxn-20070725monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-first-half-2007-financial-results-next-wednesday-adxn-20070718monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-pharmaceuticals-attracts-venture-funding-from-leading-european-vc-firms-adxn-20020711monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-enrolls-first-patient-in-its-phase-ii-clinical-trial-of-al001-lithium-in-br-alzn-20250519monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-initiates-first-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-tak-alzn-20250513monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-announces-initiation-date-of-phase-ii-clinical-trial-of-al001-for-treatment-alzn-20250311monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-announces-initiation-date-of-phase-ii-clinical-trial-of-al001-for-treatment-alzn-20250304monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-announces-initiation-date-of-first-phase-ii-clinical-trial-of-al001-to-take-alzn-20250225monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-completes-new-management-team-for-2019-alzn-20181226monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-appoints-new-ceo-bio-pharma-executive-stephan-jackman-alzn-20181120monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-secures-new-licenses-from-usf-to-treat-alzheimer-s-disease-alzn-20181029monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-launches-pursuit-to-secure-fda-ind-and-first-stage-clinicals-alzn-20171025monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-announces-tv-icon-willie-aames-as-international-spokesperson-alzn-20170109monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-launches-regulation-a-tier-ii-sec-qualified-offering-alzn-20170103monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-to-present-at-lsi-usa-26-amix-20260311monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-selected-to-present-new-long-term-pain-mitigation-data-in-pancreatic-can-amix-20260219monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-announces-abstract-selected-for-poster-presentation-at-the-2026-amer-amix-20251218monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-announces-pricing-of-5-0-million-private-placement-priced-at-the-mar-amix-20251118monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-reports-positive-subgroup-results-demonstrating-sustained-improvemen-amix-20251117monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-to-participate-in-virtual-investor-webinar-hosted-by-ladenburg-thalm-amix-20250818monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-to-present-at-the-webull-financial-corporate-connect-webinar-series--amix-20250815monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-finalizes-design-review-of-first-ever-intravascular-nerve-sensing-ca-amix-20250814monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-participates-in-the-virtual-investor-what-s-your-story-summer-spotli-amix-20250722monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-exercise-of-warrants-for-2-5-million-gross-proceeds-amix-20250722monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-granted-new-u-s-patent-to-advance-minimally-invasive-nerve-focused-t-amix-20250721monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-announces-release-of-the-next-ceo-corner-segment-amix-20250707monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-treats-first-patient-in-follow-on-market-expansion-phase-poc-2-of-pr-amix-20250630monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-granted-new-u-s-patent-for-innovative-catheter-based-platform-techno-amix-20250627monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-granted-approval-to-expand-proof-of-concept-human-clinical-study-dou-amix-20250605monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-granted-key-u-s-patent-for-innovative-catheter-based-platform-techno-amix-20250515monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-ceo-brad-hauser-to-present-at-virtual-investor-s-closing-bell-event-amix-20250514monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-highlights-compelling-patient-testimonial-showing-rapid-pain-relief-from-first-i-amix-20250505monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-nasdaq-amix-participates-in-virtual-investor-what-this-means-segment-amix-20250501monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-reports-positive-outcomes-in-initial-phase-of-first-in-human-proof-o-amix-20250430monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-technology-and-early-proof-of-concept-study-results-to-be-featured-i-amix-20250424monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-amix-20250417monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-granted-new-european-patent-for-proprietary-catheter-based-technolog-amix-20250416monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-engages-leading-medical-experts-to-guide-u-s-clinical-and-regulatory-amix-20250408monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-to-highlight-technology-and-early-proof-of-concept-study-results-in--amix-20250403monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-amix-20250321monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-granted-u-s-patent-covering-sensing-data-collection-and-processing-w-amix-20250320monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-advances-toward-u-s-clinical-trials-in-2025-with-completed-integrati-amix-20250314monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-announces-abstract-highlighting-technology-and-early-proof-of-concep-amix-20250306monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-nasdaq-amix-to-present-at-the-lsi-usa-25-emerging-medtech-summit-amix-20250226monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-selected-for-podium-presentation-at-the-2025-crt-annual-meeting-amix-20250220monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conferen-amix-20250219monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-reports-third-quarter-fiscal-year-2025-financial-results-and-provide-amix-20250213monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-nasdaq-amix-announces-release-of-the-next-ceo-corner-segment-amix-20250124monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-finalizes-design-of-asic-microchip-for-sensing-technology-catheter-f-amix-20250117monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-nasdaq-amix-to-participate-in-the-virtual-investor-closing-bell-seri-amix-20250115monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-announces-abstract-highlighting-preliminary-positive-clinical-result-amix-20250113monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-announces-u-s-patent-granted-covering-the-treatment-of-cancerous-tum-amix-20241230monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-nasdaq-amix-announces-release-of-the-next-ceo-corner-segment-amix-20241223monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-drives-towards-u-s-pivotal-trial-with-appointment-of-vice-president--amix-20241219monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-achieves-design-lock-for-rf-ablation-catheter-following-successful-c-amix-20241205monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-announces-closing-of-10-0-million-underwritten-public-offering-inclu-amix-20241125monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-announces-pricing-of-9-0-million-underwritten-public-offering-amix-20241122monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-reports-second-quarter-fiscal-year-2025-financial-results-and-provid-amix-20241111monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-reports-new-positive-topline-results-from-first-15-patients-7-day-da-amix-20241031monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-s-dr-robert-schwartz-discusses-what-positive-4-6-week-follow-up-data-amix-20241030monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-to-participate-in-a-virtual-investor-what-this-means-segment-on-wedn-amix-20241025monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-announces-reverse-stock-split-amix-20241022monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-to-participate-in-the-2024-healthcare-virtual-summit-presented-by-ma-amix-20241008monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-nasdaq-amix-announces-release-of-the-next-ceo-corner-segment-amix-20240926monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-selected-to-present-at-the-2024-octane-medical-innovation-forum-amix-20240920monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-announces-83-reduction-of-pain-at-4-6-week-follow-up-from-lead-in-patients-in-on-amix-20240909monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-to-present-at-h-c-wainwright-26th-annual-global-investment-conferenc-amix-20240827monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-announces-abstract-accepted-for-podium-presentation-at-the-2024-cirs-amix-20240821monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-reports-first-quarter-fiscal-year-2025-financial-results-and-reitera-amix-20240813monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-nasdaq-amix-announces-release-of-the-next-ceo-corner-segment-amix-20240802monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-completes-licensing-transaction-for-fda-cleared-ablation-technology-amix-20240724monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-nasdaq-amix-to-participate-in-the-virtual-investor-closing-bell-seri-amix-20240722monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-nasdaq-amix-participates-in-virtual-investor-what-this-means-segment-amix-20240718monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-enters-into-definitive-agreement-to-license-intellectual-property-for-fda-cleare-amix-20240715monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-nasdaq-amix-announces-launch-of-ceo-corner-platform-amix-20240711monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-nasdaq-amix-reviews-positive-results-seen-in-pancreatic-cancer-pain--amix-20240703monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-announces-positive-topline-results-from-first-five-lead-in-patients-in-ongoing-h-amix-20240618monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-enhances-executive-leadership-team-with-appointment-of-proven-medical-technology-amix-20240617monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-to-announce-preliminary-topline-results-from-first-five-lead-in-patients-in-ongo-amix-20240610monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-announces-approval-of-protocol-amendment-by-ethics-committee-upon-completion-of--amix-20240603monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-reports-full-year-2024-financial-results-and-provides-corporate-upda-amix-20240531monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-preclinical-study-successfully-demonstrates-that-nerve-ablation-can-slow-tumor-m-amix-20240523monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-nasdaq-amix-to-participate-in-the-virtual-investor-closing-bell-seri-amix-20240514monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-enters-into-agreement-with-noisefigure-research-inc-to-develop-next-generation-o-amix-20240425monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-to-present-at-live-with-webull-corporate-connect-virtual-biotech-investment-webi-amix-20240424monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-announces-issuance-of-u-s-patent-covering-proprietary-catheter-based-technology--amix-20240416monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-announces-positive-findings-from-preclinical-study-demonstrating-potential-to-im-amix-20240409monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-to-participate-in-the-virtual-investor-lunch-break-the-team-behind-the-amix-tick-amix-20240408monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-to-present-at-the-medinvest-biotech-pharma-investor-conference-amix-20240327monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-nasdaq-amix-to-present-at-the-benzinga-virtual-healthcare-summit-2024-amix-20240320monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-appoints-jennifer-cook-as-chief-business-officer-amix-20240319monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-completes-first-three-patient-procedures-in-human-clinical-trial-targeting-multi-amix-20240314monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-enrolls-first-patients-in-human-clinical-trial-targeting-multi-billion-dollar-pa-amix-20240306monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-signs-key-clinical-agreements-in-preparation-to-begin-march-2024-human-clinical--amix-20240229monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-nasdaq-amix-to-participate-in-the-virtual-investor-lunch-break-the-a-amix-20240223monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-secures-principal-investigators-and-completes-clinical-training-for-first-human--amix-20240222monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-begins-human-poc-clinical-trial-targeting-multi-billion-dollar-pancreatic-cancer-amix-20240216monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-reports-third-quarter-fy2024-financial-results-and-reiterates-upcomi-amix-20240214monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-receives-ethics-committee-authorization-for-proof-of-concept-human-c-amix-20240206monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-nasdaq-amix-to-present-at-the-virtual-investor-new-to-the-street-eve-amix-20240201monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-to-ring-the-nasdaq-stock-market-closing-bell-on-thursday-february-1--amix-20240131monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-completes-8-000-000-transaction-for-exclusive-worldwide-rights-to-te-amix-20240130monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-completes-transaction-for-exclusive-worldwide-rights-to-technology-f-amix-20240130monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-nasdaq-amix-commences-trading-on-nasdaq-amix-20240129monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-announces-closing-of-11-2-million-in-gross-proceeds-from-initial-pub-amix-20240126monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-successfully-completes-preclinical-safety-study-to-support-program-a-amix-20240112monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-completes-formation-of-engineering-development-team-and-provides-pro-amix-20240111monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-to-present-at-the-startup-investing-webinar-amix-20240111monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-provides-business-overview-and-highlights-upcoming-milestones-amix-20240104monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-to-participate-in-the-virtual-investor-fireside-chat-amix-20231214monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-to-present-at-the-virtual-investor-event-titled-a-breakthrough-medic-amix-20231206monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-announces-appointment-of-christopher-c-capelli-m-d-to-board-of-direc-amix-20231116monthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-inc-launches-social-media-channels-amix-20231108monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-provides-business-update-outlining-upcoming-milestones-and-reports-2026-artl-20260514monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-announces-peer-reviewed-publication-supporting-its-fabp5-inhibitor-art26-12-as-a-no-artl-20260420monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-regains-compliance-with-nasdaq-listing-requirements-artl-20260407monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-closing-of-11-0-million-private-placement-priced-at-the-marke-artl-20260330monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-expands-art27-13-development-as-a-potential-companion-therapy-to-glp-1--artl-20260325monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-announces-third-party-fully-funded-clinical-study-agreement-to-evaluate-art27-13-in-artl-20260318monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-reverse-stock-split-artl-20260306monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-bioscience-commends-presidential-executive-order-expanding-cbd-research-and-access--artl-20251223monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-publication-of-new-peer-reviewed-study-demonstrating-intraper-artl-20251203monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-closing-of-3-0-million-public-offering-artl-20250905monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-pricing-of-3-0-million-public-offering-artl-20250904monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-proposed-underwritten-public-offering-artl-20250903monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-affirms-strong-partnering-outlook-for-art27-13-following-positive-inter-artl-20250903monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-positive-interim-phase-2-cares-results-for-the-treatment-of-c-artl-20250903monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-new-data-from-an-initial-food-effect-investigation-with-art26-artl-20250825monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-provides-business-update-and-reports-second-quarter-2025-financial-resu-artl-20250813monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-receives-notice-of-allowance-from-european-patent-office-for-the-patent-artl-20250811monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-9-475-million-at-the-market-private-placement-to-initiate-sol-artl-20250804monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-receives-favorable-uk-mhra-guidance-for-a-phase-1-trial-of-art12-11-the-artl-20250801monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-positive-preclinical-efficacy-data-for-art26-12-in-osteoarthr-artl-20250709monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-positive-preclinical-efficacy-with-art12-11-in-stress-induced-artl-20250707monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-positive-first-in-human-data-for-art26-12-a-novel-non-opioid--artl-20250630monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-1-425-million-at-the-market-private-placement-financing-artl-20250626monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-reverse-stock-split-artl-20250611monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-s-fatty-acid-binding-protein-5-inhibitor-art26-12-compares-favorably-to-naproxen-in-artl-20250605monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-provides-business-update-and-reports-first-quarter-2025-financial-resul-artl-20250513monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-publication-of-new-peer-reviewed-research-demonstrating-art26-artl-20250428monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-novel-scientific-insights-for-art26-12-at-the-4th-ace-drug-d-artl-20250331monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-provides-business-update-and-reports-fiscal-2024-year-end-financial-res-artl-20250303monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-new-data-on-art12-11-tablets-showing-improved-pharmacokinetic-artl-20250214monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-its-new-data-on-art12-11-tablets-compared-to-epidiolex-at-th-artl-20250211monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-successful-completion-of-first-cohort-in-a-phase-1-study-of-a-artl-20250113monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-presentation-of-phase-1-data-with-art27-13-in-cancer-related--artl-20241209monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-key-data-on-three-development-programs-at-the-7th-cannabinoi-artl-20241118monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-promising-new-data-on-novel-non-opioid-treatment-approach-for-artl-20241113monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-third-quarter-2024-financial-results-and-provides-business-upda-artl-20241112monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-acceptance-of-art26-12-into-the-national-institutes-of-health-artl-20241105monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-ceo-to-participate-in-fireside-chat-at-the-maxim-group-virtual-healthca-artl-20241009monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conferen-artl-20240904monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-second-quarter-2024-financial-results-and-provides-business-upd-artl-20240813monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-receives-fda-clearance-of-its-ind-application-for-art26-12-a-selective--artl-20240715monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-presents-comparative-data-from-key-preclinical-studies-on-art12-11-at-t-artl-20240703monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-data-supporting-broad-potential-utility-of-its-fabp-inhibitor-artl-20240702monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-presents-preclinical-data-on-art26-12-in-breast-cancer-induced-bone-pai-artl-20240701monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-presents-important-new-data-on-art26-12-at-the-57th-annual-scientific-m-artl-20240604monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-presents-highly-encouraging-data-towards-developing-a-solid-dosage-form-artl-20240529monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-first-quarter-2024-financial-results-and-provides-business-upda-artl-20240513monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-pharma-partnering-summit-2024-on-may-14th-artl-20240510monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-publication-of-peer-reviewed-article-highlighting-fabp7-as-a--artl-20240423monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-ceo-to-appear-on-benzinga-all-access-on-april-23rd-at-approximately-10--artl-20240422monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-fiscal-2023-year-end-financial-results-and-provides-business-up-artl-20240325monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-selected-as-a-finalist-in-johnson-johnson-s-innovation-challenge-artl-20240312monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-publication-of-new-peer-reviewed-pre-clinical-research-demons-artl-20240123monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-selection-of-worldwide-clinical-trials-as-clinical-research-o-artl-20240108monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-presents-new-preclinical-data-on-art12-11-at-the-4th-annual-med-cannabi-artl-20231205monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-important-new-preclinical-data-on-art12-11-at-the-4th-annual-artl-20231130monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-third-quarter-2023-financial-results-and-provides-business-upda-artl-20231113monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-publication-of-new-peer-reviewed-research-demonstrating-prote-artl-20231109monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-preclinical-data-showcasing-research-on-art26-12-and-art12-1-artl-20231102monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-13th-congress-of-the-european-pain-federation-on-sept-artl-20230913monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-completes-positive-pre-ind-meeting-with-fda-for-art26-12-artl-20230907monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-6th-cannabinoid-derived-drug-development-summit-on-se-artl-20230906monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conferen-artl-20230905monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-second-quarter-2023-financial-results-and-provides-business-upd-artl-20230810monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-new-mechanism-of-action-data-on-art26-12-at-the-gordon-resea-artl-20230719monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-ceo-to-participate-in-the-benzinga-all-access-event-on-july-11-artl-20230710monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-sponsorship-of-the-william-a-devane-early-career-investigator-artl-20230628monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-important-new-data-on-art26-12-demonstrating-positive-effects-artl-20230627monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-superior-preclinical-pharmaceutical-properties-and-efficacy-of--artl-20230626monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-selected-for-oral-presentation-to-report-positive-research-findings-on--artl-20230607monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-first-quarter-2023-financial-results-and-provides-business-upda-artl-20230511monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-initiates-the-phase-2a-portion-of-its-cares-trial-evaluatingart27-13-fo-artl-20230425monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-fiscal-2022-year-end-financial-results-and-provides-business-up-artl-20230331monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-completes-enrollment-of-the-phase-1b-stage-of-its-cares-clinical-trial--artl-20230202monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-sequire-biotechnology-conference-on-february-2nd-artl-20230126monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-third-quarter-2022-financial-results-and-provides-business-upda-artl-20221108monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference-on-sept-artl-20220922monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conferen-artl-20220907monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-positive-pre-clinical-results-with-its-novel-inhibitor-to-fatty-artl-20220816monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-second-quarter-2022-financial-results-and-provides-business-upd-artl-20220809monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-completes-enrollment-of-the-first-three-cohorts-in-its-cares-study-eval-artl-20220719monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-presents-positive-pre-clinical-results-of-art26-12-a-novel-fabp5-inhibi-artl-20220627monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-selected-for-oral-presentation-at-the-32nd-annual-icrs-symposium-in-gal-artl-20220624monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-ld-micro-invitational-xii-on-june-7th-artl-20220601monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-h-c-wainwright-global-investment-conference-on-may-24-artl-20220516monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-first-quarter-2022-financial-results-and-provides-business-upda-artl-20220512monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-positive-pre-clinical-results-for-lead-program-in-cancer-relate-artl-20220413monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-expands-collaboration-with-trinity-college-dublin-to-investigate-cellular-biology-o-artl-20220328monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-participate-in-the-2022-virtual-growth-conference-presented-by-maxim-artl-20220322monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-four-month-2021-financial-results-in-connection-with-its-amende-artl-20220321monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-receives-notice-of-allowance-for-method-of-use-patent-in-the-united-sta-artl-20220302monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-first-quarter-fiscal-year-2022-financial-results-and-provides-b-artl-20220112monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-anticipates-accelerated-clinical-development-for-art27-13-following-its-classificat-artl-20220111monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-leadership-to-participate-on-endocannabinoid-panel-at-the-h-c-wainwrigh-artl-20220110monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-fiscal-2021-year-end-financial-results-and-provides-business-up-artl-20211129monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conferen-artl-20210908monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-publication-of-study-results-comparing-the-pharmacological-ef-artl-20210804monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-third-quarter-fiscal-2021-financial-results-and-provides-busine-artl-20210712monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-2021-ladenburg-thalmann-healthcare-conference-on-july-artl-20210707monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-two-poster-presentations-featured-at-the-31st-annual-icrs-sym-artl-20210622monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-ld-micro-virtual-invitational-xi-on-june-9th-artl-20210602monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-second-quarter-fiscal-2021-financial-results-and-provides-busin-artl-20210413monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-doses-first-patient-in-cares-study-with-art27-13-for-the-treatment-of-c-artl-20210412monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-accepted-into-the-alderley-park-oncology-development-program-for-fabp5--artl-20210319monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-inc-to-present-at-the-q1-virtual-investor-summit-on-march-23rd-artl-20210311monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-appoints-finance-and-healthcare-industry-executive-tamara-a-seymour-to--artl-20210309monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-h-c-wainwright-global-life-sciences-conference-on-mar-artl-20210302monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-positive-pre-clinical-data-associated-with-proprietary-cbd-co-artl-20210217monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-appointment-of-andrew-yates-ph-d-as-senior-vice-president-and-artl-20210216monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-receives-3-0-million-in-net-proceeds-from-exercise-of-warrants-artl-20210208monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-research-collaboration-with-trinity-college-dublin-to-investi-artl-20210202monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-lsx-world-congress-virtual-conference-artl-20210129monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-first-quarter-fiscal-year-2021-financial-results-and-provides-b-artl-20210114monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-h-c-wainwright-bioconnect-2021-conference-artl-20210105monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-files-patent-application-for-new-formulation-of-art27-13-artl-20201209monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-13th-annual-ld-micro-main-event-conference-on-decembe-artl-20201208monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-appointment-of-senior-pharmaceutical-executive-gregory-r-reye-artl-20201202monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-and-university-of-western-ontario-awarded-research-grant-by-mitacs-artl-20201123monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-clinical-trial-authorization-to-commence-cancer-appetite-reco-artl-20201116monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-fourth-quarter-and-fiscal-2020-year-end-financial-results-and-p-artl-20201104monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-files-patent-on-use-of-fatty-acid-binding-protein-5-inhibitors-for-trea-artl-20201021monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-inc-announces-closing-of-7-6-million-underwritten-public-offering-and-f-artl-20201014monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-inc-announces-pricing-of-6-6-million-upsized-underwritten-public-offeri-artl-20201009monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-receives-ethics-approval-to-commence-its-cancer-appetite-recovery-phase-artl-20200929monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-h-c-wainwright-22nd-annual-global-investment-conferen-artl-20200911monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-participate-in-two-keynote-panels-at-3rd-annual-international-cannab-artl-20200910monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-third-quarter-fiscal-year-2020-financial-results-and-provides-b-artl-20200714monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-expands-stony-brook-commercial-license-agreement-for-fabp5-platform-for-artl-20200629monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-participate-in-bio-digital-and-the-investor-summit-conferences-artl-20200603monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-awarded-composition-of-matter-patent-for-novel-cbd-cocrystal-artl-20200512monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-second-quarter-fiscal-year-2020-financial-results-and-provides--artl-20200414monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-biocom-s-10th-annual-global-life-sciences-partnering-conf-artl-20200224monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-nci-grant-of-4-2-million-to-stony-brook-university-to-advance-artl-20200203monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-lsx-world-congress-in-london-artl-20200129monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-first-quarter-fiscal-year-2020-financial-results-and-provides-b-artl-20200114monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-appointment-of-seasoned-finance-and-industry-executive-john-w-artl-20191209monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-fourth-quarter-and-fiscal-year-2019-financial-results-and-provi-artl-20191125monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-publication-of-positive-non-clinical-fatty-acid-binding-prote-artl-20191118monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-annual-investival-showcase-in-london-artl-20191114monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-selection-of-aptus-clinical-ltd-as-clinical-research-organiza-artl-20191029monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-to-present-at-the-dawson-james-securities-5th-annual-small-cap-growth-c-artl-20191022monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-cannabidiol-cbd-studies-referenced-in-september-issue-of-nature-medicin-artl-20190918monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-reports-third-quarter-2019-financial-results-and-provides-corporate-upd-artl-20190715monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-closing-of-8-0-million-public-offering-and-partial-exercise-a-artl-20190625monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-pricing-of-8-0-million-public-offering-and-uplisting-to-nasda-artl-20190621monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-advances-ip-portfolio-with-new-u-s-utility-patent-application-positi-adil-20260429monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-submits-application-to-fda-commissioner-s-national-priority-voucher--adil-20260427monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-successfully-completes-manufacturing-of-demonstration-batch-producti-adil-20260422monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-reports-2025-fiscal-year-financial-results-and-provides-business-upd-adil-20260306monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides-business-u-adil-20251114monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-pricing-of-3-6-million-public-offering-adil-20250617monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-submits-briefing-package-to-guide-upcoming-fda-meeting-adil-20250616monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-advances-toward-phase-3-development-for-ad04-adil-20250611monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-business-u-adil-20250515monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-receives-milestone-payment-from-adovate-following-initiation-of-phas-adil-20250513monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administra-adil-20250508monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-a-warrant-inducement-transaction-for-2-75-million-in-gross-adil-20250502monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-expands-intellectual-property-portfolio-with-new-u-s-patent-granted--adil-20250501monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-reports-2024-fiscal-year-financial-results-and-provides-business-upd-adil-20250304monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-receives-positive-response-from-fda-meeting-regarding-proposed-in-vi-adil-20250225monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-granted-new-u-s-patent-expanding-coverage-of-its-genetic-based-appro-adil-20250219monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-awarded-new-u-s-patent-covering-genotype-specific-treatment-of-opioi-adil-20250212monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-positive-clinical-study-results-from-the-ad04-103-pharmaco-adil-20250129monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-granted-key-u-s-patent-for-the-treatment-of-alcohol-and-drug-depende-adil-20241203monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-positive-topline-results-from-the-ad04-103-pharmacokinetic-adil-20241114monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-business-u-adil-20241113monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-appoints-vinay-shah-as-chief-financial-officer-adil-20241105monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-to-present-at-the-2024-thinkequity-conference-adil-20241023monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-receives-notice-of-allowance-for-u-s-patent-covering-expanded-genoty-adil-20241017monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-commends-the-national-institute-on-alcohol-abuse-and-alcoholism-s-ne-adil-20241015monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-database-lock-in-pharmacokinetics-study-of-ad04-for-the-tr-adil-20240919monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-to-present-at-the-h-c-wainwright-26th-annual-global-investment-confe-adil-20240904monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-reports-second-quarter-2024-financial-results-and-provides-business--adil-20240814monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-signs-agreement-with-boudicca-dx-to-advance-regulatory-strategy-for--adil-20240813monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-last-patient-dosed-in-pharmacokinetics-study-of-ad04-for-t-adil-20240807monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-files-new-patent-application-to-protect-core-assets-and-extend-ip-ex-adil-20240731monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-advances-to-second-cohort-in-pharmacokinetics-study-of-ad04-for-the--adil-20240723monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-publication-in-leading-peer-reviewed-journal-supporting-th-adil-20240620monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-achieves-important-milestone-of-first-patient-dosed-in-pharmacokinet-adil-20240605monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-ceo-to-present-at-the-spring-microcap-rodeo-conference-on-june-6th-adil-20240529monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-business-u-adil-20240515monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-granted-key-patent-from-the-united-states-patent-and-trademark-offic-adil-20240422monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-peer-reviewed-publication-highlighting-promising-safety-da-adil-20240410monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-reports-2023-fiscal-year-financial-results-and-provides-business-upd-adil-20240402monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-exercise-of-warrants-for-3-5-million-gross-proceeds-adil-20240302monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-awarded-new-patent-from-the-united-states-patent-and-trademark-offic-adil-20240228monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-awarded-new-patent-notice-of-allowance-from-the-united-states-patent-adil-20240213monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-announces-appointment-of-tony-goodman-as-chief-operating-officer-adil-20240118monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-receives-final-reimbursement-payment-from-adovate-adil-20231220monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirement-adil-20231129monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-reports-third-quarter-2023-financial-results-and-provides-business-u-adil-20231114monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-chief-medical-officer-and-key-opinion-leaders-to-discuss-new-aspects-adil-20231031monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-closing-of-4-million-private-placement-priced-at-the-marke-adil-20231024monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-4-million-private-placement-priced-at-the-market-under-nas-adil-20231020monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-awarded-notice-of-allowance-for-key-patent-combining-use-of-the-comp-adil-20231019monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-wins-frost-sullivan-s-2023-north-american-precision-medicine-for-add-adil-20231018monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-to-host-a-virtual-key-opinion-leader-webinar-to-discuss-the-unmet-ne-adil-20230928monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-to-present-at-the-h-c-wainwright-25th-annual-global-investment-confe-adil-20230905monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-chief-medical-officer-and-key-opinion-leaders-to-discuss-the-need-fo-adil-20230828monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements-adil-20230823monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-reports-second-quarter-2023-financial-results-and-provides-business--adil-20230821monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-reverse-stock-split-to-regain-compliance-with-nasdaq-s-min-adil-20230804monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-provides-business-update-following-favorable-comments-from-us-and-eu-regulatory-meet-adil-20230711monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-to-present-at-the-2023-jefferies-global-healthcare-conference-on-jun-adil-20230601monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-reports-first-quarter-2023-financial-results-and-provides-business-u-adil-20230512monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-receives-notice-of-exercise-from-adovate-for-the-acquisition-of-purn-adil-20230510monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-reports-2022-fiscal-year-financial-results-and-provides-business-upd-adil-20230330monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-engages-the-keswick-group-to-advance-partnering-activities-for-the-c-adil-20230321monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-to-present-at-the-35th-annual-roth-conference-on-march-14th-adil-20230308monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-provides-update-on-regulatory-strategy-for-ad04-for-treatment-of-alc-adil-20230306monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-schedules-business-update-conference-call-adil-20230302monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-closing-of-0-75-million-at-the-market-registered-direct-of-adil-20230227monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-pricing-of-0-75-million-at-the-market-registered-direct-of-adil-20230224monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-confirms-scheduling-of-meetings-with-fda-and-european-regulatory-age-adil-20230221monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-enters-into-option-agreement-for-sale-of-purnovate-assets-to-adenome-adil-20230201monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides-business-u-adil-20221114monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-positive-in-vivo-data-for-purnovate-s-pnv-5030-as-a-potent-adil-20220926monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-positive-in-vivo-non-clinical-data-with-purnovate-s-pnv-60-adil-20220906monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-names-cary-claiborne-as-chief-executive-officer-adil-20220822monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-provides-business-update-and-reports-second-quarter-2022-financial-r-adil-20220816monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-topline-results-for-onward-phase-3-trial-for-ad04-in-patie-adil-20220720monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-to-announce-topline-results-of-onward-phase-3-trial-for-ad04-in-pati-adil-20220718monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-provides-letter-to-shareholders-from-ceo-william-stilley-adil-20220628monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-database-lock-for-the-onward-phase-3-clinical-trial-adil-20220627monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-awarded-additional-u-s-patent-combining-the-use-of-the-company-s-pro-adil-20220614monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-research-collaboration-with-the-medical-college-of-wiscons-adil-20220519monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-provides-business-update-and-reports-first-quarter-2022-financial-re-adil-20220516monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-research-collaboration-with-uc-san-diego-to-advance-purnov-adil-20220504monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-ceo-to-participate-in-a-fireside-chat-at-the-2022-virtual-growth-con-adil-20220322monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-completion-of-last-patient-last-visit-in-its-onward-phase--adil-20220224monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-closing-of-10-million-financing-adil-20220216monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-pricing-of-10-million-registered-direct-offering-adil-20220211monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-positive-in-vivo-data-for-purnovate-s-pnv-5032-as-a-potent-adil-20220209monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-receives-notice-of-allowance-on-u-s-patent-for-the-treatment-for-opi-adil-20220124monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-to-present-at-the-h-c-wainwright-bioconnect-2022-conference-adil-20220110monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-completes-private-placement-of-common-stock-at-4-00-per-share-adil-20211222monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-announces-cary-j-claiborne-a-renowned-pharmaceutical-executive-and-current-board-mem-adil-20211208monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-positive-pre-clinical-data-for-pnv2-as-a-drug-candidate-fo-adil-20211129monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-private-placement-of-common-stock-at-4-00-per-share-and-ca-adil-20211110monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-schedules-conference-call-to-provide-clinical-update-and-discuss-lat-adil-20211109monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-appoints-renowned-pharmaceutical-executive-cary-j-claiborne-to-board-of-directors-adil-20211103monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-announces-positive-pre-clinical-data-for-purnovate-s-pnv-5030-as-a-drug-candidate-fo-adil-20211021monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-to-present-at-dawson-james-securities-6th-annual-small-cap-growth-co-adil-20211018monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-greater-than-50-of-patients-expected-to-complete-onward-ph-adil-20210930monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-research-collaboration-agreement-with-the-university-of-vi-adil-20210928monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-ceo-william-stilley-invited-to-participate-in-maxim-group-s-virtual-panel-series-con-adil-20210915monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-confe-adil-20210907monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-exceeds-enrollment-target-in-onward-phase-3-trial-of-ad04-for-the-tr-adil-20210831monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-reaches-full-enrollment-target-for-onward-phase-3-trial-of-ad04-for--adil-20210820monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-to-host-conference-call-today-at-11am-eastern-to-provide-clinical-up-adil-20210820monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-schedules-conference-call-to-provide-clinical-update-and-discuss-pos-adil-20210812monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-awarded-u-s-and-international-patents-for-the-treatment-of-alcohol-a-adil-20210810monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-closing-of-5-million-private-placement-priced-at-a-premium-adil-20210805monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-reports-ceo-op-ed-featured-on-nasdaq-com-adil-20210729monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-announces-positive-pre-clinical-data-for-its-adenosine-pain-platform-adil-20210714monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-announces-5-000-000-above-market-private-placement-at-3-00-per-share-adil-20210707monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-joins-russell-microcap-index-adil-20210628monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-provides-regulatory-and-development-update-adil-20210624monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-plans-to-enter-genetic-testing-market-following-allowance-of-u-s-pat-adil-20210622monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-comments-on-article-in-the-atlantic-highlighting-the-second-pandemic-adil-20210607monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-announces-funding-of-management-led-2-100-000-above-market-private-placement-at-3-00-adil-20210603monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-featured-on-multiple-news-broadcasts-nationwide-regarding-the-second-adil-20210518monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-founder-and-chief-medical-officer-dr-bankole-johnson-featured-guest-on-the-black-new-adil-20210317monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-announces-management-led-2-100-000-above-market-private-placement-at-3-00-per-share-adil-20210315monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-schedules-town-hall-to-discuss-positive-updates-regarding-pharmaceutical-pipeline-an-adil-20210226monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-receives-1-425-million-in-net-proceeds-from-exercise-of-warrants-adil-20210226monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-achieves-50-enrollment-in-onward-phase-3-trial-adil-20210225monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-to-file-fast-track-application-for-ad04-with-the-fda-adil-20210223monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-featured-on-cbs-in-san-francisco-adil-20190228monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-closing-of-9-2-million-underwritten-public-offering-and-ex-adil-20190226monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-pricing-of-8-0-million-underwritten-public-offering-adil-20190221monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-partnership-with-catalent-to-package-and-distribute-adial--adil-20190220monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-submits-continuation-patent-application-for-use-of-ad04-in-opioid-de-adil-20190215monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-appoints-leading-addiction-specialist-to-its-scientific-advisory-boa-adil-20190212monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-ceo-to-appear-on-cbs-and-fox-affiliates-to-discuss-ad04-as-a-potenti-adil-20190201monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-receives-1-2-million-in-proceeds-through-the-exercise-of-warrants-adil-20190124monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-appoints-two-additional-global-thought-leaders-to-its-scientific-adv-adil-20190117monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-to-present-at-the-2019-wall-street-conference-adil-20190110monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-retires-all-outstanding-debt-adil-20181224monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-amendment-to-license-agreement-with-the-university-of-virg-adil-20181219monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-planned-expansion-of-lead-asset-ad04-into-opioid-addiction-adil-20181213monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-professor-hannu-alho-emeritus-professor-of-addiction-medic-adil-20181210monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-establishes-scientific-advisory-board-and-appoints-global-thought-le-adil-20181129monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-chairman-featured-in-doctors-channel-video-discussing-alcohol-use-di-adil-20181121monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-engages-cro-to-begin-phase-3-clinical-trials-of-ad04-for-the-treatme-adil-20181119monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-provides-business-update-for-the-third-quarter-of-2018-adil-20181114monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-to-present-at-dawson-james-securities-4th-annual-small-cap-growth-co-adil-20181023monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-to-ring-the-nasdaq-stock-market-opening-bell-this-morning-at-9-30-am-adil-20180904monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-appointment-of-monika-rogozinska-as-senior-vice-president--adil-20180815monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-closing-of-initial-public-offering-adil-20180731monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-pricing-of-initial-public-offering-adil-20180727monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-llc-announces-issuance-of-first-u-s-patent-adil-20140501monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-chairman-bankole-a-johnson-to-head-university-of-maryland-school-of--adil-20140219monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-strategic-partnership-with-cato-bioventures-adil-20131104monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-chairman-dr-bankole-johnson-to-present-on-personalized-medicine-at-t-adil-20131023monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-chairman-bankole-a-johnson-accepts-position-at-the-university-of-mar-adil-20130821monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-publication-of-study-on-ad04-for-the-treatment-of-patients-adil-20130812monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-chairman-dr-bankole-johnson-selected-to-deliver-5th-annual-jack-mend-adil-20130516monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-initiates-patient-dosing-in-phase-iib-trial-evaluating-npx-5-for-adjustment-pbm-20260423monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-positioned-as-world-s-only-licensed-pharmaceutical-grade-ibogaine-supplier--pbm-20260420monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine-pbm-20260417monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-expands-australian-clinical-site-network-to-five-sites-advancing-npx-5-supp-pbm-20260408monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-announces-exercise-of-put-option-by-psylabs-and-strategic-equity-investment-pbm-20260220monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-approves-put-option-agreement-with-psylabs-to-secure-strategic-supply-and-s-pbm-20260213monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-announces-effective-date-for-1-for-6-25-reverse-stock-split-pbm-20260128monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-announces-adjournment-of-annual-and-special-shareholder-meeting-on-january--pbm-20260122monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-announces-effective-date-for-1-for-6-25-reverse-stock-split-pbm-20260115monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-approves-2026-financial-strategy-board-authorizes-share-buyback-on-value-op-pbm-20260112monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-ceo-letter-highlights-clinical-progress-ethical-sourcing-of-ibogaine-strong-pbm-20251209monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-announces-groundbreaking-psilocybin-longevity-research-program-pbm-20251125monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-group-s-nasdaq-listed-associate-psyence-biomedical-further-strengthens-scientific--pbm-20250325monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-group-s-nasdaq-listed-associate-psyence-biomedical-names-albert-p-garcia-romeu-ph--pbm-20250310monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-announces-closing-of-2-0-million-private-placement-pbm-20241227monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-announces-2-0-million-private-placement-pbm-20241223monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomedical-regains-full-compliance-with-all-nasdaq-continued-listing-requirements-pbm-20241223monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-highlights-recent-progress-on-active-phase-iib-clinical-trial-pbm-20241217monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-executes-binding-agreements-with-optimi-health-corp-pbm-20241210monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-group-enters-into-agreements-with-its-nasdaq-listed-associate-psyence-biomedical-t-pbm-20241206monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomedical-issues-shareholder-update-highlighting-recent-progress-pbm-20241203monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomedical-announces-favorable-result-of-nasdaq-listing-qualifications-hearing-pbm-20241120monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomedical-announces-effective-date-for-1-for-75-share-consolidation-pbm-20241119monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomedical-announces-results-from-annual-and-special-general-meeting-share-consoli-pbm-20241112monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-group-announces-closing-of-previously-announced-disposal-of-its-stake-in-psylabs-pbm-20241031monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomedical-announces-closing-of-previously-announced-acquisition-of-psyence-group--pbm-20241031monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-group-s-nasdaq-listed-associate-psyence-biomedical-announces-recruitment-of-second-pbm-20241025monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-announces-recruitment-of-second-clinical-trial-site-for-ongoing-phase-iib-c-pbm-20241024monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-provides-progress-update-on-psylabs-e-u-good-manufacturing-practices-gmp-ce-pbm-20241017monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-group-enters-into-debt-for-equity-swap-agreement-with-its-nasdaq-listed-associate--pbm-20241014monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-provides-update-on-previously-announced-acquisition-of-clairvoyant-pbm-20241004monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-group-enters-into-agreement-to-dispose-of-stake-in-psylabs-pbm-20240920monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-enters-into-agreement-to-acquire-stake-in-psylabs-pbm-20240919monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-group-s-nasdaq-listed-associate-psyence-biomed-issues-shareholder-update-recapping-pbm-20240918monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-group-s-nasdaq-listed-associate-psyence-biomedical-announces-initiation-of-first-t-pbm-20240916monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-issues-shareholder-update-recapping-recent-progress-and-previewing-key-upco-pbm-20240916monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomedical-ltd-announces-receipt-of-staff-delisting-determination-from-nasdaq-pbm-20240913monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-announces-initiation-of-first-trial-site-in-australia-for-its-phase-iib-stu-pbm-20240909monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-announces-the-signing-of-a-conditional-binding-term-sheet-for-the-acquisiti-pbm-20240906monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-announces-worldwide-exclusive-licensing-agreement-with-psylabs-to-supply-na-pbm-20240904monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-announces-registration-statement-on-form-f-1-for-up-to-25-million-equity-li-pbm-20240830monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-s-pbm-20240827monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-enters-into-25-million-common-stock-purchase-agreement-with-white-lion-capi-pbm-20240731monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-group-s-nasdaq-listed-associate-psyence-biomedical-announces-export-of-nature-deri-pbm-20240726monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-announces-export-of-nature-derived-psilocybin-to-australia-and-provides-upd-pbm-20240724monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomedical-ltd-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency-pbm-20240704monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-to-participate-in-the-a-g-p-virtual-healthcare-company-showcase-pbm-20240517monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-announces-phase-iib-clinical-trial-listing-on-the-australian-new-zealand-cl-pbm-20240417monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomedical-welcomes-results-of-a-recent-study-highlighting-benefits-of-nature-deri-pbm-20240318monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomedical-ltd-receives-nasdaq-notifications-regarding-market-value-of-listed-secu-pbm-20240315monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-group-s-nasdaq-listed-associate-psyence-biomedical-receives-human-research-ethics--pbm-20240312monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomedical-ltd-issues-shareholder-letter-recapping-recent-progress-and-outlining-k-pbm-20240312monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-group-provides-corporate-update-following-successful-spac-spin-out-of-therapeutic--pbm-20240311monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomedical-s-subsidiary-psyence-australia-receives-human-research-ethics-committee-pbm-20240306monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomedical-ltd-approved-to-list-on-nasdaq-following-completion-of-business-combina-pbm-20240125monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-group-inc-subsidiary-psyence-biomedical-ltd-announces-signing-of-definitive-agreem-pbm-20240116monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-group-announces-sec-effectiveness-of-f-4-for-proposed-business-combination-between-pbm-20231115monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-group-announces-sec-registration-filing-with-nasdaq-spac-newcourt-and-signing-of-a-pbm-20230802monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-receives-positive-listing-determination-from-nasdaq-mbio-20241112monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-granted-orphan-drug-designation-by-u-s-fda-for-mb-108-hsv-1-oncolytic-virus-to-mbio-20241107monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-exercise-of-warrants-for-4-million-gross-proceeds-mbio-20241024monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-closing-of-2-5-million-registered-direct-offering-priced-at-the-mark-mbio-20240621monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-2-5-million-registered-direct-offering-priced-at-the-market-under-na-mbio-20240620monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-favorable-efficacy-and-safety-data-from-complete-waldenstrom-macrogl-mbio-20240617monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-closing-of-4-million-public-offering-mbio-20240502monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-pricing-of-4-million-public-offering-mbio-20240430monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-vision-for-car-t-cell-therapy-platform-expansion-into-autoimmune-dis-mbio-20240328monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-full-year-2023-financial-results-and-recent-corporate-highlights-mbio-20240311monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-the-b-riley-securities-4th-annual-oncology-conference-mbio-20240111monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-presents-updated-phase-1-2-multicenter-clinical-data-for-mb-106-at-the-2023-am-mbio-20231211monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-third-quarter-2023-financial-results-and-recent-corporate-highlights-mbio-20231114monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-mb-106-cd20-targeted-car-t-data-selected-for-presentation-at-65th-am-mbio-20231102monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-closing-of-4-4-million-registered-direct-offering-priced-at-the-mark-mbio-20231030monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-4-4-million-registered-direct-offering-priced-at-the-market-under-na-mbio-20231026monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-upcoming-september-2023-investor-conferences-mbio-20230907monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-first-data-from-ongoing-multicenter-phase-1-2-clinical-trial-evaluat-mbio-20230816monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-second-quarter-2023-financial-results-and-recent-corporate-highlights-mbio-20230814monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-two-august-2023-investor-conferences-mbio-20230803monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-amendment-and-closing-of-strategic-manufacturing-partnership-transac-mbio-20230731monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-participation-in-upcoming-scientific-meetings-mbio-20230706monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-final-results-from-follicular-lymphoma-cohort-of-single-institution--mbio-20230615monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-updated-results-from-waldenstrom-macroglobulinemia-cohort-of-ongoing-mbio-20230612monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-strategic-manufacturing-partnership-and-portfolio-updates-mbio-20230518monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-first-quarter-2023-financial-results-and-recent-corporate-highlights-mbio-20230512monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-1-mbio-20230511monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-reverse-stock-split-mbio-20230403monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-full-year-2022-financial-results-and-recent-corporate-highlights-mbio-20230329monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-cantor-s-the-future-of-oncology-virtual-symposium-mbio-20230328monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-the-b-riley-securities-3rd-annual-oncology-conference-mbio-20230117monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-provides-car-t-cell-therapy-portfolio-updates-and-2023-anticipated-milestones-mbio-20221219monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-third-quarter-2022-financial-results-and-recent-corporate-highlights-mbio-20221114monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-phase-1-2-clinical-trial-data-of-mb-106-a-first-in-class-cd20-target-mbio-20221027monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-first-patient-treated-in-its-multicenter-phase-1-2-clinical-trial-of-mbio-20221006monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-upcoming-september-2022-investor-conferences-mbio-20220908monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-second-quarter-2022-financial-results-and-recent-corporate-highlights-mbio-20220811monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-first-patient-successfully-treated-by-ex-vivo-lentiviral-gene-therap-mbio-20220727monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-orphan-drug-designation-granted-to-mb-106-a-cd20-targeted-autologous-mbio-20220622monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-updated-interim-results-from-follicular-lymphoma-cohort-of-ongoing-p-mbio-20220613monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-updated-interim-data-on-x-linked-severe-combined-immunodeficiency-tr-mbio-20220519monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-first-quarter-2022-financial-results-and-recent-corporate-highlights-mbio-20220512monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-results-from-follicular-lymphoma-cohort-of-ongoing-phase-1-2-clinica-mbio-20220512monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-data-on-treatment-with-lentiviral-viral-vector-gene-therapy-for-x-li-mbio-20220503monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-updated-interim-phase-1-2-data-for-mb-106-cd20-targeted-car-t-therap-mbio-20220425monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-upcoming-mb-106-cd20-targeted-car-t-data-presentations-mbio-20220421monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-present-at-the-virtual-fortress-biotech-r-d-summit-hosted-by-b-riley-securi-mbio-20220404monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-full-year-2021-financial-results-and-recent-corporate-highlights-mbio-20220323monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-three-march-2022-investor-conferences-mbio-20220310monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-city-of-hope-university-of-alabama-at-birmingham-and-nationwide-chil-mbio-20220309monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-completes-a-75-million-debt-financing-with-runway-growth-capital-mbio-20220308monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-city-of-hope-mb-105-prostate-stem-cell-antigen-car-t-data-selected-f-mbio-20220215monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-selected-as-a-bronze-winner-in-eighteenth-annual-team-massachusetts-economic-i-mbio-20220208monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-provides-an-update-on-its-ind-application-for-mb-207-a-lentiviral-gene-therapy-mbio-20220124monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-mb-106-cd20-targeted-car-t-data-selected-for-presentation-at-the-202-mbio-20220107monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-three-january-2022-virtual-investor-conferences-mbio-20220105monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-added-to-the-nasdaq-biotechnology-index-mbio-20211216monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-updated-interim-phase-1-2-data-for-mb-106-in-patients-with-relapsed--mbio-20211213monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-host-key-opinion-leader-webinar-on-mb-106-a-potential-treatment-for-b-cell--mbio-20211209monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-third-quarter-2021-financial-results-and-recent-corporate-highlights-mbio-20211112monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-exclusive-worldwide-license-agreement-with-leiden-university-medical-mbio-20211110monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-mb-106-cd20-targeted-car-t-data-selected-for-presentation-at-63rd-am-mbio-20211104monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-awarded-nih-grant-for-mb-106-cd20-targeted-car-t-cell-therapy-for-treatment-of-mbio-20211101monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-chardan-s-virtual-5th-annual-genetic-medicines-conference-mbio-20210930monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-three-september-2021-investor-conferences-mbio-20210909monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-second-quarter-2021-financial-results-and-recent-corporate-highlights-mbio-20210816monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-collaborates-with-mayo-clinic-on-novel-car-t-technology-mbio-20210812monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-receives-european-medicines-agency-prime-designation-for-mb-107-to-treat-x-lin-mbio-20210802monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-awarded-massachusetts-life-sciences-center-tax-incentive-mbio-20210617monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-present-at-the-raymond-james-human-health-innovation-conference-mbio-20210616monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-updated-interim-phase-1-2-data-for-mb-106-cd20-targeted-car-t-in-pat-mbio-20210611monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-host-key-opinion-leader-webinar-on-mb-106-cd20-targeted-car-t-for-the-treat-mbio-20210607monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-first-quarter-2021-financial-results-and-recent-corporate-highlights-mbio-20210514monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-mb-106-cd20-targeted-car-t-data-selected-for-presentation-at-europea-mbio-20210512monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-fda-acceptance-of-ind-application-for-mb-106-a-cd20-targeted-car-t-t-mbio-20210510monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-chardan-s-5th-annual-genetic-medicines-manufacturing-summit-mbio-20210421monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-full-year-2020-financial-results-and-recent-corporate-highlights-mbio-20210324monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-three-march-2021-virtual-investor-conferences-mbio-20210304monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-joins-global-movement-to-raise-awareness-for-rare-diseases-and-supports-rare-d-mbio-20210226monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-provides-updates-on-its-lentiviral-gene-therapies-for-the-treatment-of-x-linke-mbio-20210202monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-three-january-2021-virtual-investor-conferences-mbio-20210105monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-interim-phase-1-2-data-for-mb-106-in-patients-with-relapsed-or-refra-mbio-20201207monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-host-key-opinion-leader-call-on-mb-106-for-the-treatment-of-relapsed-or-ref-mbio-20201201monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-positive-opinion-from-the-european-medicines-agency-on-orphan-drug-d-mbio-20201124monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-and-minaris-regenerative-medicine-sign-technology-transfer-and-gmp-manufacturi-mbio-20201123monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-third-quarter-2020-financial-results-and-recent-corporate-highlights-mbio-20201106monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-mb-106-data-selected-for-presentation-at-the-62nd-american-society-o-mbio-20201104monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-initial-phase-1-data-on-mb-105-for-patients-with-psca-positive-castr-mbio-20201026monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-mb-105-data-selected-for-presentation-at-the-virtual-27th-annual-pro-mbio-20201008monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-licenses-lentiboost-technology-from-sirion-biotech-mbio-20201006monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-chardan-s-virtual-4th-annual-genetic-medicines-conference-20-mbio-20201001monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-first-patient-dosed-in-multicenter-phase-1-2-clinical-trial-of-mb-10-mbio-20201001monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-orphan-drug-designation-for-mb-207-for-the-treatment-of-x-linked-sev-mbio-20200922monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-three-september-2020-virtual-investor-conferences-mbio-20200910monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-orphan-drug-designation-for-mb-107-for-the-treatment-of-x-linked-sev-mbio-20200902monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-rare-pediatric-disease-designation-for-mb-207-for-the-treatment-of-x-mbio-20200831monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-rare-pediatric-disease-designation-for-mb-107-for-the-treatment-of-x-mbio-20200817monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-present-at-the-virtual-fortress-biotech-corporate-access-summit-mbio-20200817monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-second-quarter-2020-financial-results-and-recent-corporate-highlights-mbio-20200810monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-pricing-of-public-offering-of-common-stock-mbio-20200611monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-proposed-public-offering-of-common-stock-mbio-20200610monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-host-virtual-annual-meeting-of-stockholders-mbio-20200604monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-presentations-at-23rd-annual-meeting-of-the-american-society-of-gene-mbio-20200512monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-first-quarter-2020-financial-results-and-recent-corporate-highlights-mbio-20200511monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-receives-advanced-therapy-medicinal-product-classification-from-european-medic-mbio-20200420monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-full-year-2019-financial-results-and-recent-corporate-highlights-mbio-20200316monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-first-subject-treated-in-phase-1-2-trial-with-the-optimized-cd20-tar-mbio-20200218monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-present-at-the-phacilitate-leaders-world-world-stem-cell-summit-2020-mbio-20200122monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-updated-clinical-data-on-mb-107-lentiviral-gene-therapy-for-patients-mbio-20191209monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-the-evercore-isi-2nd-annual-healthconx-conference-mbio-20191202monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-third-quarter-2019-financial-results-and-recent-corporate-highlights-mbio-20191112monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-mb-107-lentiviral-gene-therapy-and-mb-106-cd20-targeted-car-t-data-s-mbio-20191106monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-dosing-of-first-participant-in-phase-1-clinical-trial-of-mb-108-onco-mbio-20191024monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-city-of-hope-receives-4-1-million-in-grant-awards-for-recently-opene-mbio-20191010monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-october-2019-investor-conferences-mbio-20190926monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-phase-1-clinical-trial-evaluating-mb-105-for-prostate-stem-cell-anti-mbio-20190923monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-present-at-scientific-conferences-in-september-2019-mbio-20190909monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-present-at-september-2019-investor-conferences-mbio-20190829monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-license-agreement-with-csl-behring-for-the-cytegrity-stable-producer-mbio-20190827monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-and-st-jude-children-s-research-hospital-announce-mb-107-lentiviral-gene-thera-mbio-20190822monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-9-28-million-grant-to-fund-phase-1-trial-of-car-t-therapy-mb-103-in--mbio-20190813monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-present-at-11th-annual-bioprocessing-summit-mbio-20190812monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-second-quarter-2019-financial-results-and-recent-corporate-highlights-mbio-20190809monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-receives-orphan-drug-designation-for-mb-102-cd123-car-t-for-the-treatment-of-a-mbio-20190724monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-and-st-jude-children-s-research-hospital-to-participate-in-panel-discussion-at-mbio-20190523monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-and-nationwide-children-s-hospital-receive-orphan-drug-designation-for-mb-108--mbio-20190516monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-present-at-the-cell-gene-therapy-usa-congress-2019-mbio-20190513monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-first-quarter-2019-financial-results-and-recent-corporate-highlights-mbio-20190510monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-full-exercise-of-option-mbio-20190508monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-city-of-hope-opens-first-of-its-kind-multiple-myeloma-car-t-cell-the-mbio-20190508monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-pricing-of-public-offering-of-common-stock-mbio-20190430monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-proposed-public-offering-of-common-stock-mbio-20190429monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-present-at-the-world-orphan-drug-congress-usa-2019-mbio-20190409monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-20-million-venture-debt-financing-agreement-with-horizon-technology--mbio-20190401monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-full-year-2018-financial-results-and-recent-corporate-highlights-mbio-20190318monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-present-at-oppenheimer-s-29th-annual-healthcare-conference-mbio-20190313monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-and-nationwide-children-s-hospital-enter-into-exclusive-worldwide-license-agre-mbio-20190220monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-receives-orphan-drug-designation-for-mb-102-cd123-car-t-for-the-treatment-of-b-mbio-20181220monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-presentation-of-mb-102-cd123-car-safety-and-efficacy-data-at-aacr-sp-mbio-20181128monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-third-quarter-2018-financial-results-and-recent-corporate-highlights-mbio-20181113monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-updates-on-car-t-cell-therapy-clinical-trials-with-city-of-hope-mbio-20181030monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-appoints-martina-a-sersch-m-d-ph-d-as-chief-medical-officer-mbio-20181015monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-present-at-8th-annual-partnering-forum-at-cell-gene-meeting-on-the-mesa-mbio-20181001monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-presentations-on-car-t-therapies-at-4th-annual-car-tcr-summit-2018-mbio-20180904monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-september-investor-conferences-mbio-20180830monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-second-quarter-2018-financial-results-and-recent-corporate-highlights-mbio-20180813monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-and-st-jude-children-s-research-hospital-enter-into-exclusive-worldwide-licens-mbio-20180813monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-present-at-10th-annual-bioprocessing-summit-mbio-20180809monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-completes-pre-ind-meeting-with-fda-for-mb-102-cd123-car-t-mbio-20180719monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-added-to-russell-2000-3000-and-microcap-indexes-mbio-20180625monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-opening-of-car-t-cell-therapy-manufacturing-facility-in-worcester-ma-mbio-20180622monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-present-at-june-investor-conferences-mbio-20180531monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-preclinical-data-on-potency-of-its-car-t-cells-in-glioblastoma-publi-mbio-20180530monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-first-quarter-2018-financial-results-mbio-20180514monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-present-at-biotech-innovations-conference-mbio-20180404monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-fourth-quarter-and-full-year-2017-financial-results-and-recent-corpora-mbio-20180329monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-present-at-car-t-congress-usa-mbio-20180319monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-key-leadership-appointments-mbio-20180315monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-present-at-march-investor-conferences-mbio-20180313monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-present-at-the-255th-american-chemical-society-national-meeting-exposition-mbio-20180312monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-immuno-oncology-panel-at-bio-ceo-investor-conference-mbio-20180206monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-participate-in-lifesci-advisors-corporate-access-event-in-san-francisco-jan-mbio-20171214monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-s-mb-102-cd123-car-car-t-therapy-achieves-complete-response-in-acute-myeloid-l-mbio-20171211monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-license-agreement-with-harvard-university-and-research-collaboration-mbio-20171204monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-third-quarter-2017-financial-results-and-recent-corporate-highlights-mbio-20171114monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-appointment-of-brian-achenbach-as-vice-president-of-finance-and-corp-mbio-20171114monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-mb-102-data-selected-for-oral-presentation-at-59th-american-society--mbio-20171101monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-preclinical-data-on-regional-delivery-of-mb-103-her2-chimeric-antigen--mbio-20171031monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-establishes-car-t-cell-therapy-manufacturing-facility-in-massachusetts-mbio-20171030monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-12-8-million-grant-to-fund-phase-1-trial-of-car-t-therapy-mb-101-in--mbio-20171011monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-expansion-of-car-t-pipeline-into-cd20-directed-immunotherapies-mbio-20170914monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-to-present-at-the-car-tcr-summit-2017-mbio-20170905monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-commences-trading-on-the-nasdaq-global-market-mbio-20170822monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-second-quarter-2017-financial-results-and-recent-corporate-highlights-mbio-20170814monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reports-first-quarter-2017-financial-results-and-recent-corporate-highlights-mbio-20170515monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-appointment-of-manuel-litchman-m-d-as-president-and-chief-executive--mbio-20170424monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-oral-presentation-of-initial-clinical-data-for-mb-101-il13ra2-specif-mbio-20160505monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-presentations-of-mb-101-a-novel-il13ra2-specific-car-t-cells-product-mbio-20160418monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-completes-database-lock-for-its-phase-1b-clear-clinical-study-o-revb-20220714monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-completion-of-dosing-for-a-phase-1b-clear-clinical-st-revb-20220613monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-financial-results-for-the-three-months-ended-march-31-revb-20220516monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-outlines-details-on-the-upcoming-data-analysis-for-phase-2b-vir-revb-20220324monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-to-present-at-the-2022-virtual-growth-conference-presented-by-m-revb-20220322monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-enrollment-and-dosing-complete-for-phase-2b-viral-cha-revb-20220315monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-to-present-at-the-34th-annual-roth-conference-revb-20220308monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-to-present-at-2022-bio-ceo-investor-conference-revb-20220207monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-raises-7-76-million-in-equity-financing-revb-20220124monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-first-group-of-patients-dosed-in-phase-2b-viral-chall-revb-20220120monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-first-patient-enrolled-and-dosed-in-phase-1b-clinical-revb-20220118monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-data-demonstrating-revtx-99-in-vitro-anti-viral-activ-revb-20220111monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-appoints-joseph-a-bellanti-m-d-to-scientific-advisory-board-revb-20211206monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-initiation-of-a-phase-2b-study-to-assess-efficacy-of--revb-20211201monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-creation-and-appointments-to-scientific-advisory-boar-revb-20211129monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-initiation-of-a-phase-1b-clinical-study-of-revtx-99-f-revb-20211115monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-engages-partnering-advisor-medworld-advisors-to-optimize-value--revb-20211101monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-engages-destum-partners-inc-to-identify-strategic-partners-for--revb-20211025monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-receives-approval-to-begin-a-phase-1b-clinical-study-of-revtx-9-revb-20211004monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-receives-approval-to-initiate-phase-2b-viral-challenge-study-of-revb-20210928monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-nasdaq-snyr-appoints-pedro-colmenares-as-director-of-sales-marketing-for--snyr-20251216monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-to-present-at-the-2025-gateway-conference-on-september-4th-snyr-20250821monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-nasdaq-snyr-announces-nationwide-eg-america-rollout-for-focusfactor-focus-snyr-20250818monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-reports-second-quarter-2025-financial-results-and-its-tenth-consecutive-q-snyr-20250814monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-second-quarter-2025-earnings-and-conference-call-information-snyr-20250731monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-nasdaq-snyr-secures-retail-deals-with-mckesson-canada-and-others-as-focus-snyr-20250714monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-nasdaq-snyr-secures-landmark-retail-and-distribution-wins-across-north-am-snyr-20250630monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-nasdaq-snyr-expands-focusfactor-to-uae-turkey-ignites-global-growth-and-new-re-snyr-20250618monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-nasdaq-snyr-taps-former-coca-cola-executive-to-help-drive-focusfactor-energy-d-snyr-20250610monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-announces-new-20-million-long-term-credit-facility-snyr-20250604monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-announces-appointment-of-erik-shields-as-vice-president-of-beverage-snyr-20250529monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-reports-growth-in-earnings-per-share-for-its-first-quarter-2025-financial-snyr-20250515monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-first-quarter-2025-earnings-and-conference-call-information-snyr-20250501monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-reports-its-eighth-consecutive-quarter-of-profitability-and-its-fourth-quarter-snyr-20250331monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-fourth-quarter-and-full-year-2024-earnings-and-conference-call--snyr-20250320monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-to-attend-37th-annual-roth-conference-snyr-20250303monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-reports-its-seventh-consecutive-quarter-of-profitability-and-its-third-quarter-snyr-20241206monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-third-quarter-2024-earnings-and-conference-call-information-snyr-20241126monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-closing-of-initial-public-offering-snyr-20241024monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-prices-10-35-million-initial-public-offering-snyr-20241022monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-announces-intention-to-deregister-and-terminate-reporting-obligations-snyr-20200630monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-first-quarter-2020-results-snyr-20200629monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-fiscal-2019-year-end-results-snyr-20200429monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-third-quarter-2019-results-snyr-20191114monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-second-quarter-2019-results-snyr-20190813monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-first-quarter-2019-results-snyr-20190503monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-fiscal-2018-year-end-results-snyr-20190329monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-insider-buying-snyr-20181210monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-third-quarter-2018-results-snyr-20181113monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-canadian-retail-expansion-snyr-20180823monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-expansion-into-mexico-snyr-20180816monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-second-quarter-2018-results-snyr-20180814monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-first-quarter-2018-results-snyr-20180515monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-fiscal-2017-year-end-results-snyr-20180402monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-to-present-at-30th-annual-roth-conference-on-march-13th-snyr-20180305monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-third-quarter-2017-results-snyr-20171121monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-hires-patrick-mccullough-as-president-snyr-20171019monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-jeffrey-kadanoff-joins-as-cfo-snyr-20171016monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-gale-bensussen-joins-its-board-of-directors-snyr-20171011monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-second-quarter-2017-results-snyr-20170814monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-hires-robin-mendenhall-to-lead-sales-of-its-beauty-brand-portfolio-snyr-20170811monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-secures-up-to-us-30-million-of-growth-capital-snyr-20170810monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-accelerates-growth-with-opening-of-tech-centre-in-los-angeles-snyr-20170627monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-acquires-per-fekt-beauty-brand-expanding-its-presence-in-the-cosmetics-an-snyr-20170622monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-private-placement-offering-of-up-to-us-20-million-snyr-20170503monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-first-quarter-2017-results-snyr-20170501monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-re-launches-focusfactor-online-with-exclusive-new-product-line-new-websit-snyr-20170418monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-launches-digital-arm-the-synergy-effect-the-ultimate-growth-and-innovatio-snyr-20170411monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-launches-new-brand-sneaky-vaunt-r-and-sets-the-new-growth-benchmark-since-snyr-20170404monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-fiscal-2016-year-end-results-snyr-20170327monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-creates-deeper-partnership-with-knight-therapeutics-snyr-20170104monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-third-quarter-2016-earnings-release-snyr-20161027monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-second-quarter-2016-earnings-release-snyr-20160810monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-first-quarter-2016-earnings-release-snyr-20160425monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-acquires-flat-tummy-tea-an-australian-company-with-significant-social-med-snyr-20151116monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-acquires-another-quality-brand-in-urgentrx-snyr-20151116monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-names-al-baumeler-evp-sales-marketing-retail-snyr-20150820monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-acquires-anti-aging-business-from-hand-md-corp-r-snyr-20150819monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-s-mtnb-20260403monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-the-termination-of-mat2203-partnership-negotiations-and-implem-mtnb-20241031monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-second-quarter-2024-financial-results-and-provides-a-business-up-mtnb-20240814monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-to-discuss-second-quarter-2024-financial-resu-mtnb-20240807monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-successful-treatment-of-patient-with-limb-threatening-mucor-infe-mtnb-20240624monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-s-oral-mat2203-to-be-featured-in-fireside-chat-hosted-by-a-g-p-with-anti-mtnb-20240613monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-first-quarter-2024-financial-results-and-provides-a-business-upd-mtnb-20240509monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-s-lnc-platform-for-the-delivery-of-small-oligonucleotides-featured-in-tw-mtnb-20240507monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-to-discuss-first-quarter-2024-financial-resul-mtnb-20240502monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-prices-10-million-registered-direct-offering-mtnb-20240403monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-2023-financial-results-and-provides-a-business-update-mtnb-20240327monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-positive-in-vivo-safety-data-with-its-oral-lnc-docetaxel-formu-mtnb-20240325monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-regains-compliance-with-nyse-american-continued-listing-standards-mtnb-20240322monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-provides-positive-outcomes-update-on-the-mat2203-compassionate-expanded--mtnb-20240226monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-successfully-reaches-agreement-with-fda-for-a-single-phase-3-registratio-mtnb-20240220monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-biotech-showcase-2024-mtnb-20240103monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-demonstrates-in-vivo-biological-activity-and-disease-improvement-in-two--mtnb-20231227monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-provides-update-to-mat2203-regulatory-and-development-pathway-following--mtnb-20231221monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-third-quarter-2023-financial-results-and-provides-a-business-upd-mtnb-20231108monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-positive-in-vivo-efficacy-results-of-oral-lnc-docetaxel-formul-mtnb-20231107monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-to-discuss-third-quarter-2023-financial-resul-mtnb-20231101monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-two-investment-conferences-in-october-2023-mtnb-20230928monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-feature-mat2203-in-a-pipeline-presentation-at-idweek-mtnb-20230927monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-notification-of-nyse-american-continued-listing-deficiency-mtnb-20230922monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-participate-in-the-h-c-wainwright-global-investment-conference-mtnb-20230906monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-publication-of-results-from-the-phase-2-enact-clinical-trial-o-mtnb-20230822monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-second-quarter-2023-financial-results-and-provides-a-business-up-mtnb-20230809monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-participate-in-the-btig-virtual-biotechnology-conference-2023-mtnb-20230802monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-to-discuss-second-quarter-2023-financial-resu-mtnb-20230726monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-jmp-securities-life-sciences-conference-on-may-15-2023-mtnb-20230511monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-first-quarter-2023-financial-results-and-provides-a-business-upd-mtnb-20230510monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-to-discuss-first-quarter-2023-financial-resul-mtnb-20230503monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-2022-financial-results-and-provides-a-business-update-mtnb-20230315monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-to-discuss-2022-financial-results-and-provide-mtnb-20230308monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-that-mat2203-will-be-featured-in-two-oral-presentations-at-ecc-mtnb-20230302monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-provides-business-update-and-2023-strategic-outlook-mtnb-20230130monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-provide-corporate-update-and-2023-business-outlook-on-january-30-2023-mtnb-20230123monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-collaboration-with-national-resilience-to-explore-and-evaluate-mtnb-20230112monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-third-quarter-2022-financial-results-and-highlights-recent-progr-mtnb-20221102monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-discussing-third-quarter-2022-operational-and-mtnb-20221027monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-positive-interim-data-from-the-phase-2-enact-trial-of-mat2203--mtnb-20221021monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-thinkequity-annual-global-investment-conference-mtnb-20221021monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-infectious-diseases-society-of-america-idsa-has-selected-the-e-mtnb-20221019monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-new-mat2203-oral-amphotericin-b-data-during-idweek-2022-mtnb-20221012monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-chairman-succession-plan-mtnb-20220921monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conferenc-mtnb-20220907monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-second-quarter-2022-financial-results-and-highlights-recent-prog-mtnb-20220811monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-participate-in-the-btig-biotechnology-conference-mtnb-20220801monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2022-financial-and--mtnb-20220728monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-positive-opinion-by-the-european-medicines-agency-on-orphan-dr-mtnb-20220725monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-ld-micro-invitational-xii-conference-mtnb-20220531monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-first-quarter-2022-financial-results-and-operational-highlights-mtnb-20220512monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-discussing-first-quarter-2022-financial-and-o-mtnb-20220505monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-12th-annual-bionj-biopartnering-conference-mtnb-20220503monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-needham-virtual-healthcare-conference-mtnb-20220406monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-participate-in-the-2022-virtual-growth-conference-presented-by-maxim--mtnb-20220322monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-fourth-quarter-and-full-year-2021-financial-results-and-operatio-mtnb-20220308monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2021--mtnb-20220228monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-provides-business-update-and-2022-strategic-outlook-mtnb-20220125monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-provide-corporate-update-and-2022-business-outlook-on-january-25-2022-mtnb-20220118monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-unanimous-dsmb-approval-to-progress-into-fourth-and-final-coho-mtnb-20211216monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-thomas-hoover-m-b-a-as-chief-business-officer-mtnb-20211206monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-participate-in-33rd-annual-piper-sandler-virtual-healthcare-conferenc-mtnb-20211118monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-third-quarter-2021-financial-results-and-operational-highlights-mtnb-20211108monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-discussing-third-quarter-2021-financial-and-o-mtnb-20211102monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-selected-to-participate-in-the-b-riley-fall-2021-growth-biotech-best-ide-mtnb-20211025monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-initiates-dosing-in-phase-1-study-of-potential-first-oral-aminoglycoside-mtnb-20211021monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-accomplished-biotechnology-executive-and-drug-developer-kathry-mtnb-20210920monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-webcast-of-presentation-at-the-h-c-wainwright-global-investmen-mtnb-20210914monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-positive-data-in-the-ongoing-enact-trial-of-mat2203-oral-ampho-mtnb-20210913monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-issuance-of-u-s-patent-protecting-mat2203-to-treat-or-prevent--mtnb-20210816monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-second-quarter-2021-financial-results-and-operational-highlights-mtnb-20210810monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-participate-in-btig-virtual-biotechnology-conference-mtnb-20210803monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and--mtnb-20210727monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-hold-virtual-r-d-day-on-june-17-2021-mtnb-20210520monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-first-quarter-2021-financial-results-and-operational-highlights-mtnb-20210510monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-participate-in-7th-annual-truist-securities-life-sciences-summit-mtnb-20210428monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-discussing-first-quarter-2021-financial-and-o-mtnb-20210427monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-needham-healthcare-conference-mtnb-20210408monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-fourth-quarter-and-full-year-2020-financial-results-and-operatio-mtnb-20210329monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020--mtnb-20210315monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-barclays-global-healthcare-conference-mtnb-20210301monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-topline-results-from-enhance-it-study-of-lypdiso-against-vasce-mtnb-20210201monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-icr-conference-2021-mtnb-20210106monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-fda-conditional-acceptance-of-lypdiso-as-the-brand-name-for-ma-mtnb-20210104monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-collaboration-with-the-national-institute-of-allergy-and-infec-mtnb-20201207monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-files-preliminary-proxy-for-special-meeting-of-stockholders-mtnb-20201207monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-hui-liu-ph-d-m-b-a-as-chief-technology-officer-mtnb-20201201monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-awarded-up-to-3-75-million-from-the-cystic-fibrosis-foundation-to-suppor-mtnb-20201120monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-participate-in-annual-piper-sandler-healthcare-conference-mtnb-20201119monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-third-quarter-2020-financial-results-and-operational-highlights-mtnb-20201106monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-discussing-third-quarter-2020-financial-and-o-mtnb-20201023monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-unanimous-dsmb-approval-to-progress-into-second-cohort-of-pati-mtnb-20201019monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-positive-end-of-phase-2-meeting-with-the-fda-for-mat9001-in-se-mtnb-20200915monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-industry-veteran-natasha-giordano-to-board-of-directors-mtnb-20200914monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-participate-on-anti-fungal-ceo-panel-during-the-m-vest-virtual-confer-mtnb-20200910monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-completes-enrollment-of-enhance-it-study-of-mat9001-against-vascepa-mtnb-20200827monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-participate-in-two-upcoming-virtual-investor-conferences-mtnb-20200826monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-publication-of-results-from-phase-1-portion-of-the-enact-study-mtnb-20200820monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-second-quarter-2020-financial-results-and-operational-highlights-mtnb-20200810monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-participate-in-the-btig-virtual-biotech-conference-2020-mtnb-20200804monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2020-financial-and--mtnb-20200728monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-resumes-enrollment-in-the-enhance-it-and-enact-clinical-trials-mtnb-20200630monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-jefferies-virtual-healthcare-conference-mtnb-20200526monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-first-quarter-2020-financial-results-and-operational-highlights-mtnb-20200511monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-discussing-first-quarter-2020-financial-and-o-mtnb-20200504monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-participate-in-panel-discussion-during-maxim-group-infectious-disease-mtnb-20200428monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-provides-comment-on-impact-of-vascepa-patent-litigation-on-mat9001-and-u-mtnb-20200331monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-fourth-quarter-and-full-year-2019-financial-results-and-operatio-mtnb-20200309monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-initiation-of-enhance-it-study-of-mat9001-against-vascepa-mtnb-20200305monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-james-a-underberg-m-d-to-its-mat9001-scientific-advisory-board-mtnb-20200304monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2019--mtnb-20200224monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-dsmb-approval-to-commence-part-2-of-enact-study-of-mat2203-ora-mtnb-20200219monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-closing-of-public-offering-of-common-stock-mtnb-20200114monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-pricing-of-public-offering-of-common-stock-mtnb-20200110monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-proposed-public-offering-of-common-stock-mtnb-20200109monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-feasibility-evaluation-with-third-large-biopharmaceutical-comp-mtnb-20191212monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-31st-annual-piper-jaffray-healthcare-conference-mtnb-20191118monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-third-quarter-2019-financial-results-and-provides-corporate-upda-mtnb-20191113monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-discussing-third-quarter-2019-operational-and-mtnb-20191106monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-initiates-enact-study-of-mat2203-oral-amphotericin-b-for-the-treatment-o-mtnb-20191014monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-receives-orphan-drug-designation-from-u-s-fda-for-mat2203-for-the-treatm-mtnb-20191007monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-2019-cantor-global-healthcare-conference-mtnb-20190927monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-pre-screening-of-patients-to-determine-eligibility-for-phase-2-mtnb-20190925monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-h-c-wainwright-21st-annual-global-investment-conferenc-mtnb-20190828monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-second-quarter-2019-financial-results-and-provides-corporate-upd-mtnb-20190813monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2019-operational-an-mtnb-20190730monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-receives-qualified-infectious-disease-product-qidp-and-fast-track-design-mtnb-20190725monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-9th-annual-ld-micro-invitational-mtnb-20190603monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-publication-of-mat2203-preclinical-cryptococcal-meningitis-dat-mtnb-20190528monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-abstract-accepted-for-presentation-at-asm-microbe-2019-mtnb-20190521monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-a-research-collaboration-with-viiv-healthcare-to-evaluate-form-mtnb-20190515monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-provides-corporate-update-and-reports-first-quarter-2019-financial-resul-mtnb-20190514monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-host-conference-call-and-webcast-to-discuss-first-quarter-2019-operat-mtnb-20190508monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-ring-nyse-opening-bell-on-may-6-2019-mtnb-20190502monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-selected-to-present-at-the-bionj-ninth-annual-biopartnering-conference-mtnb-20190501monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-2018-financial-results-and-provides-corporate-update-mtnb-20190402monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-announce-full-year-2018-operational-and-financial-results-on-april-2--mtnb-20190326monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-a-research-evaluation-with-top-global-pharma-company-based-on--mtnb-20190110monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-keith-a-kucinski-cpa-mba-as-chief-financial-officer-mtnb-20190103monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-biotech-showcase-2019-mtnb-20181220monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-harold-e-bays-m-d-to-its-cardiovascular-health-scientific-advis-mtnb-20181219monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-assembles-world-class-scientific-advisory-board-to-guide-clinical-develo-mtnb-20181206monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-third-quarter-2018-financial-results-and-provides-corporate-upda-mtnb-20181112monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-issuance-of-key-u-s-patent-for-prescription-only-next-generati-mtnb-20181018monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-8th-annual-partnership-opportunities-in-drug-delivery--mtnb-20181016monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-global-pharmaceutical-drug-development-industry-leader-theresa--mtnb-20181015monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-microcap-conference-mtnb-20180925monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-appointment-of-industry-leader-patrick-g-lepore-to-board-of-di-mtnb-20180906monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-rodman-renshaw-20th-annual-global-investment-conferenc-mtnb-20180905monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-u-s-fda-development-of-non-traditional-therapies-for-b-mtnb-20180816monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-second-quarter-2018-financial-results-and-provides-corporate-upd-mtnb-20180810monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-closing-of-8-0-million-public-offering-mtnb-20180622monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-pricing-of-8-0-million-public-offering-mtnb-20180619monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-20th-ichs-symposium-on-infections-in-the-immunocomprom-mtnb-20180612monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-preclinical-data-at-asm-microbe-2018-further-demonstrating-th-mtnb-20180606monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-first-quarter-2018-financial-results-and-provides-corporate-upda-mtnb-20180510monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-host-quarterly-update-conference-call-mtnb-20180507monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-selected-to-present-at-the-bionj-eighth-annual-biopartnering-conference-mtnb-20180501monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-positive-preclinical-data-of-mat2203-at-the-28th-european-con-mtnb-20180419monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-2017-financial-results-mtnb-20180326monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-jerome-d-jabbour-as-chief-executive-officer-and-provides-corpor-mtnb-20180316monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-oppenheimer-28th-annual-healthcare-conference-mtnb-20180315monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-host-2017-financial-results-and-corporate-update-conference-call-and--mtnb-20180312monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-achieves-statistical-endpoint-for-success-in-phase-2a-clinical-study-of--mtnb-20180108monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-matthew-a-wikler-m-d-m-b-a-f-i-d-s-a-to-board-of-directors-mtnb-20171214monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-2017-third-quarter-financial-results-and-provides-corporate-upda-mtnb-20171115monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-dawson-james-securities-3rd-annual-small-cap-growth-co-mtnb-20171011monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-mtnb-20170919monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-retains-jsb-partners-to-pursue-strategic-options-for-mat9001-mtnb-20170912monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-2017-second-quarter-financial-results-and-reaffirms-clinical-and-mtnb-20170808monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-canaccord-genuity-37th-annual-growth-conference-mtnb-20170803monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-host-quarterly-update-conference-call-mtnb-20170801monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-topline-data-from-phase-2-clinical-study-of-orally-administered--mtnb-20170626monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-interim-data-from-nih-conducted-phase-2a-clinical-study-of-ora-mtnb-20170603monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-presents-positive-preclinical-efficacy-data-of-mat2203-in-mouse-model-of-mtnb-20170602monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-2017-jefferies-global-healthcare-conference-mtnb-20170601monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-two-upcoming-data-presentations-of-lead-product-candidate-mat2-mtnb-20170530monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-2017-first-quarter-financial-results-and-provides-corporate-upda-mtnb-20170516monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-presents-positive-preclinical-data-of-orally-available-dna-vaccines-at-t-mtnb-20170424monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-dominick-dipaolo-as-senior-vice-president-of-quality-and-regula-mtnb-20170418monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-2016-financial-results-and-provides-corporate-update-mtnb-20170403monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-eric-j-ende-m-b-a-m-d-to-its-board-of-directors-mtnb-20170330monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-host-fiscal-year-2016-update-conference-call-mtnb-20170329monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-ring-nyse-closing-bell-on-march-29th-2017-mtnb-20170328monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-positive-topline-data-from-phase-1-study-of-mat2501-mtnb-20170327monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-29th-annual-roth-conference-mtnb-20170310monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-positive-preclinical-efficacy-results-of-mat2501-in-an-in-vitr-mtnb-20170308monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-and-nih-niaid-initiate-open-label-extension-to-phase-2a-study-of-mat2203-mtnb-20170306monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-trading-on-nyse-mkt-to-commence-march-2-2017-mtnb-20170227monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-provides-business-outlook-and-sets-corporate-milestones-for-2017-mtnb-20170126monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-noble-capital-markets-thirteenth-annual-investor-conferenc-mtnb-20170123monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-successfully-completes-warrant-tender-offer-raises-13-5-million-from-exe-mtnb-20170119monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-biotech-showcase-2017-mtnb-20170106monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-receives-contract-award-from-cystic-fibrosis-foundation-therapeutics-to--mtnb-20161208monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-commences-dosing-in-phase-1-study-of-orally-administered-aminoglycoside--mtnb-20161205monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-initiates-enrollment-and-commences-patient-dosing-in-phase-2-study-of-ma-mtnb-20161121monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-2016-third-quarter-financial-results-and-provides-corporate-upda-mtnb-20161115monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-researchers-among-rutgers-university-recipients-of-2016-edison-patent-aw-mtnb-20161103monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-presents-preclinical-data-of-orally-administered-encochleated-influenza--mtnb-20161026monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-receives-notice-of-allowance-of-u-s-patent-for-novel-lipid-crystal-nano--mtnb-20161024monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-2nd-annual-dawson-james-securities-growth-stock-confer-mtnb-20161013monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-commences-patient-dosing-in-nih-sponsored-phase-2a-study-with-lead-anti--mtnb-20160928monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-completes-private-placement-of-8-0-million-mtnb-20160913monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-s-lead-antifungal-product-candidate-mat2203-granted-qidp-and-fast-track--mtnb-20160907monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-18th-annual-rodman-renshaw-global-investment-conferenc-mtnb-20160906monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-presentation-of-cryptococcal-meningitis-preclinical-data-of-ma-mtnb-20160713monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-receives-issuance-of-key-u-s-patent-for-novel-lipid-crystal-nano-particl-mtnb-20160622monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-presents-preclinical-data-of-mat2501-at-asm-microbe-icaac-2016-mtnb-20160620monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-acceptance-of-abstract-on-efficacy-and-tolerability-of-encochl-mtnb-20160608monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-2015-financial-results-and-provides-business-update-mtnb-20160331monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-28th-annual-roth-conference-mtnb-20160310monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-granted-u-s-orphan-drug-designation-for-mat2501-for-treatment-of-non-tub-mtnb-20160307monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-receives-notice-of-allowance-of-u-s-patent-for-novel-lipid-crystal-nano--mtnb-20160210monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-commences-patient-enrollment-in-nih-sponsored-phase-2a-study-with-mat220-mtnb-20160208monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-receives-fda-clearance-to-initiate-phase-1-clinical-study-of-mat2501-for-mtnb-20160201monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-biotech-showcase-on-january-12-2016-mtnb-20160105monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-files-investigational-new-drug-application-with-u-s-fda-for-lead-antibac-mtnb-20160104monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-s-lead-antifungal-product-candidate-mat2203-granted-qidp-and-fast-track--mtnb-20151217monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-s-lead-antibacterial-development-candidate-mat2501-granted-qidp-designat-mtnb-20151214monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-8th-annual-ld-micro-main-event-on-december-3-2015-mtnb-20151119monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-reports-2015-third-quarter-financial-results-and-provides-business-updat-mtnb-20151110monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-receives-notice-of-allowance-of-u-s-patent-for-encochleated-sirna-mtnb-20151026monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-selected-to-present-at-cavendish-global-health-impact-forum-mtnb-20151022monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-14th-annual-bio-investor-forum-on-october-20-2015-mtnb-20151014monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-presents-preclinical-pk-and-efficacy-data-of-encochleated-atovaquone-in--mtnb-20151010monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-receives-institutional-review-board-approval-to-commence-nih-sponsored-p-mtnb-20151005monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-presents-pre-clinical-data-showing-anti-bacterial-activity-of-mat2501-en-mtnb-20150919monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-s-mat2203-encochleated-formulation-of-amphotericin-b-shows-potential-to--mtnb-20150918monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-international-expert-and-thought-leader-on-invasive-fungal-infe-mtnb-20150917monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-17th-annual-rodman-renshaw-global-investment-conferenc-mtnb-20150902monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-cochleate-technology-pioneer-raphael-j-mannino-ph-d-as-senior-v-mtnb-20150901monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-s-lead-antifungal-product-candidate-mat2203-granted-qidp-and-fast-track--mtnb-20150818monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-abstract-on-pharmacokinetics-and-efficacy-of-encochleated-atov-mtnb-20150727monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-infectious-diseases-expert-david-s-perlin-ph-d-to-scientific-ad-mtnb-20150723monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-two-abstracts-accepted-for-presentation-on-preclinical-data-of-mtnb-20150714monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-12th-anti-infectives-partnering-and-deal-making-confer-mtnb-20150707monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-s-mat9001-demonstrates-superiority-in-reducing-triglycerides-lipids-apol-mtnb-20150615monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-bio-international-convention-on-june-18-2015-mtnb-20150610monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-acceptance-of-late-breaking-abstract-on-mat9001-comparative-st-mtnb-20150604monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-s-mat9001-meets-primary-and-secondary-endpoints-in-first-human-trial-ver-mtnb-20150601monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-ld-micro-invitational-on-june-2-2015-mtnb-20150528monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-fourth-annual-seethru-equity-microcap-investor-confere-mtnb-20150526monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-completes-private-placement-of-10-million-mtnb-20150410monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-2nd-annual-growth-capital-expo-on-april-13-2015-mtnb-20150407monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-completes-enrollment-in-first-human-trial-of-mat9001-mtnb-20150330monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-27th-annual-roth-conference-on-march-11-2015-mtnb-20150304monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-17th-annual-bio-ceo-investor-conference-on-february-9--mtnb-20150205monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-establishes-lipid-based-anti-infective-platform-with-acquisition-of-aqua-mtnb-20150130monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-biotech-showcase-2015-conference-on-january-14-2015-mtnb-20150107monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-provides-update-on-clinical-development-program-for-mat9001-following-fd-mtnb-20141223monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-leading-clinical-lipid-specialist-and-metabolism-researcher-kev-mtnb-20141124monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-two-investor-conferences-in-early-december-mtnb-20141120monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-commences-dosing-in-first-human-trial-of-lead-product-candidate-mat9001-mtnb-20141112monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-receives-notice-of-allowance-of-u-s-patent-for-mat9001-mtnb-20141110monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-cardiologist-and-lipidology-expert-christie-m-ballantyne-m-d-to-mtnb-20141104monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-receives-authorization-from-health-canada-to-initiate-human-clinical-stu-mtnb-20141029monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-submits-investigational-new-drug-application-for-lead-product-candidate--mtnb-20141020monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-the-13th-annual-bio-investor-forum-on-wednesday-october-8--mtnb-20140930monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-holdings-inc-approved-to-trade-on-otcqb-venture-stage-marketplace-mtnb-20140908monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-to-present-at-three-investor-conferences-in-september-mtnb-20140904monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-launches-digital-corporate-communication-channels-mtnb-20140731monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-to-present-at-the-biotech-showcase-annual-conference-on-january-8-2018-aztr-20180103monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-to-present-at-the-planet-microcap-showcase-vegas-2025-on-april-23-2025-shph-20250421monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-developing-pretreatment-diagnostic-blood-tests-for-prostate-cancer-files-pr-shph-20250410monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-announces-closing-of-5-75-million-underwritten-offering-shph-20250313monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-announces-pricing-of-5-75-million-underwritten-offering-shph-20250312monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-announces-appointment-of-christopher-cooper-as-interim-co-ceo-to-enhance-bu-shph-20250312monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-provides-corporate-update-and-reports-2024-results-shph-20250226monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-reaches-milestone-in-patient-enrollment-for-phase-2-clinical-trial-of-ropid-shph-20250121monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-ja-shph-20250107monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-enters-into-sponsored-research-agreement-with-the-university-of-california--shph-20241219monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-expands-patient-enrollment-for-phase-2-clinical-trial-of-ropidoxuridine-for-shph-20241126monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-provides-third-quarter-2024-corporate-update-shph-20241113monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-holdings-inc-announces-pricing-of-4-5-million-public-offering-pric-shph-20241030monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-pays-off-senior-secured-convertible-note-shph-20241029monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-doses-first-patients-in-phase-2-clinical-trial-of-ropidoxuridine-for-treatm-shph-20241029monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-completes-clinical-trial-site-enrollment-for-phase-2-of-ropidoxuridine-for--shph-20241028monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-to-present-at-the-2024-thinkequity-conference-on-wednesday-october-shph-20241028monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-expands-clinical-trial-site-enrollment-for-phase-2-of-ropidoxuridine-for-tr-shph-20240916monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-announces-issuance-of-u-s-patent-for-selective-histone-deacetylase-inhibito-shph-20240905monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-provides-second-quarter-2024-corporate-update-shph-20240904monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-regains-compliance-with-nasdaq-minimum-bid-price-requirement-shph-20240828monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-receives-notice-of-nasdaq-non-compliance-with-listing-rule-5250-c-1-shph-20240826monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-ready-to-enroll-patients-in-phase-2-clinical-trial-of-ropidoxuridine-for-tr-shph-20240814monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-s-selective-hdac-inhibitor-exhibits-atm-activation-and-modulation-of-er-exp-shph-20240719monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-appoints-timothy-lorber-as-chief-financial-officer-shph-20240618monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-to-participate-in-the-lytham-partners-spring-2024-investor-conference-on-ma-shph-20240522monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-provides-first-quarter-2024-corporate-update-shph-20240514monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-to-present-at-the-planet-microcap-showcase-vegas-2024-on-wednesday-shph-20240423monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-to-present-at-the-emerging-growth-conference-on-april-4-2024-shph-20240403monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-to-present-at-the-emerging-growth-conference-on-march-6-2024-shph-20240305monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-strategic-partnership-with-transferai-to-drive-efficienci-cldi-20260429monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-presents-new-data-on-its-lead-asset-cld-401-at-the-aacr-annual-meet-cldi-20260421monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-presents-new-data-on-its-differentiated-approach-to-in-situ-t-cell--cldi-20260420monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-participation-in-redchip-s-april-16-virtual-investor-conf-cldi-20260415monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-speaker-presentation-at-asgct-conference-in-boston-on-may-cldi-20260407monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-rec-cldi-20260327monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-closing-of-6-0-million-underwritten-public-offering-and-f-cldi-20260310monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-pricing-of-5-2-million-underwritten-public-offering-cldi-20260306monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-proposed-public-offering-cldi-20260305monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-new-data-to-be-presented-on-its-therapeutic-lead-cld-401--cldi-20251030monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-announces-reverse-stock-split-expected-to-begin-trading-on-a-1-for-12-split-adjuste-cldi-20250725monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-inc-nyse-american-cldi-platform-designed-to-transform-landscape-of--cldi-20250710monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-exercise-of-warrants-for-4-6-million-of-gross-proceeds-cldi-20250709monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-inc-nyse-american-cldi-developing-precision-genetic-medicine-platfo-cldi-20250708monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-shareholder-letter-from-ceo-cldi-20250627monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-presents-systemic-oncolytic-platform-with-cd55-enhanced-expression--cldi-20250602monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-reports-first-quarter-2025-financial-results-and-recent-operational-cldi-20250514monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-il15-superagonist-as-first-payload-to-be-delivered-by-sys-cldi-20250428monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-reports-inducement-grant-under-nyse-american-llc-company-guide-sect-cldi-20250425monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-chief-executive-officer-transition-and-appointment-of-eri-cldi-20250423monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-fda-clearance-of-ind-application-for-cld-201-in-solid-tum-cldi-20250417monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-appointment-of-guy-travis-clifton-md-as-chief-medical-off-cldi-20250410monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-closing-of-3-9-million-registered-direct-offering-and-con-cldi-20250331monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-rec-cldi-20250331monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-pricing-of-3-9-million-registered-direct-offering-and-con-cldi-20250328monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-and-city-of-hope-provide-update-on-a-phase-1-clinical-trial-with-cl-cldi-20250326monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-demonstrated-ability-to-deliver-transient-gene-therapy-pa-cldi-20250310monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-commencement-of-recruitment-for-multiple-dose-cld-101-tri-cldi-20250224monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-bolstered-cash-balance-and-termination-of-its-standby-equ-cldi-20250128monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-presentation-of-new-data-of-systemic-virotherapy-rtnova-p-cldi-20250113monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-closing-of-4-25-million-public-offering-of-common-stock-cldi-20250110monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-pricing-of-4-25-million-public-offering-of-common-stock-cldi-20250110monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-proposed-public-offering-cldi-20250108monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-presents-data-supporting-rtnova-systemic-technology-to-target-metas-cldi-20241118monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-closing-of-7-5-million-public-offering-of-common-stock-cldi-20241115monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-pricing-of-7-5-million-public-offering-of-common-stock-cldi-20241114monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-proposed-public-offering-cldi-20241113monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results-cldi-20241112monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-to-present-data-supporting-rtnova-at-upcoming-scientific-conference-cldi-20241024monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-pricing-of-2-million-registered-direct-offering-and-concu-cldi-20241023monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-fda-clearance-of-the-northwestern-university-ind-applicat-cldi-20240930monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results-cldi-20240813monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-launch-of-nova-cell-subsidiary-and-3-million-aggregate-in-cldi-20240729monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-issuance-of-new-u-s-patent-covering-novel-supernova-techn-cldi-20240718monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-appointment-of-dr-mark-gilbert-to-medical-advisory-board-cldi-20240716monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-debuts-as-a-publicly-traded-company-focused-on-arming-the-immune-sy-cldi-20230913monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-commitment-of-25-million-in-series-b-funding-to-advance-s-cldi-20230623monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-and-first-light-acquisition-group-flag-announce-merger-agreement-to-cldi-20230109monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-and-edoc-acquisition-corp-agree-to-merge-and-create-a-publicly-list-cldi-20220202monthly0.5https://www.biopharmawatch.com/news/CDT/cdt-equity-stockholders-approve-all-proposals-at-special-meeting-positioning-the-company-f-cdt-20260318monthly0.5https://www.biopharmawatch.com/news/CDT/cdt-equity-increases-bitcoin-holding-cdt-20251017monthly0.5https://www.biopharmawatch.com/news/CDT/cdt-equity-inc-announces-reverse-stock-split-cdt-20251009monthly0.5https://www.biopharmawatch.com/news/CDT/cdt-equity-identifies-new-biological-target-validating-ai-driven-repurposing-strategy-cdt-20250826monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-to-present-at-a-g-p-s-annual-healthcare-company-showcase-gri-20260518monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-reports-first-quarter-2026-financial-results-new-data-reinforcing-differentiated-p-gri-20260514monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-dive-gri-20260408monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-reverse-stock-split-gri-20260121monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-additional-positive-data-from-phase-2a-study-in-idiopathic-pulmonary-fib-gri-20260108monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-closing-of-8-0-million-public-offering-gri-20251212monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-reports-6-week-interim-biomarker-data-in-ongoing-phase-2a-study-in-idiopathic-pulm-gri-20250731monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-s-gri-0621-demonstrates-encouraging-safety-results-at-planned-interim-6-week-analy-gri-20250626monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-to-present-at-a-g-p-s-annual-healthcare-company-showcase-gri-20250516monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-reports-first-quarter-2025-financial-results-and-confirms-gri-0621-phase-2a-ipf-tr-gri-20250515monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-s-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-o-gri-20250508monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-continues-to-drive-enrollment-in-ongoing-phase-2a-study-of-gri-0621-in-idiopathic--gri-20250507monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-abstract-selected-for-poster-discussion-session-at-the-2025-american-tho-gri-20250416monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-closing-of-5-0-million-public-offering-gri-20250402monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-pricing-of-5-0-million-public-offering-gri-20250401monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-reports-encouraging-interim-2-week-safety-results-from-ongoing-phase-2a-study-of-g-gri-20250401monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-bolsters-intellectual-property-portfolio-with-granting-of-two-global-patents-for-e-gri-20250331monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment-gri-20250318monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-reports-full-year-2024-financial-results-and-reiterates-expected-clinical-data-rea-gri-20250317monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-regains-compliance-with-nasdaq-s-minimum-bid-price-rule-gri-20250311monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-reverse-stock-split-gri-20250219monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference-gri-20250219monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-european-patent-office-issued-a-decision-to-grant-notice-for-patent-cove-gri-20241223monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-to-participate-in-the-virtual-investor-closing-bell-series-gri-20241206monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-showcases-gri-0621-s-potential-to-reduce-inflammation-type-1-cytokines-and-reduce--gri-20241121monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-reports-third-quarter-2024-financial-results-and-outlines-progress-towards-clinica-gri-20241114monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-raises-a-total-of-13-9-million-in-gross-proceeds-since-the-beginning-of-2024-gri-20241024monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-exercise-of-warrants-gri-20241021monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-presents-positive-preclinical-data-demonstrating-gri-0621-s-ability-to-inhibit-inv-gri-20241016monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-to-present-at-the-22nd-international-colloquium-on-lung-and-airway-fibrosis-gri-20241007monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-granted-japan-patent-for-proprietary-natural-killer-t-nkt-cell-modulators-for-prev-gri-20240930monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-receives-authorization-to-conduct-phase-2a-biomarker-study-evaluating-gri-0621-in--gri-20240926monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-nasdaq-gri-to-participate-in-a-virtual-investor-ceo-connect-segment-gri-20240925monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-participates-in-virtual-investor-kol-connect-segment-gri-20240918monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-gri-20240905monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-to-present-at-the-2024-european-respiratory-congress-gri-20240904monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-reports-second-quarter-2024-financial-results-and-provides-corporate-update-gri-20240814monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-nasdaq-gri-to-participate-in-the-virtual-investor-lunch-break-series-gri-20240715monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-nasdaq-gri-participates-in-virtual-investor-what-this-means-segment-gri-20240711monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-regains-compliance-with-nasdaq-gri-20240708monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-publication-of-positive-preclinical-data-from-lead-program-gri-0621-in-t-gri-20240702monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-to-present-at-the-8th-annual-ipf-summit-gri-20240701monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-closing-of-4-0-million-public-offering-gri-20240628monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-korea-patent-granted-for-proprietary-natural-killer-t-nkt-cell-modulator-gri-20240627monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-pricing-of-4-million-public-offering-gri-20240627monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-reverse-stock-split-gri-20240614monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-pitch-conference-gri-20240611monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-nasdaq-gri-participates-in-virtual-investor-what-this-means-segment-highlighting-p-gri-20240522monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-presents-positive-preclinical-data-from-pipeline-of-nkt-cell-modulators-in-develop-gri-20240521monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-presents-positive-preclinical-data-demonstrating-lead-program-gri-0621-reduces-the-gri-20240520monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-to-present-at-alliance-global-partner-s-2024-healthcare-company-showcase-gri-20240514monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-reports-first-quarter-2024-financial-results-and-provides-corporate-update-gri-20240513monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-abstracts-accepted-for-presentation-at-the-14th-international-congress-o-gri-20240429monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-to-present-at-live-with-webull-corporate-connect-virtual-biotech-investment-webina-gri-20240425monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-expands-intellectual-property-protection-for-proprietary-natural-killer-t-nkt-cell-gri-20240416monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-abstract-accepted-for-poster-presentation-at-the-2024-american-thoracic--gri-20240408monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-reports-full-year-2023-financial-results-and-provides-corporate-update-gri-20240401monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-to-present-at-the-medinvest-biotech-pharma-investor-conference-gri-20240328monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-notice-of-allowance-for-canadian-patent-covering-proprietary-natural-kil-gri-20240314monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-receives-mhra-authorization-to-conduct-phase-2a-biomarker-study-evaluating-gri-062-gri-20240304monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-pricing-of-5-5-million-public-offering-gri-20240202monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-reverse-stock-split-gri-20240126monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-commences-patient-enrollment-in-phase-2a-biomarker-study-evaluating-lead-program-g-gri-20231205monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-nasdaq-gri-announces-fda-clearance-of-ind-for-lead-program-gri-0621-a-type-1-invar-gri-20231127monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-nasdaq-gri-reports-third-quarter-2023-financial-results-and-provides-corporate-upd-gri-20231115monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-presents-data-supporting-innovative-pipeline-of-nkt-cell-modulators-for-the-treatm-gri-20231031monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-presents-translational-data-demonstrating-connection-between-nkt-cells-and-the-pat-gri-20231019monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-partnership-with-the-respiratory-translational-research-collaboration-to-gri-20231017monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-nasdaq-gri-to-participate-in-the-virtual-investor-ask-the-ceo-conference-gri-20231011monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-publication-of-comprehensive-invariant-nkt-inkt-cell-review-in-frontiers-gri-20231005monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-gri-20230906monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-enters-into-asset-purchase-agreement-with-aardvark-therapeutics-inc-for-the-sale-o-gri-20230823monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-nasdaq-gri-reports-second-quarter-2023-financial-results-and-provides-corporate-up-gri-20230814monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-presents-encouraging-preclinical-data-indicating-oral-administration-of-gri-0803-i-gri-20230807monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-nasdaq-gri-to-present-at-benzinga-s-virtual-biotech-conference-gri-20230803monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-the-gri-opportunity-spotlight-event-gri-20230724monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-inc-nasdaq-gri-to-participate-in-the-virtual-investor-summer-spotlight-series-gri-20230705monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-nasdaq-gri-bolsters-patent-portfolio-gri-20230627monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-nasdaq-gri-to-participate-in-the-healthcare-virtual-conference-presented-by-maxim--gri-20230615monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-nasdaq-gri-announces-corporate-rebranding-and-launch-of-new-website-gri-20230613monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-nasdaq-gri-provides-business-outlook-and-highlights-upcoming-milestones-for-innova-gri-20230522monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event-gri-20230427monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-nasdaq-gri-announces-appointment-of-leanne-kelly-as-chief-financial-officer-gri-20230425monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-nasdaq-gri-announces-board-of-director-appointments-adding-leadership-and-expertis-gri-20230424monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-hills-farm-announces-farmer-s-reserve-collection-limited-edition-premium-strains-pa-snoa-20210209monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-inc-company-investigated-by-the-portnoy-law-firm-snoa-20210202monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-alert-bragar-eagel-squire-p-c-is-investigating-sonoma-pharmaceutica-snoa-20201201monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-inc-investors-company-investigated-by-the-portnoy-law-firm-snoa-20201126monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-reports-second-quarter-fy-2020-financial-results-snoa-20191114monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-reports-first-quarter-fy-2020-financial-results-snoa-20190813monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-reports-fiscal-year-and-fourth-quarter-2019-financial-results-snoa-20190708monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-1-for-9-reverse-split-of-outstanding-common-stock-snoa-20190619monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-sells-animal-health-rights-in-asia-and-europe-for-2-7-million-snoa-20190521monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-substantial-cost-cutting-measures-snoa-20190312monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-management-changes-snoa-20181214monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-pricing-of-public-offering-of-units-snoa-20181117monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-reports-record-revenue-in-second-quarter-fy-2019-snoa-20181108monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-second-quarter-fy-2019-financial-results-and-conference-c-snoa-20181101monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-newly-published-results-from-study-of-hypochlorous-acid-i-snoa-20181025monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-launches-new-ceramax-skin-barrier-lotion-with-skin-enriching-lipogr-snoa-20181017monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-licensing-of-antimicrobial-hypochlorous-acid-solution-for-snoa-20180926monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-appoints-phillipe-weigerstorfer-to-board-of-directors-snoa-20180919monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-results-from-study-of-sonoma-s-performance-stabilized-hoc-snoa-20180828monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-reports-first-quarter-fy-2019-financial-results-snoa-20180808monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-first-quarter-fy-2019-financial-results-and-conference-ca-snoa-20180725monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-reports-fiscal-year-and-fourth-quarter-2018-financial-results-snoa-20180613monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-fiscal-year-fourth-quarter-2018-financial-results-and-con-snoa-20180531monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-names-marc-umscheid-chief-operating-officer-snoa-20180508monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-receives-four-new-uae-regulatory-approvals-that-include-acne-and-an-snoa-20180417monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-fda-approval-for-antimicrobial-post-therapy-gel-snoa-20180405monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-introduces-new-and-improved-acuicyn-antimicrobial-eyelid-and-eyelas-snoa-20180327monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-to-present-at-roth-capital-partners-30th-annual-growth-stock-confer-snoa-20180309monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-closing-of-5-million-public-offering-of-common-stock-snoa-20180307monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-pricing-of-5-million-public-offering-of-common-stock-snoa-20180302monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-reports-record-total-revenue-of-4-8-million-for-third-quarter-fy-20-snoa-20180207monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-fiscal-third-quarter-2018-financial-results-and-conferenc-snoa-20180125monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-receives-three-new-united-arab-emirates-regulatory-approvals-acuicy-snoa-20180109monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-second-fda-approval-to-add-antimicrobial-language-to-alev-snoa-20171205monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-fda-approval-of-expanded-indication-for-alevicyn-to-add-a-snoa-20171116monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-reports-robust-top-line-growth-for-second-quarter-fy-2018-with-61-p-snoa-20171109monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-receives-brazilian-approvals-to-market-multiple-hypochlorous-acid-b-snoa-20171031monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-fiscal-second-quarter-2018-financial-results-and-conferen-snoa-20171026monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-u-s-commercialization-of-loyon-for-relief-of-scaling-burn-snoa-20171003monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-commercialization-of-microcynah-animal-healthcare-product-snoa-20170914monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-reports-financial-results-for-first-quarter-of-fiscal-year-2018-snoa-20170808monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-fiscal-first-quarter-2018-financial-results-and-conferenc-snoa-20170725monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-record-quarterly-prescription-data-snoa-20170713monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-publication-of-consensus-report-describing-celacyn-s-hypo-snoa-20170628monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-two-singapore-approvals-for-microcyn-hypochlorous-acid-fo-snoa-20170620monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-reports-financial-results-for-fourth-quarter-and-fiscal-year-2017-snoa-20170605monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-fiscal-year-fourth-quarter-2017-financial-results-and-con-snoa-20170602monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-receives-two-new-united-arab-emirates-regulatory-approvals-pediacyn-snoa-20170412monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-receives-u-s-fda-clearance-of-loyon-skin-descaler-for-relief-of-sca-snoa-20170329monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-receives-final-1-5-million-payment-from-sale-of-latin-america-busin-snoa-20170323monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-results-from-sebuderm-gel-study-in-treatment-of-seborrhei-snoa-20170316monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-reports-financial-results-for-fiscal-third-quarter-2017-snoa-20170209monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-appoints-marc-umscheid-as-chief-strategy-and-marketing-officer-snoa-20170131monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-fiscal-third-quarter-2017-financial-results-and-conferenc-snoa-20170126monthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-cayman-limited-announces-financial-results-for-the-six-months-ended-june--cupr-20251209monthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-forms-joint-venture-company-with-aiodine-laboratory-to-develop-and-market-novel-io-cupr-20251118monthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-cayman-limited-announces-pricing-of-12-million-initial-public-offering-cupr-20250505monthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-cayman-limited-announces-closing-of-initial-public-offering-cupr-20250411monthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-cayman-limited-announces-pricing-of-12-million-initial-public-offering-cupr-20250410monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-fda-orphan-drug-designation-for-rhb-204-for-the-treatment-of-n-rdhl-20201014monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-partnerships-to-expand-manufacturing-for-covid-19-therapeutic--rdhl-20201013monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-adds-israel-rights-to-movantik-from-astrazeneca-rdhl-20201008monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-s-opaganib-covid-19-study-passes-second-independent-committee-review-rdhl-20201007monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-bio-investor-and-bio-europe-2020-virtual-conferences-rdhl-20201006monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-to-present-at-the-morgan-stanley-annual-global-healthcare-conference-and-additiona-rdhl-20200909monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-s-opaganib-demonstrates-complete-inhibition-of-sars-cov-2-rdhl-20200908monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-s-opaganib-awarded-covid-19-grant-by-state-of-pennsylvania-rdhl-20200903monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-recommendation-from-independent-committee-to-continue-rdhl-20200827monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-q2-2020-financial-results-and-operational-highlights-rdhl-20200813monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-cosmo-pharmaceuticals-to-expand-strategic-partnership-with-exclusive-rdhl-20200813monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-s-phase-2-3-covid-19-study-approved-in-mexico-rdhl-20200811monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-second-quarter-financial-results-and-business-highlights-confere-rdhl-20200807monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-s-phase-2-3-covid-19-study-approved-in-mexico-rdhl-20200806monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-participate-in-upcoming-btig-and-intellisight-conferences-rdhl-20200805monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-new-agreement-with-daiichi-sankyo-for-movantik-rdhl-20200803monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-fda-clearance-for-pivotal-phase-3-study-with-rhb-204-for-ntm-i-rdhl-20200731monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-initiates-global-phase-2-3-study-for-covid-19-rdhl-20200730monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-publishes-positive-ibs-d-phase-2-study-data-in-the-american-journal-of-g-rdhl-20200728monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-increases-patient-access-to-talicia-with-envisionrx-formularies-rdhl-20200727monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-accelerates-phase-2-3-covid-19-program-with-addition-of-brazil-and-mexic-rdhl-20200722monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-seeks-sec-review-of-suspicious-trading-activity-rdhl-20200721monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-approval-for-phase-2-3-covid-19-study-in-russia-rdhl-20200716monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-sachs-novel-coronavirus-investment-forum-rdhl-20200701monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-approval-for-covid-19-phase-2-3-study-with-opaganib-in-the-uk-rdhl-20200629monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-virtual-life-sciences-investor-forum-on-june-25-rdhl-20200622monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-expands-opaganib-covid-19-phase-2-3-study-with-clinical-trial-applicatio-rdhl-20200618monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-virtual-life-sciences-investor-forum-on-june-25-rdhl-20200618monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-submits-covid-19-clinical-trial-application-for-phase-2-3-study-with-opa-rdhl-20200610monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-provide-update-on-its-covid-19-and-other-development-programs-at-medi-rdhl-20200608monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-bio-digital-rdhl-20200601monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-jefferies-virtual-healthcare-conference-rdhl-20200528monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-q1-2020-financial-results-and-recent-highlights-including-initi-rdhl-20200527monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-first-quarter-financial-results-conference-call-on-may-27-2020-rdhl-20200520monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-ubs-virtual-global-healthcare-conference-rdhl-20200511monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-fda-approval-for-covid-19-clinical-study-with-opaganib-in-the-u-rdhl-20200508monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-publication-of-talicia-pivotal-phase-3-study-results-in-annals-rdhl-20200505monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-strengthens-coverage-for-talicia-with-preferred-brand-position-on-prime--rdhl-20200428monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-agreement-with-niaid-to-evaluate-rhb-107-against-covid-19-rdhl-20200420monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-initial-update-from-its-opaganib-covid-19-compassionate-use-pro-rdhl-20200413monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-approval-of-compassionate-use-of-opaganib-for-covid-19-in-ital-rdhl-20200406monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-first-covid-19-patient-treated-with-opaganib-in-israel-under-c-rdhl-20200406monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-completes-acquisition-of-movantik-from-astrazeneca-rdhl-20200402monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-business-update-rdhl-20200325monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-virtual-life-sciences-investor-forum-on-march-26-rdhl-20200323monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-preferred-position-for-talicia-on-express-scripts-national-pre-rdhl-20200313monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-update-on-opaganib-yeliva-rdhl-20200311monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-barclays-global-healthcare-conference-rdhl-20200310monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-u-s-commercial-launch-of-talicia-for-h-pylori-infection-rdhl-20200309monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-full-year-2019-financial-results-and-operational-highlights-rdhl-20200304monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-full-year-2019-financial-results-conference-call-on-march-4-2020-rdhl-20200227monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-enters-115-million-non-dilutive-financing-agreement-with-healthcare-roya-rdhl-20200225monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-acquires-rights-to-movantik-from-astrazeneca-rdhl-20200225monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-9th-annual-svb-leerink-global-healthcare-conference-rdhl-20200218monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-launches-h-pylori-disease-state-awareness-field-campaign-ahead-of-talici-rdhl-20200127monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-focus-commercial-efforts-on-talicia-and-aemcolo-discontinuing-promoti-rdhl-20200121monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-regains-rights-to-its-proprietary-bowel-preparation-rhb-106-rdhl-20200102monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-initiates-u-s-promotion-of-aemcolo-for-travelers-diarrhea-rdhl-20191217monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-third-quarter-2019-financial-results-and-operational-highlights-rdhl-20191119monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-third-quarter-2019-financial-results-conference-call-on-november-rdhl-20191113monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-publication-of-rhb-102-gastroenteritis-phase-3-study-results-i-rdhl-20191112monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-fda-approval-of-talicia-for-treatment-of-h-pylori-in-adults-rdhl-20191104monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-bio-europe-2019-conference-rdhl-20191029monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-new-phase-3-data-on-rhb-105-and-rhb-104-at-the-american-colle-rdhl-20191028monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-36-million-strategic-investment-by-cosmo-pharmaceuticals-and-u-rdhl-20191018monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-sponsors-no-stomach-for-cancer-s-symposium-ahead-of-stomach-cancer-aware-rdhl-20191016monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-full-results-from-positive-map-us-phase-3-study-and-supportive-rdhl-20191011monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-h2-2019-r-d-update-rdhl-20190926monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-upcoming-investor-conferences-in-september-rdhl-20190827monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-acceptance-of-oral-presentations-on-rhb-105-h-pylori-and-rhb-1-rdhl-20190821monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-second-quarter-2019-financial-results-and-operational-highlights-rdhl-20190723monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-second-quarter-2019-financial-results-conference-call-on-july-23-rdhl-20190715monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-fda-acceptance-of-new-drug-application-for-talicia-rdhl-20190703monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-allowance-for-new-u-s-patent-covering-rhb-104-for-crohn-s-disea-rdhl-20190610monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-appoints-dr-june-almenoff-as-chief-scientific-officer-rdhl-20190528monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-2019-bio-international-convention-rdhl-20190523monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-expands-commercial-management-team-ahead-of-planned-talicia-launch-rdhl-20190521monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-first-quarter-2019-financial-results-and-operational-highlights-rdhl-20190507monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-submits-new-drug-application-for-talicia-for-h-pylori-infection-rdhl-20190507monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-first-quarter-2019-financial-results-conference-call-on-may-7-20-rdhl-20190430monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-three-conferences-in-april-rdhl-20190404monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-bio-europe-spring-2019-conference-rdhl-20190318monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-31st-annual-roth-conference-rdhl-20190311monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-new-european-and-japanese-patents-for-talicia-rdhl-20190304monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-full-year-2018-financial-results-and-operational-highlights-rdhl-20190226monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-full-year-2018-financial-results-conference-call-on-february-26--rdhl-20190221monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-strengthens-management-team-with-appointment-of-rick-d-scruggs-as-chief--rdhl-20190220monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-8th-annual-svb-leerink-healthcare-conference-rdhl-20190219monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-fifth-u-s-patent-covering-talicia-for-h-pylori-infection-rdhl-20190117monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-closing-of-20-million-underwritten-offering-rdhl-20181211monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-pricing-of-20-million-underwritten-offering-rdhl-20181206monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-proposed-public-offering-of-its-american-depositary-shares-rdhl-20181204monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-top-line-results-from-confirmatory-phase-3-study-with-rdhl-20181203monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-bmo-2018-prescriptions-for-success-healthcare-conference-rdhl-20181129monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-presentation-on-yeliva-opaganib-for-multiple-myeloma-at-eortc--rdhl-20181114monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-third-quarter-2018-financial-results-and-business-highlights-rdhl-20181113monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-third-quarter-2018-financial-results-conference-call-on-november-rdhl-20181106monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-analyst-and-investor-webcast-on-talicia-for-h-pylori-infection-o-rdhl-20181029monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-bio-europe-2018-conference-rdhl-20181025monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-final-patient-assessed-in-confirmatory-phase-iii-study-with-ta-rdhl-20181024monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-additional-data-from-positive-phase-iii-study-of-rhb-104-in-cr-rdhl-20181022monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-late-breaking-abstract-on-positive-phase-iii-crohn-s-disease-study-with--rdhl-20181010monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-ladenburg-thalmann-2018-healthcare-conference-rdhl-20180920monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-end-of-phase-ii-meeting-with-fda-on-bekinda-for-ibs-d-rdhl-20180912monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-advancement-to-second-stage-of-phase-iia-study-with-yeliva-for-rdhl-20180906monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-completion-of-enrollment-for-confirmatory-phase-iii-study-with-rdhl-20180904monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-second-quarter-2018-financial-results-and-provides-update-on-ope-rdhl-20180830monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-second-quarter-2018-financial-results-conference-call-on-august--rdhl-20180824monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-allowance-for-new-u-s-patent-covering-rhb-106-an-encapsulated-b-rdhl-20180820monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-closing-of-25-million-underwritten-offering-rdhl-20180814monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-allowance-for-new-u-s-patent-covering-rhb-104-for-crohn-s-disea-rdhl-20180813monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-pricing-of-25-million-underwritten-offering-rdhl-20180809monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-elaborates-on-its-announced-positive-top-line-results-from-phase-iii-stu-rdhl-20180801monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-top-line-results-from-phase-iii-study-of-rhb-104-in-c-rdhl-20180730monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-initiates-co-promotion-of-hiv-aids-anti-diarrheal-drug-mytesi-rdhl-20180725monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-enrolls-400th-patient-in-confirmatory-phase-iii-study-with-talicia-for-h-rdhl-20180724monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-uplisting-to-nasdaq-global-market-rdhl-20180723monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-allowance-of-two-new-rhb-104-patents-ahead-of-top-line-phase-i-rdhl-20180702monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-u-s-co-promotion-agreement-with-napo-pharmaceuticals-for-hiv-a-rdhl-20180628monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-positive-phase-ii-results-of-bekinda-for-ibs-d-at-digestive-d-rdhl-20180530monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-new-u-s-patent-for-its-experimental-ebola-therapy-rdhl-20180529monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-investor-webcast-on-rhb-104-for-crohn-s-disease-on-may-15-rdhl-20180514monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-first-quarter-2018-financial-results-rdhl-20180508monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-last-patient-assessed-for-primary-endpoint-in-rhb-104-phase-ii-rdhl-20180507monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-enrollment-of-300th-patient-in-confirmatory-phase-iii-study-wi-rdhl-20180504monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-first-quarter-2018-financial-results-conference-call-on-may-8-20-rdhl-20180501monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-semi-annual-business-update-rdhl-20180409monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-two-oral-presentations-on-bekinda-24-mg-for-acute-gastroenteri-rdhl-20180327monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-ddw-2018-poster-of-distinction-on-positive-phase-ii-results-wi-rdhl-20180326monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-h-c-wainwright-annual-global-life-sciences-conference-rdhl-20180320monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-poster-presentation-on-new-potential-therapeutic-applications--rdhl-20180319monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-fourth-quarter-and-full-year-2017-investor-update-rdhl-20180222monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-fourth-quarter-and-full-year-2017-financial-results-conference-c-rdhl-20180213monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-bio-ceo-investor-conference-rdhl-20180201monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-express-scripts-subsidiary-inside-rx-add-enteragam-to-savings-progra-rdhl-20180117monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-final-results-from-phase-ii-study-with-bekinda-for-ibs-d-rdhl-20180116monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-initiation-of-phase-iia-study-with-abc294640-yeliva-for-cholan-rdhl-20171222monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-2017-year-end-business-update-rdhl-20171205monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-closing-of-public-offering-of-its-american-depositary-shares-rdhl-20171113monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-2017-third-quarter-financial-results-rdhl-20171113monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-last-patient-enrolled-in-the-phase-iii-study-with-rhb-104-for--rdhl-20171109monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-prices-public-offering-of-its-american-depositary-shares-rdhl-20171108monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-proposed-public-offering-of-its-american-depositary-shares-rdhl-20171107monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-third-quarter-2017-financial-results-conference-call-on-november-rdhl-20171106monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-enteragam-poster-presentation-at-the-ispor-20th-annual-europea-rdhl-20171106monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-intelgenx-submit-new-drug-application-to-fda-for-rizaport-for-migrai-rdhl-20171101monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-bio-europe-2017-conference-rdhl-20171026monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-notice-of-allowance-for-a-new-u-s-patent-covering-rhb-104-rdhl-20171023monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-fda-orphan-drug-designation-for-mesupron-for-pancreatic-cancer-rdhl-20171020monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-poster-presentation-at-the-2017-aacr-nci-eortc-molecular-targe-rdhl-20171019monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-bionetwork-2017-partnering-summit-rdhl-20171010monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-top-line-results-from-phase-ii-study-of-bekinda-in-pa-rdhl-20171003monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-accelerates-rhb-104-phase-iii-study-in-crohn-s-disease-with-top-line-res-rdhl-20171002monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-announce-top-line-results-from-bekinda-12-mg-phase-ii-study-for-ibs-d-rdhl-20170928monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-notice-of-allowance-for-a-new-u-s-patent-covering-its-combinati-rdhl-20170918monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-rdhl-20170918monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-initiates-promotion-of-esomeprazole-strontium-delayed-release-capsules-4-rdhl-20170913monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-10th-annual-biopharm-america-international-partnering--rdhl-20170907monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-rodman-renshaw-19th-annual-global-investment-conferenc-rdhl-20170831monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-u-s-commercialization-agreement-for-fda-approved-gi-product-es-rdhl-20170817monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-2017-semi-annual-business-update-rdhl-20170810monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-unanimous-positive-dsmb-recommendation-for-continuation-of-the-rdhl-20170731monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-2017-second-quarter-financial-results-rdhl-20170725monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-second-quarter-2017-financial-results-conference-call-on-july-25-rdhl-20170718monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-last-patient-visit-in-bekinda-phase-ii-study-for-ibs-d-rdhl-20170717monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-expected-timeline-for-dsmb-meeting-and-provides-update-on-enro-rdhl-20170712monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-conference-call-on-successful-phase-iii-top-line-results-with-be-rdhl-20170619monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-confirmatory-phase-iii-study-initiated-with-rhb-105-talicia-fo-rdhl-20170615monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-successful-phase-iii-top-line-results-with-bekinda-for-acute-g-rdhl-20170614monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-initiates-promotion-of-donnatal-and-enteragam-in-the-u-s-rdhl-20170613monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-2017-bio-international-convention-rdhl-20170606monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-poster-presentation-of-the-positive-rhb-105-phase-iii-results--rdhl-20170504monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-2017-first-quarter-financial-results-rdhl-20170503monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-first-quarter-2017-financial-results-conference-call-on-may-3-20-rdhl-20170425monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-enrollment-of-last-patient-in-the-bekinda-phase-ii-study-for-i-rdhl-20170424monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-peer-reviewed-publication-of-the-positive-yeliva-phase-i-study-rdhl-20170420monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-r-d-day-on-bekinda-for-acute-gastroenteritis-and-ibs-d-rdhl-20170419monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-notice-of-allowance-for-two-additional-u-s-patents-covering-bek-rdhl-20170418monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-intelgenx-announce-marketing-approval-of-rizaport-for-migraines-in-l-rdhl-20170413monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-exclusive-u-s-license-from-entera-health-for-commercial-gi-pro-rdhl-20170405monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-fda-orphan-drug-designation-for-yeliva-for-the-treatment-of-cho-rdhl-20170404monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-biocentury-future-leaders-in-the-biotech-industry-conferen-rdhl-20170330monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-2017-map-conference-rdhl-20170322monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-first-patient-dosed-in-the-open-label-extension-study-to-the-p-rdhl-20170321monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-bio-europe-spring-2017-conference-rdhl-20170313monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-s-co-promotion-partner-concordia-announces-u-s-district-court-grants-tre-rdhl-20170307monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-availability-of-its-annual-report-on-form-20-f-through-its-web-rdhl-20170223monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-2016-fourth-quarter-and-full-year-financial-results-rdhl-20170223monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-completes-treatment-of-last-patient-in-bekinda-phase-iii-study-for-acute-rdhl-20170221monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-fourth-quarter-and-full-year-2016-financial-results-conference-c-rdhl-20170216monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-enrollment-of-last-patient-in-bekinda-phase-iii-study-for-acut-rdhl-20170213monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-bio-ceo-investor-conference-rdhl-20170206monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-2017-semi-annual-business-update-rdhl-20170112monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-qidp-fast-track-designation-granted-by-fda-to-rhb-104-for-nont-rdhl-20170111monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-first-dosing-in-rhb-105-supportive-pk-studies-ahead-of-confirm-rdhl-20170110monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-s-rhb-105-positive-phase-iii-study-results-for-h-pylori-infection-presen-rdhl-20170109monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-exercise-of-stock-options-by-directors-and-senior-management-rdhl-20170109monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-yeliva-abc294640-abstract-presentation-at-the-2017-cholangioca-rdhl-20170106monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-new-research-collaboration-with-aarhus-university-for-oncology-rdhl-20170105monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-the-positive-results-of-the-first-phase-iii-study-with-rhb-10-rdhl-20170104monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-exercise-of-underwriters-option-rdhl-20170103monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-exclusive-u-s-co-promotion-agreement-with-concordia-for-gi-dru-rdhl-20170103monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-biotech-showcase-2017-rdhl-20161228monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-closing-of-concurrent-public-offering-and-registered-direct-of-rdhl-20161227monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-prices-concurrent-public-offering-and-registered-direct-offering-of-its--rdhl-20161221monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-proposed-concurrent-public-offering-and-registered-direct-offe-rdhl-20161220monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-first-patient-dosed-in-phase-ib-ii-study-with-yeliva-for-multi-rdhl-20161219monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-intelgenx-announce-definitive-agreement-for-commercialization-of-riz-rdhl-20161214monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-and-unanimous-dsmb-recommendation-for-continuation-of-rdhl-20161213monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-phase-iia-48-week-final-results-further-supporting-potential-o-rdhl-20161212monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-jefferies-microbiome-summit-rdhl-20161205monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-yeliva-abc294640-poster-presentation-at-the-2016-eortc-nci-aac-rdhl-20161121monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-german-equity-forum-2016-rdhl-20161116monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-2016-third-quarter-financial-results-rdhl-20161114monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-positive-fda-type-b-meeting-on-rhb-105-for-h-pylori-infection-ah-rdhl-20161110monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-third-quarter-2016-financial-results-conference-call-on-november-rdhl-20161107monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-jefferies-2016-london-healthcare-conference-rdhl-20161107monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-update-on-ongoing-phase-iii-and-phase-ii-studies-with-bekinda-a-rdhl-20161103monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-withdrawal-of-public-offering-of-its-american-depositary-share-rdhl-20161102monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-investor-conference-call-today-at-18-00-edt-following-announceme-rdhl-20161101monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-proposed-public-offering-of-its-american-depository-shares-rdhl-20161101monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-bio-europe-2016-conference-rdhl-20161031monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-allowance-of-a-patent-in-japan-supporting-rhb-104-for-multiple-rdhl-20161018monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-bio-investor-forum-2016-rdhl-20161013monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-webcast-today-at-8-30-am-edt-following-announcement-of-progress--rdhl-20161006monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-progress-update-on-rhb-104-phase-iii-crohn-s-disease-program-an-rdhl-20161006monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-initiation-of-phase-ii-study-with-yeliva-in-hepatocellular-car-rdhl-20161005monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-bionetwork-west-2016-partnering-summit-rdhl-20160927monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-intelgenx-announce-rizaport-commercialization-term-sheet-with-pharma-rdhl-20160921monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-research-collaboration-with-stanford-university-for-yeliva-rdhl-20160912monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-phase-ib-ii-study-with-yeliva-initiated-for-multiple-myeloma-a-rdhl-20160908monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-9th-annual-biopharm-america-international-partnering-c-rdhl-20160901monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-rodman-renshaw-18th-annual-global-investment-conferenc-rdhl-20160831monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-approval-of-a-european-patent-supporting-rhb-104-for-multiple--rdhl-20160829monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-2016-semi-annual-r-d-update-rdhl-20160811monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-last-patient-visit-in-phase-iia-study-with-rhb-104-for-multipl-rdhl-20160801monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-2016-second-quarter-financial-results-rdhl-20160726monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-additional-u-s-patent-covering-rhb-105-ahead-of-confirmatory-ph-rdhl-20160721monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-second-quarter-2016-financial-results-conference-call-on-july-26-rdhl-20160719monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-research-collaboration-with-nih-for-potential-ebola-treatment-rdhl-20160713monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-intelgenx-announce-definitive-agreement-for-commercialization-of-riz-rdhl-20160705monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-publication-demonstrating-potential-efficacy-of-rhb-104-for-cr-rdhl-20160622monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-final-results-with-primary-and-secondary-endpoints-me-rdhl-20160621monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-first-patients-dosed-in-phase-ii-study-with-bekinda-for-ibs-d-rdhl-20160620monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-jmp-securities-life-sciences-conference-rdhl-20160615monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-2016-bio-international-convention-rdhl-20160531monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-jefferies-2016-healthcare-conference-rdhl-20160530monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-national-cancer-institute-grant-supporting-yeliva-phase-ii-hep-rdhl-20160504monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-bionetwork-east-2016-partnering-summit-rdhl-20160425monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-2016-first-quarter-financial-results-rdhl-20160420monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-participate-in-the-fbr-co-healthcare-series-focused-on-infectious-dis-rdhl-20160419monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-fda-meeting-on-rhb-105-path-to-approval-and-planned-c-rdhl-20160418monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-first-quarter-2016-financial-results-conference-call-on-april-20-rdhl-20160413monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-initiates-phase-ii-study-of-bekinda-for-irritable-bowel-syndrome-rdhl-20160411monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-interim-results-from-phase-iia-proof-of-concept-study-supporti-rdhl-20160331monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-intelgenx-announce-rizaport-commercialization-term-sheet-with-grupo--rdhl-20160329monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-bio-europe-spring-2016-conference-rdhl-20160328monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-peer-reviewed-publication-demonstrating-therapeutic-potential--rdhl-20160310monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-28th-annual-roth-conference-rdhl-20160309monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-successful-final-results-of-phase-iii-study-with-rhb-105-for-h-p-rdhl-20160308monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-2016-r-d-update-rdhl-20160301monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-availability-of-its-annual-report-on-form-20-f-through-its-web-rdhl-20160225monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-2015-fourth-quarter-and-full-year-financial-results-rdhl-20160225monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-notice-of-allowance-for-u-s-patent-covering-rizaport-for-migra-rdhl-20160218monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-2015-fourth-quarter-and-year-end-financial-results-conference-ca-rdhl-20160218monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-appoints-dr-june-s-almenoff-and-ms-theresa-m-stevens-to-advisory-board-rdhl-20160217monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-successful-pk-study-with-bekinda-12-mg-and-submission-to-fda-o-rdhl-20160211monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-notice-of-allowance-of-fifth-u-s-patent-covering-rhb-104-phase--rdhl-20160210monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-issues-letter-to-shareholders-rdhl-20160209monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-collaboration-with-germany-s-fraunhofer-institute-for-oncology-rdhl-20160208monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-18th-annual-bio-ceo-investor-conference-rdhl-20160202monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-biotech-showcase-2016-rdhl-20160105monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-appointment-of-micha-ben-chorin-as-chief-financial-officer-rdhl-20151230monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-appointment-of-rick-d-scruggs-to-board-of-directors-rdhl-20151215monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-completion-of-dosing-in-phase-iia-study-of-rhb-104-for-multipl-rdhl-20151130monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-passing-of-board-member-alicia-rotbard-rdhl-20151130monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-jefferies-autumn-2015-global-healthcare-conference-rdhl-20151112monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-results-for-the-third-quarter-of-2015-rdhl-20151109monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-intelgenx-announce-first-european-marketing-approval-of-rizaport-tm--rdhl-20151109monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-third-quarter-2015-financial-results-conference-call-on-november-rdhl-20151029monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-bio-europe-2015-conference-rdhl-20151028monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-top-line-results-from-yeliva-tm-abc294640-phase-i-stu-rdhl-20151026monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-gelbart-kahana-biomed-conference-on-october-25-2015-rdhl-20151022monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-planned-management-changes-rdhl-20151022monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-national-cancer-institute-grant-awarded-to-apogee-biotechnolog-rdhl-20151022monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-bionetwork-west-partnering-summit-rdhl-20151019monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-update-on-bekinda-tm-ongoing-phase-iii-study-for-gastroenteriti-rdhl-20151014monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-intelgenx-announce-rizaport-tm-rhb-103-marketing-authorization-appli-rdhl-20150910monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-2-million-national-cancer-institute-grant-for-yeliva-tm-abc294-rdhl-20150909monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-standard-of-care-eradication-data-from-the-rhb-105-phase-iii-s-rdhl-20150908monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-rodman-renshaw-17th-annual-global-investment-conferenc-rdhl-20150902monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-last-patient-visit-in-the-phase-i-study-with-yeliva-tm-abc2946-rdhl-20150901monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-notice-of-allowance-for-new-israeli-patent-covering-rhb-104-for-rdhl-20150827monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-peer-reviewed-publication-demonstrating-therapeutic-potential--rdhl-20150824monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-rhb-104-phase-iii-crohn-s-program-at-the-international-resear-rdhl-20150812monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-results-for-the-second-quarter-of-2015-rdhl-20150729monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-update-on-rhb-106-program-partnered-with-salix-pharmaceuticals-rdhl-20150727monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-second-quarter-2015-financial-results-conference-call-on-july-29-rdhl-20150723monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-closing-of-public-offering-of-its-american-depository-shares-rdhl-20150722monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-prices-public-offering-of-its-american-depository-shares-rdhl-20150716monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-size-of-proposed-public-offering-of-its-american-depository-sh-rdhl-20150715monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-extends-option-agreement-for-phase-ii-stage-pancreatic-cancer-drug-rp101-rdhl-20150715monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-proposed-public-offering-of-its-american-depository-shares-rdhl-20150714monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-authorization-in-australia-and-new-zealand-for-ongoing-phase-ii-rdhl-20150706monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-notice-of-allowance-for-two-additional-u-s-patents-covering-rhb-rdhl-20150701monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-initiates-phase-i-ii-study-of-abc294640-for-refractory-lymphoma-rdhl-20150629monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-acceptance-of-phase-iii-trial-application-in-europe-with-rhb-1-rdhl-20150616monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-2015-bio-international-convention-rdhl-20150616monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-conference-call-today-to-review-positive-phase-iii-top-line-resu-rdhl-20150615monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-successfully-meets-primary-endpoint-in-phase-iii-study-of-rhb-105-for-h--rdhl-20150615monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-completion-of-patient-enrollment-in-the-phase-iia-study-of-rhb-rdhl-20150609monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-completes-treatment-of-last-patient-with-rhb-105-in-phase-iii-study-rdhl-20150608monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-update-on-development-pipeline-and-expected-timing-for-rhb-105--rdhl-20150603monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-jefferies-2015-global-healthcare-conference-rdhl-20150527monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-s-investor-webcast-forum-provides-update-on-the-rhb-105-phase-iii-progra-rdhl-20150518monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-biotrinity-2015-partnering-conference-rdhl-20150508monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-investor-webcast-forum-following-completion-of-rhb-105-dosing-in-rdhl-20150507monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-oppenheimer-16th-annual-israeli-conference-rdhl-20150504monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-results-for-the-first-quarter-of-2015-rdhl-20150430monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-bionetwork-east-2015-partnering-conference-rdhl-20150428monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-completion-of-patient-enrollment-in-a-phase-iii-study-of-rhb-1-rdhl-20150427monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-first-quarter-2015-financial-results-conference-call-on-april-30-rdhl-20150421monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-notice-of-allowance-for-additional-u-s-patent-for-rhb-105-h-pyl-rdhl-20150416monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-acquires-phase-ii-first-in-class-oral-small-molecule-sk2-inhibitor-from--rdhl-20150331monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-3rd-annual-autoimmune-inflammation-leaders-forum-2015-rdhl-20150323monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-bio-europe-spring-2015-international-partnering-conference-rdhl-20150303monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-27th-annual-roth-conference-rdhl-20150303monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-2014-fourth-quarter-and-year-end-financial-results-rdhl-20150226monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-2014-fourth-quarter-and-year-end-financial-results-conference-ca-rdhl-20150219monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-full-exercise-of-underwriters-over-allotment-option-rdhl-20150218monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-closing-of-public-offering-of-its-american-depository-shares-rdhl-20150213monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-life-sciences-israel-tm-2015-3rd-annual-international--rdhl-20150212monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-prices-public-offering-of-its-american-depository-shares-rdhl-20150210monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-proposed-public-offering-of-its-american-depository-shares-rdhl-20150209monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-update-on-progress-with-rhb-104-ongoing-phase-iii-program-for-c-rdhl-20150129monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-17th-annual-bio-ceo-investor-conference-rdhl-20150128monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-biotech-showcase-tm-2015-conference-in-san-francisco-rdhl-20150109monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-business-outlook-and-anticipated-key-milestones-for-2015-rdhl-20150105monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-acceptance-for-review-of-bekinda-tm-european-marketing-applica-rdhl-20141231monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-acquires-technology-from-university-of-minnesota-as-part-of-ongoing-rhb--rdhl-20141218monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-first-patients-enrolled-in-the-phase-iii-study-of-rhb-102-beki-rdhl-20141217monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-submits-bekinda-tm-rhb-102-european-marketing-authorization-application--rdhl-20141209monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-sponsor-and-exhibit-its-ongoing-phase-iii-crohn-s-program-at-the-isra-rdhl-20141202monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-intelgenx-announce-acceptance-for-review-of-european-marketing-appli-rdhl-20141201monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-results-for-the-third-quarter-of-2014-rdhl-20141110monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-third-quarter-2014-financial-results-conference-call-on-november-rdhl-20141028monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-20th-annual-bio-europe-international-partnering-confer-rdhl-20141022monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-intelgenx-submit-european-marketing-authorization-application-for-mi-rdhl-20141001monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-14th-annual-biotech-in-europe-forum-for-global-partner-rdhl-20140916monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-7th-annual-biopharm-america-international-partnering-c-rdhl-20140915monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-rodman-renshaw-16th-annual-global-investment-conferenc-rdhl-20140904monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-initiates-phase-iii-study-of-rhb-102-for-gastroenteritis-rdhl-20140903monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-update-on-expansion-of-ongoing-rhb-105-phase-iii-study-targetin-rdhl-20140827monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-acquires-option-for-phase-ii-pancreatic-cancer-drug-rp101-rdhl-20140813monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-results-for-the-second-quarter-of-2014-rdhl-20140723monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-second-quarter-2014-financial-results-conference-call-on-july-24-rdhl-20140716monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-acquires-phase-ii-oncology-drug-mesupron-r-from-wilex-ag-rdhl-20140630monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-preliminary-pre-clinical-data-with-rhb-104-for-the-tr-rdhl-20140626monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-2014-bio-international-convention-rdhl-20140618monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-wells-fargo-securities-9th-annual-healthcare-conferenc-rdhl-20140611monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-new-rhb-104-patent-in-japan-and-provides-update-on-phase-iii-c-rdhl-20140605monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-jefferies-2014-global-healthcare-conference-rdhl-20140602monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-fda-clearance-for-phase-iii-study-with-rhb-102-planned-to-comm-rdhl-20140522monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-intelgenx-report-positive-rhb-103-bioavailability-study-results-in-s-rdhl-20140521monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-chinabio-partnering-forum-2014-rdhl-20140501monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-results-for-the-first-quarter-of-2014-rdhl-20140430monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-successful-rhb-102-bioavailability-clinical-trial-and-planned-su-rdhl-20140430monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-first-quarter-2014-financial-results-conference-call-on-may-1-20-rdhl-20140429monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-intelgenx-announce-commencement-of-a-bioavailability-study-with-rhb--rdhl-20140428monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-intelgenx-provide-an-update-on-fda-s-ongoing-review-of-the-nda-for-r-rdhl-20140424monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-european-scientific-advice-meeting-regarding-rhb-102--rdhl-20140407monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-26th-annual-roth-conference-rdhl-20140307monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-update-on-rhb-102-development-and-intellectual-property-rdhl-20140307monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-intelgenx-submit-response-to-fda-crl-for-rhb-103-migraine-oral-film-rdhl-20140303monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-salix-pharmaceuticals-announce-worldwide-exclusive-license-agreement-rdhl-20140227monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-2013-fourth-quarter-and-year-end-financial-results-rdhl-20140225monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-intelgenx-receive-complete-response-letter-from-fda-for-rhb-103-oral-rdhl-20140204monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-closes-previously-announced-11-7-million-private-placement-rdhl-20140122monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-definitive-agreement-for-11-7-million-private-placement-rdhl-20140114monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-update-on-pk-program-in-support-of-ongoing-rhb-104-phase-iii-cr-rdhl-20140106monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-definitive-agreement-for-2-5-million-private-placement-from-br-rdhl-20131231monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-positive-pk-results-in-support-of-ongoing-rhb-105-phase-iii-h-py-rdhl-20131223monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-first-patients-dosed-in-phase-iii-study-of-rhb-105-for-h-pylor-rdhl-20131217monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-first-patient-dosed-in-phase-iii-study-of-rhb-104-for-crohn-s--rdhl-20131125monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-scientific-advice-meeting-and-european-marketing-appl-rdhl-20131118monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-results-for-the-third-quarter-of-2013-rdhl-20131112monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-19th-annual-bio-europe-international-partnering-confer-rdhl-20131031monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-initiates-phase-iii-study-of-rhb-105-for-h-pylori-infection-rdhl-20131030monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-2013-annual-bionetwork-conference-rdhl-20131023monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-fda-acceptance-of-ind-application-for-rhb-105-h-pylori-phase-i-rdhl-20131022monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-s-rhb-104-combination-achieves-80-remission-in-independent-pediatric-cro-rdhl-20131015monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-positive-pk-clinical-studies-towards-planned-nda-with-rhb-102-an-rdhl-20131008monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-initiates-phase-iii-study-of-rhb-104-for-crohn-s-disease-rdhl-20131001monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-annual-biopharm-america-international-partnering-confe-rdhl-20130911monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-pre-clinical-results-for-lupus-with-rhb-104-rdhl-20130910monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-stifel-nicolaus-annual-healthcare-conference-rdhl-20130903monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-european-regulatory-meetings-regarding-its-european-p-rdhl-20130820monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-pre-clinical-rheumatoid-arthritis-results-with-rhb-10-rdhl-20130730monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-results-for-the-second-quarter-of-2013-rdhl-20130722monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-update-on-planned-nda-filing-for-rhb-102-once-daily-anti-emetic-rdhl-20130711monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-jmp-securities-annual-healthcare-conference-in-new-yor-rdhl-20130703monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-fda-acceptance-for-review-of-rhb-103-nda-for-acute-migraine-an-rdhl-20130618monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-commences-patient-screening-in-a-phase-iia-clinical-trial-with-rhb-104-f-rdhl-20130605monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-fda-meeting-regarding-the-regulatory-path-towards-nda-rdhl-20130529monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-jefferies-2013-global-healthcare-conference-in-new-yor-rdhl-20130528monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-financial-results-for-the-first-quarter-of-2013-rdhl-20130502monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-submits-new-drug-application-to-u-s-fda-for-rhb-103-anti-migraine-oral-t-rdhl-20130327monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-positive-feedback-from-a-scientific-advice-meeting-in-europe-re-rdhl-20130319monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-25th-annual-roth-conference-rdhl-20130306monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-update-on-development-progress-and-planned-nda-submission-for-r-rdhl-20130225monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-2012-fourth-quarter-and-year-end-results-rdhl-20130219monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-notice-of-allowance-from-the-united-states-patent-and-trademar-rdhl-20130219monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-date-of-2012-financial-results-and-corporate-update-conference-rdhl-20130214monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-issuance-of-new-u-s-patent-and-provides-update-on-rhb-104-for--rdhl-20130107monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-nasdaq-listing-and-commencement-of-trading-under-the-ticker-rd-rdhl-20121227monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-reports-8-study-drug-doses-in-phase-iia-clinical-trial-of-onp-002-for-mild-traum-ogen-20260420monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-files-annual-report-on-form-10-k-ogen-20260317monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-initiates-phase-iia-clinical-trial-site-activation-ogen-20260312monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-explores-expansion-of-cns-platform-pursuing-acquistion-of-assets-in-brain-health-ogen-20260311monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-receives-hrec-approval-for-phase-iia-clinical-trial-of-onp-002-as-a-treatment-fo-ogen-20260310monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-health-and-disability-ethics-committee-submission-for-phase-iia-co-ogen-20250409monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-participates-in-the-3rd-nasal-formulation-delivery-summit-ogen-20250407monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-provides-q1-2025-shareholder-update-on-strategic-and-financial-progress-ogen-20250327monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-filing-of-2024-annual-report-on-form-10-k-ogen-20250318monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-submits-investigator-s-brochure-for-phase-ii-clinical-trial-of-onp-002-in-mi-ogen-20250306monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-chief-medical-officer-dr-james-p-kelly-to-present-at-the-emergencies-in-medi-ogen-20250225monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-chief-medical-officer-dr-james-kelly-joins-the-medical-board-of-the-leigh-st-ogen-20250224monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-partnership-with-brainbox-solutions-to-revolutionize-concussion-di-ogen-20250211monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-chief-medical-officer-dr-james-p-kelly-to-participate-in-the-12th-annual-bra-ogen-20250205monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-provides-shareholder-update-on-strategic-progress-and-announces-janet-huffma-ogen-20250121monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-conversion-of-preferred-shares-and-elimination-of-liquidation-pref-ogen-20241216monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-to-present-at-the-centurion-one-capital-2nd-annual-bahamas-summit-ogen-20241018monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-updates-shareholders-on-concussion-drug-progress-and-phase-ii-trial-preparat-ogen-20241009monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-successfully-completes-key-fda-recognized-study-for-onp-002-ogen-20241008monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-closing-of-public-offering-ogen-20240905monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-pricing-of-public-offering-ogen-20240904monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-completes-spray-dry-drug-manufacturing-and-intranasal-device-filling-in-anti-ogen-20240821monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-provides-update-on-its-drug-intended-to-treat-concussion-and-non-compliance--ogen-20240816monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-shows-concussion-drug-onp-002-designed-for-acute-field-delivery-stable-acros-ogen-20240814monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-concussion-drug-successfully-completes-fda-required-genotoxicity-s-ogen-20240812monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-concussion-drug-onp-002-successfully-clears-fda-required-cardiotox-ogen-20240808monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-improves-intranasal-drug-formulation-for-treating-concussed-patients-ogen-20240710monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-develops-automated-intranasal-device-for-treating-concussed-patients-ogen-20240627monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-closing-of-public-offering-ogen-20240626monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-pricing-of-public-offering-ogen-20240625monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-proposed-public-offering-ogen-20240624monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-nyse-american-acceptance-of-plan-of-compliance-ogen-20240620monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-appoints-william-frank-peacock-md-as-chief-clinical-officer-ogen-20240522monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-to-host-webinar-panel-on-neurotrauma-medicine-ogen-20240517monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-prepares-intranasal-pharmaceutical-onp-002-for-phase-ii-concussion-trial-ogen-20240516monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-partners-with-avance-clinical-for-phase-ii-concussion-trial-in-australia-ogen-20240507monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-substitute-director-nominees-for-its-upcoming-annual-and-special-meeting-o-xrtx-20260318monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-usd-114-500-private-placement-xrtx-20250731monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-usd-925-000-private-placement-xrtx-20250626monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-usd-3-million-offering-xrtx-20250519monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-provides-update-on-fda-type-b-meeting-request-xrtx-20250430monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-grant-of-european-patent-xrtx-20250428monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-receipt-of-nasdaq-notification-regarding-minimum-bid-price-deficiency-xrtx-20250417monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-update-for-discussion-with-the-fda-xrtx-20250319monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-commences-gout-program-nda-discussions-with-the-fda-xrtx-20250224monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-to-present-at-microcap-conference-xrtx-20250129monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-change-of-auditor-xrtx-20250117monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-adds-late-stage-gout-program-to-pipeline-xrtx-20250106monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-strengthens-executive-team-xrtx-20241219monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-presentation-at-the-rare-and-genetic-disease-summit-xrtx-20241212monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-sponsored-study-presented-at-the-american-society-of-nephrology-kidney-week-2024-xrtx-20241024monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-closing-of-us-1-5-million-registered-direct-offering-and-concurrent-privat-xrtx-20241018monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-pricing-of-us-1-5-million-registered-direct-offering-and-concurrent-privat-xrtx-20241017monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-initiates-precision-medicine-program-xrtx-20241009monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-results-of-annual-and-special-meeting-of-shareholders-xrtx-20240913monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-re-filing-of-ye-2023-and-q2-2024-md-a-xrtx-20240912monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-reminds-shareholders-of-voting-deadline-for-upcoming-annual-and-special-meeting-of-s-xrtx-20240906monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-highlights-pioneering-research-indicating-a-role-for-genetic-regulation-of-xanthine--xrtx-20240829monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-filing-and-mailing-of-the-meeting-documents-in-connection-with-the-annual--xrtx-20240823monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-presentation-at-american-society-of-nephrology-kidney-week-2024-xrtx-20240820monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-to-present-at-bio-international-convention-2024-xrtx-20240604monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-reprices-balance-of-warrants-issued-in-connection-with-october-2021-us-ipo-xrtx-20240517monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-reprices-warrants-issued-in-connection-with-previous-private-placements-xrtx-20240430monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-publication-of-key-research-in-adpkd-xrtx-20240422monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-welcomes-new-member-to-the-board-of-directors-xrtx-20240408monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-participation-in-spring-2024-investor-conferences-xrtx-20240408monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-new-clinical-advisory-board-member-xrtx-20240327monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-highlights-achievements-of-2023-and-preparation-for-registration-clinical-trial-xrtx-20240319monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-reprices-warrants-issued-in-connection-with-previous-private-placements-xrtx-20240311monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-finalizes-2-7-million-prospectus-supplement-and-concurrent-private-placement-for-the-xrtx-20240304monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-raises-2-5-million-under-prospectus-supplement-and-concurrent-private-placement-for--xrtx-20240215monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-files-an-amended-and-restated-prospectus-supplement-for-the-offering-of-units-xrtx-20240202monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-2-million-public-offering-xrtx-20240115monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-submits-a-new-patent-for-the-treatment-of-chronic-kidney-disease-xrtx-20240103monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-welcomes-new-member-to-the-board-of-directors-xrtx-20240102monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-us-atm-offering-xrtx-20231130monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-meets-nasdaq-continued-listing-requirements-xrtx-20231129monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-clarifies-timing-for-share-consolidation-xrtx-20231110monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-share-consolidation-xrtx-20231108monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-sponsored-study-presented-at-the-american-society-of-nephrology-kidney-week-2023-xrtx-20231102monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-results-of-special-meeting-of-shareholders-xrtx-20231027monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-date-for-rescheduled-special-meeting-of-shareholders-xrtx-20231025monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-rescheduling-of-special-meeting-of-shareholders-xrtx-20231025monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-reports-that-independent-proxy-firm-iss-recommends-shareholders-vote-for-the-share-c-xrtx-20231012monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-calls-special-meeting-of-shareholders-xrtx-20231004monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-sponsored-study-selected-for-presentation-at-the-american-society-of-nephrology-kidn-xrtx-20230928monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-participation-at-upcoming-investor-conferences-xrtx-20230911monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-joins-the-kidney-foundation-and-kidney-march-xrtx-20230907monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-submits-orphan-drug-designation-application-to-the-european-medicines-agency-ema-to--xrtx-20230829monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-appoints-chief-financial-officer-xrtx-20230804monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-results-of-annual-and-special-meeting-of-shareholders-xrtx-20230629monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-reminds-shareholders-to-vote-ahead-of-the-proxy-voting-deadline-for-the-company-s-up-xrtx-20230624monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-pkd-presentation-xrtx-20230606monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-180-day-extension-to-regain-compliance-with-nasdaq-minimum-bid-price-defic-xrtx-20230524monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-receipt-of-fda-orphan-drug-designation-to-treat-autosomal-dominant-kidney--xrtx-20230421monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-type-d-meeting-with-fda-to-be-held-may-1-2023-xrtx-20230314monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-provides-update-on-2022-achievements-and-2023-planned-milestones-xrtx-20230207monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-submission-of-orphan-drug-designation-request-for-xrx-008-program-to-treat-xrtx-20230201monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-positive-topline-results-from-xrx-oxy-101-clinical-trial-xrtx-20230119monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-files-new-provisional-patent-to-diagnose-and-treat-individuals-most-at-risk-of-polyc-xrtx-20230103monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-completion-of-dosing-in-xrx-oxy-101-clinical-study-xrtx-20221219monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-new-proof-of-concept-data-in-autosomal-dominant-polycystic-kidney-disease--xrtx-20221208monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-completion-of-screening-and-enrollment-in-bridging-pharmacokinetics-study-xrtx-20221128monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-receipt-of-nasdaq-notification-regarding-minimum-bid-price-deficiency-xrtx-20221125monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-therapeutics-appoints-stacy-evans-m-d-mba-as-chief-business-officer-xrtx-20221116monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-presents-new-proof-of-concept-data-at-american-society-of-nephrology-xrtx-20221103monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-participation-at-upcoming-investor-conferences-xrtx-20221103monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-receives-further-no-objection-letter-from-health-canada-xrtx-20221026monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-sponsored-american-society-of-nephrology-study-abstract-available-online-xrtx-20221025monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-closing-of-us-5-million-public-offering-xrtx-20221007monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-us-5-million-public-offering-xrtx-20221004monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-completes-positive-pre-phase-3-meeting-with-the-us-food-and-drug-administration-xrtx-20220919monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-sponsored-study-selected-for-presentation-at-the-american-society-of-nephrology-kidn-xrtx-20220901monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-positive-topline-results-from-part-2-pharmacokinetics-bridging-study-xrtx-20220822monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-pre-phase-3-meeting-date-with-us-food-and-drug-administration-xrtx-20220804monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-reports-annual-special-meeting-results-xrtx-20220722monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-submission-to-european-medicines-agency-xrtx-20220719monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-positive-topline-results-from-pharmacokinetics-bridging-clinical-trial-xrtx-20220713monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-pre-phase-3-meeting-request-with-us-food-and-drug-administration-fda-xrtx-20220707monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-fireside-chat-with-xortx-ceo-xrtx-20220621monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-to-present-at-bio-international-convention-2022-xrtx-20220613monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-to-present-at-ld-micro-invitational-2022-xrtx-20220608monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-welcomes-new-member-to-the-board-of-directors-and-appoints-chair-xrtx-20220606monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-to-present-at-h-c-wainwright-global-investment-conference-2022-xrtx-20220525monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-opens-an-ind-for-xrx-008-program-for-autosomal-dominant-polycystic-kidney-disease-xrtx-20220505monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-initiates-dosing-of-human-subjects-in-the-xrx-oxy-101-clinical-trial-xrtx-20220503monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-receives-small-and-medium-enterprise-status-for-the-european-union-xrtx-20220420monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-receives-no-objection-letter-from-health-canada-xrtx-20220412monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-grant-of-us-patent-xrtx-20220407monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-files-ind-with-us-fda-xrtx-20220331monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-files-new-pct-patent-to-treat-and-protect-individuals-most-at-risk-to-severe-viral-i-xrtx-20220323monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-therapeutics-announces-submission-of-clinical-trial-application-to-conduct-bridging--xrtx-20220314monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-provides-corporate-update-xrtx-20220131monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-appointment-of-chief-technology-officer-xrtx-20220120monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-to-participate-in-h-c-wainwright-bioconnect-2022-virtual-conference-xrtx-20220110monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-reports-annual-special-meeting-results-xrtx-20211221monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-therapeutics-announces-filing-of-provision-patent-for-polycystic-kidney-disease-xrtx-20211221monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-therapeutics-announces-publication-of-mt-sinai-study-of-hospitalized-covid-19-patien-xrtx-20211210monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-research-coverage-initiated-by-a-g-p-alliance-global-partners-xrtx-20211209monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-therapeutics-appoints-altasciences-as-cro-for-clinical-study-xrtx-20211202monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-therapeutics-announces-annual-and-special-meeting-of-shareholders-xrtx-20211123monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-therapeutics-announces-partial-exercise-of-over-allotment-option-pursuant-to-us-publ-xrtx-20211109monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-therapeutics-clarifies-halt-of-trading-in-canada-and-timing-for-commencement-of-trad-xrtx-20211104monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-therapeutics-receives-final-approval-to-list-on-the-tsx-venture-exchange-xrtx-20211102monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-therapeutics-announces-closing-of-us-12-million-public-offering-xrtx-20211015monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-results-from-mount-sinai-s-covid-19-clinical-study-xrtx-20211014monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-to-present-at-the-ld-micro-main-event-xrtx-20211014monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-therapeutics-announces-pricing-of-us-12-million-public-offering-and-nasdaq-listing-xrtx-20211013monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-therapeutics-announces-share-consolidation-xrtx-20210920monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-therapeutics-reports-special-meeting-results-xrtx-20210902monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-grant-of-european-patent-xrtx-20210901monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-new-clinical-advisory-board-member-xrtx-20210831monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-therapeutics-calls-special-meeting-of-shareholders-xrtx-20210813monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-therapeutics-strengthens-executive-team-xrtx-20210714monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-welcomes-jaqueline-le-saux-to-board-of-directors-xrtx-20210617monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-welcomes-new-member-to-board-of-directors-xrtx-20210513monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-notice-to-grant-european-patent-xrtx-20210406monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-to-present-at-zoom-with-ld-micro-xrtx-20210316monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-to-present-and-participate-in-the-sachs-14th-annual-european-life-sciences-ceo-forum-xrtx-20210309monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-files-new-provisional-patent-to-treat-and-protect-individuals-most-at-risk-to-severe-xrtx-20210308monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-confirms-1-million-in-warrant-exercise-proceeds-xrtx-20210302monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-participating-in-wuxi-healthcare-forum-xrtx-20210301monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-to-present-at-bio-ceo-and-investor-conference-xrtx-20210217monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-closes-over-subscribed-private-placement-xrtx-20210210monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-over-subscribed-private-placement-xrtx-20210208monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-increase-to-private-placement-xrtx-20210128monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-provides-corporate-update-xrtx-20210119monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-grants-options-xrtx-20210112monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-private-placement-xrtx-20210107monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-grant-of-european-patent-xrtx-20201229monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-topline-results-from-mount-sinai-s-covid-19-clinical-study-xrtx-20201116monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-participation-in-virtual-conferences-xrtx-20201028monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-reports-annual-special-meeting-results-xrtx-20201023monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-receives-positive-feedback-from-fda-on-covid-19-related-acute-kidney-injury-xrtx-20201008monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-highlights-new-studies-of-acute-kidney-disease-due-to-covid-19-infection-xrtx-20200915monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-files-u-s-fda-pre-ind-meeting-request-for-xrx-101-oxypurinol-covid-19-program-and-pr-xrtx-20200831monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-change-to-board-of-directors-xrtx-20200828monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-appoints-dr-david-sans-in-new-york-as-director-corporate-development-xrtx-20200807monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-partners-with-mount-sinai-s-icahn-school-of-medicine-on-us-based-clinical-trial-in-c-xrtx-20200804monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-mr-anthony-j-giovinazzo-to-join-as-special-advisor-to-the-board-of-directo-xrtx-20200623monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-provides-program-update-regarding-xrx-008-for-adpkd-and-xrx-101-for-coronavirus-covi-xrtx-20200519monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-appoints-lonza-for-gmp-manufacturing-and-formulation-of-xrx-101-oxypurinol-for-coron-xrtx-20200430monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-provides-overview-and-update-of-key-activities-xrtx-20200430monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-new-clinical-advisory-board-member-xrtx-20200326monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-launches-xrx-101-following-the-filing-of-a-provisional-patent-to-potentially-treat-r-xrtx-20200316monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-launches-xrx-101-a-new-program-to-treat-coronavirus-covid-19-infection-xrtx-20200316monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-first-tranche-closing-of-non-brokered-private-placement-xrtx-20200302monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-re-pricing-of-private-placement-xrtx-20200201monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-positive-phase-2-results-in-type-2-diabetic-nephropathy-t2dn-xrtx-20190920monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-highlights-new-research-on-polycystic-kidney-disease-awareness-day-xrtx-20190904monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-virtual-investor-conference-live-webcast-xrtx-20190730monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-reports-annual-special-meeting-results-xrtx-20190719monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-shares-nature-nephrology-review-xrtx-20190715monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-provides-overview-and-announces-5-million-financing-to-advance-clinical-trials-xrtx-20190429monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-shares-findings-of-diabetes-study-in-youths-supporting-high-uric-acid-advances-kidne-xrtx-20190416monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-shares-findings-of-new-diabetes-study-supporting-uric-acid-as-an-independent-risk-fa-xrtx-20190325monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-signs-loi-for-co-development-and-licensing-agreement-with-japan-s-teijin-pharma-limi-xrtx-20190312monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-to-present-at-nobleconxv-noble-capital-markets-15th-annual-investor-conference-xrtx-20190128monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-receives-fda-response-on-orphan-drug-designation-application-xrtx-20181126monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-appointment-of-cfo-xrtx-20181107monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-revision-to-polycystic-kidney-disease-clinical-development-plan-xrtx-20181023monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-new-clinical-advisory-board-members-xrtx-20181015monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-submission-of-orphan-drug-designation-application-xrtx-20180910monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-submits-fda-pre-ind-meeting-documents-xrtx-20180813monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-reports-on-annual-special-meeting-and-provides-corporate-update-xrtx-20180628monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-filing-of-fda-pre-ind-meeting-request-letter-xrtx-20180608monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-to-commence-trading-on-the-otcqb-venture-market-xrtx-20180606monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-appoints-chairman-xrtx-20180508monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-pkd-foundation-collaboration-xrtx-20180419monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-issuance-of-stock-options-xrtx-20180321monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-therapeutics-provides-corporate-update-xrtx-20180227monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-therapeutics-appoints-dave-matthews-cfo-xrtx-20180222monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-therapeutics-announces-appointment-of-allan-williams-and-paul-van-damme-xrtx-20180129monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-moves-principal-office-to-new-york-city-sbfm-20231204monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-reports-2023-second-quarter-results-revenues-up-3-600-sbfm-20230811monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-reports-2023-first-quarter-results-revenues-up-2-100-sbfm-20230511monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-reports-full-year-ended-december-31-2022-financial-results-and-provides-sbfm-20230405monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-signs-exclusive-worldwide-license-with-university-of-arizona-for-plpro--sbfm-20230228monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-signs-research-agreement-with-the-jewish-general-hospital-to-advance-th-sbfm-20230210monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-announces-share-repurchase-program-sbfm-20230119monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-s-annual-letter-to-shareholders-sbfm-20221220monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-enters-into-a-collaboration-agreement-with-a-leading-lipid-nanoparticle-sbfm-20221116monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-announces-the-acquisition-of-nora-pharma-adding-10-7-million-in-revenue-sbfm-20221020monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-files-its-second-quarter-report-with-the-sec-sbfm-20220804monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-increases-support-for-anti-coronavirus-collaborative-research-with-the--sbfm-20220728monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-inc-announces-closing-of-19-5-million-private-placement-priced-at-the-m-sbfm-20220428monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-inc-announces-pricing-of-19-5-million-private-placement-priced-at-the-m-sbfm-20220426monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-files-patent-application-covering-recently-announced-mrna-molecules-fou-sbfm-20220425monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-s-newly-designed-mrna-molecules-prove-effective-against-multidrug-resis-sbfm-20220405monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-inc-announces-closing-of-8-0-million-private-placement-priced-at-the-ma-sbfm-20220314monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-inc-announces-pricing-of-8-0-million-private-placement-priced-at-the-ma-sbfm-20220310monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-expands-anti-coronavirus-drug-development-program-by-signing-a-collabor-sbfm-20220225monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-inc-announces-closing-of-8-million-public-offering-and-uplisting-to-the-sbfm-20220217monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-inc-announces-pricing-of-8-million-public-offering-and-uplisting-to-the-sbfm-20220215monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-announces-1-361-000-in-debt-reduction-sbfm-20211222monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-expands-board-of-directors-sbfm-20211103monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-files-a-patent-application-covering-mrna-molecules-for-treatment-of-neu-sbfm-20211006monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-s-coronavirus-treatment-anticipated-to-be-effective-against-delta-and-t-sbfm-20210812monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-opens-twitter-account-for-increased-shareholder-engagement-sbfm-20210727monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-receives-0-9-million-in-additional-funding-from-rb-capital-sbfm-20210720monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-employs-mrna-vaccine-technology-to-expand-its-fight-against-multidrug-r-sbfm-20210708monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-mice-study-for-covid-19-treatment-progressing-as-planned-sbfm-20210609monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-s-adva-27a-destroys-cancer-cells-expressing-p-glycoprotein-a-marker-pre-sbfm-20210525monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-eliminates-250-000-in-variable-rate-convertible-debt-and-provides-an-up-sbfm-20210520monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-reports-improved-cash-position-in-2021q1-filing-sbfm-20210513monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-upgrades-covid-19-provisional-patent-application-to-full-pct-applicatio-sbfm-20210504monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-reports-favorable-mtd-results-for-covid-19-treatment-sbfm-20210419monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-reaches-2-000-000-financing-for-coronavirus-treatment-sbfm-20210323monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-receives-notice-of-allowance-for-a-new-patent-application-extending-pro-sbfm-20210311monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-receives-recently-ordered-new-batch-of-adva-27a-and-initiates-qa-qc-tes-sbfm-20210304monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-launches-ecommerce-store-for-its-science-based-nutritional-supplements-sbfm-20210301monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-announces-issuance-of-notice-of-allowance-for-the-patent-application-co-sbfm-20150324monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-aims-to-follow-in-herceptin-s-footsteps-sbfm-20110810monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-looking-to-mimic-roche-s-billion-dollar-cancer-drug-success-sbfm-20110727monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-announces-1-33-million-registered-direct-offering-scni-20230915monthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-inc-announces-10-million-registered-direct-offering-sxtc-20260109monthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-inc-announces-strategic-ai-insights-initiative-to-optimize-tradi-sxtc-20260108monthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-inc-regained-compliance-with-nasdaq-s-minimum-bid-price-rule-sxtc-20231026monthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-inc-received-nasdaq-notification-letter-regarding-bid-price-defi-sxtc-20221107monthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-inc-announces-1-for-20-reverse-share-split-sxtc-20220518monthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-inc-prices-3-5-million-underwritten-public-offering-of-ordinary--sxtc-20220118monthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-inc-announces-proposed-underwritten-public-offering-of-ordinary--sxtc-20220114monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights-gctk-20260514monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-ide-submission-for-u-s-clinical-study-of-its-novel-implantable-contin-gctk-20260507monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-publication-of-peer-reviewed-study-in-the-journal-of-diabetes-researc-gctk-20260430monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-publication-of-peer-reviewed-study-supporting-long-life-sensor-design-gctk-20260421monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporat-gctk-20260330monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-reports-third-quarter-2025-financial-results-and-provides-update-on-recent-corp-gctk-20251113monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-inc-reminds-shareholders-to-vote-gctk-20251028monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-to-showcase-long-term-continuous-blood-glucose-monitor-at-american-diabetes-ass-gctk-20250604monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-strengthens-board-of-directors-with-election-of-victoria-e-carr-brendel-phd-gctk-20250528monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-establishes-patient-advisory-board-to-inform-diabetes-technology-development-gctk-20250520monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-reports-first-quarter-2025-financial-results-and-recent-corporate-highlights-gctk-20250514monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-ethical-approval-for-long-term-clinical-study-of-continuous-blood-glu-gctk-20250513monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-to-participate-in-forgetdiabetes-a-prominent-european-research-initiative-to-de-gctk-20250416monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-and-onetwo-analytics-to-collaborate-for-clinical-study-analysis-on-its-continuo-gctk-20250403monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-reports-full-year-2024-financial-results-and-recent-corporate-highlights-gctk-20250331monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-to-present-first-in-human-study-results-for-continuous-blood-glucose-monitor-at-gctk-20250319monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-appoints-guillermo-umpierrez-md-cdces-face-macp-as-new-medical-advisory-board-m-gctk-20250226monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-inc-announces-pricing-of-3-0-million-public-offering-gctk-20250204monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-successful-completion-of-its-first-human-clinical-study-of-continuous-gctk-20250204monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-reverse-stock-split-gctk-20250130monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-strengthens-leadership-team-with-appointment-of-new-chief-financial-officer-gctk-20250129monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-iso-13485-2016-certification-gctk-20250121monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-strenghtens-leadership-team-with-addition-of-industry-veteran-as-vice-president-gctk-20250115monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-to-present-at-techbio-showcase-2025-gctk-20250107monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-start-of-enrollment-for-human-clinical-study-of-continuous-blood-gluc-gctk-20241203monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-inc-announces-closing-of-10-0-million-public-offering-and-concurrent-private-pl-gctk-20241114monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-inc-announces-pricing-of-10-0-million-public-offering-gctk-20241113monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-to-present-at-2024-biofuture-conference-gctk-20241022monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-oral-poster-presentations-at-the-2024-diabetes-technology-meeting-gctk-20241001monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-new-vice-president-of-clinical-operations-gctk-20240827monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-s-innovative-blood-glucose-monitoring-concept-resonates-with-patients-with-diab-gctk-20240815monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-poster-presentation-on-continuous-blood-glucose-monitor-survey-data-a-gctk-20240805monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-new-funding-for-development-of-its-continuous-blood-glucose-monitor-gctk-20240731monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-the-appointment-of-andy-balo-to-board-of-directors-gctk-20240620monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-reports-successful-completion-of-first-reported-long-term-preclinical-study-of--gctk-20240613monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-to-present-in-the-june-2024-sidoti-small-cap-conference-gctk-20240610monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-90-day-preclinical-study-results-that-demonstrate-sustained-accuracy--gctk-20240605monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-s-epidural-glucose-monitoring-sensor-demonstrates-successful-30-day-safety-perf-gctk-20240516monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-reverse-stock-split-gctk-20240515monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-abstracts-accepted-for-poster-presentation-at-84th-scientific-session-gctk-20240502monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-closing-of-private-placement-gctk-20240422monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-expansion-of-its-continuous-glucose-monitoring-technology-to-epidural-gctk-20240416monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-increased-sensor-longevity-for-its-implantable-continuous-blood-gluco-gctk-20240402monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-expands-leadership-team-with-new-vice-president-of-quality-gctk-20240312monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-selects-cirtec-medical-as-manufacturer-for-its-implantable-continuous-blood-glu-gctk-20240227monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-early-accuracy-data-for-its-implantable-continuous-glucose-monitor-gctk-20240102monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-180-day-extension-to-regain-compliance-with-nasdaq-minimum-bid-price--gctk-20231130monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-shareholder-update-gctk-20231113monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-preclinical-testing-with-implantable-continuous-glucose-monitor-gctk-20231012monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-the-appointment-of-erin-carter-to-board-of-directors-gctk-20230831monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-new-vp-of-marketing-gctk-20230828monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-positive-data-from-feasibility-study-for-implantable-continuous-gluco-gctk-20230725monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-closes-10-million-underwritten-public-offering-of-common-stock-gctk-20230417monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-pricing-of-10-million-underwritten-public-offering-of-common-stock-gctk-20230413monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-proposed-underwritten-public-offering-of-common-stock-gctk-20230412monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-provides-shareholder-update-gctk-20230314monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-the-hiring-of-dr-mark-tapsak-gctk-20221014monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-to-begin-research-development-of-novel-continuous-glucose-monitoring-system-gctk-20221010monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-inc-provides-development-update-on-its-gen-2-non-invasive-glucose-monitor-gctk-20220622monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-inc-announces-effectiveness-of-corporate-name-change-and-ticker-symbol-change-gctk-20220314monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-subsidiary-neurothera-labs-75-signs-definitive-agreement-to-acquire-majority-stak-sprc-20260310monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-resolves-to-launch-innovative-quantum-computing-enabled-3d-protein-modeling-initi-sprc-20250925monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-clearmind-collaboration-leads-to-publication-of-international-patent-application--sprc-20250807monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-updates-regarding-proposed-merger-form-f-4-registration-statement-has-b-sprc-20250730monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-clearmind-collaboration-leads-to-filing-of-international-patent-application-for-n-sprc-20250730monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-regains-compliance-with-nasdaq-minimum-bid-price-notification-sprc-20250722monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-1-for-21-reverse-share-split-sprc-20250624monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-publication-of-japanese-patent-application-sprc-20250527monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-clearmind-collaboration-leads-to-publication-of-european-patent-for-psychedelic-b-sprc-20250512monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-clearmind-collaboration-leads-to-filing-of-international-patent-application-for-n-sprc-20250425monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-clearmind-collaboration-leads-to-publication-of-patent-application-for-cocaine-ad-sprc-20250310monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-signs-definitive-agreement-to-sell-mitocarex-computational-drug-discovery-company-sprc-20250303monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-extends-2-million-loan-to-support-automax-s-growth-following-automax-s-entry-into-sprc-20250227monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-secures-favorable-settlement-in-lawsuit-it-filed-receiving-cash-compensation-and--sprc-20250218monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-clearmind-collaboration-leads-to-publication-of-patent-for-binge-behaviour-combin-sprc-20250204monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-require-sprc-20250115monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-automax-enters-the-direct-import-market-with-a-13-million-first-shipment-of-jac-e-sprc-20250113monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-po-sprc-20250107monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-clearmind-medicine-collaboration-announces-the-publication-of-european-patent-app-sprc-20250106monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-renewal-of-approval-by-israeli-medical-cannabis-agency-for-its-clinical-sprc-20241231monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-automax-announces-13-million-first-delivery-of-jac-vehicles-following-regulatory--sprc-20241226monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-provides-updates-on-status-of-spin-off-of-its-advanced-clinical-stage-pharmaceuti-sprc-20241216monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-secures-fda-green-light-to-us-launch-of-its-pivotal-phase-iib-clinical-trial-for--sprc-20240930monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-signs-non-binding-letter-of-intent-to-sell-stake-in-mitocarex-sprc-20240926monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-receives-fda-approval-to-initiate-phase-iib-clinical-trial-for-tourette-syndrome--sprc-20240923monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-takes-major-step-forward-with-ind-application-submitted-to-the-fda-for-phase-iib--sprc-20240918monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-clearmind-medicine-collaboration-announces-the-publication-of-an-international-pa-sprc-20240916monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-advances-1-85-million-loan-to-automax-following-automax-s-direct-import-agreement-sprc-20240911monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-clearmind-medicine-collaboration-leads-to-publication-of-international-patent-app-sprc-20240906monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-clearmind-medicine-collaboration-leads-to-publication-of-application-for-innovati-sprc-20240829monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-grants-global-rights-for-pain-therapy-to-biotech-company-in-agreement-worth-up-to-sprc-20240828monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-submitted-ind-application-to-the-fda-for-sci-110-phase-iib-clinical-trial-for-pat-sprc-20240823monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-mitocarex-appointed-professor-nir-peled-seasoned-oncologist-to-its-scientific-adv-sprc-20240822monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-enrollment-of-the-first-five-patients-in-the-clinical-trial-of-its-inno-sprc-20240819monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-finalizes-exclusive-global-out-licensing-agreement-for-its-pain-therapy-valued-at-sprc-20240816monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-updates-regarding-the-status-of-the-automax-merger-sprc-20240814monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-s-collaboration-with-clearmind-medicine-continues-to-bear-fruit-with-new-scientif-sprc-20240806monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-mitocarex-confirms-potential-significant-role-of-its-drug-target-in-non-small-cel-sprc-20240722monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-signs-non-binding-letter-of-intent-for-exclusive-global-out-licensing-of-pain-tre-sprc-20240717monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-announces-receipt-of-nasdaq-minimum-bid-price-notification-sprc-20240716monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-u-s-patent-application-for-treating-metabolic-syndrome-and-weight-loss-sprc-20240716monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-signs-non-binding-letter-of-intent-for-spin-off-of-advanced-clinical-stage-pharma-sprc-20240708monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-secures-strategic-advantage-with-grant-of-european-patent-sprc-20240531monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-to-acquire-automax-sprc-20240411monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-clearmind-collaboration-evolves-with-new-international-patent-application-for-pre-sprc-20240327monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-mitocarex-unveils-groundbreaking-discovery-of-small-molecule-structure-in-anti-ca-sprc-20240321monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-granted-another-patent-strengthening-its-core-technology-in-canada-sprc-20240318monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-achieves-major-milestone-with-first-patient-dosed-in-autism-spectrum-disorder-cli-sprc-20240314monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-mitocarex-reveals-promising-results-with-discovery-of-novel-anti-cancer-small-mol-sprc-20240312monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-enrollment-of-first-patient-for-its-clinical-trial-for-children-with-au-sprc-20240308monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-granted-patent-for-core-technology-in-multiple-jurisdictions-in-europe-sprc-20240307monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-issued-canadian-patent-for-opioids-reduction-use-in-pain-management-technology-sprc-20240306monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-delivers-treatment-for-autism-spectrum-disorder-clinical-trial-enabling-commencem-sprc-20240229monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-clearmind-partnership-yields-three-new-international-patent-applications-for-mdma-sprc-20240227monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-and-clearmind-continue-to-strengthen-international-patent-portfolio-with-next-gen-sprc-20240220monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-initiation-of-patient-recruitment-for-its-clinical-trial-with-sci-210-i-sprc-20240129monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-announces-20-million-standby-equity-purchase-agreement-sprc-20240124monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-advances-the-acquisition-process-of-a-leading-vehicle-importer-company-in-israel--sprc-20240119monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-and-clearmind-medicine-reflect-on-successful-collaboration-in-2023-aiming-to-upgr-sprc-20240104monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-positive-results-for-mitocarex-bio-with-its-drug-discovery-platform-sprc-20231213monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-provides-updates-regarding-the-non-binding-letter-of-intent-to-acquire-leading-ve-sprc-20231207monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-adopts-limited-duration-shareholder-rights-plan-sprc-20231128monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-positive-results-from-its-weight-loss-and-metabolic-disorder-program-wi-sprc-20231128monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-positive-results-for-mitocarex-bio-with-its-drug-discovery-platform-sprc-20231127monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-signs-non-binding-letter-of-intent-to-merge-with-leading-vehicle-importer-company-sprc-20231122monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-celebrates-major-breakthrough-positive-results-show-its-treatment-has-a-remarkabl-sprc-20231115monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-aims-to-change-tourette-syndrome-treatments-will-start-a-phase-iib-trial-with-its-sprc-20231110monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-granted-patent-from-the-australian-patent-office-for-its-reduction-of-opioids-use-sprc-20231031monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-granted-patent-for-its-core-technology-from-the-australian-patent-office-sprc-20231024monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-regains-compliance-with-nasdaq-minimum-bid-price-notification-sprc-20231016monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-announces-closing-of-5-026-million-private-placement-sprc-20231013monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-announces-pricing-of-5-026-million-private-placement-sprc-20231011monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-granted-european-patent-for-its-core-technology-sprc-20231003monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-initiated-its-clinical-trial-with-sci-210-in-pediatrics-with-autism-spectrum-diso-sprc-20230929monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-expected-implementation-of-1-for-26-reverse-share-split-sprc-20230927monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-1-for-26-reverse-share-split-sprc-20230920monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-engages-investment-bank-to-identify-potential-strategic-transaction-opportunities-sprc-20230912monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-initiation-of-randomized-phase-iib-clinical-trial-of-its-proprietary-sc-sprc-20230907monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-require-sprc-20230907monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-closes-1-3-million-underwritten-public-offering-sprc-20230814monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-announces-pricing-of-1-3-million-underwritten-public-offering-sprc-20230810monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-announces-proposed-underwritten-public-offering-of-approximately-1-3-million-sprc-20230809monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-and-clearmind-collaboration-continues-to-increase-its-patent-portfolio-in-the-fie-sprc-20230801monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-to-commence-its-clinical-trial-with-sci-210-in-children-with-autism-spectrum-diso-sprc-20230714monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-receives-approval-to-conduct-phase-iib-clinical-trial-for-sci-110-to-treat-touret-sprc-20230630monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-irb-approval-to-conduct-its-phase-iib-trial-in-tourette-syndrome-sprc-20230621monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-and-clearmind-medicine-to-conduct-a-study-evaluating-their-combination-treatment--sprc-20230616monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-grants-an-exclusive-license-for-the-sales-of-cannamide-on-the-amazon-marketplace--sprc-20230607monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-successful-final-phase-iia-results-meeting-end-points-of-its-phase-iia--sprc-20230602monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-makes-another-step-towards-unlocking-potential-value-appoints-new-strategy-and-bu-sprc-20230530monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-s-drug-discovery-joint-venture-mitocarex-bio-successfully-developed-its-core-algo-sprc-20230508monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-completed-treatment-of-last-patient-enrolled-for-its-phase-iia-clinical-trial-for-sprc-20230502monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-and-clearmind-collaboration-strengthens-ip-portfolio-with-patent-application-in-t-sprc-20230421monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-receives-final-approval-to-commence-its-phase-iib-clinical-trial-for-sci-110-to-t-sprc-20230404monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-completes-the-sale-of-a-49-interest-in-its-subsidiary-that-owns-wellution-for-3-m-sprc-20230328monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-announces-receipt-of-nasdaq-minimum-bid-price-notification-sprc-20230310monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-receives-approval-to-conduct-its-phase-iib-clinical-trial-for-sci-110-to-treat-to-sprc-20230309monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-successfully-completed-production-of-its-proprietary-drug-candidate-sci-110-for-i-sprc-20230306monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-signs-agreement-for-the-supply-of-cbd-rich-cannabis-oil-for-its-clinical-trial-on-sprc-20230227monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-signs-a-definitive-agreement-to-sell-49-interest-in-its-subsidiary-that-owns-well-sprc-20230223monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-and-clearmind-reveal-three-unique-combinations-of-future-psychedelic-based-compou-sprc-20230222monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-s-drug-discovery-joint-venture-mitocarex-bio-successfully-reached-first-milestone-sprc-20230217monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-and-clearmind-collaboration-strengthens-ip-portfolio-with-three-provisional-paten-sprc-20230215monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-corporate-restructuring-plan-sprc-20230125monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-to-investigate-and-evaluate-concerns-of-illegal-trading-of-its-ordinary-shares-sprc-20230123monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-receives-approval-to-conduct-its-clinical-trial-in-children-with-autism-spectrum--sprc-20230118monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-additional-positive-results-from-the-third-part-of-clearmind-medicine-i-sprc-20230117monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-signs-agreement-to-conduct-its-clinical-trial-in-autism-spectrum-disorder-with-so-sprc-20230109monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-announces-efficacy-of-psychedelic-based-obesity-treatment-of-clearmind-medici-sprc-20230105monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-enters-into-non-binding-letter-of-intent-to-sell-a-50-interest-in-its-subsidiary--sprc-20221214monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-positive-study-results-with-sci-210-a-cannabidiol-based-treatment-for-e-sprc-20221207monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-regains-compliance-with-nasdaq-minimum-closing-bid-price-rule-sprc-20221129monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-enters-into-letter-of-intent-with-an-e-commerce-company-to-establish-a-joint-vent-sprc-20221115monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-gains-competitive-edge-with-additional-u-s-patent-granted-sprc-20221108monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announced-positive-interim-results-meeting-primary-endpoints-at-phase-iia-study-i-sprc-20221107monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-wellution-signs-an-agreement-with-logistics-facilities-in-new-jersey-to-supports--sprc-20221101monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-wellution-successfully-launched-a-new-keto-gummies-apple-cider-vinegar-product-an-sprc-20221028monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-announces-receipt-of-nasdaq-minimum-bid-price-notification-sprc-20221012monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-completes-the-acquisition-of-wellution-top-seller-of-american-food-supplements-an-sprc-20220930monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-and-clearmind-medicine-inc-collaboration-yields-3rd-patent-application-for-th-sprc-20220922monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-enters-agreement-to-acquire-wellution-top-seller-of-american-food-supplements-and-sprc-20220914monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-announces-additional-positive-results-for-the-cocaine-addiction-treatment-of--sprc-20220824monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-the-full-exercise-of-pre-funded-warrants-sprc-20220819monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-will-deposit-1-million-in-escrow-for-its-intention-to-enter-into-an-agreement-to--sprc-20220818monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-signs-a-non-binding-letter-of-intent-to-acquire-american-food-supplements-and-cos-sprc-20220815monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-issued-israeli-patent-for-its-core-technology-for-treating-central-nervous-system-sprc-20220812monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-israeli-ministry-of-health-approval-to-conduct-its-clinical-trial-in-au-sprc-20220808monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-signs-clinical-trial-agreement-with-yale-university-to-conduct-its-phase-iib-tria-sprc-20220801monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-expanding-its-clinical-operations-to-include-a-u-s-site-towards-its-pha-sprc-20220708monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-s-jv-mitocarex-bio-launches-its-advanced-new-laboratory-facility-sprc-20220707monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-board-of-directors-to-promote-buyback-program-of-up-to-1-million-sprc-20220706monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-successfully-completed-the-development-of-its-proprietary-drug-candidate-sci-110--sprc-20220629monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-ethics-committee-approval-to-conduct-its-clinical-trial-in-autism-spect-sprc-20220623monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-reinforces-its-new-jv-for-targeting-discovery-with-a-global-expert-in-the-field-o-sprc-20220615monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-s-board-of-directors-provides-strategic-decision-sprc-20220609monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-announces-initial-positive-results-for-the-cocaine-addiction-treatment-of-cle-sprc-20220607monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-and-clearmind-medicine-inc-collaboration-yields-another-patent-application-fo-sprc-20220602monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-announces-closing-of-10-million-private-placement-priced-at-the-market-sprc-20220601monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-to-collaborate-with-polyrizon-for-brain-targeting-using-intranasal-hydrogel-syste-sprc-20220531monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-pricing-of-10-million-private-placement-priced-at-the-market-sprc-20220527monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-ethics-committee-approval-to-conduct-a-phase-iib-trial-in-tourette-synd-sprc-20220526monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-and-clearmind-medicine-inc-collaboration-yields-positive-results-for-its-psychede-sprc-20220524monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-and-clearmind-medicine-inc-collaboration-yields-new-patent-application-for-ps-sprc-20220510monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-files-annual-report-for-year-ended-december-31-2021-and-provides-corporate-update-sprc-20220502monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-closing-of-new-jv-targeting-discovery-of-potential-drugs-for-cancers-an-sprc-20220331monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-issues-letter-to-shareholders-bdrx-20260514monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-announces-partnership-with-syngene-to-manufacture-mtx240-gmp-clinical-trial-suppli-bdrx-20260402monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-announces-pricing-of-10-million-public-offering-bdrx-20251218monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-announces-enrolment-of-first-european-patients-into-pivotal-phase-3-serenta-trial--bdrx-20251201monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-activates-first-european-site-for-registrational-phase-3-serenta-trial-in-fap-bdrx-20251124monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-announces-activation-of-first-clinical-study-site-for-phase-3-serenta-trial-in-fam-bdrx-20250625monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-announces-recruitment-of-first-patient-in-phase-2-study-of-tolimidone-in-type-1-di-bdrx-20250604monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-pharmaceuticals-plc-biodexa-or-the-company-notice-of-general-meeting-bdrx-20250522monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-announces-award-of-additional-3-0m-grant-from-cprit-to-support-registrational-erap-bdrx-20250522monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-receives-orphan-drug-designation-in-europe-for-erapa-in-fap-bdrx-20250512monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-announces-successful-outcome-of-a-type-c-meeting-with-fda-regarding-the-phase-3-pr-bdrx-20250310monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-announces-appointment-of-precision-for-medicine-llc-as-cro-for-european-component--bdrx-20250306monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparation-bdrx-20250224monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-pharmaceuticals-plc-to-present-at-the-emerging-growth-conference-on-february-19-20-bdrx-20250213monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-receives-us-fda-fast-track-designation-for-erapa-in-familial-adenomatous-polyposis-bdrx-20250210monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-strengthens-management-team-appointment-of-dr-gary-a-shangold-as-chief-medical-off-bdrx-20250122monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-pharmaceuticals-plc-biodexa-or-the-company-regains-compliance-for-continued-listin-bdrx-20241112monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-announces-successful-appeal-of-nasdaq-delisting-bdrx-20241015monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-provides-update-on-progression-free-and-overall-survival-in-phase-1-study-of-mtx11-bdrx-20241004monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-announces-phase-2a-study-of-tolimidone-in-type-1-diabetes-approved-by-health-canad-bdrx-20240716monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-announces-positive-phase-2-clinical-trial-results-of-erapa-at-12-months-in-familia-bdrx-20240624monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-announces-7-million-of-gross-proceeds-from-warrant-exercises-bdrx-20240522monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-s-licensor-emtora-to-announce-phase-2-clinical-trial-results-of-erapa-in-familial--bdrx-20240430monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-enters-into-exclusive-license-to-erapa-a-phase-3-ready-asset-for-the-treatment-of--bdrx-20240426monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-announces-positive-top-line-phase-i-clinical-trial-results-for-diffuse-midline-gli-bdrx-20240223monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-reports-12-month-survival-in-magic-g1-study-of-mtx110-in-recurrent-glioblastoma-pa-bdrx-20240208monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-announces-allowance-of-u-s-patent-covering-tolimidone-bdrx-20240207monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-ceo-issues-shareholder-letter-highlighting-progress-in-2023-and-expected-milestone-bdrx-20240122monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-appoints-ann-merchant-to-the-board-of-directors-bdrx-20231229monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-announces-closing-of-6-0-million-underwritten-public-offering-including-full-exerc-bdrx-20231221monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-announces-pricing-of-5-2-million-underwritten-public-offering-bdrx-20231219monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-enters-into-agreements-to-acquire-exclusive-worldwide-license-to-tolimidone-a-phas-bdrx-20231127monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-completes-recruitment-of-cohort-a-in-study-of-mtx110-in-patients-with-recurrent-gl-bdrx-20231003monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-to-present-recruitment-and-treatment-update-in-phase-1-study-of-mtx-110-magic-g1-s-bdrx-20230921monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-pharmaceuticals-launches-new-corporate-and-clinical-trials-websites-bdrx-20230728monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-regain-compliance-with-nasdaq-minimum-bid-price-requirement-bdrx-20230724monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-pharmaceuticals-plc-announces-closing-of-3-32-million-registered-direct-offering-bdrx-20230526monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-pharmaceuticals-plc-announces-us-3-32-million-registered-direct-offering-bdrx-20230524monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-pharmaceuticals-enters-into-non-binding-letter-of-intent-for-proposed-acquisition--bdrx-20230518monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-announces-1-for-10-reverse-share-split-slxn-20260526monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-u-slxn-20260518monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-announces-exercise-of-warrants-for-1-million-gross-proceeds-slxn-20260515monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-reports-positive-preliminary-immunotherapy-findings-for-sil204-in-kr-slxn-20260514monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-prov-slxn-20260317monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-urges-shareholders-to-vote-ahead-of-march-16-extraordinary-general-m-slxn-20260305monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-to-attend-7th-annual-rnai-based-therapeutics-summit-slxn-20260121monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-releases-ceo-letter-to-shareholders-highlighting-2025-s-significant--slxn-20260106monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-announces-submission-of-phase-2-3-clinical-trial-application-to-isra-slxn-20251216monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equi-slxn-20251126monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business--slxn-20250812monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-announces-1-for-15-reverse-share-split-slxn-20250716monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-announces-positive-results-in-preclinical-study-demonstrating-signif-slxn-20250709monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-announces-groundbreaking-preclinical-results-sil204-shows-strong-eff-slxn-20250529monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-completes-key-preclinical-studies-exploring-sil204-s-potential-impac-slxn-20250521monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-u-slxn-20250513monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-announces-collaboration-with-global-therapeutics-leader-catalent-on--slxn-20250423monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-unveils-innovative-expanded-development-plan-for-sil204-based-on-rec-slxn-20250328monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil-slxn-20250321monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-reports-full-year-2024-financial-results-and-provides-business-updat-slxn-20250318monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-reports-groundbreaking-positive-initial-data-from-systemic-administr-slxn-20250305monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-announces-completion-of-initial-study-in-orthotopic-pancreatic-cance-slxn-20250225monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-announces-exercise-of-warrants-for-3-3-million-gross-proceeds-slxn-20250129monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-reports-strong-tumor-growth-reduction-from-systemic-administration-o-slxn-20250128monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-announces-pricing-of-5-0-million-public-offering-slxn-20250116monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-announces-additional-promising-preclinical-data-for-sil-204-demonstr-slxn-20250115monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-slxn-20250113monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-collaborates-with-evonik-on-advanced-sirna-formulation-development-slxn-20241217monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-appoints-renowned-cancer-therapeutics-expert-prof-amnon-peled-to-boa-slxn-20241210monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-announces-1-for-9-reverse-share-split-slxn-20241122monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-to-present-at-the-noble-capital-markets-20th-annual-emerging-growth--slxn-20241120monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-to-present-at-the-h-c-wainright-26th-annual-global-investment-confer-slxn-20240903monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-ltd-and-moringa-acquisition-corp-announce-closing-of-their-business--slxn-20240815monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-a-clinical-stage-oncology-focused-biotechnology-company-to-become-publicly-traded-slxn-20240222monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-provides-first-quarter-2026-corporate-update-bjdx-20260507monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-provides-corporate-update-and-2026-strategic-outlook-bjdx-20260306monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-announces-4-5-million-private-placement-priced-at-the-market-under-nas-bjdx-20251009monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-provides-mid-year-business-and-corporate-update-bjdx-20250603monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-announces-reverse-stock-split-bjdx-20241113monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-announces-closing-of-8-75-million-underwritten-public-offering-bjdx-20240628monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-announces-pricing-of-8-75-million-underwritten-public-offering-bjdx-20240627monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-announces-reverse-stock-split-bjdx-20240617monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-announces-closing-of-3-5-million-public-offering-bjdx-20240102monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-announces-pricing-of-3-5-million-public-offering-bjdx-20231228monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-inc-announces-initiation-of-multicenter-clinical-study-evaluating-symp-bjdx-20231227monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-inc-reports-third-quarter-2023-financial-results-bjdx-20231109monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-announces-1-59-million-registered-direct-offering-priced-at-the-market-bjdx-20230825monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-announces-clinical-update-and-reports-second-quarter-2023-financial-re-bjdx-20230816monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-bjdx-20230810monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-announces-reverse-stock-split-bjdx-20230721monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-updates-symphony-il-6-regulatory-strategy-bjdx-20230519monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-reports-first-quarter-2023-financial-results-bjdx-20230510monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-reports-2022-financial-results-bjdx-20230320monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-signs-collaboration-agreement-with-blood-centers-of-america-bjdx-20230216monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-inc-reports-third-quarter-2022-financial-results-bjdx-20221109monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-inc-to-present-at-the-h-c-wainwright-24th-annual-global-investment-con-bjdx-20220830monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-inc-to-host-key-opinion-leader-event-on-il-6-testing-in-critical-care--bjdx-20220816monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-inc-reports-second-quarter-2022-financial-results-bjdx-20220726monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-completes-planned-clinical-studies-for-symphony-il-6-test-bjdx-20220706monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-reports-fda-agrees-to-consider-its-plan-to-pursue-a-de-novo-regulatory-pathway-for-bjdx-20220609monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-inc-reports-first-quarter-2022-financial-results-bjdx-20220420monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-appoints-edwin-rule-as-vice-president-regulatory-quality-and-complianc-bjdx-20220328monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-appoints-kenneth-fisher-as-chief-financial-officer-bjdx-20220324monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-inc-reports-fourth-quarter-and-full-year-2021-financial-results-and-pr-bjdx-20220310monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-inc-announces-its-pre-submission-filing-package-for-the-symphony-il-6--bjdx-20220131monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-inc-completes-90-subjects-in-multicenter-clinical-study-addressing-rap-bjdx-20220113monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-inc-appoints-mark-feinberg-m-d-as-chief-medical-advisor-bjdx-20220105monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-inc-reports-third-quarter-2021-financial-results-bjdx-20211216monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-inc-announces-pricing-of-upsized-21-6-million-initial-public-offering-bjdx-20211110monthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-appoints-david-white-as-chief-executive-officer-and-sammy-dorf-as-member-of-the--onco-20260331monthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-inc-announces-receipt-of-additional-notice-from-nasdaq-onco-20250430monthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-announces-new-clinical-data-for-its-innovative-prostate-cancer-test-proclarix-ac-onco-20250319monthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-inc-announces-receipt-of-notice-from-nasdaq-regarding-late-filing-of-quarterly-r-onco-20241212monthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-announces-financing-through-a-2-0-million-private-placement-of-series-c-preferre-onco-20241003monthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-inc-announces-1-for-40-reverse-stock-split-and-results-of-the-annual-meeting-of--onco-20240920monthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-announces-closing-of-warrant-exercise-for-1-11-million-gross-proceeds-onco-20240715monthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-announces-exercise-of-warrants-for-1-11-million-gross-proceeds-onco-20240711monthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-announces-appointment-of-seasoned-biotech-executives-dr-ajit-singh-and-dr-thomas-onco-20240213monthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-chief-executive-officer-dr-neil-j-campbell-issues-letter-to-shareholders-onco-20231219monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-enters-pivotal-value-inflection-phase-with-planned-phase-3-study-of-amplige-aim-20260416monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-provides-routine-update-on-annual-filings-aim-20260413monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-final-approval-of-novel-cancer-therapy-patent-in-japan-combining--aim-20260318monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-closing-of-its-rights-offering-aim-20260307monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-key-dates-and-terms-related-to-announced-rights-offering-aim-20260123monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-stock-dividend-aim-20251230monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-aim-20251210monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-participate-in-live-fireside-chat-on-virtual-investor-closing-bell-serie-aim-20251201monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-third-quarter-2025-financial-results-and-highlights-continued-progr-aim-20251118monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-present-at-the-webull-financial-corporate-connect-webinar-series-biotech-aim-20250814monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-builds-positive-momentum-and-reiterates-focus-on-driving-ampligen-clinical--aim-20250804monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-closing-of-8-0-million-public-offering-aim-20250731monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-pricing-of-8-0-million-public-offering-aim-20250729monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-positive-mid-year-safety-and-efficacy-data-from-phase-2-study-evalu-aim-20250728monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-recent-presentation-on-the-potential-of-private-public-partnershi-aim-20250702monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-nyse-american-notice-of-noncompliance-with-minimum-stockholders-e-aim-20250620monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-resumes-trading-on-nyse-american-aim-20250617monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-granted-u-s-patent-covering-methods-of-manufacturing-therapeutic-dsrna-incl-aim-20250612monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-nyse-american-removal-of-trading-suspension-aim-20250612monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-1-for-100-reverse-stock-split-aim-20250611monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-the-presentation-of-ampligen-oncology-data-at-the-recent-annual-m-aim-20250508monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-trading-under-the-ticker-aimi-on-the-pink-open-market-aim-20250407monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal-aim-20250404monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-co-aim-20250327monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference-aim-20250311monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance-aim-20250226monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-appoints-david-chemerow-to-board-of-directors-as-an-independent-director-aim-20250226monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-releases-virtual-investor-what-this-means-segment-aim-20250211monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-that-it-will-not-proceed-with-an-offering-pursuant-to-its-registr-aim-20250211monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-a-planned-follow-up-clinical-study-evaluating-a-combination-treat-aim-20250207monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-publication-of-final-clinical-study-results-for-amp-518-clinical--aim-20250123monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-highlights-new-article-finding-links-between-covid-19-and-me-cfs-aim-20250122monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-highlights-key-2024-achievements-and-outlines-upcoming-2025-26-value-drivin-aim-20250115monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-notification-of-noncompliance-with-additional-nyse-american-conti-aim-20241217monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-expands-patent-portfolio-with-new-netherlands-composition-and-methods-paten-aim-20241212monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-participates-in-virtual-investor-kol-connect-segment-aim-20241206monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-publication-of-breast-cancer-data-from-roswell-park-comprehensive-aim-20241119monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-third-quarter-2024-financial-results-and-provides-corporate-update-aim-20241115monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-discuss-third-quarter-2024-financial-results-on-november-15-2024-and-hos-aim-20241106monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-participate-in-the-2024-healthcare-virtual-summit-presented-by-maxim-gro-aim-20241009monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-granted-u-s-patent-for-ampligen-for-the-treatment-of-endometriosis-aim-20241003monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-pricing-of-1-26-million-registered-direct-offering-aim-20240930monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-participate-in-virtual-investor-ceo-connect-segment-aim-20240927monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-positive-preliminary-data-in-phase-1b-2-study-of-ampligen-and-imfin-aim-20240919monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-that-analysis-of-amp-518-complete-clinical-patient-data-underscor-aim-20240911monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-print-publication-and-further-positive-findings-from-a-study-eval-aim-20240820monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-second-quarter-2024-financial-results-and-provides-corporate-update-aim-20240816monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-discuss-second-quarter-2024-financial-results-on-august-16-2024-and-host-aim-20240813monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-aim-20240729monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-aim-20240703monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-participate-in-the-virtual-investor-pitch-conference-aim-20240610monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-participate-in-the-virtual-investor-lunch-break-series-aim-20240603monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-pricing-of-2-0-million-registered-direct-offering-aim-20240531monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-participate-in-two-upcoming-investor-conferences-aim-20240520monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-first-quarter-2024-financial-results-and-provides-corporate-update-aim-20240516monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-discuss-first-quarter-2024-financial-results-on-may-16-2024-and-host-con-aim-20240509monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-completes-cgmp-manufacturing-of-clinical-vials-of-ampligen-aim-20240506monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-first-dose-level-is-generally-well-tolerated-in-phase-1b-2-study--aim-20240429monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-aim-20240425monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-aim-20240418monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-charles-lapp-md-as-a-consulting-medical-officer-for-its-me-cfs-an-aim-20240415monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-aim-20240411monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-positive-top-line-protocol-planned-interim-report-data-from-the-s-aim-20240410monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-co-aim-20240402monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-present-at-the-medinvest-biotech-pharma-investor-conference-aim-20240328monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-discuss-fourth-quarter-and-full-year-2023-financial-results-on-april-2-2-aim-20240326monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-publication-of-positive-findings-from-a-study-evaluating-ampligen-aim-20240325monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-aim-20240322monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-aim-20240320monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-participate-in-the-virtual-investor-lunch-break-the-aim-opportunity-aim-20240315monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-launch-of-ceo-corner-platform-aim-20240307monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-outlines-recent-progress-across-clinical-development-pipeline-and-provides--aim-20240229monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-first-subject-dosed-in-the-netherlands-for-phase-1b-2-study-evalu-aim-20240214monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-positive-topline-results-from-phase-2-study-evaluating-ampligen-for-aim-20240208monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-receives-erasmus-medical-center-ethics-board-authorization-for-phase-2-stud-aim-20240124monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-that-the-first-subject-is-enrolled-in-the-phase-1b-2-study-evalua-aim-20240122monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-open-enrollment-for-phase-1b-2-study-evaluating-ampligen-rintatol-aim-20240110monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-bolsters-intellectual-property-estate-for-ampligen-with-issuance-of-two-key-aim-20231128monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-completes-treatment-of-last-subject-in-phase-2-study-evaluating-ampligen-fo-aim-20231121monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-third-quarter-2023-financial-results-and-provides-clinical-pipeline-aim-20231115monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-publication-of-data-from-roswell-park-comprehensive-cancer-center-aim-20231114monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-discuss-third-quarter-2023-financial-results-on-november-15-2023-and-hos-aim-20231109monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-encouraging-translational-data-from-phase-2-study-evaluating-ampl-aim-20231108monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-abstract-accepted-for-poster-presentation-at-the-society-for-immu-aim-20231030monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-engages-business-development-firm-azenova-llc-to-catalyze-partnering-develo-aim-20231017monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-selected-to-present-at-the-3rd-annual-marie-sklodowska-curie-symposium-on-c-aim-20230922monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-report-of-complete-topline-data-from-roswell-park-comprehensive-c-aim-20230911monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-aim-20230905monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-second-quarter-financial-results-and-provides-clinical-pipeline-upd-aim-20230815monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-discuss-second-quarter-2023-financial-results-on-august-15-2023-and-host-aim-20230809monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-completion-of-enrollment-in-phase-2-study-evaluating-ampligen-for-aim-20230808monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-issues-notice-that-an-unaffiliated-third-party-and-organization-are-providi-aim-20230718monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-enrolls-and-doses-first-subject-in-phase-2-study-evaluating-ampligen-for-th-aim-20230710monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-participate-in-the-virtual-investor-summer-spotlight-series-aim-20230705monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-publication-of-positive-findings-from-a-pre-clinical-study-evalua-aim-20230627monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-authorizations-from-competent-authority-and-ethics-board-in-the-n-aim-20230627monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-participate-in-the-healthcare-virtual-conference-presented-by-maxim-grou-aim-20230614monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-outlines-recent-significant-progress-across-clinical-development-pipeline-a-aim-20230612monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-first-quarter-financial-results-and-provides-pipeline-update-aim-20230515monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-discuss-first-quarter-2023-financial-results-on-may-16-2023-and-host-con-aim-20230509monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-appoints-preeminent-biotechnology-pioneer-w-neal-burnette-ph-d-as-chairman--aim-20230412monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-central-irb-approval-of-phase-2-study-protocol-evaluating-amplige-aim-20230404monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-co-aim-20230403monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-bolsters-board-of-directors-with-appointment-of-pharmaceutical-industry-vet-aim-20230330monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugu-aim-20230327monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-late-breaking-presentation-at-the-international-conference-on-ant-aim-20230316monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-publication-of-new-analysis-of-the-mechanism-of-action-of-amplige-aim-20230308monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-issues-letter-to-stockholders-aim-20230306monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-phase-2-study-of-ampligen-for-the-treatment-of-pancreatic-cancer--aim-20230228monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-participate-in-solve-m-e-and-the-biotechnology-innovation-organization-b-aim-20230217monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-enters-into-pancreatic-cancer-clinical-research-agreements-with-astrazeneca-aim-20230117monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-broadens-patent-portfolio-with-new-netherlands-utility-patent-covering-ampl-aim-20230109monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-present-at-the-virtual-investor-2023-companies-to-watch-event-aim-20230105monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-appoints-christopher-mcaleer-ph-d-as-scientific-officer-aim-20221212monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-positive-safety-tolerability-and-biological-activity-data-for-intra-aim-20221208monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-abstract-accepted-for-poster-presentation-at-the-british-society--aim-20221202monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-third-quarter-2022-financial-results-and-provides-corporate-update-aim-20221115monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-presentation-of-new-data-from-roswell-park-comprehensive-cancer-c-aim-20221114monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-receives-orphan-drug-designation-for-ampligen-rintatolimod-for-the-treatmen-aim-20221102monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-fda-clearance-of-ind-application-to-evaluate-ampligen-in-phase-2--aim-20221012monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-present-at-the-virtual-investor-long-covid-event-aim-20220921monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference-aim-20220907monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-selected-to-present-at-the-2nd-annual-marie-sklodowska-curie-symposium-on-c-aim-20220906monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-and-study-collaborator-roswell-park-commence-enrollment-in-an-nci-funded-ph-aim-20220830monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-commencement-of-phase-2-study-of-ampligen-for-the-treatment-of-pa-aim-20220818monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-second-quarter-2022-financial-results-and-provides-corporate-update-aim-20220815monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-positive-pilot-study-data-from-expanded-access-program-evaluating-a-aim-20220728monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-additional-patient-data-from-single-center-named-patient-program-ev-aim-20220720monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-that-recently-received-director-nominations-from-jorgl-activist-g-aim-20220718monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-present-at-the-virtual-investor-innovations-in-oncology-spotlight-series-aim-20220714monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-secures-new-state-of-the-art-facility-for-product-development-and-testing-aim-20220621monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-bolsters-intellectual-property-portfolio-for-ampligen-with-issuance-of-new--aim-20220613monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-present-at-the-h-c-wainwright-global-investment-conference-aim-20220519monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-provides-update-on-ampligen-long-covid-development-program-aim-20220518monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-first-quarter-2022-financial-results-and-provides-corporate-update-aim-20220516monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-participate-in-a-solve-m-e-signature-event-long-covid-research-policy-an-aim-20220512monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-provides-summary-of-ampligen-data-supporting-synergistic-potential-with-che-aim-20220421monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-provides-progress-on-advancement-of-ampligen-clinical-development-program-f-aim-20220412monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-positive-data-from-phase-2a-study-evaluating-ampligen-as-a-compon-aim-20220411monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-co-aim-20220331monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-abstract-accepted-for-presentation-at-15th-annual-ihpba-world-con-aim-20220328monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-participate-in-the-2022-virtual-growth-conference-presented-by-maxim-gro-aim-20220323monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-receives-ind-clearance-from-the-u-s-fda-to-advance-its-phase-2-study-of-amp-aim-20220316monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-abstract-from-university-of-pittsburgh-medical-center-accepted-fo-aim-20220309monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-abstracts-from-roswell-park-comprehensive-cancer-center-accepted--aim-20220309monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-publication-of-positive-data-from-late-stage-pancreatic-cancer-ea-aim-20220308monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-strategic-sale-of-new-brunswick-new-jersey-facility-to-allocate-a-aim-20220307monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-appoints-robert-dickey-iv-as-chief-financial-officer-aim-20220303monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-participate-in-a-solve-m-e-diagnostics-and-treatments-webinar-aim-20220126monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-publication-of-positive-results-from-phase-1-2-study-of-intraperi-aim-20220124monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-present-at-the-virtual-investor-2022-top-picks-conference-aim-20220119monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-s-ampligen-safety-data-presented-at-eighth-european-scientific-working-grou-aim-20211209monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-ceo-to-participate-in-two-upcoming-investor-conferences-aim-20211206monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-provides-third-quarter-2021-business-update-aim-20211116monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-submits-ind-and-accompanying-fast-track-application-for-phase-2-trial-of-am-aim-20211019monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-publishes-phase-1-clinical-study-data-supporting-the-safety-of-ampligen-as--aim-20211006monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-provides-clinical-updates-on-planned-phase-2-study-of-ampligen-in-patients--aim-20211004monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-clinical-trial-agreement-for-a-phase-2a-human-challenge-trial-of--aim-20210930monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-submits-pre-ind-application-to-the-fda-for-phase-2-clinical-studies-of-ampl-aim-20210928monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-files-provisional-patent-application-for-ampligen-as-an-early-onset-intrana-aim-20210927monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-positive-progress-on-requested-fda-meeting-for-proposed-ampligen--aim-20210921monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-provides-an-update-on-its-pending-phase-2a-human-challenge-trial-using-its--aim-20210920monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-submits-pre-ind-application-to-the-fda-for-phase-2-clinical-study-of-amplig-aim-20210908monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-filing-of-provisional-patent-application-for-use-of-ampligen-as-b-aim-20210825monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-provides-second-quarter-2021-business-update-aim-20210817monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-phase-2a-human-challenge-trial-to-test-its-drug-ampligen-as-an-in-aim-20210709monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-host-investor-update-webcast-on-wednesday-july-14th-at-11-00-am-et-aim-20210706monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-completes-all-treatments-in-phase-1-human-safety-study-of-intranasal-admini-aim-20210621monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-s-ampligen-featured-in-peer-reviewed-journal-cancers-as-a-potential-therapy-aim-20210614monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-two-year-extension-of-agreement-with-shenzhen-smoore-technology-l-aim-20210527monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-positive-safety-data-from-the-third-cohort-of-its-phase-1-intrana-aim-20210526monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-provides-first-quarter-2021-business-update-aim-20210518monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-ceo-thomas-k-equels-participates-in-fireside-chat-with-ascendiant-capital-m-aim-20210503monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-positive-safety-data-in-second-cohort-of-phase-1-clinical-study-i-aim-20210427monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-positive-safety-data-in-first-cohort-of-phase-1-clinical-study-in-aim-20210407monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-2020-year-end-financial-results-aim-20210331monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-addition-of-single-agent-ampligen-arm-to-cancer-center-s-ongoing--aim-20210322monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-present-at-the-q1-virtual-investor-summit-on-march-24th-aim-20210311monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-participate-at-m-vest-llc-and-maxim-group-llc-inaugural-emerging-growth--aim-20210310monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-first-healthy-subjects-dosed-in-phase-1-intranasal-ampligen-clini-aim-20210308monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-to-present-at-the-h-c-wainwright-global-life-sciences-conference-on-march-9-aim-20210304monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-s-subsidiary-receives-orphan-medicinal-product-designation-by-the-european--aim-20210224monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-ethics-committee-approval-to-commence-phase-1-clinical-study-of-a-aim-20210216monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-the-expansion-of-its-pancreatic-cancer-program-to-include-new-pat-aim-20210210monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-completes-and-closes-atm-facility-current-capital-expected-to-meet-needs-fo-aim-20210205monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-enters-into-agreement-for-proposed-intranasal-safety-study-of-ampligen-aim-20210129monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-reschedules-investor-conference-call-to-january-21-2021-at-11am-et-aim-20210115monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-postpones-investor-conference-call-will-reschedule-for-a-later-date-aim-20210111monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-first-covid-19-induced-chronic-fatigue-long-hauler-patient-dosed--aim-20210106monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-availability-of-the-me-cfs-clinical-trial-of-its-drug-ampligen-fo-aim-20201224monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-inc-s-drug-ampligen-awarded-fda-s-orphan-drug-designation-status-for-the-tr-aim-20201221monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-provides-third-quarter-2020-business-update-aim-20201113monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-plos-one-s-publication-of-new-data-analyses-showing-importance-of-aim-20201102monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-ceo-to-participate-in-virtual-panel-presentation-at-the-23rd-annual-bioflor-aim-20201022monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-irb-approval-to-enroll-covid-19-long-haulers-in-the-amp-511-me-cf-aim-20201006monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-files-three-provisional-patent-applications-surrounding-ampligen-for-use-ag-aim-20200211monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-engages-ibn-investorbrandnetwork-to-bolster-its-corporate-communications-efforts-adtx-20220609monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-alert-bragar-eagel-squire-p-c-investigates-merger-of-adtx-and-encourages-investors--adtx-20220104monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-provides-business-update-and-files-third-quarter-2020-10-q-adtx-20201113monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-announces-first-aditxtengage-event-continuing-series-of-investor-opportunities-to-e-adtx-20201002monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-signs-collaboration-agreement-with-salveo-diagnostics-to-commercialize-aditxtscore--adtx-20200903monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-submits-emergency-use-authorization-eua-application-for-aditxtscore-for-covid-19-adtx-20200824monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-introduces-aditxtscore-for-covid-19-and-announces-the-completion-of-validation-stud-adtx-20200806monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-to-present-at-zooming-with-ld-adtx-20200722monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-cmo-discusses-novel-investigational-car-t-therapy-during-multiple-myeloma-awarenes-aclx-20250318monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-presents-continued-robust-long-term-responses-from-its-cart-ddbcma-phase-1-expansi-aclx-20211213monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-to-present-new-clinical-data-from-its-cart-ddbcma-phase-1-trial-in-patients-with-r-aclx-20211104monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-announces-presentation-of-positive-clinical-results-from-ongoing-phase-1-study-of--aclx-20210604monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-to-present-data-from-phase-1-study-of-cart-ddbcma-demonstrating-continued-positive-aclx-20210519monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-announces-executive-appointments-aclx-20210419monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-closes-115-million-series-c-financing-to-advance-its-pipeline-of-adaptive-and-cont-aclx-20210413monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-announces-fda-clearance-of-ind-application-for-aclx-001-a-controllable-cell-therap-aclx-20210406monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-appoints-rami-elghandour-as-chairman-and-chief-executive-officer-aclx-20210126monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment--aclx-20201207monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-announces-clinical-data-to-be-presented-at-the-62nd-american-society-of-hematology-aclx-20201105monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-to-present-at-jefferies-virtual-cell-therapy-summit-aclx-20201002monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-announces-evansmds-grant-awarded-for-collaboration-with-johns-hopkins-and-universi-aclx-20200824monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-presents-preclinical-data-for-arc-sparx-platform-technology-in-targeting-cd123-pos-aclx-20200622monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-to-present-at-jefferies-virtual-healthcare-conference-aclx-20200602monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-to-present-at-the-ubs-virtual-global-healthcare-conference-aclx-20200519monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-to-present-preclinical-data-of-its-novel-arc-sparx-platform-technology-in-targetin-aclx-20200513monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-to-present-preclinical-efficacy-data-of-the-arc-sparx-platform-technology-at-the-2-aclx-20200429monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-announces-fda-orphan-drug-designation-for-cart-ddbcma-for-the-treatment-of-multipl-aclx-20200312monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-announces-first-patient-treated-with-t-cell-therapy-utilizing-the-company-s-novel--aclx-20200228monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-raises-85-million-in-a-series-b-financing-to-advance-its-intelligent-cell-therapy--aclx-20191003monthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-reports-first-quarter-2025-financial-results-and-continued-portfolio-progress-mtsr-20250512monthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-reports-fourth-quarter-and-full-year-2024-financial-results-and-continued-portfoli-mtsr-20250326monthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-to-present-at-td-cowen-s-45th-annual-health-care-conference-mtsr-20250226monthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-announces-closing-of-initial-public-offering-and-full-exercise-and-closing-of-unde-mtsr-20250205monthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-announces-pricing-of-initial-public-offering-mtsr-20250130monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-to-feature-new-insights-from-cmnd-100-psychedelic-clinical-trial-on-ins-cmnd-20260605monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-ceo-dr-adi-zuloff-shani-named-delegate-to-federal-policy-summit-on-psyc-cmnd-20260515monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-reports-successful-ongoing-treatment-of-participants-at-us-sites-in-its-cmnd-20260319monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-advances-recruitment-for-cmnd-100-trial-s-third-cohort-at-yale-johns-ho-cmnd-20260311monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-publication-of-international-patent-for-novel-therapy-targeti-cmnd-20260310monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-files-annual-report-on-form-20-f-for-the-fiscal-year-ended-october--cmnd-20260120monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-reflects-on-a-transformative-2025-key-clinical-advancements-expanded-gl-cmnd-20251224monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-successful-completion-of-second-cohort-enrollment-in-ongoing--cmnd-20251216monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-s-meai-spotlighted-in-prestigious-review-leading-experts-affirm-transfo-cmnd-20251212monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-successfully-regains-compliance-with-nasdaq-s-minimum-stockholders-equi-cmnd-20251212monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-1-for-40-reverse-share-split-cmnd-20251210monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-receipt-of-nasdaq-minimum-bid-price-notification-cmnd-20251205monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-advances-cmnd-100-to-dosing-phase-at-hadassah-medical-center-in-ongoing-cmnd-20251202monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-charges-forward-in-alcoholism-treatment-positive-cohort-data-full-dsmb--cmnd-20251201monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-kicks-off-patient-enrollment-at-tel-aviv-sourasky-medical-center-adding-cmnd-20251125monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-s-data-and-safety-monitoring-board-unanimously-approves-continuation-of-cmnd-20251124monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-positive-top-line-results-from-first-cohort-of-its-fda-approv-cmnd-20251118monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-files-israeli-patent-for-novel-non-hallucinogenic-neuroplastogen-treatm-cmnd-20251117monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-receives-final-approval-to-expand-its-fda-regulated-phase-1-2a-clinical-cmnd-20251113monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-completes-first-cohort-treatment-in-its-fda-approved-phase-i-iia-clinic-cmnd-20251030monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-enrolls-last-patient-for-the-first-cohort-of-its-fda-approved-phase-i-i-cmnd-20251021monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-publication-of-u-s-patent-application-targeting-binge-behavio-cmnd-20251020monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-s-convenes-inaugural-scientific-advisory-board-meeting-to-advance-psych-cmnd-20250925monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-secures-10-million-securities-purchase-agreement-to-explore-strategic-o-cmnd-20250919monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-publication-of-international-patent-application-for-novel-com-cmnd-20250807monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-receives-irb-approval-for-phase-1-2a-clinical-trial-for-alcohol-use-dis-cmnd-20250805monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-files-international-patent-application-for-novel-combination-therapy-ta-cmnd-20250730monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-completes-initiation-of-leading-israeli-clinical-site-for-phase-i-iia-t-cmnd-20250723monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-expands-its-clinical-trial-for-alcohol-use-new-site-activated-and-additional-par-cmnd-20250715monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-irb-approval-for-phase-1-2a-clinical-trial-for-alcohol-use-di-cmnd-20250703monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-first-participant-ever-dosed-with-its-cmnd-100-treatment-in-g-cmnd-20250630monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-expands-global-clinical-trial-targeting-multibillion-dollar-alcohol-use-cmnd-20250627monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-enrolls-first-patient-in-its-clinical-trial-for-alcoholism-treatment-cmnd-20250625monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-joins-forces-with-leading-us-political-firm-to-promote-psychedelic-ther-cmnd-20250624monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-adds-leading-israeli-clinical-site-to-its-ongoing-clinical-trial-for-al-cmnd-20250623monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-engages-leading-government-and-political-affairs-firm-to-advance-psyche-cmnd-20250612monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-enrollment-of-first-patient-in-phase-i-iia-clinical-trial-for-cmnd-20250605monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-to-host-live-webinar-gazing-through-the-crystal-ball-featuring-leading--cmnd-20250520monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-publication-of-european-patent-for-psychedelic-based-combinat-cmnd-20250512monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-files-international-patent-application-for-novel-treatment-of-anorexia--cmnd-20250425monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-completes-the-initiation-of-its-alcohol-use-disorder-phase-i-iia-clinic-cmnd-20250423monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-to-host-live-webinar-gazing-through-the-crystal-ball-featuring-leading--cmnd-20250421monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-receives-notice-of-allowance-for-united-states-patent-covering-binge-be-cmnd-20250417monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-launches-first-u-s-clinical-site-for-its-fda-approved-clinical-trial-to-cmnd-20250416monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-first-u-s-clinical-site-initiation-for-cmnd-100-clinical-tria-cmnd-20250410monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-the-publication-of-international-patent-application-for-next--cmnd-20250408monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-launches-its-edc-system-to-support-its-phase-i-ii-clinical-trial-of-its-meai-bas-cmnd-20250401monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-s-fda-approved-clinical-trial-for-cmnd-100-moves-forward-as-drug-arrive-cmnd-20250321monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-to-evaluate-intranasal-delivery-of-its-psychedelic-drug-combination-cmnd-20250319monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-initiation-of-first-in-human-clinical-trial-with-cmnd-100-in--cmnd-20250318monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-publication-of-patent-for-cocaine-addiction-psychedelic-combi-cmnd-20250310monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-publication-of-patent-for-binge-behavior-psychedelic-combinat-cmnd-20250204monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-shareholders-meeting-results-cmnd-20250107monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-the-publication-of-european-patent-application-for-binge-beha-cmnd-20250106monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-granted-patent-for-binge-behavior-treatment-by-the-macau-international--cmnd-20250102monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-looks-to-move-forward-with-its-novel-psychedelic-meai-based-alcohol-sub-cmnd-20241226monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-receives-irb-approval-for-its-fda-regulated-clinical-trial-cmnd-20241224monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-and-dr-glitter-pty-ltd-sign-term-sheet-for-mutual-development-of-novel--cmnd-20241216monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-irb-approval-for-fda-first-in-human-clinical-trial-of-cmnd-10-cmnd-20241010monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-the-notice-of-an-international-patent-application-for-pioneer-cmnd-20240916monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-and-yissum-file-international-patent-application-for-revolutionary-psyc-cmnd-20240912monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-publication-of-international-patent-application-for-innovativ-cmnd-20240906monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-publication-of-its-patent-application-for-innovative-ketamine-cmnd-20240829monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-granted-u-s-patent-approval-for-binge-behavior-treatment-cmnd-20240821monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-and-yissum-expand-collaboration-with-international-patent-application-f-cmnd-20240816monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-new-scientific-publication-shows-meai-s-potential-as-a-novel-weight-los-cmnd-20240806monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-concludes-the-successful-participation-in-the-psychedelic-medicine-isra-cmnd-20240731monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-signs-an-agreement-to-source-manufacturers-and-distributors-for-its-alc-cmnd-20240719monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-obtains-ind-approval-from-the-fda-to-start-the-phase-i-iia-clinical-tri-cmnd-20240716monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-submission-of-us-patent-application-for-treating-metabolic-sy-cmnd-20240716monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-to-present-groundbreaking-research-at-psychedelic-medicine-israel-2024--cmnd-20240712monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-granted-patent-approval-in-hong-kong-for-its-binge-behaviors-treatment-cmnd-20240628monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-secured-exclusive-global-rights-to-innovative-psychedelic-compounds-for-cmnd-20240620monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-revolutionizes-the-13-billion-nonalcoholic-beverages-market-with-its-ps-cmnd-20240611monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-advances-its-proprietary-psychedelic-based-synthetic-alcohol-beverage-p-cmnd-20240510monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-secures-exclusive-global-rights-to-breakthrough-psychedelic-compounds-f-cmnd-20240507monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-applies-to-cease-being-a-reporting-issuer-in-canada-cmnd-20240430monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-exclusive-licensing-agreement-for-generation-3-0-psychedelic--cmnd-20240417monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-files-u-s-patent-application-for-psychedelic-based-treatment-for-eating-cmnd-20240410monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-ceo-issues-letter-to-shareholders-cmnd-20240409monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-international-patent-application-for-preventing-and-treating--cmnd-20240327monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-obtains-clearance-for-its-psychedelic-based-alcoholism-clinical-trial-cmnd-20240313monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-received-approval-for-a-voluntary-delisting-of-its-common-shares-from-t-cmnd-20240313monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-submits-three-additional-international-patent-applications-for-innovati-cmnd-20240227monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-receives-approval-to-commence-its-phase-i-iia-clinical-trial-of-cmnd-10-cmnd-20240223monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-submits-three-international-patent-applications-for-next-generation-cla-cmnd-20240220monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-receives-patent-approval-for-its-psychedelic-based-treatment-of-binge-b-cmnd-20240205monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-exclusive-long-term-licensing-agreement-with-leading-israeli--cmnd-20240201monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-closes-us-2-4-million-registered-direct-and-private-placement-cmnd-20240116monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-announces-pricing-of-2-4-million-registered-direct-and-private-plac-cmnd-20240111monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-completed-type-a-meeting-with-the-fda-cmnd-20240110monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-and-scisparc-reflect-on-successful-collaboration-in-2023-aiming-to-upgr-cmnd-20240104monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-it-is-in-compliance-with-all-applicable-nasdaq-listing-standa-cmnd-20231214monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-achieved-positive-results-in-cocaine-addiction-treatment-cmnd-20231205monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-positive-results-from-its-weight-loss-and-metabolic-disorder--cmnd-20231128monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-to-participate-in-traditional-vs-novel-psychedelics-virtual-event-with--cmnd-20231127monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-1-for-30-reverse-share-split-cmnd-20231121monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-receipt-of-nasdaq-delisting-notice-and-plan-for-immediate-rec-cmnd-20231117monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-shareholders-meeting-results-cmnd-20231115monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-to-pioneer-psychedelic-clinical-trials-for-alcohol-use-disorder-with-iv-cmnd-20231109monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-to-present-at-the-8th-annual-dawson-james-conference-on-october-12th-cmnd-20231005monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-closes-us-2-25-million-public-offering-cmnd-20230918monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-pricing-of-us-2-25-million-public-offering-cmnd-20230914monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-clinical-research-collaboration-with-johns-hopkins-university-cmnd-20230906monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-collaboration-with-cts-ltd-a-leading-pharmaceutical-and-consu-cmnd-20230814monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-files-patent-application-with-uspto-for-the-treatment-of-dyskinesia-fur-cmnd-20230801monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-share-based-payment-for-the-company-s-consultants-cmnd-20230717monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-and-scisparc-to-conduct-study-evaluating-combination-treatment-for-obes-cmnd-20230616monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-to-host-virtual-investor-conference-on-psychedelics-for-obesity-cmnd-20230609monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-first-us-site-for-its-phase-i-iia-clinical-trial-evaluating-c-cmnd-20230522monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-receipt-of-nasdaq-minimum-bid-price-notification-cmnd-20230519monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-to-host-virtual-investor-conference-on-psychedelics-for-obesity-cmnd-20230517monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-irb-approval-to-conduct-clinical-trial-on-alcohol-use-disorde-cmnd-20230512monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-retains-crescendo-communications-llc-for-investor-relations-and-announc-cmnd-20230509monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-strengthens-scientific-advisory-board-with-appointment-of-prof-joseph-t-cmnd-20230508monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-clinical-supply-agreement-for-its-upcoming-clinical-trial-cmnd-20230502monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-forms-a-data-and-safety-monitoring-board-to-oversee-its-first-in-human--cmnd-20230427monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-expanding-ip-portfolio-with-new-us-patent-application-for-treatment-of--cmnd-20230421monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-engages-experienced-contract-research-organization-to-support-its-first-cmnd-20230420monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-closes-us-3-5-million-public-offering-cmnd-20230406monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-pricing-of-us-3-5-million-public-offering-cmnd-20230404monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-submits-ind-application-to-fda-for-its-proprietary-cmnd-100-treating-al-cmnd-20230316monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-appoints-professor-henry-r-kranzler-m-d-to-scientific-advisory-board-cmnd-20230314monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-shareholders-meeting-results-cmnd-20221229monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-announces-initiation-of-cmnd-100-manufacturing-program-to-address-its-upcoming-c-cmnd-20221123monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-closing-of-us-7-5-million-public-offering-and-uplisting-to-th-cmnd-20221117monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-pricing-of-us-7-5-million-public-offering-and-uplisting-to-th-cmnd-20221115monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-featured-in-psychedelics-tonight-streaming-on-altrd-tv-cmnd-20221011monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-announces-notice-of-proposed-stock-consolidation-cmnd-20220925monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-applies-for-patent-to-treat-obesity-and-metabolic-syndrome-cmnd-20220922monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-share-based-payment-for-one-of-the-company-s-consultants-cmnd-20220916monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-additional-positive-pre-clinical-results-for-its-cocaine-addi-cmnd-20220824monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-appoints-new-chief-financial-officer-cmnd-20220615monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-positive-pre-clinical-results-for-cocaine-addiction-treatment-cmnd-20220607monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-and-scisparc-collaboration-yields-another-patent-application-for-cocain-cmnd-20220602monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-granted-patent-approval-for-psychedelic-based-alcohol-substitute-in-ind-cmnd-20220601monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-announces-successful-pre-ind-meeting-with-u-s-fda-for-cmnd-100-for-alcohol-use-d-cmnd-20220526monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-and-scisparc-collaboration-yields-positive-results-for-its-psychedelic--cmnd-20220524monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-successful-pre-clinical-results-in-meai-treatment-for-alcohol-cmnd-20220519monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-announces-pre-ind-meeting-date-with-fda-cmnd-20220513monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-and-scisparc-ltd-collaboration-yields-new-provisional-patent-applic-cmnd-20220510monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-strengthens-its-scientific-advisory-board-with-substance-abuse-and-mental-health-cmnd-20220509monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-to-partner-with-microdose-for-psychedelic-capital-mar-2022-today-thursd-cmnd-20220324monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-positive-results-on-cmnd-100-trials-cmnd-20220317monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-scisparc-launch-a-psychedelic-pharma-collaboration-cmnd-20220308monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-to-host-a-psychedelics-for-alcoholism-event-for-investors-on-february-2-cmnd-20220217monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-share-based-compensation-plan-cmnd-20220209monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-secures-cad-1-6-million-in-private-placement-cmnd-20220208monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-now-fully-eligible-for-settlement-through-the-depository-trust-company--cmnd-20220131monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-engages-the-independent-trading-group-as-a-market-maker-and-thunder11-a-cmnd-20220126monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-to-host-psychedelic-for-alcoholism-from-molecule-to-medicine-virtual-ev-cmnd-20220119monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-s-vp-of-business-development-presented-at-the-canadian-psychedelics-ass-cmnd-20220113monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-strengthens-presence-in-north-america-with-new-senior-appointments-cmnd-20220111monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-establishes-third-r-d-partnership-with-the-hebrew-university-cmnd-20220110monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-launches-study-for-binge-eating-with-the-hebrew-university-using-its-pr-cmnd-20211124monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-to-pursue-dual-listing-on-nasdaq-cmnd-20211122monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-signs-development-and-supply-agreement-to-produce-its-drug-candidate-meai-psyche-cmnd-20211026monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-appoints-distinguished-addiction-experts-professor-wim-van-den-brink-an-cmnd-20211014monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-files-provisional-patent-application-related-to-methods-of-drug-assiste-cmnd-20211013monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-partners-with-clinipace-to-commence-processes-towards-fda-approval-cmnd-20211007monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-to-host-psychedelics-for-alcoholism-virtual-educational-event-on-octobe-cmnd-20211001monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-partners-with-the-hebrew-university-to-develop-novel-psychedelic-drug-cmnd-20210921monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-issues-shareholder-letter-cmnd-20210720monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-highlight-2026-priorities-and-program-milestones-at-the-44th-annu-tern-20260107monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-tern-20260102monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-tern-20251002monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-corporate-tern-20250805monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-tern-20250804monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-selected-for-oral-presentation-at-european-hematology-association-co-tern-20250514monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-corporate--tern-20250508monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-tern-20250502monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-participate-in-the-citizens-life-sciences-conference-tern-20250430monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grant-to-new-employees-under-nasdaq-listing-rule--tern-20250402monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-corp-tern-20250320monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grant-to-new-chief-financial-officer-under-nasdaq-tern-20250226monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-provides-program-updates-and-announces-participation-at-td-cowen-45t-tern-20250225monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-appoints-andrew-gengos-as-chief-financial-officer-tern-20250224monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-appoints-robert-azelby-to-board-of-directors-tern-20250220monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-scienc-tern-20250205monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5-tern-20250203monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-present-at-43rd-annual-j-p-morgan-healthcare-conference-tern-20250108monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5-tern-20250102monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-announces-positive-early-data-from-phase-1-cardinal-trial-of-tern-70-tern-20241203monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5-tern-20241202monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-appoints-heather-turner-j-d-to-board-of-directors-tern-20241118monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-third-quarter-2024-financial-results-and-corporate-updates-tern-20241112monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-participate-in-upcoming-november-investor-conferences-tern-20241106monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5-tern-20241007monthly0.5https://www.biopharmawatch.com/news/TERN/terns-announces-closing-of-public-offering-of-shares-of-common-stock-and-pre-funded-warran-tern-20240912monthly0.5https://www.biopharmawatch.com/news/TERN/terns-announces-pricing-of-upsized-150-15-million-public-offering-tern-20240911monthly0.5https://www.biopharmawatch.com/news/TERN/terns-announces-proposed-public-offering-tern-20240909monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-announces-positive-phase-1-clinical-trial-results-with-tern-601-once-tern-20240909monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-second-quarter-2024-financial-results-and-corporate-updates-tern-20240805monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5-tern-20240801monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-appoints-biotech-executive-elona-kogan-as-chief-legal-officer-and-an-tern-20240729monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-highlights-new-preclinical-data-supporting-tern-501-in-combination-w-tern-20240621monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-tern-20240603monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-participate-in-upcoming-june-investor-conferences-tern-20240530monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-participate-in-ubs-obesity-therapeutics-day-tern-20240517monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-first-quarter-2024-financial-results-and-corporate-updates-tern-20240513monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-announces-leadership-changes-tern-20240508monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-participate-in-the-citizens-jmp-life-sciences-conference-2024-tern-20240507monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5-tern-20240503monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-announces-data-from-ongoing-phase-1-pharmacokinetic-study-of-alloste-tern-20240429monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-appoints-melita-sun-jung-as-chief-business-officer-tern-20240410monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-and-corp-tern-20240314monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-announces-orphan-drug-designation-granted-to-tern-701-for-the-treatm-tern-20240311monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5-tern-20240307monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences-tern-20240227monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grants-to-new-chief-executive-officer-under-nasda-tern-20240207monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-appoints-amy-burroughs-as-chief-executive-officer-tern-20240207monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5-tern-20240202monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-highlight-2024-priorities-and-clinical-milestones-at-the-42nd-ann-tern-20240104monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5-tern-20240103monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-present-at-the-jmp-securities-hematology-and-oncology-summit-tern-20231129monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-mourns-the-loss-of-senthil-sundaram-former-chief-executive-officer-tern-20231127monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-third-quarter-2023-financial-results-and-corporate-updates-tern-20231114monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-participate-in-upcoming-november-investor-conferences-tern-20231109monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-tern-20231103monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-announces-first-participant-dosed-in-phase-1-clinical-trial-of-tern--tern-20231102monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-participate-in-upcoming-investor-conferences-tern-20231019monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-announces-global-phase-1-clinical-trial-design-of-tern-701-for-the-t-tern-20231016monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-tern-20231003monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-tern-20230906monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-participate-in-upcoming-september-investor-conferences-tern-20230905monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-second-quarter-2023-financial-results-and-corporate-updates-tern-20230808monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5-tern-20230803monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-announces-leadership-transition-tern-20230803monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-host-virtual-key-opinion-leader-event-to-discuss-tern-701-and-adv-tern-20230718monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-tern-20230705monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-highlights-new-preclinical-data-for-tern-601-program-in-obesity-at-t-tern-20230626monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-present-at-goldman-sachs-44th-annual-global-healthcare-conference-tern-20230606monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-tern-20230602monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-announces-publication-of-tern-701-trial-in-progress-abstract-for-the-tern-20230525monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-present-at-upcoming-investor-conferences-tern-20230524monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-highlight-new-preclinical-data-for-tern-601-program-in-obesity-at-tern-20230522monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-first-quarter-2023-financial-results-and-corporate-updates-tern-20230515monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-participate-in-the-jmp-securities-2023-life-sciences-conference-tern-20230509monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-tern-20230503monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-and-corp-tern-20230327monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncolo-tern-20230327monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-provides-program-updates-and-announces-participation-at-upcoming-mar-tern-20230302monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-participate-in-guggenheim-healthcare-talks-2023-oncology-conferen-tern-20230202monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-present-at-b-riley-securities-3rd-annual-oncology-conference-tern-20230112monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-highlight-2023-priorities-and-clinical-milestones-at-the-41st-ann-tern-20230105monthly0.5https://www.biopharmawatch.com/news/TERN/terns-announces-closing-of-public-offering-of-shares-of-common-stock-including-full-exerci-tern-20221223monthly0.5https://www.biopharmawatch.com/news/TERN/terns-announces-pricing-of-75-million-public-offering-tern-20221221monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-tern-20221220monthly0.5https://www.biopharmawatch.com/news/TERN/terns-announces-proposed-public-offering-tern-20221219monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-present-at-the-2022-jmp-securities-hematology-and-oncology-summit-tern-20221201monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-third-quarter-2022-financial-results-and-corporate-highlight-tern-20221109monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-highlights-results-from-phase-1-clinical-trial-of-tern-501-at-aasld--tern-20221104monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-present-positive-clinical-data-in-nash-at-aasld-the-liver-meeting-tern-20221026monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-present-at-the-h-c-wainwright-6th-annual-nash-investor-conference-tern-20221011monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-present-at-the-h-c-wainwright-24th-annual-global-investment-confe-tern-20220907monthly0.5https://www.biopharmawatch.com/news/TERN/terns-announces-65-million-oversubscribed-offering-tern-20220812monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-second-quarter-2022-financial-results-and-corporate-highligh-tern-20220808monthly0.5https://www.biopharmawatch.com/news/TERN/terns-announces-appointment-of-radhika-tripuraneni-m-d-m-p-h-to-board-of-directors-tern-20220727monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-highlights-clinical-data-from-multiple-nash-programs-in-five-present-tern-20220622monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-present-clinical-data-on-multiple-nash-programs-at-the-easl-inter-tern-20220608monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-appoints-kerry-russell-as-chief-medical-officer-tern-20220601monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-first-quarter-2022-financial-results-and-business-updates-tern-20220516monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-present-at-the-21st-annual-needham-virtual-healthcare-conference-tern-20220404monthly0.5https://www.biopharmawatch.com/news/TERN/terns-reports-top-line-results-from-phase-1-aviation-trial-of-vap-1-inhibitor-tern-201-tern-20220321monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-and-corp-tern-20220303monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-participate-in-the-cowen-42nd-annual-healthcare-conference-tern-20220228monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-appoints-jeffrey-r-jasper-ph-d-as-senior-vice-president-head-of-rese-tern-20220106monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-present-at-40th-annual-j-p-morgan-health-care-conference-tern-20220103monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-third-quarter-2021-financial-results-and-corporate-highlight-tern-20211115monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-highlights-positive-clinical-data-from-multiple-nash-programs-at-aas-tern-20211112monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-present-positive-clinical-data-on-nash-programs-at-aasld-the-live-tern-20211018monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-present-at-h-c-wainwright-5th-annual-nash-investor-conference-tern-20211005monthly0.5https://www.biopharmawatch.com/news/TERN/terns-appoints-veteran-biopharmaceutical-executive-ann-e-taylor-m-d-to-board-of-directors-tern-20210928monthly0.5https://www.biopharmawatch.com/news/TERN/terns-completes-part-1-enrollment-of-aviation-phase-1b-nash-clinical-trial-of-vap-1-inhibi-tern-20210908monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-present-at-upcoming-investor-conferences-tern-20210902monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-reports-second-quarter-2021-financial-results-and-corporate-highligh-tern-20210816monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-present-at-upcoming-investor-conferences-tern-20210803monthly0.5https://www.biopharmawatch.com/news/TERN/terns-announces-initiation-of-patient-dosing-in-aviation-phase-1b-nash-clinical-trial-of-v-tern-20210624monthly0.5https://www.biopharmawatch.com/news/TERN/terns-reports-positive-top-line-results-from-phase-2a-lift-study-of-fxr-agonist-tern-101-i-tern-20210614monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-to-host-conference-call-to-discuss-top-line-results-from-phase-2a-li-tern-20210613monthly0.5https://www.biopharmawatch.com/news/TERN/terns-to-present-at-the-ubs-global-healthcare-virtual-conference-participate-in-the-j-p-mo-tern-20210519monthly0.5https://www.biopharmawatch.com/news/TERN/terns-reports-first-quarter-2021-financial-results-and-provides-corporate-update-tern-20210513monthly0.5https://www.biopharmawatch.com/news/TERN/terns-to-present-at-the-19th-annual-virtual-needham-healthcare-conference-tern-20210407monthly0.5https://www.biopharmawatch.com/news/TERN/terns-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-corporate-u-tern-20210330monthly0.5https://www.biopharmawatch.com/news/TERN/terns-announces-initiation-of-dosing-in-phase-1-clinical-trial-of-tern-501-its-thr-beta-ag-tern-20210322monthly0.5https://www.biopharmawatch.com/news/TERN/terns-to-present-on-vap-1-and-fxr-at-nash-tag-conference-2021-tern-20210308monthly0.5https://www.biopharmawatch.com/news/TERN/terns-to-present-at-the-cowen-41st-annual-health-care-conference-tern-20210223monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-inc-announces-closing-of-initial-public-offering-and-exercise-in-ful-tern-20210210monthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-inc-announces-pricing-of-upsized-initial-public-offering-of-common-s-tern-20210204monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-reaches-target-enrollment-of-phase-3-anchor-trial-evaluating-cd388-for-cdtx-20251124monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-report-third-quarter-2025-financial-results-and-host-quarterly-conf-cdtx-20251023monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-late-breaking-clinical-phase-2-data-on-cd388-at-id-week-202-cdtx-20251013monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-expanded-and-accelerated-phase-3-plan-for-cd388-a-non-vaccin-cdtx-20250924monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-presents-data-on-cd388-from-its-phase-2b-navigate-trial-and-preclinica-cdtx-20250917monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-september-investor-conferences-cdtx-20250904monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-a-cdtx-20250903monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-corporate-update-and-reports-second-quarter-2025-financial-re-cdtx-20250807monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-report-second-quarter-2025-financial-results-and-host-quarterly-con-cdtx-20250724monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cdtx-20250701monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-inclusion-in-the-russell-2000-and-russell-3000-indexes-cdtx-20250630monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-announces-closing-of-upsized-public-offering-and-full-exercise-of-underwriters-opti-cdtx-20250626monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-announces-pricing-of-upsized-public-offering-of-common-stock-cdtx-20250625monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-announces-proposed-public-offering-of-common-stock-cdtx-20250623monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-positive-topline-results-from-its-phase-2b-navigate-trial-ev-cdtx-20250623monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-host-virtual-r-d-day-to-discuss-cd388-as-a-potential-universal-once-cdtx-20250515monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-two-upcoming-investor-conferences-cdtx-20250513monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-corporate-update-and-reports-first-quarter-2025-financial-res-cdtx-20250508monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-promotion-of-nicole-davarpanah-to-chief-medical-officer-and--cdtx-20250501monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-the-citizens-life-sciences-conference-cdtx-20250430monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-report-first-quarter-2025-financial-results-and-host-inaugural-quar-cdtx-20250424monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-cdtx-20250401monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conferenc-cdtx-20250401monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-world-health-organization-meeting-on-h5n1-influenza--cdtx-20250319monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-con-cdtx-20250318monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-publication-of-cd388-preclinical-data-in-nature-microbiology-cdtx-20250317monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-202-cdtx-20250306monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-appointment-of-frank-karbe-as-chief-financial-officer-cdtx-20250218monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conferenc-cdtx-20250130monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-completes-enrollment-of-phase-2b-navigate-trial-evaluating-cd388-for-p-cdtx-20241204monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-105-million-private-placement-cdtx-20241121monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-evercore-7th-annual-healthconx-conference-cdtx-20241119monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-corporate-update-and-reports-third-quarter-2024-financial-res-cdtx-20241107monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-two-upcoming-november-investor-conferences-cdtx-20241031monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-two-presentations-on-drug-fc-conjugate-cd388-at-idweek-2024-cdtx-20241016monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-cdtx-20241004monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-two-presentations-on-innovative-drug-fc-conjugate-cd388-at-t-cdtx-20240925monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-first-subjects-dosed-in-phase-2b-navigate-trial-evaluating-c-cdtx-20240923monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-strengthens-its-scientific-advisory-board-with-infectious-disease-expe-cdtx-20240919monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-restructures-workforce-to-focus-on-planned-clinical-development-of-cd3-cdtx-20240912monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-cdtx-20240905monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-appointment-of-jim-beitel-as-chief-business-officer-cdtx-20240819monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-corporate-update-and-reports-second-quarter-2024-financial-re-cdtx-20240813monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-cdtx-20240703monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-preclinical-data-on-cd388-at-asm-microbe-2024-conference-cdtx-20240530monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-corporate-update-and-reports-first-quarter-2024-financial-res-cdtx-20240515monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-regains-compliance-with-nasdaq-continued-listing-rules-cdtx-20240515monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-presentations-highlighting-phase-1-and-phase-2a-clinical-dat-cdtx-20240426monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-alert-bragar-eagel-squire-p-c-is-investigating-cidara-therapeutics-inc-cdtx-20240426monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-reacquires-global-development-and-commercial-rights-to-cd388-and-annou-cdtx-20240424monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-divestiture-of-rezafungin-to-mundipharma-to-focus-on-advanci-cdtx-20240424monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-202-cdtx-20240422monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-receipt-of-nasdaq-delinquency-notice-cdtx-20240422monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-reverse-stock-split-cdtx-20240422monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-presents-promising-new-data-on-novel-drug-fc-conjugate-candidates-at-t-cdtx-20240405monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-preclincal-data-on-multiple-novel-drug-fc-conjugate-candida-cdtx-20240306monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-receives-11-14-million-milestone-payment-following-european-approval-o-cdtx-20240212monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-approval-of-rezzayo-by-the-mhra-for-the-treatment-of-invasiv-cdtx-20240129monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-european-approval-of-rezzayo-rezafungin-for-the-treatment-of-cdtx-20231222monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-presents-new-promising-preclincal-data-on-novel-dual-acting-drug-fc-co-cdtx-20231207monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-completion-of-enrollment-in-phase-3-restore-trial-of-rezafun-cdtx-20231206monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-new-preclinical-data-on-novel-dual-acting-drug-fc-conjugate-cdtx-20231130monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-named-as-a-san-diego-metro-area-top-workplace-cdtx-20231120monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-corporate-update-and-reports-third-quarter-2023-financial-res-cdtx-20231102monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-and-mundipharma-receive-positive-chmp-opinion-for-rezafungin-for-the-t-cdtx-20231013monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-presents-new-preclinical-and-clinical-data-on-novel-drug-fc-conjugate--cdtx-20231011monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-cdtx-20230929monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-new-data-on-novel-drug-fc-conjugate-cd388-at-idweek-2023-cdtx-20230927monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-host-virtual-research-development-day-on-its-cloudbreak-development-cdtx-20230907monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-to-present-at-the-25th-annual-h-c-wainwright-global-investment-conference-cdtx-20230906monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-janssen-s-election-to-proceed-under-its-license-agreement-re-cdtx-20230906monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-appointment-of-nicole-davarpanah-m-d-j-d-as-senior-vice-pres-cdtx-20230816monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-corporate-update-and-reports-second-quarter-2023-financial-re-cdtx-20230803monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-update-on-rezzayo-rezafungin-for-injection-cdtx-20230731monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-update-on-status-of-ongoing-cd388-influenza-program-cdtx-20230720monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-added-to-russell-microcap-index-cdtx-20230626monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-receives-u-s-fda-fast-track-designation-for-cd388-a-novel-drug-fc-conj-cdtx-20230622monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-ongoing-development-of-drug-fc-conjugates-dfc-including-cd7-cdtx-20230620monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-adenosine-pathway-targeted-cancer-immunotherapy-summit-cdtx-20230613monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-corporate-update-and-reports-first-quarter-2023-financial-res-cdtx-20230511monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-presents-new-preclinical-data-on-novel-drug-fc-conjugate-cd388-at-the--cdtx-20230503monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-receives-20-million-milestone-payment-following-fda-approval-of-rezzay-cdtx-20230424monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-upcoming-investor-conferences-cdtx-20230331monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-202-cdtx-20230323monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-and-melinta-therapeutics-announce-fda-approval-of-rezzayo-rezafungin-f-cdtx-20230322monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-presents-preclinical-data-on-cd73-targeting-drug-fc-conjugate-at-the-2-cdtx-20230307monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-closing-of-public-offerings-of-common-stock-and-preferred-st-cdtx-20230307monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-pricing-of-public-offerings-of-common-stock-and-preferred-st-cdtx-20230303monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-underwritten-public-offerings-of-common-stock-and-preferred--cdtx-20230302monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-promising-interim-phase-2a-data-assessing-the-safety-and-eff-cdtx-20230301monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-to-present-at-esmo-targeted-anticancer-therapies-congress-cdtx-20230228monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-cdtx-20230214monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-and-wuxi-xdc-expand-collaboration-for-ind-enabling-cmc-development-to--cdtx-20230201monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-and-melinta-therapeutics-announce-fda-advisory-committee-recommends-ap-cdtx-20230125monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-nominates-first-oncology-clinical-development-candidate-from-its-cloud-cdtx-20230104monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-issuance-of-first-u-s-patent-for-cd388-cdtx-20221201monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-two-leading-independent-proxy-advisory-firms-recommend-stock-cdtx-20221129monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-and-melinta-therapeutics-announce-publication-of-data-from-the-global--cdtx-20221128monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-the-world-antiviral-congress-2022-cdtx-20221123monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-the-stifel-healthcare-conference-cdtx-20221108monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-corporate-update-and-reports-third-quarter-2022-financial-res-cdtx-20221103monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-new-data-for-rezafungin-at-idweek-2022-cdtx-20221017monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-receives-11-1-million-milestone-payment-from-mundipharma-cdtx-20221004monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-fda-acceptance-for-priority-review-of-new-drug-application-f-cdtx-20220920monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-initiation-of-phase-2a-human-viral-challenge-trial-to-evalua-cdtx-20220913monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-the-24th-annual-h-c-wainwright-global-investment-confere-cdtx-20220906monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-corporate-update-and-reports-second-quarter-2022-financial-re-cdtx-20220809monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-submits-nda-for-rezafungin-and-announces-license-agreement-with-melint-cdtx-20220727monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-host-research-and-development-day-cdtx-20220627monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-corporate-update-and-reports-first-quarter-2022-financial-res-cdtx-20220511monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-and-mundipharma-to-present-results-from-global-phase-3-restore-trial-o-cdtx-20220414monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-the-completion-of-dosing-the-first-cohort-of-healthy-volunte-cdtx-20220331monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-202-cdtx-20220307monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-fda-acceptance-of-its-investigational-new-drug-application-f-cdtx-20220214monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cdtx-20220106monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-and-mundipharma-announce-positive-topline-results-from-the-global-phas-cdtx-20211214monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-named-a-san-diego-metro-area-top-workplace-for-the-fifth-consecutive-y-cdtx-20211122monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-third-quarter-2021-financial-results-cdtx-20211110monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-closing-of-concurrent-public-offerings-of-common-stock-and-p-cdtx-20211013monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-pricing-of-concurrent-public-offerings-of-common-stock-and-p-cdtx-20211008monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-commencement-of-concurrent-public-offerings-of-common-stock--cdtx-20211007monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cdtx-20211001monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-new-data-for-rezafungin-at-timm-congress-cdtx-20210929monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-new-data-for-rezafungin-at-idweek-2021-cdtx-20210927monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-two-upcoming-investor-conferences-cdtx-20210907monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-host-research-and-development-day-cdtx-20210902monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-appoints-preetam-shah-ph-d-mba-as-chief-financial-officer-and-chief-bu-cdtx-20210901monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-and-mundipharma-announce-completion-of-enrollment-in-the-phase-3-resto-cdtx-20210817monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-second-quarter-2021-financial-results-cdtx-20210812monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference-cdtx-20210805monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-new-data-for-rezafungin-at-the-international-society-for-hu-cdtx-20210727monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-presents-new-analyses-from-multiple-rezafungin-studies-at-eccmid-2021-cdtx-20210712monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cdtx-20210707monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-leadership-update-cdtx-20210701monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-o-cdtx-20210630monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-the-raymond-james-human-health-innovation-conference-cdtx-20210614monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-to-present-at-mycology-2021-conference-cdtx-20210602monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-first-quarter-2021-financial-results-cdtx-20210513monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-the-20th-annual-needham-virtual-healthcare-conference-cdtx-20210407monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-agreement-with-janssen-to-develop-and-commercialize-avcs-for-cdtx-20210405monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cdtx-20210401monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference-cdtx-20210303monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-202-cdtx-20210225monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-new-data-for-rezafungin-at-the-21st-ichs-symposium-cdtx-20210217monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-new-data-for-rezafungin-and-influenza-avcs-at-the-21st-ichs-cdtx-20210211monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-key-additions-to-its-board-of-directors-cdtx-20210125monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-cdtx-20210105monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-appoints-biotechnology-industry-veteran-christopher-kurtz-as-executive-cdtx-20201215monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-preclinical-data-for-influenza-avcs-at-the-7th-eswi-influen-cdtx-20201201monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-new-clinical-data-for-rezafungin-at-esicm-lives-2020-cdtx-20201130monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-named-a-san-diego-metro-area-top-workplace-for-the-fourth-consecutive--cdtx-20201116monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-two-upcoming-investor-conferences-cdtx-20201111monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-third-quarter-2020-financial-results-cdtx-20201105monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-new-clinical-and-preclinical-data-for-rezafungin-and-influen-cdtx-20201021monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-the-2020-american-college-of-clinical-pharmacy-accp-annu-cdtx-20201013monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-new-clinical-and-preclinical-data-for-rezafungin-and-influe-cdtx-20200914monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-upcoming-investor-conferences-cdtx-20200902monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-second-quarter-2020-financial-results-cdtx-20200813monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-the-2020-wedbush-pacgrow-healthcare-virtual-conference-cdtx-20200804monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-formation-of-scientific-advisory-board-cdtx-20200727monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-b-riley-virtual-summer-series-panel-on-antiviral-the-cdtx-20200717monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-added-to-russell-3000-index-cdtx-20200629monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-cantor-fitzgerald-virtual-symposium-winning-ways-to--cdtx-20200623monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-the-raymond-james-human-health-innovations-conference-cdtx-20200611monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-doses-first-patient-in-pivotal-phase-3-respect-trial-of-rezafungin-for-cdtx-20200520monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-first-quarter-2020-financial-results-cdtx-20200513monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-new-clinical-and-preclinical-data-for-rezafungin-and-influen-cdtx-20200505monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-antifungal-and-covid-19-therapeutics-panels-at-maxim-cdtx-20200428monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-the-19th-annual-needham-virtual-healthcare-conference-cdtx-20200407monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-201-cdtx-20200304monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-transplantation-cellular-therapy-tct-and-mycology-2020-m-cdtx-20200218monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-closing-of-rights-offering-cdtx-20200212monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-commencement-of-rights-offering-cdtx-20200122monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-proposed-rights-offering-cdtx-20200110monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-two-upcoming-medical-conferences-cdtx-20191203monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-named-a-san-diego-metro-area-top-workplace-for-the-third-consecutive-y-cdtx-20191118monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-third-quarter-2019-financial-results-cdtx-20191108monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-hosting-key-opinion-leader-meeting-on-rezafungin-and-cloudbreak-progra-cdtx-20191105monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-new-clinical-and-preclinical-data-at-two-upcoming-medical-c-cdtx-20191003monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-two-upcoming-investor-conferences-cdtx-20190916monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-second-quarter-2019-financial-results-cdtx-20190808monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-the-2019-wedbush-pacgrow-healthcare-conference-cdtx-20190807monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-reports-positive-topline-results-in-phase-2-strive-b-trial-of-antifung-cdtx-20190729monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-first-quarter-2019-financial-results-cdtx-20190509monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-the-18th-annual-needham-healthcare-conference-cdtx-20190403monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2018-financial-r-cdtx-20190228monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-third-quarter-2018-financial-results-cdtx-20181108monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-two-upcoming-investor-conferences-cdtx-20180924monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-second-quarter-2018-financial-results-cdtx-20180808monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-offering-of-common-stock-and-warrants-cdtx-20180521monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-first-quarter-2018-financial-results-cdtx-20180510monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-clinical-data-updates-for-its-lead-antifungal-rezafungin-cdtx-20180321monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-reports-positive-topline-results-from-phase-2-strive-trial-of-lead-ant-cdtx-20180319monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-rezafungin-data-at-the-european-society-for-blood-and-marro-cdtx-20180308monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-announces-appointment-of-chrysa-mineo-as-independent-director-cdtx-20180301monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2017-financial-r-cdtx-20180227monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-presentations-at-the-8th-advances-against-aspergillosis-conf-cdtx-20180129monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-completes-enrollment-in-phase-2-strive-trial-evaluating-novel-antifung-cdtx-20171128monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-named-a-san-diego-metro-area-2017-top-workplace-cdtx-20171113monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-third-quarter-2017-financial-results-cdtx-20171108monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-report-third-quarter-2017-financial-results-and-provide-corporate-u-cdtx-20171101monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-pricing-of-20-million-private-placement-of-common-stock-cdtx-20171019monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-presentations-at-idweek-2017-and-the-8th-trends-in-medical-m-cdtx-20170925monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-two-upcoming-conferences-cdtx-20170918monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-participate-in-keynote-panel-discussion-at-the-2017-world-antimicro-cdtx-20170907monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-second-quarter-2017-financial-results-cdtx-20170809monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-first-quarter-2017-financial-results-cdtx-20170510monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-host-investor-day-on-april-6-2017-cdtx-20170329monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2016-financial-r-cdtx-20170315monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-reports-unfavorable-results-of-phase-2-radiant-trial-of-cd101-topical--cdtx-20170221monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-third-quarter-2016-financial-results-cdtx-20161110monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-the-stifel-2016-healthcare-conference-cdtx-20161108monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-and-square-1-bank-announce-20-million-credit-facility-cdtx-20161102monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-closing-of-public-offering-of-common-stock-including-exercis-cdtx-20161013monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-pricing-of-public-offering-of-common-stock-cdtx-20161007monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-commencement-of-public-offering-of-common-stock-cdtx-20161006monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-the-leerink-partners-roundtable-series-rare-disease-immu-cdtx-20160920monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-reports-second-quarter-2016-financial-results-and-provides-corporate-update-cdtx-20160811monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-the-cantor-fitzgerald-annual-healthcare-conference-cdtx-20160706monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-expands-management-team-cdtx-20160705monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-the-jefferies-2016-healthcare-conference-cdtx-20160602monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-reports-first-quarter-2016-financial-results-and-provides-corporate-update-cdtx-20160512monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-the-needham-company-15th-annual-healthcare-conference-cdtx-20160405monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-reports-fourth-quarter-and-full-year-2015-financial-results-and-provides-corporate--cdtx-20160318monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-participation-in-leerink-partners-5th-annual-global-healthca-cdtx-20160203monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-positive-data-from-phase-1-clinical-trial-of-cd101-iv-and-re-cdtx-20151116monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-the-jefferies-2015-global-healthcare-conference-in-londo-cdtx-20151110monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-reports-second-quarter-2015-financial-results-and-provides-corporate-update-cdtx-20150811monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-to-present-at-the-wedbush-pacgrow-2015-healthcare-conference-cdtx-20150805monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-set-to-join-russell-indexes-cdtx-20150623monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-reports-first-quarter-2015-financial-results-and-provides-corporate-update-cdtx-20150521monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-pricing-of-initial-public-offering-cdtx-20150415monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-to-attend-and-share-new-clinical-data-at-the-47th-annual-heart-rhythm-s-vtak-20260423monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-secures-u-s-patent-allowance-on-foundational-surgical-technology-establ-vtak-20260421monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-to-attend-the-annual-european-heart-rhythm-association-conference-vtak-20260408monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-engages-strategic-advisor-vtak-20260402monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-reports-2025-results-and-updates-on-strategic-expansion-vtak-20260331monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-secures-up-to-88-million-in-strategic-institutional-financing-commi-vtak-20260311monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-s-locket-suture-retention-device-to-be-featured-in-live-cases-at-islaa--vtak-20260306monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-announces-strategic-sale-of-non-core-assets-to-strengthen-balance-sheet-vtak-20260219monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-receives-first-purchase-order-for-locket-in-germany-vtak-20260122monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-received-new-vivo-purchase-order-from-leading-hospital-in-slovenia-vtak-20260120monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-vtak-announces-expansion-of-locket-into-an-eighth-european-country-sinc-vtak-20251218monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-secures-tender-from-leading-hospital-in-hungary-vtak-20251203monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-announces-launch-of-locket-in-switzerland-vtak-20251201monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-announces-successful-locket-launch-in-south-africa-vtak-20251120monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-announces-third-vivo-installation-in-france-vtak-20251118monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-vtak-reports-third-quarter-and-first-nine-months-2025-results-of-operat-vtak-20251113monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-enters-distribution-agreement-with-fumedica-ag-to-bring-locket-to-switz-vtak-20251016monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-announces-two-new-patents-to-be-issued-by-uspto-vtak-20250930monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-announces-tender-win-and-first-purchase-order-in-croatia-vtak-20250910monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-announces-september-10th-2025-record-date-for-october-10th-2025-special-vtak-20250904monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-announces-introduction-of-the-locket-product-line-into-italy-vtak-20250902monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-announces-first-procedures-in-france-as-locket-expansion-continues-vtak-20250828monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-receives-notification-of-new-patent-issuance-for-vivo-product-line-vtak-20250825monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-announces-the-start-of-enrollment-for-the-locket-compare-study-vtak-20250821monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-receives-approval-for-locket-in-the-united-kingdom-vtak-20250818monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-announces-effectiveness-of-1-for-19-reverse-stock-split-vtak-20250815monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-reports-results-of-operations-for-second-quarter-2025-vtak-20250811monthly0.5https://www.biopharmawatch.com/news/VTAK/catheters-market-size-to-hit-usd-95-56-billion-by-2032-driven-by-a-surge-in-chronic-diseas-vtak-20250715monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-announces-first-purchase-order-from-university-hospital-in-rennes-f-vtak-20250707monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-forms-new-joint-venture-called-kardionav-to-exploit-patented-ai-tec-vtak-20250630monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-comments-on-recent-market-activity-vtak-20250612monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-vtak-reports-key-progress-for-the-locket-product-vtak-20250612monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-secures-vivo-purchase-order-from-sahlgrenska-university-hospital-vtak-20250609monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-announces-first-quarter-2025-update-and-financial-results-vtak-20250514monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-announces-1-5-million-private-placement-equity-financing-and-potent-vtak-20250512monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-completes-acquisition-of-cardionomic-heart-failure-assets-vtak-20250506monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-to-attend-and-participate-in-the-46th-heart-rhythm-society-vtak-20250424monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-to-acquire-assets-in-development-for-late-stage-treatment-for-acute-dec-vtak-20250423monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-makes-nyse-american-section-610-b-public-announcement-vtak-20250417monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-receives-notice-of-first-patent-allowance-in-the-us-for-locket-prod-vtak-20250414monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-announces-fourth-quarter-and-full-year-2024-update-and-financial-re-vtak-20250328monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-to-participate-in-and-share-data-at-upcoming-industry-conferences-vtak-20250326monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-to-attend-and-participate-in-the-western-atrial-fibrillation-symposium-vtak-20250227monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-to-attend-and-participate-in-the-13th-internation-symposium-on-left-atr-vtak-20250206monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-announces-the-closing-of-its-acquisition-of-perikard-llc-vtak-20250204monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-introducer-sheaths-market-size-on-track-to-expand-at-6-1-cagr-reaching-usd-1-7-bi-vtak-20241007monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-related-bloodstream-infection-market-size-to-reach-usd-2-52-bn-by-2033-vtak-20240718monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-introducer-sheaths-market-by-qualitative-analysis-2023-2029-by-proficient-market--vtak-20230609monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-publication-of-long-term-efficacy-and-safety-data-from--swtx-20251021monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-receives-positive-chmp-opinion-for-mirdametinib-for-the-treatment-swtx-20250523monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-expected-chmp-opinion-in-q2-2025-for-nirogacestat-for-t-swtx-20250427monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-h-swtx-20250220monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-fda-approval-of-gomekli-mirdametinib-for-the-treatment--swtx-20250211monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on--swtx-20250130monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-preliminary-fourth-quarter-and-full-year-2024-financial-r-swtx-20250113monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-swtx-20250103monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-participate-in-the-7th-annual-evercore-isi-healthconx-conferen-swtx-20241126monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-participate-in-the-jefferies-london-healthcare-conference-swtx-20241112monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-third-quarter-2024-financial-results-and-recent-business--swtx-20241112monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-mirdametinib-data-to-be-presented-at-the-2024-society-f-swtx-20241111monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-publication-of-the-pivotal-phase-2b-reneu-trial-evaluat-swtx-20241111monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-long-term-efficacy-and-safety-data-from-phase-3-defi-tr-swtx-20241107monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-participate-in-guggenheim-s-inaugural-healthcare-innovation-co-swtx-20241105monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-report-third-quarter-2024-financial-results-on-tuesday-novembe-swtx-20241022monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-second-quarter-2024-financial-results-and-recent-business-swtx-20240807monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-appoints-dr-martin-mackay-to-its-board-of-directors-swtx-20240729monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-report-second-quarter-2024-financial-results-on-wednesday-augu-swtx-20240723monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-completes-submission-of-new-drug-application-to-the-fda-for-mirda-swtx-20240701monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-swtx-20240605monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-data-to-be-presented-at-the-2024-american-society-of-cl-swtx-20240523monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-participate-in-the-bofa-securities-2024-health-care-conference-swtx-20240508monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-first-quarter-2024-financial-results-and-highlights-recen-swtx-20240502monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-abstracts-accepted-for-presentation-at-the-2024-america-swtx-20240424monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-report-first-quarter-2024-financial-results-thursday-may-2-202-swtx-20240418monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-initiates-rolling-submission-of-new-drug-application-to-the-fda-f-swtx-20240304monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-european-medicines-agency-validation-for-marketing-auth-swtx-20240229monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-h-swtx-20240227monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-at-upcoming-investor-conferences-swtx-20240222monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-6th-annual-biot-swtx-20240131monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-highlights-2023-accomplishments-and-anticipated-milestones-for-20-swtx-20240108monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-swtx-20231221monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-closing-of-upsized-public-offering-of-common-stock-and--swtx-20231208monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-pricing-of-upsized-public-offering-of-common-stock-swtx-20231205monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-proposed-public-offering-of-common-stock-swtx-20231204monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-participate-in-the-6th-annual-evercore-isi-healthconx-conferen-swtx-20231129monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-fda-approval-of-ogsiveo-nirogacestat-as-the-first-and-o-swtx-20231127monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-positive-topline-results-from-the-phase-2b-reneu-trial--swtx-20231116monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-third-quarter-2023-financial-results-and-recent-business--swtx-20231102monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-presentation-of-additional-data-from-phase-3-defi-trial-swtx-20231101monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer-swtx-20230911monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-second-quarter-2023-financial-results-and-recent-business-swtx-20230802monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-swtx-20230607monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-pdufa-date-extension-for-nirogacestat-nda-swtx-20230605monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-full-enrollment-of-phase-2-trial-evaluating-nirogacesta-swtx-20230530monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-presentation-of-additional-data-from-phase-3-defi-trial-swtx-20230525monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-participate-in-the-td-cowen-4th-annual-oncology-innovation-sum-swtx-20230524monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-clinical-data-presentations-of-nirogacestat-in-combinat-swtx-20230511monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-first-quarter-2023-financial-results-and-recent-business--swtx-20230503monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-participate-in-the-bank-of-america-securities-2023-health-care-swtx-20230502monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-and-beigene-present-clinical-data-on-lifirafenib-in-combination-with-mirdameti-swtx-20230417monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-new-england-journal-of-medicine-publication-of-phase-3--swtx-20230308monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-participate-in-the-cowen-43rd-annual-health-care-conference-swtx-20230301monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-r-swtx-20230228monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-fda-acceptance-and-priority-review-of-new-drug-applicat-swtx-20230227monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-highlights-2022-accomplishments-and-anticipated-milestones-for-20-swtx-20230109monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-swtx-20230103monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-completes-submission-of-new-drug-application-to-the-fda-for-nirog-swtx-20221227monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-participate-in-the-evercore-isi-5th-annual-healthconx-conferen-swtx-20221122monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-third-quarter-2022-financial-results-and-recent-business--swtx-20221103monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-dosing-of-first-patient-in-phase-2-trial-evaluating-nir-swtx-20220929monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-data-from-phase-3-defi-trial-evaluating-nirogacestat-in-swtx-20220910monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-225-million-private-placement-financing-swtx-20220907monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-announces-expansion-of-global-non-exclusive-collaboration-with-gsk-for-nirogac-swtx-20220907monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-late-breaking-oral-presentation-of-phase-3-defi-data-at-swtx-20220819monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-second-quarter-2022-financial-results-and-recent-business-swtx-20220804monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-at-the-2022-wedbush-pacgrow-healthcare-conference-swtx-20220802monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-progress-across-the-company-s-targeted-oncology-portfo-swtx-20220610monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-at-the-goldman-sachs-43rd-annual-global-healthcare-con-swtx-20220609monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-highlights-nirogacestat-clinical-data-at-the-2022-asco-annual-mee-swtx-20220526monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-nirogacestat-achieved-primary-and-all-key-secondary-end-swtx-20220524monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-host-virtual-r-d-day-on-june-10-2022-swtx-20220516monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-first-quarter-2022-financial-results-and-recent-business--swtx-20220505monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with--swtx-20220419monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-r-swtx-20220224monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-at-upcoming-investor-conferences-swtx-20220201monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-swtx-20220104monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-clinical-collaboration-with-abbvie-to-evaluate-nirogace-swtx-20211210monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-dosing-of-first-patient-in-phase-1b-2-trial-evaluating--swtx-20211206monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-full-enrollment-of-phase-2b-reneu-trial-evaluating-mird-swtx-20211129monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-participate-in-the-4th-annual-evercore-isi-healthconx-conferen-swtx-20211123monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-third-quarter-2021-financial-results-and-recent-business--swtx-20211104monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-the-initiation-of-an-expanded-phase-2-cohort-and-additi-swtx-20211027monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-collaborate-with-ab-magnitude-on-target-identification-and-dis-swtx-20211020monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-collaborate-with-leading-academic-institutions-to-advance-port-swtx-20211020monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-co-swtx-20210907monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-enters-into-research-collaboration-with-leading-cancer-institute--swtx-20210830monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-second-quarter-2021-financial-results-and-recent-business-swtx-20210804monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-at-the-12th-annual-wedbush-pacgrow-healthcare-conferen-swtx-20210803monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-phase-1b-2a-clinical-trial-of-mirdametinib-in-patients--swtx-20210803monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-appoints-dr-james-cassidy-as-chief-medical-officer-swtx-20210727monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-issuance-of-new-u-s-composition-of-matter-patent-to-pol-swtx-20210720monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-initiation-of-phase-1-2-clinical-trial-of-mirdametinib--swtx-20210616monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-presentation-of-updated-interim-data-from-the-phase-2b--swtx-20210615monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-clinical-collaboration-with-seagen-to-evaluate-nirogace-swtx-20210607monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-at-the-goldman-sachs-42nd-annual-global-healthcare-con-swtx-20210601monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-at-the-cowen-2nd-annual-oncology-innovation-summit-swtx-20210514monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-appoints-dr-mike-burgess-as-head-of-research-and-development-swtx-20210510monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-first-quarter-2021-financial-results-and-recent-business--swtx-20210506monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-expands-targeted-oncology-pipeline-with-exclusive-worldwide-licen-swtx-20210506monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-dosing-of-first-patient-in-phase-1b-combination-study-e-swtx-20210401monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-appoints-bhavesh-ashar-as-chief-commercial-officer-swtx-20210322monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-r-swtx-20210225monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-interim-data-from-phase-2b-reneu-trial-of-mirdametinib-fo-swtx-20210225monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-at-upcoming-investor-conferences-swtx-20210222monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-at-the-guggenheim-healthcare-talks-2021-oncology-day-swtx-20210204monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-swtx-20210105monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-executive-leadership-promotions-swtx-20201215monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-participate-in-the-evercore-isi-healthconx-conference-swtx-20201124monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-third-quarter-2020-financial-results-and-recent-business--swtx-20201112monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exe-swtx-20201013monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-pricing-of-public-offering-of-common-stock-swtx-20201008monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-proposed-public-offering-of-common-stock-swtx-20201006monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-clinical-collaboration-with-pfizer-inc-to-evaluate-niro-swtx-20201005monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-participate-in-h-c-wainwright-precision-oncology-investor-conf-swtx-20200922monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-enters-into-sponsored-research-agreement-with-fred-hutchinson-can-swtx-20200918monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-collaboration-with-children-s-oncology-group-to-conduct-swtx-20200916monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-clinical-collaboration-with-janssen-to-evaluate-nirogac-swtx-20200914monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-second-quarter-2020-financial-results-and-recent-business-swtx-20200812monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-at-the-2020-wedbush-pacgrow-healthcare-conference-swtx-20200804monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-full-enrollment-of-phase-3-defi-trial-evaluating-niroga-swtx-20200722monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-dosing-of-first-patient-in-phase-1b-combination-study-e-swtx-20200622monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-at-the-goldman-sachs-41st-annual-global-healthcare-con-swtx-20200602monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-appoints-julie-hambleton-m-d-to-its-board-of-directors-swtx-20200526monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-first-quarter-2020-financial-results-and-recent-business--swtx-20200512monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-issuance-of-new-u-s-composition-of-matter-patent-to-pol-swtx-20200318monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-r-swtx-20200312monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-at-the-cowen-and-company-40th-annual-health-care-confe-swtx-20200218monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-swtx-20200106monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-reports-third-quarter-2019-financial-results-and-recent-business--swtx-20191112monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-initiation-of-phase-2b-reneu-clinical-trial-of-mirdamet-swtx-20191024monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-closing-of-initial-public-offering-and-exercise-in-full-swtx-20190917monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-announces-pricing-of-initial-public-offering-swtx-20190912monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-etnb-20250804monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-etnb-20250709monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-etnb-20250606monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-etnb-20250509monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-upcoming-investor-conferences-etnb-20250506monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-first-quarter-2025-financial-results-and-corporate-updates-etnb-20250501monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-the-leerink-partners-global-healthcare-conference-etnb-20250303monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-fourth-quarter-and-full-year-2024-financial-results-and-corporate-updates-etnb-20250227monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-etnb-20250206monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-closing-of-its-public-offering-and-full-exercise-of-underwriters-option-to-etnb-20250203monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-inc-announces-pricing-of-250-0-million-public-offering-of-common-stock-and-pre-funde-etnb-20250129monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-inc-announces-proposed-underwritten-public-offering-of-common-stock-and-pre-funded-w-etnb-20250127monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-provides-business-update-and-outlook-for-2025-etnb-20250113monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-etnb-20241219monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-etnb-20241129monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference-etnb-20241126monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-presents-new-analyses-evaluating-pegozafermin-and-potential-benefit-of-non-invasive--etnb-20241115monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-inc-announces-upsized-pricing-of-125-0-million-public-offering-of-common-stock-and-p-etnb-20241113monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-inc-announces-proposed-underwritten-public-offering-of-common-stock-and-pre-funded-w-etnb-20241112monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-third-quarter-2024-financial-results-and-corporate-updates-etnb-20241107monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-the-ubs-global-healthcare-conference-etnb-20241105monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-present-new-analyses-from-enliven-phase-2b-pegozafermin-trial-in-metabolic-dysfun-etnb-20241015monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-etnb-20241011monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-the-h-c-wainwright-8th-annual-mash-investor-conference-etnb-20240930monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-etnb-20240919monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-appointment-of-teresa-perney-ph-d-as-chief-regulatory-and-quality-officer-etnb-20240916monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-upcoming-investor-conferences-etnb-20240829monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-etnb-20240809monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-appoints-francis-sarena-as-chief-operating-officer-etnb-20240807monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-second-quarter-2024-financial-results-and-corporate-updates-etnb-20240805monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-appoints-charles-mcwherter-ph-d-to-its-board-of-directors-etnb-20240805monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-etnb-20240712monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-etnb-20240614monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-present-48-week-data-from-enliven-phase-2b-pegozafermin-trial-in-metabolic-dysfun-etnb-20240522monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-initiates-phase-3-enlighten-cirrhosis-trial-of-pegozafermin-in-metabolic-dysfunction-etnb-20240514monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-etnb-20240510monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-first-quarter-2024-financial-results-and-provides-corporate-update-etnb-20240509monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-the-bofa-securities-2024-health-care-conference-etnb-20240508monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-host-key-opinion-leader-webinar-on-pegozafermin-s-opportunity-in-advanced-mash-etnb-20240502monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-appoints-biotech-industry-veteran-martin-babler-to-its-board-of-directors-etnb-20240417monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-etnb-20240405monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-receives-ema-prime-status-for-pegozafermin-in-the-treatment-of-metabolic-dysfunction-etnb-20240327monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-initiates-phase-3-enlighten-fibrosis-trial-of-pegozafermin-in-non-cirrhotic-metaboli-etnb-20240312monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-etnb-20240308monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-the-leerink-partners-global-biopharma-conference-etnb-20240305monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-corporate-u-etnb-20240229monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-the-oppenheimer-34th-annual-healthcare-life-sciences-conference-etnb-20240206monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-etnb-20240205monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-etnb-20231219monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-closing-of-its-upsized-public-offering-and-full-exercise-of-underwriters-o-etnb-20231212monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-inc-announces-upsized-pricing-of-150-0-million-public-offering-of-common-stock-and-p-etnb-20231207monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-inc-announces-proposed-underwritten-public-offering-of-common-stock-and-pre-funded-w-etnb-20231206monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reaches-alignment-with-the-fda-and-ema-on-phase-3-program-for-pegozafermin-in-nonalc-etnb-20231204monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-new-positive-long-term-data-from-the-enliven-phase-2b-trial-of-pegozafermi-etnb-20231127monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-the-6th-annual-evercore-isi-healthconx-conference-etnb-20231121monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-additional-data-from-the-enliven-phase-2b-trial-of-pegozafermin-in-patient-etnb-20231112monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-third-quarter-2023-financial-results-and-provides-corporate-updates-etnb-20231108monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-etnb-20231003monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-pegozafermin-in-n-etnb-20230921monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-the-2023-cantor-global-healthcare-conference-etnb-20230920monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference-etnb-20230905monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-second-quarter-2023-financial-results-and-provides-corporate-update-etnb-20230809monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-etnb-20230712monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-publishes-positive-results-from-phase-2-entrigue-trial-of-pegozafermin-in-patients-w-etnb-20230624monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-etnb-20230607monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-late-breaker-oral-presentation-of-data-from-the-phase-2-enliven-study-of-p-etnb-20230607monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-initiates-phase-3-entrust-trial-of-pegozafermin-in-patients-with-severe-hypertriglyc-etnb-20230523monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-first-quarter-2023-financial-results-and-provides-corporate-update-etnb-20230504monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-upcoming-investor-conferences-etnb-20230502monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-inc-announces-upsized-pricing-of-275-million-public-offering-of-common-stock-etnb-20230324monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-inc-announces-proposed-underwritten-public-offering-of-common-stock-and-pre-funded-w-etnb-20230322monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-s-phase-2b-enliven-trial-of-pegozafermin-in-nonalcoholic-steatohepatitis-nash-achiev-etnb-20230322monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-u-etnb-20230310monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-presents-new-analysis-of-data-from-phase-2-entrigue-trial-of-pegozafermin-in-patient-etnb-20230304monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-present-additional-pegozafermin-data-in-severe-hypertriglyceridemia-from-phase-2--etnb-20230221monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-the-svb-securities-global-biopharma-conference-etnb-20230208monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-provides-business-update-and-outlook-for-2023-etnb-20230104monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-publication-of-results-of-phase-1b-2a-study-of-pegozafermin-for-the-treatm-etnb-20221212monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-third-quarter-2022-financial-results-and-provides-corporate-update-etnb-20221110monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-presents-additional-exploratory-analyses-from-the-phase-1b-2a-nash-study-of-pegozafe-etnb-20221105monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-the-h-c-wainwright-6th-annual-nash-investor-conference-etnb-20221013monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference-etnb-20220907monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-presents-positive-results-from-entrigue-phase-2-trial-of-pegozafermin-in-patients-wi-etnb-20220826monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-completion-of-enrollment-in-enliven-the-phase-2b-trial-of-pegozafermin-for-etnb-20220818monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-second-quarter-2022-financial-results-and-provides-corporate-update-etnb-20220811monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-closing-of-its-upsized-94-5-million-public-offering-of-common-stock-pre-fu-etnb-20220705monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-inc-announces-upsized-pricing-of-94-5-million-public-offering-of-common-stock-pre-fu-etnb-20220629monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-inc-announces-proposed-underwritten-public-offering-of-common-stock-pre-funded-warra-etnb-20220628monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-positive-topline-results-from-entrigue-phase-2-trial-of-pegozafermin-in-pati-etnb-20220628monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-present-additional-pegozafermin-data-at-easl-international-liver-congress-2022-etnb-20220621monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-first-quarter-2022-financial-results-and-provides-corporate-update-etnb-20220511monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-upcoming-investor-conferences-etnb-20220503monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-host-key-opinion-leader-webinar-on-severe-hypertriglyceridemia-shtg-etnb-20220426monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-corporate-u-etnb-20220324monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-appointment-of-e-morrey-atkinson-ph-d-to-its-board-of-directors-etnb-20220224monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-positive-topline-results-from-an-expansion-cohort-of-the-phase-1b-2a-trial-o-etnb-20220124monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-presents-new-data-from-phase-1b-2a-nash-study-showing-bio89-100-reduces-spleen-volum-etnb-20211114monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-third-quarter-2021-financial-results-and-provides-corporate-update-etnb-20211111monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-appointment-of-kathy-laporte-to-its-board-of-directors-etnb-20211103monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-present-new-sub-analysis-from-phase-1b-2a-nash-study-of-bio89-100-at-aasld-s-the--etnb-20211025monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-the-cantor-global-healthcare-conference-etnb-20210921monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference-etnb-20210908monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-second-quarter-2021-financial-results-and-provides-corporate-update-etnb-20210812monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-upcoming-investor-conferences-etnb-20210803monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-completed-target-enrollment-in-histology-cohort-to-evaluate-bio89-100-for-the-treatm-etnb-20210802monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-upcoming-investor-conferences-etnb-20210616monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-initiates-phase-2b-enliven-trial-of-bio89-100-for-the-treatment-of-nash-etnb-20210610monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-first-quarter-2021-financial-results-and-provides-corporate-update-etnb-20210512monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-present-at-upcoming-investor-conferences-etnb-20210505monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-plans-for-phase-2b-enliven-trial-in-nash-etnb-20210405monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-corporate-u-etnb-20210324monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-presents-additional-analysis-of-phase-1b-2a-nash-study-at-the-annual-endo-2021-confe-etnb-20210320monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-etnb-20210311monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-the-h-c-wainwright-global-life-sciences-conference-etnb-20210303monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-present-at-the-42nd-annual-raymond-james-institutional-investors-conference-etnb-20210224monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-provides-business-outlook-for-2021-etnb-20210105monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-the-h-c-wainwright-bioconnect-2021-conference-etnb-20210104monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference-etnb-20201124monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-presents-updated-clinical-data-from-positive-phase-1b-2a-study-of-bio89-100-in-nash--etnb-20201113monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-third-quarter-2020-financial-results-and-provides-corporate-update-etnb-20201110monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-present-data-from-phase-1b-2a-study-of-bio89-100-in-nash-at-aasld-s-the-liver-mee-etnb-20201102monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-present-at-upcoming-investor-conference-etnb-20200928monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-pricing-of-upsized-public-offering-of-common-stock-etnb-20200917monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-proposed-public-offering-of-common-stock-etnb-20200914monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-positive-topline-results-from-its-phase-1b-2a-trial-of-bio89-100-in-nash-etnb-20200914monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-announce-topline-results-from-phase-1b-2a-study-of-bio89-100-in-nash-etnb-20200913monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-initiates-phase-2-trial-of-bio89-100-in-patients-with-severe-hypertriglyceridemia-etnb-20200903monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-second-quarter-2020-financial-results-and-provides-corporate-update-etnb-20200813monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-present-at-upcoming-investor-conferences-etnb-20200803monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-closing-of-upsized-public-offering-of-common-stock-and-exercise-in-full-of-etnb-20200713monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-pricing-of-upsized-public-offering-of-common-stock-etnb-20200708monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-proposed-public-offering-of-common-stock-etnb-20200706monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-appoints-veteran-finance-executive-lota-zoth-to-board-of-directors-etnb-20200604monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-first-quarter-2020-financial-results-and-provides-corporate-update-etnb-20200513monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-present-at-upcoming-investor-conferences-etnb-20200508monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-closing-of-enrollment-in-its-phase-1b-2a-nash-trial-and-reports-new-precli-etnb-20200413monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-appoints-healthcare-industry-veteran-steven-altschuler-m-d-as-chairman-of-the-board--etnb-20200325monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-corporate-u-etnb-20200318monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-to-present-at-the-svb-leerink-9th-annual-global-healthcare-conference-etnb-20200221monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-reports-third-quarter-2019-financial-results-and-provides-corporate-update-etnb-20191218monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-closing-of-upsized-initial-public-offering-and-exercise-in-full-of-the-und-etnb-20191113monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-presentations-of-bio89-100-data-at-the-liver-meeting-2019-etnb-20191111monthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-announces-pricing-of-upsized-initial-public-offering-etnb-20191111monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-e-akro-20251007monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-investigation-initiated-by-former-louisiana-attorney-general-kahn-swick-akro-20250918monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-goldman-sachs-46th-annual-global-healthcare-conferenc-akro-20250603monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-akro-20250528monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-upda-akro-20250512monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-and-histoindex-present-new-analyses-of-phase-2b-harmony-trial-in-oral-a-akro-20250510monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-presents-week-96-results-from-phase-2b-symmetry-clinical-trial-of-efrux-akro-20250509monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-publication-of-phase-2b-symmetry-trial-in-the-new-england-jou-akro-20250509monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-bofa-securities-2025-healthcare-conference-akro-20250507monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-upcoming-poster-and-oral-presentations-at-the-easl-congress-2-akro-20250430monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provide-akro-20250228monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-fu-akro-20250130monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-pricing-of-upsized-public-offering-of-common-stock-and-pre-fu-akro-20250129monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-proposed-public-offering-of-common-stock-akro-20250127monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-preliminary-topline-results-showing-statistically-significant-r-akro-20250127monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-preliminary-topline-week-96-results-from-phase-2b-symmetry-s-akro-20250124monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-completes-enrollment-of-the-double-blind-portion-of-the-phase-3-synchro-akro-20250113monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-akro-20250107monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-7th-annual-evercore-isi-healthconx-conference-akro-20241126monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-showcase-new-analyses-of-phase-2b-harmony-study-in-presentations-at--akro-20241115monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-jefferies-london-healthcare-conference-akro-20241113monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-upda-akro-20241108monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-data-reinforcing-the-efficacy-of-efruxifermin-at-the-75th-an-akro-20241021monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-h-c-wainwright-8th-annual-mash-virtual-conference-akro-20240930monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-first-patient-dosed-in-phase-3-synchrony-outcomes-study-of-ef-akro-20240909monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-morgan-stanley-22nd-annual-global-healthcare-conferen-akro-20240828monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-upd-akro-20240809monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-o-akro-20240620monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti--akro-20240619monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-por-akro-20240617monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-o-akro-20240613monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti--akro-20240612monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-por-akro-20240611monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-initiation-of-phase-3-synchrony-outcomes-trial-of-efruxifermi-akro-20240611monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-presents-poster-and-late-breaking-oral-presentation-on-efx-at-the-easl--akro-20240608monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-por-akro-20240606monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-o-akro-20240606monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti--akro-20240605monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-o-akro-20240530monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-akro-20240529monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti--akro-20240529monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-akro-symmetry-study-under-fire-in-class-action-akro-investors-with-subs-akro-20240528monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-akro-symmetry-study-under-fire-in-class-action-akro-investors-with-subs-akro-20240523monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-inc-akro-investors-june-25-2024-filing-deadline-in-securities-class-act-akro-20240523monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-o-akro-20240523monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti--akro-20240522monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-akro-symmetry-study-under-fire-in-class-action-akro-investors-with-subs-akro-20240520monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-akro-symmetry-study-under-fire-in-class-action-akro-investors-with-subs-akro-20240516monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-akro-symmetry-study-under-fire-in-class-action-akro-investors-with-subs-akro-20240513monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-upda-akro-20240510monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-o-akro-20240509monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-bofa-securities-2024-health-care-conference-akro-20240508monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti--akro-20240508monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-akro-slides-after-failed-trial-hit-with-class-action-lawsuit-hagens-ber-akro-20240506monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-akro-slides-after-failed-trial-hit-with-class-action-lawsuit-hagens-ber-akro-20240502monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti--akro-20240501monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-appoints-scott-gangloff-as-chief-technology-officer-akro-20240430monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-a-akro-20240430monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-class-action-investigation-johnson-fistel-has-commenced-an-investigatio-akro-20240328monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-class-action-investigation-johnson-fistel-has-commenced-an-investigatio-akro-20240315monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercise--akro-20240308monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-publication-of-phase-2b-symmetry-cohort-d-study-in-clinical-g-akro-20240307monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-pricing-of-public-offering-of-common-stock-akro-20240306monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-proposed-public-offering-of-common-stock-akro-20240304monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-statistically-significant-histological-improvements-at-week-96--akro-20240304monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-topline-week-96-results-from-phase-2b-harmony-study-investig-akro-20240229monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provide-akro-20240229monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-class-action-investigation-johnson-fistel-has-commenced-an-investigatio-akro-20240226monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-akro-20240103monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-first-patients-dosed-in-efruxifermin-phase-3-synchrony-progra-akro-20231218monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-upda-akro-20231113monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-late-breaking-oral-and-poster-presentations-on-efx-at-aasld--akro-20231110monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-upcoming-healthcare-conferences-in-november-akro-20231108monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-h-c-wainwright-7th-annual-nash-virtual-investor-confe-akro-20231017monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-encouraging-36-week-analysis-of-96-week-phase-2b-symmetry-study-akro-20231010monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-results-from-phase-2b-symmetry-study-investigating-efruxifer-akro-20231009monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-publication-of-the-harmony-phase-2b-trial-results-in-the-lanc-akro-20231004monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-upcoming-healthcare-conferences-in-september-akro-20230831monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-report-results-of-phase-2b-symmetry-study-in-october-2023-akro-20230828monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-second-quarter-2023-financial-results-and-provides-business-upd-akro-20230811monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-presents-analyses-of-phase-2b-harmony-study-at-the-2023-international-l-akro-20230623monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-phase-2b-symmetry-cohort-d-study-met-safety-tolerability-endpoints-and--akro-20230605monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-results-from-phase-2b-expansion-cohort-of-symmetry-trial-eva-akro-20230601monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-jefferies-healthcare-conference-akro-20230531monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-pricing-of-220-0-million-underwritten-offering-of-common-stoc-akro-20230516monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-first-quarter-2023-financial-results-and-provides-business-upda-akro-20230515monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-positive-end-of-phase-2-meeting-with-the-fda-and-synchrony-ph-akro-20230329monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-akro-20230317monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-appoints-patrick-lamy-as-senior-vice-president-commercial-strategy-akro-20230110monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-akro-20230104monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-completes-enrollment-of-phase-2b-symmetry-study-and-announces-expected--akro-20221221monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-upcoming-healthcare-conferences-in-november-akro-20221110monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-late-breaking-oral-and-poster-presentations-on-efx-today-at--akro-20221107monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-third-quarter-2022-financial-results-and-provides-business-upda-akro-20221104monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-h-c-wainwright-6th-annual-nash-investor-conference-akro-20221011monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-closing-of-upsized-public-offering-of-common-stock-and-full-e-akro-20220919monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-pricing-of-upsized-public-offering-of-common-stock-akro-20220915monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-proposed-public-offering-of-common-stock-akro-20220913monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-results-from-phase-2b-harmony-trial-investigating-efruxiferm-akro-20220908monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-second-quarter-2022-financial-results-and-provides-business-upd-akro-20220804monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-presents-analysis-at-the-2022-international-liver-congress-showing-that-akro-20220627monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-two-financing-transactions-with-pfizer-inc-and-hercules-capit-akro-20220616monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-keystone-symposium-on-efruxifermin-as-a-therapy-for-nash-akro-20220613monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-akro-20220601monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-first-quarter-2022-financial-results-akro-20220506monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-upcoming-healthcare-conferences-in-may-akro-20220502monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-akro-20220225monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-completes-enrollment-of-phase-2b-harmony-study-in-pre-cirrhotic-nash-pa-akro-20220208monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-akro-20220104monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-evercore-isi-4th-annual-healthconx-virtual-conference-akro-20211126monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-presents-new-analysis-of-phase-2a-balanced-study-data-showing-additional-qualitative-akro-20211112monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-third-quarter-2021-financial-results-and-provides-business-upda-akro-20211112monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-jefferies-london-healthcare-conference-akro-20211109monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-receives-fda-fast-track-designation-for-efruxifermin-efx-for-the-treatm-akro-20211019monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-h-c-wainwright-5th-annual-nash-investor-conference-akro-20211005monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference-akro-20210907monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-second-quarter-2021-financial-results-and-provides-business-upd-akro-20210813monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-appoints-judy-chou-ph-d-to-its-board-of-directors-akro-20210714monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-presents-at-the-american-diabetes-association-s-81st-scientific-session-akro-20210625monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-presents-analyses-at-the-2021-international-liver-congress-showing-norm-akro-20210621monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-efruxifermin-efx-results-showing-histologic-improvement-in-e-akro-20210601monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-present-at-the-jefferies-virtual-healthcare-conference-akro-20210528monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-first-quarter-2021-financial-results-and-provides-business-upda-akro-20210513monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-appoints-yuan-xu-to-its-board-of-directors-akro-20210426monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-announces-first-patient-randomized-for-dosing-in-phase-2b-study-of-efru-akro-20210323monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-announces-positive-histological-improvements-in-cirrhotic-nash-f4-patients-after-16--akro-20210322monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-to-announce-new-data-from-an-evaluation-of-efruxifermin-efx-in-cirrhoti-akro-20210322monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-akro-20210316monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-eight-oral-presentations-at-the-49th-macula-society-annual-meeting-apls-20260219monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-highlights-commercial-execution-and-strategic-priorities-at-the-44th-annual-j-p-mo-apls-20260112monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-participate-in-upcoming-investor-conferences-apls-20251125monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-second-quarter-2025-financial-results-apls-20250731monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-conference-call-on-july-31-2025-to-discuss-second-quarter--apls-20250724monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-to-receive-up-to-300-million-from-royalty-purchase-agreement-with-sobi-for-ex-u-s--apls-20250701monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-and-sobi-announce-empaveli-pegcetacoplan-showed-sustained-efficacy-at-one-year-in--apls-20250606monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-goldman-sachs-46th-annual-global-healthcare-conf-apls-20250604monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-first-quarter-2025-financial-results-apls-20250507monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20250506monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-conference-call-on-may-7-2025-to-discuss-first-quarter-202-apls-20250430monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-craig-wheeler-to-join-the-board-of-directors-apls-20250421monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-fda-acceptance-and-priority-review-of-the-supplemental-new-drug-applicat-apls-20250401monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-apls-20250228monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-td-cowen-45th-annual-health-care-conference-apls-20250224monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-and-sobi-announce-ema-validation-of-indication-extension-application-for-aspaveli--apls-20250220monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-conference-call-on-february-28-2025-to-discuss-fourth-quar-apls-20250214monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20250204monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-receives-approval-of-syfovre-pegcetacoplan-in-australia-for-geographic-atrophy-ga-apls-20250127monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-highlights-commercial-growth-and-strategic-priorities-at-43rd-annual-j-p-morgan-he-apls-20250113monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-keli-walbert-to-join-the-board-of-directors-apls-20250110monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20250107monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-apls-20250106monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-alert-bragar-eagel-squire-p-c-is-investigating-apellis-pharmaceuticals-inc-on-beha-apls-20241224monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20241206monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20241127monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-a-fireside-chat-at-the-jefferies-london-healthcare-confere-apls-20241112monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-third-quarter-2024-financial-results-apls-20241105monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-conference-call-on-november-5-2024-to-discuss-third-quarte-apls-20241022monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-oral-presentation-at-american-society-of-nephrology-asn-kidney-week-on-p-apls-20241016monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20241004monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-a-fireside-chat-at-the-ubs-virtual-ophthalmology-day-apls-20240925monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-receives-negative-chmp-opinion-for-pegcetacoplan-for-geographic-atrophy-ga-in-the--apls-20240920monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20240906monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20240829monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-and-sobi-announce-positive-topline-results-from-phase-3-valiant-study-of-pegcetaco-apls-20240808monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20240806monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-second-quarter-2024-financial-results-apls-20240801monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-conference-call-on-august-1-2024-to-discuss-second-quarter-apls-20240718monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-five-abstracts-accepted-for-oral-presentation-at-the-american-society-of-apls-20240709monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-plans-to-seek-re-examination-following-negative-chmp-opinion-for-pegcetacoplan-for-apls-20240628monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-a-fireside-chat-at-the-goldman-sachs-45th-annual-global-he-apls-20240605monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-refinances-existing-debt-with-up-to-475-million-non-dilutive-credi-apls-20240514monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-first-quarter-2024-financial-results-apls-20240507monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-a-fireside-chat-at-the-bank-of-america-securities-healthca-apls-20240506monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-11-oral-presentations-at-the-association-for-research-in-vision-and-opht-apls-20240501monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-pegcetacoplan-maa-review-has-been-reset-to-day-180-of-initial-assessment-apls-20240426monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-conference-call-on-may-7-2024-to-discuss-first-quarter-202-apls-20240423monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20240404monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-a-fireside-chat-at-the-23rd-annual-needham-virtual-healthc-apls-20240401monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-appoints-leading-expert-dr-philip-ferrone-as-chief-medical-retina-advisor-apls-20240311monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20240306monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-apls-20240227monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20240226monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-conference-call-on-february-27-2024-to-discuss-fourth-quar-apls-20240220monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20240206monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-negative-chmp-opinion-for-pegcetacoplan-for-ga-in-the-european-union-and-apls-20240126monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-preliminary-fourth-quarter-and-full-year-2023-u-s-net-product-revenues-apls-20240108monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20240105monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-apls-20240102monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-a-fireside-chat-at-the-goldman-sachs-healthcare-c-suite-un-apls-20231228monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-provides-update-on-ongoing-regulatory-review-of-pegcetacoplan-for-ga-in-the-europe-apls-20231214monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20231206monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-a-fireside-chat-at-the-6th-annual-evercore-isi-healthconx--apls-20231121monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20231106monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-alert-bragar-eagel-squire-p-c-is-investigating-apellis-pharmaceuticals-inc-on-beha-apls-20231103monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-third-quarter-2023-financial-results-apls-20231101monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-conference-call-on-november-1-2023-to-discuss-third-quarte-apls-20231025monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-to-present-positive-phase-2-noble-results-of-pegcetacoplan-in-post-transplant-recu-apls-20231017monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20231005monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-preliminary-u-s-net-revenues-of-approximately-74-million-for-syfovre-peg-apls-20231005monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-u-s-fda-approval-of-the-empaveli-injector-a-device-to-streamline-self-ad-apls-20231002monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-exc-apls-20230927monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-inc-nasdaq-apls-deadline-alert-bernstein-liebhard-llp-reminds-inve-apls-20230925monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-receives-permanent-j-code-j2781-for-syfovre-pegcetacoplan-injection-effective-octo-apls-20230925monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-inc-nasdaq-apls-deadline-alert-bernstein-liebhard-llp-reminds-inve-apls-20230920monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick--apls-20230920monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-exc-apls-20230913monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-inc-nasdaq-apls-deadline-alert-bernstein-liebhard-llp-reminds-inve-apls-20230912monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20230906monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick--apls-20230906monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-inc-nasdaq-apls-deadline-alert-bernstein-liebhard-llp-reminds-inve-apls-20230905monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20230905monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20230830monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-exc-apls-20230830monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your--apls-20230829monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-corporate-restructuring-to-drive-growth-of-syfovre-pegcetacoplan-injecti-apls-20230829monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-inc-nasdaq-apls-shareholder-alert-bernstein-liebhard-llp-reminds-i-apls-20230829monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick--apls-20230823monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-provides-updates-on-injection-kits-and-rare-safety-events-with-syfovre-pegcetacopl-apls-20230822monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-inc-nasdaq-apls-deadline-alert-bernstein-liebhard-llp-reminds-inve-apls-20230822monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-exc-apls-20230816monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your--apls-20230809monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick--apls-20230809monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-inc-nasdaq-apls-deadline-alert-bernstein-liebhard-llp-reminds-inve-apls-20230808monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-inc-apls-investor-alert-robbins-llp-reminds-shareholders-of-class--apls-20230808monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20230804monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-inc-shareholder-alert-bernstein-liebhard-llp-announces-that-a-secu-apls-20230804monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-apls-faces-shareholder-class-action-lawsuit-johnson-fistel-encoura-apls-20230802monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-second-quarter-2023-financial-results-apls-20230731monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-provides-update-on-review-of-rare-safety-events-with-syfovre-pegcetacoplan-injecti-apls-20230729monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-conference-call-on-july-31-2023-to-discuss-second-quarter--apls-20230724monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-seven-abstracts-accepted-for-oral-presentation-at-the-american-society-o-apls-20230710monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20230706monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-goldman-sachs-44th-annual-global-healthcare-conf-apls-20230607monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20230606monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-reports-top-line-results-from-phase-2-meridian-study-in-als-apls-20230525monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20230505monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-first-quarter-2023-financial-results-apls-20230504monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-bank-of-america-securities-2023-healthcare-confe-apls-20230503monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-conference-call-on-may-4-2023-to-discuss-first-quarter-202-apls-20230427monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-presents-phase-3-functional-analyses-of-syfovre-pegcetacoplan-injection-for-geogra-apls-20230423monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-validation-of-four-marketing-applications-for-pegcetacoplan-for-geograph-apls-20230421monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-partners-with-acclaimed-actor-henry-winkler-to-raise-awareness-of-geographic-atrop-apls-20230417monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20230406monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20230306monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20230301monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-and-pre-funde-apls-20230227monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-and-pre-funde-apls-20230223monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-proposed-public-offering-of-common-stock-and-pre-funded--apls-20230222monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-apls-20230221monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20230213monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20230106monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-appoints-leading-retina-specialist-dr-caroline-baumal-as-chief-medical-officer-apls-20230105monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-apls-20230103monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-submits-marketing-authorization-application-to-the-european-medicines-agency-for-p-apls-20221216monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20221207monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20221122monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-fda-acceptance-of-nda-amendment-and-new-pdufa-date-of-february-26-2023-f-apls-20221118monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-third-quarter-2022-financial-results-apls-20221107monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20221104monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-plans-to-submit-24-month-phase-3-data-to-the-fda-for-pegcetacoplan-nda-f-apls-20221103monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-to-present-new-long-term-data-reinforcing-the-robust-efficacy-and-safety-profile-o-apls-20221103monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-conference-call-on-nov-7-2022-to-discuss-third-quarter-202-apls-20221031monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20221007monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-24-month-phase-3-post-hoc-results-showing-treatment-with-pegcetacoplan-l-apls-20220930monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-four-oral-presentations-of-data-from-the-phase-3-derby-and-oaks-studies--apls-20220930monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-new-presentation-time-at-the-bank-of-america-global-heal-apls-20220912monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20220907monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20220901monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-24-month-results-showing-increased-effects-over-time-with-pegcetacoplan--apls-20220824monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-second-quarter-2022-financial-results-apls-20220808monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20220804monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-conference-call-on-aug-8-2022-to-discuss-second-quarter-20-apls-20220801monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-agreements-to-exchange-approximately-75-6-million-in-principal-amount-of-apls-20220727monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-fda-acceptance-and-priority-review-of-the-new-drug-application-for-pegce-apls-20220719monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-five-oral-presentations-in-geographic-atrophy-ga-highlighted-at-the-asrs-apls-20220714monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20220706monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-expands-r-d-collaboration-with-affilogic-to-develop-targeted-complement-therapies--apls-20220622monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-and-sobi-report-new-data-reinforcing-the-robust-efficacy-and-safety-profile-of-emp-apls-20220610monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-and-sobi-announce-first-patient-dosed-in-phase-3-valiant-study-of-pegcetacoplan-fo-apls-20220607monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20220606monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20220601monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-submission-of-new-drug-application-to-the-fda-for-pegcetacoplan-for-geog-apls-20220601monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-seven-abstracts-in-pnh-to-be-presented-at-the-european-hematology-associ-apls-20220512monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20220506monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-bank-of-america-securities-2022-healthcare-confe-apls-20220505monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-first-quarter-2022-financial-results-apls-20220504monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-dr-peter-hillmen-renowned-hematologist-and-pnh-expert-to-join-company-apls-20220503monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-detailed-18-month-results-from-phase-3-derby-and-oaks-studies-of-pegceta-apls-20220502monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-conference-call-on-may-4-2022-to-discuss-first-quarter-202-apls-20220426monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-results-from-new-global-survey-conducted-by-the-harris-poll-revealing-th-apls-20220421monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-21st-annual-needham-virtual-healthcare-conferenc-apls-20220404monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-and-full-exer-apls-20220328monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-apls-20220324monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-proposed-public-offering-of-common-stock-apls-20220323monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-pegcetacoplan-showed-continuous-and-clinically-meaningful-effects-at-mon-apls-20220316monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20220302monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-apls-20220228monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-conference-call-on-february-28-2022-to-discuss-fourth-quar-apls-20220222monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20220106monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-apls-20220103monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-and-sobi-announce-eu-approval-of-aspaveli-pegcetacoplan-for-treatment-of-pnh-apls-20211215monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-and-sobi-report-empaveli-pegcetacoplan-demonstrated-sustained-normalization-of-cli-apls-20211213monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-4th-annual-evercore-isi-healthconx-conference-apls-20211129monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-and-full-exer-apls-20211118monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-apls-20211116monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-proposed-public-offering-of-common-stock-apls-20211115monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-reiterates-plans-to-submit-a-new-drug-application-in-the-first-half-of-2022-for-pe-apls-20211112monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-three-oral-presentations-of-the-phase-3-derby-and-oaks-data-in-geographi-apls-20211110monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-third-quarter-2021-financial-results-apls-20211108monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-to-present-new-data-reinforcing-empaveli-pegcetacoplan-efficacy-and-safety-in-pati-apls-20211104monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20211103monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-conference-call-on-november-8-2021-to-discuss-third-quarte-apls-20211101monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-and-sobi-receive-positive-chmp-opinion-for-aspaveli-pegcetacoplan-for-the-treatmen-apls-20211015monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20211006monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-detailed-results-from-phase-3-derby-and-oaks-studies-presented-at-retina-apls-20210930monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-2021-cantor-virtual-global-healthcare-conference-apls-20210920monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-top-line-results-from-phase-3-derby-and-oaks-studies-in-geographic-atrop-apls-20210909monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20210907monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-to--apls-20210903monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-second-quarter-2021-financial-results-apls-20210809monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20210806monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-conference-call-on-august-9-2021-to-discuss-second-quarter-apls-20210729monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-closing-of-previously-announced-exchanges-of-approximately-201-1-million-apls-20210726monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-agreements-to-exchange-approximately-198-6-million-in-principal-amount-o-apls-20210708monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20210707monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-and-beam-therapeutics-enter-exclusive-research-collaboration-to-apply-base-editing-apls-20210630monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-r-d-day-on-june-30-2021-apls-20210623monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20210603monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-u-s-food-and-drug-administration-fda-approval-of-empaveli-pegcetacoplan--apls-20210514monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-to-present-long-term-pegcetacoplan-data-in-pnh-at-the-european-hematology-associat-apls-20210512monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20210507monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-first-quarter-2021-financial-results-apls-20210428monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-hold-first-quarter-2021-earnings-conference-call-on-april-28-20-apls-20210421monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-to-showcase-leadership-in-retina-at-association-for-research-in-vision-and-ophthal-apls-20210416monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-provides-24-month-update-from-phase-1b-study-of-pegcetacoplan-in-patients-with-geo-apls-20210413monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-and-sobi-the-new-england-journal-of-medicine-publishes-phase-3-pegasus-study-resul-apls-20210317monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study-evaluating-pe-apls-20210310monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20210305monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-provides-update-on-apl-9-for-severe-covid-19-apls-20210304monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results-apls-20210225monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20210222monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-hold-fourth-quarter-and-full-year-2020-earnings-conference-call-apls-20210218monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20210205monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-closing-of-previously-announced-exchanges-of-approximately-126-1-million-apls-20210126monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-investor-event-on-geographic-atrophy-on-january-28-2021-apls-20210121monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-agreements-to-exchange-approximately-107-5-million-in-principal-amount-o-apls-20210107monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-apls-20210105monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-and-sobi-report-positive-top-line-results-at-48-weeks-from-the-phase-3-pegasus-stu-apls-20201210monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-reports-pegcetacoplan-demonstrates-greater-treatment-responses-and-quality-of-life-apls-20201207monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20201204monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-2020-evercore-isi-healthconx-conference-apls-20201130monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-p-apls-20201119monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-fda-acceptance-and-priority-review-of-the-new-drug-application-for-pegce-apls-20201116monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-ge-apls-20201113monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20201111monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-to-present-new-data-supporting-the-efficacy-and-safety-of-pegcetacoplan-in-pnh-at--apls-20201105monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-third-quarter-2020-financial-results-apls-20201102monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-and-sobi-enter-collaboration-for-global-co-development-and-ex-us-commercialization-apls-20201027monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-18-month-data-from-phase-1b-study-of-pegcetacoplan-in-patients-with-geog-apls-20201019monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-new-data-demonstrating-correlation-between-complement-activation-and-cov-apls-20201015monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-to-present-positive-results-from-the-phase-2-discovery-study-of-pegcetacoplan-in-c-apls-20201009monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20201007monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-initiates-registrational-programs-of-pegcetacoplan-in-patients-with-c3g-ic-mpgn-an-apls-20201005monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-new-analysis-demonstrating-targeted-c3-therapy-pegcetacoplan-slows-progr-apls-20201003monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-stifel-s-2020-immunology-and-inflammation-virtual-su-apls-20200924monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-late-breaking-presentation-of-targeted-c3-therapy-pegcetacoplan-in-patie-apls-20200921monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-submission-of-pegcetacoplan-marketing-applications-to-fda-and-ema-for-pa-apls-20200915monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20200904monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20200902monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20200821monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20200807monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-second-quarter-2020-financial-results-apls-20200731monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20200707monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-completes-enrollment-in-two-phase-3-studies-of-the-targeted-c3-therapy-pegcetacopl-apls-20200707monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-bmo-2020-prescriptions-for-success-healthcare-co-apls-20200616monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-investor-conference-call-to-discuss-phase-3-pegasus-data-to-be-presented-apls-20200610monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20200605monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-goldman-sachs-41st-annual-global-healthcare-conf-apls-20200604monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20200529monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-initiates-phase-1-2-study-of-apl-9-in-patients-with-severe-covid-19-apls-20200528monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-plans-to-submit-nda-for-pegcetacoplan-in-paroxysmal-nocturnal-hemoglobin-apls-20200521monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-to-present-pivotal-paroxysmal-nocturnal-hemoglobinuria-pnh-data-at-25th-eha-annual-apls-20200514monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-bofa-securities-2020-health-care-conference-apls-20200508monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20200507monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-private-placement-of-convertible-senior-notes-apls-20200507monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-first-quarter-2020-financial-results-apls-20200429monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-reports-analysis-from-phase-1b-geographic-atrophy-study-apls-20200428monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results-apls-20200227monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-40th-annual-cowen-health-care-conference-apls-20200226monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20200116monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-and-full-exer-apls-20200113monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-apls-20200109monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-proposed-public-offering-of-common-stock-apls-20200107monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-reports-positive-top-line-results-from-phase-3-head-to-head-study-of-pegcetacoplan-apls-20200107monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-apls-20200102monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20191126monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20191115monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-presents-first-data-on-apl-2-in-c3-glomerulopathy-at-asn-kidney-week-apls-20191108monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20191107monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-third-quarter-2019-business-update-and-financial-results-apls-20191105monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-to-present-data-on-apl-2-in-complement-3-glomerulopathy-at-asn-kidney-week-2019-apls-20191011monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20191004monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20190927monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-2019-cantor-global-healthcare-conference-apls-20190926monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-closing-of-offering-of-convertible-senior-notes-apls-20190916monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-pricing-of-offering-of-convertible-senior-notes-apls-20190912monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-proposed-private-offering-of-200-million-of-convertible--apls-20190911monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20190909monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20190828monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20190828monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20190816monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-second-quarter-2019-business-update-and-financial-results-apls-20190731monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20190726monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-expands-leadership-team-appoints-lucia-celona-as-chief-people-offi-apls-20190722monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-will-commence-apl-9-program-to-control-the-complement-system-in-ho-apls-20190718monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20190708monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-completes-enrollment-of-phase-3-apl-2-pegcetacoplan-head-to-head-s-apls-20190627monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-presents-data-from-ongoing-apl-2-phase-2-study-in-patients-with-co-apls-20190615monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20190606monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20190524monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20190517monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20190513monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-first-quarter-2019-business-update-and-financial-results-apls-20190508monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20190405monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20190322monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20190312monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-and-full-exer-apls-20190311monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-apls-20190307monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-proposed-public-offering-of-common-stock-apls-20190306monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-cowen-39th-annual-health-care-conference-apls-20190304monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-resumes-dosing-in-its-phase-3-program-for-patients-with-geographic-atrophy-apls-20190304monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals-for-apl-2-in-hema-apls-20190228monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-2018-financial-results-apls-20190226monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-apls-20190212monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-apl-2-receives-fast-track-designation-from-the-fda-for-the-treatme-apls-20190211monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-apl-2-receives-orphan-drug-designation-from-the-fda-for-the-treatment-of-autoimmun-apls-20190205monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-appoints-thomas-lackner-as-senior-vice-president-head-of-europe-apls-20190131monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-apls-20190102monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-apl-2-receives-orphan-drug-designation-from-the-fda-for-the-treatm-apls-20181220monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-provides-update-on-its-phase-3-program-for-patients-with-geographi-apls-20181220monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-presents-new-data-from-ongoing-apl-2-phase-2-study-in-patients-wit-apls-20181203monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-presents-updated-data-from-a-clinical-study-of-apl-2-in-patients-w-apls-20181202monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-expands-leadership-team-appoints-adam-townsend-as-chief-commercial-apls-20181120monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-third-quarter-2018-business-update-and-financial-results-apls-20181113monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-apls-20181107monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-poster-presentations-at-the-american-society-of-hematolo-apls-20181101monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-2018-cantor-fitzgerald-global-healthcare-confere-apls-20180928monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-first-patient-dosed-in-its-phase-3-clinical-program-for--apls-20180912monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-that-all-four-severely-anemic-soliris-treated-patients-w-apls-20180904monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-second-quarter-2018-business-update-and-financial-results-apls-20180731monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-apl-2-receives-fast-track-designation-from-fda-for-the-treatment-o-apls-20180724monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-first-patient-enrolled-in-phase-3-apl-2-head-to-head-stu-apls-20180626monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-provides-update-on-two-phase-ib-trials-for-patients-with-paroxysma-apls-20180626monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-host-r-d-day-on-june-26-2018-apls-20180619monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-jefferies-2018-global-healthcare-conference-apls-20180531monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-first-quarter-2018-business-update-and-financial-results-apls-20180430monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-closing-of-offering-of-common-stock-apls-20180423monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-pricing-of-offering-of-common-stock-apls-20180419monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-proposed-offering-of-common-stock-apls-20180416monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-provides-update-on-phase-1b-open-label-study-of-apl-2-in-pnh-patie-apls-20180416monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-2017-financial-results-apls-20180319monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-participate-in-upcoming-investor-conferences-apls-20180223monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-18-month-results-of-phase-2-study-filly-of-apl-2-in-geog-apls-20180222monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-apls-20180102monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-finalizes-phase-3-clinical-trial-plans-for-geographic-atrophy-treatment-with-apl-2-apls-20171220monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-expands-management-team-appoints-timothy-sullivan-chief-financial--apls-20171219monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-inc-nasdaq-apls-to-ring-the-nasdaq-stock-market-closing-bell-apls-20171213monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-presents-update-on-phase-1b-pharoah-trial-of-apl-2-in-patients-wit-apls-20171208monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-closing-of-its-initial-public-offering-apls-20171113monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-announces-pricing-of-initial-public-offering-apls-20171109monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-reports-positive-interim-results-from-phase-1b-clinical-trials-of-apl-2-in-pnh-apls-20161202monthly0.5https://www.biopharmawatch.com/news/APLS/apellis-to-present-safety-and-efficacy-data-from-clinical-trials-of-apl-2-in-pnh-at-decemb-apls-20161121monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-presents-data-from-the-caplyta-adjunctive-mdd-phase-3-program-at--itci-20241211monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-submits-supplemental-new-drug-application-snda-to-fda-for-caplyta-itci-20241203monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-participate-in-three-upcoming-investor-conferences-itci-20241119monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-presentations-at-the-2024-psych-congress-and-nei-congre-itci-20241107monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-positive-topline-results-in-phase-3-trial-evaluating-ca-itci-20241105monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-third-quarter-2024-financial-results-provides-corporate-u-itci-20241030monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-third-quarter-2024-financial-results-conference-call-and--itci-20241017monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-presentations-at-the-2024-european-college-of-neuropsyc-itci-20240923monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-three-upcoming-investor-conferences-itci-20240828monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-canaccord-genuity-44th-annual-growth-conference-itci-20240808monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-appointment-of-sanjeev-narula-as-chief-financial-office-itci-20240807monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-second-quarter-2024-financial-results-provides-corporate--itci-20240807monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-second-quarter-2024-financial-results-conference-call-and-itci-20240724monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-positive-topline-results-in-second-phase-3-trial-evalua-itci-20240618monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-45th-annual-goldman-sachs-global-healthcare-con-itci-20240610monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-jefferies-global-healthcare-conference-itci-20240529monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-highlights-data-presentations-at-the-american-society-of-clinical-itci-20240523monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-participate-in-two-upcoming-investor-conferences-itci-20240508monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-first-quarter-2024-financial-results-itci-20240507monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-first-quarter-2024-financial-results-conference-call-and--itci-20240430monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-closing-of-575-million-public-offering-including-full-e-itci-20240424monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-prices-public-offering-of-common-stock-itci-20240418monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-proposed-public-offering-of-common-stock-itci-20240416monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-positive-phase-3-topline-results-from-study-501-evaluat-itci-20240416monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-executive-appointments-and-leadership-changes-itci-20240319monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-participate-in-three-upcoming-investor-conferences-itci-20240306monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-44th-annual-td-cowen-health-care-conference-itci-20240227monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-fourth-quarter-and-full-year-2023-financial-results-and-p-itci-20240222monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-fourth-quarter-and-full-year-2023-financial-results-confe-itci-20240208monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-itci-20240102monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-highlights-data-presentations-at-the-american-college-of-neuropsy-itci-20231205monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-6th-annual-evercore-isi-healthconx-conference-itci-20231115monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-third-quarter-2023-financial-results-and-raises-2023-capl-itci-20231102monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-participate-in-two-upcoming-investor-conferences-itci-20231031monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-third-quarter-2023-financial-results-conference-call-and--itci-20231026monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-2023-cantor-fitzgerald-global-healthcare-confer-itci-20230920monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-presentations-at-psych-congress-2023-including-positive-itci-20230911monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-morgan-stanley-21st-annual-global-healthcare-co-itci-20230905monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference-itci-20230804monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-second-quarter-2023-financial-results-and-raises-2023-cap-itci-20230803monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-second-quarter-2023-financial-results-conference-call-and-itci-20230728monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-goldman-sachs-44th-annual-global-healthcare-con-itci-20230605monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-caplyta-data-presentations-at-the-american-society-of-c-itci-20230531monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-first-quarter-2023-financial-results-and-provides-corpora-itci-20230504monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-two-upcoming-investor-conferences-itci-20230502monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-first-quarter-2023-financial-results-conference-call-and--itci-20230426monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-22nd-annual-needham-virtual-healthcare-conferen-itci-20230411monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-positive-topline-results-from-study-403-evaluating-luma-itci-20230328monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-fourth-quarter-and-full-year-2022-financial-results-and-p-itci-20230301monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-fourth-quarter-and-full-year-2022-financial-results-confe-itci-20230214monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-svb-securities-global-biopharma-conference-itci-20230208monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-itci-20230103monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-highlights-new-caplyta-bipolar-depression-data-presentations-at-t-itci-20221208monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-participate-at-two-upcoming-investor-conferences-itci-20221110monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-third-quarter-2022-financial-results-and-provides-corpora-itci-20221103monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-third-quarter-2022-financial-results-conference-call-and--itci-20221027monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-second-quarter-2022-financial-results-and-provides-corpor-itci-20220809monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-second-quarter-2022-financial-results-conference-call-and-itci-20220802monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-highlights-lumateperone-bipolar-depression-data-presentations-at--itci-20220613monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-first-quarter-2022-financial-results-and-provides-corpora-itci-20220510monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-first-quarter-2022-financial-results-conference-call-and--itci-20220503monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-fda-approval-of-new-dosage-strengths-for-caplyta-lumate-itci-20220425monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-appointment-of-e-rene-salas-to-board-of-directors-itci-20220421monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-21st-annual-needham-virtual-healthcare-conferen-itci-20220405monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-fourth-quarter-and-full-year-2021-financial-results-and-p-itci-20220301monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-fourth-quarter-and-full-year-2021-financial-results-confe-itci-20220222monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-11th-annual-svb-leerink-global-healthcare-confe-itci-20220210monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-closing-of-460-million-public-offering-including-full-e-itci-20220107monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-prices-public-offering-of-common-stock-itci-20220105monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-proposed-public-offering-of-common-stock-itci-20220103monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-itci-20220103monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-u-s-fda-approval-of-caplyta-lumateperone-for-the-treatm-itci-20211220monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-mourns-the-passing-of-director-dr-richard-lerner-itci-20211206monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-third-quarter-2021-financial-results-and-provides-corpora-itci-20211109monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-third-quarter-2021-financial-results-conference-call-and--itci-20211102monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-amended-start-time-to-virtual-event-on-wednesday-octobe-itci-20211018monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-a-virtual-event-to-feature-highlights-of-several-of-its-d-itci-20211008monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-publication-of-lumateperone-pivotal-phase-3-study-in-bi-itci-20210927monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-2021-cantor-virtual-global-healthcare-conferenc-itci-20210922monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-publications-highlighting-beneficial-effects-of-phospho-itci-20210920monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-canaccord-genuity-41st-annual-growth-conference-itci-20210810monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-second-quarter-2021-financial-results-and-provides-corpor-itci-20210809monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-second-quarter-2021-financial-results-conference-call-and-itci-20210802monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-two-upcoming-investor-conferences-itci-20210526monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-first-quarter-2021-financial-results-and-provides-corpora-itci-20210510monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-two-upcoming-investor-conferences-itci-20210505monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-first-quarter-2021-financial-results-conference-call-and--itci-20210504monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-fda-acceptance-of-caplyta-lumateperone-sndas-for-the-tr-itci-20210503monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-investor-webcast-and-presentations-on-lumateperone-prog-itci-20210422monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-board-of-director-nominations-in-advance-of-2021-annual-itci-20210420monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-presents-data-on-antitumor-effects-of-phosphodiesterase-i-inhibit-itci-20210412monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-fourth-quarter-and-full-year-2020-financial-results-and-p-itci-20210225monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-expansion-of-its-pipeline-with-the-introduction-of-a-ne-itci-20210224monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-applies-for-fda-approval-of-caplyta-lumateperone-for-the-treatmen-itci-20210222monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-svb-leerink-10th-annual-global-healthcare-confe-itci-20210219monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-fourth-quarter-and-full-year-2020-financial-results-confe-itci-20210217monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-itci-20210105monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-the-initiation-of-clinical-trials-for-iti-llai-a-long-a-itci-20201229monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-highlights-lumateperone-presentations-at-the-59th-annual-meeting--itci-20201209monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference-itci-20201130monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-third-quarter-2020-financial-results-and-provides-corpora-itci-20201109monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-third-quarter-2020-financial-results-conference-call-and--itci-20201104monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-the-appointment-of-dr-suresh-durgam-as-chief-medical-of-itci-20201001monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-morgan-stanley-18th-annual-global-healthcare-co-itci-20200915monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-cantor-virtual-global-healthcare-conference-itci-20200914monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-prices-public-offering-of-common-stock-itci-20200911monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-proposed-public-offering-of-common-stock-itci-20200909monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-positive-topline-results-from-study-402-evaluating-luma-itci-20200909monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-second-quarter-2020-financial-results-and-provides-corpor-itci-20200810monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-second-quarter-2020-financial-results-conference-call-and-itci-20200804monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-positive-top-line-results-from-iti-214-phase-i-ii-study-itci-20200629monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-2020-rbc-capital-markets-global-healthcare-conf-itci-20200514monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-virtual-annual-meeting-of-stockholders-itci-20200513monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-first-quarter-2020-financial-results-and-provides-corpora-itci-20200507monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-first-quarter-2020-financial-results-conference-call-and--itci-20200429monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-itci-20200416monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-initiates-promotional-activities-for-caplyta-lumateperone-for-the-itci-20200402monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-availability-of-caplyta-lumateperone-for-adult-patients-itci-20200323monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-fourth-quarter-and-full-year-2019-financial-results-and-p-itci-20200302monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-fourth-quarter-and-full-year-2019-financial-results-confe-itci-20200224monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-itci-20200221monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-9th-annual-svb-leerink-global-healthcare-confer-itci-20200218monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-prices-public-offering-of-common-stock-itci-20200108monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-proposed-public-offering-of-common-stock-itci-20200106monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-itci-20200102monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-highlights-lumateperone-presentations-at-the-58th-annual-meeting--itci-20191212monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-data-on-lumateperone-and-iti-333-at-the-58th-annual-me-itci-20191204monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-provides-corporate-update-and-reports-third-quarter-2019-financia-itci-20191105monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-third-quarter-2019-financial-results-conference-call-and--itci-20191029monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-2019-cantor-global-healthcare-conference-itci-20190930monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-progression-to-higher-dose-cohort-in-iti-214-translatio-itci-20190925monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-provides-lumateperone-regulatory-update-itci-20190910monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-provides-corporate-update-and-reports-second-quarter-2019-financi-itci-20190807monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-canaccord-genuity-39th-annual-growth-conference-itci-20190806monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-conference-call-to-provide-regulatory-update-following-re-itci-20190805monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-provides-update-on-fda-advisory-committee-meeting-for-lumateperon-itci-20190723monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-positive-top-line-results-from-a-phase-3-trial-of-lumat-itci-20190708monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-appoints-karen-patruno-sheehy-esq-as-senior-vice-president-chief--itci-20190702monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-jmp-securities-life-sciences-conference-itci-20190619monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-fda-advisory-committee-meeting-to-review-the-nda-for-lu-itci-20190613monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-jefferies-2019-global-healthcare-conference-itci-20190530monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-2019-rbc-capital-markets-global-healthcare-conferen-itci-20190516monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-presentations-on-lumateperone-schizophrenia-program-at--itci-20190515monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-first-quarter-2019-financial-results-and-provides-corpora-itci-20190508monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-first-quarter-2019-financial-results-conference-call-and--itci-20190502monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-mourns-the-passing-of-co-founder-and-nobel-laureate-dr-paul-green-itci-20190416monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-presents-additional-results-from-long-term-open-label-safety-stud-itci-20190415monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-presentation-of-lumateperone-long-term-open-label-safet-itci-20190409monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-continues-to-strengthen-its-commercial-leadership-team-john-a-bar-itci-20190326monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-cowen-and-company-39th-annual-health-care-confe-itci-20190305monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-fourth-quarter-and-full-year-2018-financial-results-and-p-itci-20190227monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-8th-annual-svb-leerink-global-healthcare-confer-itci-20190221monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-fourth-quarter-and-full-year-2018-financial-results-confe-itci-20190220monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-itci-20190103monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-update-on-iti-007-201-clinical-trial-for-treatment-of-a-itci-20181218monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-favorable-results-from-long-term-open-label-safety-swit-itci-20181211monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-fda-acceptance-of-new-drug-application-for-lumateperone-itci-20181211monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-provides-corporate-update-and-reports-third-quarter-2018-financia-itci-20181107monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-third-quarter-2018-financial-results-conference-call-and--itci-20181101monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-favorable-safety-profile-for-iti-214-in-a-phase-1-2-cli-itci-20181023monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-presents-results-from-iti-214-phase-1-2-clinical-trial-in-patient-itci-20181017monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-appoints-mark-neumann-as-executive-vice-president-chief-commercia-itci-20181016monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-completes-submission-of-new-drug-application-for-lumateperone-for-itci-20180928monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-itci-20180926monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-appoints-michael-olchaskey-as-senior-vice-president-head-of-regul-itci-20180925monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-appoints-dr-suresh-durgam-as-senior-vice-president-late-stage-cli-itci-20180820monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-provides-corporate-update-and-reports-second-quarter-2018-financi-itci-20180802monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-second-quarter-2018-financial-results-conference-call-and-itci-20180726monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-publication-highlighting-iti-214-mechanism-of-action-an-itci-20180723monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-initiates-rolling-submission-of-new-drug-application-for-lumatepe-itci-20180606monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-presents-data-on-symptom-improvement-by-lumateperone-on-negative--itci-20180531monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-jefferies-2018-global-healthcare-conference-itci-20180530monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-presentations-on-lumateperone-at-the-american-society-o-itci-20180529monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-bank-of-america-merrill-lynch-2018-health-care--itci-20180509monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-presentations-on-lumateperone-at-two-upcoming-medical-c-itci-20180504monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-first-quarter-2018-financial-results-and-provides-corpora-itci-20180503monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-presents-data-on-iti-214-at-the-2018-american-academy-of-neurolog-itci-20180426monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-positive-pre-nda-meeting-with-fda-for-lumateperone-for--itci-20180313monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-cowen-and-company-38th-annual-health-care-confe-itci-20180308monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-fourth-quarter-and-full-year-2017-financial-results-and-p-itci-20180301monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-fourth-quarter-and-full-year-2017-financial-results-confe-itci-20180222monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-upcoming-investor-conferences-itci-20180207monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-itci-20180102monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-presents-data-on-lumateperone-iti-214-and-iti-333-at-the-56th-ann-itci-20171207monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-participate-at-the-29th-annual-piper-jaffray-healthcare-confer-itci-20171127monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-receives-fda-fast-track-designation-for-lumateperone-for-the-trea-itci-20171120monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-presents-data-on-mechanism-of-action-of-lumateperone-and-iti-214--itci-20171114monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-expands-its-executive-team-with-the-appointment-of-dr-andrew-satl-itci-20171113monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-third-quarter-2017-financial-results-and-provides-corpora-itci-20171108monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-third-quarter-2017-financial-results-conference-call-and--itci-20171103monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-full-exercise-of-underwriters-option-to-purchase-additi-itci-20171005monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-commencement-of-enrollment-of-a-clinical-trial-evaluati-itci-20171003monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-closing-of-150-million-public-offering-of-common-stock-itci-20171002monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-prices-150-million-public-offering-of-common-stock-itci-20170928monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-proposed-public-offering-of-common-stock-itci-20170926monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-participate-at-upcoming-investor-conferences-itci-20170918monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-positive-topline-data-from-6-week-open-label-safety-swi-itci-20170907monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-positive-regulatory-update-on-schizophrenia-program-itci-20170823monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-second-quarter-2017-financial-results-and-provides-corpor-itci-20170809monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-presents-at-the-2017-international-college-of-neuro-psychopharmac-itci-20170720monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-american-society-of-clinical-psychopharmacology-itci-20170525monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-data-on-its-novel-compound-iti-333-at-the-society-of-b-itci-20170518monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-first-quarter-2017-financial-results-and-provides-corpora-itci-20170510monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-presents-data-supporting-the-potential-for-potent-and-rapid-antid-itci-20170508monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-19th-annual-conference-of-the-international-soc-itci-20170504monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-provides-corporate-update-on-schizophrenia-program-itci-20170501monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-fourth-quarter-and-full-year-2016-financial-results-and-p-itci-20170301monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-cowen-and-company-37th-annual-health-care-confe-itci-20170228monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-fourth-quarter-and-full-year-2016-financial-results-confe-itci-20170222monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-itci-20170104monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-55th-annual-meeting-of-the-american-college-of--itci-20161201monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-participate-at-upcoming-investor-conferences-itci-20161123monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-third-quarter-2016-financial-results-and-provides-corpora-itci-20161109monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-third-quarter-2016-financial-results-conference-call-and--itci-20161102monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-presents-the-iti-007-clinical-development-program-in-schizophreni-itci-20161031monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-top-line-results-from-the-second-phase-3-trial-of-iti-0-itci-20160928monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-second-quarter-2016-financial-results-and-provides-corpor-itci-20160804monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-second-quarter-2016-financial-results-conference-call-and-itci-20160725monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-cantor-fitzgerald-s-2nd-annual-healthcare-conferenc-itci-20160706monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-completion-of-enrollment-of-iti-007-302-phase-3-clinical--itci-20160630monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-initiation-of-iti-007-201-phase-3-clinical-trial-for-th-itci-20160628monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-jmp-securities-life-sciences-conference-itci-20160615monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-jefferies-2016-healthcare-conference-itci-20160531monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-american-society-of-clinical-psychopharmacology-itci-20160526monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-presents-at-the-annual-meetings-of-the-society-of-biological-psyc-itci-20160518monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-american-psychiatric-association-169th-annual-m-itci-20160510monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-bank-of-america-merrill-lynch-2016-health-care--itci-20160504monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-first-quarter-2016-financial-results-and-provides-corpora-itci-20160428monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-first-quarter-2016-financial-results-conference-call-and--itci-20160421monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-presents-additional-iti-007-data-at-the-5th-biennial-schizophreni-itci-20160406monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-15th-annual-needham-healthcare-conference-itci-20160404monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-upcoming-presentations-at-the-5th-biennial-schizophreni-itci-20160330monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-cowen-and-company-36th-annual-health-care-confe-itci-20160229monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-fourth-quarter-and-full-year-2015-financial-results-and-p-itci-20160225monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-fourth-quarter-and-full-year-2015-financial-results-confe-itci-20160218monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-2016-rbc-capital-markets-healthcare-conference-itci-20160216monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-leerink-partners-5th-annual-global-healthcare-c-itci-20160201monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-initiation-of-patient-enrollment-for-iti-007-phase-3-clin-itci-20151223monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference-itci-20151221monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-presents-additional-efficacy-and-safety-data-from-the-positive-ph-itci-20151209monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-54th-annual-meeting-of-the-american-college-of--itci-20151207monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-participate-at-upcoming-investor-conferences-itci-20151123monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-jefferies-autumn-2015-global-healthcare-conference--itci-20151111monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-ctad-2015-conference-itci-20151106monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-third-quarter-2015-financial-results-and-provides-corpora-itci-20151105monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-third-quarter-2015-financial-results-conference-call-and--itci-20151029monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-cns-summit-2015-conference-itci-20151009monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-closing-of-345-million-public-offering-including-exerci-itci-20150928monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-ladenburg-thalmann-2015-healthcare-conference-itci-20150924monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-prices-300-million-public-offering-of-common-stock-itci-20150922monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-completion-of-phase-1-studies-for-iti-214-a-phosphodies-itci-20150921monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-proposed-public-offering-of-common-stock-itci-20150921monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-positive-top-line-results-from-the-first-phase-3-trial--itci-20150916monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-publication-of-positive-phase-2-schizophrenia-study-in--itci-20150901monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-second-quarter-2015-financial-results-and-provides-corpor-itci-20150805monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-expands-leadership-team-itci-20150803monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-second-quarter-2015-financial-results-conference-call-and-itci-20150730monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-phase-3-clinical-development-program-for-the-treatment--itci-20150722monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-initiation-of-randomization-for-iti-007-302-phase-3-trial-itci-20150623monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-jmp-securities-life-sciences-conference-2015-itci-20150617monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-completion-of-enrollment-with-450-patients-randomized-in--itci-20150615monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-jefferies-2015-global-healthcare-conference-itci-20150526monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-further-analyses-of-the-phase-2-clinical-trial-of-iti-0-itci-20150518monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-2015-ubs-global-healthcare-conference-itci-20150511monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-bank-of-america-merrill-lynch-2015-health-care--itci-20150507monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-first-quarter-2015-financial-results-and-provides-corpora-itci-20150430monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-first-quarter-2015-financial-results-conference-call-and--itci-20150424monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-presents-the-iti-007-clinical-development-program-at-the-15th-int-itci-20150331monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-15th-international-congress-on-schizophrenia-re-itci-20150325monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-fourth-quarter-and-full-year-2014-financial-results-and-p-itci-20150312monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-closing-of-130-million-public-offering-including-exerci-itci-20150311monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-prices-114-million-public-offering-of-common-stock-itci-20150306monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-proposed-public-offering-of-common-stock-itci-20150304monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-cowen-and-company-35th-annual-healthcare-confer-itci-20150223monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-2015-rbc-capital-markets-healthcare-conference-itci-20150217monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-leerink-global-healthcare-conference-itci-20150202monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-33rd-annual-j-p-morgan-healthcare-conference-itci-20150112monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-enrollment-of-first-patient-in-phase-3-trial-of-iti-007-itci-20141125monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-additional-results-from-phase-i-ii-clinical-trial-for-i-itci-20141121monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-third-quarter-2014-financial-results-and-provides-corpora-itci-20141103monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-and-takeda-announce-mutual-termination-of-collaboration-to-develo-itci-20141103monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-conference-call-on-monday-november-3-at-8-30-am-eastern-t-itci-20141027monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-topline-safety-results-from-phase-i-ii-clinical-trial-f-itci-20141013monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-results-from-phase-i-ii-clinical-trial-for-iti-007-in--itci-20141006monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-financial-results-for-second-quarter-ended-june-30-2014-itci-20140812monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-host-conference-call-on-tuesday-august-12-at-8-30-am-eastern-t-itci-20140805monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-the-appointment-of-michael-halstead-as-senior-vice-pres-itci-20140731monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-be-added-to-the-russell-3000-r-and-russell-2000-r-indexes-itci-20140627monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-participate-in-a-fireside-chat-at-the-9th-annual-jmp-securitie-itci-20140613monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-upcoming-scientific-conferences-itci-20140612monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-presents-new-data-from-the-phase-2-clinical-trial-of-iti-007-in-s-itci-20140506monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-first-quarter-2014-financial-results-itci-20140505monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-to-present-at-the-deutsche-bank-39th-annual-health-care-conferenc-itci-20140501monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-upcoming-presentations-on-iti-007-at-the-american-psych-itci-20140430monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-multiple-presentations-on-iti-007-at-the-4th-biennial-s-itci-20140407monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-upcoming-presentations-at-the-4th-biennial-schizophreni-itci-20140402monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-reports-fourth-quarter-and-full-year-2013-financial-results-itci-20140325monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-full-year-2025-financial-results-and-corporate-updates-fold-20260220monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-third-quarter-2025-financial-results-on-november-4-2025-fold-20251023monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-september-2025-fold-20250829monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-second-quarter-2025-financial-results-and-corporate-updates-fold-20250731monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-second-quarter-2025-financial-results-on-july-31-2025-fold-20250721monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-june-2025-fold-20250530monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-bank-of-america-2025-health-care-conference-fold-20250507monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-first-quarter-2025-financial-results-and-corporate-updates-fold-20250501monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-first-quarter-2025-financial-results-on-may-1-2025-fold-20250421monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-stockholder-alert-kaskela-law-llc-announces-investigation-of-amicus-therapeutics-in-fold-20250407monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2025-fold-20250227monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-full-year-2024-financial-results-and-corporate-updates-fold-20250219monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-full-year-2024-financial-results-on-february-19-2025-fold-20250210monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-presentations-and-posters-at-the-21st-annual-worldsymposium--fold-20250203monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-reports-preliminary-2024-revenue-and-provides-2025-strategic-outlook-fold-20250112monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-fold-20250102monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-third-quarter-2024-financial-results-and-corporate-updates-fold-20241106monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-november-2024-fold-20241101monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-third-quarter-2024-financial-results-on-november-6-2024-fold-20241028monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-settlement-of-galafold-migalastat-patent-litigation-with-tev-fold-20241017monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-participation-at-the-world-muscle-society-annual-congress-20-fold-20241004monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-september-2024-fold-20240903monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-participation-at-the-ssiem-2024-annual-symposium-fold-20240903monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-september-2024-fold-20240830monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-second-quarter-2024-financial-results-and-corporate-updates-fold-20240808monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-second-quarter-2024-financial-results-on-august-8-2024-fold-20240730monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-goldman-sachs-45th-annual-global-healthcare-conferen-fold-20240605monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-receives-prix-galien-u-k-award-for-pombiliti-cipaglucosidase-alfa-opfo-fold-20240604monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-first-quarter-2024-financial-results-and-corporate-updates-fold-20240509monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-bank-of-america-2024-health-care-conference-fold-20240508monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-first-quarter-2024-financial-results-on-may-9-2024-fold-20240501monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-issues-2024-environmental-social-and-governance-esg-report-fold-20240320monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2024-fold-20240301monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-full-year-2023-financial-results-and-corporate-updates-fold-20240228monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-full-year-2023-financial-results-on-february-28-2024-fold-20240215monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-receives-the-2024-new-treatment-award-for-pombiliti-cipaglucosidase-al-fold-20240208monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-presentations-and-posters-at-the-20th-annual-worldsymposium--fold-20240201monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-reports-preliminary-2023-revenue-and-provides-2024-strategic-outlook-fold-20240107monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-fold-20240103monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-congratulates-executive-chairman-john-f-crowley-on-appointment-as-next-fold-20231205monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-third-quarter-2023-financial-results-and-corporate-updates-fold-20231108monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-november-2023-fold-20231101monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-third-quarter-2023-financial-results-on-november-8-2023-fold-20231027monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-presentation-and-posters-at-world-muscle-society-2023-fold-20231003monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-and-blackstone-enter-into-430-million-strategic-financing-collaboratio-fold-20231002monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-fda-approval-and-launch-of-new-treatment-for-pompe-disease-fold-20230928monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-september-2023-fold-20230901monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-presentation-and-posters-at-the-ssiem-annual-symposium-2023-fold-20230829monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-appoints-simon-harford-as-chief-financial-officer-fold-20230821monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-approval-and-launch-of-new-pompe-disease-therapy-in-the-unit-fold-20230815monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-second-quarter-2023-financial-results-and-corporate-updates-fold-20230808monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-second-quarter-2023-financial-results-on-august-8-2023-fold-20230731monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-approval-and-launch-of-new-pompe-disease-therapy-in-the-euro-fold-20230627monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-first-quarter-2023-financial-results-and-corporate-updates-fold-20230510monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-bank-of-america-2023-health-care-conference-fold-20230502monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-first-quarter-2023-financial-results-on-may-10-2023-fold-20230501monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-receives-positive-chmp-opinion-for-opfolda-miglustat-for-late-onset-po-fold-20230426monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-european-commission-approval-for-pombiliti-in-patients-with--fold-20230327monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-full-year-2022-financial-results-and-corporate-updates-fold-20230301monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-cowen-43rd-annual-health-care-conference-fold-20230227monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-positive-long-term-data-from-phase-3-open-label-extension-st-fold-20230222monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-full-year-2022-financial-results-on-march-1-2023-fold-20230214monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-presentations-and-posters-at-the-19th-annual-worldsymposium--fold-20230213monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference-fold-20230208monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-reports-preliminary-2022-revenue-and-provides-2023-strategic-outlook-fold-20230109monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-fold-20230103monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-receives-positive-chmp-opinion-for-pombiliti-cipaglucosidase-alfa-for--fold-20221216monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-stifel-2022-healthcare-conference-fold-20221115monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-provides-eu-regulatory-update-for-at-gaa-fold-20221107monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-third-quarter-2022-financial-results-and-corporate-updates-fold-20221107monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-third-quarter-2022-financial-results-on-november-7-2022-fold-20221027monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-participation-at-world-muscle-society-2022-fold-20221011monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-participation-at-the-2022-aanem-annual-meeting-fold-20220921monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-morgan-stanley-20th-annual-global-healthcare-confere-fold-20220908monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-second-quarter-2022-financial-results-fold-20220804monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-second-quarter-2022-financial-results-on-august-4-2022-fold-20220726monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-goldman-sachs-43rd-annual-global-healthcare-conferen-fold-20220608monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-receives-notification-of-pdufa-date-extensions-for-at-gaa-fold-20220510monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-first-quarter-2022-financial-results-fold-20220509monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-bank-of-america-2022-healthcare-conference-fold-20220504monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-first-quarter-2022-financial-results-on-may-9-2022-fold-20220426monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-announces-issuance-of-new-u-s-composition-of-matter-patent-for-galafold-migalastat--fold-20220419monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-positive-long-term-data-from-phase-1-2-study-of-at-gaa-in-po-fold-20220316monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-presentation-and-posters-at-the-2022-mda-clinical-scientific-fold-20220310monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-cowen-42nd-annual-health-care-conference-fold-20220301monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-full-year-2021-financial-results-and-corporate-updates-fold-20220224monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-full-year-2021-financial-results-on-february-24-2022-fold-20220210monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-presentations-and-posters-at-the-18th-annual-worldsymposium--fold-20220207monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-reports-preliminary-2021-revenue-and-provides-2022-strategic-outlook-a-fold-20220110monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-fold-20220105monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-4th-annual-evercore-isi-healthconx-virtual-conferenc-fold-20211124monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-presentations-at-the-14th-international-congress-of-inborn-e-fold-20211122monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-stifel-2021-virtual-healthcare-conference-fold-20211111monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-third-quarter-2021-financial-results-and-corporate-updates-fold-20211109monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-third-quarter-2021-financial-results-on-november-9-2021-fold-20211103monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-and-arya-sciences-acquisition-corp-iv-announce-formation-of-a-next-gen-fold-20210929monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-presentations-at-the-26th-international-annual-congress-of-t-fold-20210920monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-september-2021-fold-20210903monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-second-quarter-2021-financial-results-and-corporate-updates-fold-20210805monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-btig-virtual-biotechnology-conference-fold-20210804monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-european-commission-approval-of-galafold-migalastat-for-adol-fold-20210802monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-second-quarter-2021-financial-results-on-august-5-2021-fold-20210727monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-appoints-eiry-w-roberts-m-d-to-its-board-of-directors-fold-20210614monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-united-kingdom-s-mhra-grants-early-access-to-at-gaa-fold-20210608monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-goldman-sachs-42nd-annual-global-healthcare-conferen-fold-20210528monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-upcoming-presentations-at-the-16th-international-congress-on-fold-20210521monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-first-quarter-2021-financial-results-and-corporate-updates-fold-20210510monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-may-2021-fold-20210507monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-upcoming-presentations-at-the-american-society-of-gene-cell--fold-20210505monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-successful-pre-bla-meeting-with-u-s-fda-for-at-gaa-for-the-t-fold-20210503monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-recognized-as-a-great-place-to-work-in-europe-fold-20210428monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-first-quarter-2021-financial-results-on-may-10-2021-fold-20210426monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-presentation-and-posters-at-the-2021-mda-clinical-scientific-fold-20210315monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-full-year-2020-financial-results-and-corporate-updates-fold-20210301monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-fold-20210218monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-full-year-2020-financial-results-on-march-1-2021-fold-20210217monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-at-gaa-shows-clinically-meaningful-significant-improvements-in-both-musculoskeletal-fold-20210211monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-presents-positive-preclinical-fabry-disease-gene-therapy-data-at-the-1-fold-20210208monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-positive-initial-clinical-data-for-cln3-batten-disease-gene--fold-20210208monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-presentations-and-posters-at-the-17th-annual-worldsymposium--fold-20210121monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-reports-preliminary-2020-revenue-and-provides-2021-outlook-fold-20210111monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-fold-20210105monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-named-a-great-place-to-work-certified-company-in-2020-fold-20201207monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors-fold-20201202monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-initiates-rolling-biologic-license-application-to-the-u-s-food-and-dru-fold-20201201monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference-fold-20201123monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-third-quarter-2020-financial-results-and-corporate-updates-fold-20201105monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-credit-suisse-29th-annual-virtual-healthcare-confere-fold-20201102monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-third-quarter-2020-financial-results-on-november-5-2020-fold-20201022monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-additional-positive-interim-clinical-data-for-cln6-batten-di-fold-20201012monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-receives-european-medicines-agency-prime-designation-for-cln6-batten-d-fold-20200924monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-september-2020-fold-20200903monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-second-quarter-2020-financial-results-and-corporate-updates-fold-20200810monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-btig-virtual-biotechnology-conference-fold-20200804monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-second-quarter-2020-financial-results-on-august-10-2020-fold-20200728monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-secures-400-million-non-dilutive-debt-financing-fold-20200717monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-goldman-sachs-41st-annual-global-healthcare-conferen-fold-20200604monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-virtual-2020-annual-meeting-of-shareholders-fold-20200508monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-first-quarter-2020-financial-results-and-corporate-updates-fold-20200507monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-upcoming-presentations-at-the-american-society-of-gene-cell--fold-20200505monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-first-quarter-2020-financial-results-on-may-7-2020-fold-20200424monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-confirms-business-continuity-2020-strategic-priorities-and-announces-p-fold-20200323monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-opens-new-global-research-and-gene-therapy-center-of-excellence-in-philadelphia-fold-20200305monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-full-year-2019-financial-results-and-2020-corporate-updates-fold-20200302monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-cowen-company-40th-annual-health-care-conference-fold-20200226monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-full-year-2019-financial-results-on-march-2-2020-fold-20200219monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-presentations-and-posters-at-16th-annual-worldsymposium-2020-fold-20200207monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-provides-full-year-2020-strategic-outlook-and-financial-guidance-fold-20200113monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-preliminary-2019-galafold-revenue-exceeding-upper-end-of-pri-fold-20200109monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-provides-updates-on-clinical-regulatory-and-manufacturing-advancements-fold-20200107monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-third-quarter-2019-financial-results-and-corporate-updates-fold-20191111monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-third-quarter-2019-financial-results-on-november-11-2019-fold-20191030monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-announces-additional-positive-interim-clinical-data-for-cln6-batten-disease-gene-th-fold-20191024monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-preliminary-third-quarter-2019-revenue-and-financial-outlook-fold-20191010monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-additional-positive-data-in-pompe-disease-phase-1-2-study-of-fold-20191002monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-upcoming-medical-and-investor-conferences-in-october-201-fold-20191001monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-september-2019-fold-20190904monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-second-quarter-2019-financial-results-and-corporate-updates-fold-20190808monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-receives-marketing-authorization-for-galafold-migalastat-for-fabry-dis-fold-20190802monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-announces-positive-interim-clinical-data-for-aav-gene-therapy-in-children-with-cln6-fold-20190801monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-second-quarter-2019-financial-results-on-august-8-2019-fold-20190729monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-and-catalent-biologics-enter-strategic-partnership-for-gene-therapy-de-fold-20190702monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-and-brammer-bio-a-part-of-thermo-fisher-scientific-enter-strategic-gen-fold-20190701monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-adds-key-executives-in-gene-therapy-science-and-global-commercial-lead-fold-20190613monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-closing-of-underwritten-offering-of-common-stock-fold-20190604monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-upcoming-scientific-and-investor-conferences-fold-20190603monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-prices-underwritten-offering-of-common-stock-fold-20190531monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-public-offering-of-common-stock-fold-20190529monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-and-the-university-of-pennsylvania-announce-major-expansion-of-gene-th-fold-20190529monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-appoints-burke-w-whitman-to-its-board-of-directors-fold-20190513monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-bank-of-america-merrill-lynch-2019-health-care-confe-fold-20190510monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-first-quarter-2019-financial-results-and-corporate-updates-fold-20190508monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-presents-positive-preclinical-pompe-disease-gene-therapy-data-at-the-a-fold-20190430monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-first-quarter-2019-financial-results-on-may-8-2019-fold-20190425monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-preclinical-pompe-disease-gene-therapy-data-at-the-american-fold-20190415monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-issued-two-u-s-patents-for-pompe-enzyme-atb200-fold-20190320monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-full-year-2018-financial-results-and-2019-corporate-updates-fold-20190228monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-establishes-global-research-and-gene-therapy-center-of-excellence-in-philadelphia-fold-20190226monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-full-year-2018-financial-results-on-february-28-2019-fold-20190212monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-positive-data-in-pompe-disease-phase-1-2-study-for-up-to-24--fold-20190205monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-presentations-and-posters-at-15th-annual-worldsymposium-2019-fold-20190118monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-provides-full-year-2019-strategic-outlook-and-financial-guidance-fold-20190107monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-fold-20190103monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-phase-1-2-study-of-gene-therapy-for-cln3-batten-disease-fold-20190103monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-first-patient-dosed-in-phase-3-propel-pivotal-study-of-at-ga-fold-20181220monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-executive-team-updates-fold-20181219monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-awarded-united-kingdom-prix-galien-medal-for-galafold-migalastat-fold-20181211monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-credit-suisse-27th-annual-healthcare-conference-fold-20181112monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-third-quarter-2018-financial-results-and-corporate-updates-fold-20181105monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-third-quarter-2018-financial-results-on-november-5-2018-fold-20181029monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-host-analyst-day-2018-today-in-new-york-city-fold-20181011monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-enters-research-and-development-collaboration-with-university-of-penns-fold-20181008monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-positive-18-month-data-in-pompe-disease-phase-1-2-study-at-2-fold-20181005monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-presentation-and-poster-at-the-23rd-international-congress-o-fold-20181002monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-leerink-partners-roundtable-series-rare-disease-onco-fold-20180926monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-acquires-gene-therapy-portfolio-of-ten-clinical-and-pre-clinical-stage-fold-20180920monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-board-appointments-fold-20180911monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-regulatory-and-clinical-updates-for-at-gaa-in-pompe-disease-fold-20180910monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-september-2018-fold-20180831monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-second-quarter-2018-financial-results-and-corporate-updates-fold-20180807monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-second-quarter-2018-financial-results-on-august-7-2018-fold-20180731monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-european-regulatory-and-clinical-updates-for-at-gaa-in-pompe-fold-20180626monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-appoints-president-and-coo-bradley-l-campbell-to-board-of-directors-fold-20180608monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-goldman-sachs-39th-annual-global-healthcare-conference-fold-20180601monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-launches-galafold-migalastat-for-fabry-disease-in-japan-fold-20180530monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-bank-of-america-merrill-lynch-2018-health-care-conferenc-fold-20180509monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-first-quarter-2018-financial-results-and-corporate-updates-fold-20180508monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-first-quarter-2018-financial-results-on-may-8-2018-fold-20180426monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-honors-fabry-disease-awareness-month-and-international-pompe-day-fold-20180417monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-approval-of-galafold-migalastat-for-fabry-disease-in-japan-fold-20180323monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2018-fold-20180305monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-full-year-2017-financial-results-and-2018-corporate-updates-fold-20180228monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-launches-healing-beyond-disease-initiatives-to-change-people-s-lives-l-fold-20180227monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-closing-of-underwritten-offering-of-common-stock-fold-20180221monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-full-year-2017-financial-results-on-february-28-2018-fold-20180221monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-prices-underwritten-offering-of-common-stock-fold-20180216monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-public-offering-of-common-stock-fold-20180214monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-leerink-partners-7th-annual-global-healthcare-conference-fold-20180213monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-additional-positive-data-in-pompe-disease-phase-1-2-study-at-fold-20180207monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-presentations-and-posters-at-14th-annual-worldsymposium-2018-fold-20180122monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-launches-galafold-migalastat-for-treatment-of-fabry-disease-in-spain-fold-20180117monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-provides-full-year-2018-strategic-outlook-and-financial-guidance-fold-20180108monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-fold-20171221monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-submits-new-drug-application-to-u-s-fda-for-migalastat-for-treatment-o-fold-20171214monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-third-quarter-2017-financial-results-and-corporate-updates-fold-20171108monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-third-quarter-2017-financial-results-on-november-8-2017-fold-20171025monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-appoints-michael-c-diem-md-as-senior-vice-president-of-business-and-co-fold-20171006monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-additional-positive-data-in-pompe-disease-phase-1-2-study-at-fold-20171004monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-leerink-partners-roundtable-series-rare-disease-immuno-o-fold-20170920monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-approval-for-galafold-migalastat-for-treatment-of-fabry-dise-fold-20170914monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-top-line-phase-3-results-for-sd-101-in-epidermolysis-bullosa-fold-20170913monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-highlight-fabry-disease-program-at-the-13th-international-congress--fold-20170825monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-approval-for-galafold-migalastat-for-treatment-of-fabry-dise-fold-20170815monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-second-quarter-2017-financial-results-and-corporate-updates-fold-20170807monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-second-quarter-2017-financial-results-on-august-7-2017-fold-20170725monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-closing-of-underwritten-offering-of-common-stock-and-full-ex-fold-20170718monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-prices-underwritten-offering-of-common-stock-fold-20170713monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-public-offering-of-common-stock-fold-20170712monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-submits-japanese-new-drug-application-for-migalastat-for-fabry-disease-fold-20170628monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-goldman-sachs-38th-annual-global-healthcare-conference-fold-20170607monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-receives-rare-pediatric-disease-designation-for-sd-101-for-patients-wi-fold-20170531monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-planned-analysis-of-primary-endpoints-in-phase-3-epidermolys-fold-20170519monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-positive-functional-data-from-initial-patients-in-pompe-phas-fold-20170515monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-two-upcoming-investor-conferences-fold-20170510monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-first-quarter-2017-financial-results-and-corporate-updates-fold-20170509monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-first-quarter-2017-financial-results-on-may-9-2017-fold-20170502monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-launches-galafold-migalastat-for-treatment-of-fabry-disease-in-france-fold-20170502monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-honors-fabry-disease-awareness-month-and-international-pompe-day-fold-20170406monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-completes-enrollment-in-essence-phase-3-epidermolysis-bullosa-clinical-fold-20170403monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-launches-galafold-migalastat-for-treatment-of-fabry-disease-in-italy-fold-20170308monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-fold-20170302monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-full-year-2016-financial-results-and-corporate-updates-fold-20170301monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-launches-galafold-migalastat-for-treatment-of-fabry-disease-in-the-uni-fold-20170227monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-full-year-2016-financial-results-and-corporate-updates-on--fold-20170222monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-presents-additional-positive-preliminary-phase-1-2-data-at-worldsympos-fold-20170216monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-presents-important-new-scientific-findings-and-preclinical-data-for-po-fold-20170215monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-highlights-new-fabry-program-data-at-worldsymposium-2017-fold-20170215monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-leerink-partners-6th-annual-global-healthcare-confer-fold-20170206monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-presentations-and-posters-at-13th-annual-worldsymposium-2017-fold-20170124monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-provides-full-year-2017-strategic-outlook-and-financial-guidance-fold-20170109monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-fold-20161223monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-closing-of-offering-of-senior-convertible-notes-and-exercise-fold-20161221monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-pricing-of-offering-of-convertible-senior-notes-fold-20161216monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-proposed-offering-of-convertible-senior-notes-fold-20161214monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-positive-preliminary-data-from-phase-1-2-study-of-novel-trea-fold-20161208monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-u-s-regulatory-pathway-for-migalastat-for-fabry-disease-fold-20161128monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-third-quarter-2016-financial-results-and-corporate-updates-fold-20161107monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-third-quarter-2016-financial-results-on-november-7-2016-fold-20161101monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-leerink-roundtable-series-rare-disease-immuno-oncology-fold-20160922monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-robert-w-baird-co-2016-healthcare-conference-fold-20160901monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-highlight-fabry-disease-program-at-society-for-the-study-of-inborn--fold-20160831monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-second-quarter-2016-financial-results-and-corporate-updates-fold-20160809monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-submit-japanese-new-drug-application-for-migalastat-for-fabry-disea-fold-20160803monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-second-quarter-2016-financial-results-on-august-9-2016-fold-20160801monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-appoints-former-fda-division-deputy-director-andrew-mulberg-as-vice-pr-fold-20160712monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-expands-biologics-pipeline-with-new-preclinical-program-for-cyclin-dep-fold-20160706monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-appoints-craig-a-wheeler-to-board-of-directors-fold-20160610monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-goldman-sachs-37th-annual-global-healthcare-conferen-fold-20160601monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-european-commission-approval-for-galafold-migalastat-in-pati-fold-20160531monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-bank-of-america-merrill-lynch-2016-health-care-confe-fold-20160505monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-first-quarter-2016-financial-results-and-corporate-updates-fold-20160503monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-first-quarter-2016-financial-results-on-may-3-2016-fold-20160426monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-receives-positive-chmp-opinion-for-approval-of-migalastat-in-patients--fold-20160401monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-expanded-access-program-for-migalastat-fold-20160322monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-cowen-and-company-36th-annual-health-care-conference-fold-20160302monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-highlights-new-phase-3-fabry-data-and-preclinical-pompe-data-at-worlds-fold-20160301monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-full-year-2015-financial-results-and-corporate-updates-fold-20160226monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-full-year-2015-financial-results-and-corporate-updates-on--fold-20160218monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-presentations-and-posters-at-12th-annual-worldsymposium-2016-fold-20160210monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-strengthens-executive-leadership-team-fold-20160209monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-leerink-partners-5th-annual-global-healthcare-confer-fold-20160203monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-provides-full-year-2016-strategic-outlook-and-financial-guidance-fold-20160111monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference-and-3rd-fold-20160104monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-commences-phase-1-2-study-of-novel-ert-for-treatment-of-pompe-disease-fold-20151222monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-shareholders-are-reminded-of-the-december-7-2015-deadline-to-seek-lead-fold-20151116monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-goldman-sachs-us-emerging-smid-cap-growth-conference-fold-20151112monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-third-quarter-2015-financial-results-and-corporate-updates-fold-20151103monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-third-quarter-2015-financial-results-on-november-3-2015-fold-20151027monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-host-fda-update-conference-call-today-fold-20151002monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-provides-u-s-regulatory-update-for-migalastat-monotherapy-fold-20151002monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-completes-acquisition-of-scioderm-inc-fold-20150930monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-leerink-partners-rare-disease-roundtable-fold-20150922monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-plans-to-submit-new-drug-application-nda-for-migalastat-for-fabry-dise-fold-20150915monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-acquire-rare-disease-company-scioderm-inc-fold-20150831monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-second-quarter-2015-financial-results-and-corporate-updates-fold-20150805monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-second-quarter-2015-financial-results-on-august-5-2015-fold-20150729monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-joins-russell-3000-r-and-russell-2000-r-indexes-fold-20150629monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-galafold-tm-marketing-authorization-application-maa-validate-fold-20150625monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-closing-of-underwritten-offering-of-common-stock-and-full-ex-fold-20150617monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-prices-underwritten-offering-of-common-stock-fold-20150612monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-public-offering-of-common-stock-fold-20150610monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-strengthens-executive-leadership-team-fold-20150608monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-submits-marketing-authorization-application-maa-for-full-approval-of-f-fold-20150603monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-fabry-monotherapy-granted-accelerated-assessment-by-european-regulator-fold-20150526monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-first-quarter-2015-financial-results-and-corporate-updates-fold-20150505monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-first-quarter-2015-financial-results-on-may-5-2015-fold-20150501monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-appoints-david-allsop-as-senior-vice-president-international-fold-20150427monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-honors-fabry-disease-awareness-month-and-international-pompe-day-fold-20150409monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-provides-positive-global-regulatory-updates-from-ema-and-fda-meetings--fold-20150319monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-full-year-2014-financial-results-and-corporate-updates-fold-20150303monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-cowen-and-company-35th-annual-health-care-conference-fold-20150226monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-full-year-2014-financial-results-on-march-3-2015-fold-20150225monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-additional-positive-phase-3-fabry-data-on-patient-reported-o-fold-20150210monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-presents-preclinical-data-on-next-generation-pompe-ert-at-worldsymposi-fold-20150210monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-leerink-global-healthcare-conference-fold-20150204monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-presentations-and-posters-at-lysosomal-disease-network-world-fold-20150126monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-provides-full-year-2015-strategic-outlook-and-financial-guidance-fold-20150112monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-positive-phase-3-data-on-cardiac-endpoints-from-fabry-monoth-fold-20150108monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-program-updates-at-33rd-annual-j-p-morgan-healthcare-confer-fold-20141222monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-added-to-nasdaq-biotechnology-index-nbi-fold-20141222monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-submit-european-marketing-application-for-migalastat-monotherapy-fo-fold-20141211monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-oppenheimer-healthcare-conference-fold-20141204monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-closing-of-underwritten-offering-of-common-stock-and-full-ex-fold-20141124monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-prices-underwritten-offering-of-common-stock-fold-20141119monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-public-offering-of-common-stock-fold-20141117monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-positive-phase-3-data-on-cardiac-and-composite-endpoints-fro-fold-20141115monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-third-quarter-2014-financial-results-and-corporate-updates-fold-20141106monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-timing-of-third-quarter-2014-financial-results-upcoming-scie-fold-20141103monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-additional-positive-phase-3-data-from-fabry-monotherapy-stud-fold-20141019monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-leerink-partners-rare-disease-roundtable-fold-20140930monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-positive-phase-3-data-from-fabry-monotherapy-study-012-fold-20140820monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-second-quarter-2014-financial-results-and-corporate-updates-fold-20140807monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-second-quarter-2014-financial-results-on-august-7-2014-fold-20140731monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-provides-updates-and-final-analysis-plan-for-phase-3-fabry-monotherapy-fold-20140630monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-ubs-global-healthcare-conference-fold-20140514monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-first-quarter-2014-financial-results-and-corporate-updates-fold-20140505monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-first-quarter-2014-financial-results-fold-20140501monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-positive-12-and-24-month-data-from-phase-3-fabry-monotherapy-fold-20140429monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-13th-annual-needham-healthcare-conference-fold-20140327monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-full-year-2013-financial-results-and-corporate-updates-fold-20140303monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-appoints-jay-a-barth-md-as-chief-medical-officer-and-promotes-bradley--fold-20140303monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-cowen-and-company-34th-annual-health-care-conference-fold-20140227monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-inc-fold-to-ring-the-nasdaq-stock-market-closing-bell-fold-20140227monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-full-year-2013-financial-results-on-march-3-2014-fold-20140226monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-highlights-data-featured-at-lysosomal-disease-network-world-symposium--fold-20140212monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-2014-leerink-global-healthcare-conference-fold-20140211monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-presentations-and-posters-at-lysosomal-disease-network-world-fold-20140130monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-provides-full-year-2014-strategic-outlook-and-financial-guidance-fold-20140113monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-32nd-annual-j-p-morgan-healthcare-conference-fold-20140110monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-completes-debt-financing-of-up-to-25-million-follows-15-million-equity-fold-20131230monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-and-gsk-announce-revised-fabry-agreement-fold-20131120monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-strengthens-biologics-business-strategy-fold-20131120monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-third-quarter-2013-financial-results-fold-20131112monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-leerink-swann-rare-disease-roundtable-fold-20130926monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-ceo-john-f-crowley-to-advocate-for-rare-and-orphan-disease-community-i-fold-20130911monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-enters-collaboration-with-biogen-idec-for-parkinson-s-disease-fold-20130910monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-stifel-nicolaus-2013-healthcare-conference-fold-20130905monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-two-august-investor-conferences-fold-20130808monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-second-quarter-2013-financial-results-fold-20130807monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-second-quarter-2013-financial-results-on-august-7-2013-fold-20130801monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-chaperone-advanced-replacement-therapy-in-development-for-mu-fold-20130625monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-host-conference-call-today-at-8-00-a-m-et-to-discuss-regulatory-str-fold-20130617monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-jefferies-2013-global-healthcare-conference-fold-20130530monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-ubs-global-healthcare-conference-fold-20130514monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-first-quarter-2013-financial-results-and-corporate-updates-fold-20130509monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-first-quarter-2013-financial-results-on-may-9-2013-fold-20130502monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-12th-annual-needham-healthcare-conference-fold-20130424monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-full-year-2012-financial-results-and-corporate-updates-fold-20130312monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-full-year-2012-financial-results-on-march-12-2013-fold-20130307monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-introduces-proprietary-chart-platform-technology-fold-20130304monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-cowen-and-company-33rd-annual-health-care-conference-fold-20130227monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-presents-additional-6-month-results-from-phase-3-fabry-monotherapy-stu-fold-20130215monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-advances-chaperone-enzyme-replacement-therapy-ert-combination-platform-fold-20130214monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-presents-additional-results-from-phase-2-chaperone-enzyme-replacement--fold-20130213monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-posters-and-presentations-at-lysosomal-disease-network-world-fold-20130207monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-participate-in-bio-ceo-investor-conference-and-leerink-swann-global-fold-20130204monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-provides-full-year-2013-financial-guidance-and-strategic-outlook-fold-20130107monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-positive-results-from-all-four-cohorts-in-phase-2-chaperone--fold-20130104monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-31st-annual-j-p-morgan-healthcare-conference-fold-20130102monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-and-glaxosmithkline-announce-top-line-6-month-primary-treatment-period-fold-20121219monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-lazard-capital-markets-healthcare-conference-fold-20121112monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-additional-preliminary-results-from-ongoing-phase-2-chaperon-fold-20121108monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-third-quarter-2012-financial-results-corporate-updates-fold-20121105monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-updated-results-from-phase-2-extension-study-of-migalastat-h-fold-20121105monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-third-quarter-2012-financial-results-on-november-5-2012-fold-20121101monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-achieves-target-enrollment-in-second-phase-3-fabry-monotherapy-study-fold-20121022monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-data-presentations-and-posters-at-upcoming-scientific-meetin-fold-20121016monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-positive-pompe-program-updates-fold-20121011monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-ubs-annual-global-life-sciences-conference-fold-20120913monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-presents-updated-patient-screening-profiles-from-phase-3-fabry-study-fold-20120906monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-posters-and-presentations-at-society-for-the-study-of-inborn-fold-20120827monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-canaccord-genuity-growth-conference-fold-20120809monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-second-quarter-2012-financial-results-corporate-updates-fold-20120807monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-second-quarter-2012-financial-results-on-august-7-2012-fold-20120801monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-and-glaxosmithkline-expand-fabry-disease-collaboration-fold-20120717monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-publication-of-bliss-quantitative-histology-method-in-archiv-fold-20120702monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-positive-preliminary-results-from-ongoing-phase-2-chaperone--fold-20120626monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-appoints-robert-essner-to-board-of-directors-fold-20120620monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-appoints-ted-w-love-m-d-to-board-of-directors-fold-20120613monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-participate-in-three-june-conferences-fold-20120604monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-added-to-nasdaq-biotechnology-index-fold-20120521monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-first-quarter-2012-financial-results-fold-20120510monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-first-quarter-2012-financial-results-on-may-10-2012-fold-20120504monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-names-william-d-baird-iii-chief-financial-officer-fold-20120416monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-closing-of-underwritten-offering-of-common-stock-and-exercis-fold-20120307monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-prices-underwritten-offering-of-common-stock-fold-20120302monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-proposed-public-offering-of-common-stock-fold-20120301monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-2012-rbc-global-healthcare-conference-fold-20120228monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-fourth-quarter-and-full-year-2011-financial-results-fold-20120213monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-presents-patient-screening-profiles-from-phase-3-fabry-study-fold-20120213monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-leerink-swann-2012-global-healthcare-conference-fold-20120210monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-presents-preclinical-studies-of-chaperone-at3375-for-gaucher-disease-fold-20120209monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-fourth-quarter-and-full-year-2011-financial-results-on-feb-fold-20120208monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-awarded-grant-from-muscular-dystrophy-association-for-pompe-disease-pr-fold-20120207monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-posters-and-presentations-at-lysosomal-disease-network-world-fold-20120130monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-appoints-bradley-l-campbell-as-chief-business-officer-fold-20120123monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-provides-full-year-2012-strategic-outlook-and-financial-guidance-fold-20120109monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-positive-preliminary-results-from-ongoing-phase-2-chaperone--fold-20120106monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-30th-annual-j-p-morgan-healthcare-conference-fold-20111222monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-completes-enrollment-of-67-patients-in-phase-3-study-of-migalastat-hcl-fold-20111219monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-first-patient-in-phase-2-study-for-pompe-disease-fold-20111201monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-lazard-capital-markets-8th-annual-healthcare-conference--fold-20111109monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-third-quarter-2011-financial-results-fold-20111101monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-third-quarter-2011-financial-results-on-november-1-2011-fold-20111027monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-close-of-patient-recruitment-in-first-phase-3-study-of-amiga-fold-20111019monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-ubs-global-life-sciences-conference-on-monday-september--fold-20110914monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-and-glaxosmithkline-commence-second-phase-3-study-of-amigal-tm-for-fab-fold-20110912monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-management-team-addition-and-changes-fold-20110901monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-stifel-nicolaus-annual-healthcare-conference-on-wednesda-fold-20110831monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-second-quarter-2011-financial-results-and-multiple-upcoming--fold-20110808monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-present-at-canaccord-genuity-growth-conference-on-wednesday-august--fold-20110803monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-second-quarter-2011-financial-results-on-august-8-2011-fold-20110802monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-john-f-crowley-to-return-as-chairman-and-chief-executive-off-fold-20110629monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-to-announce-first-quarter-2011-financial-results-on-may-4-2011-fold-20110427monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-fold-president-and-chief-executive-officer-to-ring-the-nasdaq-stock-ma-fold-20070531monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-announces-closing-of-public-offering-and-full-exercise-of-the-underwriters-option--glto-20260212monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-highlights-key-strategic-priorities-and-anticipated-2026-milestones-glto-20260112monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-announces-key-additions-to-leadership-team-glto-20260106monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-inc-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-glto-20251216monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-announces-acquisition-of-damora-therapeutics-glto-20251110monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-reports-second-quarter-2025-operating-and-financial-results-glto-20250805monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-reports-first-quarter-2025-operating-and-financial-results-glto-20250508monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-reports-third-quarter-2024-financial-results-glto-20241101monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-strengthens-board-of-directors-with-appointment-of-dr-amy-wechsler-glto-20241015monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-completes-strategic-review-to-focus-on-oncology-and-liver-disease-and-acquires-acu-glto-20241007monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-announces-reverse-stock-split-glto-20240828monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-announces-first-patient-dosed-in-an-investigator-initiated-phase-2-trial-of-gb1211-glto-20240501monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-presents-updated-clinical-data-at-esmo-congress-2023-and-provides-update-on-phase--glto-20231023monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-announces-plans-to-explore-strategic-alternatives-glto-20230926monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-to-present-at-investor-conferences-in-september-glto-20230831monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-announces-topline-results-from-phase-2b-galactic-1-trial-of-gb0139-for-the-treatme-glto-20230815monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-reports-second-quarter-operating-and-financial-results-glto-20230731monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-set-to-join-russell-microcap-index-glto-20230620monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-to-present-at-the-upcoming-jefferies-healthcare-conference-glto-20230530monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-completes-dosing-in-52-week-phase-2b-galactic-1-trial-of-gb0139-in-idiopathic-pulm-glto-20230523monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-to-present-poster-at-upcoming-ats-2023-international-conference-glto-20230517monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-reports-first-quarter-operating-and-financial-results-glto-20230428monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-to-present-two-posters-at-aacr-annual-meeting-2023-glto-20230413monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-reports-operating-and-financial-results-for-the-year-ended-december-31-2022-glto-20230309monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-to-participate-in-oppenheimer-s-33rd-annual-healthcare-conference-glto-20230302monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-to-participate-in-svb-securities-global-biopharma-conference-glto-20230201monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-announces-upcoming-poster-presentation-detailing-results-from-the-intermediate-ass-glto-20221207monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-reports-third-quarter-operating-and-financial-results-glto-20221108monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-presents-positive-clinical-data-at-aasld-showing-statistically-significant-improve-glto-20221108monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-to-participate-in-jefferies-london-healthcare-conference-glto-20221103monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-to-present-topline-data-from-gulliver-2-clinical-trial-showing-gb1211-reduced-sign-glto-20221031monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-s-galectin-3-inhibitor-gb1211-to-be-studied-in-combination-with-pembrolizumab-in-p-glto-20221019monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-to-host-virtual-investor-event-and-webcast-to-review-topline-data-from-gulliver-2--glto-20221017monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-to-participate-at-h-c-wainwright-24th-annual-global-investment-conference-glto-20220906monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-announces-publication-supporting-the-predictive-role-of-galectin-3-on-overall-surv-glto-20220829monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-reports-second-quarter-operating-and-financial-results-glto-20220729monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-announces-first-patient-enrolled-in-phase-2-trial-of-gb1211-in-combination-with-at-glto-20220616monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-to-participate-at-jefferies-healthcare-conference-glto-20220531monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-to-present-new-data-on-oral-galectin-3-inhibitor-gb1211-at-the-2022-asco-annual-me-glto-20220526monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-to-participate-at-upcoming-investor-conferences-glto-20220502monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-reports-first-quarter-operating-and-financial-results-glto-20220429monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-completes-enrollment-in-global-phase-2b-galactic-1-trial-of-gb0139-for-the-treatme-glto-20220426monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-completes-enrollment-in-phase-1b-2a-gulliver-2-trial-of-its-selective-oral-galecti-glto-20220329monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-reports-financial-results-for-the-year-ended-december-31-2021-glto-20220217monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-to-participate-at-upcoming-investor-conferences-glto-20220207monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-publishes-results-showing-safety-and-efficacy-of-the-gb0139-inhaled-galectin-3-inh-glto-20220127monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-adds-experienced-biotech-executive-stephanie-oestreich-as-chief-business-officer-glto-20220105monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-provides-enrollment-update-on-phase-2a-mylox-1-trial-and-reiterates-expected-timin-glto-20211220monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-announces-positive-preliminary-results-for-oral-galectin-3-inhibitor-gb1211-in-par-glto-20211213monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-reports-third-quarter-operating-and-financial-results-glto-20211104monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-announces-clinical-collaboration-with-roche-for-phase-2-trial-of-gb1211-in-combina-glto-20211102monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-hosting-a-key-opinion-leader-webinar-on-gb1211-a-potential-treatment-for-non-small-glto-20211028monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-to-present-at-upcoming-investor-conferences-glto-20211026monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-to-present-at-2021-cantor-virtual-global-healthcare-conference-glto-20210915monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-announces-first-patient-treated-in-phase-2-trial-of-oral-galectin-3-inhibitor-gb12-glto-20210913monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-announces-first-patient-treated-in-phase-2a-trial-of-the-oral-loxl2-inhibitor-gb20-glto-20210818monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-reports-second-quarter-operating-and-financial-results-glto-20210805monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-resumes-recruitment-in-phase-2b-global-galactic-1-trial-of-gb0139-for-idiopathic-p-glto-20210713monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-s-gb0139-shows-favorable-safety-and-tolerability-profile-with-promising-changes-in-glto-20210622monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-hosting-expert-perspectives-webinar-on-the-current-myelofibrosis-treatment-landsca-glto-20210602monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-appoints-garrett-winslow-as-general-counsel-glto-20210511monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-to-present-at-upcoming-investor-conferences-and-host-myelofibrosis-key-opinion-lea-glto-20210506monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-reports-first-quarter-financial-results-and-provides-a-corporate-update-glto-20210504monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-reports-financial-results-for-the-year-ended-december-31-2020-and-provides-a-corpo-glto-20210329monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-hosting-expert-perspective-panel-on-the-evolving-treatment-landscape-for-idiopathi-glto-20210323monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-announces-outcome-of-data-safety-monitoring-board-interim-review-of-phase-2b-galac-glto-20210315monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-to-present-at-upcoming-investor-conferences-glto-20210209monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-appoints-anne-prener-to-its-board-of-directors-glto-20210108monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-to-take-part-in-two-panel-discussions-at-the-lifesci-partners-10th-annual-healthca-glto-20210104monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-reports-third-quarter-2020-operating-financial-results-and-provides-a-corporate-up-glto-20201211monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-publishes-gb0139-phase-2a-idiopathic-pulmonary-fibrosis-ipf-results-in-european-re-glto-20201130monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-appoints-experienced-healthcare-executive-jayson-dallas-to-board-of-directors-glto-20201123monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-announces-pricing-of-initial-public-offering-glto-20201029monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-raises-64-million-to-accelerate-development-of-clinical-pipeline-glto-20200925monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-s-oral-galectin-3-inhibitor-gb1211-well-tolerated-in-phase-1-clinical-data-present-glto-20200915monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-inc-receives-u-s-and-eu-orphan-drug-designations-for-gb0139-in-idiopathic-pulmonar-glto-20200827monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-appoints-new-chair-and-strengthens-board-of-directors-glto-20200519monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-advances-phase-2b-study-of-gb0139-in-idiopathic-pulmonary-fibrosis-recruitment-rem-glto-20200506monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-presents-gb0139-preclinical-and-clinical-data-on-anti-fibrotic-activity-as-online--glto-20200504monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-appoints-jonathan-freve-as-chief-financial-officer-glto-20200427monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-appoints-industry-leader-bertil-lindmark-md-phd-as-chief-medical-officer-glto-20200203monthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-and-pharmakea-merge-to-create-strong-clinical-stage-company-developing-first-in-cl-glto-20200107monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-outcome-of-the-court-sanction-hearing-avdl-20260210monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-that-avadel-shareholders-approve-the-proposed-acquisition-avdl-20260112monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-completion-of-enrollment-in-phase-3-revitalyz-trial-in-id-avdl-20251218monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-board-of-directors-declares-lundbeck-proposal-a-company-superior-proposal-avdl-20251117monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-receives-unsolicited-proposal-from-lundbeck-avdl-20251114monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20250910monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20250807monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-reports-second-quarter-2025-financial-results-and-raises-2025-reven-avdl-20250807monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2025-financ-avdl-20250731monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20250721monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-unanimous-appeals-court-decision-upholding-fda-approval-o-avdl-20250630monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20250616monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-receives-orphan-drug-designation-from-fda-for-lumryz-sodium-oxybate-avdl-20250605monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-new-data-on-lumryz-sodium-oxybate-for-extended-release-o-avdl-20250529monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-jefferies-global-healthcare-conference-avdl-20250529monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-expands-leadership-team-with-appointment-of-susan-rodriguez-as-chie-avdl-20250513monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-con-avdl-20250513monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20250508monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-reports-first-quarter-2025-financial-results-and-raises-guidance-avdl-20250507monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-favorable-ruling-in-appeal-of-delaware-court-injunction-avdl-20250506monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-first-quarter-2025-financi-avdl-20250430monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-and-nference-announce-publication-of-real-world-data-on-sodium-oxybate-treatment-pa-avdl-20250417monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20250410monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-update-at-needham-virtual-healthcare-conference-avdl-20250408monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-24th-annual-needham-healthcare-conference-avdl-20250401monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-publications-in-cns-drugs-supplement-highlighting-key-clinical-issues-for-avdl-20250325monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-avdl-20250305monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-reiterates-2025-guidance-as-it-reports-fourth-quarter-and-full-year-avdl-20250303monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-fourth-quarter-and-full-ye-avdl-20250224monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-appoints-kevin-springman-as-vice-president-of-sales-avdl-20250224monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20250220monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-appoints-sev-melkonian-as-vice-president-of-patient-services-distri-avdl-20250122monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-preliminary-2024-results-and-2025-commercial-priorities-to-accelerate-the-avdl-20250108monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20250106monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-provide-a-corporate-update-and-preliminary-fourth-quarter-and-fu-avdl-20250103monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-jefferies-london-healthcare-conference-avdl-20241113monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-corporate-update-and-reports-third-quarter-2024-financial--avdl-20241112monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-third-quarter-2024-financi-avdl-20241104monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-favorable-ruling-in-administrative-procedure-act-litigati-avdl-20241031monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-and-nference-announce-publication-of-real-world-data-in-sleep-advan-avdl-20241024monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-fda-approval-of-lumryz-sodium-oxybate-extended-release-or-avdl-20241017monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-publication-of-data-highlighting-efficacy-of-lumryz-sodiu-avdl-20240925monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-publication-of-restore-data-highlighting-challenges-with--avdl-20240903monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-avdl-20240828monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-publication-in-clinical-therapeutics-of-data-highlighting-avdl-20240820monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-corporate-update-and-reports-second-quarter-2024-financial-avdl-20240808monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2024-financ-avdl-20240801monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-first-patient-dosed-in-phase-3-revitalyz-trial-of-lumryz--avdl-20240731monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-join-russell-3000-index-avdl-20240627monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-avdl-20240530monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-shares-new-lumryz-sodium-oxybate-for-extended-release-oral-suspensi-avdl-20240522monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-appoints-naseem-amin-m-d-to-its-board-of-directors-avdl-20240521monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-corporate-update-and-reports-first-quarter-2024-financial--avdl-20240508monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-first-quarter-2024-financi-avdl-20240501monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-23rd-annual-needham-healthcare-conference-avdl-20240401monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-avdl-20240305monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-issues-statement-on-patent-litigation-avdl-20240304monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-corporate-update-and-reports-fourth-quarter-and-full-year--avdl-20240304monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-fourth-quarter-and-full-ye-avdl-20240226monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences--avdl-20240207monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-strong-lumryz-launch-performance-and-provides-preliminary-avdl-20240108monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-corporate-update-and-reports-third-quarter-2023-financial--avdl-20231108monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-avdl-20231107monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-third-quarter-financial-re-avdl-20231030monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-data-supporting-clinical-profile-for-lumryz-sodium-oxybat-avdl-20231020monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-jefferies-biotech-cns-neuro-summit-avdl-20231005monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-avdl-20230831monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-corporate-update-and-reports-second-quarter-2023-financial-avdl-20230809monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20230803monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-financial-r-avdl-20230802monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20230720monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20230706monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-host-commercial-day-on-june-29-for-lumryz-sodium-oxybate-extende-avdl-20230622monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-sponsors-the-academy-of-sleep-medicine-foundation-s-2023-young-inve-avdl-20230614monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-publication-of-study-data-in-advances-in-therapy-highligh-avdl-20230613monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20230606monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-u-s-commercial-launch-of-lumryz-sodium-oxybate-for-the-tr-avdl-20230605monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-jefferies-healthcare-conference-avdl-20230601monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-data-supporting-clinical-profile-for-lumryz-at-sleep-2023-avdl-20230531monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-corporate-update-and-reports-first-quarter-2023-financial--avdl-20230504monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20230503monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-final-fda-approval-of-lumryz-sodium-oxybate-for-extended--avdl-20230501monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20230420monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-22nd-annual-needham-healthcare-conference-avdl-20230410monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20230403monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-corporate-update-and-reports-fourth-quarter-and-full-year--avdl-20230330monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-fourth-quarter-and-full-ye-avdl-20230330monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-pricing-of-public-offering-of-adss-and-series-b-preferred-avdl-20230330monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-proposed-underwritten-public-offering-of-adss-and-series--avdl-20230329monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-enters-into-royalty-agreement-with-rtw-investments-for-up-to-75-mil-avdl-20230329monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-fda-authorization-to-import-tentatively-approved-lumryz-a-avdl-20230322monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20230321monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-requests-final-fda-approval-for-lumryz-sodium-oxybate-extended-rele-avdl-20230302monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20230216monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference-avdl-20230208monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20230203monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-publication-of-real-world-data-highlighting-the-risk-of-a-avdl-20230124monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20230123monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20230110monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20221219monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20221201monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-avdl-20221122monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20221121monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-favorable-ruling-on-motion-to-delist-rems-patent-from-fda-avdl-20221118monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-jefferies-london-healthcare-conference-avdl-20221110monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-corporate-update-and-reports-third-quarter-2022-financial--avdl-20221109monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-avdl-20221107monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-third-quarter-financial-re-avdl-20221102monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-presents-new-real-world-data-describing-demographic-characteristics-and-comorbiditi-avdl-20221024monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-healthcare-conference-avdl-20220922monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-h-c-wainwright-global-investment-conference-avdl-20220907monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-corporate-update-and-reports-second-quarter-2022-financial-avdl-20220809monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-financial-r-avdl-20220802monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-tentative-approval-of-lumryz-sodium-oxybate-extended-rele-avdl-20220719monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-corporate-update-avdl-20220629monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-and-the-american-academy-of-sleep-medicine-foundation-announce-an-e-avdl-20220603monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-jefferies-healthcare-conference-avdl-20220602monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-to-present-clinical-data-for-ft218-at-sleep-2022-avdl-20220519monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-h-c-wainwright-global-investment-conference-avdl-20220518monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-corporate-update-and-reports-first-quarter-2022-financial--avdl-20220509monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-first-quarter-financial-re-avdl-20220502monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-comment-on-recent-trading-activity-avdl-20220426monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-interim-data-from-the-open-label-restore-study-at-the-202-avdl-20220425monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-publication-of-positive-secondary-endpoint-data-from-pivo-avdl-20220406monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-avdl-20220322monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-corporate-update-and-reports-fourth-quarter-and-full-year--avdl-20220317monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-appointment-of-brandi-robinson-as-senior-vice-president-c-avdl-20220314monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-fourth-quarter-and-full-ye-avdl-20220314monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-new-positive-data-for-once-at-bedtime-ft218-for-narcolepsy-and-once-night-avdl-20220311monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-oppenheimer-32nd-annual-healthcare-conference-avdl-20220310monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-to-present-new-clinical-data-at-world-sleep-2022-avdl-20220301monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-appoints-dr-douglas-williamson-as-chief-medical-officer-avdl-20220214monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-11th-annual-svb-leerink-global-healthcare-confere-avdl-20220210monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-avdl-20211122monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-in-november-avdl-20211109monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-corporate-update-and-reports-third-quarter-2021-financial--avdl-20211108monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-third-quarter-2021-financi-avdl-20211101monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-presents-new-data-supporting-clinical-benefit-with-once-at-bedtime-ft218-and-prefer-avdl-20211019monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-ongoing-fda-review-of-nda-for-ft218-for-patients-with-nar-avdl-20211015monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-recognizes-world-narcolepsy-day-and-announces-new-data-presentations-from-pivotal-p-avdl-20210920monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-avdl-20210902monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-publication-of-data-from-pivotal-phase-3-rest-on-trial-of-avdl-20210816monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-corporate-update-and-reports-second-quarter-2021-financial-avdl-20210809monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021-financ-avdl-20210802monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-annual-healthcare-conference-2-avdl-20210707monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-presents-new-clinical-data-from-pivotal-phase-3-rest-on-trial-supporting-clinical-b-avdl-20210609monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-to-present-new-efficacy-and-safety-data-from-pivotal-phase-3-rest-on-trial-of-ft218-avdl-20210603monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-expands-leadership-team-with-three-strategic-hires-avdl-20210602monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference-avdl-20210525monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-corporate-update-and-reports-first-quarter-2021-financial--avdl-20210510monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-first-quarter-2021-financi-avdl-20210429monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-presents-new-data-from-its-pivotal-rest-on-phase-3-trial-of-ft218-once-nightly-sodi-avdl-20210417monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-to-present-new-data-from-its-pivotal-rest-on-phase-3-study-of-ft218-at-the-american-avdl-20210408monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-participate-in-a-fireside-chat-at-stifel-s-third-annual-cns-day--avdl-20210318monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-corporate-update-and-reports-fourth-quarter-and-full-year--avdl-20210309monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-and-the-american-academy-of-sleep-medicine-foundation-announce-an-e-avdl-20210304monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-publication-of-once-nightly-ft218-pharmacokinetic-studies-avdl-20210302monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-ft218-in-adult-avdl-20210301monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-participate-in-fireside-chats-at-upcoming-march-2021-investor-co-avdl-20210225monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-provide-a-company-update-and-report-fourth-quarter-and-full-year-avdl-20210223monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-appoints-richard-kim-as-chief-commercial-officer-to-lead-the-commer-avdl-20210217monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-participate-in-a-fireside-chat-at-the-10th-annual-svb-leerink-gl-avdl-20210210monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-submission-of-new-drug-application-for-ft218-to-the-fda-avdl-20201216monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-added-to-nasdaq-biotechnology-index-avdl-20201215monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-appoints-dr-jennifer-gudeman-as-vice-president-of-medical-and-clini-avdl-20201207monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-upcoming-december-2020-investor-conferences-avdl-20201123monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-upcoming-november-2020-investor-conferences-avdl-20201111monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-reports-third-quarter-2020-financial-results-and-provides-update-on-avdl-20201109monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-report-third-quarter-2020-financial-results-on-november-9th-avdl-20201026monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-to-present-at-the-oppenheimer-fall-healthcare-life-sciences-medtech-summit-avdl-20200917monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-ft218-leadership-transition-avdl-20200914monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-to-present-at-h-c-wainwright-22nd-annual-global-investment-conference-avdl-20200911monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-reports-second-quarter-2020-financial-results-and-recent-business-u-avdl-20200810monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-report-second-quarter-2020-financial-results-on-august-10th-avdl-20200727monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-first-patient-dosed-in-open-label-extension-switch-study--avdl-20200713monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-sale-of-hospital-sterile-injectable-drug-portfolio-for-42-0-million-avdl-20200701monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-bio-digital-avdl-20200608monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-jefferies-virtual-healthcare-conference-avdl-20200601monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-reports-first-quarter-2020-financial-results-avdl-20200511monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-report-first-quarter-2020-financial-results-on-may-11th-avdl-20200504monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-pricing-of-public-offering-avdl-20200429monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-proposed-underwritten-public-offering-avdl-20200427monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-positive-topline-results-from-its-pivotal-phase-3-rest-on-avdl-20200427monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-completes-the-rest-on-phase-3-pivotal-trial-of-ft218-for-excessive--avdl-20200325monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results-avdl-20200312monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-report-fourth-quarter-and-year-end-2019-financial-results-on-mar-avdl-20200227monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-65-million-private-placement-with-leading-biotech-investm-avdl-20200221monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-completes-enrollment-in-the-rest-on-phase-3-pivotal-trial-of-ft218--avdl-20191217monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-receives-u-s-fda-approval-for-nouress-av001-a-cysteine-hydrochlorid-avdl-20191216monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-appoints-dr-mark-mccamish-to-its-board-of-directors-avdl-20191210monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-key-appointments-to-leadership-team-to-support-continued--avdl-20191202monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-achieves-enrollment-target-in-rest-on-phase-3-pivotal-trial-of-ft21-avdl-20191125monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-avdl-20191121monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-reports-third-quarter-2019-financial-results-and-raises-revenue-gui-avdl-20191112monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-report-third-quarter-2019-financial-results-on-november-12th-avdl-20191029monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-resignation-of-kevin-kotler-from-board-of-directors-avdl-20191004monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-pharmacokinetic-pk-data-for-once-nightly-ft218-that-will--avdl-20190924monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-fda-agreement-to-reduce-the-sample-size-for-the-ongoing-p-avdl-20190923monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-an-oral-presentation-on-investigational-once-nightly-sodi-avdl-20190918monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2019-healthcare-conference-on--avdl-20190917monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-reports-second-quarter-2019-financial-results-and-provides-company--avdl-20190809monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-receives-new-pdufa-date-for-av001-of-december-15-2019-avdl-20190808monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-further-strengthens-clinical-and-medical-team-avdl-20190801monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-report-second-quarter-2019-financial-results-avdl-20190729monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-to-present-new-data-on-once-nightly-sodium-oxybate-at-sleep-2019-conference-avdl-20190604monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-appoints-gregory-j-divis-chief-executive-officer-avdl-20190603monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-av001-avdl-20190522monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-reports-first-quarter-2019-financial-results-avdl-20190508monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-report-first-quarter-2019-financial-results-avdl-20190429monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-appointment-of-jordan-dubow-m-d-as-chief-medical-officer-avdl-20190429monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-reports-fourth-quarter-and-full-year-2018-financial-results-avdl-20190315monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-report-fourth-quarter-and-full-year-2018-financial-results-avdl-20190307monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-clarifies-announcement-of-corporate-restructuring-avdl-20190207monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-restructuring-to-focus-on-ft218-clinical-development-prog-avdl-20190207monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-changes-to-management-team-and-board-of-directors-avdl-20190103monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-appoints-kevin-kotler-to-the-company-s-board-of-directors-avdl-20181211monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-reports-third-quarter-2018-financial-results-avdl-20181105monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-presents-data-on-quality-of-life-improvement-in-patients-on-noctiva-at-american-uro-avdl-20181029monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-report-third-quarter-2018-financial-results-avdl-20181025monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-presents-data-for-noctiva-at-2018-american-urogynecologic-society-a-avdl-20181015monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-journal-of-urology-publication-of-phase-3-data-on-noctiva-avdl-20180928monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2018-healthcare-conference-avdl-20180925monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-2018-wells-fargo-healthcare-conference-avdl-20180830monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-reports-second-quarter-2018-financial-results-avdl-20180807monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-report-second-quarter-2018-results-avdl-20180717monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-avdl-20180531monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-to-present-late-breaker-data-and-product-theater-forum-at-the-2018-american-urologi-avdl-20180518monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-reports-first-quarter-2018-results-avdl-20180502monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-launches-noctiva-the-first-and-only-fda-approved-treatment-for-nocturia-due-to-noct-avdl-20180501monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-deutsche-bank-43rd-annual-health-care-conference-avdl-20180430monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-report-first-quarter-2018-results-avdl-20180424monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-acceptance-of-late-breaker-presentation-for-noctiva-at-th-avdl-20180403monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-promotion-of-gregory-j-divis-to-chief-operating-officer-avdl-20180322monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-avdl-20180309monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-reports-fourth-quarter-and-full-year-2017-results-avdl-20180308monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-report-fourth-quarter-and-full-year-2017-results-avdl-20180226monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-pricing-of-125-0-million-4-50-exchangeable-senior-notes-d-avdl-20180214monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-proposed-exchangeable-senior-notes-offering-avdl-20180213monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-divestiture-of-pediatric-business-avdl-20180212monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-receives-orphan-drug-designation-from-fda-for-ft-218-for-the-treatm-avdl-20180110monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-issues-2018-corporate-outlook-avdl-20171229monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-29th-annual-piper-jaffray-healthcare-conference-avdl-20171127monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-reports-third-quarter-2017-results-avdl-20171108monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-host-analyst-and-investor-meeting-avdl-20171106monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-report-third-quarter-2017-results-avdl-20171020monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-data-presentation-for-noctiva-at-the-american-urogynecolo-avdl-20171005monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-avdl-20170913monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-enters-into-exclusive-license-agreement-for-noctiva-avdl-20170905monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-the-2017-wells-fargo-healthcare-conference-avdl-20170829monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-enters-into-exclusive-negotiations-with-serenity-pharmaceuticals-fo-avdl-20170817monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-reports-second-quarter-2017-results-avdl-20170808monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-report-second-quarter-2017-results-avdl-20170720monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-avdl-20170530monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-supports-the-narcolepsy-network-s-5th-annual-dream-big-walk-avdl-20170517monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-reports-first-quarter-2017-results-avdl-20170509monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-avdl-20170424monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-report-first-quarter-2017-results-avdl-20170417monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-planned-reduction-of-french-workforce-avdl-20170330monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-announces-25-million-share-repurchase-program-avdl-20170307monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-reports-fourth-quarter-and-full-year-2016-results-avdl-20170307monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-avdl-20170302monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-report-fourth-quarter-and-full-year-2016-results-avdl-20170214monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-avdl-20170206monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-2017-guidance-and-business-update-avdl-20170105monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-appoints-gregory-j-divis-chief-commercial-officer-avdl-20170103monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-class-action-deadline-tomorrow-bragar-eagel-squire-p-c-urges-soleno-th-slno-20260504monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-deadline-tomorrow-rosen-global-investor-counsel-encourages-soleno-ther-slno-20260504monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-deadline-rosen-leading-investor-counsel-encourages-soleno-therapeutics-slno-20260502monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess--slno-20260430monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-slno-shareholder-alert-bernstein-liebhard-llp-reminds-soleno-thera-slno-20260430monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-notice-of-may-5-2026-application-deadline-for-class-action-lawsuit-slno-20260429monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-deadline-rosen-national-trial-lawyers-encourages-soleno-therapeutics-inc-investors--slno-20260429monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess--slno-20260423monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-notice-of-may-5-2026-application-deadline-for-class-action-lawsuit-slno-20260422monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess--slno-20260416monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-notice-of-may-5-2026-application-deadline-for-class-action-lawsuit-slno-20260415monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-lawsuit-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-bee-slno-20260409monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess--slno-20260409monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-slno-deadline-alert-bernstein-liebhard-llp-reminds-soleno-therapeu-slno-20260409monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-notice-of-may-5-2026-application-deadline-for-class-action-lawsuit-slno-20260408monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-slno-class-action-lawsuit-investors-face-may-5-2026-deadline-slno-20260406monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-slno-faces-securities-class-action-amid-hyperphagia-drug-launch-disrup-slno-20260406monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-slno-faces-securities-class-action-amid-hyperphagia-drug-launch-disrup-slno-20260402monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-slno-shareholder-alert-bernstein-liebhard-llp-reminds-soleno-thera-slno-20260402monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess--slno-20260402monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-notice-of-may-5-2026-application-deadline-for-class-action-lawsuit-slno-20260401monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-slno-faces-securities-class-action-amid-hyperphagia-drug-launch-disrup-slno-20260331monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-slno-class-action-lawsuit-seeks-recovery-for-investors-may-5-2026--slno-20260327monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-slno-faces-securities-class-action-amid-hyperphagia-drug-launch-disrup-slno-20260327monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-slno-shareholder-alert-bernstein-liebhard-llp-reminds-soleno-thera-slno-20260326monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-investors-with-substantial-losses-have-opportunity-to-lead-investo-slno-20260326monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess--slno-20260326monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-slno-faces-securities-class-action-amid-hyperphagia-drug-launch-disrup-slno-20260325monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-notice-of-may-5-2026-application-deadline-for-class-action-lawsuit-slno-20260325monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-slno-investors-may-5-2026-filing-deadline-in-securities-fraud-clas-slno-20260323monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-slno-faces-securities-class-action-amid-hyperphagia-drug-launch-disrup-slno-20260323monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-slno-faces-securities-class-action-amid-hyperphagia-drug-launch-disrup-slno-20260319monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-slno-shareholder-alert-bernstein-liebhard-llp-reminds-soleno-thera-slno-20260319monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess--slno-20260319monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-notice-of-may-5-2026-application-deadline-for-class-action-lawsuit-slno-20260318monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-slno-faces-securities-class-action-amid-hyperphagia-drug-launch-disrup-slno-20260317monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-slno-faces-securities-class-action-amid-hyperphagia-drug-launch-disrup-slno-20260313monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-slno-class-action-lawsuit-investors-face-may-5-2026-deadline-slno-20260313monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-slno-shareholder-alert-bernstein-liebhard-llp-reminds-soleno-thera-slno-20260312monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess--slno-20260312monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-class-action-notice-robbins-llp-reminds-investors-of-the-lead-plai-slno-20260311monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-slno-faces-securities-class-action-amid-hyperphagia-drug-launch-disrup-slno-20260311monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-notice-of-may-5-2026-application-deadline-for-class-action-lawsuit-slno-20260311monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-slno-investor-alert-investors-with-large-losses-in-soleno-therapeu-slno-20260310monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-lawsuit-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-bee-slno-20260309monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-slno-faces-investor-scrutiny-amid-disappointing-vykat-xr-starts-discon-slno-20260116monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-select-preliminary-fourth-quarter-and-full-year-2025-results-slno-20260112monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-slno-faces-investor-scrutiny-amid-disappointing-vykat-xr-starts-discon-slno-20251113monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-inc-investigated-by-the-portnoy-law-firm-slno-20251112monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-slno-faces-investor-scrutiny-amid-disappointing-vykat-xr-starts-discon-slno-20251106monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-slno-drops-amid-critical-scorpion-report-hagens-berman-slno-20251009monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-slno-reminder-bragar-eagel-squire-p-c-reminds-investors-of-the-investigation-into-s-slno-20251009monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-investigation-alert-bragar-eagel-squire-p-c-continues-investigation-into-therapeuti-slno-20250925monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-slno-drops-amid-critical-scorpion-report-hagens-berman-slno-20250925monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-alert-bragar-eagel-squire-p-c-is-investigating-soleno-therapeutics-inc-on-behalf-of-slno-20250918monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-slno-drops-amid-critical-scorpion-report-hagens-berman-slno-20250918monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-alert-bragar-eagel-squire-p-c-is-investigating-soleno-therapeutics-inc-on-behalf-of-slno-20250911monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-slno-drops-amid-critical-scorpion-report-hagens-berman-slno-20250911monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-alert-bragar-eagel-squire-p-c-is-investigating-soleno-therapeutics-inc-on-behalf-of-slno-20250908monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-upcoming-september-conferences-slno-20250827monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-slno-drops-amid-critical-scorpion-report-hagens-berman-slno-20250826monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-alert-bragar-eagel-squire-p-c-is-investigating-soleno-therapeutics-inc-on-behalf-of-slno-20250826monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-slno-drops-amid-critical-scorpion-report-hagens-berman-slno-20250819monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-update-on-u-s-launch-of-vykat-tm-xr-and-reports-second-quarte-slno-20250806monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-report-second-quarter-2025-financial-results-on-august-6-2025-at-4--slno-20250728monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-proposed-200-million-public-offering-of-common-stock-slno-20250710monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-preliminary-financial-and-operational-results-for-the-second-slno-20250710monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-two-presentations-featuring-vykat-tm-xr-in-prader-willi-synd-slno-20250701monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-highlights-new-data-on-vykat-tm-xr-at-the-2025-united-in-hope-internat-slno-20250625monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-multiple-presentations-at-the-2025-united-in-hope-internatio-slno-20250620monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-submission-and-ema-validation-of-marketing-authorization-app-slno-20250522monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-upcoming-june-conferences-slno-20250521monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-data-presentation-showing-that-resumption-of-treatment-with--slno-20250520monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-presentations-featuring-vykat-tm-xr-in-prader-willi-syndrome-slno-20250515monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-presentations-featuring-vykat-tm-xr-in-prader-willi-syndrome-slno-20250513monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-oral-presentations-featuring-vykat-tm-xr-in-prader-willi-syn-slno-20250508monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-update-on-u-s-launch-of-vykat-tm-xr-and-reports-first-quarter-slno-20250507monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-report-first-quarter-2025-financial-results-and-host-inaugural-quar-slno-20250423monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-vykat-tm-xr-launch-slno-20250414monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-u-s-fda-approval-of-vykat-tm-xr-to-treat-hyperphagia-in-prad-slno-20250326monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-202-slno-20250227monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-upcoming-february-investor-conferences-slno-20250129monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-enters-into-200-million-debt-financing-with-oxford-finance-llc-slno-20241217monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-piper-sandler-36th-annual-healthcare-conference-slno-20241127monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-fda-extension-of-review-period-for-dccr-diazoxide-choline-ex-slno-20241126monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-oral-presentations-featuring-diazoxide-choline-extended-rele-slno-20241114monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-third-quarter-2024-financial-res-slno-20241106monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-upcoming-november-investor-conferences-slno-20241028monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-the-passing-of-former-chairman-ernest-mario-ph-d-slno-20241021monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-regulatory-update-on-dccr-diazoxide-choline-extended-release-slno-20241008monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-present-at-2024-cantor-global-healthcare-conference-slno-20240916monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-u-s-fda-acceptance-for-filing-and-priority-review-of-nda-for-slno-20240827monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-slno-20240819monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-updates-to-its-board-of-directors-slno-20240815monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-second-quarter-2024-financial-re-slno-20240807monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-submission-of-new-drug-application-to-the-u-s-fda-for-dccr-d-slno-20240628monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-slno-20240624monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-set-to-join-russell-3000-index-slno-20240604monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-oral-presentation-featuring-dccr-diazoxide-choline-extended--slno-20240522monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-upcoming-investor-conferences-slno-20240522monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-stands-with-the-prader-willi-syndrome-community-slno-20240515monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-first-quarter-2024-financial-res-slno-20240509monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-pricing-of-approximately-138-million-public-offering-of-comm-slno-20240503monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-proposed-public-offering-of-common-stock-slno-20240502monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-peer-reviewed-publication-of-data-comparing-dccr-treatment-t-slno-20240430monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-receives-breakthrough-therapy-designation-from-u-s-fda-for-dccr-diazox-slno-20240429monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-slno-20240419monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-slno-20240308monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-202-slno-20240306monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-present-at-the-td-cowen-44th-annual-health-care-conference-slno-20240222monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-present-at-upcoming-february-investor-conferences-slno-20240201monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-slno-20240129monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-strengthens-leadership-team-with-key-appointments-slno-20240124monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-slno-20240105monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-slno-20231110monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-third-quarter-2023-financial-res-slno-20231107monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-long-term-open-lab-slno-20231106monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-dccr-data-presentation-at-the-foundation-for-prader-willi-re-slno-20231004monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-closing-of-underwritten-public-offering-of-common-stock-and--slno-20231002monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-pricing-of-approximately-120-million-underwritten-public-off-slno-20230928monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-proposed-public-offering-of-common-stock-and-or-pre-funded-w-slno-20230927monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-positive-statistically-significant-top-line-results-from-ran-slno-20230926monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-present-at-the-cantor-global-healthcare-conference-slno-20230925monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-appointment-of-industry-veteran-matthew-pauls-j-d-m-b-a-to-b-slno-20230816monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-second-quarter-2023-financial-re-slno-20230808monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-first-quarter-2023-financial-res-slno-20230509monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-completes-enrollment-in-randomized-withdrawal-period-of-study-c602-of--slno-20230503monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-an-slno-20230328monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-202-slno-20230321monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference-slno-20230307monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-complet-slno-20230126monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-financing-commitment-for-up-to-60-million-slno-20221219monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-third-quarter-2022-financial-res-slno-20221109monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-initiation-of-randomized-withdrawal-study-of-dccr-for-the-tr-slno-20221003monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-con-slno-20220906monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-second-quarter-2022-financial-re-slno-20220810monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-regulatory-update-on-dccr-for-the-treatment-of-prader-willi-s-slno-20220720monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-presentation-of-dccr-data-at-the-11th-international-prader-w-slno-20220711monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-presents-long-term-data-for-dccr-showing-metabolic-and-body-compositio-slno-20220613monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-presentations-at-endo-2022-slno-20220607monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-presentations-at-the-2022-european-congress-of-endocrinology-slno-20220519monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-the-h-c-wainwright-global-investment-conference-slno-20220517monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-first-quarter-2022-financial-res-slno-20220510monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-presentation-of-long-term-hyperphagia-and-behavioral-data-in-slno-20220502monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-closing-of-approximately-15-million-underwritten-public-offe-slno-20220401monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-202-slno-20220331monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-pricing-of-approximately-15-million-underwritten-public-offe-slno-20220329monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-proposed-underwritten-public-offering-slno-20220328monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-the-bio-ceo-investor-conference-slno-20220208monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-slno-20220128monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-regulatory-update-on-dccr-for-the-treatment-of-prader-willi-s-slno-20220124monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-the-lifesci-partners-11th-annual-corporate-access-ev-slno-20220105monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-slno-20211119monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-third-quarter-2021-financial-res-slno-20211110monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-the-2021-cantor-virtual-global-healthcare-conference-slno-20210923monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-the-oppenheimer-fall-healthcare-life-sciences-and-me-slno-20210916monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-positive-data-showing-continued-significant-improvements-in--slno-20210908monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-second-quarter-2021-financial-re-slno-20210728monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-regulatory-update-on-dccr-for-the-treatment-of-prader-willi-s-slno-20210706monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-receives-orphan-drug-designation-from-fda-for-diazoxide-choline-for-th-slno-20210602monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-host-webinar-highlighting-dccr-for-treatment-of-prader-willi-syndro-slno-20210521monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-the-oppenheimer-rare-orphan-disease-summit-slno-20210520monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-first-quarter-2021-financial-res-slno-20210505monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-presentation-of-positive-behavioral-data-from-ongoing-extens-slno-20210504monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-participates-in-prader-willi-syndrome-pws-dccr-town-hall-slno-20210415monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-to-participate-in-the-31st-annual-oppenheimer-healthcare-conference-slno-20210309monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-regulatory-update-on-dccr-for-the-treatment-of-prader-willi-s-slno-20210308monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-202-slno-20210303monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-collaboration-with-vanderbilt-university-to-discover-and-dev-slno-20210223monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-recap-of-key-opinion-leader-webinar-on-dccr-for-treatment-of--slno-20210205monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-host-key-opinion-leader-meeting-on-dccr-for-the-treatment-of-prader-slno-20210128monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference-slno-20210104monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-regulatory-update-on-dccr-for-the-treatment-of-prader-willi-s-slno-20201211monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-third-quarter-2020-financial-res-slno-20201110monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-presentation-of-body-composition-results-from-destiny-pws-a--slno-20201103monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-late-breaking-oral-presentation-with-body-composition-result-slno-20201029monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-updated-top-line-results-from-phase-iii-trial-of-dccr-for-tr-slno-20200930monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-fireside-chat-at-the-oppenheimer-fall-healthcare-lif-slno-20200915monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-second-quarter-2020-financial-re-slno-20200810monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-added-to-russell-3000-index-slno-20200629monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-closing-of-57-5-million-public-offering-of-common-stock-incl-slno-20200626monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-pricing-of-50-million-public-offering-of-common-stock-slno-20200624monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-proposed-public-offering-of-common-stock-slno-20200623monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-top-line-results-from-phase-iii-trial-of-dccr-for-treatment--slno-20200608monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-first-quarter-2020-financial-res-slno-20200512monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-publication-evaluating-potential-role-of-activating-atp-sens-slno-20200423monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-present-at-the-30th-annual-oppenheimer-healthcare-conference-slno-20200311monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-201-slno-20200304monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-completes-target-enrollment-in-ongoing-destiny-pws-phase-iii-trial-of--slno-20200106monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-third-quarter-2019-financial-res-slno-20191113monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-closing-of-15-4-million-public-offering-of-common-stock-slno-20191025monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-pricing-of-13-4-million-public-offering-of-common-stock-slno-20191023monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-proposed-public-offering-of-common-stock-slno-20191022monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-positive-outcome-from-second-planned-data-safety-monitoring--slno-20191002monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-publication-of-results-from-previously-completed-phase-ii-tr-slno-20190924monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-the-oppenheimer-fall-summit-focused-on-specialty-pha-slno-20190919monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-second-quarter-2019-financial-re-slno-20190807monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-update-on-ongoing-destiny-pws-phase-iii-trial-of-dccr-in-prad-slno-20190725monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-appointment-of-veteran-industry-executive-birgitte-volck-m-d-slno-20190612monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-first-quarter-2019-financial-res-slno-20190513monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-appointment-of-industry-veteran-gwen-a-melincoff-to-board-of-slno-20190429monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-present-at-the-2019-h-c-wainwright-global-life-sciences-conference-slno-20190403monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-the-roth-battle-of-nash-thrones-spring-investor-conf-slno-20190325monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-201-slno-20190318monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-two-upcoming-investor-conferences-slno-20190311monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-16-5-million-private-placement-slno-20181219monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-presents-clinical-fat-loss-data-on-dccr-at-the-obesity-society-meeting-slno-20181115monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-third-quarter-2018-financial-res-slno-20181115monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-presents-clinical-data-on-dccr-at-2018-foundation-for-prader-willi-res-slno-20181008monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-presents-clinical-data-on-dccr-at-late-breaking-session-of-european-so-slno-20181001monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-participate-in-oppenheimer-fall-summit-focused-on-specialty-pharma--slno-20180919monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-present-dccr-clinical-data-at-late-breaking-sessions-of-the-europea-slno-20180917monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-expansion-of-ongoing-phase-iii-trial-of-dccr-in-prader-willi-slno-20180906monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-issuance-of-new-u-s-patent-for-dccr-covering-treatment-of-lo-slno-20180904monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-second-quarter-2018-financial-re-slno-20180814monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-receives-fast-track-designation-from-fda-for-dccr-for-treatment-of-pra-slno-20180730monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-present-corporate-update-at-the-bio-international-convention-slno-20180604monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-first-quarter-2018-financial-res-slno-20180516monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-initiation-of-phase-iii-clinical-trial-of-dccr-in-prader-wil-slno-20180514monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-201-slno-20180402monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-successful-end-of-phase-ii-meeting-with-fda-for-dccr-in-prad-slno-20180220monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-15-million-private-placement-slno-20171212monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-joint-venture-agreement-for-development-and-commercializatio-slno-20171208monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-to-present-at-the-piper-jaffray-29th-annual-healthcare-conference-slno-20171122monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-third-quarter-2017-financial-res-slno-20171114monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-regains-compliance-with-nasdaq-listing-requirements-slno-20171023monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-receives-positive-opinion-from-european-orphan-committee-for-dccr-in-p-slno-20171012monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-issuance-of-new-u-s-patent-for-dccr-covering-treatment-of-hy-slno-20171011monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-1-for-5-reverse-stock-split-slno-20171005monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-receipt-of-scientific-advice-from-the-european-medicines-age-slno-20170925monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-presents-updated-safety-and-efficacy-data-from-clinical-trial-of-dccr--slno-20170915monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-issuance-of-new-u-s-patent-for-dccr-in-treatment-of-prader-w-slno-20170913monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-cfo-transition-slno-20170905monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-provides-corporate-update-and-reports-second-quarter-2017-financial-re-slno-20170811monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-sale-of-non-strategic-assets-to-flexicare-inc-slno-20170724monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-successful-completion-of-fda-meeting-for-dccr-in-prader-will-slno-20170705monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-rapt-20260107monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-proposed-public-offering-of-common-stock-rapt-20251021monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-report-topline-data-from-phase-2-clinical-trial-of-rpt904-in-chronic--rapt-20251019monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-participate-in-multiple-upcoming-investor-conferences-rapt-20250827monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-second-quarter-2025-financial-results-rapt-20250807monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-names-two-industry-veterans-to-its-board-of-directors-rapt-20250623monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-effective-date-for-1-for-8-reverse-stock-split-rapt-20250613monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-participate-in-upcoming-investor-conferences-rapt-20250604monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-first-quarter-2025-financial-results-rapt-20250508monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-deepens-expertise-in-allergic-diseases-with-appointment-of-jessica-savag-rapt-20250415monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-participate-in-upcoming-investor-conferences-rapt-20250307monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-rapt-20250306monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-rapt-20250109monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-names-lori-lyons-williams-chair-of-the-company-s-board-of-directors-rapt-20250106monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-150-million-private-placement-rapt-20241223monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-and-shanghai-jemincare-pharmaceutical-announce-exclusive-license-agreeme-rapt-20241223monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-third-quarter-2024-financial-results-rapt-20241112monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-second-quarter-2024-financial-results-rapt-20240808monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-first-quarter-2024-financial-results-rapt-20240509monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-promising-results-from-phase-2-trial-of-tivumecirnon-in-combin-rapt-20240409monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-alert-bragar-eagel-squire-p-c-is-investigating-rapt-therapeutics-inc-on-behalf-of-rap-rapt-20240312monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-rapt-20240307monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-multiple-late-breaking-presentations-at-the-upcoming-american--rapt-20240305monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-rapt-20240221monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-clinical-hold-on-studies-evaluating-zelnecirnon-rapt-20240220monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-bolsters-leadership-team-with-the-appointment-of-nipun-davar-ph-d-as-sen-rapt-20240213monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-6th-annual-biotechnolo-rapt-20240131monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-rapt-20240102monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-publication-of-phase-1a-1b-clinical-trial-of-zelnecirnon-rpt19-rapt-20231127monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-third-quarter-2023-financial-results-rapt-20231113monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-positive-data-including-objective-response-rates-and-progressi-rapt-20231103monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-participate-in-several-upcoming-investor-conferences-in-november-rapt-20231101monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-two-flx475-presentations-at-the-society-for-immunotherapy-of-c-rapt-20231018monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-participate-in-several-upcoming-investor-conferences-in-september-rapt-20230830monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-second-quarter-2023-financial-results-rapt-20230811monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-participate-in-the-goldman-sachs-global-healthcare-conference-rapt-20230607monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-biomarker-data-corroborating-demonstrated-clinical-activity-a-rapt-20230525monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-first-quarter-2023-financial-results-rapt-20230511monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-the-appointment-of-michael-listgarten-as-general-counsel-rapt-20230503monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-cli-rapt-20230426monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-initiation-of-phase-2a-trial-of-rpt193-in-patients-with-modera-rapt-20230329monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-inc-company-investigated-by-the-portnoy-law-firm-rapt-20230326monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-fourth-quarter-and-year-end-financial-results-rapt-20230314monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference-rapt-20230207monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-rapt-20230103monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-presents-update-from-its-phase-1-2-clinical-trial-for-flx475-as-monother-rapt-20221208monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-flx475-phase-1-2-data-at-the-european-society-for-medical-onc-rapt-20221201monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-pricing-of-public-offering-of-common-stock-rapt-20221118monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-proposed-public-offering-of-common-stock-rapt-20221117monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-third-quarter-2022-financial-results-rapt-20221110monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-participate-in-several-upcoming-investor-conferences-rapt-20221109monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-strengthens-leadership-team-with-two-new-key-hires-rapt-20220928monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-participate-in-several-upcoming-investor-conferences-in-september-rapt-20220831monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-second-quarter-2022-financial-results-rapt-20220811monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-private-placement-financing-of-50-million-rapt-20220525monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-initiation-of-phase-2b-trial-of-rpt193-in-patients-with-modera-rapt-20220523monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-first-quarter-2022-financial-results-rapt-20220511monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-expands-leadership-team-with-multiple-key-hires-rapt-20220504monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-biomarker-data-from-phase-1b-trial-of-rpt193-consistent-with-d-rapt-20220328monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-fourth-quarter-and-year-end-2021-financial-results-rapt-20220310monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-participate-in-the-11th-annual-svb-leerink-healthcare-conference-rapt-20220209monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-rapt-20220104monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-third-quarter-2021-financial-results-rapt-20211110monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-appoints-industry-veteran-lori-lyons-williams-to-its-board-of-directors-rapt-20211109monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-participate-in-upcoming-investor-conferences-rapt-20211108monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-upcoming-oral-presentation-of-rpt193-phase-1b-data-at-the-4th--rapt-20211018monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-late-breaking-oral-presentation-of-positive-results-from-phase-rapt-20210930monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-at-the-2021-cantor-virtual-healthcare-conference-rapt-20210920monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-rpt193-phase-1b-data-at-30th-european-academy-of-dermatology--rapt-20210920monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-at-upcoming-investor-conferences-rapt-20210903monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-second-quarter-2021-financial-results-rapt-20210811monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercise-o-rapt-20210618monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-pricing-of-public-offering-of-common-stock-rapt-20210616monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-proposed-public-offering-of-common-stock-rapt-20210614monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-positive-topline-results-from-phase-1b-trial-of-rpt193-monothera-rapt-20210614monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-report-top-line-data-from-phase-1b-trial-of-rpt193-in-atopic-dermatit-rapt-20210613monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-at-the-ubs-global-healthcare-virtual-conference-rapt-20210520monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-first-quarter-2021-financial-results-rapt-20210511monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-completes-enrollment-in-phase-1b-trial-of-rpt193-in-atopic-dermatitis-rapt-20210322monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-fourth-quarter-and-year-end-2020-financial-results-rapt-20210311monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-report-promising-preclinical-studies-supporting-its-pipeline-of-immun-rapt-20210310monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-participate-in-two-investor-conferences-in-march-rapt-20210303monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference-rapt-20210219monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-rapt-20210105monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conferenc-rapt-20201123monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-third-quarter-2020-financial-results-rapt-20201116monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-positive-initial-data-from-ongoing-phase-1-2-clinical-trial-of-f-rapt-20201116monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-announce-initial-data-from-phase-1-2-clinical-trial-of-flx475-in-mult-rapt-20201115monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-at-the-stifel-2020-virtual-healthcare-conference-rapt-20201113monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-appoints-lisa-butterfield-ph-d-and-lawrence-fong-m-d-to-scientific-advis-rapt-20201014monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-at-upcoming-virtual-investor-conferences-rapt-20200903monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-second-quarter-2020-financial-results-rapt-20200813monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-appoints-phyllis-loud-gray-as-vice-president-of-human-resources-rapt-20200805monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-at-the-bmo-2020-prescriptions-for-success-healthcare-conferen-rapt-20200617monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-poster-presentation-at-the-american-society-of-clinical-oncolo-rapt-20200529monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-at-the-jefferies-virtual-global-healthcare-conference-rapt-20200526monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-highlights-early-results-for-rpt193-at-society-for-investigative-dermato-rapt-20200515monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-first-quarter-2020-financial-results-rapt-20200514monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-at-the-ubs-virtual-global-healthcare-conference-rapt-20200512monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-fourth-quarter-2019-financial-results-and-provides-business-upda-rapt-20200330monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-management-promotions-rapt-20200304monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-upcoming-investor-conference-presentations-rapt-20200219monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-pricing-of-75-million-public-offering-rapt-20200207monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-announces-proposed-offering-of-common-stock-rapt-20200204monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-rapt-20200107monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-to-be-added-to-the-russell-2000-and-russell-microcap-indices-rapt-20191216monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-reports-third-quarter-2019-financial-results-and-recent-highlights-rapt-20191211monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-appoints-mary-ann-gray-ph-d-to-board-of-directors-rapt-20191210monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-appoints-rodney-young-as-chief-financial-officer-rapt-20191204monthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-and-hanmi-pharmaceutical-announce-collaboration-to-develop-and-commercia-rapt-20191203monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-to-present-at-wedbush-pacgrow-healthcare-conference-kalv-20170808monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-provides-operational-update-and-reports-fiscal-fourth-quarter-and-kalv-20170727monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-to-present-at-jefferies-healthcare-conference-kalv-20170601monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-to-recognize-hae-day-2017-kalv-20170515monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-inc-nasdaq-kalv-to-ring-the-nasdaq-stock-market-closing-bell-kalv-20170512monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-reports-fiscal-third-quarter-results-kalv-20170316monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-appoints-dr-andreas-maetzel-senior-vice-president-of-medical-kalv-20170309monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-appoints-edward-p-feener-ph-d-as-chief-scientific-officer-kalv-20161129monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-announces-closing-of-merger-with-carbylan-therapeutics-kalv-20161122monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-petosemtamab-in-metastatic-colorectal-cancer-abstract-selected-for-plenary-mrus-20251013monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-second-quarter-2025-and-provides-business-update-mrus-20250805monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-n-v-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrus-20250804monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-n-v-announces-pricing-of-public-offering-of-common-shares-mrus-20250604monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-n-v-announces-proposed-public-offering-of-common-shares-mrus-20250603monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-upcoming-investor-conferences-mrus-20250527monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-petosemtamab-with-pembrolizumab-interim-data-demonstrates-robust-efficacy-and-durabi-mrus-20250522monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-the-journal-publication-of-petosemtamab-mechanism-of-action-mrus-20250515monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-bofa-securities-2025-health-care-conference-mrus-20250508monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-first-quarter-2025-and-provides-business-update-mrus-20250507monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-abstract-accepted-for-presentation-at-the-2025-asco-annual-meeting-mrus-20250423monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-a-fireside-chat-at-the-24th-annual-needham-virtual-healthcare-conf-mrus-20250401monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-fourth-quarter-and-full-year-2024-and-provides-b-mrus-20250227monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-upcoming-investor-conferences-mrus-20250225monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-citi-s-2025-virtual-oncology-leadership-summit-mrus-20250213monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-and-biohaven-announce-collaboration-to-co-develop-three-novel-bispecific-adc-program-mrus-20250113monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-first-patient-dosed-in-phase-2-trial-of-petosemtamab-in-3l-mcrc-mrus-20241216monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-petosemtamab-monotherapy-interim-data-continues-to-demonstrate-clinically-meaningful-mrus-20241207monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-fda-approval-of-bizengri-zenocutuzumab-zbco-for-nrg1-pancreatic-adenocarci-mrus-20241204monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-and-partner-therapeutics-announce-license-agreement-for-the-u-s-commercialization-of-mrus-20241202monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-publication-of-an-abstract-on-petosemtamab-as-2l-treatment-of-r-m-hnscc-at-mrus-20241201monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-upcoming-investor-conferences-mrus-20241106monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-receives-fda-extension-of-pdufa-for-zenocutuzumab-mrus-20241105monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-third-quarter-2024-and-provides-business-update-mrus-20241031monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-first-patient-dosed-in-liger-hn1-a-phase-3-trial-evaluating-petosemtamab-i-mrus-20240930monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-abstract-accepted-for-presentation-at-the-esmo-asia-congress-2024-mrus-20240917monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-canaccord-genuity-s-44th-annual-growth-conference-mrus-20240806monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-second-quarter-2024-and-provides-business-update-mrus-20240801monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-first-patient-dosed-in-liger-hn2-a-phase-3-trial-evaluating-petosemtamab-i-mrus-20240724monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-first-patient-dosed-in-phase-2-trial-of-petosemtamab-in-2l-crc-mrus-20240708monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-appoints-fabian-zohren-m-d-ph-d-as-chief-medical-officer-mrus-20240701monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-mcla-129-demonstrates-promising-single-agent-efficiency-in-metex14-nsclc-in-poster-p-mrus-20240603monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-presents-interim-data-on-mcla-145-monotherapy-and-in-combination-with-pembrolizumab--mrus-20240602monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-pricing-of-upsized-public-offering-of-common-shares-mrus-20240530monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-a-fireside-chat-at-the-jefferies-global-healthcare-conference-mrus-20240529monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-n-v-announces-proposed-public-offering-of-common-shares-mrus-20240528monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-petosemtamab-in-combination-with-pembrolizumab-interim-data-demonstrates-robust-resp-mrus-20240528monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-publication-of-an-abstract-on-petosemtamab-with-pembrolizumab-as-1l-treatm-mrus-20240523monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-publication-of-abstracts-for-presentation-at-the-2024-asco-annual-meeting-mrus-20240523monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-first-quarter-2024-and-provides-business-update-mrus-20240508monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-u-s-fda-acceptance-and-priority-review-of-biologics-license-application-fo-mrus-20240506monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-abstracts-accepted-for-presentation-at-the-2024-asco-annual-meeting-mrus-20240424monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-presents-preclinical-data-demonstrating-efficacy-of-zeno-in-cancer-models-with-high--mrus-20240408monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-a-fireside-chat-at-the-23rd-annual-needham-virtual-healthcare-conf-mrus-20240403monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-publication-of-an-abstract-for-presentation-at-the-aacr-annual-meeting-202-mrus-20240305monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-a-fireside-chat-at-the-leerink-partners-global-biopharma-conferenc-mrus-20240304monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-fourth-quarter-and-full-year-2023-and-provides-b-mrus-20240228monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-upcoming-investor-conferences-mrus-20240131monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-presents-interim-data-on-mcla-129-at-esmo-asia-congress-2023-mrus-20231203monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-publication-of-abstracts-on-mcla-129-for-presentation-at-esmo-asia-congres-mrus-20231126monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-third-quarter-2023-and-provides-business-update-mrus-20231102monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-upcoming-investor-conferences-mrus-20231101monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-zeno-interim-data-continues-to-demonstrate-robust-and-durable-responses-in-nrg1-canc-mrus-20231023monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-business-update-conference-call-mrus-20231015monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-abstracts-accepted-for-presentation-at-the-esmo-asia-congress-2023-mrus-20231006monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-upcoming-investor-conferences-mrus-20230831monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-pricing-of-public-offering-of-common-shares-mrus-20230810monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-n-v-announces-proposed-public-offering-of-common-shares-mrus-20230809monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-second-quarter-2023-and-provides-business-update-mrus-20230807monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-two-clinical-abstracts-on-zenocutuzumab-zeno-in-nrg1-fusion-nrg1-non-small-mrus-20230728monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-appoints-life-sciences-strategic-and-financial-industry-veteran-greg-perry-as-chief--mrus-20230615monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-a-fireside-chat-at-the-jefferies-healthcare-conference-2023-mrus-20230531monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-first-quarter-2023-and-provides-business-update-mrus-20230504monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-petosemtamab-interim-data-demonstrates-clinically-meaningful-activity-in-previously--mrus-20230417monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-publication-of-an-abstract-on-petosemtamab-in-advanced-gastric-esophageal--mrus-20230414monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-petosemtamab-in-previously-treated-head-and-neck-squamous-cell-carcinoma-a-mrus-20230314monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-publication-of-an-abstract-on-preclinical-mechanism-of-action-of-mcla-129--mrus-20230314monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-fourth-quarter-and-full-year-2022-and-provides-b-mrus-20230228monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-upcoming-investor-conferences-mrus-20230201monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-provides-2023-outlook-mrus-20230108monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-a-fireside-chat-at-the-stifel-2022-healthcare-conference-mrus-20221109monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-third-quarter-and-provides-business-update-mrus-20221103monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-presents-first-in-human-data-on-mcla-129-at-the-34th-eortc-nci-aacr-ena-symposium-on-mrus-20221026monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-publication-of-abstract-on-mcla-129-at-the-34th-eortc-nci-aacr-ena-symposi-mrus-20221012monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-poster-presentation-on-mcla-129-at-the-34th-eortc-nci-aacr-symposium-on-mo-mrus-20220907monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-a-panel-discussion-at-citi-s-17th-annual-biopharma-conference-mrus-20220901monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-second-quarter-and-provides-business-update-mrus-20220808monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-presents-clinical-data-on-zenocutuzumab-zeno-in-nrg1-fusion-nrg1-cancer-at-the-2022--mrus-20220605monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-a-fireside-chat-at-the-jefferies-healthcare-conference-mrus-20220603monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-publication-of-abstract-of-zenocutuzumab-in-nrg1-fusion-nrg1-cancer-at-the-mrus-20220526monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-the-h-c-wainwright-global-investment-conference-mrus-20220517monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-first-quarter-2022-and-provides-business-update-mrus-20220509monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-publication-in-nature-cancer-on-petosemtamab-s-mcla-158-unique-mechanism-o-mrus-20220425monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-presents-preclinical-data-on-mcla-129-at-the-american-association-for-cancer-researc-mrus-20220408monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-a-fireside-chat-at-the-21st-annual-needham-virtual-healthcare-conf-mrus-20220406monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-publication-of-abstract-on-mcla-129-at-the-american-association-for-cancer-mrus-20220308monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-fourth-quarter-and-full-year-2021-and-provides-b-mrus-20220228monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-upcoming-investor-conferences-mrus-20220203monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-appoints-shannon-campbell-as-chief-commercial-officer-and-regains-worldwide-rights-t-mrus-20220125monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-presents-updated-analysis-of-zenocutuzumab-trastuzumab-and-vinorelbine-in-patients-w-mrus-20211210monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-presents-clinical-data-on-mcla-145-at-the-esmo-immuno-oncology-congress-2021-mrus-20211206monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-poster-presentation-on-clinical-data-on-mcla-145-at-the-esmo-immuno-oncolo-mrus-20211202monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-a-fireside-chat-at-the-jefferies-london-healthcare-conference-virt-mrus-20211110monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-pricing-of-public-offering-of-common-shares-mrus-20211105monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-n-v-announces-proposed-public-offering-of-common-shares-mrus-20211104monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-regulatory-update-on-zenocutuzumab-financial-results-for-the-third-quarter-mrus-20211102monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-presents-early-clinical-data-on-mcla-158-and-preclinical-data-on-zenocutuzumab-at-th-mrus-20211007monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-poster-presentations-on-zenocutuzumab-and-mcla-158-at-the-aacr-nci-eortc-v-mrus-20210930monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-upcoming-investor-conferences-mrus-20210907monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-second-quarter-and-provides-business-update-mrus-20210805monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-publication-in-nature-communications-on-mcla-145-s-novel-mechanism-of-acti-mrus-20210721monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-william-blair-s-biotech-focus-conference-2021-mrus-20210707monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-presents-clinical-data-on-zenocutuzumab-in-nrg1-fusion-nrg1-cancers-at-the-american--mrus-20210604monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-a-fireside-chat-at-the-jefferies-virtual-healthcare-conference-mrus-20210526monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-publication-of-abstract-on-zenocutuzumab-in-nrg1-fusion-nrg1-cancers-at-th-mrus-20210519monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-collaborations-in-israel-italy-and-spain-to-increase-screening-and-identif-mrus-20210513monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-a-fireside-chat-at-the-2021-rbc-capital-markets-global-healthcare--mrus-20210511monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-first-quarter-and-provides-business-update-mrus-20210506monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-first-patient-treated-in-phase-1-2-clinical-trial-of-mcla-129-in-advanced--mrus-20210503monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-fourth-quarter-and-full-year-2020-and-provides-b-mrus-20210316monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-poster-presentations-for-zenocutuzumab-and-mcla-129-at-the-american-associ-mrus-20210310monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-a-fireside-chat-at-the-33rd-annual-roth-conference-mrus-20210308monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-upcoming-investor-conferences-mrus-20210201monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-pricing-of-public-offering-of-common-shares-mrus-20210121monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-n-v-announces-proposed-public-offering-of-common-shares-mrus-20210119monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-collaborations-with-nationwide-medical-organizations-in-the-netherlands-an-mrus-20210112monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-presentation-of-phase-1-clinical-data-for-mcla-158-at-the-american-society-mrus-20210111monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-granted-fda-fast-track-designation-of-zenocutuzumab-for-the-treatment-of-patients-wi-mrus-20210107monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-and-sema4-enter-into-an-agreement-to-support-merus-phase-1-2-clinical-trial-of-zenoc-mrus-20201217monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-the-jefferies-virtual-london-healthcare-conference-mrus-20201116monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-poster-presentations-on-mcla-145-at-society-for-immunotherapy-of-cancer-mrus-20201109monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-third-quarter-and-provides-business-update-mrus-20201105monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-global-investments-expands-its-florida-trading-operations-to-miami-adds-veteran-trad-mrus-20201015monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-and-mytomorrows-announce-expansion-of-collaboration-for-screening-and-enrgy-clinical-mrus-20201012monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-the-2020-wedbush-pacgrow-healthcare-conference-mrus-20200807monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-second-quarter-and-provides-business-update-mrus-20200806monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-fda-orphan-drug-designation-of-zenocutuzumab-for-the-treatment-of-pancreat-mrus-20200727monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-appoints-andrew-joe-m-d-as-chief-medical-officer-mrus-20200727monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-and-caris-life-sciences-announce-collaboration-to-detect-nrg1-fusions-in-cancer-pati-mrus-20200713monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-fireside-chat-at-the-jefferies-virtual-healthcare-conference-mrus-20200601monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-the-acceptance-of-six-abstracts-at-upcoming-medical-conferences-and-provid-mrus-20200514monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-first-quarter-and-provides-business-update-mrus-20200511monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-fourth-quarter-and-full-year-2019-and-provides-b-mrus-20200312monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-chief-executive-officer-transition-mrus-20191216monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-third-quarter-2019-and-provides-business-update-mrus-20191112monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-pricing-of-public-offering-of-common-shares-mrus-20191105monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-n-v-announces-proposed-underwritten-public-offering-of-common-shares-mrus-20191104monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-bispecific-antibody-mcla-128-shows-encouraging-early-clinical-activity-in-patients-w-mrus-20191027monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-presentation-and-poster-on-mcla-128-and-mcla-129-programs-at-the-aacr-nci--mrus-20191025monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-second-quarter-2019-and-provides-business-update-mrus-20190819monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-the-jefferies-2019-healthcare-conference-mrus-20190603monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-first-quarter-2019-and-provides-business-update-mrus-20190530monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-2019-annual-general-meeting-of-shareholders-mrus-20190523monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-the-rbc-capital-markets-2019-healthcare-conference-mrus-20190520monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-first-patient-treated-in-phase-1-clinical-trial-of-mcla-145-for-advanced-s-mrus-20190509monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-full-year-2018-and-provides-business-update-mrus-20190403monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-and-incyte-present-mcla-145-program-preclinical-data-at-the-aacr-annual-meeting-2019-mrus-20190401monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-the-cowen-co-39th-annual-health-care-conference-mrus-20190311monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-guggenheim-healthcare-talks-idea-forum-mrus-20190207monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-ind-clearance-for-mcla-145-mrus-20190107monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-strategic-collaboration-with-betta-pharmaceuticals-to-develop-and-commerci-mrus-20190102monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-third-quarter-2018-and-provides-business-update-mrus-20181227monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-global-settlement-and-end-to-all-patent-litigation-with-regeneron-pharmace-mrus-20181220monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-the-jefferies-2018-london-healthcare-conference-mrus-20181108monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-mrus-20180927monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-strengthens-team-with-key-appointments-mrus-20180927monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-citi-s-13th-annual-biotech-conference-mrus-20180830monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-formation-of-a-scientific-advisory-board-mrus-20180822monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-financial-results-for-the-second-quarter-2018-mid-year-operating-results-mrus-20180810monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-the-2018-wedbush-pacgrow-healthcare-conference-mrus-20180807monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-recent-corporate-developments-and-financial-results-for-the-first-quarter--mrus-20180726monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-annual-meeting-of-shareholders-mrus-20180705monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-the-jefferies-2018-healthcare-conference-mrus-20180531monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-first-patient-dosed-in-phase-1-clinical-trial-of-mcla-158-in-patients-with-mrus-20180524monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-unique-mechanism-of-action-of-mcla-128-that-potently-blocks-her3-signaling-mrus-20180515monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-recent-corporate-developments-and-financial-results-for-the-fourth-quarter-mrus-20180426monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-report-full-year-2017-financial-results-and-corporate-developments-on-april-26-20-mrus-20180419monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-and-the-vall-d-hebron-institute-of-oncology-announce-research-collaboration-to-devel-mrus-20180320monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-ono-pharmaceuticals-exercise-of-its-option-for-new-research-and-license-ag-mrus-20180314monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-intellectual-property-portfolio-expands-with-two-new-patents-mrus-20180313monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-the-cowen-co-38th-annual-health-care-conference-mrus-20180306monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-55-8-million-private-placement-offering-of-common-stock-mrus-20180214monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-participation-in-four-investor-conferences-in-february-2018-mrus-20180205monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-first-patient-dosed-in-a-phase-2-clinical-trial-of-mcla-128-in-two-metasta-mrus-20180126monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-global-investments-expands-business-by-establishing-florida-office-adding-veteran-tr-mrus-20180125monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-and-simcere-announce-strategic-collaboration-on-multiple-bispecific-antibodies-mrus-20180108monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-provides-clinical-updates-for-mcla-117-and-mcla-158-programs-mrus-20180104monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-mrus-20180102monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-the-u-s-court-of-appeals-for-the-federal-circuit-denies-regeneron-s-petiti-mrus-20171227monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-third-quarter-2017-financial-results-and-clinical-highlights-mrus-20171130monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-the-jefferies-london-healthcare-conference-mrus-20171109monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-the-bio-investor-forum-mrus-20171010monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-intellectual-property-portfolio-expands-with-two-new-patents-for-its-biclonics-techn-mrus-20170920monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-second-quarter-2017-financial-results-and-highlights-recent-progress-mrus-20170919monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-two-investor-conferences-in-september-2017-mrus-20170830monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-the-2017-wedbush-pacgrow-healthcare-conference-mrus-20170809monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-first-quarter-2017-financial-results-and-mid-year-operating-results-mrus-20170711monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-report-first-quarter-2017-financial-mid-year-operating-results-on-july-11-2017-mrus-20170706monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-the-jefferies-2017-global-healthcare-conference-mrus-20170601monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-promising-results-from-mcla-128-phase-1-2-study-in-metastatic-breast-cance-mrus-20170517monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-annual-meeting-of-shareholders-mrus-20170509monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-fourth-quarter-and-full-year-2016-financial-results-and-corporate-developm-mrus-20170428monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-data-from-a-phase-1-2-study-of-mcla-128-to-be-presented-at-the-2017-americ-mrus-20170420monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-named-biocapital-europe-2017-company-of-the-year-mrus-20170316monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-the-cowen-co-37th-annual-health-care-conference-mrus-20170227monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-the-leerink-partners-6th-annual-global-healthcare-conference-mrus-20170209monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-closing-of-global-strategic-research-collaboration-with-incyte-to-discover-mrus-20170123monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-and-the-institute-for-research-in-biomedicine-irb-barcelona-form-research-collaborat-mrus-20170105monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-favorable-decisions-in-europe-and-japan-for-patents-covering-genetically-m-mrus-20161115monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-the-jefferies-london-healthcare-conference-mrus-20161110monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-n-v-receives-1-5-million-eureka-eurostars-grant-with-aquila-biomedical-ltd-to-jointl-mrus-20161109monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-third-quarter-2016-financial-results-and-corporate-developments-mrus-20161107monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-strengthens-executive-management-team-with-the-appointment-of-john-crowley-as-chief--mrus-20161103monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-expands-executive-management-team-with-the-appointment-of-l-andres-sirulnik-md-phd-a-mrus-20161026monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-receives-milestone-payment-from-ono-pharmaceutical-for-selection-of-bispecific-antib-mrus-20161019monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-participate-in-upcoming-investor-conferences-mrus-20160831monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-at-the-2016-wedbush-pacgrow-healthcare-conference-mrus-20160810monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-second-quarter-2016-financial-results-and-reviews-recent-clinical-progress-mrus-20160808monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-first-quarter-2016-financial-results-and-highlights-recent-clinical-progre-mrus-20160712monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-n-v-signs-commercial-multi-product-license-for-probiogen-s-glymaxx-adcc-enhancement--mrus-20160601monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-n-v-announces-closing-of-partial-exercise-of-underwriters-over-allotment-option-mrus-20160531monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-n-v-announces-closing-of-initial-public-offering-mrus-20160524monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-n-v-nasdaq-mrus-to-ring-the-nasdaq-stock-market-closing-bell-in-celebration-of-ipo-mrus-20160519monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-pricing-of-initial-public-offering-mrus-20160519monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-first-patient-dosed-in-phase-1-2-trial-evaluating-bispecific-antibody-cand-mrus-20160504monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-to-present-interim-clinical-data-from-ongoing-phase-1-2-clinical-trial-of-its-lead-b-mrus-20160415monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-issuance-of-three-u-s-patents-strengthening-its-biclonics-technology-platf-mrus-20160309monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-and-gustave-roussy-form-strategic-collaboration-to-develop-innovative-bispecific-ant-mrus-20160104monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-appoints-hui-liu-as-chief-business-officer-mrus-20151216monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-announces-final-ruling-in-inequitable-conduct-case-against-regeneron-mrus-20151103monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-labs-international-inc-enters-into-a-bought-deal-for-gross-proceeds-of-c-60-million-mrus-20150413monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-labs-international-inc-announces-20-million-bought-deal-financing-mrus-20140313monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-labs-and-envoy-update-shareholder-meeting-matters-mrus-20111208monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-reports-first-quarter-2025-financial-results-and-recent-business-highlights-trml-20250502monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-busi-trml-20250313monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-highlights-cardiovascular-inflammation-focus-and-announces-key-clinical-and-trml-20241210monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-to-host-investor-day-on-tuesday-december-10-2024-trml-20241114monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-reports-third-quarter-2024-financial-results-and-recent-business-highlights-trml-20241107monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-to-present-at-upcoming-investor-conferences-trml-20241031monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-to-host-expert-webinar-on-human-genetic-validation-for-il-6-inhibition-in-c-trml-20241015monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-to-showcase-two-poster-presentations-at-the-2024-cardiometabolic-health-con-trml-20241011monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-announces-formation-of-cardiovascular-scientific-advisory-board-trml-20241008monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-to-present-at-upcoming-investor-conferences-trml-20240903monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-reports-second-quarter-2024-financial-results-and-recent-business-highlight-trml-20240808monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-presents-phase-2-tranquility-study-design-at-american-society-of-preventive-trml-20240802monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-announces-the-promotion-of-ryan-robinson-to-chief-financial-officer-trml-20240627monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-to-present-at-the-jefferies-global-healthcare-conference-trml-20240523monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-initiates-clinical-development-of-tour006-for-cardiovascular-diseases-with--trml-20240516monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-reports-first-quarter-2024-financial-results-and-recent-business-highlights-trml-20240513monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-busi-trml-20240319monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-to-present-at-upcoming-investor-conferences-trml-20240227monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-to-present-at-the-guggenheim-healthcare-talks-6th-annual-biotechnology-conf-trml-20240201monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-announces-closing-of-172-5-million-public-offering-of-common-stock-includin-trml-20240129monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-announces-pricing-of-public-offering-of-common-stock-trml-20240125monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-announces-proposed-public-offering-of-common-stock-trml-20240124monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-announces-expected-upcoming-key-milestones-for-the-clinical-development-of--trml-20240108monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-added-to-the-nasdaq-biotechnology-index-trml-20231215monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-appoints-dr-clay-siegall-as-chairman-of-the-board-trml-20231214monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-to-present-at-upcoming-investor-conferences-trml-20231101monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-announces-closing-of-merger-with-talaris-therapeutics-and-concurrent-privat-trml-20231019monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-appoints-gerhard-hagn-as-svp-head-of-commercial-and-business-development-trml-20230920monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-announces-fda-clearance-of-investigational-new-drug-ind-application-for-tou-trml-20230828monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-and-times-pharmacy-announce-partnership-to-offer-heplisav-b-hepatitis-b-vaccine-to-dvax-20200710monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-h-c-wainwright-virtual-fireside-chat-series-dvax-20200622monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-first-participants-dosed-in-phase-1-clinical-trial-evaluating-clover-bio-dvax-20200619monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-completes-enrollment-of-clinical-trial-evaluating-heplisav-b-in-patients-undergoin-dvax-20200609monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-william-blair-40th-annual-growth-stock-conference-dvax-20200528monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-technologies-announces-closing-of-80-5-million-public-offering-of-common-stock-and-dvax-20200527monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-technologies-announces-pricing-of-70-0-million-public-offering-of-common-stock-dvax-20200522monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-technologies-announces-proposed-public-offering-of-common-stock-dvax-20200521monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-first-quarter-2020-financial-results-dvax-20200507monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-interim-analysis-of-ongoing-clinical-trial-evaluating-heplisav-b-in-patien-dvax-20200428monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-first-quarter-2020-financial-results-and-host-conference-call-on-may-7-2-dvax-20200423monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-and-sinovac-announce-collaboration-to-develop-a-coronavirus-covid-19-vaccine-dvax-20200416monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-donates-10-000-doses-of-heplisav-b-hepatitis-b-vaccine-recombinant-adjuvanted-vacc-dvax-20200408monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-provides-business-update-on-covid-19-pandemic-impact-dvax-20200402monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-and-cepi-announce-collaboration-to-support-global-effort-to-develop-a-vaccine-for--dvax-20200326monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-and-clover-biopharmaceuticals-announce-research-collaboration-to-evaluate-coronavi-dvax-20200324monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-fourth-quarter-and-full-year-2019-financial-results-dvax-20200311monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-collaboration-with-the-university-of-queensland-and-the-coalition-for-ep-dvax-20200302monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-fourth-quarter-and-full-year-2019-financial-results-and-host-conference--dvax-20200224monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-cowen-40th-annual-health-care-conference-dvax-20200218monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-appoints-ryan-spencer-as-chief-executive-officer-and-to-board-of-directors-dvax-20191216monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-partnership-with-albertsons-companies-pharmacies-to-offer-heplisav-b-hep-dvax-20191205monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-heplisav-b-post-marketing-requirement-interim-report-completed-dvax-20191203monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-stifel-2019-healthcare-conference-dvax-20191107monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-third-quarter-2019-financial-results-dvax-20191106monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-third-quarter-2019-financial-results-and-host-conference-call-on-novembe-dvax-20191024monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-2019-cantor-global-healthcare-conference-dvax-20190930monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-andrew-hack-m-d-ph-d-has-joined-board-of-directors-dvax-20190812monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-technologies-announces-pricing-of-70-1-million-public-offering-of-common-stock-non-dvax-20190808monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-technologies-announces-proposed-public-offering-of-common-stock-non-voting-preferr-dvax-20190807monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-second-quarter-2019-financial-results-dvax-20190807monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-technologies-to-report-second-quarter-2019-financial-results-and-host-conference-c-dvax-20190724monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-william-blair-co-annual-growth-stock-conference-dvax-20190603monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-presents-phase-2-data-on-sd-101-in-combination-with-keytruda-pembrolizumab-for-pat-dvax-20190601monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-strategic-restructuring-to-focus-on-its-vaccine-business-dvax-20190523monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-first-quarter-2019-financial-results-dvax-20190508monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-first-patient-enrolled-in-study-of-heplisav-b-hepatitis-b-vaccine-recomb-dvax-20190502monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-technologies-to-report-first-quarter-2019-financial-results-and-host-conference-ca-dvax-20190425monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-data-on-toll-like-receptor-9-agonist-sd-101-at-the-asco-annual-meeting--dvax-20190418monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-presents-phase-1b-data-on-inhaled-dv281-tlr9-agonist-at-the-2019-aacr-annual-meeti-dvax-20190402monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-s-sd-101-and-4sc-s-domatinostat-demonstrate-synergy-and-induce-a-systemic-anti-tum-dvax-20190401monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-european-medicines-agency-accepts-marketing-authorization-application-fo-dvax-20190328monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-on-inhaled-tlr9-agonist-dv281-at-the-aacr-annual-meeting-2019-dvax-20190320monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-exercises-option-for-75-million-in-non-dilutive-debt-dvax-20190318monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-39th-annual-cowen-healthcare-conference-dvax-20190306monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-fourth-quarter-and-full-year-2018-financial-results-dvax-20190226monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-technologies-to-report-fourth-quarter-and-full-year-2018-financial-results-and-hos-dvax-20190212monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-37th-annual-j-p-morgan-healthcare-conference-dvax-20190103monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-third-quarter-2018-financial-results-progress-on-heplisav-b-launch-and-upd-dvax-20181105monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-host-third-quarter-2018-financial-results-conference-call-dvax-20181029monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-s-sd-101-in-combination-with-keytruda-pembrolizumab-continues-to-show-a-70-overall-dvax-20181020monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-technologies-and-quantum-leap-healthcare-collaborative-announce-selection-of-sd-10-dvax-20181015monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-new-data-for-sd-101-in-combination-with-keytruda-pembrolizumab-at-the-e-dvax-20181009monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-2018-cantor-global-healthcare-conference-dvax-20180927monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-publication-of-preclinical-study-of-tlr9-agonist-in-lung-cancer-dvax-20180904monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-publication-of-two-papers-in-leading-oncology-journal-highlighting-data--dvax-20180828monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-second-quarter-2018-financial-results-dvax-20180806monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-host-second-quarter-2018-financial-results-conference-call-dvax-20180730monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-appoints-scientific-advisory-board-to-support-its-oncology-and-vaccine-programs-dvax-20180628monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-presents-analysis-of-data-for-participants-aged-60-to-70-with-diabetes-from-its-ph-dvax-20180625monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-william-blair-38th-annual-growth-stock-conference-dvax-20180611monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-data-for-phase-1b-2-trial-of-sd-101-in-combination-with-keytruda-pembroliz-dvax-20180604monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-new-data-for-sd-101-in-combination-with-keytruda-pembrolizumab-at-the-2-dvax-20180516monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-first-quarter-2018-financial-results-dvax-20180508monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-technologies-corporation-announces-inducement-grants-under-nasdaq-listing-rule-563-dvax-20180507monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-host-first-quarter-2018-financial-results-conference-call-dvax-20180502monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-s-heplisav-b-acip-recommendations-published-in-the-cdc-s-morbidity-and-mortality-w-dvax-20180423monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-provides-new-durability-of-response-data-for-sd-101-in-combination-with-keytruda-p-dvax-20180417monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-interim-data-for-sd-101-in-combination-with-keytruda-pembrolizumab-in-pati-dvax-20180416monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-technologies-corporation-announces-inducement-grants-under-nasdaq-listing-rule-563-dvax-20180403monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-acceptance-of-two-data-abstracts-for-sd-101-in-combination-with-keytruda-dvax-20180315monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-fourth-quarter-and-year-end-2017-financial-results-dvax-20180308monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-cowen-co-annual-health-care-conference-dvax-20180305monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-technologies-corporation-announces-inducement-grants-under-nasdaq-listing-rule-563-dvax-20180301monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-s-heplisav-b-hepatitis-b-vaccine-recombinant-adjuvanted-recommended-by-cdc-advisor-dvax-20180221monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-secures-175-million-in-non-dilutive-debt-financing-dvax-20180220monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-rbc-capital-markets-global-healthcare-conference-dvax-20180214monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-technologies-corporation-announces-inducement-grants-under-nasdaq-listing-rule-563-dvax-20180202monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-technologies-corporation-announces-inducement-grants-under-nasdaq-listing-rule-563-dvax-20180112monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-heplisav-b-is-now-available-in-the-united-states-for-the-prevention-of-h-dvax-20180108monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-j-p-morgan-36th-annual-healthcare-conference-dvax-20180104monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-technologies-corporation-announces-inducement-grants-under-nasdaq-listing-rule-563-dvax-20171205monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-evercore-isi-biopharma-catalyst-deep-dive-conference-dvax-20171127monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-fda-approval-of-heplisav-b-tm-for-prevention-of-hepatitis-b-in-adults-dvax-20171109monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-third-quarter-2017-financial-results-dvax-20171103monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-initiates-clinical-trial-in-non-small-cell-lung-cancer-with-a-novel-inhaled-tlr9-a-dvax-20171019monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-upcoming-investor-conferences-dvax-20170905monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-exercise-in-full-of-over-allotment-option-and-completion-of-public-offer-dvax-20170815monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-prices-public-offering-of-common-stock-dvax-20170810monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-proposed-public-offering-of-common-stock-dvax-20170808monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-provides-u-s-regulatory-update-on-heplisav-b-tm-following-fda-advisory-committee-m-dvax-20170803monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-second-quarter-2017-financial-results-dvax-20170802monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-fda-advisory-committee-vote-in-favor-of-heplisav-b-tm-dvax-20170728monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-presents-updated-data-for-sd-101-in-combination-with-keytruda-r-pembrolizumab-high-dvax-20170602monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-data-on-sd-101-in-combination-with-keytruda-r-at-the-2017-american-soci-dvax-20170519monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-first-quarter-2017-financial-results-dvax-20170508monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-fda-advisory-committee-meeting-to-review-heplisav-b-dvax-20170403monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-upcoming-data-presentations-for-three-tlr9-agonist-programs-at-the-2017--dvax-20170320monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-fourth-quarter-and-year-end-2016-financial-results-and-company-update-dvax-20170313monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-presents-promising-clinical-data-from-lead-immuno-oncology-candidate-sd-101-at-the-dvax-20170306monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-cowen-and-company-37th-annual-health-care-conference-dvax-20170302monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-fda-acceptance-for-review-of-its-complete-response-to-november-2016-crl--dvax-20170228monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-2017-rbc-capital-markets-global-healthcare-conference-dvax-20170216monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-j-p-morgan-35th-annual-healthcare-conference-dvax-20170109monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-restructures-and-emphasizes-immuno-oncology-program-dvax-20170105monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-presents-clinical-data-from-lead-cancer-immunotherapy-candidate-sd-101-in-combinat-dvax-20161205monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-webcast-cancer-r-d-day-on-december-9-2016-dvax-20161201monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-clinical-data-from-immuno-oncology-product-candidate-sd-101-dvax-20161130monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-receives-complete-response-letter-from-u-s-food-and-drug-administration-for-biolog-dvax-20161114monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-presents-early-clinical-data-from-lead-cancer-immunotherapy-candidate-sd-101-at-so-dvax-20161109monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-third-quarter-2016-financial-results-and-company-update-dvax-20161107monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-secures-committed-financing-from-deerfield-for-100-million-of-senior-secured-notes-dvax-20161027monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-presents-data-showing-that-heplisav-b-provides-significantly-higher-seroprotection-dvax-20161026monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-presents-early-clinical-data-from-lead-cancer-immunotherapy-candidate-sd-101-at-es-dvax-20161009monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-provides-regulatory-update-on-heplisav-b-dvax-20160905monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-second-quarter-2016-financial-results-dvax-20160805monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-fda-advisory-committee-meeting-to-review-heplisav-b-dvax-20160805monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-presents-new-efficacy-data-on-hepatitis-b-vaccine-heplisav-b-tm-in-adults-with-typ-dvax-20160611monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-two-upcoming-investor-conferences-dvax-20160518monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-first-quarter-2016-financial-results-dvax-20160509monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-receives-notification-of-pdufa-extension-for-heplisav-b-to-december-15-2016-dvax-20160427monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-presents-pivotal-phase-3-data-showing-heplisav-b-tm-provides-significantly-higher--dvax-20160418monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-presents-encouraging-data-from-clinical-trial-of-immuno-oncology-product-candidate-dvax-20160418monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-data-from-pivotal-phase-3-heplisav-b-tm-trial-dvax-20160404monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-fda-acceptance-for-review-of-biologics-license-application-and-pdufa-act-dvax-20160330monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-data-presentations-at-aacr-annual-meeting-dvax-20160317monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-fourth-quarter-and-year-end-2015-financial-results-dvax-20160308monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-participate-in-the-cowen-and-company-36th-annual-health-care-conference-dvax-20160302monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-participate-in-2016-rbc-capital-markets-global-healthcare-conference-dvax-20160217monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-and-astrazeneca-amend-their-agreement-for-asthma-drug-candidate-dvax-20160119monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-j-p-morgan-34th-annual-healthcare-conference-dvax-20160111monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-top-line-results-of-phase-3-heplisav-b-tm-study-dvax-20160107monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-host-webcast-conference-call-tomorrow-to-review-heplisav-b-tm-phase-3-clinical--dvax-20160106monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-presents-clinical-data-from-lead-cancer-immunotherapy-candidate-sd-101-at-ash-annu-dvax-20151205monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-presentation-of-clinical-data-at-ash-annual-meeting-dvax-20151130monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-third-quarter-2015-financial-results-dvax-20151105monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-initiates-immuno-oncology-clinical-trial-evaluating-sd-101-in-combination-with-mer-dvax-20151008monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-participate-in-two-upcoming-investor-conferences-dvax-20150903monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-second-quarter-2015-financial-results-dvax-20150807monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-exercise-in-full-of-over-allotment-option-and-completion-of-public-offer-dvax-20150728monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-prices-public-offering-of-common-stock-dvax-20150722monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-proposed-public-offering-of-common-stock-dvax-20150721monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-third-independent-dsmb-recommendation-to-continue-phase-3-study-of-hepli-dvax-20150709monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-william-blair-35th-annual-growth-stock-health-care-conference-dvax-20150609monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-first-quarter-2015-financial-results-dvax-20150507monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-fourth-quarter-and-year-end-2014-financial-results-dvax-20150305monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-second-independent-dsmb-recommendation-to-continue-phase-3-study-of-hepl-dvax-20150302monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-cowen-and-company-35th-annual-health-care-conference-dvax-20150227monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-2015-rbc-capital-markets-global-healthcare-conference-dvax-20150219monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-laura-brege-has-joined-board-of-directors-and-denise-gilbert-will-retire-dvax-20150206monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-33rd-annual-j-p-morgan-healthcare-conference-dvax-20150112monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-secures-40-million-credit-facility-with-hercules-technology-growth-capital-dvax-20141229monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-webcast-of-r-d-day-dvax-20141209monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-and-astrazeneca-to-advance-tlr9-agonist-for-treatment-of-asthma-into-phase-2a-clin-dvax-20141208monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-regains-full-rights-to-investigational-tlr-7-9-inhibitor-dv1179-following-expirati-dvax-20141128monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-independent-dsmb-recommendation-to-continue-phase-3-study-of-heplisav-b--dvax-20141110monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-one-for-ten-reverse-stock-split-dvax-20141107monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-third-quarter-2014-financial-results-dvax-20141105monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-initiates-phase-1-2-study-of-tlr-9-agonist-immunotherapy-in-b-cell-lymphoma-dvax-20141013monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-resignation-of-dino-dina-from-board-of-directors-dvax-20141007monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-completes-enrollment-of-phase-3-study-of-heplisav-b-tm-dvax-20140922monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-second-quarter-2014-financial-results-and-safety-and-pharmacodynamic-resul-dvax-20140807monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-william-blair-2014-growth-stock-conference-dvax-20140609monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-jefferies-global-healthcare-conference-dvax-20140602monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-first-quarter-2014-financial-results-dvax-20140505monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-initiates-phase-3-study-of-heplisav-b-tm-dvax-20140415monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-fourth-quarter-and-year-end-2013-financial-results-dvax-20140310monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-receive-5-4-million-milestone-dvax-20140303monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-34th-annual-cowen-company-health-care-conference-dvax-20140228monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-withdrawal-of-european-marketing-application-for-heplisav-tm-dvax-20140218monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-32nd-annual-j-p-morgan-healthcare-conference-dvax-20140110monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-submission-of-responses-to-ema-day-120-list-of-questions-for-heplisav-tm-dvax-20131219monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-resignation-of-j-tyler-martin-from-board-of-directors-dvax-20131127monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-third-quarter-2013-financial-results-dvax-20131107monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-prices-public-offerings-of-common-stock-and-series-b-convertible-preferred-stock-dvax-20131025monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-proposed-public-offerings-of-common-stock-and-series-b-convertible-prefe-dvax-20131024monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-on-heplisav-tm-regulatory-path-dvax-20131016monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-initiates-first-human-trial-in-asthma-program-dvax-20131009monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-second-quarter-2013-financial-results-dvax-20130729monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-appoints-robert-janssen-m-d-as-chief-medical-officer-dvax-20130711monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-appoints-natale-ricciardi-to-its-board-of-directors-dvax-20130708monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-jmp-securities-healthcare-conference-dvax-20130702monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-chief-scientific-officer-awarded-prestigious-immunology-prize-dvax-20130619monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-william-blair-33rd-annual-growth-stock-conference-dvax-20130611monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-feedback-from-fda-meeting-regarding-heplisav-tm-biologic-license-applicati-dvax-20130610monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-first-quarter-2013-financial-results-dvax-20130506monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-names-eddie-gray-as-chief-executive-officer-and-member-of-the-board-of-directors-dvax-20130430monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-appoints-david-novack-as-senior-vice-president-operations-and-quality-dvax-20130321monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-fourth-quarter-and-year-end-2012-financial-results-dvax-20130301monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-cowen-and-company-33rd-annual-healthcare-conference-dvax-20130226monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-receives-fda-complete-response-letter-on-heplisav-tm-biologic-license-application-dvax-20130225monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-31st-annual-j-p-morgan-healthcare-conference-dvax-20121217monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-fda-advisory-committee-meeting-outcome-for-heplisav-tm-dvax-20121115monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-third-quarter-2012-financial-results-dvax-20121101monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-initiate-phase-1-studies-for-tlr-9-agonist-for-asthma-dvax-20121031monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-fda-advisory-committee-to-review-heplisav-tm-dvax-20120828monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-marketing-authorization-application-for-heplisav-tm-accepted-for-review-by-europea-dvax-20120822monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-appoints-christine-larson-as-chief-financial-officer-dvax-20120813monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-second-quarter-2012-financial-results-dvax-20120801monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-submits-heplisav-tm-for-eu-marketing-authorization-dvax-20120724monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-appoints-david-happel-vice-president-global-sales-and-marketing-dvax-20120710monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-7th-annual-jmp-securities-healthcare-conference-dvax-20120709monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-new-cpt-code-for-adult-two-dose-hepatitis-b-vaccination-schedule-dvax-20120702monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-fda-acceptance-of-heplisav-tm-bla-dvax-20120626monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-jefferies-2012-global-healthcare-conference-dvax-20120529monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-prices-public-offering-of-common-stock-dvax-20120509monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-proposed-public-offering-of-common-stock-dvax-20120508monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-embarks-on-transition-to-commercialization-dvax-20120508monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-first-quarter-2012-financial-results-dvax-20120427monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-heplisav-tm-bla-submission-dvax-20120426monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-final-phase-3-data-for-heplisav-tm-in-ckd-patients-and-new-data-from-boost-dvax-20120327monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-fourth-quarter-and-year-end-2011-financial-results-dvax-20120306monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-two-upcoming-investor-healthcare-conferences-dvax-20120214monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-on-heplisav-tm-pre-bla-meeting-with-fda-dvax-20120202monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-and-astrazeneca-agree-to-conduct-toxicology-studies-for-tlr-9-agonist-for-asthma-dvax-20111221monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-initiates-proof-of-mechanism-trial-in-lupus-patients-dvax-20111220monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-exercise-in-full-of-overallotment-option-and-completion-of-public-offeri-dvax-20111108monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-prices-public-offering-of-common-stock-dvax-20111103monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-proposed-public-offering-of-common-stock-dvax-20111102monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-confirms-heplisav-tm-submission-strategies-with-u-s-fda-and-ema-dvax-20111027monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-third-quarter-2011-financial-results-dvax-20111027monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-phase-3-data-in-chronic-kidney-disease-demonstrates-superiority-of-heplisav-tm-vs--dvax-20111027monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-and-glaxosmithkline-expand-their-worldwide-strategic-alliance-dvax-20111021monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-newsmakers-in-the-biotech-industry-conference-dvax-20111014monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-host-analyst-investor-day-webcast-october-27-2011-dvax-20111012monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-positive-immunogenicity-data-from-an-analysis-of-hypo-responsive-populatio-dvax-20111010monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-diabetic-subset-data-from-modified-intent-to-treat-analysis-of-the-heplisa-dvax-20111006monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-and-astrazeneca-to-advance-tlr-9-agonist-into-clinic-for-asthma-dvax-20111005monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-modified-intent-to-treat-analysis-from-the-heplisav-tm-phase-3-trial-in-he-dvax-20111003monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-complete-results-from-the-heplisav-tm-phase-3-trial-in-healthy-adults-over-dvax-20110918monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-additional-immunogenicity-data-for-heplisav-tm-phase-3-trial-dvax-20110916monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-ubs-global-life-sciences-conference-dvax-20110916monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-receives-600-000-sbir-grant-for-tlr-research-dvax-20110907monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-william-blair-company-s-2011-life-sciences-conference-dvax-20110901monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-wedbush-2011-life-sciences-conference-dvax-20110811monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-phase-3-demonstrates-superiority-and-safety-of-heplisav-tm-vs-engerix-b-r-dvax-20110720monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-second-quarter-2011-financial-results-dvax-20110720monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-conference-call-webcast-tomorrow-on-topline-phase-3-data-and-q2-financial-results-dvax-20110719monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-jefferies-2011-global-healthcare-conference-dvax-20110606monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-completes-phase-3-study-of-heplisav-tm-dvax-20110525monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-first-quarter-2011-financial-results-dvax-20110505monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-initiates-first-human-trial-in-lupus-program-dvax-20110420monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-fourth-quarter-and-year-end-2010-financial-results-dvax-20110308monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-cowen-healthcare-conference-dvax-20110303monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-s-two-phase-3-heplisav-trials-cleared-by-dsmb-to-continue-to-study-completion-dvax-20110223monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-additional-positive-phase-1b-immunogenicity-data-for-hepatitis-b-therapy-c-dvax-20110222monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-new-phase-1a-and-phase-1b-data-for-universal-flu-vaccine-candidate-dvax-20110222monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-completes-enrollment-for-phase-3-study-of-heplisav-tm-in-subjects-with-chronic-kid-dvax-20110110monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-phase-1b-safety-and-immunogenicity-results-for-hepatitis-b-therapy-candida-dvax-20101223monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-phase-1a-safety-and-immunogenicity-results-for-universal-flu-vaccine-dvax-20101207monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-new-employment-inducement-awards-dvax-20101112monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-2010-third-quarter-financial-results-dvax-20101104monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-exercise-in-full-of-overallotment-option-and-closing-of-public-offering--dvax-20101102monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-oppenheimer-healthcare-conference-dvax-20101101monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-prices-public-offering-of-common-stock-dvax-20101028monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-proposed-public-offering-of-common-stock-dvax-20101027monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-s-heplisav-demonstrates-superior-seroprotection-in-diabetics-compared-to-engerix-b-dvax-20101022monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-host-analyst-investor-day-webcast-october-29-2010-dvax-20101021monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-biocentury-newsmakers-conference-dvax-20101020monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-new-heplisav-tm-data-in-diabetics-dvax-20101011monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-s-heplisav-demonstrates-superior-seroprotection-in-diabetics-compared-to-engerix-b-dvax-20101004monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-s-two-phase-3-heplisav-trials-cleared-by-dsmb-to-continue-dvax-20100928monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-begins-phase-1b-study-for-universal-flu-vaccine-dvax-20100923monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-30-million-at-the-market-common-stock-purchase-agreement-dvax-20100920monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-ubs-global-life-sciences-conference-dvax-20100916monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-2010-second-quarter-financial-results-dvax-20100730monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-wedbush-life-sciences-conference-dvax-20100729monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-promotes-j-tyler-martin-m-d-to-president-dvax-20100727monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-completes-enrollment-and-first-immunizations-in-universal-flu-vaccine-study-dvax-20100727monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-new-employment-inducement-awards-dvax-20100723monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-appoints-daniel-kisner-m-d-to-board-of-directors-dvax-20100722monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-initiates-first-human-trial-in-universal-flu-vaccine-program-dvax-20100707monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-awarded-nih-grant-to-explore-feasibility-of-universal-papilloma-virus-vaccine-dvax-20100706monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-s-two-phase-3-heplisav-trials-cleared-by-dsmb-to-continue-immunizations-dvax-20100527monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-completes-over-2000-first-immunizations-in-phase-3-study-dvax-20100506monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-2010-first-quarter-financial-results-dvax-20100506monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-s-two-phase-3-heplisav-trials-cleared-by-dsmb-to-continue-immunizations-dvax-20100427monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-positive-data-on-universal-flu-vaccine-candidate-dvax-20100426monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-s-chronic-kidney-disease-study-confirms-heplisav-s-enhanced-seroprotection-against-dvax-20100414monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-raises-44-million-through-public-offering-of-common-stock-and-warrants-dvax-20100413monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-new-employment-inducement-awards-dvax-20100409monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-positive-findings-from-detailed-safety-analysis-of-heplisav-tm-dvax-20100323monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-anticipates-earlier-bla-submission-for-heplisav-tm-dvax-20100316monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-and-merck-agree-on-final-reimbursements-dvax-20100315monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-selects-clinical-candidate-in-universal-flu-vaccine-program-dvax-20100225monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-and-glaxosmithkline-select-clinical-candidate-in-the-endosomal-tlr-inhibitor-progr-dvax-20100218monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-receives-canadian-approval-to-conduct-phase-3-trials-of-heplisav-tm-dvax-20100216monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-initiates-large-scale-phase-3-trial-of-heplisav-tm-dvax-20100208monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-positive-phase-1b-data-for-sd-101-in-chronic-hepatitis-c-infection-dvax-20100126monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-expands-commercial-and-clinical-leadership-dvax-20100112monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-completes-symphony-dynamo-acquisition-dvax-20100104monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-s-european-manufacturing-facility-approved-for-commercial-production-of-heplisav-h-dvax-20091209monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-completes-enrollment-of-first-cohort-of-patients-in-phase-1b-clinical-trial-for-he-dvax-20091119monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-acquire-symphony-dynamo-inc-including-20-million-in-unrestricted-cash-dvax-20091110monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-implements-engineering-enhancements-to-silicon-28-enrichment-facility-success-aspi-20260526monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-to-host-business-update-conference-call-on-april-13-2026-at-8-00-am-et-aspi-20260410monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-to-participate-in-canaccord-genuity-s-2nd-annual-cg-virtual-sustainability-su-aspi-20260310monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-announces-establishment-of-quantum-leap-energy-strategic-advisory-board-bolst-aspi-20260219monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-announces-quantum-leap-energy-to-establish-global-headquarters-in-austin-tx-aspi-20260217monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-announces-endowment-of-new-photonics-chair-at-wits-university-to-advance-phot-aspi-20251128monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-issues-letter-to-shareholders-aspi-20250902monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-hosts-south-african-investors-in-advance-of-secondary-listing-on-the-joha-aspi-20250826monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-and-its-subsidiary-quantum-leap-energy-llc-enter-into-a-memorandum-of-und-aspi-20250815monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-announces-expected-commencement-of-dual-listing-on-johannesburg-stock-exc-aspi-20250808monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-and-isobio-inc-announce-series-seed-funding-of-isobio-inc-to-advance-inno-aspi-20250728monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-announces-pricing-of-60-million-underwritten-registered-direct-offering-o-aspi-20250723monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-announces-updates-on-the-progress-of-commercial-production-at-its-three-e-aspi-20250717monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-enhances-the-quantum-leap-energy-llc-qle-executive-leadership-team-with-t-aspi-20250611monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-to-host-investor-access-event-in-south-africa-from-june-16-18-2025-aspi-20250604monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-and-isotopia-announce-supply-agreement-for-gadolinium-160-to-accelerate-terbi-aspi-20250604monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-announces-pricing-of-50-million-underwritten-registered-direct-offering-o-aspi-20250602monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-issues-letter-to-shareholders-aspi-20250529monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-announces-an-agreement-relating-to-the-potential-acquisition-of-renergen--aspi-20250520monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-to-host-investor-webcast-on-tuesday-may-20-2025-at-8-00-a-m-est-aspi-20250519monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-enters-into-definitive-agreements-with-terrapower-including-loan-agreemen-aspi-20250519monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-announces-proposed-secondary-listing-on-the-johannesburg-stock-exchange-aspi-20250424monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-announces-changes-in-boards-of-asp-isotopes-inc-and-quantum-leap-energy-l-aspi-20250415monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-completes-commissioning-of-first-quantum-enrichment-laser-system-and-star-aspi-20250401monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-announces-fourth-quarter-and-fiscal-year-2024-financial-results-webinar-aspi-20250331monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-commences-commercial-production-of-enriched-silicon-28-at-its-second-aero-aspi-20250327monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-commences-commercial-production-of-enriched-carbon-14-at-its-first-aerody-aspi-20250226monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-to-present-at-canaccord-genuity-sustainability-summit-on-wednesday-februa-aspi-20250225monthly0.5https://www.biopharmawatch.com/news/ASPI/aspi-deadline-tomorrow-rosen-a-leading-investor-rights-law-firm-encourages-asp-isotopes-in-aspi-20250202monthly0.5https://www.biopharmawatch.com/news/ASPI/aspi-deadline-rosen-leading-investor-counsel-encourages-asp-isotopes-inc-investors-with-lo-aspi-20250130monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-accused-of-deceiving-investors-with-bogus-nuclear-tech-claims-hagens-ber-aspi-20250130monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-febr-aspi-20250129monthly0.5https://www.biopharmawatch.com/news/ASPI/aspi-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-asp-isotopes-inc-investo-aspi-20250129monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-class-action-the-gross-law-firm-reminds-asp-isotopes-inc-investors-of-the-aspi-20250129monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-continue-to-slump-despite-response-to-short-seller-report-hagens-berman-aspi-20250128monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-accused-of-deceiving-investors-with-bogus-nuclear-tech-claims-hagens-ber-aspi-20250127monthly0.5https://www.biopharmawatch.com/news/ASPI/aspi-deadline-alert-asp-isotopes-aspi-investors-with-losses-encouraged-to-contact-hagens-b-aspi-20250126monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-febr-aspi-20250124monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-continue-to-slump-despite-response-to-short-seller-report-hagens-berman-aspi-20250124monthly0.5https://www.biopharmawatch.com/news/ASPI/aspi-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-asp-isotopes-inc-investo-aspi-20250123monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-continue-to-slump-despite-response-to-short-seller-report-hagens-berman-aspi-20250122monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsk-aspi-20250122monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-continue-to-slump-despite-response-to-short-seller-report-hagens-berman-aspi-20250120monthly0.5https://www.biopharmawatch.com/news/ASPI/aspi-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-asp-isotopes-inc-investo-aspi-20250117monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-accused-of-deceiving-investors-with-bogus-nuclear-tech-claims-hagens-ber-aspi-20250117monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-continue-to-slump-despite-response-to-short-seller-report-hagens-berman-aspi-20250115monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-continue-to-slump-despite-response-to-short-seller-report-hagens-berman-aspi-20250113monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-hosts-investor-access-event-in-south-africa-providing-updates-on-its-sili-aspi-20250113monthly0.5https://www.biopharmawatch.com/news/ASPI/aspi-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-asp-isotopes-inc-investo-aspi-20250112monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-accused-of-deceiving-investors-with-bogus-nuclear-tech-claims-hagens-ber-aspi-20250110monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-class-action-lawsuit-alert-johnson-fistel-announces-shareholders-with-los-aspi-20250109monthly0.5https://www.biopharmawatch.com/news/ASPI/aspi-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-asp-isotopes-inc-investo-aspi-20250106monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-continue-to-slump-despite-response-to-short-seller-report-hagens-berman-aspi-20250106monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-continue-to-slump-despite-response-to-short-seller-report-hagens-berman-aspi-20250102monthly0.5https://www.biopharmawatch.com/news/ASPI/aspi-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-asp-isotopes-inc-investo-aspi-20241231monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-continue-to-slump-despite-response-to-short-seller-report-hagens-berman-aspi-20241230monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-befo-aspi-20241230monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-class-action-lawsuit-alert-johnson-fistel-announces-shareholders-with-los-aspi-20241230monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been--aspi-20241227monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-continue-to-slump-despite-response-to-short-seller-report-hagens-berman-aspi-20241226monthly0.5https://www.biopharmawatch.com/news/ASPI/aspi-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-asp-isotopes-inc-investo-aspi-20241225monthly0.5https://www.biopharmawatch.com/news/ASPI/aspi-stock-news-shareholder-rights-law-firm-robbins-llp-urges-asp-isotopes-inc-stockholder-aspi-20241224monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-accused-of-deceiving-investors-with-bogus-nuclear-tech-claims-hagens-ber-aspi-20241223monthly0.5https://www.biopharmawatch.com/news/ASPI/aspi-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-asp-isotopes-inc-investo-aspi-20241219monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-accused-of-deceiving-investors-with-bogus-nuclear-tech-claims-hagens-ber-aspi-20241219monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-class-action-levi-korsinsky-reminds-asp-isotopes-inc-investors-of-the-pen-aspi-20241219monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been--aspi-20241219monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-aspi-20241218monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-class-action-lawsuit-alert-johnson-fistel-announces-shareholders-with-los-aspi-20241217monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-accused-of-deceiving-investors-with-bogus-nuclear-tech-claims-hagens-ber-aspi-20241216monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-issues-letter-to-shareholders-aspi-20241216monthly0.5https://www.biopharmawatch.com/news/ASPI/aspi-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-asp-isotopes-inc-investo-aspi-20241213monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-responds-to-short-seller-report-aspi-20241213monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-accused-of-deceiving-investors-with-bogus-nuclear-tech-claims-hagens-ber-aspi-20241212monthly0.5https://www.biopharmawatch.com/news/ASPI/aspi-shareholder-alert-asp-isotopes-inc-sued-for-securities-fraud-investors-should-contact-aspi-20241211monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm--aspi-20241210monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been--aspi-20241210monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-febr-aspi-20241209monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-shareholder-notice-robbins-llp-reminds-investors-of-the-aspi-securities-c-aspi-20241209monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-class-action-lawsuit-alert-johnson-fistel-announces-shareholders-with-los-aspi-20241209monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-accused-of-deceiving-investors-with-bogus-nuclear-tech-claims-hagens-ber-aspi-20241209monthly0.5https://www.biopharmawatch.com/news/ASPI/aspi-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-asp-isotopes-inc-investo-aspi-20241206monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been--aspi-20241206monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-accused-of-deceiving-investors-with-bogus-nuclear-tech-claims-hagens-ber-aspi-20241205monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-alert-bragar-eagel-squire-p-c-is-investigating-asp-isotopes-inc-on-behalf-of--aspi-20241204monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-stock-tanks-after-scathing-short-seller-report-hagens-berman-aspi-20241202monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-to-host-investor-access-event-in-south-africa-from-january-14-16-2025-aspi-20241202monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-aspi-stock-tanks-after-scathing-short-seller-report-hagens-berman-aspi-20241126monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-responds-to-short-seller-report-aspi-20241126monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-completes-construction-and-starts-the-commissioning-of-silicon-28-enrichm-aspi-20241126monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-enters-into-memorandum-of-understanding-with-the-south-african-nuclear-en-aspi-20241114monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-announces-closing-of-public-offering-and-full-exercise-of-underwriter-s-optio-aspi-20241104monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-announces-pricing-of-public-offering-of-common-stock-aspi-20241101monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-announces-proposed-public-offering-of-common-stock-aspi-20241031monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-to-present-at-the-emerging-growth-conference-on-wednesday-october-30-2024-aspi-20241030monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-enters-into-term-sheet-with-terrapower-llc-for-construction-of-a-haleu-pr-aspi-20241030monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-enriches-ytterbium-176-during-commissioning-phase-of-first-quantum-enrich-aspi-20241017monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-completes-construction-phase-of-ytterbium-176-enrichment-facility-aspi-20240903monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-announces-closing-of-public-offering-and-full-exercise-of-underwriter-s-optio-aspi-20240715monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-announces-pricing-of-public-offering-of-common-stock-aspi-20240712monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-announces-proposed-public-offering-of-common-stock-aspi-20240711monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-enhances-executive-leadership-team-with-the-appointment-of-heather-kiessl-aspi-20240613monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-announces-closing-of-an-additional-offering-of-convertible-notes-by-quant-aspi-20240606monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-receives-purchase-order-from-a-leading-global-industrial-gases-company-fo-aspi-20240603monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-issues-letter-to-stockholders-aspi-20240411monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-enters-into-warrant-inducement-transaction-for-approximately-5-5-million--aspi-20240409monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-enters-into-a-contract-with-u-s-based-small-modular-reactor-smr-company-f-aspi-20240408monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-enters-into-purchase-agreement-with-a-leading-semiconductor-company-for-t-aspi-20240401monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-announces-signing-of-purchase-agreement-for-offering-of-convertible-notes-aspi-20240229monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-announces-increase-in-offering-size-of-convertible-notes-by-quantum-leap--aspi-20240222monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-announces-proposed-offering-of-convertible-notes-by-quantum-leap-energy-aspi-20240219monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-provides-update-on-plans-to-spin-out-its-wholly-owned-subsidiary-quantum--aspi-20240216monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-provides-corporate-update-aspi-20240110monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-enters-into-memorandum-of-understanding-mou-with-second-us-based-small-mo-aspi-20231127monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-enters-strategic-relationship-with-pet-labs-pharmaceuticals-for-the-distr-aspi-20231029monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-announces-closing-of-9-1-million-private-placement-of-common-stock-aspi-20231027monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-announces-private-placement-of-approximately-8-million-shares-of-common-stock-aspi-20231009monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-issues-letter-to-shareholders-aspi-20231003monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-enters-into-memorandum-of-understanding-with-a-small-modular-reactor-comp-aspi-20230928monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-secures-9-million-supply-contract-with-us-customer-for-highly-enriched-is-aspi-20230627monthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-inc-announces-pricing-of-initial-public-offering-and-nasdaq-listing-aspi-20221110monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-inc-investigated-by-the-portnoy-law-firm-vtyx-20260429monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-reports-second-quarter-2025-financial-results-and-highlights-recent-cor-vtyx-20250807monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-reports-first-quarter-2025-financial-results-and-highlights-recent-corp-vtyx-20250508monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-reports-fourth-quarter-and-full-year-2024-financial-results-and-highlig-vtyx-20250227monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences--vtyx-20250205monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-highlights-2025-pipeline-strategy-and-provides-clinical-updates-on-its--vtyx-20250114monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-alert-bragar-eagel-squire-p-c-is-investigating-ventyx-biosciences-inc-on-behalf-of--vtyx-20241211monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-participate-in-three-upcoming-investor-conferences-vtyx-20241112monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-reports-third-quarter-2024-financial-results-and-highlights-recent-corp-vtyx-20241107monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-presents-new-52-week-results-from-the-phase-2-trial-of-vtx002-tamuzimod-vtyx-20241015monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-27-million-strategic-investment-from-sanofi-vtyx-20240923monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-initiation-of-dosing-in-a-phase-2a-trial-of-vtx3232-in-patien-vtyx-20240906monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-departure-of-chief-financial-officer-vtyx-20240830monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-participate-in-two-upcoming-investor-conferences-vtyx-20240828monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-reports-second-quarter-2024-financial-results-and-highlights-recent-cor-vtyx-20240808monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-results-from-the-phase-2-trial-of-vtx958-in-participants-with-vtyx-20240729monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-stock-alert-ventyx-s-nasdaq-vtyx-board-is-being-investigated-for-insider-trading-lo-vtyx-20240625monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-investor-alert-ventyx-s-nasdaq-vtyx-board-is-being-investigated-for-insider-trading-vtyx-20240622monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-investor-reminder-ventyx-nasdaq-vtyx-shareholders-are-urged-to-contact-bfa-law-abou-vtyx-20240620monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-insider-trading-alert-ventyx-nasdaq-vtyx-shareholders-are-urged-to-contact-bfa-law--vtyx-20240618monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-stock-notice-ventyx-nasdaq-vtyx-shareholders-are-reminded-to-contact-bfa-law-about--vtyx-20240615monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-reminder-bfa-law-is-investigating-ventyx-nasdaq-vtyx-directors-for-insider-trading--vtyx-20240613monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-investigation-announcement-ventyx-nasdaq-vtyx-stock-drops-20-investors-are-urged-to-vtyx-20240611monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-news-notice-ventyx-nasdaq-vtyx-shareholders-are-urged-to-contact-bfa-law-about-the--vtyx-20240608monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-positive-preclinical-data-for-cns-penetrant-nlrp3-inhibitor-v-vtyx-20240605monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-alert-bragar-eagel-squire-p-c-is-investigating-ventyx-biosciences-inc-on-behalf-of--vtyx-20240604monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-shareholder-reminder-bfa-law-reminds-ventyx-biosciences-inc-nasdaq-vtyx-shareholder-vtyx-20240601monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-participate-in-three-upcoming-investor-conferences-vtyx-20240516monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-appointment-of-matthew-moore-as-chief-operating-officer-vtyx-20240516monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-inc-nasdaq-vtyx-shareholder-alert-the-directors-of-ventyx-biosciences-i-vtyx-20240514monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-inc-investor-alert-nasdaq-vtyx-the-directors-of-ventyx-biosciences-inc--vtyx-20240511monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-reports-first-quarter-2024-financial-results-and-highlights-recent-corp-vtyx-20240509monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-report-first-quarter-2024-financial-results-on-may-9-2024-vtyx-20240502monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-inc-nasdaq-vtyx-deadline-alert-bernstein-liebhard-llp-reminds-ventyx-bi-vtyx-20240422monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losse-vtyx-20240415monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-inc-nasdaq-vtyx-deadline-alert-bernstein-liebhard-llp-reminds-investors-vtyx-20240415monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-inc-class-action-levi-korsinsky-reminds-ventyx-investors-of-the-pending-vtyx-20240404monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-inc-nasdaq-vtyx-deadline-alert-bernstein-liebhard-llp-reminds-investors-vtyx-20240401monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsk-vtyx-20240328monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-inc-nasdaq-vtyx-deadline-alert-bernstein-liebhard-llp-reminds-investors-vtyx-20240325monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-inc-nasdaq-vtyx-deadline-alert-bernstein-liebhard-llp-reminds-investors-vtyx-20240318monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-inc-shareholder-alert-bernstein-liebhard-llp-announces-that-a-securitie-vtyx-20240311monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losse-vtyx-20240311monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-reports-clinical-data-for-its-nlrp3-inhibitor-portfolio-and-provides-pi-vtyx-20240311monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-inc-class-action-levi-korsinsky-reminds-ventyx-investors-of-the-pending-vtyx-20240307monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-100-million-private-placement-of-common-stock-vtyx-20240307monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-participate-in-two-upcoming-investor-conferences-vtyx-20240306monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-host-virtual-investor-event-on-march-11-2024-vtyx-20240304monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed--vtyx-20240304monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-reports-fourth-quarter-and-full-year-2023-financial-results-and-highlig-vtyx-20240227monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-present-results-of-the-phase-2-trial-of-vtx002-in-ulcerative-colitis-vtyx-20240222monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-participate-in-the-oppenheimer-34th-annual-healthcare-life-sciences--vtyx-20240206monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-participate-in-the-35th-annual-piper-sandler-healthcare-conference-vtyx-20231121monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-participate-in-the-jefferies-london-healthcare-conference-vtyx-20231110monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-reports-third-quarter-2023-financial-results-and-highlights-recent-corp-vtyx-20231109monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-results-from-the-phase-2-trial-of-vtx958-in-patients-with-mod-vtyx-20231106monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-positive-results-from-the-phase-2-trial-of-vtx002-in-patients-vtyx-20231009monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-participate-in-two-upcoming-investor-conferences-vtyx-20230830monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-reports-second-quarter-2023-financial-results-and-highlights-recent-cor-vtyx-20230810monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-report-second-quarter-2023-financial-results-on-august-10-2023-vtyx-20230803monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-participate-in-the-canaccord-genuity-43rd-annual-growth-conference-vtyx-20230802monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-initiation-of-dosing-in-a-phase-1-trial-of-vtx3232-a-novel-cn-vtyx-20230614monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-completion-of-enrollment-of-the-phase-2-trial-of-vtx002-in-ul-vtyx-20230607monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-participate-in-two-upcoming-investor-conferences-vtyx-20230531monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-reports-first-quarter-2023-financial-results-and-highlights-recent-corp-vtyx-20230511monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023-vtyx-20230504monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-vi-vtyx-20230324monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-reports-fourth-quarter-and-full-year-2022-financial-results-and-highlig-vtyx-20230323monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march--vtyx-20230315monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-provides-update-on-silicon-valley-bank-financial-exposure-vtyx-20230311monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-participate-in-three-upcoming-investor-conferences-vtyx-20230228monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-pipeline-updates-and-highlights-strategic-priorities-at-inves-vtyx-20230126monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-appoints-allison-j-hulme-ph-d-and-onaiza-cadoret-manier-to-its-board-of-vtyx-20230112monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-host-r-d-event-on-january-26-2023-vtyx-20230105monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-dosing-of-the-first-patient-in-the-phase-2-serenity-trial-of--vtyx-20221201monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-participate-in-two-upcoming-investor-conferences-vtyx-20221122monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-reports-third-quarter-2022-financial-results-and-highlights-recent-corp-vtyx-20221103monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-report-third-quarter-2022-financial-results-on-november-3-2022-vtyx-20221027monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-participate-in-three-upcoming-investor-conferences-vtyx-20221027monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-176-6-million-private-placement-of-common-stock-vtyx-20220919monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-participate-in-two-upcoming-investor-conferences-vtyx-20220829monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-reports-second-quarter-2022-financial-results-and-highlights-recent-cor-vtyx-20220815monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-positive-topline-phase-1-data-for-its-selective-allosteric-ty-vtyx-20220815monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-report-topline-results-from-the-phase-1-trial-of-its-tyk-2-inhibitor-vtyx-20220811monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-positive-topline-phase-1-data-for-its-peripheral-nlrp3-inhibi-vtyx-20220629monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-participate-in-the-jefferies-healthcare-conference-vtyx-20220601monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-reports-first-quarter-2022-financial-results-and-highlights-recent-corp-vtyx-20220512monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-appointment-of-william-sandborn-md-as-president-and-chief-med-vtyx-20220509monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-report-first-quarter-2022-financial-results-on-may-12-2022-vtyx-20220505monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-reports-full-year-2021-financial-results-and-highlights-recent-corporat-vtyx-20220323monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-participate-in-the-barclays-global-healthcare-conference-vtyx-20220307monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-first-patient-dosed-in-a-phase-2-clinical-trial-of-vtx002-for-vtyx-20211206monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-to-participate-in-two-upcoming-investor-conferences-vtyx-20211119monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-reports-third-quarter-financial-results-and-provides-business-update-vtyx-20211117monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-closing-of-upsized-initial-public-offering-and-full-exercise--vtyx-20211025monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-pricing-of-upsized-initial-public-offering-vtyx-20211021monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-announces-key-appointments-and-closing-of-51-0-million-series-b-convert-vtyx-20210920monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-inc-neo-cybn-nyse-american-cybn-leads-out-in-psychedelic-based-therapeutics-space-cybn-20220307monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-inc-neo-cybn-nyse-american-cybn-unleashing-power-of-psychedelics-cybn-20220303monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-mindmed-and-field-trip-health-headline-psyc-s-first-ceo-round-table-event-cybn-20220214monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-to-present-at-the-life-sciences-investor-forum-on-june-24th-cybn-20210623monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-inc-neo-cybn-at-forefront-of-psychedelic-revolution-cybn-20210326monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-inc-neo-cybn-in-prime-position-as-interest-in-psychedelic-medicine-surges-cybn-20210325monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-inc-neo-cybn-looking-to-solve-long-standing-problem-with-mdd-treatment-cybn-20201218monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-inc-neo-cybn-acquisition-three-pillar-approach-reason-for-optimistic-mdd-outlook-cybn-20201217monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-closes-acquisition-of-adelia-therapeutics-bolsters-scientific-team-and-grows-ip-port-cybn-20201214monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-and-clarmin-announce-closing-of-cdn-45-million-oversubscribed-private-placement-and--cybn-20201019monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-corp-ceo-discusses-ongoing-efforts-to-develop-one-of-the-first-commercially-approved-cybn-20200915monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-announces-publication-in-diabetic-macular-edema-opt-20250107monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-43rd-annual-j-p-morgan-healthcare-conference-opt-20241219monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-s-wet-amd-program-to-be-featured-at-floretina-2024-opt-20241126monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-participate-in-citi-2024-global-healthcare-conference-opt-20241125monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-appoints-kathy-connell-to-board-of-directors-opt-20241115monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-s-wet-amd-program-featured-at-ophthalmology-events-opt-20241112monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-participate-in-november-investor-conferences-opt-20241104monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-files-notice-of-annual-general-meeting-opt-20241016monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-wet-amd-program-to-be-presented-at-innovate-retina-opt-20241010monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-appoints-chief-medical-officer-and-chief-financial-officer-as-company-prepares-for--opt-20241008monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-participate-in-the-ubs-virtual-ophthalmology-day-2024-opt-20240930monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-joins-the-s-p-asx-300-index-opt-20240923monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-announces-completion-of-drug-substance-ppq-campaign-validating-manufacturing-proces-opt-20240918monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-announces-executive-leadership-changes-and-senior-hires-opt-20240905monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-participate-in-h-c-wainwright-26th-global-investment-conference-and-cantor-2024--opt-20240903monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-reports-full-year-financial-results-and-business-updates-opt-20240830monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-participate-in-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference-au-opt-20240808monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-welcomes-international-retina-thought-leaders-to-join-its-medical-advisory-board-opt-20240717monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-announces-results-of-the-a-55-9m-us-36-9m-retail-entitlement-offer-opt-20240715monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-announces-publication-on-vegf-c-and-d-signaling-pathways-as-potential-targets-for-t-opt-20240709monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-a-55-0m-us-36-9m-retail-entitlement-offer-opens-opt-20240619monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-successfully-completes-placement-and-institutional-component-of-entitlement-offer-r-opt-20240613monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-announces-placement-and-partially-underwritten-entitlement-offer-to-raise-up-to-app-opt-20240612monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-clinical-trials-at-the-summit-meeting-opt-20240603monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-completes-enrollment-in-pivotal-phase-3-clinical-program-with-sozinibercept-in-wet--opt-20240528monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-announces-upcoming-presentations-at-the-retina-world-congress-2024-opt-20240501monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-the-ois-retina-innovation-summit-at-arvo-opt-20240425monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-appoints-john-han-pharmd-as-vp-medical-affairs-opt-20240408monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-appoints-sujal-shah-to-the-board-of-directors-opt-20240403monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-host-key-opinion-leader-event-on-sozinibercept-opt-302-in-wet-age-related-macula-opt-20240319monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-participate-in-the-leerink-partners-global-biopharma-conference-opt-20240305monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-reports-half-year-financial-results-and-business-updates-opt-20240228monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-appoints-arshad-m-khanani-md-ma-fasrs-as-chief-medical-advisor-opt-20240219monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-completes-enrollment-in-first-pivotal-trial-with-sozinibercept-opt-20240214monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-strengthens-team-with-key-clinical-and-regulatory-hires-opt-20240201monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-receive-us-35m-commitment-and-additional-us-50m-funding-opt-20231227monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-receives-a-8-8-million-r-d-tax-incentive-opt-20231219monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-the-floretina-2023-congress-opt-20231201monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-the-jefferies-2023-london-healthcare-conference-opt-20231109monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-eyecelerator-forum-at-the-2023-american-academy-of-ophthalmology-aao--opt-20231030monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-appoints-u-s-based-leadership-with-fred-guerard-as-ceo-and-peter-lang-as-cfo-opt-20231027monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-participate-at-the-2023-euretina-congress-opt-20231002monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-opt-20230907monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-successfully-completes-institutional-offer-and-increases-capital-raising-to-a-90-0m-opt-20230828monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-announces-sozinibercept-as-the-nonproprietary-drug-name-for-opt-302-opt-20230726monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-the-2023-ophthalmology-innovation-summit-opt-20230724monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-feature-at-the-american-society-of-retina-specialists-2023-annual-meeting-opt-20230713monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-announces-departure-of-chief-medical-officer-and-appointment-of-senior-medical-advi-opt-20230710monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-appoints-anshul-thakral-as-non-executive-director-of-the-board-opt-20230608monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-the-jefferies-2023-healthcare-conference-opt-20230525monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-participate-in-ef-hutton-hosted-discussion-on-opt-302-and-the-wet-amd-market-opt-20230517monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-the-jmp-securities-life-sciences-conference-opt-20230508monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-participate-at-the-h-c-wainwright-bioconnect-conference-at-nasdaq-opt-20230428monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-receives-a-8-7-million-r-d-tax-incentive-opt-20230307monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-participate-in-fireside-chat-at-oppenheimer-s-33rd-annual-healthcare-conference-opt-20230306monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-phase-2b-trial-results-of-opt-302-in-combination-with-lucentis-for-wet-amd-publishe-opt-20230213monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-svb-leerink-global-biopharma-conference-opt-20230206monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-sequire-biotechnology-conference-opt-20230130monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-announce-mst-access-hosted-conference-call-with-professor-jason-s-slakter-md-opt-20221212monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-the-floretina-2022-congress-opt-20221206monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-jefferies-london-healthcare-conference-opt-20221110monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-expands-leadership-team-with-the-appointment-of-timothy-e-morris-as-chief-financial-opt-20221024monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-reports-fiscal-year-2022-financial-results-and-corporate-highlights-opt-20220830monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-announces-presentation-at-h-c-wainwright-2nd-annual-ophthalmology-virtual-conferenc-opt-20220816monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-successfully-closes-well-supported-us-90-million-equity-financing-opt-20220815monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-secures-up-to-us-170-million-in-non-dilutive-financing-for-opt-302-in-wet-amd-opt-20220815monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-upcoming-investor-conferences-opt-20220511monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-presentation-at-the-retina-world-congress-2022-opt-20220510monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-data-for-opt-302-in-combination-with-ranibizumab-for-polypoidal-choroidal-vasculopa-opt-20220505monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-presenting-clinical-data-at-arvo-2022-annual-meeting-opt-20220429monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-strengthens-its-board-of-directors-opt-20220422monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-oppenheimer-s-32nd-annual-healthcare-conference-opt-20220310monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-expands-leadership-team-with-the-appointment-of-joel-naor-m-d-m-sc-mba-as-chief-med-opt-20220302monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-data-for-opt-302-in-patients-with-polypoidal-choroidal-vasculopathy-pcv-presented-a-opt-20220214monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-svb-leerink-global-healthcare-conference-opt-20220210monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-announces-presentation-at-the-angiogenesis-exudation-and-degeneration-2022-conferen-opt-20220209monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-receives-a-6-6-m-r-d-tax-incentive-opt-20220124monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-h-c-wainwright-bioconnect-virtual-conference-opt-20220104monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-appoints-chief-commercial-officer-to-lead-commercialization-of-opt-302-for-wet-amd-opt-20220103monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-granted-chinese-patent-covering-opt-302-opt-20211026monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-opens-patient-enrollment-in-the-asia-pacific-region-for-the-opt-302-shore-and-coast-opt-20211019monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-opens-patient-recruitment-in-europe-for-pivotal-phase-3-shore-and-coast-wet-amd-tri-opt-20211004monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-september-investor-conferences-opt-20210902monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-reports-fiscal-year-2021-financial-results-and-corporate-highlights-opt-20210830monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference-opt-20210810monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-expands-global-phase-3-shore-and-coast-wet-amd-trials-of-opt-302-into-canada-opt-20210809monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-s-opt-302-granted-fda-fast-track-designation-for-wet-age-related-macular-degenerati-opt-20210706monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-appoints-company-secretary-and-vice-president-of-finance-opt-20210614monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-appoints-julia-a-haller-md-and-judith-robertson-to-board-of-directors-opt-20210601monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-company-secretary-resignation-opt-20210406monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-receives-fda-waiver-for-pediatric-study-plan-for-opt-302-in-wet-amd-opt-20210331monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-treats-first-patient-in-phase-3-pivotal-trials-of-opt-302-in-wet-amd-opt-20210315monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-opt-20210310monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-finalizes-study-designs-and-start-up-activities-for-phase-3-pivotal-clinical-trials-opt-20210224monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference-opt-20210217monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-announces-pricing-of-initial-public-offering-in-the-united-states-opt-20201016monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-announces-launch-of-proposed-initial-public-offering-in-the-united-states-opt-20201012monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-appoint-dr-jeremy-levin-as-chairman-of-the-board-opt-20201005monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-files-registration-statement-for-proposed-initial-public-offering-in-the-united-sta-opt-20200925monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-appoints-us-based-non-executive-director-opt-20200910monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-announces-plans-to-conduct-registered-public-offering-and-listing-in-the-united-sta-opt-20200824monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-completes-successful-meetings-with-fda-and-ema-for-opt-302-phase-3-clinical-program-opt-20200821monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-host-wet-amd-and-dme-key-opinion-leader-symposium-on-august-5-2020-edt-opt-20200728monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-reports-new-data-of-opt-302-in-diabetic-macular-edema-at-the-2020-annual-meeting-of-opt-20200727monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-clinical-data-of-opt-302-in-diabetic-macular-edema-to-be-presented-at-american-soci-opt-20200723monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-reports-positive-phase-2a-trial-results-of-opt-302-in-diabetic-macular-edema-opt-20200609monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-host-investor-teleconference-opt-20200609monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-completes-patient-dosing-in-phase-2a-dme-trial-opt-20200330monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-the-9th-annual-svb-leerink-global-healthcare-conference-opt-20200218monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-completes-recruitment-in-phase-2a-clinical-trial-of-opt-302-for-diabetic-macular-ed-opt-20200107monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-presents-additional-data-from-opt-302-phase-2b-wet-amd-trial-at-the-ophthalmology-i-opt-20191014monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-the-ophthalmology-innovation-summit-in-san-francisco-opt-20191003monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-presents-positive-data-from-opt-302-phase-2b-wet-amd-trial-at-euretina-congress-opt-20190906monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-s-phase-2b-study-of-opt-302-in-wet-amd-to-be-presented-in-late-breaking-session-of--opt-20190904monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-meets-primary-endpoint-in-phase-2b-study-of-opt-302-in-wet-amd-opt-20190806monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-host-investor-teleconference-opt-20190805monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-s-patent-application-covering-opt-302-to-be-granted-by-european-patent-office-opt-20190730monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-completes-final-patient-visit-in-phase-2b-wet-amd-clinical-trial-opt-20190515monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-s-phase-2b-trial-in-wet-amd-advances-with-a-second-positive-independent-safety-comm-opt-20190307monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-granted-japanese-patent-covering-opt-302-opt-20190129monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-confirms-final-patient-enrolment-in-phase-2b-wet-amd-clinical-trial-opt-20181126monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-completes-patient-recruitment-ahead-of-schedule-in-phase-2b-wet-amd-clinical-trial-opt-20181114monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-provides-update-on-wet-amd-and-diabetic-macular-edema-key-opinion-leader-forum-opt-20181029monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-reports-positive-three-month-data-from-phase-1b-dose-escalation-study-for-opt-302-i-opt-20181026monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-update-at-the-ophthalmology-innovation-summit-in-chicago-opt-20181024monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-host-wet-amd-and-diabetic-macular-edema-key-opinion-leader-forum-in-new-york-cit-opt-20180924monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-presents-phase-1-2a-data-of-opt-302-in-wet-amd-at-the-retina-society-2018-annual-me-opt-20180914monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-receives-positive-interim-review-from-independent-safety-committee-in-phase-2b-wet--opt-20180905monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-doses-first-patient-in-phase-2a-trial-for-opt-302-in-diabetic-macular-edema-opt-20180730monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-meets-primary-safety-objective-with-opt-302-in-phase-1b-diabetic-macular-edema-clin-opt-20180726monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-s-phase-2b-wet-amd-clinical-trial-reaches-mid-way-point-of-patient-recruitment-opt-20180702monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-doses-patients-in-europe-and-israel-in-phase-2b-study-of-opt-302-for-wet-amd-opt-20180327monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-initiates-opt-302-diabetic-macular-edema-clinical-trial-opt-20180103monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-doses-first-patient-in-phase-2b-study-of-opt-302-for-wet-amd-opt-20171219monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-presents-additional-positive-data-from-opt-302-phase-1-2a-wet-amd-trial-at-asrs-mee-opt-20170815monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-the-american-society-of-retinal-specialists-annual-meeting-and-the-op-opt-20170809monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-present-at-the-wedbush-pacgrow-healthcare-conference-opt-20170807monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-receives-notice-of-allowance-for-key-patent-covering-opt-302-in-the-united-states-opt-20170706monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-completes-a-45-million-capital-raising-opt-20170428monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-reports-positive-phase-1-2a-clinical-results-for-opt-302-in-wet-amd-opt-20170403monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-conference-call-webcast-update-on-opt-302-phase-1-2a-wet-amd-clinical-trial-opt-20170331monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-receives-positive-feedback-from-european-regulatory-agencies-for-the-opt-302-clinic-opt-20170320monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-completes-fda-meeting-to-inform-opt-302-wet-amd-clinical-program-opt-20170308monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-completes-patient-enrolment-in-phase-1-2a-wet-amd-clinical-trial-opt-20161121monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-s-phase-1-data-from-wet-amd-clinical-trial-presented-at-euretina-congress-2016-opt-20160912monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-reports-positive-data-from-wet-amd-clinical-trial-opt-20160725monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-to-host-conference-call-providing-update-on-phase-1-wet-amd-clinical-trial-with-opt-opt-20160725monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-doses-first-patient-in-phase-2a-dose-expansion-study-for-opt-302-in-wet-amd-opt-20160505monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-phase-1-wet-amd-clinical-trial-with-opt-302-meets-primary-safety-objective-opt-20160421monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-completes-patient-enrolment-for-opt-302-phase-1-dose-escalation-trial-in-patients-w-opt-20160330monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20260402monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-announces-ceo-transition-and-appointment-of-siddhartha-kadia-as-presiden-mlab-20260309monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20260107monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-on-january-14-202-mlab-20251219monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-to-announce-third-quarter-results-on-february-3-2026-mlab-20251203monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-announces-first-quarter-results-mlab-20250805monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20250703monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-to-announce-first-quarter-results-on-august-5-2025-mlab-20250702monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20250407monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-announces-third-quarter-results-mlab-20250204monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-to-announce-third-quarter-results-on-february-4-2025-mlab-20250117monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20250106monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-announces-second-quarter-results-mlab-20241107monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20241002monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-announces-first-quarter-results-mlab-20240805monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20240708monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-announces-fourth-quarter-and-full-fiscal-year-2024-results-mlab-20240605monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-revises-earnings-announcement-date-for-unaudited-fourth-quarter-and--mlab-20240531monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-revises-earnings-announcement-date-for-unaudited-fourth-quarter-and--mlab-20240522monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-announces-amendment-to-credit-facility-and-repurchase-of-senior-convertible-note-mlab-20240408monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20240404monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-to-announce-unaudited-fourth-quarter-and-full-fiscal-year-2024-resul-mlab-20240401monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-releases-second-annual-responsible-business-program-brochure-mlab-20240315monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-announces-third-quarter-results-mlab-20240205monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-appoints-mark-capone-to-its-board-of-directors-mlab-20240108monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20240104monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-completes-the-acquisition-of-gke-science-technology-co-mlab-20240103monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-to-announce-second-quarter-results-on-february-5-2024-mlab-20231214monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-announces-second-quarter-results-mlab-20231106monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-gke-gmbh-complementary-sterilization-indicators-and-healthcare-channels-mlab-20231016monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20231003monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-to-announce-second-quarter-results-on-november-6-2023-mlab-20230913monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-announces-commitment-to-disclose-scope-1-and-2-greenhouse-gas-emissi-mlab-20230824monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-announces-first-quarter-results-mlab-20230803monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20230705monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-to-announce-first-quarter-results-on-august-3-2023-mlab-20230621monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-announces-unaudited-fourth-quarter-and-full-fiscal-year-2023-results-mlab-20230525monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20230403monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-reports-immaterial-financial-exposure-to-silicon-valley-bank-closure-mlab-20230313monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-to-announce-fourth-quarter-and-full-fiscal-year-2023-results-on-may--mlab-20230309monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-announces-third-quarter-results-mlab-20230206monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20230103monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-to-announce-third-quarter-results-on-february-6-2023-mlab-20221216monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-belyntic-s-peptide-purification-business-mlab-20221117monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-appoints-shiraz-ladiwala-as-lead-independent-director-mlab-20221104monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-announces-second-quarter-results-mlab-20221103monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20221003monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-announces-first-quarter-results-mlab-20220804monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20220706monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-appoints-tony-tripeny-to-its-board-of-directors-mlab-20220627monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-fourth-quarter-and-full-fiscal-year-results-mlab-20220531monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20220406monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-announces-third-quarter-results-mlab-20220203monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20220106monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-announces-second-quarter-results-mlab-20211104monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-closes-acquisition-of-agena-bioscience-mlab-20211020monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20211001monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-announces-agreement-to-acquire-agena-bioscience-inc-mlab-20210914monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-announces-first-quarter-results-mlab-20210805monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20210706monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-fourth-quarter-and-full-fiscal-year-results-mlab-20210601monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20210405monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-third-quarter-results-for-fy21-mlab-20210203monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20210105monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-second-quarter-results-for-fy21-mlab-20201105monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20201001monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-first-quarter-results-mlab-20200806monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20200706monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-announces-full-exercise-of-underwriters-option-to-purchase-additiona-mlab-20200616monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-announces-upsizing-and-pricing-of-public-offering-of-common-stock-mlab-20200610monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-announces-proposed-public-offering-of-common-stock-mlab-20200608monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-fourth-quarter-and-full-fiscal-year-results-mlab-20200601monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20200401monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-third-quarter-results-mlab-20200210monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20200110monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-record-second-quarter-revenues-and-adjusted-operating-income-mlab-20191106monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-gyros-protein-technologies-mlab-20191101monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20191001monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-announces-closing-of-public-offerings-of-common-stock-and-convertibl-mlab-20190812monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-announces-pricing-of-public-offerings-of-common-stock-and-convertibl-mlab-20190808monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-inc-announces-proposed-public-offering-of-common-stock-and-convertible-s-mlab-20190806monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-record-first-quarter-revenues-and-adjusted-operating-income-mlab-20190730monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20190709monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-record-revenues-and-adjusted-operating-income-for-fiscal-year-2019-mlab-20190603monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20190408monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-announces-changes-in-the-composition-of-its-board-of-directors-mlab-20190306monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-record-third-quarter-revenues-and-adjusted-operating-income-mlab-20190204monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-s-board-announces-death-of-board-member-h-stuart-campbell-mlab-20190109monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20190103monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-leading-continuous-monitoring-hardware-business-mlab-20181129monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-record-second-quarter-revenues-mlab-20181031monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20181002monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-record-first-quarter-revenues-and-net-income-mlab-20180731monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20180709monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-record-revenues-and-adjusted-operating-income-for-the-fourth-quarter-and-mlab-20180605monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-transition-of-its-chief-sales-and-marketing-officer-mlab-20180411monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20180404monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-third-quarter-results-mlab-20180205monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20180102monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-exploration-corp-signs-letter-agreement-with-j-p-mariwell-inc-mlab-20171222monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-sterilization-and-disinfection-process-control-business-mlab-20171108monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-second-quarter-results-mlab-20171106monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-sterilization-process-control-business-mlab-20171005monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20171003monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-transition-of-its-chief-executive-officer-mlab-20170901monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-record-first-quarter-revenues-mlab-20170731monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20170705monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-record-net-income-and-adjusted-net-income-mlab-20170607monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20170405monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-record-third-quarter-revenues-and-adjusted-net-income-mlab-20170202monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20170103monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-hospital-focused-cold-chain-monitoring-business-mlab-20161107monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-additional-dental-sterilizer-testing-business-mlab-20161104monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-record-second-quarter-revenues-and-adjusted-net-income-mlab-20161102monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20161004monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-cold-chain-manufacturing-capabilities-mlab-20160810monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-16-percent-increase-in-first-quarter-revenues-mlab-20160728monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20160706monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-additional-canadian-dental-sterilizer-testing-business-mlab-20160705monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-biotech-appoints-leading-tricore-reference-laboratory-expert-to-inaugural-scientific--mlab-20160629monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-record-net-income-and-revenues-mlab-20160602monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20160412monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-an-additional-dental-sterilizer-testing-business-mlab-20160408monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-canadian-distribution-rights-for-its-biological-indicators-division-mlab-20160406monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-record-third-quarter-revenues-and-adjusted-net-income-mlab-20160202monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20160105monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-additional-european-distribution-rights-for-its-biological-indicators-d-mlab-20160104monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-record-second-quarter-revenues-mlab-20151102monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reaches-settlement-with-amega-scientific-corporation-and-its-owner-mlab-20151028monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-additional-european-distribution-rights-for-its-biological-indicators-d-mlab-20151015monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20151002monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-dental-sterilizer-testing-business-mlab-20150806monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-23-percent-increase-in-first-quarter-net-income-mlab-20150803monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20150708monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-canada-s-infitrak-inc-mlab-20150706monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-record-net-income-and-revenues-mlab-20150601monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20150402monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-announces-filing-of-a-universal-shelf-registration-statement-mlab-20150304monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-its-uk-and-germany-distribution-of-biological-indicators-mlab-20150302monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-record-third-quarter-revenues-and-net-income-mlab-20150202monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20150106monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-record-second-quarter-revenues-and-net-income-mlab-20141103monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-its-uk-and-irish-republic-distributor-of-biological-indicators-mlab-20141031monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-a-process-challenge-device-business-mlab-20141015monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20141014monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-46-increase-in-first-quarter-revenues-mlab-20140806monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20140717monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-reports-record-net-income-and-revenues-mlab-20140602monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend-mlab-20140423monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-the-bgi-instruments-business-mlab-20140415monthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-acquires-its-french-distributor-of-biological-indicators-mlab-20140404monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-essential-oil-market-trends-opportunities-and-forecasts-to-2030-overcoming-supply-cha-sage-20250603monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-shareholder-alert-kaskela-law-llc-announces-investigation-of-sage-therapeutics-inc-na-sage-20250410monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-shareholder-alert-bronstein-gewirtz-grossman-llc-announces-that-sage-therapeutics-inc-sage-20241028monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-deadline-rosen-trusted-investor-counsel-encourages-sage-therapeutics-inc-investors-to-sage-20241025monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-sage-20241024monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-deadline-notice-rosen-a-highly-recognized-law-firm-encourages-sage-therapeutics-inc-i-sage-20241022monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-shareholder-alert-bronstein-gewirtz-grossman-llc-announces-that-sage-therapeutics-inc-sage-20241022monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-sage-20241021monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-inc-nasdaq-sage-deadline-alert-bernstein-liebhard-llp-reminds-sage-thera-sage-20241021monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-deadline-rlf-a-top-ranked-law-firm-encourages-sage-therapeutics-inc-investors-with-lo-sage-20241020monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-shareholder-alert-bronstein-gewirtz-grossman-llc-announces-that-sage-therapeutics-inc-sage-20241016monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-inc-nasdaq-sage-deadline-alert-bernstein-liebhard-llp-reminds-sage-thera-sage-20241014monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-shareholder-alert-bronstein-gewirtz-grossman-llc-announces-that-sage-therapeutics-inc-sage-20241010monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-inc-sued-for-securities-law-violations-contact-the-gross-law-firm-before-sage-20241008monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-inc-nasdaq-sage-deadline-alert-bernstein-liebhard-llp-reminds-sage-thera-sage-20241007monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-reminder-robbins-llp-urges-sage-investors-to-obtain-legal-counsel-in-light-of-the-pen-sage-20241005monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-inc-nasdaq-sage-deadline-alert-bernstein-liebhard-llp-reminds-sage-thera-sage-20240930monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-shareholder-alert-bronstein-gewirtz-grossman-llc-announces-that-sage-therapeutics-inc-sage-20240929monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-lawsuit-alert-the-gross-law-firm-notifies-sage-therapeutics-inc-investors-of-a-class--sage-20240924monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-shareholder-alert-bronstein-gewirtz-grossman-llc-announces-that-sage-therapeutics-inc-sage-20240923monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-inc-nasdaq-sage-deadline-alert-bernstein-liebhard-llp-reminds-sage-thera-sage-20240923monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-investor-alert-robbins-geller-rudman-dowd-llp-announces-that-sage-therapeutics-inc-in-sage-20240920monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-class-action-sage-therapeutics-inc-stockholders-should-contact-robbins-llp-for-inform-sage-20240917monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-shareholder-alert-bronstein-gewirtz-grossman-llc-announces-that-sage-therapeutics-inc-sage-20240917monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-inc-nasdaq-sage-deadline-alert-bernstein-liebhard-llp-reminds-sage-thera-sage-20240916monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-shareholder-alert-bronstein-gewirtz-grossman-llc-announces-that-sage-therapeutics-inc-sage-20240911monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-inc-nasdaq-sage-deadline-alert-bernstein-liebhard-llp-reminds-sage-thera-sage-20240909monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-investor-deadline-robbins-geller-rudman-dowd-llp-announces-that-sage-therapeutics-inc-sage-20240907monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-shareholder-alert-bronstein-gewirtz-grossman-llc-announces-that-sage-therapeutics-inc-sage-20240905monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-class-action-alert-robbins-llp-reminds-stockholders-of-the-sage-therapeutics-inc-clas-sage-20240904monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-investors-have-opportunity-to-lead-sage-therapeutics-inc-securities-fraud-lawsuit-wit-sage-20240903monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-inc-nasdaq-sage-deadline-alert-bernstein-liebhard-llp-reminds-sage-thera-sage-20240903monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-investor-notice-robbins-geller-rudman-dowd-llp-announces-that-sage-therapeutics-inc-i-sage-20240901monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-ag-sage-20240831monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-shareholder-alert-bronstein-gewirtz-grossman-llc-announces-that-sage-therapeutics-inc-sage-20240830monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-inc-nasdaq-sage-investor-alert-investors-with-large-losses-in-sage-thera-sage-20240830monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-investor-alert-robbins-geller-rudman-dowd-llp-announces-that-sage-therapeutics-inc-in-sage-20240829monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-inc-sage-investigation-bronstein-gewirtz-grossman-llc-encourages-investo-sage-20240806monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-inc-sage-investigation-bronstein-gewirtz-grossman-llc-encourages-investo-sage-20240731monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-inc-sage-investigation-bronstein-gewirtz-grossman-llc-encourages-investo-sage-20240725monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-inc-company-investigated-by-the-portnoy-law-firm-sage-20230828monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-and-biogen-announce-positive-pivotal-phase-3-results-for-zuranolone-an-i-sage-20210615monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-to-present-data-at-the-society-of-biological-psychiatry-71st-annual-scie-sage-20160328monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-to-report-fourth-quarter-and-full-year-2015-financial-results-on-wednesd-sage-20160217monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-proposed-public-offering-of-common-stock-sage-20160105monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-to-present-at-the-piper-jaffray-27th-annual-healthcare-conference-sage-20151124monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-announces-third-quarter-2015-financial-results-and-recent-pipeline-progress-sage-20151105monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-announces-presentations-at-upcoming-november-investor-conferences-sage-20151103monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-to-report-third-quarter-2015-financial-results-on-thursday-november-5-2015-sage-20151029monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-to-present-data-at-upcoming-scientific-conferences-sage-20151008monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-announces-initiation-of-phase-1-and-first-dosing-of-sage-217-sage-20151006monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-to-participate-in-the-4th-annual-leerink-partners-rare-disease-roundtabl-sage-20150923monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-expands-leadership-team-with-key-appointments-sage-20150921monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-results-from-successful-exploratory-trial-in-essential-tremor-sage-20150903monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-announces-first-patient-treated-in-phase-3-status-trial-of-sage-547-in-super-refracto-sage-20150817monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-second-quarter-2015-financial-results-and-highlights-recent-pr-sage-20150812monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-receives-special-protocol-assessment-for-phase-3-status-trial-of-sage-547-in-super-re-sage-20150806monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-to-present-at-the-canaccord-genuity-35th-annual-growth-conference-sage-20150805monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-inc-nasdaq-sage-to-ring-the-nasdaq-stock-market-opening-bell-sage-20150708monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-positive-top-line-data-in-exploratory-trial-of-sage-547-in-pos-sage-20150609monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-to-participate-in-the-goldman-sachs-36th-annual-global-healthcare-confer-sage-20150603monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-sage-547-progress-and-first-quarter-2015-financial-results-sage-20150514monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-achieves-77-percent-response-rate-in-completed-phase-1-2-clinical-trial--sage-20150514monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-to-present-at-ubs-global-healthcare-conference-sage-20150512monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-to-report-first-quarter-2015-financial-results-on-thursday-may-14-sage-20150507monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-closing-of-138-million-public-offering-of-common-stock-includi-sage-20150421monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-first-patient-treated-under-phase-3-expanded-access-protocol-t-sage-20150420monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-pricing-of-public-offering-of-common-stock-sage-20150415monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-proposed-public-offering-of-common-stock-sage-20150413monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-presentations-at-upcoming-scientific-conferences-sage-20150409monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-positive-end-of-phase-2-meeting-with-fda-and-planned-initiatio-sage-20150402monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-reports-fourth-quarter-and-full-year-2014-financial-results-sage-20150227monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-appoints-new-vice-presidents-to-lead-key-organizational-functions-sage-20150213monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-participation-in-february-conferences-sage-20150128monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-initiates-phase-2a-trial-of-sage-547-in-postpartum-depression-sage-20150112monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-reports-updated-data-from-ongoing-clinical-trial-and-emergency-use-progr-sage-20150109monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-to-present-at-33rd-annual-j-p-morgan-healthcare-conference-sage-20150105monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-added-to-nasdaq-biotechnology-index-sage-20141217monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-reports-third-quarter-2014-results-sage-20141111monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-reports-positive-top-line-phase-2-data-of-sage-547-in-patients-with-supe-sage-20141110monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-six-scientific-presentations-at-neuroscience-2014-the-society--sage-20141107monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-to-present-at-credit-suisse-23rd-annual-healthcare-conference-sage-20141105monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-initiates-exploratory-study-of-sage-547-in-essential-tremor-sage-20141023monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-to-participate-in-the-2014-leerink-partners-rare-disease-roundtable-sage-20140925monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-appoints-michael-f-cola-to-the-company-s-board-of-directors-sage-20140916monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-reports-fourth-quarter-and-full-year-2024-financial-results-and-provide-vigl-20250313monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-reports-third-quarter-2024-financial-results-and-provides-business-upda-vigl-20241107monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-present-at-guggenheim-healthcare-innovation-conference-vigl-20241105monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-announces-fda-has-removed-partial-clinical-hold-on-vg-3927-vigl-20240917monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-present-at-cantor-global-healthcare-conference-vigl-20240916monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-present-at-upcoming-september-investor-conferences-vigl-20240829monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-reports-second-quarter-2024-financial-results-and-provides-business-upd-vigl-20240813monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-highlights-publication-on-alsp-genetic-mutation-prevalence-in-neurology-vigl-20240801monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-presents-data-on-its-small-molecule-trem2-agonist-program-at-2024-alzheimer-s-associ-vigl-20240730monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-announces-interim-data-from-its-ongoing-phase-1-clinical-trial-evaluati-vigl-20240724monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-announces-upcoming-presentations-on-its-small-molecule-trem2-agonist-vg-3927-at-the--vigl-20240718monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-provides-update-on-clinical-development-strategy-to-pursue-potential-ac-vigl-20240718monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-announces-40-million-strategic-investment-from-sanofi-vigl-20240627monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-present-in-upcoming-june-investor-conferences-vigl-20240530monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-present-at-the-citizens-jmp-life-sciences-conference-vigl-20240508monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-reports-first-quarter-2024-financial-results-and-provides-business-upda-vigl-20240507monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-presents-key-findings-from-illuminate-ignite-studies-in-alsp-at-the-2024-american-ac-vigl-20240417monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-reports-fourth-quarter-and-full-year-2023-financial-results-and-provide-vigl-20240326monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-appoints-petra-kaufmann-m-d-as-chief-medical-officer-vigl-20240320monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-announces-upcoming-presentations-at-2024-american-academy-of-neurology-annual-meetin-vigl-20240313monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-present-at-stifel-2024-virtual-cns-days-vigl-20240312monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-announces-oral-presentation-on-small-molecule-trem2-agonist-vg-3927-as-a-potential-d-vigl-20240306monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-presents-poster-on-impacts-of-misdiagnosis-and-genetic-testing-on-adult-onset-leukoe-vigl-20240229monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-present-at-guggenheim-6th-annual-biotechnology-conference-vigl-20240207monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-provides-2023-year-in-review-and-highlights-upcoming-2024-milestones-vigl-20240103monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-present-at-evercore-isi-6th-annual-healthconx-conference-vigl-20231122monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-reports-positive-interim-data-from-phase-2-ignite-proof-of-concept-clin-vigl-20231116monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-reports-third-quarter-2023-financial-results-and-provides-business-upda-vigl-20231107monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-announces-first-participant-dosed-in-phase-1-clinical-trial-in-healthy--vigl-20231017monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-present-at-jefferies-inaugural-biotech-cns-neuro-summit-vigl-20231005monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-receives-positive-opinion-from-european-medicines-agency-on-orphan-drug-vigl-20230926monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-presents-vgl101-complete-phase-1-data-and-phase-2-ignite-trial-design-a-vigl-20230911monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-announces-update-on-its-small-molecule-trem2-agonist-program-vigl-20230908monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-present-at-2023-morgan-stanley-global-healthcare-conference-vigl-20230908monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-reports-second-quarter-2023-financial-results-and-provides-business-upd-vigl-20230808monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-appoints-christopher-j-silber-m-d-as-chief-medical-officer-vigl-20230807monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-present-at-2023-jefferies-global-healthcare-conference-vigl-20230601monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-reports-first-quarter-2023-financial-results-and-provides-business-upda-vigl-20230510monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-appoints-samantha-budd-haeberlein-ph-d-to-board-of-directors-vigl-20230509monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-launches-alspaware-to-provide-access-to-no-cost-genetic-testing-and-cou-vigl-20230508monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-announces-fda-has-lifted-the-partial-clinical-hold-on-vgl101-vigl-20230330monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-present-at-stifel-2023-cns-days-vigl-20230322monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-reports-fourth-quarter-and-full-year-2022-financial-results-and-provide-vigl-20230321monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-announces-multiple-presentations-on-lead-indication-alsp-at-the-2023-am-vigl-20230302monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-vigl-20230103monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-appoints-david-gray-ph-d-as-chief-scientific-officer-and-announces-chan-vigl-20221215monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-announces-first-patient-dosed-in-the-ignite-phase-2-clinical-trial-to-e-vigl-20221214monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-host-alsp-kol-event-on-december-6-2022-vigl-20221128monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-reports-third-quarter-2022-financial-results-and-provides-business-upda-vigl-20221110monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-present-at-upcoming-investor-conferences-vigl-20221107monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-announces-interim-topline-results-from-its-ongoing-phase-1-clinical-tri-vigl-20221102monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-receives-fda-fast-track-designation-for-vgl101-for-the-treatment-of-pat-vigl-20221101monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-present-at-2022-morgan-stanley-global-healthcare-conference-vigl-20220901monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-announces-75-million-private-placement-financing-vigl-20220812monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-reports-second-quarter-2022-financial-results-and-provides-business-upd-vigl-20220808monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-present-at-2022-wedbush-pacgrow-healthcare-virtual-conference-vigl-20220802monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-presents-preclinical-data-on-vgl101-for-adult-onset-leukoencephalopathy-vigl-20220801monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-strengthens-board-of-directors-with-appointment-of-suzanne-bruhn-ph-d-vigl-20220728monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-expands-vgl101-phase-1-trial-to-australia-vigl-20220607monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-present-at-2022-jefferies-global-healthcare-conference-vigl-20220601monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-reports-first-quarter-2022-financial-results-and-provides-business-high-vigl-20220512monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-expands-leadership-team-and-board-of-directors-vigl-20220420monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-reports-fourth-quarter-and-full-year-2021-financial-results-and-provide-vigl-20220325monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-present-at-stifel-2022-cns-days-vigl-20220321monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-to-present-key-considerations-for-lead-indication-alsp-at-the-2022-amer-vigl-20220303monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-announces-closing-of-initial-public-offering-vigl-20220111monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-announces-pricing-of-initial-public-offering-vigl-20220107monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-f-itos-20250820monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-present-preclinical-data-on-potential-best-in-class-anti-trem2-antibody-eos-215-a-itos-20250325monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business-up-itos-20250305monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-announces-2025-strategic-priorities-and-anticipated-milestones-itos-20250110monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-itos-20250108monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-presents-interim-a2a-005-clinical-trial-data-translational-and-preclini-itos-20241212monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-participate-in-upcoming-investor-conferences-itos-20241126monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-third-quarter-2024-financial-results-and-provides-business-updates-itos-20241112monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-highlight-inupadenant-preclinical-translational-and-phase-2-a2a-005--itos-20241024monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-announces-clinically-meaningful-objective-response-rate-observed-at-every-dose-in-fo-itos-20240914monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-participate-in-upcoming-investor-conferences-itos-20240828monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-announces-late-breaking-oral-presentation-of-phase-2-galaxies-lung-201--itos-20240820monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-second-quarter-2024-financial-results-and-provides-business-updates-itos-20240808monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-announces-appointment-of-david-feltquate-as-chief-medical-officer-itos-20240805monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-announces-first-patient-dosed-in-galaxies-lung-301-phase-3-study-earning-35-million--itos-20240708monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-and-gsk-initiate-galaxies-lung-301-phase-3-study-assessing-belrestotug-and-dostarlim-itos-20240617monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-first-quarter-2024-financial-results-and-provides-business-updates-itos-20240510monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-announces-120-million-registered-direct-offering-itos-20240510monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-presents-eos-984-preclinical-data-demonstrating-restoration-of-t-cell-activity-from--itos-20240407monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-appoints-oncology-veteran-jill-desimone-to-its-board-of-directors-itos-20240306monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business-up-itos-20240306monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-highlight-preclinical-data-on-first-in-class-eos-984-targeting-ent1-at-the-americ-itos-20240305monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-participate-in-upcoming-investor-conferences-itos-20240301monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-announces-2024-strategic-priorities-and-anticipated-milestones-itos-20240108monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-itos-20240103monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-present-at-the-piper-sandler-35th-annual-healthcare-conference-itos-20231121monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-third-quarter-2023-financial-results-and-provides-business-updates-itos-20231107monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-participate-in-upcoming-investor-conferences-itos-20230906monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-second-quarter-2023-financial-results-and-provides-business-updates-itos-20230808monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-first-quarter-2023-financial-results-and-provides-business-updates-itos-20230510monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-business-up-itos-20230315monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-present-at-cowen-43rd-annual-health-care-conference-itos-20230228monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-present-at-svb-securities-global-biopharma-conference-itos-20230207monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-provides-business-updates-and-clinical-development-plans-for-2023-itos-20230109monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-itos-20230103monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-present-at-the-piper-sandler-34th-annual-healthcare-conference-itos-20221122monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-third-quarter-2022-financial-results-and-provides-business-updates-itos-20221110monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-second-quarter-2022-financial-results-and-provides-business-update-itos-20220810monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-present-at-the-2022-wedbush-pacgrow-healthcare-conference-itos-20220802monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-first-quarter-2022-financial-results-and-provides-business-update-itos-20220512monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-presents-new-data-for-anti-tigit-antibody-eos-448-gsk4428859a-at-the-aacr-annual-mee-itos-20220408monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-business-up-itos-20220323monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-present-at-the-cowen-42nd-annual-health-care-conference-itos-20220301monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-participate-in-upcoming-investor-conferences-in-february-itos-20220210monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-provides-clinical-development-plans-and-promotes-yvonne-mcgrath-ph-d-to-chief-scient-itos-20220110monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-itos-20220103monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-announces-new-data-for-its-anti-tigit-antibody-eos-448-at-the-american-society-of-he-itos-20211209monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-third-quarter-2021-financial-results-and-provides-corporate-updates-itos-20211110monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-report-third-quarter-2021-financial-results-on-november-10-2021-itos-20211103monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-participate-in-upcoming-september-investor-conferences-itos-20210901monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-second-quarter-2021-financial-results-and-provides-business-update-itos-20210812monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-report-second-quarter-2021-financial-results-and-provide-corporate-update-on-augu-itos-20210805monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-present-at-wedbush-pacgrow-healthcare-conference-2021-itos-20210803monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021-itos-20210708monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-and-gsk-announce-development-and-commercialisation-collaboration-for-eo-itos-20210614monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-announces-new-phase-1-2a-data-indicating-antitumor-activity-of-inupaden-itos-20210604monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-present-at-the-jefferies-virtual-healthcare-conference-itos-20210526monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-first-quarter-2021-financial-results-and-provides-business-update-itos-20210513monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-report-first-quarter-2021-financial-results-and-provide-corporate-update-on-may-1-itos-20210506monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-appoints-tony-ho-m-d-and-robert-iannone-m-d-m-s-c-e-two-highly-accomplished-r-d-exec-itos-20210503monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-announces-new-preliminary-data-indicating-clinical-activity-with-its-an-itos-20210410monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-business-up-itos-20210324monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-present-at-upcoming-investor-conferences-in-march-itos-20210223monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference-itos-20210217monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-itos-20210105monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-present-at-piper-sandler-32nd-annual-healthcare-conference-itos-20201123monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-third-quarter-2020-financial-results-and-provides-business-update-itos-20201112monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-appoints-matthew-roden-ph-d-to-board-of-directors-itos-20201112monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-participate-in-upcoming-investor-conferences-in-november-itos-20201105monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-to-participate-in-upcoming-investor-conferences-in-september-itos-20200908monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-second-quarter-2020-financial-results-and-provides-business-update-itos-20200901monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-announces-pricing-of-initial-public-offering-itos-20200724monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-presents-preclinical-data-for-its-anti-tigit-antibody-eos-448-at-the-aa-itos-20200622monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-present-preclinical-data-for-its-anti-tigit-antibody-eos-448-at-the--itos-20200615monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-strengthens-leadership-team-itos-20200609monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-appoints-ann-d-rhoads-to-board-of-directors-itos-20200601monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-presents-data-from-first-in-human-study-of-a2a-receptor-antagonist-at-a-itos-20200427monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-present-data-from-first-in-human-study-of-a2a-receptor-antagonist-at-itos-20200420monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-closes-125-million-series-b2-financing-itos-20200401monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-initiates-phase-1-2-study-with-highly-innovative-anti-tigit-antibody-in-itos-20200227monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-present-at-cowen-40th-annual-health-care-conference-itos-20200224monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-present-at-svb-leerink-9th-annual-global-healthcare-conference-itos-20200218monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-awarded-15-million-in-non-dilutive-funding-by-the-walloon-region-itos-20200130monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-announces-collaboration-with-merck-investigating-the-combination-of-its-itos-20191212monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-present-at-piper-jaffray-31st-annual-healthcare-conference-itos-20191126monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-announces-appointment-of-matthew-call-as-chief-operating-officer-itos-20190813monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-present-at-2019-wedbush-pacgrow-healthcare-conference-itos-20190807monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-present-at-ubs-global-healthcare-conference-itos-20190513monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-initiates-phase-1-1b-trial-with-differentiated-adenosine-a2a-antagonist-itos-20190417monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-announces-eight-data-presentations-for-a2a-receptor-antagonist-and-anti-itos-20190329monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-appoints-joanne-jenkins-lager-m-d-as-chief-medical-officer-itos-20190326monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-participate-in-upcoming-u-s-conferences-in-march-itos-20190305monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-participate-in-upcoming-conferences-in-november-itos-20181107monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-present-data-at-2018-sitc-annual-meeting-itos-20181106monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-participate-in-upcoming-u-s-conferences-in-september-itos-20180829monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-participate-in-upcoming-u-s-conferences-in-august-itos-20180806monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-appoints-scott-chappel-as-chief-scientific-officer-itos-20180703monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-expands-board-of-directors-with-the-appointment-of-david-hallal-as-chai-itos-20180627monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-completes-75-million-series-b-financing-itos-20180620monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-present-preclinical-data-from-a2a-receptor-antagonist-and-anti-tigit-itos-20180412monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-present-new-preclinical-data-from-a2a-receptor-antagonist-and-anti-t-itos-20180209monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-regains-worldwide-rights-to-clinical-stage-ido1-inhibitor-itos-20180104monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-present-new-data-at-upcoming-2017-sitc-annual-meeting-itos-20171106monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-sa-iteos-therapeutics-to-present-at-the-2017-wedbush-pacgrow-healthcare-itos-20170808monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-granted-eur-7-5-million-non-dilutive-funding-by-the-walloon-region-itos-20170728monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-sa-appoints-mohamed-ragab-m-d-as-vice-president-corporate-development-itos-20170629monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-sa-iteos-therapeutics-to-present-data-for-novel-a2a-receptor-antagonist-itos-20170403monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-to-present-at-the-2017-bio-ceo-investor-conference-itos-20170210monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-health-announces-new-leaders-to-its-executive-ranks-mgrm-20251008monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-health-selected-as-complex-chronic-disease-solutions-provider-of-the-year-by-heal-mgrm-20250924monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-positive-interim-data-for-inz-701-in-infants-and-young-children-w-inzy-20250110monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-inzy-20241127monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-present-at-upcoming-investor-conferences-inzy-20241111monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-third-quarter-2024-financial-results-and-provides-business-highligh-inzy-20241105monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-positive-interim-data-from-phase-1-seaport-1-trial-of-inz-701-inzy-20241024monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-presentation-of-interim-data-from-phase-1-seaport-1-trial-at-the--inzy-20241017monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-appointment-of-biopharmaceutical-commercial-leader-erik-harris-to-inzy-20241007monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-presents-new-data-at-the-american-society-for-bone-and-mineral-research-asb-inzy-20240926monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-participate-at-the-2024-wells-fargo-healthcare-conference-inzy-20240829monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-second-quarter-2024-financial-results-and-provides-business-highlig-inzy-20240806monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-publishes-preclinical-data-supporting-inz-701-as-a-potential-therapy-for-a--inzy-20240725monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-fda-fast-track-designation-for-inz-701-in-abcc6-deficiency-inzy-20240702monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-presentation-and-sponsored-symposium-at-the-11th-international-co-inzy-20240621monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-present-at-the-jefferies-global-healthcare-conference-inzy-20240530monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-present-recently-announced-data-from-phase-1-2-trials-of-inz-701-in-adul-inzy-20240523monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-participate-at-the-bank-of-america-securities-2024-health-care-conferenc-inzy-20240508monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-first-quarter-2024-financial-results-and-provides-business-highligh-inzy-20240507monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-inzy-20240503monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-positive-topline-data-from-ongoing-phase-1-2-trials-of-inz-701-in-inzy-20240408monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-inzy-20240405monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-participate-at-the-23rd-annual-needham-virtual-healthcare-conference-inzy-20240402monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-report-topline-data-from-ongoing-phase-1-2-trials-of-inz-701-in-adults-w-inzy-20240326monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-full-year-2023-financial-results-and-provides-business-highlights-inzy-20240312monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-participate-in-the-td-cowen-44th-annual-health-care-conference-inzy-20240226monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-inzy-20240206monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-inzy-20231205monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-participate-in-upcoming-investor-conferences-inzy-20231109monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-third-quarter-2023-financial-results-and-provides-business-highligh-inzy-20231107monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-inzy-20231103monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-presentation-at-the-american-society-of-nephrology-asn-kidney-wee-inzy-20231026monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-highlights-inclusion-of-generalized-arterial-calcification-of-infancy-gaci--inzy-20231010monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-three-poster-presentations-at-the-american-society-for-bone-and-m-inzy-20231006monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-positive-interim-data-from-ongoing-phase-1-2-trials-of-inz-701-in-inzy-20230926monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-host-virtual-investor-and-analyst-event-on-sep-26-2023-inzy-20230920monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-inzy-20230906monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-inzy-20230905monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-second-quarter-2023-financial-results-and-provides-business-highlig-inzy-20230808monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-inzy-20230803monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-inc-announces-closing-of-public-offering-of-common-stock-inzy-20230801monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-inc-announces-pricing-of-public-offering-of-common-stock-inzy-20230728monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-inc-announces-proposed-offering-of-common-stock-inzy-20230727monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-updates-on-global-development-strategy-of-inz-701-for-the-treatme-inzy-20230726monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-provide-enpp1-deficiency-program-update-on-july-26-2023-inzy-20230719monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-dosing-of-first-infant-with-enpp1-deficiency-in-a-phase-1b-trial--inzy-20230627monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-present-at-the-jefferies-healthcare-conference-inzy-20230602monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-first-quarter-2023-financial-results-and-provides-business-highligh-inzy-20230509monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-inzy-20230503monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-present-recently-announced-preliminary-data-from-ongoing-phase-1-2-trial-inzy-20230414monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-participate-at-the-22nd-annual-needham-virtual-healthcare-conference-inzy-20230411monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-to-newly-appoi-inzy-20230404monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-full-year-2022-financial-results-and-provides-business-highlights-inzy-20230322monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-participate-in-the-cowen-43rd-annual-health-care-conference-inzy-20230301monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-positive-topline-data-from-ongoing-phase-1-2-trials-of-inz-701-inzy-20230216monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-host-virtual-investor-and-analyst-event-on-feb-16-2023-inzy-20230206monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-investor-and-analyst-event-and-highlights-2022-progress-inzy-20230109monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-peer-reviewed-publication-revealing-increased-prevalence-of-enpp1-inzy-20221205monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-participate-at-the-bofa-securities-biotech-smid-cap-conference-inzy-20221201monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-third-quarter-2022-financial-results-and-provides-business-updates-inzy-20221110monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-participate-in-upcoming-investor-conferences-inzy-20221107monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-first-self-administration-of-inz-701-in-ongoing-enpp1-deficiency--inzy-20221103monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-publication-of-comprehensive-enpp1-variant-database-inzy-20221031monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-present-at-h-c-wainwright-24th-annual-global-investment-conference-inzy-20220906monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-second-quarter-2022-financial-results-and-provides-business-updates-inzy-20220815monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-secures-flexible-debt-facility-for-up-to-70-million-with-k2-healthventures-inzy-20220726monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-positive-preliminary-data-from-phase-1-2-clinical-trial-of-inz-70-inzy-20220719monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-partnership-with-rady-children-s-institute-for-genomic-medicine-t-inzy-20220616monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-appoints-kurt-gunter-m-d-as-chief-medical-officer-inzy-20220607monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-present-at-the-2022-jefferies-healthcare-conference-inzy-20220601monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-first-quarter-2022-financial-results-and-provides-business-highligh-inzy-20220510monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-present-at-upcoming-investor-conferences-inzy-20220503monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-73-million-underwritten-offering-priced-at-the-market-inzy-20220414monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-provides-update-for-phase-1-2-clinical-trials-in-abcc6-deficiency-and-enpp1-inzy-20220412monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-present-at-the-21st-annual-needham-virtual-healthcare-conference-inzy-20220406monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-positive-preliminary-data-from-phase-1-2-clinical-trial-of-inz-70-inzy-20220404monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-full-year-2021-financial-results-and-provides-business-highlights-inzy-20220315monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-strengthens-management-team-with-two-executive-appointments-inzy-20220308monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-present-at-cowen-42nd-annual-health-care-conference-inzy-20220301monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-dosing-of-first-patient-in-first-in-human-clinical-trial-of-inz-7-inzy-20211115monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-present-at-upcoming-investor-conferences-inzy-20211111monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-third-quarter-2021-financial-results-and-provides-business-highligh-inzy-20211109monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-presentation-of-data-from-enpp1-deficiency-development-program-at-inzy-20211004monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-present-at-the-2021-cantor-virtual-global-healthcare-conference-inzy-20210922monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-q2-2021-financial-results-and-provides-business-highlights-inzy-20210811monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-participate-in-2021-wedbush-pacgrow-healthcare-virtual-conference-inzy-20210804monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-receives-orphan-drug-designation-for-inz-701-from-the-european-medicines-ag-inzy-20210721monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-appointment-of-gayle-gironda-as-senior-vice-president-human-resou-inzy-20210713monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-announces-acceptance-of-first-european-clinical-trial-application-for-phase-1-2-cl-inzy-20210609monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-q1-2021-financial-results-and-provides-business-highlights-inzy-20210512monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-presents-preclinical-data-suggesting-utility-of-inz-701-as-a-potential-trea-inzy-20210507monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-present-at-the-bofa-securities-2021-virtual-healthcare-conference-inzy-20210506monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-publishes-data-supporting-inz-701-as-a-potential-treatment-for-enpp1-defici-inzy-20210429monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-and-researchers-from-thomas-jefferson-university-to-present-preclinical-dat-inzy-20210428monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-presents-data-from-burden-of-illness-study-in-patients-with-enpp1-deficienc-inzy-20210414monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-to-present-burden-of-illness-data-at-the-2021-acmg-annual-clinical-genetics-inzy-20210408monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-expands-its-scientific-advisory-board-inzy-20210401monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-full-year-2020-financial-results-and-provides-business-highlights-inzy-20210325monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-appoints-deborah-wenkert-m-d-as-senior-vice-president-and-chief-medical-off-inzy-20210204monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-authorization-to-proceed-in-u-s-and-u-k-with-phase-1-2-clinical-t-inzy-20210104monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-third-quarter-2020-financial-results-and-provides-business-highligh-inzy-20201112monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-appoints-kevin-b-johnson-ph-d-mba-as-senior-vice-president-regulatory-affai-inzy-20201109monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-appoints-yves-sabbagh-ph-d-as-senior-vice-president-and-chief-scientific-of-inzy-20201013monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-reports-second-quarter-2020-financial-results-and-provides-business-highlig-inzy-20200903monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-closing-of-initial-public-offering-and-full-exercise-by-underwrit-inzy-20200730monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-announces-pricing-of-initial-public-offering-inzy-20200724monthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-acquires-enpp1-deficiency-program-assets-from-alexion-pharmaceuticals-inzy-20200717monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-announces-third-quarter-2024-financial-results-thrd-20241107monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-to-participate-in-upcoming-investor-conferences-in-september-thrd-20240910monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-to-participate-in-upcoming-investor-conferences-thrd-20240826monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-announces-second-quarter-2024-financial-results-and-provides-business-u-thrd-20240808monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-to-participate-in-the-jefferies-global-healthcare-conference-thrd-20240528monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-announces-first-quarter-2024-financial-results-and-provides-business-up-thrd-20240515monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-appoints-geoff-mcdonough-m-d-to-its-board-of-directors-thrd-20240328monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-announces-fourth-quarter-and-full-year-2023-financial-results-thrd-20240326monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-to-participate-in-the-44th-annual-td-cowen-health-care-conference-thrd-20240226monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-appoints-christopher-murphy-as-chief-financial-and-business-officer-and-thrd-20240104monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-announces-third-quarter-2023-financial-results-thrd-20231109monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-announces-leadership-changes-thrd-20231031monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-to-participate-in-the-morgan-stanley-global-healthcare-conference-thrd-20230831monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-announces-second-quarter-2023-financial-results-thrd-20230810monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-announces-next-generation-oral-kit-inhibitor-product-candidate-thb335-thrd-20230725monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-announces-first-quarter-2023-financial-results-thrd-20230511monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-announces-fourth-quarter-and-year-end-2022-financial-results-thrd-20230329monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-announces-discontinuation-of-phase-1b-study-of-thb001-in-chronic-induci-thrd-20221215monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-to-participate-in-fireside-chat-at-the-evercore-isi-5th-annual-healthco-thrd-20221121monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-announces-third-quarter-2022-financial-results-and-provides-corporate-u-thrd-20221109monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-announces-closing-of-upsized-initial-public-offering-and-full-exercise--thrd-20220919monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-announces-pricing-of-upsized-initial-public-offering-thrd-20220914monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-appoints-thomas-m-soloway-to-its-board-of-directors-thrd-20220809monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick--ymab-20250820monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-first-quarter-2025-financial-and-operating-results-on-may-13-2025-ymab-20250506monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-cd38-sada-pre-ta-ymab-20250425monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-reports-fourth-quarter-2024-financial-results-and-recent-corporate-developments-ymab-20250304monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-publication-of-phase-2-interim-results-in-nature-communications-ymab-20250303monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-ma-ymab-20250220monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-presents-translational-pharmacokinetics-of-gd2-sada-from-pretargeted-rit-platform-a-ymab-20250131monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit-ymab-20250110monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-provides-strategic-business-update-and-2025-priorities-ymab-20250110monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-ymab-20241223monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-presents-sada-platform-preclinical-data-and-trial-in-progress-posters-at-the-2024-a-ymab-20241207monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-participate-at-citi-s-2024-global-healthcare-conference-ymab-20241127monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-reports-third-quarter-2024-financial-results-and-recent-corporate-developments-ymab-20241108monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-and-nobelpharma-announce-exclusive-license-and-distribution-agreement-for-danyelza--ymab-20241104monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-third-quarter-2024-conference-call-and-webcast-ymab-20241025monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-participate-in-upcoming-investor-conferences-in-october-ymab-20241001monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-presents-neuroblastoma-research-on-naxitamab-and-sada-prit-technology-platform-at-a-ymab-20240906monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-participate-in-upcoming-investor-conferences-in-september-ymab-20240903monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-reports-second-quarter-2024-financial-results-and-recent-corporate-developments-ymab-20240812monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-participate-in-upcoming-investor-conferences-in-august-ymab-20240807monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-second-quarter-2024-conference-call-and-webcast-ymab-20240805monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-appoints-seasoned-biopharma-executive-peter-pfreundschuh-as-chief-financial-officer-ymab-20240701monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-preclinical-gd2-sada-data-to-be-presented-at-2024-snmmi-annual-meeting-ymab-20240607monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-deepens-radiopharmaceutical-leadership-with-appointment-of-norman-lafrance-m-d-as-c-ymab-20240605monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-publication-of-preclinical-gd2-sada-data-at-2024-asco-annual-meeting-ymab-20240601monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-new-interim-analysis-of-phase-2-data-for-naxitamab-at-2024-asco-annual-me-ymab-20240601monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-reports-first-quarter-2024-financial-results-and-recent-corporate-developments-ymab-20240507monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-first-quarter-2024-financial-and-operating-results-on-may-7-2024-ymab-20240426monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-present-at-2024-asco-annual-meeting-ymab-20240425monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-announces-resignation-of-chief-financial-officer-ymab-20240314monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-appoints-oncology-executive-mary-tagliaferri-m-d-to-its-board-of-directors-ymab-20240304monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-corporate-de-ymab-20240229monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-fourth-quarter-and-full-year-2023-financial-and-operating-results-on-fe-ymab-20240216monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-to-present-at-42nd-annual-j-p-morgan-healthcare-conference-ymab-20240102monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-added-to-the-nasdaq-biotechnology-index-ymab-20231213monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-reports-third-quarter-2023-financial-results-and-recent-corporate-developments-ymab-20231113monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-third-quarter-2023-financial-and-operating-results-on-november-13-2023-ymab-20231031monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-names-michael-rossi-as-president-and-chief-executive-officer-and-director-ymab-20231018monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-announces-u-s-fda-clearance-of-investigational-new-drug-application-fo-ymab-20231017monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-publication-in-cancers-ymab-20231016monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-data-to-be-presented-at-the-55th-congress-of-the-international-society-of-ymab-20230921monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-participate-at-upcoming-investor-conferences-in-september-ymab-20230906monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-reports-second-quarter-2023-financial-results-and-recent-corporate-developments-ymab-20230810monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-participate-at-upcoming-investor-conferences-ymab-20230802monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-second-quarter-2023-financial-and-operating-results-on-august-10-2023-ymab-20230801monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-presentation-of-naxitamab-data-at-asco-ymab-20230526monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-presentation-of-gd2-sada-study-at-asco-ymab-20230526monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-danyelza-naxitamab-gqgk-for-the-treatment-of-high-risk-neuroblastoma-approved-in-br-ymab-20230523monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-reports-first-quarter-2023-financial-results-and-recent-corporate-developments-and--ymab-20230508monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-first-quarter-2023-financial-and-operating-results-on-may-8-2023-ymab-20230428monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-presentation-of-naxitamab-data-at-aacr-ymab-20230418monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-first-patient-dosed-in-phase-1-clinical-trial-of-gd2-sada-ymab-20230405monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-reports-fourth-quarter-and-full-year-2022-financial-results-and-recent-corporate-de-ymab-20230330monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-2022-financial-and-operating-results-on-march-30-2023-ymab-20230321monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-please-contact-the-portnoy-law-firm-to-recover-your-losses-march-2-ymab-20230317monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess--ymab-20230315monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-nasdaq-ymab-shareholder-class-action-alert-bernstein-liebhard-llp--ymab-20230313monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-please-contact-the-portnoy-law-firm-to-recover-your-losses-march-2-ymab-20230310monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-ymab-class-action-notice-robbins-llp-urges-shareholders-to-contact-ymab-20230308monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-ymab-20230308monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-nasdaq-ymab-shareholder-class-action-alert-bernstein-liebhard-llp--ymab-20230306monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess--ymab-20230301monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-ymab-20230222monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-please-contact-the-portnoy-law-firm-to-recover-your-losses-march-2-ymab-20230217monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess--ymab-20230215monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-nasdaq-ymab-shareholder-class-action-alert-bernstein-liebhard-llp--ymab-20230214monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-ymab-class-action-notice-robbins-llp-urges-shareholders-to-contact-ymab-20230209monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-ymab-20230208monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-nasdaq-ymab-shareholder-class-action-alert-bernstein-liebhard-llp--ymab-20230207monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-ymab-investor-alert-robbins-llp-reminds-shareholders-of-lead-plain-ymab-20230202monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-and-the-european-medicines-agency-reach-agreement-on-the-pediatric-investigation-pl-ymab-20230202monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess--ymab-20230201monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-nasdaq-ymab-shareholder-class-action-alert-bernstein-liebhard-llp--ymab-20230131monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-nasdaq-ymab-shareholder-class-action-alert-bernstein-liebhard-llp--ymab-20230126monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-ymab-shareholder-alert-robbins-llp-reminds-investors-of-class-acti-ymab-20230124monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-please-contact-the-portnoy-law-firm-to-recover-your-losses-march-2-ymab-20230122monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-nasdaq-ymab-shareholder-class-action-alert-bernstein-liebhard-llp--ymab-20230120monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-nasdaq-ymab-investor-alert-kaplan-fox-kilsheimer-llp-notifies-y-ma-ymab-20230119monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-class-action-lawsuit-announced-johnson-fistel-encourages-shareholders--ymab-20230118monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-restructuring-plan-and-provides-financial-outlook-following-complete-resp-ymab-20230104monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-to-present-at-41st-annual-j-p-morgan-healthcare-conference-ymab-20230103monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-partnership-regarding-early-access-program-for-danyelza-naxitamab-gqgk-in-ymab-20221221monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-pipeline-update-ymab-20221214monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-danyelza-naxitamab-gqgk-for-the-treatment-of-high-risk-neuroblastoma-approved-in-ch-ymab-20221208monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-host-annual-research-and-development-day-in-new-york-ymab-20221206monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-nasdaq-ymab-investor-update-kaplan-fox-continues-to-investigate-po-ymab-20221202monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-complete-response-letter-for-omburtamab-biologics-license-application-ymab-20221201monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-reports-third-quarter-2022-financial-results-and-recent-corporate-developments-ymab-20221107monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-shareholder-alert-kaplan-fox-investigates-potential-securities-fra-ymab-20221104monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-third-quarter-2022-financial-and-operating-results-on-november-7-2022-ymab-20221102monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-nasdaq-ymab-investor-alert-kaplan-fox-investigates-potential-secur-ymab-20221031monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-outcome-of-fda-advisory-committee-meeting-on-omburtamab-ymab-20221028monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-investigated-by-block-leviton-for-potential-securities-law-violations--ymab-20221026monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-pivotal-data-for-omburtamab-ymab-20221003monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-regulatory-filing-for-danyelza-naxitamab-gqgk-in-brazil-ymab-20220926monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-scheduling-of-fda-advisory-committee-meeting-for-omburtamab-ymab-20220901monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-and-takeda-announces-marketing-authorization-in-israel-for-danyelza-naxitamab-gqgk--ymab-20220830monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-second-quarter-financial-results-and-recent-corporate-developments-ymab-20220808monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-second-quarter-2022-financial-and-operating-results-on-august-8-2022-ymab-20220802monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-clearance-of-ind-for-gd2-sada-ymab-20220712monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-fda-acceptance-of-biologics-license-application-for-omblastys-omburtamab--ymab-20220531monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-naxitamab-chemoimmunotherapy-investigational-trial-for-high-risk-neurobla-ymab-20220526monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-first-quarter-financial-results-and-recent-corporate-developments-ymab-20220509monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-first-quarter-2022-financial-and-operating-results-on-may-9-2022-ymab-20220503monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-executive-management-changes-and-provides-2022-revenue-guidance-and-finan-ymab-20220427monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-presentation-of-sada-technology-at-aacr-ymab-20220408monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-submission-of-omburtamab-biologics-license-application-to-fda-ymab-20220401monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-corporate-de-ymab-20220224monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-2021-financial-and-operating-results-on-february-24-2022-ymab-20220217monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-completion-of-pre-bla-meeting-with-fda-for-omburtamab-ymab-20220211monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-to-present-at-40th-annual-j-p-morgan-healthcare-conference-ymab-20220105monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-pipeline-update-ymab-20211215monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-hosting-virtual-research-and-development-day-ymab-20211206monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-third-quarter-financial-results-and-recent-corporate-developments-ymab-20211104monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-provides-regulatory-update-on-omburtamab-for-the-treatment-of-patients-with-neurobl-ymab-20211104monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-third-2021-financial-and-operating-results-on-november-4-2021-ymab-20211028monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-177lu-omburtamab-dtpa-for-the-treatment-of-patients-with-medulloblastoma-granted-ra-ymab-20211007monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-data-to-be-presented-at-siop-2021-ymab-20210916monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-priority-review-of-bla-for-danyelza-naxitamab-gqgk-in-china-ymab-20210913monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-host-key-opinion-leader-webinar-on-danyelza-naxitamab-gqgk-frontline-and-hits-da-ymab-20210910monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-second-quarter-financial-results-and-recent-corporate-developments-ymab-20210805monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-second-quarter-2021-financial-and-operating-results-on-august-5-2021-ymab-20210729monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-nmpa-submission-of-bla-for-danyelza-naxitamab-gqgk-in-china-ymab-20210706monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-177lu-omburtamab-dtpa-for-the-treatment-of-patients-with-medulloblastoma-receives-p-ymab-20210625monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-provides-regulatory-update-on-omburtamab-for-the-treatment-of-patients-with-neurobl-ymab-20210623monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-frontline-data-for-danyelza-naxitamab-gqgk-in-high-risk-neuroblastoma-ymab-20210604monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-update-on-omburtamab-for-dipg-ymab-20210604monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-enters-into-exclusive-distribution-agreement-with-adium-pharma-s-a-for-danyelza-nax-ymab-20210519monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-update-on-sada-technology-ymab-20210513monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-first-quarter-financial-results-and-recent-corporate-developments-ymab-20210506monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-first-quarter-2021-financial-and-operating-results-on-may-6-2021-ymab-20210429monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-data-to-be-presented-at-2021-asco-annual-meeting-ymab-20210429monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-submits-omburtamab-marketing-authorization-application-to-the-european-medicines-ag-ymab-20210427monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-provides-regulatory-update-on-omburtamab-ymab-20210420monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-gpa33-sada-data-presented-at-aacr-ymab-20210412monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-2020-financial-results-and-recent-corporate-developments-ymab-20210225monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-inc-announces-closing-of-public-offering-and-full-exercise-of-the-unde-ymab-20210222monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-2020-financial-and-operating-results-on-february-25-2021-ymab-20210219monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-pricing-of-public-offering-of-common-stock-ymab-20210218monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-proposed-public-offering-of-common-stock-ymab-20210216monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference-ymab-20210106monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-sale-of-priority-review-voucher-ymab-20201228monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-signs-license-agreement-with-sciclone-for-danyelza-naxitamab-gqgk-and-omburtamab-in-ymab-20201218monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-signs-distribution-agreement-with-swixx-for-danyelza-naxitamab-gqgk-and-omburtamab--ymab-20201218monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-pipeline-update-ymab-20201216monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-update-on-danyelza-naxitamab-gqgk-at-esmo-ymab-20201209monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-host-virtual-research-development-day-on-wednesday-december-16-ymab-20201207monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-and-takeda-announce-exclusive-license-and-distribution-agreement-for-danyelza-naxit-ymab-20201204monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-update-on-omburtamab-in-dipg-ymab-20201119monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-third-quarter-2020-financial-results-and-recent-corporate-developments-ymab-20201105monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-third-quarter-2020-financial-and-operating-results-on-november-5-2020-ymab-20201029monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-fda-clearance-of-ind-for-lutetium-177-labeled-omburtamab-antibody-for-adu-ymab-20201026monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-update-on-naxitamab-and-omburtamab-in-neuroblastoma-ymab-20201016monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-fda-clearance-of-ind-for-its-lutetium-177-labeled-omburtamab-antibody-ymab-20201014monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-nivatrotamab-for-the-treatment-of-patients-with-neuroblastoma-granted-orphan-drug-d-ymab-20201007monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-provides-regulatory-update-on-omburtamab-for-the-treatment-of-patients-with-neurobl-ymab-20201005monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-second-quarter-2020-financial-results-and-recent-corporate-developments-ymab-20200806monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-completion-of-submission-of-omburtamab-biologics-license-application-to-f-ymab-20200806monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-second-quarter-2020-financial-and-operating-results-on-august-6-2020-ymab-20200804monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-data-to-be-presented-at-2020-siop-ymab-20200727monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-update-on-sada-technology-and-new-preclinical-sada-construct-ymab-20200714monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-initiation-of-submission-of-omburtamab-rolling-biologics-license-applicat-ymab-20200630monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-u-s-fda-acceptance-of-biologics-license-application-for-danyelza-naxitama-ymab-20200602monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-data-to-be-presented-at-2020-asco-annual-meeting-ymab-20200513monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-first-quarter-2020-financial-results-and-recent-corporate-developments-ymab-20200507monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-2019-financial-and-operating-results-on-may-7-2020-ymab-20200430monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-appointment-of-laura-j-hamill-to-its-board-of-directors-ymab-20200424monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-enters-into-worldwide-exclusive-license-agreement-for-sada-technology-a-novel-radio-ymab-20200415monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-submission-of-naxitamab-biologics-license-application-to-u-s-fda-ymab-20200401monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-2019-financial-results-and-recent-corporate-developments-ymab-20200312monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-2019-financial-and-operating-results-on-march-12-2020-ymab-20200305monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-positive-pre-bla-meeting-with-fda-for-omburtamab-ymab-20200226monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-to-present-at-38th-annual-j-p-morgan-healthcare-conference-ymab-20200107monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-gd2-gd3-vaccine-granted-rare-pediatric-disease-designation-ymab-20191212monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-positive-naxitamab-frontline-data-ymab-20191211monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-and-the-european-medicines-agency-pediatric-committee-reach-agreement-on-the-pediat-ymab-20191205monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-host-r-d-event-and-live-webcast-on-wednesday-december-11-ymab-20191205monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-initiates-rolling-submission-of-biologics-license-application-to-u-s-fda-for-naxita-ymab-20191129monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-update-on-omburtamab-in-dsrct-ymab-20191115monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-third-quarter-2019-financial-results-and-recent-corporate-developments-ymab-20191113monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-third-quarter-2019-financial-and-operating-results-on-november-13-ymab-20191106monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-closing-of-public-offering-and-full-exercise-of-the-underwriters-option-t-ymab-20191101monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-pricing-of-public-offering-of-common-stock-ymab-20191030monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-proposed-public-offering-of-common-stock-ymab-20191029monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-positive-omburtamab-clinical-data-ymab-20191028monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-naxitamab-update-ymab-20191025monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-data-to-be-presented-at-2019-ctos-ymab-20190830monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-second-quarter-2019-financial-results-and-recent-corporate-developments-ymab-20190814monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-to-announce-second-quarter-2019-financial-and-operating-results-on-august-14-ymab-20190807monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-successful-pre-bla-meeting-with-fda-for-naxitamab-ymab-20190708monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-recruitment-status-for-pivotal-trials-ymab-20190701monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-secures-commercial-radiolabeling-capacity-ymab-20190701monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-data-to-be-presented-at-2019-siop-ymab-20190626monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-data-to-be-presented-at-2019-asco-annual-meeting-ymab-20190515monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-development-update-on-cancer-vaccine-program-ymab-20190514monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-first-quarter-2019-financial-results-and-recent-corporate-developments-ymab-20190510monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-to-present-at-the-bank-of-america-merrill-lynch-healthcare-conference--ymab-20190508monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference-in-lo-ymab-20190403monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-2018-financial-results-and-corporate-development-highlights-ymab-20190322monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-to-present-at-cowen-s-39th-annual-health-care-conference-ymab-20190308monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-to-present-at-pegs-boston-ymab-20190213monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-to-present-at-37th-annual-j-p-morgan-healthcare-conference-ymab-20181213monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-announces-fda-clearance-of-ind-for-its-bispecific-gd2-antibody-ymab-20181210monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-third-quarter-2018-financial-results-and-recent-corporate-developments-ymab-20181113monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-announces-closing-of-initial-public-offering-and-full-exercise-of-unde-ymab-20180925monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-therapeutics-announces-pricing-of-initial-public-offering-ymab-20180921monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-receives-breakthrough-therapy-designation-for-naxitamab-for-the-treatment-of-high-r-ymab-20180822monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-to-host-virtual-investor-event-to-share-new-phase-2-data-and-phase-3-program--slrn-20250103monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-announces-topline-results-from-phase-2b-3-study-of-izokibep-for-the-treatment-slrn-20241210monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-reports-third-quarter-2024-financial-results-and-recent-highlights-slrn-20241113monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-to-report-third-quarter-2024-financial-results-and-corporate-update-on-novemb-slrn-20241106monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-forms-scientific-and-patient-advisory-board-featuring-leading-voices-in-thyro-slrn-20241016monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-announces-positive-results-from-global-phase-3-clinical-trial-of-izokibep-in--slrn-20240919monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-announces-positive-proof-of-concept-data-from-phase-1-2-clinical-trial-of-lon-slrn-20240910monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-to-participate-in-upcoming-investor-conferences-slrn-20240822monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-announces-positive-phase-3-data-for-izokibep-in-hidradenitis-suppurativa-focu-slrn-20240813monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-to-report-second-quarter-2024-financial-results-and-corporate-update-on-augus-slrn-20240806monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-announces-positive-16-week-data-from-its-global-phase-2b-3-trial-of-izokibep--slrn-20240605monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-announces-lonigutamab-phase-1-2-proof-of-concept-data-to-be-shared-during-lat-slrn-20240529monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-alert-bragar-eagel-squire-p-c-is-investigating-acelyrin-inc-on-behalf-of-long-ter-slrn-20240518monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-provides-business-update-and-highlights-key-upcoming-milestones-slrn-20240509monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-announces-leadership-transition-slrn-20240509monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-to-report-first-quarter-2024-financial-results-and-corporate-update-on-may-13-slrn-20240429monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-reports-full-year-2023-financial-results-and-recent-highlights-slrn-20240328monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-announces-positive-phase-1-2-proof-of-concept-data-for-lonigutamab-first-subc-slrn-20240320monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-announces-positive-top-line-results-from-its-global-phase-2b-3-clinical-trial-slrn-20240311monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-announces-long-term-32-week-data-from-the-phase-2b-trial-of-izokibep-in-hidra-slrn-20240311monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-appoints-agnes-lee-as-senior-vice-president-investor-relations-and-corporate--slrn-20240215monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-deadline-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-laws-slrn-20240113monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-shareholder-notice-faruqi-faruqi-securities-litigation-partner-james-josh-wilson--slrn-20240110monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-shareholder-action-reminder-faruqi-faruqi-securities-litigation-partner-james-jos-slrn-20240105monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-slrn-faces-investor-fraud-lawsuit-for-allegedly-lying-about-drug-candidate-s-prog-slrn-20240101monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-shareholder-notice-faruqi-faruqi-securities-litigation-partner-james-josh-wilson--slrn-20231227monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-slrn-20231225monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-slrn-20231221monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-appoints-lynn-tetrault-to-board-of-directors-slrn-20231220monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-ongoing-deadline-alert-faruqi-faruqi-securities-litigation-partner-james-josh-wil-slrn-20231219monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-slrn-shareholder-reminder-kessler-topaz-meltzer-check-llp-reminds-slrn-invest-slrn-20231216monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-slrn-20231216monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-slrn-discloses-cro-errors-in-izokibep-program-in-wake-of-investor-class-action-ha-slrn-20231215monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-shareholder-action-reminder-faruqi-faruqi-securities-litigation-partner-james-jos-slrn-20231215monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-investor-update-kaplan-fox-kilsheimer-llp-notifies-acelyrin-investors-of-a-cl-slrn-20231213monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-january--slrn-20231213monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-slrn-discloses-cro-errors-in-izokibep-program-in-wake-of-investor-class-action-ha-slrn-20231211monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-slrn-20231211monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-investor-deadline-approaching-faruqi-faruqi-securities-litigation-partner-james-j-slrn-20231207monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-slrn-discloses-cro-errors-in-izokibep-program-in-wake-of-investor-class-action-ha-slrn-20231207monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-slrn-20231206monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-lawsuit-reminder-contact-robbins-llp-for-information-about-your-rights-agains-slrn-20231204monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-shareholder-alert-faruqi-faruqi-securities-litigation-partner-james-josh-wilson-e-slrn-20231202monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-slrn-20231201monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-january--slrn-20231128monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-provides-update-on-izokibep-clinical-development-program-slrn-20231127monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-ongoing-deadline-alert-faruqi-faruqi-securities-litigation-partner-james-josh-wil-slrn-20231126monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-slrn-20231126monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-slrn-class-action-alert-robbins-llp-reminds-investors-of-the-lead-plaintiff-d-slrn-20231121monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-slrn-20231121monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-slrn-faces-lawsuit-after-allegedly-lying-about-drug-candidate-s-progress-hagens-b-slrn-20231120monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-slrn-20231116monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-reports-third-quarter-2023-financial-results-and-recent-highlights-slrn-20231107monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-appoints-patricia-turney-as-chief-technical-operations-officer-slrn-20231106monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-to-report-third-quarter-2023-financial-results-and-corporate-update-on-novemb-slrn-20231031monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-scales-for-continued-late-stage-growth-with-the-appointment-of-dr-shephard-mp-slrn-20231003monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-announces-top-line-results-from-placebo-controlled-clinical-trial-of-izokibep-slrn-20230911monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-to-present-at-the-morgan-stanley-21st-annual-global-healthcare-conference-slrn-20230906monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-reports-second-quarter-2023-financial-results-and-recent-highlights-slrn-20230814monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-to-present-second-quarter-2023-financial-results-and-corporate-update-on-augu-slrn-20230807monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer-slrn-20230718monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-reports-first-quarter-2023-financial-results-and-recent-highlights-slrn-20230615monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-drug-delivery-technologies-are-reshaping-alzheimer-s-and-biodefense-research-cnsp-20260513monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-drug-delivery-breakthroughs-unlock-significant-biotech-market-opportunities-cnsp-20260511monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-inc-featured-in-syndicated-broadcast-covering-activation-of-first-clin-cnsp-20221007monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-digital-therapeutics-market-to-grow-at-a-31-6-cagr-from-2022-to-2030-mdc-research-cnsp-20220419monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-inc-featured-in-syndicated-broadcast-covering-dosing-of-first-patients-cnsp-20211011monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-featured-in-syndicated-broadcast-covering-recent-fda-approval-of-ind-a-cnsp-20201228monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-featured-in-syndicated-broadcast-covering-recent-announcements-for-gli-cnsp-20201124monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-and-image-analysis-group-partner-to-further-the-development-of-berubic-cnsp-20200924monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-announces-us-drug-manufacturing-milestones-cnsp-20200903monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-appoints-john-fortson-as-chief-financial-officer-xray-20260611monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-continues-to-expand-u-s-distribution-network-to-strengthen-access-to-its-d-xray-20260526monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-participate-in-the-2026-stifel-jaws-paws-conference-xray-20260520monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-fourth-quarter-and-full-year-2025-results-provides-full-year-2026--xray-20260226monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-and-burkhart-dental-supply-announce-expanded-distribution-partnership-to-i-xray-20260224monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-fourth-quarter-and-full-year-conference-call-on-february-26-xray-20260205monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-and-benco-dental-announce-expanded-partnership-to-include-dental-technolog-xray-20260113monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-xray-20260106monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-second-quarter-2025-results-xray-20250807monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20250527monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-participate-in-the-2025-stifel-jaws-paws-conference-xray-20250519monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-first-quarter-2025-results-xray-20250508monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-first-quarter-conference-call-on-may-8th-xray-20250409monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-appoints-david-ferguson-as-global-business-unit-leader-xray-20250317monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-participate-in-the-leerink-partners-global-healthcare-conference-2025-xray-20250304monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-fourth-quarter-and-full-year-2024-results-provides-full-year-2025--xray-20250227monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-alert-bragar-eagel-squire-p-c-is-investigating-dentsply-sirona-inc-on-behalf-of-l-xray-20250214monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-initiates-review-of-strategic-alternatives-for-wellspect-healthcare-xray-20250211monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-appoints-michael-barber-and-daniel-scavilla-as-new-board-members-xray-20250206monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-alert-bragar-eagel-squire-p-c-is-investigating-dentsply-sirona-inc-on-behalf-of-l-xray-20250130monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-fourth-quarter-and-full-year-2024-conference-call-on-february-27th-xray-20250127monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-j-xray-20250124monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-fi-xray-20250121monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsi-xray-20250116monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-repositioning-of-byte-within-aligner-portfolio-xray-20250114monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsi-xray-20250113monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsi-xray-20250108monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-xray-20250108monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-j-xray-20250107monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-xray-20241227monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-j-xray-20241223monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-nasdaq-xray-deadline-alert-bernstein-liebhard-llp-reminds-dentsply-sir-xray-20241223monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-xray-20241219monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-nasdaq-xray-deadline-alert-bernstein-liebhard-llp-reminds-dentsply-sir-xray-20241218monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20241213monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-fi-xray-20241210monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-xray-20241210monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-nasdaq-xray-deadline-alert-bernstein-liebhard-llp-reminds-dentsply-sir-xray-20241209monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-xray-20241204monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-j-xray-20241203monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-participate-in-the-7th-annual-evercore-isi-healthconx-conference-xray-20241203monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-appoints-herman-v-cueto-interim-chief-financial-officer-xray-20241203monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-investor-alert-robbins-llp-reminds-xray-stockholders-of-the-pending-cl-xray-20241202monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-nasdaq-xray-investor-alert-investors-with-large-losses-in-dentsply-sir-xray-20241202monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-breaking-news-bfa-law-announces-that-dentsply-sirona-inc-has-been-sued-for-securi-xray-20241127monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-third-quarter-2024-results-xray-20241107monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-conference-call-regarding-update-on-byte-aligner-products-xray-20241025monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-provides-update-on-byte-aligner-products-xray-20241024monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-third-quarter-conference-call-on-november-7th-xray-20241009monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-participate-in-upcoming-investor-conferences-xray-20240829monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-initiates-search-for-new-cfo-xray-20240820monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-second-quarter-2024-results-and-announces-second-phase-of-transfor-xray-20240731monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-second-quarter-conference-call-on-july-31st-xray-20240709monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-provides-update-on-june-investor-conference-participation-xray-20240612monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-participate-in-upcoming-investor-conferences-xray-20240530monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20240522monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-participate-in-upcoming-investor-conferences-xray-20240508monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-first-quarter-2024-results-xray-20240502monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-first-quarter-conference-call-on-may-2nd-xray-20240409monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-retirement-of-eric-k-brandt-from-the-board-of-directors-xray-20240229monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-fourth-quarter-and-full-year-2023-results-provides-full-year-2024--xray-20240229monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-fourth-quarter-and-full-year-2023-conference-call-on-february-29th-xray-20240129monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-j-p-morgan-healthcare-conference-provides-update-on-anticipa-xray-20240109monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-xray-20240103monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20231221monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-participate-in-upcoming-investor-conferences-xray-20231110monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-its-investor-day-and-introduce-three-year-financial-targets-xray-20231109monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-appointment-of-mr-brian-gladden-as-new-board-member-xray-20231102monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-third-quarter-2023-results-xray-20231102monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-third-quarter-conference-call-on-november-2nd-xray-20231018monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-planned-board-succession-xray-20230929monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-investor-day-on-november-9-2023-xray-20230925monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-participate-in-the-baird-2023-global-healthcare-conference-xray-20230818monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-second-quarter-2023-results-xray-20230802monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-second-quarter-conference-call-on-august-3rd-xray-20230712monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20230524monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-participate-in-upcoming-investor-conferences-xray-20230508monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-first-quarter-2023-results-xray-20230503monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-first-quarter-conference-call-on-may-3rd-xray-20230405monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-150-million-accelerated-share-repurchase-program-xray-20230306monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-fourth-quarter-and-full-year-2022-results-provides-full-year-2023--xray-20230228monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-organizational-changes-to-simplify-structure-enhance-profitabili-xray-20230216monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-fourth-quarter-and-full-year-2022-conference-call-on-february-28th-xray-20230202monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-j-p-morgan-healthcare-conference-provides-update-on-anticipa-xray-20230111monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-xray-20221220monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20221215monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-third-quarter-2022-results-xray-20221114monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-participate-in-upcoming-investor-conferences-xray-20221111monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-third-quarter-conference-call-on-november-14th-xray-20221109monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-completes-internal-investigation-xray-20221101monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-appoints-glenn-coleman-as-chief-financial-officer-xray-20220922monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-appoints-simon-campion-as-chief-executive-officer-xray-20220825monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-receives-notice-of-filing-delinquency-from-nasdaq-xray-20220815monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-provides-business-update-xray-20220804monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-remind-xray-20220727monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-nasdaq-xray-shareholder-class-action-alert-bernstein-liebhard-llp-remi-xray-20220726monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000--xray-20220720monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-nasdaq-xray-shareholder-class-action-alert-bernstein-liebhard-llp-remi-xray-20220719monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-remind-xray-20220713monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-nasdaq-xray-shareholder-class-action-alert-bernstein-liebhard-llp-remi-xray-20220712monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-nasdaq-xray-shareholder-class-action-alert-bernstein-liebhard-llp-remi-xray-20220706monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000--xray-20220706monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-remind-xray-20220629monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-nasdaq-xray-shareholder-class-action-alert-bernstein-liebhard-llp-remi-xray-20220628monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-nasdaq-xray-shareholder-class-action-alert-bernstein-liebhard-llp-remi-xray-20220622monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000--xray-20220622monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-portno-xray-20220620monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-nasdaq-xray-shareholder-class-action-alert-bernstein-liebhard-llp-remi-xray-20220615monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-remind-xray-20220615monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000--xray-20220608monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-nasdaq-xray-shareholder-class-action-alert-bernstein-liebhard-llp-anno-xray-20220607monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-investigation-alert-bernstein-liebhard-is-investigating-dentsply-siron-xray-20220601monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20220527monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-receives-notice-of-filing-delinquency-from-nasdaq-xray-20220518monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-investigation-alert-bernstein-liebhard-is-investigating-dentsply-siron-xray-20220513monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-investigated-by-block-leviton-for-potential-securities-law-violations--xray-20220511monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-investors-company-investigated-by-the-portnoy-law-firm-xray-20220511monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-preliminary-first-quarter-2022-results-xray-20220510monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-opens-the-gateway-to-a-new-digital-universe-with-cloud-based-solution-ds-c-xray-20220504monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-changes-first-quarter-conference-call-date-to-may-10th-xray-20220502monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-alert-bragar-eagel-squire-p-c-is-investigating-dentsply-sirona-inc-on-behalf-of-d-xray-20220426monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-investors-company-investigated-by-the-portnoy-law-firm-xray-20220426monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-dents-xray-20220420monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-provides-corporate-update-xray-20220419monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-cfo-jorge-gomez-resigns-to-assume-cfo-position-at-another-public-company-xray-20220411monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-appointment-of-mr-john-p-groetelaars-as-new-board-member-xray-20220406monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-first-quarter-conference-call-on-may-5th-xray-20220405monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-participate-in-the-piper-sandler-virtual-dental-day-xray-20220318monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-150-million-accelerated-share-repurchase-program-xray-20220309monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-fourth-quarter-and-full-year-2021-results-xray-20220228monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-latest-steps-to-further-drive-its-leadership-in-digital-dentistr-xray-20220225monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-appointment-of-dr-dorothea-wenzel-as-new-board-member-xray-20220224monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-fourth-quarter-and-full-year-2021-conference-call-on-february-28th-xray-20220204monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-xray-20211230monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20211216monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-and-3shape-expand-their-strategic-partnership-with-seamless-connectivity-f-xray-20211208monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-upcoming-virtual-investor-conferences-xray-20211109monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-third-quarter-2021-results-xray-20211104monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-third-quarter-2021-conference-call-on-november-4th-xray-20211006monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-a-comprehensive-restage-of-its-implant-business-xray-20210924monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-new-sustainability-strategy-beyond-taking-action-for-a-brighter--xray-20210923monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-world-2021-to-feature-broad-range-of-new-products-and-services-for-dental--xray-20210915monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-baird-2021-global-healthcare-conference-on-september-15t-xray-20210902monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-second-quarter-2021-results-xray-20210805monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-second-quarter-2021-conference-call-on-august-5th-xray-20210706monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-acquires-the-assets-of-propel-orthodontics-a-leading-innovator-in-orthodon-xray-20210604monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-increases-quarterly-cash-dividend-by-10-xray-20210527monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-four-upcoming-virtual-investor-conferences-xray-20210524monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-first-quarter-2021-results-xray-20210506monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-first-quarter-2021-conference-call-on-may-6th-xray-20210407monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-2021-barclays-global-healthcare-conference-on-march-10th-xray-20210309monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-fourth-quarter-and-full-year-2020-results-xray-20210301monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20210225monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-fourth-quarter-and-full-year-2020-conference-call-on-march-1st-xray-20210205monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-xray-20210107monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-acquires-byte-a-leading-direct-to-consumer-doctor-directed-clear-aligner-c-xray-20210104monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20201210monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-wolfe-research-virtual-healthcare-conference-on-november-xray-20201112monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-credit-suisse-29th-annual-virtual-healthcare-conference-xray-20201109monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-2020-third-quarter-results-xray-20201105monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-third-quarter-2020-conference-call-on-november-5th-xray-20201012monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-appointment-of-clyde-hosein-as-new-board-member-xray-20200916monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-baird-2020-global-healthcare-conference-xray-20200904monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-second-quarter-2020-results-xray-20200806monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20200729monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-second-quarter-2020-conference-call-on-august-6th-xray-20200722monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-wins-summary-judgment-against-edge-endo-and-us-endodontics-in-patent-i-xray-20200624monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-stifel-2020-virtual-jaws-and-paws-conference-on-may-27th-xray-20200525monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20200521monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-preliminary-first-quarter-2020-results-xray-20200508monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-first-quarter-2020-conference-call-on-may-7th-xray-20200501monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-2020-barclays-global-healthcare-conference-on-march-11th-xray-20200310monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-fourth-quarter-and-full-year-2019-results-xray-20200302monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20200229monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-fourth-quarter-and-full-year-2019-conference-call-on-march-2nd-xray-20200204monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-xray-20200110monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20191212monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-third-quarter-2019-financial-performance-xray-20191107monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-third-quarter-2019-conference-call-on-november-7th-xray-20191024monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-appointment-of-janet-vergis-as-new-board-member-xray-20190925monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-2019-baird-global-healthcare-conference-on-september-4th-xray-20190830monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-strong-second-quarter-2019-results-xray-20190802monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-second-quarter-2019-conference-call-on-august-2nd-xray-20190711monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-appointment-of-jorge-m-gomez-as-chief-financial-officer-xray-20190708monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-2019-william-blair-growth-stock-conference-on-june-6th-xray-20190530monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-stifel-2019-dental-veterinary-conference-on-may-29th-xray-20190523monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-board-approves-relocation-of-headquarters-to-charlotte-n-c-and-announces-c-xray-20190523monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20190522monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-solid-first-quarter-2019-results-xray-20190503monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-first-quarter-2019-conference-call-on-may-3rd-xray-20190409monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-preliminary-fourth-quarter-and-full-year-2018-results-xray-20190301monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20190228monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-xray-the-goldman-sachs-group-inc-gs-allergan-plc-agn-ja-solar-holdings-xray-20190219monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-remind-xray-20190209monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000--xray-20190202monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-fourth-quarter-and-full-year-2018-conference-call-on-march-1st-xray-20190201monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000--xray-20190105monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that--xray-20181227monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-remind-xray-20181222monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-xray-20181221monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20181214monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-third-quarter-2018-results-announces-restructuring-plan-to-drive-v-xray-20181108monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-third-quarter-2018-conference-call-on-november-8th-xray-20181022monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-baird-2018-global-healthcare-conference-on-september-5th-xray-20180830monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-second-quarter-2018-results-xray-20180807monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-second-quarter-2018-conference-call-on-august-7th-xray-20180720monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20180626monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-stifel-2018-dental-veterinary-conference-on-may-30th-xray-20180527monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-first-quarter-2018-results-xray-20180506monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20180425monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-host-first-quarter-2018-conference-call-on-may-7th-xray-20180425monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-acquisition-of-technology-solutions-provider-orametrix-xray-20180326monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-preliminary-fourth-quarter-and-full-year-2017-results-xray-20180301monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-report-fourth-quarter-and-fiscal-2017-results-xray-20180227monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20180214monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-the-addition-of-new-board-members-xray-20180117monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-xray-20180105monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20171212monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-third-quarter-2017-results-xray-20171103monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-report-third-quarter-2017-results-on-november-3rd-xray-20171025monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-additions-to-executive-leadership-team-xray-20171016monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-leadership-changes-xray-20171002monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-second-quarter-2017-results-xray-20170809monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-report-second-quarter-2017-results-on-august-9th-xray-20170801monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20170628monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-announces-expanded-distribution-in-canada-xray-20170628monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20170622monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-expands-and-extends-relationship-with-pacific-dental-services-llc-xray-20170616monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-first-quarter-2017-results-xray-20170509monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-report-first-quarter-2017-results-on-may-9-xray-20170503monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-fourth-quarter-and-full-year-2016-results-xray-20170217monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-raises-quarterly-cash-dividend-xray-20170217monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-report-fourth-quarter-and-fiscal-2016-results-on-february-17-xray-20170210monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-declares-quarterly-cash-dividend-xray-20161215monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-third-quarter-2016-results-xray-20161104monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-to-report-third-quarter-2016-results-on-november-4-xray-20161021monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-inc-to-join-the-nasdaq-100-index-beginning-june-20-2016-xray-20160611monthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-and-sirona-announce-combination-to-create-the-dental-solutions-company-in-13-bill-xray-20150915monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-inc-announces-receipt-of-washington-state-radioactive-materials-license-for-isopet-m-vvos-20260611monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-first-quarter-2026-financial-results-and-provides-operational-u-vvos-20260520monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-schedules-release-of-full-year-2025-financial-results-and-conference-ca-vvos-20260415monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-completes-private-placement-with-existing-private-equity-investor-new-s-vvos-20260407monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-inc-strengthens-patent-protection-with-new-u-s-patent-issuance-and-precisiongel-trad-vvos-20260128monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-inc-summarizes-progress-in-its-animal-therapy-division-vvos-20251222monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-inc-summarzes-preogress-in-its-animal-therapy-division-vvos-20251222monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-inc-issues-shareholder-update-letter-vvos-20251106monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-inc-strengthens-strategic-collaboration-with-exubrion-therapeutics-vvos-20251029monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-inc-demonstrates-precision-in-precision-radionuclide-therapy-vvos-20250908monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-inc-files-critical-patent-for-hydrogel-electron-beam-sterilization-vvos-20250903monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-schedules-release-of-first-quarter-2025-financial-results-and-conferenc-vvos-20250514monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-inc-reports-continued-progress-in-india-human-clinical-trial-for-radiogel-precision--vvos-20250415monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-ca-vvos-20250328monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-expands-strategic-alliance-in-colorado-and-seeks-new-sleep-center-affil-vvos-20250224monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-participate-in-fireside-chat-with-water-tower-research-on-february-1-vvos-20250218monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-inc-reports-encouraging-human-clinical-trial-results-and-announces-expansion-plans-vvos-20250204monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-inc-s-isopet-division-achieves-exceptional-growth-in-2024-expanding-certified-veteri-vvos-20241226monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-inc-announces-launch-of-groundbreaking-radiogel-precision-radionuclide-therapy-human-vvos-20241223monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-schedules-release-of-third-quarter-2024-financial-results-and-conferenc-vvos-20241113monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-inc-certifies-new-clinic-for-isopet-precision-radionuclide-therapytm-vvos-20241018monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-granted-cpt-coverage-and-reimbursement-codes-for-all-vivos-care-oral-me-vvos-20241008monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-inc-extended-its-isopet-precision-radionuclide-therapytm-to-exotics-vvos-20240930monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-schedules-release-of-second-quarter-2024-financial-results-and-conferen-vvos-20240814monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-inc-provides-ide-submission-status-update-conversion-to-pre-sub-filing-accepted-by-t-vvos-20240729monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-inc-submits-the-application-to-the-fda-for-authority-to-initiate-human-clinical-tria-vvos-20240628monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-positive-results-from-7-month-multi-site-pilot-of-its-new-pro-vvos-20240627monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-schedules-release-of-first-quarter-2024-financial-results-and-conferenc-vvos-20240514monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-flagship-care-oral-medical-devices-receive-full-approval-for-medicare-r-vvos-20240409monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-schedules-release-of-fourth-quarter-and-full-year-2023-financial-result-vvos-20240328monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-exercise-of-warrants-for-approximately-4-0-million-aggregate--vvos-20240215monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-highlights-significant-favorable-market-developments-creating-exciting--vvos-20240206monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-sees-positive-preliminary-metrics-following-unprecedented-fda-510-k-cle-vvos-20240108monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-presents-groundbreaking-event-empowering-women-to-champion-airway-vvos-20231211monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-receives-first-ever-fda-510-k-clearance-for-oral-device-treatment-of-se-vvos-20231129monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-third-quarter-2023-financial-results-and-provides-operational-u-vvos-20231114monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-schedules-release-of-third-quarter-2023-financial-results-and-conferenc-vvos-20231109monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-closes-4-million-private-placement-vvos-20231102monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-pricing-of-4-million-private-placement-priced-at-the-market-u-vvos-20231031monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-reverse-stock-split-vvos-20231026monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-signs-nationwide-distribution-agreement-with-lincare-vvos-20231024monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-begin-clinical-trial-at-stanford-medicine-vvos-20231011monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-strategic-collaboration-in-the-middle-east-north-africa-regio-vvos-20231005monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-executes-strategic-agreements-with-ormco-and-on-demand-orthodontist-to--vvos-20231004monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reschedules-second-quarter-2023-financial-results-conference-call-vvos-20230816monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-reschedule-second-quarter-2023-financial-results-conference-call-vvos-20230814monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-schedules-release-of-second-quarter-2023-financial-results-and-conferen-vvos-20230811monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-schedules-release-of-first-quarter-2023-financial-results-and-conferenc-vvos-20230606monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-schedules-release-of-fourth-quarter-and-full-year-2022-financial-result-vvos-20230330monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-participate-in-fireside-chat-at-the-35th-annual-roth-conference-vvos-20230308monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-present-at-the-emerging-growth-conference-on-february-22-2023-vvos-20230221monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-regains-compliance-with-nasdaq-listing-requirements-vvos-20230120monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-closes-8-million-private-placement-vvos-20230109monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-receives-fda-510-k-clearance-of-its-flagship-dna-oral-appliance-for-tre-vvos-20230104monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-schedules-release-of-second-and-third-quarter-2022-financial-results-an-vvos-20221216monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-new-revenue-stream-through-strategic-medical-billing-relation-vvos-20221215monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-receipt-of-notice-from-nasdaq-regarding-late-filing-of-quarte-vvos-20220826monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-provides-update-on-second-quarter-earnings-delay-vvos-20220822monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-reschedule-second-quarter-2022-financial-results-conference-call-vvos-20220815monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-schedules-second-quarter-2022-financial-results-conference-call-vvos-20220809monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-exclusive-distribution-agreement-with-gm-instruments-ltd-for--vvos-20220629monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-sleep-2022-annual-meeting-presentation-highlights-retrospective-study-d-vvos-20220614monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-present-at-upcoming-sleep-2022-annual-meeting-vvos-20220526monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-first-quarter-2022-financial-results-and-operational-update-vvos-20220516monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-schedules-first-quarter-2022-financial-results-conference-call-vvos-20220428monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-opens-third-u-s-multidisciplinary-center-to-treat-patients-suffering-fr-vvos-20220426monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-schedules-fourth-quarter-and-full-year-2021-financial-results-conferenc-vvos-20220331monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-rebrands-proprietary-clinical-protocol-for-treating-patients-with-breat-vvos-20220303monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-participate-in-upcoming-investor-conferences-vvos-20220302monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-present-at-march-2022-world-sleep-congress-in-rome-vvos-20220224monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-files-for-us-patent-on-proprietary-new-clinical-protocols-after-seeing--vvos-20220127monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-18x-increase-in-sleep-apnea-diagnostic-testing-by-vivos-denti-vvos-20220119monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-mmrna-oral-appliance-now-eligible-for-medicare-reimbursement-vvos-20211214monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-registration-with-health-canada-to-manufacture-and-sell-sleep-vvos-20211209monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-participate-at-the-benzinga-global-small-cap-conference-vvos-20211203monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-third-quarter-2021-financial-results-and-operational-update-vvos-20211115monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-participate-at-the-q4-virtual-investor-summit-vvos-20211115monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-schedules-third-quarter-2021-financial-results-conference-call-vvos-20211109monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-participate-at-the-benzinga-global-small-cap-conference-vvos-20211022monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-2021-annual-breathing-wellness-conference-presented-by-the-vi-vvos-20211019monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-and-candid-announce-strategic-collaboration-to-deliver-a-comprehensive--vvos-20211018monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-formation-of-new-medical-consortium-to-advance-the-company-s--vvos-20210923monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-participate-at-the-benzinga-healthcare-small-cap-conference-vvos-20210922monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conf-vvos-20210908monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-and-empower-sleep-launch-cooperative-relationship-aimed-at-significantl-vvos-20210826monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-second-quarter-2021-financial-results-and-operational-update-vvos-20210812monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-participate-at-the-q3-virtual-investor-summit-vvos-20210809monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call-vvos-20210809monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-opens-state-of-the-art-international-training-center-in-denver-vvos-20210729monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-founder-chief-medical-officer-releases-new-book-highlighting-his-ground-vvos-20210526monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-first-quarter-2021-financial-results-and-operational-update-vvos-20210517monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-schedules-first-quarter-2021-financial-results-conference-call-vvos-20210513monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-pricing-of-24-million-follow-on-offering-vvos-20210507monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-integrative-cardiologist-dr-mimi-guarneri-as-new-medical-dire-vvos-20210414monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-participate-at-the-emerging-growth-conference-vvos-20210412monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-launch-myocorrect-orofacial-myofunctional-therapy-service-vvos-20210330monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-participate-at-the-benzinga-biotech-small-cap-conference-vvos-20210322monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-schedules-fourth-quarter-and-full-year-2020-financial-results-conferenc-vvos-20210318monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-participate-at-the-q1-virtual-investor-summit-vvos-20210311monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-the-opening-of-the-first-pneusomnia-integrated-medical-dental-vvos-20210308monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-participate-in-the-virtual-33rd-annual-roth-conference-on-march-15-1-vvos-20210301monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-submits-fda-510-k-application-for-the-vivos-mmrna-oral-appliance-vvos-20210202monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generatio-vvos-20210129monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-launches-aireo2-patient-management-technology-to-treat-patients-with-ob-vvos-20210106monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-pricing-of-21m-initial-public-offering-vvos-20201211monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-filing-of-registration-statement-for-proposed-initial-public--vvos-20201009monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-announces-corporate-rebrand-to-streamex-corp-bsgm-20250910monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-supplements-clarification-on-recent-schedule-14a-filing-closing-of-mer-bsgm-20250903monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-streamex-announce-closing-of-15-million-public-offering-bsgm-20250815monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-announces-pricing-of-15-million-public-offering-bsgm-20250814monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-announces-proposed-public-offering-bsgm-20250813monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-signs-definitive-share-exchange-agreement-with-streamex-exchange-c-bsgm-20250523monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-confirms-full-compliance-with-nasdaq-requirements-for-continued-listin-bsgm-20250326monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-common-stock-to-resume-trading-on-the-nasdaq-exchange-wednesday-octobe-bsgm-20241022monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-announces-intent-to-acquire-the-assets-of-neuro-kinesis-corporation-bsgm-20240731monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-improves-balance-sheet-announces-reduction-in-outstanding-payables-dur-bsgm-20240725monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-appoints-mr-ferdinand-groenewald-to-position-of-interim-chief-financia-bsgm-20240610monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-chief-executive-officer-mr-anthony-amato-issues-the-following-letter-t-bsgm-20240521monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-announces-new-appointments-to-its-now-fully-constituted-board-of-d-bsgm-20240503monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-appoints-mr-anthony-amato-to-position-of-chief-executive-officer-e-bsgm-20240430monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-issues-letter-to-shareholders-detailing-technology-innovations-and-strategic-focus--bsgm-20231206monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-adds-five-new-patent-awards-to-100-total-patent-portfolio-covering-digital-signal-p-bsgm-20231101monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-ai-sciences-achieves-infrastructure-and-technology-progress-in-development-of-gener-bsgm-20230824monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-ai-sciences-receives-2-2-million-in-seed-funding-to-advance-development-of-artifici-bsgm-20230725monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-awarded-us-patent-claims-for-its-universal-notch-filter-technology-bsgm-20230217monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-executes-agreement-with-bellin-health-for-the-acquisition-of-its-pure-ep-technology-bsgm-20230110monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-signs-master-research-agreement-with-cleveland-clinic-to-explore-expanded-applicati-bsgm-20221024monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-invited-to-attend-and-sponsor-venice-arrhythmias-2022-bsgm-20221012monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-executes-purchase-agreement-with-methodist-hospital-san-antonio-and-expands-custome-bsgm-20221007monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-launches-pure-ep-software-version-6-with-accuviz-module-bsgm-20220922monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-s-cardiac-signal-processing-technology-to-be-featured-at-kansas-city-heart-rhythm-s-bsgm-20220817monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-announces-new-evaluation-agreement-for-its-pure-ep-system-with-cleveland-clinic-bsgm-20220622monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-s-pure-ep-system-to-be-featured-during-eplive-2022-bsgm-20220525monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-issues-shareholder-letter-with-corporate-update-on-recent-achievem-bsgm-20220511monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-to-present-at-heart-rhythm-2022-bsgm-20220419monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-partners-with-summit-blue-capital-to-provide-equipment-leasing-ser-bsgm-20220329monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-announces-3-million-financing-with-family-office-bsgm-20220322monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-appoints-john-sieckhaus-as-chief-operating-officer-bsgm-20220316monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-awarded-us-patent-claims-for-its-pure-ep-noise-filtering-technology-bsgm-20220126monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-selects-access-strategy-partners-to-accelerate-commercial-sales-bsgm-20211221monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-expands-its-clinical-footprint-in-florida-bsgm-20211216monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-appoints-gray-fleming-as-chief-commercial-officer-bsgm-20211201monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-initiates-artificial-intelligence-development-program-with-technion-israel-institut-bsgm-20211116monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-to-host-live-roundtable-webinar-to-discuss-clinical-data-delivered-with-its-signal--bsgm-20211111monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-adds-to-its-clinical-footprint-in-texas-bsgm-20211110monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-installs-its-signal-processing-technology-for-arrhythmia-care-at-a-leading-hospital-bsgm-20211108monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-increases-case-volume-estimates-bsgm-20211101monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-s-pure-ep-system-to-be-featured-in-a-live-patient-case-during-annual-international--bsgm-20211012monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-appoints-medical-device-industry-leader-to-its-board-of-directors-bsgm-20210921monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-increases-installation-footprint-adding-st-elizabeth-s-medical-center-to-roster-of--bsgm-20210913monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-s-signal-processing-system-for-arrhythmia-care-to-be-featured-at-the-kansas-city-he-bsgm-20210819monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-to-host-presentations-from-physician-users-of-its-signal-processing-system-for-arrh-bsgm-20210720monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-latest-installation-broadens-clinical-footprint-for-its-signal-processing-technolog-bsgm-20210713monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-to-host-conference-call-to-unblind-clinical-data-collected-with-its-signal-processi-bsgm-20210712monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiol-bsgm-20210707monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-s-signal-processing-technology-for-electrophysiology-to-be-featured-during-2021-sta-bsgm-20210628monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-to-present-new-clinical-data-at-heart-rhythm-2021-annual-conventio-bsgm-20210615monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-to-present-at-the-ld-micro-invitational-xi-virtual-event-bsgm-20210607monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-to-present-at-the-jefferies-virtual-healthcare-conference-bsgm-20210528monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-to-present-at-the-oppenheimer-medtech-tools-diagnostics-summit-bsgm-20210521monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-invited-to-present-at-wall-street-conference-bsgm-20210503monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-to-present-at-the-20th-annual-needham-virtual-healthcare-conferenc-bsgm-20210405monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-awarded-u-s-patent-claims-for-the-noise-filtering-methods-for-its-signal-processing-bsgm-20210330monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-and-mayo-clinic-collaborate-on-new-r-d-program-to-develop-transformative-ai-and-mac-bsgm-20210202monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-deploys-vuzix-m400-smart-glasses-to-offer-remote-servicing-capabilities-in-complian-bsgm-20210113monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-s-division-neuroclear-technologies-signs-a-research-agreement-with-the-university-o-bsgm-20201218monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-the-ld-500-virtual-conference-bsgm-20200825monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-the-proactive-investors-one2one-virtual-event-on-august--bsgm-20200730monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-participate-in-ld-micro-s-zooming-with-ld-bsgm-20200723monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-participate-in-the-b-riley-fbr-virtual-infectious-disease-summit-bsgm-20200717monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-adopts-stockholder-rights-agreement-bsgm-20200716monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-appoints-tony-zook-to-the-board-of-directors-bsgm-20200701monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-closes-17-5-million-common-stock-offering-bsgm-20200629monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-announces-17-5-million-common-stock-only-registered-direct-offerin-bsgm-20200624monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-s-pure-ep-system-to-be-presented-in-heart-rhythm-society-2020-science--bsgm-20200604monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-expands-intellectual-property-portfolio-bsgm-20200603monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-appoints-john-w-osborn-ph-d-as-consultant-on-autonomic-neuromodulation-bsgm-20200304monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-announces-new-collaboration-on-development-of-artificial-intelligence--bsgm-20191203monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-signs-three-new-licensing-agreements-with-mayo-clinic-bsgm-20191126monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-welcomes-the-creation-of-new-bioelectronic-medicine-alliance-bsgm-20191118monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-issues-november-2019-shareholder-letter-bsgm-20191114monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-invests-in-union-college-s-internship-program-bsgm-20191107monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-opens-a-technology-development-office-in-rochester-mn-bsgm-20191015monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-signs-a-new-licensing-agreement-with-mayo-clinic-bsgm-20190912monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-to-receive-15-units-of-pure-ep-system-from-manufacturer-for-commer-bsgm-20190715monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-added-to-membership-of-russell-3000-index-bsgm-20190701monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-issues-june-2019-shareholder-letter-bsgm-20190620monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-set-to-join-russell-3000-index-bsgm-20190610monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-receives-4-6-million-in-cash-warrant-and-option-exercises-bsgm-20190603monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-the-9th-annual-ld-micro-invitational-bsgm-20190530monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-completes-patient-cases-at-indiana-university-bsgm-20190506monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-completes-private-placement-bsgm-20190314monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-the-ld-micro-virtual-conference-bsgm-20190308monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-the-31st-annual-roth-conference-bsgm-20190307monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-appoints-barry-keenan-as-vice-president-of-engineering-bsgm-20190306monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-issues-2019-shareholder-letter-bsgm-20190212monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-id-partners-with-mitek-to-enable-digital-identity-proofing-for-fast-and-secure-gest-bsgm-20190205monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-appoints-john-kowalski-to-lead-commercialization-of-pure-ep-bsgm-20190205monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-commence-first-in-human-studies-at-mayo-clinic-bsgm-20181206monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-signs-agreement-with-texas-cardiac-arrhythmia-institute-for-first-in-h-bsgm-20181127monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-reinvests-in-lafayette-college-s-internshift-progam-bsgm-20181120monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-announces-new-research-program-with-mayo-clinic-bsgm-20181113monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-ring-nasdaq-opening-bell-on-november-13-2018-bsgm-20181112monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-opens-business-office-in-norwalk-ct-bsgm-20181031monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-the-4th-annual-dawson-james-small-cap-growth-conference-bsgm-20181029monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-retains-gilmartin-group-for-investor-relations-bsgm-20180924monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-begins-trading-on-nasdaq-bsgm-20180921monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-commence-trading-on-the-nasdaq-bsgm-20180919monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-issues-shareholder-letter-bsgm-20180911monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-announces-1-for-2-5-reverse-stock-split-for-pending-uplist-to-nasd-bsgm-20180910monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-the-microcap-leadership-summit-bsgm-20180822monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-closes-private-placement-bsgm-20180817monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-announces-fda-510-k-clearance-for-pure-ep-system-bsgm-20180814monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-completes-private-placement-bsgm-20180813monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-added-to-ld-micro-index-bsgm-20180806monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-files-application-to-uplist-to-the-nasdaq-bsgm-20180801monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-ranked-top-50-for-the-silicon-review-s-innovative-companies-to-watch-i-bsgm-20180724monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-the-40th-international-conference-of-the-ieee-engineerin-bsgm-20180711monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-the-emerging-medical-technologies-spotlight-bsgm-20180629monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-the-8th-annual-ld-micro-invitational-bsgm-20180601monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-announces-acceptance-of-paper-for-the-40th-international-conference-of-bsgm-20180509monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-completes-private-placement-bsgm-20180501monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-partner-with-high-lantern-group-bsgm-20180426monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-the-microcap-conference-bsgm-20180406monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-issues-2018-shareholder-letter-bsgm-20180405monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-announces-participation-in-bates-college-s-purposeful-work-initiative-bsgm-20180321monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-partner-with-focus-marketing-bsgm-20180222monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-open-operations-center-in-austin-texas-bsgm-20180213monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-completes-private-placement-bsgm-20180108monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-appoints-new-chief-financial-officer-to-facilitate-growth-trajectory-bsgm-20180103monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-digital-medicine-medtech-showcase-at-biotech-showcase-bsgm-20171228monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-issues-shareholder-letter-for-2017-bsgm-20171221monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-adds-role-of-chief-regulatory-and-compliance-officer-in-preparation-fo-bsgm-20171114monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-speak-at-digital-silver-forum-in-helsinki-finland-on-november-28-bsgm-20171108monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-partners-with-sherpa-technology-group-bsgm-20171102monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-announces-results-of-independent-product-assessment-study-for-pure-ep--bsgm-20171026monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-adds-role-of-manufacturing-project-leader-as-company-continues-to-adva-bsgm-20171024monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-advances-towards-commercialization-into-the-global-electrophysiology-m-bsgm-20171019monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-the-dawson-james-small-cap-growth-conference-bsgm-20171013monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-welcomes-joseph-w-rafferty-as-chief-commercialization-officer-bsgm-20171011monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-enters-into-strategic-development-work-with-health-research-internatio-bsgm-20170711monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-ceo-ken-londoner-interviewed-by-medgadget-bsgm-20170613monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-launches-new-corporate-website-bsgm-20170608monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-welcomes-natasha-russkina-as-managing-director-europe-bsgm-20170531monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-heart-rhythm-society-s-scientific-sessions-on-may-11-in--bsgm-20170505monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-announces-eu-institutional-investor-roadshow-bsgm-20170502monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-joseph-gunnar-pioneers-2017-conference-on-may-2-bsgm-20170428monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-attend-the-heart-rhythm-society-s-scientific-sessions-may-10-13-in--bsgm-20170426monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-provides-shareholder-update-bsgm-20170425monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-monaco-growth-forums-in-london-monaco-bsgm-20170411monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-completes-private-placement-bsgm-20170407monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-announces-participation-in-lafayette-college-s-internshift-summer-prog-bsgm-20170330monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-announces-collaboration-with-mayo-clinic-physician-team-corrected-vers-bsgm-20170323monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-announces-strategic-partnership-with-mayo-clinic-bsgm-20170317monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-seethruequity-3rd-annual-innovations-investor-conference-bsgm-20170221monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-donates-to-american-heart-association-in-sponsorship-of-american-heart-bsgm-20170210monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-announces-eu-institutional-investor-roadshow-bsgm-20170130monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-monaco-growth-conference-in-dubai-u-a-e-bsgm-20170125monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-issues-shareholder-letter-bsgm-20170120monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-pure-ep-system-featured-in-the-journal-of-the-american-college-of-card-bsgm-20170111monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-today-at-the-emerging-medical-technologies-summit-bsgm-20161111monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-the-microcap-conference-in-philadelphia-bsgm-20161019monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-the-dawson-james-2016-small-cap-growth-stock-conference-bsgm-20161012monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-the-fifth-annual-oktoberinvestfest-us-bavaria-germany-in-bsgm-20160927monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-sponsors-the-11th-international-symposium-on-ventricular-arrhythmias-bsgm-20160926monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-achieves-important-milestone-bsgm-20160811monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-issues-shareholder-letter-bsgm-20160719monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-the-38th-annual-international-conference-of-the-ieee-eng-bsgm-20160607monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-the-drexel-hamilton-micro-cap-investor-forum-bsgm-20160505monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-bsgm-completes-private-placement-bsgm-20160502monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-attend-heart-rhythm-society-s-37th-annual-scientific-sessions-may-4-bsgm-20160427monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-announces-advanced-research-program-with-mayo-clinic-bsgm-20160328monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-the-28th-annual-roth-conference-bsgm-20160309monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-initiates-technology-development-with-minnetronix-bsgm-20160222monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-noblecon12-bsgm-20160112monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-8th-annual-biotech-showcase-bsgm-20160106monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-signs-agreement-to-conduct-pre-clinical-studies-at-ucla-bsgm-20150729monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-appoints-david-weild-to-its-board-of-directors-as-audit-committee--bsgm-20150526monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-present-at-the-marcum-microcap-conference-in-new-york-on-may-27-bsgm-20150520monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-to-open-its-headquarters-in-minneapolis-bsgm-20150414monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-appoints-patrick-gallagher-to-its-board-of-directors-bsgm-20140722monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-names-med-devices-veteran-exec-gregory-d-cash-ceo-president-director-bsgm-20140721monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-appoints-david-j-drachman-as-chief-executive-officer-chairman-bsgm-20130918monthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-announces-approval-of-z-squared-inc-s-nasdaq-listing-application-coep-20260407monthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-therapeutics-s-4-declared-effective-by-sec-proxy-mailing-begins-in-anticipation-of-coep-20260106monthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-pharma-enters-into-agreement-to-acquire-elto-pharma-coep-20181128monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-in-hlvx-20250820monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-reports-first-quarter-2025-financial-results-and-highlights-recent-company-progre-hlvx-20250508monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-reports-third-quarter-2024-financial-results-and-highlights-recent-company-progre-hlvx-20241107monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-reports-second-quarter-2024-financial-results-and-highlights-recent-company-progr-hlvx-20240808monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-announces-reduction-in-force-hlvx-20240731monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-inc-hlvx-investigation-bronstein-gewirtz-grossman-llc-encourages-investors-to-see-hlvx-20240719monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-inc-hlvx-investigation-bronstein-gewirtz-grossman-llc-encourages-investors-to-see-hlvx-20240714monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-inc-hlvx-investigation-bronstein-gewirtz-grossman-llc-encourages-investors-to-see-hlvx-20240709monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-reports-topline-data-from-nest-in1-phase-2b-clinical-study-of-hil-214-in-infants-hlvx-20240708monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-reports-first-quarter-2024-financial-results-and-highlights-recent-company-progre-hlvx-20240509monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-reports-full-year-2023-financial-results-and-highlights-recent-company-progress-hlvx-20240320monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-to-present-at-guggenheim-6th-annual-biotechnology-conference-hlvx-20240205monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-announces-executive-management-appointment-of-sean-mcloughlin-as-chief-operating--hlvx-20240118monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-and-kangh-announce-exclusive-license-agreement-for-hexavalent-vlp-norovirus-vacci-hlvx-20240108monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-hlvx-20240103monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-reports-third-quarter-2023-financial-results-and-highlights-recent-company-progre-hlvx-20231109monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-to-present-at-upcoming-investor-conferences-hlvx-20231101monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-to-participate-in-fireside-chat-at-the-2023-cantor-global-healthcare-conference-hlvx-20230926monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-the-und-hlvx-20230925monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-announces-pricing-of-public-offering-of-common-stock-hlvx-20230920monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-announces-proposed-public-offering-of-common-stock-hlvx-20230919monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-reports-second-quarter-2023-financial-results-and-highlights-recent-company-progr-hlvx-20230814monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-reports-first-quarter-2023-financial-results-and-highlights-recent-company-progre-hlvx-20230512monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-announces-appointment-of-nanette-cocero-ph-d-mba-to-its-board-of-directors-hlvx-20230509monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-announces-completion-of-enrollment-of-nest-in1-phase-2b-clinical-study-of-hil-214-hlvx-20230425monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-reports-full-year-2022-financial-results-and-highlights-recent-company-progress-hlvx-20230317monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-announces-executive-management-appointments-and-promotions-hlvx-20230109monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-hlvx-20230104monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-announces-positive-immunogenicity-results-for-run-in-cohort-of-nest-in1-phase-2b--hlvx-20221205monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-to-participate-in-november-investor-conferences-hlvx-20221110monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-reports-third-quarter-2022-financial-results-and-highlights-recent-company-progre-hlvx-20221110monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-to-participate-in-j-p-morgan-biotech-2022-conference-call-series-hlvx-20220901monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-announces-positive-recommendation-from-safety-data-monitoring-committee-for-nest--hlvx-20220831monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-to-participate-in-fireside-chat-at-the-svb-securities-virtual-vaccine-forum-hlvx-20220815monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progr-hlvx-20220810monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-announces-results-from-5-year-clinical-study-supporting-long-term-immunogenicity--hlvx-20220720monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-reports-first-quarter-2022-financial-results-and-highlights-recent-company-progre-hlvx-20220608monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-op-hlvx-20220503monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-announces-initiation-of-phase-2b-clinical-trial-of-hil-214-vaccine-candidate-for--hlvx-20220502monthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-announces-pricing-of-upsized-initial-public-offering-hlvx-20220429monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-report-second-quarter-2025-financial-results-on-august-11-2025-asrt-20250805monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-reports-first-quarter-2025-financial-results-asrt-20250512monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-reports-fourth-quarter-and-full-year-2024-financial-results-asrt-20250312monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-on-mar-asrt-20250305monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asrt-20250103monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-appoints-mark-reisenauer-to-its-board-of-directors-asrt-20241217monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-announces-results-of-rolvedon-eflapegrastim-xnst-injection-same-day-dosing-clinic-asrt-20241213monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-appoints-paul-schwichtenberg-to-new-cto-role-mary-pietryga-as-cco-asrt-20241212monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-reports-third-quarter-2024-financial-results-asrt-20241111monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-provides-response-to-letter-from-short-seller-asrt-20241111monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-report-third-quarter-2024-financial-results-on-november-11-2024-asrt-20241030monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-to-participate-in-the-maxim-group-healthcare-virtual-summit-on-october-15-2024-asrt-20241011monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asrt-20241004monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-to-participate-in-the-hc-wainwright-and-lake-street-conferences-in-new-york-city--asrt-20240903monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-reports-second-quarter-2024-financial-results-asrt-20240807monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-report-second-quarter-2024-financial-results-on-august-7-2024-asrt-20240724monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asrt-20240709monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-alert-bragar-eagel-squire-p-c-is-investigating-assertio-holdings-inc-on-behalf-of-asrt-20240704monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asrt-20240606monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-to-participate-in-the-sidoti-small-cap-conference-on-june-12-2024-asrt-20240605monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-announces-the-appointment-of-brendan-p-o-grady-as-new-ceo-asrt-20240529monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-to-participate-in-benchmark-healthcare-conference-on-may-21-22-asrt-20240517monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-to-participate-in-agp-healthcare-conference-on-may-21-asrt-20240516monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-to-present-at-the-citizens-jmp-life-sciences-conference-in-new-york-city-asrt-20240510monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-reports-first-quarter-2024-financial-results-asrt-20240506monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-report-first-quarter-2024-financial-results-on-may-6-2024-asrt-20240425monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-to-present-at-ld-micro-invitational-conference-in-new-york-city-asrt-20240401monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-alert-bragar-eagel-squire-p-c-is-investigating-assertio-holdings-inc-on-behalf-of-asrt-20240328monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-reports-fourth-quarter-and-full-year-2023-financial-results-asrt-20240311monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-investors-company-investigated-by-the-portnoy-law-firm-asrt-20240304monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-deadline-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-laws-asrt-20240302monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-release-fourth-quarter-and-full-year-2023-financial-results-on-ma-asrt-20240229monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-investors-company-investigated-by-the-portnoy-law-firm-asrt-20240227monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-nasdaq-asrt-deadline-alert-bernstein-liebhard-llp-reminds-investors--asrt-20240226monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-shareholder-notice-faruqi-faruqi-securities-litigation-partner-james-josh-wilson--asrt-20240223monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-sued-for-securities-law-violations-investors-should-contact-levi-kor-asrt-20240222monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-nasdaq-asrt-deadline-alert-bernstein-liebhard-llp-reminds-investors--asrt-20240220monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-asrt-faces-lawsuit-analyst-slashes-price-target-amid-ceo-s-departure-hag-asrt-20240216monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-sued-for-securities-law-violations-investors-should-contact-block-levito-asrt-20240216monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-investor-deadline-approaching-faruqi-faruqi-faruqi-llp-securities-litigation-part-asrt-20240215monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-nasdaq-asrt-deadline-alert-bernstein-liebhard-llp-reminds-investors--asrt-20240213monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-asrt-faces-lawsuit-analyst-slashes-price-target-amid-ceo-s-departure-hag-asrt-20240212monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-investor-deadline-approaching-faruqi-faruqi-securities-litigation-partner-james-j-asrt-20240208monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-nasdaq-asrt-deadline-alert-bernstein-liebhard-llp-reminds-investors--asrt-20240206monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-investors-company-investigated-by-the-portnoy-law-firm-asrt-20240205monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-asrt-faces-lawsuit-analyst-slashes-price-target-amid-ceo-s-departure-hag-asrt-20240202monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-sued-for-securities-law-violations-investors-should-contact-block-levito-asrt-20240202monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-investor-deadline-approaching-faruqi-faruqi-securities-litigation-partner-james-j-asrt-20240201monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-asrt-faces-lawsuit-analyst-slashes-price-target-amid-ceo-s-departure-hag-asrt-20240129monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-nasdaq-asrt-deadline-alert-bernstein-liebhard-llp-reminds-investors--asrt-20240129monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-investors-company-investigated-by-the-portnoy-law-firm-asrt-20240124monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-shareholder-notice-faruqi-faruqi-securities-litigation-partner-james-josh-wilson--asrt-20240124monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-asrt-faces-lawsuit-as-analyst-slashes-price-target-amid-ceo-s-departure--asrt-20240122monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-nasdaq-asrt-deadline-alert-bernstein-liebhard-llp-reminds-investors--asrt-20240122monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-nasdaq-asrt-securities-fraud-contact-berger-montague-to-discuss-your-asrt-20240119monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-shareholder-notice-faruqi-faruqi-securities-litigation-partner-james-josh-wilson--asrt-20240117monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-sued-for-securities-law-violations-investors-should-contact-block-levito-asrt-20240117monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-asrt-class-action-notice-robbins-llp-reminds-investors-of-lead-plain-asrt-20240116monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-nasdaq-asrt-deadline-alert-bernstein-liebhard-llp-reminds-investors--asrt-20240116monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-asrt-faces-lawsuit-after-ceo-sacked-hagens-berman-asrt-20240115monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-shareholder-alert-bernstein-liebhard-llp-announces-that-a-securities-asrt-20240110monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-shareholder-notice-faruqi-faruqi-securities-litigation-partner-james-josh-wilson--asrt-20240110monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-asrt-sacks-ceo-amid-securities-fraud-class-action-hagens-berman-asrt-20240109monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-asrt-20240109monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-sued-for-securities-law-violations-investors-should-contact-block-levito-asrt-20240108monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asrt-20240105monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-announces-leadership-transition-asrt-20240103monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-appoints-sravan-emany-to-its-board-of-directors-asrt-20231114monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-release-third-quarter-2023-financial-results-on-november-8-2023-asrt-20231102monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asrt-20231006monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asrt-20230825monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asrt-20230808monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-closes-spectrum-pharmaceuticals-transaction-asrt-20230731monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-announces-favorable-vote-on-proposed-acquisition-of-spectrum-pharmac-asrt-20230727monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-report-second-quarter-2023-financial-results-on-thursday-august-3-asrt-20230724monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-joins-russell-3000-index-asrt-20230626monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-updates-first-quarter-2023-financial-results-call-time-to-tuesday-ma-asrt-20230505monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-report-first-quarter-2023-financial-results-on-tuesday-may-9-2023-asrt-20230427monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-acquire-spectrum-pharmaceuticals-inc-in-all-stock-and-cvr-transac-asrt-20230425monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asrt-20230407monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-announces-preliminary-fourth-quarter-and-full-year-2022-results-asrt-20230221monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-announces-fda-orange-book-listing-for-new-sympazan-oral-film-patent-asrt-20230109monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asrt-20230106monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-host-investor-and-business-development-meetings-january-9-11-2023-asrt-20221213monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-report-third-quarter-2022-financial-results-on-tuesday-november-8-asrt-20221027monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-signs-exclusive-license-for-sympazan-clobazam-oral-film-from-aquesti-asrt-20221027monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-report-second-quarter-2022-financial-results-on-monday-august-8-2-asrt-20220725monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asrt-20220712monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-participate-in-ld-micro-invitational-xii-conference-asrt-20220601monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-report-first-quarter-2022-financial-results-after-the-close-of-ma-asrt-20220422monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-partners-with-blinkrx-to-support-healthcare-providers-and-patients-u-asrt-20220331monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-report-fourth-quarter-and-full-year-2021-financial-results-before-asrt-20220302monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-participate-in-the-h-c-wainwright-bioconnect-virtual-conference-asrt-20220110monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-announces-the-acquisition-of-otrexup-methotrexate-a-drug-device-comb-asrt-20211215monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-announces-preliminary-court-approval-of-shareholder-derivative-settl-asrt-20211112monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-report-third-quarter-2021-financial-results-after-the-close-of-ma-asrt-20211026monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-participate-in-upcoming-investor-events-asrt-20211004monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-report-second-quarter-2021-financial-results-after-the-close-of-m-asrt-20210720monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement-asrt-20210604monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-announces-1-for-4-reverse-stock-split-asrt-20210517monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-announces-adjournment-of-annual-meeting-of-shareholders-asrt-20210517monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-partners-with-cove-a-leading-migraine-telemedicine-platform-to-launc-asrt-20210505monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-report-first-quarter-2021-financial-results-after-the-close-of-ma-asrt-20210422monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-present-at-virtual-roth-conference-on-monday-march-15-2021-asrt-20210301monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-to-report-fourth-quarter-and-full-year-2020-financial-results-after--asrt-20210218monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-announces-closing-of-registered-direct-offering-of-34-3-million-asrt-20210212monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-announces-pricing-of-34-3-million-registered-direct-offering-asrt-20210210monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-announces-closing-of-registered-direct-offering-of-14-million-asrt-20210209monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-announces-pricing-of-14-million-registered-direct-offering-asrt-20210205monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-provides-business-update-and-announces-third-quarter-2025-financial-r-mrsn-20251114monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-second-quarter-2025-conference-call-on-august-13-2025-mrsn-20250806monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-mrsn-20250404monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-upcoming-oral-presentation-of-emi-le-clinical-data-at-europ-mrsn-20250401monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-provides-business-update-and-announces-fourth-quarter-and-full-year-2-mrsn-20250303monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-upcoming-investor-conferences-mrsn-20250225monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2-mrsn-20250224monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-mrsn-20250207monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-participate-in-the-guggenheim-smid-cap-biotech-conference-mrsn-20250130monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-additional-fda-fast-track-designation-granted-to-emiltatug--mrsn-20250110monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-positive-initial-clinical-data-from-phase-1-clinical-trial--mrsn-20250110monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-provides-business-update-and-announces-third-quarter-2024-financial-r-mrsn-20241113monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-third-quarter-2024-conference-call-on-november-13-2024-mrsn-20241106monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-provides-business-update-and-announces-second-quarter-2024-financial--mrsn-20240813monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-second-quarter-2024-conference-call-on-august-13-2024-mrsn-20240806monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-upcoming-investor-conferences-mrsn-20240522monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-provides-business-update-and-announces-first-quarter-2024-financial-r-mrsn-20240509monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20240503monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-first-quarter-2024-conference-call-on-may-9-2024-mrsn-20240502monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20240404monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-provides-business-update-and-announces-fourth-quarter-and-full-year-2-mrsn-20240228monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-upcoming-investor-conferences-mrsn-20240227monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2023-conference-call-on-february--mrsn-20240221monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-participate-in-guggenheim-s-6th-annual-biotechnology-conference-mrsn-20240201monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-business-updates-expected-2024-milestones-and-upcoming-pres-mrsn-20240105monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20231201monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-provides-business-update-and-announces-third-quarter-2023-financial-r-mrsn-20231107monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-third-quarter-2023-conference-call-on-november-7-2023-mrsn-20231031monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-fda-has-lifted-clinical-hold-on-phase-1-clinical-trial-of-x-mrsn-20231031monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-changes-in-leadership-mrsn-20230906monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-second-quarter-2023-financial-results-mrsn-20230808monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20230804monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-topline-data-from-uplift-clinical-trial-in-patients-with-pl-mrsn-20230727monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20230706monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-ther-mrsn-20230623monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-partial-clinical-hold-on-up-next-and-upgrade-a-clinical-tri-mrsn-20230615monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20230602monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-upcoming-investor-conferences-mrsn-20230524monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-provides-business-update-and-announces-first-quarter-2023-financial-r-mrsn-20230509monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20230504monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference-mrsn-20230503monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-first-quarter-2023-conference-call-on-may-9-2023-mrsn-20230502monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-upcoming-presentations-at-2023-asco-annual-meeting-mrsn-20230426monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20230406monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-clinical-hold-on-xmt-2056-phase-1-clinical-trial-mrsn-20230313monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-provides-statement-about-svb-mrsn-20230311monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20230303monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-provides-business-update-and-announces-fourth-quarter-and-full-year-2-mrsn-20230228monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2022-conference-call-on-february--mrsn-20230221monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20230203monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-upcoming-investor-conferences-mrsn-20230202monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-initiates-expansion-portion-of-upgrade-a-combination-clinical-trial-i-mrsn-20230201monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-initiation-of-phase-1-trial-of-xmt-2056-in-her2-expressing--mrsn-20230125monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20230106monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-provides-business-update-and-announces-strategic-objectives-and-expec-mrsn-20230106monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-research-collaboration-and-commercial-license-agreement-wit-mrsn-20221222monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20221202monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-jefferies-london-healthcare-conference-mrsn-20221108monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-provides-business-update-and-announces-third-quarter-2022-financial-r-mrsn-20221107monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20221104monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-third-quarter-2022-conference-call-on-november-7-2022-mrsn-20221031monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-completion-of-enrollment-in-uplift-a-single-arm-registratio-mrsn-20221006monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20221004monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-launch-of-oncology-facets-a-resource-for-healthcare-provide-mrsn-20220930monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-fda-fast-track-designation-granted-to-xmt-1660-for-the-trea-mrsn-20220912monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-upcoming-investor-conferences-mrsn-20220906monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20220902monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-initiation-of-phase-1-trial-of-xmt-1660-in-breast-endometri-mrsn-20220816monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-provides-business-update-and-announces-second-quarter-2022-financial--mrsn-20220808monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-option-agreement-with-gsk-for-the-co-development-and-commer-mrsn-20220808monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20220804monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-second-quarter-2022-conference-call-on-august-8-2022-and-pres-mrsn-20220803monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-chief-people-officer-carla-poulson-named-one-of-savoy-magazine-s-2022-mrsn-20220722monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20220708monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20220603monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-upcoming-investor-conferences-mrsn-20220526monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-fda-grant-of-orphan-drug-designation-to-xmt-2056-for-the-tr-mrsn-20220519monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-provides-business-update-and-announces-first-quarter-2022-financial-r-mrsn-20220509monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20220506monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-first-quarter-2022-conference-call-on-may-9-2022-mrsn-20220502monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mrsn-20220406monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-preclinical-data-on-xmt-1660-xmt-2056-and-the-immunosynthe-mrsn-20220405monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-an-analysis-from-the-expansion-cohort-of-the-phase-1-trial-mrsn-20220315monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-the-cowen-42nd-annual-health-care-conference-mrsn-20220302monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-fourth-quarter-and-full-year-2021-financial-results-and-pro-mrsn-20220228monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-conference-call-announcing-fourth-quarter-and-year-end-2021-f-mrsn-20220222monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conferenc-mrsn-20220210monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-research-collaboration-and-license-agreement-with-janssen-t-mrsn-20220203monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-2022-strategic-priorities-and-milestones-mrsn-20220107monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-mrsn-20220105monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-named-to-2021-list-of-top-places-to-work-in-massachusetts-by-the-bost-mrsn-20211202monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-participate-in-the-upcoming-4th-annual-evercore-isi-healthconx-con-mrsn-20211123monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-the-upcoming-stifel-2021-virtual-healthcare-conference-mrsn-20211110monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-third-quarter-2021-financial-results-and-provides-business--mrsn-20211109monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-conference-call-announcing-third-quarter-2021-financial-resul-mrsn-20211102monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-mrsn-20211027monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-appointment-of-mohan-bala-ph-d-as-svp-strategic-product-pla-mrsn-20211025monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-target-and-presents-new-preclinical-data-for-xmt-2056-first-mrsn-20211007monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-announce-target-and-present-new-preclinical-data-for-xmt-2056-at-t-mrsn-20210930monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-upcoming-investor-conferences-mrsn-20210907monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-provide-update-on-the-progress-of-its-upri-clinical-development-st-mrsn-20210901monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-mrsn-20210818monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-appointment-of-tushar-misra-ph-d-as-chief-manufacturing-off-mrsn-20210816monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-second-quarter-2021-financial-results-and-provides-business-mrsn-20210806monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-the-12th-annual-wedbush-pacgrow-healthcare-conference-mrsn-20210804monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-conference-call-announcing-second-quarter-2021-financial-resu-mrsn-20210730monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-initiation-of-the-upgrade-phase-1-platinum-combination-coho-mrsn-20210728monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-mrsn-20210526monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-first-quarter-2021-financial-results-and-provides-business--mrsn-20210510monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-conference-call-announcing-first-quarter-2021-financial-resul-mrsn-20210503monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-mrsn-20210428monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-appointment-of-alejandra-carvajal-as-senior-vice-president--mrsn-20210426monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-presents-preclinical-data-highlighting-potential-of-xmt-2056-and-xmt--mrsn-20210410monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-selection-of-the-n-mrsn-20210409monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-initiation-of-uplift-single-arm-registration-strategy-for-u-mrsn-20210409monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-publication-of-two-manuscripts-detailing-preclinical-studie-mrsn-20210315monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-appointment-of-allene-diaz-to-board-of-directors-mrsn-20210311monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-three-posters-at-upcoming-virtual-2021-american-associatio-mrsn-20210310monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-fourth-quarter-and-full-year-2020-financial-results-and-pro-mrsn-20210226monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-conference-call-announcing-fourth-quarter-and-year-end-2020-f-mrsn-20210219monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-confe-mrsn-20210217monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-mrsn-20210122monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-mrsn-20210106monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-corporate-and-pipeline-updates-and-2021-goals-and-anticipat-mrsn-20210105monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-virtual-analyst-and-investor-event-mrsn-20201217monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-mrsn-20201202monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-appoints-arvin-yang-m-d-ph-d-as-senior-vice-president-and-chief-medic-mrsn-20201130monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-reports-preclinical-data-from-immunosynthen-sting-agonist-adc-platfor-mrsn-20201111monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-webinar-highlighting-immunosynthen-sting-agonist-adc-platform-mrsn-20201109monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-third-quarter-2020-financial-results-and-provides-business--mrsn-20201109monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-29th-annual-credit-suisse-virtual-healthcare-conference-mrsn-20201104monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-conference-call-announcing-third-quarter-2020-financial-resul-mrsn-20201102monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-preclinical-data-from-immunosynthen-sting-agonist-adc-plat-mrsn-20201014monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-reports-updated-interim-data-from-the-ovarian-cancer-cohort-of-the-xm-mrsn-20200917monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-updated-interim-data-from-the-ovarian-cancer-cohort-of-the-mrsn-20200910monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-upcoming-investor-conferences-mrsn-20200903monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-mrsn-20200902monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-appoints-chuck-miller-as-senior-vice-president-of-regulatory-affairs-mrsn-20200831monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-receives-fda-fast-track-designation-for-xmt-1536-for-the-treatment-of-mrsn-20200811monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-second-quarter-2020-financial-results-and-provides-business-mrsn-20200807monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-upcoming-investor-conferences-mrsn-20200804monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-conference-call-announcing-second-quarter-2020-financial-resu-mrsn-20200731monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-presents-preclinical-data-from-its-innovative-dolasynthen-and-immunos-mrsn-20200622monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercis-mrsn-20200602monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-pricing-of-public-offering-of-common-stock-mrsn-20200529monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-jefferies-virtual-global-healthcare-conference-mrsn-20200528monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-proposed-public-offering-of-common-stock-mrsn-20200528monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-reports-positive-interim-data-from-the-expansion-portion-of-the-xmt-1-mrsn-20200527monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-two-posters-at-the-american-association-for-cancer-researc-mrsn-20200515monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-initiation-of-xmt-1592-phase-1-dose-escalation-study-mrsn-20200514monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-interim-data-from-phase-1-expansion-of-xmt-1536-at-the-ame-mrsn-20200513monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-report-interim-data-from-phase-1-dose-expansion-of-xmt-1536-mrsn-20200513monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-first-quarter-2020-financial-results-and-provides-business--mrsn-20200508monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-conference-call-announcing-first-quarter-2020-financial-resul-mrsn-20200429monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-appointment-of-martin-h-huber-m-d-to-board-of-directors-mrsn-20200415monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-raises-65-million-in-gross-proceeds-through-its-at-the-market-facilit-mrsn-20200408monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-reports-updated-data-from-the-xmt-1536-phase-1-dose-escalation-study-mrsn-20200330monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-report-updated-data-from-the-xmt-1536-phase-1-dose-escalation-stud-mrsn-20200320monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-fourth-quarter-and-full-year-2019-financial-results-and-pro-mrsn-20200228monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-conference-call-announcing-fourth-quarter-and-year-end-2019-f-mrsn-20200221monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-upcoming-investor-conferences-mrsn-20200218monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-pipeline-updates-and-2020-strategic-priorities-and-mileston-mrsn-20200110monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-mrsn-20200102monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-presents-new-preclinical-data-from-immunosynthen-platform-at-the-soci-mrsn-20191108monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-third-quarter-2019-financial-results-and-provides-business--mrsn-20191106monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-conference-call-announcing-third-quarter-2019-financial-resul-mrsn-20191030monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-the-2019-cantor-global-healthcare-conference-mrsn-20190927monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-upcoming-investor-conferences-mrsn-20190828monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-initiation-of-expansion-study-of-xmt-1536-in-patients-with--mrsn-20190820monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-second-quarter-2019-financial-results-and-provides-business-mrsn-20190808monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-the-wedbush-pacgrow-healthcare-conference-mrsn-20190806monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-conference-call-announcing-second-quarter-2019-financial-resu-mrsn-20190801monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-appointment-of-brian-c-deschuytner-as-senior-vice-president-mrsn-20190612monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-presents-interim-phase-1-data-for-xmt-1536-at-the-2019-american-society-of-clinica-mrsn-20190601monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-the-jefferies-2019-global-healthcare-conference-mrsn-20190530monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-interim-phase-1-data-on-xmt-1536-at-the-2019-american-soci-mrsn-20190520monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-first-quarter-2019-financial-results-and-provides-business--mrsn-20190509monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-conference-call-announcing-first-quarter-2019-financial-resul-mrsn-20190502monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference-mrsn-20190401monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-poster-and-presentation-at-the-american-association-for-can-mrsn-20190325monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-fourth-quarter-and-full-year-2018-financial-results-and-pro-mrsn-20190308monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-the-cowen-and-company-39th-annual-healthcare-conference-mrsn-20190306monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercis-mrsn-20190305monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-conference-call-announcing-fourth-quarter-and-year-end-2018-f-mrsn-20190301monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-pricing-of-public-offering-of-common-stock-mrsn-20190301monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-proposed-public-offering-of-common-stock-mrsn-20190228monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-the-8th-annual-svb-leerink-global-healthcare-conference-mrsn-20190220monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-strategic-priorities-and-goals-for-2019-and-beyond-mrsn-20190104monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-mrsn-20190102monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-appoints-dirk-huebner-m-d-as-chief-medical-officer-mrsn-20181127monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-third-quarter-2018-financial-results-and-provides-business--mrsn-20181113monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-presents-pre-clinical-data-at-aacr-nci-eortc-on-two-additional-propri-mrsn-20181112monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-scientists-present-updates-on-xmt-1522-xmt-1536-and-the-dolaflexin-platform-at-wor-mrsn-20181112monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-the-credit-suisse-27th-annual-healthcare-conference-mrsn-20181108monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-conference-call-announcing-third-quarter-2018-financial-resul-mrsn-20181106monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-upcoming-investor-conferences-mrsn-20180926monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-presents-new-preclinical-data-on-xmt-1536-at-the-international-associ-mrsn-20180925monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-announces-fda-lifts-partial-clinical-hold-for-xmt-1522-mrsn-20180917monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-upcoming-investor-conferences-mrsn-20180830monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-second-quarter-2018-financial-results-and-provides-business-mrsn-20180814monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-the-wedbush-pacgrow-healthcare-conference-mrsn-20180808monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-conference-call-announcing-second-quarter-2018-financial-resu-mrsn-20180808monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-partial-clinical-hold-for-xmt-1522-clinical-trial-mrsn-20180719monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-presents-interim-dose-escalation-data-on-xmt-1522-in-select-cancers-at-asco-2018-mrsn-20180604monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-mrsn-20180531monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-interim-phase-1-data-on-xmt-1522-at-the-2018-american-soci-mrsn-20180522monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-first-quarter-2018-financial-results-and-provides-business--mrsn-20180514monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-conference-call-announcing-first-quarter-2018-financial-resul-mrsn-20180507monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-the-deutsche-bank-43rd-annual-health-care-conference-mrsn-20180501monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-presents-preclinical-data-further-demonstrating-differentiating-aspec-mrsn-20180417monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-poster-presentations-demonstrating-differentiating-aspects--mrsn-20180409monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-fourth-quarter-and-full-year-2017-financial-results-and-pro-mrsn-20180328monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-host-conference-call-announcing-fourth-quarter-and-full-year-2017--mrsn-20180321monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-strengthens-board-of-directors-leadership-with-appointment-of-willard-h-dere-m-d-p-mrsn-20180319monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-appoints-david-a-spellman-as-chief-financial-officer-mrsn-20180312monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-upcoming-investor-conferences-mrsn-20180207monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-outlines-2017-milestones-and-2018-goals-mrsn-20180108monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-mrsn-20171220monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-added-to-nasdaq-biotechnology-index-mrsn-20171215monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-announces-first-patient-dosed-with-xmt-1536-in-phase-1-study-in-patients-with-napi-mrsn-20171212monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-announces-third-quarter-2017-financial-results-and-provides-business-updates-mrsn-20171109monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-announces-fda-clearance-of-ind-application-for-xmt-1536-a-first-in-class-antibody--mrsn-20171030monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-presents-new-data-on-xmt-1536-a-napi2b-targeting-antibody-drug-conjug-mrsn-20171030monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-poster-presentation-at-aacr-nci-eortc-international-confere-mrsn-20171023monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-appoints-lawrence-m-alleva-to-board-of-directors-mrsn-20170905monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-participate-in-investor-conferences-in-september-mrsn-20170831monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-announces-second-quarter-2017-financial-results-and-provides-business-updates-mrsn-20170811monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-appoints-kristen-hege-m-d-to-board-of-directors-mrsn-20160906monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-announces-series-c-financing-mrsn-20160616monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-new-immunoconjugate-demonstrates-anti-cancer-activity-in-non-small-ce-mrsn-20160418monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-data-on-new-preclinical-product-candidate-at-the-2016-amer-mrsn-20160318monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-lead-immunoconjugate-continues-to-demonstrate-complete-tumor-regressi-mrsn-20151211monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-poster-at-the-2015-san-antonio-breast-cancer-symposium-mrsn-20151130monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-at-world-adc-san-diego-mrsn-20151015monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-lead-fleximer-r-immunoconjugate-demonstrates-potent-activity-in-low-h-mrsn-20150417monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-to-present-late-breaking-poster-at-aacr-annual-meeting-2015-mrsn-20150415monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-and-jade-biosciences-announce-merger-agreement-avte-20241031monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-to-explore-strategic-alternatives-avte-20240708monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-investors-investigation-on-behalf-of-investors-the-portnoy-law-firm-avte-20240620monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-announces-24-week-topline-results-from-the-phase-2b-portion-of-impah-avte-20240617monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-presents-baseline-data-from-the-phase-2b-portion-of-the-impahct-tria-avte-20240521monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-announces-first-quarter-financial-results-and-business-highlights-avte-20240513monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-to-present-patient-baseline-characteristics-of-the-phase-2b-portion--avte-20240327monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-announces-full-year-2023-financial-results-and-business-highlights-avte-20240325monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-board-of-directors-appoints-habib-dable-as-board-chair-avte-20240306monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-announces-simultaneous-completion-of-enrollment-in-phase-2b-portion--avte-20231120monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-announces-third-quarter-financial-results-and-business-highlights-avte-20231113monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-announces-second-quarter-financial-results-and-business-highlights-avte-20230814monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-appoints-habib-dable-to-its-board-of-directors-avte-20230711monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-to-present-at-jefferies-global-healthcare-conference-avte-20230601monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-presents-nonclinical-pharmacokinetic-data-in-support-of-av-101-a-nov-avte-20230522monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-announces-first-quarter-financial-results-and-business-highlights-avte-20230515monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-announces-full-year-2022-financial-results-and-business-highlights-avte-20230329monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-to-present-at-cowen-43rd-annual-health-care-conference-avte-20230302monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-appoints-donald-santel-to-its-board-of-directors-avte-20230123monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-publishes-results-of-phase-1-study-evaluating-av-101-for-the-treatme-avte-20221117monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-announces-third-quarter-2022-financial-results-avte-20221114monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-presents-novel-phase-2b-phase-3-impahct-trial-design-at-chest-annual-avte-20221018monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-announces-second-quarter-2022-financial-results-avte-20220815monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-to-present-at-jefferies-global-healthcare-conference-avte-20220602monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-presents-phase-1-data-for-av-101-a-novel-dry-powder-inhaled-formulat-avte-20220516monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-announces-first-quarter-2022-financial-results-avte-20220516monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-announces-full-year-2021-financial-results-avte-20220330monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-to-present-at-cowen-42nd-annual-health-care-conference-avte-20220302monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-announces-initiation-of-impahct-phase-2b-phase-3-trial-of-av-101-in--avte-20211215monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-announces-third-quarter-2021-financial-results-avte-20211115monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-announces-its-addition-to-the-russell-2000-index-avte-20210917monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-announces-second-quarter-2021-financial-results-avte-20210816monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-appoints-allison-dorval-to-its-board-of-directors-avte-20210719monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-announces-closing-of-initial-public-offering-with-exercise-in-full-o-avte-20210702monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-announces-pricing-of-upsized-initial-public-offering-avte-20210630monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-appoints-timothy-noyes-as-chief-executive-officer-avte-20210518monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-emerges-from-ra-capital-incubator-with-72-6-million-funding-for-pote-avte-20200806monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-and-inmagene-biopharmaceuticals-announce-kristin-yarema-ph-d-as-chief-execu-ikna-20250723monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-announces-stockholder-approval-of-merger-with-inmagene-biopharmaceuticals-ikna-20250715monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-announces-iss-and-glass-lewis-recommend-stockholders-vote-for-proposed-merg-ikna-20250711monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-and-inmagene-biopharmaceuticals-announce-agreement-for-merger-and-private-p-ikna-20241223monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-reports-third-quarter-2024-financial-results-ikna-20241107monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-reports-second-quarter-2024-financial-results-ikna-20240808monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-reports-first-quarter-2024-financial-results-and-corporate-update-ikna-20240513monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-to-present-at-the-stifel-2024-virtual-targeted-oncology-forum-ikna-20240410monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-reports-fourth-quarter-and-full-year-2023-financial-results-ikna-20240312monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-to-participate-in-td-cowen-44th-annual-health-care-conference-ikna-20240227monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-appoints-caroline-germa-m-d-as-chief-medical-officer-ikna-20240221monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-outlines-key-priorities-and-provides-corporate-updates-ikna-20240118monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-shares-initial-positive-and-differentiated-dose-escalation-data-from-ik-930-ikna-20231109monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-to-present-at-multiple-november-2023-investor-conferences-ikna-20231107monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-to-participate-in-september-2023-investor-conferences-ikna-20230905monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-reports-second-quarter-2023-financial-results-and-corporate-update-ikna-20230810monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-acquires-pionyr-immunotherapeutics-in-all-stock-transaction-ikna-20230807monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-to-participate-in-upcoming-investor-conferences-ikna-20230524monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-reports-first-quarter-2023-financial-results-and-highlights-advancements-ac-ikna-20230515monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-announces-40-million-underwritten-offering-ikna-20230515monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-to-participate-in-the-stifel-2023-virtual-targeted-oncology-days-ikna-20230420monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-shares-differentiation-profile-of-ik-930-a-novel-hippo-pathway-inhibitor-in-ikna-20230417monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-reports-fourth-quarter-and-full-year-2022-financial-results-ikna-20230314monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-presents-preclinical-data-on-ik-595-best-in-class-next-generation-mek-raf-c-ikna-20230307monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-receives-fda-fast-track-designation-for-novel-ahr-antagonist-ik-175-in-comb-ikna-20230306monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-to-participate-in-cowen-43rd-annual-health-care-conference-ikna-20230228monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-appoints-owen-hughes-as-board-chair-ikna-20221219monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-announces-new-program-in-next-generation-mek-raf-inhibition-and-provides-co-ikna-20221128monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference-ikna-20221122monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-announces-initial-clinical-data-from-ik-175-program-in-urothelial-carcinoma-ikna-20221110monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-reports-third-quarter-2022-financial-results-and-provides-a-corporate-updat-ikna-20221107monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-presents-preclinical-data-at-the-34th-eortc-nci-aacr-symposium-on-novel-tea-ikna-20221026monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-provides-research-development-update-on-ik-930-program-targeting-the-hippo--ikna-20221018monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-to-present-initial-phase-1a-b-results-from-novel-ahr-inhibition-program-at--ikna-20221005monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-to-participate-in-september-2022-investor-conferences-ikna-20220906monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-reports-second-quarter-2022-financial-results-and-provides-a-corporate-upda-ikna-20220811monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-to-participate-in-the-william-blair-biotech-focus-conference-2022-ikna-20220706monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-receives-fda-fast-track-designation-for-novel-tead-inhibitor-ik-930-to-trea-ikna-20220622monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-to-participate-in-spring-2022-investor-conferences-ikna-20220518monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-reports-first-quarter-2022-financial-results-and-provides-a-corporate-updat-ikna-20220512monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-and-vall-d-hebron-institute-of-oncology-announce-research-development-colla-ikna-20220502monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-to-present-at-the-american-society-of-clinical-oncology-asco-2022-annual-me-ikna-20220428monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-appoints-jotin-marango-m-d-ph-d-as-chief-financial-officer-and-head-of-corporate-dev-ikna-20220413monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-reports-fourth-quarter-and-full-year-2021-financial-results-and-corporate-u-ikna-20220317monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-to-present-preclinical-findings-on-ik-930-a-novel-tead-inhibitor-at-the-202-ikna-20220307monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-to-participate-in-cowen-42nd-annual-health-care-conference-ikna-20220301monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-appoints-richard-wooster-ph-d-to-its-board-of-directors-ikna-20220126monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-presents-data-at-sitc-36th-annual-meeting-describing-the-indication-selecti-ikna-20211112monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-reports-third-quarter-2021-financial-results-and-corporate-update-ikna-20211110monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-to-participate-in-november-2021-virtual-investor-conferences-ikna-20211104monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-announces-fda-acceptance-of-ind-application-of-novel-tead-inhibitor-ik-930-ikna-20211102monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-presents-data-at-aacr-nci-eortc-virtual-conference-demonstrating-potential--ikna-20211007monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-to-present-a-trial-in-progress-update-translational-data-and-indication-sel-ikna-20211001monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-to-participate-in-september-2021-virtual-investor-conferences-ikna-20210902monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-reports-second-quarter-2021-financial-results-and-provides-update-on-key-pr-ikna-20210812monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-to-participate-in-targeted-oncology-panel-at-the-william-blair-biotech-focu-ikna-20210708monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-third-quarter-2024-financial-results-and-provides-corporate-upda-igms-20241108monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-three-upcoming-investor-conferences-igms-20241104monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-strategic-pivot-to-focus-exclusively-on-autoimmunity-igms-20240930monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-stifel-2024-virtual-immunology-and-inflammation-summit-igms-20240910monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-second-quarter-2024-financial-results-and-provides-corporate-upd-igms-20240814monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-jefferies-healthcare-conference-igms-20240529monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-first-quarter-2024-financial-results-and-provides-corporate-upda-igms-20240508monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-2024-rbccm-global-healthcare-conference-igms-20240507monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-refocusing-of-sanofi-collaboration-igms-20240417monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-stifel-2024-virtual-targeted-oncology-forum-igms-20240410monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-fourth-quarter-and-full-year-2023-financial-results-and-provides-igms-20240307monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-guggenheim-healthcare-talks-6th-annual-biotechnology-con-igms-20240201monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-igms-20240103monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-strategic-pipeline-prioritization-and-cash-runway-extension-igms-20231205monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-third-quarter-2023-financial-results-igms-20231113monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-two-upcoming-investor-conferences-igms-20231107monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-retirement-of-chairman-michael-loberg-ph-d-from-board-of-directo-igms-20231003monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-morgan-stanley-21st-annual-global-healthcare-conference-igms-20230906monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-second-quarter-2023-financial-results-igms-20230803monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-announces-closing-of-upsized-public-offering-and-concurrent-private-placement-and-full-igms-20230703monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-announces-pricing-of-107-3-million-upsized-public-offering-and-concurrent-private-plac-igms-20230622monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-announces-proposed-public-offering-and-concurrent-private-placement-igms-20230621monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-update-on-igm-8444-phase-1-trial-and-future-clinical-development-igms-20230602monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-jefferies-healthcare-conference-igms-20230601monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-fda-clearance-to-begin-clinical-studies-of-imvotamab-in-lupus-an-igms-20230531monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-host-conference-call-and-webcast-to-provide-igm-8444-clinical-update-igms-20230530monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-first-quarter-2023-financial-results-and-provides-corporate-upda-igms-20230512monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-two-upcoming-investor-conferences-igms-20230502monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-stifel-2023-targeted-oncology-days-igms-20230419monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-six-presentations-at-the-american-association-for-cancer-researc-igms-20230413monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-fourth-quarter-and-full-year-2022-financial-results-and-provides-igms-20230330monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-announce-fourth-quarter-and-full-year-2022-financial-results-and-host-c-igms-20230327monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-guggenheim-2023-oncology-conference-igms-20230202monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-initiates-first-in-human-clinical-trial-of-igm-7354-in-solid-tumors-igms-20230117monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-update-on-igm-8444-phase-1-trial-and-future-clinical-development-igms-20230109monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-igms-20230103monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-presents-data-from-t-cell-engager-portfolio-for-hematologic-malignancies-a-igms-20221211monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-bank-of-america-biotech-smid-cap-conference-igms-20221201monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-three-upcoming-investor-conferences-igms-20221108monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-third-quarter-2022-financial-results-and-provides-corporate-upda-igms-20221103monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-and-adc-therapeutics-announce-clinical-collaboration-agreement-to-evaluate-igms-20221102monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-three-upcoming-investor-conferences-igms-20220906monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-second-quarter-2022-financial-results-and-provides-corporate-upd-igms-20220808monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-2022-jefferies-healthcare-conference-igms-20220601monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-2022-rbc-capital-markets-global-healthcare-conference-igms-20220510monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-first-quarter-2022-financial-results-and-provides-corporate-upda-igms-20220509monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-closing-of-global-collaboration-agreement-with-sanofi-igms-20220506monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-announces-closing-of-230-0-million-public-offering-igms-20220406monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-announces-pricing-of-200-0-million-public-offering-igms-20220330monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-announces-proposed-public-offering-igms-20220329monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-fourth-quarter-and-full-year-2021-financial-results-and-provides-igms-20220329monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-host-conference-call-and-webcast-today-to-discuss-global-collaboration--igms-20220329monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-advances-novel-antibody-igm-6268-into-clinical-trials-for-the-treatment-an-igms-20220209monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-guggenheim-2022-oncology-conference-igms-20220203monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-igms-20220105monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-presents-clinical-data-from-igm-2323-in-patients-with-advanced-b-cell-mali-igms-20211211monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-collaborate-on-the-study-of-igm-and-iga-antibodies-for-the-prevention-o-igms-20211208monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-host-conference-call-and-webcast-to-review-igm-2323-data-presented-at-t-igms-20211206monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-jefferies-london-healthcare-conference-igms-20211110monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-stifel-2021-virtual-healthcare-conference-igms-20211108monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-third-quarter-2021-financial-results-and-provides-corporate-upda-igms-20211104monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-leadership-appointments-and-formation-of-igm-infectious-diseases-igms-20211011monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-2021-cantor-virtual-global-healthcare-conference-igms-20210923monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-participate-in-three-upcoming-investor-conferences-igms-20210907monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-second-quarter-2021-financial-results-and-provides-corporate-upd-igms-20210809monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-the-appointment-of-chris-h-takimoto-m-d-ph-d-f-a-c-p-as-chief-me-igms-20210729monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-expansion-of-igm-platform-into-infectious-diseases-publication-o-igms-20210603monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-jefferies-virtual-healthcare-conference-igms-20210526monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-2021-rbc-capital-markets-global-healthcare-conference-igms-20210512monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-first-quarter-2021-financial-results-and-provides-corporate-upda-igms-20210506monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-truist-securities-life-sciences-summit-igms-20210427monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-appoints-george-gauthier-as-chief-commercial-officer-igms-20210412monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-fourth-quarter-and-full-year-2020-financial-results-and-provides-igms-20210330monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-announce-fourth-quarter-and-year-end-2020-financial-results-and-host-co-igms-20210324monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-appoints-lisa-decker-ph-d-as-chief-business-officer-igms-20210315monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-guggenheim-healthcare-talks-2021-idea-forum-oncology-day-igms-20210205monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-enters-into-exclusive-licensing-agreement-with-medivir-for-birinapant-igms-20210111monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-igms-20210107monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-announces-closing-of-230-million-public-offering-and-full-exercise-of-underwriters-opt-igms-20201211monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-announces-pricing-of-upsized-200-million-public-offering-igms-20201209monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-announces-proposed-public-offering-igms-20201207monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-presents-first-clinical-data-from-igm-2323-in-non-hodgkin-s-lymphoma-at-20-igms-20201205monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-host-conference-call-and-webcast-to-review-igm-2323-data-presented-at-t-igms-20201130monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-confere-igms-20201123monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-three-upcoming-investor-conferences-igms-20201109monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-third-quarter-2020-financial-results-and-provides-corporate-upda-igms-20201105monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-first-clinical-data-from-igm-2323-in-non-hodgkin-s-lymphoma-at--igms-20201104monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-initiates-first-in-human-clinical-trial-of-igm-8444-for-the-treatment-of-s-igms-20200930monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-four-upcoming-investor-conferences-igms-20200902monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-second-quarter-2020-financial-results-and-provides-corporate-upd-igms-20200806monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-2020-wedbush-pacgrow-healthcare-virtual-conference-igms-20200804monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-jefferies-2020-healthcare-conference-igms-20200528monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-the-2020-rbc-capital-markets-global-healthcare-conference-igms-20200512monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-first-quarter-2020-financial-results-and-provides-corporate-upda-igms-20200507monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-participate-in-canaccord-genuity-horizons-in-oncology-virtual-event-igms-20200403monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-fourth-quarter-and-full-year-2019-financial-results-and-provides-igms-20200326monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-announce-fourth-quarter-and-year-end-2019-financial-results-and-host-co-igms-20200319monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-two-upcoming-investor-conferences-igms-20200304monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-two-upcoming-investor-conferences-igms-20200206monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-appoints-eric-humke-m-d-ph-d-as-vice-president-clinical-development-apopto-igms-20200107monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-to-present-at-three-upcoming-investor-conferences-igms-20191112monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-third-quarter-2019-financial-results-igms-20191107monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-initiates-first-in-human-phase-1-clinical-trial-of-igm-2323-for-the-treatm-igms-20191002monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-closing-of-initial-public-offering-including-full-exercise-of-un-igms-20190920monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-announces-pricing-of-initial-public-offering-igms-20190918monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-name-change-to-filana-therapeutics-inc-sava-20260310monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-topline-phase-3-refocus-alz-data-sava-20250325monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-2024-financial-results-and-provides-business-update-sava-20250303monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-licenses-simufilam-method-of-treatment-patent-sava-20250227monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-sued-for-securities-law-violations-investors-should-contact-levi-kors-sava-20250210monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of--sava-20250206monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-ll-sava-20250205monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses--sava-20250204monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-class-action-levi-korsinsky-reminds-cassava-sciences-inc-investors-of-sava-20250204monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-nasdaq-sava-deadline-alert-bernstein-liebhard-llp-reminds-cassava-sci-sava-20250203monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of--sava-20250130monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-ll-sava-20250129monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-nasdaq-sava-deadline-alert-bernstein-liebhard-llp-reminds-cassava-sci-sava-20250127monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of--sava-20250123monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-ll-sava-20250122monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-investors-february-10-2025-filing-deadline-in-securities-class-action-sava-20250121monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-sava-20250121monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-nasdaq-sava-deadline-alert-bernstein-liebhard-llp-reminds-cassava-sci-sava-20250121monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of--sava-20250116monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-ll-sava-20250115monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-nasdaq-sava-deadline-alert-bernstein-liebhard-llp-reminds-cassava-sci-sava-20250113monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-sued-for-securities-law-violations-investors-should-contact-levi-kors-sava-20250113monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-sava-investors-february-10-2025-filing-deadline-in-securities-class-a-sava-20250109monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of--sava-20250109monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-ll-sava-20250108monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses--sava-20250107monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-provides-a-business-update-sava-20250107monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-nasdaq-sava-deadline-alert-bernstein-liebhard-llp-reminds-cassava-sci-sava-20250107monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-nasdaq-sava-deadline-alert-bernstein-liebhard-llp-reminds-cassava-sci-sava-20241230monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-sava-20241224monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-nasdaq-sava-deadline-alert-bernstein-liebhard-llp-reminds-cassava-sci-sava-20241223monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-stockholder-alert-robbins-llp-reminds-investors-of-the-sava-class-act-sava-20241220monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-nasdaq-sava-investor-alert-investors-with-large-losses-in-cassava-sci-sava-20241218monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-ll-sava-20241218monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-sava-20241218monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-sued-for-securities-law-violations-investors-should-contact-levi-kors-sava-20241216monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-topline-phase-3-data-did-not-meet-co-primary-endpoints-sava-20241125monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-to-hold-corporate-update-on-november-25th-sava-20241125monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-appoints-freda-nassif-as-chief-commercial-officer-sava-20241118monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-q3-2024-financial-and-operating-results-sava-20241107monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-to-report-third-quarter-2024-results-on-november-7-2024-sava-20241031monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-resolves-sec-investigation-sava-20240926monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-completion-of-an-interim-safety-review-of-oral-simufilam-on-goi-sava-20240924monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-names-rick-barry-as-chief-executive-officer-sava-20240909monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-to-present-at-the-h-c-wainwright-global-investment-conference-sava-20240903monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-q2-2024-financial-results-and-operational-updates-sava-20240808monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-mourns-the-death-of-board-member-sanford-sandy-robertson-sava-20240805monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-to-hold-conference-call-to-discuss-recent-developments-and-provide-a-comp-sava-20240801monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-expansion-of-open-label-extension-trials-sava-20240730monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-changes-in-executive-leadership-enhanced-corporate-governance-a-sava-20240717monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-issues-statement-on-former-science-advisor-sava-20240628monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-q1-2024-financial-results-and-clinical-updates-on-phase-3-trials--sava-20240510monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-over-125-million-raised-from-warrant-distribution-sava-20240508monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-alert-bragar-eagel-squire-p-c-is-investigating-cassava-sciences-inc-on-behalf-of-l-sava-20240405monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses--sava-20240401monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-completion-of-an-interim-safety-review-of-oral-simufilam-on-goi-sava-20240325monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-virtual-presentation-at-the-ad-pd-2024-international-conference-sava-20240304monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-full-year-2023-financial-results-and-corporate-updates-sava-20240228monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-shareholder-notice-faruqi-faruqi-securities-litigation-partner-james-josh-wilson-e-sava-20240223monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-investor-deadline-approaching-faruqi-faruqi-llp-securities-litigation-par-sava-20240215monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-deadline-alert-faruqi-faruqi-securities-litigation-partner-james-josh-wilson-encou-sava-20240208monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-sava-20240206monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-sued-for-securities-law-violations-investors-should-contact-block-leviton-sava-20240205monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-completes-dividend-distribution-of-warrants-to-shareholders-sava-20240105monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-dividend-distribution-of-warrants-to-shareholders-sava-20231212monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-appoints-three-new-members-to-its-board-of-directors-sava-20231207monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-third-quarter-2023-financial-and-operating-results-sava-20231107monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-completes-enrollment-for-pivotal-phase-3-program-of-simufilam-in-alzheime-sava-20231106monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-to-present-at-the-jefferies-biotech-cns-neuro-summit-in-ny-sava-20231005monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-completes-patient-enrollment-for-pivotal-phase-3-clinical-trial-of-oral-s-sava-20231002monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-positive-interim-safety-review-of-simufilam-on-going-phase-3-tr-sava-20230918monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-science-publication-that-confirms-mechanism-of-action-of-simufi-sava-20230913monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-science-publication-that-confirms-mechanism-of-action-of-simufi-sava-20230911monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-invited-to-present-in-four-upcoming-investor-conferences-sava-20230906monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-q2-2023-financial-results-and-operating-updates-sava-20230803monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-investigation-update-by-former-louisiana-attorney-general-kahn-swick-foti-sava-20230708monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-investigation-update-by-former-louisiana-attorney-general-kahn-swick-foti-sava-20230625monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-to-present-at-the-jefferies-global-healthcare-conference-sava-20230601monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-completes-patient-dosing-in-a-randomized-controlled-trial-of-simufilam-in-sava-20230511monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-q1-2023-financial-results-and-operating-updates-sava-20230501monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-to-present-at-the-2023-h-c-wainwright-investor-conference-sava-20230426monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-full-year-2022-financial-results-and-operating-updates-sava-20230228monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-patient-enrollment-update-for-phase-3-studies-of-simufilam-for--sava-20230208monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-positive-top-line-clinical-results-in-phase-2-study-evaluating--sava-20230124monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-mourns-the-death-of-board-member-and-officer-nadav-friedmann-phd-md-sava-20221220monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-completion-of-dosing-in-open-label-study-of-simufilam-for-alzhe-sava-20221206monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-closing-of-50-million-registered-direct-offering-sava-20221122monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-50-million-registered-direct-offering-of-common-stock-sava-20221118monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-third-quarter-financial-results-for-2022-and-business-updates-sava-20221107monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-files-lawsuit-against-perpetrators-of-short-and-distort-campaign-sava-20221103monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-expansion-of-leadership-team-sava-20221027monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-initiation-of-an-open-label-extension-study-sava-20221013monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-to-present-at-the-h-c-wainwright-global-investment-conference-sava-20220908monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-second-quarter-financial-results-for-2022-mid-year-corporate-upda-sava-20220803monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-responds-to-media-reports-sava-20220727monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-investors-company-investigated-by-the-portnoy-law-firm-sava-20220721monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-first-quarter-financial-results-for-2022-and-updates-on-phase-3-c-sava-20220505monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-invited-to-participate-in-b-riley-securities-neuroscience-conference-sava-20220425monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-alert-bragar-eagel-squire-p-c-is-investigating-cassava-sciences-inc-on-behalf-of-c-sava-20220423monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-fireside-chat-and-presentation-tuesday-april-5th-sava-20220330monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-full-year-2021-financial-results-and-operating-updates-sava-20220228monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-launches-clinical-website-to-support-phase-3-studies-of-oral-simufilam-in-sava-20211223monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-initiates-a-second-phase-3-study-of-simufilam-for-the-treatment-of-patien-sava-20211118monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-investigation-alert-wolf-haldenstein-adler-freeman-herz-llp-is-invest-sava-20211117monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-third-quarter-2021-financial-results-sava-20211110monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-nasdaq-sava-shareholder-lawsuit-deadline-reminder-bernstein-liebhard--sava-20211012monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-initiates-a-phase-3-efficacy-trial-of-simufilam-for-the-treatment-of-pati-sava-20211006monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-top-line-results-of-12-month-interim-analysis-from-open-label-s-sava-20210922monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-to-present-at-h-c-wainwright-s-23rd-annual-global-investment-conference-sava-20210909monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-releases-a-public-statement-regarding-recent-allegations-sava-20210903monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-cassava-scien-sava-20210901monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-inc-investors-company-investigated-by-the-portnoy-law-firm-sava-20210827monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-releases-statement-regarding-plasma-p-tau-analysis-from-a-previously-disc-sava-20210827monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-investigation-block-leviton-investigates-cassava-sciences-inc-for-potenti-sava-20210825monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-responds-to-allegations-sava-20210825monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-agreement-with-fda-on-special-protocol-assessments-spa-for-its--sava-20210824monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-second-quarter-2021-financial-results-sava-20210803monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-conference-call-for-second-quarter-financial-results-sava-20210802monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-positive-biomarker-data-with-simufilam-in-alzheimer-s-disease-sava-20210729monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-positive-cognition-data-with-simufilam-in-alzheimer-s-disease-sava-20210729monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-positive-data-with-savadx-from-a-randomized-controlled-phase-2b-sava-20210726monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-to-present-new-clinical-dataset-at-2021-alzheimer-s-association-internati-sava-20210721monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-selects-clinical-research-organization-for-phase-3-clinical-program-in-al-sava-20210621monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-provides-mid-year-corporate-update-clinical-development-progress-and-anno-sava-20210621monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-to-present-at-the-raymond-james-2021-human-health-innovation-conference-sava-20210617monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-the-appointment-of-richard-j-barry-to-its-board-of-directors-sava-20210614monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-to-participate-in-q-a-panel-discussion-on-alzheimer-s-disease-sava-20210524monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-new-2-7-million-research-grant-award-from-national-institutes-o-sava-20210512monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-initiation-of-cognition-maintenance-study-in-alzheimer-s-diseas-sava-20210510monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-invited-to-participate-in-b-riley-securities-neuroscience-conference-sava-20210427monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-invited-by-the-nih-to-participate-in-sachs-4th-annual-neuroscience-innova-sava-20210426monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-first-quarter-2021-financial-results-and-announces-guidance-on-cl-sava-20210421monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-full-year-2020-financial-results-and-business-highlights-sava-20210323monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam-sava-20210309monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-to-present-at-the-h-c-wainwright-global-life-sciences-conference-sava-20210308monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference-sava-20210223monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-positive-end-of-phase-2-meeting-with-fda-and-outlines-pivotal-p-sava-20210222monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-closing-of-200-million-registered-direct-offering-sava-20210212monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-200-million-registered-direct-offering-of-common-stock-sava-20210210monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-significant-program-progress-and-expected-key-milestones-in-202-sava-20210208monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-simufilam-improves-cognition-and-behavior-in-alzheimer-s-disease-in-inter-sava-20210202monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-appoints-dr-james-kupiec-as-chief-clinical-development-officer-sava-20210104monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-pricing-of-75-million-public-offering-of-common-stock-sava-20201113monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-proposed-public-offering-of-common-stock-sava-20201112monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-third-quarter-2020-financial-results-sava-20201109monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-additional-clinical-data-from-a-phase-2b-study-of-sumifilam-in--sava-20201104monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-phase-2b-clinical-results-in-alzheimer-s-selected-as-late-breaking-news-a-sava-20200930monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-final-results-of-a-phase-2b-clinical-study-of-sumifilam-in-pati-sava-20200914monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-to-hold-conference-call-on-monday-september-14-2020-at-8-30-am-et-sava-20200911monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-to-present-at-h-c-wainwright-s-22nd-annual-global-investment-conference-sava-20200909monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-new-patent-grant-sava-20200903monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-lead-drug-candidate-pti-125-is-assigned-the-chemical-drug-name--sava-20200824monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-second-quarter-2020-financial-results-and-mid-year-business-rev-sava-20200812monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-to-give-keynote-presentation-on-savadx-at-a-scientific-conference-sava-20200709monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-added-to-russell-indexes-and-provides-phase-2b-study-update-sava-20200616monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-presentation-at-the-jefferies-virtual-healthcare-conference-and-sava-20200603monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-first-quarter-2020-financial-results-and-provides-business-update-sava-20200506monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-new-2-5-million-research-grant-award-from-national-institutes-o-sava-20200423monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-full-year-2019-financial-results-and-anticipated-key-milestones-sava-20200326monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-initiation-of-an-open-label-study-to-evaluate-pti-125-in-patien-sava-20200325monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-clinical-update-and-business-progress-across-neuroscience-pipel-sava-20200319monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-phase-2a-study-of-pti-125-published-in-the-journal-of-preventio-sava-20200211monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-completion-of-patient-enrollment-of-a-phase-2b-study-in-alzheim-sava-20200128monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-additional-positive-phase-2a-clinical-data-in-alzheimer-s-disea-sava-20191206monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-recent-clinical-highlights-and-third-quarter-2019-financial-res-sava-20191029monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-clinical-results-in-alzheimer-s-selected-as-late-breaking-news-at-ctad-20-sava-20191024monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-initiates-phase-2b-clinical-study-in-alzheimer-s-patients-sava-20190916monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-positive-phase-2a-clinical-results-in-alzheimer-s-patients-sava-20190909monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-to-present-at-h-c-wainwright-s-21st-annual-global-investment-conference-sava-20190903monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-second-quarter-2019-financial-results-sava-20190812monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-to-present-at-maxim-group-s-conference-on-alzheimer-s-disease-sava-20190618monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-new-website-launch-sava-20190528monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-reports-first-quarter-2019-financial-results-sava-20190429monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-completes-patient-enrollment-for-a-phase-2a-study-in-patients-with-alzhei-sava-20190415monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-reporting-date-for-fourth-quarter-and-full-year-2024-financial-results-optn-20250311monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-1-for-15-reverse-stock-split-optn-20241226monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-piper-sandler-36th-annual-healthcare-conference-optn-20241202monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-third-quarter-2024-financial-results-and-recent-operational-highlights-optn-20241112monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-reporting-date-for-third-quarter-2024-financial-results-optn-20241105monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-optn-20241016monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-appoints-terry-kohler-as-chief-financial-officer-optn-20241007monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-optn-20240826monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-second-quarter-2024-financial-results-and-recent-operational-highlights-optn-20240808monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-reporting-date-for-second-quarter-2024-financial-results-optn-20240802monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-h-c-wainwright-2nd-annual-bioconnect-investor-conference-at-nas-optn-20240517monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-first-quarter-2024-financial-results-and-recent-operational-highlights-optn-20240514monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-reporting-date-for-first-quarter-2024-financial-results-optn-20240510monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-55-million-registered-direct-offering-optn-20240509monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-provides-corporate-update-on-xhance-launch-and-outlook-and-announces-preliminary--optn-20240425monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-needham-virtual-healthcare-conference-optn-20240404monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-operationa-optn-20240307monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-reporting-date-for-fourth-quarter-2023-financial-results-optn-20240229monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-the-publication-of-reopen-phase-3-clinical-trial-program-evaluating-xha-optn-20240118monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-3-month-extension-of-fda-review-period-for-the-supplemental-new-drug-ap-optn-20231206monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-35th-annual-piper-sandler-healthcare-conference-optn-20231122monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-third-quarter-2023-financial-results-and-operational-updates-optn-20231109monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-reporting-date-for-third-quarter-2023-financial-results-optn-20231027monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-2023-cantor-global-healthcare-conference-optn-20230922monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-second-quarter-2023-financial-results-and-operational-updates-optn-20230810monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-preliminary-second-quarter-2023-xhance-net-revenue-of-19-5-million-optn-20230727monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-optn-20230616monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-jefferies-healthcare-conference-optn-20230602monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-first-quarter-2023-financial-results-and-operational-updates-optn-20230511monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-fda-acceptance-of-supplemental-new-drug-application-for-xhance-optn-20230504monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-reporting-date-for-first-quarter-2023-financial-results-optn-20230501monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-optn-20230418monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-needham-virtual-healthcare-conference-optn-20230412monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-fourth-quarter-and-full-year-2022-financial-results-and-recent-operationa-optn-20230307monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-reporting-date-for-fourth-quarter-2022-financial-results-optn-20230228monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-submits-supplemental-new-drug-application-for-xhance-label-expansion-optn-20230221monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-ceo-transition-and-business-update-optn-20230131monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-appoints-paul-spence-as-chief-commercial-officer-optn-20221215monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-departure-of-acting-chief-financial-officer-optn-20221209monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-corporate-updates-and-presentation-at-the-34th-annual-piper-sandler-hea-optn-20221130monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-pricing-of-public-offering-of-common-stock-and-warrants-optn-20221121monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-proposed-public-offering-of-common-stock-and-warrants-optn-20221121monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-third-quarter-2022-financial-results-and-operational-updates-optn-20221110monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-reopen2-presentation-at-the-american-college-of-asthma-allergy-and-immu-optn-20221109monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-reporting-date-for-third-quarter-2022-financial-results-optn-20221107monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-late-breaking-abstract-podium-presentation-at-idweek-2022-optn-20221021monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-reopen1-abstract-selected-for-presentation-at-the-american-rhinologic-s-optn-20220906monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-second-quarter-2022-financial-results-and-operational-updates-optn-20220811monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-reporting-date-for-second-quarter-2022-financial-results-optn-20220808monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-that-xhance-significantly-reduced-incidence-of-exacerbations-for-patien-optn-20220713monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-additional-positive-results-from-reopen2-and-initial-results-from-poole-optn-20220708monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-positive-top-line-results-of-reopen2-its-second-phase-3-clinical-trial--optn-20220613monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-departure-of-chief-financial-officer-optn-20220603monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-first-quarter-2022-financial-results-and-operational-updates-optn-20220512monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-reporting-date-for-first-quarter-2022-financial-results-optn-20220505monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-appointment-of-r-john-fletcher-to-the-board-optn-20220426monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-needham-virtual-healthcare-conference-optn-20220408monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-operationa-optn-20220308monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-positive-top-line-results-in-reopen1-a-landmark-phase-3-trial-for-xhance--optn-20220307monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-reporting-date-for-fourth-quarter-2021-financial-results-optn-20220304monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-appointment-of-two-new-members-to-board-of-directors-optn-20211213monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-piper-sandler-virtual-healthcare-conference-optn-20211123monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-optn-20211118monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-closing-of-46-0-million-public-offering-of-common-stock-optn-20211118monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-pricing-of-public-offering-of-common-stock-optn-20211116monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-proposed-public-offering-of-common-stock-optn-20211115monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-third-quarter-2021-financial-results-and-recent-operational-highlights-optn-20211115monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-reporting-date-for-third-quarter-2021-financial-results-optn-20211110monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-completes-patient-recruitment-in-second-pivotal-trial-for-xhance-in-chronic-sinus-optn-20211028monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-cantor-virtual-global-healthcare-conference-optn-20210922monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-optn-20210825monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-second-quarter-2021-financial-results-and-recent-operational-highlights-optn-20210811monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-completes-patient-recruitment-in-pivotal-trial-for-xhance-in-chronic-sinusitis-optn-20210730monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-preliminary-second-quarter-2021-xhance-net-revenue-of-18-4-million-optn-20210728monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-technology-inventor-per-djupesland-named-winner-of-european-inventor-award-2021-f-optn-20210624monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-jefferies-virtual-healthcare-conference-optn-20210601monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-first-quarter-2021-financial-results-and-operational-updates-optn-20210505monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-reporting-date-for-first-quarter-2021-financial-results-and-upcoming-he-optn-20210428monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-needham-virtual-healthcare-conference-optn-20210412monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-fourth-quarter-and-full-year-2020-financial-results-and-recent-operationa-optn-20210303monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-reporting-date-for-fourth-quarter-2020-financial-results-optn-20210217monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-optn-20210125monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-optn-20201221monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-changes-to-board-of-directors-optn-20201201monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-third-quarter-2020-financial-results-and-recent-operational-highlights-optn-20201105monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-preliminary-third-quarter-2020-xhance-net-revenue-of-15-4-million-optn-20201022monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-cantor-virtual-global-healthcare-conference-optn-20200914monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-pricing-of-public-offering-of-common-stock-optn-20200814monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-proposed-public-offering-of-common-stock-optn-20200813monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-second-quarter-2020-financial-results-and-recent-operational-highlights-optn-20200804monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-reporting-date-for-second-quarter-2020-financial-results-optn-20200730monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-names-catherine-e-owen-as-director-optn-20200729monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-anti-covid-19-product-candidate-optn-20200630monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-bmo-2020-prescriptions-for-success-healthcare-conference-optn-20200622monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-named-a-2020-best-place-to-work-by-philadelphia-business-journal-optn-20200619monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-host-its-annual-meeting-of-stockholders-in-virtual-format-optn-20200527monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-2020-jefferies-virtual-healthcare-conference-optn-20200526monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-2020-rbc-capital-markets-global-healthcare-virtual-conference-optn-20200514monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-first-quarter-2020-financial-results-and-operational-updates-optn-20200507monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-report-first-quarter-2020-financial-results-and-corporate-updates-on-may-7-202-optn-20200430monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-fourth-quarter-and-full-year-2019-financial-results-and-recent-operationa-optn-20200305monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-report-fourth-quarter-and-full-year-2019-financial-results-and-corporate-updat-optn-20200227monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-appoints-victor-clavelli-as-chief-commercial-officer-optn-20200219monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-peer-reviewed-publication-of-the-fourth-major-xhance-registration-trial-optn-20191217monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-piper-jaffray-31st-annual-healthcare-conference-optn-20191126monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-pricing-of-public-offering-of-common-stock-optn-20191121monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-proposed-public-offering-of-common-stock-optn-20191120monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-third-quarter-2019-financial-results-and-recent-operational-highlights-optn-20191112monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-report-third-quarter-2019-financial-results-and-corporate-updates-on-november--optn-20191101monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-appoints-michael-richardson-to-new-position-of-vice-president-business-developmen-optn-20191004monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-2019-cantor-global-healthcare-conference-optn-20190927monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-license-agreement-related-to-onzetra-xsail-optn-20190926monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-departure-of-chief-commercial-officer-optn-20190917monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-150-million-debt-financing-from-pharmakon-optn-20190912monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-second-quarter-2019-financial-results-and-recent-operational-highlights-optn-20190812monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-report-second-quarter-2019-financial-results-and-corporate-updates-on-august-1-optn-20190801monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-bmo-capital-markets-prescriptions-for-success-healthcare-confer-optn-20190620monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-named-a-2019-best-place-to-work-by-philadelphia-business-journal-optn-20190619monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-first-quarter-2019-financial-results-and-recent-operational-highlights-optn-20190509monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-report-first-quarter-2019-financial-results-and-corporate-updates-on-may-9-201-optn-20190425monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-fourth-quarter-and-full-year-2018-financial-results-and-recent-operationa-optn-20190306monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-report-fourth-quarter-2018-financial-results-and-corporate-updates-on-march-6--optn-20190227monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-issuance-of-four-additional-u-s-patents-covering-xhance-optn-20190219monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-highlight-data-at-the-2019-aaaai-annual-meeting-in-san-francisco-optn-20190215monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-license-agreement-optn-20190204monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-update-to-license-agreement-with-avanir-pharmaceuticals-for-onzetra-xsa-optn-20181211monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-first-patient-enrolled-in-clinical-trial-of-xhance-for-chronic-sinusiti-optn-20181210monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-bmo-capital-markets-prescriptions-for-success-healthcare-confer-optn-20181205monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-third-quarter-2018-financial-results-and-recent-operational-highlights-optn-20181113monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-report-third-quarter-2018-financial-results-and-corporate-updates-on-november--optn-20181031monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-highlight-data-at-two-upcoming-scientific-meetings-optn-20181003monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-2018-cantor-global-healthcare-conference-optn-20180924monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-second-quarter-2018-financial-results-and-recent-operational-highlights-optn-20180814monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-report-second-quarter-2018-financial-results-and-corporate-updates-on-august-1-optn-20180807monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-named-a-2018-best-place-to-work-by-philadelphia-business-journal-optn-20180702monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-publication-of-pivotal-efficacy-and-long-term-safety-data-for-xhance-in-optn-20180621monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-ceo-peter-miller-and-president-and-coo-ramy-mahmoud-named-ey-life-sciences-entrep-optn-20180615monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-closing-of-public-offering-and-exercise-in-full-of-the-underwriters-opt-optn-20180611monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-pricing-of-public-offering-of-common-stock-optn-20180607monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-launch-of-public-offering-of-common-stock-optn-20180604monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-first-quarter-2018-financial-results-and-recent-operational-highlights-optn-20180514monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-report-first-quarter-2018-financial-results-and-corporate-updates-on-may-14-20-optn-20180507monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-ceo-peter-miller-and-president-coo-ramy-mahmoud-named-ey-entrepreneur-of-the-year-optn-20180423monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-named-emerging-company-of-the-year-by-life-sciences-pennsylvania-optn-20180315monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-fourth-quarter-and-full-year-2017-financial-results-and-recent-operationa-optn-20180313monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-report-fourth-quarter-and-full-year-2017-financial-results-and-corporate-updat-optn-20180306monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-highlight-data-at-the-2018-aaaai-wao-joint-congress-optn-20180227monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-names-sandra-l-helton-as-director-and-chairperson-of-the-company-s-audit-committe-optn-20180222monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-the-2018-rbc-capital-markets-healthcare-conference-optn-20180215monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-leerink-partners-7th-annual-global-healthcare-conference-optn-20180209monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-100-million-debt-financing-from-athyrium-capital-management-optn-20180102monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-bmo-capital-markets-prescription-for-success-healthcare-conference-optn-20171207monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-third-quarter-2017-financial-results-and-recent-operating-highlights-optn-20171127monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-report-third-quarter-2017-financial-results-and-operational-highlights-on-nove-optn-20171120monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-piper-jaffray-healthcare-conference-optn-20171117monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-to-present-at-jefferies-2017-london-healthcare-conference-optn-20171108monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-expands-leadership-team-with-key-hires-optn-20171030monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-nasdaq-optn-to-ring-the-nasdaq-stock-market-opening-bell-optn-20171024monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-op-optn-20171017monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-pricing-of-initial-public-offering-optn-20171013monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-s-abuse-deterrent-opioid-poised-for-fda-approval-drrx-20160714monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corp-s-ceo-james-e-brown-interviewed-by-the-life-sciences-report-drrx-20160202monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-announces-pricing-of-a-public-offering-of-46-7-million-of-common-stock-and-pre-funde-kzr-20200609monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-announces-proposed-public-offering-of-common-stock-kzr-20200608monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-provides-data-update-from-mission-study-of-kzr-616-kzr-20200603monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-to-participate-in-fireside-chat-during-the-jefferies-virtual-healthcar-kzr-20200528monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-announces-presentations-during-upcoming-scientific-conferences-kzr-20200520monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-first-quarter-2020-financial-results-and-provides-business-upd-kzr-20200507monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-strengthens-executive-team-with-the-appointment-of-noreen-r-henig-md-a-kzr-20200504monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-provides-statement-regarding-covid-19-pandemic-kzr-20200409monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-fourth-quarter-and-year-end-2019-financial-results-and-provide-kzr-20200312monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-to-present-at-cowen-and-company-s-40th-annual-healthcare-conference-kzr-20200226monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-announces-closing-of-56-8-million-public-offering-of-common-stock-and-pre-funded-war-kzr-20200204monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-announces-pricing-of-49-4-million-public-offering-of-common-stock-and-pre-funded-war-kzr-20200131monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-kzr-20200130monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-enhances-clinical-expertise-with-the-appointment-of-elizabeth-garner-m-kzr-20191219monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-highlights-therapeutic-potential-of-protein-secretion-inhibitors-at-th-kzr-20191209monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-to-present-at-the-piper-jaffray-31st-annual-healthcare-conference-kzr-20191127monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-to-present-at-upcoming-investor-conferences-kzr-20191114monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-announces-promising-new-data-with-kzr-616-at-the-american-college-of-rheumatology-an-kzr-20191112monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-to-host-conference-call-and-webcast-during-the-american-college-of-rhe-kzr-20191108monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-third-quarter-2019-financial-results-and-provides-business-upd-kzr-20191106monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-announces-presentations-of-four-abstracts-at-the-2019-acr-arp-annual-m-kzr-20191001monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-to-present-at-the-2019-cantor-global-healthcare-conference-kzr-20190927monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-announces-presentations-at-upcoming-investor-conferences-kzr-20190828monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-second-quarter-2019-financial-results-and-provides-business-up-kzr-20190807monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-announces-promising-data-from-first-in-patient-study-of-kzr-616-at-eul-kzr-20190613monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-to-host-conference-call-and-webcast-at-the-eular-2019-annual-meeting-t-kzr-20190610monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-announces-acceptance-of-abstract-for-presentation-of-first-in-patient--kzr-20190528monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-announces-presentations-at-two-upcoming-investor-conferences-kzr-20190514monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-first-quarter-2019-financial-results-and-provides-business-upd-kzr-20190507monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-to-present-at-the-18th-annual-needham-healthcare-conference-kzr-20190403monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-announces-presentations-at-upcoming-scientific-conferences-kzr-20190328monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-fourth-quarter-and-year-end-2018-financial-results-and-provide-kzr-20190326monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-announces-initiation-of-clinical-study-to-test-a-new-drug-product-form-kzr-20190306monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-to-present-at-the-cowen-and-company-39th-annual-health-care-conference-kzr-20190305monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-strengthens-management-team-appoints-celia-economides-as-senior-vice-p-kzr-20190304monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-to-present-at-the-bmo-prescriptions-for-success-healthcare-conference-kzr-20181205monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-third-quarter-2018-financial-results-and-provides-business-upd-kzr-20181108monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-to-present-at-jefferies-2018-london-healthcare-conference-kzr-20181107monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-to-present-at-2018-wells-fargo-healthcare-conference-kzr-20180829monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-second-quarter-2018-financial-results-and-provides-business-up-kzr-20180809monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-strengthens-market-position-with-landmark-hifi-2-data-supporting-focal-one-roboti-edap-20260430monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-announce-third-quarter-2023-financial-results-on-november-9-2023-edap-20231026monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-announce-second-quarter-2023-financial-results-on-august-24-2023-edap-20230810monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-announce-third-quarter-2022-financial-results-on-wednesday-november-16th-20-edap-20221102monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-hosting-urology-expert-panel-and-live-focal-one-technology-demonstration-edap-20220926monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-announce-second-quarter-2022-financial-results-on-august-24th-2022-edap-20220803monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-announce-first-quarter-2022-financial-results-on-may-17-2022-edap-20220510monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-announce-fourth-quarter-2021-financial-results-on-wednesday-march-30-2022-edap-20220321monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-announce-third-quarter-2021-financial-results-on-wednesday-november-17-2021-edap-20211110monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-announce-first-quarter-2021-financial-results-on-may-11-2021-edap-20210504monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-announce-fourth-quarter-and-full-year-2020-financial-results-on-march-30-20-edap-20210323monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-announce-third-quarter-2020-financial-results-on-november-18-2020-edap-20201109monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-announce-second-quarter-2020-financial-results-on-august-26-2020-edap-20200819monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-announce-first-quarter-2020-financial-results-on-may-13-2020-edap-20200506monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-announce-fourth-quarter-and-year-ended-december-31-2019-financial-results-o-edap-20200324monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-announce-third-quarter-and-nine-months-2019-financial-results-on-wednesday--edap-20191024monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-pre-announces-strong-98-growth-in-hifu-sales-in-the-second-quarter-2019-edap-20190725monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-edap-announces-positive-outcome-from-cpt-panel-for-hifu-reimbursement-in-the-u-s-edap-20190610monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-announce-first-quarter-2019-financial-results-on-wednesday-may-15-2019-edap-20190502monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-to-showcase-suite-of-therapeutic-ultrasound-products-during-the-american--edap-20190429monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-reports-q4-and-full-year-2018-results-edap-20190401monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-university-of-chicago-medicine-becomes-first-hospital-in-the-midwest-to-acquir-edap-20190401monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-tms-sa-to-announce-fourth-quarter-and-fiscal-year-2018-financial-results--edap-20190321monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-hifu-pioneer-houston-methodist-hospital-acquires-edap-s-next-generation-focal--edap-20190304monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-uci-health-medical-center-becomes-first-in-the-u-s-to-treat-patients-using-eda-edap-20190205monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-announces-the-purchase-of-focal-one-hifu-by-maimonides-medical-center-bro-edap-20190118monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-announces-sales-of-two-additional-focal-one-devices-in-brazil-edap-20190114monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-john-wayne-cancer-institute-first-us-medical-center-to-acquire-edap-s-breakthr-edap-20190103monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-announces-expiration-of-second-and-final-tranche-of-outstanding-warrants-edap-20181129monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-to-present-a-corporate-update-at-the-30th-annual-piper-jaffray-conference-edap-20181120monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-reports-2018-third-quarter-results-edap-20181114monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-tms-sa-to-announce-third-quarter-2018-financial-results-on-wednesday-nove-edap-20181106monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-urologic-oncologists-from-top-us-teaching-hospitals-gather-in-montreal-to-lear-edap-20181025monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-announces-expiration-of-tranche-of-outstanding-warrants-edap-20181015monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-announces-the-installation-of-a-third-focal-one-hifu-device-in-brazil-edap-20180927monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-houston-methodist-medical-center-research-study-sheds-positive-light-on-use-of-edap-20180926monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-announces-installation-of-first-focal-one-hifu-device-in-south-korea-edap-20180920monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-reports-2018-second-quarter-results-edap-20180829monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-tms-sa-to-announce-second-quarter-2018-financial-results-on-thursday-augu-edap-20180724monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-announces-fda-clearance-for-focal-one-edap-20180607monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-reports-2018-first-quarter-results-edap-20180514monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-tms-sa-to-announce-first-quarter-2018-financial-results-on-monday-may-14-edap-20180502monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-reports-first-us-cohort-study-results-of-focal-hifu-prostate-ablation-sho-edap-20180403monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-reports-2017-annual-results-edap-20180327monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-announces-cigna-as-first-major-u-s-private-health-insurer-to-cover-hifu-f-edap-20180321monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-edap-tms-to-announce-year-end-2017-financial-results-on-tuesday-march-27-2018-edap-20180314monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-reports-third-quarter-2017-results-edap-20171115monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-to-announce-third-quarter-2017-financial-results-on-wednesday-november-15-2017-edap-20171101monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-to-present-at-the-19th-annual-rodman-renshaw-global-investment-conference-edap-20170824monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-reports-record-second-quarter-and-first-half-2017-results-edap-20170823monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-to-announce-second-quarter-2017-financial-results-on-wednesday-august-23-2017-edap-20170810monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-reports-first-quarter-2017-results-edap-20170517monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-report-first-quarter-2017-financial-results-on-may-17-2017-edap-20170502monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-report-fourth-quarter-and-full-year-2016-results-on-april-3-2017-edap-20170314monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-retains-cg-capital-as-new-investor-relations-counsel-edap-20161212monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-to-present-at-the-18th-annual-rodman-and-renshaw-global-investment-conference-edap-20160906monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-closes-11-5-million-registered-direct-offering-edap-20160414monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-raise-11-5-million-in-registered-direct-offering-edap-20160407monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-to-present-at-rodman-and-renshaw-global-investment-conference-edap-20150902monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-significantly-strengthens-financial-profile-edap-20120329monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-raise-5-625-million-in-registered-direct-offering-edap-20120323monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-launches-ablatherm-hifu-enlight-patient-awareness-program-edap-20080222monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-sa-to-present-at-roth-20th-annual-oc-growth-stock-conference-edap-20080213monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-s-a-reports-2007-fourth-quarter-and-year-end-preliminary-unaudited-revenues-edap-20080207monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-s-a-edap-chief-executive-officer-to-ring-the-nasdaq-stock-market-closing-bell-edap-20071214monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-s-a-2007-third-quarter-hifu-revenues-increase-edap-20071126monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-tms-s-a-closes-20-million-placement-to-fully-fund-its-u-s-clinical-studies-edap-20071105monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-changes-name-to-insight-molecular-diagnostics-inc-imdx-moves-headquarters-to-nash-ocx-20250617monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-q1-2025-results-and-business-progress-ocx-20250512monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-provides-positive-update-on-clinical-trial-progress-ocx-20250430monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-s-proprietary-assay-demonstrates-long-term-clinical-validity-ocx-20250429monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025-ocx-20250318monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-participate-in-j-p-morgan-week-and-host-investor-meetings-ocx-20241209monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-demonstrates-potential-for-liquid-biopsy-of-brain-tumors-in-new-study-ocx-20241204monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-dd-cfdna-assay-detects-kidney-transplant-rejection-11-months-ahead-of-standard-pr-ocx-20241202monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-commercial-launch-progress-on-track-to-sign-20-transplant-centers-by-end--ocx-20241112monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-announce-third-quarter-2024-financial-results-on-nov-12-ocx-20241106monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-participation-in-the-ld-micro-main-event-xvii-conference-in-los-angeles-ocx-20241016monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-s-determaio-immuno-oncology-assay-predicts-response-to-atezolizumab-in-phase-2-cl-ocx-20241008monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-signs-leading-transplant-centers-in-us-and-germany-ocx-20241002monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-announces-10-2-million-private-placement-of-securities-priced-at-the--ocx-20241002monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-s-vitagraft-kidney-used-to-monitor-effect-of-daratumumab-on-anti-body-mediated-re-ocx-20240812monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-successful-graftassure-beta-launch-and-q2-2024-results-ocx-20240808monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-august-investor-conferences-participation-ocx-20240805monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-announce-second-quarter-2024-financial-results-on-august-8-ocx-20240801monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-bolsters-executive-team-with-key-cfo-appointment-prism-marketview-highlights-stra-ocx-20240624monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-appoints-andrea-james-as-chief-financial-officer-ocx-20240617monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-first-quarter-2024-financial-results-ocx-20240515monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-announce-first-quarter-2024-financial-results-ocx-20240513monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-full-year-2023-financial-results-ocx-20240412monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-announces-15-8-million-private-placement-of-securities-priced-at-the--ocx-20240412monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-and-bio-rad-partner-on-global-launch-of-transplant-assay-ocx-20240411monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-announce-fourth-quarter-and-full-year-2024-financial-results-ocx-20240409monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-present-at-the-sequire-investor-summit-in-puerto-rico-ocx-20240116monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-begins-fda-submissions-process-for-vitagraft-transplant-assays-ocx-20231206monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-third-quarter-2023-financial-results-ocx-20231109monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-announce-third-quarter-2023-financial-results-ocx-20231103monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-1-for-20-reverse-stock-split-ocx-20230724monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-begins-manufacturing-transplant-blood-test-ocx-20230627monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-first-quarter-2023-financial-results-ocx-20230511monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-announce-first-quarter-2023-financial-results-ocx-20230427monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-presents-new-data-at-aacr-ocx-20230418monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-reduction-in-force-ocx-20230412monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-publication-of-determaio-results-from-atezotribe-study-in-metastatic-co-ocx-20230407monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-pricing-of-13-86-million-public-offering-of-common-stock-ocx-20230403monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-preliminary-fourth-quarter-and-full-year-2022-financial-results-and-plans-ocx-20230331monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-date-change-for-fourth-quarter-and-full-year-2022-earnings-call-ocx-20230329monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-announce-fourth-quarter-and-full-year-2022-financial-results-ocx-20230315monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-appoints-joshua-riggs-as-president-and-chief-executive-officer-ocx-20230302monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-completes-razor-genomics-transaction-ocx-20230222monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-initiatives-to-focus-corporate-strategy-ocx-20221216monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-the-appointment-of-louis-e-silverman-as-a-member-of-its-board-of-direct-ocx-20221130monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-executive-leadership-changes-ocx-20221130monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-third-quarter-2022-financial-results-ocx-20221110monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-announce-third-quarter-2022-financial-results-ocx-20221027monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-unanimous-recommendation-from-the-advisory-panel-for-clinical-diagnosti-ocx-20220907monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-participate-at-the-lake-street-6th-annual-best-ideas-growth-conference-ocx-20220831monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-five-year-va-contract-for-determarx-ocx-20220830monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-publication-of-the-validation-of-determaio-in-predicting-immune-therapy-ocx-20220824monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-second-quarter-2022-financial-results-ocx-20220810monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-participate-at-upcoming-investor-conferences-ocx-20220803monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-the-appointment-of-john-peter-gutfreund-as-independent-member-of-its-bo-ocx-20220801monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-announce-second-quarter-2022-financial-results-ocx-20220727monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-market-entry-and-early-adopter-program-for-transplant-rejection-monitor-ocx-20220713monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-presents-determaio-data-in-podium-presentation-at-esmo-world-congress-on-gastroin-ocx-20220706monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-hosting-key-opinion-webinar-on-the-role-of-determaio-and-the-tumor-microenvironme-ocx-20220622monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-presents-determaio-data-at-asco-2022-supporting-the-test-s-potential-to-expand-th-ocx-20220526monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-first-quarter-2022-financial-results-ocx-20220511monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-completes-validation-of-therasure-transplant-monitor-test-ocx-20220505monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-announce-first-quarter-2022-financial-results-ocx-20220428monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-present-new-data-at-asco-2022-underpinning-pan-cancer-clinical-utility-of-dete-ocx-20220427monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-announces-pricing-of-public-offering-of-common-stock-and-warrants-ocx-20220414monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-announces-proposed-public-offering-of-common-stock-and-warrants-ocx-20220413monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-announces-pricing-of-registered-direct-offering-of-11-765-shares-of-s-ocx-20220413monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-presents-confirmatory-data-for-determaio-at-the-american-association-for-cancer-r-ocx-20220411monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-present-new-data-confirming-association-of-io-score-with-response-to-immunothe-ocx-20220328monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-corporat-ocx-20220310monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-fourth-quarter-and-full-year-2021-financial-results-on-thursday-march-1-ocx-20220301monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-present-at-the-btig-medtech-digital-health-life-science-diagnostic-tools-confe-ocx-20220210monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-development-and-co-marketing-agreement-with-thermo-fisher-scientific-to-ocx-20220118monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-peer-reviewed-publication-in-cancers-showing-utility-of-determacni-bloo-ocx-20220104monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-and-burning-rock-complete-technology-transfer-part-two-and-prepare-for-scaled-dis-ocx-20211208monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-hosting-business-update-call-ocx-20211206monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-present-new-data-on-determaio-clinical-test-for-immunotherapy-response-in-trip-ocx-20211202monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-third-quarter-2021-financial-results-and-provides-corporate-update-ocx-20211109monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-the-clinical-launch-of-determaio-immunotherapy-response-prediction-test-ocx-20211104monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-strengthens-transplant-intellectual-property-portfolio-with-us-patent-covering-di-ocx-20211027monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-third-quarter-2021-financial-results-on-tuesday-november-9th-ocx-20211026monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-appoints-gisela-a-paulsen-as-chief-operating-officer-ocx-20211007monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-publishes-study-demonstrating-predictive-potential-for-determaio-test-in-triple-n-ocx-20210930monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-oral-presentation-of-new-data-on-its-determaio-immunotherapy-response-t-ocx-20210920monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-hosting-two-part-key-opinion-leader-event-series-ocx-20210920monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-present-new-data-on-determaio-from-neotripapdl1-trial-in-oral-presentation-fro-ocx-20210913monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-participate-in-the-5th-annual-lake-street-capital-markets-best-ideas-growth-co-ocx-20210907monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-launches-first-real-world-evidence-rwe-registry-to-evaluate-biomarker-impact-on-e-ocx-20210817monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-second-quarter-2021-financial-results-and-provides-corporate-update-ocx-20210810monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-participate-in-upcoming-investor-events-ocx-20210809monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-second-quarter-2021-financial-results-on-tuesday-august-10-ocx-20210727monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-celebrates-women-thoracic-surgeons-in-shesmysurgeon-campaign-ocx-20210622monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-collaboration-with-gruppo-oncologico-del-nord-ovest-to-evaluate-oncocyt-ocx-20210603monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-selected-as-new-day-one-launch-site-for-qiagen-s-companion-diagnostics-test-to-id-ocx-20210601monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-first-quarter-2021-financial-results-and-provides-corporate-update-ocx-20210517monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-first-quarter-2021-financial-results-on-monday-may-17-ocx-20210504monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-present-new-data-on-determaio-test-as-a-predictor-of-immunotherapy-response-in-ocx-20210428monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-enters-the-rapidly-growing-immune-therapy-monitoring-market-with-the-closing-of-t-ocx-20210419monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-hosting-key-opinion-leader-call-on-novel-biomarkers-in-identifying-appropriate-re-ocx-20210414monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-presents-new-data-at-2021-american-association-for-cancer-research-annual-meeting-ocx-20210410monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-participate-in-fireside-chat-at-the-20th-annual-needham-virtual-healthcare-con-ocx-20210406monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-provides-corporate-update-and-reports-fourth-quarter-and-annual-2020-financial-re-ocx-20210316monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-peer-reviewed-publication-of-data-assessing-use-of-determaio-to-identif-ocx-20210316monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-present-new-data-at-2021-american-association-for-cancer-research-aacr-annual--ocx-20210315monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-formation-of-medical-advisory-board-ocx-20210309monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-agreement-with-multiplan-network-expanding-patient-access-to-determarx-ocx-20210304monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-fourth-quarter-and-full-year-2020-financial-results-on-tuesday-march-16-ocx-20210303monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-closes-second-investment-in-razor-genomics-to-complete-acquisition-ocx-20210225monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-begin-trading-on-the-nasdaq-stock-market-on-march-8-2021-ocx-20210223monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-participate-in-fireside-chat-at-the-btig-medtech-digital-health-life-science-d-ocx-20210216monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-closing-of-40-million-public-offering-of-common-stock-ocx-20210209monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-pricing-of-35-million-public-offering-of-common-stock-ocx-20210205monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-proposed-public-offering-of-common-stock-ocx-20210204monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-definitive-agreement-to-acquire-chronix-biomedical-inc-ocx-20210202monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-present-new-data-at-the-iaslc-2020-world-conference-on-lung-cancer-ocx-20210128monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-25-million-registered-offering-ocx-20210120monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-present-at-the-23rd-annual-needham-virtual-growth-conference-ocx-20210112monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-present-at-the-15th-annual-ld-micro-main-event-ocx-20201215monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-and-burning-rock-execute-strategic-agreement-to-distribute-determarx-in-china-ocx-20201215monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-hosting-key-opinion-leader-call-on-proprietary-molecular-tests-for-ca-ocx-20201207monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-participate-at-32nd-annual-piper-sandler-virtual-healthcare-conference-ocx-20201118monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-presents-new-data-on-its-determaio-test-at-association-for-molecular-pathology-am-ocx-20201118monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-third-quarter-2020-financial-results-and-provides-corporate-update-ocx-20201112monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-present-determaio-test-data-at-the-2020-society-for-immunotherapy-of-cancer-si-ocx-20201109monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-third-quarter-2020-financial-results-on-thursday-november-12-ocx-20201102monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-named-one-of-the-2020-best-places-to-work-in-orange-county-in-its-first-year-in-i-ocx-20201028monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-third-quarter-growth-of-determarx-physician-adoption-and-testing-volume-ocx-20201020monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-new-prospective-data-demonstrating-that-treatment-informed-by-determarx-ocx-20201014monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-and-fondazione-michelangelo-a-leading-non-profit-cancer-research-foundation-annou-ocx-20201008monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-agrees-to-enter-licensing-and-collaboration-agreement-with-chronix-biomedical-ocx-20201001monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-participate-at-the-lake-street-capital-markets-4th-annual-best-ideas-growth-co-ocx-20200914monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-receives-final-pricing-decision-for-determarx-molecular-test-for-lung-cancer-from-ocx-20200909monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-and-the-guardian-research-network-announce-strategic-alliance-ocx-20200903monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-addition-of-experienced-healthcare-executive-jennifer-carter-md-mph-mba-ocx-20200827monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-participate-at-needham-virtual-cancer-diagnostics-conference-ocx-20200813monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-hold-kol-webinar-highlighting-clinical-data-on-its-determaio-test-for-immunoth-ocx-20200811monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-provides-corporate-update-and-reports-second-quarter-2020-financial-results-ocx-20200729monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-rapid-adoption-of-determarx-in-community-health-systems-ocx-20200728monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-hold-kol-webinar-showcasing-new-data-and-real-world-usage-of-determarx-ocx-20200723monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-second-quarter-2020-financial-results-on-wednesday-july-29-ocx-20200720monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-final-local-coverage-determination-from-noridian-healthcare-solutions-f-ocx-20200720monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-distribution-agreement-with-progenetics-ltd-expanding-commercial-availa-ocx-20200716monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-provides-an-update-on-the-rapid-growth-of-determarx-physician-adoption-and-testin-ocx-20200714monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-completion-of-determadx-clinical-validation-study-ocx-20200629monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-transitions-to-revenue-generation-as-multiple-payers-begin-determarx-reimbursemen-ocx-20200615monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-new-data-to-be-presented-at-the-2020-american-society-of-clinical-oncol-ocx-20200513monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-provides-corporate-update-and-reports-first-quarter-2020-financial-results-ocx-20200512monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-peer-reviewed-publication-of-data-demonstrating-the-potential-of-its-tn-ocx-20200505monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-first-quarter-2020-financial-results-on-tuesday-may-12-ocx-20200505monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-the-publication-of-new-long-term-patient-follow-up-data-for-determarx-a-ocx-20200501monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-final-medicare-lcd-from-palmetto-for-determarx-ocx-20200430monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-10-7-million-registered-offering-ocx-20200424monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-distribution-agreement-with-core-diagnostics-expanding-commercial-avail-ocx-20200423monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-participate-at-19th-annual-needham-virtual-healthcare-conference-ocx-20200407monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2019-financial-ocx-20200325monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-the-launch-of-clia-validated-determaio-a-novel-gene-expression-based-im-ocx-20200319monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-fourth-quarter-and-fiscal-2019-financial-results-on-wednesday-march-25-ocx-20200318monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-closes-merger-agreement-to-acquire-insight-genetics-ocx-20200205monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-relocation-of-its-headquarters-to-orange-county-california-ocx-20200130monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-the-commercial-availability-of-determarx-the-first-test-for-chemotherap-ocx-20200113monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-definitive-agreement-to-acquire-insight-genetics-ocx-20200110monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-successful-completion-of-clia-validation-study-of-determadx-ocx-20200107monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-7-6-million-registered-offering-ocx-20200103monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-participate-at-two-upcoming-investor-conferences-in-new-york-ocx-20191127monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-provides-corporate-update-and-reports-third-quarter-2019-financial-results-ocx-20191114monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-third-quarter-2019-financial-results-on-thursday-november-14-2019-ocx-20191111monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-strategic-support-of-go2-foundation-for-lung-cancer-ocx-20191108monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-present-data-on-physician-decision-making-around-lung-nodule-management-for-th-ocx-20191031monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-present-data-from-a-study-examining-its-liquid-biopsy-test-during-the-chest-an-ocx-20191015monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-closes-initial-investment-in-razor-genomics-and-acquires-rights-to-commercialize--ocx-20191001monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-definitive-agreement-to-acquire-razor-genomics-ocx-20190905monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-provides-corporate-update-and-reports-second-quarter-2019-financial-results-ocx-20190814monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-second-quarter-2019-financial-results-on-wednesday-august-14-2019-ocx-20190731monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-strengthens-board-of-directors-with-addition-of-industry-veteran-melinda-griffith-ocx-20190724monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-provides-mid-year-update-ocx-20190626monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-be-added-to-the-russell-2000-3000-and-microcap-indexes-ocx-20190611monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-chief-executive-officer-transition-ocx-20190606monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-participation-at-the-2019-bio-international-convention-ocx-20190529monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-strengthens-senior-management-team-with-two-new-hires-ocx-20190529monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-presents-positive-results-from-r-d-validation-study-of-determavu-at-the-american--ocx-20190521monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-provides-corporate-update-and-reports-first-quarter-2019-financial-results-ocx-20190514monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-first-quarter-2019-financial-results-on-tuesday-may-14-ocx-20190508monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-successful-completion-of-analytical-validation-study-and-commencement-o-ocx-20190425monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2018-financial-ocx-20190401monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-present-late-breaking-abstract-at-the-american-thoracic-society-2019-internati-ocx-20190401monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-fourth-quarter-and-full-year-2018-financial-results-on-monday-april-1-2-ocx-20190325monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-to-present-at-cowen-and-company-39th-annual-health-care-conference-in-ocx-20190306monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-initiation-of-analytical-validation-study-ocx-20190304monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-closing-of-public-offering-of-common-stock-ocx-20190212monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-pricing-of-public-offering-of-common-stock-ocx-20190208monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-proposed-public-offering-of-common-stock-ocx-20190207monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-successful-results-of-determavu-r-d-validation-study-ocx-20190129monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-schedules-announcement-and-conference-call-to-discuss-results-from-key-r-d-valida-ocx-20190128monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-transition-to-ion-torrent-next-generation-sequencing-platform-ocx-20190103monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-provides-progress-update-on-ongoing-studies-ocx-20181220monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-to-present-at-the-ld-micro-11th-annual-main-event-investor-conference-ocx-20181130monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-to-present-at-the-piper-jaffray-30th-annual-health-care-conference-ocx-20181119monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-third-quarter-2018-financial-results-and-progress-in-determavu-developmen-ocx-20181113monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-third-quarter-2018-financial-results-on-november-13-2018-ocx-20181106monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-completes-successful-transition-to-new-diagnostic-testing-platform-and-initiates--ocx-20181029monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-to-present-at-the-bio-ceo-investor-forum-ocx-20181017monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-second-quarter-2018-financial-results-and-positive-corporate-developments-ocx-20180814monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-second-quarter-2018-financial-results-on-august-14-2018-ocx-20180730monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-at-market-3-59-million-offering-of-common-stock-and-warrants-ocx-20180727monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-encouraging-new-study-results-for-lung-cancer-blood-test-ocx-20180709monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-first-quarter-2018-financial-results-ocx-20180515monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-first-quarter-2018-financial-results-on-may-15-2018-ocx-20180508monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-fourth-quarter-and-full-year-2017-financial-results-ocx-20180402monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-files-patents-for-190-newly-identified-novel-lung-cancer-biomarkers-ocx-20180402monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-names-cavan-redmond-chairman-of-the-board-of-directors-ocx-20180402monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-fourth-quarter-and-full-year-2017-financial-results-on-april-2-2018-ocx-20180329monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-the-closing-of-a-10-million-private-placement-of-common-stock-ocx-20180329monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-initial-results-of-determavu-feasibility-on-new-platforms-enhancements--ocx-20180308monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-presents-positive-data-from-its-liquid-biopsy-breast-cancer-diagnostic-test-at-th-ocx-20171207monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-present-data-from-its-liquid-biopsy-breast-cancer-diagnostic-test-at-the-san-a-ocx-20171201monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-initiates-search-for-new-independent-director-ocx-20171129monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-to-participate-in-the-benchmark-company-llc-micro-cap-discovery-one-o-ocx-20171127monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-third-quarter-2017-financial-results-ocx-20171114monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-third-quarter-2017-financial-results-on-november-14-2017-ocx-20171106monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-successful-completion-of-clia-lab-validation-study-of-its-determavu-lun-ocx-20170927monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-positive-analytical-validation-study-results-of-determavu-lung-cancer-dia-ocx-20170918monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-present-data-from-its-liquid-biopsy-breast-cancer-diagnostic-test-at-the-san-a-ocx-20170911monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-receives-clia-certification-for-its-cancer-diagnostics-laboratory-ocx-20170907monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-confirms-launch-plans-for-lung-cancer-diagnostic-test-reports-progress-toward-cli-ocx-20170814monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-latest-lung-cancer-diagnostic-test-data-accepted-for-slide-presentation-at-chest--ocx-20170807monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-second-quarter-financial-results-on-august-14-2017-ocx-20170726monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-receives-5-74-million-in-proceeds-from-exercise-of-warrants-ocx-20170725monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-analytical-validation-study-of-its-lung-cancer-diagnostic-test-confirms-previousl-ocx-20170724monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-added-to-russell-3000-index-and-russell-2000-index-ocx-20170626monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-successful-completion-of-follow-on-breast-cancer-diagnostic-study-ocx-20170615monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-set-to-join-russell-3000-index-ocx-20170612monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-presents-positive-lung-cancer-blood-test-data-at-american-thoracic-society-ocx-20170522monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-executive-to-address-next-generation-dx-summit-on-successful-reimbursement-strate-ocx-20170509monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-establishes-medical-advisory-committee-to-enhance-development-strategy-for-lung-c-ocx-20170504monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-continues-to-make-progress-towards-commercialization-reports-first-quarter-2017-r-ocx-20170428monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-submits-application-for-clia-certification-of-its-laboratory-ocx-20170321monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-successful-results-of-lung-cancer-diagnostic-test-study-targets-2017-prod-ocx-20170306monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-to-present-at-cowen-and-company-37th-annual-health-care-conference-ocx-20170301monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-reports-fourth-quarter-and-full-year-2016-financial-results-ocx-20170227monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-receives-2-million-in-proceeds-from-early-exercise-of-warrants-ocx-20170221monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-to-present-at-the-19th-annual-bio-ceo-investor-conference-and-the-201-ocx-20170213monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-wins-buzz-of-bio-for-the-2017-bio-ceo-investor-conference-ocx-20170127monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-present-interim-data-from-its-lung-cancer-diagnostic-test-study-at-the-america-ocx-20170124monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-provides-updated-timelines-on-diagnostic-test-development-and-commercialization-p-ocx-20170104monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-publication-of-breast-cancer-diagnostic-test-abstract-poster-to-be-pres-ocx-20161114monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-third-quarter-2016-financial-results-ocx-20161110monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-promotes-lyndal-hesterberg-to-senior-vice-president-research-and-development-ocx-20161108monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-third-quarter-financial-results-on-november-10-2016-ocx-20161102monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-sponsored-symposium-at-the-2016-american-college-of-chest-physician-s-c-ocx-20161024monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-and-the-wistar-institute-present-lung-cancer-diagnostic-data-at-the-chest-2016-an-ocx-20161017monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-to-present-at-the-bio-investor-forum-ocx-20161014monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-to-present-at-the-2016-aegis-growth-conference-ocx-20160920monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-present-initial-data-on-its-breast-cancer-diagnostic-test-at-the-prestigious-s-ocx-20160908monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-to-present-at-the-annual-gateway-conference-ocx-20160907monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-announces-the-closing-of-two-private-placement-transactions-generatin-ocx-20160829monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-second-quarter-2016-financial-results-ocx-20160811monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-commences-analytical-verification-study-for-lung-cancer-diagnostic-test-ocx-20160810monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-and-the-wistar-institute-announce-presentation-of-lung-data-at-chest-2016-annual--ocx-20160727monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-second-quarter-financial-results-on-august-11-2016-ocx-20160721monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-presents-positive-bladder-cancer-diagnostic-data-at-the-2016-american-society-of--ocx-20160606monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-release-bladder-cancer-data-at-the-2016-american-society-of-clinical-oncology--ocx-20160519monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-first-quarter-2016-financial-results-ocx-20160518monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-report-first-quarter-financial-results-on-may-18-2016-ocx-20160512monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-s-bladder-cancer-abstract-to-be-featured-in-a-poster-discussion-session-at-the-20-ocx-20160421monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-and-the-wistar-institute-announce-positive-results-in-the-development-of-a-blood--ocx-20160404monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-reports-full-year-2015-financial-results-ocx-20160330monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-to-present-at-the-2016-bio-ceo-investor-conference-ocx-20160202monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-and-the-wistar-institute-enter-into-global-licensing-agreement-ocx-20160127monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-corporation-initiates-trading-on-the-nyse-mkt-ocx-20160104monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-highlights-key-g4x-launch-milestones-and-showcases-groundbreaking-3d-spatial-mult-omic-20250224monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-enters-into-agreement-to-be-acquired-by-deerfield-for-20-00-in-cash-per--omic-20241223monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-reports-recent-updates-and-third-quarter-2024-financial-results-omic-20241112monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-receives-non-binding-acquisition-proposal-from-concentra-biosciences-and-omic-20240919monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-receives-non-binding-acquisition-proposal-from-deerfield-omic-20240912monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-reports-recent-highlights-and-second-quarter-2024-financial-results-omic-20240813monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-to-report-second-quarter-2024-financial-results-on-august-13-2024-omic-20240730monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-omic-20240715monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-announces-1-for-30-reverse-stock-split-omic-20240621monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-to-present-at-the-goldman-sachs-global-healthcare-conference-omic-20240529monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-reports-recent-highlights-and-first-quarter-2024-financial-results-omic-20240514monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-to-report-first-quarter-2024-financial-results-on-may-14-2024-omic-20240501monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-reports-recent-highlights-and-fourth-quarter-and-full-year-2023-financia-omic-20240318monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-to-report-fourth-quarter-and-full-year-2023-financial-results-on-march-1-omic-20240304monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-showcases-new-g4x-spatial-sequencer-at-agbt-and-announces-significant-ad-omic-20240205monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-unveils-g4x-spatial-sequencer-transforming-the-landscape-of-in-situ-mult-omic-20240205monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-reports-instrument-shipments-and-preliminary-unaudited-fourth-quarter-20-omic-20240107monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-reports-recent-highlights-and-third-quarter-2023-financial-results-omic-20231114monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-to-report-third-quarter-2023-financial-results-on-november-14-2023-omic-20231024monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-to-present-at-the-gilmartin-group-emerging-growth-company-showcase-omic-20230908monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-reports-recent-highlights-and-second-quarter-2023-financial-results-omic-20230809monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-appoints-genomics-veteran-marcia-eisenberg-ph-d-to-board-of-directors-omic-20230808monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-announces-participation-in-the-ubs-medtech-tools-and-genomics-summit-omic-20230802monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-to-report-second-quarter-2023-financial-results-on-august-9-2023-omic-20230726monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-to-present-at-the-goldman-sachs-global-healthcare-conference-omic-20230601monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-reports-recent-highlights-and-first-quarter-2023-financial-results-omic-20230509monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-to-report-first-quarter-2023-financial-results-on-may-9-2023-omic-20230425monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-reports-recent-highlights-and-fourth-quarter-and-full-year-2022-financia-omic-20230302monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-to-present-at-cowen-s-43rd-annual-health-care-conference-omic-20230223monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-to-report-fourth-quarter-2022-financial-results-on-march-2-2023-omic-20230216monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-launches-max-read-kits-for-single-cell-sequencing-on-the-g4-at-agbt-omic-20230206monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-showcases-new-g4-sequencing-platform-data-with-11-industry-leading-genom-omic-20230206monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-joins-the-10x-genomics-compatible-partner-program-omic-20230202monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-reports-instrument-shipments-and-preliminary-unaudited-fourth-quarter-20-omic-20230109monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-omic-20221221monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-reports-recent-highlights-and-third-quarter-2022-financial-results-omic-20221107monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-to-report-third-quarter-2022-financial-results-on-november-7-2022-omic-20221024monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-announces-updated-presentation-time-at-the-inaugural-gilmartin-group-eme-omic-20220825monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-to-present-at-the-inaugural-gilmartin-group-emerging-growth-company-show-omic-20220818monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-reports-recent-highlights-and-second-quarter-2022-financial-results-omic-20220809monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-announces-rescheduled-presentation-time-at-the-ubs-genomics-2-0-and-medt-omic-20220808monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-appoints-sam-ropp-ph-d-as-chief-commercial-officer-omic-20220802monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-to-present-at-the-ubs-genomics-2-0-and-medtech-innovations-summit-omic-20220728monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-systems-inc-to-report-second-quarter-2022-financial-results-on-august-9--omic-20220728monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-and-olink-collaborate-to-enable-olink-explore-on-the-g4-max-read-sequenc-omic-20220607monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-and-twinstrand-biosciences-collaborate-to-develop-ultra-high-accuracy-ng-omic-20220606monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-to-present-at-the-goldman-sachs-43rd-annual-global-healthcare-conference-omic-20220603monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-systems-inc-reports-recent-highlights-and-first-quarter-2022-financial-r-omic-20220510monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-collaborates-with-nvidia-to-deliver-market-leading-next-generation-seque-omic-20220510monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-announces-formation-of-scientific-advisory-board-omic-20220510monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-systems-inc-to-report-first-quarter-2022-financial-results-on-may-10-202-omic-20220426monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-systems-inc-reports-recent-highlights-fourth-quarter-and-full-year-2021--omic-20220302monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-systems-inc-to-present-at-the-42nd-annual-cowen-health-care-conference-omic-20220301monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-partners-with-agilent-to-enable-the-sureselect-target-enrichment-reagent-omic-20220228monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-partners-with-qiagen-to-enable-qiaseq-kits-for-the-g4-sequencing-platfor-omic-20220228monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-g4-sequencing-platform-shows-high-performance-with-kapa-library-preparat-omic-20220228monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-systems-inc-to-report-fourth-quarter-and-full-year-2021-financial-result-omic-20220223monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-partners-with-lexogen-to-enable-rna-library-prep-for-the-g4-sequencing-p-omic-20220110monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-partners-with-watchmaker-genomics-to-enable-the-watchmaker-dna-library-p-omic-20220110monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-partners-with-dovetail-genomics-to-enable-dovetail-kits-for-the-g4-seque-omic-20220110monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-partners-with-twist-bioscience-to-enable-the-twist-ngs-target-enrichment-omic-20220110monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-partners-with-new-england-biolabs-to-enable-nebnext-kits-for-the-g4-sequ-omic-20220110monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-systems-inc-to-present-at-the-40th-annual-j-p-morgan-healthcare-conferen-omic-20220107monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-appoints-genomics-research-pioneer-elaine-r-mardis-ph-d-to-board-of-dire-omic-20220106monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-and-broad-institute-partner-to-integrate-advanced-sequencing-technology--omic-20220106monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-launches-the-g4-sequencing-platform-omic-20211216monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-systems-inc-reports-recent-highlights-and-third-quarter-financial-result-omic-20211109monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-systems-inc-to-report-third-quarter-2021-financial-results-on-november-9-omic-20211028monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-systems-inc-to-present-at-the-ubs-genomics-2-0-and-medtech-innovations-s-omic-20210805monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-systems-inc-announces-second-quarter-financial-results-and-operations-up-omic-20210803monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-systems-inc-announces-closing-of-initial-public-offering-and-full-exerci-omic-20210601monthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-systems-inc-announces-pricing-of-upsized-initial-public-offering-of-comm-omic-20210527monthly0.5https://www.biopharmawatch.com/news/OMIC/singularity-university-announces-inaugural-synthetic-biology-accelerator-program-omic-20120517monthly0.5https://www.biopharmawatch.com/news/OMIC/singularity-university-announces-new-corporate-partnership-with-genentech-to-explore-the-f-omic-20120206monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-advm-20250605monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-first-quarter-2025-financial-results-and-provides-pipeline-advm-20250514monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-advm-20250502monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-fourth-quarter-and-full-year-2024-financial-results-and-pr-advm-20250415monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-advm-20250404monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-initiates-artemis-phase-3-study-evaluating-ixo-vec-for-wet-amd-advm-20250303monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-advm-20250228monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-the-cowen-45th-annual-health-care-conference-advm-20250225monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-scie-advm-20250205monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-advm-20241206monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-advm-20241120monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-positive-52-week-luna-and-4-year-optic-results-and-provi-advm-20241118monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-webcast-to-report-52-week-luna-phase-2-clinical-data-and-advm-20241115monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-third-quarter-2024-financial-results-provides-corporate-hi-advm-20241104monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-appoints-jason-l-mitchell-as-chief-commercial-officer-as-it-prepar-advm-20241016monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-advm-20240905monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-upcoming-fall-investor-conferences-advm-20240904monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-second-quarter-2024-financial-results-and-provides-program-advm-20240812monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-the-h-c-wainwright-4th-annual-ophthalmology-virt-advm-20240802monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-fda-regenerative-medicine-advanced-therapy-rmat-designat-advm-20240801monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-presents-positive-ixo-vec-clinical-data-from-the-26-week-interim-a-advm-20240717monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-host-webcast-to-review-clinical-data-from-the-26-week-interim-a-advm-20240710monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-td-cowen-s-genetic-medicines-rna-summit-advm-20240618monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-first-quarter-2024-financial-results-and-provides-pipeline-advm-20240509monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-upcoming-may-investor-conferences-advm-20240503monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-luna-26-week-phase-2-interim-analysis-at-the-asrs-annua-advm-20240425monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-fourth-quarter-and-full-year-2023-financial-results-and-pr-advm-20240318monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-the-td-cowen-44th-annual-health-care-conference-advm-20240228monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-the-oppenheimer-34th-annual-healthcare-life-scie-advm-20240212monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-positive-preliminary-efficacy-and-safety-data-from-luna--advm-20240208monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-127-5-million-private-placement-financing-advm-20240205monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-will-host-webcast-to-review-luna-phase-2-preliminary-efficacy-and--advm-20240201monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-appoints-romuald-corbau-ph-d-as-chief-scientific-officer-advm-20240129monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-luna-preliminary-efficacy-and-safety-data-at-the-47th-a-advm-20231207monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-the-evercore-isi-6th-annual-healthconx-conferenc-advm-20231128monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-third-quarter-2023-financial-results-and-pipeline-highligh-advm-20231109monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-appoints-c-david-nicholson-ph-d-to-its-board-of-directors-advm-20231106monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-3-year-efficacy-and-safety-results-from-the-optic-extens-advm-20231104monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-positive-aflibercept-protein-level-data-from-the-luna-ph-advm-20230926monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-upcoming-investor-conferences-advm-20230921monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-advm-20230905monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-appoints-andrew-ramelmeier-ph-d-as-chief-technology-officer-advm-20230821monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-the-h-c-wainwright-3rd-annual-ophthalmology-virt-advm-20230814monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-completes-enrollment-of-phase-2-luna-trial-in-wet-amd-and-reports--advm-20230810monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-grants-license-to-ray-therapeutics-inc-for-the-aav-7m8-intravitrea-advm-20230612monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-the-jefferies-healthcare-conference-advm-20230602monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-new-executive-leadership-roles-advm-20230525monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-presents-nonclinical-data-in-support-of-ixo-vec-s-phase-2-clinical-advm-20230518monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-introduces-an-intravitreal-gene-therapy-program-for-geographic-atr-advm-20230518monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-first-quarter-2023-financial-results-advm-20230511monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-rbc-capital-markets-global-healthcare-conference-advm-20230510monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-upcoming-data-presentations-at-asgct-2023-including-data-advm-20230502monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-presents-nonclinical-data-at-the-2023-arvo-annual-meeting-supporti-advm-20230423monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-granted-innovative-licensing-and-access-pathway-designation-in-the-advm-20230418monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-upcoming-nonclinical-data-presentation-supporting-stagge-advm-20230417monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-fourth-quarter-and-full-year-2022-financial-results-and-pr-advm-20230330monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-at-upcoming-investor-conferences-advm-20230227monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-advm-20230118monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-advm-20221206monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-third-quarter-2022-financial-results-advm-20221110monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-presents-positive-end-of-study-results-from-the-optic-trial-in-wet-advm-20221104monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-upcoming-data-presentation-at-the-retina-society-annual--advm-20221027monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-presents-anatomical-improvements-in-intraretinal-and-subretinal-fl-advm-20220930monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-the-chardan-6th-annual-genetic-medicines-confere-advm-20220927monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit-advm-20220923monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-upcoming-data-presentation-at-aao-2022-advm-20220923monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-first-subject-dosed-with-ixo-vec-in-the-phase-2-luna-tri-advm-20220914monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-advm-20220908monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-to-present-at-the-inaugural-gilmartin-group-emerging-growth-company-showcase-advm-20220826monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-second-quarter-2022-financial-results-advm-20220811monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-the-2nd-annual-h-c-wainwright-ophthalmology-virt-advm-20220810monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-advm-20220801monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-presents-best-corrected-visual-acuity-and-central-subfield-thickne-advm-20220715monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-upcoming-data-presentation-at-asrs-2022-advm-20220708monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-completes-ind-amendment-and-prepares-to-initiate-the-phase-2-luna--advm-20220706monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-granted-priority-medicines-prime-designation-by-european-medicines-advm-20220624monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-presents-three-year-aflibercept-protein-expression-and-improvement-advm-20220609monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-new-data-at-the-macula-society-s-2022-annual-meeting-advm-20220602monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-presents-research-pipeline-data-supporting-utility-of-its-propriet-advm-20220519monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-presents-data-at-asgct-further-supporting-phase-2-development-plans-for-advm-022-advm-20220517monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-first-quarter-2022-financial-results-advm-20220512monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-advm-20220509monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-upcoming-data-presentations-at-asgct-2022-advm-20220502monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-presents-additional-efficacy-and-safety-data-from-the-optic-trial--advm-20220501monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-upcoming-data-presentations-at-arvo-2022-advm-20220419monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-proceeds-with-ind-amendment-for-advm-022-phase-2-trial-in-wet-amd--advm-20220406monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-fourth-quarter-and-full-year-2021-financial-results-advm-20220329monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-appoints-rabia-gurses-ozden-m-d-and-soo-j-hong-m-b-a-to-board-of-directors-advm-20220317monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-the-42nd-annual-cowen-healthcare-conference-advm-20220228monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-appoints-richard-beckman-m-d-as-chief-medical-officer-advm-20220207monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-appoints-star-seyedkazemi-pharm-d-as-chief-development-officer-advm-20220106monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-granted-orphan-drug-designation-by-fda-for-gene-therapy-candidate--advm-20220104monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-provides-advm-022-development-update-and-anticipated-corporate-mil-advm-20211221monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-appoints-rupert-d-souza-ph-d-m-b-a-as-chief-financial-officer-advm-20211206monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-reports-third-quarter-2021-results-advm-20211104monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-presents-clinical-data-on-advm-022-at-the-american-society-of-retina-specialists-3-advm-20211009monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-presents-2-year-optic-data-demonstrating-sustained-durability-and-promising-safety-advm-20211001monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-to-present-data-from-advm-022-clinical-trials-at-upcoming-medical-conferences-advm-20210927monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-appoints-global-regulatory-leader-jim-wang-ph-d-as-senior-vice-president-head-of-r-advm-20210823monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-reports-second-quarter-2021-results-advm-20210805monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-provides-update-on-advm-022-and-the-infinity-trial-in-patients-with-diabetic-macul-advm-20210722monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-announces-appointment-of-jon-williams-ph-d-as-vice-president-clinical-affairs-advm-20210701monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-announces-changes-to-management-team-advm-20210624monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-appoints-cmo-and-cso-advm-20210601monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-stockholders-re-elect-all-adverum-director-nominees-at-2021-annual-meeting-advm-20210512monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-issues-statement-regarding-upcoming-annual-meeting-of-stockholders-advm-20210510monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-reports-first-quarter-2021-results-advm-20210506monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-presents-long-term-data-through-march-10-2021-from-the-optic-trial-advm-20210501monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patie-advm-20210428monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-files-investor-presentation-highlighting-significant-strategic-progress-and-purpos-advm-20210422monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-mails-letter-to-stockholders-highlighting-world-class-board-of-directors-overseein-advm-20210421monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-new-data-from-the-optic-trial-of-advm-022-intravitreal--advm-20210416monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-files-definitive-proxy-materials-and-mails-letter-to-stockholders-detailing-streng-advm-20210415monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-announces-senior-appointments-for-patient-access-and-clinical-operations-as-advm-0-advm-20210330monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-advm-20210318monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-announces-board-slate-for-2021-annual-meeting-and-reiterates-commitment-to-stockho-advm-20210317monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-announces-shortened-timelines-and-clear-development-path-for-advm-022-intravitreal-advm-20210301monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-to-host-conference-call-and-webcast-to-highlight-updated-advm-022-development-plan-advm-20210222monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-appoints-esteemed-healthcare-executive-reed-v-tuckson-m-d-to-board-of-directors-advm-20210222monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-appoints-christopher-j-derespino-as-chief-business-officer-advm-20210218monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-to-present-data-from-the-optic-phase-1-trial-with-advm-022-intravitreal-gene-thera-advm-20210210monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-publication-of-preclinical-long-term-safety-data-on-advm-advm-20210202monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-completes-patient-enrollment-for-infinity-phase-2-trial-of-advm-02-advm-20210111monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-new-gmp-gene-therapy-manufacturing-facility-advm-20210107monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-at-39th-annual-j-p-morgan-healthcare-conference-advm-20210105monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-appoints-pharmaceutical-industry-veteran-dawn-svoronos-to-board-of-advm-20201214monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-presents-at-the-piper-sandler-annual-virtual-healthcare-conference-advm-20201123monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-positive-interim-data-from-cohorts-1-4-from-optic-phase--advm-20201114monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-recent-business-progress-and-third-quarter-2020-financial--advm-20201105monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-new-data-from-the-optic-phase-1-trial-of-advm-022-intra-advm-20201020monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-appointment-of-christopher-j-morrison-ph-d-as-vice-presi-advm-20200915monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-the-cantor-virtual-global-healthcare-conference-advm-20200910monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-closing-of-217-million-public-offering-of-common-stock-advm-20200818monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-pricing-of-public-offering-of-common-stock-advm-20200813monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-200-million-public-offering-of-common-stock-advm-20200811monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-positive-interim-data-from-cohorts-1-4-from-optic-phase--advm-20200810monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-host-a-conference-call-and-webcast-to-report-second-quarter-202-advm-20200729monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-appointment-of-thomas-kochy-as-vice-president-commercial-advm-20200721monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-first-patient-randomized-in-phase-2-infinity-trial-of-ad-advm-20200713monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-completion-of-patient-dosing-in-cohort-4-of-the-optic-ph-advm-20200706monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-leadership-transition-advm-20200615monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-goldman-sachs-41st-annual-global-healthcare-conf-advm-20200604monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-new-infinity-phase-2-trial-for-advm-022-in-diabetic-macu-advm-20200528monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-host-a-conference-call-and-webcast-to-report-first-quarter-2020-advm-20200521monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-positive-interim-data-from-cohorts-1-3-of-optic-phase-1-tr-advm-20200504monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-virtual-presentations-of-data-through-asgct-and-arvo-advm-20200430monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-host-a-conference-call-and-webcast-to-present-new-data-from-the-advm-20200427monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-doses-first-patient-in-cohort-4-of-optic-phase-1-clinical-trial-of-advm-20200427monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-appoints-ophthalmology-industry-veteran-scott-whitcup-m-d-to-board-advm-20200420monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-recent-business-progress-and-fourth-quarter-2019-financial-advm-20200312monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-data-presentations-at-arvo-2020-advm-20200311monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-host-a-conference-call-and-webcast-to-report-fourth-quarter-201-advm-20200305monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-appoints-angela-thedinga-as-chief-technology-officer-advm-20200225monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-at-upcoming-investor-conferences-advm-20200219monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-closing-of-150-million-public-offering-of-common-stock-advm-20200214monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-pricing-of-public-offering-of-common-stock-advm-20200212monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-100-million-public-offering-of-common-stock-advm-20200210monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-new-interim-data-from-cohorts-1-and-2-of-optic-phase-1-tri-advm-20200208monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-additional-data-from-the-optic-phase-1-trial-with-advm--advm-20200128monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-moves-to-new-headquarters-and-expands-laboratory-space-in-redwood--advm-20200127monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-continued-momentum-with-optic-trial-for-advm-022-intravitr-advm-20200112monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-additional-clinical-data-from-first-cohort-of-optic-phase--advm-20200111monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-at-upcoming-conferences-advm-20191218monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-piper-jaffray-s-31st-annual-healthcare-conferenc-advm-20191120monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-shareholder-alert-kehoe-law-firm-p-c-investigating-potential-secur-advm-20191111monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-recent-business-progress-and-third-quarter-2019-financial--advm-20191107monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-host-a-conference-call-and-webcast-to-report-third-quarter-2019-advm-20191031monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-expands-leadership-team-with-the-appointment-of-peter-soparkar-as--advm-20191030monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-doses-first-patient-in-third-cohort-of-optic-phase-1-clinical-tria-advm-20191024monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-data-presentations-at-the-european-society-of-gene-and-c-advm-20191023monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-additional-clinical-data-from-first-cohort-of-optic-phase--advm-20191011monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-additional-clinical-data-from-first-cohort-of-optic-pha-advm-20190926monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-positive-24-week-data-from-first-cohort-of-optic-phase-1-t-advm-20190912monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-host-a-conference-call-and-webcast-to-present-24-week-data-from-advm-20190904monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-24-week-data-from-first-cohort-of-optic-trial-of-advm-0-advm-20190828monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-second-quarter-2019-financial-results-and-provides-corpora-advm-20190808monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-board-and-senior-management-changes-advm-20190801monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-host-a-conference-call-and-webcast-to-report-second-quarter-201-advm-20190725monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-appoints-senior-leaders-advm-20190715monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-data-at-upcoming-conferences-advm-20190708monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-doses-first-patient-in-second-cohort-of-optic-phase-1-clinical-tri-advm-20190610monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-provides-update-on-optic-phase-1-trial-for-advm-022-in-wet-amd-advm-20190516monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-first-quarter-2019-financial-results-and-provides-corporat-advm-20190508monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-board-changes-advm-20190502monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-30-month-preclinical-safety-and-expression-data-for-adv-advm-20190502monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-presents-first-preclinical-data-on-dosing-contralateral-eye-with-a-advm-20190430monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-appoints-thomas-leung-as-chief-financial-officer-advm-20190424monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-new-preclinical-data-on-advm-022-gene-therapy-for-wet-a-advm-20190416monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-provides-clinical-program-update-on-advm-022-gene-therapy-for-wet--advm-20190415monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-appoints-ophthalmology-industry-veteran-aaron-osborne-mbbs-mrcopht-advm-20190401monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-participate-in-upcoming-conferences-advm-20190318monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-fourth-quarter-2018-financial-results-and-provides-corpora-advm-20190306monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-to-present-at-the-cowen-39th-annual-health-care-conference-advm-20190228monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-to-present-at-the-8th-annual-svb-leerink-global-healthcare-conference-advm-20190213monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-presentation-of-preclinical-long-term-safety-data-of-adv-advm-20190211monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-provides-2019-outlook-advm-20190107monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-advm-20181220monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-appoints-mike-fitzgerald-as-vice-president-human-resources-advm-20181203monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-publication-of-preclinical-long-term-expression-and-effi-advm-20181203monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-announces-first-patient-dosed-in-optic-phase-1-trial-of-advm-022-gene-therapy-in-w-advm-20181119monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-to-present-at-30th-annual-piper-jaffray-healthcare-conference-advm-20181113monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-third-quarter-2018-financial-results-and-provides-corporat-advm-20181108monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-provides-program-updates-advm-20181101monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-appointment-of-leone-patterson-as-ceo-and-member-of-the--advm-20181017monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-data-presented-at-the-european-society-of-gene-and-cell--advm-20181017monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-receives-fast-track-designation-for-advm-022-gene-therapy-for-the--advm-20180919monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-to-present-at-cantor-global-healthcare-conference-advm-20180918monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-ind-active-for-advm-022-a-novel-gene-therapy-to-treat-we-advm-20180829monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-receives-orphan-drug-designation-for-advm-053-a-novel-gene-therapy-advm-20180824monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-second-quarter-2018-financial-results-and-provides-corpora-advm-20180808monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-clinical-progress-across-gene-therapy-pipeline-advm-20180801monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-appoints-katherine-bock-as-vice-president-investor-relations-corpo-advm-20180724monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-at-the-2018-jefferies-global-healthcare-conference-advm-20180604monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-presents-additional-long-term-preclinical-data-on-advm-022-in-wet--advm-20180518monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-first-quarter-2018-financial-results-and-provides-corporat-advm-20180509monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-leadership-changes-advm-20180503monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-long-term-preclinical-efficacy-data-on-advm-022-gene-the-advm-20180501monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-fourth-quarter-2017-financial-results-and-provides-corpora-advm-20180306monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-at-upcoming-investor-conferences-advm-20180226monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-completion-of-dosing-of-first-cohort-of-patients-in-the--advm-20180226monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-closing-of-69-million-public-offering-advm-20180212monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-pricing-of-60-million-public-offering-of-common-stock-advm-20180208monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-proposed-public-offering-of-common-stock-advm-20180207monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-and-editas-medicine-extend-research-collaboration-advm-20180125monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-provides-2018-outlook-advm-20180104monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-doses-first-patient-in-the-advance-phase-1-2-clinical-trial-of-adv-advm-20171228monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-begins-patient-enrollment-in-the-advance-phase-1-2-clinical-trial--advm-20171205monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-at-upcoming-conferences-advm-20171115monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-third-quarter-2017-financial-results-and-provides-corporat-advm-20171108monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-appoints-linda-neuman-m-d-as-vice-president-clinical-development-advm-20171002monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-at-upcoming-conferences-advm-20170928monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-presents-updated-preclinical-data-on-advm-022-in-wet-amd-at-the-20-advm-20170927monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-appoints-eric-g-carter-m-d-ph-d-to-board-of-directors-advm-20170907monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-at-biocentury-s-24th-annual-newsmakers-in-the-biotech-i-advm-20170907monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-second-quarter-2017-financial-results-and-provides-update-advm-20170808monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-inc-announces-appointment-of-athena-countouriotis-m-d-as-svp-and-c-advm-20170620monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-at-the-jefferies-global-healthcare-conference-advm-20170522monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-inc-announces-data-presentations-at-the-arvo-and-asgct-2017-annual-advm-20170510monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-first-quarter-2017-financial-results-and-provides-update-advm-20170509monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-inc-appoints-richard-n-spivey-pharm-d-ph-d-to-board-of-directors-advm-20170420monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-updated-presentation-time-for-arm-5th-annual-cell-gene-t-advm-20170417monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-at-the-arm-5th-annual-cell-gene-therapy-investor-day-advm-20170406monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-inc-appoints-patrick-machado-j-d-to-board-of-directors-advm-20170314monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-fourth-quarter-and-full-year-2016-financial-results-and-pr-advm-20170306monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-at-upcoming-investor-conferences-advm-20170221monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-at-phacilitate-cell-gene-therapy-world-2017-advm-20170118monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-at-upcoming-investor-conferences-advm-20161109monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-inc-reports-third-quarter-2016-financial-results-advm-20161108monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-announces-data-presentations-at-the-european-society-of-gene-and-c-advm-20161020monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-provides-update-on-alpha-1-antitrypsin-deficiency-program-advm-20161014monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-inc-announces-new-executive-chair-and-ceo-advm-20161014monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-to-present-at-the-2016-ophthalmology-innovation-summit-at-the-amer-advm-20161013monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-presents-preclinical-data-on-novel-gene-therapy-candidates-for-the-advm-20160916monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-inc-reports-second-quarter-2016-financial-results-advm-20160809monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-and-editas-medicine-announce-collaboration-to-explore-delivery-of--advm-20160809monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-provides-wet-amd-program-update-advm-20160707monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-announces-effectiveness-of-scheme-of-arrangement-and-completion-of-acquisit-mura-20251205monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-announces-sanction-of-the-scheme-by-the-high-court-mura-20251203monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-announces-that-mural-shareholders-approve-the-proposed-acquisition-by-xra-5-mura-20251024monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-announces-entry-into-agreement-to-be-acquired-by-xra-5-corp-a-wholly-owned--mura-20250820monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-highlights-pipeline-progress-and-anticipated-2025-catalysts-mura-20250109monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mura-20241203monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-announces-publication-highlighting-promising-clinical-antitumor-activity-sh-mura-20241120monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-announces-third-quarter-2024-financial-results-and-provides-update-on-pipel-mura-20241113monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-to-participate-in-two-upcoming-investor-conferences-mura-20241111monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-presents-clinical-and-preclinical-data-across-its-pipeline-at-the-39th-annu-mura-20241107monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mura-20241104monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-to-present-clinical-and-preclinical-data-at-the-39th-annual-meeting-of-the--mura-20241007monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mura-20241002monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-s-first-virtual-investor-day-to-highlight-late-stage-clinical-progress-mura-20240926monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-strengthens-board-of-directors-with-the-appointment-of-sachiyo-minegishi-mura-20240923monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-to-host-first-virtual-investor-day-on-september-26-2024-mura-20240910monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mura-20240904monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-to-present-at-two-upcoming-investor-conferences-mura-20240827monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-announces-second-quarter-2024-financial-results-and-provides-update-on-pipe-mura-20240813monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mura-20240802monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-appoints-veteran-business-development-executive-george-golumbeski-ph-d-to-i-mura-20240731monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mura-20240702monthly0.5https://www.biopharmawatch.com/news/MURA/mural-to-present-and-host-1x1-investor-meetings-at-the-14th-annual-east-coast-ideas-invest-mura-20240605monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mura-20240604monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-presents-clinical-data-from-artistry-3-at-the-american-society-of-clinical--mura-20240523monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-announces-first-quarter-2024-financial-results-and-provides-business-update-mura-20240514monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mura-20240503monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-announces-upcoming-presentation-at-2024-american-society-of-clinical-oncolo-mura-20240424monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-presents-preclinical-data-for-il-18-and-il-12-programs-at-the-2024-american-mura-20240409monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mura-20240404monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-announces-fourth-quarter-and-year-end-2023-financial-results-and-provides-b-mura-20240326monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-announces-upcoming-presentations-at-2024-american-association-for-cancer-re-mura-20240305monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mura-20240304monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-to-present-at-the-td-cowen-44th-annual-health-care-conference-mura-20240227monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mura-20240205monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-announces-enhancements-to-late-stage-clinical-trials-mura-20240108monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-launches-to-advance-pipeline-of-novel-engineered-cytokine-immunotherapies-mura-20231115monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit-fgen-20251202monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-third-quarter-2025-financial-results-fgen-20251103monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-second-quarter-2025-financial-results-and-provides-business-update-fgen-20250811monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-second-quarter-2025-financial-results-fgen-20250804monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-appoints-michael-kauffman-m-d-ph-d-to-its-board-of-directors-fgen-20250609monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-first-quarter-2025-financial-results-and-provides-business-update-fgen-20250512monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-first-quarter-2025-financial-results-fgen-20250505monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference-fgen-20250402monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-publication-of-results-from-phase-1-monotherapy-study-of-fg-3246-in-pat-fgen-20250328monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-fourth-quarter-and-full-year-2024-financial-results-fgen-20250317monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-fourth-quarter-and-full-year-2024-financial-results-fgen-20250303monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-the-sale-of-fibrogen-china-to-astrazeneca-for-approximately-160-million-fgen-20250220monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-appoints-david-delucia-as-chief-financial-officer-fgen-20241216monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-third-quarter-2024-financial-results-fgen-20241112monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-third-quarter-2024-financial-results-fgen-20241104monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-fgen-20240903monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-second-quarter-2024-financial-results-and-provides-business-update-fgen-20240806monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-second-quarter-2024-financial-results-fgen-20240730monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-topline-results-from-two-late-stage-pamrevlumab-pancreatic-cancer-studi-fgen-20240730monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-host-part-ii-of-virtual-kol-investor-event-series-to-review-fg-3246-developmen-fgen-20240618monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-clinical-trial-supply-agreement-with-regeneron-pharmaceuticals-to-evalu-fgen-20240603monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-fda-clearance-of-investigational-new-drug-application-for-fg-3165-a-gal-fgen-20240603monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-present-at-goldman-sachs-45th-annual-global-healthcare-conference-fgen-20240603monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-presentation-of-positive-interim-data-from-the-phase-1b-study-of-fg-324-fgen-20240523monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-participate-in-upcoming-investor-conferences-fgen-20240507monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-first-quarter-2024-financial-results-fgen-20240506monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-first-quarter-2024-financial-results-fgen-20240429monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-clinical-data-from-dose-escalation-phase-1b-study-of-fg-3246-for46-in-c-fgen-20240424monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-topline-results-from-phase-1-monotherapy-study-of-fg-3246-in-patients-w-fgen-20240402monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-present-at-23rd-annual-needham-virtual-healthcare-conference-fgen-20240326monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-appoints-deyaa-adib-m-d-as-chief-medical-officer-fgen-20240311monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-fourth-quarter-and-full-year-2023-financial-results-fgen-20240226monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-regains-all-rights-to-roxadustat-from-astrazeneca-in-the-united-states-and-other--fgen-20240226monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-fourth-quarter-and-full-year-2023-financial-results-fgen-20240220monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-host-part-i-of-virtual-kol-investor-event-series-to-review-pamrevlumab-clinica-fgen-20240205monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-completion-of-the-pamrevlumab-arm-in-precision-promise-pancreatic-cance-fgen-20240125monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-presents-data-from-phase-3-matterhorn-trial-of-roxadustat-in-patients-with-anemia-fgen-20231209monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-astellas-evrenzo-roxadustat-making-in-roads-in-european-market-as-in-class-challe-fgen-20231208monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-third-quarter-2023-financial-results-fgen-20231106monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-third-quarter-2023-financial-results-fgen-20231023monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-topline-results-from-lelantos-2-a-phase-3-clinical-study-of-pamrevlumab-fgen-20230829monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-second-quarter-2023-financial-results-fgen-20230807monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-leadership-transition-fgen-20230725monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-second-quarter-2023-financial-results-fgen-20230724monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-investigation-continued-by-former-louisiana-attorney-general-kahn-swick-foti-llc--fgen-20230701monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-topline-results-from-phase-3-zephyrus-1-study-of-pamrevlumab-for-the-tr-fgen-20230626monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-investigation-continued-by-former-louisiana-attorney-general-kahn-swick-foti-llc--fgen-20230617monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-topline-results-from-lelantos-1-phase-3-clinical-study-of-pamrevlumab-i-fgen-20230607monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-present-at-jefferies-global-healthcare-conference-fgen-20230606monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-investigation-continued-by-former-louisiana-attorney-general-kahn-swick-foti-llc--fgen-20230606monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-positive-topline-results-from-china-pivotal-phase-3-clinical-trial-of-r-fgen-20230518monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-first-quarter-2023-financial-results-fgen-20230508monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics-fgen-20230508monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-results-for-matterhorn-a-phase-3-clinical-study-of-roxadustat-for-the-t-fgen-20230505monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-non-dilutive-term-loan-financing-for-up-to-150-million-with-morgan-stan-fgen-20230501monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-first-quarter-2023-financial-results-fgen-20230424monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-completion-of-patient-enrollment-in-zephyrus-2-a-phase-3-clinical-study-fgen-20230403monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-fourth-quarter-and-full-year-2022-financial-results-fgen-20230227monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-present-at-cowen-s-43rd-annual-health-care-conference-fgen-20230227monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-fourth-quarter-and-full-year-2022-financial-results-fgen-20230217monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-present-at-svb-securities-global-biopharma-conference-fgen-20230202monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-participate-at-bank-of-america-2022-biotech-smid-cap-virtual-conference-fgen-20221128monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-third-quarter-2022-financial-results-fgen-20221107monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-50-million-royalty-monetization-financing-with-novaquest-capital-manage-fgen-20221107monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-participate-at-stifel-2022-healthcare-conference-fgen-20221101monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-third-quarter-2022-financial-results-fgen-20221024monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-completion-of-patient-enrollment-in-matterhorn-a-phase-3-clinical-study-fgen-20220826monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-second-quarter-2022-financial-results-fgen-20220808monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-second-quarter-2022-financial-results-fgen-20220725monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-shareholder-alert-shareholder-class-action-survives-in-part-motion-to-dismiss-sho-fgen-20220719monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-participate-at-william-blair-biotech-focus-conference-2022-fgen-20220701monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-completion-of-patient-enrollment-in-lelantos-2-a-phase-3-clinical-study-fgen-20220608monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-present-at-jefferies-healthcare-conference-fgen-20220526monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-first-quarter-2022-financial-results-fgen-20220509monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-first-quarter-2022-financial-results-fgen-20220425monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-completion-of-patient-enrollment-in-zephyrus-1-a-phase-3-clinical-study-fgen-20220420monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-fourth-quarter-and-full-year-2021-financial-results-fgen-20220228monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-fourth-quarter-and-full-year-2021-financial-results-fgen-20220214monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-present-at-svb-leerink-11th-annual-global-healthcare-conference-fgen-20220204monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-present-at-h-c-wainwright-bioconnect-virtual-conference-fgen-20220104monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-exercises-exclusive-license-option-for-hifibio-s-ccr8-program-fgen-20211220monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-third-quarter-2021-financial-results-fgen-20211109monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-present-at-upcoming-investor-conferences-fgen-20211102monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-third-quarter-2021-financial-results-fgen-20211026monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-analyses-from-roxadustat-global-phase-3-program-at-american-society-of--fgen-20211025monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-positive-topline-results-from-phase-2-clinical-trial-of-roxadustat-for--fgen-20210825monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-retirement-of-pat-cotroneo-and-appointment-of-juan-graham-as-chief-fina-fgen-20210816monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-receives-complete-response-letter-from-the-fda-for-roxadustat-for-anemia-of-chron-fgen-20210811monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-second-quarter-2021-financial-results-fgen-20210809monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-second-quarter-2021-financial-results-fgen-20210729monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-outcome-of-fda-advisory-committee-review-of-roxadustat-for-treatment-of-fgen-20210715monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-appoints-john-hunter-ph-d-as-chief-scientific-officer-fgen-20210712monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-and-hifibio-announce-transformative-partnership-to-advance-next-generation-therap-fgen-20210617monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portn-fgen-20210611monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-deadline-alert-faruqi-faruqi-llp-securities-litigation-partner-james-josh-wilson--fgen-20210609monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portn-fgen-20210604monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-deadline-alert-faruqi-faruqi-llp-securities-litigation-partner-james-josh-wilson--fgen-20210528monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-present-at-upcoming-investor-conferences-fgen-20210527monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portn-fgen-20210525monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-deadline-alert-faruqi-faruqi-llp-securities-litigation-partner-james-josh-wilson--fgen-20210521monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portn-fgen-20210511monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-first-quarter-2021-financial-results-fgen-20210510monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portn-fgen-20210505monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-first-quarter-2021-financial-results-fgen-20210503monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-present-at-upcoming-investor-conference-fgen-20210428monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portn-fgen-20210425monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portn-fgen-20210421monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-receives-rare-pediatric-disease-designation-from-the-u-s-fda-for-pamrevlumab-for--fgen-20210415monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that-a-s-fgen-20210414monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-receives-fast-track-designation-from-the-u-s-fda-for-pamrevlumab-for-the-treatmen-fgen-20210412monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-inc-investors-company-investigated-by-the-portnoy-law-firm-fgen-20210408monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-fda-advisory-committee-to-review-roxadustat-new-drug-application-tentat-fgen-20210406monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-provides-additional-information-on-roxadustat-fgen-20210406monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-initiates-lelantos-2-second-phase-3-clinical-study-of-pamrevlumab-for-the-treatme-fgen-20210316monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-provides-regulatory-update-on-roxadustat-fgen-20210301monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-fourth-quarter-and-full-year-2020-financial-results-fgen-20210301monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-report-fourth-quarter-and-full-year-2020-financial-results-fgen-20210218monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-to-present-at-upcoming-investor-conferences-fgen-20210212monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-advances-phase-3-clinical-development-of-pamrevlumab-for-the-treatment-of-idiopat-fgen-20201222monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-showcase-next-generation-portable-blood-volume-analyzer-at-acc-26-hig-dxr-20260317monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-to-debut-new-rapid-portable-blood-volume-analyzer-at-sccm-2026-critical-care-congres-dxr-20260310monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-duke-university-study-on-blood-volume-analysis-in-heart-failure-published--dxr-20250514monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-s-blood-volume-analysis-diagnostic-reaches-two-new-u-s-healthcare-systems-dxr-20250513monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-the-45th-international-society-for-heart-and-lung-transpla-dxr-20250422monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-showcase-innovative-blood-volume-analysis-at-medaxiom-cardiovascular--dxr-20250417monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-submits-510-k-to-fda-for-next-generation-blood-volume-analyzer-dxr-20250410monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-new-data-from-duke-university-and-highlights-key-bva-insights--dxr-20250402monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-expands-blood-volume-analysis-technology-across-midwest-wisconsin-and-new-jersey-hea-dxr-20250328monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-reports-increase-in-nav-to-7-25-per-share-and-116-5-percent-increase-in--dxr-20250304monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-host-investor-conference-call-to-discuss-fiscal-year-2024-financial-r-dxr-20250304monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-ceo-and-president-michael-feldschuh-provides-corporate-update-in-letter--dxr-20250304monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-expands-blood-volume-analysis-services-at-major-midwest-healthcare-center-dxr-20250228monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-expands-blood-volume-analysis-technology-to-major-new-jersey-hospitals-dxr-20250227monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-new-data-on-blood-volume-analysis-from-duke-and-yale-universit-dxr-20250219monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-to-exhibit-at-world-s-largest-critical-care-conference-dxr-20250218monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-s-blood-volume-analysis-uncovers-hidden-heart-failure-subtype-in-nearly-1-in-5-patie-dxr-20250214monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-expands-its-bva-100-blood-volume-diagnostic-to-two-new-hospital-systems-adding-to-sa-dxr-20241218monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-s-innovative-bva-100-blood-volume-diagnostic-featured-at-medaxiom-cv-transforum-fall-dxr-20241009monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-participate-in-a-fireside-chat-at-the-2024-maxim-healthcare-virtual-s-dxr-20241008monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-streamlines-regulatory-strategy-for-groundbreaking-diagnostic-device-dxr-20240927monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-the-heart-failure-society-of-america-annual-scientific-mee-dxr-20240919monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-receives-300k-matching-fund-award-from-launch-tennessee-dxr-20240905monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-ceo-and-president-michael-feldschuh-delivers-corporate-update-in-shareho-dxr-20240903monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conferenc-dxr-20240903monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-launch-of-bva-program-at-mid-south-largest-integrated-network-dxr-20240829monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-awarded-1-9m-contract-by-the-u-s-air-force-for-development-of-its-next-g-dxr-20240806monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-expands-to-three-new-facilities-as-blood-volume-analysis-technology-gains-momentum-n-dxr-20240805monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-awarded-new-u-s-defense-health-agency-contract-for-added-capabilities-to-dxr-20240724monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-s-bva-100-blood-volume-diagnostic-expands-to-three-new-centers-gains-tra-dxr-20240711monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-showcase-the-benefits-of-bva-100-guided-care-at-the-american-associat-dxr-20240618monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-appoints-john-l-jefferies-m-d-as-chief-medical-officer-dxr-20240605monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-the-medaxiom-cardiovascular-transforum-conference-spring-2-dxr-20240415monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-new-hospital-account-at-leading-chicago-hospital-dxr-20240410monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-the-american-college-of-cardiology-for-acc-24-dxr-20240401monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-acquires-volumex-and-megatope-from-its-existing-supplier-along-with-glof-dxr-20240325monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-hold-investor-call-discussing-fiscal-year-2023-financial-results-and--dxr-20240322monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-ceo-and-president-michael-feldschuh-provides-corporate-update-in-letter--dxr-20240318monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-reports-increase-in-nav-to-7-08-per-share-and-31-8-percent-increase-in-u-dxr-20240318monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-sales-to-three-new-hospitals-furthering-expansion-of-its-user-base-dxr-20240311monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-the-technology-and-heart-failure-therapeutics-conference-dxr-20240226monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-starts-2024-with-ongoing-growth-in-new-blood-volume-analyzer-acquisition-dxr-20240212monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-closes-q4-2023-with-growth-in-new-sales-to-hospital-systems-and-increase-dxr-20240207monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-the-society-of-nuclear-medicine-and-molecular-imaging-mid--dxr-20240129monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-the-society-for-critical-care-medicine-2024-critical-care--dxr-20240116monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-awarded-additional-new-patent-for-smart-blood-volume-guidance-technology-to-improve--dxr-20240109monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-submits-dual-510-k-clia-waiver-application-to-the-fda-for-its-advanced-n-dxr-20240102monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-awarded-new-patent-for-remote-monitoring-of-blood-volume-dxr-20231109monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-awarded-support-from-the-national-institutes-of-health-nih-catalyze-prec-dxr-20231004monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-the-heart-failure-society-of-america-annual-scientific-mee-dxr-20230927monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-the-medaxiom-cardiovascular-transforum-conference-fall-23--dxr-20230926monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-awarded-305k-grant-from-the-national-institutes-of-health-to-develop-blo-dxr-20230911monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conferenc-dxr-20230907monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-ceo-and-president-michael-feldschuh-provides-corporate-update-in-letter--dxr-20230828monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-reports-a-20-64-percent-increase-in-diagnostic-test-kits-revenue-from-pr-dxr-20230828monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-further-acquisitions-and-increased-utilization-of-its-bva-100--dxr-20230711monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-awarded-1-1-million-contract-from-the-united-states-defense-health-agenc-dxr-20230705monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-partial-exercise-of-over-allotment-option-in-secondary-offerin-dxr-20230622monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-showcase-the-benefits-of-bva-100-guided-care-at-the-american-associat-dxr-20230620monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-accelerates-blood-volume-analysis-adoption-with-the-launch-of-ezbva-lab-services-dxr-20230615monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-participate-in-the-maxim-group-virtual-healthcare-conference-dxr-20230612monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-closing-of-4-0-million-underwritten-public-offering-dxr-20230525monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-pricing-of-4-0-million-underwritten-public-offering-dxr-20230522monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-proposed-underwritten-public-offering-dxr-20230519monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-the-medaxiom-cardiovascular-transforum-conference-spring-2-dxr-20230417monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-the-43rd-international-society-for-heart-and-lung-transpla-dxr-20230413monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-significant-expansion-with-five-hospitals-implementing-its-bva-dxr-20230327monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-ceo-and-president-michael-feldschuh-provides-corporate-update-in-letter--dxr-20230303monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-reports-a-37-increase-in-nav-to-6-75-per-share-for-the-year-ended-decemb-dxr-20230302monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-report-fiscal-year-2022-financial-results-on-wednesday-march-1-2023-a-dxr-20230301monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-appoints-linda-cooper-vice-president-project-management-dxr-20230217monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-joins-the-heart-failure-society-of-america-hfsa-as-a-corporate-member-dxr-20230119monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-the-society-for-critical-care-medicine-2023-critical-care--dxr-20230113monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-closing-of-2-1-million-underwritten-public-offering-and-exerci-dxr-20221117monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-pricing-of-2-0-million-underwritten-public-offering-dxr-20221115monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-launch-of-proposed-underwritten-public-offering-dxr-20221114monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-american-heart-association-s-scientific-sessions-2022-dxr-20221031monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-and-present-at-the-medaxiom-cardiovascular-transforum-confere-dxr-20221004monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-the-annual-scientific-meeting-of-the-heart-failure-society-dxr-20220926monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-attend-the-h-c-wainwright-24th-annual-global-investment-conference-dxr-20220906monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-ceo-and-president-michael-feldschuh-provides-corporate-update-in-letter--dxr-20220829monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-reports-a-92-6-percent-revenue-increase-in-diagnostic-operating-division-dxr-20220825monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-report-first-half-2022-financial-results-on-thursday-august-25-2022-a-dxr-20220824monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-a-49-4-increase-in-its-single-use-diagnostic-kits-year-over-ye-dxr-20220727monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-partnership-with-medaxiom-to-advance-awareness-and-further-ado-dxr-20220721monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-completes-nih-funded-i-corps-program-for-commercialization-of-clinical-decision-supp-dxr-20220718monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-cooperative-research-and-development-phase-ii-agreement-with-the-uniformed-dxr-20220627monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-showcase-the-benefits-of-bva-100-guided-care-at-the-american-associat-dxr-20220613monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-s-blood-volume-analyzer-bva-100-to-be-used-as-a-key-metric-in-study-of-long-hauler-c-dxr-20220525monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-present-at-the-h-c-wainwright-company-global-investment-conference-dxr-20220512monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-participate-in-the-maxim-group-2022-virtual-growth-conference-dxr-20220323monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-ceo-and-president-michael-feldschuh-provides-corporate-update-in-letter--dxr-20220301monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-1-35-per-share-nav-increase-and-files-annual-report-for-fiscal-dxr-20220301monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-commences-trading-on-the-nasdaq-capital-market-dxr-20220202monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-commence-trading-on-the-nasdaq-capital-market-on-february-2-2022-dxr-20220120monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-present-at-the-h-c-wainwright-bioconnect-2022-virtual-conference-dxr-20220106monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-key-milestones-achieved-for-multicenter-bva-100-study-in-hospitalized-pati-dxr-20220105monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-awarded-new-patent-for-blood-volume-guidance-technology-to-improve-treatment-and-out-dxr-20220104monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-presents-new-data-validating-the-benefit-of-the-bva-100-blood-test-for-o-dxr-20211116monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-receives-200k-matching-fund-award-from-launch-tennessee-dxr-20211001monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-presents-new-data-validating-the-benefit-of-the-bva-100-blood-test-for-h-dxr-20210914monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-dxr-20210908monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-virtual-c-dxr-20210907monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-ceo-and-president-michael-feldschuh-provides-corporate-update-in-letter--dxr-20210901monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-reports-a-26-5-percent-rise-in-diagnostic-sales-revenue-in-form-n-csr-fi-dxr-20210830monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-s-blood-volume-bva-100-diagnostic-demonstrates-clinical-utility-in-critically-ill-co-dxr-20210804monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-non-government-distribution-agreement-with-concordance-healthc-dxr-20210722monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-present-at-the-summer-solstice-best-ideas-from-the-buy-side-conferenc-dxr-20210528monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-61-increase-in-q1-2021-sales-revenue-and-further-acquisitions--dxr-20210513monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-receives-national-institutes-of-health-nih-funding-notification-for-land-dxr-20210506monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-participate-in-benzinga-biotech-small-cap-conference-dxr-20210318monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-to-participate-in-the-maxim-group-2021-emerging-growth-virtual-conference-dxr-20210316monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-novel-fluorescent-tracer-and-phase-two-us-air-force-contract-a-dxr-20210315monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-to-present-at-the-h-c-wainwright-global-life-sciences-conference-dxr-20210304monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-0-48-per-share-nav-increase-and-files-annual-report-for-fiscal-dxr-20210226monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-receives-iso-13485-quality-management-system-certification-for-the-blood-dxr-20210219monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-awarded-grant-from-the-center-for-advancing-point-of-care-technologies-c-dxr-20210205monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-the-society-for-critical-care-medicine-50th-congress-virtu-dxr-20210126monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-new-distribution-agreement-with-l1-enterprises-government-distributor-dxr-20210113monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-to-present-at-the-inaugural-h-c-wainwright-bioconnect-2021-conference-dxr-20210108monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-further-acquisitions-of-its-bva-100-blood-volume-analyzer-by-l-dxr-20201210monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-present-at-the-13th-annual-ld-micro-main-event-2020-dxr-20201209monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-to-present-at-the-2020-microcap-rodeo-best-ideas-bowl-dxr-20201012monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-and-showcase-compelling-new-data-at-the-heart-failure-society-dxr-20200928monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-to-present-at-the-inaugural-sepsis-alliance-summit-dxr-20200915monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-to-present-at-h-c-wainwright-22nd-annual-global-investment-conference-dxr-20200910monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-present-at-the-ld-500-virtual-investor-conference-dxr-20200831monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-reports-a-29-6-percent-rise-in-sales-revenue-for-six-months-in-filing-of-dxr-20200824monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-cooperative-research-and-development-agreement-with-the-uniformed-services-dxr-20200804monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-pricing-of-7-0-million-registered-direct-offering-dxr-20200720monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-prospective-randomized-control-trial-at-duke-university-medical-center-to--dxr-20200716monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-initiation-of-first-of-its-kind-multicenter-bva-100-study-in-hospitalized--dxr-20200715monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-new-distribution-agreement-with-american-medical-depot-government-distribu-dxr-20200708monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-appointment-of-henry-d-cremisi-md-facp-and-joy-goudie-esq-to-t-dxr-20200630monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-ceo-michael-feldschuh-to-participate-in-maxim-group-s-covid-19-virtual-c-dxr-20200526monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-s-bva-100-published-in-novel-study-in-american-heart-association-journal-circulation-dxr-20200522monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-awarded-1-1-million-contract-from-united-states-department-of-defense-dod-for-rapid--dxr-20200423monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-s-bva-100-test-used-to-guide-treatment-in-covid-19-patient-dxr-20200320monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-contracted-to-adapt-its-blood-volume-analyzer-technology-for-u-s-air-for-dxr-20200309monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-closing-of-2-0-million-registered-direct-offering-priced-at-th-dxr-20200306monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-pricing-of-2-0-million-registered-direct-offering-priced-at-th-dxr-20200303monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-engagement-with-hospitals-and-government-for-use-of-the-blood--dxr-20200302monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-rise-in-kit-sales-and-files-form-n-csr-for-2019-dxr-20200302monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-the-society-for-critical-care-medicine-49th-congress-dxr-20200212monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-american-heart-association-s-scientific-sessions-2019-dxr-20191112monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-to-present-at-the-inaugural-microcap-rodeo-investor-conference-on-october-15-2019-at-dxr-20191010monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-the-23rd-annual-scientific-meeting-of-the-heart-failure-so-dxr-20190911monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-a-38-percent-rise-in-bva-100-cardiology-kit-sales-and-net-gain-dxr-20190904monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-the-acquisition-of-the-bva-100-blood-volume-analyzer-by-a-lead-dxr-20190806monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-new-research-initiative-with-leading-hospital-in-the-southeast-dxr-20190618monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-present-at-the-ld-micro-9th-annual-invitational-on-june-4th-2019-dxr-20190531monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-new-partnership-with-leading-hospital-in-north-carolina-to-int-dxr-20190530monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-the-society-of-hospital-medicine-shm-annual-conference-201-dxr-20190322monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-addresses-and-corrects-erroneous-seeking-alpha-healthcare-news-editor-ar-dxr-20190321monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-present-at-the-31st-annual-roth-conference-on-march-19-2019-dxr-20190315monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-showcase-reduction-in-mortality-and-hospital-readmissions-with-bva-10-dxr-20190313monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-rise-in-kit-sales-and-files-form-n-csr-for-2018-dxr-20190304monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-the-society-for-critical-care-medicine-48th-congress-dxr-20190213monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-appoints-guido-manzo-vice-president-of-sales-dxr-20190123monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-acquisition-of-bva-100-blood-volume-analyzer-to-aspirus-wausau-dxr-20190110monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-selected-for-u-s-army-contract-to-develop-a-blood-volume-analyzer-for-im-dxr-20181107monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-initiates-strategic-collaboration-with-chf-solutions-inc-to-manage-patie-dxr-20181101monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-appoints-robert-j-michel-as-chief-financial-officer-dxr-20180928monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-present-at-the-microcap-conference-on-october-2-2018-dxr-20180925monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-exhibit-at-the-22nd-annual-scientific-meeting-of-the-heart-failure-so-dxr-20180912monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-a-23-percent-rise-in-bva-100-kit-sales-in-the-area-of-cardiolo-dxr-20180824monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-appoints-kathryn-a-kornafel-vice-president-of-marketing-and-commercial-d-dxr-20180612monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-initiates-study-with-virginia-commonwealth-university-to-measure-improve-dxr-20180604monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-present-at-the-ld-micro-8th-annual-invitational-on-june-4-2018-dxr-20180530monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-retains-core-ir-as-investor-relations-firm-of-record-dxr-20180529monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-to-present-at-the-microcap-conference-on-april-9th-and-10th-in-new-york-city-at-the--dxr-20180405monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-to-exhibit-at-the-american-association-of-heart-failure-nurses-2018-advanced-heart-f-dxr-20180322monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-positive-new-critical-care-research-highlighting-benefit-from--dxr-20180309monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-rise-in-kit-sales-new-device-sale-and-filing-of-form-n-csr-for-dxr-20180308monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-revises-2017-dividend-dxr-20171228monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-2017-dividend-dxr-20171221monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-share-buyback-program-dxr-20171101monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-holds-annual-meeting-provides-business-growth-update-and-strategic-plan-dxr-20170629monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-hiring-of-chief-financial-officer-dxr-20170531monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-delay-in-filing-of-form-n-csr-for-december-31-2016-and-the-uni-dxr-20170410monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-death-of-founder-chief-medical-officer-and-developer-of-blood--dxr-20170201monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-dividend-patent-approval-title-change-dxr-20161118monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-two-new-studies-from-the-mayo-clinic-and-lankenau-medical-cent-dxr-20160929monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-filing-of-form-n-csr-for-june-30-2016-dxr-20160915monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-hiring-of-chief-financial-officer-dxr-20160617monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-upcoming-filing-of-form-n-csr-for-december-31-2015-and-recent--dxr-20160229monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-return-of-dr-joseph-feldschuh-after-pancreatic-cancer-surgery-dxr-20160217monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-sale-of-bva-100-blood-volume-analyzer-to-nebraska-medicine-dxr-20160208monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-an-increased-dividend-and-the-appointment-of-michael-feldschuh-dxr-20151210monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-filing-of-form-n-q-for-september-30-2015-dxr-20151127monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-hire-of-senior-vice-president-marketing-and-commercial-development-dxr-20150902monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-filing-of-form-n-csr-for-june-30-2015-dxr-20150828monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-an-update-on-its-stock-buyback-program-and-changes-in-marketing-dxr-20150813monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-the-receipt-of-a-contract-for-the-placement-of-a-bva-100-blood-volume-anal-dxr-20150623monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-the-receipt-of-a-contract-for-the-placement-of-a-bva-100-blood-volume-anal-dxr-20150428monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-receives-two-patents-one-for-measurement-of-total-body-albumin-and-a-second-patent-f-dxr-20150409monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-receives-notification-of-patent-approval-and-issues-an-update-on-its-stock-buyback-p-dxr-20150317monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-placement-of-two-bva-100-blood-volume-analyzers-dxr-20150313monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-filing-of-form-n-csr-for-december-31-2014-dxr-20150227monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-major-research-studies-dxr-20150130monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-appoints-michael-feldschuh-as-executive-vice-president-dxr-20141218monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-a-major-study-with-the-mayo-clinic-dxr-20141211monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-payment-of-a-dividend-dxr-20141117monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-publication-of-a-study-comparing-two-widely-used-surrogate-tests-for-estim-dxr-20141103monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-research-agreement-with-virginia-commonwealth-university-on-bu-dxr-20141021monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-filing-of-form-n-csr-for-june-30-2014-dxr-20140829monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-to-explore-possible-partnership-or-partial-sale-of-the-company-dxr-20140619monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-s-idant-laboratories-subsidiary-earns-american-association-of-blood-bank-dxr-20140430monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-filing-of-form-n-csr-for-december-31-2013-dxr-20140228monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-dr-joseph-feldschuh-president-and-ceo-sustained-a-fractured-hi-dxr-20140211monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-a-research-study-that-proves-micro-samples-are-feasible-for-accurate-blood-dxr-20140115monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-payment-of-a-dividend-dxr-20131115monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-a-study-on-the-significant-diagnostic-benefits-to-congestive-h-dxr-20131025monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-results-of-blood-volume-measurement-study-at-the-mayo-clinic-p-dxr-20131008monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-filing-of-form-n-csr-for-june-30-2013-dxr-20130823monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-receipt-of-blood-banking-contract-from-prestigious-law-firm-st-dxr-20130807monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-publication-of-blood-volume-determination-a-nuclear-medicine-t-dxr-20130711monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-the-bi-monthly-publication-of-a-medical-column-by-its-presiden-dxr-20130613monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-placement-of-bva-100-blood-volume-analyzer-at-austin-nuclear-p-dxr-20130516monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-the-sale-of-a-bva-100-blood-volume-analyzer-to-banner-good-sam-dxr-20130307monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-filing-of-form-n-csr-for-december-31-2012-and-volumex-kit-sale-dxr-20130301monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-payment-of-a-dividend-dxr-20121129monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-that-pci-nuclear-pharmacy-acquires-bva-100-blood-volume-analyzer-dxr-20121119monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-basic-blood-volume-research-study-on-renal-dialysis-patients-dxr-20121108monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-filing-of-form-n-csr-for-june-30-2012-and-volumex-kit-sales-fo-dxr-20120904monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-sale-of-bva-100-blood-volume-analyzer-and-payment-of-a-dividend-dxr-20120803monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-placement-of-bva-100-blood-volume-analyzer-at-new-york-presbyterian-weill--dxr-20120718monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-placement-of-bva-100-blood-volume-analyzer-at-north-alabama-radiopharmacy-dxr-20120712monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-filing-of-form-n-2-and-seven-trial-agreements-for-the-daxor-bv-dxr-20120629monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-placement-of-three-bva-100-blood-volume-analyzers-dxr-20120621monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-filing-of-form-n-q-for-march-31-2012-and-volumex-kit-sales-for-dxr-20120525monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-year-end-2011-earnings-dxr-20120328monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-that-shertech-pharmacy-acquires-bva-100-blood-volume-analyzer-dxr-20120323monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-receipt-of-order-granting-request-to-withdraw-petition-for-review-and-noti-dxr-20120215monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-that-shertech-pharmacy-corp-acquires-bva-100-blood-volume-analyzer-to-serv-dxr-20120201monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-that-the-mayo-clinic-in-scottsdale-arizona-acquires-bva-100-blood-volume-a-dxr-20120112monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-the-veterans-affairs-new-york-harbor-healthcare-system-va-nyhhs-acquires-b-dxr-20111219monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-that-the-va-medical-center-in-washington-d-c-acquires-bva-100-blood-volume-dxr-20111213monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-that-harborview-medical-center-of-seattle-wa-acquires-bva-100-blood-volume-dxr-20111122monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-intention-to-register-as-an-investment-company-under-the-inves-dxr-20111118monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-third-quarter-2011-earnings-dxr-20111114monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-payment-of-a-fourth-quarter-dividend-dxr-20111108monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-filing-of-patents-for-total-body-albumin-analyzer-dxr-20111025monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-signed-trial-agreement-from-schnitzler-cardiovascular-consulta-dxr-20111013monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-decision-by-sec-on-administrative-proceeding-dxr-20110901monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-second-quarter-2011-earnings-dxr-20110809monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-that-hartford-hospital-of-hartford-ct-acquires-bva-100-blood-volume-analyz-dxr-20110616monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-first-quarter-2011-earnings-and-payment-of-a-dividend-dxr-20110513monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-publication-of-research-article-which-reports-that-the-blood-volume-analyz-dxr-20110405monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-fourth-quarter-dividend-and-patent-update-dxr-20101130monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-third-quarter-dividend-and-update-on-use-of-blood-volume-analyzer-in-heart-dxr-20100902monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-second-quarter-2010-earnings-and-team-hf-study-dxr-20100813monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-first-quarter-2010-earnings-and-payment-of-a-dividend-dxr-20100511monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-that-the-university-of-florida-college-of-veterinary-medicine-in-gainesvil-dxr-20100428monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-nyse-amex-dxr-announces-year-end-2009-earnings-dxr-20100329monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-that-medical-university-of-south-carolina-in-charleston-purchases-blood-vo-dxr-20091201monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-special-year-end-dividend-dxr-20091123monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-that-durham-va-medical-center-acquires-bva-100-blood-volume-analyzer-to-as-dxr-20091019monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-that-susquehanna-health-of-williamsport-pa-acquires-bva-100-blood-volume-a-dxr-20091007monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-that-pacific-cardiology-of-honolulu-hi-acquires-bva-100-blood-volume-analy-dxr-20090831monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-third-quarter-dividend-dxr-20090817monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-embarks-on-team-hf-multi-center-heart-failure-treatment-clinical-study-dxr-20090728monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-first-quarter-2009-earnings-and-payment-of-a-dividend-dxr-20090512monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-to-present-at-taglich-brothers-6th-annual-small-cap-equity-conference-dxr-20090414monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-fresno-heart-surgical-hospital-of-fresno-ca-acquires-bva-100-blood-volume--dxr-20090223monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-publication-in-the-american-journal-of-surgery-concerning-blood-volume-in--dxr-20090210monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-tahlequah-city-hospital-of-tahlequah-ok-acquires-bva-100-blood-volume-anal-dxr-20090130monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-special-year-end-dividend-dxr-20081201monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-publication-of-clinical-study-involving-anemia-and-heart-failure-fourth-qu-dxr-20081015monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-a-union-hospital-purchase-and-a-separate-trial-of-blood-volume-analyzer-bv-dxr-20080813monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-international-publication-of-clinical-study-involving-critically-ill-surgi-dxr-20080716monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-quarterly-dividend-dxr-20080714monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-kaiser-permanente-of-los-angeles-ca-purchases-bva-100-blood-volume-analyze-dxr-20080506monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-westchester-medical-center-of-valhalla-ny-purchases-blood-volume-analyzer--dxr-20080421monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-st-francis-hospital-of-wilmington-de-purchases-blood-volume-analyzer-bva-1-dxr-20080417monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-publication-of-clinical-study-demonstrating-blood-volume-analysis-benefits-dxr-20080317monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-announces-queen-s-medical-center-of-honolulu-hi-purchases-second-blood-v-dxr-20071026monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-virginia-commonwealth-university-medical-center-of-richmond-va-acquires-bl-dxr-20071001monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-oregon-health-and-science-university-of-portland-or-acquires-bva-100-blood-dxr-20070924monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-northcrest-medical-center-of-springfield-tn-acquires-blood-volume-analyzer-dxr-20070906monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-publication-in-journal-of-emergency-and-intensive-care-medicine-which-stat-dxr-20070801monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-publication-of-symposium-issue-on-blood-volume-in-the-american-journal-of--dxr-20070723monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-christiana-care-health-system-acquires-second-blood-volume-analyzer-bva-10-dxr-20070709monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-bva-100-blood-volume-analyzer-purchase-agreements-from-geisinger-medical-c-dxr-20070629monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-tripler-army-medical-center-of-honolulu-hi-acquires-bva-100-blood-volume-a-dxr-20070626monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-valley-hospital-of-ridgewood-nj-purchases-blood-volume-analyzer-bva-100-dxr-20070615monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-saint-luke-s-hospital-of-bethlehem-pa-acquires-second-blood-volume-analyze-dxr-20070612monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-oklahoma-va-medical-center-of-oklahoma-city-ok-acquires-bva-100-blood-volu-dxr-20070607monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-publication-in-the-journal-of-nuclear-medicine-technology-on-expanding-cli-dxr-20070529monthly0.5https://www.biopharmawatch.com/news/DXR/daxor-announces-agreement-with-nyu-medical-center-for-a-frozen-autologous-blood-program-dxr-20070517monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-reports-second-quarter-2025-financial-results-and-provides-business-update-evok-20250814monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-reports-first-quarter-2025-financial-results-and-provides-business-update-evok-20250513monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-inc-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides--evok-20250313monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-to-report-fourth-quarter-and-full-year-2024-results-on-march-13-2025-evok-20250306monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors-evok-20250224monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-highlights-gimoti-as-a-leading-solution-for-gastroparesis-treatment-as-domper-evok-20241219monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-receives-notices-of-allowance-for-two-additional-us-patent-applications-prote-evok-20241203monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-inc-reports-third-quarter-2024-financial-results-evok-20241107monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-eversana-announce-statistically-significant-improvement-in-patient-outcomes-f-evok-20241028monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-to-showcase-award-winning-research-at-the-2024-american-college-of-gastroente-evok-20241023monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-announces-the-appointment-of-ben-smeal-to-the-board-of-directors-evok-20241022monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-announces-proceeds-from-existing-warrants-and-board-expansion-evok-20241001monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-reaffirms-its-commitment-to-patients-with-gastroparesis-amid-industry-develop-evok-20240919monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-to-participate-in-gastroenterology-and-hepatology-advanced-practice-providers-evok-20240909monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-to-present-at-h-c-wainwright-s-26th-annual-global-investment-conference-evok-20240904monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-inc-reports-second-quarter-2024-financial-results-evok-20240813monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-inc-supports-gastroparesis-awareness-month-evok-20240808monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-inc-announces-reverse-stock-split-evok-20240730monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-reports-commercial-strategy-progress-positive-momentum-for-gimoti-evok-20240617monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-to-present-additional-gimoti-healthcare-utilization-data-focused-on-gastropar-evok-20240516monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-reports-first-quarter-2024-financial-results-evok-20240514monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-to-host-virtual-key-opinion-leader-kol-webinar-on-the-evolving-landscape-of-g-evok-20240417monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-announces-senior-leadership-transition-with-promotion-of-matthew-j-d-onofrio--evok-20240321monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-reports-fourth-quarter-and-full-year-2023-financial-results-evok-20240314monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-to-report-fourth-quarter-and-full-year-2023-results-on-march-14-2024-evok-20240307monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-announces-closing-of-7-5-million-public-offering-evok-20240214monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-announces-pricing-of-underwritten-public-offering-of-up-to-30-million-evok-20240209monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-announces-fda-orange-book-listing-of-new-gimoti-patent-evok-20231127monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-reports-third-quarter-2023-financial-results-evok-20231109monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-eversana-unveil-cost-savings-real-world-data-demonstrating-meaningfully-reduc-evok-20231031monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-s-abstract-entitled-superiority-of-nasal-spray-compared-to-orally-administere-evok-20231018monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-receives-notice-of-allowance-from-uspto-for-gimoti-evok-20230914monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-reports-second-quarter-2023-financial-results-evok-20230810monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-and-eversana-announce-abstract-acceptance-at-2023-american-neurogastroenterol-evok-20230807monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-and-eversana-announce-abstract-selection-for-plenary-oral-presentation-at-the-evok-20230725monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-to-host-first-key-opinion-leader-webinar-on-healthcare-resource-utilization-d-evok-20230614monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-reports-first-quarter-2023-financial-results-evok-20230515monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-s-real-world-healthcare-utilization-data-comparing-gimoti-to-oral-metoclopram-evok-20230504monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-receives-notice-of-allowance-from-uspto-for-gimoti-related-patent-evok-20230406monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-eversana-announce-compelling-real-world-data-on-the-impact-of-gimoti-in-reduc-evok-20230323monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-reports-fourth-quarter-and-full-year-2022-financial-results-evok-20230321monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-to-report-fourth-quarter-and-full-year-2022-results-on-march-21-2023-evok-20230315monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-and-eversana-selected-to-present-results-of-real-world-healthcare-utilization-evok-20230221monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-announces-teva-ends-pursuit-of-paragraph-iv-anda-against-gimoti-evok-20230130monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-announces-acceptance-of-an-abstract-at-the-academy-of-managed-care-pharmacy-a-evok-20230118monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-strengthens-its-intellectual-property-portfolio-with-a-notice-of-allowance-fr-evok-20221130monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-reports-record-third-quarter-2022-financial-results-evok-20221109monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-to-report-third-quarter-results-on-november-9-2022-evok-20221102monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-to-participate-in-the-2022-american-college-of-gastroenterology-annual-scient-evok-20221020monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-receives-notice-of-allowance-from-uspto-for-a-patent-related-to-gimoti-evok-20220920monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-to-participate-in-h-c-wainwright-24th-annual-global-investment-conference-evok-20220906monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-and-eversana-expand-patient-access-to-gimoti-with-new-telehealth-solution-evok-20220816monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-reports-second-quarter-2022-financial-results-evok-20220810monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-first-quarter-2026-financial-results-and-provides-business-update-glpg-20260506monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notifications-from-bank-of-america-glpg-20260310monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-subscription-right-plan-glpg-20260306monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-appoints-tania-philipp-as-chief-human-resources-officer-glpg-20260305monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notifications-from-bank-of-america-glpg-20260304monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-welcomes-dr-paulo-fontoura-to-its-board-of-directors-glpg-20260219monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-from-bank-of-america-glpg-20260216monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notifications-from-bank-of-america-glpg-20260210monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-topline-results-from-two-phase-3-enabling-studies-with-selective-tyk2--glpg-20251218monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-appointment-of-fred-blakeslee-as-general-counsel-glpg-20251016monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-provides-update-on-strategic-alternatives-for-its-cell-therapy-business-glpg-20251001monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-subscription-right-plan-glpg-20250807monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-nv-announces-u-s-fda-regenerative-medicine-advanced-therapy-rmat-designation-gra-glpg-20250806monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-bolster-leadership-team-with-seasoned-life-sciences-executives-to-accelerate-bus-glpg-20250723monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-welcomes-seasoned-pharmaceutical-executives-dawn-svoronos-and-jane-griffiths-to--glpg-20250723monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-half-year-2025-financial-results-and-provides-second-quarter-business-up-glpg-20250723monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-appoints-aaron-cox-as-chief-financial-officer-glpg-20250623monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-presented-new-data-at-icml-2025-from-cohort-3-of-atalanta-1-in-relapsed-refracto-glpg-20250618monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-new-atalanta-1-car-t-data-at-eha-2025-highlighting-low-toxicity-and-r-glpg-20250612monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-subscription-right-plan-glpg-20250527monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-oral-presentations-at-eha-and-icml-2025-featuring-promising-new-data-f-glpg-20250514monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-strategic-update-on-proposed-separation-executive-leadership-transitio-glpg-20250513monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-first-quarter-2025-financial-results-recent-business-highlights-and-near-glpg-20250423monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-executive-leadership-updates-glpg-20250421monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-departure-of-thad-huston-cfo-and-coo-as-of-august-1-2025-glpg-20250415monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-publishes-2024-annual-report-and-announces-annual-shareholders-meeting-glpg-20250327monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-at-upcoming-investor-conferences-glpg-20250224monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-and-13d-filing-from-tang-capital-glpg-20250217monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-full-year-2024-results-and-provides-fourth-quarter-business-update-glpg-20250212monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-unlock-shareholder-value-by-declaring-its-intent-to-separate-into-two-publicl-glpg-20250108monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-glpg-20250107monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-encouraging-new-results-from-ongoing-phase-1-2-study-of-cd19-car-t-cel-glpg-20241207monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-results-of-pioneering-innovation-in-cancer-cell-therapy-at-ash-2024-glpg-20241105monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-third-quarter-2024-financial-results-and-provides-business-update-glpg-20241030monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-welcomes-oleg-nodelman-to-its-board-of-directors-to-support-strategic-growth-glpg-20241007monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-from-ecor1-capital-glpg-20240930monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-from-ecor1-capital-glpg-20240916monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-from-fmr-llc-glpg-20240903monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-fda-clearance-of-ind-application-for-phase-1-2-atalanta-1-study-of-cd1-glpg-20240823monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-from-fmr-llc-glpg-20240820monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-half-year-2024-financial-results-and-provides-second-quarter-business-up-glpg-20240801monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-presents-encouraging-new-data-for-cd19-car-t-candidate-glpg5101-in-non-hodgkin-l-glpg-20240614monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-adaptimmune-sign-clinical-collaboration-agreement-with-an-option-to-exclusiv-glpg-20240530monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-subscription-right-plans-glpg-20240516monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-blood-centers-of-america-announce-strategic-collaboration-to-accelerate-gala-glpg-20240515monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-first-quarter-2024-financial-results-glpg-20240502monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-shareholders-adopt-all-resolutions-proposed-by-the-board-of-directors-at-the-ann-glpg-20240430monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-showcases-innovative-approach-in-hematological-cancer-care-with-clinical-and-tra-glpg-20240404monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-publishes-2023-annual-report-and-announces-annual-and-extraordinary-shareholders-glpg-20240328monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-appoints-andrew-dickinson-as-non-executive-non-independent-director-to-its-board-glpg-20240326monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-full-year-2023-results-and-outlook-for-2024-glpg-20240222monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-presents-at-ebmt-eha-annual-meeting-2024-glpg-20240215monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-completes-transaction-to-transfer-jyseleca-business-to-alfasigma-glpg-20240131monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-enters-into-strategic-collaboration-agreement-with-thermo-fisher-scientific-to-f-glpg-20240104monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-establishes-strategic-collaboration-with-bridgene-biosciences-to-expand-small-mo-glpg-20240103monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-signs-agreement-to-transfer-jyseleca-business-to-alfasigma-glpg-20240102monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-start-of-papilio-1-phase-1-2-multiple-myeloma-study-of-point-of-care-m-glpg-20231219monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-presents-new-encouraging-data-at-ash-2023-from-ongoing-cd19-car-t-studies-with-g-glpg-20231209monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-host-kol-event-on-december-10-2023-at-11-00-am-pst-to-discuss-new-data-presen-glpg-20231207monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-third-quarter-2023-results-and-releases-new-encouraging-data-from-car-t--glpg-20231102monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-concludes-strategic-evaluation-and-signs-letter-of-intent-to-transfer-jyseleca-b-glpg-20231030monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-appoints-simon-sturge-to-its-board-of-directors-glpg-20230919monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-start-of-phase-2-study-with-selective-tyk2-inhibitor-glpg3667-in-patie-glpg-20230828monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-first-half-year-2023-financial-results-glpg-20230803monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-appoints-thad-huston-as-chief-financial-officer-and-chief-operating-officer-glpg-20230615monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-appoints-dr-susanne-schaffert-as-non-executive-independent-director-to-its-board-glpg-20230612monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-showcase-car-t-point-of-care-manufacturing-and-initial-phase-1-2-cll-data-wit-glpg-20230605monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-start-of-phase-2-study-with-selective-tyk2-inhibitor-glpg3667-in-patie-glpg-20230523monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-demonstrates-commitment-to-immunology-with-new-data-in-rheumatoid-arthritis-at-e-glpg-20230522monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-subscription-right-plans-glpg-20230505monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-first-quarter-2023-financial-results-glpg-20230504monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-departure-of-bart-filius-chief-operating-officer-and-chief-financial-o-glpg-20230502monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-phase-3-program-with-filgotinib-in-patients-with-active-axial-spondylo-glpg-20230426monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-shareholders-approve-all-resolutions-proposed-by-the-board-of-directors-at-the-a-glpg-20230425monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-novalix-enter-into-an-integrated-drug-discovery-collaboration-glpg-20230330monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-publishes-2022-annual-report-and-announces-annual-shareholders-meeting-glpg-20230323monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-subscription-right-exercises-glpg-20230320monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-new-data-from-long-term-extension-study-of-filgotinib-in-ulcerative-c-glpg-20230227monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-full-year-2022-results-and-outlook-for-2023-glpg-20230223monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-presented-encouraging-initial-safety-and-efficacy-data-at-2023-ebmt-eha-for-poin-glpg-20230209monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-topline-results-from-phase-3-diversity-trial-of-filgotinib-in-crohn-s--glpg-20230208monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-from-fmr-llc-glpg-20230110monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-at-41th-annual-j-p-morgan-healthcare-conference-glpg-20230103monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-from-fmr-llc-glpg-20221223monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-changes-to-executive-committee-glpg-20221222monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-cellpoint-presented-encouraging-initial-data-at-ash-2022-for-glpg5101-a-cd19-glpg-20221213monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-chmp-adoption-of-prac-s-recommendation-for-jyseleca-following-extensiv-glpg-20221111monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-encouraging-initial-data-from-filosophy-real-world-arthritis-study-at-glpg-20221108monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-presents-roadmap-for-pipeline-and-commercial-growth-at-its-r-d-day-2022-glpg-20221104monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-strategy-to-accelerate-innovation-and-reports-strong-third-quarter-202-glpg-20221103monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-host-its-r-d-update-2022-in-new-york-on-4-november-2022-glpg-20221017monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-provides-further-insights-into-the-treatment-of-ulcerative-colitis-at-the-upcomi-glpg-20221006monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-positive-chmp-opinion-for-jyseleca-european-label-update-based-on-testi-glpg-20221003monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-subscription-right-exercises-glpg-20220927monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-from-fmr-llc-glpg-20220829monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-at-upcoming-investor-conferences-glpg-20220824monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-from-fmr-llc-glpg-20220818monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-from-fmr-llc-glpg-20220808monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-acquire-cellpoint-and-aboundbio-to-accelerate-access-to-next-generation-cell--glpg-20220621monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-subscription-right-exercises-glpg-20220620monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-from-fmr-llc-glpg-20220601monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-showcase-commitment-to-rheumatoid-arthritis-care-at-the-upcoming-european-lea-glpg-20220525monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-subscription-right-plans-glpg-20220506monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-demonstrates-regulatory-and-commercial-progress-in-q1-2022-glpg-20220505monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-appointment-of-dr-paul-stoffels-as-chairman-of-the-board-glpg-20220426monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-publishes-2021-annual-report-and-announces-extraordinary-and-annual-shareholders-glpg-20220324monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-subscription-right-exercises-glpg-20220318monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-2021-results-set-stage-for-future-growth-glpg-20220224monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-from-ecor1-capital-glpg-20220203monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-provides-further-insights-into-the-treatment-of-ulcerative-colitis-at-the-europe-glpg-20220202monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-subscription-right-plan-glpg-20220126monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-appoints-paul-stoffels-as-chief-executive-officer-glpg-20220126monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-subscription-right-plan-glpg-20220113monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-at-40th-annual-j-p-morgan-healthcare-conference-glpg-20220106monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-subscription-right-exercises-glpg-20211203monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-completes-patient-recruitment-for-mangrove-phase-2-trial-with-glpg2737-in-polycy-glpg-20211122monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-commercial-and-operational-progress-at-q3-financial-results-glpg-20211104monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-presents-new-data-from-the-selection-phase-3-program-at-the-united-european-gast-glpg-20211004monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-completion-of-patient-enrollment-for-diversity-phase-3-study-with-filg-glpg-20211004monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-subscription-right-exercises-glpg-20210920monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-positive-chmp-opinion-for-jyseleca-filgotinib-for-the-treatment-of-adu-glpg-20210917monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-planned-retirement-of-ceo-glpg-20210830monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-h1-financial-results-with-refocused-pipeline-and-operational-progress-glpg-20210805monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-positive-topline-results-with-selective-tyk2-inhibitor-glpg3667-in-phase-glpg-20210714monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-demonstrates-early-clinical-activity-with-sik2-3-inhibition-in-inflammation-glpg-20210714monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-new-data-supporting-rapid-symptom-improvement-and-sustained-steroid-fr-glpg-20210710monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-departure-of-cso-piet-wigerinck-later-this-year-glpg-20210622monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-subscription-right-exercises-glpg-20210607monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-data-on-rheumatoid-arthritis-at-the-upcoming-european-league-against--glpg-20210527monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-first-patient-enrolled-in-filosophy-study-to-advance-understanding-of--glpg-20210518monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-refocuses-pipeline-and-rightsizes-operations-glpg-20210506monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-subscription-right-plans-glpg-20210430monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-appoints-bart-filius-as-president-and-chief-operating-officer-glpg-20210324monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-subscription-right-exercises-glpg-20210319monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-cable-systems-and-xtera-to-deliver-advanced-submarine-network-to-ecuador-and-the-glpg-20210319monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-primary-endpoint-for-the-ongoing-filgotinib-manta-and-manta-ray-safety-s-glpg-20210304monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-gilead-discontinue-isabela-phase-3-trials-in-ipf-glpg-20210210monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-at-39th-annual-j-p-morgan-healthcare-conference-glpg-20210106monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-ceo-makes-donation-of-10-million-in-the-form-of-personal-shares-to-african-parks-glpg-20201223monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-subscription-right-exercises-glpg-20201204monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-first-dosing-in-mangrove-phase-2-trial-with-glpg2737-in-polycystic-kid-glpg-20201201monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-positive-topline-results-with-glpg1205-in-ipf-patients-in-pinta-proof-of-glpg-20201130monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-q3-2020-results-glpg-20201105monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-r-d-roundtable-showcases-toledo-program-glpg-20201027monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-servier-report-topline-results-for-roccella-phase-2-clinical-trial-with-glpg-glpg-20201015monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-first-dosing-with-toledo-compound-glpg3970-in-psoriasis-trial-glpg-20200929monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-subscription-right-exercises-glpg-20200918monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-new-insights-in-ipf-and-related-clinical-developments-at-the-european-glpg-20200826monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-that-gilead-received-a-complete-response-letter-for-filgotinib-for-the-glpg-20200818monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-solid-h1-2020-progress-glpg-20200806monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-subscription-right-exercises-glpg-20200528monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-subscription-right-plans-glpg-20200417monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-ryvu-announce-research-collaboration-glpg-20200416monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20200317monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-appoints-michele-manto-as-chief-commercial-officer-glpg-20200123monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-completes-recruitment-of-pinta-trial-in-idiopathic-pulmonary-fibrosis-glpg-20200113monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-at-38th-annual-j-p-morgan-healthcare-conference-glpg-20200109monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-completes-recruitment-of-novesa-trial-in-systemic-sclerosis-glpg-20191205monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20191125monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-from-wellington-management-group-llp-glpg-20191118monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercise-by-gilead-glpg-20191106monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-from-wellington-management-group-llp-glpg-20191025monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-from-wellington-management-group-llp-glpg-20191007monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-phase-1-trial-for-second-toledo-compound-glpg-20190924monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20190919monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20190620monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-on-historic-first-quarter-2019-glpg-20190425monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-morphosys-announce-initiation-of-gecko-phase-2-study-with-mor106-in-atopic-d-glpg-20190423monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-warrant-plans-glpg-20190410monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20190320monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-starts-first-phase-1-trial-with-toledo-compound-glpg-20190107monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-novesa-phase-2a-trial-in-patients-with-systemic-sclerosis-glpg-20190106monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-at-37th-annual-j-p-morgan-healthcare-conference-glpg-20181221monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-initiation-of-isabela-phase-3-program-with-glpg1690-in-patients-with-idi-glpg-20181217monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-fast-track-designation-from-fda-for-glpg1972-s201086-in-osteoarthritis-glpg-20181127monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20181123monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-initiation-of-pinta-phase-2-trial-with-glpg1205-in-patients-with-idiopat-glpg-20181031monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-abbvie-restructure-cf-collaboration-glpg-20181024monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20181003monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-initiation-of-global-roccella-phase-2-clinical-trial-with-glpg1972-s2010-glpg-20180924monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-issues-new-shares-as-result-of-public-offering-glpg-20180917monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-closing-of-public-offering-of-american-depositary-shares-for-gross-pro-glpg-20180917monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-morphosys-announce-start-of-a-phase-1-subcutaneous-bridging-study-with-mor10-glpg-20180913monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-raises-300-million-gross-proceeds-in-a-u-s-public-offering-glpg-20180913monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-launch-of-proposed-public-offering-glpg-20180912monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-design-for-pinta-phase-2-trial-with-glpg1205-in-ipf-glpg-20180709monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20180620monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-morphosys-announce-initiation-of-the-iguana-phase-2-clinical-trial-with-mor1-glpg-20180501monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-presents-strong-disease-modifying-effects-in-preclinical-model-of-osteoarthritis-glpg-20180427monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-first-quarter-2018-results-glpg-20180425monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-initiation-of-falcon-clinical-trial-in-cystic-fibrosis-glpg-20180424monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-warrant-plan-glpg-20180419monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-isabela-phase-3-program-in-ipf-glpg-20180412monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20180320monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-delivered-in-2017-glpg-20180222monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-morphosys-present-results-from-a-phase-1-study-with-mor106-in-atopic-dermati-glpg-20180217monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-exercises-co-promotion-option-for-filgotinib-with-collaboration-partner-gilead-s-glpg-20171214monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-enter-nasdaq-biotech-index-glpg-20171211monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20171123monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-phase-1-study-with-novel-cf-corrector-glpg3221-glpg-20171121monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-moving-forward-in-cf-programs-at-nacfc-2017-glpg-20171102monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-q3-clinical-success-with-glpg1690-and-mor106-highlights-strength-of-deep-pipelin-glpg-20171026monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-morphosys-report-first-promising-signs-of-clinical-activity-in-a-phase-1-stu-glpg-20170927monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20170921monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20170620monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-r-d-update-2017-rapidly-advancing-our-product-candidates-glpg-20170620monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-warrant-plan-glpg-20170517monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-hold-annual-r-d-update-2017-on-20-june-glpg-20170517monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-presents-three-posters-on-filgotinib-in-crohn-s-disease-at-ddw-2017-glpg-20170507monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-presents-pre-clinical-data-with-selective-adamts-5-inhibitor-glpg1972-for-osteoa-glpg-20170429monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-first-quarter-2017-results-glpg-20170427monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-new-phase-2-proof-of-concept-study-with-filgotinib-in-cutaneous-lupus--glpg-20170425monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-capital-increase-glpg-20170421monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-closing-of-public-offering-of-american-depositary-shares-for-gross-pro-glpg-20170421monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-raises-338-million-gross-proceeds-in-a-u-s-public-offering-glpg-20170418monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-launch-of-proposed-public-offering-glpg-20170417monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20170406monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-doses-first-psoriatic-arthritis-patient-with-filgotinib-glpg-20170405monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-three-new-phase-2-proof-of-concept-studies-with-filgotinib-glpg-20170404monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-phase-1-study-with-novel-cf-potentiator-glpg3067-glpg-20170322monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-doses-first-healthy-volunteer-with-cf-combo-glpg2222-and-glpg2451-glpg-20170223monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-strong-financial-results-and-newsflow-rich-pipeline-glpg-20170223monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-doses-first-patient-with-novel-cf-corrector-glpg2222-glpg-20170201monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-warrant-plan-glpg-20170120monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20161129monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-phase-1-study-with-cystic-fibrosis-drug-glpg2737-glpg-20161128monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-selected-for-stoxx-europe-600-index-glpg-20161124monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-progress-in-cf-programs-at-nacfc-2016-glpg-20161027monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20160919monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-from-federated-glpg-20160729monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-r-d-update-2016-glpg-20160615monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-selected-for-aex-index-glpg-20160609monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-warrant-plan-glpg-20160601monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20160519monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-starts-phase-1-study-with-potentiator-glpg2451-for-cf-glpg-20160509monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-abbvie-expand-their-cystic-fibrosis-collaboration-glpg-20160429monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-kick-starts-2016-with-q1-cash-position-of-eu988-m-glpg-20160428monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-additional-data-with-filgotinib-from-the-phase-2-fitzroy-study-glpg-20160421monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-morphosys-initiate-phase-1-study-in-joint-antibody-program-mor106-glpg-20160407monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-a-phase-2a-study-with-glpg1690-in-idiopathic-pulmonary-fibrosis-patien-glpg-20160406monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20160403monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20160401monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-doses-first-cf-patient-with-g551d-mutation-in-saphira-1-study-glpg-20160316monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-selected-for-bel-20-index-glpg-20160307monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-largest-cash-balance-ever-glpg-20160303monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-from-johnson-johnson-glpg-20160301monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-starts-saphira-phase-2-study-with-glpg1837-in-cystic-fibrosis-patients-glpg-20160216monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-from-wellington-management-group-llp-glpg-20160201monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-results-with-glpg1205-in-ulcerative-colitis-glpg-20160126monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-gilead-complete-closing-of-their-global-collaboration-for-filgotinib-glpg-20160119monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-advances-cf-clinical-development-glpg-20160119monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-gilead-cleared-by-us-ftc-to-close-their-global-partnership-on-filgotinib-glpg-20160113monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-warrant-plans-glpg-20151222monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-from-wellington-management-group-llp-glpg-20151222monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-gilead-announce-global-partnership-to-develop-filgotinib-for-the-treatment-o-glpg-20151217monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20151204monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-phase-1-first-in-human-study-with-glpg1972-receives-eu3-5-million-mile-glpg-20151120monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-third-quarter-2015-cash-position-of-eu374-m-glpg-20151112monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-builds-on-strong-profile-of-filgotinib-in-7-presentations-at-acr-2015-glpg-20151108monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-advances-triple-combination-therapy-in-cystic-fibrosis-glpg-20151015monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-promising-findings-in-cystic-fibrosis-programs-at-nacfc-2015-glpg-20151008monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-raises-eu1-2-million-through-warrant-exercises-glpg-20151002monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-raises-1-2-million-through-warrant-exercises-glpg-20151002monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-advance-filgotinib-to-phase-3-in-rheumatoid-arthritis-glpg-20150925monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-presents-promising-pre-clinical-and-phase-1-results-with-autotaxin-inhibitor-glp-glpg-20150922monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-on-track-to-deliver-on-pipeline-in-second-half-2015-glpg-20150805monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-selective-jak1-inhibitor-filgotinib-meets-key-efficacy-endpoints-shows-acr70-res-glpg-20150729monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-licenses-organoid-technology-from-the-hub-foundation-for-use-in-cystic-fibrosis--glpg-20150715monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-raises-eu4-4-million-through-warrant-exercises-glpg-20150619monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-raises-4-4-million-through-warrant-exercises-glpg-20150619monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-completes-recruitment-for-origin-phase-2-trial-with-glpg1205-in-ulcerative-colit-glpg-20150618monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-darwin-1-and-2-studies-have-completed-24-weeks-of-treatment-glpg-20150610monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notifications-glpg-20150526monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-closing-of-nasdaq-ipo-glpg-20150519monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-capital-increase-glpg-20150519monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-full-exercise-of-underwriters-option-to-purchase-additional-shares-glpg-20150518monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-nasdaq-glpg-to-ring-the-nasdaq-stock-market-opening-bell-glpg-20150514monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-raises-275-million-gross-proceeds-with-nasdaq-ipo-glpg-20150514monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-size-of-global-offering-increased-to-250-million-glpg-20150512monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-launch-of-proposed-global-offering-glpg-20150506monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-listed-10-years-on-euronext-amsterdam-and-brussels-glpg-20150506monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-warrant-plan-glpg-20150501monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-files-registration-statement-in-the-united-states-for-a-proposed-global-offering-glpg-20150415monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-jak1-inhibitor-filgotinib-glpg0634-meets-primary-and-other-key-efficacy-endpoint-glpg-20150414monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-raises-eu5-8-million-through-warrant-exercises-board-and-executive-committee-mem-glpg-20150327monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-raises-5-8-million-through-warrant-exercises-board-and-executive-committee-membe-glpg-20150327monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-regains-rights-to-glpg1690-announces-end-of-alliance-with-janssen-glpg-20150317monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-be-included-in-amsterdam-midcap-index-glpg-20150306monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-2014-financial-results-glpg-20150306monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-that-the-last-patient-in-darwin-1-has-completed-12-weeks-of-treatment-glpg-20150223monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-positive-phase-1-results-for-glpg1690-glpg-20150216monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-eu1-6-million-iwt-grant-for-hepatitis-b-program-glpg-20150211monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-1-6-million-iwt-grant-for-hepatitis-b-program-glpg-20150211monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-eu2-5-million-iwt-grant-for-antibiotic-research-glpg-20150122monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-2-5-million-iwt-grant-for-antibiotic-research-glpg-20150122monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-starts-phase-2-trial-with-glpg1205-in-ulcerative-colitis-patients-glpg-20150108monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-first-phase-1-study-in-cystic-fibrosis-and-will-receive-milestone-paym-glpg-20141219monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-regains-full-rights-to-gpr84-inhibitor-glpg1205-glpg-20141216monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-selects-second-component-of-its-investigational-cystic-fibrosis-combination-trea-glpg-20141212monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20141209monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-completes-recruitment-for-darwin-2-monotherapy-study-with-glpg0634-filgotinib-in-glpg-20141124monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-presents-clean-drug-drug-interaction-profile-with-glpg0634-filgotinib-at-acr-201-glpg-20141117monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-completes-recruitment-for-darwin-1-study-with-glpg0634-filgotinib-in-ra-glpg-20141112monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-calchan-collaborate-on-osteoarthritis-research-ps2-4-million-grant-awarded-b-glpg-20141027monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-discloses-novel-target-and-presents-favorable-phase-1-data-for-glpg1205-at-ueg-w-glpg-20141020monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-warrant-plan-glpg-20141017monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-presents-novel-cystic-fibrosis-combination-therapy-at-nacfc-glpg-20141009monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20140925monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-high-participation-rate-in-long-term-extension-study-with-glpg0634-in-ra-glpg-20140918monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-cash-position-of-eu232-m-provides-solid-basis-for-r-d-pipeline-investment-glpg-20140808monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-cash-position-of-232-m-provides-solid-basis-for-r-d-pipeline-investment-glpg-20140808monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-milestone-in-osteoarthritis-alliance-with-servier-glpg-20140805monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-warrant-plan-glpg-20140725monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-raises-eu1-9-million-through-warrant-exercises-glpg-20140704monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-raises-1-9-million-through-warrant-exercises-glpg-20140704monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-phase-1-study-with-glpg1690-triggering-eu6-6-m-milestone-in-the-allian-glpg-20140701monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-cystic-fibrosis-program-progresses-towards-therapy-for-largest-patient-group-glpg-20140617monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-hold-annual-r-d-update-on-17-june-2014-in-new-york-glpg-20140512monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-management-change-glpg-20140428monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-raises-eu2-4-million-through-warrant-exercises-glpg-20140410monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-raises-2-4-million-through-warrant-exercises-glpg-20140410monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-favorable-pre-clinical-data-on-glpg1790-a-selective-ephrin-receptor-k-glpg-20140318monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-2013-financial-results-glpg-20140307monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-eu2-million-from-osteoarthritis-alliance-with-servier-glpg-20140307monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-2-million-from-osteoarthritis-alliance-with-servier-glpg-20140307monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-provides-status-update-for-gsk2586184-in-gsk-s-psoriasis-lupus-and-ulcerative-co-glpg-20140228monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-glpg0634-and-glpg0974-at-international-conference-on-ibd-glpg-20140221monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-completes-patient-recruitment-in-proof-of-concept-study-with-glpg0974-in-ulcerat-glpg-20140217monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-eu2-3-million-iwt-grant-for-fibrosis-research-glpg-20140203monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-2-3-million-iwt-grant-for-fibrosis-research-glpg-20140203monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-eu2-9-million-iwt-grant-for-cystic-fibrosis-research-glpg-20140113monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-2-9-million-iwt-grant-for-cystic-fibrosis-research-glpg-20140113monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-selects-pre-clinical-candidate-for-cystic-fibrosis-glpg-20131216monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20131206monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-positive-phase-1-results-for-glpg1205-glpg-20131204monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-gsk2586184-jak1-molecule-moves-into-phase-2-for-ulcerative-colitis-glpg-20131127monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-that-biofocus-has-signed-an-integrated-drug-discovery-collaboration-wi-glpg-20131120monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-business-update-glpg-20131115monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-subsidiary-biofocus-signs-agreement-with-biogen-idec-in-scleroderma-glpg-20131112monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20131021monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-presents-superior-potentiator-series-for-cf-glpg-20131017monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-phase-1-data-on-ffa2-antagonist-glpg0974-at-ueg-week-in-berlin-glpg-20131016monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-glpg0634-at-acr-glpg-20131016monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-warrant-plan-glpg-20130918monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-appoints-david-smith-as-ceo-of-service-division-glpg-20130820monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-half-year-revenues-up-21-glpg-20130809monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-delivers-novel-osteoarthritis-molecules-in-alliance-with-servier-glpg-20130723monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-2-4-million-iwt-grant-for-psoriasis-research-glpg-20130708monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-phase-1-trial-as-part-of-its-alliance-with-janssen-pharmaceutica-nv-glpg-20130702monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20130701monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-presents-glpg0634-at-eular-poster-session-glpg-20130613monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-warrant-plan-glpg-20130517monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-business-update-glpg-20130517monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-three-posters-on-glpg0634-at-eular-glpg-20130513monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-completes-private-placement-by-issuance-of-2-696-831-new-ordinary-shares-glpg-20130429monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-raises-54-million-glpg-20130424monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-raise-capital-via-a-private-placement-of-new-shares-glpg-20130424monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-starts-phase-2a-study-with-glpg0974-in-ulcerative-colitis-glpg-20130423monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-discovers-novel-candidate-drug-to-treat-breast-cancer-glpg-20130422monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-presents-scope-of-glpg0634-phase-2b-program-glpg-20130416monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20130408monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-gives-r-d-update-glpg-20130327monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-start-phase-2a-study-with-glpg0974-in-ibd-patients-glpg-20130327monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-host-annual-r-d-update-on-27-march-glpg-20130320monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-record-revenues-in-2012-increasing-momentum-in-clinical-pipeline-glpg-20130308monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-roche-conclude-strategic-alliance-glpg-20130308monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-7-5-million-in-servier-alliances-glpg-20130306monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-gsk2586184-jak1-molecule-progresses-to-phase-2-studies-glpg-20130205monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-2-5-million-iwt-grant-for-ibd-research-glpg-20130130monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-delivers-candidate-drug-in-its-alliance-with-janssen-pharmaceutica-nv-and-receiv-glpg-20130116monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-fidelta-a-third-galapagos-service-division-glpg-20130115monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-acquires-cangenix-a-structure-based-drug-discovery-company-glpg-20130115monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-2-7-million-iwt-grant-for-antibacterial-research-glpg-20130110monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-delivers-candidate-drug-in-gsk-alliance-and-receives-milestone-payment-glpg-20130109monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-at-the-31st-annual-j-p-morgan-healthcare-conference-glpg-20130106monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20121217monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-opens-ind-for-glpg0634-in-the-us-glpg-20121203monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-discovers-novel-class-of-antibiotics-glpg-20121126monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-business-update-glpg-20121116monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-positive-ruling-on-patent-income-deduction-glpg-20121112monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-second-phase-i-study-with-glpg0974-glpg-20121024monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20120914monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-warrant-plans-glpg-20120903monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-subsidiary-biofocus-and-ono-sign-a-drug-discovery-agreement-in-the-field-of-cns--glpg-20120903monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-delivers-solid-half-year-results-2012-glpg-20120803monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-delivers-candidate-drug-in-osteoarthritis-alliance-with-servier-glpg-20120724monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20120629monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-wins-2012-european-mediscience-awards-glpg-20120622monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-glpg0634-phase-ii-poc-results-at-eular-glpg-20120605monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-glpg-20120523monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-nv-business-update-glpg-20120518monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-phase-iia-study-with-glpg0634-glpg-20120514monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-egm-convocation-glpg-20120427monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-gives-r-d-update-glpg-20120418monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20120405monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-nv-convocation-annual-general-shareholder-meeting-glpg-20120323monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-delivers-candidate-drug-in-its-alliance-with-janssen-pharmaceutica-nv-and-receiv-glpg-20120321monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-glpg-20120306monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-nv-pipeline-promise-confirmed-mixed-financial-results-for-2011-but-with-excellen-glpg-20120302monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-3-5-million-in-milestones-in-osteoarthritis-alliance-with-servier-glpg-20120302monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-gsk-decision-to-exercise-option-for-investigational-medicines-glpg0778-glpg-20120221monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-clinical-study-with-glpg0974-the-first-anti-inflammatory-candidate-dru-glpg-20111221monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20111219monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-achieves-clinical-proof-of-mechanism-milestone-in-gsk-alliance-glpg-20111219monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-4-million-in-milestones-from-servier-in-their-osteoarthritis-alliance-glpg-20111215monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-glpg0634-shows-excellent-efficacy-and-safety-in-rheumatoid-arthritis-phase-ii-st-glpg-20111122monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-business-update-glpg-20111110monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-results-for-selective-jak1-inhibitor-in-rheumatoid-arthritis-patients-glpg-20111107monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-wins-2011-scrip-award-for-biotech-company-of-the-year-glpg-20111104monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-second-extension-to-services-collaboration-with-chiesi-glpg-20111012monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-genentech-extend-drug-discovery-collaboration-glpg-20110818monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-half-year-results-2011-glpg-20110805monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-proof-of-mechanism-clinical-study-for-candidate-cachexia-drug-glpg0492-glpg-20110720monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20110701monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-phase-ii-trial-for-glpg0634-glpg-20110609monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-deliver-four-presentations-at-eular-2011-glpg-20110524monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-approval-of-all-egm-proposals-creates-new-warrant-plans-glpg-20110523monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-business-update-glpg-20110513monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notifications-glpg-20110512monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-second-proof-of-mechanism-clinical-study-in-gsk-alliance-glpg-20110511monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-delivers-validated-oncology-targets-to-janssen-glpg-20110420monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-discontinues-phase-ii-trial-for-glpg0259-focuses-resources-on-other-rheumatoid-a-glpg-20110415monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20110330monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-starts-phase-ib-clinical-study-in-cancer-patients-glpg-20110314monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-record-revenues-and-increased-profitability-in-2010-glpg-20110304monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-delivers-candidate-drug-in-gsk-alliance-receives-6-7-million-glpg-20110302monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-4-million-in-milestones-from-servier-glpg-20110208monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-warrant-plan-glpg-20110207monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-2-7-million-grant-for-antiviral-drug-discovery-glpg-20110207monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-merck-co-inc-agree-to-end-strategic-alliances-glpg-20110204monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-achieves-137-million-revenues-in-2010-outlook-for-continued-strong-2011-performa-glpg-20110204monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-7-4-m-milestone-in-arthritis-alliance-with-glaxosmithkline-glpg-20110111monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-affiliate-biofocus-extends-collaboration-with-amgen-into-2012-glpg-20101217monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-achieves-milestones-broadens-scope-of-roche-alliance-glpg-20101216monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-glpg-20101207monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-candidate-cachexia-drug-glpg0492-shows-good-safety-and-profile-suitable-for-once-glpg-20101202monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-business-update-glpg-20101112monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notification-glpg-20101101monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-3-7-million-grant-for-cystic-fibrosis-program-glpg-20101028monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-transparency-notifications-glpg-20101027monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-completes-private-placement-by-issuance-of-2-389-347-new-ordinary-shares-glpg-20101022monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-successfully-completes-placement-of-2-389-347-new-ordinary-shares-glpg-20101019monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-offering-of-new-ordinary-shares-glpg-20101018monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-achieves-milestones-in-two-strategic-alliances-glpg-20101018monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-affiliate-biofocus-extends-collaboration-with-chiesi-glpg-20101014monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-the-national-cancer-institute-sign-compound-management-agreement-glpg-20101012monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-wins-2010-european-biotechnica-award-glpg-20101005monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-affiliate-argenta-and-janssen-pharmaceutica-enter-in-integrated-cancer-drug-disc-glpg-20101004monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-starts-phase-ii-clinical-trial-in-rheumatoid-arthritis-patients-glpg-20100928monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reaches-agreement-to-acquire-glaxosmithkline-research-centre-in-zagreb-croatia-glpg-20100908monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-appointment-of-howard-rowe-to-board-of-directors-increases-share-capit-glpg-20100907monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-half-year-results-in-line-with-full-year-guidance-glpg-20100806monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-phase-i-study-for-jak-inhibitor-glpg0634-acquires-full-rights-to-compo-glpg-20100806monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-university-of-bristol-enter-drug-discovery-collaboration-in-chronic-pain-glpg-20100716monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-receives-transparency-notifica-glpg-20100628monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-achieves-milestones-in-osteoporosis-alliance-glpg-20100525monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-clinical-studies-with-glpg0492-a-candidate-drug-for-cachexia-glpg-20100520monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-business-update-glpg-20100514monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-roche-expand-copd-alliance-glpg-20100511monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-chdi-foundation-inc-enter-new-five-year-collaboration-for-huntington-s-disea-glpg-20100429monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-appointment-of-ronald-brus-to-board-creates-new-warrant-plans-glpg-20100428monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-glpg0187-first-in-human-trial-results-cancelled-glpg-20100419monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-raises-2-1-million-from-warrant-exercises-management-increases-shareholding-glpg-20100408monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-build-cystic-fibrosis-drug-pipeline-glpg-20100319monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-record-revenues-and-net-profit-for-2009-foresees-sustained-profitability-glpg-20100305monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-successfully-completes-phase-i-clinical-trials-for-rheumatoid-arthritis-candidat-glpg-20100223monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-delivers-third-candidate-drug-in-gsk-alliance-receives-5-7-million-glpg-20100222monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-morphosys-expand-antibody-alliance-glpg-20100218monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-acquires-argenta-discovery-s-service-operations-glpg-20100202monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-delivers-strong-2009-performance-expects-positive-operating-income-in-2010-glpg-20100129monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-candidate-metastasis-drug-shows-good-safety-and-biomarker-response-glpg-20100119monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-achieves-milestones-in-strategic-alliances-with-merck-co-inc-glpg-20100115monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-service-division-achieves-eur-1-6-m-in-payments-glpg-20100112monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-roche-initiate-strategic-alliance-in-copd-glpg-20100111monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-glaxosmithkline-broaden-arthritis-alliance-glpg-20091216monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-4-m-milestone-for-first-clinical-trial-in-glaxosmithkline-alliance-glpg-20091208monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-ceo-increases-shareholding-glpg-20091207monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-achieves-multiple-milestones-in-rheumatoid-arthritis-alliance-glpg-20091203monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-receives-eureka-innovation-label-and-oseo-funding-glpg-20091126monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-nanocort-phase-ii-clinical-trial-for-multiple-sclerosis-glpg-20091117monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-business-update-glpg-20091113monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-successfully-completes-placement-of-2-125-925-new-ordinary-shares-glpg-20091016monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-offering-of-new-ordinary-shares-glpg-20091015monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-expands-strategic-alliance-in-metabolic-disease-with-merck-co-inc-glpg-20091014monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-achieves-first-milestone-in-anti-infectives-alliance-with-glaxosmithkline-glpg-20091007monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-expanded-drug-discovery-collaboration-with-schering-plough-glpg-20090924monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-collaborates-with-charley-s-fund-nash-avery-foundation-to-develop-sarm-candidate-glpg-20090917monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-second-phase-i-clinical-trial-for-glpg0259-glpg-20090910monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-revenue-growth-and-improved-net-result-in-1h-2009-glpg-20090807monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-successfully-completes-first-phase-i-study-for-glpg0259-glpg-20090806monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-achieves-milestone-in-osteoporosis-collaboration-with-lilly-glpg-20090723monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-delivers-second-pre-clinical-candidate-in-alliance-with-glaxosmithkline-and-rece-glpg-20090707monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-awarded-innovative-enterprise-qualification-in-france-glpg-20090630monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-initiates-clinical-studies-with-glpg0187-a-candidate-drug-for-bone-metastasis-glpg-20090616monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-appointment-of-new-cfo-and-board-member-creates-new-warrant-plan-glpg-20090603monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-achieves-milestone-payment-in-rheumatoid-arthritis-alliance-glpg-20090528monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-business-update-glpg-20090515monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-opsona-therapeutics-initiate-drug-discovery-collaboration-glpg-20090421monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-enters-strategic-alliance-in-inflammatory-diseases-with-merck-co-inc-glpg-20090420monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-creates-new-warrant-plan-glpg-20090401monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-enters-the-clinic-with-rheumatoid-arthritis-candidate-drug-glpg-20090327monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-to-present-r-d-update-on-27-march-2009-glpg-20090323monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-confirms-2008-financial-results-foresees-strong-growth-in-2009-glpg-20090306monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reveals-key-drug-target-for-alzheimer-s-disease-glpg-20090213monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-awarded-grant-to-accelerate-drug-discovery-glpg-20090211monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-2008-trading-update-and-2009-guidance-glpg-20090128monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-glaxosmithkline-expand-anti-infectives-alliance-glpg-20090119monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-achieves-milestone-payments-for-rheumatoid-arthritis-alliance-glpg-20090114monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-enters-strategic-alliance-in-diabetes-and-obesity-with-merck-co-inc-glpg-20090109monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-delivers-pre-clinical-candidate-drug-in-alliance-with-glaxosmithkline-and-receiv-glpg-20090105monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-selects-pre-clinical-candidate-drug-for-cachexia-glpg-20090105monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-glaxosmithkline-expand-osteoarthritis-alliance-glpg-20081222monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-extends-drug-discovery-collaboration-with-amgen-into-2010-glpg-20081218monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-dart-neuroscience-llc-sign-drug-discovery-and-compound-management-agreements-glpg-20081209monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-merck-serono-enter-new-collaboration-agreements-glpg-20081118monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-business-update-glpg-20081114monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-sells-san-diego-chemistry-facility-to-chemventures-glpg-20081105monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-and-chdi-enter-new-collaboration-agreements-glpg-20081029monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-acquires-structure-based-drug-discovery-from-sareum-glpg-20080826monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-transfers-predictive-drug-discovery-databases-to-embl-s-european-bioinformatics--glpg-20080723monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-first-milestone-in-osteoporosis-collaboration-with-lilly-glpg-20080718monthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-technology-group-participated-in-2026-cba-china-annual-conference-wok-20260605monthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-technology-group-ltd-announces-1-for-100-reverse-stock-split-effective-decemb-wok-20251224monthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-technology-group-ltd-receives-nasdaq-notification-regarding-minimum-bid-price-wok-20250411monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-first-quarter-2025-financial-results-and-updates-on-clinica-snse-20250506monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-favorable-preliminary-dose-expansion-data-for-solnerstotug--snse-20250327monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-oppenheimer-s-35th-annual-healthcare-life-science-snse-20250204monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-provides-corporate-update-and-highlights-key-upcoming-milestones-snse-20250108monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-citi-s-2024-global-healthcare-conference-snse-20241127monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-third-quarter-2024-financial-results-and-recent-business-hi-snse-20241114monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-present-at-two-upcoming-scientific-conferences-snse-20241029monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-present-preclinical-data-on-sns-103-at-the-cri-enci-eighth-inter-snse-20240904monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-present-at-upcoming-conferences-snse-20240904monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-second-quarter-2024-financial-results-and-recent-business-h-snse-20240806monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-jefferies-global-healthcare-conference-snse-20240530monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-presents-promising-clinical-data-from-phase-1-dose-escalation-study-snse-20240523monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-first-quarter-2024-financial-results-and-recent-business-hi-snse-20240509monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-present-topline-clinical-data-from-the-sns-101-phase-i-dose-esca-snse-20240424monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-canaccord-genuity-s-horizons-in-oncology-virtual--snse-20240409monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-announces-nature-communications-publication-describing-mechanism-of-snse-20240404monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-the-3rd-annual-vista-symposium-snse-20240322monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-present-new-preclinical-data-at-upcoming-scientific-conferences-snse-20240306monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-full-year-2023-financial-results-and-recent-business-highli-snse-20240228monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-present-at-upcoming-conferences-snse-20240207monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-provides-corporate-update-and-highlights-key-upcoming-milestones-snse-20240104monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-third-quarter-2023-financial-results-and-recent-business-hi-snse-20231107monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-favorable-clinical-data-for-sns-101-at-2023-sitc-annual-mee-snse-20231103monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-appoints-stephanie-krebs-ms-mba-as-chief-business-officer-snse-20231101monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-present-initial-clinical-data-from-dose-escalation-trial-of-sns--snse-20231025monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-presents-trial-in-progress-poster-for-phase-1-2-clinical-study-of-s-snse-20231023monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-announces-initiation-of-combination-arm-for-phase-1-2-clinical-stud-snse-20230927monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-presents-new-preclinical-data-reinforcing-sns-101-pharmacokinetic-p-snse-20230921monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-present-new-preclinical-data-supporting-mechanism-of-action-phar-snse-20230913monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-upcoming-investor-conferences-snse-20230830monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-second-quarter-2023-financial-results-and-recent-business-h-snse-20230803monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-canaccord-genuity-s-43rd-annual-growth-conference-snse-20230802monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-host-virtual-key-opinion-leader-event-a-new-vista-for-cancer-car-snse-20230613monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-announces-first-patient-dosed-in-phase-1-2-clinical-trial-of-sns-10-snse-20230601monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-jefferies-global-healthcare-conference-snse-20230531monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-first-quarter-2023-financial-results-and-recent-business-hi-snse-20230509monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-announces-ind-clearance-by-u-s-fda-enabling-phase-1-initiation-for--snse-20230420monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-presents-new-preclinical-data-on-sns-103-targeting-entpdase1-cd39-a-snse-20230418monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-canaccord-genuity-s-horizons-in-oncology-virtual--snse-20230413monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-cantor-fitzgerald-s-future-of-oncology-virtual-sy-snse-20230330monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-full-year-2022-financial-results-and-recent-business-highli-snse-20230328monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-announces-submission-of-investigational-new-drug-ind-application-fo-snse-20230321monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active--snse-20230314monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-adopts-stockholder-rights-agreement-snse-20230307monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-oppenheimer-s-33rd-annual-healthcare-conference-snse-20230306monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista--snse-20230221monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-citi-s-2023-virtual-oncology-leadership-summit-snse-20230216monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-101-a-conditionally-active--snse-20230214monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-signs-cooperative-research-and-development-agreement-crada-with-the-snse-20230206monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-announces-clinical-supply-agreement-with-regeneron-for-phase-1-2-cl-snse-20230105monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-provides-update-on-strategic-priorities-snse-20221208monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conferen-snse-20221122monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-announces-collaboration-with-washington-university-st-louis-to-supp-snse-20221121monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-presents-preclinical-data-at-the-37th-society-for-immunotherapy-of--snse-20221110monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-third-quarter-2022-financial-results-and-recent-business-hi-snse-20221108monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-host-virtual-key-opinion-leader-webinar-lessons-from-vista-new-s-snse-20221107monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-the-13th-annual-jefferies-global-healthcare-confe-snse-20221102monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-present-new-preclinical-data-at-the-society-for-immunotherapy-of-snse-20221005monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista--snse-20220930monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-present-preclinical-data-for-sns-101-a-conditionally-active-vist-snse-20220921monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-announces-new-preclinical-data-demonstrating-favorable-pharmacokine-snse-20220831monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-upcoming-investor-conferences-snse-20220823monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-second-quarter-2022-financial-results-and-recent-business-h-snse-20220809monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-appoints-patrick-gallagher-mba-mph-as-chief-business-officer-snse-20220601monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-jefferies-healthcare-conference-snse-20220525monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-first-quarter-2022-financial-results-and-recent-business-hi-snse-20220510monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-full-year-2021-financial-results-and-business-highlights-snse-20220310monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-appoints-william-ringo-mba-as-chair-of-board-of-directors-snse-20220309monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-the-32nd-annual-oppenheimer-healthcare-conference-snse-20220303monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-citi-s-2022-virtual-immuno-oncology-summit-snse-20220211monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-announces-executive-promotions-snse-20220106monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-named-a-winner-of-comparably-s-best-ceo-award-snse-20211216monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-announces-addition-to-the-nasdaq-biotechnology-index-snse-20211213monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-the-piper-sandler-33rd-annual-healthcare-conferen-snse-20211119monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-ph-selective-anti-vista-ant-snse-20211112monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-third-quarter-2021-results-and-recent-business-highlights-snse-20211109monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-participate-in-the-berenberg-virtual-u-s-ceo-conference-on-tuesd-snse-20211103monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-101-a-proprietary-anti-vist-snse-20211001monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-second-quarter-2021-results-and-highlights-recent-in-vivo-d-snse-20210804monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-appoints-kristian-humer-to-its-board-of-directors-snse-20210802monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-announces-prioritization-of-next-generation-multi-antigenic-immunop-snse-20210628monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-announces-new-clinical-data-from-the-ongoing-phase-1-2-combination--snse-20210519monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-first-quarter-2021-results-and-provides-business-update-snse-20210512monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-appoints-maura-gillison-m-d-ph-d-and-richard-ulevitch-ph-d-to-its-i-snse-20210505monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-appoints-jessie-m-english-ph-d-to-its-board-of-directors-snse-20210405monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-full-year-2020-results-and-provides-business-update-snse-20210325monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-announces-inclusion-in-russell-2000-index-snse-20210322monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-to-present-at-oppenheimer-31st-annual-virtual-healthcare-conference-snse-20210309monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-announces-closing-of-initial-public-offering-snse-20210210monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-announces-pricing-of-upsized-initial-public-offering-snse-20210204monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-exclusive-license-to-lasofoxifene-phase-3-development-program-for--atha-20251218monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reports-second-quarter-2025-financial-results-and-provides-business-update-atha-20250807monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reports-first-quarter-2025-financial-results-and-pipeline-and-business-updat-atha-20250509monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-presents-preclinical-data-highlighting-neuroprotective-effects-of-ath-1105-i-atha-20241206monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reports-third-quarter-2024-financial-results-and-pipeline-and-business-updat-atha-20241107monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-present-results-from-phase-2-3-lift-ad-clinical-trial-of-fosgonimeton-at--atha-20241022monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-focus-on-advancement-of-ath-1105-for-the-treatment-of-neurodegenerative-d-atha-20240917monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-topline-results-from-phase-2-3-lift-ad-clinical-trial-of-fosgonime-atha-20240903monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reports-second-quarter-2024-financial-results-and-pipeline-and-business-upda-atha-20240801monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-presents-preclinical-data-demonstrating-new-insights-into-the-mechanism-by-w-atha-20240731monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-last-patient-completed-lift-ad-clinical-trial-of-fosgonimeton-in-m-atha-20240709monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-completes-first-cohort-in-phase-1-clinical-trial-of-ath-1105-an-oral-small-m-atha-20240611monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-participate-in-upcoming-june-conferences-atha-20240529monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-proposed-settlement-of-stockholder-derivative-action-atha-20240517monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reports-first-quarter-2024-financial-results-and-pipeline-and-business-updat-atha-20240515monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-participate-in-upcoming-may-conferences-atha-20240502monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-appoints-javier-san-martin-m-d-as-chief-medical-officer-atha-20240415monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-publication-of-preclinical-data-highlighting-fosgonimeton-treatmen-atha-20240411monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-upcoming-poster-presentation-at-american-academy-of-neurology-aan--atha-20240403monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-presents-clinical-and-preclinical-data-supporting-therapeutic-potential-of-f-atha-20240308monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reports-full-year-2023-financial-results-and-pipeline-and-business-updates-atha-20240222monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-publication-in-frontiers-in-neuroscience-highlighting-therapeutic--atha-20240208monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-provides-2024-clinical-pipeline-outlook-and-business-update-atha-20240108monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-completes-enrollment-of-phase-2-3-lift-ad-clinical-trial-of-fosgonimeton-in--atha-20240103monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-encouraging-results-from-shape-phase-2-clinical-trial-of-fosgonime-atha-20231212monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-participate-in-sidoti-december-small-cap-investor-conference-atha-20231129monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reports-third-quarter-2023-financial-results-and-pipeline-and-business-updat-atha-20231109monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-participate-in-jefferies-london-healthcare-conference-atha-20231108monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-presents-preclinical-data-further-supporting-the-therapeutic-potential-of-at-atha-20231005monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-participate-in-upcoming-october-conferences-atha-20230928monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-participate-in-the-2023-cantor-fitzgerald-global-healthcare-conference-atha-20230919monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reports-second-quarter-2023-financial-results-and-pipeline-and-business-upda-atha-20230810monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-presents-phase-2-clinical-data-correlating-improvements-in-biomarkers-of-neu-atha-20230717monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-upcoming-presentations-at-the-alzheimer-s-association-internationa-atha-20230706monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-participate-in-upcoming-june-conferences-atha-20230531monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-appoints-andrew-gengos-as-chief-financial-officer-and-chief-business-officer-atha-20230522monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reports-first-quarter-2023-financial-results-and-recent-pipeline-and-busines-atha-20230511monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-participate-in-upcoming-may-investor-conferences-atha-20230508monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-presents-new-clinical-and-preclinical-data-at-the-american-academy-of-neurol-atha-20230425monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-20-atha-20230411monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-f-atha-20230328monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reports-full-year-2022-financial-results-and-recent-pipeline-and-business-up-atha-20230323monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-present-at-upcoming-neuroscience-focused-investor-conferences-atha-20230308monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-present-data-supporting-therapeutic-potential-of-enhancing-hgf-met-neurot-atha-20230306monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-publication-in-journal-of-alzheimer-s-disease-highlighting-need-fo-atha-20230201monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-promotion-of-kevin-church-ph-d-to-chief-scientific-officer-atha-20230131monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-provides-2023-pipeline-outlook-atha-20230105monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-publication-of-fosgonimeton-preclinical-results-in-neurotherapeuti-atha-20221221monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-ath-1105-in-al-atha-20221205monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-host-virtual-r-d-event-on-december-7-2022-from-2-00-3-30-pm-eastern-time-atha-20221201monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-highlights-therapeutic-potential-of-fosgonimeton-in-presentation-of-addition-atha-20221129monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-present-preclinical-data-highlighting-therapeutic-potential-of-ath-1105-i-atha-20221128monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-present-additional-biomarker-data-from-act-ad-phase-2-study-of-fosgonimet-atha-20221121monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-hgf-met-platfo-atha-20221116monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reports-third-quarter-2022-financial-results-and-recent-clinical-and-corpora-atha-20221110monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-present-at-stifel-2022-healthcare-conference-atha-20221109monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-present-preclinical-data-highlighting-therapeutic-potential-of-hgf-met-pl-atha-20221107monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-advances-phase-2-3-lift-ad-clinical-study-of-fosgonimeton-in-mild-to-moderat-atha-20221017monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-provides-update-on-plans-for-ongoing-lift-ad-clinical-study-of-fosgonimeton--atha-20220906monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reports-second-quarter-2022-financial-results-and-recent-clinical-and-corpor-atha-20220815monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-presents-data-from-act-ad-phase-2-proof-of-concept-clinical-study-of-fosgoni-atha-20220803monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-presents-preclinical-data-at-the-alzheimer-s-association-international-confe-atha-20220802monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-present-clinical-and-preclinical-data-at-alzheimer-s-association-internat-atha-20220725monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-topline-results-from-act-ad-phase-2-proof-of-concept-study-of-fosg-atha-20220622monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-formation-of-scientific-advisory-board-comprised-of-renowned-leade-atha-20220607monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-presents-preclinical-data-at-the-2022-peripheral-nerve-society-pns-annual-me-atha-20220516monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reports-first-quarter-2022-financial-results-and-provides-pipeline-and-busin-atha-20220512monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-extends-ongoing-open-label-extension-study-for-lift-ad-and-act-ad-clinical-t-atha-20220509monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-doses-first-subject-in-phase-1-clinical-trial-of-hgf-met-positive-modulator--atha-20220404monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-highlights-strong-execution-of-strategy-and-positioning-for-the-future-atha-20220330monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reports-full-year-2021-financial-results-and-provides-clinical-update-atha-20220324monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-appointment-of-dr-michael-a-panzara-to-its-board-of-directors-atha-20220321monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-participate-in-two-upcoming-investor-conferences-atha-20220321monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-presents-study-overview-and-baseline-data-from-act-ad-phase-2-trial-of-fosgo-atha-20220320monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-host-fourth-quarter-and-full-year-2021-financial-results-and-business-upd-atha-20220317monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-present-overview-and-update-from-act-ad-phase-2-trial-of-fosgonimeton-ath-atha-20220314monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-presents-preclinical-data-of-fosgonimeton-ath-1017-and-ath-1020-at-the-ameri-atha-20220302monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-present-preclinical-data-at-the-american-society-for-experimental-neuroth-atha-20220222monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-publication-of-phase-1-results-for-fosgonimeton-ath-1017-in-the-jo-atha-20220222monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-appointment-of-grant-pickering-to-its-board-of-directors-atha-20220131monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-initiation-of-patient-dosing-in-shape-a-phase-2-clinical-trial-of--atha-20220125monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-provides-2022-pipeline-outlook-atha-20220105monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reports-third-quarter-2021-financial-results-and-business-update-atha-20211110monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-presents-overview-and-update-from-act-ad-and-lift-ad-trials-of-ath-1017-in-m-atha-20211110monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-present-at-upcoming-investor-conferences-atha-20211108monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-host-educational-webinar-on-the-clinical-applications-of-erp-p300-atha-20211029monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-completion-of-enrollment-in-phase-2-act-ad-trial-evaluating-ath-10-atha-20211022monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-leadership-changes-mark-litton-ph-d-m-b-a-named-president-and-chie-atha-20211021monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-present-updates-from-phase-2-3-trials-of-ath-1017-at-the-2021-clinical-tr-atha-20210929monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit--atha-20210824monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at-the--atha-20210823monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit--atha-20210817monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reports-second-quarter-2021-financial-results-and-business-update-atha-20210816monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-mourns-the-loss-of-chair-of-board-of-directors-tadataka-yamada-m-d-atha-20210805monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit--atha-20210730monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimer-s-associatio-atha-20210719monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-initiation-of-open-label-extension-study-for-lift-ad-and-act-ad-cl-atha-20210706monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit--atha-20210628monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-investor-alert-have-you-suffered-losses-greater-than-100-000-investing-in-at-atha-20210628monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-tha-atha-20210628monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-investor-alert-kaplan-fox-investigates-potential-securities-violations-at-at-atha-20210624monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-inc-investors-company-investigated-by-the-portnoy-law-firm-atha-20210618monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-chief-operating-officer-mark-litton-assumes-day-to-day-leadership-responsibi-atha-20210617monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-appoints-rachel-lenington-as-chief-technology-officer-head-of-product-develo-atha-20210614monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-present-at-upcoming-investor-conferences-atha-20210609monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-appoints-mark-worthington-as-general-counsel-atha-20210601monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-present-at-upcoming-investor-conferences-atha-20210526monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reports-first-quarter-2021-financial-results-and-provides-business-highlight-atha-20210513monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-participate-in-panel-discussion-at-sachs-4th-annual-neuroscience-innovati-atha-20210421monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-host-educational-webinar-on-targeting-hgf-met-a-naturally-occurring-neuro-atha-20210408monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-bus-atha-20210325monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-present-at-stifel-s-3rd-annual-cns-conference-atha-20210324monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-participate-in-panel-and-corporate-presentations-at-life-science-innovati-atha-20210323monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors-atha-20210308monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-present-at-h-c-wainwright-co-global-life-sciences-conference-atha-20210302monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-exercise-of-underwriters-option-to-purchase-additional-shares-atha-20210210monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-pricing-of-public-offering-of-common-stock-atha-20210121monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-proposed-public-offering-of-common-stock-atha-20210119monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-atha-20210107monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-announces-appointment-of-kelly-a-romano-to-its-board-of-directors-atha-20201214monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-to-present-at-bio-investor-forum-glyc-20141003monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-announces-a-delay-in-the-initiation-of-the-phase-3-trial-with-rivipansel-glyc-20140926monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-to-present-at-biocentury-s-21st-annual-newsmakers-in-the-biotech-industry-co-glyc-20140922monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-inc-glyc-to-ring-the-nasdaq-stock-market-closing-bell-glyc-20140410monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-inc-files-voluntary-petitions-for-relief-under-chapter-11-lipo-20260331monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-issues-letter-from-the-ceo-to-stockholders-following-nasdaq-delist-lipo-20250625monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-reports-positive-topline-phase-2a-results-for-lp-310-in-the-treatm-lipo-20250211monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-granted-fda-approval-for-expanded-access-program-for-lp-310-in-ora-lipo-20250206monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-announces-publication-in-cureus-on-non-steroid-treatment-of-oral-l-lipo-20241203monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-announces-completion-of-first-cohort-in-phase-2a-trial-of-lp-310-f-lipo-20241121monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-secures-extended-market-exclusivity-with-issuance-of-u-s-patent-fo-lipo-20241112monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-announces-1-for-8-reverse-stock-split-lipo-20241101monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-to-present-at-2024-spartan-capital-investor-conference-lipo-20241029monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-announces-u-s-patent-allowance-for-innovative-liposomal-drug-deliv-lipo-20241015monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-to-present-at-2024-maxim-healthcare-virtual-summit-lipo-20241009monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-reports-encouraging-early-tolerability-results-in-phase-2a-trial-o-lipo-20240924monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-to-participate-at-h-c-wainwright-s-26th-annual-global-investment-c-lipo-20240827monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-launches-innovative-registry-to-advance-oral-lichen-planus-researc-lipo-20240822monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-unveils-advanced-bladder-imaging-technique-at-icicj-conference-lipo-20240821monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-doses-first-two-patients-in-phase-2a-oral-lichen-planus-clinical-t-lipo-20240812monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-announces-closing-of-1-28-million-registered-direct-offering-of-co-lipo-20240801monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-announces-1-28-million-registered-direct-offering-of-common-stock--lipo-20240801monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-initiates-phase-2a-trial-for-lp-310-in-oral-lichen-planus-enrolls--lipo-20240729monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-announces-completion-of-site-initiation-visit-for-phase-2a-trial-o-lipo-20240531monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-announces-abstract-publication-at-2024-american-society-of-clinica-lipo-20240529monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-expands-its-advisory-board-to-include-oncology-expertise-lipo-20240417monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-to-publish-abstract-detailing-compelling-preclinical-support-for-n-lipo-20240405monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-announces-fda-type-c-meeting-for-lp-10-for-hemorrhagic-cystitis-lipo-20240403monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-announces-fda-clearance-of-ind-for-lp-410-for-oral-graft-versus-ho-lipo-20240305monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-to-present-at-propthink-digital-investor-conference-lipo-20240220monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-marks-successful-first-year-with-strategic-progress-and-key-milest-lipo-20231220monthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-corp-enters-into-agreement-to-be-acquired-by-xoma-royalty-corporation--tsbx-20250627monthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-corp-reports-third-quarter-2024-financial-results-and-provides-recent--tsbx-20241112monthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-corp-reports-second-quarter-2024-financial-results-and-provides-recent-tsbx-20240814monthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-corp-reports-first-quarter-2024-financial-results-and-provides-recent--tsbx-20240513monthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-appoints-william-waddill-to-its-board-of-directors-tsbx-20240416monthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-corp-reports-fourth-quarter-and-full-year-2023-financial-results-and-p-tsbx-20240321monthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-to-participate-in-upcoming-investor-conferences-tsbx-20240221monthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-announces-the-passing-of-chief-legal-officer-p-joseph-campisi-jr-esq-tsbx-20240220monthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-to-participate-in-the-piper-sandler-35th-annual-healthcare-conference-tsbx-20231127monthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-corp-reports-third-quarter-2023-financial-results-and-provides-recent--tsbx-20231110monthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-presents-preclinical-data-highlighting-potential-for-selected-tumor-in-tsbx-20231103monthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-expands-scientific-advisory-board-with-appointment-of-dr-jeffrey-s-web-tsbx-20231030monthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-to-present-preclinical-data-for-selected-tumor-infiltrating-lymphocyte-tsbx-20230928monthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-corp-reports-second-quarter-2023-financial-results-and-provides-busine-tsbx-20230901monthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-corp-announces-pricing-of-upsized-initial-public-offering-tsbx-20230721monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-inc-announces-pct-patent-filing-for-mgx-0024-antiviral-technology-to-includ-mgrx-20260306monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-patented-mgx-0024-achieves-zero-respiratory-related-mortality-in-29-000-bir-mgrx-20260223monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-inc-announces-2-5-million-registered-direct-and-private-placements-priced-a-mgrx-20251218monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-provides-clarification-on-launch-of-branded-glp-1-weight-management-program-mgrx-20251114monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-inc-completes-acquisition-of-mushroom-based-wellness-and-innovations-patent-mgrx-20241219monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-inc-initiates-investigation-into-potential-stock-manipulation-scheme-follow-mgrx-20241204monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-inc-regains-full-compliance-with-nasdaq-minimum-bid-price-requirement-mgrx-20241031monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-inc-announces-1-for-15-reverse-stock-split-as-part-of-nasdaq-compliance-pla-mgrx-20241011monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-ceo-jacob-cohen-featured-on-benzinga-all-access-mgrx-20240718monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-inc-announces-completion-of-first-batch-of-mango-ed-products-for-marketing--mgrx-20240528monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-granted-180-day-extension-to-meet-nasdaq-minimum-bid-price-requirement-and--mgrx-20240502monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-acquires-global-patent-portfolio-to-revolutionize-preventive-care-mgrx-20240425monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-subsidiary-mangorx-mexico-executes-technical-agreement-with-mexican-pharmac-mgrx-20240412monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-inc-announces-pricing-of-1-200-000-public-offering-mgrx-20231215monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-launches-mangorx-mexico-subsidiary-paving-the-way-for-over-the-counter-reta-mgrx-20231206monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-selects-trybe-labs-as-its-nationwide-blood-collection-and-testing-services--mgrx-20231129monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-inc-launches-charitable-initiative-in-support-of-men-s-health-awareness-mon-mgrx-20231102monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-launches-tiktok-influencer-initiative-and-becomes-the-presenting-sponsor-of-mgrx-20231026monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-inc-provides-update-to-shareholders-on-q3-achievements-and-guidance-on-year-mgrx-20231019monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-announces-tv-air-dates-for-interview-featuring-ceo-jacob-cohen-on-bloomberg-mgrx-20231013monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-announces-the-official-launch-of-mangorx-affiliate-marketing-program-to-enh-mgrx-20231012monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-brand-mangorx-announced-as-raindance-film-festival-s-headline-sponsor-mgrx-20230914monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-expands-its-nationwide-marketing-efforts-with-a-multiplatform-audio-powerho-mgrx-20230907monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-launches-new-high-production-quality-ad-providing-fresh-insight-into-its-pr-mgrx-20230830monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-launches-new-sildenafil-based-erectile-dysfunction-product-with-signature-m-mgrx-20230816monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-partners-with-greater-ny-chamber-of-commerce-for-mass-marketing-sales-of-fl-mgrx-20230809monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-inc-names-award-winning-globally-recognized-lucky-break-pr-as-public-relati-mgrx-20230802monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-engages-premier-global-software-development-firm-redlime-solutions-to-expan-mgrx-20230801monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-inc-adds-top-men-s-podcast-pillow-talk-with-ryan-pownall-to-sponsorship-por-mgrx-20230727monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-engaged-by-social-media-sensation-adam22-as-exclusive-new-sponsor-of-hit-po-mgrx-20230718monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-inc-announces-tv-air-dates-for-interview-featuring-ceo-jacob-cohen-on-fox-b-mgrx-20230712monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-launches-make-america-hard-again-campaign-merchandise-website-mgrx-20230627monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-ceo-to-feature-in-upcoming-interview-at-nasdaq-marketsite-studio-on-fox-bus-mgrx-20230622monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-inc-announces-upcoming-launch-of-its-sildenafil-based-mango-flavored-rapid--mgrx-20230621monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-inc-signs-sponsorship-agreement-with-gas-digital-network-to-promote-mango-a-mgrx-20230615monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-signs-deal-with-barstool-sports-to-market-mango-on-popular-only-stans-podca-mgrx-20230608monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-adds-renowned-tech-entrepreneur-and-investor-aaron-andrew-to-advisory-board-mgrx-20230525monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-to-ring-nasdaq-stock-market-closing-bell-on-may-18-mgrx-20230518monthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-launches-new-some-things-are-better-hard-viral-video-ad-campaign-mgrx-20230511monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-inc-announces-results-of-shareholder-meeting-and-appointment-of-full-ti-csci-20260618monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-inc-reports-q1-2026-results-csci-20260512monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-inc-provides-update-on-its-plan-to-suspend-u-s-public-company-reporting-csci-20260420monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-comments-on-unusual-market-activity-csci-20260407monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-inc-reports-fourth-quarter-and-full-year-2025-financial-results-and-pro-csci-20260325monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-provides-strategic-update-csci-20260305monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-announces-exclusive-distribution-agreement-with-wuzhou-drug-international-for-mac-csci-20251201monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-inc-announces-leadership-change-csci-20251114monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-inc-reports-third-quarter-2025-financial-results-and-provides-strategic-csci-20251111monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-inc-reports-first-quarter-2025-financial-results-and-provides-a-corpora-csci-20250513monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-inc-reports-fourth-quarter-and-full-year-2024-financial-results-and-pro-csci-20250409monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-inc-announces-successful-phase-1-results-supporting-initiation-of-phase-csci-20250313monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-inc-provides-corporate-update-and-highlights-pipeline-prioritization-csci-20241223monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-inc-reports-third-quarter-2024-financial-results-and-provides-update-on-csci-20241112monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-announces-change-to-board-of-directors-csci-20241008monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-inc-provides-updates-on-merger-integration-management-succession-plans--csci-20240923monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-inc-announces-top-line-results-of-phase-3-detect-trial-for-the-diagnosi-csci-20240827monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-inc-reports-second-quarter-2024-financial-results-csci-20240813monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-shareholder-notice-faruqi-faruqi-securities-litigation-partner-james-josh-wilso-bcli-20231227monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsui-bcli-20231225monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsui-bcli-20231221monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-ongoing-deadline-alert-faruqi-faruqi-securities-litigation-partner-james-josh-w-bcli-20231219monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsui-bcli-20231216monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-shareholder-action-reminder-faruqi-faruqi-securities-litigation-partner-james-j-bcli-20231215monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsui-bcli-20231211monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsui-bcli-20231205monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsui-bcli-20231130monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsui-bcli-20231125monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-inc-class-action-reminder-contact-robbins-llp-for-information-bcli-20231121monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsui-bcli-20231120monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsui-bcli-20231114monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsui-bcli-20231109monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-inc-bcs-investor-notice-robbins-llp-reminds-investors-of-clas-bcli-20231108monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-announce-first-quarter-financial-results-and-provide-a-cor-bcli-20200429monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-awarded-1-5-million-non-dilutive-grant-for-2020-by-the-israel-innovation-author-bcli-20200403monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-appoints-renowned-distinguished-economist-prof-jacob-frenkel-chairman-of-the-bo-bcli-20200331monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-hold-a-conference-call-to-update-investors-on-corporate-steps-taken-to-addre-bcli-20200316monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-raises-10-0-million-in-common-stock-sale-at-8-00-per-share-bcli-20200306monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-operational-highlights-and-financial-results-for-the-year-ended-decem-bcli-20200218monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-s-chief-operating-officer-to-present-at-noble-capital-markets-sixteenth-annual--bcli-20200217monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-and-fda-agree-to-potential-nurown-regulatory-pathway-for-appr-bcli-20200211monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-announce-fourth-quarter-and-full-year-2019-financial-resul-bcli-20200210monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-ceo-to-provide-company-update-at-the-bio-ceo-investor-conference-bcli-20200204monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-receives-notice-of-intention-to-grant-additional-eu-patent-for-nurown-bcli-20200129monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutic-s-coo-and-cmo-dr-ralph-kern-to-present-at-the-10th-annual-cali-bcli-20200121monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-the-2020-biotech-showcase-and-3rd-annual-neuros-bcli-20200107monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-issues-2019-letter-to-shareholders-bcli-20191218monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-selected-as-buzz-of-bio-2020-winner-bcli-20191211monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-make-scientific-presentations-at-the-30th-international-sy-bcli-20191126monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-the-mount-sinai-medical-center-as-a-progressive-ms-phase-2-clinical-t-bcli-20191125monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-publication-of-nurown-als-phase-2-randomized-clinic-bcli-20191120monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-research-grant-award-from-the-national-multiple-scl-bcli-20191114monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-financial-results-for-the-third-quarter-of-2019-and-provides-a-corpor-bcli-20191114monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-grant-of-a-new-japanese-patent-for-nurown-bcli-20191113monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-ralph-kern-md-mhsc-to-present-at-the-7th-internatio-bcli-20191112monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-announce-third-quarter-financial-results-and-provide-a-com-bcli-20191105monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-the-dawson-james-securities-5th-annual-small-ca-bcli-20191025monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-president-and-ceo-to-be-featured-as-keynote-speaker-at-cell-s-bcli-20191024monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-presentations-at-neuromuscular-drug-development-summit-bcli-20191023monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-s-nurown-phase-3-als-clinical-trial-now-fully-enrolled-bcli-20191011monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-notice-of-us-patent-allowance-for-nurown-cellular-therapeutic-technol-bcli-20191007monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-nurown-phase-2-biomarker-data-at-north-east-amyotr-bcli-20191002monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-support-for-fda-guidelines-on-als-drug-development-bcli-20190927monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-strengthens-senior-executive-management-team-with-the-appointment-of-preetam-sh-bcli-20190909monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-late-breaking-news-eposter-at-the-35th-ectrims-con-bcli-20190906monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-financial-results-for-the-second-quarter-of-2019-and-provides-a-corpo-bcli-20190813monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-announce-second-quarter-financial-results-and-provide-a-co-bcli-20190805monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-presents-poster-at-consortium-of-multiple-sclerosis-centers-cmsc-33rd-annual-me-bcli-20190531monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-second-clinical-site-to-enroll-patients-in-its-progressive-ms-phase-2-bcli-20190530monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-senior-management-to-present-at-bio-2019-bcli-20190528monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-ceo-to-present-at-the-world-advanced-therapy-and-regenerative-medicine-congress-bcli-20190513monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-financial-results-for-the-first-quarter-of-2019-and-provides-a-corpor-bcli-20190510monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-s-cellular-technology-platform-expanded-to-include-exosomes-for-neurodegenerati-bcli-20190430monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-grant-of-an-additional-new-european-patent-for-nurown-bcli-20190326monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-first-patient-enrolled-in-phase-2-clinical-trial-of-progressive-ms-bcli-20190314monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-host-business-update-conference-call-bcli-20190307monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-first-contracted-u-s-clinical-site-for-phase-2-progressive-ms-study-bcli-20190222monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-present-at-2019-sachs-associates-european-life-sciences-ceo-forum-in-zurich--bcli-20190221monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-issues-a-statement-to-patients-and-shareholders-bcli-20190219monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-present-at-2019-bio-ceo-investor-conference-and-extracellular-vesicles-in-di-bcli-20190204monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-the-2019-noblecon15-annual-investor-conference--bcli-20190125monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-granted-additional-patent-for-nurown-in-israel-bcli-20190122monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-present-nurown-phase-3-study-update-at-the-9th-annual-california-als-researc-bcli-20190111monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-the-2019-biotech-showcase-and-sachs-associates--bcli-20190103monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-issues-2018-letter-to-shareholders-bcli-20181227monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-expands-manufacturing-of-nurown-for-phase-2-progressive-ms-trial-bcli-20181226monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-the-29th-international-symposium-on-als-mnd-bcli-20181204monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-submission-of-ind-for-nurown-in-progressive-multipl-bcli-20181119monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-november-clinical-and-investor-conferences-bcli-20181107monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-financial-results-for-the-third-quarter-of-2018-and-provides-a-corpor-bcli-20181029monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-announce-third-quarter-financial-results-and-provide-corporate-update-on-mon-bcli-20181017monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-poster-receives-clinical-abstract-award-at-neals-conference-bcli-20181004monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-highlights-translational-data-and-presentations-supporting-nurown-technology-pl-bcli-20181003monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-granted-new-u-s-patent-for-industrial-scale-manufacturing-of-nurown-bcli-20180913monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-present-at-fda-and-scientific-workshops-highlighting-innovation-in-als-trial-bcli-20180912monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-new-presentation-time-at-the-h-c-wainwright-co-20th-bcli-20180905monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-appoints-arturo-araya-as-chief-commercial-officer-bcli-20180904monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-provide-corporate-update-at-the-h-c-wainwright-co-20th-ann-bcli-20180829monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-successful-interim-safety-analysis-in-phase-3-trial-bcli-20180823monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-inc-s-ceo-tony-fiorino-interviewed-by-the-life-sciences-repor-bcli-20150521monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-files-patent-application-for-stem-cell-procedure-with-potential-for-multiple-sc-bcli-20060126monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-makes-progress-towards-human-stem-cell-therapy-for-parkinson-s-bcli-20051213monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-inc-naov-2025-product-pipeline-and-strategy-analysis-report-naov-20251021monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-adjourns-special-meeting-of-stockholders-naov-20211221monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-to-showcase-painshield-products-at-75th-annual-workers-compensation-education-naov-20211208monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-encouraging-interim-results-in-real-world-patient-study-of-uroshiel-naov-20211207monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-early-success-in-the-marketing-of-painshield-to-veteran-s-administr-naov-20211202monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-ceo-brian-murphy-provides-business-update-in-letter-to-shareholders-naov-20211028monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-positive-results-from-indepenent-double-blind-trial-of-painshield-naov-20211011monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-enters-worker-s-compensation-market-through-agreement-with-orchid-medical-naov-20210929monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-extends-line-up-of-pain-management-products-naov-20210914monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-reports-second-quarter-2021-financial-results-provides-business-update-naov-20210816monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-plan-to-expand-product-portfolio-with-introduction-of-painshield-re-naov-20210816monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-receives-registration-approval-for-painshield-from-tga-australia-naov-20210811monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journa-naov-20210722monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-provides-business-update-naov-20210603monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-adjourns-special-meeting-of-stockholders-naov-20210427monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-expanded-cms-reimbursement-approval-for-painshield-naov-20210426monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-adjourns-special-meeting-of-stockholders-naov-20210414monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-receives-reimbursement-approval-from-u-s-centers-for-medicare-medicaid-servic-naov-20200401monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-looks-to-expand-use-of-its-uroshield-due-to-the-potential-to-impact-comorbidi-naov-20200327monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-closing-of-3-2-million-private-placement-naov-20190624monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-planned-launch-of-cbd-patch-and-cream-for-painshield-designed-to-am-naov-20190605monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-publication-of-painshield-trigeminal-neuralgia-study-in-the-journal-naov-20190225monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-enters-collaboration-agreement-with-fritz-clinic-to-offer-painshield-as-an-al-naov-20190111monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-expanded-agreement-with-mds-pharm-ltd-to-include-distribution-of-ur-naov-20181227monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-signs-major-distributor-in-india-for-uroshield-naov-20181220monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-signs-with-exclusive-distributor-in-switzerland-for-uroshield-naov-20181218monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-selection-of-leading-international-contract-manufacturer-to-support-naov-20181211monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-publication-of-study-measuring-the-effect-of-surface-acoustic-waves-naov-20181206monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-provides-business-update-for-the-third-quarter-of-2018-naov-20181114monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-to-present-at-dawson-james-securities-4th-annual-small-cap-growth-conference-naov-20181022monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-provides-business-update-for-the-second-quarter-of-2018-naov-20180816monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-reports-successful-trial-results-for-use-of-painshield-in-patients-with-trige-naov-20180724monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-exclusive-agreement-for-distribution-of-painshield-and-woundshield--naov-20180605monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-provides-business-update-for-the-first-quarter-2018-naov-20180517monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-partners-with-fabrication-enterprises-inc-for-distribution-of-painshield-in-t-naov-20180509monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-to-present-at-the-3rd-annual-disruptive-growth-healthcare-conference-hosted-b-naov-20180501monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-inc-nasdaq-naov-to-ring-the-nasdaq-stock-market-closing-bell-naov-20180118monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-participate-in-fireside-chat-at-a-g-p-s-annual-healthcare-company-showcase-rvph-20260518monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-reports-first-quarter-2026-financial-results-and-recent-business-highlights-rvph-20260513monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-announces-proposed-public-offering-rvph-20260318monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-announces-publication-on-clinical-vocal-biomarker-data-from-the-recover-phase-3-cli-rvph-20260108monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-announces-pricing-of-10-million-public-offering-rvph-20250626monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-announces-proposed-public-offering-rvph-20250625monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-participate-in-the-h-c-wainwright-6th-annual-neuro-perspectives-hybrid-conferenc-rvph-20250605monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-announces-positive-full-dataset-for-1-year-phase-3-recover-open-label-extension-stu-rvph-20250602monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-participate-in-upcoming-investor-conferences-in-may-2025-rvph-20250520monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-reports-first-quarter-2025-financial-results-and-recent-business-highlights-rvph-20250515monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-participate-in-the-a-g-p-healthcare-company-showcase-rvph-20250513monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-participate-in-the-citizens-life-sciences-conference-rvph-20250429monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-present-late-breaking-poster-on-the-recover-long-term-open-label-extension-trial-rvph-20250424monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-reports-full-year-2024-financial-results-and-recent-business-highlights-rvph-20250331monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-present-brilaroxazine-topline-data-for-long-term-ole-portion-of-recover-study-in-rvph-20250330monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-rvph-20250204monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-participate-in-the-2025-bio-ceo-investor-conference-rvph-20250130monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-rvph-20250107monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-announces-pricing-of-18-0-million-public-offering-of-common-stock-and-warrants-rvph-20241217monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-announces-proposed-public-offering-rvph-20241216monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-announces-positive-preliminary-topline-data-for-the-long-term-open-label-extension--rvph-20241216monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-reports-third-quarter-2024-financial-results-and-recent-business-highlights-rvph-20241114monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-announces-enrollment-update-for-open-label-extension-study-evaluating-brilaroxazine-rvph-20241112monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-present-positive-speech-latency-data-for-brilaroxazine-in-schizophrenia-from-the-rvph-20241106monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-participate-in-the-ubs-global-healthcare-conference-rvph-20241031monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-participate-in-the-2024-maxim-healthcare-virtual-summit-rvph-20241008monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-participate-in-the-3rd-annual-roth-healthcare-opportunities-conference-rvph-20241002monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-to-participate-in-the-lytham-partners-fall-2024-investor-conference-rvph-20240926monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-announces-new-vocal-biomarker-data-from-phase-3-recover-trial-of-brilaroxazine-in-s-rvph-20240909monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-participate-in-the-h-c-wainwright-26th-annual-global-investment-conference-rvph-20240904monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-host-virtual-kol-event-to-discuss-vocal-biomarker-data-from-phase-3-recover-tria-rvph-20240827monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-announces-pricing-of-5-0-million-underwritten-offering-priced-at-th-rvph-20240821monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-reports-second-quarter-2024-financial-results-and-recent-business-highlights-rvph-20240814monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-announces-grant-of-u-s-patent-covering-use-of-brilaroxazine-for-the-treatment-of-id-rvph-20240806monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-announces-grant-of-european-patent-covering-use-of-brilaroxazine-for-the-treatment--rvph-20240709monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-announces-closing-of-3-million-registered-direct-offering-priced-at-the-market-unde-rvph-20240529monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-announces-3-million-registered-direct-offering-priced-at-the-market-under-nasdaq-ru-rvph-20240528monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-participate-in-the-bio-international-convention-rvph-20240521monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-announces-enrollment-update-for-open-label-extension-study-evaluating-brilaroxazine-rvph-20240515monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-reports-first-quarter-2024-financial-results-and-recent-business-highlights-rvph-20240514monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-present-new-preclinical-efficacy-data-on-brilaroxazine-in-idiopathic-pulmonary-f-rvph-20240513monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-present-new-non-clinical-pharmacology-data-on-brilaroxazine-at-the-aspet-2024-an-rvph-20240509monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-alert-bragar-eagel-squire-p-c-is-investigating-reviva-pharmaceuticals-holdings-inc--rvph-20240425monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-announces-fda-alignment-on-brilaroxazine-clinical-trials-for-nda-in-schizophrenia-rvph-20240415monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-reports-full-year-2023-financial-results-and-recent-business-highlights-rvph-20240415monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-present-recover-phase-3-clinical-trial-data-for-brilaroxazine-in-schizophrenia-a-rvph-20240328monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-present-recover-phase-3-clinical-trial-data-for-brilaroxazine-in-schizophrenia-a-rvph-20240326monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-present-at-the-ubs-virtual-cns-day-rvph-20240311monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-present-at-the-36th-annual-roth-conference-rvph-20240307monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-to-present-at-the-2024-bio-ceo-investor-conference-rvph-20240220monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-to-host-kol-event-to-discuss-topline-data-from-phase-3-recover-trial-of-brilaroxazi-rvph-20240206monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-to-participate-in-a-fireside-chat-at-the-lytham-partners-2024-inves-rvph-20240125monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-provides-corporate-and-program-updates-and-highlights-key-upcoming-milestones-rvph-20240104monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-reports-full-year-2022-financial-results-and-recent-bu-rvph-20230330monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-reports-third-quarter-2022-financial-results-and-recen-rvph-20221114monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-announces-8-5-million-registered-direct-offering-and-c-rvph-20220906monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-reports-second-quarter-2022-financial-results-and-rece-rvph-20220815monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-reports-first-quarter-2022-financial-results-and-recen-rvph-20220516monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-interview-to-air-on-bloomberg-u-s-on-the-redchip-money-rvph-20220324monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-to-participate-at-the-maxim-virtual-growth-conference-rvph-20220322monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-to-present-at-upcoming-virtual-investor-conferences-rvph-20220318monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-reports-full-year-2021-financial-results-and-recent-bu-rvph-20220315monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-receives-fda-may-proceed-letter-for-pivotal-phase-3-cl-rvph-20220110monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-reports-third-quarter-2021-financial-results-and-recen-rvph-20211115monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-reports-second-quarter-2021-financial-results-and-rece-rvph-20210816monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-reports-2020-financial-results-and-provides-corporate--rvph-20210322monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-holdings-inc-to-present-at-the-maxim-group-inaugural-2021-emerging--rvph-20210311monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-inc-and-tenzing-acquisition-corp-complete-their-business-combinatio-rvph-20201214monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-appointment-of-robert-liscouski-as-chairman-of-the-board-of-directo-mynz-20260311monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-and-oncovanguard8-enter-into-agreement-to-bring-coloalert-to-south-america-mynz-20251118monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-half-year-2025-update-accelerating-fda-pathway-for-nextgen-colorectal-cancer--mynz-20250715monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-secures-public-funding-to-advance-innovative-pancreatic-cancer-screening-test-mynz-20250625monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-initiates-feasibility-study-of-biomarker-panel-in-pancreatic-cancer-project-mynz-20250610monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-pricing-of-4-0-million-follow-on-offering-of-ordinary-shares-and-wa-mynz-20250520monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-interim-read-out-for-its-eaarly-detect-2-clinical-study-mynz-20250516monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-enters-into-technology-partnership-with-edx-medical-group-mynz-20250429monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-provides-first-quarter-2025-corporate-update-and-path-to-fda-premarket-approv-mynz-20250428monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-reports-2024-financial-results-and-provides-corporate-update-mynz-20250401monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-enrolls-first-patient-in-its-eaarly-detect-2-clinical-study-mynz-20250327monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-and-liquid-biosciences-make-groundbreaking-discovery-of-mrna-biomarkers-for-b-mynz-20250313monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-expands-into-switzerland-with-labor-team-w-mynz-20250220monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-and-ganzimmun-announce-launch-of-enhanced-coloalert-colorectal-cancer-screeni-mynz-20250211monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-n-v-regains-compliance-with-nasdaq-capital-market-listing-requirements-mynz-20250127monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-initiates-u-s-clinical-study-to-evaluate-performance-of-next-generation-test--mynz-20250121monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-forms-agreement-with-quest-diagnostics-to-provide-clinical-trials-laboratory--mynz-20241219monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-closing-of-8-0-million-follow-on-offering-mynz-20241216monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-pricing-of-8-0-million-follow-on-offering-priced-at-the-market-unde-mynz-20241213monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-stock-split-mynz-20241129monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-and-thermo-fisher-scientific-sign-a-collaboration-agreement-for-the-developme-mynz-20241112monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-reports-mid-year-2024-financial-results-and-provides-corporate-update-mynz-20241021monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-reports-increased-demand-for-enhanced-coloalert-existing-partners-to-transiti-mynz-20241008monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-publishes-ceo-statement-ceo-guido-baechler-eyes-major-growth-and-u-s-fda-tria-mynz-20241001monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-petra-smeltzer-starke-to-join-company-as-brand-ambassador-mynz-20240918monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-partners-with-liquid-biosciences-to-leverage-the-power-of-artificial-intellig-mynz-20240904monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-launches-enhanced-coloalert-with-cutting-edge-features-to-optimize-screening--mynz-20240725monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-submission-for-fda-breakthrough-device-designation-for-its-next-gen-mynz-20240709monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-provides-half-year-2024-corporate-update-mynz-20240702monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-presented-industry-leading-results-of-its-pooled-study-at-asco-2024-mynz-20240603monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-reports-results-of-2024-annual-general-meeting-mynz-20240531monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-present-new-pooled-colorectal-cancer-screening-data-its-largest-study-to-d-mynz-20240528monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-awarded-poster-of-distinction-at-digestive-disease-week-positioning-the-compa-mynz-20240520monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-present-results-of-colorectal-cancer-screening-study-eaarly-detect-at-dige-mynz-20240507monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-reports-positive-topline-results-from-pooled-study-evaluating-novel-mrna-biom-mynz-20240425monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-reports-full-year-2023-financial-results-mynz-20240409monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-organizes-hallo-doc-event-to-highlight-innovations-in-colorectal-cancer-treat-mynz-20240319monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-webinar-on-early-detection-of-colorectal-cancer-exploring-new-laboratory-diag-mynz-20240318monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-presents-coloalert-at-udh-congress-2024-leading-the-way-in-evidence-based-can-mynz-20240312monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-partners-with-trusted-health-advisors-to-support-u-s-go-to-market-strategy-fo-mynz-20240305monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-showcase-at-the-gynecology-conference-in-stuttgart-germany-strengthening-c-mynz-20240227monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-distribution-partnership-with-praxisdienst-for-coloalert-mynz-20240222monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-establishes-strategic-partnership-with-tomalab-to-expand-availability-of-colo-mynz-20240221monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-establishes-physician-led-laboratory-expanding-service-offering-for-privately-mynz-20240206monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-provides-year-end-corporate-review-2023-mynz-20240109monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-and-bantleon-partner-to-elevate-corporate-health-with-second-phase-of-crc-scr-mynz-20231219monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-showcases-coloalert-at-two-prominent-gastroenterology-conferences-in-poland-mynz-20231212monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-reports-positive-topline-results-from-u-s-eaarly-detect-study-evaluating-nove-mynz-20231205monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-s-presentation-at-the-35th-annual-piper-sandler-healthcare-conference-to-be-m-mynz-20231129monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-present-at-the-35th-annual-piper-sandler-healthcare-conference-mynz-20231120monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-reports-third-quarter-2023-financial-results-and-provides-corporate-update-mynz-20231116monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-closing-of-5-0-million-registered-direct-offering-mynz-20231115monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-pricing-of-5-0-million-registered-direct-offering-mynz-20231113monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-partners-with-liquid-biosciences-to-harness-the-power-of-artificial-intellige-mynz-20231109monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-showcase-coloalert-at-leading-global-healthcare-event-medica-mynz-20231107monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-appoints-tarrin-khairi-taraki-as-vp-of-commercial-operations-mynz-20231026monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-presents-groundbreaking-results-of-colofuture-study-mynz-20231018monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-showcase-coloalert-at-ueg-week-2023-in-copenhagen-denmark-mynz-20231011monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-attend-the-jonestrading-2023-healthcare-summit-mynz-20231005monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania-mynz-20231004monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-o-mynz-20230927monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-mynz-20230920monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-s-colofuture-study-evaluating-its-novel-mrna-biomarkers-reports-groundbreakin-mynz-20230913monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-present-at-the-h-c-wainwright-global-investment-conference-mynz-20230829monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-live-launch-of-coloalert-with-testdna-laboratory-in-poland-mynz-20230822monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-financial-half-year-results-2023-and-provides-corporate-update-mynz-20230815monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-live-launch-of-coloalert-with-marylebone-laboratory-in-the-united-k-mynz-20230801monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-collaboration-with-fugene-genetics-in-israel-mynz-20230718monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-secures-up-to-50m-in-new-funding-mynz-20230629monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-attend-esmo-world-congress-on-gastrointestinal-cancer-2023-in-barcelona-sp-mynz-20230628monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-expands-into-romania-through-partnership-with-bioclinica-mynz-20230620monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-expands-commercial-footprint-into-poland-mynz-20230531monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-first-quarter-2023-financial-results-and-provides-corporate-update-mynz-20230516monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-partners-with-microba-life-sciences-for-the-development-of-pancalert-mynz-20230510monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-addition-of-eurofins-gelamed-to-its-growing-network-of-lab-partners-mynz-20230503monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-participate-in-digestive-disease-week-2023-mynz-20230501monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-commence-quarterly-reporting-and-present-at-equity-forum-spring-conference-mynz-20230427monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-mynz-20230426monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-provides-full-year-2022-financial-results-mynz-20230410monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-expands-corporate-health-program-for-coloalert-with-the-addition-of-three-new-mynz-20230404monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-reports-positive-results-from-feasibility-study-evaluating-its-portfolio-of-n-mynz-20230329monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-present-at-sidoti-virtual-investor-conference-march-22-23-mynz-20230321monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-mynz-20230315monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-launches-number-of-educational-events-in-germany-to-raise-awareness-for-crc-s-mynz-20230308monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-recognizes-colorectal-cancer-awareness-month-throughout-blue-march-2023-mynz-20230301monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-appear-on-clearthink-ir-s-virtual-live-event-on-wednesday-march-1-2023-at--mynz-20230228monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-acquires-entire-intellectual-property-portfolio-for-its-colorectal-cancer-dia-mynz-20230221monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-expands-european-commercial-footprint-and-enters-markets-in-spain-and-uk-mynz-20230215monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-launches-corporate-health-program-in-germany-for-coloalert-mynz-20230118monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-provides-year-end-2022-corporate-review-mynz-20230103monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-enrolls-first-patient-in-eaarly-detect-study-evaluating-integration-of-novel--mynz-20221220monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-irb-approval-and-initiation-of-us-pivotal-fda-clinical-study-mynz-20221206monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-appoints-amy-levin-as-vice-president-of-regulatory-affairs-to-oversee-global--mynz-20221129monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-participate-in-deutsche-eigenkapitalforum-and-cantor-fitzgerald-s-medical--mynz-20221122monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-u-s-extension-of-colofuture-study-to-evaluate-integration-of-novel--mynz-20221115monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-provides-third-quarter-2022-update-mynz-20221102monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-strengthens-board-of-directors-with-nomination-of-dr-heiner-dreismann-and-gre-mynz-20220928monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-appoints-dr-douglas-rex-to-its-medical-advisory-board-mynz-20220920monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-reports-first-half-2022-financial-results-mynz-20220907monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-present-at-the-h-c-wainwright-annual-global-investment-conference-mynz-20220901monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-appoints-dr-d-kim-turgeon-of-university-of-michigan-health-to-its-medical-adv-mynz-20220823monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-and-dante-genomics-announce-full-commercial-availability-of-coloalert-in-ital-mynz-20220816monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-appoints-former-qiagen-executive-dr-frank-krieg-schneider-as-vice-president-o-mynz-20220803monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-appoints-dr-timothy-wang-to-newly-formed-medical-advisory-board-mynz-20220719monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-today-to-provide-corporate-update-for-first-half-of-2022-mynz-20220712monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-provides-corporate-update-for-first-half-of-2022-mynz-20220705monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-enrolls-first-patient-in-colofuture-study-evaluating-integration-of-novel-mrn-mynz-20220628monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-appoints-vice-president-of-clinical-affairs-to-lead-us-clinical-studies-in-su-mynz-20220614monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-successfully-completes-conformity-assessment-to-ivdr-achieving-new-level-of-e-mynz-20220601monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-dante-labs-announce-partnership-for-the-commercialization-of-coloalert-in-eur-mynz-20220519monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-participate-in-h-c-wainwright-global-investment-conference-and-equity-foru-mynz-20220517monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-host-key-opinion-leader-event-at-ddw-2022-mynz-20220509monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-provides-product-development-update-on-pancalert-mynz-20220505monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-appoints-darin-leigh-as-chief-commercial-officer-mynz-20220426monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-first-quarter-2022-results-mynz-20220412monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-completes-successful-pre-submission-process-with-the-u-s-fda-for-coloalert-s--mynz-20220331monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-ring-nasdaq-stock-market-closing-bell-mynz-20220321monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-appoints-key-clinical-trial-partners-for-colofuture-study-mynz-20220317monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-year-end-2021-results-mynz-20220309monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-and-partners-join-international-awareness-campaign-for-colorectal-cancer-awar-mynz-20220302monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-provides-u-s-regulatory-review-update-for-coloalert-mynz-20220223monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-appoints-oncology-expert-dr-rainer-metzger-to-strategic-advisory-board-mynz-20220209monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-initiates-clinical-study-to-evaluate-integrating-novel-mrna-biomarkers-into-c-mynz-20220204monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-the-closing-of-its-25-8-million-public-follow-on-offering-of-common-mynz-20220128monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-appoints-steve-quinn-as-vp-business-development-mynz-20220127monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-pricing-of-follow-on-offering-mynz-20220126monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-engages-dcn-dx-to-support-clinical-study-evaluating-novel-mrna-biomarkers-for-mynz-20220119monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-appoints-michele-pedrocchi-former-head-of-roche-diagnostics-business-developm-mynz-20220112monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-present-at-the-h-c-wainwright-bioconnect-virtual-conference-mynz-20220111monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-acquires-exclusive-rights-to-novel-mrna-biomarkers-mynz-20220105monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-appoints-karen-richards-as-vice-president-regulatory-affairs-to-lead-us-fda-a-mynz-20211221monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-expands-coloalert-commercialization-with-ganzimmun-diagnostics-in-europe-mynz-20211214monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-launches-ecommerce-store-for-coloalert-to-assist-patient-access-during-covid--mynz-20211207monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-establishes-partnership-with-precision-for-medicine-to-support-coloalert-s-u--mynz-20211130monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-appoints-dr-soren-thestrup-nielsen-m-d-to-strategic-advisory-board-mynz-20211118monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-to-exhibit-coloalert-at-medica-2021-the-world-s-largest-medical-trade-fair-mynz-20211115monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-appoints-former-roche-division-president-heiner-dreismann-to-strategic-adviso-mynz-20211111monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-exercise-of-over-allotment-option-mynz-20211108monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-commences-trading-on-nasdaq-under-ticker-symbol-mynz-mynz-20211108monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-n-v-announces-pricing-of-initial-public-offering-mynz-20211104monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-deco-slrx-20251218monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-1-for-8-reverse-stock-split-slrx-20240612monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-and-p-slrx-20240322monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-provides-update-on-strategic-review-process-and-plans-to-support-ongoing-seclidem-slrx-20240222monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-issued-u-s-patent-for-next-generation-targeted-protein-degraders-slrx-20240116monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-completes-fda-type-b-meeting-for-seclidemstat-ewing-sarcoma-development-program-slrx-20231107monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reports-second-quarter-2023-financial-results-and-provides-a-busi-slrx-20230810monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-plans-to-explore-strategic-alternatives-and-implement-m-slrx-20230808monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-receives-fda-clearance-of-sp-3164-investigational-new-drug-applic-slrx-20230711monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-th-slrx-20230612monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-closing-of-6-million-private-placement-priced-at-the-ma-slrx-20230516monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-6-million-private-placement-priced-at-the-market-under--slrx-20230512monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reports-first-quarter-2023-financial-results-and-provides-a-busin-slrx-20230511monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practi-slrx-20230501monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-presents-compelling-data-in-two-sp-3164-targeted-protein-degrader-slrx-20230420monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-the-diamond-equity-research-emerging-growth-invitat-slrx-20230404monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-and-p-slrx-20230327monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-two-abstracts-accepted-for-presentation-at-the-american-slrx-20230315monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-in-vitro-data-on-seclidemstat-in-small-cell-lung-cance-slrx-20230307monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-receives-1-48-million-from-the-cancer-prevention-and-research-ins-slrx-20230216monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-presents-sp-3164-preclinical-data-at-the-inaugural-molecular-glue-slrx-20230127monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-sp-3164-targeted-protein-degrader-preclinical-data-at--slrx-20230119monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-issuance-of-new-u-s-patent-for-next-generation-targeted-slrx-20230105monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-presents-sp-3164-data-demonstrating-activity-in-preclinical-lymph-slrx-20221213monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-hold-conference-call-to-discuss-recent-clinical-and-preclinica-slrx-20221208monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-interim-results-from-phase-1-2-trial-of-seclidemstat-as-slrx-20221201monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides-busines-slrx-20221110monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-two-presentations-at-the-2022-american-society-of-hemat-slrx-20221103monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-presents-favorable-preclinical-data-on-sp-3164-at-the-5th-annual--slrx-20221027monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-sp-3164-at-the-5th-annual-targeted-protein-degradation-slrx-20221019monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-pause-in-new-patient-enrollment-in-its-phase-1-2-trial--slrx-20221018monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-1-for-25-reverse-stock-split-slrx-20221014monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference-slrx-20220920monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-ceo-issues-letter-to-stockholders-slrx-20220913monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-adds-two-mayo-clinic-sites-to-its-ongoing-phase-1-2-trial-of-secl-slrx-20220822monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reports-second-quarter-2022-financial-results-and-provides-busine-slrx-20220808monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-adds-seattle-cancer-care-alliance-and-oregon-health-sciences-as-c-slrx-20220804monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-and-volitionrx-enter-into-r-d-collaboration-agreement-slrx-20220802monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-host-second-quarter-2022-financial-results-and-business-update-slrx-20220729monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-participate-in-bio-international-convention-2022-slrx-20220609monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-h-c-wainwright-global-investment-conference-slrx-20220518monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reports-business-highlights-with-first-quarter-2022-financial-res-slrx-20220512monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-completes-sp-3164-pre-investigational-new-drug-meeting-process-wi-slrx-20220511monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-report-first-quarter-2022-financial-results-and-highlight-rece-slrx-20220505monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-inc-announces-2-3-million-registered-direct-offering-slrx-20220422monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reports-business-highlights-with-fourth-quarter-and-full-year-202-slrx-20220310monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-report-fourth-quarter-and-full-year-2021-financial-results-and-slrx-20220303monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-the-diamond-equity-research-emerging-growth-invitat-slrx-20220217monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-participate-in-the-2022-bio-ceo-investor-conference-slrx-20220208monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-appoints-daniela-santiesteban-ph-d-to-director-of-targeted-protei-slrx-20220203monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-expands-oncology-pipeline-through-strategic-acquisition-of-target-slrx-20220113monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-virtual-h-c-wainwright-bioconnect-participate-in-vi-slrx-20220106monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-achieves-dosing-milestone-in-ongoing-phase-1-2-sarcoma-trial-slrx-20211229monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-the-virtual-life-science-investor-forum-slrx-20211215monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-participate-in-annual-benchmark-company-discovery-one-on-one-c-slrx-20211129monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reports-third-quarter-2021-financial-results-and-highlights-recen-slrx-20211104monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-report-third-quarter-2021-financial-results-and-highlight-rece-slrx-20211026monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-and-nationwide-children-s-hospital-disclose-research-findings-fro-slrx-20211007monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-the-2021-biofuture-conference-slrx-20211005monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-and-nationwide-children-s-hospital-announce-poster-presentation-a-slrx-20210930monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-receives-2-7-million-in-payment-from-the-cancer-prevention-and-re-slrx-20210928monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-the-virtual-benzinga-healthcare-small-cap-conferenc-slrx-20210927monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-and-fox-chase-cancer-center-launch-research-partnership-slrx-20210922monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-added-to-ftse-global-micro-cap-index-slrx-20210920monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-the-virtual-life-science-investor-forum-slrx-20210915monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-the-virtual-h-c-wainwright-23rd-annual-global-inves-slrx-20210908monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-the-virtual-diamond-equity-research-emerging-growth-slrx-20210812monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reports-second-quarter-2021-financial-results-and-highlights-rece-slrx-20210805monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results-slrx-20210729monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-aundrietta-duncan-ph-d-to-present-during-virtual-epigen-slrx-20210714monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-adds-fox-chase-cancer-center-to-ongoing-trial-of-seclidemstat-as--slrx-20210713monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conferenc-slrx-20210709monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-new-clinical-trial-to-study-seclidemstat-in-hematologic-slrx-20210615monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-host-virtual-key-opinion-leader-and-investor-event-slrx-20210610monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-presents-new-research-data-demonstrating-seclidemstat-s-safety-do-slrx-20210607monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-discloses-key-findings-from-three-abstracts-to-be-presented-at-am-slrx-20210519monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reports-first-quarter-financial-results-with-business-highlights-slrx-20210512monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-report-first-quarter-2021-financial-results-slrx-20210505monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-titles-of-three-abstracts-accepted-for-poster-presentat-slrx-20210429monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-acceptance-of-three-abstracts-for-poster-presentations--slrx-20210419monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reports-business-highlights-with-fourth-quarter-and-full-year-202-slrx-20210318monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-report-fourth-quarter-and-full-year-2020-financial-results-slrx-20210311monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-announces-closing-of-23-million-underwritten-public-offering-of-common-stock-foll-slrx-20210308monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-announces-pricing-of-20-million-underwritten-public-offering-of-common-stock-slrx-20210304monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-announces-proposed-public-offering-of-common-stock-slrx-20210303monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-initiates-expansion-stage-of-phase-1-2-clinical-trial-of-seclidem-slrx-20210224monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-the-diamond-equity-research-emerging-growth-invitat-slrx-20210222monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-completes-dose-escalation-stage-of-phase-1-2-clinical-trial-in-relapsed-and-refra-slrx-20210217monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-bio-ceo-investor-digital-conference-slrx-20210216monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirem-slrx-20210121monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discuss-slrx-20210115monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-receives-second-installment-of-1-7-million-in-payments-from-the-c-slrx-20210113monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-participate-in-biotech-showcase-digital-and-bio-jpm-during-j-p-slrx-20201222monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-announces-exercise-of-warrants-for-3-5-million-of-gross-proceeds-to-be-used-for-o-slrx-20201211monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-receives-first-installment-of-1-7-million-in-payments-from-the-ca-slrx-20201210monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium-slrx-20201117monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reports-business-highlights-and-third-quarter-2020-financial-resu-slrx-20201111monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-report-third-quarter-2020-financial-results-slrx-20201104monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-bio-investor-forum-digital-slrx-20201013monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-upcoming-investor-conferences-slrx-20200910monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-during-virtual-ld-500-conference-slrx-20200827monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reports-business-highlights-and-second-quarter-2020-financial-res-slrx-20200812monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-report-second-quarter-2020-financial-results-slrx-20200805monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-announces-issuance-of-new-patent-for-seclidemstat-by-european-patent-office-slrx-20200805monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-announces-closing-of-6-2-million-underwritten-public-offering-and-full-exercise-o-slrx-20200803monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-announces-pricing-of-5-3-million-underwritten-public-offering-slrx-20200730monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-announces-proposed-public-offering-of-common-stock-slrx-20200729monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-expand-clinical-program-to-target-additional-sarcomas-in-ewing-slrx-20200729monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-move-to-new-corporate-offices-at-texas-medical-center-slrx-20200728monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-names-nadeem-mirza-m-d-m-p-h-as-senior-vice-president-clinical-de-slrx-20200723monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-invited-to-present-seclidemstat-research-at-meeting-of-the-pediat-slrx-20200602monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-trial-in-progress-poster-at-asco20-virtual-scientific--slrx-20200527monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reports-first-quarter-2020-financial-results-slrx-20200514monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-acceptance-of-abstract-for-2020-asco-virtual-scientific-slrx-20200514monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-report-first-quarter-2020-financial-results-slrx-20200507monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-board-of-director-nominations-in-advance-of-2020-annual-slrx-20200429monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-deliver-virtual-presentation-at-the-emerging-growth-invitation-slrx-20200422monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results-slrx-20200323monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-announces-allowance-of-new-european-patent-covering-seclidemstat-slrx-20200304monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-attend-the-oppenheimer-healthcare-conference-slrx-20200302monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-announces-closing-of-11-0-million-underwritten-public-offering-and-full-exercise--slrx-20200211monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-the-noble-capital-markets-16th-annual-small-microca-slrx-20200210monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-announces-pricing-of-9-6-million-underwritten-public-offering-slrx-20200207monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-the-bio-ceo-investor-conference-slrx-20200205monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-announces-publication-of-scientific-paper-highlighting-potential-of-combining-sec-slrx-20200204monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-biotech-showcase-2020-slrx-20191219monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-hosting-key-opinion-leader-call-on-epigenetics-the-regulatory-sys-slrx-20191217monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-receives-fda-fast-track-designation-for-lead-drug-candidate-secli-slrx-20191216monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-trial-in-progress-poster-at-epigenetics-symposium-15-y-slrx-20191212monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reports-three-and-nine-month-2019-financial-results-slrx-20191113monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-and-aspire-capital-announce-a-10-9m-common-stock-purchase-agreeme-slrx-20191028monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-slrx-20191014monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-adds-memorial-sloan-kettering-cancer-center-and-nationwide-childr-slrx-20191008monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-achieves-dose-escalation-milestones-in-ongoing-phase-1-2-ewing-sa-slrx-20190924monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-senior-leadership-changes-slrx-20190913monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-supports-childhood-cancer-awareness-month-slrx-20190912monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-ceo-issues-letter-to-stockholders-slrx-20190812monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-to-ring-the-nasdaq-stock-market-opening-bell-slrx-20190729monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-successfully-monetizes-legacy-consumer-product-slrx-20190724monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-enrolls-first-patient-in-a-phase-1-clinical-study-of-its-novel-in-slrx-20190722monthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-announces-closing-of-strategic-merger-with-flex-pharma-slrx-20190722monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-strengthens-leadership-with-appointment-of-healthcare-executive-z-brtx-20260618monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-completes-phase-2-dosing-of-brtx-100-advancing-lead-regenerative-spine-prog-brtx-20260526monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-reports-expanded-phase-2-blinded-dataset-for-brtx-100-showing-sus-brtx-20260507monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-present-new-data-at-isct-2026-highlighting-its-ongoing-phase-2-brtx-20260430monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-strategic-partnership-with-global-dermatology-leader-dr-brtx-20260421monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-strategic-collaboration-with-203-creates-to-build-and-c-brtx-20260407monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-reports-positive-phase-2-blinded-data-for-brtx-100-demonstrating--brtx-20260330monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-present-positive-phase-2-blinded-data-for-brtx-100-demonstrati-brtx-20260319monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-announces-closing-of-5-0-million-public-offering-brtx-20260214monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-granted-type-b-meeting-with-fda-to-discuss-accelerated-bla-approval-pathway-brtx-20251117monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-report-third-quarter-2025-financial-results-and-host-conferenc-brtx-20251105monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-reports-second-quarter-2025-financial-results-and-provides-busine-brtx-20250812monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-announces-share-repurchase-program-brtx-20250617monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-reports-compelling-preliminary-data-for-fda-fast-tracked-brtx-100-an-autolo-brtx-20250613monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-welcomes-serial-regenerative-medicine-entrepreneur-company-builder-and-lead-brtx-20250610monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-to-present-major-update-on-promising-preliminary-phase-2-brtx-100-data-at-i-brtx-20250609monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-reports-first-quarter-2025-financial-results-and-provides-busines-brtx-20250514monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-report-first-quarter-2025-financial-results-and-host-conferenc-brtx-20250508monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-to-present-a-brtx-100-clinical-update-at-isct-2025-brtx-20250507monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-to-participate-in-benzinga-all-access-show-today-to-discuss-recent-achievem-brtx-20250415monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-confirms-no-material-impact-from-reciprocal-tariffs-all-brtx-100-production-brtx-20250410monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-reports-2024-financial-results-and-provides-business-update-brtx-20250327monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-report-2024-financial-results-and-host-conference-call-on-marc-brtx-20250320monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-announces-fda-clearance-of-ind-for-phase-2-trial-of-brtx-100-in-chronic-cer-brtx-20250227monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-announces-updated-time-for-february-27th-webcasted-conference-call-to-discu-brtx-20250227monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-to-provide-a-positive-fda-update-on-clinical-pipeline-brtx-20250225monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-receives-fda-fast-track-designation-for-brtx-100-chronic-lumbar-disc-diseas-brtx-20250220monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-notice-of-allowance-of-key-new-patent-protecting-thermo-brtx-20241205monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-reports-positive-preliminary-phase-2-brtx-100-clinical-data-brtx-20241113monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-reports-third-quarter-2024-financial-results-and-provides-busines-brtx-20241112monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-present-new-clinical-data-at-the-ors-psrs-7th-international-sp-brtx-20241106monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-receives-expanded-tissue-license-from-new-york-state-department-o-brtx-20241105monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-receives-patent-allowance-for-thermostem-metabolic-disease-progra-brtx-20241031monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-participate-in-upcoming-ubs-and-maxim-group-investor-events-brtx-20241010monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-participate-in-the-3rd-annual-roth-healthcare-opportunities-co-brtx-20241003monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-ifats-2024-presentation-to-feature-thermostem-platform-s-potentia-brtx-20240919monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-reports-second-quarter-2024-financial-results-and-provides-busine-brtx-20240813monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-report-second-quarter-2024-financial-results-and-host-conferen-brtx-20240806monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-chief-scientist-named-new-section-editor-of-the-prestigious-journ-brtx-20240723monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-notice-of-allowance-for-patent-covering-fundamental-asp-brtx-20240627monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-regains-compliance-with-nasdaq-listing-rule-5250-c-1-reports-firs-brtx-20240617monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-in-substantive-discussions-for-potential-license-agreement-for-th-brtx-20240613monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-inc-to-attend-the-jefferies-2024-healthcare-conference-brtx-20240604monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-receipt-of-nasdaq-non-compliance-notice-brtx-20240524monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-provides-first-quarter-2024-business-update-brtx-20240514monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-enhances-preclinical-metabolic-program-with-a-novel-exosome-based-brtx-20240508monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-report-first-quarter-2024-financial-results-and-host-conferenc-brtx-20240430monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-transformative-commercial-agreement-with-cartessa-a-glo-brtx-20240430monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-fda-clearance-of-phase-2-brtx-100-clinical-study-protoc-brtx-20240416monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-partners-with-galen-patient-recruitment-to-accelerate-completion--brtx-20240408monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-filing-of-form-s-1-registration-statement-to-register-f-brtx-20240403monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-filing-of-2023-annual-report-on-form-10-k-brtx-20240401monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-participate-in-the-36th-annual-roth-conference-brtx-20240311monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-exercise-of-warrants-and-issuance-of-new-warrants-in-a--brtx-20240206monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-presents-preliminary-clinical-data-from-phase-2-study-of-brtx-100-brtx-20240205monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-present-preliminary-brtx-100-clinical-data-at-the-orthopaedic--brtx-20240201monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-receives-a-notice-of-allowance-by-the-united-states-patent-and-tr-brtx-20231212monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-inc-to-participate-at-the-roth-mkm-healthcare-opportunities-confe-brtx-20231009monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-enters-into-supply-agreement-with-evolutionary-biologics-brtx-20230912monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-activation-of-northwell-health-in-the-company-s-phase-2-brtx-20230908monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-2-1-million-registered-direct-offering-brtx-20230711monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-receives-unanimous-recommendation-from-data-safety-monitoring-boa-brtx-20230627monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-inc-to-participate-in-the-healthcare-virtual-conference-presented-brtx-20230616monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-key-milestone-of-dosing-completion-in-safety-cohort-of--brtx-20230612monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-inc-to-attend-the-jefferies-2023-healthcare-conference-brtx-20230601monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-receives-license-from-new-york-state-department-of-health-to-act--brtx-20230531monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-receives-notice-of-allowance-by-the-japanese-patent-and-trademark-brtx-20230515monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-and-northwell-health-enter-into-agreement-to-participate-in-the-c-brtx-20230508monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-inc-to-participate-at-the-ef-hutton-global-conference-may-10-11-i-brtx-20230504monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-completion-of-patient-enrollment-for-safety-run-in-comp-brtx-20230424monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-seek-fda-approval-to-expand-the-clinical-application-of-brtx-1-brtx-20230313monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-participate-at-the-35th-annual-roth-mkm-conference-on-march-12-brtx-20230307monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-receives-notice-of-allowance-by-the-united-states-patent-and-trad-brtx-20230302monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-notice-of-allowance-by-the-european-patent-office-for-p-brtx-20230208monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-sbir-phase-i-grant-to-explore-the-therapeutic-effects-o-brtx-20221206monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-enters-agreement-with-regenexx-granting-brtx-exclusive-license-ri-brtx-20221205monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-participate-at-the-rhk-capital-disruptive-growth-conference-on-brtx-20221129monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-participate-at-the-rhk-capital-disruptive-growth-conference-on-brtx-20221116monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-ceo-lance-alstodt-to-be-interviewed-on-famela-and-friends-talk-ra-brtx-20221020monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-present-at-the-dawson-james-securities-7th-annual-small-cap-gr-brtx-20220928monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-participate-in-the-roth-inaugural-healthcare-opportunities-con-brtx-20220927monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-present-at-the-h-c-wainwright-24th-annual-global-investment-co-brtx-20220907monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-first-patient-enrolled-for-the-company-s-phase-2-clinic-brtx-20220630monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-clinical-trial-contract-with-second-site-for-the-compan-brtx-20220622monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-clinical-site-initiation-for-the-company-s-phase-2-clin-brtx-20220613monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-hosts-principal-investigator-meeting-for-its-brtx-100-phase-2-cli-brtx-20220429monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-selection-of-10-clinical-sites-for-its-phase-2-clinical-brtx-20220418monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-cgmp-cell-manufacturing-facility-certification-brtx-20220404monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-research-collaboration-with-professor-tore-bengtsson-to-brtx-20220310monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-notice-of-allowance-on-key-patent-for-its-brtx-100-disc-brtx-20220216monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-it-has-initiated-its-phase-2-clinical-trial-to-treat-ch-brtx-20220207monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-ring-nasdaq-stock-market-closing-bell-brtx-20220207monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-notice-of-allowance-for-new-patent-application-in-japan-brtx-20220202monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-named-one-of-ten-most-innovative-regenerative-medicine-companies--brtx-20220126monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-the-appointment-of-robert-paccasassi-to-vice-president--brtx-20220111monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-present-at-h-c-wainwright-bioconnect-virtual-conference-brtx-20220106monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-awarded-an-sttr-phase-i-grant-to-explore-the-therapeutic-effects--brtx-20220104monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-cro-agreement-with-prc-clinical-for-its-brtx-100-phase--brtx-20211221monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-ceo-interviewing-live-on-the-james-hicks-newmedia-show-brtx-20211221monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-inc-releases-year-end-message-brtx-20211220monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-filing-of-ten-patent-applications-related-to-its-brtx-1-brtx-20211202monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-enters-into-letter-of-intent-with-prc-clinical-brtx-20211119monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-appoints-robert-kristal-as-chief-financial-officer-brtx-20211110monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-closing-of-23-million-public-offering-brtx-20211109monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-prices-23-million-public-offering-and-uplisting-to-the-nasdaq-cap-brtx-20211105monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-implementation-of-reverse-stock-split-in-preparation-fo-brtx-20211026monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-nomination-of-two-new-members-to-the-board-of-directors-brtx-20211026monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-receives-notice-of-allowance-for-patent-application-in-israel-for-brtx-20210923monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-receives-patent-in-australia-related-to-its-off-the-shelf-thermos-brtx-20210902monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-receives-patent-in-japan-related-to-its-off-the-shelf-thermostem--brtx-20210831monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-awarded-one-of-top-10-spine-device-companies-by-medtech-outlook-brtx-20210819monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-discusses-upcoming-annual-meeting-of-stockholders-brtx-20210811monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-filing-of-registration-statement-for-proposed-public-of-brtx-20210809monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-present-at-the-emerging-growth-conference-on-june-9-2021-brtx-20210607monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-expanding-its-cell-therapy-manufacturing-facility-brtx-20210510monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-compliance-with-sec-reporting-requirements-and-stop-sig-brtx-20210503monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-appointment-of-nickolay-v-kukekov-ph-d-to-its-board-of--brtx-20210405monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-notice-of-allowance-for-a-new-patent-application-relate-brtx-20210331monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-notices-of-allowance-for-three-patent-applications-for--brtx-20210322monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-filing-of-2019-annual-report-on-form-10-k-brtx-20210318monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-provides-end-of-year-shareholder-letter-brtx-20210105monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-emerges-from-chapter-11-reorganization-brtx-20201120monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-featured-in-ieee-pulse-magazine-s-cover-story-about-stem-cell-the-brtx-20191216monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-receives-patent-in-israel-for-its-metabolic-program-brtx-20191212monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-receives-a-second-patent-in-australia-for-its-metabolic-program-brtx-20191023monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-scientific-advisory-board-member-and-clinical-director-of-regener-brtx-20190916monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-comments-on-recent-promotional-activity-brtx-20190914monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-new-initiative-to-target-polycystic-ovarian-syndrome-brtx-20190911monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-stockholders-approve-institutional-investor-agreement-and-exchang-brtx-20190905monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-signs-5-4-million-financing-with-institutional-investor-brtx-20190731monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-present-at-the-22nd-annual-american-society-of-gene-and-cell-t-brtx-20190429monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-the-creation-of-a-disc-advisory-committee-brtx-20190227monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-receives-notice-of-allowance-for-key-metabolic-patent-in-the-unit-brtx-20181115monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-the-appointment-of-lance-alstodt-as-executive-vp-and-ch-brtx-20181018monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-metabolic-research-collaboration-with-university-of-pen-brtx-20180924monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-publication-of-study-results-validating-the-benefits-of-brtx-20180815monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-appoints-jason-m-lipetz-m-d-to-its-scientific-advisory-board-brtx-20180725monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-reports-positive-findings-from-independent-review-of-its-brtx-100-brtx-20180611monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-appoints-wayne-j-olan-m-d-as-clinical-director-of-regenerative-di-brtx-20180507monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-the-appointment-of-adam-d-bergstein-as-sr-vp-planning-a-brtx-20180122monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-receives-notice-of-allowance-for-key-metabolic-patent-in-japan-brtx-20171017monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-published-study-of-licensed-technology-to-treat-lumbar--brtx-20171005monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-present-at-6th-annual-marcum-microcap-conference-brtx-20170614monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-receives-notice-of-acceptance-for-key-metabolic-patent-in-austral-brtx-20170420monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-receives-fda-clearance-to-initiate-phase-2-clinical-trial-for-the-brtx-20170208monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-submits-ind-application-to-fda-to-treat-patients-with-degenerativ-brtx-20170109monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-publication-in-medical-journal-of-positive-results-of-l-brtx-20160912monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-presentation-at-3rd-annual-regenerative-medicine-essent-brtx-20160713monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-completion-of-human-safety-and-feasibility-study-on-the-brtx-20160628monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-present-at-5th-annual-marcum-microcap-conference-brtx-20160531monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-promising-data-to-advance-its-program-for-the-treatment-brtx-20160523monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-deepens-board-of-directors-with-addition-of-robert-b-catell-forme-brtx-20160223monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-names-lead-cell-based-lumbar-disc-therapeutic-product-brtx-20160209monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-provides-company-updates-with-shareholder-letter-brtx-20151221monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-appoints-john-m-desmarais-j-d-to-its-board-of-directors-brtx-20151202monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-granted-key-metabolic-patent-brtx-20151119monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-patent-granted-for-its-licensed-curved-needle-device-brtx-20151103monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-research-collaboration-with-university-of-pennsylvania-brtx-20150915monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-evaluate-cell-delivery-technology-to-advance-metabolic-program-brtx-20150720monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-inc-announces-reverse-stock-split-in-preparation-for-planned-upli-brtx-20150706monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-announces-conversion-of-5-15-million-of-debt-to-equity-brtx-20150602monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-present-thermostem-r-data-at-21st-annual-meeting-of-the-intern-brtx-20150527monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-to-present-at-the-2015-marcum-microcap-conference-in-new-york-cit-brtx-20150526monthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-ceo-mark-weinreb-interviewed-by-the-life-sciences-report-brtx-20130725monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-2025-annual-financial-results-vcnx-20260430monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-announces-60-million-agreement-to-finance-a-phase-2b-clinical-trial-of-pepine-vcnx-20251223monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-to-report-promising-new-efficacy-data-for-signal-ad-phase-1b-2-trial-of-pepinemab-vcnx-20241024monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-provides-update-on-new-findings-for-signal-ad-phase-1b-2-trial-of-pepinemab-in-al-vcnx-20240814monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-positive-data-for-signal-ad-phase-1b-2-trial-of-pepinemab-in-alzheimer-s--vcnx-20240731monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-to-report-topline-data-for-signal-ad-phase-1b-2-trial-of-pepinemab-in-alzheimer-s-vcnx-20240717monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-completion-of-last-patient-visit-in-randomized-signal-ad-phase-1b-2-study-vcnx-20240606monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-first-quarter-2024-financial-results-and-provides-corporate-update-vcnx-20240515monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-2023-financial-results-and-provides-corporate-update-vcnx-20240402monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-announces-1-5-million-registered-direct-offering-and-concurrent-private-place-vcnx-20240327monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-multiple-new-agreements-for-access-to-activmab-antigen-virus-technology-vcnx-20240221monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-announces-reverse-stock-split-vcnx-20240215monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-pricing-of-3-7-million-pipe-financing-vcnx-20240207monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-third-quarter-2023-financial-results-and-provides-corporate-update-vcnx-20231113monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-clinical-benefit-in-interim-analyses-from-two-phase-2-studies-of-pepinema-vcnx-20231031monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-positive-effect-of-pepinemab-treatment-on-new-biomarker-of-brain-inflamma-vcnx-20231026monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-pricing-of-9-6-million-public-offering-vcnx-20230929monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-s-next-generation-activmab-technology-published-in-mabs-a-leading-biotech-journal-vcnx-20230928monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-to-present-update-on-pdac-pepinemab-study-new-activmab-application-vcnx-20230927monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-groundbreaking-findings-at-medical-conferences-supporting-development-of--vcnx-20230926monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-announces-reverse-stock-split-vcnx-20230922monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-second-quarter-2023-financial-results-and-provides-corporate-update-vcnx-20230814monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-to-participate-in-the-jefferies-healthcare-conference-track-6-on-friday-june--vcnx-20230601monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-first-quarter-2023-financial-results-and-provides-corporate-update-vcnx-20230515monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-completes-enrollment-in-phase-1b-2-signal-ad-alzheimer-s-disease-study-of-pepinem-vcnx-20230425monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-new-activmab-application-published-in-nature-communications-for-directed-evolutio-vcnx-20230412monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-private-placement-with-commitments-of-5-0-million-vcnx-20230403monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-2022-financial-results-and-provides-corporate-update-of-continued-progres-vcnx-20230403monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-to-present-at-the-2023-aaic-advancements-immunity-conference-vcnx-20230323monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-initiation-of-single-arm-open-label-phase-ib-2-study-to-evaluate-pepine-vcnx-20230321monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-that-keynote-b-84-has-reached-targeted-enrollment-for-pre-planned-interim-vcnx-20230309monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-first-patient-dosed-with-anti-ccr8-antibody-licensed-to-surface-oncolog-vcnx-20230109monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-3-8-million-private-placement-vcnx-20221128monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-third-quarter-2022-results-and-provides-corporate-update-vcnx-20221114monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-and-its-collaborators-present-two-abstracts-related-to-pepinemab-combination-immu-vcnx-20221110monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-second-quarter-2022-results-and-provides-corporate-update-excellent-progr-vcnx-20220815monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-s-phase-2-signal-study-to-evaluate-pepinemab-antibody-in-huntington-s-disease-vcnx-20220808monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-announces-presentation-at-the-2022-alzheimer-s-association-international-conf-vcnx-20220729monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-to-participate-in-the-jefferies-healthcare-conference-on-friday-june-10-2022--vcnx-20220525monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-first-quarter-2022-results-and-provides-corporate-update-vcnx-20220516monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-announces-upcoming-presentation-at-the-pegs-boston-conference-expo-highlighti-vcnx-20220425monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-2021-financial-results-and-provides-corporate-update-vcnx-20220331monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-announces-upcoming-presentation-at-the-2022-american-association-for-cancer-r-vcnx-20220309monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-to-present-at-chdi-s-17th-annual-hd-therapeutics-conference-meeting-vcnx-20220224monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-6-6-million-private-placement-vcnx-20220127monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-two-complete-responses-in-first-three-patients-enrolled-in-the-phase-1b-2-vcnx-20220126monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-phase-ib-keynote-b84-combination-study-of-keytruda-and-pepinemab-in-patie-vcnx-20220104monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-to-present-at-the-society-for-immunotherapy-of-cancer-s-sitc-36th-annual-meet-vcnx-20211110monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-to-present-at-the-clinical-trials-on-alzheimer-s-disease-ctad-meeting-vcnx-20211109monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-third-quarter-2021-financial-results-and-provides-corporate-update-vcnx-20211108monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-to-present-at-the-12th-annual-jefferies-london-healthcare-conference-vcnx-20211104monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-to-present-at-the-virtual-huntington-s-study-group-meeting-on-november-4-6-2021-vcnx-20211101monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-to-present-at-the-oppenheimer-co-inc-fall-healthcare-life-sciences-and-medtech-su-vcnx-20210917monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-ceo-dr-maurice-zauderer-presented-new-and-promising-phase-2-signal-trial-data-in--vcnx-20210915monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-second-quarter-2021-financial-results-and-provides-corporate-update-vcnx-20210816monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-to-chair-panel-q-a-session-and-present-poster-at-the-xv-european-meeting-on-glial-vcnx-20210630monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-activation-of-clinical-sites-to-enroll-patients-in-studies-of-pepinemab-vcnx-20210608monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-to-present-at-the-jefferies-2021-virtual-healthcare-conference-vcnx-20210519monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-first-quarter-2021-financial-results-and-provides-corporate-update-vcnx-20210517monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-publication-of-results-from-classical-lung-phase-1b-2-clinical-trial-in-vcnx-20210421monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-fourth-quarter-2020-financial-results-and-provides-corporate-update-vcnx-20210316monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-vcnx-20210311monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-licensing-of-anti-ccr8-antibody-to-surface-oncology-vcnx-20210222monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-signing-of-two-multi-project-deals-with-leading-pharmaceutical-companie-vcnx-20210219monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-to-participate-in-the-lifesci-partners-10th-annual-healthcare-corporate-access-ev-vcnx-20210105monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-third-quarter-2020-financial-results-and-provides-corporate-update-vcnx-20201113monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-to-present-additional-signal-data-at-huntington-study-group-2020-medical-conferen-vcnx-20201029monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-to-present-at-the-virtual-investor-kol-roundtable-vcnx-20201026monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-clinical-collaboration-with-merck-to-evaluate-pepinemab-in-combination--vcnx-20200917monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-appointment-of-robert-scala-as-chief-commercial-officer-vcnx-20200827monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-second-quarter-2020-financial-results-and-provides-corporate-update-vcnx-20200814monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-provides-update-of-potentially-pivotal-signal-clinical-trial-in-huntington-s-dise-vcnx-20200707monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-to-present-at-the-virtual-investor-fireside-chat-series-vcnx-20200609monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-first-quarter-2020-financial-results-and-provides-corporate-update-vcnx-20200514monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-to-present-updated-results-from-classical-lung-phase-1b-2-study-of-pepinemab-vx15-vcnx-20200513monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-delivers-virtual-presentation-at-the-advances-in-alzheimer-s-and-parkinson-s-ther-vcnx-20200407monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-up-to-16-5-million-in-equity-financing-agreements-and-provides-an-updat-vcnx-20200331monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-corporat-vcnx-20200309monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-three-oral-presentations-highlighting-semaphorin-4d-sema4d-at-the-asco--vcnx-20200206monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-3-million-award-from-the-alzheimer-s-drug-discovery-foundation-vcnx-20191210monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-details-scientific-rationale-for-expanding-pepinemab-clinical-programs-to-include-vcnx-20191209monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-award-notice-from-the-alzheimer-s-association-2020-part-the-cloud-progr-vcnx-20191114monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-third-quarter-2019-financial-results-and-provides-corporate-update-vcnx-20191112monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-presents-updated-interim-data-from-a-phase-1b-2-study-of-pepinemab-vx15-2503-in-c-vcnx-20191109monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-presents-updated-interim-data-from-a-phase-1b-2-study-of-pepinemab-vx15-2503-in-c-vcnx-20190927monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-to-present-at-the-ladenburg-thalmann-2019-healthcare-conference-vcnx-20190924monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-second-quarter-2019-financial-results-and-provides-corporate-update-vcnx-20190814monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-full-enrollment-achieved-in-ongoing-classical-lung-phase-1b-2-trial-of--vcnx-20190813monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-13-8-million-private-placement-vcnx-20190731monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-presents-updated-interim-results-from-a-phase-1b-2-study-of-pepinemab-in-combinat-vcnx-20190603monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-poster-presentations-at-the-2019-asco-annual-meeting-vcnx-20190515monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-first-quarter-2019-financial-results-and-provides-corporate-update-vcnx-20190515monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-summary-of-key-data-presented-at-the-2019-annual-meeting-of-the-american-asso-vcnx-20190409monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-to-provide-clinical-data-on-posters-presented-at-the-2019-annual-meeting-of-t-vcnx-20190401monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-to-present-at-the-oppenheimer-co-29th-annual-healthcare-conference-on-march-1-vcnx-20190313monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-fourth-quarter-2018-financial-results-and-provides-corporate-update-vcnx-20190313monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-to-present-data-on-its-anti-sema4d-compound-at-the-american-association-for-c-vcnx-20190306monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-presented-previously-disclosed-data-from-ongoing-phase-1-2-trial-of-vx15-2503-vcnx-20190117monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-announces-completion-of-enrollment-for-its-signal-huntington-s-disease-trial-vcnx-20190116monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-gives-podium-presentation-and-poster-at-the-society-for-immunotherapy-of-canc-vcnx-20181115monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-reports-third-quarter-2018-financial-results-and-provides-corporate-update-vcnx-20181113monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-presents-overview-of-the-clinical-development-of-vx15-pepinemab-for-the-poten-vcnx-20181112monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-to-present-data-on-its-semaphorin-4d-monoclonal-antibody-programs-at-two-conf-vcnx-20181106monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-to-participate-on-a-panel-and-meet-with-investors-at-the-btig-healthcare-conf-vcnx-20181023monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-presents-preliminary-data-on-its-anti-semaphorin-4d-monocolonal-antibody-tech-vcnx-20181002monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-to-participate-in-podium-and-poster-sessions-at-the-fourth-cri-cimt-eati-aacr-vcnx-20180927monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-to-present-at-the-ladenburg-thalmann-2018-healthcare-conference-vcnx-20180925monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-pricing-of-initial-public-offering-vcnx-20180809monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-to-host-key-opinion-leader-luncheon-on-huntington-s-disease-vcnx-20180130monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-announces-research-collaboration-employing-activmab-platform-technology-and-a-vcnx-20180108monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-announces-the-first-patient-treated-in-a-phase-ib-ii-combination-study-with-a-vcnx-20171026monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-announces-preliminary-data-from-the-signal-clinical-trial-investigational-dru-vcnx-20170424monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-clinical-collaboration-with-merck-kgaa-darmstadt-germany-to-evaluate-th-vcnx-20161006monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-announces-continuation-of-the-signal-clinical-trial-vcnx-20160909monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-receives-orphan-drug-designation-from-u-s-fda-for-its-lead-antibody-product-c-vcnx-20160823monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-receives-fda-fast-track-designation-for-vx15-antibody-for-the-treatment-of-huntin-vcnx-20160801monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-publication-of-results-from-a-phase-i-trial-of-anti-semaphorin-4d-antib-vcnx-20151020monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-announces-the-initiation-of-a-phase-2-clinical-trial-of-its-investigational-v-vcnx-20150624monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-provides-an-update-on-its-vx15-2503-phase-1-clinical-trial-in-multiple-sclerosis--vcnx-20150331monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-signs-multi-target-antibody-discovery-deal-with-five-prime-therapeutics-vcnx-20150319monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-the-publication-of-data-demonstrating-preclinical-efficacy-in-an-animal-vcnx-20150217monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-announces-receipt-of-notice-from-nasdaq-regarding-late-filing-of-quar-ocea-20241122monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-announces-receipt-of-nasdaq-staff-determination-letter-ocea-20241022monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-nasdaq-ocea-announces-publication-of-new-data-deepening-understanding-ocea-20241001monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-nasdaq-ocea-announces-patent-issued-for-pfgarp-malaria-antibodies-cen-ocea-20240827monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-announces-receipt-of-notice-from-nasdaq-regarding-late-filing-of-quar-ocea-20240823monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-congratulates-joint-venture-partner-virion-therapeutics-on-po-ocea-20240605monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-announces-receipt-of-notice-from-nasdaq-regarding-late-filing-of-quar-ocea-20240530monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-nasdaq-ocea-announces-patent-allowance-for-malaria-antibodies-that-ha-ocea-20240516monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-announces-receipt-of-notice-from-nasdaq-regarding-late-filing-of-annu-ocea-20240424monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-congratulates-jv-partner-virion-therapeutics-on-promising-fir-ocea-20240328monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-announces-joint-venture-partner-virion-therapeutics-to-presen-ocea-20240229monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-announces-publication-of-groundbreaking-breast-cancer-research-uncove-ocea-20231205monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-announces-receipt-of-notice-from-nasdaq-regarding-late-filing-of-quar-ocea-20231129monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-announces-positive-preclinical-oncology-data-for-vron-0300-pr-ocea-20231114monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-announces-first-patients-dosed-by-joint-venture-partner-virio-ocea-20231026monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-announces-1-million-falk-award-for-malaria-drug-candidate-add-ocea-20231024monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-announces-enrollment-of-patients-for-phase-1b-study-for-chron-ocea-20231017monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-and-virion-therapeutics-form-joint-venture-supporting-multi-national-firs-ocea-20231012monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-announces-loan-commitment-from-largest-stockholder-up-to-10-million-ocea-20231004monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-announces-non-dilutive-amendment-to-existing-agreement-with-a-key-financi-ocea-20231003monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-announces-newly-published-findings-demonstrating-ability-to-restore-treat-ocea-20231003monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-will-host-an-r-d-update-today-on-malaria-and-fibrosis-program-ocea-20230914monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-insight-announces-richard-curran-as-new-president-ocea-20230908monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-announces-new-patent-for-anti-fibrosis-discovery-with-allowan-ocea-20230829monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-provides-latest-updates-on-its-broad-programs-in-malaria-fibr-ocea-20230810monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-share-price-target-now-averaging-18-21-based-on-research-and--ocea-20230809monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-nasdaq-ocea-celebrates-95-lung-cancer-tumor-reduction-results-on-worl-ocea-20230801monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-s-nasdaq-ocea-mrna-based-vaccine-candidate-generates-over-90-killing-of-m-ocea-20230711monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-joins-the-russell-2000-index-ocea-20230627monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-nasdaq-ocea-announces-u-s-patent-issued-for-bispecific-cancer-immunot-ocea-20230626monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-extends-patent-rights-for-breakthrough-idiopathic-pulmonary-f-ocea-20230623monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-announces-share-price-target-increase-to-17-63-by-fundamental-ocea-20230621monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-nasdaq-ocea-announces-malaria-vaccine-patent-granted-in-brazil-the-25-ocea-20230608monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-announces-initiation-of-coverage-by-taglich-brothers-with-a-s-ocea-20230601monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-nasdaq-ocea-announces-addition-to-the-russell-2000-index-ocea-20230525monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-nasdaq-ocea-announces-patent-award-for-novel-cancer-immunotherapy-tre-ocea-20230523monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-enters-into-a-25-million-convertible-note-facility-ocea-20230516monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-announces-70-increase-in-price-target-by-ef-hutton-from-10-to-ocea-20230501monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-announces-new-glioblastoma-results-validating-profound-tumor--ocea-20230427monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-on-world-malaria-day-announces-sharing-of-new-malaria-vaccine-ocea-20230425monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-announces-notice-of-allowance-for-u-s-patent-application-for--ocea-20230420monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-announces-notice-of-allowance-for-u-s-patent-application-for--ocea-20230413monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-will-target-pulmonary-fibrosis-discoveries-as-novel-treatment-ocea-20230406monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-details-novel-malaria-therapeutic-discoveries-at-the-nih-labo-ocea-20230321monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-announces-initiation-of-equity-analyst-coverage-by-fundamenta-ocea-20230316monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-announces-initiation-of-equity-analyst-coverage-by-ef-hutton--ocea-20230314monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-shares-detailed-research-data-on-anti-tumor-pathway-discoveri-ocea-20230309monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-nasdaq-ocea-announces-award-of-new-patent-to-scientific-co-founder-dr-ocea-20230228monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-nasdaq-ocea-celebrates-discovery-of-bispecific-antibodies-and-immune-chec-ocea-20230223monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-to-ring-the-nasdaq-stock-market-opening-bell-ocea-20230216monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-debuts-as-publicly-traded-company-focused-on-accelerating-the-commerciali-ocea-20230215monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-and-aesther-healthcare-acquisition-corp-announce-the-award-of-new-patents-ocea-20230209monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-and-aesther-healthcare-acquisition-corp-announce-publication-of-discovery-ocea-20230130monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-provides-corporate-update-and-company-summary-ocea-20230124monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-files-registration-statement-for-proposed-initial-public-offering-ocea-20210610monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-fourth-quarter-and-full-year-2024-financial-results-and-bu-ubx-20250307monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-third-quarter-2024-financial-results-and-business-updates-ubx-20241104monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-host-in-person-ophthalmology-day-in-new-york-on-tuesday-october-15--ubx-20240924monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-participate-in-upcoming-investor-conferences-ubx-20240812monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-second-quarter-2024-financial-results-and-business-updates-ubx-20240806monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-reports-granting-of-new-employment-inducement-award-ubx-20240724monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-appointment-of-alicia-tozier-as-chief-strategy-officer-ubx-20240722monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-first-quarter-2024-financial-results-and-business-updates-ubx-20240514monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-upcoming-presentations-at-the-arvo-2024-annual-meeting-ubx-20240425monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-extension-of-phase-2b-aspire-clinical-study-evaluating-ubx13-ubx-20240423monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-fourth-quarter-and-full-year-2023-financial-results-and-bu-ubx-20240415monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-doses-first-patients-in-phase-2-aspire-study-of-ubx1325-in-dme-ubx-20231212monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-third-quarter-2023-financial-results-and-business-updates-ubx-20231113monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-exercise-of-warrants-for-4-38-million-in-gross-proceeds-ubx-20231110monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-48-week-results-from-phase-2-envision-study-of-ubx1325-in-pa-ubx-20230927monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-second-quarter-2023-financial-results-and-business-updates-ubx-20230808monthly0.5https://www.biopharmawatch.com/news/UBX/unity-announces-design-of-phase-2b-aspire-study-evaluating-ubx1325-in-diabetic-macular-ede-ubx-20230621monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-first-quarter-2023-financial-results-and-business-updates-ubx-20230509monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-positive-48-week-results-from-phase-2-behold-study-of-ubx132-ubx-20230424monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-host-program-update-on-behold-the-phase-2-clinical-trial-of-ubx1325-ubx-20230423monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-results-from-phase-2-envision-study-of-ubx1325-in-patients-w-ubx-20230327monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-fourth-quarter-and-full-year-2022-financial-results-and-bu-ubx-20230315monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-participate-in-the-cowen-43rd-annual-health-care-conference-ubx-20230228monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-participate-in-the-svb-securities-global-biopharma-conference-ubx-20230215monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-host-investor-call-to-review-data-from-the-ubx1325-program-and-prov-ubx-20230209monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-reports-granting-of-new-employment-inducement-award-ubx-20230118monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-third-quarter-2022-financial-results-and-business-updates-ubx-20221108monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-positive-24-week-data-from-phase-2-behold-study-of-ubx1325-i-ubx-20221101monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-host-program-update-on-behold-the-phase-2-clinical-trial-of-ubx1325-ubx-20221031monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-reverse-stock-split-effective-at-5-00-pm-eastern-time-today-ubx-20221019monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-s-investor-and-analyst-day-to-highlight-ubx1325-program-in-age-related-ubx-20221011monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-host-investor-and-analyst-day-to-discuss-clinical-development-progr-ubx-20221006monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-completes-enrollment-in-phase-2-envision-study-of-ubx1325-in-wet-age-r-ubx-20220919monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-participate-in-upcoming-investor-conferences-ubx-20220831monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-pricing-of-upsized-underwritten-public-offering-ubx-20220818monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-proposed-public-offering-of-common-stock-ubx-20220816monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-second-quarter-2022-financial-results-and-business-updates-ubx-20220812monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-positive-data-in-phase-2-behold-study-of-ubx1325-in-patients-ubx-20220812monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-host-investor-call-on-12-and-18-week-data-from-phase-2-behold-study-ubx-20220811monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-present-clinical-data-at-the-american-society-of-retina-specialists-ubx-20220712monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-reports-granting-of-new-employment-inducement-award-ubx-20220629monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-appointment-of-accomplished-finance-and-operations-executive-ubx-20220526monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-participate-in-the-ubs-2022-global-healthcare-conference-ubx-20220525monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-first-quarter-2022-financial-results-and-business-updates-ubx-20220510monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-presentations-at-arvo-2022-showcase-ubx1325-as-an-investigational-nove-ubx-20220505monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-present-clinical-data-at-the-association-for-research-in-vision-oph-ubx-20220421monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-doses-first-patient-in-envision-the-phase-2-study-of-ubx1325-in-wet-ag-ubx-20220419monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-completes-enrollment-in-behold-the-phase-2-study-of-senolytic-candidat-ubx-20220412monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-fourth-quarter-and-full-year-2021-financial-results-and-bu-ubx-20220315monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-participate-in-the-cowen-42nd-annual-health-care-conference-ubx-20220301monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-additional-data-from-phase-1-study-of-ubx1325-in-advanced-va-ubx-20220214monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-restructuring-to-advance-corporate-strategy-and-focus-on-key-ubx-20220203monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-reports-granting-of-new-employment-inducement-award-ubx-20220202monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-provides-program-updates-and-anticipated-milestones-for-2022-ubx-20220104monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-reports-granting-of-new-employment-inducement-award-ubx-20211222monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-third-quarter-2021-financial-results-and-business-updates-ubx-20211110monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-improvement-in-visual-acuity-sustained-through-24-weeks-foll-ubx-20211109monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-reports-granting-of-new-employment-inducement-awards-ubx-20211103monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-reports-granting-of-new-employment-inducement-awards-ubx-20211006monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-positive-12-week-data-from-phase-1-clinical-trial-of-ubx1325-ubx-20211005monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-participate-in-upcoming-investor-conferences-ubx-20210907monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-reports-granting-of-new-employment-inducement-awards-ubx-20210818monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-participate-in-the-h-c-wainwright-ophthalmology-virtual-confere-ubx-20210816monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-second-quarter-2021-financial-results-and-business-updates-ubx-20210810monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-reports-granting-of-new-employment-inducement-awards-ubx-20210728monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-host-investor-call-with-retinal-expert-robert-bhisitkul-m-d-ph-d-to-ubx-20210723monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-positive-data-from-phase-1-clinical-trial-of-ubx1325-in-pati-ubx-20210706monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-reports-granting-of-new-employment-inducement-awards-ubx-20210602monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-first-quarter-2021-financial-results-and-business-updates-ubx-20210511monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-presents-ubx1325-data-demonstrating-improvement-in-retinal-vasculature-ubx-20210501monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-present-preclinical-data-on-clinical-candidate-molecule-ubx1325-at--ubx-20210428monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-reports-granting-of-new-employment-inducement-awards-ubx-20210421monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-fourth-quarter-and-full-year-2020-financial-results-and-bu-ubx-20210323monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-reports-granting-of-new-employment-inducement-award-ubx-20210311monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-appointment-of-alexander-nguyen-as-general-counsel-ubx-20210308monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-participate-in-upcoming-march-investor-conferences-ubx-20210226monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-reports-granting-of-new-employment-inducement-awards-ubx-20210224monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-reports-granting-of-new-employment-inducement-awards-ubx-20210203monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-appoints-mike-sapieha-ph-d-as-chief-scientific-advisor-ubx-20210201monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-reports-granting-of-new-employment-inducement-awards-ubx-20201216monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-appointment-of-clinical-development-and-industry-veteran-gil-ubx-20201214monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-third-quarter-2020-financial-results-and-clinical-program--ubx-20201104monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-first-patient-dosed-in-phase-1-study-of-ubx1325-in-diabetic--ubx-20201012monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-actions-to-focus-on-senolytic-programs-in-ophthalmology-and--ubx-20200915monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-participate-in-upcoming-september-investor-conferences-ubx-20200904monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-appointment-of-lynne-sullivan-as-chief-financial-officer-ubx-20200831monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-12-week-data-from-ubx0101-phase-2-clinical-study-in-patients-ubx-20200817monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-80m-debt-financing-from-hercules-capital-ubx-20200804monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-second-quarter-2020-financial-results-and-clinical-program-ubx-20200731monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-announce-second-quarter-2020-financial-results-ubx-20200724monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-cfo-transition-ubx-20200706monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-provides-updates-on-lead-development-programs-ubx-20200701monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-participate-in-fireside-chat-at-the-goldman-sachs-41st-annual-globa-ubx-20200611monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-to-participate-in-the-goldman-sachs-41st-annual-global-healthcare-conf-ubx-20200528monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-first-quarter-2020-financial-results-and-business-updates-ubx-20200507monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-announce-first-quarter-2020-financial-results-ubx-20200504monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-completes-enrollment-in-phase-1b-study-of-ubx0101-ubx-20200331monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-start-of-new-ceo-and-new-employment-inducement-grants-ubx-20200330monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-fourth-quarter-and-full-year-2019-financial-results-ubx-20200311monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-announce-fourth-quarter-and-full-year-2019-financial-results-ubx-20200303monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-appoints-anirvan-ghosh-ph-d-as-chief-executive-officer-ubx-20200302monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-provides-pipeline-and-business-updates-ubx-20200225monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-participate-in-the-cowen-and-company-40th-annual-health-care-co-ubx-20200224monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-third-quarter-2019-financial-results-and-business-updates-ubx-20191106monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-announces-first-patient-dosed-in-phase-2-study-of-ubx0101-in-osteo-ubx-20191031monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-announces-upcoming-scientific-presentations-at-acr-2019-annual-mee-ubx-20191024monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-announce-third-quarter-2019-financial-results-ubx-20191023monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-participate-in-the-2019-cantor-global-healthcare-conference-ubx-20190920monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-participate-in-upcoming-investor-conferences-ubx-20190827monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-second-quarter-2019-financial-results-and-program-updates-ubx-20190807monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-announces-plan-for-phase-2-clinical-study-of-ubx0101-in-osteoarthr-ubx-20190730monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-announce-second-quarter-2019-financial-results-ubx-20190730monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-reports-promising-topline-data-from-phase-1-first-in-human-study-of-ub-ubx-20190618monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-and-ucsf-enter-exclusive-license-agreement-on-alpha-klotho-protein-ubx-20190529monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-present-at-upcoming-investor-conferences-ubx-20190523monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-first-quarter-2019-financial-results-ubx-20190508monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-announce-first-quarter-2019-financial-results-ubx-20190429monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-fourth-quarter-and-full-year-2018-financial-results-and-pr-ubx-20190306monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-participate-in-the-cowen-39th-annual-health-care-conference-ubx-20190304monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-announce-fourth-quarter-and-full-year-2018-financial-results-ubx-20190225monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-expands-ongoing-ubx0101-phase-1-study-to-further-evaluate-sasp-factors-ubx-20190122monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-completion-of-ubx1967-license-and-advance-into-ind-enabling--ubx-20190103monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-appoints-margo-roberts-ph-d-to-board-of-directors-ubx-20181204monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-additional-cohort-to-evaluate-higher-dose-in-ongoing-ubx0101-ubx-20181203monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-host-investor-analyst-event-on-cellular-senescence-ubx-20181113monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-third-quarter-2018-financial-results-ubx-20181107monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-announce-third-quarter-2018-financial-results-ubx-20181031monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-participate-in-the-cantor-fitzgerald-annual-global-healthcare-c-ubx-20180924monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-participate-in-the-morgan-stanley-16th-annual-global-healthcare-ubx-20180905monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-second-quarter-2018-financial-results-ubx-20180809monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-announce-second-quarter-2018-financial-results-ubx-20180731monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-announces-first-patient-treated-in-ubx0101-phase-1-trial-for-osteo-ubx-20180625monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-added-to-russell-3000-2000-and-microcap-indexes-ubx-20180613monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-reports-first-quarter-2018-financial-results-ubx-20180607monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-participate-in-the-goldman-sachs-39th-annual-global-healthcare--ubx-20180605monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-to-announce-first-quarter-2018-financial-results-ubx-20180529monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-appoints-camille-landis-as-senior-vice-president-of-corporate-deve-ubx-20180514monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-announces-closing-of-initial-public-offering-ubx-20180507monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-inc-announces-pricing-of-initial-public-offering-of-common-stock-ubx-20180502monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-announces-third-quarter-2021-results-and-business-update-ptix-20211116monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-to-host-virtual-science-review-wednesday-september-8th-at-10-am-et-ptix-20210830monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-announces-second-quarter-2021-results-and-provides-business-update-ptix-20210817monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-updates-timeline-for-commencement-of-patient-enrollment-for-pt0011-ptix-20210723monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-to-host-webinar-with-dr-maurizio-fava-for-its-lead-molecule-pt0011-ptix-20210706monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-to-present-at-the-h-c-wainwright-psychedelics-in-psychiatry-and-be-ptix-20210616monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-inc-announces-closing-of-13-2-million-public-offering-and-uplistin-ptix-20210429monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-inc-announces-nasdaq-uplisting-and-pricing-of-13-2-million-public--ptix-20210427monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-completes-2-0-million-convertible-note-financing-ptix-20200908monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-s-neuropeptide-shows-strong-efficacy-in-treating-depression-and-anxiety-of-esta-ptix-20170928monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-responds-to-fraudulent-press-release-ptpi-20220728monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-kicks-off-social-media-campaign-with-celebrity-physician-dr-drew-pi-ptpi-20220719monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-reports-first-quarter-2022-financial-results-and-provides-corporate-ptpi-20220516monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-to-pursue-505-b-2-pathway-for-h-100-company-s-novel-topical-investi-ptpi-20220503monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-to-present-at-the-planet-microcap-showcase-2022-ptpi-20220428monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-inc-engages-massachusetts-general-hospital-in-a-sponsored-research--ptpi-20220426monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-announces-positive-results-of-over-the-counter-otc-label-comprehens-ptpi-20220419monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-reports-year-end-2021-financial-results-and-corporate-highlights-ptpi-20220401monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-to-present-at-the-q1-investor-summit-conference-ptpi-20220303monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-to-participate-in-noblecon17-ptpi-20210119monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-and-shanghai-lishan-biopharmaceuticals-co-announce-exclusive-licensing-agreement-f-evgn-20260205monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-and-tmg-announce-collaboration-to-develop-nematode-resistant-soybean-through-genom-evgn-20181218monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-s-leading-insect-control-genes-demonstrate-effectiveness-against-insects-with-resi-evgn-20181127monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-establishment-of-ag-chemicals-subsidiary-agplenus-ltd-evgn-20181119monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-third-quarter-2018-financial-results-evgn-20181114monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-for-the-third-quarter-of-2018-earnings-announcement-schedule-evgn-20181024monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-a-significant-milestone-in-its-next-generation-herbicide-pipeline-evgn-20180905monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-second-quarter-2018-financial-results-evgn-20180808monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-for-the-second-quarter-of-2018-evgn-20180718monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-and-imamt-enter-a-collaboration-in-the-field-of-insect-resistance-traits-in-cotton-evgn-20180717monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-positive-yield-results-in-its-bio-stimulant-program-for-wheat-evgn-20180710monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-first-quarter-2018-financial-results-evgn-20180529monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-for-the-first-quarter-of-2018-earnings-announcement-schedule-evgn-20180510monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-and-marrone-bio-innovations-announce-phase-advancement-in-their-insect-control-col-evgn-20180508monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-files-annual-report-for-the-year-ended-december-31-2017-evgn-20180401monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-fourth-quarter-and-full-year-2017-financial-results-evgn-20180228monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-positive-results-in-its-novel-mode-of-action-herbicide-program-evgn-20180227monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-for-the-fourth-quarter-and-full-year-2017-earnings-announcement--evgn-20180212monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-participate-in-israeli-consortium-to-develop-phenotyping-tools-and-systems-for--evgn-20180129monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-positive-2nd-year-field-trial-results-in-corn-bio-stimulant-ag-biologica-evgn-20180110monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-third-quarter-2017-financial-results-evgn-20171122monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-for-the-third-quarter-of-2017-earnings-announcement-schedule-evgn-20171102monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-revised-and-expanded-market-focus-and-new-corporate-structure-evgn-20171030monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-rahan-meristem-announce-positive-results-in-2nd-year-field-trials-addressing-black-evgn-20170926monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-present-at-the-26th-asian-pacific-weed-science-society-conference-evgn-20170823monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-second-quarter-2017-financial-results-evgn-20170810monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-for-the-second-quarter-of-2017-earnings-announcement-schedule-evgn-20170720monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-achieves-important-milestone-in-monsanto-crop-disease-collaboration-evgn-20170711monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-positive-results-in-insect-control-seed-trait-program-and-advancement-to-evgn-20170620monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-first-quarter-2017-financial-results-evgn-20170517monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-files-annual-report-for-the-year-ended-december-31-2016-evgn-20170504monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-for-the-first-quarter-of-2017-earnings-announcement-schedule-evgn-20170426monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-present-innovative-approach-for-improving-cannabis-for-medical-needs-at-cannate-evgn-20170307monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-fourth-quarter-and-full-year-2016-financial-results-evgn-20170227monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-and-icl-innovation-sign-collaboration-for-development-of-crop-enhancers-evgn-20170214monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-fourth-quarter-and-full-year-2016-earnings-announcement-schedule-evgn-20170213monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-transfer-stock-exchange-listing-to-nasdaq-evgn-20161219monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-third-quarter-2016-financial-results-evgn-20161121monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-positive-field-trial-results-in-ag-biologicals-program-evgn-20161116monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-third-quarter-2016-earnings-announcement-schedule-evgn-20161102monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-and-imamt-sign-collaboration-for-genomic-promoter-discovery-and-validation-in-cott-evgn-20161019monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-joint-microbial-diversity-activity-with-university-of-missouri-evgn-20160913monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-participation-at-the-18th-annual-rodman-renshaw-global-investment-confer-evgn-20160901monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-appoints-a-new-member-to-board-of-directors-and-a-new-chief-operating-officer-evgn-20160811monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-second-quarter-2016-financial-results-evgn-20160811monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-participate-at-piper-jaffray-global-agriculture-symposium-evgn-20160801monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-second-quarter-2016-earnings-announcement-schedule-evgn-20160725monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-present-at-crops-and-chemicals-2016-conference-evgn-20160713monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-financial-results-for-the-first-quarter-of-2016-evgn-20160519monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-and-marrone-bio-innovations-disclose-positive-results-in-insect-control-collaborat-evgn-20160516monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-present-the-potential-of-integrating-novel-genome-editing-technology-with-its-c-evgn-20160503monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-s-first-quarter-2016-earnings-announcement-schedule-evgn-20160502monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-files-annual-report-for-the-year-ended-december-31-2015-evgn-20160425monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-selected-for-photosynthesis-research-consortium-within-european-horizon-2020-progr-evgn-20160419monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-fourth-quarter-and-full-year-2015-financial-results-evgn-20160301monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-discloses-positive-results-in-yield-improvement-collaboration-with-monsanto-utiliz-evgn-20160223monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-s-fourth-quarter-and-full-year-2015-earnings-announcement-schedule-evgn-20160209monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-appoints-eyal-leibovitz-as-chief-financial-officer-evgn-20151222monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-officially-opens-research-and-development-facility-in-st-louis-missouri-evgn-20151119monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-present-at-ld-micro-invitational-evgn-20150528monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-files-annual-report-for-the-year-ended-december-31-2014-evgn-20150430monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-s-first-quarter-2015-earnings-announcement-schedule-evgn-20150428monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-ceo-ofer-haviv-and-marrone-bio-innovations-ceo-pam-marrone-to-participate-in-profi-evgn-20150427monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-discloses-first-collaboration-with-leading-multinational-food-company-for-improvin-evgn-20150318monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-introduces-biology-driven-ag-chemical-discovery-platform-evgn-20150224monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-establish-research-and-development-facility-in-the-united-states-evgn-20150209monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-s-fourth-quarter-and-full-year-2014-earnings-announcement-schedule-evgn-20150205monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-new-gene-optimization-program-being-incorporated-into-yield-environmental-stress-c-evgn-20150204monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-third-quarter-2014-financial-results-evgn-20141110monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-expansion-of-crop-protection-activities-evgn-20141029monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-s-third-quarter-2014-earnings-announcement-schedule-evgn-20141022monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-subsidiary-and-embrapa-to-cooperate-on-advancing-castor-cultivation-in-brazil-evgn-20141020monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-second-quarter-2014-financial-results-evgn-20140820monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-present-at-credit-suisse-2014-basic-materials-conference-evgn-20140819monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-first-quarter-2009-financial-results-evgn-20090519monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-fourth-quarter-and-annual-2008-financial-results-evgn-20090311monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-third-quarter-2008-financial-results-evgn-20081128monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-appointment-of-dr-sandra-milligan-as-interim-ceo-awh-20241216monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-successfully-reaches-the-first-milestone-of-the-arpa-h-10-million-aw-awh-20241203monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-reports-selected-third-quarter-2024-financial-results-awh-20241114monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-expands-co-marketing-and-distribution-collaboration-with-bioreferenc-awh-20241107monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-announce-third-quarter-earnings-results-and-host-a-conference-cal-awh-20241104monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-issues-letter-to-shareholders-and-announces-virtual-research-develop-awh-20241025monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-selected-to-receive-10-million-award-from-arpa-h-s-sprint-for-women--awh-20241023monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-receives-approval-from-new-york-state-department-of-health-for-ovawa-awh-20241015monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-publication-of-data-demonstrating-performance-of-its-in-de-awh-20240910monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-present-at-the-h-c-wainwright-26th-annual-global-investment-confe-awh-20240906monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-selected-as-a-spoke-for-the-investor-catalyst-hub-awh-20240905monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-partners-with-dorsata-to-create-new-clinical-workflow-tool-for-adnex-awh-20240827monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-reports-second-quarter-2024-financial-results-awh-20240812monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-s-announces-a-poster-presentation-at-the-27th-annual-national-associ-awh-20240805monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-poster-presentation-at-the-menopause-society-s-2024-annual-awh-20240801monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-announce-second-quarter-earnings-results-and-host-a-conference-ca-awh-20240731monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-appoints-mr-john-ragard-to-its-board-of-directors-awh-20240729monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-preliminary-second-quarter-2024-ovasuite-product-volume-an-awh-20240711monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-closing-of-1-9-million-private-placement-equity-financing-awh-20240709monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-1-935-million-private-placement-equity-financing-awh-20240701monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-provides-commercial-reimbursement-and-cash-guidance-updates-awh-20240613monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-present-at-the-a-g-p-healthcare-showcase-on-may-21-awh-20240516monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-reports-first-quarter-2024-financial-results-awh-20240515monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-announce-first-quarter-earnings-results-and-host-a-conference-cal-awh-20240508monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-publication-of-two-ovawatch-peer-reviewed-manuscripts-awh-20240507monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-enhances-its-commercial-offering-with-the-formal-launch-of-longitudi-awh-20240502monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-anthem-blue-cross-to-provide-coverage-for-ovasuite-sm-in-c-awh-20240409monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-reports-fourth-quarter-and-full-year-2023-financial-results-awh-20240328monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-new-time-for-its-fourth-quarter-and-2023-year-end-earnings-awh-20240325monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-present-at-the-medinvest-biotech-pharma-investor-conference-awh-20240321monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-expands-senior-leadership-team-with-the-addition-of-sandra-milligan--awh-20240318monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-announce-fourth-quarter-and-2023-year-end-earnings-results-and-ho-awh-20240311monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-present-at-the-cancer-advocacy-group-of-louisiana-s-3rd-annual-ne-awh-20240222monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-late-breaking-poster-presentation-at-the-upcoming-71st-ann-awh-20240212monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-ovasuite-sm-distribution-agreement-in-the-philippines-awh-20240206monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-5-5-million-registered-direct-offering-and-concurrent-priv-awh-20240125monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-host-r-d-day-with-updates-on-the-development-of-the-company-s-ova-awh-20231219monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-participate-in-corporate-access-events-during-jp-morgan-healthcar-awh-20231214monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-provides-a-development-update-on-its-portfolio-of-noninvasive-tests--awh-20231206monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-secures-reimbursement-for-ova1plus-r-from-california-medicaid-medi-c-awh-20231128monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-receives-final-crosswalk-pricing-determination-from-the-centers-for--awh-20231127monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-reports-third-quarter-2023-financial-results-awh-20231113monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-supports-centers-for-medicare-medicaid-services-cms-proposed-rule-to-awh-20231109monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-announce-third-quarter-earnings-results-and-host-a-conference-cal-awh-20231031monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-sees-poster-on-its-mirna-based-ovarian-cancer-test-presented-at-the--awh-20231025monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-establishes-a-new-clinical-advisory-board-awh-20231023monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-present-at-the-bioventure-nexus-conference-awh-20230929monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-regains-nasdaq-compliance-awh-20230913monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-dr-jody-berry-as-new-chief-scientific-officer-awh-20230911monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-signs-exclusive-sample-procurement-agreement-with-the-university-of--awh-20230831monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-present-at-the-h-c-wainwright-25th-annual-global-investment-confe-awh-20230829monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-michelle-snider-as-senior-vice-president-commercial-strate-awh-20230828monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-reports-second-quarter-2023-financial-results-awh-20230814monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-transition-of-its-chief-scientific-officer-chief-operating-awh-20230809monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-announce-second-quarter-earnings-results-and-host-a-conference-ca-awh-20230731monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-4-7-million-registered-direct-offering-awh-20230720monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-fr-awh-20230628monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-appoints-dr-winfred-parnell-to-its-board-of-directors-awh-20230605monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-regained-compliance-with-nasdaq-s-minimum-bid-price-requirement-awh-20230602monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-the-publication-of-three-abstracts-by-the-american-society-awh-20230531monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-participate-at-william-blair-s-43rd-annual-growth-stock-conferenc-awh-20230530monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-present-at-the-2023-american-college-of-obstetricians-and-gynecol-awh-20230519monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-names-torsten-hombeck-as-chief-financial-officer-awh-20230516monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-host-investor-day-on-ovawatch-sm-and-endocheck-market-opportuniti-awh-20230515monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-launches-its-new-to-the-street-media-series-on-may-8-2023-world-ovar-awh-20230515monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-reports-first-quarter-2023-financial-results-awh-20230511monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-1-for-15-reverse-stock-split-awh-20230511monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-signs-an-exclusive-licensing-agreement-with-dana-farber-cancer-insti-awh-20230511monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-appoints-three-new-members-to-its-board-of-directors-awh-20230509monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-preliminary-first-quarter-2023-ovasuite-volume-increase-of-awh-20230427monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-reports-fourth-quarter-and-full-year-2022-financial-results-awh-20230322monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-announce-year-end-2022-financial-results-and-host-conference-call-awh-20230303monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-national-payer-coverage-for-ovawatch-awh-20230303monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-preliminary-fourth-quarter-2022-volume-preliminary-results-awh-20230109monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-publication-of-real-world-data-validating-use-of-ovawatch--awh-20230106monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-three-reimbursement-milestones-that-improve-patient-access-awh-20221227monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-the-commercial-launch-of-ovawatch-sm-awh-20221129monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-reports-third-quarter-2022-financial-results-awh-20221110monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-announce-third-quarter-2022-financial-results-and-host-conference-awh-20221101monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-participate-at-the-upcoming-microcap-rodeo-windy-city-roundup-202-awh-20221006monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-formal-launch-of-co-marketing-and-distribution-collaborati-awh-20221005monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-publication-of-its-second-generation-multivariate-index-as-awh-20220912monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-announces-pricing-of-9-0-million-public-offering-awh-20220823monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-announces-proposed-public-offering-awh-20220822monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-hosting-women-s-health-webinar-on-ovarian-cancer-risk-assessments-ut-awh-20220818monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-reports-second-quarter-2022-financial-results-awh-20220810monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-announce-second-quarter-2022-financial-results-and-host-conferenc-awh-20220801monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-appointment-of-two-new-board-members-awh-20220623monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-publication-of-paper-validating-ovawatch-algorithm-in-the--awh-20220616monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-participate-in-the-upcoming-investor-conferences-awh-20220512monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-reports-first-quarter-2022-financial-results-awh-20220511monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-announce-first-quarter-2022-financial-results-and-host-conference-awh-20220429monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-reports-fourth-quarter-and-full-year-2021-financial-results-awh-20220323monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-announce-year-end-2021-financial-results-and-host-conference-call-awh-20220315monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-appointment-of-celeste-fralick-ph-d-to-its-board-of-direct-awh-20220228monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-expands-senior-leadership-team-with-addition-of-mr-michael-newto-awh-20220222monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-participate-in-the-upcoming-winter-wonderland-best-ideas-conferen-awh-20220208monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-the-addition-of-465-000-covered-lives-through-medicaid-cre-awh-20220131monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-fourth-quarter-operational-metrics-and-provides-updates-on-awh-20220105monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-executes-an-agreement-with-axia-women-s-health-to-launch-aspira-syne-awh-20220105monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-appoints-minh-merchant-as-general-counsel-awh-20220105monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-reports-third-quarter-2021-financial-results-awh-20211110monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-to-report-third-quarter-2021-financial-results-on-november-10-awh-20211101monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-black-women-s-health-imperative-lead-congressional-briefing-awh-20210930monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-executes-four-aspira-synergytm-technology-transfer-agreements-awh-20210929monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-to-present-at-the-cantor-fitzgerald-virtual-global-healthcare-co-awh-20210921monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-kicks-off-ovarian-cancer-awareness-month-by-further-establishing-its-awh-20210909monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-reports-second-quarter-2021-financial-results-awh-20210812monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-to-report-second-quarter-2021-financial-results-on-august-12-awh-20210727monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laborato-awh-20210708monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-releases-analytical-and-initial-clinical-validation-performance-for--awh-20210603monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-to-participate-in-the-william-blair-growth-stock-conference-awh-20210519monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-reports-first-quarter-2021-financial-results-awh-20210513monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-to-reveal-3rd-generation-ovarian-cancer-risk-assessment-technology-a-awh-20210513monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and--awh-20210512monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-expands-leadership-team-with-industry-veteran-awh-20210511monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-to-report-first-quarter-2021-financial-results-on-may-13-awh-20210505monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-reports-fourth-quarter-and-full-year-2020-financial-results-awh-20210325monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-announces-an-agreement-for-the-development-and-commercialization-awh-20210325monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-to-report-fourth-quarter-and-full-year-2020-financial-results-awh-20210318monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medicall-awh-20210315monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-appoints-nicole-sandford-to-its-board-of-directors-awh-20210222monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-recognizes-the-importance-of-bridging-the-gap-in-ovarian-cancer-risk-awh-20210217monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-to-participate-in-btig-s-virtual-medtech-digital-health-life-sci-awh-20210212monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-to-add-nccn-management-recommendations-to-its-proprietary-aspira-awh-20210210monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-announces-pricing-of-45-million-public-offering-of-common-stock-awh-20210204monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-announces-proposed-public-offering-of-common-stock-awh-20210203monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-announces-it-is-now-a-highmark-contracted-provider-in-pennsylvan-awh-20210128monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-to-participate-in-virtual-investor-events-awh-20210104monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-awh-20201119monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-reports-third-quarter-2020-financial-results-awh-20201112monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-strengthens-executive-leadership-with-new-appointments-awh-20201110monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-strengthens-board-of-directors-with-the-addition-of-dr-sandra-e-broo-awh-20201109monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-to-present-at-the-canaccord-genuity-virtual-medtech-diagnostics--awh-20201105monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-to-report-third-quarter-2020-financial-results-on-november-12th-awh-20201104monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-announces-it-is-now-an-anthem-bluecross-blueshield-of-georgia-pa-awh-20201014monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-to-present-at-microcap-rodeo-best-ideas-bowl-october-13-16-awh-20201009monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-to-host-key-opinion-leader-call-on-ovarian-cancer-diagnostics-in-awh-20200915monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-to-present-at-cantor-virtual-healthcare-conference-awh-20200908monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-reports-second-quarter-2020-financial-results-awh-20200813monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-to-report-second-quarter-2020-financial-results-on-august-13th-awh-20200731monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-announces-equity-financing-of-approximately-11-million-awh-20200701monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-announces-first-patient-enrolled-in-prospective-ovanex-study-for-awh-20200629monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-inc-announces-additional-adjournment-of-special-meeting-urges-stockholders--vinc-20250716monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-inc-urges-stockholders-to-vote-for-approval-of-dissolution-proposal-and-ann-vinc-20250707monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-inc-announces-adjournment-of-special-meeting-will-reconvene-meeting-on-july-vinc-20250618monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-to-implement-cost-controls-to-support-advancing-phase-1-study-of-vip943-vinc-20241204monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reports-third-quarter-2024-financial-results-vinc-20241112monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-reports-positive-initial-clinical-data-from-ongoing-vip943-phase-1-dose-escalation-vinc-20241007monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reports-second-quarter-2024-financial-results-vinc-20240808monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reports-first-quarter-2024-financial-results-and-provides-corporate-update-vinc-20240514monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-announces-pricing-of-underwritten-public-offering-of-common-stock-and-warra-vinc-20240426monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-announces-proposed-underwritten-public-offering-of-common-stock-and-warrant-vinc-20240425monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-presents-positive-preliminary-phase-1-data-for-vip236-and-updates-on-pipeli-vinc-20240408monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-to-host-virtual-investor-event-reviewing-preliminary-phase-1-vip236-data-presented-vinc-20240401monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reports-fourth-quarter-and-full-year-2023-financial-results-and-corporate-u-vinc-20240329monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-to-present-three-posters-at-the-american-association-for-cancer-research-aacr-annu-vinc-20240305monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-announces-compelling-clinical-efficacy-of-enitociclib-in-combination-with-v-vinc-20240107monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-presents-preclinical-vip943-and-vip924-posters-at-ash-2023-vinc-20231210monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reports-third-quarter-2023-financial-results-and-provides-corporate-update-vinc-20231114monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-to-present-three-posters-at-ash-2023-in-december-vinc-20231102monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-to-participate-at-the-cantor-fitzgerald-global-healthcare-conference-2023-vinc-20230919monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-doses-first-patient-in-the-phase-1-clinical-trial-evaluating-vip943-vinc-20230914monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-announces-fda-clearance-of-ind-for-vip943-vinc-20230822monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reports-second-quarter-2023-financial-results-and-provides-corporate-update-vinc-20230807monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reports-first-quarter-2023-financial-results-and-provides-corporate-update-vinc-20230511monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-presents-preclinical-data-on-vip924-a-first-in-class-antibody-drug-conjugat-vinc-20230419monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-presents-preclinical-data-on-novel-small-molecule-drug-conjugates-at-the-am-vinc-20230417monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-presents-preclinical-data-on-vip236-a-first-in-class-small-molecule-drug-co-vinc-20230417monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-a--vinc-20230328monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-announces-poster-presentations-at-the-american-association-for-cancer-resea-vinc-20230314monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-to-participate-at-the-svb-securities-global-biopharma-conference-vinc-20230206monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-provides-american-society-of-hematology-annual-meeting-2022-poster-highligh-vinc-20221212monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-presents-preclinical-data-on-vip943-in-acute-myeloid-leukemia-models-at-the-vinc-20221211monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reports-third-quarter-2022-financial-results-and-provides-a-corporate-updat-vinc-20221110monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-announces-upcoming-poster-presentations-at-the-64th-american-society-of-hem-vinc-20221103monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reports-second-quarter-2022-financial-results-and-provides-a-corporate-upda-vinc-20220811monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-presents-preclinical-and-clinical-data-on-ptefb-cdk9-inhibitor-vip152-in-ly-vinc-20220610monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-provides-key-strategic-update-vinc-20220606monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reports-first-quarter-2022-financial-results-and-provides-a-corporate-updat-vinc-20220512monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-presents-preclinical-and-preliminary-clinical-data-on-ptefb-cdk9-inhibitor--vinc-20220408monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-a--vinc-20220329monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-announces-poster-presentation-at-the-american-association-for-cancer-resear-vinc-20220308monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-to-participate-in-the-svb-leerink-11th-annual-global-healthcare-conference-vinc-20220209monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-publishes-preclinical-data-demonstrating-therapeutic-potential-of-small-mol-vinc-20220203monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-announces-first-patient-dosed-in-phase-1-dose-escalation-study-of-vip152-in-vinc-20211217monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-presents-data-on-ptefb-cdk9-inhibitor-vip152-in-dlbcl-and-cll-at-the-63rd-a-vinc-20211211monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-receives-orphan-drug-designation-from-european-commission-for-vip152-for-th-vinc-20211207monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-hosting-key-opinion-leader-webinar-on-vip152-data-presented-at-the-american-vinc-20211206monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reports-third-quarter-2021-financial-results-and-provides-a-corporate-updat-vinc-20211112monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-announces-presentations-at-the-american-society-of-hematology-annual-meetin-vinc-20211104monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-announces-50-million-private-placement-vinc-20210916monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-to-participate-in-the-2021-wells-fargo-virtual-healthcare-conference-vinc-20210907monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reports-second-quarter-2021-financial-results-and-provides-a-corporate-upda-vinc-20210812monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-announces-inclusion-in-russell-3000-and-microcap-indexes-vinc-20210628monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-presents-clinical-data-on-vip512-its-ptefb-cdk9-inhibitor-in-patients-with--vinc-20210604monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-announces-first-patient-dosed-in-phase-1b-study-of-vip152-in-myc-driven-rel-vinc-20210603monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-to-participate-in-the-jefferies-virtual-healthcare-conference-vinc-20210526monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reports-first-quarter-2021-financial-results-and-provides-a-corporate-updat-vinc-20210517monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-announces-completion-of-public-warrant-redemption-vinc-20210506monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-announces-fda-clearance-of-ind-for-phase-1b-study-of-vip152-in-chronic-lymp-vinc-20210420monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-presents-preclinical-data-on-vip236-its-lead-small-molecule-drug-conjugate--vinc-20210410monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-to-host-key-opinion-leader-webinar-on-bioconjugation-and-cdk9-inhibitors-fo-vinc-20210407monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-announces-redemption-of-public-warrants-vinc-20210405monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-announces-formation-of-scientific-advisory-board-to-advance-its-clinical-pi-vinc-20210401monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-a--vinc-20210323monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-announces-poster-presentation-at-the-american-association-for-cancer-resear-vinc-20210310monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-strengthens-management-team-with-three-new-appointments-vinc-20210302monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-to-host-key-opinion-leader-webinar-on-vip152-for-the-treatment-of-hematolog-vinc-20210224monthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-to-participate-in-the-10th-annual-svb-leerink-global-healthcare-conference-vinc-20210217monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-year-end-2025-results-highlights-accelerating-settlement-activity-an-prph-20260415monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-provides-business-update-highlighting-advancing-crown-medical-collections-ac-prph-20260317monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-initiates-potential-sale-or-strategic-partnership-of-be-smart-and-advances-c-prph-20260203monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-provides-crown-medical-collections-update-250-insurance-payors-engaged-appro-prph-20260126monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-uplists-from-pink-sheets-to-otc-market-prph-20260122monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reported-results-for-the-third-quarter-ended-september-30-2025-and-will-hold-prph-20251119monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-to-present-third-quarter-2025-financial-results-on-november-19-prph-20251118monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-urges-shareholders-to-vote-by-november-23-on-proxy-proposals-prph-20251117monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-study-validating-be-smart-esophageal-cancer-test-accepted-by-journ-prph-20251022monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-full-uspto-approval-for-issuance-of-u-s-patent-protecting-esophage-prph-20250812monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-to-present-second-quarter-2025-financial-results-on-august-13-2025-prph-20250811monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-special-meeting-of-shareholders-and-filing-of-preliminary-proxy-st-prph-20250729monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-closing-of-3-million-senior-secured-convertible-notes-financing-prph-20250723monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-board-of-directors-authorizes-management-to-explore-strategic-reverse-merger-prph-20250721monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-receives-additional-180-day-extension-from-nasdaq-to-regain-compliance-w-prph-20250626monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-successful-study-demonstrating-performance-of-be-smart-test-in-det-prph-20250617monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-formation-of-clinical-science-advisory-board-to-accelerate-commerc-prph-20250606monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-financial-results-for-the-three-months-ended-march-31-2025-prph-20250520monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-to-present-first-quarter-2025-financial-results-on-may-20-2025-prph-20250513monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-announces-financial-results-for-the-year-ended-december-31-2024-prph-20250331monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-to-present-2024-year-end-financial-results-on-march-31-2025-prph-20250327monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-investor-summit-virtual-on-march-11-prph-20250307monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-examines-strategic-opportunities-to-leverage-its-dtc-multi-media-infrastruct-prph-20250225monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-excellent-progress-with-crown-medical-collections-targeting-over-5-prph-20250220monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-hires-stuart-hollenshead-as-coo-the-former-coo-and-cbo-of-barstool-sports-prph-20250218monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-closing-of-23-6-million-sale-of-pharmaloz-manufacturing-to-houston-prph-20250122monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-secures-global-private-equity-backing-nears-major-lozenge-deal-adds-seasoned-prph-20241211monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-financial-results-for-the-three-months-ended-september-30-2024-prph-20241113monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-closing-of-public-offering-of-common-stock-prph-20241112monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-to-present-third-quarter-2024-financial-results-on-november-13-2024-prph-20241111monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-pricing-of-public-offering-of-common-stock-prph-20241108monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-proposed-public-offering-of-common-stock-prph-20241107monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-launches-dna-complete-transforming-direct-to-consumer-genetic-testing-for-he-prph-20241104monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-2024-thinkequity-conference-prph-20241022monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-positive-updates-on-strategic-initiatives-company-anticipates-mult-prph-20241017monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-august-20th-virtual-investor-summit-microcap-event-prph-20240819monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-financial-results-for-the-three-months-ended-june-30-2024-prph-20240814monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-collaboration-with-forward-healthcare-consultants-to-aid-in-the-co-prph-20240813monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-to-present-second-quarter-2024-financial-results-on-august-14-prph-20240807monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-update-on-pharmaloz-manufacturing-inc-progress-prph-20240711monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-financial-results-for-the-three-months-ended-march-31-2024-and-hig-prph-20240509monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-to-present-first-quarter-2024-financial-results-on-may-9-prph-20240502monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-planet-microcap-showcase-vegas-2024-on-wednesday-may-1-202-prph-20240425monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-unveils-project-zenq-ai-prph-20240416monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-seeks-to-transform-esophageal-cancer-detection-and-management-with-launch-of-prph-20240410monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-prph-20240402monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-financial-results-for-the-year-ended-december-31-2023-and-signific-prph-20240315monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-2023-year-end-financial-results-on-march-15-2024-prph-20240308monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-significant-progress-in-be-smart-esophageal-cancer-test-developmen-prph-20240220monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-preliminary-positive-results-for-dietary-supplement-equivir-prph-20240214monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-ushers-in-new-genomics-era-with-jason-karkus-at-the-helm-of-nebula-genomics-prph-20240130monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-poised-to-ramp-up-growth-at-pharmaloz-and-nebula-genomics-in-2024-prph-20240104monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-financial-results-for-the-three-months-ended-september-30-2023-prph-20231109monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-host-third-quarter-2023-financial-results-conference-call-on-thursday-nov-prph-20231102monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-substantial-growth-expectations-for-pharmaloz-manufacturing-subsid-prph-20231017monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-thinkequity-conference-prph-20231012monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-updated-conference-call-dial-in-information-for-thursday-august-10-prph-20230810monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-financial-results-for-the-three-months-ended-june-30-2023-prph-20230810monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-teams-up-with-certis-oncology-to-accelerate-development-of-novel-linebacker--prph-20230803monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-host-second-quarter-2023-financial-results-conference-call-on-thursday-au-prph-20230802monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-sets-the-course-for-expansion-into-the-mena-region-with-cutting-edge-gen-prph-20230622monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-diamond-equity-research-emerging-growth-invitational-on-tu-prph-20230607monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-cancer-therapeutic-linebacker-1-pre-clinical-studies-with-dana-farber-harvar-prph-20230601monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-financial-results-for-the-three-months-ended-march-31-2023-prph-20230511monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-hires-dr-matthew-halpert-to-drive-company-s-key-therapeutic-and-diagnostic-o-prph-20230508monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-host-first-quarter-2023-financial-results-conference-call-on-thursday-may-prph-20230504monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-linebacker-1-cancer-therapeutic-shows-promising-mechanisms-of-action-as-both-prph-20230503monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-ceo-ted-karkus-named-one-of-inc-magazine-s-10-most-innovative-healthcare-lea-prph-20230428monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-launch-of-redesigned-corporate-website-prph-20230425monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-planet-microcap-showcase-vegas-2023-on-wednesday-april-26--prph-20230418monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-record-financial-results-for-the-year-ended-december-31-2022-prph-20230328monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-host-2022-year-end-financial-results-conference-call-on-tuesday-march-28--prph-20230321monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-new-6-million-stock-repurchase-program-prph-20230315monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-data-presentation-for-its-be-smart-esophageal-cancer-test-prph-20230313monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-nebula-genomics-subsidiary-introduces-lowest-ever-ngs-pricing-of-249-for-its-prph-20230307monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-collaboration-with-mprobe-inc-and-mayo-clinic-for-the-continuing-d-prph-20230301monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-plans-to-initiate-clinical-trial-of-equivir-otc-prph-20230222monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-esophageal-cancer-early-detection-test-be-smart-featured-in-peer-reviewed-ar-prph-20230216monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-plans-for-major-expansion-of-its-pharmaloz-manufacturing-inc-subsi-prph-20230215monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-provides-update-on-linebacker-1-cancer-co-therapy-program-and-outlines-devel-prph-20230206monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-closes-acquisition-of-be-smart-esophageal-pre-cancer-diagnostic-screening-te-prph-20230105monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-acquires-rights-to-novel-esophageal-cancer-test-prph-20221219monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-planet-microcap-showcase-virtual-2022-on-wednesday-decembe-prph-20221130monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-record-third-quarter-2022-financial-results-prph-20221110monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-collaboration-with-dana-farber-cancer-institute-prph-20221108monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-investor-summit-group-s-q4-conference-prph-20221108monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-host-third-quarter-2022-financial-results-conference-call-on-thursday-nov-prph-20221104monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-collaboration-with-g42-healthcare-prph-20221019monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-thinkequity-conference-prph-20221018monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference-se-prph-20220906monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-record-second-quarter-2022-financial-results-prph-20220811monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-host-second-quarter-2022-financial-results-conference-call-on-thursday-au-prph-20220805monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-new-6-million-stock-repurchase-plan-prph-20220726monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-prph-20220721monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-licensing-of-new-investigational-cancer-compounds-prph-20220721monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-host-live-webcast-to-discuss-business-developments-on-thursday-july-21-20-prph-20220719monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-formation-of-prophase-biopharma-inc-pbio-for-the-licensing-and-dev-prph-20220628monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-significant-laboratory-expansion-prph-20220613monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-h-c-wainwright-2022-global-investment-conference-prph-20220518monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-record-first-quarter-2022-financial-results-prph-20220513monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-spring-into-action-best-ideas-virtual-investor-conference-prph-20220511monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-appointment-of-bill-white-as-chief-financial-officer-prph-20220510monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-host-first-quarter-2022-financial-results-conference-call-on-friday-may-1-prph-20220506monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-planet-microcap-showcase-2022-on-wednesday-may-4-2022-prph-20220427monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-record-financial-results-for-the-fourth-quarter-and-full-year-ende-prph-20220330monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-host-fourth-quarter-and-full-year-2021-financial-results-conference-call--prph-20220324monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-special-cash-dividend-prph-20220216monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-microcap-rodeo-winter-wonderland-best-ideas-virtual-confer-prph-20220203monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-record-covid-19-testing-in-q4-2021-prph-20220113monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-h-c-wainwright-bioconnect-2022-virtual-conference-prph-20220105monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-continues-to-build-strong-leadership-with-key-promotions-and-additions-to-ma-prph-20211216monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-announces-inducement-award-under-nasdaq-listing-rule-5635-c-4-prph-20211123monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-financial-results-for-the-three-months-ended-september-30-2021-prph-20211112monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-q4-investor-summit-conference-prph-20211110monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-host-third-quarter-2021-financial-results-conference-call-on-friday-novem-prph-20211105monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-provides-business-update-prph-20211013monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-ld-micro-main-event-conference-prph-20211006monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-benzinga-healthcare-small-cap-conference-prph-20210922monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-6-million-stock-repurchase-program-prph-20210908monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-virtual-confe-prph-20210907monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-two-upcoming-august-conferences-prph-20210816monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-financial-results-for-the-quarter-ended-june-30-2021-prph-20210813monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-acquires-whole-genome-sequencing-company-nebula-genomics-prph-20210811monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-host-second-quarter-2021-financial-results-conference-call-on-friday-augu-prph-20210809monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-20-prph-20210712monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-engages-core-ir-for-investor-relations-public-relations-and-shareholder-comm-prph-20210701monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-added-to-the-russell-microcap-index-prph-20210628monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-diversifies-with-formation-of-genomics-and-global-healthcare-subsidiaries-prph-20210610monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-ld-micro-invitational-xi-virtual-conference-prph-20210528monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-first-quarter-2021-financial-results-and-announces-0-30-special-cash-prph-20210513monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-partners-with-dutchess-county-new-york-to-provide-covid-19-testing-prph-20210506monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-provide-covid-19-testing-for-oyster-bay-township-in-new-york-prph-20210422monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-host-first-quarter-2021-financial-results-conference-call-on-thursday-may-prph-20210415monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-fourth-quarter-and-full-year-2020-financial-results-prph-20210331monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-acquires-digital-covid-vaccination-and-testing-passport-solution-prph-20210330monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-host-fourth-quarter-and-full-year-2020-financial-results-conference-call--prph-20210315monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-begins-advanced-saliva-based-viral-pcr-multiplex-testing-for-covid-19-influe-prph-20210209monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-exceeding-initial-goals-as-covid-19-lab-testing-business-ramps-up-prph-20210201monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-opening-of-large-clia-lab-covid-testing-facility-in-garden-city-ne-prph-20210129monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-announces-closing-of-public-offering-prph-20210121monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-pricing-of-public-offering-of-common-stock-prph-20210119monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-proposed-public-offering-of-common-stock-prph-20210115monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-noblecon17-annual-small-microcap-investor-conference-on-tu-prph-20210111monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-5-5-million-registered-direct-offering-of-common-stock-and-warrant-prph-20210105monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-expands-covid-19-testing-capacity-with-new-25-000-square-feet-testing-facili-prph-20201208monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-and-nine-months-ended-september-30-2-prph-20201116monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-present-at-the-virtual-fall-investor-summit-on-monday-november-16-2020-at-prph-20201110monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-completes-acquisition-of-clia-accredited-lab-and-provides-corporate-update-prph-20201102monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-definitive-agreement-to-acquire-clia-accredited-lab-certified-for--prph-20201023monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-engages-industry-expert-to-advise-on-possible-acquisition-of-clia-accredited-prph-20200930monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-engages-mz-group-to-lead-strategic-investor-relations-and-shareholder-commun-prph-20200930monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-at-the-market-equity-facility-prph-20200923monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-announces-10-million-unsecured-debt-financing-prph-20200918monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-and-six-months-ended-june-30-2020-prph-20200811monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-months-ended-march-31-2020-prph-20200512monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-year-ended-december-31-2019-prph-20200325monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-announces-special-cash-dividend-prph-20191120monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-months-and-nine-months-ended-septemb-prph-20191112monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-months-and-six-months-ended-june-30--prph-20190812monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-months-ended-march-31-2019-prph-20190514monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-announces-change-in-tax-treatment-of-2018-dividends-prph-20190409monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-year-ended-december-31-2018-prph-20190326monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-appoints-monica-brady-as-chief-financial-officer-prph-20190117monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-announces-special-cash-dividend-prph-20181226monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-months-and-nine-months-ended-septemb-prph-20181114monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-months-and-six-months-ended-june-30--prph-20180821monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-announces-restatement-of-previously-issued-financial-statements-arising--prph-20180814monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-months-ended-march-31-2018-prph-20180515monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-announces-special-cash-dividend-prph-20180507monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-year-ended-december-31-2017-prph-20180321monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-release-fiscal-2017-results-on-wednesday-march-21st-prph-20180316monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-announces-new-compensatory-arrangement-with-chief-executive-officer-and--prph-20180221monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-announces-final-results-of-its-tender-offer-prph-20171221monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-announces-preliminary-results-of-its-tender-offer-prph-20171219monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-announces-commencement-of-tender-offer-to-repurchase-up-to-1-7-million-s-prph-20171121monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-months-and-nine-months-ended-septemb-prph-20171113monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-announces-intention-to-commence-tender-offer-to-repurchase-up-to-1-700-0-prph-20171110monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-announces-final-results-of-its-tender-offer-prph-20170929monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-announces-preliminary-results-of-its-tender-offer-prph-20170926monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-announces-commencement-of-tender-offer-to-repurchase-up-to-4-0-million-s-prph-20170825monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-announces-intention-to-commence-tender-offer-to-repurchase-up-to-4-000-0-prph-20170816monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-months-and-six-months-ended-june-30--prph-20170811monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-repurchases-1-061-980-shares-of-its-common-stock-prph-20170613monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-months-ended-march-31-2017-prph-20170515monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-provides-shareholder-update-prph-20170405monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-completes-sale-of-cold-eeze-r-business-to-mylan-prph-20170329monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-year-ended-december-31-2016-prph-20170227monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-schedules-an-investor-conference-call-for-tuesday-january-10th-at-4-30-pm-prph-20170109monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-announces-agreement-to-sell-cold-eeze-r-brand-prph-20170109monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-arbitration-decision-in-phusion-laboratories-phosphagenics-dispute-prph-20161116monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-months-and-nine-months-ended-septemb-prph-20161114monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-months-and-six-months-ended-june-30--prph-20160809monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-release-second-quarter-2016-results-on-tuesday-august-9th-prph-20160805monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-months-ended-march-31-2016-prph-20160510monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-nasdaq-prph-to-ring-the-nasdaq-stock-market-closing-bell-prph-20160407monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-fourth-quarter-and-year-ended-december-31--prph-20160329monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-release-fourth-quarter-year-end-results-on-tuesday-march-29th-prph-20160325monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-discusses-the-current-cold-season-and-announces-launch-of-new-product-line-t-prph-20160113monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-and-nine-months-ended-september-30-2-prph-20151112monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-nasdaq-prph-to-ring-the-nasdaq-stock-market-closing-bell-prph-20150917monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-and-six-months-ended-june-30-2015-prph-20150812monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-establishes-3-2-million-share-equity-line-prph-20150805monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-months-ended-march-31-2015-prph-20150513monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-fourth-quarter-and-year-ended-december-31--prph-20150325monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-inc-ceo-chairman-ted-william-karkus-to-be-interviewed-on-clear-channel-ihear-prph-20141211monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-and-nine-months-ended-september-30-2-prph-20141113monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-expects-to-report-a-3-6-million-impairment-charge-relating-to-its-phusion-joint-v-prph-20140910monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-finalizes-resolution-of-long-standing-litigations-prph-20140910monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-and-six-months-ended-june-30-2014-prph-20140812monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-establishes-3-0-million-share-equity-line-prph-20140529monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-first-quarter-ended-march-31-2014-prph-20140512monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-fourth-quarter-and-year-ended-december-31--prph-20140327monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-and-nine-months-ended-september-30-2-prph-20131113monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-and-six-months-ended-june-30-2013-prph-20130813monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-first-quarter-ended-march-31-2013-prph-20130506monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-fourth-quarter-and-year-ended-december-31--prph-20130326monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-establishes-2-5-million-share-equity-line-prph-20121127monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-and-nine-months-ended-september-30-2-prph-20121114monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-rejects-non-binding-revised-proposal-from-matrixx-initiatives-to-be-acquired-prph-20121029monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-rejects-non-binding-proposal-to-be-acquired-for-1-40-per-share-from-matrixx--prph-20120917monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-three-and-six-months-ended-june-30-2012-prph-20120813monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-first-quarter-ended-march-31-2012-prph-20120510monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-financial-results-for-the-fourth-quarter-and-year-ended-december-31--prph-20120306monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-release-fourth-quarter-results-on-tuesday-march-6th-prph-20120229monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-third-quarter-2011-results-prph-20111109monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-release-third-quarter-results-on-wednesday-november-9th-prph-20111102monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-second-quarter-2011-results-prph-20110810monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-release-second-quarter-results-on-wednesday-august-10th-prph-20110804monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-receives-nasdaq-notice-prph-20110705monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reports-first-quarter-2011-results-prph-20110513monthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-to-release-first-quarter-results-on-friday-may-13th-prph-20110506monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-provides-corporate-update-lyra-20260112monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-upd-lyra-20250812monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-to-present-52-week-extension-stage-results-for-enlighten-1-phase-3-study-lyra-20250507monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate-upda-lyra-20250506monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-lyra-20250313monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-upda-lyra-20241112monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-fully-enrolls-pivotal-phase-3-enlighten-2-trial-of-lyr-210-for-the-treat-lyra-20241015monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-to-present-study-results-for-lyr-210-and-lyr-220-in-two-presentations-at-lyra-20240927monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-upd-lyra-20240814monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-cost-cutting-measures-to-preserve-capital-lyra-20240521monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-topline-results-from-phase-3-enlighten-1-trial-for-lyr-210-in-ch-lyra-20240506monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-first-quarter-2024-financial-results-and-provides-corporate-upda-lyra-20240430monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-lyra-20240426monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-lyra-20240321monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-lyra-20240301monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-third-quarter-2023-financial-results-and-provides-corporate-upda-lyra-20231107monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-to-participate-in-upcoming-investor-conferences-lyra-20231107monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-appointment-of-ronan-o-brien-as-chief-legal-officer-lyra-20231016monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-positive-topline-results-from-beacon-phase-2-study-of-lyr-220--lyra-20230912monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-to-participate-in-upcoming-investor-conferences-lyra-20230906monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-fully-enrolls-pivotal-phase-3-enlighten-i-trial-of-lyr-210-for-the-treat-lyra-20230829monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-second-quarter-2023-financial-results-and-provides-corporate-upd-lyra-20230808monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-to-present-at-william-blair-virtual-biotechnology-conference-lyra-20230713monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-lyra-20230602monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-to-present-at-jefferies-healthcare-conference-lyra-20230602monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-closing-of-50-0-million-private-placement-lyra-20230601monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-50-0-million-private-placement-lyra-20230526monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-upda-lyra-20230512monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference-lyra-20230509monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-restart-of-pivotal-phase-3-enlighten-ii-clinical-trial-of-lyr--lyra-20230425monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-lyra-20230329monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-appointment-of-john-bishop-ph-d-as-chief-technology-officer-lyra-20230227monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-completion-of-enrollment-in-the-beacon-phase-2-clinical-trial--lyra-20230206monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-lyra-20230117monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-to-present-at-upcoming-investor-conferences-lyra-20221109monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-third-quarter-2022-financial-results-and-provides-corporate-upda-lyra-20221108monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-publication-of-positive-lantern-results-in-the-international-f-lyra-20210921monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-four-abstracts-selected-for-presentations-at-upcoming-ers-and--lyra-20210920monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-appoints-jason-cavalier-as-chief-financial-officer-lyra-20210913monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-publication-of-preclinical-pharmacokinetics-and-drug-release-c-lyra-20210909monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conferenc-lyra-20210907monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-to-host-virtual-chronic-rhinosinusitis-kol-event-on-august-31-lyra-20210817monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-second-quarter-2021-financial-results-and-highlights-recent-acco-lyra-20210809monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-to-report-second-quarter-2021-financial-results-on-august-9-lyra-20210726monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-to-present-at-upcoming-virtual-healthcare-conference-lyra-20210712monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-positive-topline-results-of-pharmacokinetic-study-of-lyr-210-i-lyra-20210630monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-presents-clinical-data-demonstrating-lyr-210-s-local-anti-inflammatory-e-lyra-20200910monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-to-present-data-supporting-lyr-210-for-the-treatment-of-chronic-rhinosin-lyra-20200903monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-second-quarter-2020-financial-results-and-provides-corporate-upd-lyra-20200805monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-to-present-at-the-btig-virtual-biotechnology-conference-lyra-20200804monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-pamela-nelson-as-senior-vice-president-of-regulatory-affairs-lyra-20200804monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-to-participate-in-fireside-chat-at-the-william-blair-biotech-focus-confe-lyra-20200730monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-to-report-second-quarter-2020-financial-results-and-provide-corporate-up-lyra-20200724monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-robert-richard-ph-d-as-senior-vice-president-of-research-and-d-lyra-20200707monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-set-to-join-the-russell-2000-index-and-russell-3000-index-lyra-20200625monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-first-quarter-2020-financial-results-and-provides-corporate-upda-lyra-20200528monthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-reports-record-revenue-in-the-second-quarter-of-2023-and-reiterates-full-year-2023-r-akya-20230807monthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-biosciences-announces-pricing-of-public-offering-of-common-stock-akya-20230608monthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-biosciences-announces-public-offering-of-common-stock-akya-20230607monthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-reports-record-revenue-in-the-fourth-quarter-of-2022-and-provides-full-year-2023-rev-akya-20230306monthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-reports-record-revenue-with-40-yoy-growth-in-the-third-quarter-and-raises-full-year--akya-20221107monthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-reports-second-quarter-2022-operating-results-and-raises-full-year-2022-revenue-guid-akya-20220808monthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-reports-first-quarter-2022-operating-results-and-raises-full-year-2022-revenue-guida-akya-20220505monthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-reports-fourth-quarter-and-full-year-2021-operating-results-and-provides-2022-financ-akya-20220314monthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-reports-third-quarter-2021-financial-results-and-issues-full-year-2021-guidance-akya-20211108monthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-reports-53-revenue-growth-in-the-second-quarter-of-2021-akya-20210810monthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-reports-first-quarter-2021-financial-results-and-issues-full-year-2021-guidance-akya-20210518monthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-o-akya-20210420monthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-biosciences-announces-pricing-of-initial-public-offering-akya-20210416monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-inc-provides-notice-of-fundamental-change-and-make-whole-fundamental-chan-cdmo-20250205monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-poised-for-significant-growth-with-new-partners-gho-capital-and-ampersand-cdmo-20250205monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-announces-expiration-of-hart-scott-rodino-waiting-period-for-pending-acqu-cdmo-20241230monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-recommends-stockholders-vote-for-value-maximizing-transaction-cdmo-20241218monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-reports-financial-results-for-second-quarter-ended-october-31-2024-cdmo-20241210monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-to-be-acquired-by-gho-capital-partners-and-ampersand-capital-partners-in--cdmo-20241106monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-reports-financial-results-for-first-quarter-ended-july-31-2024-cdmo-20240909monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-reports-financial-results-for-fourth-quarter-and-fiscal-year-ended-april--cdmo-20240702monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-reports-financial-results-for-third-quarter-ended-january-31-2024-cdmo-20240424monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-announces-pricing-of-private-placement-of-convertible-notes-cdmo-20240307monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-announces-proposed-private-placement-of-convertible-notes-cdmo-20240306monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-reports-financial-results-for-second-quarter-ended-october-31-2023-cdmo-20231207monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-reports-financial-results-for-first-quarter-ended-july-31-2023-cdmo-20230907monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-reports-financial-results-for-fourth-quarter-and-fiscal-year-ended-april--cdmo-20230621monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-reports-financial-results-for-third-quarter-ended-january-31-2023-and-rec-cdmo-20230313monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-reports-financial-results-for-second-quarter-ended-october-31-2022-and-re-cdmo-20221206monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-reports-financial-results-for-first-quarter-ended-july-31-2022-and-recent-cdmo-20220906monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-reports-financial-results-for-fourth-quarter-and-full-fiscal-year-ended-a-cdmo-20220629monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-reports-financial-results-for-third-quarter-ended-january-31-2022-and-rec-cdmo-20220308monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-reports-financial-results-for-second-quarter-ended-october-31-2021-and-re-cdmo-20211207monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-announces-closing-of-public-offering-of-common-stock-cdmo-20201214monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-announces-pricing-of-public-offering-of-common-stock-cdmo-20201210monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-announces-proposed-public-offering-of-common-stock-cdmo-20201209monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-announces-closing-of-public-offering-of-common-stock-cdmo-20180220monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-announces-pricing-of-public-offering-of-common-stock-cdmo-20180215monthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-announces-proposed-offering-of-common-stock-cdmo-20180214monthly0.5https://www.biopharmawatch.com/news/EYEN/eyenovia-inc-announces-closing-of-offering-of-common-stock-eyen-20200821monthly0.5https://www.biopharmawatch.com/news/EYEN/eyenovia-inc-prices-public-offering-of-common-stock-eyen-20200819monthly0.5https://www.biopharmawatch.com/news/EYEN/eyenovia-inc-announces-proposed-public-offering-of-common-stock-eyen-20200818monthly0.5https://www.biopharmawatch.com/news/EYEN/eyenovia-inc-prices-public-offering-of-common-stock-eyen-20190711monthly0.5https://www.biopharmawatch.com/news/EYEN/eyenovia-inc-announces-proposed-public-offering-of-common-stock-eyen-20190710monthly0.5https://www.biopharmawatch.com/news/EYEN/eyenovia-prices-public-offering-of-common-stock-eyen-20181219monthly0.5https://www.biopharmawatch.com/news/HEPA/hepion-pharmaceuticals-successfully-completes-application-to-the-otcqb-hepa-20250625monthly0.5https://www.biopharmawatch.com/news/HEPA/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-wi-hepa-20241202monthly0.5https://www.biopharmawatch.com/news/HEPA/hepion-pharmaceuticals-announces-exercise-of-warrants-for-approximately-2-0-million-aggreg-hepa-20240216monthly0.5https://www.biopharmawatch.com/news/HEPA/hepion-pharmaceuticals-announces-5-0-million-registered-direct-offering-and-concurrent-pri-hepa-20230929monthly0.5https://www.biopharmawatch.com/news/HEPA/hepion-pharmaceuticals-inc-announces-reverse-stock-split-hepa-20230510monthly0.5https://www.biopharmawatch.com/news/HEPA/hepion-pharmaceuticals-inc-granted-180-day-extension-by-nasdaq-to-meet-the-minimum-bid-pri-hepa-20221205monthly0.5https://www.biopharmawatch.com/news/HEPA/hepion-pharmaceuticals-announces-pricing-of-20-0-million-private-placement-of-convertible--hepa-20221104monthly0.5https://www.biopharmawatch.com/news/HEPA/hepion-pharmaceuticals-announces-further-adjournment-of-annual-meeting-of-stockholders-hepa-20220722monthly0.5https://www.biopharmawatch.com/news/HEPA/hepion-pharmaceuticals-announces-adjournment-of-annual-meeting-of-stockholders-hepa-20220624monthly0.5https://www.biopharmawatch.com/news/HEPA/hepion-pharmaceuticals-urges-shareholders-to-vote-for-all-proposals-ahead-of-its-upcoming--hepa-20220531monthly0.5https://www.biopharmawatch.com/news/HEPA/hepion-pharmaceuticals-announces-pricing-of-public-offering-hepa-20210216monthly0.5https://www.biopharmawatch.com/news/ENTO/entero-therapeutics-announces-exercise-of-warrants-and-issuance-of-new-warrants-in-a-priva-ento-20240711monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-confirms-nasdaq-delisting-sskn-20260219monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-pricing-of-2-42-million-registered-direct-offering-of-commo-sskn-20250903monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-present-at-the-h-c-wainwright-27th-annual-global-investment-confer-sskn-20250902monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-ip-portfolio-holds-exclusivity-in-combination-therapies-of-its-xtrac--sskn-20250902monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-second-quarter-2025-financial-results-and-provides-a-corporat-sskn-20250813monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-moves-to-accelerate-medicare-and-private-payer-coverage-from-expanded-sskn-20250807monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-second-quarter-2025-financial-results-on-august-13-2025-and-sskn-20250731monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-historic-expansion-of-cpt-codes-for-reimbursement-of-308nm--sskn-20250519monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-first-quarter-2025-financial-results-and-provides-a-corporate-sskn-20250514monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-the-d-boral-capital-inaugural-global-conference-sskn-20250508monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-first-quarter-2025-financial-results-on-may-14-2025-and-pro-sskn-20250507monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-fourth-quarter-and-full-year-2024-financial-results-and-provi-sskn-20250327monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-sskn-20250321monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-highlights-new-clinical-study-from-japan-demonstrating-superiority-of-sskn-20250320monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-the-benchmark-company-13th-annual-discovery-investo-sskn-20241205monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-third-quarter-2024-financial-results-and-provides-a-corporate-sskn-20241113monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-favorable-court-order-in-complaint-against-laseroptek-monar-sskn-20241111monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-third-quarter-2024-financial-results-on-november-13-2024-an-sskn-20241106monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-xtrac-excimer-laser-was-focus-of-two-lectures-at-major-japanese-annua-sskn-20241015monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-fireside-chat-at-the-2024-maxim-healthcare-virtual--sskn-20241008monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-present-at-the-iaccess-alpha-buyside-best-ideas-fall-conference-20-sskn-20240917monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-the-lake-street-capital-markets-8th-annual-best-ide-sskn-20240905monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-present-at-the-h-c-wainwright-26th-annual-global-investment-confer-sskn-20240903monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-files-complaint-against-laseroptek-monarch-laser-services-and-the-pin-sskn-20240826monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-second-quarter-2024-financial-results-and-provides-a-corporat-sskn-20240814monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-second-quarter-2024-financial-results-on-august-14-2024-and-sskn-20240807monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-the-9th-annual-virtual-needham-medtech-diagnostics--sskn-20240806monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-completes-2-1-million-direct-offering-with-participation-from-insider-sskn-20240723monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-approval-of-xtrac-momentum-1-0-device-in-japan-sskn-20240722monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-theraclear-x-acne-therapy-system-found-safe-and-effective-in-study-pu-sskn-20240717monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-pre-announces-second-quarter-2024-financial-results-sskn-20240711monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-sponsors-webinars-featuring-leading-dermatologists-discussing-benefit-sskn-20240612monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-theraclear-x-acne-therapy-system-found-to-be-safe-and-effective-for-a-sskn-20240607monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-june-dermatology-conferences-sskn-20240604monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-first-quarter-2024-financial-results-and-provides-a-corporate-sskn-20240515monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-surpasses-100-domestic-installations-of-theraclear-x-devices-as-of-ma-sskn-20240514monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-the-benchmark-healthcare-house-call-virtual-1x1-inv-sskn-20240513monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-first-quarter-2024-financial-results-on-may-15-2024-and-pro-sskn-20240508monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-xtrac-comeback-placements-in-the-first-quarter-of-2024-sskn-20240430monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-1-for-10-reverse-stock-split-sskn-20240426monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-present-at-the-planet-microcap-showcase-vegas-2024-sskn-20240423monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-renewal-of-exclusive-distribution-agreements-in-china-and-j-sskn-20240409monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-fourth-quarter-and-full-year-2023-earnings-sskn-20240327monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-fourth-quarter-and-full-year-2023-financial-results-on-marc-sskn-20240313monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-initiative-to-expand-treatment-coverage-sskn-20240307monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-successful-amendment-to-credit-agreement-with-midcap-financ-sskn-20240226monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-present-poster-showcasing-safety-and-efficacy-of-theraclear-x-for--sskn-20240108monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-granted-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-requirement-sskn-20240103monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-expansion-of-distribution-agreement-with-kosmo-meditech-sskn-20231229monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-science-announces-strengthening-of-leadership-team-sskn-20231204monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-the-benchmark-12th-annual-discovery-one-on-one-inve-sskn-20231201monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-third-quarter-2023-revenue-sskn-20231114monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-third-quarter-2023-financial-results-on-november-14-2023-sskn-20231102monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sskn-20231031monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-science-announces-leadership-change-sskn-20231030monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-upcoming-medical-conferences-sskn-20231003monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-present-at-upcoming-october-conferences-sskn-20230927monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-host-virtual-kol-event-on-xtrac-and-theraclear-x-sskn-20230824monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-second-quarter-2023-revenue-sskn-20230809monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-upcoming-august-conferences-sskn-20230801monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-second-quarter-2023-financial-results-on-august-9-2023-sskn-20230728monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-announces-jcad-publication-photopneumatic-technology-for-the-treatment-of-mild-to-m-sskn-20230711monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-secures-additional-12-million-financing-with-midcap-financial-sskn-20230706monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-appoints-dr-uri-geiger-to-chairman-of-its-board-of-directors-sskn-20230630monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-first-patients-treated-in-theraclear-x-clinical-study-for-a-sskn-20230530monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-theraclear-x-product-demonstration-at-music-city-scale-symp-sskn-20230519monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-first-quarter-2023-revenue-sskn-20230515monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-enters-india-market-with-exclusive-distribution-agreement-with-spectr-sskn-20230515monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-inaugural-ef-hutton-global-conference-sskn-20230508monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-first-quarter-2023-financial-results-on-may-15-2023-sskn-20230502monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-pre-announces-first-quarter-2023-results-sskn-20230412monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-record-fourth-quarter-2022-revenue-sskn-20230331monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reschedules-fourth-quarter-2022-conference-call-and-webcast-to-friday-sskn-20230328monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-fourth-quarter-2022-financial-results-on-march-28-2023-sskn-20230314monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-affirms-no-exposure-to-silicon-valley-bank-sskn-20230313monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-the-launch-of-new-patient-focused-xtrac-website-sskn-20230302monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-regaining-compliance-with-nasdaq-s-minimum-price-rule-sskn-20230227monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-theraclear-x-product-demonstration-at-inaugural-winter-clin-sskn-20230216monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-expects-record-full-year-2022-revenue-sskn-20230201monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-poster-accepted-at-odac-dermatology-aesthetic-surgical-conf-sskn-20230113monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-expands-into-300-million-market-with-exclusive-distribution-agreement-sskn-20230109monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-at-cantor-medical-aesthetic-dermatology-ophthalmology--sskn-20221202monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-strong-third-quarter-2022-financial-results-sskn-20221109monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-third-quarter-2022-financial-results-on-november-9-2022-sskn-20221026monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-at-upcoming-investor-conferences-sskn-20221006monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-present-at-the-inaugural-gilmartin-group-emerging-growth-company-s-sskn-20220822monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-second-quarter-2022-financial-results-sskn-20220810monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-upcoming-kol-call-hosted-by-ladenburg-thalmann-sskn-20220802monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-second-quarter-2022-financial-results-on-august-10-2022-sskn-20220727monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-u-s-commercial-launch-of-theraclear-x-acne-therapy-system-sskn-20220725monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-the-lytham-partners-summer-2022-investor-conference-sskn-20220607monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-names-michael-e-goodman-as-head-of-international-sales-sskn-20220516monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-first-quarter-2022-financial-results-sskn-20220511monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-deploy-stayinfront-touchrx-crm-sskn-20220428monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-first-quarter-2022-financial-results-on-may-11-2022-sskn-20220427monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-becomes-corporate-sponsor-of-the-global-vitiligo-foundation-sskn-20220330monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-the-lytham-partners-spring-2022-investor-conference-sskn-20220328monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-record-fourth-quarter-2021-revenue-sskn-20220321monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-names-john-bagdasarian-as-vice-president-of-professional-relations-sskn-20220314monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-fourth-quarter-and-full-year-2021-financial-results-on-marc-sskn-20220307monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-the-upcoming-oppenheimer-32nd-annual-healthcare-con-sskn-20220303monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-appoints-patricia-s-walker-m-d-ph-d-to-its-board-of-directors-sskn-20220214monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-commercial-launch-of-xtrac-momentum-1-0-and-first-installat-sskn-20220209monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-expands-into-israel-with-leading-medical-device-distributor-sskn-20220118monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-preliminary-fourth-quarter-and-full-year-2021-financial-res-sskn-20220110monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-acquisition-of-acne-treatment-device-assets-from-theravant--sskn-20220110monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-present-at-the-h-c-wainwright-bioconnect-virtual-conference-sskn-20211227monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-board-of-directors-transition-sskn-20211209monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-third-quarter-2021-financial-results-sskn-20211110monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-third-quarter-2021-financial-results-on-november-10-2021-sskn-20211027monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-cfo-transition-sskn-20211004monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-present-at-fall-harvest-best-ideas-from-the-buy-side-on-wednesday--sskn-20210929monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-upcoming-investor-conferences-sskn-20210902monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-second-quarter-2021-financial-results-sskn-20210816monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-acquisition-of-the-u-s-dermatology-business-of-ra-medical-s-sskn-20210816monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-second-quarter-2021-financial-results-on-august-16-2021-sskn-20210802monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-appointment-of-new-vp-of-marketing-sskn-20210802monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-the-oppenheimer-medtech-tools-diagnostics-summit-sskn-20210518monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-first-quarter-2021-financial-results-sskn-20210512monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-first-quarter-2021-financial-results-on-may-12-2021-sskn-20210428monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-appoints-william-d-humphries-to-its-board-of-directors-sskn-20210412monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-fourth-quarter-and-full-year-2020-financial-results-sskn-20210324monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-present-at-the-lytham-partners-spring-2021-investor-conference-sskn-20210316monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-independent-study-published-in-the-journal-of-the-european--sskn-20210315monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-fourth-quarter-and-full-year-2020-financial-results-on-marc-sskn-20210310monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-expanded-distribution-agreement-in-china-with-wuhan-miracle-sskn-20210309monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sskn-20210301monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-ceo-transition-sskn-20210301monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-preliminary-fourth-quarter-2020-financial-results-and-opera-sskn-20210112monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-the-introduction-of-home-by-xtrac-sskn-20210112monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-the-h-c-wainwright-bioconnect-virtual-conference-sskn-20210106monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-announces-successful-renewal-of-note-payable-sskn-20201228monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-third-quarter-2020-financial-results-sskn-20201110monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-present-at-three-upcoming-investor-conferences-sskn-20201105monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-report-third-quarter-2020-financial-results-on-november-10-2020-sskn-20201103monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-xtrac-technology-found-to-be-most-effective-and-most-economical-treat-sskn-20201102monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-expanding-medical-coverage-for-excimer-laser-treatment-of-d-sskn-20201019monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-new-recurring-revenue-direct-distribution-contract-with-jme-sskn-20200914monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-present-at-two-upcoming-investor-conferences-sskn-20200908monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-second-quarter-2020-financial-results-sskn-20200811monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-host-second-quarter-2020-financial-results-and-business-update-con-sskn-20200804monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-first-quarter-2020-financial-results-sskn-20200512monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-host-first-quarter-2020-financial-results-and-business-update-conf-sskn-20200505monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-receives-forgivable-loan-under-the-paycheck-protection-program-sskn-20200427monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-announces-preliminary-first-quarter-2020-revenue-and-provides-bus-sskn-20200420monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-announces-study-published-in-the-journal-of-drugs-in-dermatology-sskn-20200406monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-fourth-quarter-and-year-end-2019-financial-results-sskn-20200317monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-host-fourth-quarter-and-year-end-2019-financial-results-and-busine-sskn-20200310monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-receives-a-510-k-clearance-for-its-xtrac-momentum-308nm-excimer-l-sskn-20200123monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-announces-preliminary-q4-fy-2019-revenue-and-key-financial-metric-sskn-20200113monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-announces-successful-completion-of-debt-refinancing-sskn-20200106monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-announces-compliance-with-nasdaq-listing-rules-sskn-20191119monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-filed-its-quarterly-reports-for-the-first-three-quarters-of-2019-on-form-10-q-sskn-20191118monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-the-13th-annual-canaccord-genuity-medical-technolog-sskn-20191114monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-receives-extension-to-stay-of-suspension-from-nasdaq-listing-sskn-20191030monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-receives-nasdaq-notice-of-non-compliance-sskn-20191007monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-ladenburg-thalmann-2019-healthcare-conference-sskn-20190910monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-h-c-wainwright-s-annual-healthcare-conference-sskn-20190828monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-receives-notice-of-filing-delinquency-from-nasdaq-sskn-20190816monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-preliminary-second-quarter-2019-financial-results-and-updat-sskn-20190806monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-canaccord-genuity-39th-annual-growth-conference-sskn-20190724monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-direct-distribution-contract-with-kosmo-meditech-in-korea-sskn-20190708monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-present-at-upcoming-investor-conferences-sskn-20190611monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-receives-notice-of-filing-delinquency-from-nasdaq-sskn-20190517monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-preliminary-first-quarter-2019-financial-results-and-update-sskn-20190514monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-receives-notice-of-filing-delinquency-from-nasdaq-sskn-20190405monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-preliminary-fourth-quarter-and-full-year-2018-revenue-resul-sskn-20190402monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-oppenheimer-s-29th-annual-healthcare-conference-sskn-20190305monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-present-a-corporate-overview-at-the-cowen-39th-annual-healthcare-c-sskn-20190227monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-the-btig-medtech-life-science-and-diagnostic-tools--sskn-20190213monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-secures-exclusive-license-for-treating-vitiligo-using-an-excimer-lase-sskn-20181211monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-third-quarter-2018-financial-results-sskn-20181113monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-host-3rd-quarter-2018-financial-results-and-business-update-confer-sskn-20181030monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-present-at-dawson-james-securities-4th-annual-small-cap-growth-con-sskn-20181017monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-launch-of-the-xtrac-s3-sskn-20181010monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-completion-of-a-clinical-study-and-the-first-commercial-acc-sskn-20181001monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-ladenburg-thalmann-2018-healthcare-conference-sskn-20180924monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-panel-discussion-at-the-medtech-conference-sskn-20180917monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-h-c-wainwright-s-20th-annual-global-investment-conf-sskn-20180827monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-strategic-agreement-with-a-large-private-equity-backed-grou-sskn-20180820monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-second-quarter-2018-financial-results-sskn-20180813monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-fda-granted-510-k-clearance-for-the-multi-micro-dose-tip-fo-sskn-20180806monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-host-2nd-quarter-2018-financial-results-and-business-update-confer-sskn-20180802monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-licensing-agreement-for-certain-melafind-assets-sskn-20180723monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-510-k-submission-for-its-multi-micro-dose-tip-accessory-for-sskn-20180619monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-participate-in-panel-discussion-at-cantor-fitzgerald-dermatology-a-sskn-20180613monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-present-at-jmp-2018-life-sciences-conference-sskn-20180612monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-closing-of-a-17-million-equity-financing-and-the-formal-app-sskn-20180529monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-17-million-equity-financing-led-by-accelmed-growth-partners-sskn-20180402monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-fourth-quarter-and-fiscal-year-2017-financial-results-sskn-20180402monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-reschedules-fiscal-2017-financial-results-and-corporate-update-ca-sskn-20180329monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-to-report-fiscal-2017-financial-results-on-thursday-march-29-sskn-20180327monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-delays-fourth-quarter-and-fiscal-2017-financial-results-sskn-20180306monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-to-report-4th-quarter-and-fiscal-2017-financial-results-on-thursd-sskn-20180221monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-appointment-of-luann-via-as-chairperson-of-the-board-sskn-20171220monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-exploration-of-strategic-alternatives-sskn-20171218monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-departure-of-chief-financial-officer-sskn-20171206monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-third-quarter-2017-financial-results-sskn-20171109monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-to-report-3rd-quarter-2017-financial-results-on-thursday-november-sskn-20171026monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-agreement-with-medresults-network-a-gpo-exclusive-to-the-ae-sskn-20171017monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-closing-of-agreement-to-eliminate-40-7-million-of-outstandi-sskn-20170925monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-present-at-the-rodman-renshaw-19th-annual-global-investment-confer-sskn-20170911monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-second-quarter-2017-financial-results-sskn-20170810monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-to-report-2nd-quarter-2017-financial-results-on-thursday-august-1-sskn-20170727monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-announces-agreement-to-eliminate-40-7-million-of-outstanding-senior-s-sskn-20170607monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-first-quarter-2017-financial-results-sskn-20170511monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-announces-the-appointment-of-james-l-coyne-to-its-board-of-direct-sskn-20170510monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-announces-launch-of-the-nordlys-system-and-announces-2017-revenue-sskn-20170427monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-to-report-1st-quarter-2017-financial-results-on-thursday-may-11-sskn-20170427monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-announces-1-for-5-reverse-stock-split-sskn-20170406monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-announces-a-strategic-alliance-with-ellipse-usa-llc-sskn-20170314monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-fourth-quarter-and-full-year-2016-financial-results-sskn-20170309monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-to-report-fiscal-year-end-2016-financial-results-on-thursday-marc-sskn-20170223monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-third-quarter-2016-financial-results-sskn-20161110monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-names-frank-mccaney-as-president-and-ceo-sskn-20161101monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-to-report-3rd-quarter-2016-financial-results-on-thursday-november-sskn-20161027monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-second-quarter-2016-financial-results-sskn-20160811monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-to-report-2nd-quarter-2016-financial-results-on-thursday-august-1-sskn-20160728monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-to-host-key-opinion-leader-lunch-sskn-20160613monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-first-quarter-2016-financial-results-sskn-20160512monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-to-report-1st-quarter-2016-financial-results-on-thursday-may-12-sskn-20160429monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-reports-fourth-quarter-2015-financial-results-sskn-20160310monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-announces-fda-approval-of-pma-supplemental-for-melafind-sskn-20160310monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-to-report-4th-quarter-2015-results-on-thursday-march-10-sskn-20160225monthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-inc-announces-refinancing-of-10-0-million-of-short-term-debt-sskn-20160105monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-provides-business-update-and-reports-third-quarter-2024-financial-results-allk-20241106monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-phase-1-trial-results-of-subcutaneous-ak006-in-healthy-volunteers-allk-20241010monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-provides-business-update-and-reports-second-quarter-2024-financial-results-allk-20240807monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-positive-results-from-its-ongoing-phase-1-trial-of-ak006-in-healthy-volu-allk-20240625monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-first-patient-dosed-in-phase-1-trial-of-ak006-in-chronic-spontaneous-urt-allk-20240528monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-provides-business-update-and-reports-first-quarter-2024-financial-results-allk-20240509monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-provides-business-update-and-reports-fourth-quarter-and-full-year-2023-financial-r-allk-20240314monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-presents-preclinical-data-highlighting-inhibition-of-mrgprx2-mediated-mast-cell-ac-allk-20240226monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-publication-highlighting-ak006-mast-cell-inhibition-allk-20240212monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-a-restructuring-to-focus-on-development-of-ak006-allk-20240116monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-phase-2-lirentelimab-trials-in-atopic-dermatitis-and-chronic-spontaneous-allk-20240116monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-provides-business-update-and-reports-third-quarter-2023-financial-results-allk-20231113monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-appoints-neil-graham-to-its-board-of-directors-allk-20230830monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-provides-business-update-and-reports-second-quarter-2023-financial-results-allk-20230809monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-appoints-rand-sutherland-and-dolca-thomas-to-its-board-of-directors-allk-20230802monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-presents-preclinical-data-at-eaaci-hybrid-congress-2023-highlighting-lirentelimab--allk-20230612monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-upcoming-presentation-on-lirentelimab-and-ak006-mast-cell-inhibition-at--allk-20230605monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-provides-business-update-and-reports-first-quarter-2023-financial-results-allk-20230509monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-provides-business-update-and-reports-fourth-quarter-and-full-year-2022-financial-r-allk-20230306monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-publication-of-ak006-mechanism-of-action-manuscript-in-communications-bi-allk-20221129monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-presents-preclinical-data-on-ak007-a-siglec-10-antagonist-antibody-at-the-society--allk-20221110monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-provides-business-update-and-reports-third-quarter-2022-financial-results-allk-20221107monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-pricing-of-150-million-underwritten-offering-of-common-stock-allk-20220919monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-initiation-of-phase-2b-clinical-trial-of-subcutaneous-lirentelimab-in-ch-allk-20220912monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-topline-phase-3-data-from-the-eodyssey-study-in-patients-with-eosinophil-allk-20220909monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-provides-business-update-and-reports-second-quarter-2022-financial-results-allk-20220804monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-the-appointment-of-dr-amy-ladd-to-its-board-of-directors-allk-20220725monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-provides-business-update-and-reports-first-quarter-2022-financial-results-allk-20220506monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-provides-business-update-and-reports-fourth-quarter-and-full-year-2021-financial-r-allk-20220301monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-to-host-investor-day-on-february-15-allk-20220201monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-topline-phase-3-data-from-the-enigma-2-study-and-phase-2-3-data-from-the-allk-20211222monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-expansion-of-lirentelimab-development-into-atopic-dermatitis-chronic-spo-allk-20211130monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-provides-business-update-and-reports-third-quarter-2021-financial-results-allk-20211108monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-presents-data-at-acg-2021-from-prospective-study-showing-high-prevalence-rates-of--allk-20211025monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-multiple-presentations-related-to-eosinophil-and-mast-cell-driven-diseas-allk-20211024monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-provides-business-update-and-reports-second-quarter-2021-financial-results-allk-20210809monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-completes-patient-enrollment-in-phase-3-eosinophilic-gastritis-and-or-eosinophilic-allk-20210607monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-reports-first-quarter-2021-financial-results-and-provides-business-update-allk-20210510monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-appoints-baird-radford-as-chief-financial-officer-allk-20210419monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-multiple-presentations-related-to-eosinophil-and-mast-cell-driven-diseas-allk-20210330monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-business--allk-20210301monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-appoints-natalie-holles-to-its-board-of-directors-allk-20201222monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-reports-third-quarter-2020-financial-results-and-provides-business-update-allk-20201109monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-presentation-from-its-eosinophilic-gastrointestinal-diseases-program-at--allk-20201102monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-pricing-of-public-offering-of-common-stock-allk-20201029monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-previews-preliminary-financial-results-for-the-three-months-ended-september-30-202-allk-20201027monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-proposed-public-offering-of-common-stock-allk-20201027monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-results-from-a-phase-1-study-of-subcutaneously-administered-lirentelimab-allk-20201026monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-publication-of-results-from-the-phase-2-study-of-lirentelimab-ak002-in-p-allk-20201021monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-reports-second-quarter-2020-financial-results-and-provides-business-update-allk-20200810monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-initiates-patient-recruitment-for-ak002-registrational-studies-allk-20200603monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-multiple-presentations-related-to-eosinophil-and-mast-cell-driven-diseas-allk-20200521monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-a-presentation-of-antolimab-in-patients-with-severe-allergic-conjunctivi-allk-20200511monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-reports-first-quarter-2020-financial-results-allk-20200511monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-deadline-alert-faruqi-faruqi-llp-encourages-investors-who-suffered-losses-exceedin-allk-20200509monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-final-deadline-rosen-a-top-ranked-firm-encourages-allakos-inc-investors-to-contact-allk-20200508monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-positive-interim-results-from-an-open-label-extension-study-of-antolimab-allk-20200504monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-deadline-alert-faruqi-faruqi-llp-encourages-investors-who-suffered-losses-exceedin-allk-20200426monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-multiple-presentations-related-to-eosinophil-and-mast-cell-driven-diseas-allk-20200421monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-the-initiation-of-antolimab-ak002-clinical-studies-allk-20200324monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-positive-phase-1-results-with-antolimab-ak002-in-mast-cell-gastrointesti-allk-20200324monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-business--allk-20200225monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-multiple-presentations-related-to-eosinophil-and-mast-cell-driven-diseas-allk-20200224monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-inc-investigated-by-block-leviton-llp-for-violations-of-federal-securities-laws-allk-20191219monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-reports-third-quarter-2019-financial-results-allk-20191112monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-multiple-presentations-from-its-eosinophilic-gastrointestinal-diseases-p-allk-20191028monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-upsizing-and-pricing-of-public-offering-of-common-stock-allk-20190807monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-proposed-public-offering-of-common-stock-allk-20190805monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-reports-second-quarter-2019-financial-results-allk-20190805monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-ak002-met-all-prespecified-primary-and-secondary-endpoints-in-phase-2-ra-allk-20190805monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-reports-first-quarter-2019-financial-results-allk-20190508monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-positive-results-with-ak002-in-patients-with-severe-allergic-conjunctivi-allk-20190507monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-reports-fourth-quarter-and-full-year-2018-financial-results-and-2018-corporate-hig-allk-20190314monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-positive-phase-1-results-with-ak002-in-indolent-systemic-mastocytosis-allk-20190219monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-positive-phase-2-results-for-ak002-in-patients-with-xolair-refractory-ch-allk-20190211monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-to-host-investor-day-on-february-19-in-new-york-city-allk-20190204monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-positive-phase-2-results-in-patients-with-cholinergic-urticaria-and-symp-allk-20190129monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-clinical-update-and-third-quarter-2018-financial-results-allk-20181108monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-presents-data-from-its-eosinophilic-gastrointestinal-diseases-program-at-the-ameri-allk-20181008monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-second-quarter-2018-financial-results-allk-20180829monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-opt-allk-20180724monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-pricing-of-initial-public-offering-allk-20180719monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-highlights-data-demonstrating-potential-of-ak002-to-rapidly-deplete-eosinophils-at-allk-20180305monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-secures-100-million-in-series-b-financing-allk-20171213monthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-announces-additions-to-senior-leadership-team-allk-20170815monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-second-quarter-2018-business-update-and-financial-results-lptx-20180808monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-first-quarter-2018-financial-results-lptx-20180511monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-fourth-quarter-and-full-year-2017-financial-results-and-announce-lptx-20180223monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-18-million-private-placement-offering-lptx-20171115monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-third-quarter-2017-financial-results-and-announces-first-patient-lptx-20171113monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-second-quarter-2017-financial-results-lptx-20170811monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-first-quarter-2017-financial-results-lptx-20170512monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-and-macrocure-complete-merger-transaction-lptx-20170123monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-pursue-strategic-sale-of-its-business-through-voluntary-chapter-11-clsd-20251124monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-first-quarter-2025-financial-results-on-wednesday-may-14-20-clsd-20250508monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-fourth-quarter-and-full-year-2024-financial-results-and-pro-clsd-20250327monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-six-abstracts-accepted-for-presentation-at-association-for--clsd-20250324monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-s-lead-clinical-program-cls-ax-in-wet-amd-and-suprachoroidal-delivery-clsd-20250320monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-fourth-quarter-and-full-year-2024-financial-results-and-pro-clsd-20250312monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-successful-end-of-phase-2-meeting-with-the-fda-and-alignmen-clsd-20250306monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-s-asia-pacific-partner-arctic-vision-announced-acceptance-of-its-new--clsd-20250220monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-additional-data-from-the-cls-ax-odyssey-phase-2b-trial-pres-clsd-20250210monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-fireside-chat-at-the-oppenheimer-35th-annual-health-clsd-20250204monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-multiple-medical-meeting-presentations-focused-on-the-advan-clsd-20250128monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-its-asia-pacific-partner-arctic-vision-received-approval-of-clsd-20250122monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-publication-of-critical-insights-into-retinal-drug-developm-clsd-20241219monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-extends-global-footprint-with-numerous-presentations-at-medical-meeti-clsd-20241125monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-third-quarter-2024-financial-results-and-provides-corporate-clsd-20241112monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-partner-arctic-vision-executes-commercial-collaboration-agreement-wit-clsd-20241107monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-fireside-chat-at-the-stifel-2024-healthcare-confere-clsd-20241106monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-appoints-tony-gibney-as-new-chair-of-the-board-of-directors-clsd-20241104monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-third-quarter-2024-financial-results-and-provide-corporate--clsd-20241031monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-s-positive-odyssey-wet-amd-data-and-suprachoroidal-injection-platform-clsd-20241022monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-positive-topline-results-from-odyssey-phase-2b-trial-of-sup-clsd-20241009monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-completion-of-final-participant-visit-in-odyssey-phase-2b-t-clsd-20240827monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-second-quarter-2024-financial-results-and-provides-corporat-clsd-20240812monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-the-h-c-wainwright-4th-annual-ophthalmology-virtual-clsd-20240808monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-second-quarter-2024-financial-results-on-monday-august-12-2-clsd-20240801monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-s-partner-arctic-vision-reports-positive-topline-results-from-phase-3-clsd-20240729monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-opens-registration-for-suprachoroidal-delivery-kol-webinar-to-be-held-clsd-20240722monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-appoints-dr-glenn-yiu-to-its-scientific-advisory-board-clsd-20240711monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-host-virtual-key-opinion-leader-event-on-the-use-and-versatility-o-clsd-20240627monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-s-leadership-in-suprachoroidal-delivery-featured-in-multiple-presenta-clsd-20240612monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-publication-of-consensus-guidelines-for-drug-delivery-via-s-clsd-20240521monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-first-quarter-2024-financial-results-and-provides-corporate-clsd-20240509monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-fireside-chat-at-the-citizens-jmp-life-sciences-con-clsd-20240508monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-first-quarter-2024-financial-results-and-provide-corporate--clsd-20240430monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-appoints-seasoned-biotechnology-executive-anthony-s-gibney-to-its-boa-clsd-20240416monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-fireside-chat-at-the-23rd-annual-needham-virtual-he-clsd-20240402monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-appoints-victor-chong-m-d-mba-as-chief-medical-officer-clsd-20240318monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-fourth-quarter-and-full-year-2023-financial-results-and-pro-clsd-20240312monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-fourth-quarter-and-full-year-2023-financial-results-and-pro-clsd-20240229monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-pricing-of-15-million-registered-direct-offering-clsd-20240207monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-reports-significant-progress-in-odyssey-phase-2b-trial-of-cls-ax-in-w-clsd-20231214monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-third-quarter-2023-financial-results-and-provides-corporate-clsd-20231113monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-fireside-chat-at-the-stifel-2023-healthcare-confere-clsd-20231108monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-s-versatile-suprachoroidal-injection-platform-highlighted-in-four-oph-clsd-20231107monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-presentations-at-the-american-academy-of-ophthalmology-2023-clsd-20231102monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-completes-recruitment-in-odyssey-phase-2b-clinical-trial-of-cls-ax-in-clsd-20231101monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-third-quarter-2023-financial-results-and-provide-corporate--clsd-20231031monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-positive-oasis-and-extension-study-data-presented-at-the-retina-socie-clsd-20231016monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-advancement-of-xipere-in-asia-pacific-for-suprachoroidal-tr-clsd-20231004monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-a-panel-discussion-at-the-jonestrading-2023-healthc-clsd-20231003monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-panel-discussion-at-the-cantor-global-healthcare-co-clsd-20230919monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-second-quarter-2023-financial-results-and-provides-corporat-clsd-20230814monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-upcoming-investor-conferences-in-august-2023-clsd-20230802monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-second-quarter-2023-financial-results-and-provide-corporate-clsd-20230801monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-highlights-excellent-safety-profile-of-cls-ax-and-potential-for-exten-clsd-20230731monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-s-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-a-clsd-20230720monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-enrollment-of-multiple-participants-in-its-odyssey-phase-2b-clsd-20230717monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-asia-pacific-partner-arctic-vision-announces-the-acceptance-in-austra-clsd-20230710monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-opens-enrollment-in-odyssey-phase-2b-clinical-trial-of-cls-ax-axitini-clsd-20230601monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-first-quarter-2023-financial-results-and-provides-corporate-clsd-20230511monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-a-fireside-chat-at-the-jmp-securities-life-sciences-clsd-20230509monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-first-quarter-2023-financial-results-and-provide-corporate--clsd-20230502monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-presents-compelling-data-at-the-association-for-research-in-vision-an-clsd-20230427monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-s-suprachoroidal-injection-platform-to-be-featured-at-the-association-clsd-20230419monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-plans-for-odyssey-phase-2b-clinical-trial-of-cls-ax-axitini-clsd-20230418monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-a-fireside-chat-at-the-22nd-annual-needham-virtual--clsd-20230412monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-enhances-scientific-advisory-board-with-the-appointment-of-two-distin-clsd-20230405monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-fourth-quarter-and-full-year-2022-financial-results-and-pro-clsd-20230309monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-fourth-quarter-and-full-year-2022-financial-results-and-pro-clsd-20230223monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-positive-data-presentations-on-cls-ax-oasis-clinical-trial--clsd-20230221monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-oasis-data-to-be-presented-at-multiple-upcoming-medical-meetings-in-f-clsd-20230207monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-leadership-team-update-clsd-20230206monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-positive-6-month-results-from-oasis-extension-study-with-su-clsd-20230202monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-multiple-upcoming-investor-and-ophthalmology-confer-clsd-20221122monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-a-fireside-chat-at-the-stifel-2022-healthcare-confe-clsd-20221110monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-third-quarter-2022-financial-results-and-provides-corporate-clsd-20221109monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-positive-results-in-safety-durability-and-biologic-effect-i-clsd-20221109monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-oasis-phase-1-2a-clinical-trial-results-and-host-conference-clsd-20221108monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-third-quarter-2022-financial-results-and-provide-corporate--clsd-20221102monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-corporate-overview-and-upcoming-catalysts-at-eyecelerator--clsd-20220927monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-ophthalmology-futures-retina-forum-2022-clsd-20220825monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-second-quarter-2022-financial-results-and-provides-corporat-clsd-20220809monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-enters-into-non-dilutive-financing-agreement-with-healthcare-royalty--clsd-20220808monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-three-upcoming-investor-conferences-in-august-2022-clsd-20220803monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-second-quarter-2022-financial-results-and-provide-corporate-clsd-20220727monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-completes-dosing-in-oasis-phase-1-2a-clinical-trial-of-cls-ax-axitini-clsd-20220726monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-suprachoroidal-delivery-technology-to-be-featured-at-upcoming-asrs-an-clsd-20220707monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-expands-leadership-team-with-appointment-of-susan-coultas-ph-d-as-chi-clsd-20220614monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-the-jmp-securities-life-sciences-conference-clsd-20220608monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-first-quarter-2022-financial-results-and-provides-corporate-clsd-20220511monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-poster-presentation-at-arvo-2022-annual-meeting-demonstrates-versatil-clsd-20220505monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-first-quarter-2022-financial-results-and-provide-corporate--clsd-20220429monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-needham-virtual-healthcare-conference-clsd-20220406monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-fourth-quarter-and-full-year-2021-financial-results-and-pro-clsd-20220310monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-appoints-benjamin-r-yerxa-ph-d-to-its-board-of-directors-clsd-20220303monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-two-upcoming-investor-conferences-in-march-2022-clsd-20220301monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-fourth-quarter-and-full-year-2021-financial-results-and-pro-clsd-20220225monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-s-suprachoroidal-injection-platform-featured-at-the-angiogenesis-exud-clsd-20220214monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-s-suprachoroidal-injection-platform-to-be-featured-at-the-angiogenesi-clsd-20220202monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-positive-safety-results-from-oasis-phase-1-2a-clinical-tria-clsd-20211221monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-added-to-the-nasdaq-biotechnology-index-clsd-20211213monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-features-fda-approved-xipere-in-multiple-presentations-at-the-america-clsd-20211116monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-upcoming-investor-events-in-november-and-december-2-clsd-20211111monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-third-quarter-2021-financial-results-and-provides-corporate-clsd-20211110monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-third-quarter-2021-financial-results-and-provide-corporate--clsd-20211028monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-delivers-podium-and-poster-presentations-at-the-american-society-of-r-clsd-20211013monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-multiple-poster-presentations-at-the-retina-society-54th-an-clsd-20211004monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-completion-of-dosing-in-cohort-2-of-phase-1-2a-clinical-tri-clsd-20210921monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-expands-xipere-license-agreement-with-arctic-vision-to-include-austra-clsd-20210909monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-ophthalmology-futures-european-2021-virtual-retina--clsd-20210823monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-second-quarter-2021-financial-results-and-provides-corporat-clsd-20210810monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-two-upcoming-investor-conferences-in-august-2021-clsd-20210804monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-second-quarter-2021-financial-results-and-provide-corporate-clsd-20210727monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-positive-safety-results-from-cohort-1-of-oasis-phase-1-2a-c-clsd-20210615monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-two-upcoming-investor-conferences-in-june-2021-clsd-20210609monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-first-quarter-2021-financial-results-and-provides-corporate-clsd-20210517monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-multiple-poster-presentations-at-the-association-for-resear-clsd-20210510monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-first-quarter-2021-financial-results-and-provide-corporate--clsd-20210504monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-resubmission-of-new-drug-application-for-xipere-for-treatme-clsd-20210503monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-needham-virtual-healthcare-conference-and-wet-amd-d-clsd-20210405monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-fourth-quarter-and-full-year-2020-financial-results-and-pro-clsd-20210310monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-completion-of-patient-dosing-in-first-cohort-of-phase-1-2a--clsd-20210302monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-fourth-quarter-and-full-year-2020-financial-results-and-pro-clsd-20210224monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-two-upcoming-investor-conferences-in-march-2021-clsd-20210223monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-cls-ax-axitinib-injectable-suspension-presentation-delivere-clsd-20210216monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-featured-in-multiple-data-presentations-at-the-44th-virtual-annual-ma-clsd-20210208monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-first-patients-enrolled-in-phase-1-2a-clinical-trial-of-cls-clsd-20210112monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-pricing-of-12-million-registered-direct-offering-clsd-20210106monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-data-presentations-at-the-american-academy-ophthalmology-aa-clsd-20201116monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-stifel-2020-virtual-healthcare-conference-clsd-20201111monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-third-quarter-2020-financial-results-and-provides-corporate-clsd-20201110monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-third-quarter-2020-financial-results-and-provide-corporate--clsd-20201030monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-clinical-data-presentations-at-the-retina-society-2020-and--clsd-20200923monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-s-oncology-licensing-partner-doses-first-patient-in-its-phase-2-study-clsd-20200911monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-virtual-h-c-wainwright-22nd-annual-global-investmen-clsd-20200909monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-s-licensing-partner-doses-first-patient-in-its-phase-2-gene-therapy-t-clsd-20200909monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-expands-patent-portfolio-in-the-u-s-and-europe-clsd-20200826monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-second-quarter-2020-financial-results-and-provides-corporat-clsd-20200810monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-u-s-fda-acceptance-of-investigational-new-drug-application--clsd-20200810monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-2020-wedbush-pacgrow-healthcare-virtual-conference-clsd-20200804monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-second-quarter-2020-financial-results-and-provide-corporate-clsd-20200730monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-multiple-presentations-at-the-asrs-2020-virtual-annual-meet-clsd-20200727monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-numerous-presentations-at-the-arvo-2020-meeting-clsd-20200617monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-first-quarter-2020-financial-results-clsd-20200508monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-revises-nda-resubmission-timeline-and-xipere-commercial-partnership-w-clsd-20200428monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-appoints-nancy-j-hutson-ph-d-to-its-board-of-directors-clsd-20200422monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-establishes-scientific-advisory-board-with-distinguished-retinal-phys-clsd-20200409monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-needham-virtual-healthcare-conference-clsd-20200408monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-fourth-quarter-and-full-year-2019-financial-results-and-pro-clsd-20200311monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-appoints-dr-george-lasezkay-as-president-and-chief-executive-officer-clsd-20200311monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-license-agreement-with-arctic-vision-for-xipere-triamcinolo-clsd-20200311monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-fourth-quarter-and-full-year-2019-financial-results-and-pro-clsd-20200227monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-two-upcoming-investor-conferences-in-march-2020-clsd-20200226monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-pipeline-highlighted-in-oral-presentations-at-the-annual-angiogenesis-clsd-20200225monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-presentations-to-be-given-at-angiogenesis-and-macula-societ-clsd-20200205monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-clsd-20200106monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-stifel-2019-healthcare-conference-clsd-20191113monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-third-quarter-2019-financial-results-and-provides-corporate-clsd-20191106monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-third-quarter-2019-financial-results-and-provide-corporate--clsd-20191030monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-option-exercise-by-regenxbio-for-global-license-for-use-of--clsd-20191030monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-suprachoroidal-injection-platform-featured-in-multiple-presentations--clsd-20191017monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-multiple-presentations-to-be-given-at-the-american-academy--clsd-20191003monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-featured-at-multiple-european-scientific-retinal-congresses-clsd-20190919monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-janney-montgomery-scott-healthcare-conference-clsd-20190903monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-second-quarter-2019-financial-results-and-provides-corporat-clsd-20190807monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-2019-wedbush-pacgrow-healthcare-conference-clsd-20190806monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-second-quarter-2019-financial-results-and-provide-corporate-clsd-20190731monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-multiple-oral-presentations-delivered-at-the-american-socie-clsd-20190731monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-multiple-oral-presentations-to-be-given-at-the-american-soc-clsd-20190718monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-license-agreement-with-aura-biosciences-for-suprachoroidal--clsd-20190709monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-jmp-securities-life-sciences-conference-clsd-20190611monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-ubs-global-healthcare-conference-clsd-20190515monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-first-quarter-2019-financial-results-and-provides-corporate-clsd-20190508monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-s-suprachoroidal-space-injection-platform-featured-at-multiple-ophtha-clsd-20190501monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-first-quarter-2019-financial-results-and-provide-corporate--clsd-20190425monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-multiple-presentations-on-its-suprachoroidal-space-injectio-clsd-20190418monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-appoints-dr-george-lasezkay-as-interim-ceo-clsd-20190408monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-18th-annual-needham-healthcare-conference-clsd-20190402monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-fourth-quarter-and-full-year-2018-financial-results-and-pro-clsd-20190312monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-cowen-and-company-39th-annual-health-care-conferenc-clsd-20190304monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-2018-financial-results-and-provide-corporate-update-on-tues-clsd-20190227monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-receives-notification-of-fda-acceptance-of-nda-filing-for-xipere-tria-clsd-20190220monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-s-suprachoroidal-injection-platform-featured-in-multiple-oral-present-clsd-20190219monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-clsd-20190102monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-submits-new-drug-application-for-xipere-for-the-treatment-of-macular--clsd-20181219monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-third-quarter-2018-financial-results-and-provides-corporate-clsd-20181108monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-stifel-2018-healthcare-conference-clsd-20181107monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-third-quarter-2018-financial-results-on-thursday-november-8-clsd-20181105monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-sapphire-phase-3-study-of-combination-therapy-in-retinal-ve-clsd-20181105monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-appoints-thomas-a-ciulla-m-d-mba-as-chief-medical-officer-clsd-20181025monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-xipere-and-peachtree-to-be-front-and-center-at-aao-2018-clsd-20181022monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-appoints-veteran-supply-chain-executive-thomas-crawford-as-vice-presi-clsd-20181019monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-appoints-jeffrey-edwards-to-board-of-directors-clsd-20180926monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-appoints-viral-kansara-as-vice-president-discovery-clsd-20180912monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-appoints-accomplished-pharmaceutical-industry-legal-executive-leslie--clsd-20180911monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-2018-janney-healthcare-conference-clsd-20180910monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-2018-wedbush-pacgrow-healthcare-conference-clsd-20180809monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-second-quarter-2018-financial-results-and-provides-corporat-clsd-20180808monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-second-quarter-2018-financial-results-on-august-8-2018-conf-clsd-20180801monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-data-from-its-pivotal-phase-3-peachtree-trial-in-macular-e-clsd-20180716monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-appoints-carol-hoang-as-vice-president-medical-affairs-clsd-20180711monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-completion-of-patient-enrollment-in-first-of-two-phase-3-cl-clsd-20180613monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-participate-in-2018-jmp-securities-life-sciences-conference-clsd-20180611monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-positive-topline-results-from-phase-2-clinical-trial-of-cls-clsd-20180531monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-2018-ubs-global-health-care-conference-clsd-20180516monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-first-quarter-2018-financial-results-and-provides-corporate-clsd-20180509monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-first-quarter-2018-financial-results-on-may-9-2018-conferen-clsd-20180502monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-17th-annual-needham-healthcare-conference-clsd-20180321monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-fourth-quarter-2017-financial-results-and-provides-corporat-clsd-20180314monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-report-fourth-quarter-and-full-year-2017-financial-results-on-marc-clsd-20180308monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-to-present-at-the-cowen-and-company-38th-annual-health-care-conferenc-clsd-20180308monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-announces-pricing-of-public-offering-of-common-stock-clsd-20180308monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-announces-proposed-public-offering-of-common-stock-clsd-20180306monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-provides-update-on-two-phase-3-clinical-trials-of-cls-ta-in-retinal-v-clsd-20180306monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-positive-topline-results-from-pivotal-phase-3-clinical-tria-clsd-20180305monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-schedules-conference-call-to-review-topline-results-from-pivotal-phas-clsd-20180302monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-organizational-changes-designed-to-support-transition-to-a--clsd-20180226monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-clsd-20171220monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-to-participate-in-stifel-2017-healthcare-conference-clsd-20171113monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-s-phase-1-2-open-label-clinical-trial-of-cls-ta-with-and-without-eyle-clsd-20171113monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-announces-third-quarter-2017-financial-results-and-provides-corpo-clsd-20171108monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-to-report-third-quarter-2017-financial-results-on-november-8-2017-clsd-20171101monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-completion-of-patient-enrollment-in-phase-2-clinical-trial--clsd-20171024monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-announces-second-quarter-2017-financial-results-and-provides-corp-clsd-20170809monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-announces-participation-in-upcoming-events-clsd-20170808monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-announces-changes-to-its-board-of-directors-clsd-20170808monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-completion-of-patient-enrollment-in-pivotal-phase-3-peachtr-clsd-20170807monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-to-report-second-quarter-2017-financial-results-on-august-9-2017--clsd-20170802monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-announces-first-patient-randomized-in-phase-2-clinical-trial-of-cls-t-clsd-20170711monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-to-participate-in-2017-jmp-securities-life-sciences-conference-clsd-20170613monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-s-tanzanite-extension-study-in-patients-with-macular-edema-associated-clsd-20170608monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-announces-first-quarter-2017-financial-results-and-provides-corpo-clsd-20170510monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-to-report-first-quarter-2017-financial-results-on-may-10-2017-con-clsd-20170503monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-to-present-at-the-deutsche-bank-42nd-annual-health-care-conferenc-clsd-20170426monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-announces-completion-of-patient-enrollment-in-phase-1-2-open-labe-clsd-20170420monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-enters-into-strategic-collaboration-with-eyekor-to-support-clinical-d-clsd-20170331monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-to-present-at-the-16th-annual-needham-healthcare-conference-clsd-20170328monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-announces-fourth-quarter-and-full-year-2016-financial-results-clsd-20170314monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-to-report-fourth-quarter-and-full-year-2016-financial-results-on--clsd-20170307monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-to-present-at-the-cowen-and-company-37th-annual-health-care-confe-clsd-20170301monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-receives-notice-of-allowance-for-ninth-u-s-patent-clsd-20170301monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-redirects-pre-clinical-amd-research-resources-toward-ongoing-dme--clsd-20170227monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-announces-first-patient-randomized-in-phase-3-clinical-trial-of-z-clsd-20170216monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-receives-notice-of-allowance-for-seventh-u-s-patent-clsd-20170105monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-to-present-at-j-p-morgan-healthcare-conference-clsd-20170105monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-appoints-richard-beckman-m-d-as-chief-medical-officer-clsd-20170104monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-added-to-nasdaq-biotechnology-index-clsd-20161214monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-announces-pricing-of-public-offering-of-common-stock-clsd-20161209monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-announces-proposed-offering-of-common-stock-clsd-20161207monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-announces-first-patient-enrolled-in-phase-1-2-clinical-trial-of-z-clsd-20161115monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-announces-third-quarter-2016-financial-results-and-provides-corpo-clsd-20161109monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-to-present-at-the-2016-stifel-healthcare-conference-on-wednesday--clsd-20161108monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-names-rick-mcelheny-as-vice-president-business-development-clsd-20161108monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-to-report-third-quarter-2016-financial-results-and-host-conferenc-clsd-20161102monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-to-report-clinical-trial-results-at-2016-retina-sub-specialty-day-clsd-20161010monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-to-present-at-the-2016-ladenburg-thalmann-healthcare-conference-clsd-20160920monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-reports-second-quarter-2016-financial-results-clsd-20160811monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-to-present-at-the-2016-wedbush-pacgrow-healthcare-conference-clsd-20160810monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-to-report-second-quarter-2016-financial-results-clsd-20160804monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-to-present-data-from-phase-2-dogwood-clinical-trial-for-the-treat-clsd-20160803monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-announces-promotion-of-glenn-noronha-ph-d-to-chief-scientific-off-clsd-20160801monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-announces-patient-treatment-comparison-from-the-phase-2-trial-tan-clsd-20160726monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-nasdaq-clsd-to-ring-the-nasdaq-stock-market-closing-bell-clsd-20160608monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-announces-pricing-of-initial-public-offering-clsd-20160602monthly0.5https://www.biopharmawatch.com/news/ME/23andme-receives-court-approval-for-sale-to-ttam-research-institute-a-nonprofit-public-ben-me-20250630monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-safety-response-and-mrd-clinical-data-from-tuscany-phase-1-2-clinical-tria-apto-20260615monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-announces-update-on-anticipated-timing-of-closing-of-the-plan-of-arrang-apto-20260529monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-first-quarter-2026-results-apto-20260513monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-announces-update-on-anticipated-timing-of-closing-of-the-plan-of-arrang-apto-20260430monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-announces-results-of-special-shareholders-meeting-announces-receipt-of--apto-20260331monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-announces-amendment-to-arrangement-agreement-and-details-of-postponed-s-apto-20260224monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-announces-rescheduling-of-special-meeting-of-shareholders-to-approve-th-apto-20251219monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-s-tuspetinib-triple-drug-therapy-featured-at-the-2025-ash-annual-meeting-high-rate--apto-20251206monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-announces-arrangement-agreement-for-acquisition-by-hanmi-pharmaceutical-apto-20251119monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-third-quarter-2025-results-apto-20251113monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-tuspetinib-clinical-data-from-ongoing-tuscany-trial-in-newly-diagnosed-aml-selected-apto-20251103monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-s-tuspetinib-exceeds-expectations-when-combined-with-standard-of-care-treatment-acr-apto-20251016monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-and-hanmi-pharmaceutical-extend-loan-agreement-to-continue-development-of-tuspetini-apto-20250922monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-announces-results-of-reconvened-annual-and-special-shareholders-meeting-apto-20250822monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-early-data-demonstrating-tuspetinib-improves-standard-of-care-treatment-acr-apto-20250818monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-second-quarter-2025-results-apto-20250813monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-enrollment-is-open-for-160-mg-dosing-cohort-of-tuspetinib-in-phase-1-2-tuscany-tria-apto-20250806monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-selects-ernst-young-global-limited-as-its-new-independent-auditor-and-calls-reconve-apto-20250801monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-receives-second-advance-under-the-loan-agreement-with-hanmi-pharmaceutical-to-conti-apto-20250715monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-upgraded-to-trade-on-otcqb-market-apto-20250701monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-deferral-of-interest-payment-apto-20250630monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-and-hanmi-enter-new-loan-agreement-to-advance-development-of-tuspetinib-in-triplet--apto-20250620monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-provides-corporate-updates-apto-20250617monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-safety-response-and-mrd-clinical-data-from-tuscany-phase-1-2-clinical-tria-apto-20250612monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-results-from-annual-and-special-meeting-of-shareholders-apto-20250527monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-dosing-of-first-patient-with-120-mg-of-tuspetinib-in-phase-1-2-tuscany-tr-apto-20250520monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-selected-for-prestigious-oral-presentation-of-data-from-tuscany-phase-1-2-clinical--apto-20250514monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-first-quarter-2025-results-apto-20250508monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-provides-clinical-update-for-the-tuspetinib-based-triple-drug-frontline-therapy-in--apto-20250505monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-auditor-not-standing-for-re-appointment-apto-20250423monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-the-2025-bloom-burton-co-healthcare-investor-conference-apto-20250423monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-common-shares-to-delist-from-nasdaq-as-of-april-2-2025-apto-20250401monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-year-end-2024-results-and-corporate-highlights-apto-20250328monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-apto-20250317monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-positive-clinical-safety-review-committee-csrc-approval-to-dose-escalate--apto-20250220monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-reverse-share-split-apto-20250218monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-enters-into-25-million-committed-equity-facility-and-establishes-new-at-the-market--apto-20250213monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-s-frontline-triple-drug-therapy-with-tuspetinib-achieves-notable-responses-in-newly-apto-20250212monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-first-aml-patients-dosed-with-tuspetinib-triplet-frontline-therapy-in-tus-apto-20250109monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-positive-decision-by-nasdaq-hearings-panel-apto-20241219monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-publication-of-preclinical-data-in-aacr-journal-demonstrating-tuspetinib--apto-20241212monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-clinical-data-featured-in-poster-presentation-at-the-2024-ash-annual-meeting-suppor-apto-20241209monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-signs-crada-with-nci-to-develop-tuspetinib-for-aml-and-mds-in-newly-launched-myelom-apto-20241203monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-inc-announces-closing-of-8-million-public-offering-apto-20241125monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-inc-announces-pricing-of-8-million-public-offering-apto-20241122monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-initiates-tuscany-phase-1-2-study-for-newly-diagnosed-aml-patients-to-receive-tuspe-apto-20241120monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-third-quarter-2024-apto-20241108monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-results-from-special-meeting-of-shareholders-apto-20240905monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-receives-10-million-through-a-facility-agreement-with-hanmi-negotiating-future-coll-apto-20240830monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-adjournment-of-its-special-meeting-of-shareholders-apto-20240815monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-second-quarter-2024-apto-20240808monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-receipt-of-deficiency-notice-from-nasdaq-apto-20240719monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-results-from-annual-and-special-meeting-of-shareholders-apto-20240618monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-tuspetinib-tus-clinical-and-preclinical-findings-at-european-hematology-as-apto-20240614monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-closing-of-4-43-million-registered-direct-offering-priced-at-the-market-u-apto-20240603monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-4-43-million-registered-direct-offering-priced-at-the-market-under-nasdaq-apto-20240531monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-first-quarter-2024-apto-20240514monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-report-first-quarter-2024-financial-results-and-provide-clinical-strategy-update-apto-20240506monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-fourth-quarter-and-full-year-2023-apto-20240326monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-report-fourth-quarter-and-year-end-2023-financial-results-and-provide-corporate--apto-20240318monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-closing-of-9-7-million-public-offering-and-concurrent-4-million-private-p-apto-20240131monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-pricing-of-8-4-million-public-offering-and-a-concurrent-4-million-private-apto-20240126monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-tuspetinib-clinical-data-featured-in-oral-presentation-at-the-2023-ash-annual-meeti-apto-20231209monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-appoints-fletcher-payne-chief-business-officer-expanding-his-executive-role-apto-20231130monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-third-quarter-2023-apto-20231109monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-tuspetinib-clinical-data-selected-for-oral-presentation-at-the-2023-ash-annual-meet-apto-20231102monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-highlights-from-clinical-update-webcast-featuring-latest-available-data-on-apto-20231030monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-report-third-quarter-2023-financial-results-and-hold-conference-call-on-thursday-apto-20231026monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-hold-clinical-update-and-kol-data-review-of-aml-drug-tuspetinib-on-monday-octobe-apto-20231023monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-clinical-and-preclinical-data-to-be-presented-at-european-school-of-haematology-esh-apto-20231016monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-the-cantor-global-healthcare-conference-apto-20230918monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-closing-of-3-million-investment-by-hanmi-pharmaceutical-apto-20230906monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-apto-20230824monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-second-quarter-2023-apto-20230810monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-report-second-quarter-2023-financial-results-and-hold-conference-call-on-thursda-apto-20230727monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-apto-20230626monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-highlights-from-clinical-update-apto-20230610monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-provides-update-on-reverse-stock-split-apto-20230605monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-hold-interim-clinical-update-webcast-on-saturday-june-10-2023-apto-20230531monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-enters-into-25-million-committed-equity-facility-apto-20230525monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-announces-results-of-annual-and-special-meeting-of-shareholders-apto-20230523monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-first-quarter-2023-apto-20230508monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-participate-in-rbc-capital-markets-2023-global-healthcare-conference-apto-20230504monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-report-first-quarter-2023-financial-results-and-hold-conference-call-on-monday-m-apto-20230424monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-participate-in-canaccord-genuity-s-2023-horizons-in-oncology-virtual-conference-apto-20230410monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-participate-in-cantor-s-the-future-of-oncology-virtual-symposium-apto-20230328monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-fourth-quarter-and-full-year-2022-apto-20230323monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-immaterial-financial-exposure-to-silicon-valley-bank-apto-20230310monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-report-fourth-quarter-and-full-year-2022-financial-results-and-hold-conference-c-apto-20230309monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-present-at-oppenheimer-33rd-annual-healthcare-conference-apto-20230302monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-initiates-dosing-of-tuspetinib-in-aptivate-expansion-trial-in-patients-with-acute-m-apto-20230130monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-present-at-biotech-showcase-2023-conference-apto-20221228monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-establishes-new-at-the-market-facility-apto-20221212monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-updated-clinical-responses-breadth-of-activity-and-safety-across-four-dos-apto-20221211monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-hold-clinical-update-and-data-review-of-aml-drug-tuspetinib-on-sunday-december-1-apto-20221207monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-treats-first-patient-with-continuous-dosing-of-new-g3-formulation-of-luxeptinib-apto-20221114monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-clinical-data-to-be-presented-at-the-2022-ash-annual-meeting-apto-20221103monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-third-quarter-2022-apto-20221101monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-report-third-quarter-2022-financial-results-and-hold-conference-call-on-tuesday--apto-20221018monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-participate-in-cantor-oncology-hematology-hemeonc-conference-apto-20220914monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-strengthens-board-of-directors-with-appointment-of-bernd-r-seizinger-m-d-ph-d-apto-20220913monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-s-new-g3-formulation-of-luxeptinib-boosts-bioavailability-apto-20220912monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference-apto-20220830monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-second-quarter-2022-apto-20220802monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-the-canaccord-genuity-42nd-annual-growth-conference-apto-20220727monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-report-second-quarter-2022-financial-results-and-hold-conference-call-on-tuesday-apto-20220719monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-appoints-fletcher-payne-as-senior-vice-president-chief-financial-officer-apto-20220627monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-highlights-from-corporate-update-and-kol-event-apto-20220602monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-announces-results-of-annual-meeting-of-shareholders-apto-20220531monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-provide-program-updates-at-kol-webinar-on-thursday-june-2nd-apto-20220525monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-hold-kol-event-and-corporate-update-thursday-june-2nd-apto-20220512monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-first-quarter-2022-apto-20220509monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-receives-fast-track-designation-for-hm43239-in-relapsed-refractory-aml-patients-and-apto-20220504monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-2022-rbc-capital-markets-global-healthcare-conference-apto-20220503monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-report-first-quarter-2022-financial-results-and-hold-conference-call-on-monday-m-apto-20220425monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-executive-management-changes-apto-20220407monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-canaccord-genuity-s-2022-horizons-in-oncology-virtual-conference-apto-20220331monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-fourth-quarter-and-full-year-2021-apto-20220322monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-report-fourth-quarter-and-full-year-2021-financial-results-and-hold-conference-c-apto-20220308monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-oppenheimer-s-32nd-annual-healthcare-conference-apto-20220301monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-participate-in-two-biotech-events-in-january-2022-apto-20211229monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-provides-update-on-apto-253-program-apto-20211220monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-hold-corporate-update-monday-december-13th-apto-20211129monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-the-piper-sandler-33rd-annual-healthcare-conference-apto-20211122monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-third-quarter-2021-apto-20211111monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-clinical-data-to-be-presented-at-the-2021-ash-annual-meeting-apto-20211104monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-enters-into-exclusive-worldwide-license-agreement-with-hanmi-pharmaceutical-for-cli-apto-20211104monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-report-third-quarter-2021-financial-results-and-hold-conference-call-on-thursday-apto-20211026monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-expands-senior-leadership-team-apto-20211025monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-september-investor-conferences-apto-20210830monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-second-quarter-2021-apto-20210803monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-report-second-quarter-2021-financial-results-and-hold-conference-call-on-tuesday-apto-20210720monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-highlights-from-eha-during-corporate-update-event-apto-20210611monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-announces-results-of-annual-meeting-of-shareholders-apto-20210601monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-hold-corporate-update-friday-june-11th-apto-20210527monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-upcoming-investor-conferences-apto-20210512monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-first-quarter-2021-apto-20210504monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-report-first-quarter-2021-financial-results-and-hold-conference-call-on-tuesday--apto-20210426monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-canaccord-genuity-2021-horizons-in-oncology-virtual-conference-apto-20210408monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-fourth-quarter-and-full-year-2020-apto-20210323monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-expands-senior-leadership-team-apto-20210316monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-fourth-quarter-and-year-end-december-31-2020-financial-results-and-hold--apto-20210302monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-highlights-from-ash-and-corporate-update-event-apto-20201206monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-hold-corporate-update-sunday-december-6th-apto-20201201monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-third-quarter-2020-apto-20201110monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-cg-806-and-apto-253-data-at-the-2020-ash-annual-meeting-apto-20201104monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-third-quarter-ended-september-30-2020-financial-results-and-hold-confere-apto-20201027monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-initiates-dosing-of-cg-806-in-patients-with-acute-myeloid-leukemia-apto-20201019monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-oppenheimer-fall-healthcare-life-sciences-medtech-summit-apto-20200915monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-september-investor-conferences-apto-20200909monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-present-at-canaccord-genuity-40th-annual-growth-conference-apto-20200806monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-second-quarter-2020-apto-20200804monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-second-quarter-ended-june-30-2020-financial-results-and-hold-conference--apto-20200721monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-pricing-of-public-offering-of-common-shares-apto-20200716monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-proposed-public-offering-of-common-shares-apto-20200715monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-fda-allowance-of-ind-for-phase-1a-b-study-of-cg-806-in-acute-myeloid-leuk-apto-20200629monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-early-phase-1a-b-cg-806-clinical-findings-at-the-25th-congress-of-the-euro-apto-20200612monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-announces-results-of-annual-meeting-of-shareholders-apto-20200602monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-early-cg-806-clinical-findings-at-the-25th-congress-of-the-european-hema-apto-20200514monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-2020-rbc-capital-markets-global-healthcare-virtual-conference-apto-20200507monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-establishes-new-at-the-market-facility-apto-20200505monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-first-quarter-2020-apto-20200505monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-preliminary-clinical-data-on-cg-806-at-aacr-virtual-annual-meeting-2020-apto-20200427monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-files-proxy-statement-announces-online-only-annual-general-meeting-apto-20200424monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-first-quarter-ended-march-31-2020-financial-results-and-hold-conference--apto-20200421monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-fourth-quarter-and-full-year-2019-apto-20200310monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-fourth-quarter-and-year-end-december-31-2019-financial-results-and-hold--apto-20200225monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-host-key-opinion-leader-event-present-at-bio-ceo-investor-conference-apto-20200129monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-present-at-biotech-showcase-2020-conference-apto-20200107monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-closing-of-public-offering-of-common-shares-apto-20191219monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-pricing-of-public-offering-of-common-shares-apto-20191217monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-proposed-public-offering-of-common-shares-apto-20191216monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-new-preclinical-cg-806-data-at-the-2019-ash-annual-meeting-apto-20191209monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-highlights-from-corporate-event-at-ash-apto-20191207monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-appoints-rafael-bejar-m-d-ph-d-as-chief-medical-officer-apto-20191204monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-31st-annual-piper-jaffray-healthcare-conference-apto-20191202monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-bio-europe-conference-apto-20191107monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-new-cg-806-data-at-the-2019-ash-annual-meeting-apto-20191106monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-third-quarter-ended-september-30-2019-apto-20191105monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-third-quarter-ended-september-30-2019-financial-results-and-hold-confere-apto-20191022monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-participate-at-5th-international-conference-on-acute-myeloid-leukemia-of-the-eur-apto-20191010monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-participate-in-oppenheimer-fall-summit-focused-on-specialty-pharma-and-rare-dise-apto-20190916monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-second-quarter-ended-june-30-2019-apto-20190806monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-present-at-canaccord-genuity-39th-annual-growth-conference-apto-20190730monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-second-quarter-ended-june-30-2019-financial-results-and-hold-conference--apto-20190723monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-doses-first-cll-patient-in-phase-1-study-of-cg-806-and-doses-third-cohort-in-phase--apto-20190716monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-new-preclinical-data-for-cg-806-at-the-24th-congress-of-the-european-hemat-apto-20190614monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-announces-results-of-annual-and-special-meeting-of-shareholders-apto-20190604monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-appoints-jotin-marango-m-d-ph-d-as-chief-business-officer-apto-20190603monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-closing-of-public-offering-of-common-shares-apto-20190603monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-the-jefferies-2019-healthcare-conference-apto-20190531monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-pricing-of-public-offering-of-common-shares-apto-20190530monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-proposed-public-offering-of-common-shares-apto-20190529monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-establishes-new-at-the-market-facility-apto-20190524monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-new-preclinical-data-for-cg-806-at-the-24th-congress-of-the-european-hem-apto-20190516monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-may-investor-conferences-apto-20190513monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-commencement-of-previously-announced-20-0-million-common-share-purchase-a-apto-20190510monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-first-quarter-ended-march-31-2019-apto-20190507monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-the-bloom-burton-co-healthcare-investor-conference-2019-apto-20190424monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-first-quarter-ended-march-31-2019-financial-results-and-hold-conference--apto-20190423monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-the-h-c-wainwright-annual-global-life-sciences-conference-apto-20190402monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-new-preclinical-data-on-cg-806-and-apto-253-at-the-2019-aacr-annual-meetin-apto-20190401monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-fda-allowance-of-investigational-new-drug-application-for-cg-806-apto-20190325monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-fourth-quarter-and-year-ended-december-31-2018-apto-20190312monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-participate-in-upcoming-investor-conferences-in-march-2019-apto-20190307monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-and-crystalgenomics-announce-issuance-of-australian-patent-for-cg-806-apto-20190304monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-new-cg-806-and-apto-253-data-at-the-2019-aacr-annual-meeting-apto-20190228monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-fourth-quarter-and-year-end-december-31-2018-financial-results-and-hold--apto-20190226monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-submits-ind-application-for-cg-806-apto-20190225monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-the-8th-annual-svb-leerink-global-healthcare-conference-apto-20190219monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-present-at-biotech-showcase-2019-conference-apto-20190102monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-highlights-from-cg-806-kol-event-apto-20181212monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-new-preclinical-data-on-cg-806-pan-flt3-pan-btk-inhibitor-at-ash-60th-annu-apto-20181203monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-doses-first-patient-in-re-initiation-of-phase-1b-clinical-study-of-apto-apto-20181126monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-participate-in-upcoming-investor-conferences-host-key-opinion-leader-event-and-p-apto-20181120monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-third-quarter-ended-september-30-2018-apto-20181106monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-new-cg-806-data-at-the-2018-ash-annual-meeting-apto-20181101monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-third-quarter-ended-september-30-2018-financial-results-on-november-6-20-apto-20181023monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-and-crystalgenomics-announce-issuance-of-european-patent-for-cg-806-apto-20180927monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-upcoming-investor-conferences-in-october-2018-apto-20180925monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-upcoming-investor-conferences-in-september-2018-apto-20180829monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-appointment-of-carol-ashe-to-board-of-directors-apto-20180815monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-second-quarter-ended-june-30-2018-apto-20180807monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-present-at-canaccord-genuity-38th-annual-growth-conference-apto-20180802monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-the-2018-global-congress-on-oncology-and-cancer-apto-20180731monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-second-quarter-ended-june-30-2018-financial-results-and-hold-conference--apto-20180724monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-and-crystalgenomics-announce-issuance-of-japanese-patent-for-cg-806-apto-20180710monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-participate-at-the-oppenheimer-co-inc-boston-oncology-insight-summit-apto-20180709monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-new-cg-806-data-at-the-23rd-congress-of-the-european-hematology-associatio-apto-20180615monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-enters-into-license-agreement-with-crystalgenomics-to-acquire-cg-806-rights-in-chin-apto-20180614monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-announces-results-of-annual-meeting-of-shareholders-apto-20180605monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-two-publications-of-preclinical-data-elucidating-the-anticancer-mechanism-apto-20180604monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-enters-into-us-20-million-common-share-purchase-agreement-with-aspire-capital-fund--apto-20180531monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-new-cg-806-data-at-the-23rd-congress-of-the-european-hematology-associat-apto-20180517monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-first-quarter-ended-march-31-2018-apto-20180510monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-exercises-early-option-for-cg-806-license-from-crystalgenomics-apto-20180507monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-first-quarter-ended-march-31-2018-financial-results-and-hold-conference--apto-20180501monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-appointment-of-caroline-m-loewy-to-board-of-directors-apto-20180425monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-the-bloom-burton-co-healthcare-investor-conference-2018-apto-20180424monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-preclinical-data-on-apto-253-at-2018-aacr-annual-meeting-apto-20180417monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-new-preclinical-data-on-cg-806-pan-flt3-pan-btk-inhibitor-at-2018-aacr-ann-apto-20180416monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-the-h-c-wainwright-annual-global-life-sciences-conference-apto-20180403monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-establishes-new-at-the-market-facility-apto-20180328monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-fourth-quarter-and-year-ended-december-31-2017-apto-20180327monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-new-cg-806-and-apto-253-data-at-the-2018-aacr-annual-meeting-apto-20180315monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-fourth-quarter-and-year-end-december-31-2017-financial-results-and-hold--apto-20180308monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-announces-exclusive-license-agreement-for-dual-bet-kinase-targeting-pro-apto-20180307monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-participate-in-upcoming-investor-conferences-in-march-2018-apto-20180306monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-files-new-preliminary-base-shelf-prospectus-to-replace-expired-base-pro-apto-20180207monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-present-at-biotech-showcase-2018-conference-apto-20180102monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-presents-new-preclinical-data-on-cg-806-pan-flt3-pan-btk-inhibitor-at-ash-59th-annu-apto-20171211monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-third-quarter-ended-september-30-2017-apto-20171114monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-third-quarter-ended-september-30-2017-financial-results-and-hold-confere-apto-20171107monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-new-cg-806-data-at-the-2017-ash-annual-meeting-apto-20171101monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-enters-into-15-5-million-common-shares-purchase-agreement-with-aspire-capital-fund--apto-20171030monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-the-17th-annual-biotech-in-europe-forum-apto-20170919monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosicences-and-crystalgenomics-announce-issuance-of-u-s-patent-for-cg-806-apto-20170912monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-present-at-the-19th-annual-rodman-renshaw-global-investment-conferen-apto-20170905monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-second-quarter-ended-june-30-2017-apto-20170808monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-present-at-canaccord-genuity-37th-annual-growth-conference-apto-20170803monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-second-quarter-ended-june-30-2017-financial-results-and-hold-conference--apto-20170801monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-announces-results-of-annual-meeting-of-shareholders-apto-20170606monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-results-for-the-first-quarter-ended-march-31-2017-apto-20170511monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-participate-at-the-bloom-burton-co-healthcare-investor-conference-20-apto-20170425monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-first-quarter-ended-march-31-2017-financial-results-and-hold-conference--apto-20170424monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-present-cg-806-data-at-aacr-hematologic-malignancies-meeting-apto-20170419monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-fourth-quarter-and-year-end-2016-results-apto-20170328monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-announces-planned-departure-of-chief-business-officer-apto-20170327monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-participate-in-upcoming-investor-conferences-apto-20170302monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-present-at-canaccord-genuity-rare-disease-biopharma-1x1-day-apto-20170202monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-prioritizes-development-of-cg-806-first-in-class-flt3-btk-inhibitor-apto-20170123monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-present-at-biotech-showcase-2017-conference-apto-20170105monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-provides-update-on-apto-253-development-apto-20161229monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-reports-financial-results-for-the-third-quarter-ended-september-30-2016-apto-20161115monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-third-quarter-ended-september-30-2016-financial-results-and-hold-confere-apto-20161110monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-new-apto-253-data-at-the-2016-ash-annual-meeting-apto-20161103monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-provides-update-on-fda-clinical-hold-of-apto-253-apto-20161013monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-submits-formal-response-to-clinical-hold-for-apto-253-apto-20160912monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-reports-financial-results-for-the-second-quarter-ended-june-30-2016-apto-20160809monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-present-at-canaccord-genuity-36th-annual-growth-conference-apto-20160809monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-second-quarter-ended-june-30-2016-financial-results-and-hold-conference--apto-20160804monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-announces-results-of-annual-meeting-of-shareholders-apto-20160621monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-provides-corporate-update-in-advance-of-annual-meeting-of-shareholders-apto-20160621monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-and-crystalgenomics-announce-exclusive-agreement-for-non-covalent-btk-f-apto-20160608monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-bioscience-reports-results-for-the-first-quarter-ended-march-31-2016-apto-20160510monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-first-quarter-ended-march-31-2016-financial-results-and-hold-conference--apto-20160502monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-reports-fourth-quarter-and-year-end-2015-results-apto-20160329monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-release-fourth-quarter-and-year-end-december-31-2015-financial-results-and-hold--apto-20160314monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-participate-in-upcoming-investor-conferences-apto-20160303monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-to-present-at-the-2016-rbc-capital-markets-global-healthcare-conference-apto-20160218monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-participate-in-upcoming-investor-conferences-apto-20151130monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-voluntarily-suspends-clinical-dosing-of-apto-253-to-review-drug-manufacturing-proce-apto-20151120monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-reports-results-for-the-third-quarter-ended-september-30-2015-apto-20151110monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-announces-collaborations-for-new-multi-targeting-epigenetic-therapeutic-apto-20151110monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-host-third-quarter-ended-september-30-2015-financial-results-confere-apto-20151105monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-present-at-the-2015-bio-investor-forum-apto-20151015monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-present-at-15th-annual-biotech-in-europe-forum-apto-20150928monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-present-at-canaccord-genuity-35th-annual-growth-conference-apto-20150810monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-reports-results-for-the-second-quarter-ended-june-30-2015-apto-20150804monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-host-second-quarter-ended-june-30-2015-financial-results-conference--apto-20150730monthly0.5https://www.biopharmawatch.com/news/APTO/aptose-biosciences-to-present-at-the-10th-annual-jmp-securities-life-sciences-conference-apto-20150622monthly0.5https://www.biopharmawatch.com/news/NKGN/nkgen-biotech-provides-clarification-on-quotation-display-and-trading-status-on-the-otc-ex-nkgn-20251009monthly0.5https://www.biopharmawatch.com/news/NKGN/nkgen-biotech-chairman-ceo-paul-y-song-m-d-personally-invests-2-65-million-cash-to-acceler-nkgn-20250508monthly0.5https://www.biopharmawatch.com/news/NKGN/nkgen-biotech-inc-to-transition-from-the-nasdaq-global-market-to-otc-markets-reverse-stock-nkgn-20250304monthly0.5https://www.biopharmawatch.com/news/NKGN/nkgen-biotech-receives-notifications-from-nasdaq-related-to-delayed-quarterly-report-and-d-nkgn-20241126monthly0.5https://www.biopharmawatch.com/news/NKGN/nkgen-biotech-receives-notification-from-nasdaq-related-to-delayed-quarterly-report-nkgn-20240822monthly0.5https://www.biopharmawatch.com/news/NKGN/nkgen-biotech-inc-to-become-publicly-traded-company-via-business-combination-with-graf-acq-nkgn-20230415monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-positive-clinical-update-on-afm24-atezolizumab-combination-therapy-in-non--afmd-20241217monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-promising-phase-1-efficacy-and-safety-data-for-afm28-in-relapsed-refractor-afmd-20241209monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combinat-afmd-20241209monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-positive-results-demonstrating-safety-and-efficacy-of-acimtamig-and-allo-afmd-20241208monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-acimtamig-and-allonk-combination-granted-regenerative-medicine-advanced--afmd-20241205monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-third-quarter-2024-financial-results-business-update-afmd-20241114monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-report-third-quarter-2024-financial-results-corporate-update-on-november-14-202-afmd-20241106monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-acceptance-of-three-abstracts-at-the-2024-ash-annual-meeting-including-a-afmd-20241105monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-cantor-global-healthcare-conference-2024-afmd-20240910monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-second-quarter-2024-financial-results-business-update-afmd-20240905monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-appoints-shawn-m-leland-as-chief-executive-officer-afmd-20240903monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-report-second-quarter-2024-financial-results-corporate-update-on-september-5-20-afmd-20240829monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-first-quarter-2024-financial-results-business-update-afmd-20240612monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-report-first-quarter-2024-financial-results-corporate-update-on-june-12-2024-afmd-20240605monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-provides-follow-up-data-of-afm24-plus-atezolizumab-showing-durable-responses-in-he-afmd-20240601monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-receives-fast-track-designation-for-combination-therapy-of-afm24-with-atezolizumab-afmd-20240529monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-annual-general-meeting-of-shareholders-afmd-20240528monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-positive-early-efficacy-and-progression-free-survival-results-of-afm24-1-afmd-20240523monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-acceptance-of-an-abstract-on-preclinical-data-of-its-innate-cell-engager-afmd-20240514monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-acceptance-of-afm24-clinical-abstract-at-the-2024-annual-meeting-of-the--afmd-20240424monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-2023-financial-results-and-operational-progress-afmd-20240328monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-report-full-year-2023-financial-results-corporate-update-on-march-28-2024-afmd-20240321monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-1-for-10-reverse-stock-split-afmd-20240306monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-provides-clinical-response-update-on-afm24-102-trial-in-egfr-wildtype-non-small-ce-afmd-20240108monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-leadership-change-and-organizational-restructuring-afmd-20240108monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-sale-of-wholly-owned-subsidiary-abcheck-afmd-20240103monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-positive-data-for-afm24-in-combination-with-the-pd-l1-checkpoint-inhibit-afmd-20231211monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-updated-phase-1-2-data-from-acimtamig-in-combination-with-allogeneic-nk--afmd-20231211monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-host-investor-conference-call-highlighting-clinical-data-for-acimtamig-afm13-an-afmd-20231204monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-third-quarter-2023-financial-results-and-highlights-operational-progress-afmd-20231114monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-acimtamig-as-international-nonproprietary-name-for-afm13-afmd-20231109monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-report-third-quarter-2023-financial-results-corporate-update-on-november-14-202-afmd-20231107monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-preclinical-data-showing-that-addition-of-an-innate-cell-engager-to-nk-an-afmd-20231103monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-oral-presentation-of-phase-1-2-data-from-afm13-in-combination-with-allog-afmd-20231102monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-participate-in-upcoming-investor-conferences-afmd-20231101monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-listing-transfer-to-nasdaq-capital-markets-afmd-20231004monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-acceptance-of-an-abstract-comparing-nk-cells-redirected-by-innate-cell-e-afmd-20230927monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-cantor-global-healthcare-conference-2023-afmd-20230921monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-t-afmd-20230912monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-h-c-wainwright-annual-global-investment-conference-afmd-20230907monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-publication-in-the-journal-mabs-on-leveraging-fcrn-ph-hplc-as-a-method-t-afmd-20230822monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-second-quarter-2023-financial-results-and-highlights-operational-progress-afmd-20230810monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-report-second-quarter-2023-financial-results-corporate-update-on-august-10-2023-afmd-20230803monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-an-asco-breakthrough-poster-presentation-with-clinical-data-of-afm24-in--afmd-20230731monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board-afmd-20230622monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-acceptance-of-abstracts-at-the-17th-international-conference-on-malignan-afmd-20230609monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-afm24-monotherapy-data-in-non-small-cell-lung-cancer-at-the-annual-meetin-afmd-20230603monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-2023-jefferies-healthcare-conference-afmd-20230530monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-publication-of-afm24-clinical-abstracts-for-the-annual-meeting-of-the-am-afmd-20230525monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-first-quarter-2023-financial-results-and-highlights-operational-progress-afmd-20230523monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-ind-clearance-for-a-phase-2-clinical-trial-investigating-afm13-and-ab-10-afmd-20230523monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-annual-general-meeting-of-shareholders-afmd-20230522monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-report-first-quarter-2023-financial-results-corporate-update-on-may-23-2023-afmd-20230516monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-abstracts-at-the-annual-meeting-of-the-european-hematology-association-afmd-20230511monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-afm24-clinical-abstracts-accepted-for-the-annual-meeting-of-the-american-afmd-20230426monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-shares-preclinical-data-on-afm13-s-mechanism-of-action-demonstrating-its-potential-afmd-20230417monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-final-data-demonstrating-safety-and-efficacy-of-afm13-phase-2-redirect-st-afmd-20230416monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirem-afmd-20230406monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-first-patient-successfully-dosed-in-the-first-in-human-study-of-afm28-fo-afmd-20230329monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-2022-financial-results-and-operational-progress-afmd-20230323monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-report-full-year-2022-financial-results-corporate-update-on-march-23-2023-afmd-20230316monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-presentations-of-clinical-data-from-afm13-phase-2-redirect-and-pre-clini-afmd-20230314monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-participate-in-fireside-chat-at-the-h-c-wainwright-cell-therapy-virtual-confere-afmd-20230222monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-svb-securities-2023-global-biopharma-conference-afmd-20230208monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-on-corporate-progress-and-provides-regulatory-update-for-afm13-afmd-20230109monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-approval-of-clinical-trial-application-in-france-for-a-phase-1-study-of--afmd-20221222monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-updated-data-for-afm28-demonstrating-efficient-elimination-of-leukemic-st-afmd-20221212monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-topline-data-from-afm13-monotherapy-phase-2-redirect-study-in-patients-wit-afmd-20221210monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-provides-updated-clinical-data-from-phase-1-2-study-of-afm13-precomplexed-with-cor-afmd-20221210monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-host-investor-event-highlighting-afm13-clinical-development-at-2022-ash-annual--afmd-20221201monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-third-quarter-2022-financial-results-and-highlights-recent-clinical-and-co-afmd-20221115monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-provides-data-update-from-two-phase-1-2a-trials-with-its-innate-cell-engager-afm24-afmd-20221107monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-report-third-quarter-2022-financial-results-corporate-update-on-november-15-202-afmd-20221104monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-and-artiva-biotherapeutics-announce-partnership-to-advance-combination-therapy-of--afmd-20221103monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-presentation-of-phase-1-2-data-from-afm13-in-combination-with-allogeneic-afmd-20221103monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-2022-jefferies-london-healthcare-conference-afmd-20221101monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-two-clinical-update-presentations-on-its-novel-bispecific-innate-cell-en-afmd-20221005monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-provide-a-clinical-update-on-afm24-monotherapy-dose-escalation-at-european-soci-afmd-20220904monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-upcoming-investor-conferences-afmd-20220901monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-second-quarter-2022-financial-results-and-highlights-recent-operational-pr-afmd-20220811monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-report-second-quarter-2022-financial-results-corporate-update-on-august-11-2022-afmd-20220804monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-establishes-scientific-advisory-board-afmd-20220630monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-preclinical-data-of-novel-innate-cell-engager-afm28-at-the-annual-meeting-afmd-20220610monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-first-quarter-2022-financial-results-and-highlights-recent-operational-pro-afmd-20220601monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-highlights-trial-designs-of-three-afm24-ongoing-clinical-studies-at-the-annual-mee-afmd-20220526monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-2022-jefferies-healthcare-conference-afmd-20220526monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-report-first-quarter-2022-financial-results-corporate-update-on-june-1-2022-afmd-20220524monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-annual-general-meeting-of-shareholders-afmd-20220524monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-data-on-innate-cell-engagers-afm24-and-afm28-at-19th-meeting-of-the-socie-afmd-20220516monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-preclinical-data-demonstrating-cytotoxic-activity-of-its-novel-innate-c-afmd-20220512monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-provides-update-on-asco-afm13-104-oral-presentation-afmd-20220506monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-clinical-update-and-trial-in-progress-posters-at-the-annual-meeting-of-t-afmd-20220427monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-closing-of-public-offering-of-common-shares-and-full-exercise-of-underwr-afmd-20220418monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-pricing-of-upsized-90-million-public-offering-of-common-shares-afmd-20220413monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-proposed-public-offering-of-common-shares-afmd-20220412monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-updated-clinical-data-from-phase-1-2-study-of-afm13-precomplexed-with-cor-afmd-20220410monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-findings-from-the-dose-escalation-phase-of-the-first-in-human-study-of-af-afmd-20220408monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-2021-financial-results-and-highlights-recent-operational-progress-afmd-20220331monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-report-full-year-2021-financial-results-corporate-update-on-march-31-2022-afmd-20220324monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-clinical-updates-at-the-annual-meeting-of-the-american-association-for-c-afmd-20220308monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-publication-of-preclinical-data-demonstrating-cytotoxic-potency-and-effi-afmd-20220209monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-upcoming-investor-events-afmd-20220208monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-completion-of-enrollment-in-redirect-the-registration-directed-study-of--afmd-20220106monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-afmd-20220105monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-shares-preclinical-data-on-innate-cell-engagers-afm28-and-afm13-at-the-63rd-americ-afmd-20211213monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-host-virtual-investor-call-today-to-discuss-treatment-of-cd30-positive-lymphoma-afmd-20211209monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-initiates-patient-recruitment-for-a-phase-1-2a-trial-of-innate-cell-engager-afm24--afmd-20211208monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-100-objective-response-rate-at-highest-dose-in-phase-1-2-study-of-cord-b-afmd-20211122monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-shares-preclinical-data-on-mechanism-of-action-of-two-innate-cell-engagers-at-the--afmd-20211112monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-third-quarter-2021-financial-results-and-highlights-operational-progress-afmd-20211110monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-upcoming-investor-conferences-afmd-20211109monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-and-nkgen-biotech-announce-initiation-of-patient-recruitment-in-a-first-in-human-p-afmd-20211108monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-new-innate-cell-engager-afm28-targeting-cd123-to-treat-acute-myeloid-leu-afmd-20211104monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-poster-presentations-at-the-63rd-american-society-of-hematology-annual-m-afmd-20211104monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-report-third-quarter-2021-financial-results-corporate-update-on-november-10-202-afmd-20211029monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-acceptance-of-three-abstracts-with-preclinical-data-on-its-innate-cell-e-afmd-20211001monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-second-quarter-2021-financial-results-and-highlights-operational-progress-afmd-20210908monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-upcoming-investor-conferences-afmd-20210826monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-report-second-quarter-2021-financial-results-corporate-update-on-september-8-20-afmd-20210823monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-publication-of-comprehensive-preclinical-data-demonstrating-the-therapeu-afmd-20210730monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-first-quarter-2021-financial-results-and-highlights-operational-progress-afmd-20210701monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-report-first-quarter-2021-financial-results-corporate-update-july-1-2021-afmd-20210622monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-appointment-of-uta-kemmerich-keil-to-its-supervisory-board-afmd-20210616monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-jefferies-virtual-healthcare-conference-2021-afmd-20210526monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-virtual-annual-general-meeting-of-shareholders-afmd-20210520monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-publication-of-preclinical-data-in-clinical-cancer-research-supporting-t-afmd-20210513monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-2020-financial-results-and-highlights-recent-operational-progress-afmd-20210415monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-highlights-the-potential-of-its-innate-cell-engager-afm24-as-egfr-targeting-therap-afmd-20210412monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cor-afmd-20210409monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-report-full-year-2020-financial-results-corporate-update-on-april-15-2021-afmd-20210408monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-and-nkmax-america-announce-fda-clearance-of-ind-application-to-study-the-combinati-afmd-20210331monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-presentations-at-the-aacr-annual-meeting-2021-afmd-20210310monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-continuation-of-redirect-a-registration-directed-study-of-afm13-in-ptcl--afmd-20210310monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-collaboration-with-roche-to-study-afm24-in-combination-with-pd-l1-checkp-afmd-20210203monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-closing-of-public-offering-of-common-shares-and-full-exercise-of-underwr-afmd-20210115monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-pricing-of-100-000-000-public-offering-of-common-shares-afmd-20210113monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-proposed-public-offering-of-common-shares-afmd-20210112monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-afmd-20210111monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-25-million-debt-financing-agreement-with-silicon-valley-bank-afmd-20210111monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-pipeline-and-business-update-afmd-20210107monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-updated-afm13-clinical-data-presentation-at-the-american-society-of-hema-afmd-20201207monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-publication-of-final-study-results-of-its-innate-cell-engager-candidate--afmd-20201119monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-third-quarter-2020-financial-results-and-highlights-recent-operational-pro-afmd-20201110monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-and-roivant-sciences-announce-licensing-and-strategic-collaboration-agreement-to-d-afmd-20201109monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-presentations-on-its-afm13-innate-cell-engager-at-the-62nd-american-soci-afmd-20201104monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-upcoming-investor-conferences-afmd-20201104monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-report-3rd-quarter-2020-financial-results-corporate-update-november-10-2020-afmd-20201103monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-and-nkmax-america-to-study-the-combination-of-afm24-an-egfr-targeted-innate-cell-e-afmd-20201020monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-presentation-of-preclinical-data-on-afm13-targeted-nk-cells-at-the-35th--afmd-20201014monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-dosing-of-first-patient-in-phase-1-clinical-trial-of-cord-blood-derived--afmd-20201006monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-jefferies-virtual-cell-therapy-summit-afmd-20200929monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-upcoming-investor-conferences-afmd-20200902monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-second-quarter-2020-financial-results-and-operational-progress-afmd-20200811monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-two-new-appointments-to-its-supervisory-board-afmd-20200805monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-report-second-quarter-2020-financial-results-corporate-update-august-11-2020-afmd-20200804monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-annual-general-meeting-of-shareholders-afmd-20200710monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-first-quarter-2020-financial-results-and-operational-progress-afmd-20200623monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-presentation-of-data-on-genentech-s-ro7297089-and-afm24-both-innate-cell-afmd-20200622monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-successful-completion-of-first-dose-cohort-in-first-in-human-phase-1-2a--afmd-20200617monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-report-first-quarter-2020-financial-results-corporate-update-june-23-2020-compa-afmd-20200616monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-appointment-of-angus-smith-as-chief-financial-officer-afmd-20200611monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-highlights-study-design-of-its-afm13-redirect-trial-at-the-asco-2020-virtual-meeti-afmd-20200529monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-jefferies-virtual-healthcare-conference-afmd-20200528monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-abstracts-on-innate-cell-engagers-from-its-rock-platform-accepted-for-pr-afmd-20200515monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-2019-financial-results-and-recent-operational-progress-afmd-20200428monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-first-patient-successfully-dosed-in-first-in-human-phase-1-2a-study-of-a-afmd-20200416monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-provides-covid-19-related-business-update-and-announces-full-year-2019-financial-r-afmd-20200402monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-fda-granted-orphan-drug-designation-for-lead-innate-cell-engager-afm13-f-afmd-20200401monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-participation-at-upcoming-virtual-investor-conferences-afmd-20200326monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-appointment-of-arndt-schottelius-m-d-ph-d-as-chief-scientific-officer-afmd-20200317monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-svb-leerink-9th-annual-global-healthcare-conference-afmd-20200219monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-mourns-passing-of-chief-financial-officer-dr-florian-fischer-afmd-20200203monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-appointment-of-andreas-harstrick-m-d-as-chief-medical-officer-afmd-20200110monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-addition-to-nasdaq-biotechnology-index-afmd-20191217monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-third-quarter-2019-financial-results-and-recent-operational-progress-afmd-20191119monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-third-quarter-2019-financial-results-and-corporate-update-conference-cal-afmd-20191114monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-jefferies-2019-london-healthcare-conference-afmd-20191114monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-closing-of-public-offering-of-common-shares-and-exercise-of-underwriters-afmd-20191113monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-pricing-of-public-offering-of-common-shares-afmd-20191108monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-proposed-public-offering-of-common-shares-afmd-20191107monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-highlights-progress-on-nk-cell-engager-collaboration-with-genentech-afmd-20191107monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-fda-clearance-of-ind-to-commence-first-in-human-phase-1-2a-study-of-afm2-afmd-20191107monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-progress-on-key-clinical-development-programs-afmd-20191015monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-participate-in-investor-conferences-in-september-afmd-20190828monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-second-quarter-2019-financial-and-operational-results-afmd-20190807monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-second-quarter-2019-financial-results-and-corporate-update-conference-ca-afmd-20190731monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-added-to-the-russell-2000-3000-and-microcap-indexes-afmd-20190701monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-clinical-data-update-on-lead-product-candidate-afm13-in-cd30-lymphoma-at-afmd-20190624monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-data-on-afm13-at-the-15th-international-conference-on-malignant-lymphom-afmd-20190612monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-annual-general-meeting-of-shareholders-afmd-20190604monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-jefferies-2019-healthcare-conference-afmd-20190529monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-r-d-strategy-to-focus-on-innate-immunity-portfolio-reports-first-quarter-afmd-20190522monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-first-quarter-2019-financial-results-and-corporate-update-conference-cal-afmd-20190516monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-provides-regulatory-update-on-afm11-clinical-program-afmd-20190417monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-highlights-afm24-innate-cell-engager-novel-mechanism-of-action-and-potential-for-t-afmd-20190401monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-2018-financial-results-and-operational-progress-afmd-20190327monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-full-year-2018-financial-results-conference-call-on-march-27-2019-afmd-20190320monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-milestone-payment-from-genentech-and-rock-platform-presentation-at-innat-afmd-20190319monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-data-on-afm13-and-afm24-at-aacr-annual-meeting-2019-afmd-20190227monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-upcoming-investor-conferences-afmd-20190221monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-afmd-20190104monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-u-s-registrational-pathway-and-updated-clinical-development-plan-for-afm-afmd-20181207monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-data-at-ash-2018-substantiating-opportunity-for-afm13-as-mono-and-combina-afmd-20181203monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-host-research-development-day-on-friday-december-7-2018-in-new-york-city-afmd-20181128monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-jefferies-2018-london-healthcare-conference-afmd-20181108monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-financial-results-for-third-quarter-2018-and-operational-progress-afmd-20181107monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-oral-presentation-and-five-poster-presentations-at-the-2018-american-soc-afmd-20181101monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-third-quarter-2018-financial-results-and-corporate-update-conference-cal-afmd-20181031monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-places-afm11-cd19-cd3-targeting-t-cell-engager-phase-1-program-on-clinical-hold-afmd-20181008monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-2018-wells-fargo-securities-healthcare-conference-afmd-20180830monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-collaboration-with-genentech-to-develop-novel-nk-cell-engager-based-immu-afmd-20180827monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-financial-results-for-second-quarter-2018-and-operational-progress-afmd-20180808monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-second-quarter-2018-financial-results-and-corporate-update-conference-ca-afmd-20180803monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-updated-data-of-afm13-in-combination-with-keytruda-pembrolizumab-in-pati-afmd-20180615monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-jefferies-global-healthcare-conference-afmd-20180530monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-annual-general-meeting-of-shareholders-afmd-20180518monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-financial-results-for-first-quarter-2018-afmd-20180515monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-first-quarter-2018-financial-results-and-corporate-update-conference-cal-afmd-20180508monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-deutsche-bank-s-43rd-annual-health-care-conference-afmd-20180503monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-introduces-rock-tm-platform-for-tailored-immune-cell-engagers-afmd-20180503monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-poster-at-aacr-highlighting-progress-toward-novel-egfr-targeting-therapy-afmd-20180416monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-financial-results-for-fourth-quarter-and-year-end-2017-afmd-20180320monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-appoints-dr-leila-alland-as-chief-medical-officer-afmd-20180319monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-data-on-afm24-at-aacr-annual-meeting-2018-afmd-20180315monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-fourth-quarter-and-year-end-2017-financial-results-and-corporate-update--afmd-20180313monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-cowen-and-company-38th-annual-health-care-conference-afmd-20180308monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-closing-of-public-offering-of-common-stock-and-exercise-of-underwriters--afmd-20180215monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-pricing-of-public-offering-of-common-stock-afmd-20180213monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-proposed-public-offering-of-common-stock-afmd-20180212monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-new-data-for-afm13-from-two-separate-clinical-trials-in-hodgkin-and-cd30-p-afmd-20180201monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-data-from-phase-1b-combination-study-of-afm13-with-pembrolizumab-at-ash-afmd-20171211monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-jefferies-2017-london-healthcare-conference-afmd-20171115monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-financial-results-for-third-quarter-2017-afmd-20171107monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-26th-annual-credit-suisse-healthcare-conference-afmd-20171102monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-clinical-and-preclinical-data-on-immune-cell-engagers-at-ash-afmd-20171101monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-third-quarter-2017-financial-results-and-corporate-update-conference-cal-afmd-20171030monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-leerink-partners-roundtable-series-rare-disease-immuno-oncology-afmd-20170922monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-appoints-dr-wolfgang-fischer-as-chief-operating-officer-afmd-20170913monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-2017-wells-fargo-healthcare-conference-boston-afmd-20170904monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-financial-results-for-second-quarter-2017-afmd-20170801monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-second-quarter-2017-financial-results-and-corporate-update-conference-ca-afmd-20170725monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-preclinical-data-on-afm24-and-afm26-at-eacr-aacr-sic-2017-afmd-20170627monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-data-on-first-in-class-bcma-targeting-immune-cell-engager-afm26-at-asco-a-afmd-20170606monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-jefferies-2017-global-healthcare-conference-new-york-afmd-20170530monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-annual-general-meeting-of-shareholders-afmd-20170522monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-immune-cell-engager-data-at-asco-annual-meeting-and-eacr-aacr-sic-speci-afmd-20170517monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-financial-results-for-first-quarter-2017-afmd-20170517monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-first-quarter-2017-financial-results-and-corporate-update-conference-cal-afmd-20170510monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-data-on-immune-cell-engager-pipeline-at-the-aacr-annual-meeting-2017-afmd-20170405monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-financial-results-for-fourth-quarter-and-year-end-2016-afmd-20170330monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-fourth-quarter-and-year-end-2016-financial-results-and-corporate-update--afmd-20170323monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-oppenheimer-27th-annual-healthcare-conference-new-york-afmd-20170315monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-data-on-immune-cell-engagers-at-the-aacr-annual-meeting-2017-afmd-20170301monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-cowen-and-company-37th-annual-health-care-conference-afmd-20170228monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-leerink-partners-6th-annual-global-healthcare-conference-afmd-20170208monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-closing-of-public-offering-of-common-stock-afmd-20170125monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-pricing-of-public-offering-of-common-stock-afmd-20170120monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-proposed-public-offering-of-common-stock-afmd-20170119monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-provides-update-on-nk-cell-immuno-oncology-platform-afmd-20170111monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-and-md-anderson-announce-clinical-immuno-oncology-development-collaboration-afmd-20170104monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-new-preclinical-data-on-bi-and-trispecific-immune-cell-engagers-at-ash-afmd-20161206monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-jefferies-2016-london-healthcare-conference-afmd-20161109monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-preclinical-data-on-bi-and-trispecific-immune-cell-engagers-at-ash-afmd-20161108monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-financial-results-for-third-quarter-2016-afmd-20161102monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-credit-suisse-25th-annual-healthcare-conference-afmd-20161031monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-third-quarter-2016-financial-results-and-corporate-update-conference-cal-afmd-20161026monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-preclinical-data-on-lead-candidate-afm13-at-the-annual-meeting-of-the-soc-afmd-20161004monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-leerink-partners-roundtable-series-rare-disease-immuno-oncology-afmd-20160922monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-upcoming-investor-conferences-afmd-20160901monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-financial-results-for-second-quarter-2016-and-provides-corporate-update-afmd-20160810monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-second-quarter-2016-financial-results-and-corporate-update-conference-ca-afmd-20160803monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-jefferies-2016-healthcare-conference-afmd-20160531monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-annual-general-meeting-of-shareholders-afmd-20160523monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-financial-results-for-first-quarter-2016-afmd-20160518monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-ubs-global-healthcare-conference-new-york-afmd-20160517monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-first-quarter-2016-financial-results-and-corporate-update-conference-cal-afmd-20160511monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-data-on-egfrwt-and-egfrviii-targeting-nk-and-t-cell-tandabs-at-the-aacr-a-afmd-20160421monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-data-on-afm13-mediated-innate-adaptive-immune-crosstalk-at-the-aacr-annua-afmd-20160421monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-financial-results-for-fourth-quarter-and-year-end-2015-afmd-20160330monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-fourth-quarter-and-year-end-2015-financial-results-and-corporate-update--afmd-20160323monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-data-on-nk-and-t-cell-engagers-at-the-aacr-annual-meeting-2016-afmd-20160317monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-cowen-and-company-36th-annual-health-care-conference-afmd-20160229monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-speak-at-symposium-on-emerging-approaches-in-cancer-immunotherapy-afmd-20160222monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-leerink-partners-5th-annual-global-healthcare-conference-afmd-20160204monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-enters-into-collaboration-with-merck-to-evaluate-afm13-in-combination-with-keytrud-afmd-20160125monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-appoints-dr-joerg-windisch-as-chief-operating-officer-and-adds-dr-bernhard-ehmer-t-afmd-20160121monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-host-hodgkin-s-lymphoma-day-with-key-opinion-leaders-on-january-26th-in-new-yor-afmd-20160120monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-addition-of-dr-andrew-evens-to-scientific-advisory-board-afmd-20160114monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-noble-financial-capital-markets-12th-annual-investor-conference-afmd-20160112monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-added-to-nasdaq-biotech-index-afmd-20151214monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-additional-data-on-combination-of-afm13-with-checkpoint-inhibitors-at-ash-afmd-20151206monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-data-comparing-t-cell-and-nk-cell-engaging-tandabs-afm11-and-afm12-at-ash-afmd-20151206monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-appointment-of-andrew-curtis-to-lead-corporate-strategy-and-business-dev-afmd-20151202monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-oppenheimer-26th-annual-healthcare-conference-new-york-afmd-20151201monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-ceo-to-present-at-the-jefferies-2015-global-healthcare-conference-london-afmd-20151111monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-financial-results-for-third-quarter-2015-afmd-20151110monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-data-on-potency-of-nk-and-t-cell-egfrviii-tandabs-at-sitc-afmd-20151106monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-data-on-nk-and-t-cell-engagers-at-ash-afmd-20151105monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-third-quarter-2015-financial-results-and-corporate-update-conference-cal-afmd-20151103monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-significant-investment-by-an-existing-shareholder-afmd-20151014monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-data-on-potency-of-nk-and-t-cell-egfrviii-tandabs-at-sitc-afmd-20151006monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-leerink-partners-inaugural-immuno-oncology-roundtable-conference-afmd-20150923monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-financial-results-for-second-quarter-2015-afmd-20150804monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-second-quarter-2015-financial-results-and-corporate-update-conference-ca-afmd-20150728monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-added-to-russell-2000-r-index-afmd-20150630monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-added-to-russell-2000-index-afmd-20150630monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-opening-of-us-operations-and-key-us-based-hires-afmd-20150623monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-newly-formed-scientific-advisory-board-afmd-20150603monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-asco-data-demonstrate-consistent-potency-of-nk-cell-engaging-combination-therapy-w-afmd-20150529monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-asco-data-for-the-cd33-cd3-tandab-program-demonstrate-that-cd33-and-cd3-binding-af-afmd-20150529monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-jefferies-2015-healthcare-conference-new-york-afmd-20150527monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-financial-results-for-first-quarter-2015-afmd-20150521monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-data-at-asco-to-highlight-potency-of-nk-cell-engaging-combination-thera-afmd-20150513monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-first-quarter-2015-financial-results-conference-call-afmd-20150513monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-announces-shareholder-meeting-afmd-20150512monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-announces-closing-of-public-offering-of-common-stock-and-exercise-of-underwrit-afmd-20150512monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-ubs-global-healthcare-conference-new-york-afmd-20150512monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-announces-pricing-of-public-offering-of-common-stock-afmd-20150507monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-announces-proposed-public-offering-of-common-stock-afmd-20150504monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-financial-results-for-fourth-quarter-and-year-end-2014-afmd-20150325monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-completes-tandab-development-candidate-activities-meeting-amphivena-s-and-janssen--afmd-20150324monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-fourth-quarter-and-year-end-2014-financial-results-conference-call-afmd-20150318monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-27th-annual-roth-conference-afmd-20150303monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-bio-ceo-investor-conference-and-at-the-leerink-partners-global-h-afmd-20150203monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-nasdaq-afmd-to-ring-the-nasdaq-stock-market-opening-bell-afmd-20150129monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-appoints-dr-martin-treder-as-chief-scientific-officer-afmd-20150120monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-receives-eur-2-4-million-3-million-research-grant-from-german-government-to-fund-t-afmd-20150107monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-presents-final-data-for-afm13-phase-1-trial-at-ash-afmd-20141208monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-financial-results-for-third-quarter-2014-afmd-20141118monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-to-present-at-the-jefferies-global-healthcare-conference-london-afmd-20141112monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-third-quarter-2014-financial-results-conference-call-afmd-20141111monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-closing-of-initial-public-offering-afmd-20140917monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-pricing-of-initial-public-offering-afmd-20140912monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-secures-29-7m-in-private-financing-from-current-and-new-investors-afmd-20140902monthly0.5https://www.biopharmawatch.com/news/SCPH/scpharmaceuticals-announces-pricing-of-50-0-million-public-offering-scph-20240812monthly0.5https://www.biopharmawatch.com/news/SCPH/scpharmaceuticals-announces-proposed-underwritten-public-offering-of-common-stock-and-pre--scph-20240812monthly0.5https://www.biopharmawatch.com/news/SCPH/scpharmaceuticals-announces-proposed-underwritten-public-offering-of-common-stock-scph-20221121monthly0.5https://www.biopharmawatch.com/news/SCPH/scpharmaceuticals-inc-reports-fourth-quarter-2017-financial-results-scph-20180320monthly0.5https://www.biopharmawatch.com/news/SCPH/scpharmaceuticals-inc-announces-closing-of-over-allotment-option-in-its-initial-public-off-scph-20171129monthly0.5https://www.biopharmawatch.com/news/SCPH/scpharmaceuticals-inc-announces-closing-of-initial-public-offering-scph-20171129monthly0.5https://www.biopharmawatch.com/news/SCPH/scpharmaceuticals-inc-announces-pricing-of-initial-public-offering-scph-20171117monthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-announces-filing-of-special-meeting-materials-and-receipt-of-interim-ord-thtx-20250818monthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-enters-into-definitive-agreement-to-be-acquired-by-cb-biotechnology-an-a-thtx-20250703monthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-presents-novel-data-at-acthiv-2025-underscoring-importance-of-managing-e-thtx-20250502monthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-reports-financial-results-for-the-first-quarter-2025-and-reviews-key-ach-thtx-20250409monthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-receives-fda-approval-for-egrifta-wr-tesamorelin-f8-to-treat-excess-visc-thtx-20250325monthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-reports-financial-results-for-the-fourth-quarter-and-full-year-of-fiscal-thtx-20250226monthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-reports-strong-financial-results-and-announces-positive-net-income-for-t-thtx-20241010monthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-reports-financial-results-and-announces-positive-net-income-for-second-q-thtx-20240710monthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-receives-refusal-to-file-letter-for-trogarzo-intramuscular-method-of-adm-thtx-20240227monthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-reports-financial-results-for-the-fourth-quarter-and-full-year-of-fiscal-thtx-20240221monthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-submits-sbla-for-trogarzo-intramuscular-im-method-of-administration-to-f-thtx-20240102monthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-announces-us-40-million-bought-deal-public-offering-of-units-thtx-20210112monthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-announces-us-50-million-bought-deal-offering-of-5-75-convertible-unsecur-thtx-20180530monthly0.5https://www.biopharmawatch.com/news/ONVO/organovo-holdings-inc-announces-pricing-of-5-25-million-public-offering-onvo-20240509monthly0.5https://www.biopharmawatch.com/news/ONVO/organovo-holdings-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-onvo-20220218monthly0.5https://www.biopharmawatch.com/news/ONVO/organovo-holdings-founder-calls-on-board-of-directors-to-accept-stockholders-opposition-to-onvo-20200402monthly0.5https://www.biopharmawatch.com/news/ONVO/organovo-holdings-founder-issues-letter-regarding-alternative-paths-to-illogical-merger-wi-onvo-20200323monthly0.5https://www.biopharmawatch.com/news/ONVO/organovo-founder-issues-letter-to-stockholders-regarding-major-missteps-and-misjudgment-of-onvo-20200319monthly0.5https://www.biopharmawatch.com/news/ONVO/organovo-holdings-inc-nasdaq-onvo-to-ring-the-nasdaq-stock-market-opening-bell-onvo-20161017monthly0.5https://www.biopharmawatch.com/news/ONVO/organovo-issues-fiscal-year-2016-and-long-range-outlook-onvo-20150909monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-provides-business-update-and-reports-first-quarter-2026-financial-results-vxrt-20260507monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-announces-share-purchase-agreement-for-up-to-25-million-with-lincoln-park-capital-vxrt-20260417monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-provides-business-update-and-reports-second-quarter-2025-financial-results-vxrt-20250813monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-ceo-issues-letter-to-stockholders-vxrt-20250808monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-submits-proxy-statement-for-reverse-stock-split-to-support-resumption-of-trading-on-vxrt-20250724monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-announces-trading-on-otcqx-best-market-vxrt-20250708monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-s-founder-and-chief-scientific-officer-provides-video-update-to-stockholders-vxrt-20250529monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-announces-adjournment-of-annual-meeting-of-stockholders-vxrt-20250521monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vxrt-20250520monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-approves-resolutions-to-narrow-proposed-reverse-split-range-and-proposes-reducing-a-vxrt-20250516monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-provides-business-update-and-reports-first-quarter-2025-financial-results-vxrt-20250513monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-addresses-frequently-asked-questions-on-reverse-stock-split-proposal-in-definitive--vxrt-20250512monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vxrt-20250327monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-provides-business-update-and-reports-full-year-2024-financial-results-vxrt-20250320monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vxrt-20241119monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vxrt-20240830monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-announces-40-million-underwritten-offering-of-common-stock-vxrt-20240613monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vxrt-20240523monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vxrt-20240320monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-announces-10-0-million-registered-direct-offering-with-ra-capital-management-vxrt-20240116monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-inc-announces-pricing-of-15-000-000-public-offering-of-common-stock-vxrt-20230607monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-inc-announces-proposed-public-offering-of-common-stock-vxrt-20230606monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-provides-business-update-and-reports-fourth-quarter-and-full-year-2020-financial-re-vxrt-20210225monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-reports-third-quarter-2020-financial-results-and-provides-business-update-vxrt-20201112monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-announces-second-quarter-2020-results-vxrt-20200806monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-raises-approximately-90m-in-gross-proceeds-through-its-at-the-market-facility-vxrt-20200713monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-announces-first-quarter-2020-financial-results-and-provides-corporate-update-vxrt-20200512monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-announces-fourth-quarter-and-full-year-2019-financial-results-and-provides-corporat-vxrt-20200319monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-announces-10-0-million-registered-direct-offering-priced-at-the-market-vxrt-20200227monthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-announces-pricing-of-8-million-underwritten-public-offering-vxrt-20190926monthly0.5https://www.biopharmawatch.com/news/ACHL/achilles-therapeutics-receives-approval-to-transfer-to-nasdaq-capital-market-achl-20241119monthly0.5https://www.biopharmawatch.com/news/ACHL/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requir-achl-20240517monthly0.5https://www.biopharmawatch.com/news/ACHL/achilles-therapeutics-announces-filing-of-registration-statement-for-proposed-initial-publ-achl-20210301monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-inc-to-be-acquired-by-battery-ventures-in-all-cash-transaction-enz-20250624monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-second-quarter-fiscal-year-2025-results-enz-20250317monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-first-quarter-fiscal-year-2025-results-and-provides-a-company-update-enz-20241216monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-fourth-quarter-and-fiscal-year-2024-results-and-announces-cash-divide-enz-20241029monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-third-quarter-fiscal-2024-results-and-provides-business-update-enz-20240613monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-second-quarter-fiscal-2024-results-and-provides-business-update-enz-20240313monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-results-of-its-annual-meeting-of-shareholders-and-officer-appointment-enz-20240201monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-first-quarter-fiscal-2024-results-and-provides-business-update-enz-20231215monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-fourth-quarter-and-fiscal-year-2023-results-and-provides-business-upd-enz-20231106monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-announces-departure-of-hamid-erfanian-and-appointment-of-kara-cannon-as-inter-enz-20230906monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-completes-sale-of-clinical-laboratory-to-labcorp-enz-20230724monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-third-quarter-fiscal-year-2023-financial-results-enz-20230614monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-significant-progress-towards-completing-the-clinical-lab-asset-sale-enz-20230522monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-inc-announces-date-of-special-meeting-of-shareholders-enz-20230424monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-second-quarter-fiscal-year-2023-financial-results-enz-20230321monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-agrees-to-sell-clinical-laboratory-to-labcorp-enz-20230316monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-first-quarter-fiscal-year-2023-financial-results-and-provides-busines-enz-20221212monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-inc-to-report-first-quarter-fiscal-2023-financial-results-and-business-update-enz-20221207monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-inc-announces-date-of-annual-shareholders-meeting-enz-20221108monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-inc-appoints-patricia-eckert-cpa-as-interim-cfo-enz-20221020monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-fourth-quarter-and-fiscal-year-2022-financial-results-and-provides-bu-enz-20221014monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-to-report-fourth-quarter-2022-financial-results-and-business-update-on-friday-enz-20221010monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-inc-opens-expanded-life-sciences-laboratory-and-office-facilities-in-farmingd-enz-20221006monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-inc-launches-ampiview-gene-expression-platform-with-first-products-targeting--enz-20220926monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-to-launch-monkeypox-testing-services-this-week-enz-20220811monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-appoints-matthew-kupferberg-as-general-counsel-enz-20220803monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-third-quarter-fiscal-2022-results-and-provides-leadership-and-corpora-enz-20220609monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-to-report-third-quarter-2022-financial-results-and-business-update-on-thursda-enz-20220602monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-announces-new-york-state-department-of-health-approval-of-hpv-molecular-diagn-enz-20220419monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-results-of-its-annual-meeting-of-shareholders-enz-20220412monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-adjourns-annual-meeting-of-shareholders-to-complete-vote-on-proposal-enz-20220406monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-adjourns-annual-meeting-of-shareholders-until-april-8-2022-enz-20220401monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-appoints-david-bench-and-kara-cannon-to-new-executive-management-positions-enz-20220328monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-second-quarter-fiscal-2022-result-and-provides-leadership-and-corpora-enz-20220314monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-to-present-at-the-keybanc-capital-markets-life-sciences-medtech-investor-foru-enz-20220310monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-to-report-second-quarter-2022-financial-results-and-business-update-on-monday-enz-20220308monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-first-quarter-2022-financial-results-and-provides-business-update-enz-20211215monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-to-report-first-quarter-2022-financial-results-and-business-update-on-wednesd-enz-20211202monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-inducement-awards-to-new-chief-executive-officer-enz-20211109monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-expands-gotestmenow-online-portal-to-provide-patients-with-direct-access-to-p-enz-20211021monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-fourth-quarter-and-fiscal-year-2021-financial-results-and-provides-bu-enz-20211012monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-to-report-fourth-quarter-and-full-year-2021-financial-results-and-business-up-enz-20210928monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference-enz-20210902monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-receives-fda-emergency-use-authorization-for-rapid-extraction-method-on-propr-enz-20210720monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-announces-online-service-with-trustassure-to-schedule-timely-pcr-testing-requ-enz-20210615monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-third-quarter-fiscal-2021-results-enz-20210609monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-to-report-third-quarter-2021-financial-results-on-wednesday-june-9-enz-20210601monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-to-present-at-the-keybanc-capital-markets-life-sciences-medtech-investor-foru-enz-20210317monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-second-quarter-fiscal-2021-results-company-provides-leadership-and-co-enz-20210315monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-to-participate-in-the-h-c-wainwright-global-life-sciences-conference-enz-20210304monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-to-report-second-quarter-2021-financial-results-on-monday-march-15-enz-20210301monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-s-board-of-directors-forms-new-corporate-development-and-planning-succession--enz-20210120monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-to-participate-in-the-lifesci-partners-10th-annual-healthcare-corporate-acces-enz-20210105monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-receives-fda-emergency-use-authorization-for-testing-pooled-samples-on-three--enz-20210104monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-hosting-key-opinion-leader-call-on-genflex-molecular-system-for-covid-19-and--enz-20201215monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-first-quarter-fiscal-2021-financial-results-and-provides-business-upd-enz-20201209monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-to-report-first-quarter-2021-financial-results-on-wednesday-december-9-enz-20201202monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-announces-appointment-of-ian-b-walters-md-to-its-board-of-directors-enz-20201125monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-announces-appointment-of-mary-tagliaferri-md-to-its-board-of-directors-enz-20201118monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-launches-gotestmenow-online-platform-for-consumers-to-directly-order-covid-19-enz-20201027monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-busi-enz-20201013monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-to-report-fourth-quarter-and-fiscal-year-2020-financial-results-on-tuesday-oc-enz-20201006monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-doubles-capacity-in-response-to-increasing-demand-for-covid-19-testing-enz-20200908monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-to-provide-access-to-covid-19-testing-at-more-than-50-ny-pharmacies-in-collab-enz-20200721monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-receives-emergency-use-authorization-for-proprietary-test-system-for-detectio-enz-20200713monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-to-provide-covid-19-testing-to-farmingdale-state-college-staff-and-students-a-enz-20200630monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-reports-third-quarter-2020-financial-results-enz-20200608monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-to-announce-third-quarter-2020-financial-results-on-monday-june-8-2020-enz-20200603monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-launches-proprietary-test-for-detection-of-coronavirus-sars-cov-2-igg-antibod-enz-20200520monthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-crosswave-communications-penford-and-actuant-events-to-be-broadcast-by-vcall--enz-20020315monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cmrx-20250218monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cmrx-20250124monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-submits-dordaviprone-new-drug-application-for-accelerated-approval-to-u-s-fda-for-cmrx-20241230monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-submit-dordaviprone-for-accelerated-approval-to-u-s-fda-for-patients-with-recu-cmrx-20241209monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cmrx-20241206monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-updated-phase-2-response-assessment-of-dordaviprone-in-recurrent-h3-k27-cmrx-20241111monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-third-quarter-2024-financial-results-and-provides-operational-update-cmrx-20241107monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-third-quarter-2024-financial-results-and-provide-an-operational-update--cmrx-20241101monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-cmrx-20241018monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-h-c-wainwright-26th-annual-global-investment-conference-cmrx-20240903monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-cmrx-20240830monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-second-quarter-2024-financial-results-and-provides-operational-update-cmrx-20240813monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-second-quarter-2024-financial-results-and-provide-an-operational-update-cmrx-20240806monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cmrx-20240705monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-participate-in-fireside-chat-at-jefferies-global-healthcare-conference-cmrx-20240530monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-first-quarter-2024-financial-results-and-provides-operational-update-cmrx-20240501monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-first-quarter-2024-financial-results-and-provide-an-operational-update--cmrx-20240424monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cmrx-20240416monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-appoints-marc-d-kozin-to-board-of-directors-cmrx-20240321monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-fourth-quarter-and-year-end-2023-financial-results-and-provides-operation-cmrx-20240229monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-td-cowen-44th-annual-health-care-conference-cmrx-20240227monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-fourth-quarter-and-year-end-2023-financial-results-and-provide-an-opera-cmrx-20240222monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-appoints-lisa-decker-to-board-of-directors-cmrx-20231229monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-promotes-michelle-laspaluto-to-chief-financial-officer-cmrx-20231204monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-cmrx-20231124monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-strengthens-executive-leadership-team-with-appointment-of-thomas-riga-as-chief-op-cmrx-20231116monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-third-quarter-2023-financial-results-and-provides-operational-update-cmrx-20231102monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-third-quarter-2023-financial-results-and-provide-an-operational-update--cmrx-20231026monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-participate-in-upcoming-investor-conferences-cmrx-20230905monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-data-highlighting-clinical-efficacy-and-molecular-mechanisms-of-respons-cmrx-20230816monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-second-quarter-2023-financial-results-and-provides-operational-update-cmrx-20230803monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-second-quarter-2023-financial-results-and-provide-an-operational-update-cmrx-20230727monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-promotion-of-michael-t-andriole-to-president-and-chief-executive-office-cmrx-20230627monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-participate-in-fireside-chat-at-jefferies-global-healthcare-conference-cmrx-20230531monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-participate-in-cancer-moonshot-brain-cancers-forum-on-glioblastoma-gbm-and-dif-cmrx-20230525monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-first-quarter-2023-financial-results-and-provides-operational-update-cmrx-20230504monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-first-quarter-2023-financial-results-and-provide-an-operational-update--cmrx-20230427monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-presentation-of-multiple-imipridone-datasets-at-american-association-fo-cmrx-20230418monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-fourth-quarter-and-year-end-2022-financial-results-and-provides-operation-cmrx-20230302monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-cowen-and-company-43rd-annual-health-care-conference-cmrx-20230228monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-fourth-quarter-and-year-end-2022-financial-results-and-provide-an-opera-cmrx-20230223monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-41st-annual-j-p-morgan-healthcare-conference-cmrx-20230105monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-successful-launch-of-onc201-phase-3-action-study-at-society-for-neuro-o-cmrx-20221208monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-responds-to-rubric-capital-management-cmrx-20221110monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-third-quarter-2022-financial-results-and-provides-operational-update-cmrx-20221103monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-third-quarter-2022-financial-results-and-provide-an-operational-update--cmrx-20221027monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-closing-of-tembexa-sale-to-emergent-biosolutions-cmrx-20220926monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-h-c-wainwright-24th-annual-global-investment-conference-cmrx-20220906monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-awarded-barda-contract-for-tembexa-as-medical-countermeasure-for-smallpox-cmrx-20220829monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-second-quarter-2022-financial-results-and-provides-operational-update-cmrx-20220808monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-appoints-christopher-l-jordan-as-vice-president-regulatory-affairs-cmrx-20220808monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-wedbush-pacgrow-healthcare-conference-cmrx-20220802monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-second-quarter-2022-financial-results-and-provide-an-operational-update-cmrx-20220801monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-tembexa-procurement-agreement-for-approximately-25-3-million-with-publi-cmrx-20220624monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-9-3-million-international-tembexa-procurement-agreement-cmrx-20220623monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-jefferies-global-healthcare-conference-cmrx-20220601monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-h-c-wainwright-global-investment-conference-cmrx-20220517monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-first-quarter-2022-financial-results-and-provides-operational-update-cmrx-20220516monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-sale-of-tembexa-to-emergent-biosolutions-for-up-to-337-5-million-plus-r-cmrx-20220516monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-participate-in-maxim-group-panel-discussion-cmrx-20220512monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-first-quarter-2022-financial-results-and-provide-an-operational-update--cmrx-20220509monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-maxim-group-2022-virtual-growth-conference-cmrx-20220321monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-fourth-quarter-and-year-end-2021-financial-results-and-provides-operation-cmrx-20220301monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-cowen-and-company-42nd-annual-health-care-conference-cmrx-20220228monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-in-collaboration-with-the-rapidly-emerging-antiviral-drug-development-initiative--cmrx-20220224monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-fourth-quarter-and-year-end-2021-financial-results-and-provide-an-opera-cmrx-20220222monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-b-riley-virtual-oncology-conference-cmrx-20220120monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-publication-of-positive-onc201-data-from-phase-2-study-in-neuroendocrin-cmrx-20220118monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-virtual-h-c-wainwright-bioconnect-2022-conference-cmrx-20220103monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-positive-onc201-data-in-recurrent-h3-k27m-mutant-diffuse-midline-glioma-cmrx-20211119monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-jefferies-london-healthcare-conference-cmrx-20211112monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-upcoming-presentations-at-the-society-for-neuro-oncology-annual-meeting-cmrx-20211111monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-third-quarter-2021-financial-results-and-provides-operational-update-cmrx-20211104monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-positive-topline-results-for-onc201-in-recurrent-h3-k27m-mutant-glioma-cmrx-20211104monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-credit-suisse-30th-annual-healthcare-conference-cmrx-20211101monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-third-quarter-2021-financial-results-and-provide-an-operational-update--cmrx-20211028monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference-cmrx-20210907monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-second-quarter-2021-financial-results-and-provides-operational-update-cmrx-20210805monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-2021-wedbush-pacgrow-healthcare-conference-cmrx-20210803monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-second-quarter-2021-financial-results-and-provide-an-operational-update-cmrx-20210729monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-receives-u-s-food-and-drug-administration-approval-for-tembexa-brincidofovir-for--cmrx-20210604monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-jefferies-virtual-healthcare-conference-cmrx-20210525monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-upcoming-presentations-at-the-american-society-of-clinical-oncology-202-cmrx-20210519monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-cowen-and-company-2nd-annual-virtual-oncology-innovation-summit-cmrx-20210513monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-first-quarter-2021-financial-results-and-provides-operational-update-cmrx-20210506monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-first-quarter-2021-financial-results-and-provide-an-operational-update--cmrx-20210429monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-appoints-vicki-vakiener-to-board-of-directors-cmrx-20210426monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-upcoming-presentations-at-the-american-association-for-cancer-research--cmrx-20210408monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-virtual-h-c-wainwright-global-life-sciences-conference-cmrx-20210302monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-fourth-quarter-and-year-end-2020-financial-results-and-provides-operation-cmrx-20210225monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-promising-topline-results-from-first-cohort-of-a-randomized-covid-19-tria-cmrx-20210225monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-fourth-quarter-and-year-end-2020-financial-results-and-provide-an-opera-cmrx-20210218monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-option--cmrx-20210125monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-pricing-of-public-offering-of-common-stock-cmrx-20210121monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-proposed-75-000-000-public-offering-of-common-stock-cmrx-20210119monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-acquires-oncoceutics-to-expand-pipeline-with-late-stage-oncology-program-cmrx-20210108monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-virtual-h-c-wainwright-bioconnect-2021-conference-cmrx-20210106monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-fda-acceptance-of-new-drug-application-for-brincidofovir-as-a-medical-c-cmrx-20201207monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-credit-suisse-29th-annual-healthcare-conference-cmrx-20201105monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-third-quarter-2020-financial-results-and-provides-operational-update-cmrx-20201105monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-third-quarter-2020-financial-results-and-provide-an-operational-update--cmrx-20201029monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-participate-in-upcoming-investor-conferences-cmrx-20200910monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-second-quarter-2020-financial-results-and-provides-operational-update-cmrx-20200810monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-second-quarter-2020-financial-results-and-provide-an-operational-update-cmrx-20200803monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-appoints-allen-melemed-m-d-as-chief-medical-officer-cmrx-20200622monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-h-c-wainwright-virtual-fireside-chat-series-cmrx-20200618monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-jefferies-virtual-healthcare-conference-cmrx-20200528monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-first-quarter-2020-financial-results-and-provides-operational-update-cmrx-20200507monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-initiation-of-a-phase-2-3-study-of-dstat-in-acute-lung-injury-for-patie-cmrx-20200429monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-receives-fda-clearance-for-rolling-submission-of-new-drug-application-for-brincid-cmrx-20200428monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-cowen-and-company-40th-annual-health-care-conference-cmrx-20200226monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-fourth-quarter-and-year-end-2019-financial-results-and-provides-operation-cmrx-20200225monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-appoints-pratik-s-multani-m-d-to-board-of-directors-cmrx-20200224monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-fourth-quarter-and-year-end-2019-financial-results-and-provide-an-opera-cmrx-20200218monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-presents-data-supporting-brincidofovir-as-a-potential-treatment-for-smallpox-at-2-cmrx-20200129monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-presents-updated-results-from-phase-2-clinical-trial-of-dstat-in-refractory-myelo-cmrx-20191210monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-third-quarter-2019-financial-results-and-provides-operational-update-cmrx-20191105monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-upcoming-investor-conferences-cmrx-20191104monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-third-quarter-2019-financial-results-and-provide-an-operational-updat-cmrx-20191029monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-exclusive-global-license-agreement-with-symbio-pharmaceuticals-for-brin-cmrx-20190930monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-2019-cantor-global-healthcare-conference-cmrx-20190927monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-second-quarter-2019-financial-results-and-operational-update-cmrx-20190808monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-exclusive-worldwide-license-of-phase-3-ready-cx-01-for-development-in-a-cmrx-20190731monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-first-quarter-2019-financial-results-and-strategy-update-cmrx-20190509monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-first-quarter-2019-financial-results-on-may-9-2019-cmrx-20190502monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-management-updates-cmrx-20190408monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-fourth-quarter-and-full-year-2018-financial-results-cmrx-20190305monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-cowen-and-company-39th-annual-health-care-conference-cmrx-20190304monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-fourth-quarter-and-full-year-2018-financial-results-on-march-5-2019-cmrx-20190226monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-presents-results-from-post-hoc-analysis-of-phase-3-study-cmrx-20190222monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-management-transition-cmrx-20190206monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-cmrx-20190104monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-third-quarter-2018-financial-results-cmrx-20181108monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-stifel-2018-healthcare-conference-cmrx-20181107monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-third-quarter-2018-financial-results-on-november-8-2018-cmrx-20181101monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-presents-preclinical-data-demonstrating-antiviral-activity-of-brincidofovir-again-cmrx-20181027monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-host-annual-investor-update-on-october-17-2018-cmrx-20181011monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-presents-results-from-multiple-ascending-dose-study-of-iv-brincidofovir-at-idweek-cmrx-20181005monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-cantor-fitzgerald-global-healthcare-conference-cmrx-20180926monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-participate-in-september-investor-conferences-cmrx-20180829monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-second-quarter-2018-financial-results-cmrx-20180808monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-second-quarter-2018-financial-results-on-august-8-2018-cmrx-20180801monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-discovery-and-demonstrated-preclinical-activity-supporting-ongoing-phas-cmrx-20180612monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-receives-orphan-drug-designation-from-the-fda-for-brincidofovir-for-the-treatment-cmrx-20180607monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-address-congressional-subcommittee-in-support-of-reauthorization-of-the-pandem-cmrx-20180605monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-first-quarter-2018-financial-results-cmrx-20180507monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-deutsche-bank-43rd-annual-health-care-conference-cmrx-20180502monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-first-quarter-2018-financial-results-on-may-7-2018-cmrx-20180430monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-h-c-wainwright-annual-global-life-sciences-conference-cmrx-20180402monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-martha-j-demski-as-board-chair-appoints-new-members-to-board-of-directo-cmrx-20180329monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-cowen-and-company-38th-annual-health-care-conference-cmrx-20180307monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-fourth-quarter-and-full-year-2017-financial-results-cmrx-20180301monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-fourth-quarter-and-full-year-2017-financial-results-on-march-1-2018-cmrx-20180222monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-initiates-adapt-study-for-oral-brincidofovir-and-advances-iv-brincidofovir-to-pat-cmrx-20180105monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-cmrx-20180103monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-third-quarter-2017-financial-results-cmrx-20171108monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-stifel-2017-healthcare-conference-cmrx-20171107monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-third-quarter-2017-financial-results-on-november-8-2017-cmrx-20171101monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-cantor-fitzgerald-global-healthcare-conference-cmrx-20170920monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-appoints-heather-knight-trent-pharmd-as-vice-president-of-regulatory-affairs-cmrx-20170912monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-second-quarter-2017-financial-results-cmrx-20170807monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-second-quarter-2017-financial-results-on-august-7-2017-cmrx-20170731monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-first-quarter-2017-financial-results-cmrx-20170509monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-first-quarter-2017-financial-results-on-may-9-2017-cmrx-20170502monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-host-annual-investor-update-on-april-27-2017-cmrx-20170420monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-fourth-quarter-and-full-year-2016-financial-results-cmrx-20170302monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-cowen-and-company-37th-annual-health-care-conference-cmrx-20170228monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-fourth-quarter-and-full-year-2016-financial-results-on-march-2-2017-cmrx-20170223monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-final-data-from-advise-trial-of-brincidofovir-at-bmt-tandem-meetings-cmrx-20170222monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-preliminary-data-from-ongoing-phase-1-dose-escalation-study-of-intraven-cmrx-20170106monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-appoints-randall-lanier-phd-as-chief-science-officer-and-roy-w-ware-phd-mba-as-ch-cmrx-20170105monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-cmrx-20170104monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-presents-data-from-a-preclinical-study-of-intravenous-brincidofovir-at-aaps-cmrx-20161117monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-upcoming-investor-conferences-cmrx-20161109monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-third-quarter-2016-financial-results-cmrx-20161107monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-third-quarter-2016-financial-results-on-november-7-2016-cmrx-20161031monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-presentation-at-idweek-of-detailed-24-week-results-from-advise-trial-of-cmrx-20161027monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-morgan-stanley-global-healthcare-conference-cmrx-20160906monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-second-quarter-2016-financial-results-cmrx-20160808monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-second-quarter-2016-financial-results-on-august-8-2016-cmrx-20160801monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-participate-in-panel-on-north-carolina-s-role-in-biodefense-preparation-at-med-cmrx-20160607monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-top-line-interim-advise-data-and-first-quarter-2016-financial-results-cmrx-20160509monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-first-quarter-2016-financial-results-on-may-9-2016-cmrx-20160503monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-barclays-global-healthcare-conference-cmrx-20160309monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-cowen-and-company-36th-annual-health-care-conference-cmrx-20160301monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-fourth-quarter-and-full-year-2015-financial-results-cmrx-20160229monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-fourth-quarter-and-full-year-2015-financial-results-on-february-29-20-cmrx-20160222monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-presentation-of-detailed-results-from-phase-3-suppress-trial-at-bmt-tan-cmrx-20160221monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-presents-positive-results-from-brincidofovir-pivotal-study-in-animal-model-for-sm-cmrx-20160208monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference-cmrx-20160105monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-top-line-results-from-phase-3-suppress-trial-of-brincidofovir-cmrx-20151228monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-27th-annual-piper-jaffray-healthcare-conference-cmrx-20151124monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-stifel-2015-healthcare-conference-cmrx-20151111monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-third-quarter-2015-financial-results-cmrx-20151105monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-third-quarter-2015-financial-results-on-november-5-2015-cmrx-20151029monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-initiates-phase-3-sustain-and-surpass-trials-of-brincidofovir-for-prevention-of-c-cmrx-20151022monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-webcast-annual-investor-update-on-october-22-2015-cmrx-20151015monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-presents-preliminary-data-on-brincidofovir-in-liver-transplant-recipients-with-ad-cmrx-20151007monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-presents-new-research-on-hospital-readmission-rates-in-hematopoietic-cell-transpl-cmrx-20150921monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-and-barda-announce-contract-extension-of-13-0-million-for-the-continued-developme-cmrx-20150914monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-morgan-stanley-global-healthcare-conference-cmrx-20150911monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-provides-clinical-development-update-for-brincidofovir-cmrx-20150908monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-second-quarter-2015-financial-results-cmrx-20150806monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-completes-targeted-enrollment-for-brincidofovir-phase-3-advise-trial-for-adenovir-cmrx-20150803monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-second-quarter-2015-financial-results-on-august-6-2015-cmrx-20150730monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-positive-topline-results-from-brincidofovir-pivotal-study-in-animal-mod-cmrx-20150723monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-jmp-life-sciences-conference-cmrx-20150618monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-exercise-in-full-of-option-to-purchase-additional-shares-of-common-stoc-cmrx-20150616monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-prices-public-offering-of-common-stock-cmrx-20150610monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-commencement-of-public-offering-of-common-stock-cmrx-20150609monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-completes-targeted-enrollment-for-brincidofovir-phase-3-suppress-trial-cmrx-20150608monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-ubs-global-healthcare-conference-cmrx-20150512monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-first-quarter-financial-results-cmrx-20150511monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-first-quarter-2015-financial-results-on-may-11-2015-cmrx-20150504monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-barclays-global-healthcare-conference-cmrx-20150306monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-fourth-quarter-and-full-year-2014-financial-results-cmrx-20150306monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-fourth-quarter-and-year-end-2014-financial-results-on-march-6-2015-cmrx-20150227monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-provides-update-on-anticipated-suppress-enrollment-cmrx-20150226monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-cowen-co-35th-annual-health-care-conference-cmrx-20150225monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-presents-update-on-preliminary-data-from-advise-study-of-brincidofovir-for-adenov-cmrx-20150212monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-focusing-efforts-on-cmv-and-adenovirus-pivotal-trials-cmrx-20150130monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-receives-notice-of-allowance-for-brincidofovir-composition-of-matter-patent-exten-cmrx-20150112monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-provides-update-on-brincidofovir-pivotal-phase-3-advise-trial-for-the-treatment-o-cmrx-20150108monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-33rd-annual-j-p-morgan-healthcare-conference-cmrx-20150107monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-provides-recap-of-2014-events-cmrx-20141223monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-and-contravir-pharmaceuticals-establish-strategic-collaboration-for-antiviral-dru-cmrx-20141218monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-appoints-ronald-c-renaud-jr-to-board-of-directors-cmrx-20141217monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-piper-jaffray-healthcare-conference-cmrx-20141125monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-s-brincidofovir-selected-for-use-in-ebola-clinical-trial-in-west-africa-by-intern-cmrx-20141113monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-stifel-healthcare-conference-cmrx-20141111monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-third-quarter-2014-financial-results-cmrx-20141107monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-completion-of-public-offering-of-common-stock-and-exercise-in-full-of-o-cmrx-20141105monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-names-two-new-executives-peter-payne-as-senior-vice-president-business-developmen-cmrx-20141103monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-third-quarter-financial-results-on-november-7-2014-cmrx-20141031monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-prices-public-offering-of-common-stock-cmrx-20141030monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-commencement-of-public-offering-of-common-stock-cmrx-20141029monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-provides-update-on-research-and-development-progress-cmrx-20141016monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-webcast-r-d-update-on-october-15th-cmrx-20141013monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-s-brincidofovir-shows-potential-survival-benefit-in-adenovirus-infection-cmrx-20141008monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-emergency-investigational-new-drug-applications-for-brincidofovir-autho-cmrx-20141006monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-appoints-w-garrett-nichols-md-ms-as-chief-medical-officer-cmrx-20140904monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-s-brincidofovir-has-in-vitro-activity-against-ebola-cmrx-20140903monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-s-brincidofovir-selected-for-two-oral-presentations-highlighting-resistance-data--cmrx-20140902monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-morgan-stanley-healthcare-conference-cmrx-20140902monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-and-barda-announce-continued-partnership-in-the-development-of-brincidofovir-for--cmrx-20140902monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-second-quarter-2014-financial-results-cmrx-20140807monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-second-quarter-financial-results-on-august-7-2014-cmrx-20140731monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-three-abstracts-to-be-presented-at-the-2014-world-transplant-congress-cmrx-20140708monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-mourns-passing-of-director-rodman-l-drake-cmrx-20140626monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-new-directors-cmrx-20140623monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-jmp-securities-healthcare-conference-cmrx-20140617monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-completion-of-public-offering-of-common-stock-and-exercise-in-full-of-o-cmrx-20140527monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-prices-public-offering-of-common-stock-cmrx-20140521monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-commencement-of-public-offering-of-common-stock-cmrx-20140519monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-regains-worldwide-rights-to-cmx157-cmrx-20140516monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-first-quarter-2014-financial-results-cmrx-20140509monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-s-brincidofovir-cmx001-data-accepted-for-three-presentations-at-27th-internationa-cmrx-20140506monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-first-quarter-financial-results-on-may-9-2014-cmrx-20140502monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-appointment-of-m-michelle-berrey-m-d-m-p-h-as-chief-executive-officer-cmrx-20140409monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-appoints-lisa-ricciardi-to-board-of-directors-cmrx-20140401monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-a-summary-of-brincidofovir-s-cmx001-hematologic-safety-at-the-annual-m-cmrx-20140324monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-issues-statement-thanking-the-fda-for-collaboration-in-developing-protocol-to-tre-cmrx-20140315monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-provide-brincidofovir-to-josh-hardy-as-first-patient-in-new-open-label-study-i-cmrx-20140311monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-fourth-quarter-and-full-year-2013-financial-results-cmrx-20140307monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-s-brincidofovir-cmx001-safety-and-antiviral-data-presented-at-2014-bmt-tandem-mee-cmrx-20140228monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-fourth-quarter-financial-results-on-march-7-2014-cmrx-20140227monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-cowen-34th-annual-health-care-conference-cmrx-20140225monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-s-brincidofovir-cmx001-selected-for-two-oral-presentations-at-the-2014-bmt-tandem-cmrx-20140221monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-16th-annual-bio-ceo-investor-conference-cmrx-20140203monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-32nd-annual-j-p-morgan-healthcare-conference-cmrx-20131219monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-appoints-linda-m-richardson-as-chief-commercial-officer-cmrx-20131218monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-added-to-nasdaq-biotechnology-index-nbi-cmrx-20131217monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-25th-annual-piper-jaffray-healthcare-conference-cmrx-20131126monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-third-quarter-2013-financial-results-cmrx-20131114monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-report-third-quarter-financial-results-on-november-14-2013-cmrx-20131105monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-completion-of-secondary-offering-of-common-stock-cmrx-20131023monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-pricing-of-secondary-offering-of-common-stock-cmrx-20131018monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-proposed-public-offering-of-common-stock-cmrx-20131008monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-publication-of-positive-phase-2-results-of-brincidofovir-cmx001-in-the--cmrx-20130926monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-20th-annual-biocentury-newsmakers-conference-cmrx-20130918monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-presents-brincidofovir-cmx001-adenovirus-phase-2-results-cmrx-20130911monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-initiates-phase-3-suppress-trial-of-brincidofovir-cmx001-for-prevention-of-cytome-cmrx-20130909monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-morgan-stanley-and-stifel-healthcare-conferences-in-september-cmrx-20130906monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-second-quarter-2013-financial-results-cmrx-20130814monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-top-line-data-from-cmx001-phase-2-adenovirus-study-and-late-breaker-pre-cmrx-20130814monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-second-quarter-financial-results-on-august-14-2013-cmrx-20130807monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-elects-rodman-l-drake-to-board-of-directors-cmrx-20130802monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-jmp-securities-healthcare-conference-cmrx-20130702monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-join-russell-indexes-on-june-28-2013-cmrx-20130625monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-and-barda-continue-collaboration-on-development-of-cmx001-as-a-medical-countermea-cmrx-20130603monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-s-cmx001-resistance-data-presented-at-the-26th-international-conference-on-antivi-cmrx-20130516monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-first-quarter-2013-financial-results-cmrx-20130513monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-announce-first-quarter-financial-results-on-may-13-2013-cmrx-20130506monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-presents-at-annual-ebmt-meeting-antiviral-activity-of-cmx001-in-patients-with-lif-cmrx-20130429monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-to-present-at-the-12th-annual-needham-healthcare-conference-cmrx-20130426monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-final-study-design-for-phase-3-suppress-trial-of-cmx001-for-prevention--cmrx-20130424monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-completion-of-initial-public-offering-and-exercise-of-underwriters-over-cmrx-20130416monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-announces-pricing-of-initial-public-offering-cmrx-20130411monthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-cmrx-to-ring-the-nasdaq-stock-market-opening-bell-in-celebration-of-ipo-cmrx-20130411monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-life-sciences-virtual-investor-forum-bpth-20250609monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-host-corporate-update-conference-call-on-may-29-2025-bpth-20250522monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-achieves-third-pre-clinical-milestone-confirming-potential-of-bp1001-a-a-bpth-20250501monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-full-year-2024-financial-results-bpth-20250328monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-pre-clinical-results-signaling-increased-potential-for-bp1001--bpth-20250318monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-provides-key-clinical-updates-bpth-20250213monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-provides-2025-clinical-and-operational-update-bpth-20250110monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-preclinical-testing-of-bp1001-a-as-potential-treatment-for-obe-bpth-20241219monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-outlines-rationale-for-development-of-bp1001-a-as-potential-treatment-fo-bpth-20241211monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-third-quarter-2024-financial-results-bpth-20241115monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-third-quarter-2024-financial-results-on-november-15-2024-bpth-20241108monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-closing-of-4-0-million-private-placement-priced-at-the-market--bpth-20241010monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-4-0-million-private-placement-priced-at-the-market-under-nasda-bpth-20241009monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-initiates-development-of-therapeutic-program-for-treatment-of-obesity-bpth-20241008monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-publication-in-biomedicines-bpth-20240916monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-h-c-wainwright-26th-annual-global-investment-conference-bpth-20240903monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-solid-tumor-patient-response-supporting-bp1001-a-s-compelling-po-bpth-20240821monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-second-quarter-2024-financial-results-bpth-20240815monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-second-quarter-2024-financial-results-on-august-15-2024-bpth-20240808monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-provides-clinical-update-and-expansion-plans-bpth-20240708monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-presents-data-from-ongoing-phase-2-combination-study-of-prexigebersen-fo-bpth-20240614monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-closing-of-4-0-million-private-placement-priced-at-the-market--bpth-20240605monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-4-0-million-private-placement-priced-at-the-market-under-nasda-bpth-20240604monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-presents-data-from-ongoing-phase-2-combination-study-of-prexigebersen-fo-bpth-20240603monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-data-at-2024-european-hematology-association-congress-bpth-20240524monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-data-at-american-society-of-clinical-oncology-asco-annual-mee-bpth-20240523monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-first-quarter-2024-financial-results-bpth-20240515monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-first-quarter-2024-financial-results-on-may-15-2024-bpth-20240508monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-inc-announces-closing-of-1-2-million-registered-direct-offering-priced-a-bpth-20240419monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-inc-announces-1-2-million-registered-direct-offering-priced-at-the-marke-bpth-20240418monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-successful-completion-of-higher-dose-second-cohort-in-phase-1--bpth-20240418monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-expands-global-patent-portfolio-bpth-20240415monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-provides-2024-clinical-and-operational-update-bpth-20240402monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-full-year-2023-financial-results-bpth-20240308monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-fourth-quarter-and-full-year-2023-financial-results-on-march-bpth-20240301monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-1-for-20-reverse-stock-split-bpth-20240221monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-completion-of-first-dose-cohort-in-phase-1-clinical-trial-eval-bpth-20240110monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-successfully-completes-first-dose-cohort-of-phase-1-1b-clinical-trial-of-bpth-20231214monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-third-quarter-2023-financial-results-bpth-20231115monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-third-quarter-2023-financial-results-on-november-15-2023-bpth-20231108monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-host-virtual-key-opinion-leader-event-to-discuss-prexigebersen-and-ad-bpth-20231024monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-bpth-20230908monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-second-quarter-2023-financial-results-bpth-20230815monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-second-quarter-2023-financial-results-on-august-15-2023-bpth-20230808monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-inc-announces-pricing-of-2-1-million-public-offering-bpth-20230803monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-positive-results-from-interim-analysis-of-phase-2-clinical-tri-bpth-20230801monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-successful-completion-of-first-dose-cohort-in-phase-1-1b-clini-bpth-20230717monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-first-quarter-2023-financial-results-bpth-20230512monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-first-quarter-2023-financial-results-on-may-12-2023-bpth-20230505monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-full-year-2022-financial-results-bpth-20230331monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-fourth-quarter-and-full-year-2022-financial-results-on-march-bpth-20230324monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-provides-clinical-and-operational-update-bpth-20230316monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-first-patient-dosed-in-phase-1-1b-clinical-trial-of-bp1001-a-i-bpth-20221207monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-third-quarter-2022-financial-results-bpth-20221115monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-third-quarter-2022-financial-results-on-november-15-2022-bpth-20221108monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-inc-announces-2-0-million-registered-direct-offering-and-concurrent-priv-bpth-20221107monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-first-patient-dosed-in-phase-1-1b-study-of-bp1002-in-refractor-bpth-20221024monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-h-c-wainwright-24th-annual-global-investment-conference-bpth-20220906monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-second-quarter-2022-financial-results-bpth-20220816monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-second-quarter-2022-financial-results-on-august-16-2022-bpth-20220809monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-first-quarter-2022-financial-results-bpth-20220517monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-first-quarter-2022-financial-results-on-may-17-2022-bpth-20220510monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-presents-bp1003-data-at-2022-american-association-for-cancer-research-an-bpth-20220412monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-appoints-aline-sherwood-to-board-of-directors-bpth-20220406monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-full-year-2021-financial-results-bpth-20220311monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-the-2022-american-association-for-cancer-research-annual-m-bpth-20220308monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-full-year-2021-financial-results-on-march-11-2022-bpth-20220304monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-h-c-wainwright-bioconnect-2022-virtual-conference-bpth-20220105monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-presents-data-from-ongoing-phase-2-study-of-prexigebersen-at-2021-americ-bpth-20211213monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-third-quarter-2021-financial-results-bpth-20211112monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-third-quarter-2021-financial-results-on-november-12-2021-bpth-20211105monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-clinical-data-at-the-63rd-annual-american-society-of-hematolo-bpth-20211104monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-clearance-of-investigational-new-drug-application-for-phase-1--bpth-20211027monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-clearance-of-investigational-new-drug-application-for-bp1002-i-bpth-20210824monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-second-quarter-2021-financial-results-bpth-20210813monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-second-quarter-2021-financial-results-on-august-13-2021-bpth-20210806monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-granted-key-mechanism-of-action-u-s-patent-for-bp1003-bpth-20210622monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-first-quarter-2021-financial-results-bpth-20210514monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-first-quarter-2021-financial-results-on-may-14-2021-bpth-20210507monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-announces-publication-in-biomedicines-bpth-20210422monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-presents-bp1002-data-at-2021-american-association-for-cancer-research-an-bpth-20210412monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-successful-completion-of-safety-cohort-of-triple-combination-o-bpth-20210405monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-the-2021-american-association-for-cancer-research-annual-m-bpth-20210311monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-full-year-2020-financial-results-bpth-20210310monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-full-year-2020-financial-results-on-march-10-2021-bpth-20210303monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-inc-announces-closing-of-13-0-million-public-offering-of-common-stock-bpth-20210218monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-inc-announces-pricing-of-13-0-million-public-offering-of-common-stock-bpth-20210216monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-inc-announces-proposed-public-offering-of-common-stock-bpth-20210213monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-receives-third-u-s-patent-grant-related-to-manufacture-of-platform-technology-bpth-20210210monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-first-patient-dosed-in-phase-1-clinical-trial-of-bp1002-bpth-20201119monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-third-quarter-2020-financial-results-bpth-20201113monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-third-quarter-2020-financial-results-on-november-13-2020-bpth-20201106monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-receives-notice-of-allowance-for-strategic-patent-for-prexigebersen-in-combinatio-bpth-20201022monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-the-h-c-wainwright-22nd-annual-global-investment-conferenc-bpth-20200909monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-second-quarter-2020-financial-results-bpth-20200814monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-first-patient-dosed-in-amended-stage-2-of-the-phase-2-clinical-bpth-20200813monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-second-quarter-2020-financial-results-on-august-14-2020-bpth-20200807monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-presents-at-2020-american-society-of-clinical-oncology-annual-meeting-bpth-20200529monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-first-quarter-2020-financial-results-bpth-20200515monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-the-2020-american-society-of-clinical-oncology-annual-meet-bpth-20200513monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-first-quarter-2020-financial-results-on-may-15-2020-bpth-20200508monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-presents-at-2020-american-association-for-cancer-research-annual-meeting-bpth-20200427monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-the-2020-american-association-for-cancer-research-annual-m-bpth-20200413monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-appoints-ernst-young-as-new-auditor-bpth-20200311monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-full-year-2019-financial-results-bpth-20200306monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-fourth-quarter-and-full-year-2019-financial-results-on-march-bpth-20200228monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-provides-clinical-update-and-2020-business-outlook-bpth-20200108monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-successful-completion-of-safety-testing-in-stage-2-of-phase-2--bpth-20191126monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-closing-of-8-0-million-registered-direct-offering-priced-at-th-bpth-20191125monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-8-0-million-registered-direct-offering-priced-at-the-market-bpth-20191121monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-clearance-of-investigational-new-drug-application-for-bp1002-bpth-20191121monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-third-quarter-2019-financial-results-bpth-20191115monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-third-quarter-2019-financial-results-on-november-15-2019-bpth-20191108monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-appoints-martina-molsbergen-to-board-of-directors-bpth-20191015monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-updates-intellectual-property-portfolio-with-addition-of-recently-issued-second-p-bpth-20190925monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-the-h-c-wainwright-21st-annual-global-investment-conferenc-bpth-20190903monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-announces-patient-dosing-in-amended-phase-2-prexigebersen-trial-in-acute-myeloid--bpth-20190826monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-second-quarter-2019-financial-results-bpth-20190815monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-second-quarter-2019-financial-results-on-august-15-2019-bpth-20190808monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-first-quarter-2019-financial-results-bpth-20190516monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-first-quarter-2019-financial-results-on-may-16-2019-bpth-20190510monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-presents-preclinical-data-at-american-association-for-cancer-research-an-bpth-20190403monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-full-year-2018-financial-results-bpth-20190320monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-fourth-quarter-and-full-year-2018-financial-results-on-march-bpth-20190315monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-inc-announces-18-5-million-registered-direct-offering-of-common-stock-bpth-20190312monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-announces-clinical-update-to-interim-analysis-of-phase-2-prexigebersen-trial-in-a-bpth-20190306monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-data-at-the-2019-aacr-annual-meeting-bpth-20190228monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-inc-announces-closing-of-1-7-million-registered-direct-offering-priced-a-bpth-20190123monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-inc-announces-1-7-million-registered-direct-offering-priced-at-the-marke-bpth-20190118monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-1-for-20-reverse-stock-split-bpth-20190118monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-inc-announces-closing-of-public-offering-of-common-stock-bpth-20190117monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-inc-announces-pricing-of-public-offering-of-common-stock-bpth-20190115monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-inc-announces-proposed-public-offering-of-common-stock-bpth-20190114monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-provides-clinical-update-and-2019-business-outlook-bpth-20181227monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-presents-interim-data-from-phase-2-study-evaluating-prexigebersen-as-a-t-bpth-20181203monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-third-quarter-2018-financial-results-bpth-20181115monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-third-quarter-2018-financial-results-on-november-15-2018-bpth-20181108monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-clinical-data-at-the-60th-annual-american-society-of-hematolo-bpth-20181101monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-inc-announces-closing-of-1-5-million-registered-direct-offering-bpth-20180925monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-inc-announces-1-5-million-registered-direct-offering-bpth-20180921monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-the-h-c-wainwright-20th-annual-global-investment-conferenc-bpth-20180829monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-first-patient-dosed-in-expansion-of-phase-2-trial-of-prexigebe-bpth-20180827monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-appoints-dr-jason-b-fleming-to-scientific-advisory-board-bpth-20180816monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-second-quarter-2018-financial-results-bpth-20180815monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-second-quarter-2018-financial-results-on-august-15-2018-bpth-20180808monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-first-quarter-2018-financial-results-bpth-20180516monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-appoints-dr-anas-younes-to-scientific-advisory-board-bpth-20180510monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-first-quarter-2018-financial-results-on-may-16-2018-bpth-20180509monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-full-year-2017-financial-results-bpth-20180403monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-interim-data-from-phase-2-clinical-trial-of-prexigebersen-in-c-bpth-20180403monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-publication-in-the-lancet-haematology-bpth-20180329monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-fourth-quarter-and-full-year-2017-financial-results-on-april-bpth-20180327monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-data-at-the-2018-aacr-annual-meeting-bpth-20180315monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-the-30th-annual-roth-conference-bpth-20180306monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-1-for-10-reverse-stock-split-bpth-20180209monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-the-bio-ceo-investor-conference-bpth-20180205monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-appoints-paul-aubert-to-its-board-of-directors-bpth-20180205monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-provides-clinical-update-and-2018-business-outlook-bpth-20171229monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-third-quarter-2017-financial-results-bpth-20171109monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-highlights-advancements-in-preclinical-discovery-efforts-bpth-20171106monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-inc-announces-4-million-registered-direct-offering-bpth-20171103monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-third-quarter-2017-financial-results-on-november-10-2017-bpth-20171103monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-the-rodman-renshaw-annual-healthcare-conference-bpth-20170905monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-second-quarter-2017-financial-results-bpth-20170810monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-second-quarter-2017-financial-results-on-august-10-2017-bpth-20170803monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-receives-notice-of-allowance-for-key-u-s-composition-of-matter-patent-bpth-20170719monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-appoints-mark-colonnese-to-its-board-of-directors-bpth-20170717monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-first-quarter-2017-financial-results-bpth-20170511monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-first-quarter-2017-financial-results-on-may-11-2017-bpth-20170504monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-appointment-of-dr-william-hahne-as-vice-president-of-clinical--bpth-20170417monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-presents-results-showing-potential-of-bp1002-as-treatment-for-aggressive-bpth-20170405monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-full-year-2016-financial-results-bpth-20170315monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-the-oppenheimer-27th-annual-healthcare-conference-bpth-20170314monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-rescheduled-date-and-time-of-fourth-quarter-and-full-year-2016-bpth-20170313monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-data-at-the-2017-aacr-annual-meeting-bpth-20170310monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-fourth-quarter-and-full-year-2016-financial-results-on-march-bpth-20170309monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-appoints-dr-craig-hooper-to-scientific-advisory-board-bpth-20170221monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-the-19th-annual-bio-ceo-investor-conference-bpth-20170207monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-presents-clinical-data-evaluating-bp1001-as-a-treatment-for-chronic-myel-bpth-20161206monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-third-quarter-2016-financial-results-bpth-20161110monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-third-quarter-2016-financial-results-on-november-10-2016-bpth-20161104monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-data-at-the-2016-ash-annual-meeting-bpth-20161104monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-announces-orphan-drug-designation-in-the-european-union-for-bp1001-for-the-treatm-bpth-20161103monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-first-patient-dosed-in-phase-2-trial-evaluating-bp1001-in-acut-bpth-20161102monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-the-rodman-renshaw-18th-annual-global-investment-conferenc-bpth-20160906monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-second-quarter-2016-financial-results-bpth-20160810monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-second-quarter-2016-financial-results-on-august-10-2016-bpth-20160803monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-the-2nd-annual-cantor-fitzgerald-healthcare-conference-bpth-20160706monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-inc-announces-10-million-registered-direct-offering-bpth-20160629monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-announces-collaboration-with-thomas-jefferson-university-for-systemic-an-bpth-20160628monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-join-russell-3000-and-global-indexes-bpth-20160620monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-promising-data-from-phase-i-and-phase-ii-clinical-trials-of-bp10-bpth-20160606monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-data-at-2016-american-society-of-clinical-oncology-annual-mee-bpth-20160519monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-reports-first-quarter-2016-financial-results-bpth-20160511monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-present-at-18th-annual-tides-oligonucleotide-and-peptides-therapeutic-bpth-20160505monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-to-announce-first-quarter-2016-financial-results-on-may-11-2016-bpth-20160504monthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-inc-nasdaq-bpth-to-ring-the-nasdaq-stock-market-closing-bell-bpth-20141016monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-announces-corporate-update-including-cost-optimization-initiatives-strat-scpx-20250505monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-provides-2024-year-end-business-update-implements-strategic-cost-reducti-scpx-20250430monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-announces-reverse-stock-split-scpx-20250116monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-announces-collaboration-with-celltheon-corporation-a-u-s-based-cell-line-scpx-20241104monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-announces-implementation-of-new-cost-savings-measures-expected-to-save-o-scpx-20241031monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-announces-partnership-with-u-s-biotech-company-scpx-20241022monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-selected-to-join-medical-cbrn-defense-consortium-to-advance-medical-coun-scpx-20241002monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-announces-contract-with-premier-clinical-stage-biotech-company-opens-doo-scpx-20240930monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-commends-the-u-s-house-of-representatives-passage-of-the-biosecure-act-scpx-20240912monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-selected-for-rapid-response-partnership-vehicle-rrpv-to-accelerate-medical-counte-scpx-20240909monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-ceo-provides-corporate-update-highlights-expanding-sales-pipeline-enhanc-scpx-20240826monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-achieves-16-year-over-year-increase-in-revenue-for-the-second-quarter-of-scpx-20240820monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-inc-announces-closing-of-public-offering-scpx-20240819monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-inc-announces-pricing-of-public-offering-scpx-20240816monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-inc-provides-update-on-its-previously-announced-public-offering-scpx-20240809monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-announces-removal-of-nyse-american-trading-suspension-expected-to-resume-scpx-20240730monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-set-to-launch-first-mammalian-cgmp-campaign-at-san-antonio-facility-in-t-scpx-20240724monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-successfully-executes-first-cgmp-microbial-batches-at-san-antonio-facili-scpx-20240718monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-announces-reverse-stock-split-scpx-20240717monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-receives-nyse-american-notice-of-delisting-and-reports-plans-to-appeal-scpx-20240617monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-and-beyond-imagination-announce-trailblazing-partnership-to-utilize-auto-scpx-20240603monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-achieves-359-year-over-year-increase-in-revenue-for-the-first-quarter-of-scpx-20240529monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-announces-major-expansion-in-san-antonio-with-new-state-of-the-art-stora-scpx-20240520monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-inc-announces-closing-of-public-offering-scpx-20240516monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-commends-congress-on-bipartisan-legislative-action-aimed-at-bolstering-u-scpx-20240516monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-achieves-major-milestone-with-cgmp-facility-validation-for-microbial-man-scpx-20240515monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-inc-announces-pricing-of-public-offering-scpx-20240514monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-appoints-new-vp-of-business-development-shari-udoff-mcdonald-scpx-20240507monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-provides-2023-year-end-business-update-reports-570-sequential-increase-i-scpx-20240429monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-announces-receipt-of-filing-delinquency-notification-scpx-20240422monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-awarded-contract-in-excess-of-1-million-with-nih-funded-researcher-at-a--scpx-20240319monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-accepted-as-a-member-of-the-us-government-s-biomap-consortium-scpx-20240314monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-inc-announces-closing-of-public-offering-scpx-20240312monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-inc-announces-pricing-of-public-offering-scpx-20240308monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-inc-announces-proposed-public-offering-of-common-stock-scpx-20240307monthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-estimates-greater-than-375-sequential-increase-in-revenue-for-the-fourth-scpx-20240307monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-financial-results-for-fourth-quarter-and-fiscal-year-ended-december-31-2024-icad-20250319monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-advances-fight-against-breast-cancer-with-fda-cleared-next-generation-ai-solutions-an-icad-20241126monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-financial-results-for-third-quarter-ended-september-30-2024-icad-20241113monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-profound-detection-version-4-0-gains-fda-clearance-icad-20241112monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-attend-15th-annual-craig-hallum-alpha-select-conference-icad-20241106monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-third-quarter-2024-financial-results-on-november-13-2024-icad-20241105monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-highlights-global-availability-of-profound-cloud-and-international-expansion-mileston-icad-20241003monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-the-iaccess-alpha-buyside-best-ideas-fall-conference-2024-icad-20240911monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-financial-results-for-second-quarter-ended-june-30-2024-icad-20240813monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-second-quarter-2024-financial-results-on-august-13-2024-icad-20240806monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-and-windsong-radiology-announce-strategic-commercial-agreement-to-implement-ai-powere-icad-20240729monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-highlight-promising-research-on-potential-of-its-ai-algorithm-to-more-accurately-i-icad-20240626monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-the-medinvest-medtech-ai-digital-health-conference-icad-20240604monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-financial-results-for-first-quarter-ended-march-31-2024-icad-20240515monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-first-quarter-2024-financial-results-on-may-15-2024-icad-20240502monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-showcases-new-profound-cloud-enhanced-profound-detection-workstation-features-and-new-icad-20240411monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-and-densitas-partner-to-enhance-precision-breast-health-with-leading-ai-solutions-for-icad-20240409monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-profound-ai-suite-uncovers-hidden-heart-disease-risk-according-to-new-data-presente-icad-20240408monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-partners-with-rad-aid-to-advance-breast-cancer-detection-using-ai-in-underserved-regi-icad-20240403monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-unveils-profound-cloud-enabling-interoperability-and-access-to-breast-ai-solutions-at-icad-20240402monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-releases-enhanced-profound-detection-workstation-features-to-streamline-mammogram-int-icad-20240319monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-fiscal-fourth-quarter-and-full-year-2023-financial-results-icad-20240312monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-highlights-promising-clinical-data-demonstrating-ability-to-reduce-breast-interval-ca-icad-20240228monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-fourth-quarter-and-full-year-2023-financial-results-on-march-12-2024-icad-20240227monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-the-btig-at-snowbird-11th-annual-medtech-digital-health-life-scienc-icad-20240206monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-expands-board-of-directors-with-appointment-of-michael-j-doyle-fache-as-new-board-mem-icad-20240130monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-expands-executive-sales-leadership-team-as-business-grows-icad-20231218monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-ai-powered-solutions-to-help-accelerate-breast-cancer-detection-in-new-collaboratio-icad-20231128monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-profound-ai-can-predict-1-2-year-risk-for-breast-cancer-and-reveal-insights-for-hea-icad-20231127monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-and-canceriq-announce-partnership-to-integrate-ai-enabled-technology-with-best-in-cla-icad-20231120monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-the-14th-annual-craig-hallum-alpha-select-conference-icad-20231114monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-financial-results-for-third-quarter-ended-september-30-2023-icad-20231113monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-third-quarter-2023-financial-results-on-november-13-2023-icad-20231030monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-inc-announces-sale-of-xoft-its-brachytherapy-business-line-to-elekta-icad-20231023monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-financial-results-for-second-quarter-ended-june-30-2023-icad-20230814monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-and-google-health-expand-integration-of-google-s-ai-technology-with-icad-s-profound-b-icad-20230814monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-second-quarter-2023-financial-results-on-august-14-2023-icad-20230731monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-signs-strategic-commercial-agreement-with-radiology-partners-the-nation-s-largest-rad-icad-20230718monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-profound-insights-profound-impact-webinar-series-to-feature-cleveland-clinic-icad-20230712monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-offers-roi-analysis-based-on-real-world-results-from-its-profound-breast-ai-suite-at--icad-20230710monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-profound-ai-breast-suite-wins-u-s-general-services-administration-s-ai-healthcare-c-icad-20230518monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-financial-results-for-first-quarter-ended-march-31-2023-icad-20230515monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-showcases-breast-ai-suite-at-society-of-breast-imaging-symposium-world-s-largest-brea-icad-20230503monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-first-quarter-2023-financial-results-on-may-15-2023-icad-20230501monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-profound-insights-profound-impact-webinar-series-to-feature-boca-raton-regional-hos-icad-20230425monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-strengthens-leadership-team-with-appointment-of-chief-financial-officer-and-new-senio-icad-20230417monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-financial-results-for-fourth-quarter-ended-december-31-2022-and-year-end-icad-20230328monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-breast-ai-suite-empowers-customers-to-lead-the-way-in-support-of-fda-s-national-bre-icad-20230323monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-previews-fourth-quarter-financial-results-full-report-on-march-28-2023-icad-20230313monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-leadership-transition-icad-20230313monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-the-btig-snowbird-medtech-digital-health-life-science-and-diagnosti-icad-20230209monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-cfo-transition-and-hires-new-senior-vice-president-us-commercial-sales-ai-icad-20230123monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-board-of-directors-transition-icad-20230111monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-features-solis-mammography-in-upcoming-profound-insights-profound-impact-webinar-icad-20221208monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-and-google-health-ink-strategic-development-and-commercialization-agreement-icad-20221128monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-the-13th-annual-craig-hallum-alpha-select-conference-icad-20221115monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-present-at-hlth-2022-with-google-icad-20221114monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-financial-results-for-third-quarter-ended-september-30-2022-icad-20221110monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-join-forces-with-radiology-partners-the-nation-s-largest-radiology-practice-icad-20221110monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-third-quarter-2022-financial-results-on-november-10-2022-icad-20221027monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-and-solis-mammography-ink-deal-to-collaborate-on-use-of-ai-to-evaluate-risk-of-cardio-icad-20221011monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-the-lake-street-capital-markets-6th-annual-best-ideas-growth-big6-c-icad-20220907monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-customers-in-the-u-s-and-europe-increasingly-adopting-company-s-full-suite-of-breast--icad-20220829monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-financial-results-for-second-quarter-2022-icad-20220810monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-second-quarter-2022-financial-results-on-august-10-2022-icad-20220727monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-presents-its-complete-suite-of-breast-cancer-ai-solutions-at-the-european-congress-of-icad-20220713monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-profound-insights-profound-impact-webinar-series-to-highlight-profound-ai-risk-icad-20220607monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-present-at-the-jmp-securities-life-sciences-conference-on-june-15-16-2022-icad-20220606monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-cfo-transition-icad-20220525monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-financial-results-for-first-quarter-ended-march-31-2022-icad-20220511monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-profound-insights-profound-impact-webinar-series-to-feature-clinical-and-it-experts-icad-20220428monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-first-quarter-2022-financial-results-on-wednesday-may-11-icad-20220427monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-significant-commercial-momentum-for-profound-ai-among-customers-equipped-wi-icad-20220426monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-estimated-q1-revenue-and-upcoming-board-and-cfo-transitions-icad-20220421monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-launches-profound-insights-profound-impact-webinar-series-on-april-27-icad-20220419monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-additional-patients-treated-under-gliox-trial-and-continued-global-momentum-icad-20220405monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-highlights-breast-health-ai-platform-at-the-2022-healthcare-information-and-managemen-icad-20220314monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-showcases-innovative-breast-health-solutions-platform-at-national-consortium-of-breas-icad-20220310monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-present-at-the-32nd-annual-oppenheimer-healthcare-conference-icad-20220309monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-among-the-first-to-validate-its-ai-cancer-detection-solutions-with-the-nvidia-ai-ente-icad-20220302monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-present-at-the-42nd-annual-cowen-health-care-conference-icad-20220301monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-financial-results-for-fourth-quarter-and-year-ended-december-31-2021-icad-20220228monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-fourth-quarter-and-full-year-2021-financial-results-on-monday-february-28-icad-20220214monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-present-at-btig-medtech-digital-health-life-science-diagnostic-tools-conference-icad-20220208monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-breast-ai-platform-earns-u-s-department-of-defense-authorization-to-operate-icad-20220124monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-the-appointment-of-new-members-to-its-board-of-directors-icad-20220111monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-estimated-q4-and-fiscal-year-2021-revenues-icad-20220104monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-at-the-11th-annual-lifesci-partners-virtual-corporate-access-event-icad-20211223monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-at-the-imagine-ai-healthcare-investor-summit-icad-20211206monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-ceo-transition-icad-20211206monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-compelling-new-and-real-world-data-demonstrating-the-value-of-profound-ai-t-icad-20211129monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-the-12th-annual-craig-hallum-alpha-select-conference-icad-20211111monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-host-2nd-annual-virtual-investor-webinar-on-company-s-innovative-solutions-for-can-icad-20211111monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-financial-results-for-the-quarter-ended-september-30-2021-icad-20211109monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-third-quarter-2021-financial-results-on-tuesday-november-9-icad-20211026monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-launches-revolutionary-short-term-personalized-risk-assessment-solution-for-3d-mammog-icad-20210929monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-host-educational-roundtable-to-help-clinicians-and-facilities-recover-from-covid-1-icad-20210909monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-xoft-brain-iort-demonstrates-significant-improvement-in-overall-survival-in-recurre-icad-20210831monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-financial-results-for-the-quarter-ended-june-30-2021-icad-20210805monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-the-guggenheim-medtech-disruptors-summit-icad-20210802monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-second-quarter-2021-financial-results-on-thursday-august-5-icad-20210722monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-profound-ai-for-digital-breast-tomosynthesis-version-3-0-receives-ce-mark-approval-icad-20210614monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-signs-global-distribution-agreement-with-sectra-icad-20210608monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-upcoming-virtual-investor-conferences-icad-20210517monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-educational-webinar-featuring-leading-global-experts-discussing-new-multidi-icad-20210517monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-financial-results-for-first-quarter-ended-march-31-2021-icad-20210428monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-first-quarter-2021-financial-results-on-wednesday-april-28-icad-20210420monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-estimated-q1-revenues-and-upcoming-cfo-transition-icad-20210405monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-fda-clearance-for-profound-ai-version-3-0-for-3d-mammography-icad-20210315monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-closing-of-25-0-million-public-offering-of-common-stock-and-full-exercise-o-icad-20210308monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-the-cowen-41st-annual-health-care-conference-icad-20210304monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-pricing-of-22-0-million-public-offering-of-common-stock-icad-20210303monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-proposed-public-offering-of-common-stock-icad-20210302monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-financial-results-for-fourth-quarter-and-year-ended-december-31-2020-icad-20210224monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-fourth-quarter-2020-financial-results-on-wednesday-february-24-icad-20210218monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-the-btig-virtual-medtech-digital-health-life-science-diagnostic-too-icad-20210216monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-b-riley-securities-virtual-oncology-investor-conference-icad-20210119monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-the-lifesci-partners-10th-annual-healthcare-corporate-access-event-icad-20210106monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-renowned-neuro-oncologist-santosh-kesari-md-phd-to-lead-post-market-study-f-icad-20201229monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-hosting-investor-webinar-on-expanded-profound-ai-portfolio-with-new-breast-cancer-ris-icad-20201203monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-highlights-expanded-suite-of-leading-breast-health-ai-solutions-at-virtual-rsna-2020-icad-20201130monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-promising-clinical-data-to-be-presented-on-treatment-of-early-stage-breast--icad-20201125monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-over-1-000-licenses-sold-as-part-of-profound-ai-sales-icad-20201124monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-financial-results-for-third-quarter-and-nine-months-ended-september-30-2020-icad-20201105monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-third-quarter-2020-financial-results-on-thursday-november-5-icad-20201029monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-signs-distribution-agreement-with-change-healthcare-icad-20201020monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-hosting-technology-innovation-webinar-on-the-evolving-landscape-for-treating-patients-icad-20201016monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-responds-to-cms-finalized-radiation-oncology-alternative-payment-model-icad-20200921monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-iort-excluded-from-cms-s-radiation-oncology-alternative-payment-model-icad-20200918monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-compelling-data-supporting-launch-of-first-and-only-commercially-available--icad-20200915monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-hosts-free-virtual-roundtable-event-focusing-on-making-informed-decisions-for-adoptin-icad-20200909monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-present-at-the-ld-micro-500-virtual-conference-icad-20200827monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-the-guggenheim-medtech-disruptors-summit-icad-20200810monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-financial-results-for-second-quarter-and-six-months-ended-june-30-2020-icad-20200804monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-second-quarter-2020-financial-results-on-tuesday-august-4-icad-20200728monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-appoints-jeffrey-sirek-as-senior-vice-president-and-general-manager-of-xoft-icad-20200720monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-added-to-russell-2000-index-icad-20200629monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-hosts-virtual-roundtable-event-on-breast-cancer-surgery-and-targeted-radiation-during-icad-20200601monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-presents-positive-new-clinical-data-for-xoft-brain-iort-at-american-society-of-clinic-icad-20200513monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-first-quarter-2020-financial-results-icad-20200511monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-first-quarter-2020-financial-results-on-monday-may-11-icad-20200505monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-pricing-of-12-5-million-registered-direct-offering-icad-20200423monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-partners-with-the-tme-breast-care-network-to-host-virtual-event-breast-care-roundtabl-icad-20200413monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-new-credit-facility-with-bridge-bank-increasing-operational-flexibility-icad-20200331monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-launches-new-initiatives-leveraging-unique-capabilities-of-its-robust-product-portfol-icad-20200323monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-fourth-quarter-and-full-year-2019-financial-results-icad-20200227monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-fourth-quarter-2019-financial-results-on-thursday-february-27-2020-icad-20200213monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-the-40th-annual-cowen-healthcare-conference-icad-20200212monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-showcases-technology-for-cancer-discovery-to-recovery-including-profound-ai-platform--icad-20200127monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-appoints-nathaniel-dalton-to-its-board-of-directors-icad-20200113monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-profound-ai-joins-nuance-ai-marketplace-for-diagnostic-imaging-icad-20191204monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-showcase-leading-breast-health-solutions-suite-including-expanded-profound-ai-plat-icad-20191202monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-at-the-piper-healthcare-conference-icad-20191126monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-at-the-cannacord-genuity-medtech-diagnostics-forum-icad-20191118monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-financial-and-operating-results-for-the-third-quarter-and-nine-months-ended-s-icad-20191030monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-third-quarter-2019-financial-results-on-wednesday-october-30-icad-20191024monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-showcases-profound-ai-platform-at-european-society-of-breast-imaging-annual-scientifi-icad-20191001monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-exhibiting-new-updates-and-enhanced-xoft-platform-at-astro-including-single-fraction--icad-20190916monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-profound-ai-reader-study-published-in-radiology-artificial-intelligence-icad-20190910monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-profound-ai-wins-best-new-radiology-solution-in-2019-medtech-breakthrough-awards-icad-20190904monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-host-investor-meeting-at-astro-in-chicago-icad-20190903monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-second-quarter-2019-financial-results-icad-20190801monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-second-quarter-2019-financial-results-on-thursday-august-1-icad-20190729monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-profound-ai-for-2d-mammography-receives-ce-mark-approval-icad-20190711monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-the-jmp-securities-life-sciences-conference-and-piper-jaffray-heart-icad-20190618monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-closing-of-public-offering-of-common-stock-icad-20190617monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-introduces-profound-ai-for-2d-mammography-in-europe-icad-20190613monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-pricing-of-public-offering-of-common-stock-icad-20190613monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-proposed-public-offering-of-common-stock-icad-20190612monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-first-quarter-2019-financial-results-icad-20190507monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-appoints-r-scott-areglado-as-chief-financial-officer-icad-20190506monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-first-quarter-2019-financial-results-on-tuesday-may-7-icad-20190501monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-wins-three-system-public-bid-with-leading-cancer-organization-in-spain-expanding-euro-icad-20190415monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-highlight-profound-ai-solution-for-digital-breast-tomosynthesis-at-2019-society-of-icad-20190404monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-appoints-stacey-stevens-as-president-icad-20190328monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-present-corporate-overview-at-the-jefferies-2019-radiation-oncology-energy-based-t-icad-20190326monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-fourth-quarter-and-full-year-2018-financial-results-icad-20190318monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-present-corporate-overview-at-the-31st-annual-roth-conference-icad-20190314monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-fourth-quarter-and-fiscal-year-ended-december-31-2018-financial-results-on--icad-20190313monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-partner-with-leading-breast-cancer-researchers-from-karolinska-institutet-to-devel-icad-20190227monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-showcase-profound-ai-solution-for-digital-breast-tomosynthesis-at-ecr-2019-icad-20190221monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-cfo-transition-icad-20181227monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-inc-announces-7-0-million-private-placement-of-unsecured-subordinated-convertible-deb-icad-20181220monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-fda-clearance-of-profound-ai-for-digital-breast-tomosynthesis-icad-20181207monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-unveils-profound-ai-for-digital-breast-tomosynthesis-at-rsna-2018-icad-20181126monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-third-quarter-2018-financial-results-icad-20181113monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-retirement-of-ceo-ken-ferry-icad-20181109monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-third-quarter-and-nine-months-ended-september-30-2018-financial-results-on--icad-20181106monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-new-clinical-data-on-the-xoft-electronic-brachytherapy-system-for-early-sta-icad-20181023monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-exceptional-study-results-demonstrating-significant-advantages-of-revolutio-icad-20181011monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-aerb-approval-of-xoft-system-in-india-icad-20180829monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-second-quarter-2018-financial-results-icad-20180814monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-receives-fda-clearance-of-powerlook-density-assessment-for-digital-breast-tomosynthes-icad-20180808monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-second-quarter-and-six-months-ended-june-30-2018-financial-results-on-tuesd-icad-20180807monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-named-2018-medtech-breakthrough-award-winner-icad-20180606monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-first-quarter-2018-financial-results-icad-20180514monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-first-quarter-2018-financial-results-on-monday-may-14-2018-icad-20180508monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-presentation-of-positive-clinical-data-on-xoft-system-for-treatment-of-earl-icad-20180419monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-fourth-quarter-and-full-year-2017-financial-results-icad-20180322monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-fourth-quarter-and-fiscal-2017-financial-results-on-thursday-march-22-2018-icad-20180316monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-granted-ce-mark-approval-in-europe-for-powerlook-tomo-detection-2-0-artificial-intell-icad-20180301monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-named-a-top-artificial-intelligence-medical-imaging-solution-provider-by-healthcare-t-icad-20180208monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-study-demonstrating-economic-and-health-benefits-of-intraoperative-radiatio-icad-20171207monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-powerlook-tomo-detection-experiences-growing-adoption-icad-20171127monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-positive-clinical-data-on-xoft-system-for-non-melanoma-skin-cancer-treatmen-icad-20171109monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-third-quarter-2017-financial-results-icad-20171108monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-third-quarter-2017-financial-results-on-wednesday-november-8-icad-20171101monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-s-powerlook-tomo-detection-for-digital-breast-tomosynthesis-named-2017-product-of-the-icad-20171026monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-presentation-of-new-clinical-data-on-xoft-system-for-treatment-of-nonmelano-icad-20170925monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-icad-20170920monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-approval-of-xoft-axxent-balloon-applicators-by-china-food-drug-administrati-icad-20170904monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-approval-of-xoft-axxent-balloon-applicators-by-china-food-drug-administrati-icad-20170830monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-second-quarter-2017-financial-results-and-announces-13-million-credit-facilit-icad-20170808monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-present-at-the-canaccord-genuity-37th-annual-growth-conference-icad-20170801monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-second-quarter-2017-financial-results-on-tuesday-august-8-icad-20170731monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-positive-study-results-comparing-use-of-company-s-xoft-axxent-electronic-br-icad-20170719monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-two-upcoming-investor-conferences-icad-20170522monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-first-quarter-2017-financial-results-icad-20170502monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-first-early-stage-breast-cancer-patient-treated-with-intraoperative-radiati-icad-20170501monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-report-first-quarter-2017-financial-results-on-tuesday-may-2-icad-20170424monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-fourth-quarter-and-full-year-2016-financial-results-icad-20170308monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-present-at-the-29th-annual-roth-conference-icad-20170302monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-host-fourth-quarter-and-full-year-2016-financial-results-conference-call-on-wednes-icad-20170227monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-present-at-two-investor-conferences-in-november-2016-icad-20161110monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-appoints-richard-christopher-executive-vice-president-and-chief-financial-officer-icad-20161108monthly0.5https://www.biopharmawatch.com/news/ICAD/icade-bnp-paribas-primary-new-issues-no-stab-notice-icad-20161108monthly0.5https://www.biopharmawatch.com/news/ICAD/icade-bnp-paribas-primary-new-issues-pre-stabilisation-notice-icad-20161107monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-third-quarter-2016-financial-results-icad-20161102monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-host-third-quarter-2016-financial-results-conference-call-on-wednesday-november-2--icad-20161020monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-announces-management-transition-icad-20160908monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-the-36th-annual-canaccord-genuity-growth-conference-icad-20160729monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-second-quarter-2016-financial-results-icad-20160727monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-host-second-quarter-2016-financial-results-conference-call-on-wednesday-july-27-20-icad-20160714monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-participate-in-the-13th-annual-craig-hallum-institutional-investor-conference-icad-20160525monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-first-quarter-2016-financial-results-icad-20160503monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-host-first-quarter-2016-financial-results-conference-call-on-tuesday-may-3-2016-icad-20160421monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-present-at-the-28th-annual-roth-conference-icad-20160309monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-fourth-quarter-and-full-year-2015-financial-results-icad-20160301monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-host-fourth-quarter-and-full-year-2015-financial-results-conference-call-on-tuesda-icad-20160202monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-appoints-andrew-sassine-to-board-of-directors-icad-20151209monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-present-at-the-drexel-hamilton-micro-cap-investor-forum-icad-20151105monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-third-quarter-2015-financial-results-icad-20151029monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-host-third-quarter-2015-financial-results-conference-call-on-thursday-october-29-2-icad-20151015monthly0.5https://www.biopharmawatch.com/news/ICAD/icade-post-stabilisation-notice-icad-20151005monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-present-at-the-6th-annual-craig-hallum-alpha-select-conference-icad-20150914monthly0.5https://www.biopharmawatch.com/news/ICAD/icade-pre-stabilisation-notice-icad-20150902monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-present-at-sidoti-emerging-growth-conference-icad-20150824monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-second-quarter-2015-financial-results-icad-20150805monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-host-second-quarter-2015-financial-results-conference-call-on-wednesday-august-5-2-icad-20150727monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-present-at-the-5th-annual-ld-micro-invitational-icad-20150528monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-inc-withdraws-2015-financial-guidance-due-to-general-reimbursement-uncertainty-icad-20150527monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-inc-announces-information-related-to-reimbursement-levels-icad-20150506monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-first-quarter-2015-financial-results-icad-20150430monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-host-first-quarter-2015-financial-results-conference-call-on-thursday-april-30-201-icad-20150416monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-present-at-the-27th-annual-roth-conference-icad-20150302monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-fourth-quarter-and-fiscal-year-2014-financial-results-icad-20150224monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-to-host-fourth-quarter-and-full-year-2014-financial-results-conference-call-on-tuesda-icad-20150213monthly0.5https://www.biopharmawatch.com/news/ICAD/icade-sells-to-klepierre-its-stake-in-odysseum-retail-centre-in-montpellier-icad-20131202monthly0.5https://www.biopharmawatch.com/news/ICAD/icade-for-ipad-available-now-at-thinkgeek-icad-20110627monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-inc-icad-in-recognition-of-prostate-awareness-month-to-ring-the-nasdaq-stock-market-c-icad-20100901monthly0.5https://www.biopharmawatch.com/news/ICAD/icad-inc-icad-president-and-chief-executive-officer-to-ring-the-nasdaq-stock-market-closin-icad-20081017monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-senior-management-changes-vero-20260513monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-completion-of-common-stock-sale-and-short-form-merger-vero-20260401monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-receives-510-k-for-the-venus-nova-its-most-advanced-multi-application-platfo-vero-20251110monthly0.5https://www.biopharmawatch.com/news/VERO/venus-salon-suites-frisco-celebrates-first-year-under-current-ownership-vero-20250923monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-second-quarter-2025-financial-results-vero-20250814monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-second-quarter-of-fiscal-year-2025-financial-results-on-august-14-vero-20250716monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-6-5-million-debt-to-equity-exchange-transaction-vero-20250701monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-first-quarter-2025-financial-results-vero-20250515monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-raises-a-total-of-approximately-2-7-million-in-gross-proceeds-from-previousl-vero-20250414monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-1-5-million-registered-direct-offering-of-common-stock-priced-at-t-vero-20250411monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-closing-of-1-1-million-registered-direct-offering-of-common-stock--vero-20250410monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-1-1-million-registered-direct-offering-of-common-stock-priced-at-t-vero-20250409monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-first-quarter-of-fiscal-year-2025-financial-results-on-may-15-202-vero-20250407monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-11-million-debt-to-equity-exchange-transaction-vero-20250401monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-fourth-quarter-and-fiscal-year-2024-financial-results-vero-20250331monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-fourth-quarter-and-fiscal-year-2024-financial-results-on-march-31-vero-20250303monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-1-for-11-reverse-stock-split-vero-20250227monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-senior-management-changes-vero-20250225monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-third-quarter-of-fiscal-year-2024-financial-results-vero-20241113monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-expansion-of-international-distribution-network-and-certification--vero-20241107monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-third-quarter-of-fiscal-year-2024-financial-results-on-november-1-vero-20241002monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-15-million-debt-to-equity-exchange-transaction-vero-20240927monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-australian-regulatory-approval-for-venus-bliss-max-vero-20240918monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-second-quarter-of-fiscal-year-2024-financial-results-vero-20240813monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-regulatory-approval-for-venus-bliss-max-in-canada-vero-20240729monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-second-quarter-of-fiscal-year-2024-financial-results-on-august-13-vero-20240715monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-celebrates-successful-completion-of-its-nexthetics-events-across-north-ameri-vero-20240627monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-exclusive-strategic-supply-arrangement-with-skin-laundry-vero-20240617monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-regains-compliance-with-nasdaq-s-minimum-equity-requirement-vero-20240606monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-approval-for-venus-versa-pro-in-canada-vero-20240603monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-35-million-debt-to-equity-exchange-transaction-vero-20240528monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-first-quarter-of-fiscal-year-2024-financial-results-vero-20240515monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-loan-purchase-and-completion-of-first-phase-of-refinancing-vero-20240424monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-first-quarter-of-fiscal-year-2024-financial-results-on-may-15-202-vero-20240415monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-israeli-regulatory-approval-for-venus-bliss-max-vero-20240408monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-australian-regulatory-approval-for-venus-versa-pro-vero-20240403monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-fourth-quarter-and-fiscal-year-2023-financial-results-vero-20240401monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-granted-continued-listing-from-nasdaq-hearings-panel-subject-to-return-to-co-vero-20240325monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-launches-nexthetics-program-vero-20240312monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-closing-of-1-2-million-registered-direct-offering-priced-at-the-ma-vero-20240227monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-1-2-million-registered-direct-offering-priced-at-the-market-under--vero-20240223monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-ce-mark-for-venus-versa-pro-in-europe-vero-20240222monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-fourth-quarter-and-fiscal-year-2023-financial-results-on-april-1--vero-20240220monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-to-participate-in-the-btig-virtual-medtech-digital-health-life-science-d-vero-20240206monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-announces-review-of-strategic-alternatives-vero-20240124monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-announces-issuance-of-2-0m-of-convertible-notes-vero-20240119monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-launches-venus-prime-vero-20240117monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-new-international-distributors-in-the-united-kingdom-and-india-to--vero-20231218monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-third-quarter-of-fiscal-year-2023-financial-results-vero-20231114monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-launches-venus-versa-pro-its-new-multi-application-platform-for-face-and-bod-vero-20231101monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-launches-new-venus-aesthetic-intelligence-branding-and-updated-venus-ai-webs-vero-20231017monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-appoints-dr-hemanth-varghese-as-president-and-chief-operating-officer-an-vero-20231012monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-third-quarter-of-fiscal-year-2023-financial-results-on-november-1-vero-20231009monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-announces-debt-restructuring-preliminary-third-quarter-2023-revenue-resu-vero-20231005monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-receives-510-k-clearance-for-the-venus-versa-pro-system-its-new-multi-applic-vero-20230914monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conferenc-vero-20230906monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-second-quarter-of-fiscal-year-2023-financial-results-vero-20230814monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-establishment-of-medical-advisory-board-for-ai-me-its-next-generat-vero-20230713monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-second-quarter-of-fiscal-year-2023-financial-results-on-august-14-vero-20230705monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-first-quarter-of-fiscal-year-2023-financial-results-vero-20230515monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-announces-multi-tranche-private-placement-of-senior-convertible-preferre-vero-20230515monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-1-for-15-reverse-stock-split-vero-20230511monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-first-quarter-of-fiscal-year-2023-financial-results-on-may-15-202-vero-20230411monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-fourth-quarter-and-fiscal-year-2022-financial-results-introduces-f-vero-20230327monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-the-launch-of-its-latest-generation-of-artas-ix-the-world-s-most-a-vero-20230320monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-fourth-quarter-and-fiscal-year-2022-financial-results-on-march-27-vero-20230208monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-strategic-business-realignment-to-accelerate-its-path-to-long-term-vero-20230207monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-receives-510-k-clearance-for-use-of-its-ai-me-next-generation-robotic-techno-vero-20221221monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-completion-of-6-72-million-private-placement-financing-vero-20221118monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-third-quarter-of-fiscal-year-2022-financial-results-vero-20221110monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-vero-20221019monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-appoints-dr-hemanth-varghese-as-president-chief-business-officer-vero-20221011monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-vero-20221006monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-updated-release-date-of-november-10-2022-for-third-quarter-of-fisc-vero-20221005monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-appointment-of-rajiv-de-silva-as-chief-executive-officer-and-direc-vero-20221003monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-second-quarter-of-fiscal-year-2022-financial-results-updates-fisca-vero-20220812monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-second-quarter-of-fiscal-year-2022-financial-results-on-august-12-vero-20220630monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-first-quarter-of-fiscal-year-2022-financial-results-reaffirms-fisc-vero-20220512monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-receives-new-fda-510-k-clearance-for-venus-blissmax-vero-20220428monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-first-patient-treatment-in-study-evaluating-the-safety-and-efficac-vero-20220425monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-first-quarter-of-fiscal-year-2022-financial-results-on-may-12-202-vero-20220404monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-submits-fda-510-k-related-to-the-use-of-its-aime-next-generation-robotic-tec-vero-20220331monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-fourth-quarter-and-fiscal-year-2021-financial-results-introduces-f-vero-20220328monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-to-present-at-the-maxim-virtual-growth-conference-on-march-28th-vero-20220321monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-to-participate-in-the-btig-virtual-medtech-digital-health-life-science-d-vero-20220208monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-fourth-quarter-and-fiscal-year-2021-financial-results-on-march-28-vero-20220202monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-receives-fda-510-k-clearance-of-venus-blissmax-for-non-invasive-lipolysis-of-vero-20220118monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-reports-preliminary-revenue-results-for-fourth-quarter-2021-vero-20220110monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-17-million-equity-financing-led-by-masters-special-situations-vero-20211215monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-third-quarter-and-first-nine-months-of-2021-financial-results-upda-vero-20211112monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-to-participate-in-the-stifel-2021-virtual-healthcare-conference-vero-20211110monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-receives-fda-510-k-clearance-for-the-venus-freedom-vero-20211019monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-appoints-ross-j-portaro-as-president-of-global-sales-vero-20211012monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-third-quarter-of-fiscal-year-2021-financial-results-on-november-1-vero-20211004monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conferenc-vero-20210907monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-second-quarter-2021-financial-results-increases-fiscal-year-2021-r-vero-20210813monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-to-participate-in-the-sidoti-co-microcap-conference-on-august-18th-vero-20210812monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-health-canada-authorization-and-ce-mark-for-venus-fiore-feminine-h-vero-20210720monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-to-participate-in-the-ladenburg-thalmann-healthcare-conference-on-july-1-vero-20210712monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-second-quarter-of-fiscal-year-2021-financial-results-on-august-13-vero-20210708monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-first-quarter-of-2021-financial-results-increases-fiscal-year-2021-vero-20210517monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-first-quarter-of-fiscal-year-2021-financial-results-on-may-17-202-vero-20210408monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-reports-fourth-quarter-and-fiscal-year-2020-financial-results-reaffirms-fisc-vero-20210329monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-global-brand-ambassador-partnership-with-tennis-champion-and-entre-vero-20210325monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-to-participate-in-two-upcoming-investor-conferences-on-march-17th-vero-20210311monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-to-present-at-the-h-c-wainwright-annual-global-lifesciences-conference-o-vero-20210304monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-to-participate-in-the-btig-virtual-medtech-digital-health-life-science-d-vero-20210209monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-fourth-quarter-and-fiscal-year-2020-financial-results-on-march-29-vero-20210208monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-reports-preliminary-revenue-results-for-fourth-quarter-2020-introduces-fisca-vero-20210114monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-to-present-at-two-upcoming-investor-conferences-in-january-vero-20210105monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-announces-pricing-of-22-5-million-public-offering-vero-20201222monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-announces-proposed-public-offering-vero-20201221monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-debt-refinancing-vero-20201210monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-host-virtual-aesthetic-hair-restoration-technology-event-on-december-10th-vero-20201201monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-third-quarter-and-first-nine-months-of-2020-financial-results-vero-20201116monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-to-present-at-the-stifel-2020-virtual-healthcare-conference-vero-20201103monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-third-quarter-of-fiscal-year-2020-financial-results-on-november-1-vero-20201015monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-second-quarter-and-first-six-months-of-2020-financial-results-vero-20200813monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-reports-preliminary-revenue-results-for-second-quarter-2020-vero-20200716monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-announces-fda-510-k-clearance-for-venus-viva-md-vero-20200701monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-joins-russell-2000-russell-3000-and-russell-microcap-indexes-vero-20200626monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-second-quarter-of-fiscal-year-2020-financial-results-on-august-13-vero-20200625monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-announces-common-stock-purchase-agreement-for-up-to-31-million-with-linc-vero-20200616monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-announces-fda-510-k-clearance-for-venus-epileve-vero-20200615monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-first-quarter-of-2020-financial-results-vero-20200514monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-first-quarter-of-fiscal-year-2020-financial-results-on-may-14-202-vero-20200415monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-fourth-quarter-and-fiscal-year-2019-financial-results-provides-pre-vero-20200330monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-announces-22-25-million-equity-financing-vero-20200318monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-to-release-fourth-quarter-and-fiscal-year-2019-financial-results-on-march-30-vero-20200310monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-expands-executive-team-vero-20200303monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-announces-new-regulatory-clearances-vero-20200214monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-preliminary-fourth-quarter-and-fiscal-year-2019-revenue-results-in-vero-20200113monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-announces-ce-mark-and-australian-regulatory-approval-for-neograft-2-0-a--vero-20191205monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-inc-announces-ce-mark-and-health-canada-license-to-market-venus-epileve-vero-20191126monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-receives-health-canada-authorization-to-market-venus-bliss-in-canada-vero-20191119monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-third-quarter-and-first-nine-months-of-2019-financial-results-vero-20191114monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-completes-merger-with-restoration-robotics-and-combined-company-raises-28-mi-vero-20191107monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-shareholder-and-management-changes-sets-the-stage-for-continued-st-vero-20150107monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-q1-2026-financial-results-call2026-06-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-appoints-paulo-fontoura-global-head-rd2026-06-22T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HKPD/index-to-financial-statements-page-consolidated-financial-statements-for-the-six-months-en-hkpd-20260318monthly0.5https://www.biopharmawatch.com/news/HKPD/cellyan-biotechnology-co-ltd-receives-nasdaq-notice-of-bid-price-deficiency-hkpd-20260116monthly0.5https://www.biopharmawatch.com/news/HKPD/hong-kong-pharma-digital-announced-results-of-2025-annual-meeting-of-stockholders-hkpd-20251217monthly0.5https://www.biopharmawatch.com/news/HKPD/hong-x00a0-kong-pharma-digital-technology-holdings-limited-room-b1-5-f-well-town-industria-hkpd-20251124monthly0.5https://www.biopharmawatch.com/news/HKPD/employment-agreement-this-employment-agreement-the-agreement-is-entered-into-as-of-06-10-2-hkpd-20251007monthly0.5https://www.biopharmawatch.com/news/HKPD/index-to-financial-statements-page-consolidated-financial-statements-for-the-six-months-en-hkpd-20250328monthly0.5https://www.biopharmawatch.com/news/HKPD/hong-kong-pharma-digital-technology-holdings-limited-announces-pricing-of-initial-public-o-hkpd-20250114monthly0.5https://www.biopharmawatch.com/news/LUCY/innovative-eyewear-inc-announces-record-breaking-65-annual-sales-growth-in-2025-insider-bu-lucy-20260107monthly0.5https://www.biopharmawatch.com/news/LUCY/innovative-eyewear-inc-announces-4-8-million-of-gross-proceeds-raised-from-warrant-transac-lucy-20250623monthly0.5https://www.biopharmawatch.com/news/LUCY/e-xhibit-99-1-innovative-eyewear-inc-announces-exercise-of-warrants-for-1-8-million-gross--lucy-20250411monthly0.5https://www.biopharmawatch.com/news/LUCY/innovative-eyewear-inc-announces-exercise-of-warrants-for-2-6-million-gross-proceeds-miami-lucy-20240923monthly0.5https://www.biopharmawatch.com/news/LUCY/innovative-eyewear-inc-adopts-limited-duration-stockholders-rights-plan-miami-lucy-20240925monthly0.5https://www.biopharmawatch.com/news/LUCY/innovative-eyewear-inc-lucy-20240905monthly0.5https://www.biopharmawatch.com/news/LUCY/eyewear-inc-lucy-20240105monthly0.5https://www.biopharmawatch.com/news/LUCY/innovative-eyewear-announces-pricing-of-4-7-million-public-offering-miami-lucy-20230622monthly0.5https://www.biopharmawatch.com/news/LUCY/innovative-eyewear-inc-lucy-20230620monthly0.5https://www.biopharmawatch.com/news/LUCY/innovative-eyewear-inc-lucy-20221228monthly0.5https://www.biopharmawatch.com/news/LUCY/eyewear-inc-lucy-20221228monthly0.5https://www.biopharmawatch.com/news/LUCY/innovative-eyewear-inc-lucy-20221006monthly0.5https://www.biopharmawatch.com/news/LUCY/eyewear-inc-lucy-20221003monthly0.5https://www.biopharmawatch.com/news/LUCY/eyewear-inc-lucy-20220818monthly0.5https://www.biopharmawatch.com/news/HCWC/healthy-choice-wellness-corp-strengthens-balance-sheet-through-market-price-debt-for-equit-hcwc-20250303monthly0.5https://www.biopharmawatch.com/news/HCWC/healthy-choice-wellness-corp-announces-listing-on-nyse-american-pricing-of-initial-public--hcwc-20240916monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-interim-condensed-consolidated-financial-stateme-adxn-20251204monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-interim-condensed-consolidated-financial-stateme-adxn-20250930monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-interim-condensed-consolidated-financial-stateme-adxn-20250620monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-interim-condensed-consolidated-financial-stateme-adxn-20241122monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-interim-condensed-consolidated-financial-stateme-adxn-20240930monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-interim-condensed-consolidated-financial-stateme-adxn-20240606monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-interim-condensed-consolidated-financial-stateme-adxn-20231221monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-interim-condensed-consolidated-financial-stateme-adxn-20231129monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-interim-condensed-consolidated-financial-stateme-adxn-20230810monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-interim-condensed-consolidated-financial-stateme-adxn-20230511monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-interim-condensed-consolidated-financial-stateme-adxn-20221114monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-interim-condensed-consolidated-financial-stateme-adxn-20220914monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-interim-condensed-consolidated-financial-stateme-adxn-20220818monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-completes-4-2-million-equity-financing-ad-hoc-announcement-pursuant-to-art-53-lr-gen-adxn-20220726monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-interim-condensed-consolidated-financial-stateme-adxn-20220505monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-raises-10-0-million-in-equity-financing-ad-hoc-announcement-pursuant-to-art-53-lr-ge-adxn-20211217monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-provides-year-end-pipeline-development-update-ad-hoc-announcement-pursuant-to-art-53-adxn-20211215monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-interim-condensed-consolidated-financial-stateme-adxn-20211104monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-interim-condensed-consolidated-financial-stateme-adxn-20210805monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-interim-condensed-consolidated-financial-stateme-adxn-20210505monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-interim-condensed-consolidated-financial-stateme-adxn-20201103monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-condensed-consolidated-financial-statements-cons-adxn-20200812monthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-ltd-index-to-unaudited-condensed-consolidated-financial-statements-cons-adxn-20200520monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-closes-up-to-14-4-million-private-placement-and-launches-crypto-treasu-ndra-20251023monthly0.5https://www.biopharmawatch.com/news/NDRA/recent-financial-results-below-is-a-summary-of-certain-preliminary-estimates-regarding-our-ndra-20250630monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-provides-a-business-update-and-reports-first-quarter-2025-financial-re-ndra-20250515monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-fourth-quarter-and-full-year-2024-financial-results-and-provid-ndra-20250331monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement-ann-arbor-ndra-20241122monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-third-quarter-2024-financial-results-and-provides-a-business-u-ndra-20241115monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-granted-extension-to-regain-compliance-with-nasdaq-continued-listing-r-ndra-20240828monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-second-quarter-2024-financial-results-and-provides-a-business--ndra-20240822monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-announces-reverse-stock-split-shares-expected-to-begin-trading-on-spli-ndra-20240816monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-announces-leadership-changes-board-member-alexander-tokman-appointed-a-ndra-20240813monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-announces-pricing-of-8-0-million-public-offering-ann-arbor-mich-ndra-20240604monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-provides-update-following-in-person-meeting-with-fda-increases-clarity-for-endra-on--ndra-20240520monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-first-quarter-2024-financial-results-and-provides-a-business-u-ndra-20240514monthly0.5https://www.biopharmawatch.com/news/NDRA/recent-financial-results-below-is-a-summary-of-certain-preliminary-estimates-regarding-our-ndra-20240510monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-fourth-quarter-and-full-year-2023-financial-results-and-provid-ndra-20240328monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-third-quarter-2023-financial-results-and-provides-business-upd-ndra-20231114monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-second-quarter-2023-financial-results-and-provides-a-business--ndra-20230814monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-announces-adjournment-of-2023-annual-meeting-of-stockholders-to-ndra-20230706monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-first-quarter-2023-financial-results-and-provides-a-business-u-ndra-20230515monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-announces-pricing-of-upsized-4-5-million-public-offering-ann-arbor-mic-ndra-20230428monthly0.5https://www.biopharmawatch.com/news/NDRA/recent-financial-results-below-is-a-summary-of-certain-preliminary-estimates-regarding-our-ndra-20230331monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-fourth-quarter-and-full-year-2022-financial-results-and-provid-ndra-20230314monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-third-quarter-2022-financial-results-and-provides-business-upd-ndra-20221114monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-second-quarter-2022-financial-results-and-provides-business-up-ndra-20220815monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-first-quarter-2022-financial-results-and-provides-business-upd-ndra-20220512monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-raises-8-7-million-in-gross-proceeds-through-its-at-the-market-facilit-ndra-20220421monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-fourth-quarter-and-full-year-2021-financial-results-and-provid-ndra-20220330monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-provides-update-on-u-s-regulatory-strategy-for-its-taeus-system-new-pa-ndra-20220209monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-third-quarter-2021-financial-results-and-provides-business-upd-ndra-20211115monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-second-quarter-2021-financial-results-and-provides-business-up-ndra-20210812monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-appoints-irina-pestrikova-as-senior-director-of-finance-announces-depa-ndra-20210615monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-first-quarter-2021-financial-results-and-provides-business-upd-ndra-20210517monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-2020-fourth-quarter-and-full-year-financial-results-provides-b-ndra-20210325monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-extends-ge-healthcare-collaboration-agreement-for-two-y-ears-supports--ndra-20201221monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-announces-proposed-public-offering-of-common-stock-ann-a-rbor-mich-ndra-20201215monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-third-quarter-2020-financial-results-and-provides-business-upd-ndra-20201116monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-provides-business-update-and-reports-second-quarter-2020-financial-res-ndra-20200817monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-provides-business-update-and-reports-first-quarter-2020-financial-resu-ndra-20200514monthly0.5https://www.biopharmawatch.com/news/NDRA/ndra-ex991-endra-life-sciences-announces-cash-strategy-and-business-update-in-response-to--ndra-20200413monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-provides-business-update-and-reports-fourth-quarter-and-full-year-2019-ndra-20200326monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-receives-ce-mark-for-its-taeus-xae-clinical-product-targeting-non-alco-ndra-20200309monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-renews-ge-healthcare-collaboration-agreement-supports-commercializatio-ndra-20200115monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-completes-8-1-million-private-placement-ndra-20191211monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-provides-business-update-and-reports-third-quarter-2019-financial-resu-ndra-20191113monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-completes-private-placement-of-2-8-million-of-convertible-secured-note-ndra-20190729monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-announces-proposed-public-offering-of-common-stock-ann-arbor-michigan--ndra-20181107monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-inc-announces-proposed-public-offering-of-common-stock-ann-arbor-michi-ndra-20181010monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-completes-private-placement-of-1-1-million-of-convertible-secured-note-ndra-20180702monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-fourth-quarter-and-full-year-2017-financial-results-management-ndra-20180320monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-renews-and-extends-term-of-collaboration-agreement-with-ge-healthcare--ndra-20180205monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-reports-third-quarter-2017-financial-results-partnerships-with-leading-ndra-20171115monthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-announces-separation-of-units-sold-in-ipo-common-stock-and-warrants-to-ndra-20170622monthly0.5https://www.biopharmawatch.com/news/NDRA/jfif-exif-mm-q-q-q-c-7-01444-9-82-f-p6-h-u-i-c5-v-3-6x-e-v-o-z-5-z-i-ndra-20170602monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-notification-of-mexico-patent-allowance-covering-novel--biaf-20260527monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-cypath-lung-to-be-featured-at-cleveland-clinic-annual-advances-in-biaf-20260407monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-cypath-lung-test-unit-sales-surged-146-year-over-year-in-q1-2026--biaf-20260401monthly0.5https://www.biopharmawatch.com/news/BIAF/new-case-study-bioaffinity-technologies-cypath-lung-provides-actionable-results-and-helps--biaf-20260317monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-f-biaf-20260310monthly0.5https://www.biopharmawatch.com/news/BIAF/new-case-study-highlights-ability-of-bioaffinity-technologies-cypath-lung-to-reduce-diagno-biaf-20260219monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-laboratory-maintains-prestigious-college-of-american-pathologists-biaf-20260107monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-third-quarter-2025-financial-results-company-achieves-86--biaf-20251114monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-accelerating-month-over-month-growth-in-cypath-lung-test--biaf-20251105monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-acceptance-of-australian-patent-application-for-platfor-biaf-20251028monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-presents-research-supporting-cypath-lung-processing-methods-at-ch-biaf-20251020monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-notification-of-allowance-for-u-s-patent-application-fo-biaf-20251016monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-regains-compliance-with-nasdaq-listing-requirements-biaf-20251015monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-inc-announces-approximately-1-8-million-registered-direct-financi-biaf-20251008monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarte-biaf-20251007monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-pricing-of-4-8-million-public-offering-biaf-20250929monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-1-for-30-reverse-stock-split-effective-at-the-open-of-t-biaf-20250919monthly0.5https://www.biopharmawatch.com/news/BIAF/case-study-cypath-lung-identifies-lung-cancer-in-patient-with-difficult-to-diagnose-ground-biaf-20250909monthly0.5https://www.biopharmawatch.com/news/BIAF/u-s-medicine-magazine-spotlights-cypath-lung-as-promising-tool-to-improve-lung-cancer-dete-biaf-20250903monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-appoints-new-members-to-board-of-directors-financial-and-clinical-biaf-20250818monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-pricing-of-private-placement-and-warrant-inducement-tra-biaf-20250813monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-second-quarter-2025-results-cypath-lung-revenues-up-62-ye-biaf-20250814monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales-july-test-v-biaf-20250813monthly0.5https://www.biopharmawatch.com/news/BIAF/case-study-cypath-lung-detects-stage-1a-lung-cancer-in-high-risk-patient-with-inconclusive-biaf-20250729monthly0.5https://www.biopharmawatch.com/news/BIAF/case-study-cypath-lung-detects-neuroendocrine-tumor-missed-by-other-diagnostic-tools-bioaf-biaf-20250723monthly0.5https://www.biopharmawatch.com/news/BIAF/canada-awards-new-patent-to-bioaffinity-technologies-for-cypath-lung-company-s-noninvasive-biaf-20250722monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-notification-of-china-patent-award-for-company-s-noninv-biaf-20250715monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-first-quarter-2025-results-cypath-lung-sales-up-276-year--biaf-20250515monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-pricing-of-3-25-million-offering-san-antonio-texas-biaf-20250506monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-record-9-4-million-revenue-for-2024-increased-demand-expa-biaf-20250331monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-targeted-actions-to-cut-4-million-in-costs-and-drive-cy-biaf-20250306monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-warrant-inducement-for-aggregate-gross-proceeds-of-1-4--biaf-20250227monthly0.5https://www.biopharmawatch.com/news/BIAF/good-afternoon-i-am-excited-to-speak-with-you-today-and-discuss-our-plans-for-2025-as-well-biaf-20241220monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-2-4-million-revenue-for-q3-2024-expanded-cypath-lung-test-biaf-20241114monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-pricing-of-2-66-million-registered-direct-offering-conc-biaf-20241018monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-names-j-michael-edwards-as-chief-financial-officer-edwards-rejoin-biaf-20241010monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-awarded-u-s-federal-supply-schedule-contract-for-cypath-lung-test-biaf-20241009monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-cfo-to-depart-for-new-opportunity-j-michael-edwards-to-return-as--biaf-20240823monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-pricing-of-registered-direct-offering-and-concurrent-pr-biaf-20240802monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-217-sales-growth-in-second-quarter-2024-for-cypath-lung-s-biaf-20240709monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-record-q1-revenue-driven-by-accelerating-growth-of-cypath-biaf-20240515monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-fourth-quarter-and-full-year-2023-financial-results-san-a-biaf-20240401monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-pricing-of-2-5-million-registered-direct-offering-and-c-biaf-20240306monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-accelerating-sales-growth-of-cypath-lung-increasing-physi-biaf-20240305monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-appoints-jamie-platt-ph-d-to-its-board-of-directors-san-antonio-t-biaf-20231205monthly0.5https://www.biopharmawatch.com/news/BIAF/cms-posts-final-payment-determination-for-bioaffinity-technologies-cypath-lung-effective-j-biaf-20231130monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-third-quarter-2023-financial-results-and-provides-busines-biaf-20231114monthly0.5https://www.biopharmawatch.com/news/BIAF/village-oaks-pathology-serivces-p-a-d-b-a-precision-pathology-services-financial-statement-biaf-20230920monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-second-quarter-2023-financial-results-and-provides-busine-biaf-20230814monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-first-quarter-2023-financial-results-san-antonio-texas-biaf-20230515monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-names-michael-dougherty-as-chief-financial-officer-san-antonio-te-biaf-20230501monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-presents-at-cleveland-clinic-lung-cancer-symposium-san-antonio-te-biaf-20230425monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-to-ring-nasdaq-closing-bell-today-san-antonio-texas-biaf-20230405monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-fourth-quarter-and-full-year-2022-financial-results-confe-biaf-20230403monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-publication-of-peer-reviewed-paper-on-proprietary-beads-biaf-20230328monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-biaf-20230324monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-appoints-julie-anne-overton-director-of-corporate-communications--biaf-20230213monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-publication-of-results-of-clinical-trial-in-peer-review-biaf-20230124monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-notice-to-award-u-s-patent-protecting-novel-compounds-f-biaf-20230104monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-expands-diagnostic-division-with-promotions-and-new-hires-to-stre-biaf-20221215monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-presents-proprietary-cancer-therapeutic-research-at-joint-ascb-em-biaf-20221201monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-sheila-habib-md-and-david-hill-md-join-the-company-s-sc-biaf-20221110monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-to-report-third-quarter-2022-financial-results-san-antonio-tx-biaf-20221108monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-award-of-therapeutic-patents-in-china-mexico-and-austra-biaf-20221025monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-presents-results-from-flow-cytometry-analysis-of-the-lung-at-ches-biaf-20221012monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-receives-additional-7-7m-from-exercise-of-warrants-total-capital--biaf-20220928monthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-pricing-of-ipo-san-antonio-tx-biaf-20220901monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-announces-adjournment-of-2025-annual-meeting-adjourns-2025-annual--xbio-20251211monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-third-quarter-2025-financial-results-continued-execution-o-xbio-20251113monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-announces-pricing-of-4-5-million-underwritten-offering-of-common-s-xbio-20251010monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-second-quarter-2025-financial-results-expanded-strategic-p-xbio-20250813monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-first-quarter-2025-financial-results-and-provides-business-xbio-20250514monthly0.5https://www.biopharmawatch.com/news/XBIO/confidential-draft-not-for-immediate-release-xenetic-biosciences-inc-reports-full-year-202-xbio-20250319monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-third-quarter-2024-financial-results-establishing-growing--xbio-20241113monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-extends-research-and-development-collaboration-with-the-scripps-re-xbio-20241107monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-second-quarter-2024-financial-results-and-provides-busines-xbio-20240814monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-announces-executive-leadership-transition-company-s-board-of-direc-xbio-20240522monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-first-quarter-2024-financial-results-and-provides-business-xbio-20240510monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-full-year-2023-financial-results-continued-advancement-of--xbio-20240322monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-third-quarter-2023-financial-results-encouraging-growing-b-xbio-20231110monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-second-quarter-2023-financial-results-company-continues-to-xbio-20230811monthly0.5https://www.biopharmawatch.com/news/XBIO/nasdaq-xbio-xeneticbio-com-corporate-presentation-june-2023-this-presentation-contains-for-xbio-20230606monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-announces-reverse-stock-split-of-common-stock-framingham-ma-xbio-20230512monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-first-quarter-2023-financial-results-and-provides-business-xbio-20230511monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-full-year-2022-financial-results-and-provides-business-upd-xbio-20230323monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-third-quarter-2022-financial-results-and-provides-business-xbio-20221110monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-second-quarter-2022-financial-results-and-provides-busines-xbio-20220812monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-engages-catalent-for-clinical-manufacturing-to-advance-dnase-based-xbio-20220707monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-expands-oncology-pipeline-with-in-licensing-of-dnase-based-oncolog-xbio-20220427monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-full-year-2021-financial-results-and-provides-business-upd-xbio-20220323monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-third-quarter-2021-financial-results-and-provides-business-xbio-20211112monthly0.5https://www.biopharmawatch.com/news/XBIO/expanding-the-potential-of-car-t-celltherapy-nasdaq-xbio-xeneticbio-com-investorpresentati-xbio-20210913monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-second-quarter-2021-financial-results-and-provides-busines-xbio-20210813monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-announces-closing-of-12-5-million-private-placement-priced-at-a-pr-xbio-20210728monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-first-quarter-2021-financial-results-continued-execution-o-xbio-20210512monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-fourth-quarter-and-full-year-2020-financial-results-drivin-xbio-20210317monthly0.5https://www.biopharmawatch.com/news/XBIO/expanding-the-potential-of-car-t-cell-therapy-nasdaq-xbio-xeneticbio-com-2021-investor-pre-xbio-20210119monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-announces-6-0-million-registered-direct-offering-priced-at-the-mar-xbio-20201210monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-third-quarter-2020-financial-results-and-provides-corporat-xbio-20201113monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-second-quarter-2020-financial-results-and-provides-corpora-xbio-20200813monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-announces-collaboration-with-pharmsynthez-and-multiple-academic-in-xbio-20200616monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-announces-research-and-development-collaboration-with-scripps-rese-xbio-20200519monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-first-quarter-2020-financial-results-and-provides-corporat-xbio-20200514monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-2019-year-end-results-and-provides-corporate-update-compan-xbio-20200327monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-third-quarter-2019-financial-results-and-provides-corporat-xbio-20191115monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-provides-business-outlook-recent-completion-of-acquisition-of-inno-xbio-20191008monthly0.5https://www.biopharmawatch.com/news/XBIO/enhancing-lives-with-transformative-therapies-www-xeneticbio-com-nasdaq-xbio-corporate-pre-xbio-20190909monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-second-quarter-2019-financial-results-and-provides-corpora-xbio-20190815monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-closes-15-0-million-underwritten-public-offering-and-completes-acq-xbio-20190722monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-nasdaq-xbio-announces-pricing-of-15-0-million-underwritten-public--xbio-20190717monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-announces-reverse-stock-split-of-common-stock-framingham-ma-xbio-20190624monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-reports-first-quarter-2019-financial-results-and-provides-corporat-xbio-20190513monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-announces-pricing-of-3-1-million-registered-direct-offering-xbio-20190305monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-inc-nasdaq-xbio-announces-agreement-to-acquire-innovative-car-t-techno-xbio-20190304monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-reports-2017-third-quarter-financial-results-and-provides-corporate-up-xbio-20171115monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-enters-into-sublicense-agreement-related-to-its-polyxen-technology-wit-xbio-20171102monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-appoints-jeffrey-f-eisenberg-as-chief-executive-officer-lexington-ma-xbio-20171031monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-reports-2017-second-quarter-financial-results-and-provides-business-up-xbio-20170815monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-announces-appointment-of-three-directors-to-the-board-new-board-appoin-xbio-20170814monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-receives-program-update-from-partner-shire-s-phase-1-2-study-evaluatin-xbio-20170522monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-expands-executive-management-team-with-appointment-of-james-f-parslow--xbio-20170404monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-appoints-curtis-a-lockshin-ph-d-as-chief-scientific-officer-lexington--xbio-20170104monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-expands-management-team-with-key-appointment-of-jeffrey-f-eisenberg-as-xbio-20161205monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-appoints-edward-j-benz-jr-m-d-former-dana-farber-ceo-to-its-board-of-d-xbio-20161122monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-appoints-jeffrey-f-eisenberg-to-the-board-of-directors-lexington-ma-xbio-20160711monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-announces-reverse-stock-split-in-preparation-for-proposed-uplisting-to-xbio-20160601monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-appoints-renowned-chemist-and-nobel-laureate-dr-roger-d-kornberg-to-bo-xbio-20160229monthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-appoints-timothy-cot-md-mph-former-head-of-fda-orphan-drug-division-to-xbio-20140210monthly0.5https://www.biopharmawatch.com/news/PCSA/exhibits-99-1-pcsa-20240221monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-inc-mourns-the-sudden-passing-of-board-member-virgil-thompson-han-pcsa-20231109monthly0.5https://www.biopharmawatch.com/news/PCSA/for-more-information-michael-floyd-mfloyd-processapharma-com-processa-pharmaceuticals-anno-pcsa-20201013monthly0.5https://www.biopharmawatch.com/news/PCSA/for-more-information-patrick-lin-plin-processapharma-com-925-683-3218-processa-pharmaceuti-pcsa-20200330monthly0.5https://www.biopharmawatch.com/news/PCSA/for-more-information-patrick-lin-plin-processapharma-com-925-683-3218-processa-pharmaceuti-pcsa-20200317monthly0.5https://www.biopharmawatch.com/news/PCSA/for-more-information-patrick-lin-plin-processapharma-com-925-683-3218-pcsa-20200305monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pcsa-20200225monthly0.5https://www.biopharmawatch.com/news/PCSA/for-more-information-patrick-lin-plin-processapharma-com-925-683-3218-pcsa-20200213monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-1-for-7-pcsa-20191220monthly0.5https://www.biopharmawatch.com/news/PCSA/for-more-information-patrick-lin-plin-processapharma-com-925-683-3218-processa-pharmaceuti-pcsa-20190109monthly0.5https://www.biopharmawatch.com/news/PCSA/for-more-information-patrick-lin-plin-processapharma-com-925-683-3218-processa-pharmaceuti-pcsa-20181206monthly0.5https://www.biopharmawatch.com/news/PCSA/for-more-information-patrick-lin-plin-processapharma-com-925-683-3218-processa-pharmaceuti-pcsa-20181002monthly0.5https://www.biopharmawatch.com/news/PCSA/for-more-information-patrick-lin-plin-processapharma-com-925-683-3218-pcsa-20180910monthly0.5https://www.biopharmawatch.com/news/PCSA/for-more-information-patrick-lin-plin-processapharma-com-925-683-3218-processa-pharmaceuti-pcsa-20180601monthly0.5https://www.biopharmawatch.com/news/PCSA/for-more-information-investor-relations-patrick-lin-plin-processapharma-com-925-683-3218-p-pcsa-20180321monthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-announces-reverse-stock-split-and-launches-new-website-hanover-md-pcsa-20171211monthly0.5https://www.biopharmawatch.com/news/PCSA/corporate-presentation-ex-99-1-pcsa-20171206monthly0.5https://www.biopharmawatch.com/news/PCSA/investor-presentation-ex-99-1-pcsa-20171020monthly0.5https://www.biopharmawatch.com/news/PCSA/financial-statements-of-promet-therapeutics-llc-ex-99-1-promet-therapeutics-llc-financial--pcsa-20171017monthly0.5https://www.biopharmawatch.com/news/PCSA/financial-statements-as-of-december-31-2015-and-december-31-2016-and-for-the-period-from-a-pcsa-20171012monthly0.5https://www.biopharmawatch.com/news/PCSA/heatwurx-inc-announces-execution-of-definitive-asset-purchase-agreement-with-promet-therap-pcsa-20171003monthly0.5https://www.biopharmawatch.com/news/PCSA/heatwurx-announces-letter-of-intent-with-promet-therapeutics-llc-relating-to-a-reverse-mer-pcsa-20170718monthly0.5https://www.biopharmawatch.com/news/PCSA/debt-conversion-agreement-ex-99-2-debt-conversion-agreement-this-debt-conversion-agreement-pcsa-20150707monthly0.5https://www.biopharmawatch.com/news/PCSA/senior-secured-loan-agreement-ex-99-1-senior-secured-loan-agreement-this-senior-secured-lo-pcsa-20150216monthly0.5https://www.biopharmawatch.com/news/PCSA/separation-and-severance-agreement-and-release-of-claims-ex-99-1-separation-and-severance--pcsa-20141028monthly0.5https://www.biopharmawatch.com/news/PCSA/exclusive-distribution-agreement-ex-99-1-exclusive-distribution-agreement-this-exclusive-d-pcsa-20141029monthly0.5https://www.biopharmawatch.com/news/PCSA/the-hoyt-organization-310-373-0103-kent-barrett-kbarrett-hoytorg-com-katherine-carson-kcar-pcsa-20140925monthly0.5https://www.biopharmawatch.com/news/PCSA/the-hoyt-organization-310-373-0103-kent-barrett-kbarrett-hoytorg-com-katherine-carson-kcar-pcsa-20140807monthly0.5https://www.biopharmawatch.com/news/PCSA/the-hoyt-organization-310-373-0103-kent-barrett-kbarrett-hoytorg-com-katherine-carson-kcar-pcsa-20140527monthly0.5https://www.biopharmawatch.com/news/PCSA/loan-agreement-ex-99-1-loan-agreement-this-loan-agreement-the-agreement-dated-pcsa-20140106monthly0.5https://www.biopharmawatch.com/news/PCSA/heatwurx-granted-additional-patent-from-the-u-s-patent-and-trademark-office-greenwood-vill-pcsa-20131028monthly0.5https://www.biopharmawatch.com/news/PCSA/heatwurx-equipment-granted-patent-from-the-u-s-patent-and-trademark-office-greenwood-villa-pcsa-20131021monthly0.5https://www.biopharmawatch.com/news/PCSA/heatwurx-announces-management-transition-greenwood-village-co-pcsa-20130927monthly0.5https://www.biopharmawatch.com/news/PCSA/potholes-beware-lake-elsinore-bringing-an-innovative-repair-weapon-to-battle-the-city-of-l-pcsa-20130710monthly0.5https://www.biopharmawatch.com/news/PCSA/press-release-ex99-1-pcsa-20130709monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-share-buyback-program-sarasota-fl-silo-20260223monthly0.5https://www.biopharmawatch.com/news/SILO/novel-therapeutics-for-unmet-medical-needs-investor-presentation-march-2025-forward-lookin-silo-20250310monthly0.5https://www.biopharmawatch.com/news/SILO/novel-therapeutics-for-unmet-medical-needs-investor-presentation-september-2024-forward-lo-silo-20240910monthly0.5https://www.biopharmawatch.com/news/SILO/fifth-amendment-to-c-ommercial-evaluation-and-license-agreement-this-fifth-amendment-to-co-silo-20230629monthly0.5https://www.biopharmawatch.com/news/SILO/corporate-presentation-nasdaq-silo-1-fall-2022-nasdaq-silo-statement-this-presentation-con-silo-20221018monthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psil-silo-20201202monthly0.5https://www.biopharmawatch.com/news/SILO/uppercut-brands-inc-changes-name-to-silo-pharma-inc-reflecting-company-s-emerging-focusing-silo-20200928monthly0.5https://www.biopharmawatch.com/news/SILO/june-2015-to-the-shareholders-of-point-capital-inc-point-capital-has-gotten-off-to-an-incr-silo-20150603monthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-provides-business-update-and-reports-third-quarter-fiscal-2025-financial-res-hscs-20250519monthly0.5https://www.biopharmawatch.com/news/HSCS/2-the-issuances-of-warrants-to-purchase-up-to-240-000-shares-of-common-stock-at-an-exercis-hscs-20240125monthly0.5https://www.biopharmawatch.com/news/HSCS/heart-test-laboratories-inc-announces-pricing-of-6-375-million-initial-public-offering-and-hscs-20220615monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-appoints-brian-kieser-and-kevin-harris-from-new-strategic-partner-sequence-lifescie-nxgl-20260506monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-appoints-ian-blackman-as-chief-financial-officer-veteran-financial-and-m-a-leader-a-nxgl-20260427monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-new-strategic-partner-sequence-lifescience-leads-financing-with-5-5-million-to-comp-nxgl-20260421monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-signs-definitive-agreement-to-license-and-acquire-transformative-portfolio-of-comme-nxgl-20260310monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-announces-financing-of-1-797-million-relating-to-an-acquisition-targeted-to-close-i-nxgl-20260210monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-announces-spin-off-of-drug-delivery-program-into-nexgelrx-nexgel-shareholders-will--nxgl-20251211monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-reports-third-quarter-2025-financial-results-langhorne-pa-nxgl-20251111monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-reports-second-quarter-2025-financial-results-second-quarter-2025-revenue-totaled-2-nxgl-20250812monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-appoints-chief-accounting-officer-of-shutterstock-steve-ciardiello-cpa-to-its-board-nxgl-20250805monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-announces-950-000-registered-direct-offering-and-concurrent-private-placement-langh-nxgl-20250801monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-and-stada-ag-announce-expansion-of-partnership-for-north-america-langhorne-pa-nxgl-20250714monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-reports-first-quarter-2025-financial-results-first-quarter-2025-revenue-totaled-2-8-nxgl-20250513monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-reports-record-fourth-quarter-and-full-year-2024-financial-results-fourth-quarter-2-nxgl-20250324monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-issues-letter-to-shareholders-and-provides-guidance-for-2024-and-2025-management-ex-nxgl-20250122monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-appoints-joseph-f-mcguire-as-chief-financial-officer-langhorne-pa-nxgl-20250102monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-reports-record-third-quarter-2024-revenue-of-2-94-million-an-increase-of-141-year-o-nxgl-20241113monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-announces-2-000-000-registered-direct-offering-langhorne-pa-nxgl-20241111monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-preannounces-expected-record-third-quarter-2024-revenue-of-2-85-million-an-increase-nxgl-20241010monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-reports-record-second-quarter-2024-revenue-of-1-44-million-langhorne-pa-nxgl-20240814monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-announces-1-110-000-registered-direct-offering-led-by-insiders-langhorne-pa-nxgl-20240812monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-announces-preliminary-record-second-quarter-2024-revenue-of-1-4-million-and-issues--nxgl-20240708monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-acquires-international-beauty-brand-silly-george-acquisition-further-expands-nexgel-nxgl-20240516monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-reports-first-quarter-2024-revenue-of-1-27-million-an-increase-of-104-year-over-yea-nxgl-20240513monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-reports-full-year-2023-revenue-of-4-1-million-an-increase-of-99-7-year-over-year-la-nxgl-20240401monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-announces-975-000-registered-direct-offering-led-by-insiders-langhorne-pa-nxgl-20240221monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-announces-partnership-with-stada-to-distribute-and-commercialize-consumer-health-ot-nxgl-20231211monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-acquires-kenkoderm-psoriasis-skincare-line-acquisition-expands-nexgel-s-health-and--nxgl-20231205monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-reports-record-third-quarter-2023-revenue-of-1-2-million-an-increase-of-115-year-ov-nxgl-20231113monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-secures-supply-agreement-with-abbvie-langhorne-pa-nxgl-20231030monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-reports-second-quarter-2023-record-revenue-of-1-17-million-an-increase-of-108-year--nxgl-20230814monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-reports-first-quarter-2023-financial-results-2023-first-quarter-revenue-increased-5-nxgl-20230515monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-reports-fourth-quarter-and-full-year-2022-financial-results-2022-revenue-increased--nxgl-20230327monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-acquires-50-interest-in-newly-formed-joint-venture-with-c-g-laboratories-for-conver-nxgl-20230302monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-appoints-scott-henry-cfa-to-board-of-directors-and-audit-committee-langhorne-pa-nxgl-20230117monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-announces-share-repurchase-program-langhorne-pa-nxgl-20221207monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-reports-third-quarter-2022-financial-results-revenue-increased-69-6-yoy-while-gross-nxgl-20221108monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-reports-second-quarter-2022-financial-results-second-quarter-2022-revenue-increased-nxgl-20220810monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-reports-first-quarter-2022-financial-results-first-quarter-2022-revenue-increased-4-nxgl-20220512monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-reports-fourth-quarter-and-full-year-2021-financial-results-full-year-2021-revenue--nxgl-20220321monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-announces-the-launch-of-medagel-clearcomfort-hydrogel-patch-clearcomfort-patches-pr-nxgl-20220112monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-provides-2021-year-in-review-significant-progress-developing-and-identifying-innova-nxgl-20211231monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-inc-announces-listing-on-nasdaq-and-pricing-of-14-2-million-initial-public-offering-nxgl-20211221monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-announces-appointment-of-miranda-toledano-to-board-of-directors-ms-toledano-brings--nxgl-20210909monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-reports-preliminary-second-quarter-2021-financial-results-and-provides-corporate-up-nxgl-20210722monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-appoints-adam-drapczuk-as-chief-financial-officer-mr-drapczuk-brings-nearly-two-dec-nxgl-20210601monthly0.5https://www.biopharmawatch.com/news/NXGL/for-immediate-release-nxgl-20200529monthly0.5https://www.biopharmawatch.com/news/NXGL/nexgel-inc-announces-the-appointment-of-dr-jerome-zeldis-its-board-of-directors-nexgel-inc-nxgl-20200403monthly0.5https://www.biopharmawatch.com/news/NXGL/aquamed-releases-letter-to-stockholders-to-the-new-stockholders-of-aquamed-technologies-in-nxgl-20190621monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-reports-financial-results-and-provides-corporate-update-for-first-quar-envb-20260515monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-exercise-of-warrants-for-3-1-million-gross-proceeds-envb-20251211monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results-in-q3-enver-envb-20251114monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-reverse-stock-split-common-stock-will-begin-trading-on-a-spl-envb-20251023monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-exercise-of-warrants-for-2-2-million-gross-proceeds-envb-20250917monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-relocates-corporate-headquarters-to-cambridge-ma-move-aligns-with-comp-envb-20250902monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-reports-second-quarter-2025-financial-and-corporate-results-q2-marked--envb-20250814monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-reports-first-quarter-2025-financial-and-corporate-results-corporate-b-envb-20250514monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-reports-financial-results-and-provides-corporate-update-for-fourth-qua-envb-20250331monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-pricing-of-5-million-public-offering-envb-20250130monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-reports-third-quarter-2024-financial-and-corporate-results-advanced-pr-envb-20241114monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-signs-out-licensing-agreement-with-mycomedica-life-sciences-for-eb-002-envb-20241112monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-reports-second-quarter-2024-financial-and-corporate-results-prioritize-envb-20240812monthly0.5https://www.biopharmawatch.com/news/ENVB/aries-science-technology-and-enveric-biosciences-announce-licensing-agreement-aries-to-cli-envb-20240715monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-reports-first-quarter-2024-financial-and-corporate-results-revealed-se-envb-20240515monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-reports-financial-results-and-provides-corporate-update-for-fourth-qua-envb-20240326monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-signs-non-binding-term-sheets-to-pursue-the-exclusive-out-licensing-of-envb-20240319monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-signs-non-binding-term-sheets-to-pursue-the-exclusive-out-licensing-of-envb-20240229monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-unveils-library-of-preclinical-compounds-across-multiple-distinct-mole-envb-20240221monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-updates-key-data-underpinning-selection-of-eb-003-as-lead-drug-candida-envb-20240103monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-exercise-of-warrants-and-issuance-of-new-warrants-in-a-priva-envb-20231229monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-selects-eb-003-as-lead-drug-candidate-from-evm301-series-enveric-to-in-envb-20231228monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-reports-year-end-progress-for-preclinical-development-of-lead-prodrug--envb-20231227monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-selects-development-candidates-from-evm301-series-based-on-potential-t-envb-20231205monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-development-of-glycosylate-envb-20231129monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-reports-third-quarter-2023-corporate-and-financial-results-evm-301-ser-envb-20231113monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-development-of-c4-carbonot-envb-20231031monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-to-present-at-the-centurion-one-5-th-global-summit-ceo-joseph-tucker-p-envb-20231020monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-initiates-glp-toxicology-safety-pharmacology-studies-for-lead-candidat-envb-20231018monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-two-poster-presentations-at-the-6-th-neuropsychiatric-drug-d-envb-20231011monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-its-psybrary-portfolio-now-totals-over-1000-psychedelic-insp-envb-20231003monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-publication-of-a-paper-describing-a-novel-bioproduction-plat-envb-20230927monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-expands-ip-portfolio-with-new-u-s-patent-for-novel-carboxylated-psiloc-envb-20230920monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-to-present-poster-highlighting-evm301-series-at-the-international-conf-envb-20230918monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-files-provisional-patent-application-for-ai-based-computational-method-envb-20230911monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-new-u-s-patent-for-c4-carboxylic-acid-substituted-tryptamine-envb-20230905monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-strengthens-intellectual-property-portfolio-with-new-u-s-patent-for-tr-envb-20230828monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-completes-manufacturing-of-eb-373-to-supply-drug-material-for-completi-envb-20230821monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-reports-second-quarter-2023-corporate-and-financial-results-advanced-p-envb-20230814monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-reports-positive-results-from-preclinical-studies-supporting-metabolic-envb-20230724monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-reports-positive-results-from-animal-studies-demonstrating-oral-bioava-envb-20230717monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-two-poster-presentations-at-the-canadian-chemistry-conferenc-envb-20230607monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-evm301-series-of-drug-cand-envb-20230605monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-poster-presentation-at-canadian-neuroscience-meeting-2023-envb-20230530monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substit-envb-20230524monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-manuscript-detailing-the-development-of-novel-psilocin-prodr-envb-20230522monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-to-participate-in-2023-bio-international-convention-in-boston-envb-20230519monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-novel-prodrug-of-psilocin--envb-20230518monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-to-participate-in-benzinga-psychedelics-capital-conference-ceo-joseph--envb-20230410monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-reports-fourth-quarter-and-year-end-2022-corporate-and-financial-resul-envb-20230403monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-selects-australian-cro-avance-clinical-in-preparation-for-phase-1-stud-envb-20230323monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-establishes-australia-based-subsidiary-to-accelerate-its-lead-psilocin-envb-20230321monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-bioproduction-platform-using-novel-cane-toad-enzyme-for-psyc-envb-20230314monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-appoints-kevin-coveney-as-chief-financial-officer-and-reports-induceme-envb-20230228monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-names-lynn-gallant-vice-president-clinical-operations-and-reports-indu-envb-20230223monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-8-million-registered-direct-offering-and-private-placement-p-envb-20220725monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-formation-of-scientific-advisory-board-to-drive-further-grow-envb-20220719monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-reverse-stock-split-common-stock-will-begin-trading-on-a-spl-envb-20220715monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-advances-drug-development-for-mental-health-indications-and-intellectu-envb-20220713monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-plans-to-spin-off-and-dividend-its-cannabinoid-pipeline-to-s-envb-20220511monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-distribution-of-series-c-preferred-stock-to-holders-of-its-c-envb-20220503monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-reports-full-year-2021-financial-results-and-provides-business-update-envb-20220331monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-publication-of-four-patent-applications-for-psychedelic-insp-envb-20220315monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-files-portfolio-of-patent-applications-for-tryptamine-based-molecules--envb-20220301monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-proposed-public-offering-envb-20220210monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-successful-synthesis-and-filing-of-provisional-patent-for-ev-envb-20220208monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-ceo-dr-joseph-tucker-provides-2021-year-in-review-and-2022-outlook-in--envb-20220118monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-artificial-intelligence-platform-psyai-tm-has-identified-via-envb-20211005monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-closing-of-magicmed-industries-acquisition-enveric-intends-t-envb-20210917monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-approval-from-israel-s-ministry-of-health-to-begin-its-phase-envb-20210708monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-announces-definitive-agreement-to-acquire-magicmed-industries-a-pharma-envb-20210524monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-reports-first-quarter-2021-financial-results-envb-20210518monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-appoints-carter-ward-as-chief-financial-officer-envb-20210412monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-reports-full-year-2020-financial-results-and-provides-shareholder-upda-envb-20210401monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-appoints-dr-douglas-d-lind-to-company-s-board-of-directors-envb-20210318monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-signs-definitive-agreement-to-acquire-exclusive-license-for-novel-mole-envb-20210310monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-launches-development-collaboration-and-supply-agreement-with-pureform--envb-20210225monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-inc-announces-closing-of-12-8-million-registered-direct-offering-of-co-envb-20210212monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-inc-announces-12-8-million-registered-direct-offering-naples-fl-envb-20210209monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-inc-announces-closing-of-10-million-registered-direct-offering-envb-20210115monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-inc-announces-10-million-registered-direct-offering-priced-at-the-mark-envb-20210112monthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-appoints-dr-marcus-schabacker-to-board-of-directors-industry-veteran-b-envb-20210105monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri-holdings-announces-1-for-4-reverse-stock-split-immediately-following-the-spin-off-an-envb-20201231monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri-holdings-stockholders-approve-all-proposals-to-complete-tender-offer-for-jay-pharma--envb-20201229monthly0.5https://www.biopharmawatch.com/news/ENVB/jay-pharma-inc-unaudited-condensed-financial-statements-for-the-nine-months-ended-septembe-envb-20201223monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri-holdings-amalgamation-partner-jay-pharma-reports-irb-approval-for-testing-proprietar-envb-20200602monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri-holdings-to-merge-with-jay-pharma-inc-evidence-based-cannabinoid-medicine-wellness-c-envb-20200113monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-regains-compliance-with-nasdaq-listing-rule-5550-a-2-atlanta-ga-envb-20191213monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri00-announces-1-for-25-reverse-stock-split-to-regain-nasdaq-compliance-common-stock-to-envb-20191125monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri-holdings-announces-adjournment-of-annual-meeting-of-stockholders-until-envb-20191030monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri-holdings-announces-warrant-exchange-eliminates-all-adverse-warrants-atlanta-ga-envb-20190920monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri-holdings-announces-exploration-of-strategic-alternatives-to-maximize-shareholder-val-envb-20190826monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-granted-180-day-envb-20190617monthly0.5https://www.biopharmawatch.com/news/ENVB/to-the-board-of-directors-and-management-of-ameri-holdings-inc-i-hereby-resign-from-the-bo-envb-20190328monthly0.5https://www.biopharmawatch.com/news/ENVB/to-the-board-of-directors-and-management-of-ameri-holdings-inc-i-hereby-resign-from-the-bo-envb-20190211monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-envb-20181212monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-reports-second-consecutive-quarter-of-year-over-year-adjusted-ebitda-profitabilit-envb-20181114monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-appoints-barry-kostiner-chief-financial-officer-experienced-mergers-and-acquisiti-envb-20181017monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-announces-600-000-follow-on-investment-in-connection-with-recently-completed-6-00-envb-20180822monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-announces-results-of-2018-annual-meeting-of-stockholders-atlanta-ga-envb-20180817monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-reports-positive-adjusted-ebitda-for-the-second-quarter-of-2018-achieves-profitab-envb-20180814monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-announces-6-000-000-private-placement-atlanta-ga-envb-20180725monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-secures-amendment-to-preferred-stock-agreement-resulting-in-an-anticipated-1-5-mi-envb-20180626monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-announces-first-quarter-2018-financial-results-management-to-host-conference-call-envb-20180515monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-announces-fourth-quarter-and-full-year-2017-financial-results-reaffirms-financial-envb-20180402monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri-holdings-promotes-evp-brent-kelton-to-ceo-sap-veteran-to-lead-company-in-its-next-st-envb-20171227monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri-holdings-prices-public-offering-and-lists-on-the-nasdaq-capital-market-princeton-n-j-envb-20171117monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri-holdings-inc-announces-financial-results-for-the-third-quarter-of-2017-ameri-holding-envb-20171114monthly0.5https://www.biopharmawatch.com/news/ENVB/ex-99-1-ameri-holdings-inc-announces-financial-results-for-the-second-quarter-of-2017-amer-envb-20170818monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri-holdings-announces-financial-results-for-q1-2017-strategic-partnership-with-nec-corp-envb-20170516monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-announces-appointment-of-chief-financial-officer-pr-newswire-envb-20170425monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri-holdings-announces-financial-results-for-q4-2016-and-fy2016-annual-revenue-in-2016-o-envb-20170406monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-offers-to-merge-with-ciber-offer-price-of-0-75-per-cbr-share-merger-would-create--envb-20170313monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-acquires-atcg-a-sap-cloud-services-firm-princeton-n-j-envb-20170310monthly0.5https://www.biopharmawatch.com/news/ENVB/to-ameri100-s-report-on-form-8-k-filed-with-the-securities-and-exchange-commission-on-envb-20161114monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-completes-acquisition-of-sap-consulting-firm-dc-m-partners-l-l-c-acquisition-rein-envb-20160801monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-completes-acquisition-of-sap-consulting-firm-virtuoso-acquisition-reinforces-amer-envb-20160725monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-secures-10-million-financing-with-sterling-national-bank-princeton-nj-envb-20160706monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-acquires-sap-consulting-firm-bigtech-software-princeton-nj-envb-20160629monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri100-appoints-former-infosys-cfo-as-new-board-member-princeton-nj-envb-20160628monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri-holdings-inc-announces-completion-of-private-placement-princeton-nj-envb-20160421monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri-holdings-inc-announces-appointment-of-new-chief-financial-officer-princeton-nj-envb-20160128monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri-holdings-reports-financial-results-for-the-quarter-ended-envb-20151123monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri-holdings-inc-completes-acquisition-of-bellsoft-inc-transaction-reinforces-ameri-s-ac-envb-20151120monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri-holdings-reports-financial-results-for-the-quarter-ended-envb-20150819monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri-and-partners-inc-and-subsidiaries-consolidated-financial-statements-year-ended-envb-20150601monthly0.5https://www.biopharmawatch.com/news/ENVB/ameri-holdings-inc-becomes-a-public-company-completes-private-placement-of-up-to-10-millio-envb-20150526monthly0.5https://www.biopharmawatch.com/news/ENVB/investor-relations-henry-r-mandell-chairman-spatializer-audio-laboratories-inc-spatializer-envb-20080408monthly0.5https://www.biopharmawatch.com/news/ENVB/investor-relations-henry-r-mandell-chairman-spatializer-audio-laboratories-inc-spatializer-envb-20080331monthly0.5https://www.biopharmawatch.com/news/ENVB/spatializer-audio-laboratories-announces-second-quarter-financial-results-los-angeles-aug--envb-20070813monthly0.5https://www.biopharmawatch.com/news/ENVB/investor-relations-henry-r-mandell-chairman-spatializer-audio-laboratories-inc-spatializer-envb-20070702monthly0.5https://www.biopharmawatch.com/news/ENVB/investor-relations-henry-r-mandell-chairman-spatializer-audio-laboratories-inc-investor-sp-envb-20070510monthly0.5https://www.biopharmawatch.com/news/ENVB/source-spatializer-audio-laboratories-inc-spatializer-audio-laboratories-announces-year-en-envb-20070402monthly0.5https://www.biopharmawatch.com/news/ENVB/exv99w1-spatializer-audio-laboratories-announces-results-of-stockholder-vote-los-angeles-f-envb-20070221monthly0.5https://www.biopharmawatch.com/news/ENVB/investor-relations-henry-r-mandell-chairman-spatializer-audio-laboratories-inc-investor-sp-envb-20070125monthly0.5https://www.biopharmawatch.com/news/ENVB/exv99w1-contact-investor-relations-henry-r-mandell-chairman-spatializer-audio-laboratories-envb-20061114monthly0.5https://www.biopharmawatch.com/news/ENVB/investor-relations-henry-r-mandell-spatializer-audio-laboratories-inc-investor-spatializer-envb-20060919monthly0.5https://www.biopharmawatch.com/news/ENVB/investor-relations-henry-r-mandell-chairman-spatializer-audio-laboratories-inc-investor-sp-envb-20060814monthly0.5https://www.biopharmawatch.com/news/ENVB/investor-relations-henry-r-mandell-chairman-spatializer-audio-laboratories-inc-investor-sp-envb-20060515monthly0.5https://www.biopharmawatch.com/news/ENVB/to-business-and-technology-editors-spatializer-audio-laboratories-inc-reports-year-end-res-envb-20060403monthly0.5https://www.biopharmawatch.com/news/ENVB/exv99w1-contact-investor-relations-henry-r-mandell-spatializer-audio-laboratories-inc-408--envb-20060221monthly0.5https://www.biopharmawatch.com/news/ENVB/investor-relations-henry-r-mandell-chairman-spatializer-audio-laboratories-inc-408-453-418-envb-20060110monthly0.5https://www.biopharmawatch.com/news/ENVB/investor-relations-henry-r-mandell-spatializer-audio-laboratories-inc-408-453-4180-ext-201-envb-20051222monthly0.5https://www.biopharmawatch.com/news/ENVB/investor-relations-henry-r-mandell-ceo-spatializer-audio-laboratories-inc-408-453-4180-ext-envb-20051107monthly0.5https://www.biopharmawatch.com/news/ENVB/investor-relations-henry-r-mandell-ceo-spatializer-audio-laboratories-inc-408-453-4180-ext-envb-20050810monthly0.5https://www.biopharmawatch.com/news/ENVB/investor-relations-henry-r-mandell-ceo-spatializer-audio-laboratories-inc-408-453-4180-ext-envb-20050512monthly0.5https://www.biopharmawatch.com/news/ENVB/exv99w1-contact-investor-relations-henry-r-mandell-ceo-spatializer-audio-laboratories-inc--envb-20050323monthly0.5https://www.biopharmawatch.com/news/ENVB/spatializer-audio-laboratories-inc-logo-contact-investor-relations-spatializer-audio-labor-envb-20041111monthly0.5https://www.biopharmawatch.com/news/ENVB/spatializer-audio-laboratories-inc-logo-contact-investor-relations-henry-r-mandell-ceo-spa-envb-20040822monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-declares-first-quarter-2023-dividen-mtex-20230525monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-announces-new-tiered-affiliate-prog-mtex-20230523monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-announces-formation-of-subsidiary-t-mtex-20230418monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-declares-fourth-quarter-2022-divide-mtex-20230306monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-declares-third-quarter-2022-dividen-mtex-20221111monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-announces-share-repurchase-program--mtex-20220920monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-declares-second-quarter-2022-divide-mtex-20220830monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-declares-first-quarter-2022-dividen-mtex-20220603monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-declares-fourth-quarter-2021-divide-mtex-20220304monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-declares-special-2021-dividend-flow-mtex-20211122monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-announces-share-repurchase-program--mtex-20210921monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-declares-second-quarter-2021-divide-mtex-20210831monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-declares-first-quarter-2021-dividen-mtex-20210524monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-declares-fourth-quarter-2020-divide-mtex-20210302monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-declares-special-2020-dividend-flow-mtex-20201120monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-declares-increased-second-quarter-2-mtex-20200828monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-announces-share-repurchase-program--mtex-20200814monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-declares-first-quarter-2020-dividen-mtex-20200527monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-declares-fourth-quarter-2019-divide-mtex-20200214monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-announces-share-repurchase-program--mtex-20191220monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-declares-third-quarter-2019-dividen-mtex-20191118monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-declares-second-quarter-2019-divide-mtex-20190815monthly0.5https://www.biopharmawatch.com/news/MTEX/donna-giordano-972-471-6512-ir-mannatech-com-mannatech-declares-first-quarter-2019-dividen-mtex-20190531monthly0.5https://www.biopharmawatch.com/news/MTEX/diane-barton-972-471-8116-pr-mannatech-com-mannatech-declares-fourth-quarter-2018-dividend-mtex-20190312monthly0.5https://www.biopharmawatch.com/news/MTEX/diane-barton-972-471-8116-pr-mannatech-com-update-mannatech-declares-third-quarter-2018-di-mtex-20181204monthly0.5https://www.biopharmawatch.com/news/MTEX/diane-barton-972-471-8116-pr-mannatech-com-mannatech-declares-third-quarter-2018-dividend--mtex-20181114monthly0.5https://www.biopharmawatch.com/news/MTEX/diane-barton-972-471-8116-pr-mannatech-com-mannatech-announces-share-repurchase-flower-mou-mtex-20180810monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-announces-intent-to-commence-a-cash-tender-offer-to-purchase-up-to-16-million-of-mtex-20180517monthly0.5https://www.biopharmawatch.com/news/MTEX/diane-barton-972-471-8116-pr-mannatech-com-mannatech-declares-first-quarter-2018-dividend--mtex-20180510monthly0.5https://www.biopharmawatch.com/news/MTEX/diane-barton-972-471-8116-pr-mannatech-com-mannatech-declares-fourth-quarter-2017-dividend-mtex-20180312monthly0.5https://www.biopharmawatch.com/news/MTEX/diane-barton-972-471-8116-pr-mannatech-com-mannatech-declares-third-quarter-2017-dividend--mtex-20171117monthly0.5https://www.biopharmawatch.com/news/MTEX/kalyn-dabbs-972-471-7245-pr-mannatech-com-mannatech-declares-second-quarter-2017-dividend--mtex-20170814monthly0.5https://www.biopharmawatch.com/news/MTEX/kalyn-dabbs-972-471-7245-pr-mannatech-com-mannatech-declares-first-quarter-2017-dividend-c-mtex-20170602monthly0.5https://www.biopharmawatch.com/news/MTEX/kalyn-dabbs-972-471-7245-pr-mannatech-com-mannatech-declares-fourth-quarter-2016-dividend--mtex-20170223monthly0.5https://www.biopharmawatch.com/news/MTEX/kalyn-dabbs-972-471-7245-pr-mannatech-com-mannatech-appoints-kevin-robbins-to-board-of-dir-mtex-20161208monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-declares-third-quarter-2016-dividend-coppell-texas-mtex-20161115monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-third-quarter-2016-financial-results-coppell-texas-mtex-20161108monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-announces-share-repurchase-coppell-texas-mtex-20160831monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-declares-second-quarter-2016-dividend-coppell-texas-mtex-20160812monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-second-quarter-2016-financial-results-coppell-texas-mtex-20160809monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-first-quarter-2016-financial-results-coppell-texas-mtex-20160511monthly0.5https://www.biopharmawatch.com/news/MTEX/kalyn-dabbs-972-471-7245-pr-mannatech-com-mannatech-promotes-chief-accounting-officer-to-c-mtex-20160421monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-fourth-quarter-2015-financial-results-coppell-texas-mtex-20160315monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-promotes-president-alfredo-bala-to-ceo-coppell-texas-mtex-20150811monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-second-quarter-2015-financial-results-coppell-texas-mtex-20150804monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-first-quarter-2015-financial-results-coppell-texas-mtex-20150512monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-appoints-linda-k-ferrell-ph-d-to-board-of-directors-mtex-20150402monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-fourth-quarter-and-year-end-results-2014-net-sales-increase-7-1-2014-ope-mtex-20150304monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-third-quarter-2014-financial-results-coppell-texas-mtex-20141104monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-appoints-eric-w-schrier-to-board-of-directors-coppell-texas-mtex-20141103monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-second-quarter-2014-financial-results-coppell-texas-mtex-20140805monthly0.5https://www.biopharmawatch.com/news/MTEX/ben-hulet-972-471-7224-bhulet-mannatech-com-mannatech-supports-global-growth-with-appointm-mtex-20140609monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-first-quarter-2014-financial-results-coppell-texas-mtex-20140430monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-fourth-quarter-and-year-end-results-coppell-texas-mtex-20140312monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-third-quarter-2013-financial-results-coppell-texas-mtex-20131113monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-second-quarter-2013-financial-results-coppell-texas-mtex-20130731monthly0.5https://www.biopharmawatch.com/news/MTEX/correcting-replacing-mannatech-reports-first-quarter-2013-financial-results-coppell-texas-mtex-20130509monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-first-quarter-2013-financial-results-coppell-texas-mtex-20130509monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-fourth-quarter-and-year-end-results-coppell-texas-mtex-20130325monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-incorporated-announces-commencement-of-stock-option-exchange-coppell-texas-mtex-20100716monthly0.5https://www.biopharmawatch.com/news/MTEX/first-amendment-to-the-mannatech-incorporated-2008-stock-incentive-plan-this-first-amendme-mtex-20100611monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-first-quarter-results-cost-of-sales-and-commission-costs-continue-in-lin-mtex-20100505monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-fourth-quarter-year-end-results-cost-of-sales-and-commission-costs-retur-mtex-20100310monthly0.5https://www.biopharmawatch.com/news/MTEX/allison-lowe-972-499-6631-allison-lowe-hck2-com-mannatech-promotes-key-executives-supports-mtex-20100226monthly0.5https://www.biopharmawatch.com/news/MTEX/robert-c-blattberg-35-watergate-drive-sarasota-fl-34236-mtex-20091221monthly0.5https://www.biopharmawatch.com/news/MTEX/wayne-l-badovinus-8608-doral-court-west-flower-mound-tx-75022-mtex-20091130monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-third-quarter-results-higher-commission-rate-impacts-earnings-recruiting-mtex-20091103monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-names-new-svp-and-chief-global-marketing-officer-claire-zevalkink-brings-more-th-mtex-20090902monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-suspends-dividend-coppell-tx-mtex-20090821monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-second-quarter-results-higher-commission-rate-impacts-earnings-recruitin-mtex-20090804monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-set-to-significantly-expand-global-footprint-by-adding-presence-in-four-addition-mtex-20090722monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-announces-results-of-annual-shareholders-meeting-mannatech-announces-results-of--mtex-20090611monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-declares-dividend-annual-shareholders-meeting-scheduled-for-mtex-20090521monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-first-quarter-results-higher-commission-rate-temporarily-impacts-earning-mtex-20090506monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-fourth-quarter-results-continued-cost-containment-north-america-sales-de-mtex-20090311monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-names-new-svp-of-global-business-operations-randy-bancino-brings-more-than-25-ye-mtex-20090306monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reaches-settlement-with-texas-attorney-general-coppell-texas-mtex-20090226monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-declares-dividend-coppell-tx-mtex-20090220monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-founder-sam-caster-steps-down-from-the-company-s-board-j-stanley-fredrick-electe-mtex-20090202monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-declares-dividend-coppell-tx-mtex-20081119monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-announces-departure-of-chief-operating-officer-coppell-tx-mtex-20081112monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-third-quarter-results-operating-profit-turnaround-north-america-sales-de-mtex-20081106monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-receives-notice-of-termination-of-sec-investigation-coppell-texas-mtex-20081104monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-receives-wells-notice-on-previously-disclosed-inquiry-coppell-texas-mtex-20080905monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-names-new-svp-and-chief-marketing-officer-terri-maxwell-brings-over-20-years-of--mtex-20080902monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-declares-dividend-coppell-tx-mtex-20080827monthly0.5https://www.biopharmawatch.com/news/MTEX/transcript-of-mannatech-inc-mtex-second-quarter-2008-earnings-conference-call-mtex-20080808monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-second-quarter-results-sales-and-earnings-decline-additional-accrual-mad-mtex-20080808monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-sees-slower-market-growth-affecting-second-quarter-2008-results-company-plans-on-mtex-20080801monthly0.5https://www.biopharmawatch.com/news/MTEX/judge-validates-both-mannatech-ambrotose-patents-in-case-against-glycoproducts-internation-mtex-20080711monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-announces-corporate-staff-and-expense-reductions-operating-expense-reductions-co-mtex-20080710monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-announces-results-of-annual-shareholders-and-board-of-directors-meetings-shareho-mtex-20080619monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reaches-settlement-in-derivative-shareholder-lawsuits-mannatech-admits-no-wrongd-mtex-20080613monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-names-new-chief-executive-officer-president-wayne-badovinus-brings-more-than-40--mtex-20080605monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-first-quarter-results-sales-and-earnings-decline-launch-of-global-sales--mtex-20080509monthly0.5https://www.biopharmawatch.com/news/MTEX/indicates-omitted-material-that-is-the-subject-of-a-confidential-treatment-request-filed-s-mtex-20080508monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-declares-dividend-coppell-tx-mtex-20080502monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-adds-robert-toth-to-board-of-directors-toth-brings-more-than-27-years-of-industr-mtex-20080325monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reaches-settlement-in-securities-class-action-lawsuit-settlement-subject-to-fina-mtex-20080320monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-fourth-quarter-and-full-year-2007-sales-and-earnings-decline-additional--mtex-20080314monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-declares-dividend-coppell-tx-mtex-20080225monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-incorporated-issues-correction-concerning-litigation-coppell-tx-mtex-20080128monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-declares-dividend-coppell-tx-mtex-20071107monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-third-quarter-2007-earnings-continue-lower-progress-in-expense-reduction-mtex-20071108monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-declares-dividend-coppell-tx-mtex-20070927monthly0.5https://www.biopharmawatch.com/news/MTEX/bala-named-mannatech-s-senior-vice-president-of-global-sales-and-marketing-mannatech-hires-mtex-20070918monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-adds-distinguished-kellogg-professor-robert-blattberg-to-board-appointment-follo-mtex-20070907monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-s-founder-sam-caster-resigns-as-ceo-remains-as-chairman-current-president-coo-te-mtex-20070821monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-inc-reports-second-quarter-2007-net-sales-up-6-1-eps-decrease-of-80-6-coppell-tx-mtex-20070808monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-inc-pre-announces-second-quarter-2007-results-preliminary-net-sales-up-6-signifi-mtex-20070727monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-declares-dividend-and-announces-results-of-shareholders-meeting-shareholders-app-mtex-20070615monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-incorporated-consolidated-balance-sheets-in-thousands-except-share-and-per-share-mtex-20070507monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-incorporated-announces-increase-in-quarterly-dividend-coppell-tx-nasdaq-mtex-mtex-20070412monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-inc-reports-record-fourth-quarter-sales-coppell-tx-mtex-20070315monthly0.5https://www.biopharmawatch.com/news/MTEX/indicates-omitted-material-that-is-the-subject-of-a-confidential-treatment-request-filed-s-mtex-20070131monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-expresses-optimism-and-announces-new-us-patent-coppell-tx-mtex-20070104monthly0.5https://www.biopharmawatch.com/news/MTEX/fourth-amendment-to-employment-agreement-this-fourth-amendment-to-the-employment-agreement-mtex-20061121monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-inc-reports-third-quarter-earnings-coppell-tx-mtex-20061109monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-incorporated-declares-dividend-coppell-tx-nasdaq-mtex-mtex-20061002monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-inc-announces-share-purchase-plan-coppell-tx-mtex-20060831monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-announces-new-senior-vice-president-and-general-counsel-coppell-tx-mtex-20060829monthly0.5https://www.biopharmawatch.com/news/MTEX/amendment-to-consulting-agreement-this-amendment-to-consulting-agreement-this-amendment-is-mtex-20060815monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-inc-reports-record-second-quarter-earnings-diluted-e-p-s-of-0-31-increased-48-pe-mtex-20060809monthly0.5https://www.biopharmawatch.com/news/MTEX/employment-agreement-this-employment-agreement-this-agreement-is-entered-into-by-and-betwe-mtex-20060627monthly0.5https://www.biopharmawatch.com/news/MTEX/employment-agreement-this-employment-agreement-this-agreement-is-entered-into-by-and-betwe-mtex-20060614monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-announces-dividend-coppell-texas-mtex-20060614monthly0.5https://www.biopharmawatch.com/news/MTEX/litigation-consulting-and-separation-agreement-this-litigation-consulting-and-separation-a-mtex-20060602monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-announces-management-change-coppell-tx-5-16-06-mannatech-inc-nasdaq-mtex-today-a-mtex-20060519monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-first-quarter-eps-increase-of-29-coppell-texas-mtex-20060510monthly0.5https://www.biopharmawatch.com/news/MTEX/effective-mtex-20060419monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-announces-dividend-coppell-tx-mtex-20060314monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-reports-record-sales-earnings-for-2005-annual-operating-income-grows-72-exceeds--mtex-20060308monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-expects-to-announce-record-annual-sales-coppell-tx-mtex-20060213monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-inc-appoints-larry-a-jobe-to-board-of-directors-coppell-tx-mtex-20060104monthly0.5https://www.biopharmawatch.com/news/MTEX/employment-agreement-this-employment-agreement-this-agreement-is-entered-into-by-and-betwe-mtex-20051123monthly0.5https://www.biopharmawatch.com/news/MTEX/consulting-agreement-this-exclusive-consulting-agreement-is-made-and-effective-the-16-th-d-mtex-20051116monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-inc-increases-quarterly-dividend-14-coppell-tx-nasdaq-mtex-mtex-20051114monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-announces-record-quarterly-net-income-and-e-p-s-net-sales-exceeded-100-million-f-mtex-20051109monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-incorporated-declares-quarterly-dividend-coppell-tx-nasdaq-mtex-mtex-20050914monthly0.5https://www.biopharmawatch.com/news/MTEX/release-agreement-this-release-agreement-this-agreement-is-entered-into-by-and-between-man-mtex-20050810monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-incorporated-declares-quarterly-dividend-coppell-tx-nasdaq-mtex-mtex-20050617monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-inc-announces-share-repurchase-coppell-tx-mtex-20050512monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-inc-announces-new-first-quarter-records-sales-increase-46-e-p-s-up-55-coppell-tx-mtex-20050509monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-inc-announces-another-record-breaking-year-of-annual-sales-profit-coppell-tx-mtex-20050309monthly0.5https://www.biopharmawatch.com/news/MTEX/supply-agreement-this-supply-agreement-supply-agreement-is-effective-as-of-mtex-20041201monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-incorporated-declares-dividend-coppell-tx-mtex-20041111monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-inc-announces-record-quarterly-sales-earnings-coppell-tx-mtex-20041109monthly0.5https://www.biopharmawatch.com/news/MTEX/mannatech-adds-donald-buchholz-to-its-board-coppell-tx-mtex-20041007monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-and-niowave-launch-strategic-collaboration-for-radiopharmaceutical-therapeutic-deve-apvo-20260527monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-reports-87-clinical-benefit-and-81-remission-in-31-evaluable-frontline-aml-patients-apvo-20260506monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-provides-state-of-the-business-report-and-2025-financial-results-latest-mipletamig--apvo-20260326monthly0.5https://www.biopharmawatch.com/news/APVO/mipletamig-delivers-compelling-86-clinical-benefit-rate-and-no-crs-as-evaluable-aml-patien-apvo-20260310monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-announces-executive-leadership-transitions-to-support-next-phase-of-growth-clinical-apvo-20260203monthly0.5https://www.biopharmawatch.com/news/APVO/xfeff-aptevo-therapeutics-reports-3q25-financial-results-and-provides-a-business-update-89-apvo-20251106monthly0.5https://www.biopharmawatch.com/news/APVO/mipletamig-delivers-100-remission-rate-in-cohort-3-of-rainier-trial-for-aml-no-dose-limiti-apvo-20250916monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-unveils-two-next-generation-industry-leading-trispecifics-expanding-cd3-oncology-pi-apvo-20250904monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-2q25-financial-results-and-provides-a-business-update-mipletam-apvo-20250811monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-announces-8-million-offering-priced-at-the-market-under-nasdaq-rules-s-apvo-20250618monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-announces-1-for-20-reverse-stock-split-as-part-of-nasdaq-compliance-pl-apvo-20250522monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-1q25-financial-results-and-provides-an-update-on-mipletamig-9--apvo-20250515monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-2-0-million-registered-direct-offering-priced-at-the-market-under-nasd-apvo-20250421monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-2-1-million-registered-direct-offering-and-concurrent-private-placemen-apvo-20250403monthly0.5https://www.biopharmawatch.com/news/APVO/march-2025-nasdaq-apvo-forward-looking-statements-this-presentation-includes-forward-looki-apvo-20250320monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-2024-financial-results-and-provides-a-business-update-100-of-p-apvo-20250214monthly0.5https://www.biopharmawatch.com/news/APVO/confidential-11-february-2025-nasdaq-apvo-forward-looking-statements-this-presentation-inc-apvo-20250211monthly0.5https://www.biopharmawatch.com/news/APVO/of-patients-achieve-remission-within-30-days-in-cohort-1-of-bispecific-mipletamig-frontlin-apvo-20241212monthly0.5https://www.biopharmawatch.com/news/APVO/bispecific-antibody-apvo442-differentiated-to-treat-prostate-cancer-with-precision-tumor-t-apvo-20241204monthly0.5https://www.biopharmawatch.com/news/APVO/proving-the-concept-aptevo-technology-pipeline-to-exemplify-the-speed-and-power-of-modular-apvo-20241126monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-highlights-the-potential-of-the-company-s-robust-portfolio-in-cancer-immunotherapy--apvo-20241122monthly0.5https://www.biopharmawatch.com/news/APVO/first-patient-dosed-in-aptevo-s-ongoing-rainier-trial-achieves-90-reduction-in-leukemic-bl-apvo-20241120monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-3q-2024-financial-results-and-provides-a-business-update-compa-apvo-20241107monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-announces-3-0-million-offering-priced-at-the-market-under-nasdaq-rules-apvo-20240916monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-and-alligator-bioscience-announce-data-from-phase-1-alg-apv-527-monoth-apvo-20240914monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-2q-2024-financial-results-and-provides-a-business-update-seatt-apvo-20240808monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-announces-2-75-million-offering-priced-at-the-market-under-nasdaq-rule-apvo-20240628monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-1q-2024-financial-results-and-provides-a-business-update-heavi-apvo-20240508monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-announces-pricing-of-4-6-million-public-offering-seattle-wa-x2013-apvo-20240411monthly0.5https://www.biopharmawatch.com/news/APVO/alligator-bioscience-and-aptevo-therapeutics-announce-positive-interim-data-of-dose-escala-apvo-20240307monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-2023-financial-results-and-provides-a-business-update-announce-apvo-20240305monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-3q23-financial-results-and-provides-a-business-update-the-comp-apvo-20231114monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-2q23-financial-results-and-provides-a-business-update-positive-apvo-20230810monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-announces-positive-duration-of-remission-data-from-phase-1b-expansion-trial-evaluat-apvo-20230718monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-1q23-financial-results-and-provides-business-update-company-ac-apvo-20230511monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-2022-financial-results-and-provides-business-update-company-ac-apvo-20230330monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-raises-9-6-million-in-non-dilutive-funding-completes-sale-of-ixinity-d-apvo-20230330monthly0.5https://www.biopharmawatch.com/news/APVO/alligator-bioscience-aptevo-therapeutics-announce-dosing-of-first-patient-with-alg-apv-527-apvo-20230213monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-files-provisional-patent-for-fifth-bispecific-antibody-apvo711-intende-apvo-20230109monthly0.5https://www.biopharmawatch.com/news/APVO/clinical-benefit-rate-achieved-in-phase-1b-trial-evaluating-apvo436-in-combination-with-ve-apvo-20221212monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-third-quarter-2022-financial-results-and-business-highlights-c-apvo-20221110monthly0.5https://www.biopharmawatch.com/news/APVO/alligator-bioscience-and-aptevo-therapeutics-announce-that-fda-has-issued-a-may-proceed-no-apvo-20220919monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-second-quarter-2022-financial-results-and-business-highlights--apvo-20220811monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-announces-new-preliminary-remission-data-on-four-additional-patients-e-apvo-20220609monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-first-quarter-2022-financial-results-and-business-highlights-s-apvo-20220512monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-2021-apvo-20220324monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-earns-10-million-non-dilutive-milestone-payment-on-sales-of-ruxience-p-apvo-20220209monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-board-chairman-fuad-el-hibri-announces-retirement-effective-apvo-20220121monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-first-complete-remission-providing-clinical-update-for-its-pha-apvo-20211123monthly0.5https://www.biopharmawatch.com/news/APVO/for-immediate-release-apvo-20211112monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-announces-apvo436-monotherapy-is-active-in-patients-who-have-relapsed--apvo-20210817monthly0.5https://www.biopharmawatch.com/news/APVO/for-immediate-release-apvo-20210812monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-announces-expansion-phase-of-lead-anti-leukemia-drug-apvo436-in-adult--apvo-20210527monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-positive-phase-1-clinical-data-for-its-lead-leukemia-drug-cand-apvo-20210526monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-first-quarter-2021-financial-results-advances-phase-1-1b-study-apvo-20210511monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-2020-financial-results-and-provides-business-update-advances-p-apvo-20210331monthly0.5https://www.biopharmawatch.com/news/APVO/these-reserves-wer-e-based-on-the-amounts-earned-or-to-be-claimed-on-the-related-sales-and-apvo-20201214monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-announces-the-launch-of-its-second-platform-technology-adaptir-flex-tm-apvo-20201202monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-and-alligator-bioscience-advancing-the-bispecific-4-1bbx5t4-antibody-a-apvo-20201116monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-third-quarter-financial-results-and-provides-business-update-1-apvo-20201110monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-announces-second-complete-remission-in-ongoing-apvo436-phase-1-clinica-apvo-20201109monthly0.5https://www.biopharmawatch.com/news/APVO/exhbit-99-1-aptevo-therapeutics-adopts-limited-duration-stockholder-rights-plan-seattle-wa-apvo-20201108monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-secures-25-million-non-dilutive-financing-from-midcap-financial-trust--apvo-20200806monthly0.5https://www.biopharmawatch.com/news/APVO/unaudited-pro-forma-condensed-consolidated-financial-information-on-apvo-20200228monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-third-quarter-2019-financial-results-reports-record-net-revenu-apvo-20191107monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-provides-corporate-and-pipeline-update-reports-record-quarterly-ixinit-apvo-20191003monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-inc-condensed-consolidated-statements-of-operations-in-thousands-excep-apvo-20190809monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-inc-condensed-consolidated-statements-of-operations-in-thousands-excep-apvo-20190509monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-inc-consolidated-statements-of-operations-in-thousands-except-share-an-apvo-20190318monthly0.5https://www.biopharmawatch.com/news/APVO/safe-harbor-statement-this-press-release-includes-forward-looking-statements-within-the-me-apvo-20190109monthly0.5https://www.biopharmawatch.com/news/APVO/about-the-apvo414-mcrpc-clinical-study-apvo414-is-a-first-generation-bispecific-antibody-t-apvo-20181114monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-second-quarter-2018-financial-results-achieves-record-ixinity--apvo-20180809monthly0.5https://www.biopharmawatch.com/news/APVO/about-aptevo-therapeutics-inc-aptevo-therapeutics-inc-is-a-clinical-stage-biotechnology-co-apvo-20180510monthly0.5https://www.biopharmawatch.com/news/APVO/about-aptevo-therapeutics-inc-aptevo-therapeutics-inc-is-a-clinical-stage-biotechnology-co-apvo-20180313monthly0.5https://www.biopharmawatch.com/news/APVO/this-presentation-includes-forward-looking-statements-within-the-meaning-of-the-private-se-apvo-20180108monthly0.5https://www.biopharmawatch.com/news/APVO/autoimmune-disease-and-inflammation-for-more-information-please-visit-www-aptevotherapeuti-apvo-20171109monthly0.5https://www.biopharmawatch.com/news/APVO/this-presentation-includes-forward-looking-statements-within-the-meaning-of-the-private-se-apvo-20171102monthly0.5https://www.biopharmawatch.com/news/APVO/unaudited-pro-forma-condensed-consolidated-financial-information-on-apvo-20170928monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-second-quarter-2017-financial-results-showcases-differentiatin-apvo-20170810monthly0.5https://www.biopharmawatch.com/news/APVO/overview-of-adaptir-bispecific-technology-bispecifics-in-immuno-oncology-next-generation-a-apvo-20170620monthly0.5https://www.biopharmawatch.com/news/APVO/reliance-on-any-forward-looking-statement-any-forward-looking-statement-speaks-only-as-of--apvo-20170512monthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reports-2016-financial-results-and-provides-business-update-advances-m-apvo-20170331monthly0.5https://www.biopharmawatch.com/news/APVO/this-presentation-includes-forward-looking-statements-within-the-meaning-of-the-private-se-apvo-20170109monthly0.5https://www.biopharmawatch.com/news/APVO/this-presentation-includes-forward-looking-statements-within-the-meaning-of-the-private-se-apvo-20161114monthly0.5https://www.biopharmawatch.com/news/APVO/august-2016-aptevo-therapeutics-investor-presentation-forward-looking-statements-this-pres-apvo-20160801monthly0.5https://www.biopharmawatch.com/news/BCAB/certificate-of-merger-merging-ba-merger-sub-inc-with-and-into-bioatla-inc-pursuant-to-sect-bcab-20260402monthly0.5https://www.biopharmawatch.com/news/BCAB/conditionally-active-biologics-transforming-cancer-therapy-investor-presentation-non-confi-bcab-20241220monthly0.5https://www.biopharmawatch.com/news/BCAB/conditionally-active-biologics-transforming-cancer-therapy-corporate-presentation-january--bcab-20240109monthly0.5https://www.biopharmawatch.com/news/BCAB/phase-2-trial-of-mecbotamab-vedotin-ba3011-cab-axl-adc-alone-or-in-combination-with-nivolu-bcab-20231204monthly0.5https://www.biopharmawatch.com/news/BCAB/ba3011-supplemental-nsclc-and-sarcoma-data-10-2022-1-axl-ba3011-002-phase-2-part-1-disposi-bcab-20221028monthly0.5https://www.biopharmawatch.com/news/BCAB/transforming-cancer-therapy-april-2022-needham-co-annual-healthcare-conference-1-important-bcab-20220411monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-clinical-collaboration-with-bristol-myers-squibb-to-study-mecbotamab-ved-bcab-20220110monthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-private-placement-of-2-7-million-shares-proceeds-to-advance-cab-axl-and--bcab-20210929monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-inc-announces-name-and-ticker-symbol-change-to-envue-medical-inc-and-feed-new-feed-20251212monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-issues-letter-to-shareholders-envue-feeding-tube-placement-system-identified--feed-20251119monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-pricing-of-2-0-million-registered-direct-offering-priced-at-the-mar-feed-20250916monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-reverse-stock-split-common-stock-will-begin-trading-on-split-adjust-feed-20250808monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-ceo-transition-tyler-texas-feed-20250604monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-pricing-of-10-million-public-offering-of-preferred-stock-and-warran-feed-20250515monthly0.5https://www.biopharmawatch.com/news/FEED/successful-independent-study-of-the-nanovibronix-uroshield-device-published-in-the-austral-feed-20250314monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-reverse-stock-split-common-stock-will-begin-trading-on-split-adjust-feed-20250314monthly0.5https://www.biopharmawatch.com/news/FEED/envue-medical-holdings-corp-formerly-envizion-holdings-corp-index-to-financial-statements--feed-20250214monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-completion-of-pilot-phase-of-clinical-study-of-uroshield-at-the-uni-feed-20250106monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-secures-12-million-minimum-purchase-commitment-for-painshield-with-extension--feed-20241211monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-issues-letter-to-stockholders-tyler-texas-feed-20240516monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-issues-letter-to-stockholders-elmsford-n-y-feed-20240409monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-signs-agreement-for-research-and-development-of-next-generation-painshield-an-feed-20240328monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-agreement-for-clinical-study-of-uroshield-at-the-university-of-mich-feed-20231128monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-regains-nasdaq-compliance-elmsford-n-y-feed-20231121monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-issues-letter-to-shareholders-elmsford-n-y-feed-20231114monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-uroshield-products-available-on-nhs-drug-tariff-effective-november-1-receives-feed-20231107monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-gains-approval-for-inclusion-of-uroshield-products-in-nhs-prescription-servic-feed-20230927monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-presentation-of-positive-independent-testing-results-of-uroshield-a-feed-20230906monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-5-million-private-placement-priced-at-the-market-under-nasdaq-rules-feed-20230830monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-cites-positive-results-from-independent-testing-of-uroshield-university-of-so-feed-20230830monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-responds-to-cms-determination-for-painshield-elmsford-n-y-feed-20230829monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-applies-for-inclusion-of-uroshield-products-in-nhs-prescription-services-drug-feed-20230828monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-extends-distribution-agreement-with-its-largest-distributor-for-painshield-an-feed-20230823monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-distribution-agreement-with-sports-medicine-supplier-mio-guard-pain-feed-20230614monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-issues-letter-to-shareholders-elmsford-n-y-feed-20230518monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-receives-positive-final-results-of-independent-lifecycle-testing-of-painshiel-feed-20230328monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra-next-generation--feed-20230321monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-positive-results-from-independent-product-trial-of-uroshield-for-pa-feed-20230314monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-regains-nasdaq-compliance-elmsford-n-y-feed-20230303monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-to-launch-rental-program-for-painshield-and-uroshield-program-will-bring-grea-feed-20230222monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-reverse-stock-split-common-stock-will-begin-trading-on-split-adjust-feed-20230209monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-provides-update-on-expanding-access-to-painshield-receives-positive-interim-r-feed-20230118monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-feed-20221215monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-2-4-million-registered-direct-offering-priced-at-the-market-under-n-feed-20221129monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-receives-fda-510-k-premarket-clearance-for-painshield-plus-achieves-key-miles-feed-20221128monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-interim-results-of-clinical-study-for-uroshield-interim-results-ind-feed-20221116monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-receives-extension-to-satisfy-nasdaq-price-requirement-elmsford-n-y-feed-20221019monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-uroshield-approved-for-sale-through-nhs-internal-supply-chain-contract-new-co-feed-20220923monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-feed-20220914monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-distribution-of-series-f-preferred-stock-to-holders-of-its-common-s-feed-20220914monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-receipt-of-nasdaq-listing-determination-feed-20220902monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-reports-first-quarter-2022-financial-results-expanded-distribution-entry-into-feed-20220517monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-expands-board-of-directors-with-appointment-of-two-new-independent-directors--feed-20220113monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-positive-results-from-indepenent-double-blind-trial-of-painshield-s-feed-20211011monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-feed-20210817monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-reports-second-quarter-2021-financial-results-provides-business-update-signif-feed-20210816monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-provides-business-update-highlights-business-momentum-with-recent-achievement-feed-20210603monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-amends-and-expands-distribution-agreement-for-its-painshield-and-painshield-p-feed-20201211monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-6-0-million-private-placement-elmsford-n-y-feed-20201202monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-reports-third-quarter-2020-financial-results-provides-business-update-gaining-feed-20201116monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-receives-positive-nasdaq-listing-determination-elmsford-n-y-feed-20201008monthly0.5https://www.biopharmawatch.com/news/FEED/e-xhibit-99-1-nanovibronix-announces-1-5-million-bought-deal-offering-elmsford-n-y-feed-20200922monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-uroshield-receives-u-s-food-and-drug-administration-authorization-for-entry-i-feed-20200922monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-closing-of-3-4-million-bought-deal-offering-and-partial-exercise-of-feed-20200827monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-2-5-million-bought-deal-offering-elmsford-n-y-feed-20200824monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-signs-two-year-exclusive-distribution-agreement-for-painshield-ultra-pain-pro-feed-20200707monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-receives-reimbursement-approval-from-u-s-centers-for-medicare-medicaid-servic-feed-20200401monthly0.5https://www.biopharmawatch.com/news/FEED/announces-closing-of-3-2-million-private-placement-feed-20190626monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-rescheduling-of-feed-20190614monthly0.5https://www.biopharmawatch.com/news/FEED/an-effective-solution-for-the-prevention-of-bacterial-load-and-cauti-through-the-applicati-feed-20190311monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-provides-business-update-for-the-second-quarter-of-2018-revenue-increases-153-feed-20180816monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-provides-year-end-2017-business-update-and-files-10-k-elmsford-ny-feed-20180402monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-closing-of-6-000-000-public-offering-elmsford-ny-feed-20171107monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-announces-pricing-of-6-000-000-public-offering-listed-on-the-nasdaq-capital-m-feed-20171101monthly0.5https://www.biopharmawatch.com/news/FEED/nanovibronix-expands-senior-management-team-and-board-of-directors-appoints-industry-veter-feed-20161020monthly0.5https://www.biopharmawatch.com/news/RNAZ/three-platforms-one-mission-transforming-advanced-cancer-care-nasdaq-rnaz-company-forward--rnaz-20260611monthly0.5https://www.biopharmawatch.com/news/RNAZ/abcj-llc-reports-and-financial-statements-for-the-years-ended-rnaz-20251223monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-expands-leadership-with-appointment-of-jack-e-stover-to-board-of-directors-bosto-rnaz-20251222monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-nasdaq-extension-to-regain-compliance-rnaz-20241106monthly0.5https://www.biopharmawatch.com/news/RNAZ/nasdaq-determines-transcode-therapeutics-compliance-with-minimum-stockholders-equity-requi-rnaz-20240131monthly0.5https://www.biopharmawatch.com/news/RNAZ/nasdaq-panel-grants-transcode-therapeutics-extension-for-continued-listing-on-the-nasdaq-s-rnaz-20231027monthly0.5https://www.biopharmawatch.com/news/RNAZ/therapeutics-announces-pricing-of-8-million-public-offering-rnaz-20230928monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-eind-submission-rnaz-20221130monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reports-business-progress-and-third-quarter-2021-financial-results--rnaz-20211115monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-appoints-zdravka-medarova-ph-d-as-chief-technology-officer-boston-m-rnaz-20210930monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reports-business-progress-and-second-quarter-2021-financial-results-rnaz-20210823monthly0.5https://www.biopharmawatch.com/news/ADVB/purchase-agreement-this-purchase-agreement-this-agreement-dated-as-of-advb-20250606monthly0.5https://www.biopharmawatch.com/news/ADVB/advanced-biomed-inc-announces-pricing-of-initial-public-offering-tainan-taiwan-advb-20250306monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-announces-25-million-financing-houston-fblg-20241223monthly0.5https://www.biopharmawatch.com/news/FBLG/excerpt-our-current-pipeline-we-have-a-pipeline-of-product-candidates-at-various-stages-of-fblg-20240426monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-to-present-preclinical-and-clinical-data-at-the-2024-americas-committee-for-fblg-20240220monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-presents-preclinical-data-at-the-2024-keystone-symposia-for-systemic-autoim-fblg-20240213monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-announces-three-united-states-patents-for-fibroblast-technology-houston-fblg-20240208monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-announces-three-japanese-patents-on-fibroblast-technology-houston-fblg-20240206monthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-announces-direct-listing-on-nasdaq-under-the-stock-ticker-fblg-20240131monthly0.5https://www.biopharmawatch.com/news/ITOC/itonic-holdings-ltd-granted-an-extension-of-additional-180-day-by-nasdaq-to-regain-complia-itoc-20260423monthly0.5https://www.biopharmawatch.com/news/ITOC/pheton-holdings-ltd-announces-corporate-name-change-and-stock-ticker-symbol-change-itoc-20260113monthly0.5https://www.biopharmawatch.com/news/ITOC/pheton-holdings-ltd-index-to-unaudited-interim-condensed-consolidated-financial-statements-itoc-20251216monthly0.5https://www.biopharmawatch.com/news/ITOC/pheton-holdings-ltd-incorporated-in-the-cayman-islands-with-limited-liability-nasdaq-pthl--itoc-20251126monthly0.5https://www.biopharmawatch.com/news/ITOC/pheton-holdings-ltd-issues-statements-addressing-recent-market-activity-and-misleading-rum-itoc-20250801monthly0.5https://www.biopharmawatch.com/news/ITOC/pheton-holdings-ltd-results-for-the-six-months-ended-itoc-20241015monthly0.5https://www.biopharmawatch.com/news/ITOC/pheton-holdings-ltd-announces-pricing-of-initial-public-offering-itoc-20240905monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-reports-2026-clgn-20260529monthly0.5https://www.biopharmawatch.com/news/CLGN/letter-to-shareholders-collaborations-as-noted-allergan-industrie-sas-an-abbvie-company-no-clgn-20260413monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-reports-2025-clgn-20260326monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-2-0-clgn-20260205monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-ltd-4-oppenheimer-st-weizmann-science-park-rehovot-7670104-israe-clgn-20251126monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-ltd-4-oppenheimer-st-weizmann-science-park-rehovot-7670104-israe-clgn-20240820monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-issues-letter-to-shareholders-rehovot-israel-clgn-20240215monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-ltd-4-oppenheimer-st-weizmann-science-park-rehovot-7670104-israe-clgn-20230901monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-ltd-4-oppenheimer-st-weizmann-science-park-rehovot-7670104-israe-clgn-20230608monthly0.5https://www.biopharmawatch.com/news/CLGN/april-202-3-nasdaq-clgn-company-overview-our-mission-developing-and-delivering-collagen-te-clgn-20230411monthly0.5https://www.biopharmawatch.com/news/CLGN/stratasys-and-collplant-unite-technologies-to-transform-healthcare-with-industrial-scale-b-clgn-20230404monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-overview-november-2022-safe-harbor-statement-certain-statements-in-this-presenta-clgn-20221117monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-overview-august-2022-safe-harbor-statement-certain-statements-in-this-presentati-clgn-20220826monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-overview-april-2022-safe-harbor-statement-certain-statements-in-this-presentatio-clgn-20220414monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-ltd-4-oppenheimer-st-weizmann-science-park-rehovot-7670104-israe-clgn-20220325monthly0.5https://www.biopharmawatch.com/news/CLGN/cellink-and-collplant-enter-a-collaboration-agreement-to-explore-future-large-scale-produc-clgn-20220216monthly0.5https://www.biopharmawatch.com/news/CLGN/dea-r-sha-r-e-holder-s-2021-has-been-a-pivotal-and-productive-year-for-collplant-which-res-clgn-20220105monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-overview-h-c-wainwright-23-rd-annual-global-investment-conference-se-p-t-ember-2-clgn-20210913monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-ltd-4-oppenheimer-st-weizmann-science-park-rehovot-7670104-israe-clgn-20210625monthly0.5https://www.biopharmawatch.com/news/CLGN/3d-systems-corporation-collplant-333-three-d-systems-circle-4-oppenheimer-street-rock-hill-clgn-20210622monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-issues-letter-to-shareholders-expansion-of-collaboration-with-united-therapeutic-clgn-20210218monthly0.5https://www.biopharmawatch.com/news/CLGN/press-release-exhibit-1-collplant-announces-35-0-million-registered-direct-offering-of-ame-clgn-20210211monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-and-united-therapeutics-announce-exercise-of-option-that-will-expand-their-colla-clgn-20200921monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-ltd-4-oppenheimer-st-weizmann-science-park-rehovot-7670104-israe-clgn-20200901monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-ltd-4-oppenheimer-st-weizmann-science-park-rehovot-7670104-israe-clgn-20200407monthly0.5https://www.biopharmawatch.com/news/CLGN/j-clgn-20200210monthly0.5https://www.biopharmawatch.com/news/CLGN/launches-new-corporate-website-to-showcase-recent-developments-in-core-business-segments-clgn-20200204monthly0.5https://www.biopharmawatch.com/news/CLGN/systems-and-collplant-biotechnologies-join-forces-to-accelerate-breakthroughs-in-regenerat-clgn-20200113monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-publishes-letter-to-shareholders-rehovot-clgn-20191219monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-ltd-4-oppenheimer-st-weizmann-science-park-rehovot-7670104-israe-clgn-20191122monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-ltd-4-oppenheimer-st-weizmann-science-park-rehovot-7670104-israe-clgn-20190916monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-overview-hcw-global-investment-conference-september-2019-clgn-20190909monthly0.5https://www.biopharmawatch.com/news/CLGN/biotechnologies-raising-5-5-million-clgn-20190903monthly0.5https://www.biopharmawatch.com/news/CLGN/is-developing-3d-bioprinted-implants-clgn-20190805monthly0.5https://www.biopharmawatch.com/news/CLGN/clinical-results-from-collplant-s-clgn-20190604monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-reports-first-quarter-2019-clgn-20190530monthly0.5https://www.biopharmawatch.com/news/CLGN/presents-its-rhcollagen-based-bioinks-for-3d-bioprinting-of-tissues-and-organs-at-termis-a-clgn-20190528monthly0.5https://www.biopharmawatch.com/news/CLGN/jfif-c-7-01444-9-82-g-m-9-5-4-4-zp-c-n-d-1-u-jm-s-p-w-w-s-n-m-r-f-w-uyd-rd-g-e-j-u-c-m4ph--clgn-20190501monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-holdings-ltd-4-oppenheimer-st-weizmann-science-park-rehovot-7670104-israel-notic-clgn-20190501monthly0.5https://www.biopharmawatch.com/news/CLGN/reports-fourth-quarter-and-year-end-2018-financial-results-and-provides-business-update-clgn-20190401monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-renews-distribution-agreement-clgn-20190318monthly0.5https://www.biopharmawatch.com/news/CLGN/study-published-in-wounds-journal-shows-clgn-20190311monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-holdings-ltd-3-sapir-street-weizmann-science-park-ness-ziona-israel-notice-of-ex-clgn-20190221monthly0.5https://www.biopharmawatch.com/news/CLGN/announces-approval-of-its-rhcollagen-manufacturing-facility-by-clgn-20190219monthly0.5https://www.biopharmawatch.com/news/CLGN/announces-appointment-of-jonathan-m-n-clgn-20190204monthly0.5https://www.biopharmawatch.com/news/CLGN/clinical-trial-published-in-the-journal-clgn-20181210monthly0.5https://www.biopharmawatch.com/news/CLGN/reports-third-quarter-2018-financial-results-and-clgn-20181129monthly0.5https://www.biopharmawatch.com/news/CLGN/announces-closing-of-global-licensing-and-commercialization-agreement-with-united-therapeu-clgn-20181113monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-holdings-ltd-3-sapir-street-weizmann-science-park-ness-ziona-israel-notice-of-an-clgn-20181101monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-shares-will-be-traded-from-tuesday-october-30-exclusively-on-nasdaq-last-trading-clgn-20181029monthly0.5https://www.biopharmawatch.com/news/CLGN/and-united-therapeutics-announce-global-licensing-and-clgn-20181022monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-to-voluntarily-delist-from-tel-aviv-stock-exchange-clgn-20180808monthly0.5https://www.biopharmawatch.com/news/CLGN/appoints-dr-clgn-20180705monthly0.5https://www.biopharmawatch.com/news/CLGN/receives-research-and-development-project-approval-from-the-israel-innovation-authority-to-clgn-20180626monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-holdings-ltd-3-sapir-street-weizmann-science-park-ness-ziona-israel-notice-to-sh-clgn-20180607monthly0.5https://www.biopharmawatch.com/news/CLGN/files-u-s-clgn-20180508monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-holdings-ltd-3-sapir-street-weizmann-science-park-ness-ziona-israel-notice-of-ex-clgn-20180503monthly0.5https://www.biopharmawatch.com/news/CLGN/petitions-court-to-voluntarily-delist-ordinary-shares-from-the-tel-aviv-stock-exchange-clgn-20180416monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-appoints-revital-mandil-levin-clgn-20180412monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-reports-fourth-quarter-and-clgn-20180321monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-announces-ads-listing-on-nasdaq-ness-ziona-israel-clgn-20180131monthly0.5https://www.biopharmawatch.com/news/CDT/cdt-equity-inc-announces-reverse-stock-split-naples-fla-and-cambridge-united-kingdom-cdt-20260325monthly0.5https://www.biopharmawatch.com/news/CDT/cdt-equity-inc-announces-reverse-stock-split-naples-fla-and-cambridge-united-kingdom-cdt-20251009monthly0.5https://www.biopharmawatch.com/news/CDT/conduit-to-change-name-to-cdt-equity-inc-name-change-to-cdt-equity-inc-reflects-evolution--cdt-20250805monthly0.5https://www.biopharmawatch.com/news/CDT/conduit-pharmaceuticals-enters-joint-development-agreement-with-manoira-to-advance-azd1656-cdt-20250604monthly0.5https://www.biopharmawatch.com/news/CDT/conduit-pharmaceuticals-inc-announces-reverse-stock-split-naples-fla-and-cambridge-united--cdt-20250516monthly0.5https://www.biopharmawatch.com/news/CDT/conduit-pharmaceuticals-announces-leadership-changes-naples-fla-and-cambridge-united-kingd-cdt-20250416monthly0.5https://www.biopharmawatch.com/news/CDT/conduit-pharmaceuticals-inc-announces-reverse-stock-split-naples-fla-and-cambridge-united--cdt-20250123monthly0.5https://www.biopharmawatch.com/news/CDT/conduit-pharmaceuticals-to-revolutionize-drug-development-through-agreement-to-use-artific-cdt-20241212monthly0.5https://www.biopharmawatch.com/news/CDT/conduit-pharmaceuticals-enters-into-exclusive-license-agreement-with-astrazeneca-for-multi-cdt-20240808monthly0.5https://www.biopharmawatch.com/news/CDT/to-this-current-report-qualitative-and-quantitative-disclosures-about-market-risk-we-are-e-cdt-20231005monthly0.5https://www.biopharmawatch.com/news/CDT/to-this-current-report-qualitative-and-quantitative-disclosures-about-market-risk-we-are-e-cdt-20230929monthly0.5https://www.biopharmawatch.com/news/CDT/murphy-canyon-acquisition-corp-announces-stockholder-approval-of-the-proposed-combination--cdt-20230920monthly0.5https://www.biopharmawatch.com/news/CDT/murphy-canyonacquisition-corp-announces-postponement-of-its-special-meeting-of-stockholder-cdt-20230907monthly0.5https://www.biopharmawatch.com/news/CDT/murphy-canyonacquisition-corp-announces-postponement-of-its-special-meeting-of-stockholder-cdt-20230831monthly0.5https://www.biopharmawatch.com/news/CDT/prospectus-supplement-filed-pursuant-to-rule-424-b-3-to-prospectus-dated-cdt-20230811monthly0.5https://www.biopharmawatch.com/news/CDT/sec-declares-form-s-4-registration-statement-effective-for-proposed-business-combination-o-cdt-20230816monthly0.5https://www.biopharmawatch.com/news/CDT/conduit-pharmaceuticals-to-become-a-publicly-traded-company-via-merger-with-murphy-canyon--cdt-20221108monthly0.5https://www.biopharmawatch.com/news/CDT/murphy-canyon-acquisition-corp-index-to-financial-statement-page-audited-financial-stateme-cdt-20220207monthly0.5https://www.biopharmawatch.com/news/CDT/murphy-canyon-acquisition-corp-announces-pricing-of-115-million-initial-public-offering-sa-cdt-20220202monthly0.5https://www.biopharmawatch.com/news/IMRN/may-2026-ms-melissa-kostopoulos-senior-adviser-listings-compliance-melbourne-asx-limited-d-imrn-20260528monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-presentation-at-emerging-growth-conference-melbourne-australi-imrn-20260508monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-presentation-at-emerging-growth-conference-melbourne-australi-imrn-20260430monthly0.5https://www.biopharmawatch.com/news/IMRN/asx-nasdaq-announcement-immuron-double-digit-3q-sales-growth-sales-highlights-unaudited-gl-imrn-20260417monthly0.5https://www.biopharmawatch.com/news/IMRN/asx-announcement-13-april-2026-small-holding-share-sale-facility-immuron-limited-asx-imc-a-imrn-20260413monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-appendix-4d-half-year-report-1-company-details-name-of-entity-immuron-limi-imrn-20260302monthly0.5https://www.biopharmawatch.com/news/IMRN/asx-announcement-immuron-receives-r-d-tax-incentive-melbourne-australia-imrn-20260217monthly0.5https://www.biopharmawatch.com/news/IMRN/asx-nasdaq-announcement-12-february-2026-2026-extraordinary-general-meeting-results-in-acc-imrn-20260212monthly0.5https://www.biopharmawatch.com/news/IMRN/asx-announcement-9-february-2026-resignation-appointment-of-company-secretary-and-chief-fi-imrn-20260209monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-presentation-at-emerging-growth-conference-melbourne-australi-imrn-20260123monthly0.5https://www.biopharmawatch.com/news/IMRN/asx-announcement-immuron-continued-sales-growth-sales-highlights-unaudited-global-h1-sales-imrn-20260119monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-present-at-emerging-growth-conference-melbourne-australia-imrn-20260114monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-acn-063-114-045-asx-code-imc-nasdaq-code-imrn-notice-of-extraordinary-gene-imrn-20260112monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-immur-imrn-20251216monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-immur-imrn-20251211monthly0.5https://www.biopharmawatch.com/news/IMRN/uniformed-services-university-to-release-topline-data-highlights-primary-endpoint-did-not--imrn-20251210monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-immur-imrn-20251205monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3b-proposed-issue-of-securities-announcement-summary-entity-name-immuron-limited--imrn-20251204monthly0.5https://www.biopharmawatch.com/news/IMRN/asx-announcement-4-december-2025-change-of-provider-of-share-registry-management-services--imrn-20251204monthly0.5https://www.biopharmawatch.com/news/IMRN/confidential-appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-cha-imrn-20251121monthly0.5https://www.biopharmawatch.com/news/IMRN/asx-nasdaq-announcement-11-november-2025-2025-annual-general-meeting-ceo-address-immuron-l-imrn-20251112monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-immur-imrn-20251107monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3b-proposed-issue-of-securities-announcement-summary-entity-name-immuron-limited--imrn-20251106monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-imm-529-ind-approved-by-fda-key-points-immuron-receives-u-s-food-and-drug-administ-imrn-20251105monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-clinical-trial-update-imm-529-ind-currently-under-review-fda-request-for-imrn-20251031monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3h-notification-of-cessation-of-securities-announcement-summary-entity-name-immur-imrn-20251027monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-launch-proibs-for-irritable-bowel-syndrome-ibs-melbourne-australia-imrn-20251024monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-presentation-to-emerging-growth-conference-melbourne-australi-imrn-20251023monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-presentation-to-ausbiotech-invest-2025-conference-melbourne-a-imrn-20251021monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-immur-imrn-20251020monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-present-at-emerging-growth-conference-melbourne-australia-imrn-20251020monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3b-proposed-issue-of-securities-announcement-summary-entity-name-immuron-limited--imrn-20251017monthly0.5https://www.biopharmawatch.com/news/IMRN/asx-announcement-13-october-2025-immuron-q1-fy26-yoy-growth-sales-highlights-unaudited-glo-imrn-20251013monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-acn-063-114-045-asx-code-imc-nasdaq-code-imrn-notice-of-2025-annual-genera-imrn-20251010monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-submits-imm-529-ind-to-fda-key-points-immuron-submits-investigational-new-drug-ind-imrn-20251008monthly0.5https://www.biopharmawatch.com/news/IMRN/rules-4-7-3-and-4-10-3-appendix-4g-key-to-disclosures-corporate-governance-council-princip-imrn-20250926monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-presentation-to-coffee-microcaps-conference-melbourne-austral-imrn-20250916monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-appendix-4e-preliminary-final-report-1-company-details-name-of-entity-immu-imrn-20250902monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-partners-with-investorhub-melbourne-australia-imrn-20250826monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3g-notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-a-imrn-20250815monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-present-at-emerging-growth-conference-melbourne-australia-imrn-20250813monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-immur-imrn-20250720monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-immur-imrn-20250718monthly0.5https://www.biopharmawatch.com/news/IMRN/fy25-global-sales-exceed-projection-up-49-on-prior-year-sales-highlights-unaudited-global--imrn-20250717monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-immur-imrn-20250604monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-immur-imrn-20250530monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-immur-imrn-20250411monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-travelan-highest-sales-in-history-sales-highlights-unaudited-global-immuron-exceed-imrn-20250410monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-presentation-to-coffee-microcaps-conference-melbourne-austral-imrn-20250307monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-appendix-4d-half-year-report-1-company-details-name-of-entity-immuron-limi-imrn-20250228monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-presentation-to-emerging-growth-conference-melbourne-australi-imrn-20250219monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-travelan-continued-strong-sales-growth-sales-highlights-global-december-2024-quart-imrn-20250117monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-travelan-clinical-trial-update-highlights-travelan-imm-124e-phase-2-clin-imrn-20250114monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-immur-imrn-20250110monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3b-proposed-issue-of-securities-announcement-summary-entity-name-immuron-limited--imrn-20250108monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3g-notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-a-imrn-20241210monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-2024-agm-presentation-highlights-global-sales-increased-172-in-fy24-to-4-90m-recor-imrn-20241118monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3h-notification-of-cessation-of-securities-announcement-summary-entity-name-immur-imrn-20241114monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3g-notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-a-imrn-20241029monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-acn-063-114-045-asx-code-imc-nasdaq-code-imrn-notice-of-2024-annual-genera-imrn-20241018monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-travelan-continued-strong-sales-growth-sales-highlights-global-september-2024-quar-imrn-20241015monthly0.5https://www.biopharmawatch.com/news/IMRN/notice-under-section-708a-5-of-the-corporations-act-melbourne-australia-imrn-20241008monthly0.5https://www.biopharmawatch.com/news/IMRN/nmrc-reports-results-for-campylobacter-controlled-human-infection-model-study-melbourne-au-imrn-20241004monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-presentation-to-emerging-growth-conference-melbourne-australi-imrn-20240926monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-appendix-4e-30-june-2024-immuron-limited-appendix-4e-preliminary-final-rep-imrn-20240909monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-presentation-at-peak-biotech-showcase-melbourne-australia-aug-imrn-20240821monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-webinar-on-marketopen-direct-connect-melbourne-australia-imrn-20240808monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-present-at-emerging-growth-conference-melbourne-australia-imrn-20240718monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-travelan-record-sales-globally-australia-and-usa-sales-highlights-global-fy-2024-a-imrn-20240715monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-present-at-sharewise-melbourne-australia-imrn-20240709monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-present-at-sharewise-melbourne-australia-imrn-20240704monthly0.5https://www.biopharmawatch.com/news/IMRN/imm-529-pre-ind-fda-filing-melbourne-australia-imrn-20240702monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3z-final-director-s-interest-notice-rule-3-19a-3-appendix-3z-final-director-s-int-imrn-20240605monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-appendix-4d-half-year-31-december-2023-name-of-entity-immuron-limited-abn--imrn-20240528monthly0.5https://www.biopharmawatch.com/news/IMRN/board-change-melbourne-australia-imrn-20240503monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-present-at-the-watchlist-melbourne-australia-april-23-2024-imrn-20240423monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-to-host-live-virtual-event-melbourne-australia-imrn-20240415monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-travelan-sales-continued-strong-growth-sales-highlights-global-fytd-mar-2024-aud-3-imrn-20240410monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-present-at-coffee-microcaps-melbourne-australia-march-14-2-imrn-20240314monthly0.5https://www.biopharmawatch.com/news/IMRN/positive-results-support-travelan-progress-to-phase-3-clinical-trials-in-the-us-highlights-imrn-20240307monthly0.5https://www.biopharmawatch.com/news/IMRN/market-announcement-5-march-2024-immuron-limited-asx-imc-trading-halt-description-the-secu-imrn-20240305monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-appendix-4d-half-year-31-december-2023-name-of-entity-immuron-limited-abn--imrn-20240228monthly0.5https://www.biopharmawatch.com/news/IMRN/australian-biologics-festival-2024-melbourne-australia-imrn-20240221monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-achieves-record-travelan-sales-highlights-travelan-sales-ytd-jan-2024-of-2-7-milli-imrn-20240213monthly0.5https://www.biopharmawatch.com/news/IMRN/investor-webinar-presentation-melbourne-australia-imrn-20240208monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-clinical-trials-update-highlights-us-naval-medical-research-command-nmrc-campyloba-imrn-20231222monthly0.5https://www.biopharmawatch.com/news/IMRN/investor-webinar-presentation-melbourne-australia-imrn-20231128monthly0.5https://www.biopharmawatch.com/news/IMRN/constitution-of-immuron-limited-acn-063-114-045-amended-at-a-meeting-of-shareholders-held--imrn-20231122monthly0.5https://www.biopharmawatch.com/news/IMRN/agm-presentation-21-november-2023-nasdaq-imrn-asx-imc-steven-lydeamore-ceo-2-2-certain-sta-imrn-20231121monthly0.5https://www.biopharmawatch.com/news/IMRN/investor-webinar-presentation-melbourne-australia-imrn-20231113monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-present-at-ausbioinvest-melbourne-australia-imrn-20231030monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-acn-063-114-045-asx-code-imc-nasdaq-code-imrn-notice-of-2023-annual-genera-imrn-20231023monthly0.5https://www.biopharmawatch.com/news/IMRN/travelan-clinical-study-cohort-2-commences-highlights-second-cohort-of-34-healthy-voluntee-imrn-20231018monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-achieves-record-quarterly-travelan-sales-highlights-record-quarterly-travelan-sale-imrn-20231011monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-present-at-ld-micro-melbourne-australia-october-4-2023-imm-imrn-20231004monthly0.5https://www.biopharmawatch.com/news/IMRN/corporate-governance-immuron-limited-and-its-board-of-directors-are-committed-to-implement-imrn-20230928monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-achieves-record-monthly-travelan-sales-highlights-record-monthly-travelan-sales-au-imrn-20230913monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-appendix-4e-30-june-2023-immuron-limited-appendix-4e-preliminary-final-rep-imrn-20230830monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-receives-tga-gmp-clearance-highlights-immuron-receives-tga-gmp-clearance-immuron-t-imrn-20230809monthly0.5https://www.biopharmawatch.com/news/IMRN/letter-to-shareholders-highlights-ateria-has-launched-juvia-containing-breakthrough-natura-imrn-20230711monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-fy23-sales-increase-136-on-fy22-sales-highlights-australian-fy23-sales-of-a-1-16-m-imrn-20230705monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-chairman-transition-melbourne-australia-imrn-20230630monthly0.5https://www.biopharmawatch.com/news/IMRN/letter-to-shareholders-highlights-immuron-board-approves-imm-529-cgmp-manufacturing-and-to-imrn-20230622monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-presents-at-ld-micro-melbourne-australia-imrn-20230607monthly0.5https://www.biopharmawatch.com/news/IMRN/q3-fy23-business-update-presentation-melbourne-australia-imrn-20230419monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-q3-sales-reach-150-of-1h-sales-highlights-australian-q3-fy23-sales-of-a-577-k-201--imrn-20230406monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-appendix-4d-half-year-31-december-2022-name-of-entity-immuron-limited-abn--imrn-20230228monthly0.5https://www.biopharmawatch.com/news/IMRN/investor-presentation-business-update-28-february-2023-nasdaq-imrn-asx-imc-steven-lydeamor-imrn-20230228monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-to-host-investor-webinar-echibit-99-1-immuron-ceo-steven-lyde-imrn-20230215monthly0.5https://www.biopharmawatch.com/news/IMRN/us-department-of-defense-uniformed-services-university-clinical-evaluation-of-travelan-ach-imrn-20230118monthly0.5https://www.biopharmawatch.com/news/IMRN/constitution-of-immuron-limited-acn-063-114-045-amended-at-a-meeting-of-shareholders-held--imrn-20221201monthly0.5https://www.biopharmawatch.com/news/IMRN/agm-presentation-21-november-2022-steven-lydeamore-ceo-nasdaq-imrn-asx-imc-1-certain-state-imrn-20221121monthly0.5https://www.biopharmawatch.com/news/IMRN/level-3-62-lygon-street-carlton-south-victoria-australia-3053-www-immuron-com-abn-80-063-1-imrn-20221026monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-acn-063-114-045-asx-code-imc-nasdaq-code-imrn-notice-of-2022-annual-genera-imrn-20221021monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-appendix-4e-30-june-2022-immuron-limited-appendix-4e-preliminary-final-rep-imrn-20220831monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-update-on-imm-124e-sars-cov-2-research-melbourne-australia-imrn-20220819monthly0.5https://www.biopharmawatch.com/news/IMRN/us-department-of-defense-uniformed-services-university-clinical-evaluation-of-travelan-upd-imrn-20220509monthly0.5https://www.biopharmawatch.com/news/IMRN/asx-announcement-5-may-2022-immuron-appoints-mr-steven-lydeamore-as-chief-executive-office-imrn-20220505monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-north-american-travelan-sales-up-185-global-sales-up-216-key-highlights-north-amer-imrn-20220427monthly0.5https://www.biopharmawatch.com/news/IMRN/asx-announcement-wed-16-march-2022-appointment-of-paul-brennan-as-non-executive-director-i-imrn-20220316monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-appendix-4d-half-year-31-december-2021-name-of-entity-immuron-limited-abn--imrn-20220225monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-awarded-6-2-million-to-clinically-evaluate-a-military-strength-dosing-regimen-for--imrn-20220112monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-asx-imc-wednesday-15-th-december-2021-results-of-annual-general-meeting-im-imrn-20211216monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-acn-063-114-045-asx-code-imc-nasdaq-code-imrn-notice-of-2021-annual-genera-imrn-20211116monthly0.5https://www.biopharmawatch.com/news/IMRN/us-dod-uniformed-services-university-travelers-diarrhea-clinical-update-key-points-manufac-imrn-20211115monthly0.5https://www.biopharmawatch.com/news/IMRN/us-dod-naval-medical-research-center-clinical-update-key-points-manufacture-of-investigati-imrn-20211110monthly0.5https://www.biopharmawatch.com/news/IMRN/imm124e-demonstrates-antiviral-t-cell-immunity-key-points-international-patent-filed-publi-imrn-20211008monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-l-imited-abn-80-063-114-045-annual-report-30-june-2021-corporate-directory-1-chair-imrn-20210930monthly0.5https://www.biopharmawatch.com/news/IMRN/director-resignation-melbourne-australia-imrn-20210924monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-appendix-4e-30-june-2021-immuron-limited-appendix-4e-preliminary-final-rep-imrn-20210831monthly0.5https://www.biopharmawatch.com/news/IMRN/july-2021-market-update-immuron-limited-immuron-refers-to-its-market-update-of-8-june-2021-imrn-20210707monthly0.5https://www.biopharmawatch.com/news/IMRN/june-2021-market-update-further-to-recent-asx-announcement-requesting-a-trading-halt-and-s-imrn-20210608monthly0.5https://www.biopharmawatch.com/news/IMRN/imm124e-may-offer-a-new-modality-for-inhibition-of-sars-cov-2-key-points-monash-university-imrn-20210513monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-appendix-4d-half-year-31-december-2020-name-of-entity-immuron-limited-abn--imrn-20210225monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-imrn-20201125monthly0.5https://www.biopharmawatch.com/news/IMRN/notice-under-section-708a-5-of-the-corporations-act-asx-code-imc-this-notice-is-given-unde-imrn-20201118monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-imrn-20201117monthly0.5https://www.biopharmawatch.com/news/IMRN/proposed-issue-of-securities-announcement-summary-entity-name-immuron-limited-announcement-imrn-20201113monthly0.5https://www.biopharmawatch.com/news/IMRN/us-dod-naval-medical-research-center-reports-positive-immunological-responses-to-vaccine-k-imrn-20201109monthly0.5https://www.biopharmawatch.com/news/IMRN/forging-commercial-clinical-pathways-targeting-infectious-diseases-with-oral-immunotherapi-imrn-20201029monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-travelers-diarrhea-market-update-key-points-immuron-s-imm-124e-ind-program-recomme-imrn-20201012monthly0.5https://www.biopharmawatch.com/news/IMRN/time-of-agm-clarification-melbourne-australia-imrn-20200930monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-abn-80-063-114-045-annual-report-30-june-2020-corporate-directory-1-chairm-imrn-20200928monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-appendix-4e-30-june-2020-immuron-limited-appendix-4e-year-ended-30-june-20-imrn-20200901monthly0.5https://www.biopharmawatch.com/news/IMRN/this-appendix-is-not-available-as-an-online-form-please-fill-in-and-submit-as-a-pdf-announ-imrn-20200729monthly0.5https://www.biopharmawatch.com/news/IMRN/this-appendix-is-not-available-as-an-online-form-please-fill-in-and-submit-as-a-pdf-announ-imrn-20200724monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-us-20-0-million-registered-direct-offering-melbourne-australia-imrn-20200722monthly0.5https://www.biopharmawatch.com/news/IMRN/us-dod-naval-medical-research-center-receives-fda-guidance-on-the-clinical-development-pla-imrn-20200720monthly0.5https://www.biopharmawatch.com/news/IMRN/this-appendix-is-not-available-as-an-online-form-please-fill-in-and-submit-as-a-pdf-announ-imrn-20200706monthly0.5https://www.biopharmawatch.com/news/IMRN/this-appendix-is-not-available-as-an-online-form-please-fill-in-and-submit-as-a-pdf-announ-imrn-20200623monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-appendix-4d-half-year-31-december-2019-name-of-entity-immuron-limited-abn--imrn-20200619monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-and-csiro-to-produce-a-new-oral-therapeutic-for-clinical-evaluation-by-the-us-depa-imrn-20200619monthly0.5https://www.biopharmawatch.com/news/IMRN/this-appendix-is-not-available-as-an-online-form-please-fill-in-and-submit-as-a-pdf-announ-imrn-20200616monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-imrn-20200612monthly0.5https://www.biopharmawatch.com/news/IMRN/us-dod-naval-medical-research-center-requests-meeting-with-fda-for-guidance-on-two-phase-2-imrn-20200609monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-board-relinquish-cash-payment-of-fees-melbourne-australia-imrn-20200427monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-global-sales-up-60-key-highlights-immuron-achieved-60-yoy-growth-in-worldwide-prod-imrn-20200420monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3z-final-director-s-interest-notice-rule-3-19a-3-appendix-3z-final-director-s-int-imrn-20200326monthly0.5https://www.biopharmawatch.com/news/IMRN/resignation-of-ceo-director-and-cost-cutting-amidst-covid-19-wednesday-25-march-2020-melbo-imrn-20200325monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-appendix-4d-half-year-31-december-2019-name-of-entity-immuron-limited-abn--imrn-20200226monthly0.5https://www.biopharmawatch.com/news/IMRN/melbourne-australia-january-28-2020-imrn-20200128monthly0.5https://www.biopharmawatch.com/news/IMRN/gary-s-imrn-20200108monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-plans-phase-3-trial-for-imm-124e-imrn-20191121monthly0.5https://www.biopharmawatch.com/news/IMRN/1-1-forging-commercial-clinical-pathways-targeting-infectious-diseases-with-oral-immunothe-imrn-20191106monthly0.5https://www.biopharmawatch.com/news/IMRN/receives-aud-0-53m-r-d-tax-concession-refund-imrn-20191104monthly0.5https://www.biopharmawatch.com/news/IMRN/melbourne-australia-october-29-2019-imrn-20191029monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-resignation-of-board-member-imrn-20191017monthly0.5https://www.biopharmawatch.com/news/IMRN/north-american-q1-sales-up-111-yoy-imrn-20191015monthly0.5https://www.biopharmawatch.com/news/IMRN/notice-of-2019-annual-general-meeting-and-imrn-20191004monthly0.5https://www.biopharmawatch.com/news/IMRN/new-u-s-department-of-defense-research-collaboration-with-immuron-to-develop-and-clinicall-imrn-20191002monthly0.5https://www.biopharmawatch.com/news/IMRN/reports-immuron-s-travelan-demonstrates-broad-reactivity-to-vibrio-cholera-strains-from-so-imrn-20190904monthly0.5https://www.biopharmawatch.com/news/IMRN/corporate-governance-council-principles-and-recommendations-imrn-20190830monthly0.5https://www.biopharmawatch.com/news/IMRN/no-dividends-have-been-paid-or-declared-by-the-imrn-20190830monthly0.5https://www.biopharmawatch.com/news/IMRN/forging-commercial-clinical-pathways-targeting-infectious-diseases-with-oral-immunotherapi-imrn-20190816monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-reports-results-in-severe-imrn-20190809monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-completes-capital-raising-of-usd-1-35m-melbourne-australia-imrn-20190722monthly0.5https://www.biopharmawatch.com/news/IMRN/announces-proposed-public-offering-of-adss-imrn-20190717monthly0.5https://www.biopharmawatch.com/news/IMRN/of-director-s-interest-notice-imrn-20190624monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-imrn-20190624monthly0.5https://www.biopharmawatch.com/news/IMRN/1-1-forging-commercial-clinical-pathways-targeting-infectious-diseases-with-oral-immunothe-imrn-20190619monthly0.5https://www.biopharmawatch.com/news/IMRN/department-of-defense-reports-final-results-from-travelan-shigellosis-challenge-study-imrn-20190612monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-dr-gary-s-jacob-to-present-at-the-thinkequity-conference-on-imrn-20190502monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3x-initial-director-s-interest-notice-rule-3-19a-1-appendix-3x-initial-director-s-imrn-20190417monthly0.5https://www.biopharmawatch.com/news/IMRN/1-1-forging-commercial-clinical-pathways-targeting-infectious-diseases-with-oral-immunothe-imrn-20190416monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-sales-surge-by-66-in-the-third-quarter-of-fy19-key-highlights-immuron-achieved-66--imrn-20190331monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-abn-80-063-114-045-interim-financial-report-for-the-half-year-31-december--imrn-20190408monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-receives-u-s-patent-on-drug-composition-to-treat-clostridium-difficile-company-pro-imrn-20190319monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-appendix-4d-half-year-31-december-2018-name-of-entity-immuron-limited-abn--imrn-20190228monthly0.5https://www.biopharmawatch.com/news/IMRN/travelan-fy19-1st-half-update-and-geographic-expansion-into-north-america-key-highlights-i-imrn-20190129monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-receives-1-19m-r-d-tax-concession-refund-january-3-rd-2019-melbourne-australia-imm-imrn-20190103monthly0.5https://www.biopharmawatch.com/news/IMRN/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-imrn-20181127monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-asx-imc-monday-19-th-november-2018-results-of-annual-general-meeting-the-c-imrn-20181119monthly0.5https://www.biopharmawatch.com/news/IMRN/nash-clinical-trial-presentation-and-continued-revenue-growth-key-highlights-professor-aru-imrn-20181109monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-lodges-20-f-usa-annual-report-melbourne-australia-imrn-20181101monthly0.5https://www.biopharmawatch.com/news/IMRN/transcript-of-imrn-20181017monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-s-ceo-interviewed-in-us-on-the-redchip-money-report-melbourne-australia-imrn-20181016monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-abn-80-063-114-045-notice-of-annual-general-meeting-and-explanatory-memora-imrn-20181011monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-abn-80-063-114-045-annual-report-for-the-year-ended-30-june-2018-immuron-l-imrn-20180927monthly0.5https://www.biopharmawatch.com/news/IMRN/us-department-of-defense-reports-travelan-protects-against-shigella-in-primates-key-highli-imrn-20180905monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-appendix-4e-30-june-2018-immuron-limited-appendix-4e-preliminary-final-rep-imrn-20180830monthly0.5https://www.biopharmawatch.com/news/IMRN/us-department-of-defense-research-collaboration-moves-forward-key-highlights-three-us-defe-imrn-20180716monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-it-has-received-a-european-patent-grant-for-nash-treatment-melbourne-aus-imrn-20180711monthly0.5https://www.biopharmawatch.com/news/IMRN/company-announcement-resignation-of-joint-company-secretary-melbourne-australia-29-june-20-imrn-20180629monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-board-appointment-melbourne-australia-26-june-2018-australian-biopharmac-imrn-20180626monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-s-travelan-x00ae-sales-continue-to-soar-in-third-quarter-of-fy2018-in-australian-u-imrn-20180423monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-interim-financial-report-31-december-2017-contents-interim-financial-state-imrn-20180319monthly0.5https://www.biopharmawatch.com/news/IMRN/page-1-of-3-15-july-2001-form-604-corporations-act-2001-section-671b-notice-of-change-of-i-imrn-20180319monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-completes-a-5-1m-placement-to-us-fund-melbourne-australia-imrn-20180316monthly0.5https://www.biopharmawatch.com/news/IMRN/monday-12-th-march-2018-kat-kidson-principal-adviser-listings-compliance-melbourne-asx-com-imrn-20180312monthly0.5https://www.biopharmawatch.com/news/IMRN/correction-to-false-and-misleading-news-release-march-7-th-2018-melbourne-australia-immuro-imrn-20180307monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-appendix-4d-half-year-ended-31-december-2017-name-of-entity-immuron-limite-imrn-20180227monthly0.5https://www.biopharmawatch.com/news/IMRN/travelan-revenue-grows-significantly-in-us-and-australia-key-highlights-immuron-s-flag-shi-imrn-20180216monthly0.5https://www.biopharmawatch.com/news/IMRN/us-defense-reports-broad-travelan-reactivity-to-180-pathogenic-bacteria-including-camyloba-imrn-20180129monthly0.5https://www.biopharmawatch.com/news/IMRN/marcum-letteread-imrn-20180118monthly0.5https://www.biopharmawatch.com/news/IMRN/ceo-to-present-on-us-investor-tv-show-and-at-biotech-conference-january-10-th-2018-melbour-imrn-20180110monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-imrn-20180102monthly0.5https://www.biopharmawatch.com/news/IMRN/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-imrn-20171214monthly0.5https://www.biopharmawatch.com/news/IMRN/van-leeuwenhoeck-institute-updates-immuron-research-coverage-22-november-2017-melbourne-au-imrn-20171122monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-granted-us-patent-for-nash-treatment-melbourne-australia-imrn-20171114monthly0.5https://www.biopharmawatch.com/news/IMRN/travelan-experiences-strong-q1-fy2018-sales-growth-key-highlights-significant-growth-of-sa-imrn-20171108monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-imrn-20171010monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-abn-80-063-114-045-annual-report-for-the-year-ended-30-june-2017-immuron-l-imrn-20170929monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-imrn-20170914monthly0.5https://www.biopharmawatch.com/news/IMRN/page-1-of-2-15-july-2001-form-605-corporations-act-2001-section-671b-notice-of-ceasing-to--imrn-20170908monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-4e-preliminary-final-report-for-the-financial-year-ended-30-june-2017-current-rep-imrn-20170831monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-opens-clinical-site-to-evaluate-safety-and-efficacy-of-imm-529-for-treatment-of-cl-imrn-20170828monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-limited-securities-trading-policy-adopted-by-board-resolution-on-thursday-17-th-au-imrn-20170817monthly0.5https://www.biopharmawatch.com/news/IMRN/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-imrn-20170808monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-presents-nash-interim-results-at-bioshares-conference-melbourne-australia-7-august-imrn-20170807monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-announces-management-changes-melbourne-australia-3-august-2017-australian-biopharm-imrn-20170803monthly0.5https://www.biopharmawatch.com/news/IMRN/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-imrn-20170731monthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-expands-on-preliminary-success-imrn-20170713monthly0.5https://www.biopharmawatch.com/news/IMRN/ii-interim-analysis-reveals-improvement-in-liver-enzymes-ast-and-alt-with-good-safety-and--imrn-20170710monthly0.5https://www.biopharmawatch.com/news/IMRN/jfif-d-d-ducky-d-adobe-d-4-imrn-20170705monthly0.5https://www.biopharmawatch.com/news/IMRN/jfif-d-d-ducky-d-adobe-d-4-imrn-20170627monthly0.5https://www.biopharmawatch.com/news/IMRN/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-imrn-20170622monthly0.5https://www.biopharmawatch.com/news/IMRN/jfif-6exif-mm-b-j-1-r-2-i-adobe-photoshop-cs3-windows-2017-06-21-01-46-23-4-imrn-20170621monthly0.5https://www.biopharmawatch.com/news/IMRN/underwriting-agreement-between-immuron-limited-and-joseph-gunnar-co-llc-and-rodman-renshaw-imrn-20170608monthly0.5https://www.biopharmawatch.com/news/XTLB/notice-of-extraordinary-general-meeting-of-shareholders-to-be-held-on-monday-june-22-2026--xtlb-20260515monthly0.5https://www.biopharmawatch.com/news/XTLB/share-purchase-agreement-this-share-purchase-agreement-this-agreement-made-effective-as-of-xtlb-20260429monthly0.5https://www.biopharmawatch.com/news/XTLB/notice-of-extraordinary-general-meeting-of-shareholders-to-be-held-on-february-17-2026-to--xtlb-20260113monthly0.5https://www.biopharmawatch.com/news/XTLB/notice-of-annual-and-extraordinary-general-meeting-of-shareholders-to-be-held-on-july-21-2-xtlb-20250618monthly0.5https://www.biopharmawatch.com/news/XTLB/notice-of-annual-and-extraordinary-general-meeting-of-shareholders-to-be-held-on-july-21-2-xtlb-20250613monthly0.5https://www.biopharmawatch.com/news/XTLB/notice-of-annual-and-extraordinary-general-meeting-of-shareholders-to-be-held-on-july-22-2-xtlb-20240612monthly0.5https://www.biopharmawatch.com/news/XTLB/share-purchase-agreement-this-share-purchase-agreement-this-agreement-made-effective-as-of-xtlb-20240605monthly0.5https://www.biopharmawatch.com/news/XTLB/notice-of-extraordinary-general-meeting-of-shareholders-to-be-held-on-april-30-2024-to-the-xtlb-20240321monthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-to-aquire-the-social-proxy-expands-its-ip-portfolio-to-ai-web-data-the-social-proxy-is-xtlb-20240320monthly0.5https://www.biopharmawatch.com/news/XTLB/notice-of-annual-general-meeting-of-shareholders-to-be-held-on-february-23-2023-to-the-sha-xtlb-20230201monthly0.5https://www.biopharmawatch.com/news/XTLB/notice-of-annual-general-meeting-of-shareholders-to-be-held-on-february-23-2023-to-the-sha-xtlb-20230120monthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-biopharmaceuticals-ltd-condensed-interim-unaudited-consolidated-financial-statements-a-xtlb-20220824monthly0.5https://www.biopharmawatch.com/news/XTLB/notice-of-annual-general-meeting-of-shareholders-to-be-held-on-january-19-2022-to-the-shar-xtlb-20211216monthly0.5https://www.biopharmawatch.com/news/XTLB/operating-and-financial-review-and-prospects-you-should-read-the-following-discussion-and--xtlb-20210824monthly0.5https://www.biopharmawatch.com/news/XTLB/notice-of-extraordinary-general-meeting-of-shareholders-to-be-held-on-march-29-2021-to-the-xtlb-20210222monthly0.5https://www.biopharmawatch.com/news/XTLB/notice-of-annual-general-meeting-of-shareholders-to-be-held-on-december-31-2020-to-the-sha-xtlb-20201125monthly0.5https://www.biopharmawatch.com/news/XTLB/notice-of-extraordinary-general-meeting-of-shareholders-to-be-held-on-june-30-2020-to-the--xtlb-20200526monthly0.5https://www.biopharmawatch.com/news/XTLB/general-meeting-of-shareholders-xtlb-20200113monthly0.5https://www.biopharmawatch.com/news/XTLB/to-the-shareholders-of-xtl-biopharmaceuticals-xtlb-20191218monthly0.5https://www.biopharmawatch.com/news/XTLB/notice-of-annual-general-meeting-of-shareholders-to-be-held-on-december-20-2018-to-the-sha-xtlb-20181115monthly0.5https://www.biopharmawatch.com/news/XTLB/www-xtlb-20181108monthly0.5https://www.biopharmawatch.com/news/XTLB/extraordinary-general-meeting-of-shareholders-xtlb-20180410monthly0.5https://www.biopharmawatch.com/news/XTLB/2017-annual-general-meeting-of-shareholders-xtlb-20170622monthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-biopharmaceuticals-announces-2-5-million-registered-direct-offering-raanana-israel-xtlb-20170217monthly0.5https://www.biopharmawatch.com/news/XTLB/www-xtlbio-com-xtl-biopharmaceuticals-nasdaq-xtlb-tase-xtlb-ta-january-2017-xtlb-20170105monthly0.5https://www.biopharmawatch.com/news/XTLB/operating-and-financial-review-and-prospects-you-should-read-the-following-discussion-of-o-xtlb-20160927monthly0.5https://www.biopharmawatch.com/news/XTLB/in-accordance-with-regulation-7-of-the-israeli-companies-regulations-xtlb-20160218monthly0.5https://www.biopharmawatch.com/news/XTLB/operating-and-financial-review-and-prospects-you-should-read-the-following-discussion-of-o-xtlb-20150921monthly0.5https://www.biopharmawatch.com/news/XTLB/september-2015-www-xtlbio-com-xtlb-20150910monthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-biopharmaceuticals-appoints-dr-jonathan-schapiro-md-and-dr-dobroslav-melamed-to-the-bo-xtlb-20141208monthly0.5https://www.biopharmawatch.com/news/XTLB/january-2014-www-xtlbio-com-xtl-biopharmaceuticals-nasdaq-xtlb-tase-xtl-forward-looking-st-xtlb-20140124monthly0.5https://www.biopharmawatch.com/news/XTLB/of-extraordinary-general-meetings-and-further-changes-to-board-xtlb-20080828monthly0.5https://www.biopharmawatch.com/news/XTLB/unassociated-document-notification-of-annual-general-meeting-and-extraordinary-general-mee-xtlb-20080611monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-reverse-stock-split-common-stock-will-begin-trading-on-split-adjusted--sngx-20240531monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-provides-regulatory-update-on-hybryte-princeton-nj-sngx-20230414monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-reverse-stock-split-common-stock-will-begin-trading-on-split-adjusted--sngx-20230210monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-inc-29-emmons-drive-suite-b-10-princeton-nj-08540-sngx-20221219monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-advancing-to-important-sngx-20200114monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-appoints-jonathan-guarino-as-chief-sngx-20190911monthly0.5https://www.biopharmawatch.com/news/SNGX/announces-positive-recommendation-by-independent-data-monitoring-committee-on-its-phase-3--sngx-20181015monthly0.5https://www.biopharmawatch.com/news/SNGX/pearson-to-its-board-of-directors-sngx-20180725monthly0.5https://www.biopharmawatch.com/news/SNGX/driving-towards-key-inflection-points-sngx-20180719monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-inc-sngx-20180702monthly0.5https://www.biopharmawatch.com/news/SNGX/driving-towards-key-inflection-points-sngx-20180125monthly0.5https://www.biopharmawatch.com/news/SNGX/nasdaq-sngx-rising-to-the-challenges-of-rare-disease-treatment-forward-looking-statements--sngx-20170614monthly0.5https://www.biopharmawatch.com/news/SNGX/nasdaq-sngx-rising-to-the-challenges-of-rare-disease-treatment-forward-looking-statements--sngx-20170223monthly0.5https://www.biopharmawatch.com/news/SNGX/nasdaq-sngx-rising-to-the-challenges-of-rare-disease-treatment-forward-looking-statements--sngx-20170118monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-closing-of-public-offering-princeton-nj-sngx-20161216monthly0.5https://www.biopharmawatch.com/news/SNGX/announces-positive-long-term-follow-up-results-from-its-sngx-20161208monthly0.5https://www.biopharmawatch.com/news/SNGX/announces-reverse-split-in-preparation-for-proposed-sngx-20161007monthly0.5https://www.biopharmawatch.com/news/SNGX/otc-qb-sngx-rising-to-the-challenges-of-rare-disease-treatment-forward-looking-statements--sngx-20160622monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-closes-7-1-million-public-offering-princeton-nj-sngx-20130626monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-pricing-of-public-offering-sngx-20130624monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-provides-corporate-update-announces-election-of-tamar-d-howson-and-virgil-d-thom-sngx-20100927monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-first-quarter-2010-financial-results-and-reviews-accomplishments-princet-sngx-20100517monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-year-end-2009-financial-results-and-reviews-accomplishments-princeton-nj-sngx-20100401monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-press-release-3q-09-ex99-1-htm-soligenix-logo-soligenix-reports-third-quarter-20-sngx-20091113monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-initiation-of-its-confirmatory-phase-3-clinical-trial-of-orbec-in-acut-sngx-20091015monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-inc-logo-soligenix-appoints-robert-j-rubin-md-to-its-board-of-directors-princeto-sngx-20091009monthly0.5https://www.biopharmawatch.com/news/SNGX/dor-biopharma-inc-29-emmons-drive-suite-c-10-princeton-nj-08540-www-dorbiopharma-com-dor-b-sngx-20090921monthly0.5https://www.biopharmawatch.com/news/SNGX/dor-biopharma-inc-29-emmons-drive-suite-c-10-princeton-nj-08540-www-dorbiopharma-com-dor-b-sngx-20090814monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-financial-results-for-the-first-drma-20260513monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-announces-up-to-12-4-million-private-placement-priced-at-the-market-u-drma-20251224monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-third-quarter-2025-financial-re-drma-20251114monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-second-quarter-2025-financial-r-drma-20250813monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-first-quarter-2025-financial-re-drma-20250514monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-s-xyngari-phase-3-trial-hits-statistically-significant-difference-at-4-weeks-derma-drma-20250415monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-announces-exercise-of-warrants-for-6-2-million-in-gross-proceeds-pric-drma-20250327monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-year-end-2024-financial-results-drma-20250317monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-announces-2-55-million-private-placement-priced-at-the-market-under-n-drma-20250122monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-and-revance-enter-clinical-trial-collaboration-agreement-for-the-topical-applicati-drma-20250121monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-third-quarter-2024-financial-re-drma-20241113monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-announces-3-5-million-private-placement-priced-at-the-market-under-na-drma-20240916monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-second-quarter-2024-financial-r-drma-20240807monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-announces-exercise-of-warrants-for-2-66-million-in-gross-proceeds-pri-drma-20240517monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-first-quarter-2024-financial-re-drma-20240515monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-full-year-2023-financial-result-drma-20240321monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-announces-exercise-of-warrants-for-2-26-million-in-gross-proceeds-priced-at-the-ma-drma-20231116monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-third-quarter-2023-financial-re-drma-20231109monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-second-quarter-2023-financial-r-drma-20230810monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-announces-1-8-million-offering-priced-at-the-market-under-nasdaq-rule-drma-20230524monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-first-quarter-2023-financial-re-drma-20230511monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-announces-pricing-of-5-0-million-public-offering-san-diego-ca-accessw-drma-20230316monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-full-year-2022-financial-result-drma-20230221monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-announces-topline-results-from-dmt310-phase-2-clinical-trial-for-the-treatment-of--drma-20221205monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-third-quarter-2022-financial-re-drma-20221110monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-second-quarter-2022-financial-r-drma-20220815monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-first-quarter-2022-financial-re-drma-20220516monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-announces-5-0-million-private-placement-priced-at-the-market-under-na-drma-20220421monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-full-year-2021-financial-result-drma-20220328monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-appoints-life-science-executive-brittany-bradrick-to-board-of-directors-drma-20220113monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-announces-positive-results-from-dmt410-phase-1b-proof-of-concept-study-for-aesthet-drma-20211119monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-inc-reports-third-quarter-2021-financial-results-and-provides-corpora-drma-20211115monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-inc-reports-second-quarter-2021-financial-results-and-provides-corpor-drma-20210927monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-inc-announces-appointment-of-kyri-van-hoose-as-senior-vice-president--drma-20210901monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-second-quarter-of-fiscal-year-2022-financial-results-austin-texas-astc-20220211monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-announces-date-for-fiscal-year-2021-annual-meeting-and-deadlines-for-stockholder-astc-20220106monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-begins-search-for-strategic-acquisitions-austin-texas-astc-20211117monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-first-quarter-of-fiscal-year-2022-financial-results-austin-texas-astc-20211112monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-fiscal-year-2021-financial-results-austin-texas-astc-20210920monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-third-quarter-of-fiscal-year-2021-financial-results-austin-texas-astc-20210513monthly0.5https://www.biopharmawatch.com/news/ASTC/this-announcement-is-neither-an-offer-to-sell-nor-a-solicitation-of-an-offer-to-buy-any-of-astc-20210412monthly0.5https://www.biopharmawatch.com/news/ASTC/exhibit-b-budget-and-payment-schedule-19-astc-20210406monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-engages-sanmina-to-scale-manufacturing-austin-texas-astc-20210330monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-second-quarter-of-fiscal-year-2021-financial-results-austin-texas-astc-20210216monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-announces-9-25-million-registered-direct-offering-priced-at-the-market-austin-te-astc-20210211monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-first-quarter-of-fiscal-year-2021-financial-results-austin-texas-astc-20201112monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-announces-6-2-million-registered-direct-offering-priced-at-the-market-austin-tex-astc-20201029monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-announces-pricing-of-18-0-million-upsized-public-offering-austin-texas-astc-20201021monthly0.5https://www.biopharmawatch.com/news/ASTC/in-witness-whereof-the-parties-by-their-authorized-representatives-have-evidenced-their-co-astc-20201020monthly0.5https://www.biopharmawatch.com/news/ASTC/st-detect-s-tracer-1000-achieves-milestone-in-tsa-air-cargo-screening-qualification-test-a-astc-20200909monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-fiscal-year-2020-financial-results-aglab-introduces-the-aglab-1000-d2-au-astc-20200908monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-third-quarter-of-fiscal-year-2020-financial-results-austin-texas-astc-20200513monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-announces-3-27-million-registered-direct-offering-priced-at-the-market-austin-te-astc-20200327monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-announces-1-77-million-registered-direct-offering-priced-at-the-market-austin-te-astc-20200325monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-second-quarter-of-fiscal-year-2020-financial-results-austin-texas-astc-20200213monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-first-quarter-of-fiscal-year-2020-financial-results-austin-texas-astc-20191113monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-fiscal-year-2019-financial-results-austin-texas-astc-20190927monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-third-quarter-of-fiscal-year-2019-financial-results-austin-texas-astc-20190513monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-s-ceo-makes-investment-in-the-company-austin-texas-astc-20190417monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-second-quarter-of-fiscal-year-2019-financial-results-austin-texas-astc-20190212monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-first-quarter-of-fiscal-year-2019-financial-results-austin-texas-astc-20181114monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-announces-investment-from-ceo-and-current-shareholder-austin-texas-astc-20181009monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-201-west-5-th-street-suite-1275-austin-texas-78701-o-512-485-9530-f--astc-20180924monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-announces-changes-to-board-of-directors-and-compensation-actions-to-promote-cost-astc-20180629monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-third-quarter-of-fiscal-year-2018-financial-results-austin-texas-astc-20180514monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-second-quarter-of-fiscal-year-2018-financial-results-austin-texas-astc-20180208monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-first-quarter-of-fiscal-year-2018-financial-results-austin-texas-astc-20171108monthly0.5https://www.biopharmawatch.com/news/ASTC/eric-stober-chief-financial-officer-astrotech-corporation-512-485-9530-ir-contact-cathy-ma-astc-20171103monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-201-west-5th-street-suite-1275-austin-texas-78701-o-512-485-9530-f-5-astc-20170918monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-third-quarter-of-fiscal-year-2017-financial-results-austin-texas-astc-20170509monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-second-quarter-of-fiscal-year-2017-financial-results-austin-texas-astc-20170209monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-first-quarter-of-fiscal-year-2017-financial-results-total-revenue-of-1-0-astc-20161110monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-5914-w-courtyard-dr-suite-340-austin-texas-512-485-9530-fax-512-485--astc-20160926monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-third-quarter-of-fiscal-year-2016-financial-results-austin-texas-astc-20160509monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-second-quarter-of-fiscal-year-2016-financial-results-austin-texas-astc-20160209monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20151209monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-first-quarter-of-fiscal-year-2016-financial-results-iontrac-1-st-detect--astc-20151109monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20150923monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20150217monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20150203monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-board-of-directors-authorizes-a-repurchase-of-up-to-5-million-of-the-company-s-o-astc-20141216monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20141114monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-fourth-quarter-and-astc-20140930monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20140820monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-completes-internal-reorganization-to-own-100-of-subsidiary-equity-austin-tx-astc-20140611monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-to-sell-astrotech-astc-20140530monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-third-quarter-2014-financial-astc-20140514monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20140414monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20140214monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20131114monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20131015monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20130515monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-tx-78701-512-485-9530-fax-512-485-953-astc-20130214monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-tx-78701-512-485-9530-fax-512-485-953-astc-20121114monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-tx-78701-512-485-9530-fax-512-485-953-astc-20120928monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-tx-78701-512-485-9530-fax-512-485-953-astc-20120809monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-tx-78701-512-485-9530-fax-512-485-953-astc-20120522monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20120507monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20120229monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20120203monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20111115monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-78701-512-485-9530-fax-512-485--astc-20111014monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-subsidiary-wins-1-9-million-contract-for-nasa-mission-astrotech-space-operations-astc-20110922monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20110920monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20110907monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20110511monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20110502monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20110204monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20101105monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20101026monthly0.5https://www.biopharmawatch.com/news/ASTC/st-detect-corporation-111-congress-suite-400-austin-texas-78701-1-512-485-9530-fax-1-512-4-astc-20100914monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9530-fax-512-485-9531-w-astc-20100830monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-78701-512-485-9530-fax-512-485--astc-20100726monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-78701-512-485-9530-fax-512-485--astc-20100716monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-completes-review-of-strategic-alternatives-austin-texas-astc-20100714monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-78701-512-485-9530-fax-512-485--astc-20100617monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-78701-512-485-9530-fax-512-485--astc-20100517monthly0.5https://www.biopharmawatch.com/news/ASTC/third-amendment-to-loan-agreement-this-third-amendment-to-loan-agreement-this-amendment-da-astc-20100401monthly0.5https://www.biopharmawatch.com/news/ASTC/st-detect-corporation-401-congress-suite-1650-austin-texas-78701-512-485-9530-fax-512-485--astc-20100303monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-78701-512-485-9530-fax-512-485--astc-20100201monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-78701-512-485-9530-fax-512-485--astc-20091112monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-reports-financial-results-for-fourth-quarter-and-fiscal-year-2009-and-announces--astc-20090928monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9520-fax-512-485-9531-w-astc-20090731monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-401-congress-suite-1650-austin-texas-512-485-9520-fax-512-485-9531-w-astc-20090624monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-907-gemini-street-houston-texas-77058-2762-1-713-558-5000-fax-1-713--astc-20090608monthly0.5https://www.biopharmawatch.com/news/ASTC/astrotech-corporation-907-gemini-street-houston-texas-77058-2762-1-713-558-5000-fax-1-713--astc-20090512monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-907-gemini-houston-texas-77058-2762-1-713-558-5000-fax-1-713-558-5960-www-spa-astc-20081113monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-907-gemini-houston-texas-77058-1-713-558-5000-fax-1-713-558-5960-www-spacehab-astc-20081020monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-907-gemini-houston-texas-77058-2762-1-713-558-5000-fax-1-713-558-5960-www-spa-astc-20081010monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-907-gemini-houston-texas-77058-2762-1-713-558-5000-fax-1-713-558-5960-www-spa-astc-20080929monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20080609monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20080604monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20080530monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20080408monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20080212monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20080208monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20080125monthly0.5https://www.biopharmawatch.com/news/ASTC/roscoe-m-moore-iii-chief-strategic-and-technical-officer-spacehab-inc-12130-highway-3-buil-astc-20071204monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-announces-results-of-special-meeting-of-shareholders-houston-texas-astc-20071121monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20071022monthly0.5https://www.biopharmawatch.com/news/ASTC/c-spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-713-558-5000-fax-1-713-558--astc-20071005monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20071002monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20070928monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20070919monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20070831monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20070810monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20070612monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20070508monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20070405monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20070221monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20070213monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20070104monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20061214monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20061114monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20061107monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20061006monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20060905monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20060601monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20060516monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20060509monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20060228monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20060209monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20060207monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20051202monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20051201monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20051122monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-incorporated-spab-nasdaq-completes-exchange-offer-for-63-250-000-of-its-5-5-senio-astc-20051117monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20051114monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20051110monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20051108monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-incorporated-spab-nasdaq-amends-exchange-offer-and-postpones-special-meeting-of-s-astc-20051020monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-incorporated-spab-nasdaq-extends-deadline-of-exchange-offer-to-november-10-2005-h-astc-20051010monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20051004monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20050929monthly0.5https://www.biopharmawatch.com/news/ASTC/presentation-to-holders-of-outstanding-notes-presentation-to-holders-of-outstanding-notes--astc-20050915monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20050906monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20050811monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20050714monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20050602monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20041006monthly0.5https://www.biopharmawatch.com/news/ASTC/spacehab-inc-12130-highway-3-bldg-1-webster-texas-77598-1504-1-713-558-5000-fax-1-713-558--astc-20040908monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-new-data-from-captn-3-platform-tri-specific-im1240-data-generated-ppbt-20260427monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-establishes-scientific-advisory-board-to-support-development-of-captn-3-tri-ppbt-20260423monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-ai-collaboration-with-converge-bio-to-accelerate-development-of-i-ppbt-20260325monthly0.5https://www.biopharmawatch.com/news/PPBT/corporate-presentation-march-2026-advancing-the-next-generation-of-immuno-oncology-nasdaq--ppbt-20260319monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-regains-compliance-with-nasdaq-minimum-bid-price-requirement-ppbt-20260317monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-fourth-quarter-and-full-year-2025-financial-results-prioritized-dev-ppbt-20260313monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-plan-to-implement-ads-ratio-change-ads-will-begin-trading-reflect-ppbt-20260225monthly0.5https://www.biopharmawatch.com/news/PPBT/corporate-presentation-january-2026-advancing-the-next-generation-of-immuno-oncology-nasda-ppbt-20260113monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-achieves-toxicology-milestone-demonstrating-an-expanded-therapeutic-window--ppbt-20260107monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-positive-new-preclinical-data-demonstrating-multi-arm-anti-tumor-ac-ppbt-20251211monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-november-2025-corporate-presentation-2-forward-looking-statements-and-saf-ppbt-20251119monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-third-quarter-2025-financial-results-and-provides-business-update-i-ppbt-20251114monthly0.5https://www.biopharmawatch.com/news/PPBT/notice-of-extraordinary-general-meeting-of-shareholders-notice-is-hereby-given-that-an-ext-ppbt-20251028monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-receipt-of-nasdaq-minimum-bid-price-notification-rehovot-israel-o-ppbt-20251016monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-september-2025-corporate-presentation-2-forward-looking-statements-and-sa-ppbt-20250910monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-receives-intention-to-grant-a-european-patent-covering-nt219-combinations-w-ppbt-20250910monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-pricing-of-up-to-18-million-public-offering-6-million-upfront-wit-ppbt-20250904monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-new-data-supporting-the-unique-design-of-captn-3-tri-specific-ant-ppbt-20250904monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-expands-captn-3-portfolio-with-im1305-a-novel-tri-specific-antibody-targeti-ppbt-20250903monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-second-quarter-2025-financial-results-platform-validating-preclinic-ppbt-20250806monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-ceo-issues-letter-to-shareholders-highlighting-pipeline-progress-and-clinic-ppbt-20250723monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-july-2025-corporate-presentation-2-forward-looking-statements-and-safe-ha-ppbt-20250710monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-highlights-significant-advantages-of-the-novel-captn-3-tri-specific-antibod-ppbt-20250623monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-initiation-of-phase-2-study-of-nt219-in-patients-with-head-and-ne-ppbt-20250617monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-first-quarter-2025-financial-results-final-cm24-phase-2-data-presen-ppbt-20250521monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-appoints-shai-lankry-as-chief-financial-officer-u-s-based-lankry-brings-ove-ppbt-20250512monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-may-2025-corporate-presentation-2-forward-looking-statements-and-safe-har-ppbt-20250506monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-final-data-from-phase-2-study-of-cm24-in-pancreatic-cancer-patients-ppbt-20250430monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-positive-nt219-data-at-aacr-for-colorectal-and-head-and-neck-cancer-ppbt-20250428monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-publication-in-the-neuro-oncology-journal-demonstrating-the-poten-ppbt-20250416monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-to-participate-in-panel-discussion-at-canaccord-genuity-horizons-in-oncolog-ppbt-20250401monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-three-posters-accepted-for-presentation-at-the-2025-american-asso-ppbt-20250328monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-march-2025-corporate-presentation-2-forward-looking-statements-and-safe-h-ppbt-20250318monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-fourth-quarter-and-full-year-2024-financial-results-completed-succe-ppbt-20250310monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-granted-new-u-s-patent-for-nt219-in-combination-with-egfr-antibody-therapy--ppbt-20250305monthly0.5https://www.biopharmawatch.com/news/PPBT/notice-of-annual-general-meeting-of-shareholders-notice-is-hereby-given-that-an-annual-gen-ppbt-20250228monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-advances-nt219-into-phase-2-head-and-neck-cancer-trial-nt219-a-novel-agent--ppbt-20250218monthly0.5https://www.biopharmawatch.com/news/PPBT/purpl-e-biotech-announces-research-collaboration-with-the-icahn-school-of-medicine-at-moun-ppbt-20250203monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-december-2024-corporate-presentation-2-forward-looking-statements-and-saf-ppbt-20241206monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-closing-of-2-8-million-registered-direct-offering-of-american-dep-ppbt-20241205monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-2-8-million-registered-direct-offering-of-american-depositary-sha-ppbt-20241203monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-positive-final-results-from-randomized-phase-2-study-of-cm24-in-sec-ppbt-20241202monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-third-quarter-2024-financial-results-topline-data-from-phase-2-cm24-ppbt-20241115monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-identifies-potential-new-serum-biomarker-for-its-lead-oncology-therapeutic--ppbt-20241104monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-presents-new-data-for-its-novel-tri-specific-t-cell-and-nk-cell-engagers-an-ppbt-20241025monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-to-present-data-for-its-tri-specific-antibody-platform-captn-3-at-the-eortc-ppbt-20241010monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-october-2024-corporate-presentation-2-forward-looking-statements-and-safe-ppbt-20241009monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-additional-positive-interim-data-from-its-randomized-phase-2-study--ppbt-20240918monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-august-2024-corporate-presentation-2-forward-looking-statements-and-safe--ppbt-20240819monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-second-quarter-2024-financial-results-and-business-highlights-posit-ppbt-20240816monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-receives-extension-to-regain-compliance-with-the-nasdaq-s-minimum-bid-price-ppbt-20240725monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-july-2024-corporate-presentation-2-forward-looking-statements-and-safe-ha-ppbt-20240719monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-closing-of-exercise-of-warrants-for-2-million-gross-proceeds-ppbt-20240702monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-exercise-of-warrants-for-2-million-gross-proceeds-ppbt-20240701monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-additional-positive-interim-results-from-its-randomized-phase-2-pan-ppbt-20240627monthly0.5https://www.biopharmawatch.com/news/PPBT/notice-of-annual-general-meeting-of-shareholders-notice-is-hereby-given-that-an-annual-gen-ppbt-20240626monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-june-2024-corporate-presentation-forward-looking-statements-and-safe-harb-ppbt-20240604monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-positive-late-breaking-interim-randomized-phase-2-data-at-asco-20-ppbt-20240601monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-first-quarter-2024-financial-results-cm24-phase-2-pancreatic-cancer-ppbt-20240521monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-may-2024-corporate-presentation-2-forward-looking-statements-and-safe-har-ppbt-20240502monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-s-randomized-phase-2-cm24-pancreatic-cancer-study-selected-as-late-breaking-ppbt-20240425monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-to-present-new-data-on-its-oncology-drug-nt219-at-aacr-2024-nt219-found-to--ppbt-20240328monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-preclinical-proof-of-concept-for-its-tribody-platform-technology-co-ppbt-20240314monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-march-2024-corpor-a-te-presen-t-a-tion-fo-r-war-d-lo-o-kin-g-sta-t-em-e-n-ppbt-20240306monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-fourth-quarter-and-full-year-2023-financial-results-ppbt-20240305monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-presents-data-of-its-phase-1-head-neck-cancer-of-nt219-in-combination-with--ppbt-20240227monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-convenes-a-head-neck-cancer-scientific-advisory-board-in-preparation-for-nt-ppbt-20240212monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reaches-recommended-phase-2-dose-for-nt219-ppbt-20240201monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-appoints-dr-yael-margolin-to-its-board-of-directors-dr-margolin-brings-35-y-ppbt-20231220monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-completes-patient-enrollment-in-phase-2-pancreatic-cancer-trial-this-accele-ppbt-20231214monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-november-2023-corpo-r-a-te-presen-t-a-tion-fo-r-ward-lookin-g-sta-t-emen--ppbt-20231121monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-third-quarter-2023-financial-results-initial-activity-in-head-and-n-ppbt-20231121monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-fortifies-nt219-patent-protection-new-patent-granted-in-china-for-pharmaceu-ppbt-20231102monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-closing-of-5-million-registered-direct-offering-ppbt-20231019monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-5-million-registered-direct-offering-ppbt-20231017monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-october-2023-corporate-presentation-2-forward-looking-statements-and-safe-ppbt-20231013monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-potential-biomarker-data-support-cm24-s-mechanism-of-action-ppbt-20231006monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-positive-interim-and-preliminary-results-from-nt219-phase-1-2-study-ppbt-20231003monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-to-present-new-cm24-pancreatic-cancer-biomarker-data-at-aacr-special-confer-ppbt-20230921monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-september-2023-corporate-presentation-forward-looking-statements-and-safe-ppbt-20230913monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-second-quarter-2023-financial-results-financial-results-represent-c-ppbt-20230822monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-positive-results-of-cm24-dose-escalation-in-advanced-pancreatic-can-ppbt-20230711monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-first-quarter-2023-financial-results-and-provides-business-update-e-ppbt-20230516monthly0.5https://www.biopharmawatch.com/news/PPBT/notice-of-annual-general-meeting-of-shareholders-notice-is-hereby-given-that-an-annual-gen-ppbt-20230501monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-debuts-scientific-advisory-board-scientific-advisory-board-inaugurates-new--ppbt-20230425monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-new-preclinical-data-on-potential-of-nt219-to-re-sensitize-resistan-ppbt-20230419monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-temporary-medical-leave-of-ceo-gil-efron-board-of-directors-appoint-ppbt-20230324monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-biomarker-data-from-cm24-phase-1-dose-escalation-study-reduction-in-ppbt-20230316monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-first-patient-dosed-in-open-label-randomized-part-of-cm24-phase-2-ppbt-20230214monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-fourth-quarter-and-full-year-2022-financial-results-expands-pipelin-ppbt-20230208monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-february-2023-corporate-presentation-2-forward-looking-statements-and-saf-ppbt-20230203monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-expands-pipeline-of-first-in-class-therapeutics-with-acquisition-of-immunor-ppbt-20230202monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-january-2023-corporate-presentation-2-forward-looking-statements-and-safe-ppbt-20230106monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-and-mor-research-applications-announce-research-collaboration-to-identify-p-ppbt-20230103monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-presents-new-data-on-mechanism-of-action-for-cm24-at-the-aacr-special-confe-ppbt-20221115monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-november-2022-corporate-presentation-2-forward-looking-statements-and-saf-ppbt-20221109monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-third-quarter-2022-financial-results-well-capitalized-with-cash-run-ppbt-20221108monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-appoints-lior-fhima-as-chief-financial-officer-seasoned-financial-executive-ppbt-20221102monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-second-quarter-2022-financial-results-ppbt-20220804monthly0.5https://www.biopharmawatch.com/news/PPBT/notice-of-annual-general-meeting-of-shareholders-notice-is-hereby-given-that-an-annual-gen-ppbt-20220718monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-executive-leadership-changes-gil-efron-appointed-as-chief-executi-ppbt-20220714monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-june-2022-corporate-presentation-forward-looking-statements-and-safe-harb-ppbt-20220606monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-presents-phase-1-interim-monotherapy-data-for-nt219-at-asco-2022-demonstrat-ppbt-20220527monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-the-initiation-of-phase-2-study-for-cm24-in-2l-pdac-patients-deci-ppbt-20220517monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-first-quarter-2022-financial-results-ppbt-20220512monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-presents-positive-interim-phase-1b-study-results-for-cm24-at-the-american-a-ppbt-20220411monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-reports-second-half-and-full-year-2021-financial-results-ppbt-20220209monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-issues-letter-to-shareholders-ppbt-20220204monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-appoints-life-sciences-industry-investor-ori-hershkovitz-to-its-board-of-di-ppbt-20220106monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-appoints-senior-business-development-executive-fabien-sebille-as-chief-busi-ppbt-20211209monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-initiation-of-part-2-of-ongoing-phase-1-2-clinical-trial-evaluati-ppbt-20211206monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-november-2021-corporate-presentation-2-forward-looking-statements-and-saf-ppbt-20211116monthly0.5https://www.biopharmawatch.com/news/PPBT/notice-of-annual-general-meeting-of-shareholders-notice-is-hereby-given-that-an-annual-gen-ppbt-20211110monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-ltd-consolidated-unaudited-statements-of-financial-position-as-of-september-ppbt-20211104monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-expands-research-collaboration-in-immuno-oncology-in-combination-with-nt219-ppbt-20211026monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-publication-in-nature-cancer-demonstrating-mechanisms-behind-canc-ppbt-20211022monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-to-present-overview-of-ongoing-phase-1b-2-clinical-trial-of-cm24-for-treatm-ppbt-20210913monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-provides-corporate-update-and-reports-first-half-2021-financial-results-ppbt-20210805monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-ltd-consolidated-unaudited-statements-of-financial-position-as-of-march-31--ppbt-20210609monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-presents-new-clinical-data-from-nt219-at-the-2021-asco-annual-meeting-nt219-ppbt-20210604monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-to-present-new-clinical-data-from-nt219-at-the-2021-asco-annual-meeting-ini-ppbt-20210520monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-appoints-seasoned-biopharmaceutical-industry-executive-suzana-nahum-zilberb-ppbt-20210519monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-dosing-of-first-patient-in-phase-1b-2-clinical-trial-of-cm24-in-a-ppbt-20210423monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-presents-additional-mechanism-of-action-data-for-nt219-at-american-associat-ppbt-20210413monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-announces-initiation-of-phase-1b-2-clinical-trial-of-cm24-for-treatment-of--ppbt-20210319monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-appoints-biopharmaceutical-industry-veteran-robert-gagnon-to-board-of-direc-ppbt-20210303monthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-provides-corporate-update-and-reports-second-half-and-full-year-2020-financ-ppbt-20210301monthly0.5https://www.biopharmawatch.com/news/PPBT/nasdaq-tase-ppbt-january-2021-corporate-presentation-2-forward-looking-statements-and-safe-ppbt-20210106monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-name-change-to-purple-biotech-ltd-new-name-reflects-company-s-evolution-to-ppbt-20201210monthly0.5https://www.biopharmawatch.com/news/PPBT/corporate-presentation-november-2020-2-forward-looking-statements-and-safe-harbor-certain--ppbt-20201112monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-expands-planned-phase-1-2-clinical-trial-of-cm24-in-non-small-cell-lung-cancer-with--ppbt-20201109monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-receives-notice-of-allowance-for-a-u-s-patent-covering-its-anti-cancer-drug-c-ppbt-20201027monthly0.5https://www.biopharmawatch.com/news/PPBT/notice-of-annual-general-meeting-of-shareholders-notice-is-hereby-given-that-an-annual-gen-ppbt-20201022monthly0.5https://www.biopharmawatch.com/news/PPBT/new-mechanism-of-action-data-for-nt219-presented-at-epigenetics-and-metabolism-aacr-specia-ppbt-20201016monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-dosing-of-first-patient-in-phase-1-2-clinical-trial-of-nt219-in-advanced-c-ppbt-20200908monthly0.5https://www.biopharmawatch.com/news/PPBT/the-companies-law-5759-1999-a-company-limited-by-shares-amended-and-restated-articles-of-a-ppbt-20200817monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-announces-ads-ratio-change-ppbt-20200812monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-provides-corporate-update-and-reports-first-half-2020-financial-results-ppbt-20200811monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-initiation-of-phase-1-2-clinical-trial-of-nt219-in-advanced-cancer-patient-ppbt-20200708monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-receives-notice-of-intention-to-grant-a-european-patent-covering-cm24-its-ant-ppbt-20200708monthly0.5https://www.biopharmawatch.com/news/PPBT/proxy-statement-extraordinary-general-meeting-of-shareholders-this-proxy-statement-is-bein-ppbt-20200702monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-issues-ceo-shareholder-letter-providing-business-update-emerging-oncology-pip-ppbt-20200702monthly0.5https://www.biopharmawatch.com/news/PPBT/notice-of-extraordinary-general-meeting-of-shareholders-notice-is-hereby-given-that-an-ext-ppbt-20200701monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-closes-35-0-million-registered-direct-offering-tel-aviv-israel-ppbt-20200625monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-35-0-million-registered-direct-offering-tel-aviv-israel-ppbt-20200623monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-u-s-fda-acceptance-of-investigational-new-drug-application-to-conduct-phas-ppbt-20200522monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-u-s-commercial-launch-of-consensi-ppbt-20200520monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-to-present-preclinical-data-on-nt219-at-american-association-of-cancer-research-virt-ppbt-20200519monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-to-present-phase-1-data-on-cm-24-in-patients-with-advanced-cancer-at-american-societ-ppbt-20200514monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-closes-10-million-registered-direct-offering-tel-aviv-israel-ppbt-20200508monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-10-million-registered-direct-offering-tel-aviv-israel-ppbt-20200506monthly0.5https://www.biopharmawatch.com/news/PPBT/thank-you-corporate-presentation-may-2020-forward-looking-statements-and-safe-harbor-certa-ppbt-20200504monthly0.5https://www.biopharmawatch.com/news/PPBT/neither-this-security-nor-the-securities-for-which-this-security-is-exercisable-have-been--ppbt-20200420monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-closes-6-0-million-public-offering-tel-aviv-ppbt-20200317monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-pricing-of-6-0-million-public-offering-tel-aviv-ppbt-20200312monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-expands-planned-nt-219-clinical-program-for-difficult-to-treat-cancers-phase--ppbt-20200224monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-provides-corporate-update-and-reports-full-year-2019-financial-results-ppbt-20200211monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-receives-issue-notification-for-a-u-s-patent-covering-its-anti-ceacam1-cancer-ppbt-20200203monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-receives-notice-of-intention-to-grant-european-patent-covering-the-use-of-nt--ppbt-20200124monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-announces-appointment-of-bertrand-liang-m-d-ph-d-as-chief-medical-officer-ppbt-20200109monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-granted-additional-180-day-extension-by-nasdaq-to-comply-with-bid-price-rule-ppbt-20200108monthly0.5https://www.biopharmawatch.com/news/PPBT/2019-annual-general-meeting-ppbt-20191119monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-limited-notice-of-2019-annual-general-meeting-of-shareholders-notice-is-hereb-ppbt-20191112monthly0.5https://www.biopharmawatch.com/news/PPBT/thank-you-corporate-presentation-october-2019-ppbt-20191018monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-announces-amended-marketing-and-distribution-agreement-with-coeptis-and-provi-ppbt-20191011monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-appoints-eric-k-rowinsky-m-d-as-chairman-of-its-board-appointment-of-industry-ppbt-20191002monthly0.5https://www.biopharmawatch.com/news/PPBT/thank-you-corporate-presentation-september-2019-ppbt-20190910monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-presents-newly-released-data-for-nt-219-in-reversing-pancreatic-cancer-drug-r-ppbt-20190909monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-to-present-at-the-h-c-wainwright-21st-annual-healthcare-conference-ppbt-20190903monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-to-present-new-data-on-nt-219-targeting-cancer-drug-resistance-at-the-aacr-pa-ppbt-20190829monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-announces-significant-progress-in-closing-of-famewave-acquisition-deal-orbime-ppbt-20190816monthly0.5https://www.biopharmawatch.com/news/PPBT/administrative-enforcement-agreement-finalized-between-kitov-pharma-and-the-israeli-securi-ppbt-20190814monthly0.5https://www.biopharmawatch.com/news/PPBT/enforcement-arrangement-signed-on-between-the-israel-securities-authority-22-kanfei-neshar-ppbt-20190813monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-reports-first-half-2019-financial-results-and-provides-business-update-ppbt-20190808monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-receives-nasdaq-notification-regarding-minimum-bid-requirements-ppbt-20190712monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-successfully-completes-ind-enabling-studies-to-advance-nt219-for-the-treatment-of-pa-ppbt-20190627monthly0.5https://www.biopharmawatch.com/news/PPBT/thank-you-kitov-pharma-nt219-overcoming-cancer-drug-resistance-isaac-israel-chief-executiv-ppbt-20190516monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-receives-notice-of-allowance-for-additional-u-s-patent-covering-its-commercial-produ-ppbt-20190510monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-to-present-clinical-development-plan-for-oncology-candidate-nt-219-at-the-18th-mixii-ppbt-20190509monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-retirement-of-founder-and-executive-chairman-dr-paul-waymack-dr-waymack-wi-ppbt-20190501monthly0.5https://www.biopharmawatch.com/news/PPBT/jfif-c-c-ppbt-20190415monthly0.5https://www.biopharmawatch.com/news/PPBT/famewave-announces-clinical-collaboration-with-bristol-myers-squibb-for-the-planned-phase--ppbt-20190412monthly0.5https://www.biopharmawatch.com/news/PPBT/proxy-statement-annex-a1-amendment-to-stock-purchase-agreement-this-amendment-number-1-the-ppbt-20190408monthly0.5https://www.biopharmawatch.com/news/PPBT/proxy-statement-further-to-our-notice-of-special-general-meeting-of-shareholders-the-meeti-ppbt-20190322monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-ltd-notice-of-special-general-meeting-of-shareholders-notice-is-hereby-given--ppbt-20190314monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-to-acquire-clinical-stage-candidate-cm-24-creating-a-transformational-immuno-oncolog-ppbt-20190314monthly0.5https://www.biopharmawatch.com/news/PPBT/thank-you-corporate-presentation-february-2019-ppbt-20190211monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-reports-year-end-2018-financial-results-and-provides-business-update-ppbt-20190207monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-closes-6-million-registered-direct-offering-tel-aviv-israel-ppbt-20190118monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-pricing-of-6-million-registered-direct-offering-tel-aviv-israel-ppbt-20190116monthly0.5https://www.biopharmawatch.com/news/PPBT/new-data-on-kitov-s-nt219-demonstrates-its-unique-mechanism-of-action-and-anti-cancer-effe-ppbt-20190115monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-signs-marketing-and-distribution-agreement-for-its-lead-product-consensi-in-the-u-s--ppbt-20190103monthly0.5https://www.biopharmawatch.com/news/PPBT/the-companies-law-5759-1999-a-company-limited-by-shares-amended-and-restated-articles-of-a-ppbt-20181219monthly0.5https://www.biopharmawatch.com/news/PPBT/notice-of-2018-annual-general-meeting-ppbt-20181109monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-appoints-gil-efron-as-deputy-chief-executive-officer-and-chief-financial-officer-sim-ppbt-20181011monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-to-present-data-on-nt219-in-combination-with-keytruda-and-erbitux-at-aacr-internatio-ppbt-20180926monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-updates-on-motions-in-usa-initiated-by-kitov-chairman-tel-aviv-israel-ppbt-20180918monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-ltd-condensed-consolidated-unaudited-interim-financial-statements-as-of-ppbt-20180917monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharma-provides-corporate-update-and-reports-first-half-2018-financial-results-tel-a-ppbt-20180829monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-settlement-of-shareholder-class-action-litigation-tel-aviv-israel-ppbt-20180730monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-to-host-business-update-conference-call-on-monday-july-2-tel-aviv-israel-ppbt-20180627monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-positive-pre-clinical-data-from-nt219-demonstrating-its-dose-dependent-ant-ppbt-20180615monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-pricing-of-8-150-000-registered-direct-offering-tel-aviv-israel-ppbt-20180601monthly0.5https://www.biopharmawatch.com/news/PPBT/fda-approves-kitov-s-consensi-for-treatment-of-osteoarthritis-pain-and-hypertension-new-dr-ppbt-20180531monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-consensi-commercialization-agreement-for-china-kitov-to-receive-milestone--ppbt-20180511monthly0.5https://www.biopharmawatch.com/news/PPBT/tyrnovo-to-present-at-2018-annual-meeting-of-the-american-association-for-cancer-research--ppbt-20180413monthly0.5https://www.biopharmawatch.com/news/PPBT/tyrnovo-to-present-at-bio-europe-spring-2018-conference-treatment-with-tyrnovo-s-nt219-in--ppbt-20180308monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-publishes-annual-report-for-2017-and-issues-ceo-letter-to-shareholde-ppbt-20180305monthly0.5https://www.biopharmawatch.com/news/PPBT/unofficial-english-translation-from-hebrew-corporations-authority-registrar-of-companies-a-ppbt-20180129monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-consensi-as-brand-name-for-kit-302-ppbt-20171214monthly0.5https://www.biopharmawatch.com/news/PPBT/thank-you-innovative-biopharmaceuticals-corporate-presentation-november-2017-ppbt-20171129monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-announces-receipt-of-fda-s-favorable-response-to-nt219-s-pre-ind-mee-ppbt-20171101monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-announces-phase-iii-iv-clinical-trial-for-kit-302-successfully-meets-ppbt-20171026monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-boosts-ownership-in-tyrnovo-and-oncology-platform-through-exchange-of-shares-for-sto-ppbt-20171006monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-filing-by-fda-of-new-drug-application-for-kit-302-ppbt-20171002monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-holdings-ltd-the-company-in-accordance-with-section-318-b-of-the-isr-ppbt-20170928monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-holdings-ltd-condensed-consolidated-interim-financial-statements-as--ppbt-20170816monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-submits-new-drug-application-to-fda-for-kit-302-ppbt-20170731monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-results-of-study-demonstrating-nt-219-enhanced-efficacy-of-keytruda-in-imm-ppbt-20170718monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-announces-pricing-of-3-5-million-registered-direct-offering-tel-aviv-ppbt-20170711monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-updates-on-kit-302-new-drug-application-anticipated-pdufa-date-with-fda-for-approval-ppbt-20170626monthly0.5https://www.biopharmawatch.com/news/PPBT/thank-you-corporate-presentation-june-2017-ppbt-20170615monthly0.5https://www.biopharmawatch.com/news/PPBT/jfif-c-c-ppbt-20170612monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-ltd-unaudited-pro-forma-condensed-consolidated-statement-of-financia-ppbt-20170612monthly0.5https://www.biopharmawatch.com/news/PPBT/is-hereby-given-that-a-special-general-meeting-of-shareholders-the-meeting-or-the-special--ppbt-20170608monthly0.5https://www.biopharmawatch.com/news/PPBT/pharmaceuticals-holdings-limited-ppbt-20170601monthly0.5https://www.biopharmawatch.com/news/PPBT/u-s-food-and-drug-administration-grants-kitov-a-waiver-for-new-drug-application-filing-fee-ppbt-20170403monthly0.5https://www.biopharmawatch.com/news/PPBT/management-s-discussion-and-analysis-of-financial-condition-and-results-of-operations-as-o-ppbt-20170327monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-license-agreement-for-kit-302-in-south-korea-definitive-agreement-grants-k-ppbt-20170308monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-settlement-agreement-with-minority-shareholder-of-recently-acquired-tyrnov-ppbt-20170210monthly0.5https://www.biopharmawatch.com/news/PPBT/unofficial-english-translation-tase-logo-tel-aviv-stock-exchange-ppbt-20170209monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-granted-notice-of-allowance-from-u-s-patent-trademark-office-for-kit-302-patent-furt-ppbt-20170201monthly0.5https://www.biopharmawatch.com/news/PPBT/thank-you-streamlined-innovative-drug-development-tyrnovo-s-nt-219-a-new-concept-in-cancer-ppbt-20170123monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-to-host-business-update-call-on-monday-ppbt-20170117monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-enters-immuno-oncology-field-through-acquisition-of-tyrnovo-tyrnovo-s-nt219-drug-can-ppbt-20170112monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-successfully-completes-all-kit-302-testing-required-for-new-drug-application-to-u-s--ppbt-20161207monthly0.5https://www.biopharmawatch.com/news/PPBT/the-companies-law-5759-1999-a-company-limited-by-shares-amended-and-restated-articles-of-a-ppbt-20161206monthly0.5https://www.biopharmawatch.com/news/PPBT/jfif-c-c-r-ppbt-20161102monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-holdings-limited-notice-of-2016-annual-general-meeting-of-shareholde-ppbt-20161027monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-reports-successful-results-for-additional-kit-302-pharmacokinetic-bioequivalence-stu-ppbt-20160927monthly0.5https://www.biopharmawatch.com/news/PPBT/company-presentation-september-2016-2016-kitov-pharmaceuticals-holdings-ltd-kitov-pharmace-ppbt-20160907monthly0.5https://www.biopharmawatch.com/news/PPBT/pharmaceuticals-to-present-data-from-ppbt-20160906monthly0.5https://www.biopharmawatch.com/news/PPBT/pharmaceuticals-holdings-ltd-ppbt-20160817monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-issuance-of-u-s-patent-securing-long-term-exclusivity-for-kit-302-ahead-of-ppbt-20160810monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-announces-closing-of-a-12-million-follow-on-public-offering-in-the-u-ppbt-20160705monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-announces-pricing-of-12-million-follow-on-public-offering-in-the-u-s-ppbt-20160629monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-s-lead-drug-kit-302-achieves-manufacturing-milestone-ahead-of-planned-nda-filing-wit-ppbt-20160628monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-reports-new-data-demonstrating-kit-302-has-beneficial-effects-on-kidney-function-fin-ppbt-20160624monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-announces-completion-of-manufacturing-pivotal-batches-of-kit-302-required-for-regist-ppbt-20160527monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-holdings-limited-special-general-meeting-of-shareholders-ppbt-20160524monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-holdings-limited-notice-of-special-general-meeting-of-shareholders-n-ppbt-20160520monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-receives-pre-nda-meeting-response-from-fda-for-kit-302-supporting-its-nda-submission-ppbt-20160512monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-reports-kit-302-study-successfully-meets-u-s-food-drug-administration-bioequivalence-ppbt-20160510monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-to-present-at-pioneers-2016-presented-by-joseph-gunnar-in-nyc-on-ppbt-20160505monthly0.5https://www.biopharmawatch.com/news/PPBT/amendment-of-the-articles-145-unless-provided-otherwise-herein-and-specifically-in-article-ppbt-20160303monthly0.5https://www.biopharmawatch.com/news/PPBT/2015-annual-general-meeting-ppbt-20160125monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-to-present-at-biotech-showcase-in-san-francisco-on-ppbt-20160111monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-appoints-dr-gil-ben-menachem-as-v-p-of-business-development-seasoned-ppbt-20160108monthly0.5https://www.biopharmawatch.com/news/PPBT/summary-translation-into-english-of-staff-position-of-the-israel-securities-authority-isra-ppbt-20151217monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-reports-additional-data-from-its-phase-iii-trial-on-the-beneficial-b-ppbt-20151217monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-holdings-ltd-the-company-notice-of-a-special-general-meeting-of-the--ppbt-20151211monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-to-announce-interim-results-of-the-pivotal-phase-iii-trial-on-ppbt-20151210monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-holdings-ltd-the-company-ppbt-20151206monthly0.5https://www.biopharmawatch.com/news/PPBT/company-presentation-december-2015-2015-kitov-pharmaceuticals-ltd-ppbt-20151201monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-holdings-ltd-condensed-consolidated-interim-financial-statements-as--ppbt-20151201monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-holdings-announces-closing-of-u-s-initial-public-offering-tel-aviv-i-ppbt-20151125monthly0.5https://www.biopharmawatch.com/news/PPBT/kitov-pharmaceuticals-holdings-announces-pricing-of-u-s-initial-public-offering-and-nasdaq-ppbt-20151120monthly0.5https://www.biopharmawatch.com/news/INM/filed-by-newsfilecorp-com-nasdaq-inm-suite-1445-885-west-georgia-st-vancouver-bc-canada-v6-inm-20260604monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-e-inm-20260519monthly0.5https://www.biopharmawatch.com/news/INM/filed-by-newsfilecorp-com-nasdaq-inm-suite-1445-885-west-georgia-st-vancouver-bc-canada-v6-inm-20260519monthly0.5https://www.biopharmawatch.com/news/INM/filed-by-newsfilecorp-com-nasdaq-inm-suite-1445-885-west-georgia-st-vancouver-bc-canada-v6-inm-20260507monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-e-inm-20260427monthly0.5https://www.biopharmawatch.com/news/INM/filed-by-newsfilecorp-com-nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8--inm-20260327monthly0.5https://www.biopharmawatch.com/news/INM/filed-by-newsfilecorp-com-nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8--inm-20260323monthly0.5https://www.biopharmawatch.com/news/INM/filed-by-newsfilecorp-com-nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8--inm-20260309monthly0.5https://www.biopharmawatch.com/news/INM/pro-forma-information-on-continuing-operations-the-following-unaudited-pro-forma-consolida-inm-20260306monthly0.5https://www.biopharmawatch.com/news/INM/filed-by-newsfilecorp-com-nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8--inm-20260211monthly0.5https://www.biopharmawatch.com/news/INM/filed-by-newsfilecorp-com-nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8--inm-20251217monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-e-inm-20251212monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-email-i-inm-20251118monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-email-i-inm-20251016monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-email-i-inm-20251009monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-email-i-inm-20250923monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-email-i-inm-20250905monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-email-i-inm-20250728monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-email-i-inm-20250625monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-email-i-inm-20250512monthly0.5https://www.biopharmawatch.com/news/INM/resignation-to-lnmed-pharmaceuticals-inc-the-company-attention-andrew-hull-chairman-dear-a-inm-20250214monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-email-i-inm-20250212monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-email-i-inm-20250203monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-email-i-inm-20250122monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-email-i-inm-20241218monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-email-i-inm-20241119monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-email-i-inm-20241114monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-e-inm-20241108monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-email-i-inm-20241105monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-email-i-inm-20241028monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-email-i-inm-20241024monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-email-i-inm-20241022monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-inmed-pharmaceuticals-reports-full-year-fiscal-2024-financial-results-and-provi-inm-20240930monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-1445-885-w-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-emai-inm-20240920monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-1445-885-west-georgia-st-vancouver-bc-canada-v6c-3e8-tel-1-604-669-7207-email-i-inm-20240821monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20240820monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20240730monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20240610monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20240514monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20240418monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20240416monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20240404monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20240320monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20240213monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20240209monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20240119monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20240116monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20231219monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20231129monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20231114monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20231102monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20231024monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20230929monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20230907monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20230725monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20230720monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20230622monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20230601monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20230524monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20230519monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20230515monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20230328monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20230313monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20230306monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20230217monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20230110monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20221215monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20221212monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20221118monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20221116monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20221111monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20221026monthly0.5https://www.biopharmawatch.com/news/INM/burrard-st-3rd-floor-vancouver-bc-v6c-3b9-www-computershare-com-inm-20220929monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220923monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220909monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220823monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220809monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220725monthly0.5https://www.biopharmawatch.com/news/INM/inmed-announces-appointment-of-chief-operating-officer-inm-20220718monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220614monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220609monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220606monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220602monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220513monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220505monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220428monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220421monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220419monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220317monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220308monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220215monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220210monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220119monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20220105monthly0.5https://www.biopharmawatch.com/news/INM/baymedica-inc-audited-financial-statements-year-ended-december-31-2020-and-independent-aud-inm-20211222monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20211123monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20211110monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20211103monthly0.5https://www.biopharmawatch.com/news/INM/burrard-st-3rd-floor-vancouver-date-inm-20211027monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20211013monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20210930monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20210924monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20210921monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20210913monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20210909monthly0.5https://www.biopharmawatch.com/news/INM/inmed-pharmaceuticals-to-webcast-live-at-virtualinvestorconferences-com-september-8-th-inm-inm-20210907monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20210812monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20210702monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20210629monthly0.5https://www.biopharmawatch.com/news/INM/dated-june-29-2021-e-xhibit-99-1-nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canad-inm-20210629monthly0.5https://www.biopharmawatch.com/news/INM/inmed-pharmaceuticals-to-webcast-live-at-life-sciences-investor-forum-june-24-th-inmed-inv-inm-20210622monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20210617monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20210609monthly0.5https://www.biopharmawatch.com/news/INM/nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-7207-emai-inm-20210513monthly0.5https://www.biopharmawatch.com/news/INM/tsx-in-nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-72-inm-20210506monthly0.5https://www.biopharmawatch.com/news/INM/tsx-in-nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-72-inm-20210504monthly0.5https://www.biopharmawatch.com/news/INM/tsx-in-nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-72-inm-20210428monthly0.5https://www.biopharmawatch.com/news/INM/u-n-l-o-c-k-i-n-g-t-h-e-p-o-t-e-n-t-i-a-l-o-f-c-a-n-n-a-b-i-n-o-i-d-m-e-d-i-c-i-n-e-s-comp-inm-20210428monthly0.5https://www.biopharmawatch.com/news/INM/tsx-in-nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-72-inm-20210426monthly0.5https://www.biopharmawatch.com/news/INM/tsx-in-nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-72-inm-20210304monthly0.5https://www.biopharmawatch.com/news/INM/tsx-in-nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-72-inm-20210216monthly0.5https://www.biopharmawatch.com/news/INM/tsx-in-nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-72-inm-20210211monthly0.5https://www.biopharmawatch.com/news/INM/tsx-in-nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-72-inm-20210205monthly0.5https://www.biopharmawatch.com/news/INM/tsx-in-nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-72-inm-20210119monthly0.5https://www.biopharmawatch.com/news/INM/u-n-l-o-c-k-i-n-g-t-h-e-p-o-t-e-n-t-i-a-l-o-f-c-a-n-n-a-b-i-n-o-i-d-m-e-d-i-c-i-n-e-s-corp-inm-20201231monthly0.5https://www.biopharmawatch.com/news/INM/tsx-in-nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-72-inm-20210108monthly0.5https://www.biopharmawatch.com/news/INM/tsx-in-nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-72-inm-20210106monthly0.5https://www.biopharmawatch.com/news/INM/tsx-in-nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-72-inm-20201203monthly0.5https://www.biopharmawatch.com/news/INM/tsx-in-nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-72-inm-20201125monthly0.5https://www.biopharmawatch.com/news/INM/tsx-in-nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-72-inm-20201118monthly0.5https://www.biopharmawatch.com/news/INM/tsx-in-nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-72-inm-20201116monthly0.5https://www.biopharmawatch.com/news/INM/tsx-in-nasdaq-inm-suite-310-815-w-hastings-st-vancouver-bc-canada-v6c-1b4-tel-1-604-669-72-inm-20201113monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-inc-index-to-audited-financial-statements-page-report-of-independent-re-artl-20260317monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-announces-reverse-stock-split-shares-expected-to-begin-trading-on-a-spl-artl-20260306monthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-inc-index-to-audited-financial-statements-page-report-of-independent-re-artl-20250711monthly0.5https://www.biopharmawatch.com/news/ARTL/new-preclinical-cell-line-data-of-artelo-biosciences-art27-13-demonstrate-anti-proliferati-artl-20181009monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-fiscal-second-quarter-2026-financial-results-and-provides-corporate-upd-xair-20251114monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-fiscal-first-quarter-2026-financial-results-and-provides-corporate-upda-xair-20250812monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corpor-xair-20250618monthly0.5https://www.biopharmawatch.com/news/XAIR/neuronos-secures-2-0-million-in-funding-to-advance-development-of-an-innovative-autism-the-xair-20250324monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-announces-agreements-expanding-global-distribution-of-lungfit-ph-distribution-a-xair-20250311monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-fiscal-third-quarter-2025-financial-results-and-provides-corporate-upda-xair-20250214monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-requi-xair-20250205monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-cancer-announces-approval-by-the-israeli-ministry-of-health-to-conduct-a-phase-1b-c-xair-20241203monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-receives-ce-mark-in-europe-for-the-lungfit-ph-system-indication-covers-newborn--xair-20241202monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-fiscal-second-quarter-2025-financial-results-and-provides-corporate-upd-xair-20241118monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-announces-20-6-million-private-placement-offering-priced-at-the-market-under-na-xair-20240927monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-fiscal-first-quarter-2025-financial-results-and-provides-corporate-upda-xair-20240809monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-fiscal-fourth-quarter-and-full-year-2024-financial-results-and-provides-xair-20240624monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-appoints-david-webster-as-chief-commercial-officer-mr-webster-brings-more-than--xair-20240613monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-announces-pricing-of-16-0-million-registered-direct-offering-of-common-stock-an-xair-20240320monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-financial-results-for-third-quarter-of-fiscal-year-2024-commercial-dema-xair-20240212monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-financial-results-for-second-quarter-of-fiscal-year-2024-provides-fisca-xair-20231113monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-and-getz-healthcare-enter-strategic-collaboration-to-commercialize-lungfit-ph-i-xair-20230907monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-financial-results-for-first-quarter-of-fiscal-year-2024-reported-commer-xair-20230810monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-financial-results-for-fourth-quarter-and-fiscal-year-end-2023-successfu-xair-20230622monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-secures-up-to-40-million-debt-financing-funding-to-support-the-commercializatio-xair-20230615monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-appoints-jeff-myers-m-d-ph-d-as-chief-medical-officer-dr-myers-brings-extensive-xair-20230323monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-financial-results-for-the-third-quarter-of-fiscal-year-2023-u-s-commerc-xair-20230209monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-financial-results-for-the-second-quarter-of-fiscal-year-2023-commercial-xair-20221114monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-announces-positive-data-from-at-home-pilot-study-in-patients-with-refractory-nt-xair-20221017monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-affiliate-beyond-cancer-doses-initial-patient-in-first-in-human-phase-1-study-o-xair-20220823monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-financial-results-for-the-first-quarter-of-fiscal-year-2023-initiated-u-xair-20220815monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-financial-results-for-fourth-fiscal-quarter-and-year-end-2022-lungfit-p-xair-20220628monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-financial-results-for-the-third-quarter-of-fiscal-year-2022-lungfit-ph--xair-20220210monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-provides-regulatory-update-for-lungfit-xair-20211209monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-financial-results-for-the-second-quarter-of-fiscal-year-2022-u-s-fda-ac-xair-20211111monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-announces-formation-of-beyond-cancer-a-new-private-company-dedicated-to-oncolog-xair-20211104monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-positive-interim-results-for-lungfit-go-pilot-study-using-high-concentr-xair-20211020monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-provides-global-regulatory-update-for-lungfit-ph-fda-inspection-of-facilities-i-xair-20210921monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-announces-cfo-transition-xair-20210820monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-financial-results-for-the-first-quarter-of-fiscal-year-2022-u-s-fda-rev-xair-20210810monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-financial-results-for-fourth-fiscal-quarter-and-year-end-2021-submitted-xair-20210610monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-presents-data-in-hospitalized-patients-with-viral-lung-infections-including-cov-xair-20210513monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-receives-grant-for-up-to-2-17-million-from-the-cystic-fibrosis-foundation-to-ad-xair-20210216monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-financial-results-for-third-quarter-of-fiscal-year-2021-and-provides-bu-xair-20210209monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-initiates-patient-screening-for-lungfit-go-pilot-study-for-at-home-self-adminis-xair-20201207monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-submits-premarket-approval-application-to-fda-for-lungfit-ph-to-treat-persisten-xair-20201111monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-financial-results-for-first-quarter-of-fiscal-year-2021-and-provides-bu-xair-20200806monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-financial-results-for-fiscal-fourth-quarter-and-year-end-2020-reported--xair-20200622monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-announces-positive-preclinical-data-supporting-high-concentration-nitric-oxide--xair-20200622monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-receives-approval-from-health-canada-to-study-nitric-oxide-generated-and-delive-xair-20200526monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-achieves-primary-endpoint-in-pilot-bronchiolitis-study-high-concentration-nitri-xair-20200520monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-enters-into-new-common-stock-purchase-agreement-extending-relationship-with-lin-xair-20200515monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-to-initiate-clinical-study-evaluating-high-concentration-nitric-oxide-for-the-t-xair-20200416monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-submits-investigational-device-exemption-ide-to-the-united-states-food-and-drug-xair-20200316monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-hosting-analyst-day-today-xair-20200305monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-signs-agreement-with-mesa-specialty-gases-equipment-for-nitric-oxide-and-nitrog-xair-20191125monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-financial-results-for-fiscal-first-quarter-2020-began-trading-under-new-xair-20190816monthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-tm-announces-new-nasdaq-ticker-symbol-is-xair-new-ticker-xair-to-be-effective-m-xair-20190715monthly0.5https://www.biopharmawatch.com/news/XAIR/correcting-and-replacing-ait-therapeutics-reports-financial-results-for-fiscal-fourth-quar-xair-20190628monthly0.5https://www.biopharmawatch.com/news/XAIR/ait-therapeutics-announces-8-million-pipe-financing-garden-city-ny-and-rehovot-israel-xair-20190604monthly0.5https://www.biopharmawatch.com/news/XAIR/ait-therapeutics-announces-uplisting-to-the-nasdaq-capital-market-trading-expected-to-begi-xair-20190503monthly0.5https://www.biopharmawatch.com/news/XAIR/ait-therapeutics-inc-condensed-proforma-consolidated-balance-sheet-xair-20190226monthly0.5https://www.biopharmawatch.com/news/XAIR/ait-therapeutics-reports-financial-results-for-fiscal-third-quarter-2019-announced-transfo-xair-20190213monthly0.5https://www.biopharmawatch.com/news/XAIR/ait-nearing-definitive-agreement-to-license-commercial-rights-of-its-novel-ventilator-comp-xair-20181228monthly0.5https://www.biopharmawatch.com/news/XAIR/ait-therapeutics-appoints-douglas-j-beck-as-chief-financial-officer-seasoned-expert-with-t-xair-20181026monthly0.5https://www.biopharmawatch.com/news/XAIR/ait-therapeutics-reports-financial-results-for-first-fiscal-quarter-2019-started-commercia-xair-20180814monthly0.5https://www.biopharmawatch.com/news/XAIR/ait-therapeutics-announces-20-million-common-stock-purchase-agreement-with-institutional-i-xair-20180813monthly0.5https://www.biopharmawatch.com/news/XAIR/ait-therapeutics-reports-financial-results-for-three-months-ended-xair-20180619monthly0.5https://www.biopharmawatch.com/news/CDIO/leading-the-next-frontier-in-precision-cardiovascular-medicine-2026-nasdaq-cdio-1-certain--cdio-20260210monthly0.5https://www.biopharmawatch.com/news/CDIO/cardio-diagnostics-holdings-inc-announces-1-for-30-reverse-stock-split-chicago-il-business-cdio-20250508monthly0.5https://www.biopharmawatch.com/news/CDIO/company-update-revolutionizing-cardiovascular-medicine-with-epigenetics-and-ai-certain-sta-cdio-20250221monthly0.5https://www.biopharmawatch.com/news/CDIO/company-update-revolutionizing-cardiovascular-medicine-with-epigenetics-and-ai-march-2024--cdio-20240402monthly0.5https://www.biopharmawatch.com/news/CDIO/cardio-diagnostics-holdings-inc-regains-nasdaq-minimum-bid-price-requirement-chicago-cdio-20231206monthly0.5https://www.biopharmawatch.com/news/CDIO/cardio-diagnostics-holdings-inc-announces-financing-agreement-with-yorkville-advisors-glob-cdio-20230308monthly0.5https://www.biopharmawatch.com/news/CDIO/shall-have-the-meanings-ascribed-to-them-in-the-current-report-on-form-8-k-the-form-8-k-fi-cdio-20221031monthly0.5https://www.biopharmawatch.com/news/CDIO/mana-capital-acquisition-corp-announces-intention-to-further-extend-period-to-consummate-i-cdio-20220922monthly0.5https://www.biopharmawatch.com/news/CDIO/cardio-diagnostics-announces-issuance-of-u-s-patent-for-compositions-and-methods-for-detec-cdio-20220921monthly0.5https://www.biopharmawatch.com/news/CDIO/transforming-cardiovascular-cardiovascular-health-through-our-ai-driven-integrated-genetic-cdio-20220826monthly0.5https://www.biopharmawatch.com/news/CDIO/mana-capital-acquisition-corp-announces-intention-to-extend-period-to-consummate-initial-b-cdio-20220823monthly0.5https://www.biopharmawatch.com/news/CDIO/mana-capital-acquisition-corp-and-cardio-diagnostics-inc-announce-definitive-business-comb-cdio-20220531monthly0.5https://www.biopharmawatch.com/news/CDIO/mana-capital-acquisition-corp-announces-the-separate-trading-of-its-common-stock-warrants--cdio-20220114monthly0.5https://www.biopharmawatch.com/news/CDIO/mana-capital-acquisition-corp-balance-sheet-actual-as-of-cdio-20211126monthly0.5https://www.biopharmawatch.com/news/CDIO/index-to-financial-statement-page-audited-financial-statement-of-mana-capital-acquisition--cdio-20211126monthly0.5https://www.biopharmawatch.com/news/CDIO/mana-capital-acquisition-corp-announces-pricing-of-62-million-initial-public-offering-dove-cdio-20211122monthly0.5https://www.biopharmawatch.com/news/AMIX/breakthrough-technology-that-could-transform-nerve-targeted-treatments-disclaimer-all-stat-amix-20240304monthly0.5https://www.biopharmawatch.com/news/GELS/may-2026-upcoming-special-meeting-of-shareholders-dear-shareholder-gelteq-limited-the-comp-gels-20260602monthly0.5https://www.biopharmawatch.com/news/GELS/the-ne-xt-e-v-ol-ut-ion-in-o-r-al-d-ru-g-n-utr-ien-t-deli-v-e-ry-gelteq-limited-2025-all-r-gels-20251209monthly0.5https://www.biopharmawatch.com/news/GELS/are-to-gelteq-and-or-its-subsidiaries-overview-we-are-a-clinical-and-science-based-company-gels-20250630monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-fda-acceptance-of-ind-application-for-mb-109-a-novel-combination-of--mbio-20231026monthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-announces-reverse-stock-split-worcester-ma-mbio-20230403monthly0.5https://www.biopharmawatch.com/news/MBIO/consulting-agreement-this-consulting-agreement-the-agreement-is-made-effective-as-of-mbio-20220422monthly0.5https://www.biopharmawatch.com/news/MBIO/loan-and-security-agreement-this-loan-and-security-agreement-as-amended-restated-supplemen-mbio-20220304monthly0.5https://www.biopharmawatch.com/news/MBIO/corporate-presentation-june-2017-forward-looking-safe-harbor-statement-this-presentation-c-mbio-20170605monthly0.5https://www.biopharmawatch.com/news/MBIO/corporate-overview-nasdaq-fbio-october-2016-mbio-20161020monthly0.5https://www.biopharmawatch.com/news/BGMS/e-xhibit-99-1-bio-green-med-solution-inc-announces-business-combination-agreement-to-acqui-bgms-20260604monthly0.5https://www.biopharmawatch.com/news/BGMS/bio-green-med-solution-inc-bio-green-med-solution-reports-first-quarter-financial-results--bgms-20260514monthly0.5https://www.biopharmawatch.com/news/BGMS/bio-green-med-solution-inc-bio-green-med-solution-reports-fourth-quarter-and-full-year-202-bgms-20260330monthly0.5https://www.biopharmawatch.com/news/BGMS/bio-green-med-solution-reports-third-quarter-financial-results-and-provides-business-updat-bgms-20251113monthly0.5https://www.biopharmawatch.com/news/BGMS/bio-green-med-solution-inc-announces-closing-of-strategic-acquisition-of-fitters-sdn-bhd-k-bgms-20250912monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-financial-res-bgms-20250813monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-comments-on-recent-stock-price-volat-bgms-20250716monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-amendment-to-exchange-agre-bgms-20250707monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-bgms-20250702monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-announces-3-bgms-20250620monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-bgms-20250603monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-reports-first-quarter-financial-results-and-provides-business-upd-bgms-20250514monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-bgms-20250507monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-announces-execution-of-share-exchange-agreement-to-make-fitte-bgms-20250506monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-financial-res-bgms-20250402monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-announces-1-bgms-20250324monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-announces-closing-of-a-bgms-20250227monthly0.5https://www.biopharmawatch.com/news/BGMS/investors-cyclacel-pharmaceuticals-announces-agreement-for-the-acquisition-of-preferred-st-bgms-20250103monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-closing-of-exercise-of-war-bgms-20241114monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-third-quarter-financial-resu-bgms-20241112monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-t-hat-bgms-20241024monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-financial-res-bgms-20240814monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-first-quarter-financial-resu-bgms-20240514monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-8-0-million-private-placem-bgms-20240430monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-and-p-bgms-20240319monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cycc-biotech-showcase-january-2024-translating-cancer-biology-bgms-20240109monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-announces-registered-direct-and-private-placement-offering-priced-bgms-20231222monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-third-quarter-financial-resu-bgms-20231113monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-financial-res-bgms-20230809monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-first-quarter-financial-resu-bgms-20230511monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-bgms-20230306monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-third-quarter-2022-financial-bgms-20221109monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-reports-second-quarter-2022-financial-results-and-provides-busine-bgms-20220810monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyc-lacel-pharmaceuticals-reports-first-quarter-2022-financia-bgms-20220511monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-bgms-20220328monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-third-quarter-2021-financial-bgms-20211110monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-2021-financia-bgms-20210811monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-first-quarter-2021-financial-bgms-20210512monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-prices-12-65-million-underwritten-pu-bgms-20210312monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-bgms-20210225monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-at-the-market-7-million-st-bgms-20201222monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-third-quarter-2020-financial-bgms-20201111monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-appointment-of-mark-kirsch-bgms-20201023monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-2020-financia-bgms-20200812monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-first-quarter-2020-financial-bgms-20200512monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-announces-pricing-of-20-million-public-offering-berk-bgms-20200421monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-collaboration-with-the-uni-bgms-20200420monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-bgms-20200226monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-third-quarter-2019-financial-bgms-20191113monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-2019-financia-bgms-20190813monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-first-quarter-2019-financial-bgms-20190514monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-bgms-20190327monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-reports-third-quarter-2018-financial-results-conference-call-sche-bgms-20181112monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-and-md-anderson-cancer-center-announ-bgms-20181004monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-appoints-robert-j-spiegel-m-d-to-boa-bgms-20180912monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-2018-financia-bgms-20180809monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-first-quarter-2018-financial-bgms-20180514monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-bgms-20180328monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-announces-presentation-of-results-from-phase-3-seaml-bgms-20171212monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-reports-third-quarter-2017-financial-results-conference-call-sche-bgms-20171109monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-2017-financia-bgms-20170809monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-announces-selection-of-recommended-phase-2-dose-for--bgms-20170807monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-announces-closing-of-15-2-million-underwritten-publi-bgms-20170721monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-announces-pricing-of-13-2-million-underwritten-publi-bgms-20170719monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-first-quarter-2017-financial-bgms-20170511monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-bgms-20170328monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-announces-top-line-results-from-pivotal-phase-3-seam-bgms-20170223monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-3-rd-quarter-2016-financial--bgms-20161114monthly0.5https://www.biopharmawatch.com/news/BGMS/reports-2nd-quarter-2016-financial-results-bgms-20160810monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-announces-reverse-stock-split-berkeley-heights-nj-bgms-20160527monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-first-quarter-2016-financial-bgms-20160511monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-announces-receipt-of-nasdaq-extension-berkeley-heigh-bgms-20160411monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-reports-fourth-bgms-20160324monthly0.5https://www.biopharmawatch.com/news/BGMS/announces-receipt-of-nasdaq-staff-determination-bgms-20160205monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-third-quarter-2015-financial-bgms-20151112monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-2015-financia-bgms-20150811monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-reports-first-quarter-2015-financial-results-approximately-20-of--bgms-20150512monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-bgms-20150324monthly0.5https://www.biopharmawatch.com/news/BGMS/announces-proposed-public-offering-of-common-stock-bgms-20150304monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-announces-enrollment-of-486-patients-dsmb-recommenda-bgms-20141216monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-third-quarter-2014-financial-bgms-20141111monthly0.5https://www.biopharmawatch.com/news/BGMS/cell-cycle-to-treat-aml-and-mds-bgms-20140926monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-appoints-samuel-l-barker-ph-d-to-boa-bgms-20140911monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-2014-financia-bgms-20140812monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-p-r-e-s-s-r-e-l-e-a-s-e-cyclacel-pharmaceuticals-reports-firs-bgms-20140513monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-proposed-public-offering-o-bgms-20140403monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-bgms-20140325monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-reports-third-quarter-2013-financial-results-confere-bgms-20131112monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-reports-second-quarter-2013-financial-results-confer-bgms-20130814monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-closing-of-underwritten-of-bgms-20130521monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-proposed-public-offering-o-bgms-20130515monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-reports-first-quarter-2013-financial-results-confere-bgms-20130513monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-announces-sale-of-four-cyclacel-romidepsin-related-p-bgms-20130404monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-bgms-20130327monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-enters-into-a-20-million-common-stock-purchase-agree-bgms-20121217monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-reports-third-quarter-2012-financial-results-enrollm-bgms-20121112monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-regains-compliance-with-nasdaq-minimum-bid-price-lis-bgms-20120913monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-announces-reverse-stock-split-stock-will-begin-tradi-bgms-20120827monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-reports-second-quarter-2012-financial-results-confer-bgms-20120814monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-important-bgms-20120514monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-reports-first-quarter-2012-financial-results-confere-bgms-20120514monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-bgms-20120329monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-announces-3-0-million-financing-to-fund-ongoing-liti-bgms-20120322monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-press-release-cyclacel-pharmaceuticals-reports-third-quarter--bgms-20111114monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-receives-deficiency-notice-from-nasd-bgms-20110922monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-press-release-cyclacel-pharmaceuticals-reports-second-quarter-bgms-20110811monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-announces-pricing-of-underwritten-offering-of-common-stock-an-bgms-20110701monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-financial-results-for-first--bgms-20110512monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-bgms-20110323monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-begins-pivotal-phase-3-seamless-trial-of-sapacitabine-as-front-line-treatment-for-bgms-20110113monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-announces-topline-results-from-the-appraise-phase-2b-study-of-seliciclib-in-heavi-bgms-20101221monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-third-quarter-2010-bgms-20101111monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-bgms-20101006monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-bgms-20101007monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-announces-private-placement-financing-for-up-to-22-1-million-proceeds-to-advance--bgms-20101005monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-reaches-agreement-with-fda-on-a-special-protocol-assessment-for-p-bgms-20100913monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-6-bgms-20100813monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-press-release-cyclacel-pharmaceuticals-reports-second-quarter-bgms-20100805monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-p-r-e-s-s-r-e-l-e-a-s-e-cyclacel-pharmaceuticals-reports-fina-bgms-20100513monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-2009-financial-results-confe-bgms-20100323monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-regains-nasdaq-compliance-berkeley-heights-nj-bgms-20100127monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-cyclacel-completes-previously-announced-registered-direct-off-bgms-20100125monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-to-raise-up-to-7-9-million-in-registered-direct-offering-berkeley-heights-nj-bgms-20100121monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-p-r-e-s-s-r-e-l-e-a-s-e-cyclacel-completes-previously-announc-bgms-20100113monthly0.5https://www.biopharmawatch.com/news/BGMS/cyclacel-pharmaceuticals-inc-press-release-cyclacel-to-raise-up-to-9-5-million-in-register-bgms-20100111monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-reverse-stock-split-to-regain-compliance-with-nasdaq-s-min-adil-20260206monthly0.5https://www.biopharmawatch.com/news/ADIL/issued-by-adial-pharmaceuticals-inc-on-august-14-2025-egrave-xhibit-99-1-adial-pharmaceuti-adil-20250814monthly0.5https://www.biopharmawatch.com/news/ADIL/december-2021-confidential-medicines-f-or-a-ddi-c-tion-investor-presentation-january-2025--adil-20250108monthly0.5https://www.biopharmawatch.com/news/ADIL/item-7-management-s-discussion-and-analysis-of-financial-condition-and-results-of-operatio-adil-20230927monthly0.5https://www.biopharmawatch.com/news/ADIL/december-2021-confidential-medicines-f-or-a-ddi-c-tion-h-c-wainwright-global-investment-co-adil-20230911monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-reverse-stock-split-to-regain-compliance-with-nasdaq-s-min-adil-20230807monthly0.5https://www.biopharmawatch.com/news/ADIL/december-2021-confidential-medicines-f-or-a-ddi-c-tion-adil-20230609monthly0.5https://www.biopharmawatch.com/news/ADIL/an-adial-company-adial-pharmaceuticals-announces-positive-in-vivo-data-for-purnovate-s-pnv-adil-20220926monthly0.5https://www.biopharmawatch.com/news/ADIL/the-phase-3-onward-trial-meets-its-screening-target-and-nears-enrollment-completion-study--adil-20210706monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-closes-acquisition-of-purnovate-acquisition-expands-adial-s-portfoli-adil-20210126monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-enters-agreement-to-acquire-purnovate-a-developer-of-potential-thera-adil-20201210monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-provides-update-on-its-onward-pivotal-phase-3-trial-of-ad04-for-trea-adil-20201103monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-fda-reactivation-of-its-investigational-new-drug-applicati-adil-20201021monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-covid-19-point-of-care-antibody-test-granted-first-ever-fd-adil-20200929monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-files-for-expedited-review-of-ad04-with-the-fda-charlottesville-va-adil-20200925monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-and-iremedy-partner-to-sell-covid-19-antibody-test-kits-to-u-s-medic-adil-20200922monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-third-party-sales-and-distribution-agreement-with-brik-for-adil-20200806monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-approval-to-commence-landmark-onward-pivotal-phase-3-trial-adil-20200611monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-pricing-of-5-2-million-registered-direct-offering-priced-a-adil-20200609monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-and-biolab-sciences-enter-into-distribution-agreement-for-covid-19-a-adil-20200608monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-commences-phase-3-trial-of-ad04-for-alcohol-use-disorder-charlottesv-adil-20200206monthly0.5https://www.biopharmawatch.com/news/ADIL/medicines-for-addiction-may-2019-investor-presentation-nasdaq-adil-adil-20190430monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-appointment-of-bankole-johnson-m-d-as-chief-medical-office-adil-20190326monthly0.5https://www.biopharmawatch.com/news/ADIL/pharmaceuticals-announces-pricing-of-8-0-million-underwritten-public-offering-adil-20190226monthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-receives-1-2-million-adil-20190125monthly0.5https://www.biopharmawatch.com/news/ADIL/treating-addiction-investor-presentation-september-2018-william-stilley-ceo-adil-20180924monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-announces-reverse-stock-split-atlanta-ga-alzn-20250508monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-reports-second-quarter-2025-financial-results-and-provides-update-on-clinic-alzn-20241212monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-regains-compliance-with-nasdaq-listing-standards-atlanta-ga-alzn-20241015monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-regains-compliance-with-nasdaq-s-minimum-bid-price-requirement-atlanta-ga-alzn-20240731monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-announces-reverse-stock-split-atlanta-ga-alzn-20240712monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-announces-favorable-decision-from-nasdaq-hearings-panel-atlanta-ga-alzn-20240522monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-inc-corporate-presentation-may-2024-safe-harbor-statement-2-this-presentati-alzn-20240515monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-announces-agreement-for-registered-direct-offering-and-concurrent-private-p-alzn-20240509monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-announces-termination-of-at-the-market-equity-offering-program-atlanta-ga-alzn-20240507monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-regains-compliance-with-nasdaq-s-minimum-bid-price-requirement-atlanta-ga-alzn-20231116monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-announces-reverse-stock-split-atlanta-ga-alzn-20231030monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-granted-extension-by-nasdaq-panel-to-regain-compliance-with-the-minimum-bid-alzn-20230922monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-announces-positive-phase-iia-clinical-trial-results-for-al001-topline-data--alzn-20230622monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-inc-corporate-presentation-april-2023-safe-harbor-statement-2-this-presenta-alzn-20230425monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-announces-the-initiation-of-a-phase-i-iia-trial-for-its-immunotherapy-vacci-alzn-20230403monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-announces-completion-of-clinical-portion-of-phase-iia-multiple-ascending-do-alzn-20230322monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-reports-third-fiscal-quarter-financial-results-and-provides-a-business-upda-alzn-20230316monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-inc-corporate-presentation-january-2023-safe-harbor-statement-2-this-presen-alzn-20230120monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-inc-corporate-presentation-november-2022-safe-harbor-statement-2-this-prese-alzn-20221116monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-receives-fda-study-may-proceed-letter-for-phase-i-iia-trial-under-its-inves-alzn-20221031monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-announces-addition-of-healthy-subjects-to-ongoing-phase-iia-clinical-trial--alzn-20221005monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-submits-ind-application-for-phase-i-iia-trial-for-an-immunotherapy-alzn002--alzn-20220929monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-has-regained-compliance-with-nasdaq-s-minimum-bid-price-requirement-atlanta-alzn-20220922monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-inc-corporate-presentation-august-2022-safe-harbor-statement-2-this-present-alzn-20220815monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-receives-positive-pre-ind-response-from-fda-for-al001-treatment-of-bipolar--alzn-20220718monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-inc-corporate-presentation-june-2022-safe-harbor-statement-2-this-presentat-alzn-20220606monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-inc-corporate-presentation-april-2022-safe-harbor-statement-2-this-presenta-alzn-20220420monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-inc-corporate-presentation-april-2022-safe-harbor-statement-2-this-presenta-alzn-20220418monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-announces-positive-topline-data-from-phase-1-first-in-human-clinical-trial--alzn-20211217monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-receives-positive-pre-ind-response-from-fda-for-al002-a-cell-based-therapeu-alzn-20210930monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-announces-it-has-contracted-with-altasciences-to-conduct-a-phase-i-relative-alzn-20210817monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-announces-additional-investment-under-its-investigational-new-drug-applicat-alzn-20210804monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-receives-fda-study-may-proceed-letter-for-phase-1-clinical-study-under-its--alzn-20210728monthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-receives-positive-results-for-al002-in-a-glp-toxicology-study-using-a-trans-alzn-20210723monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-reports-first-quarter-2026-financial-results-irb-approval-secured-for--ensc-20260515monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-secures-second-financing-from-2025-agreement-to-advance-breakthrough-p-ensc-20260407monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-fourth-qua-ensc-20260330monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-secures-4-million-financing-unlocking-up-to-20-million-in-total-financ-ensc-20251117monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-reports-third-quarter-2025-financial-results-third-quarter-highlighted-ensc-20251114monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-reports-second-quarter-2025-financial-results-and-latest-program-updat-ensc-20250813monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-reports-first-quarter-2025-financial-results-receives-u-s-patent-for-g-ensc-20250513monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-inc-announces-exercise-of-warrants-for-2-2-million-gross-proceeds-san--ensc-20250423monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-inc-announces-1-1-million-registered-direct-offering-priced-at-the-mar-ensc-20250331monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-reports-fourth-quarter-and-full-year-2024-financial-results-secures-st-ensc-20250310monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-reports-third-quarter-2024-financial-results-awarded-14-million-multi--ensc-20241112monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-inc-announces-5-million-concurrent-registered-direct-offering-and-exer-ensc-20240829monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-reports-second-quarter-2024-financial-results-pf614-mpar-progressing-t-ensc-20240814monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-regains-compliance-with-nasdaq-san-diego-ca-ensc-20240528monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-reports-first-quarter-2024-financial-results-pf614-s-phase-3-clinical--ensc-20240513monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-reports-fourth-quarter-and-full-year-2023-financial-results-corporate--ensc-20240315monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-inc-announces-exercise-of-warrants-for-4-7-million-gross-proceeds-san--ensc-20240213monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-postpones-special-meeting-of-stockholders-to-ensc-20231219monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-completion-of-1-7-million-convertible-note-financing-additio-ensc-20231128monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-reports-third-quarter-2023-financial-results-pf614-201-clinical-study--ensc-20231109monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-secures-1-7-million-convertible-note-financing-additional-funding-from-ensc-20231024monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-reports-second-quarter-2023-financial-results-progression-toward-full--ensc-20230811monthly0.5https://www.biopharmawatch.com/news/ENSC/exhibit-no-99-1-ensysce-biosciences-regains-compliance-with-nasdaq-san-diego-ca-accesswire-ensc-20230613monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-inc-announces-closing-of-7-million-public-offering-san-diego-ca-access-ensc-20230512monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-reports-fourth-quarter-and-full-year-2022-financial-results-corporate--ensc-20230331monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-inc-announces-3-million-registered-direct-offering-february-03-2023-8--ensc-20230203monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-the-distribution-of-series-a-preferred-stock-to-holders-of-i-ensc-20230201monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-pricing-of-4-1-million-public-offering-san-diego-ca-accesswi-ensc-20221207monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-fda-guidance-on-the-clinical-development-pathway-for-pf614-a-ensc-20221114monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-results-of-special-meeting-of-stockholders-ensc-20220908monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-provides-business-update-and-reports-second-quarter-2022-financial-res-ensc-20220811monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-completion-of-8-million-convertible-note-financing-ensc-20220809monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-secures-8-million-convertible-note-financing-additional-funding-from-i-ensc-20220701monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-provides-business-update-and-reports-first-quarter-2022-financial-resu-ensc-20220512monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-new-clinical-results-from-trials-pf614-102-and-pf614-mpar-10-ensc-20220505monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-15-million-convertible-note-financing-san-diego-september-27-ensc-20210924monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-announces-closing-of-merger-ensysce-common-stock-to-commence-trading-u-ensc-20210701monthly0.5https://www.biopharmawatch.com/news/ENSC/leisure-acquisition-corp-announces-receipt-of-and-plan-to-appeal-nasdaq-listing-determinat-ensc-20210601monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-inc-and-leisure-acquisition-corp-announce-appointment-of-dave-humphrey-ensc-20210218monthly0.5https://www.biopharmawatch.com/news/ENSC/leisure-acquisition-corp-lacq-conference-call-regarding-potential-business-combination-bet-ensc-20210203monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-investor-presentation-february-2021-general-this-presentation-the-pres-ensc-20210203monthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-inc-and-leisure-acquisition-corp-to-host-investor-call-regarding-busin-ensc-20210203monthly0.5https://www.biopharmawatch.com/news/ENSC/leisure-acquisition-corp-enters-into-merger-agreement-for-business-combination-with-ensysc-ensc-20210201monthly0.5https://www.biopharmawatch.com/news/ENSC/disclaimer-general-this-presentation-does-not-constitute-an-offer-or-invitation-for-the-sa-ensc-20200219monthly0.5https://www.biopharmawatch.com/news/ENSC/investor-presentation-59-196-february-2020-92-214-173-0-125-245-174-196-211-0-205-151-0-12-ensc-20200211monthly0.5https://www.biopharmawatch.com/news/ENSC/investor-presentation-january-2020-ensc-20200127monthly0.5https://www.biopharmawatch.com/news/ENSC/gagnier-communications-moderator-lindsay-barber-01-07-20-4-15-p-m-et-confirmation-7934997--ensc-20200107monthly0.5https://www.biopharmawatch.com/news/ENSC/jfif-6-6-424-lddl-z-6-6-424-lddl-z-1-2aq-ensc-20200107monthly0.5https://www.biopharmawatch.com/news/ENSC/gateway-casinos-entertainment-limited-ensc-20200106monthly0.5https://www.biopharmawatch.com/news/ENSC/gateway-casinos-entertainment-limited-and-leisure-acquisition-corp-ensc-20191230monthly0.5https://www.biopharmawatch.com/news/ENSC/leisure-acquisition-corp-announces-the-separate-trading-of-its-common-stock-and-warrants-c-ensc-20171228monthly0.5https://www.biopharmawatch.com/news/ENSC/leisure-acquisition-corp-index-to-balance-sheet-page-report-of-independent-registered-publ-ensc-20171205monthly0.5https://www.biopharmawatch.com/news/ENSC/leisure-acquisition-corp-announces-pricing-of-200-000-000-initial-public-offering-ensc-20171201monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-announces-results-of-annual-and-special-meeting-of-shareholders-pbm-20260213monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-approves-a-put-option-agreement-with-psylabs-to-secure-strategic-supply-and-pbm-20260213monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomedical-ltd-121-richmond-steet-west-penthouse-suite-1300-toronto-ontario-m5h-2k-pbm-20260113monthly0.5https://www.biopharmawatch.com/news/PBM/to-this-report-this-discussion-contains-forward-looking-statements-that-involve-risks-unce-pbm-20260108monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomedical-ltd-unaudited-condensed-consolidated-interim-financial-statements-for-t-pbm-20251120monthly0.5https://www.biopharmawatch.com/news/PBM/subscription-agreement-between-the-subscriber-listed-in-the-schedule-of-particulars-and-ps-pbm-20250905monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-chief-of-global-impact-to-speak-at-psychedelic-science-2025-investors-entre-pbm-20250618monthly0.5https://www.biopharmawatch.com/news/PBM/master-services-agreement-date-21-st-may-2025-parties-southern-star-research-pty-ltd-acn-1-pbm-20250611monthly0.5https://www.biopharmawatch.com/news/PBM/investor-presentation-nasdaq-pbm-may-2025-2-psyence-biomedical-ltd-healing-minds-with-scie-pbm-20250520monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-announces-effective-date-for-1-for-7-97-reverse-stock-split-pbm-20250501monthly0.5https://www.biopharmawatch.com/news/PBM/sent-via-electronic-delivery-to-neil-psyencebiomed-com-taryn-psyencebiomed-com-bpoignant-d-pbm-20250416monthly0.5https://www.biopharmawatch.com/news/PBM/level-7-330-collins-street-melbourne-vic-3000-psyence-australia-info-psyencebiomed-com-1-4-pbm-20250402monthly0.5https://www.biopharmawatch.com/news/PBM/corporate-update-psyence-biomedical-ltd-redefines-psychedelic-medicine-with-a-multi-asset--pbm-20250401monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomedical-ltd-notice-of-special-meeting-of-shareholders-and-management-informatio-pbm-20250331monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomedical-ltd-formerly-the-carve-out-of-psyence-biomed-corp-unaudited-condensed-c-pbm-20250123monthly0.5https://www.biopharmawatch.com/news/PBM/to-the-current-report-on-form-6-k-filed-by-the-company-with-the-u-s-securities-and-exchang-pbm-20241023monthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomedical-ltd-notice-of-annual-and-special-meeting-of-shareholders-and-management-pbm-20241023monthly0.5https://www.biopharmawatch.com/news/PBM/debt-for-equity-exchange-agreement-this-debt-for-equity-exchange-agreement-this-agreement--pbm-20240930monthly0.5https://www.biopharmawatch.com/news/PBM/execution-version-17-september-2024-share-purchase-and-sale-agreement-between-psyence-grou-pbm-20240917monthly0.5https://www.biopharmawatch.com/news/PBM/licence-agreement-for-alcohol-use-disorder-and-substance-use-disorder-this-agreement-agree-pbm-20240905monthly0.5https://www.biopharmawatch.com/news/PBM/investor-presentation-nasdaq-pbm-september-2024-psyence-biomedical-ltd-healing-minds-with--pbm-20240830monthly0.5https://www.biopharmawatch.com/news/PBM/common-stock-purchase-agreement-this-common-stock-purchase-agreement-this-agreement-is-ent-pbm-20240725monthly0.5https://www.biopharmawatch.com/news/PBM/first-addendum-to-the-license-agreement-pbm-20240724monthly0.5https://www.biopharmawatch.com/news/CANF/scientific-publication-of-can-fite-and-vetbiolix-validates-piclidenoson-s-potential-in-the-canf-20260518monthly0.5https://www.biopharmawatch.com/news/CANF/notice-of-2026-annual-general-meeting-of-shareholders-to-be-held-on-may-28-2026-to-the-sha-canf-20260423monthly0.5https://www.biopharmawatch.com/news/CANF/notice-of-special-general-meeting-of-shareholders-to-be-held-on-march-3-2026-to-the-shareh-canf-20260127monthly0.5https://www.biopharmawatch.com/news/CANF/notice-of-special-general-meeting-of-shareholders-to-be-held-on-november-3-2025-to-the-sha-canf-20251003monthly0.5https://www.biopharmawatch.com/news/CANF/operating-and-financial-review-and-prospects-you-should-read-the-following-selected-financ-canf-20250828monthly0.5https://www.biopharmawatch.com/news/CANF/notice-of-2025-annual-general-meeting-of-shareholders-to-be-held-on-june-23-2025-to-the-sh-canf-20250516monthly0.5https://www.biopharmawatch.com/news/CANF/disappearance-of-decompensated-liver-cirrhosis-episodes-after-treatment-with-can-fite-s-na-canf-20250218monthly0.5https://www.biopharmawatch.com/news/CANF/us-patent-office-granted-can-fite-namodenoson-patent-for-use-as-anti-obesity-drug-the-namo-canf-20250127monthly0.5https://www.biopharmawatch.com/news/CANF/recognition-of-the-american-society-of-clinical-oncology-asco-of-the-liver-protective-effe-canf-20241230monthly0.5https://www.biopharmawatch.com/news/CANF/years-survival-with-complete-cure-for-a-patient-with-advanced-liver-cancer-being-treated-w-canf-20241204monthly0.5https://www.biopharmawatch.com/news/CANF/significant-positive-results-from-osteoarthritis-clinical-study-in-dogs-treated-with-picli-canf-20241018monthly0.5https://www.biopharmawatch.com/news/CANF/fda-grants-orphan-drug-designation-to-can-fite-s-namodenoson-for-pancreatic-cancer-canf-20241009monthly0.5https://www.biopharmawatch.com/news/CANF/projected-income-of-325m-to-can-fite-over-the-next-10-years-after-vetbiolix-exercised-its--canf-20240924monthly0.5https://www.biopharmawatch.com/news/CANF/operating-and-financial-review-and-prospects-you-should-read-the-following-selected-financ-canf-20240829monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-provides-namodenoson-patent-update-broad-protection-of-namodenoson-is-expected-ti-canf-20240729monthly0.5https://www.biopharmawatch.com/news/CANF/improvement-in-patient-with-decompensated-liver-cirrhosis-upon-treatment-with-namodenoson--canf-20240701monthly0.5https://www.biopharmawatch.com/news/CANF/positive-results-from-osteoarthritis-clinical-study-in-dogs-reported-by-can-fite-s-partner-canf-20240628monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-breakthrough-findings-demonstrate-namodenoson-anti-cancer-and-protective-effect-m-canf-20240624monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-received-irb-approval-for-the-treatment-of-pancreatic-cancer-with-namodenoson-in--canf-20240610monthly0.5https://www.biopharmawatch.com/news/CANF/notice-of-2024-canf-20240607monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-updates-on-its-advanced-liver-cancer-pivotal-phase-3-study-namodenoson-granted-or-canf-20240605monthly0.5https://www.biopharmawatch.com/news/CANF/independent-scientists-published-a-review-article-demonstrating-that-can-fite-drugs-have-t-canf-20240529monthly0.5https://www.biopharmawatch.com/news/CANF/notice-of-2024-canf-20240522monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-75-oncologists-and-coordinators-from-europe-us-and-israel-participated-in-a-confe-canf-20240513monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-fda-grants-ind-clearance-for-namodenoson-to-treat-mash-patients-in-a-phase-iib-st-canf-20240509monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-received-notice-of-allowance-from-the-european-patent-office-for-the-treatment-of-canf-20240506monthly0.5https://www.biopharmawatch.com/news/CANF/long-term-complete-response-to-can-fite-s-namodenoson-in-patient-with-advanced-liver-cance-canf-20240425monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-scientific-article-published-by-kol-presents-namodenoson-as-a-promising-drug-cand-canf-20240415monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-submits-fda-with-an-ind-application-to-conduct-phase-iib-clinical-trial-of-namode-canf-20240403monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-2023-financial-results-and-clinical-update-ewopharma-acquired-marketing-r-canf-20240328monthly0.5https://www.biopharmawatch.com/news/CANF/namodenoson-treatment-for-pancreatic-and-liver-cancer-data-will-be-discussed-in-out-licens-canf-20240311monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-broadens-its-strong-intellectual-property-ip-for-nash-received-patent-allowance-i-canf-20240228monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-expands-the-out-licensing-deal-with-ewopharma-to-include-the-pancreatic-cancer-in-canf-20240130monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-top-scientific-journal-published-positive-data-from-the-comfort-1-phase-iii-psori-canf-20240129monthly0.5https://www.biopharmawatch.com/news/CANF/the-anti-obesity-effect-of-can-fite-s-namodenoson-molecular-mechanism-of-action-in-pre-cli-canf-20231220monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-received-fda-positive-response-to-psoriasis-pediatric-plan-fda-encouraged-the-com-canf-20231218monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-namodenoson-for-the-treatment-of-pancreatic-cancer-patients-progress-in-clinica-canf-20231204monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-third-quarter-2023-financial-results-and-clinical-update-advanced-liver-c-canf-20231130monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-complete-response-and-6-9-years-overall-survival-in-a-patient-with-advanced-liver-canf-20231122monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-issues-business-update-all-clinical-programs-and-business-development-activities--canf-20231101monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-namodenoson-inhibits-pancreatic-carcinoma-published-in-leading-scientific-journal-canf-20231030monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-to-harness-artificial-intelligence-to-develop-novel-anti-cancer-drugs-can-fite-si-canf-20231026monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-to-share-its-rare-genetic-disease-lowe-syndrome-novel-treatment-with-orphan-drug--canf-20231009monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-novel-approach-for-the-treatment-of-pancreatic-carcinoma-with-namodenoson-receive-canf-20230927monthly0.5https://www.biopharmawatch.com/news/CANF/small-molecules-for-big-clinical-needs-nyse-american-canf-september-2023-investor-presenta-canf-20230907monthly0.5https://www.biopharmawatch.com/news/CANF/operating-and-financial-review-and-prospects-you-should-read-the-following-selected-financ-canf-20230831monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-enters-rare-genetic-disease-field-based-on-impactful-findings-of-a-fondazione-tel-canf-20230824monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-submitted-to-fda-a-pediatric-plan-to-allow-registration-of-piclidenoson-for-the-t-canf-20230818monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-granted-breakthrough-abstract-award-for-namodenoson-in-treatment-of-advanced-live-canf-20230717monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-receives-u-s-fda-s-go-ahead-for-piclidenoson-psoriasis-registration-plan-fda-enco-canf-20230629monthly0.5https://www.biopharmawatch.com/news/CANF/notice-of-2023-annual-general-meeting-of-shareholders-to-be-held-on-july-31-2023-to-the-sh-canf-20230623monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-to-submit-ind-for-the-treatment-of-pancreatic-cancer-patients-with-namodenoson-na-canf-20230613monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-first-quarter-2023-financial-results-provides-clinical-update-canf-20230601monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-namodenoson-s-inhibition-of-pancreatic-carcinoma-receives-recognition-from-the-am-canf-20230530monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-to-initiate-exploratory-phase-2-trial-with-namodenoson-in-pancreatic-cancer-patie-canf-20230509monthly0.5https://www.biopharmawatch.com/news/CANF/inhibition-of-pancreatic-cancer-by-namodenoson-molecular-mechanism-of-action-discovered-by-canf-20230502monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-new-management-structure-as-advanced-stage-pipeline-moves-toward-commer-canf-20230424monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-ema-gives-green-light-for-piclidenoson-pivotal-phase-iii-clinical-trial-for-psori-canf-20230410monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-2022-financial-results-provides-clinical-update-canf-20230330monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-to-treat-decompensated-liver-cirrhosis-patients-with-namodenoson-under-compassion-canf-20230313monthly0.5https://www.biopharmawatch.com/news/CANF/novel-approach-to-treating-advanced-liver-cancer-with-namodenoson-published-in-leading-sci-canf-20230214monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-namodenoson-significantly-inhibits-pancreatic-cancer-in-preclinical-studies-a-pat-canf-20230124monthly0.5https://www.biopharmawatch.com/news/CANF/notice-of-special-general-meeting-of-shareholders-to-be-held-on-february-21-2023-to-the-sh-canf-20230113monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-7-5-million-concurrent-registered-direct-offering-and-private-placement-canf-20230111monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-submits-market-registration-plan-to-european-medicines-agency-for-piclidenoson-in-canf-20230110monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-ads-ratio-change-canf-20221230monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-updates-namodenoson-increases-survival-for-the-most-severe-patients-with-advanced-canf-20221228monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-partner-vetbiolix-is-heading-into-a-european-multicentric-clinical-trial-with-p-canf-20221208monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-third-quarter-2022-financial-results-provides-clinical-update-canf-20221125monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-positive-new-data-from-it-s-phase-iii-psoriasis-study-will-be-presented-today-at--canf-20221102monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-findings-showing-the-complete-clearance-of-cancer-in-patient-treated-with-namoden-canf-20221025monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-new-phase-iii-psoriasis-data-showing-superior-safety-improved-efficacy-presented--canf-20220912monthly0.5https://www.biopharmawatch.com/news/CANF/operating-and-financial-review-and-prospects-you-should-read-the-following-selected-financ-canf-20220825monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-drug-namodenoson-approved-for-compassionate-use-treatment-of-advanced-liver-can-canf-20220823monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-selected-to-present-the-positive-psoriasis-phase-iii-data-at-the-31-st-european-a-canf-20220822monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-progress-in-the-development-of-piclidenoson-for-osteoarthritis-in-pets-th-canf-20220817monthly0.5https://www.biopharmawatch.com/news/CANF/notice-of-2022-annual-general-meeting-of-shareholders-to-be-held-on-august-29-2022-to-the--canf-20220725monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-to-submit-fda-ema-registration-plans-for-piclidenoson-in-the-oral-treatment-of-mo-canf-20220711monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-positive-top-line-results-from-piclidenoson-phase-iii-comfort-tm-study--canf-20220629monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-cf602-reverses-erectile-dysfunction-in-diabetic-pre-clinical-model-study-publis-canf-20220624monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-publication-of-clinical-study-data-for-piclidenoson-and-namodenoson-in--canf-20220609monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-first-quarter-2022-financial-results-provides-clinical-update-canf-20220526monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-granted-key-nash-patent-in-israel-phase-iib-nash-study-is-currently-enrolling-pat-canf-20220516monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-ceo-to-present-namodenoson-s-efficacy-in-liver-cancer-as-expert-speaker-at-the--canf-20220502monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-is-developing-a-topical-piclidenoson-psoriasis-treatment-that-shows-efficacy-in-a-canf-20220405monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-2021-financial-results-provides-clinical-update-cash-balance-of-18-9-mill-canf-20220324monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-namodenoson-s-treatment-of-liver-fibrosis-receives-notice-of-allowance-from-u-s-p-canf-20220314monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-findings-in-the-treatment-of-liver-diseases-with-cannabinoids-to-be-presented-a-canf-20220311monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-phase-iii-psoriasis-study-data-expected-q2-2022-canf-20220308monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-first-patient-enrolled-in-phase-iib-nash-clinical-trial-with-namodenoso-canf-20220131monthly0.5https://www.biopharmawatch.com/news/CANF/prior-to-phase-iii-psoriasis-data-release-can-fite-reports-that-piclidenoson-destroys-path-canf-20220113monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-issues-letter-to-shareholders-q1-2022-psoriasis-phase-iii-data-commencement-of-en-canf-20220105monthly0.5https://www.biopharmawatch.com/news/CANF/following-complete-clearance-of-cancer-lesions-in-advanced-liver-cancer-patient-can-fite-i-canf-20211229monthly0.5https://www.biopharmawatch.com/news/CANF/liver-cancer-patient-treated-with-can-fite-s-namodenoson-clears-all-cancer-lesions-under-o-canf-20211220monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-phase-iii-psoriasis-study-to-complete-16-week-treatment-of-last-patient-in-janu-canf-20211207monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-third-quarter-2021-financial-results-provides-clinical-update-canf-20211126monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-piclidenoson-commences-clinical-study-for-the-treatment-of-canine-osteoarthriti-canf-20211123monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-nash-patents-granted-and-allowed-in-japan-hong-kong-and-mexico-can-fite-continu-canf-20211028monthly0.5https://www.biopharmawatch.com/news/CANF/positive-data-from-phase-iia-can-fite-nash-study-published-in-leading-peer-reviewed-scient-canf-20211021monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-completes-patient-enrollment-in-phase-iii-psoriasis-study-positive-interim-analys-canf-20210902monthly0.5https://www.biopharmawatch.com/news/CANF/operating-and-financial-review-and-prospects-you-should-read-the-following-selected-financ-canf-20210826monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-10-0-million-registered-direct-offering-canf-20210812monthly0.5https://www.biopharmawatch.com/news/CANF/yossi-borenstein-ceo-and-founder-of-shizim-group-has-been-elected-to-the-can-fite-board-yo-canf-20210805monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-gears-up-to-initiate-pivotal-phase-iii-liver-cancer-study-fda-granted-namodenoson-canf-20210708monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-enters-projected-3-billion-veterinary-osteoarthritis-market-signs-agreement-with--canf-20210628monthly0.5https://www.biopharmawatch.com/news/CANF/notice-of-special-meeting-of-shareholders-to-be-held-on-july-29-2021-to-the-shareholders-a-canf-20210623monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-receives-notice-of-patent-allowance-in-china-for-nash-treatment-namodenoson-is-ou-canf-20210616monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-to-initiate-phase-iib-nash-study-with-its-drug-candidate-namodenoson-a-prior-phas-canf-20210602monthly0.5https://www.biopharmawatch.com/news/CANF/notice-of-2021-annual-general-meeting-of-shareholders-to-be-held-on-june-7-2021-to-the-sha-canf-20210601monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-first-quarter-2021-financial-results-provides-clinical-update-can-fite-canf-20210527monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2-canf-20210429monthly0.5https://www.biopharmawatch.com/news/CANF/notice-of-2021-annual-general-meeting-of-shareholders-to-be-held-on-may-31-2021-to-the-sha-canf-20210423monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-expands-its-phase-ii-covid-19-study-to-europe-the-phase-ii-study-is-under-fda-pro-canf-20210422monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-initiates-preclinical-studies-required-by-fda-and-ema-for-the-registration-of-its-canf-20210420monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-cannabis-compound-inhibits-liver-cancer-growth-in-preclinical-studies-patent-appl-canf-20210405monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-summary-of-existing-out-licensing-deals-with-potential-milestone-payments-of-up-t-canf-20210330monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-2020-financial-results-provides-clinical-development-update-5m-cash-infus-canf-20210325monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-topical-administration-of-cf602-fully-recovers-erectile-dysfunction-in-diabetic-m-canf-20210318monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-signs-42-7-m-illion-out-licensing-deal-with-ewopharma-swiss-ewopharma-to-market-p-canf-20210316monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-enrolls-first-patient-in-phase-ii-covid-19-study-under-fda-protocol-piclidenoson--canf-20210305monthly0.5https://www.biopharmawatch.com/news/CANF/new-positive-data-from-can-fite-s-liver-cancer-phase-ii-clinical-study-with-namodenoson-ov-canf-20210222monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-inhibition-of-liver-fibrosis-by-cannabis-compounds-in-preclinical-studi-canf-20210201monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-nash-indication-highlighted-in-webinar-by-kol-dr-harrison-namodenoson-may-have--canf-20210128monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-publication-of-namodenoson-liver-cancer-study-in-peer-reviewed-journal--canf-20210108monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-receives-israel-ministry-of-health-approval-to-conduct-research-with-cannabinoids-canf-20201215monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-on-progress-with-its-namodenoson-nash-program-top-nash-u-s-key-opinion-le-canf-20201214monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-third-quarter-2020-financial-results-provides-clinical-update-company-to--canf-20201130monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-namodenoson-abstract-selected-as-best-of-the-liver-meeting-in-the-nash-category-canf-20201124monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-presented-nash-phase-ii-namodenoson-data-at-a-late-breaking-session-of-the-americ-canf-20201116monthly0.5https://www.biopharmawatch.com/news/CANF/notice-of-2020-annual-general-meeting-of-shareholders-to-be-held-on-december-2-2020-to-the-canf-20201028monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-to-host-conference-call-to-update-shareholders-on-positive-interim-results-of-its-canf-20201015monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-positive-phase-iii-psoriasis-interim-data-analysis-independent-data-mon-canf-20201006monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-selected-to-deliver-late-breaking-oral-presentation-on-namodenoson-s-treatment-of-canf-20200930monthly0.5https://www.biopharmawatch.com/news/CANF/fda-clears-can-fite-to-commence-phase-ii-covid-19-study-piclidenoson-has-a-robust-anti-inf-canf-20200831monthly0.5https://www.biopharmawatch.com/news/CANF/operating-and-financial-review-and-prospects-you-should-read-the-following-selected-financ-canf-20200827monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-receives-notification-of-patent-grant-from-european-patent-office-for-namodenoson-canf-20200825monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-submits-investigational-new-drug-application-to-u-s-fda-for-covid-19-phase-ii-stu-canf-20200727monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-completes-development-of-an-assay-to-identify-clinically-active-cannabis-derived--canf-20200720monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-completes-phase-ii-covid-19-protocol-based-on-fda-guidance-plans-to-file-ind-shor-canf-20200715monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-3-4-million-registered-direct-offering-canf-20200706monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-final-data-analysis-from-phase-ii-nash-study-highly-significant-and-sus-canf-20200630monthly0.5https://www.biopharmawatch.com/news/CANF/notice-of-special-meeting-of-shareholders-to-be-held-on-august-5-2020-to-the-shareholders--canf-20200629monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-8-0-million-registered-direct-offering-canf-20200610monthly0.5https://www.biopharmawatch.com/news/CANF/following-pre-ind-guidance-from-fda-can-fite-to-advance-piclidenoson-into-phase-ii-covid-1-canf-20200609monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-concludes-successful-meeting-with-european-medicines-agency-ema-regarding-phase-i-canf-20200604monthly0.5https://www.biopharmawatch.com/news/CANF/kost-forer-gabbay-kasierer-144-menachem-begin-road-tel-aviv-6492102-israel-tel-972-3-62325-canf-20200601monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-receives-notice-of-allowance-for-namodenoson-patent-in-the-treatment-of-nash-nafl-canf-20200521monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-additional-findings-from-successful-phase-ii-nash-study-25-mg-dose-of-nam-canf-20200518monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-pre-ind-submission-to-u-s-fda-for-piclidenoson-in-the-treatment-of-covi-canf-20200515monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-received-approval-for-covid-19-clinical-trial-in-israel-patient-enrollment-and-do-canf-20200413monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-positive-top-line-results-from-its-phase-ii-nash-study-with-namodenoson-m-canf-20200407monthly0.5https://www.biopharmawatch.com/news/CANF/notice-of-special-meeting-of-shareholders-to-be-held-on-april-21-2020-to-the-shareholders--canf-20200402monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-implements-interim-analysis-for-its-phase-iii-psoriasis-trial-with-data-expected--canf-20200330monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-2019-financial-results-provides-clinical-development-update-piclidenoson--canf-20200327monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-piclidenoson-is-submitted-for-compassionate-use-treatment-for-coronavirus-patient-canf-20200323monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-to-participate-in-digital-bio-europe-spring-partnering-conference-looks-to-partne-canf-20200318monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-progress-in-compassionate-use-program-treating-advanced-liver-cancer-patients-wit-canf-20200316monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-to-explore-the-anti-coronavirus-effects-of-piclidenoson-in-collaboration-with-lew-canf-20200313monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-new-pre-clinical-studies-demonstrate-inhibition-of-fat-cell-expansion-by-cannabis-canf-20200311monthly0.5https://www.biopharmawatch.com/news/CANF/nyse-american-canf-tase-cfbi-can-fite-presentation-march-2020-nyse-american-canf-tase-cfbi-canf-20200309monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-updates-on-clinical-milestone-for-its-phase-iii-rheumatoid-arthritis-study-with-p-canf-20200305monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-is-filing-drug-safety-update-report-showing-positive-safety-results-from-phase-ii-canf-20200303monthly0.5https://www.biopharmawatch.com/news/CANF/pre-clinical-studies-demonstrate-cbd-s-robust-anti-cancer-effect-against-liver-cancer-can--canf-20200227monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-files-patent-for-namodenoson-to-overcome-drug-resistance-to-checkpoint-inhibitors-canf-20200224monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-granted-patent-allowance-for-its-nash-drug-namodenoson-in-south-korea-results-of--canf-20200218monthly0.5https://www.biopharmawatch.com/news/CANF/notice-of-special-general-meeting-of-shareholders-to-be-held-on-february-20-2020-to-the-sh-canf-20200213monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-submits-liver-cancer-phase-iii-protocol-and-registration-plan-to-ema-for-namodeno-canf-20200213monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-completes-50-patient-enrollment-in-phase-iii-rheumatoid-arthritis-study-implement-canf-20200203monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-and-univo-pharmaceuticals-collaboration-result-in-discovery-and-applied-patent-fo-canf-20200116monthly0.5https://www.biopharmawatch.com/news/CANF/notice-of-special-general-meeting-of-shareholders-to-be-held-on-february-13-2020-to-the-sh-canf-20200109monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-exercise-of-warrants-for-cash-proceeds-of-2-4-million-canf-20200109monthly0.5https://www.biopharmawatch.com/news/CANF/data-from-the-phase-ii-liver-cancer-study-with-namodenoson-will-be-presented-at-the-iscort-canf-20200107monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-ceo-issues-letter-to-shareholders-q1-2020-topline-results-from-nash-phase-ii-stud-canf-20200106monthly0.5https://www.biopharmawatch.com/news/CANF/new-data-from-hadassah-medical-center-lab-show-can-fite-s-namodenoson-induces-weight-loss--canf-20200103monthly0.5https://www.biopharmawatch.com/news/CANF/golan-bitton-univo-pharmaceutical-ceo-elected-to-the-can-fite-board-a-strategic-partnershi-canf-20191226monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-completes-50-patient-enrollment-in-its-phase-iii-psoriasis-trial-psoriasis-therap-canf-20191209monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-third-quarter-2019-financial-results-provides-clinical-update-reached-agr-canf-20191129monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-granted-patents-for-its-sexual-dysfunction-drug-the-drug-s-unique-mechanism-of-ac-canf-20191119monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-granted-u-s-patent-for-piclidenoson-in-the-treatment-of-osteoarthritis-positionin-canf-20191111monthly0.5https://www.biopharmawatch.com/news/CANF/2019-annual-general-meeting-of-shareholders-canf-20191106monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-initiates-compassionate-use-program-for-namodenoson-in-the-treatment-of-liver-can-canf-20191104monthly0.5https://www.biopharmawatch.com/news/CANF/u-s-fda-agreed-with-can-fite-s-proposed-pivotal-phase-iii-trial-design-to-support-a-new-dr-canf-20191031monthly0.5https://www.biopharmawatch.com/news/CANF/and-gebro-pharma-holding-european-conference-on-development-commercialization-of-phase-iii-canf-20191017monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-completes-patient-enrollment-in-phase-ii-nash-study-of-namodenoson-topline-result-canf-20191015monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-publication-of-namodenoson-nash-mechanism-of-action-in-international-jo-canf-20191010monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-presents-new-data-on-the-treatment-of-advanced-liver-cancer-with-namodenoson-at-t-canf-20190923monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-enters-into-strategic-agreement-with-univo-pharmaceuticals-to-develop-cannabinoid-canf-20190910monthly0.5https://www.biopharmawatch.com/news/CANF/nyse-american-canf-tase-cfbi-can-fite-presentation-september-2019-nyse-american-canf-tase--canf-20190906monthly0.5https://www.biopharmawatch.com/news/CANF/operating-and-financial-review-and-prospects-you-should-read-the-following-discussion-of-o-canf-20190830monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-second-quarter-2019-financial-results-provides-clinical-update-upfront-pa-canf-20190829monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-to-treat-advanced-liver-cancer-patients-with-namodenoson-under-compassionate-use--canf-20190806monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-signs-agreement-with-kyongbo-pharm-for-the-distribution-in-south-korea-of-piclide-canf-20190801monthly0.5https://www.biopharmawatch.com/news/CANF/findings-from-can-fite-s-phase-canf-20190603monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-first-quarter-2019-financial-results-provides-clinical-update-preparatory-canf-20190529monthly0.5https://www.biopharmawatch.com/news/CANF/the-anti-nash-effect-of-namodenoson-will-be-presented-at-the-international-conference-on-f-canf-20190523monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-phase-ii-liver-cancer-data-selected-for-presentation-at-a-leading-liver-cancer--canf-20190520monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-preparation-for-end-of-phase-ii-meeting-with-fda-to-initiate-the-phase--canf-20190506monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-ads-ratio-change-canf-20190501monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-receives-1-000-000-payment-from-ckd-for-distribution-of-namodenoson-in-south-kore-canf-20190415monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-late-breaking-abstract-presentation-on-namodenoson-phase-ii-results-at--canf-20190410monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-announces-3-2-million-registered-direct-offering-canf-20190402monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-2018-financial-results-provides-clinical-update-global-distribution-deals-canf-20190328monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-phase-ii-advanced-liver-cancer-top-line-results-for-its-orphan-fast-tra-canf-20190326monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-expands-its-namodenoson-distribution-deal-with-ckd-in-south-korea-with-nash-indic-canf-20190225monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-receives-notice-of-allowance-from-u-s-patent-and-trademark-office-for-osteoarthri-canf-20190204monthly0.5https://www.biopharmawatch.com/news/CANF/nyse-american-canf-tase-cfbi-can-fite-presentation-pnina-fishman-ceo-motti-farbstein-cfo-f-canf-20190201monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-drugs-potential-ability-to-treat-cytokine-release-syndrome-in-cancer-immunother-canf-20190130monthly0.5https://www.biopharmawatch.com/news/CANF/of-special-general-meeting-of-shareholders-canf-20190124monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-ceo-letter-to-shareholders-near-term-milestones-include-advanced-liver--canf-20190124monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-announces-registered-direct-offering-canf-20190118monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-pre-clinical-data-positions-namodenoson-as-an-anti-obesity-agent-company-filed-pa-canf-20190108monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-enters-into-collaboration-agreement-to-explore-namodenoson-s-anti-nash-effect-wit-canf-20181210monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-third-quarter-2018-financial-results-and-provides-clinical-development-up-canf-20181130monthly0.5https://www.biopharmawatch.com/news/CANF/prior-to-phase-ii-liver-cancer-data-release-can-fite-brings-on-board-an-oncologist-expert--canf-20181120monthly0.5https://www.biopharmawatch.com/news/CANF/due-to-patient-survival-top-line-results-of-the-namodenoson-phase-ii-advanced-liver-cancer-canf-20181031monthly0.5https://www.biopharmawatch.com/news/CANF/annual-general-meeting-of-shareholders-canf-20181025monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-to-present-on-its-liver-cancer-drug-namodenoson-at-the-nyc-oncology-investor-conf-canf-20181025monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-ceo-to-present-as-expert-speaker-on-namodenoson-at-nash-summit-europe-2018-canf-20181018monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-to-present-the-anti-fibrogenic-effects-of-namodenoson-at-the-hepatic-fibrosis-con-canf-20180912monthly0.5https://www.biopharmawatch.com/news/CANF/top-line-results-of-the-namodenoson-phase-ii-advanced-liver-cancer-trial-expected-by-end-o-canf-20180904monthly0.5https://www.biopharmawatch.com/news/CANF/operating-and-financial-review-and-prospects-you-should-read-the-following-discussion-of-o-canf-20180831monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-enrollment-of-first-patient-in-its-comfort-phase-iii-trial-of-piclideno-canf-20180821monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-ltd-and-its-subsidiaries-consolidated-financial-statements-as-of-decemb-canf-20180808monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-receives-from-cms-medical-venture-investment-limited-2-000-000-upfront-payment-as-canf-20180807monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-signs-multi-million-dollar-development-and-distribution-agreement-for-piclidenoso-canf-20180806monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-granted-australian-and-chinese-patents-for-erectile-dysfunction-drug-erectile-dys-canf-20180717monthly0.5https://www.biopharmawatch.com/news/CANF/drugs-with-mechanism-of-action-utilized-by-namodenoson-are-recommended-by-leading-u-s-rese-canf-20180628monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-updates-on-status-of-phase-ii-advanced-liver-cancer-trial-accumulated-safety-data-canf-20180619monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-on-new-pre-clinical-developments-with-its-nash-drug-namodenoson-robust-an-canf-20180611monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-first-quarter-2018-financial-results-and-provides-clinical-update-company-canf-20180601monthly0.5https://www.biopharmawatch.com/news/CANF/piclidenoson-mechanism-of-action-in-psoriasis-published-in-journal-of-immunology-research-canf-20180425monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-2017-financial-results-provides-clinical-update-oslash-a-multi-million-do-canf-20180323monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-announces-5-million-registered-direct-offering-canf-20180309monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-to-participate-in-panel-discussions-on-latest-drug-developments-in-nash-at-the-30-canf-20180306monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-on-the-progress-of-its-phase-ii-nash-study-with-drug-candidate-namodenoso-canf-20180228monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-the-submission-of-safety-reports-for-piclidenoson-and-namodenoson-to-fd-canf-20180222monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-announces-new-pre-clinical-data-supporting-a-novel-anti-nash-mechanism--canf-20180212monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-receives-from-gebro-holdings-2-200-000-payment-as-part-of-distribution-agreement--canf-20180125monthly0.5https://www.biopharmawatch.com/news/CANF/notice-of-special-general-meeting-of-shareholders-to-be-held-on-february-22-2018-to-the-sh-canf-20180118monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-12-months-activities-milestones-for-2018-expected-milestones-in-the-next-12-month-canf-20180111monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-signs-multi-million-dollar-distribution-agreement-for-piclidenoson-in-3-european--canf-20180108monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-enters-into-collaborative-research-agreement-with-hadassah-medical-center-to-furt-canf-20180103monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-on-the-progress-of-its-phase-ii-liver-cancer-with-namodenoson-accumulated-canf-20171218monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-third-quarter-2017-financial-results-provides-clinical-update-namodenoson-canf-20171127monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-enrolls-first-patient-in-phase-ii-nafld-nash-study-with-namodenoson-data-show-nam-canf-20171127monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-former-subsidiary-ophthalix-successfully-completes-merger-with-wize-pharma-canf-20171117monthly0.5https://www.biopharmawatch.com/news/CANF/special-general-meeting-of-shareholders-canf-20171115monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-enrollment-of-first-patient-in-its-acrobat-phase-iii-trial-of-piclideno-canf-20171030monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-issued-patent-in-korea-for-piclidenoson-in-the-treatment-of-psoriasis-can-fite-ha-canf-20171017monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-files-patent-application-to-treat-cytokine-release-syndrome-a-potentially-life-th-canf-20170918monthly0.5https://www.biopharmawatch.com/news/CANF/operating-and-financial-review-and-prospects-you-should-read-the-following-discussion-of-o-canf-20170915monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-presentation-september-2017-this-presentation-contains-forward-looking-statements-canf-20170908monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-second-quarter-2017-financial-results-provides-clinical-update-phase-ii-l-canf-20170901monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-receives-milestone-payment-from-ckd-pharmaceuticals-its-distribution-partner-in-k-canf-20170823monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-completes-patient-enrolment-for-its-phase-ii-study-of-namodenoson-in-the-treatmen-canf-20170809monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-successfully-completes-human-cardiodynamic-safety-trial-for-piclidenoson-strong-s-canf-20170807monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-phase-ii-nafld-nash-trial-with-namodenoson-set-to-commence-patient-enrollment-f-canf-20170717monthly0.5https://www.biopharmawatch.com/news/CANF/jfif-c-c-canf-20170619monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-concludes-successful-clinical-investigator-meeting-for-its-acrobat-phase-iii-tria-canf-20170608monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-establishes-clinical-advisory-board-for-nafld-nash-board-members-are-key-opinion--canf-20170605monthly0.5https://www.biopharmawatch.com/news/CANF/new-preclinical-data-on-can-fite-s-namodenoson-to-be-presented-at-1-st-international-confe-canf-20170602monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-first-quarter-2017-financial-results-provides-clinical-update-phase-iii-t-canf-20170530monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-files-clinical-trial-application-in-canada-for-piclidenoson-ahead-of-upcoming-acr-canf-20170516monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-liver-protective-drug-namodenoson-enters-phase-ii-trial-for-treatment-of-nafld--canf-20170503monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-phase-iii-acrobat-trial-in-rheumatoid-arthritis-approved-by-institutional-revie-canf-20170425monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-2016-financial-results-provides-clinical-update-phase-iii-trial-of-piclid-canf-20170331monthly0.5https://www.biopharmawatch.com/news/CANF/new-preclinical-data-show-can-fite-s-namodenoson-cf102-prevents-progression-of-liver-fibro-canf-20170228monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-gears-up-for-acrobat-its-phase-iii-trial-of-piclidenoson-in-rheumatoid-arthritis--canf-20170208monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-announces-5-million-registered-direct-offering-canf-20170119monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-receives-irb-approval-to-commence-patient-enrollment-in-phase-ii-nafld-nash-trial-canf-20170109monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-presentation-january-2017-this-presentation-contains-forward-looking-statements-a-canf-20170106monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-receives-500-000-payment-as-part-of-3-million-distribution-deal-for-liver-cancer--canf-20161221monthly0.5https://www.biopharmawatch.com/news/CANF/new-preclinical-data-show-can-fite-s-namodenoson-cf102-inhibits-liver-fibrosis-supports-po-canf-20161216monthly0.5https://www.biopharmawatch.com/news/CANF/jfif-d-d-ducky-d-adobe-d-g-canf-20161207monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-financial-results-for-nine-months-ended-canf-20161125monthly0.5https://www.biopharmawatch.com/news/CANF/american-medical-association-s-usan-world-health-organization-s-inn-approve-namodenoson-as-canf-20161116monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-receives-notice-of-allowance-from-u-s-patent-and-trademark-office-for-erectile-dy-canf-20161109monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-ltd-proxy-for-a-special-general-meeting-of-series-10-warrant-holders-to-canf-20161102monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-advances-towards-a-pivotal-phase-iii-clinical-trial-in-psoriasis-with-piclidenoso-canf-20161101monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-signs-distribution-deal-for-liver-cancer-drug-cf102-in-south-korea-deal-provides--canf-20161025monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-submits-protocol-for-phase-ii-trial-of-cf102-in-the-treatment-of-nafld-nash-leadi-canf-20161013monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-new-data-on-cf102-s-liver-protective-regenerative-properties-published-in-canf-20160920monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-receives-notice-of-allowance-for-psoriasis-patent-in-europe-ahead-of-phase-iii-tr-canf-20160913monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-ltd-interim-condensed-consolidated-financial-statements-as-of-june-30-2-canf-20160829monthly0.5https://www.biopharmawatch.com/news/CANF/reports-financial-results-for-six-months-ended-june-30-2016-canf-20160826monthly0.5https://www.biopharmawatch.com/news/CANF/completes-phase-ii-study-design-for-cf102-in-the-treatment-of-nash-nafld-canf-20160725monthly0.5https://www.biopharmawatch.com/news/CANF/ophthalix-announces-phase-ii-glaucoma-data-canf-20160705monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-new-data-showing-its-psoriasis-drug-may-offer-efficacy-similar-to-industr-canf-20160615monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-submits-psoriasis-phase-iii-protocol-and-registration-plan-to-ema-for-piclidenoso-canf-20160607monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reaches-agreement-with-ema-on-pivotal-phase-iii-clinical-trial-with-piclidenoson--canf-20160601monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-first-quarter-2016-financial-results-provides-clinical-pipeline-update-canf-20160527monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-new-pre-clinical-data-for-cf602-demonstrating-statistically-significant-canf-20160411monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-2015-financial-results-provides-clinical-pipeline-update-canf-20160401monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-submits-phase-iii-protocol-design-and-registration-plan-to-european-medicines-age-canf-20160317monthly0.5https://www.biopharmawatch.com/news/CANF/u-s-canf-20160119monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-presentation-january-2016-this-presentation-contains-forward-looking-statements-a-canf-20160111monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-submits-phase-iii-protocol-to-irb-for-cf101-in-the-treatment-of-rheumatoid-arthri-canf-20160105monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-cf101-granted-patent-in-japan-for-intraocular-pressure-a-key-cause-of-glaucoma--canf-20151217monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-subsidiary-ophthalix-announces-completion-of-patient-enrollment-in-phase-ii-glauc-canf-20151207monthly0.5https://www.biopharmawatch.com/news/CANF/reports-financial-results-for-nine-months-ended-september-30-2015-canf-20151127monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-compelling-pre-clinical-data-on-cf102-in-the-treatment-of-non-alcoholic-canf-20151123monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-ltd-instructions-to-the-bank-of-new-york-mellon-as-depositary-must-be-r-canf-20151026monthly0.5https://www.biopharmawatch.com/news/CANF/new-study-demonstrates-cf602-mechanism-of-action-to-improve-sexual-dysfunction-ind-submiss-canf-20151022monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-announces-4-8-million-registered-direct-offering-continued-investment-f-canf-20151013monthly0.5https://www.biopharmawatch.com/news/CANF/european-medicines-agency-grants-orphan-designation-to-can-fite-s-cf102-in-the-treatment-o-canf-20151012monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-to-present-cf101-psoriasis-data-at-late-breaking-session-of-the-eadv-congress-in--canf-20150929monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-announces-9-million-registered-direct-offering-canf-20150920monthly0.5https://www.biopharmawatch.com/news/CANF/u-s-food-and-drug-administration-grants-fast-track-designation-to-can-fite-s-cf102-in-the--canf-20150917monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-ltd-interim-condensed-consolidated-financial-statements-as-of-june-30-2-canf-20150903monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-financial-results-for-six-months-ended-canf-20150827monthly0.5https://www.biopharmawatch.com/news/CANF/world-health-organization-accepted-piclidenoson-as-proposed-new-generic-name-for-can-fite--canf-20150729monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-cf602-sexual-dysfunction-drug-backed-by-new-preclinical-data-progresses-towards-canf-20150629monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-subsidiary-ophthalix-signs-definitive-agreement-to-acquire-improved-vision-system-canf-20150619monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-to-exhibit-at-bio-international-convention-in-philadelphia-on-june-15-18-2015-canf-20150615monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-granted-notice-of-allowance-for-patent-covering-manufacturing-process-of-cf101-in-canf-20150610monthly0.5https://www.biopharmawatch.com/news/CANF/jfif-c-c-o-canf-20150529monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-phase-ii-liver-cancer-trial-approved-in-europe-first-patient-dosed-in-europe-th-canf-20150511monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-subsidiary-ophthalix-signs-term-sheet-to-acquire-improved-vision-systems-ltd-new--canf-20150504monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-positive-results-from-further-analysis-of-phase-ii-iii-psoriasis-trial-da-canf-20150427monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-applies-for-orphan-drug-designation-in-europe-for-cf102-in-the-treatment-of-liver-canf-20150420monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-top-line-results-from-phase-ii-iii-trial-for-cf101-in-treatment-of-psoria-canf-20150330monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-signs-multi-million-dollar-distribution-agreement-for-cf101-in-canada-with-cipher-canf-20150323monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-completes-development-of-commercial-biomarker-test-to-predict-patients-response-t-canf-20150318monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-receives-notice-of-allowance-in-u-s-for-psoriasis-patent-company-just-completed-p-canf-20150217monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-completes-phase-ii-iii-trial-for-cf101-in-treatment-of-psoriasis-data-expected-to-canf-20150204monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-cf602-demonstrates-efficacy-in-treatment-of-sexual-dysfunction-in-preclinical-s-canf-20150127monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-upcoming-2015-clinical-milestones-for-its-pipeline-of-drugs-in-4-indica-canf-20150106monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-completes-the-design-of-the-rheumatoid-arthritis-phase-iii-study-of-its-lead-drug-canf-20141230monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-doses-first-patient-in-global-phase-ii-liver-cancer-trial-for-cf102-trial-follows-canf-20141222monthly0.5https://www.biopharmawatch.com/news/CANF/second-part-of-the-glaucoma-phase-ii-study-has-been-approved-in-a-european-country-cf101-i-canf-20141215monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-8-million-at-the-market-registered-direct-offering-canf-20141202monthly0.5https://www.biopharmawatch.com/news/CANF/us-researchers-published-scientific-findings-that-are-a-potential-breakthrough-for-prevent-canf-20141201monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-near-term-milestones-timetable-for-2014-2015-canf-20141118monthly0.5https://www.biopharmawatch.com/news/CANF/jfif-c-c-r-1a-qa-q-2-b-r-3br-456789-cdef-canf-20141118monthly0.5https://www.biopharmawatch.com/news/CANF/u-s-patent-and-trademark-office-issues-can-fite-patent-for-cf102-in-the-treatment-of-liver-canf-20140930monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-ltd-and-its-subsidiaries-interim-condensed-consolidated-financial-state-canf-20140917monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-issued-japanese-patent-for-cf102-in-the-treatment-of-liver-regeneration-and-funct-canf-20140905monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-first-six-months-2014-results-canf-20140902monthly0.5https://www.biopharmawatch.com/news/CANF/new-data-shows-high-efficacy-for-can-fite-s-cf101-in-rheumatoid-arthritis-and-psoriasis-pa-canf-20140806monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-cf102-approved-for-compassionate-use-in-israel-for-liver-cancer-patient-patient-canf-20140710monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-completes-patient-enrollment-in-its-phase-ii-iii-psoriasis-trial-final-results-ar-canf-20140617monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-subsidiary-ophthalix-provides-an-update-on-its-clinical-developments-and-strategi-canf-20140609monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-that-the-us-fda-has-agreed-with-its-phase-ii-liver-cancer-protocol-can--canf-20140602monthly0.5https://www.biopharmawatch.com/news/CANF/notice-of-2014-annual-general-meeting-of-shareholders-to-be-held-on-july-7-2014-to-the-sha-canf-20140530monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-first-quarter-2014-results-canf-20140529monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-receives-patent-in-european-union-for-treatment-of-liver-function-following-surge-canf-20140507monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-submits-protocol-to-u-s-fda-for-phase-ii-liver-cancer-study-tufts-university-will-canf-20140429monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-initiates-the-development-of-an-a3ar-biomarker-test-kit-to-predict-patients-respo-canf-20140421monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-phase-ii-study-protocol-to-treat-patients-with-advanced-liver-cancer-with-cf102-h-canf-20140317monthly0.5https://www.biopharmawatch.com/news/CANF/securities-purchase-agreement-securities-purchase-agreement-the-agreement-dated-as-of-canf-20140310monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-the-addition-of-a-key-opinion-leader-to-boost-its-rheumatoid-arthritis--canf-20140303monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-granted-patent-on-the-manufacturing-of-cf101-in-japan-the-patent-confers-exclusiv-canf-20140225monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-provides-update-on-key-milestones-for-2014-petach-tikva-israel-canf-20140218monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-submitted-phase-ii-study-protocol-with-cf102-to-treat-patients-with-advanced-live-canf-20140206monthly0.5https://www.biopharmawatch.com/news/CANF/summary-of-the-application-for-compromise-or-settlement-in-accordance-with-the-application-canf-20140123monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-to-present-new-clinical-data-from-a-further-analysis-of-its-clinical-studies-of-c-canf-20140113monthly0.5https://www.biopharmawatch.com/news/CANF/it-is-hereby-resolved-1-transition-of-the-reporting-format-of-the-company-in-accordance-wi-canf-20140107monthly0.5https://www.biopharmawatch.com/news/CANF/ophthalix-to-retrospectively-analyze-the-phase-iii-dry-eye-syndrome-study-data-based-on-th-canf-20131231monthly0.5https://www.biopharmawatch.com/news/CANF/ophthalix-announces-top-line-results-of-phase-iii-study-with-cf101-for-dry-eye-syndrome-pe-canf-20131230monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-announces-top-line-results-of-phase-iib-study-with-cf101-as-a-monothera-canf-20131223monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-granted-a-u-s-patent-for-the-utilization-of-the-a3-adenosine-receptor-a-canf-20131219monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-ltd-interim-consolidated-financial-statements-as-of-september-30-2013-u-canf-20131129monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-announces-approval-of-adr-listing-on-nyse-mkt-petach-tikva-israel-canf-20131115monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-ltd-9-30-2013-unaudited-pro-forma-interim-consolidated-balance-sheet-1--canf-20131108monthly0.5https://www.biopharmawatch.com/news/CANF/u-s-patent-and-trademark-office-grants-a-patent-for-the-reduction-of-intraocular-pressure--canf-20131105monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-executes-confidentiality-agreements-with-pharmaceutical-and-biotechnology-compani-canf-20131104monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-investor-presentation-fall-2013-pnina-fishman-phd-ceo-page-2-this-presentation-co-canf-20131028monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-fund-raising-results-in-shelf-offering-completed-on-the-tel-aviv-stock--canf-20131023monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-fund-raising-in-order-to-satisfy-qualification-requirments-to-register-on-the-nys-canf-20131023monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-announces-expected-clinical-activity-milestones-through-the-end-of-2013-canf-20131022monthly0.5https://www.biopharmawatch.com/news/CANF/about-can-fite-biopharma-ltd-can-fite-biopharma-ltd-is-an-israeli-public-company-the-ordin-canf-20131002monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-biopharma-ltd-interim-consolidated-financial-statements-as-of-june-30-2013-unaudi-canf-20130916monthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-s-level-ii-adrs-commence-trading-on-the-u-s-otc-markets-petach-tikva-israel-canf-20130912monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-announces-reverse-stock-split-inbs-20251212monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-reports-fiscal-2026-first-quarter-financial-results-and-operatio-inbs-20251112monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-expects-to-report-record-fiscal-first-quarter-2026-revenue-of-ov-inbs-20251104monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-secures-33-new-customer-accounts-in-the-fiscal-2026-first-quarte-inbs-20251030monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-advances-preparations-and-provides-updated-timeline-for-anticipa-inbs-20250926monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-provides-update-on-fda-510-k-clearance-process-for-intelligent-f-inbs-20250917monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-reports-fiscal-2025-fourth-quarter-and-full-year-results-highlig-inbs-20250815monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-announces-preliminary-fiscal-fourth-quarter-revenue-with-double--inbs-20250807monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-strengthens-fda-510-k-package-with-new-cybersecurity-and-perform-inbs-20250806monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-enters-into-agreements-to-raise-3-8-million-in-gross-proceed-inbs-20250725monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-to-strengthen-fda-510-k-submission-with-new-positive-data-demons-inbs-20250723monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-accelerates-global-growth-with-smartest-patch-agreement-reinforc-inbs-20250716monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-adds-next-gen-wearable-for-extended-drug-detection-to-product-of-inbs-20250715monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-accelerates-global-adoption-of-fingerprint-drug-testing-company--inbs-20250515monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-announces-fiscal-q3-2025-financial-results-and-key-operational-a-inbs-20250513monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-secures-key-u-s-patent-strengthening-ip-protection-ahead-of-plan-inbs-20250326monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-fda-clearance-process-remains-on-track-for-2025-u-s-launch-inbs-20250325monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-to-expand-u-s-ip-portfolio-with-expected-patent-grant-inbs-20250320monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-announces-proposed-public-offering-of-common-stock-inbs-20250219monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-announces-fiscal-q2-2025-financial-results-and-key-operational-a-inbs-20250213monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-releases-shareholder-letter-detailing-2024-growth-and-2025-u-s-e-inbs-20250210monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-expands-with-uk-partnership-driving-global-growth-ahead-of-plann-inbs-20250207monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-expects-to-achieve-32-6-gross-profit-expansion-and-increased-pro-inbs-20250206monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-expands-global-reach-with-multilingual-drug-screening-system-upg-inbs-20250131monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-adds-quantum-tm-to-400-account-portfolio-utilizing-breakthrough--inbs-20250129monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-partners-with-ivy-diagnostics-to-expand-in-europe-s-3-6-billion--inbs-20250128monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-announces-510-k-submission-to-us-fda-for-fingerprint-sweat-based-inbs-20241218monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-achieves-94-1-accuracy-in-method-comparison-study-following-posi-inbs-20241126monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-announces-positive-results-of-pk-study-a-key-milestone-on-path-t-inbs-20241113monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-reports-fiscal-2025-first-quarter-financial-results-and-operatio-inbs-20241107monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-announces-preliminary-unaudited-fiscal-2025-first-quarter-revenu-inbs-20241029monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-concludes-in-clinic-testing-for-clinical-study-plan-advancing-to-inbs-20240927monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-reports-fiscal-2024-fourth-quarter-and-full-year-financial-r-inbs-20240919monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-announces-preliminary-full-fiscal-year-2024-revenue-growth-o-inbs-20240909monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-announces-progress-toward-completion-of-clinical-study-plan--inbs-20240905monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-reports-118-year-over-year-growth-in-customer-employee-base--inbs-20240903monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-achieves-major-milestone-with-over-1-000-installed-intellige-inbs-20240821monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-highlights-growing-need-for-drug-testing-solutions-in-key-in-inbs-20240813monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-partners-with-cenexel-to-conduct-clinical-study-as-part-of-fda-5-inbs-20240801monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-announces-qabastech-as-exclusive-distributor-in-saudi-arabia-inbs-20240724monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-advances-on-fda-510-k-pathway-with-biocompatibility-study-su-inbs-20240718monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-completes-in-clinic-portion-of-pharmacokinetic-pk-study-part-of--inbs-20240628monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-begins-subject-dosing-and-sampling-for-fda-510-k-pharmacokinetic-inbs-20240618monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-successfully-completes-recruitment-and-begins-subject-screening--inbs-20240529monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-unveils-key-performance-indicator-growth-in-the-united-kingdom-a-inbs-20240523monthly0.5https://www.biopharmawatch.com/news/INBS/innovative-fingerprint-drug-screening-solution-showcased-at-the-uk-s-premier-health-and-sa-inbs-20240517monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-reports-fiscal-2024-third-quarter-and-nine-month-financial-r-inbs-20240508monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-announces-preliminary-unaudited-fiscal-third-quarter-and-nin-inbs-20240331monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-subsidiary-broadens-intellectual-property-portfolio-with-grant-o-inbs-20240411monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-announces-10-1-million-private-placement-priced-at-the-market-un-inbs-20240311monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-partners-with-cliantha-research-to-conduct-clinical-study-as-par-inbs-20240228monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement-inbs-20240216monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-reports-fiscal-second-quarter-and-six-month-financial-result-inbs-20240209monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-announces-exercise-of-previously-issued-warrants-for-1-77-mi-inbs-20240205monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-announces-preliminary-unaudited-fiscal-second-quarter-and-si-inbs-20240202monthly0.5https://www.biopharmawatch.com/news/INBS/leading-uk-timber-processor-and-packaging-manufacturer-james-jones-sons-ltd-adopts-intelli-inbs-20240129monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-announces-reverse-stock-split-inbs-20240125monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-receives-nata-accreditation-for-its-revolutionary-fingerprint-sw-inbs-20231219monthly0.5https://www.biopharmawatch.com/news/INBS/pro-forma-balance-sheet-inbs-20231218monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-reports-fiscal-2024-first-quarter-financial-results-and-oper-inbs-20231108monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-adds-logistics-firm-to-fingerprint-drug-screening-portfolio-and--inbs-20231005monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-announces-pricing-of-4-000-000-underwritten-public-offering-inbs-20231002monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-obtains-iso-recertification-for-its-intelligent-fingerprinting-d-inbs-20230927monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-successfully-debuts-intelligent-fingerprinting-drug-screening-so-inbs-20230921monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-completes-critical-development-milestone-in-plans-to-add-ketamin-inbs-20230908monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-reports-fiscal-2023-fourth-quarter-and-full-year-financial-r-inbs-20230824monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-secures-8-new-customers-with-a-combined-workforce-of-over-10-000-inbs-20230801monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-signs-south-american-distribution-agreement-with-tscom-for-finge-inbs-20230706monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-receives-guidance-from-u-s-fda-on-a-regulatory-pathway-for-expan-inbs-20230628monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-receives-non-dilutive-grant-funding-of-usd-1-43-million-grant-fu-inbs-20230620monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-plans-to-add-fentanyl-testing-as-it-further-enhances-its-fingerp-inbs-20230516monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-reports-fiscal-2023-third-quarter-financial-results-and-oper-inbs-20230511monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-scales-reach-throughout-asia-pacific-region-with-addition-of-sal-inbs-20230502monthly0.5https://www.biopharmawatch.com/news/INBS/uk-food-processing-equipment-manufacturer-latest-to-adopt-intelligent-bio-solutions-portab-inbs-20230426monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-secures-uk-patent-for-intelligent-fingerprinting-dsr-plus-cartri-inbs-20230418monthly0.5https://www.biopharmawatch.com/news/INBS/a-f-sprinklers-selects-intelligent-bio-solutions-latest-dsr-plus-screening-unit-to-support-inbs-20230327monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-selects-hasta-laboratory-as-drug-testing-specialist-in-austr-inbs-20230313monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-announces-proposed-public-offering-inbs-20230307monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-regains-compliance-with-nasdaq-listing-requirement-new-york--inbs-20230301monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-files-fda-513-g-regulatory-submission-for-intelligent-finger-inbs-20230216monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-reports-fiscal-2023-second-quarter-financial-results-and-ope-inbs-20230215monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-announces-reverse-stock-split-inbs-20230209monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-announces-leading-food-industry-logistics-provider-to-implem-inbs-20230207monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-announces-closing-of-private-placement-offering-inbs-20221222monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-announces-cancellation-of-fy-2021-annual-meeting-of-stockhol-inbs-20221221monthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-inc-reports-first-quarter-ending-inbs-20221109monthly0.5https://www.biopharmawatch.com/news/INBS/gbs-inc-initiates-company-name-change-to-intelligent-bio-solutions-inc-inbs-and-announces--inbs-20221026monthly0.5https://www.biopharmawatch.com/news/INBS/gbs-inc-acquires-intelligent-fingerprinting-limited-and-its-proprietary-drugs-of-abuse-scr-inbs-20221004monthly0.5https://www.biopharmawatch.com/news/INBS/gbs-inc-reports-fourth-quarter-and-full-year-ended-inbs-20220831monthly0.5https://www.biopharmawatch.com/news/INBS/gbs-inc-enters-into-exclusivity-agreement-for-an-acquisition-of-unique-point-of-care-diagn-inbs-20220616monthly0.5https://www.biopharmawatch.com/news/INBS/gbs-inc-reports-third-quarter-2022-financial-results-and-recent-business-highlights-initia-inbs-20220511monthly0.5https://www.biopharmawatch.com/news/INBS/gbs-inc-announces-institutional-review-board-approval-to-initiate-clinical-trial-at-sutter-inbs-20220331monthly0.5https://www.biopharmawatch.com/news/INBS/gbs-inc-reports-second-quarter-2022-financial-results-and-recent-business-highlights-discu-inbs-20220210monthly0.5https://www.biopharmawatch.com/news/INBS/gbs-inc-announces-application-for-fda-breakthrough-device-designation-to-fast-track-rapid--inbs-20211213monthly0.5https://www.biopharmawatch.com/news/INBS/gbs-inc-announces-plans-for-clinical-sars-cov-2-antibody-trials-following-validation-study-inbs-20211130monthly0.5https://www.biopharmawatch.com/news/INBS/life-science-biosensor-diagnostics-pty-ltd-statement-in-relation-to-recent-sale-of-shares--inbs-20211122monthly0.5https://www.biopharmawatch.com/news/INBS/gbs-inc-reports-first-quarter-2022-financial-results-and-recent-business-highlights-inbs-20211111monthly0.5https://www.biopharmawatch.com/news/INBS/gbs-inc-announces-executive-leadership-changes-to-accelerate-product-development-and-manuf-inbs-20211101monthly0.5https://www.biopharmawatch.com/news/INBS/gbs-inc-announces-its-pre-submission-package-is-with-the-fda-new-york-new-york-inbs-20211013monthly0.5https://www.biopharmawatch.com/news/INBS/gbs-inc-reports-fourth-quarter-and-full-year-2021-preliminary-financial-results-and-recent-inbs-20210811monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio-sxtp-20260115monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharmaceuticals-inc-confidential-all-rights-reserved-october-2025-1-8-26-webinar-d-sxtp-20260108monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharmaceuticals-inc-confidential-all-rights-reserved-september-2025-h-c-wainwright-sxtp-20250909monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharmaceuticals-announces-pricing-of-up-to-10-million-public-offering-5-million-up-sxtp-20250715monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharma-announces-1-075-million-registered-direct-offering-priced-at-the-market-und-sxtp-20250205monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharma-announces-1-043-million-registered-direct-offering-priced-at-the-market-und-sxtp-20250129monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharma-announces-irb-approval-of-phase-ii-study-to-evaluate-tafenoquine-for-chroni-sxtp-20250128monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharmaceuticals-enrolls-first-patient-in-tafenoquine-expanded-access-clinical-stud-sxtp-20250108monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharmaceuticals-inc-announces-arakoda-promotional-pilot-in-advance-of-expanded-u-s-sxtp-20241003monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharmaceuticals-inc-announces-4-million-private-placement-priced-at-the-market-und-sxtp-20240904monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharmaceuticals-inc-regains-compliance-with-nasdaq-listing-requirements-washington-sxtp-20240828monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharma-provides-university-of-kentucky-with-right-of-reference-to-arakoda-nda-in-s-sxtp-20240812monthly0.5https://www.biopharmawatch.com/news/SXTP/of-60-degrees-pharmaceuticals-inc-dated-as-of-august-6-2024-e-xhibit-99-1-60-degrees-pharm-sxtp-20240806monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharmaceuticals-awarded-contract-with-u-s-army-for-arakoda-supply-chain-upgrade-su-sxtp-20240725monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharma-announces-irb-approval-of-clinical-study-of-tafenoquine-for-treatment-of-ba-sxtp-20240709monthly0.5https://www.biopharmawatch.com/news/SXTP/first-patient-enrolled-in-60-degrees-pharmaceuticals-clinical-trial-of-tafenoquine-for-bab-sxtp-20240627monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharmaceuticals-receives-fda-orphan-drug-designation-for-tafenoquine-for-treatment-sxtp-20240611monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharmaceuticals-receives-fda-comments-on-tafenoquine-babesiosis-clinical-trial-pro-sxtp-20240502monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharmaceuticals-announces-communication-from-the-fda-of-intention-to-respond-to-ta-sxtp-20240314monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharmaceuticals-to-sponsor-pre-clinical-studies-of-tafenoquine-use-in-candida-spp--sxtp-20240220monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharmaceuticals-announces-pricing-of-2-4-million-public-offering-washington-sxtp-20240130monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharma-plans-pivotal-babesiosis-study-with-tafenoquine-following-jan-17-fda-meetin-sxtp-20240122monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharmaceuticals-suspends-phase-iib-study-of-tafenoquine-for-covid-19-pivots-to-ref-sxtp-20231012monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharma-withdraws-covid-phase-iib-ind-will-resubmit-pending-assessment-of-ability-t-sxtp-20230918monthly0.5https://www.biopharmawatch.com/news/SXTP/degrees-pharmaceuticals-announces-pricing-of-initial-public-offering-washington-sxtp-20230712monthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-gene-lab-corp-announces-appointment-of-dr-muthu-meyyappan-as-chief-commercial-off-bglc-20260311monthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-gene-lab-corp-completes-chemrex-governance-restructuring-appoints-matthew-barsing-bglc-20260223monthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-launches-regional-deployment-of-vitaguard-mrd-infrastructure-positioned-to-challe-bglc-20260128monthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-gene-lab-corp-nasdaq-bglc-and-fidelion-diagnostics-execute-exclusive-southeast-as-bglc-20251201monthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-gene-lab-corp-files-100-million-shelf-registration-and-establishes-20-million-at--bglc-20251113monthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-gene-lab-corp-nasdaq-bglc-announces-strategic-agreements-with-fidelion-diagnostic-bglc-20251112monthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-gene-lab-corp-signs-strategic-partnership-term-sheet-with-birchbiomed-inc-collabo-bglc-20251020monthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-gene-lab-corp-and-fidelion-diagnostics-announce-landmark-alliance-touted-as-a-new-bglc-20250730monthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-gene-lab-corp-regains-nasdaq-compliance-signaling-strategic-stability-and-growth--bglc-20250430monthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-gene-lab-corp-and-ml-tech-partner-to-enhance-ethereum-focused-treasury-strategy-bglc-20250307monthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-gene-lab-corp-announces-board-approval-of-ethereum-treasury-strategy-and-release--bglc-20250305monthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-gene-lab-corporation-announces-entry-into-biogas-sector-via-teaming-agreement-wit-bglc-20240925monthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-gene-lab-corp-signs-strategic-outsourcing-agreement-with-vitarray-global-pte-ltd-bglc-20240914monthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-gene-lab-corp-announces-new-business-developments-for-subsidiary-chemrex-with-inv-bglc-20240911monthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-gene-lab-corp-announces-successful-securities-commission-of-malaysia-mycif-co-inv-bglc-20240828monthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-gene-lab-corp-completes-strategic-rm-1-million-investment-in-ascension-innovation-bglc-20240826monthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-gene-lab-corp-agrees-to-invest-rm-1-2-million-in-ascension-innovation-aisb-to-adv-bglc-20240418monthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-gene-lab-corp-announces-pricing-of-5-million-public-offering-and-uplisting-to-the-bglc-20230720monthly0.5https://www.biopharmawatch.com/news/BGLC/chemrex-corporation-sdn-bhd-index-to-the-audited-financial-statements-years-ended-bglc-20210311monthly0.5https://www.biopharmawatch.com/news/BGLC/rna-as-a-screening-tool-and-biomarker-for-disease-a-paradigm-shift-in-medical-risk-stratif-bglc-20201222monthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-announces-nasdaq-uplisting-and-pricing-of-4-million-public-offering-prop-ppcb-20250814monthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-appoints-carlo-campiciano-as-chief-financial-officer-cfo-adds-substantia-ppcb-20190624monthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-completes-scientific-advice-meeting-with-mhra-company-receives-guidance--ppcb-20180410monthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-completes-successful-reproduction-run-for-prp-company-requests-scientifi-ppcb-20180314monthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-receives-allowance-of-key-patent-application-in-the-eu-patent-covers-a-p-ppcb-20180220monthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-authorizes-reverse-stock-split-ppcb-20170331monthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-enters-into-contract-manufacturing-agreement-with-amatsiqbiologicals-development-a-ppcb-20160823monthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-receives-investment-to-initiate-glp-safety-toxicology-study-for-prp-set-to-initiat-ppcb-20160705monthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-demonstrates-significant-anti-tumor-efficacy-in-pancreatic-and-ovarian-cancer-prec-ppcb-20151117monthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-enters-into-5-million-equity-purchase-agreement-with-southridge-partners-melbourne-ppcb-20140922monthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-to-begin-trading-on-the-otc-bulletin-board-under-the-symbol-ppcb-20120627monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-financial-results-for-the-three-and-twelve-months-end-revb-20260226monthly0.5https://www.biopharmawatch.com/news/REVB/transcript-of-corporate-update-revb-20251203monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-financial-results-for-the-three-and-nine-months-ended-revb-20251106monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-cancellation-of-adjournment-of-revb-20251029monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-adjournment-of-revb-20251015monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-exercise-of-warrants-for-9-6-million-in-gross-proceed-revb-20250911monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-announces-groundbreaking-top-line-results-from-prime-clinical-study-revb-20250909monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-financial-results-for-the-three-and-six-months-ended-revb-20250808monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-1-for-3-reverse-stock-split-effective-revb-20250707monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-pricing-of-4-million-public-offering-san-diego-ca-x20-revb-20250529monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-announces-retirement-of-george-tidmarsh-md-phd-from-board-of-direct-revb-20250523monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-financial-results-for-the-three-months-ended-revb-20250508monthly0.5https://www.biopharmawatch.com/news/REVB/gemini-priming-attenuates-inflammation-in-human-peripheral-blood-mononuclear-cells-x2013-o-revb-20250317monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-financial-results-for-the-three-and-twelve-months-end-revb-20250306monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-receives-continued-nasdaq-listing-approval-san-diego-ca-x2013-revb-20250224monthly0.5https://www.biopharmawatch.com/news/REVB/rebalancing-inflammation-to-optimize-health-nasdaq-revb-www-revbiosciences-com-this-presen-revb-20250211monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-starts-its-prime-phase-1b-clinical-study-of-gemini-in-ckd-patients--revb-20250121monthly0.5https://www.biopharmawatch.com/news/REVB/nasdaq-grants-revelation-biosciences-inc-continued-listing-san-diego-ca-x2013-revb-20250106monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-fda-acceptance-of-gemini-ind-phase-1b-study-in-ckd-pa-revb-20241202monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-financial-results-for-the-three-and-nine-months-ended-revb-20241108monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-gemini-induces-dose-dependent-significant-increases-in-il-10-san-di-revb-20240924monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-financial-results-for-the-three-and-six-months-ended-revb-20240809monthly0.5https://www.biopharmawatch.com/news/REVB/assignment-form-to-assign-the-foregoing-warrant-execute-this-form-and-supply-required-info-revb-20240624monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-financial-results-for-the-three-months-ended-revb-20240510monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-financial-results-for-the-three-and-twelve-months-end-revb-20240322monthly0.5https://www.biopharmawatch.com/news/REVB/gemini-is-a-proprietary-formulation-of-phosphorylated-hexaacyl-disaccharide-phad-a-synthet-revb-20240312monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-pricing-of-6-2-million-public-offering-san-diego-ca-x-revb-20240201monthly0.5https://www.biopharmawatch.com/news/REVB/developing-innovative-therapeutics-to-address-unmet-needs-corporate-presentation-january-2-revb-20240130monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-financial-results-for-the-three-and-nine-months-ended-revb-20231113monthly0.5https://www.biopharmawatch.com/news/REVB/developing-innovative-therapeutics-to-address-unmet-needs-corporate-presentation-october-2-revb-20231012monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-appointment-of-lakhmir-chawla-m-d-to-board-of-directo-revb-20231002monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-financial-results-for-the-three-and-six-months-ended-revb-20230811monthly0.5https://www.biopharmawatch.com/news/REVB/reminder-revelation-biosciences-inc-urges-all-stockholders-to-vote-at-the-2023-annual-meet-revb-20230629monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-adjournment-of-2023-annual-meeting-of-stockholders-to-revb-20230612monthly0.5https://www.biopharmawatch.com/news/REVB/developing-innovative-therapeutics-to-address-unmet-needs-corporate-presentation-may-2023--revb-20230525monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-financial-results-for-the-three-months-ended-revb-20230522monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-financial-results-for-the-three-and-twelve-months-end-revb-20230403monthly0.5https://www.biopharmawatch.com/news/REVB/allergies-revdx-x2011-501-is-being-developed-as-a-rapid-diagnostic-that-can-be-used-to-det-revb-20230213monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-1-for-35-reverse-stock-split-effective-revb-20230201monthly0.5https://www.biopharmawatch.com/news/REVB/developing-innovative-therapeutics-to-address-unmet-needs-corporate-presentation-january-2-revb-20230110monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-pricing-of-upcoming-automatic-unit-separation-san-die-revb-20230110monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-financial-results-for-the-three-and-nine-months-ended-revb-20221110monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-positive-results-in-preclinical-model-of-acute-and-ch-revb-20221025monthly0.5https://www.biopharmawatch.com/news/REVB/developing-innovative-therapeutics-to-address-unmet-needs-corporate-presentation-october-2-revb-20221006monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-announces-financial-results-for-the-three-and-six-months-ended-revb-20220817monthly0.5https://www.biopharmawatch.com/news/REVB/in-the-company-s-8-k-dated-1-14-2022-and-gr-oss-proceeds-of-7-76m-from-the-company-s-recen-revb-20220315monthly0.5https://www.biopharmawatch.com/news/REVB/in-the-company-s-8-k-dated-1-14-2022-and-gr-oss-proceeds-of-7-76m-from-the-company-s-recen-revb-20220211monthly0.5https://www.biopharmawatch.com/news/REVB/shall-have-the-meanings-ascribed-to-them-in-the-current-report-on-form-8-k-the-form-8-k-fi-revb-20220114monthly0.5https://www.biopharmawatch.com/news/REVB/developing-innovative-therapeutics-and-diagnostics-to-address-unmet-needs-corporate-presen-revb-20220113monthly0.5https://www.biopharmawatch.com/news/REVB/petra-acquisition-inc-announces-share-redemption-backstop-and-forward-purchase-agreements--revb-20211221monthly0.5https://www.biopharmawatch.com/news/REVB/this-promissory-note-has-not-been-registered-under-the-securities-act-of-1933-as-amended-t-revb-20210917monthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inc-a-life-sciences-company-developing-therapeutics-and-diagnostics-revb-20210830monthly0.5https://www.biopharmawatch.com/news/REVB/petra-acquisition-inc-receives-expected-nasdaq-notification-regarding-delayed-form-10-q-ne-revb-20210601monthly0.5https://www.biopharmawatch.com/news/REVB/petra-acquisition-inc-announces-securities-to-commence-separate-trading-new-york-ny-revb-20201110monthly0.5https://www.biopharmawatch.com/news/REVB/petra-acquisition-inc-index-to-financial-statement-page-report-of-independent-registered-p-revb-20201013monthly0.5https://www.biopharmawatch.com/news/REVB/petra-acquisition-inc-announces-pricing-of-70-million-initial-public-offering-new-york-ny-revb-20201008monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-termination-of-prior-planned-merger-and-continues-pursuit-of-alternati-pulm-20260228monthly0.5https://www.biopharmawatch.com/news/PULM/exhibti-99-1-pulmatrix-announces-year-end-and-q4-2023-financial-results-and-provides-corpo-pulm-20240328monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-stopping-the-pur1900-phase-2b-study-patient-enrollment-and-closing-the-pulm-20231231monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-second-quarter-2023-financial-results-and-provides-corporate-update-su-pulm-20230810monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-submission-of-ind-application-to-fda-to-initiate-a-phase-2-trial-of-in-pulm-20230711monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-first-quarter-2023-financial-results-and-provides-corporate-update-pat-pulm-20230512monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-year-end-and-q4-financial-2022-results-and-provides-corporate-update-p-pulm-20230330monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-first-patient-dosed-in-phase-2b-study-of-pur1900-for-treatment-of-alle-pulm-20230206monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-to-host-key-opinion-leader-webinar-pur3100-for-the-treatment-of-acute-migraine-u-pulm-20230125monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-positive-top-line-results-from-a-phase-1-study-with-pur3100-a-novel-or-pulm-20230104monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-third-quarter-2022-financial-results-and-provides-corporate-update-pur-pulm-20221110monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-patient-dosing-completed-for-its-novel-inhaled-therapy-pur3100-for-acu-pulm-20220926monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-second-quarter-2022-financial-results-and-provides-corporate-update-pu-pulm-20220808monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-first-subject-dosed-in-phase-1-study-of-pur3100-for-acute-migraine-new-pulm-20220712monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-first-quarter-2022-financial-results-and-provides-corporate-update-end-pulm-20220512monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-year-end-and-q4-financial-2021-results-and-provides-corporate-update-pulm-20220329monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-positive-top-line-data-evaluating-pur1800-in-patients-with-stable-pulm-20220321monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-regains-compliance-with-nasdaq-listing-requirements-pulm-20220317monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-expansion-of-executive-leadership-team-to-progress-clinical-pipeline-pulm-20220301monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-inc-announces-1-for-20-reverse-stock-split-pulm-20220224monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-closing-of-6-75-million-registered-direct-offering-pulm-20211217monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-6-75-million-registered-direct-offering-pulm-20211215monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-reports-third-quarter-2021-financial-results-and-provides-business-update-pulmaz-pulm-20211110monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-resolution-of-contract-dispute-with-cipla-pulm-20211109monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-reports-second-quarter-2021-financial-results-and-provides-business-update-pur18-pulm-20210810monthly0.5https://www.biopharmawatch.com/news/PULM/lexington-mass-pulm-20210727monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-reports-first-quarter-2021-financial-results-and-provides-business-update-pur180-pulm-20210511monthly0.5https://www.biopharmawatch.com/news/PULM/corrected-pulmatrix-to-regain-full-rights-to-pur1800-and-narrow-spectrum-kinase-inhibitor--pulm-20210412monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-reports-2020-financial-results-and-provides-business-update-initiated-pur1800-ph-pulm-20210323monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-reports-third-quarter-2020-financial-results-and-business-updates-focused-pipeli-pulm-20201112monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-progress-by-sensory-cloud-toward-commercial-launch-of-fend-in-fall-202-pulm-20200708monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-changes-to-board-of-directors-pulm-20200626monthly0.5https://www.biopharmawatch.com/news/PULM/execution-version-pulm-20200416monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-8-0-million-registered-direct-offering-priced-at-the-market-under-nasd-pulm-20200416monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-and-sensory-cloud-announce-partnership-to-develop-and-commercialize-a-potential--pulm-20200416monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-receives-fast-track-designation-for-pulmazole-for-the-treatment-of-asthma-abpa-pulm-20200130monthly0.5https://www.biopharmawatch.com/news/PULM/this-presentation-contains-forward-looking-statements-all-statements-other-than-statements-pulm-20200113monthly0.5https://www.biopharmawatch.com/news/PULM/safe-harbor-this-presentation-contains-forward-looking-statements-all-statements-other-tha-pulm-20191119monthly0.5https://www.biopharmawatch.com/news/PULM/safe-harbor-this-presentation-contains-forward-looking-statements-all-statements-other-tha-pulm-20190822monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-and-cipla-technologies-llc-enter-into-definitive-agreement-for-the-development-a-pulm-20190415monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-inc-announces-closing-of-16-6-million-upsized-public-offering-underwriter-exerci-pulm-20190408monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-inc-announces-pricing-of-14-4-million-upsized-public-offering-pulm-20190403monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-enters-into-binding-term-sheet-with-cipla-technologies-llc-for-the-development-a-pulm-20190401monthly0.5https://www.biopharmawatch.com/news/PULM/execution-version-pulm-20190124monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-inc-announces-closing-of-public-offering-of-common-stock-pulm-20190205monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-inc-announces-proposed-public-offering-of-common-stock-pulm-20190130monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-inc-announces-proposed-public-offering-of-common-stock-pulm-20190128monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-3-0-pulm-20181129monthly0.5https://www.biopharmawatch.com/news/PULM/safe-harbor-this-presentation-contains-forward-looking-statements-all-statements-other-tha-pulm-20180801monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-pricing-of-15-2-pulm-20180329monthly0.5https://www.biopharmawatch.com/news/PULM/safe-harbor-this-presentation-contains-forward-looking-statements-forward-looking-statemen-pulm-20180209monthly0.5https://www.biopharmawatch.com/news/PULM/safe-harbor-this-presentation-contains-forward-looking-statements-forward-looking-statemen-pulm-20180117monthly0.5https://www.biopharmawatch.com/news/PULM/safe-harbor-this-presentation-contains-forward-looking-statements-forward-looking-statemen-pulm-20171114monthly0.5https://www.biopharmawatch.com/news/PULM/disclaimers-forward-looking-statements-this-presentation-contains-forward-looking-statemen-pulm-20170911monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-licenses-inhaled-copd-drug-pur0200-to-vectura-group-plc-the-agreement-will-accel-pulm-20170907monthly0.5https://www.biopharmawatch.com/news/PULM/disclaimers-forward-looking-statements-this-presentation-contains-forward-looking-statemen-pulm-20170815monthly0.5https://www.biopharmawatch.com/news/PULM/disclaimers-forward-looking-statements-this-presentation-contains-forward-looking-statemen-pulm-20170803monthly0.5https://www.biopharmawatch.com/news/PULM/amit-d-munshi-joins-pulmatrix-s-board-of-directors-mr-munshi-brings-over-25-years-of-execu-pulm-20170615monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-licenses-novel-drug-candidates-from-respivert-ltd-a-wholly-owned-subsidiary-of-j-pulm-20170613monthly0.5https://www.biopharmawatch.com/news/PULM/disclaimers-forward-looking-statements-this-presentation-contains-forward-looking-statemen-pulm-20170228monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-over-3-0-million-registered-direct-offering-pulm-20170203monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-5-pulm-20170130monthly0.5https://www.biopharmawatch.com/news/PULM/disclaimers-forward-looking-statements-this-presentation-contains-forward-looking-statemen-pulm-20170127monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-reports-third-quarter-2016-financial-results-and-business-update-pulm-20161104monthly0.5https://www.biopharmawatch.com/news/PULM/disclaimers-forward-looking-statements-this-presentation-contains-forward-looking-statemen-pulm-20161025monthly0.5https://www.biopharmawatch.com/news/PULM/disclaimers-forward-looking-statements-this-presentation-contains-forward-looking-statemen-pulm-20160913monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-reports-q2-2016-financial-results-pulm-20160804monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-and-mylan-report-positive-pharmacokinetic-bioavailability-data-in-pilot-study-of-pulm-20160719monthly0.5https://www.biopharmawatch.com/news/PULM/disclaimers-forward-looking-statements-this-presentation-contains-forward-looking-statemen-pulm-20160602monthly0.5https://www.biopharmawatch.com/news/PULM/disclaimers-forward-looking-statements-this-presentation-contains-forward-looking-statemen-pulm-20160309monthly0.5https://www.biopharmawatch.com/news/PULM/disclaimers-forward-looking-statements-this-presentation-contains-forward-looking-statemen-pulm-20160111monthly0.5https://www.biopharmawatch.com/news/PULM/bio-investor-conference-pulm-20151020monthly0.5https://www.biopharmawatch.com/news/PULM/virtual-investor-conference-pulm-20150806monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-appoints-william-duke-jr-as-chief-financial-officer-lexington-mass-pulm-20150625monthly0.5https://www.biopharmawatch.com/news/PULM/lexington-mass-and-hertfordshire-england-and-pittsburgh-pulm-20150616monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-raises-10-million-private-placement-to-begin-trading-on-nasdaq-under-pulm-pulmat-pulm-20150616monthly0.5https://www.biopharmawatch.com/news/PULM/ruthigen-and-pulmatrix-stockholders-approve-merger-santa-rosa-ca-and-lexington-ma-pulm-20150612monthly0.5https://www.biopharmawatch.com/news/PULM/ruthigen-reports-fiscal-second-quarter-2015-financial-results-to-host-conference-call-at-4-pulm-20141113monthly0.5https://www.biopharmawatch.com/news/PULM/ruthigen-reports-fiscal-first-quarter-2015-financial-results-santa-rosa-calif-pulm-20140814monthly0.5https://www.biopharmawatch.com/news/PULM/ruthigen-reports-fourth-quarter-and-fiscal-year-2014-financial-results-santa-rosa-calif-pulm-20140630monthly0.5https://www.biopharmawatch.com/news/PULM/ruthigen-announces-pricing-of-initial-public-offering-santa-rosa-ca-pulm-20140321monthly0.5https://www.biopharmawatch.com/news/PASW/all-resolutions-passed-at-ping-an-biomedical-agm-clearing-path-for-restructured-share-capi-pasw-20260319monthly0.5https://www.biopharmawatch.com/news/PASW/ping-an-biomedical-co-ltd-22-f-china-united-plaza-1002-1008-tai-nan-west-street-cheung-sha-pasw-20260309monthly0.5https://www.biopharmawatch.com/news/PASW/ping-an-biomedical-co-ltd-receives-strategic-investment-from-leading-industry-capital-acce-pasw-20260109monthly0.5https://www.biopharmawatch.com/news/PASW/ping-an-biomedical-co-ltd-announces-receipt-of-nasdaq-minimum-bid-price-deficiency-letter--pasw-20251128monthly0.5https://www.biopharmawatch.com/news/PASW/majestic-ideal-holdings-ltd-index-to-unaudited-condensed-consolidated-financial-statements-pasw-20250929monthly0.5https://www.biopharmawatch.com/news/PASW/majestic-ideal-holdings-ltd-announces-approval-of-name-change-to-ping-an-biomedical-co-ltd-pasw-20250912monthly0.5https://www.biopharmawatch.com/news/PASW/majestic-ideal-holdings-ltd-22-f-china-united-plaza-1002-1008-tai-nan-west-street-cheung-s-pasw-20250903monthly0.5https://www.biopharmawatch.com/news/PASW/majestic-ideal-holdings-ltd-statement-of-policy-concerning-trading-in-company-securities-a-pasw-20250716monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-registered-direct-offering-of-10-million-bedminster-n-j-mtnb-20240403monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-positive-in-vivo-safety-data-with-its-oral-lnc-docetaxel-formu-mtnb-20240327monthly0.5https://www.biopharmawatch.com/news/MTNB/three-patients-with-invasive-fusarium-infection-in-matinas-biopharma-s-oral-mat2203-compas-mtnb-20240322monthly0.5https://www.biopharmawatch.com/news/MTNB/compassionate-use-patient-treated-with-matinas-biopharma-s-mat2203-and-showing-complete-cl-mtnb-20230418monthly0.5https://www.biopharmawatch.com/news/MTNB/biontech-and-matinas-biopharma-announce-exclusive-research-collaboration-to-evaluate-novel-mtnb-20220411monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-announces-proposed-public-offering-of-common-stock-bedminster-n-j-mtnb-20190314monthly0.5https://www.biopharmawatch.com/news/MTNB/prominent-cardiovascular-expert-james-j-ferguson-m-d-facc-faha-joins-matinas-biopharma-as--mtnb-20190225monthly0.5https://www.biopharmawatch.com/news/MTNB/www-matinasbiopharma-com-nyse-mkt-mtnb-canaccord-genuity-37-th-annual-growth-conference-je-mtnb-20170808monthly0.5https://www.biopharmawatch.com/news/MTNB/biopharma-appoints-dominick-dipaolo-as-senior-vice-president-of-quality-and-regulatory-com-mtnb-20170418monthly0.5https://www.biopharmawatch.com/news/MTNB/www-matinasbiopharma-com-otcqb-mtnb-transforming-the-way-potent-medicines-for-infectious-d-mtnb-20161006monthly0.5https://www.biopharmawatch.com/news/MTNB/www-matinasbiopharma-com-otcqb-mtnb-transforming-the-way-potent-medicines-for-infectious-d-mtnb-20150904monthly0.5https://www.biopharmawatch.com/news/MTNB/unaudited-pro-forma-condensed-combined-financial-statements-of-matinas-biopharma-holdings--mtnb-20150319monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-establishes-lipid-based-anti-infective-platform-with-acquisition-of-aqua-mtnb-20150202monthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-receives-fda-feedback-on-ind-submission-and-provides-update-on-clinical--mtnb-20141223monthly0.5https://www.biopharmawatch.com/news/MTNB/corporate-presentation-forward-looking-statement-this-presentation-contains-forward-lookin-mtnb-20140808monthly0.5https://www.biopharmawatch.com/news/MTNB/slide-presentation-corporate-presentation-forward-looking-statement-this-presentation-cont-mtnb-20140430monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-announces-insider-buying-westbrook-maine-december-10th-2018-synergy-chc-c-snyr-20181211monthly0.5https://www.biopharmawatch.com/news/SNYR/embargoed-for-use-before-contact-after-8-00pm-eastern-jack-ross-chairman-ceo-snyr-20171019monthly0.5https://www.biopharmawatch.com/news/SNYR/embargoed-for-use-before-contact-after-5-30pm-eastern-jack-ross-chairman-ceo-snyr-20171012monthly0.5https://www.biopharmawatch.com/news/SNYR/embargoed-for-use-before-contact-after-8am-eastern-jack-ross-chairman-ceo-snyr-20170810monthly0.5https://www.biopharmawatch.com/news/SNYR/embargoed-for-use-before-contact-after-8am-eastern-jack-ross-chairman-ceo-snyr-20170622monthly0.5https://www.biopharmawatch.com/news/SNYR/embargoed-for-use-before-contact-after-9am-eastern-jack-ross-chairman-ceo-snyr-20151116monthly0.5https://www.biopharmawatch.com/news/SNYR/embargoed-for-use-before-contact-after-9am-eastern-jack-ross-chairman-ceo-snyr-20150819monthly0.5https://www.biopharmawatch.com/news/SNYR/embargoed-for-use-before-contact-after-5pm-eastern-jack-ross-chairman-ceo-snyr-20150701monthly0.5https://www.biopharmawatch.com/news/SNYR/jack-ross-chairman-ceo-synergy-strips-jack-synergystrips-com-615-939-9004-synergy-strips-c-snyr-20150126monthly0.5https://www.biopharmawatch.com/news/SNYR/exhibit-99-3-synergy-strips-corp-financial-statements-table-of-contents-condensed-balance--snyr-20140715monthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-strips-corp-financial-statements-for-the-year-ended-december-31-2013-and-2012-tabl-snyr-20140507monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-announces-1-for-40-reverse-stock-split-ispc-20260424monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-achieves-85-reduction-in-human-biospecimen-shipping-time-woburn-ma-ispc-20260409monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-approached-by-crypto-currency-companies-for-200-million-treasury-discussions-wob-ispc-20250904monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-announces-completion-of-milestone-1-in-digital-transformation-journey-with-sales-ispc-20250821monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-to-establish-200m-corporate-treasury-built-around-solana-cryptocurrency-with-blo-ispc-20250807monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-inc-announces-pricing-of-approximately-1-75-million-private-placement-priced-at--ispc-20250731monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-inc-announces-pricing-of-4-million-underwritten-offering-ispc-20250724monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-secures-suppliers-for-covid-style-hmpv-outbreak-ispc-20250116monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-will-serve-as-a-preferred-provider-of-cancer-biospecimens-woburn-ma-ispc-20241220monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-reports-positive-results-on-next-day-quote-program-for-researchers-and-providers-ispc-20241213monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-appoints-robert-lim-as-ceo-and-director-ispc-20241212monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-inc-announces-pricing-of-5-million-public-offering-of-common-stock-and-pre-funde-ispc-20241029monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-announces-1-for-20-reverse-stock-split-ispc-20240911monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-reports-second-quarter-2024-results-revenue-increased-76-year-over-year-to-appro-ispc-20240806monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-reports-first-quarter-2024-results-ispc-20240507monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-reports-full-year-2023-results-lexington-mass-march-14-2024-ispecimen-inc-nasdaq-ispc-20240314monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-reports-third-quarter-2023-financial-and-operating-results-sequential-quarterly--ispc-20231102monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-preannounces-third-quarter-2023-revenue-increase-of-60-70-sequentially-managemen-ispc-20231023monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-announces-organizational-changes-to-enhance-operational-efficiencies-and-drive-p-ispc-20230906monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-reports-second-quarter-2023-financial-and-operating-results-ispc-20230802monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-reports-first-quarter-2023-results-quarterly-revenue-increased-17-year-over-year-ispc-20230504monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-reports-full-year-2022-results-reported-record-quarterly-revenue-of-3-2-million--ispc-20230314monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-names-tracy-curley-as-chief-executive-officer-previously-appointed-interim-ceo-i-ispc-20230110monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-reports-third-quarter-2022-financial-and-operating-results-reported-revenue-of-2-ispc-20221108monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-names-chief-financial-officer-tracy-curley-interim-ceo-current-president-and-ceo-ispc-20220922monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-reports-second-quarter-2022-financial-and-operating-results-enhanced-ispecimen-m-ispc-20220804monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-reports-first-quarter-2022-financial-and-operating-results-recently-launched-enh-ispc-20220510monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-reports-full-year-2021-financial-results-record-fy-2021-revenue-of-11-1-million--ispc-20220217monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-inc-announces-closing-of-approximately-21-million-private-placement-ispc-20211201monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-inc-announces-21-million-private-placement-ispc-20211128monthly0.5https://www.biopharmawatch.com/news/ISPC/connect-innovate-november-2021-investor-presentation-transforming-biospecimen-procurement--ispc-20211104monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-reports-second-quarter-2021-financial-results-delivered-revenue-growth-of-93-yea-ispc-20210810monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-announces-closing-of-over-allotment-option-in-connection-with-its-initial-public-ispc-20210701monthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-announces-pricing-of-initial-public-offering-ispc-20210616monthly0.5https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-announces-1-for-12-reverse-stock-split-cambridge-dcoy-20260305monthly0.5https://www.biopharmawatch.com/news/DCOY/salarius-pharmaceuticals-changes-corporate-name-to-decoy-therapeutics-and-nasdaq-ticker-sy-dcoy-20260108monthly0.5https://www.biopharmawatch.com/news/DCOY/report-of-independent-registered-public-accounting-firm-to-the-board-of-directors-and-shar-dcoy-20250822monthly0.5https://www.biopharmawatch.com/news/DCOY/unaudited-pro-forma-consolidated-combined-financial-information-the-following-unaudited-pr-dcoy-20250110monthly0.5https://www.biopharmawatch.com/news/DCOY/document-salarius-pharmaceuticals-inc-announces-2-3-million-registered-direct-offering-hou-dcoy-20220422monthly0.5https://www.biopharmawatch.com/news/DCOY/salarius-announces-pricing-of-5-3-million-underwritten-public-offering-houston-dcoy-20200730monthly0.5https://www.biopharmawatch.com/news/DCOY/salarius-announces-proposed-public-offering-of-common-stock-houston-texas-dcoy-20200729monthly0.5https://www.biopharmawatch.com/news/DCOY/salarius-announces-pricing-of-9-6-million-underwritten-public-offering-houston-texas-dcoy-20200207monthly0.5https://www.biopharmawatch.com/news/DCOY/salarius-pharmaceuticals-and-aspire-capital-announce-a-10-9m-common-stock-purchase-agreeme-dcoy-20191028monthly0.5https://www.biopharmawatch.com/news/DCOY/salariusleader-salarius-pharmaceuticals-announces-senior-leadership-changes-scott-jordan-a-dcoy-20190913monthly0.5https://www.biopharmawatch.com/news/DCOY/salariusstockh-salarius-pharmaceuticals-ceo-issues-letter-to-stockholders-houston-tx-dcoy-20190812monthly0.5https://www.biopharmawatch.com/news/DCOY/salarius-pharmaceuticals-successfully-monetizes-legacy-consumer-product-completes-sale-of--dcoy-20190724monthly0.5https://www.biopharmawatch.com/news/DCOY/salarius-pharmaceuticals-announces-closing-of-strategic-merger-with-flex-pharma-to-begin-t-dcoy-20190722monthly0.5https://www.biopharmawatch.com/news/DCOY/flex-pharma-and-salarius-pharmaceuticals-announce-merger-agreement-to-accelerate-clinical--dcoy-20190104monthly0.5https://www.biopharmawatch.com/news/DCOY/flex-pharma-reports-year-end-2014-financial-results-conference-call-scheduled-today-at-9-0-dcoy-20150317monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-reverse-stock-split-gri-s-common-stock-is-expected-to-begin-trading-on-a-gri-20260121monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-reverse-stock-split-gri-s-common-stock-is-expected-to-begin-trading-on-a-gri-20250219monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-pricing-of-4-0-million-public-offering-gri-20240627monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-reverse-stock-split-gri-s-common-stock-is-expected-to-begin-trading-on-a-gri-20240614monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-reports-first-quarter-2024-financial-results-and-provides-corporate-update-interim-gri-20240510monthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-reverse-stock-split-gri-s-common-stock-is-expected-to-begin-trading-on-a-gri-20240130monthly0.5https://www.biopharmawatch.com/news/GRI/vallon-pharmaceuticals-completes-merger-with-gri-bio-inc-combined-company-will-operate-as--gri-20230424monthly0.5https://www.biopharmawatch.com/news/GRI/vallon-pharmaceuticals-and-gri-bio-to-present-at-the-virtual-investor-2023-companies-to-wa-gri-20230111monthly0.5https://www.biopharmawatch.com/news/GRI/vallon-pharmaceuticals-and-gri-bio-enter-into-merger-agreement-with-goal-of-advancing-inno-gri-20221214monthly0.5https://www.biopharmawatch.com/news/GRI/vallon-pharmaceuticals-reports-third-quarter-2022-financial-results-philadelphia-pa-gri-20221103monthly0.5https://www.biopharmawatch.com/news/GRI/document-exhibit-10-1-vallon-pharmaceuticals-reports-second-quarter-2022-financial-results-gri-20220728monthly0.5https://www.biopharmawatch.com/news/GRI/vallon-pharmaceuticals-announces-3-9-million-registered-direct-offering-philadelphia-pa-ma-gri-20220426monthly0.5https://www.biopharmawatch.com/news/GRI/document-vallon-pharmaceuticals-announces-achievement-of-last-patient-last-visit-in-pivota-gri-20211223monthly0.5https://www.biopharmawatch.com/news/GRI/vallon-pharmaceuticals-reports-third-quarter-2021-financial-results-and-provides-corporate-gri-20211112monthly0.5https://www.biopharmawatch.com/news/GRI/vallon-pharmaceuticals-provides-update-on-recent-pipeline-and-corporate-advancements-lead--gri-20211012monthly0.5https://www.biopharmawatch.com/news/GRI/vallon-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-corporat-gri-20210810monthly0.5https://www.biopharmawatch.com/news/GRI/vallon-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides-corporate-gri-20210513monthly0.5https://www.biopharmawatch.com/news/GRI/vallon-pharmaceuticals-continues-advancement-of-pivotal-study-in-lead-development-program--gri-20210413monthly0.5https://www.biopharmawatch.com/news/GRI/working-to-reduce-adhd-medication-abuse-nasdaq-vlon-vallon-pharma-com-investor-presentatio-gri-20210226monthly0.5https://www.biopharmawatch.com/news/GRI/vallon-pharmaceuticals-announces-pricing-of-initial-public-offering-gri-20210209monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-21-business-park-drive-branford-connecticut-06405-203-646-6446-supplement-to-pr-aztr-20250618monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-announces-q2-2024-financial-results-and-provides-business-updates-branford-conn-aztr-20240812monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-announces-pricing-of-10-0-million-public-offering-aztr-20240723monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-announces-q1-2024-financial-results-and-provides-business-updates-branford-conn-aztr-20240509monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-announces-full-year-2023-financial-results-and-provides-business-updates-branfo-aztr-20240315monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-announces-pricing-of-public-offering-aztr-20240213monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-announces-third-quarter-2023-financial-results-and-business-updates-branford-co-aztr-20231114monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-merges-with-united-dogecoin-to-become-the-world-s-largest-public-dogecoin-miner-th-shph-20260430monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-announces-3-5-million-public-offering-gaithersburg-md-shph-20260306monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-to-present-at-the-planet-microcap-showcase-vegas-2025-on-shph-20250423monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-files-provisional-patent-for-psma-ligand-conjugates-to-treat-prostate-cance-shph-20250410monthly0.5https://www.biopharmawatch.com/news/SHPH/draft-goal-to-release-at-tuesday-november-26-9am-et-shuttle-pharma-expands-patient-enrollm-shph-20241126monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-to-present-at-the-2024-thinkequity-conference-on-wednesday-shph-20241030monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-provides-fourth-quarter-2023-corporate-update-gaithersburg-md-shph-20240322monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-announces-its-intent-to-pursue-a-rights-offering-rockville-md-shph-20240213monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-receives-fda-approval-to-proceed-with-phase-ii-clinical-trial-of-r-shph-20240108monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-submits-ind-application-to-the-u-s-fda-for-ropidoxuridine-phase-ii-shph-20231211monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-to-present-at-the-emerging-growth-conference-on-shph-20231130monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-provides-third-quarter-2023-corporate-update-rockville-md-shph-20231114monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-advances-prostate-cancer-predictive-biomarker-program-through-exclusive-lic-shph-20231030monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-to-participate-in-the-lytham-partners-fall-2023-investor-conference-rockvil-shph-20231010monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-announces-results-of-pre-ind-meeting-with-fda-for-ropidoxuridine-phase-ii-c-shph-20230925monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-provides-second-quarter-2023-corporate-update-rockville-md-shph-20230815monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-completes-manufacturing-of-active-pharmaceutical-ingredient-api-fo-shph-20230803monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-provides-first-quarter-2023-corporate-update-rockville-md-shph-20230526monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-confere-shph-20230517monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-engages-ui-pharmaceuticals-for-formulation-and-clinical-batch-manu-shph-20230309monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-to-present-at-lytham-partners-investor-select-conference-on-januar-shph-20230126monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-announces-private-placement-of-4-3-million-of-senior-secured-conve-shph-20230112monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-appoints-bette-jacobs-to-its-board-of-directors-rockville-md-shph-20221101monthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-announces-closing-of-initial-public-offering-shph-20220906monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-inc-investor-presentation-january-2026-legal-disclaimers-r-investor-snoa-20260112monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-inc-investor-presentation-september-2025-legal-disclaimers-or-inves-snoa-20250929monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-inc-investor-presentation-april-2025-1-legal-disclaimers-or-investo-snoa-20250428monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-inc-investor-presentation-april-2025-legal-disclaimers-or-investor--snoa-20250407monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-inc-investor-presentation-october-2024-legal-disclaimers-investor-p-snoa-20241022monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-announces-1-for-20-reverse-split-of-outstanding-common-stock-snoa-20240828monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-inc-investor-presentation-snoa-20240409monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-inc-investor-presentation-april-2024-legal-disclaimers-investor-pre-snoa-20240402monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-inc-investor-presentation-january-2024-legal-disclaimers-investor-p-snoa-20240110monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-inc-investor-presentation-october-2023-legal-disclaimers-investor-p-snoa-20231011monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-inc-may-2023-1-legal-disclaimers-investor-presentation-this-communi-snoa-20230510monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-inc-january-202-3-legal-disclaimers-investor-presentation-this-comm-snoa-20230106monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-inc-nasdaq-snoa-january-2022-1-legal-disclaimers-investor-presentat-snoa-20220106monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-inc-nasdaq-snoa-march-2021-legal-disclaimers-investor-presentation--snoa-20210304monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-inc-nasdaq-snoa-january-2021-legal-disclaimers-investor-presentatio-snoa-20210111monthly0.5https://www.biopharmawatch.com/news/SNOA/dan-k-turner-iii-snoa-20181127monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-reports-record-revenue-in-second-quarter-fy-2019-total-revenue-of-4-snoa-20181108monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-reports-first-quarter-fy-2019-financial-results-total-revenue-up-20-snoa-20180808monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-reports-fiscal-year-and-fourth-quarter-2018-financial-results-stron-snoa-20180613monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-reports-financial-results-for-first-quarter-of-fiscal-year-2018-pro-snoa-20170808monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-reports-financial-results-for-fourth-quarter-and-fiscal-year-2017-p-snoa-20170605monthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-reports-financial-results-for-fiscal-third-quarter-2017-u-s-product-snoa-20170209monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-financial-results-for-fiscal-second-quarter-2017-u-s-pr-snoa-20161031monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-financial-results-for-first-quarter-of-fiscal-year-2017-snoa-20160728monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-financial-results-for-fiscal-year-2016-and-fourth-quart-snoa-20160616monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-announces-proposed-underwritten-public-offering-of-common-stock-snoa-20160317monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-third-quarter-financial-results-u-s-dermatology-and-res-snoa-20160204monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-financial-results-for-the-second-quarter-of-fiscal-year-snoa-20151105monthly0.5https://www.biopharmawatch.com/news/SNOA/investor-presentation-at-dawson-james-investor-conference-snoa-20151015monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-financial-results-for-the-first-quarter-of-fiscal-year--snoa-20150730monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-financial-results-for-the-fourth-quarter-of-fiscal-year-snoa-20150611monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-financial-results-for-the-second-quarter-of-fiscal-year-snoa-20141113monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-revenues-of-3-4-million-and-net-loss-of-70-000-for-firs-snoa-20140807monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-revenues-of-2-9-million-and-net-income-of-7-5-million-f-snoa-20140612monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-revenues-of-3-3-million-for-third-quarter-of-fiscal-201-snoa-20140213monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-revenues-of-4-1-million-for-second-quarter-of-fiscal-20-snoa-20131119monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-revenues-of-3-4-million-for-first-quarter-of-fiscal-201-snoa-20130808monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-inc-1129-n-mcdowell-blvd-petaluma-california-94954-707-283-0550-snoa-20130729monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-revenues-of-15-5-million-for-fiscal-year-2013-product-r-snoa-20130613monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-announces-two-key-agreements-with-company-s-subsidiary-ruthigen-snoa-20130606monthly0.5https://www.biopharmawatch.com/news/SNOA/the-safe-harbor-statement-under-the-private-securities-litigation-reform-act-of-1995-this--snoa-20130530monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-announces-proposed-public-offering-of-common-stock-and-intentio-snoa-20130306monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-revenues-of-3-5-million-for-the-third-quarter-of-fiscal-snoa-20130213monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-achieves-net-worth-of-4-5-million-pro-forma-as-of-snoa-20121105monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-record-revenues-of-4-5-million-for-the-second-quarter-o-snoa-20121101monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-record-revenues-of-4-1-million-for-the-first-quarter-of-snoa-20120802monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-inc-1129-n-mcdowell-blvd-petaluma-california-94954-707-283-0550-snoa-20120727monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-fiscal-fourth-quarter-2012-financial-results-conference-snoa-20120607monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-fiscal-third-quarter-2012-financial-results-conference--snoa-20120202monthly0.5https://www.biopharmawatch.com/news/SNOA/unassociated-document-for-immediate-release-oculus-innovative-sciences-reports-record-fisc-snoa-20111103monthly0.5https://www.biopharmawatch.com/news/SNOA/unassociated-document-for-immediate-release-oculus-innovative-sciences-reports-record-firs-snoa-20110804monthly0.5https://www.biopharmawatch.com/news/SNOA/logo-jpg-for-immediate-release-oculus-innovative-sciences-reports-record-fourth-quarter-be-snoa-20110602monthly0.5https://www.biopharmawatch.com/news/SNOA/unassociated-document-for-immediate-release-oculus-innovative-sciences-reports-record-thir-snoa-20110203monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-record-revenue-in-second-quarter-fiscal-year-2011-excee-snoa-20101104monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-financial-results-for-first-quarter-of-fiscal-year-2011-snoa-20100805monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-fy-2010-financial-results-and-reviews-upcoming-microcyn-snoa-20100603monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-fy-2009-financial-results-and-discusses-worldwide-reven-snoa-20090611monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-reports-59-increase-in-first-quarter-product-revenue-conference-snoa-20080805monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-announces-fiscal-fourth-quarter-and-full-year-2008-financial-re-snoa-20080611monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-inc-announces-13-9-snoa-20080328monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-announces-fiscal-third-quarter-2008-quarterly-results-and-clini-snoa-20080207monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-announces-10-million-private-placement-of-common-stock-petaluma-snoa-20070808monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-announces-fiscal-first-quarter-2008-financial-results-petaluma--snoa-20070809monthly0.5https://www.biopharmawatch.com/news/SNOA/oculus-innovative-sciences-announces-fiscal-third-quarter-2007-results-petaluma-ca-snoa-20070222monthly0.5https://www.biopharmawatch.com/news/CLDI/nyse-american-to-commence-delisting-proceedings-with-respect-to-the-warrants-of-calidi-bio-cldi-20241018monthly0.5https://www.biopharmawatch.com/news/CLDI/exhibit-1-cldi-20240912monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-to-effect-reverse-stock-split-calidi-common-stock-expected-to-begin-trading-on-a-1--cldi-20240705monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-exercise-of-warrants-for-2-1-million-gross-proceeds-cldi-20240531monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-reports-first-quarter-2024-operating-and-financial-results-three-up-cldi-20240515monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-inc-announces-closing-of-6-1-million-public-offering-san-diego-cali-cldi-20240419monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-reports-fourth-quarter-and-full-year-2023-operating-and-financial-r-cldi-20240315monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-reports-third-quarter-2023-operating-and-financial-results-announce-cldi-20231114monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-announces-appointment-of-andrew-jackson-as-chief-financial-officer--cldi-20231030monthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-inc-condensed-consolidated-balance-sheets-in-thousands-except-for-p-cldi-20230919monthly0.5https://www.biopharmawatch.com/news/CLDI/first-light-acquisition-group-announces-nyse-approval-for-listing-of-business-combination--cldi-20230912monthly0.5https://www.biopharmawatch.com/news/CLDI/first-light-acquisition-group-inc-further-adjourns-special-meeting-of-stockholders-to-cldi-20230824monthly0.5https://www.biopharmawatch.com/news/CLDI/first-light-acquisition-group-inc-adjourns-special-meeting-of-stockholders-to-cldi-20230824monthly0.5https://www.biopharmawatch.com/news/CLDI/the-following-is-a-presentation-for-use-by-calidi-biotherapeutics-inc-and-first-light-acqu-cldi-20230816monthly0.5https://www.biopharmawatch.com/news/CLDI/revolutionizing-cancer-therapies-with-a-durable-and-systemic-antitumor-immune-response-uti-cldi-20230210monthly0.5https://www.biopharmawatch.com/news/CLDI/first-light-acquisition-group-inc-announces-approval-of-extension-amendment-to-certificate-cldi-20221215monthly0.5https://www.biopharmawatch.com/news/CLDI/first-light-acquisition-group-inc-transfers-listing-to-nyse-american-llc-cldi-20221114monthly0.5https://www.biopharmawatch.com/news/CLDI/first-light-acquisition-group-inc-announces-approval-of-extension-amendment-to-certificate-cldi-20220916monthly0.5https://www.biopharmawatch.com/news/CLDI/weil-draft-9-8-2022-first-light-acquisition-group-inc-adjourns-special-meeting-of-stockhol-cldi-20220909monthly0.5https://www.biopharmawatch.com/news/CLDI/first-light-acquisition-group-inc-announces-the-separate-trading-of-its-shares-of-class-a--cldi-20211028monthly0.5https://www.biopharmawatch.com/news/CLDI/first-light-acquisition-group-inc-index-to-financial-statement-report-of-independent-regis-cldi-20210914monthly0.5https://www.biopharmawatch.com/news/CLDI/first-light-acquisition-group-inc-announces-pricing-of-200-million-initial-public-offering-cldi-20210909monthly0.5https://www.biopharmawatch.com/news/VIVS/vivosim-labs-appoints-tony-lialin-as-chief-commercial-officer-veteran-commercial-leader-to-vivs-20250814monthly0.5https://www.biopharmawatch.com/news/VIVS/vivosim-announces-emergence-from-stealth-mode-to-provide-technologies-for-fda-turn-away-fr-vivs-20250424monthly0.5https://www.biopharmawatch.com/news/VIVS/vivosim-to-carry-forward-organovo-3d-bioprinting-san-diego-ca-x2013-vivs-20250423monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-provides-update-on-cash-and-nasdaq-continued-listing-requirements-san-diego-ca-x2-vivs-20250402monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-provides-business-update-san-diego-ca-x2013-vivs-20250327monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-announces-close-of-the-sale-of-fxr-program-to-eli-lilly-and-company-san-diego-ca--vivs-20250325monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-announces-reverse-stock-split-vivs-20250319monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises-vivs-20250306monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-s-fxr-program-including-fxr314-to-be-acquired-by-eli-lilly-and-company-san-diego--vivs-20250225monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-holdings-inc-announces-pricing-of-5-25-million-public-offering-vivs-20240508monthly0.5https://www.biopharmawatch.com/news/VIVS/certain-statements-contained-in-this-presentation-or-in-other-documents-of-organovo-holdin-vivs-20240501monthly0.5https://www.biopharmawatch.com/news/VIVS/certain-statements-contained-in-this-presentation-or-in-other-documents-of-organovo-holdin-vivs-20240207monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-announces-postponement-of-annual-meeting-of-stockholders-san-diego-ca-vivs-20220906monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-and-bico-cellink-reach-licensing-agreement-on-bioprinting-patents-vivs-20220223monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-announces-adjournment-of-annual-meeting-of-shareholders-due-to-lack-of-quorum-sol-vivs-20210917monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-regains-compliance-with-nasdaq-minimum-bid-price-requirement-san-diego-ca-vivs-20200903monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-announces-one-for-twenty-reverse-stock-split-san-diego-vivs-20200817monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-announces-termination-of-merger-agreement-with-tarveda-therapeutics-san-diego-bus-vivs-20200407monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-holdings-inc-reminds-stockholders-about-adjourned-special-meeting-of-stockholders-vivs-20200331monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-holdings-inc-announces-adjournment-of-special-meeting-of-stockholders-vivs-20200327monthly0.5https://www.biopharmawatch.com/news/VIVS/tarveda-therapeutics-and-sciclone-pharmaceuticals-international-establish-licensing-agreem-vivs-20200319monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-relations-organovo-holdings-inc-1-858-224-1000-ir-organovo-com-organovo-acknowled-vivs-20191002monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-holdings-inc-1-858-224-1000-ext-3000-ir-organovo-com-vivs-20190807monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-press-contact-steve-kunszabo-organovo-holdings-inc-1-858-224-1092-skunszabo-organ-vivs-20190522monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-press-contact-steve-kunszabo-steve-kunszabo-organovo-holdings-inc-1-858-224-1092--vivs-20190220monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-press-contact-steve-kunszabo-organovo-holdings-inc-1-858-224-1092-skunszabo-organ-vivs-20190207monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-press-contact-steve-kunszabo-organovo-holdings-inc-1-858-224-1092-skunszabo-organ-vivs-20181206monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-press-contact-steve-kunszabo-organovo-holdings-inc-1-858-224-1092-skunszabo-organ-vivs-20181108monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-press-contact-steve-kunszabo-organovo-holdings-inc-1-858-224-1092-skunszabo-organ-vivs-20180809monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-press-contact-steve-kunszabo-organovo-holdings-inc-1-858-224-1092-skunszabo-organ-vivs-20180531monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-contact-press-contact-steve-kunszabo-jessica-yingling-organovo-holdings-inc-littl-vivs-20180208monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-contact-press-contact-steve-kunszabo-organovo-holdings-inc-1-858-224-1092-skunsza-vivs-20171109monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-press-contact-steve-kunszabo-organovo-holdings-inc-1-858-224-1092-skunszabo-organ-vivs-20171004monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-contact-press-contact-steve-kunszabo-jessica-yingling-organovo-holdings-inc-littl-vivs-20170809monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-contact-press-contact-steve-kunszabo-jessica-yingling-organovo-holdings-inc-littl-vivs-20170607monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-contact-press-contact-steve-kunszabo-jessica-yingling-ph-d-organovo-holdings-inc--vivs-20170411monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-contact-press-contact-steve-kunszabo-jessica-yingling-organovo-holdings-inc-littl-vivs-20170209monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-contact-press-contact-steve-kunszabo-organovo-holdings-inc-1-858-224-1092-skunsza-vivs-20161103monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-contact-press-contact-steve-kunszabo-jessica-yingling-organovo-holdings-inc-littl-vivs-20161020monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-contact-press-contact-steve-kunszabo-jessica-yingling-organovo-holdings-inc-littl-vivs-20161011monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-contact-press-contact-steve-kunszabo-jessica-yingling-organovo-holdings-inc-littl-vivs-20160818monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-contact-press-contact-steve-kunszabo-organovo-holdings-inc-1-858-224-1092-skunsza-vivs-20160804monthly0.5https://www.biopharmawatch.com/news/VIVS/confidential-organovo-inc-6275-nancy-ridge-drive-suite-110-san-diego-ca-92121-vivs-20160729monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-contact-press-contact-steve-kunszabo-organovo-holdings-inc-1-858-224-1092-skunsza-vivs-20160726monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-contact-press-contact-steve-kunszabo-jessica-yingling-organovo-holdings-inc-littl-vivs-20160609monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-contact-press-contact-steve-kunszabo-organovo-holdings-inc-1-858-224-1092-skunsza-vivs-20160208monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-contact-press-contact-steve-kunszabo-jessica-yingling-organovo-holdings-inc-littl-vivs-20160119monthly0.5https://www.biopharmawatch.com/news/VIVS/investor-contact-press-contact-steve-kunszabo-jessica-yingling-organovo-holdings-inc-littl-vivs-20151109monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-reports-first-quarter-fiscal-2016-financial-results-and-corporate-highlights-vivs-20150810monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-holdings-inc-prices-40-million-public-offering-of-common-stock-vivs-20150618monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-reports-fiscal-2015-financial-results-corporate-highlights-and-total-contract-boo-vivs-20150609monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-holdings-inc-pre-announces-preliminary-fiscal-2015-fourth-quarter-and-year-end-fi-vivs-20150421monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-describes-first-fully-cellular-3d-bioprinted-kidney-tissue-vivs-20150401monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-provides-market-update-vivs-20150313monthly0.5https://www.biopharmawatch.com/news/VIVS/forward-looking-statements-copyright-2015-organovo-holdings-inc-nyse-mkt-onvo-the-company--vivs-20150305monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-holdings-inc-to-provide-corporate-update-and-investor-presentation-in-a-live-inte-vivs-20150227monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-holdings-inc-6275-nancy-ridge-dr-san-diego-ca-92121-vivs-20150226monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-holdings-inc-reports-second-quarter-results-vivs-20150209monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-appoints-dr-kirk-malloy-to-board-of-directors-vivs-20141208monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-to-present-at-the-26th-annual-piper-jaffray-healthcare-conference-vivs-20141120monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-announces-commercial-release-of-the-exvive3d-human-liver-tissue-san-diego-vivs-20141118monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-holdings-inc-reports-second-quarter-results-vivs-20141110monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-highlights-liver-toxicology-achievement-reports-q1-fiscal-2015-results-vivs-20140812monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-reports-fiscal-2014-financial-results-vivs-20140612monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-announces-pre-release-availability-of-3d-liver-contract-services-04-29-2014-vivs-20140429monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-provides-guidance-on-retail-investor-conference-03-28-2014-vivs-20140328monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-reports-q3-fiscal-2014-results-provides-business-update-vivs-20140207monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-announces-first-delivery-of-3d-liver-tissue-to-key-opinion-leader-01-29-2014-vivs-20140129monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-announces-collaboration-with-national-institutes-of-health-01-14-2014-san-diego-c-vivs-20140114monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-provides-guidance-on-upcoming-retail-investor-conference-11-20-2013-vivs-20131120monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-reports-q2-fiscal-2014-results-vivs-20131112monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-holdings-inc-to-webcast-live-at-retailinvestorconferences-com-september-12th-comp-vivs-20130909monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-vivs-20130709monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-appoints-tamar-d-howson-to-board-of-directors-06-10-2013-san-diego-organovo-holdi-vivs-20130524monthly0.5https://www.biopharmawatch.com/news/VIVS/changing-the-shape-of-medical-research-and-practice-keith-murphy-chairman-and-chief-execut-vivs-20130315monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-holdings-inc-announces-completion-of-2-3-million-outstanding-warrant-redemption-vivs-20130319monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-reports-2012-financial-results-vivs-20130318monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-holdings-inc-announces-redemption-of-2-4-million-outstanding-warrants-02-05-2013--vivs-20130205monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-partners-with-autodesk-research-to-develop-3d-bioprinting-software-vivs-20121218monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-reports-q3-2012-financial-results-vivs-20121116monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-holdings-inc-joins-vivs-20121008monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-holdings-inc-to-webcast-live-at-retailinvestorconferences-com-on-august-2nd-07-30-vivs-20120730monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-holdings-appoints-james-t-glover-to-board-of-directors-vivs-20120709monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-announces-close-of-15-2-million-private-placement-to-advance-3d-vivs-20120319monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-named-to-mit-technology-review-s-2012-tr50-list-of-the-world-s-most-innovative-co-vivs-20120228monthly0.5https://www.biopharmawatch.com/news/VIVS/organovo-announces-6-5-million-private-placement-to-advance-3d-vivs-20120214monthly0.5https://www.biopharmawatch.com/news/ATPC/agape-atp-corporation-regains-compliance-with-nasdaq-minimum-bid-price-requirement-kuala-l-atpc-20260312monthly0.5https://www.biopharmawatch.com/news/ATPC/agape-atp-corporation-forges-strategic-collaboration-with-uae-based-citadel-investment-par-atpc-20260310monthly0.5https://www.biopharmawatch.com/news/ATPC/agape-atp-corporation-announces-1-for-50-reverse-stock-split-kuala-lumpur-malaysia-06-febr-atpc-20260206monthly0.5https://www.biopharmawatch.com/news/ATPC/agape-atp-corporation-receives-nasdaq-notice-on-minimum-bid-price-requirement-atpc-20260129monthly0.5https://www.biopharmawatch.com/news/ATPC/agape-atp-corporation-issues-statement-on-recent-market-activity-and-reaffirms-strategic-o-atpc-20251212monthly0.5https://www.biopharmawatch.com/news/ATPC/agape-atp-corporation-signs-strategic-partnerships-agreement-to-advance-global-energy-and--atpc-20250708monthly0.5https://www.biopharmawatch.com/news/ATPC/agape-atp-corporation-secured-landmark-jet-fuel-supply-agreement-with-swiss-one-oil-gas-ag-atpc-20250403monthly0.5https://www.biopharmawatch.com/news/ATPC/agape-atp-corporation-successfully-completes-23-million-private-placement-strengthening-gr-atpc-20250325monthly0.5https://www.biopharmawatch.com/news/ATPC/agape-atp-corporation-announces-key-usd23-0-million-private-placement-to-institutional-inv-atpc-20250305monthly0.5https://www.biopharmawatch.com/news/ATPC/atpc-expands-global-market-footprint-to-spearhead-medical-innovation-with-mous-in-indonesi-atpc-20241129monthly0.5https://www.biopharmawatch.com/news/ATPC/agape-atp-corporation-synergising-innovation-across-business-pillars-to-make-the-world-a-b-atpc-20241010monthly0.5https://www.biopharmawatch.com/news/ATPC/agape-atp-corporation-regains-compliance-with-nasdaq-s-minimum-bid-price-rule-kuala-lumpur-atpc-20240917monthly0.5https://www.biopharmawatch.com/news/ATPC/agape-atp-corporation-addresses-recent-corporate-exercise-and-strategic-developments-rever-atpc-20240830monthly0.5https://www.biopharmawatch.com/news/ATPC/agape-atp-corporation-announces-us-1-million-share-repurchase-plan-kuala-lumpur-22-novembe-atpc-20231117monthly0.5https://www.biopharmawatch.com/news/ATPC/agape-atp-corporation-statement-of-policy-concerning-trading-in-company-securities-adopted-atpc-20231013monthly0.5https://www.biopharmawatch.com/news/ATPC/agape-superior-living-sdn-bhd-unaudited-condensed-consolidated-balance-sheets-march-31-atpc-20200706monthly0.5https://www.biopharmawatch.com/news/ATPC/agape-superior-living-sdn-bhd-consolidated-financial-statements-years-ended-december-31-20-atpc-20200512monthly0.5https://www.biopharmawatch.com/news/GLMD/colospan-ltd-financial-statements-as-of-december-31-2025-contents-page-independent-auditor-glmd-20260608monthly0.5https://www.biopharmawatch.com/news/GLMD/to-our-report-of-foreign-private-issuer-on-form-6-k-filed-with-the-securities-and-exchange-glmd-20260130monthly0.5https://www.biopharmawatch.com/news/GLMD/to-our-report-of-foreign-private-issuer-on-form-6-k-filed-with-the-securities-and-exchange-glmd-20251208monthly0.5https://www.biopharmawatch.com/news/GLMD/to-our-report-of-foreign-private-issuer-on-form-6-k-filed-with-the-securities-and-exchange-glmd-20251204monthly0.5https://www.biopharmawatch.com/news/GLMD/to-our-report-of-foreign-private-issuer-on-form-6-k-filed-with-the-securities-and-exchange-glmd-20251201monthly0.5https://www.biopharmawatch.com/news/GLMD/to-our-report-of-foreign-private-issuer-on-form-6-k-filed-with-the-securities-and-exchange-glmd-20251126monthly0.5https://www.biopharmawatch.com/news/GLMD/to-our-report-of-foreign-private-issuer-on-form-6-k-filed-with-the-securities-and-exchange-glmd-20251118monthly0.5https://www.biopharmawatch.com/news/GLMD/to-our-report-of-foreign-private-issuer-on-form-6-k-to-be-filed-with-the-securities-and-ex-glmd-20250825monthly0.5https://www.biopharmawatch.com/news/GLMD/the-companies-law-5759-1999-amended-and-restated-articles-of-association-of-galmed-pharmac-glmd-20250815monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-ltd-c-o-meitar-law-offices-abba-hillel-silver-rd-ramat-gan-5250608-glmd-20240920monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-ltd-16-tiomkin-st-tel-aviv-6578317-israel-glmd-20230809monthly0.5https://www.biopharmawatch.com/news/GLMD/onkai-inc-consolidated-financial-statements-as-of-december-31-2022-u-s-dollars-in-thousand-glmd-20230802monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-ltd-16-tiomkin-st-tel-aviv-6578317-israel-glmd-20230330monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-ltd-16-tiomkin-st-tel-aviv-6578317-israel-glmd-20220517monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-updates-business-and-clinical-development-strategy-to-better-leverage-aramchol-s-an-glmd-20220502monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-ltd-16-tiomkin-st-tel-aviv-6578317-israel-glmd-20210719monthly0.5https://www.biopharmawatch.com/news/GLMD/the-company-except-as-otherwise-indicated-herein-or-as-the-context-otherwise-requires-refe-glmd-20210216monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-and-mybiotics-to-collaborate-in-development-of-bespoke-microbiome-signature-for-ara-glmd-20201109monthly0.5https://www.biopharmawatch.com/news/GLMD/gannex-and-galmed-expand-development-programs-for-nash-through-research-collaboration-of-a-glmd-20200909monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-ltd-16-tiomkin-st-tel-aviv-6578317-israel-glmd-20200708monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-ltd-16-tiomkin-st-tel-aviv-6578317-israel-glmd-20190404monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-ltd-16-tiomkin-st-tel-aviv-6578317-israel-glmd-20180719monthly0.5https://www.biopharmawatch.com/news/GLMD/june-2018-safe-harbor-and-disclaimer-statement-this-presentation-contains-forward-looking--glmd-20180618monthly0.5https://www.biopharmawatch.com/news/GLMD/aramchol-treating-nash-through-prevention-and-reversal-of-fibrosis-january-2018-safe-harbo-glmd-20180103monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-reports-second-quarter-glmd-20170731monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-ltd-16-tiomkin-st-tel-aviv-6578317-israel-glmd-20170427monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-present-at-international-liver-congress-data-that-shows-aramchol-glmd-20170405monthly0.5https://www.biopharmawatch.com/news/GLMD/pharmaceuticals-announces-that-it-has-raised-approximately-glmd-20160929monthly0.5https://www.biopharmawatch.com/news/GLMD/pharmaceuticals-announces-the-appointment-of-dr-glmd-20160908monthly0.5https://www.biopharmawatch.com/news/GLMD/pharmaceuticals-reports-second-quarter-2016-financial-results-and-provides-business-update-glmd-20160803monthly0.5https://www.biopharmawatch.com/news/GLMD/announces-the-appointment-of-glmd-20160801monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-ltd-16-tiomkin-st-tel-aviv-6578317-israel-glmd-20160420monthly0.5https://www.biopharmawatch.com/news/GLMD/aramchol-tm-demonstrates-significant-anti-fibrotic-effect-in-a-pre-clinical-model-of-fatty-glmd-20160330monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-the-commencement-of-patient-screening-in-the-arrest-study-glmd-20150813monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-ltd-8-shaul-hamelech-blvd-amot-mishpat-bldg-tel-aviv-israel-6473307-glmd-20150402monthly0.5https://www.biopharmawatch.com/news/GLMD/and-perrigo-execute-manufacturing-agreement-glmd-20150128monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-ltd-8-shaul-hamelech-blvd-amot-hamishpat-bldg-tel-aviv-israel-64733-glmd-20141106monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-fda-clearance-of-ind-of-aramchol-for-the-treatment-of-fatty-liver-disorde-glmd-20140722monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-the-filing-of-a-provisional-patent-application-for-the-us-glmd-20140609monthly0.5https://www.biopharmawatch.com/news/GLMD/recently-published-independent-research-supports-the-importance-of-reverse-cholesterol-tra-glmd-20140604monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-ltd-8-shaul-hamelech-blvd-tel-aviv-6473307-israel-glmd-20140507monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-closing-of-initial-public-offering-and-full-exercise-of-u-glmd-20140312monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-pricing-of-initial-public-offering-tel-aviv-israel-prnews-glmd-20140312monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fiscal-year-end-aemd-20260610monthly0.5https://www.biopharmawatch.com/news/AEMD/corporate-presentation-the-hemopurifier-forward-looking-statements-2-this-investor-present-aemd-20250821monthly0.5https://www.biopharmawatch.com/news/AEMD/earnings-script-aethlon-medical-announces-financial-results-for-the-fiscal-fourth-quarter--aemd-20250627monthly0.5https://www.biopharmawatch.com/news/AEMD/nasdaq-aemd-www-aethlonmedical-com-corporate-presentation-april-2024-forward-looking-state-aemd-20240425monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-inc-2020-equity-incentive-plan-adopted-by-the-board-of-directors-aemd-20220919monthly0.5https://www.biopharmawatch.com/news/AEMD/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-aemd-20210610monthly0.5https://www.biopharmawatch.com/news/AEMD/nasdaq-aemd-investor-presentation-january-2021-2-this-investor-presentation-contains-forwa-aemd-20210111monthly0.5https://www.biopharmawatch.com/news/AEMD/amendment-to-convertible-notes-this-amendment-to-convertible-notes-this-agreement-effectiv-aemd-20190506monthly0.5https://www.biopharmawatch.com/news/AEMD/image-of-ebola-viruses-exiting-host-cells-courtesy-of-niaid-nyc-o-ncology-c-onference-n-as-aemd-20181030monthly0.5https://www.biopharmawatch.com/news/AEMD/sabrina-martucci-johnson-joins-aethlon-medical-s-board-of-directors-aemd-20180110monthly0.5https://www.biopharmawatch.com/news/AEMD/department-of-health-human-services-public-health-service-food-and-drug-administration-109-aemd-20170908monthly0.5https://www.biopharmawatch.com/news/AEMD/image-of-ebola-viruses-exiting-host-cells-courtesy-of-niaid-1-the-following-presentation-m-aemd-20170911monthly0.5https://www.biopharmawatch.com/news/AEMD/image-of-ebola-viruses-exiting-host-cells-courtesy-of-niaid-bio-i-nternational-c-onvention-aemd-20170621monthly0.5https://www.biopharmawatch.com/news/AEMD/a-e-thlon-medical-inc-nasdaq-aemd-roth-investor-conference-march-14-2017-jim-joyce-chairma-aemd-20170313monthly0.5https://www.biopharmawatch.com/news/AEMD/a-e-thlon-medical-inc-nasdaq-aemd-bio-international-convention-san-francisco-aemd-20160607monthly0.5https://www.biopharmawatch.com/news/AEMD/a-e-thlon-medical-inc-nasdaq-aemd-sachs-immuno-oncology-bd-l-investment-forum-june-3-2016--aemd-20160603monthly0.5https://www.biopharmawatch.com/news/AEMD/a-e-thlon-medical-inc-therapeutic-partnering-opportunities-in3-medical-device-summit-aemd-20151111monthly0.5https://www.biopharmawatch.com/news/AEMD/forward-looking-statements-the-following-presentation-may-contain-predictions-estimates-an-aemd-20150910monthly0.5https://www.biopharmawatch.com/news/AEMD/forward-looking-statements-the-following-presentation-may-contain-predictions-estimates-an-aemd-20150618monthly0.5https://www.biopharmawatch.com/news/AEMD/a-case-study-using-lectin-affinity-plasmapheresis-in-the-treatment-of-ebola-virus-disease--aemd-20150612monthly0.5https://www.biopharmawatch.com/news/AEMD/jim-joyce-chairman-ceo-exosomes-2014-september-18-19-2014-san-diego-california-extracorpor-aemd-20140923monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-receives-government-contract-award-from-darpa-contract-program-will-suppor-aemd-20111003monthly0.5https://www.biopharmawatch.com/news/AEMD/jim-joyce-chairman-ceo-forward-looking-statements-my-presentation-contains-predictions-est-aemd-20110301monthly0.5https://www.biopharmawatch.com/news/AEMD/the-evolution-of-therapeutic-filtration-to-improve-hepatitis-c-virus-hcv-treatment-outcome-aemd-20110201monthly0.5https://www.biopharmawatch.com/news/AEMD/u-s-department-of-health-and-human-services-barda-industry-day-presentation-washington-dc-aemd-20110112monthly0.5https://www.biopharmawatch.com/news/AEMD/jim-joyce-chairman-aemd-20101209monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-names-rod-kenley-president-san-diego-ca-aemd-20101028monthly0.5https://www.biopharmawatch.com/news/AEMD/description-of-common-stock-the-authorized-capital-stock-of-aethlon-medical-inc-the-compan-aemd-20100730monthly0.5https://www.biopharmawatch.com/news/AEMD/policy-statement-on-inside-information-and-securities-trading-of-aethlon-medical-inc-as-ad-aemd-20100301monthly0.5https://www.biopharmawatch.com/news/AEMD/final-aethlon-medical-and-fusion-capital-enter-into-private-placement-agreement-and-mutual-aemd-20080501monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-logo-here-for-immediate-release-contact-jeff-richardson-senior-director-communicat-aemd-20070322monthly0.5https://www.biopharmawatch.com/news/AEMD/the-treatment-of-h5n1-avian-influenza-report-released-by-aethlon-medical-wednesday-march-1-aemd-20060315monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-inc-for-immediate-release-contact-jeff-richardson-senior-director-communic-aemd-20060223monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-inc-for-immediate-release-contact-anne-hoversten-aethlon-medical-inc-inves-aemd-20050802monthly0.5https://www.biopharmawatch.com/news/AIM/contains-forward-looking-statements-within-the-meaning-of-the-private-securities-litigatio-aim-20250228monthly0.5https://www.biopharmawatch.com/news/AIM/confidential-draft-not-for-immediate-release-aim-immunotech-announces-a-planned-follow-up--aim-20250207monthly0.5https://www.biopharmawatch.com/news/AIM/erasmus-medical-center-safety-committee-grants-approval-to-proceed-with-phase-2-study-of-a-aim-20250205monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-cash-conservation-plan-independent-board-members-to-receive-100-o-aim-20241127monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-inc-aim-20240930monthly0.5https://www.biopharmawatch.com/news/AIM/north-market-street-p-o-box-951-wilmington-de-19801-0951-302-984-6000-www-potteranderson-c-aim-20230823monthly0.5https://www.biopharmawatch.com/news/AIM/confidential-draft-not-for-immediate-release-aim-immunotech-announces-late-breaking-presen-aim-20230316monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-issues-letter-to-stockholders-year-marked-by-noteworthy-operational-executi-aim-20230306monthly0.5https://www.biopharmawatch.com/news/AIM/confidential-draft-not-for-immediate-release-aim-immunotech-enters-into-pancreatic-cancer--aim-20230117monthly0.5https://www.biopharmawatch.com/news/AIM/unofficial-translation-european-committee-brussels-19feb2021-c-2021-1285-final-implementat-aim-20210224monthly0.5https://www.biopharmawatch.com/news/AIM/clinical-trials-amed-is-funding-at-least-five-research-projects-related-to-covid-19-aside--aim-20201005monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-signs-clinical-trial-agreement-with-roswell-park-comprehensive-cancer-cente-aim-20200709monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-signs-material-transfer-and-research-agreement-with-japan-s-national-instit-aim-20200706monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-provides-update-on-commercial-launch-of-ampligen-in-argentina-for-the-treat-aim-20200615monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-and-shenzhen-smoore-technology-announce-an-agreement-to-research-utilizing--aim-20200406monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-further-efforts-to-establish-clinical-trials-assessing-ampligen-a-aim-20200326monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-s-drug-ampligen-to-be-tested-by-japan-s-national-institute-of-infectious-di-aim-20200309monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-issues-stockholder-update-and-details-its-expectations-for-2020-aim-20191204monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-provides-comprehensive-clinical-trials-update-with-major-inflection-points--aim-20191007monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-inc-announces-pricing-of-8-million-public-offering-ocala-fl-aim-20190925monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-inc-announces-a-second-dod-award-this-one-of-8-3-million-to-fund-phase-2-cl-aim-20190924monthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-names-ellen-lintal-as-new-chief-financial-officer-aim-20190916monthly0.5https://www.biopharmawatch.com/news/AIM/hemispherx-biopharma-inc-changes-name-to-aim-immunotech-inc-reflecting-ampligen-s-immuno-m-aim-20190823monthly0.5https://www.biopharmawatch.com/news/AIM/hemispherx-biopharma-cfo-adam-pascale-announces-retirement-ocala-fla-aim-20190628monthly0.5https://www.biopharmawatch.com/news/AIM/hemispherx-biopharma-stockholders-approve-reverse-stock-split-ocala-fla-aim-20190531monthly0.5https://www.biopharmawatch.com/news/AIM/hemispherx-biopharma-updates-the-terms-of-previously-announced-rights-offering-and-announc-aim-20190227monthly0.5https://www.biopharmawatch.com/news/AIM/hemispherx-biopharma-announces-commencement-of-a-new-45-subject-clinical-trial-combining-a-aim-20190211monthly0.5https://www.biopharmawatch.com/news/AIM/hemispherx-biopharma-announces-key-dates-and-timeline-for-stockholder-participation-in-rig-aim-20190206monthly0.5https://www.biopharmawatch.com/news/AIM/hemispherx-outlines-ampligen-combination-therapy-clinical-study-strategy-for-the-treatment-aim-20181022monthly0.5https://www.biopharmawatch.com/news/AIM/hemispherx-biopharma-signs-clinical-trial-agreement-with-roswell-park-comprehensive-cancer-aim-20181010monthly0.5https://www.biopharmawatch.com/news/AIM/dear-fellow-stockholders-as-you-probably-know-we-recently-announced-the-completion-of-fill-aim-20180502monthly0.5https://www.biopharmawatch.com/news/AIM/hemispherx-announces-pricing-of-2-57-million-registered-direct-offering-at-a-premium-to-ma-aim-20180420monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-charles-jones-cjones-associates-public-relations-888-557-6480-305-aim-20170815monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-charles-jones-cjones-associates-public-relations-888-557-6480-305-aim-20170331monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-charles-jones-cjones-associates-public-relations-888-557-6480-cjo-aim-20170206monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-charles-jones-cjones-associates-public-relations-888-557-6480-305-aim-20161115monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-charles-jones-cjones-associates-public-relations-888-557-6480-305-aim-20160922monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-charles-jones-cjones-associates-public-relations-888-557-6480-305-aim-20160919monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-charles-jones-cjones-associates-public-relations-888-557-6480-cjo-aim-20160901monthly0.5https://www.biopharmawatch.com/news/AIM/com-pany-investor-contact-charles-jones-cjones-associates-public-relations-office-888-557--aim-20160824monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-charles-jones-cjones-associates-public-relations-office-888-557-6-aim-20160819monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-charles-jones-cjones-associates-public-relations-888-557-6480-305-aim-20160817monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-charles-jones-cjones-associates-public-relations-888-557-6480-305-aim-20160815monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-charles-jones-cjones-associates-public-relations-office-888-557-6-aim-20160711monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-charles-jones-cjones-associates-public-relations-office-888-557-6-aim-20160608monthly0.5https://www.biopharmawatch.com/news/AIM/united-states-district-court-eastern-district-of-pennsylvania-mark-zicherman-derivatively--aim-20160608monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-charles-jones-cjones-associates-public-relations-888-557-6480-305-aim-20160524monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-charles-jones-cjones-associates-public-relations-888-557-6480-305-aim-20160329monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-charles-jones-cjones-associates-public-relations-office-888-557-6-aim-20160222monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-charles-jones-cjones-associates-public-relations-office-888-557-6-aim-20160203monthly0.5https://www.biopharmawatch.com/news/AIM/hemispherx-receives-new-u-s-composition-of-matter-patent-covering-ampligen-formulations-no-aim-20140527monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-dianne-will-hemispherx-biopharma-inc-518-398-6222-ir-hemispherx-n-aim-20131204monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-dianne-will-hemispherx-biopharma-inc-518-398-6222-ir-hemispherx-n-aim-20131003monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-dianne-will-hemispherx-biopharma-inc-518-398-6222-ir-hemispherx-n-aim-20130729monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-dianne-will-hemispherx-biopharma-inc-518-398-6222-ir-hemispherx-n-aim-20130204monthly0.5https://www.biopharmawatch.com/news/AIM/company-investor-contact-dianne-will-hemispherx-biopharma-inc-518-398-6222-ir-hemispherx-n-aim-20121221monthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-inc-announces-approval-of-2-million-share-repurchase-plan-hcti-20260311monthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-announces-approximately-3-959-million-registered-direct-financing-of-c-hcti-20260226monthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-inc-announces-1-for-60-reverse-stock-split-as-part-of-nasdaq-complianc-hcti-20260206monthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-inc-signs-definitive-agreement-with-teyame-ai-llc-which-is-forecasted--hcti-20260122monthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-inc-signs-advance-agreement-for-the-acquisition-of-next-generation-ai--hcti-20251210monthly0.5https://www.biopharmawatch.com/news/HCTI/update-healthcare-triangle-announces-warrant-inducement-for-aggregate-gross-proceeds-of-ap-hcti-20251002monthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-inc-nasdaq-hcti-transforming-healthcare-through-ehr-cloud-and-a-i-driv-hcti-20250915monthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-inc-announces-1-for-249-reverse-stock-split-as-part-of-nasdaq-complian-hcti-20250730monthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-inc-announces-nasdaq-hearings-panel-s-grant-of-the-company-s-request-f-hcti-20250707monthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-completes-strategic-acquisition-of-niyama-healthcare-and-ezovion-solut-hcti-20250616monthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-announces-the-appointment-of-chief-financial-officer-and-director-on-t-hcti-20250411monthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-announces-the-appointment-of-chief-operating-officer-hcti-20250318monthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-inc-announces-15-2-million-pipe-offering-healthcare-triangle-inc-nasda-hcti-20250227monthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-inc-appoints-anand-kumar-as-interim-hcti-20240312monthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-inc-completes-2-0-million-private-placement-debt-offering-hcti-20240102monthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-inc-announces-1-for-10-reverse-stock-split-as-part-of-nasdaq-complianc-hcti-20230525monthly0.5https://www.biopharmawatch.com/news/HCTI/by-electronic-delivery-to-rt-healthcaretriangle-com-rcarmel-cmfllp-com-hcti-20221229monthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-announces-6-5-million-private-placement-hcti-20220711monthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-hcti-acquires-devcool-an-electronic-health-record-ehr-focused-healthca-hcti-20211213monthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-inc-announces-pricing-of-13-0-million-initial-public-offering-hcti-20211012monthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-announces-a-1-5-reverse-stock-split-effective-pre-market-opening-on-ivf-20260327monthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-closes-acquisition-of-indiana-based-fertility-clinic-family-beginnings-stra-ivf-20260219monthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-aligns-executive-leadership-structure-to-support-growth-strategy-terah-krig-ivf-20251230monthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-signs-definitive-purchase-agreement-to-acquire-indiana-based-fertility-clin-ivf-20251217monthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-announces-pricing-of-4-0-million-private-placement-priced-at-the-market-und-ivf-20251202monthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-announces-a-1-8-reverse-stock-split-effective-pre-market-opening-on-ivf-20251128monthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-announces-third-quarter-2025-financial-results-ivf-20251117monthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-announces-second-quarter-2025-financial-results-ivf-20250814monthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-announces-a-1-3-reverse-stock-split-effective-pre-market-opening-on-ivf-20250721monthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-announces-first-quarter-2025-financial-results-company-now-exclusively-focu-ivf-20250520monthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-announces-2024-financial-results-with-116-annual-revenue-growth-and-further-ivf-20250430monthly0.5https://www.biopharmawatch.com/news/IVF/naya-announces-a-1-12-reverse-stock-split-effective-pre-market-opening-on-ivf-20250318monthly0.5https://www.biopharmawatch.com/news/IVF/naya-biosciences-announces-pricing-of-9-5-million-public-offering-sarasota-fla-and-miami-ivf-20250113monthly0.5https://www.biopharmawatch.com/news/IVF/naya-therapeutics-inc-former-name-naya-biosciences-inc-for-the-years-ended-december-31-202-ivf-20241212monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-and-naya-biosciences-close-merger-combined-company-to-operate-as-naya-bios-ivf-20241014monthly0.5https://www.biopharmawatch.com/news/IVF/invo-reports-record-second-quarter-2024-financial-results-with-481-revenue-growth-and-a-1--ivf-20240814monthly0.5https://www.biopharmawatch.com/news/IVF/invo-reports-record-first-quarter-2024-financial-results-353-revenue-growth-with-improveme-ivf-20240515monthly0.5https://www.biopharmawatch.com/news/IVF/invo-reports-fourth-quarter-and-full-year-2023-financial-results-ivf-20240416monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-regains-compliance-with-nasdaq-minimum-stockholders-equity-requirement-ivf-20231128monthly0.5https://www.biopharmawatch.com/news/IVF/invo-reports-record-third-quarter-2023-financial-results-company-expects-to-host-conferenc-ivf-20231113monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-announces-commencement-of-waiver-solicitation-from-holders-of-the-company--ivf-20231109monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-and-naya-biosciences-announce-definitive-merger-agreement-to-establish-exp-ivf-20231023monthly0.5https://www.biopharmawatch.com/news/IVF/invo-reports-second-quarter-2023-financial-results-company-to-host-conference-call-today-a-ivf-20230814monthly0.5https://www.biopharmawatch.com/news/IVF/invo-closes-acquisition-of-wisconsin-fertility-institute-transformational-and-accretive-ac-ivf-20230811monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-announces-pricing-of-4-5-million-public-offering-ivf-20230804monthly0.5https://www.biopharmawatch.com/news/IVF/invo-announces-a-1-20-reverse-stock-split-effective-pre-market-opening-on-ivf-20230728monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-inc-unaudited-pro-forma-condensed-combined-financial-statements-on-ivf-20230630monthly0.5https://www.biopharmawatch.com/news/IVF/wisconsin-fertility-and-reproductive-surgery-associates-s-c-and-fertility-labs-of-wisconsi-ivf-20230621monthly0.5https://www.biopharmawatch.com/news/IVF/invo-reports-first-quarter-2023-financial-results-company-to-host-conference-call-today-at-ivf-20230515monthly0.5https://www.biopharmawatch.com/news/IVF/invo-reports-fourth-quarter-and-full-year-2022-financial-results-company-to-host-conferenc-ivf-20230417monthly0.5https://www.biopharmawatch.com/news/IVF/resignation-ivf-20230331monthly0.5https://www.biopharmawatch.com/news/IVF/invo-provides-preliminary-update-on-fy2022-financial-results-ivf-20230330monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-announces-pricing-of-3-0-million-registered-direct-offering-priced-at-the--ivf-20230324monthly0.5https://www.biopharmawatch.com/news/IVF/invo-signs-binding-agreements-to-acquire-wisconsin-fertility-institute-accretive-acquisiti-ivf-20230320monthly0.5https://www.biopharmawatch.com/news/IVF/wisconsin-fertility-and-reproductive-surgery-associates-s-c-and-fertility-labs-of-wisconsi-ivf-20230320monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-enters-distribution-agreement-for-taiwan-ivf-20230105monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-reports-third-quarter-2022-financial-results-company-to-host-conference-ca-ivf-20221114monthly0.5https://www.biopharmawatch.com/news/IVF/draft-invo-bioscience-reports-second-quarter-2022-financial-results-company-to-host-confer-ivf-20220815monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-reports-first-quarter-2022-financial-results-company-to-host-conference-ca-ivf-20220516monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-reports-2021-financial-results-company-to-host-conference-call-today-at-4--ivf-20220331monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-reports-third-quarter-2021-financial-and-operating-results-and-provides-bu-ivf-20211115monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-regains-full-u-s-commercialization-rights-ivf-20211108monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-reports-second-quarter-2021-financial-and-operating-results-and-provides-b-ivf-20210816monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-signs-joint-venture-agreement-with-bloom-fertility-to-open-an-invocell-fer-ivf-20210630monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-appoints-andrea-goren-as-chief-financial-officer-ivf-20210615monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-reports-first-quarter-2021-financial-and-operating-results-and-provides-bu-ivf-20210517monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-appoints-michael-j-campbell-and-steven-m-shum-to-its-board-of-directors-ivf-20171011monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-appoints-renowned-fertility-specialist-dr-kevin-doody-to-its-board-of-dire-ivf-20170411monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-receives-fda-clearance-for-invocell-fertility-treatment-revolutionary-devi-ivf-20151103monthly0.5https://www.biopharmawatch.com/news/IVF/reserve-equity-financing-agreement-this-agreement-dated-as-of-the-28-day-of-october-2009-t-ivf-20091103monthly0.5https://www.biopharmawatch.com/news/IVF/invo-bioscience-announces-the-closing-to-the-bridge-financing-ivf-20090916monthly0.5https://www.biopharmawatch.com/news/IVF/unassociated-document-bioxcell-inc-a-development-stage-company-contents-page-1-report-of-i-ivf-20081212monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-first-half-2025-financial-results-and-operational-highlights-e-rdhl-20250905monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-first-half-2024-business-highlights-a-transformed-redhill-nume-rdhl-20240829monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-h1-23-financial-results-and-operational-highlights-rhb-107-incl-rdhl-20230817monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-h1-22-highlights-and-q3-22-estimates-financial-update-q2-22-net-rdhl-20221107monthly0.5https://www.biopharmawatch.com/news/RDHL/securities-and-exchange-commission-rdhl-20200922monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-virtualinvestorconferences-com-online-event-on-rdhl-20150305monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-ltd-21-ha-arba-a-street-tel-aviv-64739-israel-notice-of-annual-general-m-rdhl-20130626monthly0.5https://www.biopharmawatch.com/news/RDHL/convenience-translation-from-hebrew-redhill-biopharma-ltd-the-company-notice-is-hereby-giv-rdhl-20130620monthly0.5https://www.biopharmawatch.com/news/RDHL/press-release-date-rdhl-20130214monthly0.5https://www.biopharmawatch.com/news/XRTX/3710-33rd-street-nw-calgary-alberta-canada-t2l-xrtx-20260303monthly0.5https://www.biopharmawatch.com/news/XRTX/source-xortx-therapeutics-inc-xrtx-20251029monthly0.5https://www.biopharmawatch.com/news/XRTX/notice-of-change-of-auditor-xrtx-20250122monthly0.5https://www.biopharmawatch.com/news/XRTX/3710-33rd-street-nw-calgary-alberta-canada-t2l-2m1-xrtx-20240822monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-us-atm-offering-calgary-ab-xrtx-20231130monthly0.5https://www.biopharmawatch.com/news/XRTX/3710-33rd-street-nw-calgary-alberta-canada-t2l-2m1-xrtx-20231004monthly0.5https://www.biopharmawatch.com/news/XRTX/execution-version-xrtx-20221004monthly0.5https://www.biopharmawatch.com/news/XRTX/amended-and-restated-annual-information-form-xrtx-20220413monthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-to-participate-in-h-c-xrtx-20220110monthly0.5https://www.biopharmawatch.com/news/XRTX/condensed-interim-consolidated-financial-statements-for-the-three-and-nine-months-ended-xrtx-20211129monthly0.5https://www.biopharmawatch.com/news/XRTX/suite-4000-421-7th-avenue-sw-calgary-alberta-canada-t2p-4k9-xrtx-20211123monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrac-k-announces-uspto-approval-for-issuance-of-patents-for-proprietary-cbgm-platform-gctk-20260129monthly0.5https://www.biopharmawatch.com/news/GCTK/e-xhibit-99-1-glucotrack-reports-third-quarter-2025-financial-results-and-provides-update--gctk-20251113monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-inc-encourages-shareholders-to-vote-the-special-meeting-of-shareholders-reconve-gctk-20251103monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-inc-reminds-shareholders-to-vote-the-special-meeting-of-shareholders-held-on-gctk-20251031monthly0.5https://www.biopharmawatch.com/news/GCTK/amendment-to-glucotrack-inc-2024-equity-incentive-plan-this-amendment-this-amendment-to-th-gctk-20250522monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-establishes-patient-advisory-board-to-inform-diabetes-technology-development-pa-gctk-20250503monthly0.5https://www.biopharmawatch.com/news/GCTK/e-xhibit-99-1-glucotrack-and-onetwo-analytics-to-collaborate-for-clinical-study-analysis-o-gctk-20250403monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-reverse-stock-split-1-for-20-reverse-stock-split-to-become-effective--gctk-20250130monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-iso-13485-2016-certification-iso-certification-highlights-commitment--gctk-20250121monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-to-present-at-techbio-showcase-2025-presentation-to-feature-an-update-on-the-co-gctk-20250107monthly0.5https://www.biopharmawatch.com/news/GCTK/john-ballantyne-former-biotechnology-executive-joins-the-glucotrack-board-of-directors-bio-gctk-20240903monthly0.5https://www.biopharmawatch.com/news/GCTK/e-xhibit-99-1-glucotrack-reports-successful-completion-of-first-reported-long-term-preclin-gctk-20240613monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-reverse-stock-split-1-for-5-reverse-stock-split-to-become-effective-a-gctk-20240515monthly0.5https://www.biopharmawatch.com/news/GCTK/e-xhibit-99-1-glucotrack-announces-180-day-extension-to-regain-compliance-with-nasdaq-mini-gctk-20231130monthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-inc-underwriting-agreement-new-york-new-york-gctk-20230413monthly0.5https://www.biopharmawatch.com/news/GCTK/new-independent-director-brings-significant-public-company-leadership-and-corporate-govern-gctk-20191104monthly0.5https://www.biopharmawatch.com/news/GCTK/consulting-agreement-this-consulting-agreement-agreement-dated-as-of-gctk-20190801monthly0.5https://www.biopharmawatch.com/news/GCTK/integrity-applications-signs-distribution-agreement-for-its-glucotrack-glucose-monitoring--gctk-20180725monthly0.5https://www.biopharmawatch.com/news/MNDR/mobile-health-network-solutions-2-venture-drive-07-08-vision-exchange-singapore-608526-not-mndr-20260518monthly0.5https://www.biopharmawatch.com/news/MNDR/mobile-health-network-solutions-enters-into-non-binding-strategic-memorandum-to-facilitate-mndr-20260513monthly0.5https://www.biopharmawatch.com/news/MNDR/mobile-health-network-solutions-enters-into-non-binding-us-119-million-strategic-framework-mndr-20260504monthly0.5https://www.biopharmawatch.com/news/MNDR/mobile-health-network-solutions-reports-improved-gross-margin-and-cash-position-reduced-op-mndr-20260312monthly0.5https://www.biopharmawatch.com/news/MNDR/rules-of-the-mhns-employee-incentive-plan-1-name-of-the-plan-the-mhns-employee-incentive-p-mndr-20260212monthly0.5https://www.biopharmawatch.com/news/MNDR/mobile-health-network-solutions-announces-change-of-address-effective-mndr-20260113monthly0.5https://www.biopharmawatch.com/news/MNDR/mobile-health-network-solutions-reports-fy2025-results-and-operational-update-singapore-mndr-20251031monthly0.5https://www.biopharmawatch.com/news/MNDR/mobile-health-network-solutions-2-venture-drive-07-06-07-vision-exchange-singapore-608526--mndr-20250825monthly0.5https://www.biopharmawatch.com/news/MNDR/insider-trading-and-confidentiality-policy-as-adopted-by-the-board-of-directors-effective--mndr-20250821monthly0.5https://www.biopharmawatch.com/news/MNDR/mobile-health-network-solutions-announces-h1-fy2025-results-continues-on-drive-towards-sca-mndr-20250613monthly0.5https://www.biopharmawatch.com/news/MNDR/standby-equity-purchase-agreement-this-standby-equity-purchase-agreement-this-agreement-da-mndr-20250214monthly0.5https://www.biopharmawatch.com/news/MNDR/mobile-health-network-solutions-2-venture-drive-07-06-07-vision-exchange-singapore-608526--mndr-20250117monthly0.5https://www.biopharmawatch.com/news/MNDR/mobile-health-network-solutions-announces-closing-of-city-gate-clinic-charts-path-forward--mndr-20241224monthly0.5https://www.biopharmawatch.com/news/MNDR/mobile-health-network-solutions-delinquency-notification-letter-from-nasdaq-singapore-mndr-20240920monthly0.5https://www.biopharmawatch.com/news/MNDR/mobile-health-network-solutions-revenue-rises-approximately-120-in-the-first-six-months-of-mndr-20240521monthly0.5https://www.biopharmawatch.com/news/MNDR/apac-telehealth-leader-mndr-expects-revenue-growth-in-h12024-vs-h12023-singapore-mndr-20240422monthly0.5https://www.biopharmawatch.com/news/MNDR/mobile-health-network-solutions-announces-closing-of-initial-public-offering-singapore-mndr-20240412monthly0.5https://www.biopharmawatch.com/news/MNDR/mobile-health-network-solutions-announces-pricing-of-9-million-initial-public-offering-sin-mndr-20240409monthly0.5https://www.biopharmawatch.com/news/VBIO/valion-bio-appoints-melinda-lackey-as-general-counsel-seasoned-biopharmaceutical-attorney--vbio-20260504monthly0.5https://www.biopharmawatch.com/news/VBIO/biotech-veteran-michael-k-handley-named-ceo-of-tivic-health-systems-to-spearhead-strategic-vbio-20260304monthly0.5https://www.biopharmawatch.com/news/VBIO/nasdaq-tivc-www-tivichealth-com-ir-tivichealth-com-january-2026-jennifer-ernst-ceo-tivic-h-vbio-20260120monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-acquires-ready-to-scale-cgmp-manufacturing-and-development-assets-to-accelerate-comm-vbio-20251211monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-reports-findings-of-clinical-optimization-trial-of-non-invasive-cervical-vagu-vbio-20251113monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-receives-two-investigational-new-drug-applications-for-entolimod-for-the-treatment-o-vbio-20250820monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-reports-second-quarter-2025-financial-results-company-advances-its-tlr5-agonist-prog-vbio-20250814monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-completes-optimization-study-for-its-non-invasive-vagus-nerve-stimulation-dev-vbio-20250625monthly0.5https://www.biopharmawatch.com/news/VBIO/nasdaq-tivc-a-diversified-immunotherapeutics-company-ir-tivichealth-com-x2013-may-2025-x20-vbio-20250522monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-reports-first-quarter-2025-financial-results-and-provides-updates-on-business-transf-vbio-20250515monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-enters-gmp-manufacturing-validation-agreement-with-scorpius-biomanufacturing--vbio-20250514monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-reports-white-house-briefing-and-fda-meetings-secured-positive-interest-in-po-vbio-20250422monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-systems-inc-regains-compliance-with-nasdaq-minimum-bid-price-listing-rule-fre-vbio-20250410monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-reports-year-end-2024-financial-results-and-provides-overview-of-strategy-for-transf-vbio-20250321monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-and-feinstein-institute-present-new-data-showing-personalized-vagus-nerve-sti-vbio-20250306monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-systems-inc-announces-reverse-stock-split-fremont-calif-x2013-vbio-20250305monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team-vbio-20250224monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-acquires-exclusive-worldwide-rights-to-phase-iii-tlr5-agonist-from-statera-bi-vbio-20250212monthly0.5https://www.biopharmawatch.com/news/VBIO/ceo-letter-to-shareholders-issued-by-tivic-health-provides-updates-on-vagus-nerve-stimulat-vbio-20241223monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-reports-third-quarter-2024-financial-results-and-provides-business-update-pre-record-vbio-20241114monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-receives-approval-from-institutional-review-board-for-ncvns-optimization-stud-vbio-20240918monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-accelerates-vns-commercial-strategy-development-partners-with-leading-growth--vbio-20240917monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-appoints-lisa-wolf-as-interim-chief-financial-officer-kimberly-bambach-ms-wol-vbio-20240913monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-reports-second-quarter-2024-financial-results-san-francisco-x2013-business-wire-x201-vbio-20240814monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-christina-valauri-appointed-to-board-of-directors-wall-street-capital-markets-vbio-20240618monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-partners-with-the-feinstein-institutes-to-advance-its-patent-pending-non-inva-vbio-20240522monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-reports-first-quarter-2024-financial-results-and-subsequent-events-san-francisco-x20-vbio-20240515monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-announces-pricing-of-4-0-million-public-offering-vbio-20240509monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-announces-successful-completion-of-non-invasive-vagus-nerve-stimulation-study-vbio-20240508monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-reports-fiscal-year-2023-financial-results-san-francisco-x2013-business-wire-x2013-vbio-20240325monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-reports-third-quarter-2023-financial-results-71-gross-profit-increase-30-decrease-in-vbio-20231114monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-partners-with-instep-health-to-access-over-2-500-healthcare-providers-and-the-vbio-20230926monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-systems-inc-regains-compliance-with-nasdaq-listing-requirements-vbio-20230920monthly0.5https://www.biopharmawatch.com/news/VBIO/x1f-press-release-tivic-health-systems-inc-announces-reverse-stock-split-san-francisco-x20-vbio-20230822monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-reports-second-quarter-2023-financial-results-san-francisco-x2013-business-wire-x201-vbio-20230814monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-announces-proposed-public-offering-of-common-stock-san-francisco-x2013-vbio-20230804monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-expands-ip-protection-with-issuance-of-sixth-patent-for-its-bioelectronic-pla-vbio-20230731monthly0.5https://www.biopharmawatch.com/news/VBIO/letter-from-the-ceo-of-tivic-health-jennifer-ernst-tivic-health-ceo-provides-additional-in-vbio-20230728monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-announces-proposed-public-offering-of-common-stock-san-francisco-x2013-vbio-20230714monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-announces-proposed-public-offering-of-common-stock-san-francisco-x2013-vbio-20230707monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-to-reconvene-annual-meeting-of-stockholders-vbio-20230609monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-reports-first-quarter-2023-financial-results-gross-profit-increase-by-61-3-extends-i-vbio-20230515monthly0.5https://www.biopharmawatch.com/news/VBIO/p-r-e-s-s-r-e-l-e-a-s-e-tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-an-vbio-20230501monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-the-feinstein-institutes-for-medical-research-announce-pilot-study-to-test-novel-non-vbio-20230413monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-expands-bioelectronic-portfolio-files-patent-application-for-new-approach-to-non-inv-vbio-20230411monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-reports-fiscal-year-2022-financial-results-san-francisco-x2013-business-wire--vbio-20230331monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-systems-inc-announces-pricing-of-public-offering-san-francisco-x2013-vbio-20230208monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-and-reliefband-technologies-llc-terminate-acquisition-agreement-tivic-remains-vbio-20221209monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-signs-agreement-with-alom-to-manage-product-supply-chain-assembly-and-logisti-vbio-20221201monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-reports-third-quarter-2022-financial-results-65-growth-in-year-to-date-revenu-vbio-20221114monthly0.5https://www.biopharmawatch.com/news/VBIO/make-text-into-real-text-use-vector-graphic-for-logo-72-or-150-the-future-of-medicine-is-e-vbio-20221007monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-to-acquire-assets-of-reliefband-company-intends-to-dramatically-expand-produc-vbio-20221017monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-reports-strong-growth-in-second-quarter-2022-financial-results-265-growth-in--vbio-20220815monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-reports-first-quarter-2022-financial-results-77-year-over-year-growth-in-unit-vbio-20220516monthly0.5https://www.biopharmawatch.com/news/VBIO/april-investor-presentation-nasdaq-tivc-electrons-as-medicine-targeting-inflammatory-respo-vbio-20220418monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-announces-key-executive-appointments-strengthening-leadership-team-veronica-c-vbio-20220405monthly0.5https://www.biopharmawatch.com/news/VBIO/bioelectronic-medicine-non-invasively-targeting-immune-system-responses-2021-december-inve-vbio-20211208monthly0.5https://www.biopharmawatch.com/news/VBIO/tivic-health-systems-inc-announces-pricing-of-initial-public-offering-menlo-park-ca-vbio-20211110monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-inc-announces-pricing-of-6-0-million-public-offering-fort-lauderdale-fl-sbfm-20260519monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-reports-fiscal-2025-revenue-of-36-3-million-a-4-1-increase-over-prior-y-sbfm-20260406monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-reports-2025-first-quarter-results-revenues-up-18-over-same-period-last-sbfm-20250515monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-inc-announces-2-46-million-registered-direct-offering-priced-at-the-mar-sbfm-20250403monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-reports-revenue-of-34-9m-in-fiscal-2024-up-45-from-last-year-fort-laude-sbfm-20250401monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-announces-the-appointment-of-new-chief-commercial-officer-fort-lauderda-sbfm-20250115monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-reports-2024-third-quarter-results-year-to-date-revenues-up-54-fort-lau-sbfm-20241106monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-reports-2024-second-quarter-results-second-qtr-revenues-up-67-ytd-reven-sbfm-20240819monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-reports-2024-first-quarter-results-revenues-up-54-new-york-ny-accesswir-sbfm-20240521monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-reports-operating-results-for-the-fiscal-year-ended-december-31-2023-sa-sbfm-20240401monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-inc-announces-pricing-of-10-0-million-underwritten-public-offering-new--sbfm-20240215monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20230921monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20230811monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20230511monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20230228monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20230210monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20221020monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-inc-6500-trans-canada-highway-4th-floor-pointe-claire-quebec-canada-h9r-sbfm-20220324monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20220225monthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-inc-otc-markets-sbfm-to-the-extent-that-statements-in-this-presentation-sbfm-20220208monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20211222monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20211103monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20201019monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20200915monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20200603monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20190312monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20180914monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20180104monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20170905monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20170626monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20160315monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20151228monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20151009monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20150804monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20141119monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20140429monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20110617monthly0.5https://www.biopharmawatch.com/news/SBFM/for-immediate-release-sbfm-20110121monthly0.5https://www.biopharmawatch.com/news/SBFM/mountain-west-business-solutions-acquires-sunshine-biopharma-littleton-co-date-mountain-we-sbfm-20091020monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-highlights-2025-key-operational-scientific-and-corporate-milestones-and-pro-bblg-20260108monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-ceo-issues-letter-to-stockholders-highlighting-company-update-and-outlook-b-bblg-20250904monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-announces-pricing-of-5-0-million-public-offering-bblg-20250627monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-regains-compliance-with-nasdaq-continued-listing-requirements-burlington-ma-bblg-20250626monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-announces-1-for-6-reverse-stock-split-bblg-20250606monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-appoints-phillip-t-meikle-to-its-board-of-directors-brings-30-years-of-comm-bblg-20241021monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-announces-exercise-of-warrants-for-2-1-million-gross-proceeds-burlington-ma-bblg-20240802monthly0.5https://www.biopharmawatch.com/news/BBLG/first-two-patients-treated-in-pilot-clinical-study-with-bone-biologics-nb1-bone-graft-devi-bblg-20240620monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-announces-pricing-of-2-0-million-public-offering-bblg-20240304monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-reports-progress-with-nb1-clinical-program-burlington-mass-bblg-20240301monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-appoints-healthcare-finance-veteran-robert-e-gagnon-to-board-of-directors-b-bblg-20240111monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-regains-compliance-with-nasdaq-continued-listing-requirements-burlington-ma-bblg-20240110monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-announces-1-for-8-reverse-stock-split-bblg-20231218monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-announces-registered-direct-offering-priced-at-the-market-under-nasdaq-rule-bblg-20231116monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-prices-5-0-million-underwritten-public-offering-burlington-mass-bblg-20230614monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-ceo-issues-letter-to-stockholders-burlington-mass-bblg-20221025monthly0.5https://www.biopharmawatch.com/news/BBLG/draft-1-october-7-2022-bone-biologics-announces-closing-of-5-100-000-underwritten-public-o-bblg-20221012monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-prices-5-100-000-underwritten-public-offering-burlington-mass-bblg-20221007monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-enters-into-supply-agreement-with-mtf-biologics-for-demineralized-bone-matr-bblg-20220307monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-corp-announces-closing-of-public-offering-and-uplisting-to-nasdaq-bblg-20211018monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-corp-announces-pricing-of-7-9-million-public-offering-uplisting-to-the-nasd-bblg-20211013monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-preclinical-study-shows-rhnell-1-effectively-promotes-bone-formation-01-07--bblg-20200109monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-receives-human-research-ethics-committee-hrec-approval-for-the-first-center-bblg-20190325monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-completes-500-000-of-financing-burlington-ma-bblg-20180329monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-adds-osteoporosis-and-trauma-indications-to-its-portfolio-burlington-ma-bblg-20170823monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-completes-1-4-million-round-of-financing-burlington-bblg-20170822monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-announces-appointment-of-bret-hankey-to-company-s-board-of-directors-burlin-bblg-20170803monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-corporation-announces-commencement-of-a-private-placement-of-securities-bur-bblg-20170724monthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-announces-signing-of-option-to-license-revolutionary-bone-growth-factor-nel-bblg-20160614monthly0.5https://www.biopharmawatch.com/news/BBLG/shannon-webber-o-412-749-9299-x5-c-412-608-2393-e-shannon-atlasstories-com-bone-biologics--bblg-20160229monthly0.5https://www.biopharmawatch.com/news/RDGT/ridgetech-inc-announces-1-for-150-reverse-share-split-rdgt-20260403monthly0.5https://www.biopharmawatch.com/news/RDGT/report-of-independent-registered-public-accounting-firm-to-the-board-of-directors-and-shar-rdgt-20251204monthly0.5https://www.biopharmawatch.com/news/RDGT/ridgetech-inc-5th-floor-building-6-no-100-18th-street-baiyang-sub-district-qiantang-distri-rdgt-20251112monthly0.5https://www.biopharmawatch.com/news/RDGT/ridgetech-inc-reports-fiscal-year-2025-financial-results-rdgt-20250728monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-inc-4-th-floor-building-5-renxin-yaju-gong-shu-district-hangzhou-ci-rdgt-20250205monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-announces-strategic-business-restructuring-to-strengthen-wholesale--rdgt-20250203monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-reports-fiscal-year-2024-financial-results-rdgt-20240730monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-announces-3-37-million-registered-direct-offering-rdgt-20240611monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-announces-changes-to-board-of-directors-rdgt-20240531monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-announces-2-74-million-registered-direct-offering-rdgt-20240510monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-announces-1-53-million-registered-direct-offering-rdgt-20240429monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-regains-compliance-with-nasdaq-minimum-bid-price-requirement-rdgt-20240319monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-inc-announces-1-for-20-reverse-stock-split-rdgt-20240227monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-inc-hai-wai-hai-tongxin-mansion-floor-6-gong-shu-district-hangzhou--rdgt-20240126monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-granted-a-second-extension-to-meet-nasdaq-minimum-bid-price-require-rdgt-20231214monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-inc-hai-wai-hai-tongxin-mansion-floor-6-gong-shu-district-hangzhou--rdgt-20231116monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-announces-2-59-million-registered-direct-offering-rdgt-20230926monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-announced-receipt-of-nasdaq-notification-regarding-minimum-bid-pric-rdgt-20230616monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-reports-fiscal-year-2023-financial-results-rdgt-20230615monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-announces-2-625-million-registered-direct-offering-rdgt-20230120monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-inc-hai-wai-hai-tongxin-mansion-floor-6-gong-shu-district-hangzhou--rdgt-20221103monthly0.5https://www.biopharmawatch.com/news/RDGT/securities-purchase-agreement-this-securities-purchase-agreement-the-agreement-is-made-as--rdgt-20221006monthly0.5https://www.biopharmawatch.com/news/RDGT/securities-purchase-agreement-this-securities-purchase-agreement-the-agreement-is-made-as--rdgt-20220729monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-reports-fiscal-year-2022-financial-results-rdgt-20220728monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-regains-compliance-with-nasdaq-minimum-bid-price-requirement-rdgt-20220427monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-inc-announces-1-for-12-reverse-stock-split-rdgt-20220406monthly0.5https://www.biopharmawatch.com/news/RDGT/to-the-report-on-form-6-k-filed-by-china-jo-jo-drugstores-inc-on-rdgt-20220301monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-granted-extension-to-meet-nasdaq-minimum-bid-price-requirement-hang-rdgt-20220125monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-reports-first-half-of-fiscal-year-2022-financial-results-rdgt-20220121monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-inc-hai-wai-hai-tongxin-mansion-floor-6-gong-shu-district-hangzhou--rdgt-20211228monthly0.5https://www.biopharmawatch.com/news/RDGT/china-jo-jo-drugstores-completes-redomiciliation-merger-rdgt-20210730monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-first-quarter-2026-financial-results-and-business-highl-rkda-20260514monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-exercise-of-preferred-investment-options-for-2-1-millio-rkda-20260112monthly0.5https://www.biopharmawatch.com/news/RKDA/beliefs-concerning-the-availability-of-adequate-funding-to-support-the-company-s-future-op-rkda-20251229monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-third-quarter-2025-financial-results-and-business-highl-rkda-20251107monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-second-quarter-and-first-half-2025-financial-results-an-rkda-20250814monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-first-quarter-2025-financial-results-and-business-highl-rkda-20250508monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-fourth-quarter-and-full-year-2024-financial-results-and-rkda-20250320monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-roosevelt-resources-business-combination-december-2024-filed-by-arcadi-rkda-20241211monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-contact-roosevelt-resources-contact-sue-wandell-jerrel-branson-ir-arca-rkda-20241206monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-strong-third-quarter-2024-financial-results-and-busines-rkda-20241112monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-second-quarter-and-first-half-2024-financial-results-an-rkda-20240813monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-inc-unaudited-pro-forma-consolidated-financial-information-on-rkda-20240514monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-first-quarter-2024-financial-results-and-business-highl-rkda-20240509monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-fourth-quarter-and-full-year-2023-financial-results-and-rkda-20240328monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-strong-third-quarter-2023-financial-results-and-busines-rkda-20231109monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-second-quarter-and-first-half-2023-financial-results-an-rkda-20230810monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-strategic-review-x2013-company-will-explore-a-range-of--rkda-20230720monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-first-quarter-2023-financial-results-from-operations-an-rkda-20230511monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-fourth-quarter-and-full-year-2022-financial-results-and-rkda-20230330monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-cfo-transition-pam-haley-to-be-replaced-by-thomas-j-sch-rkda-20221130monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-strong-third-quarter-2022-financial-results-and-busines-rkda-20221110monthly0.5https://www.biopharmawatch.com/news/RKDA/execution-version-rkda-20220812monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-strong-second-quarter-and-first-half-2022-financial-res-rkda-20220811monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-first-quarter-2022-financial-results-x2013-sales-increa-rkda-20220512monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-fourth-quarter-and-full-year-2021-financial-results-and-rkda-20220330monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-names-stan-jacot-as-ceo-transformational-change-leader-and-cpg-ve-rkda-20220202monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-appoints-kevin-comcowich-to-interim-ceo-davis-calif-rkda-20211220monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-strong-third-quarter-financial-results-and-business-hig-rkda-20211115monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-announces-leadership-transition-company-seeks-new-ceo-as-it-further-ex-rkda-20210907monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-announces-strong-second-quarter-and-first-half-2021-financial-results--rkda-20210816monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-first-quarter-2021-financial-results-and-business-highl-rkda-20210517monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-rkda-announces-fourth-quarter-and-full-year-2020-financial-results-and-rkda-20210330monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-welcomes-debbie-carosella-to-board-of-directors-prominent-leader-in-co-rkda-20210224monthly0.5https://www.biopharmawatch.com/news/RKDA/execution-version-rkda-20201217monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-inc-unaudited-pro-forma-condensed-consolidated-financial-information-a-rkda-20201118monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-announces-third-quarter-rkda-20201112monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-announces-second-quarter-and-first-half-2020-financial-results-and-bus-rkda-20200813monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-announces-first-quarter-2020-financial-results-and-business-highlights-rkda-20200513monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-announces-fourth-quarter-and-full-year-2019-financial-results-and-busi-rkda-20200325monthly0.5https://www.biopharmawatch.com/news/RKDA/lisa-weser-trailblaze-lisa-trailblaze-co-1-314-625-4633-arcadia-biosciences-announces-thir-rkda-20191106monthly0.5https://www.biopharmawatch.com/news/RKDA/lisa-weser-trailblaze-lisa-trailblaze-co-1-314-625-4633-arcadia-biosciences-announces-seco-rkda-20190814monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-first--rkda-20190508monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-fourth-rkda-20190327monthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-a-leader-in-advanced-agricultural-breeding-and-gene-optimization-annou-rkda-20190228monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-third--rkda-20181107monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-second-rkda-20180808monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-albert-d-bolles-ph-d-joins-arcadia-b-rkda-20180515monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-first--rkda-20180509monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-10-mil-rkda-20180319monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-fourth-rkda-20180320monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-third--rkda-20171109monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-second-rkda-20170810monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-first--rkda-20170510monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-fourth-rkda-20170308monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-third--rkda-20161110monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-adds-kevin-comco-rkda-20161102monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-names-new-chief--rkda-20160908monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-second-rkda-20160809monthly0.5https://www.biopharmawatch.com/news/RKDA/s-t-anl-e-y-higgins-s-e-nior-di-rec-tor-l-isting-qu-a-li-f-i-ca-tions-the-n-a-sd-a-q-s-to--rkda-20160721monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-change-rkda-20160714monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-first--rkda-20160510monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-fourth-rkda-20160308monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-depart-rkda-20160211monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-ceo-to-take-shor-rkda-20160113monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-refinances-and-c-rkda-20151230monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-third--rkda-20151105monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-cfo-ch-rkda-20151005monthly0.5https://www.biopharmawatch.com/news/RKDA/jeff-bergau-jeff-bergau-arcadiabio-com-1-312-217-0419-arcadia-biosciences-announces-second-rkda-20150810monthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-cayman-limited-incorporated-in-the-cayman-islands-with-limited-liability--cupr-20260428monthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-cayman-limited-incorporated-in-the-cayman-islands-with-limited-liability--cupr-20260421monthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-cayman-limited-index-to-unaudited-condensed-consolidated-financial-statem-cupr-20251209monthly0.5https://www.biopharmawatch.com/news/SLXN/sile-ncing-oncogenes-at-the-level-of-gene-expression-nasdaq-slxn-corporate-presentation-se-slxn-20240909monthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-ltd-unaudited-condensed-consolidated-financial-statements-june-30-20-slxn-20240821monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-announces-third-quarter-update-and-financial-results-fort-mill-sc-vtak-20241113monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-announces-exercise-of-warrants-for-4-9-million-of-gross-proceeds-fo-vtak-20241025monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-announces-pricing-of-3-1-million-underwritten-public-offering-fort--vtak-20240830monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-nyse-american-vtak-reports-q2-2024-highlights-and-operational-perfo-vtak-20240814monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-nyse-american-vtak-reports-preliminary-unaudited-revenue-for-the-se-vtak-20240630monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-nyse-american-vtak-reports-q1-2024-highlights-and-operational-perfo-vtak-20240506monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-nyse-american-vtak-releases-operational-performance-report-q4-and-a-vtak-20240402monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-vtak-reports-unaudited-preliminary-fourth-quarter-and-full-year-202-vtak-20240110monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-reports-third-quarter-results-of-operations-and-filing-of-third-qua-vtak-20231222monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-reports-second-quarter-results-of-operations-fort-mill-sc-vtak-20231218monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-receives-notice-from-nyse-american-regarding-late-filing-of-quarterly-r-vtak-20230825monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-announces-first-quarter-results-fort-mill-sc-vtak-20230602monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-receives-notice-from-nyse-american-regarding-late-filing-of-quarterly-r-vtak-20230530monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-announces-delayed-10-q-filing-fort-mill-sc-vtak-20230522monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-provides-first-corporate-update-since-merger-sales-and-clinical-field-f-vtak-20230516monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-announces-resignation-of-ceo-board-committee-seeking-replacement-fort-mill-sc-vtak-20230418monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-inc-s-management-s-discussion-and-analysis-of-financial-condition-and-r-vtak-20230329monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-vtak-20230329monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-completes-merger-with-catheter-precision-medtech-veteran-and-catheter-p-vtak-20230109monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-regains-compliance-with-nyse-american-continued-listing-standards-carls-vtak-20221214monthly0.5https://www.biopharmawatch.com/news/VTAK/to-the-company-s-current-report-on-form-8-k-filed-on-vtak-20221202monthly0.5https://www.biopharmawatch.com/news/VTAK/to-the-company-s-current-report-on-form-8-k-filed-on-vtak-20221129monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-reports-third-quarter-2022-financial-results-carlsbad-calif-vtak-20221114monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-expands-u-s-customer-base-for-vivo-for-non-invasive-arrythmia-location--vtak-20221020monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-raises-7-6-million-through-completed-at-the-market-facility-carlsbad-ca-vtak-20221017monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-files-a-method-of-use-u-s-patent-application-for-its-vivo-technology-mt-vtak-20221004monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-s-vivo-technology-to-be-featured-in-three-presentations-at-the-global-s-vtak-20220929monthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-names-fatih-ayoglu-as-business-development-manager-emea-mt-olive-n-j-an-vtak-20220927monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-announces-results-of-its-special-meeting-of-stockholders-and-a-1-for-50-vtak-20220920monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-enters-into-definitive-merger-agreement-with-catheter-precision-combine-vtak-20220912monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-receives-nyse-american-notice-carlsbad-calif-vtak-20220902monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-reports-second-quarter-2022-financial-results-carlsbad-calif-vtak-20220815monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-enters-into-agreements-to-raise-6-2-million-through-previously-issued-w-vtak-20220722monthly0.5https://www.biopharmawatch.com/news/VTAK/e-xhibit-99-1-ra-medical-systems-appoints-brian-d-conn-interim-chief-financial-officer-car-vtak-20220718monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-reports-first-quarter-2022-financial-results-conference-call-begins-at--vtak-20220516monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-reports-2021-fourth-quarter-and-full-year-financial-results-conference--vtak-20220323monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-inc-announces-pricing-of-12-0-million-underwritten-public-offering-carl-vtak-20220204monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-reports-2021-third-quarter-financial-results-conference-call-begins-at--vtak-20211115monthly0.5https://www.biopharmawatch.com/news/VTAK/disclaimer-certain-statements-in-this-presentation-and-the-accompanying-oral-commentary-ar-vtak-20210824monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-reports-2021-second-quarter-financial-results-conference-call-begins-at-vtak-20210816monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-announces-sale-of-pharos-dermatology-business-company-focused-on-the-la-vtak-20210816monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-reports-2021-first-quarter-financial-results-conference-call-begins-at--vtak-20210511monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-reports-2020-fourth-quarter-and-full-year-financial-results-conference--vtak-20210316monthly0.5https://www.biopharmawatch.com/news/VTAK/disclaimer-certain-statements-in-this-presentation-and-the-accompanying-oral-commentary-ar-vtak-20210308monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-appoints-susanne-l-meline-to-its-board-of-directors-carlsbad-calif-vtak-20210204monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-reports-progress-with-extending-dabra-catheter-shelf-life-completes-qua-vtak-20210127monthly0.5https://www.biopharmawatch.com/news/VTAK/disclaimer-certain-statements-in-this-presentation-and-the-accompanying-oral-commentary-ar-vtak-20210105monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-announces-settlement-resolving-previously-announced-united-states-depar-vtak-20210104monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-announces-transfer-of-listing-to-nyse-american-carlsbad-calif-vtak-20201217monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-announces-1-for-25-reverse-stock-split-carlsbad-calif-vtak-20201116monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-reports-2020-third-quarter-financial-results-conference-call-begins-at--vtak-20201112monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-inc-2018-equity-incentive-plan-as-amended-and-restated-on-october-12-20-vtak-20201013monthly0.5https://www.biopharmawatch.com/news/VTAK/rmed-ex991-6-pptx-htm-ra-medical-systems-inc-nyse-rmed-corporate-presentation-september-20-vtak-20200914monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-reports-2020-second-quarter-financial-results-conference-call-begins-at-vtak-20200811monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-announces-pricing-of-12-0-million-upsized-public-offering-carlsbad-cali-vtak-20200730monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-announces-pricing-of-10-0-million-public-offering-carlsbad-calif-vtak-20200520monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-receives-continued-listing-standard-notice-from-the-nyse-carlsbad-calif-vtak-20200522monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-reports-2020-first-quarter-financial-results-conference-call-begins-at--vtak-20200513monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-appoints-joan-stafslien-to-its-board-of-directors-carlsbad-calif-vtak-20200429monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-appoints-medtech-executive-will-mcguire-as-ceo-and-director-carlsbad-ca-vtak-20200312monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-reports-2019-fourth-quarter-and-full-year-financial-results-conference--vtak-20200310monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-receives-nyse-failure-to-satisfy-a-continued-listing-rule-notification--vtak-20191206monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-reports-third-quarter-2019-financial-results-carlsbad-calif-vtak-20191129monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-announces-substantial-completion-of-audit-committee-investigation-carls-vtak-20191031monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-receives-nyse-notice-related-to-delay-in-form-10-q-filing-carlsbad-cali-vtak-20190823monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-reports-preliminary-second-quarter-2019-financial-results-announces-lea-vtak-20190812monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-reports-first-quarter-2019-financial-results-submits-ide-for-atherectom-vtak-20190513monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-reports-2018-fourth-quarter-and-full-year-financial-results-introduces--vtak-20190314monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-reports-third-quarter-2018-results-revenue-increased-nearly-60-year-ove-vtak-20181113monthly0.5https://www.biopharmawatch.com/news/VTAK/ra-medical-systems-announces-closing-of-initial-public-offering-and-full-exercise-of-the-u-vtak-20181001monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-and-sanyoseiko-expand-strategic-partnership-to-advance-commercializati-bjdx-20251009monthly0.5https://www.biopharmawatch.com/news/BJDX/immediate-release-date-bjdx-20250407monthly0.5https://www.biopharmawatch.com/news/BJDX/immediate-release-date-bjdx-20231227monthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-inc-reports-third-quarter-2022-financial-results-acton-massachusetts-bjdx-20221025monthly0.5https://www.biopharmawatch.com/news/BJDX/immediate-release-bluejay-diagnostics-inc-reports-second-quarter-2022-financial-results-ac-bjdx-20220726monthly0.5https://www.biopharmawatch.com/news/BJDX/immediate-release-bluejay-diagnostics-inc-reports-first-quarter-2022-financial-results-act-bjdx-20220420monthly0.5https://www.biopharmawatch.com/news/BJDX/immediate-release-bluejay-diagnostics-appoints-kenneth-fisher-as-chief-financial-officer-a-bjdx-20220324monthly0.5https://www.biopharmawatch.com/news/BJDX/immediate-release-bluejay-diagnostics-inc-reports-fourth-quarter-and-full-year-2021-financ-bjdx-20220310monthly0.5https://www.biopharmawatch.com/news/BJDX/immediate-release-date-bjdx-20220131monthly0.5https://www.biopharmawatch.com/news/BJDX/immediate-release-date-bjdx-20211216monthly0.5https://www.biopharmawatch.com/news/NUWE/source-nuwellis-inc-nuwe-20260616monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-first-quarter-2026-financial-results-minneapolis-nuwe-20260512monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-fourth-quarter-and-full-year-2025-financial-results-minneapolis-nuwe-20260310monthly0.5https://www.biopharmawatch.com/news/NUWE/minneapolis-mn-nuwe-20260226monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-announces-5-million-private-placement-and-warrant-inducement-transaction-priced-a-nuwe-20260129monthly0.5https://www.biopharmawatch.com/news/NUWE/minneapolis-mn-nuwe-20260123monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-reports-third-quarter-2025-results-and-continued-operational-momentum-company-del-nuwe-20251112monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-reports-second-quarter-2025-financial-results-and-business-highlights-minneap-nuwe-20250814monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-first-quarter-2025-financial-results-and-business-highlights-minnea-nuwe-20250513monthly0.5https://www.biopharmawatch.com/news/NUWE/investor-presentation-april-2025-making-aquadex-the-standard-of-care-for-fluid-management--nuwe-20250403monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-fourth-quarter-and-full-year-2024-financial-results-minneapolis-mn-nuwe-20250311monthly0.5https://www.biopharmawatch.com/news/NUWE/minneapolis-mn-nuwe-20250224monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-regains-compliance-with-nasdaq-listing-requirements-minneapolis-dec-19-2-024-nuwe-nuwe-20241219monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-third-quarter-2024-financial-results-and-recent-highlights-minneapo-nuwe-20241111monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-announces-exercise-of-warrants-for-5-1-million-of-gross-proceeds-minneapolis-nove-nuwe-20241107monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-announces-pricing-of-916-000-registered-direct-offering-priced-at-the-market-unde-nuwe-20240823monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-second-quarter-2024-financial-results-minneapolis-mn-nuwe-20240813monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-announces-pricing-of-2-0-million-offering-priced-at-the-market-under-nasdaq-rules-nuwe-20240724monthly0.5https://www.biopharmawatch.com/news/NUWE/july-2024-investor-presentation-aquadex-flexflow-and-aquadex-smartflow-are-registered-trad-nuwe-20240717monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-marks-first-commercial-sale-of-quelimmune-therapy-to-cincinnati-children-s-minnea-nuwe-20240717monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-announces-reverse-stock-split-minneapolis-nuwe-20240626monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-and-davita-extend-supply-and-collaboration-agreement-pilot-phase-pilot-collaborat-nuwe-20240606monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-first-quarter-2024-financial-results-minneapolis-mn-nuwe-20240507monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-announces-pricing-of-2-7-million-public-offering-minneapolis-nuwe-20240426monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-fourth-quarter-and-full-year-2023-financial-results-strengthens-its-nuwe-20240305monthly0.5https://www.biopharmawatch.com/news/NUWE/new-case-series-demonstrates-potential-of-aquadex-therapy-for-end-stage-liver-disease-pati-nuwe-20240206monthly0.5https://www.biopharmawatch.com/news/NUWE/for-investor-purposes-only-not-for-product-promotion-2024-nuwellis-inc-january-2024-invest-nuwe-20240109monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-third-quarter-2023-financial-results-minneapolis-mn-nuwe-20231107monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-announces-board-of-directors-transition-nuwellis-announces-appointment-of-dr-arch-nuwe-20231101monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-announces-pricing-of-2-25-million-public-offering-of-series-j-convertible-redeema-nuwe-20231013monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-provides-regulatory-update-on-seastar-medical-s-selective-cytopheretic-device-use-nuwe-20231010monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-announces-plan-for-cfo-transition-minneapolis-nuwe-20230808monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-second-quarter-2023-financial-results-minneapolis-mn-nuwe-20230808monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-pilot-agreement-with-davita-inc-supply-agreement-to-pilot-ultrafilt-nuwe-20230620monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-announces-the-appointment-of-mike-mccormick-to-its-board-of-directors-minneapolis-nuwe-20230605monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-first-quarter-2023-financial-results-minneapolis-mn-nuwe-20230509monthly0.5https://www.biopharmawatch.com/news/NUWE/march-2023-investor-presentation-2023-nuwellis-inc-safe-harbor-statement-forward-looking-s-nuwe-20230314monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-fourth-quarter-and-full-year-2022-financial-results-q4-revenue-up-4-nuwe-20230228monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-reports-preliminary-fourth-quarter-and-full-year-2022-revenue-results-minneapolis-nuwe-20230109monthly0.5https://www.biopharmawatch.com/news/NUWE/seastar-medical-and-nuwellis-enter-into-a-u-s-license-and-distribution-agreement-for-seast-nuwe-20221229monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-compliance-with-nasdaq-listing-requirements-minneapolis-nuwe-20221227monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-adjournment-of-special-meeting-of-stockholders-due-to-lack-of-quoru-nuwe-20221208monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-receives-180-day-extension-to-meet-nasdaq-minimum-bid-price-requirement-minne-nuwe-20221130monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-reports-third-quarter-2022-financial-results-minneapolis-mn-nuwe-20221108monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-announces-pricing-of-9-6-million-upsized-underwritten-public-offering-nuwe-20221014monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-announces-data-demonstrating-statistically-superior-clinical-benefit-of-aquadex-t-nuwe-20221003monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-announces-the-activation-of-new-sites-for-its-pivotal-reverse-hf-trial-reverse-hf-nuwe-20220927monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-second-quarter-2022-financial-results-minneapolis-mn-nuwe-20220809monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-adjournment-of-annual-meeting-of-stockholders-due-to-lack-of-quorum-nuwe-20220517monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-first-quarter-2022-financial-results-minneapolis-mn-nuwe-20220510monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-fourth-quarter-and-full-year-2021-financial-results-minneapolis-mn-nuwe-20220301monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-third-quarter-2021-financial-results-minneapolis-mn-nuwe-20211109monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-pricing-of-8-7-million-underwritten-public-offering-of-common-stock-nuwe-20210915monthly0.5https://www.biopharmawatch.com/news/NUWE/s-e-p-t-e-m-b-e-r-2-0-2-1-for-investor-purposes-only-not-for-product-promotion-2021-nuwell-nuwe-20210909monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-inc-announces-35-percent-increase-in-revenue-for-second-quarter-2021-over-previou-nuwe-20210810monthly0.5https://www.biopharmawatch.com/news/NUWE/nuwellis-announces-new-appointments-to-leadership-team-george-montague-to-serve-as-chief-f-nuwe-20210622monthly0.5https://www.biopharmawatch.com/news/NUWE/q1-2021-earnings-release-v8-nuwellis-inc-announces-18-percent-increase-in-revenue-for-firs-nuwe-20210511monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-shifts-commercial-focus-changes-name-to-nuwellis-the-new-name-reflects-the-company-s-c-nuwe-20210427monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-pricing-of-18-1-million-underwritten-public-offering-of-common-nuwe-20210317monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-49-5-percent-increase-in-revenue-for-fourth-quarter-2020-and-p-nuwe-20210302monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-appoints-nestor-jaramillo-jr-as-president-and-chief-executive-officer-nuwe-20210119monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-52-percent-increase-in-revenue-for-third-quarter-2020-and-prov-nuwe-20201110monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-receives-180-day-extension-to-meet-nasdaq-minimum-bid-price-requirement-nuwe-20200901monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-pricing-of-12-5-million-underwritten-public-offering-nuwe-20200819monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-14-percent-increase-in-revenue-for-second-quarter-2020-over-pr-nuwe-20200804monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-promotes-nestor-jaramillo-jr-to-president-and-chief-operating-officer-nuwe-20200625monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-adjournment-of-annual-meeting-of-stockholders-scheduled-to-rec-nuwe-20200522monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-34-percent-increase-in-revenue-for-first-quarter-2020-over-pre-nuwe-20200512monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-registered-direct-offering-priced-at-the-market-nuwe-20200501monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-pricing-of-registered-direct-offering-priced-at-the-market-nuwe-20200330monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-pricing-of-registered-direct-offering-nuwe-20200320monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-fourth-quarter-financial-results-and-provides-company-update-e-nuwe-20200303monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-pricing-of-8-4-million-underwritten-public-offering-nuwe-20200124monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-third-quarter-financial-results-and-provides-company-update-ed-nuwe-20191105monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-pricing-of-registered-direct-offering-priced-at-the-market-nuwe-20191104monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-pricing-of-registered-direct-offering-nuwe-20191023monthly0.5https://www.biopharmawatch.com/news/NUWE/corporate-presentation-nasdaq-chfs-nuwe-20190924monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-appoints-world-renowned-heart-failure-cardiologist-maria-rosa-costanzo-m-nuwe-20190904monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-53-percent-increase-in-revenues-for-second-quarter-2019-over-p-nuwe-20190806monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-17-percent-increase-in-revenues-for-first-quarter-2019-over-pr-nuwe-20190507monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-pricing-of-10-8-million-underwritten-public-offering-eden-prai-nuwe-20190308monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-80-revenue-growth-for-its-fourth-quarter-and-provides-company--nuwe-20190220monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-42-revenue-growth-for-its-third-quarter-and-provides-company-u-nuwe-20181106monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-27-revenue-growth-for-its-second-quarter-and-provides-company--nuwe-20180807monthly0.5https://www.biopharmawatch.com/news/NUWE/department-of-veterans-affairs-awards-a-6-5-million-blanket-purchase-agreement-to-chf-solu-nuwe-20180725monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-closing-of-common-stock-offering-nuwe-20180703monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-pricing-of-common-stock-offering-nuwe-20180629monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-25-percent-increase-in-revenues-for-first-quarter-2018-over-pr-nuwe-20180508monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-11-4-percent-revenue-growth-for-its-fourth-quarter-and-provide-nuwe-20180320monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-nuwe-20171128monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-21-revenue-growth-for-its-third-quarter-2017-and-provides-comp-nuwe-20171031monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-nuwe-20171030monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-announces-1-for-20-reverse-split-ratio-nuwe-20171012monthly0.5https://www.biopharmawatch.com/news/NUWE/chf-solutions-inc-announces-18-revenue-growth-for-its-second-quarter-and-provides-company--nuwe-20170808monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-company-name-change-to-chf-solutions-inc-and-new-nasdaq-ticker-sy-nuwe-20170523monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-first-quarter-2017-financial-results-and-provides-company-update--nuwe-20170509monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-closing-of-9-2-million-underwritten-public-offering-and-full-exer-nuwe-20170424monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-receives-nasdaq-listing-extension-nuwe-20170329monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-fourth-quarter-2016-financial-results-and-provides-company-update-nuwe-20170302monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-compliant-with-nasdaq-bid-price-requirement-nuwe-20170210monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-appoints-steve-brandt-and-matthew-e-likens-to-board-of-directors-eden-prair-nuwe-20170203monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-1-for-30-reverse-stock-split-eden-prairie-mn-nuwe-20170112monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-urges-stockholders-to-vote-for-proposals-at-january-9-special-stockholder-m-nuwe-20161221monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-receipt-of-nasdaq-extension-to-comply-with-listing-requirements-e-nuwe-20161122monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-receipt-of-additional-nasdaq-staff-determination-eden-prairie-mn-nuwe-20161117monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-third-quarter-2016-financial-results-and-provides-company-update--nuwe-20161108monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-exchange-and-3-8-million-offering-eden-prairie-mn-nuwe-20161031monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-strategic-realignment-eden-prairie-mn-nuwe-20160929monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-receipt-of-nasdaq-staff-determination-to-request-hearing-eden-pra-nuwe-20160923monthly0.5https://www.biopharmawatch.com/news/NUWE/company-update-investmnt-conference-minneapolis-mn-nuwe-20160824monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-second-quarter-2016-financial-results-and-provides-company-update-nuwe-20160809monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-strategic-acquisition-of-aquadex-product-line-from-baxter-and-a-n-nuwe-20160808monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-3-5-million-offering-nuwe-20160721monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-clinical-update-and-product-development-strategy-nuwe-20160711monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-first-quarter-2016-financial-results-and-provides-company-update--nuwe-20160503monthly0.5https://www.biopharmawatch.com/news/NUWE/this-image-cannot-currently-be-display-ed-corporate-update-march-2016-www-sunshineheart-co-nuwe-20160308monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-fourth-quarter-and-twelve-months-2015-financial-results-and-provi-nuwe-20160303monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-the-appointment-of-john-erb-as-its-chief-executive-officer-nuwe-20160302monthly0.5https://www.biopharmawatch.com/news/NUWE/first-amendment-to-loan-and-security-agreement-this-first-amendment-to-loan-and-security-a-nuwe-20151209monthly0.5https://www.biopharmawatch.com/news/NUWE/separation-and-release-agreement-this-separation-and-release-agreement-this-agreement-is-m-nuwe-20151130monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-third-quarter-2015-results-and-provides-corporate-update-eden-pra-nuwe-20151103monthly0.5https://www.biopharmawatch.com/news/NUWE/hemodynamicsof-c-pulse-aortic-counterpulsation-and-beyond-www-sunshineheart-com-dimitrios--nuwe-20151013monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-to-present-hemodynamic-data-supporting-mechanism-of-action-of-the-c-pulse-s-nuwe-20151008monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-fda-approves-key-protocol-amendment-for-counter-hf-us-pivotal-stu-nuwe-20150831monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-second-quarter-2015-results-and-provides-corporate-update-eden-pr-nuwe-20150804monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-provides-update-on-counter-hf-us-pivotal-study-for-c-pulse-heart-assist-sys-nuwe-20150723monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-exercises-2-million-milestone-advance-from-silicon-valley-bank-eden-prairie-nuwe-20150629monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-fda-approval-to-resume-enrollment-in-counter-hf-us-pivotal-study--nuwe-20150526monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-first-quarter-2015-results-and-provides-corporate-update-eden-pra-nuwe-20150505monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-provides-update-on-u-s-pivotal-study-of-c-pulse-heart-assist-system-eden-pr-nuwe-20150416monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-fourth-quarter-and-twelve-months-2014-financial-results-and-provi-nuwe-20150317monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-provides-update-on-u-s-pivotal-study-of-c-pulse-heart-assist-system-eden-pr-nuwe-20150306monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-receives-fda-approval-for-interim-analysis-of-u-s-pivotal-trial-of-c-pulse--nuwe-20150225monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-inc-secures-up-to-10-million-in-growth-capital-from-silicon-valley-bank-ede-nuwe-20150219monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-provides-corporate-update-eden-prairie-mn-nuwe-20150112monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-provides-clarification-following-third-quarter-2014-financial-results-confe-nuwe-20141103monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-to-provide-clinical-updates-from-the-north-american-feasibility-study-and-o-nuwe-20140916monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-provides-corporate-update-eden-prairie-mn-nuwe-20140113monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-to-provide-summary-of-initial-options-hf-data-and-additional-clinical-updat-nuwe-20131029monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-inc-prices-40-0-million-public-offering-of-common-shares-eden-prairie-mn-nuwe-20130919monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-inc-announces-proposed-public-offering-of-common-shares-eden-prairie-mn-nuwe-20130918monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-adopts-stockholder-rights-plan-eden-prairie-mn-june-x-2013-sunshine-heart-i-nuwe-20130614monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-inc-prices-13-1-million-public-offering-of-common-shares-eden-prairie-mn-an-nuwe-20130411monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-inc-announces-proposed-public-offering-of-common-shares-eden-prairie-mn-and-nuwe-20130410monthly0.5https://www.biopharmawatch.com/news/NUWE/asx-announcement-sunshine-heart-announces-donal-o-dwyer-will-retire-from-board-of-director-nuwe-20130402monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-appoints-jon-salveson-to-board-of-directors-eden-prairie-mn-and-sydney-aust-nuwe-20130313monthly0.5https://www.biopharmawatch.com/news/NUWE/asx-announcement-asx-grants-conditional-approval-to-delist-eden-prairie-mn-and-sydney-aust-nuwe-20130206monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-appoints-warren-watson-to-board-of-directors-seasoned-leader-in-cardiology--nuwe-20130130monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-enters-into-a-25-million-common-stock-purchase-agreement-with-aspire-capita-nuwe-20130115monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-provides-clinical-update-eden-prairie-mn-and-sydney-australia-nuwe-20130107monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-resignation-of-director-eden-prairie-mn-and-sydney-australia-13-n-nuwe-20121113monthly0.5https://www.biopharmawatch.com/news/NUWE/sunshine-heart-announces-3q12-financial-results-key-regulatory-and-financing-milestones-ac-nuwe-20121108monthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-inc-announces-effective-date-of-dual-class-share-structure-ji-an--upc-20260211monthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-inc-an-exempted-company-with-limited-liability-incorporated-in-th-upc-20250729monthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-inc-announces-share-consolidation-jiangxi-china-upc-20250320monthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-inc-receives-staff-determination-notice-from-nasdaq-related-to-de-upc-20250225monthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-inc-incorporated-in-the-cayman-islands-with-limited-liability-nas-upc-20250211monthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-inc-receives-nasdaq-delisting-notice-subject-to-hearing-request-j-upc-20250203monthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-inc-incorporated-in-the-cayman-islands-with-limited-liability-nas-upc-20250130monthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-inc-announces-15-million-registered-direct-offering-jiangxi-china-upc-20241209monthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-inc-announces-share-consolidation-jiangxi-china-upc-20241113monthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-inc-receives-nasdaq-notification-regarding-minimum-bid-price-defi-upc-20241101monthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-inc-and-subsidiaries-condensed-consolidated-balance-sheets-as-of-upc-20240920monthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-inc-incorporated-in-the-cayman-islands-with-limited-liability-nas-upc-20240903monthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-inc-and-subsidiaries-condensed-consolidated-balance-sheets-unaudi-upc-20230831monthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-inc-incorporated-in-the-cayman-islands-with-limited-liability-nas-upc-20230524monthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-inc-incorporated-in-the-cayman-islands-with-limited-liability-nas-upc-20220829monthly0.5https://www.biopharmawatch.com/news/UPC/index-to-financial-statements-universe-pharmaceuticals-inc-and-subsidiaries-table-of-conte-upc-20220816monthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-inc-receives-nasdaq-notification-regarding-minimum-bid-price-defi-upc-20220719monthly0.5https://www.biopharmawatch.com/news/UPC/management-s-discussion-and-analysis-of-financial-condition-and-results-of-operation-the-f-upc-20210802monthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-inc-announces-full-exercise-of-underwriter-s-over-allotment-optio-upc-20210331monthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-inc-announces-pricing-and-trading-of-initial-public-offering-ji-a-upc-20210323monthly0.5https://www.biopharmawatch.com/news/SXTC/management-s-discussion-and-analysis-of-financial-condition-and-results-of-operations-the--sxtc-20251231monthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-inc-incorporated-in-the-british-virgin-islands-with-limited-liab-sxtc-20250715monthly0.5https://www.biopharmawatch.com/news/SXTC/management-s-discussion-and-analysis-of-financial-condition-and-results-of-operations-the--sxtc-20250328monthly0.5https://www.biopharmawatch.com/news/SXTC/warrant-exchange-agreement-this-warrant-exchange-agreement-this-agreement-between-china-sx-sxtc-20250313monthly0.5https://www.biopharmawatch.com/news/SXTC/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-sxtc-20250121monthly0.5https://www.biopharmawatch.com/news/SXTC/employment-agreement-this-employment-agreement-the-agreement-is-entered-into-as-of-the-eff-sxtc-20250123monthly0.5https://www.biopharmawatch.com/news/SXTC/management-s-discussion-and-analysis-of-financial-condition-and-results-of-operations-the--sxtc-20240405monthly0.5https://www.biopharmawatch.com/news/SXTC/management-s-discussion-and-analysis-of-financial-condition-and-results-of-operations-the--sxtc-20230224monthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-inc-condensed-consolidated-financial-statements-for-the-six-mont-sxtc-20220114monthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-inc-178-taidong-road-north-taizhou-jiangsu-people-s-republic-of--sxtc-20210303monthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-inc-condensed-consolidated-financial-statements-for-the-six-mont-sxtc-20210128monthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-inc-condensed-consolidated-interim-financial-statements-unaudite-sxtc-20200522monthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-inc-condensed-consolidated-interim-financial-statements-unaudite-sxtc-20200422monthly0.5https://www.biopharmawatch.com/news/SXTC/employment-agreement-this-employment-agreement-the-agreement-is-entered-into-as-of-sxtc-20200308monthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-inc-178-taidong-road-north-taizhou-jiangsu-people-s-republic-of--sxtc-20200131monthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-inc-announces-pricing-of-a-15-million-pipe-financing-sxtc-20190417monthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-inc-announces-financial-results-for-the-six-months-ended-sxtc-20190328monthly0.5https://www.biopharmawatch.com/news/BNBX/bnb-plus-corp-bnbx-secures-initial-commitments-for-4-1m-in-strategic-financing-silvermine--bnbx-20260523monthly0.5https://www.biopharmawatch.com/news/BNBX/bnb-plus-corp-bnbx-appoints-james-haft-as-independent-board-director-digital-asset-and-inf-bnbx-20260205monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-rebrands-as-bnb-plus-corp-elects-josh-kruger-as-chairman-of-the-board-rebrand--bnbx-20251117monthly0.5https://www.biopharmawatch.com/news/BNBX/consulting-agreement-this-consulting-agreement-agreement-is-entered-into-as-of-bnbx-20251104monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-closes-up-to-58-million-private-placement-announces-initial-bnb-holdi-bnbx-20251022monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-to-begin-trading-under-new-ticker-bnbx-reflecting-digital-asset-treas-bnbx-20251007monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-announces-private-placement-of-up-to-58-million-to-initiate-bnb-treas-bnbx-20251001monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-third-quarter-fiscal-2025-financial-results-bnbx-20250814monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sharpens-strategic-focus-on-synthetic-dna-manufacturing-for-biotherapeutics-ap-bnbx-20250630monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-retirement-of-chairperson-and-ceo-dr-james-a-hayward-president-and-c-bnbx-20250617monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-1-for-15-reverse-stock-split-effective-bnbx-20250529monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-second-quarter-fiscal-2025-financial-results-therapeutic-dna-productio-bnbx-20250515monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-1-for-50-reverse-stock-split-effective-bnbx-20250314monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-first-quarter-fiscal-2025-financial-results-and-highlights-operational-bnbx-20250213monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-inc-empowering-the-genetic-medicines-revolution-nasdaq-apdn-january-2-bnbx-20250113monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-fourth-quarter-and-fiscal-year-2024-financial-results-announces-stra-bnbx-20241217monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-pricing-of-6-5-million-registered-direct-offering-and-concurrent-pri-bnbx-20241030monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-regains-compliance-with-nasdaq-minimum-bid-price-requirement-stony-brook-n-y-bnbx-20240918monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-third-quarter-fiscal-year-2024-financial-results-conference-call-web-bnbx-20240808monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-pricing-of-12-million-public-offering-stony-brook-n-y-bnbx-20240528monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-second-quarter-fiscal-year-2024-financial-results-bnbx-20240510monthly0.5https://www.biopharmawatch.com/news/BNBX/cell-free-enzymatic-dna-empowering-the-genetic-medicines-revolution-nasdaq-apdn-the-statem-bnbx-20240501monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-1-for-20-reverse-stock-split-bnbx-20240422monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-first-quarter-fiscal-year-2024-financial-results-company-on-track-to-bnbx-20240208monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-3-44-million-registered-direct-offering-priced-at-the-market-under-n-bnbx-20240131monthly0.5https://www.biopharmawatch.com/news/BNBX/a-next-generation-platform-for-genetic-medicine-manufacturing-nasdaq-apdn-bnbx-20240108monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-fourth-quarter-fiscal-year-2023-financial-results-conference-call-we-bnbx-20231207monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-third-quarter-fiscal-2023-financial-results-and-provides-corporate-upd-bnbx-20230810monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-acquires-rna-polymerase-developer-spindle-biotech-launches-lineaivt-tm-platfor-bnbx-20230713monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-second-quarter-fiscal-2023-financial-results-and-provides-corporate-up-bnbx-20230511monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-first-quarter-fiscal-2023-financial-results-total-revenues-of-5-3-mill-bnbx-20230209monthly0.5https://www.biopharmawatch.com/news/BNBX/fourth-quarter-and-fiscal-year-bnbx-20221214monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-third-quarter-fiscal-2022-financial-results-clinical-testing-services--bnbx-20220811monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-pricing-of-12-million-upsized-public-offering-priced-at-a-premium-to-bnbx-20220804monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-initiates-analytical-validation-of-pcr-based-diagnostic-test-specific-to-monke-bnbx-20220802monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-inc-the-future-of-rna-therapies-produced-with-lineardna-ivt-templates-bnbx-20220727monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-second-quarter-fiscal-2022-financial-results-revenues-at-record-6-1-mi-bnbx-20220512monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-pricing-of-4-2-million-registered-direct-offering-bnbx-20220222monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-first-quarter-fiscal-2022-financial-results-feature-record-quarterly-revenues--bnbx-20220210monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-fourth-quarter-and-full-fiscal-year-2021-financial-results-continuing--bnbx-20211209monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-third-quarter-fiscal-2021-revenues-increased-294-year-over-year-to-1-bnbx-20210812monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-second-fiscal-quarter-2021-financial-results-feature-384-year-over-year-growth-bnbx-20210513monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-appoints-clay-shorrock-as-chief-legal-officer-and-executive-director-of-busine-bnbx-20210401monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-first-fiscal-quarter-2021-revenues-at-upper-end-of-guided-range-report-bnbx-20210211monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-promotes-judith-murrah-to-chief-operating-officer-bnbx-20210120monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-closing-of-15-million-registered-direct-offering-priced-at-the-marke-bnbx-20210113monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-pricing-of-15-million-registered-direct-offering-priced-at-the-marke-bnbx-20210111monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-2020-year-end-and-fiscal-fourth-quarter-financial-results-receives-sec-bnbx-20201217monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-repayment-of-secured-convertible-notes-repayment-funded-by-warrant-e-bnbx-20201014monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-signs-master-services-agreement-with-stony-brook-university-hospital-for-covid-bnbx-20200929monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-fiscal-third-quarter-2020-financial-results-company-to-hold-conference-bnbx-20200806monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-2020-fiscal-second-quarter-financial-results-company-to-hold-conferenc-bnbx-20200514monthly0.5https://www.biopharmawatch.com/news/BNBX/infectious-disease-virtual-conference-may-2020-jim-hayward-ph-d-sc-d-president-ceo-james-h-bnbx-20200505monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-2020-fiscal-first-quarter-financial-results-company-to-hold-conference-bnbx-20200206monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-2019-year-end-and-fiscal-fourth-quarter-financial-results-company-to-h-bnbx-20191212monthly0.5https://www.biopharmawatch.com/news/BNBX/sent-via-electronic-delivery-bnbx-20191121monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-announces-closing-of-upsized-12-0-million-underwritten-public-offerin-bnbx-20191115monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-announces-pricing-of-upsized-12-0-million-underwritten-public-offerin-bnbx-20191113monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-announces-appointment-of-scott-l-anchin-to-board-of-directors-appoint-bnbx-20191108monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-announces-1-for-40-reverse-stock-split-common-stock-to-begin-trading--bnbx-20191101monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-receives-extension-from-nasdaq-bnbx-20191003monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-fiscal-third-quarter-2019-financial-results-company-to-hold-conference-bnbx-20190813monthly0.5https://www.biopharmawatch.com/news/BNBX/linearx-acquires-assets-and-intellectual-property-of-vitatex-platform-for-functional-isola-bnbx-20190808monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-raises-1-5-million-in-secured-convertible-notes-existing-notes-amended-as-part-bnbx-20190717monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-fiscal-second-quarter-2019-financial-results-company-to-hold-conferenc-bnbx-20190509monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-fiscal-first-quarter-2019-financial-results-company-to-hold-conference-bnbx-20190207monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-closing-of-2-75-million-public-offering-of-common-stock-and-warrants-bnbx-20181227monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-proposed-public-offering-of-common-stock-and-warrants-stony-brook-n--bnbx-20181219monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-selected-preliminary-unaudited-fiscal-2018-year-end-and-fourth-quart-bnbx-20181213monthly0.5https://www.biopharmawatch.com/news/BNBX/analyst-day-december-2018-2-forward-looking-statements-this-presentation-and-various-remar-bnbx-20181206monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-subsidiary-linearx-inc-signs-joint-development-agreement-with-takis-and-evviva-bnbx-20180920monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-closing-of-1-65-million-private-placement-of-secured-convertible-not-bnbx-20180904monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-fiscal-third-quarter-2018-financial-results-company-to-hold-conference-bnbx-20180813monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-fiscal-second-quarter-2018-financial-results-submits-drug-master-file--bnbx-20180503monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-signs-definitive-agreements-with-colorcon-for-molecular-tagging-in-the-pharmac-bnbx-20180405monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-fiscal-first-quarter-2018-financial-results-company-to-hold-conference-bnbx-20180208monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-reports-year-end-and-fiscal-fourth-quarter-results-company-to-hold-co-bnbx-20171228monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-4-8-million-registered-direct-offering-of-common-stock-bnbx-20171220monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-announces-selected-preliminary-unaudited-fiscal-fourth-quarter-and-year-end-re-bnbx-20171215monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-reports-fiscal-third-quarter-2017-financial-results-company-to-hold-conference-bnbx-20170810monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-raises-1-8-million-in-private-placement-led-by-executive-officers-boa-bnbx-20170628monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-signs-new-licensing-agreement-with-himatsingka-america-new-agreement--bnbx-20170627monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-reports-fiscal-second-quarter-2017-financial-results-company-to-hold--bnbx-20170511monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-reports-fiscal-first-quarter-2017-financial-results-company-to-hold-c-bnbx-20170209monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-reports-fiscal-fourth-quarter-and-year-end-results-company-to-hold-co-bnbx-20161206monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-announces-5-million-private-placement-stony-brook-n-y-bnbx-20161102monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-appoints-robert-b-catell-to-its-board-of-directors-chairman-of-new-yo-bnbx-20161014monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-reports-fiscal-third-quarter-2016-results-company-to-hold-conference--bnbx-20160811monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-reports-fiscal-second-quarter-2016-financial-results-company-to-hold--bnbx-20160512monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-reports-fiscal-first-quarter-2016-financial-results-company-to-hold-c-bnbx-20160210monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-reports-bnbx-20151215monthly0.5https://www.biopharmawatch.com/news/BNBX/fiscal-third-quarter-revenues-bnbx-20150811monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-quarterly-revenues-increase-138-year-over-year-in-second-quarter-fisc-bnbx-20150512monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-inc-announces-closing-of-12-0-million-public-offering-and-partial-exe-bnbx-20150401monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-reports-fiscal-first-quarter-2015-results-record-quarterly-revenue-in-bnbx-20150210monthly0.5https://www.biopharmawatch.com/news/BNBX/press-release-for-immediate-release-bnbx-20141209monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-inc-announces-closing-of-9-1-million-underwritten-offering-stony-broo-bnbx-20141117monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-announces-reverse-stock-bnbx-20141029monthly0.5https://www.biopharmawatch.com/news/BNBX/press-release-bnbx-20140828monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-inc-50-health-sciences-drive-stony-brook-new-york-11790-631-240-8800-bnbx-20140715monthly0.5https://www.biopharmawatch.com/news/BNBX/missile-defense-agency-awards-applied-dna-sciences-phase-ii-sbir-contract-for-counterfeit--bnbx-20140715monthly0.5https://www.biopharmawatch.com/news/BNBX/press-release-bnbx-20111107monthly0.5https://www.biopharmawatch.com/news/BNBX/martin-guitar-to-protect-against-counterfeiting-via-partnership-with-applied-dna-sciences--bnbx-20110719monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-and-disc-graphics-sign-agreement-to-protect-packaging-in-north-americ-bnbx-20110714monthly0.5https://www.biopharmawatch.com/news/BNBX/about-apdn-apdn-sells-patented-dna-security-solutions-to-protect-products-brands-and-intel-bnbx-20110623monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-earns-its-stripes-textile-based-signature-dna-anti-counterfeiting-pro-bnbx-20100629monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-averages-35-growth-over-last-four-quarters-announces-fourth-quarter-a-bnbx-20081216monthly0.5https://www.biopharmawatch.com/news/BNBX/stockholder-newsletter-november-2008-to-our-stockholders-apdn-highlights-in-the-world-toda-bnbx-20081110monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-signs-250-000-feasibility-study-to-develop-cotton-marker-protecting-5-bnbx-20070702monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-enters-printing-ink-markets-signs-agreement-with-printcolor-screen-lt-bnbx-20070604monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-enters-textile-markets-with-champion-thread-company-bnbx-20070510monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-and-iimak-enter-joint-development-and-marketing-agreement-stony-brook-bnbx-20070424monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-acquires-applied-dna-sciences-europe-ltd-bnbx-20070404monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-logo-bnbx-20070323monthly0.5https://www.biopharmawatch.com/news/BNBX/e65898-ex99-1-txt-press-release-applied-dna-sciences-logo-applied-dna-sciences-acquires-li-bnbx-20070208monthly0.5https://www.biopharmawatch.com/news/BNBX/e65717-ex99-1-txt-press-release-applied-dna-sciences-logo-security-solutions-applied-dna-s-bnbx-20060509monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-launches-signature-tm-botanical-dna-authentication-program-stony-broo-bnbx-20060505monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-announces-resignations-and-appointment-of-new-directors-bnbx-20060323monthly0.5https://www.biopharmawatch.com/news/BNBX/from-the-desk-of-r-b-rob-hutchison-3489-canterbury-place-surrey-bc-canada-v3s-0g8-to-the-b-bnbx-20050715monthly0.5https://www.biopharmawatch.com/news/BNBX/applied-dna-sciences-inc-9229-west-sunset-blvd-suite-830-los-angeles-ca-90069-tel-310-860--bnbx-20040818monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-not-for-distribution-to-united-states-newswire-services-or-for-d-imcc-20221011monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-im-cannabis-closes-second-tranche-of-non-brokered-private-placem-imcc-20221005monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-date-imcc-20220912monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-not-for-distribution-to-united-states-newswire-services-or-for-d-imcc-20220824monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-6-certificate-of-compliance-to-canadian-securities-exchange-imcc-20220822monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-date-imcc-20220818monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-510-burrard-st-3rd-floor-vancouver-bc-v6c-3b9-imcc-20220812monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-focus-medical-s-import-of-400-kilograms-of-premium-indoor-grown-drie-imcc-20220119monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-corp-appoints-rinat-efrima-as-new-chief-executive-officer-of-imc-holdings-the--imcc-20220113monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-7-monthly-progress-report-name-of-listed-issuer-im-cannabis-imcc-20220110monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-11-notice-of-proposed-stock-option-grant-or-amendment-name--imcc-20211230monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-7-monthly-progress-report-name-of-listed-issuer-im-cannabis-imcc-20211207monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-to-launch-wagners-brand-in-germany-im-cannabis-expects-to-export-premium-indoo-imcc-20211207monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-9-notice-of-issuance-or-proposed-issuance-of-listed-securit-imcc-20211201monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-to-acquire-oranim-jerusalem-s-leading-medical-cannabis-pharmacy-transaction-po-imcc-20211201monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-focus-medical-s-receipt-of-israeli-ministry-of-health-import-permit--imcc-20211129monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-corp-condensed-interim-consolidated-financial-statements-as-of-september-30-20-imcc-20211124monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-fourth-installment-of-shares-in-connection-with-the-panaxia-transact-imcc-20211123monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-third-quarter-2021-financial-results-and-provides-outlook-and-busine-imcc-20211115monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-9-notice-of-issuance-or-proposed-issuance-of-listed-securit-imcc-20211122monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-7-monthly-progress-report-name-of-listed-issuer-im-cannabis-imcc-20211105monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-9-notice-of-issuance-or-proposed-issuance-of-listed-securit-imcc-20211020monthly0.5https://www.biopharmawatch.com/news/IMCC/imc-announces-third-installment-of-shares-in-connection-with-the-panaxia-transaction-toron-imcc-20211020monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-7-monthly-progress-report-name-of-listed-issuer-im-cannabis-imcc-20211006monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-9-notice-of-issuance-or-proposed-issuance-of-listed-securit-imcc-20210928monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-9-notice-of-issuance-or-proposed-issuance-of-listed-securit-imcc-20210907monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-im-cannabis-corp-condensed-interim-consolidated-financial-statem-imcc-20210817monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-7-monthly-progress-report-name-of-listed-issuer-im-cannabis-imcc-20210809monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-imc-announces-results-of-its-annual-general-and-special-meeting--imcc-20210803monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-imc-accelerates-its-israeli-retail-position-through-acquisition--imcc-20210728monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-im-cannabis-provides-update-on-german-operations-and-financial-o-imcc-20210723monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-9-notice-of-issuance-or-proposed-issuance-of-listed-securit-imcc-20210709monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-im-cannabis-closes-acquisition-of-mym-nutraceuticals-toronto-can-imcc-20210709monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-7-monthly-progress-report-name-of-listed-issuer-im-cannabis-imcc-20210708monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-mym-shareholders-overwhelmingly-approve-plan-of-arrangement-with-imcc-20210709monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-im-cannabis-corp-annual-general-and-special-meeting-of-sharehold-imcc-20210701monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-im-cannabis-proposed-acquisition-of-mym-receives-positive-recomm-imcc-20210628monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-im-cannabis-clinical-survey-confirms-effectiveness-of-proprietar-imcc-20210617monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-5-quarterly-listing-statement-name-of-listed-issuer-im-cann-imcc-20210611monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-im-cannabis-announces-supply-agreement-with-canadian-lp-the-flow-imcc-20210607monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-imc-reports-first-closing-of-the-panaxia-acquisition-and-provide-imcc-20210602monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-11-notice-of-proposed-stock-option-grant-or-amendment-name--imcc-20210520monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-im-cannabis-corp-interim-condensed-consolidated-financial-statem-imcc-20210518monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-im-cannabis-announces-closing-of-us-35-million-equity-financing--imcc-20210510monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-im-cannabis-announces-pricing-of-proposed-public-offering-of-sec-imcc-20210505monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-imcc-20210503monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-im-cannabis-acquires-israel-s-largest-retail-and-online-pharmacy-imcc-20210430monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-51-102f4-business-acquisition-report-item-1-identity-of-com-imcc-20210429monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-2020-annual-report-im-cannabis-corp-consolidated-financial-state-imcc-20210426monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--imcc-20210331monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-9-notice-of-issuance-or-proposed-issuance-of-listed-securit-imcc-20210401monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-option-agreement-this-option-agreement-the-agreement-is-made-and-imcc-20210402monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--imcc-20210318monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-form-11-notice-of-proposed-stock-option-grant-or-amendment-name--imcc-20210324monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-imc-closes-acquisition-of-trichome-establishing-global-growth-pl-imcc-20210318monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-second-amending-agreement-this-second-amending-agreement-the-sec-imcc-20210314monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-imc-announces-filing-of-preliminary-short-form-base-shelf-prospe-imcc-20210312monthly0.5https://www.biopharmawatch.com/news/IMCC/filed-by-newsfilecorp-com-supplemental-warrant-indenture-this-second-supplemental-warrant--imcc-20210309monthly0.5https://www.biopharmawatch.com/news/ONCO/july-16-2025-onconetix-and-ocuvex-therapeutics-announce-execution-of-definitive-merger-agr-onco-20250716monthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-inc-consulting-agreement-this-consulting-agreement-the-agreement-shall-be-effect-onco-20250228monthly0.5https://www.biopharmawatch.com/news/ONCO/settlement-agreement-this-settlement-agreement-the-settlement-agreement-is-entered-into-as-onco-20250115monthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-inc-formerly-known-as-blue-water-biotech-inc-and-blue-water-vaccines-inc-the-com-onco-20240905monthly0.5https://www.biopharmawatch.com/news/ONCO/release-of-claims-as-used-in-this-release-of-claims-this-release-the-term-claims-will-incl-onco-20240613monthly0.5https://www.biopharmawatch.com/news/ONCO/proteomedix-ag-financial-statements-and-independent-auditors-report-for-the-years-ended-onco-20240227monthly0.5https://www.biopharmawatch.com/news/ONCO/release-of-claims-i-dr-neil-j-campbell-understand-and-of-my-own-free-will-enter-into-this--onco-20240112monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-biotech-acquires-proteomedix-as-part-of-transformation-to-commercial-stage-onco-onco-20231218monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-biotech-signs-non-binding-term-sheet-to-acquire-a-commercial-stage-oncology-com-onco-20231102monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-biotech-issues-letter-to-shareholders-blue-water-biotech-issues-letter-to-share-onco-20231030monthly0.5https://www.biopharmawatch.com/news/ONCO/general-release-of-claims-i-jon-garfield-hereby-grant-this-general-release-of-claims-relea-onco-20231010monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-biotech-inc-announces-notification-from-nasdaq-related-to-delayed-quarterly-rep-onco-20230828monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-biotech-and-copay-consultants-collaborate-to-build-copay-assistance-programs-fo-onco-20230810monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-biotech-announces-closing-of-warrant-exercise-and-issuance-of-new-warrants-in-a-onco-20230803monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-biotech-announces-exercise-of-warrants-and-issuance-of-new-warrants-in-a-privat-onco-20230801monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-biotech-and-knipper-health-join-forces-to-distribute-samples-for-entadfi-and-zo-onco-20230731monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-biotech-teams-with-upscripthealth-to-launch-telemedicine-platform-for-benign-pr-onco-20230725monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-biotech-issues-ceo-shareholder-letter-providing-update-on-commercial-launch-act-onco-20230717monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-biotech-teams-with-advantage-point-solutions-to-provide-healthcare-payer-covera-onco-20230711monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-biotech-secures-license-from-ohio-state-board-of-pharmacy-to-operate-as-pharmac-onco-20230706monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-biotech-teams-with-bfw-advertising-to-market-and-advertise-commercial-product-p-onco-20230706monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-biotech-announces-preclinical-data-supporting-immunogenicity-of-novel-monkeypox-onco-20230628monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-biotech-collaborates-with-iqvia-to-build-medical-sales-representative-team-to-m-onco-20230621monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-biotech-expands-commercial-portfolio-by-acquiring-six-fda-approved-drugs-across-onco-20230614monthly0.5https://www.biopharmawatch.com/news/ONCO/corporate-overview-entadfi-opportunity-may-2023-nasdaq-bwv-forward-looking-statements-2-th-onco-20230515monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-biotech-reports-first-quarter-2023-financial-results-and-recent-business-highli-onco-20230512monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-biotech-to-present-corporate-overview-and-entadfi-launch-plan-at-the-jmp-securi-onco-20230510monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-biotech-to-participate-in-the-american-urological-association-annual-meeting-20-onco-20230425monthly0.5https://www.biopharmawatch.com/news/ONCO/moderator-00-00-hello-and-thank-you-for-standing-by-my-name-is-regina-and-i-will-be-your-c-onco-20230424monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-announces-acquisition-of-entadfi-an-fda-approved-benign-prostatic-hyperplasia-a-onco-20230420monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-vaccines-announces-signing-of-sponsored-research-agreement-with-the-university--onco-20230412monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-vaccines-reports-year-2022-financial-results-and-recent-business-highlights-onco-20230309monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-vaccines-announces-appointment-of-seasoned-public-market-and-private-equity-inv-onco-20230117monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-vaccines-to-present-at-biotech-showcase-2023-during-the-41-st-annual-j-p-morgan-onco-20230109monthly0.5https://www.biopharmawatch.com/news/ONCO/january-2023-nasdaq-bwv-the-presentation-the-presentation-has-been-prepared-by-blue-water--onco-20230106monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-vaccines-announces-institutional-research-coverage-by-two-notable-healthcare-fo-onco-20221212monthly0.5https://www.biopharmawatch.com/news/ONCO/mucosal-vaccines-to-protect-against-mucosal-infections-may-be-the-right-answer-to-address--onco-20221207monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-vaccines-to-present-update-on-novel-live-attenuated-intranasally-delivered-stre-onco-20221201monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-vaccines-announces-exclusive-global-license-agreement-for-chlamydia-vaccine-can-onco-20221121monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-vaccines-reports-third-quarter-2022-financial-results-and-recent-business-highl-onco-20221110monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-vaccines-announces-appointment-of-vuk-jeremi-previous-chair-of-the-council-of-e-onco-20221108monthly0.5https://www.biopharmawatch.com/news/ONCO/intranasal-live-attenuated-pneumococcus-vaccine-to-protect-against-pneumonia-aom-and-poten-onco-20221013monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-vaccines-announces-plans-to-evaluate-efficacy-of-streptococcus-pneumoniae-vacci-onco-20221011monthly0.5https://www.biopharmawatch.com/news/ONCO/september-2022-nasdaq-bwv-the-presentation-the-presentation-has-been-prepared-by-blue-wate-onco-20220912monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-vaccines-announces-appointment-of-retired-deloitte-consulting-senior-managing-d-onco-20220822monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-vaccines-announces-10-million-private-placement-priced-at-the-market-under-nasd-onco-20220809monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-vaccines-announces-signing-of-sponsored-research-agreement-with-cincinnati-chil-onco-20220720monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-vaccines-announces-sponsored-research-agreement-amendment-to-continue-funding-u-onco-20220531monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-vaccines-presents-new-data-supporting-universal-influenza-vaccine-candidate-at--onco-20220421monthly0.5https://www.biopharmawatch.com/news/ONCO/universal-influenza-vaccine-program-bwv-101-developing-a-single-vaccine-to-protect-against-onco-20220420monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-vaccines-announces-closing-of-8-million-private-placement-priced-at-the-market--onco-20220420monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-vaccines-announces-8-million-private-placement-priced-at-the-market-under-nasda-onco-20220418monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-vaccines-announces-publication-in-nano-research-supporting-novel-s-p-vaccine-pl-onco-20220322monthly0.5https://www.biopharmawatch.com/news/ONCO/blue-water-vaccines-announces-pricing-of-approximate-20m-initial-public-offering-cincinnat-onco-20220217monthly0.5https://www.biopharmawatch.com/news/PRFX/investor-presentation-july-2022-2-painreform-ltd-www-painreform-com-post-operative-pain-ma-prfx-20220729monthly0.5https://www.biopharmawatch.com/news/PRFX/painreform-announces-6-0-million-private-placement-prfx-20210308monthly0.5https://www.biopharmawatch.com/news/PRFX/notice-of-extraordinary-general-meeting-of-shareholders-to-be-held-on-february-23-2021-to--prfx-20210119monthly0.5https://www.biopharmawatch.com/news/PRFX/painreform-appoints-rita-keynan-as-vice-president-of-pharmaceutical-operations-prfx-20210106monthly0.5https://www.biopharmawatch.com/news/PRFX/investor-presentation-january-2021-2-painreform-ltd-www-painreform-com-post-operative-pain-prfx-20210105monthly0.5https://www.biopharmawatch.com/news/PRFX/painreform-announces-appointment-of-lotus-clinical-research-as-cro-for-phase-3-clinical-tr-prfx-20210104monthly0.5https://www.biopharmawatch.com/news/PRFX/painreform-appoints-senior-pharmaceutical-executive-and-finance-veteran-ilan-hadar-as-chie-prfx-20201123monthly0.5https://www.biopharmawatch.com/news/PRFX/painreform-welcomes-successful-healthcare-and-capital-markets-executive-dr-ellen-baron-to--prfx-20201111monthly0.5https://www.biopharmawatch.com/news/PRFX/painreform-welcomes-senior-pharmaceutical-executive-and-venture-capitalist-augustine-lawlo-prfx-20201109monthly0.5https://www.biopharmawatch.com/news/PRFX/painreform-highlights-surgical-advantages-of-prf-110-studies-demonstrate-unique-benefits-o-prfx-20201019monthly0.5https://www.biopharmawatch.com/news/PRFX/painreform-ltd-condensed-financial-statements-as-of-june-30-2020-unaudited-u-s-dollars-in--prfx-20200930monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-doses-first-patient-in-phase-iia-clinical-trial-of-onp-002-for-mild-traumatic-br-ogen-20260331monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-q3-2025-shareholder-update-building-on-solid-ground-from-vision-to-execution-res-ogen-20251112monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-regains-full-nyse-american-compliance-company-resolves-stockholder-equity-defici-ogen-20251021monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-q2-2025-shareholder-update-advancing-brain-first-recovery-platform-toward-clinic-ogen-20250811monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-notification-of-noncompliance-with-additional-nyse-american-contin-ogen-20240419monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-appoints-james-kelly-md-chief-medical-officer-to-lead-phase-ii-clinical-trials-f-ogen-20240318monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-closing-of-public-offering-ogen-20240301monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-pricing-of-public-offering-ogen-20240227monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-proposed-public-offering-sarasota-fla-ogen-20240227monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-leadership-transition-ogen-20240212monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-expiration-of-its-investment-banking-engagement-agreement-sarasota-ogen-20240207monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-preparing-for-phase-ii-clinical-trials-to-treat-concussion-ogen-20240205monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-termination-of-at-the-market-offering-program-ogen-20240123monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-completes-acquisition-of-odyssey-health-s-neurological-assets-ogen-20240102monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-issues-update-to-shareholders-tampa-fla-ogen-20231102monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-to-acquire-odyssey-health-s-neurological-drug-technology-pipeline-including-conc-ogen-20231005monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-enters-into-agreement-with-lantern-bioworks-for-replacement-therapy-assets-poten-ogen-20230929monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-private-placement-tampa-fl-ogen-20230807monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-project-to-develop-a-variant-agnostic-protein-antigen-for-use-in-its-covid-19-in-ogen-20230605monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-positive-results-in-several-lantibiotics-compounds-against-mrsa-and-vr-ogen-20230314monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-appoints-janet-huffman-as-chief-financial-officer-strengthening-executive-leader-ogen-20230308monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-enters-into-an-exclusive-global-license-agreement-with-inspirevax-to-develop-int-ogen-20230301monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-receives-nyse-american-notice-tampa-fl-ogen-20221220monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-new-chair-tampa-fl-ogen-20221219monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-issues-letter-to-shareholders-tampa-fla-ogen-20220930monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-favorable-preliminary-toxicology-data-for-intranasal-covid-19-vaccine--ogen-20220824monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-appoints-seasoned-vaccine-executive-kimberly-murphy-as-president-and-chief-execu-ogen-20220623monthly0.5https://www.biopharmawatch.com/news/OGEN/may-17-2022-oragenics-issues-letter-to-shareholders-tampa-fla-ogen-20220517monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-extends-collaboration-to-develop-vaccines-against-future-variants-of-coronavirus-ogen-20220406monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-engages-kbi-biopharma-to-support-development-of-intranasal-covid-19-vaccine-cand-ogen-20220310monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-adjournment-of-annual-meeting-of-shareholders-due-to-lack-of-quorum-ta-ogen-20220126monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-positive-covid-19-challenge-study-results-evaluating-multiple-formulat-ogen-20211201monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-a-nnounces-adjournment-of-annual-meeting-of-shareholders-due-to-lack-of-quorum-t-ogen-20211123monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-awarded-a-250-000-grant-from-the-national-institute-of-general-medical-sciences--ogen-20211004monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-initiates-covid-19-challenge-study-evaluating-multiple-formulations-of-its-sars--ogen-20210915monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-sars-cov-2-spike-protein-produces-neutralizing-antibodies-in-mice-with-intramusc-ogen-20210830monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-postponement-of-annual-meeting-of-shareholders-tampa-fla-ogen-20210824monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-enters-into-licensing-agreement-with-the-national-research-council-of-canada-to--ogen-20210727monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-adjournment-of-annual-meeting-of-shareholders-due-to-lack-of-quorum-ta-ogen-20210701monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-issues-letter-to-shareholders-executive-chairman-affirms-company-direction-with--ogen-20210518monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announce-changes-in-management-and-board-of-directors-tampa-fla-ogen-20210503monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-recent-capital-raise-and-warrant-exercises-totaling-21-9-million-and-t-ogen-20210212monthly0.5https://www.biopharmawatch.com/news/OGEN/sars-cov-2-spike-protein-licensed-by-oragenics-from-the-nih-demonstrates-protective-immuni-ogen-20210202monthly0.5https://www.biopharmawatch.com/news/OGEN/january-7-2021-oragenics-enters-into-material-transfer-agreement-with-adjuvance-technologi-ogen-20210107monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-closing-of-6-5-ogen-20201229monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-6-5-million-registered-direct-offering-tampa-fl-ogen-20201224monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-closing-of-6-0-ogen-20201124monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-prices-5-25-ogen-20201120monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-proposed-underwritten-public-offering-ogen-20201119monthly0.5https://www.biopharmawatch.com/news/OGEN/fda-broadly-supports-oragenics-pre-ind-development-program-for-its-sars-cov-2-vaccine-re-a-ogen-20201006monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-provides-an-update-on-funding-for-its-sars-cov-2-vaccine-tampa-ogen-20200928monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-to-present-at-the-h-c-wainwright-22nd-annual-global-virtual-investment-confe-ogen-20200911monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-signs-process-development-and-manufacturing-agreement-with-avid-bioservices-for--ogen-20200820monthly0.5https://www.biopharmawatch.com/news/OGEN/preclinical-study-shows-sars-cov-2-spike-protein-licensed-by-oragenics-from-the-nih-produc-ogen-20200722monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-provides-update-on-sars-cov-2-covid-19-program-terminates-ag013-oral-mucositis-d-ogen-20200710monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-acquires-noachis-terra-inc-to-develop-its-terracov2-nih-generated-sars-cov-2-cov-ogen-20200504monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-early-top-line-results-of-phase-2-clinical-trial-of-ag013-for-oral-ogen-20200415monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-completion-of-enrollment-of-its-phase-2-clinical-trial-for-ag013-ogen-20191202monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-ogen-20191022monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-presents-interim-data-on-the-ag013-phase-2-clinical-trial-at-the-european-societ-ogen-20190930monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-phase-2-clinical-trial-of-ag013-reaches-enrollment-of-158-ogen-20190925monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-to-present-interim-data-on-ag013-ogen-20190923monthly0.5https://www.biopharmawatch.com/news/OGEN/safe-harbor-statement-certain-statements-made-in-this-presentation-include-forward-looking-ogen-20190901monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-closing-of-12-5-million-underwritten-public-offering-ogen-20190325monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-pricing-of-12-5-ogen-20190321monthly0.5https://www.biopharmawatch.com/news/OGEN/organics-announces-proposed-underwritten-public-offering-ogen-20190320monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-enrollment-of-60-th-patient-in-clinical-trial-ogen-20190315monthly0.5https://www.biopharmawatch.com/news/OGEN/safe-harbor-statement-certain-statements-made-in-this-presentation-include-forward-looking-ogen-20181113monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-receives-clearance-to-enroll-patients-in-belgium-into-its-phase-2-clinical-t-ogen-20181017monthly0.5https://www.biopharmawatch.com/news/OGEN/safe-harbor-statement-certain-statements-made-in-this-presentation-include-forward-looking-ogen-20180930monthly0.5https://www.biopharmawatch.com/news/OGEN/safe-harbor-statement-certain-statements-made-in-this-presentation-include-forward-looking-ogen-20180925monthly0.5https://www.biopharmawatch.com/news/OGEN/safe-harbor-statement-certain-statements-made-in-this-presentation-include-forward-looking-ogen-20180808monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-closing-of-13-8-million-underwritten-public-offering-and-full-exer-ogen-20180717monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-pricing-of-12-million-underwritten-public-offering-ogen-20180713monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-reports-positive-interim-safety-analysis-results-from-its-phase-2-clinical-trial-ogen-20180530monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-and-texas-a-m-university-system-granted-u-s-patent-for-lantibiotic-mu1140-ogen-20180523monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-pricing-of-1-8-million-registered-direct-offering-ogen-20180406monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-reverse-stock-split-ogen-20180108monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-regains-compliance-with-nyse-american-continued-listing-standards-ogen-20171113monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-closing-of-3-3-million-preferred-stock-private-placement-and-3-4-milli-ogen-20171109monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-completion-of-second-closing-of-3-0-million-preferred-stock-private-pl-ogen-20170726monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-notification-of-noncompliance-with-additional-nyse-mkt-continued-l-ogen-20170609monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-3-0-million-preferred-stock-private-placement-and-2-4-million-loan-tam-ogen-20170511monthly0.5https://www.biopharmawatch.com/news/OGEN/safe-harbor-statement-certain-statements-made-in-this-presentation-include-forward-looking-ogen-20170418monthly0.5https://www.biopharmawatch.com/news/OGEN/safe-harbor-statement-certain-statements-made-in-this-presentation-include-forward-looking-ogen-20170131monthly0.5https://www.biopharmawatch.com/news/OGEN/u-s-fda-grants-fast-track-designation-for-the-development-of-oragenics-ag013-for-oral-muco-ogen-20161121monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-receives-supportive-fda-feedback-for-initiating-a-phase-2-study-protocol-for-ora-ogen-20160830monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-selects-new-lantibiotic-for-further-development-in-clostridium-difficile-infecti-ogen-20160823monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-nyse-mkt-acceptance-of-its-plan-of-compliance-ogen-20160719monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-closing-of-4-667-million-private-placement-tampa-fl-ogen-20160630monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-completion-of-sale-of-consumer-probiotic-business-tampa-fl-ogen-20160627monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-entry-into-definitive-agreement-to-sell-consumer-probiotic-business-ta-ogen-20160623monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-new-president-chief-executive-officer-and-member-of-the-board-of-direc-ogen-20160606monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-notification-of-noncompliance-with-nyse-mkt-continued-listing-stan-ogen-20160513monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-reports-positive-in-vivo-antibiotic-efficacy-data-in-critical-animal-study-lead--ogen-20150728monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-shareholders-re-elect-existing-board-of-directors-approve-and-ratify-other-propo-ogen-20150717monthly0.5https://www.biopharmawatch.com/news/OGEN/intrexon-and-oragenics-expand-collaboration-to-pursue-development-of-biotherapeutics-for-t-ogen-20150610monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-to-explore-strategic-alternatives-for-its-otc-probiotic-products-business-ta-ogen-20141222monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-change-in-management-and-board-of-directors-for-immediate-release--ogen-20141030monthly0.5https://www.biopharmawatch.com/news/OGEN/certain-statements-made-in-this-presentation-include-forward-looking-actions-that-oragenic-ogen-20140116monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-completion-of-public-offering-of-common-stock-tampa-fla-ogen-20131120monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-prices-public-offering-of-common-stock-tampa-fla-ogen-20131115monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-proposed-public-offering-of-common-stock-tampa-ogen-20131114monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-breakthrough-antibiotic-analog-generation-in-intrexon-collaboration-ma-ogen-20131031monthly0.5https://www.biopharmawatch.com/news/OGEN/certain-statements-made-in-this-presentation-include-forward-looking-actions-that-oragenic-ogen-20131001monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-and-intrexon-to-develop-genetically-modified-probiotics-new-exclusive-channel-co-ogen-20131001monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-collaboration-demonstrates-initial-success-in-the-second-phase-of-lantibiotics-p-ogen-20130826monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-approval-of-common-stock-listing-on-nyse-mkt-tampa-fla-ogen-20130408monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-completion-of-13-million-private-placement-financing-and-conversion-of-ogen-20120802monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-12-86-million-private-placement-financing-tampa-fla-ogen-20120731monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-and-intrexon-announce-worldwide-exclusive-collaboration-for-lantibiotics-for-imm-ogen-20120606monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-the-completion-of-2-5-million-of-secured-debt-funding-and-exchange-of--ogen-20120326monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-appointment-of-michael-sullivan-as-chief-financial-officer-for-imm-ogen-20120202monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-fourth-amendment-to-unsecured-revolving-line-of-credit-to-provide-500--ogen-20111214monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-retirement-of-dr-jeffrey-hillman-for-immediate-release-tampa-fl-ogen-20111014monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-third-amendment-to-unsecured-revolving-line-of-credit-to-provide-up-to-ogen-20110630monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-new-president-chief-executive-officer-and-member-of-the-board-of-direc-ogen-20110524monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-adds-independent-director-dr-alan-dunton-to-its-board-of-directors-for-immediate-ogen-20110404monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-second-amendment-to-unsecured-revolving-line-of-credit-to-provide--ogen-20110207monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-launches-evoraplus-oral-care-probiotics-into-gnc-stores-for-immediate-releas-ogen-20100907monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-entering-into-agreement-to-provide-2-0mm-equity-financing-which-includ-ogen-20100707monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-adds-two-new-independent-board-members-dr-frederick-w-telling-and-charles-l-pope-ogen-20100607monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-and-ricci-pharma-sign-agreement-expected-to-provide-evoraplus-and-evorakids--ogen-20100412monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-4-th-quarter-update-oragenics-is-scheduled-to-sell-its-acclaimed-probiotic-o-ogen-20091216monthly0.5https://www.biopharmawatch.com/news/OGEN/unassociated-document-for-immediate-release-oragenics-announces-5-000-000-in-new-financing-ogen-20090630monthly0.5https://www.biopharmawatch.com/news/OGEN/corporate-overview-january-2009-this-presentation-does-not-constitute-an-offering-of-any-s-ogen-20090115monthly0.5https://www.biopharmawatch.com/news/OGEN/oni-biopharma-announces-evoraplus-website-now-available-to-consumers-commencement-of-tradi-ogen-20081212monthly0.5https://www.biopharmawatch.com/news/OGEN/oni-biopharma-announces-its-listing-on-alternext-paris-oni-biopharma-will-be-the-first-us--ogen-20081210monthly0.5https://www.biopharmawatch.com/news/OGEN/oni-biopharma-announces-proposed-rights-offering-to-shareholders-alachua-fl-ogen-20081205monthly0.5https://www.biopharmawatch.com/news/OGEN/oni-biopharma-inc-offers-investor-update-topics-include-1-appeal-of-american-stock-exchang-ogen-20081031monthly0.5https://www.biopharmawatch.com/news/OGEN/oni-biopharma-appoints-new-chief-operational-officer-alachua-fl-ogen-20080701monthly0.5https://www.biopharmawatch.com/news/OGEN/oni-biopharma-inc-announces-closing-on-2-600-000-in-equity-financing-friday-june-13-9-00-a-ogen-20080613monthly0.5https://www.biopharmawatch.com/news/OGEN/oni-biopharma-inc-announces-definitive-term-sheet-for-2-600-000-in-equity-financing-for-im-ogen-20080602monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-oni-biopharma-inc-receives-notification-letter-from-american-stock-exchange--ogen-20080516monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-changes-name-to-oni-biopharma-inc-for-immediate-release-alachua-fl-may13-200-ogen-20080513monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-test-marketing-of-probiora3-chewable-tablets-for-immediate-release-ala-ogen-20080509monthly0.5https://www.biopharmawatch.com/news/OGEN/dr-marc-siegel-and-kevin-sills-join-oragenics-board-of-directors-for-immediate-release-ala-ogen-20080428monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-inc-announces-the-early-exercise-of-warrants-for-immediate-release-alachua-fl-ogen-20080303monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-the-exercise-of-warrants-and-a-management-change-alachua-fl-ogen-20080212monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-issuing-of-amended-warrants-alachua-fl-ogen-20080129monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-the-appointment-of-two-new-board-members-alachua-fl-ogen-20080121monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-announces-retirement-of-its-ceo-selects-a-new-ceo-and-president-and-appoints-a-n-ogen-20080102monthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-appoints-dr-ronald-p-evens-to-its-board-of-directors-for-immediate-release-alach-ogen-20070618monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-announces-receipt-of-nasdaq-notice-regarding-minimum-stockholders-equity-requiremen-akan-20260618monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-regains-compliance-with-nasdaq-periodic-filing-requirement-filing-of-annual-re-akan-20260612monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-announces-receipt-of-nasdaq-noncompliance-letter-toronto-on-akan-20260522monthly0.5https://www.biopharmawatch.com/news/AKAN/notice-of-adjourned-special-meeting-of-shareholders-notice-is-hereby-given-that-a-special--akan-20260513monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-adjourns-shareholder-meeting-toronto-ontario-akan-20260429monthly0.5https://www.biopharmawatch.com/news/AKAN/ontario-ministry-of-government-and-consumer-services-articles-of-amendment-business-corpor-akan-20260326monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-announces-reverse-stock-split-toronto-on-akan-20260409monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-adjourns-shareholder-meeting-toronto-ontario-akan-20260407monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-notice-of-special-meeting-to-be-held-on-march-31-2026-and-management-informati-akan-20260331monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-driving-recurring-revenue-growth-2-million-cash-flow-secured-through-fiber-acq-akan-20260326monthly0.5https://www.biopharmawatch.com/news/AKAN/first-towers-fiber-corp-owns-the-largest-dark-fiber-network-in-central-mexico-toronto-onta-akan-20260227monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-announces-closing-of-7-0-million-convertible-note-offering-toronto-ontario-akan-20260123monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-announces-7-0-million-convertible-note-offering-toronto-ontario-akan-20260120monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-announces-reverse-stock-split-toronto-on-akan-20260108monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-welcomes-momentum-towards-cannabis-reform-in-the-united-states-toronto-ontario-akan-20251218monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-researching-security-requirements-for-full-cultivation-license-toronto-ontario-news-akan-20251113monthly0.5https://www.biopharmawatch.com/news/AKAN/notice-of-adjourned-special-meeting-of-shareholders-notice-is-hereby-given-that-a-special--akan-20251030monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-increasing-its-cannabis-investment-toronto-ontario-newsfile-corp-akan-20251020monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-to-accelerate-recurring-revenue-with-expansion-of-up-to-20-new-cellular-towers-toro-akan-20251016monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-addresses-impacts-of-postal-strike-on-receiving-materials-for-its-upcoming-spe-akan-20251010monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-notice-of-special-meeting-to-be-held-on-october-30-2025-and-management-informa-akan-20251009monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-among-the-leaders-of-deployment-in-mexico-s-largest-telecommunication-infrastructur-akan-20250930monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-unaudited-condensed-interim-consolidated-statements-of-financial-position-expr-akan-20251001monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-announces-12-0-million-convertible-note-offering-toronto-ontario-akan-20250912monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-announces-closing-of-share-exchange-with-first-towers-and-fiber-corp-first-tow-akan-20250822monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-announces-reverse-stock-split-toronto-on-akan-20250822monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-notice-of-special-meeting-to-be-held-on-august-29-2025-and-management-informat-akan-20250808monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-notice-of-annual-general-and-special-meeting-to-be-held-on-april-30-2025-and-m-akan-20250416monthly0.5https://www.biopharmawatch.com/news/AKAN/share-exchange-agreement-this-share-exchange-agreement-is-made-effective-as-of-akan-20250305monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-announces-reverse-stock-split-london-uk-akan-20241112monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-unaudited-condensed-interim-consolidated-statements-of-financial-position-expr-akan-20241030monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-announces-closing-of-underwritten-public-offering-london-akan-20241004monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-announces-pricing-of-underwritten-public-offering-london-akan-20241002monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-secures-hemp-cultivation-license-in-canada-building-on-previous-development-ag-akan-20240916monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corporation-announces-completion-of-f-3-shelf-registration-statement-london-united--akan-20240614monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-has-regained-compliance-with-nasdaq-s-minimum-bid-price-requirement-london-uk-akan-20240612monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-announces-stock-consolidation-london-uk-akan-20240521monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-announces-closing-of-registered-direct-offering-london-akan-20240517monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-announces-registered-direct-offering-london-akan-20240517monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-receives-notice-of-non-compliance-from-nasdaq-london-uk-akan-20240516monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-announces-settlement-agreement-with-former-ceo-tejinder-virk-london-uk-akan-20240513monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-announces-plans-to-be-among-international-first-movers-pending-completion-of-l-akan-20240510monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-appoints-cooper-to-the-board-of-directors-london-uk-akan-20240425monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-announces-no-equity-financing-until-further-notice-london-uk-akan-20240415monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-looks-to-commercialize-and-capitalize-on-germany-s-legalization-of-cannabis-opening-akan-20240412monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-announces-closing-of-the-sale-of-rpk-london-akan-20240411monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-announces-strategic-plan-to-evaluate-and-enter-bitcoin-blockchain-ai-segments--akan-20240328monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-announces-closing-of-underwritten-public-offering-london-akan-20240327monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-announces-pricing-of-underwritten-public-offering-london-akan-20240325monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-notice-of-annual-general-and-special-meeting-to-be-held-on-march-22-2024-and-m-akan-20240311monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-signs-share-purchase-and-escrow-agreements-for-the-sale-of-portuguese-assets-t-akan-20240229monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-provides-further-update-on-annual-meeting-of-its-shareholders-london-akan-20240220monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-provides-update-on-annual-meeting-of-its-shareholders-london-akan-20240220monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-discusses-positive-trends-in-uk-cannabis-market-london-akan-20240213monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-announces-closing-of-registered-direct-offering-priced-at-the-market-under-nasdaq-r-akan-20240202monthly0.5https://www.biopharmawatch.com/news/AKAN/filed-by-newsfilecorp-com-akanda-corp-announces-registered-direct-offering-priced-at-the-m-akan-20240202monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-entered-into-non-binding-letter-of-intent-for-sale-of-rpk-london-akan-20240201monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-receives-additional-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-b-akan-20240104monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-unaudited-condensed-interim-consolidated-statements-of-financial-position-expr-akan-20231229monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corporation-announces-cfo-appointment-london-akan-20231211monthly0.5https://www.biopharmawatch.com/news/AKAN/execution-copy-amended-and-restated-option-to-purchase-this-amended-and-restated-option-to-akan-20230922monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-announces-signing-of-option-to-develop-canadian-thc-and-cbd-farming-facility-f-akan-20230920monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency-london-akan-20230706monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-announces-termination-of-loan-agreement-frankfurt-germany-london-business-wire-akan-20230530monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-announces-loan-agreement-frankfurt-and-london-akan-20230428monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corporation-has-regained-compliance-with-nasdaq-s-minimum-bid-price-requirement-lon-akan-20230329monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corporation-announces-1-for-10-reverse-stock-split-london-akan-20230308monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corporation-announces-cfo-appointment-london-akan-20230307monthly0.5https://www.biopharmawatch.com/news/AKAN/canmart-ends-ceo-service-agreement-akanda-approves-appointment-of-director-london-february-akan-20230217monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-s-chief-executive-officer-submits-resignation-london-akan-20230207monthly0.5https://www.biopharmawatch.com/news/AKAN/x200b-akanda-corp-unaudited-condensed-consolidated-statements-of-financial-position-expres-akan-20230104monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-s-chief-executive-officer-on-paid-leave-of-absence-akan-20221223monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-notice-of-annual-general-and-special-meeting-to-be-held-on-november-22-2022-akan-20221101monthly0.5https://www.biopharmawatch.com/news/AKAN/europe-s-premium-cannabis-cultivator-november-2022-disclaimer-forward-looking-statements-v-akan-20221114monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency-london-oct-akan-20220927monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-plans-first-shipment-of-medical-cannabis-to-germany-and-anticipates-leading-market--akan-20220928monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-partners-with-cookies-to-bring-the-iconic-cannabis-brand-and-high-thc-strains-to-eu-akan-20220913monthly0.5https://www.biopharmawatch.com/news/AKAN/founder-of-aurora-cannabis-terry-booth-joins-akanda-as-chair-of-advisory-board-proven-glob-akan-20220908monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-bolsters-leadership-team-to-scale-medical-cannabis-platform-across-europe-tom-flow--akan-20220824monthly0.5https://www.biopharmawatch.com/news/AKAN/cansativa-group-and-akanda-corp-to-bring-new-medical-cannabis-flowers-to-germany-frankfurt-akan-20220809monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-to-contest-unauthorized-liquidation-of-its-lesotho-based-subsidiary-bophelo-bio-sci-akan-20220726monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-to-supply-tetra-bio-pharma-with-pharmaceutical-grade-cannabis-for-fda-trials-of-qix-akan-20220712monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-notice-of-resolution-in-lieu-of-meeting-notice-is-hereby-given-that-on-akan-20220623monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-announces-changes-to-board-of-directors-and-postponement-of-annual-general-meeting--akan-20220623monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-notice-of-annual-general-meeting-to-be-held-on-june-24-2022-akan-20220606monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-completes-acquisition-of-holigen-advancing-cannabis-leadership-position-in-europe-t-akan-20220502monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-to-acquire-portugal-based-holigen-securing-a-cannabis-sector-leadership-position-in-akan-20220420monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-closes-initial-public-offering-london-akan-20220317monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-closes-its-first-day-of-trading-on-the-nasdaq-capital-market-london-akan-20220315monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-common-shares-set-to-commence-trading-today-on-nasdaq-under-ticker-symbol-akan-akan-20220315monthly0.5https://www.biopharmawatch.com/news/AKAN/akanda-corp-announces-pricing-of-initial-public-offering-london-akan-20220314monthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-announces-third-quarter-business-and-financial-highlights-recapitalization-reduced-pfsa-20251119monthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-outlines-potential-path-to-250-million-revenue-by-2030-driven-by-sequential-lumee--pfsa-20251030monthly0.5https://www.biopharmawatch.com/news/PFSA/nasdaq-pfsa-october-2025-investor-presentation-pioneering-real-time-biochemistry-that-driv-pfsa-20251021monthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-invests-additional-1-million-in-digital-treasury-assets-pfsa-20251007monthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-welcomes-former-acting-u-s-veterans-affairs-secretary-peter-o-rourke-as-lead-indep-pfsa-20250811monthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-inc-and-subsidiary-condensed-consolidated-balance-sheets-in-thousands-except-share-pfsa-20250815monthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-inc-provides-strategy-overview-and-business-update-for-investors-pfsa-20250806monthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-announces-closing-of-business-combination-and-the-commencement-of-trading-on-nasda-pfsa-20250714monthly0.5https://www.biopharmawatch.com/news/PFSA/annex-a-proposed-amendment-to-the-amended-and-restated-certificate-of-incorporation-of-nor-pfsa-20250318monthly0.5https://www.biopharmawatch.com/news/PFSA/northview-acquisition-corporation-announces-receipt-of-notice-from-nasdaq-regarding-failur-pfsa-20241226monthly0.5https://www.biopharmawatch.com/news/PFSA/northview-acquisition-corporation-announces-receipt-of-notice-from-nasdaq-regarding-filing-pfsa-20241211monthly0.5https://www.biopharmawatch.com/news/PFSA/northview-acquisition-corporation-announces-exception-granted-by-nasdaq-to-permit-to-the-c-pfsa-20240913monthly0.5https://www.biopharmawatch.com/news/PFSA/northview-acquisition-corporation-announces-receipt-of-notice-from-nasdaq-regarding-filing-pfsa-20240607monthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-inc-a-digital-health-company-pioneering-the-next-generation-of-personalized-medici-pfsa-20221107monthly0.5https://www.biopharmawatch.com/news/PFSA/northview-acquisition-corp-announces-upcoming-automatic-unit-separation-new-york-new-york-pfsa-20220119monthly0.5https://www.biopharmawatch.com/news/PFSA/northview-acquisition-corporation-index-to-financial-statement-page-report-of-independent--pfsa-20211222monthly0.5https://www.biopharmawatch.com/news/PFSA/northview-acquisition-corp-announces-pricing-of-upsized-165-000-000-initial-public-offerin-pfsa-20211220monthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-technology-group-ltd-an-exempted-company-with-limited-liability-incorporated--wok-20260210monthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-technology-group-ltd-unaudited-condensed-consolidated-balance-sheets-in-u-s-d-wok-20251202monthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-technology-group-ltd-an-exempted-company-with-limited-liability-incorporated--wok-20251021monthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-technology-group-ltd-unaudited-condensed-consolidated-balance-sheets-in-u-s-d-wok-20250825monthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-technology-group-ltd-an-exempted-company-with-limited-liability-incorporated--wok-20250822monthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-technology-group-ltd-wok-20250520monthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-technology-group-ltd-announces-implementation-of-dual-class-share-structure-e-wok-20250306monthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-technology-group-ltd-an-exempted-company-with-limited-liability-incorporated--wok-20250116monthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-technology-group-ltd-announces-pricing-of-initial-public-offering-hangzhou-ch-wok-20240823monthly0.5https://www.biopharmawatch.com/news/VRAX/filed-as-part-of-the-form-6-k-report-containing-the-notice-of-meeting-and-proxy-statement--vrax-20260522monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-ceo-james-foster-outlines-strategic-priorities-and-near-term-milestones-in-l-vrax-20260414monthly0.5https://www.biopharmawatch.com/news/VRAX/filed-as-part-of-the-form-6-k-administration-the-2026-plan-will-be-administered-by-the-com-vrax-20260130monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-group-limited-announces-5-million-private-placement-london-vrax-20251203monthly0.5https://www.biopharmawatch.com/news/VRAX/unaudited-condensed-consolidated-interim-financial-statements-as-of-vrax-20251202monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-enrolls-first-patients-in-clinical-study-assessing-t-cell-dysfunction-in-pos-vrax-20250318monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-presents-data-on-t-cell-dysfunction-in-post-acute-infection-syndromes-at-the-vrax-20250313monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-to-present-at-19th-world-immune-regulation-meeting-vrax-20250305monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-believes-technology-aligns-with-united-states-department-of-health-and-human-vrax-20250225monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-ceo-james-foster-issues-letter-to-shareholders-london-vrax-20241217monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-announces-agreement-with-tebubio-to-expand-distribution-of-immuneselect-acro-vrax-20241210monthly0.5https://www.biopharmawatch.com/news/VRAX/unaudited-condensed-consolidated-interim-financial-statements-as-of-vrax-20241120monthly0.5https://www.biopharmawatch.com/news/VRAX/filed-as-part-of-the-form-6-k-administration-the-2024-plan-will-be-administered-by-the-com-vrax-20241031monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-announces-distribution-agreement-with-europa-biosite-to-commercialize-immune-vrax-20241023monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-group-limited-announces-5-million-registered-direct-offering-of-ordinary-sha-vrax-20240821monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-launches-portfolio-of-immune-profiling-solutions-evaluating-adaptive-immunit-vrax-20240425monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-group-limited-to-participate-at-escmid-global-2024-london-vrax-20240416monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-announces-receipt-of-nasdaq-notification-letter-regarding-minimum-bid-price--vrax-20240315monthly0.5https://www.biopharmawatch.com/news/VRAX/unaudited-condensed-consolidated-interim-financial-statements-as-of-vrax-20240112monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-forges-strategic-research-collaboration-with-university-of-manchester-and-th-vrax-20231221monthly0.5https://www.biopharmawatch.com/news/VRAX/companies-act-revised-company-limited-by-shares-virax-biolabs-group-limited-third-amended--vrax-20231220monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-ceo-james-foster-issues-letter-to-shareholders-london-vrax-20231218monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-group-limited-announces-1-for-10-share-consolidation-london-vrax-20231214monthly0.5https://www.biopharmawatch.com/news/VRAX/filed-as-part-of-the-form-6-k-administration-the-plan-will-be-administered-by-the-compensa-vrax-20231108monthly0.5https://www.biopharmawatch.com/news/VRAX/e-xhibit-99-1-virax-biolabs-group-limited-the-company-clawback-policy-introduction-the-boa-vrax-20231031monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-group-announces-early-access-program-launch-of-research-use-only-viraximmune-vrax-20230912monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-group-appoints-dr-nigel-mccracken-as-chief-operating-officer-to-oversee-grow-vrax-20230901monthly0.5https://www.biopharmawatch.com/news/VRAX/nasdaq-approves-180-day-extension-for-virax-biolabs-group-to-meet-minimum-1-bid-london-vrax-20230803monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-group-continues-growth-and-expansion-with-the-addition-of-research-and-labor-vrax-20230718monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-ceo-james-foster-issues-letter-to-shareholders-london-united-kingdom-and-dub-vrax-20230614monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-group-announces-establishment-of-regional-headquarters-at-dubai-science-park-vrax-20230504monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-group-limited-has-entered-into-an-agreement-for-the-distribution-of-marburg--vrax-20230419monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-group-limited-announces-4-million-private-placement-priced-at-the-market-und-vrax-20230308monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-group-limited-introduces-avian-influenza-a-virus-real-time-pcr-test-kit-lond-vrax-20230307monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-group-limited-announces-purchase-order-to-launch-covid-19-and-influenza-a-b--vrax-20230207monthly0.5https://www.biopharmawatch.com/news/VRAX/unaudited-condensed-interim-financial-statements-as-of-vrax-20230202monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-ceo-james-foster-issues-letter-to-shareholders-london-vrax-20230202monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-introduces-human-papillomavirus-x201c-hpv-x201d-test-kit-kit-available-now-f-vrax-20230104monthly0.5https://www.biopharmawatch.com/news/VRAX/covid-19-rapid-antigen-test-distributed-by-virax-biolabs-receives-emergency-use-authorizat-vrax-20221206monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-appoints-richard-pallin-as-the-vice-president-of-in-vitro-diagnostic-sales-l-vrax-20221115monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-group-limited-announces-3-8-million-private-placement-london-vrax-20221104monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-introduces-rsv-influenza-covid-triple-virus-antigen-rapid-test-kit-kits-avai-vrax-20221103monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-group-limited-announces-initiation-of-its-virax-immune-covid-19-analytical-p-vrax-20221026monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-group-limited-announces-distribution-agreement-to-market-monkeypox-virus-rea-vrax-20220922monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-introduces-monkeypox-virus-antigen-rapid-test-kit-kits-available-in-septembe-vrax-20220920monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-presents-at-h-c-wainwright-s-24th-annual-global-investment-conference-london-vrax-20220912monthly0.5https://www.biopharmawatch.com/news/VRAX/virax-biolabs-to-present-at-h-c-wainwright-s-24th-annual-global-investment-conference-in-n-vrax-20220906monthly0.5https://www.biopharmawatch.com/news/VRAX/charter-of-the-audit-committee-of-the-board-of-directors-of-virax-biolabs-group-limited-co-vrax-20220726monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-1-for-9-reverse-share-split-following-the-reverse-share-split-the-compa-sprc-20260302monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-interim-consolidated-financial-statements-as-of-june-30-2025-unaudited-index--sprc-20251118monthly0.5https://www.biopharmawatch.com/news/SPRC/miza-iii-ventures-inc-and-scisparc-ltd-asset-and-share-purchase-agreement-october-9-2025-t-sprc-20251009monthly0.5https://www.biopharmawatch.com/news/SPRC/framework-agreement-this-framework-agreement-the-agreement-is-dated-as-of-sprc-20251006monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-and-its-subsidiaries-consolidated-financial-statements-as-of-december-31-2024-sprc-20250722monthly0.5https://www.biopharmawatch.com/news/SPRC/the-companies-law-1999-a-limited-liability-company-amended-and-restated-articles-of-associ-sprc-20250626monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-1-for-21-reverse-share-split-following-the-reverse-share-split-the-comp-sprc-20250624monthly0.5https://www.biopharmawatch.com/news/SPRC/in-this-report-of-foreign-private-issuer-on-form-6-k-information-has-been-prepared-based-o-sprc-20250609monthly0.5https://www.biopharmawatch.com/news/SPRC/in-this-report-of-foreign-private-issuer-on-form-6-k-4-information-has-been-prepared-based-sprc-20241129monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-interim-consolidated-financial-statements-as-of-june-30-2024-unaudited-index--sprc-20241104monthly0.5https://www.biopharmawatch.com/news/SPRC/to-the-company-s-report-of-foreign-private-issuer-on-form-6-k-furnished-to-the-u-s-securit-sprc-20240927monthly0.5https://www.biopharmawatch.com/news/SPRC/automax-motors-ltd-consolidated-financial-statements-as-for-sprc-20240502monthly0.5https://www.biopharmawatch.com/news/SPRC/execution-copy-agreement-and-plan-of-merger-among-scisparc-ltd-an-israeli-limited-company--sprc-20240410monthly0.5https://www.biopharmawatch.com/news/SPRC/corporate-presentation-nasdaq-sprc-october-2023-this-presentation-of-scisparc-ltd-the-comp-sprc-20231018monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-interim-consolidated-financial-statements-as-of-june-30-2023-unaudited-index--sprc-20231016monthly0.5https://www.biopharmawatch.com/news/SPRC/to-the-company-s-report-of-foreign-private-issuer-on-form-6-k-furnished-to-the-u-s-securit-sprc-20230814monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-ordinary-shares-no-par-value-at-the-market-issuance-sales-agreement-sprc-20230516monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-completes-the-sale-of-a-49-interest-in-its-subsidiary-that-owns-wellution-for-3-m-sprc-20230322monthly0.5https://www.biopharmawatch.com/news/SPRC/the-following-risk-factors-update-and-supplement-and-should-be-read-together-with-the-risk-sprc-20230216monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-corporate-restructuring-plan-scisparc-will-examine-the-possibility-of-a-sprc-20230125monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-interim-consolidated-financial-statements-as-of-june-30-2022-unaudited-index--sprc-20221231monthly0.5https://www.biopharmawatch.com/news/SPRC/august-x00a0-11-2022-dear-scisparc-ltd-shareholders-we-cordially-invite-you-to-attend-the--sprc-20220811monthly0.5https://www.biopharmawatch.com/news/SPRC/letter-agreement-sprc-20220630monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-positive-results-from-psychedelic-based-pre-clinical-trial-results-demo-sprc-20220317monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-launches-new-jv-targeting-discovery-of-potential-drugs-for-cancers-and-infectious-sprc-20220310monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-enters-collaboration-for-the-development-of-innovative-psychedelic-based-pharmace-sprc-20220308monthly0.5https://www.biopharmawatch.com/news/SPRC/corporate-presentation-nasdaq-sprc-february-2022-this-presentation-of-scisparc-ltd-the-com-sprc-20220222monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-advances-its-phase-iib-clinical-trial-in-patients-with-tourette-syndrome-with-its-sprc-20220118monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-recruitment-of-first-patient-for-its-phase-iia-clinical-trial-in-alzhei-sprc-20220106monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-issued-u-s-patent-for-its-core-technology-that-treats-central-nervous-systems-dis-sprc-20220104monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-provides-updates-upon-conclusion-of-2021-sprc-20211229monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-s-ordinary-shares-to-commence-trading-on-nasdaq-capital-market-today-sprc-20211222monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-approval-of-uplisting-to-the-nasdaq-capital-market-sprc-20211220monthly0.5https://www.biopharmawatch.com/news/SPRC/other-than-as-expressly-set-forth-above-this-amendment-does-not-and-does-not-purport-to-am-sprc-20210826monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-interim-consolidated-financial-statements-as-of-june-30-2021-unaudited-index--sprc-20210816monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-completion-of-corporate-rebranding-and-launch-of-new-website-sprc-20210804monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-updates-regarding-its-phase-iib-study-in-tourette-syndrome-scisparc-int-sprc-20210726monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-to-commence-phase-iia-clinical-trial-of-sci-110-for-the-treatment-of-alzheimer-s--sprc-20210707monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-sprc-20210625monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-ltd-announces-8-15-million-private-placement-sprc-20210301monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-corporate-presentation-february-2021-safe-harbor-statement-this-presentation-of-s-sprc-20210224monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-to-conduct-a-phase-iia-clinical-trial-in-alzheimer-s-patients-using-the-company-s-sprc-20210217monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-announces-rebranding-and-business-updates-sprc-20210211monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-engages-procaps-for-development-and-production-of-cannamide-and-its-sci-110-produ-sprc-20210210monthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-initiates-commercial-production-of-its-cannamide-pills-the-anti-inflammatory-chro-sprc-20210209monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-announces-name-change-to-scisparc-ltd-sprc-20210128monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-sprc-20210125monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-and-cyntar-ventures-entered-a-non-binding-letter-of-intent-for-the-di-sprc-20210105monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-announces-upgrade-to-otcqb-venture-market-sprc-20201208monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-sprc-20201202monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-to-collaborate-with-the-university-of-calgary-to-further-examine-its--sprc-20201202monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-announces-pricing-of-4-2-million-offering-sprc-20201119monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-ltd-interim-consolidated-financial-statements-as-of-june-30-2020-unau-sprc-20201009monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-sprc-20200925monthly0.5https://www.biopharmawatch.com/news/SPRC/developing-cannabinoid-based-pharmaceuticals-corporate-presentation-september-2020-saf-e-h-sprc-20200916monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-sprc-20200820monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-announces-otc-pink-ticker-symbol-trpxy-and-removal-of-injunction-by-i-sprc-20200709monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-raises-2-6-million-in-private-placement-tel-aviv-israel-sprc-20200629monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-sprc-20200623monthly0.5https://www.biopharmawatch.com/news/SPRC/share-transfer-agreement-this-share-transfer-agreement-the-agreement-is-made-and-entered-i-sprc-20200515monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-appoints-prof-ari-shamiss-m-d-m-p-a-to-the-company-s-board-of-directo-sprc-20200507monthly0.5https://www.biopharmawatch.com/news/SPRC/nasdaq-hearings-panel-grants-therapix-biosciences-extension-to-regain-compliance-with-list-sprc-20200428monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-announces-appointment-of-new-ceo-mr-gilad-bar-lev-appointed-ceo-effec-sprc-20200422monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-ltd-signs-securities-purchase-agreement-sprc-20200319monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-ltd-receives-nasdaq-notification-regarding-minimum-bid-requirements-sprc-20200227monthly0.5https://www.biopharmawatch.com/news/SPRC/nasdaq-hearings-panel-grants-therapix-sprc-20200207monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-sprc-20191211monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-announces-sprc-20191204monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-announces-the-continued-development-of-thx-210-respectrum-cannabinoid-sprc-20191202monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-announces-receipt-of-notice-of-delisting-from-nasdaq-and-intention-to-sprc-20191120monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-enters-into-mou-for-business-combination-with-heavenly-rx-ltd-sprc-20191119monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-announces-positive-sprc-20191113monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-and-destiny-biosciences-global-corp-mutually-decide-to-discontinue-ne-sprc-20191107monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-announces-positive-data-from-recent-pre-clinical-study-for-new-drug-c-sprc-20191015monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-provides-update-on-planned-merger-with-destiny-biosciences-global-cor-sprc-20191010monthly0.5https://www.biopharmawatch.com/news/SPRC/nasdaq-grants-therapix-biosciences-extension-to-comply-with-stockholders-equity-requiremen-sprc-20190827monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-announces-canadian-product-license-issuance-for-therapea-cannamide-a--sprc-20190723monthly0.5https://www.biopharmawatch.com/news/SPRC/biosciences-signs-loi-to-merge-with-destiny-biosciences-global-corp-sprc-20190723monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-announces-first-quarter-2019-condensed-financial-data-sprc-20190704monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-announces-interim-results-of-phase-iia-study-at-assuta-medical-center-sprc-20190618monthly0.5https://www.biopharmawatch.com/news/SPRC/biosciences-issues-shareholder-update-letter-sprc-20190529monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-announces-receipt-of-nasdaq-notification-regarding-minimum-stockholde-sprc-20190523monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-announces-pricing-of-2-25-million-registered-direct-offering-tel-aviv-sprc-20190328monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-appoints-ambassador-ron-prosor-as-executive-advisor-sprc-20190319monthly0.5https://www.biopharmawatch.com/news/SPRC/the-cannabinoids-of-the-future-sprc-20190212monthly0.5https://www.biopharmawatch.com/news/SPRC/general-meeting-of-shareholders-sprc-20190117monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-terminates-fsd-acquisition-sprc-20181221monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-provides-update-regarding-fsd-acquisition-sprc-20181211monthly0.5https://www.biopharmawatch.com/news/SPRC/investors-therapix-biosciences-therapix-biosciences-reports-third-quarter-2018-financial-r-sprc-20181203monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-clarifies-terms-of-recently-issued-convertible-debenture-sprc-20181129monthly0.5https://www.biopharmawatch.com/news/SPRC/management-s-discussion-and-analysis-of-financial-condition-and-results-of-operations-the--sprc-20181128monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-issues-1-500-000-convertible-debenture-sprc-20181126monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-signs-binding-loi-to-be-acquired-by-fsd-pharma-for-48-million-sprc-20181024monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-ltd-therapix-biosciences-reports-second-quarter-2018-financial-result-sprc-20180820monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-reports-first-quarter-2018-financial-results-and-provides-business-up-sprc-20180531monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-reports-third-quarter-2017-financial-results-and-provides-business-up-sprc-20171109monthly0.5https://www.biopharmawatch.com/news/SPRC/notice-of-annual-general-meeting-exhibit-1-therapix-biosciences-ltd-notice-of-2017-sprc-20170918monthly0.5https://www.biopharmawatch.com/news/SPRC/biosciences-reports-second-quarter-2017-financial-results-and-provides-business-update-sprc-20170810monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-announces-ceo-change-sprc-20170524monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-and-the-hannover-medical-school-enter-into-an-investigator-initiated--sprc-20170508monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-announces-the-appointment-of-josh-blacher-as-chief-financial-officer-sprc-20170503monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-signs-exclusive-license-agreement-with-yissum-for-nasal-drug-delivery-technology--sprc-20170405monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-ltd-announces-full-exercise-of-underwriters-over-allotment-option-tel-sprc-20170403monthly0.5https://www.biopharmawatch.com/news/SPRC/therapix-biosciences-ltd-announces-closing-of-u-s-initial-public-offering-of-american-depo-sprc-20170327monthly0.5https://www.biopharmawatch.com/news/VRXA/veraxa-biotech-establishes-in-vitro-proof-of-concept-for-novel-vrxa-20260618monthly0.5https://www.biopharmawatch.com/news/VRXA/biotech-to-debut-as-a-publicly-traded-company-pioneering-vrxa-20260611monthly0.5https://www.biopharmawatch.com/news/SLBT/sl-bio-ltd-and-horizon-space-acquisition-ii-announce-closing-of-business-combination-and-l-slbt-20260612monthly0.5https://www.biopharmawatch.com/news/HELP/filed-by-newsfilecorp-com-helus-pharma-announces-topline-results-in-phase-2-signal-detecti-help-20260305monthly0.5https://www.biopharmawatch.com/news/HELP/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--help-20251230monthly0.5https://www.biopharmawatch.com/news/HELP/filed-by-newsfilecorp-com-cybin-inc-shares-of-common-stock-help-20251230monthly0.5https://www.biopharmawatch.com/news/HELP/filed-by-newsfilecorp-com-execution-version-securities-purchase-agreement-this-securities--help-20251028monthly0.5https://www.biopharmawatch.com/news/HELP/filed-by-newsfilecorp-com-help-20250917monthly0.5https://www.biopharmawatch.com/news/HELP/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--help-20250902monthly0.5https://www.biopharmawatch.com/news/HELP/filed-by-newsfilecorp-com-help-20250714monthly0.5https://www.biopharmawatch.com/news/HELP/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--help-20250210monthly0.5https://www.biopharmawatch.com/news/HELP/filed-by-newsfilecorp-com-cybin-inc-shares-of-common-stock-help-20250210monthly0.5https://www.biopharmawatch.com/news/HELP/filed-by-newsfilecorp-com-cybin-reports-positive-phase-2-data-for-cyb003-demonstrating-bre-help-20241118monthly0.5https://www.biopharmawatch.com/news/HELP/filed-by-newsfilecorp-com-help-20240418monthly0.5https://www.biopharmawatch.com/news/HELP/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--help-20240313monthly0.5https://www.biopharmawatch.com/news/HELP/filed-by-newsfilecorp-com-help-20231110monthly0.5https://www.biopharmawatch.com/news/HELP/filed-by-newsfilecorp-com-small-pharma-inc-formerly-unilock-capital-corp-consolidated-fina-help-20231113monthly0.5https://www.biopharmawatch.com/news/HELP/filed-by-newsfilecorp-com-small-pharma-inc-interim-condensed-consolidated-financial-statem-help-20231113monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-provides-2021-year-end-summary-toronto-canada-help-20211222monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-to-participate-in-the-11th-annual-lifesci-partners-corporate-access-event-and-h-c-wa-help-20211221monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-awarded-notice-of-allowance-from-u-s-patent-and-trademark-office-for-cyb004-deuterat-help-20211215monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-confirms-scientific-advice-meeting-with-uk-medical-and-healthcare-products-regulator-help-20211208monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-to-present-at-the-stifel-gmp-2-nd-annual-future-of-healthcare-conference-on-help-20211202monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-to-participate-in-the-h-c-wainwright-2-nd-annual-psychedelics-conference-on-help-20211130monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-announces-additional-adelia-milestone-achievements-toronto-canada-help-20211126monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-awards-grant-for-psychedelic-treatment-clinic-at-lenox-hill-hospital-to-benefit-unde-help-20211123monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-to-present-at-the-jefferies-london-healthcare-conference-toronto-canada-help-20211111monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-to-announce-second-quarter-fy2021-financial-results-and-business-update-on-help-20211109monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-announces-positive-cyb003-data-demonstrating-significant-advantages-over-oral-psiloc-help-20211108monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-granted-dea-schedule-i-manufacturing-license-the-company-also-welcomes-leah-gibson-a-help-20211104monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-hosting-research-and-development-briefing-on-help-20211102monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-announces-launch-of-embark-psychedelic-facilitator-training-program-toronto-canada-help-20211028monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-announces-fda-investigational-new-drug-authorization-of-cybin-s-sponsored-feasibilit-help-20211026monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-announces-completion-of-74-pre-clinical-psychedelic-molecule-studies-the-company-exp-help-20211019monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-files-an-international-patent-application-covering-psychedelic-delivery-methods-toro-help-20211012monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-announces-additional-adelia-milestone-achievements-toronto-canada-help-20211007monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-announces-appointment-of-dr-amir-inamdar-as-chief-medical-officer-for-european-opera-help-20211001monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-to-present-at-upcoming-cantor-and-benzinga-investor-conferences-toronto-canada-help-20210927monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-to-present-at-the-h-c-wainwright-23-rd-annual-global-investment-conference-on-septem-help-20210909monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-announces-additional-adelia-milestone-achievements-toronto-canada-help-20210831monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-files-two-additional-international-patent-applications-in-support-of-the-company-s-r-help-20210819monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-announces-election-of-theresa-firestone-as-director-results-of-shareholders-meeting--help-20210816monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-announces-additional-adelia-milestone-achievements-toronto-canada-help-20210812monthly0.5https://www.biopharmawatch.com/news/HELP/form-51-102f3-material-change-report-item-1-name-and-address-of-company-cybin-inc-formerly-help-20210727monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-to-present-at-canaccord-genuity-s-41-st-annual-growth-conference-on-august-10-th-tor-help-20210809monthly0.5https://www.biopharmawatch.com/news/HELP/cybin-to-commence-trading-on-the-nyse-american-on-august-5-toronto-canada-help-20210804monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-condensed-interim-consolidated-financial-statements-for-the-three-a-cmnd-20260615monthly0.5https://www.biopharmawatch.com/news/CMND/agreement-this-agreement-this-agreement-is-entered-into-as-of-cmnd-20260612monthly0.5https://www.biopharmawatch.com/news/CMND/conversion-agreement-this-conversion-agreement-this-agreement-is-entered-into-as-of-cmnd-20260519monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-filing-of-eu-ropean-patent-application-for-novel-psychedelic--cmnd-20260505monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-welcomes-president-trump-s-executive-order-as-a-historic-catalyst-for-p-cmnd-20260418monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-condensed-interim-consolidated-financial-statements-for-the-three-m-cmnd-20260312monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-management-information-circular-for-the-annual-general-and-special--cmnd-20251128monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-condensed-interim-consolidated-financial-statements-for-the-three-a-cmnd-20250911monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-files-international-patent-application-for-novel-combination-therapy-ta-cmnd-20250728monthly0.5https://www.biopharmawatch.com/news/CMND/www-clearmindmedicine-com-novel-psychedelics-for-treating-addictions-obesity-mental-health-cmnd-20250729monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-condensed-interim-consolidated-financial-statements-for-the-three-a-cmnd-20250612monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-condensed-interim-consolidated-financial-statements-for-the-three-m-cmnd-20250313monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-management-information-circular-for-the-annual-and-special-meeting--cmnd-20241206monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-condensed-interim-consolidated-financial-statements-for-the-three-a-cmnd-20240916monthly0.5https://www.biopharmawatch.com/news/CMND/www-clearmindmedicine-com-creating-an-alternative-to-alcohol-corporate-presentation-2024-n-cmnd-20240820monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-condensed-interim-consolidated-financial-statements-for-the-three-a-cmnd-20240613monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-condensed-interim-consolidated-financial-statements-for-the-three-m-cmnd-20240319monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-announces-receipt-of-nasdaq-delisting-notice-and-plan-for-immediate-rec-cmnd-20231114monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-management-information-circular-for-the-annual-and-special-meeting--cmnd-20231024monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-condensed-interim-consolidated-financial-statements-for-the-three-a-cmnd-20230913monthly0.5https://www.biopharmawatch.com/news/CMND/dr-fatima-cody-stanford-associate-professor-of-medicine-and-pediatrics-at-harvard-medical--cmnd-20230711monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-condensed-interim-consolidated-financial-statements-for-the-three-a-cmnd-20230614monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-condensed-interim-consolidated-financial-statements-for-the-three-m-cmnd-20230317monthly0.5https://www.biopharmawatch.com/news/CMND/israel-based-clearmind-medicine-files-patent-applications-for-three-unique-combinations-of-cmnd-20230222monthly0.5https://www.biopharmawatch.com/news/CMND/israel-based-clearmind-medicine-strengthening-ip-portfolio-with-three-provisional-patent-a-cmnd-20230215monthly0.5https://www.biopharmawatch.com/news/CMND/israeli-based-clearmind-medicine-to-host-virtual-investor-conference-on-psychedelics-for-o-cmnd-20230208monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-consolidated-financial-statements-expressed-in-canadian-dollars-f-1-cmnd-20230201monthly0.5https://www.biopharmawatch.com/news/CMND/israeli-biotech-clearmind-medicine-announces-positive-pre-clinical-results-treating-major--cmnd-20230131monthly0.5https://www.biopharmawatch.com/news/CMND/hebrew-university-yissum-and-israeli-biotech-clearmind-medicine-s-psychedelic-derived-obes-cmnd-20230125monthly0.5https://www.biopharmawatch.com/news/CMND/israel-based-clearmind-successfully-completed-two-r-d-projects-with-the-hebrew-university--cmnd-20230119monthly0.5https://www.biopharmawatch.com/news/CMND/israel-based-clearmind-announces-additional-positive-results-from-the-third-part-of-its-pr-cmnd-20230117monthly0.5https://www.biopharmawatch.com/news/CMND/israel-based-clearmind-medicine-successfully-completes-production-of-cmnd-100-drug-candida-cmnd-20230110monthly0.5https://www.biopharmawatch.com/news/CMND/israel-based-clearmind-medicine-shows-efficacy-of-psychedelic-derived-obesity-treatment-in-cmnd-20230105monthly0.5https://www.biopharmawatch.com/news/CMND/israel-based-clearmind-medicine-announces-first-clinical-center-to-join-its-clinical-trial-cmnd-20221228monthly0.5https://www.biopharmawatch.com/news/CMND/israel-based-clearmind-medicine-granted-u-s-patent-for-psychedelic-based-alcohol-substitut-cmnd-20221221monthly0.5https://www.biopharmawatch.com/news/CMND/israeli-based-biotech-company-clearmind-medicine-inc-s-ceo-dr-adi-zuloff-shani-issues-lett-cmnd-20221215monthly0.5https://www.biopharmawatch.com/news/CMND/israeli-based-biotech-company-clearmind-completes-ind-enabling-studies-for-cmnd-100-the-me-cmnd-20221213monthly0.5https://www.biopharmawatch.com/news/CMND/israeli-biotech-clearmind-medicine-appoints-ex-red-bull-executive-special-advisor-for-deve-cmnd-20221209monthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-inc-notice-of-annual-and-special-meeting-of-shareholders-notice-is-here-cmnd-20221201monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-reports-profitable-first-quarter-2026-results-bolstered-by-margins-and-cash-flow--trlv-20260507monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-reports-fourth-quarter-and-full-year-2025-results-with-60-gross-margin-and-record-trlv-20260226monthly0.5https://www.biopharmawatch.com/news/TRLV/document-trulieve-announces-closing-of-us-140-million-private-placement-of-10-5-senior-sec-trlv-20251217monthly0.5https://www.biopharmawatch.com/news/TRLV/document-trulieve-announces-us-100-million-private-placement-of-10-5-senior-secured-notes--trlv-20251209monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-reports-third-quarter-2025-results-demonstrating-operational-discipline-and-cash--trlv-20251105monthly0.5https://www.biopharmawatch.com/news/TRLV/document-trulieve-announces-notice-of-redemption-for-all-us-368-million-of-its-8-0-senior--trlv-20251104monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-reports-second-quarter-2025-results-highlighting-progress-on-2025-plan-second-qua-trlv-20250806monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-reports-first-quarter-2025-results-demonstrating-core-business-strength-first-qua-trlv-20250507monthly0.5https://www.biopharmawatch.com/news/TRLV/document-trulieve-announces-appointment-of-ryan-blust-as-interim-chief-financial-officer-trlv-20250307monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-reports-fourth-quarter-and-full-year-2024-results-highlighting-margins-and-cash-f-trlv-20250227monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-reports-third-quarter-2024-results-ahead-of-florida-adult-use-vote-third-quarter--trlv-20241105monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-reports-second-quarter-2024-results-exceeding-quarterly-guidance-second-quarter-p-trlv-20240806monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-reports-first-quarter-2024-results-demonstrating-core-business-strength-and-cash--trlv-20240509monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-reports-fourth-quarter-and-full-year-2023-results-highlighting-year-end-momentum--trlv-20240229monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-announces-completion-of-redemption-of-all-us-130-million-9-75-senior-secured-note-trlv-20231201monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-announces-notice-of-redemption-for-all-us-130-million-of-its-9-75-senior-secured--trlv-20231108monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-announces-filing-of-amended-federal-tax-returns-claiming-143-million-refund-talla-trlv-20231013monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-announces-purchase-of-8-senior-secured-notes-due-2026-tallahassee-fla-trlv-20230921monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-reports-second-quarter-2023-results-highlighting-progress-on-2023-plan-sold-11-6--trlv-20230809monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-announces-appointment-of-ryan-blust-as-interim-chief-financial-officer-trlv-20230721monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-announces-appointment-of-tim-mullany-as-chief-financial-officer-trlv-20230619monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-reports-first-quarter-2023-results-marking-progress-on-cash-objectives-record-4-2-trlv-20230510monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-reports-fourth-quarter-and-record-full-year-2022-results-exceeding-1-2-billion-in-trlv-20230308monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-announces-closing-of-71-5-million-financing-trlv-20221221monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-reports-third-quarter-2022-results-and-drives-forward-progress-on-strategic-visio-trlv-20221109monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-delivers-record-second-quarter-2022-results-driven-by-organic-retail-sales-revenu-trlv-20220810monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-starts-year-with-record-first-quarter-2022-results-record-revenue-of-318-3-millio-trlv-20220512monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-caps-transformational-year-with-record-fourth-quarter-and-full-year-2021-results--trlv-20220330monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-announces-closing-of-75-million-private-placement-of-8-senior-secured-notes-trlv-20220128monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-reports-record-third-quarter-2021-results-and-15-th-consecutive-profitable-quarte-trlv-20211115monthly0.5https://www.biopharmawatch.com/news/TRLV/forward-looking-statements-and-industry-and-market-data-unless-the-context-otherwise-requi-trlv-20211001monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-announces-closing-of-350-million-private-placement-of-8-senior-secured-notes-trlv-20211006monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-completes-acquisition-of-harvest-health-recreation-inc-creating-the-largest-and-m-trlv-20211001monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-announces-350-million-private-placement-of-8-senior-secured-notes-leverages-indus-trlv-20210930monthly0.5https://www.biopharmawatch.com/news/TRLV/live-without-investor-presentation-limits-august-2021-forward-looking-statements-and-indus-trlv-20210815monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-reports-record-second-quarter-2021-earnings-and-expansion-into-new-markets-achiev-trlv-20210812monthly0.5https://www.biopharmawatch.com/news/TRLV/relief-you-can-rely-on-investor-presentation-june-2021-forward-looking-statements-and-indu-trlv-20210604monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-reports-record-first-quarter-2021-revenue-of-193-8m-net-income-of-30-1m-and-adjus-trlv-20210513monthly0.5https://www.biopharmawatch.com/news/TRLV/forward-looking-statement-forward-looking-statements-made-in-this-document-are-made-only-a-trlv-20210510monthly0.5https://www.biopharmawatch.com/news/TRLV/trulieve-reports-fourth-quarter-and-full-year-2020-results-and-announces-full-year-2021-gu-trlv-20210323monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-announces-pricing-of-offering-philadelphia-vancouver-british-columbi-bctxl-20260531monthly0.5https://www.biopharmawatch.com/news/BCTXL/briapro-therapeutics-corp-condensed-interim-consolidated-financial-statements-for-the-thre-bctxl-20260331monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-and-briapro-enter-into-asset-purchase-agreement-for-exclusive-soluble-cd80-licens-bctxl-20260218monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-announces-pricing-of-30-million-public-offering-philadelphia-vancouv-bctxl-20260113monthly0.5https://www.biopharmawatch.com/news/BCTXL/briapro-therapeutic-corp-condesed-interim-consolidated-financial-statements-for-the-three--bctxl-20251229monthly0.5https://www.biopharmawatch.com/news/BCTXL/briapro-therapeutic-corp-consolidated-financial-statements-for-the-period-ended-july-31-20-bctxl-20251201monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-announces-proposed-effective-date-of-share-consolidation-philadelphia-and-vancouv-bctxl-20250821monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-announces-pricing-of-15-million-public-offering-philadelphia-and-van-bctxl-20250715monthly0.5https://www.biopharmawatch.com/news/BCTXL/briapro-therapeutic-corp-condesed-interim-consolidated-financial-statements-for-the-three--bctxl-20250618monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-announces-pricing-of-13-8-million-public-offering-philadelphia-and-v-bctxl-20250424monthly0.5https://www.biopharmawatch.com/news/BCTXL/briapro-therapeutic-corp-condesed-interim-consolidated-financial-statements-for-the-three--bctxl-20250312monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-announces-proposed-public-offering-of-common-shares-philadelphia-and-bctxl-20250203monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-announces-completion-of-15-1-share-consolidation-philadelphia-and-vancouver-briti-bctxl-20250127monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-announces-proposed-effective-date-of-share-consolidation-philadelphia-and-vancouv-bctxl-20250103monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-announces-rescheduling-of-its-annual-general-meeting-of-shareholders-to-bctxl-20250103monthly0.5https://www.biopharmawatch.com/news/BCTXL/briapro-therapeutic-corp-condesed-interim-consolidated-financial-statements-for-the-three--bctxl-20241216monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-announces-proposed-public-offering-philadelphia-and-vancouver-britis-bctxl-20241211monthly0.5https://www.biopharmawatch.com/news/BCTXL/briapro-therapeutic-corp-consolidated-financial-statements-for-the-period-ended-july-31-20-bctxl-20241101monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-announces-5-million-offering-priced-at-the-market-under-nasdaq-rules-bctxl-20241001monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-reports-100-resolution-of-brain-metastasis-in-breast-cancer-patient-with-eye-bulg-bctxl-20241001monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-announces-8-5-million-offering-priced-at-the-market-under-nasdaq-rul-bctxl-20240911monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-announces-presentation-at-the-2024-society-for-immunotherapy-of-cancer-sitc-annua-bctxl-20240909monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-quadruples-progression-free-survival-pfs-in-patient-with-eye-bulging-metastatic-b-bctxl-20240718monthly0.5https://www.biopharmawatch.com/news/BCTXL/briapro-therapeutic-corp-condesed-interim-financial-statements-for-the-three-and-nine-mont-bctxl-20240614monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-announces-pricing-of-5-0-million-registered-direct-offering-philadel-bctxl-20240515monthly0.5https://www.biopharmawatch.com/news/BCTXL/briapro-therapeutic-corp-condesed-interim-financial-statements-for-the-three-and-six-month-bctxl-20240402monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-reports-unprecedented-preliminary-survival-and-clinical-benefit-in-antibody-drug--bctxl-20231220monthly0.5https://www.biopharmawatch.com/news/BCTXL/briapro-therapeutic-corp-condesed-interim-financial-statements-for-the-three-month-period--bctxl-20231214monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-records-new-responder-with-remarkable-improvement-of-eye-bulging-metastatic-tumor-bctxl-20231130monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-reports-unprecedented-anti-tumor-activity-of-its-next-generation-personalized-bre-bctxl-20231103monthly0.5https://www.biopharmawatch.com/news/BCTXL/briapro-therapeutic-corp-financial-statements-for-the-period-ended-july-31-2023-expressed--bctxl-20231025monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-reports-benchmark-beating-patient-survival-and-clinical-benefit-in-advanced-metas-bctxl-20230908monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-corp-announces-closing-of-plan-of-arrangement-spinning-out-briapro-t-bctxl-20230831monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-receives-court-approval-for-the-share-arrangement-spinning-out-briapro-therapeuti-bctxl-20230825monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-corp-announces-voting-results-from-special-meeting-shareholders-over-bctxl-20230821monthly0.5https://www.biopharmawatch.com/news/BCTXL/fda-approves-briacell-s-pivotal-registrational-study-design-in-advanced-metastatic-breast--bctxl-20230627monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-enters-definitive-arrangement-agreement-for-the-spin-out-of-briapro-therapeutics--bctxl-20230525monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-closes-4-million-strategic-investment-by-prevail-partners-llc-at-us-8-63-per-shar-bctxl-20230519monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-announces-4-million-strategic-investment-and-clinical-alliance-with-prevail-partn-bctxl-20230515monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-presents-positive-data-demonstrating-survival-and-clinical-benefits-in-advanced-m-bctxl-20230417monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-announces-intention-to-spin-out-certain-pre-clinical-assets-into-a-newly-created--bctxl-20230331monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-reports-positive-survival-data-in-advanced-metastatic-breast-cancer-9-of-11-women-bctxl-20230223monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-corp-announces-results-of-shareholder-meeting-philadelphia-pa-and-va-bctxl-20230209monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-ceo-letter-to-shareholders-positive-fda-feedback-on-our-pivotal-study-for-lead-cl-bctxl-20230124monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-to-investigate-alleged-illegal-trading-of-public-securities-philadelphia-pa-and-v-bctxl-20230123monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-announces-positive-end-of-phase-ii-meeting-with-the-fda-for-bria-imt-combination--bctxl-20230118monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-announces-new-patent-issuance-bria-ots-ind-timing-guidance-and-additional-clinica-bctxl-20230110monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-announces-positive-clinical-and-quality-of-life-data-in-advanced-metastatic-breas-bctxl-20221208monthly0.5https://www.biopharmawatch.com/news/BCTXL/ipa-s-subsidiary-biostrand-and-briacell-announce-artificial-intelligence-collaboration-and-bctxl-20221130monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-reports-positive-breast-cancer-efficacy-data-with-bria-imt-immunotherapy-treatmen-bctxl-20221110monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-corp-condensed-consolidated-financial-statements-as-of-bctxl-20221028monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-announces-successful-completion-of-phase-i-portion-of-clinical-study-in-advanced--bctxl-20221021monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-partners-with-caris-life-sciences-to-expand-patient-outreach-and-molecular-profil-bctxl-20220914monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-secures-license-for-a-promising-novel-anti-cancer-agent-philadelphia-pa-and-vanco-bctxl-20220804monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-partners-with-waisman-biomanufacturing-to-manufacture-and-supply-prostate-cancer--bctxl-20220705monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-enters-research-agreement-to-identify-novel-targets-for-cancer-treatment-philadel-bctxl-20220629monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-anti-cancer-technology-published-in-leading-cancer-drug-discovery-journal-anti-ca-bctxl-20220624monthly0.5https://www.biopharmawatch.com/news/BCTXL/condensed-interim-consolidated-financial-statements-for-the-three-and-nine-months-ended-bctxl-20220613monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-adds-additional-clinical-sites-to-broaden-patient-access-and-further-boost-enroll-bctxl-20220518monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-receives-fda-fast-track-approval-for-targeted-breast-cancer-immunotherapy-u-s-foo-bctxl-20220413monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-presents-development-details-of-bria-ots-platform-technology-at-the-american-asso-bctxl-20220412monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-advances-preparatory-work-for-new-bria-ots-breast-cancer-clinical-trial-bria-ots--bctxl-20220407monthly0.5https://www.biopharmawatch.com/news/BCTXL/condensed-interim-consolidated-financial-statements-for-the-three-and-six-months-ended-bctxl-20220315monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-adds-two-clinical-trial-sites-to-accelerate-patient-enrollment-philadelphia-pa-an-bctxl-20220228monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-appoints-leading-immunologist-dr-alexander-kharazi-to-its-scientific-advisory-boa-bctxl-20220223monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-appoints-renowned-oncologist-giuseppe-del-priore-md-mph-as-chief-medical-officer--bctxl-20220216monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-to-present-at-the-aacr-2022-provides-corporate-buyback-and-insider-buying-update--bctxl-20220210monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-corp-announces-results-of-2022-annual-and-special-meeting-of-shareho-bctxl-20220119monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-corp-notice-of-annual-general-and-special-meeting-and-management-inf-bctxl-20220105monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-to-uplist-and-trade-on-the-toronto-stock-exchange-from-tsx-venture-exchange-under-bctxl-20211229monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-announces-insiders-intention-to-purchase-up-to-10-of-public-market-securities-ins-bctxl-20211217monthly0.5https://www.biopharmawatch.com/news/BCTXL/condensed-interim-consolidated-financial-statements-for-the-three-months-ended-bctxl-20211215monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-summarizes-clinical-data-poster-presented-at-the-2021-san-antonio-breast-cancer-s-bctxl-20211209monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-adds-mary-crowley-cancer-research-center-as-a-clinical-trial-site-for-its-phase-i-bctxl-20211118monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-announces-update-on-previously-announced-securities-buyback-program-and-participa-bctxl-20211112monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-adds-pioneering-immunologist-and-cancer-immunotherapy-expert-suzanne-ostrand-rose-bctxl-20211105monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-appoints-renowned-pharmaceutical-veteran-jane-gross-ph-d-to-its-board-of-director-bctxl-20211102monthly0.5https://www.biopharmawatch.com/news/BCTXL/consolidated-financial-statements-for-the-years-ended-bctxl-20211029monthly0.5https://www.biopharmawatch.com/news/BCTXL/october-is-breast-cancer-awareness-month-briacell-is-advancing-the-fight-with-its-immunoth-bctxl-20211005monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-announces-tsxv-acceptance-of-normal-course-issuer-bid-berkeley-calif-and-vancouve-bctxl-20210922monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-announces-securities-buyback-to-purchase-up-to-10-of-common-shares-and-up-to-10-o-bctxl-20210909monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-appoints-marc-lustig-to-its-board-of-directors-berkeley-calif-and-va-bctxl-20210901monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference-sep-bctxl-20210823monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology--bctxl-20210819monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-o-bctxl-20210714monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-to-present-at-three-upcoming-investor-conferences-berkeley-calif-and-vancouver-br-bctxl-20210712monthly0.5https://www.biopharmawatch.com/news/BCTXL/condensed-interim-consolidated-financial-statements-for-the-three-and-nine-months-ended-bctxl-20210630monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-expands-breast-cancer-platform-technology-into-prostate-melanoma-and-bctxl-20210616monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-announces-proceeds-of-us-12-88-million-from-warrant-exercises-procee-bctxl-20210610monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-to-hold-corporate-and-clinical-update-conference-call-wednesday-bctxl-20210609monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-corp-announces-closing-of-us-27-2-million-private-placement-berkeley-bctxl-20210607monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-corp-announces-us-27-2-million-private-placement-berkeley-calif-and--bctxl-20210603monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-reports-12-0-months-overall-survival-benefit-in-advanced-breast-cancer-100-resolu-bctxl-20210602monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-corp-announces-results-of-shareholder-meeting-berkeley-calif-and-van-bctxl-20210519monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-to-participate-at-upcoming-conferences-and-appoints-senior-r-d-director-berkeley--bctxl-20210511monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-announces-investor-and-media-outreach-programs-berkeley-calif-and-vancouver-briti-bctxl-20210415monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-announces-closing-of-over-allotment-option-in-connection-with-u-s-public-offering-bctxl-20210412monthly0.5https://www.biopharmawatch.com/news/BCTXL/condensed-interim-consolidated-financial-statements-for-the-three-and-six-months-ended-bctxl-20210401monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-therapeutics-to-present-at-the-american-association-for-cancer-research-annual-me-bctxl-20210330monthly0.5https://www.biopharmawatch.com/news/BCTXL/briacell-announces-pricing-of-us-25-million-public-offering-and-nasdaq-listing-berkeley-ca-bctxl-20210223monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerus-scni-20260512monthly0.5https://www.biopharmawatch.com/news/SCNI/recipharm-israel-ltd-audited-financial-statements-as-of-scni-20260508monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerus-scni-20251113monthly0.5https://www.biopharmawatch.com/news/SCNI/standby-equity-purchase-agreement-this-standby-equity-purchase-agreement-this-agreement-da-scni-20250910monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-reports-q1-2025-financial-results-highlighting-strong-cdmo-revenue-momentum-and-red-scni-20250602monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-announces-10-scni-20250305monthly0.5https://www.biopharmawatch.com/news/SCNI/standby-equity-purchase-agreement-this-standby-equity-purchase-agreement-this-agreement-da-scni-20250303monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-publishes-financial-results-and-provides-business-update-shareholders-equity-up-fro-scni-20241125monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerus-scni-20241015monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-publishes-q2-2024-financial-results-and-provides-business-update-restructures-29-mi-scni-20240909monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-regains-full-compliance-with-nasdaq-listing-requirements-jerusalem-israel-august-29-scni-20240827monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerus-scni-20240805monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerus-scni-20240708monthly0.5https://www.biopharmawatch.com/news/SCNI/click-to-edit-master-title-style-corporate-presentation-june-2024-nasdaq-scni-non-confiden-scni-20240614monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-con-scni-20240605monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-announces-receipt-of-a-nasdaq-staff-determination-letter-regardi-scni-20240520monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-announces-receipt-of-nasdaq-delisting-notification-and-appeal-th-scni-20240430monthly0.5https://www.biopharmawatch.com/news/SCNI/click-to-edit-master-title-style-corporate-presentation-april-2024-nasdaq-scni-non-confide-scni-20240425monthly0.5https://www.biopharmawatch.com/news/SCNI/click-to-edit-master-title-style-elevating-dermatological-drug-development-through-advance-scni-20240417monthly0.5https://www.biopharmawatch.com/news/SCNI/click-to-edit-master-title-style-corporate-presentation-january-2024-nasdaq-scni-click-to--scni-20240118monthly0.5https://www.biopharmawatch.com/news/SCNI/click-to-edit-master-title-style-corporate-presentation-january-2024-nasdaq-scni-click-to--scni-20240109monthly0.5https://www.biopharmawatch.com/news/SCNI/y-ea-s-t-p-i-chi-a-pas-t-or-i-s-il-17-is-a-cytokine-that-plays-a-key-role-in-the-developme-scni-20230922monthly0.5https://www.biopharmawatch.com/news/SCNI/y-ea-s-t-p-i-chi-a-pas-t-or-i-s-10-1-10-2-10-3-10-4-10-5-10-6-titer-tcid-50-g-limit-of-det-scni-20230911monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-rebrands-as-scinai-immunotherapeutics-ltd-to-reflect-new-focu-scni-20230906monthly0.5https://www.biopharmawatch.com/news/SCNI/yeast-pichia-pastoris-10-1-10-2-10-3-10-4-10-5-10-6-titer-tcid-50-g-limit-of-detection-9-8-scni-20230906monthly0.5https://www.biopharmawatch.com/news/SCNI/n-o-n-c-o-n-f-i-d-e-n-t-i-al-p-r-e-s-e-n-t-at-i-o-n-a-u-g-u-s-t-22-2023-this-communication-scni-20230823monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-financial-statements-as-of-june-30-2023-u-s-dollars-in-thousa-scni-20230818monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-reports-second-quarter-financial-results-and-provides-business-update-jerusalem-i-scni-20230811monthly0.5https://www.biopharmawatch.com/news/SCNI/nasdaq-grants-biondvax-extension-to-regain-compliance-with-listing-rules-jerusalem-israel-scni-20230801monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerusa-scni-20230712monthly0.5https://www.biopharmawatch.com/news/SCNI/nasdaq-bvxv-july-2023-2-this-communication-is-not-a-prospectus-or-offer-of-securities-for--scni-20230705monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerusa-scni-20230705monthly0.5https://www.biopharmawatch.com/news/SCNI/nasdaq-bvxv-may-2023-2-this-communication-is-not-a-prospectus-or-offer-of-securities-for-s-scni-20230504monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-s-innovative-inhaled-anti-sars-cov-2-nanoab-virtually-prevented-illness-when-admi-scni-20230123monthly0.5https://www.biopharmawatch.com/news/SCNI/amir-reichman-ceo-biotech-showcase-january-2023-2-this-communication-is-not-a-prospectus-o-scni-20230108monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-s-innovative-inhaled-covid-19-therapy-virtually-eliminated-sars-cov-2-virus-in-pr-scni-20230106monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-ceo-issues-letter-to-shareholders-jerusalem-israel-scni-20221230monthly0.5https://www.biopharmawatch.com/news/SCNI/nasdaq-bvxv-january-2023-2-this-communication-is-not-a-prospectus-or-offer-of-securities-f-scni-20221229monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-closing-of-8-million-underwritten-public-offering-jerusalem-scni-20221220monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-pricing-of-8-million-underwritten-public-offering-jerusalem-scni-20221216monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-regains-nasdaq-compliance-jerusalem-scni-20221212monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-third-quarter-2022-financial-results-and-provides-business-update-jerus-scni-20221130monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-reports-successful-results-in-preclinical-in-vivo-study-of-its-innovative-inhaled-scni-20221129monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerusa-scni-20221110monthly0.5https://www.biopharmawatch.com/news/SCNI/raft-meeting-6-9-november-2022-dalit-weinstein-fischer-2-this-communication-is-not-a-prosp-scni-20221108monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerusa-scni-20221104monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-financial-plans-to-support-its-ongoing-nanoab-pipeline-development-jeru-scni-20220930monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-s-strategic-research-collaboration-with-max-planck-and-umg-significant-progress-t-scni-20220920monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-second-quarter-2022-financial-results-and-provides-business-update-jeru-scni-20220825monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-and-european-investment-bank-sign-definitive-amendment-extending-maturity-of-loan-scni-20220810monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-receives-supportive-scientific-advice-from-the-paul-ehrlich-institute-pei-for-cov-scni-20220607monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-first-quarter-2022-financial-results-and-provides-business-update-jerus-scni-20220601monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerusa-scni-20220412monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerusa-scni-20220408monthly0.5https://www.biopharmawatch.com/news/SCNI/analyst-and-investor-webinar-scni-20220404monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerusa-scni-20220404monthly0.5https://www.biopharmawatch.com/news/SCNI/n-a-s-d-a-q-b-v-x-v-j-a-n-u-a-r-y-202-2-2-this-communication-contains-forward-looking-stat-scni-20220111monthly0.5https://www.biopharmawatch.com/news/SCNI/former-cfo-of-gsk-s-global-vaccines-business-mr-jay-green-joins-biondvax-s-board-of-direct-scni-20211227monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-pricing-of-9-0-million-follow-on-underwritten-offering-of-american-depo-scni-20211227monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-interim-financial-statements-as-of-september-30-2021-nis-in-t-scni-20211227monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-signs-definitive-agreements-for-development-and-commercialization-of-innovative-n-scni-20211222monthly0.5https://www.biopharmawatch.com/news/SCNI/amir-reichman-ceo-nasdaq-bvxv-december-2021-2-this-communication-is-not-a-prospectus-or-of-scni-20211213monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-third-quarter-2021-financial-results-and-provides-business-update-jerus-scni-20211130monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-notice-of-annual-general-meeting-of-shareholders-and-provides-a-busines-scni-20211124monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerusa-scni-20211122monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerusa-scni-20211112monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-advances-its-growth-strategy-towards-a-new-pipeline-based-on-innovative-vhh-antib-scni-20211019monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-second-quarter-2021-financial-results-and-provides-business-update-jeru-scni-20210826monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-first-quarter-2021-financial-results-and-provides-business-update-jerus-scni-20210623monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-fourth-quarter-and-full-year-2020-financial-results-and-provides-busine-scni-20210513monthly0.5https://www.biopharmawatch.com/news/SCNI/letter-to-shareholders-letter-from-biondvax-s-new-ceo-to-shareholders-scni-20210323monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-company-presentation-biondvax-pharmaceuticals-ltd-jerusalem-i-scni-20210322monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerusa-scni-20210304monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerusa-scni-20210224monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerusa-scni-20210217monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-exercise-in-full-of-underwriter-s-over-allotment-option-in-follow-on-of-scni-20210210monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-closing-of-12-1-million-follow-on-underwritten-offering-jerusalem-israe-scni-20210202monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-pricing-of-12-1-million-follow-on-underwritten-offering-of-american-dep-scni-20210129monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-launch-of-proposed-underwritten-follow-on-offering-of-american-deposita-scni-20210128monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-third-quarter-2020-financial-results-business-update-jerusalem-israel-scni-20210128monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-appointment-of-amir-reichman-as-new-ceo-pharma-industry-veteran-in-vacc-scni-20210121monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-topline-results-from-phase-3-clinical-trial-of-the-m-001-universal-infl-scni-20201023monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-at-the-market-atm-equity-offering-program-jerusalem-israel-scni-20201002monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-condensed-interim-financial-statements-as-of-june-30-2020-nis-scni-20201002monthly0.5https://www.biopharmawatch.com/news/SCNI/the-new-paradigm-the-universal-flu-vaccine-september-2020-2-this-presentation-is-not-a-pro-scni-20200901monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-second-quarter-2020-financial-results-jerusalem-israel-scni-20200820monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-notice-of-annual-general-meeting-of-shareholders-and-provides-a-clinica-scni-20200813monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerusa-scni-20200805monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerusa-scni-20200728monthly0.5https://www.biopharmawatch.com/news/SCNI/last-of-12-400-participants-completes-final-visit-in-biondvax-s-m-001-universal-flu-vaccin-scni-20200701monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-first-quarter-2020-financial-results-jerusalem-israel-scni-20200630monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-fourth-quarter-and-full-year-2019-financial-results-and-provides-busine-scni-20200612monthly0.5https://www.biopharmawatch.com/news/SCNI/nih-report-on-phase-2-clinical-trial-of-biondvax-s-m-001-universal-influenza-vaccine-candi-scni-20200610monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-receipt-of-4-2-million-through-exercise-of-warrants-jerusalem-israel-scni-20200520monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-upcoming-expiration-of-public-warrants-jerusalem-israel-scni-20200504monthly0.5https://www.biopharmawatch.com/news/SCNI/new-directors-elected-to-biondvax-s-board-of-directors-jerusalem-israel-scni-20200324monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-s-ceo-comments-on-impact-of-covid-19-pandemic-on-the-company-s-ongoing-phase-3-cl-scni-20200319monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerusa-scni-20200225monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerusa-scni-20200210monthly0.5https://www.biopharmawatch.com/news/SCNI/preliminary-data-from-nih-niaid-sponsored-phase-2-clinical-trial-of-biondvax-s-m-001-unive-scni-20200205monthly0.5https://www.biopharmawatch.com/news/SCNI/amendment-no-1-to-ads-warrant-agent-agreement-this-amendment-no-1-to-ads-warrant-agent-agr-scni-20200116monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerusa-scni-20200113monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-jerusalem-biopark-2-nd-floor-hadassah-ein-kerem-campus-jerusa-scni-20191231monthly0.5https://www.biopharmawatch.com/news/SCNI/third-quarter-2019-financial-results-and-business-update-scni-20191126monthly0.5https://www.biopharmawatch.com/news/SCNI/enrollment-and-randomization-of-12-463-participants-complete-in-biondvax-s-pivotal-clinica-scni-20191118monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-receives-4m-from-the-european-investment-bank-eib-in-support-of-ongoing-universal-scni-20191007monthly0.5https://www.biopharmawatch.com/news/SCNI/welcomes-new-chairman-of-the-board-and-announces-scni-20190828monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-rights-offering-fully-subscribed-at-us-20-million-funds-to-complete-ong-scni-20190716monthly0.5https://www.biopharmawatch.com/news/SCNI/first-participant-enrolled-in-second-cohort-of-biondvax-s-pivotal-clinical-efficacy-phase--scni-20190708monthly0.5https://www.biopharmawatch.com/news/SCNI/patent-covering-manufacturing-process-of-biondvax-s-m-001-universal-flu-vaccine-allowed-in-scni-20190618monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-first-quarter-2019-scni-20190530monthly0.5https://www.biopharmawatch.com/news/SCNI/letter-from-biondvax-ceo-regarding-biondvax-s-proposed-rights-offering-scni-20190514monthly0.5https://www.biopharmawatch.com/news/SCNI/announces-fourth-quarter-and-full-year-2018-financial-results-and-update-scni-20190501monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-notice-of-an-extraordinary-general-meeting-of-shareholders-to-scni-20190423monthly0.5https://www.biopharmawatch.com/news/SCNI/investment-bank-eib-extends-financing-agreement-to-24-million-scni-20190422monthly0.5https://www.biopharmawatch.com/news/SCNI/the-phase-3-universal-flu-vaccine-j-oshua-p-hillipson-a-pril-2-2019-scni-20190408monthly0.5https://www.biopharmawatch.com/news/SCNI/last-participant-out-in-usa-phase-2-clinical-trial-of-biondvax-s-m-001-universal-influenza-scni-20190321monthly0.5https://www.biopharmawatch.com/news/SCNI/quarter-2018-financial-results-scni-20181114monthly0.5https://www.biopharmawatch.com/news/SCNI/universal-flu-vaccine-phase-3-clinical-trial-completes-first-season-s-enrollment-of-4-098--scni-20181029monthly0.5https://www.biopharmawatch.com/news/SCNI/receives-8m-from-the-european-investment-bank-eib-in-support-of-manufacturing-facility-and-scni-20181023monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-moves-to-new-universal-flu-vaccine-manufacturing-facility-state-of-the-art-facili-scni-20180820monthly0.5https://www.biopharmawatch.com/news/SCNI/second-quarter-2018-financial-results-scni-20180822monthly0.5https://www.biopharmawatch.com/news/SCNI/arrangement-to-conclude-proceedings-subject-to-conditions-in-accordance-with-section-b-to--scni-20180820monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-receives-second-6m-tranche-disbursement-from-the-european-investment-bank-eib-scni-20180814monthly0.5https://www.biopharmawatch.com/news/SCNI/first-participant-enrolled-in-biondvax-s-universal-flu-vaccine-pivotal-phase-3-clinical-tr-scni-20180808monthly0.5https://www.biopharmawatch.com/news/SCNI/biotech-executive-mark-germain-joins-biondvax-s-board-of-directors-scni-20180628monthly0.5https://www.biopharmawatch.com/news/SCNI/receives-its-first-6m-tranche-disbursement-scni-20180625monthly0.5https://www.biopharmawatch.com/news/SCNI/first-quarter-2018-financial-scni-20180529monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-fourth-quarter-and-full-year-2017-financial-results-and-update-scni-20180430monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-begins-nih-sponsored-phase-2-clinical-trial-of-its-universal-flu-vaccine-in-the-u-scni-20180411monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-appoints-cro-to-conduct-pivotal-clinical-efficacy-phase-3-trial-of-its-novel-univ-scni-20180313monthly0.5https://www.biopharmawatch.com/news/SCNI/of-annual-and-extraordinary-general-meeting-of-shareholders-scni-20180222monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-plans-phase-3-clinical-trial-following-receipt-of-scientific-advice-from-the-euro-scni-20171227monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-s-ceo-issues-letter-to-shareholders-ness-ziona-israel-scni-20171205monthly0.5https://www.biopharmawatch.com/news/SCNI/provides-third-quarter-2017-financial-results-and-update-scni-20171130monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-and-nih-sign-clinical-trial-scni-20171124monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-closing-of-10-million-public-offering-of-american-depositary-shares-and-scni-20170918monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-pricing-of-public-offering-of-american-depositary-shares-scni-20170913monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-public-offering-of-american-depositary-shares-scni-20170913monthly0.5https://www.biopharmawatch.com/news/SCNI/provides-second-quarter-2017-financial-results-and-update-scni-20170831monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-receives-additional-grant-funding-israel-innovation-authority-approves-additional-scni-20170814monthly0.5https://www.biopharmawatch.com/news/SCNI/signs-lease-agreement-for-mid-size-commercial-facility-to-manufacture-universal-flu-vaccin-scni-20170720monthly0.5https://www.biopharmawatch.com/news/SCNI/ceo-provides-first-half-2017-general-corporate-update-scni-20170703monthly0.5https://www.biopharmawatch.com/news/SCNI/contract-is-made-on-june-2017-between-scni-20170619monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-scni-20170530monthly0.5https://www.biopharmawatch.com/news/SCNI/approved-for-grant-from-israel-s-ministry-of-economy-and-industry-to-scni-20170331monthly0.5https://www.biopharmawatch.com/news/SCNI/receives-us-2-8-million-investment-scni-20170103monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-phase-2b-trial-preliminary-safety-results-the-universal-flu-vaccine-candidate-is--scni-20161129monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-scni-20161128monthly0.5https://www.biopharmawatch.com/news/SCNI/position-notice-on-behalf-of-the-board-of-directors-of-biondvax-pharmaceuticals-ltd-the-co-scni-20160912monthly0.5https://www.biopharmawatch.com/news/SCNI/jfif-c-7-01444-9-82-s-ex-j-d-b-s-h-bf0-2-i-y-d-l1-b-w-o-l-w-i-s-a-sx-v-e-f-vf-d-zc-u-x-i-e-scni-20160912monthly0.5https://www.biopharmawatch.com/news/SCNI/jfif-c-c-r-1a-qa-q-2-b-r-3br-456789-cdef-scni-20160908monthly0.5https://www.biopharmawatch.com/news/SCNI/shai-ashkenazi-appointed-to-biondvax-s-scientific-advisory-board-scni-20160908monthly0.5https://www.biopharmawatch.com/news/SCNI/jfif-exif-mm-8icc-profile-kcms-mntrrgb-xyz-6-acspmsft-dell-koda-cprt-wtpt-scni-20160901monthly0.5https://www.biopharmawatch.com/news/SCNI/jfif-c-c-m-scni-20160818monthly0.5https://www.biopharmawatch.com/news/SCNI/accompanying-notes-are-an-integral-part-of-the-interim-financial-statements-scni-20160818monthly0.5https://www.biopharmawatch.com/news/SCNI/thousands-except-per-share-data-scni-20160531monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-receives-additional-grant-approval-israel-s-national-authority-for-technological--scni-20160218monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-s-universal-flu-vaccine-receives-additional-us-patent-broadens-biondvax-s-global--scni-20160127monthly0.5https://www.biopharmawatch.com/news/SCNI/patent-approval-for-biondvax-biondvax-receives-approval-for-a-patent-for-its-universal-flu-scni-20151222monthly0.5https://www.biopharmawatch.com/news/SCNI/receives-approval-for-patent-in-korea-for-its-universal-flu-scni-20151117monthly0.5https://www.biopharmawatch.com/news/SCNI/quarter-2015-financial-results-and-update-scni-20151109monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-successful-recruitment-of-the-first-participants-in-a-phase-iib-clinica-scni-20151021monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-establishes-capability-for-the-manufacture-of-clinical-grade-universal-flu-vaccin-scni-20151001monthly0.5https://www.biopharmawatch.com/news/SCNI/announces-intent-to-launch-a-phase-2-trial-in-the-scni-20150902monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-second-quarter-2015-financial-results-and-update-nes-ziona-israel-scni-20150824monthly0.5https://www.biopharmawatch.com/news/SCNI/results-show-that-biondvax-s-universal-flu-vaccine-scni-20150803monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-to-close-trading-on-nasdaq-on-july-scni-20150706monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-presents-bvx-006-preliminary-phase-ii-results-the-universal-flu-vaccine-at-higher-scni-20150629monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-announces-a-closing-of-over-allotment-option-ness-ziona-israe-scni-20150624monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-fda-acceptance-of-ind-application-for-its-investigational-universal-flu-scni-20150617monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-to-present-at-workshop-on-immunoassay-standardization-for-universal-flu-vaccines--scni-20150615monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-selected-as-part-of-ocs-iati-delegation-to-2015-bio-international-convention-in-p-scni-20150611monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-announces-first-quarter-2015-financial-results-nes-ziona-israel-scni-20150601monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-announces-closing-of-u-s-initial-public-offering-nes-ziona-is-scni-20150515monthly0.5https://www.biopharmawatch.com/news/SCNI/biondvax-pharmaceuticals-ltd-announces-pricing-of-u-s-initial-public-offering-of-1-910-000-scni-20150511monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-pharmaceuticals-plc-biodexa-or-the-company-results-of-annual-general-meeting-biode-bdrx-20250627monthly0.5https://www.biopharmawatch.com/news/BDRX/and-registered-in-england-and-wales-with-registered-no-bdrx-20250523monthly0.5https://www.biopharmawatch.com/news/BDRX/notice-of-general-meeting-biodexa-pharmaceuticals-plc-incorporated-and-registered-in-engla-bdrx-20250522monthly0.5https://www.biopharmawatch.com/news/BDRX/it-is-commonly-abbreviated-as-cik-bdrx-20240926monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-pharmaceuticals-plc-annual-report-and-accounts-2023biodexa-pharmaceuticals-plcannu-bdrx-20240515monthly0.5https://www.biopharmawatch.com/news/BDRX/april-2024-biodexa-pharmaceuticals-plc-biodexa-or-the-company-or-together-with-its-subsidi-bdrx-20240419monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-pharmaceuticals-plc-biodexa-or-the-company-biodexa-announces-pricing-of-5-2-millio-bdrx-20231221monthly0.5https://www.biopharmawatch.com/news/BDRX/november-2023-biodexa-pharmaceuticals-plc-biodexa-or-the-company-biodexa-enters-into-agree-bdrx-20231127monthly0.5https://www.biopharmawatch.com/news/BDRX/june-2023-biodexa-pharmaceuticals-plc-biodexa-or-the-company-receipt-of-nasdaq-delisting-d-bdrx-20230614monthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-pharmaceuticals-plc-annual-report-2022biodexa-pharmaceuticals-plc-formerly-midatec-bdrx-20230601monthly0.5https://www.biopharmawatch.com/news/BDRX/not-for-publication-distribution-or-release-directly-or-indirectly-in-whole-or-in-part-in--bdrx-20230524monthly0.5https://www.biopharmawatch.com/news/BDRX/april-2023-biodexa-pharmaceuticals-plc-biodexa-or-the-company-or-together-with-its-subsidi-bdrx-20230428monthly0.5https://www.biopharmawatch.com/news/BDRX/april-2023-biodexa-pharmaceuticals-plc-biodexa-or-the-company-exercise-of-pre-funded-warra-bdrx-20230419monthly0.5https://www.biopharmawatch.com/news/BDRX/april-2023-biodexa-pharmaceuticals-plc-biodexa-or-the-company-exercise-of-pre-funded-warra-bdrx-20230412monthly0.5https://www.biopharmawatch.com/news/BDRX/april-2023-biodexa-pharmaceuticals-plc-biodexa-or-the-company-exercise-of-pre-funded-warra-bdrx-20230407monthly0.5https://www.biopharmawatch.com/news/BDRX/april-2023-biodexa-pharmaceuticals-plc-biodexa-or-the-company-exercise-of-pre-funded-warra-bdrx-20230405monthly0.5https://www.biopharmawatch.com/news/BDRX/march-2023-biodexa-pharmaceuticals-plc-biodexa-or-the-company-exercise-of-warrants-and-iss-bdrx-20230330monthly0.5https://www.biopharmawatch.com/news/BDRX/march-2023-midatech-pharma-plc-midatech-or-the-company-new-preclinical-r-d-programme-focus-bdrx-20230327monthly0.5https://www.biopharmawatch.com/news/BDRX/march-2023-midatech-pharma-plc-midatech-or-the-company-results-of-general-meeting-share-co-bdrx-20230324monthly0.5https://www.biopharmawatch.com/news/BDRX/march-2023-midatech-pharma-plc-midatech-or-the-company-further-re-notice-of-general-meetin-bdrx-20230310monthly0.5https://www.biopharmawatch.com/news/BDRX/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-bdrx-20230308monthly0.5https://www.biopharmawatch.com/news/BDRX/february-2023-midatech-pharma-plc-midatech-or-the-company-closing-of-us-6-0-million-privat-bdrx-20230215monthly0.5https://www.biopharmawatch.com/news/BDRX/this-announcement-and-the-information-contained-herein-the-announcement-is-restricted-and--bdrx-20230209monthly0.5https://www.biopharmawatch.com/news/BDRX/january-2023-midatech-pharma-plc-midatech-or-the-company-result-of-general-meeting-appoint-bdrx-20230123monthly0.5https://www.biopharmawatch.com/news/BDRX/january-2023-midatech-pharma-plc-midatech-or-the-company-planned-dose-escalation-in-phase--bdrx-20230112monthly0.5https://www.biopharmawatch.com/news/BDRX/information-relating-to-midatech-midatech-business-midatech-is-focused-on-the-research-and-bdrx-20230111monthly0.5https://www.biopharmawatch.com/news/BDRX/this-document-and-the-enclosed-form-of-proxy-are-important-and-require-your-immediate-atte-bdrx-20230106monthly0.5https://www.biopharmawatch.com/news/BDRX/not-for-publication-distribution-or-release-directly-or-indirectly-in-whole-or-in-part-in--bdrx-20221219monthly0.5https://www.biopharmawatch.com/news/BDRX/explanatory-note-on-bdrx-20221213monthly0.5https://www.biopharmawatch.com/news/BDRX/not-for-publication-distribution-or-release-directly-or-indirectly-in-whole-or-in-part-in--bdrx-20221213monthly0.5https://www.biopharmawatch.com/news/BDRX/november-2022-midatech-pharma-plc-midatech-or-the-company-first-patient-enrolled-in-phase--bdrx-20221114monthly0.5https://www.biopharmawatch.com/news/BDRX/september-2022-midatech-pharma-plc-midatech-or-the-company-adr-ratio-change-midatech-pharm-bdrx-20220914monthly0.5https://www.biopharmawatch.com/news/BDRX/june-2022-midatech-pharma-plc-midatech-or-the-company-directorate-change-midatech-pharma-p-bdrx-20220621monthly0.5https://www.biopharmawatch.com/news/BDRX/june-2022-midatech-pharma-plc-midatech-or-the-company-retirement-of-chairman-and-proposed--bdrx-20220610monthly0.5https://www.biopharmawatch.com/news/BDRX/june-2022-midatech-pharma-plc-midatech-or-the-company-fast-track-designation-granted-to-mt-bdrx-20220606monthly0.5https://www.biopharmawatch.com/news/BDRX/april-2022-midatech-pharma-plc-midatech-or-the-company-or-together-with-its-subsidiaries-t-bdrx-20220426monthly0.5https://www.biopharmawatch.com/news/BDRX/april-2022-midatech-pharma-plc-midatech-or-the-company-receipt-of-nasdaq-notice-midatech-p-bdrx-20220414monthly0.5https://www.biopharmawatch.com/news/BDRX/march-2022-midatech-pharma-plc-midatech-or-the-company-midatech-announces-r-d-collaboratio-bdrx-20220309monthly0.5https://www.biopharmawatch.com/news/BDRX/january-2022-midatech-pharma-plc-midatech-or-the-company-midatech-announces-extension-of-r-bdrx-20220118monthly0.5https://www.biopharmawatch.com/news/BDRX/december-2021-midatech-pharma-plc-midatech-or-the-company-investigational-new-drug-applica-bdrx-20211213monthly0.5https://www.biopharmawatch.com/news/BDRX/september-2021-midatech-pharma-plc-midatech-or-the-company-interim-results-for-the-six-mon-bdrx-20210917monthly0.5https://www.biopharmawatch.com/news/BDRX/june-2021-midatech-pharma-plc-midatech-or-the-company-result-of-2021-annual-general-meetin-bdrx-20210818monthly0.5https://www.biopharmawatch.com/news/BDRX/june-2021-not-for-publication-distribution-or-release-directly-or-indirectly-in-whole-or-i-bdrx-20210629monthly0.5https://www.biopharmawatch.com/news/BDRX/june-2021-midatech-pharma-plc-midatech-or-the-company-breakthrough-data-on-the-successful--bdrx-20210617monthly0.5https://www.biopharmawatch.com/news/BDRX/april-2021-midatech-pharma-plc-midatech-or-the-company-or-together-with-its-subsidiaries-t-bdrx-20210430monthly0.5https://www.biopharmawatch.com/news/BDRX/march-2021-midatech-pharma-plc-midatech-or-the-company-non-binding-heads-of-terms-for-mtx1-bdrx-20210325monthly0.5https://www.biopharmawatch.com/news/BDRX/january-2021-midatech-pharma-plc-midatech-or-the-company-business-update-midatech-pharma-p-bdrx-20210126monthly0.5https://www.biopharmawatch.com/news/BDRX/december-2020-midatech-pharma-plc-midatech-or-the-company-mtx110-programmes-to-be-presente-bdrx-20201215monthly0.5https://www.biopharmawatch.com/news/BDRX/november-2020-midatech-pharma-plc-midatech-or-the-company-mtx110-phase-i-trial-results-in--bdrx-20201124monthly0.5https://www.biopharmawatch.com/news/BDRX/october-2020-midatech-pharma-plc-midatech-or-the-company-headline-results-of-mtx110-phase--bdrx-20201019monthly0.5https://www.biopharmawatch.com/news/BDRX/september-2020-midatech-pharma-plc-midatech-or-the-company-interim-results-for-the-six-mon-bdrx-20200910monthly0.5https://www.biopharmawatch.com/news/BDRX/august-2020-midatech-pharma-plc-midatech-or-the-company-exercise-of-warrants-and-issue-of--bdrx-20200819monthly0.5https://www.biopharmawatch.com/news/BDRX/august-2020-midatech-pharma-plc-midatech-or-the-company-registration-statement-on-form-f-1-bdrx-20200814monthly0.5https://www.biopharmawatch.com/news/BDRX/july-2020-midatech-pharma-plc-midatech-or-the-company-result-of-2020-annual-general-meetin-bdrx-20200804monthly0.5https://www.biopharmawatch.com/news/BDRX/july-2020-midatech-pharma-plc-midatech-or-the-company-broker-option-fully-exercised-and-to-bdrx-20200727monthly0.5https://www.biopharmawatch.com/news/BDRX/july-2020-not-for-publication-distribution-or-release-directly-or-indirectly-in-whole-or-i-bdrx-20200727monthly0.5https://www.biopharmawatch.com/news/BDRX/july-2020-midatech-pharma-plc-midatech-or-the-company-corporate-update-and-termination-of--bdrx-20200723monthly0.5https://www.biopharmawatch.com/news/BDRX/july-2020-midatech-pharma-plc-midatech-or-the-company-midatech-adds-to-collaborative-busin-bdrx-20200721monthly0.5https://www.biopharmawatch.com/news/BDRX/june-2020-midatech-pharma-plc-midatech-or-the-company-preliminary-results-for-the-year-end-bdrx-20200616monthly0.5https://www.biopharmawatch.com/news/BDRX/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-eu-regulati-bdrx-20200609monthly0.5https://www.biopharmawatch.com/news/BDRX/june-2020-midatech-pharma-plc-midatech-or-the-company-midatech-enters-into-research-collab-bdrx-20200608monthly0.5https://www.biopharmawatch.com/news/BDRX/may-2020-midatech-pharma-plc-midatech-or-the-company-midatech-pharma-plc-announces-closing-bdrx-20200521monthly0.5https://www.biopharmawatch.com/news/BDRX/may-2020-midatech-pharma-plc-midatech-or-the-company-amendment-to-relationship-agreement-m-bdrx-20200512monthly0.5https://www.biopharmawatch.com/news/BDRX/not-for-release-publication-or-distribution-in-whole-or-in-part-directly-or-indirectly-in--bdrx-20200420monthly0.5https://www.biopharmawatch.com/news/BDRX/march-2020-midatech-pharma-plc-midatech-or-the-company-announcement-of-strategic-review-te-bdrx-20200331monthly0.5https://www.biopharmawatch.com/news/BDRX/march-2020-midatech-pharma-plc-midatech-or-the-company-result-of-general-meeting-adr-ratio-bdrx-20200302monthly0.5https://www.biopharmawatch.com/news/BDRX/february-2020-midatech-pharma-plc-midatech-or-the-company-midatech-pharma-announces-postin-bdrx-20200212monthly0.5https://www.biopharmawatch.com/news/BDRX/january-2020-midatech-pharma-plc-midatech-or-the-company-positive-results-from-mtd201-102--bdrx-20200108monthly0.5https://www.biopharmawatch.com/news/BDRX/december-2019-midatech-pharma-plc-midatech-or-the-company-receipt-of-nasdaq-notice-midatec-bdrx-20191216monthly0.5https://www.biopharmawatch.com/news/BDRX/december-2019-midatech-pharma-plc-midatech-or-the-company-midatech-pharma-announces-confir-bdrx-20191205monthly0.5https://www.biopharmawatch.com/news/BDRX/october-2019-midatech-pharma-plc-midatech-or-the-company-midatech-pharma-plc-announces-clo-bdrx-20191021monthly0.5https://www.biopharmawatch.com/news/BDRX/october-2019-midatech-pharma-plc-midatech-or-the-company-total-voting-rights-midatech-aim--bdrx-20191028monthly0.5https://www.biopharmawatch.com/news/BDRX/october-2019-midatech-pharma-plc-midatech-or-the-company-midatech-s-mtx110-receives-orphan-bdrx-20191024monthly0.5https://www.biopharmawatch.com/news/BDRX/october-2019-midatech-pharma-plc-midatech-or-the-company-commencement-of-mtd201-phase-1-st-bdrx-20191009monthly0.5https://www.biopharmawatch.com/news/BDRX/october-2019-midatech-pharma-plc-midatech-or-the-company-issue-of-equity-for-midatech-empl-bdrx-20191007monthly0.5https://www.biopharmawatch.com/news/BDRX/october-2019-midatech-pharma-plc-midatech-or-the-company-pdmr-dealing-midatech-aim-mtph-l--bdrx-20191004monthly0.5https://www.biopharmawatch.com/news/BDRX/october-2019-midatech-pharma-plc-midatech-or-the-company-award-of-options-to-a-director-mi-bdrx-20191002monthly0.5https://www.biopharmawatch.com/news/BDRX/midatech-will-host-a-conference-call-and-live-q-a-session-today-monday-30-september-2019-a-bdrx-20190930monthly0.5https://www.biopharmawatch.com/news/BDRX/september-2019-a-shelf-registration-statement-has-been-filed-with-the-united-states-securi-bdrx-20190924monthly0.5https://www.biopharmawatch.com/news/BDRX/september-2019-midatech-pharma-plc-midatech-or-the-company-mtd201-phase-1-study-approval-m-bdrx-20190920monthly0.5https://www.biopharmawatch.com/news/BDRX/september-2019-midatech-pharma-plc-midatech-or-the-company-receipt-of-spanish-government-l-bdrx-20190911monthly0.5https://www.biopharmawatch.com/news/BDRX/september-2019-midatech-pharma-plc-midatech-or-the-company-directorate-change-midatech-pha-bdrx-20190909monthly0.5https://www.biopharmawatch.com/news/BDRX/july-2019-midatech-pharma-plc-midatech-or-the-company-appointment-of-non-executive-directo-bdrx-20190731monthly0.5https://www.biopharmawatch.com/news/BDRX/july-2019-midatech-pharma-plc-midatech-or-the-company-midatech-announces-positive-safety-r-bdrx-20190719monthly0.5https://www.biopharmawatch.com/news/BDRX/july-2019-midatech-pharma-plc-midatech-or-the-company-mtx110-update-midatech-pharma-plc-ai-bdrx-20190703monthly0.5https://www.biopharmawatch.com/news/BDRX/june-2019-midatech-pharma-plc-midatech-or-the-company-result-of-agm-midatech-pharma-plc-ai-bdrx-20190619monthly0.5https://www.biopharmawatch.com/news/BDRX/june-2019-midatech-pharma-plc-midatech-or-the-company-mtd201-development-plan-midatech-pha-bdrx-20190613monthly0.5https://www.biopharmawatch.com/news/BDRX/may-2019-midatech-pharma-plc-midatech-or-the-company-posting-of-annual-report-notice-of-ag-bdrx-20190524monthly0.5https://www.biopharmawatch.com/news/BDRX/midatech-will-host-a-conference-call-and-live-q-a-session-today-wednesday-24-april-2019-at-bdrx-20190424monthly0.5https://www.biopharmawatch.com/news/BDRX/march-2019-midatech-pharma-plc-midatech-or-the-company-approval-received-for-spanish-gover-bdrx-20190329monthly0.5https://www.biopharmawatch.com/news/BDRX/march-2019-midatech-pharma-plc-midatech-or-the-company-adr-ratio-change-midatech-pharma-ai-bdrx-20190320monthly0.5https://www.biopharmawatch.com/news/BDRX/not-for-publication-distribution-or-release-directly-or-indirectly-in-whole-or-in-part-in--bdrx-20190226monthly0.5https://www.biopharmawatch.com/news/BDRX/february-2019-midatech-pharma-plc-midatech-company-or-group-posting-of-circular-and-notice-bdrx-20190208monthly0.5https://www.biopharmawatch.com/news/BDRX/not-for-publication-distribution-or-release-directly-or-indirectly-in-whole-or-in-part-in--bdrx-20190205monthly0.5https://www.biopharmawatch.com/news/BDRX/this-announcement-contains-inside-information-for-the-purposes-of-the-market-abuse-regulat-bdrx-20190129monthly0.5https://www.biopharmawatch.com/news/BDRX/january-2019-midatech-pharma-plc-midatech-company-or-group-midatech-receives-fda-feedback--bdrx-20190125monthly0.5https://www.biopharmawatch.com/news/BDRX/january-2019-midatech-pharma-plc-midatech-company-or-group-midatech-announces-eur-1-5-mill-bdrx-20190110monthly0.5https://www.biopharmawatch.com/news/BDRX/december-2018-midatech-pharma-plc-midatech-company-or-group-midatech-announces-q-sphera-mi-bdrx-20181220monthly0.5https://www.biopharmawatch.com/news/BDRX/november-2018-midatech-pharma-plc-midatech-company-or-group-completion-of-midatech-pharma--bdrx-20181108monthly0.5https://www.biopharmawatch.com/news/BDRX/november-2018-midatech-pharma-plc-midatech-company-or-group-nasdaq-minimum-bid-price-exten-bdrx-20181101monthly0.5https://www.biopharmawatch.com/news/BDRX/october-2018-midatech-pharma-plc-midatech-company-or-group-result-of-general-meeting-midat-bdrx-20181015monthly0.5https://www.biopharmawatch.com/news/BDRX/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-bdrx-20180928monthly0.5https://www.biopharmawatch.com/news/BDRX/september-2018-midatech-pharma-plc-midatech-or-the-company-posting-of-circular-and-notice--bdrx-20180928monthly0.5https://www.biopharmawatch.com/news/BDRX/august-2018-midatech-pharma-plc-midatech-or-the-company-midatech-announces-interim-results-bdrx-20180831monthly0.5https://www.biopharmawatch.com/news/BDRX/august-2018-issue-of-equity-for-midatech-share-incentive-plan-midatech-pharma-aim-mtph-nas-bdrx-20180801monthly0.5https://www.biopharmawatch.com/news/BDRX/july-2018-trading-update-midatech-pharma-aim-mtph-nasdaq-mtp-the-international-specialty-p-bdrx-20180725monthly0.5https://www.biopharmawatch.com/news/BDRX/july-2018-midatech-pharma-plc-midatech-company-or-group-midatech-pharma-us-announces-co-pr-bdrx-20180723monthly0.5https://www.biopharmawatch.com/news/BDRX/june-2018-midatech-pharma-plc-midatech-company-or-group-midatech-pharma-us-enrols-first-pa-bdrx-20180608monthly0.5https://www.biopharmawatch.com/news/BDRX/june-2018-midatech-pharma-plc-midatech-company-or-group-2017-annual-report-and-agm-notific-bdrx-20180601monthly0.5https://www.biopharmawatch.com/news/BDRX/may-2018-midatech-pharma-plc-midatech-company-or-group-midatech-commences-us-clinical-stud-bdrx-20180525monthly0.5https://www.biopharmawatch.com/news/BDRX/may-2018-midatech-pharma-plc-midatech-company-or-group-midatech-commences-equivalence-stud-bdrx-20180521monthly0.5https://www.biopharmawatch.com/news/BDRX/may-2018-midatech-pharma-plc-midatech-or-the-company-statement-regarding-share-price-movem-bdrx-20180503monthly0.5https://www.biopharmawatch.com/news/BDRX/midatech-will-host-a-conference-call-and-live-q-a-session-today-monday-23-april-2018-at-14-bdrx-20180423monthly0.5https://www.biopharmawatch.com/news/BDRX/april-2018-midatech-pharma-plc-midatech-or-the-company-notice-of-preliminary-results-midat-bdrx-20180409monthly0.5https://www.biopharmawatch.com/news/BDRX/march-2018-midatech-pharma-plc-midatech-or-the-company-midatech-announces-changes-in-senio-bdrx-20180315monthly0.5https://www.biopharmawatch.com/news/BDRX/february-2018-midatech-pharma-plc-midatech-or-the-company-midatech-receives-orphan-drug-de-bdrx-20180228monthly0.5https://www.biopharmawatch.com/news/BDRX/february-2018-midatech-pharma-plc-midatech-company-or-group-trading-update-midatech-aim-mt-bdrx-20180214monthly0.5https://www.biopharmawatch.com/news/BDRX/january-2018-midatech-pharma-plc-midatech-company-or-group-midatech-and-ucsf-receive-ind-a-bdrx-20180116monthly0.5https://www.biopharmawatch.com/news/BDRX/january-9018-midatech-pharma-plc-midatech-or-the-company-midatech-receives-confirmation-th-bdrx-20180109monthly0.5https://www.biopharmawatch.com/news/BDRX/january-2018-midatech-pharma-plc-midatech-or-the-company-midatech-enters-into-a-loan-agree-bdrx-20180102monthly0.5https://www.biopharmawatch.com/news/BDRX/december-2017-midatech-pharma-plc-midatech-or-the-company-midatech-pharma-us-initiates-gel-bdrx-20171220monthly0.5https://www.biopharmawatch.com/news/BDRX/november-2017-midatech-pharma-plc-midatech-or-the-company-midatech-receives-manufacturing--bdrx-20171122monthly0.5https://www.biopharmawatch.com/news/BDRX/november-2017-midatech-pharma-plc-midatech-company-or-group-issue-of-equity-for-midatech-p-bdrx-20171107monthly0.5https://www.biopharmawatch.com/news/BDRX/october-2017-midatech-pharma-plc-midatech-or-the-company-result-of-open-offer-result-of-ge-bdrx-20171016monthly0.5https://www.biopharmawatch.com/news/BDRX/september-2017-midatech-pharma-plc-midatech-or-the-company-results-of-placing-to-raise-6-m-bdrx-20170929monthly0.5https://www.biopharmawatch.com/news/BDRX/this-announcement-including-the-appendices-and-the-information-contained-herein-is-restric-bdrx-20170928monthly0.5https://www.biopharmawatch.com/news/BDRX/september-2017-midatech-pharma-plc-midatech-company-or-group-notice-of-interim-results-mid-bdrx-20170907monthly0.5https://www.biopharmawatch.com/news/BDRX/september-2017-midatech-pharma-plc-midatech-company-or-group-midatech-submits-mtd201-cta-f-bdrx-20170905monthly0.5https://www.biopharmawatch.com/news/BDRX/july-2017-midatech-pharma-plc-midatech-company-or-group-completion-of-pre-clinical-liver-c-bdrx-20170726monthly0.5https://www.biopharmawatch.com/news/BDRX/execution-copy-confidential-treatment-requested-certain-portions-of-this-document-have-bee-bdrx-20170719monthly0.5https://www.biopharmawatch.com/news/BDRX/july-2017-midatech-pharma-plc-midatech-company-or-group-trading-update-and-notice-of-resul-bdrx-20170718monthly0.5https://www.biopharmawatch.com/news/BDRX/june-2017-midatech-pharma-plc-midatech-company-or-group-r-d-manufacturing-site-visit-for-i-bdrx-20170613monthly0.5https://www.biopharmawatch.com/news/BDRX/june-2017-midatech-pharma-plc-midatech-company-or-group-midatech-signs-global-license-agre-bdrx-20170607monthly0.5https://www.biopharmawatch.com/news/BDRX/may-2017-midatech-pharma-plc-midatech-company-or-group-midatech-announces-progress-update--bdrx-20170522monthly0.5https://www.biopharmawatch.com/news/BDRX/may-2017-midatech-pharma-plc-midatech-company-or-group-issue-of-equity-for-midatech-pharma-bdrx-20170519monthly0.5https://www.biopharmawatch.com/news/BDRX/may-2017-midatech-pharma-plc-midatech-company-or-group-result-of-annual-general-meeting-mi-bdrx-20170504monthly0.5https://www.biopharmawatch.com/news/BDRX/midatech-will-host-a-conference-call-and-live-q-a-session-today-tuesday-4-april-2017-at-14-bdrx-20170403monthly0.5https://www.biopharmawatch.com/news/BDRX/march-2017-midatech-pharma-plc-midatech-company-or-group-notice-of-preliminary-results-mid-bdrx-20170314monthly0.5https://www.biopharmawatch.com/news/BDRX/march-2017-midatech-pharma-plc-midatech-or-the-company-midatech-announces-successful-initi-bdrx-20170310monthly0.5https://www.biopharmawatch.com/news/BDRX/february-2017-midatech-pharma-plc-midatech-or-the-company-midatech-enters-into-a-loan-agre-bdrx-20170227monthly0.5https://www.biopharmawatch.com/news/BDRX/january-2017-midatech-pharma-plc-midatech-company-or-group-trading-update-midatech-pharma--bdrx-20170120monthly0.5https://www.biopharmawatch.com/news/BDRX/december-2016-midatech-pharma-plc-midatech-or-the-company-director-pdmr-shareholding-midat-bdrx-20161220monthly0.5https://www.biopharmawatch.com/news/BDRX/november-2016-midatech-pharma-plc-midatech-or-the-company-midatech-provides-update-on-agre-bdrx-20161122monthly0.5https://www.biopharmawatch.com/news/BDRX/november-2016-midatech-pharma-plc-midatech-or-the-company-midatech-selects-mtr104-candidat-bdrx-20161115monthly0.5https://www.biopharmawatch.com/news/BDRX/this-announcement-and-the-information-contained-herein-is-restricted-and-is-not-for-public-bdrx-20161028monthly0.5https://www.biopharmawatch.com/news/BDRX/this-announcement-including-the-appendices-and-the-information-contained-herein-is-restric-bdrx-20161011monthly0.5https://www.biopharmawatch.com/news/BDRX/august-2016-midatech-pharma-plc-midatech-or-the-company-trading-update-and-notice-of-resul-bdrx-20160810monthly0.5https://www.biopharmawatch.com/news/BDRX/july-2016-grant-funding-received-to-explore-midatech-s-gold-nanoparticle-technology-in-imm-bdrx-20160707monthly0.5https://www.biopharmawatch.com/news/BDRX/june-2016-annual-report-posting-midatech-pharma-aim-mtph-nasdaq-mtp-announces-that-in-acco-bdrx-20160701monthly0.5https://www.biopharmawatch.com/news/BDRX/june-2016-midatech-pharma-plc-midatech-or-the-company-issue-of-equity-and-director-s-deali-bdrx-20160627monthly0.5https://www.biopharmawatch.com/news/BDRX/may-2016-midatech-pharma-plc-midatech-or-the-company-midatech-pharma-announces-clinical-pi-bdrx-20160518monthly0.5https://www.biopharmawatch.com/news/BDRX/may-2016-midatech-pharma-plc-midatech-or-the-company-agm-statement-and-update-on-trading-m-bdrx-20160511monthly0.5https://www.biopharmawatch.com/news/BDRX/april-2016-midatech-pharma-plc-midatech-or-the-company-midatech-pharma-announces-positive--bdrx-20160426monthly0.5https://www.biopharmawatch.com/news/BDRX/april-2016-midatech-pharma-plc-midatech-or-the-company-midatech-achieves-positive-dosing-d-bdrx-20160421monthly0.5https://www.biopharmawatch.com/news/BDRX/midatech-will-host-a-conference-call-and-live-q-a-session-today-wednesday-13-april-2016-at-bdrx-20160413monthly0.5https://www.biopharmawatch.com/news/BDRX/april-2016-midatech-pharma-plc-midatech-or-the-company-midatech-s-commercial-launch-of-zup-bdrx-20160411monthly0.5https://www.biopharmawatch.com/news/BDRX/march-2016-midatech-pharma-plc-midatech-the-company-or-the-group-notice-of-audited-full-ye-bdrx-20160310monthly0.5https://www.biopharmawatch.com/news/BDRX/february-2016-midatech-pharma-plc-midatech-the-company-or-the-group-midatech-pharma-recogn-bdrx-20160229monthly0.5https://www.biopharmawatch.com/news/BDRX/for-filings-with-the-fsa-include-the-annex-for-filings-with-issuer-exclude-the-annex-tr-1--bdrx-20160225monthly0.5https://www.biopharmawatch.com/news/BDRX/january-2016-midatech-pharma-plc-midatech-the-company-or-the-group-pre-close-trading-updat-bdrx-20160106monthly0.5https://www.biopharmawatch.com/news/BDRX/january-2016-midatech-pharma-plc-midatech-or-the-company-midatech-signs-licencing-agreemen-bdrx-20160105monthly0.5https://www.biopharmawatch.com/news/BDRX/december-2015-midatech-pharma-plc-midatech-or-the-company-issue-of-equity-midatech-aim-mtp-bdrx-20151230monthly0.5https://www.biopharmawatch.com/news/BDRX/december-2015-midatech-pharma-plc-midatech-or-the-company-midatech-agrees-to-acquire-marke-bdrx-20151218monthly0.5https://www.biopharmawatch.com/news/BDRX/december-2015-midatech-pharma-plc-midatech-or-the-company-midatech-signs-supply-agreement--bdrx-20151214monthly0.5https://www.biopharmawatch.com/news/BDRX/not-for-release-publication-or-distribution-in-whole-or-in-part-in-or-into-or-from-any-jur-bdrx-20151207monthly0.5https://www.biopharmawatch.com/news/BDRX/not-for-release-publication-or-distribution-in-whole-or-in-part-in-or-into-or-from-any-jur-bdrx-20151203monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-inc-nasdaq-adtx-press-release-for-immediate-release-aditxt-inc-appoints-jeffrey-m-b-adtx-20260601monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-inc-nasdaq-adtx-announces-1-for-27-reverse-stock-split-effective-at-the-open-of-tra-adtx-20260518monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-inc-nasdaq-adtx-announces-1-for-8-reverse-stock-split-effective-at-the-open-of-trad-adtx-20260305monthly0.5https://www.biopharmawatch.com/news/ADTX/dated-november-18-2025-e-xhibit-99-1-aditxt-provides-updates-on-its-growth-vision-for-bitx-adtx-20251118monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-inc-nasdaq-adtx-announces-1-for-113-reverse-stock-split-effective-at-the-open-of-tr-adtx-20251103monthly0.5https://www.biopharmawatch.com/news/ADTX/00-00-alright-all-welcome-everybody-to-wall-street-reporters-next-super-stock-live-stream--adtx-20250811monthly0.5https://www.biopharmawatch.com/news/ADTX/jack-marks-00-24-okay-welcome-everybody-to-wall-street-reporters-next-super-stock-live-str-adtx-20250724monthly0.5https://www.biopharmawatch.com/news/ADTX/page-1-pearsanta-pioneering-the-future-of-early-disease-detection-transforming-lives-throu-adtx-20250721monthly0.5https://www.biopharmawatch.com/news/ADTX/jack-marks-00-01-okay-and-we-re-live-alright-welcome-everybody-to-wall-street-reporter-s-n-adtx-20250710monthly0.5https://www.biopharmawatch.com/news/ADTX/00-00-welcome-everybody-to-wall-street-reporters-next-super-stock-live-stream-where-we-bri-adtx-20250701monthly0.5https://www.biopharmawatch.com/news/ADTX/amro-albanna-00-07-okay-we-re-just-gonna-we-re-just-gonna-go-ahead-and-wait-a-few-seconds--adtx-20250609monthly0.5https://www.biopharmawatch.com/news/ADTX/amro-albanna-00-04-welcome-everybody-just-as-always-i-m-gonna-wait-a-few-seconds-here-to-s-adtx-20250602monthly0.5https://www.biopharmawatch.com/news/ADTX/amro-albanna-00-20-jeff-as-we-have-done-in-the-past-let-s-just-wait-to-see-who-s-joining-i-adtx-20250519monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-announces-termination-of-arrangement-agreement-with-appili-therapeutics-will-elimin-adtx-20250519monthly0.5https://www.biopharmawatch.com/news/ADTX/amro-albanna-00-12-i-see-one-attendee-jeff-00-35-hello-everybody-i-see-people-are-joining--adtx-20250515monthly0.5https://www.biopharmawatch.com/news/ADTX/amro-albanna-00-05-all-right-welcome-everybody-i-do-see-people-are-starting-to-join-so-i-m-adtx-20250505monthly0.5https://www.biopharmawatch.com/news/ADTX/amro-albanna-00-09-so-steve-we-ll-just-wait-a-couple-few-seconds-here-because-for-some-rea-adtx-20250422monthly0.5https://www.biopharmawatch.com/news/ADTX/amro-albanna-00-03-all-right-so-we-ll-go-ahead-and-just-wait-for-i-guess-five-or-10-second-adtx-20250414monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-inc-nasdaq-adtx-regains-compliance-with-nasdaq-listing-requirements-mountain-view-c-adtx-20250409monthly0.5https://www.biopharmawatch.com/news/ADTX/amro-albanna-00-03-all-right-folks-those-that-are-just-joining-us-we-re-going-to-go-ahead--adtx-20250407monthly0.5https://www.biopharmawatch.com/news/ADTX/amro-albanna-00-04-very-good-let-s-get-started-thank-you-for-joining-this-is-again-our-adi-adtx-20250331monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technolog-adtx-20250324monthly0.5https://www.biopharmawatch.com/news/ADTX/amro-albanna-00-00-okay-here-we-go-welcome-everyone-thank-you-for-joining-us-in-our-weekly-adtx-20250324monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-inc-nasdaq-adtx-announces-1-for-250-reverse-stock-split-effective-at-the-open-of-tr-adtx-20250312monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-subsidiary-adimune-to-ship-drug-substances-for-final-drug-product-formulation-of-ad-adtx-20250306monthly0.5https://www.biopharmawatch.com/news/ADTX/00-05-340-00-05-700-amro-albanna-great-00-05-980-00-06-220-amro-albanna-welcome-00-06-620--adtx-20250224monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-s-board-of-directors-unanimously-approve-positioning-pearsanta-for-ipo-to-support-g-adtx-20250113monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-s-subsidiary-adimune-successfully-completes-preclinical-efficacy-and-safety-studies-adtx-20241212monthly0.5https://www.biopharmawatch.com/news/ADTX/amro-albanna-00-03-great-jeff-how-you-doing-today-jeff-ramson-00-05-i-m-good-amro-how-are--adtx-20241105monthly0.5https://www.biopharmawatch.com/news/ADTX/dr-drew-pinsky-00-26-alright-welcome-everyone-thank-you-so-much-for-being-here-i-am-truly--adtx-20241030monthly0.5https://www.biopharmawatch.com/news/ADTX/sylvia-hermina-joins-aditxt-s-board-of-directors-elevating-leadership-with-broader-perspec-adtx-20241029monthly0.5https://www.biopharmawatch.com/news/ADTX/amro-albanna-00-00-jeff-we-can-get-started-jeff-ramson-00-02-yeah-go-ahead-amro-albanna-00-adtx-20241011monthly0.5https://www.biopharmawatch.com/news/ADTX/making-promising-innovations-possible-together-amro-albanna-co-founder-chairman-ceo-safe-h-adtx-20240909monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-announces-1-2-million-registered-direct-offering-priced-at-the-market-under-nasdaq--adtx-20240809monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-and-evofem-amend-and-restate-merger-agreement-targeting-september-30-closing-evofem-adtx-20240717monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-announces-pricing-of-4-2-million-private-placement-priced-at-the-market-under-nasda-adtx-20240503monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-signs-a-definitive-agreement-to-acquire-appili-therapeutics-inc-developer-of-a-biod-adtx-20240402monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-inc-acquires-proprietary-electroencephalography-eeg-brain-monitoring-technologies-a-adtx-20240129monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-inc-s-subsidiary-pearsanta-inc-acquires-mdna-life-sciences-inc-s-proprietary-mitomi-adtx-20240108monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-announces-6-million-private-placement-priced-at-the-market-under-nasdaq-rules-richm-adtx-20231229monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-inc-regains-compliance-with-nasdaq-stockholders-equity-requirement-richmond-va-adtx-20240102monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-inc-enters-into-definitive-agreement-to-acquire-evofem-biosciences-inc-creator-of-p-adtx-20231212monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-nasdaq-adtx-making-promising-innovations-possible-together-this-presentation-contai-adtx-20230913monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-announces-10-0-million-private-placement-priced-at-the-market-under-nasdaq-rules-ri-adtx-20230831monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-inc-nasdaq-adtx-provides-shareholder-update-and-planned-strategy-for-achieving-comm-adtx-20230818monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-inc-nasdaq-adtx-announces-1-for-40-reverse-stock-split-effective-at-the-open-of-tra-adtx-20230818monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-inc-s-wholly-owned-subsidiary-pearsanta-inc-looks-to-expand-customer-base-payor-acc-adtx-20230621monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-respons-adtx-20230420monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-announces-1-9-million-registered-direct-offering-priced-at-the-market-under-nasdaq--adtx-20230420monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-issues-shareholder-update-richmond-va-adtx-20230417monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-inc-nasdaq-adtx-announces-that-it-has-regained-compliance-with-nasdaq-listing-requi-adtx-20220929monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-announces-pricing-of-20-0-million-public-offering-richmond-va-adtx-20220916monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-adtx-20220914monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-inc-nasdaq-adtx-accelerating-innovation-this-presentation-contains-forward-looking--adtx-20220718monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-signs-revenue-sharing-agreement-with-cellvera-for-up-to-30m-and-hosts-a-live-busine-adtx-20220405monthly0.5https://www.biopharmawatch.com/news/ADTX/mc-maxwell-colbert-good-afternoon-and-welcome-to-aditxt-inc-s-online-business-update-and-t-adtx-20220121monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-signs-amendment-to-extend-worldwide-licensing-agreement-granting-exclusivity-in-all-adtx-20211229monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-signs-share-exchange-agreement-to-acquire-aipharma-if-complete-the-transaction-woul-adtx-20211228monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-inc-signs-non-binding-letter-of-intent-to-acquire-point-of-care-diagnostic-technolo-adtx-20211213monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-announces-closing-of-17-4-million-firm-commitment-public-offering-of-common-stock-a-adtx-20211207monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-extends-the-timeline-to-sign-the-definitive-agreement-to-acquire-aipharma-global-to-adtx-20211203monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-announces-pricing-of-4-25-million-public-offering-aditxt-inc-aditxt-nasdaq-adtx-a-b-adtx-20211004monthly0.5https://www.biopharmawatch.com/news/ADTX/innovation-in-monitoring-and-treatment-of-the-immune-system-safe-harbor-statement-this-pre-adtx-20211012monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-signs-a-transaction-agreement-to-acquire-aipharma-rights-holder-of-antiviral-tablet-adtx-20211005monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-appoints-corinne-pankovcin-as-president-and-thomas-j-farley-as-chief-financial-offi-adtx-20210927monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-inc-signs-letter-of-intent-for-exclusive-rights-to-negotiate-the-acquisition-of-a-b-adtx-20210830monthly0.5https://www.biopharmawatch.com/news/ADTX/delta-variant-a-perfect-storm-is-brewing-in-certain-parts-america-health-official-explains-adtx-20210803monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-opens-its-first-high-capacity-immune-monitoring-center-in-richmond-va-aditxtscore-t-adtx-20210708monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-announces-the-appointment-of-dr-lauren-chung-to-its-board-of-directors-as-an-indepe-adtx-20210621monthly0.5https://www.biopharmawatch.com/news/ADTX/a-letter-from-amro-albanna-i-am-proud-of-our-accomplishments-since-the-completion-of-our-i-adtx-20210525monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-to-establish-state-of-the-art-immune-monitoring-center-in-richmond-va-aditxtscore-c-adtx-20210503monthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-corporate-overview-nasdaq-adtx-march-2021-1-this-presentation-contains-forward-look-adtx-20210324monthly0.5https://www.biopharmawatch.com/news/ADTX/aditx-therapeutics-announces-pricing-of-9-6-million-follow-on-public-offering-adtx-20200902monthly0.5https://www.biopharmawatch.com/news/ADTX/corporate-presentation-september-2020-nasdaq-adtx-monitoring-and-reprogramming-the-immune--adtx-20200908monthly0.5https://www.biopharmawatch.com/news/ADTX/corporate-presentation-july-2020-nasdaq-adtx-monitoring-and-reprogramming-the-immune-syste-adtx-20200730monthly0.5https://www.biopharmawatch.com/news/ADTX/aditx-therapeutics-inc-aditxt-announces-pricing-of-initial-public-offering-will-trade-on-t-adtx-20200630monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-derek-leckow-exact-sciences-corp-investorrelations-exactsciences-com-608--exas-20260213monthly0.5https://www.biopharmawatch.com/news/EXAS/abbott-to-acquire-exact-sciences-a-leader-in-large-and-fast-growing-cancer-screening-and-p-exas-20251120monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-derek-leckow-exact-sciences-corp-investorrelations-exactsciences-com-608--exas-20251103monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-derek-leckow-exact-sciences-corp-investorrelations-exactsciences-com-608--exas-20250806monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-derek-leckow-exact-sciences-corp-investorrelations-exactsciences-com-608--exas-20250501monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-derek-leckow-exact-sciences-corp-investorrelations-exactsciences-com-608--exas-20250219monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-erik-holznecht-exact-sciences-corp-investorrelations-exactsciences-com-60-exas-20250112monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-erik-holznecht-exact-sciences-corp-investorrelations-exactsciences-com-60-exas-20241105monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-erik-holznecht-exact-sciences-corp-investorrelations-exactsciences-com-60-exas-20240731monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-nathan-harrill-exact-sciences-corp-investorrelations-exactsciences-com-60-exas-20240508monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-nathan-harrill-exact-sciences-corp-nharrill-exactsciences-com-608-535-865-exas-20240411monthly0.5https://www.biopharmawatch.com/news/EXAS/document-exact-sciences-names-aaron-bloomer-as-new-chief-financial-officer-exas-20240415monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-nathan-harrill-exact-sciences-corp-investorrelations-exactsciences-com-60-exas-20240221monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-nathan-harrill-exact-sciences-corp-investorrelations-exactsciences-com-60-exas-20240107monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-erik-holznecht-exact-sciences-corp-investorrelations-exactsciences-com-60-exas-20231101monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20230801monthly0.5https://www.biopharmawatch.com/news/EXAS/exas-20230621ex991-exas-20230621monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20230509monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20230223monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20230221monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20230108monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20221103monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20220802monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20220426monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20220222monthly0.5https://www.biopharmawatch.com/news/EXAS/megan-jones-meganjones-exactsciences-com-608-535-8815-media-contact-katie-boyce-kboyce-exa-exas-20220109monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20211102monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20210728monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20210504monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20210216monthly0.5https://www.biopharmawatch.com/news/EXAS/megan-jones-meganjones-exactsciences-com-608-535-8815-media-contact-katie-boyce-kboyce-exa-exas-20210110monthly0.5https://www.biopharmawatch.com/news/EXAS/exact-sciences-contacts-investor-relations-megan-jones-meganjones-exactsciences-com-608-53-exas-20210105monthly0.5https://www.biopharmawatch.com/news/EXAS/megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-for-immediate-re-exas-20201027monthly0.5https://www.biopharmawatch.com/news/EXAS/exact-sciences-to-acquire-thrive-becoming-a-leader-in-blood-based-multi-cancer-screening-b-exas-20201027monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20201027monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20200730monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20200506monthly0.5https://www.biopharmawatch.com/news/EXAS/exact-sciences-announces-offering-of-850-million-convertible-senior-notes-due-2028-exas-20200224monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20200211monthly0.5https://www.biopharmawatch.com/news/EXAS/megan-jones-meganjones-exactsciences-com-608-535-8815-media-contact-cara-connelly-cconnell-exas-20200113monthly0.5https://www.biopharmawatch.com/news/EXAS/exact-sciences-completes-combination-with-genomic-health-creating-leading-global-cancer-di-exas-20191108monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20191029monthly0.5https://www.biopharmawatch.com/news/EXAS/voting-agreement-this-voting-agreement-dated-as-of-exas-20190728monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20190729monthly0.5https://www.biopharmawatch.com/news/EXAS/exact-sciences-and-genomic-health-to-combine-creating-leading-global-cancer-diagnostics-co-exas-20190729monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20190430monthly0.5https://www.biopharmawatch.com/news/EXAS/exact-sciences-announces-offering-of-600-million-convertible-senior-notes-due-2027-exas-20190305monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20190221monthly0.5https://www.biopharmawatch.com/news/EXAS/megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-media-contact-j--exas-20190106monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20181030monthly0.5https://www.biopharmawatch.com/news/EXAS/exact-sciences-contact-j-p-fielder-jpfielder-exactsciences-com-1-608-210-5220-pfizer-conta-exas-20180822monthly0.5https://www.biopharmawatch.com/news/EXAS/investor-contact-megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-exas-20180801monthly0.5https://www.biopharmawatch.com/news/EXAS/exact-sciences-announces-offering-of-1-0-convertible-senior-notes-due-2025-exas-20180607monthly0.5https://www.biopharmawatch.com/news/EXAS/megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-media-contact-j--exas-20180426monthly0.5https://www.biopharmawatch.com/news/EXAS/megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-for-immediate-re-exas-20180222monthly0.5https://www.biopharmawatch.com/news/EXAS/to-the-company-s-current-report-on-form-8-k-filed-with-the-sec-on-exas-20180111monthly0.5https://www.biopharmawatch.com/news/EXAS/exact-sciences-corporation-supplemental-regulation-fd-disclosure-dated-january-11-2018-thi-exas-20180111monthly0.5https://www.biopharmawatch.com/news/EXAS/megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-for-immediate-re-exas-20180107monthly0.5https://www.biopharmawatch.com/news/EXAS/megan-jones-exact-sciences-corp-meganjones-exactsciences-com-608-535-8815-for-immediate-re-exas-20171030monthly0.5https://www.biopharmawatch.com/news/EXAS/megan-reiss-exact-sciences-corp-meganreiss-exactsciences-com-608-535-8815-for-immediate-re-exas-20170725monthly0.5https://www.biopharmawatch.com/news/EXAS/exact-sciences-announces-agreement-to-sell-7-000-000-common-shares-exas-20170606monthly0.5https://www.biopharmawatch.com/news/EXAS/megan-reiss-exact-sciences-corp-meganreiss-exactsciences-com-for-immediate-release-cologua-exas-20170427monthly0.5https://www.biopharmawatch.com/news/EXAS/j-p-fielder-exact-sciences-corp-jpfielder-exactsciences-com-608-210-5220-for-immediate-rel-exas-20170221monthly0.5https://www.biopharmawatch.com/news/EXAS/embargoed-until-exas-20170108monthly0.5https://www.biopharmawatch.com/news/EXAS/exact-sciences-completes-68-000-cologuard-tests-during-the-third-quarter-revenues-exceed-2-exas-20161026monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-announces-intention-to-adjourn-and-reconvene-special-meeting-of-stockh-rnam-20260223monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-announces-expected-record-date-for-spin-off-rnam-20260202monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-third-quarter-2025-financial-results-and-recent-highlights-ann-rnam-20251110monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-enters-into-agreement-to-be-acquired-by-novartis-ag-novartis-to-acquir-rnam-20251026monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-announces-proposed-public-offering-of-common-stock-rnam-20250910monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-second-quarter-2025-financial-results-and-recent-highlights-al-rnam-20250807monthly0.5https://www.biopharmawatch.com/news/RNAM/forward-looking-statements-we-caution-the-reader-that-this-presentation-contains-forward-l-rnam-20250609monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-first-quarter-2025-financial-results-and-recent-highlights-on--rnam-20250508monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-fourth-quarter-2024-financial-results-and-recent-highlights-bu-rnam-20250227monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-third-quarter-2024-financial-results-and-recent-highlights-enr-rnam-20241107monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-second-quarter-2024-financial-results-and-recent-highlights-av-rnam-20240809monthly0.5https://www.biopharmawatch.com/news/RNAM/geoffrey-grande-cfa-619-837-5014-investors-aviditybio-com-rnam-20240614monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-first-quarter-2024-financial-results-and-recent-highlights-ini-rnam-20240509monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-announces-oversubscribed-400-million-private-placement-funding-from-ne-rnam-20240229monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-fourth-quarter-and-year-end-2023-financial-results-and-recent--rnam-20240228monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-third-quarter-2023-financial-results-and-recent-highlights-avi-rnam-20231108monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-second-quarter-2023-financial-results-and-recent-highlights-ad-rnam-20230808monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-first-quarter-2023-financial-results-and-recent-highlights-pos-rnam-20230509monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-fourth-quarter-and-year-end-2022-financial-results-and-recent--rnam-20230228monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-inc-announces-proposed-public-offering-of-common-stock-rnam-20221215monthly0.5https://www.biopharmawatch.com/news/RNAM/forward-looking-statements-we-caution-the-reader-that-this-presentation-contains-forward-l-rnam-20221214monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-third-quarter-2022-financial-results-and-recent-highlights-com-rnam-20221108monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-second-quarter-2022-financial-results-and-recent-highlights-co-rnam-20220809monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-first-quarter-2022-financial-results-and-recent-highlights-rnam-20220510monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-fourth-quarter-and-year-end-2021-financial-results-and-recent--rnam-20220301monthly0.5https://www.biopharmawatch.com/news/RNAM/forward-looking-statements-we-caution-the-reader-that-this-presentation-contains-forward-l-rnam-20211209monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-third-quarter-2021-financial-results-and-recent-highlights-ini-rnam-20211109monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-second-quarter-2021-financial-results-and-recent-highlights-rnam-20210809monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-inc-announces-proposed-public-offering-of-common-stock-rnam-20210802monthly0.5https://www.biopharmawatch.com/news/RNAM/forward-looking-statements-we-caution-the-reader-that-this-presentation-contains-forward-l-rnam-20210802monthly0.5https://www.biopharmawatch.com/news/RNAM/forward-looking-statements-we-caution-the-reader-that-this-presentation-contains-forward-l-rnam-20210519monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-first-quarter-2021-financial-results-and-recent-highlights-rnam-20210512monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-fourth-quarter-and-year-end-2020-financial-results-and-recent--rnam-20210315monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-third-quarter-2020-financial-results-and-recent-highlights-la--rnam-20201110monthly0.5https://www.biopharmawatch.com/news/RNAM/avidity-biosciences-reports-second-quarter-2020-financial-results-and-recent-highlights-su-rnam-20200810monthly0.5https://www.biopharmawatch.com/news/MTSR/pfizer-and-metsera-enter-into-merger-agreement-amendment-metsera-s-board-of-directors-reaf-mtsr-20251107monthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-issues-statement-in-response-to-litigation-ruling-new-york-ny-5-november-2025-mets-mtsr-20251106monthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-receives-amended-proposal-from-novo-nordisk-metsera-declares-novo-nordisk-amended--mtsr-20251104monthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-issues-statement-in-response-to-litigation-new-york-ny-3-november-2025-metsera-inc-mtsr-20251103monthly0.5https://www.biopharmawatch.com/news/MTSR/draft-privileged-confidential-subject-to-review-by-counsel-31-october-2025-4-30-pm-et-mets-mtsr-20251103monthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-receives-unsolicited-proposal-from-novo-nordisk-metsera-declares-novo-nordisk-prop-mtsr-20251030monthly0.5https://www.biopharmawatch.com/news/MTSR/for-immediate-release-mtsr-20250922monthly0.5https://www.biopharmawatch.com/news/HOLX/blackstone-and-tpg-complete-acquisition-of-hologic-accomplished-medtech-leader-joe-almeida-holx-20260407monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-chief-executive-officer-steve-macmillan-to-retire-upon-close-of-go-private-transac-holx-20260406monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-first-quarter-of-fiscal-2026-revenue-of-1-047-8-mi-holx-20260129monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-fourth-quarter-of-fiscal-2025-revenue-of-1-049-5-m-holx-20251103monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-to-be-acquired-by-blackstone-and-tpg-for-up-to-79-per-share-hologic-stockholders-t-holx-20251021monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-third-quarter-of-fiscal-2025-revenue-of-1-023-8-mi-holx-20250730monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-second-quarter-of-fiscal-2025-revenue-of-1-005-3-m-holx-20250501monthly0.5https://www.biopharmawatch.com/news/HOLX/wayde-mcmillan-elected-to-hologic-board-of-directors-marlborough-mass-holx-20250404monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-first-quarter-of-fiscal-2025-company-reports-gaap--holx-20250205monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-preliminary-revenue-results-for-first-quarter-of-fiscal-2025-revenue-of--holx-20250112monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-fourth-quarter-of-fiscal-2024-revenue-of-987-9-mil-holx-20241104monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-third-quarter-of-fiscal-2024-revenue-of-1-011-4-mi-holx-20240729monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-second-quarter-of-fiscal-2024-revenue-of-1-017-8-m-holx-20240502monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-first-quarter-of-fiscal-2024-revenue-of-1-013-1-mi-holx-20240201monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-preliminary-revenue-results-for-first-quarter-of-fiscal-2024-revenue-of--holx-20240107monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-fourth-quarter-of-fiscal-2023-revenue-of-945-3-mil-holx-20231109monthly0.5https://www.biopharmawatch.com/news/HOLX/nanaz-mohtashami-elected-to-hologic-board-of-directors-marlborough-mass-business-wire-holx-20230922monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-third-quarter-of-fiscal-2023-revenue-of-984-4-mill-holx-20230731monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-second-quarter-of-fiscal-2023-revenue-of-1-026-5-m-holx-20230501monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-first-quarter-of-fiscal-2023-revenue-of-1-074-mill-holx-20230201monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-preliminary-revenue-results-for-first-quarter-of-fiscal-2023-revenue-of--holx-20230108monthly0.5https://www.biopharmawatch.com/news/HOLX/stacey-d-stewart-elected-to-hologic-board-of-directors-marlborough-mass-business-wire-holx-20221209monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-fourth-quarter-of-fiscal-2022-revenue-of-953-milli-holx-20221031monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-third-quarter-of-fiscal-2022-revenue-of-1-003-bill-holx-20220727monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-second-quarter-of-fiscal-2022-revenue-of-1-436-bil-holx-20220427monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-first-quarter-of-fiscal-2022-revenue-of-1-471-bill-holx-20220202monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-preliminary-revenue-results-for-first-quarter-of-fiscal-2022-revenue-of--holx-20220109monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-fourth-quarter-of-fiscal-2021-revenue-of-1-317-bil-holx-20211101monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-third-quarter-of-fiscal-2021-revenue-of-1-168-bill-holx-20210728monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-second-quarter-of-fiscal-2021-revenue-of-1-538-bil-holx-20210428monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-to-acquire-mobidiag-innovator-in-near-patient-acute-care-diagnostic-testing-for-ap-holx-20210408monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-first-quarter-of-fiscal-2021-revenue-of-1-61-billi-holx-20210127monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-preliminary-financial-results-for-first-quarter-of-fiscal-2021-revenue-o-holx-20210108monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-fourth-quarter-of-fiscal-2020-revenue-of-1-347-bil-holx-20201104monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-pricing-of-offering-of-950-million-of-3-250-senior-notes-due-2029-holx-20200914monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-offering-of-950-million-of-senior-notes-due-2029-proceeds-from-offering--holx-20200914monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-third-quarter-of-fiscal-2020-revenue-of-822-9-mill-holx-20200729monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-second-quarter-of-fiscal-2020-revenue-of-756-1-mil-holx-20200429monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-preliminary-revenue-results-for-second-quarter-of-fiscal-2020-withdraws--holx-20200407monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-s-molecular-test-for-the-novel-coronavirus-sars-cov-2-receives-fda-emergency-use-a-holx-20200316monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-first-quarter-of-fiscal-2020-revenue-of-850-5-mill-holx-20200129monthly0.5https://www.biopharmawatch.com/news/HOLX/exhibit-hologic-announces-preliminary-financial-results-for-first-quarter-of-fiscal-2020-r-holx-20200112monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-completes-divestiture-of-cynosure-medical-aesthetics-business-holx-20191230monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-to-sell-cynosure-medical-aesthetics-business-to-clayton-dubilier-rice-company-plan-holx-20191120monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-fourth-quarter-of-fiscal-2019-revenue-of-865-8-mil-holx-20191106monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-third-quarter-of-fiscal-2019-revenue-of-852-4-mill-holx-20190731monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-second-quarter-of-fiscal-2019-revenue-of-818-4-mil-holx-20190501monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-first-quarter-of-fiscal-2019-revenue-of-830-7-mill-holx-20190130monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-preliminary-revenues-increase-approximately-5-to-831-million-in-first-quarter-of-f-holx-20190107monthly0.5https://www.biopharmawatch.com/news/HOLX/ludwig-n-hantson-elected-to-hologic-board-of-directors-marlborough-mass-business-wire-holx-20181119monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-fourth-quarter-of-fiscal-2018-revenue-of-813-5-mil-holx-20181107monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-chief-financial-officer-change-bob-mcmahon-to-depart-karleen-oberton-chi-holx-20180731monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-third-quarter-of-fiscal-2018-company-tops-revenue--holx-20180731monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-second-quarter-of-fiscal-2018-revenue-of-789-3-mil-holx-20180502monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-first-quarter-of-fiscal-2018-revenue-of-791-1-mill-holx-20180208monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-upcoming-put-option-and-notice-of-redemption-of-2-00-convertible-senior--holx-20180129monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-pricing-of-offering-of-1-billion-of-senior-notes-marlborough-mass-holx-20180116monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-offering-of-1-billion-of-senior-notes-proceeds-expected-to-contribute-to-holx-20180116monthly0.5https://www.biopharmawatch.com/news/HOLX/namal-nawana-elected-to-hologic-board-of-directors-holx-20180111monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-preliminary-revenues-increase-8-to-approximately-791-million-in-the-first-quarter--holx-20180108monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-upcoming-put-option-and-notice-of-redemption-of-2-00-convertible-senior--holx-20171114monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-fourth-quarter-of-fiscal-2017-company-posts-revenu-holx-20171108monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-pricing-of-offering-of-350-million-aggregate-principal-amount-of-4-375-s-holx-20171004monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-offering-of-350-million-of-senior-notes-due-2025-proceeds-expected-to-co-holx-20171004monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-enters-into-amended-and-restated-five-year-secured-credit-agreement-initial-procee-holx-20171004monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-third-quarter-of-fiscal-2017-company-posts-revenue-holx-20170802monthly0.5https://www.biopharmawatch.com/news/HOLX/charles-j-dockendorff-elected-to-hologic-board-of-directors-holx-20170516monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-second-quarter-of-fiscal-2017-gaap-diluted-eps-of--holx-20170510monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-completes-acquisition-of-cynosure-transaction-provides-entry-into-large-fast-growi-holx-20170322monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-to-acquire-cynosure-leader-in-medical-aesthetics-systems-and-technologies-in-all-c-holx-20170214monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-completes-divestiture-of-blood-screening-business-strengthens-efforts-to-build-a-s-holx-20170131monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-first-quarter-of-fiscal-2017-gaap-diluted-eps-of-0-holx-20170201monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-to-divest-blood-screening-business-to-partner-grifols-for-1-85-billion-transaction-holx-20161214monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-upcoming-put-option-and-notice-of-redemption-of-2-00-convertible-exchang-holx-20161109monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-fourth-quarter-of-fiscal-2016-gaap-diluted-eps-of--holx-20161102monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-third-quarter-of-fiscal-2016-gaap-diluted-eps-of-0-holx-20160727monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-second-quarter-of-fiscal-2016-gaap-diluted-eps-of--holx-20160427monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-first-quarter-of-fiscal-2016-revenue-of-695-2-mill-holx-20160127monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-fourth-quarter-of-fiscal-2015-revenue-of-702-8-mil-holx-20151104monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-third-quarter-of-fiscal-2015-revenues-of-693-9-mil-holx-20150729monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-pricing-of-offering-of-1-0-billion-aggregate-principal-amount-of-5-250-s-holx-20150618monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-offering-of-1-0-billion-of-senior-notes-due-2022-proceeds-used-to-redeem-holx-20150618monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-changes-to-board-of-directors-steve-macmillan-replaces-david-lavance-as--holx-20150617monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-second-quarter-fiscal-2015-revenues-of-655-5-milli-holx-20150429monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-announces-financial-results-for-first-quarter-fiscal-2015-revenues-increase-6-6-to-holx-20150128monthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-preliminary-revenues-increased-7-to-653-million-in-the-first-quarter-of-fiscal-201-holx-20150112monthly0.5https://www.biopharmawatch.com/news/BGNE/reconciliation-of-gaap-operating-income-guidance-to-non-gaap-operating-income-guidance-for-bgne-20260506monthly0.5https://www.biopharmawatch.com/news/BGNE/fourth-quarter-full-year-2025-2024-2025-2024-free-cash-flow-non-gaap-net-cash-provided-by--bgne-20260226monthly0.5https://www.biopharmawatch.com/news/BGNE/three-months-ended-september-30-nine-months-ended-bgne-20251106monthly0.5https://www.biopharmawatch.com/news/BGNE/three-months-ended-june-30-six-months-ended-bgne-20250806monthly0.5https://www.biopharmawatch.com/news/BGNE/reconciliation-of-gaap-to-adjusted-eps-basic-gaap-earnings-loss-per-share-basic-0-00-0-19--bgne-20250507monthly0.5https://www.biopharmawatch.com/news/BGNE/reconciliation-of-selected-gaap-measures-to-non-gaap-measures-amounts-in-thousands-of-u-s--bgne-20250227monthly0.5https://www.biopharmawatch.com/news/BGNE/reconciliation-of-selected-gaap-measures-to-non-gaap-measures-amounts-in-thousands-of-u-s--bgne-20241112monthly0.5https://www.biopharmawatch.com/news/BGNE/reconciliation-of-selected-gaap-measures-to-non-gaap-measures-in-thousands-except-per-shar-bgne-20240807monthly0.5https://www.biopharmawatch.com/news/BGNE/reconciliation-of-selected-gaap-measures-to-non-gaap-measures-in-thousands-except-per-shar-bgne-20240508monthly0.5https://www.biopharmawatch.com/news/BGNE/financial-information-on-bgne-20240426monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-receives-european-commission-approval-for-tislelizumab-as-treatment-for-non-small--bgne-20240423monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-receives-fda-approval-for-tevimbra-for-the-treatment-of-advanced-or-metastatic-eso-bgne-20240314monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-oncology-company-that-is-discovering-and-developing-inno-bgne-20240226monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-biotechnology-company-that-is-discovering-and-developing-bgne-20231109monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-biotechnology-company-that-is-discovering-and-developing-bgne-20230802monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-biotechnology-company-that-is-discovering-and-developing-bgne-20230504monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-biotechnology-company-that-is-developing-and-commerciali-bgne-20230227monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-biotechnology-company-that-is-developing-and-commerciali-bgne-20221109monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-receives-european-commission-approval-for-brukinsa-zanubrutinib-for-the-treatment--bgne-20221102monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-positive-topline-results-from-final-progression-free-survival-analysis-o-bgne-20221012monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-receives-positive-chmp-opinion-for-brukinsa-zanubrutinib-for-the-treatment-of-adul-bgne-20220919monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-data-presentations-at-esmo-2022-including-late-breaking-oral-presentatio-bgne-20220910monthly0.5https://www.biopharmawatch.com/news/BGNE/financial-information-on-bgne-20220830monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-acceptance-of-11th-regulatory-submission-for-pd-1-inhibitor-tislelizumab-bgne-20220823monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-positive-global-phase-3-trial-results-for-pd-1-inhibitor-tislelizumab-in-bgne-20220809monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-biotechnology-company-that-is-developing-and-commerciali-bgne-20220804monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-provides-regulatory-update-on-the-u-s-biologics-license-application-bla-for-pd-1-i-bgne-20220714monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-late-breaking-data-at-esmo-gi-showing-overall-survival-benefit-for-tisle-bgne-20220630monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-acceptance-of-supplemental-biologics-license-application-in-china-for-an-bgne-20220621monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-highlights-growing-portfolio-and-pipeline-targeting-hematologic-malignancies-at-eu-bgne-20220610monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-clinical-data-presentations-at-2022-asco-annual-meeting-demonstrate-mature-and-gro-bgne-20220526monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-science-driven-biotechnology-company-focused-on-developi-bgne-20220505monthly0.5https://www.biopharmawatch.com/news/BGNE/financial-information-on-bgne-20220428monthly0.5https://www.biopharmawatch.com/news/BGNE/china-nmpa-approves-tislelizumab-for-patients-with-second-line-esophageal-squamous-cell-ca-bgne-20220420monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-european-medicines-agency-acceptance-of-marketing-authorization-applicat-bgne-20220406monthly0.5https://www.biopharmawatch.com/news/BGNE/china-nmpa-approves-tislelizumab-for-patients-with-microsatellite-instability-high-or-mism-bgne-20220311monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-science-driven-biotechnology-company-focused-on-developi-bgne-20220225monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-european-medicines-agency-acceptance-of-applications-for-brukinsa-zanubr-bgne-20220222monthly0.5https://www.biopharmawatch.com/news/BGNE/drs-margaret-dugan-and-alessandro-riva-appointed-to-beigene-board-of-directors-industry-le-bgne-20220201monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-acceptance-of-a-supplemental-new-drug-application-in-china-for-brukinsa--bgne-20220120monthly0.5https://www.biopharmawatch.com/news/BGNE/china-nmpa-approves-tislelizumab-as-second-or-third-line-treatment-for-patients-with-local-bgne-20220110monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-expands-collaboration-with-novartis-to-develop-and-commercialize-beigene-s-tigit-i-bgne-20211220monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-closing-of-its-rmb22-2-billion-us-3-5-billion-initial-public-offering-on-bgne-20211215monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-presents-results-from-phase-3-trial-of-tislelizumab-in-nasopharyngeal-cancer-at-es-bgne-20211210monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-pricing-of-its-rmb22-2-billion-us-3-5-billion-initial-public-offering-on-bgne-20211206monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-launches-proposed-initial-public-offering-on-the-star-market-in-china-cambridge-ma-bgne-20211123monthly0.5https://www.biopharmawatch.com/news/BGNE/financial-information-beigene-ltd-the-company-previously-submitted-a-listing-application-f-bgne-20211116monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-science-driven-biotechnology-company-focused-on-developi-bgne-20211104monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-and-nanolek-announce-approval-in-russia-for-brukinsa-zanubrutinib-for-treatment-of-bgne-20211020monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-first-regulatory-approval-in-australia-for-brukinsa-zanubrutinib-for-tre-bgne-20211007monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-receives-positive-chmp-opinion-for-brukinsa-zanubrutinib-for-the-treatment-of-adul-bgne-20210917monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-u-s-fda-acceptance-of-biologics-license-application-for-tislelizumab-in--bgne-20210913monthly0.5https://www.biopharmawatch.com/news/BGNE/u-s-fda-grants-brukinsa-zanubrutinib-approval-in-waldenstr-m-s-macroglobulinemia-this-mark-bgne-20210901monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-acceptance-of-a-supplemental-biologics-license-application-in-china-for--bgne-20210822monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-and-eusa-pharma-announce-china-nmpa-approval-of-qarziba-dinutuximab-beta-for-patie-bgne-20210817monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-science-driven-biotechnology-company-focused-on-developi-bgne-20210805monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-approval-in-canada-of-brukinsa-zanubrutinib-for-the-treatment-of-patient-bgne-20210726monthly0.5https://www.biopharmawatch.com/news/BGNE/financial-information-beigene-ltd-the-company-previously-submitted-a-listing-application-f-bgne-20210728monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-acceptance-of-a-supplemental-biologics-license-application-in-china-for--bgne-20210707monthly0.5https://www.biopharmawatch.com/news/BGNE/financial-information-beigene-ltd-the-company-previously-submitted-a-listing-application-a-bgne-20210630monthly0.5https://www.biopharmawatch.com/news/BGNE/china-nmpa-approves-tislelizumab-in-non-small-cell-lung-cancer-and-hepatocellular-carcinom-bgne-20210623monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-china-nmpa-approval-of-brukinsa-zanubrutinib-for-the-treatment-of-patien-bgne-20210618monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-first-patient-dosed-in-global-phase-3-trial-of-anti-tigit-antibody-ocipe-bgne-20210617monthly0.5https://www.biopharmawatch.com/news/BGNE/shoreline-biosciences-and-beigene-announce-strategic-worldwide-collaboration-to-develop-an-bgne-20210609monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-presents-clinical-data-from-two-pivotal-trials-of-tislelizumab-at-the-2021-asco-an-bgne-20210604monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-u-s-fda-acceptance-and-priority-review-of-supplemental-new-drug-applicat-bgne-20210519monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-ltd-the-company-previously-submitted-a-listing-application-the-listing-application-bgne-20210514monthly0.5https://www.biopharmawatch.com/news/BGNE/china-nmpa-approves-parp-inhibitor-pamiparib-for-patients-with-previously-treated-advanced-bgne-20210507monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-science-driven-biotechnology-company-focused-on-developi-bgne-20210506monthly0.5https://www.biopharmawatch.com/news/BGNE/brukinsa-zanubrutinib-demonstrates-superior-objective-response-rate-by-investigator-assess-bgne-20210428monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-presents-clinical-data-on-sitravatinib-in-combination-with-tislelizumab-at-the-aac-bgne-20210411monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-first-commercial-manufacturing-approval-for-its-state-of-the-art-biologi-bgne-20210407monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-new-chief-financial-officer-julia-wang-current-cfo-and-chief-strategy-of-bgne-20210330monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-initiates-phase-1-clinical-trial-for-hpk1-inhibitor-bgb-15025-cambridge-mass-beiji-bgne-20210310monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-acceptance-of-a-supplemental-biologics-license-application-in-china-for--bgne-20210305monthly0.5https://www.biopharmawatch.com/news/BGNE/health-canada-approves-brukinsa-zanubrutinib-for-the-treatment-of-waldenstr-m-s-macroglobu-bgne-20210302monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-closing-of-collaboration-with-novartis-to-develop-and-commercialize-anti-bgne-20210226monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-commercial-stage-biotechnology-company-focused-on-discov-bgne-20210225monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-u-s-fda-acceptance-of-supplemental-new-drug-application-for-brukinsa-zan-bgne-20210217monthly0.5https://www.biopharmawatch.com/news/BGNE/financial-information-beigene-ltd-the-company-submitted-a-listing-application-the-listing--bgne-20210129monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-positive-topline-results-for-global-phase-3-trial-of-tislelizumab-in-eso-bgne-20210127monthly0.5https://www.biopharmawatch.com/news/BGNE/eusa-pharma-and-beigene-announce-acceptance-of-a-biologics-license-application-for-sylvant-bgne-20210125monthly0.5https://www.biopharmawatch.com/news/BGNE/china-national-medical-products-administration-approves-tislelizumab-in-combination-with-c-bgne-20210113monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-collaboration-with-novartis-to-develop-and-commercialize-anti-pd-1-antib-bgne-20210111monthly0.5https://www.biopharmawatch.com/news/BGNE/disclosures-certain-statements-contained-in-this-presentation-and-in-the-accompanying-oral-bgne-20210111monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-inclusion-of-three-innovative-oncology-products-in-china-national-reimbu-bgne-20201227monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-data-on-brukinsa-zanubrutinib-from-phase-2-trial-in-marginal-zone-lympho-bgne-20201206monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-launches-proposed-public-offering-by-selling-shareholders-cambridge-mass-and-beiji-bgne-20201201monthly0.5https://www.biopharmawatch.com/news/BGNE/document-beigene-announces-the-approval-of-xgeva-denosumab-in-china-for-the-prevention-of--bgne-20201119monthly0.5https://www.biopharmawatch.com/news/BGNE/document-beigene-announces-that-rationale-303-trial-of-tislelizumab-in-non-small-cell-lung-bgne-20201117monthly0.5https://www.biopharmawatch.com/news/BGNE/document-eusa-pharma-and-beigene-announce-acceptance-of-a-biologics-license-application-fo-bgne-20201109monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-commercial-stage-biotechnology-company-focused-on-discov-bgne-20201105monthly0.5https://www.biopharmawatch.com/news/BGNE/bioatla-and-beigene-revise-global-development-and-commercialization-agreement-for-novel-co-bgne-20201006monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-acceptance-and-priority-review-by-health-canada-of-new-drug-submission-f-bgne-20200909monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-commercial-stage-biotechnology-company-focused-on-discov-bgne-20200827monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-appoints-corsee-sanders-ph-d-to-its-board-of-directors-cambridge-mass-and-bgne-20200825monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-commercial-stage-biotechnology-company-focused-on-discov-bgne-20200806monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-pricing-of-approximately-2-08-billion-registered-direct-offering-cambrid-bgne-20200712monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-begins-commercializing-xgeva-denosumab-in-china-beijing-china-and-bgne-20200630monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-european-medicines-agency-acceptance-of-its-marketing-authorization-appl-bgne-20200618monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-commercial-stage-biotechnology-company-focused-on-discov-bgne-20200511monthly0.5https://www.biopharmawatch.com/news/BGNE/exhibit-china-national-medical-products-administration-approves-beigene-s-tislelizumab-for-bgne-20200410monthly0.5https://www.biopharmawatch.com/news/BGNE/exhibit-beigene-announces-supply-update-for-abraxane-in-china-nmpa-has-suspended-the-impor-bgne-20200325monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-commercial-stage-research-based-biotechnology-company-fo-bgne-20200302monthly0.5https://www.biopharmawatch.com/news/BGNE/exhibit-beigene-reports-third-quarter-2019-financial-results-cambridge-mass-and-bgne-20191112monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-commercial-stage-research-based-biotechnology-company-fo-bgne-20190808monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-regains-full-global-rights-to-its-investigational-anti-pd-1-antibody-tislelizumab--bgne-20190617monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-commercial-stage-research-based-biotechnology-company-fo-bgne-20190509monthly0.5https://www.biopharmawatch.com/news/BGNE/about-beigene-beigene-is-a-global-commercial-stage-research-based-biotechnology-company-fo-bgne-20190227monthly0.5https://www.biopharmawatch.com/news/BGNE/corporate-presentation-january-6-2019-bgne-20190107monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-announces-acceptance-of-new-drug-application-for-anti-pd-1-antibody-tislelizumab-i-bgne-20180831monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-ltd-beigene-initiates-new-phase-3-trial-of-anti-pd-1-antibody-tislelizumab-combine-bgne-20180809monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-ltd-beigene-announces-pricing-of-its-hk-7-08-billion-us-903-million-hong-kong-init-bgne-20180802monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-ltd-beigene-announces-proposed-hong-kong-initial-public-offering-and-global-offeri-bgne-20180727monthly0.5https://www.biopharmawatch.com/news/BGNE/beigene-ltd-beigene-announces-plan-to-pursue-accelerated-approval-in-the-u-s-of-btk-inhibi-bgne-20180722monthly0.5https://www.biopharmawatch.com/news/BGNE/business-overview-we-are-a-commercial-stage-biotechnology-company-focused-on-developing-an-bgne-20180720monthly0.5https://www.biopharmawatch.com/news/VRNA/merck-to-acquire-verona-pharma-expanding-its-portfolio-to-include-ohtuvayre-ensifentrine-a-vrna-20250709monthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-reports-strong-ohtuvayre-tm-launch-and-provides-preliminary-fourth-quarter-a-vrna-20250107monthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-announces-us-fda-approval-of-ohtuvayre-tm-ensifentrine-ohtuvayre-is-indicate-vrna-20240626monthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-announces-650-million-strategic-financing-with-oaktree-and-omers-non-dilutiv-vrna-20240509monthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-enters-into-debt-facility-of-up-to-400-million-with-oxford-finance-and-hercu-vrna-20240102monthly0.5https://www.biopharmawatch.com/news/VRNA/enhance-1-phase-3-data-december-2022-nasdaq-vrna-www-veronapharma-com-forward-looking-stat-vrna-20221220monthly0.5https://www.biopharmawatch.com/news/VRNA/document-verona-pharma-reports-fourth-quarter-and-full-year-2021-financial-results-and-pro-vrna-20220303monthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-completes-enrollment-in-enhance-1-48-week-subset-enhance-2-screening-complet-vrna-20220105monthly0.5https://www.biopharmawatch.com/news/VRNA/document-verona-pharma-reports-third-quarter-2021-financial-results-and-provides-corporate-vrna-20211109monthly0.5https://www.biopharmawatch.com/news/VRNA/document-verona-pharma-reports-second-quarter-2021-financial-results-and-provides-corporat-vrna-20210805monthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-reports-first-quarter-2021-financial-results-and-provides-corporate-update-e-vrna-20210429monthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-cor-vrna-20210225monthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-plc-operational-update-and-financial-results-for-the-third-quarter-ended-vrna-20171109monthly0.5https://www.biopharmawatch.com/news/VRNA/issue-of-shares-vrna-20170919monthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-announces-positive-top-line-data-from-phase-2a-clinical-trial-in-copd-with-r-vrna-20170907monthly0.5https://www.biopharmawatch.com/news/VRNA/pdmr-dealing-vrna-20170821monthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-plc-interim-results-for-the-six-months-ended-vrna-20170808monthly0.5https://www.biopharmawatch.com/news/VRNA/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-regulation--vrna-20170525monthly0.5https://www.biopharmawatch.com/news/VRNA/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-regulation--vrna-20170516monthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-announces-director-purchases-and-related-party-transactions-vrna-20170428monthly0.5https://www.biopharmawatch.com/news/CTLT/novo-holdings-completes-acquisition-of-catalent-catalent-to-strengthen-its-leading-positio-ctlt-20241218monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-and-novo-holdings-fulfill-all-regulatory-closing-conditions-for-pending-transacti-ctlt-20241214monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-and-novo-holdings-receive-european-commission-unconditional-approval-for-pending--ctlt-20241206monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-com-catalent-inc-ctlt-20241105monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-issues-open-letter-to-customers-regarding-pending-acquisition-by-novo-holdings-co-ctlt-20241021monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-com-catalent-inc-ctlt-20240829monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-stockholders-approve-transaction-with-novo-holdings-somerset-n-j-ctlt-20240529monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-com-catalent-inc-ctlt-20240508monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-com-catalent-inc-ctlt-20240209monthly0.5https://www.biopharmawatch.com/news/CTLT/novo-holdings-to-acquire-catalent-catalent-stockholders-to-receive-63-50-per-share-in-cash-ctlt-20240202monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-announces-closing-of-incremental-term-loans-somerset-n-j-ctlt-20231219monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-paul-surdez-catalent-inc-732-537-6325-investors-catalent-com-catalent-reg-ctlt-20231215monthly0.5https://www.biopharmawatch.com/news/CTLT/reflect-revisions-to-preliminary-reported-financial-results-for-the-three-months-and-fisca-ctlt-20231208monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-com-catalent-inc-ctlt-20231115monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-receives-nyse-notice-regarding-late-form-10-k-filing-somerset-n-j-ctlt-20230915monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-announces-governance-enhancements-and-new-initiatives-to-drive-value-adding-four--ctlt-20230829monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-com-catalent-inc-ctlt-20230829monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-appoints-matti-masanovich-senior-vice-president-chief-financial-officer-somerset--ctlt-20230620monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-com-catalent-inc-ctlt-20230612monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-to-hold-business-update-call-related-to-delay-of-third-quarter-2023-results-and-r-ctlt-20230519monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-announces-postponement-of-third-quarter-2023-results-and-conference-call-somerset-ctlt-20230512monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-delays-third-quarter-results-and-conference-call-and-provides-update-on-fiscal-20-ctlt-20230508monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-provides-business-update-and-names-ricky-hopson-as-interim-chief-financial-office-ctlt-20230414monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-com-catalent-inc-ctlt-20230207monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-announces-changes-to-its-board-of-directors-board-of-directors-selects-j-martin-c-ctlt-20221219monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-com-catalent-inc-ctlt-20221101monthly0.5https://www.biopharmawatch.com/news/CTLT/document-14-schoolhouse-road-somerset-nj-08873-usa-catalent-com-1-888-solution-76588466-pr-ctlt-20220919monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-com-catalent-inc-ctlt-20220829monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-chris-halling-44-0-7580-041073-chris-halling-catalent-com-paul-surdez-1-7-ctlt-20220705monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-com-catalent-inc-ctlt-20220503monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-com-catalent-inc-ctlt-20220201monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-announces-plan-for-alessandro-maselli-to-become-new-ceo-effective-ctlt-20220105monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-com-catalent-inc-ctlt-20211102monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-announces-upsizing-and-pricing-of-private-offering-of-senior-unsecured-notes-due--ctlt-20210923monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-announces-launch-of-private-offering-of-450-million-of-senior-unsecured-notes-due-ctlt-20210923monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-com-catalent-inc-ctlt-20210830monthly0.5https://www.biopharmawatch.com/news/CTLT/earnings-release-investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-ctlt-20210504monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-announces-upsizing-and-pricing-of-private-offering-of-senior-unsecured-notes-due--ctlt-20210210monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-announces-launch-of-private-offering-of-475-million-of-senior-unsecured-notes-due-ctlt-20210210monthly0.5https://www.biopharmawatch.com/news/CTLT/earnings-release-investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-ctlt-20210202monthly0.5https://www.biopharmawatch.com/news/CTLT/earnings-release-investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-ctlt-20201103monthly0.5https://www.biopharmawatch.com/news/CTLT/earnings-release-investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-ctlt-20200831monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-com-catalent-inc-ctlt-20200730monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-inc-announces-pricing-of-public-offering-of-common-stock-somerset-n-j-ctlt-20200611monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-inc-announces-public-offering-of-common-stock-somerset-n-j-ctlt-20200610monthly0.5https://www.biopharmawatch.com/news/CTLT/earnings-release-investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-ctlt-20200505monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-announces-next-generation-of-cell-gene-therapy-leadership-somerset-n-j-ctlt-20200430monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-announces-upsizing-and-pricing-of-private-offering-of-senior-unsecured-notes-due--ctlt-20200220monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-announces-launch-of-private-offering-of-450-million-of-senior-unsecured-notes-due-ctlt-20200219monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-inc-announces-pricing-of-public-offering-of-common-stock-somerset-n-j-ctlt-20200203monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-inc-announces-public-offering-of-common-stock-somerset-n-j-ctlt-20200203monthly0.5https://www.biopharmawatch.com/news/CTLT/earnings-release-investor-contact-catalent-inc-paul-surdez-732-537-6325-investors-catalent-ctlt-20200203monthly0.5https://www.biopharmawatch.com/news/CTLT/earnings-release-investor-contact-catalent-inc-thomas-castellano-732-537-6325-investors-ca-ctlt-20191105monthly0.5https://www.biopharmawatch.com/news/CTLT/earnings-release-investor-contact-catalent-inc-thomas-castellano-732-537-6325-investors-ca-ctlt-20190827monthly0.5https://www.biopharmawatch.com/news/CTLT/of-catalent-s-current-report-on-form-8-k-filed-with-the-securities-and-exchange-commission-ctlt-20190624monthly0.5https://www.biopharmawatch.com/news/CTLT/schoolhouse-road-somerset-nj-08873-usa-catalent-com-1-888-solution-76588466-investor-conta-ctlt-20190520monthly0.5https://www.biopharmawatch.com/news/CTLT/earnings-release-investor-contact-catalent-inc-thomas-castellano-732-537-6325-investors-ca-ctlt-20190507monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-to-acquire-gene-therapy-leader-paragon-bioservices-inc-for-1-2-billion-will-provi-ctlt-20190415monthly0.5https://www.biopharmawatch.com/news/CTLT/chris-halling-44-0-7580-041073-chris-halling-catalent-com-richard-kerns-44-0-161-728-5880--ctlt-20190213monthly0.5https://www.biopharmawatch.com/news/CTLT/earnings-release-investor-contact-catalent-inc-thomas-castellano-732-537-6325-investors-ca-ctlt-20190205monthly0.5https://www.biopharmawatch.com/news/CTLT/earnings-release-investor-contact-catalent-inc-thomas-castellano-732-537-6325-investors-ca-ctlt-20181106monthly0.5https://www.biopharmawatch.com/news/CTLT/earnings-release-investor-contact-catalent-inc-thomas-castellano-732-537-6325-investors-ca-ctlt-20180828monthly0.5https://www.biopharmawatch.com/news/CTLT/chris-halling-catalent-inc-44-0-7580-41073-chris-halling-catalent-com-investor-contact-tho-ctlt-20180814monthly0.5https://www.biopharmawatch.com/news/CTLT/to-its-current-report-on-form-8-k-filed-ctlt-20180725monthly0.5https://www.biopharmawatch.com/news/CTLT/to-its-current-report-on-form-8-k-filed-ctlt-20180723monthly0.5https://www.biopharmawatch.com/news/CTLT/to-its-current-report-on-form-8-k-filed-on-ctlt-20180501monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-catalent-inc-thomas-castellano-732-537-6325-investors-catalent-com-catale-ctlt-20180220monthly0.5https://www.biopharmawatch.com/news/CTLT/to-its-current-report-on-form-8-k-filed-on-ctlt-20180205monthly0.5https://www.biopharmawatch.com/news/CTLT/to-its-current-report-on-form-8-k-filed-on-ctlt-20171106monthly0.5https://www.biopharmawatch.com/news/CTLT/chris-halling-44-0-7580-041073-chris-halling-catalent-com-investor-contact-thomas-castella-ctlt-20171024monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-thomas-castellano-catalent-inc-732-537-6325-investors-catalent-com-catale-ctlt-20171018monthly0.5https://www.biopharmawatch.com/news/CTLT/of-catalent-s-form-8-k-filed-ctlt-20170925monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-inc-announces-pricing-of-public-offering-of-common-stock-to-fund-part-of-its-acqu-ctlt-20170926monthly0.5https://www.biopharmawatch.com/news/CTLT/catalent-inc-announces-public-offering-of-common-stock-to-fund-part-of-its-acquisition-of--ctlt-20170925monthly0.5https://www.biopharmawatch.com/news/CTLT/cook-pharmica-llc-financial-statements-year-ended-ctlt-20170925monthly0.5https://www.biopharmawatch.com/news/CTLT/earnings-release-investor-contact-catalent-inc-thomas-castellano-732-537-6325-investors-ca-ctlt-20170828monthly0.5https://www.biopharmawatch.com/news/CTLT/earnings-release-investor-contact-catalent-inc-thomas-castellano-732-537-6325-investors-ca-ctlt-20170504monthly0.5https://www.biopharmawatch.com/news/CTLT/earnings-release-investor-contact-catalent-inc-thomas-castellano-732-537-6325-investors-ca-ctlt-20170206monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-thomas-castellano-catalent-inc-732-537-6325-investors-catalent-com-catale-ctlt-20161212monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-thomas-castellano-catalent-inc-732-537-6325-investors-catalent-com-catale-ctlt-20161202monthly0.5https://www.biopharmawatch.com/news/CTLT/investor-contact-thomas-castellano-catalent-inc-732-537-6325-investors-catalent-com-catale-ctlt-20161128monthly0.5https://www.biopharmawatch.com/news/CTLT/earnings-release-investor-contact-catalent-inc-thomas-castellano-732-537-6325-investors-ca-ctlt-20161107monthly0.5https://www.biopharmawatch.com/news/CTLT/earnings-release-investor-contact-catalent-inc-thomas-castellano-732-537-6325-investors-ca-ctlt-20160829monthly0.5https://www.biopharmawatch.com/news/CTLT/earnings-release-investor-contact-catalent-inc-thomas-castellano-732-537-6325-investors-ca-ctlt-20160504monthly0.5https://www.biopharmawatch.com/news/CTLT/earnings-release-investor-contact-catalent-inc-thomas-castellano-732-537-6325-investors-ca-ctlt-20160209monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-third-quarter-2023-financial-and-operating-results-and-provi-elox-20231113monthly0.5https://www.biopharmawatch.com/news/ELOX/rare-thinking-for-rare-solutions-small-molecule-gene-therapy-august-2023-2-forward-looking-elox-20230821monthly0.5https://www.biopharmawatch.com/news/ELOX/baseline-characteristics-of-patients-that-have-completed-therapy-patient-age-sex-col4-gene-elox-20230713monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-first-quarter-2023-financial-and-operating-results-and-provi-elox-20230515monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-fourth-quarter-2022-financial-and-operating-results-and-prov-elox-20230403monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-announces-reverse-stock-split-effective-elox-common-stock-expected-t-elox-20221202monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-third-quarter-2022-financial-and-operating-results-and-provi-elox-20221110monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-topline-results-from-phase-2-combination-clinical-trial-of-e-elox-20220914monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-second-quarter-2022-financial-and-operating-results-and-prov-elox-20220815monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-announces-changes-to-board-of-directors-lindsay-androski-jd-mba-brin-elox-20220705monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-first-quarter-2022-financial-and-operating-results-and-provi-elox-20220510monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-fourth-quarter-2021-financial-and-operating-results-and-prov-elox-20220331monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-positive-topline-results-from-monotherapy-arms-of-phase-2-cl-elox-20211117monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-third-quarter-2021-financial-and-operating-results-and-provi-elox-20211109monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-second-quarter-2021-financial-and-operating-results-and-prov-elox-20210816monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-provides-enrollment-update-for-ongoing-phase-2-clinical-studies-for--elox-20210706monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-developm-elox-20210527monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-inc-announces-closing-of-public-offering-of-common-stock-including-f-elox-20210518monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-first-quarter-2021-financial-and-operating-results-and-provi-elox-20210506monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-adds-additional-treatment-arm-to-ongoing-phase-2-clinical-studies-fo-elox-20210429monthly0.5https://www.biopharmawatch.com/news/ELOX/rare-thinking-for-rare-solutions-creating-a-world-leader-in-ribosome-targeted-genetic-ther-elox-20210420monthly0.5https://www.biopharmawatch.com/news/ELOX/creating-a-leader-in-ribosomal-rna-targeted-genetic-therapy-eloxx-a-cquires-zikani-therape-elox-20210401monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-and-operating-re-elox-20210311monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-announces-cystic-fibrosis-foundation-cf-foundation-to-provide-increa-elox-20210113monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-third-quarter-2020-financial-and-operating-results-and-provi-elox-20201105monthly0.5https://www.biopharmawatch.com/news/ELOX/enrollment-in-the-u-s-phase-2-clinical-trial-in-cystic-fibrosis-has-resumed-after-being-pa-elox-20200812monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-second-quarter-2020-financial-and-operating-results-and-prov-elox-20200806monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-receives-u-s-orphan-drug-designation-for-elx-02-for-the-treatment-of-elox-20200804monthly0.5https://www.biopharmawatch.com/news/ELOX/enrollment-in-phase-2-clinical-trial-in-cystic-fibrosis-has-been-resumed-in-israel-and-eur-elox-20200617monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-first-quarter-2020-financial-and-operating-results-and-provi-elox-20200507monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-provides-update-on-the-impact-of-novel-coronavirus-covid-19-on-phase-elox-20200325monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-and-operating-re-elox-20200305monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-strengthens-its-commitment-to-cystic-fibrosis-through-reallocating-resources-reitera-elox-20200226monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-provides-update-on-progress-of-its-phase-2-clinical-programs-for-elx-elox-20200114monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-third-quarter-2019-financial-and-operating-results-and-provi-elox-20191105monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-second-quarter-2019-financial-and-operating-results-and-prov-elox-20190807monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-announces-initiation-of-phase-2-clinical-trial-for-elx-02-in-cystino-elox-20190807monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-announces-open-investigational-new-drug-application-ind-for-a-phase--elox-20190731monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-and-full-exerci-elox-20190624monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-announces-proposed-public-offering-of-common-stock-waltham-ma-elox-20190619monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-first-quarter-2019-financial-and-operating-results-and-provi-elox-20190502monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-fourth-quarter-and-full-year-2018-financial-and-operating-re-elox-20190308monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-third-quarter-2018-financial-and-operating-results-and-provi-elox-20181108monthly0.5https://www.biopharmawatch.com/news/ELOX/unlocking-protein-production-with-translational-read-through-for-rare-genetic-diseases-can-elox-20181002monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-second-quarter-2018-financial-and-operating-results-and-prov-elox-20180807monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-expands-leadership-team-with-two-global-pharmaceutical-executives-to-accelerate-grow-elox-20180625monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-first-quarter-2018-financial-and-operating-results-and-provi-elox-20180510monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-announces-proposed-public-offering-of-common-stock-waltham-ma-elox-20180424monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-reports-full-year-2017-financial-and-operating-results-and-provides--elox-20180320monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-appoints-biotech-leader-dr-jasbir-seehra-co-founder-of-acceleron-pha-elox-20180228monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-appoints-robert-ward-chairman-and-chief-executive-officer-biopharmac-elox-20171227monthly0.5https://www.biopharmawatch.com/news/ELOX/sevion-therapeutics-announces-1-for-20-reverse-stock-split-san-diego-ca-elox-20171219monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-secures-us-8-million-investment-from-lsp-increasing-total-raised-in--elox-20170802monthly0.5https://www.biopharmawatch.com/news/ELOX/eloxx-pharmacueticals-receives-a-us-6-million-investment-from-kip-and-dcs-to-advance-a-nov-elox-20170626monthly0.5https://www.biopharmawatch.com/news/ELOX/sevion-therapeutics-inc-and-eloxx-pharmaceuticals-ltd-announce-the-entering-into-of-an-acq-elox-20170602monthly0.5https://www.biopharmawatch.com/news/ELOX/sevion-therapeutics-reports-first-quarter-2016-financial-results-elox-20151117monthly0.5https://www.biopharmawatch.com/news/ELOX/sevion-therapeutics-reports-fiscal-year-2015-financial-results-san-diego-ca-elox-20151014monthly0.5https://www.biopharmawatch.com/news/ELOX/sevion-therapeutics-announces-immuno-oncology-discovery-program-at-elox-20150616monthly0.5https://www.biopharmawatch.com/news/ELOX/sevion-therapeutics-reports-third-quarter-2015-financial-results-san-diego-ca-elox-20150515monthly0.5https://www.biopharmawatch.com/news/ELOX/sevion-therapeutics-reports-second-quarter-2015-financial-results-san-diego-ca-elox-20150219monthly0.5https://www.biopharmawatch.com/news/ELOX/sevion-announces-antibody-discovery-collaboration-with-johnson-johnson-innovation-and-jans-elox-20141222monthly0.5https://www.biopharmawatch.com/news/ELOX/sevion-therapeutics-presents-results-of-sns01-t-phase-1b-2a-dose-escalation-study-at-ash-a-elox-20141208monthly0.5https://www.biopharmawatch.com/news/ELOX/sevion-therapeutics-reports-first-quarter-2015-financial-results-bridgewater-nj-elox-20141117monthly0.5https://www.biopharmawatch.com/news/ELOX/sevion-therapeutics-announces-new-ticker-symbol-svon-bridgewater-n-j-october-3-rd-2014-sev-elox-20141003monthly0.5https://www.biopharmawatch.com/news/ELOX/sevion-therapeutics-reports-fiscal-year-2014-financial-results-bridgewater-n-j-elox-20140929monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-closes-enrollment-in-its-phase-1b-2a-sns01-t-study-bridgewater-n-j-elox-20140829monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-inc-corporate-overview-otc-qb-snti-bio-san-diego-june-2014-1-certain--elox-20140627monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-completes-acquisition-of-fabrus-bridgewater-nj-elox-20140519monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-reports-second-quarter-of-fiscal-year-2014-financial-results-bridgewa-elox-20140509monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-announces-presentation-on-the-effectiveness-of-eif5a-in-inhibiting-tumor-progressi-elox-20140428monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-opens-two-new-clinical-trial-sites-and-initiates-treatment-of-the-first-patient-in-elox-20140312monthly0.5https://www.biopharmawatch.com/news/ELOX/in-non-clinical-cancer-studies-senesco-s-therapeutic-candidate-sns01-t-works-synergistical-elox-20140304monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-reports-second-quarter-of-fiscal-year-2014-financial-results-bridgewa-elox-20140218monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-inc-changing-cancer-therapy-annual-meeting-2014-elox-20140211monthly0.5https://www.biopharmawatch.com/news/ELOX/first-patient-in-cohort-4-receives-infusion-of-senesco-s-therapeutic-candidate-sns01-t-for-elox-20140109monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-announces-letter-of-intent-to-merge-with-fabrus-phil-frost-investor-in-senesco-and-elox-20131230monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-announces-up-to-25-2-million-equity-financing-bridgewater-n-j-elox-20131212monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-s-drug-candidate-sns01-t-selectively-kills-cancer-cells-and-not-healthy-cells-in-d-elox-20131210monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-announces-results-of-cohort-3-in-sns01-t-phase-1b-2a-trial-more-robust-effects-obs-elox-20131209monthly0.5https://www.biopharmawatch.com/news/ELOX/completion-of-cohort-3-in-phase-1b-2a-study-in-multiple-myeloma-and-non-hodgkins-b-cell-ly-elox-20131204monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-reports-first-quarter-of-fiscal-year-2014-financial-results-bridgewat-elox-20131115monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-opens-new-clinical-trial-site-elox-20131024monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-announces-reverse-stock-split-bridgewater-n-j-elox-20131018monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-announces-1-725-million-equity-financing-bridgewater-n-j-elox-20131001monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-reports-fiscal-year-2013-financial-results-bridgewater-n-j-elox-20130912monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-announces-results-of-cohort-2-of-its-sns01-t-phase-1b-2a-trial-bridgewater-n-j-jun-elox-20130619monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-reports-second-quarter-fiscal-2013-financial-results-bridgewater-n-j--elox-20130516monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-announces-1-255-million-equity-financing-bridgewater-n-j-elox-20130509monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-announces-start-of-cohort-3-in-phase-1b-2a-study-in-multiple-myeloma-and-non-hodgk-elox-20130506monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-announces-completion-of-cohort-2-of-its-phase-1b-2a-trial-bridgewater-n-j-april-22-elox-20130422monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-inc-elox-20130401monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-reports-second-quarter-fiscal-2013-financial-results-bridgewater-n-j--elox-20130215monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-announces-3-0-million-equity-financing-bridgewater-n-j-elox-20130104monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-provides-summary-of-sns01-t-progress-in-phase-1b-2a-trial-interim-results-presente-elox-20121210monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-provides-corporate-update-bridgewater-n-j-elox-20121126monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-announces-quotation-of-common-stock-on-the-over-the-counter-securities-market-brid-elox-20121121monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-announces-delisting-of-common-stock-from-nyse-mkt-llc-and-pending-transfer-to-an-o-elox-20121121monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-reports-first-quarter-fiscal-2013-financial-results-bridgewater-n-j-n-elox-20121115monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-announces-expansion-of-phase-1b-2a-study-to-include-diffuse-large-b-cell-lymphoma--elox-20121107monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-reports-fiscal-year-2012-financial-results-bridgewater-n-j-elox-20120918monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-announces-first-dose-of-sns01-t-elox-20120913monthly0.5https://www.biopharmawatch.com/news/ELOX/combining-sns01-t-with-bortezomib-significantly-increases-its-effectiveness-in-model-of-mu-elox-20120910monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-receives-notice-of-non-compliance-from-nyse-mkt-bridgewater-n-j-augus-elox-20120822monthly0.5https://www.biopharmawatch.com/news/ELOX/highly-statistically-significant-tumor-growth-inhibition-by-a-combination-of-lenalidomide--elox-20120815monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-s-lead-therapeutic-candidate-sns01-t-granted-orphan-drug-status-from-fda-for-treat-elox-20120730monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-provides-sns01-t-update-on-phase-1b-2a-multiple-myeloma-trial-bridgewater-n-j-june-elox-20120604monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-reports-fiscal-2012-third-quarter-results-bridgewater-n-j-business-wi-elox-20120515monthly0.5https://www.biopharmawatch.com/news/ELOX/combination-of-lenalidomide-and-sns01-t-effective-in-cancer-model-tumors-eliminated-in-ove-elox-20120501monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-adds-additional-clinical-site-to-evaluate-sns01-t-in-multiple-myeloma-bridgewater--elox-20120307monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-announces-additional-1-0-million-equity-financing-follow-on-to-january-2012-financ-elox-20120302monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-adds-second-clinical-site-to-evaluate-sns01-t-in-multiple-myeloma-bridgewater-n-j--elox-20120301monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-reports-second-quarter-fiscal-2012-financial-results-bridgewater-n-j--elox-20120215monthly0.5https://www.biopharmawatch.com/news/ELOX/biocorp-ventures-and-senesco-enter-into-license-agreement-for-the-application-of-eif5a-to--elox-20120214monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-announces-2-0-million-equity-financing-bridgewater-n-j-january-9-th-2012-senesco-t-elox-20120111monthly0.5https://www.biopharmawatch.com/news/ELOX/unassociated-document-sns01-t-demonstrates-synergy-with-lenalidomide-in-cancer-model-resul-elox-20120103monthly0.5https://www.biopharmawatch.com/news/ELOX/unassociated-document-company-contact-investor-relations-contact-senesco-technologies-inc--elox-20111227monthly0.5https://www.biopharmawatch.com/news/ELOX/unassociated-document-senesco-receives-milestone-payment-from-bayer-cropscience-bridgewate-elox-20111201monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-reports-first-quarter-fiscal-2012-financial-results-bridgewater-n-j-b-elox-20111115monthly0.5https://www.biopharmawatch.com/news/ELOX/unassociated-document-senesco-initiates-dosing-in-phase-1b-2a-clinical-study-of-sns01-t-fi-elox-20111103monthly0.5https://www.biopharmawatch.com/news/ELOX/unassociated-document-senesco-technologies-provides-corporate-update-bridgewater-n-j-elox-20111026monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-reports-fiscal-year-2011-financial-results-bridgewater-n-j-elox-20110929monthly0.5https://www.biopharmawatch.com/news/ELOX/unassociated-document-senesco-finalizes-agreement-with-mayo-clinic-to-study-sns01-t-in-mul-elox-20110824monthly0.5https://www.biopharmawatch.com/news/ELOX/unassociated-document-senesco-technologies-selects-criterium-to-manage-multiple-myeloma-st-elox-20110808monthly0.5https://www.biopharmawatch.com/news/ELOX/unassociated-document-senesco-technologies-told-by-fda-it-may-proceed-sns01-t-ind-is-open--elox-20110620monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-reports-third-quarter-fiscal-2011-financial-results-new-brunswick-n-j-elox-20110516monthly0.5https://www.biopharmawatch.com/news/ELOX/unassociated-document-senesco-s-lead-therapeutic-candidate-sns01-t-waiting-for-update-to-v-elox-20110310monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-reports-second-quarter-fiscal-2011-financial-results-new-brunswick-n--elox-20110210monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-announces-ind-filing-with-fda-for-sns01-t-new-brunswick-n-j-elox-20110124monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-lead-therapeutic-candidate-sns01-t-granted-orphan-drug-status-from-fd-elox-20110103monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-inc-lippert-heilshorn-associates-inc-leslie-j-browne-ph-d-anne-marie--elox-20101115monthly0.5https://www.biopharmawatch.com/news/ELOX/unassociated-document-company-contact-investor-relations-contact-senesco-technologies-inc--elox-20101102monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-inc-lippert-heilshorn-associates-inc-leslie-j-browne-ph-d-anne-marie--elox-20100929monthly0.5https://www.biopharmawatch.com/news/ELOX/unassociated-document-company-contact-investor-relations-contact-senesco-technologies-inc--elox-20100524monthly0.5https://www.biopharmawatch.com/news/ELOX/draft-1-may-12-2010-company-contact-investor-relations-contact-senesco-technologies-inc-li-elox-20100518monthly0.5https://www.biopharmawatch.com/news/ELOX/draft-1-company-contact-investor-relations-contact-senesco-technologies-inc-lippert-heilsh-elox-20100505monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-inc-fd-jack-van-hulst-brian-ritchie-chief-executive-officer-brian-rit-elox-20100408monthly0.5https://www.biopharmawatch.com/news/ELOX/unassociated-document-company-contact-investor-relations-contact-senesco-technologies-inc--elox-20100405monthly0.5https://www.biopharmawatch.com/news/ELOX/unassociated-document-company-contact-investor-relations-contact-senesco-technologies-inc--elox-20100329monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-inc-fd-jack-van-hulst-brian-ritchie-chief-executive-officer-brian-rit-elox-20100305monthly0.5https://www.biopharmawatch.com/news/ELOX/unassociated-document-company-contact-investor-relations-contact-senesco-technologies-inc--elox-20100222monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-inc-fd-joel-brooks-brian-ritchie-chief-financial-officer-brian-ritchi-elox-20100217monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-inc-fd-jack-van-hulst-brian-ritchie-president-and-chief-executive-off-elox-20100204monthly0.5https://www.biopharmawatch.com/news/ELOX/unassociated-document-company-contact-investor-relations-contact-senesco-technologies-inc--elox-20100119monthly0.5https://www.biopharmawatch.com/news/ELOX/investor-relations-contact-senesco-technologies-inc-fd-joel-brooks-brian-ritchie-chief-fin-elox-20091117monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-inc-fd-jack-van-hulst-brian-ritchie-president-and-chief-executive-off-elox-20091116monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-inc-fd-bruce-galton-brian-ritchie-chief-executive-officer-brian-ritch-elox-20091109monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-inc-fd-bruce-galton-brian-ritchie-chief-executive-officer-brian-ritch-elox-20091104monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-inc-joel-brooks-chief-financial-officer-jbrooks-senesco-com-732-296-8-elox-20090929monthly0.5https://www.biopharmawatch.com/news/ELOX/media-relations-contact-senesco-technologies-inc-fd-fd-joel-brooks-brian-ritchie-irma-gome-elox-20090729monthly0.5https://www.biopharmawatch.com/news/ELOX/arborgen-and-senesco-announce-wood-quality-results-summerville-s-c-july-7-prnewswire-arbor-elox-20090710monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-inc-fd-joel-brooks-brian-ritchie-chief-financial-officer-brian-ritchi-elox-20090709monthly0.5https://www.biopharmawatch.com/news/ELOX/media-relations-senesco-technologies-inc-fd-fd-bruce-galton-brian-ritchie-irma-gomez-dib-c-elox-20090609monthly0.5https://www.biopharmawatch.com/news/ELOX/media-relations-senesco-technologies-inc-fd-fd-bruce-galton-brian-ritchie-irma-gomez-dib-c-elox-20090526monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-inc-fd-joel-brooks-brian-ritchie-chief-financial-officer-brian-ritchi-elox-20090504monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-inc-fd-joel-brooks-brian-ritchie-chief-financial-officer-brian-ritchi-elox-20090218monthly0.5https://www.biopharmawatch.com/news/ELOX/senesco-technologies-inc-fd-bruce-galton-brian-ritchie-chief-executive-officer-brian-ritch-elox-20090203monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-approval-of-all-proposals-at-2026-annual-meeting-of-stockholders-lis-jagx-20260610monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-compliant-with-nasdaq-bid-price-rule-jagx-s-securities-continue-to-be-listed-jagx-20260527monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-granted-extension-until-jagx-20260427monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-2025-financials-net-revenue-increase-of-5-in-q4-2025-vs-q3-2025-jagu-jagx-20260407monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-enters-into-u-s-license-agreement-with-future-pak-for-crofelemer-providing-u-jagx-20260112monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-approval-of-all-proposals-at-december-2025-special-meeting-of-stockh-jagx-20251208monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-approval-of-all-proposals-at-august-2025-annual-meeting-of-stockhold-jagx-20250819monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-extension-of-the-maturity-date-of-its-convertible-promissory-notes-jagx-20250624monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-1-5-million-registered-direct-offering-priced-at-the-market-under--jagx-20250521monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-first-quarter-2025-financials-the-combined-net-q1-2025-revenue-of-ap-jagx-20250430monthly0.5https://www.biopharmawatch.com/news/JAGX/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-jagx-20250426monthly0.5https://www.biopharmawatch.com/news/JAGX/proof-of-concept-results-show-crofelemer-reduced-total-parenteral-nutrition-in-patients-wi-jagx-20250430monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-to-present-initial-results-from-the-proof-of-concept-study-of-crofelemer-for-jagx-20250428monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-nasdaq-jagx-overview-x2013-april-2025-forward-looking-statements-2-this--jagx-20250425monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-nasdaq-jagx-overview-x2013-april-2025-forward-looking-statements-2-this--jagx-20250421monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-closing-of-bridge-financing-priced-at-the-market-under-nasdaq-rule-jagx-20250401monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-2024-financials-2024-net-revenue-up-approximately-20-over-2023-the-t-jagx-20250331monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-ceo-board-members-other-c-suite-members-and-institutional-and-accredited-inv-jagx-20250326monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-announces-reverse-stock-split-reverse-split-approved-at-march-2025-speci-jagx-20250318monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-approval-of-all-proposals-at-march-2025-special-meeting-of-stockhold-jagx-20250313monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-adopts-limited-duration-stockholder-rights-plan-to-ensure-stockholders-can-r-jagx-20250227monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-third-quarter-2024-financial-results-the-combined-net-q3-2024-revenu-jagx-20241113monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-second-quarter-2024-financial-results-the-combined-net-q2-2024-reven-jagx-20240813monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-phase-3-ontarget-trial-results-for-its-cancer-supportive-care-drug-c-jagx-20240723monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-regains-compliance-with-nasdaq-s-bid-price-requirement-jagx-s-securities-con-jagx-20240626monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-approval-of-all-proposals-at-june-2024-annual-meeting-of-stockholder-jagx-20240621monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-announces-reverse-stock-split-reverse-split-approved-at-april-2024-speci-jagx-20240523monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-approval-of-all-proposals-at-april-2024-special-meeting-of-stockhold-jagx-20240409monthly0.5https://www.biopharmawatch.com/news/JAGX/gen-to-commercialize-jaguar-health-s-crofelemer-in-turkey-and-eight-neighboring-countries--jagx-20240320monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-receives-additional-180-day-grace-period-to-regain-compliance-with-nasdaq-s--jagx-20231108monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-second-quarter-2023-financial-results-net-revenue-increased-36-in-q2-jagx-20230814monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-approval-of-all-proposals-at-2023-annual-meeting-of-stockholders-san-jagx-20230707monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-replenishment-of-new-employee-inducement-plan-under-nasdaq-listing-jagx-20230519monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-first-quarter-2023-financial-results-net-revenue-decreased-in-q1-202-jagx-20230515monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-completes-enrollment-in-its-pivotal-phase-3-ontarget-trial-of-crofelemer-for-prophy-jagx-20230509monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-2022-financial-results-prescription-revenues-up-179-to-11-9-million--jagx-20230327monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-regains-compliance-with-nasdaq-s-bid-price-requirement-jagx-s-securities-con-jagx-20230208monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-synworld-technologies-mutually-agree-to-terminate-license-and-commercializat-jagx-20230201monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-voting-results-from-january-2023-special-meeting-of-stockholders-all-jagx-20230123monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-provides-company-updates-and-reports-2022-third-quarter-financials-prescript-jagx-20221114monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-voting-results-from-2022-special-meeting-of-stockholders-all-proposa-jagx-20220930monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-secures-additional-capital-through-sale-of-royalty-rights-related-to-future--jagx-20220825monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-receives-additional-180-day-grace-period-to-regain-compliance-with-nasdaq-s--jagx-20220819monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-appoints-senior-healthcare-and-investment-executive-dr-anula-jayasuriya-to-b-jagx-20220705monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-enters-exclusive-crofelemer-license-and-commercialization-agreement-with-syn-jagx-20220629monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-voting-results-from-2022-annual-meeting-of-stockholders-all-proposal-jagx-20220610monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-provides-company-updates-and-reports-2022-first-quarter-financials-mytesi-ne-jagx-20220510monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-provides-company-updates-and-reports-2021-financials-core-2022-development-i-jagx-20220311monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-2021-third-quarter-financial-results-mytesi-prescription-volume-incr-jagx-20211117monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-closing-of-private-placement-priced-at-a-premium-to-market-partici-jagx-20210914monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-voting-results-from-2021-annual-meeting-of-stockholders-proposals-1--jagx-20210903monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-subsidiary-napo-pharmaceuticals-signs-license-agreement-with-its-italian-sub-jagx-20210819monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-adjournment-of-annual-meeting-of-stockholders-until-friday-jagx-20210806monthly0.5https://www.biopharmawatch.com/news/JAGX/napo-eu-s-p-a-jaguar-health-s-italian-subsidiary-and-dragon-spac-s-p-a-announce-close-of-8-jagx-20210719monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-adjournment-of-annual-meeting-of-stockholders-until-friday-jagx-20210715monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-adjournment-of-annual-meeting-of-stockholders-until-friday-jagx-20210611monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-dragon-spac-announce-initial-funding-of-us-10-8-million-into-dragon-spac-nap-jagx-20210601monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-reports-2021-first-quarter-financial-results-first-quarter-2021-mytesi-g-jagx-20210517monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-adjournment-of-annual-meeting-of-stockholders-until-friday-jagx-20210514monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-to-host-investor-webcast-monday-may-17-th-at-8-30-am-eastern-time-regarding--jagx-20210511monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-10-8-million-registered-direct-offering-for-the-benefit-of-napo-eu-jagx-20210429monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-upsizing-of-at-the-market-atm-financing-program-by-15-3-million-wi-jagx-20210415monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-promotes-carol-lizak-to-chief-financial-officer-san-francisco-ca-jagx-20210406monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-2020-financial-results-and-business-updates-mytesi-net-sales-and-gro-jagx-20210331monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-signs-definitive-agreement-for-5-million-non-dilutive-financing-transaction--jagx-20210309monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-closing-of-6-0-million-issuance-and-sale-of-designation-backed-not-jagx-20210120monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-15-million-registered-direct-offering-priced-above-the-market-unde-jagx-20210113monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-exploring-possibility-of-conditional-marketing-authorization-for-proposed-in-jagx-20210111monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-voting-results-from-special-meeting-of-stockholders-announces-decemb-jagx-20201222monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-and-its-subsidiary-napo-pharmaceuticals-enter-into-fifth-amendment-to-the-ac-jagx-20201210monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-plan-to-develop-and-commercialize-crofelemer-the-company-s-novel-p-jagx-20201130monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-reports-2020-third-quarter-financial-results-third-quarter-2020-mytesi-n-jagx-20201116monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-to-host-investor-call-monday-november-16th-at-8-30-a-m-eastern-regarding-q3--jagx-20201110monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-receives-positive-nasdaq-listing-determination-san-francisco-ca-jagx-20201029monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-provides-updates-regarding-company-capitalization-strategy-jaguar-has-closed-jagx-20201013monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-signs-agreement-for-non-dilutive-financing-transaction-involving-the-sale-of-jagx-20201001monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-nasdaq-jagx-overview-september-2020-forward-looking-statements-2-this-pr-jagx-20200916monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-and-its-subsidiary-napo-pharmaceuticals-enter-into-third-amendment-to-the-ac-jagx-20200910monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-completes-transactions-that-increase-stockholders-equity-above-5-000-000-amo-jagx-20200902monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-and-its-subsidiary-napo-pharmaceuticals-enter-into-a-second-amendment-to-the-jagx-20200814monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-reports-2020-second-quarter-financial-results-q2-2020-mytesi-net-sales-a-jagx-20200813monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-to-host-investor-call-august-13th-at-8-30-a-m-eastern-regarding-q2-2020-fina-jagx-20200813monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-activation-of-investigational-new-drug-ind-for-crofelemer-mytesi-f-jagx-20200806monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-voting-results-from-jagx-20200721monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-and-its-subsidiary-napo-pharmaceuticals-enter-an-amendment-to-the-accounts-r-jagx-20200629monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-and-its-subsidiary-napo-pharmaceuticals-enter-accounts-receivable-purchase-a-jagx-20200513monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-reports-2020-first-quarter-financial-results-reminder-company-to-host-in-jagx-20200515monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-to-host-investor-call-may-15th-at-8-30-a-m-eastern-regarding-q1-2020-financi-jagx-20200514monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-statement-on-mytesi-crofelemer-april-2020-price-adjustment-and-commitment-to-jagx-20200504monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-enters-deal-with-atlas-sciences-to-develop-np-500-a-jaguar-non-core-plant-ba-jagx-20200416monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-2019-financial-results-and-business-updates-mytesi-net-sales-and-gro-jagx-20200406monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-to-host-investor-call-april-6th-at-8-30-a-m-eastern-regarding-q4-2019-financ-jagx-20200403monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-secures-non-dilutive-capital-through-sale-of-royalty-rights-related-to-futur-jagx-20200305monthly0.5https://www.biopharmawatch.com/news/JAGX/director-resignation-jaguar-health-inc-the-company-effective-as-of-jagx-20200221monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-reports-2019-third-quarter-financial-results-reminder-company-to-host-in-jagx-20191114monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-that-interim-analysis-requirement-met-in-phase-2-halt-d-study-eval-jagx-20191114monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-to-host-investor-call-nov-14th-at-9-a-m-eastern-regarding-interim-analysis-o-jagx-20191114monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-eliminates-certain-royalty-obligations-reducing-future-cogs-for-mytesi-and-c-jagx-20191004monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-promotes-jonathan-wolin-to-chief-of-staff-chief-compliance-officer-general-c-jagx-20190909monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-appoints-carol-lizak-chief-accounting-officer-san-francisco-ca-jagx-20190816monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-reports-2019-second-quarter-financial-results-mytesi-net-sales-and-gross-jagx-20190814monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-pricing-of-14-4-million-underwritten-public-offering-san-francisco-jagx-20190719monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-strengthens-company-s-balance-sheet-by-reducing-approximately-10-5-million-o-jagx-20190715monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-strengthens-company-s-balance-sheet-by-reducing-approximately-10-5-million-o-jagx-20190628monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-regains-compliance-with-all-applicable-nasdaq-stock-market-listing-standards-jagx-20190624monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-ceo-and-board-members-invest-in-bridge-financing-san-francisco-ca-jagx-20190605monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-refinances-10-5-million-of-secured-debt-including-an-extension-of-the-maturi-jagx-20190603monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-eliminates-more-than-6-4-million-in-secured-promissory-notes-to-strengthen-c-jagx-20190529monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-reports-voting-results-from-jagx-20190524monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-reports-2019-first-quarter-financial-results-mytesi-net-sales-and-gross--jagx-20190524monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-reports-2018-fourth-quarter-and-year-end-financial-results-mytesi-gross--jagx-20190410monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-reports-voting-results-from-jagx-20190228monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-adjournment-of-special-meeting-of-stockholders-until-thursday-jagx-20190228monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-investor-presentation-january-2019-forward-looking-statements-this-prese-jagx-20190128monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-provides-fourth-quarter-2018-commercial-sales-updates-napo-pharmaceuticals-i-jagx-20190107monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-to-host-investor-call-january-7-th-at-8-a-m-eastern-to-review-4q-18-performa-jagx-20190102monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-reports-third-quarter-2018-results-mytesi-gross-sales-and-net-sales-grew-jagx-20181115monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-expects-to-file-third-quarter-2018-financial-results-november-14-th-comp-jagx-20181029monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-pricing-of-9-million-underwritten-public-offering-san-francisco-ca-jagx-20181002monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-investor-presentation-september-2018-this-presentation-contains-forward--jagx-20180928monthly0.5https://www.biopharmawatch.com/news/JAGX/knight-therapeutics-and-jaguar-health-announce-strategic-partnership-knight-receives-licen-jagx-20180924monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-provides-second-quarter-2018-financial-updates-napo-pharmaceuticals-inc--jagx-20180712monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-nasdaq-jagx-subsidiary-napo-pharmaceuticals-and-redhill-biopharma-enter-u-s--jagx-20180628monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-appoints-pharmaceutical-industry-veteran-david-macnaughtan-to-board-of-direc-jagx-20180620monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-appoints-senior-commercial-pharmaceutical-executive-greg-divis-to-board-of-d-jagx-20180618monthly0.5https://www.biopharmawatch.com/news/JAGX/exhibit-9-9-1-jaguar-health-inc-announces-1-for-15-reverse-stock-split-shares-of-common-st-jagx-20180601monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-appoints-robert-j-griffing-chief-commercialization-officer-of-jaguar-subsidi-jagx-20180529monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-inc-reports-first-quarter-2018-operational-updates-and-voting-results-from-2-jagx-20180518monthly0.5https://www.biopharmawatch.com/news/JAGX/severance-plan-benefits-for-section-16-officers-1-current-section-16-officers-ceo-cfo-evp--jagx-20180518monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-appoints-jonathan-b-siegel-to-board-of-directors-san-francisco-ca-jagx-20180402monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-up-to-16-2-million-in-equity-financings-in-separate-private-placem-jagx-20180326monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-subsidiary-napo-pharmaceuticals-signs-agreement-with-pharmacy-services-provi-jagx-20180302monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-provides-updates-regarding-commercial-educational-product-development-progra-jagx-20180122monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-to-host-conference-call-monday-january-22-nd-at-4-15-p-m-eastern-time-to-pro-jagx-20180118monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-and-dubai-based-seed-mena-enter-collaboration-agreement-for-equilevia-jaguar-jagx-20171214monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-announces-adjournment-of-special-meeting-of-stockholders-until-friday-jagx-20171201monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-enters-share-purchase-agreement-for-2-million-shares-and-common-stock-purcha-jagx-20171127monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-files-first-quarterly-earnings-report-since-july-2017-merger-with-napo-pharm-jagx-20171120monthly0.5https://www.biopharmawatch.com/news/JAGX/year-to-date-gross-sales-for-mytesi-the-fda-approved-human-prescription-drug-product-of-ja-jagx-20171114monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-to-host-earnings-conference-call-tuesday-november-14-th-at-4-30-p-m-eastern--jagx-20171109monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-prices-4-25-million-public-offering-of-common-stock-san-francisco-ca-jagx-20170929monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-subsidiary-napo-pharmaceuticals-and-glenmark-pharmaceuticals-sign-agreement-returni-jagx-20170925monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-subsidiary-napo-pharmaceuticals-expands-mytesi-salesforce-with-hire-of-exper-jagx-20170915monthly0.5https://www.biopharmawatch.com/news/JAGX/napo-pharmaceuticals-inc-condensed-consolidated-balance-sheets-jagx-20170829monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-company-name-now-updated-on-nasdaq-com-post-merger-jaguar-s-post-merger-mark-jagx-20170816monthly0.5https://www.biopharmawatch.com/news/JAGX/napo-pharmaceuticals-inc-index-to-consolidated-financial-statements-page-unaudited-interim-jagx-20170804monthly0.5https://www.biopharmawatch.com/news/JAGX/the-merger-of-jaguar-animal-health-and-napo-pharmaceuticals-is-effective-the-combined-comp-jagx-20170731monthly0.5https://www.biopharmawatch.com/news/JAGX/stockholders-of-jaguar-animal-health-and-napo-pharmaceuticals-vote-to-approve-merger-merge-jagx-20170727monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-animal-health-to-hold-special-meeting-of-stockholders-jagx-20170707monthly0.5https://www.biopharmawatch.com/news/JAGX/general-overview-june-2017-this-presentation-contains-forward-looking-statements-all-state-jagx-20170526monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-signs-distribution-agreement-for-japan-for-neonorm-foal-neonorm-calf-jaguar-receive-jagx-20170428monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-and-napo-issue-commercial-updates-jaguar-kicks-off-neonorm-foal-tv-campaign-neonorm-jagx-20170406monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-animal-health-and-napo-pharmaceuticals-enter-definitive-merger-agreement-merger-wil-jagx-20170331monthly0.5https://www.biopharmawatch.com/news/JAGX/general-overview-february-2017-this-presentation-contains-forward-looking-statements-all-s-jagx-20170221monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-animal-health-enters-binding-agreement-of-terms-to-merge-with-napo-pharmaceuticals--jagx-20170208monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-animal-health-elanco-enter-global-collaboration-for-development-co-promotion-of-can-jagx-20170131monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-animal-health-appoints-dr-ari-azhir-to-board-of-directors-san-francisco-ca-jagx-20161219monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-animal-health-and-henry-schein-inc-sign-exclusive-distribution-agreement-for-neonor-jagx-20161212monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-animal-health-announces-private-placement-of-common-stock-and-warrants-san-francisc-jagx-20161123monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-animal-health-and-napo-pharmaceuticals-announce-details-for-proposed-merger-merger--jagx-20161006monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-animal-health-signs-exclusive-distribution-agreement-for-croton-lechleri-botanical--jagx-20160907monthly0.5https://www.biopharmawatch.com/news/JAGX/dear-fellow-stockholders-fiscal-year-2015-was-a-year-of-important-progress-for-jaguar-anim-jagx-20160502monthly0.5https://www.biopharmawatch.com/news/JAGX/corporate-presentation-may-2016-this-presentation-contains-forward-looking-statements-all--jagx-20160505monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-animal-health-appoints-john-micek-iii-to-board-of-director-s-san-francisco-ca-jagx-20160406monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-animal-health-appoints-karen-wright-as-chief-financial-officer-jagx-20151216monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-animal-health-signs-crofelemer-formulation-development-and-manufacturing-contract-w-jagx-20151015monthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-animal-health-signs-crofelemer-manufacturing-supply-agreement-with-glenmark-pharmac-jagx-20150928monthly0.5https://www.biopharmawatch.com/news/ITCI/johnson-johnson-strengthens-neuroscience-leadership-with-acquisition-of-intra-cellular-the-itci-20250113monthly0.5https://www.biopharmawatch.com/news/ITCI/for-the-purpose-of-incorporating-the-information-set-forth-herein-by-reference-into-the-re-itci-20240416monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-itci-20240319monthly0.5https://www.biopharmawatch.com/news/ITCI/for-the-purpose-of-incorporating-the-information-set-forth-herein-by-reference-into-the-re-itci-20220105monthly0.5https://www.biopharmawatch.com/news/ITCI/for-the-purpose-of-incorporating-the-information-set-forth-herein-by-reference-into-the-re-itci-20200911monthly0.5https://www.biopharmawatch.com/news/ITCI/for-the-purpose-of-incorporating-the-information-set-forth-herein-by-reference-into-the-re-itci-20200106monthly0.5https://www.biopharmawatch.com/news/ITCI/fda-approves-intra-cellular-therapies-novel-antipsychotic-caplyta-lumateperone-for-the-tre-itci-20191223monthly0.5https://www.biopharmawatch.com/news/ITCI/safe-harbor-statement-this-presentation-contains-forward-looking-statements-within-the-mea-itci-20180108monthly0.5https://www.biopharmawatch.com/news/ITCI/for-the-purpose-of-incorporating-the-information-set-forth-herein-by-reference-into-the-re-itci-20170928monthly0.5https://www.biopharmawatch.com/news/ITCI/for-the-purpose-of-incorporating-the-information-set-forth-herein-by-reference-into-the-re-itci-20150923monthly0.5https://www.biopharmawatch.com/news/ITCI/for-the-purpose-of-incorporating-the-information-set-forth-herein-by-reference-into-the-re-itci-20150306monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-initiation-of-phase-i-ii-clinical-trial-for-iti-007-in--itci-20140303monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-pricing-of-public-offering-of-common-stock-to-begin-tra-itci-20140130monthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-announces-positive-topline-phase-ii-clinical-results-of-iti-007-f-itci-20131209monthly0.5https://www.biopharmawatch.com/news/ITCI/f-inancial-s-tatements-intra-cellular-therapies-inc-years-ended-itci-20131015monthly0.5https://www.biopharmawatch.com/news/ITCI/f-inancial-s-tatements-intra-cellular-therapies-inc-years-ended-itci-20130905monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-announces-select-preliminary-2025-financial-results-complete-fourth-quarter-and-ful-masi-20260112monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-hosts-2025-investor-day-and-details-strategic-roadmap-for-durable-growth-announces--masi-20251203monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-third-quarter-2025-results-irvine-california-masi-20251104monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-completes-sale-of-consumer-audio-business-to-harman-international-irvine-california-masi-20250923monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-second-quarter-2025-results-irvine-california-masi-20250805monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-first-quarter-2025-results-irvine-california-masi-20250506monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-to-sell-consumer-audio-business-to-harman-international-divestiture-supports-masimo-masi-20250506monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-updated-fu-masi-20250225monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-announces-leadership-transition-katie-szyman-appointed-chief-executive-officer-and--masi-20250121monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-announces-select-preliminary-2024-financial-results-and-2025-guidance-complete-four-masi-20250116monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-third-quarter-2024-financial-results-third-quarter-2024-highlights-healthca-masi-20241105monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-appoints-timothy-scannell-and-wendy-lane-to-board-of-directors-mr-scannell-and-ms-l-masi-20241018monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-provides-leadership-and-business-updates-appoints-michelle-brennan-as-interim-ceo-f-masi-20240925monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-second-quarter-2024-financial-results-second-quarter-2024-highlights-consol-masi-20240806monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-files-complaint-seeking-injunction-requiring-politan-to-correct-material-misstateme-masi-20240716monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-announces-preliminary-second-quarter-2024-revenue-and-select-financial-results-irvi-masi-20240709monthly0.5https://www.biopharmawatch.com/news/MASI/safe-harbor-statement-this-presentation-contains-forward-looking-statements-within-the-mea-masi-20240620monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-first-quarter-2024-financial-results-first-quarter-2024-highlights-consolid-masi-20240507monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-corporation-board-of-directors-authorizes-management-to-evaluate-the-separation-of--masi-20240322monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-fourth-quarter-and-full-year-2023-financial-results-fourth-quarter-2023-hig-masi-20240227monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-announces-new-member-of-the-board-of-directors-bob-chapek-joins-masimo-s-board-of-d-masi-20240116monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-announces-select-preliminary-2023-financial-results-and-2024-guidance-complete-four-masi-20240110monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-announces-new-member-of-the-board-of-directors-rolf-a-classon-joins-masimo-s-board--masi-20231107monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-third-quarter-2023-financial-results-third-quarter-2023-highlights-consolid-masi-20231107monthly0.5https://www.biopharmawatch.com/news/MASI/united-states-international-trade-commission-washington-d-c-in-the-matter-of-certain-light-masi-20231027monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-second-quarter-2023-financial-results-second-quarter-2023-highlights-consol-masi-20230808monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-announces-preliminary-second-quarter-2023-revenue-results-management-to-announce-an-masi-20230717monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-chairman-and-ceo-joe-kiani-waives-rights-under-director-change-in-control-provision-masi-20230606monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-first-quarter-2023-financial-results-first-quarter-2023-highlights-consolid-masi-20230509monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-announces-changes-to-governance-structure-and-practices-h-michael-cohen-selec-ted-a-masi-20230323monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-fourth-quarter-and-full-year-2022-financial-results-fourth-quarter-2022-hig-masi-20230228monthly0.5https://www.biopharmawatch.com/news/MASI/united-states-international-trade-commission-washington-d-c-in-the-matter-of-certain-light-masi-20230110monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-hosts-investor-day-to-detail-next-phase-of-its-growth-trajectory-masimo-s-technolog-masi-20221213monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-third-quarter-2022-financial-results-third-quarter-2022-highlights-consolid-masi-20221108monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-appoints-new-leader-for-consumer-division-blair-tripodi-named-chief-operating-offic-masi-20220919monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-second-quarter-2022-financial-results-second-quarter-2022-highlights-consol-masi-20220809monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-first-quarter-2022-financial-results-first-quarter-2022-highlights-revenue--masi-20220503monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-closes-acquisition-of-sound-united-leading-developer-of-premium-consumer-sound-and--masi-20220412monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-announces-certain-preliminary-first-quarter-2022-financial-results-and-reaffirms-fu-masi-20220330monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-fourth-quarter-and-full-year-2021-financial-results-and-announces-agreement-masi-20220215monthly0.5https://www.biopharmawatch.com/news/MASI/document-second-amendment-to-the-november-4-2015-amended-and-restated-employment-agreement-masi-20220114monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-announces-select-preliminary-full-year-2021-financial-results-and-2022-guidance-com-masi-20220111monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-third-quarter-2021-financial-results-third-quarter-2021-highlights-product--masi-20211026monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-second-quarter-2021-financial-results-second-quarter-2021-highlights-produc-masi-20210727monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-first-quarter-2021-financial-results-first-quarter-2021-highlights-product--masi-20210426monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-fourth-quarter-and-full-year-2020-financial-results-fourth-quarter-2020-hig-masi-20210223monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-expands-suite-of-advanced-measurements-through-acquisition-of-uk-based-lidco-group--masi-20210202monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-announces-select-preliminary-full-year-2020-financial-results-and-2021-guidance-com-masi-20210113monthly0.5https://www.biopharmawatch.com/news/MASI/document-not-for-release-publication-or-distribution-in-whole-or-in-part-directly-or-indir-masi-20201102monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-third-quarter-2020-financial-results-third-quarter-2020-highlights-product--masi-20201027monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-announces-select-preliminary-third-quarter-2020-financial-results-and-updated-full--masi-20201006monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-second-quarter-2020-financial-results-q2-2020-highlights-product-revenue-in-masi-20200728monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-first-quarter-2020-financial-results-q1-2020-highlights-product-revenue-inc-masi-20200428monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-announces-preliminary-unaudited-first-quarter-2020-product-revenue-complete-first-q-masi-20200401monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-fourth-quarter-and-full-year-2019-financial-results-fourth-quarter-2019-hig-masi-20200219monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-announces-select-preliminary-full-year-2019-financial-results-and-2020-guidance-com-masi-20200114monthly0.5https://www.biopharmawatch.com/news/MASI/that-was-included-in-our-current-report-on-form-8-k-that-was-filed-with-the-sec-today-supp-masi-20191030monthly0.5https://www.biopharmawatch.com/news/MASI/that-was-included-in-our-current-report-on-form-8-k-that-was-filed-with-the-sec-today-supp-masi-20190731monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-hosts-2019-investor-day-irvine-california-masi-20190516monthly0.5https://www.biopharmawatch.com/news/MASI/that-was-included-in-our-current-report-on-form-8-k-that-was-filed-with-the-sec-today-supp-masi-20190506monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-fourth-quarter-and-full-year-2018-financial-results-fourth-quarter-2018-hig-masi-20190226monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-announces-select-preliminary-full-year-2018-financial-results-and-2019-outlook-comp-masi-20190109monthly0.5https://www.biopharmawatch.com/news/MASI/julie-a-shimer-ph-d-joins-masimo-s-board-of-directors-irvine-california-masi-20190107monthly0.5https://www.biopharmawatch.com/news/MASI/that-was-included-in-our-current-report-on-form-8-k-that-was-filed-with-the-sec-today-supp-masi-20181031monthly0.5https://www.biopharmawatch.com/news/MASI/h-michael-cohen-joins-masimo-s-board-of-directors-irvine-california-masi-20180802monthly0.5https://www.biopharmawatch.com/news/MASI/that-was-included-in-our-current-report-on-form-8-k-that-was-filed-with-the-sec-today-supp-masi-20180801monthly0.5https://www.biopharmawatch.com/news/MASI/that-was-included-in-our-current-report-on-form-8-k-that-was-filed-with-the-sec-today-supp-masi-20180502monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-fourth-quarter-2017-financial-results-q4-2017-highlights-compared-to-q4-201-masi-20180227monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-third-quarter-2017-financial-results-q3-2017-highlights-compared-to-q3-2016-masi-20171031monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-second-quarter-2017-financial-results-q2-2017-highlights-compared-to-q2-201-masi-20170802monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-first-quarter-2017-financial-results-q1-2017-highlights-compared-to-q1-2016-masi-20170503monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-fourth-quarter-and-fiscal-year-2016-financial-results-q4-2016-highlights-co-masi-20170214monthly0.5https://www.biopharmawatch.com/news/MASI/philips-and-masimo-sign-multi-year-business-partnership-agreement-in-patient-monitoring-an-masi-20161107monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-third-quarter-2016-financial-results-q3-2016-highlights-compared-to-q3-2015-masi-20161102monthly0.5https://www.biopharmawatch.com/news/MASI/adam-mikkelson-of-camber-capital-management-joins-masimo-s-board-of-directors-irvine-calif-masi-20161027monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-announces-amendment-to-nellcor-royalty-agreement-irvine-california-masi-20160902monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-second-quarter-2016-financial-results-q2-2016-highlights-compared-to-q2-201-masi-20160803monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-first-quarter-2016-financial-results-q1-2016-highlights-compared-to-q1-2015-masi-20160504monthly0.5https://www.biopharmawatch.com/news/MASI/masimo-reports-fourth-quarter-and-fiscal-year-2015-financial-results-q4-2015-highlights-co-masi-20160223monthly0.5https://www.biopharmawatch.com/news/MRUS/foundation-support-agreement-between-merus-n-v-as-the-company-and-stichting-continu-teit-m-mrus-20250929monthly0.5https://www.biopharmawatch.com/news/MRUS/disclaimer-this-presentation-including-any-oral-commentary-that-accompanies-this-presentat-mrus-20230109monthly0.5https://www.biopharmawatch.com/news/MRUS/closing-in-on-cancer-september-2020-disclaimer-this-presentation-including-any-oral-commen-mrus-20200902monthly0.5https://www.biopharmawatch.com/news/MRUS/disclaimer-this-presentation-including-any-oral-commentary-that-accompanies-this-presentat-mrus-20200519monthly0.5https://www.biopharmawatch.com/news/MRUS/disclaimer-this-presentation-including-any-oral-commentary-that-accompanies-this-presentat-mrus-20200109monthly0.5https://www.biopharmawatch.com/news/MRUS/exhibit-1-merus-n-v-unaudited-condensed-consolidated-statement-of-financial-position-note-mrus-20191112monthly0.5https://www.biopharmawatch.com/news/MRUS/exhibit-1-merus-n-v-unaudited-condensed-consolidated-statement-of-financial-position-note-mrus-20190819monthly0.5https://www.biopharmawatch.com/news/MRUS/exhibit-1-lease-for-office-space-and-other-commercial-space-within-the-meaning-of-article--mrus-20190731monthly0.5https://www.biopharmawatch.com/news/MRUS/exhibit-1-minutes-of-the-annual-general-meeting-of-shareholders-merus-n-v-june-12-2019-min-mrus-20190612monthly0.5https://www.biopharmawatch.com/news/MRUS/exhibit-1-merus-n-v-unaudited-condensed-consolidated-statement-of-financial-position-note-mrus-20190530monthly0.5https://www.biopharmawatch.com/news/MRUS/exhibit-1-convening-notice-this-is-the-convening-notice-for-the-annual-general-meeting-of--mrus-20190523monthly0.5https://www.biopharmawatch.com/news/MRUS/exhibit-1-merus-announces-financial-results-for-the-full-year-2018-and-provides-business-u-mrus-20190403monthly0.5https://www.biopharmawatch.com/news/MRUS/exhibit-1-merus-n-v-unaudited-condensed-consolidated-statement-of-financial-position-after-mrus-20190206monthly0.5https://www.biopharmawatch.com/news/MRUS/exhibit-1-index-to-financial-statements-consolidated-financial-statements-as-at-mrus-20181227monthly0.5https://www.biopharmawatch.com/news/MRUS/exhibit-1-merus-n-v-unaudited-condensed-consolidated-statement-of-financial-position-after-mrus-20180810monthly0.5https://www.biopharmawatch.com/news/MRUS/exhibit-1-merus-n-v-unaudited-condensed-consolidated-statement-of-financial-position-after-mrus-20180727monthly0.5https://www.biopharmawatch.com/news/MRUS/exhibit-1-minutes-of-the-annual-general-meeting-of-shareholders-merus-n-v-july-20-2018-min-mrus-20180720monthly0.5https://www.biopharmawatch.com/news/MRUS/convening-notice-this-is-the-convening-notice-for-the-annual-general-meeting-of-shareholde-mrus-20180705monthly0.5https://www.biopharmawatch.com/news/MRUS/to-the-company-s-report-on-form-6-k-for-the-three-months-ended-mrus-20180216monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-n-v-unaudited-condensed-consolidated-statement-of-financial-position-after-appropria-mrus-20171201monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-n-v-unaudited-condensed-consolidated-statement-of-financial-position-after-appropria-mrus-20170922monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-n-v-unaudited-condensed-consolidated-statement-of-financial-position-after-appropria-mrus-20170711monthly0.5https://www.biopharmawatch.com/news/MRUS/correcting-and-replacing-merus-announces-fourth-quarter-and-full-year-2016-financial-resul-mrus-20170428monthly0.5https://www.biopharmawatch.com/news/MRUS/convening-notice-this-is-the-convening-notice-for-the-annual-general-meeting-of-shareholde-mrus-20170509monthly0.5https://www.biopharmawatch.com/news/MRUS/incyte-and-merus-announce-global-strategic-research-collaboration-to-discover-and-develop--mrus-20161221monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-n-v-unaudited-condensed-consolidated-statement-of-financial-position-after-appropria-mrus-20161107monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-n-v-unaudited-condensed-consolidated-statement-of-financial-position-after-appropria-mrus-20160808monthly0.5https://www.biopharmawatch.com/news/MRUS/merus-n-v-unaudited-condensed-consolidated-statement-of-financial-position-after-appropria-mrus-20160712monthly0.5https://www.biopharmawatch.com/news/ACLX/gilead-ashleigh-koss-media-public-affairs-gilead-com-jacquie-ross-investors-investor-relat-aclx-20260223monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-announces-new-positive-data-for-its-immagine-1-study-in-patients-with-relapsed-and-aclx-20251206monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-provides-third-quarter-2025-financial-results-aclx-20251029monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-provides-second-quarter-2025-financial-results-and-business-highlights-presented-p-aclx-20250807monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-announces-new-positive-data-for-its-immagine-1-study-in-patients-with-relapsed-and-aclx-20250514monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-provides-first-quarter-2025-financial-results-and-business-highlights-immagine-1-d-aclx-20250508monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-appoints-andrew-galligan-and-kristin-myers-to-its-board-of-directors-mr-galligan-a-aclx-20250320monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-provides-fourth-quarter-and-year-end-2024-financial-results-and-business-highlight-aclx-20250227monthly0.5https://www.biopharmawatch.com/news/ACLX/th-investor-relations-event-at-the-66-ash-annual-meeting-aclx-20241209monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-announces-new-positive-data-for-its-immagine-1-study-in-patients-with-relapsed-or--aclx-20241209monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-provides-third-quarter-2024-financial-results-and-business-highlights-recently-rel-aclx-20241107monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-to-present-clinical-data-for-its-phase-1-and-immagine-1-studies-in-patients-with-r-aclx-20241105monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-provides-second-quarter-2024-financial-results-and-business-updates-earned-a-68m-m-aclx-20240808monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-provides-first-quarter-2024-financial-results-aclx-20240509monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-provides-fourth-quarter-and-year-end-2023-financial-results-and-business-highlight-aclx-20240228monthly0.5https://www.biopharmawatch.com/news/ACLX/th-investor-relations-event-at-the-65-ash-annual-meeting-aclx-20231211monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-announces-continued-robust-long-term-responses-from-its-cart-ddbcma-anito-cel-phas-aclx-20231211monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-and-kite-announce-expansion-in-strategic-partnership-arcellx-to-receive-200m-equit-aclx-20231115monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-provides-third-quarter-2023-financial-results-and-business-highlights-recently-rel-aclx-20231113monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-announces-oral-presentation-for-its-cart-ddbcma-phase-1-trial-in-patients-with-rel-aclx-20231102monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-announces-partial-clinical-hold-lifted-on-immagine-1-phase-2-clinical-program-and--aclx-20230814monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-announces-clinical-hold-for-its-immagine-1-phase-2-clinical-program-fda-has-provid-aclx-20230619monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-provides-first-quarter-financial-results-aclx-20230508monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-provides-fourth-quarter-and-year-end-2022-financial-results-and-business-highlight-aclx-20230329monthly0.5https://www.biopharmawatch.com/news/ACLX/kite-and-arcellx-close-agreement-to-co-develop-and-co-commercialize-late-stage-clinical-ca-aclx-20230130monthly0.5https://www.biopharmawatch.com/news/ACLX/corporate-presentation-december-2022-forward-looking-statements-this-presentation-contains-aclx-20221212monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-and-kite-announce-strategic-collaboration-to-co-develop-and-co-commercialize-late--aclx-20221209monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-reports-third-quarter-2022-financial-results-and-business-progress-initiated-immag-aclx-20221114monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-provides-business-highlights-and-reports-second-quarter-2022-financial-results-com-aclx-20220815monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-announces-closing-of-upsized-public-offering-of-common-stock-and-underwriters-full-aclx-20220621monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-appoints-michelle-gilson-as-chief-financial-officer-aclx-20220523monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-appoints-olivia-ware-to-its-board-of-directors-replaces-lewis-t-rusty-williams-m-d-aclx-20220516monthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-provides-business-updates-and-reports-first-quarter-2022-financial-results-first-p-aclx-20220512monthly0.5https://www.biopharmawatch.com/news/ACLX/statements-are-neither-promises-nor-guarantees-and-are-subject-to-a-variety-of-risks-and-u-aclx-20220324monthly0.5https://www.biopharmawatch.com/news/APLS/tender-and-support-agreement-this-tender-and-support-agreement-this-agreement-dated-as-of-apls-20260331monthly0.5https://www.biopharmawatch.com/news/APLS/empaveli-commercial-launch-off-to-a-strong-start-as-of-apls-20211231monthly0.5https://www.biopharmawatch.com/news/NARI/source-stryker-corporation-nari-20250106monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-third-quarter-2024-financial-results-irvine-nari-20241028monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-announces-chief-financial-officer-retirement-and-succession-plan-mitch-hill--nari-20240730monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-second-quarter-2024-financial-results-irvine-nari-20240730monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-first-quarter-2024-financial-results-irvine-nari-20240430monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-fourth-quarter-2023-financial-results-irvine-california-nari-20240228monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-announces-preliminary-2023-revenue-and-2024-guidance-irvine-california-janua-nari-20240109monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-closes-acquisition-of-limflow-nari-20231115monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-expands-its-patient-focused-mission-with-agreement-to-acquire-limflow-announ-nari-20231101monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-third-quarter-2023-financial-results-irvine-california-nari-20231101monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-second-quarter-2023-financial-results-irvine-california-nari-20230802monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-first-quarter-2023-financial-results-irvine-california-nari-20230503monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-fourth-quarter-and-full-year-2022-financial-results-irvine-californi-nari-20230227monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-announces-preliminary-2022-revenue-and-2023-guidance-irvine-california-x2013-nari-20230110monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-third-quarter-2022-financial-results-irvine-california-x2013-nari-20221102monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-investor-day-sandy-boynton-beach-fl-financial-information-unless-otherwise-i-nari-20220920monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-announces-leadership-succession-plan-drew-hykes-to-succeed-bill-hoffman-as-c-nari-20220803monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-second-quarter-2022-financial-results-irvine-california-x2013-nari-20220803monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-first-quarter-2022-financial-results-irvine-california-x2013-nari-20220504monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-appoints-robert-warner-to-board-of-directors-irvine-california-x2013-nari-20220301monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-fourth-quarter-and-full-year-2021-financial-results-irvine-californi-nari-20220223monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-preliminary-fourth-quarter-2021-revenue-irvine-california-x2013-nari-20220110monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-third-quarter-2021-financial-results-irvine-california-x2013-nari-20211109monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-appoints-dana-g-mead-jr-to-board-of-directors-irvine-california-x2013-nari-20211001monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-second-quarter-2021-financial-results-irvine-california-x2013-nari-20210810monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-appoints-outset-medical-executive-rebecca-chambers-to-board-of-directors-irv-nari-20210622monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-first-quarter-2021-financial-results-nari-20210511monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-fourth-quarter-and-full-year-2020-financial-results-nari-20210309monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-preliminary-fourth-quarter-2020-revenue-nari-20210113monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-third-quarter-2020-financial-results-irvine-california-nari-20201112monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-announces-promotion-of-drew-hykes-to-chief-operating-officer-irvine-californ-nari-20200917monthly0.5https://www.biopharmawatch.com/news/NARI/inari-medical-reports-second-quarter-2020-financial-results-irvine-california-nari-20200811monthly0.5https://www.biopharmawatch.com/news/TERN/merck-to-acquire-terns-pharmaceuticals-inc-expanding-its-hematology-pipeline-with-tern-701-tern-20260325monthly0.5https://www.biopharmawatch.com/news/TERN/terns-reports-positive-top-line-results-from-phase-1-proof-of-concept-clinical-trial-of-th-tern-20211109monthly0.5https://www.biopharmawatch.com/news/SWTX/merck-kgaa-darmstadt-germany-to-acquire-springworks-therapeutics-to-accelerate-sustainable-swtx-20250428monthly0.5https://www.biopharmawatch.com/news/SWTX/defi-a-phase-3-trial-of-nirogacestat-for-progressing-desmoid-tumors-dt-bernd-kasper-ravin--swtx-20220910monthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-appoints-carlos-alb-n-to-its-board-of-directors-swtx-20220715monthly0.5https://www.biopharmawatch.com/news/SWTX/june-10-2022-springworks-r-d-day-swtx-20220610monthly0.5https://www.biopharmawatch.com/news/SWTX/corporate-presentation-december-2019-nasdaq-swtx-forward-looking-statements-this-presentat-swtx-20191209monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-financial-results-for-the-first-quarter-2024-en-morf-20240425monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-financial-results-for-the-full-year-2023-report-morf-20240222monthly0.5https://www.biopharmawatch.com/news/MORF/excerpt-of-transcript-from-the-question-and-answer-session-of-a-morphic-holding-inc-public-morf-20240110monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-to-present-at-the-42-nd-annual-j-p-morgan-healthcare-conference-dr-praveen-tipirne-morf-20240103monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-financial-results-for-the-third-quarter-2023-pr-morf-20231103monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-holdings-announces-ceo-dr-praveen-tipirneni-to-take-temporary-medical-leave-of-abs-morf-20230926monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-financial-results-for-the-second-quarter-2023-r-morf-20230803monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-therapeutic-announces-proposed-public-offering-morf-20230502monthly0.5https://www.biopharmawatch.com/news/MORF/emerald-1-topline-data-morf-20230425monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-financial-results-for-the-first-quarter-2023-in-morf-20230425monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-financial-results-for-the-full-year-2022-initia-morf-20230223monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-financial-results-for-the-third-quarter-2022-co-morf-20221102monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-complete-enrollment-of-emerald-1-main-cohort-ahead-of-projections-phase--morf-20221024monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-financial-results-for-the-second-quarter-2022-c-morf-20220803monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-names-bruce-rogers-as-president-of-morphic-therapeutic-and-blaise-lippa-as-chief-s-morf-20220512monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-financial-results-for-the-first-quarter-2022-in-morf-20220504monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-financial-results-for-the-full-year-2021-presen-morf-20220224monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-third-quarter-2021-financial-results-morf-057-p-morf-20211104monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-second-quarter-2021-financial-results-morf-057--morf-20210804monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco-21-virtual-congr-morf-20210528monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-first-quarter-2021-financial-results-expanded-r-morf-20210429monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-therapeutic-announces-pricing-of-upsized-245-0-million-public-offering-morf-20210302monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-financial-results-for-the-full-year-2020-announ-morf-20210301monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-therapeutic-announces-appointment-of-dr-martin-w-edwards-as-member-of-its-board-of-morf-20201204monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-third-quarter-2020-financial-results-initiated--morf-20201109monthly0.5https://www.biopharmawatch.com/news/MORF/delivering-a-new-generation-of-integrin-medicines-october-2020-forward-looking-statements--morf-20200923monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-second-quarter-2020-financial-results-company-s-morf-20200810monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-first-quarter-2020-financial-results-data-prese-morf-20200506monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-appointment-of-marc-schegerin-md-as-chief-financial-officer-and-chief-op-morf-20200407monthly0.5https://www.biopharmawatch.com/news/MORF/delivering-a-new-generation-of-integrin-medicines-praveen-tipirneni-md-cowen-40-th-annual--morf-20200304monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-financial-results-for-the-full-year-2019-waltha-morf-20200227monthly0.5https://www.biopharmawatch.com/news/MORF/delivering-a-new-generation-of-integrin-medicines-praveen-tipirneni-md-jp-morgan-38-th-ann-morf-20200111monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-third-quarter-2019-financial-results-xb7-morf-7-morf-20191112monthly0.5https://www.biopharmawatch.com/news/MORF/morphic-announces-corporate-highlights-and-second-quarter-2019-financial-results-successfu-morf-20190812monthly0.5https://www.biopharmawatch.com/news/AKRO/in-akero-therapeutics-phase-2b-harmony-study-both-the-50mg-and-28mg-efx-doses-achieved-sta-akro-20220913monthly0.5https://www.biopharmawatch.com/news/AKRO/restoring-balance-renewing-life-corporate-presentation-june-2022-safe-harbor-this-presenta-akro-20220608monthly0.5https://www.biopharmawatch.com/news/AKRO/a-global-disease-a-pioneering-treatment-corporate-presentation-september-2021-confidential-akro-20210909monthly0.5https://www.biopharmawatch.com/news/AKRO/a-global-disease-a-pioneering-treatment-corporate-presentation-april-2021-confidential-cor-akro-20210413monthly0.5https://www.biopharmawatch.com/news/AKRO/a-global-disease-a-pioneering-treatment-akero-therapeutics-inc-jp-morgan-presentation-janu-akro-20210111monthly0.5https://www.biopharmawatch.com/news/AKRO/a-global-disease-a-pioneering-treatment-akero-therapeutics-inc-corporate-presentation-nove-akro-20201116monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-third-quarter-2020-financial-results-akro-20201112monthly0.5https://www.biopharmawatch.com/news/AKRO/a-global-disease-a-pioneering-treatment-akero-therapeutics-inc-corporate-presentation-octo-akro-20201015monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-second-quarter-2020-financial-results-akro-20200812monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-announces-strongly-positive-histological-data-across-all-efruxifermin-dose-groups-in-akro-20200630monthly0.5https://www.biopharmawatch.com/news/AKRO/a-global-disease-a-pioneering-treatment-akero-therapeutics-inc-may-2020-confidential-2-saf-akro-20200507monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-first-quarter-2020-financial-results-akro-20200513monthly0.5https://www.biopharmawatch.com/news/AKRO/all-akr-001-dose-groups-met-week-12-efficacy-endpoints-in-nash-phase-2a-balanced-study-all-akro-20200331monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-akro-20200316monthly0.5https://www.biopharmawatch.com/news/AKRO/restoring-metabolic-balance-transforming-lives-developing-medicines-to-reverse-the-course--akro-20200113monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-recent-highlights-and-third-quarter-2019-akro-20191112monthly0.5https://www.biopharmawatch.com/news/AKRO/restoring-metabolic-balance-transforming-lives-corporate-presentation-developing-medicines-akro-20190906monthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-reports-recent-highlights-and-second-quarter-2019-financial-results-adv-akro-20190812monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-third-quarter-2024-financial-results-axnx-20241107monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-second-quarter-2024-financial-results-generated-record-revenue-gross-margi-axnx-20240801monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-first-quarter-2024-financial-results-axnx-20240430monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-stockholders-approve-merger-agreement-with-boston-scientific-irvine-calif-business-axnx-20240325monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-fourth-quarter-and-fiscal-year-2023-financial-results-irvine-calif-busines-axnx-20240228monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-preliminary-4q23-and-fiscal-year-2023-revenue-irvine-calif-business-wire-a-axnx-20231231monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-third-quarter-2023-financial-results-generated-quarterly-revenue-of-93-1-m-axnx-20231030monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-announces-cfo-retirement-and-appoints-successor-axnx-20230821monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-second-quarter-2023-financial-results-generated-quarterly-revenue-of-92-9--axnx-20230727monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-first-quarter-2023-financial-results-generated-quarterly-revenue-of-70-7-m-axnx-20230501monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-fourth-quarter-and-fiscal-year-2022-financial-results-generated-record-qua-axnx-20230301monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-preliminary-fiscal-year-2022-revenue-and-provides-fiscal-year-2023-revenue-axnx-20230111monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-third-quarter-2022-financial-results-generated-record-quarterly-revenue-of-axnx-20221031monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-announces-proposed-public-offering-of-common-stock-axnx-20220802monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-second-quarter-2022-financial-results-generated-record-quarterly-revenue-o-axnx-20220801monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-first-quarter-2022-financial-results-axnx-20220505monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-receives-fda-approval-for-recharge-free-sacral-neuromodulation-system-axonics-sets-axnx-20220307monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-fourth-quarter-and-fiscal-year-2021-financial-results-total-revenue-of-53--axnx-20220224monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-preliminary-fourth-quarter-and-fiscal-year-2021-revenue-quarterly-revenue--axnx-20220106monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-third-quarter-2021-financial-results-axnx-20211104monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-second-quarter-2021-financial-results-total-revenue-of-45-9-million-in-2q2-axnx-20210805monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-announces-appointment-of-dr-esteban-l-pez-to-its-board-of-directors-axnx-20210715monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-announces-proposed-public-offering-of-common-stock-axnx-20210511monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-first-quarter-2021-financial-results-axnx-20210506monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-expands-into-stress-urinary-incontinence-with-the-acquisition-of-bulkamid-combinat-axnx-20210225monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-fourth-quarter-and-fiscal-year-2020-results-axnx-20210225monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-preliminary-fourth-quarter-and-fiscal-year-2020-revenue-axnx-20210125monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-announces-appointment-of-david-m-demski-to-board-of-directors-axnx-20201214monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-third-quarter-2020-results-axonics-generated-net-revenue-of-35-2-million-i-axnx-20201104monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-second-quarter-2020-results-irvine-ca-axnx-20200806monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-preliminary-second-quarter-2020-revenue-irvine-ca-axnx-20200713monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-announces-proposed-public-offering-of-common-stock-axnx-20200507monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-reports-first-quarter-2020-results-irvine-ca-axnx-20200505monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-names-michael-h-carrel-as-chairman-of-its-board-of-directors-axnx-20200429monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-announces-fourth-quarter-and-fiscal-2019-financial-results-irvine-ca-axnx-20200304monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-announces-preliminary-fourth-quarter-and-full-year-2019-revenue-axnx-20200109monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-announces-full-exercise-of-underwriters-option-to-purchase-additional-shares-axnx-20191212monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-announces-closing-of-110-million-public-offering-of-common-stock-axnx-20191122monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-announces-proposed-public-offering-of-common-stock-axnx-20191119monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-announces-u-s-food-drug-administration-approval-for-its-sacral-neuromodulation-sys-axnx-20191114monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-announces-third-quarter-2019-financial-results-and-operational-update-irvine-ca-axnx-20191114monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-responds-to-patent-action-by-medtronic-believes-claims-are-without-merit-and-an-at-axnx-20191105monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-announces-u-s-food-drug-administration-approval-for-its-sacral-neuromodulation-sys-axnx-20190909monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-announces-second-quarter-2019-financial-results-and-operational-update-irvine-ca-axnx-20190805monthly0.5https://www.biopharmawatch.com/news/AXNX/exhibit-axonics-announces-first-quarter-2019-financial-results-and-operational-update-irvi-axnx-20190508monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-appoints-nancy-l-snyderman-m-d-and-jane-e-kiernan-to-its-board-of-directors-irvine-axnx-20190408monthly0.5https://www.biopharmawatch.com/news/AXNX/exhibit-axonics-announces-fourth-quarter-and-full-year-2018-financial-results-and-operatio-axnx-20190305monthly0.5https://www.biopharmawatch.com/news/AXNX/exhibit-axonics-appoints-michael-h-carrel-to-its-board-of-directors-irvine-ca-axnx-20190304monthly0.5https://www.biopharmawatch.com/news/AXNX/axonics-modulation-technologies-inc-announces-pricing-of-initial-public-offering-of-common-axnx-20181031monthly0.5https://www.biopharmawatch.com/news/CDTX/merck-to-acquire-cidara-therapeutics-inc-diversifying-its-portfolio-to-include-late-phase--cdtx-20251114monthly0.5https://www.biopharmawatch.com/news/CDTX/presentation-materials-ex9912025-06x23-nasdaq-cdtx-navigate-ph-2b-cdtx-20250623monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-provides-corporate-update-and-reports-first-quarter-2025-financial-res-cdtx-20250430monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-inc-amended-and-restated-non-employee-director-compensation-policy-app-cdtx-20250107monthly0.5https://www.biopharmawatch.com/news/CDTX/issued-december-14-2021-document-cidara-therapeutics-and-mundipharma-announce-positive-top-cdtx-20211214monthly0.5https://www.biopharmawatch.com/news/CDTX/corporate-participants-tracey-sebastian-lifesci-advisors-jeff-stein-president-and-chief-ex-cdtx-20210405monthly0.5https://www.biopharmawatch.com/news/CDTX/form-of-instructions-as-to-use-of-cidara-therapeutics-inc-subscription-rights-certificates-cdtx-20200122monthly0.5https://www.biopharmawatch.com/news/CDTX/slide-presentation-ex99120200113-new-hope-for-serious-infections-corporate-presentation-ja-cdtx-20200113monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-provides-corporate-update-and-reports-third-quarter-2019-cdtx-20191107monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-and-mundipharma-form-strategic-partnership-to-develop-and-commercializ-cdtx-20190903monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-inc-strive-part-b-results-cdtx-20190729monthly0.5https://www.biopharmawatch.com/news/CDTX/earnings-release-exhibit-ex-99-1-for-immediate-release-cidara-provides-corporate-update-an-cdtx-20190509monthly0.5https://www.biopharmawatch.com/news/CDTX/earnings-release-exhibit-ex-99-1-for-immediate-release-cidara-provides-corporate-update-an-cdtx-20190228monthly0.5https://www.biopharmawatch.com/news/CDTX/earnings-release-exhibit-ex-99-1-for-immediate-release-cidara-provides-corporate-update-an-cdtx-20181108monthly0.5https://www.biopharmawatch.com/news/CDTX/earnings-release-exhibit-ex-99-1-for-immediate-release-cidara-provides-corporate-update-an-cdtx-20180808monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-offering-of-common-stock-and-warrants-cidara-therapeutics-in-cdtx-20180523monthly0.5https://www.biopharmawatch.com/news/CDTX/earnings-release-exhibit-for-immediate-release-cidara-provides-corporate-update-and-report-cdtx-20180510monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-inc-strive-phase-2-part-a-topline-results-conference-call-cdtx-20180319monthly0.5https://www.biopharmawatch.com/news/CDTX/earnings-release-exhibit-for-immediate-release-cidara-provides-corporate-update-and-report-cdtx-20180227monthly0.5https://www.biopharmawatch.com/news/CDTX/earnings-release-exhibit-for-immediate-release-cidara-provides-corporate-update-and-report-cdtx-20171108monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-inc-top-line-phase-2-radiant-results-for-cd101-topical-conference-call-cdtx-20170221monthly0.5https://www.biopharmawatch.com/news/CDTX/forward-looking-statements-these-slides-and-the-accompanying-oral-presentation-the-present-cdtx-20170109monthly0.5https://www.biopharmawatch.com/news/CDTX/exhibit-for-immediate-release-cidara-provides-corporate-update-and-reports-third-quarter-2-cdtx-20161110monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-announces-commencement-of-public-offering-of-common-stock-s-cdtx-20161006monthly0.5https://www.biopharmawatch.com/news/CDTX/risk-factors-an-investment-in-our-securities-involves-a-high-degree-of-risk-you-should-con-cdtx-20161006monthly0.5https://www.biopharmawatch.com/news/CDTX/forward-looking-statements-these-slides-and-the-accompanying-oral-presentation-the-present-cdtx-20160928monthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-inc-condensed-statements-of-operations-three-months-ended-june-30-six--cdtx-20150811monthly0.5https://www.biopharmawatch.com/news/BPMC/contingent-value-rights-agreement-by-and-between-aventis-inc-and-continental-stock-transfe-bpmc-20250715monthly0.5https://www.biopharmawatch.com/news/BPMC/sanofi-to-acquire-blueprint-medicines-expanding-portfolio-in-rare-immunological-disease-an-bpmc-20250602monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-driving-growth-and-innovation-with-operational-excellence-kate-havilan-bpmc-20250113monthly0.5https://www.biopharmawatch.com/news/BPMC/rlf1-31971120v-1-in-the-court-of-chancery-of-the-state-of-delaware-in-re-blueprint-medicin-bpmc-20241218monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-corporation-2024-stock-incentive-plan-section-1-general-purpose-of-the-bpmc-20240614monthly0.5https://www.biopharmawatch.com/news/BPMC/the-powerful-mast-cell-a-promising-target-in-treating-allergic-and-inflammatory-diseases-bpmc-20240425monthly0.5https://www.biopharmawatch.com/news/BPMC/aaaai-2023-annual-meeting-not-for-promotional-use-2023-blueprint-medicines-corporation-suk-bpmc-20230227monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-corporation-kate-haviland-president-and-ceo-j-p-morgan-healthcare-conf-bpmc-20230109monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-company-overview-september-2022-kristine-g-systemic-mastocytosis-patie-bpmc-20220907monthly0.5https://www.biopharmawatch.com/news/BPMC/jefferies-healthcare-conference-june-9-2022-kristine-g-systemic-mastocytosis-patient-pione-bpmc-20220609monthly0.5https://www.biopharmawatch.com/news/BPMC/precision-that-moves-diane-l-patient-with-egfr-driven-lung-cancer-blueprint-medicines-call-bpmc-20220408monthly0.5https://www.biopharmawatch.com/news/BPMC/pioneering-the-science-of-time-cyndi-n-systemic-mastocytosis-patient-forward-looking-state-bpmc-20220101monthly0.5https://www.biopharmawatch.com/news/BPMC/celebrating-our-first-decade-of-innovation-in-precision-medicine-advancing-our-next-wave-o-bpmc-20210412monthly0.5https://www.biopharmawatch.com/news/BPMC/xa9-2021-blueprint-medicines-corporation-r-s-living-with-systemic-mastocytosis-precision-t-bpmc-20210111monthly0.5https://www.biopharmawatch.com/news/BPMC/xa9-2020-blueprint-medicines-corporation-r-s-living-with-systemic-mastocytosis-topline-dat-bpmc-20200922monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-fda-approval-of-gavreto-pralsetinib-for-the-treatment-of-adu-bpmc-20200908monthly0.5https://www.biopharmawatch.com/news/BPMC/pralsetinib-data-review-and-registration-program-update-may-29-2020-asco-2020-virtual-meet-bpmc-20200529monthly0.5https://www.biopharmawatch.com/news/BPMC/voyager-clinical-trial-top-line-results-april-28-2020-conference-call-xa9-2020-blueprint-m-bpmc-20200428monthly0.5https://www.biopharmawatch.com/news/BPMC/xa9-2020-blueprint-medicines-corporation-r-s-living-with-systemic-mastocytosis-precision-t-bpmc-20200401monthly0.5https://www.biopharmawatch.com/news/BPMC/xa9-2020-blueprint-medicines-corporation-r-s-living-with-systemic-mastocytosis-pioneer-cli-bpmc-20200316monthly0.5https://www.biopharmawatch.com/news/BPMC/precision-that-moves-x2122-staying-one-step-ahead-of-disease-r-t-living-with-gist-j-p-morg-bpmc-20200113monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-outlines-precision-therapy-research-vision-provides-update-on-discover-bpmc-20191105monthly0.5https://www.biopharmawatch.com/news/BPMC/ipsen-and-blueprint-medicines-announce-exclusive-global-license-agreement-to-develop-and-c-bpmc-20191016monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-second-quarter-2019-financial-results-nda-and-maa-submitted-fo-bpmc-20190801monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-submits-new-drug-application-to-u-s-food-and-drug-administration-for-a-bpmc-20190614monthly0.5https://www.biopharmawatch.com/news/BPMC/diane-legg-founder-of-lungstrong-visits-blueprint-medicines-in-june-2018-advances-in-preci-bpmc-20190603monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-first-quarter-2019-financial-results-avapritinib-nda-for-pdgfr-bpmc-20190509monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-pricing-of-public-offering-of-shares-of-common-stock-bpmc-20190328monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-accelerated-regulatory-submission-plans-and-recent-clinical--bpmc-20190327monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-global-business-strategy-bpmc-20190107monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-updated-results-from-ongoing-explorer-clinical-trial-of-avap-bpmc-20181202monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-updated-navigator-trial-results-in-patients-with-advanced-ga-bpmc-20181115monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-presents-foundational-preclinical-data-supporting-the-development-of-b-bpmc-20181001monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-proof-of-concept-data-showing-combination-of-blu-667-and-osi-bpmc-20180926monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-second-quarter-2018-financial-results-x2013-presented-data-fro-bpmc-20180801monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-proof-of-concept-data-for-highly-selective-ret-inhibitor-blu-bpmc-20180415monthly0.5https://www.biopharmawatch.com/news/BPMC/a-blueprint-for-a-healthier-tomorrow-bpmc-20180108monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-proposed-public-offering-of-shares-of-common-stock-bpmc-20171211monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-new-data-from-ongoing-phase-1-clinical-trial-of-blu-285-in-p-bpmc-20171110monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-third-quarter-2017-financial-results-x2013-presented-clinical--bpmc-20171031monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-appointment-of-christopher-murray-ph-d-as-senior-vice-presid-bpmc-20171010monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-new-data-from-ongoing-phase-1-clinical-trial-of-blu-554-in-p-bpmc-20170910monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-updated-data-from-ongoing-phase-1-clinical-trial-of-blu-554-bpmc-20170821monthly0.5https://www.biopharmawatch.com/news/BPMC/wednesday-bpmc-20170809monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-second-quarter-2017-financial-results-x2013-blu-285-granted-br-bpmc-20170802monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-first-quarter-2017-financial-results-x2013-dosed-first-patient-bpmc-20170503monthly0.5https://www.biopharmawatch.com/news/BPMC/a-blueprint-for-a-healthier-tomorrow-proprietary-discovery-platform-for-highly-selective-a-bpmc-20170405monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-fourth-quarter-and-full-year-2016-financial-results-bpmc-20170309monthly0.5https://www.biopharmawatch.com/news/BPMC/revolutionizing-the-development-of-targeted-medicines-for-the-treatment-of-serious-disease-bpmc-20170109monthly0.5https://www.biopharmawatch.com/news/BPMC/robust-portfolio-with-diverse-clinical-stage-assets-initial-diseases-discovery-pre-clinica-bpmc-20161205monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-proof-of-concept-data-from-phase-1-clinical-trial-of-blu-285-bpmc-20161205monthly0.5https://www.biopharmawatch.com/news/BPMC/www-cellsignal-com-ic50-nm-inhibitor-fgfr4-fgfr1-3-blu-554-5-624-2203-azd4547-160-0-2-2-5--bpmc-20161201monthly0.5https://www.biopharmawatch.com/news/BPMC/www-cellsignal-com-del556-558-y823d-tumour-volume-mm3-days-after-the-start-of-treatment-0--bpmc-20161201monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-proof-of-concept-data-from-phase-1-clinical-trial-of-blu-285-bpmc-20161201monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-proof-of-concept-data-from-global-phase-1-clinical-trial-of--bpmc-20161129monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-appointment-of-marion-dorsch-ph-d-bpmc-20161114monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-third-quarter-2016-financial-results-bpmc-20161110monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-appoints-lonnel-coats-to-board-of-directors-cambridge-mass-february-4--bpmc-20160208monthly0.5https://www.biopharmawatch.com/news/BPMC/this-presentation-contains-forward-looking-statements-as-defined-in-the-private-securities-bpmc-20160111monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-strengthens-executive-leadership-team-kate-haviland-named-chief-busine-bpmc-20160106monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-third-quarter-2015-financial-results-x2013-initiated-phase-1-c-bpmc-20151109monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-second-quarter-2015-financial-results-and-provides-business-up-bpmc-20150810monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-first-quarter-2015-financial-results-successfully-completed-in-bpmc-20150617monthly0.5https://www.biopharmawatch.com/news/GLTO/damora-therapeutics-appoints-biotechnology-leader-jennifer-jarrett-as-president-and-chief--glto-20260323monthly0.5https://www.biopharmawatch.com/news/GLTO/company-logo-disclaimers-the-information-contained-in-this-presentation-has-been-prepared--glto-20260112monthly0.5https://www.biopharmawatch.com/news/GLTO/unaudited-pro-forma-condensed-consolidated-financial-statements-on-glto-20241007monthly0.5https://www.biopharmawatch.com/news/GLTO/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-gal-glto-20230106monthly0.5https://www.biopharmawatch.com/news/GLTO/gb2064-shows-reduction-in-fibrosis-of-the-bone-marrow-in-patients-with-myelofibrosis-valid-glto-20220929monthly0.5https://www.biopharmawatch.com/news/GLTO/forward-looking-statements-this-presentation-contains-forward-looking-statements-that-invo-glto-20220105monthly0.5https://www.biopharmawatch.com/news/GLTO/first-in-class-small-molecule-anti-fibrotic-and-anti-cancer-agents-january-2021-forward-lo-glto-20210105monthly0.5https://www.biopharmawatch.com/news/DAWN/servier-and-day-one-biopharmaceuticals-announce-acquisition-to-expand-servier-s-rare-oncol-dawn-20260306monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-biopharmaceuticals-targeted-therapies-for-people-of-all-ages-march-2026-disclaimer-dawn-20260302monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-produc-dawn-20251231monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-completes-acquisition-of-mersana-therapeutics-acquisition-expands-day-one-s-pipeli-dawn-20260105monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-announces-three-year-follow-up-data-from-ojemda-tovorafenib-phase-2-firefly-1-tria-dawn-20251124monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-reports-second-quarter-2025-financial-results-and-corporate-progress-ojemda-tm-tov-dawn-20250805monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-reports-first-quarter-2025-financial-results-and-corporate-progress-ojemda-tm-tovo-dawn-20250506monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-reports-fourth-quarter-and-full-year-2024-financial-results-and-corporate-progress-dawn-20250225monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-reports-preliminary-2024-ojemda-net-product-revenue-and-highlights-2025-corporate--dawn-20250113monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-media-laura-cooper-head-of-communications-media-dayonebio-com-day-one-investors-li-dawn-20241030monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-biopharmaceuticals-inc-condensed-statements-of-operations-in-thousands-except-shar-dawn-20240730monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-announces-oversubscribed-175-0-million-private-placement-dawn-20240730monthly0.5https://www.biopharmawatch.com/news/DAWN/ipsen-and-day-one-enter-into-exclusive-ex-u-s-licensing-agreement-to-commercialize-tovoraf-dawn-20240725monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-expands-pipeline-with-potential-first-in-class-clinical-stage-antibody-drug-conjug-dawn-20240618monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-biopharmaceuticals-targeted-therapies-for-people-of-all-ages-june-2024-1-disclaime-dawn-20240612monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-announces-sale-of-priority-review-voucher-for-108-million-dawn-20240530monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-reports-first-quarter-2024-financial-results-and-corporate-progress-ojemda-tovoraf-dawn-20240506monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-s-ojemda-tovorafenib-receives-us-fda-accelerated-approval-for-relapsed-or-refracto-dawn-20240423monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-reports-fourth-quarter-and-full-year-2023-financial-results-and-corporate-progress-dawn-20240226monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-announces-two-new-appointments-to-board-of-directors-dawn-20240117monthly0.5https://www.biopharmawatch.com/news/DAWN/nasdaq-dawn-day-one-biopharmaceuticals-targeted-therapies-for-people-of-all-ages-nd-42-ann-dawn-20240108monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-announces-tovorafenib-firefly-1-data-published-in-nature-medicine-data-subsets-to--dawn-20231117monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-media-laura-cooper-head-of-communications-media-dayonebio-com-day-one-investors-li-dawn-20231106monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-announces-fda-acceptance-of-nda-and-priority-review-for-tovorafenib-in-relapsed-or-dawn-20231030monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-announces-updated-firefly-1-data-for-tovorafenib-and-completion-of-rolling-nda-sub-dawn-20230911monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-announces-vrk1-license-agreement-and-research-collaboration-with-sprint-bioscience-dawn-20230815monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-biopharmaceuticals-inc-selected-consolidated-balance-sheet-data-unaudited-in-thous-dawn-20230807monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-biopharmaceuticals-targeted-therapies-for-people-of-all-ages-june-2023-day-one-bio-dawn-20230612monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-announces-pricing-of-public-offering-of-common-stock-dawn-20230606monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-biopharmaceuticals-targeted-therapies-for-people-of-all-ages-june-2023-day-one-bio-dawn-20230605monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-media-laura-cooper-head-of-communications-media-dayonebio-com-day-one-investors-li-dawn-20230501monthly0.5https://www.biopharmawatch.com/news/DAWN/clinical-activity-of-the-type-ii-pan-raf-inhibitor-tovorafenib-in-braf-fusion-melanoma-jee-dawn-20230420monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-biopharmaceuticals-targeted-therapies-for-people-of-all-ages-march-2023-day-one-bi-dawn-20230320monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-reports-fourth-quarter-and-full-year-2022-financial-results-and-corporate-progress-dawn-20230306monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-announces-topline-data-from-pivotal-phase-2-firefly-1-trial-demonstrating-meaningf-dawn-20230109monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-reports-third-quarter-2022-financial-results-and-corporate-progress-topline-result-dawn-20221107monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-appoints-garry-nicholson-as-chairman-of-the-board-of-directors-dawn-20220912monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-reports-second-quarter-2022-financial-results-and-corporate-progress-reported-posi-dawn-20220804monthly0.5https://www.biopharmawatch.com/news/DAWN/targeted-therapies-for-people-of-all-ages-june-2022-june-2022-disclaimer-this-presentation-dawn-20220624monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-announces-pricing-of-upsized-public-offering-of-common-stock-dawn-20220614monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-announces-positive-initial-data-from-pivotal-firefly-1-trial-of-tovorafenib-day101-dawn-20220612monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-reports-first-quarter-2022-financial-results-and-provides-business-update-initial--dawn-20220512monthly0.5https://www.biopharmawatch.com/news/DAWN/targeted-therapies-for-people-of-all-ages-april-2022-disclaimer-this-presentation-and-the--dawn-20220413monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-reports-fourth-quarter-and-full-year-2021-financial-results-and-corporate-progress-dawn-20220307monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-to-present-at-the-40-th-annual-j-p-morgan-healthcare-conference-dawn-20220105monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-reports-third-quarter-2021-financial-results-and-corporate-progress-enrollment-pro-dawn-20211108monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-announces-presentation-at-2021-connective-tissue-oncology-society-ctos-virtual-ann-dawn-20211103monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-appoints-scott-garland-to-board-of-directors-dawn-20210817monthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-reports-second-quarter-2021-financial-results-and-corporate-progress-day101-grante-dawn-20210810monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-inc-announces-agreement-to-be-acquired-by-roche-89bio-stockholders-to-receive-up-to-20-etnb-20250917monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-second-quarter-2025-financial-results-and-corporate-updates-enlighten-fibrosis-etnb-20250807monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-first-quarter-2025-financial-results-and-corporate-updates-topline-histology-d-etnb-20250501monthly0.5https://www.biopharmawatch.com/news/ETNB/powerful-science-meaningful-medicines-changing-lives-nasdaq-etnb-april-2025-disclaimers-th-etnb-20250409monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-fourth-quarter-and-full-year-2024-financial-results-and-corporate-updates-enli-etnb-20250227monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-provides-business-update-and-outlook-for-2025-completed-enrollment-in-phase-3-entrust--etnb-20241231monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-third-quarter-2024-financial-results-and-corporate-updates-the-phase-3-enlight-etnb-20241107monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-appoints-francis-sarena-as-chief-operating-officer-etnb-20240807monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-second-quarter-2024-financial-results-and-corporate-updates-the-phase-3-enligh-etnb-20240805monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-first-quarter-2024-financial-results-and-provides-corporate-update-initiated-p-etnb-20240509monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-appoints-biotech-industry-veteran-martin-babler-to-its-board-of-directors-etnb-20240417monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-corporate-upd-etnb-20240229monthly0.5https://www.biopharmawatch.com/news/ETNB/powerful-science-meaningful-medicines-changing-lives-nasdaq-etnb-december-2023-disclaimers-etnb-20231206monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reaches-alignment-with-the-fda-and-ema-on-phase-3-program-for-pegozafermin-in-nonalcoh-etnb-20231204monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-announces-new-positive-long-term-data-from-the-enliven-phase-2b-trial-of-pegozafermin--etnb-20231127monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-third-quarter-2023-financial-results-and-provides-corporate-updates-pegozaferm-etnb-20231108monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-second-quarter-2023-financial-results-and-provides-corporate-update-published--etnb-20230809monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-first-quarter-2023-financial-results-and-provides-corporate-update-positive-to-etnb-20230504monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-s-phase-2b-enliven-trial-of-pegozafermin-in-nonalcoholic-steatohepatitis-nash-achieved-etnb-20230322monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-upd-etnb-20230310monthly0.5https://www.biopharmawatch.com/news/ETNB/cautionary-note-regarding-forward-looking-statements-this-presentation-contains-forward-lo-etnb-20230215monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-third-quarter-2022-financial-results-and-provides-corporate-update-completed-e-etnb-20221110monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-second-quarter-2022-financial-results-and-provides-corporate-update-reported-p-etnb-20220811monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-positive-topline-results-from-entrigue-phase-2-trial-of-pegozafermin-in-patien-etnb-20220628monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-first-quarter-2022-financial-results-and-provides-corporate-update-entrigue-ph-etnb-20220511monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-corporate-upd-etnb-20220324monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-announces-appointment-of-e-morrey-atkinson-ph-d-to-its-board-of-directors-etnb-20220224monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-positive-topline-results-from-an-expansion-cohort-of-the-phase-1b-2a-trial-of--etnb-20220124monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-third-quarter-2021-financial-results-and-provides-corporate-update-etnb-20211111monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-announces-appointment-of-kathy-laporte-to-its-board-of-directors-etnb-20211103monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-second-quarter-2021-financial-results-and-provides-corporate-update-initiated--etnb-20210812monthly0.5https://www.biopharmawatch.com/news/ETNB/cautionary-note-regarding-forward-looking-statements-this-presentation-contains-forward-lo-etnb-20210610monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-first-quarter-2021-financial-results-and-provides-corporate-update-enliven-pha-etnb-20210512monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-corporate-upd-etnb-20210324monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-third-quarter-2020-financial-results-and-provides-corporate-update-updated-cli-etnb-20201110monthly0.5https://www.biopharmawatch.com/news/ETNB/cautionary-note-regarding-forward-looking-statements-this-presentation-contains-forward-lo-etnb-20201005monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-announces-positive-topline-results-from-its-phase-1b-2a-trial-of-bio89-100-in-nash-all-etnb-20200914monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-appoints-veteran-finance-executive-lota-zoth-to-board-of-directors-etnb-20200604monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-first-quarter-2020-financial-results-and-provides-corporate-update-topline-res-etnb-20200513monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-announces-closing-of-enrollment-in-its-phase-1b-2a-nash-trial-and-reports-new-preclini-etnb-20200413monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-appoints-healthcare-industry-veteran-steven-altschuler-m-d-as-chairman-of-the-board-of-etnb-20200325monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-corporate-upd-etnb-20200318monthly0.5https://www.biopharmawatch.com/news/ETNB/bio-reports-third-quarter-2019-financial-results-and-provides-corporate-update-upsized-ini-etnb-20191218monthly0.5https://www.biopharmawatch.com/news/ANABV/anaptys-announces-first-quarter-2026-financial-results-and-provides-business-update-x2022--anabv-20260512monthly0.5https://www.biopharmawatch.com/news/ANABV/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-g-anabv-20260420monthly0.5https://www.biopharmawatch.com/news/ANABV/anaptys-board-of-directors-approves-spin-off-of-first-tracks-biotherapeutics-board-sets-sp-anabv-20260327monthly0.5https://www.biopharmawatch.com/news/ANABV/anaptys-provides-update-on-business-separation-and-announces-fourth-quarter-and-full-year--anabv-20260303monthly0.5https://www.biopharmawatch.com/news/ANABV/anaptysbio-presentation-exhibit-anabv-20200115monthly0.5https://www.biopharmawatch.com/news/ANABV/anaptysbio-announces-pricing-of-public-offering-of-common-stock-anabv-20180925monthly0.5https://www.biopharmawatch.com/news/ANABV/anaptysbio-reports-positive-topline-data-from-phase-2a-proof-of-concept-clinical-trial-of--anabv-20180924monthly0.5https://www.biopharmawatch.com/news/ANABV/anaptysbio-announces-positive-top-line-proof-of-concept-data-for-anb020-in-moderate-to-sev-anabv-20180326monthly0.5https://www.biopharmawatch.com/news/ANABV/anaptysbio-announces-appointment-of-j-anthony-ware-m-d-to-board-of-directors-san-diego-aug-anabv-20170824monthly0.5https://www.biopharmawatch.com/news/ANABV/anaptysbio-announces-first-quarter-2017-financial-results-and-provides-pipeline-update-top-anabv-20170511monthly0.5https://www.biopharmawatch.com/news/ANABV/anaptysbio-announces-2016-operating-results-and-pipeline-progress-data-from-ongoing-anb020-anabv-20170308monthly0.5https://www.biopharmawatch.com/news/FOLD/biomarin-contacts-amicus-contacts-traci-mccarty-investors-andrew-faughnan-investors-biomar-fold-20251219monthly0.5https://www.biopharmawatch.com/news/FOLD/dimerix-and-amicus-therapeutics-announce-exclusive-license-agreement-for-dmx-200-in-the-un-fold-20250430monthly0.5https://www.biopharmawatch.com/news/FOLD/at-the-forefront-of-therapies-for-rare-diseases-corporate-overview-september-2023-2-forwar-fold-20230927monthly0.5https://www.biopharmawatch.com/news/FOLD/corporate-overviewnovember-2022at-the-forefront-of-therapies-for-rare-diseases-2-forward-l-fold-20221116monthly0.5https://www.biopharmawatch.com/news/FOLD/u-s-fda-defers-action-on-filing-for-at-gaa-in-late-onset-pompe-disease-fda-issues-deferred-fold-20221028monthly0.5https://www.biopharmawatch.com/news/FOLD/corporate-overview-september-2022-at-the-forefront-of-therapies-for-rare-diseases-2-forwar-fold-20220914monthly0.5https://www.biopharmawatch.com/news/FOLD/european-medicines-agency-validates-amicus-therapeutics-marketing-authorization-applicatio-fold-20211203monthly0.5https://www.biopharmawatch.com/news/FOLD/the-lancet-neurology-publishes-pivotal-phase-3-propel-study-results-of-at-gaa-in-late-onse-fold-20211118monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-second-quarter-fold-20210805monthly0.5https://www.biopharmawatch.com/news/FOLD/general-corporate-gene-therapy-overview-at-the-forefront-of-the-human-genome-medicine-revo-fold-20200514monthly0.5https://www.biopharmawatch.com/news/FOLD/document-amicus-therapeutics-confirms-business-continuity-2020-strategic-priorities-and-an-fold-20200323monthly0.5https://www.biopharmawatch.com/news/FOLD/exhibit-amicus-therapeutics-announces-full-year-2019-financial-results-and-2020-corporate--fold-20200302monthly0.5https://www.biopharmawatch.com/news/FOLD/perspectives-on-pompe-progress-persistence-and-passion-fold-20200212monthly0.5https://www.biopharmawatch.com/news/FOLD/exhibit-amicus-therapeutics-announces-presentations-and-posters-at-16-th-annual-world-symp-fold-20200207monthly0.5https://www.biopharmawatch.com/news/FOLD/exhibit-amicus-therapeutics-announces-preliminary-2019-galafold-revenue-exceeding-upper-en-fold-20200109monthly0.5https://www.biopharmawatch.com/news/FOLD/exhibit-amicus-therapeutics-provides-updates-on-clinical-regulatory-and-manufacturing-adva-fold-20200107monthly0.5https://www.biopharmawatch.com/news/FOLD/exhibit-amicus-therapeutics-announces-third-quarter-2019-financial-results-and-corporate-u-fold-20191111monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-second-quarter-20-19-financial-results-and-corporate-updates-fold-20190808monthly0.5https://www.biopharmawatch.com/news/FOLD/exhibit-amicus-announces-positive-interim-clinical-data-for-aav-gene-therapy-in-children-w-fold-20190801monthly0.5https://www.biopharmawatch.com/news/FOLD/july-2019-general-corporate-gene-therapy-overview-2-forward-looking-statements-this-presen-fold-20190709monthly0.5https://www.biopharmawatch.com/news/FOLD/general-corporate-gene-therapy-overview-at-the-forefront-of-the-human-genome-medicine-revo-fold-20190708monthly0.5https://www.biopharmawatch.com/news/FOLD/exhibit-amicus-therapeutics-and-catalent-biologics-enter-strategic-partnership-for-gene-th-fold-20190627monthly0.5https://www.biopharmawatch.com/news/FOLD/exhibit-amicus-therapeutics-and-brammer-bio-a-part-of-thermo-fisher-scientific-enter-strat-fold-20190701monthly0.5https://www.biopharmawatch.com/news/FOLD/exhibit-amicus-therapeutics-and-the-university-of-pennsylvania-announce-major-expansion-of-fold-20190529monthly0.5https://www.biopharmawatch.com/news/FOLD/corporate-overview-may-2019-2-forward-looking-statements-this-presentation-contains-forwar-fold-20190514monthly0.5https://www.biopharmawatch.com/news/FOLD/exhibit-amicus-therapeutics-announces-first-quarter-2019-financial-results-and-corporate-u-fold-20190508monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-presents-positive-preclinical-pompe-disease-gene-therapy-data-at-ameri-fold-20190430monthly0.5https://www.biopharmawatch.com/news/FOLD/exhibit-amicus-therapeutics-issued-two-u-s-patents-for-pompe-enzyme-atb200-new-intellectua-fold-20190320monthly0.5https://www.biopharmawatch.com/news/FOLD/exhibit-amicus-therapeutics-announces-full-year-2018-financial-results-and-2019-corporate--fold-20190228monthly0.5https://www.biopharmawatch.com/news/FOLD/exhibit-amicus-establishes-global-research-and-gene-therapy-center-of-excellence-in-philad-fold-20190226monthly0.5https://www.biopharmawatch.com/news/FOLD/exhibit-u-s-fda-grants-breakthrough-therapy-designation-btd-to-amicus-at-gaa-in-late-onset-fold-20190225monthly0.5https://www.biopharmawatch.com/news/FOLD/th-annual-j-p-morgan-healthcare-conference-john-f-crowley-chairman-and-chief-executive-off-fold-20190108monthly0.5https://www.biopharmawatch.com/news/FOLD/corporate-overview-november-2018-2-forward-looking-statements-this-presentation-contains-f-fold-20181114monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-establishes-gene-therapy-pipeline-for-lysosomal-storage-disorders-lsds-conference-c-fold-20180920monthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-announces-board-appointments-lynn-d-bleil-appointed-to-board-of-direct-fold-20180911monthly0.5https://www.biopharmawatch.com/news/FOLD/galafold-migalastat-u-s-approval-call-fold-20180813monthly0.5https://www.biopharmawatch.com/news/FOLD/fda-approves-galafold-migalastat-for-the-treatment-of-certain-adult-patients-with-fabry-di-fold-20180810monthly0.5https://www.biopharmawatch.com/news/FOLD/u-s-fda-files-new-drug-application-under-priority-review-for-migalastat-for-treatment-of-f-fold-20180212monthly0.5https://www.biopharmawatch.com/news/FOLD/th-annual-j-p-morgan-healthcare-conference-john-f-crowley-chairman-and-chief-executive-off-fold-20180109monthly0.5https://www.biopharmawatch.com/news/RAPT/stock-exchange-announcement-for-media-and-investors-only-issued-20-january-2026-london-uk--rapt-20260120monthly0.5https://www.biopharmawatch.com/news/RAPT/the-science-to-overcome-inflammation-corporate-presentation-january-2026-disclaimer-statem-rapt-20260114monthly0.5https://www.biopharmawatch.com/news/RAPT/the-science-to-overcome-inflammation-october-20-2025-phase-2-topline-results-of-rpt904-jyb-rapt-20251020monthly0.5https://www.biopharmawatch.com/news/RAPT/disclaimer-statements-in-this-presentation-that-are-not-statements-of-historical-fact-are--rapt-20250708monthly0.5https://www.biopharmawatch.com/news/RAPT/disclaimer-statements-in-this-presentation-that-are-not-statements-of-historical-fact-are--rapt-20250609monthly0.5https://www.biopharmawatch.com/news/RAPT/january-2025-corporate-presentation-disclaimer-statements-in-this-presentation-that-are-no-rapt-20250113monthly0.5https://www.biopharmawatch.com/news/RAPT/transforming-the-treatment-of-inflammation-and-cancer-january-2023-corporate-presentation--rapt-20230109monthly0.5https://www.biopharmawatch.com/news/RAPT/transforming-the-treatment-of-cancer-and-inflammation-september-2022-corporate-presentatio-rapt-20220906monthly0.5https://www.biopharmawatch.com/news/RAPT/legal-disclaimers-statements-in-this-presentation-that-are-not-statements-of-historical-fa-rapt-20210927monthly0.5https://www.biopharmawatch.com/news/RAPT/legal-disclaimers-statements-in-this-presentation-the-presentation-for-rapt-therapeutics-i-rapt-20200109monthly0.5https://www.biopharmawatch.com/news/SLNO/neurocrine-to-acquire-soleno-therapeutics-expanding-its-endocrinology-and-rare-disease-por-slno-20260406monthly0.5https://www.biopharmawatch.com/news/SLNO/2025-soleno-therapeutics-certain-notices-and-disclaimers-forward-looking-statements-this-p-slno-20250818monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-proposed-200-slno-20250710monthly0.5https://www.biopharmawatch.com/news/SLNO/corporate-presentation-july-2023-soleno-therapeutics-certain-notices-and-disclaimers-forwa-slno-20230710monthly0.5https://www.biopharmawatch.com/news/SLNO/dear-members-of-the-pws-community-we-at-soleno-therapeutics-would-like-to-provide-an-updat-slno-20210415monthly0.5https://www.biopharmawatch.com/news/SLNO/2020-soleno-therapeutics-certain-notices-and-disclaimers-forward-looking-statements-this-p-slno-20200608monthly0.5https://www.biopharmawatch.com/news/SLNO/2020-soleno-therapeutics-certain-notices-and-disclaimers-forward-looking-statements-this-p-slno-20200110monthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-positive-outcome-from-planned-data-safety-monitoring-board-r-slno-20190318monthly0.5https://www.biopharmawatch.com/news/SLNO/exhibit-soleno-therapeutics-announces-15-million-private-placement-financing-to-support-pl-slno-20171212monthly0.5https://www.biopharmawatch.com/news/SLNO/exhibit-soleno-therapeutics-announces-joint-venture-agreement-for-development-and-commerci-slno-20171208monthly0.5https://www.biopharmawatch.com/news/SLNO/exhibit-soleno-therapeutics-announces-cfo-transition-david-o-toole-to-depart-company-inter-slno-20170905monthly0.5https://www.biopharmawatch.com/news/SLNO/essentialis-inc-financial-statements-for-the-years-ended-december-31-2016-and-2015-essenti-slno-20170724monthly0.5https://www.biopharmawatch.com/news/SLNO/exhibit-soleno-therapeutics-announces-sale-of-non-strategic-assets-to-flexicare-inc-slno-20170724monthly0.5https://www.biopharmawatch.com/news/SLNO/essentialis-inc-financial-statements-for-the-years-ended-december-31-2016-and-2015-essenti-slno-20170410monthly0.5https://www.biopharmawatch.com/news/SLNO/capnia-completes-merger-with-essentialis-creating-rare-disease-therapeutics-company-lead-c-slno-20170308monthly0.5https://www.biopharmawatch.com/news/SLNO/certain-notices-and-disclaimers-forward-looking-statements-this-presentation-contains-forw-slno-20170109monthly0.5https://www.biopharmawatch.com/news/SLNO/dccr-in-prader-willi-syndrome-summary-of-presentation-at-fpwr-2016-introduction-prader-wil-slno-20170103monthly0.5https://www.biopharmawatch.com/news/SLNO/capnia-and-essentialis-announce-merger-to-create-rare-disease-therapeutics-company-combine-slno-20161227monthly0.5https://www.biopharmawatch.com/news/SLNO/capnia-announces-private-placement-of-up-to-13-8-million-of-convertible-preferred-stock-slno-20160629monthly0.5https://www.biopharmawatch.com/news/SLNO/capnia-names-rajen-dalal-to-board-of-directors-appointment-adds-significant-leadership-exp-slno-20160418monthly0.5https://www.biopharmawatch.com/news/SLNO/capnia-signs-exclusive-nationwide-distribution-agreement-for-cosense-capnia-and-bemes-ente-slno-20160126monthly0.5https://www.biopharmawatch.com/news/SLNO/capnia-granted-orphan-designation-for-nasal-co2-for-the-treatment-of-trigeminal-neuralgia-slno-20151221monthly0.5https://www.biopharmawatch.com/news/SLNO/financial-statements-neoforce-group-inc-index-to-financial-statements-report-of-independen-slno-20151124monthly0.5https://www.biopharmawatch.com/news/SLNO/capnia-announces-private-placement-of-up-to-10-million-of-convertible-preferred-stock-and--slno-20151012monthly0.5https://www.biopharmawatch.com/news/SLNO/acquisition-strengthens-capnia-s-presence-in-neonatology-neoforce-president-and-chief-exec-slno-20150908monthly0.5https://www.biopharmawatch.com/news/SLNO/capnia-announces-10-million-at-the-market-firm-commitment-stock-purchase-agreement-with-as-slno-20150727monthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-s-business-overview-we-are-a-late-stage-clinical-biotechnology-company-developi-trml-20240124monthly0.5https://www.biopharmawatch.com/news/TRML/index-to-unaudited-condensed-financial-statements-page-unaudited-condensed-financial-state-trml-20231114monthly0.5https://www.biopharmawatch.com/news/TRML/talaris-therapeutics-announces-stockholder-approval-of-merger-with-tourmaline-bio-combined-trml-20231017monthly0.5https://www.biopharmawatch.com/news/TRML/talaris-therapeutics-declares-special-dividend-in-connection-with-proposed-merger-with-tou-trml-20231006monthly0.5https://www.biopharmawatch.com/news/TRML/sell-side-analyst-day-trml-20230926monthly0.5https://www.biopharmawatch.com/news/TRML/this-communication-contains-forward-looking-statements-within-the-meaning-of-the-safe-harb-trml-20230913monthly0.5https://www.biopharmawatch.com/news/TRML/talaris-therapeutics-and-tourmaline-bio-announce-merger-agreement-merger-to-create-nasdaq--trml-20230622monthly0.5https://www.biopharmawatch.com/news/TRML/talaris-therapeutics-announces-leadership-transition-boston-ma-and-louisville-ky-trml-20230526monthly0.5https://www.biopharmawatch.com/news/TRML/talaris-therapeutics-announces-plans-to-explore-strategic-alternatives-and-implements-rest-trml-20230216monthly0.5https://www.biopharmawatch.com/news/TRML/talaris-therapeutics-announces-third-quarter-financial-results-and-corporate-update-enroll-trml-20221110monthly0.5https://www.biopharmawatch.com/news/TRML/talaris-therapeutics-provides-update-on-freedom-1-phase-3-clinical-trial-boston-ma-and-lou-trml-20221020monthly0.5https://www.biopharmawatch.com/news/TRML/disclaimer-this-presentation-contains-forward-looking-statements-and-information-of-talari-trml-20220630monthly0.5https://www.biopharmawatch.com/news/TRML/talaris-therapeutics-announces-changes-to-board-of-directors-boston-ma-and-louisville-ky-trml-20220517monthly0.5https://www.biopharmawatch.com/news/TRML/talaris-therapeutics-announces-first-quarter-financial-results-and-corporate-update-multip-trml-20220512monthly0.5https://www.biopharmawatch.com/news/TRML/talaris-therapeutics-announces-fourth-quarter-and-year-end-financial-results-and-provides--trml-20220317monthly0.5https://www.biopharmawatch.com/news/TRML/talaris-therapeutics-announces-third-quarter-2021-financial-results-and-provides-business--trml-20211112monthly0.5https://www.biopharmawatch.com/news/TRML/talaris-therapeutics-announces-initiation-of-phase-2-clinical-trial-of-fcr001-in-delayed-t-trml-20211029monthly0.5https://www.biopharmawatch.com/news/TRML/talaris-therapeutics-announces-second-quarter-2021-financial-results-and-provides-business-trml-20210812monthly0.5https://www.biopharmawatch.com/news/TRML/talaris-therapeutics-announces-first-quarter-2021-financial-results-and-provides-business--trml-20210614monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-presents-multiple-clinical-updates-at-eha2026-congress-poster-presentatio-aapgv-20260614monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapgv-20260612monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapgv-20260610monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-presents-its-first-dataset-on-mdm2-p53-inhibitor-alrizomadlin-apg-115-in--aapgv-20260531monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapgv-20260528monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapgv-20260522monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-to-present-17-clinical-advances-at-2026-european-hematology-association-c-aapgv-20260512monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-rockville-md-and-aapgv-20260512monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-aapgv-20260501monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-to-present-data-from-multiple-trials-including-three-rapid-oral-presentat-aapgv-20260421monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-to-present-four-promising-preclinical-studies-demonstrating-the-potential-aapgv-20260419monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapgv-20260401monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-reports-full-year-2025-unaudited-financial-results-and-provides-business--aapgv-20260326monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-to-present-data-from-four-preclinical-studies-in-its-innovative-pipeline--aapgv-20260317monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapgv-20260316monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapgv-20260311monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-rockville-md-and-aapgv-20260223monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026-rockvil-aapgv-20260209monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-announces-ind-clearance-by-the-china-cde-for-btk-degrader-apg-3288-rockvi-aapgv-20260205monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-outlined-its-global-innovation-strategy-during-presentation-at-44-th-annu-aapgv-20260114monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-announces-ind-clearance-by-the-u-s-food-and-drug-administration-for-btk-d-aapgv-20260106monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapgv-20251226monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-to-present-at-44-th-annual-j-p-morgan-healthcare-conference-rockville-md--aapgv-20251217monthly0.5https://www.biopharmawatch.com/news/AAPGV/ash-2025-updated-data-for-ascentage-pharma-s-olverembatinib-in-second-line-cml-cp-showing--aapgv-20251208monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-presents-pivotal-china-registrational-study-data-for-lisaftoclax-in-oral--aapgv-20251206monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-announces-global-registrational-phase-iii-study-of-olverembatinib-in-firs-aapgv-20251204monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-to-host-webcast-highlighting-key-data-from-ash-2025-rockville-md-and-aapgv-20251201monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapgv-20251128monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-announces-publication-of-olverembatinib-phase-ib-safety-efficacy-and-nove-aapgv-20251124monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-in-december-2025-ro-aapgv-20251119monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-to-present-data-from-two-clinical-studies-for-bcl-2-inhibitor-lisaftoclax-aapgv-20251103monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025-rock-aapgv-20251029monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-in-october-2025-roc-aapgv-20251007monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-in-september-2025-r-aapgv-20250825monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-reports-2025-interim-unaudited-six-months-financial-results-and-business--aapgv-20250821monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-announces-global-registrational-phase-iii-study-of-lisaftoclax-for-first--aapgv-20250817monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapgv-20250808monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-to-participate-in-evercore-china-biotech-summit-aapgv-20250801monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapgv-20250714monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapgv-20250717monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-announces-pricing-of-top-up-placement-rockville-md-and-aapgv-20250714monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapgv-20250710monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapgv-20250708monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapgv-20250627monthly0.5https://www.biopharmawatch.com/news/AAPGV/eha-2025-multiple-studies-report-encouraging-data-of-olverembatinib-in-ph-all-rockville-md-aapgv-20250615monthly0.5https://www.biopharmawatch.com/news/AAPGV/thirteen-studies-of-ascentage-pharma-s-assets-including-olverembatinib-and-lisaftoclax-sel-aapgv-20250609monthly0.5https://www.biopharmawatch.com/news/AAPGV/live-from-asco-2025-ascentage-pharma-releases-promising-clinical-data-on-alrizomadlin-mono-aapgv-20250602monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-announces-clinical-data-of-lisaftoclax-which-shows-therapeutic-potential--aapgv-20250522monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapgv-20250520monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-presents-results-from-five-preclinical-studies-at-2025-american-associati-aapgv-20250428monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-to-present-data-from-two-clinical-studies-at-2025-asco-annual-meeting-inc-aapgv-20250423monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapgv-20250421monthly0.5https://www.biopharmawatch.com/news/AAPGV/pelcitoclax-apg-1252-apg-2449-apg-5918-lisaftoclax-apg-2575-alrizomadlin-apg-115-incorpora-aapgv-20250417monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapgv-20250408monthly0.5https://www.biopharmawatch.com/news/AAPGV/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapgv-20250331monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-reports-full-year-2024-unaudited-financial-results-and-business-updates-r-aapgv-20250327monthly0.5https://www.biopharmawatch.com/news/AAPGV/ascentage-pharma-to-present-five-preclinical-studies-from-innovative-pipeline-at-american--aapgv-20250325monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-announces-expiration-of-hsr-act-waiting-period-for-pending-acquisition-by-zimme-fna-20250311monthly0.5https://www.biopharmawatch.com/news/FNA/execution-version-voting-agreement-this-voting-agreement-this-agreement-dated-as-of-fna-20250128monthly0.5https://www.biopharmawatch.com/news/FNA/zimmer-biomet-media-investors-heather-zoumas-lubeski-445-248-0577-heather-zoumaslubeski-zi-fna-20250128monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-announces-preliminary-unaudited-revenue-for-fourth-quarter-and-full-year-2024-fna-20250113monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-appoints-dave-demski-to-board-of-directors-englewood-co-fna-20241211monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-reports-third-quarter-2024-financial-results-and-raises-2024-net-revenue-guidan-fna-20241112monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-appoints-chadi-chahine-as-chief-financial-officer-and-executive-vice-president--fna-20240808monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-reports-first-quarter-2024-financial-results-and-reaffirms-2024-net-revenue-gui-fna-20240508monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-announces-cfo-transition-provides-preliminary-unaudited-net-revenue-for-first-q-fna-20240404monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-2024-n-fna-20240229monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-announces-preliminary-unaudited-revenue-for-fourth-quarter-and-full-year-2023-fna-20240108monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-announces-new-150-million-credit-facility-replacing-existing-90-million-credit--fna-20231107monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-reports-third-quarter-2023-financial-results-and-reaffirms-2023-net-revenue-gui-fna-20231107monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-reports-second-quarter-2023-financial-results-and-reaffirms-2023-net-revenue-gu-fna-20230802monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-reports-first-quarter-2023-financial-results-and-reaffirms-2023-net-revenue-gui-fna-20230504monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-2023-f-fna-20230302monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-announces-preliminary-unaudited-revenue-for-fourth-quarter-and-full-year-2022-e-fna-20230110monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-reports-third-quarter-2022-financial-results-and-increases-2022-net-revenue-gui-fna-20221110monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-reports-second-quarter-2022-financial-results-and-increases-2022-net-revenue-gu-fna-20220803monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-reports-first-quarter-2022-financial-results-and-increases-2022-net-revenue-gui-fna-20220509monthly0.5https://www.biopharmawatch.com/news/FNA/foot-ankle-specialists-march-2022-http-www-enduringjourneys-com-uploads-north-225-jpg-2-co-fna-20220308monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-2022-n-fna-20220308monthly0.5https://www.biopharmawatch.com/news/FNA/2016-year-incorporated-20-employees-helsinki-headquarters-18-million-leading-international-fna-20220112monthly0.5https://www.biopharmawatch.com/news/FNA/paragon-28-reports-third-quarter-2021-financial-results-and-provides-2021-fourth-quarter-n-fna-20211122monthly0.5https://www.biopharmawatch.com/news/VERV/verve-therapeutics-announces-pipeline-progress-and-reports-first-quarter-2025-financial-re-verv-20250514monthly0.5https://www.biopharmawatch.com/news/VERV/verve-therapeutics-announces-pipeline-progress-and-reports-fourth-quarter-and-full-year-20-verv-20250227monthly0.5https://www.biopharmawatch.com/news/VERV/verve-therapeutics-announces-pipeline-progress-and-reports-third-quarter-2024-financial-re-verv-20241105monthly0.5https://www.biopharmawatch.com/news/VERV/verve-therapeutics-announces-pipeline-progress-and-reports-second-quarter-2024-financial-r-verv-20240808monthly0.5https://www.biopharmawatch.com/news/VERV/verve-therapeutics-announces-pipeline-progress-and-reports-first-quarter-2024-financial-re-verv-20240508monthly0.5https://www.biopharmawatch.com/news/VERV/verve-therapeutics-provides-pipeline-progress-and-reports-fourth-quarter-and-full-year-202-verv-20240227monthly0.5https://www.biopharmawatch.com/news/VERV/verve-therapeutics-announces-pricing-of-public-offering-of-common-stock-and-concurrent-pri-verv-20231128monthly0.5https://www.biopharmawatch.com/news/VERV/verve-therapeutics-highlights-recent-company-progress-and-reports-third-quarter-2023-finan-verv-20231107monthly0.5https://www.biopharmawatch.com/news/VERV/verve-therapeutics-highlights-recent-company-progress-and-reports-second-quarter-2023-fina-verv-20230810monthly0.5https://www.biopharmawatch.com/news/VERV/verve-therapeutics-announces-pipeline-progress-and-expansion-and-reports-first-quarter-202-verv-20230515monthly0.5https://www.biopharmawatch.com/news/VERV/verve-therapeutics-provides-pipeline-progress-and-reports-fourth-quarter-and-full-year-202-verv-20230302monthly0.5https://www.biopharmawatch.com/news/VERV/verve-therapeutics-provides-regulatory-update-on-verve-101-investigational-new-drug-applic-verv-20221107monthly0.5https://www.biopharmawatch.com/news/VERV/verve-therapeutics-provides-corporate-updates-and-reports-second-quarter-2022-financial-re-verv-20220809monthly0.5https://www.biopharmawatch.com/news/VERV/verve-therapeutics-announces-pricing-of-upsized-public-offering-of-common-stock-verv-20220721monthly0.5https://www.biopharmawatch.com/news/VERV/verve-therapeutics-announces-clearance-of-first-verve-101-clinical-trial-application-and-o-verv-20220510monthly0.5https://www.biopharmawatch.com/news/VERV/verve-therapeutics-announces-pipeline-progress-and-reports-fourth-quarter-and-full-year-20-verv-20220314monthly0.5https://www.biopharmawatch.com/news/VERV/verve-therapeutics-announces-pipeline-progress-and-reports-third-quarter-2021-financial-re-verv-20211110monthly0.5https://www.biopharmawatch.com/news/VERV/verve-therapeutics-announces-business-and-program-highlights-and-reports-second-quarter-20-verv-20210812monthly0.5https://www.biopharmawatch.com/news/KALV/confidential-chiesi-group-completes-acquisition-of-kalvista-pharmaceuticals-positioned-to--kalv-20260611monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-provides-operational-update-and-reports-third-quarter-financial-r-kalv-20251110monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-appoints-bilal-arif-as-chief-operating-officer-and-linea-aspesi-a-kalv-20251006monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-announces-appointment-of-bethany-l-sensenig-to-board-of-directors-kalv-20251002monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-announces-proposed-offering-of-110-0-million-of-convertible-senio-kalv-20250924monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-provides-operational-update-and-reports-fiscal-quarter-financial--kalv-20250911monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-provides-operational-update-and-fiscal-year-2025-financial-result-kalv-20250710monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-announces-fda-approval-of-ekterly-sebetralstat-first-and-only-ora-kalv-20250707monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-enters-into-licensing-agreement-with-kaken-pharmaceutical-to-comm-kalv-20250408monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-inc-condensed-consolidated-statement-of-operations-in-thousands-e-kalv-20250312monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-appoints-jeb-ledell-as-chief-operating-officer-cambridge-ma-and-salisbury-england-kalv-20241216monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-inc-condensed-consolidated-statement-of-operations-in-thousands-e-kalv-20241205monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-appoints-laurence-reid-ph-d-to-board-of-directors-cambridge-mass--kalv-20241126monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-announces-pricing-of-a-55-million-underwritten-offering-of-common-kalv-20241104monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-enters-into-non-dilutive-synthetic-royalty-financing-with-dri-hea-kalv-20241104monthly0.5https://www.biopharmawatch.com/news/KALV/in-addition-kalvista-received-validation-of-its-maa-from-the-ema-in-august-2024-kalvista-e-kalv-20240910monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-inc-condensed-consolidated-statements-of-cash-flows-in-thousands--kalv-20240905monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-inc-condensed-consolidated-statements-of-cash-flows-in-thousands--kalv-20240711monthly0.5https://www.biopharmawatch.com/news/KALV/forward-looking-statements-this-press-release-contains-forward-looking-statements-within-t-kalv-20240422monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-inc-condensed-consolidated-statements-of-cash-flows-in-thousands--kalv-20240311monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-announces-appointment-of-benjamin-l-palleiko-as-chief-executive-o-kalv-20240307monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-announces-pricing-of-a-160-1-million-public-offering-of-common-st-kalv-20240215monthly0.5https://www.biopharmawatch.com/news/KALV/corporate-overview-february-2024-forward-looking-statements-this-presentation-and-the-acco-kalv-20240213monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-inc-condensed-consolidated-statements-of-cash-flows-in-thousands--kalv-20231207monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-reports-first-fiscal-quarter-results-and-provides-operational-upd-kalv-20230907monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-inc-condensed-consolidated-statements-of-cash-flows-in-thousands--kalv-20230710monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-reports-third-fiscal-quarter-results-enrollment-in-sebetralstat-k-kalv-20230309monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-announces-benjamin-l-palleiko-promoted-to-president-expanded-role-kalv-20230105monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-reports-second-fiscal-quarter-results-phase-1-clinical-trial-for--kalv-20221208monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-announces-appointment-of-brian-j-g-pereira-m-d-as-board-chairman--kalv-20221017monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-reports-first-fiscal-quarter-results-kvd824-phase-2-clinical-tria-kalv-20220908monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-provides-operational-update-and-fiscal-year-financial-results-x20-kalv-20220707monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-reports-third-fiscal-quarter-results-x2013-kvd900-phase-3-konfide-kalv-20220310monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-announces-initiation-of-kvd900-phase-3-konfident-clinical-trial-k-kalv-20220307monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-reports-second-fiscal-quarter-results-x2013-preparing-for-initiat-kalv-20211209monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-reports-first-fiscal-quarter-results-fda-end-of-phase-2-meeting-f-kalv-20210909monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-provides-operational-update-and-fiscal-year-financial-results-fda-kalv-20210713monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-presents-phase-2-clinical-data-of-oral-kvd900-for-treatment-of-ha-kalv-20210605monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-reports-third-fiscal-quarter-results-recent-kvd900-phase-2-clinic-kalv-20210311monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-announces-pricing-of-an-upsized-193-5-million-public-offering-of--kalv-20210210monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-reports-second-fiscal-quarter-results-kvd900-phase-2-clinical-tri-kalv-20201210monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-reports-first-fiscal-quarter-results-kvd900-on-demand-data-expect-kalv-20200914monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-provides-operational-update-and-fiscal-year-financial-results-kvd-kalv-20200701monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-reports-fiscal-third-quarter-results-oral-hereditary-angioedema-f-kalv-20200310monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-reports-fiscal-second-quarter-results-kvd900-phase-2-trial-data-f-kalv-20191203monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-reports-fiscal-first-quarter-results-phase-2-clinical-trial-of-kv-kalv-20190909monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-provides-operational-update-and-fiscal-year-financial-results-kvd-kalv-20190715monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-reports-fiscal-third-quarter-results-oral-hereditary-angioedema-h-kalv-20190314monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-reports-fiscal-second-quarter-results-kvd900-enlarged-phase-2-tri-kalv-20181214monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-cambridge-ma-kalv-20180906monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-provides-operational-update-and-fiscal-year-financial-results-kvd-kalv-20180731monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-inc-2017-equity-incentive-plan-notice-of-performance-based-restri-kalv-20180629monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-reports-fiscal-third-quarter-results-enrollment-ongoing-for-a-pha-kalv-20180316monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-reports-fiscal-second-quarter-results-regulatory-filing-submitted-kalv-20171214monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-announces-collaboration-with-merck-covers-development-of-investig-kalv-20171010monthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-reports-fiscal-first-quarter-results-portfolio-of-oral-plasma-kal-kalv-20170914monthly0.5https://www.biopharmawatch.com/news/KALV/edited-transcript-kalv-20160624monthly0.5https://www.biopharmawatch.com/news/KALV/carbylan-therapeutics-and-kalvista-pharmaceuticals-conference-call-to-discuss-proposed-tra-kalv-20160622monthly0.5https://www.biopharmawatch.com/news/KALV/carbylan-therapeutics-inc-and-kalvista-pharmaceuticals-ltd-enter-into-share-purchase-agree-kalv-20160615monthly0.5https://www.biopharmawatch.com/news/KALV/carbylan-therapeutics-announces-decision-to-pursue-strategic-transaction-carbylan-to-suspe-kalv-20160415monthly0.5https://www.biopharmawatch.com/news/KALV/carbylan-therapeutics-engages-wedbush-pacgrow-to-advise-on-strategic-alternatives-palo-alt-kalv-20160317monthly0.5https://www.biopharmawatch.com/news/KALV/carbylan-therapeutics-reports-top-line-results-from-cor1-1-clinical-trial-of-hydros-ta-in--kalv-20160201monthly0.5https://www.biopharmawatch.com/news/KALV/carbylan-therapeutics-announces-third-quarter-2015-financial-results-palo-alto-calif-kalv-20151111monthly0.5https://www.biopharmawatch.com/news/KALV/carbylan-therapeutics-announces-second-quarter-2015-financial-results-palo-alto-calif-kalv-20150811monthly0.5https://www.biopharmawatch.com/news/KALV/carbylan-therapeutics-announces-first-quarter-2015-financial-results-palo-alto-calif-kalv-20150519monthly0.5https://www.biopharmawatch.com/news/VTYX/lilly-to-acquire-ventyx-biosciences-to-advance-oral-therapies-targeting-inflammatory-media-vtyx-20260107monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-highlights-2025-pipeline-strategy-and-provides-clinical-updates-on-its--vtyx-20241231monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-2023-r-d-day-vtyx-20230126monthly0.5https://www.biopharmawatch.com/news/VTYX/corporate-presentation-december-2022-1-forward-looking-statements-ventyx-biosciences-inc-w-vtyx-20221130monthly0.5https://www.biopharmawatch.com/news/VTYX/corporate-presentation-first-quarter-2022-forward-looking-statements-ventyx-cautions-you-t-vtyx-20220315monthly0.5https://www.biopharmawatch.com/news/VTYX/corporate-presentation-fourth-quarter-2021-page-1-forward-looking-statements-ventyx-cautio-vtyx-20211130monthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-inc-ipo-closing-press-release-ventyx-biosciences-announces-closing-of-u-vtyx-20211025monthly0.5https://www.biopharmawatch.com/news/MNMD/corporate-presentation-may-2026-this-presentation-the-x201c-presentation-x201d-has-been-pr-mnmd-20260519monthly0.5https://www.biopharmawatch.com/news/MNMD/definium-therapeutics-announces-first-patient-dosed-in-ascend-the-second-phase-3-pivotal-s-mnmd-20260512monthly0.5https://www.biopharmawatch.com/news/MNMD/definium-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights-t-mnmd-20260507monthly0.5https://www.biopharmawatch.com/news/MNMD/definium-therapeutics-highlights-dt120-odt-lysergide-tartrate-clinical-advancements-and-co-mnmd-20260422monthly0.5https://www.biopharmawatch.com/news/MNMD/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates-emerge-mnmd-20260226monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-rebrands-to-definium-therapeutics-advancing-a-leading-late-stage-psychiatry-pipeli-mnmd-20260113monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-reports-q3-2025-financial-results-and-business-updates-anticipated-topline-data-re-mnmd-20251106monthly0.5https://www.biopharmawatch.com/news/MNMD/mind-medicine-mindmed-inc-announces-proposed-public-offering-mnmd-20251029monthly0.5https://www.biopharmawatch.com/news/MNMD/corporate-presentation-october-2025-2-this-presentation-the-presentation-has-been-prepared-mnmd-20251029monthly0.5https://www.biopharmawatch.com/news/MNMD/journal-of-the-american-medical-association-jama-publishes-results-from-first-ever-randomi-mnmd-20250904monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-reports-q2-2025-financial-results-and-business-updates-strong-enrollment-continues-mnmd-20250731monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-strengthens-executive-team-with-appointment-of-brandi-roberts-cpa-as-chief-financi-mnmd-20250527monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-reports-first-quarter-2025-financial-results-and-recent-business-updates-dosed-fir-mnmd-20250508monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-first-patient-dosed-in-phase-3-emerge-study-of-mm120-in-major-depressive-mnmd-20250415monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-up-mnmd-20250306monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-first-patient-dosed-in-panorama-the-second-pivotal-phase-3-study-of-mm12-mnmd-20250130monthly0.5https://www.biopharmawatch.com/news/MNMD/corporate-presentation-january-2025-corporate-presentation-january-2025-this-presentation--mnmd-20250113monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-first-patient-dosed-in-phase-3-voyage-study-of-mm120-in-generalized-anxi-mnmd-20241216monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-reports-third-quarter-2024-financial-results-and-business-updates-on-track-to-init-mnmd-20241107monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-reports-second-quarter-2024-financial-results-and-business-updates-completed-end-o-mnmd-20240813monthly0.5https://www.biopharmawatch.com/news/MNMD/mind-medicine-mindmed-inc-announces-proposed-public-offering-mnmd-20240809monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-constructive-end-of-phase-2-meeting-with-u-s-fda-for-mm120-in-generalize-mnmd-20240620monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-reports-first-quarter-2024-financial-results-and-business-updates-announced-positi-mnmd-20240508monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-voluntary-delisting-from-cboe-canada-all-common-shares-will-remain-liste-mnmd-20240401monthly0.5https://www.biopharmawatch.com/news/MNMD/mind-medicine-mindmed-inc-announces-pricing-of-underwritten-offering-of-common-shares-and--mnmd-20240307monthly0.5https://www.biopharmawatch.com/news/MNMD/mm120-for-generalized-anxiety-disorder-gad-phase-2b-full-topline-data-odt-pk-bridging-stud-mnmd-20240307monthly0.5https://www.biopharmawatch.com/news/MNMD/thursday-march-7-2023-6-00-am-est-mindmed-receives-fda-breakthrough-therapy-designation-an-mnmd-20240307monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-reports-2023-financial-results-and-business-updates-announced-statistically-signif-mnmd-20240228monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-business-update-and-anticipated-milestones-for-2024-recently-announced-s-mnmd-20240108monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm-120-in-generalized-an-mnmd-20231214monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-reports-third-quarter-2023-financial-results-and-business-highlights-x2013-topline-mnmd-20231102monthly0.5https://www.biopharmawatch.com/news/MNMD/company-logo-mindmed-investor-presentation-august-2023-disclaimer-this-presentation-the-x2-mnmd-20230814monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-reports-second-quarter-2023-financial-results-and-business-highlights-x2013-toplin-mnmd-20230803monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-investor-presentation-investor-day-2023-mm-120-for-generalized-anxiety-disorder-di-mnmd-20230620monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-adjourns-annual-general-meeting-of-shareholders-meeting-will-resume-on-wednesday-mnmd-20230615monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-to-present-data-on-the-preclinical-activity-of-mm-402-at-the-american-society-of-c-mnmd-20230524monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-enrollment-milestone-in-phase-2b-trial-of-mm-120-in-generalized-anxiety--mnmd-20230517monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-reports-first-quarter-2023-financial-results-and-business-highlights-x2013-key-mm--mnmd-20230504monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-files-preliminary-proxy-statement-for-2023-annual-meeting-presents-highly-qualifie-mnmd-20230418monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-collaborators-announce-positive-topline-data-from-phase-2-trial-of-lysergide-lsd-i-mnmd-20230414monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-reports-full-year-2022-financial-results-and-business-highlights-x2013-company-pos-mnmd-20230309monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-provides-corporate-update-and-2023-outlook-company-positioned-for-key-mm-120-phase-mnmd-20230109monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-reports-third-quarter-2022-financial-results-and-business-highlights-x2013-phase-2-mnmd-20221110monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-proposed-public-offering-of-common-shares-new-york-mnmd-20220927monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-compliance-with-nasdaq-listing-requirements-mnmd-20220914monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-completes-1-for-15-reverse-share-split-common-shares-will-begin-trading-on-a-split-mnmd-20220829monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-reports-second-quarter-2022-financial-results-and-business-highlights-x2013-phase--mnmd-20220811monthly0.5https://www.biopharmawatch.com/news/MNMD/corporate-overview-july-2022-3-corporate-overview-july-2022-4-mnmd-20220721monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-reports-first-quarter-2022-financial-results-and-business-highlights-advanced-clin-mnmd-20220516monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase--mnmd-20220511monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-corporate-over-april-2022-disclaimer-this-presentation-the-presentation-has-been-p-mnmd-20220426monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-reports-full-year-2021-financial-results-and-business-highlights-fda-cleared-mindm-mnmd-20220328monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-transition-of-mnmd-20220325monthly0.5https://www.biopharmawatch.com/news/MNMD/fda-clears-mindmed-ind-for-mm-120-in-treatment-of-generalized-anxiety-disorder-fda-clearan-mnmd-20220125monthly0.5https://www.biopharmawatch.com/news/MNMD/stephen-hurst-resigns-from-mindmed-board-of-directors-mnmd-20220107monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-transitions-to-management-team-bradford-cross-chief-technology-officer-t-mnmd-20211229monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-provides-status-update-on-ind-for-phase-2b-trial-of-lsd-for-the-treatment-of-gener-mnmd-20211221monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-appoints-robert-barrow-as-chief-executive-officer-and-director-mr-barrow-previousl-mnmd-20211214monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-initiates-phase-2a-lsd-trial-for-the-treatment-of-adult-adhd-enrolling-patients-in-mnmd-20211217monthly0.5https://www.biopharmawatch.com/news/MNMD/form-51-102f3-material-change-report-item-1-name-and-address-of-company-mind-medicine-mind-mnmd-20211213monthly0.5https://www.biopharmawatch.com/news/MNMD/for-immediate-release-mnmd-20211209monthly0.5https://www.biopharmawatch.com/news/MNMD/notice-of-change-of-auditor-pursuant-to-national-instrument-51-102-of-the-canadian-securit-mnmd-20211201monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-to-participate-at-the-benzinga-global-small-cap-conference-mnmd-20211202monthly0.5https://www.biopharmawatch.com/news/MNMD/for-immediate-release-mnmd-20211201monthly0.5https://www.biopharmawatch.com/news/MNMD/ehhibit-99-1-for-immediate-release-mnmd-20211116monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-financial-results-for-the-third-quarter-2021-and-business-highlights-cas-mnmd-20211115monthly0.5https://www.biopharmawatch.com/news/MNMD/mind-medicine-mindmed-inc-condensed-consolidated-interim-financial-statements-expressed-in-mnmd-20211112monthly0.5https://www.biopharmawatch.com/news/MNMD/for-immediate-release-mnmd-20211112monthly0.5https://www.biopharmawatch.com/news/MNMD/for-immediate-release-mnmd-20211105monthly0.5https://www.biopharmawatch.com/news/MNMD/for-immediate-release-mnmd-20211026monthly0.5https://www.biopharmawatch.com/news/MNMD/form-51-102f3-material-change-report-item-1-name-and-address-of-company-mind-medicine-mind-mnmd-20210929monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-appointment-of-andreas-krebs-and-carol-vallone-as-directors-and-transiti-mnmd-20210930monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-and-bioxcel-therapeutics-publish-an-international-patent-application-describing-a--mnmd-20210902monthly0.5https://www.biopharmawatch.com/news/MNMD/for-immediate-release-mnmd-20210824monthly0.5https://www.biopharmawatch.com/news/MNMD/for-immediate-release-mnmd-20210817monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-2021-q2-financial-results-cash-balance-of-157-usd-million-195-cad-millio-mnmd-20210813monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-discover-develop-deploy-www-mindmed-co-psychedelic-inspired-medicines-august-2021--mnmd-20210813monthly0.5https://www.biopharmawatch.com/news/MNMD/mind-medicine-mindmed-inc-condensed-consolidated-interim-financial-statements-expressed-in-mnmd-20210813monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-appoints-dr-robert-dworkin-to-scientific-advisory-board-new-york-ny-mnmd-20210810monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-joins-digital-medicine-society-to-improve-health-outcomes-and-equity-using-technol-mnmd-20210803monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-initiation-of-phase-1-clinical-trial-of-intravenous-dmt-new-york-ny-mnmd-20210728monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-chosen-to-participate-in-cowen-s-psychedelics-novel-mechanisms-in-neuropsychiatry--mnmd-20210712monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-partnership-with-datavant-a-leading-health-data-connectivity-company-new-mnmd-20210708monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-appoints-mgh-psychiatrist-in-chief-dr-maurizio-fava-to-scientific-advisory-board-n-mnmd-20210623monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-appoints-pharmaceutical-veteran-peter-bergethon-m-d-to-scientific-advisory-board-n-mnmd-20210617monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-chief-executive-officer-transition-new-york-ny-mnmd-20210609monthly0.5https://www.biopharmawatch.com/news/MNMD/mind-medicine-mindmed-inc-the-corporation-annual-and-special-meeting-of-shareholders-repor-mnmd-20210527monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-and-liechti-lab-in-basel-switzerland-publish-first-pharmacogenetic-data-on-lsd-to--mnmd-20210526monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposo-mnmd-20210524monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-the-approval-of-mescaline-study-basel-switzerland-mnmd-20210520monthly0.5https://www.biopharmawatch.com/news/MNMD/the-chopra-foundation-and-mindmed-enter-into-letter-of-intent-to-partner-on-the-future-of--mnmd-20210518monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-receives-fda-type-c-meeting-response-for-project-lucy-phase-2b-clinical-trial-mind-mnmd-20210517monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-bolsters-management-team-appoints-peter-mack-phd-as-vice-president-of-pharmaceutic-mnmd-20210513monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-announces-project-angie-targeting-the-treatment-of-pain-with-psychedelics-new-york-mnmd-20210505monthly0.5https://www.biopharmawatch.com/news/MNMD/notice-of-annual-and-special-meeting-and-management-information-circular-with-respect-to-t-mnmd-20210428monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-begins-trading-on-nasdaq-new-york-ny-mnmd-20210427monthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-to-commence-trading-on-nasdaq-new-york-ny-mnmd-20210423monthly0.5https://www.biopharmawatch.com/news/EHAB/enhabit-completes-previously-announced-acquisition-by-kinderhook-industries-to-become-a-pr-ehab-20260515monthly0.5https://www.biopharmawatch.com/news/EHAB/enhabit-sets-stockholder-meeting-date-of-ehab-20260416monthly0.5https://www.biopharmawatch.com/news/EHAB/enhabit-to-be-acquired-by-kinderhook-industries-enhabit-inc-stockholders-to-receive-13-80--ehab-20260223monthly0.5https://www.biopharmawatch.com/news/EHAB/enhabit-and-encompass-health-collect-43-1-million-from-individual-defendants-in-delaware-f-ehab-20260212monthly0.5https://www.biopharmawatch.com/news/EHAB/enhabit-home-health-hospice-announces-ceo-transition-plan-barb-jacobsmeyer-to-step-down-bo-ehab-20250806monthly0.5https://www.biopharmawatch.com/news/EHAB/enhabit-home-health-hospice-to-nominate-stephan-rodgers-to-board-of-directors-dallas-tx-ehab-20250225monthly0.5https://www.biopharmawatch.com/news/EHAB/enhabit-announces-participation-in-upcoming-bofa-home-care-conference-dallas-tx-ehab-20241119monthly0.5https://www.biopharmawatch.com/news/EHAB/delaware-court-of-chancery-awards-damages-and-other-relief-to-encompass-health-and-enhabit-ehab-20241204monthly0.5https://www.biopharmawatch.com/news/EHAB/and-incorporated-by-reference-in-the-company-s-current-report-on-form-8-k-filed-with-the-s-ehab-20230330monthly0.5https://www.biopharmawatch.com/news/EHAB/enhabit-home-health-hospice-completes-spin-off-from-encompass-health-enhabit-also-announce-ehab-20220701monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-preliminary-unaudited-fourth-quarter-and-full-year-2024-financial-highli-dvax-20241231monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-preliminary-unaudited-fourth-quarter-and-full-year-2022-financial-highli-dvax-20221231monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-technologies-corporation-non-employee-director-compensation-policy-effective-octob-dvax-20211021monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-dynavax-announces-second-quarter-2019-financial-results-x2022-second-quarter-2019-dvax-20190807monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-announces-first-quarter-2019-financial-results-x202-dvax-20190508monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-announces-fourth-quarter-2018-and-full-year-2018-fi-dvax-20190226monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-reports-third-quarter-2018-financial-results-progre-dvax-20181105monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-reports-second-quarter-2018-financial-results-hepli-dvax-20180806monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-reports-first-quarter-2018-financial-results-update-dvax-20180508monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-reports-fourth-quarter-and-year-end-2017-financial--dvax-20180308monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-fda-approval-of-heplisav-b-for-prevention-of-hepatitis-b-in-adults-first-dvax-20171109monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-third-quarter-2017-dvax-20171103monthly0.5https://www.biopharmawatch.com/news/DVAX/robert-s-green-state-bar-no-136183-james-robert-noblin-state-bar-no-114442-lesley-e-weaver-dvax-20170901monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-second-quarter-2017-dvax-20170802monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-presents-updated-data-for-sd-101-in-combination-wit-dvax-20170605monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-reports-first-quarter-2017-dvax-20170508monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-announces-fda-advisory-committee-meeting-to-review--dvax-20170403monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-reports-fourth-quarter-and-year-end-2016-financial--dvax-20170313monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-presents-promising-clinical-data-from-lead-immuno-o-dvax-20170306monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-announces-fda-acceptance-for-review-of-its-complete-dvax-20170228monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-restructures-and-emphasizes-immuno-oncology-program-dvax-20170105monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-presents-clinical-data-from-lead-cancer-immunothera-dvax-20161205monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-receives-complete-response-letter-from-u-s-food-and-dvax-20161114monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-presents-early-clinical-data-from-lead-cancer-immun-dvax-20161109monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-2929-seventh-street-suite-100-berkeley-ca-94710-contact-mic-dvax-20161107monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-presents-data-showing-that-heplisav-b-provides-sign-dvax-20161026monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-presents-early-clinical-data-from-lead-cancer-immun-dvax-20161009monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-provides-regulatory-update-on-heplisav-b-pdufa-date-dvax-20160906monthly0.5https://www.biopharmawatch.com/news/DVAX/michael-ostrach-chief-financial-officer-510-665-7257-mostrach-dynavax-com-dynavax-reports--dvax-20160805monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-dynavax-presents-new-efficacy-data-on-hepatitis-b-vaccine-h-dvax-20160611monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-2929-seventh-street-suite-100-berkeley-ca-94710-contact-mic-dvax-20160509monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-2929-seventh-street-suite-100-berkeley-ca-94710-dynavax-rec-dvax-20160427monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-2929-seventh-street-suite-100-berkeley-ca-94710-dynavax-pre-dvax-20160419monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-2929-seventh-street-suite-100-berkeley-ca-94710-dynavax-ann-dvax-20160330monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-2929-seventh-street-suite-100-berkeley-ca-94710-contact-mic-dvax-20160308monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-2929-seventh-street-suite-100-berkeley-ca-94710-dynavax-and-dvax-20160120monthly0.5https://www.biopharmawatch.com/news/DVAX/seventh-street-suite-100-berkeley-ca-94710-dynavax-reports-top-line-results-of-phase-3-hep-dvax-20160107monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-2929-seventh-street-suite-100-berkeley-ca-94710-contact-mic-dvax-20151105monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-2929-seventh-street-suite-100-berkeley-ca-94710-dynavax-ini-dvax-20151008monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-2929-seventh-street-suite-100-berkeley-ca-94710-contact-mic-dvax-20150807monthly0.5https://www.biopharmawatch.com/news/DVAX/seventh-street-suite-100-berkeley-california-94710-contact-michael-ostrach-chief-financial-dvax-20150722monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-2929-seventh-street-suite-100-berkeley-ca-94710-contact-mic-dvax-20150709monthly0.5https://www.biopharmawatch.com/news/DVAX/for-immediate-release-contacts-merck-media-relations-dynavax-investor-media-relations-pame-dvax-20150601monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-2929-seventh-street-suite-100-berkeley-ca-94710-contact-mic-dvax-20150507monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-2929-seventh-street-suite-100-berkeley-ca-94710-contact-mic-dvax-20150305monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-2929-seventh-street-suite-100-berkeley-ca-94710-contact-mic-dvax-20150302monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-2929-seventh-street-suite-100-berkeley-ca-94710-contact-mic-dvax-20150211monthly0.5https://www.biopharmawatch.com/news/DVAX/dyn-v-ax-innovating-immunology-2929-seventh-street-suite-100-berkeley-ca-94710-contact-mic-dvax-20141229monthly0.5https://www.biopharmawatch.com/news/DVAX/d-ynavax-dynavax-technologies-2929-seventh-street-suite-100-berkeley-ca-94710-contact-mich-dvax-20141208monthly0.5https://www.biopharmawatch.com/news/DVAX/d-ynavax-dynavax-technologies-2929-seventh-street-suite-100-berkeley-ca-94710-contact-mich-dvax-20141128monthly0.5https://www.biopharmawatch.com/news/DVAX/seventh-street-suite-100-berkeley-ca-94710-contact-michael-s-ostrach-vice-president-chief--dvax-20141110monthly0.5https://www.biopharmawatch.com/news/DVAX/michael-ostrach-chief-business-and-principal-financial-officer-510-665-7257-mostrach-dynav-dvax-20141105monthly0.5https://www.biopharmawatch.com/news/DVAX/seventh-street-suite-100-berkeley-ca-94710-contact-michael-s-ostrach-vice-president-chief--dvax-20140922monthly0.5https://www.biopharmawatch.com/news/DVAX/michael-ostrach-chief-business-and-principal-financial-officer-510-665-7257-mostrach-dynav-dvax-20140807monthly0.5https://www.biopharmawatch.com/news/DVAX/michael-ostrach-chief-business-and-principal-financial-officer-510-665-7257-mostrach-dynav-dvax-20140505monthly0.5https://www.biopharmawatch.com/news/DVAX/michael-ostrach-chief-business-and-principal-financial-officer-510-665-7257-mostrach-dynav-dvax-20140310monthly0.5https://www.biopharmawatch.com/news/DVAX/seventh-street-suite-100-berkeley-ca-94710-contact-michael-ostrach-chief-business-and-prin-dvax-20140303monthly0.5https://www.biopharmawatch.com/news/DVAX/seventh-street-suite-100-berkeley-ca-94710-contact-michael-s-ostrach-vice-president-chief--dvax-20140218monthly0.5https://www.biopharmawatch.com/news/DVAX/seventh-street-suite-100-berkeley-ca-94710-contact-michael-ostrach-vice-president-and-chie-dvax-20131025monthly0.5https://www.biopharmawatch.com/news/DVAX/michael-ostrach-vice-president-and-chief-business-officer-510-665-7257-mostrach-dynavax-co-dvax-20130430monthly0.5https://www.biopharmawatch.com/news/ATRI/atrion-corporation-one-allentown-parkway-allen-tx-75002-news-release-for-immediate-release-atri-20240528monthly0.5https://www.biopharmawatch.com/news/ATRI/atrion-corporation-announces-election-of-new-director-allen-texas-atri-20230920monthly0.5https://www.biopharmawatch.com/news/ATRI/atrion-corporation-one-allentown-parkway-allen-tx-75002-news-release-for-immediate-release-atri-20210830monthly0.5https://www.biopharmawatch.com/news/ATRI/atrion-reports-third-quarter-results-allen-tx-marketwired-atri-20161103monthly0.5https://www.biopharmawatch.com/news/ATRI/atrion-reports-second-quarter-results-and-announces-dividend-increase-allen-tx-marketwired-atri-20160809monthly0.5https://www.biopharmawatch.com/news/ATRI/atrion-reports-fourth-quarter-and-full-year-2015-results-allen-tx-marketwired-atri-20160222monthly0.5https://www.biopharmawatch.com/news/ATRI/atrion-reports-fourth-quarter-and-full-year-2006-results-diluted-eps-were-up-38-for-the-qu-atri-20070215monthly0.5https://www.biopharmawatch.com/news/ATRI/atrion-reports-third-quarter-results-diluted-eps-increased-by-20-allen-texas-business-wire-atri-20061106monthly0.5https://www.biopharmawatch.com/news/ATRI/atrion-adopts-stockholder-rights-plan-monday-august-7-6-43-pm-et-allen-texas-business-wire-atri-20060807monthly0.5https://www.biopharmawatch.com/news/ATRI/atrion-reports-second-quarter-results-diluted-eps-increases-by-30-allen-texas-business-wir-atri-20060807monthly0.5https://www.biopharmawatch.com/news/ATRI/atrion-reports-first-quarter-results-diluted-eps-declines-by-12-allen-texas-business-wire-atri-20060508monthly0.5https://www.biopharmawatch.com/news/ATRI/atrion-reports-fourth-quarter-and-full-year-2005-results-diluted-eps-were-up-12-for-the-qu-atri-20060215monthly0.5https://www.biopharmawatch.com/news/ATRI/atrion-reports-third-quarter-results-diluted-eps-increased-by-21-allen-texas-business-wire-atri-20051027monthly0.5https://www.biopharmawatch.com/news/ATRI/atrion-reports-second-quarter-results-diluted-eps-increases-by-36-allen-texas-business-wir-atri-20050729monthly0.5https://www.biopharmawatch.com/news/ATRI/atrion-reports-first-quarter-results-allen-texas-business-wire-atri-20050429monthly0.5https://www.biopharmawatch.com/news/ATRI/atrion-corporation-reports-fourth-quarter-and-full-year-2004-results-diluted-eps-were-up-4-atri-20050228monthly0.5https://www.biopharmawatch.com/news/ATRI/atrion-reports-third-quarter-results-diluted-eps-increased-by-30-allen-texas-business-wire-atri-20041028monthly0.5https://www.biopharmawatch.com/news/CALT/calliditas-therapeutics-takes-certain-corporate-actions-following-announcement-by-asahi-ka-calt-20240903monthly0.5https://www.biopharmawatch.com/news/CALT/interim-report-january-june-2024-april-june-2024-compared-to-april-june-2023-net-sales-amo-calt-20240813monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20240731monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20240726monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-17-june-2024-bulletin-from-the-annual-general-meeting-of-calliditas-thera-calt-20240617monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20240530monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20240528monthly0.5https://www.biopharmawatch.com/news/CALT/interim-report-january-x2013-march-2024-q1-calliditas-therapeutics-interim-report-2024-jan-calt-20240523monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-15-may-2024-notice-of-annual-general-meeting-of-calliditas-therapeutics-ab-publ--calt-20240516monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20240506monthly0.5https://www.biopharmawatch.com/news/CALT/annual-report-2023-02calliditas-therapeutics-annual-report-2023-about-calliditas-03-2023-i-calt-20240425monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20240306monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20240221monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20240107monthly0.5https://www.biopharmawatch.com/news/CALT/calliditas-refinances-existing-term-loan-with-calt-20231227monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20231220monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20231211monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20231130monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20231124monthly0.5https://www.biopharmawatch.com/news/CALT/interim-report-january-x2013-september-2023-q3-2-calliditas-therapeutics-interim-report-q3-calt-20231107monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20231023monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20231005monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20230927monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20230818monthly0.5https://www.biopharmawatch.com/news/CALT/x200b-x200b-x200b-x200b-interim-report-january-1-x2013-june-30-2023-filing-for-full-approv-calt-20230817monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20230713monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20230621monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-30-may-2023-bulletin-from-the-annual-general-meeting-of-calliditas-therap-calt-20230530monthly0.5https://www.biopharmawatch.com/news/CALT/significant-events-in-q1-2023-in-summary-in-february-2023-calliditas-announced-that-the-me-calt-20230516monthly0.5https://www.biopharmawatch.com/news/CALT/annual-report-2022-contents-the-annual-report-of-calliditas-therapeutics-ab-publ-556659-97-calt-20230428monthly0.5https://www.biopharmawatch.com/news/CALT/nef-301-summary-of-full-phase-3-trial-results-calt-20230313monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20230312monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20230223monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20230202monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20230131monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20221230monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20221213monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20221115monthly0.5https://www.biopharmawatch.com/news/CALT/q3-2022-interim-report-january-1st-september-30th-2022-in-summary-nephropathy-igan-in-adul-calt-20221114monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20221021monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20220920monthly0.5https://www.biopharmawatch.com/news/CALT/x200b-x200b-x200b-x200b-interim-report-january-1-st-x2013-june-30-th-2022-european-approva-calt-20220819monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20220729monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20220715monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20220711monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20220630monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20220620monthly0.5https://www.biopharmawatch.com/news/CALT/x200b-x200b-x200b-x200b-interim-report-january-1-st-x2013-march-31-st-2022-start-of-tarpey-calt-20220520monthly0.5https://www.biopharmawatch.com/news/CALT/annual-report-2021-calliditas-therapeutics-is-a-commercial-stage-biopharma-company-based-i-calt-20220429monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-14-april-2022-notice-of-annual-general-meeting-of-calliditas-therapeutics-ab-pub-calt-20220414monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20220322monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20220318monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20220314monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20220224monthly0.5https://www.biopharmawatch.com/news/CALT/fda-grants-calliditas-therapeutics-accelerated-approval-of-tarpeyo-budesonide-to-reduce-pr-calt-20211215monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20211102monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-calt-20210916monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-calt-20210914monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-calt-20210831monthly0.5https://www.biopharmawatch.com/news/CALT/x200b-x200b-x200b-x200b-calliditas-therapeutics-ab-publ-interim-report-january-1-x2013-calt-20210820monthly0.5https://www.biopharmawatch.com/news/CALT/not-for-release-publication-or-distribution-in-whole-or-in-part-directly-or-indirectly-in--calt-20210812monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20210809monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20210721monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20210715monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20210528monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20210518monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20210428monthly0.5https://www.biopharmawatch.com/news/CALT/annual-report-2020-contents-the-annual-report-of-calliditas-therapeutics-ab-publ-556659-97-calt-20210427monthly0.5https://www.biopharmawatch.com/news/CALT/notice-of-annual-general-meeting-of-calliditas-calt-20210426monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20210423monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20210315monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20210218monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20210128monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20210121monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20210118monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20201216monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20201127monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20201112monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20201108monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20201103monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20201001monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20200908monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20200825monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20200813monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20200731monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20200724monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-calt-20200702monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20200630monthly0.5https://www.biopharmawatch.com/news/CALT/stockholm-sweden-calt-20200625monthly0.5https://www.biopharmawatch.com/news/ATXS/astria-therapeutics-reports-third-quarter-2025-financial-results-and-provides-a-corporate--atxs-20251112monthly0.5https://www.biopharmawatch.com/news/ATXS/voting-and-support-agreement-among-biocryst-pharmaceuticals-inc-and-certain-stockholders-o-atxs-20251014monthly0.5https://www.biopharmawatch.com/news/ATXS/astria-therapeutics-enters-into-licensing-agreement-with-kaken-pharmaceutical-to-develop-a-atxs-20250806monthly0.5https://www.biopharmawatch.com/news/ATXS/astria-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provid-atxs-20250311monthly0.5https://www.biopharmawatch.com/news/ATXS/astria-therapeutics-announces-design-of-alpha-orbit-pivotal-phase-3-trial-of-navenibart-in-atxs-20250113monthly0.5https://www.biopharmawatch.com/news/ATXS/astria-therapeutics-inc-2022-inducement-stock-incentive-plan-1-purpose-the-purpose-of-this-atxs-20241219monthly0.5https://www.biopharmawatch.com/news/ATXS/astria-therapeutics-announces-pricing-of-125-million-underwritten-offering-atxs-20240130monthly0.5https://www.biopharmawatch.com/news/ATXS/astria-therapeutics-inc-2022-inducement-stock-incentive-plan-1-purpose-the-purpose-of-this-atxs-20231220monthly0.5https://www.biopharmawatch.com/news/ATXS/astria-therapeutics-reports-third-quarter-financial-results-and-provides-a-corporate-updat-atxs-20231113monthly0.5https://www.biopharmawatch.com/news/ATXS/astria-therapeutics-announces-pricing-of-64-million-underwritten-offering-atxs-20231011monthly0.5https://www.biopharmawatch.com/news/ATXS/astria-therapeutics-announces-exclusive-worldwide-license-agreement-with-ichnos-sciences-f-atxs-20231012monthly0.5https://www.biopharmawatch.com/news/ATXS/astria-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-provid-atxs-20230322monthly0.5https://www.biopharmawatch.com/news/ATXS/astria-therapeutics-inc-2022-inducement-stock-incentive-plan-1-purpose-the-purpose-of-this-atxs-20230202monthly0.5https://www.biopharmawatch.com/news/ATXS/corporate-presentation-january-2023-1-confidential-forward-looking-statements-this-present-atxs-20230105monthly0.5https://www.biopharmawatch.com/news/ATXS/astria-therapeutics-announces-pricing-of-100-million-underwritten-offering-of-common-stock-atxs-20221215monthly0.5https://www.biopharmawatch.com/news/ATXS/astria-therapeutics-announces-positive-preliminary-results-from-the-phase-1a-clinical-tria-atxs-20221215monthly0.5https://www.biopharmawatch.com/news/ATXS/astria-therapeutics-inc-2022-inducement-stock-incentive-plan-1-purpose-the-purpose-of-this-atxs-20220222monthly0.5https://www.biopharmawatch.com/news/ATXS/astria-therapeutics-inc-amended-and-restated-2015-stock-incentive-plan-1-purpose-the-purpo-atxs-20211215monthly0.5https://www.biopharmawatch.com/news/ATXS/astria-therapeutics-reports-third-quarter-2021-financial-results-and-provides-a-corporate--atxs-20211110monthly0.5https://www.biopharmawatch.com/news/ATXS/corporate-presentation-september-2021-1-confidential-forward-looking-statements-this-prese-atxs-20210908monthly0.5https://www.biopharmawatch.com/news/ATXS/catabasis-pharmaceuticals-inc-amended-and-restated-2015-stock-incentive-plan-1-1-purpose-t-atxs-20210602monthly0.5https://www.biopharmawatch.com/news/ATXS/catabasis-pharmaceuticals-announces-acquisition-of-quellis-biosciences-inc-acquisition-inc-atxs-20210201monthly0.5https://www.biopharmawatch.com/news/ATXS/catabasis-pharmaceuticals-announces-top-line-results-for-the-phase-3-polarisdmd-trial-of-e-atxs-20201026monthly0.5https://www.biopharmawatch.com/news/ATXS/catabasis-pharmaceuticals-inc-amended-and-restated-2015-stock-incentive-plan-1-purpose-the-atxs-20200612monthly0.5https://www.biopharmawatch.com/news/ATXS/catabasis-pharmaceuticals-announces-pricing-of-23-million-underwritten-public-offering-atxs-20200130monthly0.5https://www.biopharmawatch.com/news/ATXS/october-2019-our-mission-is-to-bring-hope-and-life-changing-therapies-to-patients-and-fami-atxs-20191016monthly0.5https://www.biopharmawatch.com/news/ATXS/catabasis-pharmaceuticals-announces-pricing-of-20-million-underwritten-public-offering-atxs-20190206monthly0.5https://www.biopharmawatch.com/news/ATXS/execution-copy-sublease-agreement-by-and-between-catabasis-pharmaceuticals-inc-a-delaware--atxs-20181016monthly0.5https://www.biopharmawatch.com/news/ATXS/catabasis-pharmaceuticals-announces-pricing-of-42-million-underwritten-public-offering-atxs-20180620monthly0.5https://www.biopharmawatch.com/news/ATXS/catabasis-pharmaceuticals-aligns-resources-to-focus-on-lead-program-edasalonexent-for-the--atxs-20180417monthly0.5https://www.biopharmawatch.com/news/ATXS/catabasis-pharmaceuticals-reports-edasalonexent-preserved-muscle-function-and-substantiall-atxs-20180213monthly0.5https://www.biopharmawatch.com/news/ATXS/catabasis-pharmaceuticals-corporate-update-atxs-20171208monthly0.5https://www.biopharmawatch.com/news/ATXS/catabasis-pharmaceuticals-reports-positive-results-from-open-label-extension-of-phase-2-mo-atxs-20171004monthly0.5https://www.biopharmawatch.com/news/ATXS/catabasis-pharmaceuticals-corporate-update-atxs-20170619monthly0.5https://www.biopharmawatch.com/news/ATXS/third-amendment-of-lease-this-third-amendment-of-lease-this-amendment-is-made-as-of-this-3-atxs-20161107monthly0.5https://www.biopharmawatch.com/news/ATXS/catabasis-pharmaceuticals-completes-target-enrollment-for-part-b-of-the-movedmd-trial-a-ph-atxs-20161004monthly0.5https://www.biopharmawatch.com/news/ATXS/catabasis-pharmaceuticals-announces-pricing-of-10-million-offering-of-common-stock-cambrid-atxs-20160923monthly0.5https://www.biopharmawatch.com/news/ATXS/catabasis-pharmaceuticals-inc-severance-benefits-plan-1-establishment-of-plan-catabasis-ph-atxs-20160415monthly0.5https://www.biopharmawatch.com/news/ATXS/catabasis-pharmaceuticals-announces-resignation-of-chief-financial-officer-cambridge-ma-atxs-20160401monthly0.5https://www.biopharmawatch.com/news/ATXS/catabasis-pharmaceuticals-reports-fourth-quarter-and-full-year-2015-financial-results-and--atxs-20160302monthly0.5https://www.biopharmawatch.com/news/ATXS/final-catabasis-pharmaceuticals-reports-third-quarter-2015-financial-results-and-recent-co-atxs-20151112monthly0.5https://www.biopharmawatch.com/news/ITOS/advancing-science-designing-hope-jpm-hc-conference-january-2025-forward-looking-statements-itos-20250113monthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-announces-clinically-meaningful-objective-response-rate-observed-at-every-dose-in-fo-itos-20240916monthly0.5https://www.biopharmawatch.com/news/ITOS/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-itos-20240510monthly0.5https://www.biopharmawatch.com/news/ITOS/cancer-immunotherapies-by-design-nasdaq-itos-january-2024-forward-looking-statements-this--itos-20240110monthly0.5https://www.biopharmawatch.com/news/ITOS/better-immunotherapies-to-improve-the-lives-of-people-with-cancer-nasdaq-itos-january-2023-itos-20230109monthly0.5https://www.biopharmawatch.com/news/ITOS/targeted-immunotherapies-to-improve-the-lives-of-people-with-cancer-january-2022-nasdaq-it-itos-20220111monthly0.5https://www.biopharmawatch.com/news/ITOS/pioneering-novel-io-therapies-focused-on-key-mechanisms-of-immunosuppression-january-2021--itos-20210111monthly0.5https://www.biopharmawatch.com/news/GLPG/certain-confidential-portions-of-this-exhibit-have-been-omitted-and-replaced-with-such-ide-glpg-20250212monthly0.5https://www.biopharmawatch.com/news/GLPG/exhibit-ex99-1-galapagos-reports-half-year-2024-financial-results-and-provides-second-quar-glpg-20240801monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-publishes-2022-annual-report-and-announces-annual-shareholders-meeting-publicati-glpg-20230327monthly0.5https://www.biopharmawatch.com/news/GLPG/j-p-morgan-healthcare-conference-glpg-20230109monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-announces-strategy-to-accelerate-innovation-and-reports-strong-third-quarter-202-glpg-20221107monthly0.5https://www.biopharmawatch.com/news/GLPG/first-key-steps-in-pipeline-rebuild-and-strong-commercial-progress-in-h1-2022-first-half-y-glpg-20220808monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-commercial-and-operational-progress-at-q3-financial-results-first-nine-m-glpg-20211108monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-refocuses-pipeline-and-rightsizes-operations-first-three-months-2021-financial-r-glpg-20210511monthly0.5https://www.biopharmawatch.com/news/GLPG/publication-of-the-annual-report-and-invitation-to-the-ordinary-shareholders-meeting-meche-glpg-20210325monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-q3-2020-results-first-nine-months-2020-financial-results-group-revenues--glpg-20201109monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-solid-h1-2020-progress-first-half-year-2020-financial-results-o-group-re-glpg-20200806monthly0.5https://www.biopharmawatch.com/news/GLPG/on-track-for-clinical-read-outs-and-commercial-readiness-in-2020-first-three-month-2020-fi-glpg-20200511monthly0.5https://www.biopharmawatch.com/news/GLPG/publication-of-the-annual-report-and-invitation-to-the-ordinary-and-extraordinary-sharehol-glpg-20200327monthly0.5https://www.biopharmawatch.com/news/GLPG/solid-third-quarter-2019-performance-with-strong-balance-sheet-for-continued-r-d-growth-fi-glpg-20191025monthly0.5https://www.biopharmawatch.com/news/GLPG/invitation-to-the-special-and-extraordinary-shareholders-meetings-mechelen-belgium-20-sept-glpg-20190920monthly0.5https://www.biopharmawatch.com/news/GLPG/gilead-and-galapagos-complete-closing-of-their-transformative-research-and-development-col-glpg-20190823monthly0.5https://www.biopharmawatch.com/news/GLPG/strong-clinical-progress-in-h1-and-transformative-collaboration-with-gilead-announced-xb7--glpg-20190725monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-on-historic-first-quarter-2019-key-q1-2019-results-group-revenues-of-40--glpg-20190426monthly0.5https://www.biopharmawatch.com/news/GLPG/publication-of-the-annual-report-and-invitation-to-the-annual-shareholders-meeting-nominat-glpg-20190401monthly0.5https://www.biopharmawatch.com/news/GLPG/hallmark-third-quarter-2018-and-annual-r-d-update-at-galapagos-first-nine-months-financial-glpg-20181026monthly0.5https://www.biopharmawatch.com/news/GLPG/productive-first-half-year-at-galapagos-xb7-first-half-year-financial-results-o-group-reve-glpg-20180802monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-first-quarter-2018-results-key-q1-2018-results-group-revenues-of-44-8-mi-glpg-20180427monthly0.5https://www.biopharmawatch.com/news/GLPG/publication-of-the-annual-report-and-invitation-to-the-annual-shareholders-meeting-mechele-glpg-20180323monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-q3-clinical-success-with-glpg1690-and-mor106-highlights-strength-of-deep-pipelin-glpg-20171030monthly0.5https://www.biopharmawatch.com/news/GLPG/solid-financials-support-r-d-progress-first-half-year-financial-results-revenues-73-0-m-an-glpg-20170731monthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-first-quarter-2017-results-key-q1-2017-results-group-revenues-more-than--glpg-20170428monthly0.5https://www.biopharmawatch.com/news/GLPG/march-2017-22-00-cet-publication-of-the-annual-report-and-invitation-to-the-annual-and-ext-glpg-20170323monthly0.5https://www.biopharmawatch.com/news/GLPG/robust-progress-in-q3-2016-glpg-20161109monthly0.5https://www.biopharmawatch.com/news/GLPG/regulated-information-28-july-2016-22-00-cet-focus-on-filgotinib-and-cystic-fibrosis-first-glpg-20160801monthly0.5https://www.biopharmawatch.com/news/GLPG/regulated-information-23-june-2016-7-30-cet-invitation-to-the-special-and-extraordinary-sh-glpg-20160629monthly0.5https://www.biopharmawatch.com/news/GLPG/regulated-information-19-january-2016-22-40-cet-galapagos-and-gilead-complete-closing-of-t-glpg-20160119monthly0.5https://www.biopharmawatch.com/news/GLPG/jfif-exif-mm-b-j-1-r-2-i-adobe-photoshop-cs2-windows-2015-11-12-16-56-17-glpg-20151113monthly0.5https://www.biopharmawatch.com/news/GLPG/regulated-information-25-september-2015-16-45-cet-galapagos-to-advance-filgotinib-to-phase-glpg-20150928monthly0.5https://www.biopharmawatch.com/news/GLPG/regulated-information-10-august-2015-22-00-cet-darwin-2-24-week-monotherapy-data-in-ra-con-glpg-20150812monthly0.5https://www.biopharmawatch.com/news/GLPG/regulated-information-5-august-2015-22-00-cet-galapagos-on-track-to-deliver-on-pipeline-in-glpg-20150806monthly0.5https://www.biopharmawatch.com/news/GLPG/regulated-information-29-july-2015-galapagos-selective-jak1-inhibitor-filgotinib-meets-key-glpg-20150731monthly0.5https://www.biopharmawatch.com/news/GLPG/regulated-information-19-june-2015-galapagos-raises-4-4-million-through-warrant-exercises--glpg-20150624monthly0.5https://www.biopharmawatch.com/news/GLPG/regulated-information-18-june-2015-galapagos-completes-recruitment-for-origin-phase-2-tria-glpg-20150619monthly0.5https://www.biopharmawatch.com/news/GLPG/regulated-information-15-june-2015-abbvie-and-galapagos-present-cystic-fibrosis-corrector--glpg-20150616monthly0.5https://www.biopharmawatch.com/news/GLPG/regulated-information-10-june-2015-galapagos-darwin-1-and-2-studies-have-completed-24-week-glpg-20150611monthly0.5https://www.biopharmawatch.com/news/GLPG/regulated-information-26-may-2015-galapagos-receives-transparency-notifications-mechelen-b-glpg-20150514monthly0.5https://www.biopharmawatch.com/news/GLPG/regulated-information-18-may-2015-galapagos-announces-full-exercise-of-underwriters-option-glpg-20150514monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-voting-results-of-extraordinary-general-meeting-t-uuml-bingen-germany-bo-cvac-20251125monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-for-the-third-quarter-and-first-nine-months-of-2025-an-cvac-20251124monthly0.5https://www.biopharmawatch.com/news/CVAC/convening-notice-this-is-the-convening-notice-for-the-extraordinary-general-meeting-of-cur-cvac-20251027monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-n-v-unaudited-interim-condensed-consolidated-financial-statements-as-of-cvac-20250815monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-resolution-of-patent-litigation-with-pfizer-biontech-t-uuml-bingen-germa-cvac-20250808monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-n-v-t-bingen-germany-annual-general-meeting-of-shareholders-cvac-20250624monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-voting-results-of-general-meeting-t-uuml-bingen-germany-boston-usa-cvac-20250624monthly0.5https://www.biopharmawatch.com/news/CVAC/execution-version-purchase-agreement-dated-as-of-cvac-20250612monthly0.5https://www.biopharmawatch.com/news/CVAC/biontech-announces-strategic-transaction-to-acquire-curevac-in-public-exchange-offer-acqui-cvac-20250611monthly0.5https://www.biopharmawatch.com/news/CVAC/convening-notice-this-is-the-convening-notice-for-the-annual-general-meeting-of-curevac-n--cvac-20250523monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-for-the-first-quarter-of-2025-and-provides-business-up-cvac-20250520monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-n-v-unaudited-interim-condensed-consolidated-financial-statements-as-of-cvac-20250520monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-receives-additional-positive-validity-decision-from-european-patent-office-in-ongo-cvac-20250515monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-for-the-cvac-20250410monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-receives-u-s-fda-ind-clearance-to-initiate-phase-1-clinical-trial-for-novel-mrna-b-cvac-20250407monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-receives-positive-validity-decision-from-european-patent-office-in-litigation-agai-cvac-20250327monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-for-the-third-quarter-and-first-nine-months-of-2024-an-cvac-20241112monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-n-v-unaudited-interim-condensed-consolidated-financial-statements-as-of-cvac-20241112monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-strengthens-leadership-team-with-appointment-of-seasoned-industry-executive-axel-s-cvac-20241104monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-to-present-at-the-12th-international-mrna-health-conference-t-uuml-bingen-germany--cvac-20241104monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-s-cvgbm-cancer-vaccine-induces-promising-immune-responses-in-phase-1-study-in-glio-cvac-20240913monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-partner-gsk-announces-positive-phase-2-data-from-seasonal-influenza-mrna-vaccine-p-cvac-20240912monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-to-present-first-cvgbm-glioblastoma-cancer-vaccine-clinical-data-at-esmo-2024-cong-cvac-20240909monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-for-the-second-quarter-and-first-half-of-2024-and-prov-cvac-20240815monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-n-v-unaudited-interim-condensed-consolidated-financial-statements-as-of-cvac-20240815monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-advances-cancer-vaccine-candidate-cvgbm-to-part-b-of-phase-1-study-in-patients-wit-cvac-20240815monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-names-oncologist-and-drug-development-expert-dr-mehdi-shahidi-to-supervisory-board-cvac-20240815monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-provides-update-on-trial-dates-for-patent-litigation-across-multiple-geographies-a-cvac-20240711monthly0.5https://www.biopharmawatch.com/news/CVAC/gsk-and-curevac-to-restructure-collaboration-into-new-licensing-agreement-gsk-acquires-ful-cvac-20240703monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-n-v-t-bingen-germany-general-meeting-of-shareholders-cvac-20240624monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-voting-results-of-general-meeting-t-uuml-bingen-germany-boston-usa-cvac-20240624monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-dosing-of-first-participant-in-a-phase-2-study-in-seasonal-influenza-dev-cvac-20240528monthly0.5https://www.biopharmawatch.com/news/CVAC/convening-notice-this-is-the-convening-notice-for-the-annual-general-meeting-of-curevac-n--cvac-20240524monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-for-the-first-quarter-of-2024-and-provides-business-up-cvac-20240523monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-n-v-unaudited-interim-condensed-consolidated-financial-statements-as-of-cvac-20240523monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-for-the-fourth-quarter-and-full-year-2023-and-provides-cvac-20240424monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-start-of-combined-phase-1-2-study-in-avian-influenza-h5n1-development-in-cvac-20240424monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-appoints-thaminda-ramanayake-as-new-chief-business-officer-mr-ramanayake-brings-mo-cvac-20240424monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-and-md-anderson-enter-strategic-collaboration-to-develop-novel-cancer-vaccines-agr-cvac-20240416monthly0.5https://www.biopharmawatch.com/news/CVAC/exhbiit-99-1-curevac-announces-promising-phase-2-interim-data-from-seasonal-influenza-vacc-cvac-20240404monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-ceo-alexander-zehnder-acquires-common-shares-of-company-stock-t-uuml-bingen-german-cvac-20240117monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-positive-phase-2-interim-data-from-covid-19-vaccine-development-program--cvac-20240105monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-decision-of-german-federal-patent-court-in-broad-patent-litigation-with--cvac-20231219monthly0.5https://www.biopharmawatch.com/news/CVAC/x200b-x200b-x200b-x200b-x200b-curevac-n-v-unaudited-interim-condensed-consolidated-financi-cvac-20231114monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-for-the-third-quarter-and-first-nine-months-of-2023-an-cvac-20231114monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-solid-progress-in-phase-2-covid-19-and-seasonal-flu-clinical-development-cvac-20231101monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-reports-progress-in-intellectual-property-infringement-case-against-biontech-in-ge-cvac-20230928monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-advances-seasonal-flu-study-to-phase-2-in-collaboration-with-gsk-following-selecti-cvac-20230912monthly0.5https://www.biopharmawatch.com/news/CVAC/x200b-x200b-x200b-curevac-n-v-unaudited-interim-condensed-consolidated-financial-statement-cvac-20230817monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-for-the-second-quarter-and-first-half-of-2023-and-prov-cvac-20230817monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-dosing-of-first-participant-in-phase-2-study-of-modified-covid-19-mrna-v-cvac-20230801monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-update-to-the-management-team-t-uuml-bingen-germany-boston-usa-cvac-20230714monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-strengthens-ongoing-patent-litigations-bringing-additional-cases-under-new-intelle-cvac-20230713monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-n-v-t-bingen-germany-general-meeting-of-shareholders-cvac-20230619monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-appoints-international-financial-expert-michael-brosnan-to-supervisory-board-t-uum-cvac-20230620monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-doses-first-patient-in-phase-1-study-of-cancer-vaccine-candidate-for-surgically-re-cvac-20230620monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-voting-results-of-general-meeting-t-uuml-bingen-germany-boston-usa-cvac-20230619monthly0.5https://www.biopharmawatch.com/news/CVAC/convening-notice-this-is-the-convening-notice-for-the-annual-general-meeting-of-shareholde-cvac-20230530monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-for-the-first-quarter-of-2023-and-provides-business-up-cvac-20230530monthly0.5https://www.biopharmawatch.com/news/CVAC/x200b-x200b-curevac-n-v-unaudited-interim-condensed-consolidated-financial-statements-as-o-cvac-20230530monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-developments-in-patent-litigation-with-pfizer-biontech-motion-to-transfe-cvac-20230519monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-for-the-fourth-quarter-and-full-year-2022-and-provides-cvac-20230425monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-n-v-t-bingen-germany-extraordinary-general-meeting-of-shareholders-cvac-20230328monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-voting-results-of-extraordinary-general-meeting-t-uuml-bingen-germany-bo-cvac-20230328monthly0.5https://www.biopharmawatch.com/news/CVAC/convening-notice-this-is-the-convening-notice-for-the-extraordinary-general-meeting-of-sha-cvac-20230227monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-closing-of-250-million-follow-on-public-offering-of-common-shares-t-uuml-cvac-20230210monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-pricing-of-upsized-public-offering-of-common-shares-t-uuml-bingen-german-cvac-20230207monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-proposed-public-offering-of-common-shares-t-uuml-bingen-germany-boston-u-cvac-20230206monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-welcomes-myriam-mendila-as-new-chief-development-officer-dr-mendila-joins-curevac--cvac-20230201monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-named-as-one-of-the-world-s-most-dynamic-innovators-by-lexisnexis-curevac-recogniz-cvac-20230131monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-positive-data-in-older-adults-from-covid-19-and-flu-mrna-vaccine-develop-cvac-20230130monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-appoints-alexander-zehnder-as-ceo-from-cvac-20230109monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-positive-data-on-joint-covid-19-and-flu-mrna-vaccine-development-program-cvac-20230106monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-members-of-management-sell-shares-to-cover-tax-obligations-from-long-term-incentiv-cvac-20221214monthly0.5https://www.biopharmawatch.com/news/CVAC/x200b-x200b-curevac-n-v-unaudited-interim-condensed-consolidated-financial-statements-as-o-cvac-20221117monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-for-the-third-quarter-and-first-nine-months-of-2022-an-cvac-20221117monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-presents-preliminary-data-from-phase-1-study-expansion-of-oncology-candidate-cv810-cvac-20221111monthly0.5https://www.biopharmawatch.com/news/CVAC/k-curevac-n-v-2022-06-30-12-31-2022-q2-0001809122-false-0-0-0-0-0-0-0-0-0-0-0-0-0-12-98000-cvac-20220818monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-starts-phase-1-clinical-study-of-modified-omicron-targeting-covid-19-vaccine-candi-cvac-20220818monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-for-the-second-quarter-and-first-half-of-2022-and-prov-cvac-20220818monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-files-patent-infringement-lawsuit-in-germany-against-biontech-t-uuml-bingen-german-cvac-20220705monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-n-v-t-bingen-germany-annual-general-meeting-of-shareholders-cvac-20220622monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-voting-results-of-general-meeting-t-uuml-bingen-germany-boston-usa-cvac-20220622monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-accelerates-oncology-strategy-with-acquisition-of-frame-cancer-therapeutics-adding-cvac-20220608monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-changes-of-cdo-myriam-mendila-to-succeed-klaus-edvardsen-myriam-mendila--cvac-20220608monthly0.5https://www.biopharmawatch.com/news/CVAC/convening-notice-this-is-the-convening-notice-for-the-annual-general-meeting-of-shareholde-cvac-20220601monthly0.5https://www.biopharmawatch.com/news/CVAC/x200b-x200b-curevac-n-v-unaudited-interim-condensed-consolidated-financial-statements-as-o-cvac-20220525monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-for-the-first-quarter-of-2022-and-provides-business-up-cvac-20220525monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-partners-with-myneo-to-identify-novel-antigen-targets-for-mrna-based-cancer-vaccin-cvac-20220525monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-for-the-fourth-quarter-and-full-year-2021-and-provides-cvac-20220428monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-and-gsk-s-bivalent-second-generation-mrna-vaccine-candidate-shown-to-be-highly-eff-cvac-20220421monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-and-gsk-enter-into-pandemic-preparedness-contract-with-german-government-german-go-cvac-20220411monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-and-gsk-start-clinical-development-of-second-generation-covid-19-vaccine-candidate-cvac-20220330monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-establishes-fully-owned-company-dedicated-to-advancing-the-rna-printer-the-rna-pri-cvac-20220301monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-doses-first-participant-in-phase-1-study-with-multivalent-influenza-vaccine-candid-cvac-20220210monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-chief-technology-officer-to-pursue-new-career-outside-biotech-industry-t-uuml-bing-cvac-20220117monthly0.5https://www.biopharmawatch.com/news/CVAC/non-binding-convenience-translation-from-german-into-english-execution-version-2-nd-supple-cvac-20220113monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-n-v-unaudited-interim-condensed-consolidated-balance-sheet-and-income-statement-as-cvac-20220103monthly0.5https://www.biopharmawatch.com/news/CVAC/k-curevac-n-v-2021-09-30-12-31-2021-q3-0001809122-false-0-0-0-0-0-0-0-0-0-0-0-0-0-12-x200b-cvac-20211217monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-for-the-third-quarter-and-first-nine-months-of-2021-an-cvac-20211118monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-publishes-in-nature-preclinical-data-of-second-generation-covid-19-candidate-cv2co-cvac-20211118monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-presents-promising-data-at-sitc-from-phase-1-study-of-oncology-candidate-cv8102-sh-cvac-20211110monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-to-shift-focus-of-covid-19-vaccine-development-to-second-generation-mrna-technolog-cvac-20211012monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-streamlines-european-network-for-mrna-product-manufacturing-curevac-right-sizes-ma-cvac-20210914monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-s-cvncov-phase-2b-3-study-data-published-in-preprints-with-the-lancet-t-uuml-binge-cvac-20210831monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-preclinical-data-demonstrates-significant-reduction-of-liver-fibrosis-with-mrna-th-cvac-20210830monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-for-the-second-quarter-and-first-half-of-2021-and-prov-cvac-20210816monthly0.5https://www.biopharmawatch.com/news/CVAC/second-generation-mrna-covid-19-vaccine-candidate-cv2cov-demonstrates-improved-immune-resp-cvac-20210816monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-final-data-from-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cv-cvac-20210630monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-appointment-of-dr-malte-greune-as-chief-operating-officer-and-transition-cvac-20210630monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-n-v-t-bingen-germany-annual-general-meeting-of-shareholders-cvac-20210624monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-voting-results-of-general-meeting-t-uuml-bingen-germany-boston-usa-cvac-20210624monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-provides-supervisory-board-update-t-uuml-bingen-germany-boston-usa-cvac-20210623monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-provides-update-on-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvac-20210616monthly0.5https://www.biopharmawatch.com/news/CVAC/convening-notice-this-is-the-convening-notice-for-the-annual-general-meeting-of-shareholde-cvac-20210604monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-appoints-klaus-edvardsen-as-chief-development-officer-t-uuml-bingen-germany-boston-cvac-20210602monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-s-first-generation-covid-19-vaccine-candidate-cvncov-continues-toward-phase-2b-3-e-cvac-20210528monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-for-the-first-quarter-of-2021-and-business-updates-fir-cvac-20210526monthly0.5https://www.biopharmawatch.com/news/CVAC/second-generation-covid-19-vaccine-candidate-cv2cov-demonstrates-high-immunogenicity-again-cvac-20210513monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-swiss-ag-initiates-rolling-submission-process-for-mrna-based-covid-19-vaccine-cand-cvac-20210419monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-and-business-updates-for-the-fourth-quarter-and-full-y-cvac-20210415monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-s-covid-19-vaccine-candidate-cvncov-demonstrates-protection-against-sars-cov-2-b-1-cvac-20210323monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-expands-cvncov-covid-19-vaccine-candidate-clinical-trial-analyses-to-include-phase-cvac-20210322monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-and-novartis-sign-initial-agreement-on-manufacturing-of-covid-19-vaccine-candidate-cvac-20210304monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-initiates-rolling-submission-with-european-medicines-agency-for-covid-19-vaccine-c-cvac-20210212monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-and-uk-government-to-collaborate-on-development-of-vaccines-against-sars-cov-2-var-cvac-20210205monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-expands-lead-rna-cancer-program-phase-1-trial-in-advanced-melanoma-cv8102-recommen-cvac-20210204monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-full-exercise-of-underwriters-option-to-purchase-additional-common-share-cvac-20210204monthly0.5https://www.biopharmawatch.com/news/CVAC/for-media-and-investors-only-issued-february-3rd-2021-london-uk-t-bingen-germany-boston-us-cvac-20210203monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-closing-of-450-million-follow-on-public-offering-of-common-shares-t-uuml-cvac-20210202monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-and-rentschler-biopharma-ramp-up-for-joint-manufacturing-of-covid-19-vaccine-cvnco-cvac-20210201monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-pricing-of-450-million-follow-on-public-offering-of-common-shares-t-uuml-cvac-20210128monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-proposed-public-offering-of-common-shares-t-uuml-bingen-germany-boston-u-cvac-20210125monthly0.5https://www.biopharmawatch.com/news/CVAC/redacted-certain-identified-information-indicated-by-has-been-excluded-from-the-exhibit-be-cvac-20210119monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-s-covid-19-vaccine-candidate-cvncov-demonstrated-efficient-protection-of-non-human-cvac-20210111monthly0.5https://www.biopharmawatch.com/news/CVAC/bayer-ag-communications-51368-leverkusen-germany-tel-49-214-30-1-media-bayer-com-curevac-a-cvac-20210107monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-and-the-university-medical-center-mainz-start-phase-3-clinical-trial-for-covid-19--cvac-20201221monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-commences-global-pivotal-phase-2b-3-trial-for-covid-19-vaccine-candidate-cvncov-fi-cvac-20201214monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-and-fareva-sign-agreement-for-fill-finish-manufacturing-of-curevac-s-covid-19-vacc-cvac-20201209monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-appoints-antony-blanc-as-chief-business-officer-and-chief-commercial-officer-t-uum-cvac-20201204monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-announces-financial-results-and-business-updates-for-the-third-quarter-and-first-n-cvac-20201130monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-establishes-european-based-network-to-ramp-up-manufacturing-of-its-covid-19-vaccin-cvac-20201117monthly0.5https://www.biopharmawatch.com/news/CVAC/european-commission-announces-that-tomorrow-it-will-authorize-the-agreement-with-curevac-f-cvac-20201116monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-s-covid-19-vaccine-candidate-cvncov-suitable-for-standard-fridge-temperature-logis-cvac-20201112monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-publishes-detailed-interim-phase-1-data-of-its-covid-19-vaccine-candidate-cvncov-d-cvac-20201102monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-reports-positive-interim-phase-1-data-for-its-covid-19-vaccine-candidate-cvncov-ba-cvac-20201102monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-reports-positive-preclinical-data-for-its-covid-19-vaccine-candidate-cvncov-strong-cvac-20201023monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-initiates-phase-2a-clinical-trial-of-covid-19-vaccine-candidate-study-conducted-in-cvac-20200929monthly0.5https://www.biopharmawatch.com/news/CVAC/curevac-expected-to-receive-up-to-252-million-euros-from-the-german-federal-ministry-of-re-cvac-20200904monthly0.5https://www.biopharmawatch.com/news/RGLS/statements-contained-in-this-presentation-regarding-matters-that-are-not-historical-facts--rgls-20250327monthly0.5https://www.biopharmawatch.com/news/RGLS/appendix-a-regulus-therapeutics-inc-2019-equity-incentive-plan-adopted-by-the-board-of-dir-rgls-20240517monthly0.5https://www.biopharmawatch.com/news/RGLS/r-egulus-t-herapeutics-i-nc-2019-e-quity-i-ncentive-p-lan-a-dopted-by-the-b-oard-of-d-irec-rgls-20230614monthly0.5https://www.biopharmawatch.com/news/RGLS/execution-version-securities-purchase-agreement-this-securities-purchase-agreement-this-ag-rgls-20230413monthly0.5https://www.biopharmawatch.com/news/RGLS/r-egulus-t-herapeutics-i-nc-2022-e-mployee-s-tock-p-urchase-p-lan-a-dopted-by-the-b-oard-o-rgls-20220613monthly0.5https://www.biopharmawatch.com/news/RGLS/execution-version-securities-purchase-agreement-this-s-ecurities-p-urchase-a-greement-this-rgls-20211124monthly0.5https://www.biopharmawatch.com/news/RGLS/safe-harbor-statement-statements-contained-in-this-presentation-regarding-matters-that-are-rgls-20211018monthly0.5https://www.biopharmawatch.com/news/RGLS/safe-harbor-statement-statements-contained-in-this-presentation-regarding-matters-that-are-rgls-20210521monthly0.5https://www.biopharmawatch.com/news/RGLS/safe-harbor-statement-statements-contained-in-this-presentation-regarding-matters-that-are-rgls-20201201monthly0.5https://www.biopharmawatch.com/news/RGLS/r-egulus-t-herapeutics-i-nc-2019-e-quity-i-ncentive-p-lan-a-dopted-by-the-b-oard-of-d-irec-rgls-20190806monthly0.5https://www.biopharmawatch.com/news/RGLS/company-overview-we-are-a-clinical-stage-biopharmaceutical-company-focused-on-discovering--rgls-20170719monthly0.5https://www.biopharmawatch.com/news/RGLS/amended-and-restated-employment-agreement-this-a-mended-and-r-estated-e-mployment-a-greeme-rgls-20170524monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-third-quarter-2016-financial-results-conference-call-today-at-5-00-p-m-rgls-20161101monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-second-quarter-2015-financial-results-and-recent-highlights-advanced-clini-rgls-20150804monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-commencement-of-public-offering-of-common-stock-la-jolla-california-octo-rgls-20141029monthly0.5https://www.biopharmawatch.com/news/RGLS/amended-and-restated-employment-agreement-this-a-mended-and-r-estated-e-mployment-a-greeme-rgls-20140919monthly0.5https://www.biopharmawatch.com/news/RGLS/text-omitted-and-filed-separately-with-the-securities-and-exchange-commission-confidential-rgls-20130807monthly0.5https://www.biopharmawatch.com/news/RGLS/fifth-amendment-to-lease-this-fifth-amendment-to-lease-this-amendment-is-entered-into-as-o-rgls-20130626monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-provides-update-on-road-to-the-clinic-strategy-and-reports-first-quarter-2013-fina-rgls-20130514monthly0.5https://www.biopharmawatch.com/news/VACH/veraxa-biotech-strengthens-financial-position-with-27-5-million-vach-20260529monthly0.5https://www.biopharmawatch.com/news/VACH/biotech-shareholders-approve-merger-and-issuance-of-new-shares-to-voyager-acquisition-corp-vach-20260227monthly0.5https://www.biopharmawatch.com/news/VACH/u-n-l-o-c-k-i-n-g-n-e-x-t-g-e-n-e-r-a-t-i-o-n-t-h-e-r-a-p-i-e-s-t-o-t-r-e-a-t-c-a-n-c-e-r--vach-20250905monthly0.5https://www.biopharmawatch.com/news/VACH/voyager-acquisition-corp-vach-20250423monthly0.5https://www.biopharmawatch.com/news/VACH/voyager-acquisition-corp-index-to-financial-statement-page-balance-sheet-of-voyager-acquis-vach-20240812monthly0.5https://www.biopharmawatch.com/news/VACH/voyager-acquisition-corp-announces-pricing-of-220-000-000-initial-public-offering-vach-20240808monthly0.5https://www.biopharmawatch.com/news/AVDL/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-avdl-20260212monthly0.5https://www.biopharmawatch.com/news/AVDL/not-for-release-publication-or-distribution-in-whole-or-in-part-in-into-or-from-any-jurisd-avdl-20260112monthly0.5https://www.biopharmawatch.com/news/AVDL/alkermes-plc-announces-increased-offer-to-acquire-avadel-pharmaceuticals-plc-not-for-relea-avdl-20251119monthly0.5https://www.biopharmawatch.com/news/AVDL/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-the-market--avdl-20251117monthly0.5https://www.biopharmawatch.com/news/AVDL/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-the-market--avdl-20251114monthly0.5https://www.biopharmawatch.com/news/AVDL/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-avdl-20251022monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-announces-preliminary-2024-results-and-2025-commercial-priorities-to-accelerate-the-avdl-20241231monthly0.5https://www.biopharmawatch.com/news/AVDL/provides-corporate-update-and-reports-fourth-quarter-and-full-year-2022-financial-avdl-20230330monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-provides-corporate-update-pursuing-strategies-to-accelerate-final-a-avdl-20220629monthly0.5https://www.biopharmawatch.com/news/AVDL/positive-data-for-once-at-bedtime-ft218-for-narcolepsy-and-once-nightly-dosing-preference--avdl-20220311monthly0.5https://www.biopharmawatch.com/news/AVDL/january-2020-1-avadel-pharmaceuticals-plc-repositioned-executing-new-strategy-safe-harbor--avdl-20200110monthly0.5https://www.biopharmawatch.com/news/AVDL/piper-jaffray-healthcare-conference-december-2019-1-avadel-pharmaceuticals-plc-repositione-avdl-20191205monthly0.5https://www.biopharmawatch.com/news/AVDL/the-pharmacokinetics-of-once-nightly-controlled-release-sodium-oxybate-ft218-overview-of-r-avdl-20190925monthly0.5https://www.biopharmawatch.com/news/AVDL/the-power-of-medicine-reinvented-avadel-2019-all-rights-reserved-avadel-pharmaceuticals-pl-avdl-20190924monthly0.5https://www.biopharmawatch.com/news/AVDL/irish-statutory-accounts-table-of-contents-avadel-pharmaceuticals-plc-directors-report-and-avdl-20190613monthly0.5https://www.biopharmawatch.com/news/AVDL/irish-statutory-accounts-table-of-contents-avadel-pharmaceuticals-plc-directors-report-and-avdl-20180606monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-plc-unaudited-pro-forma-condensed-combined-financial-information-ov-avdl-20180216monthly0.5https://www.biopharmawatch.com/news/AVDL/to-this-current-report-on-form-8-k-while-avadel-may-be-engaged-in-various-other-claims-and-avdl-20180214monthly0.5https://www.biopharmawatch.com/news/AVDL/slide-presentation-avdl-20170907monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-enters-into-exclusive-license-agreement-for-noctiva-noctiva-is-the--avdl-20170905monthly0.5https://www.biopharmawatch.com/news/AVDL/noctiva-exclusive-license-agreement-avadel-pharmaceuticals-enters-into-exclusive-negotiati-avdl-20170817monthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-plc-initial-financial-statements-for-the-period-from-1-december-201-avdl-20170505monthly0.5https://www.biopharmawatch.com/news/AVDL/earnings-release-exhibit-avadel-pharmaceuticals-reports-fourth-quarter-and-full-year-2016--avdl-20170307monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-completes-cross-border-merger-and-becomes-avadel-pharmaceuticals-plc-d-avdl-20170104monthly0.5https://www.biopharmawatch.com/news/AVDL/exhibit-flamel-technologies-to-present-at-jefferies-2016-london-healthcare-conference-lyon-avdl-20161109monthly0.5https://www.biopharmawatch.com/news/AVDL/exhibit-flamel-technologies-reports-third-quarter-2016-results-total-revenues-were-32-1-mi-avdl-20161107monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-to-host-investor-analyst-meeting-lyon-france-september-19-20-16-flamel-avdl-20160920monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-hires-vice-president-of-sales-lyon-france-avdl-20160831monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-shareholder-approval-of-cross-border-merger-company-to-reinc-avdl-20160812monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-reports-second-quarter-2016-results-total-revenues-of-38-9-million-201-avdl-20160808monthly0.5https://www.biopharmawatch.com/news/AVDL/june-2016-1-june-2016-2-forward-looking-statements-this-presentation-may-include-forward-l-avdl-20160607monthly0.5https://www.biopharmawatch.com/news/AVDL/expert-report-cross-border-merger-of-ftsa-and-avadel-31-may-avdl-20160602monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-reports-first-quarter-2016-results-total-revenues-of-36-2-million-adju-avdl-20160509monthly0.5https://www.biopharmawatch.com/news/AVDL/may-2016-2-forward-looking-statements-this-presentation-may-include-forward-looking-statem-avdl-20160504monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-receives-fda-approval-of-akovaz-lyon-france-avdl-20160502monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-files-special-protocol-assessment-for-once-nightly-sodium-oxybate-lyon-avdl-20160331monthly0.5https://www.biopharmawatch.com/news/AVDL/notice-of-meeting-combined-shareholders-meeting-friday-avdl-20160322monthly0.5https://www.biopharmawatch.com/news/AVDL/march-2016-2-forward-looking-statements-this-document-includes-statements-concerning-our-o-avdl-20160314monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-reports-fourth-quarter-and-full-year-2015-results-full-year-product-re-avdl-20160310monthly0.5https://www.biopharmawatch.com/news/AVDL/february-2016-1-february-2016-2-forward-looking-statements-this-document-includes-statemen-avdl-20160223monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-to-present-at-rbc-capital-markets-2016-global-healthcare-conference-ly-avdl-20160211monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-acquires-fsc-diversifies-product-portfolio-and-brings-established-comm-avdl-20160208monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-provides-update-on-corporate-progress-clinical-programs-continue-to-mo-avdl-20160108monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-third-quarter-avdl-20141112monthly0.5https://www.biopharmawatch.com/news/AVDL/e-xhibit-99-1-flamel-technologies-announces-second-quarter-of-fiscal-year-2014-results-com-avdl-20140804monthly0.5https://www.biopharmawatch.com/news/AVDL/june-24-2014-at-11-00-a-m-avdl-20140604monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-first-quarter-of-fiscal-year-2014-results-company-recognized-avdl-20140512monthly0.5https://www.biopharmawatch.com/news/AVDL/technologies-announces-receipt-of-complete-response-letter-from-fda-avdl-20140506monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-fourth-quarter-and-full-year-2013-results-company-closes-sal-avdl-20140325monthly0.5https://www.biopharmawatch.com/news/AVDL/notice-agenda-dear-shareholders-we-are-pleased-to-invite-you-to-attend-the-extraordinary-g-avdl-20140131monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-third-quarter-2013-results-second-nda-from-eacute-clat-portf-avdl-20131031monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-second-quarter-2013-results-bloxiverz-product-launch-underwa-avdl-20130729monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-results-of-2013-annual-meeting-avdl-20130624monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-fda-approval-of-bloxiverz-lyon-france-avdl-20130603monthly0.5https://www.biopharmawatch.com/news/AVDL/translated-from-french-flamel-technologies-soci-t-anonyme-with-a-share-capital-of-euros-3--avdl-20130520monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-obtains-rights-to-two-molecules-of-trigger-lock-product-line-lyon-fran-avdl-20130523monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-first-quarter-2013-results-conference-call-with-management-t-avdl-20130507monthly0.5https://www.biopharmawatch.com/news/AVDL/judge-dismisses-2007-class-action-case-against-flamel-technologies-lyon-france-avdl-20130322monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-fourth-quarter-and-full-year-2012-results-conference-call-wi-avdl-20130228monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-15-million-debt-financing-to-advance-r-d-efforts-announces-a-avdl-20130207monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-third-quarter-2012-results-and-other-updates-conference-call-avdl-20121204monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-fda-acceptance-of-new-drug-application-lyon-france-avdl-20121018monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-second-quarter-2012-results-continued-development-of-interna-avdl-20120725monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-results-of-annual-meeting-and-election-of-stephen-h-willard--avdl-20120625monthly0.5https://www.biopharmawatch.com/news/AVDL/translated-from-french-flamel-technologies-soci-t-anonyme-with-a-share-capital-of-euros-3--avdl-20120522monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-first-quarter-2012-results-lyon-france-avdl-20120507monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-fourth-quarter-and-year-end-2011-results-flamel-to-acquire-e-avdl-20120314monthly0.5https://www.biopharmawatch.com/news/AVDL/unassociated-document-flamel-technologies-announces-profitable-third-quarter-results-recen-avdl-20111102monthly0.5https://www.biopharmawatch.com/news/AVDL/unassociated-document-flamel-technologies-announces-increase-in-cash-position-second-quart-avdl-20110725monthly0.5https://www.biopharmawatch.com/news/AVDL/unassociated-document-flamel-technologies-and-digna-biotech-announce-multiple-product-deve-avdl-20110627monthly0.5https://www.biopharmawatch.com/news/AVDL/unassociated-document-flamel-technologies-announces-results-of-annual-meeting-lyon-france-avdl-20110624monthly0.5https://www.biopharmawatch.com/news/AVDL/unassociated-document-flamel-technologies-announces-nomination-of-ambassador-craig-staplet-avdl-20110531monthly0.5https://www.biopharmawatch.com/news/AVDL/unassociated-document-flamel-technologies-announces-expanded-partnership-relations-first-q-avdl-20110509monthly0.5https://www.biopharmawatch.com/news/AVDL/unassociated-document-for-immediate-release-flamel-technologies-announces-filing-of-lawsui-avdl-20110504monthly0.5https://www.biopharmawatch.com/news/AVDL/unassociated-document-flamel-technologies-announces-micropump-license-agreement-3-million--avdl-20110428monthly0.5https://www.biopharmawatch.com/news/AVDL/unassociated-document-flamel-technologies-announces-fourth-quarter-and-year-end-2010-resul-avdl-20110303monthly0.5https://www.biopharmawatch.com/news/AVDL/unassociated-document-for-immediate-release-flamel-technologies-announces-third-quarter-re-avdl-20101104monthly0.5https://www.biopharmawatch.com/news/AVDL/unassociated-document-flamel-technologies-achieves-clinical-milestone-with-merck-serono-on-avdl-20101019monthly0.5https://www.biopharmawatch.com/news/AVDL/unassociated-document-flamel-technologies-announces-three-new-partnership-agreements-secon-avdl-20100728monthly0.5https://www.biopharmawatch.com/news/AVDL/unassociated-document-flamel-technologies-announces-results-of-annual-meeting-lyon-france-avdl-20100625monthly0.5https://www.biopharmawatch.com/news/AVDL/translated-from-french-flamel-technologies-soci-t-anonyme-with-a-share-capital-of-euros-2--avdl-20100527monthly0.5https://www.biopharmawatch.com/news/AVDL/unassociated-document-flamel-technologies-announces-expanded-partnership-relations-first-q-avdl-20100505monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-fourth-quarter-and-year-end-2009-results-fourth-quarter-high-avdl-20100308monthly0.5https://www.biopharmawatch.com/news/AVDL/unassociated-document-for-immediate-release-flamel-technologies-announces-the-initiation-o-avdl-20091218monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-third-quarter-2009-results-additional-new-projects-cash-incr-avdl-20091116monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-second-quarter-2009-results-multiple-new-projects-cash-incre-avdl-20090805monthly0.5https://www.biopharmawatch.com/news/AVDL/media-and-investor-contact-marie-kennedy-805-372-3543-charles-mosseri-marlio-401-480-9729--avdl-20090713monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-results-of-annual-meeting-lyon-france-avdl-20090624monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-new-feasibility-projects-technology-access-fee-avdl-20090622monthly0.5https://www.biopharmawatch.com/news/AVDL/translated-from-french-flamel-technologies-soci-t-anonyme-with-a-share-capital-of-euros-2--avdl-20090527monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-profitable-first-quarter-results-increased-cash-levels-avdl-20090511monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-to-receive-4-million-milestone-payment-from-glaxosmithkline-lyon-franc-avdl-20090320monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-fourth-quarter-and-year-end-2008-results-fourth-quarter-high-avdl-20090304monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-appointment-of-jeffery-s-vick-as-chief-business-officer-avdl-20090223monthly0.5https://www.biopharmawatch.com/news/AVDL/flamel-technologies-announces-merck-serono-s-exercise-of-option-to-license-medusa-technolo-avdl-20090217monthly0.5https://www.biopharmawatch.com/news/PRTC/may-2026-puretech-health-plc-puretech-founded-entity-seaport-therapeutics-announces-pricin-prtc-20260501monthly0.5https://www.biopharmawatch.com/news/PRTC/april-2026-puretech-health-plc-puretech-announces-annual-results-for-year-ended-prtc-20260429monthly0.5https://www.biopharmawatch.com/news/PRTC/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-the-uk-vers-prtc-20251218monthly0.5https://www.biopharmawatch.com/news/PRTC/december-2025-puretech-health-plc-results-of-annual-general-meeting-on-prtc-20251210monthly0.5https://www.biopharmawatch.com/news/PRTC/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-the-uk-vers-prtc-20250716monthly0.5https://www.biopharmawatch.com/news/PRTC/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-the-uk-vers-prtc-20250708monthly0.5https://www.biopharmawatch.com/news/PRTC/june-2025-puretech-health-plc-results-of-annual-general-meeting-the-annual-general-meeting-prtc-20250616monthly0.5https://www.biopharmawatch.com/news/PRTC/april-2025-puretech-health-plc-puretech-announces-annual-results-for-year-ended-prtc-20250430monthly0.5https://www.biopharmawatch.com/news/PRTC/not-for-release-publication-or-distribution-in-whole-or-in-part-in-into-or-from-any-jurisd-prtc-20250407monthly0.5https://www.biopharmawatch.com/news/PRTC/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-the-uk-vers-prtc-20241216monthly0.5https://www.biopharmawatch.com/news/PRTC/october-2024-puretech-health-plc-puretech-founded-entity-seaport-therapeutics-closes-225-m-prtc-20241021monthly0.5https://www.biopharmawatch.com/news/PRTC/september-2024-puretech-health-plc-puretech-invented-karxt-receives-u-s-food-and-drug-admi-prtc-20240927monthly0.5https://www.biopharmawatch.com/news/PRTC/august-2024-puretech-health-plc-results-of-annual-general-meeting-on-13-june-2024-update-s-prtc-20240828monthly0.5https://www.biopharmawatch.com/news/PRTC/august-2024-puretech-health-plc-puretech-appoints-michele-holcomb-phd-to-board-of-director-prtc-20240822monthly0.5https://www.biopharmawatch.com/news/PRTC/the-information-contained-in-this-announcement-is-not-for-release-publication-or-distribut-prtc-20240624monthly0.5https://www.biopharmawatch.com/news/PRTC/june-2024-puretech-health-plc-puretech-announces-change-of-board-role-raju-kucherlapati-ph-prtc-20240620monthly0.5https://www.biopharmawatch.com/news/PRTC/june-2024-puretech-health-plc-results-of-annual-general-meeting-the-annual-general-meeting-prtc-20240613monthly0.5https://www.biopharmawatch.com/news/PRTC/june-2024-puretech-health-plc-result-of-general-meeting-puretech-health-plc-nasdaq-prtc-ls-prtc-20240606monthly0.5https://www.biopharmawatch.com/news/PRTC/june-2024-puretech-health-plc-proposed-100-million-tender-offer-at-250-pence-per-ordinary--prtc-20240604monthly0.5https://www.biopharmawatch.com/news/PRTC/puretech-health-plc-puretech-founded-entity-akili-interactive-and-virtual-therapeutics-ann-prtc-20240529monthly0.5https://www.biopharmawatch.com/news/PRTC/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-the-uk-vers-prtc-20240520monthly0.5https://www.biopharmawatch.com/news/PRTC/april-2024-puretech-health-plc-puretech-announces-annual-results-for-year-ended-prtc-20240425monthly0.5https://www.biopharmawatch.com/news/PRTC/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-the-uk-vers-prtc-20240409monthly0.5https://www.biopharmawatch.com/news/PRTC/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-the-uk-vers-prtc-20240319monthly0.5https://www.biopharmawatch.com/news/PRTC/march-2024-puretech-health-plc-bristol-myers-squibb-completes-acquisition-of-puretech-s-fo-prtc-20240318monthly0.5https://www.biopharmawatch.com/news/PRTC/december-2023-puretech-health-plc-puretech-year-end-update-and-outlook-for-2024-strong-str-prtc-20231220monthly0.5https://www.biopharmawatch.com/news/PRTC/june-2023-puretech-health-plc-results-of-annual-general-meeting-the-annual-general-meeting-prtc-20230613monthly0.5https://www.biopharmawatch.com/news/PRTC/puretech-health-plc-6-tide-street-suite-400-boston-ma-02210-tel-617-482-2333-fax-617-482-3-prtc-20230612monthly0.5https://www.biopharmawatch.com/news/PRTC/april-2023-puretech-health-plc-puretech-announces-annual-results-for-year-ended-prtc-20230428monthly0.5https://www.biopharmawatch.com/news/PRTC/march-2023-puretech-health-plc-puretech-health-and-royalty-pharma-enter-into-karxt-royalty-prtc-20230323monthly0.5https://www.biopharmawatch.com/news/PRTC/march-2023-puretech-health-plc-puretech-founded-entity-karuna-therapeutics-announces-posit-prtc-20230320monthly0.5https://www.biopharmawatch.com/news/PRTC/december-2022-puretech-health-plc-puretech-provides-end-of-year-report-on-key-progress-rap-prtc-20221222monthly0.5https://www.biopharmawatch.com/news/PRTC/november-2022-puretech-health-plc-director-declaration-pursuant-to-listing-rule-9-6-14-2-p-prtc-20221110monthly0.5https://www.biopharmawatch.com/news/PRTC/not-for-release-publication-or-distribution-in-whole-or-in-part-in-into-or-from-any-jurisd-prtc-20221011monthly0.5https://www.biopharmawatch.com/news/PRTC/not-for-release-publication-or-distribution-in-whole-or-in-part-in-into-or-from-any-jurisd-prtc-20221006monthly0.5https://www.biopharmawatch.com/news/PRTC/experienced-r-d-team-and-our-network-of-industry-leading-collaborators-we-strive-to-overco-prtc-20220825monthly0.5https://www.biopharmawatch.com/news/PRTC/august-2022-puretech-health-plc-puretech-founded-entity-akili-to-list-on-nasdaq-following--prtc-20220822monthly0.5https://www.biopharmawatch.com/news/PRTC/august-2022-puretech-health-plc-puretech-to-receive-up-to-approximately-115-4-million-from-prtc-20220809monthly0.5https://www.biopharmawatch.com/news/PRTC/june-2022-puretech-health-plc-results-of-annual-general-meeting-the-annual-general-meeting-prtc-20220615monthly0.5https://www.biopharmawatch.com/news/PRTC/may-2022-puretech-health-plc-puretech-announces-share-buyback-programme-update-puretech-he-prtc-20220509monthly0.5https://www.biopharmawatch.com/news/PRTC/may-2022-puretech-health-plc-puretech-announces-share-buyback-programme-of-up-to-50-millio-prtc-20220505monthly0.5https://www.biopharmawatch.com/news/PRTC/puretech-announces-annual-results-for-year-ended-prtc-20220426monthly0.5https://www.biopharmawatch.com/news/PRTC/march-2022-puretech-health-plc-puretech-appoints-sharon-barber-lui-to-board-of-directors-a-prtc-20220324monthly0.5https://www.biopharmawatch.com/news/PRTC/january-2022-puretech-health-plc-puretech-founded-entity-akili-interactive-a-leader-in-dig-prtc-20220126monthly0.5https://www.biopharmawatch.com/news/PRTC/january-2022-puretech-health-plc-puretech-founded-entity-gelesis-the-maker-of-plenity-for--prtc-20220114monthly0.5https://www.biopharmawatch.com/news/PRTC/november-2021-puretech-health-plc-puretech-receives-approximately-100-million-from-sale-of-prtc-20211110monthly0.5https://www.biopharmawatch.com/news/PRTC/november-2021-puretech-health-plc-puretech-announces-participation-at-the-jefferies-london-prtc-20211109monthly0.5https://www.biopharmawatch.com/news/PRTC/october-2021-puretech-health-plc-block-listing-application-puretech-health-plc-nasdaq-prtc-prtc-20211012monthly0.5https://www.biopharmawatch.com/news/PRTC/united-kingdom-0800-640-6441-united-kingdom-local-020-3936-2999-united-states-1-855-9796-6-prtc-20210824monthly0.5https://www.biopharmawatch.com/news/PRTC/july-2021-puretech-health-plc-puretech-founded-entity-gelesis-the-maker-of-plenity-to-beco-prtc-20210719monthly0.5https://www.biopharmawatch.com/news/PRTC/may-2021-puretech-health-plc-results-of-annual-general-meeting-the-annual-general-meeting--prtc-20210527monthly0.5https://www.biopharmawatch.com/news/PRTC/march-2021-puretech-health-plc-puretech-announces-board-member-retirement-puretech-health--prtc-20210318monthly0.5https://www.biopharmawatch.com/news/PRTC/march-2021-puretech-health-plc-notice-of-results-puretech-health-plc-nasdaq-prtc-lse-prtc--prtc-20210315monthly0.5https://www.biopharmawatch.com/news/PRTC/february-2021-puretech-health-plc-puretech-receives-approximately-118-million-from-sale-of-prtc-20210210monthly0.5https://www.biopharmawatch.com/news/PRTC/this-announcement-is-not-for-release-publication-or-distribution-in-whole-or-in-part-in-in-prtc-20210205monthly0.5https://www.biopharmawatch.com/news/PRTC/january-2021-puretech-health-plc-puretech-adds-bharatt-chowrira-puretech-s-president-and-c-prtc-20210201monthly0.5https://www.biopharmawatch.com/news/VIGL/contingent-value-rights-agreement-by-and-between-sanofi-and-computershare-inc-and-computer-vigl-20250805monthly0.5https://www.biopharmawatch.com/news/VIGL/form-of-voting-and-support-agreement-this-voting-and-support-agreement-this-agreement-is-m-vigl-20250522monthly0.5https://www.biopharmawatch.com/news/VIGL/forward-looking-statements-this-presentation-contains-forward-looking-statements-which-are-vigl-20240111monthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-small-molecule-kol-event-vigl-20230913monthly0.5https://www.biopharmawatch.com/news/VIGL/forward-looking-statements-this-presentation-contains-forward-looking-statements-which-are-vigl-20230109monthly0.5https://www.biopharmawatch.com/news/VIGL/forward-looking-statements-2-vigil-neuroscience-inc-2022-all-rights-reserved-this-presenta-vigl-20221206monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-second-quarter-2025-financial-results-achieved-23-2-million-in-sage-20250730monthly0.5https://www.biopharmawatch.com/news/SAGE/supernus-pharmaceuticals-to-acquire-sage-therapeutics-strengthening-its-neuropsychiatry-pr-sage-20250616monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-first-quarter-2025-financial-results-and-highlights-pipeline-a-sage-20250429monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-fourth-quarter-and-full-year-2024-financial-results-and-highli-sage-20250211monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-board-of-directors-initiates-review-of-strategic-alternatives-and-reject-sage-20250127monthly0.5https://www.biopharmawatch.com/news/SAGE/safe-harbor-statement-the-slides-presented-today-and-the-accompanying-oral-presentations-c-sage-20250113monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-topline-results-from-the-phase-2-dimension-study-of-dalzanemdo-sage-20241120monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-third-quarter-2024-financial-results-and-highlights-pipeline-a-sage-20241029monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-topline-results-from-the-phase-2-lightwave-study-of-dalzanemdo-sage-20241008monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-second-quarter-2024-financial-results-and-highlights-pipeline--sage-20240731monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-and-biogen-announce-topline-results-from-phase-2-kinetic-2-study-of-sage-sage-20240724monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-phase-2-surveyor-study-reinforces-cognitive-impact-of-huntingt-sage-20240611monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-first-quarter-2024-financial-results-and-highlights-pipeline-a-sage-20240425monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-topline-results-from-phase-2-precedent-study-of-dalzanemdor-sa-sage-20240417monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-fourth-quarter-and-full-year-2023-financial-results-and-highli-sage-20240214monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-third-quarter-2023-financial-results-and-highlights-pipeline-a-sage-20231107monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-second-quarter-2023-financial-results-and-highlights-pipeline--sage-20230807monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-first-quarter-2023-financial-results-and-highlights-pipeline-a-sage-20230502monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-fourth-quarter-and-full-year-2022-financial-results-and-highli-sage-20230216monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-and-biogen-announce-fda-accepts-filing-of-new-drug-application-and-grant-sage-20230206monthly0.5https://www.biopharmawatch.com/news/SAGE/j-p-morgan-healthcare-conference-january-2023-safe-harbor-statement-the-slides-presented-t-sage-20230109monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-and-biogen-complete-rolling-submission-of-new-drug-application-for-zuran-sage-20221206monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-a-sage-20221108monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-second-quarter-2022-financial-results-and-highlights-pipeline--sage-20220802monthly0.5https://www.biopharmawatch.com/news/SAGE/in-the-court-of-chancery-of-the-state-of-delaware-john-solak-derivatively-on-behalf-of-sag-sage-20220714monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-and-biogen-announce-that-the-phase-3-skylark-study-of-zuranolone-in-post-sage-20220601monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-first-quarter-2022-financial-results-and-highlights-pipeline-a-sage-20220503monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-fourth-quarter-and-full-year-2021-financial-results-and-highli-sage-20220224monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-and-biogen-announce-the-phase-3-coral-study-met-its-primary-and-key-seco-sage-20220216monthly0.5https://www.biopharmawatch.com/news/SAGE/safe-harbor-statement-the-slides-presented-today-and-the-accompanying-oral-presentations-c-sage-20220110monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-and-biogen-announce-positive-one-year-zuranolone-50-mg-data-in-the-ongoi-sage-20211201monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-third-quarter-2021-financial-results-and-highlights-pipeline-a-sage-20211102monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-and-biogen-announce-plans-to-submit-a-new-drug-application-nda-for-zuran-sage-20211019monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-second-quarter-2021-financial-results-and-highlights-pipeline--sage-20210803monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-first-quarter-2021-financial-results-and-highlights-pipeline-a-sage-20210504monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-and-biogen-announce-sage-324-phase-2-placebo-controlled-kinetic-study-in-sage-20210412monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-continued-positive-zuranolone-data-for-both-30-mg-and-50-mg-do-sage-20210318monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-fourth-quarter-and-full-year-2020-financial-results-and-highli-sage-20210224monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-provides-2021-corporate-strategy-update-at-j-p-morgan-healthcare-confere-sage-20210107monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-third-quarter-2020-financial-results-and-highlights-pipeline-a-sage-20201105monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-positive-interim-topline-zuranolone-safety-and-tolerability-da-sage-20201015monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-appoints-barry-greene-to-board-of-directors-sage-20201001monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-second-quarter-2020-financial-results-and-highlights-pipeline--sage-20200810monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-first-quarter-2020-financial-results-and-highlights-pipeline-a-sage-20200507monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-restructuring-to-advance-corporate-strategy-and-pipeline-chang-sage-20200407monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-development-plan-for-zuranolone-sage-217-following-breakthroug-sage-20200318monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-fourth-quarter-and-full-year-2019-financial-results-and-highli-sage-20200227monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-reports-topline-results-from-pivotal-phase-3-mountain-study-of-sage-217--sage-20191205monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-third-quarter-2019-financial-results-and-highlights-pipeline-a-sage-20191112monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-second-quarter-2019-financial-results-and-highlights-pipeline--sage-20190806monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-clinical-updates-and-progress-across-neuroscience-pipeline-dur-sage-20190724monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-u-s-drug-enforcement-administration-scheduling-of-zulresso-bre-sage-20190614monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-first-quarter-2019-financial-results-and-highlights-pipeline-a-sage-20190502monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-fda-approval-of-zulresso-tm-brexanolone-injection-the-first-an-sage-20190319monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-closing-of-575-million-public-offering-of-common-stock-includi-sage-20190227monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-proposed-public-offering-of-common-stock-sage-20190225monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-fourth-quarter-and-full-year-2018-financial-results-and-highli-sage-20190219monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-appoints-elizabeth-barrett-and-george-golumbeski-to-board-of-directors-c-sage-20190123monthly0.5https://www.biopharmawatch.com/news/SAGE/safe-harbor-statement-the-slides-presented-today-and-the-accompanying-oral-presentations-c-sage-20190107monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-receives-notification-of-pdufa-extension-for-zulresso-brexanolone-inject-sage-20181120monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-third-quarter-2018-financial-results-and-highlights-pipeline-a-sage-20181106monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-fda-advisory-committee-votes-17-1-in-support-of-benefit-risk-p-sage-20181102monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-second-quarter-2018-financial-results-and-highlights-pipeline--sage-20180807monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-and-shionogi-co-ltd-enter-strategic-collaboration-to-develop-and-commerc-sage-20180613monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-announces-pivotal-phase-3-trial-status-for-sage-217-in-major-depressive-disorder-and--sage-20180612monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-fda-acceptance-of-nda-filing-and-grant-of-priority-review-for--sage-20180530monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-first-quarter-2018-financial-results-and-provides-update-on-pi-sage-20180503monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-fourth-quarter-and-full-year-2017-financial-results-and-provid-sage-20180222monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-proposed-public-offering-of-common-stock-sage-20180207monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-receives-fda-breakthrough-therapy-designation-for-sage-217-for-the-treat-sage-20180207monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-positive-results-from-placebo-controlled-trial-in-a-model-of-i-sage-20180131monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-to-provide-pipeline-update-at-j-p-morgan-healthcare-conference-and-outli-sage-20180108monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-reports-positive-top-line-results-from-phase-2-placebo-controlled-trial--sage-20171207monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-closing-of-345-million-public-offering-of-common-stock-includi-sage-20171117monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-proposed-public-offering-of-common-stock-sage-20171113monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-brexanolone-achieves-primary-endpoints-in-both-phase-3-clinica-sage-20171109monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-appoints-asha-nayak-m-d-ph-d-to-board-of-directors-sage-20171108monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-third-quarter-2017-financial-results-and-provides-pipeline-upd-sage-20171102monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-reports-top-line-results-from-phase-3-status-trial-of-brexanolone-in-sup-sage-20170912monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-second-quarter-2017-financial-results-and-provides-pipeline-up-sage-20170803monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-first-quarter-2017-financial-results-and-provides-pipeline-upd-sage-20170509monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-fourth-quarter-and-full-year-2016-financial-results-and-provid-sage-20170223monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-third-quarter-2016-financial-results-and-provides-srse-europea-sage-20161103monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-second-quarter-2016-financial-results-and-provides-corporate-u-sage-20160809monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-appoints-geno-germano-to-company-s-board-of-directors-sage-20160719monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-reports-positive-top-line-results-including-demonstration-of-30-day-durability-from-p-sage-20160712monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-announces-initiation-of-phase-1-and-first-dosing-of-sage-217-sage-s-first-oral-compou-sage-20151006monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-announces-sage-547-progress-and-first-quarter-2015-financial-results-sag-sage-20150514monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-reports-fourth-quarter-and-full-year-2014-financial-results-multiple-cli-sage-20150227monthly0.5https://www.biopharmawatch.com/news/SAGE/confidential-draft-not-for-release-sage-therapeutics-reports-updated-data-from-ongoing-cli-sage-20150109monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-reports-third-quarter-2014-results-sage-547-phase-1-2-study-meets-primar-sage-20141112monthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-reports-second-quarter-2014-financial-results-successfully-completed-ini-sage-20140814monthly0.5https://www.biopharmawatch.com/news/CDXC/document-niagen-bioscience-inc-reports-first-quarter-2026-financial-results-net-sales-incr-cdxc-20260506monthly0.5https://www.biopharmawatch.com/news/CDXC/niagen-bioscience-increases-share-repurchase-program-to-20-million-cdxc-20260319monthly0.5https://www.biopharmawatch.com/news/CDXC/niagen-bioscience-reports-30-year-over-year-net-sales-increase-to-129-4-million-103-net-in-cdxc-20260304monthly0.5https://www.biopharmawatch.com/news/CDXC/niagen-bioscience-to-streamline-and-focus-its-operations-with-the-sale-of-chromadex-refere-cdxc-20260224monthly0.5https://www.biopharmawatch.com/news/CDXC/niagen-bioscience-acquires-core-nicotinamide-riboside-nr-patent-portfolio-from-queen-s-uni-cdxc-20251222monthly0.5https://www.biopharmawatch.com/news/CDXC/niagen-bioscience-announces-10-million-share-repurchase-program-cdxc-20251106monthly0.5https://www.biopharmawatch.com/news/CDXC/document-niagen-bioscience-inc-reports-third-quarter-2025-financial-results-and-reaffirms--cdxc-20251104monthly0.5https://www.biopharmawatch.com/news/CDXC/document-niagen-bioscience-inc-reports-second-quarter-2025-financial-results-and-increases-cdxc-20250806monthly0.5https://www.biopharmawatch.com/news/CDXC/document-niagen-bioscience-inc-reports-first-quarter-2025-financial-results-and-increases--cdxc-20250507monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-evolves-into-niagen-bioscience-marking-a-new-era-of-uncovering-the-potential-of--cdxc-20250319monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-reports-fourth-quarter-and-fiscal-year-2024-results-full-year-net-sa-cdxc-20250304monthly0.5https://www.biopharmawatch.com/news/CDXC/document-chromadex-corporation-reports-third-quarter-2024-financial-results-total-net-sale-cdxc-20241031monthly0.5https://www.biopharmawatch.com/news/CDXC/document-chromadex-corporation-reports-second-quarter-2024-financial-results-total-net-sal-cdxc-20240807monthly0.5https://www.biopharmawatch.com/news/CDXC/document-chromadex-corporation-reports-first-quarter-2024-financial-results-total-net-sale-cdxc-20240508monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-reports-fourth-quarter-and-fiscal-year-2023-results-fourth-quarter-n-cdxc-20240306monthly0.5https://www.biopharmawatch.com/news/CDXC/document-chromadex-corporation-reports-third-quarter-2023-financial-results-total-net-sale-cdxc-20231108monthly0.5https://www.biopharmawatch.com/news/CDXC/document-chromadex-corporation-reports-second-quarter-2023-financial-results-strong-quarte-cdxc-20230809monthly0.5https://www.biopharmawatch.com/news/CDXC/document-chromadex-corporation-reports-first-quarter-2023-financial-results-record-net-sal-cdxc-20230510monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-reports-fourth-quarter-and-fiscal-year-2022-results-record-revenue-i-cdxc-20230308monthly0.5https://www.biopharmawatch.com/news/CDXC/document-chromadex-corporation-reports-third-quarter-2022-financial-results-total-net-sale-cdxc-20221102monthly0.5https://www.biopharmawatch.com/news/CDXC/document-chromadex-corporation-reports-first-quarter-2022-financial-results-total-net-sale-cdxc-20220512monthly0.5https://www.biopharmawatch.com/news/CDXC/document-chromadex-corporation-reports-fourth-quarter-and-fiscal-year-2021-results-total-n-cdxc-20220309monthly0.5https://www.biopharmawatch.com/news/CDXC/document-chromadex-corporation-reports-third-quarter-2021-financial-results-total-company--cdxc-20211103monthly0.5https://www.biopharmawatch.com/news/CDXC/document-chromadex-corporation-reports-second-quarter-2021-financial-results-tru-niagen-ne-cdxc-20210803monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-reports-first-quarter-2021-financial-results-tru-niagen-xae-revenue--cdxc-20210506monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-reports-2020-financial-results-revenue-for-the-three-month-period-en-cdxc-20210310monthly0.5https://www.biopharmawatch.com/news/CDXC/securities-purchase-agreement-this-securities-purchase-agreement-this-x201c-agreement-x201-cdxc-20210220monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-reports-third-quarter-2020-financial-results-revenue-for-the-three-m-cdxc-20201104monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-reports-second-quarter-2020-financial-results-second-quarter-2020-hi-cdxc-20200806monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-amended-2017-equity-incentive-plan-adopted-by-the-board-of-directors-cdxc-20200622monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-reports-first-quarter-2020-financial-results-first-quarter-2020-high-cdxc-20200511monthly0.5https://www.biopharmawatch.com/news/CDXC/securities-purchase-agreement-this-securities-purchase-agreement-this-x201c-agreement-x201-cdxc-20200427monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-reports-2019-financial-results-fourth-quarter-2019-highlights-vs-fou-cdxc-20200310monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-reports-third-quarter-2019-financial-results-third-quarter-2019-high-cdxc-20191112monthly0.5https://www.biopharmawatch.com/news/CDXC/confidential-execution-version-registration-rights-agreement-this-registration-rights-agre-cdxc-20190815monthly0.5https://www.biopharmawatch.com/news/CDXC/confidential-execution-version-securities-purchase-agreement-this-securities-purchase-agre-cdxc-20190813monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-reports-second-quarter-2019-financial-results-second-quarter-2019-ne-cdxc-20190807monthly0.5https://www.biopharmawatch.com/news/CDXC/omnibus-amendment-to-note-purchase-agreement-and-convertible-promissory-notes-this-omnibus-cdxc-20190630monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corp-and-nestl-xe9-health-science-enter-global-commercial-license-and-supply-agr-cdxc-20190514monthly0.5https://www.biopharmawatch.com/news/CDXC/execution-version-note-purchase-agreement-this-note-purchase-agreement-this-x201c-agreemen-cdxc-20190509monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-reports-first-quarter-2019-financial-results-first-quarter-2019-net--cdxc-20190509monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-reports-2018-financial-results-full-year-2018-net-revenues-increased-cdxc-20190307monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corp-and-nestl-xe9-health-science-enter-global-commercial-license-and-supply-agr-cdxc-20181220monthly0.5https://www.biopharmawatch.com/news/CDXC/presentation-untitled-document-cdxc-20181204monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-reports-third-quarter-2018-financial-results-third-quarter-2018-net--cdxc-20181107monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-and-dartmouth-college-file-patent-infringement-lawsuit-against-elysium-health-cdxc-20180918monthly0.5https://www.biopharmawatch.com/news/CDXC/e-xhibit-99-1-chromadex-corporation-reports-second-quarter-2018-financial-results-second-q-cdxc-20180809monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-2017-equity-incentive-plan-adopted-by-the-board-of-directors-cdxc-20180628monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-reports-first-quarter-2018-financial-results-first-quarter-2018-net--cdxc-20180510monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-appoints-frank-jaksch-as-executive-chairman-rob-fried-as-chief-executive-officer-cdxc-20180423monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-reports-2017-financial-results-fourth-quarter-2017-net-revenues-incr-cdxc-20180308monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-reports-preliminary-2017-results-fourth-quarter-2017-net-revenues-ex-cdxc-20180212monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corporation-2017-equity-incentive-plan-adopted-by-the-board-of-directors-cdxc-20180123monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-reports-third-quarter-2017-financial-results-company-reports-third-quarter-2017--cdxc-20171109monthly0.5https://www.biopharmawatch.com/news/CDXC/securities-purchase-agreement-this-securities-purchase-agreement-this-x201c-agreement-x201-cdxc-20171103monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-appoints-kevin-farr-as-new-cdxc-20171009monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-sells-its-analytical-testing-business-to-labcorp-to-accelerate-the-expansion-of--cdxc-20170823monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-announces-closing-of-third-and-final-tranche-of-the-25-million-strategic-investm-cdxc-20170821monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-reports-second-quarter-2017-financial-results-company-reports-revenue-of-5-3-mil-cdxc-20170810monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-announces-an-exclusive-worldwide-patent-license-and-research-agreement-with-the--cdxc-20170612monthly0.5https://www.biopharmawatch.com/news/CDXC/first-amendment-to-securities-purchase-agreement-this-first-amendment-to-securities-purcha-cdxc-20170524monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-reports-first-quarter-2017-financial-results-changes-in-q1-and-new-investor-set--cdxc-20170511monthly0.5https://www.biopharmawatch.com/news/CDXC/registration-rights-agreement-this-registration-rights-agreement-the-x201c-agreement-x201d-cdxc-20170429monthly0.5https://www.biopharmawatch.com/news/CDXC/securities-purchase-agreement-this-securities-purchase-agreement-this-x201c-agreement-x201-cdxc-20170426monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-appoints-steven-d-rubin-j-d-to-its-board-of-directors-cdxc-20170328monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-reports-2016-record-revenue-as-ingredient-sales-grew-34-q4-total-revenue-increas-cdxc-20170316monthly0.5https://www.biopharmawatch.com/news/CDXC/a-letter-from-the-chromadex-chief-executive-officer-cdxc-20170223monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-expects-to-report-record-fourth-quarter-as-revenue-increased-approximately-29-q4-cdxc-20170214monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-reports-third-quarter-2016-financial-results-company-reports-revenue-of-21-2-mil-cdxc-20161110monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-establishes-5-million-credit-facility-with-bridge-bank-cdxc-20161108monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-appoints-kurt-gustafson-to-its-board-of-directors-cdxc-20161027monthly0.5https://www.biopharmawatch.com/news/CDXC/1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33--cdxc-20160913monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-reports-record-revenue-as-ingredients-sales-climb-83-compared-to-previous-year-p-cdxc-20160811monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-names-former-chairman-ceo-of-the-quaker-oats-company-william-smithburg-to-its-bo-cdxc-20160607monthly0.5https://www.biopharmawatch.com/news/CDXC/resignation-letter-cdxc-20160513monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-approved-for-listing-on-the-nasdaq-capital-market-company-will-begin-trading-on--cdxc-20160421monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-announces-reverse-stock-split-as-company-seeks-to-list-its-common-stock-on-the-n-cdxc-20160412monthly0.5https://www.biopharmawatch.com/news/CDXC/investor-presentation-of-chromadex-corporation-ex99-1-htm-cdxc-20160315monthly0.5https://www.biopharmawatch.com/news/CDXC/a-letter-from-the-chromadex-chief-executive-officer-cdxc-20160106monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-enters-into-an-exclusive-joint-development-agreement-with-the-procter-gamble-com-cdxc-20151105monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-announces-2-000-000-registered-direct-offering-financing-increases-stockholder-e-cdxc-20151105monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-welcomes-business-media-executive-and-academy-award-winning-producer-rob-fried-t-cdxc-20150713monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-expands-patent-rights-to-pterostilbene-cdxc-20150604monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-announces-exclusive-worldwide-license-and-supply-agreement-for-anthocyanin-rich--cdxc-20150521monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-appoints-former-glaxosmithkline-executive-jeff-baxter-to-its-board-of-directors-cdxc-20150420monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-appoints-former-nestl-executive-steve-allen-as-chairman-company-reduces-number-o-cdxc-20150303monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-s-niagen-nicotinamide-riboside-meets-primary-endpoint-in-first-human-clinical-st-cdxc-20150211monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-receives-750-000-cash-from-previous-sale-of-its-bluscience-line-cdxc-20141203monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-licenses-exclusive-worldwide-patent-rights-from-the-university-of-mississippi-fo-cdxc-20141202monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-secures-5-0-million-in-growth-capital-financing-from-hercules-cdxc-20140930monthly0.5https://www.biopharmawatch.com/news/CDXC/university-of-california-irvine-completes-pterostilbene-study-for-prevention-of-skin-damag-cdxc-20140922monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-licenses-exclusive-patent-rights-from-dartmouth-college-for-pharmaceutical-use-o-cdxc-20140603monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-announces-62-million-ingredient-agreement-with-network-marketing-company-5linx-f-cdxc-20140106monthly0.5https://www.biopharmawatch.com/news/CDXC/1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-cdxc-20131204monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-acquires-new-exclusive-worldwide-patent-rights-for-pteropure-pterostilbene-relat-cdxc-20130805monthly0.5https://www.biopharmawatch.com/news/CDXC/niagen-supply-aggreement-this-agreement-the-agreement-is-made-and-entered-into-as-of-cdxc-20130709monthly0.5https://www.biopharmawatch.com/news/CDXC/htm-chromadex-adds-to-its-exclusive-worldwide-patent-rights-for-nicotinamide-riboside-nr-w-cdxc-20130308monthly0.5https://www.biopharmawatch.com/news/CDXC/1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-cdxc-20121205monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-acquires-spherix-consulting-spherix-consulting-brings-technical-and-regulatory-s-cdxc-20121203monthly0.5https://www.biopharmawatch.com/news/CDXC/presentation-abstract-session-13-poster-session-ii-thursday-cdxc-20120920monthly0.5https://www.biopharmawatch.com/news/CDXC/1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-cdxc-20120830monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-licenses-exclusive-patent-rights-for-nicotinamide-riboside-nr-vitamin-technologi-cdxc-20120716monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-corp-names-co-founder-frank-jaksch-ceo-president-cdxc-20120612monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-announces-management-changes-cdxc-20120217monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-to-raise-10-85m-in-sale-of-common-stock-cdxc-20120201monthly0.5https://www.biopharmawatch.com/news/CDXC/investor-presentation-ex99-1-htm-cdxc-20120127monthly0.5https://www.biopharmawatch.com/news/CDXC/irvine-calif-cdxc-20120123monthly0.5https://www.biopharmawatch.com/news/CDXC/investor-presentation-slides-ex99-1-htm-ex-99-1-http-investors-chromadex-com-phoenix-zhtml-cdxc-20110614monthly0.5https://www.biopharmawatch.com/news/CDXC/chromadex-receives-investment-from-the-frost-group-llc-capital-will-allow-chromadex-to-pur-cdxc-20100426monthly0.5https://www.biopharmawatch.com/news/ELYM/climb-bio-inc-2021-equity-incentive-plan-adopted-by-the-compensation-committee-of-the-boar-elym-20260608monthly0.5https://www.biopharmawatch.com/news/ELYM/climb-bio-reports-first-quarter-2026-financial-results-and-provides-business-updates-robus-elym-20260507monthly0.5https://www.biopharmawatch.com/news/ELYM/confidential-climb-bio-hosts-budoprutug-r-d-spotlight-event-highlighting-topline-subcutane-elym-20260505monthly0.5https://www.biopharmawatch.com/news/ELYM/climb-bio-inc-announces-110-0-million-private-placement-elym-20260428monthly0.5https://www.biopharmawatch.com/news/ELYM/climb-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-busines-elym-20260305monthly0.5https://www.biopharmawatch.com/news/ELYM/climb-bio-announces-pipeline-progress-and-strategic-priorities-for-2026-first-patients-dos-elym-20260108monthly0.5https://www.biopharmawatch.com/news/ELYM/in-the-superior-court-of-the-state-of-delaware-climb-bio-inc-plaintiff-v-c-a-no-ccld-alumi-elym-20251231monthly0.5https://www.biopharmawatch.com/news/ELYM/climb-bio-reports-third-quarter-2025-financial-results-and-provides-business-updates-prism-elym-20251106monthly0.5https://www.biopharmawatch.com/news/ELYM/climb-bio-announces-clym116-preclinical-data-highlighting-potential-for-best-in-class-ther-elym-20250929monthly0.5https://www.biopharmawatch.com/news/ELYM/climb-bio-reports-second-quarter-2025-financial-results-and-provides-business-updates-clin-elym-20250812monthly0.5https://www.biopharmawatch.com/news/ELYM/climb-bio-reports-first-quarter-2025-financial-results-and-provides-business-updates-clini-elym-20250514monthly0.5https://www.biopharmawatch.com/news/ELYM/climb-bio-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides-business-elym-20250325monthly0.5https://www.biopharmawatch.com/news/ELYM/climb-bio-reports-third-quarter-2024-financial-results-and-business-highlights-appointed-d-elym-20241112monthly0.5https://www.biopharmawatch.com/news/ELYM/climb-bio-to-provide-budoprutug-development-strategy-and-corporate-update-at-virtual-inves-elym-20241015monthly0.5https://www.biopharmawatch.com/news/ELYM/eliem-therapeutics-inc-condensed-consolidated-balance-sheets-in-thousands-unaudited-elym-20240814monthly0.5https://www.biopharmawatch.com/news/ELYM/eliem-therapeutics-announces-the-closing-of-its-acquisition-of-tenet-medicines-and-concurr-elym-20240627monthly0.5https://www.biopharmawatch.com/news/ELYM/eliem-therapeutics-announces-agreement-to-acquire-tenet-medicines-and-concurrent-120-milli-elym-20240411monthly0.5https://www.biopharmawatch.com/news/ELYM/summary-of-proposed-terms-for-transaction-between-eliem-therapeutics-inc-and-target-form-o-elym-20240319monthly0.5https://www.biopharmawatch.com/news/ELYM/eliem-therapeutics-announces-plans-to-explore-strategic-alternatives-seattle-and-cambridge-elym-20230720monthly0.5https://www.biopharmawatch.com/news/ELYM/eliem-therapeutics-reports-first-quarter-financial-results-and-business-highlights-present-elym-20230511monthly0.5https://www.biopharmawatch.com/news/ELYM/eliem-therapeutics-reports-fourth-quarter-and-year-end-financial-results-and-business-high-elym-20230306monthly0.5https://www.biopharmawatch.com/news/ELYM/eliem-therapeutics-provides-strategic-update-and-announces-leadership-transition-elym-20230209monthly0.5https://www.biopharmawatch.com/news/ELYM/eliem-therapeutics-reports-third-quarter-financial-and-business-highlights-positioned-to-i-elym-20221114monthly0.5https://www.biopharmawatch.com/news/ELYM/eliem-therapeutics-provides-update-on-pipeline-progress-company-is-positioned-to-initiate--elym-20221005monthly0.5https://www.biopharmawatch.com/news/ELYM/eliem-therapeutics-reports-second-quarter-financial-and-business-highlights-initiated-phas-elym-20220815monthly0.5https://www.biopharmawatch.com/news/ELYM/eliem-therapeutics-reports-first-quarter-financial-and-business-highlights-seattle-and-cam-elym-20220516monthly0.5https://www.biopharmawatch.com/news/ELYM/clinical-stage-neurology-company-focused-on-neuronal-excitability-disorders-corporate-pres-elym-20220328monthly0.5https://www.biopharmawatch.com/news/ELYM/eliem-therapeutics-reports-fourth-quarter-and-year-end-financial-and-business-highlights-c-elym-20220307monthly0.5https://www.biopharmawatch.com/news/ELYM/eliem-therapeutics-reports-third-quarter-financial-and-business-highlights-advanced-etx-15-elym-20211108monthly0.5https://www.biopharmawatch.com/news/ELYM/eliem-therapeutics-reports-second-quarter-financial-results-on-track-to-advance-two-clinic-elym-20210913monthly0.5https://www.biopharmawatch.com/news/TSVT/seventy-bio-enters-into-definitive-agreement-to-be-acquired-by-bristol-myers-squibb-5-00-p-tsvt-20250310monthly0.5https://www.biopharmawatch.com/news/TSVT/unaudited-pro-forma-financial-information-on-tsvt-20240401monthly0.5https://www.biopharmawatch.com/news/TSVT/unleash-time-2seventy-bio-company-presentation-march-2023-cautionary-note-regarding-forwar-tsvt-20230307monthly0.5https://www.biopharmawatch.com/news/TSVT/seventy-bio-announces-proposed-public-offering-of-common-stock-tsvt-20230228monthly0.5https://www.biopharmawatch.com/news/TSVT/item-1a-risk-factors-an-investment-in-shares-of-our-common-stock-involves-a-high-degree-of-tsvt-20230228monthly0.5https://www.biopharmawatch.com/news/TSVT/tsvt8-k192023-unleash-time-2seventy-bio-company-presentation-january-2023-cautionary-note--tsvt-20230109monthly0.5https://www.biopharmawatch.com/news/TSVT/document-2seventy-bio-announces-expanded-translational-collaboration-with-regeneron-to-dev-tsvt-20230106monthly0.5https://www.biopharmawatch.com/news/TSVT/document-2seventy-bio-to-present-data-from-karmma-2-study-of-abecma-idecabtagene-vicleucel-tsvt-20221103monthly0.5https://www.biopharmawatch.com/news/TSVT/document-2seventy-bio-and-jw-therapeutics-announce-strategic-partnership-to-accelerate-the-tsvt-20221027monthly0.5https://www.biopharmawatch.com/news/TSVT/document-2seventy-bio-announces-plans-to-initiate-karmma-9-study-of-abecma-idecabtagene-vi-tsvt-20220907monthly0.5https://www.biopharmawatch.com/news/TSVT/document-bristol-myers-squibb-and-2seventy-bio-announce-top-line-results-from-karmma-3-tri-tsvt-20220810monthly0.5https://www.biopharmawatch.com/news/TSVT/document-2seventy-bio-presents-new-preclinical-data-on-bbt369-an-investigational-dual-targ-tsvt-20220408monthly0.5https://www.biopharmawatch.com/news/TSVT/seventy-bio-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-operati-tsvt-20220322monthly0.5https://www.biopharmawatch.com/news/TSVT/seventy-bio-secures-170-million-in-private-placement-equity-financing-proceeds-to-support--tsvt-20220316monthly0.5https://www.biopharmawatch.com/news/TSVT/seventy-bio-announces-expanded-collaboration-agreement-with-novo-nordisk-to-continue-devel-tsvt-20220106monthly0.5https://www.biopharmawatch.com/news/TSVT/seventy-bio-presents-data-across-multiple-cell-therapy-programs-at-ash-2021-annual-meeting-tsvt-20211213monthly0.5https://www.biopharmawatch.com/news/TSVT/seventy-bio-reports-third-quarter-financial-results-and-recent-operational-progress-sc-dar-tsvt-20211201monthly0.5https://www.biopharmawatch.com/news/TSVT/seventy-bio-to-present-data-from-its-portfolio-of-oncology-cell-therapies-at-the-63-rd-ame-tsvt-20211104monthly0.5https://www.biopharmawatch.com/news/TSVT/dear-bluebird-bio-inc-stockholder-in-january-2021-we-announced-a-transformative-milestone--tsvt-20211019monthly0.5https://www.biopharmawatch.com/news/YMAB/serb-pharmaceuticals-agrees-to-acquire-y-mabs-therapeutics-acquisition-to-include-naxitama-ymab-20250804monthly0.5https://www.biopharmawatch.com/news/YMAB/radiopharmaceutical-r-d-update-ymab-20250528monthly0.5https://www.biopharmawatch.com/news/YMAB/for-the-years-ended-ymab-20250304monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-provides-strategic-business-update-and-2025-priorities-company-establishes-two-busi-ymab-20241231monthly0.5https://www.biopharmawatch.com/news/YMAB/oncology-leadership-in-pretargeted-radioimmunotherapy-platform-and-antibody-based-therapie-ymab-20240109monthly0.5https://www.biopharmawatch.com/news/YMAB/the-chmp-has-adopted-a-negative-opinion-for-omburtamab-for-the-treatment-of-cns-lm-metasta-ymab-20221216monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-pipeline-update-new-york-ny-ymab-20221214monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-pivotal-data-for-omburtamab-new-york-ny-ymab-20221003monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-clearance-of-ind-for-gd2-sada-new-york-ny-ymab-20220712monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-pipeline-update-new-york-ny-ymab-20211215monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-177-lu-omburtamab-dtpa-for-the-treatment-of-patients-with-medulloblastoma-granted-r-ymab-20211007monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-177-lu-omburtamab-dtpa-for-the-treatment-of-patients-with-medulloblastoma-receives--ymab-20210625monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-update-on-omburtamab-for-dipg-new-york-ny-ymab-20210604monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-update-on-sada-technology-new-york-ny-ymab-20210513monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-provides-regulatory-update-on-omburtamab-new-york-ny-ymab-20210420monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-sale-of-priority-review-voucher-new-york-ny-ymab-20201228monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-pipeline-update-new-york-ny-ymab-20201216monthly0.5https://www.biopharmawatch.com/news/YMAB/fda-approves-y-mabs-danyelza-naxitamab-gqgk-for-the-treatment-of-neuroblastoma-new-york-ny-ymab-20201125monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-update-on-omburtamab-in-dipg-new-york-ny-ymab-20201119monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-update-on-omburtamab-in-dsrct-new-york-ny-ymab-20191115monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-naxitamab-update-new-york-ny-ymab-20191025monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-secures-commercial-radiolabeling-capacity-new-york-ny-ymab-20190701monthly0.5https://www.biopharmawatch.com/news/YMAB/disclaimer-this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-ymab-20190312monthly0.5https://www.biopharmawatch.com/news/YMAB/y-mabs-announces-appointment-of-g-rard-ber-to-its-board-of-directors-and-planned-departure-ymab-20181211monthly0.5https://www.biopharmawatch.com/news/YMAB/bispecific-gd2-antibody-in-vivo-data-to-be-presented-at-ash-new-york-ny-ymab-20181101monthly0.5https://www.biopharmawatch.com/news/YMAB/naxitamab-receives-positive-opinion-for-orphan-medicinal-product-designation-approval-in-t-ymab-20181023monthly0.5https://www.biopharmawatch.com/news/MGRM/zimmer-biomet-completes-acquisition-of-monogram-technologies-transaction-creates-the-broad-mgrm-20251007monthly0.5https://www.biopharmawatch.com/news/MGRM/text-message-target-audience-registered-holders-action-requested-the-monogram-technologies-mgrm-20250829monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-acquisition-by-zimmer-biomet-faqs-available-here-https-www-monogramtechnologies-c-mgrm-20250731monthly0.5https://www.biopharmawatch.com/news/MGRM/dear-shareholders-we-ve-added-a-frequently-asked-questions-faq-section-to-our-investor-rel-mgrm-20250730monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-technologies-acquisition-by-zimmer-biomet-frequently-asked-questions-for-monogram-mgrm-20250714monthly0.5https://www.biopharmawatch.com/news/MGRM/execution-version-voting-agreement-this-voting-agreement-this-agreement-dated-as-of-mgrm-20250711monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-technologies-announces-the-mandatory-conversion-of-8-00-series-d-convertible-cumu-mgrm-20250708monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-technologies-granted-regulatory-approval-to-import-mb-s-tka-system-for-clinical-i-mgrm-20250429monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-technologies-announces-fda-510-k-clearance-for-the-monogram-mb-s-tka-system-monog-mgrm-20250317monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-technologies-reports-full-year-2024-financial-results-completed-all-supplemental--mgrm-20250312monthly0.5https://www.biopharmawatch.com/news/MGRM/provides-regulatory-update-on-mb-s-tka-system-and-clinical-trial-preparation-in-india-mgrm-20250225monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-technologies-provides-510-k-submission-update-following-positive-meeting-with-fda-mgrm-20241218monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-technologies-announces-management-and-related-parties-complete-open-market-purcha-mgrm-20241202monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-technologies-reports-third-quarter-2024-financial-results-closed-an-upsized-and-o-mgrm-20241114monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-technologies-named-orthopedic-joint-replacement-company-of-the-year-2024-award-fr-mgrm-20241029monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-technologies-issues-correction-to-press-release-announcing-it-received-an-fda-res-mgrm-20241003monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-technologies-announces-closing-of-upsized-and-oversubscribed-13-million-public-of-mgrm-20241002monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-technologies-announces-preferred-stock-dividends-austin-tx-mgrm-20240930monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-technologies-upsizes-8-00-series-d-convertible-cumulative-preferred-stock-and-war-mgrm-20240911monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-technologies-secures-initial-strategic-clinical-trial-collaboration-clinical-tria-mgrm-20240812monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-technologies-submits-510-k-application-for-mb-s-tka-system-clearance-application--mgrm-20240719monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-orthopaedics-completes-corporate-name-change-to-monogram-technologies-new-name-re-mgrm-20240515monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-orthopaedics-reports-first-quarter-2024-financial-results-verification-and-valida-mgrm-20240514monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-provides-regulatory-update-following-meeting-with-fda-510-k-submission-with-fda-a-mgrm-20240501monthly0.5https://www.biopharmawatch.com/news/MGRM/nasdaq-mgrm-revolutionizing-orthopedic-surgery-implants-fy-2023-investor-call-thursday-mgrm-20240321monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-orthopaedics-reports-full-year-2023-financial-results-510-k-submission-with-fda-o-mgrm-20240315monthly0.5https://www.biopharmawatch.com/news/MGRM/nasdaq-mgrm-revolutionizing-orthopedic-surgery-implants-1-forward-looking-statements-legal-mgrm-20231020monthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-orthopaedics-secures-first-conditional-purchase-order-to-initiate-pilot-program-w-mgrm-20230718monthly0.5https://www.biopharmawatch.com/news/INZY/biomarin-contacts-inozyme-contacts-traci-mccarty-investors-stefan-riley-investors-biomarin-inzy-20250516monthly0.5https://www.biopharmawatch.com/news/INZY/enpp1-clinical-development-strategy-and-illustrative-goals-for-trials-in-adult-and-childre-inzy-20211115monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-announces-voluntary-delisting-from-nasdaq-takes-effect-melbourne-australia-opt-20251121monthly0.5https://www.biopharmawatch.com/news/OPT/results-of-annual-general-meeting-melbourne-australia-opt-20251111monthly0.5https://www.biopharmawatch.com/news/OPT/asx-announcement-opt-20251031monthly0.5https://www.biopharmawatch.com/news/OPT/opthea-streamlines-global-operations-and-focuses-on-australian-market-company-announces-in-opt-20251030monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-27-october-2025-appointment-of-company-secretary-and-cfo-melb-opt-20251027monthly0.5https://www.biopharmawatch.com/news/OPT/notice-of-annual-general-meeting-and-explanatory-notes-opthea-01-opthea-notice-of-annual-g-opt-20251010monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-6-october-2025-opthea-receives-a-10-8-million-r-d-tax-incenti-opt-20251006monthly0.5https://www.biopharmawatch.com/news/OPT/2024-2025-corporate-governance-statement-rules-4-7-3-and-4-10-3-opt-20250915monthly0.5https://www.biopharmawatch.com/news/OPT/securities-and-exchange-commission-opt-20250829monthly0.5https://www.biopharmawatch.com/news/OPT/corporate-update-investor-call-x2013-20-august-2025-dr-jeremy-levin-x2013-chairman-of-the--opt-20250820monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20250819monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20250602monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20250410monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20250331monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20250324monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20250303monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20250228monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20250226monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20250218monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20250207monthly0.5https://www.biopharmawatch.com/news/OPT/disclaimer-and-forward-looking-statements-this-presentation-includes-general-background-in-opt-20250128monthly0.5https://www.biopharmawatch.com/news/OPT/disclaimer-and-forward-looking-statements-this-presentation-includes-general-background-in-opt-20241231monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20250108monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20241219monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20241126monthly0.5https://www.biopharmawatch.com/news/OPT/disclaimer-and-forward-looking-statements-this-presentation-includes-general-background-in-opt-20241119monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20241115monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20241112monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20241104monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-31-october-2024-quarterly-activity-report-q1-fy25-highlights--opt-20241101monthly0.5https://www.biopharmawatch.com/news/OPT/disclaimer-and-forward-looking-statements-this-presentation-includes-general-background-in-opt-20241028monthly0.5https://www.biopharmawatch.com/news/OPT/x2013-2024-notice-of-meeting-and-explanatory-notes-a-transformative-treatment-for-wet-amd--opt-20241016monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20241016monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20241010monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20241008monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20240930monthly0.5https://www.biopharmawatch.com/news/OPT/introduction-and-objectives-speaker-arshad-khanani-md-ma-fasrs-consultant-abbvie-adverum-a-opt-20240910monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20240923monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20240918monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20240910monthly0.5https://www.biopharmawatch.com/news/OPT/disclaimer-and-forward-looking-statements-this-presentation-includes-general-background-in-opt-20240830monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20240905monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-3rd-september-2024-opthea-to-participate-in-h-c-wainwright-26-opt-20240903monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-8-august-2024-opthea-to-participate-in-the-h-c-wainwright-4-t-opt-20240808monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-17-july-2024-opthea-welcomes-international-retina-thought-lea-opt-20240717monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-15-july-2024-opthea-announces-results-of-the-a-55-9m-us-36-9m-opt-20240715monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-9-july-2024-opthea-announces-publication-on-vegf-c-and-d-sign-opt-20240709monthly0.5https://www.biopharmawatch.com/news/OPT/authorized-for-release-to-asx-by-company-secretary-investor-inquiries-join-our-email-datab-opt-20240620monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-14-june-2024-opthea-successfully-completes-placement-and-inst-opt-20240614monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-12-june-2024-opthea-prospectus-further-to-the-announcements-t-opt-20240612monthly0.5https://www.biopharmawatch.com/news/OPT/important-notice-and-disclaimer-important-you-must-read-the-following-before-continuing-or-opt-20240612monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-12-june-2024-opthea-announces-placement-and-partially-underwr-opt-20240612monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-3-june-2024-opthea-to-present-at-clinical-trials-at-the-summi-opt-20240603monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-28-may-2024-opthea-completes-enrollment-in-pivotal-phase-3-cl-opt-20240528monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-1-may-2024-opthea-announces-upcoming-presentations-at-the-ret-opt-20240501monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-30-april-2024-quarterly-activity-report-q3-fy24-highlights-x2-opt-20240430monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-25-april-2024-opthea-to-present-at-the-ois-retina-innovation--opt-20240425monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-9-april-2024-opthea-appoints-john-han-pharmd-as-vp-medical-af-opt-20240409monthly0.5https://www.biopharmawatch.com/news/OPT/disclaimer-this-presentation-includes-general-background-information-about-the-activities--opt-20240403monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-5-april-2024-opthea-to-participate-in-the-23-rd-annual-needha-opt-20240404monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-4-april-2024-opthea-appoints-sujal-shah-to-the-board-of-direc-opt-20240404monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-19-march-2024-opthea-to-host-key-opinion-leader-event-on-sozi-opt-20240319monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-06-march-2024-opthea-to-participate-in-the-leerink-partners-g-opt-20240306monthly0.5https://www.biopharmawatch.com/news/OPT/disclaimer-this-presentation-includes-general-background-information-about-the-activities--opt-20240304monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-29-february-2024-opthea-reports-half-year-financial-results-a-opt-20240229monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-20-february-2024-opthea-appoints-arshad-m-khanani-md-ma-fasrs-opt-20240220monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-14-february-2024-opthea-completes-enrollment-in-first-pivotal-opt-20240214monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-01-february-2024-optheastrengthens-team-with-key-clinical-and-opt-20240201monthly0.5https://www.biopharmawatch.com/news/OPT/disclaimer-this-presentation-includes-general-background-information-about-the-activities--opt-20240111monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-27-december-2023-opthea-to-receive-us-35m-commitment-and-addi-opt-20231227monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-19-december-2023-opthea-receives-a-8-8-million-r-d-tax-incent-opt-20231219monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-30-november-2023-opthea-to-present-at-the-floretina-2023-cong-opt-20231203monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-30-november-2023-opthea-chairman-s-address-to-the-2023-annual-opt-20231130monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20231109monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20231030monthly0.5https://www.biopharmawatch.com/news/OPT/hope-is-on-the-horizon-notice-of-annual-general-meeting-and-explanatory-notes-notice-of-an-opt-20231027monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20231027monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20231002monthly0.5https://www.biopharmawatch.com/news/OPT/securities-and-exchange-commission-opt-20230928monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20230907monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-31-august-2023-opthea-retail-entitlement-offer-opens-on-monda-opt-20230824monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-28-august-2023-opthea-successfully-completes-institutional-of-opt-20230824monthly0.5https://www.biopharmawatch.com/news/OPT/important-notice-and-disclaimer-important-you-must-read-the-following-before-continuing-or-opt-20230824monthly0.5https://www.biopharmawatch.com/news/OPT/disclosures-presenter-s-financial-disclosures-adverum-c-gemini-genentech-inc-iveric-bio-ng-opt-20230801monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20230726monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20230724monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20230710monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20230608monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20230525monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20230517monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20230508monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20230428monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20230307monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20230223monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20230213monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20230206monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20230130monthly0.5https://www.biopharmawatch.com/news/OPT/disclaimer-this-presentation-includes-general-background-information-about-the-activities--opt-20221231monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20221212monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20221206monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-16-november-2022-opthea-chairman-s-address-to-the-2022-annual-opt-20221116monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-10-november-2022-opthea-to-present-at-jefferies-london-health-opt-20221110monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20221024monthly0.5https://www.biopharmawatch.com/news/OPT/september-2022-market-announcements-office-australian-securities-exchange-limited-20-bridg-opt-20220926monthly0.5https://www.biopharmawatch.com/news/OPT/notice-of-extraordinary-general-meeting-and-explanatory-notes-in-this-document-you-will-fi-opt-20220824monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-25-august-2022-share-purchase-plan-letter-to-eligible-shareho-opt-20220825monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20220511monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20220505monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-opt-20220429monthly0.5https://www.biopharmawatch.com/news/OPT/appendix-3x-initial-director-s-interest-notice-rule-3-19a-1-appendix-3x-initial-director-s-opt-20220422monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-april-22-2022-opthea-strengthens-its-board-of-directors-elect-opt-20220422monthly0.5https://www.biopharmawatch.com/news/OPT/index-to-condensed-consolidated-financial-statements-page-condensed-consolidated-statement-opt-20220330monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-10-march-2022-opthea-to-present-at-oppenheimer-s-32nd-annual--opt-20220310monthly0.5https://www.biopharmawatch.com/news/OPT/asx-and-media-release-2-march-2022-opthea-expands-leadership-team-with-the-appointment-of--opt-20220302monthly0.5https://www.biopharmawatch.com/news/OPT/february-2022-h-a-l-f-y-e-a-r-f-i-n-a-n-c-i-a-l-r-e-p-o-r-t-3-1-d-e-c-e-m-b-e-r-2-0-2-1-in-opt-20220228monthly0.5https://www.biopharmawatch.com/news/OPT/asx-and-media-release-14-february-2022-opthea-data-for-opt-302-in-patients-with-polypoidal-opt-20220212monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-10-february-2022-opthea-to-present-at-svb-leerink-global-heal-opt-20220210monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-9-february-2022-opthea-announces-presentation-at-the-angiogen-opt-20220209monthly0.5https://www.biopharmawatch.com/news/OPT/asx-and-media-release-1-february-2022-opthea-announces-establishment-of-at-the-market-equi-opt-20220201monthly0.5https://www.biopharmawatch.com/news/OPT/asx-and-media-release-24-january-2022-opthea-receives-a-6-6-m-r-d-tax-incentive-melbourne--opt-20220124monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-4-january-2022-opthea-to-present-at-h-c-wainwright-bioconnect-opt-20220104monthly0.5https://www.biopharmawatch.com/news/OPT/asx-and-media-release-3-january-2022-opthea-appoints-chief-commercial-officer-to-lead-comm-opt-20220103monthly0.5https://www.biopharmawatch.com/news/OPT/asx-and-media-release-26-october-2021-opthea-granted-chinese-patent-covering-opt-302-melbo-opt-20211026monthly0.5https://www.biopharmawatch.com/news/OPT/asx-and-media-release-19-october-2021-opthea-chairman-s-address-to-the-2021-annual-general-opt-20211020monthly0.5https://www.biopharmawatch.com/news/OPT/asx-and-media-release-4-october-2021-opthea-opens-patient-recruitment-in-europe-for-pivota-opt-20211004monthly0.5https://www.biopharmawatch.com/news/OPT/additional-agm-resolution-addendum-to-the-notice-of-annual-general-meeting-and-explanatory-opt-20210920monthly0.5https://www.biopharmawatch.com/news/OPT/notice-of-annual-general-meeting-and-explanatory-notes-date-tuesday-19-october-2021-time-9-opt-20210913monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-2-september-2021-opthea-to-present-at-september-investor-conf-opt-20210902monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-10-august-2021-opthea-to-present-at-the-h-c-wainwright-ophtha-opt-20210810monthly0.5https://www.biopharmawatch.com/news/OPT/asx-and-media-release-9-august-2021-opthea-expands-global-phase-3-shore-and-coast-wet-amd--opt-20210809monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-6-july-2021-opthea-s-opt-302-granted-fda-fast-track-designati-opt-20210706monthly0.5https://www.biopharmawatch.com/news/OPT/announcement-summary-entity-name-opthea-limited-announcement-type-new-announcement-date-of-opt-20210622monthly0.5https://www.biopharmawatch.com/news/OPT/asx-nasdaq-and-media-release-14-june-2021-opthea-appoints-company-secretary-and-vice-presi-opt-20210612monthly0.5https://www.biopharmawatch.com/news/OPT/appendix-3x-initial-director-s-interest-notice-rule-3-19a-1-appendix-3x-initial-director-s-opt-20210608monthly0.5https://www.biopharmawatch.com/news/OPT/asx-and-media-release-6-april-2021-opthea-company-secretary-resignation-melbourne-australi-opt-20210406monthly0.5https://www.biopharmawatch.com/news/OPT/asx-and-media-release-31-march-2021-opthea-receives-fda-waiver-for-pediatric-study-plan-fo-opt-20210331monthly0.5https://www.biopharmawatch.com/news/OPT/announcement-summary-entity-name-opthea-limited-announcement-type-new-announcement-date-of-opt-20210325monthly0.5https://www.biopharmawatch.com/news/OPT/asx-and-media-release-15-march-2021-opthea-treats-first-patient-in-phase-3-pivotal-trials--opt-20210315monthly0.5https://www.biopharmawatch.com/news/OPT/this-appendix-is-not-available-as-an-online-form-please-fill-in-and-submit-as-a-pdf-announ-opt-20210305monthly0.5https://www.biopharmawatch.com/news/OPT/asx-and-media-release-24-february-2021-opthea-finalizes-study-designs-and-start-up-activit-opt-20210224monthly0.5https://www.biopharmawatch.com/news/OPT/february-2021-half-year-financial-report-31-december-2020-in-accordance-with-listing-rule--opt-20210222monthly0.5https://www.biopharmawatch.com/news/OPT/february-2021-opthea-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conferenc-opt-20210217monthly0.5https://www.biopharmawatch.com/news/OPT/january-2021-market-announcements-office-australian-securities-exchange-limited-20-bridge--opt-20210119monthly0.5https://www.biopharmawatch.com/news/OPT/notice-of-general-meeting-and-explanatory-notes-date-tuesday-19-january-2021-time-9-00-am--opt-20201217monthly0.5https://www.biopharmawatch.com/news/OPT/asx-release-27-october-2020-opthea-receives-a-8-5m-r-d-tax-incentive-melbourne-australia-2-opt-20201019monthly0.5https://www.biopharmawatch.com/news/OPT/asx-and-media-release-16-october-2020-opthea-announces-pricing-of-initial-public-offering--opt-20201016monthly0.5https://www.biopharmawatch.com/news/SLRN/investor-presentation-april-2025-disclaimer-forward-looking-statements-this-communication--slrn-20250421monthly0.5https://www.biopharmawatch.com/news/SLRN/creating-substantial-shareholder-value-through-the-advancement-of-immunology-treatments-ma-slrn-20250306monthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-inc-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-und-slrn-20230509monthly0.5https://www.biopharmawatch.com/news/THRD/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-thrd-20250612monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-inc-condensed-consolidated-balance-sheet-data-unaudited-in-thousands-thrd-20250327monthly0.5https://www.biopharmawatch.com/news/THRD/focused-on-advancing-the-next-wave-of-medicine-for-inflammatory-diseases-ma-r-c-h-2-0-2-5--thrd-20250311monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-inc-condensed-consolidated-balance-sheet-data-unaudited-in-thousands-thrd-20241107monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-inc-condensed-consolidated-balance-sheet-data-unaudited-in-thousands-thrd-20240808monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-inc-condensed-consolidated-balance-sheet-data-unaudited-in-thousands-thrd-20240326monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-inc-condensed-consolidated-balance-sheet-data-unaudited-in-thousands-thrd-20231109monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-inc-condensed-consolidated-balance-sheet-data-unaudited-in-thousands-thrd-20230810monthly0.5https://www.biopharmawatch.com/news/THRD/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-thrd-20230725monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-inc-condensed-consolidated-balance-sheet-data-unaudited-in-thousands-thrd-20230511monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-inc-condensed-consolidated-balance-sheet-data-unaudited-in-thousands-thrd-20230329monthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-inc-condensed-consolidated-balance-sheet-data-unaudited-in-thousands-thrd-20221109monthly0.5https://www.biopharmawatch.com/news/THRD/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-thrd-20221011monthly0.5https://www.biopharmawatch.com/news/CYBN/filed-by-newsfilecorp-com-helus-pharma-announces-topline-results-in-phase-2-signal-detecti-cybn-20260305monthly0.5https://www.biopharmawatch.com/news/CYBN/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--cybn-20251230monthly0.5https://www.biopharmawatch.com/news/CYBN/filed-by-newsfilecorp-com-cybin-inc-shares-of-common-stock-cybn-20251230monthly0.5https://www.biopharmawatch.com/news/CYBN/filed-by-newsfilecorp-com-execution-version-securities-purchase-agreement-this-securities--cybn-20251028monthly0.5https://www.biopharmawatch.com/news/CYBN/filed-by-newsfilecorp-com-cybn-20250917monthly0.5https://www.biopharmawatch.com/news/CYBN/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--cybn-20250902monthly0.5https://www.biopharmawatch.com/news/CYBN/filed-by-newsfilecorp-com-cybn-20250714monthly0.5https://www.biopharmawatch.com/news/CYBN/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--cybn-20250210monthly0.5https://www.biopharmawatch.com/news/CYBN/filed-by-newsfilecorp-com-cybin-inc-shares-of-common-stock-cybn-20250210monthly0.5https://www.biopharmawatch.com/news/CYBN/filed-by-newsfilecorp-com-cybin-reports-positive-phase-2-data-for-cyb003-demonstrating-bre-cybn-20241118monthly0.5https://www.biopharmawatch.com/news/CYBN/filed-by-newsfilecorp-com-cybn-20240418monthly0.5https://www.biopharmawatch.com/news/CYBN/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--cybn-20240313monthly0.5https://www.biopharmawatch.com/news/CYBN/filed-by-newsfilecorp-com-cybn-20231110monthly0.5https://www.biopharmawatch.com/news/CYBN/filed-by-newsfilecorp-com-small-pharma-inc-formerly-unilock-capital-corp-consolidated-fina-cybn-20231113monthly0.5https://www.biopharmawatch.com/news/CYBN/filed-by-newsfilecorp-com-small-pharma-inc-interim-condensed-consolidated-financial-statem-cybn-20231113monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-provides-2021-year-end-summary-toronto-canada-cybn-20211222monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-to-participate-in-the-11th-annual-lifesci-partners-corporate-access-event-and-h-c-wa-cybn-20211221monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-awarded-notice-of-allowance-from-u-s-patent-and-trademark-office-for-cyb004-deuterat-cybn-20211215monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-confirms-scientific-advice-meeting-with-uk-medical-and-healthcare-products-regulator-cybn-20211208monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-to-present-at-the-stifel-gmp-2-nd-annual-future-of-healthcare-conference-on-cybn-20211202monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-to-participate-in-the-h-c-wainwright-2-nd-annual-psychedelics-conference-on-cybn-20211130monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-announces-additional-adelia-milestone-achievements-toronto-canada-cybn-20211126monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-awards-grant-for-psychedelic-treatment-clinic-at-lenox-hill-hospital-to-benefit-unde-cybn-20211123monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-to-present-at-the-jefferies-london-healthcare-conference-toronto-canada-cybn-20211111monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-to-announce-second-quarter-fy2021-financial-results-and-business-update-on-cybn-20211109monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-announces-positive-cyb003-data-demonstrating-significant-advantages-over-oral-psiloc-cybn-20211108monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-granted-dea-schedule-i-manufacturing-license-the-company-also-welcomes-leah-gibson-a-cybn-20211104monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-hosting-research-and-development-briefing-on-cybn-20211102monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-announces-launch-of-embark-psychedelic-facilitator-training-program-toronto-canada-cybn-20211028monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-announces-fda-investigational-new-drug-authorization-of-cybin-s-sponsored-feasibilit-cybn-20211026monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-announces-completion-of-74-pre-clinical-psychedelic-molecule-studies-the-company-exp-cybn-20211019monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-files-an-international-patent-application-covering-psychedelic-delivery-methods-toro-cybn-20211012monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-announces-additional-adelia-milestone-achievements-toronto-canada-cybn-20211007monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-announces-appointment-of-dr-amir-inamdar-as-chief-medical-officer-for-european-opera-cybn-20211001monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-to-present-at-upcoming-cantor-and-benzinga-investor-conferences-toronto-canada-cybn-20210927monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-to-present-at-the-h-c-wainwright-23-rd-annual-global-investment-conference-on-septem-cybn-20210909monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-announces-additional-adelia-milestone-achievements-toronto-canada-cybn-20210831monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-files-two-additional-international-patent-applications-in-support-of-the-company-s-r-cybn-20210819monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-announces-election-of-theresa-firestone-as-director-results-of-shareholders-meeting--cybn-20210816monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-announces-additional-adelia-milestone-achievements-toronto-canada-cybn-20210812monthly0.5https://www.biopharmawatch.com/news/CYBN/form-51-102f3-material-change-report-item-1-name-and-address-of-company-cybin-inc-formerly-cybn-20210727monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-to-present-at-canaccord-genuity-s-41-st-annual-growth-conference-on-august-10-th-tor-cybn-20210809monthly0.5https://www.biopharmawatch.com/news/CYBN/cybin-to-commence-trading-on-the-nyse-american-on-august-5-toronto-canada-cybn-20210804monthly0.5https://www.biopharmawatch.com/news/SMLR/supplemental-business-disclosures-regarding-strive-inc-on-smlr-20251209monthly0.5https://www.biopharmawatch.com/news/SMLR/unaudited-pro-forma-combined-consolidated-financial-information-the-following-unaudited-pr-smlr-20251114monthly0.5https://www.biopharmawatch.com/news/SMLR/supplemental-business-disclosures-regarding-strive-inc-on-smlr-20251110monthly0.5https://www.biopharmawatch.com/news/SMLR/supplemental-business-disclosures-regarding-strive-inc-on-smlr-20251106monthly0.5https://www.biopharmawatch.com/news/SMLR/is-attached-is-based-in-part-on-certain-assumptions-regarding-the-merger-that-strive-belie-smlr-20250924monthly0.5https://www.biopharmawatch.com/news/SMLR/of-strive-s-current-report-on-form-8-k-filed-with-the-sec-on-smlr-20250915monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-reports-second-quarter-2025-financial-results-btc-holdings-of-5-021-and--smlr-20250731monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-reports-first-quarter-2025-financial-results-btc-yield-of-22-2-ytd-now-h-smlr-20250513monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-announces-updated-btc-atm-activity-purchased-additional-165-btc-now-hold-smlr-20250430monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-announces-updated-btc-atm-activity-purchased-additional-111-btc-now-hold-smlr-20250425monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-reports-fourth-quarter-and-full-year-2024-financial-results-with-a-btc-y-smlr-20250218monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-announces-updated-btc-activity-monetizes-minority-investment-to-purchase-smlr-20250204monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-announces-proposed-private-offering-of-75-0-million-of-convertible-senio-smlr-20250123monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-announces-select-preliminary-unaudited-fourth-quarter-2024-financial-res-smlr-20250123monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-announces-updated-btc-and-atm-activity-purchased-additional-237-btc-now--smlr-20250113monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-announces-updated-btc-and-atm-activity-purchased-additional-211-btc-now--smlr-20241216monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-announces-updated-btc-and-atm-activity-purchased-additional-303-btc-now--smlr-20241205monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-announces-updated-btc-and-atm-activity-purchased-additional-297-btc-now--smlr-20241125monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-announces-btc-and-atm-activity-raised-21-5-million-purchased-additional--smlr-20241118monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-reports-third-quarter-2024-financial-results-and-additional-bitcoin-purc-smlr-20241104monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-announces-additional-bitcoin-purchases-santa-clara-calif-smlr-20240826monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-reports-second-quarter-2024-financial-results-and-additional-bitcoin-pur-smlr-20240805monthly0.5https://www.biopharmawatch.com/news/SMLR/bitcoin-strategy-related-supplemental-disclosures-bitcoin-treasury-strategy-we-are-not-reg-smlr-20240731monthly0.5https://www.biopharmawatch.com/news/SMLR/bitcoin-strategy-related-supplemental-disclosures-bitcoin-treasury-strategy-we-are-not-reg-smlr-20240711monthly0.5https://www.biopharmawatch.com/news/SMLR/bitcoin-strategy-related-supplemental-disclosures-bitcoin-treasury-strategy-summary-this-s-smlr-20240606monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-announces-bitcoin-treasury-strategy-s-anta-clara-ca-smlr-20240528monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-reports-first-quarter-2024-financial-results-2024-q1-highlights-compared-smlr-20240507monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-reports-fourth-quarter-and-full-year-2023-financial-results-2023-q4-and--smlr-20240305monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-reports-third-quarter-and-year-to-date-2023-financial-results-2023-q3-hi-smlr-20231109monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-reports-second-quarter-and-first-half-of-2023-financial-results-2023-q2--smlr-20230810monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-announces-appointment-of-chief-financial-officer-record-quarterly-revenu-smlr-20230711monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-reports-first-quarter-2023-financial-results-2023-q1-highlights-revenue--smlr-20230510monthly0.5https://www.biopharmawatch.com/news/SMLR/nasdaq-smlr-needham-virtual-healthcare-conference-april-2023-forward-looking-statements-th-smlr-20230417monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-reports-fourth-quarter-and-full-year-2022-financial-results-2022-q4-and--smlr-20230321monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-third-quarter-and-year-to-date-2022-financial-results-2022-q3-quarterly-hig-smlr-20221101monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-second-quarter-and-first-half-of-2022-financial-results-2022-q2-quarterly-h-smlr-20220802monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-first-quarter-2022-financial-results-2022-q1-highlights-compared-to-the-cor-smlr-20220502monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-s-board-of-directors-authorizes-an-up-to-20-0-million-stock-repurchase-p-smlr-20220314monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-fourth-quarter-and-year-to-date-2021-financial-results-2021-highlights-comp-smlr-20220228monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-third-quarter-and-year-to-date-2021-financial-results-highlights-year-to-da-smlr-20211101monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-second-quarter-and-first-half-of-2021-financial-results-2021-q2-highlights--smlr-20210802monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-first-quarter-2021-financial-results-2021-q1-highlights-compared-to-the-cor-smlr-20210503monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-record-fourth-quarter-and-year-end-2020-financial-results-2020-highlights-c-smlr-20210301monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-record-third-quarter-and-year-to-date-2020-financial-results-2020-q3-highli-smlr-20201105monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-second-quarter-and-first-half-2020-financial-results-2020-q2-highlights-com-smlr-20200803monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-first-quarter-2020-financial-results-2020-q1-highlights-compared-to-the-cor-smlr-20200504monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-record-fourth-quarter-and-year-end-2019-financial-results-2019-highlights-c-smlr-20200303monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-record-third-quarter-and-year-to-date-2019-financial-results-2019-q3-highli-smlr-20191030monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-record-second-quarter-and-first-half-2019-financial-results-2019-q2-highlig-smlr-20190726monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-first-quarter-2019-financial-results-2019-q1-highlights-compared-to-the-cor-smlr-20190429monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-fourth-quarter-and-year-end-2018-financial-results-2018-highlights-compared-smlr-20190227monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-third-quarter-and-year-to-date-2018-financial-results-san-jose-cal-smlr-20181026monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-second-quarter-and-first-half-2018-financial-results-continued-growth-in-re-smlr-20180731monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-first-quarter-2018-financial-results-profitability-continues-san-jose-cal-smlr-20180501monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-fourth-quarter-and-yearly-2017-financial-results-first-quarterly-profit-ach-smlr-20180228monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-third-quarter-and-year-to-date-2017-financial-results-strong-revenue-growth-smlr-20171031monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-second-quarter-and-first-half-2017-financial-results-strong-revenue-growth--smlr-20170802monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-first-quarter-2017-financial-results-inventory-and-manufacturing-capacity-g-smlr-20170509monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-fourth-quarter-and-annual-2016-financial-results-continuing-to-increase-mar-smlr-20170310monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-third-quarter-and-year-to-date-2016-financial-results-closer-to-the-thresho-smlr-20161028monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-inc-to-begin-trading-on-otcqb-portland-ore-smlr-20160811monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-second-quarter-and-year-to-date-2016-financial-results-sequential-revenue-g-smlr-20160729monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-2016-first-quarter-financial-results-improvement-in-operating-expenses-supp-smlr-20160429monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-2015-annual-and-fourth-quarter-financial-results-year-over-year-revenue-gro-smlr-20160219monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-third-quarter-2015-financial-results-year-over-year-growth-of-74-quarterly--smlr-20151030monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-second-quarter-2015-financial-results-year-over-year-growth-of-54-quarterly-smlr-20150731monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-first-quarter-2015-financial-results-period-over-period-growth-of-44-quarte-smlr-20150501monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-2014-annual-and-fourth-quarter-financial-results-annual-growth-of-60-and-qu-smlr-20150206monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-third-quarter-2014-financial-results-portland-ore-smlr-20141031monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-second-quarter-2014-financial-results-portland-ore-smlr-20140725monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-inc-appoints-risk-management-and-business-development-expert-aidan-m-col-smlr-20140708monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-inc-appoints-managed-care-leader-abbie-leibowitz-m-d-to-its-board-of-dir-smlr-20140626monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-inc-appoints-healthcare-technology-expert-wayne-t-pan-m-d-ph-d-to-its-bo-smlr-20140514monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-scientific-inc-appoints-medical-device-and-pharmaceutical-industry-leader-bruce-j-b-smlr-20140506monthly0.5https://www.biopharmawatch.com/news/SMLR/semler-reports-first-quarter-2014-financial-results-semler-builds-momentum-with-revenue-up-smlr-20140422monthly0.5https://www.biopharmawatch.com/news/RVNC/crown-laboratories-announces-completion-of-acquisition-of-revance-therapeutics-the-busines-rvnc-20250206monthly0.5https://www.biopharmawatch.com/news/RVNC/crown-laboratories-and-revance-amend-the-a-r-merger-agreement-to-increase-offer-price-to-3-rvnc-20250121monthly0.5https://www.biopharmawatch.com/news/RVNC/crown-laboratories-and-revance-enter-into-amended-and-restated-merger-agreement-johnson-ci-rvnc-20241209monthly0.5https://www.biopharmawatch.com/news/RVNC/twelfth-waiver-to-agreement-and-plan-of-merger-this-twelfth-waiver-to-agreement-and-plan-o-rvnc-20241205monthly0.5https://www.biopharmawatch.com/news/RVNC/eleventh-waiver-to-agreement-and-plan-of-merger-this-eleventh-waiver-to-agreement-and-plan-rvnc-20241203monthly0.5https://www.biopharmawatch.com/news/RVNC/tenth-waiver-to-agreement-and-plan-of-merger-this-tenth-waiver-to-agreement-and-plan-of-me-rvnc-20241129monthly0.5https://www.biopharmawatch.com/news/RVNC/ninth-waiver-to-agreement-and-plan-of-merger-this-ninth-waiver-to-agreement-and-plan-of-me-rvnc-20241126monthly0.5https://www.biopharmawatch.com/news/RVNC/eighth-waiver-to-agreement-and-plan-of-merger-this-eighth-waiver-to-agreement-and-plan-of--rvnc-20241119monthly0.5https://www.biopharmawatch.com/news/RVNC/seventh-waiver-to-agreement-and-plan-of-merger-this-seventh-waiver-to-agreement-and-plan-o-rvnc-20241112monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-third-quarter-2024-financial-results-provides-corporate-update-on-rvnc-20241107monthly0.5https://www.biopharmawatch.com/news/RVNC/sixth-waiver-to-agreement-and-plan-of-merger-this-sixth-waiver-to-agreement-and-plan-of-me-rvnc-20241101monthly0.5https://www.biopharmawatch.com/news/RVNC/fifth-waiver-to-agreement-and-plan-of-merger-this-fifth-waiver-to-agreement-and-plan-of-me-rvnc-20241025monthly0.5https://www.biopharmawatch.com/news/RVNC/fourth-waiver-to-agreement-and-plan-of-merger-this-fourth-waiver-to-agreement-and-plan-of--rvnc-20241018monthly0.5https://www.biopharmawatch.com/news/RVNC/third-waiver-to-agreement-and-plan-of-merger-this-third-waiver-to-agreement-and-plan-of-me-rvnc-20241003monthly0.5https://www.biopharmawatch.com/news/RVNC/second-waiver-to-agreement-and-plan-of-merger-this-second-waiver-to-agreement-and-plan-of--rvnc-20240919monthly0.5https://www.biopharmawatch.com/news/RVNC/waiver-to-agreement-and-plan-of-merger-this-waiver-to-agreement-and-plan-of-merger-this-wa-rvnc-20240827monthly0.5https://www.biopharmawatch.com/news/RVNC/crown-laboratories-and-revance-announce-entry-into-merger-agreement-combination-provides-o-rvnc-20240812monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-second-quarter-2024-financial-results-provides-corporate-update-q2-total-d-rvnc-20240808monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-first-quarter-2024-financial-results-provides-corporate-update-total-net-p-rvnc-20240509monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-fourth-quarter-and-full-year-2023-financial-results-provides-corporate-upd-rvnc-20240228monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-provides-corporate-update-preliminary-fourth-quarter-and-full-year-2023-financial--rvnc-20240108monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-third-quarter-2023-financial-results-provides-corporate-update-q3-total-pr-rvnc-20231108monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-provides-corporate-update-at-investor-day-nashville-tenn-business-wire-rvnc-20230919monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-second-quarter-2023-financial-results-provides-corporate-update-q2-total-r-rvnc-20230808monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-first-quarter-2023-financial-results-provides-corporate-update-q1-total-re-rvnc-20230509monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-fourth-quarter-and-full-year-2022-financial-results-provides-corporate-upd-rvnc-20230228monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-provides-an-update-on-daxxify-commercial-launch-and-preliminary-fourth-quarter-and-rvnc-20230109monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-third-quarter-2022-financial-results-provides-corporate-update-received-fd-rvnc-20221108monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-second-quarter-2022-financial-results-provides-corporate-update-pdufa-date-rvnc-20220809monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-first-quarter-2022-financial-results-provides-corporate-update-pdufa-date--rvnc-20220510monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-fourth-quarter-and-full-year-2021-financial-results-provides-corporate-upd-rvnc-20220228monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-provides-preliminary-fourth-quarter-and-full-year-2021-financial-results-and-a-cor-rvnc-20211222monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-third-quarter-2021-financial-results-provides-corporate-update-q3-revenue--rvnc-20211109monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-second-quarter-2021-financial-results-provides-corporate-update-q2-revenue-rvnc-20210805monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-first-quarter-2021-financial-results-provides-corporate-update-q1-revenue--rvnc-20210510monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-fourth-quarter-and-full-year-2020-financial-results-fourth-quarter-and-ful-rvnc-20210222monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-provides-corporate-update-and-anticipated-milestones-for-2021-rvnc-20210107monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-therapeutics-inc-125-000-000-rvnc-20201127monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-third-quarter-2020-financial-results-and-provides-corporate-update-confere-rvnc-20201109monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-positive-results-from-aspen-1-phase-3-trial-of-daxibotulinumtoxina-for-inj-rvnc-20201014monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-second-quarter-2020-financial-results-provides-corporate-update-conference-rvnc-20200806monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-announces-agreement-to-acquire-hintmd-and-its-proprietary-fintech-platform-for-aes-rvnc-20200519monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-first-quarter-2020-financial-results-provides-corporate-update-conference--rvnc-20200507monthly0.5https://www.biopharmawatch.com/news/RVNC/of-our-current-report-on-form-8-k-filed-rvnc-20200210monthly0.5https://www.biopharmawatch.com/news/RVNC/250-000-000-revance-therapeutics-inc-1-75-convertible-senior-notes-due-2027-purchase-agree-rvnc-20200211monthly0.5https://www.biopharmawatch.com/news/RVNC/to-revance-s-current-report-on-form-8-k-filed-with-the-securities-and-exchange-commission--rvnc-20200210monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-provides-corporate-update-and-anticipated-milestones-for-2020-rvnc-20200109monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-third-quarter-2019-financial-results-provides-corporate-update-conference--rvnc-20191104monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-second-quarter-2019-financial-results-provides-corporate-update-conference-rvnc-20190805monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-adds-iconic-brand-builder-jill-beraud-to-board-of-directors-beraud-will-also-chair-rvnc-20190606monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-first-quarter-2019-financial-results-and-provides-corporate-update-confere-rvnc-20190508monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-releases-fourth-quarter-and-full-year-2018-results-successful-2018-positive-sakura-rvnc-20190226monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-s-rt002-demonstrates-unprecedented-efficacy-and-duration-in-largest-ever-aesthetic-rvnc-20181204monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-releases-third-quarter-2018-results-chief-financial-officer-toby-schilke-and-inter-rvnc-20181101monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-releases-second-quarter-2018-results-newark-calif-august-2-revance-therapeutics-in-rvnc-20180802monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-releases-first-quarter-2018-results-newark-calif-may-8-revance-therapeutics-inc-na-rvnc-20180508monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-investor-day-highlights-new-neuroscience-indications-in-development-lead-product-f-rvnc-20180419monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-therapeutics-inc-shares-of-common-stock-par-value-0-001-per-share-controlled-equit-rvnc-20180313monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-releases-fourth-quarter-and-full-year-2017-results-announces-collaboration-and-lic-rvnc-20180228monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-announces-interim-phase-2a-results-for-rt002-in-treating-plantar-fasciitis-rvnc-20180108monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-provides-update-on-anticipated-clinical-milestones-and-financial-outlook-for-2018--rvnc-20180104monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-s-rt002-meets-primary-and-all-secondary-endpoints-achieves-6-month-duration-in-piv-rvnc-20171205monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-releases-third-quarter-2017-results-sakura-1-2-phase-3-pivotal-trials-on-track-to--rvnc-20171102monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-appoints-mark-foley-to-its-board-of-directors-newark-calif-september-6-2017-revanc-rvnc-20170905monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-releases-second-quarter-2017-results-rvnc-20170803monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-therapeutics-expands-leadership-team-appointing-todd-zavodnick-chief-commercial-of-rvnc-20170802monthly0.5https://www.biopharmawatch.com/news/RVNC/forward-looking-statements-safe-harbor-this-presentation-contains-forward-looking-statemen-rvnc-20170606monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-additional-positive-week-24-efficacy-results-from-rt002-injectable-phase-2-rvnc-20170607monthly0.5https://www.biopharmawatch.com/news/RVNC/study-objectives-to-assess-the-safety-and-preliminary-efficacy-of-rt002-for-injection-in-s-rvnc-20170518monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-therapeutics-1q-2017-conference-call-tuesday-may-9-2017-operator-welcome-to-the-re-rvnc-20170509monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-releases-first-quarter-2017-results-completed-enrollment-in-sakura-1-2-phase-3-piv-rvnc-20170509monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-releases-fourth-quarter-and-full-year-2016-results-cash-and-investments-of-185-5-m-rvnc-20170227monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-provides-clinical-milestones-and-financial-outlook-for-2017-reports-2016-unaudited-rvnc-20170105monthly0.5https://www.biopharmawatch.com/news/RVNC/forward-looking-statements-safe-harbor-this-presentation-contains-forward-looking-statemen-rvnc-20161212monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-releases-third-quarter-2016-results-rvnc-20161103monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-releases-second-quarter-2016-results-completes-enrollment-of-second-cohort-of-pati-rvnc-20160804monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-appoints-industry-leader-julian-s-gangolli-to-its-board-of-directors-rvnc-20160705monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-reports-results-for-rt001-topical-phase-3-trial-for-lateral-canthal-lines-revance--rvnc-20160613monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-expands-botulinum-toxin-assets-by-acquiring-intellectual-property-ip-portfolio-por-rvnc-20160602monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-releases-first-quarter-2016-results-completes-enrollment-in-realise-1-phase-3-tria-rvnc-20160509monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-releases-fourth-quarter-and-full-year-2015-results-announces-2016-outlook-on-track-rvnc-20160302monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-specifies-2016-clinical-program-milestones-updates-2015-year-end-cash-and-investme-rvnc-20160107monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-announces-positive-phase-2-results-for-rt001-botulinum-toxin-type-a-topical-gel-to-rvnc-20151223monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-therapeutics-inc-amended-and-restated-2014-inducement-plan-adopted-by-board-on-aug-rvnc-20151214monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-therapeutics-releases-third-quarter-2015-results-momentum-continues-on-multiple-cl-rvnc-20151109monthly0.5https://www.biopharmawatch.com/news/RVNC/as-used-in-this-current-report-on-form-8-k-or-this-current-report-revance-therapeutics-rev-rvnc-20151029monthly0.5https://www.biopharmawatch.com/news/RVNC/forward-looking-statements-safe-harbor-this-presentation-contains-forward-looking-statemen-rvnc-20151029monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-therapeutics-releases-second-quarter-2015-results-plans-to-move-forward-on-multipl-rvnc-20150806monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-therapeutics-announces-change-in-role-of-jacob-waugh-rvnc-20150702monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-therapeutics-to-initiate-two-key-trials-for-rt001-its-topical-botulinum-toxin-type-rvnc-20150603monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-therapeutics-releases-first-quarter-2015-financial-results-completes-enrollment-in-rvnc-20150513monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-therapeutics-releases-fourth-quarter-and-full-year-2014-financial-results-and-reit-rvnc-20150302monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-appoints-dr-philip-vickers-to-its-board-of-directors-rvnc-20150226monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-therapeutics-defines-clinical-program-milestones-and-provides-financial-guidance-f-rvnc-20150112monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-therapeutics-releases-third-quarter-2014-results-confirmation-of-plans-to-initiate-rvnc-20141112monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-therapeutics-releases-second-quarter-2014-financial-results-reiterates-full-year-f-rvnc-20140812monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-therapeutics-releases-first-quarter-2014-financial-results-reiterates-full-year-fi-rvnc-20140513monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-therapeutics-releases-fourth-quarter-and-full-year-2013-financial-results-and-prov-rvnc-20140326monthly0.5https://www.biopharmawatch.com/news/RVNC/revance-to-add-angus-c-russell-as-chairman-to-its-board-of-directors-newark-c-alif-rvnc-20140305monthly0.5https://www.biopharmawatch.com/news/THAR/canton-strategic-holdings-inc-announces-authorization-of-share-repurchase-program-thar-20260616monthly0.5https://www.biopharmawatch.com/news/THAR/canton-strategic-holdings-reports-full-year-2025-financial-and-operational-results-first-a-thar-20260331monthly0.5https://www.biopharmawatch.com/news/THAR/canton-strategic-holdings-inc-chairman-and-ceo-mark-wendland-elected-to-canton-foundation--thar-20260303monthly0.5https://www.biopharmawatch.com/news/THAR/confidential-draft-tharimmune-inc-announces-corporate-rebrand-to-canton-strategic-holdings-thar-20260218monthly0.5https://www.biopharmawatch.com/news/THAR/tharimmune-inc-appoints-mark-wendland-chairman-of-the-board-and-names-angela-radkowski-chi-thar-20260206monthly0.5https://www.biopharmawatch.com/news/THAR/tharimmune-elects-jill-sommers-and-william-wiley-to-board-of-directors-new-directors-stren-thar-20260202monthly0.5https://www.biopharmawatch.com/news/THAR/tharimmune-announces-expanded-role-as-super-validator-on-canton-network-advances-digital-a-thar-20260126monthly0.5https://www.biopharmawatch.com/news/THAR/tharimmune-inc-announces-closing-of-55-million-underwritten-registered-direct-offering-thar-20260122monthly0.5https://www.biopharmawatch.com/news/THAR/tharimmune-inc-announces-pricing-of-55-million-underwritten-registered-offering-thar-20260120monthly0.5https://www.biopharmawatch.com/news/THAR/tharimmune-inc-appoints-jacob-asbury-as-chief-financial-officer-to-advance-canton-coin-tre-thar-20251212monthly0.5https://www.biopharmawatch.com/news/THAR/tharimmune-inc-closes-545-million-private-placement-to-establish-canton-coin-treasury-stra-thar-20251106monthly0.5https://www.biopharmawatch.com/news/THAR/tharimmune-inc-announces-private-placement-of-approximately-540-million-led-by-drw-and-lib-thar-20251103monthly0.5https://www.biopharmawatch.com/news/THAR/tharimmune-thar-20250831monthly0.5https://www.biopharmawatch.com/news/THAR/nancy-davis-visionary-philanthropist-and-founder-of-race-to-erase-ms-and-cure-addiction-no-thar-20250805monthly0.5https://www.biopharmawatch.com/news/THAR/tharimmune-announces-pricing-of-1-74-million-registered-direct-public-offering-of-common-s-thar-20250723monthly0.5https://www.biopharmawatch.com/news/THAR/tharimmune-announces-2-02-million-private-placement-to-advance-development-programs-bridge-thar-20241206monthly0.5https://www.biopharmawatch.com/news/THAR/tharimmune-acquires-global-license-and-partners-with-intract-pharma-to-develop-an-oral-for-thar-20240916monthly0.5https://www.biopharmawatch.com/news/THAR/tharimmune-announces-2-08-million-private-placement-bridgewater-n-j-accesswire-thar-20240620monthly0.5https://www.biopharmawatch.com/news/THAR/tharimmune-announces-1-for-15-reverse-stock-split-bridgewater-n-j-thar-20240522monthly0.5https://www.biopharmawatch.com/news/THAR/tharimmune-reports-positive-phase-1-data-on-th104-its-lead-therapeutic-candidate-for-chron-thar-20231127monthly0.5https://www.biopharmawatch.com/news/THAR/tharimmune-announces-1-for-25-reverse-stock-split-bridgewater-n-j-thar-20231117monthly0.5https://www.biopharmawatch.com/news/THAR/tharimmune-executes-exclusive-global-licensing-agreement-for-innovative-clinical-stage-ass-thar-20231106monthly0.5https://www.biopharmawatch.com/news/THAR/hillstream-biopharma-progressing-towards-acquiring-clinical-stage-asset-and-announces-corp-thar-20230925monthly0.5https://www.biopharmawatch.com/news/THAR/hillstream-biopharma-strengthens-its-board-of-directors-with-appointment-of-kelly-anderson-thar-20230515monthly0.5https://www.biopharmawatch.com/news/THAR/hillstream-biopharma-announces-proposed-public-offering-bridgewater-n-j-thar-20230427monthly0.5https://www.biopharmawatch.com/news/ALIM/ani-pharmaceuticals-and-alimera-sciences-announce-closing-date-of-merger-ani-and-alimera-s-alim-20240911monthly0.5https://www.biopharmawatch.com/news/ALIM/alimera-sciences-takes-legal-action-against-ani-pharmaceuticals-to-enforce-merger-agreemen-alim-20240910monthly0.5https://www.biopharmawatch.com/news/ALIM/ani-pharmaceuticals-to-further-expand-rare-disease-business-through-acquisition-of-alimera-alim-20240624monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-xfeff-xfeff-xfeff-for-immediate-release-xfeff-xfeff-alimera-sciences-reports-first-q-alim-20240514monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-for-immediate-release-xfeff-alimera-sciences-reports-fourth-quarter-and-full-year-20-alim-20240307monthly0.5https://www.biopharmawatch.com/news/ALIM/alimera-sciences-names-elliot-maltz-as-chief-financial-officer-and-reports-inducement-gran-alim-20240102monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-xfeff-alimera-sciences-appoints-todd-wood-as-president-of-u-s-operations-and-reports-alim-20231212monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-for-immediate-release-xfeff-alimera-appoints-maggie-a-pax-t-o-its-board-of-directors-alim-20231108monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-f-or-immediate-release-alimera-sciences-reports-third-quarter-2023-results-xfeff-xb7-alim-20231026monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-xfeff-alimera-sciences-appoints-jason-werner-as-chief-operating-officer-xfeff-dr-phi-alim-20231002monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-f-or-immediate-release-alimera-sciences-reports-second-quarter-202-3-results-xfeff-x-alim-20230810monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-xfeff-for-immediate-release-xfeff-alimera-acquires-u-s-commercial-rights-to-yutiq-xa-alim-20230518monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-for-immediate-release-xfeff-xfeff-alimera-sciences-reports-first-quarter-2023-result-alim-20230515monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-for-immediate-release-xfeff-alimera-sciences-announces-2022-financial-results-and-bu-alim-20230331monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-for-immediate-release-xfeff-xfeff-alimera-improves-capital-structure-strengthens-bal-alim-20230324monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-for-immediate-release-xfeff-alimera-appoints-roger-sawhney-m-d-t-o-its-board-of-dire-alim-20230301monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-xfeff-for-immediate-release-xfeff-xfeff-alimera-sciences-appoints-industry-veteran-r-alim-20230109monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-for-immediate-release-xfeff-alimera-sciences-announces-agreement-to-extend-amortizat-alim-20221208monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-for-immediate-release-xfeff-alimera-sciences-announces-third-quarter-2022-financial--alim-20221114monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-for-immediate-release-xfeff-alimera-sciences-announces-second-quarter-2022-financial-alim-20220727monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-xfeff-xfeff-xfeff-for-immediate-release-xfeff-alimera-sciences-reports-first-quarter-alim-20220509monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-alimera-sciences-reports-fourth-quarter-and-fy-2021-re-alim-20220224monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-xfeff-xfeff-alimera-sciences-welcomes-ophthalmic-strategic-consultant-erin-parsons-t-alim-20211201monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-xfeff-xfeff-for-immediate-release-xfeff-alimera-sciences-announces-third-quarter-20--alim-20211028monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-xfeff-xfeff-xfeff-xfeff-f-or-immediate-release-alimera-sciences-announces-second-qua-alim-20210813monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-xfeff-xfeff-xfeff-xfeff-f-or-immediate-release-alimera-sciences-announces-first-quar-alim-20210428monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-xfeff-xfeff-for-immediate-release-xfeff-xfeff-alimera-sciences-receives-20-million-f-alim-20210414monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-for-immediate-release-xfeff-alimera-sciences-rep-alim-20210225monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-for-immediate-release-xfeff-alimera-sciences-announces-alim-20210119monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-for-immediate-release-xfeff-alimera-sciences-ann-alim-20201028monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-for-immediate-release-xfeff-alimera-sciences-ann-alim-20200730monthly0.5https://www.biopharmawatch.com/news/ALIM/xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-for-immediate-release-xfeff-alimera-sciences-initiates-alim-20200630monthly0.5https://www.biopharmawatch.com/news/ALIM/alimera-sciences-announces-first-quarter-2020-financial-results-and-provides-corporate-upd-alim-20200429monthly0.5https://www.biopharmawatch.com/news/ALIM/alimera-sciences-receives-1-8-million-loan-under-the-paycheck-protection-act-atlanta-alim-20200423monthly0.5https://www.biopharmawatch.com/news/ALIM/alimera-sciences-pre-announces-expected-top-line-revenue-for-q1-2020-and-provides-covid-19-alim-20200413monthly0.5https://www.biopharmawatch.com/news/ALIM/alimera-sciences-reports-record-fourth-quarter-and-2019-results-fourth-quarter-highlights--alim-20200226monthly0.5https://www.biopharmawatch.com/news/ALIM/for-press-inquiries-jules-abraham-for-alimera-sciences-917-885-7378-julesa-coreir-com-for--alim-20200224monthly0.5https://www.biopharmawatch.com/news/ALIM/for-press-inquiries-jules-abraham-for-alimera-sciences-917-885-7378-julesa-coreir-com-for--alim-20200106monthly0.5https://www.biopharmawatch.com/news/ALIM/exhibit-for-immediate-release-for-press-inquiries-jules-abraham-for-alimera-sciences-917-8-alim-20191107monthly0.5https://www.biopharmawatch.com/news/ALIM/for-press-inquiries-jules-abraham-for-alimera-sciences-917-885-7378-julesa-coreir-com-for--alim-20191002monthly0.5https://www.biopharmawatch.com/news/ALIM/alimera-sciences-board-of-directors-approves-reverse-stock-split-and-10b5-1-stock-purchase-alim-20190905monthly0.5https://www.biopharmawatch.com/news/ALIM/alimera-sciences-announces-second-quarter-2019-financial-results-and-provides-corporate-up-alim-20190729monthly0.5https://www.biopharmawatch.com/news/ALIM/for-press-inquiries-for-investor-inquiries-jules-abraham-scott-gordon-for-alimera-sciences-alim-20190719monthly0.5https://www.biopharmawatch.com/news/ALIM/for-press-inquiries-for-investor-inquiries-katie-brazel-cg-capital-for-alimera-sciences-fo-alim-20180904monthly0.5https://www.biopharmawatch.com/news/ALIM/for-press-inquiries-for-investor-inquiries-katie-brazel-cg-capital-for-alimera-sciences-fo-alim-20180108monthly0.5https://www.biopharmawatch.com/news/ALIM/for-press-inquiries-katie-brazel-for-alimera-sciences-404-317-8361-kbrazel-bellsouth-net-f-alim-20160811monthly0.5https://www.biopharmawatch.com/news/ALIM/penetration-of-iluvien-alimera-s-belief-that-its-refinancing-plans-will-provide-additional-alim-20160726monthly0.5https://www.biopharmawatch.com/news/ALIM/alimera-sciences-inc-index-to-financial-statements-page-report-of-independent-registered-p-alim-20150918monthly0.5https://www.biopharmawatch.com/news/ALIM/alimera-sciences-announces-closing-of-50-0-million-financing-with-deerfield-management-atl-alim-20141215monthly0.5https://www.biopharmawatch.com/news/ALIM/alimera-sciences-announces-agreement-with-deerfield-management-for-50-0-million-financing--alim-20141128monthly0.5https://www.biopharmawatch.com/news/ALIM/for-press-inquiries-katie-brazel-fleishman-hillard-for-alimera-sciences-404-739-0150-katie-alim-20121204monthly0.5https://www.biopharmawatch.com/news/ALIM/for-investor-inquiries-john-mills-icr-for-alimera-sciences-310-954-1105-john-mills-icrinc--alim-20121107monthly0.5https://www.biopharmawatch.com/news/ALIM/icr-llc-for-alimera-sciences-john-mills-310-954-1105-john-mills-icrinc-com-for-press-inqui-alim-20121002monthly0.5https://www.biopharmawatch.com/news/ALIM/for-investor-inquiries-john-mills-icr-for-alimera-sciences-310-954-1105-john-mills-icrinc--alim-20120809monthly0.5https://www.biopharmawatch.com/news/ALIM/icr-llc-for-alimera-sciences-john-mills-310-954-1105-john-mills-icrinc-com-alimera-science-alim-20120718monthly0.5https://www.biopharmawatch.com/news/ALIM/for-investor-inquiries-john-mills-icr-for-alimera-sciences-310-954-1105-john-mills-icrinc--alim-20120511monthly0.5https://www.biopharmawatch.com/news/ALIM/for-investor-inquiries-john-mills-icr-for-alimera-sciences-310-954-1105-john-mills-icrinc--alim-20120308monthly0.5https://www.biopharmawatch.com/news/ALIM/for-press-inquiries-katie-brazel-fleishman-hillard-for-alimera-sciences-404-739-0150-katie-alim-20120228monthly0.5https://www.biopharmawatch.com/news/ALIM/for-press-inquiries-for-investor-inquiries-katie-brazel-fleishman-hillard-for-alimera-scie-alim-20111111monthly0.5https://www.biopharmawatch.com/news/ALIM/investor-contact-icr-llc-john-mills-310-954-1105-john-mills-icrinc-com-alimera-sciences-re-alim-20111103monthly0.5https://www.biopharmawatch.com/news/ALIM/iluvien-r-fame-tm-study-fluocinolone-acetonide-in-diabetic-macular-edema-36-month-results--alim-20110825monthly0.5https://www.biopharmawatch.com/news/ALIM/investor-contact-icr-llc-john-mills-310-954-1105-john-mills-icrinc-com-alimera-sciences-re-alim-20110804monthly0.5https://www.biopharmawatch.com/news/ALIM/for-press-inquiries-for-investor-inquiries-katie-brazel-fleishman-hillard-john-mills-icr-f-alim-20110801monthly0.5https://www.biopharmawatch.com/news/ALIM/investor-contact-icr-llc-john-mills-310-954-1105-john-mills-icrinc-com-alimera-sciences-ex-alim-20110517monthly0.5https://www.biopharmawatch.com/news/ALIM/investor-contact-icr-llc-john-mills-310-954-1105-john-mills-icrinc-com-alimera-sciences-re-alim-20110505monthly0.5https://www.biopharmawatch.com/news/ALIM/fluocinolone-acetonide-in-diabetic-macular-edema-fame-tm-study-36-month-results-andrew-n-a-alim-20110503monthly0.5https://www.biopharmawatch.com/news/ALIM/fame-tm-study-fluocinolone-acetonide-in-diabetic-macular-edema-month-36-results-peter-a-ca-alim-20110214monthly0.5https://www.biopharmawatch.com/news/ALIM/alimera-sciences-reports-fourth-quarter-2010-financial-results-reiterates-positive-36-mont-alim-20110210monthly0.5https://www.biopharmawatch.com/news/ALIM/for-press-inquiries-for-investor-inquiries-katie-brazel-fleishman-hillard-for-alimera-scie-alim-20110203monthly0.5https://www.biopharmawatch.com/news/ALIM/for-press-inquiries-for-investor-inquiries-katie-brazel-fleishman-hillard-john-mills-icr-f-alim-20101223monthly0.5https://www.biopharmawatch.com/news/IMAB/novabridge-biosciences-receives-fda-fast-track-designation-for-givastomig-in-first-line-he-imab-20260616monthly0.5https://www.biopharmawatch.com/news/IMAB/novabridge-appoints-mark-hagler-as-president-and-chief-commercial-officer-to-advance-comme-imab-20260422monthly0.5https://www.biopharmawatch.com/news/IMAB/novabridge-reports-full-year-2025-financial-results-and-provides-business-update-x2022-suc-imab-20260407monthly0.5https://www.biopharmawatch.com/news/IMAB/novabridge-announces-productive-fda-type-b-meeting-on-potential-accelerated-approval-pathw-imab-20260316monthly0.5https://www.biopharmawatch.com/news/IMAB/novabridge-and-visara-announce-positive-results-from-vis-101-phase-2a-wet-amd-study-x2022--imab-20260309monthly0.5https://www.biopharmawatch.com/news/IMAB/novabridge-to-host-business-update-call-to-review-phase-2a-data-for-vis-101-in-wet-amd-on--imab-20260303monthly0.5https://www.biopharmawatch.com/news/IMAB/company-presentation-february-2026-disclaimer-this-presentation-has-been-prepared-by-novab-imab-20260225monthly0.5https://www.biopharmawatch.com/news/IMAB/novabridge-appoints-biotech-leader-emmett-t-cunningham-jr-md-phd-mph-as-vice-chairman-of-t-imab-20260219monthly0.5https://www.biopharmawatch.com/news/IMAB/novabridge-doses-first-patient-in-global-randomized-phase-2-study-of-givastomig-combined-w-imab-20260217monthly0.5https://www.biopharmawatch.com/news/IMAB/company-presentation-february-2026-disclaimer-this-presentation-has-been-prepared-by-novab-imab-20260206monthly0.5https://www.biopharmawatch.com/news/IMAB/novabridge-presents-positive-givastomig-dose-expansion-data-from-the-phase-1b-combination--imab-20260106monthly0.5https://www.biopharmawatch.com/news/IMAB/novabridge-presents-positive-ragistomig-phase-1-dose-expansion-data-at-esmo-io-x2022-ragis-imab-20251210monthly0.5https://www.biopharmawatch.com/news/IMAB/novabridge-announces-presentation-of-ragistomig-expanded-phase-1-data-at-esmo-io-x2022-rag-imab-20251204monthly0.5https://www.biopharmawatch.com/news/IMAB/novabridge-biosciences-supplemental-and-updated-disclosures-novabridge-biosciences-the-com-imab-20251031monthly0.5https://www.biopharmawatch.com/news/IMAB/novabridge-subsidiary-visara-assigns-its-exclusive-license-to-everest-medicines-for-vis-10-imab-20251029monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-nasdaq-imab-transitions-to-novabridge-biosciences-nasdaq-nbp-with-trading-effective-imab-20251030monthly0.5https://www.biopharmawatch.com/news/IMAB/updated-safety-efficacy-and-biomarker-analysis-from-the-phase-i-monotherapy-study-of-givas-imab-20251024monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-to-present-positive-updated-givastomig-monotherapy-data-at-2025-aacr-nci-eortc-molec-imab-20251023monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-intention-to-undertake-strategic-transformation-to-global-biotech-platform-imab-20251016monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-x5929-x5883-x751f-x7269-2440-research-boulevard-suite-400-rockville-md-20850-proxy-s-imab-20250924monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-acceleration-of-givastomig-investment-and-leadership-appointments-x2022-ex-imab-20250908monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-the-appointment-of-seasoned-biotech-executives-to-the-board-of-directors-a-imab-20250825monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-reports-second-quarter-2025-financial-results-and-provides-business-update-x2022-pos-imab-20250820monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-completes-enrollment-in-planned-phase-1b-dose-expansion-study-for-givastomig-in-comb-imab-20250811monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-pricing-of-65-million-underwritten-offering-of-american-depositary-shares--imab-20250801monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-strengthens-givastomig-intellectual-property-portfolio-through-acquisition-of-bridge-imab-20250717monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-presents-positive-givastomig-phase-1b-dose-escalation-data-in-combination-with-immun-imab-20250702monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-highlights-positive-givastomig-phase-1b-dose-escalation-data-in-combination-with-imm-imab-20250626monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-regains-compliance-with-nasdaq-minimum-bid-price-requirement-rockville-md-imab-20250612monthly0.5https://www.biopharmawatch.com/news/IMAB/transforming-potential-into-reality-i-mab-biopharma-june-2025-legal-disclaimer-this-presen-imab-20250602monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-reports-first-quarter-2025-financial-results-and-provides-business-update-x2022-prio-imab-20250515monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-givastomig-abstract-accepted-for-oral-presentation-at-esmo-gi-2025-the-esm-imab-20250430monthly0.5https://www.biopharmawatch.com/news/IMAB/transforming-potential-into-reality-i-mab-biopharma-april-2025-legal-disclaimer-this-prese-imab-20250404monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-reports-full-year-2024-financial-results-and-provides-business-update-x2022-continue-imab-20250403monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requiremen-imab-20250321monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-accelerated-givastomig-phase-1b-study-progress-x2022-enrollment-completed--imab-20250307monthly0.5https://www.biopharmawatch.com/news/IMAB/transforming-potential-into-reality-i-mab-biopharma-february-2025-legal-disclaimer-this-pr-imab-20250227monthly0.5https://www.biopharmawatch.com/news/IMAB/transforming-potential-into-reality-i-mab-biopharma-january-2025-legal-disclaimer-this-pre-imab-20250113monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-open-market-purchases-of-company-american-depositary-shares-by-board-membe-imab-20250108monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-portfolio-prioritization-of-givastomig-cldn18-2-x-4-1bb-bispecific-antibod-imab-20250106monthly0.5https://www.biopharmawatch.com/news/IMAB/transforming-potential-into-reality-i-mab-biopharma-imab-20241203monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-reports-third-quarter-2024-results-x2022-givastomig-data-presented-at-esmo-2024-and--imab-20241101monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-appoints-sean-fu-phd-mba-as-chief-executive-officer-rockville-md-imab-20241106monthly0.5https://www.biopharmawatch.com/news/IMAB/transforming-potential-into-reality-i-mab-biopharma-imab-20241024monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-presents-updated-phase-1-givastomig-data-at-esmo-2024-expanded-phase-1-monotherapy-s-imab-20240916monthly0.5https://www.biopharmawatch.com/news/IMAB/secondment-agreement-this-secondment-agreement-the-x201c-agreement-x201d-is-made-effective-imab-20240828monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-reports-1h-2024-financial-results-pipeline-progress-and-business-updates-x2022-compl-imab-20240828monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-appoints-u-s-auditor-pricewaterhousecoopers-llp-pwc-engagement-is-part-of-i-mab-s-co-imab-20240807monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-leadership-transitions-rockville-md-imab-20240715monthly0.5https://www.biopharmawatch.com/news/IMAB/transforming-potential-into-reality-i-mab-biopharma-imab-20240605monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-collaboration-with-bristol-myers-squibb-to-evaluate-givastomig-in-a-combin-imab-20240605monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-encouraging-phase-1-clinical-data-of-pd-l1x4-1bb-bispecific-antibody-ragis-imab-20240523monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-closing-of-the-divestiture-of-business-operations-in-china-rockville-md-imab-20240402monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-reports-full-year-2023-financial-results-and-business-update-recently-announced-agre-imab-20240315monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-signs-agreement-to-divest-its-assets-and-business-operations-in-china-agreement-mark-imab-20240207monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-and-abl-bio-announce-latest-updates-of-pd-l1-and-4-1bb-bispecific-antibody-tj-l14b-a-imab-20231010monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-provides-mid-year-2023-financial-results-business-and-corporate-updates-significant--imab-20230817monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-the-appointment-of-raj-kannan-as-ceo-gaithersburg-md-and-shanghai-china-imab-20230622monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-encouraging-phase-1b-2-study-results-of-patients-with-advanced-nsclc-recei-imab-20230525monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-year-e-imab-20230501monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-first-patient-dosed-in-phase-3-registrational-study-of-cd47-antibody-lemzo-imab-20230424monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-positive-outcome-in-arbitration-relating-to-agreements-with-tracon-award-i-imab-20230425monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-year-e-imab-20230331monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-index-to-consolidated-financial-statements-unaudited-interim-condensed-consolidated--imab-20221110monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-positive-phase-2-data-of-lemzoparlimab-in-combination-with-azacitidine-aza-imab-20220910monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-six-mo-imab-20220830monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-reports-latest-phase-2-clinical-data-of-its-differentiated-cd73-antibody-uliledlimab-imab-20220526monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-provides-updates-on-status-under-holding-foreign-companies-accountable-act-shanghai--imab-20220505monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-year-e-imab-20220428monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-appointments-of-richard-yeh-as-chief-operating-officer-and-john-hayslip-as-imab-20220428monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-voluntary-lock-ups-by-key-shareholders-and-senior-management-for-long-term-imab-20220331monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-year-e-imab-20220331monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-year-e-imab-20220329monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-receives-fda-orphan-drug-designation-for-its-novel-claudin-18-2-x-4-1bb-bispecific-a-imab-20220303monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-s-announcement-on-unusual-price-movement-shanghai-china-and-gaithersburg-md-i-mab-th-imab-20220128monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-strengthens-management-team-designed-to-accelerate-global-pipeline-development-and-t-imab-20211221monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-presents-interim-clinical-data-of-lemzoparlimab-in-combination-with-rituximab-in-rel-imab-20211214monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-to-pursue-dual-listing-plan-on-the-main-board-of-the-stock-exchange-of-hong-kong-lim-imab-20211207monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-first-two-patients-dosed-in-u-s-phase-2-combination-trial-of-uliledlimab-w-imab-20211203monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-index-to-consolidated-financial-statements-unaudited-interim-condensed-consolidated--imab-20211112monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-and-abl-bio-report-preclinical-data-of-4-1bb-targeting-bispecific-antibodies-at-2021-imab-20211109monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-to-present-clinical-data-of-lemzoparlimab-in-combination-with-rituximab-in-non-hodgk-imab-20211105monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-strengthens-senior-executive-team-with-new-chief-financial-officer-and-chief-strateg-imab-20211101monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-ind-approval-for-phase-2-clinical-trial-of-efineptakin-alfa-in-combination-imab-20211018monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-advances-late-stage-development-of-its-differentiated-cd38-antibody-felzartamab-tj20-imab-20211013monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-reports-multiple-positive-clinical-updates-of-differentiated-cd47-antibody-lemzoparl-imab-20210930monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-six-mo-imab-20210831monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-establishment-of-environmental-social-and-governance-committee-i-mab-recei-imab-20210819monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-reports-positive-interim-analysis-from-phase-2-3-study-of-its-gm-csf-antibody-plonma-imab-20210811monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-ind-acceptance-for-phase-2-clinical-trial-of-efineptakin-alfa-in-combinati-imab-20210722monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-authorization-of-a-renewed-stock-repurchase-program-by-the-company-up-to-u-imab-20210729monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-preliminary-proposal-for-potential-dual-listing-on-the-star-market-of-the--imab-20210727monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-china-nmpa-approval-for-phase-1b-trial-of-felzartamab-in-systemic-lupus-er-imab-20210625monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-first-patient-dosed-in-china-phase-2-combination-trial-of-lemzoparlimab-wi-imab-20210518monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-positive-topline-phase-2-results-for-olamkicept-in-ulcerative-colitis-shan-imab-20210426monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-and-abl-bio-announce-first-patient-dosed-in-phase-1-trial-of-bispecific-antibody-tj--imab-20210406monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-reports-financial-results-for-full-year-of-2020-and-provides-business-updates-18-sig-imab-20210329monthly0.5https://www.biopharmawatch.com/news/IMAB/registered-secondary-public-offering-of-american-depositary-shares-by-certain-pre-ipo-shar-imab-20210209monthly0.5https://www.biopharmawatch.com/news/IMAB/proposed-registered-secondary-public-offering-of-american-depositary-shares-by-certain-pre-imab-20210205monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-index-to-consolidated-financial-statements-unaudited-interim-condensed-consolidated--imab-20210205monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-multiple-clinical-advancements-of-its-differentiated-cd73-antibody-uliledl-imab-20210205monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-to-hold-investor-call-and-expand-clinical-data-analysis-on-efficacy-signal-of-lemzop-imab-20201112monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-preclinical-data-on-differentiated-anti-c5ar-antibody-tj210-mor210-at-sitc-imab-20201111monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-reports-phase-1-clinical-trial-data-of-highly-differentiated-anti-cd47-monoclonal-an-imab-20201109monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-receives-china-cde-approval-to-initiate-phase-3-clinical-trial-of-eftansomatropin-in-imab-20201005monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-china-nmpa-clearance-for-phase-1-clinical-trial-of-lemzoparlimab-in-relaps-imab-20200921monthly0.5https://www.biopharmawatch.com/news/IMAB/morphosys-and-i-mab-announce-fda-clearance-of-ind-application-for-mor210-tj210-in-patients-imab-20200917monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-418-million-private-placement-with-hillhouse-capital-led-consortium-ordina-imab-20200904monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-reports-financial-results-for-the-six-months-ended-june-30-and-provides-corporate-up-imab-20200831monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-first-patient-dosed-in-phase-1b-study-of-plonmarlimab-in-rheumatoid-arthri-imab-20200817monthly0.5https://www.biopharmawatch.com/news/IMAB/china-nmpa-accepts-ind-application-for-eftansomatropin-pivotal-trial-in-pediatric-patients-imab-20200804monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-drives-commercialization-strategy-with-appointment-of-ivan-yifei-zhu-as-chief-commer-imab-20200728monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-authorization-of-stock-repurchase-program-up-to-20-million-shanghai-china--imab-20200715monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-and-abl-bio-to-present-preclinical-data-for-joint-bispecific-antibody-program-at-the-imab-20200612monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-reports-interim-results-from-part-1-study-for-anti-gm-csf-antibody-tjm2-to-treat-cov-imab-20200528monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-and-genexine-announce-china-nmpa-clearance-for-phase-2-clinical-trial-of-tj107-hyleu-imab-20200521monthly0.5https://www.biopharmawatch.com/news/IMAB/first-patient-dosed-with-i-mab-s-cd73-antibody-tjd5-in-phase-1-2-clinical-trial-in-china-f-imab-20200513monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-and-morphosys-announce-first-patient-dosed-in-phase-3-clinical-trial-of-tj202-mor202-imab-20200427monthly0.5https://www.biopharmawatch.com/news/IMAB/april-2020-i-mab-presentation-disclaimer-this-presentation-has-been-prepared-by-i-mab-the--imab-20200408monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-ind-clearance-from-fda-for-tjm2-to-treat-cytokine-release-syndrome-crs-ass-imab-20200403monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-first-patient-dosed-in-phase-1-2a-clinical-trial-of-anti-cd47-antibody-tjc-imab-20200402monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-financial-results-for-the-full-year-ended-imab-20200331monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-enters-into-strategic-regional-partnership-with-kalbe-genexine-biologics-for-commerc-imab-20200330monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-expands-global-out-licensing-and-business-development-efforts-fernando-j-sall-s-ph-d-imab-20200327monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-appoints-gigi-feng-as-vice-president-and-global-head-of-corporate-communications-sha-imab-20200323monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-biopharma-announces-development-of-tjm2-to-treat-cytokine-release-syndrome-associate-imab-20200313monthly0.5https://www.biopharmawatch.com/news/IMAB/i-mab-announces-partial-exercise-of-over-allotment-option-in-initial-public-offering-shang-imab-20200210monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-fourth-quarter-and-full-year-2024-financial-results-nvro-20250304monthly0.5https://www.biopharmawatch.com/news/NVRO/globus-medical-to-acquire-nevro-corp-to-expand-treatment-options-for-patients-audubon-pa-a-nvro-20250206monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-third-quarter-2024-financial-results-reaffirms-full-year-2024-revenue-guidan-nvro-20241111monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-second-quarter-2024-financial-results-initiates-process-aimed-at-acceleratin-nvro-20240806monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-first-quarter-2024-financial-results-announces-additional-restructuring-step-nvro-20240507monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-enters-into-cooperation-agreement-with-engaged-capital-appoints-kirt-p-karros-to-boa-nvro-20240221monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-fourth-quarter-and-full-year-2023-financial-results-provides-full-year-and-f-nvro-20240221monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-announces-preliminary-fourth-quarter-and-full-year-2023-revenue-results-fourth-quart-nvro-20240109monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-announces-acquisition-of-vyrsa-technologies-refinances-with-200m-structured-debt-mat-nvro-20231130monthly0.5https://www.biopharmawatch.com/news/NVRO/investors-and-media-rod-macleod-cfo-nevro-corp-ir-nevro-com-greg-chodaczek-gilmartin-group-nvro-20231101monthly0.5https://www.biopharmawatch.com/news/NVRO/investors-and-media-rod-macleod-cfo-nevro-corp-650-433-3247-rod-macleod-nevro-com-greg-cho-nvro-20230801monthly0.5https://www.biopharmawatch.com/news/NVRO/investors-and-media-julie-dewey-irc-nevro-corp-chief-corp-communications-and-investor-rela-nvro-20230426monthly0.5https://www.biopharmawatch.com/news/NVRO/investors-and-media-julie-dewey-irc-nevro-corp-chief-corp-communications-and-investor-rela-nvro-20230419monthly0.5https://www.biopharmawatch.com/news/NVRO/investors-and-media-julie-dewey-irc-nevro-corp-chief-corp-communications-and-investor-rela-nvro-20230216monthly0.5https://www.biopharmawatch.com/news/NVRO/investors-and-media-julie-dewey-irc-nevro-corp-chief-corp-communications-and-investor-rela-nvro-20230109monthly0.5https://www.biopharmawatch.com/news/NVRO/investors-and-media-julie-dewey-irc-nevro-corp-chief-corp-communications-investor-relation-nvro-20221102monthly0.5https://www.biopharmawatch.com/news/NVRO/investors-and-media-julie-dewey-irc-nevro-corp-chief-corp-communications-investor-relation-nvro-20220803monthly0.5https://www.biopharmawatch.com/news/NVRO/investors-and-media-julie-dewey-irc-nevro-corp-chief-corp-communications-and-investor-rela-nvro-20220801monthly0.5https://www.biopharmawatch.com/news/NVRO/investors-and-media-julie-dewey-irc-nevro-corp-chief-corp-communications-investor-relation-nvro-20220504monthly0.5https://www.biopharmawatch.com/news/NVRO/investors-and-media-julie-dewey-irc-nevro-corp-chief-corp-communications-investor-relation-nvro-20220223monthly0.5https://www.biopharmawatch.com/news/NVRO/investors-and-media-julie-dewey-irc-nevro-corp-chief-corp-communications-and-investor-rela-nvro-20220110monthly0.5https://www.biopharmawatch.com/news/NVRO/investors-and-media-julie-dewey-irc-nevro-corp-vice-president-investor-relations-corp-comm-nvro-20211108monthly0.5https://www.biopharmawatch.com/news/NVRO/investors-and-media-julie-dewey-irc-nevro-corp-vice-president-investor-relations-corp-comm-nvro-20210831monthly0.5https://www.biopharmawatch.com/news/NVRO/investors-and-media-julie-dewey-irc-nevro-corp-vice-president-investor-relations-corp-comm-nvro-20210804monthly0.5https://www.biopharmawatch.com/news/NVRO/investors-and-media-julie-dewey-irc-nevro-corp-vice-president-investor-relations-corp-comm-nvro-20210719monthly0.5https://www.biopharmawatch.com/news/NVRO/investors-and-media-julie-dewey-irc-nevro-corp-vice-president-investor-relations-corp-comm-nvro-20210505monthly0.5https://www.biopharmawatch.com/news/NVRO/investors-and-media-julie-dewey-irc-nevro-corp-vice-president-investor-relations-corp-comm-nvro-20210224monthly0.5https://www.biopharmawatch.com/news/NVRO/investors-and-media-julie-dewey-irc-nevro-corp-vice-president-investor-relations-corp-comm-nvro-20210112monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-announces-director-appointment-industry-veteran-sue-siegel-joins-the-board-founding--nvro-20201203monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-announces-third-quarter-2020-financial-results-worldwide-revenues-increase-8-nevro-t-nvro-20201105monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-announces-second-quarter-2020-financial-results-nvro-20200805monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-first-quarter-2020-financial-results-nvro-20200505monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-provides-first-quarter-and-fy2020-update-preliminary-unaudited-first-quarter-2020-wo-nvro-20200401monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-fourth-quarter-and-full-year-2019-financial-results-provides-expanded-2020-g-nvro-20200225monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-announces-preliminary-unaudited-fourth-quarter-and-full-year-2019-revenue-company-pr-nvro-20200114monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-appoints-karen-n-prange-to-the-company-s-board-of-directors-nvro-20191218monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-third-quarter-2019-financial-results-company-raises-2019-guidance-announces--nvro-20191106monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-second-quarter-2019-financial-results-redwood-city-calif-aug-8-2019-nevro-co-nvro-20190808monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-first-quarter-2019-financial-results-redwood-city-calif-may-9-2019-nevro-cor-nvro-20190509monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-announces-new-ceo-board-appointments-and-agreement-with-broadfin-capital-d-keith-gro-nvro-20190319monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-fourth-quarter-and-full-year-2018-financial-results-redwood-city-calif-febru-nvro-20190221monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-announces-preliminary-unaudited-fourth-quarter-and-full-year-2018-revenue-nvro-20190107monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-third-quarter-2018-financial-results-redwood-city-calif-november-5-2018-nevr-nvro-20181105monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-second-quarter-2018-financial-results-redwood-city-calif-august-2-2018-nevro-nvro-20180802monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-announces-patent-litigation-update-parties-file-to-dismiss-remaining-claims-boston-s-nvro-20180730monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-announces-patent-litigation-update-summary-judgment-ruling-affirms-method-claims-cov-nvro-20180725monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-announces-preliminary-unaudited-second-quarter-2018-revenue-and-updates-full-year-20-nvro-20180716monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-first-quarter-2018-financial-results-redwood-city-calif-may-7-2018-nevro-cor-nvro-20180507monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-fourth-quarter-and-full-year-2017-financial-results-and-provides-2018-outloo-nvro-20180222monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-announces-preliminary-unaudited-fourth-quarter-and-fiscal-year-2017-revenue-company--nvro-20180108monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-third-quarter-2017-financial-results-redwood-city-calif-november-6-2017-nevr-nvro-20171106monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-second-quarter-2017-financial-results-redwood-city-calif-august-7-2017-nevro-nvro-20170807monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-announces-preliminary-unaudited-second-quarter-2017-revenue-and-business-update-comp-nvro-20170705monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-first-quarter-2017-financial-results-redwood-city-calif-may-8-2017-nevro-cor-nvro-20170508monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-fourth-quarter-and-full-year-2016-financial-results-and-provides-2017-outloo-nvro-20170223monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-third-quarter-2016-financial-results-updates-revenue-guidance-for-full-year--nvro-20161107monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-second-quarter-2016-financial-results-updates-worldwide-revenue-guidance-for-nvro-20160808monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-first-quarter-2016-financial-results-updates-worldwide-revenue-guidance-for--nvro-20160509monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-announces-executive-succession-chairman-and-ceo-michael-demane-to-transition-to-exec-nvro-20160229monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-fourth-quarter-and-full-year-2015-financial-results-redwood-city-calif-nvro-20160229monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-announces-preliminary-unaudited-fourth-quarter-and-fiscal-year-2015-revenue-company--nvro-20160111monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-third-quarter-2015-financial-results-updates-worldwide-revenue-guidance-for--nvro-20151109monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-second-quarter-2015-financial-results-updates-international-revenue-guidance-nvro-20150806monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-announces-filing-of-petitions-for-inter-partes-review-of-u-s-patent-no-8-359-102-men-nvro-20150511monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-first-quarter-2015-financial-results-menlo-park-calif-nvro-20150511monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-fourth-quarter-and-full-year-2014-financial-results-menlo-park-calif-nvro-20150318monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-appoints-dr-brad-vale-to-its-board-of-directors-menlo-park-calif-nvro-20150302monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-receives-approvable-letter-from-u-s-food-and-drug-administration-for-senza-spinal-co-nvro-20150122monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-reports-third-quarter-financial-results-menlo-park-calif-nvro-20141202monthly0.5https://www.biopharmawatch.com/news/NVRO/nevro-corp-announces-full-exercise-of-over-allotment-option-and-closing-of-initial-public--nvro-20141112monthly0.5https://www.biopharmawatch.com/news/GNFT/genfit-combined-shareholders-meeting-of-november-27-2019-availability-of-preparatory-docum-gnft-20191021monthly0.5https://www.biopharmawatch.com/news/GNFT/genfit-board-of-directors-represented-by-chairman-jean-fran-ois-mouney-appoints-pascal-pri-gnft-20190903monthly0.5https://www.biopharmawatch.com/news/GNFT/may-8-2019-french-official-legal-announcement-gnft-20190514monthly0.5https://www.biopharmawatch.com/news/PROC/sofgen-pharma-s-a-soci-t-anonyme-si-ge-social-9-rue-de-bitbourg-l-1273-luxembourg-r-c-s-lu-proc-20251205monthly0.5https://www.biopharmawatch.com/news/PROC/dear-shareholders-we-are-pleased-to-inform-you-that-an-extraordinary-general-meeting-of-sh-proc-20251119monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-secures-130-million-in-equity-investment-and-completes-comprehensive-debt-re-proc-20250409monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-s-a-soci-t-anonyme-si-ge-social-9-rue-de-bitbourg-l-1273-luxembourg-r-c-s-lu-proc-20250325monthly0.5https://www.biopharmawatch.com/news/PROC/dear-shareholders-we-are-in-regret-to-inform-you-that-the-extraordinary-general-meeting-of-proc-20250307monthly0.5https://www.biopharmawatch.com/news/PROC/dear-shareholders-we-are-pleased-to-inform-you-that-an-extraordinary-general-meeting-of-sh-proc-20250219monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-receives-delisting-notice-from-nasdaq-miami-usa-barranquilla-col-proc-20250203monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-receives-additional-delinquency-letter-miami-usa-barranquilla-col-proc-20250103monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-s-a-soci-t-anonyme-si-ge-social-9-rue-de-bitbourg-l-1273-luxembourg-r-c-s-lu-proc-20241220monthly0.5https://www.biopharmawatch.com/news/PROC/execution-version-procaps-group-s-a-secured-convertible-note-subscription-agreement-this-s-proc-20241129monthly0.5https://www.biopharmawatch.com/news/PROC/dear-shareholders-we-are-pleased-to-inform-you-that-an-extraordinary-general-meeting-of-sh-proc-20241129monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-receives-nasdaq-listing-determination-to-request-hearing-and-further-stay-pending--proc-20241115monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-issues-shareholder-letter-update-miami-usa-proc-20241101monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-issues-shareholder-letter-update-miami-usa-proc-20240918monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-issues-shareholder-letter-miami-usa-proc-20240903monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-announces-new-chairman-ruben-minski-decides-to-stepdown-as-executive-chairma-proc-20240628monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-receives-nasdaq-notice-related-to-late-filing-of-its-form-20-f-miami-usa-bar-proc-20240520monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-delays-filing-of-annual-report-on-form-20-f-miami-usa-barranquilla-col-proc-20240514monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-delays-filing-of-annual-report-on-form-20-f-miami-usa-barranquilla-col-proc-20240501monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-announces-formation-of-strategic-committee-to-explore-value-creation-alternatives--proc-20240304monthly0.5https://www.biopharmawatch.com/news/PROC/dear-shareholders-we-hereby-inform-you-that-at-the-request-of-a-shareholder-a-general-meet-proc-20240105monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-s-a-and-subsidiaries-the-group-unaudited-condensed-consolidated-interim-fina-proc-20231226monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-reports-third-quarter-2023-results-net-revenues-increased-5-in-9m23-year-ove-proc-20231226monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-announces-appointment-of-jose-antonio-vieira-as-chief-executive-officer-star-proc-20231122monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-appoints-sandra-s-nchez-y-oldenhage-to-board-of-directors-experienced-pharma-profe-proc-20231023monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-announces-the-expansion-of-its-oncology-portfolio-the-agreement-substantiall-proc-20230907monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-s-a-and-subsidiaries-the-group-unaudited-condensed-consolidated-interim-fina-proc-20230905monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-reports-second-quarter-2023-results-net-revenues-increased-7-in-1h23-year-ov-proc-20230905monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-loan-agreement-execution-version-confidential-loan-agreement-between-procaps-s-a-a-proc-20230816monthly0.5https://www.biopharmawatch.com/news/PROC/dear-shareholders-i-am-pleased-to-inform-you-that-the-annual-general-meeting-of-shareholde-proc-20230614monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-s-a-and-subsidiaries-the-group-unaudited-condensed-consolidated-interim-fina-proc-20230606monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-reports-first-quarter-2023-results-constant-currency-net-revenues-increased--proc-20230605monthly0.5https://www.biopharmawatch.com/news/PROC/q22-2022-financial-results-proc-20230515monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-reports-fourth-quarter-and-full-year-2022-results-constant-currency-net-reve-proc-20230512monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-issues-shareholder-letter-and-provides-preliminary-fiscal-year-2022-financial-resu-proc-20230213monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-announces-key-changes-to-the-board-of-directors-international-corporate-executive--proc-20230119monthly0.5https://www.biopharmawatch.com/news/PROC/one-of-the-fastest-growing-and-innovative-pharma-organizations-in-latin-america-jp-morgan--proc-20230110monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-announces-termination-of-acquisition-agreement-with-grupo-somar-company-to-p-proc-20230103monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-to-present-at-2023-annual-j-p-morgan-healthcare-conference-miami-usa-barranquilla--proc-20221229monthly0.5https://www.biopharmawatch.com/news/PROC/update-on-proposed-acquisition-of-grupo-somar-miami-usa-barranquilla-col-proc-20221222monthly0.5https://www.biopharmawatch.com/news/PROC/q22-9m22-financial-results-proc-20221116monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-reports-third-quarter-and-nine-months-2022-results-constant-currency-net-rev-proc-20221114monthly0.5https://www.biopharmawatch.com/news/PROC/q22-1h22-financial-results-proc-20220829monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-to-host-second-quarter-and-first-half-2022-conference-call-on-wednesday-miam-proc-20220830monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-reports-second-quarter-and-first-half-2022-results-net-revenues-increased-14-proc-20220830monthly0.5https://www.biopharmawatch.com/news/PROC/one-of-the-fastest-growing-and-innovative-pharma-organizations-in-latin-america-june-2022--proc-20220629monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-s-a-and-subsidiaries-the-group-unaudited-condensed-consolidated-interim-fina-proc-20220615monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-reports-preliminary-first-quarter-2022-results-net-revenues-increased-by-11--proc-20220602monthly0.5https://www.biopharmawatch.com/news/PROC/dear-shareholders-i-am-pleased-to-inform-you-that-the-annual-general-meeting-of-shareholde-proc-20220601monthly0.5https://www.biopharmawatch.com/news/PROC/acquisition-of-grupo-somar-may-2022-establishing-procaps-as-one-of-the-fastest-growing-pha-proc-20220518monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-to-acquire-grupo-somar-including-qu-mica-y-farmacia-gelcaps-and-related-enti-proc-20220517monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-reports-fourth-quarter-and-fiscal-year-2021-financial-results-fiscal-year-20-proc-20220505monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-announces-capacity-expansion-plans-in-the-united-states-with-construction-of-proc-20220202monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-announces-appointment-of-melissa-angelini-as-investor-relations-director-pha-proc-20220128monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-acquires-1st-u-s-based-softgel-production-facility-and-pharmaceutical-r-d-ce-proc-20220112monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-s-a-and-subsidiaries-the-group-unaudited-condensed-consolidated-interim-fina-proc-20211217monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-s-a-and-subsidiaries-the-group-unaudited-condensed-consolidated-interim-stat-proc-20211210monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-reports-record-third-quarter-2021-financial-results-third-quarter-2021-net-r-proc-20211119monthly0.5https://www.biopharmawatch.com/news/PROC/procaps-group-completes-business-combination-with-union-acquisition-corp-ii-combined-compa-proc-20210930monthly0.5https://www.biopharmawatch.com/news/TLIS/talis-biomedical-announces-exploration-of-strategic-alternatives-and-cost-reduction-plan-t-tlis-20231114monthly0.5https://www.biopharmawatch.com/news/TLIS/talis-biomedical-announces-second-quarter-2023-financial-results-and-business-update-confe-tlis-20230810monthly0.5https://www.biopharmawatch.com/news/TLIS/talis-biomedical-announces-andrew-lukowiak-ph-d-as-president-and-chief-scientific-officer--tlis-20230802monthly0.5https://www.biopharmawatch.com/news/TLIS/new-data-presented-at-the-infectious-disease-society-for-obstetrics-and-gynecology-idsog-a-tlis-20230727monthly0.5https://www.biopharmawatch.com/news/TLIS/talis-biomedical-regains-compliance-with-nasdaq-minimum-bid-price-requirement-redwood-city-tlis-20230724monthly0.5https://www.biopharmawatch.com/news/TLIS/talis-biomedical-appoints-former-roche-molecular-ceo-heiner-dreismann-to-board-of-director-tlis-20230523monthly0.5https://www.biopharmawatch.com/news/TLIS/talis-biomedical-announces-business-update-and-first-quarter-2023-financial-results-confer-tlis-20230511monthly0.5https://www.biopharmawatch.com/news/TLIS/talis-announces-fourth-quarter-and-full-year-2022-financial-results-redwood-city-calif-x20-tlis-20230322monthly0.5https://www.biopharmawatch.com/news/TLIS/talis-biomedical-reports-third-quarter-2022-financial-results-redwood-city-calif-x2013-tlis-20221103monthly0.5https://www.biopharmawatch.com/news/TLIS/talis-biomedical-provides-business-update-and-reports-second-quarter-financial-results-con-tlis-20220802monthly0.5https://www.biopharmawatch.com/news/TLIS/talis-biomedical-announces-first-quarter-2022-financial-results-conference-call-and-webcas-tlis-20220510monthly0.5https://www.biopharmawatch.com/news/TLIS/talis-biomedical-provides-business-update-and-reports-fourth-quarter-and-full-year-2021-fi-tlis-20220315monthly0.5https://www.biopharmawatch.com/news/TLIS/talis-biomedical-announces-third-quarter-2021-financial-results-and-business-progress-conf-tlis-20211115monthly0.5https://www.biopharmawatch.com/news/TLIS/talis-biomedical-granted-fda-emergency-use-authorization-eua-for-covid-19-molecular-point--tlis-20211108monthly0.5https://www.biopharmawatch.com/news/TLIS/talis-biomedical-announces-ceo-transition-kim-popovits-to-serve-as-interim-tlis-20210830monthly0.5https://www.biopharmawatch.com/news/TLIS/talis-biomedical-announces-second-quarter-2021-financial-results-and-business-progress-con-tlis-20210810monthly0.5https://www.biopharmawatch.com/news/TLIS/talis-biomedical-announces-first-quarter-2021-financial-results-and-business-progress-conf-tlis-20210511monthly0.5https://www.biopharmawatch.com/news/TLIS/talis-provides-update-on-regulatory-pathway-for-emergency-use-authorization-eua-of-its-tal-tlis-20210308monthly0.5https://www.biopharmawatch.com/news/OMI/accendra-health-announces-early-results-of-offers-and-consent-solicitations-richmond-va-omi-20260610monthly0.5https://www.biopharmawatch.com/news/OMI/accendra-health-announces-offers-and-consent-solicitations-richmond-va-omi-20260522monthly0.5https://www.biopharmawatch.com/news/OMI/project-huskies-management-presentation-may-2026-this-presentation-may-contain-material-no-omi-20260511monthly0.5https://www.biopharmawatch.com/news/OMI/accendra-health-reports-first-quarter-2026-financial-results-and-announces-comprehensive-b-omi-20260511monthly0.5https://www.biopharmawatch.com/news/OMI/accendra-health-reports-fourth-quarter-2025-financial-results-completed-sale-of-products-h-omi-20260219monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-inc-completes-sale-of-products-healthcare-services-business-to-platinum-equity-omi-20251231monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-announces-corporate-name-change-to-accendra-health-inc-accendra-health-to-trad-omi-20251218monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-reports-third-quarter-2025-financial-results-signed-definitive-agreement-for-t-omi-20251030monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-announces-definitive-agreement-to-divest-products-healthcare-services-segment--omi-20251007monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-reports-second-quarter-2025-financial-results-classified-products-healthcare-s-omi-20250811monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-and-rotech-healthcare-mutually-agree-to-terminate-previously-announced-acquisi-omi-20250605monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-reports-first-quarter-2025-financial-results-top-line-growth-led-by-the-patien-omi-20250508monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-announces-upsize-and-pricing-of-senior-secured-notes-offering-omi-20250402monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-announces-launch-of-senior-secured-notes-offering-omi-20250326monthly0.5https://www.biopharmawatch.com/news/OMI/disclaimer-forward-looking-statements-this-presentation-contains-certain-forward-looking-s-omi-20250320monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-reports-fourth-quarter-full-year-financial-results-and-announces-sale-process--omi-20250228monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-launches-financing-for-rotech-acquisition-and-provides-preliminary-fourth-quar-omi-20250203monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-reports-third-quarter-2024-financial-results-top-line-growth-driven-by-continu-omi-20241104monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-names-jonathan-leon-executive-vice-president-chief-financial-officer-richmond--omi-20240923monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-reports-second-quarter-2024-financial-results-top-line-expansion-driven-by-sol-omi-20240802monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-inc-signs-definitive-agreement-to-acquire-rotech-healthcare-holdings-inc-for-1-omi-20240723monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-inc-releases-preliminary-second-quarter-2024-financial-results-reaffirms-2024--omi-20240723monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-reports-first-quarter-2024-financial-results-gross-margin-expansion-of-79-basi-omi-20240503monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-reports-fourth-quarter-and-full-year-2023-financial-results-business-delivered-omi-20240220monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-owens-minor-unveils-long-term-strategy-at-investor-day-today-outlines-new-five-omi-20231206monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-announces-executive-leadership-team-changes-company-also-provides-preliminary--omi-20221012monthly0.5https://www.biopharmawatch.com/news/OMI/index-to-financial-statements-audited-consolidated-financial-statements-of-apria-inc-repor-omi-20220329monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-announces-upsize-and-pricing-of-600-million-of-senior-notes-due-2030-richmond--omi-20220323monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-announces-launch-of-senior-notes-offering-richmond-va-business-wire-omi-20220318monthly0.5https://www.biopharmawatch.com/news/OMI/investor-presentation-omi-20220228monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-inc-signs-definitive-agreement-to-acquire-apria-inc-highly-complementary-trans-omi-20220110monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-announces-pricing-of-500-million-of-senior-notes-due-2029-richmond-va-omi-20210304monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-announces-launch-of-senior-notes-offering-richmond-va-omi-20210302monthly0.5https://www.biopharmawatch.com/news/OMI/document-two-new-members-elected-to-owens-minor-board-of-directors-omi-20210224monthly0.5https://www.biopharmawatch.com/news/OMI/use-of-non-gaap-measures-the-foregoing-tables-contain-financial-measures-that-are-not-calc-omi-20200305monthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-names-board-member-robert-sledd-chairman-and-interim-president-and-ceo-company-omi-20181108monthly0.5https://www.biopharmawatch.com/news/OMI/safe-harbor-this-presentation-is-intended-to-be-disclosure-through-methods-reasonably-desi-omi-20180409monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-and-garda-mutually-agree-to-delay-launch-of-tender-offer-asrt-20260508monthly0.5https://www.biopharmawatch.com/news/ASRT/privileged-confidential-prepared-at-the-request-of-counsel-press-release-assertio-and-gard-asrt-20260505monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-and-garda-mutually-agree-to-extend-tender-offer-deadline-asrt-20260429monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-announces-leadership-transition-2025-10-28-appoints-industry-veteran-and-current--asrt-20251030monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-nasdaq-asrt-q3-2024-earnings-conference-call-november-11-2024-4-30-p-asrt-20241112monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-inc-nasdaq-asrt-q4-2023-earnings-conference-call-march-11-2024-4-30-pm-e-asrt-20240312monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-and-spectrum-pharmaceuticals-transaction-asrt-20230425monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-announces-exchange-offer-of-30-million-of-its-currently-outstanding-6-50-converti-asrt-20230223monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-announces-proposed-convertible-senior-notes-offering-to-refinance-existing-13-sen-asrt-20220822monthly0.5https://www.biopharmawatch.com/news/ASRT/notice-of-shareholder-derivative-litigation-proposed-settlement-and-settlement-hearing-to--asrt-20211026monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-announces-5-0-million-insurance-settlement-and-general-corporate-updates-asrt-20210203monthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-announces-restructuring-plan-and-leadership-changes-expected-to-reduce-costs-by-4-asrt-20201215monthly0.5https://www.biopharmawatch.com/news/HLVX/we-caution-you-that-this-presentation-contains-forward-looking-statements-of-hillevax-inc--hlvx-20240108monthly0.5https://www.biopharmawatch.com/news/HLVX/we-caution-you-that-this-presentation-contains-forward-looking-statements-of-hillevax-inc--hlvx-20230109monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-completes-the-previously-announced-arrangement-with-affiliates-of-kings-qipt-20260316monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-receives-final-order-approving-arrangement-cincinnati-ohio-qipt-20260305monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-voting-results-from-special-meeting-of-shareholders-cincinnat-qipt-20260303monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2025-financial-results-cincinnat-qipt-20251215monthly0.5https://www.biopharmawatch.com/news/QIPT/voting-and-support-agreement-this-voting-and-support-agreement-this-agreement-between-1567-qipt-20251215monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-confirms-receipt-of-forager-s-repetitive-undervalued-offer-board-denoun-qipt-20250827monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-partners-with-three-major-health-systems-to-form-strategic-joint-ventur-qipt-20250812monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-reports-improved-fiscal-third-quarter-2025-results-posts-positive-organ-qipt-20250811monthly0.5https://www.biopharmawatch.com/news/QIPT/e-xhibit-99-1-quipt-home-medical-acquires-healthcare-system-owned-medical-equipment-provid-qipt-20250707monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-confirms-receipt-of-unsolicited-acquisition-proposal-cincinnati-ohio-qipt-20250521monthly0.5https://www.biopharmawatch.com/news/QIPT/three-three-six-six-months-months-months-months-ended-march-ended-march-ended-march-ended-qipt-20250512monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-unveils-strategic-priorities-for-2025-to-enhance-shareholder-value-and--qipt-20250324monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-cooperation-agreement-with-kanen-wealth-management-remains-co-qipt-20250304monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results-posts-strong-s-qipt-20250210monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-reports-fourth-quarter-and-fiscal-year-2024-financial-results-posts-str-qipt-20241216monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-condensed-consolidated-interim-financial-statements-2024-third-qua-qipt-20240814monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-to-announce-fiscal-third-quarter-2024-financial-results-on-august--qipt-20240731monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-2024-equity-incentive-plan-1-establishment-purpose-and-term-of-pla-qipt-20240604monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-condensed-consolidated-interim-financial-statements-2024-second-qu-qipt-20240515monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-announces-filing-of-final-base-shelf-prospectus-cincinnati-ohio-qipt-20240509monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-to-announce-fiscal-second-quarter-2024-financial-results-on-may-15-qipt-20240506monthly0.5https://www.biopharmawatch.com/news/QIPT/form-51-102f3-material-change-report-1-name-and-address-of-company-quipt-home-medical-corp-qipt-20240502monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-normal-course-issuer-bid-cincinnati-ohio-qipt-20240502monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-voting-results-from-its-annual-general-and-special-meeting-of-qipt-20240328monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-participation-in-the-36th-annual-roth-investor-conference-on--qipt-20240312monthly0.5https://www.biopharmawatch.com/news/QIPT/annual-general-special-meeting-of-shareholders-to-be-held-on-qipt-20240228monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-condensed-consolidated-interim-financial-statements-2024-first-qua-qipt-20240214monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-to-announce-fiscal-first-quarter-2024-financial-results-on-qipt-20240201monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-announces-filing-of-preliminary-base-shelf-prospectus-to-replace-r-qipt-20231227monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-reports-record-fourth-quarter-and-fiscal-year-2023-financial-results-po-qipt-20231218monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-to-announce-fourth-quarter-and-full-year-2023-financial-results-on-qipt-20231205monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-announces-multi-state-acquisition-adding-approximately-9-million-in-annualized-reven-qipt-20230911monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-condensed-consolidated-interim-financial-statements-2023-third-qua-qipt-20230814monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-date-and-time-for-fiscal-q3-2023-conference-call-and-audio-we-qipt-20230801monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-to-participate-at-the-43-rd-annual-canaccord-growth-conference-fireside-qipt-20230724monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-up-listing-to-the-toronto-stock-exchange-cincinnati-ohio-qipt-20230620monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-termination-of-at-the-market-equity-program-cincinnati-ohio-qipt-20230601monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-on-preliminary-list-to-join-russell-2000-and-3000-indexes-cincinnati-oh-qipt-20230523monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-condensed-consolidated-interim-financial-statements-2023-second-qu-qipt-20230516monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-us-40-000-000-equity-distribution-agreement-qipt-20230515monthly0.5https://www.biopharmawatch.com/news/QIPT/consent-of-independent-registered-public-accounting-firm-we-have-issued-our-report-dated-qipt-20230516monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-date-and-time-for-fiscal-q2-2023-conference-call-and-audio-we-qipt-20230508monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-receives-conditional-approval-to-graduate-to-the-toronto-stock-exchange-qipt-20230502monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-closing-of-public-offering-and-private-placement-for-aggregat-qipt-20230425monthly0.5https://www.biopharmawatch.com/news/QIPT/form-51-102f3-material-change-report-1-name-and-address-of-company-quipt-home-medical-corp-qipt-20230417monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-bought-deal-public-offering-of-common-shares-term-sheet-qipt-20230417monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-new-national-insurance-contract-with-top-5-health-insurer-bas-qipt-20230404monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-to-participate-at-the-sidoti-small-cap-virtual-investor-conference-on-m-qipt-20230315monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-named-as-a-top-performing-company-to-the-2023-tsx-venture-50-list-cinci-qipt-20230221monthly0.5https://www.biopharmawatch.com/news/QIPT/form-51-102f4-business-acquisition-report-item-1-identity-of-company-1-1-name-and-address--qipt-20230216monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-condensed-consolidated-interim-financial-statements-2023-first-qua-qipt-20230214monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-date-and-time-for-fiscal-q1-2023-conference-call-and-audio-we-qipt-20230207monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-code-of-business-conduct-and-ethics-qipt-20230207monthly0.5https://www.biopharmawatch.com/news/QIPT/amended-and-restated-credit-and-guaranty-agreement-dated-as-of-qipt-20230124monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-acquires-60-million-in-revenues-and-13-million-adjusted-ebitda-with-strategic-acquis-qipt-20230103monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-reports-record-fourth-quarter-and-fiscal-year-2022-financial-results-po-qipt-20221221monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-date-and-time-for-q4-and-full-year-fiscal-2022-conference-cal-qipt-20221214monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-closing-of-upsized-senior-credit-facilities-for-110-million-t-qipt-20220919monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-formerly-protech-home-medical-corp-condensed-consolidated-interim--qipt-20220816monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-commitment-letter-for-80-million-of-senior-credit-facilities--qipt-20220815monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-to-participate-at-the-sidoti-virtual-investor-conference-on-august-17-t-qipt-20220811monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-announces-early-conversion-of-2019-convertible-debentures-strengthening-balance-shee-qipt-20220809monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-date-and-time-for-fiscal-q3-2022-conference-call-and-audio-we-qipt-20220803monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-supply-contract-with-cardinal-health-further-expanding-contin-qipt-20220725monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-to-participate-at-the-42-nd-annual-canaccord-growth-conference-on-augus-qipt-20220719monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-surpasses-200-000-active-patients-adding-approximately-7-million-in-annualized-reven-qipt-20220711monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-enters-louisiana-adding-approximately-6-5-million-in-annualized-revenues-and-anticip-qipt-20220621monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-expands-in-california-with-acquisition-of-norcal-respiratory-reaching-90-locations-n-qipt-20220607monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-on-preliminary-list-to-join-russell-microcap-index-cincinnati-ohio-qipt-20220606monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-formerly-protech-home-medical-corp-condensed-consolidated-interim--qipt-20220516monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-date-and-time-for-fiscal-q2-2022-conference-call-and-audio-we-qipt-20220503monthly0.5https://www.biopharmawatch.com/news/QIPT/notice-to-reader-the-unaudited-condensed-consolidated-interim-financial-statements-for-the-qipt-20220427monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-accelerates-national-expansion-efforts-with-acquisition-of-multi-state-operator-good-qipt-20220419monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-to-participate-at-the-sidoti-virtual-investor-conference-on-march-23-rd-qipt-20220315monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-formerly-protech-home-medical-corp-condensed-consolidated-interim--qipt-20220215monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-new-independent-board-member-mr-brian-j-wessel-appointed-to-b-qipt-20220203monthly0.5https://www.biopharmawatch.com/news/QIPT/form-51-102f3-material-change-report-1-name-and-address-of-company-quipt-home-medical-corp-qipt-20220128monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-announces-revocation-of-management-cease-trade-order-cincinnati-ohio-qipt-20220131monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-reports-record-fourth-quarter-and-fiscal-year-2021-financial-results-po-qipt-20220127monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-provides-bi-weekly-status-update-cincinnati-ohio-qipt-20220113monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-announces-the-passing-of-board-member-eugene-ewing-cincinnati-ohio-qipt-20220112monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-adds-13-million-in-annualized-revenue-1-6-million-in-net-income-anticipated-2-9-mill-qipt-20220104monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-announces-receipt-of-management-cease-trade-order-and-provides-bi-weekly-status-upda-qipt-20211230monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-annual-information-form-for-the-year-ended-qipt-20220103monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-announces-record-preliminary-fourth-quarter-2021-results-and-provides-a-qipt-20211216monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-announces-execution-of-loi-to-acquire-leader-in-comprehensive-respiratory-care-withi-qipt-20211122monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-announces-strategic-acquisition-of-biomedical-services-company-in-the-southeastern-u-qipt-20211117monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-announces-execution-of-loi-to-acquire-leading-respiratory-supplier-with-approximatel-qipt-20211116monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-continues-national-expansion-with-closing-of-strategic-acquisition-in-central-illino-qipt-20211109monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-reaches-150-000-active-patients-with-closing-of-strategic-acquisition-in-mississippi-qipt-20211005monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-to-participate-at-upcoming-investor-conferences-cincinnati-ohio-qipt-20210916monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-to-ring-nasdaq-opening-bell-on-september-2-2021-cincinnati-ohio-qipt-20210901monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-reports-record-third-quarter-fiscal-2021-financial-results-posts-revenu-qipt-20210823monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-to-report-third-quarter-2021-financial-results-on-august-23-2021-c-qipt-20210811monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-to-participate-at-the-41-st-annual-canaccord-growth-conference-on-augus-qipt-20210728monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-enters-four-new-states-with-closings-of-strategic-acquisitions-national-expansion-co-qipt-20210714monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-to-present-at-access-to-giving-virtual-investor-conference-on-july-13-t-qipt-20210712monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-announces-proceeds-from-exercise-of-warrants-proceeds-of-17-5-million-received-over--qipt-20210708monthly0.5https://www.biopharmawatch.com/news/QIPT/quipt-home-medical-corp-formerly-protech-home-medical-corp-condensed-consolidated-interim--qipt-20210602monthly0.5https://www.biopharmawatch.com/news/COEP/z-squared-inc-enters-50-million-committed-equity-forward-purchase-agreement-to-s-upport-ai-coep-20260604monthly0.5https://www.biopharmawatch.com/news/COEP/z-squared-inc-outlines-phase-1-plan-to-reach-100-mw-of-ai-ready-infrastructure-for-inferen-coep-20260519monthly0.5https://www.biopharmawatch.com/news/COEP/z-squared-to-acquire-skycore-digital-adding-24-mw-of-energized-ai-infrastructure-with-expa-coep-20260429monthly0.5https://www.biopharmawatch.com/news/COEP/z-squared-provides-additional-information-on-previously-disclosed-pro-rata-distribution-coep-20260427monthly0.5https://www.biopharmawatch.com/news/COEP/z-squared-announces-completion-of-business-combination-with-coeptis-therapeutics-and-listi-coep-20260427monthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-therapeutics-inc-and-z-squared-inc-announce-merger-agreement-aim-to-create-the-lar-coep-20250425monthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-therapeutics-regains-compliance-with-nasdaq-listing-rule-5550-a-2-wexford-pa-coep-20250122monthly0.5https://www.biopharmawatch.com/news/COEP/certificate-of-amendment-of-amended-and-restated-certificate-of-incorporation-of-coeptis-t-coep-20241227monthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-therapeutics-unveils-new-technology-division-coeptis-technologies-coeptis-technolo-coep-20241212monthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-therapeutics-executes-binding-letter-of-intent-to-acquire-ai-powered-marketing-sol-coep-20241203monthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-therapeutics-granted-continued-listing-from-nasdaq-hearings-panel-to-regain-compli-coep-20240919monthly0.5https://www.biopharmawatch.com/news/COEP/certificate-of-designation-of-preferences-rights-and-limitations-of-series-a-convertible-p-coep-20240620monthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-therapeutics-holdings-inc-all-rights-reserved-coeptis-therapeutics-holdings-inc-co-coep-20231205monthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-therapeutics-announces-2-million-private-placement-wexford-pa-coep-20231024monthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-therapeutics-completes-exclusive-license-for-allogeneic-immuno-oncology-platform-a-coep-20230817monthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-therapeutics-holdings-inc-announces-pricing-of-3-5-million-underwritten-offering-w-coep-20230614monthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-therapeutics-receives-approval-to-transfer-to-the-nasdaq-capital-market-trading-to-coep-20230609monthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-therapeutics-holdings-inc-all-rights-reserved-coeptis-therapeutics-holdings-inc-co-coep-20230606monthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-therapeutics-appoints-brian-cogley-as-chief-financial-officer-15-year-accounting-a-coep-20230517monthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-therapeutics-enters-into-sponsored-research-agreement-with-the-university-of-pitts-coep-20230131monthly0.5https://www.biopharmawatch.com/news/COEP/index-to-financial-statements-coeptis-therapeutics-inc-page-report-of-independent-register-coep-20221103monthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-therapeutics-inc-all-rights-reserved-coeptis-therapeutics-inc-corporate-overview-2-coep-20220706monthly0.5https://www.biopharmawatch.com/news/COEP/this-promissory-note-note-has-not-been-registered-under-the-securities-act-of-1933-as-amen-coep-20220518monthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-therapeutics-inc-and-bull-horn-holdings-corp-announce-merger-agreement-transaction-coep-20220419monthly0.5https://www.biopharmawatch.com/news/COEP/bull-horn-holdings-corp-announces-receipt-of-notice-from-nasdaq-regarding-late-filing-of-q-coep-20210903monthly0.5https://www.biopharmawatch.com/news/COEP/bull-horn-holdings-corp-announces-receipt-of-notice-from-nasdaq-regarding-late-filing-of-q-coep-20210528monthly0.5https://www.biopharmawatch.com/news/COEP/bull-horn-holdings-corp-announces-separate-trading-of-its-ordinary-shares-and-warrants-com-coep-20201217monthly0.5https://www.biopharmawatch.com/news/COEP/bull-horn-holdings-corp-index-to-financial-statement-report-of-independent-registered-publ-coep-20201103monthly0.5https://www.biopharmawatch.com/news/COEP/bull-horn-holdings-corp-announces-pricing-of-75-000-000-initial-public-offering-new-york-n-coep-20201029monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-announces-completion-of-acquisition-by-xenotherapeutics-inc-cambridge-mass-montreal-rptx-20260128monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-shareholders-approve-acquisition-by-xenotherapeutics-inc-cambridge-mass-montreal-bu-rptx-20260116monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-enters-into-definitive-agreement-to-be-acquired-by-xenotherapeutics-in-rptx-20251114monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-business-update-and-reports-second-quarter-2025-financial-res-rptx-20250808monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-enters-exclusive-worldwide-licensing-agreement-with-debiopharm-for-lun-rptx-20250715monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-business-and-clinical-update-and-reports-first-quarter-2025-f-rptx-20250513monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-announces-out-licensing-of-its-discovery-platforms-to-dcx-biotherapeut-rptx-20250501monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-announces-leadership-transitions-steve-forte-executive-vice-president--rptx-20250331monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-business-and-clinical-update-and-reports-fourth-quarter-and-f-rptx-20250303monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-announces-portfolio-re-prioritization-partnering-initiatives-and-cost--rptx-20250109monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-announces-positive-results-of-the-lunresertib-and-camonsertib-combinat-rptx-20241212monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-business-and-clinical-update-and-reports-third-quarter-2024-f-rptx-20241107monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-announces-strategic-reprioritization-to-focus-on-broad-clinical-portfo-rptx-20240828monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-business-and-clinical-update-and-reports-second-quarter-2024--rptx-20240806monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-business-and-clinical-update-and-reports-first-quarter-2024-f-rptx-20240507monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-appoints-steven-h-stein-m-d-to-its-board-of-directors-cambridge-ma-mon-rptx-20240426monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2023-rptx-20240228monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-to-regain-global-rights-to-camonsertib-repare-will-regain-control-of-i-rptx-20240212monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-announces-achievement-of-40-million-roche-clinical-milestone-payment-rptx-20240125monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-corporate-update-and-highlights-anticipated-key-2024-mileston-rptx-20240108monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-unveils-two-programs-expected-to-enter-clinical-trials-in-2024-rp-1664-rptx-20231115monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-business-update-and-reports-third-quarter-2023-financial-resu-rptx-20231109monthly0.5https://www.biopharmawatch.com/news/RPTX/agenda-welcome-introduction-lloyd-m-segal-president-ceo-lunresertib-preliminary-mythic-mon-rptx-20231013monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-announces-positive-initial-data-from-phase-1-mythic-clinical-trial-eva-rptx-20231013monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-business-update-and-reports-second-quarter-2023-financial-res-rptx-20230809monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-reports-proof-of-concept-for-lunresertib-rp-6306-in-clinic-initial-mon-rptx-20230607monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-business-update-and-reports-first-quarter-2023-financial-resu-rptx-20230509monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-appoints-susan-molineaux-ph-d-to-its-board-of-directors-cambridge-ma-m-rptx-20230428monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-presents-initial-clinical-data-from-the-phase-1-2-tresr-and-attacc-tri-rptx-20230418monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2022-rptx-20230228monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-business-update-and-reports-third-quarter-2022-financial-resu-rptx-20221109monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-business-update-and-reports-second-quarter-2022-financial-res-rptx-20220804monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-announces-a-worldwide-license-and-collaboration-agreement-with-roche-f-rptx-20220601monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-business-update-and-reports-first-quarter-2022-financial-resu-rptx-20220505monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2021-rptx-20220301monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-corporate-update-and-highlights-key-milestones-anticipated-in-rptx-20220107monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-business-update-and-reports-third-quarter-2021-financial-resu-rptx-20211110monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-announces-proposed-public-offering-of-common-shares-cambridge-mass-mon-rptx-20211027monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-presents-preliminary-phase-1-monotherapy-clinical-data-from-the-ongoin-rptx-20211008monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-appoints-thomas-civik-to-its-board-and-as-new-chairman-former-ceo-of-f-rptx-20210907monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-business-update-and-reports-second-quarter-2021-financial-res-rptx-20210812monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-business-update-and-reports-first-quarter-2021-financial-resu-rptx-20210513monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-to-highlight-program-progress-for-rp-6306-at-today-s-virtual-investor--rptx-20210408monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2020-rptx-20210304monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-reports-third-quarter-2020-financial-results-and-operational-highlight-rptx-20201111monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-reports-second-quarter-2020-financial-results-and-operational-highligh-rptx-20200813monthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-announces-closing-of-upsized-initial-public-offering-and-exercise-in-f-rptx-20200623monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-provides-business-update-and-announces-first-quarter-2025-financial-r-mrsn-20250515monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-provides-statement-about-mrsn-20230310monthly0.5https://www.biopharmawatch.com/news/MRSN/interim-data-from-the-ovarian-cancer-expansion-cohort-and-next-steps-for-upri-development--mrsn-20210910monthly0.5https://www.biopharmawatch.com/news/MRSN/information-relating-to-part-ii-item-14-other-expenses-of-issuance-and-distribution-the-ex-mrsn-20200601monthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-reports-positive-interim-data-from-the-expansion-portion-of-the-xmt-1-mrsn-20200529monthly0.5https://www.biopharmawatch.com/news/MRSN/accelerating-adc-innovation-because-patients-are-waiting-january-2020-legal-disclaimer-thi-mrsn-20200110monthly0.5https://www.biopharmawatch.com/news/MRSN/information-relating-to-part-ii-item-14-other-expenses-of-issuance-and-distribution-the-ex-mrsn-20190304monthly0.5https://www.biopharmawatch.com/news/MRSN/unleashing-the-targeted-power-of-adcs-february-2019-this-presentation-contains-forward-loo-mrsn-20190228monthly0.5https://www.biopharmawatch.com/news/FONR/fonar-press-release-news-fonar-corporation-for-immediate-release-the-inventor-of-mr-scanni-fonr-20221130monthly0.5https://www.biopharmawatch.com/news/FONR/fonar-press-release-news-fonar-corporation-for-immediate-release-the-inventor-of-mr-scanni-fonr-20190513monthly0.5https://www.biopharmawatch.com/news/FONR/fonar-corporation-press-release-dated-february-11-2019-news-fonar-corporation-and-subsidia-fonr-20190212monthly0.5https://www.biopharmawatch.com/news/FONR/fonar-corporation-press-release-news-fonar-corporation-for-immediate-release-the-inventor--fonr-20180213monthly0.5https://www.biopharmawatch.com/news/FONR/fonar-press-release-news-fonar-corporation-for-immediate-release-the-inventor-of-mr-scanni-fonr-20170209monthly0.5https://www.biopharmawatch.com/news/FONR/fonar-corporation-press-release-news-fonar-for-immediate-release-the-inventor-of-mr-scanni-fonr-20160921monthly0.5https://www.biopharmawatch.com/news/FONR/fonar-corporation-press-release-fonar-corporation-news-for-immediate-release-the-inventor--fonr-20160209monthly0.5https://www.biopharmawatch.com/news/FONR/fonar-corporation-press-release-news-fonar-corporation-for-immediate-release-the-inventor--fonr-20151109monthly0.5https://www.biopharmawatch.com/news/FONR/fonar-press-release-fonar-news-for-immediate-release-the-inventor-of-mr-scanning-contact-d-fonr-20150914monthly0.5https://www.biopharmawatch.com/news/FONR/fonar-corporation-news-for-immediate-release-the-inventor-of-mr-scanning-contact-daniel-cu-fonr-20150511monthly0.5https://www.biopharmawatch.com/news/FONR/fonar-press-release-news-fonar-corporation-for-immediate-release-the-inventor-of-mr-scanni-fonr-20121001monthly0.5https://www.biopharmawatch.com/news/FONR/fonar-press-release-news-for-immediate-release-contact-daniel-culver-director-of-communica-fonr-20120515monthly0.5https://www.biopharmawatch.com/news/OPTN/paratek-pharmaceuticals-completes-acquisition-of-optinose-creating-an-expanded-portfolio-o-optn-20250521monthly0.5https://www.biopharmawatch.com/news/OPTN/voting-and-support-agreement-this-voting-and-support-agreement-dated-as-of-optn-20250319monthly0.5https://www.biopharmawatch.com/news/OPTN/document-paratek-pharmaceuticals-to-acquire-optinose-creating-significant-commercial-expan-optn-20250319monthly0.5https://www.biopharmawatch.com/news/OPTN/document-optinose-announces-proposed-public-offering-of-common-stock-and-warrants-yardley--optn-20221121monthly0.5https://www.biopharmawatch.com/news/OPTN/exhibit-optinose-announces-proposed-public-offering-of-common-stock-yardley-pa-optn-20191120monthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-announces-license-agreement-related-to-optn-20190926monthly0.5https://www.biopharmawatch.com/news/OPTN/announces-150-million-debt-financing-from-pharmakon-yardley-pa-optn-20190912monthly0.5https://www.biopharmawatch.com/news/EDAP/2026-investor-day-nasdaq-focl-june-1-2026-1-edap-20260601monthly0.5https://www.biopharmawatch.com/news/EDAP/the-global-leader-in-therapeutic-ultrasound-1-edap-20260318monthly0.5https://www.biopharmawatch.com/news/EDAP/edap-announces-preliminary-record-fourth-quarter-and-edap-20260112monthly0.5https://www.biopharmawatch.com/news/EDAP/securities-and-exchange-commission-edap-20250909monthly0.5https://www.biopharmawatch.com/news/BSGM/streamex-corp-and-orca-announce-launch-of-24-7-decentralized-secondary-liquidity-infrastru-bsgm-20260527monthly0.5https://www.biopharmawatch.com/news/BSGM/streamex-corp-appoints-former-microsoft-and-paypal-lead-product-designer-kori-handy-as-vic-bsgm-20260526monthly0.5https://www.biopharmawatch.com/news/BSGM/streamex-corp-clarifies-and-refutes-inaccurate-claims-regarding-lock-up-agreements-co-foun-bsgm-20260327monthly0.5https://www.biopharmawatch.com/news/BSGM/streamex-corp-appoints-christine-plummer-former-global-controller-at-coinbase-and-managing-bsgm-20260316monthly0.5https://www.biopharmawatch.com/news/BSGM/streamex-corp-appoints-shawn-matthews-former-ceo-of-cantor-fitzgerald-co-founder-and-cio-o-bsgm-20260303monthly0.5https://www.biopharmawatch.com/news/BSGM/streamex-corp-nasdaq-stex-appoints-morgan-lekstrom-as-executive-chairman-announces-complet-bsgm-20260209monthly0.5https://www.biopharmawatch.com/news/BSGM/streamex-corp-nasdaq-stex-appoints-anthony-marciano-clinical-professor-of-finance-at-nyu-s-bsgm-20260204monthly0.5https://www.biopharmawatch.com/news/BSGM/streamex-corp-nasdaq-stex-announces-proposed-public-offering-winter-park-fl-bsgm-20260122monthly0.5https://www.biopharmawatch.com/news/BSGM/streamex-corp-nasdaq-stex-announces-issuance-of-prepayment-notice-for-previously-announced-bsgm-20260123monthly0.5https://www.biopharmawatch.com/news/BSGM/streamex-corp-nasdaq-stex-acquires-9-9-strategic-equity-stake-in-royalty-and-streaming-fir-bsgm-20251211monthly0.5https://www.biopharmawatch.com/news/BSGM/streamex-corp-nasdaq-stex-announces-appointment-of-kevin-gopaul-global-financial-executive-bsgm-20251118monthly0.5https://www.biopharmawatch.com/news/BSGM/streamex-corp-nasdaq-stex-announces-gold-bullion-purchases-closing-of-initial-usd-25-000-0-bsgm-20251105monthly0.5https://www.biopharmawatch.com/news/BSGM/streamex-corp-nasdaq-stex-announces-nasdaq-approval-for-continued-listing-on-nasdaq-capita-bsgm-20251031monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-and-streamex-exchange-corporation-announce-definitive-agreements-f-bsgm-20250707monthly0.5https://www.biopharmawatch.com/news/BSGM/streamex-and-biosig-announce-the-successful-closing-of-share-exchange-transaction-and-exec-bsgm-20250528monthly0.5https://www.biopharmawatch.com/news/BSGM/confidential-letter-of-intent-bsgm-20250505monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-regains-compliance-with-nasdaq-s-minimum-bid-price-requirement-los-angeles-ca-bsgm-20241113monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-announces-3-million-registered-direct-offering-priced-at-the-market-under-nasdaq-ru-bsgm-20240530monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-s-pure-ep-platform-with-new-near-field-tracking-algorithm-surpasses-100-patient-cas-bsgm-20240206monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-announces-reverse-stock-split-common-stock-will-begin-trading-on-split-adjusted-bas-bsgm-20240202monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-announces-cost-reductions-to-improve-its-financial-standing-and-shifts-its-core-str-bsgm-20240130monthly0.5https://www.biopharmawatch.com/news/BSGM/letter-to-shareholders-december-2023-dear-fellow-shareholders-as-we-approach-the-end-of-20-bsgm-20231206monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-announces-2-5-million-registered-direct-offering-priced-at-the-market-under-nasdaq--bsgm-20231113monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-announces-2-5-million-registered-direct-offering-priced-at-the-market-under-nasdaq--bsgm-20231109monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-appoints-global-medtech-leader-fred-hrkac-as-new-executive-vp-32-year-career-in-med-bsgm-20231107monthly0.5https://www.biopharmawatch.com/news/BSGM/securities-and-exchange-commission-bsgm-20230428monthly0.5https://www.biopharmawatch.com/news/BSGM/securities-and-exchange-commission-bsgm-20210412monthly0.5https://www.biopharmawatch.com/news/BSGM/securities-and-exchange-commission-bsgm-20210325monthly0.5https://www.biopharmawatch.com/news/BSGM/securities-and-exchange-commission-bsgm-20210225monthly0.5https://www.biopharmawatch.com/news/BSGM/securities-and-exchange-commission-bsgm-20210223monthly0.5https://www.biopharmawatch.com/news/BSGM/securities-and-exchange-commission-bsgm-20210113monthly0.5https://www.biopharmawatch.com/news/BSGM/securities-and-exchange-commission-bsgm-20201214monthly0.5https://www.biopharmawatch.com/news/BSGM/securities-and-exchange-commission-bsgm-20201106monthly0.5https://www.biopharmawatch.com/news/BSGM/securities-and-exchange-commission-bsgm-20200727monthly0.5https://www.biopharmawatch.com/news/BSGM/securities-and-exchange-commission-bsgm-20200330monthly0.5https://www.biopharmawatch.com/news/BSGM/letter-to-shareholders-the-year-in-review-what-a-difference-12-months-make-dear-biosig-sha-bsgm-20180404monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-shareholder-letter-december-2017-dear-biosig-technologies-inc-shar-bsgm-20171220monthly0.5https://www.biopharmawatch.com/news/BSGM/ip-veteran-andrew-filler-joins-biosig-technologies-board-of-directors-santa-monica-ca-bsgm-20171110monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-inc-shareholder-letter-april-2017-dear-biosig-technologies-inc-shareho-bsgm-20170424monthly0.5https://www.biopharmawatch.com/news/BSGM/corporate-presentation-2017-symbol-bsgm-disclaimer-symbol-bsgm-this-presentation-contains--bsgm-20170222monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-technologies-announces-advanced-research-program-with-mayo-clinic-minneapolis-mn-bsgm-20160323monthly0.5https://www.biopharmawatch.com/news/BSGM/fourth-amendment-to-the-biosig-technologies-inc-2012-equity-incentive-plan-this-fourth-ame-bsgm-20150522monthly0.5https://www.biopharmawatch.com/news/BSGM/biosig-appoints-patrick-gallagher-to-its-board-of-directors-los-angeles-ca-bsgm-20140722monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-provides-strategic-update-on-autoimmunity-pipeline-programs-company-haltin-igms-20241231monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-reimagining-antibody-medicines-forward-looking-statements-this-presentatio-igms-20221231monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-inc-financial-information-230-million-cash-and-investments-balance-igms-20211231monthly0.5https://www.biopharmawatch.com/news/IGMS/igm-overview-global-leaders-in-the-development-of-engineered-igm-antibodies-for-therapeuti-igms-20201231monthly0.5https://www.biopharmawatch.com/news/IGMS/risk-factors-risks-related-to-our-business-and-the-development-and-commercialization-of-ou-igms-20201207monthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-announces-50-million-registered-direct-offering-of-common-stock-xfeff-aus-sava-20221122monthly0.5https://www.biopharmawatch.com/news/SAVA/xfeff-encouraging-interim-results-at-9-months-from-an-open-label-study-of-simufilam-in-pat-sava-20210803monthly0.5https://www.biopharmawatch.com/news/SAVA/xfeff-xfeff-xfeff-cassava-sciences-selects-clinical-research-organization-for-phase-3-clin-sava-20210621monthly0.5https://www.biopharmawatch.com/news/SAVA/xfeff-cassava-sciences-announces-the-appointment-of-xfeff-richard-j-barry-to-its-board-of--sava-20210611monthly0.5https://www.biopharmawatch.com/news/SAVA/xfeff-xfeff-cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam-xfeff-sava-20210311monthly0.5https://www.biopharmawatch.com/news/SAVA/xfeff-cassava-sciences-announces-200-million-registered-direct-offering-of-common-stock-xf-sava-20210210monthly0.5https://www.biopharmawatch.com/news/SAVA/xfeff-cassava-sciences-we-focus-on-alzheimer-s-disease-february-2021-cassava-sciences-1-xf-sava-20210208monthly0.5https://www.biopharmawatch.com/news/SAVA/xfeff-cassava-sciences-appoints-dr-james-kupiec-as-chief-clinical-development-officer-xfef-sava-20210104monthly0.5https://www.biopharmawatch.com/news/SAVA/xfeff-cassava-sciences-announces-proposed-public-offering-of-common-stock-xfeff-austin-tex-sava-20201113monthly0.5https://www.biopharmawatch.com/news/SAVA/xfeff-sumifilam-significantly-improves-eleven-csf-biomarkers-in-a-randomized-placebo-contr-sava-20201107monthly0.5https://www.biopharmawatch.com/news/SAVA/xfeff-cassava-sciences-final-results-of-a-phase-2b-study-of-sumifilam-in-alzheimer-s-disea-sava-20200914monthly0.5https://www.biopharmawatch.com/news/SAVA/xfeff-cassava-sciences-one-month-oral-treatment-with-pti-125-a-new-drug-candidate-reduces--sava-20191205monthly0.5https://www.biopharmawatch.com/news/SAVA/pain-therapeutics-inc-xfeff-xfeff-xfeff-xfeff-pain-therapeutics-announces-name-change-to-c-sava-20190328monthly0.5https://www.biopharmawatch.com/news/SAVA/xfeff-xfeff-pain-therapeutics-inc-xfeff-xfeff-pain-therapeutics-announces-feedback-from-re-sava-20190131monthly0.5https://www.biopharmawatch.com/news/SAVA/xfeff-pain-therapeutics-inc-xfeff-for-more-information-contact-ruth-araya-pain-therapeutic-sava-20181011monthly0.5https://www.biopharmawatch.com/news/SAVA/xfeff-xfeff-pain-therapeutics-inc-overview-of-neuroprotection-program-non-confidential-oct-sava-20181004monthly0.5https://www.biopharmawatch.com/news/SAVA/xfeff-pain-therapeutics-inc-xfeff-xfeff-for-more-information-contact-ruth-araya-pain-thera-sava-20180820monthly0.5https://www.biopharmawatch.com/news/SAVA/xfeff-pain-therapeutics-inc-xfeff-for-more-information-contact-ruth-araya-pain-therapeutic-sava-20170510monthly0.5https://www.biopharmawatch.com/news/SAVA/jfif-d-d-ducky-2-adobe-d-sava-20130510monthly0.5https://www.biopharmawatch.com/news/SAVA/v073384-ex991-txt-pain-therapeutics-announces-first-quarter-2007-financial-results-south-s-sava-20070502monthly0.5https://www.biopharmawatch.com/news/SAVA/pain-therapeutics-announces-fourth-quarter-and-year-end-2006-financial-results-south-san-f-sava-20070205monthly0.5https://www.biopharmawatch.com/news/SAVA/pain-therapeutics-announces-third-quarter-2006-sava-20061025monthly0.5https://www.biopharmawatch.com/news/AVTE/jade-biosciences-announces-proposed-underwritten-public-offering-san-francisco-and-vancouv-avte-20260603monthly0.5https://www.biopharmawatch.com/news/AVTE/disclaimers-forward-looking-statements-certain-statements-contained-in-or-made-orally-duri-avte-20260601monthly0.5https://www.biopharmawatch.com/news/AVTE/jade-biosciences-reports-first-quarter-2026-financial-results-and-provides-corporate-updat-avte-20260507monthly0.5https://www.biopharmawatch.com/news/AVTE/jade-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides--avte-20260306monthly0.5https://www.biopharmawatch.com/news/AVTE/jade-biosciences-outlines-key-2026-objectives-and-strategy-to-advance-pipeline-of-potentia-avte-20260105monthly0.5https://www.biopharmawatch.com/news/AVTE/jade-biosciences-announces-45-million-private-placement-san-francisco-and-vancouver-britis-avte-20251215monthly0.5https://www.biopharmawatch.com/news/AVTE/jade-biosciences-reports-third-quarter-2025-financial-results-and-provides-corporate-updat-avte-20251113monthly0.5https://www.biopharmawatch.com/news/AVTE/jade-biosciences-announces-135-million-private-placement-san-francisco-and-vancouver-briti-avte-20251007monthly0.5https://www.biopharmawatch.com/news/AVTE/jade-biosciences-reports-second-quarter-2025-financial-results-and-provides-corporate-upda-avte-20250813monthly0.5https://www.biopharmawatch.com/news/AVTE/jade-biosciences-appoints-brad-dahms-as-chief-financial-officer-san-francisco-and-vancouve-avte-20250701monthly0.5https://www.biopharmawatch.com/news/AVTE/financial-statements-jade-biosciences-inc-condensed-consolidated-balance-sheets-unaudited--avte-20250514monthly0.5https://www.biopharmawatch.com/news/AVTE/jade-biosciences-completes-closing-of-merger-with-aerovate-therapeutics-and-previously-ann-avte-20250428monthly0.5https://www.biopharmawatch.com/news/AVTE/company-overview-april-2025-nasdaq-jbio-disclaimers-forward-looking-statements-certain-sta-avte-20250429monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-stockholders-approve-proposed-merger-with-jade-biosciences-and-all-r-avte-20250421monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-declares-special-cash-dividend-in-connection-with-the-proposed-merge-avte-20250409monthly0.5https://www.biopharmawatch.com/news/AVTE/aerovate-therapeutics-announces-range-of-expected-cash-dividend-in-connection-with-the-pro-avte-20250407monthly0.5https://www.biopharmawatch.com/news/AVTE/meaningfully-improving-the-lives-of-patients-with-rare-cardiopulmonary-disease-targeting-t-avte-20240327monthly0.5https://www.biopharmawatch.com/news/AVTE/meaningfully-improving-the-lives-of-patients-with-rare-cardiopulmonary-disease-targeting-t-avte-20240108monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-announces-record-first-quarter-revenue-of-8-8-million-reflecting-35-annual-growth-zom-20260506monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-announces-record-fourth-quarter-revenue-of-10-5-million-and-full-year-revenue-of--zom-20260316monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-announces-third-quarter-2025-financial-results-revenue-up-16-to-8-1-million-with--zom-20251104monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-announces-second-quarter-2025-financial-results-revenue-up-14-to-7-million-with-6-zom-20250806monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-announces-first-quarter-2025-financial-results-revenue-of-6-5-million-68-gross-ma-zom-20250515monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-reports-record-revenue-of-7-9-million-for-the-fourth-quarter-and-27-3-million-for-zom-20250313monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-corp-announces-transition-to-otcqb-market-zomedica-s-ticker-symbol-will-change-to-zom-20250304monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-appoints-scott-a-jordan-executive-vice-president-finance-chief-financial-officer--zom-20241219monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-announces-third-quarter-2024-financial-results-revenue-up-10-to-7-million-72-gros-zom-20241107monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-reports-record-revenue-of-7-3-million-for-the-fourth-quarter-and-25-2-million-for-zom-20240814monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-announces-first-quarter-2024-financial-results-revenue-up-14-to-6-3-million-66-gr-zom-20240509monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-reports-record-revenue-of-7-3-million-for-the-fourth-quarter-and-25-2-million-for-zom-20240401monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-provides-corporate-nyse-american-listing-update-ann-arbor-mi-accesswire-zom-20240313monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-announces-record-third-quarter-2023-financial-results-revenue-up-31-to-6-3-millio-zom-20231113monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-announces-acquisition-of-truforma-platform-developer-qorvo-biotech-llc-accelerati-zom-20231005monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-provides-corporate-update-zom-20230913monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-closes-acquisition-of-structured-monitoring-products-adding-revolutionary-vetguar-zom-20230905monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-announces-record-second-quarter-2023-financial-results-revenue-up-43-to-6-0-milli-zom-20230810monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-announces-record-first-quarter-20-23-financial-results-revenue-up-45-to-5-5-milli-zom-20230511monthly0.5https://www.biopharmawatch.com/news/ZOM/hold-for-release-until-6-30-am-et-zom-20230508monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-appoints-new-chief-financial-officer-ann-arbor-mi-accesswire-zom-20230317monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-corporation-reports-2022-results-18-9-million-revenue-72-gross-margin-156-million-zom-20230315monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-reports-preliminary-results-for-the-fourth-quarter-and-full-year-2022-ann-arbor-m-zom-20230209monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-expands-relationship-with-structured-medical-products-and-begins-commercializing--zom-20230117monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-announces-third-quarter-2022-financial-results-4-78-million-revenue-75-gross-marg-zom-20221114monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-appoints-dr-pamela-nichols-dvm-to-board-of-directors-ann-arbor-mi-accesswire-zom-20220823monthly0.5https://www.biopharmawatch.com/news/ZOM/hold-for-release-until-4-01-pm-zom-20220815monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-acquires-assets-of-leading-tpem-tm-company-assisi-animal-health-ann-arbor-mi-acce-zom-20220718monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-announces-new-global-manufacturing-distribution-center-ann-arbor-mi-accesswire-zom-20220707monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-finalizes-acquisition-of-veterinary-imaging-company-revo-squared-ann-arbor-mi-acc-zom-20220706monthly0.5https://www.biopharmawatch.com/news/ZOM/hold-for-release-until-wednesday-june-15-th-zom-20220615monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-announces-first-quarter-2022-revenues-of-3-8-million-74-gross-margin-192-3-millio-zom-20220510monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-corporation-reports-2021-fourth-quarter-full-year-results-fourth-quarter-2021-pul-zom-20220301monthly0.5https://www.biopharmawatch.com/news/ZOM/zomedica-announces-third-quarter-2021-financial-results-zom-20211112monthly0.5https://www.biopharmawatch.com/news/IKNA/imagenebio-reports-first-quarter-2026-financial-results-and-provides-img-007-program-updat-ikna-20260507monthly0.5https://www.biopharmawatch.com/news/IKNA/imagenebio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-compan-ikna-20260310monthly0.5https://www.biopharmawatch.com/news/IKNA/imagenebio-corporate-overview-fourth-quarter-2025-disclaimer-and-forward-looking-statement-ikna-20251119monthly0.5https://www.biopharmawatch.com/news/IKNA/imagenebio-reports-third-quarter-2025-financial-results-and-provides-img-007-program-updat-ikna-20251112monthly0.5https://www.biopharmawatch.com/news/IKNA/i-magene-b-io-i-nc-2025-e-quity-i-nducement-p-lan-a-dopted-by-the-b-oard-of-d-irectors-j-u-ikna-20250801monthly0.5https://www.biopharmawatch.com/news/IKNA/corporate-overview-july-2025-disclaimer-this-presentation-contains-forward-looking-stateme-ikna-20250729monthly0.5https://www.biopharmawatch.com/news/IKNA/inmagene-biopharmaceuticals-announces-completion-of-merger-with-ikena-oncology-and-concurr-ikna-20250728monthly0.5https://www.biopharmawatch.com/news/IKNA/inmagene-doses-first-patient-in-the-adaptive-phase-2b-trial-of-img-007-a-nondepleting-anti-ikna-20250701monthly0.5https://www.biopharmawatch.com/news/IKNA/additional-information-and-where-to-find-it-investors-and-security-holders-will-be-able-to-ikna-20241223monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-announces-strategic-update-ikena-to-discontinue-development-of-ik-930-ik-59-ikna-20240528monthly0.5https://www.biopharmawatch.com/news/IKNA/november-2021-disclaimer-this-presentation-contains-forward-looking-statements-and-informa-ikna-20211110monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-reports-first-quarter-2021-financial-results-and-outlines-key-corporate-obj-ikna-20210513monthly0.5https://www.biopharmawatch.com/news/IKNA/ikena-oncology-appoints-dr-maria-koehler-to-its-board-of-directors-boston-ma-ikna-20210415monthly0.5https://www.biopharmawatch.com/news/ADVM/floretina-december-2025-ixo-vec-gene-therapy-for-namd-clinical-progress-from-the-luna-phas-advm-20251204monthly0.5https://www.biopharmawatch.com/news/ADVM/forward-looking-statements-statements-contained-in-this-press-release-regarding-events-or--advm-20250922monthly0.5https://www.biopharmawatch.com/news/ADVM/preserving-sight-for-life-webcast-to-present-52-week-luna-and-4-year-optic-results-and-piv-advm-20241118monthly0.5https://www.biopharmawatch.com/news/ADVM/ixo-vec-phase-2-results-from-the-26-week-interim-analysis-company-conference-call-july-17t-advm-20240717monthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-reports-fourth-quarter-and-full-year-2023-financial-results-and-pr-advm-20240321monthly0.5https://www.biopharmawatch.com/news/ADVM/forward-looking-statements-statements-contained-in-this-document-and-any-accompanying-pres-advm-20240208monthly0.5https://www.biopharmawatch.com/news/ADVM/execution-version-efiled-jan-24-2024-08-26pm-est-transaction-id-71868895-case-no-2022-1062-advm-20240124monthly0.5https://www.biopharmawatch.com/news/ADVM/dosing-first-phase-2-luna-trial-participant-with-ixoberogene-soroparvovec-ixo-vec-formerly-advm-20220811monthly0.5https://www.biopharmawatch.com/news/ADVM/a-dverum-b-iotechnologies-i-nc-n-on-e-mployee-d-irector-c-ompensation-p-olicy-a-dopted-by--advm-20201209monthly0.5https://www.biopharmawatch.com/news/ADVM/additional-information-about-our-capitalization-from-advm-20180207monthly0.5https://www.biopharmawatch.com/news/ADVM/dear-paul-i-am-writing-to-inform-you-that-i-am-resigning-from-the-board-of-adverum-biotech-advm-20170201monthly0.5https://www.biopharmawatch.com/news/ADVM/forward-looking-statements-statements-contained-in-this-document-regarding-matters-that-ar-advm-20161013monthly0.5https://www.biopharmawatch.com/news/ADVM/avalanche-biotechnologies-closes-transaction-with-annapurna-therapeutics-and-changes-name--advm-20160512monthly0.5https://www.biopharmawatch.com/news/ADVM/avalanche-advm-20160510monthly0.5https://www.biopharmawatch.com/news/ADVM/avalanche-biotechnologies-inc-reports-first-quarter-2016-financial-results-advm-20160506monthly0.5https://www.biopharmawatch.com/news/ADVM/forward-looking-statements-statements-contained-in-this-document-regarding-matters-that-ar-advm-20160310monthly0.5https://www.biopharmawatch.com/news/ADVM/avalanche-biotechnologies-reports-fourth-quarter-and-fiscal-2015-advm-20160303monthly0.5https://www.biopharmawatch.com/news/ADVM/cautionary-statements-regarding-forward-looking-statements-statements-contained-in-this-do-advm-20160222monthly0.5https://www.biopharmawatch.com/news/ADVM/forward-looking-statements-statements-contained-in-this-document-regarding-matters-that-ar-advm-20160217monthly0.5https://www.biopharmawatch.com/news/ADVM/avalanche-biotechnologies-inc-conference-call-8-00-am-et-advm-20160201monthly0.5https://www.biopharmawatch.com/news/ADVM/avalanche-biotechnologies-and-annapurna-therapeutics-announce-proposed-merger-combined-sci-advm-20160201monthly0.5https://www.biopharmawatch.com/news/ADVM/avalanche-biotechnologies-inc-names-paul-b-cleveland-as-advm-20151120monthly0.5https://www.biopharmawatch.com/news/ADVM/avalanche-biotechnologies-inc-reports-third-quarter-2015-financial-results-advm-20151109monthly0.5https://www.biopharmawatch.com/news/ADVM/avalanche-biotechnologies-inc-reports-second-quarter-2015-financial-results-and-provides-u-advm-20150813monthly0.5https://www.biopharmawatch.com/news/ADVM/avalanche-biotechnologies-announces-leadership-transition-thomas-w-chalberg-jr-ph-d-resign-advm-20150723monthly0.5https://www.biopharmawatch.com/news/ADVM/avalanche-biotechnologies-inc-announces-positive-top-line-phase-2a-results-for-ava-101-in--advm-20150615monthly0.5https://www.biopharmawatch.com/news/ADVM/avalanche-biotechnologies-inc-reports-first-quarter-2015-financial-results-advm-20150513monthly0.5https://www.biopharmawatch.com/news/ADVM/avalanche-biotechnologies-inc-reports-fourth-quarter-and-fiscal-2014-financial-results-advm-20150305monthly0.5https://www.biopharmawatch.com/news/ADVM/avalanche-biotechnologies-inc-reports-third-quarter-2014-financial-results-advm-20141112monthly0.5https://www.biopharmawatch.com/news/ADVM/kathy-vincent-310-403-8951-kathy-kathyvincent-com-avalanche-biotechnologies-inc-appoints-i-advm-20140923monthly0.5https://www.biopharmawatch.com/news/ADVM/avalanche-biotechnologies-to-present-at-the-newsmakers-in-the-biotech-industry-conference-advm-20140919monthly0.5https://www.biopharmawatch.com/news/ADVM/avalanche-biotechnologies-inc-reports-second-quarter-2014-financial-results-advm-20140911monthly0.5https://www.biopharmawatch.com/news/ADVM/investor-contact-chris-erdman-macdougall-biomedical-communications-781-235-3060-cerdman-ma-advm-20140805monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-becomes-skyai-inc-with-new-ticker-symbol-skya-establishing-category-defi-stss-20260527monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-inc-amended-and-restated-audit-committee-charter-adopted-stss-20260115monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-announces-100-million-stock-repurchase-program-stss-20251002monthly0.5https://www.biopharmawatch.com/news/STSS/unaudited-pro-forma-condensed-consolidated-financial-information-the-purpose-of-the-follow-stss-20251006monthly0.5https://www.biopharmawatch.com/news/STSS/privileged-confidential-prepared-at-the-direction-of-counsel-close-press-release-sharps-te-stss-20250828monthly0.5https://www.biopharmawatch.com/news/STSS/privileged-confidential-prepared-at-the-direction-of-counsel-press-release-sharps-technolo-stss-20250825monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-begins-shipments-across-three-customer-orders-under-previously-announced-stss-20250604monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-regains-compliance-with-nasdaq-minimum-bid-price-listing-rule-stss-20250522monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-receives-100k-initial-purchase-order-from-hungarian-vaccine-provider-for-stss-20250506monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-secures-400k-initial-purchase-order-from-u-s-leader-in-iv-flushing-solut-stss-20250430monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-announces-reverse-stock-split-stss-20250424monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-inc-reminds-shareholders-to-vote-before-important-shareholder-meeting-on-stss-20250320monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-inc-announces-pricing-of-upsized-20-0-million-underwritten-public-offeri-stss-20250129monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-s-ceo-issues-shareholder-letter-highlighting-hungary-manufacturing-facil-stss-20241205monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-signs-sales-agreements-to-support-major-european-healthcare-network-and--stss-20241205monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-inc-announces-stockholders-stss-20241014monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-inc-reminds-shareholders-to-vote-before-important-shareholder-meeting-on-stss-20240930monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-inc-announces-3-5-million-bridge-financing-stss-20240923monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-announces-continued-listing-on-nasdaq-pending-results-of-an-upcoming-spe-stss-20240912monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-enters-into-a-five-year-sales-agreement-with-strategic-u-s-medical-produ-stss-20240725monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-ceo-urges-shareholders-to-vote-in-support-of-the-three-proposals-by-the--stss-20240709monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-urges-shareholders-to-approve-the-proposals-in-connection-with-the-speci-stss-20240703monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-receives-30-million-purchase-order-for-prefillable-copolymer-syringes-to-stss-20240613monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-secures-sc-asset-purchase-exclusivity-with-1-million-escrow-deposit-inje-stss-20240605monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-s-sc-asset-purchase-and-200-million-syringe-sales-agreement-paves-the-wa-stss-20240531monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-positioned-to-address-supply-chain-disruptions-resulting-from-recent-fda-stss-20240528monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-and-roncadelle-operations-sign-worldwide-sales-and-distribution-agreemen-stss-20240304monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-signs-loi-with-roncadelle-operations-intended-to-open-worldwide-sales-an-stss-20240118monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-announces-5-6-million-registered-direct-and-private-placement-priced-at--stss-20230927monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-issues-letter-to-shareholders-covering-the-announced-asset-purchase-agre-stss-20230928monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-signs-asset-purchase-agreement-to-acquire-injectez-specialty-copolymer-s-stss-20230926monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-announces-pricing-of-3-8-million-private-placement-priced-at-the-market--stss-20230201monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-inc-to-introduce-new-specialized-prefillable-syringe-systems-in-2023-hig-stss-20230110monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-begins-manufacturing-at-its-hungary-facility-for-the-company-s-innovativ-stss-20221220monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-and-nephron-pharmaceuticals-signs-distribution-agreement-for-its-innovat-stss-20221213monthly0.5https://www.biopharmawatch.com/news/STSS/nephron-pharmaceuticals-corporation-and-sharps-technology-inc-announce-manufacturing-and-r-stss-20221110monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-completes-acquisition-of-safegard-medical-syringe-manufacturing-facility-stss-20220714monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-announces-letter-to-shareholders-stss-20220608monthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-announces-pricing-of-initial-public-offering-stss-20220413monthly0.5https://www.biopharmawatch.com/news/MEIP/lite-strategy-reports-fiscal-2026-third-quarter-results-lite-strategy-continues-to-deliver-meip-20260513monthly0.5https://www.biopharmawatch.com/news/MEIP/lite-strategy-reports-fiscal-2026-second-quarter-results-second-quarter-performance-driven-meip-20260217monthly0.5https://www.biopharmawatch.com/news/MEIP/lite-strategy-announces-25m-share-repurchase-program-signalling-shift-from-initial-litecoi-meip-20251029monthly0.5https://www.biopharmawatch.com/news/MEIP/lite-strategy-inc-nasdaq-lits-is-the-first-u-s-listed-public-company-to-adopt-litecoin-as--meip-20250910monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-acquires-litecoin-launches-100m-institutional-treasury-strategy-with-charlie-le-meip-20250804monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-announces-100-000-000-private-placement-to-initiate-litecoin-treasury-strategy--meip-20250718monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-reports-third-quarter-fiscal-year-2025-cash-position-evaluation-of-strategic-al-meip-20250513monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-reports-second-quarter-fiscal-year-2025-cash-position-evaluation-of-strategic-a-meip-20250212monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-reports-first-quarter-fiscal-year-2025-cash-position-reaffirms-continuation-of--meip-20241112monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-reports-fiscal-year-end-2024-cash-position-confirms-continuation-of-evaluation--meip-20240919monthly0.5https://www.biopharmawatch.com/news/MEIP/voruciclib-an-oral-cdk9-inhibitor-for-aml-and-other-malignancies-july-2024-forward-looking-meip-20240730monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-to-consider-strategic-alternatives-company-commences-a-cash-preservation-plan-i-meip-20240722monthly0.5https://www.biopharmawatch.com/news/MEIP/nasdaq-meip-corporate-overview-novel-drug-candidates-to-address-known-resistance-mechanism-meip-20240521monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-reports-third-quarter-fiscal-year-2024-results-and-operational-highlights-ongoi-meip-20240509monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-reports-second-quarter-fiscal-year-2024-results-and-operational-highlights-san--meip-20240213monthly0.5https://www.biopharmawatch.com/news/MEIP/inability-to-protect-our-patents-or-proprietary-rights-and-obtain-necessary-rights-to-thir-meip-20231211monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-reports-first-quarter-fiscal-year-2024-results-and-operational-highlights-san-d-meip-20231109monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-enters-into-agreement-with-anson-funds-and-cable-car-capital-commits-to-capital-meip-20231101monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-adopts-limited-duration-stockholder-rights-plan-responds-to-substantial-stock-a-meip-20231002monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-reports-fiscal-year-2023-results-and-operational-highlights-conference-call-tod-meip-20230926monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-announces-results-of-special-meeting-of-stockholders-meip-20230723monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-reminds-shareholders-to-vote-today-for-the-infinity-transaction-meip-20230719monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-encourages-shareholders-to-vote-for-the-infinity-transaction-meip-20230717monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-postpones-special-meeting-of-shareholders-meip-20230713monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-reminds-shareholders-to-vote-for-the-merger-with-infinity-pharmaceuticals-glass-meip-20230707monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-highlights-recommendation-by-leading-independent-proxy-advisory-firm-iss-to-vot-meip-20230705monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-mails-letter-to-shareholders-reiterating-value-creating-potential-of-proposed-t-meip-20230629monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-responds-to-anson-and-cable-car-meip-20230627monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-and-infinity-pharmaceuticals-host-video-webcast-providing-overview-and-update-o-meip-20230619monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-announces-planned-departure-of-chief-financial-officer-brian-drazba-and-appoint-meip-20230613monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-announces-planned-departure-of-ceo-daniel-p-gold-ph-d-and-appointment-of-david--meip-20230602monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-board-of-directors-rejects-unsolicited-proposal-meip-20230601monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-confirms-receipt-of-unsolicited-acquisition-proposal-meip-20230530monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-reports-third-quarter-fiscal-year-2023-results-and-operational-highlights-mei-b-meip-20230511monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-announces-1-for-20-meip-20230414monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-and-infinity-pharmaceuticals-announce-definitive-merger-agreement-to-advance-th-meip-20230223monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-reports-second-quarter-fiscal-year-2023-results-and-operational-highlights-mei--meip-20230209monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-and-kyowa-kirin-announce-discontinuation-of-zandelisib-development-outside-of-j-meip-20221208monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-reports-first-quarter-fiscal-year-2023-results-and-operational-highlights-mei-b-meip-20221114monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-reports-third-quarter-fiscal-year-2022-results-and-operational-highlights-mei-b-meip-20220523monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-and-kyowa-kirin-provide-regulatory-update-on-zandelisib-following-meeting-with--meip-20220325monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-announces-pricing-of-public-offering-of-common-stock-san-diego-meip-20211201monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-and-kyowa-kirin-announce-data-from-the-ongoing-global-phase-2-tidal-study-evalu-meip-20211130monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-appoints-biotechnology-executive-sujay-kango-to-its-board-of-directors-meip-20211123monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-announces-planned-chief-financial-officer-transition-brian-drazba-chief-financi-meip-20210805monthly0.5https://www.biopharmawatch.com/news/MEIP/forward-looking-statements-this-presentation-contains-and-our-officers-and-representatives-meip-20210614monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-announces-the-retirement-of-chief-medical-officer-robert-mass-and-promotion-of--meip-20210430monthly0.5https://www.biopharmawatch.com/news/MEIP/forward-looking-statements-this-presentation-contains-and-our-officers-and-representatives-meip-20210331monthly0.5https://www.biopharmawatch.com/news/MEIP/helsinn-group-and-mei-pharma-discontinue-the-phase-3-study-with-pracinostat-in-aml-after-c-meip-20200702monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-appoints-cheryl-cohen-product-launch-and-commercialization-veteran-to-its-board-meip-20200414monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-and-kyowa-kirin-announce-global-license-development-and-commercialization-agree-meip-20200414monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-announces-pricing-of-public-offering-of-common-stock-san-diego-meip-20191217monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-appoints-longtime-industry-consultant-and-executive-tamar-howson-to-its-board-o-meip-20190703monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-presents-clinical-results-for-me-344-in-combination-with-bevacizumab-in-early-h-meip-20190601monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-presents-preclinical-data-demonstrating-voruciclib-synergistically-induces-apop-meip-20181201monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-and-kyowa-hakko-kirin-announce-license-agreement-to-develop-and-commercialize-m-meip-20181105monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-promotes-david-m-urso-to-chief-operating-officer-meip-20180716monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-presents-phase-1b-clinical-data-for-me-401-in-patients-with-indolent-b-cell-mal-meip-20180604monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-announces-75-million-private-placement-meip-20180514monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-appoints-industry-veteran-frederick-w-driscoll-to-its-board-of-directors-meip-20180226monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-announces-exclusive-license-agreement-with-presage-biosciences-for-voruciclib-a-meip-20170905monthly0.5https://www.biopharmawatch.com/news/MEIP/mei-pharma-announces-appointment-of-brian-drazba-as-chief-financial-officer-san-diego-meip-20170403monthly0.5https://www.biopharmawatch.com/news/MEIP/helsinn-group-and-mei-pharma-enter-strategic-agreement-for-the-development-and-commerciali-meip-20160808monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-vice-president-investor-relations-corporate-communications-858-792-3729-pdes-meip-20151210monthly0.5https://www.biopharmawatch.com/news/MEIP/aza-pracinostat-in-aml-introduction-elderly-aml-patients-deemed-unsuitable-for-intensive-t-meip-20151208monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-vice-president-investor-relations-corporate-communications-858-792-3729-pdes-meip-20150902monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-vice-president-investor-relations-corporate-communications-858-792-3729-pdes-meip-20150323monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-vice-president-investor-relations-corporate-communications-858-792-3729-pdes-meip-20141212monthly0.5https://www.biopharmawatch.com/news/MEIP/forward-looking-statements-these-slides-and-the-accompanying-oral-presentation-contain-for-meip-20141209monthly0.5https://www.biopharmawatch.com/news/MEIP/pracinostat-in-combination-with-azacitidine-produces-a-high-rate-and-rapid-onset-of-diseas-meip-20141208monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-vice-president-investor-relations-corporate-communications-858-792-3729-pdes-meip-20140909monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-vice-president-investor-relations-corporate-communications-858-792-3729-pdes-meip-20140902monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-vice-president-investor-relations-corporate-communications-858-792-3729-pdes-meip-20140408monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-meip-20131025monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-meip-20131021monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-meip-20130618monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-meip-20130611monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-meip-20130405monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-meip-20130211monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-meip-20130130monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-meip-20121219monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-meip-20121105monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-meip-20120808monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pete-de-meip-20120306monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pete-de-meip-20111229monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pete-de-meip-20110928monthly0.5https://www.biopharmawatch.com/news/MEIP/reminder-marshall-edwards-to-host-conference-call-on-thursday-september-29-san-diego-meip-20110927monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pete-de-meip-20110908monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pete-de-meip-20110602monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pete-de-meip-20110510monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pete-de-meip-20110502monthly0.5https://www.biopharmawatch.com/news/MEIP/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pete-de-meip-20110316monthly0.5https://www.biopharmawatch.com/news/MEIP/execution-version-voting-agreement-this-voting-agreement-this-agreement-dated-as-of-meip-20101221monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-to-host-conference-call-on-meip-20100908monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-contact-pete-de-spain-sr-director-investor-relations-corporate-commun-meip-20100810monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-contacts-warren-lancaster-203-966-2556-warren-lancaster-marshalledwar-meip-20100617monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-announces-final-results-from-halted-phase-3-clinical-trial-of-phenoxodiol-meip-20100601monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-contacts-warren-lancaster-1-203-966-2556-usa-warren-lancaster-marshal-meip-20100524monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-contacts-warren-lancaster-1-203-966-2556-usa-warren-lancaster-marshal-meip-20100506monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-contacts-warren-lancaster-1-203-966-2556-usa-warren-lancaster-marshal-meip-20100426monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-contacts-warren-lancaster-1-203-966-2556-usa-warren-lancaster-marshal-meip-20100420monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-contacts-warren-lancaster-1-203-966-2556-usa-warren-lancaster-marshal-meip-20100319monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-contact-warren-lancaster-1-203-966-2556-usa-warren-lancaster-marshall-meip-20100208monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-contacts-warren-lancaster-1-203-966-2556-usa-warren-lancaster-marshal-meip-20091201monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-contacts-warren-lancaster-1-203-966-2556-usa-warren-lancaster-marshal-meip-20090922monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-contacts-warren-lancaster-1-203-966-2556-usa-warren-lancaster-marshal-meip-20090805monthly0.5https://www.biopharmawatch.com/news/MEIP/biotech-analyst-joins-board-of-directors-of-marshall-edwards-inc-new-canaan-ct-and-sydney--meip-20090324monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-announces-resignation-of-stephen-breckenridge-from-board-of-directors-meip-20081219monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-raises-10-000-000-in-public-offering-washington-dc-and-sydney-austral-meip-20080730monthly0.5https://www.biopharmawatch.com/news/MEIP/exv99w1-ovature-phase-iii-trial-update-under-u-s-law-a-new-drug-cannot-be-marketed-until-i-meip-20070821monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-raises-16-4-million-in-private-equity-financing-washington-dc-and-syd-meip-20070806monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-contact-david-sheon-202-518-6384-usa-mr-christopher-naughton-ceo-mars-meip-20070404monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-contact-david-sheon-202-518-6384-usa-mr-christopher-naughton-ceo-mars-meip-20070328monthly0.5https://www.biopharmawatch.com/news/MEIP/christopher-naughton-ceo-marshall-edwards-inc-612-8877-6196-david-sheon-sciwords-llc-202-5-meip-20061130monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-raises-a-total-of-approximately-18-million-in-private-equity-financin-meip-20060712monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-raises-approximately-14-million-in-private-equity-financing-washingto-meip-20060712monthly0.5https://www.biopharmawatch.com/news/MEIP/asx-media-release-7-june-2006-novogen-renegotiates-phenoxodiol-licence-payment-novogen-lim-meip-20060609monthly0.5https://www.biopharmawatch.com/news/MEIP/blake-dawson-waldron-l-a-w-y-e-r-s-licence-agreement-novogen-research-pty-limited-abn-87-0-meip-20060516monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-contact-david-sheon-202-518-6384-usa-mr-christopher-naughton-ceo-mars-meip-20060329monthly0.5https://www.biopharmawatch.com/news/MEIP/marshall-edwards-inc-fda-grants-fast-track-designation-for-phenoxodiol-in-oral-dosage-form-meip-20050126monthly0.5https://www.biopharmawatch.com/news/KLTO/greenland-mines-ltd-nasdaq-grml-visit-greenlandmines-com-for-more-information-may-13-14-20-klto-20260514monthly0.5https://www.biopharmawatch.com/news/KLTO/greenland-mines-secures-additional-180-day-period-for-nasdaq-bid-price-compliance-extensio-klto-20260323monthly0.5https://www.biopharmawatch.com/news/KLTO/klotho-neurosciences-completes-rebranding-to-greenland-mines-ltd-and-change-of-nasdaq-tick-klto-20260312monthly0.5https://www.biopharmawatch.com/news/KLTO/investor-webcast-klto-20260312monthly0.5https://www.biopharmawatch.com/news/KLTO/klotho-neurosciences-acquires-greenland-mines-corp-securing-control-of-a-68-billion-pallad-klto-20260304monthly0.5https://www.biopharmawatch.com/news/KLTO/klotho-neurosciences-inc-klotho-initiates-manufacturing-of-klto-202-product-candidate-usin-klto-20250812monthly0.5https://www.biopharmawatch.com/news/KLTO/klotho-neurosciences-inc-partners-with-aavnergene-inc-to-make-klotho-s-gene-therapy-assets-klto-20250722monthly0.5https://www.biopharmawatch.com/news/KLTO/klotho-neurosciences-inc-regains-full-compliance-with-nasdaq-minimum-closing-bid-price-and-klto-20250716monthly0.5https://www.biopharmawatch.com/news/KLTO/klotho-neurosciences-inc-granted-fda-orphan-drug-designation-for-klto-202-for-treatment-of-klto-20250710monthly0.5https://www.biopharmawatch.com/news/KLTO/klotho-neurosciences-moves-forward-with-manufacturing-gene-therapy-for-the-treatment-of-klto-20250630monthly0.5https://www.biopharmawatch.com/news/KLTO/klotho-neurosciences-raises-over-11-million-retires-all-debt-and-exceeds-nasdaq-stockholde-klto-20250616monthly0.5https://www.biopharmawatch.com/news/KLTO/klotho-neuroscience-inc-announces-an-approach-to-increase-longevity-and-healthy-life-span--klto-20250609monthly0.5https://www.biopharmawatch.com/news/KLTO/dr-robert-langer-co-founder-of-moderna-joins-scientific-advisory-board-of-klotho-neuroscie-klto-20240930monthly0.5https://www.biopharmawatch.com/news/KLTO/strategic-asset-leasing-inc-13576-walnut-street-omaha-ne-68144-financial-statements-and-no-klto-20240620monthly0.5https://www.biopharmawatch.com/news/KLTO/using-gene-therapy-to-address-the-aging-process-investor-presentation-q3-2023-disclaimer-2-klto-20230811monthly0.5https://www.biopharmawatch.com/news/KLTO/anew-medical-inc-enters-into-definitive-merger-agreement-with-redwoods-acquisition-corp-an-klto-20230530monthly0.5https://www.biopharmawatch.com/news/KLTO/redwoods-acquisition-corp-announces-receipt-of-nasdaq-listing-delinquency-letter-and-nasda-klto-20230531monthly0.5https://www.biopharmawatch.com/news/KLTO/index-to-unaudited-pro-forma-financial-statement-unaudited-pro-forma-balance-sheet-as-of-klto-20220407monthly0.5https://www.biopharmawatch.com/news/KLTO/index-to-financial-statement-report-of-independent-registered-public-accounting-firm-f-2-f-klto-20220404monthly0.5https://www.biopharmawatch.com/news/KRON/kronos-bio-enters-into-agreement-to-be-acquired-by-concentra-biosciences-for-0-57-in-cash--kron-20250501monthly0.5https://www.biopharmawatch.com/news/KRON/kronos-bio-inc-condensed-statements-of-operations-and-comprehensive-loss-in-thousands-exce-kron-20250318monthly0.5https://www.biopharmawatch.com/news/KRON/document-kronos-bio-reports-third-quarter-2024-financial-results-and-corporate-update-incl-kron-20241113monthly0.5https://www.biopharmawatch.com/news/KRON/document-kronos-bio-reports-second-quarter-2024-financial-results-and-pipeline-update-firs-kron-20240808monthly0.5https://www.biopharmawatch.com/news/KRON/document-kronos-bio-reports-first-quarter-2024-financial-results-152-0-million-cash-runway-kron-20240509monthly0.5https://www.biopharmawatch.com/news/KRON/kronos-bio-inc-statements-of-operations-and-comprehensive-loss-in-thousands-except-per-sha-kron-20240321monthly0.5https://www.biopharmawatch.com/news/KRON/document-kronos-bio-reports-recent-business-progress-and-third-quarter-2023-financial-resu-kron-20231113monthly0.5https://www.biopharmawatch.com/news/KRON/results-as-of-1-june-2023-28-patients-enrolled-in-dose-escalation-up-to-60-mg-patients-had-kron-20231005monthly0.5https://www.biopharmawatch.com/news/KRON/document-kronos-bio-reports-recent-business-progress-and-second-quarter-2023-financial-res-kron-20230808monthly0.5https://www.biopharmawatch.com/news/KRON/document-kronos-bio-reports-recent-business-progress-and-first-quarter-2023-financial-resu-kron-20230510monthly0.5https://www.biopharmawatch.com/news/KRON/kronos-bio-inc-statements-of-operations-and-comprehensive-loss-in-thousands-except-share-a-kron-20230315monthly0.5https://www.biopharmawatch.com/news/KRON/document-kronos-bio-reports-recent-business-progress-and-third-quarter-2022-financial-resu-kron-20221108monthly0.5https://www.biopharmawatch.com/news/KRON/document-kronos-bio-reports-recent-business-progress-and-second-quarter-2022-financial-res-kron-20220804monthly0.5https://www.biopharmawatch.com/news/KRON/document-kronos-bio-reports-recent-business-progress-and-first-quarter-2022-financial-resu-kron-20220504monthly0.5https://www.biopharmawatch.com/news/KRON/marni-kottle-kronos-bio-415-218-7111-mkottle-kronosbio-com-investors-claudia-styslinger-ar-kron-20220224monthly0.5https://www.biopharmawatch.com/news/KRON/document-kronos-bio-reports-recent-business-progress-and-third-quarter-financial-results-c-kron-20211109monthly0.5https://www.biopharmawatch.com/news/KRON/document-kronos-bio-reports-recent-business-progress-and-second-quarter-financial-results--kron-20210812monthly0.5https://www.biopharmawatch.com/news/KRON/document-kronos-bio-reports-recent-business-progress-and-first-quarter-financial-results-a-kron-20210511monthly0.5https://www.biopharmawatch.com/news/KRON/about-kronos-bio-inc-kronos-bio-is-a-clinical-stage-biopharmaceutical-company-dedicated-to-kron-20210323monthly0.5https://www.biopharmawatch.com/news/KRON/third-quarter-financial-highlights-cash-cash-equivalents-and-short-term-investments-as-of-kron-20201118monthly0.5https://www.biopharmawatch.com/news/KRON/kronos-bio-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters--kron-20201014monthly0.5https://www.biopharmawatch.com/news/OCX/imdx-reports-q1-2026-results-and-update-on-progress-toward-graftassure-commercialization-p-ocx-20260513monthly0.5https://www.biopharmawatch.com/news/OCX/imdx-submits-graftassuredx-for-fda-review-and-reports-q4-2025-results-submitted-graftassur-ocx-20260326monthly0.5https://www.biopharmawatch.com/news/OCX/imdx-announces-26-0-ocx-20260211monthly0.5https://www.biopharmawatch.com/news/OCX/imdx-reports-q3-2025-results-and-progress-toward-2026-commercial-launch-on-track-to-submit-ocx-20251110monthly0.5https://www.biopharmawatch.com/news/OCX/imdx-reports-q2-2025-results-and-momentum-toward-graftassuredx-launch-reiterating-timeline-ocx-20250811monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-prices-29-1-million-equity-offering-proceeds-expected-to-fund-transplant-assay-th-ocx-20250210monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-successful-graftassure-tm-beta-launch-and-q2-2024-results-interest-in-k-ocx-20240808monthly0.5https://www.biopharmawatch.com/news/OCX/e-xhibit-99-1-oncocyte-reports-first-quarter-2024-financial-results-conference-call-on-wed-ocx-20240515monthly0.5https://www.biopharmawatch.com/news/OCX/now-officially-available-we-are-excited-to-announce-the-official-launch-of-vitagraft-kidne-ocx-20240123monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-second-quarter-2023-financial-results-conference-call-on-thursday-ocx-20230810monthly0.5https://www.biopharmawatch.com/news/OCX/were-derived-from-the-company-s-historical-consolidated-financial-statements-and-are-being-ocx-20230223monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-the-appointment-of-john-peter-gutfreund-as-independent-member-of-its-bo-ocx-20220728monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-ocx-20220413monthly0.5https://www.biopharmawatch.com/news/OCX/news-oncocyte-announces-development-and-co-marketing-agreement-with-thermo-fisher-scientif-ocx-20220118monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-to-begin-trading-on-the-nasdaq-stock-market-on-ocx-20210225monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-announces-25-million-registered-offering-offering-led-by-current-shareholder-and--ocx-20210120monthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-ocx-20201215monthly0.5https://www.biopharmawatch.com/news/OCX/amendment-to-oncocyte-corporation-2018-equity-incentive-plan-approved-by-shareholders-ocx-20190717monthly0.5https://www.biopharmawatch.com/news/OCX/equity-incentive-plan-oncocyte-corporation-1-purpose-eligibility-1-1-general-purpose-the-n-ocx-20180829monthly0.5https://www.biopharmawatch.com/news/OCX/seasoned-healthcare-executive-albert-p-parker-appointed-chief-operating-officer-of-oncocyt-ocx-20180809monthly0.5https://www.biopharmawatch.com/news/OCX/seasoned-financial-executive-joins-oncocyte-as-chief-financial-officer-ocx-20171115monthly0.5https://www.biopharmawatch.com/news/OCX/liquid-biopsies-next-generation-cancer-molecular-diagnostics-william-annettchief-executive-ocx-20160908monthly0.5https://www.biopharmawatch.com/news/OCX/don-m-bailey-appointed-to-oncocyte-corporation-s-board-of-directors-experienced-senior-exe-ocx-20160829monthly0.5https://www.biopharmawatch.com/news/KZR/aurinia-pharmaceuticals-to-acquire-kezar-life-sciences-for-6-955-in-cash-per-share-plus-a--kzr-20260330monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-announces-positive-topline-results-from-the-portola-phase-2a-trial-eva-kzr-20250325monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-third-quarter-2024-financial-results-and-provides-business-upd-kzr-20241112monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-announces-positive-idmc-safety-review-of-portola-trial-of-zetomipzomib-kzr-20241017monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-confirms-receipt-of-unsolicited-non-binding-acquisition-proposal-kzr-20241010monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-announces-clinical-hold-of-zetomipzomib-ind-for-treatment-of-lupus-nep-kzr-20241004monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-announces-cessation-of-enrollment-and-dosing-in-the-phase-2b-palizade--kzr-20240930monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-second-quarter-2024-financial-results-and-provides-business-up-kzr-20240813monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-first-quarter-2024-financial-results-and-provides-business-upd-kzr-20240509monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-fourth-quarter-and-year-end-2023-financial-results-and-provide-kzr-20240314monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-third-quarter-2023-financial-results-and-provides-business-upd-kzr-20231113monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-announces-strategic-restructuring-to-prioritize-clinical-stage-assets--kzr-20231003monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-and-everest-medicines-enter-into-an-agreement-to-develop-and-commercia-kzr-20230920monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-second-quarter-2023-financial-results-and-provides-business-up-kzr-20230810monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-first-quarter-2023-financial-results-and-provides-business-upd-kzr-20230511monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-fourth-quarter-and-year-end-2022-financial-results-and-provide-kzr-20230315monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-third-quarter-2022-financial-results-and-provides-business-upd-kzr-20221110monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-presents-positive-complete-results-from-the-mission-phase-2-trial-eval-kzr-20221103monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-second-quarter-2022-financial-results-and-provides-business-up-kzr-20220811monthly0.5https://www.biopharmawatch.com/news/KZR/forward-looking-statements-and-topline-data-disclaimer-this-presentation-contains-forward--kzr-20220627monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-first-quarter-2022-financial-results-and-provides-business-upd-kzr-20220512monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-announces-topline-results-from-presidio-trial-of-zetomipzomib-for-the-treatment-of-d-kzr-20220503monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-reports-fourth-quarter-and-year-end-2021-financial-results-and-provides-business-upd-kzr-20220317monthly0.5https://www.biopharmawatch.com/news/KZR/this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-private-se-kzr-20211115monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-reports-third-quarter-financial-results-and-provides-business-update-target-enrollme-kzr-20211109monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-second-quarter-financial-results-and-provides-business-updates-kzr-20210812monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-presents-results-of-the-completed-mission-phase-1b-study-of-kzr-616-at-eular-2021-kz-kzr-20210602monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-first-quarter-financial-results-and-provides-business-updates--kzr-20210512monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-fourth-quarter-and-year-end-2020-financial-results-and-provide-kzr-20210311monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-third-quarter-2020-financial-results-and-provides-business-upd-kzr-20201105monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-reports-second-quarter-2020-financial-results-and-provides-clinical-an-kzr-20200805monthly0.5https://www.biopharmawatch.com/news/KZR/whether-as-a-result-of-new-information-future-events-or-otherwise-company-overview-we-are--kzr-20200608monthly0.5https://www.biopharmawatch.com/news/KZR/whether-as-a-result-of-new-information-future-events-or-otherwise-1-company-overview-we-ar-kzr-20200130monthly0.5https://www.biopharmawatch.com/news/KZR/forward-looking-statements-disclaimer-this-presentation-contains-forward-looking-statement-kzr-20191003monthly0.5https://www.biopharmawatch.com/news/KZR/kezar-life-sciences-announces-closing-of-initial-public-offering-and-exercise-in-full-of-t-kzr-20180625monthly0.5https://www.biopharmawatch.com/news/SGMO/disclosures-for-andrew-d-leavitt-md-conflict-disclosure-research-support-none-director-off-sgmo-20210114monthly0.5https://www.biopharmawatch.com/news/SGMO/pfizer-and-sangamo-announce-updated-phase-1-2-results-showing-sustained-factor-viii-activi-sgmo-20201207monthly0.5https://www.biopharmawatch.com/news/SGMO/pfizer-media-contact-steve-danehy-sgmo-20200618monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-reports-business-highlights-and-first-quarter-2020-financial-results--sgmo-20200511monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-conferenc-sgmo-20200228monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-reports-third-quarter-2019-financial-results-conference-call-and-webc-sgmo-20191106monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-reports-second-quarter-2019-financial-results-conference-call-and-web-sgmo-20190807monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-reports-first-quarter-2019-financial-results-conference-call-and-webc-sgmo-20190508monthly0.5https://www.biopharmawatch.com/news/SGMO/to-the-company-s-current-report-on-form-8-k-a-filed-with-the-sec-on-sgmo-20190403monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-inc-point-richmond-tech-center-501-canal-boulevard-richmond-ca-94804--sgmo-20190228monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-inc-point-richmond-tech-center-501-canal-boulevard-richmond-ca-94804--sgmo-20181108monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-inc-point-richmond-tech-center-501-canal-boulevard-richmond-ca-94804--sgmo-20180808monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-to-acquire-txcell-the-proposed-acquisition-would-combine-sangamo-s-ex-sgmo-20180723monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-inc-stock-option-grant-notice-2018-equity-incentive-plan-sangamo-ther-sgmo-20180615monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-inc-point-richmond-tech-center-501-canal-boulevard-richmond-ca-94804--sgmo-20180508monthly0.5https://www.biopharmawatch.com/news/SGMO/are-made-as-of-the-date-hereof-and-sangamo-undertakes-no-duty-to-update-such-information-e-sgmo-20180424monthly0.5https://www.biopharmawatch.com/news/SGMO/unless-the-context-indicates-otherwise-the-terms-sangamo-we-us-and-our-refer-to-sangamo-th-sgmo-20180417monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-inc-point-richmond-tech-center-501-canal-boulevard-richmond-ca-94804--sgmo-20180222monthly0.5https://www.biopharmawatch.com/news/SGMO/this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-safe-harbo-sgmo-20180108monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-inc-amended-and-restated-2013-stock-incentive-plan-article-one-genera-sgmo-20171114monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-inc-point-richmond-tech-center-501-canal-boulevard-richmond-ca-94804--sgmo-20171109monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-inc-point-richmond-tech-center-501-canal-boulevard-richmond-ca-94804--sgmo-20170809monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-inc-point-richmond-tech-center-501-canal-boulevard-richmond-ca-94804--sgmo-20170621monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-inc-point-richmond-tech-center-501-canal-boulevard-richmond-ca-94804--sgmo-20170510monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-inc-point-richmond-tech-center-501-canal-boulevard-richmond-ca-94804--sgmo-20170228monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-reports-third-quarter-2016-financial-results-company-highlights-progre-sgmo-20161026monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-reports-second-quarter-2016-financial-results-company-to-host-conferen-sgmo-20160803monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-announces-retirement-of-edward-lanphier-as-president-and-ceo-sandy-mac-sgmo-20160601monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-reports-first-quarter-2016-financial-results-sgmo-20160502monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-reports-fourth-quarter-and-full-year-2015-financial-results-company-be-sgmo-20160209monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-reports-third-quarter-2015-financial-results-increases-year-end-cash-g-sgmo-20151028monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-and-shire-restructure-collaboration-to-accelerate-development-of-zfp-therapeutics--sgmo-20150902monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-reports-second-quarter-2015-financial-results-sgmo-20150805monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-reports-first-quarter-2015-financial-results-sgmo-20150422monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-reports-fourth-quarter-and-full-year-2014-financial-results-sgmo-20150210monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-reports-third-quarter-2014-financial-results-sgmo-20141022monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-reports-second-quarter-2014-financial-results-sgmo-20140723monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-appoints-h-stewart-parker-to-its-board-of-directors-sgmo-20140619monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-reports-first-quarter-2014-financial-results-partnership-with-biogen-i-sgmo-20140506monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-inc-point-richmond-tech-center-501-canal-boulevard-richmond-ca-94804-5-sgmo-20140320monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-reports-fourth-quarter-and-full-year-2013-financial-results-significan-sgmo-20140211monthly0.5https://www.biopharmawatch.com/news/SGMO/biogen-idec-and-sangamo-biosciences-announce-global-collaboration-to-develop-treatments-fo-sgmo-20140109monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-reports-third-quarter-2013-financial-results-recent-financing-enhances-sgmo-20131023monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-inc-point-richmond-tech-center-501-canal-boulevard-richmond-ca-94804-5-sgmo-20130918monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-inc-point-richmond-tech-center-501-canal-boulevard-richmond-ca-94804-5-sgmo-20130912monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-to-acquire-ceregene-acquisition-provides-significant-portfolio-of-aav--sgmo-20130826monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-reports-second-quarter-2013-financial-results-sgmo-20130724monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-reports-first-quarter-2013-financial-results-sgmo-20130508monthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-biosciences-reports-fourth-quarter-and-full-year-2012-financial-results-sgmo-20130206monthly0.5https://www.biopharmawatch.com/news/ALRN/rein-therapeutics-announces-pricing-of-50-million-underwritten-public-offering-of-common-s-alrn-20260430monthly0.5https://www.biopharmawatch.com/news/ALRN/rein-therapeutics-receives-fda-clearance-to-resume-u-s-phase-2-trial-of-lti-03-in-idiopath-alrn-20251103monthly0.5https://www.biopharmawatch.com/news/ALRN/rein-therapeutics-receives-european-regulatory-approval-to-initiate-phase-2-trial-of-lti-0-alrn-20251009monthly0.5https://www.biopharmawatch.com/news/ALRN/rein-therapeutics-wins-u-k-approval-to-launch-phase-2-clinical-trial-of-lti-03-in-idiopath-alrn-20250819monthly0.5https://www.biopharmawatch.com/news/ALRN/rein-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-updat-alrn-20250515monthly0.5https://www.biopharmawatch.com/news/ALRN/aileron-therapeutics-reports-third-quarter-2024-financial-results-and-recent-business-high-alrn-20241114monthly0.5https://www.biopharmawatch.com/news/ALRN/aileron-therapeutics-reports-second-quarter-2024-financial-results-and-business-highlights-alrn-20240814monthly0.5https://www.biopharmawatch.com/news/ALRN/aileron-therapeutics-reports-first-quarter-2024-financial-results-and-business-highlights--alrn-20240515monthly0.5https://www.biopharmawatch.com/news/ALRN/aileron-therapeutics-announces-pricing-of-underwritten-registered-direct-offering-priced-a-alrn-20240501monthly0.5https://www.biopharmawatch.com/news/ALRN/aileron-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provi-alrn-20240415monthly0.5https://www.biopharmawatch.com/news/ALRN/aileron-therapeutics-announces-ceo-transition-current-president-and-chief-operating-office-alrn-20240312monthly0.5https://www.biopharmawatch.com/news/ALRN/aileron-therapeutics-announces-acquisition-of-lung-therapeutics-acquisition-includes-multi-alrn-20231031monthly0.5https://www.biopharmawatch.com/news/ALRN/aileron-therapeutics-inc-2021-stock-incentive-plan-1-purpose-the-purpose-of-this-2021-stoc-alrn-20210617monthly0.5https://www.biopharmawatch.com/news/ALRN/aileron-therapeutics-announces-35-9-million-registered-direct-offering-alrn-20210106monthly0.5https://www.biopharmawatch.com/news/ALRN/prevention-of-chemotherapy-induced-myelosuppression-in-sclc-patients-treated-with-the-dual-alrn-20201025monthly0.5https://www.biopharmawatch.com/news/ALRN/aileron-therapeutics-announces-common-stock-purchase-agreement-for-up-to-15-million-with-l-alrn-20200921monthly0.5https://www.biopharmawatch.com/news/ALRN/aileron-therapeutics-announces-pricing-of-public-offering-of-common-stock-alrn-20200604monthly0.5https://www.biopharmawatch.com/news/ALRN/alrn-6924-ongoing-ph1b-clinical-trial-in-small-cell-lung-cancer-patients-receiving-topotec-alrn-20200601monthly0.5https://www.biopharmawatch.com/news/ALRN/aileron-therapeutics-announces-management-change-watertown-mass-alrn-20190909monthly0.5https://www.biopharmawatch.com/news/ALRN/aileron-therapeutics-strengthens-board-of-directors-with-appointments-of-william-t-mckee-a-alrn-20190624monthly0.5https://www.biopharmawatch.com/news/ALRN/aileron-therapeutics-completes-26m-private-placement-satter-medical-technology-partners-le-alrn-20190403monthly0.5https://www.biopharmawatch.com/news/ALRN/aileron-therapeutics-announces-pricing-of-26m-private-placement-alrn-20190329monthly0.5https://www.biopharmawatch.com/news/ALRN/aileron-therapeutics-announces-the-appointment-of-dr-manuel-aivado-as-chief-executive-offi-alrn-20180906monthly0.5https://www.biopharmawatch.com/news/ALRN/aileron-therapeutics-announces-changes-to-management-cambridge-ma-alrn-20180515monthly0.5https://www.biopharmawatch.com/news/ALRN/aileron-therapeutics-appoints-jeffrey-a-bailey-to-its-board-of-directors-alrn-20180319monthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-s-first-virtual-investor-day-to-highlight-late-stage-clinical-progress-key--mura-20240926monthly0.5https://www.biopharmawatch.com/news/MURA/forward-looking-statements-certain-statements-set-forth-in-this-presentation-constitute-x2-mura-20240108monthly0.5https://www.biopharmawatch.com/news/MURA/dear-alkermes-plc-shareholder-in-november-2022-we-announced-a-transformative-milestone-for-mura-20231106monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-announces-ceo-transition-geoff-mcdonough-md-to-step-down-as-ceo-president-a-gbio-20251022monthly0.5https://www.biopharmawatch.com/news/GBIO/confidential-generation-bio-announces-new-data-for-its-novel-ctlnp-delivery-system-and-ear-gbio-20250812monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-reports-business-highlights-and-fourth-quarter-and-full-year-2024-financial-gbio-20250313monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-to-apply-ctlnp-delivery-technology-to-develop-sirna-therapeutics-for-t-cell-gbio-20250106monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-reports-recent-business-highlights-and-third-quarter-2024-financial-results-gbio-20241106monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-reports-second-quarter-2024-financial-results-cash-balance-of-217-million-s-gbio-20240807monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-announces-recent-business-highlights-and-first-quarter-2024-financial-resul-gbio-20240513monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-reports-business-highlights-and-fourth-quarter-and-full-year-2023-financial-gbio-20240306monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-announces-strategic-reorganization-to-extend-cash-runway-for-development-of-gbio-20231129monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-reports-business-highlights-and-third-quarter-2023-financial-results-immune-gbio-20231109monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-announces-demonstration-of-highly-selective-t-cell-transduction-in-vivo-wit-gbio-20231026monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-announces-breakthrough-in-its-non-viral-genetic-medicine-platform-with-nove-gbio-20231018monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-reports-second-quarter-2023-financial-results-second-quarter-2023-cash-bala-gbio-20230802monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-reports-business-highlights-and-first-quarter-2023-financial-results-compan-gbio-20230510monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-outlines-2023-strategic-priorities-and-reports-fourth-quarter-and-full-year-gbio-20230223monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-reports-business-highlights-and-third-quarter-2022-financial-results-cash-b-gbio-20221103monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-reports-business-highlights-and-second-quarter-2022-financial-results-cash--gbio-20220804monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-announces-update-to-its-gmp-manufacturing-strategy-company-projects-smaller-gbio-20220621monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-reports-business-highlights-and-first-quarter-2022-financial-results-compan-gbio-20220505monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-outlines-2022-strategic-priorities-and-reports-fourth-quarter-and-full-year-gbio-20220224monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-provides-update-on-preclinical-studies-for-hemophilia-a-program-innovations-gbio-20211214monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-reports-business-highlights-and-third-quarter-2021-financial-results-new-pr-gbio-20211110monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-reports-business-highlights-and-second-quarter-2021-financial-results-cambr-gbio-20210811monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-announces-plan-to-scale-next-generation-rapid-enzymatic-manufacturing-proce-gbio-20210714monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-presents-preclinical-data-demonstrating-broad-potential-of-gene-therapy-pla-gbio-20210512monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-reports-fourth-quarter-and-full-year-2020-financial-results-262-3-million-c-gbio-20210318monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-appoints-ron-cooper-to-its-board-of-directors-cambridge-mass-gbio-20210218monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-reports-third-quarter-2020-business-updates-and-financial-results-on-track--gbio-20201110monthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-reports-business-updates-and-second-quarter-2020-financial-results-cambridg-gbio-20200811monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-nasdaq-hyft-ceo-dr-jennifer-bath-to-join-absci-nasdaq-absi-and-a-leading-ai-compu-ipa-20260612monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-holdings-corp-nasdaq-hyft-launches-reefiq-a-biological-context-layer-for-ai-drug--ipa-20260610monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-s-preclinical-dengue-data-support-a-hyft-computational-prediction-immunogens-desi-ipa-20260602monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-holdings-deploys-pandemic-response-platform-via-hyft-technology-as-ebola-and-hant-ipa-20260527monthly0.5https://www.biopharmawatch.com/news/IPA/the-biology-came-first-over-20-partner-owned-drug-programs-have-reached-clinical-trials-as-ipa-20260518monthly0.5https://www.biopharmawatch.com/news/IPA/sedi-insider-activity-report-period-march-18-27-2026-source-sedi-issuer-no-5542-all-prices-ipa-20260331monthly0.5https://www.biopharmawatch.com/news/IPA/sedi-insider-activity-report-period-march-16-x2013-20-2026-source-sedi-issuer-no-5542-all--ipa-20260321monthly0.5https://www.biopharmawatch.com/news/IPA/the-following-management-s-discussion-and-analysis-x201c-md-a-x201d-should-be-read-in-conj-ipa-20260312monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-holdings-corp-reports-q3-fiscal-2026-financial-results-third-consecutive-quarter--ipa-20260312monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-announces-b-cell-llama-a-nanobody-discovery-platform-designed-for-the-bispecific--ipa-20260306monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-holdings-corp-to-report-third-quarter-fiscal-year-2026-financial-results-on-ipa-20260302monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-applies-hyft-technology-to-detect-functional-adjacency-linked-to-portfolio-risk-i-ipa-20260127monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-validates-platform-precision-with-breakthrough-discovery-targeting-pathogenic-tdp-ipa-20260114monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-advances-universal-influenza-program-with-a-breakthrough-functional-insight-valid-ipa-20260112monthly0.5https://www.biopharmawatch.com/news/IPA/the-following-management-s-discussion-and-analysis-x201c-md-a-x201d-should-be-read-in-conj-ipa-20251215monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-reports-record-growth-and-announces-strategic-progress-on-its-ai-asset-pipeline-v-ipa-20251215monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-holdings-corp-to-report-financial-results-and-recent-business-highlights-for-seco-ipa-20251208monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-cto-dr-dirk-van-hyfte-to-join-fireside-chat-at-ai-drug-discovery-development-summ-ipa-20251113monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-holdings-corp-the-x201c-company-x201d-revised-statement-of-executive-compensation-ipa-20251106monthly0.5https://www.biopharmawatch.com/news/IPA/report-of-voting-results-submitted-pursuant-to-section-11-3-of-national-instrument-51-102--ipa-20251009monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-appoints-r-scott-areglado-as-chief-financial-officer-to-strengthen-financial-lead-ipa-20251020monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-appoints-dr-thomas-w-lynch-as-chief-business-officer-to-accelerate-commercial-exp-ipa-20251015monthly0.5https://www.biopharmawatch.com/news/IPA/unaudited-pro-forma-financial-information-overview-on-ipa-20251014monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-announces-share-repurchase-program-austin-texas-x2013-mindwalk-holdings-corp-x201-ipa-20251009monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-advances-ai-designed-glp-1-program-with-first-in-class-dual-pathway-regimen-for-a-ipa-20250922monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-holdings-corp-tm-formerly-immunoprecise-antibodiestm-reports-record-7-6-million-q-ipa-20250915monthly0.5https://www.biopharmawatch.com/news/IPA/the-following-management-s-discussion-and-analysis-x201c-md-a-x201d-should-be-read-in-conj-ipa-20250915monthly0.5https://www.biopharmawatch.com/news/IPA/mindwalk-to-report-financial-results-and-recent-business-highlights-for-first-quarter-fisc-ipa-20250910monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-rebrands-as-mindwalk-announces-nasdaq-ticker-change-to-x201c-hyft-x201d-an-e-ipa-20250903monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-to-participate-at-h-c-wainwright-s-27th-annual-global-investment--ipa-20250902monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-advances-ai-discovered-and-developed-universal-dengue-vaccine-initiative-mov-ipa-20250827monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ltd-divests-netherlands-facilities-to-avs-bio-to-accelerate-bio-n-ipa-20250806monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ltd-3204-4464-markham-street-victoria-bc-canada-v8z-7x8-ph-1-250--ipa-20250801monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ipa-reports-record-full-fiscal-year-2025-results-record-fourth-qu-ipa-20250729monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-releases-new-findings-showing-lens-ai-quickly-flags-anti-drug-antibody-risk--ipa-20250724monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-appoints-healthcare-data-visionary-jeff-fried-to-advisory-board-austin-texas-ipa-20250721monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-regains-compliance-with-nasdaq-minimum-bid-price-requirement-austin-texas-x2-ipa-20250711monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors-austin-ipa-20250707monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-validates-lens-ai-epitope-mapping-platform-across-broad-range-of-unseen-ther-ipa-20250703monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-advances-universal-dengue-vaccine-confirming-safety-immune-activation-and-st-ipa-20250605monthly0.5https://www.biopharmawatch.com/news/IPA/ai-designed-glp-1-peptides-from-immunoprecise-antibodies-surpass-semaglutide-in-receptor-a-ipa-20250612monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-announces-ai-driven-breakthrough-in-universal-dengue-vaccine-discovery-lens--ipa-20250605monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-engages-core-ir-to-enhance-investor-engagement-efforts-ipa-20250521monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-s-lens-ai-platform-delivers-x-ray-x2013-level-epitope-mapping-insights-in-hours-matchi-ipa-20250512monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-wit-ipa-20250411monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-and-ribopro-partner-to-advance-mrna-driven-antibody-discovery-unlocking-new-frontiers--ipa-20250410monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ipa-reports-financial-results-and-recent-business-highlights-for--ipa-20250328monthly0.5https://www.biopharmawatch.com/news/IPA/the-following-management-s-discussion-and-analysis-x201c-md-a-x201d-should-be-read-in-conj-ipa-20250328monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-and-a-global-biotechnology-leader-enter-into-a-usd-8m-10m-partner-ipa-20250313monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-to-reschedule-financial-results-and-recent-business-highlights-for-third-quarter-fisca-ipa-20250312monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-announces-key-leadership-changes-austin-texas-x2013-immunoprecise-ipa-20250224monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ipa-announces-completion-of-at-the-market-equity-offering-and-ful-ipa-20250203monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ipa-announces-completion-of-at-the-market-equity-offering-and-ful-ipa-20250127monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-immunoprecise-antibodies-pioneers-ai-designed-glp-1-therapies-a-potential-new-chapter--ipa-20250122monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and--ipa-20250117monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--ipa-20241231monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ipa-demonstrates-strong-market-confidence-with-insider-share-purc-ipa-20241223monthly0.5https://www.biopharmawatch.com/news/IPA/the-following-management-s-discussion-and-analysis-x201c-md-a-x201d-should-be-read-in-conj-ipa-20241210monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ipa-reports-financial-results-and-recent-business-highlights-for--ipa-20241210monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-to-report-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-ye-ipa-20241203monthly0.5https://www.biopharmawatch.com/news/IPA/report-of-voting-results-submitted-pursuant-to-section-11-3-of-national-instrument-51-102--ipa-20241114monthly0.5https://www.biopharmawatch.com/news/IPA/billion-market-breakthrough-ipa-pioneers-high-impact-antibody-development-for-next-generat-ipa-20241113monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-to-host-techday-cutting-edge-ai-and-biologics-innovation-victoria-british-co-ipa-20241104monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-advances-anti-aging-research-with-mayo-clinic-study-poised-to-tap-into-81-bi-ipa-20241028monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-to-participate-at-the-ai-driven-drug-discovery-summit-usa-2024-vi-ipa-20241021monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-date-ipa-20241010monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-celebrates-nobel-prize-in-chemistry-advances-in-ai-powered-protei-ipa-20241010monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-subsidiary-signs-material-transfer-agreement-with-biotheus-talem-therapeutic-ipa-20241002monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-advances-therapeutic-innovation-with-groundbreaking-rabbit-antibo-ipa-20240926monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-date-ipa-20240920monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ltd-3204-4464-markham-street-victoria-british-columbia-v8z-7x8-ipa-20240917monthly0.5https://www.biopharmawatch.com/news/IPA/the-following-management-s-discussion-and-analysis-x201c-md-a-x201d-should-be-read-in-conj-ipa-20240916monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ipa-reports-financial-results-and-recent-business-highlights-for--ipa-20240916monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-to-report-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-ye-ipa-20240910monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-to-participate-at-h-c-wainwright-s-26th-annual-global-investment--ipa-20240826monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-receives-nasdaq-notification-regarding-minimum-bid-requirements-v-ipa-20240823monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-successfully-engineers-in-silico-antibodies-to-elusive-tumor-prot-ipa-20240819monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ipa-reports-financial-results-and-business-updates-for-fourth-qua-ipa-20240729monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-to-reschedule-financial-results-and-recent-business-highlights-re-ipa-20240723monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-immunoprecise-announces-financing-agreement-with-yorkville-advis-ipa-20240716monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-to-report-financial-results-and-recent-business-highlights-for-fourth-quarter-and-fisc-ipa-20240715monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-appoints-kristin-taylor-as-chief-financial-officer-victoria-british-columbia-ipa-20240627monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-s-subsidiary-biostrand-and-pgxai-announce-strategic-collaboration-to-develop-first-in--ipa-20240625monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-immunoprecise-antibodies-ltd-subsidiary-biostrand-receives-prest-ipa-20240612monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-biostrand-immunoprecise-antibodies-subsidiary-announces-immediat-ipa-20240610monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-ipa-s-subsidiary-biostrand-announces-advanced-large-language-mod-ipa-20240603monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-intersystems-and-ipa-s-subsidiary-biostrand-unveil-the-innovativ-ipa-20240328monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-ipa-acquires-the-carterra-lsa-instrument-to-enhance-antibody-dis-ipa-20240320monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-ipa-reports-financial-results-and-recent-business-highlights-for-ipa-20240314monthly0.5https://www.biopharmawatch.com/news/IPA/the-following-management-s-discussion-and-analysis-x201c-md-a-x201d-should-be-read-in-conj-ipa-20240314monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-ipa-s-subsidiary-biostrand-unveils-major-breakthrough-in-life-sc-ipa-20240307monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ltd-condensed-interim-consolidated-financial-statements-for-the-t-ipa-20240215monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--ipa-20231208monthly0.5https://www.biopharmawatch.com/news/IPA/the-following-management-s-discussion-and-analysis-md-a-should-be-read-in-conjunction-with-ipa-20231214monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-reports-financial-results-and-recent-business-highlights-for-second-quarter-fiscal-yea-ipa-20231214monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-announces-closing-of-1-265-million-public-offering-of-common-shares-victoria-british-c-ipa-20231208monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-announces-pricing-of-1-1-million-public-offering-of-common-shares-victoria-british-col-ipa-20231206monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-announces-proposed-public-offering-of-common-shares-victoria-british-columbia-business-ipa-20231205monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ltd-announces-key-board-and-board-committee-chair-appointments-an-ipa-20231127monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-report-of-voting-results-submitted-pursuant-to-section-11-3-of-n-ipa-20231109monthly0.5https://www.biopharmawatch.com/news/IPA/biostrand-unveils-a-revolutionary-approach-to-biological-sequence-retrieval-a-fusion-of-na-ipa-20231113monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-s-subsidiary-biostrand-provides-an-update-on-lens-ai-biostrand-unveils-groundbreaking--ipa-20231025monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-provides-update-on-growth-strategy-and-recent-share-price-movement-victoria-british-co-ipa-20231023monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-immunoprecise-antibodies-ltd-unit-3204-4464-markham-street-victo-ipa-20231016monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--ipa-20230919monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-date-ipa-20230922monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-announces-cfo-transition-brad-mcconn-to-step-down-later-this-mont-ipa-20230919monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-immunoprecise-antibodies-ltd-3204-4464-markham-street-victoria-b-ipa-20230915monthly0.5https://www.biopharmawatch.com/news/IPA/the-following-management-s-discussion-and-analysis-x201c-md-a-x201d-should-be-read-in-conj-ipa-20230914monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-ipa-20230914monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--ipa-20230905monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-to-report-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-ye-ipa-20230908monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-announces-board-refreshment-ipa-appoints-barry-a-springer-dirk-witters-and-chris-buyse-ipa-20230905monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-responds-to-13d-filing-ipa-responds-to-13d-filing-by-ingalls-snyder-llc-victoria-briti-ipa-20230809monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-invites-investors-and-stakeholders-to-exclusive-interview-with-ma-ipa-20230714monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-reports-financial-results-and-recent-business-highlights-for-full-fiscal-yea-ipa-20230707monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-to-report-financial-results-and-recent-business-highlights-for-fourth-quarter-and-fisc-ipa-20230629monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-s-subsidiary-biostrand-unveils-use-case-for-solving-the-information-integration-dilemm-ipa-20230613monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-releases-new-hyft-powered-in-silico-humanization-platform-aims-to-disrupt-the-transgen-ipa-20230606monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-s-subsidiary-biostrand-solves-the-information-integration-dilemma-iid-for-systems-biol-ipa-20230530monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-to-present-at-jefferies-healthcare-conference-2023-victoria-british-columbia-business--ipa-20230517monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-immunoprecise-antibodies-ltd-stock-option-plan-1-purpose-of-plan-ipa-20230424monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--ipa-20230316monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-s-subsidiary-talem-enters-into-exclusive-research-collaboration-and-license--ipa-20230330monthly0.5https://www.biopharmawatch.com/news/IPA/european-patent-office-to-grant-biokey-s-patent-application-for-foundational-hyft-technolo-ipa-20230327monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-presents-novel-t-cell-engaging-bispecific-antibodies-addressing-a-unique-onc-ipa-20230323monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-reports-financial-results-and-recent-business-highlights-for-third-quarter-fiscal-year-ipa-20230316monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ltd-management-discussion-and-analysis-for-the-nine-months-ended--ipa-20230316monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-subsidiary-talem-therapeutics-announces-a-multi-target-ai-driven--ipa-20230315monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-to-report-financial-results-and-recent-business-highlights-for-third-quarter-fiscal-ye-ipa-20230307monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-report-of-voting-results-submitted-pursuant-to-section-11-3-of-n-ipa-20230105monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-reports-financial-results-and-recent-business-highlights-for-second-quarter-fiscal-yea-ipa-20221215monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ltd-management-discussion-and-analysis-for-the-six-months-ended-o-ipa-20221215monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-s-subsidiary-biostrand-completes-integration-of-20-million-proprietary-structural-hyft-ipa-20221208monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-to-report-financial-results-and-recent-business-highlights-for-second-quarter-fiscal-y-ipa-20221205monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-s-subsidiary-biostrand-and-briacell-announce-artificial-intelligence-collaboration-and-ipa-20221130monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ltd-announces-voluntary-delisting-from-tsx-venture-exchange-victo-ipa-20221122monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-2-immunoprecise-antibodies-ltd-unit-3204-4464-markham-street-vic-ipa-20221117monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-immunoprecise-antibodies-ltd-3204-4464-markham-street-victoria-b-ipa-20221028monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-ipa-20221014monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-s-subsidiary-talem-therapeutics-licenses-antibodies-for-three-omnichicken-derived-prog-ipa-20221012monthly0.5https://www.biopharmawatch.com/news/IPA/niaid-confirms-ipa-s-polytope-tatx-03-neutralizing-activity-against-the-currently-spreadin-ipa-20220914monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ltd-management-discussion-and-analysis-for-the-three-months-ended-ipa-20220914monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-ipa-20220914monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-to-report-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-ye-ipa-20220908monthly0.5https://www.biopharmawatch.com/news/IPA/live-virus-assays-at-ludwig-maximilians-universit-t-m-nchen-confirm-polytope-s-efficacy-ag-ipa-20220829monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-reports-financial-results-and-recent-business-highlights-for-full-fiscal-yea-ipa-20220729monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-to-report-financial-results-and-recent-business-highlights-for-fourth-quarter-and-full-ipa-20220729monthly0.5https://www.biopharmawatch.com/news/IPA/histopathology-data-of-preclinical-repeated-dose-toxicity-study-and-ex-vivo-human-tissue-c-ipa-20220712monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-s-subsidiary-biostrand-secures-second-vlaio-research-grant-ipa-subsidiary-biostrand-re-ipa-20220509monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--ipa-20220413monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-s-advanced-polytope-tatx-03-a-multi-antibody-cocktail-potently-prevents-in-vitro-infec-ipa-20220420monthly0.5https://www.biopharmawatch.com/news/IPA/filed-by-newsfilecorp-com-ipa-announces-agreement-to-acquire-biostrand-bv-revolutionizing--ipa-20220329monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-completes-acquisition-of-belgian-technology-companies-biostrand-biokey-and-bioclue-add-ipa-20220414monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-announces-agreement-to-acquire-biostrand-bv-revolutionizing-biotherapeutics-with-metho-ipa-20220329monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-reports-financial-results-and-recent-business-highlights-for-third-quarter-f-ipa-20220316monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ltd-management-discussion-and-analysis-for-the-nine-months-ended--ipa-20220316monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-updates-on-investigational-new-drug-ind-enabling-program-for-polytope-tatx-03-in-vivo--ipa-20220309monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-selected-to-work-with-elektrofi-on-covid-19-therapeutic-delivery-and-future-pandemic-p-ipa-20220314monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-sets-third-quarter-fiscal-2022-financial-results-and-recent-business-highlig-ipa-20220308monthly0.5https://www.biopharmawatch.com/news/IPA/immunotherapeutic-polytope-from-immunoprecise-ipa-potently-neutralizes-the-sars-cov-2-omic-ipa-20220127monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-relocates-european-subsidiary-to-leed-certified-campus-to-continue-to-advanc-ipa-20220118monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-announces-grant-of-stock-options-victoria-british-columbia-busine-ipa-20220117monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-announces-grant-of-stock-options-victoria-british-columbia-busine-ipa-20220111monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-announces-grant-of-stock-options-victoria-british-columbia-busine-ipa-20220103monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-and-chempartner-biologics-announce-polytope-tatx-03-antibody-cock-ipa-20211220monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ltd-management-discussion-and-analysis-for-the-six-months-ended-o-ipa-20211213monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-reports-financial-results-and-recent-business-highlights-for-second-quarter--ipa-20211213monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-reports-financial-results-and-recent-business-highlights-for-second-quarter--ipa-20211207monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-update-on-its-sars-cov-2-polytope-multi-antibody-cocktail-development-progra-ipa-20211130monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-to-present-at-the-benchmark-company-s-discovery-one-on-one-virtual-video-inv-ipa-20211124monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ltd-unit-3204-4464-markham-street-victoria-bc-v8z-7x8-notice-of-a-ipa-20211029monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-announces-resignation-of-director-victoria-british-columbia-business-wire-ipa-20211109monthly0.5https://www.biopharmawatch.com/news/IPA/notice-of-change-of-auditor-to-grant-thornton-llp-crowe-mackay-llp-and-to-british-columbia-ipa-20211101monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-announces-at-the-market-facility-of-up-to-us-50-million-victoria-british-col-ipa-20211013monthly0.5https://www.biopharmawatch.com/news/IPA/talem-therapeutics-announces-multi-target-antibody-discovery-research-collaboration-with-p-ipa-20211007monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-f-ipa-20210909monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ltd-management-discussion-and-analysis-for-the-three-months-ended-ipa-20210909monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-s-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation-vic-ipa-20210908monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-announces-participation-at-the-h-c-wainwright-23-nd-annual-global-investment-ipa-20210907monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-f-ipa-20210903monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-welcomes-vice-president-of-client-relations-and-vice-president-of-marketing--ipa-20210804monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-reports-financial-results-and-recent-business-highlights-for-full-fiscal-yea-ipa-20210728monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-s-polytope-tatx-03-antibody-cocktail-potently-neutralizes-sars-cov-2-delta-v-ipa-20210722monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-to-report-financial-results-and-business-highlights-for-fiscal-year-2021-the-ipa-20210715monthly0.5https://www.biopharmawatch.com/news/IPA/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-disco-ipa-20210622monthly0.5https://www.biopharmawatch.com/news/IPA/histopathology-preclinical-data-from-immunoprecise-s-polytope-program-confirms-lung-inflam-ipa-20210617monthly0.5https://www.biopharmawatch.com/news/IPA/preclinical-data-from-immunoprecise-s-drug-pipeline-to-be-presented-during-the-bio-interna-ipa-20210615monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-announces-appointment-of-dr-ilse-roodink-to-the-role-of-chief-scientific-off-ipa-20210602monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-names-dr-dion-neame-to-strategic-advisory-board-victoria-british-columbia-bu-ipa-20210525monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-moves-sars-cov-2-polytope-cocktail-program-s-path-toward-ind-filing-demonstr-ipa-20210520monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record-victoria-brit-ipa-20210421monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-launches-tatx-112-candidate-antibody-program-for-the-treatment-of-cancer-and-ipa-20210408monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-identifies-a-unique-antibody-23-h7-that-demonstrates-in-vivo-efficacy-an-alt-ipa-20210325monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ltd-management-discussion-and-analysis-for-the-nine-months-ended--ipa-20210318monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-reports-financial-results-and-recent-business-highlights-for-third-quarter-o-ipa-20210317monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-announces-results-from-a-comprehensive-screening-of-27-proprietar-ipa-20210316monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-announces-participation-at-the-h-c-wainwright-global-life-sciences-conferenc-ipa-20210304monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-announces-data-from-preclinical-study-of-tatx-03-polytope-monoclonal-antibod-ipa-20210219monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-announces-closing-of-over-allotment-option-associated-with-the-recently-completed-boug-ipa-20210210monthly0.5https://www.biopharmawatch.com/news/IPA/ipa-announces-closing-of-21-7-million-bought-deal-offering-of-common-shares-victoria-briti-ipa-20210208monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-ltd-condensed-interim-consolidated-financial-statements-for-the-t-ipa-20210203monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-announces-grant-of-stock-options-victoria-british-columbia-busine-ipa-20210106monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-antibodies-to-participate-in-january-conferences-victoria-british-columbia-b-ipa-20210106monthly0.5https://www.biopharmawatch.com/news/IPA/immunoprecise-partners-on-launch-of-sars-cov-2-nanomedicine-therapy-program-innovative-nov-ipa-20201230monthly0.5https://www.biopharmawatch.com/news/CTCX/longevity-health-holdings-closes-strategic-investment-and-appoints-ram-ajjarapu-as-chairma-ctcx-20260317monthly0.5https://www.biopharmawatch.com/news/CTCX/longevity-health-holdings-announces-merger-with-thplasma-and-termination-of-20-20-ctcx-20250714monthly0.5https://www.biopharmawatch.com/news/CTCX/longevity-health-holdings-inc-announces-successful-fundraising-via-atm-sale-pittsburgh-pa--ctcx-20250527monthly0.5https://www.biopharmawatch.com/news/CTCX/longevity-health-holdings-announces-continued-nasdaq-listing-to-complete-merger-with-20-20-ctcx-20250521monthly0.5https://www.biopharmawatch.com/news/CTCX/longevity-health-holdings-announces-business-updates-pittsburgh-pa-gaithersburg-md-ctcx-20250515monthly0.5https://www.biopharmawatch.com/news/CTCX/longevity-health-holdings-inc-announces-reverse-stock-split-pittsburgh-pa-x2013-ctcx-20250512monthly0.5https://www.biopharmawatch.com/news/CTCX/longevity-health-holdings-announces-execution-of-merger-agreement-with-20-20-biolabs-pitts-ctcx-20250414monthly0.5https://www.biopharmawatch.com/news/CTCX/c-armell-corp-rebrands-as-longevity-health-holdings-to-highlight-business-focus-ctcx-20250310monthly0.5https://www.biopharmawatch.com/news/CTCX/carmell-announces-closing-of-elevai-skincare-acquisition-carmell-corporation-nasdaq-ctcx-a-ctcx-20250116monthly0.5https://www.biopharmawatch.com/news/CTCX/carmell-announces-execution-of-definitive-agreement-to-acquire-elevai-skincare-a-leader-in-ctcx-20250102monthly0.5https://www.biopharmawatch.com/news/CTCX/carmell-announces-pipe-investment-from-existing-and-new-investors-to-support-commercial-bu-ctcx-20241224monthly0.5https://www.biopharmawatch.com/news/CTCX/november-2024-a-bio-aesthetics-revolution-certain-statements-in-this-presentation-regardin-ctcx-20241120monthly0.5https://www.biopharmawatch.com/news/CTCX/carmell-corporation-appoints-new-ceo-following-addition-to-the-russell-microcap-index-beau-ctcx-20240729monthly0.5https://www.biopharmawatch.com/news/CTCX/to-the-company-s-current-report-on-form-8-k-filed-on-ctcx-20240404monthly0.5https://www.biopharmawatch.com/news/CTCX/statement-contained-in-this-press-release-we-caution-you-that-these-statements-are-based-o-ctcx-20240401monthly0.5https://www.biopharmawatch.com/news/CTCX/pittsburgh-ctcx-20240320monthly0.5https://www.biopharmawatch.com/news/CTCX/carmell-corp-announces-addition-of-dr-bradley-calobrace-to-scientific-advisory-board-pitts-ctcx-20240116monthly0.5https://www.biopharmawatch.com/news/CTCX/carmell-corp-announces-addition-of-dr-sean-kelishadi-to-scientific-advisory-board-pittsbur-ctcx-20240111monthly0.5https://www.biopharmawatch.com/news/CTCX/carmell-corp-announces-addition-of-dr-gregory-a-buford-to-scientific-advisory-board-pittsb-ctcx-20240110monthly0.5https://www.biopharmawatch.com/news/CTCX/carmell-corp-announces-addition-of-dr-adam-rubinstein-to-scientific-advisory-board-pittsbu-ctcx-20240109monthly0.5https://www.biopharmawatch.com/news/CTCX/carmell-corp-announces-addition-of-dr-jason-d-bloom-to-scientific-advisory-board-pittsburg-ctcx-20240108monthly0.5https://www.biopharmawatch.com/news/CTCX/carmell-corp-announces-addition-of-scott-frisch-and-gilles-spenlehauer-to-board-of-directo-ctcx-20231115monthly0.5https://www.biopharmawatch.com/news/CTCX/carmell-corporation-announces-completion-of-post-merger-integration-with-axolotl-biologix--ctcx-20230905monthly0.5https://www.biopharmawatch.com/news/CTCX/carmell-therapeutics-corporation-condensed-financial-statements-table-of-contents-page-con-ctcx-20230815monthly0.5https://www.biopharmawatch.com/news/CTCX/carmell-announces-successful-closing-of-merger-with-axolotl-biologix-and-launch-of-a-new-b-ctcx-20230809monthly0.5https://www.biopharmawatch.com/news/CTCX/carmell-therapeutics-announces-merger-with-axolotl-biologix-a-profitable-regenerative-medi-ctcx-20230727monthly0.5https://www.biopharmawatch.com/news/CTCX/unaudited-pro-forma-condensed-combined-financial-information-defined-terms-included-below--ctcx-20230720monthly0.5https://www.biopharmawatch.com/news/CTCX/carmell-therapeutics-merger-with-alpha-healthcare-acquisition-corp-iii-nasdaq-alpa-ctcx-20230706monthly0.5https://www.biopharmawatch.com/news/CTCX/alpha-healthcare-acquisition-corp-iii-announces-non-binding-letter-of-intent-to-acquire-a--ctcx-20230627monthly0.5https://www.biopharmawatch.com/news/CTCX/alpha-healthcare-acquisition-corp-iii-announces-merger-with-carmell-therapeutics-a-phase-2-ctcx-20230104monthly0.5https://www.biopharmawatch.com/news/CTCX/alpha-healthcare-acquisition-corp-iii-report-of-independent-registered-public-accounting-f-ctcx-20220909monthly0.5https://www.biopharmawatch.com/news/CTCX/alpha-healthcare-acquisition-corp-iii-announces-the-separate-trading-of-its-class-a-common-ctcx-20210916monthly0.5https://www.biopharmawatch.com/news/CTCX/alpha-healthcare-acquisition-corp-iii-report-of-independent-registered-public-accounting-f-ctcx-20210729monthly0.5https://www.biopharmawatch.com/news/CTCX/alpha-healthcare-acquisition-corp-iii-announces-pricing-of-150-million-initial-public-offe-ctcx-20210726monthly0.5https://www.biopharmawatch.com/news/NBY/novabay-pharmaceuticals-inc-regains-compliance-with-nyse-american-continued-listing-standa-nby-20251020monthly0.5https://www.biopharmawatch.com/news/NBY/novabay-pharmaceuticals-issues-a-reminder-of-nby-20250918monthly0.5https://www.biopharmawatch.com/news/NBY/novabay-pharmaceuticals-announces-one-time-special-cash-dividend-of-0-80-per-share-nby-20250826monthly0.5https://www.biopharmawatch.com/news/NBY/novabay-pharmaceuticals-enters-into-6-million-securities-purchase-agreement-with-investor--nby-20250819monthly0.5https://www.biopharmawatch.com/news/NBY/novabay-pharmaceuticals-announces-cfo-transition-30-year-finance-veteran-jack-mcgovern-joi-nby-20170710monthly0.5https://www.biopharmawatch.com/news/NBY/novabay-pharmaceuticals-successfully-regains-compliance-with-nyse-continued-listing-requir-nby-20161031monthly0.5https://www.biopharmawatch.com/news/NBY/novabay-pharmaceuticals-completes-11-8-million-private-placement-emeryville-calif-nby-20160802monthly0.5https://www.biopharmawatch.com/news/NBY/novabay-pharmaceuticals-appoints-todd-zavodnick-to-its-board-of-directors-closes-first-tra-nby-20160509monthly0.5https://www.biopharmawatch.com/news/NBY/novabay-pharmaceuticals-announces-2-83-million-private-placement-investors-include-insider-nby-20160224monthly0.5https://www.biopharmawatch.com/news/NBY/novabay-pharmaceuticals-expects-fourth-quarter-2015-avenova-sales-to-exceed-1-5-million-av-nby-20160111monthly0.5https://www.biopharmawatch.com/news/NBY/novabay-pharmaceuticals-secures-3-million-bridge-loan-backers-include-novabay-board-member-nby-20160107monthly0.5https://www.biopharmawatch.com/news/NBY/novabay-pharmaceuticals-announces-restructuring-to-focus-on-avenova-commercialization-and--nby-20151119monthly0.5https://www.biopharmawatch.com/news/NBY/novabay-announces-proposed-public-offering-of-common-stock-and-warrants-emeryville-calif-b-nby-20151027monthly0.5https://www.biopharmawatch.com/news/NBY/novabay-pharmaceuticals-provides-update-on-avenova-sales-growth-reports-progress-with-inte-nby-20151008monthly0.5https://www.biopharmawatch.com/news/NBY/novabay-pharmaceuticals-appoints-mark-m-sieczkarek-solta-medical-chairman-and-ceo-and-dr-m-nby-20140109monthly0.5https://www.biopharmawatch.com/news/NBY/novabay-pharmaceuticals-announces-positive-results-from-phase-2-clinical-study-of-auriclos-nby-20130916monthly0.5https://www.biopharmawatch.com/news/NBY/novabay-pharmaceuticals-inc-announces-pricing-of-public-offering-of-common-stock-and-warra-nby-20121206monthly0.5https://www.biopharmawatch.com/news/NBY/former-alcon-executive-with-significant-experience-in-ophthalmic-drug-development-to-overs-nby-20111004monthly0.5https://www.biopharmawatch.com/news/NBY/exhibit-b-novabay-pharmaceuticals-nby-20110629monthly0.5https://www.biopharmawatch.com/news/NBY/novabay-pharmaceuticals-appoints-gail-maderis-baybio-president-and-ceo-and-former-genzyme--nby-20101011monthly0.5https://www.biopharmawatch.com/news/ALVR/kalaris-reports-first-quarter-2026-financial-results-and-provides-business-updates-patient-alvr-20260512monthly0.5https://www.biopharmawatch.com/news/ALVR/kalaris-reports-full-year-2025-financial-results-and-provides-business-updates-positive-in-alvr-20260317monthly0.5https://www.biopharmawatch.com/news/ALVR/forward-looking-statements-disclaimer-this-presentation-contains-forward-looking-statement-alvr-20260309monthly0.5https://www.biopharmawatch.com/news/ALVR/kalaris-therapeutics-announces-oversubscribed-50-0-million-private-placement-alvr-20251217monthly0.5https://www.biopharmawatch.com/news/ALVR/kalaris-therapeutics-reports-initial-positive-phase-1a-data-for-th103-in-treatment-na-ve-n-alvr-20251217monthly0.5https://www.biopharmawatch.com/news/ALVR/kalaris-reports-third-quarter-2025-financial-results-and-provides-business-updates-phase-1-alvr-20251112monthly0.5https://www.biopharmawatch.com/news/ALVR/kalaris-reports-second-quarter-2025-financial-results-and-provides-business-updates-contin-alvr-20250813monthly0.5https://www.biopharmawatch.com/news/ALVR/kalaris-reports-first-quarter-2025-financial-results-and-provides-business-highlights-acti-alvr-20250514monthly0.5https://www.biopharmawatch.com/news/ALVR/kalaris-announces-closing-of-merger-with-allovir-kalaris-is-focused-on-developing-th103-a--alvr-20250319monthly0.5https://www.biopharmawatch.com/news/ALVR/kalaris-and-allovir-announce-stockholder-approval-of-merger-combined-company-expected-to-t-alvr-20250312monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-and-kalaris-therapeutics-announce-agreement-for-transformational-merger-to-create--alvr-20241108monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-provides-updates-on-phase-3-clinical-development-program-for-posoleucel-an-allogen-alvr-20231222monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-reports-third-quarter-2023-financial-results-posoleucel-a-highly-innovative-off-th-alvr-20231102monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-reports-second-quarter-2023-financial-results-company-s-three-phase-3-global-regis-alvr-20230803monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-announces-proposed-public-offering-of-common-stock-cambridge-mass-alvr-20230621monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-reports-first-quarter-2023-financial-results-company-s-three-posoleucel-phase-3-gl-alvr-20230504monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-appoints-derek-adams-ph-d-to-board-of-directors-waltham-mass-alvr-20230223monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-reports-full-year-2022-financial-results-and-2023-outlook-completion-of-enrollment-alvr-20230215monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-announces-plans-to-complete-enrollment-in-three-phase-3-posoleucel-studies-in-2023-alvr-20230109monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-reports-third-quarter-2022-financial-results-posoleucel-continues-to-advance-in-th-alvr-20221103monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-reports-second-quarter-2022-financial-results-three-phase-3-posoleucel-registratio-alvr-20220804monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-announces-126-6-million-registered-direct-offering-proceeds-support-the-completion-alvr-20220727monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-reports-first-quarter-2022-financial-results-initiated-posoleucel-registrational-s-alvr-20220505monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-appoints-shawn-tomasello-to-its-board-of-directors-waltham-mass-alvr-20220331monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-reports-full-year-2021-financial-results-and-2022-outlook-three-ongoing-phase-3-re-alvr-20220210monthly0.5https://www.biopharmawatch.com/news/ALVR/a-leader-in-allogeneic-off-the-shelf-virus-specific-t-cell-therapies-j-p-morgan-healthcare-alvr-20220110monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-announces-departure-of-chief-medical-officer-agustin-melian-waltham-mass-alvr-20211216monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-announces-positive-preliminary-data-from-the-ongoing-phase-2-posoleucel-multi-viru-alvr-20211211monthly0.5https://www.biopharmawatch.com/news/ALVR/a-leader-in-allogeneic-off-the-shelf-virus-specific-t-cell-therapies-november-2021-confide-alvr-20211115monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-reports-third-quarter-2021-financial-results-company-is-prioritizing-prevention-an-alvr-20211105monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-reports-second-quarter-2021-financial-results-posoleucel-viralym-m-alvr105-proof-o-alvr-20210806monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-reports-first-quarter-2021-financial-results-viralym-m-pivotal-trial-in-virus-asso-alvr-20210506monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-appoints-diana-m-brainard-m-d-as-chief-executive-officer-effective-alvr-20210322monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-reports-full-year-2020-financial-results-initiated-phase-3-pivotal-clinical-trial--alvr-20210211monthly0.5https://www.biopharmawatch.com/news/ALVR/disclaimer-this-presentation-has-been-prepared-by-allovir-inc-we-us-our-allovir-or-the-com-alvr-20210114monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-announces-fda-clearance-of-investigational-new-drug-application-for-alvr106-an-all-alvr-20201217monthly0.5https://www.biopharmawatch.com/news/ALVR/positive-phase-2-proof-of-concept-data-for-viralym-m-and-burden-of-disease-data-presented--alvr-20201207monthly0.5https://www.biopharmawatch.com/news/ALVR/preclinical-data-demonstrate-anti-viral-activity-of-allovir-s-alvr109-an-allogeneic-off-th-alvr-20201205monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-reports-third-quarter-2020-financial-results-completed-initial-public-offering-rai-alvr-20201110monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-announces-the-fda-clearance-of-investigational-new-drug-application-ind-for-alvr10-alvr-20200917monthly0.5https://www.biopharmawatch.com/news/ALVR/allovir-reports-second-quarter-2020-financial-results-cambridge-mass-alvr-20200902monthly0.5https://www.biopharmawatch.com/news/ENOB/lunai-bioworks-enob-20260617monthly0.5https://www.biopharmawatch.com/news/ENOB/lunai-bioworks-enob-20260520monthly0.5https://www.biopharmawatch.com/news/ENOB/lunai-bioworks-inc-announces-postponement-of-special-meeting-of-stockholders-to-enob-20260428monthly0.5https://www.biopharmawatch.com/news/ENOB/lunai-bioworks-executes-20m-strategic-transaction-at-fixed-1-50-conversion-acquiring-bbb-d-enob-20260326monthly0.5https://www.biopharmawatch.com/news/ENOB/lunai-bioworks-regains-compliance-with-nasdaq-minimum-bid-price-requirement-enob-20251016monthly0.5https://www.biopharmawatch.com/news/ENOB/exchange-agreement-this-exchange-agreement-this-agreement-is-entered-into-as-of-2025-the-e-enob-20250709monthly0.5https://www.biopharmawatch.com/news/ENOB/renovaro-and-biosymetrics-announce-definitive-merger-agreement-to-advance-ai-driven-biomar-enob-20250226monthly0.5https://www.biopharmawatch.com/news/ENOB/renovaro-to-acquire-predictive-oncology-in-all-stock-transaction-acquisition-provides-acce-enob-20250106monthly0.5https://www.biopharmawatch.com/news/ENOB/renovaro-inc-announces-10-million-in-equity-committed-los-angeles-enob-20240614monthly0.5https://www.biopharmawatch.com/news/ENOB/renovaro-inc-and-amsterdam-umc-cancer-center-poised-to-advance-cancer-immunotherapy-los-an-enob-20240524monthly0.5https://www.biopharmawatch.com/news/ENOB/renovarocube-to-acquire-100-ownership-of-cyclomics-reinforcing-cutting-edge-cancer-diagnos-enob-20240424monthly0.5https://www.biopharmawatch.com/news/ENOB/ai-pioneer-gedi-cube-and-biotech-innovator-renovaro-biosciences-combine-forces-to-accelera-enob-20240213monthly0.5https://www.biopharmawatch.com/news/ENOB/renovaro-biosciences-announces-results-of-special-meeting-of-shareholders-los-angeles-enob-20240125monthly0.5https://www.biopharmawatch.com/news/ENOB/message-from-renovaro-bioscience-inc-s-ceo-the-hon-mark-dybul-md-accelerating-healthcare-w-enob-20240116monthly0.5https://www.biopharmawatch.com/news/ENOB/renovaro-biosciences-appoints-two-finance-industry-experts-to-board-of-directors-los-angel-enob-20231010monthly0.5https://www.biopharmawatch.com/news/ENOB/ai-company-gedicube-and-renovaro-biosciences-sign-definitive-agreement-to-combine-message--enob-20231002monthly0.5https://www.biopharmawatch.com/news/ENOB/renovaro-biosciences-and-ai-health-company-gedi-cube-sign-definitive-agreement-to-combine--enob-20230929monthly0.5https://www.biopharmawatch.com/news/ENOB/letter-of-intent-enob-20230801monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-inc-announces-adjournment-of-2023-enob-20230623monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-announces-that-its-cancer-platform-remains-on-track-for-trials-in-hum-enob-20230608monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-ceo-letter-to-shareholders-turning-the-page-a-promising-future-los-an-enob-20230403monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-announces-a-scientific-presentation-of-proof-of-concept-studies-for-a-enob-20230329monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-achieves-full-compliance-with-nasdaq-filing-requirements-enob-20230313monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-announces-receipt-of-notice-from-nasdaq-regarding-delayed-filing-of-f-enob-20230223monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-announces-receipt-of-notice-from-nasdaq-regarding-delayed-filing-of-f-enob-20221130monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-forges-ahead-with-focused-approach-promising-future-enob-20221024monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-announces-receipt-of-notice-from-nasdaq-regarding-delayed-filing-of-a-enob-20221021monthly0.5https://www.biopharmawatch.com/news/ENOB/ceo-s-letter-to-shareholders-06-01-2022-updated-09-23-2022-dear-shareholders-i-have-spoken-enob-20220923monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-inc-nasdaq-enob-enob-20220706monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-announces-findings-from-a-rigorous-internal-review-of-scientific-data-enob-20220701monthly0.5https://www.biopharmawatch.com/news/ENOB/01-2022-updated-06-06-2022-dear-shareholders-i-have-spoken-to-some-of-you-about-the-seriou-enob-20220607monthly0.5https://www.biopharmawatch.com/news/ENOB/dear-shareholders-i-have-spoken-to-some-of-you-about-the-serious-and-disturbing-news-that--enob-20220602monthly0.5https://www.biopharmawatch.com/news/ENOB/scientific-leaders-agree-on-promise-of-enochian-biosciences-los-angeles-enob-20220531monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-board-learns-of-arrest-of-co-founder-and-inventor-and-expresses-stron-enob-20220525monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-announces-the-appointment-of-executive-vice-president-of-research-and-enob-20220420monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-announces-appointment-of-senior-vice-president-for-clinical-operation-enob-20220407monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-inventor-and-co-founder-presents-data-on-novel-clinical-approaches-as-enob-20220405monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-and-caring-cross-announce-a-partnership-to-potentially-increase-the-e-enob-20220315monthly0.5https://www.biopharmawatch.com/news/ENOB/update-enochian-biosciences-at-the-cutting-edge-the-future-of-biotech-is-disruptive-scienc-enob-20220124monthly0.5https://www.biopharmawatch.com/news/ENOB/distinguished-scientific-and-public-health-leaders-to-join-enochian-biosciences-scientific-enob-20210830monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-names-the-hon-dr-mark-dybul-as-chief-executive-officer-dr-dybul-s-dee-enob-20210720monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-announces-29-million-registered-direct-offering-priced-at-the-market--enob-20210614monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-elegant-simplicity-integrating-diverse-scientific-approaches-to-devel-enob-20210216monthly0.5https://www.biopharmawatch.com/news/ENOB/securities-and-exchange-commission-enob-20200915monthly0.5https://www.biopharmawatch.com/news/ENOB/enochian-biosciences-announces-three-scientific-presentations-on-potential-hiv-and-hbv-cur-enob-20200513monthly0.5https://www.biopharmawatch.com/news/ENOB/wolfe-axelrod-weinberger-associates-llc-stephen-d-axelrod-cfa-don-weinberger-212-370-4500--enob-20160405monthly0.5https://www.biopharmawatch.com/news/ENOB/wolfe-axelrod-weinberger-associates-llc-stephen-d-axelrod-cfa-donald-c-weinberger-212-370--enob-20140930monthly0.5https://www.biopharmawatch.com/news/ENOB/wolfe-axelrod-weinberger-associates-llc-stephen-d-axelrod-cfa-donald-c-weinberger-212-370--enob-20140814monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-announces-potential-best-in-class-spy002-anti-tl1a-part-a-induction-results-from-sky-agle-20260615monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-upd-agle-20260505monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-announces-potential-best-in-class-spy001-part-a-induction-results-from-skyline-trial-agle-20260413monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provide-agle-20260219monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-therapeutics-poised-for-transformational-2026-with-six-expected-proof-of-concept-rea-agle-20260112monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-upd-agle-20251104monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-up-agle-20250805monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-therapeutics-announces-positive-interim-phase-1-results-for-two-next-generation-tl1a-agle-20250617monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate-upd-agle-20250508monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provide-agle-20250227monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-therapeutics-highlights-2025-priorities-and-robust-pipeline-of-upcoming-clinical-rea-agle-20241231monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-therapeutics-announces-positive-interim-results-from-phase-1-healthy-volunteer-trial-agle-20241112monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-upd-agle-20241107monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-therapeutics-announces-expected-acceleration-of-spy003-il-23p19-clinical-timelines-a-agle-20241014monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-up-agle-20240807monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-therapeutics-appoints-accomplished-biopharma-leader-dr-sandra-milligan-to-its-board--agle-20240515monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-therapeutics-reports-first-quarter-2024-financial-results-and-provides-corporate-upd-agle-20240509monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-therapeutics-announces-180-million-private-placement-agle-20240318monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provide-agle-20240229monthly0.5https://www.biopharmawatch.com/news/AGLE/spyre-therapeutics-announces-180-million-private-placement-agle-20231207monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-announces-name-change-to-spyre-therapeutics-appoints-ceo-and-additi-agle-20231128monthly0.5https://www.biopharmawatch.com/news/AGLE/item-7-management-s-discussion-and-analysis-of-financial-condition-and-results-of-operatio-agle-20231115monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-third-quarter-2023-financial-results-and-provides-corporate-agle-20231109monthly0.5https://www.biopharmawatch.com/news/AGLE/corporate-overview-24-october-2023-disclosures-the-information-contained-in-this-presentat-agle-20231024monthly0.5https://www.biopharmawatch.com/news/AGLE/report-of-independent-registered-public-accounting-firm-to-the-board-of-directors-of-aegle-agle-20231010monthly0.5https://www.biopharmawatch.com/news/AGLE/disclosures-the-information-contained-in-this-presentation-has-been-prepared-by-aeglea-bio-agle-20230908monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-expands-executive-leadership-team-with-appointment-of-industry-vete-agle-20230905monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-second-quarter-2023-financial-results-acquisition-of-spyre--agle-20230811monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-announces-sale-of-pegzilarginase-to-immedica-pharma-global-rights-t-agle-20230727monthly0.5https://www.biopharmawatch.com/news/AGLE/disclosures-the-information-contained-in-this-presentation-has-been-prepared-by-spyre-ther-agle-20230623monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-announces-acquisition-of-spyre-therapeutics-acquisition-of-spyre-an-agle-20230622monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-first-quarter-2023-financial-results-39-8-million-of-cash-a-agle-20230511monthly0.5https://www.biopharmawatch.com/news/AGLE/forward-looking-statements-2023-aeglea-biotherapeutics-this-presentation-by-aeglea-biother-agle-20230425monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-announces-interim-results-from-ongoing-phase-1-2-clinical-trial-of--agle-20230412monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-pro-agle-20230302monthly0.5https://www.biopharmawatch.com/news/AGLE/forward-looking-statements-2023-aeglea-biotherapeutics-this-presentation-and-the-accompany-agle-20230109monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-third-quarter-2022-financial-results-and-provides-program-u-agle-20221103monthly0.5https://www.biopharmawatch.com/news/AGLE/reimagining-the-potential-of-human-enzyme-therapeutics-corporate-overview-september-2022-n-agle-20220906monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-second-quarter-2022-financial-results-and-provides-program--agle-20220804monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-first-quarter-2022-financial-results-and-provides-program-u-agle-20220505monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-presents-additional-data-from-peace-phase-3-study-of-pegzilarginase-agle-20220411monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-pro-agle-20220308monthly0.5https://www.biopharmawatch.com/news/AGLE/forward-looking-statements-2022-aeglea-biotherapeutics-external-2-this-presentation-and-th-agle-20220105monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-announces-achievement-of-primary-endpoint-in-phase-3-study-of-pegzi-agle-20211206monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-third-quarter-2021-financial-results-and-corporate-highligh-agle-20211104monthly0.5https://www.biopharmawatch.com/news/AGLE/company-logo-forward-looking-statements-2021-aeglea-biotherapeutics-external-2-this-presen-agle-20210909monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-second-quarter-2021-financial-results-and-corporate-highlig-agle-20210805monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-first-quarter-2021-financial-results-and-corporate-highligh-agle-20210510monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-cor-agle-20210318monthly0.5https://www.biopharmawatch.com/news/AGLE/forward-looking-statements-2020-aeglea-biotherapeutics-external-2-this-presentation-and-th-agle-20210105monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-third-quarter-2020-financial-results-and-corporate-highligh-agle-20201105monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-second-quarter-2020-financial-results-and-corporate-highlig-agle-20200810monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-announces-1-year-data-for-pegzilarginase-in-patients-with-arginase--agle-20200526monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-first-quarter-2020-financial-results-and-corporate-highligh-agle-20200507monthly0.5https://www.biopharmawatch.com/news/AGLE/forward-looking-statements-this-presentation-and-the-accompanying-oral-presentation-contai-agle-20200408monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-highlig-agle-20200224monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-submits-cta-application-for-its-novel-engineered-human-enzyme-desig-agle-20200113monthly0.5https://www.biopharmawatch.com/news/AGLE/forward-looking-statements-this-presentation-and-the-accompanying-oral-presentation-contai-agle-20191203monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-third-quarter-2019-financial-results-and-corporate-highligh-agle-20191106monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-announces-positive-20-dose-data-for-pegzilarginase-in-patients-with-agle-20190903monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-second-quarter-2019-financial-results-and-corporate-highlig-agle-20190806monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-first-quarter-2019-financial-results-and-corporate-highligh-agle-20190507monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-announces-new-positive-phase-1-2-data-for-pegzilarginase-in-patient-agle-20190407monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-and-cor-agle-20190307monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-announces-design-of-pivotal-phase-3-peace-trial-evaluating-pegzilar-agle-20181211monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-reports-third-quarter-2018-financial-results-and-recent-corporate-h-agle-20181108monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-announces-positive-interim-clinical-data-for-pegzilarginase-in-adva-agle-20181022monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-announces-new-positive-interim-clinical-data-and-improvements-in-di-agle-20181017monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-announces-positive-interim-clinical-data-and-completion-of-enrollme-agle-20180904monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-provides-corporate-update-and-reports-second-quarter-2018-financial-agle-20180809monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-provides-corporate-update-and-reports-first-quarter-2018-financial--agle-20180508monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-prices-public-offering-of-common-stock-agle-20180418monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-presents-new-phase-1-2-trial-data-demonstrating-clinically-relevant-agle-20180412monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-provides-key-clinical-data-update-from-phase-1-2-trial-in-arginase--agle-20180313monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-provides-corporate-update-and-reports-third-quarter-2017-financial--agle-20171107monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-provides-corporate-update-and-reports-second-quarter-2017-financial-agle-20170809monthly0.5https://www.biopharmawatch.com/news/AGLE/resignation-letter-agle-20170718monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-prices-public-offering-of-common-stock-austin-texas-agle-20170606monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-provides-corporate-update-and-reports-first-quarter-2017-financial--agle-20170509monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year--agle-20170323monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-provides-corporate-update-and-reports-third-quarter-2016-financial--agle-20161109monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-announces-second-quarter-2016-financial-results-austin-texas-agle-20160809monthly0.5https://www.biopharmawatch.com/news/AGLE/aeglea-biotherapeutics-announces-first-quarter-2016-financial-results-austin-texas-agle-20160519monthly0.5https://www.biopharmawatch.com/news/AGLE/targeting-chronic-lymphocytic-leukemia-by-interfering-glutathione-synthesis-using-a-novel--agle-20160419monthly0.5https://www.biopharmawatch.com/news/AGLE/abstract-1042-development-of-aeb1102-an-engineered-human-arginase-1-for-patients-with-soli-agle-20160418monthly0.5https://www.biopharmawatch.com/news/GOCO/and-the-company-s-ability-to-realize-the-intended-benefits-of-the-restructuring-our-abilit-goco-20260608monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-prioritizes-consumer-fit-renewal-economics-and-cash-discipline-while-continuing-l-goco-20260331monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-prioritizes-retention-quality-and-strategic-flexibility-as-medicare-advantage-mar-goco-20251113monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-announces-strategic-capital-and-governance-actions-to-support-long-term-value-cre-goco-20250807monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-reports-first-quarter-2025-results-chicago-goco-20250513monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-reports-strong-fourth-quarter-and-fiscal-year-2024-results-driven-by-a-successful-goco-20250227monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-reports-third-quarter-2024-results-chicago-goco-20241107monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-reports-second-quarter-2024-results-chicago-goco-20240808monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-reports-first-quarter-2024-results-chicago-goco-20240509monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-reports-fourth-quarter-and-fiscal-2023-results-chicago-goco-20240314monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-reports-third-quarter-2023-results-chicago-goco-20231109monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-reports-second-quarter-2023-results-during-the-first-quarter-of-2023-the-company--goco-20230810monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-reports-first-quarter-2023-results-chicago-goco-20230508monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-reports-fourth-quarter-and-fiscal-2022-results-chicago-goco-20230316monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-announces-strong-preliminary-aep-operating-results-from-efficient-model-and-expan-goco-20230117monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-reports-third-quarter-2022-results-chicago-goco-20221110monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-receives-50-million-strategic-investment-to-support-long-term-growth-opportunitie-goco-20220926monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-reports-second-quarter-2022-results-chicago-goco-20220815monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-reports-first-quarter-2022-results-reaffirms-full-year-guidance-chicago-goco-20220510monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-reports-fourth-quarter-and-fiscal-2021-results-focusing-on-optimization-in-2022-c-goco-20220315monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-reports-third-quarter-2021-results-reaffirms-full-year-guidance-chicago-goco-20211109monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-reports-second-quarter-2021-results-revises-full-year-2021-growth-outlook-chicago-goco-20210811monthly0.5https://www.biopharmawatch.com/news/GOCO/document-gohealth-reports-first-quarter-2021-results-reaffirms-full-year-2021-growth-outlo-goco-20210512monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-reports-fourth-quarter-and-fiscal-2020-results-expects-continued-strong-growth-in-goco-20210308monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-reports-third-quarter-2020-results-and-increases-2020-outlook-as-a-result-of-stro-goco-20201111monthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-reports-second-quarter-2020-results-and-provides-2020-outlook-growth-fueled-by-st-goco-20200819monthly0.5https://www.biopharmawatch.com/news/ATHA/leonabio-reports-first-quarter-2026-financial-results-and-provides-business-update-advanci-atha-20260507monthly0.5https://www.biopharmawatch.com/news/ATHA/leonabio-reports-full-year-2025-financial-results-and-provides-business-update-acquired-li-atha-20260326monthly0.5https://www.biopharmawatch.com/news/ATHA/julie-rathbun-leonabio-com-206-769-9219-atha-20260109monthly0.5https://www.biopharmawatch.com/news/ATHA/this-presentation-and-the-accompanying-oral-commentary-contain-forward-looking-statements--atha-20210111monthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reports-third-quarter-2020-financial-results-and-provides-business-highlight-atha-20201112monthly0.5https://www.biopharmawatch.com/news/FGEN/kyntra-bio-reports-first-quarter-2026-financial-results-and-provides-business-update-x2022-fgen-20260511monthly0.5https://www.biopharmawatch.com/news/FGEN/kyntra-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-busine-fgen-20260316monthly0.5https://www.biopharmawatch.com/news/FGEN/described-in-kyntra-bio-s-most-recent-annual-report-on-form-10-k-and-quarterly-report-on-f-fgen-20260107monthly0.5https://www.biopharmawatch.com/news/FGEN/virtual-kol-investor-event-series-part-ii-review-fg-3246-development-program-in-metastatic-fgen-20240626monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-leadership-transition-appoints-thane-wettig-as-interim-chief-executive--fgen-20230725monthly0.5https://www.biopharmawatch.com/news/FGEN/astellas-receives-european-commission-approval-for-first-in-class-evrenzo-tm-roxadustat-fo-fgen-20210819monthly0.5https://www.biopharmawatch.com/news/FGEN/expertise-in-hypoxia-inducible-factor-hif-and-connective-tissue-growth-factor-ctgf-biology-fgen-20210816monthly0.5https://www.biopharmawatch.com/news/FGEN/uncertainties-related-to-the-continued-progress-and-timing-of-our-various-programs-includi-fgen-20210811monthly0.5https://www.biopharmawatch.com/news/FGEN/eluminex-biosciences-investors-media-zhenze-john-hu-ph-d-mpd-business-development-john-hu--fgen-20210720monthly0.5https://www.biopharmawatch.com/news/FGEN/astellas-receives-positive-chmp-opinion-for-evrenzo-tm-roxadustat-for-adult-patients-with--fgen-20210625monthly0.5https://www.biopharmawatch.com/news/FGEN/reliance-on-these-forward-looking-statements-which-speak-only-as-of-the-date-of-this-relea-fgen-20210407monthly0.5https://www.biopharmawatch.com/news/FGEN/media-jennifer-harrington-1-610-574-9196-jennifer-harrington-gcihealth-com-fgen-20210406monthly0.5https://www.biopharmawatch.com/news/FGEN/annual-report-on-form-10-k-for-the-fiscal-year-ended-fgen-20201218monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-third-quarter-2020-financial-results-strong-third-quarter-china-roxadusta-fgen-20201105monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-second-quarter-2020-financial-results-strong-second-quarter-china-roxadus-fgen-20200806monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-inc-media-inquiries-sara-iacovino-1-703-474-4452-sara-iacovino-gcihealth-com-inve-fgen-20200806monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-first-quarter-2020-financial-results-roxadustat-u-s-nda-review-and-e-u-ma-fgen-20200507monthly0.5https://www.biopharmawatch.com/news/FGEN/master-supply-agreement-this-master-supply-agreement-the-agreement-is-effective-as-of-fgen-20200324monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-fourth-quarter-and-full-year-2019-financial-results-x2022-roxadustat-nda--fgen-20200302monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-inc-media-inquiries-sara-iacovino-1-703-474-4452-sara-iacovino-gcihealth-com-inve-fgen-20200211monthly0.5https://www.biopharmawatch.com/news/FGEN/astellas-submits-supplemental-new-drug-application-for-approval-of-evrenzo-roxadustat-for--fgen-20200130monthly0.5https://www.biopharmawatch.com/news/FGEN/this-presentation-contains-forward-looking-statements-that-involve-substantial-risks-and-u-fgen-20200110monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-inc-media-inquiries-sara-iacovino-1-703-474-4452-sara-iacovino-gcihealth-com-inve-fgen-20200106monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-submits-new-drug-application-to-the-u-s-fda-for-roxadustat-in-patients-with-anemi-fgen-20191223monthly0.5https://www.biopharmawatch.com/news/FGEN/zhang-l-wang-f-wang-l-et-al-prevalence-of-chronic-kidney-disease-in-china-a-cross-sectiona-fgen-20191202monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-third-quarter-2019-financial-results-roxadustat-positive-pooled-phase-3-e-fgen-20191111monthly0.5https://www.biopharmawatch.com/news/FGEN/about-fibrogen-fibrogen-inc-headquartered-in-san-francisco-california-with-subsidiary-offi-fgen-20191108monthly0.5https://www.biopharmawatch.com/news/FGEN/predict-potential-continue-and-similar-words-although-some-forward-looking-statements-are--fgen-20191108monthly0.5https://www.biopharmawatch.com/news/FGEN/this-release-contains-forward-looking-statements-regarding-our-strategy-future-plans-and-p-fgen-20191011monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-initiation-of-phase-2-clinical-trial-of-roxadustat-for-the-treatment-of-fgen-20190926monthly0.5https://www.biopharmawatch.com/news/FGEN/roxadustat-approved-in-japan-for-the-treatment-of-anemia-associated-with-chronic-kidney-di-fgen-20190920monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-inc-karen-l-bergman-vice-president-investor-relations-and-corporate-communication-fgen-20190826monthly0.5https://www.biopharmawatch.com/news/FGEN/roxadustat-fgen-20190821monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-second-quarter-2019-financial-results-on-track-to-submit-u-s-nda-for-roxa-fgen-20190808monthly0.5https://www.biopharmawatch.com/news/FGEN/forward-looking-statements-this-release-contains-forward-looking-statements-regarding-our--fgen-20190725monthly0.5https://www.biopharmawatch.com/news/FGEN/about-pamrevlumab-pamrevlumab-is-a-first-in-class-antibody-developed-by-fibrogen-to-inhibi-fgen-20190722monthly0.5https://www.biopharmawatch.com/news/FGEN/pamrevlumab-mechanism-of-action-overall-summary-of-study-fg-3019-079-in-non-ambulatory-sub-fgen-20190628monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-fgen-20190605monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-first-quarter-2019-financial-results-x2022-positive-topline-results-from--fgen-20190509monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-fgen-20190415monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-fourth-quarter-and-full-year-2018-financial-results-roxadustat-approved-i-fgen-20190227monthly0.5https://www.biopharmawatch.com/news/FGEN/this-presentation-contains-forward-looking-statements-that-involve-substantial-risks-and-u-fgen-20190107monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-positive-topline-results-from-three-global-phase-3-trials-of-roxadustat-fgen-20181220monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-approval-of-roxadustat-in-china-for-the-treatment-of-anemia-in-chronic--fgen-20181217monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-appoints-maykin-ho-ph-d-fgen-20181206monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-third-quarter-2018-financial-results-roxadustat-new-drug-applications-und-fgen-20181108monthly0.5https://www.biopharmawatch.com/news/FGEN/asn-kidney-week-2018-data-presented-from-two-japanese-phase-3-studies-on-roxadustat-in-the-fgen-20181030monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-presents-results-from-two-phase-3-studies-of-roxadustat-for-the-treatment-of-anem-fgen-20181025monthly0.5https://www.biopharmawatch.com/news/FGEN/astellas-submits-new-drug-application-in-japan-of-roxadustat-for-the-treatment-of-anemia-a-fgen-20181001monthly0.5https://www.biopharmawatch.com/news/FGEN/astellas-announces-positive-topline-results-for-global-phase-3-trial-of-roxadustat-in-chro-fgen-20180920monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-fgen-20180912monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-second-quarter-2018-financial-results-roxadustat-u-s-phase-3-topline-clin-fgen-20180807monthly0.5https://www.biopharmawatch.com/news/FGEN/my-michael-yee-jefferies-tn-thomas-b-neff-fibrogen-py-k-peony-yu-fibrogen-sp-seth-porter-f-fgen-20180608monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-completion-of-enrollment-in-u-s-phase-3-clinical-program-for-roxadustat-fgen-20180607monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-presents-clinical-results-of-pamrevlumab-treatment-in-patients-with-locally-advan-fgen-20180603monthly0.5https://www.biopharmawatch.com/news/FGEN/astellas-and-fibrogen-announce-topline-results-from-double-blind-japan-phase-3-study-for-r-fgen-20180531monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-presents-latest-data-from-praise-phase-2b-study-of-pamrevlumab-in-idiopathic-pulm-fgen-20180521monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-first-quarter-2018-financial-results-pamrevlumab-data-to-be-presented-at--fgen-20180509monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-fourth-quarter-and-full-year-2017-financial-results-roxadustat-u-s-phase--fgen-20180227monthly0.5https://www.biopharmawatch.com/news/FGEN/this-presentation-the-accompanying-modules-and-in-each-case-the-oral-commentary-contain-fo-fgen-20180108monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-third-quarter-2017-financial-results-roxadustat-nda-filing-accepted-for-c-fgen-20171108monthly0.5https://www.biopharmawatch.com/news/FGEN/astellas-and-fibrogen-announce-positive-topline-results-from-first-japan-phase-3-trial-for-fgen-20171031monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-acceptance-by-china-fda-of-roxadustat-new-drug-application-nda-for-trea-fgen-20171018monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-appoints-gerald-lema-to-board-of-directors-san-francisco-ca-fgen-20170919monthly0.5https://www.biopharmawatch.com/news/FGEN/praise-background-pamrevlumab-fg-3019-a-human-mab-targeting-ctgf-preclinical-data-supporti-fgen-20170913monthly0.5https://www.biopharmawatch.com/news/FGEN/cancer-roxadustat-the-company-s-most-advanced-product-candidate-is-an-oral-small-molecule--fgen-20170816monthly0.5https://www.biopharmawatch.com/news/FGEN/q2-2017-fibrogen-inc-earnings-call-fgen-20170807monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-second-quarter-2017-financial-results-company-announces-positive-topline--fgen-20170807monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-first-quarter-2017-financial-results-conference-call-and-webcast-to-be-he-fgen-20170509monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-inc-announces-pricing-of-follow-on-fgen-20170406monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-china-fda-approval-of-cta-to-conduct-pivotal-phase-2-3-clinical-trial-o-fgen-20170331monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-fiscal-2016-financial-results-conference-call-and-webcast-to-be-held-toda-fgen-20170301monthly0.5https://www.biopharmawatch.com/news/FGEN/this-presentation-the-accompanying-modules-and-in-each-case-the-oral-commentary-contain-fo-fgen-20170216monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-s-roxadustat-fg-4592-meets-primary-endpoints-in-two-phase-3-anemia-studies-in-chi-fgen-20170130monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-financial-results-for-the-third-quarter-of-2016-and-provides-corporate-up-fgen-20161108monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-financial-results-for-the-second-quarter-of-2016-enrollment-completed-in--fgen-20160808monthly0.5https://www.biopharmawatch.com/news/FGEN/astellas-and-fibrogen-announce-first-patient-treated-in-phase-3-studies-and-positive-phase-fgen-20160725monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-initiation-by-astellas-of-phase-3-clinical-study-in-japan-of-roxadustat-fgen-20160609monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-financial-results-for-the-first-quarter-of-2016-continued-progress-in-rox-fgen-20160509monthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-announces-fiscal-2015-financial-results-webcast-conference-call-scheduled-for-4-3-fgen-20160229monthly0.5https://www.biopharmawatch.com/news/FGEN/this-presentation-the-accompanying-modules-and-in-each-case-the-oral-commentary-contain-fo-fgen-20160211monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-to-hold-extraordinary-general-meeting-of-shareholders-lsb-20260528monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-enters-into-amended-merger-agreement-for-going-private-transaction-lsb-20260429monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-announces-receipt-of-a-revised-preliminary-non-binding-proposal-to-acq-lsb-20260325monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-announces-receipt-of-buyer-group-notice-and-postponement-of-extraordin-lsb-20260206monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-to-hold-extraordinary-general-meeting-of-shareholders-lsb-20260120monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-enters-into-definitive-agreement-for-going-private-transaction-lsb-20251104monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-announces-transition-to-otc-market-following-nasdaq-delisting-beijing-lsb-20250922monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-announces-receipt-of-delisting-determination-letter-from-nasdaq-beijin-lsb-20250912monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-announces-appointment-of-independent-financial-advisor-and-legal-couns-lsb-20250910monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-announces-receipt-of-a-revised-preliminary-non-binding-proposal-to-acq-lsb-20250828monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-announces-receipt-of-a-preliminary-non-binding-proposal-to-acquire-the-lsb-20250818monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-announces-fiscal-year-2025-financial-results-sup2-total-revenue-reache-lsb-20250731monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-announces-us-15-million-private-placement-financing-beijing-lsb-20250708monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-co-ltd-amended-2024-share-incentive-plan-adopted-by-the-board-of-direc-lsb-20250312monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-reports-unaudited-financial-results-for-the-first-half-of-fiscal-year--lsb-20241219monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-granted-phase-iii-clinical-trial-approval-to-explore-simplified-regime-lsb-20241025monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-provides-fiscal-half-year-2025-financial-guidance-and-reaffirms-fiscal-lsb-20241008monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-announces-results-of-extraordinary-general-meeting-on-share-consolidat-lsb-20240927monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-co-ltd-incorporated-in-the-cayman-islands-with-limited-liability-nasda-lsb-20240910monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-announces-leadership-transitions-gaithersburg-md-september-4-2024-prne-lsb-20240901monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-announces-name-change-to-lakeshore-biopharma-gaithersburg-md-lsb-20240524monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-announces-results-of-extraordinary-general-meeting-gaithersburg-md-lsb-20240521monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-to-hold-extraordinary-general-meeting-on-lsb-20240507monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-receives-additional-180-day-extension-by-nasdaq-to-regain-compliance-with-min-lsb-20240429monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-announces-unaudited-financial-results-for-the-first-nine-months-of-fiscal-yea-lsb-20240419monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-granted-phase-i-clinical-trial-license-of-therapeutic-chronic-hepatitis-b-vir-lsb-20240418monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-announces-positive-interim-results-of-pivotal-phase-3-clinical-study-of-pika--lsb-20240409monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-announces-full-repayment-of-us-40-000-000-loan-facility-gaithersburg-md-lsb-20240403monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-announces-board-changes-and-strategic-leadership-appointments-in-chinese-subs-lsb-20240305monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-announces-results-of-extraordinary-general-meeting-held-on-lsb-20240222monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-announces-results-of-extraordinary-general-meeting-and-responds-to-false-stat-lsb-20240216monthly0.5https://www.biopharmawatch.com/news/LSB/respectively-to-the-current-report-on-form-6-k-furnished-by-the-company-with-the-united-st-lsb-20240214monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-announces-appointment-of-new-directors-gaithersburg-md-lsb-20240214monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-announces-us-40-million-private-placement-financing-gaithersburg-md-lsb-20240209monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-announces-unaudited-financial-results-for-the-first-half-of-fiscal-year-2024--lsb-20240122monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-announces-changes-to-its-board-committees-gaithersburg-md-january-8-2024-prne-lsb-20240107monthly0.5https://www.biopharmawatch.com/news/LSB/digitally-signed-by-advance-performance-exponents-inc-date-2023-12-22-13-00-25-05-00-reaso-lsb-20231228monthly0.5https://www.biopharmawatch.com/news/LSB/noble-capital-markets-initiates-coverage-on-ys-biopharma-with-outperform-rating-and-us-5-2-lsb-20231114monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-announces-completion-of-subject-enrollment-in-pivotal-phase-3-clinical-trial--lsb-20231031monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-announces-receipt-of-nasdaq-notice-gaithersburg-md-lsb-20231026monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-announces-first-subject-enrollment-in-pivotal-phase-3-clinical-trial-of-pika--lsb-20230926monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-announces-purchase-of-shares-by-company-officers-gaithersburg-md-lsb-20230824monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-announces-unaudited-financial-results-for-the-first-quarter-of-fiscal-year-20-lsb-20230815monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-s-pika-rabies-vaccine-receives-phase-3-clinical-trial-approval-from-philippin-lsb-20230601monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-to-participate-in-the-virtual-benchmark-healthcare-house-call-conference-on-lsb-20230518monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-s-pika-rabies-vaccine-receives-phase-3-clinical-trial-approval-in-pakistan-ga-lsb-20230516monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-announces-record-vaccine-revenues-and-preliminary-financial-results-for-fy202-lsb-20230331monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-s-pika-recombinant-covid-19-vaccine-demonstrates-superior-antibody-neutraliza-lsb-20230327monthly0.5https://www.biopharmawatch.com/news/LSB/ys-biopharma-to-ring-the-opening-bell-and-debut-on-nasdaq-ys-biopharma-ordinary-shares-and-lsb-20230316monthly0.5https://www.biopharmawatch.com/news/FLGC/filed-by-newsfilecorp-com-transparency-first-an-update-on-zerostack-s-financials-and-progr-flgc-20251009monthly0.5https://www.biopharmawatch.com/news/FLGC/filed-by-newsfilecorp-com-flora-growth-corp-unaudited-pro-forma-consolidated-financial-sta-flgc-20250923monthly0.5https://www.biopharmawatch.com/news/FLGC/filed-by-newsfilecorp-com-flora-growth-corp-announces-pricing-of-2-7-million-registered-di-flgc-20230919monthly0.5https://www.biopharmawatch.com/news/FLGC/filed-by-newsfilecorp-com-flora-growth-corp-to-acquire-australian-vaporizers-expects-immed-flgc-20230918monthly0.5https://www.biopharmawatch.com/news/FLGC/filed-by-newsfilecorp-com-flora-growth-corp-unaudited-pro-forma-consolidated-statement-of--flgc-20230825monthly0.5https://www.biopharmawatch.com/news/FLGC/filed-by-newsfilecorp-com-flora-growth-corp-reports-second-quarter-2023-financial-results-flgc-20230810monthly0.5https://www.biopharmawatch.com/news/FLGC/filed-by-newsfilecorp-com-flora-growth-corp-announces-update-on-sale-of-colombian-assets-e-flgc-20230725monthly0.5https://www.biopharmawatch.com/news/FLGC/flora-growth-corp-appoints-clifford-starke-as-chief-executive-officer-and-dany-vaiman-as-c-flgc-20230627monthly0.5https://www.biopharmawatch.com/news/FLGC/flora-growth-corp-to-effect-reverse-stock-split-fort-lauderdale-florida-toronto-flgc-20230607monthly0.5https://www.biopharmawatch.com/news/FLGC/flora-growth-reports-first-quarter-2023-financial-results-flora-generated-20-1-million-in--flgc-20230515monthly0.5https://www.biopharmawatch.com/news/FLGC/flora-growth-corp-announces-the-appointment-of-hussein-rakine-as-ceo-and-member-of-the-boa-flgc-20230418monthly0.5https://www.biopharmawatch.com/news/FLGC/flora-growth-reports-2022-year-end-financial-results-37-2m-in-revenue-314-growth-year-over-flgc-20230331monthly0.5https://www.biopharmawatch.com/news/FLGC/flora-growth-issues-2023-revenue-guidance-of-90-million-to-105-million-reflecting-anticipa-flgc-20230130monthly0.5https://www.biopharmawatch.com/news/FLGC/flora-growth-receives-additional-180-day-extension-by-nasdaq-to-regain-compliance-with-min-flgc-20230106monthly0.5https://www.biopharmawatch.com/news/FLGC/flora-growth-closes-acquisition-of-franchise-global-health-cementing-foothold-in-germany-a-flgc-20221227monthly0.5https://www.biopharmawatch.com/news/FLGC/flora-growth-corp-announces-pricing-of-5-0-million-registered-direct-offering-fort-lauderd-flgc-20221209monthly0.5https://www.biopharmawatch.com/news/FLGC/flora-growth-reports-third-quarter-2022-financial-results-revenue-for-the-three-month-peri-flgc-20221128monthly0.5https://www.biopharmawatch.com/news/FLGC/arrangement-agreement-flora-growth-corp-and-flgc-20221021monthly0.5https://www.biopharmawatch.com/news/FLGC/flora-growth-corp-interim-condensed-consolidated-financial-statements-for-the-six-months-e-flgc-20220919monthly0.5https://www.biopharmawatch.com/news/FLGC/flora-growth-reports-h1-2022-financial-results-h1-2022-revenue-increased-to-15-0-million-u-flgc-20220815monthly0.5https://www.biopharmawatch.com/news/FLGC/executive-employment-agreement-this-executive-employment-agreement-agreement-is-made-as-of-flgc-20220707monthly0.5https://www.biopharmawatch.com/news/FLGC/flora-growth-announces-results-of-annual-meeting-of-shareholders-appointment-of-brandon-ko-flgc-20220706monthly0.5https://www.biopharmawatch.com/news/FLGC/flora-growth-corp-the-corporation-by-law-no-1-a-a-by-law-relating-generally-to-the-transac-flgc-20220701monthly0.5https://www.biopharmawatch.com/news/FLGC/flora-growth-corp-announces-5-million-share-repurchase-program-fort-lauderdale-florida-tor-flgc-20220616monthly0.5https://www.biopharmawatch.com/news/FLGC/flora-growth-corporation-notice-of-annual-and-special-meeting-of-shareholders-dear-flora-g-flgc-20220606monthly0.5https://www.biopharmawatch.com/news/FLGC/flora-growth-reports-fiscal-year-end-2021-results-flora-reports-9-0-million-in-revenue-for-flgc-20220510monthly0.5https://www.biopharmawatch.com/news/FLGC/of-flora-growth-corp-dated-march-17-2022-flora-growth-appoints-former-amazon-executive-tim-flgc-20220317monthly0.5https://www.biopharmawatch.com/news/FLGC/of-flora-growth-corp-dated-february-28-2022-exhihbit-99-1-flora-growth-completes-acquisiti-flgc-20220228monthly0.5https://www.biopharmawatch.com/news/FLGC/of-flora-growth-corp-dated-november-23-2021-flora-growth-closes-34-5-million-public-offeri-flgc-20211123monthly0.5https://www.biopharmawatch.com/news/FLGC/of-flora-growth-corp-dated-november-19-2021-flora-growth-announces-pricing-of-30-million-p-flgc-20211119monthly0.5https://www.biopharmawatch.com/news/FLGC/of-flora-growth-corp-dated-november-15-2021-flora-growth-completes-acquisition-of-vessel-b-flgc-20211115monthly0.5https://www.biopharmawatch.com/news/FLGC/of-flora-growth-corp-dated-september-17-2021-flora-growth-announces-unaudited-financial-re-flgc-20210917monthly0.5https://www.biopharmawatch.com/news/FLGC/of-flora-growth-corp-dated-august-19-2021-flora-growth-reports-h1-2021-financial-results-a-flgc-20210819monthly0.5https://www.biopharmawatch.com/news/FLGC/mr-stan-bharti-resignation-letter-effective-as-of-august-5-2021-resignation-to-the-board-o-flgc-20210813monthly0.5https://www.biopharmawatch.com/news/FLGC/dated-july-22-2021-flora-growth-announces-warrant-extensions-toronto-ontario-flgc-20210722monthly0.5https://www.biopharmawatch.com/news/FLGC/dated-may-13-2021-flora-growth-corp-announces-closing-of-initial-public-offering-toronto-o-flgc-20210513monthly0.5https://www.biopharmawatch.com/news/FLGC/dated-may-11-2021-flora-growth-corp-announces-pricing-of-initial-public-offering-toronto-o-flgc-20210511monthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-inc-unaudited-pro-forma-condensed-financial-information-on-snse-20260521monthly0.5https://www.biopharmawatch.com/news/SNSE/disclaimer-this-presentation-has-been-prepared-by-sensei-biotherapeutics-inc-the-company-w-snse-20240603monthly0.5https://www.biopharmawatch.com/news/SNSE/disclaimer-this-presentation-has-been-prepared-by-sensei-biotherapeutics-inc-the-company-w-snse-20240104monthly0.5https://www.biopharmawatch.com/news/SNSE/disclaimer-this-presentation-has-been-prepared-by-sensei-biotherapeutics-inc-the-company-w-snse-20230627monthly0.5https://www.biopharmawatch.com/news/SNSE/disclaimer-this-presentation-has-been-prepared-by-sensei-biotherapeutics-inc-the-company-w-snse-20230420monthly0.5https://www.biopharmawatch.com/news/SNSE/disclaimer-this-presentation-has-been-prepared-by-sensei-biotherapeutics-inc-the-company-w-snse-20230313monthly0.5https://www.biopharmawatch.com/news/SNSE/robert-pierce-md-world-vaccine-congress-2022-washington-dc-sns-101-a-unique-tumor-selectiv-snse-20220420monthly0.5https://www.biopharmawatch.com/news/SNSE/training-the-immune-system-to-fight-cancer-john-k-celebi-mba-president-chief-executive-off-snse-20220110monthly0.5https://www.biopharmawatch.com/news/SNSE/this-presentation-has-been-prepared-by-sensei-biotherapeutics-inc-the-company-we-us-and-is-snse-20211206monthly0.5https://www.biopharmawatch.com/news/SNSE/vista-science-symposium-snse-20211116monthly0.5https://www.biopharmawatch.com/news/SNSE/this-presentation-has-been-prepared-by-sensei-biotherapeutics-inc-the-company-we-us-and-is-snse-20210908monthly0.5https://www.biopharmawatch.com/news/RENB/lunai-bioworks-renb-20260617monthly0.5https://www.biopharmawatch.com/news/RENB/lunai-bioworks-renb-20260520monthly0.5https://www.biopharmawatch.com/news/RENB/lunai-bioworks-inc-announces-postponement-of-special-meeting-of-stockholders-to-renb-20260428monthly0.5https://www.biopharmawatch.com/news/RENB/lunai-bioworks-executes-20m-strategic-transaction-at-fixed-1-50-conversion-acquiring-bbb-d-renb-20260326monthly0.5https://www.biopharmawatch.com/news/RENB/lunai-bioworks-regains-compliance-with-nasdaq-minimum-bid-price-requirement-renb-20251016monthly0.5https://www.biopharmawatch.com/news/RENB/exchange-agreement-this-exchange-agreement-this-agreement-is-entered-into-as-of-2025-the-e-renb-20250709monthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-to-acquire-predictive-oncology-in-all-stock-transaction-acquisition-provides-acce-renb-20250106monthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-inc-announces-10-million-in-equity-committed-los-angeles-renb-20240614monthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-inc-and-amsterdam-umc-cancer-center-poised-to-advance-cancer-immunotherapy-los-an-renb-20240524monthly0.5https://www.biopharmawatch.com/news/RENB/renovarocube-to-acquire-100-ownership-of-cyclomics-reinforcing-cutting-edge-cancer-diagnos-renb-20240424monthly0.5https://www.biopharmawatch.com/news/RENB/ai-pioneer-gedi-cube-and-biotech-innovator-renovaro-biosciences-combine-forces-to-accelera-renb-20240213monthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-biosciences-announces-results-of-special-meeting-of-shareholders-los-angeles-renb-20240125monthly0.5https://www.biopharmawatch.com/news/RENB/message-from-renovaro-bioscience-inc-s-ceo-the-hon-mark-dybul-md-accelerating-healthcare-w-renb-20240116monthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-biosciences-appoints-two-finance-industry-experts-to-board-of-directors-los-angel-renb-20231010monthly0.5https://www.biopharmawatch.com/news/RENB/ai-company-gedicube-and-renovaro-biosciences-sign-definitive-agreement-to-combine-message--renb-20231002monthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-biosciences-and-ai-health-company-gedi-cube-sign-definitive-agreement-to-combine--renb-20230929monthly0.5https://www.biopharmawatch.com/news/RENB/letter-of-intent-renb-20230801monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-inc-announces-adjournment-of-2023-renb-20230623monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-announces-that-its-cancer-platform-remains-on-track-for-trials-in-hum-renb-20230608monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-ceo-letter-to-shareholders-turning-the-page-a-promising-future-los-an-renb-20230403monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-announces-a-scientific-presentation-of-proof-of-concept-studies-for-a-renb-20230329monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-achieves-full-compliance-with-nasdaq-filing-requirements-renb-20230313monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-announces-receipt-of-notice-from-nasdaq-regarding-delayed-filing-of-f-renb-20230223monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-announces-receipt-of-notice-from-nasdaq-regarding-delayed-filing-of-f-renb-20221130monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-forges-ahead-with-focused-approach-promising-future-renb-20221024monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-announces-receipt-of-notice-from-nasdaq-regarding-delayed-filing-of-a-renb-20221021monthly0.5https://www.biopharmawatch.com/news/RENB/ceo-s-letter-to-shareholders-06-01-2022-updated-09-23-2022-dear-shareholders-i-have-spoken-renb-20220923monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-inc-nasdaq-enob-renb-20220706monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-announces-findings-from-a-rigorous-internal-review-of-scientific-data-renb-20220701monthly0.5https://www.biopharmawatch.com/news/RENB/01-2022-updated-06-06-2022-dear-shareholders-i-have-spoken-to-some-of-you-about-the-seriou-renb-20220607monthly0.5https://www.biopharmawatch.com/news/RENB/dear-shareholders-i-have-spoken-to-some-of-you-about-the-serious-and-disturbing-news-that--renb-20220602monthly0.5https://www.biopharmawatch.com/news/RENB/scientific-leaders-agree-on-promise-of-enochian-biosciences-los-angeles-renb-20220531monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-board-learns-of-arrest-of-co-founder-and-inventor-and-expresses-stron-renb-20220525monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-announces-the-appointment-of-executive-vice-president-of-research-and-renb-20220420monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-announces-appointment-of-senior-vice-president-for-clinical-operation-renb-20220407monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-inventor-and-co-founder-presents-data-on-novel-clinical-approaches-as-renb-20220405monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-and-caring-cross-announce-a-partnership-to-potentially-increase-the-e-renb-20220315monthly0.5https://www.biopharmawatch.com/news/RENB/update-enochian-biosciences-at-the-cutting-edge-the-future-of-biotech-is-disruptive-scienc-renb-20220124monthly0.5https://www.biopharmawatch.com/news/RENB/distinguished-scientific-and-public-health-leaders-to-join-enochian-biosciences-scientific-renb-20210830monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-names-the-hon-dr-mark-dybul-as-chief-executive-officer-dr-dybul-s-dee-renb-20210720monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-announces-29-million-registered-direct-offering-priced-at-the-market--renb-20210614monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-elegant-simplicity-integrating-diverse-scientific-approaches-to-devel-renb-20210216monthly0.5https://www.biopharmawatch.com/news/RENB/securities-and-exchange-commission-renb-20200915monthly0.5https://www.biopharmawatch.com/news/RENB/enochian-biosciences-announces-three-scientific-presentations-on-potential-hiv-and-hbv-cur-renb-20200513monthly0.5https://www.biopharmawatch.com/news/RENB/wolfe-axelrod-weinberger-associates-llc-stephen-d-axelrod-cfa-don-weinberger-212-370-4500--renb-20160405monthly0.5https://www.biopharmawatch.com/news/RENB/wolfe-axelrod-weinberger-associates-llc-stephen-d-axelrod-cfa-donald-c-weinberger-212-370--renb-20140930monthly0.5https://www.biopharmawatch.com/news/RENB/wolfe-axelrod-weinberger-associates-llc-stephen-d-axelrod-cfa-donald-c-weinberger-212-370--renb-20140814monthly0.5https://www.biopharmawatch.com/news/CYTH/ex-10-1-2-ex-99855-htm-exhibit-10-1-ex-99855-htm-exhibit-10-1-amendment-to-employment-agre-cyth-20171107monthly0.5https://www.biopharmawatch.com/news/CYTH/ctd-holdings-closes-on-2-million-private-placement-william-s-shanahan-former-president-of--cyth-20160607monthly0.5https://www.biopharmawatch.com/news/CYTH/joseph-j-farnan-jr-joins-ctd-holdings-board-of-directors-alachua-fla-marketwired-cyth-20151104monthly0.5https://www.biopharmawatch.com/news/CYTH/n-scott-fine-named-ceo-of-ctd-holdings-company-expands-executive-team-markus-w-sieger-name-cyth-20150916monthly0.5https://www.biopharmawatch.com/news/CYTH/ctd-holdings-receives-1-3-million-follow-on-investment-led-by-u-s-pharmacia-investment-arm-cyth-20150713monthly0.5https://www.biopharmawatch.com/news/CYTH/fda-accepts-ctd-holdings-drug-master-file-for-second-generation-orphan-drug-file-allows-do-cyth-20150127monthly0.5https://www.biopharmawatch.com/news/CYTH/ctd-holdings-names-new-board-chairman-vice-chairman-n-scott-fine-becomes-chairman-of-the-b-cyth-20141001monthly0.5https://www.biopharmawatch.com/news/CYTH/ctd-holdings-closes-1-725-million-private-placement-investment-builds-company-strength-in--cyth-20140722monthly0.5https://www.biopharmawatch.com/news/CYTH/ctd-holdings-names-new-chief-executive-dr-jeffrey-tate-promoted-to-ceo-c-e-rick-strattan-t-cyth-20140709monthly0.5https://www.biopharmawatch.com/news/CYTH/ctd-holdings-inc-closes-on-private-placement-investment-to-speed-development-of-orphan-dru-cyth-20140220monthly0.5https://www.biopharmawatch.com/news/CYTH/ctd-holdings-inc-announces-that-its-form-10-q-for-the-first-quarter-2012-will-be-delayed-d-cyth-20120516monthly0.5https://www.biopharmawatch.com/news/PTHL/itonic-holdings-ltd-granted-an-extension-of-additional-180-day-by-nasdaq-to-regain-complia-pthl-20260423monthly0.5https://www.biopharmawatch.com/news/PTHL/pheton-holdings-ltd-announces-corporate-name-change-and-stock-ticker-symbol-change-pthl-20260113monthly0.5https://www.biopharmawatch.com/news/PTHL/pheton-holdings-ltd-index-to-unaudited-interim-condensed-consolidated-financial-statements-pthl-20251216monthly0.5https://www.biopharmawatch.com/news/PTHL/pheton-holdings-ltd-incorporated-in-the-cayman-islands-with-limited-liability-nasdaq-pthl--pthl-20251126monthly0.5https://www.biopharmawatch.com/news/PTHL/pheton-holdings-ltd-issues-statements-addressing-recent-market-activity-and-misleading-rum-pthl-20250801monthly0.5https://www.biopharmawatch.com/news/PTHL/pheton-holdings-ltd-results-for-the-six-months-ended-pthl-20241015monthly0.5https://www.biopharmawatch.com/news/PTHL/pheton-holdings-ltd-announces-pricing-of-initial-public-offering-pthl-20240905monthly0.5https://www.biopharmawatch.com/news/CARA/tvardi-therapeutics-announces-first-quarter-cara-20260508monthly0.5https://www.biopharmawatch.com/news/CARA/tvardi-therapeutics-announces-fourth-quarter-and-full-year-2025-results-and-provides-busin-cara-20260331monthly0.5https://www.biopharmawatch.com/news/CARA/overview-january-2026-this-presentation-contains-forward-looking-statements-that-involve-s-cara-20260116monthly0.5https://www.biopharmawatch.com/news/CARA/overview-november-2025-this-presentation-contains-forward-looking-statements-that-involve--cara-20251119monthly0.5https://www.biopharmawatch.com/news/CARA/tvardi-therapeutics-announces-third-quarter-2025-results-and-provides-business-update-on-t-cara-20251113monthly0.5https://www.biopharmawatch.com/news/CARA/tvardi-therapeutics-provides-update-on-preliminary-data-from-phase-2-revert-trial-in-idiop-cara-20251013monthly0.5https://www.biopharmawatch.com/news/CARA/tvardi-therapeutics-announces-second-quarter-2025-results-and-provides-business-update-on--cara-20250814monthly0.5https://www.biopharmawatch.com/news/CARA/overview-june-2025-this-presentation-contains-forward-looking-statements-that-involve-subs-cara-20250609monthly0.5https://www.biopharmawatch.com/news/CARA/tvardi-therapeutics-announces-completion-of-enrollment-in-phase-2-clinical-trial-of-tti-10-cara-20250527monthly0.5https://www.biopharmawatch.com/news/CARA/tvardi-therapeutics-announces-first-quarter-2025-results-and-provides-business-update-comp-cara-20250513monthly0.5https://www.biopharmawatch.com/news/CARA/tvardi-therapeutics-announces-closing-of-merger-with-cara-therapeutics-merger-creates-a-na-cara-20250416monthly0.5https://www.biopharmawatch.com/news/CARA/overview-april-2025-this-presentation-and-any-accompanying-oral-commentary-have-been-prepa-cara-20250411monthly0.5https://www.biopharmawatch.com/news/CARA/tvardi-therapeutics-inc-index-to-financial-statements-page-report-of-independent-registere-cara-20250401monthly0.5https://www.biopharmawatch.com/news/CARA/overview-january-2025-2-disclaimer-and-forward-looking-statements-this-presentation-and-an-cara-20250121monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-and-tvardi-therapeutics-announce-entry-into-merger-agreement-proposed-me-cara-20241218monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-outcome-of-part-a-of-kourage-1-study-evaluating-oral-difelikef-cara-20240612monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-first-quarter-2024-financial-results-topline-efficacy-and-safety-cara-20240513monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-fourth-quarter-and-full-year-2023-financial-results-announced--cara-20240304monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-prioritizes-late-stage-notalgia-paresthetica-program-and-extends-cash-ru-cara-20240122monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-outcome-from-dose-finding-part-a-of-kind-1-study-evaluating-or-cara-20231218monthly0.5https://www.biopharmawatch.com/news/CARA/corporate-presentation-november-2023-2-forward-looking-statements-statements-contained-in--cara-20231113monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-third-quarter-2023-financial-results-non-dilutive-financing-agre-cara-20231113monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-up-to-40-0-million-non-dilutive-financing-agreement-with-healt-cara-20231102monthly0.5https://www.biopharmawatch.com/news/CARA/corporate-presentation-august-2023-2-forward-looking-statements-statements-contained-in-th-cara-20230807monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-second-quarter-2023-financial-results-2q23-total-revenue-of-6-9m-cara-20230807monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-appoints-helen-m-boudreau-to-board-of-directors-cara-20230803monthly0.5https://www.biopharmawatch.com/news/CARA/corporate-presentation-may-2023-2-forward-looking-statements-statements-contained-in-this--cara-20230515monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-first-quarter-2023-financial-results-1q23-total-revenue-of-6-2m--cara-20230515monthly0.5https://www.biopharmawatch.com/news/CARA/corporate-presentation-march-2023-2-forward-looking-statements-statements-contained-in-thi-cara-20230323monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-fourth-quarter-and-full-year-2022-financial-results-4q22-total-cara-20230306monthly0.5https://www.biopharmawatch.com/news/CARA/j-p-morgan-healthcare-conference-cara-20230109monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-november-2022-forward-looking-statements-statements-contained-in-this-pr-cara-20221107monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-third-quarter-2022-financial-results-net-revenue-was-16-2m-for-3-cara-20221107monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-appointment-of-lisa-von-moltke-m-d-to-its-board-of-directors-cara-20221103monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer-cara-20220912monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-corporate-presentation-august-2022-forward-looking-statements-statements-cara-20220808monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-second-quarter-2022-financial-results-net-revenue-was-23m-for-2q-cara-20220808monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-positive-topline-results-from-komfort-phase-2-trial-of-oral-di-cara-20220630monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-first-quarter-2022-financial-results-korsuva-difelikefalin-injec-cara-20220509monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-corporate-presentation-march-2022-forward-looking-statements-statements--cara-20220311monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-korsuva-dife-cara-20220301monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-j-p-morgan-2022-christopher-a-posner-president-ceo-forward-looking-state-cara-20220110monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-cms-grants-tdapa-to-korsuva-difelikefalin-injection-korsuva-re-cara-20211220monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-third-quarter-2021-financial-results-korsuva-cr845-difelikefalin-cara-20211108monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-ceo-transition-current-cara-director-and-accomplished-commerci-cara-20211103monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-and-vifor-pharma-announce-u-s-fda-approval-of-korsuva-difelikefalin-inje-cara-20210823monthly0.5https://www.biopharmawatch.com/news/CARA/targeting-pruritus-with-first-in-class-therapeutics-august-12-th-2021-2-confidential-for-i-cara-20210812monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-second-quarter-2021-financial-results-new-drug-application-nda-f-cara-20210809monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-first-quarter-2021-financial-results-u-s-food-and-drug-administr-cara-20210510monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-topline-results-from-kare-phase-2-dose-ranging-trial-of-oral-k-cara-20210429monthly0.5https://www.biopharmawatch.com/news/CARA/vfmcrp-and-cara-therapeutics-announce-european-medicines-agency-has-accepted-to-review-the-cara-20210330monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-and-vifor-pharma-announce-u-s-fda-acceptance-and-priority-review-of-nda--cara-20210308monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-u-s-fda-acce-cara-20210225monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-kor-cara-20201228monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-third-quarter-2020-financial-results-conference-call-toda-y-at-4-cara-20201109monthly0.5https://www.biopharmawatch.com/news/CARA/vifor-pharma-and-cara-therapeutics-sign-us-license-agreement-for-iv-korsuva-to-treat-dialy-cara-20201020monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-appoints-thomas-reilly-as-chief-financial-officer-cara-20201001monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-second-quarter-2020-financial-results-conference-call-today-at-4-cara-20200810monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-completion-of-interim-statistical-assessment-for-kare-phase-2--cara-20200617monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-first-quarter-2020-financial-results-conference-call-today-at-4--cara-20200511monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-and-vifor-fresenius-medical-care-renal-pharma-announce-positive-results--cara-20200421monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-clinical-updates-on-track-to-report-topline-data-for-kalm-2-phas-cara-20200325monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-conference-c-cara-20200227monthly0.5https://www.biopharmawatch.com/news/CARA/targeting-pruritus-with-novel-peripherally-restricted-kappa-agonist-therapeutics-jp-morgan-cara-20200114monthly0.5https://www.biopharmawatch.com/news/CARA/targeting-pruritus-with-novel-peripherally-restricted-kappa-agonist-therapeutics-december--cara-20191216monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-positive-topline-data-from-phase-2-trial-of-oral-korsuva-in-ch-cara-20191203monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-third-quarter-2019-financial-results-conference-call-today-at-4--cara-20191105monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-enters-into-commercial-license-agreement-with-enteris-biopharma-inc-for--cara-20190821monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-second-quarter-2019-financial-results-conference-call-today-at-4-cara-20190807monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-pricing-of-126-5-million-offering-of-common-stock-cara-20190724monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-proposed-offering-of-common-stock-cara-20190724monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-positive-results-from-kalm-1-pivotal-phase-3-trial-of-korsuva--cara-20190529monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-first-quarter-2019-financial-results-conference-call-today-at-4--cara-20190507monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-conference-c-cara-20190312monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-third-quarter-2018-financial-results-conference-call-today-at-4--cara-20181106monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-appoints-joana-goncalves-m-d-as-chief-medical-officer-former-vp-of-medic-cara-20181023monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-second-quarter-2018-financial-results-conference-call-today-at-4-cara-20180807monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-pricing-of-85-5-million-offering-of-common-stock-cara-20180718monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-proposed-offering-of-common-stock-cara-20180717monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-positive-top-line-data-from-adaptive-phase-2-3-trial-of-i-v-cr84-cara-20180627monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-and-vifor-fresenius-medical-care-renal-pharma-vfmcrp-enter-into-ex-u-s-l-cara-20180523monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-first-quarter-2018-financial-results-conference-call-today-at-4--cara-20180509monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-fourth-quarter-and-full-year-2017-financial-results-conference-c-cara-20180315monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-third-quarter-2017-financial-results-management-to-host-conferen-cara-20171102monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-second-quarter-2017-financial-results-conference-call-today-at-4-cara-20170803monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-first-quarter-2017-financial-results-reported-statistically-sign-cara-20170504monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-proposed-offering-of-common-stock-cara-20170329monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-positive-top-line-data-from-part-a-of-phase-2-3-trial-of-i-v-c-cara-20170328monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-fourth-quarter-and-full-year-2016-financial-results-conference-c-cara-20170309monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-third-quarter-2016-financial-results-currently-enrolling-three-l-cara-20161103monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-second-quarter-2016-financial-results-resumed-patient-enrollment-cara-20160804monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-first-quarter-2016-financial-results-conference-call-today-at-4--cara-20160505monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-fourth-quarter-and-full-year-2015-financial-results-conference-c-cara-20160310monthly0.5https://www.biopharmawatch.com/news/CARA/forward-looking-statements-this-presentation-contains-certain-forward-looking-statements-t-cara-20160111monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-third-quarter-2015-financial-results-initiated-phase-3-program-f-cara-20151109monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-second-quarter-2015-financial-results-reported-statistically-sig-cara-20150810monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-proposed-offering-of-common-stock-cara-20150727monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-announces-positive-results-from-phase-2-trial-in-uremic-pruritus-novel-p-cara-20150723monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-first-quarter-2015-financial-results-end-of-phase-2-meeting-with-cara-20150512monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-fourth-quarter-and-full-year-2014-financial-results-phase-3-pivo-cara-20150326monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-third-quarter-2014-financial-results-reported-positive-top-line--cara-20141110monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-second-quarter-2014-financial-results-conference-call-today-at-4-cara-20140807monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-first-quarter-2014-financial-results-conference-call-today-at-4--cara-20140512monthly0.5https://www.biopharmawatch.com/news/CARA/cara-therapeutics-reports-fourth-quarter-and-full-year-2013-financial-results-conference-c-cara-20140327monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-reports-second-quarter-fiscal-year-2026-financial-results-and-rece-aneb-20260212monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-announces-its-intent-to-commence-a-self-tender-offer-austin-texas-aneb-20251222monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-reports-first-quarter-fiscal-year-2026-financial-results-and-recen-aneb-20251113monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and--aneb-20250929monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-announces-update-on-going-private-transaction-and-strategic-altern-aneb-20250912monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-approves-plan-to-terminate-registration-of-its-common-stock-aneb-20250723monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-reports-third-quarter-fiscal-year-2025-financial-results-and-recen-aneb-20250513monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-reports-second-quarter-fiscal-year-2025-financial-results-and-rece-aneb-20250214monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-announces-positive-regulatory-update-for-selonabant-in-acute-canna-aneb-20241223monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-reports-first-quarter-fiscal-year-2025-financial-results-and-recen-aneb-20241113monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-reports-fourth-quarter-and-fiscal-year-2024-financial-results-and--aneb-20240925monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-awarded-nida-grant-for-its-investigational-iv-treatment-for-acute--aneb-20240722monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-reports-third-quarter-fiscal-year-2024-financial-results-and-recen-aneb-20240515monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-reports-second-quarter-fiscal-year-2024-financial-results-and-rece-aneb-20240213monthly0.5https://www.biopharmawatch.com/news/ANEB/exhibit-99-1-anebulo-pharmaceuticals-reports-first-quarter-fiscal-year-2024-financial-resu-aneb-20231114monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-reports-fourth-quarter-and-fiscal-year-2023-financial-results-and--aneb-20230920monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-reports-third-quarter-fiscal-2023-financial-results-and-recent-upd-aneb-20230511monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-reports-second-quarter-fiscal-year-2023-financial-results-and-rece-aneb-20230210monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-reports-first-quarter-fiscal-year-2023-financial-results-and-recen-aneb-20221110monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-announces-6-6-million-private-placement-financing-austin-texas-aneb-20220926monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-reports-fourth-quarter-and-fiscal-year-2022-financial-results-and--aneb-20220909monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-appoints-kenneth-cundy-ph-d-as-chief-scientific-officer-austin-tex-aneb-20220524monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-reports-third-quarter-fiscal-year-2022-financial-results-and-recen-aneb-20220511monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-doses-more-than-half-of-the-subjects-in-part-a-of-a-phase-2-clinic-aneb-20220401monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-reports-second-quarter-fiscal-year-2022-financial-results-and-rece-aneb-20220211monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-names-biotechnology-industry-executive-simon-allen-as-ceo-and-dire-aneb-20220104monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-announces-initiation-of-phase-2-clinical-study-evaluating-aneb-001-aneb-20220103monthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-reports-first-quarter-fiscal-year-2022-financial-results-and-provi-aneb-20211112monthly0.5https://www.biopharmawatch.com/news/DRRX/investor-contact-media-contact-garen-sarafian-katie-savastano-ir-bauschhealth-com-corporat-drrx-20250729monthly0.5https://www.biopharmawatch.com/news/DRRX/key-opinion-leader-discussion-larsucosterol-alcohol-associated-hepatitis-may-16th-2023-age-drrx-20230516monthly0.5https://www.biopharmawatch.com/news/DRRX/disclaimer-this-presentation-and-various-remarks-we-make-during-this-presentation-contain--drrx-20230203monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-appoints-two-new-board-members-cupertino-ca-drrx-20190425monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-provides-corporate-update-live-webcast-today-at-8-00-a-m-eastern-time-drrx-20190107monthly0.5https://www.biopharmawatch.com/news/DRRX/results-of-fda-advisory-committee-meeting-for-drrx-20180626monthly0.5https://www.biopharmawatch.com/news/DRRX/acute-organ-inj-ury-chronic-metabolic-disease-s-such-as-nonalcoholic-fatty-liver-disease-n-drrx-20170920monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-provides-remoxy-update-pain-therapeutics-announced-today-that-an-fda-advisory-commi-drrx-20160701monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-fda-acceptance-of-remoxy-nda-pdufa-date-of-drrx-20160414monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-posimir-program-update-cupertino-ca-drrx-20160407monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-second-quarter-2015-financial-results-and-update-of-programs--drrx-20150803monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-provides-update-on-posidur-program-cupertino-calif-drrx-20141111monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-secures-20-million-debt-financing-cupertino-ca-drrx-20140626monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-first-quarter-2014-financial-results-and-update-of-programs-c-drrx-20140501monthly0.5https://www.biopharmawatch.com/news/DRRX/impax-and-durect-sign-a-63-million-agreement-to-develop-and-commercialize-durect-s-eladur--drrx-20140107monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-update-on-remoxy-cupertino-ca-drrx-20130510monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-third-quarter-2011-financial-results-and-update-of-programs-c-drrx-20111103monthly0.5https://www.biopharmawatch.com/news/DRRX/zogenix-and-durect-announce-development-and-license-agreement-for-antipsychotic-product-ca-drrx-20110712monthly0.5https://www.biopharmawatch.com/news/DRRX/remoxy-new-drug-application-resubmitted-cupertino-ca-drrx-20101227monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-second-quarter-2010-financial-results-cupertino-ca-drrx-20100804monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-secures-50-million-committed-equity-financing-facility-cupertino-ca-drrx-20100701monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-reports-data-from-european-phase-iib-hysterectomy-study-of-posidur-saber-bupivacain-drrx-20100616monthly0.5https://www.biopharmawatch.com/news/DRRX/hospira-and-durect-sign-agreement-to-develop-and-commercialize-posidur-saber-bupivacaine-i-drrx-20100607monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-first-quarter-2010-financial-results-cupertino-ca-drrx-20100510monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-commencement-of-phase-iib-eladur-transdur-bupivacaine-clinica-drrx-20100407monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-fourth-quarter-and-year-end-2009-financial-results-cupertino--drrx-20100224monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-initiates-u-s-pivotal-phase-iii-posidur-clinical-trial-besst-bupivacaine-effectiven-drrx-20100119monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-reports-positive-phase-iib-data-from-posidur-clinical-program-cupertino-ca-drrx-20091217monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-third-quarter-2009-financial-results-drrx-20091029monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-c-orporation-4-444-444-shares-s-ubscription-a-greement-durect-corporation-2-results-drrx-20090910monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-license-of-adhd-drug-candidate-in-selected-asian-and-south-pacific-countr-drrx-20090818monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-second-quarter-2009-financial-results-drrx-20090803monthly0.5https://www.biopharmawatch.com/news/DRRX/remoxy-nda-update-cupertino-ca-drrx-20090707monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-appoints-dr-joseph-stauffer-as-chief-medical-officer-and-executive-vice-president-c-drrx-20090616monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-first-quarter-2009-financial-results-drrx-20090506monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-reports-positive-phase-iib-data-from-transdur-sufentanil-clinical-program-cupertino-drrx-20090316monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-fourth-quarter-and-year-end-2008-financial-results-cupertino--drrx-20090209monthly0.5https://www.biopharmawatch.com/news/DRRX/pain-therapeutics-receives-complete-response-letter-from-fda-for-drrx-20081211monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-third-quarter-2008-financial-results-drrx-20081103monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-s-collaboration-with-alpharma-clears-hsr-review-and-is-effective-cupertino-ca-drrx-20081029monthly0.5https://www.biopharmawatch.com/news/DRRX/alpharma-to-develop-and-commercialize-durect-s-eladur-pain-patch-cupertino-ca-drrx-20080922monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-the-ind-submission-for-a-third-abuse-resistant-opioid-pain-medication-bas-drrx-20080827monthly0.5https://www.biopharmawatch.com/news/DRRX/remoxy-nda-filing-accepted-by-fda-and-priority-review-granted-cupertino-ca-drrx-20080812monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-second-quarter-2008-financial-results-drrx-20080805monthly0.5https://www.biopharmawatch.com/news/DRRX/eladur-development-update-durect-receives-orphan-drug-designation-for-bupivacaine-for-post-drrx-20080630monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-s-convertible-notes-exchange-into-equity-at-maturity-cupertino-ca-drrx-20080617monthly0.5https://www.biopharmawatch.com/news/DRRX/new-drug-application-submitted-for-remoxy-oradur-based-oxycodone-cupertino-ca-drrx-20080610monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-first-quarter-2008-financial-results-drrx-20080507monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-fourth-quarter-and-year-end-2007-financial-results-cupertino--drrx-20080205monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-positive-eladur-phase-iia-study-results-cupertino-ca-drrx-20071218monthly0.5https://www.biopharmawatch.com/news/DRRX/primary-endpoint-of-pivotal-phase-iii-clinical-trial-achieved-for-remoxy-cupertino-ca-drrx-20071206monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-third-quarter-2007-financial-results-drrx-20071101monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-second-quarter-2007-financial-results-drrx-20070807monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-reports-positive-results-from-posidur-phase-iib-hernia-trial-triggering-8-million-m-drrx-20070717monthly0.5https://www.biopharmawatch.com/news/DRRX/patient-recruitment-completed-for-pivotal-phase-iii-study-of-remoxy-cupertino-ca-drrx-20070711monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-the-initiation-of-sufentanil-patch-phase-ii-study-by-endo-pharmaceuticals-drrx-20070627monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-second-quarter-2025-financial-results-cmt-sord-program-advanc-aplt-20250813monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-inc-545-fifth-avenue-suite-1400-new-york-ny-10017-212-220-9319-www-ap-aplt-20250613monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-first-quarter-2025-financial-results-company-to-present-full--aplt-20250513monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-fourth-quarter-and-year-end-2024-financial-results-appointed--aplt-20250414monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-third-quarter-2024-financial-results-nda-and-maa-for-govorest-aplt-20241107monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-second-quarter-2024-financial-results-nda-and-maa-for-govores-aplt-20240807monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-first-quarter-2024-financial-results-govorestat-nda-for-class-aplt-20240509monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-march-2024-various-statements-in-this-presentation-concerning-the-com-aplt-20240311monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-fourth-quarter-and-year-end-2023-financial-results-nda-for-go-aplt-20240306monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-announces-100-million-private-placement-financing-includes-significan-aplt-20240228monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-third-quarter-2023-financial-results-regulatory-submissions-o-aplt-20231109monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-second-quarter-2023-financial-results-regulatory-progress-for-aplt-20230810monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-first-quarter-2023-financial-results-demonstrated-long-term-c-aplt-20230511monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-announces-clinical-benefit-of-govorestat-at-007-in-action-galactosemi-aplt-20230424monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-fourth-quarter-and-year-end-2022-financial-results-progress-i-aplt-20230323monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-third-quarter-2022-financial-results-aplt-20221109monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-second-quarter-2022-financial-results-completed-public-equity-aplt-20220812monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-first-quarter-2022-financial-results-continued-progress-in-th-aplt-20220512monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-fourth-quarter-and-year-end-2021-financial-results-progress-i-aplt-20220310monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-corporate-presentation-february-2022-this-presentation-is-made-by-app-aplt-20220215monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-third-quarter-2021-financial-results-data-from-pilot-trial-of-aplt-20211112monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-second-quarter-2021-financial-results-nda-submission-for-at-0-aplt-20210812monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-first-quarter-2021-financial-results-phase-2-pilot-study-of-a-aplt-20210511monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-fourth-quarter-and-year-end-2020-financial-results-at-007-act-aplt-20210318monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-third-quarter-2020-financial-results-continued-enrollment-in--aplt-20201112monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-second-quarter-2020-financial-results-aplt-20200811monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-first-quarter-2020-financial-results-aplt-20200511monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-announces-full-data-and-scientific-presentations-from-the-pivotal-pha-aplt-20200421monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-fourth-quarter-and-year-end-2019-financial-results-aplt-20200313monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-third-quarter-2019-financial-results-aplt-20191113monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-inc-announces-pricing-of-20-million-private-placement-of-common-stock-aplt-20191112monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-announces-initiation-of-phase-3-registrational-trial-of-at-001-in-dia-aplt-20190904monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-second-quarter-2019-financial-results-aplt-20190812monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-at-007-sad-data-from-healthy-volunteer-portion-of-phase-1-2-a-aplt-20190808monthly0.5https://www.biopharmawatch.com/news/APLT/corporate-overview-august-2019-disclaimer-this-presentation-is-made-by-applied-therapeutic-aplt-20190806monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-announces-initiation-of-phase-1-2-study-of-at-007-aplt-20190624monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-reports-first-quarter-2019-financial-results-strengthened-financial-p-aplt-20190621monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-to-present-data-highlighting-at-001-for-the-treatment-of-diabetic-car-aplt-20190607monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-announces-fda-orphan-drug-designation-for-at-007-aplt-20190528monthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-to-present-data-at-esc-hf-highlighting-at-001-a-novel-potent-and-sele-aplt-20190524monthly0.5https://www.biopharmawatch.com/news/ACST/corporate-presentation-june-2026-summary-2-forward-looking-statements-statements-in-this-p-acst-20260618monthly0.5https://www.biopharmawatch.com/news/ACST/grace-therapeutics-announces-2026-fiscal-year-end-financial-results-provides-business-upda-acst-20260618monthly0.5https://www.biopharmawatch.com/news/ACST/corporate-presentation-april-2026-summary-2-forward-looking-statements-statements-in-this--acst-20260427monthly0.5https://www.biopharmawatch.com/news/ACST/grace-therapeutics-provides-regulatory-update-on-new-drug-application-for-gtx-104-fda-issu-acst-20260423monthly0.5https://www.biopharmawatch.com/news/ACST/grace-therapeutics-announces-third-quarter-2026-financial-results-provides-business-update-acst-20260212monthly0.5https://www.biopharmawatch.com/news/ACST/grace-therapeutics-announces-second-quarter-2026-financial-results-provides-business-updat-acst-20251113monthly0.5https://www.biopharmawatch.com/news/ACST/grace-therapeutics-secures-approximately-4-0-million-through-common-warrant-exercises-foll-acst-20251023monthly0.5https://www.biopharmawatch.com/news/ACST/grace-therapeutics-granted-sixth-u-s-patent-covering-i-v-dosing-regimen-for-gtx-104-grant--acst-20250918monthly0.5https://www.biopharmawatch.com/news/ACST/grace-therapeutics-announces-u-s-food-and-drug-administration-acceptance-for-review-of-new-acst-20250827monthly0.5https://www.biopharmawatch.com/news/ACST/grace-therapeutics-announces-first-quarter-2026-financial-results-provides-business-update-acst-20250812monthly0.5https://www.biopharmawatch.com/news/ACST/grace-therapeutics-announces-submission-of-new-drug-application-to-u-s-food-and-drug-admin-acst-20250625monthly0.5https://www.biopharmawatch.com/news/ACST/grace-therapeutics-announces-2025-fiscal-year-end-results-provides-business-update-held-ty-acst-20250623monthly0.5https://www.biopharmawatch.com/news/ACST/grace-therapeutics-announces-alignment-with-the-fda-supporting-the-planned-nda-submission--acst-20250409monthly0.5https://www.biopharmawatch.com/news/ACST/corporate-presentation-march-2025-summary-2-forward-looking-statements-statements-in-this--acst-20250303monthly0.5https://www.biopharmawatch.com/news/ACST/grace-therapeutics-announces-third-fiscal-quarter-2025-financial-results-provides-business-acst-20250213monthly0.5https://www.biopharmawatch.com/news/ACST/grace-therapeutics-announces-results-from-pivotal-phase-3-strive-on-safety-trial-of-gtx-10-acst-20250210monthly0.5https://www.biopharmawatch.com/news/ACST/grace-therapeutics-announces-second-fiscal-quarter-2025-financial-results-provides-busines-acst-20241113monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-announces-corporate-name-change-to-grace-therapeutics-inc-name-change-reflects-exte-acst-20241028monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-announces-completion-of-patient-enrollment-in-pivotal-phase-3-strive-on-safety-tria-acst-20240925monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-inc-condensed-consolidated-statements-of-loss-and-comprehensive-loss-unaudit-acst-20240809monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-announces-achievement-of-50-enrollment-in-pivotal-phase-3-strive-on-safety-trial-co-acst-20240627monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-inc-consolidated-statements-of-operations-and-comprehensive-loss-year-ended-acst-20240621monthly0.5https://www.biopharmawatch.com/news/ACST/company-overview-nasdaq-acst-april-2024-forward-looking-statements-statements-in-this-pres-acst-20240401monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-announces-third-fiscal-quarter-2024-financial-results-and-business-highlights-x2022-acst-20240212monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-inc-condensed-consolidated-interim-statements-of-loss-and-comprehensive-loss-acst-20231113monthly0.5https://www.biopharmawatch.com/news/ACST/in-such-forward-looking-statements-as-a-result-of-various-risks-and-uncertainties-includin-acst-20231023monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-announces-7-5-million-private-placement-equity-financing-princeton-nj-acst-20230926monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-announces-first-quarter-2024-financial-results-and-business-highlights-x2022-new-le-acst-20230811monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-announces-1-for-6-reverse-stock-split-laval-qu-bec-acst-20230707monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-announces-alignment-with-fda-on-gtx-104-pivotal-phase-3-safety-trial-protocol-and-c-acst-20230705monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-reports-fiscal-year-2023-operational-results-laval-qu-bec-acst-20230623monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-announces-appointment-of-prashant-kohli-as-ceo-laval-qu-bec-acst-20230404monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-inc-centralizes-marketplace-for-shares-on-the-nasdaq-with-voluntary-delistin-acst-20230313monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-reports-third-quarter-2023-operational-results-company-to-host-conference-ca-acst-20230214monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-reports-second-quarter-2023-operational-results-company-to-host-conference-c-acst-20221114monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-announces-court-dismissal-of-stockholder-litigation-laval-qu-bec-acst-20220930monthly0.5https://www.biopharmawatch.com/news/ACST/dated-september-29-2022-announcing-voting-results-of-annual-and-special-meeting-ex-99-1-ac-acst-20220929monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-reports-first-quarter-2023-operational-results-company-to-host-conference-ca-acst-20220811monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-reports-fiscal-year-2022-operational-results-company-to-host-conference-call-acst-20220621monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-announces-positive-results-for-pharmacokinetic-bridging-study-with-intraveno-acst-20220518monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-appoints-healthcare-industry-leader-michael-l-derby-to-its-board-of-director-acst-20220325monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-provides-business-update-for-the-third-quarter-of-fiscal-2022-provides-updat-acst-20220214monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-announces-interim-data-meets-all-primary-endpoints-for-pivotal-pk-study-for--acst-20211202monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-announces-annual-stock-option-grants-acst-20211115monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-provides-business-update-for-the-second-quarter-of-fiscal-2022-acst-20211110monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-provides-update-following-acquisition-of-grace-therapeutics-and-regains-comp-acst-20210922monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-provides-business-update-for-the-first-quarter-of-fiscal-2022-acst-20210812monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-provides-fiscal-2021-year-end-business-update-acst-20210622monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-intends-to-request-hearing-before-nasdaq-panel-to-present-plan-of-compliance-acst-20210517monthly0.5https://www.biopharmawatch.com/news/ACST/lock-up-agreement-this-agreement-is-entered-into-as-of-may-7-2021-by-and-between-acasti-ph-acst-20210507monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-provides-update-on-recent-financing-activities-acst-20210309monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-announces-results-for-third-quarter-of-fiscal-2021-acst-20210209monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-provides-update-on-recent-financing-activities-acst-20210127monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-provides-business-update-for-the-second-quarter-of-fiscal-2021-acst-20201116monthly0.5https://www.biopharmawatch.com/news/ACST/in-this-by-law-and-all-other-by-laws-of-the-corporation-unless-acst-20201002monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-announces-review-process-of-strategic-alternatives-acst-20200929monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-appoints-seasoned-executive-brian-d-acst-20200918monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-announces-filing-and-mailing-of-information-circular-and-change-in-record-date-acst-20200911monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-reports-topline-triglyceride-results-from-phase-3-trilogy-2-study-of-capre-i-acst-20200831monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-provides-business-update-for-the-first-quarter-of-fiscal-2021-acst-20200813monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-submits-statistical-analysis-plan-to-fda-and-remains-on-track-to-report-tril-acst-20200731monthly0.5https://www.biopharmawatch.com/news/ACST/jfif-c-0-0-1-a-qa-2q-bb-3rr-8ddu-r-acst-20200630monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-receives-fda-response-to-trilogy-1-briefing-package-acst-20200619monthly0.5https://www.biopharmawatch.com/news/ACST/special-meeting-of-shareholders-acst-20190806monthly0.5https://www.biopharmawatch.com/news/ACST/management-s-discussion-and-analysis-of-the-financial-situation-acst-20190214monthly0.5https://www.biopharmawatch.com/news/ACST/management-s-discussion-and-analysis-of-the-financial-situation-acst-20181114monthly0.5https://www.biopharmawatch.com/news/ACST/special-meeting-of-shareholders-acst-20170717monthly0.5https://www.biopharmawatch.com/news/ACST/correction-acasti-pharma-grants-stock-options-laval-qu-bec-canada-acst-20170616monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-grants-stock-options-laval-qu-bec-canada-acst-20170614monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-to-present-at-upcoming-international-industry-conferences-laval-qu-bec-canad-acst-20170612monthly0.5https://www.biopharmawatch.com/news/ACST/management-discussion-and-analysis-of-the-financial-situation-and-operating-results-thirte-acst-20170606monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-reports-fourth-quarter-and-full-year-2017-financial-results-company-achieves-acst-20170606monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-and-cordenpharma-announce-large-scale-production-of-capre-with-new-continuou-acst-20170531monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-presents-capre-clinical-data-at-national-lipid-association-scientific-sessio-acst-20170518monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-granted-additional-composition-use-patents-in-taiwan-and-australia-safeguards-valua-acst-20170424monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-to-present-capre-omega-3-bridging-study-results-at-national-lipid-associatio-acst-20170412monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-provides-update-on-capre-phase-3-development-program-outcome-of-the-end-of-p-acst-20170330monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-forms-scientific-advisory-board-and-appoints-two-leading-cardiovascular-dise-acst-20170308monthly0.5https://www.biopharmawatch.com/news/ACST/not-for-distribution-to-u-s-newswire-services-or-for-dissemination-in-the-united-states-ac-acst-20170221monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-grants-incentive-stock-and-options-laval-qu-bec-canada-acst-20170224monthly0.5https://www.biopharmawatch.com/news/ACST/general-by-law-of-acasti-pharma-inc-the-corporation-table-of-contents-1-definitions-1-1-1--acst-20170221monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-reports-third-quarter-2017-financial-results-key-developments-include-advanc-acst-20170112monthly0.5https://www.biopharmawatch.com/news/ACST/business-description-of-and-risk-factors-relating-to-acasti-pharma-inc-dated-as-of-acst-20161205monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-appoints-linda-o-keefe-as-chief-financial-officer-laval-qu-bec-canada-acst-20161128monthly0.5https://www.biopharmawatch.com/news/ACST/source-acasti-pharma-inc-acasti-announces-stock-ticker-symbol-change-to-acst-on-the-tsxv-l-acst-20161103monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-builds-intellectual-property-portfolio-with-newly-issued-u-s-patent-for-capr-acst-20161026monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-reports-second-quarter-2017-financial-results-key-developments-include-new-l-acst-20161011monthly0.5https://www.biopharmawatch.com/news/ACST/acasti-pharma-reports-positive-capre-omega-3-bridging-study-data-results-support-streamlin-acst-20160914monthly0.5https://www.biopharmawatch.com/news/ACST/notice-of-change-in-fiscal-year-end-section-4-8-of-national-instrument-51-102-to-autorit-d-acst-20160805monthly0.5https://www.biopharmawatch.com/news/ACST/source-acasti-pharma-inc-acasti-announces-the-election-of-its-directors-change-of-fiscal-y-acst-20160715monthly0.5https://www.biopharmawatch.com/news/ACST/notice-of-annual-and-special-meeting-of-shareholders-to-the-shareholders-of-acasti-phama-i-acst-20160614monthly0.5https://www.biopharmawatch.com/news/ACST/source-acasti-pharma-inc-acasti-announces-grant-of-stock-options-laval-qu-bec-canada-acst-20160530monthly0.5https://www.biopharmawatch.com/news/ACST/management-discussion-and-analysis-of-the-financial-situation-and-operating-results-years--acst-20160526monthly0.5https://www.biopharmawatch.com/news/ACST/source-acasti-pharma-inc-acasti-announces-fourth-quarter-and-fiscal-year-results-laval-qu--acst-20160525monthly0.5https://www.biopharmawatch.com/news/ACST/source-acasti-pharma-inc-jan-d-alvise-appointed-president-ceo-of-acasti-pharma-seasoned-ex-acst-20160512monthly0.5https://www.biopharmawatch.com/news/ACST/source-acasti-pharma-inc-nasdaq-grants-acasti-cure-period-to-regain-compliance-with-audit--acst-20160322monthly0.5https://www.biopharmawatch.com/news/ACST/source-acasti-pharma-inc-acasti-announces-management-appointment-and-changes-to-the-board--acst-20160301monthly0.5https://www.biopharmawatch.com/news/ACST/source-acasti-pharma-inc-acasti-announces-share-for-debt-laval-qu-bec-canada-acst-20160205monthly0.5https://www.biopharmawatch.com/news/ACST/notice-of-annual-and-special-meeting-of-shareholders-acst-20150617monthly0.5https://www.biopharmawatch.com/news/ACST/source-neptune-technologies-bioressources-inc-acasti-pharma-inc-and-neurobiopharm-inc-nept-acst-20140530monthly0.5https://www.biopharmawatch.com/news/ACST/annual-information-form-fiscal-year-ended-acst-20140530monthly0.5https://www.biopharmawatch.com/news/ACST/jfif-exif-mm-b-j-1-r-2-i-adobe-photoshop-cs2-windows-2014-05-28-09-39-02-j-acst-20140528monthly0.5https://www.biopharmawatch.com/news/ACST/notice-of-annual-and-special-meeting-of-shareholders-acst-20140528monthly0.5https://www.biopharmawatch.com/news/ACST/execution-version-acasti-pharma-inc-as-the-corporation-and-computershare-trust-company-of--acst-20131203monthly0.5https://www.biopharmawatch.com/news/ACST/execution-acst-20131127monthly0.5https://www.biopharmawatch.com/news/ACST/this-prepayment-agreement-is-made-on-acst-20131029monthly0.5https://www.biopharmawatch.com/news/ACST/notice-of-annual-and-special-meeting-of-shareholders-acst-20130528monthly0.5https://www.biopharmawatch.com/news/ACST/jfif-exif-mm-b-j-1-r-2-i-adobe-photoshop-cs-windows-2013-05-28-07-50-22-m-acst-20130528monthly0.5https://www.biopharmawatch.com/news/POAI/1-this-presentation-contains-forward-looking-statements-as-de-ned-by-the-private-securitie-poai-20251117monthly0.5https://www.biopharmawatch.com/news/POAI/securities-purchase-agreement-poai-20250930monthly0.5https://www.biopharmawatch.com/news/POAI/corporate-overview-cancer-quest-2020-project-september-2019-predictive-oncology-p-o-a-i-poai-20190926monthly0.5https://www.biopharmawatch.com/news/POAI/a-leader-in-artificial-intelligence-ai-driven-knowledge-based-precision-medicine-aipt-corp-poai-20190517monthly0.5https://www.biopharmawatch.com/news/POAI/precision-therapeutics-reports-first-quarter-2019-financial-results-and-provides-corporate-poai-20190515monthly0.5https://www.biopharmawatch.com/news/POAI/corporate-mission-to-apply-artificial-intelligence-ai-to-personalized-medicine-and-drug-di-poai-20181030monthly0.5https://www.biopharmawatch.com/news/POAI/committed-to-providing-products-and-services-that-ensure-the-best-possible-patient-outcome-poai-20170815monthly0.5https://www.biopharmawatch.com/news/POAI/skyline-medical-signs-binding-letter-of-intent-for-merger-transaction-with-cytobioscience-poai-20170802monthly0.5https://www.biopharmawatch.com/news/POAI/skyline-medical-announces-results-for-year-end-2014-minneapolis-mn-poai-20150430monthly0.5https://www.biopharmawatch.com/news/POAI/skyline-medical-announces-results-for-third-quarter-and-first-nine-months-of-2014-increase-poai-20141112monthly0.5https://www.biopharmawatch.com/news/POAI/skyline-medical-inc-announces-second-quarter-2014-results-17-streamway-units-sold-17-trial-poai-20140808monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-reports-fourth-quarter-and-full-year-2025-financial-results-waltham-mas-rbot-20260309monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-announces-full-year-2026-cash-burn-guidance-waltham-mass-business-wire-rbot-20251215monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-announces-reduction-in-2025-cash-burn-outlook-announces-new-committee-a-rbot-20251203monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-reports-third-quarter-2025-financial-results-waltham-mass-business-wire-rbot-20251112monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-announces-pricing-of-5-9-million-registered-direct-offering-rbot-20251008monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-announces-appointment-of-joseph-doherty-as-chairman-of-the-board-waltha-rbot-20250925monthly0.5https://www.biopharmawatch.com/news/RBOT/transforming-surgery-open-like-access-minimally-invasive-vicarious-surgical-this-presentat-rbot-20250923monthly0.5https://www.biopharmawatch.com/news/RBOT/transforming-surgery-open-like-access-minimally-invasive-vicarious-surgical-legal-disclaim-rbot-20250908monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-reports-second-quarter-2025-financial-results-waltham-mass-business-wir-rbot-20250812monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-announces-leadership-transition-stephen-from-healthcare-industry-vetera-rbot-20250731monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-announces-election-of-new-directors-waltham-mass-business-wire-vicariou-rbot-20250627monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-reports-first-quarter-2025-financial-results-waltham-mass-business-wire-rbot-20250512monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-receives-continued-listing-standard-notice-from-the-nyse-waltham-mass-b-rbot-20250411monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-announces-president-transition-to-board-member-role-waltham-mass-busine-rbot-20250324monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-reports-fourth-quarter-and-full-year-2024-financial-results-version-1-0-rbot-20250317monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-announces-appointment-of-sarah-romano-as-chief-financial-officer-ms-rom-rbot-20250313monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-announces-planned-retirement-of-chief-operating-officer-waltham-mass-bu-rbot-20250218monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-announces-departure-of-chief-financial-officer-waltham-mass-business-wi-rbot-20241206monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-reports-third-quarter-2024-financial-results-waltham-mass-business-wire-rbot-20241112monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-reports-second-quarter-2024-financial-results-waltham-mass-business-wir-rbot-20240812monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-announces-reverse-stock-split-waltham-mass-business-wire-vicarious-surg-rbot-20240610monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-reports-first-quarter-2024-financial-results-waltham-mass-business-wire-rbot-20240429monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-reports-fourth-quarter-and-full-year-2023-financial-results-version-1-0-rbot-20240304monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-strengthens-executive-team-with-appointment-of-randy-clark-as-company-p-rbot-20240129monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-reports-third-quarter-2023-financial-results-waltham-mass-business-wire-rbot-20231113monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-receives-continued-listing-standard-notice-from-nyse-waltham-mass-busin-rbot-20230920monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-announces-launch-of-proposed-public-offering-rbot-20230802monthly0.5https://www.biopharmawatch.com/news/RBOT/investor-presentation-july-2023-disclaimer-vicarious-surgical-investor-presentation-july-2-rbot-20230727monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-reports-second-quarter-2023-financial-results-and-announces-clinical-pl-rbot-20230727monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-announces-promotion-of-john-mazzola-to-chief-operating-officer-waltham--rbot-20230518monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-reports-first-quarter-2023-financial-results-waltham-mass-business-wire-rbot-20230508monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-reports-fourth-quarter-and-full-year-2022-financial-results-meets-full--rbot-20230213monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-announces-changes-to-board-of-directors-victoria-carr-brendel-ph-d-elec-rbot-20230123monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-reports-third-quarter-2022-financial-results-waltham-mass-business-wire-rbot-20221107monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-announces-changes-to-board-of-directors-tech-focused-venture-capitalist-rbot-20221020monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-announces-upcoming-beta-2-demonstration-day-waltham-mass-rbot-20221013monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-reports-second-quarter-2022-financial-results-waltham-mass-business-wir-rbot-20220808monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-reports-first-quarter-2022-financial-results-waltham-mass-business-wire-rbot-20220509monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-investor-presentation-march-2022-investor-presentation-march-2022-vicar-rbot-20220308monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-reports-fourth-quarter-and-full-year-2021-financial-results-waltham-mas-rbot-20220303monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-reports-third-quarter-2021-financial-results-waltham-mass-business-wire-rbot-20211108monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-enters-long-term-lease-expanding-footprint-for-continued-growth-waltham-rbot-20211020monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-inc-unaudited-condensed-balance-sheets-in-thousands-except-share-and-pe-rbot-20210923monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-business-combination-approved-stock-to-begin-trading-on-the-new-york-st-rbot-20210915monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-inc-and-d8-holdings-corp-announce-additional-pipe-commitments-waltham-m-rbot-20210909monthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-inc-and-d8-holdings-corp-announce-definitive-business-combination-agree-rbot-20210415monthly0.5https://www.biopharmawatch.com/news/RBOT/d8-holdings-corp-announces-the-separate-trading-of-its-class-a-ordinary-shares-and-warrant-rbot-20200904monthly0.5https://www.biopharmawatch.com/news/RBOT/d8-holdings-corp-report-of-independent-registered-public-accounting-firm-f-2-balance-sheet-rbot-20200724monthly0.5https://www.biopharmawatch.com/news/RBOT/d8-holdings-corp-announces-pricing-of-upsized-300-million-initial-public-offering-rbot-20200714monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-inc-letter-from-the-ceo-dear-fellow-stockholders-over-the-past-few-lipo-20250619monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-announces-2-million-private-placement-priced-at-the-market-under-n-lipo-20231024monthly0.5https://www.biopharmawatch.com/news/LIPO/a-clinical-stage-biotechnology-company-addressing-serious-diseases-with-significant-unmet--lipo-20230911monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-reports-first-quarter-2023-financial-results-and-corporate-update--lipo-20230515monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-provides-business-update-and-reports-2022-financial-results-company-successfully-c-lipo-20230331monthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-announces-successful-top-line-results-of-phase-2a-clinical-trial-o-lipo-20230111monthly0.5https://www.biopharmawatch.com/news/EVOK/are-qualified-in-their-entirety-by-this-cautionary-statement-this-caution-is-made-under-th-evok-20240209monthly0.5https://www.biopharmawatch.com/news/EVOK/source-evoke-pharma-inc-evoke-pharma-inc-condensed-balance-sheets-evok-20220510monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-daniel-kontoh-boateng-dkb-partners-tel-862-213-1398-dboateng-dkbpartners--evok-20220308monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-daniel-kontoh-boateng-dkb-partners-tel-862-213-1398-dboateng-dkbpartners--evok-20211110monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-christine-petraglia-tel-917-633-8980-cpetraglia-theruthgro-evok-20210812monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-christine-petraglia-james-salierno-tel-917-633-8980-973-25-evok-20210512monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-christine-petraglia-james-salierno-tel-917-633-8980-973-25-evok-20210311monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-announces-proposed-public-offering-of-common-stock-evok-20210113monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-jan-medina-cfa-tel-646-536-7035-jmedina-theruthgroup-com-m-evok-20201110monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-tram-bui-tel-646-536-7035-alobo-theruthgroup-com-evoke-pha-evok-20200806monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-tram-bui-tel-646-536-7035-tbui-theruthgroup-com-evoke-phar-evok-20200512monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-tram-bui-tel-646-536-7035-tbui-theruthgroup-com-evoke-phar-evok-20200312monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-tram-bui-tel-646-536-7035-tbui-theruthgroup-com-evoke-phar-evok-20191107monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-s-prior-press-releases-and-in-the-periodic-reports-it-files-with-the-securities-and--evok-20190808monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-tram-bui-tel-646-536-7035-tbui-theruthgroup-com-evoke-phar-evok-20190508monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-tram-bui-tel-646-536-7035-tbui-theruthgroup-com-evoke-phar-evok-20190306monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-tram-bui-tel-646-536-7035-tbui-theruthgroup-com-evoke-phar-evok-20181113monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-tram-bui-tel-646-536-7035-tbui-theruthgroup-com-evoke-phar-evok-20180809monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-tram-bui-tel-646-536-7035-tbui-theruthgroup-com-evoke-phar-evok-20180514monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-tram-bui-tel-646-536-7035-tbui-theruthgroup-com-evoke-phar-evok-20180307monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-tram-bui-tel-646-536-7035-tbui-theruthgroup-com-evoke-phar-evok-20171114monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-david-burke-tel-646-536-7009-dburke-theruthgroup-com-evoke-evok-20170515monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-tram-bui-tel-646-536-7035-tbui-theruthgroup-com-evoke-phar-evok-20170315monthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-announces-proposed-public-offering-of-common-stock-evok-20170215monthly0.5https://www.biopharmawatch.com/news/EVOK/evok-ex991-112-pptx-htm-nasdaq-evok-january-2017-exh-99-1-forward-looking-statements-this--evok-20170109monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-david-burke-tel-646-536-7009-dburke-theruthgroup-com-media-evok-20161109monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-david-burke-tel-646-536-7009-dburke-theruthgroup-com-media-evok-20160815monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-david-burke-o-646-536-7009-c-917-618-2651-dburke-theruthgr-evok-20160729monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-david-burke-o-646-536-7009-c-917-618-2651-dburke-theruthgr-evok-20160720monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-david-burke-tel-646-536-7009-dburke-theruthgroup-com-media-evok-20160511monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-david-burke-tel-646-536-7009-dburke-theruthgroup-com-media-evok-20160310monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-david-burke-tel-646-536-7009-dburke-theruthgroup-com-media-evok-20151112monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-david-burke-tel-646-536-7009-dburke-theruthgroup-com-media-evok-20150813monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-david-burke-tel-646-536-7009-dburke-theruthgroup-com-media-evok-20150514monthly0.5https://www.biopharmawatch.com/news/EVOK/forward-looking-statements-confidential-this-presentation-contains-forward-looking-stateme-evok-20150311monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-david-burke-tel-646-536-7009-dburke-theruthgroup-com-media-evok-20150304monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-david-burke-tel-646-536-7009-mailto-dburke-theruthgroup-co-evok-20140513monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-david-burke-tel-646-536-7009-dburke-theruthgroup-com-media-evok-20140325monthly0.5https://www.biopharmawatch.com/news/EVOK/investor-contact-the-ruth-group-stephanie-carrington-david-burke-tel-646-536-7017-7009-sca-evok-20131113monthly0.5https://www.biopharmawatch.com/news/HOTH/adelina-4702663-rocket-one-appoints-major-general-malcolm-b-frost-ret-to-space-and-defense-hoth-20260603monthly0.5https://www.biopharmawatch.com/news/HOTH/conf-4700878-rocket-one-appoints-dr-supriyo-bandyopadhyay-as-lead-technical-advisor-of-ai--hoth-20260601monthly0.5https://www.biopharmawatch.com/news/HOTH/rocket-one-accepted-into-amd-ai-developer-program-to-advance-simulation-of-next-generation-hoth-20260528monthly0.5https://www.biopharmawatch.com/news/HOTH/january-2026-innovating-for-everyone-clinical-stage-biopharmaceutical-company-focused-on-n-hoth-20260116monthly0.5https://www.biopharmawatch.com/news/HOTH/october-2025-innovating-for-everyone-clinical-stage-biopharmaceutical-company-focused-on-n-hoth-20251014monthly0.5https://www.biopharmawatch.com/news/HOTH/ht-001-the-first-therapy-for-egfr-inhibitor-induced-cutaneous-toxicities-innovating-for-ev-hoth-20250624monthly0.5https://www.biopharmawatch.com/news/HOTH/june-2025-innovating-for-everyone-clinical-stage-biopharmaceutical-company-focused-on-next-hoth-20250606monthly0.5https://www.biopharmawatch.com/news/HOTH/december-2024-innovating-for-everyone-clinical-stage-biopharmaceutical-company-focused-on--hoth-20241129monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-a-1-25-reverse-stock-split-effective-pre-market-opening-on-hoth-20221026monthly0.5https://www.biopharmawatch.com/news/HOTH/clinical-stage-biopharmaceutical-company-focused-on-next-generation-therapeutics-meeting-u-hoth-20220425monthly0.5https://www.biopharmawatch.com/news/HOTH/clinical-stage-biopharmaceutical-company-focused-on-next-generation-therapeutics-meeting-u-hoth-20210901monthly0.5https://www.biopharmawatch.com/news/HOTH/introduction-to-ht-kit-an-mrna-frame-shifting-therapeutic-significantly-inhibits-tumor-gro-hoth-20210524monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-appoints-dr-stefanie-johns-ph-d-as-chief-scientific-officer-hoth-20200831monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-announces-proposed-public-offering-of-common-stock-hoth-20200323monthly0.5https://www.biopharmawatch.com/news/HOTH/nasdaq-hoth-fall-2019-corporate-presentation-hoth-20191021monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-and-zyl-therapeutics-hoth-20190823monthly0.5https://www.biopharmawatch.com/news/HOTH/may-2019-corporate-presentation-hoth-20190429monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inc-announces-pricing-of-initial-public-offering-and-trading-on-the-nasd-hoth-20190215monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-announces-intention-to-voluntarily-delist-and-deregister-its-common-stock-hook-20250718monthly0.5https://www.biopharmawatch.com/news/HOOK/not-for-release-publication-or-distribution-in-whole-or-in-part-in-into-or-from-any-jurisd-hook-20250220monthly0.5https://www.biopharmawatch.com/news/HOOK/in-the-court-of-chancery-for-the-state-of-delaware-in-re-hookipa-pharma-inc-c-a-no-verifie-hook-20250129monthly0.5https://www.biopharmawatch.com/news/HOOK/not-for-release-publication-or-distribution-in-whole-or-in-part-in-into-or-from-any-jurisd-hook-20250110monthly0.5https://www.biopharmawatch.com/news/HOOK/not-for-release-publication-or-distribution-in-whole-or-in-part-in-into-or-from-any-jurisd-hook-20250107monthly0.5https://www.biopharmawatch.com/news/HOOK/not-for-release-publication-or-distribution-in-whole-or-in-part-in-into-or-from-any-jurisd-hook-20250102monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-reports-third-quarter-2024-financial-results-and-provides-recent-business-u-hook-20241114monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-announces-board-of-directors-changes-new-york-and-vienna-hook-20240830monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-reports-second-quarter-2024-financial-results-and-recent-business-highlight-hook-20240808monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-announces-leadership-changes-to-intensify-focus-on-hb-200-hook-20240722monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-announces-updated-phase-2-clinical-data-at-the-american-society-for-clinica-hook-20240604monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-announces-positive-clinical-data-to-be-presented-at-the-american-society-fo-hook-20240523monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-reports-first-quarter-2024-financial-results-and-recent-business-highlights-hook-20240509monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-announces-pivotal-phase-2-3-trial-design-for-hb-200-in-combination-with-pem-hook-20240425monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-busi-hook-20240322monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-provides-update-on-business-priorities-and-oncology-partnership-programs-ho-hook-20240129monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-announces-21-25-million-equity-investment-from-gilead-sciences-gilead-purch-hook-20231220monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-reports-third-quarter-2023-financial-results-and-recent-business-highlights-hook-20231109monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-announces-executive-leadership-change-new-york-and-vienna-hook-20230913monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-reports-second-quarter-2023-financial-results-and-recent-business-highlight-hook-20230810monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-announces-pricing-of-50-0-million-public-offering-of-common-stock-and-non-v-hook-20230531monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-announces-positive-preliminary-phase-2-data-on-hb-200-in-combination-with-p-hook-20230531monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-reports-first-quarter-2023-financial-results-and-recent-business-highlights-hook-20230511monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-2023-outl-hook-20230315monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-appoints-terry-coelho-to-its-board-of-directors-new-york-us-and-vienna-aust-hook-20230313monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-appoints-katia-schlienger-m-d-ph-d-chief-medical-officer-and-malte-peters-m-hook-20221215monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-announces-third-quarter-2022-financial-results-and-provides-a-business-upda-hook-20221114monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-announces-strategic-collaboration-and-license-agreement-with-roche-to-develop-nove-hook-20221020monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-reports-second-quarter-2022-financial-results-and-corporate-updates-hb-200--hook-20220811monthly0.5https://www.biopharmawatch.com/news/HOOK/the-field-allows-up-to-17-characters-hook-20220622monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-announces-positive-phase-1-data-and-phase-2-plans-for-hb-200-program-for-the-treat-hook-20220605monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-reports-first-quarter-2022-financial-results-and-recent-highlights-hb-200-p-hook-20220516monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-announces-promotion-of-christine-d-baker-to-chief-operating-officer-new-york-us-an-hook-20220502monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-appoints-tim-reilly-ph-d-to-its-board-of-directors-new-york-us-and-vienna-a-hook-20220420monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-2022-outl-hook-20220324monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-announces-pricing-of-75-0-million-public-offering-of-common-stock-and-non-v-hook-20220302monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-announces-proposed-public-offering-of-common-stock-and-non-voting-convertib-hook-20220301monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-and-gilead-amend-collaboration-and-license-agreement-to-develop-immunotherapies-ag-hook-20220215monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-reports-third-quarter-2021-financial-results-and-recent-highlights-clinical-hook-20211110monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-advances-hb-200-program-to-phase-2-and-prioritizes-oncology-portfolio-based-on-cli-hook-20211101monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-reports-second-quarter-2021-financial-results-and-recent-highlights-phase-1-hook-20210812monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-reports-first-quarter-2021-financial-results-and-recent-highlights-oncology-hook-20210512monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-2021-outl-hook-20210318monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-announces-proposed-public-offering-of-common-stock-and-preferred-stock-new--hook-20201208monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-interim-phase-1-monotherapy-data-of-hb-201-for-the-treatment-of-advanced-hpv16-can-hook-20201207monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-announces-positive-phase-2-interim-safety-immunogenicity-and-efficacy-data-for-its-hook-20201130monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-reports-third-quarter-2020-financial-results-and-provides-a-corporate-updat-hook-20201112monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-reports-second-quarter-2020-financial-results-and-provides-a-corporate-upda-hook-20200813monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-announces-positive-phase-2-interim-safety-and-immunogenicity-results-for-its-cmv-v-hook-20200622monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-announces-changes-to-its-board-of-directors-resignation-of-sander-van-deventer-new-hook-20200619monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-reports-first-quarter-2020-financial-results-and-provides-a-corporate-updat-hook-20200514monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-a--hook-20200319monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-reports-third-quarter-2019-financial-results-and-provides-a-corporate-updat-hook-20191112monthly0.5https://www.biopharmawatch.com/news/HOOK/hookipa-pharma-reports-second-quarter-2019-financial-results-and-clinical-progress-highlig-hook-20190812monthly0.5https://www.biopharmawatch.com/news/GLYC/document-kelun-biotech-and-crescent-biopharma-announce-strategic-partnership-to-develop-an-glyc-20251204monthly0.5https://www.biopharmawatch.com/news/GLYC/crescent-biopharma-completes-closing-of-merger-with-glycomimetics-and-previously-announced-glyc-20250616monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-stockholders-approve-proposed-merger-with-crescent-biopharma-and-all-related-glyc-20250605monthly0.5https://www.biopharmawatch.com/news/GLYC/january-2025-crescent-biopharma-overview-2-disclaimer-this-presentation-is-for-information-glyc-20250113monthly0.5https://www.biopharmawatch.com/news/GLYC/november-2024-crescent-biopharma-overview-2-disclaimer-this-presentation-is-for-informatio-glyc-20241107monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-announces-national-cancer-institute-phase-2-3-study-of-uproleselan-did-not-m-glyc-20241029monthly0.5https://www.biopharmawatch.com/news/GLYC/about-glycomimetics-inc-glycomimetics-is-a-late-clinical-stage-biotechnology-company-disco-glyc-20240730monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-announces-comprehensive-results-from-pivotal-phase-3-study-of-uproleselan-in-glyc-20240604monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-announces-results-of-pivotal-phase-3-study-of-uproleselan-in-relapsed-refrac-glyc-20240506monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-highlights-and-financial-results-for-fourth-quarter-and-full-year-20-glyc-20240327monthly0.5https://www.biopharmawatch.com/news/GLYC/x2022-to-the-extent-that-statements-contained-in-this-presentation-are-not-descriptions-of-glyc-20240301monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-highlights-and-financial-results-for-third-quarter-2023-topline-resu-glyc-20231103monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-highlights-and-financial-results-for-second-quarter-2023-topline-res-glyc-20230802monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-highlights-and-financial-results-for-first-quarter-2023-pivotal-phas-glyc-20230503monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-highlights-and-financial-results-for-fourth-quarter-and-year-end-202-glyc-20230329monthly0.5https://www.biopharmawatch.com/news/GLYC/xa9-2021-glycomimetics-inc-all-rights-reserved-glycobiology-based-therapeutics-transformin-glyc-20230302monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-highlights-and-financial-results-for-third-quarter-2022-u-s-food-and-glyc-20221109monthly0.5https://www.biopharmawatch.com/news/GLYC/xa9-2021-glycomimetics-inc-all-rights-reserved-glycobiology-based-therapeuticstransforming-glyc-20221004monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-highlights-and-financial-results-for-second-quarter-2022-u-s-food-an-glyc-20220803monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-highlights-and-financial-results-for-first-quarter-2022-mid-year-202-glyc-20220428monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-highlights-and-financial-results-for-fourth-quarter-and-full-year-20-glyc-20220303monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-highlights-and-financial-results-for-third-quarter-2021-significant--glyc-20211102monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-highlights-and-financial-results-for-second-quarter-2021-completion--glyc-20210805monthly0.5https://www.biopharmawatch.com/news/GLYC/g-lycomimetics-reports-highlights-and-financial-results-for-first-quarter-2021-glycomimeti-glyc-20210503monthly0.5https://www.biopharmawatch.com/news/GLYC/g-lycomimetics-reports-highlights-and-financial-results-for-fourth-quarter-and-full-year-2-glyc-20210302monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-promotes-dr-eric-feldman-to-chief-medical-officer-rockville-md-glyc-20210223monthly0.5https://www.biopharmawatch.com/news/GLYC/g-lycomimetics-reports-highlights-and-financial-results-for-third-quarter-2020-enrollment--glyc-20201106monthly0.5https://www.biopharmawatch.com/news/GLYC/g-lycomimetics-reports-highlights-and-financial-results-for-second-quarter-2020-enrollment-glyc-20200731monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-operational-highlights-and-financial-results-for-first-quarter-2020--glyc-20200501monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-highlights-and-financial-results-for-fourth-quarter-and-year-end-201-glyc-20200228monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-and-apollomics-announce-exclusive-collaboration-and-license-agreement-to-dev-glyc-20200106monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-third-quarter-2019-financial-results-and-recent-operational-developm-glyc-20191107monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-top-line-results-from-pfizer-s-phase-3-clinical-trial-evaluating-riv-glyc-20190805monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-second-quarter-2019-financial-results-and-recent-operational-highlig-glyc-20190801monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-first-quarter-2019-results-and-recent-operational-highlights-xb7-enr-glyc-20190502monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-fourth-quarter-and-year-end-2018-results-xb7-initiated-first-company-glyc-20190306monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-announces-transition-plan-for-board-of-directors-xb7-current-board-member-ti-glyc-20190305monthly0.5https://www.biopharmawatch.com/news/GLYC/scott-jackson-veteran-biopharmaceutical-executive-glyc-20181128monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-third-quarter-2018-results-and-highlights-recent-company-achievement-glyc-20181102monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-second-quarter-2018-results-and-highlights-recent-company-achievemen-glyc-20180809monthly0.5https://www.biopharmawatch.com/news/GLYC/innovation-today-healing-tomorrow-july-2018-corporate-overview-nasdaq-glyc-glycomimetics-i-glyc-20180725monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-first-quarter-2018-results-xb7-based-on-guidance-from-the-us-food-an-glyc-20180503monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-announces-proposed-public-offering-of-common-stock-rockville-md-business-wir-glyc-20180319monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-fourth-quarter-and-year-end-2017-results-xb7-in-an-oral-presentation-glyc-20180306monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-program-updates-and-third-quarter-2017-restults-ongoing-discussions--glyc-20171108monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-program-updates-and-second-quarter-2017-restults-xb7-fda-granted-bre-glyc-20170803monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-glyc-20170612monthly0.5https://www.biopharmawatch.com/news/GLYC/unless-the-context-otherwise-requires-we-use-the-terms-glycomimetics-the-company-we-us-and-glyc-20170525monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-program-updates-and-first-quarter-2017-results-xb7-completed-enrollm-glyc-20170508monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-appoints-scott-koenig-of-macrogenics-glyc-20170313monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-fourth-quarter-and-year-end-2016-results-glyc-20170301monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-third-quarter-2016-results-and-progress-in-clinical-development-glyc-20161104monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-second-quarter-2016-results-rockville-md-glyc-20160804monthly0.5https://www.biopharmawatch.com/news/GLYC/unless-the-context-otherwise-requires-we-use-the-terms-x201c-glycomimetics-x201d-the-x201c-glyc-20160617monthly0.5https://www.biopharmawatch.com/news/GLYC/the-treatment-of-patients-with-relapsed-or-refractory-acute-myeloid-leukemia-aml-remains-a-glyc-20160610monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-first-quarter-2016-glyc-20160504monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-appoints-immunogen-ceo-daniel-junius-to-board-of-directors-gaithersburg-md-m-glyc-20160321monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-fourth-quarter-and-year-end-2015-glyc-20160229monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-third-quarter-2015-results-rockville-md-november-12-2015-x2013-glyco-glyc-20151112monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-second-quarter-2015-glyc-20150806monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-first-quarter-2015-glyc-20150505monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-provides-update-on-pfizer-s-plans-to-intitiate-phase-3-trial-with-rivipansel-glyc-20150407monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-fourth-quarter-and-year-end-2014-results-year-end-cash-and-cash-equi-glyc-20150316monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-third-quarter-2014-glyc-20141031monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-second-quarter-2014-glyc-20140731monthly0.5https://www.biopharmawatch.com/news/GLYC/source-glycomimetics-contact-brian-hahn-email-bhahn-glycomimetics-com-phone-240-243-1207-g-glyc-20140710monthly0.5https://www.biopharmawatch.com/news/GLYC/glycomimetics-reports-first-quarter-2014-glyc-20140508monthly0.5https://www.biopharmawatch.com/news/GLYC/31-2014-glycomimetics-reports-fourth-quarter-and-year-end-2013-results-gaithersburg-md-bus-glyc-20140404monthly0.5https://www.biopharmawatch.com/news/IINN/qtrex-expands-into-quantum-processor-interface-with-single-build-cryogenic-chip-carrier-ba-iinn-20260618monthly0.5https://www.biopharmawatch.com/news/IINN/qtrex-awarded-government-grant-to-advance-the-world-s-first-native-rf-dielectric-material--iinn-20260609monthly0.5https://www.biopharmawatch.com/news/IINN/qtrex-secures-purchase-order-from-a-u-s-based-fortune-500-company-for-an-ame-system-and-re-iinn-20260601monthly0.5https://www.biopharmawatch.com/news/IINN/additively-manufactured-electronics-and-fabrica-product-lines-product-lines-of-nano-dimens-iinn-20260528monthly0.5https://www.biopharmawatch.com/news/IINN/nyu-langone-issues-580-000-purchase-order-for-inspira-s-fda-cleared-art100-following-multi-iinn-20260518monthly0.5https://www.biopharmawatch.com/news/IINN/technologies-ceo-issues-letter-to-shareholders-on-strategic-direction-and-value-creation-p-iinn-20260511monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-secures-596-000-ame-system-order-from-leading-irish-technological-university-ra-an-iinn-20260501monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-and-qarakal-sign-joint-development-agreement-iinn-20260430monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-completes-commercial-deployment-of-its-iinn-20260416monthly0.5https://www.biopharmawatch.com/news/IINN/to-the-company-s-report-of-foreign-private-issuer-on-form-6-k-filed-with-the-sec-on-iinn-20260406monthly0.5https://www.biopharmawatch.com/news/IINN/technologies-appoints-yoav-rozanovich-as-chief-business-officer-to-drive-immediate-revenue-iinn-20260414monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-enters-quantum-computing-sector-targeting-a-critical-connectivity-bottleneck-with--iinn-20260406monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-announces-acquisition-of-iinn-20260406monthly0.5https://www.biopharmawatch.com/news/IINN/technologies-terminates-atm-and-sepa-equity-facilities-to-prepare-for-next-strategic-phase-iinn-20260331monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-reports-full-year-2025-iinn-20260326monthly0.5https://www.biopharmawatch.com/news/IINN/receives-nasdaq-notification-regarding-minimum-market-value-deficiency-iinn-20260225monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-expands-u-s-iinn-20260218monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-announces-receipt-of-nasdaq-notification-regarding-minimum-bid-price--iinn-20260212monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-outlines-strategic-vision-and-transaction-framework-for-breast-cancer-liquid-biops-iinn-20260108monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-reaffirms-49-5-million-in-binding-purchase-orders-and-aligns-executio-iinn-20251223monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-oxy-b-h-n-ltd-notice-of-annual-and-extraordinary-general-meeting-of-s-iinn-20251125monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-activates-u-s-based-consulting-firm-to-execute-transformational-initiatives-ra-ana-iinn-20250731monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-regains-compliance-with-nasdaq-minimum-bid-price-requirement-ra-anana-israel-iinn-20250718monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-achieves-all-key-objectives-in-previously-announced-government-talks-forging-a-pat-iinn-20250710monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-in-high-level-government-talks-to-advance-national-integration-of-the-art100-and-e-iinn-20250707monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-secures-22-5-million-purchase-order-launches-full-revenue-execution-p-iinn-20250702monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-s-art100-in-use-at-tier-1-u-s-hospitals-generating-strong-clinical-interest-and-ac-iinn-20250611monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-scales-up-art100-production-capabilities-amid-advanced-negotiation-with-european-g-iinn-20250605monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-oxy-b-h-n-ltd-notice-of-extraordinary-general-meeting-of-shareholders-iinn-20250530monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-initiates-global-commercial-rollout-of-fda-cleared-art100-system-foll-iinn-20250529monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-aligns-executive-team-amid-corporate-structuring-initiatives-ra-anana-iinn-20250527monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-art100-system-approved-by-israel-s-largest-healthcare-provider-for-use-in-organ-tr-iinn-20250507monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-achieves-above-99-gas-exchange-efficiency-in-vortx-technology-in-vivo-animal-testi-iinn-20250423monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-generates-first-revenues-from-deployment-of-inspira-art100-systems-th-iinn-20250415monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-oxy-b-h-n-ltd-notice-of-extraordinary-general-meeting-of-shareholders-iinn-20250407monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-announces-successful-treatment-of-first-patient-with-inspira-art100-a-iinn-20250407monthly0.5https://www.biopharmawatch.com/news/IINN/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-iinn-20241227monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-oxy-b-h-n-ltd-notice-of-annual-general-meeting-of-shareholders-notice-iinn-20241125monthly0.5https://www.biopharmawatch.com/news/IINN/see-disclaimers-on-slides-1-16-copyright-2018-2024-inspira-technologies-oxy-b-h-n-ltd-all--iinn-20241112monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-oxy-b-h-n-ltd-interim-condensed-financial-statements-as-of-june-30-20-iinn-20240815monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-business-plan-targets-company-to-aggressively-promote-inspira-art100-in--iinn-20240620monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-art100-receives-fda-510-k-clearance-ra-anana-israel-iinn-20240528monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-oxy-b-h-n-ltd-notice-of-extraordinary-general-meeting-of-shareholders-iinn-20240308monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-oxy-b-h-n-ltd-notice-of-extraordinary-general-meeting-of-shareholders-iinn-20240304monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-oxy-b-h-n-ltd-notice-of-annual-general-meeting-of-shareholders-notice-iinn-20231122monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-oxy-b-h-n-ltd-interim-condensed-financial-statements-as-of-june-30-20-iinn-20231002monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-tm-announces-510-k-fda-submission-of-inspira-tm-art100-towards-commercialization-m-iinn-20230913monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-tm-art100-completes-usability-study-in-boston-massachusetts-u-s-ra-anana-israel-iinn-20230809monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-will-reveal-the-new-alice-tm-device-at-the-world-s-largest-extracorpo-iinn-20230516monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-is-developing-the-vortx-tm-blood-oxygenator-a-unique-technology-for-s-iinn-20230511monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-tm-technologies-announces-first-in-human-of-hyla-tm-blood-sensor-in-clinical-study-iinn-20230322monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-tm-technologies-receives-approval-from-sheba-medical-center-to-conduct-clinical-st-iinn-20230213monthly0.5https://www.biopharmawatch.com/news/IINN/copyright-2018-2023-inspira-technologies-oxy-b-h-n-ltd-all-rights-reserved-1-investor-pres-iinn-20230206monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-tm-technologies-granted-patent-by-u-s-patent-office-for-the-inspira-tm-art-system--iinn-20230123monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-tm-technologies-begins-manufacturing-of-the-alice-tm-cpb-device-ahead-of-planned-2-iinn-20221220monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-tm-technologies-signs-a-strategic-agreement-in-europe-to-potentially-provide-26-1--iinn-20221122monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-tm-technologies-granted-patent-by-the-israeli-patent-office-for-key-safety-compone-iinn-20221110monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-oxy-b-h-n-ltd-interim-condensed-financial-statements-as-of-june-30-20-iinn-20220929monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-oxy-b-h-n-ltd-notice-of-annual-and-extraordinary-general-meeting-of-s-iinn-20220908monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-tm-technologies-performed-hyla-tm-blood-sensor-in-vivo-study-in-preparation-of-pla-iinn-20220907monthly0.5https://www.biopharmawatch.com/news/IINN/copyright-2018-2022-inspira-technologies-oxy-b-h-n-ltd-all-rights-reserved-august-2022-inv-iinn-20220808monthly0.5https://www.biopharmawatch.com/news/IINN/revolutionizing-acute-respiratory-care-february-2022-copyright-2018-2022-inspira-technolog-iinn-20220201monthly0.5https://www.biopharmawatch.com/news/IINN/about-art-system-this-presentation-contains-express-or-implied-forward-looking-statements--iinn-20220106monthly0.5https://www.biopharmawatch.com/news/IINN/amended-articles-the-companies-law-1999-a-limited-liability-company-articles-of-associatio-iinn-20211220monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-oxy-b-h-n-ltd-notice-of-extraordinary-general-meeting-of-shareholders-iinn-20211112monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-oxy-b-h-n-ltd-interim-condensed-financial-statements-as-of-june-30-20-iinn-20211027monthly0.5https://www.biopharmawatch.com/news/IINN/revolutionizing-acute-respiratory-care-o-c-t-ob-er-2021-copyright-2018-2021-inspira-techno-iinn-20211012monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-oxy-b-h-n-ltd-iinn-iinnw-p-1-roprietary-inspira-technologies-oxy-b-h--iinn-20210913monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-delisting-from-nasdaq-philadelphia-pennsylvania-and-oxford-united-ki-adap-20251020monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-q2-financial-results-and-provides-business-update-q2-tecelra-sales-of--adap-20250813monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-entry-into-definitive-agreement-for-sale-of-tecelra-lete-cel-afami-c-adap-20250728monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-q1-financial-results-and-provides-business-update-tecelra-launch-2025--adap-20250513monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-provides-q4-and-full-year-2024-business-update-tecelra-launch-momentum-acceler-adap-20250320monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-changes-to-its-executive-leadership-team-based-in-the-uk-helen-tayto-adap-20241219monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-q3-2024-financial-and-business-updates-tecelra-launch-on-track-with-9--adap-20241113monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-s-lete-cel-achieves-primary-endpoint-in-pivotal-trial-42-of-people-with-advanc-adap-20241113monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-q2-2024-financial-and-business-updates-adaptimmune-received-u-s-fda-ac-adap-20240812monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-receives-u-s-fda-accelerated-approval-of-tecelra-afamitresgene-autoleucel-the--adap-20240801monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-and-galapagos-sign-clinical-collaboration-agreement-with-an-option-to-exclusiv-adap-20240530monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-q1-2024-financial-and-business-updates-afami-cel-commercial-and-regula-adap-20240515monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-secures-up-to-125-million-debt-financing-with-hercules-capital-first-tranche-o-adap-20240515monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-q4-full-year-2023-financial-results-and-business-updates-u-s-fda-accep-adap-20240306monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-hires-chief-commercial-officer-in-advance-of-q3-2024-pdufa-date-for-afami-cel--adap-20240227monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-u-s-fda-acceptance-of-biologics-license-application-for-afami-cel-fo-adap-20240131monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-projects-sarcoma-franchise-to-deliver-us-peak-year-sales-up-to-400-million-pre-adap-20240104monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-completes-submission-of-rolling-biologics-license-application-bla-to-u-s-fda-f-adap-20231206monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-third-quarter-financial-results-and-business-update-afami-cel-overall--adap-20231108monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-positive-data-with-lete-cel-1-from-an-interim-analysis-of-the-pivotal--adap-20231031monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-second-quarter-financial-results-and-business-update-substantial-progr-adap-20230809monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-completion-of-strategic-combination-with-tcr-sup2-therapeutics-creat-adap-20230601monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-first-quarter-financial-results-and-business-update-completed-submissi-adap-20230512monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-and-gsk-have-agreed-terms-for-transfer-of-prame-and-ny-eso-target-programs-bac-adap-20230411monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-fourth-quarter-and-full-year-financial-results-and-business-update-bla-adap-20230306monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-and-tcr-sup2-therapeutics-announce-strategic-combination-to-create-a-preeminen-adap-20230306monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-changes-to-board-of-directors-philadelphia-pennsylvania-and-oxford-u-adap-20230216monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-third-quarter-financial-results-and-business-update-adaptimmune-will-f-adap-20221108monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-increased-response-rate-and-durability-of-response-in-its-phase-1-surp-adap-20221108monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-positive-data-in-its-surpass-trial-outlines-plans-for-advanced-clinica-adap-20220909monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-second-quarter-financial-results-and-business-update-reaffirming-finan-adap-20220804monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-first-quarter-financial-results-and-business-update-pooled-data-from-c-adap-20220509monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-appointment-of-joanna-brewer-as-chief-scientific-officer-philadelphi-adap-20220504monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-fourth-quarter-and-full-year-2021-financial-results-and-business-updat-adap-20220314monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-appointment-of-cintia-piccina-as-chief-commercial-officer-philadelph-adap-20220126monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-positive-results-from-its-pivotal-spearhead-1-trial-in-patients-with-s-adap-20211112monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-third-quarter-financial-results-and-business-update-strategic-collabor-adap-20211104monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-clinical-responses-across-five-solid-tumor-indications-with-an-overa-adap-20210913monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-enters-into-a-strategic-collaboration-with-genentech-to-research-develop-and-c-adap-20210907monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-second-quarter-financial-results-and-business-update-spearhead-1-data--adap-20210809monthly0.5https://www.biopharmawatch.com/news/ADAP/two-complete-responses-and-response-rate-of-41-for-people-with-synovial-sarcoma-reported-a-adap-20210519monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-first-quarter-financial-results-and-business-update-initial-spearhead--adap-20210506monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-fourth-quarter-full-year-2020-financial-results-and-business-update-ou-adap-20210225monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-to-showcase-market-potential-for-spear-t-cell-portfolio-and-pipeline-with-mult-adap-20201120monthly0.5https://www.biopharmawatch.com/news/ADAP/durable-responses-with-adp-a2m4-in-synovial-sarcoma-with-confirmed-responses-in-44-of-pati-adap-20201119monthly0.5https://www.biopharmawatch.com/news/ADAP/two-confirmed-responses-and-five-out-of-six-patients-with-initial-tumor-reductions-from-ea-adap-20201109monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-q3-financial-results-and-business-update-data-from-phase-1-trial-with--adap-20201105monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-provides-full-contents-of-its-sitc-abstract-for-the-phase-1-surpass-trial-phil-adap-20201015monthly0.5https://www.biopharmawatch.com/news/ADAP/promising-data-from-phase-1-trial-with-adp-a2afp-in-liver-cancer-at-the-international-live-adap-20200828monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-q2-financial-results-and-business-update-reported-responses-in-multipl-adap-20200806monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-therapeutics-plc-proposes-public-offering-of-american-depositary-shares-philad-adap-20200601monthly0.5https://www.biopharmawatch.com/news/ADAP/spear-t-cells-targeting-mage-a4-demonstrate-new-responses-in-esophagogastric-junction-egj--adap-20200529monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-q1-financial-results-upfront-payment-of-50m-received-from-astellas-and-adap-20200514monthly0.5https://www.biopharmawatch.com/news/ADAP/spear-t-cells-derived-from-stem-cells-kill-cancer-targets-adaptimmune-presents-advances-fr-adap-20200512monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-to-report-q1-financial-results-on-thursday-adap-20200429monthly0.5https://www.biopharmawatch.com/news/ADAP/positive-opinion-for-orphan-drug-designation-for-adp-a2m4-for-the-treatment-of-soft-tissue-adap-20200428monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-fourth-quarter-full-year-2019-financial-results-and-business-update-co-adap-20200227monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-appointment-of-gavin-wood-as-chief-financial-officer-philadelphia-pa-adap-20200218monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-therapeutics-plc-announces-full-exercise-and-closing-of-underwriters-option-to-adap-20200207monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-therapeutics-plc-proposes-public-offering-of-american-depositary-shares-philad-adap-20200122monthly0.5https://www.biopharmawatch.com/news/ADAP/astellas-and-adaptimmune-enter-into-agreement-to-co-develop-and-co-commercialize-stem-cell-adap-20200114monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-appoints-elliot-norry-as-chief-medical-officer-and-makes-changes-to-r-d-leader-adap-20200113monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-that-spear-t-cell-platform-delivers-initial-responses-in-four-solid--adap-20200113monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-third-quarter-2019-financial-results-and-business-update-clinical-resp-adap-20191106monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-appointment-of-michael-garone-as-interim-chief-financial-officer-phi-adap-20191001monthly0.5https://www.biopharmawatch.com/news/ADAP/clear-benefit-for-patients-with-synovial-sarcoma-demonstrated-in-updated-data-from-ongoing-adap-20190930monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-and-noile-immune-announce-agreement-to-develop-spear-t-cell-products-expressin-adap-20190827monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-second-quarter-2019-financial-results-and-business-update-started-spea-adap-20190801monthly0.5https://www.biopharmawatch.com/news/ADAP/new-executive-team-announced-at-adaptimmune-adrian-rawcliffe-to-assume-ceo-role-from-adap-20190801monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-starts-spearhead-1-trial-with-adp-a2m4-spear-t-cells-for-patients-with-synovia-adap-20190725monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-has-initiated-a-radiation-sub-study-to-enhance-antitumor-activity-seen-with-ad-adap-20190722monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-starts-the-surpass-clinical-trial-with-its-first-next-generation-spear-t-cells-adap-20190718monthly0.5https://www.biopharmawatch.com/news/ADAP/adrian-rawcliffe-to-succeed-james-noble-as-adaptimmune-chief-executive-officer-james-noble-adap-20190627monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-and-alpine-immune-sciences-announce-collaboration-and-license-agreement-to-dev-adap-20190515monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-transforming-t-cell-therapy-clinical-and-business-update-disclaimer-this-prese-adap-20190506monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-first-quarter-2019-financial-results-clinical-update-issued-in-a-separ-adap-20190506monthly0.5https://www.biopharmawatch.com/news/ADAP/significant-clinical-progress-as-adaptimmune-announces-responses-with-adp-a2m4-in-synovial-adap-20190506monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-to-present-data-demonstrating-that-its-off-the-shelf-process-produces-t-cells--adap-20190502monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-presents-safety-data-with-evidence-of-tumor-necrosis-in-one-patient-from-adp-a-adap-20190402monthly0.5https://www.biopharmawatch.com/news/ADAP/source-adaptimmune-therapeutics-plc-adap-20190227monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-fourth-quarter-full-year-2018-financial-results-and-business-update-on-adap-20190227monthly0.5https://www.biopharmawatch.com/news/ADAP/dose-escalation-in-liver-cancer-study-with-adp-a2afp-afp-spear-t-cells-and-moving-to-expan-adap-20190107monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-that-gwen-binder-will-leave-in-january-2019-philadelphia-and-oxford--adap-20181212monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-third-quarter-2018-financial-results-and-business-update-progressed-to-adap-20181106monthly0.5https://www.biopharmawatch.com/news/ADAP/updated-data-from-ongoing-mage-a10-and-mage-a4-studies-presented-at-the-2018-esmo-congress-adap-20181020monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-therapeutics-plc-announces-closing-of-registered-direct-offering-of-american-d-adap-20180907monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-therapeutics-plc-announces-registered-direct-offering-of-american-depositary-s-adap-20180905monthly0.5https://www.biopharmawatch.com/news/ADAP/third-dosing-cohort-to-be-initiated-in-mage-a4-spear-t-cell-basket-study-after-favorable-r-adap-20180815monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-second-quarter-2018-financial-results-and-business-update-dosing-patie-adap-20180802monthly0.5https://www.biopharmawatch.com/news/ADAP/gsk-and-adaptimmune-complete-transition-of-ny-eso-spear-t-cell-therapy-program-to-gsk-lond-adap-20180724monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-favorable-review-of-safety-from-one-billion-cell-dose-cohort-in-mage-adap-20180718monthly0.5https://www.biopharmawatch.com/news/ADAP/july-2018-mr-john-furey-446-boxwood-road-bryn-mawr-pennsylvania-usa-dear-john-letter-of-ap-adap-20180706monthly0.5https://www.biopharmawatch.com/news/ADAP/updated-myxoid-round-cell-liposarcoma-data-with-ny-eso-presented-at-asco-annual-meeting-fu-adap-20180602monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-first-quarter-2018-financial-results-and-business-update-dosing-patien-adap-20180509monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-changes-to-board-of-directors-philadelphia-pa-and-oxford-u-k-adap-20180412monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-fourth-quarter-full-year-2017-financial-results-and-business-update-re-adap-20180315monthly0.5https://www.biopharmawatch.com/news/ADAP/building-an-integrated-spear-t-cell-company-january-2018-1-disclaimer-2-this-presentation--adap-20180108monthly0.5https://www.biopharmawatch.com/news/ADAP/exibhit-99-1-adaptimmune-announces-two-manufacturing-achievements-on-its-way-to-become-the-adap-20180108monthly0.5https://www.biopharmawatch.com/news/ADAP/ny-eso-data-presented-at-the-connective-tissue-oncology-society-ctos-annual-meeting-confir-adap-20171109monthly0.5https://www.biopharmawatch.com/news/ADAP/exhibi-t-99-1-adaptimmune-reports-third-quarter-2017-financial-results-and-business-update-adap-20171102monthly0.5https://www.biopharmawatch.com/news/ADAP/gsk-exercises-option-over-spear-t-cell-therapy-program-targeting-ny-eso-philadelphia-pa-an-adap-20170907monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-second-quarter-2017-financial-results-a-registered-direct-offering-in--adap-20170803monthly0.5https://www.biopharmawatch.com/news/ADAP/ny-eso-spear-t-cells-in-synovial-sarcoma-adap-20170606monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-an-oral-presentation-on-data-from-ny-eso-study-in-synovial-sarcoma-a-adap-20170605monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-an-oral-presentation-and-four-trials-in-progress-posters-at-the-amer-adap-20170526monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-initiation-of-study-to-evaluate-spear-t-cell-therapy-targeting-ny-es-adap-20170525monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-initiation-of-study-to-evaluate-spear-t-cell-therapy-targeting-mage--adap-20170516monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-first-quarter-2017-financial-results-offerings-in-march-and-april-rais-adap-20170510monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-therapeutics-plc-announces-closing-of-42-million-registered-direct-offering-ph-adap-20170410monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-therapeutics-plc-announces-registered-direct-offering-of-american-depositary-s-adap-20170405monthly0.5https://www.biopharmawatch.com/news/ADAP/march-2017-corporate-presentation-disclaimer-this-presentation-contains-forward-looking-st-adap-20170313monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-therapeutics-plc-proposes-public-offering-of-american-depositary-shares-philad-adap-20170321monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-broadens-executive-team-philadelphia-pa-and-oxford-uk-adap-20170315monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-fourth-quarter-and-full-year-2016-financial-results-opened-two-new-ind-adap-20170313monthly0.5https://www.biopharmawatch.com/news/ADAP/jp-morgan-january-2017-disclaimer-this-presentation-contains-forward-looking-statements-as-adap-20170109monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-fda-acceptance-of-ind-application-for-affinity-enhanced-t-cell-thera-adap-20170109monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-and-bellicum-pharmaceuticals-enter-a-strategic-collaboration-to-evaluate-next--adap-20161219monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-initiation-of-myxoid-round-cell-liposarcoma-study-philadelphia-pa-an-adap-20161205monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-presents-preclinical-data-from-a-new-wholly-owned-spear-t-cell-and-a-second-ge-adap-20161111monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-third-quarter-2016-financial-results-u-s-food-and-drug-administration--adap-20161110monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-removal-of-partial-clinical-hold-in-myxoid-round-cell-liposarcoma-mr-adap-20161109monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-appointment-of-tal-zaks-to-board-of-directors-philadelphia-pa-and-ox-adap-20161108monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-board-changes-philadelphia-pa-and-oxford-united-kingdom-adap-20161027monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-collaboration-with-msd-to-evaluate-keytruda-pembrolizumab-in-combina-adap-20161027monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-initiation-of-triple-tumor-study-to-evaluate-its-spear-t-cell-therap-adap-20161018monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-provides-update-on-study-of-ny-eso-spear-t-cell-therapy-in-synovial-sarcoma-at-adap-20161009monthly0.5https://www.biopharmawatch.com/news/ADAP/md-anderson-cancer-center-and-adaptimmune-form-strategic-alliance-to-advance-development-o-adap-20160926monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-strategic-manufacturing-agreement-with-pct-to-support-development-of-adap-20160919monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-second-quarter-2016-financial-results-conference-call-to-be-held-today-adap-20160808monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-partial-clinical-hold-of-planned-pivotal-study-of-ny-eso-spear-t-cel-adap-20160803monthly0.5https://www.biopharmawatch.com/news/ADAP/private-and-confidential-23-may-2016-ms-barbara-duncan-62-lakeshore-drive-eastchester-new--adap-20160623monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-commercial-development-and-supply-agreement-for-thermo-fisher-scient-adap-20160621monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-receives-positive-opinion-for-orphan-drug-designation-in-the-european-union-fo-adap-20160620monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-data-from-clinical-studies-of-ny-eso-1-spear-t-cells-in-multiple-can-adap-20160605monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-strengthens-board-with-appointment-of-barbara-duncan-philadelphia-pa-and-oxfor-adap-20160524monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-first-quarter-2016-financial-results-philadelphia-pa-and-oxford-united-adap-20160512monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-therapeutics-plc-the-company-incorporated-and-registered-in-england-and-wales--adap-20160429monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-presents-corporate-and-clinical-updates-at-investor-and-analyst-day-philadelph-adap-20160422monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-investor-and-analyst-day-2016-adap-20160422monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-fda-acceptance-of-ind-application-for-affinity-enhanced-t-cell-thera-adap-20160407monthly0.5https://www.biopharmawatch.com/news/ADAP/u-s-food-and-drug-administration-grants-orphan-drug-designation-to-adaptimmune-s-t-cell-th-adap-20160330monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-financial-results-for-the-six-month-period-ended-adap-20160317monthly0.5https://www.biopharmawatch.com/news/ADAP/u-s-food-and-drug-administration-grants-breakthrough-therapy-designation-for-adaptimmune-s-adap-20160209monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-and-gsk-expand-strategic-immunotherapy-collaboration-agreement-accelerates-dev-adap-20160202monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-expands-t-cell-engineering-expertise-to-develop-affinity-enhanced-t-cell-thera-adap-20160107monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-initiation-of-study-to-evaluate-its-new-affinity-enhanced-t-cell-the-adap-20151217monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-transforming-t-cell-therapy-presentation-materials-december-2015-disclaimer-th-adap-20151215monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-and-universal-cells-announce-collaboration-to-develop-allogeneic-t-cell-therap-adap-20151201monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-initiates-phase-i-ii-trial-evaluating-its-affinity-enhanced-t-cell-therapy-tar-adap-20151124monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-engineered-tcr-t-cell-therapy-presentation-materials-november-2015-disclaimer--adap-20151118monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-first-quarter-financial-results-for-fiscal-year-2015-16-philadelphia-p-adap-20151113monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-therapeutics-plc-the-company-incorporated-and-registered-in-england-and-wales--adap-20151112monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-data-from-clinical-study-of-ny-eso-affinity-enhanced-t-cell-therapy--adap-20151105monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-to-participate-in-the-2015-bio-investor-forum-philadelphia-pa-and-oxford-unite-adap-20151016monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-reports-full-fiscal-year-2015-financial-results-conference-call-to-be-held-tod-adap-20151013monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-new-research-and-development-facility-in-oxfordshire-enterprise-zone-adap-20151006monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-to-participate-in-two-upcoming-investor-conferences-philadelphia-pa-and-oxford-adap-20150914monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-expansion-of-senior-team-to-augment-clinical-expertise-and-support-g-adap-20150909monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-expands-trial-of-t-cell-therapy-for-synovial-sarcoma-and-achieves-clinical-mil-adap-20150901monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-s-ny-eso-1-tcr-engineered-t-cells-demonstrate-durable-persistence-clinical-act-adap-20150720monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-fda-acceptance-of-investigational-new-drug-ind-application-for-mage--adap-20150702monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-data-from-clinical-studies-of-ny-eso-1-specific-t-cells-in-multiple--adap-20150601monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-new-additions-to-senior-clinical-management-oxford-uk-and-philadelph-adap-20150520monthly0.5https://www.biopharmawatch.com/news/ADAP/adaptimmune-announces-appointment-of-new-vice-president-of-investor-relations-oxford-uk-an-adap-20150512monthly0.5https://www.biopharmawatch.com/news/CHEK/mbody-ai-corp-inc-index-to-financial-statements-table-of-contents-page-report-of-independe-chek-20260512monthly0.5https://www.biopharmawatch.com/news/CHEK/mbody-ai-corp-expands-fortune-500-deployment-advancing-national-robotics-rollout-proven-pi-chek-20260326monthly0.5https://www.biopharmawatch.com/news/CHEK/mbody-ai-and-check-cap-ltd-mbai-submit-nasdaq-listing-application-for-merger-close-propose-chek-20260224monthly0.5https://www.biopharmawatch.com/news/CHEK/mbody-ai-corp-inc-index-to-financial-statements-table-of-contents-page-report-of-independe-chek-20260130monthly0.5https://www.biopharmawatch.com/news/CHEK/check-cap-clears-key-nasdaq-requirement-advancing-mbody-ai-merger-toward-completion-milest-chek-20260126monthly0.5https://www.biopharmawatch.com/news/CHEK/consolidated-unaudited-financial-statements-of-check-cap-ltd-a-s-of-and-for-the-six-months-chek-20251230monthly0.5https://www.biopharmawatch.com/news/CHEK/mbody-ai-to-begin-trading-under-new-nasdaq-ticker-symbol-mbai-mbai-ticker-change-for-check-chek-20251201monthly0.5https://www.biopharmawatch.com/news/CHEK/mbody-ai-chek-secures-98-shareholder-approval-to-become-leading-nasdaq-embodied-ai-company-chek-20251117monthly0.5https://www.biopharmawatch.com/news/CHEK/check-cap-ltd-check-cap-building-29-abba-hushi-avenue-p-o-box-1271-isfiya-3009000-israel-n-chek-20250912monthly0.5https://www.biopharmawatch.com/news/CHEK/check-cap-ltd-consolidated-unaudited-balance-sheets-u-s-dollars-in-thousands-except-share--chek-20241231monthly0.5https://www.biopharmawatch.com/news/CHEK/check-cap-ltd-check-cap-building-29-abba-hushi-avenue-p-o-box-1271-isfiya-3009000-israel-a-chek-20240415monthly0.5https://www.biopharmawatch.com/news/CHEK/check-cap-ltd-check-cap-building-29-abba-hushi-avenue-p-o-box-1271-isfiya-3009000-israel-a-chek-20240320monthly0.5https://www.biopharmawatch.com/news/CHEK/business-combination-agreement-between-nobul-ai-corp-and-check-cap-ltd-dated-as-of-march-2-chek-20240325monthly0.5https://www.biopharmawatch.com/news/CHEK/proxy-statement-extraordinary-general-meeting-of-shareholders-this-proxy-statement-is-furn-chek-20240328monthly0.5https://www.biopharmawatch.com/news/CHEK/graham-schmidt-chek-20240122monthly0.5https://www.biopharmawatch.com/news/CYCC/e-xhibit-99-1-bio-green-med-solution-inc-announces-business-combination-agreement-to-acqui-cycc-20260604monthly0.5https://www.biopharmawatch.com/news/CYCC/bio-green-med-solution-inc-bio-green-med-solution-reports-first-quarter-financial-results--cycc-20260514monthly0.5https://www.biopharmawatch.com/news/CYCC/bio-green-med-solution-inc-bio-green-med-solution-reports-fourth-quarter-and-full-year-202-cycc-20260330monthly0.5https://www.biopharmawatch.com/news/CYCC/bio-green-med-solution-reports-third-quarter-financial-results-and-provides-business-updat-cycc-20251113monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-financial-res-cycc-20250813monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-comments-on-recent-stock-price-volat-cycc-20250716monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-amendment-to-exchange-agre-cycc-20250707monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-cycc-20250702monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-announces-3-cycc-20250620monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-reports-first-quarter-financial-results-and-provides-business-upd-cycc-20250514monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-cycc-20250507monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-announces-execution-of-share-exchange-agreement-to-make-fitte-cycc-20250506monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-financial-res-cycc-20250402monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-announces-1-cycc-20250324monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-announces-closing-of-a-cycc-20250227monthly0.5https://www.biopharmawatch.com/news/CYCC/investors-cyclacel-pharmaceuticals-announces-agreement-for-the-acquisition-of-preferred-st-cycc-20250103monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-closing-of-exercise-of-war-cycc-20241114monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-third-quarter-financial-resu-cycc-20241112monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-t-hat-cycc-20241024monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-financial-res-cycc-20240814monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-first-quarter-financial-resu-cycc-20240514monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-8-0-million-private-placem-cycc-20240430monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-and-p-cycc-20240319monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cycc-biotech-showcase-january-2024-translating-cancer-biology-cycc-20240109monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-announces-registered-direct-and-private-placement-offering-priced-cycc-20231222monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-third-quarter-financial-resu-cycc-20231113monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-financial-res-cycc-20230809monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-first-quarter-financial-resu-cycc-20230511monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-cycc-20230306monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-third-quarter-2022-financial-cycc-20221109monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-reports-second-quarter-2022-financial-results-and-provides-busine-cycc-20220810monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyc-lacel-pharmaceuticals-reports-first-quarter-2022-financia-cycc-20220511monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-cycc-20220328monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-third-quarter-2021-financial-cycc-20211110monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-2021-financia-cycc-20210811monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-first-quarter-2021-financial-cycc-20210512monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-prices-12-65-million-underwritten-pu-cycc-20210312monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-cycc-20210225monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-at-the-market-7-million-st-cycc-20201222monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-third-quarter-2020-financial-cycc-20201111monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-appointment-of-mark-kirsch-cycc-20201023monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-2020-financia-cycc-20200812monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-first-quarter-2020-financial-cycc-20200512monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-announces-pricing-of-20-million-public-offering-berk-cycc-20200421monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-collaboration-with-the-uni-cycc-20200420monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-cycc-20200226monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-third-quarter-2019-financial-cycc-20191113monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-2019-financia-cycc-20190813monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-first-quarter-2019-financial-cycc-20190514monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-cycc-20190327monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-reports-third-quarter-2018-financial-results-conference-call-sche-cycc-20181112monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-and-md-anderson-cancer-center-announ-cycc-20181004monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-appoints-robert-j-spiegel-m-d-to-boa-cycc-20180912monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-2018-financia-cycc-20180809monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-first-quarter-2018-financial-cycc-20180514monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-cycc-20180328monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-announces-presentation-of-results-from-phase-3-seaml-cycc-20171212monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-reports-third-quarter-2017-financial-results-conference-call-sche-cycc-20171109monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-2017-financia-cycc-20170809monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-announces-selection-of-recommended-phase-2-dose-for--cycc-20170807monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-announces-closing-of-15-2-million-underwritten-publi-cycc-20170721monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-announces-pricing-of-13-2-million-underwritten-publi-cycc-20170719monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-first-quarter-2017-financial-cycc-20170511monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-cycc-20170328monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-announces-top-line-results-from-pivotal-phase-3-seam-cycc-20170223monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-3-rd-quarter-2016-financial--cycc-20161114monthly0.5https://www.biopharmawatch.com/news/CYCC/reports-2nd-quarter-2016-financial-results-cycc-20160810monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-announces-reverse-stock-split-berkeley-heights-nj-cycc-20160527monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-first-quarter-2016-financial-cycc-20160511monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-announces-receipt-of-nasdaq-extension-berkeley-heigh-cycc-20160411monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-reports-fourth-cycc-20160324monthly0.5https://www.biopharmawatch.com/news/CYCC/announces-receipt-of-nasdaq-staff-determination-cycc-20160205monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-third-quarter-2015-financial-cycc-20151112monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-2015-financia-cycc-20150811monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-reports-first-quarter-2015-financial-results-approximately-20-of--cycc-20150512monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-cycc-20150324monthly0.5https://www.biopharmawatch.com/news/CYCC/announces-proposed-public-offering-of-common-stock-cycc-20150304monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-announces-enrollment-of-486-patients-dsmb-recommenda-cycc-20141216monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-third-quarter-2014-financial-cycc-20141111monthly0.5https://www.biopharmawatch.com/news/CYCC/cell-cycle-to-treat-aml-and-mds-cycc-20140926monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-appoints-samuel-l-barker-ph-d-to-boa-cycc-20140911monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-second-quarter-2014-financia-cycc-20140812monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-p-r-e-s-s-r-e-l-e-a-s-e-cyclacel-pharmaceuticals-reports-firs-cycc-20140513monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-proposed-public-offering-o-cycc-20140403monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-cycc-20140325monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-reports-third-quarter-2013-financial-results-confere-cycc-20131112monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-reports-second-quarter-2013-financial-results-confer-cycc-20130814monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-closing-of-underwritten-of-cycc-20130521monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-announces-proposed-public-offering-o-cycc-20130515monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-reports-first-quarter-2013-financial-results-confere-cycc-20130513monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-announces-sale-of-four-cyclacel-romidepsin-related-p-cycc-20130404monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-cycc-20130327monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-enters-into-a-20-million-common-stock-purchase-agree-cycc-20121217monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-reports-third-quarter-2012-financial-results-enrollm-cycc-20121112monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-regains-compliance-with-nasdaq-minimum-bid-price-lis-cycc-20120913monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-announces-reverse-stock-split-stock-will-begin-tradi-cycc-20120827monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-reports-second-quarter-2012-financial-results-confer-cycc-20120814monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-important-cycc-20120514monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-reports-first-quarter-2012-financial-results-confere-cycc-20120514monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-cycc-20120329monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-announces-3-0-million-financing-to-fund-ongoing-liti-cycc-20120322monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-press-release-cyclacel-pharmaceuticals-reports-third-quarter--cycc-20111114monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-receives-deficiency-notice-from-nasd-cycc-20110922monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-press-release-cyclacel-pharmaceuticals-reports-second-quarter-cycc-20110811monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-announces-pricing-of-underwritten-offering-of-common-stock-an-cycc-20110701monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-financial-results-for-first--cycc-20110512monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-cycc-20110323monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-begins-pivotal-phase-3-seamless-trial-of-sapacitabine-as-front-line-treatment-for-cycc-20110113monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-announces-topline-results-from-the-appraise-phase-2b-study-of-seliciclib-in-heavi-cycc-20101221monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-pharmaceuticals-reports-third-quarter-2010-cycc-20101111monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cycc-20101006monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-cycc-20101007monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-announces-private-placement-financing-for-up-to-22-1-million-proceeds-to-advance--cycc-20101005monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-reaches-agreement-with-fda-on-a-special-protocol-assessment-for-p-cycc-20100913monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-6-cycc-20100813monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-press-release-cyclacel-pharmaceuticals-reports-second-quarter-cycc-20100805monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-p-r-e-s-s-r-e-l-e-a-s-e-cyclacel-pharmaceuticals-reports-fina-cycc-20100513monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-2009-financial-results-confe-cycc-20100323monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-regains-nasdaq-compliance-berkeley-heights-nj-cycc-20100127monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-cyclacel-completes-previously-announced-registered-direct-off-cycc-20100125monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-to-raise-up-to-7-9-million-in-registered-direct-offering-berkeley-heights-nj-cycc-20100121monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-p-r-e-s-s-r-e-l-e-a-s-e-cyclacel-completes-previously-announc-cycc-20100113monthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-inc-press-release-cyclacel-to-raise-up-to-9-5-million-in-register-cycc-20100111monthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-corp-condensed-consolidated-statement-of-operations-and-comprehensive--tsbx-20250509monthly0.5https://www.biopharmawatch.com/news/TSBX/this-presentation-and-any-accompanying-oral-commentary-have-been-prepared-by-turnstone-bio-tsbx-20240305monthly0.5https://www.biopharmawatch.com/news/CHRO/legal-disclaimer-this-presentation-of-pelthos-therapeutics-inc-we-us-our-or-the-company-co-chro-20260528monthly0.5https://www.biopharmawatch.com/news/CHRO/pelthos-therapeutics-secures-up-to-50-million-senior-secured-term-loan-facility-from-horiz-chro-20260113monthly0.5https://www.biopharmawatch.com/news/CHRO/corporate-presentation-q1-2026-2-legal-disclaimer-this-presentation-of-pelthos-therapeutic-chro-20260112monthly0.5https://www.biopharmawatch.com/news/CHRO/pelthos-therapeutics-acquires-xeglyze-abametapir-topical-treatment-for-head-lice-acquisiti-chro-20260105monthly0.5https://www.biopharmawatch.com/news/CHRO/pelthos-therapeutics-expands-board-of-directors-with-the-appointment-of-andrew-einhorn-sea-chro-20251223monthly0.5https://www.biopharmawatch.com/news/CHRO/pelthos-therapeutics-announces-third-quarter-fiscal-2025-financial-results-conference-call-chro-20251113monthly0.5https://www.biopharmawatch.com/news/CHRO/pelthos-therapeutics-acquires-xepi-ozenoxacin-cream-1-and-announces-18-million-private-con-chro-20251107monthly0.5https://www.biopharmawatch.com/news/CHRO/corporate-presentation-q-4-2-02-5-1-legal-disclaimer-this-presentation-of-pelthos-therapeu-chro-20251014monthly0.5https://www.biopharmawatch.com/news/CHRO/lnhc-inc-condensed-balance-sheets-in-thousands-unaudited-chro-20250916monthly0.5https://www.biopharmawatch.com/news/CHRO/q-3-2-0-2-5-1-legal-disclaimer-this-presentation-of-pelthos-therapeutics-inc-we-us-our-or--chro-20250903monthly0.5https://www.biopharmawatch.com/news/CHRO/pelthos-therapeutics-reports-second-quarter-2025-financial-results-for-legacy-operations-a-chro-20250818monthly0.5https://www.biopharmawatch.com/news/CHRO/channel-therapeutics-announces-reverse-common-stock-split-in-conjunction-with-the-close-of-chro-20250627monthly0.5https://www.biopharmawatch.com/news/CHRO/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-ameri-chro-20250501monthly0.5https://www.biopharmawatch.com/news/CHRO/ot-pelthos-therapeuties-corporate-corporate-presentation-presentation-q-2-2-0-2-5-so-nsd-n-chro-20250417monthly0.5https://www.biopharmawatch.com/news/CHRO/chromocell-announces-name-change-to-channel-therapeutics-corporation-and-provides-therapeu-chro-20241121monthly0.5https://www.biopharmawatch.com/news/CHRO/chromocell-announces-stock-repurchase-plan-freehold-n-j-chro-20241024monthly0.5https://www.biopharmawatch.com/news/CHRO/chromocell-announces-stock-repurchase-plan-freehold-n-j-chro-20240807monthly0.5https://www.biopharmawatch.com/news/CHRO/chromocell-therapeutics-corporation-1-chromocell-therapeutics-corporation-potential-breakt-chro-20240729monthly0.5https://www.biopharmawatch.com/news/CHRO/chromocell-issues-letter-to-stockholders-from-chief-executive-officer-freehold-n-j-chro-20240409monthly0.5https://www.biopharmawatch.com/news/CHRO/chromocell-announces-formal-launch-of-eye-pain-treatment-program-and-hiring-of-dr-simon-ch-chro-20240321monthly0.5https://www.biopharmawatch.com/news/CHRO/chromocell-names-frank-knuettel-as-chief-executive-officer-removing-interim-status-held-si-chro-20240318monthly0.5https://www.biopharmawatch.com/news/CHRO/chromocell-therapeutics-corporation-1-chromocell-therapeutics-corporation-potential-breakt-chro-20240313monthly0.5https://www.biopharmawatch.com/news/CHRO/chromocell-therapeutics-announces-pricing-of-upsized-6-6-initial-public-offering-freehold--chro-20240216monthly0.5https://www.biopharmawatch.com/news/ORGS/orgenesis-secures-up-to-5-million-equity-investment-from-williamsburg-venture-holdings-fun-orgs-20250128monthly0.5https://www.biopharmawatch.com/news/ORGS/orgenesis-announces-reverse-stock-split-germantown-md-orgs-20240923monthly0.5https://www.biopharmawatch.com/news/ORGS/orgenesis-inc-announces-2-3-million-private-placement-germantown-md-orgs-20240304monthly0.5https://www.biopharmawatch.com/news/ORGS/orgenesis-inc-announces-pricing-of-1-1-million-registered-direct-offering-germantown-maryl-orgs-20231108monthly0.5https://www.biopharmawatch.com/news/ORGS/orgenesis-announces-withdrawal-of-proposed-public-offering-germantown-maryland-orgs-20231030monthly0.5https://www.biopharmawatch.com/news/ORGS/orgenesis-inc-announces-pricing-of-3-7-million-registered-direct-offering-germantown-md-orgs-20230223monthly0.5https://www.biopharmawatch.com/news/ORGS/orgenesis-inc-announces-14-8-million-private-placement-germantown-md-orgs-20220331monthly0.5https://www.biopharmawatch.com/news/ORGS/orgenesis-reports-revenue-growth-of-364-for-2021-and-provides-business-update-orgenesis-to-orgs-20220330monthly0.5https://www.biopharmawatch.com/news/ORGS/transcript-of-video-at-https-www-youtube-com-watch-v-vsou4uojhms-orgenesis-is-a-global-bio-orgs-20211015monthly0.5https://www.biopharmawatch.com/news/ORGS/orgenesis-provides-fiscal-2020-year-end-results-and-corporate-update-expands-pocare-therap-orgs-20210309monthly0.5https://www.biopharmawatch.com/news/ORGS/the-information-provided-in-each-item-contained-in-this-exhibit-is-presented-only-in-conne-orgs-20201116monthly0.5https://www.biopharmawatch.com/news/ORGS/orgenesis-announces-agreement-to-acquire-koligo-therapeutics-a-leader-in-personalized-cell-orgs-20200929monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-orgs-20200506monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-orgs-20200121monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-orgenesis-first-quarter-2019-revenue-increases-177-to-a-record-7-orgs-20190509monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-orgs-20181029monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-orgs-20180720monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-orgenesis-reports-73-increase-in-revenue-for-the-second-quarter--orgs-20180717monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-orgenesis-announces-a-strategic-corporate-regrouping-of-its-cdmo-orgs-20180124monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-orgs-20180109monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-for-immediate-release-orgs-20171116monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-for-immediate-release-orgenesis-provides-update-regarding-aip-ce-orgs-20170308monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-for-immediate-release-orgenesis-approved-for-euro-12-3-million-e-orgs-20170213monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-for-immediate-release-orgenesis-to-collaborate-with-the-global-s-orgs-20150407monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-for-immediate-release-orgenesis-appoints-itamar-raz-as-newest-me-orgs-20150316monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-for-immediate-release-orgenesis-approved-for-2-015-000-euros-gra-orgs-20141124monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-for-immediate-release-orgenesis-receives-patent-for-potential-cu-orgs-20141014monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-scott-carmer-named-as-ceo-of-orgenesis-north-america-germantown--orgs-20140804monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-orgenesis-signs-agreement-with-masthercell-to-scale-manufacturin-orgs-20140707monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-consent-resolution-of-the-board-of-directors-of-orgenesis-inc-th-orgs-20131223monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-news-release-for-immediate-release-orgenesis-announces-managemen-orgs-20130107monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-news-release-for-immediate-release-orgenesis-appoints-leading-di-orgs-20121127monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-o-rgenesis-i-nc-g-lobal-s-hare-i-ncentive-p-lan-2012-1-name-and--orgs-20120531monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-orgenesis-inc-appoints-ex-fda-officer-and-diabetes-authority-to--orgs-20120531monthly0.5https://www.biopharmawatch.com/news/ORGS/filed-by-newsfilecorp-com-orgenesis-inc-enters-into-agreement-to-commence-advanced-studies-orgs-20120411monthly0.5https://www.biopharmawatch.com/news/ORGS/business-outsources-services-inc-announces-letter-of-intent-to-negotiate-autologous-insuli-orgs-20110808monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-advances-plan-to-re-list-natick-mass-x2013-alur-20260617monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-advances-plan-to-regain-listing-compliance-files-appeal-to-nyse-on-decision-to-in-alur-20260312monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-receives-u-s-fda-approval-for-the-allurion-gastric-balloon-system-featuring-the-a-alur-20260223monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-reports-third-quarter-2025-financial-results-and-provides-business-update-alur-20251112monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-reports-second-quarter-2025-financial-results-and-provides-business-update-natick-alur-20250813monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-announces-new-strategic-direction-with-increasing-focus-on-low-dose-glp-1-combina-alur-20250805monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-reports-first-quarter-2025-financial-results-and-provides-business-update-natick--alur-20250514monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-announces-postponement-of-special-meeting-of-stockholders-meeting-to-now-be-held--alur-20250403monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business-alur-20250326monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-to-raise-approximately-6-1-million-of-gross-proceeds-in-offering-and-concurrent-p-alur-20250219monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-relaunches-in-france-ansm-the-french-regulatory-authority-clears-allurion-to-resu-alur-20250213monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-to-raise-approximately-7-4-million-of-gross-proceeds-in-offering-priced-at-the-ma-alur-20250124monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-announces-private-placement-of-common-stock-and-preliminary-unaudited-financial-r-alur-20250114monthly0.5https://www.biopharmawatch.com/news/ALUR/index-to-financial-statements-allurion-technologies-inc-and-subsidiaries-page-audited-cons-alur-20250108monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-technologies-inc-announces-reverse-stock-split-alur-20241224monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-reports-third-quarter-2024-financial-results-and-provides-business-update-natick--alur-20241113monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-receives-continued-listing-standards-notice-from-nyse-alur-20240905monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-announces-the-appointment-of-eli-lilly-veteran-keith-johns-to-its-board-of-direct-alur-20240903monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-receives-continued-listing-standards-notice-from-nyse-alur-20240815monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-reports-second-quarter-2024-financial-results-and-provides-business-update-result-alur-20240813monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-announces-pricing-of-20-million-public-offering-and-concurrent-private-placement-alur-20240628monthly0.5https://www.biopharmawatch.com/news/ALUR/investor-presentation-1-disclaimer-this-presentation-the-information-contained-herein-and--alur-20240626monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-reports-first-quarter-2024-financial-results-and-provides-business-update-alur-20240514monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-announces-preliminary-first-quarter-2024-results-generated-quarter-over-quarter-r-alur-20240430monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-closes-48-million-convertible-senior-secured-note-financing-with-rtw-investments--alur-20240417monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-reports-fourth-quarter-and-full-year-2023-financial-results-and-reiterates-2024-g-alur-20240321monthly0.5https://www.biopharmawatch.com/news/ALUR/milena-alberti-perez-joins-allurion-board-of-directors-as-audit-committee-chair-natick-ma--alur-20240312monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-announces-preliminary-fourth-quarter-and-full-year-2023-results-and-provides-2024-alur-20231231monthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-reports-third-quarter-2023-financial-results-and-provides-business-update-complet-alur-20231113monthly0.5https://www.biopharmawatch.com/news/ALUR/unaudited-pro-forma-condensed-combined-financial-information-the-following-unaudited-pro-f-alur-20230807monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-nasdaq-delisting-and-transition-to-bcli-20250717monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-nasdaq-bcli-2-safe-harbor-statement-statements-in-this-announ-bcli-20241001monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-in-person-meeting-with-the-fda-to-discuss-confirmat-bcli-20231120monthly0.5https://www.biopharmawatch.com/news/BCLI/b-rainstorm-cell-therapeutics-announces-first-quarter-2023-financial-results-and-provides--bcli-20230515monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-presents-new-biomarker-analyses-from-nurown-s-phase-3-als-trial-at-the-als-one--bcli-20221007monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-second-quarter-2022-financial-results-and-provides--bcli-20220815monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-first-quarter-2022-financial-results-and-provides-a-bcli-20220516monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-full-year-2021-financial-results-and-provides-a-cor-bcli-20220328monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-third-quarter-2021-financial-results-and-provides-a-bcli-20220128monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-appointment-of-menghis-bairu-md-to-board-of-directo-bcli-20211028monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-full-year-2020-financial-results-and-provides-a-corporate-update-comp-bcli-20210204monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-financial-results-for-the-third-quarter-of-2020-and-provides-a-corpor-bcli-20201015monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-nurown-data-to-be-highlighted-at-the-27th-international-symposium-on--bcli-20161205monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-reports-second-quarter-2015-financial-results-and-provides-co-bcli-20150813monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-strengthens-executive-team-announces-the-appointment-of-yoram-bibring-as-chief--bcli-20150803monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-raises-10-5-million-in-private-placement-financing-new-york-n-bcli-20140613monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-expands-pipeline-with-initiation-of-pre-clinical-study-in-autism-new-york-bcli-20140610monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-appoints-tony-fiorino-md-phd-as-chief-executive-officer-new-y-bcli-20140609monthly0.5https://www.biopharmawatch.com/news/BCLI/first-patient-enrolled-in-brainstorm-s-phase-ii-als-trial-at-massachusetts-general-hospita-bcli-20140606monthly0.5https://www.biopharmawatch.com/news/BCLI/positive-interim-phase-iia-als-data-with-brainstorm-s-nurown-presented-at-joint-congress-o-bcli-20140602monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-redemption-of-outstanding-warrants-for-cash-new-york-bcli-20140529monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-exchange-of-outstanding-warrants-new-york-bcli-20140425monthly0.5https://www.biopharmawatch.com/news/BCLI/preliminary-findings-of-brainstorm-s-phase-iia-study-reported-as-extremely-optimistic-new--bcli-20131210monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-pricing-of-underwritten-public-offering-new-york-ny-bcli-20130813monthly0.5https://www.biopharmawatch.com/news/BCLI/phase-ii-als-clinical-trial-with-brainstorm-cell-therapeutics-nurown-to-be-expanded-to-a-t-bcli-20130318monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-s-clinical-trial-is-fast-tracked-to-phase-iia-representing-a-major-milestone-fo-bcli-20130107monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-and-octane-to-develop-revolutionary-bioreactor-based-nurown-stem-cells-producti-bcli-20121217monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-receives-3-million-nis-grant-from-israel-s-office-of-the-chief-scientist-ticker-bcli-20121212monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-reports-outstanding-als-interim-clinical-trial-results-new-york-petach-tikva-is-bcli-20120723monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-pricing-of-public-offering-of-common-stock-and-warrants-new-york-peta-bcli-20120717monthly0.5https://www.biopharmawatch.com/news/BCLI/israeli-channel-2-reports-dramatic-change-in-patient-with-als-and-mg-following-compassiona-bcli-20120703monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-receives-1-3-million-nis-grant-from-israel-s-office-of-the-chief-scientist-dr-a-bcli-20120614monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-clinical-data-supporting-safety-and-efficacy-of-nurown-based-on-initi-bcli-20120117monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-signs-mou-for-collaboration-with-massachusetts-general-hospital-and-university--bcli-20110720monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-intends-to-adjourn-annual-meeting-of-stockholders-until-bcli-20110602monthly0.5https://www.biopharmawatch.com/news/BCLI/ministry-of-health-approves-brainstorm-s-nurown-for-the-first-clinical-trial-of-adult-stem-bcli-20110517monthly0.5https://www.biopharmawatch.com/news/BCLI/unassociated-document-brainstorm-cell-therapeutics-raises-3-6-million-from-institutional-a-bcli-20110228monthly0.5https://www.biopharmawatch.com/news/BCLI/unassociated-document-brainstorm-receives-approval-to-begin-clinical-trial-of-adult-stem-c-bcli-20101011monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-webcast-script-moderator-thank-you-all-for-joining-us-and-listening-to-brainsto-bcli-20091224monthly0.5https://www.biopharmawatch.com/news/BCLI/rami-efrati-former-vp-business-development-and-marketing-for-nice-systems-government-divis-bcli-20071012monthly0.5https://www.biopharmawatch.com/news/BCLI/healthcare-industry-leader-dr-jonathan-c-javitt-joins-brainstorm-cell-therapeutics-board-o-bcli-20070827monthly0.5https://www.biopharmawatch.com/news/BCLI/brai-nstorm-cell-therapeutics-elects-moshe-lion-to-its-board-of-directors-new-york-bcli-20070716monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-enters-into-agreement-for-up-to-5-million-equity-financing-ch-bcli-20070703monthly0.5https://www.biopharmawatch.com/news/BCLI/ex-10-1-2-v063104-ex99-1-htm-v063104-ex99-1-converted-by-secpublisher-2-1-1-8-created-by-b-bcli-20070123monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-shareholders-extend-lock-up-agreement-new-york-tel-aviv-israel-business-wire-bcli-20060329monthly0.5https://www.biopharmawatch.com/news/BCLI/v015753-ex99-1-txt-for-immediate-release-brainstorm-cell-therapeutics-appoints-dr-robert-s-bcli-20050331monthly0.5https://www.biopharmawatch.com/news/BCLI/v014747-ex99-1-txt-for-immediate-release-majority-of-brainstorm-shareholders-reaffirm-thei-bcli-20050322monthly0.5https://www.biopharmawatch.com/news/BCLI/v013639-ex99-1-txt-for-immediate-release-brainstorm-completes-1-5-million-private-placemen-bcli-20050301monthly0.5https://www.biopharmawatch.com/news/BCLI/v011465-ex99-1-txt-press-contact-belinda-banks-s-s-public-relations-212-946-2823-belinda-s-bcli-20050120monthly0.5https://www.biopharmawatch.com/news/BCLI/v09654-ex99-1-txt-press-contact-belinda-banks-s-s-public-relations-212-946-2823-belinda-ss-bcli-20041207monthly0.5https://www.biopharmawatch.com/news/BCLI/v08242-ex99-1-txt-press-contact-belinda-banks-s-s-public-relations-212-946-2823-belinda-ss-bcli-20041109monthly0.5https://www.biopharmawatch.com/news/GRTX/obsidian-therapeutics-and-galera-therapeutics-announce-merger-agreement-and-350-million-co-grtx-20260414monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-therapeutics-completes-acquisition-of-nova-pharmaceuticals-grtx-20241231monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-announces-board-approval-of-complete-liquidation-and-dissolution-company-reports-se-grtx-20240814monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-reports-first-quarter-2024-financial-results-and-recent-corporate-updates-company-s-grtx-20240513monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-adopts-limited-duration-stockholder-rights-agreement-malvern-pa-grtx-20240503monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-corporate-up-grtx-20240328monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-reports-third-quarter-2023-financial-results-and-recent-corporate-updates-fda-confi-grtx-20231114monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-announces-receipt-of-type-a-meeting-minutes-and-strategic-update-fda-confirms-need--grtx-20231031monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-reports-second-quarter-2023-financial-results-and-recent-corporate-updates-company--grtx-20230814monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-receives-complete-response-letter-from-u-s-fda-for-avasopasem-manganese-the-company-grtx-20230810monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-reports-first-quarter-2023-financial-results-and-recent-corporate-updates-avasopase-grtx-20230511monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-reports-fourth-quarter-and-full-year-2022-financial-results-and-recent-corporate-up-grtx-20230308monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-submits-new-drug-application-for-avasopasem-for-severe-oral-mucositis-nda-based-on--grtx-20221212monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-reports-third-quarter-2022-financial-results-and-recent-corporate-updates-company-o-grtx-20221109monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-announces-presentation-of-phase-3-roman-long-term-follow-up-data-at-2022-american-s-grtx-20221026monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-reports-second-quarter-2022-financial-results-and-recent-corporate-updates-company--grtx-20220809monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-reports-first-quarter-2022-financial-results-and-recent-corporate-updates-company-p-grtx-20220516monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-corporate-up-grtx-20220310monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-announces-primary-endpoint-met-statistical-significance-in-corrected-topline-effica-grtx-20211214monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-therapeutics-inc-selected-consolidated-balance-sheet-data-unaudited-in-thousands-se-grtx-20211110monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-announces-results-of-phase-3-roman-trial-of-avasopasem-for-radiotherapy-induced-sev-grtx-20211019monthly0.5https://www.biopharmawatch.com/news/GRTX/forward-looking-statements-2021-galera-therapeutics-inc-certain-information-contained-in-t-grtx-20210908monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-reports-second-quarter-2021-financial-results-and-recent-accomplishments-completed--grtx-20210810monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-reports-first-quarter-2021-financial-results-and-recent-accomplishments-phase-3-rom-grtx-20210511monthly0.5https://www.biopharmawatch.com/news/GRTX/transforming-radiotherapy-for-patients-with-cancer-april-2021-forward-looking-statements-c-grtx-20210428monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-recent-grtx-20210311monthly0.5https://www.biopharmawatch.com/news/GRTX/transforming-radiotherapy-transforming-radiotherapy-with-with-dismutase-mimetics-dismutase-grtx-20210106monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-therapeutics-reports-third-quarter-2020-financial-results-and-provides-business-upd-grtx-20201110monthly0.5https://www.biopharmawatch.com/news/GRTX/disclaimers-and-forward-looking-statements-certain-information-contained-in-this-presentat-grtx-20200916monthly0.5https://www.biopharmawatch.com/news/GRTX/disclaimers-and-forward-looking-statements-certain-information-contained-in-this-presentat-grtx-20200909monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-therapeutics-reports-second-quarter-2020-financial-results-and-provides-business-up-grtx-20200810monthly0.5https://www.biopharmawatch.com/news/GRTX/disclaimers-and-forward-looking-statements-certain-information-contained-in-this-presentat-grtx-20200714monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-therapeutics-reports-first-quarter-2020-financial-results-and-provides-business-upd-grtx-20200512monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-recent-grtx-20200310monthly0.5https://www.biopharmawatch.com/news/GRTX/galera-therapeutics-reports-third-quarter-2019-financial-results-and-provides-business-upd-grtx-20191210monthly0.5https://www.biopharmawatch.com/news/TNFA/q-c-technologies-appoints-ai-systems-leader-chelsea-voss-to-board-of-directors-new-york-ny-tnfa-20260120monthly0.5https://www.biopharmawatch.com/news/TNFA/quantum-class-computing-developer-q-c-technologies-welcomes-strategic-advisor-martin-shkre-tnfa-20251209monthly0.5https://www.biopharmawatch.com/news/TNFA/q-c-technologies-formerly-tnf-pharmaceuticals-commences-trading-on-nasdaq-under-new-ticker-tnfa-20250926monthly0.5https://www.biopharmawatch.com/news/TNFA/tnf-pharmaceuticals-announces-closing-of-7-million-private-placement-financing-priced-at-a-tnfa-20250904monthly0.5https://www.biopharmawatch.com/news/TNFA/tnf-pharmaceuticals-secures-exclusive-global-rights-to-innovative-light-speed-computing-ac-tnfa-20250902monthly0.5https://www.biopharmawatch.com/news/TNFA/tnf-pharmaceuticals-announces-strategic-equity-investment-priced-at-a-premium-to-market-pr-tnfa-20241002monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-announces-corporate-rebranding-to-new-name-tnf-pharmaceuticals-inc-ne-tnfa-20240724monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-appoints-accomplished-biopharmaceutical-leader-and-current-board-memb-tnfa-20240617monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-secures-strategic-investments-up-to-42-million-in-two-part-funding-fr-tnfa-20240521monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-for-cont-tnfa-20240305monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-announces-reverse-stock-split-to-maintain-nasdaq-listing-common-stock-tnfa-20240215monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-plans-fda-cleared-phase-2-clinical-trial-of-mymd-1-in-rheumatoid-arth-tnfa-20231206monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-announces-preclinical-study-results-showing-novel-cannabidiol-analog-supera-cbd-reduc-tnfa-20231019monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-to-present-updated-statistically-significant-phase-2-data-for-mymd-1--tnfa-20231004monthly0.5https://www.biopharmawatch.com/news/TNFA/fda-accepts-mymd-pharmaceuticals-investigational-new-drug-application-ind-for-phase-2-stud-tnfa-20230814monthly0.5https://www.biopharmawatch.com/news/TNFA/transcript-of-mymd-pharmaceuticals-inc-mymd-pharmaceuticals-phase-2-trial-update-tnfa-20230802monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-reports-statistically-significant-positive-topline-phase-2-results-fo-tnfa-20230802monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-provides-dosing-update-on-phase-2-multi-center-clinical-trial-of-mymd-tnfa-20230412monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-and-charles-river-present-positive-data-for-next-generation-oral-tnf--tnfa-20230320monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-joins-lot-network-in-effort-to-protect-company-and-shareholders-from-patent-trolls-ba-tnfa-20230308monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-announces-u-s-drug-enforcement-administration-dea-determines-supera-cbd-is-not-a-cont-tnfa-20230302monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-announces-upcoming-presentation-of-preclinical-rheumatoid-arthritis-d-tnfa-20230228monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-announces-15-million-offering-with-existing-investors-baltimore-tnfa-20230221monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-to-present-data-on-oral-tnf-a-inhibitor-mymd-1-at-the-british-society-tnfa-20221206monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-announces-upcoming-presentation-of-late-breaking-data-for-mymd-1-at-t-tnfa-20221117monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-announces-publication-of-phase-1-data-for-oral-tnf-alpha-inhibitor-my-tnfa-20221114monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-provides-dosing-update-on-phase-2-multi-center-clinical-trial-of-mymd-tnfa-20220920monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-receives-grant-from-european-patent-office-for-supera-cbd-compound-al-tnfa-20220830monthly0.5https://www.biopharmawatch.com/news/TNFA/data-showing-mymd-pharmaceuticals-mymd-1-may-extend-life-and-improve-health-published-in-t-tnfa-20220803monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-advances-phase-2-multi-center-clinical-trial-of-mymd-1-as-a-therapy-f-tnfa-20220726monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-to-collaborate-with-bascom-palmer-eye-institute-to-study-mymd-1-in-op-tnfa-20220712monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-advances-phase-2-multi-center-clinical-trial-of-mymd-1-as-a-therapy-f-tnfa-20220621monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-lead-compound-mymd-1-demonstrates-superior-anti-inflammatory-effects--tnfa-20220412monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-enrolls-first-patient-in-phase-2-clinical-trial-of-mymd-1-as-a-therap-tnfa-20220223monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-announces-positive-clinical-data-in-advance-of-upcoming-phase-2-trial-tnfa-20220208monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-announces-issuance-of-new-u-s-patent-covering-mymd-1-in-a-method-of-t-tnfa-20220105monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-receives-fda-ind-clearance-to-begin-phase-2-trial-of-mymd-1-for-exten-tnfa-20211116monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-president-chris-chapman-m-d-named-medical-honoree-of-the-year-by-the--tnfa-20211026monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-to-discuss-its-novel-therapies-for-aging-and-related-diseases-at-the--tnfa-20211019monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-to-detail-its-two-upcoming-phase-2-trials-at-the-benzinga-rising-star-tnfa-20211005monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-announces-new-data-demonstrating-8-000-times-higher-potency-of-novel--tnfa-20210922monthly0.5https://www.biopharmawatch.com/news/TNFA/mymd-pharmaceuticals-announces-fourth-quarter-2021-initiation-of-phase-2-clinical-trial-of-tnfa-20210913monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-and-mymd-pharmaceuticals-announce-stockholder-approval-of-merger-shares--tnfa-20210419monthly0.5https://www.biopharmawatch.com/news/TNFA/reminder-akers-biosciences-schedules-conference-call-to-discuss-merger-with-mymd-pharmaceu-tnfa-20201118monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-and-mymd-pharmaceuticals-sign-definitive-merger-agreement-immunotherapie-tnfa-20201112monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-and-premas-biotech-announce-sars-cov-2-positive-proof-of-concept-results-tnfa-20200827monthly0.5https://www.biopharmawatch.com/news/TNFA/execution-version-tnfa-20200810monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-and-premas-biotech-announce-initiation-of-animal-studies-company-intends-tnfa-20200707monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-closes-4-8-million-registered-direct-offering-priced-at-the-market-under-tnfa-20200518monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-announces-4-8-million-registered-direct-offering-priced-at-the-market-un-tnfa-20200514monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-and-premas-biotech-announce-successful-completion-of-vaccine-prototype-o-tnfa-20200514monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-and-premas-biotech-announce-successful-expression-of-coronavirus-antigen-tnfa-20200408monthly0.5https://www.biopharmawatch.com/news/TNFA/execution-version-tnfa-20200407monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-and-premas-biotech-announce-progress-in-its-vaccine-development-for-covi-tnfa-20200406monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-acquires-licenses-to-coronavirus-vaccine-candidate-from-premas-biotech-e-tnfa-20200324monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-inc-provides-notice-of-proposed-settlement-of-derivative-litigation-thor-tnfa-20200117monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-announces-q3-2018-earnings-sales-of-flagship-pifa-heparin-pf-4-rapid-ass-tnfa-20181115monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-announces-a-leadership-change-strategic-update-legal-settlement-and-an-a-tnfa-20181008monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-granted-180-day-extension-by-nasdaq-to-meet-minimum-bid-price-requiremen-tnfa-20180530monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-receives-notice-of-delinquent-form-10-q-filing-from-nasdaq-thorofare-n-j-tnfa-20180525monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-announces-closing-of-6-900-000-public-offering-thorofare-n-j-tnfa-20171221monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-prices-6-000-000-public-offering-thorofare-n-j-tnfa-20171218monthly0.5https://www.biopharmawatch.com/news/TNFA/january-2017-this-announcement-contains-inside-information-akers-biosciences-inc-issue-of--tnfa-20170110monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-announces-pricing-of-public-offering-of-1-667-000-shares-and-833-500-war-tnfa-20170109monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-appoints-dr-raza-bokhari-as-non-executive-director-thorofare-n-j-tnfa-20151112monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-appoints-former-congressman-rob-andrews-to-the-board-thorofare-n-j-tnfa-20150630monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-announces-joint-venture-to-market-rapid-diagnostic-tests-in-china-akers--tnfa-20141023monthly0.5https://www.biopharmawatch.com/news/TNFA/akers-biosciences-co-founder-and-executive-chairman-to-assume-duties-of-president-tnfa-20140312monthly0.5https://www.biopharmawatch.com/news/MYNZ/quantum-cyber-executes-exclusive-quantum-antenna-license-agreement-positoning-the-quantum--mynz-20260615monthly0.5https://www.biopharmawatch.com/news/MYNZ/n-a-s-d-a-q-q-u-c-y-c-o-r-p-o-r-a-t-e-p-r-e-s-e-n-t-a-t-i-o-n-j-u-n-e-2-0-2-6-autonomous-d-mynz-20260514monthly0.5https://www.biopharmawatch.com/news/MYNZ/quantum-cyber-strengthens-balance-sheet-with-over-15-million-in-aggregate-financing-cap-ta-mynz-20260526monthly0.5https://www.biopharmawatch.com/news/MYNZ/to-this-form-6-k-this-discussion-and-analysis-contains-forward-looking-statements-based-up-mynz-20250926monthly0.5https://www.biopharmawatch.com/news/MYNZ/minutes-of-the-proceedings-at-the-annual-general-meeting-of-mainz-biomed-n-v-a-public-comp-mynz-20250605monthly0.5https://www.biopharmawatch.com/news/MYNZ/notice-of-annual-general-meeting-of-mainz-biomed-n-v-notice-is-given-that-an-annual-genera-mynz-20250502monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-announces-stock-split-berkeley-us-and-mynz-20241129monthly0.5https://www.biopharmawatch.com/news/MYNZ/minutes-of-the-proceedings-at-the-extraordinary-general-meeting-of-mainz-biomed-n-v-a-publ-mynz-20241115monthly0.5https://www.biopharmawatch.com/news/MYNZ/to-this-form-6-k-this-discussion-and-analysis-contains-forward-looking-statements-based-up-mynz-20241018monthly0.5https://www.biopharmawatch.com/news/MYNZ/announcement-of-annual-general-meeting-of-mainz-biomed-n-v-23-april-2024-mainz-biomed-n-v--mynz-20240424monthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-usa-inc-carve-out-plan-1-purpose-the-mainz-biomed-usa-inc-carve-out-plan-as-m-mynz-20240223monthly0.5https://www.biopharmawatch.com/news/MYNZ/to-this-form-6-k-this-discussion-and-analysis-contain-forward-looking-statements-based-upo-mynz-20231116monthly0.5https://www.biopharmawatch.com/news/MYNZ/to-this-form-6-k-this-discussion-and-analysis-contain-forward-looking-statements-based-upo-mynz-20230815monthly0.5https://www.biopharmawatch.com/news/MYNZ/minutes-of-the-proceedings-at-the-annual-general-meeting-of-mainz-biomed-n-v-a-public-comp-mynz-20230628monthly0.5https://www.biopharmawatch.com/news/MYNZ/announcement-annual-general-meeting-mainz-biomed-n-v-mynz-20230519monthly0.5https://www.biopharmawatch.com/news/MYNZ/to-this-form-6-k-this-discussion-and-analysis-contain-forward-looking-statements-based-upo-mynz-20230516monthly0.5https://www.biopharmawatch.com/news/MYNZ/this-document-is-an-unofficial-english-translation-of-a-document-prepared-in-dutch-in-prep-mynz-20221220monthly0.5https://www.biopharmawatch.com/news/MYNZ/announcement-extraordinary-general-meeting-mainz-biomed-n-v-3-november-2022-mainz-biomed-n-mynz-20221104monthly0.5https://www.biopharmawatch.com/news/MYNZ/to-this-form-6-k-this-discussion-and-analysis-contain-forward-looking-statements-based-upo-mynz-20220907monthly0.5https://www.biopharmawatch.com/news/MYNZ/minutes-of-the-proceedings-at-the-annual-general-meeting-of-mainz-biomed-n-v-a-public-comp-mynz-20220701monthly0.5https://www.biopharmawatch.com/news/MYNZ/announcement-annual-general-meeting-mainz-biomed-n-v-20-may-2022-mainz-biomed-n-v-announce-mynz-20220603monthly0.5https://www.biopharmawatch.com/news/MYNZ/mynz-shares-have-commenced-trading-on-the-nasdaq-capital-market-berkeley-us-mainz-germany--mynz-20211104monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-to-be-acquired-by-electrocore-neurometrix-shareholders-to-receive-cash-and-con-nuro-20241217monthly0.5https://www.biopharmawatch.com/news/NURO/document-neurometrix-reports-q3-2024-business-highlights-company-continues-to-pursue-revie-nuro-20241105monthly0.5https://www.biopharmawatch.com/news/NURO/document-neurometrix-reports-q2-2024-business-highlights-and-update-on-review-of-strategic-nuro-20240806monthly0.5https://www.biopharmawatch.com/news/NURO/document-neurometrix-announces-steps-taken-to-enhance-shareholder-value-joshua-s-horowitz--nuro-20240419monthly0.5https://www.biopharmawatch.com/news/NURO/document-neurometrix-reports-q2-2023-business-highlights-nuro-20230727monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-inc-statements-of-operations-unaudited-quarters-ended-june-30-six-months-ended-nuro-20220630monthly0.5https://www.biopharmawatch.com/news/NURO/document-neurometrix-reports-q3-2021-financial-results-nuro-20211021monthly0.5https://www.biopharmawatch.com/news/NURO/document-neurometrix-reports-q2-2021-financial-results-nuro-20210722monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q1-2021-financial-results-nuro-20210422monthly0.5https://www.biopharmawatch.com/news/NURO/document-neurometrix-reports-q4-and-full-year-2020-financial-results-nuro-20210128monthly0.5https://www.biopharmawatch.com/news/NURO/exhibit-neurometrix-reports-q3-2020-financial-results-nuro-20201022monthly0.5https://www.biopharmawatch.com/news/NURO/exhibit-neurometrix-reports-q2-2020-financial-results-nuro-20200723monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q1-2020-financial-results-nuro-20200423monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q4-and-full-year-2019-financial-results-nuro-20200127monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q3-2019-financial-results-nuro-20191017monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q2-2019-financial-results-nuro-20190718monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q1-2019-financial-results-nuro-20190425monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q4-and-full-year-2018-financial-results-nuro-20190124monthly0.5https://www.biopharmawatch.com/news/NURO/exhibit-neurometrix-reports-agreement-with-gsk-healthcare-on-2019-quell-joint-development--nuro-20181211monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q3-2018-financial-results-3-8m-gsk-milestone-improved-operating-perfor-nuro-20181017monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q2-2018-financial-results-initial-3-8m-milestone-achieved-under-gsk-st-nuro-20180719monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q1-2018-financial-results-glaxosmithkline-collaboration-is-quarter-hig-nuro-20180419monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q4-and-full-year-2017-financial-results-q4-revenue-4-9m-up-33-full-yea-nuro-20180125monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-and-glaxosmithkline-consumer-healthcare-announce-strategic-collaboration-to-de-nuro-20180117monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q4-and-full-year-2016-financial-results-2016-revenue-12-0m-up-65-year--nuro-20170126monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-announces-7-0-million-private-placement-of-preferred-stock-and-warrants-will-n-nuro-20161220monthly0.5https://www.biopharmawatch.com/news/NURO/nasdaq-nuro-shai-n-gozani-md-phd-tom-higgins-president-ceo-chief-financial-officer-novembe-nuro-20161031monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q3-2016-financial-results-revenue-up-65-year-over-year-to-3-4-million--nuro-20160930monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q2-2016-financial-results-and-highlights-revenue-up-116-year-over-year-nuro-20160630monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-announces-21-3-million-at-the-market-private-placement-of-preferred-stock-and--nuro-20160603monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q1-2016-financial-results-and-highlights-year-over-year-revenue-up-77--nuro-20160331monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q4-2015-financial-results-and-highlights-6-675-quell-devices-shipped-u-nuro-20160128monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-preliminary-financial-highlights-for-2015-waltham-mass-business-wire-n-nuro-20160111monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-announces-13-8-million-at-the-market-private-placement-of-preferred-stock-and--nuro-20151229monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q3-2015-financial-results-and-highlights-approximately-4-500-quell-dev-nuro-20151022monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q2-2015-financial-results-and-highlights-quell-commercial-launch-miles-nuro-20150722monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q1-2015-financial-results-and-highlights-diabetes-product-revenue-grow-nuro-20150421monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q4-2014-financial-results-and-highlights-revenue-growth-record-diabete-nuro-20150212monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-third-quarter-2014-financial-results-and-business-highlights-record-di-nuro-20141028monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-second-quarter-2014-financial-results-and-business-highlights-record-n-nuro-20140724monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-announces-8-million-preferred-stock-placement-waltham-mass-business-wire-nuro-20140624monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-first-quarter-2014-financial-results-and-business-highlights-record-nu-nuro-20140424monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q4-and-full-year-2013-results-nuro-20140213monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-previews-selected-highlights-of-q4-2013-waltham-mass-business-wire-neurometrix-nuro-20131231monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q3-2013-results-progress-in-building-broad-distribution-channel-for-se-nuro-20131023monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-appoints-david-van-avermaete-to-board-of-directors-nuro-20131001monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q2-2013-results-focused-on-building-broad-distribution-channel-for-nuro-20130725monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q1-2013-results-launch-of-sensus-pain-management-device-highlights-the-nuro-20130425monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q4-2012-results-nuro-20130219monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-announces-one-for-six-reverse-stock-split-shares-of-common-stock-will-begin-tr-nuro-20130215monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q3-2012-results-commercial-and-regulatory-progress-in-diabetes-portfol-nuro-20121025monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-receives-six-month-extension-of-grace-period-to-regain-compliance-with-nasdaq--nuro-20120920monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q2-2012-results-commercial-progress-in-diabetes-market-nuro-20120726monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q1-2012-results-operational-and-strategic-progress-in-diabetes-busines-nuro-20120424monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q4-2011-results-closes-8-5-million-public-offering-of-common-stock-and-nuro-20120215monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-announces-pricing-of-securities-offering-nuro-20120207monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q3-2011-results-updates-on-nc-stat-dpncheck-commercial-launch-waltham--nuro-20111027monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-announces-one-for-six-reverse-stock-split-shares-of-common-stock-will-begin-tr-nuro-20110902monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q2-2011-results-commercial-nc-stat-dpncheck-activity-to-start-during-q-nuro-20110728monthly0.5https://www.biopharmawatch.com/news/NURO/nipro-diagnostics-and-neurometrix-announce-diabetes-focused-collaboration-for-the-retail-m-nuro-20110615monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q1-2011-results-nc-stat-dpncheck-development-progress-waltham-mass-bus-nuro-20110428monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q4-2010-financial-results-strategic-focus-on-diabetes-17m-cash-at-year-nuro-20110203monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-announces-new-strategic-direction-primary-focus-on-diabetes-waltham-mass-busin-nuro-20110104monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-names-nancy-e-katz-to-board-of-directors-waltham-mass-business-wire-nuro-20101217monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q3-2010-financial-results-progress-in-new-sales-channel-reduced-cash-c-nuro-20101109monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q2-2010-financial-results-product-distribution-and-development-strateg-nuro-20100810monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-q1-2010-financial-results-waltham-mass-business-wire-nuro-20100511monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-2009-financial-results-waltham-mass-business-wire-nuro-20100210monthly0.5https://www.biopharmawatch.com/news/NURO/united-states-district-court-district-of-massachusetts-gordon-mitchell-derivatively-on-cas-nuro-20091221monthly0.5https://www.biopharmawatch.com/news/NURO/federal-court-dismisses-securities-class-action-lawsuit-against-neurometrix-inc-waltham-ma-nuro-20091214monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-reports-third-quarter-2009-financial-results-waltham-mass-business-wire-nuro-20091105monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-names-thomas-t-higgins-chief-financial-officer-waltham-mass-nuro-20090910monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-completes-private-placement-raising-18-7-million-waltham-ma-nuro-20090910monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-to-raise-18-68-million-neurometrix-inc-nasdaq-nuro-a-healthcare-company-transf-nuro-20090904monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-inc-announces-second-quarter-2009-financial-results-waltham-mass-business-wire-nuro-20090805monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-inc-reports-total-revenues-of-6-8-million-for-the-first-quarter-of-2009-waltha-nuro-20090506monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-inc-reports-total-revenues-of-7-2-million-for-the-fourth-quarter-of-2008-walth-nuro-20090210monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-comments-on-reports-that-american-medical-association-s-cpt-editorial-panel-wi-nuro-20090127monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-inc-reports-total-revenues-of-7-3-million-for-the-third-quarter-of-2008-decrea-nuro-20081101monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-inc-reports-total-revenues-of-8-5-million-for-the-second-quarter-of-2008-decre-nuro-20080805monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-inc-reports-total-revenues-of-9-1-million-for-the-first-quarter-of-2008-decrea-nuro-20080506monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-inc-reports-total-revenues-of-10-1-million-for-the-fourth-quarter-of-2007-a-de-nuro-20080212monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-inc-nuro-20080205monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-inc-reports-total-revenues-of-11-3-million-for-the-third-quarter-of-2007-a-dec-nuro-20071030monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-inc-reports-total-revenues-of-11-5-million-for-the-second-quarter-of-2007-a-de-nuro-20070731monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-inc-reports-total-revenues-of-11-8-million-for-the-first-quarter-of-2007-uncha-nuro-20070501monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-inc-adopts-shareholder-rights-plan-waltham-massachusetts-business-wire-nuro-20070308monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-inc-reports-total-revenues-of-14-2-million-for-the-fourth-quarter-of-2006-repr-nuro-20070201monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-inc-reports-total-revenues-of-15-3-million-for-the-third-quarter-of-2006-68-gr-nuro-20061026monthly0.5https://www.biopharmawatch.com/news/NURO/manufacturing-and-supply-agreement-between-parlex-polymer-flexible-circuits-inc-and-neurom-nuro-20060802monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-inc-reports-total-revenues-of-14-0-million-for-the-second-quarter-of-2006-73-g-nuro-20060727monthly0.5https://www.biopharmawatch.com/news/NURO/neurometrix-inc-reports-total-revenues-of-11-8-million-for-the-first-quarter-2006-74-growt-nuro-20060501monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-provides-update-on-its-application-to-the-supreme-court-of-british-columbi-epix-20250930monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-amends-agreement-with-xenotherapeutics-shareholders-expected-to-receive-ap-epix-20250924monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-to-adjourn-special-meeting-to-epix-20250910monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-clarifies-nasdaq-due-bill-trading-for-previously-announced-cash-distributi-epix-20250825monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-announces-ex-dividend-date-and-nasdaq-due-bill-trading-for-previously-anno-epix-20250814monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-announces-us-80-m-illion-cash-distribution-to-shareholders-south-san-franc-epix-20250806monthly0.5https://www.biopharmawatch.com/news/EPIX/letter-to-shareholders-of-essa-pharma-inc-essa-pharma-inc-suite-720-999-west-broadway-vanc-epix-20250713monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-provides-update-on-its-application-to-the-supreme-court-of-british-columbi-epix-20250723monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-severance-plan-section-1-purpose-of-the-plan-this-essa-pharma-inc-severanc-epix-20241206monthly0.5https://www.biopharmawatch.com/news/EPIX/west-broadway-suite-720-vancouver-bc-v5z-1k5-t-778-331-0962-essapharma-com-essa-pharma-pro-epix-20220510monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-epix-20210216monthly0.5https://www.biopharmawatch.com/news/EPIX/100-000-shares-essa-pharma-inc-epix-20200728monthly0.5https://www.biopharmawatch.com/news/EPIX/form-51-102f3-material-change-report-item-1-name-and-address-of-company-essa-pharma-inc-es-epix-20191017monthly0.5https://www.biopharmawatch.com/news/EPIX/form-51-102f3-material-change-report-item-1-name-and-address-of-company-essa-pharma-inc-es-epix-20190516monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-statement-of-executive-compensation-for-the-year-ended-epix-20190219monthly0.5https://www.biopharmawatch.com/news/EPIX/condensed-consolidated-interim-financial-statements-unaudited-expressed-in-united-states-d-epix-20190207monthly0.5https://www.biopharmawatch.com/news/EPIX/form-51-102f3-material-change-report-item-1-name-and-address-of-company-essa-pharma-inc-es-epix-20181022monthly0.5https://www.biopharmawatch.com/news/EPIX/condensed-consolidated-interim-financial-statements-unaudited-expressed-in-united-states-d-epix-20180814monthly0.5https://www.biopharmawatch.com/news/EPIX/form-51-102f3-material-change-report-item-1-name-and-address-of-company-essa-pharma-inc-es-epix-20180525monthly0.5https://www.biopharmawatch.com/news/EPIX/condensed-consolidated-interim-financial-statements-unaudited-expressed-in-united-states-d-epix-20180515monthly0.5https://www.biopharmawatch.com/news/EPIX/form-51-102f3-material-change-report-item-1-name-and-address-of-company-essa-pharma-inc-es-epix-20180425monthly0.5https://www.biopharmawatch.com/news/EPIX/form-51-102f3-material-change-report-item-1-name-and-address-of-company-essa-pharma-inc-es-epix-20180221monthly0.5https://www.biopharmawatch.com/news/EPIX/condensed-consolidated-interim-financial-statements-unaudited-expressed-in-united-states-d-epix-20180213monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-completes-second-tranche-of-equity-offering-raising-additional-us-5-million-houston-a-epix-20180116monthly0.5https://www.biopharmawatch.com/news/EPIX/consent-of-independent-registered-public-accounting-firm-we-consent-to-the-incorporation-b-epix-20171211monthly0.5https://www.biopharmawatch.com/news/EPIX/condensed-consolidated-interim-financial-statements-unaudited-expressed-in-united-states-d-epix-20170815monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-receipt-of-nasdaq-notice-of-market-value-deficiency-houston-and-vanc-epix-20170721monthly0.5https://www.biopharmawatch.com/news/EPIX/condensed-consolidated-interim-financial-statements-unaudited-expressed-in-united-states-d-epix-20170515monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-receives-us-1-2-million-grant-payment-from-cancer-prevention-research-institut-epix-20170405monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-to-present-at-29th-annual-roth-conference-and-rodman-renshaw-premier-series-a-future--epix-20170314monthly0.5https://www.biopharmawatch.com/news/EPIX/condensed-consolidated-interim-financial-statements-unaudited-expressed-in-united-states-d-epix-20170213monthly0.5https://www.biopharmawatch.com/news/EPIX/material-change-report-exhibit-1-0-form-51-102f3-material-change-report-item-1-name-and-ad-epix-20161118monthly0.5https://www.biopharmawatch.com/news/EPIX/condensed-consolidated-interim-financial-epix-20160812monthly0.5https://www.biopharmawatch.com/news/EPIX/form-51-102f3-material-change-report-item-1-name-and-address-of-company-essa-pharma-inc-es-epix-20160801monthly0.5https://www.biopharmawatch.com/news/EPIX/condensed-consolidated-interim-financial-statements-epix-20160513monthly0.5https://www.biopharmawatch.com/news/EPIX/via-sedar-epix-20160415monthly0.5https://www.biopharmawatch.com/news/EPIX/form-51-102f3-material-change-report-item-1-name-and-address-of-company-essa-pharma-inc-es-epix-20160321monthly0.5https://www.biopharmawatch.com/news/EPIX/condensed-consolidated-interim-financial-epix-20160216monthly0.5https://www.biopharmawatch.com/news/EPIX/form-51-102f3-material-change-report-item-1-name-and-address-of-company-essa-pharma-inc-es-epix-20160106monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-filing-of-preliminary-shelf-prospectus-and-registration-statement-va-epix-20151215monthly0.5https://www.biopharmawatch.com/news/EPIX/document-1-document-1-document-1-essa-announces-enrollment-of-first-patient-in-phase-1-2-t-epix-20151124monthly0.5https://www.biopharmawatch.com/news/EPIX/ex-1-ex-1-document-1-essa-pharma-inc-to-commence-trading-on-the-nasdaq-capital-market-hous-epix-20150702monthly0.5https://www.biopharmawatch.com/news/PXMD/jfif-c-7-01444-9-82-0-0-v-o-u-c-wi-9-wnm-o-7-p-ij-t-j-6-b-6-b-h-o-k5-e-nfb-f7g9-f-a-pxmd-20250613monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-secures-immediate-exercise-of-warrants-tarrytown-ny-accesswire-pxmd-20240903monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-files-nasdaq-delisting-appeal-notice-and-prepares-for-upcoming-fda-meeting-on-pa-pxmd-20240515monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-responds-to-emergency-request-for-iv-suramin-and-commits-to-provide-immediate-ac-pxmd-20240423monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-receives-emergency-request-for-iv-suramin-from-african-health-ministry-for-use-i-pxmd-20240416monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-achieves-key-milestone-in-the-development-of-pax-101-and-provides-update-on-pote-pxmd-20240411monthly0.5https://www.biopharmawatch.com/news/PXMD/pxmd-investor-presentation-february-2024-2024-paxmedica-inc-proprietary-information-all-ri-pxmd-20240313monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-announces-pricing-of-7-0-million-public-offering-tarrytown-new-york-pxmd-20231120monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-inc-announces-third-quarter-2023-financial-results-and-business-update-tarrytown-pxmd-20231115monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-appoints-david-hough-m-d-as-chief-medical-officer-announces-additional-managemen-pxmd-20230816monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-inc-announces-second-quarter-2023-financial-results-and-business-update-tarrytow-pxmd-20230809monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-announces-positive-top-line-results-from-the-pax-101-intravenous-suramin-phase-3-pxmd-20230724monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-grants-exclusive-pharmacy-distribution-rights-for-pax-101-to-vox-nova-llc-agreem-pxmd-20230706monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-enters-research-collaboration-agreement-with-polomar-health-for-phase-ii-study-i-pxmd-20230608monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-completes-hat-301-registrational-trial-for-pax-101-hat-301-is-the-pivotal-effica-pxmd-20230601monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-inc-provides-first-quarter-2023-business-update-phase-3-hat-301-top-line-results-pxmd-20230515monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-inc-provides-business-update-and-reports-fourth-quarter-2022-financial-results-p-pxmd-20230329monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-releases-2022-shareholder-letter-company-anticipates-multiple-milestones-in-next-pxmd-20230215monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-inc-proprietary-information-all-rights-reserved-addressing-urgent-needs-in-serio-pxmd-20221219monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-inc-enters-into-committed-equity-investment-agreement-for-up-to-20-million-with--pxmd-20221117monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-initiates-clinical-program-to-advance-pax-101-towards-fda-submission-final-study-pxmd-20221108monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-inc-proprietary-information-all-rights-reserved-addressing-urgent-needs-in-serio-pxmd-20221012monthly0.5https://www.biopharmawatch.com/news/PXMD/paxmedica-appoints-specialty-pharma-industry-leader-charles-j-casamento-to-its-board-of-di-pxmd-20221003monthly0.5https://www.biopharmawatch.com/news/MEHA/functional-brands-inc-receives-nasdaq-staff-delisting-determination-meha-20260615monthly0.5https://www.biopharmawatch.com/news/MEHA/functional-brands-announces-adjournment-of-special-meeting-of-stockholders-scheduled-to-re-meha-20260528monthly0.5https://www.biopharmawatch.com/news/MEHA/functional-brands-nasdaq-meha-enters-into-agreement-to-acquire-alchemy-a-gold-backed-block-meha-20260522monthly0.5https://www.biopharmawatch.com/news/MEHA/sw-rosewood-street-lake-oswego-oregon-97035-meha-20260519monthly0.5https://www.biopharmawatch.com/news/MEHA/functional-brands-announces-first-quarter-2026-financial-results-lake-oswego-or-meha-20260518monthly0.5https://www.biopharmawatch.com/news/MEHA/functional-brands-inc-signs-binding-letter-of-intent-for-the-acquisition-of-the-assets-of--meha-20260511monthly0.5https://www.biopharmawatch.com/news/MEHA/functional-brands-announces-fourth-quarter-and-full-year-2025-financial-results-fourth-qua-meha-20260330monthly0.5https://www.biopharmawatch.com/news/MEHA/functional-brands-announces-third-quarter-2025-financial-results-lake-oswego-or-meha-20251215monthly0.5https://www.biopharmawatch.com/news/PBLA/sun-biopharma-announces-execution-of-reverse-stock-split-represents-next-step-toward-natio-pbla-20171107monthly0.5https://www.biopharmawatch.com/news/PBLA/sun-biopharma-files-form-10-q-for-second-quarter-2017-and-provides-clinical-update-complet-pbla-20170810monthly0.5https://www.biopharmawatch.com/news/PBLA/sun-biopharma-reports-first-quarter-2017-results-raises-3-1-million-from-the-sale-of-conve-pbla-20170511monthly0.5https://www.biopharmawatch.com/news/PBLA/sun-biopharma-provides-phase-1-trial-update-patients-experience-early-signs-of-efficacy-pa-pbla-20170330monthly0.5https://www.biopharmawatch.com/news/PBLA/sun-biopharma-reports-third-quarter-201-6-results-and-provides-clinical-progress-update-co-pbla-20161110monthly0.5https://www.biopharmawatch.com/news/PBLA/sun-biopharma-files-form-10-q-for-second-quarter-201-6-and-provides-business-update-initia-pbla-20160811monthly0.5https://www.biopharmawatch.com/news/PBLA/sun-biopharma-inc-rais-es-2-0-million-through-private-placement-transaction-minneapolis-mn-pbla-20160628monthly0.5https://www.biopharmawatch.com/news/PBLA/sun-biopharma-provides-business-update-and-reports-financial-results-for-q1-2016-completes-pbla-20160512monthly0.5https://www.biopharmawatch.com/news/PBLA/sun-biopharma-reports-financial-results-for-year-ended-pbla-20160308monthly0.5https://www.biopharmawatch.com/news/PBLA/dr-dalvir-s-gill-appointed-to-sun-biopharma-board-of-directors-minneapolis-mn-march-3-2016-pbla-20160303monthly0.5https://www.biopharmawatch.com/news/PBLA/scott-kellen-appointed-chief-financial-officer-of-sun-biopharma-healthcare-executive-bring-pbla-20151002monthly0.5https://www.biopharmawatch.com/news/PBLA/j-robert-paulson-and-jeffrey-mathiesen-appointed-to-sun-biopharma-board-of-directors-two-e-pbla-20150930monthly0.5https://www.biopharmawatch.com/news/PBLA/sun-biopharma-inc-financial-statements-index-to-financial-statements-audited-financial-sta-pbla-20150911monthly0.5https://www.biopharmawatch.com/news/SLRX/decoy-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-cambridge--slrx-20260402monthly0.5https://www.biopharmawatch.com/news/SLRX/decoy-therapeutics-announces-1-for-12-reverse-stock-split-cambridge-slrx-20260305monthly0.5https://www.biopharmawatch.com/news/SLRX/report-of-independent-registered-public-accounting-firm-to-the-board-of-directors-and-shar-slrx-20250822monthly0.5https://www.biopharmawatch.com/news/SLRX/unaudited-pro-forma-consolidated-combined-financial-information-the-following-unaudited-pr-slrx-20250110monthly0.5https://www.biopharmawatch.com/news/SLRX/document-salarius-pharmaceuticals-inc-announces-2-3-million-registered-direct-offering-hou-slrx-20220422monthly0.5https://www.biopharmawatch.com/news/SLRX/salariusleader-salarius-pharmaceuticals-announces-senior-leadership-changes-scott-jordan-a-slrx-20190913monthly0.5https://www.biopharmawatch.com/news/SLRX/salariusstockh-salarius-pharmaceuticals-ceo-issues-letter-to-stockholders-houston-tx-slrx-20190812monthly0.5https://www.biopharmawatch.com/news/SLRX/flex-pharma-and-salarius-pharmaceuticals-announce-merger-agreement-to-accelerate-clinical--slrx-20190104monthly0.5https://www.biopharmawatch.com/news/SLRX/flex-pharma-reports-year-end-2014-financial-results-conference-call-scheduled-today-at-9-0-slrx-20150317monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-third-quarter-2024-financial-results-winchester-mass-sybx-20241112monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-second-quarter-2024-financial-results-winchester-mass-sybx-20240808monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-first-quarter-2024-financial-results-cambridge-mass-sybx-20240514monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-fourth-quarter-and-full-year-2023-financial-results-cambridge-mass-sybx-20240319monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-adopts-limited-duration-stockholders-rights-plan-engages-ladenburg-thalmann-as-fi-sybx-20240220monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-announces-decision-to-discontinue-synpheny-3-study-and-provides-corporate-update--sybx-20240208monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-third-quarter-2023-financial-results-and-provides-corporate-update-underw-sybx-20231109monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-achieves-research-milestone-and-earns-2-5-million-milestone-payment-from-roche-co-sybx-20231107monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-announces-pricing-of-21-0-million-underwritten-public-offering-cambridge-mass-sybx-20230929monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-announces-reverse-stock-split-cambridge-mass-sybx-20230927monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-second-quarter-2023-financial-results-and-provides-business-update-recent-sybx-20230810monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-announces-initiation-of-synpheny-3-global-pivotal-phase-3-study-evaluating-synb19-sybx-20230605monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-first-quarter-2023-financial-results-and-provides-business-update-phenylk-sybx-20230511monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-fourth-quarter-and-full-year-2022-financial-results-and-corporate-updates-sybx-20230329monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-receives-rare-pediatric-disease-designation-from-fda-for-synb1934-for-phenylketon-sybx-20230119monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-announces-achievement-of-proof-of-concept-for-synb8802-in-enteric-hyperoxaluria-b-sybx-20221215monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-announces-synb1353-achieves-proof-of-mechanism-for-treatment-of-homocystinuria-an-sybx-20221130monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-third-quarter-2022-financial-results-and-provides-business-update-top-lin-sybx-20221110monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-announces-positive-top-line-phase-2-data-for-phenylketonuria-pku-synb1934-advance-sybx-20221018monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-second-quarter-2022-financial-results-and-provides-business-update-x2013--sybx-20220811monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-first-quarter-2022-financial-results-and-provides-business-update-clinica-sybx-20220512monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-business-sybx-20220317monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-announces-appointment-of-michael-jensen-as-chief-financial-officer-sybx-20220303monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-third-quarter-financial-results-and-provides-business-update-interim-anal-sybx-20211110monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-and-ginkgo-bioworks-announce-investigational-synthetic-biotic-medicine-for-the-tr-sybx-20211109monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-announces-proposed-public-offering-of-common-stock-cambridge-mass-business-wire-sybx-20210922monthly0.5https://www.biopharmawatch.com/news/SYBX/forward-looking-statements-this-presentation-contains-forward-looking-statements-that-invo-sybx-20210920monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-second-quarter-financial-results-and-provides-business-update-proof-of-co-sybx-20210812monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-announces-initiation-of-phase-1-study-of-synb1934-a-next-generation-strain-for-th-sybx-20210715monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-enters-research-collaboration-with-roche-for-development-of-novel-therapy-to-trea-sybx-20210617monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-first-quarter-financial-results-and-provides-business-update-proof-of-con-sybx-20210513monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-announces-proposed-public-offering-of-common-stock-cambridge-mass-business-wire-sybx-20210415monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-presents-data-from-synb1891-phase-1-trial-at-american-association-for-cancer-rese-sybx-20210410monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-business-sybx-20210325monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-announces-synb8802-will-advance-to-phase-1b-proof-of-concept-study-after-proof-of-sybx-20210324monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-announces-promotion-of-dr-caroline-kurtz-to-chief-development-officer-and-strengt-sybx-20210308monthly0.5https://www.biopharmawatch.com/news/SYBX/exhibt-99-1-synlogic-appoints-lisa-kelly-croswell-to-its-board-of-directors-sybx-20210210monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-announces-advancement-of-synb1891-to-combination-arm-dosing-with-pd-l1-checkpoint-sybx-20201214monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-appoints-michael-heffernan-to-its-board-of-directors-sybx-20201209monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-initiates-phase-1-study-of-synb8802-for-the-treatment-of-enteric-hyperoxaluria-sybx-20201104monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-second-quarter-2020-financial-results-and-provides-business-update-synlog-sybx-20200806monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-hosts-first-virtual-r-d-event-live-webcast-scheduled-to-begin-at-12-30-pm-et-toda-sybx-20200527monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-first-quarter-2020-financial-results-and-provides-business-update-cash-an-sybx-20200508monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-provides-summary-of-impact-of-covid-19-on-clinical-program-progress-and-operation-sybx-20200330monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-business-sybx-20200312monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-appoints-dr-michael-burgess-to-its-board-of-directors-sybx-20200130monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-provides-program-and-business-update-and-reports-third-quarter-2019-financial-res-sybx-20191112monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-announces-appointments-of-new-cmo-head-of-regulatory-affairs-and-cfo-departure-ca-sybx-20190904monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-designed-for-life-august-2019corporate-presentation-forward-looking-statements-th-sybx-20190808monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-designed-for-life-2019-wedbush-pacgrow-healthcare-conferencescott-plevy-md-chief--sybx-20190813monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-second-quarter-2019-financial-results-and-provides-program-updates-strong-sybx-20190808monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-designed-for-life-synb1618phase1-2a-clinical-trial-topline-data-from-pku-patient--sybx-20190715monthly0.5https://www.biopharmawatch.com/news/SYBX/forward-looking-statements-this-presentation-contains-forward-looking-statements-that-invo-sybx-20190612monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-first-quarter-2019-financial-results-and-provides-business-update-company-sybx-20190509monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-designed-for-life-corporate-presentationmarch-2019-forward-looking-statements-thi-sybx-20190312monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides-business-sybx-20190312monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-appoints-patricia-n-hurter-ph-d-to-board-of-directors-cambridge-mass-business-wir-sybx-20190212monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-designed-for-life-corporate-overview-january-2019-forward-looking-statements-this-sybx-20190107monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-expands-capabilities-in-manufacturing-with-the-appointment-of-head-of-technical-o-sybx-20181212monthly0.5https://www.biopharmawatch.com/news/SYBX/corporate-presentation-designed-for-life-november-2018-forward-looking-statements-this-pre-sybx-20181113monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-third-quarter-2018-financial-results-and-provides-program-updates-advance-sybx-20181113monthly0.5https://www.biopharmawatch.com/news/SYBX/development-of-synthetic-biotic-medicines-in-oncology-designed-for-life-2018-synlogic-inc--sybx-20181113monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-appoints-dr-aoife-brennan-as-president-and-chief-executive-officer-cambridge-mass-sybx-20181002monthly0.5https://www.biopharmawatch.com/news/SYBX/h-c-wainwright-20th-annual-global-investment-conferenceaoife-brennan-m-b-b-ch-interim-pres-sybx-20180905monthly0.5https://www.biopharmawatch.com/news/SYBX/discussion-of-interim-analysis-of-data-from-phase-1-2a-clinical-trial-of-synb1618-sybx-20180904monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-second-quarter-2018-financial-results-and-provides-program-updates-data-f-sybx-20180808monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-first-quarter-2018-financial-results-and-provides-business-update-treated-sybx-20180515monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-announces-registered-direct-offering-of-common-stock-cambridge-mass-business-wire-sybx-20180406monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-fourth-quarter-and-full-year-2017-financial-results-and-provides-business-sybx-20180320monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-announces-proposed-public-offering-of-common-stock-sybx-20180123monthly0.5https://www.biopharmawatch.com/news/SYBX/corporate-overview-january-2018-a-novel-class-of-living-medicines-synthetic-biotictm-medic-sybx-20180108monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-third-quarter-2017-financial-results-and-recent-progress-reported-positiv-sybx-20171113monthly0.5https://www.biopharmawatch.com/news/SYBX/synlogic-reports-positive-top-line-phase-1-data-demonstrating-safety-and-tolerability-and--sybx-20171108monthly0.5https://www.biopharmawatch.com/news/SYBX/investor-contact-synlogic-synlogic-courtney-heath-phone-617-872-2462-email-courtney-scient-sybx-20171024monthly0.5https://www.biopharmawatch.com/news/SYBX/investor-contact-synlogic-synlogic-courtney-heath-phone-617-872-2462-email-courtney-scient-sybx-20171010monthly0.5https://www.biopharmawatch.com/news/SYBX/the-following-is-an-excerpt-of-portions-of-the-prospectus-contained-in-the-form-s-4-regist-sybx-20170926monthly0.5https://www.biopharmawatch.com/news/SYBX/investor-contact-synlogic-synlogic-courtney-heath-phone-617-872-2462-email-courtney-scient-sybx-20170828monthly0.5https://www.biopharmawatch.com/news/SYBX/mirna-therapeutics-announces-results-of-annual-meeting-of-stockholders-austin-texas-august-sybx-20170824monthly0.5https://www.biopharmawatch.com/news/SYBX/separation-agreement-this-separation-agreement-the-agreement-by-and-between-vincent-o-neil-sybx-20170519monthly0.5https://www.biopharmawatch.com/news/SYBX/investor-contact-synlogic-synlogic-courtney-heath-christina-tartaglia-phone-617-872-2462-p-sybx-20170516monthly0.5https://www.biopharmawatch.com/news/SYBX/mirna-therapeutics-reports-second-quarter-2016-financial-results-and-program-updates-austi-sybx-20160815monthly0.5https://www.biopharmawatch.com/news/SYBX/mirna-therapeutics-reports-first-quarter-2016-financial-results-and-program-updates-austin-sybx-20160512monthly0.5https://www.biopharmawatch.com/news/SYBX/mirna-therapeutics-appoints-vincent-j-o-neill-m-d-as-chief-medical-officer-austin-tx-sybx-20160425monthly0.5https://www.biopharmawatch.com/news/SYBX/mirna-therapeutics-provides-operational-update-and-reports-financial-results-for-fourth-qu-sybx-20160329monthly0.5https://www.biopharmawatch.com/news/SYBX/mirna-therapeutics-appoints-peter-greenleaf-to-its-board-of-directors-austin-tx-sybx-20160201monthly0.5https://www.biopharmawatch.com/news/SYBX/mirna-therapeutics-reports-third-quarter-financial-results-and-recent-highlights-demonstra-sybx-20151113monthly0.5https://www.biopharmawatch.com/news/SYBX/mirna-therapeutics-announces-closing-of-initial-public-offering-and-concurrent-private-pla-sybx-20151006monthly0.5https://www.biopharmawatch.com/news/BNOX/neuphoria-therapeutics-adopts-limited-duration-stockholder-rights-plan-to-protect-integrit-bnox-20251027monthly0.5https://www.biopharmawatch.com/news/BNOX/neuphoria-therapeutics-provides-update-on-affirm-1-phase-3-trial-evaluating-bnc210-for-the-bnox-20251020monthly0.5https://www.biopharmawatch.com/news/BNOX/neuphoria-provides-first-quarter-2025-business-updates-cash-runway-into-q3-2026-affirm-1-p-bnox-20250520monthly0.5https://www.biopharmawatch.com/news/BNOX/description-of-capital-stock-the-following-description-of-the-capital-stock-of-neuphoria-t-bnox-20241223monthly0.5https://www.biopharmawatch.com/news/BNOX/supreme-court-of-new-south-wales-approves-bionomics-re-domiciliation-adelaide-australia-an-bnox-20241216monthly0.5https://www.biopharmawatch.com/news/BNOX/scheme-implementation-agreement-amending-agreement-date-24-october-2024-parties-bionomics--bnox-20241108monthly0.5https://www.biopharmawatch.com/news/BNOX/bionomics-limited-announces-intention-to-re-domicile-to-the-united-states-adelaide-austral-bnox-20241001monthly0.5https://www.biopharmawatch.com/news/BNOX/securities-purchase-agreement-this-securities-purchase-agreement-this-x201c-agreement-x201-bnox-20240531monthly0.5https://www.biopharmawatch.com/news/BNOX/signed-in-accordance-with-a-resolution-of-the-directors-made-pursuant-to-section-306-3-of--bnox-20240315monthly0.5https://www.biopharmawatch.com/news/BNOX/results-of-annual-general-meeting-adelaide-australia-and-bnox-20231130monthly0.5https://www.biopharmawatch.com/news/BNOX/bionomics-announces-retirement-of-board-member-adelaide-australia-and-bnox-20231128monthly0.5https://www.biopharmawatch.com/news/BNOX/bionomics-limited-acn-075-582-740-notice-of-annual-general-meeting-explanatory-statement-a-bnox-20231103monthly0.5https://www.biopharmawatch.com/news/BNOX/bionomics-announces-successful-end-of-phase-2-meeting-with-the-fda-and-solidifies-plans-to-bnox-20231016monthly0.5https://www.biopharmawatch.com/news/BNOX/bionomics-limited-abn-55-075-582-740-statutory-accounts-director-s-report-in-accordance-wi-bnox-20230929monthly0.5https://www.biopharmawatch.com/news/BNOX/bionomics-announces-positive-topline-results-from-the-phase-2b-attune-clinical-trial-of-bn-bnox-20230928monthly0.5https://www.biopharmawatch.com/news/BNOX/factors-affecting-future-performance-this-announcement-contains-x201c-forward-looking-x201-bnox-20230731monthly0.5https://www.biopharmawatch.com/news/BNOX/asx-announcement-28-july-2023-shareholder-communication-on-the-de-listing-process-bionomic-bnox-20230728monthly0.5https://www.biopharmawatch.com/news/BNOX/for-further-information-please-contact-baker-young-gpo-box-1672-adelaide-south-australia-5-bnox-20230725monthly0.5https://www.biopharmawatch.com/news/BNOX/july-2023-lisa-banh-senior-advisor-listings-compliance-asx-compliance-pty-limited-20-bridg-bnox-20230724monthly0.5https://www.biopharmawatch.com/news/BNOX/notification-of-cessation-of-securities-part-3-issued-capital-following-changes-following--bnox-20230707monthly0.5https://www.biopharmawatch.com/news/BNOX/abn-53-075-582-740-asx-announcement-28-april-2023-quarterly-activities-and-cashflow-report-bnox-20230707monthly0.5https://www.biopharmawatch.com/news/BNOX/new-and-recent-appointee-bios-mr-fisher-is-an-experienced-corporate-advisor-and-public-com-bnox-20230703monthly0.5https://www.biopharmawatch.com/news/BNOX/abn-53-075-582-740-asx-announcement-27-april-2023-bionomics-announces-the-completion-of-en-bnox-20230427monthly0.5https://www.biopharmawatch.com/news/BNOX/abn-53-075-582-740-asx-announcement-9-march-2023-bionomics-reports-promising-update-on-ana-bnox-20230309monthly0.5https://www.biopharmawatch.com/news/BNOX/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-bnox-20230223monthly0.5https://www.biopharmawatch.com/news/BNOX/abn-53-075-582-740-bionomics-limited-asx-half-year-information-x2013-31-december-2022-lodg-bnox-20230223monthly0.5https://www.biopharmawatch.com/news/BNOX/abn-53-075-582-740-21-february-2023-asx-market-announcements-asx-limited-level-4-stock-exc-bnox-20230221monthly0.5https://www.biopharmawatch.com/news/BNOX/about-bionomics-limited-bionomics-limited-asx-bno-nasdaq-bnox-is-a-clinical-stage-biopharm-bnox-20230130monthly0.5https://www.biopharmawatch.com/news/BNOX/explanatory-statement-purpose-of-information-this-explanatory-statement-explanatory-statem-bnox-20230118monthly0.5https://www.biopharmawatch.com/news/BNOX/rule-3-19a-1-appendix-3x-initial-director-s-interest-notice-information-or-documents-not-a-bnox-20230109monthly0.5https://www.biopharmawatch.com/news/BNOX/abn-53-075-582-740-asx-announcement-19-december-2022-bionomics-reports-topline-results-in--bnox-20221219monthly0.5https://www.biopharmawatch.com/news/BNOX/about-bionomics-limited-bionomics-limited-asx-bno-nasdaq-bnox-is-a-clinical-stage-biopharm-bnox-20221216monthly0.5https://www.biopharmawatch.com/news/BNOX/abn-53-075-582-740-16-november-2022-asx-market-announcements-asx-limited-level-4-stock-exc-bnox-20221116monthly0.5https://www.biopharmawatch.com/news/BNOX/abn-53-075-582-740-asx-announcement-25-october-2022-quarterly-activities-and-cashflow-repo-bnox-20221025monthly0.5https://www.biopharmawatch.com/news/BNOX/abn-53-075-582-740-asx-announcement-18-october-2022-bionomics-receives-r-d-tax-incentive-r-bnox-20221018monthly0.5https://www.biopharmawatch.com/news/BNOX/bionomics-limited-acn-075-582-740-notice-of-annual-general-meeting-explanatory-statement-a-bnox-20221018monthly0.5https://www.biopharmawatch.com/news/BNOX/bionomics-annual-report-director-s-report-contents-page-executive-chairman-report-1-direct-bnox-20221006monthly0.5https://www.biopharmawatch.com/news/BNOX/abn-53-075-582-740-asx-announcement-4-october-2022-bionomics-to-participate-in-the-cantor--bnox-20221004monthly0.5https://www.biopharmawatch.com/news/BNOX/dr-charlie-taylor-is-an-associate-professor-of-psychiatry-at-uc-san-diego-he-received-his--bnox-20220921monthly0.5https://www.biopharmawatch.com/news/BNOX/released-on-authority-of-the-board-for-further-information-please-contact-general-ms-suzan-bnox-20220825monthly0.5https://www.biopharmawatch.com/news/BNOX/abn-53-075-582-740-asx-announcement-8-august-2022-bionomics-receives-r-d-tax-incentive-ref-bnox-20220808monthly0.5https://www.biopharmawatch.com/news/BNOX/abn-53-075-582-740-asx-announcement-29-july-2022-quarterly-activities-and-cashflow-report--bnox-20220729monthly0.5https://www.biopharmawatch.com/news/BNOX/notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-part-5-other--bnox-20220720monthly0.5https://www.biopharmawatch.com/news/BNOX/notification-of-cessation-of-securities-part-3-issued-capital-following-changes-following--bnox-20220705monthly0.5https://www.biopharmawatch.com/news/BNOX/abn-53-075-582-740-13-june-2022-bionomics-investor-webinar-bionomics-limited-asx-bno-nasda-bnox-20220613monthly0.5https://www.biopharmawatch.com/news/BNOX/rule-3-19a-2-appendix-3y-change-of-director-s-interest-notice-information-or-documents-not-bnox-20220518monthly0.5https://www.biopharmawatch.com/news/BNOX/bionomics-limited-to-participate-in-upcoming-investor-conferences-bnox-20220516monthly0.5https://www.biopharmawatch.com/news/BNOX/abn-53-075-582-740-asx-announcement-29-april-2022-quarterly-activities-and-cashflow-report-bnox-20220429monthly0.5https://www.biopharmawatch.com/news/BNOX/abn-53-075-582-740-bionomics-limited-asx-half-year-information-x2013-31-december-2021-lodg-bnox-20220223monthly0.5https://www.biopharmawatch.com/news/BNOX/abn-53-075-582-740-asx-announcement-28-january-2022-quarterly-activities-and-cashflow-repo-bnox-20220128monthly0.5https://www.biopharmawatch.com/news/BNOX/to-improve-the-lives-of-patients-with-serious-cns-disorders-corporate-presentation-nasdaq--bnox-20220112monthly0.5https://www.biopharmawatch.com/news/BNOX/abn-53-075-582-740-asx-announcement-04-january-2022-bionomics-initiates-phase-2-prevail-st-bnox-20220104monthly0.5https://www.biopharmawatch.com/news/BNOX/abn-53-075-582-740-asx-announcement-31-december-2021-resignation-of-director-bionomics-lim-bnox-20220103monthly0.5https://www.biopharmawatch.com/news/BNOX/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-bnox-20211222monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-inc-consolidated-financial-statements-rvph-20201218monthly0.5https://www.biopharmawatch.com/news/RVPH/tenzing-acquisition-corp-and-reviva-pharmaceuticals-inc-announce-shareholder-meeting-date--rvph-20201118monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-inc-business-combination-with-tenzing-acquisition-corp-nasdaq-tzac--rvph-20201106monthly0.5https://www.biopharmawatch.com/news/RVPH/tenzing-acquisition-corp-and-reviva-pharmaceuticals-inc-announce-the-appointment-of-naraya-rvph-20201104monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-inc-business-combination-with-tenzing-acquisition-corp-nasdaq-tzac--rvph-20201006monthly0.5https://www.biopharmawatch.com/news/RVPH/tenzing-acquisition-corp-and-reviva-pharmaceuticals-inc-announce-recruitment-of-les-funtle-rvph-20200914monthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-inc-business-combination-with-tenzing-acquisition-corp-nasdaq-tzac--rvph-20200727monthly0.5https://www.biopharmawatch.com/news/RVPH/tenzing-acquisition-corp-and-reviva-pharmaceuticals-inc-announce-execution-of-definitive-a-rvph-20200721monthly0.5https://www.biopharmawatch.com/news/RVPH/tenzing-acquisition-corp-announces-extension-of-deadline-to-complete-a-business-combinatio-rvph-20200521monthly0.5https://www.biopharmawatch.com/news/RVPH/tenzing-acquisition-corp-announces-extension-of-deadline-to-complete-a-business-combinatio-rvph-20200218monthly0.5https://www.biopharmawatch.com/news/RVPH/tenzing-acquisition-corp-announces-separate-trading-of-its-ordinary-shares-and-warrants-co-rvph-20181018monthly0.5https://www.biopharmawatch.com/news/RVPH/tenzing-acquisition-corp-announces-full-exercise-and-closing-of-underwriters-over-allotmen-rvph-20180830monthly0.5https://www.biopharmawatch.com/news/RVPH/tenzing-acquisition-corp-index-to-balance-sheet-report-of-independent-registered-public-ac-rvph-20180823monthly0.5https://www.biopharmawatch.com/news/RVPH/tenzing-acquisition-corp-announces-pricing-of-upsized-55-000-000-initial-public-offering-n-rvph-20180820monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-announces-wind-down-of-operations-virx-20250205monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-announces-closure-of-naval-1-clinical-trial-and-exploration-of-strate-virx-20241226monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-inc-selected-balance-sheet-highlights-in-thousands-september-30-virx-20241113monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-announces-reprioritization-of-resources-to-enhance-focus-on-nana-val--virx-20241106monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-inc-selected-balance-sheet-highlights-in-thousands-june-30-virx-20240814monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-appoints-michael-faerm-as-chief-financial-officer-san-diego-virx-20240514monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-inc-selected-balance-sheet-highlights-in-thousands-march-31-virx-20240509monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-inc-selected-balance-sheet-highlights-in-thousands-december-31-virx-20240307monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-inc-selected-balance-sheet-highlights-in-thousands-september-30-virx-20231109monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-to-host-r-d-day-highlighting-nana-val-in-epstein-barr-virus-ebv-assoc-virx-20231004monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-reports-second-quarter-2023-financial-results-and-provides-business-u-virx-20230814monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-appoints-darrel-p-cohen-m-d-ph-d-as-chief-medical-officer-virx-20230807monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-reports-first-quarter-2023-financial-results-and-provides-clinical-pr-virx-20230508monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-announces-departure-of-chief-medical-officer-san-diego-virx-20230502monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-provi-virx-20230313monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-reports-third-quarter-2022-financial-results-and-provides-updates-on--virx-20221110monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-announces-chief-executive-officer-leadership-succession-to-drive-the--virx-20220919monthly0.5https://www.biopharmawatch.com/news/VIRX/first-amendment-to-loan-and-security-agreement-this-first-amendment-to-loan-and-security-a-virx-20220826monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-appoints-jane-chung-r-ph-to-its-board-of-directors-pr-newswire-san-di-virx-20220811monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-reports-second-quarter-2022-financial-results-and-recent-updates-cont-virx-20220809monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-reports-first-quarter-2022-financial-results-and-recent-updates-conti-virx-20220510monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-provi-virx-20220316monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-reports-third-quarter-2021-financial-results-and-provides-corporate-u-virx-20211110monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-secures-50-million-credit-facility-from-silicon-valley-bank-and-oxfor-virx-20211105monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-initiates-phase-1b-2-trial-in-epstein-barr-virus-positive-ebv-solid-t-virx-20211006monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-reacquires-exclusive-development-and-commercialization-rights-for-its-virx-20210823monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-announces-the-appointment-of-flavia-borellini-ph-d-and-jane-f-barlow--virx-20210816monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-reports-second-quarter-2021-financial-results-and-provides-clinical-a-virx-20210812monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-announces-fda-clearance-of-ind-application-for-phase-1b-2-trial-in-ep-virx-20210721monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-reports-first-quarter-2021-financial-results-and-provides-clinical-an-virx-20210512monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-corporate-overview-nasdaq-virx-i-www-viracta-com-forward-looking-statements-this-c-virx-20210414monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-strengthens-company-leadership-with-new-appointments-to-the-board-of--virx-20210304monthly0.5https://www.biopharmawatch.com/news/VIRX/viracta-therapeutics-announces-closing-of-merger-with-sunesis-pharmaceuticals-and-65m-priv-virx-20210225monthly0.5https://www.biopharmawatch.com/news/VIRX/sunesis-pharmaceuticals-and-viracta-therapeutics-announce-definitive-merger-agreement-merg-virx-20201130monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-maeve-conneighton-argot-partners-212-600-1902-par-hyare-sunes-virx-20201116monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-maeve-conneighton-argot-partners-212-600-1902-par-hyare-sunes-virx-20200811monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-maeve-conneighton-argot-partners-212-600-1902-par-hyare-sunes-virx-20200507monthly0.5https://www.biopharmawatch.com/news/VIRX/march-sunesis-pharmaceuticals-snss-ex991-6-pptx-htm-corporate-overview-march-2020-safe-har-virx-20200318monthly0.5https://www.biopharmawatch.com/news/VIRX/sunesis-march-2020-update-snss-ex991-6-pptx-htm-corporate-overview-march-2020-safe-harbor--virx-20200303monthly0.5https://www.biopharmawatch.com/news/VIRX/jpm-presentation-snss-ex991-6-pptx-htm-corporate-overview-january-2020-safe-harbor-stateme-virx-20200113monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-maeve-conneighton-argot-partners-212-600-1902-willie-quinn-su-virx-20191112monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-maeve-conneighton-argot-partners-212-600-1902-willie-quinn-su-virx-20190807monthly0.5https://www.biopharmawatch.com/news/VIRX/safe-harbor-statement-this-presentation-contains-forward-looking-statements-including-stat-virx-20190710monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-maeve-conneighton-argot-partners-212-600-1902-willie-quinn-su-virx-20190508monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-maeve-conneighton-argot-partners-212-600-1902-willie-quinn-su-virx-20190307monthly0.5https://www.biopharmawatch.com/news/VIRX/snss-ex991-7-pptx-htm-jpmorgan-conference-update-january-2019-safe-harbor-statement-this-p-virx-20190107monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-maeve-conneighton-argot-partners-212-600-1902-willie-quinn-su-virx-20181202monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-maeve-conneighton-argot-partners-212-600-1902-willie-quinn-su-virx-20181105monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-maeve-conneighton-argot-partners-212-600-1902-willie-quinn-su-virx-20180807monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-maeve-conneighton-argot-partners-212-600-1902-willie-quinn-su-virx-20180508monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-maeve-conneighton-argot-partners-212-600-1902-willie-quinn-su-virx-20180308monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-maeve-conneighton-argot-partners-212-600-1902-willie-quinn-su-virx-20180207monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-maeve-conneighton-argot-partners-212-600-1902-dan-swisher-sun-virx-20171102monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-maeve-conneighton-argot-partners-212-600-1902-dan-swisher-sun-virx-20170727monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-dan-swisher-sunesis-p-virx-20170508monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-dan-swisher-sunesis-p-virx-20170501monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20170309monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20161103monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-eric-bjerkholt-argot-partners-sunesis-pharmaceuti-virx-20160912monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20160729monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20160505monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20160310monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20151221monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20151216monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20151105monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20150730monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20150723monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20150505monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20150312monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20141110monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20141006monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20140805monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20140507monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20140306monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20140210monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20131112monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20130729monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20130611monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-eric-bjerkholt-argot-partners-sunesis-pharmaceuti-virx-20130509monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20130313monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20130110monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20121108monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20120920monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20120911monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20120809monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20120515monthly0.5https://www.biopharmawatch.com/news/VIRX/sunesis-contacts-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesis-pharmaceut-virx-20120329monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-eric-bjerkholt-argot-partners-sunesis-pharmaceuti-virx-20120314monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-eric-bjerkholt-argot-partners-sunesis-pharmaceuti-virx-20120202monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20111114monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20111019monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20110811monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20110512monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-manisha-pai-millennium-pharmaceuticals-inc-617-551-7877-inves-virx-20110405monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20110329monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20110214monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20101221monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20101028monthly0.5https://www.biopharmawatch.com/news/VIRX/dated-october-1-2010-press-release-dated-virx-20101001monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20100929monthly0.5https://www.biopharmawatch.com/news/VIRX/e-xhibit-99-1-investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bj-virx-20100812monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20100630monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-andrea-rabney-argot-partners-212-600-1902-eric-bjerkholt-sune-virx-20100429monthly0.5https://www.biopharmawatch.com/news/VIRX/sunesis-pharmaceuticals-receives-nasdaq-notification-virx-20100401monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-andrea-rabney-argot-partners-212-600-1902-eric-bjerkholt-sune-virx-20100330monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-david-pitts-argot-partners-212-600-1902-eric-bjerkholt-sunesi-virx-20091207monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-and-media-inquiries-andrea-rabney-argot-partners-212-600-1902-eric-bjerkholt-sune-virx-20091116monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-contact-sunesis-pharmaceuticals-inc-eric-bjerkholt-650-266-3717-media-contact-sun-virx-20090918monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-contact-media-contact-sunesis-pharmaceuticals-inc-sunesis-pharmaceuticals-inc-eri-virx-20090729monthly0.5https://www.biopharmawatch.com/news/VIRX/e-xhibit-99-1-investor-contact-sunesis-pharmaceuticals-inc-eric-bjerkholt-650-266-3717-med-virx-20090601monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-contact-sunesis-pharmaceuticals-inc-eric-bjerkholt-650-266-3717-media-contact-sun-virx-20090506monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-contact-sunesis-pharmaceuticals-inc-eric-bjerkholt-650-266-3717-media-contact-sun-virx-20090417monthly0.5https://www.biopharmawatch.com/news/VIRX/investor-contact-sunesis-pharmaceuticals-inc-eric-bjerkholt-650-266-3717-media-contact-sun-virx-20090401monthly0.5https://www.biopharmawatch.com/news/VIRX/logo-contacts-sunesis-pharmaceuticals-inc-eric-bjerkholt-650-266-3717-media-contact-invigo-virx-20081104monthly0.5https://www.biopharmawatch.com/news/VIRX/unassociated-document-sunesis-pharmaceuticals-reports-financial-results-for-the-second-qua-virx-20080807monthly0.5https://www.biopharmawatch.com/news/VIRX/sunesis-pharmaceuticals-focuses-resources-on-development-of-voreloxin-formerly-sns-595-dev-virx-20080603monthly0.5https://www.biopharmawatch.com/news/VIRX/unassociated-document-for-immediate-release-sunesis-pharmaceuticals-reports-first-quarter--virx-20080508monthly0.5https://www.biopharmawatch.com/news/VIRX/confidential-draft-penultimate-for-sign-off-and-approval-for-immediate-release-sunesis-pha-virx-20080311monthly0.5https://www.biopharmawatch.com/news/TIVC/valion-bio-appoints-melinda-lackey-as-general-counsel-seasoned-biopharmaceutical-attorney--tivc-20260504monthly0.5https://www.biopharmawatch.com/news/TIVC/biotech-veteran-michael-k-handley-named-ceo-of-tivic-health-systems-to-spearhead-strategic-tivc-20260304monthly0.5https://www.biopharmawatch.com/news/TIVC/nasdaq-tivc-www-tivichealth-com-ir-tivichealth-com-january-2026-jennifer-ernst-ceo-tivic-h-tivc-20260120monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-acquires-ready-to-scale-cgmp-manufacturing-and-development-assets-to-accelerate-comm-tivc-20251211monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-reports-findings-of-clinical-optimization-trial-of-non-invasive-cervical-vagu-tivc-20251113monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-receives-two-investigational-new-drug-applications-for-entolimod-for-the-treatment-o-tivc-20250820monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-reports-second-quarter-2025-financial-results-company-advances-its-tlr5-agonist-prog-tivc-20250814monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-completes-optimization-study-for-its-non-invasive-vagus-nerve-stimulation-dev-tivc-20250625monthly0.5https://www.biopharmawatch.com/news/TIVC/nasdaq-tivc-a-diversified-immunotherapeutics-company-ir-tivichealth-com-x2013-may-2025-x20-tivc-20250522monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-reports-first-quarter-2025-financial-results-and-provides-updates-on-business-transf-tivc-20250515monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-enters-gmp-manufacturing-validation-agreement-with-scorpius-biomanufacturing--tivc-20250514monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-reports-white-house-briefing-and-fda-meetings-secured-positive-interest-in-po-tivc-20250422monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-systems-inc-regains-compliance-with-nasdaq-minimum-bid-price-listing-rule-fre-tivc-20250410monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-reports-year-end-2024-financial-results-and-provides-overview-of-strategy-for-transf-tivc-20250321monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-and-feinstein-institute-present-new-data-showing-personalized-vagus-nerve-sti-tivc-20250306monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-systems-inc-announces-reverse-stock-split-fremont-calif-x2013-tivc-20250305monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team-tivc-20250224monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-acquires-exclusive-worldwide-rights-to-phase-iii-tlr5-agonist-from-statera-bi-tivc-20250212monthly0.5https://www.biopharmawatch.com/news/TIVC/ceo-letter-to-shareholders-issued-by-tivic-health-provides-updates-on-vagus-nerve-stimulat-tivc-20241223monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-reports-third-quarter-2024-financial-results-and-provides-business-update-pre-record-tivc-20241114monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-receives-approval-from-institutional-review-board-for-ncvns-optimization-stud-tivc-20240918monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-accelerates-vns-commercial-strategy-development-partners-with-leading-growth--tivc-20240917monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-appoints-lisa-wolf-as-interim-chief-financial-officer-kimberly-bambach-ms-wol-tivc-20240913monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-reports-second-quarter-2024-financial-results-san-francisco-x2013-business-wire-x201-tivc-20240814monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-christina-valauri-appointed-to-board-of-directors-wall-street-capital-markets-tivc-20240618monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-partners-with-the-feinstein-institutes-to-advance-its-patent-pending-non-inva-tivc-20240522monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-reports-first-quarter-2024-financial-results-and-subsequent-events-san-francisco-x20-tivc-20240515monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-announces-pricing-of-4-0-million-public-offering-tivc-20240509monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-announces-successful-completion-of-non-invasive-vagus-nerve-stimulation-study-tivc-20240508monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-reports-fiscal-year-2023-financial-results-san-francisco-x2013-business-wire-x2013-tivc-20240325monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-reports-third-quarter-2023-financial-results-71-gross-profit-increase-30-decrease-in-tivc-20231114monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-partners-with-instep-health-to-access-over-2-500-healthcare-providers-and-the-tivc-20230926monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-systems-inc-regains-compliance-with-nasdaq-listing-requirements-tivc-20230920monthly0.5https://www.biopharmawatch.com/news/TIVC/x1f-press-release-tivic-health-systems-inc-announces-reverse-stock-split-san-francisco-x20-tivc-20230822monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-reports-second-quarter-2023-financial-results-san-francisco-x2013-business-wire-x201-tivc-20230814monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-announces-proposed-public-offering-of-common-stock-san-francisco-x2013-tivc-20230804monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-expands-ip-protection-with-issuance-of-sixth-patent-for-its-bioelectronic-pla-tivc-20230731monthly0.5https://www.biopharmawatch.com/news/TIVC/letter-from-the-ceo-of-tivic-health-jennifer-ernst-tivic-health-ceo-provides-additional-in-tivc-20230728monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-announces-proposed-public-offering-of-common-stock-san-francisco-x2013-tivc-20230714monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-announces-proposed-public-offering-of-common-stock-san-francisco-x2013-tivc-20230707monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-to-reconvene-annual-meeting-of-stockholders-tivc-20230609monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-reports-first-quarter-2023-financial-results-gross-profit-increase-by-61-3-extends-i-tivc-20230515monthly0.5https://www.biopharmawatch.com/news/TIVC/p-r-e-s-s-r-e-l-e-a-s-e-tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-an-tivc-20230501monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-the-feinstein-institutes-for-medical-research-announce-pilot-study-to-test-novel-non-tivc-20230413monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-expands-bioelectronic-portfolio-files-patent-application-for-new-approach-to-non-inv-tivc-20230411monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-reports-fiscal-year-2022-financial-results-san-francisco-x2013-business-wire--tivc-20230331monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-systems-inc-announces-pricing-of-public-offering-san-francisco-x2013-tivc-20230208monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-and-reliefband-technologies-llc-terminate-acquisition-agreement-tivic-remains-tivc-20221209monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-signs-agreement-with-alom-to-manage-product-supply-chain-assembly-and-logisti-tivc-20221201monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-reports-third-quarter-2022-financial-results-65-growth-in-year-to-date-revenu-tivc-20221114monthly0.5https://www.biopharmawatch.com/news/TIVC/make-text-into-real-text-use-vector-graphic-for-logo-72-or-150-the-future-of-medicine-is-e-tivc-20221007monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-to-acquire-assets-of-reliefband-company-intends-to-dramatically-expand-produc-tivc-20221017monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-reports-strong-growth-in-second-quarter-2022-financial-results-265-growth-in--tivc-20220815monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-reports-first-quarter-2022-financial-results-77-year-over-year-growth-in-unit-tivc-20220516monthly0.5https://www.biopharmawatch.com/news/TIVC/april-investor-presentation-nasdaq-tivc-electrons-as-medicine-targeting-inflammatory-respo-tivc-20220418monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-announces-key-executive-appointments-strengthening-leadership-team-veronica-c-tivc-20220405monthly0.5https://www.biopharmawatch.com/news/TIVC/bioelectronic-medicine-non-invasively-targeting-immune-system-responses-2021-december-inve-tivc-20211208monthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-systems-inc-announces-pricing-of-initial-public-offering-menlo-park-ca-tivc-20211110monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-and-orthocellix-enter-into-definitive-merger-agreement-to-create-comp-carm-20250623monthly0.5https://www.biopharmawatch.com/news/CARM/clinical-activity-observed-in-her2-3-patients-correlation-of-target-expression-and-clinica-carm-20240709monthly0.5https://www.biopharmawatch.com/news/CARM/ct-0508-study-101-monotherapy-patient-demographics-n-14-heavily-pre-treated-pts-with-her2--carm-20240410monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-inc-amended-and-restated-2014-stock-incentive-plan-1-purpose-the-purp-carm-20230609monthly0.5https://www.biopharmawatch.com/news/CARM/to-company-s-current-report-on-form-8-k-filed-with-the-securities-and-exchange-commission--carm-20230512monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-inc-index-to-consolidated-financial-statements-page-consolidated-fina-carm-20230404monthly0.5https://www.biopharmawatch.com/news/CARM/sesnspecialmeetingr-sesen-bio-stockholders-approve-merger-with-carisma-therapeutics-declar-carm-20230302monthly0.5https://www.biopharmawatch.com/news/CARM/sesen-bio-and-carisma-therapeutics-announce-increased-special-cash-dividend-and-stockholde-carm-20230214monthly0.5https://www.biopharmawatch.com/news/CARM/carismaprguey-carisma-therapeutics-appoints-moderna-cso-of-external-research-ventures-lin--carm-20230207monthly0.5https://www.biopharmawatch.com/news/CARM/sesen-bio-files-investor-presentation-in-connection-with-pending-carisma-therapeutics-merg-carm-20230202monthly0.5https://www.biopharmawatch.com/news/CARM/carsima-sharmapres-carisma-therapeutics-appoints-leading-solid-tumor-immunotherapy-expert--carm-20230131monthly0.5https://www.biopharmawatch.com/news/CARM/nasdaqdelistingnoti-sesen-bio-receives-nasdaq-delisting-notice-company-remains-focused-on--carm-20230130monthly0.5https://www.biopharmawatch.com/news/CARM/pressreleasef-sesen-bio-and-carisma-therapeutics-announce-substantial-increase-to-expected-carm-20221229monthly0.5https://www.biopharmawatch.com/news/CARM/3q2022earningsrele-sesen-bio-reports-third-quarter-2022-financial-results-and-business-upd-carm-20221107monthly0.5https://www.biopharmawatch.com/news/CARM/document-sesen-bio-and-carisma-therapeutics-announce-merger-agreement-transaction-to-creat-carm-20220921monthly0.5https://www.biopharmawatch.com/news/CARM/united-states-district-court-district-of-massachusetts-in-re-sesen-bio-inc-derivative-liti-carm-20220822monthly0.5https://www.biopharmawatch.com/news/CARM/derivativestipulat-1-united-states-district-court-district-of-massachusetts-in-re-sesen-bi-carm-20220830monthly0.5https://www.biopharmawatch.com/news/CARM/united-states-district-court-southern-district-of-new-york-in-re-sesen-bio-inc-carm-20220817monthly0.5https://www.biopharmawatch.com/news/CARM/vicineumprogramupd-sesen-bio-announces-strategic-decision-to-pause-clinical-development-of-carm-20220718monthly0.5https://www.biopharmawatch.com/news/CARM/20220509x1q2022ear-sesen-bio-reports-first-quarter-2022-financial-results-and-business-upd-carm-20220509monthly0.5https://www.biopharmawatch.com/news/CARM/emaqa09172021-official-address-domenico-scarlattilaan-6-1083-hs-amsterdam-the-netherlands--carm-20210917monthly0.5https://www.biopharmawatch.com/news/CARM/aua2021gurram-sandeep-gurram-sonia-bellfield-rebecca-dolan-beatriz-walter-maria-merino-sco-carm-20210910monthly0.5https://www.biopharmawatch.com/news/CARM/sesen-bio-receives-complete-response-letter-from-fda-for-vicineum-oportuzumab-monatox-qqrs-carm-20210813monthly0.5https://www.biopharmawatch.com/news/CARM/vpchiefcomplianceof-sesen-bio-strengthens-executive-leadership-team-as-the-company-approac-carm-20210811monthly0.5https://www.biopharmawatch.com/news/CARM/turkeypartnershipa-sesen-bio-announces-partnership-with-eczacibasi-pharmaceuticals-marketi-carm-20210805monthly0.5https://www.biopharmawatch.com/news/CARM/vpasstgcannounceme-sesen-bio-strengthens-leadership-team-as-the-company-approaches-the-pot-carm-20210802monthly0.5https://www.biopharmawatch.com/news/CARM/commercialupdatepr-sesen-bio-announces-significant-commercial-progress-as-the-company-appr-carm-20210726monthly0.5https://www.biopharmawatch.com/news/CARM/bodupdatexvfi-sesen-bio-announces-new-appointments-to-its-board-of-directors-peter-k-honig-carm-20210721monthly0.5https://www.biopharmawatch.com/news/CARM/chinatrialfpiprxvf-sesen-bio-and-qilu-pharmaceutical-announce-enrollment-of-first-patient--carm-20210720monthly0.5https://www.biopharmawatch.com/news/CARM/pressrelease-sesen-bio-announces-productive-late-cycle-meeting-with-the-fda-for-vicineum-n-carm-20210714monthly0.5https://www.biopharmawatch.com/news/CARM/qiluglobalsupp-sesen-bio-announces-global-supply-partnership-with-qilu-pharmaceutical-tech-carm-20210602monthly0.5https://www.biopharmawatch.com/news/CARM/1q2021earningspres-sesen-bio-reports-first-quarter-2021-financial-results-and-commercial-l-carm-20210510monthly0.5https://www.biopharmawatch.com/news/CARM/sesencommercialupd-sesen-bio-announces-commercial-launch-readiness-progress-as-the-company-carm-20210504monthly0.5https://www.biopharmawatch.com/news/CARM/of-the-annual-meeting-on-carm-20210407monthly0.5https://www.biopharmawatch.com/news/CARM/sesenbiocorporatep-nasdaq-sesn-march-2021-business-update-carm-20210331monthly0.5https://www.biopharmawatch.com/news/CARM/qiluindapprovalpr-v-sesen-bio-and-qilu-pharmaceutical-announce-approval-of-ind-application-carm-20210322monthly0.5https://www.biopharmawatch.com/news/CARM/4q2020earningsprxv-sesen-bio-reports-fourth-quarter-and-full-year-2020-financial-results-a-carm-20210228monthly0.5https://www.biopharmawatch.com/news/CARM/sesnaompressreleas-sesen-bio-announces-successful-application-orientation-meeting-aom-with-carm-20210201monthly0.5https://www.biopharmawatch.com/news/CARM/sesnqiluindsubmiss-sesen-bio-and-qilu-pharmaceutical-announce-ind-application-for-vicineum-carm-20210113monthly0.5https://www.biopharmawatch.com/news/CARM/sesenbiojanuary202-nasdaq-sesn-january-2021-business-update-carm-20210111monthly0.5https://www.biopharmawatch.com/news/CARM/sesenbiodecember202-nasdaq-sesn-december-2020-business-update-carm-20201223monthly0.5https://www.biopharmawatch.com/news/CARM/blasubmission-final-sesen-bio-submits-completed-biologics-license-application-to-the-fda-f-carm-20201221monthly0.5https://www.biopharmawatch.com/news/CARM/sesen-qilucmopr-sesen-bio-announces-commercial-manufacturing-and-global-supply-partnership-carm-20201207monthly0.5https://www.biopharmawatch.com/news/CARM/sesnhikmapartnersh-sesen-bio-announces-partnership-with-hikma-pharmaceuticals-for-the-comm-carm-20201201monthly0.5https://www.biopharmawatch.com/news/CARM/sesenbio3q2020pres-sesen-bio-reports-third-quarter-2020-financial-results-and-positive-pro-carm-20201109monthly0.5https://www.biopharmawatch.com/news/CARM/emaprexsubmissionp-sesen-bio-announces-successful-pre-submission-meeting-with-the-european-carm-20201026monthly0.5https://www.biopharmawatch.com/news/CARM/sesn-cardinalhealt-sesen-bio-announces-an-exclusive-agreement-with-cardinal-health-for-thi-carm-20201019monthly0.5https://www.biopharmawatch.com/news/CARM/updateddeck-flat-october-2020-business-update-thomas-cannell-dvm-president-ceo-carm-20201012monthly0.5https://www.biopharmawatch.com/news/CARM/sesenbiohcwconferen-h-c-wainwright-22nd-annual-global-investment-conference-thomas-cannell-carm-20200915monthly0.5https://www.biopharmawatch.com/news/CARM/sesn2q2020pressrele-sesen-bio-reports-second-quarter-2020-financial-results-and-business-u-carm-20200810monthly0.5https://www.biopharmawatch.com/news/CARM/irdeck-2020-canaccord-genuity-global-growth-conference-fireside-chat-with-dr-tom-cannell-p-carm-20200805monthly0.5https://www.biopharmawatch.com/news/CARM/july2020businessupd-july-2020-business-update-thomas-cannell-dvm-president-ceo-for-investo-carm-20200731monthly0.5https://www.biopharmawatch.com/news/CARM/corporateprese-2020-jefferies-healthcare-conference-thomas-cannell-dvm-president-ceo-for-i-carm-20200602monthly0.5https://www.biopharmawatch.com/news/CARM/sesn4q2019pr-sesen-bio-reports-fourth-quarter-and-full-year-2019-financial-results-company-carm-20200316monthly0.5https://www.biopharmawatch.com/news/CARM/sesnjpm2020fin-j-p-morgan-38th-annual-healthcare-conference-january-13-16-2020-nasdaq-sesn-carm-20200110monthly0.5https://www.biopharmawatch.com/news/CARM/updatedexhibit991sesndec-regulatory-update-carm-20191216monthly0.5https://www.biopharmawatch.com/news/CARM/sesn3qbusiness-3q-2019-business-update-carm-20191108monthly0.5https://www.biopharmawatch.com/news/CARM/sesenbiohcwainwrigh-h-c-wainwright-21st-annual-global-investment-conference-thomas-cannell-carm-20190910monthly0.5https://www.biopharmawatch.com/news/CARM/sesen-bio-announces-successful-pre-bla-meeting-with-fda-for-vicinium-fda-recommends-accele-carm-20190610monthly0.5https://www.biopharmawatch.com/news/CARM/sesen-bio-appoints-drug-development-expert-dennis-kim-m-d-mph-as-chief-medical-officer-carm-20181203monthly0.5https://www.biopharmawatch.com/news/CARM/exhibit-sesen-bio-announces-ceo-and-board-transitions-as-company-prepares-for-12-month-vis-carm-20180807monthly0.5https://www.biopharmawatch.com/news/CARM/portion-of-form-12b-25-of-eleven-biotherapeutics-inc-filed-with-the-sec-on-carm-20171115monthly0.5https://www.biopharmawatch.com/news/CARM/exhibit-eleven-biotherapeutics-prices-of-8-0-million-underwritten-public-offering-carm-20171101monthly0.5https://www.biopharmawatch.com/news/CARM/eleven-biotherapeutics-all-rights-reserved-2017-eleven-biotherapeutics-all-rights-reserved-carm-20171020monthly0.5https://www.biopharmawatch.com/news/CARM/to-the-company-s-current-report-on-form-8-k-filed-with-the-securities-and-exchange-commiss-carm-20160921monthly0.5https://www.biopharmawatch.com/news/CARM/eleven-biotherapeutics-announces-signing-of-exclusive-license-agreement-license-to-roche-c-carm-20160613monthly0.5https://www.biopharmawatch.com/news/CARM/eleven-biotherapeutics-announces-top-line-results-from-pivotal-phase-3-study-of-ebi-005-in-carm-20150518monthly0.5https://www.biopharmawatch.com/news/CARM/eleven-biotherapeutics-reports-first-quarter-2015-financial-results-management-to-host-con-carm-20150430monthly0.5https://www.biopharmawatch.com/news/CARM/eleven-biotherapeutics-reports-fourth-quarter-and-year-end-2014-financial-results-manageme-carm-20150304monthly0.5https://www.biopharmawatch.com/news/CARM/eleven-biotherapeutics-announces-additional-financing-of-20-million-proceeds-to-supplement-carm-20141125monthly0.5https://www.biopharmawatch.com/news/CARM/eleven-biotherapeutics-reports-third-quarter-2014-financial-results-management-to-host-con-carm-20141113monthly0.5https://www.biopharmawatch.com/news/CARM/eleven-biotherapeutics-reports-second-quarter-2014-financial-results-management-to-host-co-carm-20140813monthly0.5https://www.biopharmawatch.com/news/CARM/eleven-biotherapeutics-reports-fiscal-first-quarter-2014-financial-results-enrollment-comp-carm-20140515monthly0.5https://www.biopharmawatch.com/news/NOTV/this-is-a-solicitation-of-votes-to-accept-or-reject-a-plan-of-reorganization-prior-to-the--notv-20260603monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-reports-fourth-quarter-and-full-year-financial-results-for-fiscal-2025-and-provides-notv-20251203monthly0.5https://www.biopharmawatch.com/news/NOTV/correcting-and-replacing-inotiv-reports-third-quarter-financial-results-for-fiscal-2025-an-notv-20250806monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-reports-third-quarter-financial-results-for-fiscal-2025-and-provides-business-updat-notv-20250806monthly0.5https://www.biopharmawatch.com/news/NOTV/inotivinvestorday-2-may-2025-investor-day-meeting-with-management-forward-looking-statemen-notv-20250529monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-reports-second-quarter-financial-results-for-fiscal-2025-and-provides-business-upda-notv-20250507monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-reports-first-quarter-financial-results-for-fiscal-2025-and-provides-business-updat-notv-20250205monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-launches-proposed-public-offering-of-common-shares-notv-20241217monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-reports-fourth-quarter-and-full-year-financial-results-for-fiscal-2024-and-provides-notv-20241203monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-amends-its-credit-agreement-and-secures-additional-liquidity-notv-20240916monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-reports-third-quarter-financial-results-for-fiscal-2024-and-provides-business-updat-notv-20240808monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-reports-second-quarter-financial-results-for-fiscal-2024-and-provides-business-upda-notv-20240515monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-reports-first-quarter-financial-results-for-fiscal-2024-and-provides-business-updat-notv-20240207monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-reports-fourth-quarter-and-full-year-financial-results-for-fiscal-2023-and-provides-notv-20231211monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-changes-to-its-board-composition-notv-20231016monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-reports-third-quarter-financial-results-for-fiscal-2023-and-provides-business-updat-notv-20230810monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-second-quarter-fiscal-2023-financial-results-updates-select-full-year-notv-20230511monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-first-quarter-fiscal-2023-financial-results-reiterates-select-full-ye-notv-20230213monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-fourth-quarter-and-full-year-fiscal-2022-financial-results-provides-s-notv-20230110monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-provides-business-update-and-select-preliminary-fiscal-year-2022-financial-resu-notv-20221212monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-additional-site-consolidation-plan-in-the-u-s-intent-to-consult-with--notv-20221129monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-third-quarter-fiscal-2022-financial-results-increases-select-fiscal-y-notv-20220810monthly0.5https://www.biopharmawatch.com/news/NOTV/envigo-reaches-agreement-with-the-u-s-department-of-justice-and-the-u-s-department-of-agri-notv-20220718monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-site-closures-and-consolidation-plans-notv-20220613monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-second-quarter-fiscal-2022-financial-results-notv-20220512monthly0.5https://www.biopharmawatch.com/news/NOTV/to-the-company-s-current-report-on-form-8-k-filed-with-the-sec-on-notv-20220211monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-first-quarter-fiscal-2022-financial-results-notv-20220210monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-expansion-of-non-human-primate-facilities-and-services-with-acquisiti-notv-20220127monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-expansion-of-safety-assessment-offerings-with-acquisition-of-integrat-notv-20220110monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-fourth-quarter-and-full-year-fiscal-2021-financial-results-notv-20211216monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-select-preliminary-unaudited-financial-results-for-the-fourth-quarter-notv-20211207monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-shareholders-approve-acquisition-of-envigo-notv-20211104monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-expansion-of-in-vivo-pharmacology-offering-with-acquisition-of-plato--notv-20211004monthly0.5https://www.biopharmawatch.com/news/NOTV/bolder-biopath-inc-financial-statements-unaudited-notv-20210928monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-prices-upsized-125-million-convertible-senior-notes-offering-notv-20210922monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-proposed-convertible-senior-notes-offering-notv-20210921monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-and-envigo-propose-to-join-forces-to-enhance-research-and-drug-discovery-soluti-notv-20210921monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-third-quarter-fiscal-2021-financial-results-notv-20210811monthly0.5https://www.biopharmawatch.com/news/NOTV/source-inotiv-inc-notv-20210527monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-debt-financing-and-completion-of-acquisitions-of-histotox-labs-inc-an-notv-20210430monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-second-quarter-fiscal-2021-financial-results-notv-20210505monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-proposed-public-offering-of-common-shares-notv-20210420monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-announces-select-preliminary-unaudited-financial-results-for-second-quarter-and-notv-20210420monthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-inc-enhances-histopathology-offering-with-announcement-of-agreement-to-purchase-his-notv-20210413monthly0.5https://www.biopharmawatch.com/news/NOTV/bioanalytical-systems-inc-announces-corporate-name-change-to-inotiv-inc-notv-20210319monthly0.5https://www.biopharmawatch.com/news/NOTV/company-presentation-march-2021-1-forward-looking-statements-this-presentation-includes-fo-notv-20210309monthly0.5https://www.biopharmawatch.com/news/NOTV/bioanalytical-systems-inc-doing-business-as-inotiv-appoints-greg-beattie-as-chief-operatin-notv-20210211monthly0.5https://www.biopharmawatch.com/news/NOTV/bioanalytical-systems-inc-announces-first-quarter-fiscal-2021-financial-results-notv-20210209monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-beth-a-taylor-chief-financial-officer-phone-765-497-8-notv-20201221monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-beth-a-taylor-chief-financial-officer-phone-765-497-8-notv-20200918monthly0.5https://www.biopharmawatch.com/news/NOTV/h-c-wainwright-investment-conference-september-2020-forward-looking-statements-this-presen-notv-20200916monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-beth-a-taylor-chief-financial-officer-phone-765-497-8-notv-20200514monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-beth-a-taylor-chief-financial-officer-phone-765-497-8-notv-20200424monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-william-pitchford-chief-human-resources-officer-phone-notv-20200309monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-c-blumhoff-chief-financial-officer-phone-765-497-notv-20200214monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-c-blumhoff-chief-financial-officer-phone-765-497-notv-20191223monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-c-blumhoff-chief-financial-officer-phone-765-497-notv-20191203monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-c-blumhoff-chief-financial-officer-phone-765-497-notv-20191108monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-blumhoff-chief-financial-officer-vice-president--notv-20190814monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-blumhoff-chief-financial-officer-vice-president--notv-20190515monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-basi-company-contacts-joe-flynn-chief-commercial-officer-phone-314-88-notv-20190507monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-c-blumhoff-chief-financial-officer-phone-756-497-notv-20190215monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-blumhoff-chief-financial-officer-vice-president--notv-20190214monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-c-blumhoff-chief-financial-officer-phone-756-497-notv-20190116monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-blumhoff-chief-financial-officer-vice-president--notv-20181220monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-blumhoff-chief-financial-officer-vice-president--notv-20180814monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-blumhoff-chief-financial-officer-vice-president--notv-20180702monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-blumhoff-chief-financial-officer-vice-president--notv-20180515monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-blumhoff-chief-financial-officer-vice-president--notv-20180430monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-blumhoff-chief-financial-officer-vice-president--notv-20180213monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-blumhoff-chief-financial-officer-vice-president--notv-20171219monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-blumhoff-chief-financial-officer-vice-president--notv-20170814monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-blumhoff-chief-financial-officer-vice-president--notv-20170803monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-blumhoff-chief-financial-officer-vice-president--notv-20170627monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-blumhoff-chief-financial-officer-vice-president--notv-20170620monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-blumhoff-chief-financial-officer-vice-president--notv-20170515monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-blumhoff-chief-financial-officer-vice-president--notv-20170214monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-c-blumhoff-chief-financial-officer-phone-765-497-notv-20161222monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jill-c-blumhoff-chief-financial-officer-phone-765-497-notv-20160811monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-jeffrey-potrzebowski-chief-financial-officer-phone-765-497-8409-jpotr-notv-20160511monthly0.5https://www.biopharmawatch.com/news/NOTV/reports-second-quarter-results-notv-20160512monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jeffrey-potrzebowski-chief-financial-officer-vice-pre-notv-20160216monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jeffrey-potrzebowski-chief-financial-officer-vice-pre-notv-20151217monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jeffrey-potrzebowski-chief-financial-officer-vice-pre-notv-20151214monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jeffrey-potrzebowski-chief-financial-officer-vice-pre-notv-20150813monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jeffrey-potrzebowski-chief-financial-officer-vice-pre-notv-20150212monthly0.5https://www.biopharmawatch.com/news/NOTV/noble-financial-capital-markets-11-th-annual-investor-conference-jacqueline-m-notv-20150120monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jeffrey-potrzebowski-chief-financial-officer-vice-pre-notv-20141222monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jeffrey-potrzebowski-chief-financial-officer-vice-pre-notv-20140814monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jacqueline-lemke-president-ceo-phone-765-497-5829-jle-notv-20140612monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jacqueline-lemke-president-ceo-and-cfo-phone-765-497--notv-20140213monthly0.5https://www.biopharmawatch.com/news/NOTV/confidential-and-proprietary-noble-financial-capital-markets-tenth-annual-equity-conferenc-notv-20140122monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jacqueline-lemke-president-ceo-and-cfo-phone-765-497--notv-20131224monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jacqueline-lemke-president-ceo-and-cfo-phone-765-497--notv-20131104monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jacqueline-lemke-president-ceo-and-cfo-phone-765-497--notv-20131018monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jacqueline-lemke-president-ceo-and-cfo-phone-765-497--notv-20130821monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jacqueline-lemke-president-ceo-and-cfo-phone-765-497--notv-20130214monthly0.5https://www.biopharmawatch.com/news/NOTV/jacqueline-lemke-named-president-and-notv-20130212monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jacqueline-lemke-interim-president-ceo-and-cfo-phone--notv-20121227monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jacqueline-lemke-interim-president-ceo-and-cfo-phone--notv-20121109monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jacqueline-lemke-interim-president-ceo-and-cfo-phone--notv-20120814monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-jacqueline-lemke-vice-president-finance-cfo-phone-765-notv-20120511monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contacts-anthony-chilton-president-chief-executive-officer-ph-notv-20120405monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-michael-r-cox-chief-financial-officer-phone-765-497-5-notv-20120210monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-michael-r-cox-chief-financial-officer-phone-765-497-5-notv-20111230monthly0.5https://www.biopharmawatch.com/news/NOTV/unassociated-document-for-more-information-company-contact-michael-r-cox-chief-financial-o-notv-20111220monthly0.5https://www.biopharmawatch.com/news/NOTV/unassociated-document-for-more-information-company-contact-michael-r-cox-chief-financial-o-notv-20110809monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-company-contact-michael-r-cox-chief-financial-officer-phone-765-497-5-notv-20110512monthly0.5https://www.biopharmawatch.com/news/NOTV/unassociated-document-for-more-information-michael-r-cox-phone-765-497-5829-mcox-basinc-co-notv-20110506monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-phone-765-497-5829-mcox-basinc-com-bioanalytical-system-notv-20110207monthly0.5https://www.biopharmawatch.com/news/NOTV/unassociated-document-for-more-information-michael-r-cox-phone-765-497-5829-mcox-basinc-co-notv-20101222monthly0.5https://www.biopharmawatch.com/news/NOTV/unassociated-document-for-more-information-michael-r-cox-phone-765-497-5829-mcox-basinc-co-notv-20100813monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-phone-765-497-5829-mcox-basinc-com-bioanalytical-system-notv-20100514monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-765-463-4527-mcox-basinc-com-nasdaq-puts-basi-on-notice-notv-20100305monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-phone-765-497-5829-mcox-basinc-com-bioanalytical-system-notv-20100216monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-phone-765-497-5829-mcox-basinc-com-bioanalytical-system-notv-20100127monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-phone-765-497-5829-mcox-basinc-com-bioanalytical-system-notv-20100114monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-765-463-4527-mcox-basinc-com-basi-announces-compliance--notv-20091119monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-765-463-4527-mcox-basinc-com-basi-announces-david-l-oma-notv-20091014monthly0.5https://www.biopharmawatch.com/news/NOTV/unassociated-document-for-more-information-michael-r-cox-765-463-4527-mcox-basinc-com-nasd-notv-20090922monthly0.5https://www.biopharmawatch.com/news/NOTV/unassociated-document-for-more-information-michael-r-cox-phone-765-497-5829-mcox-basinc-co-notv-20090810monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-phone-765-497-5829-mcox-basinc-com-bioanalytical-system-notv-20090515monthly0.5https://www.biopharmawatch.com/news/NOTV/unassociated-document-for-more-information-michael-r-cox-phone-765-497-5829-mcox-basinc-co-notv-20090218monthly0.5https://www.biopharmawatch.com/news/NOTV/unassociated-document-for-more-information-michael-r-cox-phone-765-497-5829-mcox-basinc-co-notv-20090114monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-phone-765-497-5829-mcox-bioanalytical-com-bioanalytical-notv-20081224monthly0.5https://www.biopharmawatch.com/news/NOTV/unassociated-document-for-immediate-release-for-more-information-alice-schwind-765-497-845-notv-20081114monthly0.5https://www.biopharmawatch.com/news/NOTV/unassociated-document-for-immediate-release-for-more-information-alice-schwind-765-497-845-notv-20080926monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-phone-765-497-5829-mcox-bioanalytical-com-bioanalytical-notv-20080811monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-765-463-4527-mcox-bioanalytical-com-basi-announces-sale-notv-20080630monthly0.5https://www.biopharmawatch.com/news/NOTV/unassociated-document-for-more-information-michael-r-cox-phone-765-497-5829-mcox-bioanalyt-notv-20080211monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-phone-765-497-5829-mcox-bioanalytical-com-bioanalytical-notv-20071220monthly0.5https://www.biopharmawatch.com/news/NOTV/unassociated-document-for-more-information-michael-r-cox-765-463-4527-mcox-bioanalytical-c-notv-20071116monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-765-463-4527-mcox-bioanalytical-com-basi-announces-elec-notv-20071116monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-richard-m-shepperd-765-463-4527-dshepperd-bioanalytical-com-basi-anno-notv-20071002monthly0.5https://www.biopharmawatch.com/news/NOTV/unassociated-document-for-more-information-michael-r-cox-phone-765-497-5829-mcox-bioanalyt-notv-20070809monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-edward-m-chait-765-463-4527-echait-bioanalytical-com-basi-announces-e-notv-20070521monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-phone-765-497-5829-mcox-bioanalytical-com-bioanalytical-notv-20070508monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-phone-765-497-5829-mcox-bioanalytical-com-bioanalytical-notv-20061221monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-peter-t-kissinger-765-463-4527-pkissinger-bioanalytical-com-basi-anno-notv-20060927monthly0.5https://www.biopharmawatch.com/news/NOTV/dated-8-11-2006-for-more-information-michael-r-cox-phone-765-497-5829-mcox-bioanalytical-c-notv-20060811monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-phone-765-497-5829-mcox-bioanalytical-com-bioanalytical-notv-20060510monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-phone-765-497-5829-mcox-bioanalytical-com-bioanalytical-notv-20060515monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-phone-765-497-5829-mcox-bioanalytical-com-basi-reports--notv-20060214monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-phone-765-497-5829-mcox-bioanalytical-com-bioanalytical-notv-20060116monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-phone-765-497-5829-mcox-bioanalytical-com-bioanalytical-notv-20051222monthly0.5https://www.biopharmawatch.com/news/NOTV/basi-appoints-new-executive-vp-chief-scientific-officer-west-lafayette-in-notv-20050801monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-phone-765-497-5829-mcox-bioanalytical-com-bioanalytical-notv-20050211monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-phone-765-497-5829-mcox-bioanalytical-com-bioanalytical-notv-20041216monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-bioanalytical-systems-inc-michael-r-cox-765-497-5829-mcox-bioanalytic-notv-20041208monthly0.5https://www.biopharmawatch.com/news/NOTV/for-more-information-michael-r-cox-phone-765-497-5829-mcox-bioanalytical-com-or-evan-smith-notv-20040922monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-inc-announces-name-and-ticker-symbol-change-to-envue-medical-inc-and-feed-new-naov-20251212monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-issues-letter-to-shareholders-envue-feeding-tube-placement-system-identified--naov-20251119monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-pricing-of-2-0-million-registered-direct-offering-priced-at-the-mar-naov-20250916monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-reverse-stock-split-common-stock-will-begin-trading-on-split-adjust-naov-20250808monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-ceo-transition-tyler-texas-naov-20250604monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-pricing-of-10-million-public-offering-of-preferred-stock-and-warran-naov-20250515monthly0.5https://www.biopharmawatch.com/news/NAOV/successful-independent-study-of-the-nanovibronix-uroshield-device-published-in-the-austral-naov-20250314monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-reverse-stock-split-common-stock-will-begin-trading-on-split-adjust-naov-20250314monthly0.5https://www.biopharmawatch.com/news/NAOV/envue-medical-holdings-corp-formerly-envizion-holdings-corp-index-to-financial-statements--naov-20250214monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-completion-of-pilot-phase-of-clinical-study-of-uroshield-at-the-uni-naov-20250106monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-secures-12-million-minimum-purchase-commitment-for-painshield-with-extension--naov-20241211monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-issues-letter-to-stockholders-tyler-texas-naov-20240516monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-issues-letter-to-stockholders-elmsford-n-y-naov-20240409monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-signs-agreement-for-research-and-development-of-next-generation-painshield-an-naov-20240328monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-agreement-for-clinical-study-of-uroshield-at-the-university-of-mich-naov-20231128monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-regains-nasdaq-compliance-elmsford-n-y-naov-20231121monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-issues-letter-to-shareholders-elmsford-n-y-naov-20231114monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-uroshield-products-available-on-nhs-drug-tariff-effective-november-1-receives-naov-20231107monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-gains-approval-for-inclusion-of-uroshield-products-in-nhs-prescription-servic-naov-20230927monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-presentation-of-positive-independent-testing-results-of-uroshield-a-naov-20230906monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-5-million-private-placement-priced-at-the-market-under-nasdaq-rules-naov-20230830monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-cites-positive-results-from-independent-testing-of-uroshield-university-of-so-naov-20230830monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-responds-to-cms-determination-for-painshield-elmsford-n-y-naov-20230829monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-applies-for-inclusion-of-uroshield-products-in-nhs-prescription-services-drug-naov-20230828monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-extends-distribution-agreement-with-its-largest-distributor-for-painshield-an-naov-20230823monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-distribution-agreement-with-sports-medicine-supplier-mio-guard-pain-naov-20230614monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-issues-letter-to-shareholders-elmsford-n-y-naov-20230518monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-receives-positive-final-results-of-independent-lifecycle-testing-of-painshiel-naov-20230328monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra-next-generation--naov-20230321monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-positive-results-from-independent-product-trial-of-uroshield-for-pa-naov-20230314monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-regains-nasdaq-compliance-elmsford-n-y-naov-20230303monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-to-launch-rental-program-for-painshield-and-uroshield-program-will-bring-grea-naov-20230222monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-reverse-stock-split-common-stock-will-begin-trading-on-split-adjust-naov-20230209monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-provides-update-on-expanding-access-to-painshield-receives-positive-interim-r-naov-20230118monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-naov-20221215monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-2-4-million-registered-direct-offering-priced-at-the-market-under-n-naov-20221129monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-receives-fda-510-k-premarket-clearance-for-painshield-plus-achieves-key-miles-naov-20221128monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-interim-results-of-clinical-study-for-uroshield-interim-results-ind-naov-20221116monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-receives-extension-to-satisfy-nasdaq-price-requirement-elmsford-n-y-naov-20221019monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-uroshield-approved-for-sale-through-nhs-internal-supply-chain-contract-new-co-naov-20220923monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-naov-20220914monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-distribution-of-series-f-preferred-stock-to-holders-of-its-common-s-naov-20220914monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-receipt-of-nasdaq-listing-determination-naov-20220902monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-reports-first-quarter-2022-financial-results-expanded-distribution-entry-into-naov-20220517monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-expands-board-of-directors-with-appointment-of-two-new-independent-directors--naov-20220113monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-naov-20210817monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-provides-business-update-highlights-business-momentum-with-recent-achievement-naov-20210603monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-amends-and-expands-distribution-agreement-for-its-painshield-and-painshield-p-naov-20201211monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-6-0-million-private-placement-elmsford-n-y-naov-20201202monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-reports-third-quarter-2020-financial-results-provides-business-update-gaining-naov-20201116monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-receives-positive-nasdaq-listing-determination-elmsford-n-y-naov-20201008monthly0.5https://www.biopharmawatch.com/news/NAOV/e-xhibit-99-1-nanovibronix-announces-1-5-million-bought-deal-offering-elmsford-n-y-naov-20200922monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-uroshield-receives-u-s-food-and-drug-administration-authorization-for-entry-i-naov-20200922monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-closing-of-3-4-million-bought-deal-offering-and-partial-exercise-of-naov-20200827monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-2-5-million-bought-deal-offering-elmsford-n-y-naov-20200824monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-signs-two-year-exclusive-distribution-agreement-for-painshield-ultra-pain-pro-naov-20200707monthly0.5https://www.biopharmawatch.com/news/NAOV/announces-closing-of-3-2-million-private-placement-naov-20190626monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-rescheduling-of-naov-20190614monthly0.5https://www.biopharmawatch.com/news/NAOV/an-effective-solution-for-the-prevention-of-bacterial-load-and-cauti-through-the-applicati-naov-20190311monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-provides-year-end-2017-business-update-and-files-10-k-elmsford-ny-naov-20180402monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-closing-of-6-000-000-public-offering-elmsford-ny-naov-20171107monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-announces-pricing-of-6-000-000-public-offering-listed-on-the-nasdaq-capital-m-naov-20171101monthly0.5https://www.biopharmawatch.com/news/NAOV/nanovibronix-expands-senior-management-team-and-board-of-directors-appoints-industry-veter-naov-20161020monthly0.5https://www.biopharmawatch.com/news/TTNP/pharmaceuticals-announces-1-million-private-placement-of-convertible-preferred-stock-ttnp-20250422monthly0.5https://www.biopharmawatch.com/news/TTNP/pharmaceuticals-inc-ttnp-20241127monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-enters-into-merger-agreement-with-ke-sdn-ttnp-20240819monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-unaudited-pro-forma-condensed-financial-information-on-ttnp-20230901monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-provides-shareholder-update-signs-non-binding-letter-of-intent-for-t-ttnp-20221215monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-announces-licensing-agreement-with-ocular-therapeutix-san-francisco--ttnp-20221212monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-announces-board-expansion-ttnp-20220816monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-announces-fda-clearance-of-ind-application-for-nalmefene-implant-ttnp-20220705monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-announces-pricing-of-5-5-million-registered-direct-and-pipe-offering-ttnp-20220202monthly0.5https://www.biopharmawatch.com/news/TTNP/sustained-anti-pruritic-effect-in-mice-with-tp-2021-a-kappa-opioid-agonist-peptide-deliver-ttnp-20211109monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-receives-funding-to-develop-combination-hiv-therapeutic-and-contrace-ttnp-20211025monthly0.5https://www.biopharmawatch.com/news/TTNP/positive-early-study-results-help-pave-wave-for-titan-pharmaceuticals-to-move-forward-with-ttnp-20210201monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-announces-pricing-of-9-7-million-registered-direct-offering-south-sa-ttnp-20210115monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements-south-san-franci-ttnp-20201216monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-announces-pricing-of-8-0-million-underwritten-public-offering-south--ttnp-20201028monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-enters-into-definitive-agreement-to-acquire-jt-pharma-s-kappa-opioid-ttnp-20201028monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-announces-debt-settlement-agreement-with-molteni-and-horizon-south-s-ttnp-20201026monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-provides-a-strategic-corporate-update-south-san-francisco-ca-ttnp-20201015monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-announces-pricing-of-2-7-million-registered-direct-offering-south-sa-ttnp-20200924monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-and-indegene-enter-into-probuphine-co-promotion-ttnp-20200624monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-announces-pricing-of-2-2-million-registered-direct-offering-south-sa-ttnp-20200107monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-titan-corporate-presentation-december-2019-company-confidential-do-n-ttnp-20191210monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-announces-pricing-of-9-0-ttnp-20191016monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-receives-approval-for-second-year-of-nida-grant-funding-for-development-of-a-nalmefe-ttnp-20190918monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-announces-pricing-of-2-1-ttnp-20190807monthly0.5https://www.biopharmawatch.com/news/TTNP/copyright-titan-pharmaceuticals-2019-not-for-promotional-use-titan-pharmaceuticals-titan-c-ttnp-20190214monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-prices-9-500-000-ttnp-20180920monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-awarded-nida-grant-for-the-development-of-a-ttnp-20180910monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-and-braeburn-announce-mutual-termination-of-license-agreement-for-pr-ttnp-20180530monthly0.5https://www.biopharmawatch.com/news/TTNP/accomplished-global-pharmaceutical-executive-federico-seghi-recli-appointed-to-titan-s-ttnp-20180514monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-executes-agreement-for-acquisition-by-molteni-of-probuphine-in-europe-and-other-sele-ttnp-20180321monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-2018-titan-pharmaceuticals-inc-nasdaq-ttnp-corporate-presentation-ja-ttnp-20180108monthly0.5https://www.biopharmawatch.com/news/TTNP/first-patient-treated-with-titan-pharmaceuticals-subdermal-implant-for-parkinson-s-ttnp-20171011monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-and-opiant-pharmaceuticals-collaborate-to-explore-a-new-approach-to--ttnp-20171002monthly0.5https://www.biopharmawatch.com/news/TTNP/2017-titan-pharmaceuticals-inc-ttnp-20170921monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-receives-fda-clearance-to-begin-clinical-study-of-parkinson-s-diseas-ttnp-20170824monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-secures-10-ttnp-20170727monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-and-walter-reed-army-institute-of-research-collaborate-to-evaluate-p-ttnp-20170706monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-corporate-presentation-may-2017-2017-titan-pharmaceuticals-inc-nasda-ttnp-20170606monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-corporate-presentation-march-2017-2017-titan-pharmaceuticals-inc-nas-ttnp-20170310monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-titan-pharmaceuticals-receives-fda-communication-on-ropinirole-i-ttnp-20170227monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-corporate-presentation-january-2017-2017-titan-pharmaceuticals-inc-n-ttnp-20161230monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-titan-pharmaceuticals-appoints-two-new-board-members-south-san-f-ttnp-20170104monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-corporate-presentation-sunil-bhonsle-november-2016-2016-titan-pharma-ttnp-20161116monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-corporate-presentation-sunil-bhonsle-august-2016-2016-titan-pharmace-ttnp-20160831monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-corporate-presentation-sunil-bhonsle-june-2016-2016-titan-pharmaceut-ttnp-20160620monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-announces-fda-approval-of-probuphine-for-the-treatment-of-opioid-dep-ttnp-20160526monthly0.5https://www.biopharmawatch.com/news/TTNP/corporate-presentation-sunil-bhonsle-may-18-2016-forward-looking-statements-the-presentati-ttnp-20160519monthly0.5https://www.biopharmawatch.com/news/TTNP/corporate-presentation-sunil-bhonsle-mar-2016-forward-looking-statements-the-presentation--ttnp-20160308monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-ttnp-20160219monthly0.5https://www.biopharmawatch.com/news/TTNP/corporate-presentation-sunil-bhonsle-jan-2016-forward-looking-statements-the-presentation--ttnp-20160112monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-and-braeburn-pharmaceuticals-announce-fda-advisory-committee-recomme-ttnp-20160112monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-ttnp-20151209monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-ttnp-20151116monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-ttnp-20151008monthly0.5https://www.biopharmawatch.com/news/TTNP/corporate-presentation-sunil-bhonsle-oct-2015-forward-looking-statements-the-presentation--ttnp-20151007monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-titan-pharmaceuticals-announces-fda-s-acceptance-of-resubmission-ttnp-20150928monthly0.5https://www.biopharmawatch.com/news/TTNP/corporate-presentation-sunil-bhonsle-sep-2015-ttnp-20150909monthly0.5https://www.biopharmawatch.com/news/TTNP/corporate-presentation-sunil-bhonsle-june-2015-safe-harbor-the-presentation-may-contain-fo-ttnp-20150608monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-titan-pharmaceuticals-reports-positive-results-from-phase-3-stud-ttnp-20150609monthly0.5https://www.biopharmawatch.com/news/TTNP/corporate-presentation-sunil-bhonsle-apr-2015-ttnp-20150428monthly0.5https://www.biopharmawatch.com/news/TTNP/corporate-presentation-sunil-bhonsle-mar-2015-ttnp-20150309monthly0.5https://www.biopharmawatch.com/news/TTNP/corporate-presentation-sunil-bhonsle-dec-2014-safe-harbor-the-presentation-may-contain-for-ttnp-20141204monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-appoints-two-new-board-members-south-san-francisco-ca-ttnp-20141111monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-announces-pricing-of-public-offering-south-san-francisco-ca-ttnp-20141003monthly0.5https://www.biopharmawatch.com/news/TTNP/corporate-presentation-sunil-bhonsle-sept-2014-safe-harbor-the-presentation-may-contain-fo-ttnp-20140910monthly0.5https://www.biopharmawatch.com/news/TTNP/corporate-presentation-july-2014-2-the-presentation-may-contain-forward-looking-statements-ttnp-20140721monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-receives-notice-of-allowance-for-patent-of-implantable-polymeric-dev-ttnp-20140609monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-for-immediate-release-titan-pharmaceuticals-announces-agreement--ttnp-20140303monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-for-immediate-release-titan-pharmaceuticals-receives-official-mi-ttnp-20131223monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-titan-pharmaceuticals-announces-5-million-equity-investment-and--ttnp-20131113monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-announces-amendment-to-partnership-with-braeburn-pharmaceuticals-com-ttnp-20130529monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-receives-complete-response-letter-from-the-fda-for-probuphine-new-dr-ttnp-20130501monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-for-immediate-release-titan-pharmaceuticals-announces-fda-adviso-ttnp-20130321monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-announces-date-of-fda-advisory-committee-review-of-probuphine-for-th-ttnp-20130227monthly0.5https://www.biopharmawatch.com/news/TTNP/corporate-presentation-january-2013-the-presentation-may-contain-forward-looking-statement-ttnp-20130107monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-for-immediate-release-probuphine-receives-fda-priority-review-de-ttnp-20130103monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-for-immediate-release-titan-pharmaceuticals-licenses-exclusive-p-ttnp-20121217monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-announces-submission-of-new-drug-application-for-probuphine-for-the--ttnp-20121029monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-announces-4-25-million-stock-purchase-and-option-agreement-strategic-ttnp-20120914monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-to-raise-5-5-million-in-registered-direct-offering-south-san-francis-ttnp-20120410monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-for-immediate-release-titan-pharmaceuticals-announces-positive-r-ttnp-20120209monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-for-immediate-release-titan-pharmaceuticals-adopts-stockholder-r-ttnp-20111221monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-for-immediate-release-titan-pharmaceuticals-confirms-regulatory--ttnp-20111202monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-for-immediate-release-titan-pharmaceuticals-enters-into-15-milli-ttnp-20111115monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-titan-pharmaceuticals-provides-probuphine-update-after-meeting-w-ttnp-20111026monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-for-immediate-release-titan-pharmaceuticals-provides-additional--ttnp-20110816monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-announces-positive-top-line-results-in-confirmatory-phase-3-trial-of-ttnp-20110711monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-for-immediate-release-titan-pharmaceuticals-provides-update-on-c-ttnp-20110617monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-titan-pharmaceuticals-enters-into-a-20-million-credit-facility-w-ttnp-20110316monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-for-immediate-release-titan-reports-fourth-quarter-2010-fanapt-r-ttnp-20110203monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-reports-third-quarter-2010-fanapt-royalty-south-san-francisco-ca-ttnp-20101025monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-titan-pharmaceuticals-announces-journal-of-the-american-medical--ttnp-20101012monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-for-immediate-release-titan-receives-sbir-grant-to-investigate-l-ttnp-20100726monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-for-immediate-release-titan-reports-second-quarter-2010-fanapt-r-ttnp-20100723monthly0.5https://www.biopharmawatch.com/news/TTNP/probuphine-patent-issued-by-the-u-s-patent-and-trademark-office-south-san-francisco-ca-ttnp-20100616monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-company-media-investors-robert-farrell-jennifer-beugelmans-execu-ttnp-20081203monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-company-media-investors-robert-farrell-jennifer-beugelmans-execu-ttnp-20081030monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-contacts-robert-farrell-executive-vice-president-cfo-titan-650-2-ttnp-20080728monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-contacts-investors-media-robert-farrell-keri-p-mattox-executive--ttnp-20080728monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-contacts-investors-media-robert-farrell-keri-p-mattox-executive--ttnp-20080702monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-executive-chairman-dr-louis-r-bucalo-retires-to-pursue-other-int-ttnp-20080430monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-company-media-investors-robert-farrell-ian-clements-executive-vi-ttnp-20071218monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-company-media-investors-robert-farrell-ian-clements-executive-vi-ttnp-20071213monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-announces-that-target-enrollment-has-been-met-ahead-of-schedule-in-phase-iii-clinica-ttnp-20071204monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-company-robert-farrell-executive-vice-president-cfo-650-244-4990-ttnp-20071128monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-company-media-investors-robert-farrell-jonathan-fassberg-executi-ttnp-20070926monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-company-media-investors-robert-farrell-jonathan-fassberg-executi-ttnp-20070425monthly0.5https://www.biopharmawatch.com/news/TTNP/company-media-investors-robert-farrell-jonathan-fassberg-executive-vice-president-cfo-the--ttnp-20070316monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-initiates-phase-iii-development-program-for-probuphine-r-in-the-treatment-of-opioid--ttnp-20061026monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-to-raise-10-million-in-registered-direct-offering-of-common-stock-th-ttnp-20060316monthly0.5https://www.biopharmawatch.com/news/TTNP/company-media-investors-robert-farrell-jonathan-fassberg-executive-vice-president-cfo-the--ttnp-20050929monthly0.5https://www.biopharmawatch.com/news/TTNP/company-media-investors-robert-farrell-jonathan-fassberg-executive-vice-president-cfo-the--ttnp-20050901monthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-inc-company-robert-farrell-executive-vice-president-cfo-650-244-4990-ttnp-20050314monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-fertility-announces-fiscal-year-2025-financial-results-naya-20260602monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-fertility-receives-nasdaq-notification-regarding-late-filing-of-annual-report-on-form-naya-20260429monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-fertility-announces-a-1-5-reverse-stock-split-effective-pre-market-opening-on-naya-20260327monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-fertility-closes-acquisition-of-indiana-based-fertility-clinic-family-beginnings-stra-naya-20260219monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-fertility-enters-into-7-5-million-warrant-inducement-priced-at-the-market-under-nasda-naya-20260129monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-fertility-aligns-executive-leadership-structure-to-support-growth-strategy-terah-krig-naya-20251230monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-fertility-signs-definitive-purchase-agreement-to-acquire-indiana-based-fertility-clin-naya-20251217monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-fertility-announces-pricing-of-4-0-million-private-placement-priced-at-the-market-und-naya-20251202monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-fertility-announces-a-1-8-reverse-stock-split-effective-pre-market-opening-on-naya-20251128monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-fertility-announces-third-quarter-2025-financial-results-naya-20251117monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-fertility-announces-second-quarter-2025-financial-results-naya-20250814monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-fertility-announces-a-1-3-reverse-stock-split-effective-pre-market-opening-on-naya-20250721monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-fertility-announces-first-quarter-2025-financial-results-company-now-exclusively-focu-naya-20250520monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-fertility-announces-2024-financial-results-with-116-annual-revenue-growth-and-further-naya-20250430monthly0.5https://www.biopharmawatch.com/news/NAYA/naya-announces-a-1-12-reverse-stock-split-effective-pre-market-opening-on-naya-20250318monthly0.5https://www.biopharmawatch.com/news/NAYA/naya-biosciences-announces-pricing-of-9-5-million-public-offering-sarasota-fla-and-miami-naya-20250113monthly0.5https://www.biopharmawatch.com/news/NAYA/naya-therapeutics-inc-former-name-naya-biosciences-inc-for-the-years-ended-december-31-202-naya-20241212monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-and-naya-biosciences-close-merger-combined-company-to-operate-as-naya-bios-naya-20241014monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-reports-record-second-quarter-2024-financial-results-with-481-revenue-growth-and-a-1--naya-20240814monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-reports-record-first-quarter-2024-financial-results-353-revenue-growth-with-improveme-naya-20240515monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-reports-fourth-quarter-and-full-year-2023-financial-results-naya-20240416monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-regains-compliance-with-nasdaq-minimum-stockholders-equity-requirement-naya-20231128monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-reports-record-third-quarter-2023-financial-results-company-expects-to-host-conferenc-naya-20231113monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-announces-commencement-of-waiver-solicitation-from-holders-of-the-company--naya-20231109monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-and-naya-biosciences-announce-definitive-merger-agreement-to-establish-exp-naya-20231023monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-reports-second-quarter-2023-financial-results-company-to-host-conference-call-today-a-naya-20230814monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-closes-acquisition-of-wisconsin-fertility-institute-transformational-and-accretive-ac-naya-20230811monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-announces-pricing-of-4-5-million-public-offering-naya-20230804monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-announces-a-1-20-reverse-stock-split-effective-pre-market-opening-on-naya-20230728monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-inc-unaudited-pro-forma-condensed-combined-financial-statements-on-naya-20230630monthly0.5https://www.biopharmawatch.com/news/NAYA/wisconsin-fertility-and-reproductive-surgery-associates-s-c-and-fertility-labs-of-wisconsi-naya-20230621monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-reports-first-quarter-2023-financial-results-company-to-host-conference-call-today-at-naya-20230515monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-reports-fourth-quarter-and-full-year-2022-financial-results-company-to-host-conferenc-naya-20230417monthly0.5https://www.biopharmawatch.com/news/NAYA/resignation-naya-20230331monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-provides-preliminary-update-on-fy2022-financial-results-naya-20230330monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-announces-pricing-of-3-0-million-registered-direct-offering-priced-at-the--naya-20230324monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-signs-binding-agreements-to-acquire-wisconsin-fertility-institute-accretive-acquisiti-naya-20230320monthly0.5https://www.biopharmawatch.com/news/NAYA/wisconsin-fertility-and-reproductive-surgery-associates-s-c-and-fertility-labs-of-wisconsi-naya-20230320monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-enters-distribution-agreement-for-taiwan-naya-20230105monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-reports-third-quarter-2022-financial-results-company-to-host-conference-ca-naya-20221114monthly0.5https://www.biopharmawatch.com/news/NAYA/draft-invo-bioscience-reports-second-quarter-2022-financial-results-company-to-host-confer-naya-20220815monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-reports-first-quarter-2022-financial-results-company-to-host-conference-ca-naya-20220516monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-reports-2021-financial-results-company-to-host-conference-call-today-at-4--naya-20220331monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-reports-third-quarter-2021-financial-and-operating-results-and-provides-bu-naya-20211115monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-regains-full-u-s-commercialization-rights-naya-20211108monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-reports-second-quarter-2021-financial-and-operating-results-and-provides-b-naya-20210816monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-signs-joint-venture-agreement-with-bloom-fertility-to-open-an-invocell-fer-naya-20210630monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-appoints-andrea-goren-as-chief-financial-officer-naya-20210615monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-reports-first-quarter-2021-financial-and-operating-results-and-provides-bu-naya-20210517monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-appoints-michael-j-campbell-and-steven-m-shum-to-its-board-of-directors-naya-20171011monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-appoints-renowned-fertility-specialist-dr-kevin-doody-to-its-board-of-dire-naya-20170411monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-receives-fda-clearance-for-invocell-fertility-treatment-revolutionary-devi-naya-20151103monthly0.5https://www.biopharmawatch.com/news/NAYA/reserve-equity-financing-agreement-this-agreement-dated-as-of-the-28-day-of-october-2009-t-naya-20091103monthly0.5https://www.biopharmawatch.com/news/NAYA/invo-bioscience-announces-the-closing-to-the-bridge-financing-naya-20090916monthly0.5https://www.biopharmawatch.com/news/NAYA/unassociated-document-bioxcell-inc-a-development-stage-company-contents-page-1-report-of-i-naya-20081212monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-provides-corporate-update-raymond-james-engaged-as-financial-advisor-reduction--iobt-20260130monthly0.5https://www.biopharmawatch.com/news/IOBT/disclaimer-forward-looking-statements-certain-information-contained-in-this-presentation-i-iobt-20251118monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-reports-first-quarter-2025-financial-results-and-business-highlights-primary-en-iobt-20250514monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-reports-2024-business-highlights-preparations-for-submission-of-a-biologics-lic-iobt-20250305monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-secures-up-to-57-5-million-in-debt-financing-from-the-european-investment-bank--iobt-20241220monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-reports-third-quarter-2024-financial-results-and-provides-business-highlights-p-iobt-20241112monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-updates-on-pivotal-phase-3-trial-of-io102-io103-in-combination-with-keytruda-pe-iobt-20240830monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-reports-second-quarter-2024-financial-results-and-provides-business-highlights--iobt-20240813monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-reports-first-quarter-2024-financial-results-and-provides-business-highlights-o-iobt-20240514monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-announces-2023-fourth-quarter-and-year-end-results-completed-enrollment-of-pivo-iobt-20240305monthly0.5https://www.biopharmawatch.com/news/IOBT/disclaimer-forward-looking-statements-certain-information-contained-in-this-presentation-i-iobt-20240108monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-announces-2023-third-quarter-results-completed-enrollment-of-380-patients-in-pi-iobt-20231113monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-announces-2023-second-quarter-results-achieved-significant-enrollment-milestone-iobt-20230811monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-inc-announces-75-million-private-placement-financing-offering-includes-particip-iobt-20230807monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-strengthens-executive-management-and-us-presence-with-appointment-of-qasim-ahma-iobt-20230718monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-announces-achievement-of-significant-phase-3-clinical-trial-recruitment-milesto-iobt-20230614monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-announces-2023-first-quarter-results-the-company-expects-to-enroll-225-patients-iobt-20230511monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-announces-2022-fourth-quarter-and-year-end-results-enrollment-in-the-company-s--iobt-20230314monthly0.5https://www.biopharmawatch.com/news/IOBT/forward-looking-statements-certain-information-contained-in-this-presentation-includes-for-iobt-20230314monthly0.5https://www.biopharmawatch.com/news/IOBT/forward-looking-statements-certain-information-contained-in-this-presentation-includes-for-iobt-20230109monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-announces-third-quarter-results-for-2022-clinical-trial-site-activation-a-leadi-iobt-20221109monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-announces-appointment-of-new-chief-financial-officer-new-york-new-york-iobt-20221013monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-announces-second-quarter-results-for-2022-announced-initiation-and-dosing-of-fi-iobt-20220811monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-announces-first-quarter-results-for-2022-updated-data-from-phase-1-2-study-of-i-iobt-20220516monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-announces-year-end-results-for-2021-updated-data-from-phase-1-2-study-of-io102--iobt-20220331monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-announces-appointment-of-david-v-smith-to-its-board-of-directors-new-york-new-y-iobt-20220303monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-aps-balance-sheets-in-thousands-except-share-and-per-share-amounts-unaudited-iobt-20211217monthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-announces-third-clinical-collaboration-with-merck-to-evaluate-io102-io103-in-co-iobt-20211206monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-announces-reverse-stock-split-rochester-n-y-vcnx-20240215monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-inc-announces-reverse-stock-split-rochester-n-y-vcnx-20230922monthly0.5https://www.biopharmawatch.com/news/VCNX/neoadjuvant-pepinemab-in-combination-with-nivolumab-and-or-ipilimumab-in-resectable-stage--vcnx-20220913monthly0.5https://www.biopharmawatch.com/news/VCNX/forward-looking-statements-to-the-extent-that-statements-contained-in-this-presentation-ar-vcnx-20220610monthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-announces-6-6-million-private-placement-participants-include-a-syndicate-of-exist-vcnx-20220127monthly0.5https://www.biopharmawatch.com/news/VCNX/top-line-results-of-phase-2-signal-study-in-huntington-s-disease-support-potential-for-cog-vcnx-20200922monthly0.5https://www.biopharmawatch.com/news/VCNX/science-in-the-service-of-medicine-unique-targets-novel-mechanisms-new-medicines-vx15-pepi-vcnx-20190318monthly0.5https://www.biopharmawatch.com/news/VCNX/forward-looking-statements-to-the-extent-that-statements-contained-in-this-presentation-ar-vcnx-20180926monthly0.5https://www.biopharmawatch.com/news/OCEA/unaudited-pro-forma-condensed-combined-financial-information-introduction-the-following-un-ocea-20230215monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-ocean-biomedical-and-aesther-healthcare-acquisition-corp-announce-the-ocea-20230209monthly0.5https://www.biopharmawatch.com/news/OCEA/aesther-and-ocean-biomedical-announce-shareholder-approval-of-business-combination-new-yor-ocea-20230206monthly0.5https://www.biopharmawatch.com/news/OCEA/aesther-healthcare-acquisition-corp-nasdaq-aeha-announces-measures-regarding-excise-tax-ne-ocea-20230201monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-ocean-biomedical-and-aesther-healthcare-acquisition-corp-announce-pub-ocea-20230130monthly0.5https://www.biopharmawatch.com/news/OCEA/aesther-healthcare-acquisition-corp-nasdaq-aeha-announces-filing-of-definitive-proxy-state-ocea-20230113monthly0.5https://www.biopharmawatch.com/news/OCEA/aesther-healthcare-acquisition-corp-announces-payment-of-fee-to-extend-period-to-consummat-ocea-20221216monthly0.5https://www.biopharmawatch.com/news/OCEA/aesther-healthcare-acquisition-corp-announces-intention-to-extend-period-to-consummate-bus-ocea-20221213monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-novel-malaria-drug-discovery-presented-at-the-astmh-tropical-medicine-ocea-20221101monthly0.5https://www.biopharmawatch.com/news/OCEA/aesther-healthcare-acquisition-corp-nasdaq-aeha-and-ocean-biomedical-inc-announce-executio-ocea-20221005monthly0.5https://www.biopharmawatch.com/news/OCEA/aesther-healthcare-acquisition-corp-building-on-their-innovative-mrna-vaccine-program-ocea-ocea-20220922monthly0.5https://www.biopharmawatch.com/news/OCEA/aesther-healthcare-acquisition-corp-nasdaq-aeha-announces-filing-of-preliminary-proxy-stat-ocea-20220919monthly0.5https://www.biopharmawatch.com/news/OCEA/aesther-healthcare-acquisition-corp-announces-intention-to-extend-period-to-consummate-bus-ocea-20220912monthly0.5https://www.biopharmawatch.com/news/OCEA/aesther-healthcare-acquisition-corp-nasdaq-aeha-and-ocean-biomedical-inc-announce-75-milli-ocea-20220908monthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-inc-discovery-of-bispecific-antibodies-and-immune-checkpoint-inhibitors-w-ocea-20220906monthly0.5https://www.biopharmawatch.com/news/OCEA/8-31-22-aesther-healthcare-acquisition-corp-has-entered-into-an-agreement-and-plan-of-merg-ocea-20220831monthly0.5https://www.biopharmawatch.com/news/OCEA/aesther-healthcare-acquisition-corp-and-united-gear-assembly-inc-high-precision-gears-for--ocea-20220527monthly0.5https://www.biopharmawatch.com/news/OCEA/aesther-healthcare-acquisition-corp-announces-separate-trading-of-its-class-a-common-stock-ocea-20211105monthly0.5https://www.biopharmawatch.com/news/OCEA/aesther-healthcare-acquisition-corp-index-to-financial-statements-page-report-of-independe-ocea-20210917monthly0.5https://www.biopharmawatch.com/news/OCEA/aesther-healthcare-acquisition-corp-announces-pricing-of-100-000-000-initial-public-offeri-ocea-20210914monthly0.5https://www.biopharmawatch.com/news/ITRM/not-for-immediate-release-iterum-therapeutics-announces-filing-of-winding-up-petition-dubl-itrm-20260327monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-third-quarter-2025-financial-results-commercially-launched-orl-itrm-20251114monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-launches-orlynvah-the-first-and-only-oral-penem-antibiotic-in-the-u-s--itrm-20250820monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-second-quarter-2025-financial-results-launch-of-orlynvah-tm-ex-itrm-20250805monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-announces-extension-of-term-of-promissory-note-dublin-ireland-and-chic-itrm-20250519monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-first-quarter-2025-financial-results-preparing-for-potential-l-itrm-20250513monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-announces-5-million-registered-direct-offering-of-ordinary-shares-dubl-itrm-20250429monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-orlynvah-t-itrm-20250207monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-regains-full-nasdaq-compliance-iterum-will-continue-to-be-listed-and-t-itrm-20241121monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-third-quarter-2024-financial-results-orlynvah-tm-approved-by-f-itrm-20241025monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-receives-u-s-fda-approval-of-orlynvah-oral-sulopenem-for-the-treatment-itrm-20241025monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-second-quarter-2024-financial-results-fda-pdufa-action-date-of-itrm-20240814monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-commences-rights-offering-dublin-ireland-and-chicago-itrm-20240722monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-announces-fda-advisory-committee-meeting-to-discuss-nda-for-oral-sulop-itrm-20240621monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-receives-fda-acceptance-of-resubmission-of-nda-for-oral-sulopenem-for--itrm-20240531monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-first-quarter-2024-financial-results-nda-resubmitted-fda-actio-itrm-20240513monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-resubmits-new-drug-application-to-u-s-food-and-drug-administration-for-itrm-20240429monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-resubmissi-itrm-20240328monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-provides-business-update-resubmission-of-nda-is-on-track-for-first-hal-itrm-20240306monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-announces-positive-topline-results-from-its-phase-3-reassure-clinical--itrm-20240130monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-regains-compliance-with-nasdaq-bid-price-rule-dublin-ireland-and-chica-itrm-20231204monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-third-quarter-2023-financial-results-top-line-data-for-pivotal-itrm-20231114monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-announces-completion-of-enrollment-in-its-reassure-phase-3-clinical-tr-itrm-20231024monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-second-quarter-2023-financial-results-expect-to-complete-enrol-itrm-20230811monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-first-quarter-2023-financial-results-registration-trial-for-uu-itrm-20230512monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-plc-condensed-consolidated-statement-of-operations-in-thousands-except-itrm-20230316monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-announces-issuance-of-allowance-for-a-u-s-patent-covering-oral-sulopen-itrm-20221215monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-third-quarter-2022-financial-results-patient-enrollment-in-reg-itrm-20221110monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-announces-first-patient-dosed-in-reassure-a-phase-3-clinical-trial-of-oral-sulopene-itrm-20221020monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-announces-issuance-of-allowance-for-a-u-s-patent-covering-oral-sulopen-itrm-20220919monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-second-quarter-2022-financial-results-enrollment-in-registrati-itrm-20220812monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-announces-special-protocol-assessment-spa-agreement-with-the-fda-spa-s-itrm-20220711monthly0.5https://www.biopharmawatch.com/news/ITRM/exhibit-a-cancelled-options-itrm-20220708monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-first-quarter-2022-financial-results-general-alignment-with-fd-itrm-20220513monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-registrati-itrm-20220328monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-third-quarter-2021-financial-results-and-provides-business-upd-itrm-20211112monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-second-quarter-2021-financial-results-and-provides-business-up-itrm-20210813monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-receives-complete-response-letter-from-u-s-food-and-drug-administratio-itrm-20210726monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-provides-regulatory-update-dublin-ireland-and-chicago-itrm-20210701monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-public-limited-company-amended-and-restated-2018-equity-incentive-plan-itrm-20210623monthly0.5https://www.biopharmawatch.com/news/ITRM/assumes-no-obligation-to-update-these-forward-looking-statements-publicly-or-to-update-the-itrm-20210527monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-first-quarter-2021-financial-results-fda-review-of-nda-for-ora-itrm-20210514monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-appoints-beth-p-hecht-to-board-of-directors-patrick-heron-to-leave-the-itrm-20210316monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-nda-for-or-itrm-20210312monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-plc-announces-exercise-of-underwriter-s-option-to-purchase-additional--itrm-20210210monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-plc-announces-35-0-million-registered-direct-offering-of-ordinary-shar-itrm-20210209monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-plc-announces-10-million-bought-deal-public-offering-of-ordinary-share-itrm-20210203monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-announces-collaboration-with-eversana-to-support-oral-sulopenem-launch-itrm-20210201monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-announces-u-s-fda-filing-acceptance-of-new-drug-application-for-oral-s-itrm-20210128monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-announces-transition-of-michael-dunne-m-d-to-strategic-advisor-and-mem-itrm-20201223monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-receives-approval-to-transfer-to-nasdaq-capital-market-trading-on-nasd-itrm-20201223monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-third-quarter-2020-financial-results-nda-filing-expected-q4-20-itrm-20201116monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-announces-pricing-of-17-5-million-upsized-public-offering-dublin-irela-itrm-20201023monthly0.5https://www.biopharmawatch.com/news/ITRM/cash-resources-and-the-company-s-ability-to-continue-as-a-going-concern-the-impact-of-covi-itrm-20200930monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-announces-revised-results-of-rights-offering-dublin-ireland-and-chicag-itrm-20200902monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-announces-expiration-and-preliminary-results-of-rights-offering-dublin-itrm-20200831monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-commences-rights-offering-dublin-ireland-and-chicago-itrm-20200811monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-second-quarter-2020-financial-results-meeting-with-fda-schedul-itrm-20200806monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-informs-shareholders-of-record-date-for-planned-rights-offering-dublin-itrm-20200713monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-announces-5-million-registered-direct-offering-priced-at-the-market-un-itrm-20200630monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-announces-topline-results-from-its-phase-3-clinical-trial-of-oral-sulo-itrm-20200629monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-public-limited-company-amended-and-restated-2018-equity-incentive-plan-itrm-20200615monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-announces-5-million-registered-direct-offering-priced-at-the-market-un-itrm-20200603monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-announces-topline-results-for-a-phase-3-clinical-trial-of-oral-and-iv--itrm-20200601monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-first-quarter-2020-financial-results-phase-3-topline-results-f-itrm-20200514monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-topline-da-itrm-20200312monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-announces-52-million-private-placement-with-new-and-existing-investors-itrm-20200117monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-third-quarter-2019-financial-results-and-highlights-phase-3-to-itrm-20191112monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-second-quarter-2019-financial-results-phase-3-topline-data-ant-itrm-20190814monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-first-quarter-2019-financial-results-on-track-to-complete-enro-itrm-20190514monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-on-track-t-itrm-20190325monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-reports-third-quarter-2018-financial-results-and-recent-highlights-dublin-ireland-a-itrm-20181114monthly0.5https://www.biopharmawatch.com/news/ITRM/iterum-reports-second-quarter-2018-financial-results-and-recent-highlights-dublin-and-chic-itrm-20180814monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-announces-80m-ubx-20200804monthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-appoints-anirvan-ghosh-phd-as-chief-executive-officer-renowned-scienti-ubx-20200302monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-receives-the-delisting-decision-from-the-nasdaq-hearings-panel-south--casi-20260225monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-announces-up-to-20-million-convertible-note-financing-investment-to-f-casi-20251211monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-announces-changes-in-board-governance-james-huang-appointed-as-non-ex-casi-20251119monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-announces-third-quarter-2025-business-and-financial-results-south-san-casi-20251114monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-receives-and-appeals-delisting-determination-from-nasdaq-south-san-fr-casi-20251110monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-appoints-james-huang-to-board-of-directors-industry-veteran-brings-ov-casi-20250926monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-appoints-barbara-krebs-pohl-phd-to-board-of-directors-industry-vetera-casi-20250902monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-announces-second-quarter-2025-business-and-financial-results-south-sa-casi-20250829monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-announces-fda-clearance-of-ind-application-for-cid-103-in-renal-allog-casi-20250804monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-appoints-david-cory-as-chief-executive-officer-to-lead-u-s-company-fo-casi-20250721monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-provides-business-and-clinical-update-beijing-china-casi-20250519monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-announces-first-quarter-2025-business-and-financial-results-beijing-c-casi-20250516monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-enters-into-definitive-agreement-for-the-divestiture-of-assets-in-chi-casi-20250512monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-receives-nasdaq-deficiency-notice-regarding-minimum-market-value-requ-casi-20250507monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-announces-receipt-of-an-updated-non-binding-proposal-to-acquire-entir-casi-20250403monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-announces-fourth-quarter-and-full-year-2024-business-and-financial-re-casi-20250331monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-announces-third-quarter-2024-business-and-financial-results-beijing-c-casi-20241115monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-announces-second-quarter-2024-business-and-financial-results-beijing--casi-20240816monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-announces-appointment-of-daniel-lang-md-as-cfo-and-svp-beijing-china--casi-20240708monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-announces-plan-to-submit-ind-application-for-cid-103-an-anti-cd-38-an-casi-20240621monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-announces-15-million-private-placement-financing-by-venrock-healthcar-casi-20240627monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-announces-first-quarter-2024-business-and-financial-results-beijing-c-casi-20240514monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-announces-fourth-quarter-and-full-year-2023-business-and-financial-re-casi-20240328monthly0.5https://www.biopharmawatch.com/news/CASI/www-casipharmaceuticals-com-casi-pharmaceuticals-announces-third-quarter-2023-business-and-casi-20231114monthly0.5https://www.biopharmawatch.com/news/CASI/www-casipharmaceuticals-com-casi-pharmaceuticals-announces-market-approval-of-cnct19-by-ch-casi-20231108monthly0.5https://www.biopharmawatch.com/news/CASI/www-casipharmaceuticals-com-casi-pharmaceuticals-announces-second-quarter-2023-business-an-casi-20230811monthly0.5https://www.biopharmawatch.com/news/CASI/www-casipharmaceuticals-com-mundipharma-international-corporation-limited-mundipharma-medi-casi-20230801monthly0.5https://www.biopharmawatch.com/news/CASI/www-casipharmaceuticals-com-casi-pharmaceuticals-acquires-global-intellectual-property-rig-casi-20230720monthly0.5https://www.biopharmawatch.com/news/CASI/www-casipharmaceuticals-com-casi-pharmaceuticals-announces-first-quarter-2023-financial-re-casi-20230517monthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-announces-fourth-quarter-and-full-year-2022-financial-results-beijing-casi-20230426monthly0.5https://www.biopharmawatch.com/news/CASI/www-casipharmaceuticals-com-casi-pharmaceuticals-completes-redomiciliation-merger-beijing--casi-20230321monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-preliminary-fourth-quarter-and-full-year-2024-financial-results-ac-ttoo-20250107monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-plans-to-license-its-proprietary-technology-to-expand-its-leadersh-ttoo-20241209monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-third-quarter-2024-financial-results-achieved-34-quarterly-revenue-ttoo-20241114monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-business-update-ttoo-20241010monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-preliminary-third-quarter-2024-financial-results-achieved-35-incre-ttoo-20241007monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-achieves-successful-defense-of-patent-for-direct-from-whole-blood-pathogen-d-ttoo-20240920monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-receives-fda-clearance-to-market-the-t2candida-panel-for-pediatric-patients--ttoo-20240916monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-provides-updates-on-its-new-product-development-pipeline-progress-company-pl-ttoo-20240909monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-second-quarter-2024-financial-results-achieved-record-quarterly-an-ttoo-20240729monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-first-quarter-2024-financial-results-achieved-double-digit-growth--ttoo-20240506monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-extension-of-multi-year-capital-equipment-supplier-agreement-with--ttoo-20240328monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-unveils-t2lyme-launch-plans-and-provides-additional-business-updates-anticip-ttoo-20240320monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-new-publication-highlighting-the-clinical-benefits-and-performance-ttoo-20240318monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-4q-2023-ttoo-20240215monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-preliminary-fourth-quarter-and-full-year-2023-financial-results-ad-ttoo-20240215monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-highlights-new-clinical-data-presented-at-idweek-2023-conference-data-demons-ttoo-20231024monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-3q-2023-ttoo-20231012monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-preliminary-third-quarter-2023-financial-results-and-business-upda-ttoo-20231012monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-second-quarter-2023-financial-results-received-fda-breakthrough-de-ttoo-20230807monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-regains-compliance-with-nasdaq-s-market-value-of-listed-securities-requireme-ttoo-20230809monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-receives-extension-to-comply-with-nasdaq-listing-requirements-ttoo-20230731monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-receives-fda-breakthrough-device-designation-for-candida-auris-diagnostic-te-ttoo-20230720monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-preliminary-second-quarter-2023-financial-results-received-record--ttoo-20230712monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-clinical-collaboration-with-vanderbilt-university-medical-center-t-ttoo-20230609monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-submission-for-fda-breakthrough-device-designation-for-candida-aur-ttoo-20230605monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-second-largest-sepsis-driven-instrument-sale-in-company-history-ttoo-20230530monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-first-quarter-2023-financial-results-filed-fda-submission-for-t2bi-ttoo-20230523monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-fourth-quarter-and-full-year-2022-financial-results-achieved-recor-ttoo-20230313monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-preliminary-fourth-quarter-and-full-year-2022-financial-results-ac-ttoo-20230123monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-third-quarter-2022-financial-results-achieves-record-quarterly-sep-ttoo-20221110monthly0.5https://www.biopharmawatch.com/news/TTOO/hhs-and-the-cohen-foundation-name-t2-biosystems-a-phase-1-winner-in-lymex-diagnostics-priz-ttoo-20221107monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-highlights-multiple-new-studies-demonstrating-improved-rapid-detection-acros-ttoo-20221014monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-plan-to-commercialize-a-diagnostic-test-for-early-lyme-disease-pla-ttoo-20221013monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-preliminary-third-quarter-2022-financial-results-and-updates-2022--ttoo-20221012monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-second-quarter-2022-financial-results-t2dx-instrument-contracts-in-ttoo-20220815monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-to-explore-potential-to-develop-rapid-molecular-diagnostic-test-for-monkeypo-ttoo-20220809monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-receives-fda-breakthrough-device-designation-for-the-t2lyme-panel-molecular--ttoo-20220711monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-preliminary-second-quarter-2022-financial-results-implemented-expe-ttoo-20220706monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-first-quarter-2022-financial-results-results-driven-by-strong-seps-ttoo-20220505monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-submission-for-fda-breakthrough-device-designation-for-t2biothreat-ttoo-20220427monthly0.5https://www.biopharmawatch.com/news/TTOO/analyst-and-investor-day-nasdaq-ttoo-ttoo-20220412monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-fourth-quarter-full-year-2021-financial-results-full-year-2021-tot-ttoo-20220217monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-preliminary-fourth-quarter-and-full-year-2021-results-ttoo-20220111monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-third-quarter-2021-financial-results-ttoo-20211104monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-second-quarter-2021-financial-results-ttoo-20210805monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-1q-ttoo-20210506monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-first-quarter-2021-financial-results-ttoo-20210506monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-fourth-quarter-full-year-2020-financial-results-ttoo-20210309monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-preliminary-fourth-quarter-and-full-year-2020-results-strengthens--ttoo-20210126monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-third-quarter-2020-financial-results-total-revenues-increase-by-21-ttoo-20201104monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-barda-exercise-of-contract-option-1-valued-at-10-5-million-advance-ttoo-20200930monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-second-quarter-2020-financial-results-ttoo-20200811monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-preliminary-second-quarter-2020-financial-results-launches-the-t2s-ttoo-20200630monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-first-quarter-2020-financial-results-ttoo-20200505monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-preliminary-first-quarter-2020-financial-results-suspends-2020-fin-ttoo-20200324monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-fourth-quarter-and-full-year-2019-financial-results-ttoo-20200224monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-preliminary-fourth-quarter-2019-financial-results-enters-exclusive-ttoo-20200109monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-appoints-industry-veteran-john-sperzel-as-chief-executive-officer-ttoo-20200109monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-granting-of-ce-mark-for-t2resistance-panel-the-t2resistance-panel--ttoo-20191120monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-third-quarter-2019-financial-highlights-and-provides-corporate-updat-ttoo-20191112monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-second-quarter-2019-financial-results-and-provides-corporate-update--ttoo-20190730monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-first-quarter-2019-financial-results-and-provides-corporate-update-e-ttoo-20190502monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides-cor-ttoo-20190307monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-third-quarter-2018-financial-results-and-provides-corporate-update-q-ttoo-20181101monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-second-quarter-2018-financial-results-and-provides-corporate-update--ttoo-20180802monthly0.5https://www.biopharmawatch.com/news/TTOO/business-update-and-financial-guidance-conference-call-script-john-mcdonough-ceo-commentar-ttoo-20180529monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-receives-fda-clearance-to-market-t2bacteria-panel-for-detection-of-sepsis-ca-ttoo-20180529monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-first-quarter-2018-financial-results-and-provides-corporate-update-q-ttoo-20180508monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-fourth-quarter-and-full-year-2017-financial-results-and-business-upd-ttoo-20180306monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-cfo-transition-lexington-ma-ttoo-20180205monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-preliminary-fourth-quarter-2017-financial-results-and-provides-upd-ttoo-20180104monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-third-quarter-2017-financial-results-and-provides-company-update-sub-ttoo-20171102monthly0.5https://www.biopharmawatch.com/news/TTOO/transforming-diagnostics-patient-care-economics-september-2017-nasdaq-ttoo-forward-looking-ttoo-20170914monthly0.5https://www.biopharmawatch.com/news/TTOO/t2bacteria-panel-pivotal-clinical-study-information-on-ttoo-20170911monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-second-quarter-2017-financial-results-provides-company-update-sequen-ttoo-20170803monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-first-quarter-2017-results-and-corporate-update-ttoo-20170502monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-names-darlene-deptula-hicks-ttoo-20170501monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-inc-condensed-consolidated-statements-of-operations-and-comprehensive-loss-i-ttoo-20170308monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-fourth-quarter-and-full-year-2016-results-ttoo-20170213monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-preliminary-fourth-quarter-results-and-operational-progress-on-track-ttoo-20170109monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-inc-announces-50m-credit-facility-retiring-former-debt-facility-significantl-ttoo-20170105monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-third-quarter-results-recent-collaborations-and-strategic-investment-ttoo-20161101monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-collaboration-with-allergan-to-develop-the-first-blood-based-diagn-ttoo-20161101monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-40-million-dollar-equity-investment-by-partner-canon-u-s-a-canon-u-ttoo-20160922monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-2016-second-quarter-six-month-results-ttoo-20160801monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-preliminary-second-quarter-commercial-clinical-and-executive-perso-ttoo-20160707monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-2016-first-quarter-results-ttoo-20160502monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-to-transition-chief-financial-officer-role-to-shawn-lynch-veteran-financial--ttoo-20160502monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-preliminary-2016-first-quarter-financial-results-company-adjusts-t-ttoo-20160411monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-2015-fourth-quarter-full-year-results-t2candida-on-track-for-year-t2-ttoo-20160216monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-announces-proposed-public-offering-of-common-stock-ttoo-20151201monthly0.5https://www.biopharmawatch.com/news/TTOO/final-t2-biosystems-reports-2015-third-quarter-results-nine-new-hospitals-signed-contracts-ttoo-20151102monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-2015-second-quarter-results-ttoo-20150804monthly0.5https://www.biopharmawatch.com/news/TTOO/for-immediate-release-t2-ttoo-20150804monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-2015-first-quarter-results-ttoo-20150505monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-reports-2014-fourth-quarter-full-year-results-ttoo-20150217monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-and-canon-u-s-life-sciences-announce-joint-collaboration-to-develop-novel-te-ttoo-20150203monthly0.5https://www.biopharmawatch.com/news/TTOO/t2-biosystems-receives-fda-authorization-to-market-t2candida-and-t2dx-for-the-detection-of-ttoo-20140922monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-poised-for-new-future-with-resolution-of-federal-investigation-zyxi-20260217monthly0.5https://www.biopharmawatch.com/news/ZYXI/new-zynex-leadership-responds-to-indictment-of-former-executives-zyxi-20260122monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-financial-restructuring-puts-company-on-path-to-long-term-success-zyxi-20251216monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-reports-third-quarter-2025-financial-results-zyxi-20251117monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-appointment-of-bret-wise-to-board-of-directors-as-audit-committee-chair-zyxi-20251014monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-arrival-of-steven-dyson-as-ceo-and-appointment-of-new-leadership-in-key-ro-zyxi-20250818monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-reports-second-quarter-2025-financial-results-zyxi-20250731monthly0.5https://www.biopharmawatch.com/news/ZYXI/tricare-temporary-payment-suspension-update-zyxi-20250702monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-steven-dyson-as-new-ceo-englewood-co-zyxi-20250630monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-submits-fda-application-for-its-nico-laser-pulse-oximeter-zyxi-20250512monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-reports-first-quarter-2025-financial-results-zyxi-20250429monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-reports-fourth-quarter-and-full-year-2024-financial-results-zyxi-20250311monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-reports-third-quarter-2024-financial-results-zyxi-20241024monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-reports-second-quarter-2024-financial-results-q2-2024-revenue-increased-11-to-49-9-m-zyxi-20240725monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-reports-first-quarter-2024-financial-results-q1-2024-revenue-increased-10-to-46-5-mi-zyxi-20240430monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-reports-fourth-quarter-and-full-year-2023-financial-results-fy-2023-revenue-increase-zyxi-20240229monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-share-repurchase-program-englewood-co-zyxi-20231101monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-review-of-strategic-alternatives-englewood-co-zyxi-20231031monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-reports-third-quarter-2023-financial-results-q3-2023-revenue-increased-20-to-49-9-mi-zyxi-20231026monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-share-repurchase-program-englewood-co-zyxi-20230911monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-reports-second-quarter-2023-financial-results-q2-2023-revenue-increased-22-to-45-0-m-zyxi-20230727monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-reports-preliminary-second-quarter-2023-results-englewood-co-zyxi-20230712monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-receives-fda-clearance-of-cm-1600-monitor-for-improved-blood-and-fluid-management-en-zyxi-20230620monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-share-buyback-program-englewood-co-zyxi-20230614monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-proposed-50-million-offering-of-convertible-senior-notes-zyxi-20230503monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2023-first-quarter-earnings-englewood-co-zyxi-20230427monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-reports-preliminary-first-quarter-2023-results-englewood-co-zyxi-20230411monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2022-fourth-quarter-and-full-year-earnings-englewood-co-zyxi-20230313monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-leases-new-facility-to-accommodate-growth-zyxi-20230221monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-additional-share-buyback-program-englewood-co-zyxi-20221101monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2022-third-quarter-earnings-englewood-co-october-27-2022-zynex-inc-nasdaq--zyxi-20221027monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2022-second-quarter-earnings-englewood-co-zyxi-20220728monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-reports-preliminary-second-quarter-2022-results-and-reiterates-full-year-revenue-and-zyxi-20220711monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-additional-share-buyback-program-englewood-co-zyxi-20220609monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2022-first-quarter-earnings-englewood-co-zyxi-20220428monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-share-buyback-program-englewood-co-zyxi-20220411monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-reports-preliminary-first-quarter-2022-results-and-provides-business-update-englewoo-zyxi-20220408monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2021-fourth-quarter-and-full-year-earnings-englewood-co-zyxi-20220224monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-increased-q4-2021-adjusted-ebitda-estimate-and-18-order-growth-englewood-c-zyxi-20220118monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-acquisition-of-kestrel-labs-expanding-its-product-portfolio-in-patient-mon-zyxi-20211223monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-declares-special-cash-dividend-of-0-10-per-share-and-10-stock-dividend-englewood-co-zyxi-20211110monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2021-third-quarter-earnings-2021-third-quarter-o-revenue-increased-74-year-zyxi-20211102monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-70-order-growth-and-increases-q3-2021-adjusted-ebitda-estimate-englewood-c-zyxi-20211013monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2021-second-quarter-earnings-2021-second-quarter-revenue-increased-61-year-zyxi-20210729monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-247-order-growth-and-increases-q2-adjusted-ebitda-estimate-englewood-co-zyxi-20210715monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2021-first-quarter-earnings-2021-first-quarter-o-revenue-increased-58-year-zyxi-20210429monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-140-year-over-year-order-growth-in-q1-2021-englewood-co-zyxi-20210412monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-share-buyback-program-englewood-co-zyxi-20210308monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2020-fourth-quarter-and-full-year-earnings-2020-full-year-o-revenue-increa-zyxi-20210225monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-appoints-anna-lucsok-as-chief-operating-officer-of-zynex-medical-englewood-colo-pr-n-zyxi-20210128monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-117-year-over-year-order-growth-and-increases-adjusted-ebitda-estimate-eng-zyxi-20210112monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-third-quarter-2020-earnings-revenue-increased-69-year-over-year-to-20-0-mi-zyxi-20201027monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-appoints-neil-friery-as-president-and-chief-operating-officer-of-monitoring-solution-zyxi-20201023monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-96-year-over-year-order-growth-englewood-co-zyxi-20201012monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-continued-growth-leads-to-a-new-manufacturing-and-warehouse-facility-englewood-co-zyxi-20201006monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-reaches-400-salesperson-milestone-ahead-of-schedule-englewood-co-zyxi-20200910monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-reports-83-order-growth-for-july-and-august-englewood-co-zyxi-20200903monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-second-quarter-2020-earnings-revenue-increased-87-year-over-year-to-19-3-m-zyxi-20200728monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-inc-prices-public-offering-of-common-stock-zyxi-20200714monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-37-order-growth-and-increases-q2-and-full-year-revenue-estimates-englewood-zyxi-20200709monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2020-first-quarter-earnings-revenue-increased-66-year-over-year-to-15-2-mi-zyxi-20200428monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2019-fourth-quarter-and-full-year-earnings-2019-full-year-o-revenue-increa-zyxi-20200227monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-receives-fda-clearance-for-its-blood-volume-monitor-englewood-co-zyxi-20200225monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-expands-corporate-headquarters-to-accommodate-growth-englewood-co-zyxi-20200107monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2019-third-quarter-financial-results-revenue-increased-45-year-over-year-t-zyxi-20191029monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2019-second-quarter-earnings-revenue-increased-36-year-over-year-to-10-3-m-zyxi-20190731monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-expands-executive-team-appoints-joseph-papandrea-chief-operating-officer-englewood-c-zyxi-20190722monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2019-first-quarter-earnings-revenue-increased-34-year-over-year-to-9-2-mil-zyxi-20190430monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-expands-corporate-headquarters-to-accommodate-growth-englewood-co-zyxi-20190312monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2018-fourth-quarter-and-full-year-earnings-2018-full-year-revenue-increase-zyxi-20190212monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-uplisting-to-the-nasdaq-capital-market-englewood-co-zyxi-20190207monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2018-third-quarter-earnings-and-special-dividend-revenue-increased-19-year-zyxi-20181106monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2018-second-quarter-earnings-revenue-increased-50-year-over-year-to-7-6-mi-zyxi-20180802monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-share-buyback-program-englewood-co-zyxi-20180514monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2018-first-quarter-earnings-revenue-grew-100-year-over-year-to-6-9-million-zyxi-20180508monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2017-fourth-quarter-earnings-revenue-grew-178-year-over-year-to-8-1-millio-zyxi-20180228monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-4th-quarter-and-year-end-revenue-guidance-update-zyxi-20180108monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-share-buyback-program-zyxi-20171206monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2017-third-quarter-earnings-revenue-grew-88-year-over-year-to-6-8-million--zyxi-20171113monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2017-first-quarter-results-zyxi-20170515monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2016-year-end-results-zyxi-20170403monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-third-quarter-2016-profit-zyxi-20161110monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-second-quarter-2015-results-zyxi-20150813monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-provides-updated-guidance-for-the-second-quarter-2015-electrotherapy-revenue-stable--zyxi-20150612monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-first-quarter-2015-results-compound-pharmacy-revenues-increase-three-fold-zyxi-20150512monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-inc-provides-financial-update-zyxi-20150416monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-third-quarter-2014-results-lone-tree-colo-zyxi-20141107monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-first-quarter-2014-results-lone-tree-colo-zyxi-20140513monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2013-year-end-results-lone-tree-colo-zyxi-20140327monthly0.5https://www.biopharmawatch.com/news/ZYXI/attn-mats-wahistrom-zyxi-20131230monthly0.5https://www.biopharmawatch.com/news/ZYXI/investor-fact-sheet-zynex-inc-otcqb-zyxi-company-overview-zynex-founded-in-1996-develops-m-zyxi-20140102monthly0.5https://www.biopharmawatch.com/news/ZYXI/forward-looking-statements-statements-made-in-this-presentation-include-financial-estimate-zyxi-20131231monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-third-quarter-2013-financial-results-zyxi-20131107monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-second-quarter-2013-financial-results-zyxi-20130808monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-first-quarter-2013-financial-results-zyxi-20130508monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2012-year-end-results-lone-tree-colo-zyxi-20130314monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-third-quarter-2012-financial-results-lone-tree-colo-zyxi-20121107monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-second-quarter-2012-financial-results-zyxi-20120807monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-first-quarter-2012-financial-results-lone-tree-colo-zyxi-20120508monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2011-year-end-results-zyxi-20120315monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-record-third-quarter-2011-sales-zyxi-20111103monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-second-quarter-2011-financial-results-zynex-inc-otcbb-zyxi-a-provider-and--zyxi-20110803monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-first-quarter-2011-financial-results-zynex-inc-otcbb-zyxi-a-provider-of-no-zyxi-20110505monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-2010-year-end-results-zynex-inc-otcbb-zyxi-a-provider-of-pain-management-s-zyxi-20110310monthly0.5https://www.biopharmawatch.com/news/ZYXI/march-2011-1-march-2011-2-forward-looking-statements-statements-made-in-this-presentation--zyxi-20110307monthly0.5https://www.biopharmawatch.com/news/ZYXI/page-5-of-5-zyxi-20101109monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-new-and-expanded-credit-agreement-and-preliminary-fiscal-year-2009-net-cas-zyxi-20100322monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-signs-lease-to-move-into-larger-building-zyxi-20091113monthly0.5https://www.biopharmawatch.com/news/ZYXI/the-following-report-is-excerpted-from-the-wall-street-transcript-company-interview-thomas-zyxi-20090921monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-announces-adjustments-to-2008-quarterly-financial-statements-and-estimated-2008-net--zyxi-20090401monthly0.5https://www.biopharmawatch.com/news/ZYXI/press-release-zyxi-20070205monthly0.5https://www.biopharmawatch.com/news/ZYXI/correcting-and-replacing-zynex-medical-announces-third-quarter-net-revenue-increases-23-mo-zyxi-20061121monthly0.5https://www.biopharmawatch.com/news/ZYXI/source-zynex-medical-holdings-inc-zynex-medical-s-two-fold-increase-in-september-unit-orde-zyxi-20061024monthly0.5https://www.biopharmawatch.com/news/ZYXI/for-immediate-release-zyxi-20060317monthly0.5https://www.biopharmawatch.com/news/ZYXI/zynex-logo-for-immediate-release-zynex-medical-establishes-400-000-credit-facility-zyxi-20051005monthly0.5https://www.biopharmawatch.com/news/ZYXI/approved-by-thomas-sandgaard-for-distribution-on-6-28-05-signed-zynex-logo-thomas-sandgaar-zyxi-20050628monthly0.5https://www.biopharmawatch.com/news/ZYXI/page-1-of-2-zynex-medical-appoints-peter-j-leveton-chief-financial-officer-littleton-colo--zyxi-20050516monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-reports-full-year-2024-financial-results-afib-20250324monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-announces-operational-downsizing-afib-20241204monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-reports-third-quarter-and-year-to-date-2024-financial-results-afib-20241114monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-reports-second-quarter-and-year-to-date-2024-financial-results-afib-20240808monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-reports-first-quarter-2024-financial-results-afib-20240509monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-reports-fourth-quarter-and-full-year-2023-financial-results-afib-20240401monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-reports-third-quarter-2023-financial-results-afib-20231108monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-reports-second-quarter-2023-financial-results-afib-20230807monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-reports-first-quarter-2023-financial-results-afib-20230511monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results-carlsbad-calif-afib-20230420monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-announces-preliminary-unaudited-fourth-quarter-and-full-year-2022-results-a-afib-20230109monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-reports-third-quarter-2022-financial-results-carlsbad-calif-afib-20221110monthly0.5https://www.biopharmawatch.com/news/AFIB/caution-regarding-forward-looking-statements-this-press-release-includes-statements-that-m-afib-20221103monthly0.5https://www.biopharmawatch.com/news/AFIB/unaudited-pro-forma-condensed-consolidated-financial-information-overview-on-afib-20220811monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-reports-second-quarter-2022-financial-results-carlsbad-calif-afib-20220811monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-announces-ceo-appointment-and-preliminary-second-quarter-revenue-results-afib-20220721monthly0.5https://www.biopharmawatch.com/news/AFIB/unaudited-pro-forma-condensed-consolidated-financial-information-overview-on-afib-20220630monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-reports-first-quarter-2022-financial-results-and-ceo-transition-carlsbad-ca-afib-20220512monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-announces-agreements-to-fund-strategic-growth-priorities-carlsbad-calif-afib-20220427monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-reports-fourth-quarter-and-full-year-2021-financial-results-carlsbad-calif-afib-20220330monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-announces-restructuring-and-preliminary-unaudited-fourth-quarter-and-full-y-afib-20220119monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-reports-third-quarter-2021-financial-results-carlsbad-calif-afib-20211111monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-reports-second-quarter-2021-financial-results-carlsbad-calif-afib-20210812monthly0.5https://www.biopharmawatch.com/news/AFIB/caution-regarding-forward-looking-statements-this-press-release-includes-statements-that-m-afib-20210630monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-reports-first-quarter-2021-financial-results-carlsbad-calif-afib-20210512monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-reports-fourth-quarter-and-full-year-2020-financial-results-carlsbad-calif-afib-20210318monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-inc-appoints-new-chief-financial-officer-and-new-board-member-david-roman-a-afib-20210209monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-reports-preliminary-unaudited-fourth-quarter-and-full-year-2020-results-car-afib-20210113monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-reports-third-quarter-2020-results-carlsbad-calif-afib-20201112monthly0.5https://www.biopharmawatch.com/news/AFIB/acutus-medical-reports-second-quarter-2020-financial-results-carlsbad-calif-afib-20200917monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-announces-voluntary-delisting-from-nasdaq-and-sec-deregistration-syrs-20250228monthly0.5https://www.biopharmawatch.com/news/SYRS/society-of-hematologic-oncology-12th-annual-meeting-september-4-7-2024-george-r-brown-conv-syrs-20240905monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-provides-update-on-select-aml-1-phase-2-clinical-trial-syrs-20240812monthly0.5https://www.biopharmawatch.com/news/SYRS/forward-looking-statements-this-presentation-contains-forward-looking-statements-including-syrs-20240108monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-announces-pricing-of-45-0-million-underwritten-offering-of-common-stock-and-pre-fund-syrs-20231219monthly0.5https://www.biopharmawatch.com/news/SYRS/forward-looking-statements-this-presentation-contains-forward-looking-statements-including-syrs-20231206monthly0.5https://www.biopharmawatch.com/news/SYRS/advancing-novel-treatments-for-hematologic-malignancies-may-2023-forward-looking-statement-syrs-20230525monthly0.5https://www.biopharmawatch.com/news/SYRS/forward-looking-statements-this-presentation-contains-forward-looking-statements-including-syrs-20230109monthly0.5https://www.biopharmawatch.com/news/SYRS/forward-looking-statements-this-presentation-contains-forward-looking-statements-including-syrs-20221212monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-announces-closing-of-merger-with-tyme-technologies-and-concurrent-private-placement--syrs-20220916monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-pharmaceuticals-inc-2022-equity-incentive-plan-1-purpose-the-purpose-of-this-2022-eq-syrs-20220915monthly0.5https://www.biopharmawatch.com/news/SYRS/refinitiv-streetevents-www-refinitiv-com-contact-us-2022-refinitiv-all-rights-reserved-rep-syrs-20220706monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-to-raise-approximately-190-million-through-merger-with-tyme-technologies-and-concurr-syrs-20220705monthly0.5https://www.biopharmawatch.com/news/SYRS/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-syrs-20220607monthly0.5https://www.biopharmawatch.com/news/SYRS/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-syrs-20220110monthly0.5https://www.biopharmawatch.com/news/SYRS/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-syrs-20210920monthly0.5https://www.biopharmawatch.com/news/SYRS/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-syrs-20210526monthly0.5https://www.biopharmawatch.com/news/SYRS/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-syrs-20210225monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-announces-proposed-offering-of-common-stock-syrs-20210119monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-announces-strategic-priorities-and-expected-milestones-on-track-to-initiate-three-cl-syrs-20210111monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-closes-90-5-million-strategic-financing-syrs-20201208monthly0.5https://www.biopharmawatch.com/news/SYRS/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-syrs-20201207monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-presents-initial-data-from-phase-1-clinical-trial-of-sy-5609-its-selective-oral-cdk7-syrs-20201024monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-announces-60-million-loan-facility-with-oxford-finance-llc-initial-tranche-extends-c-syrs-20200213monthly0.5https://www.biopharmawatch.com/news/SYRS/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-syrs-20200113monthly0.5https://www.biopharmawatch.com/news/SYRS/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-syrs-20191202monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-announces-new-data-from-phase-2-trial-of-sy-1425-in-combination-with-azacitidine-dem-syrs-20191024monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-announces-update-on-selective-cdk7-inhibitor-portfolio-prioritizing-development-of-s-syrs-20191017monthly0.5https://www.biopharmawatch.com/news/SYRS/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-syrs-20190424monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-announces-proposed-concurrent-public-offerings-of-common-stock-with-warrants-to-purc-syrs-20190404monthly0.5https://www.biopharmawatch.com/news/SYRS/an-expression-makes-a-world-of-difference-january-2019-forward-looking-statements-this-pre-syrs-20190107monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-announces-promising-clinical-data-from-ongoing-phase-2-trial-of-sy-1425-in-genomical-syrs-20181202monthly0.5https://www.biopharmawatch.com/news/SYRS/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-syrs-20181115monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-reports-fourth-quarter-and-full-year-2017-financial-results-and-highlights-recent-ac-syrs-20180312monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-announces-proposed-offering-of-common-stock-syrs-20180130monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-announces-2018-strategic-priorities-and-expected-milestones-on-track-to-report-clini-syrs-20180108monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-announces-initial-clinical-data-from-ongoing-phase-2-trial-of-sy-1425-showing-biolog-syrs-20171210monthly0.5https://www.biopharmawatch.com/news/SYRS/company-overview-october-2017-cautionary-note-regarding-forward-looking-statements-this-pr-syrs-20171006monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-closes-35-million-private-financing-syrs-20170426monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-announces-35-million-private-placement-cambridge-mass-business-wire-syrs-20170421monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-pharmaceuticals-announces-2017-strategic-priorities-and-goals-2016-accomplishments-p-syrs-20170109monthly0.5https://www.biopharmawatch.com/news/SYRS/syros-pharmaceuticals-reports-second-quarter-2016-financial-results-and-provides-business--syrs-20160815monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-inc-announces-1-for-10-reverse-stock-split-bwv-20260519monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-reports-q1-2026-progress-at-proteomedix-ag-including-two-new-peer-reviewed-publi-bwv-20260513monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-inc-announces-1-for-5-reverse-stock-split-bwv-20260323monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-to-acquire-realbotix-llc-usa-based-ai-powered-humanoid-robotics-company-a-leadin-bwv-20260212monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-announces-financing-through-a-12-9-million-private-placement-of-series-d-preferr-bwv-20250926monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-announces-its-subsidiary-proteomedix-licenses-manufacturing-ip-to-immunovia-enab-bwv-20250922monthly0.5https://www.biopharmawatch.com/news/BWV/july-16-2025-onconetix-and-ocuvex-therapeutics-announce-execution-of-definitive-merger-agr-bwv-20250716monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-inc-announces-positive-decision-by-nasdaq-hearings-panel-bwv-20250616monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-inc-announces-1-for-85-reverse-stock-split-and-results-of-the-special-meeting-of-bwv-20250611monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-inc-announces-receipt-of-additional-notice-from-nasdaq-cincinnati-oh-bwv-20250522monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-inc-announces-receipt-of-additional-notice-from-nasdaq-cincinnati-oh-bwv-20250430monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-signs-letter-of-intent-for-potential-business-combination-with-ocuvex-therapeuti-bwv-20250408monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-announces-successful-clinical-validation-of-its-innovative-prostate-cancer-test--bwv-20250324monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-announces-new-clinical-data-for-its-innovative-prostate-cancer-test-proclarix-ac-bwv-20250319monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-inc-consulting-agreement-this-consulting-agreement-the-agreement-shall-be-effect-bwv-20250228monthly0.5https://www.biopharmawatch.com/news/BWV/settlement-agreement-this-settlement-agreement-the-settlement-agreement-is-entered-into-as-bwv-20250115monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-inc-announces-receipt-of-notice-from-nasdaq-regarding-late-filing-of-quarterly-r-bwv-20241212monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-announces-financing-through-a-2-0-million-private-placement-of-series-c-preferre-bwv-20241003monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-inc-announces-1-for-40-reverse-stock-split-and-results-of-the-annual-meeting-of--bwv-20240920monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-inc-formerly-known-as-blue-water-biotech-inc-and-blue-water-vaccines-inc-the-com-bwv-20240905monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-announces-closing-of-warrant-exercise-for-1-11-million-gross-proceeds-cincinnati-bwv-20240715monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-announces-exercise-of-warrants-for-1-11-million-gross-proceeds-bwv-20240711monthly0.5https://www.biopharmawatch.com/news/BWV/release-of-claims-as-used-in-this-release-of-claims-this-release-the-term-claims-will-incl-bwv-20240613monthly0.5https://www.biopharmawatch.com/news/BWV/proteomedix-ag-financial-statements-and-independent-auditors-report-for-the-years-ended-bwv-20240227monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-announces-appointment-of-seasoned-biotech-executives-dr-ajit-singh-and-dr-thomas-bwv-20240213monthly0.5https://www.biopharmawatch.com/news/BWV/release-of-claims-i-dr-neil-j-campbell-understand-and-of-my-own-free-will-enter-into-this--bwv-20240112monthly0.5https://www.biopharmawatch.com/news/BWV/onconetix-chief-executive-officer-dr-neil-j-campbell-issues-letter-to-shareholders-cincinn-bwv-20231219monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-biotech-acquires-proteomedix-as-part-of-transformation-to-commercial-stage-onco-bwv-20231218monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-biotech-signs-non-binding-term-sheet-to-acquire-a-commercial-stage-oncology-com-bwv-20231102monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-biotech-issues-letter-to-shareholders-blue-water-biotech-issues-letter-to-share-bwv-20231030monthly0.5https://www.biopharmawatch.com/news/BWV/general-release-of-claims-i-jon-garfield-hereby-grant-this-general-release-of-claims-relea-bwv-20231010monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-biotech-inc-announces-notification-from-nasdaq-related-to-delayed-quarterly-rep-bwv-20230828monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-biotech-and-copay-consultants-collaborate-to-build-copay-assistance-programs-fo-bwv-20230810monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-biotech-announces-closing-of-warrant-exercise-and-issuance-of-new-warrants-in-a-bwv-20230803monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-biotech-announces-exercise-of-warrants-and-issuance-of-new-warrants-in-a-privat-bwv-20230801monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-biotech-and-knipper-health-join-forces-to-distribute-samples-for-entadfi-and-zo-bwv-20230731monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-biotech-teams-with-upscripthealth-to-launch-telemedicine-platform-for-benign-pr-bwv-20230725monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-biotech-issues-ceo-shareholder-letter-providing-update-on-commercial-launch-act-bwv-20230717monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-biotech-teams-with-advantage-point-solutions-to-provide-healthcare-payer-covera-bwv-20230711monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-biotech-secures-license-from-ohio-state-board-of-pharmacy-to-operate-as-pharmac-bwv-20230706monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-biotech-teams-with-bfw-advertising-to-market-and-advertise-commercial-product-p-bwv-20230706monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-biotech-announces-preclinical-data-supporting-immunogenicity-of-novel-monkeypox-bwv-20230628monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-biotech-collaborates-with-iqvia-to-build-medical-sales-representative-team-to-m-bwv-20230621monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-biotech-expands-commercial-portfolio-by-acquiring-six-fda-approved-drugs-across-bwv-20230614monthly0.5https://www.biopharmawatch.com/news/BWV/corporate-overview-entadfi-opportunity-may-2023-nasdaq-bwv-forward-looking-statements-2-th-bwv-20230515monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-biotech-reports-first-quarter-2023-financial-results-and-recent-business-highli-bwv-20230512monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-biotech-to-present-corporate-overview-and-entadfi-launch-plan-at-the-jmp-securi-bwv-20230510monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-biotech-to-participate-in-the-american-urological-association-annual-meeting-20-bwv-20230425monthly0.5https://www.biopharmawatch.com/news/BWV/moderator-00-00-hello-and-thank-you-for-standing-by-my-name-is-regina-and-i-will-be-your-c-bwv-20230424monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-announces-acquisition-of-entadfi-an-fda-approved-benign-prostatic-hyperplasia-a-bwv-20230420monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-vaccines-announces-signing-of-sponsored-research-agreement-with-the-university--bwv-20230412monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-vaccines-reports-year-2022-financial-results-and-recent-business-highlights-bwv-20230309monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-vaccines-announces-appointment-of-seasoned-public-market-and-private-equity-inv-bwv-20230117monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-vaccines-to-present-at-biotech-showcase-2023-during-the-41-st-annual-j-p-morgan-bwv-20230109monthly0.5https://www.biopharmawatch.com/news/BWV/january-2023-nasdaq-bwv-the-presentation-the-presentation-has-been-prepared-by-blue-water--bwv-20230106monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-vaccines-announces-institutional-research-coverage-by-two-notable-healthcare-fo-bwv-20221212monthly0.5https://www.biopharmawatch.com/news/BWV/mucosal-vaccines-to-protect-against-mucosal-infections-may-be-the-right-answer-to-address--bwv-20221207monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-vaccines-to-present-update-on-novel-live-attenuated-intranasally-delivered-stre-bwv-20221201monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-vaccines-announces-exclusive-global-license-agreement-for-chlamydia-vaccine-can-bwv-20221121monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-vaccines-reports-third-quarter-2022-financial-results-and-recent-business-highl-bwv-20221110monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-vaccines-announces-appointment-of-vuk-jeremi-previous-chair-of-the-council-of-e-bwv-20221108monthly0.5https://www.biopharmawatch.com/news/BWV/intranasal-live-attenuated-pneumococcus-vaccine-to-protect-against-pneumonia-aom-and-poten-bwv-20221013monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-vaccines-announces-plans-to-evaluate-efficacy-of-streptococcus-pneumoniae-vacci-bwv-20221011monthly0.5https://www.biopharmawatch.com/news/BWV/september-2022-nasdaq-bwv-the-presentation-the-presentation-has-been-prepared-by-blue-wate-bwv-20220912monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-vaccines-announces-appointment-of-retired-deloitte-consulting-senior-managing-d-bwv-20220822monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-vaccines-announces-10-million-private-placement-priced-at-the-market-under-nasd-bwv-20220809monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-vaccines-announces-signing-of-sponsored-research-agreement-with-cincinnati-chil-bwv-20220720monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-vaccines-announces-sponsored-research-agreement-amendment-to-continue-funding-u-bwv-20220531monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-vaccines-presents-new-data-supporting-universal-influenza-vaccine-candidate-at--bwv-20220421monthly0.5https://www.biopharmawatch.com/news/BWV/universal-influenza-vaccine-program-bwv-101-developing-a-single-vaccine-to-protect-against-bwv-20220420monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-vaccines-announces-closing-of-8-million-private-placement-priced-at-the-market--bwv-20220420monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-vaccines-announces-8-million-private-placement-priced-at-the-market-under-nasda-bwv-20220418monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-vaccines-announces-publication-in-nano-research-supporting-novel-s-p-vaccine-pl-bwv-20220322monthly0.5https://www.biopharmawatch.com/news/BWV/blue-water-vaccines-announces-pricing-of-approximate-20m-initial-public-offering-cincinnat-bwv-20220217monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-inc-condensed-consolidated-balance-sheets-unaudited-in-thousands-ex-axdx-20240510monthly0.5https://www.biopharmawatch.com/news/AXDX/december-2023-company-presentation-1-legal-disclaimer-forward-looking-statements-this-pres-axdx-20231213monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-investor-presntation-jack-phillips-president-ceo-accelerate-diagnos-axdx-20230613monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-second-quarter-2021-financial-results-axdx-20211112monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-second-quarter-2020-financial-results-announces-new-product-axdx-20201106monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-q2-2018-financial-results-revenue-up-142-percent-global-ins-axdx-20180806monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-inc-announces-150-million-convertible-notes-offering-tucson-az-axdx-20180322monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-welcomes-dr-charles-watts-to-its-board-of-directors-axdx-20171116monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-q3-2017-financial-results-axdx-20171102monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-q2-2017-financial-results-doubles-revenue-generating-placem-axdx-20170928monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-closing-of-79-3-million-upsized-offering-axdx-20170515monthly0.5https://www.biopharmawatch.com/news/AXDX/forward-looking-statements-certain-of-the-statements-made-in-this-press-release-are-forwar-axdx-20170510monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-191-instruments-under-contract-and-3x-revenue-growth-for-fi-axdx-20170503monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-names-tom-brown-to-board-of-directors-axdx-20170315monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-inc-2016-q4-results-conference-call-monday-axdx-20170227monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-inc-2016-q3-results-conference-call-thursday-axdx-20161109monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-submits-de-novo-request-to-fda-for-accelerate-pheno-system-and-acce-axdx-20160711monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-inc-nasdaq-axdx-q1-2016-earnings-conference-call-axdx-20160512monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-pricing-of-public-offering-of-common-stock-axdx-20151209monthly0.5https://www.biopharmawatch.com/news/AXDX/unless-the-context-requires-otherwise-all-references-in-this-current-report-on-form-8-k-to-axdx-20151209monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-positive-results-from-pilot-study-of-its-investigational-id-axdx-20151202monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-new-leadership-appointments-axdx-20150417monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-names-juan-martin-as-head-of-europe-middle-east-and-africa-axdx-20150323monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-final-results-of-rights-offering-axdx-20140502monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-commences-rights-offering-company-announces-commencement-of-45-000--axdx-20140407monthly0.5https://www.biopharmawatch.com/news/AXDX/accelr8-announces-nasdaq-capital-market-listing-common-stock-to-begin-trading-on-nasdaq-un-axdx-20121213monthly0.5https://www.biopharmawatch.com/news/AXDX/accelr8-attracts-up-to-35-million-private-equity-investment-axdx-20120423monthly0.5https://www.biopharmawatch.com/news/AXDX/accelr8-announces-extension-of-baccel-industry-agreement-funding-updates-on-pilot-studies-axdx-20101130monthly0.5https://www.biopharmawatch.com/news/AXDX/accelr8-announces-preliminary-earnings-report-denver-business-wire-accelr8-technology-corp-axdx-20100823monthly0.5https://www.biopharmawatch.com/news/AXDX/accelr8-technology-corporation-receives-notice-from-nyse-amex-accelr8-technology-corporati-axdx-20100707monthly0.5https://www.biopharmawatch.com/news/AXDX/accelr8-announces-industry-agreement-for-technology-evaluation-project-axdx-20100617monthly0.5https://www.biopharmawatch.com/news/AXDX/company-logo-graphic-omitted-accelr8-and-becton-dickinson-conclude-technical-development-p-axdx-20090925monthly0.5https://www.biopharmawatch.com/news/AXDX/accelr8-and-bd-agree-on-terms-for-technology-development-program-for-the-baccel-rapid-diag-axdx-20080401monthly0.5https://www.biopharmawatch.com/news/AXDX/bd-acquires-right-to-negotiate-business-relationship-for-accelr8-s-baccel-r-rapid-diagnost-axdx-20071213monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-346-6131-brussell-cyanotech-com-cyanotech-names-mawae-morton-president-k-cyan-20170717monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-346-6131-brussell-cyanotech-com-cyanotech-names-nancy-katz-as-a-director-cyan-20161025monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-346-6131-brussell-cyanotech-com-cyanotech-names-david-mulder-as-a-direct-cyan-20160523monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-346-6131-brussell-cyanotech-com-founder-gerry-cysewski-ph-d-named-interi-cyan-20160404monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-559-4955-x101-cyanotech-names-david-l-vied-as-a-director-kailua-kona-haw-cyan-20150128monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-346-6131-brussell-cyanotech-com-cyanotech-reports-litigation-resolved-ka-cyan-20141219monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-346-6131-brussell-cyanotech-com-cyanotech-names-gerry-watts-as-chief-ope-cyan-20140818monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-559-4955-x101-cyanotech-names-jole-deal-as-chief-financial-officer-kailu-cyan-20110817monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-559-4955-x101-cyanotech-names-thomas-f-chen-as-a-director-kailua-kona-ha-cyan-20110608monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-559-4955-x101-cyanotech-names-ralph-carlton-as-a-director-kailua-kona-ha-cyan-20110128monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-559-4955-x101-brussell-cyanotech-com-cyanotech-names-brent-bailey-as-pre-cyan-20101108monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-559-4955-x101-brussell-cyanotech-com-cyanotech-chairman-gregg-robertson--cyan-20101027monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-559-4955-x101-brussell-cyanotech-com-cyanotech-director-jacobson-resigns-cyan-20100405monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-559-4955-x101-brussell-cyanotech-com-cyanotech-receives-temporary-non-co-cyan-20100312monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-559-4955-x101-brussell-cyanotech-com-cyanotech-s-board-of-directors-name-cyan-20100301monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-559-4955-x101-brussell-cyanotech-com-cyanotech-names-deanna-spooner-as-c-cyan-20081031monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-559-4955-x101-brussell-cyanotech-com-cyanotech-reports-financial-results-cyan-20080815monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-559-4955-x101-brussell-cyanotech-com-cyanotech-names-andrew-jacobson-as--cyan-20080519monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-559-4955-x101-brucerussell-ruscom-com-cyanotech-focuses-natural-astaxant-cyan-20080326monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-310-559-4955-x101-brussell-cyanotech-com-cyanotech-announces-strategic-shift-cyan-20071113monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-russell-communications-group-310-559-4955-x101-brucerussell-ruscom-com-cyano-cyan-20071009monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-russell-communications-group-310-559-4955-x101-brucerussell-ruscom-com-cyano-cyan-20070820monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-russell-communications-group-310-559-4955-x101-brucerussell-ruscom-com-cyano-cyan-20070720monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-russell-communications-group-310-559-4955-x101-brucerussell-ruscom-com-cyano-cyan-20070316monthly0.5https://www.biopharmawatch.com/news/CYAN/contac-t-bruce-russell-russell-communications-group-brucerussell-ruscom-com-cyanotech-file-cyan-20070226monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-rcg-310-559-4955x101-brucerussell-ruscom-com-cyanotech-receives-extension-fr-cyan-20061220monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-rcg-310-559-4955x101-brucerussell-ruscom-com-cyanotech-to-restate-financial--cyan-20061201monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-rcg-310-559-4955x101-brucerussell-ruscom-com-cyanotech-receives-delisting-no-cyan-20061120monthly0.5https://www.biopharmawatch.com/news/CYAN/cyanotech-corporation-form-8-k-cyan-20061114monthly0.5https://www.biopharmawatch.com/news/CYAN/cyanotech-corporation-form-8-k-cyan-20060921monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-russell-communications-group-brucerussell-ruscom-com-cyanotech-receives-deli-cyan-20060824monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-russell-communications-group-brucerussell-ruscom-com-cyanotech-continues-del-cyan-20060821monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-russell-communications-group-310-559-4955-x101-brucerussell-ruscom-com-nasda-cyan-20060602monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-russell-communications-group-310-559-4955-x101-brucerussell-ruscom-com-cyano-cyan-20060524monthly0.5https://www.biopharmawatch.com/news/CYAN/bruce-russell-russell-communications-group-310-559-4955-x101-brucerussell-ruscom-com-cyano-cyan-20060208monthly0.5https://www.biopharmawatch.com/news/CYAN/investors-and-media-russell-communications-group-bruce-russell-310-559-4955-x101-bruceruss-cyan-20051219monthly0.5https://www.biopharmawatch.com/news/CYAN/investors-and-media-russell-communications-group-bruce-russell-310-559-4955-x101-bruceruss-cyan-20051205monthly0.5https://www.biopharmawatch.com/news/CYAN/corporation-investors-and-media-cyanotech-corporation-russell-communications-group-jeffrey-cyan-20051103monthly0.5https://www.biopharmawatch.com/news/CYAN/corporation-investors-and-media-cyanotech-corporation-russell-communications-group-jeffrey-cyan-20051019monthly0.5https://www.biopharmawatch.com/news/CYAN/corporation-investors-and-media-cyanotech-corporation-russell-communications-group-jeffrey-cyan-20050811monthly0.5https://www.biopharmawatch.com/news/CYAN/corporation-investors-and-media-cyanotech-corporation-russell-communications-group-jeffrey-cyan-20050712monthly0.5https://www.biopharmawatch.com/news/CYAN/corporation-investors-and-media-cyanotech-corporation-guerrant-associates-gerald-r-cysewsk-cyan-20050608monthly0.5https://www.biopharmawatch.com/news/CYAN/cyanotech-corporation-reports-fourth-quarter-and-fiscal-year-end-2005-financial-results-co-cyan-20050518monthly0.5https://www.biopharmawatch.com/news/CYAN/a-statement-on-bmaa-in-spirulina-arthrospira-platensis-a-maxima-irvine-ca-market-wire-04-1-cyan-20050425monthly0.5https://www.biopharmawatch.com/news/CYAN/cyanotech-corporation-reports-third-quarter-fiscal-2005-financial-results-company-reports--cyan-20050127monthly0.5https://www.biopharmawatch.com/news/CYAN/corporation-investors-and-media-cyanotech-corporation-guerrant-associates-jeffrey-h-sakamo-cyan-20041230monthly0.5https://www.biopharmawatch.com/news/CYAN/corporation-investors-and-media-cyanotech-corporation-guerrant-associates-jeffrey-h-sakamo-cyan-20041214monthly0.5https://www.biopharmawatch.com/news/CYAN/dr-gerald-cysewski-chairman-president-and-ceo-of-cyanotech-talks-to-the-wall-street-transc-cyan-20041206monthly0.5https://www.biopharmawatch.com/news/CYAN/cyanotech-corporation-reports-second-quarter-fiscal-2005-financial-results-reports-sales-o-cyan-20041101monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-inc-unaudited-pro-forma-consolidated-balance-sheets-proforma-adjust-ptpi-20250620monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-announces-pricing-of-9-6-million-public-offering-of-common-stock-an-ptpi-20250218monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-announces-capital-raise-of-15-million-provides-update-on-progress-t-ptpi-20230713monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-announces-reverse-stock-split-common-stock-will-begin-trading-on-sp-ptpi-20221201monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-reports-third-quarter-2022-financial-results-and-corporate-update-n-ptpi-20221115monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-reports-record-revenue-and-gross-profit-during-second-quarter-2022--ptpi-20220815monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-announces-7-5-million-offering-ptpi-20211222monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-announces-10-million-offering-investors-included-the-company-s-larg-ptpi-20211130monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-reports-third-quarter-financial-results-and-provides-corporate-upda-ptpi-20211115monthly0.5https://www.biopharmawatch.com/news/PTPI/petros-pharmaceuticals-announces-5-7-million-registered-direct-offering-ptpi-20211014monthly0.5https://www.biopharmawatch.com/news/PTPI/to-this-form-8-k-furthermore-we-do-not-have-any-retained-or-contingent-interest-in-assets--ptpi-20201231monthly0.5https://www.biopharmawatch.com/news/PTPI/neurotrope-and-metuchen-pharmaceuticals-announce-completion-of-merger-forming-petros-pharm-ptpi-20201202monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-receipt-of-nasdaq-delisting-notice-mannheim-germany-afmd-20250514monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-filing-for-the-opening-of-insolvency-proceedings-mannheim-germany-afmd-20250513monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirem-afmd-20250421monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-unaudited-consolidated-interim-statements-of-comprehensive-loss-in-thousand-fo-afmd-20241114monthly0.5https://www.biopharmawatch.com/news/AFMD/text-advertisement-convocation-egm-2024-shareholders-of-affimed-n-v-are-invited-to-attend--afmd-20240911monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-unaudited-consolidated-interim-statements-of-comprehensive-loss-in-thousand-fo-afmd-20240905monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-appoints-shawn-m-leland-as-chief-executive-officer-mannheim-germany-afmd-20240903monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-unaudited-consolidated-statements-of-comprehensive-loss-in-thousand-for-the-th-afmd-20240612monthly0.5https://www.biopharmawatch.com/news/AFMD/agenda-and-explanatory-notes-2024-annual-general-meeting-of-affimed-n-v-to-be-held-on-wedn-afmd-20240606monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-annual-general-meeting-of-shareholders-mannheim-germany-afmd-20240528monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-2023-financial-results-and-operational-progress-afm24-combination-with-ate-afmd-20240328monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-1-for-10-reverse-stock-split-mannheim-germany-afmd-20240306monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-sale-of-wholly-owned-subsidiary-abcheck-mannheim-germany-afmd-20240103monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-unaudited-consolidated-interim-statements-of-comprehensive-loss-in-thousand-fo-afmd-20231114monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-listing-transfer-to-nasdaq-capital-markets-mannheim-germany-afmd-20231004monthly0.5https://www.biopharmawatch.com/news/AFMD/x200b-affimed-n-v-unaudited-consolidated-interim-statements-of-comprehensive-loss-in-x20ac-afmd-20230810monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board-heidelbe-afmd-20230622monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-unaudited-consolidated-statements-of-comprehensive-loss-in-thousand-for-the-th-afmd-20230523monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-annual-general-meeting-of-shareholders-heidelberg-germany-afmd-20230522monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-2022-financial-results-and-operational-progress-afm13-combination-with-ab--afmd-20230323monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-on-corporate-progress-and-provides-regulatory-update-for-afm13-afm13-combi-afmd-20221231monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-unaudited-consolidated-interim-statements-of-comprehensive-income-loss-in-thou-afmd-20221115monthly0.5https://www.biopharmawatch.com/news/AFMD/x200b-affimed-n-v-unaudited-consolidated-interim-statements-of-comprehensive-income-loss-i-afmd-20220811monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-unaudited-consolidated-statements-of-comprehensive-income-loss-in-thousand-for-afmd-20220601monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-annual-general-meeting-of-shareholders-heidelberg-germany-afmd-20220524monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-2021-financial-results-and-highlights-recent-operational-progress-complete-afmd-20220331monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-unaudited-interim-consolidated-statements-of-comprehensive-income-loss-in-thou-afmd-20211110monthly0.5https://www.biopharmawatch.com/news/AFMD/12-31-2021-q2-false-2021-06-30-exhibits-99-1-x200b-affimed-n-v-unaudited-condensed-interim-afmd-20210908monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-unaudited-consolidated-statements-of-comprehensive-income-loss-in-thousand-for-afmd-20210701monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-virtual-annual-general-meeting-of-shareholders-heidelberg-germany-afmd-20210520monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-2020-financial-results-and-highlights-recent-operational-progress-afm13-mo-afmd-20210415monthly0.5https://www.biopharmawatch.com/news/AFMD/this-presentation-and-the-accompanying-oral-commentary-contain-forward-looking-statements--afmd-20210414monthly0.5https://www.biopharmawatch.com/news/AFMD/execution-version-afmd-20201110monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-unaudited-consolidated-statements-of-comprehensive-income-loss-in-thousands-fo-afmd-20201110monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-condensed-consolidated-financial-statements-affimed-n-v-unaudited-consolidated-afmd-20200811monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-annual-general-meeting-of-shareholders-heidelberg-germany-afmd-20200710monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-unaudited-consolidated-statements-of-comprehensive-income-loss-in-thousand-not-afmd-20200623monthly0.5https://www.biopharmawatch.com/news/AFMD/execution-version-afmd-20200513monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-unaudited-consolidated-statements-of-comprehensive-income-loss-in-thousands-fo-afmd-20191119monthly0.5https://www.biopharmawatch.com/news/AFMD/draft-privileged-and-confidential-for-immediate-release-affimed-announces-proposed-public--afmd-20191107monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-condensed-consolidated-financial-statements-affimed-n-v-unaudited-consolidated-afmd-20190807monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-annual-general-meeting-of-shareholders-heidelberg-germany-afmd-20190604monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-unaudited-consolidated-statements-of-comprehensive-income-loss-in-thousand-not-afmd-20190522monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-provides-regulatory-update-on-afm11-clinical-program-heidelberg-germany-afmd-20190417monthly0.5https://www.biopharmawatch.com/news/AFMD/actualizing-the-untapped-potential-of-the-innate-immune-system-affimed-s-approach-to-advan-afmd-20190107monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-condensed-consolidated-financial-statements-affimed-n-v-unaudited-consolidated-afmd-20181107monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-places-afm11-cd19-cd3-targeting-t-cell-engager-phase-1-program-on-clinical-hold-he-afmd-20181008monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-developing-first-in-class-immune-cell-engagers-for-harnessing-innate-and-adaptive--afmd-20180827monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-index-to-condensed-consolidated-financial-statements-unaudited-consolidated-st-afmd-20180808monthly0.5https://www.biopharmawatch.com/news/AFMD/for-release-affimed-announces-updated-data-of-afm13-in-combination-with-keytruda-pembroliz-afmd-20180615monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-annual-general-meeting-of-shareholders-heidelberg-germany-afmd-20180518monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-index-to-condensed-consolidated-financial-statements-unaudited-consolidated-st-afmd-20180515monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-financial-results-for-fourth-quarter-and-year-end-2017-heidelberg-germany-afmd-20180320monthly0.5https://www.biopharmawatch.com/news/AFMD/transforming-immuno-oncology-using-next-generation-immune-cell-engagers-corporate-presenta-afmd-20180308monthly0.5https://www.biopharmawatch.com/news/AFMD/transforming-immuno-oncology-using-next-generation-immune-cell-engagers-corporate-presenta-afmd-20180105monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-index-to-condensed-consolidated-financial-statements-unaudited-condensed-conso-afmd-20171107monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-appoints-dr-wolfgang-fischer-as-chief-operating-officer-heidelberg-germany-afmd-20170913monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-index-to-condensed-consolidated-financial-statements-unaudited-condensed-conso-afmd-20170801monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-annual-general-meeting-of-shareholders-heidelberg-germany-afmd-20170522monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-index-to-condensed-consolidated-financial-statements-page-unaudited-condensed--afmd-20170517monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-financial-results-for-fourth-quarter-and-year-end-2016-heidelberg-germany-afmd-20170330monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-provides-update-on-nk-cell-immuno-oncology-platform-heidelberg-germany-afmd-20170111monthly0.5https://www.biopharmawatch.com/news/AFMD/transforming-immuno-oncology-using-next-generation-immune-cell-engagers-corporate-presenta-afmd-20170105monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-and-md-anderson-announce-clinical-immuno-oncology-development-collaboration-agreem-afmd-20170104monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-index-to-condensed-consolidated-financial-statements-unaudited-condensed-conso-afmd-20161102monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-index-to-condensed-consolidated-financial-statements-page-unaudited-condensed--afmd-20160810monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-announces-annual-general-meeting-of-shareholders-heidelberg-germany-afmd-20160523monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-n-v-index-to-condensed-consolidated-financial-statements-page-unaudited-condensed--afmd-20160518monthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-reports-financial-results-for-fourth-quarter-and-year-end-2015-successful-financin-afmd-20160330monthly0.5https://www.biopharmawatch.com/news/AFMD/exhibit-1-exhibit-1-for-immediate-release-affimed-presents-data-comparing-t-cell-and-nk-ce-afmd-20151206monthly0.5https://www.biopharmawatch.com/news/AFMD/exhibit-1-exhibit-1-affimed-n-v-index-to-condensed-consolidated-financial-statements-page--afmd-20151110monthly0.5https://www.biopharmawatch.com/news/AFMD/exhibit-1-exhibit-1-affimed-n-v-index-to-condensed-consolidated-financial-statements-page--afmd-20150521monthly0.5https://www.biopharmawatch.com/news/AFMD/exhibit-1-for-immediate-release-affimed-n-v-announces-shareholder-meeting-heidelberg-germa-afmd-20150512monthly0.5https://www.biopharmawatch.com/news/AFMD/exhibit-1-for-immediate-release-affimed-n-v-announces-pricing-of-public-offering-of-common-afmd-20150506monthly0.5https://www.biopharmawatch.com/news/CLSD/case-25-12109-tmh-doc-115-filed-12-23-25-page-1-of-18-united-states-bankruptcy-court-distr-clsd-20251229monthly0.5https://www.biopharmawatch.com/news/CLSD/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-define-clsd-20241212monthly0.5https://www.biopharmawatch.com/news/CLSD/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-define-clsd-20241009monthly0.5https://www.biopharmawatch.com/news/CLSD/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-define-clsd-20240724monthly0.5https://www.biopharmawatch.com/news/CLSD/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-define-clsd-20230202monthly0.5https://www.biopharmawatch.com/news/CLSD/healthcare-royalty-partners-is-a-registered-trademark-of-healthcare-royalty-management-llc-clsd-20220808monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-inc-selected-financial-data-in-thousands-except-share-and-per-share-d-clsd-20220310monthly0.5https://www.biopharmawatch.com/news/CLSD/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-define-clsd-20211221monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-investor-and-media-contacts-jenny-kobin-remy-bernarda-ir-clearsidebio-com-678-43-clsd-20211025monthly0.5https://www.biopharmawatch.com/news/CLSD/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-define-clsd-20210615monthly0.5https://www.biopharmawatch.com/news/CLSD/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-clsd-20210106monthly0.5https://www.biopharmawatch.com/news/CLSD/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-define-clsd-20200408monthly0.5https://www.biopharmawatch.com/news/CLSD/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-define-clsd-20191120monthly0.5https://www.biopharmawatch.com/news/CLSD/regenxbio-announces-exclusive-worldwide-option-and-license-agreement-with-clearside-biomed-clsd-20190904monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-provides-new-drug-application-update-for-xipere-tm-triamcinolone-acet-clsd-20190822monthly0.5https://www.biopharmawatch.com/news/CLSD/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-define-clsd-20190522monthly0.5https://www.biopharmawatch.com/news/CLSD/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-define-clsd-20190313monthly0.5https://www.biopharmawatch.com/news/CLSD/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-define-clsd-20190107monthly0.5https://www.biopharmawatch.com/news/CLSD/financial-disclosures-clearside-biomedical-inc-consultant-santen-consultant-agtc-consultan-clsd-20180725monthly0.5https://www.biopharmawatch.com/news/CLSD/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-define-clsd-20180620monthly0.5https://www.biopharmawatch.com/news/CLSD/patient-rescue-kaplan-meier-85-90-of-subjects-in-the-cls-ta-arm-were-not-rescued-while-a-m-clsd-20180423monthly0.5https://www.biopharmawatch.com/news/CLSD/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-define-clsd-20180327monthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-clsd-20180307monthly0.5https://www.biopharmawatch.com/news/CLSD/matters-discussed-in-this-presentation-may-constitute-forward-looking-statements-the-forwa-clsd-20170308monthly0.5https://www.biopharmawatch.com/news/WINT/windtree-therapeutics-announces-reverse-stock-split-warrington-pa-wint-20171221monthly0.5https://www.biopharmawatch.com/news/WINT/windtree-announces-initiation-of-financial-restructuring-pr-ogram-enter-s-into-3-9-million-wint-20170818monthly0.5https://www.biopharmawatch.com/news/WINT/windtree-announces-top-line-results-from-aerosurf-phase-2b-clinical-trial-for-the-treatmen-wint-20170629monthly0.5https://www.biopharmawatch.com/news/WINT/windtree-therapeutics-and-lee-s-pharmaceutical-hk-limited-enter-into-exclusive-license-and-wint-20170613monthly0.5https://www.biopharmawatch.com/news/WINT/windtree-announces-successful-completion-of-enrollment-in-aerosurf-phase-2b-clinical-trial-wint-20170602monthly0.5https://www.biopharmawatch.com/news/WINT/windtree-receives-notice-of-delisting-fro-m-nasdaq-common-stock-to-begin-trading-on-otcqb--wint-20170505monthly0.5https://www.biopharmawatch.com/news/WINT/windtree-therapeutics-reports-fourth-quarter-2016-financial-results-and-provides-key-busin-wint-20170331monthly0.5https://www.biopharmawatch.com/news/WINT/windtree-therapeutics-completes-10-5-million-private-offering-company-now-adequately-funde-wint-20170215monthly0.5https://www.biopharmawatch.com/news/WINT/windtree-therapeutics-reports-second-quarter-2016-financial-results-and-provides-key-busin-wint-20160810monthly0.5https://www.biopharmawatch.com/news/WINT/windtree-therapeutics-reports-first-quarter-2016-financial-results-and-provides-business-u-wint-20160512monthly0.5https://www.biopharmawatch.com/news/WINT/april-2016-nasdaq-wint-forward-looking-statement-2-to-the-extent-that-statements-in-this-p-wint-20160418monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-announces-appointment-of-new-chief-executive-officer-and-provides-an-update-wint-20160201monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-announces-reverse-stock-split-warrington-pa-wint-20160121monthly0.5https://www.biopharmawatch.com/news/WINT/aerosurf-phase-2-program-updateinvestor-conference-call-wint-20151112monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-provides-business-update-and-reports-third-quarter-2015-financial-results-w-wint-20151105monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-provides-business-update-and-reports-second-quarter-2015-financial-results--wint-20150810monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-announces-completion-of-40-25-million-public-offering-warrington-pa-wint-20150722monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-receives-nasdaq-notification-related-to-minimum-bid-price-warrington-pa-wint-20150701monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-announces-results-of-phase-2a-clinical-trial-of-aerosurf-encouraging-safety-wint-20150514monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-reports-first-quarter-2015-financial-results-warrington-pa-wint-20150507monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-completes-enrollment-of-aerosurf-phase-2a-clinical-trial-and-restructures-i-wint-20150416monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-reports-fourth-quarter-2014-financial-results-and-provides-update-on-surfax-wint-20150316monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-reports-third-quarter-2014-financial-results-warrington-pa-wint-20141106monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-announces-organizational-change-and-enhanced-expertise-in-neonatology-warri-wint-20141030monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-announces-strategic-collaboration-with-battelle-for-aerosurf-program-compan-wint-20141015monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-reports-second-quarter-2014-financial-results-warrington-pa-wint-20140805monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-receives-1-9-million-fast-track-sbir-grant-from-the-national-institutes-of--wint-20140617monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-reports-first-quarter-2014-financial-results-warrington-pa-wint-20140508monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-announces-new-appointments-to-management-team-warrington-pa-wint-20140325monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-reports-fourth-quarter-2013-financial-results-conference-call-today-wint-20140313monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-reports-third-quarter-2013-financial-results-conference-call-wednesday-wint-20131113monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-prices-50-million-public-offering-of-common-stock-warrington-pa-wint-20131031monthly0.5https://www.biopharmawatch.com/news/WINT/nasdaq-dsco-investor-conference-call-wint-20131017monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-announces-fda-approval-of-surfaxin-lucinactant-updated-product-specificatio-wint-20131004monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-reports-second-quarter-2013-financial-results-warrington-pa-wint-20130808monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-responds-to-fda-request-for-clarification-of-recently-submitted-surfaxin-lu-wint-20130607monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-prices-14-25-million-public-offering-of-common-stock-warrington-pa-wint-20130510monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-reports-first-quarter-2013-financial-results-warrington-pa-wint-20130507monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-receives-fda-recommendations-and-request-for-clarification-regarding-recent-wint-20130415monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-reports-fourth-quarter-2012-financial-results-warrington-pa-wint-20130313monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-receives-30-million-funding-commitment-from-deerfield-management-warrington-wint-20130213monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-announces-changes-to-board-of-directors-and-appoints-a-new-chief-executive--wint-20130104monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-reports-third-quarter-2012-financial-results-warrington-pa-wint-20121108monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-provides-commercial-update-for-surfaxin-and-afectair-conference-call-today--wint-20121024monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-reports-second-quarter-2012-financial-results-warrington-pa-wint-20120802monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-reports-first-quarter-2012-financial-results-warrington-pa-wint-20120503monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-reports-fourth-quarter-financial-results-and-highlights-recent-milestones-w-wint-20120329monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-prices-45-0-million-public-offering-of-common-stock-warrington-pa-wint-20120316monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-announces-fda-approval-of-surfaxin-lucinactant-for-prevention-of-respirator-wint-20120306monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-signs-manufacturing-agreement-for-afectair-company-makes-progress-towards-c-wint-20120208monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-cleared-to-market-afectair-in-u-s-new-proprietary-technology-simplifies-del-wint-20120202monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-reports-third-quarter-financial-results-and-progress-on-lead-programs-warri-wint-20111110monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-notified-of-pdufa-date-for-surfaxin-conference-call-today-at-3-00-pm-edt-wa-wint-20110928monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-submits-surfaxin-complete-response-to-fda-company-seeks-fda-approval-for-us-wint-20110906monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-reports-second-quarter-financial-results-and-provides-an-update-on-lead-pip-wint-20110803monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-aerosolization-program-yields-potential-new-product-offering-afectair-tm-pr-wint-20110729monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-to-report-second-quarter-2011-results-and-hold-conference-call-on-wednesday-wint-20110722monthly0.5https://www.biopharmawatch.com/news/WINT/unassociated-document-analysis-of-surfaxin-data-presented-in-first-peer-reviewed-manuscrip-wint-20110601monthly0.5https://www.biopharmawatch.com/news/WINT/unassociated-document-discovery-labs-reports-first-quarter-financial-results-and-provides--wint-20110511monthly0.5https://www.biopharmawatch.com/news/WINT/unassociated-document-discovery-labs-reports-fourth-quarter-financial-results-and-provides-wint-20110322monthly0.5https://www.biopharmawatch.com/news/WINT/unassociated-document-discovery-labs-prices-23-5-million-public-offering-of-common-stock-a-wint-20110216monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-laboratories-moderator-john-tattory-wint-20110201monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-provides-expanded-update-regarding-its-program-for-surfaxin-u-s-marketing-a-wint-20110201monthly0.5https://www.biopharmawatch.com/news/WINT/unassociated-document-discovery-labs-announces-that-nasdaq-hearing-panel-has-granted-reque-wint-20110112monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-provides-update-regarding-its-program-for-surfaxin-u-s-marketing-authorizat-wint-20110110monthly0.5https://www.biopharmawatch.com/news/WINT/unassociated-document-discovery-labs-receives-nasdaq-delisting-notification-related-to-min-wint-20101203monthly0.5https://www.biopharmawatch.com/news/WINT/unassociated-document-discovery-labs-provides-a-third-quarter-2010-business-and-financial--wint-20101109monthly0.5https://www.biopharmawatch.com/news/WINT/unassociated-document-discovery-labs-kl-4-surfactant-granted-orphan-drug-designation-for-t-wint-20101101monthly0.5https://www.biopharmawatch.com/news/WINT/v199741-ex99-1-converted-by-secpublisher-2-1-1-8-created-by-bcl-technologies-inc-for-sec-f-wint-20101022monthly0.5https://www.biopharmawatch.com/news/WINT/discovery-labs-appoints-w-thomas-amick-as-chief-executive-officer-company-leadership-solid-wint-20101015monthly0.5https://www.biopharmawatch.com/news/WINT/unassociated-document-pharmabio-expands-investment-in-discovery-labs-to-advance-surfaxin-l-wint-20101013monthly0.5https://www.biopharmawatch.com/news/VERO/growth-drivers-chad-zaring-cco-a-trusted-hair-solution-equipped-with-unique-features-desig-vero-20201202monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-announces-debt-refinancing-new-loan-and-debt-exchange-agreements-significant-vero-20201210monthly0.5https://www.biopharmawatch.com/news/VERO/risk-factors-our-operations-and-financial-results-are-subject-to-various-risk-and-uncertai-vero-20200318monthly0.5https://www.biopharmawatch.com/news/VERO/frederic-h-moll-m-d-vero-20200214monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-ltd-management-s-discussion-and-analysis-of-financial-condition-and-results--vero-20200131monthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-ltd-management-s-discussion-and-analysis-of-financial-condition-and-results--vero-20191203monthly0.5https://www.biopharmawatch.com/news/VERO/restoration-robotics-stockholders-approve-merger-agreement-with-venus-concept-ltd-and-rela-vero-20191007monthly0.5https://www.biopharmawatch.com/news/VERO/restoration-robotics-inc-condensed-consolidated-balance-sheets-unaudited-in-thousands-exce-vero-20190814monthly0.5https://www.biopharmawatch.com/news/VERO/restoration-robotics-inc-condensed-consolidated-balance-sheets-unaudited-in-thousands-exce-vero-20190515monthly0.5https://www.biopharmawatch.com/news/VERO/restoration-robotics-inc-consolidated-balance-sheets-unaudited-in-thousands-except-share-a-vero-20190315monthly0.5https://www.biopharmawatch.com/news/VERO/restoration-robotics-and-venus-concept-announce-merger-to-create-a-leading-global-medical--vero-20190315monthly0.5https://www.biopharmawatch.com/news/VERO/restoration-robotics-announces-preliminary-unaudited-fourth-quarter-2018-revenue-sold-17-a-vero-20190107monthly0.5https://www.biopharmawatch.com/news/VERO/restoration-robotics-inc-condensed-consolidated-balance-sheets-unaudited-in-thousands-exce-vero-20181105monthly0.5https://www.biopharmawatch.com/news/VERO/restoration-robotics-inc-condensed-consolidated-balance-sheets-unaudited-in-thousands-exce-vero-20180730monthly0.5https://www.biopharmawatch.com/news/VERO/restoration-robotics-inc-reports-first-quarter-2018-financial-results-san-jose-calif-vero-20180514monthly0.5https://www.biopharmawatch.com/news/VERO/restoration-robotics-reports-financial-results-for-the-fourth-quarter-and-full-year-2017-f-vero-20180305monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-third-quarter-2024-results-and-provides-business-update-chesterbrook-pa-trvn-20241107monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-receipt-of-nasdaq-delisting-notification-chesterbrook-pa-trvn-20241004monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-reverse-stock-split-chesterbrook-pa-trvn-20240808monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-second-quarter-2024-results-and-provides-business-update-trv045-novel-s1p--trvn-20240808monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-2m-non-dilutive-financing-tranche-and-reduction-in-outstanding-liabiliti-trvn-20240708monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-first-quarter-2024-results-and-provides-business-update-trv045-novel-s1p-r-trvn-20240515monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-fourth-quarter-2023-results-and-provides-corporate-update-trv045-novel-s1p-trvn-20240401monthly0.5https://www.biopharmawatch.com/news/TRVN/innovating-for-patients-nasdaq-trvn-i-january-2024-forward-looking-statements-to-the-exten-trvn-20240108monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-inc-announces-4-million-concurrent-private-placement-and-warrant-exercise-chesterb-trvn-20231227monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-third-quarter-2023-results-and-provides-business-update-company-previously-trvn-20231114monthly0.5https://www.biopharmawatch.com/news/TRVN/innovating-for-patients-nasdaq-trvn-i-october-2023-forward-looking-statements-to-the-exten-trvn-20231002monthly0.5https://www.biopharmawatch.com/news/TRVN/innovating-for-patients-nasdaq-trvn-i-september-2023-forward-looking-statements-to-the-ext-trvn-20230906monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-second-quarter-2023-results-and-provides-business-update-company-announces-trvn-20230814monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-inc-appoints-mark-corrigan-m-d-to-board-of-directors-chesterbrook-pa-trvn-20230720monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-new-topline-olinvyk-data-highlighting-reduced-cost-per-admission-from-ar-trvn-20230626monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-regains-compliance-with-nasdaq-listing-and-reaffirms-expected-near-term-milestones-trvn-20230530monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-first-quarter-2023-results-and-provides-business-update-olinvyk-receives-r-trvn-20230515monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-to-release-first-quarter-2023-financial-results-on-trvn-20230509monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-approval-of-olinvyk-in-china-trevena-s-partner-jiangsu-nhwa-receives-app-trvn-20230508monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-initial-topline-olinvyk-data-from-200-patient-real-world-clinical-outcom-trvn-20230330monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-fourth-quarter-2022-results-and-provides-business-update-company-announces-trvn-20230330monthly0.5https://www.biopharmawatch.com/news/TRVN/innovating-for-patients-nasdaq-trvn-i-january-2023-forward-looking-statements-to-the-exten-trvn-20230109monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-regains-compliance-with-nasdaq-listing-requirements-chesterbrook-pa-trvn-20221129monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-inc-announces-8-0-million-registered-direct-offering-priced-at-the-market-under-na-trvn-20221116monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-reverse-stock-split-chesterbrook-pa-trvn-20221109monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-completion-of-phase-1-study-for-trv045-novel-s1p-receptor-modulator-trv0-trvn-20221109monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-third-quarter-2022-results-and-provides-business-update-olinvyk-commercial-trvn-20221109monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-second-quarter-2022-results-and-provides-business-update-olinvyk-post-appr-trvn-20220811monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-inc-announces-registered-direct-offering-of-preferred-stock-chesterbrook-pa-trvn-20220729monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-positive-topline-olinvyk-cognitive-function-data-and-provides-general-bu-trvn-20220728monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-first-quarter-2022-results-and-provides-business-update-olinvyk-refocused--trvn-20220511monthly0.5https://www.biopharmawatch.com/news/TRVN/innovating-for-patients-nasdaq-trvn-i-march-2022-forward-looking-statements-to-the-extent--trvn-20220420monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-results-from-respiratory-physiology-study-of-head-to-head-comparison-of--trvn-20220420monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-receives-up-to-40m-in-olinvyk-ex-us-royalty-based-financing-from-r-bridge-healthca-trvn-20220331monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-fourth-quarter-and-full-year-2021-results-olinvyk-utilization-gaining-trac-trvn-20220331monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-submission-of-new-drug-application-in-china-for-olinvyk-by-its-partner-j-trvn-20220127monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-third-quarter-2021-results-advanced-olinvyk-commercial-launch-with-expande-trvn-20211115monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-second-quarter-2021-results-company-reaffirms-ye-goal-of-100-formulary-win-trvn-20210812monthly0.5https://www.biopharmawatch.com/news/TRVN/innovating-for-patients-nasdaq-trvn-i-june-2021-forward-looking-statements-to-the-extent-t-trvn-20210616monthly0.5https://www.biopharmawatch.com/news/TRVN/in-the-united-states-district-court-for-the-eastern-district-of-pennsylvania-hans-mathisen-trvn-20210521monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-first-quarter-2021-results-company-reaffirms-ye-target-of-100-formulary-ap-trvn-20210506monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-inc-appoints-marvin-h-johnson-jr-to-board-of-directors-chesterbrook-pa-trvn-20210318monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-inc-reports-fourth-quarter-and-full-year-2020-results-olinvyk-approved-in-u-s-cust-trvn-20210309monthly0.5https://www.biopharmawatch.com/news/TRVN/innovating-for-patients-nasdaq-trvninovember-2020-forward-looking-statements-to-the-extent-trvn-20201102monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-inc-announces-dea-scheduling-of-olinvyk-oliceridine-injection-olinvyk-commercial-s-trvn-20201030monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-pricing-of-50-million-public-offering-of-common-stock-chesterbrook-pa-trvn-20200812monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-proposed-public-offering-of-common-stock-chesterbrook-pa-trvn-20200811monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-fda-approval-of-olinvyk-oliceridine-injection-olinvyk-is-a-new-chemical--trvn-20200810monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-collaboration-with-imperial-college-london-to-evaluate-trv027-in-covid-1-trvn-20200602monthly0.5https://www.biopharmawatch.com/news/TRVN/innovating-for-patients-nasdaq-trvn-i-may-2020-forward-looking-statements-to-the-extent-th-trvn-20200518monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-first-quarter-2020-results-fda-review-of-oliceridine-nda-ongoing-pdufa-dat-trvn-20200507monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-fourth-quarter-and-full-year-2019-results-pdufa-date-of-trvn-20200313monthly0.5https://www.biopharmawatch.com/news/TRVN/e-xhibit-99-1-trevena-announces-fda-has-set-pdufa-date-of-trvn-20200305monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-appoints-scott-applebaum-as-chief-legal-and-compliance-officer-and-svp-of-regulato-trvn-20200213monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-resubmits-new-drug-application-for-oliceridine-oliceridine-is-a-new-chemical-entit-trvn-20200210monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-third-quarter-2019-results-and-topline-data-from-multi-dose-healthy-volunt-trvn-20191104monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-second-quarter-2019-results-enrollment-for-healthy-volunteer-qt-study-ongo-trvn-20190807monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-appoints-barry-shin-as-chief-financial-officer-chesterbrook-pa-trvn-20190627monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-first-quarter-2019-results-company-announces-receipt-of-fda-feedback-on-he-trvn-20190513monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-fourth-quarter-and-full-year-2018-results-company-announces-submission-of--trvn-20190313monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-10-million-registered-direct-offering-of-common-stock-chesterbrook-pa-trvn-20190130monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-receipt-of-type-a-meeting-minutes-and-provides-regulatory-update-for-oli-trvn-20190128monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-third-quarter-2018-financial-results-and-announces-workforce-restructuring-trvn-20181108monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-receives-complete-response-letter-for-oliceridine-from-fda-company-to-host-confere-trvn-20181102monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-oliceridine-fda-advisory-committee-meeting-outcome-chesterbrook-pa-trvn-20181011monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-completion-of-leadership-transition-and-appointment-of-new-director-carr-trvn-20181001monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-second-quarter-2018-financial-results-oliceridine-nda-remains-on-track-for-trvn-20180802monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-first-quarter-2018-financial-results-first-license-agreements-for-ex-us-de-trvn-20180503monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-retirement-of-maxine-gowen-ph-d-effective-october-1-and-planned-promotio-trvn-20180406monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-full-year-2017-earnings-olinvo-oliceridine-injection-new-drug-application--trvn-20180307monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-promotes-carrie-bourdow-to-executive-vice-president-and-chief-operating-officer-ch-trvn-20180202monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-fda-acceptance-for-review-of-new-drug-application-for-olinvo-oliceridine-trvn-20180102monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-third-quarter-2017-financial-results-and-announces-new-positive-clinical-t-trvn-20171107monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-restructuring-to-focus-resources-on-commercial-strategy-initiative-strea-trvn-20170930monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-second-quarter-2017-financial-results-and-provides-corporate-update-olinvo-trvn-20170803monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-first-quarter-2017-financial-results-and-provides-corporate-update-success-trvn-20170504monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-full-year-2016-earnings-two-positive-phase-3-pivotal-efficacy-studies-of-o-trvn-20170308monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-positive-top-line-results-from-two-phase-3-pivotal-efficacy-studies-of-i-trvn-20170221monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-third-quarter-2016-financial-results-and-provides-corporate-update-oliceri-trvn-20161103monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-second-quarter-2016-financial-results-and-provides-corporate-update-olicer-trvn-20160804monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-trv027-did-not-achieve-primary-or-secondary-endpoints-in-blast-ahf-phase-2-trvn-20160516monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-first-quarter-2016-financial-results-and-provides-corporate-update-results-trvn-20160505monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-successful-end-of-phase-2-meeting-with-fda-and-outlines-phase-3-program--trvn-20160502monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-full-year-2015-financial-results-achieved-significant-clinical-and-regulat-trvn-20160309monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-third-quarter-2015-financial-results-and-provides-corporate-update-trv130--trvn-20151110monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-inc-announces-closing-of-public-offering-of-common-stock-including-full-exercise-o-trvn-20150916monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-inc-announces-proposed-underwritten-offering-of-common-stock-trvn-20150910monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-positive-results-from-phase-2b-study-of-trv130-in-acute-postoperative-pa-trvn-20150831monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-second-quarter-2015-financial-results-and-provides-a-corporate-update-enro-trvn-20150811monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-first-quarter-2015-financial-results-and-provides-a-corporate-update-data--trvn-20150507monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-full-year-2014-financial-results-on-track-to-report-phase-2-data-for-trv13-trvn-20150318monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-appoints-anne-m-phillips-to-the-board-of-directors-trvn-20141217monthly0.5https://www.biopharmawatch.com/news/TRVN/business-overview-we-are-a-clinical-stage-biopharmaceutical-company-that-discovers-develop-trvn-20141202monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-announces-positive-top-line-results-from-phase-2a-b-study-of-trv130-in-acute-posto-trvn-20141117monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-third-quarter-2014-financial-results-and-provides-a-corporate-update-top-l-trvn-20141111monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-enters-into-35-million-tranched-term-loan-credit-facility-trvn-20140922monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-granted-key-u-s-composition-of-matter-patent-for-trv130-expansion-of-intellectual--trvn-20140916monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-second-quarter-2014-financial-results-continued-advancement-towards-signif-trvn-20140812monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-appoints-julie-h-mchugh-and-barbara-yanni-to-the-board-of-directors-trvn-20140701monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-first-quarter-2014-financial-results-announces-clinical-progress-with-trv1-trvn-20140509monthly0.5https://www.biopharmawatch.com/news/TRVN/trevena-reports-full-year-2013-financial-results-trevena-to-host-conference-call-today-at--trvn-20140320monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-announces-pricing-of-3-55-million-registered-direct-offering-redwood-city-calif-avgr-20180712monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-appoints-mark-weinswig-as-chief-financial-officer-redwood-city-california-avgr-20180613monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-announces-first-quarter-2018-financial-results-redwood-city-calif-avgr-20180514monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-enters-into-settlement-agreement-for-all-outstanding-securities-class-action-litig-avgr-20180321monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-announces-fourth-quarter-and-full-year-2017-results-redwood-city-california-avgr-20180319monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-announces-closing-of-18-million-underwritten-public-offering-secured-lenders-conve-avgr-20180216monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-announces-reverse-stock-split-redwood-city-california-avgr-20180130monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-granted-continued-listing-decision-from-nasdaq-avgr-20180119monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-secures-waiver-and-consent-to-crg-loan-agreement-redwood-city-california-avgr-20171214monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-announces-third-quarter-2017-results-redwood-city-california-avgr-20171109monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-announces-second-quarter-2017-results-redwood-city-california-avgr-20170808monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-announces-first-quarter-2017-results-redwood-city-california-avgr-20170504monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-provides-strategic-update-announces-preliminary-first-quarter-2017-results-redwood-avgr-20170410monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-announces-fourth-quarter-and-full-year-2016-results-redwood-city-california-avgr-20170306monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-announces-preliminary-fourth-quarter-2016-results-redwood-city-california-avgr-20170106monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-announces-third-quarter-2016-results-revenue-of-5-3-million-increases-95-from-thir-avgr-20161103monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-inc-announces-pricing-of-public-offering-of-common-stock-redwood-city-calif-avgr-20160811monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-inc-announces-second-quarter-2016-results-redwood-city-california-avgr-20160801monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-inc-announces-preliminary-second-quarter-2016-revenue-results-management-to-host-c-avgr-20160712monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-inc-announces-first-quarter-2016-results-initial-sales-of-pantheris-image-guided-a-avgr-20160504monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-inc-announces-fourth-quarter-and-full-year-2015-results-pantheris-commercial-launc-avgr-20160301monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-inc-announces-third-quarter-2015-results-received-fda-clearance-for-pantheris-acce-avgr-20151105monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-inc-secures-up-to-55m-in-financing-from-crg-financing-to-support-commercial-launch-avgr-20150923monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-inc-announces-second-quarter-2015-results-achieved-positive-30-day-results-for-cli-avgr-20150728monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-announces-30-day-vision-trial-results-at-europcr-2015-primary-efficacy-endpoint-ac-avgr-20150520monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-inc-announces-first-quarter-2015-results-achieves-primary-efficacy-endpoint-in-vis-avgr-20150506monthly0.5https://www.biopharmawatch.com/news/AVGR/avinger-inc-announces-fourth-quarter-and-full-year-2014-results-redwood-city-california-avgr-20150312monthly0.5https://www.biopharmawatch.com/news/CUTR/this-is-a-solicitation-of-votes-to-accept-or-reject-a-plan-of-reorganization-prior-to-the--cutr-20250303monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-announces-third-quarter-2024-financial-results-brisbane-california-cutr-20241107monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-announces-second-quarter-2024-financial-results-brisbane-california-cutr-20240808monthly0.5https://www.biopharmawatch.com/news/CUTR/revised-fourth-quarter-and-full-year-2023-non-gaap-financial-measures-cutera-inc-nasdaq-cu-cutr-20240510monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-announces-first-quarter-2024-financial-results-cutr-20240509monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-announces-fourth-quarter-and-full-year-2023-financial-results-along-with-2024-outlo-cutr-20240321monthly0.5https://www.biopharmawatch.com/news/CUTR/revised-second-quarter-2023-non-gaap-financial-measures-cutera-inc-nasdaq-cutr-cutera-or-t-cutr-20240305monthly0.5https://www.biopharmawatch.com/news/CUTR/revised-first-quarter-2023-non-gaap-financial-measures-cutera-inc-nasdaq-cutr-cutera-or-th-cutr-20240305monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-third-quarter-2023-financial-measures-cutr-20240305monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-announces-preliminary-unaudited-financial-results-for-full-year-2023-cutr-20240109monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-provides-third-quarter-2023-business-update-cutr-20231108monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-appoints-jeff-jones-as-chief-operating-officer-cutr-20230824monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-announces-second-quarter-2023-financial-results-along-with-2023-outlook-cutr-20230808monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-appoints-taylor-harris-as-chief-executive-officer-cutr-20230727monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-cancels-special-meeting-cutr-20230515monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-comments-on-termination-of-voce-capital-s-special-meeting-proxy-solicitation-resolv-cutr-20230511monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-announces-agreements-with-pura-vida-and-rtw-kevin-cameron-taylor-harris-nick-lewin--cutr-20230509monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-announces-first-quarter-2023-financial-results-cutr-20230509monthly0.5https://www.biopharmawatch.com/news/CUTR/from-cutera-corporate-cuteracorp-cutera-com-sent-monday-cutr-20230424monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-s-special-committee-updates-stockholders-on-its-recent-steps-to-protect-stockho-cutr-20230417monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-to-hold-special-meeting-of-stockholders-cutr-20230413monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-announces-executive-leadership-and-governance-changes-independent-board-member--cutr-20230412monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-receives-notification-of-deficiency-from-nasdaq-related-to-delayed-annual-report-on-cutr-20230324monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-announces-fourth-quarter-and-full-year-2022-financial-results-along-with-2023-outlo-cutr-20230228monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-announces-preliminary-unaudited-financial-results-for-full-year-2022-cutr-20230109monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes--cutr-20221207monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-provides-response-to-fda-inquiry-cutr-20221201monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-announces-third-quarter-2022-financial-results-c-ontinued-momentum-in-capital-equip-cutr-20221103monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-announces-second-quarter-2022-financial-results-record-second-quarter-revenue-drive-cutr-20220804monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-announces-proposed-private-offering-of-200-million-of-convertible-senior-notes-cutr-20220524monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-announces-record-first-quarter-2022-revenue-results-delivers-17-revenue-growth-as-r-cutr-20220510monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-announces-fourth-quarter-and-full-year-2021-financial-results-along-with-2022-o-cutr-20220222monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-appoints-janet-widmann-and-juliane-park-to-its-board-of-directors-brisbane-calif-bu-cutr-20211213monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-announces-third-quarter-2021-financial-results-with-record-revenue-and-issues-2-cutr-20211103monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-announces-second-quarter-2021-financial-results-with-record-revenue-and-issues--cutr-20210804monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-announces-pricing-of-offering-of-125-million-of-convertible-senior-notes-cutr-20210305monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-announces-proposed-private-offering-of-125-million-of-convertible-senior-notes--cutr-20210303monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-announces-proposed-public-offering-of-common-stock-cutr-20200416monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-sandra-gardiner-consultant-chief-financial-officer-415-657-5500-investor-relati-cutr-20171107monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-sandra-a-gardiner-chief-financial-officer-consulting-415-657-5500-investor-rela-cutr-20170818monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-sandra-gardiner-consultant-chief-financial-officer-415-657-5500-investor-relati-cutr-20170807monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-james-a-reinstein-president-ceo-415-657-5500-investor-relations-john-mills-icr--cutr-20170712monthly0.5https://www.biopharmawatch.com/news/CUTR/exhibits-99-1-lease-by-and-between-si-28-llc-a-california-limited-liability-company-landlo-cutr-20170502monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20170501monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20170420monthly0.5https://www.biopharmawatch.com/news/CUTR/ontacts-cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-jo-cutr-20170213monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20170111monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-and-chief-financial-officer-415-657-5500-i-cutr-20161107monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20161011monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-interim-chief-executive-officer-415-657-5500-investor-relations-jo-cutr-20160818monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20160801monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20160502monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20160208monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20151102monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20150805monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20150507monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20150218monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20150205monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20141219monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20141103monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20140804monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20140508monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20140211monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20131104monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20130805monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20130506monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20130211monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20121105monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20120921monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20120806monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20120510monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20120213monthly0.5https://www.biopharmawatch.com/news/CUTR/exhibit-99-1-for-immediate-release-for-more-information-please-contact-cutera-inc-ron-sant-cutr-20120203monthly0.5https://www.biopharmawatch.com/news/CUTR/exhibit-99-1-for-immediate-release-contacts-cutera-inc-ron-santilli-chief-financial-office-cutr-20120103monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20111107monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20111004monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20110801monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20110502monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20110202monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20110105monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20100802monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20100503monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20100208monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20100111monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20091130monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20091102monthly0.5https://www.biopharmawatch.com/news/CUTR/cutera-inc-ron-santilli-chief-financial-officer-415-657-5500-investor-relations-john-mills-cutr-20090803monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-inc-reports-q1-2026-results-toronto-ontario-csci-20260512monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-inc-condensed-interim-consolidated-financial-statements-as-of-csci-20260512monthly0.5https://www.biopharmawatch.com/news/CSCI/preliminary-proxy-statement-subject-to-completion-dated-april-20-2026-annual-general-and-s-csci-20260420monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-comments-on-unusual-market-activity-toronto-ontario-csci-20260407monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-provides-strategic-update-toronto-ontario-csci-20260305monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-inc-formerly-aeterna-zentaris-inc-condensed-interim-consolidated-financ-csci-20251112monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-inc-formerly-aeterna-zentaris-inc-condensed-interim-consolidated-financ-csci-20250814monthly0.5https://www.biopharmawatch.com/news/CSCI/annual-general-and-special-meeting-of-shareholders-to-be-held-on-june-30-2025-notice-of-an-csci-20250603monthly0.5https://www.biopharmawatch.com/news/CSCI/statement-of-executive-compensation-for-the-year-ended-december-31-2024-share-consolidatio-csci-20250520monthly0.5https://www.biopharmawatch.com/news/CSCI/false-2025-03-31-12-31-q1-0001113423-0001113423-2025-01-01-2025-03-31-0001113423-2025-03-3-csci-20250513monthly0.5https://www.biopharmawatch.com/news/CSCI/of-our-form-6-k-furnished-to-the-sec-on-csci-20241112monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-announces-appointment-of-pierre-labb-as-director-toronto-ontario-csci-20241001monthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-inc-formerly-aeterna-zentaris-inc-condensed-interim-consolidated-financ-csci-20240813monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-announces-name-change-to-cosciens-biopharma-inc-toronto-ontario-csci-20240806monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-results-of-virtual-2024-meeting-of-shareholders-toronto-ontario-csci-20240716monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-last-patient-last-visit-in-pivotal-detect-trial-for-the-diagnos-csci-20240613monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-and-ceapro-complete-merger-transaction-toronto-and-edmonton-csci-20240603monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-details-regarding-transaction-with-ceapro-toronto-on-csci-20240517monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-condensed-interim-consolidated-financial-statements-as-of-csci-20240516monthly0.5https://www.biopharmawatch.com/news/CSCI/index-to-financial-statements-of-ceapro-inc-audited-consolidated-financial-statements-of-c-csci-20240515monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-reports-first-quarter-2024-financial-results-company-ended-the-quarter-wi-csci-20240514monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-1-name-and-address-of-company-aeterna-zentaris-inc-th-csci-20240503monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-effective-date-of-share-consolidation-toronto-on-csci-20240501monthly0.5https://www.biopharmawatch.com/news/CSCI/ceapro-receives-final-court-approval-for-merger-with-aeterna-zentaris-toronto-and-edmonton-csci-20240328monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-consolidated-financial-statements-as-of-csci-20240327monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-reports-fourth-quarter-and-full-year-2023-financial-results-and-announces-csci-20240327monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-and-ceapro-merger-approved-by-securityholders-at-special-meetings-toronto-csci-20240312monthly0.5https://www.biopharmawatch.com/news/CSCI/amendment-to-arrangement-agreement-this-amendment-the-amendment-is-made-as-of-the-16-th-da-csci-20240227monthly0.5https://www.biopharmawatch.com/news/CSCI/leading-independent-proxy-advisory-firm-iss-recommends-aeterna-zentaris-and-ceapro-securit-csci-20240227monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-and-ceapro-announce-merger-of-equals-to-create-a-diversified-biopharmaceu-csci-20231214monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-condensed-interim-consolidated-financial-statements-as-of-csci-20231109monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-reports-third-quarter-2023-financial-results-launch-of-ghryvelin-in-a-num-csci-20231108monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-condensed-interim-consolidated-financial-statements-as-of-csci-20230809monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-reports-second-quarter-2023-financial-results-ended-the-quarter-with-42-2-csci-20230809monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-outlines-progress-on-development-pipeline-programs-and-provides-corporate-csci-20230713monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-report-of-voting-results-submitted-pursuant-to-section-11-3-of-nation-csci-20230614monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-results-of-virtual-2023-meeting-of-shareholders-toronto-ontario-csci-20230614monthly0.5https://www.biopharmawatch.com/news/CSCI/annual-general-and-special-meeting-of-shareholders-to-be-held-on-june-14-2023-notice-of-an-csci-20230509monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-virtual-2023-meeting-of-shareholders-toronto-ontario-csci-20230515monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-condensed-interim-consolidated-financial-statements-as-of-csci-20230509monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-reports-first-quarter-2023-financial-results-ended-the-quarter-with-46-6--csci-20230509monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-provides-update-on-macrilen-macimorelin-reiterates-advancement-of-pediatr-csci-20230405monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-consolidated-financial-statements-as-of-csci-20230323monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-reports-fourth-quarter-and-full-year-2022-financial-results-company-ended-csci-20230323monthly0.5https://www.biopharmawatch.com/news/CSCI/pharmanovia-to-market-ghryvelin-macimorelin-in-the-european-economic-area-eea-and-uk-as-di-csci-20230316monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-provides-business-update-and-outlines-key-upcoming-milestones-aeterna-zen-csci-20230117monthly0.5https://www.biopharmawatch.com/news/CSCI/condensed-interim-consolidated-financial-statements-as-at-september-30-2022-and-for-the-th-csci-20221103monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-reports-third-quarter-2022-financial-results-company-ended-the-quarter-wi-csci-20221103monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-set-to-regain-full-rights-to-macrilen-macimorelin-in-u-s-and-canada-from--csci-20220829monthly0.5https://www.biopharmawatch.com/news/CSCI/condensed-interim-consolidated-financial-statements-as-at-june-30-2022-and-for-the-three-a-csci-20220804monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-reports-second-quarter-2022-financial-results-and-recent-highlights-compa-csci-20220803monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-1-name-and-address-of-company-aeterna-zentaris-inc-ae-csci-20220718monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-effective-date-of-share-consolidation-toronto-on-csci-20220718monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-shareholder-approval-of-share-consolidation-toronto-ontario-jul-csci-20220715monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-further-adjournment-of-shareholder-meeting-toronto-ontario-csci-20220706monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-results-of-annual-meeting-of-shareholders-vote-to-approve-share-csci-20220621monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-report-of-voting-results-submitted-pursuant-to-section-11-3-of-nation-csci-20220621monthly0.5https://www.biopharmawatch.com/news/CSCI/annual-general-and-special-meeting-of-shareholders-to-be-held-on-june-21-2022-notice-of-an-csci-20220516monthly0.5https://www.biopharmawatch.com/news/CSCI/statement-of-executive-compensation-for-the-year-ended-december-31-2021-remuneration-of-di-csci-20220517monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-virtual-2022-meeting-of-shareholders-and-urges-shareholders-to--csci-20220516monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-reports-first-quarter-2022-financial-results-and-provides-business-outloo-csci-20220511monthly0.5https://www.biopharmawatch.com/news/CSCI/condensed-interim-consolidated-financial-statements-as-at-march-31-2022-and-for-the-three--csci-20220511monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-secures-new-european-patent-related-to-use-of-macimorelin-for-the-diagnos-csci-20220419monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-consolidated-financial-statements-as-of-csci-20220331monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides--csci-20220329monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-consolidated-financial-statements-as-of-csci-20220329monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-expansion-of-research-program-with-julius-maximilians-universit-csci-20220310monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-notice-of-allowance-for-u-s-patent-covering-aezs-150-for-the-po-csci-20220302monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-csci-20220126monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-provides-business-outlook-and-outlines-pipeline-priorities-company-advanc-csci-20220126monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-appoints-giuliano-la-fratta-as-chief-financial-officer-well-established-f-csci-20211223monthly0.5https://www.biopharmawatch.com/news/CSCI/condensed-interim-consolidated-financial-statements-as-at-september-30-2021-and-for-the-th-csci-20211104monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-to-present-at-the-h-c-wainwright-23-rd-annual-global-investment-conferenc-csci-20210908monthly0.5https://www.biopharmawatch.com/news/CSCI/condensed-interim-consolidated-financial-statements-as-at-csci-20210805monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-receives-nasdaq-notification-regarding-minimum-bid-price-compliance-no-im-csci-20210729monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-engages-dr-michael-levy-to-support-development-of-autoimmune-and-inflamma-csci-20210607monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-final-settlement-of-previously-disclosed-class-action-lawsuit-c-csci-20210603monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-the-start-of-preclinical-development-of-macimorelin-at-the-univ-csci-20210517monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-commences-pivotal-phase-3-detect-trial-for-the-diagnosis-of-childhood-ons-csci-20210513monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-results-of-2021-annual-meeting-of-shareholders-charleston-s-c-csci-20210505monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-appoints-michael-teifel-ph-d-as-senior-vice-president-non-clinical-develo-csci-20210503monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-the-selection-of-a-development-candidate-in-the-dc-pth-program--csci-20210506monthly0.5https://www.biopharmawatch.com/news/CSCI/condensed-interim-consolidated-financial-statements-as-at-march-31-2021-and-for-the-three--csci-20210505monthly0.5https://www.biopharmawatch.com/news/CSCI/annual-meeting-of-shareholders-to-be-held-on-may-5-2021-notice-of-annual-meeting-of-shareh-csci-20210405monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-regains-compliance-with-nasdaq-minimum-bid-price-requirement-charleston-s-csci-20210322monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-exclusive-license-agreement-and-research-contract-with-julius-m-csci-20210315monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-continues-to-demonstrate-pipeline-expansion-announces-the-initiation-of-i-csci-20210311monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-20-509-746-common-shares-no-par-value-per-share-amended-and-restated--csci-20210216monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-evaluation-and-potential-development-of-an-oral-prophylactic-ba-csci-20210202monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-expands-orphan-drug-development-pipeline-with-targeted-immunosuppressive--csci-20210128monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-csci-20210126monthly0.5https://www.biopharmawatch.com/news/CSCI/execution-copy-license-agreement-between-aeterna-zentaris-gmbh-a-corporation-incorporated--csci-20201207monthly0.5https://www.biopharmawatch.com/news/CSCI/amendment-agreement-dated-16-november-2020-by-aeterna-zentaris-gmbh-az-and-novo-nordisk-bi-csci-20201116monthly0.5https://www.biopharmawatch.com/news/CSCI/condensed-interim-consolidated-financial-statements-as-at-september-30-2020-and-for-the-th-csci-20201105monthly0.5https://www.biopharmawatch.com/news/CSCI/condensed-interim-consolidated-financial-statements-as-at-june-30-2020-and-for-the-three-m-csci-20200806monthly0.5https://www.biopharmawatch.com/news/CSCI/neither-this-security-nor-the-securities-for-which-this-security-is-exercisable-have-been--csci-20200805monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-7-0-million-registered-direct-offering-priced-at-the-market-cha-csci-20200803monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-continued-expansion-of-intellectual-property-portfolio-for-maci-csci-20200731monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-abstract-of-results-from-first-pediatric-study-of-macimorelin-a-csci-20200730monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-receives-nasdaq-notification-regarding-minimum-bid-price-compliance-no-im-csci-20200728monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-pricing-of-12-million-public-offering-charleston-s-c-csci-20200701monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-distribution-agreement-with-megapharm-ltd-to-commercialize-maci-csci-20200625monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-regains-compliance-with-nasdaq-minimum-bid-price-requirement-charleston-s-csci-20200608monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-receives-extension-from-nasdaq-to-satisfy-continuing-listing-csci-20200604monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-results-of-2020-annual-meeting-of-shareholders-charleston-s-c-csci-20200515monthly0.5https://www.biopharmawatch.com/news/CSCI/condensed-interim-consolidated-financial-statements-unaudited-aeterna-zentaris-inc-as-at-csci-20200511monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-virtual-2020-annual-meeting-of-shareholders-charleston-s-c-csci-20200508monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-reports-first-quarter-2020-financial-and-operating-results-first-quarter--csci-20200506monthly0.5https://www.biopharmawatch.com/news/CSCI/condensed-interim-consolidated-financial-statements-unaudited-aeterna-zentaris-inc-as-at-csci-20200506monthly0.5https://www.biopharmawatch.com/news/CSCI/annual-meeting-of-shareholders-to-be-held-on-may-15-2020-notice-of-annual-meeting-of-share-csci-20200402monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-receives-nasdaq-notice-of-non-compliance-no-csci-20200415monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-to-present-at-the-april-2020-virtual-investor-summit-presentation-with-li-csci-20200415monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-ema-decision-to-accept-a-modification-to-an-agreed-pediatric-in-csci-20200407monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-positive-results-in-dose-finding-pediatric-study-of-macimorelin-csci-20200406monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-consolidated-financial-statements-as-at-csci-20200331monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-settlement-of-previously-disclosed-class-action-lawsuit-charles-csci-20200312monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-closing-of-4-5-million-registered-direct-offering-priced-at-the-csci-20200221monthly0.5https://www.biopharmawatch.com/news/CSCI/neither-this-security-nor-the-securities-into-which-this-security-is-exercisable-has-been--csci-20200221monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-4-5-million-registered-direct-offering-priced-at-the-market-cha-csci-20200219monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-to-present-at-noble-capital-markets-16-th-annual-investor-conference-pres-csci-20200212monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-completion-of-patient-recruitment-in-dose-finding-pediatric-stu-csci-20200128monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-regains-csci-20200127monthly0.5https://www.biopharmawatch.com/news/CSCI/condensed-interim-consolidated-financial-statements-unaudited-aeterna-zentaris-inc-as-at-csci-20191107monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aeterna-zentaris-i-csci-20191004monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aeterna-zentaris-i-csci-20190920monthly0.5https://www.biopharmawatch.com/news/CSCI/neither-this-security-nor-the-securities-into-which-this-security-is-exercisable-has-been--csci-20190920monthly0.5https://www.biopharmawatch.com/news/CSCI/condensed-interim-consolidated-financial-statements-unaudited-aeterna-zentaris-inc-as-at-csci-20190813monthly0.5https://www.biopharmawatch.com/news/CSCI/via-sedar-aeterna-zentaris-inc-report-as-to-voting-results-submitted-pursuant-to-section-1-csci-20190508monthly0.5https://www.biopharmawatch.com/news/CSCI/condensed-interim-consolidated-financial-statements-unaudited-aeterna-zentaris-inc-as-at-csci-20190507monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-consolidated-financial-statements-as-at-csci-20190401monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aeterna-zentaris-i-csci-20190312monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aeterna-zentaris-i-csci-20181116monthly0.5https://www.biopharmawatch.com/news/CSCI/condensed-interim-consolidated-financial-statements-unaudited-aeterna-zentaris-inc-as-at-csci-20181106monthly0.5https://www.biopharmawatch.com/news/CSCI/condensed-interim-consolidated-financial-statements-unaudited-aeterna-zentaris-inc-as-at-csci-20180809monthly0.5https://www.biopharmawatch.com/news/CSCI/via-sedar-aeterna-zentaris-inc-report-as-to-voting-results-submitted-pursuant-to-section-1-csci-20180508monthly0.5https://www.biopharmawatch.com/news/CSCI/condensed-interim-consolidated-financial-statements-unaudited-aeterna-zentaris-inc-as-at-csci-20180507monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-security-class-holder-account-number-fold-form-of-proxy-annual-and-sp-csci-20180409monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-consolidated-financial-statements-as-at-csci-20180328monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-315-sigma-drive-charleston-sc-29486-www-aezsinc-com-press-release-for-csci-20180328monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aeterna-zentaris-i-csci-20180116monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aeterna-zentaris-i-csci-20171207monthly0.5https://www.biopharmawatch.com/news/CSCI/condensed-interim-consolidated-financial-statements-unaudited-aeterna-zentaris-inc-as-at-csci-20171108monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-315-sigma-drive-ste-302d-charleston-sc-29486-www-aezsinc-com-press-re-csci-20171108monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-appointment-of-interim-chief-financial-officer-charleston-sc-csci-20170925monthly0.5https://www.biopharmawatch.com/news/CSCI/terna-zentaris-inc-315-sigma-drive-suite-302d-charleston-sc-29486-www-aezsinc-com-press-re-csci-20170901monthly0.5https://www.biopharmawatch.com/news/CSCI/condensed-interim-consolidated-financial-statements-unaudited-aeterna-zentaris-inc-as-at-csci-20170811monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-315-sigma-drive-ste-302d-charleston-sc-29486-www-aezsinc-com-press-re-csci-20170811monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aeterna-zentaris-i-csci-20170720monthly0.5https://www.biopharmawatch.com/news/CSCI/via-sedar-csci-20170509monthly0.5https://www.biopharmawatch.com/news/CSCI/condensed-interim-consolidated-financial-statements-unaudited-aeterna-zentaris-inc-as-at-csci-20170508monthly0.5https://www.biopharmawatch.com/news/CSCI/consolidated-statement-of-financial-position-information-in-thousands-as-at-march-31-as-at-csci-20170508monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aeterna-zentaris-i-csci-20170501monthly0.5https://www.biopharmawatch.com/news/CSCI/terna-zentaris-inc-315-sigma-drive-suite-302d-charleston-sc-29486-www-aezsinc-com-press-re-csci-20170427monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aeterna-zentaris-i-csci-20170330monthly0.5https://www.biopharmawatch.com/news/CSCI/terna-zentaris-inc-315-sigma-drive-suite-302d-charleston-sc-29486-www-aezsinc-com-press-re-csci-20170328monthly0.5https://www.biopharmawatch.com/news/CSCI/annual-meeting-of-shareholders-to-be-held-on-may-9-2017-notice-of-annual-meeting-of-shareh-csci-20170320monthly0.5https://www.biopharmawatch.com/news/CSCI/consolidated-statement-of-financial-position-information-unaudited-december-31-in-thousand-csci-20170316monthly0.5https://www.biopharmawatch.com/news/CSCI/terna-zentaris-inc-315-sigma-drive-suite-302d-charleston-sc-29486-press-release-www-aezsin-csci-20170104monthly0.5https://www.biopharmawatch.com/news/CSCI/third-quarter-2016-management-s-discussion-and-analysis-of-financial-condition-and-results-csci-20161108monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-315-sigma-drive-ste-302d-charleston-sc-29486-www-aezsinc-com-press-re-csci-20161108monthly0.5https://www.biopharmawatch.com/news/CSCI/terna-zentaris-inc-press-release-315-sigma-drive-suite-302d-for-immediate-release-charlest-csci-20161101monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-315-sigma-drive-suite-302d-press-release-charleston-sc-29486-for-imme-csci-20161028monthly0.5https://www.biopharmawatch.com/news/CSCI/form-of-director-and-officer-indemnification-agreement-this-indemnification-agreement-the--csci-20161021monthly0.5https://www.biopharmawatch.com/news/CSCI/second-quarter-2016-management-s-discussion-and-analysis-of-financial-condition-and-result-csci-20160809monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-315-sigma-drive-ste-302d-charleston-sc-29486-www-aezsinc-com-press-re-csci-20160809monthly0.5https://www.biopharmawatch.com/news/CSCI/via-sedar-csci-20160510monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-315-sigma-drive-ste-302d-charleston-sc-29486-www-aezsinc-com-press-re-csci-20160509monthly0.5https://www.biopharmawatch.com/news/CSCI/first-quarter-2016-management-s-discussion-and-analysis-of-financial-condition-and-results-csci-20160509monthly0.5https://www.biopharmawatch.com/news/CSCI/terna-zentaris-inc-315-sigma-drive-suite-302d-charleston-sc-29483-www-aezsinc-com-press-re-csci-20160401monthly0.5https://www.biopharmawatch.com/news/CSCI/annual-meeting-of-shareholders-to-be-held-on-may-10-2016-notice-of-annual-meeting-of-share-csci-20160401monthly0.5https://www.biopharmawatch.com/news/CSCI/conformed-shareholder-rights-plan-agreement-between-aeterna-zentaris-inc-and-computershare-csci-20160330monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-315-sigma-drive-ste-302d-charleston-sc-29483-www-aezsinc-com-press-re-csci-20160329monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aeterna-zentaris-i-csci-20160129monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aeterna-zentaris-i-csci-20151209monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-65-csci-20151214monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-65-csci-20151209monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-aeterna-zentaris-inc-1-name-and-address-of-company-ae-csci-20151116monthly0.5https://www.biopharmawatch.com/news/CSCI/certificate-of-amendment-certificat-de-modification-canada-business-corporations-act-loi-c-csci-20151117monthly0.5https://www.biopharmawatch.com/news/CSCI/via-sedar-csci-20151116monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-65-csci-20151105monthly0.5https://www.biopharmawatch.com/news/CSCI/third-quarter-2015-management-s-discussion-and-analysis-of-financial-condition-and-results-csci-20151105monthly0.5https://www.biopharmawatch.com/news/CSCI/special-meeting-of-shareholders-to-be-held-on-november-16-2015-notice-of-special-meeting-o-csci-20151016monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-restructuring-of-finance-accounting-operations-and-closure-of-q-csci-20151012monthly0.5https://www.biopharmawatch.com/news/CSCI/aelig-terna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-41-csci-20150921monthly0.5https://www.biopharmawatch.com/news/CSCI/second-quarter-2015-management-s-discussion-and-analysis-of-financial-condition-and-result-csci-20150813monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-65-csci-20150813monthly0.5https://www.biopharmawatch.com/news/CSCI/via-sedar-csci-20150511monthly0.5https://www.biopharmawatch.com/news/CSCI/first-quarter-2015-management-s-discussion-and-analysis-of-financial-condition-and-results-csci-20150507monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-65-csci-20150508monthly0.5https://www.biopharmawatch.com/news/CSCI/annual-and-special-meeting-of-shareholders-to-be-held-on-may-8-2015-notice-of-annual-and-s-csci-20150317monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-csci-20150317monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-65-csci-20150311monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-65-csci-20150306monthly0.5https://www.biopharmawatch.com/news/CSCI/form-of-series-a-common-share-purchase-warrant-aeterna-zentaris-inc-warrant-shares-issue-d-csci-20150305monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-announces-proposed-public-offering-of-common-shares-and-warrants-press-re-csci-20150305monthly0.5https://www.biopharmawatch.com/news/CSCI/designates-text-that-has-been-omitted-pursuant-to-an-application-for-confidential-treatmen-csci-20141211monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-65-csci-20141106monthly0.5https://www.biopharmawatch.com/news/CSCI/third-quarter-2014-management-s-discussion-and-analysis-of-financial-condition-and-results-csci-20141104monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-65-csci-20141104monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-65-csci-20140807monthly0.5https://www.biopharmawatch.com/news/CSCI/second-quarter-2014-management-s-discussion-and-analysis-of-financial-condition-and-result-csci-20140807monthly0.5https://www.biopharmawatch.com/news/CSCI/via-sedar-csci-20140512monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-65-csci-20140509monthly0.5https://www.biopharmawatch.com/news/CSCI/first-quarter-2014-management-s-discussion-and-analysis-of-financial-condition-and-results-csci-20140508monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-csci-20140328monthly0.5https://www.biopharmawatch.com/news/CSCI/annual-meeting-of-shareholders-to-be-held-on-may-9-2014-notice-of-annual-meeting-of-shareh-csci-20140320monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-csci-20140320monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-65-csci-20140114monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-65-csci-20140109monthly0.5https://www.biopharmawatch.com/news/CSCI/common-share-purchase-warrant-aeterna-zentaris-inc-warrant-shares-issue-date-january-2014--csci-20140108monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-65-csci-20131125monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-65-csci-20131120monthly0.5https://www.biopharmawatch.com/news/CSCI/common-share-purchase-warrant-aeterna-zentaris-inc-warrant-shares-issue-date-november-2013-csci-20131119monthly0.5https://www.biopharmawatch.com/news/CSCI/a-final-base-shelf-prospectus-as-supplemented-by-a-prospectus-supplement-containing-import-csci-20131105monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-third-quarter-2013-management-s-discussion-and-analysis-of-financial-cond-csci-20131105monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-csci-20131105monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-second-quarter-2013-management-s-discussion-and-analysis-of-financial-con-csci-20130808monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-csci-20130808monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-aeterna-zentaris-inc-1-name-and-address-of-company-ae-csci-20130730monthly0.5https://www.biopharmawatch.com/news/CSCI/aelig-terna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-41-csci-20130725monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-common-shares-at-market-issuance-sales-agreement-csci-20130521monthly0.5https://www.biopharmawatch.com/news/CSCI/via-sedar-csci-20130509monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-first-quarter-2013-management-s-discussion-and-analysis-of-financial-cond-csci-20130507monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-csci-20130507monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-aeterna-zentaris-inc-1-name-and-address-of-company-ae-csci-20130415monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-annual-meeting-of-shareholders-to-be-held-on-may-8-2013-notice-of-annual--csci-20130321monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-csci-20130321monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-aeterna-zentaris-inc-1-name-and-address-of-company-ae-csci-20130311monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-aeterna-zentaris-inc-1-name-and-address-of-company-ae-csci-20121228monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-csci-20121113monthly0.5https://www.biopharmawatch.com/news/CSCI/third-quarter-2012-management-s-discussion-and-analysis-of-financial-condition-and-results-csci-20121031monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-aeterna-zentaris-inc-1-name-and-address-of-company-ae-csci-20121017monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-65-csci-20121012monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-aeterna-zentaris-inc-1-name-and-address-of-company-ae-csci-20121002monthly0.5https://www.biopharmawatch.com/news/CSCI/via-sedar-csci-20120815monthly0.5https://www.biopharmawatch.com/news/CSCI/second-quarter-2012-management-s-discussion-and-analysis-of-financial-condition-and-result-csci-20120814monthly0.5https://www.biopharmawatch.com/news/CSCI/aelig-terna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-41-csci-20120814monthly0.5https://www.biopharmawatch.com/news/CSCI/special-meeting-of-shareholders-to-be-held-on-august-15-2012-notice-of-special-meeting-of--csci-20120710monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-learns-of-class-action-lawsuits-filed-and-denies-allegations-qu-bec-city--csci-20120619monthly0.5https://www.biopharmawatch.com/news/CSCI/via-sedar-csci-20120509monthly0.5https://www.biopharmawatch.com/news/CSCI/first-quarter-2012-management-s-discussion-and-analysis-of-financial-condition-and-results-csci-20120504monthly0.5https://www.biopharmawatch.com/news/CSCI/aelig-terna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-41-csci-20120509monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-aeterna-zentaris-inc-1-name-and-address-of-company-ae-csci-20120402monthly0.5https://www.biopharmawatch.com/news/CSCI/annual-meeting-of-shareholders-to-be-held-on-may-9-2012-notice-of-annual-meeting-of-shareh-csci-20120327monthly0.5https://www.biopharmawatch.com/news/CSCI/aelig-terna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-41-csci-20120327monthly0.5https://www.biopharmawatch.com/news/CSCI/aelig-terna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-41-csci-20120123monthly0.5https://www.biopharmawatch.com/news/CSCI/third-quarter-2011-management-s-discussion-and-analysis-of-financial-condition-and-results-csci-20111110monthly0.5https://www.biopharmawatch.com/news/CSCI/second-quarter-2011-management-s-discussion-and-analysis-of-financial-condition-and-result-csci-20110811monthly0.5https://www.biopharmawatch.com/news/CSCI/terna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-652--csci-20110629monthly0.5https://www.biopharmawatch.com/news/CSCI/certificate-of-amendment-certificat-de-modification-canada-business-corporations-act-loi-c-csci-20110525monthly0.5https://www.biopharmawatch.com/news/CSCI/via-sedar-csci-20110519monthly0.5https://www.biopharmawatch.com/news/CSCI/first-quarter-2011-management-s-discussion-and-analysis-of-financial-condition-and-results-csci-20110518monthly0.5https://www.biopharmawatch.com/news/CSCI/execution-version-license-agreement-for-perifosine-by-and-between-terna-zentaris-gmbh-weis-csci-20110331monthly0.5https://www.biopharmawatch.com/news/CSCI/annual-and-special-meeting-of-shareholders-to-be-held-on-may-18-2011-notice-of-annual-and--csci-20110324monthly0.5https://www.biopharmawatch.com/news/CSCI/management-s-discussion-and-analysis-of-financial-condition-and-results-of-operations-high-csci-20110322monthly0.5https://www.biopharmawatch.com/news/CSCI/terna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-652--csci-20110222monthly0.5https://www.biopharmawatch.com/news/CSCI/third-quarter-2010-management-s-discussion-and-analysis-of-financial-condition-and-results-csci-20101110monthly0.5https://www.biopharmawatch.com/news/CSCI/terna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-652--csci-20100812monthly0.5https://www.biopharmawatch.com/news/CSCI/second-quarter-2010-management-s-discussion-and-analysis-of-financial-condition-and-result-csci-20100812monthly0.5https://www.biopharmawatch.com/news/CSCI/exhibit-5-1-montr-al-csci-20100616monthly0.5https://www.biopharmawatch.com/news/CSCI/terna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-652--csci-20100615monthly0.5https://www.biopharmawatch.com/news/CSCI/via-sedar-csci-20100514monthly0.5https://www.biopharmawatch.com/news/CSCI/first-quarter-2010-management-s-discussion-and-analysis-of-financial-condition-and-results-csci-20100513monthly0.5https://www.biopharmawatch.com/news/CSCI/terna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-652--csci-20100513monthly0.5https://www.biopharmawatch.com/news/CSCI/omitted-information-is-the-subject-of-a-request-for-confidential-treatment-pursuant-to-rul-csci-20100507monthly0.5https://www.biopharmawatch.com/news/CSCI/terna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-652--csci-20100420monthly0.5https://www.biopharmawatch.com/news/CSCI/terna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-652--csci-20100415monthly0.5https://www.biopharmawatch.com/news/CSCI/table-of-contents-annual-and-special-meeting-of-shareholders-to-be-held-on-may-13-2010-not-csci-20100323monthly0.5https://www.biopharmawatch.com/news/CSCI/omitted-information-is-the-subject-of-a-request-for-confidential-treatment-pursuant-to-rul-csci-20100330monthly0.5https://www.biopharmawatch.com/news/CSCI/management-s-discussion-and-analysis-of-financial-condition-and-results-of-operations-high-csci-20100325monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-terna-zentaris-inc-1-name-and-address-of-company-tern-csci-20091207monthly0.5https://www.biopharmawatch.com/news/CSCI/third-quarter-2009-management-s-discussion-and-analysis-of-financial-condition-and-results-csci-20091112monthly0.5https://www.biopharmawatch.com/news/CSCI/terna-zentaris-inc-1405-du-parc-technologique-blvd-qu-bec-qu-bec-canada-g1p-4p5-t-418-652--csci-20091019monthly0.5https://www.biopharmawatch.com/news/CSCI/aeterna-zentaris-logo-aeterna-zentaris-inc-1405-du-parc-technologique-blvd-quebec-quebec-c-csci-20090821monthly0.5https://www.biopharmawatch.com/news/CSCI/second-quarter-2009-management-s-discussion-and-analysis-of-financial-condition-and-result-csci-20090811monthly0.5https://www.biopharmawatch.com/news/CSCI/terna-zentaris-to-raise-us-10-million-from-institutional-investors-at-us-1-88-per-share-qu-csci-20090619monthly0.5https://www.biopharmawatch.com/news/CSCI/first-quarter-2009-management-s-discussion-and-analysis-of-financial-condition-and-results-csci-20090507monthly0.5https://www.biopharmawatch.com/news/CSCI/use-these-links-to-rapidly-review-the-document-management-proxy-circular-table-of-contents-csci-20090407monthly0.5https://www.biopharmawatch.com/news/CSCI/form-51-102f3-material-change-report-aeterna-zentaris-inc-1-name-and-address-of-company-ae-csci-20090306monthly0.5https://www.biopharmawatch.com/news/CSCI/third-quarter-2008-management-s-discussion-and-analysis-of-financial-condition-and-results-csci-20081113monthly0.5https://www.biopharmawatch.com/news/CSCI/first-quarter-2008-management-s-discussion-and-analysis-of-financial-condition-and-results-csci-20080509monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-and-cleveland-clinic-expand-strategic-collaboration-to-advance-ai-po-awh-20260526monthly0.5https://www.biopharmawatch.com/news/AWH/investor-presentation-otcqx-awhl-forward-looking-statements-this-presentation-contains-for-awh-20251231monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-announces-third-quarter-2025-financial-results-and-provides-business-update-awh-20251114monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-equity-capital-infusion-of-3-06-million-in-private-placeme-awh-20250918monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-announces-second-quarter-2025-financial-results-and-provides-business-update-awh-20250812monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-appointment-of-jane-pine-wood-to-the-board-of-directors-awh-20250715monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-provides-update-on-arpa-h-sprint-program-partnership-to-advance-wome-awh-20250611monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-announces-first-quarter-2025-financial-results-and-provides-business-update-awh-20250519monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-inc-announces-receipt-of-delisting-notification-from-nasdaq-awh-20250416monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-appoints-three-new-directors-executes-2-0-million-equity-purchase-agreement-new-dir-awh-20250408monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-reports-fourth-quarter-and-full-year-2024-financial-results-record-2-awh-20250327monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-announces-closing-of-1-37-million-private-placement-of-convertible-n-awh-20250311monthly0.5https://www.biopharmawatch.com/news/AWH/www-aspirawh-com-awh-20241024monthly0.5https://www.biopharmawatch.com/news/AWH/our-in-development-test-pipeline-is-designed-to-expand-our-ovarian-cancer-portfolio-and-ad-awh-20240702monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff--awh-20240105monthly0.5https://www.biopharmawatch.com/news/AWH/aspira-women-s-health-xae-reports-second-quarter-2023-financial-results-xfeff-continued-gr-awh-20230814monthly0.5https://www.biopharmawatch.com/news/AWH/first-quarter-total-product-revenue-of-2-3-million-an-increase-of-26-year-over-year-xfeff--awh-20230511monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-awh-20230110monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-aspira-women-s-health-reports-third-quarter-2022-financial-results-xfeff-increased-y-awh-20221110monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-aspira-women-s-health-reports-second-quarter-2022-financial-results-xfeff-increased--awh-20220810monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-aspira-women-s-health-reports-first-quarter-2022-financial-results-xfeff-product-rev-awh-20220511monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-aspira-women-s-health-reports-fourth-quarter-and-full-year-2021-financial-results-xf-awh-20220323monthly0.5https://www.biopharmawatch.com/news/AWH/valerie-palmieri-elevated-to-executive-chair-of-the-board-nicole-sandford-appointed-presid-awh-20220224monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-aspira-women-s-health-announces-fourth-quarter-operational-metrics-and-provides-upda-awh-20220105monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-aspira-women-s-health-reports-third-quarter-2021-financial-results-xfeff-xfeff-total-awh-20211110monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-aspira-women-s-health-reports-second-quarter-2021-financial-results-xfeff-xfeff-tota-awh-20210812monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-aspira-women-s-health-reports-first-quarter-2021-financial-results-conference-call-s-awh-20210513monthly0.5https://www.biopharmawatch.com/news/AWH/nicole-is-also-the-chair-of-girl-scouts-of-connecticut-director-of-the-stamford-public-edu-awh-20210222monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-inc-announces-rebranding-and-company-name-change-to-aspira-women-s-health-inc-x-awh-20200611monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-set-to-join-russell-3000-xf0d2-index-austin-texas-x2014-awh-20200609monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-first-quarter-2020-financial-results-xfeff-awh-20200514monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-fourth-quarter-2019-financial-results-xfeff-awh-20200326monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-vermillion-reports-third-quarter-2019-financial-results-xfeff-awh-20191112monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-vermillion-reports-second-quarter-2019-financial-results-xfeff-awh-20190808monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-first-quarter-2019-financial-results-conference-call-scheduled-for-toda-awh-20190514monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-fourth-quarter-and-year-end-2018-financial-results-conference-call-sche-awh-20190328monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-third-quarter-2018-financial-results-conference-call-scheduled-for-toda-awh-20181108monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-vermillion-inc-appoints-nancy-cocozza-to-its-board-of-directors-xfeff-seasoned-manag-awh-20180821monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-vermillion-reports-second-quarter-2018-financial-results-conference-call-scheduled-f-awh-20180809monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-vermillion-reports-first-quarter-2017-financial-results-conference-call-scheduled-fo-awh-20180514monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-fourth-quarter-and-fiscal-year-2017-financial-results-conference-call-a-awh-20180313monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-vermillion-appoints-bob-beechey-to-newly-created-cfo-post-austin-texas-x2014-awh-20171219monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-third-quarter-2017-results-conference-call-at-4-30-p-m-et-today-austin--awh-20171108monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-vermillion-reports-second-quarter-2017-results-conference-call-at-4-30-p-m-et-today--awh-20170809monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-first-quarter-2017-results-conference-call-at-8-30-a-m-et-today-austin--awh-20170511monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-fourth-quarter-and-full-year-2016-results-conference-call-at-4-30-p-m-e-awh-20170329monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-securities-purchase-agreement-this-securities-purchase-agreement-this-x201c-agreemen-awh-20170213monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff--awh-20170109monthly0.5https://www.biopharmawatch.com/news/AWH/xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff-xfeff--awh-20170106monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-third-quarter-2016-results-conference-call-at-4-30-p-m-et-today-austin--awh-20161110monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-second-quarter-2016-results-conference-call-at-8-00-a-m-et-today-austin-awh-20160810monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-first-quarter-2016-results-conference-call-at-4-30-p-m-et-today-austin--awh-20160516monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-fourth-quarter-and-full-year-2015-results-conference-call-at-8-30-a-m-e-awh-20160324monthly0.5https://www.biopharmawatch.com/news/AWH/michael-wood-lifesci-advisors-llc-tel-1-646-597-6983-mwood-lifesciadvisors-com-awh-20160321monthly0.5https://www.biopharmawatch.com/news/AWH/03-21-8k-ex-991-vermillion-announces-fda-clearance-of-overa-xf0e2-second-generation-ova1-x-awh-20160321monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-third-quarter-2015-financial-results-and-business-update-conference-cal-awh-20151112monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-second-quarter-2015-financial-results-and-business-update-conference-ca-awh-20150813monthly0.5https://www.biopharmawatch.com/news/AWH/share-repurchase-agreement-this-share-repurchase-agreement-x201c-agreement-x201d-dated-as--awh-20150618monthly0.5https://www.biopharmawatch.com/news/AWH/positive-top-line-results-regarding-ova2-development-and-clinical-validation-to-be-present-awh-20150514monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-first-quarter-2015-financial-results-and-provides-business-update-confe-awh-20150511monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-names-fred-ferrara-to-newly-created-cio-post-austin-texas-x2014-awh-20150402monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-fourth-quarter-and-full-year-2014-results-conference-call-at-8-30-a-m-e-awh-20150325monthly0.5https://www.biopharmawatch.com/news/AWH/03-17-8k-ex-991-vermillion-and-quest-diagnostics-announce-new-commercial-agreement-austin--awh-20150317monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-appoints-laura-miller-as-svp-of-sales-customer-experience-austin-texas-awh-20150112monthly0.5https://www.biopharmawatch.com/news/AWH/securities-purchase-agreement-this-securities-purchase-agreement-this-x201c-agreement-x201-awh-20141219monthly0.5https://www.biopharmawatch.com/news/AWH/employment-agreement-this-employment-agreement-this-x201c-agreement-x201d-between-vermilli-awh-20141217monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-third-quarter-2014-results-and-announces-expanded-strategy-conference-c-awh-20141113monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-appoints-valerie-palmieri-as-chief-operating-officer-austin-texas-x2014-awh-20141027monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-appoints-holly-b-bauzon-as-vp-of-sales-and-managed-markets-austin-texas-x2014-awh-20140821monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-second-quarter-2014-results-austin-texas-x2014-awh-20140814monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-first-quarter-2014-results-austin-texas-x2014-awh-20140515monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-appoints-chairman-of-board-james-lafrance-as-president-and-chief-executive-offi-awh-20140423monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-fourth-quarter-and-full-year-2013-results-austin-texas-x2014-awh-20140306monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-completes-17-6-million-warrant-exercise-austin-texas-x2014-awh-20131219monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-appoints-marian-e-sacco-as-svp-of-sales-and-marketing-and-chief-commercial-offi-awh-20131217monthly0.5https://www.biopharmawatch.com/news/AWH/ex-hibit-99-1-vermillion-board-of-directors-elects-james-t-lafrance-as-chairman-austin-tex-awh-20131213monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-results-of-2013-annual-meeting-austin-texas-x2014-awh-20131216monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-third-quarter-2013-results-austin-texas-x2014-awh-20131114monthly0.5https://www.biopharmawatch.com/news/AWH/k-vermillion-appoints-dr-eric-varma-to-its-board-of-directors-austin-texas-x2014-september-awh-20130916monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-second-quarter-2013-results-austin-texas-x2014-awh-20130814monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-first-quarter-2013-results-building-upon-early-success-of-ova1-recent-f-awh-20130515monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-announces-closing-of-equity-financing-austin-texas-may-14-2013-vermillion-inc-n-awh-20130514monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-announces-equity-financing-awh-20130509monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-appoints-thomas-mclain-as-president-and-chief-executive-officer-awh-20130313monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-fourth-quarter-and-full-year-2012-results-awh-20130220monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-appoints-bruce-a-huebner-as-interim-chief-executive-officer-awh-20121127monthly0.5https://www.biopharmawatch.com/news/AWH/delaware-court-of-chancery-dismisses-vermillion-dissident-shareholder-suit-with-prejudice-awh-20121119monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-third-quarter-2012-results-austin-texas-november-12-2012-vermillion-inc-awh-20121113monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-second-quarter-2012-results-awh-20120814monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-announces-ceo-succession-plan-awh-20120515monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-first-quarter-2012-results-awh-20120515monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-board-of-directors-unanimously-nominates-paul-r-sohmer-m-d-for-company-director-awh-20120427monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-resolves-non-contingent-claims-with-bio-rad-vermillion-to-be-returned-more-than-awh-20120430monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-fourth-quarter-and-full-year-2011-results-awh-20120327monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-preliminary-fourth-quarter-and-full-year-2011-results-austin-tx-awh-20120223monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-sharpens-focus-and-streamlines-operations-in-2012-awh-20120104monthly0.5https://www.biopharmawatch.com/news/AWH/vermillioncompletes-the-acquisitionof-correlogicsystems-ovarian-cancer-diagnostics-busines-awh-20111219monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-reports-results-for-third-quarter-2011-austin-tx-awh-20111109monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-enhances-management-team-with-a-key-addition-donald-g-munroe-hired-as-chief-sci-awh-20110926monthly0.5https://www.biopharmawatch.com/news/AWH/vermillion-appoints-distribution-partner-for-ova1-in-israel-and-the-palestine-territories--awh-20110803monthly0.5https://www.biopharmawatch.com/news/FRES/fresh2-group-limited-announces-plan-to-implement-ads-ratio-change-new-york-ny-fres-20240624monthly0.5https://www.biopharmawatch.com/news/FRES/fresh2-group-ltd-announces-receipt-of-a-delinquency-compliance-alert-notice-from-nasdaq-ne-fres-20240523monthly0.5https://www.biopharmawatch.com/news/FRES/fresh2-group-ltd-announces-receipt-of-a-delinquency-compliance-alert-notice-from-nasdaq-ne-fres-20240422monthly0.5https://www.biopharmawatch.com/news/FRES/fresh2-group-ltd-announces-receipt-of-a-bid-deficiency-notice-from-nasdaq-new-york-ny-fres-20240131monthly0.5https://www.biopharmawatch.com/news/FRES/fresh2-group-ltd-announces-acquisition-of-cross-border-food-e-commerce-platform-youfood-gr-fres-20240129monthly0.5https://www.biopharmawatch.com/news/FRES/appointment-of-new-independent-director-new-york-ny-fres-20231215monthly0.5https://www.biopharmawatch.com/news/FRES/unaudited-pro-forma-condensed-combined-financial-information-the-following-unaudited-pro-f-fres-20231204monthly0.5https://www.biopharmawatch.com/news/FRES/fresh2-group-limited-index-to-unaudited-condensed-consolidated-financial-statements-unaudi-fres-20231204monthly0.5https://www.biopharmawatch.com/news/FRES/fresh2-group-limited-index-to-unaudited-condensed-consolidated-financial-statements-unaudi-fres-20231109monthly0.5https://www.biopharmawatch.com/news/FRES/fresh2-group-limited-formerly-anpac-bio-medical-science-co-ltd-unaudited-pro-forma-condens-fres-20230912monthly0.5https://www.biopharmawatch.com/news/FRES/unaudited-pro-forma-condensed-combined-financial-information-on-fres-20230821monthly0.5https://www.biopharmawatch.com/news/FRES/fresh2-group-ltd-fres-rings-the-nasdaq-stock-market-opening-bell-driving-the-online-transf-fres-20230714monthly0.5https://www.biopharmawatch.com/news/FRES/fresh2-group-ltd-completes-acquisition-of-speedin-inc-a-delivery-service-provider-fres-20230728monthly0.5https://www.biopharmawatch.com/news/FRES/fresh2-group-ltd-appoints-new-chief-strategy-officer-to-drive-advancement-and-execution-of-fres-20230726monthly0.5https://www.biopharmawatch.com/news/FRES/fresh2-group-ltd-regains-compliance-with-nasdaq-listing-requirements-fres-20230612monthly0.5https://www.biopharmawatch.com/news/FRES/fresh2-group-ltd-announces-us-4-4-million-private-placement-fres-20230605monthly0.5https://www.biopharmawatch.com/news/FRES/fresh2-reports-fiscal-year-2022-annual-financial-results-fres-20230516monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-medical-science-enters-into-asset-purchase-agreement-with-easy-hundred-inc-new-y-fres-20230403monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-medical-science-announces-closing-of-3-0-million-registered-direct-offering-new--fres-20230406monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-medical-science-announces-pricing-of-3-0-million-registered-direct-offering-new--fres-20230331monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-medical-science-granted-continued-listing-by-nasdaq-hearing-panel-subject-to-mee-fres-20230323monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-medical-science-co-ltd-index-to-unaudited-condensed-interim-consolidated-financi-fres-20230320monthly0.5https://www.biopharmawatch.com/news/FRES/company-no-1563466-anpac-bio-medical-science-co-ltd-the-company-notice-of-change-of-the-ma-fres-20230307monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-medical-science-announces-us-5-million-private-placement-new-york-ny-fres-20230306monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-medical-science-acquires-gisn-hk-limited-a-technical-solution-and-outsourcing-co-fres-20230128monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-medical-science-enters-into-definitive-agreement-to-make-another-acquisition-to--fres-20230213monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-medical-science-enters-into-definitive-agreement-to-acquire-fresh2-ecommerce-inc-fres-20230209monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-medical-science-announces-signing-of-us-5-2-million-of-definitive-investment-agr-fres-20230125monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq--fres-20230120monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-reports-48-8-decrease-in-net-loss-in-first-half-of-2022-philadelphia-fres-20221216monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-announces-regaining-compliance-with-nasdaq-listing-requirement-philadelphia-pa-fres-20221130monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-announces-changes-to-the-board-of-directors-philadelphia-pa-n-ovember-10-2022-an-fres-20221107monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-granted-continued-listing-by-nasdaq-hearing-panel-subject-to-meeting-1-bid-price-fres-20221104monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-announces-plan-to-implement-ads-ratio-change-philadelphia-pa-fres-20221018monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-announces-board-and-management-changes-philadelphia-pa-fres-20221003monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-and-new-investor-group-sign-equity-investment-totaling-3-67-million-philadelphia-fres-20220926monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-appeals-nasdaq-delisting-notice-hearing-granted-and-scheduled-for-fres-20220920monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq--fres-20220912monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-announces-appointment-of-new-directors-and-co-chief-executive-officer-philadelph-fres-20220805monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-approved-written-resolutions-of-a-majority-of-the-members-addressing-the-removal-fres-20220714monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-regains-compliance-with-requirements-to-remain-listed-on-nasdaq-capital-market-p-fres-20220610monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-reports-49-1-decrease-in-net-loss-in-first-quarter-of-fiscal-2022-philadelphia-fres-20220531monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-regains-compliance-with-market-value-of-publicly-held-shares-requirement-upon-tr-fres-20220511monthly0.5https://www.biopharmawatch.com/news/FRES/nasdaq-hearing-panel-grants-anpac-bio-s-request-to-transfer-securities-from-the-nasdaq-glo-fres-20220506monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-appoints-dr-aidong-chen-as-new-chief-executive-officer-and-chairman-of-the-board-fres-20220408monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq--fres-20220326monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-medical-sciences-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-fres-20220311monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-receives-nasdaq-notification-regarding-minimum-market-value-of-publicly-held-sha-fres-20220124monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-reports-nine-months-ended-fres-20211126monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-announces-pricing-of-approximately-2-9-million-underwritten-public-offering-of-a-fres-20211109monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-medical-science-co-ltd-index-to-unaudited-condensed-interim-consolidated-financi-fres-20211012monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-study-shows-strong-correlation-between-cda-score-and-risk-of-cancer-and-diseases-fres-20211004monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-2021-first-half-revenue-up-128-5-with-non-gaap-loss-reduced-by-18-3-philadelphia-fres-20211001monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-receives-nasdaq-notification-regarding-minimum-market-value-of-listed-securities-fres-20210930monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-announces-appointment-of-new-independent-director-independent-director-has-stron-fres-20210723monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-reports-strong-first-quarter-in-2021-with-137-2-increase-in-revenue-and-record-n-fres-20210527monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-reports-fiscal-year-2020-annual-financial-results-89-1-increase-in-revenue-and-2-fres-20210430monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-regains-compliance-with-nasdaq-continued-listing-requirement-san-jose-ca-fres-20210305monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-announces-change-of-auditor-san-jose-ca-fres-20201204monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-announces-appointment-of-new-independent-director-san-jose-ca-fres-20201116monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-reports-first-six-months-of-2020-financial-results-fres-20200910monthly0.5https://www.biopharmawatch.com/news/FRES/anpac-bio-announces-appointment-of-new-chief-financial-officer-san-jose-ca-fres-20200602monthly0.5https://www.biopharmawatch.com/news/LYRA/forward-looking-statement-this-presentation-contains-forward-looking-statements-within-the-lyra-20250904monthly0.5https://www.biopharmawatch.com/news/LYRA/forward-looking-statement-this-presentation-contains-forward-looking-statements-within-the-lyra-20250609monthly0.5https://www.biopharmawatch.com/news/LYRA/forward-looking-statement-this-presentation-contains-forward-looking-statements-within-the-lyra-20250110monthly0.5https://www.biopharmawatch.com/news/LYRA/forward-looking-statement-this-presentation-contains-forward-looking-statements-within-the-lyra-20240108monthly0.5https://www.biopharmawatch.com/news/LYRA/disclaimer-this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-lyra-20230912monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-inc-condensed-consolidated-statements-of-operations-and-comprehensive-lo-lyra-20230512monthly0.5https://www.biopharmawatch.com/news/LYRA/long-acting-corticosteroid-matrices-improve-crs-cardinal-symptoms-brent-a-senior-md1-ander-lyra-20220910monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-second-quarter-2022-financial-results-and-provides-corporate-upd-lyra-20220809monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-first-quarter-2022-financial-results-and-provides-corporate-upda-lyra-20220510monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-100-5-million-private-placement-lyra-20220408monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-lyra-20220309monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-third-quarter-2021-financial-results-and-provides-corporate-upda-lyra-20211109monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-first-quarter-2021-financial-results-and-provides-corporate-upda-lyra-20210511monthly0.5https://www.biopharmawatch.com/news/LYRA/disclaimer-this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-lyra-20210413monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-provides-cor-lyra-20210309monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-announces-positive-topline-results-for-lantern-phase-2-randomized-contro-lyra-20201207monthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-reports-third-quarter-2020-financial-results-and-provides-corporate-upda-lyra-20201110monthly0.5https://www.biopharmawatch.com/news/SMFL/smart-for-life-inc-unaudited-pro-forma-condensed-consolidated-financial-statements-the-fol-smfl-20241004monthly0.5https://www.biopharmawatch.com/news/SMFL/smart-for-life-announces-definitive-agreement-to-acquire-purely-optimal-nutrition-a-premie-smfl-20240409monthly0.5https://www.biopharmawatch.com/news/SMFL/smart-for-life-inc-unaudited-pro-forma-condensed-consolidated-financial-statements-the-fol-smfl-20240202monthly0.5https://www.biopharmawatch.com/news/SMFL/smart-for-life-announces-q2-2023-financial-results-and-provides-business-update-balance-sh-smfl-20230823monthly0.5https://www.biopharmawatch.com/news/SMFL/smart-for-life-announces-successful-debt-refinancing-as-part-of-company-s-balance-sheet-tr-smfl-20230526monthly0.5https://www.biopharmawatch.com/news/SMFL/smart-for-life-announces-closing-of-1-58-million-registered-direct-offering-priced-at-the--smfl-20230519monthly0.5https://www.biopharmawatch.com/news/SMFL/smart-for-life-announces-q1-2023-financial-results-and-provides-business-update-miami-fl-smfl-20230522monthly0.5https://www.biopharmawatch.com/news/SMFL/smart-for-life-announces-900-000-registered-direct-offering-priced-at-the-market-under-nas-smfl-20230503monthly0.5https://www.biopharmawatch.com/news/SMFL/smart-for-life-reports-2022-financial-results-and-provides-business-update-revenue-increas-smfl-20230331monthly0.5https://www.biopharmawatch.com/news/SMFL/smart-for-life-announces-q3-2022-financial-results-revenue-increases-59-1-year-over-year-t-smfl-20221114monthly0.5https://www.biopharmawatch.com/news/SMFL/smart-for-life-announces-q2-2022-financial-results-revenue-increases-401-2-year-over-year--smfl-20220815monthly0.5https://www.biopharmawatch.com/news/SMFL/smart-for-life-completes-acquisition-of-ceautamed-worldwide-the-owner-of-greens-first-acqu-smfl-20220804monthly0.5https://www.biopharmawatch.com/news/SMFL/smart-for-life-on-track-to-close-pending-acquisition-of-ceautamed-worldwide-acquisition-ex-smfl-20220608monthly0.5https://www.biopharmawatch.com/news/SMFL/smart-for-life-announces-q1-2022-financial-results-company-achieves-679-year-over-year-rev-smfl-20220516monthly0.5https://www.biopharmawatch.com/news/SMFL/smart-for-life-executes-letter-of-intent-with-diamond-creek-capital-for-4-million-senior-c-smfl-20220513monthly0.5https://www.biopharmawatch.com/news/SMFL/smart-for-life-announces-fy-2021-financial-results-company-achieves-360-increase-in-revenu-smfl-20220401monthly0.5https://www.biopharmawatch.com/news/SMFL/smart-for-life-executes-definitive-agreement-to-acquire-ceautamed-worldwide-acquisition-pr-smfl-20220315monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-announces-receipt-of-nasdaq-non-compliance-notice-new-york-ny-ptix-20251126monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-announces-grant-of-new-patent-in-japan-for-its-modified-stilbenoid-ptix-20250730monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-receives-3-1-million-from-recent-warrant-activity-ptix-20250521monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-and-phytanix-announce-business-combination-to-form-neuroactive-bio-ptix-20250519monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-to-effect-1-for-14-reverse-stock-split-measure-taken-to-comply-wit-ptix-20250429monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-announces-closing-of-private-placement-for-aggregate-gross-proceed-ptix-20241105monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-announces-pricing-of-private-placement-for-aggregate-gross-proceed-ptix-20241029monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-stress-regulating-peptide-demonstrates-exceptional-safety-in-singl-ptix-20240522monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-announces-resolution-of-nasdaq-deficiency-notice-ptix-20240321monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-to-effect-1-for-4-reverse-stock-split-measure-taken-to-comply-with-ptix-20230322monthly0.5https://www.biopharmawatch.com/news/PTIX/the-face-of-an-epidemic-source-publicly-available-government-records-deaths-from-prescript-ptix-20180613monthly0.5https://www.biopharmawatch.com/news/PTIX/three-high-profile-publications-support-the-potential-of-protagenic-therapeutics-s-synthet-ptix-20180611monthly0.5https://www.biopharmawatch.com/news/PTIX/board-of-directors-garo-h-armen-phd-executive-chairman-nominating-and-corporate-governance-ptix-20170526monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-inc-and-subsidiary-consolidated-financial-statements-for-the-years-ptix-20160712monthly0.5https://www.biopharmawatch.com/news/PTIX/charter-of-the-audit-committee-of-the-board-of-directors-of-atrinsic-inc-purpose-the-princ-ptix-20160426monthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-inc-and-subsidiary-december-31-2014-and-2013-table-of-contents-pag-ptix-20160212monthly0.5https://www.biopharmawatch.com/news/PTIX/unassociated-document-atrinsic-inc-469-7-th-avenue-10th-floor-new-york-new-york-10018-octo-ptix-20111028monthly0.5https://www.biopharmawatch.com/news/PTIX/sharon-siegel-cmo-212-716-1977-ext-136-ptix-20110914monthly0.5https://www.biopharmawatch.com/news/PTIX/item-7-management-s-discussion-and-analysis-of-financial-condition-and-results-of-operatio-ptix-20110701monthly0.5https://www.biopharmawatch.com/news/PTIX/thomas-plotts-ptix-20110601monthly0.5https://www.biopharmawatch.com/news/PTIX/unassociated-document-for-immediate-release-contact-ptix-20110331monthly0.5https://www.biopharmawatch.com/news/PTIX/thomas-plotts-ptix-20110224monthly0.5https://www.biopharmawatch.com/news/PTIX/investor-relations-presentation-december-2010-this-presentation-contains-forward-looking-s-ptix-20101210monthly0.5https://www.biopharmawatch.com/news/PTIX/unassociated-document-for-immediate-release-contact-thomas-plotts-december2-2010-cfo-212-7-ptix-20101202monthly0.5https://www.biopharmawatch.com/news/PTIX/atrinsic-inc-4385727-atrinsic-inc-third-quarter-2010-ptix-20101116monthly0.5https://www.biopharmawatch.com/news/PTIX/unassociated-document-for-immediate-release-contact-ptix-20101115monthly0.5https://www.biopharmawatch.com/news/PTIX/unassociated-document-for-immediate-release-contact-ptix-20101014monthly0.5https://www.biopharmawatch.com/news/PTIX/unassociated-document-for-immediate-release-contact-thomas-plotts-cfo-212-716-1977-x-222-ptix-20100902monthly0.5https://www.biopharmawatch.com/news/PTIX/unassociated-document-for-immediate-release-contact-ptix-20100816monthly0.5https://www.biopharmawatch.com/news/PTIX/unassociated-document-atrinsic-inc-4295989-atrinsic-inc-conference-call-ptix-20100511monthly0.5https://www.biopharmawatch.com/news/PTIX/unassociated-document-for-immediate-release-contact-ptix-20100511monthly0.5https://www.biopharmawatch.com/news/PTIX/converted-by-secpublisher-2-1-1-8-created-by-bcl-technologies-inc-for-sec-filing-ptix-20100505monthly0.5https://www.biopharmawatch.com/news/PTIX/contact-ptix-20100330monthly0.5https://www.biopharmawatch.com/news/PTIX/thomas-plotts-ptix-20100201monthly0.5https://www.biopharmawatch.com/news/PTIX/jeffrey-schwartz-january-13-th-2010-interim-ceo-212-716-1977-stuart-goldfarb-appointed-to--ptix-20100113monthly0.5https://www.biopharmawatch.com/news/PTIX/unassociated-document-for-immediate-release-contact-thomas-plotts-ptix-20091230monthly0.5https://www.biopharmawatch.com/news/PTIX/unassociated-document-thomas-plotts-appointed-interim-cfo-of-atrinsic-new-york-atrinsic-na-ptix-20091221monthly0.5https://www.biopharmawatch.com/news/PTIX/atrinsic-inc-third-quarter-2009-earnings-conference-call-ptix-20091111monthly0.5https://www.biopharmawatch.com/news/PTIX/unassociated-document-for-immediate-release-contact-ptix-20091111monthly0.5https://www.biopharmawatch.com/news/PTIX/andrew-zaref-ptix-20091023monthly0.5https://www.biopharmawatch.com/news/PTIX/unassociated-document-jeffrey-schwartz-appointed-interim-ceo-of-atrinsic-new-york-atrinsic-ptix-20091007monthly0.5https://www.biopharmawatch.com/news/PTIX/unassociated-document-for-immediate-release-contact-ptix-20090814monthly0.5https://www.biopharmawatch.com/news/PTIX/asset-purchase-agreement-this-asset-purchase-agreement-this-agreement-is-entered-into-on-ptix-20090731monthly0.5https://www.biopharmawatch.com/news/PTIX/unassociated-document-for-immediate-release-contact-andrew-zaref-ptix-20090625monthly0.5https://www.biopharmawatch.com/news/PTIX/dear-fellow-shareholders-2008-was-a-transformative-year-for-our-young-company-with-the-acq-ptix-20090603monthly0.5https://www.biopharmawatch.com/news/PTIX/unassociated-document-for-immediate-release-contact-ptix-20090512monthly0.5https://www.biopharmawatch.com/news/PTIX/unassociated-document-for-immediate-release-contact-ptix-20090326monthly0.5https://www.biopharmawatch.com/news/PTIX/contact-ptix-20081112monthly0.5https://www.biopharmawatch.com/news/PTIX/contact-ptix-20080814monthly0.5https://www.biopharmawatch.com/news/PTIX/atrinsic-acquires-ringtone-com-adds-180-000-subscribers-accretive-to-shareholders-upon-clo-ptix-20080702monthly0.5https://www.biopharmawatch.com/news/PTIX/atrinsic-inc-first-quarter-2008-earnings-ptix-20080515monthly0.5https://www.biopharmawatch.com/news/PTIX/ha-yden-communications-investors-brett-maas-ptix-20080327monthly0.5https://www.biopharmawatch.com/news/PTIX/nicola-piggott-for-press-inquiries-ptix-20080204monthly0.5https://www.biopharmawatch.com/news/PTIX/nicola-piggott-for-press-inquiries-ptix-20071114monthly0.5https://www.biopharmawatch.com/news/PTIX/hill-knowlton-for-new-motion-ptix-20070927monthly0.5https://www.biopharmawatch.com/news/PTIX/karen-strickholm-505-988-4401-ptix-20070821monthly0.5https://www.biopharmawatch.com/news/PTIX/karen-strickholm-press-inquiries-505-988-4401-ptix-20070814monthly0.5https://www.biopharmawatch.com/news/PTIX/dean-oakey-financial-inquiries-ptix-20070516monthly0.5https://www.biopharmawatch.com/news/PTIX/dean-oakey-financial-inquiries-ptix-20070503monthly0.5https://www.biopharmawatch.com/news/PTIX/new-motion-inc-mplc-inc-reports-full-year-2006-and-fourth-quarter-results-80-increase-in-f-ptix-20070402monthly0.5https://www.biopharmawatch.com/news/PTIX/dean-oakey-financial-inquiries-ptix-20070306monthly0.5https://www.biopharmawatch.com/news/PTIX/mplc-inc-and-new-motion-inc-complete-acquisition-and-close-on-6-500-000-in-private-placeme-ptix-20070213monthly0.5https://www.biopharmawatch.com/news/PTIX/form-of-exchange-agreement-execution-copy-exchange-agreement-by-and-among-mplc-inc-trinad--ptix-20070131monthly0.5https://www.biopharmawatch.com/news/PTIX/form-of-series-a-convertible-preferred-stock-purchase-agreement-series-a-convertible-prefe-ptix-20070124monthly0.5https://www.biopharmawatch.com/news/PTIX/unassociated-document-contact-mplc-inc-2121-avenue-of-the-stars-suite-1650-los-angeles-ca--ptix-20061122monthly0.5https://www.biopharmawatch.com/news/PTIX/mplc-inc-bankruptcy-administrator-announces-a-one-time-cash-distribution-of-bankruptcy-pro-ptix-20051020monthly0.5https://www.biopharmawatch.com/news/MRK/merck-tulisokibart-phase-3-atlas-uc-study2026-06-22T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-positive-data-alloha-phase-1-study2026-06-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fda-expanded-access-nrx-1012026-06-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MPLT/maplight-phase-2-iris-study-results-ml-004-autism2026-06-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-influenza-prophylaxis-update2026-06-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-peer-reviewed-article-piclidenoson-namodenoson2026-06-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/abbvie-acquires-apogee-therapeutics-immunology2026-06-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/labcorp-colosense-at-home-colorectal-cancer-test2026-06-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-restructured-acquisition-colospan2026-06-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICLR/icon-microsoft-ai-clinical-development2026-06-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-propel-3-trial-results-iccbh-20262026-06-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BWAY/brainsway-accelerated-deep-tms-coverage-expansion2026-06-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-skinject-teverelix-bio-international-20262026-06-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-strategic-portfolio-expansion-license-agreement2026-06-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regnxbio-fda-alignment-navsunli-accelerated-approval2026-06-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-license-miu-della-sebela-pharmaceuticals2026-06-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTMD/biote-canada-pavilion-bio-20262026-06-22T11:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTMD/biotecanada-opens-canada-pavilion-bio-20262026-06-22T11:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFMD/life-md-launches-xyosted-self-pay-program2026-06-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-riteshr-srivastava-appointment2026-06-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-standalone-neural-sensing-program2026-06-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-blockdaemon-partnership-institutional-staking2026-06-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-zacks-investor-forum-20262026-06-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-leadership-transition-steve-kelsey2026-06-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-fda-rmat-pm359-cgd2026-06-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reveal-trial-completion-tsha-1022026-06-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-fda-breakthrough-elsunersen-seizures2026-06-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-announces-key-intellectual-property2026-06-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LABT/lakewood-amendex-patent-bisphosphocin-compounds2026-06-22T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-appoints-agnieszka-jurecka-vp-medical-affairs2026-06-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-neuromuscular-research-20262026-06-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/exelixis-phase-3-stellar-303-trial-update2026-06-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-reports-positive-preclinical-findings2026-06-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-launches-signals-ai-accelerating-scientific-rd2026-06-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-cove-3-trial-ycanthe-vp-1022026-06-22T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THC/tenet-report-second-quarter-2026-results-july-242026-06-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-global-neurosurgery-advisory-council2026-06-22T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-fda-response-cytisinicline2026-06-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-patent-allowance-topical-therapy-wound-healing2026-06-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-positive-fda-feedback-eb613-phase-3-study2026-06-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-lucid-ms-phase-2-trials2026-06-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-streeterville-financing-agreement-extension2026-06-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-treasury-update-rain-holdings-1-14-billion2026-06-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-webull-webinar-presentation2026-06-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-investor-summit-conference-20262026-06-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCR/intercure-secures-nis-22-million-private-placement-financing2026-06-22T12:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-q1-2026-results-revenue-growth2026-06-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-patent-reqorsa-cancer-therapy2026-06-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-primec-community-event-als2026-06-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-sustainability-report-20252026-06-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-expands-adapt-trial-fda-clearance2026-06-22T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-contract-manufacturing-growth2026-06-22T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-third-quarter-2026-dividend2026-06-22T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-receives-marketing-authorization-redeplo2026-06-22T16:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLF/fuel-like-ronaldo-campaign-wellness2026-06-22T19:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-public-offering2026-06-22T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-fiscal-year-2026-financial-results-call2026-06-22T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-150-million-public-offering2026-06-22T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-ceo-adam-mendelsohn-bio-convention-20262026-06-22T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-proposed-public-offering2026-06-22T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/lilly-centessa-acquisition-approved-high-court2026-06-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-closes-10-million-offering-nasdaq2026-06-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-robert-azelby-appointment2026-06-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-appoints-barry-greene-board2026-06-22T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-private-placement-19-4-million2026-06-22T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-presentation-life-sciences-investor-forum-june-20262026-06-22T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-phase-3-sigvotatug-vedotin-results2026-06-22T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-leadership-transitions2026-06-22T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-milestone-payment-sanofi-tzield-approval2026-06-22T20:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIDX/monthly-investor-webinar-series-2020-biolabs2026-06-22T20:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KARD/kardigan-ipo-closing-underwriters-option2026-06-22T21:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-2026-annual-meeting-results2026-06-22T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-webinar-neuro-oncology-update2026-06-22T21:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/doh-sanofi-partner-vaccine-innovation2026-06-22T23:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-investor-conference-inducement-grant2026-06-23T00:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-host-autoimmune-myositis-webinar2026-06-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-cenrifki-approval-eu-spms2026-06-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/wayrilz-approval-japan-immune-thrombocytopenia2026-06-23T05:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-european-commission-approval-skyrizi-pediatric-psoriasis2026-06-23T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-eu-approval-maviret-hepatitis-c2026-06-23T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/abbvie-approval-maviret-hepatitis-c2026-06-23T09:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-canada-henlius-launch-biosimilars-denosumab2026-06-23T09:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/nccn-recommends-ctdna-mrd-testing-signatera-bladder-cancer2026-06-23T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-biomag-iii-trial-freesolve-scaffold2026-06-23T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bdx-centrovena-one-vizient-contract2026-06-23T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalos-ron-philip-board-appointment2026-06-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-additional-funding-dod-support2026-06-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/frank-stokes-cfo-awards-houston-business-journal2026-06-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-appoints-samuele-butera-global-respiratory2026-06-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/access-vascular-medline-agreement-vascular-catheters2026-06-23T11:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-lumina-trial-amx0114-encals-20262026-06-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-appoints-micah-young-cfo2026-06-23T11:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-virtual-agm-june-20262026-06-23T11:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-serapha-merger-agreement-230-million-funding2026-06-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-miplyffa-pediatric-substudy-npc2026-06-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-business-update-call-june-20262026-06-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-launches-trinovium-liquid-cooling-ai2026-06-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-business-combination-zcash-mining2026-06-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/european-commission-approves-trodelvy-first-line-treatment2026-06-23T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-positive-fda-meeting-belapectin2026-06-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-phase-3-ovation-3-study-continues2026-06-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-begins-rasolute-305-trial2026-06-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-mhra-alignment-2026-uk-authorization-cordstrom2026-06-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-appoints-dr-sanders-board2026-06-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-completes-enrollment-phase-2-eoe-study2026-06-23T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCY/innovative-eyewear-partners-with-encore-optical2026-06-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-ideashare-2026-independent-pharmacies2026-06-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-positive-stability-data-spc-15-ptsd-treatment2026-06-23T12:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srx-global-investment-armr-sciences2026-06-23T12:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELV/elevance-health-clinical-review-health-os2026-06-23T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-icd-10-codes-scd-therapy2026-06-23T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-young-researcher-award-brazil2026-06-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-fda-approval-qyleki-qrx0032026-06-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-first-in-class-ms-treatment2026-06-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-liberty-system-adoption-pennsylvania2026-06-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/unfo-orthopediatrics-partner-foot-brace-newborns2026-06-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-dr-robert-wills-chairman-board2026-06-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/first-patients-dosed-phase-2-trial-dm1992026-06-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-phase-2-3-trial-sil204-pancreatic-cancer2026-06-23T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMED/minimed-launches-instinct-sensors-europe2026-06-23T12:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-awarded-breakthrough-t1d-grant-afrezza-trial2026-06-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/vectorbuilder-maxcyte-partnership-cell-engineering2026-06-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-advances-glucose-biosensing-vision2026-06-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/daniel-skovronsky-appointed-illumina-board2026-06-23T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-expands-precise-mrd-availability2026-06-23T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-versant-launch-saturnus-bio-cardiomyopathies2026-06-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-launch-saturnus-bio-rare-cardiomyopathies2026-06-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-mae-partner-expand-doula-workforce2026-06-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/highres-waters-robotic-automation-drug-discovery2026-06-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-webcast-august-4-conference-call2026-06-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/zeta-surgical-first-patient-treatment-tms-navigation-system2026-06-23T15:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-galderma-aesthetic-medicine-ai-citations2026-06-23T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-partnership-vaccine-innovation-abu-dhabi2026-06-23T17:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/javelin-biotech-pfizer-clinical-pk-predictions2026-06-23T17:49:00.000Zmonthly0.5